PT,UT,PY,TI,AB,ID,DE,SO,AU,C1,WC,SC,CR,Z9,DA,FU
J,WOS:000243601000002,2006,QUANTITATIVE DESCRIPTION OF SOIL ORGANIC MATTER DYNAMICS - A REVIEW OF APPROACHES WITH REFERENCE TO RICE-BASED CROPPING SYSTEMS,"THIS REVIEW PAPER PRESENTS A HISTORICAL OVERVIEW OF QUANTITATIVE APPROACHES USED IN DESCRIBING SOIL ORGANIC MATTER (SOM) DYNAMICS, WITH THE OBJECTIVE OF IDENTIFYING PROCESSES RELEVANT IN DESCRIBING LONG-TERM CARBON AND NITROGEN DYNAMICS IN RICE-BASED CROPPING SYSTEMS. A NUMBER OF EXISTING SOM MODELS HAVE BEEN EVALUATED BASED ON THEIR OBJECTIVES AND UNDERLYING CONCEPTS. MODELS ARE GROUPED INTO TWO BROAD CLASSES OF ANALYTICAL AND SIMULATION MODELS, AND WITHIN THE LATTER COMPREHENSIVE AND SUMMARY MODELS, BASED ON THE LEVEL OF DETAIL IN PROCESS DESCRIPTIONS. MOST OF THE EXISTING SOM MODELS HAVE BEEN DEVELOPED FOR AEROBIC, UPLAND CONDITIONS AND DESCRIBE THE PROCESSES OF DECOMPOSITION OF ORGANIC MATTER, GROWTH AND DEATH OF MICROBIAL BIOMASS, NITRIFICATION, IMMOBILIZATION, DENITRIFICATION, NH4+-VOLATILIZATION, LEACHING OF NO3-, CROP UPTAKE, EROSION AND RUNOFF. HOWEVER, IN ANAEROBIC LOWLAND CONDITIONS, THE RATES AND RELATIVE IMPORTANCE OF THE PROCESSES ARE DIFFERENT. THIS PAPER EVALUATES THE SUITABILITY OF EXISTING MODELS FOR APPLICATION UNDER ALTERNATE FLOODED AND NON-FLOODED CONDITIONS, CORRESPONDING TO ROTATIONS OF RICE-UPLAND CROPS. SINCE NO EXISTING SOM MODEL DESCRIBES THE PROCESSES FOR SUCH CONDITIONS AND THEIR EFFECT ON SOM QUANTITY AND QUALITY, A SIMULATION MODEL IS YET TO BE DEVELOPED, INCLUDING THESE PROCESSES, WHICH CAN SATISFACTORILY DESCRIBE THE CHANGES IN SOM AND CROP YIELD. THIS PAPER ALSO IDENTIFIES THE PROCESSES TO CONSIDER IN DEVELOPING A LONG-TERM SIMULATION MODEL FOR ALTERNATE FLOODED AND NON-FLOODED CONDITIONS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",LONG-TERM EXPERIMENTS; MICROBIAL BIOMASS; LOWLAND RICE; CARBON SEQUESTRATION; SIMULATING TRENDS; GRASSLAND SOILS; MODELING CARBON; YIELD DECLINES; ANNUAL INPUT; NITROGEN,SOIL ORGANIC CARBON; SOIL ORGANIC NITROGEN; MODEL; INDO-GANGETIC PLAINS; RICE; YIELD DECLINE,GEODERMA,"SHIBU, ME##LEFFELAAR, PA##VAN KEULEN, H##AGGARWAL, PK","PLANT PROD SYST GRP, NL-6700 AK WAGENINGEN, NETHERLANDS. PLANT RES INT, NL-6700 AA WAGENINGEN, NETHERLANDS. INDIAN AGR RES INST, DEPT ENVIRONM SCI, NEW DELHI 110012, INDIA.",SOIL SCIENCE,AGRICULTURE,"AGGARWAL PK, 2000, OUTLOOK AGR, V29, P259, DOI 10.5367/000000000101293329##AHUJA LR, 2000, ROOT ZONE WATER QUALITY MODEL, P1##ALLISON EE, 1973, SOIL ORGANIC MATTER##ANDERSON TH, 1989, SOIL BIOL BIOCHEM, V21, P471, DOI 10.1016/0038-0717(89)90117-X##ANDREN O, 1997, ECOL APPL, V7, P1226, DOI 10.1890/1051-0761(1997)007[1226:ITICBM]2.0.CO;2##BIRD JA, 2003, SOIL SCI SOC AM J, V67, P806, DOI 10.2136/SSSAJ2003.0806##BRADBURY NJ, 1993, J AGR SCI, V121, P363, DOI 10.1017/S0021859600085567##CASSMAN K. G., 1995, AGRICULTURAL SUSTAINABILITY: ECONOMIC, ENVIRONMENTAL AND STATISTICAL CONSIDERATIONS., P63##CHERTOV OG, 1997, ECOL MODEL, V94, P177, DOI 10.1016/S0304-3800(96)00017-8##CHERTOV OG, 1996, NATO ASI I, V38, P231, DOI DOI 10.1007/978-3-642-61094-3_16##COLEMAN D. C., 1989, DYNAMICS SOIL ORGANI##COLEMAN K, 1997, GEODERMA, V81, P29, DOI 10.1016/S0016-7061(97)00079-7##COLEMAN K, 1996, NATO ASI SERIES 1, V38, P237##CORNELISSEN AGM, 2003, THESIS WAGENINGEN U##CRASWELL ET, 1979, FATE FERTILIZER NITR, P175##DAWE D, 2000, FIELD CROP RES, V66, P175, DOI 10.1016/S0378-4290(00)00075-7##DAWE D, 2003, FIELD CROP RES, V83, P191, DOI 10.1016/S0378-4290(03)00074-1##DEBUSK WF, 1998, SOIL SCI SOC AM J, V62, P1460, DOI 10.2136/SSSAJ1998.03615995006200050045X##DEDATTA SK, 1986, FERT RES, V9, P171##DEVEVRE OC, 2001, SOIL SCI SOC AM J, V65, P499, DOI 10.2136/SSSAJ2001.652499X##DOBERMANN A, 2000, AGRON J, V92, P633, DOI 10.2134/AGRONJ2000.924633X##DOBERMANN A., 2000, CARBON NITROGEN DYNA, P1##ESSER G, 1991, MODERN ECOLOGY BASIC, P679##ESSER G, 1987, TELLUS B, V39, P459##EVANS WC, 1977, NATURE, V270, P17, DOI 10.1038/270017A0##FALLOON P, 2002, SOIL USE MANAGE, V18, P101, DOI [10.1111/J.1475-2743.2002.TB00227.X, 10.1079/SUM2001108]##FAO, 2004, ASS CARB STOCKS MOD##FRANCIS DD, 1993, AGRON J, V85, P659, DOI 10.2134/AGRONJ1993.00021962008500030026X##FRANKO U, 1995, ECOL MODEL, V81, P213, DOI 10.1016/0304-3800(94)00172-E##FRANKO U., 1996, EVALUATION SOIL ORGA, VI, P247##FRISSEL MJ, 1981, SIMULATION NITROGEN##GEORGE T, 1993, SOIL SCI SOC AM J, V57, P1526, DOI 10.2136/SSSAJ1993.03615995005700060022X##GRACE PR, 2001, NET ECOSYSTEM EXCHAN##GRACE PR, 1995, SOCRATES SOIL ORGANI##GRANT RF, 1994, SOIL SCI SOC AM J, V58, P1681, DOI 10.2136/SSSAJ1994.03615995005800060015X##GRANT RF, 1993, SOIL BIOL BIOCHEM, V25, P1317, DOI 10.1016/0038-0717(93)90046-E##GRANT RF, 2001, SOIL SCI SOC AM J, V65, P205, DOI 10.2136/SSSAJ2001.651205X##GRANT RF, 2001, MODELING CARBON AND NITROGEN DYNAMICS FOR SOIL MANAGEMENT, P173, DOI 10.1201/9781420032635.CH6##HANSEN S., 1990, DAISY SOIL PLANT ATM##HART PBS, 1984, THESIS U READING REA##HENIN S., 1945, ANNALES AGRONOMIQUES, V15, P17##IZAURRALDE RC, 2001, 1 NAT C CARB SEQ ORG##JAIN MC, 2000, NUTR CYCL AGROECOSYS, V58, P75, DOI 10.1023/A:1009882216720##JANSSEN BH, 1984, PLANT SOIL, V76, P297, DOI 10.1007/BF02205588##JANSSEN BH, 1986, VAKBL BIOL, V66, P433##JENKINSON D. S., 1987, INTECOL B, V15, P1##JENKINSON DS, 1990, PHILOS T ROY SOC B, V329, P361, DOI 10.1098/RSTB.1990.0177##JENKINSON DS, 1994, EUR J SOIL SCI, V45, P167, DOI 10.1111/J.1365-2389.1994.TB00498.X##JENKINSON DS, 1977, SOIL SCI, V123, P298, DOI 10.1097/00010694-197705000-00005##JENKINSON DS, 1991, NATURE, V351, P304, DOI 10.1038/351304A0##JENKINSON DS, 1992, SOIL BIOL BIOCHEM, V24, P295, DOI 10.1016/0038-0717(92)90189-5##JUMA NG, 1981, SIMULATION NITROGEN, P145##KARLEN DL, 1996, CROP SCI, V36, P975, DOI 10.2135/CROPSCI1996.0011183X003600040026X##KATTERER T, 2004, NUTR CYCL AGROECOSYS, V70, P179, DOI 10.1023/B:FRES.0000048481.34439.71##KEATING BA, 2003, EUR J AGRON, V18, P267, DOI 10.1016/S1161-0301(02)00108-9##KELLY RH, 1997, GEODERMA, V81, P75, DOI 10.1016/S0016-7061(97)00082-7##KIRSCHBAUM MUF, 2001, NEE WORKSH P, P18##KOLENBRANDER GJ, 1969, BEPALING WAARDE VERS##KORTLEVEN H, 1963, VERSL LANBK ONDERZ, V69##KROES JG, 1998, 46 SCDLO##KRUSEMAN G, 1993, DISENTANGLING CONCEP, V2##LADD J. N., 1988, ADVANCES IN NITROGEN CYCLING IN AGRICULTURAL ECOSYSTEMS, P113##LADD JN, 1995, SOIL BIOL BIOCHEM, V27, P777, DOI 10.1016/0038-0717(94)00243-T##LADHA JK, 2003, FIELD CROP RES, V81, P159, DOI 10.1016/S0378-4290(02)00219-8##LAL R, 2002, LAND DEGRAD DEV, V13, P469, DOI 10.1002/LDR.531##LI C., 1995, SOIL MANAGEMENT GREE, P101##LI C, 1995, GLOBAL BIOGEOCHEM CY, V10, P297##LI CS, 2003, ECOL APPL, V13, P327, DOI 10.1890/1051-0761(2003)013[0327:MSOCCI]2.0.CO;2##LI CS, 1994, GLOBAL BIOGEOCHEM CY, V8, P237, DOI 10.1029/94GB00767##LIETH H., 1975, PRIMARY PRODUCTIVITY, V8, P237, DOI DOI 10.1007/978-3-642-80913-2_12##MA LW, 2001, MODELING CARBON AND NITROGEN DYNAMICS FOR SOIL MANAGEMENT, P265##MA LW, 2001, MODELING CARBON AND NITROGEN DYNAMICS FOR SOIL MANAGEMENT, P55##MCCOWN RL, 1996, AGR SYST, V50, P255, DOI 10.1016/0308-521X(94)00055-V##MCGECHAN MB, 2001, MODELING CARBON AND NITROGEN DYNAMICS FOR SOIL MANAGEMENT, P103##MCGILL W. B., 1996, NATO ASI SERIES I, P111, DOI [DOI 10.1007/978-3-642-61094-3_9, 10.1007/978-3-642-61094-3_9]##MENGEL K, 1986, FERT RES, V9, P117, DOI 10.1007/BF01048698##MOLINA JAE, 1998, ADV AGRON, V62, P253##MOLINA JAE, 1983, SOIL SCI SOC AM J, V47, P85, DOI 10.2136/SSSAJ1983.03615995004700010017X##MUELLER T, 1996, EVALUATION SOIL ORGA, P275##NARANG RS, 2001, RICE WHEAT CROPPING, V11##NEUE HU, 1990, SOILS GREENHOUSE EFF, P457##NOIJ IGA, 1993, MODELLING NUTR MOIST, V4, P15##OLK DC, 1996, EUR J SOIL SCI, V47, P293, DOI 10.1111/J.1365-2389.1996.TB01403.X##OLSON RV, 1984, SOIL SCI SOC AM J, V48, P583, DOI 10.2136/SSSAJ1984.03615995004800030023X##PARNAS H, 1975, SOIL BIOL BIOCHEM, V7, P161, DOI 10.1016/0038-0717(75)90014-0##PARTON WJ, 1987, SOIL SCI SOC AM J, V51, P1173, DOI 10.2136/SSSAJ1987.03615995005100050015X##PARTON WJ, 1994, SOIL SCI SOC AM J, V58, P530, DOI 10.2136/SSSAJ1994.03615995005800020040X##PARTON WJ, 1988, BIOGEOCHEMISTRY, V5, P109, DOI 10.1007/BF02180320##PAUSTIAN K, 1992, SOIL SCI SOC AM J, V56, P476, DOI 10.2136/SSSAJ1992.03615995005600020023X##PAUSTIAN K., 1994, SOIL BIOTA: MANAGEMENT IN SUSTAINABLE FARMING SYSTEMS., P182##PENNING DE VRIES FWT, 1982, SIMULATION PLANT GRO, P9##POST WM, 2004, BIOSCIENCE, V54, P895, DOI 10.1641/0006-3568(2004)054[0895:EOCSIU]2.0.CO;2##POWLSON D. S., 2000, PROCEEDINGS OF THE WORKSHOP ON CARBON AND NITROGEN DYNAMICS IN FLOODED SOILS, LOS BANOS, PHILIPPINES, 19-22 APRIL 1999, P49##POWLSON DS, 1996, P NATO ADV RES WORKS, V38##PROBERT ME, 1998, AGR SYST, V56, P1, DOI 10.1016/S0308-521X(97)00028-0##RAIJMAKERS WMF, 1995, EVALUATIE METHODEN B, P104##RAM N, 1998, LONG TERM SOIL FERTI, P229##RAM N, 2000, LONG TERM SOIL FERTI, P50##REICHARDT W., 2000, CARBON NITROGEN DYNA, P101##RIJTEMA PE, 1991, FERT RES, V27, P189, DOI 10.1007/BF01051127##SANCHEZ CA, 1988, AGRON J, V80, P102, DOI 10.2134/AGRONJ1988.00021962008000010023X##SASS RL, 2002, P NATL ACAD SCI USA, V99, P11993, DOI 10.1073/PNAS.202483599##SAUERBECK D. R., 1977, SOIL ORGANIC MATTER STUDIES. PROCEEDINGS OF A SYMPOSIUM ORGANIZED BY IAEA, FAO AND AGROCHIMICA. BRAUNSCHWEIG, SEPTEMBER 1976. VOL. I., P159##SELIGMAN N. G., 1981, SIMULATION OF NITROGEN BEHAVIOUR OF SOIL-PLANT SYSTEMS., P192##SIDHU HS, 2011, SOIL SCI SOC AM J, P157##SMITH JU, 1996, AGRON J, V88, P38, DOI 10.2134/AGRONJ1996.00021962008800010008X##SMITH P, 1997, GEODERMA, V81, P1, DOI 10.1016/S0016-7061(97)88180-3##SMITH P, 2000, ADV SOIL S, P341##SPRINGER U., 1952, ZEITSCHR PFLANZENERNAHR DUNG U BODENK, V58, P193, DOI 10.1002/JPLN.19520580302##VAN DER GON HACD, 2002, P NATL ACAD SCI USA, V99, P12021, DOI 10.1073/PNAS.192276599##VAN ITTERSUM MK, 2002, NETH J AGR SCI, V50, P239##VAN ITTERSUM MK, 2003, EUR J AGRON, V18, P187, DOI 10.1016/S1161-0301(02)00095-3##VAN KEULEN H, 2001, NUTR CYCL AGROECOSYS, V61, P33, DOI 10.1023/A:1013372318868##VANDAM D, 1995, ECOL MODEL, V79, P255, DOI 10.1016/0304-3800(94)00184-J##VANKEULEN H, 1982, AGR SYST, V9, P113, DOI 10.1016/0308-521X(82)90026-9##VANKEULEN H, 1986, MODELLING AGR PRODUC, P154##VANVEEN JA, 1981, CAN J SOIL SCI, V61, P185, DOI 10.4141/CJSS81-024##VANVEEN JA, 1984, PLANT SOIL, V76, P257, DOI 10.1007/BF02205585##VANVEEN JA, 1981, SIMULATION NITROGEN, P126##VE NB, 2004, SOIL SCI SOC AM J, V68, P1278, DOI 10.2136/SSSAJ2004.1278##VERBERNE ELJ, 1990, NETH J AGR SCI, V38, P221##WANG ZP, 1993, SOIL SCI SOC AM J, V57, P382, DOI 10.2136/SSSAJ1993.03615995005700020016X##WIENHOLD BJ, 1995, AGRON J, V87, P842, DOI 10.2134/AGRONJ1995.00021962008700050010X##WILLIAMS J. R., 1995, COMPUTER MODELS OF WATERSHED HYDROLOGY., P909##WITT C, 1998, BIOL FERT SOILS, V28, P71, DOI 10.1007/S003740050465##WITT C, 2003, IFA REG C AS PAC CHE##YANG HS, 1996, THESIS WAGENINGEN AG",53,2020-11-20,NA
J,WOS:000243601000024,2006,OXIDATION AND COMPACTION OF A COLLAPSED PEAT DOME IN CENTRAL KALIMANTAN,"PEAT DOMES IN KALIMANTAN (INDONESIA) ARE REPORTED TO LOOSE THEIR DOME SHAPE AS A RESULT OF DISTURBANCE SUCH AS LOGGING AND ARTIFICIAL DRAINAGE. THE LOSS OF THE DOME SHAPE CAN BE CAUSED BY (A COMBINATION OF) TWO MAJOR PROCESSES: COMPACTION AND OXIDATION. BECAUSE NATURAL, UNDISTURBED PEAT IS A MAJOR SINK FOR ATMOSPHERIC CO2, THE DISTINCTION BETWEEN THE TWO PROCESSES IS OF UTMOST IMPORTANCE WITH REGARD TO CARBON STORAGE. IN CASE OF COMPACTION, NO CO2 NEED TO BE LOST TO THE ATMOSPHERE. IN CASE OF OXIDATION, EITHER AS A RESULT OF INCREASED DECOMPOSITION UPON IMPROVED DRAINAGE OR BY BURNING, ALL CO PRODUCED GOES TO THE ATMOSPHERE. TO ESTIMATE THE CONTRIBUTION OF OXIDATION AND COMPACTION TO THE LOSS OF PEAT DOME SHAPE, RESEARCH WAS CONDUCTED IN THE MAWAS AREA IN CENTRAL KALIMANTAN. PHYSICAL AND CHEMICAL PARAMETERS OF AN INTACT AND COLLAPSED DOME WERE COMPARED. INCREASED BULK DENSITIES IN THE COLLAPSED PEAT DOME SHOWED THAT CONSIDERABLE COMPACTION HAS OCCURRED. DEPENDING ON THE INITIAL BULK DENSITY, COMPACTION HAS PROBABLY CAUSED A SUBSIDENCE FROM 2.2 TO 4.0 IN. ACCORDING TO ASH CONTENT MEASUREMENTS, NO SIGNIFICANT OXIDATION HAS TAKEN PLACE, BUT INCREASED EC FOUND AT THE COLLAPSED DOME CAN BE DUE TO OXIDATION OF AT LEAST 2.3 CUR TO 46.9 CM PEAT, WHICH IMPLIES AN EMISSION OF RESPECTIVELY 4.2 TO 85.9 KG CO2 M(-2) OVER THE 6 YEARS SINCE COLLAPSE. COMPACTION APPEARED TO BE A MORE IMPORTANT FACTOR IN THE LOSS OF DOME STRUCTURE THAN OXIDATION BASED ON THE ESTIMATED POSSIBLE RANGES IN PEAT LOSS. COLLAPSE OF THE DOME HAD ONLY MINOR INFLUENCE ON ITS CHEMICAL PARAMETERS. REGROWTH DID NOT SEEM TO BE HINDERED BY THE COLLAPSE AND ITS CONSEQUENCES, BUT IT WAS LESS AT SITES THAT HAD SUFFERED RECENT FIRES. IF PEAT GROWTH RESUMES, COLLAPSE NEED NOT BE DETRIMENTAL TO CARBON STORAGE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NA,TROPICAL PEAT; OXIDATION; COMPACTION; PEAT DOME COLLAPSE; BULK DENSITY,GEODERMA,"KOOL, DM##BUURMAN, P##HOEKMAN, DH","UNIV WAGENINGEN & RES CTR, DEPT ENVIRONM SCI, NL-6700 AA WAGENINGEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, DEPT ENVIRONM SCI, WAGENINGEN, NETHERLANDS.",SOIL SCIENCE,AGRICULTURE,"BELLAMY DJ, 1997, BIODIVERSITY SUSTAIN, P19##*IGBP WETL INT, 2003, WETL INT NETH GLOB E##MISRA MK, 1993, BIOMASS BIOENERG, V4, P103, DOI 10.1016/0961-9534(93)90032-Y##RIELEY J. O., 1996, TROPICAL LOWLAND PEATLANDS OF SOUTHEAST ASIA. PROCEEDINGS OF A WORKSHOP ON INTEGRATED PLANNING AND MANAGEMENT OF TROPICAL LOWLAND PEATLANDS, CISARUA, INDONESIA, 3-8 JULY 1992., P17##SIEGERT F., 2002, PEATLANDS PEOPLE NAT, P142##WOSTEN JHM, 1997, GEODERMA, V78, P25, DOI 10.1016/S0016-7061(97)00013-X##WOSTEN JHM, 2002, PEATLANDS PEOPLE NAT, P51",37,2020-11-20,NA
J,WOS:000243167300010,2006,"MEASUREMENTS OF BRANCHING FRACTION, POLARIZATION, AND CHARGE ASYMMETRY OF B-+/-->RHO(+/-)F(0) AND A SEARCH FOR B-+/-->RHO(+/-)F(0)(980)","WE MEASURE THE BRANCHING FRACTION (B), POLARIZATION (F(L)), AND CP ASYMMETRY (A(CP)) OF B-+/-->RHO(+/-)RHO(0) DECAYS AND SEARCH FOR THE DECAY B-+/-->RHO(+/-)F(0)(980) BASED ON A DATA SAMPLE OF 231.8X10(6) UPSILON(4S)-> B (B) OVER BAR DECAYS COLLECTED WITH THE BABAR DETECTOR AT THE SLAC PEP-II ASYMMETRIC-ENERGY B FACTORY. IN B-+/-->RHO(+/-)RHO(0) DECAYS WE MEASURE B=(16.8 +/- 2.2 +/- 2.3)X10(-6), F(L)=0.905 +/- 0.042(-0.027)(+0.023), AND A(CP)=-0.12 +/- 0.13 +/- 0.10, AND FIND AN UPPER LIMIT ON THE BRANCHING FRACTION OF B-+/-->RHO(+/-)F(0)(980)(->PI(+)PI(-)) DECAYS OF 1.9X10(-6) AT 90% CONFIDENCE LEVEL.",CP-ASYMMETRIES,NA,PHYSICAL REVIEW LETTERS,"AUBERT, B##BONA, M##BOUTIGNY, D##COUDERC, F##KARYOTAKIS, Y##LEES, JP##POIREAU, V##TISSERAND, V##ZGHICHE, A##GRAUGES, E##PALANO, A##CHEN, JC##QI, ND##RONG, G##WANG, P##ZHU, YS##EIGEN, G##OFTE, I##STUGU, B##ABRAMS, GS##BATTAGLIA, M##BROWN, DN##BUTTON-SHAFER, J##CAHN, RN##CHARLES, E##GILL, MS##GROYSMAN, Y##JACOBSEN, RG##KADYK, JA##KERTH, LT##KOLOMENSKY, YG##KUKARTSEV, G##LYNCH, G##MIR, LM##ORIMOTO, TJ##PRIPSTEIN, M##ROE, NA##RONAN, MT##WENZEL, WA##SANCHEZ, PDA##BARRETT, M##FORD, KE##HARRISON, TJ##HART, AJ##HAWKES, CM##WATSON, AT##HELD, T##KOCH, H##LEWANDOWSKI, B##PELIZAEUS, M##PETERS, K##SCHROEDER, T##STEINKE, M##BOYD, JT##BURKE, JP##COTTINGHAM, WN##WALKER, D##ASGEIRSSON, DJ##CUHADAR-DONSZELMANN, T##FULSOM, BG##HEARTY, C##KNECHT, NS##MATTISON, TS##MCKENNA, JA##KHAN, A##KYBERD, P##SALEEM, M##SHERWOOD, DJ##TEODORESCU, L##BLINOV, VE##BUKIN, AD##DRUZHININ, VP##GOLUBEV, VB##ONUCHIN, AP##SEREDNYAKOV, SI##SKOVPEN, YI##SOLODOV, EP##TODYSHEV, KY##BONDIOLI, M##BRUINSMA, M##CHAO, M##CURRY, S##ESCHRICH, I##KIRKBY, D##LANKFORD, AJ##LUND, P##MANDELKERN, M##MOMMSEN, RK##ROETHEL, W##STOKER, DP##ABACHI, S##BUCHANAN, C##FOULKES, SD##GARY, JW##LONG, O##SHEN, BC##WANG, K##ZHANG, L##HADAVAND, HK##HILL, EJ##PAAR, HP##RAHATLOU, S##SHARMA, V##BERRYHILL, JW##CAMPAGNARI, C##CUNHA, A##DAHMES, B##HONG, TM##KOVALSKYI, D##RICHMAN, JD##BECK, TW##EISNER, AM##FLACCO, CJ##HEUSCH, CA##KROSEBERG, J##LOCKMAN, WS##NESOM, G##SCHALK, T##SCHUMM, BA##SEIDEN, A##SPRADLIN, P##WILLIAMS, DC##WILSON, MG##ALBERT, J##CHEN, E##DVORETSKII, A##FANG, F##HITLIN, DG##NARSKY, I##PIATENKO, T##PORTER, FC##RYD, A##MANCINELLI, G##MEADOWS, BT##MISHRA, K##SOKOLOFF, MD##BLANC, F##BLOOM, PC##CHEN, S##FORD, WT##HIRSCHAUER, JF##KREISEL, A##NAGEL, M##NAUENBERG, U##OLIVAS, A##RUDDICK, WO##SMITH, JG##ULMER, KA##WAGNER, SR##ZHANG, J##CHEN, A##ECKHART, EA##SOFFER, A##TOKI, WH##WILSON, RJ##WINKLMEIER, F##ZENG, Q##ALTENBURG, DD##FELTRESI, E##HAUKE, A##JASPER, H##MERKEL, J##PETZOLD, A##SPAAN, B##BRANDT, T##KLOSE, V##LACKER, HM##MADER, WF##NOGOWSKI, R##SCHUBERT, J##SCHUBERT, KR##SCHWIERZ, R##SUNDERMANN, JE##VOLK, A##BERNARD, D##BONNEAUD, GR##LATOUR, E##THIEBAUX, C##VERDERI, M##CLARK, PJ##GRADL, W##MUHEIM, F##PLAYFER, S##ROBERTSON, AI##XIE, Y##ANDREOTTI, M##BETTONI, D##BOZZI, C##CALABRESE, R##CIBINETTO, G##LUPPI, E##NEGRINI, M##PETRELLA, A##PIEMONTESE, L##PRENCIPE, E##ANULLI, F##BALDINI-FERROLI, R##CALCATERRA, A##DE SANGRO, R##FINOCCHIARO, G##PACETTI, S##PATTERI, P##PERUZZI, IM##PICCOLO, M##RAMA, M##ZALLO, A##BUZZO, A##CONTRI, R##LO VETERE, M##MACRI, MM##PASSAGGIO, S##PATRIGNANI, C##ROBUTTI, E##SANTRONI, A##TOSI, S##BRANDENBURG, G##CHAISANGUANTHUM, KS##MORII, M##WU, J##DUBITZKY, RS##MARKS, J##SCHENK, S##UWER, U##BARD, DJ##BHIMJI, W##BOWERMAN, DA##DAUNCEY, PD##EGEDE, U##FLACK, RL##NASH, JA##NIKOLICH, MB##VAZQUEZ, WP##BEHERA, PK##CHAI, X##CHARLES, MJ##MALLIK, U##MEYER, NT##ZIEGLER, V##COCHRAN, J##CRAWLEY, HB##DONG, L##EYGES, V##MEYER, WT##PRELL, S##ROSENBERG, EI##RUBIN, AE##GRITSAN, AV##DENIG, AG##FRITSCH, M##SCHOTT, G##ARNAUD, N##DAVIER, M##GROSDIDIER, G##HOCKER, A##LE DIBERDER, F##LEPELTIER, V##LUTZ, AM##OYANGUREN, A##PRUVOT, S##RODIER, S##ROUDEAU, P##SCHUNE, MH##STOCCHI, A##WANG, WF##WORMSER, G##CHENG, CH##LANGE, DJ##WRIGHT, DM##CHAVEZ, CA##FORSTER, IJ##FRY, JR##GABATHULER, E##GAMET, R##GEORGE, KA##HUTCHCROFT, DE##PAYNE, DJ##SCHOFIELD, KC##TOURAMANIS, C##BEVAN, AJ##DI LODOVICO, F##MENGES, W##SACCO, R##COWAN, G##FLAECHER, HU##HOPKINS, DA##JACKSON, PS##MCMAHON, TR##RICCIARDI, S##SALVATORE, F##WREN, AC##BROWN, DN##DAVIS, CL##ALLISON, J##BARLOW, NR##BARLOW, RJ##CHIA, YM##EDGAR, CL##LAFFERTY, GD##NAISBIT, MT##WILLIAMS, JC##YI, JI##CHEN, C##HULSBERGEN, WD##JAWAHERY, A##LAE, CK##ROBERTS, DA##SIMI, G##BLAYLOCK, G##DALLAPICCOLA, C##HERTZBACH, SS##LI, X##MOORE, TB##SAREMI, S##STAENGLE, H##COWAN, R##SCIOLLA, G##SEKULA, SJ##SPITZNAGEL, M##TAYLOR, F##YAMAMOTO, RK##KIM, H##MCLACHLIN, SE##PATEL, PM##ROBERTSON, SH##LAZZARO, A##LOMBARDO, V##PALOMBO, F##BAUER, JM##CREMALDI, L##ESCHENBURG, V##GODANG, R##KROEGER, R##SANDERS, DA##SUMMERS, DJ##ZHAO, HW##BRUNET, S##COTE, D##SIMARD, M##TARAS, P##VIAUD, FB##NICHOLSON, H##CAVALLO, N##DE NARDO, G##FABOZZI, F##GATTO, C##LISTA, L##MONORCHIO, D##PAOLUCCI, P##PICCOLO, D##SCIACCA, C##BAAK, MA##RAVEN, G##SNOEK, HL##JESSOP, CP##LOSECCO, JM##ALLMENDINGER, T##BENELLI, G##CORWIN, LA##GAN, KK##HONSCHEID, K##HUFNAGEL, D##JACKSON, PD##KAGAN, H##KASS, R##RAHIMI, AM##REGENSBURGER, JJ##TER-ANTONYAN, R##WONG, QK##BLOUNT, NL##BRAU, J##FREY, R##IGONKINA, O##KOLB, JA##LU, M##RAHMAT, R##SINEV, NB##STROM, D##STRUBE, J##TORRENCE, E##GAZ, A##MARGONI, M##MORANDIN, M##POMPILI, A##POSOCCO, M##ROTONDO, M##SIMONETTO, F##STROILI, R##VOCI, C##BENAYOUN, M##BRIAND, H##CHAUVEAU, J##DAVID, P##DEL BUONO, L##DE LA VAISSIERE, C##HAMON, O##HARTFIEL, BL##LERUSTE, P##MALCLES, J##OCARIZ, J##ROOS, L##THERIN, G##GLADNEY, L##BIASINI, M##COVARELLI, R##ANGELINI, C##BATIGNANI, G##BETTARINI, S##BUCCI, F##CALDERINI, G##CARPINELLI, M##CENCI, R##FORTI, F##GIORGI, MA##LUSIANI, A##MARCHIORI, G##MAZUR, MA##MORGANTI, M##NERI, N##PAOLONI, E##RIZZO, G##WALSH, JJ##HAIRE, M##JUDD, D##WAGONER, DE##BIESIADA, J##DANIELSON, N##ELMER, P##LAU, YP##LU, C##OLSEN, J##SMITH, AJS##TELNOV, AV##BELLINI, F##CAVOTO, G##D'ORAZIO, A##DEL RE, D##DI MARCO, E##FACCINI, R##FERRAROTTO, F##FERRONI, F##GASPERO, M##GIOI, LL##MAZZONI, MA##MORGANTI, S##PIREDDA, G##POLCI, F##TEHRANI, FS##VOENA, C##EBERT, M##SCHRODER, H##WALDI, R##ADYE, T##DE GROOT, N##FRANEK, B##OLAIYA, EO##WILSON, FF##ALEKSAN, R##EMERY, S##GAIDOT, A##GANZHUR, SF##DE MONCHENAULT, GH##KOZANECKI, W##LEGENDRE, M##VASSEUR, G##YECHE, C##ZITO, M##CHEN, XR##LIU, H##PARK, W##PUROHIT, MV##WILSON, JR##ALLEN, MT##ASTON, D##BARTOLDUS, R##BECHTLE, P##BERGER, N##CLAUS, R##COLEMAN, JP##CONVERY, MR##CRISTINZIANI, M##DINGFELDER, JC##DORFAN, J##DUBOIS-FELSMANN, GP##DUJMIC, D##DUNWOODIE, W##FIELD, RC##GLANZMAN, T##GOWDY, SJ##GRAHAM, MT##GRENIER, P##HALYO, V##HAST, C##HRYN'OVA, T##INNES, WR##KELSEY, MH##KIM, P##LEITH, DWGS##LI, S##LUITZ, S##LUTH, V##LYNCH, HL##MACFARLANE, DB##MARSISKE, H##MESSNER, R##MULLER, DR##O'GRADY, CP##OZCAN, VE##PERAZZO, A##PERL, M##PULLIAM, T##RATCLIFF, BN##ROODMAN, A##SALNIKOV, AA##SCHINDLER, RH##SCHWIENING, J##SNYDER, A##STELZER, J##SU, D##SULLIVAN, MK##SUZUKI, K##SWAIN, SK##THOMPSON, JM##VA'VRA, J##VAN BAKEL, N##WEAVER, M##WEINSTEIN, AJR##WISNIEWSKI, WJ##WITTGEN, M##WRIGHT, DH##YARRITU, AK##YI, K##YOUNG, CC##BURCHAT, PR##EDWARDS, AJ##MAJEWSKI, SA##PETERSEN, BA##ROAT, C##WILDEN, L##AHMED, S##ALAM, MS##BULA, R##ERNST, JA##JAIN, V##PAN, B##SAEED, MA##WAPPLER, FR##ZAIN, SB##BUGG, W##KRISHNAMURTHY, M##SPANIER, SM##ECKMANN, R##RITCHIE, JL##SATPATHY, A##SCHILLING, CJ##SCHWITTERS, RF##IZEN, JM##LOU, XC##YE, S##BIANCHI, F##GALLO, F##GAMBA, D##BOMBEN, M##BOSISIO, L##CARTARO, C##COSSUTTI, F##DELLA RICCA, G##DITTONGO, S##LANCERI, L##VITALE, L##AZZOLINI, V##LOPEZ-MARCH, N##MARTINEZ-VIDAL, F##BANERJEE, S##BHUYAN, B##BROWN, CM##FORTIN, D##HAMANO, K##KOWALEWSKI, R##NUGENT, IM##RONEY, JM##SOBIE, RJ##BACK, JJ##HARRISON, PF##LATHAM, TE##MOHANTY, GB##PAPPAGALLO, M##BAND, HR##CHEN, X##CHENG, B##DASU, S##DATTA, M##FLOOD, KT##HOLLAR, JJ##KUTTER, PE##MELLADO, B##MIHALYI, A##PAN, Y##PIERINI, M##PREPOST, R##WU, SL##YU, Z##NEAL, H","CNRS, IN2P3, PHYS PARTICULES LAB, F-74941 ANNECY LE VIEUX, FRANCE. UNIV SAVOIE, F-74941 ANNECY LE VIEUX, FRANCE. UNIV BARCELONA, FAC FIS, DEPT ECM, E-08028 BARCELONA, SPAIN. UNIV BARI, DIPARTMENTO FIS, I-70126 BARI, ITALY. IST NAZL FIS NUCL, I-70126 BARI, ITALY. INST HIGH ENERGY PHYS, BEIJING 100039, PEOPLES R CHINA. UNIV BERGEN, INST PHYS, N-5007 BERGEN, NORWAY. UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA. UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. RUHR UNIV BOCHUM, INST EXPT PHYS, D-44780 BOCHUM, GERMANY. UNIV BRISTOL, BRISTOL BS8 1TL, AVON, ENGLAND. UNIV BRITISH COLUMBIA, VANCOUVER, BC V6T 1Z1, CANADA. BRUNEL UNIV, UXBRIDGE UB8 3PH, MIDDX, ENGLAND. BUDKER INST NUCL PHYS, NOVOSIBIRSK 630090, RUSSIA. UNIV CALIF IRVINE, IRVINE, CA 92697 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA. UNIV CALIF SANTA BARBARA, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA CRUZ, INST PARTICLE PHYS, SANTA CRUZ, CA 95064 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CINCINNATI, CINCINNATI, OH 45221 USA. UNIV COLORADO, BOULDER, CO 80309 USA. COLORADO STATE UNIV, FT COLLINS, CO 80523 USA. UNIV DORTMUND, INST PHYS, D-44221 DORTMUND, GERMANY. TECH UNIV DRESDEN, INST KERN & TEILCHENPHYS, D-01062 DRESDEN, GERMANY. ECOLE POLYTECH, CNRS, IN2P3, LAB LEPRINCE RINGUET, F-91128 PALAISEAU, FRANCE. UNIV EDINBURGH, EDINBURGH EH9 3JZ, MIDLOTHIAN, SCOTLAND. UNIV FERRARA, DIPARTMENTO FIS, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, LAB NAZL FRASCATI, I-00044 FRASCATI, ITALY. UNIV GENOA, DIPARTIMENTO FIS, I-16146 GENOA, ITALY. IST NAZL FIS NUCL, I-16146 GENOA, ITALY. HARVARD UNIV, CAMBRIDGE, MA 02138 USA. HEIDELBERG UNIV, INST PHYS, D-69120 HEIDELBERG, GERMANY. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AZ, ENGLAND. UNIV IOWA, IOWA CITY, IA 52242 USA. IOWA STATE UNIV, AMES, IA 50011 USA. JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA. UNIV KARLSRUHE, INST EXPT KERNPHYS, D-76021 KARLSRUHE, GERMANY. CNRS, IN2P3, ACCELERATEUR LINEAIRE LAB, F-91898 ORSAY, FRANCE. UNIV PARIS 11, CTR SCI, F-91898 ORSAY, FRANCE. LAWRENCE LIVERMORE NATL LAB, LIVERMORE, CA 94550 USA. UNIV LIVERPOOL, LIVERPOOL L69 7ZE, MERSEYSIDE, ENGLAND. UNIV LONDON, LONDON E1 4NS, ENGLAND. UNIV LONDON ROYAL HOLLOWAY & BEDFORD NEW COLL, EGHAM TW10 0EX, SURREY, ENGLAND. UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA. UNIV MANCHESTER, MANCHESTER M13 9PL, LANCS, ENGLAND. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. UNIV MASSACHUSETTS, AMHERST, MA 01003 USA. MIT, NUCL SCI LAB, CAMBRIDGE, MA 02139 USA. MCGILL UNIV, MONTREAL, PQ H3A 2T8, CANADA. UNIV MILAN, DIPARTIMENTO FIS, I-20133 MILAN, ITALY. IST NAZL FIS NUCL, I-20133 MILAN, ITALY. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV MONTREAL, MONTREAL, PQ H3C 3J7, CANADA. MT HOLYOKE COLL, S HADLEY, MA 01075 USA. UNIV NAPLES FEDERICO II, DIPARTIMENTO SCI FISICHE, I-80126 NAPLES, ITALY. IST NAZL FIS NUCL, I-80126 NAPLES, ITALY. NATL INST NUCL & HIGH ENERGY PHYS, NIKHEF, NL-1009 DB AMSTERDAM, NETHERLANDS. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. UNIV OREGON, EUGENE, OR 97403 USA. UNIV PADUA, DIPARTIMENTO FIS, I-35131 PADUA, ITALY. IST NAZL FIS NUCL, I-35131 PADUA, ITALY. UNIV PARIS 07, F-75252 PARIS, FRANCE. UNIV PARIS 06, CNRS, IN2P3, LAB PHYS NUCL & HAUTES ENERGIES, F-75252 PARIS, FRANCE. UNIV PENN, PHILADELPHIA, PA 19104 USA. UNIV PERUGIA, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. IST NAZL FIS NUCL, I-06100 PERUGIA, ITALY. UNIV PISA, DIPARTIMENTO FIS, SCUOLA NORMALE SUPER PISA, I-56127 PISA, ITALY. IST NAZL FIS NUCL, I-56127 PISA, ITALY. PRAIRIE VIEW A&M UNIV, PRAIRIE VIEW, TX 77446 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. UNIV ROMA LA SAPIENZA, DIPARTIMENTO FIS, I-00185 ROME, ITALY. IST NAZL FIS NUCL, I-00185 ROME, ITALY. UNIV ROSTOCK, D-18051 ROSTOCK, GERMANY. RUTHERFORD APPLETON LAB, DIDCOT OX11 0QX, OXON, ENGLAND. CEA SACLAY, DSM DAPNIA, F-91191 GIF SUR YVETTE, FRANCE. UNIV S CAROLINA, COLUMBIA, SC 29208 USA. STANFORD LINEAR ACCELERATOR CTR, STANFORD, CA 94309 USA. STANFORD UNIV, STANFORD, CA 94305 USA. SUNY ALBANY, ALBANY, NY 12222 USA. UNIV TENNESSEE, KNOXVILLE, TN 37996 USA. UNIV TEXAS, AUSTIN, TX 78712 USA. UNIV TEXAS, RICHARDSON, TX 75083 USA. UNIV TURIN, DIPARTIMENTO FIS SPERIMENTALE, I-10125 TURIN, ITALY. IST NAZL FIS NUCL, I-10125 TURIN, ITALY. UNIV TRIESTE, DIPARTMENTO FIS, I-34127 TRIESTE, ITALY. IST NAZL FIS NUCL, I-34127 TRIESTE, ITALY. UNIV VALENCIA, CSIC, IFIC, E-46071 VALENCIA, SPAIN. UNIV VICTORIA, VICTORIA, BC V8W 3P6, CANADA. UNIV WARWICK, DEPT PHYS, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND. UNIV WISCONSIN, MADISON, WI 53706 USA. YALE UNIV, NEW HAVEN, CT 06511 USA.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"AITALA EM, 2001, PHYS REV LETT, V86, P765, DOI 10.1103/PHYSREVLETT.86.765##AUBERT B, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.051802##AUBERT B, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.131801##AUBERT B, 2004, PHYS REV D, V70, DOI [10.1103/PHYSREVD.70.032006, 10.1103/PHYSREVD.70.091103]##AUBERT B, 2005, PHYS REV LETT, V95, DOI [10.1103/PHYSREVLETT.95.041805, 10.1103/PHYSREVD.73.012006]##AUBERT B, 2003, PHYS REV LETT, V91, DOI [10.1103/PHYSREVLETT.91.201802, 10.1103/PHYSREVLETT.91.171802]##AUBERT B, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.281802##AUBERT B, 2002, NUCL INSTRUM METH A, V479, P1, DOI 10.1016/S0168-9002(01)02012-5##AUBERT B, 2006, PHYS REV D, V74, DOI 10.1103/PHYSREVD.74.031104##CABIBBO N, 1963, PHYS REV LETT, V10, P531, DOI 10.1103/PHYSREVLETT.10.531##CRANMER K, 2001, COMPUT PHYS COMMUN, V136, P198, DOI 10.1016/S0010-4655(00)00243-5##EIDELMAN S, 2004, PHYS LETT B, V592, P1, DOI 10.1016/J.PHYSLETB.2004.06.001##GRONAU M, 1990, PHYS REV LETT, V65, P3381, DOI 10.1103/PHYSREVLETT.65.3381##*HFAG, HEPEX0603003##JARLSKOG C, 1985, PHYS REV LETT, V55, P1039, DOI 10.1103/PHYSREVLETT.55.1039##KOBAYASHI M, 1973, PROG THEOR PHYS, V49, P652, DOI 10.1143/PTP.49.652##KRAMER G, 1992, PHYS REV D, V45, P193, DOI 10.1103/PHYSREVD.45.193##SOMOV A, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.171801##ZHANG J, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.221801",25,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/E000444/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000243167300012,2006,OBSERVATION OF B+->PHI PHI K+ AND EVIDENCE FOR B-0 ->PHI PHI K-0 BELOW ETA(C) THRESHOLD,WE REPORT MEASUREMENTS OF THE DECAYS B+->PHI PHI K+ AND B-0 ->PHI PHI K-0 USING A SAMPLE OF 231X10(6) B (B) OVER BAR PAIRS COLLECTED WITH THE BABAR DETECTOR AT THE PEP-II ASYMMETRIC-ENERGY B FACTORY AT THE STANFORD LINEAR ACCELERATOR CENTER. THE BRANCHING FRACTIONS ARE MEASURED TO BE B(B+->PHI PHI K+)=(7.5 +/- 1.0(STAT)+/- 0.7(SYST))X10(-6) AND B(B-0 ->PHI PHI K-0)=(4.1(-1.4)(+1.7)(STAT)+/- 0.4(SYST))X10(-6) FOR A PHI PHI INVARIANT MASS BELOW 2.85 GEV/C(2).,SEARCH; DECAYS; PHYSICS,NA,PHYSICAL REVIEW LETTERS,"AUBERT, B##BONA, M##BOUTIGNY, D##COUDERC, F##KARYOTAKIS, Y##LEES, JP##POIREAU, V##TISSERAND, V##ZGHICHE, A##GRAUGES, E##PALANO, A##CHEN, JC##QI, ND##RONG, G##WANG, P##ZHU, YS##EIGEN, G##OFTE, I##STUGU, B##ABRAMS, GS##BATTAGLIA, M##BROWN, DN##BUTTON-SHAFER, J##CAHN, RN##CHARLES, E##GILL, MS##GROYSMAN, Y##JACOBSEN, RG##KADYK, JA##KERTH, LT##KOLOMENSKY, YG##KUKARTSEV, G##LYNCH, G##MIR, LM##ORIMOTO, TJ##PRIPSTEIN, M##ROE, NA##RONAN, MT##WENZEL, WA##SANCHEZ, PD##BARRETT, M##FORD, KE##HART, AJ##HARRISON, TJ##HAWKES, CM##WATSON, AT##HELD, T##KOCH, H##LEWANDOWSKI, B##PELIZAEUS, M##PETERS, K##SCHROEDER, T##STEINKE, M##BOYD, JT##BURKE, JP##COTTINGHAM, WN##WALKER, D##ASGEIRSSON, DJ##CUHADAR-DONSZELMANN, T##FULSOM, BG##HEARTY, C##KNECHT, NS##MATTISON, TS##MCKENNA, JA##KHAN, A##KYBERD, P##SALEEM, M##SHERWOOD, DJ##TEODORESCU, L##BLINOV, VE##BUKIN, AD##DRUZHININ, VP##GOLUBEV, VB##ONUCHIN, AP##SEREDNYAKOV, SI##SKOVPEN, YI##SOLODOV, EP##TODYSHEV, KY##BONDIOLI, M##BRUINSMA, M##CHAO, M##CURRY, S##ESCHRICH, I##KIRKBY, D##LANKFORD, AJ##LUND, P##MANDELKERN, M##MOMMSEN, RK##ROETHEL, W##STOKER, DP##ABACHI, S##BUCHANAN, C##FOULKES, SD##GARY, JW##LONG, O##SHEN, BC##WANG, K##ZHANG, L##HADAVAND, HK##HILL, EJ##PAAR, HP##RAHATLOU, S##SHARMA, V##BERRYHILL, JW##CAMPAGNARI, C##CUNHA, A##DAHMES, B##HONG, TM##KOVALSKYI, D##RICHMAN, JD##BECK, TW##EISNER, AM##FLACCO, CJ##HEUSCH, CA##KROSEBERG, J##LOCKMAN, WS##NESOM, G##SCHALK, T##SCHUMM, BA##SEIDEN, A##SPRADLIN, P##WILLIAMS, DC##WILSON, MG##ALBERT, J##CHEN, E##DVORETSKII, A##FANG, F##HITLIN, DG##NARSKY, I##PIATENKO, T##PORTER, FC##RYD, A##MANCINELLI, G##MEADOWS, BT##MISHRA, K##SOKOLOFF, MD##BLANC, F##BLOOM, PC##CHEN, S##FORD, WT##HIRSCHAUER, JF##KREISEL, A##NAGEL, M##NAUENBERG, U##OLIVAS, A##RUDDICK, WO##SMITH, JG##ULMER, KA##WAGNER, SR##ZHANG, J##CHEN, A##ECKHART, EA##SOFFER, A##TOKI, WH##WILSON, RJ##WINKLMEIER, F##ZENG, Q##ALTENBURG, DD##FELTRESI, E##HAUKE, A##JASPER, H##MERKEL, J##PETZOLD, A##SPAAN, B##BRANDT, T##KLOSE, V##LACKER, HM##MADER, WF##NOGOWSKI, R##SCHUBERT, J##SCHUBERT, KR##SCHWIERZ, R##SUNDERMANN, JE##VOLK, A##BERNARD, D##BONNEAUD, GR##LATOUR, E##THIEBAUX, C##VERDERI, M##CLARK, PJ##GRADL, W##MUHEIM, F##PLAYFER, S##ROBERTSON, AI##XIE, Y##ANDREOTTI, M##BETTONI, D##BOZZI, C##CALABRESE, R##CIBINETTO, G##LUPPI, E##NEGRINI, M##PETRELLA, A##PIEMONTESE, L##PRENCIPE, E##ANULLI, F##BALDINI-FERROLI, R##CALCATERRA, A##DE SANGRO, R##FINOCCHIARO, G##PACETTI, S##PATTERI, P##PERUZZI, IM##PICCOLO, M##RAMA, M##ZALLO, A##BUZZO, A##CONTRI, R##LO VETERE, M##MACRI, MM##MONGE, MR##PASSAGGIO, S##PATRIGNANI, C##ROBUTTI, E##SANTRONI, A##TOSI, S##BRANDENBURG, G##CHAISANGUANTHUM, KS##MORII, M##WU, J##DUBITZKY, RS##MARKS, J##SCHENK, S##UWER, U##BHIMJI, W##BOWERMAN, DA##DAUNCEY, PD##EGEDE, U##FLACK, RL##NASH, JA##NIKOLICH, MB##VAZQUEZ, WP##BARD, DJ##BEHERA, PK##CHAI, X##CHARLES, MJ##MALLIK, U##MEYER, NT##ZIEGLER, V##COCHRAN, J##CRAWLEY, HB##DONG, L##EYGES, V##MEYER, WT##PRELL, S##ROSENBERG, EI##RUBIN, AE##GRITSAN, AV##DENIG, AG##FRITSCH, M##SCHOTT, G##ARNAUD, N##DAVIER, M##GROSDIDIER, G##HOCKER, A##LE DIBERDER, F##LEPELTIER, V##LUTZ, AM##OYANGUREN, A##PRUVOT, S##RODIER, S##ROUDEAU, P##SCHUNE, MH##STOCCHI, A##WANG, WF##WORMSER, G##CHENG, CH##LANGE, DJ##WRIGHT, DM##CHAVEZ, CA##FORSTER, IJ##FRY, JR##GABATHULER, E##GAMET, R##GEORGE, KA##HUTCHCROFT, DE##PAYNE, DJ##SCHOFIELD, KC##TOURAMANIS, C##BEVAN, AJ##DI LODOVICO, F##MENGES, W##SACCO, R##COWAN, G##FLAECHER, HU##HOPKINS, DA##JACKSON, PS##MCMAHON, TR##RICCIARDI, S##SALVATORE, F##WREN, AC##BROWN, DN##DAVIS, CL##ALLISON, J##BARLOW, NR##BARLOW, RJ##CHIA, YM##EDGAR, CL##LAFFERTY, GD##NAISBIT, MT##WILLIAMS, JC##YI, JI##CHEN, C##HULSBERGEN, WD##JAWAHERY, A##LAE, CK##ROBERTS, DA##SIMI, G##BLAYLOCK, G##DALLAPICCOLA, C##HERTZBACH, SS##LI, X##MOORE, TB##SAREMI, S##STAENGLE, H##COWAN, R##SCIOLLA, G##SEKULA, SJ##SPITZNAGEL, M##TAYLOR, F##YAMAMOTO, RK##KIM, H##MCLACHLIN, SE##PATEL, PM##ROBERTSON, SH##LAZZARO, A##LOMBARDO, V##PALOMBO, F##BAUER, JM##CREMALDI, L##ESCHENBURG, V##GODANG, R##KROEGER, R##SANDERS, DA##SUMMERS, DJ##ZHAO, HW##BRUNET, S##COTE, D##SIMARD, M##TARAS, P##VIAUD, FB##NICHOLSON, H##CAVALLO, N##DE NARDO, G##FABOZZI, F##GATTO, C##LISTA, L##MONORCHIO, D##PAOLUCCI, P##PICCOLO, D##SCIACCA, C##BAAK, MA##RAVEN, G##SNOEK, HL##JESSOP, CP##LOSECCO, JM##ALLMENDINGER, T##BENELLI, G##CORWIN, LA##GAN, KK##HONSCHEID, K##HUFNAGEL, D##JACKSON, PD##KAGAN, H##KASS, R##RAHIMI, AM##REGENSBURGER, JJ##TER-ANTONYAN, R##WONG, QK##BLOUNT, NL##BRAU, J##FREY, R##IGONKINA, O##KOLB, JA##LU, M##RAHMAT, R##SINEV, NB##STROM, D##STRUBE, J##TORRENCE, E##GAZ, A##MARGONI, M##MORANDIN, M##POMPILI, A##POSOCCO, M##ROTONDO, M##SIMONETTO, F##STROILI, R##VOCI, C##BENAYOUN, M##BRIAND, H##CHAUVEAU, J##DAVID, P##DEL BUONO, L##DE LA VAISSIERE, C##HAMON, O##HARTFIEL, BL##LERUSTE, P##MALCLES, J##OCARIZ, J##ROOS, L##THERIN, G##GLADNEY, L##BIASINI, M##COVARELLI, R##ANGELINI, C##BATIGNANI, G##BETTARINI, S##BUCCI, F##CALDERINI, G##CARPINELLI, M##CENCI, R##FORTI, F##GIORGI, MA##LUSIANI, A##MARCHIORI, G##MAZUR, MA##MORGANTI, M##NERI, N##PAOLONI, E##RIZZO, G##WALSH, JJ##HAIRE, M##JUDD, D##WAGONER, DE##BIESIADA, J##DANIELSON, N##ELMER, P##LAU, YP##LU, C##OLSEN, J##SMITH, AJS##TELNOV, AV##BELLINI, F##CAVOTO, G##D'ORAZIO, A##DEL RE, D##DI MARCO, E##FACCINI, R##FERRAROTTO, F##FERRONI, F##GASPERO, M##GIOI, LL##MAZZONI, MA##MORGANTI, S##PIREDDA, G##POLCI, F##TEHRANI, FS##VOENA, C##EBERT, M##SCHRODER, H##WALDI, R##ADYE, T##DE GROOT, N##FRANEK, B##OLAIYA, EO##WILSON, FF##ALEKSAN, R##EMERY, S##GAIDOT, A##GANZHUR, SF##DE MONCHENAULT, GH##KOZANECKI, W##LEGENDRE, M##VASSEUR, G##YECHE, C##ZITO, M##CHEN, XR##LIU, H##PARK, W##PUROHIT, MV##WILSON, JR##ALLEN, MT##ASTON, D##BARTOLDUS, R##BECHTLE, P##BERGER, N##CLAUS, R##COLEMAN, JP##CONVERY, MR##CRISTINZIANI, M##DINGFELDER, JC##DORFAN, J##DUBOIS-FELSMANN, GP##DUJMIC, D##DUNWOODIE, W##FIELD, RC##GLANZMAN, T##GOWDY, SJ##GRAHAM, MT##GRENIER, P##HALYO, V##HAST, C##HRYN'OVA, T##INNES, WR##KELSEY, MH##KIM, P##LEITH, DWGS##LI, S##LUITZ, S##LUTH, V##LYNCH, HL##MACFARLANE, DB##MARSISKE, H##MESSNER, R##MULLER, DR##O'GRADY, CP##OZCAN, VE##PERAZZO, A##PERL, M##PULLIAM, T##RATCLIFF, BN##SALNIKOV, AA##SCHINDLER, RH##SCHWIENING, J##SNYDER, A##STELZER, J##SU, D##SULLIVAN, MK##SUZUKI, K##SWAIN, SK##THOMPSON, JM##VA'VRA, J##VAN BAKEL, N##WEAVER, M##WEINSTEIN, AJR##WISNIEWSKI, WJ##WITTGEN, M##WRIGHT, DH##YARRITU, AK##YI, K##YOUNG, CC##BURCHAT, PR##EDWARDS, AJ##MAJEWSKI, SA##PETERSEN, BA##ROAT, C##WILDEN, L##AHMED, S##ALAM, MS##BULA, R##ERNST, JA##JAIN, V##PAN, B##SAEED, MA##WAPPLER, FR##ZAIN, SB##BUGG, W##KRISHNAMURTHY, M##SPANIER, SM##ECKMANN, R##RITCHIE, JL##SATPATHY, A##SCHILLING, CJ##SCHWITTERS, RF##IZEN, JM##LOU, XC##YE, S##BIANCHI, F##GALLO, F##GAMBA, D##BOMBEN, M##BOSISIO, L##CARTARO, C##COSSUTTI, F##DELLA RICCA, G##DITTONGO, S##LANCERI, L##VITALE, L##AZZOLINI, V##LOPEZ-MARCH, N##MARTINEZ-VIDAL, F##BANERJEE, S##BHUYAN, B##BROWN, CM##FORTIN, D##HAMANO, K##KOWALEWSKI, R##NUGENT, IM##RONEY, JM##SOBIE, RJ##BACK, JJ##HARRISON, PF##LATHAM, TE##MOHANTY, GB##PAPPAGALLO, M##BAND, HR##CHEN, X##CHENG, B##DASU, S##DATTA, M##FLOOD, KT##HOLLAR, JJ##KUTTER, PE##MELLADO, B##MIHALYI, A##PAN, Y##PIERINI, M##PREPOST, R##WU, SL##YU, Z##NEAL, H","CNRS, IN2P3, PHYS PARTICULES LAB, F-74941 ANNECY LE VIEUX, FRANCE. UNIV SAVOIE, F-74941 ANNECY LE VIEUX, FRANCE. UNIV BARCELONA, FAC FIS, DEPT ECM, E-08028 BARCELONA, SPAIN. UNIV BARI, DIPARTMENTO FIS, I-70126 BARI, ITALY. UNIV BARI, IST NAZL FIS NUCL, I-70126 BARI, ITALY. INST HIGH ENERGY PHYS, BEIJING 100039, PEOPLES R CHINA. UNIV BERGEN, INST PHYS, N-5007 BERGEN, NORWAY. UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA. UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. RUHR UNIV BOCHUM, INST EXPT PHYS 1, D-44780 BOCHUM, GERMANY. UNIV BRISTOL, BRISTOL BS8 1TL, AVON, ENGLAND. UNIV BRITISH COLUMBIA, VANCOUVER, BC V6T 1Z1, CANADA. BRUNEL UNIV, UXBRIDGE UB8 3PH, MIDDX, ENGLAND. BUDKER INST NUCL PHYS, NOVOSIBIRSK 630090, RUSSIA. UNIV CALIF IRVINE, IRVINE, CA 92697 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA. UNIV CALIF SANTA BARBARA, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA CRUZ, INST PARTICLE PHYS, SANTA CRUZ, CA 95064 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CINCINNATI, CINCINNATI, OH 45221 USA. UNIV COLORADO, BOULDER, CO 80309 USA. COLORADO STATE UNIV, FT COLLINS, CO 80523 USA. UNIV DORTMUND, INST PHYS, D-44221 DORTMUND, GERMANY. TECH UNIV DRESDEN, INST KERN & TEILCHENPHYS, D-01062 DRESDEN, GERMANY. ECOLE POLYTECH, CNRS, IN2P3, LAB LEPRINCE RINGUET, F-91128 PALAISEAU, FRANCE. UNIV EDINBURGH, EDINBURGH EH9 3JZ, MIDLOTHIAN, SCOTLAND. UNIV FERRARA, DIPARTMENTO FIS, I-44100 FERRARA, ITALY. UNIV FERRARA, IST NAZL FIS NUCL, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, LAB NAZL FRASCATI, I-00044 FRASCATI, ITALY. UNIV GENOA, DIPARTIMENTO FIS, I-16146 GENOA, ITALY. UNIV GENOA, IST NAZL FIS NUCL, I-16146 GENOA, ITALY. HARVARD UNIV, CAMBRIDGE, MA 02138 USA. UNIV HEIDELBERG, INST PHYS, D-69120 HEIDELBERG, GERMANY. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AZ, ENGLAND. UNIV IOWA, IOWA CITY, IA 52242 USA. IOWA STATE UNIV, AMES, IA 50011 USA. JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA. UNIV KARLSRUHE, INST EXPT KERNPHYS, D-76021 KARLSRUHE, GERMANY. CNRS, IN2P3, LAB ACCELERATEUR LINEAIRE, F-91898 ORSAY, FRANCE. UNIV PARIS 11, CTR SCI, F-91898 ORSAY, FRANCE. LAWRENCE LIVERMORE NATL LAB, LIVERMORE, CA 94550 USA. UNIV LIVERPOOL, LIVERPOOL L69 7ZE, MERSEYSIDE, ENGLAND. UNIV LONDON QUEEN MARY COLL, LONDON E1 4NS, ENGLAND. UNIV LONDON, ROYAL HOLLOWAY & BEDFORD NEW COLL, EGHAM TW20 0EX, SURREY, ENGLAND. UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA. UNIV MANCHESTER, MANCHESTER M13 9PL, LANCS, ENGLAND. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. UNIV MASSACHUSETTS, AMHERST, MA 01003 USA. MIT, NUCL SCI LAB, CAMBRIDGE, MA 02139 USA. MCGILL UNIV, MONTREAL, PQ H3A 2T8, CANADA. UNIV MILAN, DIPARTIMENTO FIS, I-20133 MILAN, ITALY. UNIV MILAN, IST NAZL FIS NUCL, I-20133 MILAN, ITALY. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV MONTREAL, MONTREAL, PQ H3C 3J7, CANADA. MT HOLYOKE COLL, S HADLEY, MA 01075 USA. UNIV NAPLES FEDERICO II, DIPARTIMENTO SCI FIS, I-80126 NAPLES, ITALY. UNIV NAPLES FEDERICO II, IST NAZL FIS NUCL, I-80126 NAPLES, ITALY. NATL INST NUCL & HIGH ENERGY PHYS, NIKHEF, NL-1009 DB AMSTERDAM, NETHERLANDS. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. UNIV OREGON, EUGENE, OR 97403 USA. UNIV PADUA, DIPARTIMENTO FIS, I-35131 PADUA, ITALY. UNIV PADUA, IST NAZL FIS NUCL, I-35131 PADUA, ITALY. UNIV PARIS 07, F-75252 PARIS, FRANCE. UNIV PARIS 06, CNRS, IN2P3, PHYS THEOR & HAUTES ENERGIES LAB, F-75252 PARIS, FRANCE. UNIV PENN, PHILADELPHIA, PA 19104 USA. UNIV PERUGIA, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. UNIV PERUGIA, IST NAZL FIS NUCL, I-06100 PERUGIA, ITALY. UNIV PISA, SCUOLA NORMALE SUPER PISA, DIPARTIMENTO FIS, I-56127 PISA, ITALY. UNIV PISA, IST NAZL FIS NUCL, I-56127 PISA, ITALY. PRAIRIE VIEW A&M UNIV, PRAIRIE VIEW, TX 77446 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. UNIV ROMA LA SAPIENZA, DIPARTIMENTO FIS, I-00185 ROME, ITALY. UNIV ROMA LA SAPIENZA, IST NAZL FIS NUCL, I-00185 ROME, ITALY. UNIV ROSTOCK, D-18051 ROSTOCK, GERMANY. RUTHERFORD APPLETON LAB, DIDCOT OX11 0QX, OXON, ENGLAND. CEA SACLAY, DSM DAPNIA, F-91191 GIF SUR YVETTE, FRANCE. UNIV S CAROLINA, COLUMBIA, SC 29208 USA. STANFORD LINEAR ACCELERATOR CTR, STANFORD, CA 94309 USA. STANFORD UNIV, STANFORD, CA 94305 USA. SUNY ALBANY, ALBANY, NY 12222 USA. UNIV TENNESSEE, KNOXVILLE, TN 37996 USA. UNIV TEXAS, AUSTIN, TX 78712 USA. UNIV TEXAS, RICHARDSON, TX 75083 USA. UNIV TURIN, DIPARTIMENTO FIS SPERIMENTALE, I-10125 TURIN, ITALY. UNIV TURIN, IST NAZL FIS NUCL, I-10125 TURIN, ITALY. UNIV TRIESTE, DIPARTMENTO FIS, I-34127 TRIESTE, ITALY. UNIV TRIESTE, IST NAZL FIS NUCL, I-34127 TRIESTE, ITALY. UNIV VALENCIA, CSIC, IFIC, E-46071 VALENCIA, SPAIN. UNIV VICTORIA, VICTORIA, BC V8W 3P6, CANADA. UNIV WARWICK, DEPT PHYS, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND. UNIV WISCONSIN, MADISON, WI 53706 USA. YALE UNIV, NEW HAVEN, CT 06511 USA.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"AGOSTINELLI S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8##ALBRECHT H, 1990, PHYS LETT B, V241, P278, DOI 10.1016/0370-2693(90)91293-K##ASNER DM, 1996, PHYS REV D, V53, P1039, DOI 10.1103/PHYSREVD.53.1039##AUBERT B, 2002, NUCL INSTRUM METH A, V479, P1, DOI 10.1016/S0168-9002(01)02012-5##CHEN CH, 2004, PHYS REV D, V70, DOI 10.1103/PHYSREVD.70.054006##CHUA CK, 2002, PHYS LETT B, V544, P139, DOI 10.1016/S0370-2693(02)02499-1##FAJFER S, 2004, PHYS REV D, V69, DOI 10.1103/PHYSREVD.69.114020##FLEISCHER R, 2001, PHYS LETT B, V511, P240, DOI 10.1016/S0370-2693(01)00648-7##HAZUMI M, 2004, PHYS LETT B, V583, P285, DOI 10.1016/J.PHYSLETB.2003.12.071##HUANG HC, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.241802##YAO WM, 2006, J PHYS G NUCL PARTIC, V33, P1, DOI 10.1088/0954-3899/33/1/001",4,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/E000444/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000243167300027,2006,DYNAMICS AND ENERGETICS OF GE(001) DIMERS,"THE DYNAMIC BEHAVIOR OF SURFACE DIMERS ON GE(001) HAS BEEN STUDIED BY POSITIONING THE TIP OF A SCANNING TUNNELING MICROSCOPE OVER SINGLE FLIP-FLOPPING DIMERS AND MEASURING THE TUNNELING CURRENT AS A FUNCTION OF TIME. WE OBSERVE THAT NOT JUST SYMMETRIC, BUT ALSO ASYMMETRIC APPEARING DIMERS EXHIBIT FLIP-FLOP MOTION. THE DYNAMICS OF FLIP-FLOPPING DIMERS CAN BE USED TO SENSITIVELY GAUGE THE LOCAL POTENTIAL LANDSCAPE OF THE SURFACE. THROUGH A SPATIAL AND TIME-RESOLVED MEASUREMENT OF THE FLIP-FLOP FREQUENCY OF THE DIMERS, LOCAL STRAIN FIELDS NEAR SURFACE DEFECTS CAN BE ACCURATELY PROBED.",SCANNING TUNNELING MICROSCOPY; FLIP-FLOP MOTION; BUCKLED DIMERS; SURFACE; SI(100); SI(001); ADSORPTION; GERMANIUM,NA,PHYSICAL REVIEW LETTERS,"VAN HOUSELT, A##VAN GASTEL, R##POELSEMA, B##ZANDVLIET, HJW","UNIV TWENTE, MESA INST NANOTECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"ALERHAND OL, 1988, PHYS REV LETT, V61, P1973, DOI 10.1103/PHYSREVLETT.61.1973##BUEHLER EJ, 2000, SCIENCE, V290, P506, DOI 10.1126/SCIENCE.290.5491.506##CHADI DJ, 1979, PHYS REV LETT, V43, P43, DOI 10.1103/PHYSREVLETT.43.43##DABROWSKI J, 1994, PHYS REV B, V49, P4790, DOI 10.1103/PHYSREVB.49.4790##DABROWSKI J, 2000, SILICON SURFACES FOR##GAN S, 1999, J APPL PHYS, V85, P2004, DOI 10.1063/1.369176##GARCIA A, 1993, PHYS REV B, V48, P17350, DOI 10.1103/PHYSREVB.48.17350##GURLU O, 2003, APPL PHYS LETT, V83, P4610, DOI 10.1063/1.1630383##HAMERS RJ, 1986, PHYS REV B, V34, P5343, DOI 10.1103/PHYSREVB.34.5343##HATA K, 2001, PHYS REV LETT, V86, P3084, DOI 10.1103/PHYSREVLETT.86.3084##LI YJ, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.106104##LOSCUTOFF PW, 2006, ANNU REV PHYS CHEM, V57, P467, DOI 10.1146/ANNUREV.PHYSCHEM.56.092503.141307##MARCHENKO V. I., 1981, PIS'MA V ZHURNAL EKSPERIMENTAL'NOI I TEORETICHESKOI FIZIKI, V33, P397##PENNEC Y, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.026102##SATO T, 1999, J ELECTRON MICROSC, V48, P1##SCHLIER RE, 1959, J CHEM PHYS, V30, P917, DOI 10.1063/1.1730126##TROMP RM, 1985, PHYS REV LETT, V55, P1303, DOI 10.1103/PHYSREVLETT.55.1303##YOSHIDA S, 2002, JPN J APPL PHYS 1, V41, P5017, DOI 10.1143/JJAP.41.5017##ZANDVLIET HJW, 2003, PHYS REP, V388, P1, DOI 10.1016/J.PHYSREP.2003.09.001##ZANDVLIET HJW, 1998, PHYS REV B, V57, PR6803, DOI 10.1103/PHYSREVB.57.R6803##ZANDVLIET HJW, 2000, REV MOD PHYS, V72, P593, DOI 10.1103/REVMODPHYS.72.593",25,2020-11-20,NA
J,WOS:000243244300089,2006,ITON SCHOTTKY CONTACTS FOR GAN BASED UV PHOTODETECTORS,"LATERAL SCHOTTKY ULTRAVIOLET DETECTORS WERE FABRICATED IN GAN USING INDIUM-TIN-OXYNITRIDE (ITON) AS A CONTACT METAL. THE GAN SEMICONDUCTOR MATERIAL WAS GROWN ON 2 IN. SAPPHIRE SUBSTRATE BY METAL-ORGANIC CHEMICAL VAPOR DEPOSITION (MOCVD). THE SCHOTTKY CONTACT HAS BEEN REALIZED USING ITON THAT HAS BEEN DEPOSITED USING SPUTTER TECHNIQUES. I-V CHARACTERISTICS HAVE BEEN MEASURED WITH AND WITHOUT UV ILLUMINATION. THE DEVICE SHOWS PHOTO-TO-DARK CURRENT RATIOS OF 10(3) AT -1 V BIAS. THE SPECTRAL RESPONSIVITY OF THE UV DETECTORS HAS BEEN DETERMINED. THE HIGH SPECTRAL RESPONSIVITY OF MORE THAN 30 A/W AT 240 NM IS EXPLAINED BY A HIGH INTERNAL GAIN CAUSED BY GENERATION-RECOMBINATION CENTERS AT THE ITON/GAN INTERFACE. PERSISTENT PHOTOCURRENT EFFECT HAS BEEN OBSERVED IN UV LIGHT (ON-OFF) SWITCHING OPERATION, TIME CONSTANT AND ELECTRON CAPTURE COEFFICIENT OF THE TRANSITION HAS BEEN DETERMINED. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",METAL ULTRAVIOLET PHOTODETECTORS; PHOTOCURRENT; DETECTORS,ITON; SCHOTTKY CONTACT; GAN; UV PHOTODETECTOR,APPLIED SURFACE SCIENCE,"VANHOVE, N##JOHN, J##LORENZ, A##CHENG, K##BORGHS, G##HAVERKORT, JEM","IMEC, INTERUNIV MICROELECT CTR, B-3001 LOUVAIN, BELGIUM. EINDHOVEN UNIV TECHNOL, NL-5600 MB EINDHOVEN, NETHERLANDS.","CHEMISTRY, PHYSICAL; MATERIALS SCIENCE, COATINGS & FILMS; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",CHEMISTRY; MATERIALS SCIENCE; PHYSICS,"APERATHITIS E, 2003, THIN SOLID FILMS, P101##CHEN CH, 2001, IEEE PHOTONIC TECH L, V13, P848, DOI 10.1109/68.935824##DERLUYN J, 2005, J APPL PHYS, V98, DOI 10.1063/1.2008388##HUANG ZC, 1997, J CRYST GROWTH, V170, P362, DOI 10.1016/S0022-0248(96)00576-3##KATZ O, 2004, APPL PHYS LETT, V84, P4092, DOI 10.1063/1.1753056##KIM JK, 2002, APPL PHYS LETT, V81, P4655, DOI 10.1063/1.1524035##MONROY E, 2000, J APPL PHYS, V88, P2081, DOI 10.1063/1.1305838##PAU JL, 2000, APPL PHYS LETT, V76##SCHUHLE U, 2004, PROC SPIE, V5171, P231, DOI 10.1117/12.507730##SHEU JK, 1998, APPL PHYS LETT, V72, P3317, DOI 10.1063/1.121636##WALKER D, 1999, APPL PHYS LETT, V74, P762, DOI 10.1063/1.123303",24,2020-11-20,NA
J,WOS:000243344000002,2006,IS REGIONAL AIR QUALITY MODEL DIVERSITY REPRESENTATIVE OF UNCERTAINTY FOR OZONE SIMULATION?,"WE EXAMINE WHETHER SEVEN STATE-OF-THE-ART EUROPEAN REGIONAL AIR QUALITY MODELS PROVIDE DAILY ENSEMBLES OF PREDICTED OZONE MAXIMA THAT ENCOMPASS OBSERVATIONS. USING TOOLS BORROWED FROM THE EVALUATION OF ENSEMBLE WEATHER FORECASTING, WE ANALYZE STATISTICS OF SIMULATED ENSEMBLES OF OZONE DAILY MAXIMA OVER AN ENTIRE SUMMER SEASON. ALTHOUGH THE MODEL ENSEMBLE OVERESTIMATES OZONE, THE DISTRIBUTION OF SIMULATED CONCENTRATIONS IS REPRESENTATIVE OF THE UNCERTAINTY. THE SPREAD OF SIMULATIONS IS DUE TO RANDOM FLUCTUATIONS RESULTING FROM DIFFERENCES IN MODEL FORMULATIONS AND INPUT DATA, BUT ALSO TO THE SPREAD BETWEEN INDIVIDUAL MODEL SYSTEMATIC BIASES. THE ENSEMBLE AVERAGE SKILL INCREASES AS THE SPREAD DECREASES. THE SKILL OF THE ENSEMBLE IN GIVING PROBABILISTIC PREDICTIONS OF THRESHOLD EXCEEDANCES IS ALSO DEMONSTRATED. THESE RESULTS ALLOW FOR OPTIMISM ABOUT THE ABILITY OF THIS ENSEMBLE TO SIMULATE THE UNCERTAINTY OF THE IMPACT OF EMISSION CONTROL SCENARIOS.",POLLUTION MODEL; WESTERN-EUROPE; ENSEMBLE,NA,GEOPHYSICAL RESEARCH LETTERS,"VAUTARD, R##VAN LOON, M##SCHAAP, M##BERGSTROM, R##BESSAGNET, B##BRANDT, J##BUILTJES, PJH##CHRISTENSEN, JH##CUVELIER, C##GRAFF, A##JONSON, JE##KROL, M##LANGNER, J##ROBERTS, P##ROUIL, L##STERN, R##TARRASON, L##THUNIS, P##VIGNATI, E##WHITE, L##WIND, P","CEA, CNRS, UVSQ, LSCE,IPSL LAB, F-91198 GIF SUR YVETTE, FRANCE. METEOROL SYNTHESIZING CTR W, EUROPEAN MONITORING & EVALUAT PROGRAMME, N-0313 OSLO, NORWAY. NETHERLANDS ORG APPL SCI RES, NL-7300 AH APELDOORN, NETHERLANDS. SWEDISH METEOROL & HYDROL INST, SE-60176 NORRKOPING, SWEDEN. INST NATL ENVIRONM IND & RISQUES, F-60550 VERNEUIL EN HALATTE, FRANCE. NATL ENVIRONM RES INST, DK-4000 ROSKILDE, DENMARK. COMMISS EUROPEAN COMMUNITIES, JOINT RES CTR, DIRECTORATE GEN, INST ENVIRONM & SUSTAINABIL, I-21020 ISPRA, ITALY. UMWELTBUNDESAMT, D-14193 BERLIN, GERMANY. SRON NETHERLANDS INST SPACE RES, NL-3584 CA UTRECHT, NETHERLANDS. SHELL GLOBAL SOLUT, HLTH SAFETY & ENVIRONM DEPT, CONSERVAT CLEAN AIR & WATER EUROPE, CHESTER CH1 3SH, CHESHIRE, ENGLAND. FREE UNIV BERLIN, INST METEOROL, D-12165 BERLIN, GERMANY. CONSERVAT CLEAN AIR & WATER EUROPE, HAYWARDS HEATH RH16 1NB, ENGLAND.","GEOSCIENCES, MULTIDISCIPLINARY",GEOLOGY,"ANDERSSON C, 2007, TELLUS B, V59, P77, DOI 10.1111/J.1600-0889.2006.00231.X##ATGER F, 1999, MON WEATHER REV, V127, P1941, DOI 10.1175/1520-0493(1999)127<1941:TSOEPS>2.0.CO;2##BEEKMANN M, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003391##CHRISTENSEN JH, 1997, ATMOS ENVIRON, V31, P4169, DOI 10.1016/S1352-2310(97)00264-1##CUVELIER C, 2007, ATMOS ENVIRON, V41, P189, DOI 10.1016/J.ATMOSENV.2006.07.036##DABBERDT WF, 2000, ATMOS ENVIRON, V34, P4667, DOI 10.1016/S1352-2310(00)00141-2##DELLE MONACHE L, 2003, ATMOS ENVIRON, V37, P3469, DOI 10.1016/S1352-2310(03)00475-8##DELLE MONACHE L, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006917##FROHN LM, 2002, J COMPUT PHYS, V179, P68, DOI 10.1006/JCPH.2002.7036##HANNA SR, 2001, ATMOS ENVIRON, V35, P891, DOI 10.1016/S1352-2310(00)00367-8##JOLLIFE IT, 2003, FORECAST VERIFICATIO##KROL M, 2005, ATMOS CHEM PHYS, V5, P417, DOI 10.5194/ACP-5-417-2005##MALLET V, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006149##MCKEEN S, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD005858##MOLTENI F, 1996, Q J ROY METEOR SOC, V122, P73, DOI 10.1002/QJ.49712252905##PAGOWSKI M, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL022305##SCHAAP M, 2006, IN PRRESS INT J ENV##SCHMIDT H, 2001, ATMOS ENVIRON, V35, P6277, DOI 10.1016/S1352-2310(01)00451-4##STERN R, 2003, 26 INT TECHN M AIR P##TALAGRAND O, 1998, SEM PRED EUR CENT ME##TOTH Z, 1997, MON WEATHER REV, V125, P3297, DOI 10.1175/1520-0493(1997)125<3297:EFANAT>2.0.CO;2##VANLOON M, 2006, IN PRESS ATMOS ENV##VESTRENG V, 2003, 103 MSCW NORW MET I",21,2020-11-20,NA
J,WOS:000243527800006,2006,THE ANTICANCER DRUG BLEOMYCIN INVESTIGATED BY DENSITY FUNCTIONAL THEORY,"ACTIVATED BLEOMYCIN (ABLM) IS AN OXYGENATED IRON DRUG COMPLEX WHICH EMBODIES THE DRUG'S DNA-CLEAVING ACTIVITY. THIS ACTIVITY IS EXERCISED ON DNA, IF PRESENT, BUT IF DNA IS ABSENT, THE DRUG ITSELF IS INACTIVATED. WE HAVE EMPLOYED QUANTUM DENSITY FUNCTIONAL THEORY (DFT)-BASED METHODS TO INVESTIGATE (I) THE STRUCTURE OF THE FE(II)BLM COMPLEX THAT IS FIRST FORMED IN THE HUMAN BODY AFTER DRUG'S ADMINISTRATION, AND (II) THE ACTIVATION MECHANISM OF THE O-O BOND PRESENT IN THE ABLM. WE HAVE IDENTIFIED THE CONTROVERSIAL SECOND AXIAL LIGAND AS THE ENDOGENOUS OXYGEN ATOM OF THE CARBAMOYL GROUP. OUR FIRST PRINCIPLES MOLECULAR DYNAMICS (MD) SIMULATIONS INDICATE A HOMOLYTIC CLEAVAGE AS THE MECHANISM OF THE O-O BOND ACTIVATION IN THE ABLM COMPLEX.",ACTIVATED BLEOMYCIN; ELECTRONIC-STRUCTURE; MOLECULAR-DYNAMICS; IRON BLEOMYCIN; SELF-INACTIVATION; NONHEME IRON; FE(II)-BLEOMYCIN; REACTIVITY; COMPLEX; OXYGEN,BLEOMYCIN; O-O BOND ACTIVATION; DENSITY FUNCTIONAL THEORY; CAR-PARRINELLO MOLECULAR DYNAMICS SIMULATIONS; IRON-OXO COMPLEX,MOLECULAR SIMULATION,"KARAWAJCZYK, A##BUDA, F","LEIDEN UNIV, LEIDEN INST CHEM, NL-2300 RA LEIDEN, NETHERLANDS.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"BECKE AD, 1986, J CHEM PHYS, V84, P4524, DOI 10.1063/1.450025##BERENDSEN HJ, 1981, INTERMOLECULAR FORCE, P331, DOI DOI 10.1007/978-94-015-7658-1_21##BUKOWSKI MR, 2004, J BIOL INORG CHEM, V9, P39, DOI 10.1007/S00775-003-0494-Z##BURGER RM, 1983, J BIOL CHEM, V258, P1559##BURGER RM, 1979, J BIOL CHEM, V254, P2299##BURGER RM, 1981, J BIOL CHEM, V256, P1636##BURGER RM, 1998, CHEM REV, V98, P1153, DOI 10.1021/CR960438A##CAR R, 1985, PHYS REV LETT, V55, P2471, DOI 10.1103/PHYSREVLETT.55.2471##CHENG CC, 1995, J AM CHEM SOC, V117, P2970, DOI 10.1021/JA00116A002##FEDELES F, 2001, INORG CHEM, V40, P1557, DOI 10.1021/IC000948U##FREINDORF M, 2001, J PHYS CHEM A, V105, P7267, DOI 10.1021/JP010406D##FRISCH MJ, 2004, GAUSSIAN 03 REVISION##HAY PJ, 1985, J CHEM PHYS, V82, P270, DOI 10.1063/1.448799##HUTTER J, 1997, CPMD VERSION 3 9##KARAWAJCZYK A, 2005, J BIOL INORG CHEM, V10, P33, DOI 10.1007/S00775-004-0610-8##KARAWAJCZYK A, 2006, J PHYS CHEM B, V110, P21245, DOI 10.1021/JP061673S##LAIO A, 2002, J PHYS CHEM B, V106, P7300, DOI 10.1021/JP0143138##LAIO A, 2002, J CHEM PHYS, V116, P6941, DOI 10.1063/1.1462041##LEHMANN TE, 2000, BIOCHEMISTRY-US, V39, P3886, DOI 10.1021/BI991841P##LEHMANN TE, 2002, J BIOL INORG CHEM, V7, P305, DOI 10.1007/S007750100299##LEHMANN TE, 1997, BIOCHEMISTRY-US, V36, P2807, DOI 10.1021/BI962748T##LEHNERT N, 2002, J AM CHEM SOC, V124, P10810, DOI 10.1021/JA012621D##LOEB KE, 1998, J AM CHEM SOC, V120, P1249, DOI 10.1021/JA971839Q##LOEB KE, 1995, J AM CHEM SOC, V117, P4545, DOI 10.1021/JA00121A013##NAKAMURA M, 1988, J ANTIBIOT, V41, P638, DOI 10.7164/ANTIBIOTICS.41.638##NEESE F, 2000, J AM CHEM SOC, V122, P11703, DOI 10.1021/JA001812Y##OWA T, 1990, TETRAHEDRON LETT, V31, P6063, DOI 10.1016/S0040-4039(00)98029-8##PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PHYSREVB.33.8822##SAM JW, 1994, J AM CHEM SOC, V116, P5250, DOI 10.1021/JA00091A032##SUGIYAMA M, 2002, J BIOL CHEM, V277, P2311, DOI 10.1074/JBC.M103278200##SWART M, 2004, J PHYS CHEM A, V108, P5479, DOI 10.1021/JP049043I##TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PHYSREVB.43.1993##VAN GUNSTEREN WF, 1996, BIOMOLECULAR SIMULAT##WESTRE TE, 1995, J AM CHEM SOC, V117, P1309, DOI 10.1021/JA00109A014##ZHAO CQ, 2002, J INORG BIOCHEM, V91, P259, DOI 10.1016/S0162-0134(02)00420-8",0,2020-11-20,NA
J,WOS:000242880900012,2006,ATTENTIONAL PERFORMANCE OF (C57BL/6J X 129SV)F2 MICE IN THE FIVE-CHOICE SERIAL REACTION TIME TASK,"IMPAIRED ATTENTION IS EVIDENT IN SEVERAL NEUROLOGICAL AND PSYCHIATRIC DISORDERS. IN THE PRESENT STUDY, ATTENTIONAL CAPABILITIES WERE MEASURED IN THE OPERANT FIVE-CHOICE SERIAL REACTION TIME TASK (5-CSRTT) IN MALE (C57BL/6J X 129SV)F2 HYBRID (B6129F2) MICE. MAIN AIMS WERE TO VALIDATE AND STANDARDIZE THE TEST IN THESE MICE: TO SETUP PROCEDURES, MEASURE POTENTIAL BENEFICIAL EFFECTS OF SUB-CHRONIC NICOTINE IN DEGRADED VERSIONS OF THE 5-CSRTT (BY DECREASING STIMULUS DURATION, INDUCING WHITE NOISE AND MAKING THE STIMULI UNPREDICTABLE) AND STUDY DISRUPTIVE EFFECTS OF ADDITIONAL ADMINISTRATION OF THE MUSCARINIC ANTAGONIST SCOPOLAMINE. DURING THE BASELINE PRE-NICOTINE SESSIONS, THE B6129F2 MICE ATTAINED A VERY GOOD PERFORMANCE IN THE TEST (95% ACCURACY). AS STIMULUS DURATION WAS REDUCED FROM 2 S TO 1 S, RESPONSE ACCURACY OF THE MICE DECREASED. MICE TREATED WITH NICOTINE (0. 16 MG/KG) ATTAINED SIGNIFICANTLY HIGHER RESPONSE ACCURACY AND HAD A LOWER PERCENTAGE OF INCORRECT RESPONSES IN COMPARISON WITH THE SOLVENT-TREATED ANIMALS. NO FURTHER BENEFICIAL EFFECTS OF NICOTINE WERE FOUND. REDUCED RESPONSE ACCURACY WAS ALSO OBTAINED WHEN STIMULUS DURATION WAS REDUCED FROM 1 S TO 0.5 S AND WHEN A VARIABLE INTERTRIAL INTERVAL WAS INTRODUCED. NOISE INTERPOLATION BETWEEN TRIALS DID NOT IMPAIR PERFORMANCE. FINALLY, SCOPOLAMINE (0. 16 MG/KG) DISRUPTED ATTENTIONAL FUNCTIONING. ALTHOUGH MOST STUDIES HAVE BEEN PERFORMED IN RATS, THESE RESULTS ADD TO THE EXISTING EVIDENCE THAT THE 5-CSRTT CAN ALSO BE USED TO ASSESS ATTENTIONAL PERFORMANCE IN MICE. THIS OFFERS THE OPPORTUNITY TO TEST TRANSGENIC AND KNOCKOUT MICE WITH SIMILAR BACKGROUND AS THE B6129F2 AS ANIMAL MODELS OF PSYCHIATRIC AND NEUROLOGICAL DISEASES. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",NICOTINIC ACETYLCHOLINE-RECEPTOR; SUSTAINED ATTENTION; SELECTIVE ATTENTION; PREFRONTAL CORTEX; REDUCED ATTENTION; BIPOLAR DISORDER; CHRONIC EXPOSURE; WORKING-MEMORY; BINDING-SITES; RATS,NICOTINE; FIVE-CHOICE SERIAL REACTION TIME TASK; SCOPOLAMINE; (C57BL/6JS X 129SV)F2 MICE,PHYSIOLOGY & BEHAVIOR,"DE BRUIN, NMWJ##FRANSEN, F##DUYTSCHAEVER, H##GRANTHAM, C##MEGENS, AAHP",NA,"PSYCHOLOGY, BIOLOGICAL; BEHAVIORAL SCIENCES",PSYCHOLOGY; BEHAVIORAL SCIENCES,"BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/J.1471-4159.1988.TB10600.X##BIZARRO L, 2004, BEHAV PHARMACOL, V15, P195, DOI 10.1097/01.FBP.0000131574.61491.50##BIZARRO L, 2003, DRUG ALCOHOL DEPEN, V72, P287, DOI 10.1016/J.DRUGALCDEP.2003.08.004##BREESE CR, 1997, J PHARMACOL EXP THER, V282, P7##BUISSON B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001##CARLI M, 1983, BEHAV BRAIN RES, V9, P361, DOI 10.1016/0166-4328(83)90138-9##CHUDASAMA Y, 2004, PSYCHOPHARMACOLOGY, V174, P86, DOI 10.1007/S00213-004-1805-Y##CLARK L, 2004, EUR ARCH PSY CLIN N, V254, P61, DOI 10.1007/S00406-004-0460-Y##COLE BJ, 1989, BEHAV BRAIN RES, V33, P165, DOI 10.1016/S0166-4328(89)80048-8##COMBLATT BA, 2001, AM J MED GENET, V105, P11##COMBLATT BA, 1994, SCHIZOPHR B, V20, P31##DALLEY JW, 2002, PSYCHOPHARMACOLOGY, V164, P329, DOI 10.1007/S00213-002-1215-Y##DE BRUIN N, 2006, BEHAV BRAIN RES, V172, P122, DOI 10.1016/J.BBR.2006.05.002##DE BRUIN NMWJ, 2003, NEUROBIOL LEARN MEM, V80, P63, DOI 10.1016/S1074-7427(03)00024-8##ELLIS JR, 2005, INT J NEUROPSYCHOPH, V9, P1, DOI DOI 10.1017/S1461145705005407##FARADAY MM, 1999, PHARMACOL BIOCHEM BE, V62, P273, DOI 10.1016/S0091-3057(98)00159-2##GRECO B, 2006, BEHAV BRAIN RES, V169, P325, DOI 10.1016/J.BBR.2006.02.002##GRECO B, 2005, PSYCHOPHARMACOLOGY, V179, P68, DOI 10.1007/S00213-004-2127-9##GROTTICK AJ, 2001, PHARMACOL BIOCHEM BE, V70, P505, DOI 10.1016/S0091-3057(01)00639-6##GROTTICK AJ, 2000, BEHAV BRAIN RES, V117, P197, DOI 10.1016/S0166-4328(00)00305-3##HAHN B, 2005, PSYCHOPHARMACOLOGY, V177, P438, DOI 10.1007/S00213-004-1969-5##HAHN B, 2003, PSYCHOPHARMACOLOGY, V168, P271, DOI 10.1007/S00213-003-1438-6##HAHN B, 2002, NEUROPSYCHOPHARMACOL, V27, P712, DOI 10.1016/S0893-133X(02)00348-2##HAHN B, 2002, PSYCHOPHARMACOLOGY, V162, P129, DOI 10.1007/S00213-002-1005-6##HARRISON AA, 1997, PSYCHOPHARMACOLOGY, V133, P329, DOI 10.1007/S002130050410##HIGGS S, 2000, EUR J NEUROSCI, V12, P1781, DOI 10.1046/J.1460-9568.2000.00047.X##HUMBY T, 1999, EUR J NEUROSCI, V11, P2813, DOI 10.1046/J.1460-9568.1999.00701.X##INGLIS WL, 2001, BEHAV BRAIN RES, V123, P117, DOI 10.1016/S0166-4328(01)00181-4##JONES DNC, 1995, PSYCHOPHARMACOLOGY, V120, P142, DOI 10.1007/BF02246186##JONES DNC, 1995, J NEUROSCI, V15, P7282##KLIMKEIT EI, 2005, CHILD NEUROPSYCHOL, V11, P153, DOI 10.1080/092970490911298##MARSTON HM, 2001, BEHAV BRAIN RES, V125, P189, DOI 10.1016/S0166-4328(01)00300-X##MICHIE PT, 2000, AUST NZ J PSYCHIAT, V34, PS74, DOI 10.1046/J.1440-1614.2000.00786.X##MIRZA NR, 2000, PSYCHOPHARMACOLOGY, V148, P243, DOI 10.1007/S002130050048##MIRZA NR, 1998, PSYCHOPHARMACOLOGY, V138, P266, DOI 10.1007/S002130050671##NEWHOUSE PA, 2004, CURR OPIN PHARMACOL, V4, P36, DOI 10.1016/J.COPH.2003.11.001##PATEL S, 2006, BEHAV BRAIN RES, V170, P197, DOI 10.1016/J.BBR.2006.02.019##PERRY RJ, 1999, BRAIN, V122, P383, DOI 10.1093/BRAIN/122.3.383##QURAISHI S, 2002, J AFFECT DISORDERS, V72, P209, DOI 10.1016/S0165-0327(02)00091-5##ROBBINS TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/S00213-002-1154-7##RUOTSALAINEN S, 2000, PSYCHOPHARMACOLOGY, V148, P111, DOI 10.1007/S002130050032##SACCO KA, 2005, ARCH GEN PSYCHIAT, V62, P649, DOI 10.1001/ARCHPSYC.62.6.649##SCHWARTZ RD, 1983, SCIENCE, V220, P214, DOI 10.1126/SCIENCE.6828889##SHOAIB M, 2005, PSYCHOPHARMACOLOGY, V178, P211, DOI 10.1007/S00213-004-2004-6##SPINELLI S, 2006, NEUROPHARMACOLOGY, V51, P238, DOI 10.1016/J.NEUROPHARM.2006.03.012##TSAL Y, 2005, J LEARN DISABIL-US, V38, P142, DOI 10.1177/00222194050380020401##VAN GAALEN MM, 2003, BEHAV BRAIN RES, V142, P69, DOI 10.1016/S0166-4328(02)00381-9##VANDENBERGEN H, 1997, PHYSIOL BEHAV, V61, P879, DOI 10.1016/S0031-9384(96)00612-9##WESNES K, 1984, PSYCHOPHARMACOLOGY, V84, P5, DOI 10.1007/BF00432014##WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z##WRENN CC, 2006, PHARMACOL BIOCHEM BE, V83, P428, DOI 10.1016/J.PBB.2006.03.003##YOUNG JW, 2004, NEUROPSYCHOPHARMACOL, V29, P891, DOI 10.1038/SJ.NPP.1300393##YOUNG JW, 2006, EUR NEUROPSYCHO 0429",33,2020-11-20,NA
J,WOS:000243089900005,2006,AUTOMATED DETECTION OF INFECTIOUS DISEASE OUTBREAKS: HIERARCHICAL TIME SERIES MODELS,"THE PURPOSE OF INFECTIOUS DISEASE SURVEILLANCE IS TO INFORM THE PUBLIC HEALTH POLICY MAKERS ON THE INCIDENCE AND TRENDS OF INFECTIOUS DISEASES AND TO TRIGGER APPROPRIATE ACTIONS TO CONTROL INFECTIOUS DISEASE OUTBREAKS. THE ENORMOUS AMOUNT OF DATA COLLECTED WITH AUTOMATED LABORATORY-BASED SURVEILLANCE SYSTEMS REQUIRE AUTOMATED ALGORITHMS FOR DETECTING UNEXPECTED ABERRATIONS THAT MAY SIGNAL INFECTIOUS DISEASE OUTBREAKS. IN THIS PAPER, WE EXPLORE THE POTENTIAL OF HIERARCHICAL TIME SERIES MODELS TO DETECT DEVIATIONS FROM EXPECTED INCIDENCE. AS THESE COUNT DATA ARE EXTREMELY NOISY IT CAN BE EXPECTED THAT THESE MODELS ARE SUITABLE TO DETECT SIGNAL FROM NOISE AND ACCOMMODATE FOR POSSIBLE AUTOCORRELATION. THE PROPOSED PROCEDURE CONSISTS OF THREE STEPS; (1) THE MODEL PARAMETERS ARE ESTIMATED BY EMPIRICAL BAYES ON A TRAINING PERIOD OF, E.G. A YEAR; (2) THE EXPECTED VALUES ARE UPDATED FOR SMALL TIME STEPS (E.G. DAILY) AS NEW DATA ARRIVE; (3) THRESHOLD LEVELS ARE UPDATED CONDITIONALLY ON THE PAST EXPECTED VALUES AND AN ALARM IS TRIGGERED WHEN THE THRESHOLD LEVEL IS EXCEEDED. TO TEST THE POTENTIAL OF THE MODELS WE ESTIMATED SENSITIVITY, SPECIFICITY AND TIMELINESS ON SIMULATED TIME SERIES AND COMPARED THE RESULTS WITH AN ALTERNATIVE APPROACH OF A LINEAR REGRESSION MODEL ADJUSTED FOR TRENDS AND SEASON. WE ALSO USED TWO OBSERVED SERIES FOR RUBELLA NOTIFICATIONS AND SALMONELLA INFECTIONS AND COMPARED OUR FINDINGS WITH THE EXPERT OPINIONS ON THESE SERIES. THE HIERARCHICAL TIME SERIES MODELS APPROACH SHOWS HIGH SENSITIVITY AND SPECIFICITY AND CORRECTLY IDENTIFIES OUTBREAKS AT AN EARLY STAGE. THIS, IN OUR OPINION, MAKES THE PROPOSED MODEL A RELIABLE TOOL FOR ADEQUATE AUTOMATED DETECTION OF INFECTIOUS DISEASE OUTBREAKS. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",PUBLIC-HEALTH SURVEILLANCE; AIDS INCIDENCE,TIME SERIES ANALYSES; EARLY WARNING ALGORITHM; OUTBREAK DETECTION; HIERARCHICAL MODELS,STATISTICS IN MEDICINE,"HEISTERKAMP, SH##DEKKERS, ALM##HEIJNE, JCM","NV ORGANON, BIOMETR, NL-5340 BH OSS, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, NL-3720 BA BILTHOVEN, NETHERLANDS.","MATHEMATICAL & COMPUTATIONAL BIOLOGY; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; MEDICINE, RESEARCH & EXPERIMENTAL; STATISTICS & PROBABILITY","MATHEMATICAL & COMPUTATIONAL BIOLOGY; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; RESEARCH & EXPERIMENTAL MEDICINE; MATHEMATICS","ALIOUM A, 1995, STAT MED, V14, P27, DOI 10.1002/SIM.4780140105##DEKKERS ALM, 2004, NPBATS SOFTWARE BAYE##EILERS PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/SS/1038425655##EILERS PHC, 1999, THESIS LEIDEN##FARRINGTON CP, 1996, J ROY STAT SOC A STA, V159, P547, DOI 10.2307/2983331##HEISTERKAMP SH, 1999, BIOMETRICAL J, V41, P385, DOI 10.1002/(SICI)1521-4036(199907)41:4<385::AID-BIMJ385>3.0.CO;2-Z##HEISTERKAMP SH, 1989, STAT MED, V8, P963, DOI 10.1002/SIM.4780080807##HUTWAGNER LC, 2005, STAT MED, V24, P543, DOI 10.1002/SIM.2034##KULLDORFF M, 2005, PLOS MED, V2, P216, DOI 10.1371/JOURNAL.PMED.0020059##LAZARUS R, 2002, EMERG INFECT DIS, V8, P753, DOI 10.3201/EID0808.020239##MCCULLOGH P., 1989, GEN LINEAR MODELS##ROLFHAMRE AVP, 2003, 3 SMYTTSK##STROUP DF, 1993, AM J EPIDEMIOL, V137, P373, DOI 10.1093/OXFORDJOURNALS.AJE.A116684##THUPPAL SV, 2004, THESIS CARLETON U CA##WIDDOWSON MA, 2003, EMERG INFECT DIS, V9, P1046##2003, S PLUS 6 2 DATA ANAL",17,2020-11-20,NA
J,WOS:000243089900011,2006,A RELAXATION OF THE GAMMA FRAILTY (BURR) MODEL,"FRAILTY MODELS ARE USED IN UNIVARIATE DATA TO ACCOUNT FOR INDIVIDUAL HETEROGENEITY. IN THE POPULAR GAMMA FRAILTY MODEL THE MARGINAL HAZARD HAS THE FORM OF A BURR MODEL. ALTHOUGH THE BURR MODEL IS VERY USEFUL AND CAN OFFER INSIGHT ON THE DATA, IT IS FAR FROM PERFECT. THE ESTIMATION OF THE COVARIATE EFFECTS IS LINKED TO THE BASELINE HAZARD AND THIS MAKES THE MODEL COEFFICIENTS HARD TO INTERPRET. AT THE SAME TIME, THE FRAILTIES ARE ASSUMED CONSTANT OVER TIME, WHILE BIOLOGICAL REASONING IN SOME CASES MAY INDICATE THAT FRAILTIES MAY BE TIME DEPENDENT. IN THIS PAPER WE PRESENT A RELAXATION OF THE BURR MODEL WHICH IS BASED ON LOOSENING THE LINK BETWEEN THE ESTIMATION OF THE COVARIATE EFFECTS AND THE BASELINE HAZARD. THIS CAN BE ACHIEVED BY REPLACING THE CUMULATIVE BASELINE HAZARD IN THE BURR MODEL BY A SET OF TIME FUNCTIONS, AND THE FRAILTY VARIANCE BY A VECTOR OF COEFFICIENTS DIRECTLY ESTIMATED FROM THE DATA USING A PARTIAL LIKELIHOOD. WE ILLUSTRATE THE SIMILARITIES OF THE MODEL WITH THE BURR MODEL AND A FURTHER EXTENSION OF THE LATTER, A MODEL WITH AN AUTOREGRESSIVE STOCHASTIC PROCESS FOR THE FRAILTY. WE COMPARE THE MODELS ON SIMULATED DATA SETS WITH CONSTANT AND TIME-DEPENDENT FRAILTIES AND SHOW HOW THE RELAXED BURR MODELS PERFORMS ON TWO DIFFERENT REAL DATA SETS. WE SHOW THAT THE RELAXED BURR MODEL SERVES AS A GOOD APPROXIMATION TO THE BURR MODEL WHEN THE FRAILTY IS CONSTANT, AND FURTHERMORE IT GIVES BETTER RESULTS WHEN THE FRAILTY IS TIME DEPENDENT. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",SURVIVAL ANALYSIS; REGRESSION,SURVIVAL ANALYSIS; TIME-DEPENDENT FRAILTY; BUFF MODEL; REDUCED RANK HAZARDS; NON-PROPORTIONAL HAZARDS,STATISTICS IN MEDICINE,"PERPEROGLOU, A##VAN HOUWELINGEN, HC##HENDERSON, R","LEIDEN UNIV, MED CTR, NL-2300 RC LEIDEN, NETHERLANDS. NEWCASTLE UNIV, DEPT MATH & STAT, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND.","MATHEMATICAL & COMPUTATIONAL BIOLOGY; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; MEDICINE, RESEARCH & EXPERIMENTAL; STATISTICS & PROBABILITY","MATHEMATICAL & COMPUTATIONAL BIOLOGY; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; RESEARCH & EXPERIMENTAL MEDICINE; MATHEMATICS","AALEN OO, 1988, STAT MED, V7, P1121, DOI 10.1002/SIM.4780071105##BARKER P, 2005, LIFETIME DATA ANAL, V11, P265, DOI 10.1007/S10985-004-0387-7##COX DR, 1972, J R STAT SOC B, V34, P187##GJESSING HK, 2003, ADV APPL PROBAB, V35, P532, DOI 10.1239/AAP/1051201659##HASTIE T, 1993, J ROY STAT SOC B MET, V55, P757##HENDERSON R, 2002, J AM STAT ASSOC, V97, P965, DOI 10.1198/016214502388618753##HENDERSON R, 2003, BIOMETRIKA, V90, P355, DOI 10.1093/BIOMET/90.2.355##KOOPERBERG C, 1995, J AM STAT ASSOC, V90, P78, DOI 10.2307/2291132##LUMLEY T, SURVIVAL SURVIVAL AN##MANDA SOM, 2005, STAT MED, V24, P1263, DOI 10.1002/SIM.1995##MUERS MF, 1996, THORAX, V51, P894, DOI 10.1136/THX.51.9.894##PAIK MC, 1994, BIOMETRICS, V50, P975, DOI 10.2307/2533437##PERPEROGLOU A, 2006, STAT MED, V25, P2831, DOI 10.1002/SIM.2360##R DEVELOPMENT CORE TEAM, 2004, R LANG ENV STAT COMP##THERNEAU TM, 2000, STAT BIOL HEALTH##VERWEIJ PJM, 1995, BIOMETRICS, V51, P1550, DOI 10.2307/2533286##WINTREBERT CMA, 2004, BIOMETRICAL J, V46, P512, DOI 10.1002/BIMJ.200310051##YASHIN AI, 1997, STAT SCI, V12, P20##YASHIN AI, 1999, J MULTIVARIATE ANAL, V71, P241, DOI 10.1006/JMVA.1999.1848##YAU KKW, 1998, STAT MED, V17, P1201, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1201::AID-SIM845>3.0.CO;2-7",4,2020-11-20,MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [G0400615] FUNDING SOURCE: MEDLINE
J,WOS:000243089900014,2006,COMPARING CORRELATIONS OF CONTINUOUS OBSERVATIONS FROM TWO INDEPENDENT POPULATIONS USING A SEQUENTIAL APPROACH,"A SEQUENTIAL STUDY DESIGN GENERALLY MAKES MORE EFFICIENT USE OF AVAILABLE INFORMATION THAN A FIXED SAMPLE COUNTERPART OF EQUAL POWER. THIS FEATURE IS GRADUALLY BEING EXPLOITED BY RESEARCHERS IN GENETIC AND EPIDEMIOLOGICAL INVESTIGATIONS THAT UTILIZE BANKED BIOLOGICAL RESOURCES AND IN STUDIES WHERE TIME, COST AND ETHICS ARE PROMINENT CONSIDERATIONS. RECENT WORK IN THIS AREA HAS FOCUSSED ON THE SEQUENTIAL ANALYSIS OF MATCHED CASE-CONTROL STUDIES WITH A DICHOTOMOUS TRAIT. IN THIS PAPER, WE EXTEND THE SEQUENTIAL APPROACH TO A COMPARISON OF THE ASSOCIATIONS WITHIN TWO INDEPENDENT GROUPS OF PAIRED CONTINUOUS OBSERVATIONS. SUCH A COMPARISON IS PARTICULARLY RELEVANT IN FAMILIAL STUDIES OF PHENOTYPIC CORRELATION USING TWINS. WE DEVELOP A SEQUENTIAL TWIN METHOD BASED ON THE INTRACLASS CORRELATION AND SHOW THAT USE OF SEQUENTIAL METHODOLOGY CAN LEAD TO A SUBSTANTIAL REDUCTION IN THE NUMBER OF OBSERVATIONS WITHOUT COMPROMISING THE STUDY ERROR RATES. ADDITIONALLY, OUR APPROACH PERMITS STRAIGHTFORWARD ALLOWANCE FOR OTHER EXPLANATORY FACTORS IN THE ANALYSIS. WE ILLUSTRATE OUR METHOD IN A SEQUENTIAL HERITABILITY STUDY OF DYSPLASIA THAT ALLOWS FOR THE EFFECT OF BODY MASS INDEX AND COMPARES MONOZYGOTES WITH PAIRS OF SINGLETON SISTERS. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",LINKAGE; TESTS,GENETIC EPIDEMIOLOGY; INTRACLASS CORRELATION; SEQUENTIAL METHOD; TWIN STUDY,STATISTICS IN MEDICINE,"BAKSH, MF##HAARS, G##TODD, S##VAN NOORD, PAH##WHITEHEAD, J","STRANGEWAYS RES LAB, MED RES COUNCIL, EPIDEMIOL UNIT, CAMBRIDGE CB1 8RN, ENGLAND. UNIV UTRECHT, MED CTR, STRATENUM, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3584 CG UTRECHT, NETHERLANDS. UNIV READING, MED & PHARMACEUT STAT RES UNIT, READING RG6 6FN, BERKS, ENGLAND.","MATHEMATICAL & COMPUTATIONAL BIOLOGY; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; MEDICINE, RESEARCH & EXPERIMENTAL; STATISTICS & PROBABILITY","MATHEMATICAL & COMPUTATIONAL BIOLOGY; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; RESEARCH & EXPERIMENTAL MEDICINE; MATHEMATICS","ARMITAGE P, 2002, BIOSTATISTICAL GENET, P171##BAKSH MF, 2005, STAT MED, V24, P853, DOI 10.1002/SIM.1968##BICKEL P., 1977, MATH STAT BASIC IDEA##BODDEKER IR, 2001, BIOMETRICAL J, V43, P501, DOI 10.1002/1521-4036(200108)43:4<501::AID-BIMJ501>3.0.CO;2-I##BRANDNER FA, 1933, BIOMETRIKA, V25, P102, DOI 10.2307/2332265##COX DR, 1974, THEORETICAL STAT##DEWAARD F, 1984, J CHRON DIS, V37, P1, DOI 10.1016/0021-9681(84)90123-1##DREYFUS M, 2001, OBSTET GYNECOL, V97, P29, DOI 10.1016/S0029-7844(00)01099-1##FISHER R., 1915, BIOMETRIKA, V10, P507, DOI DOI 10.2307/2331838##HAARS G, 2005, CANCER EPIDEM BIOMAR, V14, P2634, DOI 10.1158/1055-9965.EPI-05-0824##HAARS G, 2004, BREAST CANCER RES TR, V87, P149, DOI 10.1023/B:BREA.0000041621.48575.9B##HERINGS RMC, 1992, J EPIDEMIOL COMMUN H, V46, P136, DOI 10.1136/JECH.46.2.136##LAI TL, 1973, ANN STAT, V1, P659, DOI 10.1214/AOS/1176342461##*MPS RES UN, 2000, PEST 4 OP MAN##NEALE MC, 2002, BIOSTATISTICAL GENET, P743##SHAM P, 1998, STAT HUMAN GENETICS##THOMAS DC, 2004, STAT METHODS GENETIC##TURNBULL B. W., 2000, GROUP SEQUENTIAL MET##VAN DER TWEEL I, 2004, STAT MED, V23, P3755, DOI 10.1002/SIM.2071##VAN DER TWEEL I, 2000, STAT MED, V19, P3449, DOI 10.1002/1097-0258(20001230)19:24<3449::AID-SIM648>3.0.CO;2-Y##WHITEHEAD J., 1997, DESIGN ANAL SEQUENTI##ZAR J. H., 1999, BIOSTATISTICAL ANAL",1,2020-11-20,NA
J,WOS:000242425300035,2006,PROTEASOME-MEDIATED DEGRADATION OF INTEGRAL INNER NUCLEAR MEMBRANE PROTEIN EMERIN IN FIBROBLASTS LACKING A-TYPE LAMINS,"WE PREVIOUSLY IDENTIFIED AND CHARACTERIZED A HOMOZYGOUS LMNA NONSENSE MUTATION LEADING TO THE ABSENCE OF A-TYPE LAMINS IN A PREMATURE NEONATE WHO DIED AT BIRTH. WE SHOW HERE THAT THE ABSENCE OF A-TYPE LAMINS IS DUE TO DEGRADATION OF THE ABERRANT MRNA TRANSCRIPT WITH A PREMATURE TERMINATION CODON. IN CULTURED FIBROBLASTS FROM THE SUBJECT WITH THE HOMOZYGOUS LMNA NONSENSE MUTATION, THERE WAS A DECREASED STEADY-STATE EXPRESSION OF THE INTEGRAL INNER NUCLEAR MEMBRANE PROTEINS EMERIN AND NESPRIN-1 ALPHA ASSOCIATED WITH THEIR MISLOCALIZATION TO THE BULK ENDOPLASMIC RETICULUM AND A HYPERPHOSPHORYLATION OF EMERIN. TO DETERMINE IF DECREASED EMERIN EXPRESSION OCCURRED POST-TRANSLATIONALLY, WE TREATED CELLS WITH A SELECTIVE PROTEASOME INHIBITOR AND OBSERVED AN INCREASE IN EXPRESSION. OUR RESULTS SHOW THAT MISLOCALIZATION OF INTEGRAL INNER NUCLEAR MEMBRANE PROTEINS TO THE ENDOPLASMIC RETICULUM IN HUMAN CELLS LACKING A-TYPE LAMINS LEADS TO THEIR DEGRADATION AND PROVIDES THE FIRST EVIDENCE THAT THEIR DEGRADATION IS MEDIATED BY THE PROTEASOME. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",MUSCULAR-DYSTROPHY; ENVELOPE ALTERATIONS; C CONTAINS; NONSENSE; A/C; PHOSPHORYLATION; CELLS; IDENTIFICATION; MECHANISM; POSITION,NUCLEAR ENVELOPE; LAMIN; EMERIN; NESPRIN; PROTEASOME; MUSCULAR DYSTROPHY,BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,"MUCHIR, A##MASSART, C##VAN ENGELEN, BG##LAMMENS, M##BONNE, G##WORMAN, HJ","COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA. COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA. INSERM, INST MYOL, U582, F-75013 PARIS, FRANCE. UNIV PARIS 06, UMR S582, IFR 14, F-75013 PARIS, FRANCE. RADBOUD UNIV NIJMEGEN, MED CTR, NEUROMUSCULAR CTR NIJMEGEN, NIJMEGEN, NETHERLANDS. GRP HOSP PITIE SALPETRIERE, AP HP, UF MYOGENET & CARDIOGENET, SERV BIOCHIM B, F-75013 PARIS, FRANCE.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS,BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS,"AMRANI N, 2006, NAT REV MOL CELL BIO, V7, P415, DOI 10.1038/NRM1942##BRILL LM, 2004, ANAL CHEM, V76, P2763, DOI 10.1021/AC035352D##CARTEGNI L, 1997, HUM MOL GENET, V6, P2257, DOI 10.1093/HMG/6.13.2257##CARTER MS, 1996, EMBO J, V15, P5965, DOI 10.1002/J.1460-2075.1996.TB00983.X##ELLIS JA, 1998, J CELL SCI, V111, P781##GLASS CA, 1993, EMBO J, V12, P4413, DOI 10.1002/J.1460-2075.1993.TB06126.X##GUILLY MN, 1990, EXP CELL RES, V189, P145, DOI 10.1016/0014-4827(90)90267-E##HARBORTH J, 2001, J CELL SCI, V114, P4557##HARRIES LW, 2005, HUM GENET, V118, P214, DOI 10.1007/S00439-005-0023-Y##HIRANO Y, 2005, J BIOL CHEM, V280, P39925, DOI 10.1074/JBC.M503214200##INOUE K, 2004, NAT GENET, V36, P361, DOI 10.1038/NG1322##LAMMERDING J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670##LEE DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4##MUCHIR A, 2000, HUM MOL GENET, V9, P1453, DOI 10.1093/HMG/9.9.1453##MUCHIR A, 2004, PHYSIOLOGY, V19, P309, DOI 10.1152/PHYSIOL.00022.2004##MUCHIR A, 2003, EXP CELL RES, V291, P352, DOI 10.1016/J.YEXCR.2003.07.002##MUCHIR A, 2004, MUSCLE NERVE, V30, P444, DOI 10.1002/MUS.20122##NAGY E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0##PONCHEL F, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-18##RAJAVEL KS, 2001, MOL CELL BIOL, V21, P5512, DOI 10.1128/MCB.21.16.5512-5519.2001##ROBERTS RC, 2006, FEBS J, V273, P4562, DOI 10.1111/J.1742-4658.2006.05464.X##STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9##STIERLE VN, 2003, BIOCHEMISTRY-US, V42, P4819, DOI 10.1021/BI020704G##SULLIVAN T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/JCB.147.5.913##VAN ENGELEN BGM, 2005, NEUROLOGY, V64, P374, DOI 10.1212/01.WNL.0000149763.15180.00##VANDERKOOI AJ, 1996, ANN NEUROL, V39, P638##WORMAN HJ, 2000, J MEMBRANE BIOL, V177, P1, DOI 10.1007/S002320001096",28,2020-11-20,"NIAMS NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES (NIAMS) [AR048997, R01 AR048997] FUNDING SOURCE: MEDLINE; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES (NIAMS) [R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997, R01AR048997] FUNDING SOURCE: NIH REPORTER"
J,WOS:000242961600005,2006,ENZYMATICALLY OXIDIZED LACTOSE AND DERIVATIVES THEREOF AS POTENTIAL PROTEIN CROSS-LINKERS,"THE ENZYME GALACTOSE OXIDASE [EC 1. 1. 3.9] WAS APPLIED TO CONVERT LACTOSE, LACTYLAMINE AND LACTOBIONIC ACID INTO THEIR CORRESPONDING 6'-ALDEHYDE COMPOUNDS. THE POTENTIAL PROTEIN CROSS-LINKING ABILITY OF THESE OXIDIZED LACTOSE AND DERIVATIVES THEREOF WAS INVESTIGATED USING N-BUTYLAMINE AS THE MODEL COMPOUND. FIRST, OXIDIZED LACTOSE GAVE DOUBLE MAILLARD REACTION PRODUCTS THAT WERE STABLE UNDER MILD ALKALINE CONDITIONS. SECOND, REDUCTIVE AMINATION OF LACTOSE FOLLOWED BY ENZYMATIC OXIDATION GAVE CROSS-LINKS THAT WERE STABLE UNDER BOTH NEUTRAL AND ALKALINE CONDITIONS. THIRD, STABLE CROSS-LINKS WERE OBTAINED THROUGH ENZYMATIC OXIDATION AND AMIDATION OF LACTOBIONIC ACID. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",GALACTOSE DIALDEHYDE; MICRODOCHIUM-NIVALE; REDUCTIVE AMINATION; WHEY PROTEINS; TRANSGLUTAMINASE; OXIDASE; CONVERSION; LINKING; SUGARS,PROTEIN CROSS-LINKING; LACTOSE; LACTOSE DIALDEHYDE; GALACTOSE OXIDASE; MAILLARD REACTION,CARBOHYDRATE RESEARCH,"VAN WIJK, A##SIEBUM, A##SCHOEVAART, R##KIEBOOM, T","LEIDEN UNIV, LEIDEN INST CHEM, NL-2300 RA LEIDEN, NETHERLANDS.","BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY, APPLIED; CHEMISTRY, ORGANIC",BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY,"AHMAD SK, 2004, REGUL TOXICOL PHARM, V39, P256, DOI 10.1016/J.YRTPH.2004.02.003##BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4##BONNET V, 2003, EUR J ORG CHEM, V2003, P4810, DOI 10.1002/EJOC.200300449##BRUGGINK A, 2003, ORG PROCESS RES DEV, V7, P622, DOI 10.1021/OP0340311##DE WIT G., 1978, TETRAHEDRON LETT, V15, P1327##DEWIT G, 1981, CARBOHYD RES, V91, P125, DOI 10.1016/S0008-6215(00)86025-5##ELLIS GP, 1959, ADV CARBOHYD CHEM, V14, P63##FAERGEMAND M, 1997, FOOD HYDROCOLLOID, V11, P19, DOI 10.1016/S0268-005X(97)80006-9##FAERGEMAND M, 1999, FOOD HYDROCOLLOID, V13, P199, DOI 10.1016/S0268-005X(98)00085-X##GARELLICALVET R, 1993, SYNTHETIC COMMUN, V23, P35, DOI 10.1080/00397919308020398##HOAGLAND PD, 1979, CARBOHYD RES, V74, P135, DOI 10.1016/S0008-6215(00)84771-0##HODGE JE, 1953, AGR FOOD CHEM, V1, P928##ISBELL HS, 1951, J RES NAT BUR STAND, V46, P132, DOI 10.6028/JRES.046.020##KAGAN F, 1957, J AM CHEM SOC, V79, P3541, DOI 10.1021/JA01570A063##KESTER JJ, 1984, J DAIRY SCI, V67, P2757, DOI 10.3168/JDS.S0022-0302(84)81633-1##KINSELLA J E, 1989, ADV FOOD NUTR RES, V33, P343, DOI 10.1016/S1043-4526(08)60130-8##KURAISHI C, 2001, FOOD REV INT, V17, P221, DOI 10.1081/FRI-100001258##LAMMERS H, 1994, TETRAHEDRON, V50, P8103, DOI 10.1016/S0040-4020(01)85293-5##MAILLARD LC, 1912, CR HEBD ACAD SCI, V154, P66##SCHOEVAART R, 2001, CARBOHYD RES, V334, P1, DOI 10.1016/S0008-6215(01)00166-5##SCHOEVAART R, 2005, STARCH-STARKE, V57, P161, DOI 10.1002/STAR.200400357##SCHOEVAART R, 2004, TOP CATAL, V27, P3, DOI 10.1023/B:TOCA.0000013536.27551.13##SCHOEVAART R, 2002, CARBOHYD RES, V337, P899, DOI 10.1016/S0008-6215(02)00051-4##SCHOEVAART R, 2002, TETRAHEDRON LETT, V43, P3399, DOI 10.1016/S0040-4039(02)00479-3##SIEBUM A, 2006, J MOL CATAL B-ENZYM, V41, P141, DOI 10.1016/J.MOLCATB.2006.04.003##VAN BOEKEL MAJS, 1998, FOOD CHEM, V62, P403, DOI 10.1016/S0308-8146(98)00075-2##XU F, 2001, EUR J BIOCHEM, V268, P1136, DOI 10.1046/J.1432-1327.2001.01982.X",18,2020-11-20,NA
J,WOS:000243033900032,2006,NEGATIVE CONSTRAINTS UNDERLIE THE ERBB SPECIFICITY OF EPIDERMAL GROWTH FACTOR-LIKE LIGANDS,"EPIDERMAL GROWTH FACTOR (EGF)-LIKE GROWTH FACTORS BIND THEIR ERBB RECEPTORS IN A HIGHLY SELECTIVE MANNER, BUT THE MOLECULAR BASIS FOR THIS SPECIFICITY IS POORLY UNDERSTOOD. WE HAVE PREVIOUSLY SHOWN THAT CERTAIN RESIDUES IN HUMAN EGF (SER(2)-ASP(3)) AND TGF ALPHA (GLU(26)) ARE NOT ESSENTIAL FOR THEIR BINDING TO ERBB1 BUT PREVENT BINDING TO ERBB3 AND ERBB4. IN THE PRESENT STUDY, WE HAVE USED A PHAGE DISPLAY APPROACH TO AFFINITY-OPTIMIZE THE C-TERMINAL LINEAR REGION OF EGF-LIKE GROWTH FACTORS FOR BINDING TO EACH ERBB RECEPTOR AND THEREBY SHOWN THAT ARG(45) IN EGF IMPAIRS BINDING TO BOTH ERBB3 AND ERBB4. BY OMITTING ALL THESE SO-CALLED NEGATIVE CONSTRAINTS FROM EGF, WE DESIGNED A LIGAND DESIGNATED PANERBIN THAT BINDS ERBB1, ERBB3, AND ERBB4 WITH SIMILARLY HIGH AFFINITY AS THEIR WILD-TYPE LIGANDS. HOMOLOGY MODELS, BASED ON THE KNOWN CRYSTAL STRUCTURE OF TGF ALPHA-BOUND ERBB1, SHOWED THAT PANERBIN IS ABLE TO BIND ERBB1, ERBB3, AND ERBB4 IN A HIGHLY SIMILAR MANNER WITH RESPECT TO POSITION AND NUMBER OF INTERACTION SITES. UPON IN SILICO INTRODUCTION OF THE EXPERIMENTALLY KNOWN NEGATIVE CONSTRAINTS INTO PANERBIN, WE FOUND THAT ARG45 INDUCED LOCAL CHARGE REPULSION AND GLU26 INDUCED STERIC HINDRANCE IN A RECEPTOR-SPECIFIC MANNER, WHEREAS SER2-ASP3 IMPAIRED BINDING DUE TO A DISORDERED CONFORMATION. FURTHERMORE, RADIOLABELED PANERBIN WAS USED TO QUANTIFY THE LEVEL OF ALL THREE RECEPTORS ON HUMAN BREAST CANCER CELLS IN A SINGLE RADIORECEPTOR ASSAY. IT IS CONCLUDED THAT THE ERBB SPECIFICITY OF EGF-LIKE GROWTH FACTORS PRIMARILY RESULTS FROM THE PRESENCE OF A LIMITED NUMBER OF RESIDUES THAT IMPAIR THE UNINTENDED INTERACTION WITH OTHER ERBB RECEPTORS.",FACTOR RECEPTOR; EGF-RECEPTOR; CRYSTAL-STRUCTURE; ERBB-2/ERBB-3 HETERODIMERS; EXTRACELLULAR DOMAIN; TYROSINE KINASE; WILD-TYPE; CANCER; AFFINITY; BINDING,NA,JOURNAL OF BIOLOGICAL CHEMISTRY,"VAN DER WONING, SP##VAN ROTTERDAM, W##NABUURS, SB##VENSELAAR, H##JACOBS-OOMEN, S##WINGENS, M##VRIEND, G##STORTELERS, C##VAN ZOELEN, EJJ","RADBOUD UNIV NIJMEGEN, DEPT CELL BIOL, FAC SCI, NL-6525 ED NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, CTR MOL & BIOMOL INFORMAT, NL-6525 ED NIJMEGEN, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693A0##BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/JBC.270.16.9585##BIECHE I, 2003, INT J CANCER, V106, P758, DOI 10.1002/IJC.11273##GARRETT TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0##GARRETT TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6##GRAZUL-BILSKA AT, 2003, DRUG TODAY, V39, P787, DOI 10.1358/DOT.2003.39.10.799472##HARARI D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/SJ.ONC.1203973##HOBBS SS, 2005, GROWTH FACTORS, V23, P273, DOI 10.1080/08977190500199345##HOBBS SS, 2004, ONCOGENE, V23, P883, DOI 10.1038/SJ.ONC.1207250##HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/J.1460-2075.1988.TB03169.X##HOOFT RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272A0##JORISSEN RN, 2000, PROTEIN SCI, V9, P310##JUNTTILA TT, 2003, CLIN CANCER RES, V9, P5346##KIENHUIS CBM, 1991, CLIN CHEM, V37, P1749##KRIEGER E, 2004, PROTEINS, V57, P678, DOI 10.1002/PROT.20251##LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9##LUO C, 2005, PROTEINS, V59, P742, DOI 10.1002/PROT.20443##MAATTA JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/MBC.E05-05-0402##OGISO H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7##REICH A, 2002, EMBO J, V21, P4287, DOI 10.1093/EMBOJ/CDF439##REISSMANN PT, 1999, J CANCER RES CLIN, V125, P61, DOI 10.1007/S004320050243##SHYU WC, 2004, NEUROBIOL AGING, V25, P935, DOI 10.1016/J.NEUROBIOLAGING.2003.10.012##SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/SCIENCE.2470152##STEIN RA, 2000, J MOL EVOL, V50, P397, DOI 10.1007/S002390010043##STORTELERS C, 2003, J BIOL CHEM, V278, P12055, DOI 10.1074/JBC.M211948200##STORTELERS C, 2002, BIOCHEMISTRY-US, V41, P8732, DOI 10.1021/BI025878C##STORTELERS C, 2002, BIOCHEMISTRY-US, V41, P4292, DOI 10.1021/BI012016N##ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418A0##VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/JBC.270.38.22337##VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V##WINGENS M, 2006, BIOCHEMISTRY-US, V45, P4703, DOI 10.1021/BI060087M##YARDEN Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073",5,2020-11-20,NA
J,WOS:000243033900033,2006,ANALYSIS OF GROWTH OF LACTOBACILLUS PLANTARUM WCFS1 ON A COMPLEX MEDIUM USING A GENOME-SCALE METABOLIC MODEL,"A GENOME-SCALE METABOLIC MODEL OF THE LACTIC ACID BACTERIUM LACTOBACILLUS PLANTARUM WCFS1 WAS CONSTRUCTED BASED ON GENOMIC CONTENT AND EXPERIMENTAL DATA. THE COMPLETE MODEL INCLUDES 721 GENES, 643 REACTIONS, AND 531 METABOLITES. DIFFERENT STOICHIOMETRIC MODELING TECHNIQUES WERE USED FOR INTERPRETATION OF COMPLEX FERMENTATION DATA, AS L. PLANTARUM IS ADAPTED TO NUTRIENT-RICH ENVIRONMENTS AND ONLY GROWS IN MEDIA SUPPLEMENTED WITH VITAMINS AND AMINO ACIDS. (I) BASED ON EXPERIMENTAL INPUT AND OUTPUT FLUXES, MAXIMAL ATP PRODUCTION WAS ESTIMATED AND RELATED TO GROWTH RATE. (II) OPTIMIZATION OF ATP PRODUCTION FURTHER IDENTIFIED AMINO ACID CATABOLIC PATHWAYS THAT WERE NOT PREVIOUSLY ASSOCIATED WITH FREE-ENERGY METABOLISM. (III) GENOME-SCALE ELEMENTARY FLUX MODE ANALYSIS IDENTIFIED 28 POTENTIAL FUTILE CYCLES. (IV) FLUX VARIABILITY ANALYSIS SUPPLEMENTED THE ELEMENTARY MODE ANALYSIS IN IDENTIFYING PARALLEL PATHWAYS, E. G. PATHWAYS WITH IDENTICAL END PRODUCTS BUT DIFFERENT CO-FACTOR USAGE. STRONGLY INCREASED FLEXIBILITY IN THE METABOLIC NETWORK WAS OBSERVED WHEN STRICT COUPLING BETWEEN CATABOLIC ATP PRODUCTION AND ANABOLIC CONSUMPTION WAS RELAXED. THESE RESULTS ILLUSTRATE HOW A GENOME-SCALE METABOLIC MODEL AND ASSOCIATED CONSTRAINT-BASED MODELING TECHNIQUES CAN BE USED TO ANALYZE THE PHYSIOLOGY OF GROWTH ON A COMPLEX MEDIUM RATHER THAN A MINIMAL SALTS MEDIUM. HOWEVER, OPTIMIZATION OF BIOMASS FORMATION USING THE FLUX BALANCE ANALYSIS APPROACH, REPORTED TO SUCCESSFULLY PREDICT GROWTH RATE AND BY PRODUCT FORMATION IN ESCHERICHIA COLI AND SACCHAROMYCES CEREVISIAE, PREDICTED TOO HIGH BIOMASS YIELDS THAT WERE INCOMPATIBLE WITH THE OBSERVED LACTATE PRODUCTION. THE REASON IS THAT THIS APPROACH ASSUMES OPTIMAL EFFICIENCY OF SUBSTRATE TO BIOMASS CONVERSION, AND CAN THEREFORE NOT PREDICT THE METABOLICALLY INEFFICIENT LACTATE FORMATION.",LACTIC-ACID BACTERIA; BACILLUS-SUBTILIS METABOLISM; ESCHERICHIA-COLI; LACTOCOCCUS-LACTIS; SACCHAROMYCES-CEREVISIAE; ADAPTIVE EVOLUTION; FLUX ANALYSIS; NETWORK; PATHWAYS; BALANCE,NA,JOURNAL OF BIOLOGICAL CHEMISTRY,"TEUSINK, B##WIERSMA, A##MOLENAAR, D##FRANCKE, C##DE VOS, WM##SIEZEN, RJ##SMID, EJ","WAGENINGEN CTR FOOD SCI, NL-6700 AN WAGENINGEN, NETHERLANDS. NIZO FOOD RES, NL-6710 BA EDE, NETHERLANDS. RADBOUD UNIV NIJMEGEN, CTR MOL & BIOMOL INFORMAT, NL-6710 BA NIJMEGEN, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"BEARD DA, 2002, BIOPHYS J, V83, P79, DOI 10.1016/S0006-3495(02)75150-3##BERTSEKAS DIMITRI P., 1998, NETWORK OPTIMIZATION##BURGARD AP, 2004, GENOME RES, V14, P301, DOI 10.1101/GR.1926504##CHRISTIANSEN T, 2002, METAB ENG, V4, P159, DOI 10.1006/MBEN.2001.0219##COOK GM, 1994, APPL ENVIRON MICROB, V60, P1942, DOI 10.1128/AEM.60.6.1942-1948.1994##DANDEKAR T, 2003, BIOSYSTEMS, V70, P255, DOI 10.1016/S0303-2647(03)00067-4##DAUNER M, 2001, J BACTERIOL, V183, P7308, DOI 10.1128/JB.183.24.7308-7317.2001##DEKEL E, 2005, NATURE, V436, P588, DOI 10.1038/NATURE03842##EDWARDS JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379##EMMERLING M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002##FAMILI I, 2003, P NATL ACAD SCI USA, V100, P13134, DOI 10.1073/PNAS.2235812100##FELL D., 1997, UNDERSTANDING CONTRO##FISCHER E, 2005, NAT GENET, V37, P636, DOI 10.1038/NG1555##FONG SS, 2004, NAT GENET, V36, P1056, DOI 10.1038/NG1432##FONG SS, 2003, J BACTERIOL, V185, P6400, DOI 10.1128/JB.185.21.6400-6408.2003##FRANCKE C, 2005, TRENDS MICROBIOL, V13, P550, DOI 10.1016/J.TIM.2005.09.001##FUHRER T, 2005, J BACTERIOL, V187, P1581, DOI 10.1128/JB.187.5.1581-1590.2005##HOFMEYR JHS, 1995, J BIOENERG BIOMEMBR, V27, P479, DOI 10.1007/BF02110188##IBARRA RU, 2002, NATURE, V420, P186, DOI 10.1038/NATURE01149##KERR B, 2002, NATURE, V418, P171, DOI 10.1038/NATURE00823##KHARCHENKO P, 2004, BIOINFORMATICS, V20, P178, DOI 10.1093/BIOINFORMATICS/BTH930##KLAPA MI, 2003, EUR J BIOCHEM, V270, P3525, DOI 10.1046/J.1432-1033.2003.03732.X##KLEEREBEZEM M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/PNAS.0337704100##KONINGS WN, 2002, ANTON LEEUW INT J G, V82, P3, DOI 10.1023/A:1020604203977##KUEPFER L, 2005, GENOME RES, V15, P1421, DOI 10.1101/GR.3992505##MAHADEVAN R, 2003, METAB ENG, V5, P264, DOI 10.1016/J.YMBEN.2003.09.002##MELCHIORSEN CR, 2001, BIOTECHNOL BIOENG, V74, P271, DOI 10.1002/BIT.1117##NEVES AR, 2005, FEMS MICROBIOL REV, V29, P531, DOI 10.1016/J.FEMSRE.2005.04.005##NIELSEN J, 1992, CHEM ENG SCI, V47, P4225, DOI 10.1016/0009-2509(92)85104-J##NOVAK L, 2000, J BACTERIOL, V182, P1136, DOI 10.1128/JB.182.4.1136-1143.2000##OLIVEIRA AP, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-39##PATIL KR, 2005, P NATL ACAD SCI USA, V102, P2685, DOI 10.1073/PNAS.0406811102##PATIL KR, 2004, CURR OPIN BIOTECH, V15, P64, DOI 10.1016/J.COPBIO.2003.11.003##PFEIFFER T, 1999, BIOINFORMATICS, V15, P251, DOI 10.1093/BIOINFORMATICS/15.3.251##PFEIFFER T, 2001, SCIENCE, V292, P504, DOI 10.1126/SCIENCE.1058079##PFEIFFER T, 2005, TRENDS BIOCHEM SCI, V30, P20, DOI 10.1016/J.TIBS.2004.11.006##PRICE ND, 2004, NAT REV MICROBIOL, V2, P886, DOI 10.1038/NRMICRO1023##REED JL, 2006, NAT REV GENET, V7, P130, DOI 10.1038/NRG1769##RUSSELL JB, 1995, MICROBIOL REV, V59, P48, DOI 10.1128/MMBR.59.1.48-62.1995##SCHUSTER S, 2000, NAT BIOTECHNOL, V18, P326, DOI 10.1038/73786##SCHUSTER S, 2002, BIOINFORMATICS, V18, P351, DOI 10.1093/BIOINFORMATICS/18.2.351##SMIT G, 2005, FEMS MICROBIOL REV, V29, P591, DOI 10.1016/J.FEMSRE.2005.04.002##STARRENBURG MJC, 1991, APPL ENVIRON MICROB, V57, P3535, DOI 10.1128/AEM.57.12.3535-3540.1991##TEMPEST DW, 1992, FEMS MICROBIOL LETT, V100, P169, DOI 10.1016/0378-1097(92)90205-3##TEMPEST DW, 1984, ANNU REV MICROBIOL, V38, P459, DOI 10.1146/ANNUREV.MI.38.100184.002331##TEUSINK B, 2005, APPL ENVIRON MICROB, V71, P7253, DOI 10.1128/AEM.71.11.7253-7262.2005##TEUSINK B, 2006, NAT REV MICROBIOL, V4, P46, DOI 10.1038/NRMICRO1319##VANDIJKEN JP, 1993, ANTON LEEUW INT J G, V63, P343, DOI 10.1007/BF00871229##VARMA A, 1994, APPL ENVIRON MICROB, V60, P3724, DOI 10.1128/AEM.60.10.3724-3731.1994##WESTERHOFT HV, 1987, THERMODYNAMICS CONTR##WIECHERT W, 2001, METAB ENG, V3, P195, DOI 10.1006/MBEN.2001.0187",191,2020-11-20,NA
J,WOS:000243033900070,2006,THE CRH FAMILY CODING FOR CELL WALL GLYCOSYLPHOSPHATIDYLINOSITOL PROTEINS WITH A PREDICTED TRANSGLYCOSIDASE DOMAIN AFFECTS CELL WALL ORGANIZATION AND VIRULENCE OF CANDIDA ALBICANS,"IN CANDIDA ALBICANS UTR2 (CSF4), CRH11, AND CRH12 ARE MEMBERS OF A GENE FAMILY ( THE CRH FAMILY) THAT ENCODE GLYCOSYLPHOSPHATIDYLINOSITOL-DEPENDENT CELL WALL PROTEINS WITH PUTATIVE TRANSGLYCOSIDASE ACTIVITY. DELETION OF GENES OF THIS FAMILY RESULTED IN ADDITIVE SENSITIVITY TO COMPOUNDS INTERFERING WITH NORMAL CELL WALL FORMATION ( CONGO RED, CALCOFLUOR WHITE, SDS, AND HIGH CA2+ CONCENTRATIONS), SUGGESTING THAT THESE GENES CONTRIBUTE TO CELL WALL ORGANIZATION. A TRIPLE MUTANT LACKING UTR2, CRH11, AND CRH12 PRODUCED A DEFECTIVE CELL WALL, AS INFERRED FROM INCREASED SENSITIVITY TO CELL WALL- DEGRADING ENZYMES, DECREASED ABILITY OF PROTOPLASTS TO REGENERATE A NEW WALL, CONSTITUTIVE ACTIVATION OF MKC1P, THE MITOGEN-ACTIVATED PROTEIN KINASE OF THE CELL WALL INTEGRITY PATHWAY, AND AN INCREASED CHITIN CONTENT OF THE CELL WALL. IMPORTANTLY, THIS WAS ACCOMPANIED BY A DECREASE IN ALKALI- INSOLUBLE 1,3-BETA-GLUCAN BUT NOT TOTAL GLUCAN CONTENT, SUGGESTING THAT FORMATION OF THE LINKAGE BETWEEN 1,3-BETA- GLUCAN AND CHITIN MIGHT BE AFFECTED. IN SUPPORT OF THIS IDEA, LOCALIZATION OF A UTR2P-GFP FUSION PROTEIN LARGELY COINCIDED WITH AREAS OF CHITIN INCORPORATION IN C. ALBICANS. AS UTR2 AND CRH11 EXPRESSION IS REGULATED BY CALCINEURIN, A SERINE/ THREONINE PROTEIN PHOSPHATASE INVOLVED IN TOLERANCE TO ANTIFUNGAL DRUGS, CELL WALL MORPHOGENESIS, AND VIRULENCE, THIS POINTS TO A POSSIBLE RELATIONSHIP BETWEEN CALCINEURIN AND THE CRH FAMILY. DELETION OF UTR2, CRH11, AND CRH12 RESULTED IN ONLY A PARTIAL OVERLAP WITH CALCINEURIN- DEPENDENT PHENOTYPES, SUGGESTING THAT CALCINEURIN HAS ADDITIONAL TARGETS. INTERESTINGLY, CELLS DELETED FOR UTR2, CRH11, AND CRH12 WERE, LIKE A CALCINEURIN MUTANT, AVIRULENT IN A MOUSE MODEL OF SYSTEMIC INFECTION BUT RETAINED THE CAPACITY TO COLONIZE TARGET ORGANS ( KIDNEYS) AS THE WILD TYPE. IN CONCLUSION, THIS WORK ESTABLISHES THE ROLE OF UTR2, CRH11, AND CRH12 IN CELL WALL ORGANIZATION AND INTEGRITY.",CARBOHYDRATE-ACTIVE ENZYMES; ABC TRANSPORTERS CDR1; ALS GENE FAMILY; SACCHAROMYCES-CEREVISIAE; GLYCOSYL HYDROLASES; PROTEOMIC ANALYSIS; DEFECTIVE-MUTANTS; GPI PROTEINS; YEAST; CALCINEURIN,NA,JOURNAL OF BIOLOGICAL CHEMISTRY,"PARDINI, G##DE GROOT, PWJ##COSTE, AT##KARABABA, M##KLIS, FM##DE KOSTER, CG##SANGLARD, D","UNIV LAUSANNE HOSP, INST MICROBIOL, CH-1011 LAUSANNE, SWITZERLAND. UNIV AMSTERDAM, SWAMMERDAM INST LIFE SCI, NL-1018 WV AMSTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"ALBERTI-SEGUI C, 2004, YEAST, V21, P285, DOI 10.1002/YEA.1061##BADER T, 2003, INFECT IMMUN, V71, P5344, DOI 10.1128/IAI.71.9.5344-5354.2003##BAHMED K, 2003, RES MICROBIOL, V154, P215, DOI 10.1016/S0923-2508(03)00049-4##BATES S, 2006, J BIOL CHEM, V281, P90, DOI 10.1074/JBC.M510360200##BERMAN J, 2002, NAT REV GENET, V3, P918, DOI 10.1038/NRG948##BLANKENSHIP JR, 2003, EUKARYOT CELL, V2, P422, DOI 10.1128/EC.2.3.422-430.2003##BRADFORD DS, 1983, J BONE JOINT SURG AM, V65, P1220, DOI 10.2106/00004623-198365090-00002##BRAND A, 2004, EUKARYOT CELL, V3, P900, DOI 10.1128/EC.3.4.900-909.2004##BRAUN PC, 1978, J BACTERIOL, V133, P1472, DOI 10.1128/JB.133.3.1472-1477.1978##CASTILLO L, 2006, FUNGAL GENET BIOL, V43, P124, DOI 10.1016/J.FGB.2005.12.002##CHAUHAN NEERAJ, 2002, P159##CORMACK BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303##COSTE AT, 2004, EUKARYOT CELL, V3, P1639, DOI 10.1128/EC.3.6.1639-1652.2004##COUTINHO PM, 1999, ROY SOC CH, P3##CRUZ MC, 2002, EMBO J, V21, P546, DOI 10.1093/EMBOJ/21.4.546##DALLIES N, 1998, YEAST, V14, P1297, DOI 10.1002/(SICI)1097-0061(1998100)14:14<1297::AID-YEA310>3.0.CO;2-L##DE GROOT PWJ, 2004, EUKARYOT CELL, V3, P955, DOI 10.1128/EC.3.4.955-965.2004##DE GROOT PWJ, 2003, YEAST, V20, P781, DOI 10.1002/YEA.1007##DE MICHELI M, 2002, MOL MICROBIOL, V43, P1197, DOI 10.1046/J.1365-2958.2002.02814.X##DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167A0##FONZI WA, 1993, GENETICS, V134, P717##FRADIN C, 2005, MOL MICROBIOL, V56, P397, DOI 10.1111/J.1365-2958.2005.04557.X##HANAHAN D., 1985, DNA CLONING PRACTICA, P109##HAZAN I, 2002, EUKARYOT CELL, V1, P856, DOI 10.1128/EC.1.6.856-864.2002##HAZAN I, 2002, MOL BIOL CELL, V13, P134, DOI 10.1091/MBC.01-03-0116##HENRISSAT B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/BJ3160695##HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/BJ2930781##HOYER LL, 1998, CURR GENET, V33, P451, DOI 10.1007/S002940050359##HOYER LL, 2001, GENETICS, V157, P1555##HOYER LL, 2001, TRENDS MICROBIOL, V9, P176, DOI 10.1016/S0966-842X(01)01984-9##HWANG JS, 2006, YEAST, V23, P803, DOI 10.1002/YEA.1395##KAPTEYN JC, 2000, MOL MICROBIOL, V35, P601, DOI 10.1046/J.1365-2958.2000.01729.X##KAPTEYN JC, 1997, J BACTERIOL, V179, P6279, DOI 10.1128/JB.179.20.6279-6284.1997##KAPTEYN JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8##KARABABA M, 2006, MOL MICROBIOL, V59, P1429, DOI 10.1111/J.1365-2958.2005.05037.X##KLIS FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/J.1574-6976.2002.TB00613.X##LIPKE PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998##MAGNELLI P, 2002, ANAL BIOCHEM, V301, P136, DOI 10.1006/ABIO.2001.5473##MARTINEZ-LOPEZ R, 2004, MICROBIOL-SGM, V150, P3341, DOI 10.1099/MIC.0.27320-0##MERA N, 2004, J BIOSCI BIOENG, V97, P169##MOUYNA I, 2000, J BIOL CHEM, V275, P14882, DOI 10.1074/JBC.275.20.14882##MRSA V, 1993, J BACTERIOL, V175, P2102, DOI 10.1128/JB.175.7.2102-2106.1993##NAVARRO-GARCIA F, 2005, MICROBIOL-SGM, V151, P2737, DOI 10.1099/MIC.0.28038-0##NAVARRO-GARCIA F, 1998, MICROBIOL-UK, V144, P411, DOI 10.1099/00221287-144-2-411##NETEA MG, 2006, J CLIN INVEST, V116, P1642, DOI 10.1172/JCI27114##PARDO M, 2004, MICROBIOL-SGM, V150, P4157, DOI 10.1099/MIC.0.26924-0##REUSS O, 2004, GENE, V341, P119, DOI 10.1016/J.GENE.2004.06.021##RODRIGUEZ-PENA JM, 2002, J CELL SCI, V115, P2549##RODRIGUEZ-PENA JM, 2000, MOL CELL BIOL, V20, P3245, DOI 10.1128/MCB.20.9.3245-3255.2000##SANGLARD D, 2003, MOL MICROBIOL, V48, P959, DOI 10.1046/J.1365-2958.2003.03495.X##SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378##SIETSMA JH, 1990, J GEN MICROBIOL, V136, P2261, DOI 10.1099/00221287-136-11-2261##SUDBERY P, 2004, TRENDS MICROBIOL, V12, P317, DOI 10.1016/J.TIM.2004.05.008##SUNDSTROM P, 2002, CELL MICROBIOL, V4, P461, DOI 10.1046/J.1462-5822.2002.00206.X##SUNDSTROM P, 2002, INFECT IMMUN, V70, P3281, DOI 10.1128/IAI.70.6.3281-3283.2002##TABERNERO C, 1994, APPL ENVIRON MICROB, V60, P1213, DOI 10.1128/AEM.60.4.1213-1220.1994##VILADOT JL, 1998, BIOCHEMISTRY-US, V37, P11332, DOI 10.1021/BI980586Q##WHEELER RT, 2006, PLOS PATHOG, V2, P328, DOI 10.1371/JOURNAL.PPAT.0020035##YIN QY, 2005, J BIOL CHEM, V280, P20894, DOI 10.1074/JBC.M500334200",75,2020-11-20,NA
J,WOS:000243033900080,2006,TELOMERASE-INDEPENDENT REGULATION OF ATR BY HUMAN TELOMERASE RNA,"THE HUMAN TELOMERASE RNA ( HTR), TOGETHER WITH THE TELOMERASE REVERSE TRANSCRIPTASE, HTERT, CONSTITUTE THE CORE COMPONENTS OF TELOMERASE THAT IS ESSENTIAL FOR TELOMERE MAINTENANCE. WHILE HTR IS UBIQUITOUSLY EXPRESSED, HTERT IS NORMALLY RESTRICTED TO GERM CELLS AND CERTAIN STEM CELLS, BUT BOTH ARE OFTEN DEREGULATED DURING TUMORIGENESIS. HERE, WE INVESTIGATED THE EFFECTS OF CHANGES IN HTR CELLULAR LEVELS. SURPRISINGLY, WHILE INHIBITION OF HTR EXPRESSION TRIGGERS A RAPID, TELOMERASE- INDEPENDENT, GROWTH ARREST ASSOCIATED WITH P53 AND CHK1 ACTIVATION, ITS INCREASED EXPRESSION NEUTRALIZES ACTIVATION OF THESE PATHWAYS IN RESPONSE TO GENOTOXIC STRESS. THESE HTR EFFECTS ARE MEDIATED THROUGH ATR AND ARE SUFFICIENTLY STRONG TO IMPAIR ATR- MEDIATED DNA- DAMAGE CHECKPOINT RESPONSES. FURTHERMORE, IN RESPONSE TO LOW UV RADIATION, WHICH ACTIVATES ATR, ENDOGENOUS HTR LEVELS INCREASE IRRESPECTIVE OF TELOMERASE STATUS. THUS, WE UNCOVERED A NOVEL, TELOMERASE- INDEPENDENT, FUNCTION OF HTR THAT RESTRAINS ATR ACTIVITY AND PARTICIPATES IN THE RECOVERY OF CELLS FROM UV RADIATION.",IMMORTAL HUMAN-CELLS; DNA-DAMAGE; MULTISTAGE PATHOGENESIS; REVERSE-TRANSCRIPTASE; PROLIFERATION INDEX; CYCLE ARREST; EXPRESSION; COMPONENT; INHIBITION; LENGTH,NA,JOURNAL OF BIOLOGICAL CHEMISTRY,"KEDDE, M##SAGE, CI##DUURSMA, A##ZLOTORYNSKI, E##VAN LEEUWEN, B##NIJKAMP, W##BEIJERSBERGEN, R##AGAMI, R","NETHERLANDS CANC INST, DIV TUMOR BIOL, NL-1066 CX AMSTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"AGAMI R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6##BLASCO MA, 1996, NAT GENET, V12, P200, DOI 10.1038/NG0296-200##BLASCO MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4##BROCCOLI D, 1996, MOL CELL BIOL, V16, P3765##BROWN DF, 1997, J NEUROPATH EXP NEUR, V56, P1349, DOI 10.1097/00005072-199712000-00009##BROWN EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/GAD.1067403##BRUMMELKAMP TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8##BRUMMELKAMP TR, 2002, SCIENCE, V296, P550, DOI 10.1126/SCIENCE.1068999##BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/J.1460-2075.1995.TB00098.X##BRYAN TM, 1997, NAT MED, V3, P1271, DOI 10.1038/NM1197-1271##BUSBY EC, 2000, CANCER RES, V60, P2108##CASPER AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3##CHEN JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X##CHIANG YJ, 2004, MOL CELL BIOL, V24, P7024, DOI 10.1128/MCB.24.16.7024-7031.2004##CHIN L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X##CONG YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002##COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/J.1460-2075.1992.TB05245.X##DI FAGAGNA FD, 2003, NATURE, V426, P194, DOI 10.1038/NATURE02118##DI FAGAGNA FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/GAD.1214504##DOME JS, 2005, J CLIN ONCOL, V23, P9138, DOI 10.1200/JCO.2005.00.562##DUURSMA A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005##FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/SCIENCE.7544491##GONZALEZ-SUAREZ E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089##GRAVES PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/JBC.275.8.5600##GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9##HAHN WC, 1999, NAT MED, V5, P1164##HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458A0##HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6##HEFFERNAN TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002##HEMANN MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9##HERBERT BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/PNAS.96.25.14276##HERBIG U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4##KARLSEDER J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/JOURNAL.PBIO.0020240##KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/SCIENCE.7605428##KIM NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/NAR/25.13.2595##KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400A0##LI S, 2005, J BIOL CHEM, V280, P23709, DOI 10.1074/JBC.M502782200##LI S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953##LINGNER J, 1997, SCIENCE, V276, P561, DOI 10.1126/SCIENCE.276.5312.561##MAITRA A, 1999, CANCER-AM CANCER SOC, V85, P741, DOI 10.1002/(SICI)1097-0142(19990201)85:3<741::AID-CNCR25>3.0.CO;2-6##MASUTOMI K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6##MITCHELL JR, 1999, NATURE, V402, P551, DOI 10.1038/990141##MORALES CP, 1998, CANCER, V83, P652, DOI 10.1002/(SICI)1097-0142(19980815)83:4<652::AID-CNCR4>3.0.CO;2-M##PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/PNAS.92.11.4818##RIGAUT G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732##RITCHIE KB, 1999, MOL CELL BIOL, V19, P6065##RUSHING EJ, 1997, J NEUROPATH EXP NEUR, V56, P1142, DOI 10.1097/00005072-199710000-00008##SAGE J, 2003, NATURE, V424, P223, DOI 10.1038/NATURE01764##SANCAR A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/ANNUREV.BIOCHEM.73.011303.073723##SCHEEL C, 2001, ONCOGENE, V20, P3835, DOI 10.1038/SJ.ONC.1204493##SCHERR M, 2005, GENE THER, V12, P12, DOI 10.1038/SJ.GT.3302328##SCHWARTZ M, 2006, CANCER LETT, V232, P13, DOI 10.1016/J.CANLET.2005.07.039##SHAY JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2##SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2##SHECHTER D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/NCB1145##SMOGORZEWSKA A, 2002, EMBO J, V21, P4338, DOI 10.1093/EMBOJ/CDF433##SODER AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/SJ.ONC.1201066##STEWART SA, 2003, NAT GENET, V33, P492, DOI 10.1038/NG1127##TAKAI H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6##TAKATA H, 2005, MOL CELL, V17, P573, DOI 10.1016/J.MOLCEL.2005.01.014##TAKATA H, 2004, MOL CELL, V14, P515, DOI 10.1016/S1097-2765(04)00262-X##TIBBETTS RS, 1999, GENE DEV, V13, P152, DOI 10.1101/GAD.13.2.152##VERDUN RE, 2005, MOL CELL, V20, P551, DOI 10.1016/J.MOLCEL.2005.09.024##VESPA L, 2005, GENE DEV, V19, P2111, DOI 10.1101/GAD.1333805##VOORHOEVE PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X##VULLIAMY T, 2001, NATURE, V413, P432, DOI 10.1038/35096585##WRIGHT WE, 1996, DEV GENET, V18, P173##YASHIMA K, 1998, CLIN CANCER RES, V4, P229##YASHIMA K, 1997, CANCER RES, V57, P2373##YI XM, 1999, MOL CELL BIOL, V19, P3989##ZHAO H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001",53,2020-11-20,NA
J,WOS:000242974300083,2006,EFFECT OF ALUMINUM ON THE NATURE OF THE IRON SPECIES IN FE-SBA-15,"WE REPORT THE PREPARATION OF HIGHLY ORDERED MESOPOROUS FE-AL-SBA-15 WITH ISOLATED EXTRAFRAMEWORK FE SPECIES UNDER ACIDIC CONDITIONS. THE MATERIALS WERE CHARACTERIZED BY MEANS OF UV RESONANCE RAMAN SPECTROSCOPY, IN CONJUNCTION WITH BET, XRD, TEM, UV-VIS, H-2-TPR, FT-IR, AND AL-27 MAS NMR SPECTROSCOPY. THE ADDITION OF BOTH FE AND AL TO THE SYNTHESIS GEL OF SBA-15 RESULTS IN THE FORMATION OF ISOLATED EXTRAFRAMEWORK FE SPECIES LOCATED CLOSE TO THE FRAMEWORK AL IONS AND THE FE CONTENT AN ORDER OF MAGNITUDE HIGHER THAN THAT IN FE-SBA-15 SYNTHESIZED WITHOUT AL. THE EXISTENCE OF ANCHORED EXTRAFRAMEWORK FE SPECIES WAS CONFIRMED BY THE PRESENCE OF A STRONG ABSORPTION BAND AT 270 NM, HYDROGEN REDUCTION AT RELATIVELY LOW TEMPERATURE, AND THE PRESENCE OF A RESONANCE RAMAN BAND AT 1140 CM(-1). THE LOCATION OF FE IN CLOSE PROXIMITY TO FRAMEWORK AL NUCLEI IS FURTHER SUPPORTED BY AL-27 MAS NMR MEASUREMENTS. TWO CHARACTERISTIC UV RAMAN BANDS AT 510 CM(-1) AND 1090 CM(-1) EXCITED BY 244-NM LASER ARE ASSIGNED TO FE-O-SI SYMMETRIC AND ASYMMETRIC STRETCHING MODES OF ISOLATED TETRAHEDRAL FE IONS IN THE SILICA FRAMEWORK FOR FE-SBA-15. THE RESONANCE RAMAN BAND AT 1140 CM(-1) EXCITED BY 325-NM LASER IS ATTRIBUTED TO THE ASYMMETRIC STRETCHING MODE OF THE ISOLATED EXTRAFRAMEWORK IRON SPECIES IN FE-AL-SBA-15. THE ISOLATED FE SPECIES CLOSE TO FRAMEWORK AL SPECIES ARE STABLE IN ACIDIC HCL SOLUTION, WHEREAS THE MAJORITY OF FE SPECIES IN FE-SBA-15 CAN BE EASILY REMOVED.",HIGH-TEMPERATURE TREATMENT; CHEMICAL-VAPOR-DEPOSITION; STATE ION-EXCHANGE; SELECTIVE OXIDATION; NITROUS-OXIDE; MESOPOROUS MATERIALS; N2O DECOMPOSITION; EXTRAFRAMEWORK IRON; FE-SILICALITE; MFI ZEOLITES,NA,JOURNAL OF PHYSICAL CHEMISTRY B,"LI, Y##FENG, ZC##XIN, HC##FAN, FT##ZHANG, J##MAGUSIN, PCMM##HENSEN, EJM##VAN SANTEN, RA##YANG, QH##LI, C","CHINESE ACAD SCI, DALIAN INST CHEM PHYS, STATE KEY LAB CATALYSIS, DALIAN 116023, PEOPLES R CHINA. EINDHOVEN UNIV TECHNOL, SCHUIT INST CATALYSIS, NL-5600 MB EINDHOVEN, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"ARAKAWA H, 2001, CHEM REV, V101, P953, DOI 10.1021/CR000018S##BERLIER G, 2002, J CATAL, V208, P64, DOI 10.1006/JCAT.2002.3535##BERLIER G, 2003, J CATAL, V215, P264, DOI 10.1016/S0021-9517(03)00004-6##BORDIGA S, 2003, PHYS CHEM CHEM PHYS, V5, P4390, DOI 10.1039/B306041C##BORDIGA S, 1996, J CATAL, V158, P486, DOI 10.1006/JCAT.1996.0048##BORDIGA S, 2002, ANGEW CHEM INT EDIT, V41, P4734, DOI 10.1002/ANIE.200290032##CAREY P. R., 1982, BIOCH APPL RAMAN RES##CENTI G, 2001, NATO SCI SERIES, V2##EMEIS CA, 1993, J CATAL, V141, P347, DOI 10.1006/JCAT.1993.1145##FUJDALA KL, 2004, J AM CHEM SOC, V126, P10864, DOI 10.1021/JA048701+##GOLDFARB D, 1994, J AM CHEM SOC, V116, P6344, DOI 10.1021/JA00093A039##GROOTHAERT MH, 2005, J AM CHEM SOC, V127, P1394, DOI 10.1021/JA047158U##GROOTHAERT MH, 2003, J AM CHEM SOC, V125, P7629, DOI 10.1021/JA029684W##HAN Y, 2003, MICROPOR MESOPOR MAT, V57, P191, DOI 10.1016/S1387-1811(02)00590-5##HENSEN EJM, 2005, J CATAL, V233, P123, DOI 10.1016/J.JCAT.2005.04.009##HENSEN EJM, 2003, J CATAL, V220, P260, DOI 10.1016/J.JCAT.2003.09.001##HENSEN EJM, 2004, J CATAL, V221, P560, DOI 10.1016/J.JCAT.2003.09.024##HENSEN EJM, 2005, J CATAL, V233, P136, DOI 10.1016/J.JCAT.2005.04.008##HOLLAND AW, 2005, J CATAL, V235, P150, DOI 10.1016/J.JCAT.2005.07.003##JIA JF, 2004, J CATAL, V221, P119, DOI 10.1016/J.JCAT.2003.08.010##KRUK D, 2001, PHYS CHEM CHEM PHYS, V3, P4907, DOI 10.1039/B106659P##KUMAR MS, 2004, J CATAL, V227, P384, DOI 10.1016/J.JCAT.2004.08.003##LI C, 1999, ANGEW CHEM INT EDIT, V38, P2220, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2220::AID-ANIE2220>3.3.CO;2-7##LI C, 2003, J CATAL, V216, P203, DOI 10.1016/S0021-9517(02)00107-0##LI Y, 1999, APPL CATAL A-GEN, V188, P211, DOI 10.1016/S0926-860X(99)00236-7##LI Y, 2005, MICROPOR MESOPOR MAT, V84, P41, DOI 10.1016/J.MICROMESO.2005.05.021##LI Y, 2004, J PHYS CHEM B, V108, P9739, DOI 10.1021/JP049824J##LOBREE LJ, 1999, J CATAL, V186, P242, DOI 10.1006/JCAT.1999.2548##MARTURANO P, 2000, J CATAL, V192, P236, DOI 10.1006/JCAT.2000.2837##NISHIMURA Y, 1978, ADV INFRARED RAMAN S##NOZAKI C, 2002, J AM CHEM SOC, V124, P13194, DOI 10.1021/JA020388T##PANOV G. I., 2000, CATTECH, V4, P18, DOI DOI 10.1023/A:1011991110517##PARRY EP, 1963, J CATAL, V2, P371, DOI 10.1016/0021-9517(63)90102-7##PEREZ-RAMIREZ J, 2004, J CATAL, V223, P13, DOI 10.1016/J.JCAT.2004.01.007##PEREZ-RAMIREZ J, 2002, APPL CATAL B-ENVIRON, V35, P227, DOI 10.1016/S0926-3373(01)00259-4##PEREZ-RAMIREZ J, 2001, CHEM COMMUN, P693, DOI 10.1039/B100953M##RICCHIARDI G, 2001, J AM CHEM SOC, V123, P11409, DOI 10.1021/JA010607V##SAMANTA S, 2003, IND ENG CHEM RES, V42, P3012, DOI 10.1021/IE020905G##SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/PAC198557040603##STRIJKERS GJ, 2005, MAGN RESON MATER PHY, V18, P186, DOI 10.1007/S10334-005-0111-Y##SUN K, 2003, J CATAL, V238, P186##SUN KQ, 2004, CHEM COMMUN, P2480, DOI 10.1039/B408854A##SZEGEDI A, 2004, APPL CATAL A-GEN, V272, P257, DOI 10.1016/J.APCATA.2004.05.057##TAGUCHI A, 2005, MICROPOR MESOPOR MAT, V77, P1, DOI 10.1016/J.MICROMESO.2004.06.030##TUEL A, 1996, CHEM MATER, V8, P114, DOI 10.1021/CM950276J##TUEL A, 1998, J CHEM SOC FARADAY T, V94, P3501, DOI 10.1039/A806912C##WANG Y, 2002, J CATAL, V209, P186, DOI 10.1006/JCAT.2002.3607##XIONG G, 2000, CHEM COMMUN, P677, DOI 10.1039/B000557F##XU MC, 2002, J PHYS CHEM B, V106, P3202, DOI 10.1021/JP014222A##YANG QH, 2000, APPL CATAL A-GEN, V194, P507, DOI 10.1016/S0926-860X(99)00397-X##YU Y, 2000, J CATAL, V194, P487, DOI 10.1006/JCAT.2000.2946##ZHANG L, 2005, J MATER CHEM, V15, P2562, DOI 10.1039/B504030B##ZHANG WH, 2002, CHEM MATER, V14, P3413, DOI 10.1021/CM011686C##ZHANG YH, 2006, CHEM MATER, V18, P2347, DOI 10.1021/CM052291M##ZHAO DY, 1998, SCIENCE, V279, P548, DOI 10.1126/SCIENCE.279.5350.548##ZHAO DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/JA974025I##ZHU Q, 2004, J CATAL, V221, P575, DOI 10.1016/J.JCAT.2003.09.025##ZHU Q, 2002, CATAL LETT, V81, P205, DOI 10.1023/A:1016581107432",61,2020-11-20,NA
J,WOS:000242974300098,2006,COUPLING QUANTUM MONTE CARLO TO A NONLINEAR POLARIZABLE CONTINUUM MODEL FOR SPHERICAL SOLUTES,"STARTING FROM THE NONLINEAR DIELECTRIC RESPONSE MODEL OF SANDBERG AND EDHOLM, WE DERIVE AN ANALYTICAL EXPRESSION OF THE POLARIZATION CONTRIBUTION TO THE SOLVATION FREE ENERGY IN TERMS OF THE ELECTRONIC DENSITY OF THE SOLUTE AND THE DIELECTRIC PROPERTIES OF THE SOLVENT. THE SOLVENT INHOMOGENEITY IS TAKEN INTO ACCOUNT WITH THE USE OF A SMOOTH SWITCHING FUNCTION WHOSE SPACIAL VARIATION IS ESTABLISHED ON THE BASIS OF HOW THE SOLVENT IS ARRANGED AROUND THE SOLUTE. AN EXPLICIT FORM OF A LOCAL POTENTIAL REPRESENTING THE SOLVENT EFFECT ON THE SOLUTE IS THUS OBTAINED BY FUNCTIONAL ANALYSIS. THIS EFFECTIVE POTENTIAL CAN BE COMBINED WITH DENSITY FUNCTIONAL OR QUANTUM CHEMICAL METHODS FOR THE QUANTUM MECHANICAL TREATMENT OF THE SOLUTE. HERE, WE USE QUANTUM MONTE CARLO TECHNIQUES FOR THE SOLUTE AND APPLY THE METHOD TO THE HYDRATION OF ATOMIC IONS FINDING VERY GOOD AGREEMENT WITH EXPERIMENTAL DATA.",SOLVATION FREE-ENERGY; WAVE-FUNCTIONS; AQUEOUS-SOLUTION; REACTION FIELD; HYDRATION; WATER; IONS; POTENTIALS; SIMULATION; MOLECULES,NA,JOURNAL OF PHYSICAL CHEMISTRY B,"AMOVILLI, C##FILIPPI, C##FLORIS, FM","UNIV PISA, DIPARTIMENTO CHIM & CHIM IND, I-56126 PISA, ITALY. LEIDEN UNIV, INST LORENTZ THEORET PHYS, NL-2333 CA LEIDEN, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"AMOVILLI C, 2002, THEORET COMPUT CHEM, V10, P415, DOI 10.1016/S1380-7323(02)80015-2##AMOVILLI C, 2001, ORGANOMETALLICS, V20, P1310, DOI 10.1021/OM000854S##AMOVILLI C, 1997, J PHYS CHEM B, V101, P1051, DOI 10.1021/JP9621991##AMOVILLI C, 1998, J PHYS CHEM B, V102, P3023, DOI 10.1021/JP9803945##AMOVILLI C, 1995, CHEM PHYS, V198, P71, DOI 10.1016/0301-0104(95)00105-W##BARONE V, 1997, J CHEM PHYS, V107, P3210, DOI 10.1063/1.474671##BLAAK R, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2185092##CAMMI R, 1999, J CHEM PHYS, V110, P9877, DOI 10.1063/1.478861##CANCES E, 1997, J CHEM PHYS, V107, P3032, DOI 10.1063/1.474659##CANCES E, 2001, J CHEM PHYS, V115, P6130, DOI 10.1063/1.1401157##CAPPELLI C, 2001, J CHEM PHYS, V115, P5531, DOI 10.1063/1.1396678##CHIPMAN DM, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2203068##CHIPMAN DM, 2004, J CHEM PHYS, V120, P5566, DOI 10.1063/1.1648632##CHIPMAN DM, 1996, J CHEM PHYS, V104, P3276, DOI 10.1063/1.471017##CHIPMAN DM, 2002, J CHEM PHYS, V116, P10129, DOI 10.1063/1.1477928##COSSI M, 2003, J COMPUT CHEM, V24, P669, DOI 10.1002/JCC.10189##COSSI M, 1994, CHEM PHYS LETT, V228, P165, DOI 10.1016/0009-2614(94)00909-0##CRAMER CJ, 1999, CHEM REV, V99, P2161, DOI 10.1021/CR960149M##DANG LX, 1991, J AM CHEM SOC, V113, P2481, DOI 10.1021/JA00007A021##DAVIDSON ER, 1991, PHYS REV A, V44, P7071, DOI 10.1103/PHYSREVA.44.7071##DEBYE P, 1912, PHYS Z, V13, P97##DELVALLE FJO, 1990, CHEM PHYS, V143, P371, DOI 10.1016/0301-0104(90)87017-6##EHRENSON S, 1989, J COMPUT CHEM, V10, P77, DOI 10.1002/JCC.540100108##FELLER D, 1987, J CHEM PHYS, V86, P3424, DOI 10.1063/1.451999##FILIPPI C, 1996, J CHEM PHYS, V105, P213, DOI 10.1063/1.471865##FLORIS F, 1992, CHEM PHYS LETT, V199, P518, DOI 10.1016/0009-2614(92)85003-S##FLORIS FM, 2005, J PHYS CHEM B, V109, P24061, DOI 10.1021/JP053457+##FLORIS FM, 2001, J CHEM PHYS, V115, P4750, DOI 10.1063/1.1391479##FLORIS FM, 1999, MOL DYNAMICS CLASSIC##FRAGA S., 1976, HDB ATOMIC DATA##FRISCH MJ, 2004, GAUSSIAN 03 REVISION##GALVAN IF, 2004, J COMPUT CHEM, V25, P1227, DOI 10.1002/JCC.20048##HEUFT JM, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1853352##HORI A, 2003, CAN J PHYS, V81, P33, DOI 10.1139/P02-147##HUANG CJ, 1997, J CHEM PHYS, V107, P3007, DOI 10.1063/1.474658##HYUN JK, 1995, J PHYS CHEM-US, V99, P5187, DOI 10.1021/J100014A046##JASZUNSKI M, 2000, J PHYS CHEM A, V104, P1466, DOI 10.1021/JP994204H##KOVALENKO A, 2000, J CHEM PHYS, V113, P2793, DOI 10.1063/1.1305885##LAIDIG KE, 2000, COORDIN CHEM REV, V197, P125, DOI 10.1016/S0010-8545(99)00152-6##LI H, 2004, J COMPUT CHEM, V25, P1449, DOI 10.1002/JCC.20072##MARCUS Y., 1997, IONS PROPERTIES##MARKHAM GD, 1996, J PHYS CHEM-US, V100, P3488, DOI 10.1021/JP952531T##MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2##OHRN A, 2004, J PHYS CHEM B, V108, P8452, DOI 10.1021/JP049303W##PENG ZW, 1997, J PHYS CHEM A, V101, P7243, DOI 10.1021/JP964080Y##PLIEGO JR, 2002, PHYS CHEM CHEM PHYS, V4, P1622, DOI 10.1039/B109595A##PLIEGO JR, 2000, CHEM PHYS LETT, V332, P597, DOI 10.1016/S0009-2614(00)01305-1##RIVAIL JL, 1996, MOL PHYS, V89, P1521, DOI 10.1080/00268979609482555##SANCHEZ ML, 2000, J COMPUT CHEM, V21, P705, DOI 10.1002/(SICI)1096-987X(20000715)21:9<705::AID-JCC1>3.0.CO;2-O##SANDBERG L, 2002, J PHYS CHEM B, V106, P7889, DOI 10.1021/JP020434B##SANDBERG L, 2002, J CHEM PHYS, V116, P2936, DOI 10.1063/1.1435566##SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/JCC.540141112##TOMASI J, 2005, CHEM REV, V105, P2999, DOI 10.1021/CR9904009##UMRIGAR C. J., CHAMP IS QUANTUM MON##UMRIGAR CJ, 1988, PHYS REV LETT, V60, P1719, DOI 10.1103/PHYSREVLETT.60.1719##VANLEEUWEN R, 1995, PHYS REV A, V51, P170, DOI 10.1103/PHYSREVA.51.170",10,2020-11-20,NA
J,WOS:000242974300112,2006,DNA-BASED MOLECULAR WIRES: MULTIPLE EMISSION PATHWAYS OF INDIVIDUAL CONSTRUCTS,"THE EXTENT OF PHOTON ENERGY TRANSFER THROUGH INDIVIDUAL DNA-BASED MOLECULAR WIRES COMPOSED OF FIVE DYES IS INVESTIGATED AT THE SINGLE MOLECULAR LEVEL. COMBINING SINGLE-MOLECULE SPECTROSCOPY AND PULSE INTERLEAVED EXCITATION IMAGING, WE HAVE DIRECTLY RESOLVED THE TIME EVOLUTION SPECTRAL RESPONSE OF INDIVIDUAL CONSTRUCTS, WHILE SIMULTANEOUSLY PROBING DNA INTEGRITY. OUR DATA CLEARLY SHOW THAT INTACT WIRES EXHIBIT PHOTON-TRANSFER EFFICIENCIES CLOSE TO 100% ACROSS FIVE DYES. DYNAMICAL AND MULTIPLE PATHWAYS FOR THE PHOTON EMISSION RESULTING FROM CONFORMATIONAL FREEDOM OF THE WIRE ARE READILY UNCOVERED. THESE RESULTS PROVIDE THE BASIS FOR GUIDING THE SYNTHESIS OF DNA-BASED SUPRAMOLECULAR ARRAYS WITH IMPROVED PHOTON TRANSPORT AT THE NANOMETER SCALE.",ENERGY-TRANSFER; SINGLE MOLECULES; PHOTONIC WIRES; CHEMISTRY; DESIGN; SYSTEM,NA,JOURNAL OF PHYSICAL CHEMISTRY B,"SANCHEZ-MOSTEIRO, G##VAN DIJK, EMHP##HERNANDO, J##HEILEMANN, M##TINNEFELD, P##SAUER, M##KOBERLIN, F##PATTING, M##WAHL, M##ERDMANN, R##VAN HULST, NF##GARCIA-PARAJO, MF","ICREA, BARCELONA 08015, SPAIN. ICFO INST CIENCIES FOTON, CASTELLDEFELS 08860, SPAIN. UNIV TWENTE, APPL OPT GRP, FAC SCI & TECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV TWENTE, MESA INST TECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV AUTONOMA BARCELONA, DEPT QUIM, CERDANYOLA DEL VALLES 08193, SPAIN. UNIV OXFORD, DEPT PHYS, CLARENDON LAB, OXFORD OX1 3PU, ENGLAND. UNIV BIELEFELD, FAC PHYS, D-33615 BIELEFELD, GERMANY. PICOQUANT GMBH, D-12489 BERLIN, GERMANY. BARELONA SCI PK PCB, LAB NANOBIOENGN, BARCELONA 08028, SPAIN.","CHEMISTRY, PHYSICAL",CHEMISTRY,"AMBROISE A, 2002, J ORG CHEM, V67, P3811, DOI 10.1021/JO025561I##ANDREW P, 2000, SCIENCE, V290, P785, DOI 10.1126/SCIENCE.290.5492.785##DIETRICH A, 2002, REV MOL BIOTECHNOL, V82, P211, DOI DOI 10.1016/S1389-0352(01)00039-3##FERIGA BL, 2000, ACCOUNTS CHEM RES, V34, P504##FERINGA BL, 2000, CHEM REV, V100, P1789, DOI 10.1021/CR9900228##GARCIA-PARAJO MF, 2005, CHEMPHYSCHEM, V6, P819, DOI 10.1002/CPHC.200400630##HABUCHI S, 2005, P NATL ACAD SCI USA, V102, P9511, DOI 10.1073/PNAS.0500489102##HANNAH KC, 2004, ACCOUNTS CHEM RES, V37, P845, DOI 10.1021/AR030257C##HEILEMANN M, 2004, J AM CHEM SOC, V126, P6514, DOI 10.1021/JA049351U##HEILEMANN M, 2005, J AM CHEM SOC, V127, P3801, DOI 10.1021/JA044686X##HERNANDO J, 2003, J PHYS CHEM A, V107, P43, DOI 10.1021/JP0218995##HERNANDO J, 2004, ANGEW CHEM, V116, P4137##HOLTEN D, 2002, ACCOUNTS CHEM RES, V35, P57, DOI 10.1021/AR970264Z##HUGEL T, 2002, SCIENCE, V296, P1103, DOI 10.1126/SCIENCE.1069856##IRIE M, 2002, NATURE, V420, P759, DOI 10.1038/420759A##KIM YH, 2001, J AM CHEM SOC, V123, P76, DOI 10.1021/JA0009976##MORESCO F, 2001, PHYS REV LETT, V86, P672, DOI 10.1103/PHYSREVLETT.86.672##MULLER BK, 2005, BIOPHYS J, V89, P3508, DOI 10.1529/BIOPHYSJ.105.064766##RUETTINGER S, IN PRESS J BIOMED OP##SEEMAN NC, 2003, NATURE, V421, P427, DOI 10.1038/NATURE01406##TINNEFELD P, 2005, ANGEW CHEM INT EDIT, V44, P2642, DOI 10.1002/ANIE.200300647##TINNEFELD P, 2005, CHEMPHYSCHEM, V6, P217, DOI 10.1002/CPHC.200400513##TINNEFELD P, 2005, ANGEW CHEM, V117, P2698##VYAWAHARE S, 2004, NANO LETT, V4, P1035, DOI 10.1021/NL049660I##WAGNER RW, 1996, J AM CHEM SOC, V118, P3996, DOI 10.1021/JA9602657##WAHL M, 2004, CURR PHARM BIOTECHNO, V5, P299, DOI 10.2174/1389201043376841##XIE XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/ANNUREV.PHYSCHEM.49.1.441##YASUTOMI S, 2004, SCIENCE, V304, P1944, DOI 10.1126/SCIENCE.1098489",37,2020-11-20,ICREAICREA FUNDING SOURCE: CUSTOM
J,WOS:000242822700004,2006,EFFECTS OF HISTONE DEACETYLATION INHIBITION ON NEURONAL DIFFERENTIATION OF EMBRYONIC MOUSE NEURAL STEM CELLS,"NEURAL STEM CELLS (NSCS) ARE MULTIPOTENT CELLS THAT HAVE THE CAPACITY FOR SELF-RENEWAL AND FOR DIFFERENTIATION INTO THE MAJOR CELL TYPES OF THE NERVOUS SYSTEM, I.E. NEURONS, ASTROCYTES AND OLIGODENDROCYTES. THE MOLECULAR MECHANISMS REGULATING GENE TRANSCRIPTION RESULTING IN NSC DIFFERENTIATION AND CELL LINEAGE SPECIFICATION ARE SLOWLY BEING UNRAVELED. AN IMPORTANT MECHANISM IN TRANSCRIPTIONAL REGULATION IS MODULATION OF CHROMATIN BY HISTONE ACETYLATION AND DEACETYLATION, ALLOWING OR BLOCKING THE ACCESS OF TRANSCRIPTIONAL FACTORS TO DNA SEQUENCES. THE PRECISE INVOLVEMENT OF HISTONE ACETYLTRANSFERASES AND HISTONE DEACETYLASES (HDACS) IN THE DIFFERENTIATION OF NSCS INTO MATURE FUNCTIONAL NEURONS IS STILL TO BE REVEALED. IN THIS IN VITRO STUDY WE HAVE INVESTIGATED THE EFFECTS OF THE HDAC INHIBITOR TRICHOSTATIN A (TSA) ON THE DIFFERENTIATION PATTERN OF EMBRYONIC MOUSE NSCS DURING CULTURE IN A MINIMAL, SERUM-FREE MEDIUM, LACKING ANY INDUCTION OR GROWTH FACTOR. WE DEMONSTRATED THAT UNDER THESE BASIC CONDITIONS TSA TREATMENT INCREASED NEURONAL DIFFERENTIATION OF THE NSCS AND DECREASED ASTROCYTE DIFFERENTIATION. MOST STRIKINGLY, ELECTROPHYSIOLOGICAL RECORDINGS REVEALED THAT IN OUR MINIMAL CULTURE SYSTEM ONLY TSA-TREATED NSC-DERIVED NEURONS DEVELOPED NORMAL ELECTROPHYSIOLOGICAL MEMBRANE PROPERTIES CHARACTERISTIC FOR FUNCTIONAL, I.E. EXCITABLE AND FIRING, NEURONS. FURTHERMORE, TSA-TREATED NSC-DERIVED NEURONS WERE CHARACTERIZED BY AN INCREASED ELONGATION AND ARBORIZATION OF THE DENDRITES. OUR STUDY SHOWS THAT CHROMATIN STRUCTURE MODULATION BY HDACS PLAYS AN IMPORTANT ROLE IN THE TRANSCRIPTIONAL REGULATION OF THE NEURONAL DIFFERENTIATION OF EMBRYONIC NSCS PARTICULARLY AS FAR AS THE DEVELOPMENT OF FUNCTIONAL PROPERTIES ARE CONCERNED. MANIPULATION OF HDAC ACTIVITY MAY BE AN IMPORTANT TOOL TO GENERATE SPECIFIC NEURONAL POPULATIONS FROM NSCS FOR TRANSPLANTATION PURPOSES. (C) 2006 IBRO. PUBLISHED BY ELSEVIER LTD. ALL RIGHTS RESERVED.",SILENCING TRANSCRIPTION FACTOR; TARGET GENES; CHOLINE-ACETYLTRANSFERASE; PROGENITOR CELLS; EXPRESSION; REST; PROGRESSION; ACTIVATION; MECHANISMS; REPRESSOR,EPIGENETIC MODIFICATION; TRICHOSTATIN A; NEURONS; ASTROCYTES; CHROMATIN MODULATION,NEUROSCIENCE,"BALASUBRAMANIYAN, V##BODDEKE, E##BAKELS, R##KUST, B##KOOISTRA, S##VENEMAN, A##COPRAY, S","UNIV GRONINGEN, DEPT MED PHYSIOL, MED CTR, NL-9713 AV GRONINGEN, NETHERLANDS.",NEUROSCIENCES,NEUROSCIENCES & NEUROLOGY,"AJAMIAN F, 2004, NEUROSCI LETT, V365, P64, DOI 10.1016/J.NEULET.2004.04.087##BALASUBRAMANIYAN V, 2004, NEUROSCI RES, V49, P261, DOI 10.1016/J.NEURES.2004.02.010##BALLAS N, 2005, CELL, V121, P645, DOI 10.1016/J.CELL.2005.03.013##BALLAS N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3##BELYAEV ND, 2004, J BIOL CHEM, V279, P556, DOI 10.1074/JBC.M310353200##BENOWITZ LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2##CASPER D, 1989, BRAIN RES, V478, P85, DOI 10.1016/0006-8993(89)91479-0##CASPER D, 1989, BRAIN RES, V478, P74, DOI 10.1016/0006-8993(89)91478-9##CHEN WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/PNAS.97.1.377##CHIREUX M, 1996, MOL BRAIN RES, V39, P68, DOI 10.1016/0169-328X(96)00006-X##CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8##CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156##DI TORO R, 2005, EUR J NEUROSCI, V21, P46, DOI 10.1111/J.1460-9568.2004.03828.X##GAGE FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/SCIENCE.287.5457.1433##GROZINGER CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3##HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z##HERSH LB, 2003, LIFE SCI, V72, P2021, DOI 10.1016/S0024-3205(03)00065-1##HSIEH J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/JCB.200308101##HSIEH J, 2004, CURR OPIN GENET DEV, V14, P461, DOI 10.1016/J.GDE.2004.07.006##HSIEH J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/PNAS.0407643101##HUANG YF, 1999, NAT NEUROSCI, V2, P867##HUBBERT C, 2002, NATURE, V417, P455, DOI 10.1038/417455A##IMMANENI A, 2000, NUCLEIC ACIDS RES, V28, P3403, DOI 10.1093/NAR/28.17.3403##INOKOSHI J, 1999, BIOCHEM BIOPH RES CO, V256, P372, DOI 10.1006/BBRC.1999.0316##JAN YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7##KIM HS, 2003, BIOCHEM BIOPH RES CO, V312, P950, DOI 10.1016/J.BBRC.2003.11.012##KRAMER OH, 2003, EMBO J, V22, P3411, DOI 10.1093/EMBOJ/CDG315##LEHRMANN H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X##LUNYAK VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/SCIENCE.1076469##LUNYAK VV, 2004, ANN NY ACAD SCI, V1014, P110, DOI 10.1196/ANNALS.1294.011##MARIN-HUSSTEGE M, 2002, J NEUROSCI, V22, P10333##MARKS PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5##MCALLISTER AK, 2000, CEREB CORTEX, V10, P963, DOI 10.1093/CERCOR/10.10.963##PALMER TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/MCNE.1996.0595##PETERSON CL, 2002, MOL CELL, V9, P921, DOI 10.1016/S1097-2765(02)00534-8##REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/JNEUROSCI.12-11-04565.1992##SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/SCIENCE.7871435##SCHOENHERR CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/PNAS.93.18.9881##SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3##SCHRENK K, 2002, NEUROSCIENCE, V110, P675, DOI 10.1016/S0306-4522(01)00559-0##SU XH, 2004, MOL CELL BIOL, V24, P8018, DOI 10.1128/MCB.24.18.8018-8025.2004",104,2020-11-20,NA
J,WOS:000243110500006,2006,FEMALE PREDOMINANCE AND TRANSMISSION DISTORTION IN THE LONG-QT SYNDROME,"BACKGROUND: CONGENITAL LONG-QT SYNDROME IS A DISORDER RESULTING IN VENTRICULAR ARRHYTHMIAS AND SUDDEN DEATH. THE MOST COMMON FORMS OF THE LONG-QT SYNDROME, TYPES 1 AND 2, ARE CAUSED BY MUTATIONS IN THE POTASSIUM-CHANNEL GENES KCNQ1 AND KCNH2, RESPECTIVELY. ALTHOUGH INHERITANCE OF THE LONG-QT SYNDROME IS AUTOSOMAL DOMINANT, FEMALE PREDOMINANCE HAS OFTEN BEEN OBSERVED AND HAS BEEN ATTRIBUTED TO AN INCREASED SUSCEPTIBILITY TO CARDIAC ARRHYTHMIAS IN WOMEN. WE INVESTIGATED THE POSSIBILITY OF AN UNBALANCED TRANSMISSION OF THE DELETERIOUS TRAIT. METHODS: WE INVESTIGATED THE DISTRIBUTION OF ALLELES FOR THE LONG-QT SYNDROME IN 484 NUCLEAR FAMILIES WITH TYPE 1 DISEASE AND 269 NUCLEAR FAMILIES WITH TYPE 2 DISEASE, ALL WITH FULLY GENOTYPED OFFSPRING. THE FAMILIES WERE RECRUITED IN FIVE EUROPEAN REFERRAL CENTERS FOR THE LONG-QT SYNDROME. MUTATION SEGREGATION, SEX RATIO, AND PARENTAL TRANSMISSION WERE ANALYZED AFTER CORRECTION FOR SINGLE ASCERTAINMENT. RESULTS: CLASSIC MENDELIAN INHERITANCE RATIOS WERE NOT OBSERVED IN THE OFFSPRING OF EITHER FEMALE CARRIERS OF THE LONG-QT SYNDROME TYPE 1 OR MALE AND FEMALE CARRIERS OF THE LONG-QT SYNDROME TYPE 2. AMONG THE 1534 DESCENDANTS, THE PROPORTION OF GENETICALLY AFFECTED OFFSPRING WAS SIGNIFICANTLY GREATER THAN THAT EXPECTED ACCORDING TO MENDELIAN INHERITANCE: 870 WERE CARRIERS OF A MUTATION (57%), AND 664 WERE NONCARRIERS (43%, P<0.001). AMONG THE 870 CARRIERS, THE ALLELE FOR THE LONG-QT SYNDROME WAS TRANSMITTED MORE OFTEN TO FEMALE OFFSPRING (476 [55%]) THAN TO MALE OFFSPRING (394 [45%], P=0.005). INCREASED MATERNAL TRANSMISSION OF THE LONG-QT SYNDROME MUTATIONS TO DAUGHTERS WAS ALSO OBSERVED, POSSIBLY CONTRIBUTING TO THE EXCESS OF FEMALE PATIENTS WITH AUTOSOMAL DOMINANT LONG-QT SYNDROME. CONCLUSIONS: POSITIVE SELECTION OF THE MUTATED ALLELES THAT CAUSE THE LONG-QT SYNDROME LEADS TO TRANSMISSION DISTORTION, WITH INCREASED PROPORTIONS OF MUTATION CARRIERS AMONG THE OFFSPRING OF AFFECTED FAMILIES. ALLELES FOR THE LONG-QT SYNDROME ARE MORE OFTEN TRANSMITTED TO DAUGHTERS THAN TO SONS.",CLINICAL-COURSE; RISK-FACTOR; DE-POINTES; GENDER; AGE; SEGREGATION; LQTS,NA,NEW ENGLAND JOURNAL OF MEDICINE,"IMBODEN, M##SWAN, H##DENJOY, I##VAN LANGEN, IM##LATINEN-FORSBLOM, PJ##NAPOLITANO, C##FRESSART, V##BREITHARDT, G##BERTHET, M##PRIORI, S##HAINQUE, B##WILDE, AAM##SCHULZE-BAHR, E##FEINGOLD, J##GUICHENEY, P","UNIV PARIS 06, ASSISTANCE PUBL HOP PARIS,INST FEDERATIF RECH 14, INST MYOL, INSERM, PARIS, FRANCE. HOP LARIBOISIERE, ASSISTANCE PUBL HOP PARIS, SERV CARDIOL, F-75475 PARIS, FRANCE. GRP HOSP PITIE SALPETRIERE, ASSISTANCE PUBL HOP PARIS, SERV BIOCHIM, F-75634 PARIS, FRANCE. GRP HOSP PITIE SALPETRIERE, ASSISTANCE PUBL HOP PARIS, DEPT GENET, F-75634 PARIS, FRANCE. UNIV ZURICH, DEPT MOL EPIDEMIOL, INST SOCIAL & PREVENT MED, ZURICH, SWITZERLAND. UNIV HELSINKI, DEPT MED, HELSINKI, FINLAND. UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN GENET, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, EXPT & MOL CARDIOL GRP, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV PAVIA, I-27100 PAVIA, ITALY. FDN SALVATORE MAUGERI, IST RIC & CURA CARATTERE SCI, MOL CARDIOL LABS, PAVIA, ITALY. UNIV MUNSTER, DEPT MOL CARDIOL, LEIBNIZ INST ARTERIOSCLEROSIS RES, D-4400 MUNSTER, GERMANY. HOSP UNIV MUNSTER, DEPT CARDIOL & ANGIOL, MUNSTER, GERMANY.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"CONRATH CE, 2002, CARDIOVASC RES, V53, P770, DOI 10.1016/S0008-6363(01)00477-1##DRICI MD, 2001, DRUG SAFETY, V24, P575, DOI 10.2165/00002018-200124080-00002##FODSTAD H, 2004, ANN MED, V36, P53, DOI 10.1080/17431380410032689##GOULD TD, 1998, HUM MOL GENET, V7, P483, DOI 10.1093/HMG/7.3.483##HASHIBA K, 1987, HEART VESSELS SUPPL, V2, P47##HASHIBA K, 1992, ANN NY ACAD SCI, V644, P142, DOI 10.1111/J.1749-6632.1992.TB31008.X##IHAKA R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.1080/10618600.1996.10474713##JIANG S, 1998, GENOMICS, V53, P395, DOI 10.1006/GENO.1998.5511##KIMBROUGH J, 2001, CIRCULATION, V104, P557, DOI 10.1161/HC3001.093501##LEHMANN MH, 1997, J AM COLL CARDIOL, V29, P93, DOI 10.1016/S0735-1097(96)00454-8##LEHMANN MH, 1996, CIRCULATION, V94, P2535, DOI 10.1161/01.CIR.94.10.2535##LI CC, 1961, HUMAN GENETICS PRINC##LOCATI EH, 1998, CIRCULATION, V97, P2237, DOI 10.1161/01.CIR.97.22.2237##LYON MF, 2003, ANNU REV GENET, V37, P393, DOI 10.1146/ANNUREV.GENET.37.110801.143030##LYTTLE TW, 1993, TRENDS GENET, V9, P205, DOI 10.1016/0168-9525(93)90120-7##MAGEE AC, 1998, J MED GENET, V35, P1045, DOI 10.1136/JMG.35.12.1045##MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/JAMA.270.21.2590##MALLOY K J, 1999, J GEND SPECIF MED, V2, P37##MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136##MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17##PRIORI SG, 2003, NEW ENGL J MED, V348, P1866, DOI 10.1056/NEJMOA022147##REIK W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554##SCHOLLEN E, 2004, J MED GENET, V41, P877, DOI 10.1136/JMG.2004.022350##SPLAWSKI I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178##STRAMBABADIALE M, 1997, EUR HEART J, V18, P1000##ZAREBA W, 1995, J AM COLL CARDIOL, V26, P1685, DOI 10.1016/0735-1097(95)60383-2##ZAREBA W, 2003, J AM COLL CARDIOL, V42, P103, DOI 10.1016/S0735-1097(03)00554-0##ZAREBA W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404##ZOLLNER S, 2004, AM J HUM GENET, V74, P62, DOI 10.1086/381131",57,2020-11-20,TELETHONFONDAZIONE TELETHON [GGP04066] FUNDING SOURCE: MEDLINE
J,WOS:000243110500032,2006,"D-DIMER TESTING TO DETERMINE THE DURATION OF ANTICOAGULATION THERAPY (VOL 355, PG 1780, 2006)",NA,NA,NA,NEW ENGLAND JOURNAL OF MEDICINE,LENSING,"UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. BAYER HEALTHCARE, WUPPERTAL, GERMANY.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"LENSING, 2006, NEW ENGL J MED, V355, P1780",0,2020-11-20,NA
J,WOS:000247514400001,2006,HUMAN CORONAVIRUS 229E ENCODES A SINGLE ORF4 PROTEIN BETWEEN THE SPIKE AND THE ENVELOPE GENES,"BACKGROUND: THE GENOME OF CORONAVIRUSES CONTAINS STRUCTURAL AND NON-STRUCTURAL GENES, INCLUDING SEVERAL SO-CALLED ACCESSORY GENES. ALL GROUP IB CORONAVIRUSES ENCODE A SINGLE ACCESSORY PROTEIN BETWEEN THE SPIKE AND ENVELOPE GENES, EXCEPT FOR HUMAN CORONAVIRUS (HCOV) 229E. THE PROTOTYPE VIRUS HAS A SPLIT GENE, ENCODING THE PUTATIVE ORF4A AND ORF4B PROTEINS. TO DETERMINE WHETHER PRIMARY HCOV-229E ISOLATES EXHIBIT THIS UNUSUAL GENOME ORGANIZATION, WE ANALYZED THE ORF4A/B REGION OF FIVE CURRENT CLINICAL ISOLATES FROM THE NETHERLANDS AND THREE EARLY ISOLATES COLLECTED AT THE COMMON COLD UNIT (CCU) IN SALISBURY, UK. RESULTS: ALL DUTCH ISOLATES WERE IDENTICAL IN THE ORF4A/B REGION AT AMINO ACID LEVEL. ALL CCU ISOLATES ARE ONLY 98% IDENTICAL TO THE DUTCH ISOLATES AT THE NUCLEOTIDE LEVEL, BUT MORE CLOSELY RELATED TO THE PROTOTYPE HCOV-229E (>98%). REMARKABLY, OUR ANALYSES REVEALED THAT THE LABORATORY ADAPTED, PROTOTYPE HCOV-229E HAS A 2-NUCLEOTIDE DELETION IN THE ORF4A/B REGION, WHEREAS ALL CLINICAL ISOLATES CARRY A SINGLE ORF, 660 NT IN SIZE, ENCODING A SINGLE PROTEIN OF 219 AMINO ACIDS, WHICH IS A HOMOLOGUE OF THE ORF3 PROTEINS ENCODED BY HCOV-NL63 AND PEDV. CONCLUSION: THUS, THE GENOME ORGANIZATION OF THE GROUP IB CORONAVIRUSES HCOV-NL63, PEDV AND HCOV-229E IS IDENTICAL. IT IS POSSIBLE THAT EXTENSIVE CULTURING OF THE HCOV-229E LABORATORY STRAIN RESULTED IN TRUNCATION OF ORF4. THIS MAY INDICATE THAT THE PROTEIN IS NOT ESSENTIAL IN CELL CULTURE, BUT THE HIGHLY CONSERVED AMINO ACID SEQUENCE OF THE ORF4 PROTEIN AMONG CLINICAL ISOLATES SUGGESTS THAT THE PROTEIN PLAYS AN IMPORTANT ROLE IN VIVO.",EPIDEMIC DIARRHEA VIRUS; SEQUENCE-ANALYSIS; IN-VITRO; GENETICS; EVOLUTION; DELETION; STRAINS; GENOME; ENTRY; NL63,NA,VIROLOGY JOURNAL,"DIJKMAN, R##JEBBINK, MF##WILBRINK, B##PYRC, K##ZAAIJER, HL##MINOR, PD##FRANKLIN, S##BERKHOUT, B##THIEL, V##VAN DER HOEK, L","UNIV AMSTERDAM, ACAD MED CTR, LAB EXPT VIROL, DEPT MED MICROBIOL,CINIMA, AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, LAB CLIN VIROL, CINIMA,DEPT MED MICROBIOL, AMSTERDAM, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, LAB INFECT DIS & SCREENING, NL-3720 BA BILTHOVEN, NETHERLANDS. KANTONAL HOSP ST GALLEN, DEPT RES, ST GALLEN, SWITZERLAND.",VIROLOGY,VIROLOGY,"BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990##BRADBURNE AF, 1967, BMJ-BRIT MED J, V3, P767, DOI 10.1136/BMJ.3.5568.767##CHIBO D, 2006, J GEN VIROL, V87, P1203, DOI 10.1099/VIR.0.81662-0##DE HAAN CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/VIRO.2002.1412##DUARTE M, 1994, VIROLOGY, V198, P466, DOI 10.1006/VIRO.1994.1058##GORBALENYA AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004##HAIJEMA BJ, 2004, J VIROL, V78, P3863, DOI 10.1128/JVI.78.8.3863-3871.2004##HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734##HERREWEGH AAPM, 1995, VIROLOGY, V212, P622, DOI 10.1006/VIRO.1995.1520##HOLMES KV, 1996, FIELDS VIROLOGY, P1075##KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189##LASSNIG C, 2005, P NATL ACAD SCI USA, V102, P8275, DOI 10.1073/PNAS.0408589102##LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992##MYINT S, 1990, J MED VIROL, V31, P165, DOI 10.1002/JMV.1890310216##PYRC K, 2006, J MOL BIOL, V364, P964, DOI 10.1016/J.JMB.2006.09.074##PYRC K, 2006, ANTIMICROB AGENTS CH, V50, P2000, DOI 10.1128/AAC.01598-05##RAABE T, 1989, NUCLEIC ACIDS RES, V17, P6387, DOI 10.1093/NAR/17.15.6387##SANCHEZ CM, 1992, VIROLOGY, V190, P92, DOI 10.1016/0042-6822(92)91195-Z##SONG DS, 2003, VACCINE, V21, P1833, DOI 10.1016/S0264-410X(03)00027-6##TANG XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06##THIEL V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273##THIEL V, 1994, J GEN VIROL, V75, P3041, DOI 10.1099/0022-1317-75-11-3041##TYRRELL DAJ, 1968, BMJ-BRIT MED J, V1, P606, DOI 10.1136/BMJ.1.5592.606##VIJGEN L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005##WENTWORTH DE, 2005, VIROLOGY, V335, P185, DOI 10.1016/J.VIROL.2005.02.023##WOODS RD, 2001, CAN J VET RES, V65, P28",29,2020-11-20,NA
J,WOS:000242941700023,2006,NATURALLY OCCURRING ESTROGENS IN PROCESSED MILK AND IN RAW MILK (FROM GESTATED COWS),"THE OCCURRENCE OF THE STEROID HORMONES ESTRONE (E-1), 17 ALPHA-ESTRADIOL (ALPHA E-2), 17 BETA-ESTRADIOL (BETA E-2), AND ESTRIOL (E-3) IN PROCESSED BOVINE MILK WITH DIFFERENT FAT CONTENTS AND IN RAW MILK FROM (NON)GESTATED COWS WAS INVESTIGATED. FOLLOWING LIQUID EXTRACTION, OPTIONAL ENZYMATICAL DECONJUGATION, C-18 SOLID-PHASE EXTRACTION, AND DERIVATIZATION, ESTROGENS WERE ANALYZED USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS). FREE AND DECONJUGATED E-1 (6.2-1266 NG/L) WAS THE MAJOR ESTROGEN FOLLOWED BY ALPHA E-2 (7.2-322 NG/L) AND BETA E-2 (5.6-51 NG/L), WHEREAS E-3 WAS DETECTED REGULARLY AT THE DETECTION LIMIT OF 10 NG/L. THE LOWEST AND HIGHEST CONCENTRATIONS WERE DETERMINED IN RAW MILK FROM NONPREGNANT AND FROM COWS IN THE THIRD TRIMESTER OF GESTATION, RESPECTIVELY. THE ESTROGEN CONCENTRATION IN PROCESSED MILK COINCIDES WITH THAT OF RAW MILK BETWEEN FIRST AND SECOND TRIMESTERS, REFLECTING THE CONTRIBUTION OF LACTATING PREGNANT COWS TO THE FINAL CONSUMABLE PRODUCT. THE DAILY INTAKE OF TOTAL INVESTIGATED ESTROGENS THROUGH MILK IS 372 NG, WHICH IS DRAMATICALLY MORE THAN CURRENTLY RECOGNIZED.",ESTRONE SULFATE; MAMMARY-GLAND; FOOD; HORMONES; CANCER; PHYTOESTROGENS; SECRETION; ESTRADIOL; PLASMA; HEALTH,ENDOCRINE DISRUPTORS; FOOD SAFETY; STEROID HORMONES; ESTROGENIC ACTIVITY IN FOOD; VETERINARY PUBLIC HEALTH,JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY,"MALEKINEJAD, H##SCHERPENISSE, P##BERGWERFF, AA","UNIV UTRECHT, VET PUBL HLTH DIV, INST RISK ASSESSMENT SCI, NL-3508 TD UTRECHT, NETHERLANDS.","AGRICULTURE, MULTIDISCIPLINARY; CHEMISTRY, APPLIED; FOOD SCIENCE & TECHNOLOGY",AGRICULTURE; CHEMISTRY; FOOD SCIENCE & TECHNOLOGY,"ANARI MR, 2002, ANAL CHEM, V74, P4136, DOI 10.1021/AC025712H##ANDERSSON AM, 1999, EUR J ENDOCRINOL, V140, P477, DOI 10.1530/EJE.0.1400477##DAXENBERGER A, 2001, HUM REPROD UPDATE, V7, P340, DOI 10.1093/HUMUPD/7.3.340##DELOUIS C, 1980, J DAIRY SCI, V63, P1492, DOI 10.3168/JDS.S0022-0302(80)83110-9##ERB RE, 1977, J ANIM SCI, V45, P617##*EU COMM, 2002, OFF J EUR COMMUNIT L, V221##FORMAN D, 1994, CANCER SURV, V20, P323##FRITSCHE S, 1999, EUR FOOD RES TECHNOL, V209, P153, DOI 10.1007/S002170050475##GANMAA D, 2006, INT J CANCER, V118, P2363, DOI 10.1002/IJC.21659##GANMAA D, 2004, FERTIL STERIL, V82, P1106, DOI 10.1016/J.FERTNSTERT.2004.05.073##GANMAA D, 2005, MED HYPOTHESES, V65, P1028, DOI 10.1016/J.MEHY.2005.06.026##HARTMANN S, 1998, FOOD CHEM, V62, P7, DOI 10.1016/S0308-8146(97)00150-7##HEAP RB, 1979, BRIT VET J, V135, P462, DOI 10.1016/S0007-1935(17)32794-X##HEAP RB, 1984, J ENDOCRINOL, V101, P221, DOI 10.1677/JOE.0.1010221##HEAP RB, 1979, BRIT VET J, V135, P355, DOI 10.1016/S0007-1935(17)32838-5##JANOWSKI T, 2002, DOMEST ANIM ENDOCRIN, V23, P125, DOI 10.1016/S0739-7240(02)00151-0##LI JJ, 1995, CANCER RES, V55, P4347##LIEHR JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/ER.21.1.40##LIMER JL, 2006, INT J CANCER, V119, P515, DOI 10.1002/IJC.21863##MACDONALD IA, 1983, J LIPID RES, V24, P675##MALEKINEJAD H, 2005, VET RES, V36, P799, DOI 10.1051/VETRES:2005034##MCGARRIGLE HHG, 1983, J STEROID BIOCHEM, V18, P607, DOI 10.1016/0022-4731(83)90139-5##QIN LQ, 2004, MED HYPOTHESES, V62, P133, DOI 10.1016/S0306-9877(03)00295-0##REMESAR X, 1999, EUR J NUTR, V38, P247, DOI 10.1007/S003940050068##SCHAMS D, 1986, ANN NY ACAD SCI, V464, P75, DOI 10.1111/J.1749-6632.1986.TB15995.X##STEPHANY RW, 2004, P EUR 5 C NOORDW MAY##WALKER FMM, 1983, BRIT VET J, V139, P171##WOLFORD ST, 1979, J DAIRY SCI, V62, P1458, DOI 10.3168/JDS.S0022-0302(79)83446-3##XU X, 2004, ANAL CHEM, V76, P5829, DOI 10.1021/AC049405I##ZIERAU O, 2006, PLANTA MED, V72, P184, DOI 10.1055/S-2005-873182",104,2020-11-20,NA
J,WOS:000243344400001,2006,NIGHTTIME OZONE PROFILES IN THE STRATOSPHERE AND MESOSPHERE BY THE GLOBAL OZONE MONITORING BY OCCULTATION OF STARS ON ENVISAT,"THE GLOBAL OZONE MONITORING BY OCCULTATION OF STARS (GOMOS) INSTRUMENT ON BOARD THE EUROPEAN SPACE AGENCY'S ENVISAT SATELLITE MEASURES OZONE AND A FEW OTHER TRACE GASES USING THE STELLAR OCCULTATION METHOD. GLOBAL COVERAGE, GOOD VERTICAL RESOLUTION AND THE SELF-CALIBRATING MEASUREMENT METHOD MAKE GOMOS OBSERVATIONS A PROMISING DATA SET FOR BUILDING VARIOUS CLIMATOLOGIES. IN THIS PAPER WE PRESENT THE NIGHTTIME STRATOSPHERIC OZONE DISTRIBUTION MEASURED BY GOMOS IN 2003. WE SHOW MONTHLY LATITUDINAL DISTRIBUTIONS OF THE OZONE NUMBER DENSITY AND MIXING RATIO PROFILES, AS WELL AS THE SEASONAL VARIATIONS OF PROFILES AT SEVERAL LATITUDES. THE STRATOSPHERIC PROFILES ARE COMPARED WITH THE FORTUIN-KELDER DAYTIME OZONE CLIMATOLOGY. LARGE DIFFERENCES ARE FOUND IN POLAR AREAS AND THEY CAN BE SHOWN TO BE CORRELATED WITH LARGE INCREASES OF NO2. IN THE UPPER STRATOSPHERE, OZONE VALUES FROM GOMOS ARE SYSTEMATICALLY LARGER THAN IN THE FORTUIN-KELDER CLIMATOLOGY, WHICH CAN BE EXPLAINED BY THE DIURNAL VARIATION. IN THE MIDDLE AND LOWER STRATOSPHERE, GOMOS FINDS A FEW PERCENT LESS OZONE THAN FORTUIN-KELDER. IN THE EQUATORIAL AREA, AT HEIGHTS OF AROUND 15-22 KM, GOMOS FINDS MUCH LESS OZONE THAN FORTUIN-KELDER. FOR THE MESOSPHERE AND LOWER THERMOSPHERE, THERE HAS PREVIOUSLY BEEN NO COMPREHENSIVE NIGHTTIME OZONE CLIMATOLOGY. GOMOS IS ONE OF THE FIRST NEW INSTRUMENTS ABLE TO CONTRIBUTE TO SUCH A CLIMATOLOGY. WE CONCENTRATE ON THE CHARACTERIZATION OF THE OZONE DISTRIBUTION IN THIS REGION. THE MONTHLY LATITUDINAL AND SEASONAL DISTRIBUTIONS OF OZONE PROFILES IN THIS ALTITUDE REGION ARE SHOWN. THE ALTITUDE OF THE MESOSPHERIC OZONE PEAK AND THE SEMIANNUAL OSCILLATION OF THE NUMBER DENSITY ARE DETERMINED. GOMOS IS ALSO ABLE TO DETERMINE THE MAGNITUDE OF THE OZONE MINIMUM AROUND 80 KM. THE LOWEST SEASONAL MEAN MIXING RATIO VALUES ARE AROUND 0.13 PPM. THE FAINT TERTIARY OZONE PEAK AT 72 KM IN POLAR REGIONS DURING WINTERTIME IS OBSERVED.",ART. NO. D23305; LOWER THERMOSPHERE; SATELLITE-OBSERVATIONS; POLAR OZONE; GOMOS; INSTRUMENT; INVERSION; MIPAS; SCINTILLATION; VALIDATION,NA,JOURNAL OF GEOPHYSICAL RESEARCH-ATMOSPHERES,"KYROLA, E##TAMMINEN, J##LEPPELMEIER, GW##SOFIEVA, V##HASSINEN, S##SEPPALA, A##VERRONEN, PT##BERTAUX, JL##HAUCHECORNE, A##DALAUDIER, F##FUSSEN, D##VANHELLEMONT, F##D'ANDON, OF##BARROT, G##MANGIN, A##THEODORE, B##GUIRLET, M##KOOPMAN, R##DE MIGUEL, LS##SNOEIJ, P##FEHR, T##MEIJER, Y##FRAISSE, R","FINNISH METEOROL INST, EARTH OBSERV, FIN-00101 HELSINKI, FINLAND. CNRS, SERV AERON, F-91371 VERRIERES LE BUISSON, FRANCE. INST AERON SPATIALE BELGIQUE, BRUSSELS, BELGIUM. ACRI ST, SOPHIA ANTIPOLIS, FRANCE. EUROPEAN SPACE AGCY, EUROPEAN SPACE RES INST, FRASCATI, ITALY. EUROPEAN SPACE AGCY, EUROPEAN SPACE RES & TECHNOL CTR, NL-2200 AG NOORDWIJK, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, ENVIRONM MEASUREMENTS LAB, ENVIRONM RISKS & SAFETY DIV, NL-3720 BA BILTHOVEN, NETHERLANDS. EADS ASTRIUM, TOULOUSE, FRANCE.",METEOROLOGY & ATMOSPHERIC SCIENCES,METEOROLOGY & ATMOSPHERIC SCIENCES,"BARATH FT, 1993, J GEOPHYS RES-ATMOS, V98, P10751, DOI 10.1029/93JD00798##BERTAUX JL, 2004, ADV SPACE RES-SERIES, V33, P1029, DOI 10.1016/J.ASR.2003.09.037##BERTAUX JL, 1991, ADV SPACE RES-SERIES, V11, P237, DOI 10.1016/0273-1177(91)90426-K##BERTAUX JL, 2000, EARTH OBS Q, V67, P17##BEVILACQUA RM, 1996, GEOPHYS RES LETT, V23, P2317, DOI 10.1029/96GL01119##BOVENSMANN H, 2004, P SOC PHOTO-OPT INS, V5235, P160, DOI 10.1117/12.514228##BRACHER A, 2005, ADV SPACE RES-SERIES, V36, P855, DOI 10.1016/J.ASR.2005.04.005##BRASSEUP GP, 2005, AERONOMY MIDDLE ATMO##CHU WP, 1989, J GEOPHYS RES-ATMOS, V94, P8339, DOI 10.1029/JD094ID06P08339##DALAUDIER F, 2001, APPL OPTICS, V40, P866, DOI 10.1364/AO.40.000866##DESSLER A. E., 2000, CHEM PHYS STRATOSPHE##DOBSON GM, 1968, EXPLORING ATMOSPHERE##*EUR SPAC AG, 2001, ESA##FISCHER H, 1996, APPL OPTICS, V35, P2787, DOI 10.1364/AO.35.002787##FORTUIN JPF, 1998, J GEOPHYS RES-ATMOS, V103, P31709, DOI 10.1029/1998JD200008##FUNKE B, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD006463##GLACCUM W, 1996, J GEOPHYS RES-ATMOS, V101, P14479, DOI 10.1029/96JD00576##GRANT W.B., 1989, OZONE MEASURING INST##GURVICH AS, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005536##HARRIS N, 1999, ASSESSMENT TRENDS VE##HARTOGH P, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004576##HAUCHECORNE A, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005711##HAYS PB, 1973, PLANET SPACE SCI, V21, P273, DOI 10.1016/0032-0633(73)90011-1##HAYS PB, 1968, J ATMOS SCI, V25, P1141, DOI 10.1175/1520-0469(1968)025<1141:SSAAC>2.0.CO;2##HEDIN AE, 1991, J GEOPHYS RES, V96, P1159, DOI 10.1029/90JA02125##KAUFMANN M, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002800##KYROLA E, 2004, ADV SPACE RES-SERIES, V33, P1020, DOI 10.1016/S0273-1177(03)00590-8##KYROLA E, 1993, J GEOPHYS RES-ATMOS, V98, P7367, DOI 10.1029/92JD02678##LOGAN JA, 1994, J GEOPHYS RES-ATMOS, V99, P25553, DOI 10.1029/94JD02333##LUCKE RL, 1999, J GEOPHYS RES-ATMOS, V104, P18785, DOI 10.1029/1999JD900235##MARSH D, 2001, GEOPHYS RES LETT, V28, P4531, DOI 10.1029/2001GL013791##MARSH DR, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001505##MEIJER YJ, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004834##MURTAGH D, 2002, CAN J PHYS, V80, P309, DOI 10.1139/P01-157##ROBLE RG, 1972, PLANET SPACE SCI, V20, P1727, DOI 10.1016/0032-0633(72)90194-8##RUSSELL JM, 1999, P SOC PHOTO-OPT INS, V3756, P277, DOI 10.1117/12.366382##RUSSELL JM, 1993, J GEOPHYS RES-ATMOS, V98, P10777, DOI 10.1029/93JD00799##SEPPALA A, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021042##SEPPALA A, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025571##SIHVOLA E, 1994, GEOPHYS PUBL, V38##SINGLETON CS, 2005, ATMOS CHEM PHYS, V5, P597, DOI 10.5194/ACP-5-597-2005##SMITH AK, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD006298##SMITH AK, 2004, J ATMOS SOL-TERR PHY, V66, P839, DOI 10.1016/J JASTP.2004.01.032##SOFIEVA VF, 2004, ANN GEOPHYS-GERMANY, V22, P3411, DOI 10.5194/ANGEO-22-3411-2004##SOLOMON S, 1999, REV GEOPHYS, V37, P275, DOI 10.1029/1999RG900008##STAEHELIN J, 2001, REV GEOPHYS, V39, P231, DOI 10.1029/1999RG000059##VANHELLEMONT F, 2005, ADV SPACE RES, V36, P894, DOI 10.1016/J.ASR.2005.04.094##VERRONEN PT, 2005, J GEOPHYS RES-SPACE, V110, DOI 10.1029/2004JA010932##VERRONEN PT, 2005, ADV SPACE RES-SERIES, V36, P958, DOI 10.1016/J.ASR.2005.04.073##YEE JH, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000794##ZHOU DK, 1998, GEOPHYS RES LETT, V25, P643, DOI 10.1029/98GL00236",40,2020-11-20,NA
J,WOS:000242941600107,2006,HIGH-RESOLUTION ELECTRONIC SPECTRA OF ETHYLENEDIOXYTHIOPHENE OLIGOMERS,"THE PHOTOPHYSICAL PROPERTIES OF A SERIES OF 3,4-ETHYLENEDIOXYTHIOPHENE OLIGOMERS (OEDOT) WITH UP TO FIVE REPEAT UNITS ARE STUDIED AS FUNCTION OF CONJUGATION LENGTH USING ABSORPTION, FLUORESCENCE, PHOSPHORESCENCE, AND TRIPLET-TRIPLET ABSORPTION SPECTROSCOPY AT LOW TEMPERATURE IN A RIGID MATRIX. AT 80 K, A REMARKABLY HIGHLY RESOLVED VIBRATIONAL FINE STRUCTURE CAN BE OBSERVED IN THE ALL ELECTRONIC SPECTRA WHICH REVEALS THAT THE ELECTRONIC STRUCTURE OF THE OLIGOMERS STRONGLY COUPLES TO TWO DIFFERENT VIBRATIONAL MODES (SIMILAR TO 180 AND SIMILAR TO 50 MEV). THE ENERGIES OF THE 0-0 TRANSITIONS IN ABSORPTION, AND FLUORESCENCE, PHOSPHORESCENCE, AND TRIPLET-TRIPLET ABSORPTION ALL SHOW A RECIPROCAL DEPENDENCE ON THE INVERSE NUMBER OF REPEAT UNITS. THE TRIPLET ENERGIES INFERRED FROM THE PHOSPHORESCENCE SPECTRA ARE ACCURATELY REPRODUCED BY QUANTUM CHEMICAL DFT CALCULATIONS USING OPTIMIZED GEOMETRIES FOR THE SINGLET GROUND STATE (S-0) AND FIRST EXCITED TRIPLET STATE (T-1). USING VIBRATIONAL IR AND RAMAN SPECTROSCOPY AND QUANTUM CHEMICAL DFT CALCULATIONS FOR THE NORMAL MODES IN THE GROUND STATE, WE HAVE BEEN ABLE TO ASSIGN THE VIBRATIONS THAT COUPLE TO THE ELECTRONIC STRUCTURE TO FULLY SYMMETRIC NORMAL MODES. THE HIGH-ENERGY MODE IS ASSOCIATED WITH THE WELL-KNOWN CARBON-CARBON BOND STRETCH VIBRATION, AND THE LOW-ENERGY MODE INVOLVES A DEFORMATION OF THE BOND ANGLES WITHIN THE THIOPHENE RINGS AND A CHANGE OF C-S BOND LENGTHS. EXPERIMENTALLY OBTAINED HUANG-RHYS PARAMETERS AND THEORETICAL NORMAL MODE DEFORMATIONS ARE USED TO ANALYZE THE GEOMETRY CHANGES BETWEEN T-1 AND S-0 AND TO SEMIEXPERIMENTALLY PREDICT THE GEOMETRY IN THE S-1 STATE FOR 2EDOT.","END-CAPPED OLIGOTHIOPHENES; PI-CONJUGATED OLIGOTHIOPHENES; DENSITY-FUNCTIONAL THEORY; SPIN-ORBIT INTERACTIONS; 3,4-ETHYLENEDIOXYTHIOPHENE EDOT; BUILDING-BLOCK; ELECTROCHEMICAL POLYMERIZATION; HETEROAROMATIC MOLECULES; SINGLET-STATE; TRIPLET-STATE",NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"WASSERBERG, D##MESKERS, SCJ##JANSSEN, RAJ##MENA-OSTERITZ, E##BAUERLE, P","EINDHOVEN UNIV TECHNOL, NL-5600 MB EINDHOVEN, NETHERLANDS. UNIV ULM, INST ORGAN CHEM 2, D-89081 ULM, GERMANY.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"AKOUDAD S, 1998, SYNTHETIC MET, V93, P111, DOI 10.1016/S0379-6779(97)04100-3##ALBRECHT AC, 1963, J CHEM PHYS, V38, P354, DOI 10.1063/1.1733665##ALEMAN C, 2005, SYNTHETIC MET, V149, P151, DOI 10.1016/J.SYNTHMET.2004.12.012##APPERLOO JJ, 2002, CHEM-EUR J, V8, P2384, DOI 10.1002/1521-3765(20020517)8:10<2384::AID-CHEM2384>3.0.CO;2-L##ARGUN AA, 2004, CHEM MATER, V16, P4401, DOI 10.1021/CM049669L##ARGUN AA, 2003, ADV MATER, V15, P1338, DOI 10.1002/ADMA.200305038##BASSLER H, 1999, ACCOUNTS CHEM RES, V32, P173, DOI 10.1021/AR960228K##BIRNBAUM D, 1989, J CHEM PHYS, V90, P3506, DOI 10.1063/1.455861##BIRNBAUM D, 1991, J CHEM PHYS, V95, P4783, DOI 10.1063/1.461721##BIRNBAUM D, 1992, J CHEM PHYS, V96, P165, DOI 10.1063/1.462504##CARAS-QUINTERO D, 2004, CHEM COMMUN, P926, DOI 10.1039/B400965G##CARAS-QUINTERO D, 2002, CHEM COMMUN, P2690, DOI 10.1039/B207640C##CASADO J, 2005, J AM CHEM SOC, V127, P13364, DOI 10.1021/JA053296N##CASADO J, 2005, J PHYS CHEM B, V109, P16616, DOI 10.1021/JP0520300##CASADO J, 1999, J PHYS CHEM A, V103, P816, DOI 10.1021/JP983810U##CASTRO CM, 2002, J CHEM PHYS, V116, P10419, DOI 10.1063/1.1479724##CASTRO CM, 2002, J PHYS CHEM B, V106, P7163, DOI 10.1021/JP0145208##CORNIL J, 1997, CHEM PHYS LETT, V278, P139, DOI 10.1016/S0009-2614(97)00986-X##DE JONG MP, 2003, J CHEM PHYS, V118, P6495, DOI 10.1063/1.1558037##DKHISSI A, 2003, INT J QUANTUM CHEM, V91, P517, DOI 10.1002/QUA.10446##FICHOU D., 1999, HDB OLIGO POLYTHIOPH##FRISCH MJ, 2003, GAUSSIAN 03 REV B 04##GIERSCHNER J, 2003, SYNTHETIC MET, V138, P311, DOI 10.1016/S0379-6779(03)00030-4##GIERSCHNER J, 2002, J CHEM PHYS, V116, P8596, DOI 10.1063/1.1469612##GRIESSER HJ, 1982, CHEM PHYS, V67, P373, DOI 10.1016/0301-0104(82)85198-7##GROENENDAAL L, 2003, ADV MATER, V15, P855, DOI 10.1002/ADMA.200300376##GROENENDAAL L, 2000, ADV MATER, V12, P481, DOI DOI 10.1002/(SICI)1521-4095(200004)12:7<LESS##HERNANDEZ V, 1996, J PHYS CHEM-US, V100, P289, DOI 10.1021/JP951628C##HERNANDEZ V, 1996, J CHEM PHYS, V104, P9271, DOI 10.1063/1.471674##HICKS RG, 2000, J AM CHEM SOC, V122, P6746, DOI 10.1021/JA000752T##HUANG K, 1950, PROC R SOC LON SER-A, V204, P406, DOI 10.1098/RSPA.1950.0184##HUCHET L, 1998, J PHYS CHEM B, V102, P7776, DOI 10.1021/JP982593U##JO JH, 2004, CHEM-EUR J, V10, P2681, DOI 10.1002/CHEM.200305659##JOUSSELME B, 2006, J PHYS CHEM A, V110, P3488, DOI 10.1021/JP060254S##KLAERNER G, 1998, MACROMOLECULES, V31, P2007, DOI 10.1021/MA971073E##LERICHE P, 2006, CHEM COMMUN, P275, DOI 10.1039/B513923F##LIM EC, 1968, J CHEM PHYS, V49, P3878, DOI 10.1063/1.1670693##LIM EC, 1967, J CHEM PHYS, V47, P3270, DOI 10.1063/1.1712389##LOUARN G, 1995, J PHYS CHEM-US, V99, P11399, DOI 10.1021/J100029A016##OELKRUG D, 1996, SYNTHETIC MET, V83, P231, DOI 10.1016/S0379-6779(96)04484-0##PEETERS E, 2000, J CHEM PHYS, V112, P9445, DOI 10.1063/1.481638##PEREPICHKA IF, 2006, CHEM-EUR J, V12, P2960, DOI 10.1002/CHEM.200501284##RAIMUNDO JM, 2001, TETRAHEDRON LETT, V42, P1507, DOI 10.1016/S0040-4039(00)02317-0##REINOLD E, UNPUB##RONCALI J, 2005, J MATER CHEM, V15, P1589, DOI 10.1039/B415481A##RONCALI J, 2006, THIN SOLID FILMS, V511, P567, DOI 10.1016/J.TSF.2005.12.014##SCHENK R, 1991, J AM CHEM SOC, V113, P2634, DOI 10.1021/JA00007A042##SCOTT AP, 1996, J PHYS CHEM-US, V100, P16502, DOI 10.1021/JP960976R##SEGURA JL, 2005, ORG LETT, V7, P2345, DOI 10.1021/OL050573M##SEGURA JL, 2006, CHEM MATER, V18, P2834, DOI 10.1021/CM0602085##SOTZING GA, 1996, CHEM MATER, V8, P882, DOI 10.1021/CM9504798##SOTZING GA, 1997, ADV MATER, V9, P795, DOI 10.1002/ADMA.19970091005##STRICKLER SJ, 1962, J CHEM PHYS, V37, P814, DOI 10.1063/1.1733166##THOMAS CA, 2004, J AM CHEM SOC, V126, P16440, DOI 10.1021/JA048637W##TURBIEZ M, 2005, CHEM-EUR J, V11, P3742, DOI 10.1002/CHEM.200401058##TURBIEZ M, 2005, MACROMOLECULES, V38, P6806, DOI 10.1021/MA050655Q##TURBIEZ M, 2005, TETRAHEDRON, V61, P3045, DOI 10.1016/J.TET.2005.01.107##TURBIEZ M, 2003, J ORG CHEM, V68, P5357, DOI 10.1021/JO0345493##WASSERBERG D, 2005, CHEM PHYS LETT, V411, P273, DOI 10.1016/J.CPLETT.2005.06.039##WASSERBERG D, 2005, J PHYS CHEM B, V109, P4410, DOI 10.1021/JP0457085##WEGNER G, 1996, ELECT MAT OLIGOMER A##YASUDA T, 2005, CHEM MATER, V17, P264, DOI 10.1021/CM048532S##ZHU SS, 1997, J AM CHEM SOC, V119, P12568, DOI 10.1021/JA972794W",44,2020-11-20,NA
J,WOS:000242941600109,2006,EXPRESSION OF A SUPRAMOLECULAR COMPLEX AT A MULTIVALENT INTERFACE,"THE MULTIVALENT BINDING OF A SUPRAMOLECULAR COMPLEX AT A MULTIVALENT HOST SURFACE BY COMBINING THE ORTHOGONAL BETA-CYCLODEXTRIN (CD) HOST-GUEST AND METAL ION-ETHYLENEDIAMINE COORDINATION MOTIFS IS DESCRIBED. AS A HETEROTROPIC, DIVALENT LINKER, AN ADAMANTYL-FUNCTIONALIZED ETHYLENEDIAMINE DERIVATIVE WAS USED. THIS WAS COMPLEXED WITH CU(II) OR NI(II). THE BINDING OF THE COMPLEXES TO A CD SELF-ASSEMBLED MONOLAYER (SAM) WAS STUDIED AS A FUNCTION OF PH BY MEANS OF SURFACE PLASMON RESONANCE (SPR) SPECTROSCOPY. A HETEROTROPIC, MULTIVALENT BINDING MODEL AT INTERFACES WAS USED TO QUANTIFY THE MULTIVALENT ENHANCEMENT AT THE SURFACE. THE CU(II) COMPLEX SHOWED DIVALENT BINDING TO THE CD SURFACE WITH AN ENHANCEMENT FACTOR HIGHER THAN 100 RELATIVE TO THE FORMATION OF THE CORRESPONDING DIVALENT COMPLEX IN SOLUTION. SIMILAR BEHAVIOR WAS OBSERVED FOR THE NI(II) SYSTEM. ALTHOUGH THE NI(II) SYSTEM COULD POTENTIALLY BE TRIVALENT, ONLY DIVALENT BINDING WAS OBSERVED AT THE CD SAMS, WHICH WAS CONFIRMED BY DESORPTION EXPERIMENTS.",SELF-ASSEMBLED MONOLAYERS; HOST-GUEST INTERACTIONS; SURFACE-PLASMON RESONANCE; STRONGLY INHIBIT AGGLUTINATION; CYCLODEXTRIN MONOLAYERS; MOLECULAR PRINTBOARDS; BINDING; GOLD; IMMOBILIZATION; RECOGNITION,NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"CRESPO-BIEL, O##LIM, CW##RAVOO, BJ##REINHOUDT, DN##HUSKENS, J","UNIV TWENTE, LAB SUPRAMOL CHEM & TECHNOL, MESA INST NANOTECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV TWENTE, LAB MOL NANOFABRICAT, MESA INST NANOTECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV TWENTE, LAB STRATEG RES ORIENTAT NANOFABRICAT, MESA INST NANOTECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"AUST EF, 1994, TRENDS POLYM SCI, V2, P313##BARRIENTOS AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/CHEM.200204544##BASOLO F, 1952, J AM CHEM SOC, V74, P2373, DOI 10.1021/JA01129A504##BASOLO F, 1952, J AM CHEM SOC, V74, P5239##BEULEN MWJ, 2000, CHEM-EUR J, V6, P1176, DOI 10.1002/(SICI)1521-3765(20000403)6:7<1176::AID-CHEM1176>3.3.CO;2-T##CHEN YF, 2004, LANGMUIR, V20, P8409, DOI 10.1021/LA049560S##COTTON FA, 2002, P NATL ACAD SCI USA, V99, P4810, DOI 10.1073/PNAS.012567599##CRESPO-BIEL O, 2005, CHEM-EUR J, V11, P2426, DOI 10.1002/CHEM.200400393##DE JONG MR, 2001, CHEM-EUR J, V7, P4164, DOI 10.1002/1521-3765(20011001)7:19<4164::AID-CHEM4164>3.0.CO;2-Q##DORN IT, 1999, J MOL BIOL, V288, P1027, DOI 10.1006/JMBI.1999.2714##DOYLE EL, 2003, J AM CHEM SOC, V125, P4593, DOI 10.1021/JA021048A##FANTUZZI G, 2003, CHEM COMMUN, P1004, DOI 10.1039/B211544A##FRAGOSO A, 2002, LANGMUIR, V18, P5051, DOI 10.1021/LA0256679##FUNERIU DP, 1997, CHEM-EUR J, V3, P99, DOI 10.1002/CHEM.19970030116##FYFE MCT, 1999, COORDIN CHEM REV, V183, P139, DOI 10.1016/S0010-8545(98)00185-4##GAMSJAEGER R, 2004, LANGMUIR, V20, P5885, DOI 10.1021/LA0498206##HOFMEIER H, 2005, CHEM COMMUN, P2423, DOI 10.1039/B419171D##HOLLIDAY BJ, 2001, ANGEW CHEM INT EDIT, V40, P2022, DOI 10.1002/1521-3773(20010601)40:11<2022::AID-ANIE2022>3.3.CO;2-4##HUSKENS J, 1995, COMPUT CHEM, V19, P409, DOI 10.1016/0097-8485(95)00042-Q##HUSKENS J, 2004, J AM CHEM SOC, V126, P6784, DOI 10.1021/JA049085K##HUSKENS J, 2002, ANGEW CHEM INT EDIT, V41, P4467, DOI 10.1002/1521-3773(20021202)41:23<4467::AID-ANIE4467>3.0.CO;2-C##LIM CW, 2005, CHEM COMMUN, P5627, DOI 10.1039/B510540D##LIN CC, 2003, CHEM COMMUN, P2920, DOI 10.1039/B308995A##LUNDQUIST JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/CR000418F##MAMMEN M, 1998, ANGEW CHEM INT EDIT, V37, P2755##MANN DA, 1998, J AM CHEM SOC, V120, P10575, DOI 10.1021/JA9818506##MELLOR DP, 1943, CHEM REV, V33, P137, DOI 10.1021/CR60105A003##METALLO SJ, 2003, J AM CHEM SOC, V125, P4534, DOI 10.1021/JA030045A##MULDER A, 2004, J AM CHEM SOC, V126, P6627, DOI 10.1021/JA0317168##MULDER A, 2005, SMALL, V1, P242, DOI 10.1002/SMLL.200400063##NIJHUIS CA, 2005, LANGMUIR, V21, P7866, DOI 10.1021/LA051156L##PARK JS, 2002, J AM CHEM SOC, V124, P13366, DOI 10.1021/JA0270569##RADLER U, 2000, BIOPHYS J, V79, P3144##RAO JH, 1999, J AM CHEM SOC, V121, P2629, DOI 10.1021/JA9838763##REKHARSKY MV, 1998, CHEM REV, V98, P1875, DOI 10.1021/CR970015O##RON H, 1994, LANGMUIR, V10, P4566, DOI 10.1021/LA00024A030##ROSI NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/CR030067F##SAMORI B, 2005, ANGEW CHEM INT EDIT, V44, P1166, DOI 10.1002/ANIE.200400652##SANYAL A, 2004, LANGMUIR, V20, P5958, DOI 10.1021/LA049737I##SCHONHERR H, 2000, J AM CHEM SOC, V122, P4963, DOI 10.1021/JA994040I##SIGAL GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/JA953729U##SILLEN LG, 1964, STABILITY CONSTANTS##SMITH EA, 2003, J AM CHEM SOC, V125, P6140, DOI 10.1021/JA034165U##SPALTENSTEIN A, 1991, J AM CHEM SOC, V113, P686, DOI 10.1021/JA00002A053##THALLADI VR, 1996, CHEM COMMUN, P401, DOI 10.1039/CC9960000401##THESS A, 2002, J BIOL CHEM, V277, P36321, DOI 10.1074/JBC.M202145200##THIBAULT RJ, 2002, J AM CHEM SOC, V124, P15249, DOI 10.1021/JA026418+##TINAZLI A, 2005, CHEM-EUR J, V11, P5249, DOI 10.1002/CHEM.200500154##ULMAN A., 1991, INTRO ULTRATHIN ORGA##VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/GLYCOB/3.2.97##WHITESIDES GM, 2005, SMALL, V1, P172, DOI 10.1002/SMLL.200400130##ZHANG S, 2005, CHEM MATER, V17, P2063, DOI 10.1021/CM048222+",34,2020-11-20,NA
J,WOS:000243718900001,2006,CONSEQUENCES OF INFERTILITY IN DEVELOPING COUNTRIES: RESULTS OF A QUESTIONNAIRE AND INTERVIEW SURVEY IN THE SOUTH OF VIETNAM,"BACKGROUND: THIS STUDY EXPLORES THE PSYCHOLOGICAL, SOCIO-CULTURAL AND ECONOMIC CONSEQUENCES OF INFERTILITY ON COUPLES' LIFE. THE PURPOSE OF THIS RESEARCH IS TO IMPROVE KNOWLEDGE ABOUT THE POTENTIALLY SERIOUS IMPLICATIONS OF INFERTILITY IN THE SOUTH OF VIETNAM. METHODS: THIS STUDY INCLUDED 118 INFERTILE COUPLES WHO FILLED IN QUESTIONNAIRES AND 28 MEN AND WOMEN WHO WERE INTERVIEWED. RESULTS: DATA OF THE QUESTIONNAIRE SHOW MEN AND WOMEN DO NOT DIFFER IN THEIR RESPONSES AND ATTITUDES TOWARDS INFERTILITY. ALMOST ONE-THIRD OF THE PARTICIPANTS REQUIRE PSYCHOLOGICAL SUPPORT. INTERVIEWEES EXPERIENCE SECRECY, SOCIAL PRESSURE AND ECONOMIC HARDSHIP. CONCLUSION: OFFSPRING ARE VERY IMPORTANT TO VIETNAMESE COUPLES. THEIR FUTURE DEPENDS ON CHILDREN. FAMILY PLAYS AN IMPORTANT ROLE IN THE EXPERIENCES OF THE INFERTILE COUPLE. ECONOMIC CONSEQUENCES ARE A PARTICULAR DISTRESSING FACTOR. THERE IS A NEED FOR PSYCHOLOGICAL COUNSELLING IN THE TREATMENT OF INFERTILE COUPLES IN THE SOUTH OF VIETNAM. IT SHOULD BE REALISED THAT IN DEVELOPING COUNTRIES, DESPITE OVERPOPULATION, UNWANTED CHILDLESSNESS IS AN IMPORTANT SOCIAL AND ECONOMICAL BURDEN THAT NEEDS ATTENTION.",WOMENS EXPERIENCES; GENDER; DIAGNOSIS; DISTRESS,NA,JOURNAL OF TRANSLATIONAL MEDICINE,"WIERSEMA, NJ##DRUKKER, AJ##DUNG, MBT##NHU, GH##NHU, NT##LAMBALK, CB","VRIJE UNIV AMSTERDAM, MED CTR, DEPT OBSTET & GYNAECOL, DIV REPROD MED, AMSTERDAM, NETHERLANDS. BUNH DAN HOSP, ANDROL UNIT, HO CHI MINH CITY, VIETNAM. TU DU HOSP, DEPT OBSTET & GYNAECOL, HO CHI MINH CITY, VIETNAM.","MEDICINE, RESEARCH & EXPERIMENTAL",RESEARCH & EXPERIMENTAL MEDICINE,"ABDALLAH S, 2001, M MED ETH SOC ASP AS, P15##BELANGER D, 2002, STUD FAMILY PLANN, V33, P321, DOI 10.1111/J.1728-4465.2002.00321.X##BERG BJ, 1991, SOC SCI MED, V33, P1071, DOI 10.1016/0277-9536(91)90012-2##BOONMONGKON P, 2001, M MED ETH SOC ASP AS, P281##CONNOLLY KJ, 1992, J PSYCHOSOM RES, V36, P459, DOI 10.1016/0022-3999(92)90006-N##DALTON RJ, 2001, CTR STUDY DEMOCRACY##DALTON RJ, 2002, SOCIAL RELATIONS SOC##DYER SJ, 2002, HUM REPROD, V17, P1663, DOI 10.1093/HUMREP/17.6.1663##FRANCO JG, 2002, J ASSIST REPROD GEN, V19, P269, DOI 10.1023/A:1015706829102##GREIL AL, 1997, SOC SCI MED, V45, P1679, DOI 10.1016/S0277-9536(97)00102-0##JOHANSSON A, 1996, J PSYCHOSOM OBST GYN, V17, P59##JORDAN C, 1999, J BEHAV MED, V22, P341, DOI 10.1023/A:1018774019232##LEE TY, 2001, HUM REPROD, V16, P1762, DOI 10.1093/HUMREP/16.8.1762##NACHTIGALL RD, 1992, FERTIL STERIL, V57, P113##*NCPFP, 1993, POP FAM PLANN STRAT##NEWTON CR, 1999, FERTIL STERIL, V72, P54, DOI 10.1016/S0015-0282(99)00164-8##NGA LT, 2004, FACULTY GRADUATE STU##PAPREEN N, 2000, REPROD HEALTH MATTER, V8, P33, DOI 10.1016/S0968-8080(00)90004-1##PASHIGIAN MELISSA, 2002, INFERTILITY GLOBE NE, P134##QUI RZ, 2001, M MED ETH SOC ASP AS, P75##VANBICH P, 1999, VIETNAMESE FAMILY CH, P181##WORLD HEALTH ORGANIZATION, 1991, INF TAB AV DAT PREV",36,2020-11-20,NA
J,WOS:000243092200008,2006,EXTERNAL TIMING CONSTRAINTS FACILITATE PERFORMANCE OF EVERYDAY INTERCEPTIVE ACTIONS IN CHILDREN WITH SPASTIC HEMIPARETIC CEREBRAL PALSY,"WE EXAMINED HOW CHILDREN WITH SPASTIC HERNIPARETIC CEREBRAL PALSY (SHCP) PERFORM INTERCEPTIVE ACTIONS THEY EXPERIENCE IN DAILY LIFE. CHILDREN WERE REQUIRED TO WALK TOWARDS AND INTERCEPT A STATIONARY BALL OR A MOVING BALL, WITH EITHER THEIR IMPAIRED OR NON-IMPAIRED ARM. IN THE STATIONARY BALL CONDITION THE CHILD WAS FREE TO DETERMINE THE SPEED OF THEIR RESPONSE (INTERNAL TIMING), WHEREAS IN THE MOVING BALL CONDITION THERE WAS A RESTRICTED TIME AVAILABLE (EXTERNAL TIMING). IT WAS FOUND THAT THE REACH MOVEMENTS OF THE NON-IMPAIRED ARM WERE DIFFERENT TO THE IMPAIRED ARM, AND WERE CHARACTERIZED BY SOME OF THE TYPICAL MOVEMENT LIMITATIONS IMPOSED BY SHCP. HOWEVER, THERE WAS NO EVIDENCE OF INCREASED CONTRIBUTION FROM TRUNK MOTION OR A LENGTHENING OF REACH MOVEMENT TIME OR DECELERATION TIME. INSTEAD, THERE WAS A COORDINATED CHANGE WITH THE WALKING KINEMATICS, WHEREBY THE CHILDREN SPENT PROPORTIONATELY MORE TIME SLOWING DOWN AS THEY APPROACHED THE POINT OF INTERCEPTION WHEN REACHING WITH THE IMPAIRED ARM. THERE WERE ALSO SEVERAL DIFFERENCES IN THE RESPONSE WHEN INTERCEPTING A MOVING BALL COMPARED TO A STATIONARY BALL. WHEN THE TIMING CONSTRAINTS WERE IMPOSED EXTERNALLY (MOVING BALL) RATHER THAN INTERNALLY (STATIONARY BALL), CHILDREN REACHED WITH A REDUCED MOVEMENT TIME AND DECELERATION TIME, AND AN INCREASED PEAK WRIST VELOCITY AND ELBOW EXCURSION. THESE ADAPTATIONS TO BEHAVIOUR WERE NECESSARY TO DEAL WITH THE RESTRICTED TIME AVAILABLE TO MAKE THE INTERCEPTION IN THE MOVING BALL CONDITION COMPARED TO WHEN THE BALL WAS STATIONARY, AND REVEAL HOW CHILDREN WITH SHCP COORDINATE WALKING AND REACHING WHEN PERFORMING NATURAL INTERCEPTIVE ACTIONS. (C) 2006 ELSEVIER IRELAND LTD. ALL RIGHTS RESERVED.",MOVEMENTS; COORDINATION; TASK; SPEED,REACHING; WALKING; INTERNAL TIMING; EXTERNAL TIMING; SPASTIC HERMPARETIC CEREBRAL PALSY; CHILDREN,NEUROSCIENCE LETTERS,"RICKEN, AXC##SAVELSBERGH, GJP##BENNETT, SJ","LIVERPOOL JOHN MOORES UNIV, RES INST SPORT & EXERCISE SCI, LIVERPOOL L3 2ET, MERSEYSIDE, ENGLAND. MANCHESTER METROPOLITAN UNIV, INST BIOPHYS & CLIN RES HUMAN MOVEMENT, ALSAGER ST7 2HL, ENGLAND. FREE UNIV AMSTERDAM, FAC HUMAN MOVEMENT SCI, INST FUNDAMENTAL & CLIN HUMAN MOVEMENT SCI, NL-1081 BT AMSTERDAM, NETHERLANDS.",NEUROSCIENCES,NEUROSCIENCES & NEUROLOGY,"BOOTH CM, 2001, DEV MED CHILD NEUROL, V43, P314, DOI 10.1017/S0012162201000597##CIRSTEA MC, 2000, BRAIN, V123, P940, DOI 10.1093/BRAIN/123.5.940##LANCE JW, 1980, SPASTICITY DISORDERE, P480##LATASH ML, 1996, BEHAV BRAIN SCI, V19, P55, DOI 10.1017/S0140525X00041467##LATASH ML, 1996, DISABIL REHABIL, V18, P293, DOI 10.3109/09638289609165883##LEVIN MF, 1996, BRAIN, V119, P281, DOI 10.1093/BRAIN/119.1.281##MAJSAK MJ, 1998, BRAIN, V121, P755, DOI 10.1093/BRAIN/121.4.755##RICKEN AXC, 2005, MOTOR CONTROL, V9, P357, DOI 10.1123/MCJ.9.4.357##SHUMWAY-COOK A, 2003, DEV MED CHILD NEUROL, V45, P591, DOI 10.1017/S0012162203001099##STEENBERGEN B, 2000, HUM MOVEMENT SCI, V19, P75, DOI 10.1016/S0167-9457(00)00006-3##TARDIEU C, 1982, ARCH PHYS MED REHAB, V63, P97##UTLEY A, 1998, DEV MED CHILD NEUROL, V40, P396##VAN THIEL E, 2000, EXP BRAIN RES, V132, P230, DOI 10.1007/S002219900331##VAN THIEL E, 2001, MOTOR CONTROL, V5, P166, DOI 10.1123/MCJ.5.2.166##VANDERWEEL FR, 1991, DEV MED CHILD NEUROL, V33, P419##VOLMAN MJM, 2002, CLIN REHABIL, V16, P684, DOI 10.1191/0269215502CR540OA",9,2020-11-20,NA
J,WOS:000207443700020,2006,DOCKING OF SECRETORY VESICLES IS SYNTAXIN DEPENDENT,"SECRETORY VESICLES DOCK AT THE PLASMA MEMBRANE BEFORE THEY UNDERGO FUSION. MOLECULAR DOCKING MECHANISMS ARE POORLY DEFINED BUT BELIEVED TO BE INDEPENDENT OF SNARE PROTEINS. HERE, WE CHALLENGED THIS HYPOTHESIS BY ACUTE DELETION OF THE TARGET SNARE, SYNTAXIN, IN VERTEBRATE NEURONS AND NEUROENDOCRINE CELLS. DELETION RESULTED IN FUSION ARREST IN BOTH SYSTEMS. NO DOCKING DEFECTS WERE OBSERVED IN SYNAPSES, IN LINE WITH PREVIOUS OBSERVATIONS. HOWEVER, A DRASTIC REDUCTION IN MORPHOLOGICALLY DOCKED SECRETORY VESICLES WAS OBSERVED IN CHROMAFFIN CELLS. SYNTAXIN-DEFICIENT CHROMAFFIN CELLS SHOWED A SMALL REDUCTION IN TOTAL AND PLASMA MEMBRANE STAINING FOR THE DOCKING FACTOR MUNC18-1, WHICH APPEARS INSUFFICIENT TO EXPLAIN THE DRASTIC REDUCTION IN DOCKING. THE SUB-MEMBRANE CORTICAL ACTIN NETWORK WAS UNAFFECTED BY SYNTAXIN DELETION. THESE OBSERVATIONS EXPOSE A DOCKING ROLE FOR SYNTAXIN IN THE NEUROENDOCRINE SYSTEM. ADDITIONAL LAYERS OF REGULATION MAY HAVE EVOLVED TO MAKE SYNTAXIN REDUNDANT FOR DOCKING IN HIGHLY SPECIALIZED SYSTEMS LIKE SYNAPTIC ACTIVE ZONES.",NA,NA,PLOS ONE,"DE WIT, H##CORNELISSE, LN##TOONEN, RFG##VERHAGE, M","[VERHAGE, MATTHIJS] VRIJE UNIV AMSTERDAM, CTR NEUROGENOM & COGNIT RES, DEPT FUNCT GENOM, AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM MED CTR, AMSTERDAM, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/J.1460-2075.1993.TB06093.X##BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/J.1460-2075.1993.TB06171.X##BORISOVSKA M, 2005, EMBO J, V24, P2114, DOI 10.1038/SJ.EMBOJ.7600696##BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X##CAPOGNA M, 1997, J NEUROSCI, V17, P7190##CHIEREGATTI E, 2002, TRAFFIC, V3, P496, DOI 10.1034/J.1600-0854.2002.30706.X##DEAK F, 2004, NAT CELL BIOL, V6, P1102, DOI 10.1038/NCB1185##DIECK ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/JCB.142.2.499##FENSTER SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1##FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191A0##GERONA RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/JBC.275.9.6328##HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347A0##HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/J.1460-2075.1994.TB06834.X##HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X##KITTEL RJ, 2006, SCIENCE, V312, P1051, DOI 10.1126/SCIENCE.1126308##LANG T, 2001, EMBO J, V20, P2202, DOI 10.1093/EMBOJ/20.9.2202##MARSAL J, 1997, P NATL ACAD SCI USA, V94, P14871, DOI 10.1073/PNAS.94.26.14871##NONET ML, 1997, J NEUROSCI, V17, P8061##NONET ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/MBC.10.7.2343##OCONNOR V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/PNAS.94.22.12186##PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/PNAS.91.4.1445##RACIBORSKA DA, 1998, EUR J NEUROSCI, V10, P2617, DOI 10.1046/J.1460-9568.1998.00270.X##REIST NE, 1998, J NEUROSCI, V18, P7662##RICKMAN C, 2004, J BIOL CHEM, V279, P12574, DOI 10.1074/JBC.M310710200##ROSENMUND C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4##SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/JBC.270.18.10566##SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733A0##SCHIAVO G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/PNAS.94.3.997##SCHOCH S, 2001, SCIENCE, V294, P1117, DOI 10.1126/SCIENCE.1064335##SCHUTZ D, 2005, EUR J NEUROSCI, V21, P2419, DOI 10.1111/J.1460-9568.2005.04095.X##SHERRY DM, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-54##SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318A0##SORENSEN JB, 2006, EMBO J, V25, P955, DOI 10.1038/SJ.EMBOJ.7601003##SORENSEN JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X##TOONEN RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X##TOONEN RF, 2006, EMBO J, V25, P3725, DOI 10.1038/SJ.EMBOJ.7601256##VERHAGE M, 2000, SCIENCE, V287, P864, DOI 10.1126/SCIENCE.287.5454.864##VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0##VOETS T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9##WANG Y, 1997, NATURE, V388, P593, DOI 10.1038/41580##WASHBOURNE P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/NN783##WATANABE M, 2005, MOL BIOL CELL, V16, P4519, DOI 10.1091/MBC.E05-03-0252##WEI SH, 2000, EMBO J, V19, P1279, DOI 10.1093/EMBOJ/19.6.1279##WEIMER RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/NN1118##WEIMER RM, 2006, J NEUROSCI, V26, P8040, DOI 10.1523/JNEUROSCI.2350-06.2006##XU T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642##YANG CM, 2001, J CLIN INVEST, V107, P1311, DOI 10.1172/JCI12274##ZHANG B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9",89,2020-11-20,"NETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCH (ZONMW VENI)NETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCH (NWO) [016-066-101, 970-10-036, 916-036-043, MW-PIO 900-01-001]; NEUROBSIK MOUSE PHENOMICS CONSORTIUM [BSIK03053]; EUROPEAN COMMISSION (EU)EUROPEAN COMMISSIONEUROPEAN COMMISSION JOINT RESEARCH CENTREEUROPEAN UNION (EU) [LSHM-CT-2005-019055]"
J,WOS:000243178200017,2006,A HIGHLY EFFICIENT LIVING DONOR KIDNEY EXCHANGE PROGRAM FOR BOTH BLOOD TYPE AND CROSSMATCH INCOMPATIBLE DONOR-RECIPIENT COMBINATIONS,"BACKGROUND. LACK OF DECEASED DONORS FOR KIDNEY TRANSPLANT PATIENTS IN THE NETHERLANDS ENCOURAGED ALTERNATIVE OPTIONS TO EXPAND THE LIVING DONOR POOL FOR RECIPIENTS WHO HAVE A WILLING DONOR BUT CANNOT DONATE DIRECTLY BECAUSE OF A POSITIVE CROSSMATCH OR ABO BLOOD TYPE INCOMPATIBILITY. A NATIONAL DONOR KIDNEY EXCHANGE WAS CONSIDERED AS A POSSIBLE SOLUTION. METHODS. FROM JANUARY 2004 UNTIL JUNE 2006, 146 COUPLES FROM SEVEN KIDNEY TRANSPLANTATION CENTERS WERE ENROLLED AND PARTICIPATED IN 10 MATCH PROCEDURES. THE DUTCH TRANSPLANT FOUNDATION WAS RESPONSIBLE FOR THE ALLOCATION AND THE NATIONAL REFERENCE LABORATORY FOR HISTOCOMPATIBILITY IN LEIDEN PERFORMED ALL THE SEROLOGICAL CROSSMATCHES. RESULTS. FOR 72 OUT OF THE 146 (49%) DONOR-RECIPIENT COMBINATIONS, A MATCH WAS FOUND. THE SUCCESS RATE IN THE POSITIVE CROSSMATCH GROUP WAS SIGNIFICANTLY (P=0.0015) HIGHER THAN IN THE ABO-INCOMPATIBLE GROUP (44/69 VS. 28/77); MEDIAN PANEL REACTIVE ANTIBODIES OF THE MATCHED RECIPIENTS IN THE POSITIVE CROSSMATCH GROUP WAS 38% (0-100) AND IN THE ABO-INCOMPATIBLE GROUP 0% (0-27; P < 0.001). WE WERE LEAST SUCCESSFUL FOR ABO BLOOD TYPE INCOMPATIBLE PAIRS WITH BLOOD TYPE O RECIPIENTS, BUT FOR 9/53 (17%) THERE WERE POSSIBILITIES. THESE NINE BLOOD TYPE INCOMPATIBLE PAIRS WERE COUPLED TO NINE POSITIVE CROSSMATCH PAIRS, WHICH REFLECTS THE EFFICIENCY OF COMBINING THE TWO CATEGORIES OF DONOR-RECIPIENT COMBINATIONS INTO ONE PROGRAM. CONCLUSION. THE DONOR KIDNEY EXCHANGE PROGRAM IN THE NETHERLANDS, IN WHICH ALL SEVEN KIDNEY TRANSPLANTATION CENTERS PARTICIPATED, PROVED TO BE A SUCCESSFUL PROGRAM TO EXPAND THE NUMBER OF LIVING DONOR KIDNEY TRANSPLANTATIONS.",SENSITIZED PATIENTS; TRANSPLANTATION; RATES,KIDNEY TRANSPLANTATION; LIVING DONATION; EXCHANGE PROGRAM,TRANSPLANTATION,"DE KLERK, M##WITVLIET, MD##HAASE-KROMWIJK, BJJM##CLAAS, FHJ##WEIMAR, W","UNIV ROTTERDAM, DEPT INTERNAL MED TRANSPLANTAT, ERASMUS MED CTR, NL-3000 CA ROTTERDAM, NETHERLANDS. DUTCH TRANSPLANT FDN, LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT IMMUNOHEMATOL & BLOOD TRANSFUS, NATL REFERENCE LAB HISTOCOMPATIBIL, LEIDEN, NETHERLANDS.",IMMUNOLOGY; SURGERY; TRANSPLANTATION,IMMUNOLOGY; SURGERY; TRANSPLANTATION,"BILLER-ANDORNO NIKOLA, 2002, MED HEALTH CARE PHILOS, V5, P199, DOI 10.1023/A:1016053024671##CLAAS FHJ, 2004, TRANSPLANTATION, V78, P190, DOI 10.1097/01.TP.0000129260.86766.67##DE KLERK M, 2005, AM J TRANSPLANT, V5, P2302, DOI 10.1111/J.1600-6143.2005.01024.X##DELMONICO FL, 2004, AM J TRANSPLANT, V4, P1628, DOI 10.1111/J.1600-6143.2004.00572.X##*DUTCH TRANSPL FDN, 2005 ANN REP DUTCH T##JORDAN SC, 2006, AM J TRANSPLANT, V6, P459, DOI 10.1111/J.1600-6143.2005.01214.X##KEIZER KM, 2005, TRANSPLANT P, V37, P589, DOI 10.1016/J.TRANSPROCEED.2004.12.096##MAGEE CC, 2006, TRANSPLANT INT, V19, P87, DOI 10.1111/J.1432-2277.2005.00257.X##MONTGOMERY RA, 2006, LANCET, V368, P419, DOI 10.1016/S0140-6736(06)69115-0##TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601##TYDEN G, 2005, AM J TRANSPLANT, V5, P145, DOI 10.1111/J.1600-6143.2004.00653.X##VEATCH RM, 2006, AM J TRANSPLANT, V6, P1, DOI 10.1111/J.1600-6143.2005.01164.X##ZUIDEMA W, 2006, WORLD TRANSPL C",40,2020-11-20,NA
J,WOS:000243178200041,2006,THE IMPACT OF TRANSFORMING GROWTH FACTOR-BETA 1 GENE POLYMORPHISM ON END-STAGE RENAL FAILURE AFTER HEART TRANSPLANTATION,"BACKGROUND. NEPHROTOXICITY IS A MAJOR SIDE EFFECT OF CALCINEURIN INHIBITORS (CNI). EARLIER WE REPORTED 8% OF OUR HEART TRANSPLANT RECIPIENTS REACHING END-STAGE RENAL FAILURE (ESRF). NOW, WITH AN EXTENDED FOLLOW UP OF 20 YEARS, WE RE-EVALUATED THE DEVELOPMENT OF ESRF AND STUDIED ITS INFLUENCE ON SURVIVAL AND THE IMPACT OF POLYMORPHISMS IN CODON 10 AND 25 OF THE PROMOTER REGION OF TRANSFORMING GROWTH FACTOR (TGF)-BETA ON THE RISK OF ESRF. METHODS. IN ALL, 465 PATIENTS WERE TRANSPLANTED BETWEEN JUNE 1984 AND JUNE 2005. ALL WERE ON MAINTENANCE CNI TREATMENT. DEVELOPMENT OF ESRF WAS STUDIED IN 402/465 (86.5%) PATIENTS SURVIVING AT LEAST ONE YEAR. THEIR MEDIAN FOLLOW UP WAS EIGHT YEARS, TOTAL OBSERVATION TIME OF 3,414 YEARS. TGF-BETA POLYMORPHISMS IN CODON 10 (LEU TO PRO) AND CODON 25 (ARG TO PRO) WERE ANALYZED WITH REAL-TIME POLYMERASE CHAIN REACTION IN A COHORT OF 237 PATIENTS, WITH AN OBSERVATION TIME OF 2,329 YEARS. RESULTS. TEN-YEAR SURVIVAL OF PATIENTS SURVIVING AT LEAST ONE YEAR WAS 58.5%. SEVENTY-THREE PATIENTS (18.2%) DEVELOPED ESRF. DIALYSIS-FREE SURVIVAL WAS 60% AT 15 YEARS. THE RELATIVE RISK FOR ESRF IN PRO(10) CARRIERS WAS 2.9 (CL 1.5-5.8) COMPARED TO PATIENTS WITH THE LEU/LEU(10) GENOTYPE (P=0.002), WHILE PRO(25) CARRIERS HAD A RR OF 2.6 (CI 1.4-4.8) COMPARED TO THE ARG/ARG(25) GENOTYPE (P=0.002). SURVIVAL OF PATIENTS WITH ESRF WAS 1.5 YEARS (MEDIAN). CONCLUSION. WE FOUND A HIGHLY SIGNIFICANT ASSOCIATION BETWEEN TGF-BETA POLYMORPHISMS AND CNI INDUCED ESRF AFTER HEART TRANSPLANTATION (HTX). PRO CARRIERS OF EITHER CODON 10 OR 25 HAD A 2.6 TO 2.9 TIMES INCREASED RISK OF DEVELOPING ESRF. AS ESRF AFTER HTX RESULTS IN HIGH MORTALITY RATES THESE PATIENTS SHOULD NO LONGER RECEIVE CNI-BASED IMMUNOSUPPRESSION.",TRANSFORMING GROWTH-FACTOR-BETA-1 GENE; GROWTH-FACTOR-BETA; CORONARY-ARTERY-DISEASE; CARDIAC TRANSPLANTATION; LUNG TRANSPLANTATION; SINGLE-CENTER; CYCLOSPORINE; ASSOCIATION; NEPHROPATHY; EXPRESSION,CALCINEURIN INHIBITOR; HEART TRANSPLANTATION; RENAL FAILURE,TRANSPLANTATION,"VAN DE WETERING, J##WEIMAR, CHE##BALK, AHMM##ROODNAT, JI##HOLWEG, CTJ##BAAN, CC##VAN DOMBURG, RT##WEIMAR, W","UNIV ROTTERDAM HOSP, MED CTR, DEPT INTERNAL MED, ROTTERDAM, NETHERLANDS. UNIV ROTTERDAM HOSP, MED CTR, DEPT CARDIOL, ROTTERDAM, NETHERLANDS. UNIV ROTTERDAM HOSP, MED CTR, DEPT THORAC SURG, ROTTERDAM, NETHERLANDS.",IMMUNOLOGY; SURGERY; TRANSPLANTATION,IMMUNOLOGY; SURGERY; TRANSPLANTATION,"AL ALY Z, 2005, CLIN TRANSPLANT, V19, P683, DOI 10.1111/J.1399-0012.2005.00408.X##AWAD MR, 1998, TRANSPLANTATION, V66, P1014, DOI 10.1097/00007890-199810270-00009##BAAN CC, 2000, J HEART LUNG TRANSPL, V19, P866, DOI 10.1016/S1053-2498(00)00155-8##BLOOM RD, 2006, AM J TRANSPLANT, V6, P671, DOI 10.1111/J.1600-6143.2006.01248.X##BORDER WA, 1994, NEW ENGL J MED, V331, P1286##DI FILIPPO S, 2006, TRANSPLANTATION, V81, P934, DOI 10.1097/01.TP.0000202725.55923.37##EL-GAMEL A, 1999, J HEART LUNG TRANSPL, V18, P517, DOI 10.1016/S1053-2498(98)00024-2##GARRIDO IP, 2005, J HEART LUNG TRANSPL, V24, P1226, DOI 10.1016/J.HEALUN.2004.08.023##GOLDSTEIN DJ, 1997, TRANSPLANTATION, V63, P664, DOI 10.1097/00007890-199703150-00009##GONWA TA, 1992, J HEART LUNG TRANSPL, V11, P926##GORAL S, 1997, J HEART LUNG TRANSPL, V16, P1106##HERLITZ H, 2000, NEPHROL DIAL TRANSPL, V15, P311, DOI 10.1093/NDT/15.3.311##HOLWEG CTJ, 2001, J HEART LUNG TRANSPL, V20, P979, DOI 10.1016/S1053-2498(01)00296-0##HOLWEG CTJ, 2001, TRANSPLANTATION, V71, P1463, DOI 10.1097/00007890-200105270-00018##LI BG, 1999, HYPERTENSION, V33, P271, DOI 10.1161/01.HYP.33.1.271##LIM CS, 2005, CLIN NEPHROL, V63, P61##LINDELOW B, 2000, J AM SOC NEPHROL, V11, P951##NICHOLSON ML, 1999, BRIT J SURG, V86, P1144, DOI 10.1046/J.1365-2168.1999.01202.X##OJO AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMOA021744##PANKEWYCZ OG, 1996, KIDNEY INT, V50, P1634, DOI 10.1038/KI.1996.479##SATCHITHANANDA DK, 2002, J HEART LUNG TRANSPL, V21, P651, DOI 10.1016/S1053-2498(01)00411-9##SENECHAL M, 2004, CLIN TRANSPLANT, V18, P1, DOI 10.1111/J.1399-0012.2004.00105.X##SHIN GT, 1998, TRANSPLANTATION, V65, P313, DOI 10.1097/00007890-199802150-00003##SOLARI V, 2005, J UROLOGY, V174, P1609, DOI 10.1097/01.JU.0000179385.64585.DC##SYRRIS P, 1998, CLIN SCI, V95, P659, DOI 10.1042/CS0950659##TINAWI M, 1997, CLIN TRANSPLANT, V11, P1##TRULOCK EP, 2005, J HEART LUNG TRANSPL, V24, P956, DOI 10.1016/J.HEALUN.2005.05.019##VAN GELDER T, 1998, NEPHROL DIAL TRANSPL, V13, P2322, DOI 10.1093/NDT/13.9.2322##WABBIJN MARIKE, 2004, EXP CLIN TRANSPLANT, V2, P201##WANG XL, 1998, CLIN SCI, V95, P745, DOI 10.1042/CS19980292##YAMADA Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/JBMR.1998.13.10.1569##ZIETSE R, 1994, AM J NEPHROL, V14, P1, DOI 10.1159/000168677",30,2020-11-20,NA
J,WOS:000242935600008,2006,CORE STRUCTURE OF S2 FROM THE HUMAN CORONAVIRUS NL63 SPIKE GLYCOPROTEIN,"HUMAN CORONAVIRUS NL63 (HCOV-NL63) HAS RECENTLY BEEN IDENTIFIED AS A CAUSATIVE AGENT OF ACUTE RESPIRATORY TRACT ILLNESSES IN INFANTS AND YOUNG CHILDREN. THE HCOV-NL63 SPIKE (S) PROTEIN MEDIATES VIRION ATTACHMENT TO CELLS AND SUBSEQUENT FUSION OF THE VIRAL AND CELLULAR MEMBRANES. THIS VIRAL ENTRY PROCESS IS A PRIMARY TARGET FOR VACCINE AND DRUG DEVELOPMENT. HCOV-NL63 S IS EXPRESSED AS A SINGLE-CHAIN GLYCOPROTEIN AND CONSISTS OF AN N-TERMINAL RECEPTOR-BINDING DOMAIN (S1) AND A C-TERMINAL TRANSMEMBRANE FUSION DOMAIN (S2). THE LATTER CONTAINS TWO HIGHLY CONSERVED HEPTAD-REPEAT (HR) SEQUENCES THAT ARE EACH EXTENDED BY 14 AMINO ACIDS RELATIVE TO THOSE OF THE SARS CORONAVIRUS OR THE PROTOTYPIC MURINE CORONAVIRUS, MOUSE HEPATITIS VIRUS. LIMITED PROTEOLYSIS STUDIES OF THE HCOV-NL63 S2 FUSION CORE IDENTIFY AN ALPHA-HELICAL DOMAIN COMPOSED OF A TRIMER OF THE HR SEGMENTS N57 AND C42. THE CRYSTAL STRUCTURE OF THIS COMPLEX REVEALS THREE C42 HELICES ENTWINED IN AN OBLIQUE AND ANTIPARALLEL MANNER AROUND A CENTRAL TRIPLE-STRANDED COILED COIL FORMED BY THREE N57 HELICES. THE OVERALL GEOMETRY COMPRISES DISTINCTIVE HIGH-AFFINITY CONFORMATIONS OF INTERACTING CROSS-SECTIONAL LAYERS OF THE SIX HELICES. AS A RESULT, THIS STRUCTURE IS UNUSUALLY STABLE, WITH AN APPARENT MELTING TEMPERATURE OF 78 DEGREES C IN THE PRESENCE OF THE DENATURANT GUANIDINE HYDROCHLORIDE AT 5 M CONCENTRATION. THE EXTENDED HR REGIONS MAY THEREFORE BE REQUIRED TO PRIME THE GROUP 1 S GLYCOPROTEINS FOR THEIR FUSION-ACTIVATING CONFORMATIONAL CHANGES DURING VIRAL ENTRY. OUR RESULTS PROVIDE AN INITIAL BASIS FOR UNDERSTANDING AN INTRIGUING INTERPLAY BETWEEN THE PRESENCE OR ABSENCE OF PROTEOLYTIC MATURATION AMONG THE CORONAVIRUS GROUPS AND THE MEMBRANE FUSION ACTIVITY OF THEIR S GLYCOPROTEINS. THIS STUDY ALSO SUGGESTS A POTENTIAL STRATEGY FOR THE DEVELOPMENT OF IMPROVED HCOV-NL63 FUSION INHIBITORS.",ACUTE-RESPIRATORY-SYNDROME; HELICAL COILED COILS; ANGIOTENSIN-CONVERTING ENZYME-2; INFECTIOUS-BRONCHITIS VIRUS; MEDIATED MEMBRANE-FUSION; MOUSE HEPATITIS-VIRUS; SARS-CORONAVIRUS; MURINE CORONAVIRUS; CRYSTAL-STRUCTURE; CELL-FUSION,NA,BIOCHEMISTRY,"ZHENG, Q##DENG, YQ##LIU, J##VAN DER HOEK, L##BERKHOUT, B##LU, M","UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN RETROVIROL, NL-1105 AZ AMSTERDAM, NETHERLANDS. CORNELL UNIV, WEILL MED COLL, DEPT BIOCHEM, NEW YORK, NY 10021 USA.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"ARPIN N, 1990, ADV EXP MED BIOL, V276, P73##BAKER KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X##BOSCH BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/PNAS.0400576101##BOSCH BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003##BRIAN DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1##BROWN JH, 1996, PROTEINS, V26, P134##BRUNGER AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254##CANTOR C, 1980, BIOPHYS CHEM, V3##CASAIS R, 2003, J VIROL, V77, P9084, DOI 10.1128/JVI.77.16.9084-9089.2003##CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/BI00713A027##CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7##CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964##DE HAAN CAM, 2004, J VIROL, V78, P6048, DOI 10.1128/JVI.78.11.6048-6054.2004##DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417A0##DENG YQ, 2006, STRUCTURE, V14, P889, DOI 10.1016/J.STR.2006.03.007##DIMITROV DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/NRMICRO817##DUQUERROY S, 2005, VIROLOGY, V335, P276, DOI 10.1016/J.VIROL.2005.02.022##EARP LJ, 2005, CURR TOP MICROBIOL, V285, P25##ECKERT DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/ANNUREV.BIOCHEM.70.1.777##EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/BI00859A010##EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199A0##ESPER F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138##EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T##FOLLIS KE, 2006, VIROLOGY, V350, P358, DOI 10.1016/J.VIROL.2006.02.003##FOUCHIER RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/PNAS.0400762101##FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985##GALLAGHER TM, 1991, J VIROL, V65, P1916, DOI 10.1128/JVI.65.4.1916-1928.1991##GALLAGHER TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/VIRO.2000.0757##GIBBS AJ, 2004, ARCH VIROL, V149, P621, DOI 10.1007/S00705-003-0244-0##GONZAALEZ JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/S00705-003-0162-1##GORBALENYA AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004##HAIJEMA BJ, 2003, J VIROL, V77, P4528, DOI 10.1128/JVI.77.8.4528-4538.2003##HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080A0##HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/SCIENCE.8248779##HARRISON SC, 2005, ADV VIRUS RES, V64, P231, DOI 10.1016/S0065-3527(05)64007-9##HOFMANN H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/PNAS.0409465102##HOFMANN H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004##HUANG IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/JBC.M508381200##INGALLINELLA P, 2004, P NATL ACAD SCI USA, V101, P8709, DOI 10.1073/PNAS.0402753101##JACKWOOD MW, 2001, AVIAN DIS, V45, P366, DOI 10.2307/1592976##JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4##JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224##KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/SCIENCE.6272395##KUO LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000##LAI MMC, 2001, FIELDS VIROLOGY, P1163##LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886##LAUE T., 1992, ANAL ULTRACENTRIFUGA, P90, DOI DOI 10.1007/S00249-009-0425-1##LI WH, 2003, NATURE, V426, P450, DOI 10.1038/NATURE02145##LI WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006##LIU J, 2004, P NATL ACAD SCI USA, V101, P16156, DOI 10.1073/PNAS.0405319101##LIU SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7##LOVELL SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.3.CO;2-U##LUPAS AN, 2005, ADV PROTEIN CHEM, V70, P37, DOI 10.1016/S0065-3233(04)70003-0##MCINTOSH K, 2005, J INFECT DIS, V191, P489, DOI 10.1086/428510##MELIKYAN GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/JCB.151.2.413##MOORE MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004##MURSHUDOV GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255##NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/PROT.340110407##OTWINOWSKI Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X##PEIRIS JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMRA032498##PHILLIPS JJ, 1999, J VIROL, V73, P7752, DOI 10.1128/JVI.73.9.7752-7760.1999##POTTERTON E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126##PYRC K, 2006, ANTIMICROB AGENTS CH, V50, P2000, DOI 10.1128/AAC.01598-05##RUSSELL CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/EMBOJ/20.15.4024##SANCHEZ CM, 1999, J VIROL, V73, P7607##SCHEID A, 1974, VIROLOGY, V62, P125, DOI 10.1016/0042-6822(74)90308-0##SCHICKLI JH, 2004, J VIROL, V78, P9073, DOI 10.1128/JVI.78.17.9073-9083.2004##SCHOMAKER V, 1998, ACTA CRYSTALLOGR B, V54, P507, DOI 10.1107/S0108768198003243##SHU W, 1999, BIOCHEMISTRY-US, V38, P5378, DOI 10.1021/BI990199W##SIMMONS G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/PNAS.0505577102##SIMMONS G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/PNAS.0306446101##SKEHEL JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/ANNUREV.BIOCHEM.69.1.531##SNIJDER EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9##SONG HC, 2004, J VIROL, V78, P10328, DOI 10.1128/JVI.78.19.10328-10335.2004##STADLER K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/NRMICRO775##STORONI LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956##STRELKOV SV, 2002, J STRUCT BIOL, V137, P54, DOI 10.1006/JSBI.2002.4454##STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985##SUPEKAR VM, 2004, P NATL ACAD SCI USA, V101, P17958, DOI 10.1073/PNAS.0406128102##TRIPET B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/JBC.M400759200##VAN DER HOEK L, 2005, PLOS MED, V2, P764, DOI 10.1371/JOURNAL.PMED.0020240##VAN DER HOEK L, 2004, NAT MED, V10, P368, DOI 10.1038/NM1024##WEISSENHORN W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706##WEISSENHORN W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8##XIAO XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/J.BBRC.2003.11.054##XU YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/JBC.M408782200##XU YH, 2004, PROTEIN EXPRES PURIF, V38, P116, DOI 10.1016/J.PEP.2004.08.005##XU YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/JBC.M403760200##YANG ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004##YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420A0",31,2020-11-20,"NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES (NIAID) [R01AI042382, R21AI042382, R01AI042382, R01AI042382, R56AI042382, R01AI042382, R01AI042382, R01AI042382, R01AI042382, R01AI042382, R01AI042382, R01AI042382] FUNDING SOURCE: NIH REPORTER; NIAID NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES (NIAID) [AI042382] FUNDING SOURCE: MEDLINE"
J,WOS:000242935400002,2006,FORMATION OF ENTANGLEMENTS IN INITIALLY DISENTANGLED POLYMER MELTS,NA,MOLECULAR-WEIGHT; LINEAR-POLYMERS; POLYETHYLENE; REPTATION; CRYSTALS; ROUTE,NA,MACROMOLECULES,"LIPPITS, DR##RASTOGI, S##TALEBI, S##BAILLY, C","EINDHOVEN UNIV TECHNOL, DEPT CHEM & CHEM ENGN, NL-5600 MB EINDHOVEN, NETHERLANDS. DSM RES & PATENTS, NL-6160 MD GELEEN, NETHERLANDS. UNIV LOUGHBOROUGH, IPTME, LOUGHBOROUGH LE11 3TU, LEICS, ENGLAND. UNIV CATHOLIQUE LOUVAIN, UNITE PHYS & CHIM HAUTS POLYMERES, B-1348 LOUVAIN, BELGIUM.",POLYMER SCIENCE,POLYMER SCIENCE,"BARHAM PJ, 1991, POLYMER, V32, P393, DOI 10.1016/0032-3861(91)90440-T##CORBEIJKURELEC L, 2001, THESIS EINDHOVEN U T##DE GENNES P.G., 1979, SCALING CONCEPTS POL##DOI M., 1986, THEORY POLYM DYNAMIC##FERRY J. D, 1980, VISCOELASTIC PROPERT, P244##FETTERS LJ, 1994, MACROMOLECULES, V27, P4639, DOI 10.1021/MA00095A001##GRUTER GJM, 2000, PATENT NO. [EP 1057837, 1057837]##HIKOSAKA M, 2005, ADV POLYM SCI, V191, P137, DOI 10.1007/12_010##LIPPITS DR, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.218303##MAXWELL AS, 1996, POLYMER, V37, P3293, DOI 10.1016/0032-3861(96)88475-8##MILNER ST, 1998, PHYS REV LETT, V81, P725, DOI 10.1103/PHYSREVLETT.81.725##PSARSKI M, 2000, MACROMOLECULES, V33, P916, DOI 10.1021/MA990298H##RASTOGI S, 2005, NAT MATER, V4, P635, DOI 10.1038/NMAT1437##RASTOGI S, 2003, MACROMOL MATER ENG, V288, P964, DOI 10.1002/MAME.200300113##SHARMA KG., 2005, THESIS EINDHOVEN U T##SMITH P, 1987, J MATER SCI, V22, P523, DOI 10.1007/BF01160764##VEGA JF, 2004, J RHEOL, V48, P663, DOI 10.1122/1.1718367",60,2020-11-20,NA
J,WOS:000242935400051,2006,"FULLERENE-MODIFIED POLY(2,6-DIMETHYL-1,4-PHENYLENE OXIDE) GAS SEPARATION MEMBRANES: WHY BINDING IS BETTER THAN DISPERSING","THIS PAPER DESCRIBES THE PREPARATION, CHARACTERIZATION, AND THE PERMEATION PROPERTIES OF POLY(2,6-DIMETHYL-1,4-PHENYLENE OXIDE) (PPO) DENSE POLYMER FILMS CONTAINING FULLERENES (C-60). THE C-60 ARE EITHER DISPERSED OR COVALENTLY BONDED TO PPO AT VARIOUS CONCENTRATIONS. THE GAS PERMEABILITY RESULTS ARE VERY DIFFERENT BETWEEN COVALENTLY BONDED AND DISPERSED PPO-C-60. THE GAS PERMEABILITY OF PPO-C-60 BONDED INCREASES UP TO 80% WITH INCREASING FULLERENE CONCENTRATION. THE GAS PAIR SELECTIVITY, HOWEVER, STAYS CONSTANT. THIS BEHAVIOR IS PROBABLY DUE TO STIFFENING OF THE POLYMER STRUCTURE AND INCREASE OF FREE VOLUME. THE GAS PERMEABILITY THROUGH THE PPO-C-60 DISPERSED DECREASES IN COMPARISON TO PURE PPO. THIS REDUCTION IS DUE TO C-60 CLUSTERING IN THE POLYMER. THE CLUSTERS SEEM TO INDUCE POLYMER CRYSTALLINITY, AND THEY ARE PROBABLY ALIGNED ALONG THE FILM PLANE, CREATING AN EXTRA BARRIER FOR GAS PERMEATION.",PERMEATION; POLYMERS; SORPTION; DENSE,NA,MACROMOLECULES,"STERESCU, DM##STAMATIALIS, DF##MENDES, E##WUBBENHORST, M##WESSLING, M","UNIV TWENTE, FAC SCI & TECHNOL, MEMBRANE TECHNOL GRP, NL-7500 AE ENSCHEDE, NETHERLANDS. DELFT UNIV TECHNOL, NL-2628 BL DELFT, NETHERLANDS. KATHOLIEKE UNIV LEUVEN, DEPT PHYS & ASTRON, B-3001 LOUVAIN, BELGIUM.",POLYMER SCIENCE,POLYMER SCIENCE,"ALBERS JHM, 1992, PATENT NO. 5129920##ARNOLD ME, 2001, MACROMOLECULES, V34, P5611, DOI 10.1021/MA010355I##BARSEMA JN, 2003, J MEMBRANE SCI, V216, P195, DOI 10.1016/S0376-7388(03)00071-1##CABASSO I, 1974, J APPL POLYM SCI, V18, P1969, DOI 10.1002/APP.1974.070180706##CHEN Y, 1998, EUR POLYM J, V34, P137##DAI LM, 1999, POLYM ADVAN TECHNOL, V10, P357, DOI 10.1002/(SICI)1099-1581(199907)10:7<357::AID-PAT886>3.0.CO;2-9##FREEMAN BD, 1999, MACROMOLECULES, V32, P375, DOI 10.1021/MA9814548##GECKELER KE, 1999, POLYM INT, V48, P743##GOH SH, 2000, POLYMER, V41, P8721, DOI 10.1016/S0032-3861(00)00297-4##HIGUCHI A, 2000, J APPL POLYM SCI, V77, P529, DOI 10.1002/(SICI)1097-4628(20000718)77:3<529::AID-APP8>3.0.CO;2-Y##KANEHASHI S, 2005, J MEMBRANE SCI, V253, P117, DOI 10.1016/J.MEMSCI.2005.01.003##KHULBE KC, 2000, J MEMBRANE SCI, V171, P273, DOI 10.1016/S0376-7388(00)00311-2##KHULBE KC, 2000, J MEMBRANE SCI, V170, P81, DOI 10.1016/S0376-7388(99)00365-8##MERKEL TC, 2003, CHEM MATER, V15, P109, DOI 10.1021/CM020672J##MERKEL TC, 2002, SCIENCE, V296, P519, DOI 10.1126/SCIENCE.1069580##MULDER M., 1992, BASIC PRINCIPLES MEM##NAGAI K, 1995, J MEMBRANE SCI, V105, P261, DOI 10.1016/0376-7388(95)00065-K##NATH S, 2002, CHEM PHYS LETT, V360, P422, DOI 10.1016/S0009-2614(02)00780-7##PERCEC V, 1984, MAKROMOL CHEM, V185, P2319##POLOTSKAYA GA, 2005, RUSS J APPL CHEM+, V78, P1468, DOI 10.1007/S11167-005-0540-4##POLOTSKAYA GA, 2002, J APPL POLYM SCI, V85, P2946, DOI 10.1002/APP.10906##STERESCU DM, 2004, MACROMOL RAPID COMM, V25, P1674, DOI 10.1002/MARC.200400296##STORY BJ, 1989, J POLYM SCI POL PHYS, V27, P1927, DOI 10.1002/POLB.1989.090270910##VERDET L, 1982, ORGANOMETALLICS, V1, P380, DOI 10.1021/OM00062A024##VISSER T, 2005, J MEMBRANE SCI, V252, P265, DOI 10.1016/J.MEMSCI.2004.12.015##WANG YC, 2005, J MEMBRANE SCI, V248, P15, DOI 10.1016/J.MEMSCI.2004.09.015##WENG D, 1999, EUR POLYM J, V35, P867, DOI 10.1016/S0014-3057(98)00055-X",34,2020-11-20,NA
J,WOS:000242935400056,2006,"CLASSIFYING THE COMBINED INFLUENCE OF SHEAR RATE, TEMPERATURE, AND PRESSURE ON CRYSTALLINE MORPHOLOGY AND SPECIFIC VOLUME OF ISOTACTIC (POLY)PROPYLENE","THE USE OF THE DEBORAH NUMBER IN CLASSIFYING THE EFFECT OF SHEAR FLOW ON THE EVOLUTION OF THE SPECIFIC VOLUME AND RESULTING CRYSTALLINE MORPHOLOGY IS INVESTIGATED. WE DISTINGUISH BETWEEN FLOWS APPLIED AT LARGE UNDERCOOLINGS AND FLOWS APPLIED AT LOW UNDERCOOLINGS. IN THE FIRST CASE, THE DEBORAH NUMBER PROVIDES A GOOD CLASSIFICATION TOOL TO DETERMINE THE INFLUENCE OF FLOW ON THE EVOLUTION OF ORIENTATION AND STRUCTURAL PROPERTIES OF THE CRYSTALLINE MORPHOLOGY AND SPECIFIC VOLUME. BOTH THE DEBORAH NUMBER RELATED TO THE PROCESS OF CHAIN RETRACTION (DE(S)) OR THE DEBORAH NUMBER RELATED TO REPTATION OF CHAINS (DE(REP)) CAN EQUALLY WELL BE USED TO CLASSIFY THE INFLUENCE OF FLOW ON THE EVOLUTION OF SPECIFIC VOLUME, AS CHARACTERIZED BY THE DIMENSIONLESS TRANSITION TEMPERATURE AND DIMENSIONLESS RATE OF TRANSITION. IF, HOWEVER, FLOW IS APPLIED AT RELATIVELY LOW UNDERCOOLINGS, REMELTING OF FLOW-INDUCED CRYSTALLINE STRUCTURES AND RELAXATION OF MOLECULAR ORIENTATION PLAY A SIGNIFICANT ROLE AFTER CESSATION OF FLOW. THEREFORE, IN THESE CASES THE USE OF DEBORAH (OR ALTERNATIVELY WEISSENBERG) NUMBERS IS FOUND TO BE OF LITTLE USE IN THIS CLASSIFICATION. NOTE THAT THE DEBORAH NUMBERS ARE USED AS A CLASSIFICATION PARAMETER TO DISTINGUISH BETWEEN DIFFERENT CRYSTALLIZATION REGIMES AND NOT AS THE DRIVING FORCE FOR FLOW INDUCED CRYSTALLIZATION.",FLOW-INDUCED CRYSTALLIZATION; COOLING RATE; MOLECULAR-WEIGHT; POLYPROPYLENE,NA,MACROMOLECULES,"VAN DER BEEK, MHE##PETERS, GWM##MEIJER, HEH","EINDHOVEN UNIV TECHNOL, DUTCH POLYMER INST, NL-5600 MB EINDHOVEN, NETHERLANDS. TNO SCI & IND, DEPT DESIGN & MFG, NL-5600 HE EINDHOVEN, NETHERLANDS.",POLYMER SCIENCE,POLYMER SCIENCE,"ACIERNO S, 2003, RHEOL ACTA, V42, P243, DOI [10.1007/S00397-002-0280-9, 10.1007/S00397-002-0280-9]##DOI M., 1986, THEORY POLYMERDYNAMI##EDER G, 1997, PROCESSING POLYM, V18, P269##ELMOUMNI A, 2003, MACROMOLECULES, V36, P6453, DOI 10.1021/MA025948N##FLEISCHMANN E, 1990, J APPL POLYM SCI, V41, P1115, DOI 10.1002/APP.1990.070410520##FRITZSCHE AK, 1974, POLYM ENG SCI, V14, P401, DOI 10.1002/PEN.760140602##JANESCHITZ-KRIEGL H, 2003, RHEOL ACTA, V42, P355, DOI 10.1007/S00397-002-0247-X##JERSCHOW P, 1996, RHEOL ACTA, V35, P127, DOI 10.1007/BF00396039##KADIJK SE, 1994, POLYM ENG SCI, V34, P1535, DOI 10.1002/PEN.760342004##KELLER A., 1997, MAT SCI TEC, V18, P189##KETZMERICK R., 1989, CONTINUUM MECHANICS AND THERMODYNAMICS, V1, P113, DOI 10.1007/BF01141997##KOSCHER E, 2002, POLYMER, V43, P6931, DOI 10.1016/S0032-3861(02)00628-6##KUMARASWAMY G, 2002, MACROMOLECULES, V35, P1762, DOI 10.1021/MA0114180##MEZGHANI K, 1998, POLYMER, V39, P3735, DOI 10.1016/S0032-3861(97)10121-5##SEKI M, 2002, MACROMOLECULES, V35, P2583, DOI 10.1021/MA011359Q##SOMANI RH, 2000, MACROMOLECULES, V33, P9385, DOI 10.1021/MA001124Z##SWARTJES FHM, 2003, INT POLYM PROC, V18, P53, DOI 10.3139/217.1719##TRIBOUT C, 1996, COLLOID POLYM SCI, V274, P197, DOI 10.1007/BF00665636##VAN DER BEEK MHE, 2005, MACROMOL MATER ENG, V290, P443, DOI 10.1002/MAME.200500027##VAN DER BEEK MHE, 2005, INT POLYM PROC, V20, P111, DOI 10.3139/217.1872##VAN DER BEEK MHE, 2006, MACROMOLECULES, V39, P1805, DOI 10.1021/MA051914E##VAN MEERVELD J, 2004, RHEOL ACTA, V43, P615, DOI 10.1007/S00397-004-0358-7##VAN MEERVELD J, 2004, RHEOL ACTA, V44, P119, DOI 10.1007/S00397-004-0382-7##VLEESHOUWERS S, 1996, RHEOL ACTA, V35, P391, DOI 10.1007/BF00368990##WATANABE H, 1999, PROG POLYM SCI, V24, P1253, DOI 10.1016/S0079-6700(99)00029-5##WATANABE K, 2003, POLYMER, V44, P5843, DOI 10.1016/S0032-3861(03)00604-9##2002, ADV PHYS, V51, P1379",17,2020-11-20,NA
J,WOS:000242935400062,2006,SELF-ASSEMBLED STRUCTURES IN DIBLOCK COPOLYMERS WITH HYDROGEN-BONDED AMPHIPHILIC PLASTICIZING COMPOUNDS,"HYDROGEN-BONDING AMPHIPHILIC LOW MOLECULAR WEIGHT PLASTICIZING COMPOUNDS TO ONE BLOCK OF DIBLOCK COPOLYMERS TO FORM SUPRAMOLECULAR COMBLIKE BLOCKS LEADS TO HIERARCHICAL SELF-ASSEMBLY AT THE BLOCK COPOLYMER (LONG) AND AMPHIPHILE (SHORT) LENGTH SCALES, IN WHICH LAMELLAR-IN-LAMELLAR ORDER AND THE RELATED PHASE TRANSITIONS HAVE PREVIOUSLY BEEN SHOWN TO ALLOW THERMAL SWITCHING OF ELECTRICAL AND OPTICAL PROPERTIES [SCIENCE 1998, 280, 557; NAT. MATER. 2004, 3, 872]. IN THIS WORK OTHER HIERARCHIES AND PHASE TRANSITIONS ARE SYSTEMATICALLY SEARCHED, A PARTICULAR INTEREST BEING HIERARCHIES CONTAINING GYROID STRUCTURES AND THE RELATED ORDER-ORDER TRANSITIONS. POLYMERIC SUPRAMOLECULAR COMB-COIL DIBLOCK COPOLYMERS CONSISTING OF A POLYSTYRENE (PS) COILLIKE BLOCK AND A SUPRAMOLECULAR COMBLIKE BLOCK BASED ON POLY(4-VINYLPYRIDINE) (P4VP) ARE USED, WHERE THE PYRIDINES ARE EITHER DIRECTLY HYDROGEN BONDED WITH 3-PENTADECYLPHENOL (PDP), I.E., PS-BLOCK-P4VP(PDP)(1.0), OR FIRST PROTONATED WITH METHANESULFONIC ACID (MSA) AND THEN HYDROGEN BONDED TO PDP, I.E., PS-BLOCK-P4VP(MSA)(1.0)(PDP)(1.0). IN THIS WAY THE COMBLIKE BLOCK CAN BE NONCHARGED OR CHARGED. THE MORPHOLOGIES WERE DETERMINED USING TRANSMISSION ELECTRON MICROSCOPY (TEM) AND SMALL-ANGLE X-RAY SCATTERING (SAXS) AT DIFFERENT TEMPERATURES. IN THE CASE OF PS-BLOCK-P4VP(PDP)(1.0), ALL CLASSICAL DIBLOCK COPOLYMER MORPHOLOGIES WERE OBSERVED AT ROOM TEMPERATURE, WHERE THE P4VP(PDP)(1.0) DOMAINS CONTAIN AN ADDITIONAL LAMELLAR STRUCTURE DUE TO THE SUPRAMOLECULAR COMBLIKE BLOCKS. HERE WE REPORT NOVEL GYROID AND HEXAGONAL PERFORATED LAYER MORPHOLOGIES, I.E., WHERE THE PS AND P4VP(PDP)(1.0) BLOCKS FORM GYROID OR HEXAGONAL PERFORATED LAYER ORDER AND THE P4VP(PDP)(1.0) DOMAINS HAVE AN INTERNAL LAMELLAR ORDER. HEATING PAST CA. T = 60 DEGREES C CAUSES AN ORDER-DISORDER TRANSITION WITHIN THE P4VP(PDP)(1.0) DOMAINS. FURTHER HEATING LEADS TO GRADUALLY REDUCED HYDROGEN BONDING STRENGTH, AND IMPORTANTLY PDP BECOMES SOLUBLE IN PS AT T > CA. 120 DEGREES C. AT SUCH TEMPERATURES PDP IS FOUND IN BOTH THE P4VP AND PS DOMAINS, THUS LEADING TO CHANGES IN THE RELATIVE VOLUME FRACTIONS OF THE DOMAINS, WHICH IN TURN LEADS TO ORDER-ORDER TRANSITIONS. IN PS-BLOCK-P4VP(MSA)(1.0)(PDP)(1.0), TYPICALLY LAMELLAR AND CYLINDRICAL BLOCK COPOLYMERIC STRUCTURES WERE OBSERVED, WHERE THERE WAS AN ADDITIONAL INTERNAL LAMELLAR ORDER WITHIN THE P4VP(MSA)(1.0)(PDP)(1.0) DOMAINS. COINCIDENTALLY, AN ORDER-DISORDER TRANSITION WITHIN THE P4VP(MSA)(1.0)(PDP)(1.0) DOMAINS TAKES PLACE AT T = CA. 125 DEGREES C. ABOVE THAT TEMPERATURE, PDP IS IN BOTH PS AND P4VP(MSA)(1.0) DOMAINS, BUT MOST INTERESTINGLY AT CA. T > 175 DEGREES C PDP BECOMES A NONSOLVENT FOR P4VP(MSA)(1.0) AND IT IS THEREFORE EXPELLED TO PREDOMINANTLY TO THE PS DOMAINS. THIS MANIFESTS AS AN ORDER-ORDER TRANSITION. ALL SAMPLES EXHIBIT AT LEAST TWO THERMOREVERSIBLE ORDER-ORDER TRANSITIONS, AND SOME OF THEM SHOW EVEN FIVE CONSECUTIVE SELF-ASSEMBLED PHASES AS A FUNCTION OF TEMPERATURE. BESIDES BEING AMPHIPHILIC, PDP CAN ALSO BE REGARDED AS A PLASTICIZER, I.E., RELATIVELY NONVOLATILE SOLVENT, FOR THE P4VP, PS, AND P4VP(MSA)(1.0) WITH CHARACTERISTIC PHASE BEHAVIORS. THIS, IN COMBINATION WITH THE COMB-COIL DIBLOCK COPOLYMER COMPOSITION AND THE REVERSIBILITY OF THE HYDROGEN BONDING, ENABLES TO ACHIEVE THERMOREVERSIBLE TRANSITION SEQUENCES THAT ARE NOT EASILY ACCESSIBLE ONLY BY CHANGING THE FLORY-HUGGINS INTERACTION PARAMETER CHI BY TEMPERATURE, FOR EXAMPLE TRNSITIONS FROM A LAMELLAR TO SPHERICAL STRUCTURE. THE COMBINATION OF PHASE BEHAVIORS OF SELF-ASSEMBLY AND POLYMER/PLASTICIZER MIXTURES ALLOWS NEW STRUCTURAL HIERARCHIES AND PHASE TRANSITIONS THAT MAY LEAD TO NEW TYPES OF RESPONSIVE MATERIALS.",SUPRAMOLECULAR POLYMERIC MATERIALS; ORDER-ORDER TRANSITION; TO-GYROID TRANSITION; BLOCK-COPOLYMER; MORPHOLOGY TRANSITION; FUNCTIONAL MATERIALS; LENGTH SCALES; LAMELLAR; MICRODOMAINS; COMPLEXES,NA,MACROMOLECULES,"VALKAMA, S##RUOTSALAINEN, T##NYKANEN, A##LAIHO, A##KOSONEN, H##TEN BRINKE, G##IKKALA, O##RUOKOLAINEN, J","HELSINKI UNIV TECHNOL, DEPT ENGN MATH & PHYS, FI-02015 ESPOO, FINLAND. HELSINKI UNIV TECHNOL, CTR NEW MAT, FI-02015 ESPOO, FINLAND. UNIV GRONINGEN, CTR MAT SCI, POLYMER CHEM LAB, NL-9747 AG GRONINGEN, NETHERLANDS.",POLYMER SCIENCE,POLYMER SCIENCE,"ABETZ V, 2000, ASSEMBLIES COMPLEX B, P215##ALMDAL K, 1992, MACROMOLECULES, V25, P1743, DOI 10.1021/MA00032A019##ANTHAMATTEN M, 1999, MACROMOLECULES, V32, P8066, DOI 10.1021/MA9910989##ANTONIETTI M, 2003, NAT MATER, V2, P9, DOI 10.1038/NMAT791##BATES FS, 2005, MRS BULL, V30, P525, DOI 10.1557/MRS2005.145##BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/ANNUREV.PC.41.100190.002521##BATES FS, 1999, PHYS TODAY, V52, P32, DOI 10.1063/1.882522##BONDZIC S, 2004, MACROMOLECULES, V37, P9517, DOI 10.1021/MA048913R##BRAS W, 1998, J MACROMOL SCI PHYS, VB37, P557, DOI 10.1080/00222349808220492##CHO BK, 2004, SCIENCE, V305, P1598, DOI 10.1126/SCIENCE.1100872##EICHHORN KJ, 2003, J MOL STRUCT, V661, P161, DOI 10.1016/S0022-2860(03)00513-1##FISCHER H, 1996, ACTA POLYM, V47, P413, DOI 10.1002/ACTP.1996.010471001##FLOUDAS G, 2000, EUROPHYS LETT, V50, P182, DOI 10.1209/EPL/I2000-00252-0##HADJICHRISTIDIS N, 2001, CHEM REV, V101, P3747, DOI 10.1021/CR9901337##HADJICHRISTIDIS N, 2002, BLOCK COPOLYMERS SYN, P400##HAJDUK DA, 1997, MACROMOLECULES, V30, P3788, DOI 10.1021/MA961673Y##HAMLEY I. W., 1998, PHYS BLOCK COPOLYMER##HAMLEY IW, 1993, MACROMOLECULES, V26, P5959, DOI 10.1021/MA00074A018##HAMLEY IW, 1994, J PHYS II, V4, P2161, DOI 10.1051/JP2:1994254##HOEBEN FJM, 2005, CHEM REV, V105, P1491, DOI 10.1021/CR030070Z##IKKALA O, 2004, CHEM COMMUN, P2131, DOI 10.1039/B403983A##IKKALA O, 2002, SCIENCE, V295, P2407, DOI 10.1126/SCIENCE.1067794##KIM JK, 1998, MACROMOL CHEM PHYSIC, V199, P641, DOI 10.1002/(SICI)1521-3935(19980401)199:4<641::AID-MACP641>3.0.CO;2-D##KRISHNAMOORTI R, 2000, MACROMOLECULES, V33, P3810, DOI 10.1021/MA991841X##LOO YL, 2005, MACROMOLECULES, V38, P4947, DOI 10.1021/MA050237L##MANI S, 2000, EUR POLYM J, V36, P215, DOI 10.1016/S0014-3057(99)00052-X##MUTHUKUMAR M, 1997, SCIENCE, V277, P1225, DOI 10.1126/SCIENCE.277.5330.1225##NANDAN B, 2005, MACROMOLECULES, V38, P10117, DOI 10.1021/MA051448T##OKANO T, 1998, BIORELATED POLYM GEL##RODRIGUEZ-CABELLO JC, 2002, ADV MATER, V14, P1151, DOI 10.1002/1521-4095(20020816)14:16<1151::AID-ADMA1151>3.0.CO;2-Y##RUOKOLAINEN J, 2005, MACROMOLECULES, V38, P851, DOI 10.1021/MA0494479##RUOKOLAINEN J, 1999, ADV MATER, V11, P777, DOI 10.1002/(SICI)1521-4095(199906)11:9<777::AID-ADMA777>3.0.CO;2-M##RUOKOLAINEN J, 1999, MACROMOLECULES, V32, P1152, DOI 10.1021/MA980189N##RUOKOLAINEN J, 1998, SCIENCE, V280, P557, DOI 10.1126/SCIENCE.280.5363.557##RUOKOLAINEN J, 1998, MACROMOLECULES, V31, P3532, DOI 10.1021/MA971747L##RUSSELL VA, 1996, CHEM MATER, V8, P1654, DOI 10.1021/CM9600743##RYU CY, 1998, PHYS REV LETT, V81, P5354, DOI 10.1103/PHYSREVLETT.81.5354##SAKURAI S, 1996, MACROMOLECULES, V29, P740, DOI 10.1021/MA9502516##SAKURAI S, 1993, MACROMOLECULES, V26, P5796, DOI 10.1021/MA00073A038##SAKURAI S, 1993, MACROMOLECULES, V26, P485, DOI 10.1021/MA00055A013##STUPP SI, 1997, SCIENCE, V276, P384, DOI 10.1126/SCIENCE.276.5311.384##THUNEMANN AF, 2001, MACROMOLECULES, V34, P6978, DOI 10.1021/MA0101153##URRY DW, 1993, ANGEW CHEM INT EDIT, V32, P819, DOI 10.1002/ANIE.199308191##VALKAMA S, 2004, NAT MATER, V3, P872, DOI 10.1038/NMAT1254##VIGILD ME, 1998, MACROMOLECULES, V31, P5702, DOI 10.1021/MA9716746##WANG CY, 2002, MACROMOL RAPID COMM, V23, P49, DOI 10.1002/1521-3927(20020101)23:1<49::AID-MARC49>3.0.CO;2-X##WANG CY, 2002, MACROMOLECULES, V35, P6997, DOI 10.1021/MA0205212",138,2020-11-20,NA
J,WOS:000243101500024,2006,HEART RATE CHANGES ARE INSENSITIVE FOR DETECTING POSTASPHYXIAL SEIZURES IN NEONATES,"SEIZURES ARE A COMMON MANIFESTATION OF CNS DYSFUNCTION IN NEWBORN BABIES AND ARE ASSOCIATED WITH POOR OUTCOME. 1 SEIZURES ARE OFTEN SUBCLINICAL, DETECTABLE ONLY BY EEG. DEPENDING ON THEIR LOCATION, SEIZURES MAY AFFECT HEART FUNCTION. HEART RATE (HR) MONITORING HAS THEREFORE BEEN SUGGESTED AS METHOD FOR SEIZURE DETECTION. 2 RELATIVE IMMATURITY OF THE NEWBORN BRAIN MAY RESULT IN CARDIAC RESPONSES TO SEIZURES THAT DIFFER FROM THOSE SEEN IN OLDER PATIENTS, BUT NO STUDY HAS SYSTEMATICALLY ADDRESSED THIS ISSUE. WE STUDIED HR DURING SEIZURES IN NEWBORN BABIES THAT UNDERWENT EEG MONITORING AFTER BIRTH ASPHYXIA TO A) DETERMINE WHETHER ICTAL HR CHANGES OCCUR IN THEM AND B) ASSESS THE POTENTIAL OF HR MONITORING AS A TOOL TO SUPPORT SEIZURE DETECTION.",EPILEPTIC SEIZURES; ECG ABNORMALITIES,NA,NEUROLOGY,"CHERIAN, PJ##BLOK, JH##SWARTE, RM##GOVAERT, P##VISSER, GH","ERASMUS UNIV, MED CTR, DEPT CLIN NEUROPHYSIOL, NL-3015 GD ROTTERDAM, NETHERLANDS. ERASMUS MC SOPHIA CHILDRENS HOSP, DEPT NEONATOL, ROTTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"GRIFFIN MP, 2004, PEDIATR RES, V55, P782, DOI 10.1203/01.PDR.0000119366.21770.9E##LEUTMEZER F, 2003, EPILEPSIA, V44, P348, DOI 10.1046/J.1528-1157.2003.34702.X##LOMBROSO CT, 1993, ELECTROENCEPHALOGRAP, P803##MAYER H, 2004, NEUROLOGY, V63, P324, DOI 10.1212/01.WNL.0000129830.72973.56##MCBRIDE MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506##OMOKHODION S I, 2003, WEST AFR J MED, V22, P253##OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727##PACIA SV, 1997, EPILEPSIA, V38, P642, DOI 10.1111/J.1528-1157.1997.TB01233.X##PERSSON H, 2003, EPILEPSY RES, V57, P69, DOI 10.1016/J.EPLEPSYRES.2003.10.012##ZIJLMANS M, 2002, EPILEPSIA, V43, P847, DOI 10.1046/J.1528-1157.2002.37801.X",11,2020-11-20,NA
J,WOS:000243101500025,2006,SEVERE MYOCLONIC EPILEPSY OF INFANCY (DRAVET SYNDROME): RECOGNITION AND DIAGNOSIS IN ADULTS,"THERE IS A GROUP OF ADULT PATIENTS WITH INTRACTABLE EPILEPSY AND INTELLECTUAL DISABILITY IN WHOM NO ETIOLOGIC DIAGNOSIS HAS BEEN ESTABLISHED. DETERMINING THE ETIOLOGY IS IMPORTANT FOR TREATMENT AND FAMILY COUNSELING. MANY FAMILIES CARRY A BURDEN OF BLAME RELATED TO MISTAKEN BELIEFS ABOUT CAUSATION. SEVERE MYOCLONIC EPILEPSY OF INFANCY (SMEI; DRAVET SYNDROME) WAS DESCRIBED IN 1978(1) BUT HAS ONLY RECENTLY BEEN WIDELY RECOGNIZED AMONG CHILDHOOD EPILEPSY POPULATIONS, SPARKED BY THE DISCOVERY OF MUTATIONS IN THE NEURONAL SODIUM CHANNEL ALPHA 1 SUBUNIT (SCN1A) GENE.(2,3) PATIENTS WITH SMEI TYPICALLY PRESENT WITH RECURRENT FEBRILE HEMICLONIC OR GENERALIZED STATUS EPILEPTICUS AT AROUND AGE 6 MONTHS. BETWEEN AGES 1 AND 4, OTHER SEIZURE TYPES APPEAR, INCLUDING MYOCLONIC AND PARTIAL SEIZURES. PSYCHOMOTOR DEVELOPMENT IS NORMAL IN THE FIRST YEAR AND THEN SLOWS. THE EPILEPSY IS OFTEN INTRACTABLE, DEVELOPMENTAL OUTCOME IS POOR, AND DEATH IN CHILDHOOD IS NOT RARE.(4) ""BORDERLINE SMEI"" (SMEB) REFERS TO CASES LACKING SOME OF THE TYPICAL FEATURES SUCH AS MYOCLONIC SEIZURES.(5) ALTHOUGH SMEI HAS A CHARACTERISTIC PRESENTATION IN CHILDHOOD, ADULTS WITH SMEI ARE UNDERRECOGNIZED. TO DATE, THERE ARE FEW DATA ON LONG-TERM EVOLUTION OR THE PHENOTYPE IN ADULTS.(6,7) THIS STUDY WAS PERFORMED TO DELINEATE THE ADULT PHENOTYPE OF SMEI AND SMEB.",MUTATIONS,NA,NEUROLOGY,"JANSEN, FE##SADLEIR, LG##HARKIN, LA##VADLAMUDI, L##MCMAHON, JM##MULLEY, JC##SCHEFFER, IE##BERKOVIC, SF","UNIV MELBOURNE, AUSTIN HLTH, DEPT MED, EPILEPSY RES CTR, HEIDELBERG, VIC, AUSTRALIA. WOMENS & CHILDRENS HOSP, DEPT GENET MED, ADELAIDE, SA, AUSTRALIA. CANBERRA HOSP, DEPT NEUROL, MELBOURNE, VIC, AUSTRALIA. UNIV MELBOURNE, DEPT PAEDIAT, MELBOURNE, VIC, AUSTRALIA. ROYAL CHILDRENS HOSP, MELBOURNE, VIC, AUSTRALIA. UNIV UTRECHT, MED CTR, RUDOLF MAGNUS INST NEUROSCI, DEPT NEUROL, NL-3508 TC UTRECHT, NETHERLANDS. CAPITAL COAST HLTH, DEPT PEDIAT, WELLINGTON, NEW ZEALAND. UNIV OTAGO, DEPT PEDIAT, WELLINGTON, NEW ZEALAND.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"[ANONYMOUS], 1989, EPILEPSIA, V30, P389, DOI 10.1111/J.1528-1157.1989.TB05316.X##CLAES L, 2001, AM J HUM GENET, V68, P1327, DOI 10.1086/320609##DRAVET C, 2002, CURR PROB E, V17, P81##DRAVET C, 1978, VIE MED, V8, P543##MULLEY JC, 2005, HUM MUTAT, V25, P535, DOI 10.1002/HUMU.20178##OGINO T, 1988, JPN J PSYCHIAT NEUR, V42, P554##OHKI T, 1997, SEIZURE-EUR J EPILEP, V6, P219, DOI 10.1016/S1059-1311(97)80009-X##OHTSUKA Y, 2003, BRAIN DEV-JPN, V25, P401, DOI 10.1016/S0387-7604(03)00025-1##OHTSUKA Y, 1991, JPN J PSYCHIAT NEUR, V45, P416",85,2020-11-20,NA
J,WOS:000243101500039,2006,PTOSIS AS A FEATURE OF LATE-ONSET GLYCOGENOSIS TYPE II,NA,NA,NA,NEUROLOGY,"GROEN, WB##LEEN, WG##VOS, AMC##CRUYSBERG, JRM##VAN DOORN, PA##VAN ENGELEN, BGM","UNIV NIJMEGEN, MED CTR, NEUROMUSCULAR CTR, DEPT NEUROL, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, DEPT OPHTHALMOL, NIJMEGEN, NETHERLANDS. ERASMUS MC, DEPT NEUROL, ROTTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"AMATO AA, 2000, NEUROL CLIN, V18, P151, DOI 10.1016/S0733-8619(05)70182-1##BARNES D, 1993, JR SOC MED, V83, P50##BRADY RO, 2006, ANNU REV MED, V57, P283, DOI 10.1146/ANNUREV.MED.57.110104.115650##DE WILDE F, 1995, BULL SOC BELGE OPHTALMOL, V255, P139##GUIMARAES FC, 1995, OPHTHALMOLOGY, V102, P1218, DOI 10.1016/S0161-6420(95)30887-1##SMALL R G, 1989, OPHTHALMIC PLAST RECONSTR SURG, V5, P171##SRIDHARAN GV, 1995, AGE AGEING, V24, P21, DOI 10.1093/AGEING/24.1.21",20,2020-11-20,NA
J,WOS:000243197900011,2006,OPTIMIZING THERAPY OF SEIZURES IN CHILDREN AND ADOLESCENTS WITH ADHD,"ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) CAN COEXIST WITH EPILEPSY AND THE PREVALENCE OF ADHD IN EPILEPSY IS THREE TO FIVE TIMES GREATER THAN NORMAL. THIS MAY BE AN EFFECT OF THE EPILEPSY (PARTICULARLY AS A SECONDARY SYMPTOM OF SUBTLE SEIZURES) OR OF THE ANTIEPILEPTIC TREATMENT. THERE IS AN ONGOING DEBATE ABOUT THE NATURE OF ADHD IN EPILEPSY AND ESPECIALLY WHETHER SUCCESSIVE COMORBIDITY EXISTS (I.E., THE POSSIBILITY THAT EPILEPSY LOWERS THE THRESHOLD FOR DEVELOPING ADHD). TREATMENT OF COMORBID ADHD MAY BE DIFFICULT. METHYLPHENIDATE IS STILL THE TREATMENT OF CHOICE FOR THE CONDITION AND, ALTHOUGH IT HAS BEEN SHOWN THAT NEITHER METHYLPHENIDATE NOR OTHER PSYCHOSTIMULANTS PROVOKE SEIZURES, THERE IS STILL A POSSIBILITY THAT SEIZURE FREQUENCY MAY INCREASE IN CHILDREN WITH ACTIVE EPILEPSY.",DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT; METHYLPHENIDATE; EPILEPSY; RISK,NA,NEUROLOGY,"ALDENKAMP, AP##ARZIMANOGLOU, A##REIJS, R##VAN MIL, S","EPILEPSY CTR KEMPENHAEGHE, DEPT BEHAV SCI, NL-5590 AB HEEZE, NETHERLANDS. UNIV HOSP MAASTRICHT, DEPT NEUROL, MAASTRICHT, NETHERLANDS. HOP ROBERT DEBRE, F-75019 PARIS, FRANCE.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"ALDENKAMP T, 2004, EPILEPSIA, V45, P54, DOI 10.1111/J.0013-9580.2004.33403.X##BERMAN T, 1999, J ABNORM PSYCHOL, V108, P90, DOI 10.1037/0021-843X.108.1.90##BIEDERMAN J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2##CARTE ET, 1996, J ABNORM CHILD PSYCH, V24, P481, DOI 10.1007/BF01441570##CORBETT JA, 1985, J AM ACAD CHILD PSY, V24, P17, DOI 10.1016/S0002-7138(09)60405-2##CORKUM PV, 1993, J CHILD PSYCHOL PSYC, V34, P1217, DOI 10.1111/J.1469-7610.1993.TB01784.X##DUNN DW, 2003, DEV MED CHILD NEUROL, V45, P50, DOI 10.1017/S0012162203000094##ETTINGER AB, 1998, EPILEPSIA, V39, P874, DOI 10.1111/J.1528-1157.1998.TB01183.X##FELDMAN H, 1989, AM J DIS CHILD, V143, P1081, DOI 10.1001/ARCHPEDI.1989.02150210117030##GROSSTSUR V, 1997, J PEDIATR-US, V130, P40, DOI 10.1016/S0022-3476(97)70308-1##GUCUYENER K, 2003, J CHILD NEUROL, V18, P109, DOI 10.1177/08830738030180020601##HEMMER SA, 2001, PEDIATR NEUROL, V24, P99, DOI 10.1016/S0887-8994(00)00240-X##HERRANZ JL, 1982, EPILEPSIA, V23, P203, DOI 10.1111/J.1528-1157.1982.TB05068.X##HESDORFFER DC, 2004, ARCH GEN PSYCHIAT, V61, P731, DOI 10.1001/ARCHPSYC.61.7.731##INGRAM TTS, 1956, J MENT SCI, V102, P550##KETTER TA, 1999, NEUROLOGY, V53, PS53##LEVY F, 1997, J PAEDIATR CHILD H, V33, P384##LOSIER BJ, 1996, J CHILD PSYCHOL PSYC, V37, P971, DOI 10.1111/J.1469-7610.1996.TB01494.X##*MED EC CO, 1997, PHYS DESK REF 1998##PRUITT AW, 1985, PEDIATRICS, V76, P644##REIJS R, 2004, EPILEPSY BEHAV, V5, PS66, DOI 10.1016/J.YEBEH.2003.11.009##RICHARDS GP, 1990, J LEARN DISABIL, V23, P129, DOI 10.1177/002221949002300210##ROWLAND AS, 2001, CAN J PSYCHIAT, V46, P931##SCHUBERT R, 2005, PEDIATR NEUROL, V32, P1, DOI 10.1016/J.PEDIATRNEUROL.2004.06.007##SCHUERHOLZ LJ, 1997, J CHILD NEUROL, V12, P438, DOI 10.1177/088307389701200705##SEMRUD-CLIKEMAN M, 1999, EPILEPSIA, V40, P211, DOI 10.1111/J.1528-1157.1999.TB02077.X##SMITH DB, 1987, EPILEPSIA, V28, PS50, DOI 10.1111/J.1528-1157.1987.TB05778.X##STEIN MA, 1996, PEDIATRICS, V98, P748##SWANSON JM, 1991, J CHILD NEUROL, V6, PS119, DOI 10.1177/0883073891006001S12##TAN M, 2005, ARCH DIS CHILD, V90, P57, DOI 10.1136/ADC.2003.048504##TRIMBLE MR, 1988, EPILEPSIA, V29, PS15, DOI 10.1111/J.1528-1157.1988.TB05805.X##VINING EPG, 1987, PEDIATRICS, V80, P165##WOLF SM, 1978, PEDIATRICS, V61, P728",28,2020-11-20,NA
J,WOS:000243197900003,2006,OPTIMIZING THERAPY OF SEIZURES IN PATIENTS WITH BRAIN TUMORS,"THE MECHANISM OF EPILEPSY IN BRAIN TUMOR PATIENTS IS PROBABLY MULTIFACTORIAL, AND ITS INCIDENCE DEPENDS ON TUMOR TYPE AND LOCATION. REFRACTORY EPILEPSY IS COMMON IN PATIENTS WITH STRUCTURAL BRAIN LESIONS, AND A ROLE FOR MULTIDRUG-RESISTANCE PROTEINS HAS BEEN SUGGESTED. THE MEDICAL TREATMENT OF EPILEPSY IN BRAIN TUMOR PATIENTS HAS MAINLY BEEN STUDIED RETROSPECTIVELY, AND THE OPTIMAL MANAGEMENT OF SEIZURES WITH ANTIEPILEPTIC DRUGS (AEDS) IS UNCLEAR. ENZYME-INDUCING ANTICONVULSANTS ARE GENERALLY NOT RECOMMENDED BECAUSE THEY CAN LEAD TO INSUFFICIENT SERUM LEVELS OF CONCOMITANTLY ADMINISTERED CHEMOTHERAPEUTIC DRUGS. ALTHOUGH VALPROIC ACID IS AN ENZYME INHIBITOR AND MAY THEREFORE LEAD TO TOXIC LEVELS OF SIMULTANEOUSLY ADMINISTERED CHEMOTHERAPEUTIC AGENTS, THIS DOES NOT APPEAR TO BE A MAJOR PROBLEM IN PATIENTS WITH BRAIN TUMORS. PRELIMINARY OBSERVATIONS OF ADD-ON TREATMENT WITH THE AEDS LEVETIRACETAM. OR GABAPENTIN SUGGEST THAT THESE NON-ENZYME-INDUCING AEDS CAN BE USEFUL FOR CONTROL OF SEIZURES IN PATIENTS WITH BRAIN TUMORS. CONVERSELY, PROPHYLACTIC USE OF AEDS IN BRAIN TUMOR PATIENTS IS GENERALLY NOT RECOMMENDED.",MULTIDRUG-RESISTANCE; ANTIEPILEPTIC DRUGS; INTRACTABLE EPILEPSY; LEVETIRACETAM; PROPHYLAXIS; PHARMACORESISTANCE; TRANSPORTERS; CHEMOTHERAPY; METAANALYSIS; EXPRESSION,NA,NEUROLOGY,"VECHT, CJ##VAN BREEMEN, M","MED CTR THE HAGUE, DEPT NEUROL, NL-2501 CK THE HAGUE, NETHERLANDS.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"ARONICA E, 2005, EPILEPSIA, V46, P849, DOI 10.1111/J.1528-1167.2005.66604.X##ARONICA E, 2003, NEUROSCIENCE, V118, P417, DOI 10.1016/S0306-4522(02)00992-2##BAKER AF, 2001, CANCER TREAT REV, V27, P221, DOI 10.1053/CTRV.2001.0228##BATEMAN D E, 1988, NEUROLOGICAL RESEARCH, V10, P112##BLAHETA RA, 2002, MED RES REV, V22, P492, DOI 10.1002/MED.10017##CASCINO GD, 1990, EPILEPSIA S3, V31, P37##FICKER DM, 2005, EPILEPSIA, V46, P106##GILBAR PJ, 2001, ANN PHARMACOTHER, V35, P1367##GILMORE R, 1994, EPILEPSIA, V35, P258, DOI 10.1111/J.1528-1157.1994.TB02429.X##GLANTZ MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886##GOLDMAN B, 2003, J NATL CANCER I, V95, P255, DOI 10.1093/JNCI/95.4.255##GROSSMAN SA, 1998, CANCER CHEMOTH PHARM, V42, P118, DOI 10.1007/S002800050794##HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/J.1528-1157.1993.TB02586.X##HERMAN ST, 2002, NEUROLOGY, V59, PS21, DOI 10.1212/WNL.59.9_SUPPL_5.S21##HILDEBRAND J, 2005, NEUROLOGY, V65, P212, DOI 10.1212/01.WNL.0000168903.09277.8F##KARCESKI S, 2005, EPILEPSY BEHAV, V7, PS1, DOI 10.1016/J.YEBEH.2005.06.001##LOSCHER W, 2002, J PHARMACOL EXP THER, V301, P7, DOI 10.1124/JPET.301.1.7##MOOTS PL, 1995, ARCH NEUROL-CHICAGO, V52, P717, DOI 10.1001/ARCHNEUR.1995.00540310091021##MORRIS HH, 1993, EPILEPSIA, V34, P1038, DOI 10.1111/J.1528-1157.1993.TB02131.X##NEEF C, 1988, CLIN PHARMACOL THER, V43, P372, DOI 10.1038/CLPT.1988.45##OBERNDORFER S, 2005, J NEURO-ONCOL, V72, P255, DOI 10.1007/S11060-004-2338-2##OTOUL C, 2005, CLIN NEUROPHARMACOL, V28, P72, DOI 10.1097/01.WNF.0000159956.87511.67##PERRY JR, 1996, CAN J NEUROL SCI, V23, P128, DOI 10.1017/S0317167100038853##ROGAWSKI MA, 2002, EPILEPSY BEHAV, V3, P493, DOI 10.1016/S1525-5050(02)00557-7##SCHALLER B, 2003, EPILEPSIA, V44, P1223, DOI 10.1046/J.1528-1157.2003.05203.X##SIDDIQUI A, 2003, NEW ENGL J MED, V348, P1442, DOI 10.1056/NEJMOA021986##SIDDIQUI A, 2002, NOVATIS FDN S, V243, P174##SIRVEN JI, 2004, MAYO CLIN PROC, V79, P1489, DOI 10.4065/79.12.1489##SISODIYA S M, 2002, NOVARTIS FOUND SYMP, V243, P167##SISODIYA SM, 2002, BRAIN, V125, P22, DOI 10.1093/BRAIN/AWF002##SISODIYA SM, 2002, NOVART FDN SYMP, V243, P180##STEVENS GHJ, 2005, NEUROLOGY S1, V64, P1##TAN B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011##TANG R, 2004, LEUKEMIA, V18, P1246, DOI 10.1038/SJ.LEU.2403390##TAPHOORN MJB, 2003, SEMIN ONCOL, V30, P45, DOI 10.1053/J.SEMINONCOL.2003.11.023##VECHT CJ, 2003, SEMIN ONCOL, V30, P49, DOI 10.1053/J.SEMINONCOL.2003.11.030##VECHT CJ, 2003, LANCET NEUROL, V2, P404, DOI 10.1016/S1474-4422(03)00435-6##VILLEMURE JG, 1996, CURR OPIN NEUROL, V9, P424, DOI 10.1097/00019052-199612000-00005##WAGNER GL, 2003, SEIZURE-EUR J EPILEP, V12, P585, DOI 10.1016/S1059-1311(03)00096-7##WEN PY, 2002, CURR OPIN ONCOL, V14, P299, DOI 10.1097/00001622-200205000-00008##WOLF HK, 1996, ACTA NEUROPATHOL, V91, P376, DOI 10.1007/S004010050439",75,2020-11-20,NA
J,WOS:000243285500009,2006,PROCESSIVE ENZYME MIMIC: KINETICS AND THERMODYNAMICS OF THE THREADING AND SLIDING PROCESS,"THE KINETICS AND THERMODYNAMICS OF THE TREADING AND DETHREADING PROCESS OF POLYMERS THROUGH THE CAVITY OF A SYNTHETIC TOROIDAL HOST IS INVESTIGATED BY STUDYING ITS COMPLEXATION WITH A SERIES OF END-FUNCTIONALIZED POLYMERS OF DIFFERENT LENGTHS CONTAINING AN END GROUP THAT IS SELECTIVELY RECOGNIZED BY THE HOST. THE SYSTEM IS DESIGNED IN SUCH A WAY THAT COMPLEXATION IS ONLY OBSERVED IF THE HOST HAS TRAVELED ALL OF THE WAY ACROSS THE COMPLETE POLYMER. DETAILED KINETIC INVESTIGATIONS USING FLUORESCENCE SPECTROSCOPY HAVE REVEALED THAT THE BARRIER FOR THIS PROCESS IS LENGTH DEPENDENT AND MOST LIKELY RELATED TO THE STRETCHING OF THE POLYMER. MOREOVER, THE RESULTS INDICATE THAT OUR PREVIOUSLY REPORTED PROCESSIVE ENZYME MIMIC MOST LIKELY OPERATES BY RANDOMLY SLIDING ALONG ITS MACROMOLECULAR SUBSTRATE.",POLYPSEUDOROTAXANES; TRANSLOCATION; DNA; MOTOR; BASE,BIOMIMETIC; PHYSICAL ORGANIC; ROTAXANES; SUPRAMOLECULAR CHEMISTRY,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,"COUMANS, RGE##ELEMANS, JAAW##NOLTE, RJM##ROWAN, AE","RADBOUD UNIV NIJMEGEN, INST MOL & MAT, NL-6525 ED NIJMEGEN, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"ASHKENASY N, 2005, ANGEW CHEM INT EDIT, V44, P1401, DOI 10.1002/ANIE.200462114##BENKOVIC SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/ANNUREV.BIOCHEM.70.1.181##BREYER WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/PS.10301##COUMANS RGE, 2003, ANGEW CHEM INT EDIT, V42, P650, DOI 10.1002/ANIE.200390179##HUANG FH, 2005, PROG POLYM SCI, V30, P982, DOI 10.1016/J.PROGPOLYMSCI.2005.07.003##KASIANOWICZ JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/PNAS.93.24.13770##LI J, 2003, J AM CHEM SOC, V125, P1788, DOI 10.1021/JA026623P##MANCINI EJ, 2004, CELL, V118, P743, DOI 10.1016/J.CELL.2004.09.007##MASON PE, 1999, MACROMOLECULES, V32, P1559, DOI 10.1021/MA9807769##MUTHUKUMAR M, 2001, PHYS REV LETT, V86, P3188, DOI 10.1103/PHYSREVLETT.86.3188##SMITH DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581##THORDARSON P, 2004, ANGEW CHEM INT EDIT, V43, P4755, DOI 10.1002/ANIE.200460398##THORDARSON P, 2003, NATURE, V424, P915, DOI 10.1038/NATURE01925##VAN OIJEN AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/SCIENCE.1084387##VENTURI M, 2004, NEW J CHEM, V28, P1032, DOI 10.1039/B315933G##WENTE SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/SCIENCE.288.5470.1374##WICKNER W, 2005, SCIENCE, V310, P1452, DOI 10.1126/SCIENCE.1113752##WONG JY, 1997, SCIENCE, V275, P820, DOI 10.1126/SCIENCE.275.5301.820",41,2020-11-20,NA
J,WOS:000242878100005,2006,ALTERNATING HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION - CONSEQUENCES OF PROGRESSION TO CERVICAL INTRAEPITHELIAL NEOPLASIA?,"BACKGROUND. NEARLY EVERY DUTCH WOMAN WILL BE EXPOSED TO GENITAL HUMAN PAPILLOMAVIRUS (HPV) AT LEAST ONCE DURING HER LIFETIME, AND MOST LIKELY SEVERAL TIMES. IN THE CURRENT STUDY, THE AUTHORS INVESTIGATED THE PREVALENCE OF HIGH-RISK-HPV (HR-HPV) INFECTION AND THE LIKELIHOOD OF PROGRESSION TO CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN). METHODS. IN THIS STUDY, THE COURSE OF HR-HPV INFECTION IN 703 WOMEN WAS OBSERVED. FROM A DATABASE OF 720,016 NEGATIVE CYTOLOGY SMEARS, THE AUTHORS SELECTED 703 WOMEN BASED ON THE AVAILABILITY OF AT LEAST 2 HR-HPV POLYMERASE CHAIN REACTION TESTS. THE AUTHORS DATABASE STORES NOT ONLY THE HPV DATA BUT ALSO ALL OTHER CYTOLOGIC AND HISTOLOGIC DATA, ALLOWING THE DETECTION OF WOMEN WHO PROGRESSED FROM NEGATIVE CYTOLOGY TO CIN WITHIN A PERIOD OF 10 YEARS. RESULTS. OF THE 703 SELECTED WOMEN, 159 WERE FOUND TO HAVE ALTERNATING HR-HPV INFECTION (CHANGE FROM A NEGATIVE HR-HPV TEST TO A POSITIVE TEST OR VICE VERSA), 40 HAD A PERSISTENTLY POSITIVE HR-HPV TEST, AND 504 WOMEN HAD A PERSISTENTLY NEGATIVE HR-HPV TEST. THE PERCENTAGE OF ALTERNATING HPV INFECTION DECLINED OVER TIME FROM 37% TO 7%. OF THE WOMEN AGE OLDER THAN 40 YEARS, 17% HAD AN ALTERNATING HR-HPV INFECTION, 2 OF WHOM DEVELOPED CIN. THESE FINDINGS LED THE AUTHORS TO CONCLUDE THAT ALL THE WOMEN IN THE CURRENT STUDY WITH AN INCREASED RISK OF DEVELOPING TYPE 2 OR 3 CIN WERE IDENTIFIED USING 2 HPV TESTS. WOMEN AGE OLDER THAN 40 YEARS STILL HAVE A SIGNIFICANT RISK OF ACQUIRING A HR-HPV. CONCLUSIONS. IN LIGHT OF THE CURRENT STUDY FINDINGS, THE AUTHORS BELIEVE IT IS WORTH CONSIDERING THE INCLUSION OF WOMEN AGE 40 YEARS AND OLDER WHO HAVE NEGATIVE CYTOLOGY FOR HPV TESTING AS PART OF THE DUTCH NATIONAL SCREENING PROGRAM.",NATURAL-HISTORY; YOUNG-WOMEN; HPV; CYTOLOGY; LESIONS,HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION; ALTERNATING INFECTION; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX; HPV,CANCER CYTOPATHOLOGY,"RIJKAART, DC##BONTEKOE, TR##KORPORAAL, H##BOON, ME","LEIDEN CYTOL & PATHOL LAB, NL-2301 GB LEIDEN, NETHERLANDS. BONTEKOE RES, LEIDEN, NETHERLANDS.",ONCOLOGY; PATHOLOGY,ONCOLOGY; PATHOLOGY,"BOSCH FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/JCP.55.4.244##BULKMANS NWJ, 2004, INT J CANCER, V110, P94, DOI 10.1002/IJC.20076##BURK RD, 1996, J INFECT DIS, V174, P679, DOI 10.1093/INFDIS/174.4.679##CASTLE PE, 2005, J INFECT DIS, V191, P1808, DOI 10.1086/428779##CLIFFORD GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/SJ.BJC.6600688##CUZICK J, 2003, LANCET, V362, P1871, DOI 10.1016/S0140-6736(03)14955-0##CUZICK J, 2006, INT J CANCER, V119, P1095, DOI 10.1002/IJC.21955##GIULIANO AR, 2002, J INFECT DIS, V186, P462, DOI 10.1086/341782##HINCHLIFFE SA, 1995, BRIT J CANCER, V72, P943, DOI 10.1038/BJC.1995.438##HO GYF, 1995, J NATL CANCER I, V87, P1365, DOI 10.1093/JNCI/87.18.1365##HO GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703##KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804##MAIMAN MITCHELL, 1996, P405##MELKERT PWJ, 1993, INT J CANCER, V53, P919, DOI 10.1002/IJC.2910530609##MORRISON EAB, 1994, CLIN INFECT DIS, V18, P172, DOI 10.1093/CLINIDS/18.2.172##NOBBENHUIS MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X##REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/IJC.2910610305##RICHARDSON H, 2003, CANCER EPIDEM BIOMAR, V12, P485##ROZENDAAL L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z##ROZENDAAL L, 2000, J CLIN PATHOL, V53, P606, DOI 10.1136/JCP.53.8.606##SELLORS JW, 2003, CAN MED ASSOC J, V168, P421##TING Y, 1990, PCR PROTOCOLS GUIDE, P356##VANDENBRULE AJC, 1990, J CLIN MICROBIOL, V28, P2739, DOI 10.1128/JCM.28.12.2739-2743.1990##VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43##WACHTEL MS, 2005, MODERN PATHOL, V18, P349, DOI 10.1038/MODPATHOL.3800242##WALBOOMERS JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&LT;12::AID-PATH431&GT;3.0.CO;2-F##WHEELER CM, 1996, OBSTET GYNECOL, V88, P261, DOI 10.1016/0029-7844(96)00120-2##WOODMAN CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4",4,2020-11-20,NA
J,WOS:000242899400019,2006,"POTASSIUM PHTHALOCYANINE, KPC: ONE-DIMENSIONAL MOLECULAR STACKS BRIDGED BY K+ IONS","WE REPORT THE SYNTHESIS OF POTASSIUM PHTHALOCYANINE (KPC) AND ITS STRUCTURAL CHARACTERIZATION BY SYNCHROTRON X-RAY POWDER DIFFRACTION. WE FIND THAT WHILE KPC ADOPTS THE BETA-POLYMORPHIC STRUCTURAL TYPE (MONOCLINIC SPACE GROUP P2(1)/A) COMMON FOR MANY MPC SOLIDS, ITS STRUCTURE IS CHARACTERIZED BY UNIQUE FEATURES. THE K+ IONS, WHICH ARE STATISTICALLY DISORDERED OVER TWO SYMMETRY-EQUIVALENT POSITIONS, RESIDE IN THE INTRASTACK SPACING OF THE RODLIKE MOLECULAR ASSEMBLIES AND STRONGLY BOND EQUIDISTANTLY TO SELECTED N ATOMS OF THE TWO NEIGHBORING PC RINGS ALONG THE CHAIN DIRECTION WITH AN UNUSUAL 5-FOLD COORDINATION. THE K+-STUFFED SLIPPED STACKS OF PC UNITS DISPLAY MUCH GREATER INTRASTACK AND SLIPPAGE DISTANCES THAN THOSE OF OTHER BETA-MPC POLYMORPHS. THEY MAY BE THOUGHT AS COMPRISING DISORDERED DIMERIC (PC)(2)(2-) UNITS; THIS LEADS TO ELECTRON PAIRING AND IS CONSISTENT WITH THE OBSERVED NONMAGNETIC RESPONSE OF THE SYSTEM.",LITHIUM PHTHALOCYANINE; MANGANESE(II) PHTHALOCYANINE; MAGNESIUM PHTHALOCYANINE; MAGNETIC-PROPERTIES; CHARGE-TRANSPORT; COMPLEXES; SPECTRA; AMMONIA; METALS,NA,INORGANIC CHEMISTRY,"MARGADONNA, S##PRASSIDES, K##IWASA, Y##TAGUCHI, Y##CRACIUN, MF##ROGGE, S##MORPURGO, AF","UNIV EDINBURGH, SCH CHEM, EDINBURGH EH9 3JJ, MIDLOTHIAN, SCOTLAND. UNIV DURHAM, DEPT CHEM, DURHAM DH1 3LE, ENGLAND. TOHOKU UNIV, MAT RES INST, SENDAI, MIYAGI 9808577, JAPAN. CREST, JAPAN SCI & TECHNOL AGCY, KAWAGUCHI 3320012, JAPAN. DELFT UNIV TECHNOL, KAVLI INST NANOSCI, NL-2628 CJ DELFT, NETHERLANDS.","CHEMISTRY, INORGANIC & NUCLEAR",CHEMISTRY,"AGAWA K, 1991, PHYS REV B, V44, P2589##BARRACLOUGH CG, 1970, J CHEM PHYS, V53, P1638, DOI 10.1063/1.1674236##BASOVA TV, 2000, J STRUCT CHEM+, V41, P770, DOI 10.1023/A:1004802000669##BRINKMANN M, 1998, J MATER CHEM, V8, P675, DOI 10.1039/A707915J##CRACIUN MF, 2006, ADV MATER, V18, P320, DOI 10.1002/ADMA.200501268##CRACIUN MF, 2005, J AM CHEM SOC, V127, P12210, DOI 10.1021/JA054468J##DUMM M, 1996, J CHEM PHYS, V104, P5048, DOI 10.1063/1.471134##FIGGIS BN, 1980, ACTA CRYSTALLOGR B, V36, P2963, DOI 10.1107/S056774088001062X##FIGIGS BN, 1980, J CHEM SOC DA, P1515##HOMBORG H, 1978, Z NATURFORSCH B, V33, P1067, DOI 10.1515/ZNB-1978-1002##HOMBORG H, 1985, Z ANORG ALLG CHEM, V527, P45, DOI 10.1002/ZAAC.19855270805##JANCZAK J, 2001, POLYHEDRON, V20, P2901, DOI 10.1016/S0277-5387(01)00829-4##LEZNOFF CC, 1997, PHTHALOCYANINES PROP, V1##MARGADONNA S, 2001, PHYS REV B, V64, DOI 10.1103/PHYSREVB.64.132414##MARKS TJ, 1990, ANGEW CHEM INT EDIT, V29, P857, DOI 10.1002/ANIE.199008571##MARTIN I, 1999, PHYS REV B, V60, P530, DOI 10.1103/PHYSREVB.60.530##MASON R, 1979, J CHEM SOC DALTON, P676, DOI 10.1039/DT9790000676##MCKEON N. B., 1998, PHTHALOCYANINE MAT##MITRA S, 1983, INORG CHEM, V22, P1729, DOI 10.1021/IC00154A007##MIYOSHI H, 1973, B CHEM SOC JPN, V46, P2724, DOI 10.1246/BCSJ.46.2724##MIZUGUCHI J, 2001, J PHYS CHEM A, V105, P10719, DOI 10.1021/JP011169H##MIZUGUCHI J, 2001, J PHYS CHEM A, V105, P1121, DOI 10.1021/JP0027896##OGAWA MY, 1986, PHYS REV LETT, V57, P1177, DOI 10.1103/PHYSREVLETT.57.1177##ROSSEINSKY MJ, 1993, NATURE, V364, P425, DOI 10.1038/364425A0##SCHRAMM CJ, 1980, J AM CHEM SOC, V102, P6702, DOI 10.1021/JA00542A008##SOLIN SA, 1991, J PHYS IV, V1, P311, DOI 10.1051/JP4:1991536##SUGIMOTO H, 1986, J CHEM SOC CHEM COMM, P962, DOI 10.1039/C39860000962##SUGIMOTO H, 1983, J CHEM SOC CHEM COMM, P622, DOI 10.1039/C39830000622##TACKLEY DR, 2001, PHYS CHEM CHEM PHYS, V3, P1419, DOI 10.1039/B007763L##TACKLEY DR, 2000, PHYS CHEM CHEM PHYS, V2, P3949, DOI 10.1039/B005091L##TAGUCHI Y, 2006, J AM CHEM SOC, V128, P3313, DOI 10.1021/JA0582657##THOMPSON JA, 1999, PHYS REV B, V60, P523, DOI 10.1103/PHYSREVB.60.523##TUREK P, 1987, SOLID STATE COMMUN, V63, P741, DOI 10.1016/0038-1098(87)90122-0##WACHTEL H, 1994, THIN SOLID FILMS, V250, P219, DOI 10.1016/0040-6090(94)90189-9##YAKUSHI K, 1991, SOLID STATE COMMUN, V78, P919, DOI 10.1016/0038-1098(91)90255-T##YUKUSHI K, 1989, B CHEM SOC JPN, V62, P687##ZIOLO RF, 1981, INORG CHEM, V20, P2709, DOI 10.1021/IC50222A063##ZIOLO RF, 1981, J AM CHEM SOC, V103, P4629, DOI 10.1021/JA00405A078",22,2020-11-20,"GRANTS-IN-AID FOR SCIENTIFIC RESEARCHMINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE AND TECHNOLOGY, JAPAN (MEXT)JAPAN SOCIETY FOR THE PROMOTION OF SCIENCEGRANTS-IN-AID FOR SCIENTIFIC RESEARCH (KAKENHI) [16076201, 17684014] FUNDING SOURCE: KAKEN"
J,WOS:000242739800019,2006,NON-OBERBECK-BOUSSINESQ EFFECTS IN STRONGLY TURBULENT RAYLEIGH-BENARD CONVECTION,"NON-OBERBECK-BOUSSINESQ (NOB) EFFECTS ON THE NUSSELT NUMBER NU AND REYNOLDS NUMBER RE IN STRONGLY TURBULENT RAYLELGH-BENARD (RB) CONVECTION IN LIQUIDS WERE INVESTIGATED BOTH EXPERIMENTALLY AND THEORETICALLY. IN THE EXPERIMENTS THE HEAT CURRENT, THE TEMPERATURE DIFFERENCE, AND THE TEMPERATURE AT THE HORIZONTAL MIDPLANE WERE MEASURED. THREE CELLS OF DIFFERENT HEIGHTS L, ALL FILLED WITH WATER AND ALL WITH ASPECT RATIO GAMMA CLOSE TO 1, WERE USED. FOR EACH L, ABOUT 1.5 DECADES IN RA WERE COVERED, TOGETHER SPANNING THE RANGE 10(8) <= RA <= 10(11). FOR THE LARGEST TEMPERATURE DIFFERENCE BETWEEN THE BOTTOM AND TOP PLATES, DELTA = 40 K, THE KINEMATIC VISCOSITY AND THE THERMAL EXPANSION COEFFICIENT, OWING TO THEIR TEMPERATURE DEPENDENCE, VARIED BY MORE THAN A FACTOR OF 2. THE OBERBECK-BOUSSINESQ (OB) APPROXIMATION OF TEMPERATURE-INDEPENDENT MATERIAL PARAMETERS THUS WAS NO LONGER VALID. THE RATIO CHI OF THE TEMPERATURE DROPS ACROSS THE BOTTOM AND TOP THERMAL BOUNDARY LAYERS BECAME AS SMALL AS CHI = 0.83, WHICH MAY BE COMPARED WITH THE RATIO CHI = 1 IN THE OB CASE. NEVERTHELESS, THE NUSSELT NUMBER NU WAS FOUND TO BE ONLY SLIGHTLY SMALLER (BY AT MOST 1.4%) THAN IN THE NEXT LARGER CELL WITH THE SAME RAYLEIGH NUMBER. WHERE THE MATERIAL PARAMETERS WERE STILL NEARLY HEIGHT INDEPENDENT. THE REYNOLDS NUMBERS IN THE OB AND NOB CASE AGREED WITH EACH OTHER WITHIN THE EXPERIMENTAL RESOLUTION OF ABOUT 2%, SHOWING THAT NOB EFFECTS FOR THIS PARAMETER WERE SMALL AS WELL. THUS NU AND RE ARE RATHER INSENSITIVE AGAINST EVEN SIGNIFICANT DEVIATIONS FROM 013 CONDITIONS. THEORETICALLY, WE FIRST ACCOUNT FOR THE ROBUSTNESS OF NU WITH RESPECT TO NOB CORRECTIONS: THE NOB EFFECTS IN THE TOP BOUNDARY LAYER CANCEL THOSE WHICH ARISE IN THE BOTTOM BOUNDARY LAYER AS LONG AS THEY ARE LINEAR IN THE TEMPERATURE DIFFERENCE DELTA. THE NET EFFECTS ON NU ARE PROPORTIONAL TO DELTA(2) AND THUS INCREASE ONLY SLOWLY AND STILL REMAIN MINOR DESPITE DRASTIC MATERIAL-PARAMETER CHANGES. WE THEN EXTEND THE PRANDTL-BLASLUS BOUNDARY-LAYER THEORY TO NOB RAYLEIGH-BENARD FLOW WITH TEMPERATURE-DEPENDENT VISCOSITY AND THERMAL DIFFUSIVITY. THIS ALLOWS CALCULATION OF THE SHIFT IN THE BULK TEMPERATURE, THE TEMPERATURE DROPS ACROSS THE BOUNDARY LAYERS, AND THE RATIO CHI WITHOUT THE INTRODUCTION OF ANY FITTING, PARAMETER. THE CALCULATED QUANTITIES ARE IN VERY GOOD AGREEMENT WITH EXPERIMENT. WHEN IN ADDITION WE USE THE EXPERIMENTAL FINDING THAT FOR WATER THE SUM OF THE TOP AND BOTTOM THERMAL BOUNDARY-LAYER WIDTHS (BASED ON THE SLOPES OF THE TEMPERATURE PROFILES AT THE PLATES) REMAINS UNCHANGED UNDER NOB EFFECTS WITHIN THE EXPERIMENTAL RESOLUTION, THE THEORY ALSO GIVES THE MEASURED SMALL NUSSELT-NUMBER REDUCTION FOR THE NOB CASE. IN ADDITION, IT PREDICTS AN INCREASE BY ABOUT 0.5% OF THE REYNOLDS NUMBER, WHICH IS ALSO CONSISTENT WITH THE EXPERIMENTAL DATA. BY STUDYING THEORETICALLY HYPOTHETICAL LIQUIDS FOR WHICH ONLY ONE OF THE MATERIAL PARAMETERS IS TEMPERATURE DEPENDENT, WE ARE ABLE TO SHED FURTHER LIGHT ON THE ORIGIN OF NOB CORRECTIONS IN WATER: WHILE THE NOB DEVIATION OF CHI FROM ITS OB VALUE CHI = 1 MAINLY ORIGINATES FROM THE TEMPERATURE DEPENDENCE OF THE VISCOSITY, THE NOB CORRECTION OF THE NUSSELT NUMBER PRIMARILY ORIGINATES FROM THE TEMPERATURE DEPENDENCE OF THE THERMAL DIFFUSIVITY. FINALLY, WE GIVE PREDICTIONS FROM OUR THEORY FOR THE NOB CORRECTIONS IF GLYCEROL WERE USED AS THE OPERATING LIQUID.",ASPECT RATIO ONE; THERMAL-CONVECTION; HEAT-TRANSPORT; CYLINDRICAL CELLS; CRITICAL-POINT; PRANDTL; NUMBERS; STABILITY; PATTERNS; FLUIDS,NA,JOURNAL OF FLUID MECHANICS,"AHLERS, G##BROWN, E##ARAUJO, FF##FUNFSCHILLLNG, D##GROSSMANN, S##LOHSE, D","UNIV CALIF SANTA BARBARA, DEPT PHYS, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA BARBARA, IQCD, SANTA BARBARA, CA 93106 USA. UNIV TWENTE, DEPT SCI & TECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV TWENTE, JM BURGERS CTR FLUID DYNAM, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV MARBURG, FACHBEREICH PHYS, D-35032 MARBURG, GERMANY.","MECHANICS; PHYSICS, FLUIDS & PLASMAS",MECHANICS; PHYSICS,"AHLERS G, 1980, J FLUID MECH, V98, P137, DOI 10.1017/S0022112080000067##AHLERS G, 2001, PHYS REV E, V63, DOI 10.1103/PHYSREVE.63.015303##ASHKENAZI S, 1999, PHYS REV LETT, V83, P3641, DOI 10.1103/PHYSREVLETT.83.3641##BLASIUS H., 1908, Z MATH PHYS, V56, P1##BODENSCHATZ E, 1991, PHYS REV LETT, V67, P3078, DOI 10.1103/PHYSREVLETT.67.3078##BODENSCHATZ E, 2000, ANNU REV FLUID MECH, V32, P709, DOI 10.1146/ANNUREV.FLUID.32.1.709##BOUSSINESQ J., 1903, THEORIE ANAL CHALEUR, V2##BROWN E, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1964987##BROWN E, 2006, UNPUB REYNOLDS NUMBE##BUSSE FH, 1967, J FLUID MECH, V30, P625, DOI 10.1017/S0022112067001661##CASTAING B, 1989, J FLUID MECH, V204, P1, DOI 10.1017/S0022112089001643##CHAUMAT S, 2002, ADV TURBULENCE, PR9##CHAVANNE X, 1997, PHYS REV LETT, V79, P3648, DOI 10.1103/PHYSREVLETT.79.3648##CHAVANNE X, 2001, PHYS FLUIDS, V13, P1300, DOI 10.1063/1.1355683##CHILLA F, 2004, EUR PHYS J B, V40, P223, DOI 10.1140/EPJB/E2004-00261-3##CILIBERTO S, 1988, PHYS REV LETT, V61, P1198, DOI 10.1103/PHYSREVLETT.61.1198##FUNFSCHILLING D, 2005, J FLUID MECH, V536, P145, DOI 10.1017/S0022112005005057##FURUKAWA A, 2002, PHYS REV E, V66, DOI 10.1103/PHYSREVE.66.016302##GITTERMAN M, 1978, REV MOD PHYS, V50, P85, DOI 10.1103/REVMODPHYS.50.85##GITTERMAN M, 1971, PMM-J APPL MATH MEC, V34, P305##GROSSMANN S, 2000, J FLUID MECH, V407, P27, DOI 10.1017/S0022112099007545##GROSSMANN S, 2002, PHYS REV E, V66, DOI 10.1103/PHYSREVE.66.016305##GROSSMANN S, 2004, PHYS FLUIDS, V16, P4462, DOI 10.1063/1.1807751##GROSSMANN S, 2001, PHYS REV LETT, V86, P3316, DOI 10.1103/PHYSREVLETT.86.3316##HOARD CQ, 1970, INT J HEAT MASS TRAN, V13, P849, DOI 10.1016/0017-9310(70)90130-4##KOGAN AB, 2001, PHYS REV E, V63, DOI 10.1103/PHYSREVE.63.056310##KRAICHNAN RH, 1962, PHYS FLUIDS, V5, P1374, DOI 10.1063/1.1706533##LANDAU L.D., 1987, FLUID MECH##MEKSYN D, 1961, NEW METHODS LAMINAR##NIEMELA JJ, 2001, J FLUID MECH, V449, P169, DOI 10.1017/S0022112001006310##NIEMELA JJ, 2003, J FLUID MECH, V481, P355, DOI 10.1017/S0022112003004087##NIEMELA JJ, 2000, NATURE, V404, P837, DOI 10.1038/35009036##NIKOLAENKO A, 2005, J FLUID MECH, V523, P251, DOI 10.1017/S0022112004002289##OBERBECK A, 1879, ANN PHYS CHEM, V7, P271, DOI [DOI 10.1002/ANDP.18792430606, 10.1002/ANDP.18792430606]##OH J, PHYS REV E, V69##PAMPALONI E, 1992, J FLUID MECH, V234, P393, DOI 10.1017/S0022112092000831##PLAPP JE, 1957, THESIS CALTECH##POHLHAUSEN E, 1921, Z ANGEW MATH MECH, V1, P115, DOI 10.1002/ZAMM.19210010205##PRANDTL L, 1905, FLUSSIGKEITSBEWEGUNG, P484##PRESS WH, 1986, NUMERICAL RECIPES##QIU X L, 2001, PHYS REV LETT, V87, P094501##QIU XL, 2001, PHYS REV E, V64, DOI 10.1103/PHYSREVE.64.036304##ROCHE PE, 2001, PHYS REV E, V63, DOI 10.1103/PHYSREVE.63.045303##ROCHE PE, 2002, EUROPHYS LETT, V58, P693, DOI 10.1209/EPL/I2002-00405-1##SCHLICHTING H, 2000, BOUNDARY LAYER THEOR, P126##SHRAIMAN BI, 1990, PHYS REV A, V42, P3650, DOI 10.1103/PHYSREVA.42.3650##SUN C, 2005, J FLUID MECH, V542, P165, DOI 10.1017/S0022112005006610##VERZICCO R, 2004, PHYS FLUIDS, V16, P1965, DOI 10.1063/1.1723463##VERZICCO R, 2002, J FLUID MECH, V473, P201, DOI 10.1017/S0022112002002501##WALDEN RW, 1981, J FLUID MECH, V109, P89, DOI 10.1017/S0022112081000955##WALL DP, 1997, PHYS FLUIDS, V9, P2885, DOI 10.1063/1.869401##WU XZ, 1991, PHYS REV A, V43, P2833, DOI 10.1103/PHYSREVA.43.2833##XU XC, 2000, PHYS REV LETT, V84, P4357, DOI 10.1103/PHYSREVLETT.84.4357##ZHANG J, 1997, PHYS FLUIDS, V9, P1034, DOI 10.1063/1.869198",102,2020-11-20,NA
J,WOS:000243144600045,2006,IMAGING COLLOIDAL PARTICLE INDUCED TOPOLOGICAL DEFECTS IN A NEMATIC LIQUID CRYSTAL USING THIRD HARMONIC GENERATION MICROSCOPY,"THE NATURE OF THE THIRD-HARMONIC GENERATION (THG) PROCESS IN A NEMATIC LIQUID CRYSTAL IS INVESTIGATED FOR THE CASE OF TIGHTLY FOCUSED, LOW INTENSITY, LASER BEAMS. COLLOIDAL PARTICLE INDUCED TOPOLOGICAL DEFECTS IN A LIQUID CRYSTAL ARE VISUALIZED IN THREE-DIMENSIONS USING THE DEPENDENCE OF THE THG SIGNAL ON BOTH CHANGES IN NON-LINEAR SUSCEPTIBILITY AND THE ORIENTATION OF THE LIQUID CRYSTAL DIRECTOR RELATIVE TO THE INCIDENT LASER POLARIZATION STATE. WE HAVE FOUND THAT THE INTERPRETATION OF THG IMAGES IN A LIQUID CRYSTAL IS COMPLICATED NOT ONLY BY THE CHANGE IN POLARISATION OF THE ELECTRIC FIELD AS IT PROPAGATES THROUGH THE MEDIUM BUT ALSO BY ANISOTROPIC REFRACTIVE INDEX MISMATCH INDUCED ABERRATIONS. (C) 2006 OPTICAL SOCIETY OF AMERICA.",MATCHED 3RD-HARMONIC GENERATION,NA,OPTICS EXPRESS,"PILLAI, RS##OH-E, M##YOKOYAMA, H##BRAKENHOFF, GJ##MULLER, M","UNIV AMSTERDAM, SWAMMERDAM INST LIFE SCI, NL-1090 GB AMSTERDAM, NETHERLANDS. JAPAN SCI & TECHNOL AGCY, LIQUID CRYSTAL NANOSYST PROJECT, ERATO SORST, TSUKUBA, IBARAKI 3002635, JAPAN.",OPTICS,OPTICS,"BARAD Y, 1997, APPL PHYS LETT, V70, P922, DOI 10.1063/1.118442##BOYD R. W., 1992, NONLINEAR OPTICS##CHU SW, 2003, OPT EXPRESS, V11, P3093, DOI 10.1364/OE.11.003093##DEBARRE D, 2006, NAT METHODS, V3, P47, DOI 10.1038/NMETH813##GU YD, 2000, PHYS REV LETT, V85, P4719, DOI 10.1103/PHYSREVLETT.85.4719##KOSUGI J, 2004, APPL PHYS LETT, V84, P5013, DOI 10.1063/1.1763220##MULLER M, 1998, J MICROSC-OXFORD, V191, P266, DOI 10.1046/J.1365-2818.1998.00399.X##MUSEVIC I, 2006, SCIENCE, V313, P954, DOI 10.1126/SCIENCE.1129660##ORON D, 2003, OPT LETT, V28, P2315, DOI 10.1364/OL.28.002315##PILLAI RS, 2006, OPT EXPRESS, V14, P260, DOI 10.1364/OPEX.14.000260##POULIN P, 1997, SCIENCE, V275, P1770, DOI 10.1126/SCIENCE.275.5307.1770##POULIN P, 1998, PHYS REV E, V57, P626, DOI 10.1103/PHYSREVE.57.626##REINTJES J, 1984, NONLINEAR OPTICAL PA##SCHADT M, 1997, ANNU REV MATER SCI, V27, P305, DOI 10.1146/ANNUREV.MATSCI.27.1.305##SUPATTO W, 2005, P NATL ACAD SCI USA, V102, P1047, DOI 10.1073/PNAS.0405316102##TAI SP, 2006, OPT EXPRESS, V14, P6178, DOI 10.1364/OE.14.006178##TSANG TYF, 1995, PHYS REV A, V52, P4116, DOI 10.1103/PHYSREVA.52.4116##WEINER AM, 2000, REV SCI INSTRUM, V71, P1929, DOI 10.1063/1.1150614##YELIN D, 1999, APPL PHYS LETT, V74, P3107, DOI 10.1063/1.124077##YELIN D, 1999, PHYS REV LETT, V82, P3046, DOI 10.1103/PHYSREVLETT.82.3046",17,2020-11-20,NA
J,WOS:000242873400040,2006,CHEMICAL SYNTHESIS OF THE HPV16 E7 PROTEIN,THE FULL-LENGTH E7 ONCOPROTEIN OF HPV16 WAS PREPARED FROM TWO PEPTIDE FRAGMENTS USING NATIVE CHEMICAL LIGATION AND PURIFIED BY A SINGLE GEL-FILTRATION STEP UNDER DENATURING CONDITIONS. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.,HUMAN-PAPILLOMAVIRUS E7; PROTEIN; ONCOPROTEIN; VACCINATION; PEPTIDE,NA,TETRAHEDRON LETTERS,"FILIPPOV, DV##WELTERS, MJP##VALENTIJN, ARPM##MELIEF, CJM##VAN DER MAREL, GA##VAN DER BURG, SH##OVERKLEEFT, HS##DRIJFHOUT, JW","LEIDEN UNIV, MED CTR, DEPT IMMUNOHEMATOL & BLOOD TRANSFUS, NL-2300 RC LEIDEN, NETHERLANDS. LEIDEN UNIV, LEIDEN INST CHEM, NL-2300 RC LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT CLIN PHARM & TOXICOL, NL-2300 RC LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT CLIN ONCOL, NL-2300 RC LEIDEN, NETHERLANDS.","CHEMISTRY, ORGANIC",CHEMISTRY,"ALBERICIO F, 2004, CURR OPIN CHEM BIOL, V8, P211, DOI 10.1016/J.CBPA.2004.03.002##ALONSO LG, 2002, BIOCHEMISTRY-US, V41, P10510, DOI 10.1021/BI025579N##BANG D, 2004, ANGEW CHEM INT EDIT, V43, P2534, DOI 10.1002/ANIE.200353540##BYRNES ME, 1994, METHODS MOL BIOL REV, V36##CHAN W.C., 2000, FMOC SOLID PHASE PEP##CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/PNAS.88.1.110##CHIVA C, 1999, J PEPT SCI, V5, P131, DOI 10.1002/(SICI)1099-1387(199903)5:3<131::AID-PSC183>3.0.CO;2-Z##CLEMENTS A, 2000, BIOCHEMISTRY-US, V39, P16033, DOI 10.1021/BI002111G##DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/SCIENCE.7973629##DAWSON PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/ANNUREV.BIOCHEM.69.1.923##FLAVELL RR, 2002, ORG LETT, V4, P165, DOI 10.1021/OL016859I##HACKENG TM, 1999, P NATL ACAD SCI USA, V96, P10068, DOI 10.1073/PNAS.96.18.10068##INGENITO R, 1999, J AM CHEM SOC, V121, P11369, DOI 10.1021/JA992668N##RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990##SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4##TESSER GI, 1975, INT J PEPT PROT RES, V7, P295##VAMBUTAS A, 2005, VACCINE, V23, P5271, DOI 10.1016/J.VACCINE.2005.04.049##WALBOOMERS JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&LT;12::AID-PATH431&GT;3.0.CO;2-F##WELTERS MJP, 2004, VACCINE, V23, P305, DOI 10.1016/J.VACCINE.2004.06.008##ZWAVELING S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/JIMMUNOL.169.1.350",1,2020-11-20,NA
J,WOS:000243112300002,2006,ANALYTICAL SOLUTIONS FOR WHIRLING GROUNDWATER FLOW IN TWO-DIMENSIONAL HETEROGENEOUS ANISOTROPIC AQUIFERS,"[1] ANALYTICAL SOLUTIONS ARE DERIVED FOR STEADY STATE GROUNDWATER FLOW IN A HETEROGENEOUS, ANISOTROPIC, SEMICONFINED AQUIFER. THE AQUIFER CONSISTS OF A NUMBER OF HORIZONTAL LAYERS, WHILE EACH LAYER CONSISTS OF A NUMBER OF HOMOGENEOUS CELLS WITH DIFFERENT HYDRAULIC CONDUCTIVITY TENSORS. AN EXACT SOLUTION FOR AN ARBITRARY NUMBER OF LAYERS AND CELLS IS DERIVED USING A MULTILAYER APPROACH. HYPOTHETICAL MODELS ARE USED TO STUDY HOW FLOW IS AFFECTED BY HETEROGENEITY IN THE ANISOTROPY. WHEN THE MAJOR PRINCIPAL DIRECTION OF THE TRANSMISSIVITY TENSOR VARIES BETWEEN LAYERS, STREAMLINES HAVE THE SHAPE OF SPIRALS. BUNDLES OF SPIRALING STREAMLINES ROTATING IN THE SAME DIRECTION ARE CALLED ""GROUNDWATER WHIRLS.'' ANALYTICAL AND NUMERICAL MODELS OF HYPOTHETICAL CASES PRODUCE THE SAME FLOW PATTERNS OF GROUNDWATER WHIRLS. PROJECTED STREAMLINES MAY BE REPRESENTED BY STREAM FUNCTION CONTOURS, WHICH ALLOWS FOR EASY INTERPRETATION OF THE MAIN CHARACTERISTICS OF COMPLEX WHIRL PATTERNS. TYPICAL WHIRL PATTERNS MAY BE IDENTIFIED IN RELATIVELY SIMPLE MODELS. CLOCKWISE AND COUNTERCLOCKWISE WHIRL AXES OCCUR AT THE INTERFACES OF ADJACENT LAYERS. ONE OR MORE CLOCKWISE WHIRLS MAY OCCUR WITHIN ONE COUNTERCLOCKWISE WHIRL, AND VICE VERSA. THE PRACTICAL CONSEQUENCE OF GROUNDWATER WHIRLS IS THAT THE EXCHANGE OF WATER BETWEEN AQUIFER LAYERS IS INTENSIFIED. THIS MAY HAVE A SIGNIFICANT IMPACT ON CONTAMINANT SPREADING.",SYSTEMS,NA,WATER RESOURCES RESEARCH,"HEMKER, K##BAKKER, M","VRIJE UNIV AMSTERDAM, NL-1081 HV AMSTERDAM, NETHERLANDS. DELFT UNIV TECHNOL, FAC CIVIL ENGN & GEOSCI, WATER RESOURCES SECT, NL-2628 CN DELFT, NETHERLANDS.",ENVIRONMENTAL SCIENCES; LIMNOLOGY; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; MARINE & FRESHWATER BIOLOGY; WATER RESOURCES,"BAKKER M, 2003, J HYDROL, V271, P119, DOI 10.1016/S0022-1694(02)00319-0##BAKKER M, 2004, ADV WATER RESOUR, V27, P1075, DOI 10.1016/J.ADVWATRES.2004.08.009##BAKKER M, 2002, ADV WATER RESOUR, V25, P747, DOI 10.1016/S0309-1708(02)00074-X##BEAR J., 1972, DYNAMICS FLUIDS PORO##BRUGGEMAN G. A., 1999, DEV WATER SCI, V46##HEINZ J., 2001, THESIS U TUBINGEN TU##HEMKER CJ, 1984, J HYDROL, V72, P355, DOI 10.1016/0022-1694(84)90089-1##HEMKER K, 2004, GROUND WATER, V42, P234, DOI 10.1111/J.1745-6584.2004.TB02670.X##HEMKER K, 2004, INT C FIN EL MOD MOD##HEMKER K, 2001, STROMINGEN, V7, P5##HEMKER K, 2006, IAHS-AISH P, V304, P281##LUNT IA, 2004, SEDIMENTOLOGY, V51, P377, DOI 10.1111/J.1365-3091.2004.00627.X##MEESTERS AGCA, 2004, J HYDROL, V296, P241, DOI 10.1016/J.JHYDROL.2004.03.021##POETER E, 1990, GROUND WATER, V28, P900, DOI 10.1111/J.1745-6584.1990.TB01726.X##STRACK ODL, 1984, WATER RESOUR RES, V20, P812, DOI 10.1029/WR020I007P00812##THEIS CV., 1967, AM WATER RESOUR ASS, V4, P138##TRAN T, 1996, J HYDROL, V183, P37, DOI 10.1016/S0022-1694(96)80033-3##WHITE RR, 1994, US GEOL SURV WATER S, V2415, P45",14,2020-11-20,NA
J,WOS:000243110100001,2006,"WATER EXPANDABLE POLYSTYRENE (WEPS): PART 4. SYNTHESIS OF THE WATER EXPANDABLE BLEND OF POLYSTYRENE AND POLY(2,6-DIMETHYL-1,4-PHENYLENE ETHER)","IN PREVIOUS STUDIES, WE DISCUSSED THE USE OF WATER AS AN ENVIRONMENTALLY BENIGN BLOWING AGENT FOR FOAMING OF POLYSTYRENE BEADS, RESULTING IN SO-CALLED WEPS, VIZ. WATER EXPANDABLE POLYSTYRENE FOAM. SEVERAL GRADES OF PRECURSORS TO WEPS HAVE BEEN PREPARED BY VARYING THE WATER CONTENT AND THE MOLAR MASS, TO CONTROL THE MELT STRENGTH OF THE POLYSTYRENE MATRIX. ADDITIONALLY, WE HAVE USED (END-CAPPED) POLY(2,6-DIMETHYL-1,4-PHENYLENE ETHER) (PPE) TO CONTROL BOTH THE MELTVISCOSITY AND THE GLASS TRANSITION TEMPERATURE T-G. THE ADVANTAGE OF USING THE BLEND PS/PPE IS THAT THE PROCESSING WINDOW FOR FOAMING IS INCREASED IN VIEW OF THE DIFFERENCE BETWEEN THE T-G AND THE BOILING POINT OF WATER. USING THE NOVEL WEPS ROUTE WITH SOME ADJUSTMENTS, FOR THE FIRST TIME A WATER EXPANDABLE HOMOGENEOUS BLEND OF POLYSTYRENE AND END-CAPPED PPE WAS SUCCESSFULLY OBTAINED.",NA,NA,E-POLYMERS,"SNIJDERS, EA##NELISSEN, L##LEMSTRA, PJ","EINDHOVEN UNIV TECHNOL, EPL, DEPT POLYMER TECHNOL, NL-5600 MB EINDHOVEN, NETHERLANDS.",POLYMER SCIENCE,POLYMER SCIENCE,"BABLEY CJ, 1990, EPA450390020 US OFF##CREVECOEUR JJ, 1999, POLYMER, V40, P3685, DOI 10.1016/S0032-3861(98)00617-X##CREVECOEUR JJ, 1997, THESIS EINDHOVEN U T##GRULKE E. A., 1994, POLYM PROCESS ENG##KLEMPNER D., 1991, HDB POLYM FOAMS FOAM##NELISSEN L, 1990, POLYM COMMUN, V31, P122##NELISSEN L, 1992, POLYMER, V33, P3734, DOI 10.1016/0032-3861(92)90664-I##NELISSEN LNI, 1990, PATENT NO. 0350137",3,2020-11-20,NA
J,WOS:000242898700040,2006,LIPID RAFTS FACILITATE THE INTERACTION OF PECAM-1 WITH THE GLYCOPROTEIN VI-FCR GAMMA-CHAIN COMPLEX IN HUMAN PLATELETS,"GLYCOPROTEIN ( GP) VI, THE MAIN SIGNALING RECEPTOR FOR COLLAGEN ON PLATELETS, IS EXPRESSED IN COMPLEX WITH THE FCR GAMMA-CHAIN. THE LATTER CONTAINS AN IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF, WHICH BECOMES PHOSPHORYLATED, INITIATING A SIGNALING CASCADE LEADING TO THE RAPID ACTIVATION AND AGGREGATION OF PLATELETS. PREVIOUS STUDIES HAVE SHOWN THAT SIGNALING BY IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF-CONTAINING RECEPTORS IS COUNTERACTED BY SIGNALS FROM RECEPTORS WITH IMMUNORECEPTOR TYROSINE-BASED INHIBITORY MOTIFS. HERE WE SHOW, BY IMMUNOPRECIPITATION, THAT THE GPVI-FCR GAMMA-CHAIN COMPLEX ASSOCIATES WITH THE IMMUNORECEPTOR TYROSINE-BASED INHIBITORY MOTIF-CONTAINING RECEPTOR, PECAM-1. IN PLATELETS STIMULATED WITH COLLAGEN-RELATED PEPTIDE (CRP-XL), TYROSINE PHOSPHORYLATION OF PECAM-1 PRECEDES THAT OF THE FCR GAMMA-CHAIN, IMPLYING DIRECT REGULATION OF THE FORMER. THE GPVI-FCR GAMMA-CHAIN COMPLEX AND PECAM-1 WERE PRESENT IN BOTH LIPID RAFT AND SOLUBLE FRACTIONS IN HUMAN PLATELETS; THIS DISTRIBUTION WAS UNALTERED BY ACTIVATION WITH CRP-XL. THEIR ASSOCIATION OCCURRED IN LIPID RAFTS AND WAS LOST AFTER LIPID RAFT DEPLETION USING METHYL-BETA-CYCLODEXTRIN. WE PROPOSE THAT LIPID RAFT CLUSTERING FACILITATES THE INTERACTION OF PECAM-1 WITH THE GPVI- FCR GAMMA-CHAIN COMPLEX, LEADING TO THE DOWN-REGULATION OF THE LATTER.",CELL-ADHESION MOLECULE-1; PROTEIN-TYROSINE-PHOSPHATASE; SRC FAMILY KINASES; COLLAGEN RECEPTOR; FUNCTIONAL ASSOCIATION; ACTIN CYTOSKELETON; MURINE PLATELETS; MEMBRANE DOMAINS; PLASMA-MEMBRANE; ACTIVATION,NA,JOURNAL OF BIOLOGICAL CHEMISTRY,"LEE, FA##VAN LIER, M##RELOU, IAM##FOLEY, L##AKKERMAN, JWN##HEIJNEN, HFG##FARNDALE, RW","UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND. UNIV UTRECHT, MED CTR, DEPT HAEMATOL, LAB THROMBOSIS & HAEMOSTASIS, NL-3584 CX UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, CELL MICROSCOPY CTR, NL-3584 CX UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, INST BIOMEMBRANES, NL-3584 CX UTRECHT, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"ASSELIN J, 1997, BLOOD, V89, P1235, DOI 10.1182/BLOOD.V89.4.1235##BARROW AD, 2004, J IMMUNOL, V172, P5838, DOI 10.4049/JIMMUNOL.172.10.5838##BODIN S, 2005, J CELL SCI, V118, P759, DOI 10.1242/JCS.01648##BODIN S, 2005, J CELL SCI, V25, P25##CICMIL M, 2002, BLOOD, V99, P137, DOI 10.1182/BLOOD.V99.1.137##CICMIL M, 2000, J BIOL CHEM, V275, P27339##CLEMETSON JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/JBC.274.41.29019##CLEMETSON KJ, 2001, THROMB HAEMOSTASIS, V86, P189##DORAHY DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/BJ3190067##EZUMI Y, 1998, J EXP MED, V188, P267, DOI 10.1084/JEM.188.2.267##EZUMI Y, 2002, BLOOD, V99, P3250, DOI 10.1182/BLOOD.V99.9.3250##FALATI S, 1999, BLOOD, V94, P1648, DOI 10.1182/BLOOD.V94.5.1648.417K31_1648_1656##FARNDALE RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/J.1538-7836.2004.00665.X##GIBBINS J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/JBC.271.30.18095##GIBBINS JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5##HEIJNEN HFG, 2003, J THROMB HAEMOST, V1, P1161, DOI 10.1046/J.1538-7836.2003.00316.X##HUA CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/JBC.273.43.28332##JACKSON DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/JBC.272.11.6986##JONES KL, 2001, BLOOD, V98, P1456, DOI 10.1182/BLOOD.V98.5.1456##LIER M, 2005, J THROMB HAEMOST, V3, P2514##LOCKE D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/JBC.M111520200##MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/BJ3060337##NIESWANDT B, 2003, BLOOD, V102, P449, DOI 10.1182/BLOOD-2002-12-3882##PASQUET JM, 2000, J BIOL CHEM, V275, P28526, DOI 10.1074/JBC.M001531200##PATIL S, 2001, BLOOD, V97, P1727, DOI 10.1182/BLOOD.V97.6.1727##QUEK LS, 2000, BLOOD, V96, P4246##QUINTON TM, 2005, J THROMB HAEMOST, V3, P1036, DOI 10.1111/J.1538-7836.2005.01325.X##RATHORE V, 2003, BLOOD, V102, P3658, DOI 10.1182/BLOOD-2003-06-1888##SCHROEDER RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/JBC.273.2.1150##SIMONS K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052##THAI LM, 2003, BLOOD, V102, P3637, DOI 10.1182/BLOOD-2003-02-0496##TSUJI M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/JBC.272.38.23528##VALENSIN S, 2002, EUR J IMMUNOL, V32, P435, DOI 10.1002/1521-4141(200202)32:2<435::AID-IMMU435>3.0.CO;2-H##VILLALBA M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/JCB.200107080##WATSON SP, 2001, THROMB HAEMOSTASIS, V86, P276##WONEROW P, 2002, BIOCHEM J, V364, P755, DOI 10.1042/BJ20020128##WU XW, 1997, ARTERIOSCL THROM VAS, V17, P3154, DOI 10.1161/01.ATV.17.11.3154##WU Y, 2001, BLOOD, V97, P3836, DOI 10.1182/BLOOD.V97.12.3836##ZAJCHOWSKI LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/J.0014-2956.2001.02715.X",18,2020-11-20,MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [G0400701] FUNDING SOURCE: MEDLINE
J,WOS:000242872700016,2006,"CAPILLARY ELECTROPHORESIS FINGERPRINTING, QUANTIFICATION AND MASS-IDENTIFICATION OF VARIOUS 9-AMINOPYRENE-1,4,6-TRISULFONATE-DERIVATIZED OLIGOMERS DERIVED FROM PLANT POLYSACCHARIDES","VARIOUS PLANT POLYSACCHARIDE DERIVED MONO- AND OLIGOSACCHARIDES WERE DERIVATIZED WITH THE FLUORESCENT 9-AMINOPYRENE-1,4,6-TRISULFONATE (APTS) AND SUBJECTED TO CAPILLARY ELECTROPHORESIS (CE) IN COMBINATION WITH LASER INDUCED FLUORESCENCE (LIF) DETECTION. CE-LIF WAS SUITABLE FOR MOL-BASED QUANTIFICATION OF VARIOUS APTS-MONOSACCHARIDES. CE-LIF OF APTS-OLIGOSACCHARIDES SHOWED HIGH RESOLUTIONS, WHILE ANALYSIS TIMES WERE AT MAXIMUM 15 MIN. THE COUPLING OF CE TO ELECTROSPRAY-IONTRAP MASS SPECTROMETERY (MS) WITH ONLINE UV DETECTION SHOWED TO BE A POWERFUL TECHNIQUE IN THE IDENTIFICATION OF APTS-OLIGOSACCHARIDES. FOR THE FIRST TIME, VARIOUS APTS-XYLO-OLIGOSACCHARIDES, HAVING EITHER NO, O-ACETYL, ARABINOSYL OR XYLOSYL SUBSTITUTIONS AT VARYING POSITIONS, WERE IDENTIFIED BY USING CE-LIF AND CE-MSN. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",LASER-DESORPTION/IONIZATION-TIME; DIETARY FIBER; WHEAT-FLOUR; CELL-WALLS; OLIGOSACCHARIDES; CHROMATOGRAPHY; SEPARATION; OLIGOFRUCTOSE; GLYCOPROTEINS; SPECTROMETRY,ELECTROPHORESIS; APTS; CARBOHYDRATES; MASS SPECTROMETRY; XYLO-OLIGOSACCHARIDES,JOURNAL OF CHROMATOGRAPHY A,"KABEL, MA##HEIJNIS, WH##BAKX, EJ##KUIJPERS, R##VORAGEN, AGJ##SCHOLS, HA","WAGENINGEN UNIV, DEPT AGROTECHNOL & FOOD SCI, FOOD CHEM LAB, NL-6703 HD WAGENINGEN, NETHERLANDS.","BIOCHEMICAL RESEARCH METHODS; CHEMISTRY, ANALYTICAL",BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY,"ARENTOFT AM, 1993, J CHROMATOGR A, V652, P517, DOI 10.1016/0021-9673(93)83273-U##BEAUDOIN ME, 2005, J SEP SCI, V28, P1390, DOI 10.1002/JSSC.200500022##CABALKOVA J, 2004, ELECTROPHORESIS, V25, P487, DOI 10.1002/ELPS.200305672##CAMPA C, 2006, ELECTROPHORESIS, V27, P2027, DOI 10.1002/ELPS.200500960##CARPITA NC, 1996, ANNU REV PLANT PHYS, V47, P445, DOI 10.1146/ANNUREV.ARPLANT.47.1.445##CARPITA NC, 2001, PLANT PHYSIOL, V127, P551, DOI 10.1104/PP.010146##CHEN FTA, 1998, GLYCOBIOLOGY, V8, P1045, DOI 10.1093/GLYCOB/8.11.1045##CHEN FU-TAI A, 2003, METHODS MOL BIOL, V213, P105##DAAS PJH, 1998, ANAL BIOCHEM, V257, P195, DOI 10.1006/ABIO.1997.2554##ENGLYST HN, 1984, ANALYST, V109, P937, DOI 10.1039/AN9840900937##EVANGELISTA RA, 1995, ANAL CHEM, V67, P2239, DOI 10.1021/AC00109A051##FLAMM G, 2001, CRIT REV FOOD SCI, V41, P353, DOI 10.1080/20014091091841##GRABBER JH, 2005, CROP SCI, V45, P820, DOI 10.2135/CROPSCI2004.0191##GRUPPEN H, 1992, CARBOHYD RES, V233, P45, DOI 10.1016/S0008-6215(00)90919-4##GRUPPEN H, 1993, J CEREAL SCI, V18, P111, DOI 10.1006/JCRS.1993.1040##GUTTMAN A, 1996, ANAL BIOCHEM, V235, P236, DOI 10.1006/ABIO.1996.0118##GUTTMAN A, 1996, NATURE, V380, P461, DOI 10.1038/380461A0##HILZ H, 2006, J CHROMATOGR A, V1133, P275, DOI 10.1016/J.CHROMA.2006.08.024##IKEDA T, 1973, B CHEM SOC JPN, V2107##JOUCLA G, 2004, ELECTROPHORESIS, V25, P861, DOI 10.1002/ELPS.200305737##KABEL MA, 2001, CARBOHYD POLYM, V44, P161, DOI 10.1016/S0144-8617(00)00203-4##KABEL MA, 2003, CARBOHYD RES, V338, P69, DOI 10.1016/S0008-6215(02)00351-8##KABEL MA, 2002, CARBOHYD POLYM, V50, P191, DOI 10.1016/S0144-8617(02)00022-X##KLAMPFL CW, 2006, ELECTROPHORESIS, V27, P3, DOI 10.1002/ELPS.200500523##KORMELINK FJM, 1993, CARBOHYD RES, V249, P355, DOI 10.1016/0008-6215(93)84100-K##LEE YC, 1996, J CHROMATOGR A, V720, P137, DOI 10.1016/0021-9673(95)00222-7##LYND LR, 1996, ANNU REV ENERG ENV, V21, P403, DOI 10.1146/ANNUREV.ENERGY.21.1.403##MANGIN CM, 2001, ELECTROPHORESIS, V22, P1460, DOI 10.1002/1522-2683(200105)22:8<1460::AID-ELPS1460>3.0.CO;2-0##MCCANN M, 1991, CYTOSKELETAL BASIS P, P109##MONSARRAT B, 1999, GLYCOBIOLOGY, V9, P335, DOI 10.1093/GLYCOB/9.4.335##NIGAM P, 1995, PROCESS BIOCHEM, V30, P117, DOI 10.1016/0032-9592(95)95709-R##ROBERFROID M, 1993, CRIT REV FOOD SCI, V33, P103, DOI 10.1080/10408399309527616##ROPER H, 2002, STARCH-STARKE, V54, P89, DOI 10.1002/1521-379X(200204)54:3/4&LT;89::AID-STAR89&GT;3.0.CO;2-I##SCHOLS HA, 2000, VTT SYMP, V207, P21##SCHOLS HA, 2000, SEPARATIONS CHROMATO##SHAHEEN R, 2005, INT J ENVIRON AN CH, V85, P177, DOI 10.1080/03067310500050775##SHEEHAN J, 1999, BIOTECHNOL PROGR, V15, P817, DOI 10.1021/BP990110D##STONE BA, 2006, CEREAL FOOD WORLD, V51, P62, DOI 10.1094/CFW-51-0062##SUN Y, 2002, BIORESOURCE TECHNOL, V83, P1, DOI 10.1016/S0960-8524(01)00212-7##SUZUKI H, 1997, ANAL CHEM, V69, P4554, DOI 10.1021/AC970090Z##TIMELL TE, 1964, ADV CARBOHYD CHEM, V19, P247##TIMELL TE, 1965, ADV CARBOHYD CHEM, P409, DOI DOI 10.1016/S0096-5332(08)60304-5##VAN ALEBEEK GJWM, 2000, CARBOHYD POLYM, V43, P39, DOI 10.1016/S0144-8617(99)00207-6##VAN LAERE KMJ, 1999, APPL MICROBIOL BIOT, V51, P606, DOI 10.1007/S002530051439##VORAGEN AGJ, 1992, PLANT POLYM CARBOHYD, P3##ZEMANN A, 1997, ELECTROPHORESIS, V18, P1142, DOI 10.1002/ELPS.1150180720",40,2020-11-20,NA
J,WOS:000241323400016,2006,COUPLED TORSIONAL AND VERTICAL OSCILLATIONS OF A BEAM SUBJECTED TO BOUNDARY DAMPING,"IN THIS PAPER COUPLED TORSIONAL AND VERTICAL OSCILLATIONS OF A BEAM IN A WIND-FIELD ARE STUDIED. DIFFERENT KINDS OF DAMPERS ARE ADDED TO THE BEAM TO SUPPRESS UNDESIRABLE OSCILLATIONS. USING A TWO TIMES SCALES PERTURBATION METHOD, THE RELATIONSHIP BETWEEN THE BEAM PARAMETERS AND THE DAMPING RATES ARE OBTAINED ANALYTICALLY. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",MULTIPLE PERIODIC-SOLUTIONS; SUSPENSION BRIDGE; ASYMPTOTIC THEORY; EQUATION,NA,JOURNAL OF SOUND AND VIBRATION,"ZARUBINSKAYA, MA##VAN HORSSEN, WT","DELFT UNIV TECHNOL, FAC ELECT ENGN, DELFT INST APPL MATH, NL-2628 CD DELFT, NETHERLANDS.","ACOUSTICS; ENGINEERING, MECHANICAL; MECHANICS",ACOUSTICS; ENGINEERING; MECHANICS,"AHMED NU, 1998, SIAM J APPL MATH, V58, P853##AHMED NU, 1988, J MATH COMPUT MODELI, V10, P891##BOERTJENS GJ, 1998, NONLINEAR DYNAM, V17, P23, DOI 10.1023/A:1008232515070##BOERTJENS GJ, 2000, SIAM J APPL MATH, V60, P602, DOI 10.1137/S0036139998336766##CHEN Y, 1997, J DIFFER EQUATIONS, V136, P325, DOI 10.1006/JDEQ.1996.3155##CHOI Q. H., 1993, APPL ANAL, V50, P73, DOI DOI 10.1080/00036819308840185##DEN HARTOG J., 1956, MECH VIBRATIONS##DING ZG, 2002, T AM MATH SOC, V354, P265, DOI 10.1090/S0002-9947-01-02864-1##DING ZH, 2002, NONLINEAR ANAL-THEOR, V49, P1079, DOI 10.1016/S0362-546X(01)00726-X##HUMPHREYS LD, 1999, IMA J APPL MATH, V63, P37, DOI 10.1093/IMAMAT/63.1.37##LAZER AC, 1990, SIAM REV, V32, P537, DOI 10.1137/1032120##LAZER AC, 1987, ANN I H POINCARE-AN, V4, P243##MCKENNA PJ, 1987, ARCH RATION MECH AN, V98, P167##MCKENNA PJ, 1990, SIAM J APPL MATH, V50, P702##MOORE KS, 2002, SIAM J MATH ANAL, V33, P1411, DOI 10.1137/S0036141001388099##OTTENS HH, 80016L NLR TR##TIMOSHENKO S, 1989, THEORY PLATES SHELLS##VANHORSSEN WT, 1988, SIAM J APPL MATH, V48, P1227, DOI 10.1137/0148075##ZARUBINSKAYA M, 2005, NONLINEAR DYNAM, V40, P35, DOI 10.1007/S11071-005-3816-6",1,2020-11-20,NA
J,WOS:000241323400020,2006,ON THE FREE VIBRATIONS OF AN OSCILLATOR WITH A PERIODICALLY TIME-VARYING MASS,"IN THIS PAPER THE FREE VIBRATIONS OF A LINEAR, SINGLE DEGREE OF FREEDOM OSCILLATOR WITH A (PERIODICALLY AND STEPWISE CHANGING) TIME-VARYING MASS HAVE BEEN STUDIED. NOT ONLY SOLUTIONS OF THE OSCILLATOR EQUATION HAVE BEEN CONSTRUCTED, BUT ALSO STABILITY DIAGRAMS FOR THE FREE VIBRATIONS HAVE BEEN PRESENTED FOR VARIOUS PARAMETER VALUES. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",NA,NA,JOURNAL OF SOUND AND VIBRATION,"VAN HORSSEN, WT##ABRAMIAN, AK##HARTONO","DELFT UNIV TECHNOL, FAC ELECT ENGN MATH & COMP SCI, DELFT INST APPL MATH, NL-2628 CD DELFT, NETHERLANDS. RUSSIAN ACAD SCI, INST PROBLEMS MECH ENGN, ST PETERSBURG 199178, RUSSIA.","ACOUSTICS; ENGINEERING, MECHANICAL; MECHANICS",ACOUSTICS; ENGINEERING; MECHANICS,"CVETICANIN L, 1998, J SOUND VIB, V212, P685, DOI 10.1006/JSVI.1997.1455##HOLL HJ, 1999, COMPUT STRUCT, V73, P177, DOI 10.1016/S0045-7949(98)00281-8##IRSCHIK H., 2004, APPL MECH REV, V5, P145##VAN DER BURGH AHP, 2006, INT J NONLIN MECH, V41, P345, DOI 10.1016/J.IJNONLINMEC.2005.04.005",16,2020-11-20,NA
J,WOS:000243110900001,2006,"ISORENIERATANE RECORD IN BLACK SHALES FROM THE PARIS BASIN, FRANCE: CONSTRAINTS ON RECYCLING OF RESPIRED CO2 AS A MECHANISM FOR NEGATIVE CARBON ISOTOPE SHIFTS DURING THE TOARCIAN OCEANIC ANOXIC EVENT","THE PROMINENT NEGATIVE STABLE CARBON ISOTOPE EXCURSION IN BOTH CARBONATE AND ORGANIC CARBON RECORDED IN ORGANIC-RICH SEDIMENTS DEPOSITED DURING THE TOARCIAN OCEANIC ANOXIC EVENT (OAE) HAS COMMONLY BEEN EXPLAINED BY RECYCLING OF C-13-DEPLETED CO2 (THE SO-CALLED KUSPERT MODEL). MORE RECENTLY, THE MASSIVE RELEASE OF C-13-DEPLETED METHANE OR OTHER FORMS OF C-13-DEPLETED CARBON WAS ALSO PROPOSED TO ACCOUNT FOR THE OBSERVED NEGATIVE DELTA C-13 EXCURSIONS IN ORGANIC CARBON OF TERRIGENOUS AS WELL AS OF MARINE ORIGIN. THE OCCURRENCE OF DIAGENETIC PRODUCTS OF THE CAROTENOID ISORENIERATENE (ISORENIERATANE AND OTHER ARYL ISOPRENOIDS) IN TOARCIAN BLACK SHALES HAS BEEN REGARDED AS SUPPORTING EVIDENCE FOR THE KUSPERT HYPOTHESIS AS THEY POINT TO STRONG STRATIFICATION OF THE EPICONTINENTAL SEAS. A SECTION OF A DRILL CORE STRADDLING THE TOARCIAN OF THE PARIS BASIN (CIRFONTAINE-EN-ORNOIS) CONTAINED INTACT ISORENIERATANE, PROVIDING EVIDENCE THAT PHOTOSYNTHETIC GREEN SULPHUR BACTERIA WERE PRESENT AT THE TIME OF DEPOSITION, EVEN PRIOR TO THE OAE. HOWEVER, THE ISORENIERATANE ABUNDANCES ARE VERY LOW IN THE SECTION WHERE THE NEGATIVE DELTA C-13 EXCURSION IN ORGANIC CARBON AND PHYTANE, A CHEMICAL FOSSIL DERIVED FROM CHLOROPHYLL, OCCURS. THE ABUNDANCE OF THE ISORENIERATENE DERIVATIVES INCREASES, ONCE THE DELTA C-13 RECORDS HAVE SHIFTED TO MORE POSITIVE VALUES. THE DELTA C-13 OF ISORENIERATANE (GENERALLY CIRCA -13.1 +/- 0.5 PARTS PER THOUSAND) INDICATES THAT THE RESPIRED CO2 CONTRIBUTION AT THE CHEMOCLINE WAS LOW AND IS THUS NOT LIKELY TO BE THE MAIN CAUSE OF THE PROMINENT UP TO 7 PARTS PER THOUSAND NEGATIVE DELTA C-13 SHIFT RECORDED IN TOARCIAN ORGANIC CARBON RECORDS.",PHOTIC-ZONE ANOXIA; SEDIMENTARY ORGANIC-MATTER; STABLE CARBON; TETHYAN LOWER; GAS-HYDRATE; SW-GERMANY; METHANE; DISSOCIATION; INDICATORS; DELTA-C-13,NA,PALEOCEANOGRAPHY,"VAN BREUGEL, Y##BAAS, M##SCHOUTEN, S##MATTIOLI, E##DAMSTE, JSS","NETHERLANDS INST SEA RES, DEPT MARINE BIOGEOCHEM & TOXICOL, NL-1790 AB DEN BURG, NETHERLANDS. UNIV LYON 1, CNRS, UMR 5125, LAB PEPS,UFR SCI TERRE, F-69622 VILLEURBANNE, FRANCE.","GEOSCIENCES, MULTIDISCIPLINARY; OCEANOGRAPHY; PALEONTOLOGY",GEOLOGY; OCEANOGRAPHY; PALEONTOLOGY,"ARTHUR MA, 1990, NATO ADV SCI I C-MAT, V304, P75##BEERLING DJ, 2002, AM J SCI, V302, P28, DOI 10.2475/AJS.302.1.28##BOWN P.R., 1998, P34##BROCKS JJ, 2005, NATURE, V437, P866, DOI 10.1038/NATURE04068##CRAMER BS, 2005, PALAEOGEOGR PALAEOCL, V224, P144, DOI 10.1016/J.PALAEO.2005.03.040##DAMSTE JSS, 2006, HANDB ENVIRON CHEM, V2, P127, DOI 10.1007/698_2_005##DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087##DIDYK BM, 1978, NATURE, V272, P216, DOI 10.1038/272216A0##FARRIMOND P, 1989, MAR PETROL GEOL, V6, P136, DOI 10.1016/0264-8172(89)90017-2##HESSELBO SP, 2000, NATURE, V406, P392, DOI 10.1038/35019044##HOLLANDER DJ, 1991, REV I FR PETROL, V46, P543, DOI 10.2516/OGST:1991027##HOLLANDER DJ, 2001, GEOCHIM COSMOCHIM AC, V65, P4321, DOI 10.1016/S0016-7037(00)00506-8##JENKYNS HC, 1997, SEDIMENTOLOGY, V44, P687, DOI 10.1046/J.1365-3091.1997.D01-43.X##JENKYNS HC, 1988, AM J SCI, V288, P101, DOI 10.2475/AJS.288.2.101##JENKYNS HC, 1986, SEDIMENTOLOGY, V33, P87, DOI 10.1111/J.1365-3091.1986.TB00746.X##JENKYNS HC, 2002, J GEOL SOC LONDON, V159, P351, DOI 10.1144/0016-764901-130##JIMENEZ AP, 1996, J GEOL, V104, P399, DOI 10.1086/629836##KEMP DB, 2005, NATURE, V437, P396, DOI 10.1038/NATURE04037##KENIG F, 2004, GEOLOGY, V32, P421, DOI 10.1130/G20356.1##KOOPMANS MP, 1996, GEOCHIM COSMOCHIM AC, V60, P4873, DOI 10.1016/S0016-7037(96)00303-1##KOOPMANS MP, 1999, ORG GEOCHEM, V30, P1089, DOI 10.1016/S0146-6380(99)00088-1##KOOPMANS MP, 1996, GEOCHIM COSMOCHIM AC, V60, P4467, DOI 10.1016/S0016-7037(96)00238-4##KUSPERT W., 1982, CYCLIC EVENT STRATIF, P482, DOI DOI 10.1007/978-3-642-75829-4_36##MATTIOLI E, 2004, J GEOL SOC LONDON, V161, P685, DOI 10.1144/0016-764903-074##MATTIOLI E, 1999, RIV ITAL PALEONTOL S, V105, P343##MCELWAIN JC, 2005, NATURE, V435, P479, DOI 10.1038/NATURE03618##MOOK WG, 1974, EARTH PLANET SC LETT, V22, P169, DOI 10.1016/0012-821X(74)90078-8##PALLIANI RB, 2002, MAR MICROPALEONTOL, V46, P223##PALLIANI RB, 1998, J MICROPALAEONTOL, V17, P153, DOI 10.1144/JM.17.2.153##PANCOST RD, 2004, J GEOL SOC LONDON, V161, P353, DOI 10.1144/0016764903-059##ROHL HJ, 2001, PALAEOGEOGR PALAEOCL, V165, P27, DOI 10.1016/S0031-0182(00)00152-8##ROSALES I, 2004, PALAEOGEOGR PALAEOCL, V203, P253, DOI 10.1016/S0031-0182(03)00686-2##SCHOUTEN S, 2000, AM J SCI, V300, P1, DOI 10.2475/AJS.300.1.1##SCHWARK L, 2004, CHEM GEOL, V206, P231, DOI 10.1016/J.CHEMGEO.2003.12.008##SVENSEN H, 2004, NATURE, V429, P542, DOI 10.1038/NATURE02566##VAN BREUGEL Y, 2005, EARTH PLANET SC LETT, V235, P421, DOI 10.1016/J.EPSL.2005.04.017##VAN BREUGEL Y, 2006, AM J SCI, V306, P367, DOI 10.2475/05.2006.03##VAN DE SCHOOTBRUGGE B, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2004PA001102##VAN KAAM-PETERS HME, 1998, ORG GEOCHEM, V28, P151, DOI 10.1016/S0146-6380(97)00132-0##VETO I, 1997, PALAEOGEOGR PALAEOCL, V132, P355, DOI 10.1016/S0031-0182(97)00053-9",81,2020-11-20,NA
J,WOS:000243414600045,2006,DETECTION OF CURRENT-INDUCED SPINS BY FERROMAGNETIC CONTACTS,"DETECTION OF CURRENT-INDUCED SPIN ACCUMULATION VIA FERROMAGNETIC CONTACTS IS DISCUSSED. ONSAGER'S RELATIONS FORBID THAT IN A TWO-PROBE CONFIGURATION, SPINS EXCITED BY CURRENTS IN TIME-REVERSAL SYMMETRIC SYSTEMS CAN BE DETECTED BY SWITCHING THE MAGNETIZATION OF A FERROMANGETIC DETECTOR CONTACT. NEVERTHELESS, CURRENT-INDUCED SPINS CAN BE TRANSFERRED AS A TORQUE TO A CONTACT MAGNETIZATION AND CAN AFFECT THE CHARGE CURRENTS IN MANY-TERMINAL CONFIGURATIONS. WE DEMONSTRATE THE GENERAL CONCEPTS BY SOLVING THE MICROSCOPIC TRANSPORT EQUATIONS FOR THE DIFFUSE RASHBA SYSTEM WITH MAGNETIC CONTACTS.",SEMICONDUCTOR; POLARIZATION; INJECTION; CONDUCTION; ELECTRONS,NA,PHYSICAL REVIEW LETTERS,"ADAGIDELI, I##BAUER, GEW##HALPERIN, BI","UNIV BRITISH COLUMBIA, DEPT PHYS & ASTRON, VANCOUVER, BC V6T 1Z1, CANADA. DELFT UNIV TECHNOL, KAVLI INST NANOSCI, NL-2628 CJ DELFT, NETHERLANDS. HARVARD UNIV, DEPT PHYS, LYMAN LAB, CAMBRIDGE, MA 02138 USA.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"ADAGIDELI I, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.256602##BEENAKKER CWJ, 1994, PHYS REV LETT, V72, P2470, DOI 10.1103/PHYSREVLETT.72.2470##BLEIBAUM O, 2006, PHYS REV B, V74, DOI [10.1103/PHYSREVB.74.195330, 10.1103/PHYSREC74.195330]##BURKOV AA, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.155308##BUTTIKER M, 1986, PHYS REV LETT, V57, P1761, DOI 10.1103/PHYSREVLETT.57.1761##CASIMIR HBG, 1945, REV MOD PHYS, V17, P343, DOI 10.1103/REVMODPHYS.17.343##CHENG P, IN PRESS PHYS REV B##CHIBA D, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.216602##CROWELL P, IN PRESS##CULCER D, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.046602##DYAKONOV MI, 1971, JETP LETT-USSR, V13, P467##EDELSTEIN VM, 1990, SOLID STATE COMMUN, V73, P233, DOI 10.1016/0038-1098(90)90963-C##ETO M, 2005, J PHYS SOC JPN, V74, P1934, DOI 10.1143/JPSJ.74.1934##GALITSKI VM, 2006, PHYS REV B, V74, DOI 10.1103/PHYSREVB.74.115331##GANICHEV SD, CONDMAT043641##HAMMAR PR, 2000, PHYS REV LETT, V84, P5024, DOI 10.1103/PHYSREVLETT.84.5024##HANKIEWICZ EM, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.155305##HIRSCH JE, 1999, PHYS REV LETT, V83, P1834, DOI 10.1103/PHYSREVLETT.83.1834##HU JP, 2003, INT J MOD PHYS B, V17, P5991, DOI 10.1142/S0217979203023537##HUGHES TL, 2006, PHYS REV B, V74, DOI 10.1103/PHYSREVB.74.193316##INOUE J, 2005, SCIENCE, V309, P2004, DOI 10.1126/SCIENCE.1113956##INOUE J, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.041303##INOUE J, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.033104##JOHNSON M, 1985, PHYS REV LETT, V55, P1790, DOI 10.1103/PHYSREVLETT.55.1790##KATO Y, 2004, NATURE, V427, P50, DOI 10.1038/NATURE02202##KATO YK, 2004, SCIENCE, V306, P1910, DOI 10.1126/SCIENCE.1105514##KATO YK, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.176601##KIMURA T, CONDMAT0609304##KIOSEOGLOU G, 2004, NAT MATER, V3, P799, DOI 10.1038/NMAT1239##KOVALEV AA, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.224424##LEVITOV L. S., 1985, SOVIET PHYSICS - JETP, V61, P133##LOU X, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.176603##MARMORKOS IK, 1993, PHYS REV B, V48, P2811, DOI 10.1103/PHYSREVB.48.2811##MISHCHENKO EG, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.226602##MURAKAMI S, 2003, SCIENCE, V301, P1348, DOI 10.1126/SCIENCE.1087128##MURAKAMI S, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.235206##MURAKAMI S, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.241202##NUNEZ AS, 2006, SOLID STATE COMMUN, V139, P31, DOI 10.1016/J.SSC.2006.05.004##ONSAGER L, 1931, PHYS REV, V38, P2265, DOI 10.1103/PHYSREV.38.2265##PAREEK TP, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.033310##RUSTER C, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.027203##SAITOH E, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2199473##SCHMIDT G, 2000, PHYS REV B, V62, PR4790, DOI 10.1103/PHYSREVB.62.R4790##SHCHELUSHKIN RV, 2005, PHYS REV B, V71, DOI 10.1103/PHYSREVB.71.045123##SHEN SQ, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.081311##SHYTOV AV, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.075316##SIH V, 2005, NAT PHYS, V1, P31, DOI 10.1038/NPHYS009##SILOV AY, 2004, APPL PHYS LETT, V85, P5929, DOI 10.1063/1.1833565##SILVESTROV PG, 2006, PHYS REV B, V74, DOI 10.1103/PHYSREVB.74.165301##SINITSYN NA, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.081312##SINOVA J, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.126603##SLONCZEWSKI JC, 1996, J MAGN MAGN MATER, V159, PL1, DOI 10.1016/0304-8853(96)00062-5##VALENZUELA SO, 2006, NATURE, V442, P176, DOI 10.1038/NATURE04937##VAN WEES BJ, 2000, PHYS REV LETT, V84, P5023, DOI 10.1103/PHYSREVLETT.84.5023##VANSON PC, 1987, PHYS REV LETT, V58, P2271, DOI 10.1103/PHYSREVLETT.58.2271##VANWEES BJ, 1992, PHYS REV LETT, V69, P510, DOI 10.1103/PHYSREVLETT.69.510##VAS'KO F. T., 1979, SOVIET PHYSICS - SOLID STATE, V21, P994##WUNDERLICH J, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.047204##ZHANG SF, 2000, PHYS REV LETT, V85, P393, DOI 10.1103/PHYSREVLETT.85.393",30,2020-11-20,NA
J,WOS:000243414600005,2006,SECURITY OF QUANTUM BIT STRING COMMITMENT DEPENDS ON THE INFORMATION MEASURE,"UNCONDITIONALLY SECURE NONRELATIVISTIC BIT COMMITMENT IS KNOWN TO BE IMPOSSIBLE IN BOTH THE CLASSICAL AND THE QUANTUM WORLD. HOWEVER, WHEN COMMITTING TO A STRING OF N BITS AT ONCE, HOW FAR CAN WE STRETCH THE QUANTUM LIMITS? IN THIS LETTER, WE INTRODUCE A FRAMEWORK OF QUANTUM SCHEMES WHERE ALICE COMMITS A STRING OF N BITS TO BOB, IN SUCH A WAY THAT SHE CAN ONLY CHEAT ON A BITS AND BOB CAN LEARN AT MOST B BITS OF INFORMATION BEFORE THE REVEAL PHASE. OUR RESULTS ARE TWOFOLD: WE SHOW BY AN EXPLICIT CONSTRUCTION THAT IN THE TRADITIONAL APPROACH, WHERE THE REVEAL AND GUESS PROBABILITIES FORM THE SECURITY CRITERIA, NO GOOD SCHEMES CAN EXIST: A+B IS AT LEAST N. IF, HOWEVER, WE USE A MORE LIBERAL CRITERION OF SECURITY, THE ACCESSIBLE INFORMATION, WE CONSTRUCT SCHEMES WHERE A=4LOG(2)N+O(1) AND B=4, WHICH IS IMPOSSIBLE CLASSICALLY. OUR FINDINGS SIGNIFICANTLY EXTEND KNOWN NO-GO RESULTS FOR QUANTUM BIT COMMITMENT.",NA,NA,PHYSICAL REVIEW LETTERS,"BUHRMAN, H##CHRISTANDL, M##HAYDEN, P##LO, HK##WEHNER, S","CWI, NL-1098 SJ AMSTERDAM, NETHERLANDS. UNIV CAMBRIDGE, DAMTP, CAMBRIDGE CB3 0WA, ENGLAND. MCGILL UNIV, SCH COMP SCI, MONTREAL, PQ, CANADA. UNIV TORONTO, DEPT ECE & PHYS, TORONTO, ON M5G 3G4, CANADA.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"AHARONOV D., 2000, PROCEEDINGS OF THE THIRTY SECOND ANNUAL ACM SYMPOSIUM ON THEORY OF COMPUTING, P705, DOI 10.1145/335305.335404##BARNUM H, 2002, J MATH PHYS, V43, P2097, DOI 10.1063/1.1459754##BENNETT C. H., 1984, P IEEE INT C COMP SY, P175##BENNETT C. H., 1991, P ADV CRYPT CRYPT 90, P351##BLUM M., 1983, SIGACT NEWS, V15, P23##BRASSARD G., 1993, PROCEEDINGS. 34TH ANNUAL SYMPOSIUM ON FOUNDATIONS OF COMPUTER SCIENCE (CAT. NO.93CH3368-8), P362, DOI 10.1109/SFCS.1993.366851##BRASSARD G, 1990, P CRYPTO 90, P49##BUHRMAN H, QUANTPH0504078##CHRISTANDL M, 2005, IEEE T INFORM THEORY, V51, P3159, DOI 10.1109/TIT.2005.853338##CHRISTANDL M, QUANTPH0604183##CREPEAU C, 1994, J MOD OPTIC, V41, P2445, DOI 10.1080/09500349414552291##CREPEAU C, 1995, P CRYPTO, P110##DIVCENZO DP, 2002, IEEE T INFORM THEORY, V48, P580##DIVINCENZO DP, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.067902##GOLDREICH O, 2001, BASIC TOOLS##HARDY L, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.157901##HAYDEN P, 2004, COMMUN MATH PHYS, V250, P371, DOI 10.1007/S00220-004-1087-6##HOLEVO AS, 1973, PROBL INF T, V9, P110##JAIN R, QUANTPH0506001##KENT A, 2003, PHYS REV LETT, V90, DOI 10.1103/PHYSREVLETT.90.237901##KILIAN J., 1988, PROCEEDINGS OF THE TWENTIETH ANNUAL ACM SYMPOSIUM ON THEORY OF COMPUTING, P20, DOI 10.1145/62212.62215##KITAEV A, 2004, PHYS REV A, V69, DOI 10.1103/PHYSREVA.69.052326##KONIG R, 2005, IEEE T INFORM THEORY, V51, P2391, DOI 10.1109/TIT.2005.850087##LO HK, 1998, PHYSICA D, V120, P177, DOI 10.1016/S0167-2789(98)00053-0##LO HK, 1997, PHYS REV LETT, V78, P3410, DOI 10.1103/PHYSREVLETT.78.3410##MAYERS D, 1997, PHYS REV LETT, V78, P3414, DOI 10.1103/PHYSREVLETT.78.3414##MAYERS D, QUANTPH9603015, P43602##RENNER R, 2005, LECT NOTES COMPUT SC, V3378, P407##RENNER R, QUANTPH0512258##SPEKKENS RW, 2002, PHYS REV A, V65, DOI 10.1103/PHYSREVA.65.012310##YAO A. C. C, 1995, P 26 ANN ACM S THEOR, P67",28,2020-11-20,NA
J,WOS:000243414600066,2006,CRITICAL SCALING IN LINEAR RESPONSE OF FRICTIONLESS GRANULAR PACKINGS NEAR JAMMING,"WE STUDY THE ORIGIN OF THE SCALING BEHAVIOR IN FRICTIONLESS GRANULAR MEDIA ABOVE THE JAMMING TRANSITION BY ANALYZING THEIR LINEAR RESPONSE. THE RESPONSE TO LOCAL FORCING IS NON-SELF-AVERAGING AND FLUCTUATES OVER A LENGTH SCALE THAT DIVERGES AT THE JAMMING TRANSITION. THE RESPONSE TO GLOBAL FORCING BECOMES INCREASINGLY NONAFFINE NEAR THE JAMMING TRANSITION. THIS IS DUE TO THE PROXIMITY OF FLOPPY MODES, THE INFLUENCE OF WHICH WE CHARACTERIZE BY THE LOCAL LINEAR RESPONSE. WE SHOW THAT THE LOCAL RESPONSE ALSO GOVERNS THE ANOMALOUS SCALING OF ELASTIC CONSTANTS AND CONTACT NUMBER.",AMORPHOUS SOLIDS; STRESS-RESPONSE; ELASTICITY; DYNAMICS,NA,PHYSICAL REVIEW LETTERS,"ELLENBROEK, WG##SOMFAI, E##VAN HECKE, M##VAN SAARLOOS, W","LEIDEN UNIV, INST LORENTZ, NL-2300 RA LEIDEN, NETHERLANDS. LEIDEN UNIV, KAMERLINGH ONNES LAB, NL-2300 RA LEIDEN, NETHERLANDS.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"ALEXANDER S, 1998, PHYS REP, V296, P65, DOI 10.1016/S0370-1573(97)00069-0##ELLENBROEK WG, IN PRESS##ELLENBROEK WG, 2005, POWDERS GRAINS 2005, P377##GENG JF, 2003, PHYSICA D, V182, P274, DOI 10.1016/S0167-2789(03)00137-4##GENG JF, 2001, PHYS REV LETT, V87, DOI 10.1103/PHYSREVLETT.87.035506##GLAND N, 2006, EUR PHYS J E, V20, P179, DOI 10.1140/EPJE/I2006-10012-6##GOLDENBERG C, 2005, NATURE, V435, P188, DOI 10.1038/NATURE03497##GOLDHIRSCH I, 2002, EUR PHYS J E, V9, P245, DOI 10.1140/EPJE/I2002-10073-5##JAEGER H, 2005, PHYS WORLD, V18, P34##KASAHARA A, 2004, PHYS REV E, V70, DOI 10.1103/PHYSREVE.70.051309##LEONFORTE F, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.014203##LIU AJ, 1998, NATURE, V396, P21, DOI 10.1038/23819##MAKSE HA, 2004, PHYS REV E, V70, DOI 10.1103/PHYSREVE.70.061302##MAKSE HA, 1999, PHYS REV LETT, V83, P5070, DOI 10.1103/PHYSREVLETT.83.5070##MASON TG, 1995, PHYS REV LETT, V75, P2051, DOI 10.1103/PHYSREVLETT.75.2051##O'HERN CS, 2003, PHYS REV E, V68, DOI 10.1103/PHYSREVE.68.011306##O'HERN CS, 2001, PHYS REV LETT, V86, P111, DOI 10.1103/PHYSREVLETT.86.111##OSTOJIC S, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.208001##SERERO D, 2001, EUR PHYS J E, V6, P169, DOI 10.1007/S101890170019##SILBERT LE, 2002, PHYS REV E, V65, DOI 10.1103/PHYSREVE.65.031304##SILBERT LE, 2006, PHYS REV E, V73, DOI 10.1103/PHYSREVE.73.041304##SOMFAI E, 2005, PHYS REV E, V72, DOI 10.1103/PHYSREVE.72.021301##SONFAI E, IN PRESS PHYS REV E##SONFAI E, CONDMAT0510506##TANGUY A, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.174205##WYART M, 2005, ANN PHYS-PARIS, V30, P1, DOI 10.1051/ANPHYS:2006003##WYART M, 2005, PHYS REV E, V72, DOI 10.1103/PHYSREVE.72.051306##WYART M, 2005, EUROPHYS LETT, V72, P486, DOI 10.1209/EPL/I2005-10245-5",157,2020-11-20,NA
J,WOS:000243414600072,2006,NONLINEAR SCREENING AND GAS-LIQUID SEPARATION IN SUSPENSIONS OF CHARGED COLLOIDS,"WE CALCULATE PHASE DIAGRAMS OF CHARGED COLLOIDAL SPHERES (VALENCY Z AND RADIUS A) IN A 1:1 ELECTROLYTE FROM MULTICENTERED NONLINEAR POISSON-BOLTZMANN THEORY. OUR THEORY TAKES INTO ACCOUNT CHARGE RENORMALIZATION OF THE COLLOIDAL INTERACTIONS AND VOLUME TERMS DUE TO MANY-BODY EFFECTS. FOR VALENCIES AS SMALL AS Z = 1 AND AS LARGE AS 104 WE FIND A GAS-LIQUID SPINODAL INSTABILITY IN THE COLLOID-SALT PHASE DIAGRAM PROVIDED Z LAMBDA(B)/A GREATER THAN OR SIMILAR TO 24 +/- 1, WHERE LAMBDA(B) IS THE BJERRUM LENGTH.",DEBYE-HUCKEL THEORY; PHASE-SEPARATION; TRIPLET CORRELATIONS; RENORMALIZATION; FORCES; CONDENSATION; DISPERSIONS; CRYSTALS; THERMODYNAMICS; ELECTROLYTE,NA,PHYSICAL REVIEW LETTERS,"ZOETEKOUW, B##VAN ROIJ, R","UNIV UTRECHT, INST THEORET PHYS, NL-3584 CE UTRECHT, NETHERLANDS.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"ALEXANDER S, 1984, J CHEM PHYS, V80, P5776, DOI 10.1063/1.446600##BELLONI L, 1998, COLLOID SURFACE A, V140, P227, DOI 10.1016/S0927-7757(97)00281-1##BELLONI L, 2000, J PHYS-CONDENS MAT, V12, PR549, DOI 10.1088/0953-8984/12/46/201##BERESFORDSMITH B, 1985, J COLLOID INTERF SCI, V105, P216, DOI 10.1016/0021-9797(85)90362-5##CHAN DYC, 2001, LANGMUIR, V17, P4202, DOI 10.1021/LA001560E##DENTON AR, 2006, PHYS REV E, V73, DOI 10.1103/PHYSREVE.73.041407##DENTON AR, 2004, PHYS REV E, V70, DOI 10.1103/PHYSREVE.70.031404##DENTON AR, 2000, PHYS REV E, V62, P3855, DOI 10.1103/PHYSREVE.62.3855##DERJAGUIN BV, 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L##DIEHL A, 2001, EUROPHYS LETT, V53, P86, DOI 10.1209/EPL/I2001-00127-X##DOBNIKAR J, 2003, J CHEM PHYS, V119, P4971, DOI 10.1063/1.1595642##FISHER ME, 1993, PHYS REV LETT, V71, P3826, DOI 10.1103/PHYSREVLETT.71.3826##FUSHIKI M, 1992, J CHEM PHYS, V97, P6700, DOI 10.1063/1.463676##HYNNINEN AP, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1979490##HYNNINEN AP, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2138693##ISE N, 1983, J CHEM PHYS, V78, P536, DOI 10.1063/1.444479##ITO K, 1994, SCIENCE, V263, P66, DOI 10.1126/SCIENCE.263.5143.66##LANGMUIR I, 1938, J CHEM PHYS, V6, P873, DOI 10.1063/1.1750183##LARSEN AE, 1997, NATURE, V385, P230, DOI 10.1038/385230A0##LEVIN Y, 2003, J PHYS-CONDENS MAT, V15, PS3523, DOI 10.1088/0953-8984/15/48/012##LINSE P, 2000, J CHEM PHYS, V113, P4359, DOI 10.1063/1.1288022##LOWEN H, 1992, PHYS REV LETT, V68, P1081, DOI 10.1103/PHYSREVLETT.68.1081##MCGAHAY V, 1992, J CHEM PHYS, V97, P2609, DOI 10.1063/1.463049##MONOVOUKAS Y, 1989, J COLLOID INTERF SCI, V128, P533, DOI 10.1016/0021-9797(89)90368-8##NEU JC, 1999, PHYS REV LETT, V82, P1072, DOI 10.1103/PHYSREVLETT.82.1072##PALBERG T, 1994, PHYS REV LETT, V72, P786, DOI 10.1103/PHYSREVLETT.72.786##PANAGIOTOPOULOS AZ, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.045701##PETRIS SN, 2003, J CHEM PHYS, V118, P5248, DOI 10.1063/1.1541610##RUSS C, 2005, EUROPHYS LETT, V69, P468, DOI 10.1209/EPL/I2004-10345-8##RUSS C, 2003, J PHYS-CONDENS MAT, V15, PS3509, DOI 10.1088/0953-8984/15/48/011##RUSS C, 2002, PHYS REV E, V66, DOI 10.1103/PHYSREVE.66.011402##SHAPRAN L, 2005, COLLOID SURFACE A, V270, P220, DOI 10.1016/J.COLSURFA.2005.06.002##TATA BVR, 1997, PHYS REV LETT, V78, P2660, DOI 10.1103/PHYSREVLETT.78.2660##TATA BVR, 1992, PHYS REV LETT, V69, P3778, DOI 10.1103/PHYSREVLETT.69.3778##TRIZAC E, 2003, LANGMUIR, V19, P4027, DOI 10.1021/LA027056M##TRIZAC E, 1999, PHYS REV E, V60, P6530, DOI 10.1103/PHYSREVE.60.6530##VAN ROIJ R, 1999, PHYS REV E, V59, P2010, DOI 10.1103/PHYSREVE.59.2010##VANROIJ R, 1997, PHYS REV LETT, V79, P3082, DOI 10.1103/PHYSREVLETT.79.3082##VERWEY J. W., 1948, THEORY STABILITY LYO##VON GRUNBERG HH, 2001, EUROPHYS LETT, V55, P580, DOI 10.1209/EPL/I2001-00455-9##WARREN PB, 2006, PHYS REV E, V73, DOI 10.1103/PHYSREVE.73.011411##WARREN PB, 2000, J CHEM PHYS, V112, P4683, DOI 10.1063/1.481024##WETTE P, 2002, J CHEM PHYS, V116, P10981, DOI 10.1063/1.1480010##YOSHIDA H, 1999, LANGMUIR, V15, P2684, DOI 10.1021/LA981316B##ZOETEKOUW B, 2006, PHYS REV E, V73, DOI 10.1103/PHYSREVE.73.021403##ZOETEKOUW B, IN PRESS",31,2020-11-20,NA
J,WOS:000242996800054,2006,CHARACTERIZING A MAMMALIAN CIRCANNUAL PACEMAKER,"MANY SPECIES EXPRESS ENDOGENOUS CYCLES IN PHYSIOLOGY AND BEHAVIOR THAT ALLOW ANTICIPATION OF THE SEASONS. THE ANATOMICAL AND CELLULAR BASES OF THESE CIRCANNUAL RHYTHMS HAVE NOT BEEN DEFINED. HERE, WE PROVIDE STRONG EVIDENCE USING AN IN VIVO SOAY SHEEP MODEL THAT THE CIRCANNUAL REGULATION OF PROLACTIN SECRETION, AND ITS ASSOCIATED BIOLOGY, DERIVE FROM A PITUITARY-BASED TIMING MECHANISM. CIRCANNUAL RHYTHM GENERATION IS SEEN AS THE PRODUCT OF THE INTERACTION BETWEEN MELATONIN-REGULATED TIMER CELLS AND ADJACENT PROLACTIN- SECRETING CELLS, WHICH TOGETHER FUNCTION AS AN INTRAPITUITARY ""PACEMAKER-SLAVE"" TIMER SYSTEM. THESE NEW INSIGHTS OPEN THE WAY FOR A MOLECULAR ANALYSIS OF LONG-TERM TIMING MECHANISMS.",BEETLE ANTHRENUS-VERBASCI; PITUITARY-GLAND; PROLACTIN SECRETION; REPRODUCTIVE RHYTHM; MELATONIN SIGNAL; SYRIAN-HAMSTER; SEASONAL TIMER; CYCLES; PHOTOPERIOD; SHEEP,NA,SCIENCE,"LINCOLN, GA##CLARKE, IJ##HUT, RA##HAZLERIGG, DG","UNIV EDINBURGH, CTR REPROD BIOL, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND. QUEENS MED RES INST, EDINBURGH, MIDLOTHIAN, SCOTLAND. UNIV GRONINGEN, DEPT CHRONOBIOL, HAREN, NETHERLANDS. MONASH UNIV, DEPT PHYSIOL, MELBOURNE, VIC 3168, AUSTRALIA. UNIV ABERDEEN, SCH BIOL SCI, ABERDEEN, SCOTLAND.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"BOCKERS TM, 1997, ENDOCRINOLOGY, V138, P4101, DOI 10.1210/EN.138.10.4101##CARMICHAEL M S, 1986, J BIOL RHYTHMS, V1, P277, DOI 10.1177/074873048600100402##GWINNER E, 2001, FRONTIERS LIFE, V4, P193##GWINNER E., 1986, CIRCANNUAL RHYTHMS E##HAZLERIGG DG, 2004, CURR BIOL, V14, P334, DOI 10.1016/J.CUB.2004.01.057##JILG A, 2005, EUR J NEUROSCI, V22, P2845, DOI 10.1111/J.1460-9568.2005.04485.X##JOHNSTON JD, 2003, FASEB J, V17, P810, DOI 10.1096/FJ.02-0837COM##JOHNSTON JD, 2003, GEN COMP ENDOCR, V134, P182, DOI 10.1016/S0016-6480(03)00248-X##KARSCH FJ, 1989, BIOL REPROD, V41, P1034, DOI 10.1095/BIOLREPROD41.6.1034##KONDO N, 2006, CELL, V125, P161, DOI 10.1016/J.CELL.2006.03.017##LEDERC GM, 2005, ENDOCRINOLOGY, V146, P2782##LINCOLN G, 1999, ADV EXP MED BIOL, V460, P137##LINCOLN GA, 2005, ENDOCRINOLOGY, V146, P3782, DOI 10.1210/EN.2005-0132##LINCOLN GA, 2003, BIOL REPROD, V69, P1416, DOI 10.1095/BIOLREPROD.103.017673##LINCOLN GA, 1997, BIOL REPROD, V57, P460, DOI 10.1095/BIOLREPROD57.2.460##LINCOLN GA, 1989, J REPROD FERTIL, V85, P687, DOI 10.1530/JRF.0.0850687##LINCOLN GA, 1994, J NEUROENDOCRINOL, V6, P251, DOI 10.1111/J.1365-2826.1994.TB00580.X##LINCOLN GA, 1998, COMP BIOCHEM PHYS C, V119, P283, DOI 10.1016/S0742-8413(98)00017-6##MALPAUX B, 2001, J BIOL RHYTHM, V16, P336, DOI 10.1177/074873001129002051##MARTINET L, 1992, J REPROD FERTIL, V95, P325, DOI 10.1530/JRF.0.0950325##MCFERRAN DW, 2001, ENDOCRINOLOGY, V142, P3255, DOI 10.1210/EN.142.7.3255##MIYAZAKI Y, 2005, J COMP PHYSIOL A, V191, P883, DOI 10.1007/S00359-005-0012-6##NISIMURA T, 2002, BIOL RHYTHM RES, V33, P255, DOI 10.1076/BRHM.33.3.255.8264##PENGELLY ET, 1974, CIRCANNUAL CLOCKS, P89##STIRLAND JA, 2001, J NEUROENDOCRINOL, V13, P147, DOI 10.1046/J.1365-2826.2001.00611.X##THRUN LA, 1995, J BIOL RHYTHM, V10, P42, DOI 10.1177/074873049501000104##WILLIAMS LM, 1997, J NEUROENDOCRINOL, V9, P639, DOI 10.1046/J.1365-2826.1997.00625.X##WOODFILL CJI, 1994, BIOL REPROD, V50, P965, DOI 10.1095/BIOLREPROD50.4.965##ZUCKER IRVING, 2001, HANDBOOK OF BEHAVIORAL NEUROBIOLOGY, V12, P509",151,2020-11-20,MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [G0600678] FUNDING SOURCE: MEDLINE
J,WOS:000248802400037,2006,INTRAVASCULAR ULTRASOUND TISSUE HARMONIC IMAGING: A SIMULATION STUDY,"RECENTLY, THE IN VIVO FEASIBILITY OF TISSUE HARMONIC IMAGING (THI) WITH A MECHANICALLY-ROTATED INTRAVASCULAR ULTRASOUND (IVUS) CATHETER WAS EXPERIMENTALLY DEMONSTRATED. TO ISOLATE THE SECOND HARMONIC SIGNAL CONTENT, BOTH PULSE INVERSION ( PI) AND ANALOG FILTERING WERE USED. IN THE PRESENT PAPER, WE REPORT THE DEVELOPMENT OF A SIMULATION TOOL TO INVESTIGATE NONLINEAR IVUS BEAMS AND THE INFLUENCE OF ROTATION ON THE EFFICIENCY OF PI SIGNAL PROCESSING. NONLINEAR 20 MHZ BEAMS WERE SIMULATED IN A HOMOGENEOUS TISSUE-MIMICKING MEDIUM, RESULTING IN SECOND HARMONIC PRESSURE FIELDS AT 40 MHZ. THE ACOUSTIC RESPONSE FROM TISSUE WAS SIMULATED BY SUMMING RADIO-FREQUENCY (RF) PULSE-ECHO RESPONSES FROM MANY POINT-SCATTERERS. WHEN THE TRANSDUCER WAS ROTATED WITH RESPECT TO THE POINT-SCATTERERS, THE FUNDAMENTAL FREQUENCY SUPPRESSION USING PI DEGRADED RAPIDLY WITH INCREASING INTER-PULSE ANGLES. THE RESULTS OF THIS STUDY WILL AID IN THE OPTIMIZATION OF HARMONIC IVUS IMAGING SYSTEMS. (C) 2006 ELSEVIER B. V. ALL RIGHTS RESERVED.",ARTIFACTS; DOPPLER; IMAGES,INTRAVASCULAR ULTRASOUND; NONLINEAR; TISSUE HARMONIC IMAGING; SIMULATION,ULTRASONICS,"FRIJLINK, ME##GOERTZ, DE##BOUAKAZ, A##VAN DER STEEN, AFW","INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS. UNIV TOURS, TOURS, FRANCE.","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","BOUAKAZ A, 2003, IEEE T ULTRASON FERR, V50, P730, DOI 10.1109/TUFFC.2003.1209563##DUCK F.A., 1990, PHYS PROPERTIES TISS##DUCK FA, 2002, ULTRASOUND MED BIOL, V28, P1, DOI 10.1016/S0301-5629(01)00463-X##FOSTER FS, 2000, ULTRASOUND MED BIOL, V26, P1, DOI 10.1016/S0301-5629(99)00096-4##FRIJLINK ME, 2004, ULTRASON, P1118##FRIJLINK ME, 2005, ULTRASOUND MED BIOL, V31, P1335, DOI 10.1016/J.ULTRASMEDBIO.2005.06.006##HAMILTON M.F., 1998, NONLINEAR ACOUSTICS##HUMPHREY VF, 2000, ULTRASONICS, V38, P267, DOI 10.1016/S0041-624X(99)00122-5##HUNT JW, 1995, ULTRASOUND MED BIOL, V21, P329, DOI 10.1016/0301-5629(94)00120-3##JENSEN JA, 1993, ULTRASON, P943, DOI 10.1109/ULTSYM.1993.339652##KERR AT, 1992, ULTRASOUND MED BIOL, V18, P861, DOI 10.1016/0301-5629(92)90024-5##LEE YS, 1995, J ACOUST SOC AM, V97, P906, DOI 10.1121/1.412135##LOCKWOOD GR, 1991, ULTRASOUND MED BIOL, V17, P653, DOI 10.1016/0301-5629(91)90096-F##SAIJI Y, 2003, VASCULAR ULTRASOUND##SHEN CC, 2002, IEEE T ULTRASON FERR, V49, P1203, DOI 10.1109/TUFFC.2002.1041536##SIMPSON DH, 1999, IEEE T ULTRASON FERR, V46, P372, DOI 10.1109/58.753026##STEPANISHEN PR, 1971, J ACOUST SOC AM, V49, P1629, DOI 10.1121/1.1912541",5,2020-11-20,NA
J,WOS:000248802400027,2006,HIGH FREQUENCY ATTENUATION MEASUREMENTS OF LIPID ENCAPSULATED CONTRAST AGENTS,"A NUMBER OF RECENT STUDIES HAVE INDICATED THE POTENTIAL OF ULTRASOUND CONTRAST AGENT IMAGING AT HIGH ULTRASOUND FREQUENCIES. HOWEVER, THE ACOUSTIC PROPERTIES OF MICROBUBBLES AT FREQUENCIES ABOVE 10 MHZ REMAIN POORLY UNDERSTOOD AT PRESENT. IN THIS STUDY WE CHARACTERIZE THE HIGH FREQUENCY ATTENUATION PROPERTIES OF ( 1) BR14, ( 2) BR14 THAT HAS BEEN MECHANICALLY FILTERED ( 1 AND 2 MU M PORE SIZES) TO EXCLUDE LARGER BUBBLES, AND ( 3) THE MICRON TO SUBMICRON AGENT BG2423. A NARROWBAND PULSE-ECHO SUBSTITUTION METHOD IS EMPLOYED WITH A SERIES OF FOUR TRANSDUCERS COVERING THE FREQUENCY RANGE FROM 2 TO 50 MHZ. FOR BR14, ATTENUATION DECREASES RAPIDLY FROM 2 TO 10 MHZ AND THEN MORE GRADUALLY FROM 10 TO 50 MHZ. FOR 2 MU M FILTRATION, THE ATTENUATION PEAKS BETWEEN 10 AND 15 MHZ. FOR 1 MU M FILTRATION, ATTENUATION CONTINUES TO RISE UNTIL 50 MHZ. THE AGENT BG2423 EXHIBITS A DIFFUSE ATTENUATION PEAK IN THE RANGE OF 15-25 MHZ AND REMAINS HIGH UNTIL 50 MHZ. THESE RESULTS DEMONSTRATE A STRONG INFLUENCE OF BUBBLE SIZE ON HIGH FREQUENCY ATTENUATION CURVES, WITH BUBBLE DIAMETERS OF 1-2 MU M AND BELOW HAVING MORE PRONOUNCED ACOUSTIC ACTIVITY AT FREQUENCIES ABOVE 10 MHZ. (C) 2006 ELSEVIER B. V. ALL RIGHTS RESERVED.",IN-VITRO; ULTRASOUND; MICROSPHERES; SCATTERING,CONTRAST AGENTS; HARMONIC; SUBHARMONIC; MICROBUBBLES; HIGH FREQUENCIES; INTRAVASCULAR ULTRASOUND,ULTRASONICS,"GOERTZ, DE##FRIJLINK, ME##VOORMOLEN, MM##DE JONG, N##VAN DER STEEN, AFW","ERASMUS MC, DEPT BIOMED ENGN, NL-3015 GE ROTTERDAM, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, NL-3501 DG UTRECHT, NETHERLANDS. UNIV TWENTE, NL-7500 AE ENSCHEDE, NETHERLANDS.","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","CACHARD C, 1997, ULTRASOUND MED BIOL, V23, P705, DOI 10.1016/S0301-5629(97)00010-0##CHEN Q, 2002, ULTRASOUND MED BIOL, V28, P1041, DOI 10.1016/S0301-5629(02)00546-X##DEJONG N, 1993, ULTRASONICS, V31, P175, DOI 10.1016/0041-624X(93)90004-J##DEJONG N, 1992, ULTRASONICS, V30, P95, DOI 10.1016/0041-624X(92)90041-J##DEMOS SM, 1999, J AM COLL CARDIOL, V33, P867, DOI 10.1016/S0735-1097(98)00607-X##DENG CX, 1998, ULTRASOUND MED BIOL, V24, P383, DOI 10.1016/S0301-5629(97)00288-3##GOERTZ DE, 2006, ULTRASOUND MED BIOL, V32, P569, DOI 10.1016/J.ULTRASMEDBIO.2006.01.002##GOERTZ DE, 2006, ULTRASOUND MED BIOL, V32, P491, DOI 10.1016/J.ULTRASMEDBIO.2006.01.001##GOERTZ DE, 2005, IEEE T ULTRASON FERR, V52, P65, DOI 10.1109/TUFFC.2005.1397351##GOERTZ DE, 2003, P IEEE ULTR S, P1503##HOFF L, 2000, THESIS NORWEGIAN U S##MORAN CM, 2002, ULTRASOUND MED BIOL, V28, P785, DOI 10.1016/S0301-5629(02)00520-3",9,2020-11-20,NA
J,WOS:000248802400135,2006,A KLM-CIRCUIT MODEL OF A MULTI-LAYER TRANSDUCER FOR ACOUSTIC BLADDER VOLUME MEASUREMENTS,"IN A PRECEDING STUDY A NEW TECHNIQUE TO NON-INVASIVELY MEASURE THE BLADDER VOLUME ON THE BASIS OF NON-LINEAR WAVE PROPAGATION WAS VALIDATED. IT WAS SHOWN THAT THE HARMONIC LEVEL GENERATED AT THE POSTERIOR BLADDER WALL INCREASES FOR LARGER BLADDER VOLUMES. A DEDICATED TRANSDUCER IS NEEDED TO FURTHER VERIFY AND IMPLEMENT THIS APPROACH. THIS TRANSDUCER MUST BE CAPABLE OF BOTH TRANSMISSION OF HIGH-PRESSURE WAVES AT FUNDAMENTAL FREQUENCY AND RECEPTION OF UP TO THE THIRD HARMONIC. FOR THIS PURPOSE, A MULTI-LAYER TRANSDUCER WAS CONSTRUCTED USING A SINGLE ELEMENT PZT TRANSDUCER FOR TRANSMISSION AND A PVDF TOP-LAYER FOR RECEPTION. TO DETERMINE FEASIBILITY OF THE MULTI-LAYER CONCEPT FOR BLADDER VOLUME MEASUREMENTS, AND TO ENSURE OPTIMAL PERFORMANCE, AN EQUIVALENT MATHEMATICAL MODEL ON THE BASIS OF KLM-CIRCUIT MODELING WAS GENERATED. THIS MODEL WAS OBTAINED IN TWO SUBSEQUENT STEPS. FIRSTLY, THE PZT TRANSDUCER WAS MODELED WITHOUT PVDF-LAYER ATTACHED BY MEANS OF MATCHING THE MODEL WITH THE MEASURED ELECTRICAL INPUT IMPEDANCE. IT WAS VALIDATED USING PULSE-ECHO MEASUREMENTS. SECONDLY, THE MODEL WAS EXTENDED WITH THE PVDF-LAYER. THE TOTAL MODEL WAS VALIDATED BY CONSIDERING THE PVDF-LAYER AS A HYDROPHONE ON THE PZT TRANSDUCER SURFACE AND COMPARING THE MEASURED AND SIMULATED PVDF RESPONSES ON A WAVE TRANSMITTED BY THE PZT TRANSDUCER. THE OBTAINED RESULTS INDICATED THAT A VALID MODEL FOR THE MULTI-LAYER TRANSDUCER WAS CONSTRUCTED. THE MODEL SHOWED FEASIBILITY OF THE MULTI-LAYER CONCEPT FOR BLADDER VOLUME MEASUREMENTS. IT ALSO ALLOWED FOR FURTHER OPTIMIZATION WITH RESPECT TO ELECTRICAL MATCHING AND TRANSMIT WAVEFORM. ADDITIONALLY, THE MODEL DEMONSTRATED THE EFFECT OF MECHANICAL LOADING OF THE PVDF-LAYER ON THE PZT TRANSDUCER. (C) 2006 ELSEVIER B. V. ALL RIGHTS RESERVED.",NA,KLM-CIRCUIT MODEL; MULTI-LAYER; PVDF; BLADDER VOLUME,ULTRASONICS,"MERKS, EJW##BORSBOOM, JMG##BOM, N##VAN DER STEEN, AFW##DE JONG, N","ERASMUS MC, ROTTERDAM, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS.","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","BOUAKAZ A, 2004, ULTRASOUND MED BIOL, V30, P469, DOI 10.1016/J.ULTRASMEDBIO.2003.11.006##BROWN LF, 1989, IEEE T ULTRASON FERR, V36, P313, DOI 10.1109/58.19169##KINO G. S., 1987, ACOUSTIC WAVES DEVIC##KRIMHOLTZ R, 1970, ELECTRON LETT, V6, P398, DOI 10.1049/EL:19700280##LIU XZ, 1999, ACUSTICA, V85, P420##LOCKWOOD GR, 1994, IEEE T ULTRASON FERR, V41, P225, DOI 10.1109/58.279135##MERKS EJW, 2004, ULTRASON, P145##SAITOH S., 1985, IEEE 1985 ULTRASONICS SYMPOSIUM. PROCEEDINGS. (CAT. NO.85CH2209-5), P620##VOORMOLEN MM, 2002, IEEE ULTR S, P1229",9,2020-11-20,NA
J,WOS:000248802400022,2006,NITRIC OXIDE DELIVERY BY ULTRASONIC CRACKING: SOME LIMITATIONS,"NITRIC OXIDE ( NO) HAS BEEN IMPLICATED IN SMOOTH MUSCLE RELAXATION. ITS USE HAS BEEN WIDESPREAD IN CARDIOLOGY. DUE TO THE EFFECTIVE SCAVENGING OF NO BY HEMOGLOBIN, HOWEVER, THE DRUG HAS TO BE APPLIED LOCALLY OR IN LARGE QUANTITIES, TO HAVE THE EFFECT DESIRED. WE PROPOSE THE USE OF ENCAPSULATED MICROBUBBLES THAT ACT AS A VEHICLE TO CARRY THE GAS TO A REGION OF INTEREST. BY APPLYING A BURST OF HIGH- AMPLITUDE ULTRASOUND, THE SHELL ENCAPSULATING THE GAS CAN BE CRACKED. CONSEQUENTLY, THE GAS IS RELEASED UPON WHICH ITS DISSOLUTION AND DIFFUSION BEGINS. THIS PROCESS IS GENERALLY REFERRED TO AS ( ULTRA) SONIC CRACKING. TO TEST IF THE QUANTITIES OF RELEASED GAS ARE HIGH ENOUGH TO ALLOW FOR NO- DELIVERY IN SMALL VESSELS ( CIRCLE DIVIDE < 200 MU M), WE ANALYZED HIGH- SPEED OPTICAL RECORDINGS OF INSONIFIED STIFF-SHELLED MICROBUBBLES. THESE MICROBUBBLES WERE SUBJECTED TO ULTRASONIC CRACKING USING 0.5 OR 1.7 MHZ ULTRASOUND WITH MECHANICAL INDEX MI > 0.6. THE MEAN QUANTITY RELEASED FROM A SINGLE MICROBUBBLE IS 1.7 FMOL. THIS IS ALREADY MORE THAN THE NO PRODUCTION OF A 1 MM LONG VESSEL WITH A 50 MU M DIAMETER DURING 100 MS. HOWEVER, WE SIMULATED THAT THE DISSOLUTION TIME OF TYPICAL RELEASED NO MICROBUBBLES IS EQUAL TO THE HALF- LIFE TIME OF NO IN WHOLE BLOOD DUE TO SCAVENGING BY HEMOGLOBIN ( 1.8 MS), BUT MUCH SMALLER THAN THE EXTRAVASCULAR HALF- LIFE TIME OF NO (> 90 MS). WE CONCLUDE THAT ULTRASONIC CRACKING CAN ONLY BE A SUCCESSFUL MEANS FOR NITRIC OXIDE DELIVERY, IF THE GAS IS RELEASED IN OR NEAR THE RED BLOOD CELL- FREE PLASMA NEXT TO THE ENDOTHELIUM. A COMPLICATING FACTOR IN THE IN VIVO SITUATION IS THE VARIATION IN BLOOD PRESSURE. ALTHOUGH OUR SIMULATIONS AND ACOUSTIC MEASUREMENTS DEMONSTRATE THAT THE DISSOLUTION SPEED OF FREE GAS INCREASES WITH THE HYDROSTATIC PRESSURE, THE IN VITRO ACOUSTIC AMPLITUDES SUGGEST THAT THE NUMBER OF RELEASED MICROBUBBLES DECREASES AT HIGHER HYDROSTATIC PRESSURES. THIS INDICATES THAT ULTRASONIC CRACKING MOSTLY OCCURS DURING THE EXPANSION PHASE. (C) 2006 ELSEVIER B. V. ALL RIGHTS RESERVED.",DIFFUSION; PRESSURE,NA,ULTRASONICS,"POSTEMA, M##BOUAKAZ, A##TEN CATE, FJ##SCHMITZ, G##DE JONG, N##VAN WAMEL, A","RUHR UNIV BOCHUM, INST MED ENGN, D-44780 BOCHUM, GERMANY. UNIV TOURS, INSERM 619, TOURS, FRANCE. ERASMUS MC, CTR THORAX, DEPT CARDIOL, ROTTERDAM, NETHERLANDS. ERASMUS MC, CTR THORAX, DEPT BIOMED ENGN, ROTTERDAM, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS. UNIV TWENTE, FAC SCI & TECHNOL, PHYS FLUIDS GRP, NL-7500 AE ENSCHEDE, NETHERLANDS.","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","BILIIC I, 2001, PROG RREP 1 REG M HN, P8##BOUAKAZ A, 1999, ULTRASOUND MED BIOL, V25, P1407, DOI 10.1016/S0301-5629(99)00109-X##BUTLER AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8##DEJONG N, 1993, ACOUSTIC PROPERTIES##KOSHLAND DE, 1992, SCIENCE, V258, P1861, DOI 10.1126/SCIENCE.1470903##LANCASTER JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/NIOX.1996.0112##LANDAU L.D., 1987, FLUID MECH##LANDAU LD, 1986, THOERY ELASTICITY##LIU XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/JBC.273.30.18709##MEGSON IL, 2000, DRUG FUTURE, V25, P701, DOI 10.1358/DOF.2000.025.07.858691##PFAFFENDORF M, 2002, J CRIT CARE, V6, P7##POSTEMA M, 2004, ULTRASOUND MED BIOL, V30, P827, DOI 10.1016/J.ULTRASMEDBIO.2004.02.010##POSTEMA M, 2005, MED PHYS, V32, P3707, DOI 10.1118/1.2133718##POSTEMA M, 2005, ULTRASON, P977##POSTEMA M, 2005, IEEE T ULTRASON FERR, V52, P1035, DOI 10.1109/TUFFC.2005.1504026##POSTEMA M, 2004, ULTRASONICS, V42, P759, DOI 10.1016/J.ULTRAS.2003.12.007##POSTEMA M, 2005, BIOMED TECH, V50, P748##POSTEMA M, 2006, AIP CONF PROC, V838, P275##SHOHET RV, 2000, CIRCULATION, V101, P2554, DOI 10.1161/01.CIR.101.22.2554##SHORTENCARIER MJ, 2004, IEEE T ULTRASON FERR, V51, P822, DOI 10.1109/TUFFC.2004.1320741##TANIYAMA Y, 2002, CIRCULATION, V105, P1233, DOI 10.1161/HC1002.105228##THOMAS DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/PNAS.011379598##VAUGHN MW, 1998, AM J PHYSIOL-HEART C, V274, PH1705##VAUGHN MW, 1998, AM J PHYSIOL-HEART C, V274, PH2163##WILHELM E, 1977, CHEM REV, V77, P219, DOI 10.1021/CR60306A003",19,2020-11-20,NA
J,WOS:000243607700004,2006,ABUNDANCE AND ACTIVITY OF MAJOR GROUPS OF PROKARYOTIC PLANKTON IN THE COASTAL NORTH SEA DURING SPRING AND SUMMER,"THE DYNAMICS OF THE ABUNDANCE AND ACTIVITY OF SELECTED HETEROTROPHIC PROKARYOTIC GROUPS WERE DETERMINED IN THE COASTAL NORTH SEA DURING A COASTAL SPRING BLOOM DOMINATED BY THE PRYMNESIOPHYTE PHAEOCYSTIS GLOBOSA AND IN THE SUBSEQUENT SPRING AND SUMMER SEASON USING CATALYZED REPORTER DEPOSITION-FLUORESCENCE IN SITU HYBRIDIZATION COMBINED WITH MICROAUTORADIOGRAPHY (MICRO-CARD-FISH). BOTH CRENARCHEA AND EURYARCHAEA WERE DETECTED THROUGHOUT THE STUDY PERIOD, ALBEIT NEVER AT LEVELS THAT EXCEEDED 2% OF THE TOTAL PROKARYOTIC ABUNDANCE, CORRESPONDING TO A MAXIMUM ABUNDANCE OF 2.8 X 10(8) ARCHAEA L(-1). EURYARCHAEA WERE GENERALLY MORE ABUNDANT THAN CRENARCHAEA. ON AVERAGE, 21% OF THE CRENARCHAEA AND 35% OF THE EURYARCHAEA WERE TAKING UP LEUCINE THROUGHOUT THE STUDY PERIOD. MEMBERS OF THE BACTEROIDETES WERE ABUNDANT DURING THE P. GLOBOSA BLOOM PERIOD. AT THE SENESCENT STAGE OF THE BLOOM, BACTEROIDETES COMPRISED UP TO 63% OF THE PROKARYOTIC COMMUNITY. THE ABUNDANCES OF MEMBERS OF THE ROSEOBACTER CLADE AS WELL AS THE SAR86 CLUSTER WERE LOW DURING THE PHYTOPLANKTON SPRING BLOOM PERIOD (MEAN 2% EACH), BUT INCREASED DURING AUGUST. ON AVERAGE, 51% OF THE ROSEOBACTER, 38% OF THE BACTEROIDETES AND 39% OF THE SAR86 CLUSTER WERE TAKING UP LEUCINE. THE PERCENTAGES OF ACTIVE BACTERIA INCREASED DURING THE DECLINE OF THE P. GLOBOSA SPRING BLOOM. THE BACTEROIDETES CLUSTER SHOWED THE STRONGEST INCREASE, INDICATING THAT MEMBERS OF THIS CLUSTER ARE LIKELY TO PLAY A MAJOR ROLE IN THE DEGRADATION OF ORGANIC MATTER PRODUCED IN THE P. GLOBOSA SPRING BLOOM.",CATALYZED REPORTER DEPOSITION; IN-SITU HYBRIDIZATION; LEUCINE INCORPORATION; BIOMASS PRODUCTION; ATTACHED BACTERIA; PELAGIC BACTERIA; ORGANIC-MATTER; AMINO-ACIDS; BACTERIOPLANKTON; ARCHAEA,MARINE ARCHAEA; BACTEROIDETES; ROSEOBACTER; NORTH SEA; CARD-FISH; MICROAUTORADIOGRAPHY; BACTERIAL SUCCESSION; PHAEOCYSTIS,AQUATIC MICROBIAL ECOLOGY,"ALDERKAMP, AC##SINTES, E##HERNDL, GJ","UNIV GRONINGEN, CTR ECOL & EVOLUTIONARY STUDIES, DEPT MARINE BIOL, NL-9759 AA HAREN, NETHERLANDS. ROYAL NETHERLANDS INST SEA RES, NIOZ, DEPT BIOL OCEANOG, NL-1790 AB DEN BURG, NETHERLANDS.",ECOLOGY; MARINE & FRESHWATER BIOLOGY; MICROBIOLOGY,ENVIRONMENTAL SCIENCES & ECOLOGY; MARINE & FRESHWATER BIOLOGY; MICROBIOLOGY,"ACINAS SG, 1999, APPL ENVIRON MICROB, V65, P514##ALONSO C, 2006, APPL ENVIRON MICROB, V72, P2141, DOI 10.1128/AEM.72.3.2141-2147.2006##ALONSO C, 2005, APPL ENVIRON MICROB, V71, P1709, DOI 10.1128/AEM.71.4.1709-1716.2005##AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995##ARRIETA JM, 2002, LIMNOL OCEANOGR, V47, P594, DOI 10.4319/LO.2002.47.2.0594##BECQUEVORT S, 1998, AQUAT MICROB ECOL, V14, P39, DOI 10.3354/AME014039##BLIGHT SP, 1995, MAR ECOL PROG SER, V128, P61, DOI 10.3354/MEPS128061##BRUSSAARD CPD, 2005, HARMFUL ALGAE, V4, P875, DOI 10.1016/J.HAL.2004.12.012##BRUSSAARD CPD, 1996, MAR ECOL PROG SER, V144, P211, DOI 10.3354/MEPS144211##BRUSSAARD CPD, 1995, MAR ECOL PROG SER, V123, P259, DOI 10.3354/MEPS123259##BRUSSAARD CPD, 2004, APPL ENVIRON MICROB, V70, P1506, DOI 10.1128/AEM.70.3.1506-1513.2004##CADEE GC, 1986, NETH J SEA RES, V20, P29, DOI 10.1016/0077-7579(86)90058-X##CADEE GC, 1992, NETH I SEA RES PUBL, V20, P143##CARLSON CA, 1998, LIMNOL OCEANOGR, V43, P375, DOI 10.4319/LO.1998.43.3.0375##CARMAN KR, 1993, HDB METHODS AQUATIC, P397##COTTRELL MT, 2003, LIMNOL OCEANOGR, V48, P168, DOI 10.4319/LO.2003.48.1.0168##COTTRELL MT, 2000, APPL ENVIRON MICROB, V66, P1692, DOI 10.1128/AEM.66.4.1692-1697.2000##DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/PNAS.89.12.5685##EILERS H, 2000, APPL ENVIRON MICROB, V66, P3044, DOI 10.1128/AEM.66.7.3044-3051.2000##EILERS H, 2001, APPL ENVIRON MICROB, V67, P5134, DOI 10.1128/AEM.67.11.5134-5142.2001##FRANCIS CA, 2005, P NATL ACAD SCI USA, V102, P14683, DOI 10.1073/PNAS.0506625102##FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148A0##FUHRMAN JA, 1999, NATURE, V399, P541, DOI 10.1038/21119##GASOL JM, 2000, SCI MAR, V64, P197, DOI 10.3989/SCIMAR.2000.64N2197##GATTUSO JP, 1998, ANNU REV ECOL SYST, V29, P405, DOI 10.1146/ANNUREV.ECOLSYS.29.1.405##GLOCKNER FO, 1999, APPL ENVIRON MICROB, V65, P3721##HERNDL GJ, 2005, APPL ENVIRON MICROB, V71, P2303, DOI 10.1128/AEM.71.5.2303-2309.2005##JANSE I, 2000, AQUAT MICROB ECOL, V22, P119, DOI 10.3354/AME022119##JANSE I, 1996, AQUAT MICROB ECOL, V10, P97, DOI 10.3354/AME010097##JOIRIS C, 1982, NETH J SEA RES, V16, P260, DOI 10.1016/0077-7579(82)90035-7##KARNER MB, 2001, NATURE, V409, P507, DOI 10.1038/35054051##KIRCHMAN DL, 2002, FEMS MICROBIOL ECOL, V39, P91, DOI 10.1111/J.1574-6941.2002.TB00910.X##KONNEKE M, 2005, NATURE, V437, P543, DOI 10.1038/NATURE03911##LAANBROEK HJ, 1985, MAR ECOL PROG SER, V25, P1, DOI 10.3354/MEPS025001##LISS P. S., 1994, J MARINE SYST, V5, P1##MALMSTROM RR, 2005, APPL ENVIRON MICROB, V71, P2979, DOI 10.1128/AEM.71.6.2979-2986.2005##MALMSTROM RR, 2004, LIMNOL OCEANOGR, V49, P597, DOI 10.4319/LO.2004.49.2.0597##MASSANA R, 2001, LIMNOL OCEANOGR, V46, P1181, DOI 10.4319/LO.2001.46.5.1181##MOLLER EF, 2003, MAR ECOL PROG SER, V262, P185, DOI 10.3354/MEPS262185##MULLINS TD, 1995, LIMNOL OCEANOGR, V40, P148, DOI 10.4319/LO.1995.40.1.0148##MUNSON MA, 1997, APPL ENVIRON MICROB, V63, P4729, DOI 10.1128/AEM.63.12.4729-4733.1997##OLSEN GJ, 1994, NATURE, V371, P657, DOI 10.1038/371657A0##PERNTHALER A, 2002, APPL ENVIRON MICROB, V68, P3094, DOI 10.1128/AEM.68.6.3094-3101.2002##PERNTHALER A, 2002, APPL ENVIRON MICROB, V68, P661, DOI 10.1128/AEM.68.2.661-667.2002##PINHASSI J, 2004, APPL ENVIRON MICROB, V70, P6753, DOI 10.1128/AEM.70.11.6753-6766.2004##PRESTON CM, 1996, P NATL ACAD SCI USA, V93, P6241, DOI 10.1073/PNAS.93.13.6241##REICHENBACH H, 1991, PROKARYOTES, P356##RIEMANN L, 2000, APPL ENVIRON MICROB, V66, P578, DOI 10.1128/AEM.66.2.578-587.2000##STEIN JL, 1996, P NATL ACAD SCI USA, V93, P6228, DOI 10.1073/PNAS.93.13.6228##TEIRA E, 2006, LIMNOL OCEANOGR, V51, P60, DOI 10.4319/LO.2006.51.1.0060##TEIRA E, 2004, APPL ENVIRON MICROB, V70, P4411, DOI 10.1128/AEM.70.7.4411-4414.2004##TEIRA E, 2001, LIMNOL OCEANOGR, V46, P1370, DOI 10.4319/LO.2001.46.6.1370##TEIRA E, 2006, LIMNOL OCEANOGR, V51, P2131, DOI 10.4319/LO.2006.51.5.2131##WUCHTER C, 2003, FEMS MICROBIOL LETT, V219, P203, DOI 10.1016/S0378-1097(03)00060-0##WUCHTER C, 2006, P NATL ACAD SCI USA, V103, P12317, DOI 10.1073/PNAS.0600756103##ZUBKOV MV, 2001, ENVIRON MICROBIOL, V3, P304, DOI 10.1046/J.1462-2920.2001.00196.X",52,2020-11-20,NA
J,WOS:000243652400001,2006,A METHOD FOR ESTIMATION OF ELASTICITIES IN METABOLIC NETWORKS USING STEADY STATE AND DYNAMIC METABOLOMICS DATA AND LINLOG KINETICS,"BACKGROUND: DYNAMIC MODELING OF METABOLIC REACTION NETWORKS UNDER IN VIVO CONDITIONS IS A CRUCIAL STEP IN ORDER TO OBTAIN A BETTER UNDERSTANDING OF THE (DIS) FUNCTIONING OF LIVING CELLS. SO FAR DYNAMIC METABOLIC MODELS GENERALLY HAVE BEEN BASED ON MECHANISTIC RATE EQUATIONS WHICH OFTEN CONTAIN SO MANY PARAMETERS THAT THEIR IDENTIFIABILITY FROM EXPERIMENTAL DATA FORMS A SERIOUS PROBLEM. RECENTLY, APPROXIMATIVE RATE EQUATIONS, BASED ON THE LINEAR LOGARITHMIC (LINLOG) FORMAT HAVE BEEN PROPOSED AS A SUITABLE ALTERNATIVE WITH FEWER PARAMETERS. RESULTS: IN THIS PAPER WE PRESENT A METHOD FOR ESTIMATION OF THE KINETIC MODEL PARAMETERS, WHICH ARE EQUAL TO THE ELASTICITIES DEFINED IN METABOLIC CONTROL ANALYSIS, FROM METABOLITE DATA OBTAINED FROM DYNAMIC AS WELL AS STEADY STATE PERTURBATIONS, USING THE LINLOG KINETIC FORMAT. ADDITIONALLY, WE ADDRESS THE QUESTION OF PARAMETER IDENTIFIABILITY FROM DYNAMIC PERTURBATION DATA IN THE PRESENCE OF NOISE. THE METHOD IS ILLUSTRATED USING METABOLITE DATA GENERATED WITH A DYNAMIC MODEL OF THE GLYCOLYTIC PATHWAY OF SACCHAROMYCES CEREVISIAE BASED ON MECHANISTIC RATE EQUATIONS. ELASTICITIES ARE ESTIMATED FROM THE GENERATED DATA, WHICH DEFINE THE COMPLETE LINLOG KINETIC MODEL OF THE GLYCOLYSIS. THE EFFECT OF DATA NOISE ON THE ACCURACY OF THE ESTIMATED ELASTICITIES IS PRESENTED. FINALLY, IDENTIFIABLE SUBSET OF PARAMETERS IS DETERMINED USING INFORMATION ON THE STANDARD DEVIATIONS OF THE ESTIMATED ELASTICITIES THROUGH MONTE CARLO (MC) SIMULATIONS. CONCLUSION: THE PARAMETER ESTIMATION WITHIN THE LINLOG KINETIC FRAMEWORK AS PRESENTED HERE ALLOWS THE DETERMINATION OF THE ELASTICITIES DIRECTLY FROM EXPERIMENTAL DATA FROM TYPICAL DYNAMIC AND/OR STEADY STATE EXPERIMENTS. THESE ELASTICITIES ALLOW THE RECONSTRUCTION OF THE FULL KINETIC MODEL OF SACCHAROMYCES CEREVISIAE, AND THE DETERMINATION OF THE CONTROL COEFFICIENTS. MC SIMULATIONS REVEALED THAT CERTAIN ELASTICITIES ARE POTENTIALLY UNIDENTIFIABLE FROM DYNAMIC DATA ONLY. ADDITION OF STEADY STATE PERTURBATION OF ENZYME ACTIVITIES SOLVED THIS PROBLEM.",FLUX CONTROL COEFFICIENTS; IN-VIVO ANALYSIS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CYBERNETIC PERSPECTIVE; FRAMEWORK DEVELOPMENT; ETHANOL-PRODUCTION; PATHWAY; YEAST; PERTURBATION,NA,BMC BIOINFORMATICS,"NIKEREL, IE##VAN WINDEN, WA##VAN GULIK, WM##HEIJNEN, JJ","DELFT UNIV TECHNOL, DEPT BIOTECHNOL, NL-2628 BC DELFT, NETHERLANDS.",BIOCHEMICAL RESEARCH METHODS; BIOTECHNOLOGY & APPLIED MICROBIOLOGY; MATHEMATICAL & COMPUTATIONAL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOTECHNOLOGY & APPLIED MICROBIOLOGY; MATHEMATICAL & COMPUTATIONAL BIOLOGY,"BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/SCIENCE.2047876##CORTASSA S, 1994, ENZYME MICROB TECH, V16, P761, DOI 10.1016/0141-0229(94)90033-7##CORTASSA S, 1995, BIOTECHNOL BIOENG, V47, P193, DOI 10.1002/BIT.260470211##DELGADO J, 1993, BIOTECHNOL BIOENG, V41, P1121, DOI 10.1002/BIT.260411116##EHLDE M, 1996, BIOCHEM J, V313, P721, DOI 10.1042/BJ3130721##GALAZZO JL, 1990, ENZYME MICROB TECH, V12, P162, DOI 10.1016/0141-0229(90)90033-M##GIERSCH C, 1994, J THEOR BIOL, V169, P89, DOI 10.1006/JTBI.1994.1131##GIERSCH C, 1996, J THEOR BIOL, V182, P361, DOI 10.1006/JTBI.1996.0175##HEIJNEN JJ, 2005, BIOTECHNOL BIOENG, V91, P534, DOI 10.1002/BIT.20558##HEIJNEN JJ, 2004, METAB ENG, V6, P391, DOI 10.1016/J.YMBEN.2004.07.002##HOFMEYR JHS, 1996, J THEOR BIOL, V182, P371, DOI 10.1006/JTBI.1996.0176##KACSER H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/BST0071149##KRESNOWATI MTAP, 2005, METAB ENG, V7, P142, DOI 10.1016/J.YMBEN.2004.12.002##LIAO JC, 1992, ANN NY ACAD SCI, V665, P27, DOI 10.1111/J.1749-6632.1992.TB42571.X##MASHEGO MR, 2006, IN PRESS FEMS YEAST##MOLES CG, 2003, GENOME RES, V13, P2467, DOI 10.1101/GR.1262503##OSTERGAARD S, 2001, BIOTECHNOL BIOENG, V73, P412, DOI 10.1002/BIT.1075##RAMKRISHNA D, 1987, BIOTECHNOL PROGR, V3, P121, DOI 10.1002/BTPR.5420030302##RICHEY B, 1987, J BIOL CHEM, V262, P7157##RIZZI M, 1997, BIOTECHNOL BIOENG, V55, P592##SAVAGEAU M.A., 1976, BIOCH SYSTEMS ANAL S##SCHAEFER U, 1999, ANAL BIOCHEM, V270, P88, DOI 10.1006/ABIO.1999.4048##SCHLOSSER PM, 1994, BIOTECHNOL PROGR, V10, P141, DOI 10.1021/BP00026A003##SCHOMBURG I, 2002, NUCLEIC ACIDS RES, V30, P47, DOI 10.1093/NAR/30.1.47##SEGRE D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/PNAS.232349399##TER KUILE BH, 2001, FEBS LETT, V500, P169, DOI 10.1016/S0014-5793(01)02613-8##TEUSINK B, 2000, EUR J BIOCHEM, V267, P5313, DOI 10.1046/J.1432-1327.2000.01527.X##THEOBALD U, 1997, BIOTECHNOL BIOENG, V55, P305, DOI 10.1002/(SICI)1097-0290(19970720)55:2<305::AID-BIT8>3.0.CO;2-M##THEOBALD U, 1993, ANAL BIOCHEM, V214, P31, DOI 10.1006/ABIO.1993.1452##VANGULIK WM, 1995, BIOTECHNOL BIOENG, V48, P681, DOI 10.1002/BIT.260480617##VARMA A, 1993, J THEOR BIOL, V165, P477, DOI 10.1006/JTBI.1993.1202##VARMA A, 1993, J THEOR BIOL, V165, P503, DOI 10.1006/JTBI.1993.1203##VARNER J, 1999, BIOTECHNOL PROGR, V15, P426, DOI 10.1021/BP990018H##VARNER J, 1999, BIOTECHNOL PROGR, V15, P407, DOI 10.1021/BP990017P##VASEGHI S, 1999, METAB ENG, V1, P128, DOI 10.1006/MBEN.1998.0110##VISSER D, 2004, METAB ENG, V6, P378, DOI 10.1016/J.YMBEN.2004.07.001##VISSER D, 2003, METAB ENG, V5, P164, DOI 10.1016/S1096-7176(03)00025-9##VISSER D, 2002, BIOTECHNOL BIOENG, V79, P674, DOI 10.1002/BIT.10328##VISSER D, 2002, METAB ENG, V4, P114, DOI 10.1006/MBEN.2001.0216##VISSER D, 2004, BIOTECHNOL BIOENG, V88, P157, DOI 10.1002/BIT.20235##VOIT E. O., 2000, COMPUTATIONAL ANAL B##VOIT EO, 2004, BIOINFORMATICS, V20, P1670, DOI 10.1093/BIOINFORMATICS/BTH140##WANG LQ, 2006, METAB ENG, V8, P142, DOI 10.1016/J.YMBEN.2005.11.002##WANG LQ, 2006, METAB ENG, V8, P133, DOI 10.1016/J.YMBEN.2005.11.003##WANG LQ, 2004, BIOPHYS J, V87, P3750, DOI 10.1529/BIOPHYSJ.104.048090##WU L, 2005, ANAL BIOCHEM, V336, P164, DOI 10.1016/J.AB.2004.09.001##WU L, 2004, EUR J BIOCHEM, V271, P3348, DOI 10.1111/J.0014-2956.2004.04269.X",35,2020-11-20,NA
J,WOS:000242327900017,2006,HIGHER DIMENSIONAL VSI SPACETIMES,"WE PRESENT THE EXPLICIT METRIC FORMS FOR HIGHER DIMENSIONAL VANISHING SCALAR INVARIANT (VSI) LORENTZIAN SPACETIMES. WE NOTE THAT ALL OF THE VSI SPACETIMES BELONG TO THE HIGHER DIMENSIONAL KUNDT CLASS. WE DETERMINE ALL OF THE VSI SPACETIMES WHICH ADMIT A COVARIANTLY CONSTANT NULL VECTOR, AND WE NOTE THAT IN GENERAL IN HIGHER DIMENSIONS THESE SPACETIMES ARE OF RICCI-TYPE III AND WEYL-TYPE III. THE RICCI-TYPE N SUBCLASS IS RELATED TO THE CHIRAL NULL MODELS AND INCLUDES THE RELATIVISTIC GYRATONS AND THE HIGHER DIMENSIONAL PP-WAVE SPACETIMES. THE SPACETIMES UNDER INVESTIGATION ARE OF PARTICULAR INTEREST SINCE THEY ARE SOLUTIONS OF SUPERGRAVITY OR SUPERSTRING THEORY.",NA,NA,CLASSICAL AND QUANTUM GRAVITY,"COLEY, A##FUSTER, A##HERVIK, S##PELAVAS, N","DALHOUSIE UNIV, DEPT MATH & STAT, HALIFAX, NS B3H 3J5, CANADA. NATL INST NUCL & HIGH ENERGY PHYS, NL-1098 SJ AMSTERDAM, NETHERLANDS.","ASTRONOMY & ASTROPHYSICS; QUANTUM SCIENCE & TECHNOLOGY; PHYSICS, MULTIDISCIPLINARY; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"AMATI D, 1989, PHYS LETT B, V219, P443, DOI 10.1016/0370-2693(89)91092-7##BERGSHOEFF EA, 1993, PHYS REV D, V47, P5444, DOI 10.1103/PHYSREVD.47.5444##BLAU M, 2002, J HIGH ENERGY PHYS##BRINKMANN HW, 1925, MATH ANN, V94, P119, DOI 10.1007/BF01208647##COLEY A, 2004, CLASSICAL QUANT GRAV, V21, P5519, DOI 10.1088/0264-9381/21/23/014##COLEY A, 2004, CLASSICAL QUANT GRAV, V21, PL35, DOI 10.1088/0264-9381/21/7/L01##COLEY A, 2003, PHYS REV D, V67, DOI 10.1103/PHYSREVD.67.104020##COLEY AA, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.281601##COLEY AA, UNPUB##COLEY A, 2006, CLASSICAL QUANT GRAV, V23, P3053, DOI 10.1088/0264-9381/23/9/018##EDGAR SB, 1997, GEN RELAT GRAVIT, V29, P1309, DOI 10.1023/A:1018820031537##FROLOV VP, 2006, PHYS REV D, V73, DOI 10.1103/PHYSREVD.73.104028##FROLOV VP, 2005, PHYS REV D, V71, DOI 10.1103/PHYSREVD.71.104034##FROLOV VP, 2005, PHYS REV D, V72, DOI 10.1103/PHYSREVD.72.084031##FUSTER A, P 11 MARC GROSSM M##GUVEN R, 1987, PHYS LETT B, V191, P275, DOI 10.1016/0370-2693(87)90254-1##HOROWITZ GT, 1990, PHYS REV LETT, V64, P260, DOI 10.1103/PHYSREVLETT.64.260##HOROWITZ GT, 1995, PHYS REV D, V51, P2896, DOI 10.1103/PHYSREVD.51.2896##KOWALSKIGLIKMAN J, 1985, PHYS LETT B, V150, P125, DOI 10.1016/0370-2693(85)90153-4##MALDACENA J, 2002, J HIGH ENERGY PHYS##MEESSEN P, 2002, PHYS REV D, V65, DOI 10.1103/PHYSREVD.65.087501##METSAEV RR, 2002, NUCL PHYS B, V625, P70, DOI 10.1016/S0550-3213(02)00003-2##METSAEV RR, 2002, PHYS REV D, V65, DOI 10.1103/PHYSREVD.65.126004##MILSON R, 2005, INT J GEOM METHODS M, V2, P41, DOI 10.1142/S0219887805000491##PELAVAS N, 2005, J MATH PHYS, V46, DOI 10.1063/1.1904707##PODOLSKY J, 2006, CLASSICAL QUANT GRAV, V23, P5785, DOI 10.1088/0264-9381/23/20/002##PRAVDA V, 2004, CLASSICAL QUANT GRAV, V21, P2873, DOI 10.1088/0264-9381/21/12/007##PRAVDA V, 2002, CLASSICAL QUANT GRAV, V19, P6213, DOI 10.1088/0264-9381/19/23/318##RUSSO JG, 2002, J HIGH ENERGY PHYS##RUSSO JG, 2002, J HIGH ENERGY PHYS##RUSSO JG, 1995, NUCL PHYS B, V448, P293, DOI 10.1016/0550-3213(95)00091-6##STEPHANI H, 2003, EXACT SOLITONS EINST##TSEYTLIN AA, 1993, NUCL PHYS B, V390, P153, DOI 10.1016/0550-3213(93)90389-7##TSEYTLIN AA, 1995, CLASSICAL QUANT GRAV, V12, P2365, DOI 10.1088/0264-9381/12/10/003",57,2020-11-20,NA
J,WOS:000243584900009,2006,ACTIONABLE CLIMATE KNOWLEDGE: FROM ANALYSIS TO SYNTHESIS,"THE TRADITIONAL REDUCTIONIST APPROACH TO SCIENCE HAS A TENDENCY TO CREATE 'ISLANDS OF KNOWLEDGE IN A SEA OF IGNORANCE', WITH A MUCH STRONGER FOCUS ON ANALYSIS OF SCIENTIFIC INPUTS RATHER THAN SYNTHESIS OF SOCIALLY RELEVANT OUTCOMES. THIS MIGHT BE THE PRINCIPAL REASON WHY INTENDED END USERS OF CLIMATE INFORMATION GENERALLY FAIL TO EMBRACE WHAT THE CLIMATE SCIENCE COMMUNITY HAS TO OFFER. THE TRANSLATION OF CLIMATE INFORMATION INTO REAL-LIFE ACTION REQUIRES 3 ESSENTIAL COMPONENTS: SALIENCE (THE PERCEIVED RELEVANCE OF THE INFORMATION), CREDIBILITY (THE PERCEIVED TECHNICAL QUALITY OF THE INFORMATION) AND LEGITIMACY (THE PERCEIVED OBJECTIVITY OF THE PROCESS BY WHICH THE INFORMATION IS SHARED). WE EXPLORE EACH OF THESE COMPONENTS USING 3 CASE STUDIES FOCUSED ON DRYLAND CROPPING IN AUSTRALIA, INDIA AND BRAZIL. IN REGARDS TO 'SALIENCE' WE DISCUSS THE CHALLENGE FOR CLIMATE SCIENCE TO BE 'POLICY-RELEVANT', USING AUSTRALIAN DROUGHT POLICY AS AN EXAMPLE. IN A VILLAGE IN SOUTHERN INDIA 'CREDIBILITY' WAS GAINED THROUGH ENGAGEMENT BETWEEN SCIENTISTS AND RISK MANAGERS WITH THE AIM OF BUILDING SOCIAL CAPITAL, ACHIEVED ONLY AT HIGH COST TO SCIENCE INSTITUTIONS. FINALLY, IN BRAZIL WE FOUND THAT 'LEGITIMACY' IS A FRAGILE, YET RENEWABLE RESOURCE THAT NEEDS TO BE PART OF THE PACKAGE FOR SUCCESSFUL CLIMATE APPLICATIONS; LEGITIMACY CAN BE EASILY ERODED BUT IS DIFFICULT TO RECOVER. WE CONCLUDE THAT CLIMATE RISK MANAGEMENT REQUIRES HOLISTIC SOLUTIONS DERIVED FROM CROSS-DISCIPLINARY AND PARTICIPATORY, USER-ORIENTED RESEARCH. APPROACHES THAT COMBINE CLIMATE, AGROECOLOGICAL AND SOCIOECONOMIC MODELS PROVIDE THE SCIENTIFIC CAPABILITIES FOR ESTABLISHMENT OF 'BORDERLESS' INSTITUTIONS WITHOUT DISCIPLINARY CONSTRAINTS. SUCH INSTITUTIONS COULD PROVIDE THE NECESSARY SUPPORT AND FLEXIBILITY TO DELIVER THE SOCIAL BENEFITS OF CLIMATE SCIENCE ACROSS DIVERSE CONTEXTS. OUR CASE STUDIES SHOW THAT THIS TYPE OF SOLUTION IS ALREADY BEING APPLIED, AND SUGGEST THAT THE CLIMATE SCIENCE COMMUNITY ATTEMPT TO ADDRESS EXISTING INSTITUTIONAL CONSTRAINTS, WHICH STILL IMPEDE CLIMATE RISK MANAGEMENT.",SOUTHERN-OSCILLATION; DROUGHT POLICY; CHALLENGES; MANAGEMENT; AUSTRALIA; RAINFALL; POLITICS; CEARA,CLIMATE KNOWLEDGE; SALIENCE; CREDIBILITY; LEGITIMACY; DRYLAND CROPPING; RISK MANAGEMENT; MODELLING,CLIMATE RESEARCH,"MEINKE, H##NELSON, R##KOKIC, P##STONE, R##SELVARAJU, R##BAETHGEN, W","CSIRO, SUSTAINABLE ECOSYST, CANBERRA, ACT 2601, AUSTRALIA. ABARE, CANBERRA, ACT 2601, AUSTRALIA. TAMIL NADU AGR UNIV, COIMBATORE 641003, TAMIL NADU, INDIA. COLUMBIA UNIV, INT RES INST CLIMATE & SOC, IRI, PALISADES, NY 10964 USA. UNIV SO QUEENSLAND, FAC SCI, TOOWOOMBA, QLD 4350, AUSTRALIA. DEPT PRIMARY IND & FISHERIES, TOOWOOMBA, QLD 4350, AUSTRALIA.",ENVIRONMENTAL SCIENCES; METEOROLOGY & ATMOSPHERIC SCIENCES,ENVIRONMENTAL SCIENCES & ECOLOGY; METEOROLOGY & ATMOSPHERIC SCIENCES,"AGRAWALA S, 2001, SCI TECHNOL HUM VAL, V26, P454, DOI 10.1177/016224390102600404##ANDERSON JR, 2003, AGR SYST, V75, P161, DOI 10.1016/S0308-521X(02)00064-1##BACKHOUSE R. E., 2002, PENGUIN HIST EC##BLENCH R, 1999, 47 OV DEV I##BOTTERILL LC, 2003, AUST J POLIT HIST, V49, P61, DOI 10.1111/1467-8497.00281##BOTTERILL LC, 2005, DISASTER RESPONSE##BRUNNER R.D., 2005, ADAPTIVE GOVERNANCE##CASH D, 2005, KNOWLEDGE ACTION SYS##COHEN D, 2001, GOOD COMPANY SOCIAL##DECUNHA E, 1998, REBELLIOIN BACKLANDS##DHAR ON, 1982, J CLIMATOL, V2, P339, DOI 10.1002/JOC.3370020404##*DPTF, 1997, REV NAT DROUGHT POL##ELLIS F., 2000, RURAL LIVELIHOODS DI##FINAN T, 1999, WORKSH PUBL PHIL ENV##GLANTZ M., 2003, CLIMATE AFFAIRS PRIM##GLANTZ MH, 2005, 13 16 SEPT ISSE NCAR##HAMMER GL, 2000, APPL SEAS CLIM FOREC##HOLLING C. S, 1978, ADAPTIVE ENV ASSESSM##LAUGHLIN G, 2000, WORLD METEO, P27##LEMOS MC, 2004, WORLD DEV, V32, P2121, DOI 10.1016/J.WORLDDEV.2004.08.002##LEMOS MC, 1999, NA76GPO385 NOAA##LEMOS MCD, 2003, POLICY SCI, V36, P101##LOWE I, 2002, NEED ENV LITERACY##MEINKE H, 2005, CLIMATIC CHANGE, V70, P221, DOI 10.1007/S10584-005-5948-6##MEINKE H, 2006, INTEGRATED ASSESSMEN##NAGEL T, 2005, OXFORD COMPANION PHI##NELSON R., 2005, AUSTRALIAN COMMODITIES, V12, P171##NELSON ROHAN, 2004, FORECASTING REGIONAL##PARTHASARATHY B, 1985, J CLIMATOL, V5, P369, DOI 10.1002/JOC.3370050404##PUTNAM R., 1993, MAKING DEMOCRACY WOR##RUSSELL B., 1938, POWER NEW SOCIAL ANA##SELVARAJU R, 2003, INT J CLIMATOL, V23, P187, DOI 10.1002/JOC.869##SELVARAJU R, 1999, SOIL TILL RES, V52, P203, DOI 10.1016/S0167-1987(99)00083-5##SIVAKUMAR MVK, 1999, P START WMO INT WORS##SRIDHARAN S, 1990, VAYU MANDAL, V41, P108##STIGTER CJ, 2005, CLIMATIC CHANGE, V70, P255, DOI 10.1007/S10584-005-5949-5##STONE RC, 1996, NATURE, V384, P252, DOI 10.1038/384252A0##TADDEI RR, 2005, THESIS COLUMBIA U NE##THOMPSON D, 1998, AGR SYST, V57, P469, DOI 10.1016/S0308-521X(98)00027-4##WHITE D, 2005, DISASTER RESPONSE RI##WHITE DH, 1999, WATER INT, V24, P2, DOI 10.1080/02508069908692128##WILHITE DA, 1996, NAT HAZARDS, V13, P229",133,2020-11-20,NA
J,WOS:000243085600064,2006,FORMATION OF ONE-DIMENSIONAL MGH2 NANO-STRUCTURES BY HYDROGEN INDUCED DISPROPORTIONATION,"REMARKABLE FORMATION OF ONE-DIMENSIONAL SINGLE CRYSTALLINE MGH2 STRUCTURES IN THE NANO- AND MICRO-METERS RANGES IS REPORTED. THESE STRUCTURES HAVE BEEN TAILORED BY HYDROGEN ABSORPTION AND SUBSEQUENT DISPROPORTIONATION OF BULK MG24Y5. THE MGH2 WHISKERS HAVE BEEN STRUCTURALLY AND MORPHOLOGICALLY CHARACTERIZED BY X-RAYS DIFFRACTION, SCANNING AND TRANSMISSION ELECTRON MICROCOPIES. A GROWTH MODEL IS PROPOSED FOR THE EARLY STAGE OF THE WHISKERS FORMATION BY COMBINING SURFACE CHEMICAL AND MORPHOLOGICAL INVESTIGATIONS. THE FORMATION OF MGH2 WHISKERS OPENS NEW ENGINEERING EXPLORATIONS AND CHALLENGES FOR FURTHER EXPERIMENTAL AND THEORETICAL STUDIES. (C) 2006 ELSEVIER B.V ALL RIGHTS RESERVED.",MAGNESIUM; KINETICS; HYDRIDE; ALLOYS; NANOBELTS; STORAGE; METALS; SYSTEM; FILMS,MAGNESIUM HYDRIDE; ONE-DIMENSIONAL NANO-STRUCTURES; HYDROGEN ABSORBING MATERIALS,JOURNAL OF ALLOYS AND COMPOUNDS,"ZLOTEA, C##LU, J##ANDERSSON, Y","UPPSALA UNIV, DEPT CHEM MAT, S-75121 UPPSALA, SWEDEN. UPPSALA UNIV, MICROSTRUCT LAB, S-75121 UPPSALA, SWEDEN.","CHEMISTRY, PHYSICAL; MATERIALS SCIENCE, MULTIDISCIPLINARY; METALLURGY & METALLURGICAL ENGINEERING",CHEMISTRY; MATERIALS SCIENCE; METALLURGY & METALLURGICAL ENGINEERING,"*AMS INT, 1996, BIN ALL PHAS DIAGR##BARSOUM MW, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.206104##BERNHARDT B, 2002, THERMOCHIM ACTA, V382, P249, DOI 10.1016/S0040-6031(01)00750-X##BONHOMME F, 1996, J ALLOY COMPD, V232, P271, DOI 10.1016/0925-8388(95)01927-8##BOULET JM, 1983, J LESS-COMMON MET, V89, P151, DOI 10.1016/0022-5088(83)90261-8##CHACON C, 2005, J APPL PHYS, V97, DOI 10.1063/1.1896440##CUI Z, 2000, MATER RES BULL, V35, P1653, DOI 10.1016/S0025-5408(00)00369-X##DICK KA, 2004, NAT MATER, V3, P380, DOI 10.1038/NMAT1133##ELLINGER FH, 1955, J AM CHEM SOC, V77, P2647, DOI 10.1021/JA01614A094##FUJIMORI A, 1984, J PHYS C SOLID STATE, V17, P341, DOI 10.1088/0022-3719/17/2/021##HERLEY PJ, 1985, J APPL PHYS, V58, P292, DOI 10.1063/1.335674##IWAMURA E, 1999, THIN SOLID FILMS, V349, P191, DOI 10.1016/S0040-6090(99)00220-5##MIEDEMA AR, 1978, Z METALLKD, V69, P287##MIEDEMA AR, 1978, Z METALLKD, V69, P455##PAN ZW, 2001, SCIENCE, V291, P1947, DOI 10.1126/SCIENCE.1058120##PEDERSEN AS, 1996, SOLID STATE PHENOM, V35, P49##PEZAT M, 1980, J LESS-COMMON MET, V74, P427, DOI 10.1016/0022-5088(80)90181-2##REILLY JJ, 1968, INORG CHEM, V7, P2254, DOI 10.1021/IC50069A016##SELVAM P, 1986, INT J HYDROGEN ENERG, V11, P169, DOI 10.1016/0360-3199(86)90082-0##SELVAM P, 1990, J LESS-COMMON MET, V163, P89, DOI 10.1016/0022-5088(90)90088-2##SMITH JF, 1965, ACTA METALL MATER, V13, P889, DOI 10.1016/0001-6160(65)90080-5##SONG MY, 1984, J LESS-COMMON MET, V103, P145, DOI 10.1016/0022-5088(84)90373-4##STOUI M, 1986, J LESS-COMMON MET, V123, P9##SUN DL, 2002, J ALLOY COMPD, V333, P103, DOI 10.1016/S0925-8388(01)01712-1##THE NBS TABLES OF CHEMICAL THERMODYNAMIC PROPERTIES, 1982, J PHYS CHEM REF D S2, V11##XIA YN, 2003, ADV MATER, V15, P353, DOI 10.1002/ADMA.200390087##ZALUSKA A, 2001, APPL PHYS A-MATER, V72, P157, DOI 10.1007/S003390100783##ZENG K, 2002, MAT SCI ENG R, V38, P55, DOI 10.1016/S0927-796X(02)00007-4##ZHANG J, 2001, APPL PHYS A-MATER, V73, P773, DOI 10.1007/S003390101014",31,2020-11-20,NA
J,WOS:000243415300024,2006,TIME CORRELATION FUNCTION AND FINITE FIELD APPROACHES TO THE CALCULATION OF THE FIFTH ORDER RAMAN RESPONSE IN LIQUID XENON,"THE FIFTH ORDER, TWO-DIMENSIONAL RAMAN RESPONSE IN LIQUID XENON IS CALCULATED VIA A TIME CORRELATION FUNCTION (TCF) THEORY AND THE NUMERICALLY EXACT FINITE FIELD METHOD. BOTH EMPLOY CLASSICAL MOLECULAR DYNAMICS SIMULATIONS. THE RESULTS ARE SHOWN TO BE IN EXCELLENT AGREEMENT, SUGGESTING THE EFFICACY OF THE TCF APPROACH, IN WHICH THE RESPONSE FUNCTION IS WRITTEN APPROXIMATELY IN TERMS OF A SINGLE CLASSICAL MULTITIME TCF. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",ATOMIC LIQUID; POLARIZATION SELECTIVITY; HETERODYNE-DETECTION; MOLECULAR-ORIGINS; CS2; SPECTRUM; SPECTROSCOPY; SCATTERING,NA,JOURNAL OF CHEMICAL PHYSICS,"DEVANE, R##SPACE, B##JANSEN, TLC##KEYES, T","UNIV PENN, CTR MOL MODELING, DEPT CHEM, PHILADELPHIA, PA 19104 USA. UNIV S FLORIDA, DEPT CHEM, TAMPA, FL 33620 USA. UNIV GRONINGEN, INST THEORET PHYS, NL-9747 AG GRONINGEN, NETHERLANDS. BOSTON UNIV, DEPT CHEM, BOSTON, MA 02215 USA.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"APPLEQUIST J, 1972, J AM CHEM SOC, V94, P2952, DOI 10.1021/JA00764A010##ASTINOV V, 2000, CHEM PHYS LETT, V327, P334, DOI 10.1016/S0009-2614(00)00819-8##BLANK DA, 2000, J CHEM PHYS, V113, P771, DOI 10.1063/1.481851##BLANK DA, 1999, J CHEM PHYS, V111, P3105, DOI 10.1063/1.479591##DENNY R A, 2001, PHYS REV E STAT NONLIN SOFT MATTER PHYS, V63, P065101##DEVANE R, 2006, J PHYS CHEM B, V110, P3773, DOI 10.1021/JP0552751##DEVANE R, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2038768##DEVANE R, 2004, PHYS REV E, V70, DOI 10.1103/PHYSREVE.70.050101##DEVANE R, 2004, J CHEM PHYS, V121, P3688, DOI 10.1063/1.1776119##DEVANE R, 2003, J CHEM PHYS, V119, P6073, DOI 10.1063/1.1601607##GOLONZKA O, 2000, J CHEM PHYS, V113, P9893, DOI 10.1063/1.1330236##HASEGAWA T, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2217947##JANSEN TLC, 2002, J CHEM PHYS, V116, P9383, DOI 10.1063/1.1475763##JANSEN TLC, 2001, J CHEM PHYS, V114, P10910, DOI 10.1063/1.1374959##JANSEN TLC, 2000, J CHEM PHYS, V113, P307, DOI 10.1063/1.481795##KAUFMAN LJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.207402##KAUFMAN LJ, 2001, J CHEM PHYS, V114, P2312, DOI 10.1063/1.1337042##KIM J, 2002, PHYS REV E, V65, DOI 10.1103/PHYSREVE.65.061102##KUBARYCH KJ, 2002, J CHEM PHYS, V116, P2016, DOI 10.1063/1.1429961##MA A, 2000, PHYS REV LETT, V85, P1004, DOI 10.1103/PHYSREVLETT.85.1004##MA A, 2002, J CHEM PHYS, V116, P4962, DOI 10.1063/1.1453401##MA A, 2002, J CHEM PHYS, V116, P4972, DOI 10.1063/1.1453402##MUKAMEL S, 1996, PHYS REV E, V53, PR1, DOI 10.1103/PHYSREVE.53.R1##MURRY RL, 1997, J CHEM PHYS, V107, P9726, DOI 10.1063/1.475269##MURRY RL, 1998, J CHEM PHYS, V109, P7913, DOI 10.1063/1.477439##NAGATA Y, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2131053##NAGATA Y, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2191850##OKUMURA K, 1999, J CHEM PHYS, V111, P492, DOI 10.1063/1.479383##SAITO R, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.027401##SAITO S, 1998, J CHEM PHYS, V108, P240, DOI 10.1063/1.475375##TANIMURA Y, 1993, J CHEM PHYS, V99, P9496, DOI 10.1063/1.465484##TANIMURA Y, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.082001##THOLE BT, 1981, CHEM PHYS, V59, P341, DOI 10.1016/0301-0104(81)85176-2##VAN ZON R, 2002, PHYS REV E, V65, DOI 10.1103/PHYSREVE.65.011106",17,2020-11-20,NA
J,WOS:000243415300038,2006,SIMULATIONS OF THE DYNAMICS OF THERMAL UNDULATIONS IN LIPID BILAYERS IN THE TENSIONLESS STATE AND UNDER STRESS,"THE RELAXATION PROCESSES OF HEIGHT UNDULATIONS AND DENSITY FLUCTUATIONS IN A MEMBRANE HAVE BEEN STUDIED BY MOLECULAR DYNAMICS SIMULATIONS OF A COARSE GRAINED AMPHIPHILIC BILAYER MODEL. WE OBSERVE A DOUBLE EXPONENTIAL DECAY IN THEIR TIME CORRELATIONS, WITH RELAXATION RATES IN GOOD QUANTITATIVE AGREEMENT WITH THE THEORY BY SEIFERT AND LANGER [EUROPHYS. LETT. 23, 71 (1993)]. INTERMONOLAYER FRICTION DUE TO SLIPPAGE BETWEEN THE TWO MONOLAYERS IS SHOWN TO BE THE DOMINANT DISSIPATIVE MECHANISM AT THE HIGH WAVE NUMBERS, Q>10 MU M(-1), TYPICALLY ENCOUNTERED IN COMPUTER SIMULATIONS. WE BRIEFLY DISCUSS THE RAMIFICATIONS OF THE SLOW UNDULATORY RELAXATION PROCESS FOR THE CALCULATION OF BENDING RIGIDITIES FROM THE STATIC UNDULATION STRUCTURE FACTORS. THE RELAXATION RATES ARE SENSITIVE TO THE SURFACE TENSION, AND AT HIGH ELONGATIONS AN OSCILLATORY CONTRIBUTION IS OBSERVED IN THE TIME CORRELATION OF THE UNDULATIONS. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",NEUTRON SPIN-ECHO; MOLECULAR-DYNAMICS; SHAPE FLUCTUATIONS; INTERMONOLAYER FRICTION; MEMBRANE UNDULATIONS; AMPHIPHILIC BILAYER; SURFACE VISCOSITY; LIGHT-SCATTERING; FLUID MEMBRANES; VESICLES,NA,JOURNAL OF CHEMICAL PHYSICS,"SHKULIPA, SA##DEN OTTER, WK##BRIELS, WJ","UNIV TWENTE, FAC SCI & TECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"ABRAMOWITZ M, 1979, HDB MATH FUNCTIONS##ALLEN M. P., 1987, COMPUTER SIMULATION##ALTHOFF G, 2003, MOL CRYST LIQ CRYST, V394, P93, DOI 10.1080/15421400390193693##BECKER W. M., 1991, WORLD CELL##BIVAS I, 1999, COLLOID SURFACE A, V157, P21, DOI 10.1016/S0927-7757(99)00113-2##BONIFACINO JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1##BRANNIGAN G, 2006, BIOPHYS J, V90, P1501, DOI 10.1529/BIOPHYSJ.105.075838##CHANDLER D., 1987, INTRO MODERN STAT ME##CHIZMADZHEV YA, 1999, BIOPHYS J, V76, P2951, DOI 10.1016/S0006-3495(99)77450-3##DEN OTTER WK, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2132287##DEN OTTER WK, 2003, J CHEM PHYS, V118, P4712, DOI 10.1063/1.1543941##DIMOVA R, 2002, EUR PHYS J E, V7, P241, DOI 10.1140/EPJE/I200101032##DIMOVA R, 1999, EUR PHYS J B, V12, P589, DOI 10.1007/S100510051042##DUWE HP, 1990, PHYSICA A, V163, P410, DOI 10.1016/0378-4371(90)90349-W##EVANS E, 1994, CHEM PHYS LIPIDS, V73, P39, DOI 10.1016/0009-3084(94)90173-2##EVANS E, 2003, BIOPHYS J, V85, P2342, DOI 10.1016/S0006-3495(03)74658-X##EVANS E, 1992, SPRINGER P, V66, P148##FILIPPOV A, 2003, BIOPHYS J, V84, P3079, DOI 10.1016/S0006-3495(03)70033-2##FOURNIER JB, 2001, PHYS REV LETT, V86, P4970, DOI 10.1103/PHYSREVLETT.86.4970##FRENKEL D., 2002, UNDERSTANDING MOL SI##FREYSSINGEAS E, 1997, J PHYS II, V7, P913, DOI 10.1051/JP2:1997162##GOETZ R, 1999, PHYS REV LETT, V82, P221, DOI 10.1103/PHYSREVLETT.82.221##GOETZ R, 1998, J CHEM PHYS, V108, P7397, DOI 10.1063/1.476160##HELFRICH W, 1984, NUOVO CIMENTO D, V3, P137, DOI 10.1007/BF02452208##HENRIKSEN JR, 2004, EUR PHYS J E, V14, P149, DOI 10.1140/EPJE/I2003-10146-Y##KRAMER L, 1971, J CHEM PHYS, V55, P2097, DOI 10.1063/1.1676380##KRAUS M, 1994, J PHYS II, V4, P1117, DOI 10.1051/JP2:1994191##LINDAHL E, 2000, BIOPHYS J, V79, P426, DOI 10.1016/S0006-3495(00)76304-1##LIPOWSKY R, 1994, BIOPHYS CHEM, V49, P27, DOI 10.1016/0301-4622(93)E0079-K##MARRINK SJ, 2001, J PHYS CHEM B, V105, P6122, DOI 10.1021/JP0103474##MELEARD P, 1990, EUROPHYS LETT, V11, P355, DOI 10.1209/0295-5075/11/4/011##MERKEL R, 1989, J PHYS-PARIS, V50, P1535, DOI 10.1051/JPHYS:0198900500120153500##MIAO L, 2002, EUR PHYS J E, V9, P143, DOI 10.1140/EPJE/I2002-10068-2##MILNER ST, 1987, PHYS REV A, V36, P4371, DOI 10.1103/PHYSREVA.36.4371##PFEIFFER W, 1993, EUROPHYS LETT, V23, P457, DOI 10.1209/0295-5075/23/6/013##POTT T, 2002, EUROPHYS LETT, V59, P87, DOI 10.1209/EPL/I2002-00163-6##RAWICZ W, 2000, BIOPHYS J, V79, P328, DOI 10.1016/S0006-3495(00)76295-3##SAFRAN SA, 2003, STAT THERMODYNAMICS##SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/JPHYS:019840045090145700##SEIFERT U, 1994, BIOPHYS CHEM, V49, P13, DOI 10.1016/0301-4622(93)E0077-I##SEIFERT U, 1997, ADV PHYS, V46, P13, DOI 10.1080/00018739700101488##SEIFERT U, 1993, EUROPHYS LETT, V23, P71, DOI 10.1209/0295-5075/23/1/012##SHKULIPA SA, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.178302##SHKULIPA SA, 2005, BIOPHYS J, V89, P823, DOI 10.1529/BIOPHYSJ.105.062653##SMITH W, 1996, J MOL GRAPHICS, V14, P136, DOI 10.1016/S0263-7855(96)00043-4##STRYER L., 1995, BIOCHEMISTRY##TAKEDA T, 1999, J PHYS CHEM SOLIDS, V60, P1375, DOI 10.1016/S0022-3697(99)00122-5##TOLPEKINA TV, 2004, J CHEM PHYS, V121, P12060, DOI 10.1063/1.1815296##TOLPEKINA TV, 2004, J CHEM PHYS, V121, P8014, DOI 10.1063/1.1796254##VAZ WLC, 1985, BIOCHEMISTRY-US, V24, P781, DOI 10.1021/BI00324A037##WAUGH RE, 1982, BIOPHYS J, V38, P29, DOI 10.1016/S0006-3495(82)84527-X##YEUNG A, 1995, J PHYS II, V5, P1501, DOI 10.1051/JP2:1995196##ZILMAN AG, 1996, PHYS REV LETT, V77, P4788, DOI 10.1103/PHYSREVLETT.77.4788",27,2020-11-20,NA
J,WOS:000243107100002,2006,LINEARIZATION OF A RADIATIVE TRANSFER MODEL IN SPHERICAL GEOMETRY,"[1] FOR THE INTERPRETATION OF SATELLITE LIMB OBSERVATIONS WE INVESTIGATE THE LINEARIZATION CAPABILITY OF SPHERICAL RADIATIVE TRANSFER IN THE ULTRAVIOLET AND VISIBLE PART OF THE SOLAR SPECTRUM, WHERE MULTIPLE SCATTERING OF LIGHT COMPLICATES THE MODEL SIMULATIONS. FROM PLANE-PARALLEL RADIATIVE TRANSFER IT IS KNOWN THAT THE FORWARD-ADJOINT PERTURBATION THEORY PROVIDES A POWERFUL LINEARIZATION TOOL. ITS APPLICATION TO LIMB MEASUREMENT SIMULATIONS IS THE SUBJECT OF THIS PAPER. FIRST, WE SOLVE THE SCALAR RADIATIVE TRANSFER PROBLEM IN SPHERICAL GEOMETRY IN ITS FORWARD AND ADJOINT FORMULATION. SUBSEQUENTLY, WE APPLY THE PERTURBATION THEORY APPROACH IN THE CALCULATION OF THE DERIVATIVES OF THE INTENSITY AT THE TOP OF THE ATMOSPHERE WITH RESPECT TO THE ABSORPTION PROPERTIES OF A TRACE GAS SPECIES IN THE CASE OF A LIMB-VIEWING SATELLITE INSTRUMENT. THE CALCULATED DERIVATIVES ARE VALIDATED WITH A REFERENCE METHOD, AND THE AGREEMENT IN THE UPPER ATMOSPHERE IS VERY GOOD, WHEREAS DEVIATIONS OCCUR BELOW THE TANGENT HEIGHT. HERE THE DETERMINATION OF THE DERIVATIVES IS CLEARLY SENSITIVE TO THE DISCRETIZATION OF THE PROBLEM. FINALLY, WE PERFORM AN ANALYSIS FOR DIFFERENT VIEWING SCENARIOS TO CHARACTERIZE THE CAPABILITY OF THE DESCRIBED LINEARIZATION APPROACH.",DIFFERENTIAL-INTEGRAL APPROACH; OZONE PROFILE RETRIEVAL; WEIGHTING FUNCTIONS; SHELL ATMOSPHERE; SUNLIGHT; RESPECT,NA,JOURNAL OF GEOPHYSICAL RESEARCH-ATMOSPHERES,"WALTER, HH##LANDGRAF, J##SPADA, F##DOICU, A","NETHERLAND INST SPACE RES, NL-3584 CA UTRECHT, NETHERLANDS. INST METHOD FERNERKUNDUNG, GERMAN AEROSP CTR, D-82234 WESSLING, GERMANY. UNIV UTRECHT, INST MARINE & ATMOSPHER RES UTRECHT, NL-3584 CA UTRECHT, NETHERLANDS.",METEOROLOGY & ATMOSPHERIC SCIENCES,METEOROLOGY & ATMOSPHERIC SCIENCES,"BELL G., 1970, NUCL REACTOR THEORY##BOVENSMANN H, 1999, J ATMOS SCI, V56, P127, DOI 10.1175/1520-0469(1999)056<0127:SMOAMM>2.0.CO;2##BOX MA, 1989, BEITR PHYS ATMOS, V62, P193##BOX MA, 1988, BEITR PHYS ATMOS, V61, P303##CASE K.M., 1967, LINEAR TRANSPORT THE##HASEKAMP OP, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005260##HASEKAMP OP, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002387##HERMAN BM, 1994, APPL OPTICS, V33, P1760, DOI 10.1364/AO.33.001760##KAISER JW, 2003, J QUANT SPECTROSC RA, V77, P273, DOI 10.1016/S0022-4073(02)00125-5##KUNASZ P, 1988, J QUANT SPECTROSC RA, V39, P67, DOI 10.1016/0022-4073(88)90021-0##LANDGRAF J, 2001, J GEOPHYS RES-ATMOS, V106, P27291, DOI 10.1029/2001JD000636##LANDGRAF J, 2002, J QUANT SPECTROSC RA, V72, P327, DOI 10.1016/S0022-4073(01)00126-1##LEWINS J., 1965, IMPORTANCE ADJOINT F##LOUGHMAN RP, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003854##MARCHUK G., 1964, COSMIC RES, V2, P394##MCLINDEN CA, 2002, CAN J PHYS, V80, P375, DOI 10.1139/P01-156##OIKARINEN L, 1999, J GEOPHYS RES-ATMOS, V104, P31261, DOI 10.1029/1999JD900969##PAYNE WF, 1995, 46 INT ASTR C AM I A##POSTYLYAKOV OV, 2004, J QUANT SPECTROSC RA, V88, P297, DOI 10.1016/J.JQSRT.2004.01.009##ROZANOV A, 2001, J QUANT SPECTROSC RA, V69, P491, DOI 10.1016/S0022-4073(00)00100-X##ROZANOV AV, 2000, J GEOPHYS RES-ATMOS, V105, P22937, DOI 10.1029/2000JD900378##ROZANOV VV, 1998, J QUANT SPECTROSC RA, V60, P277, DOI 10.1016/S0022-4073(97)00150-7##ROZANOV VV, 2002, ADV SPACE RES-SERIES, V29, P1831, DOI 10.1016/S0273-1177(02)00095-9##SPADA F, 2006, ATMOS CHEM PHYS DISC, V6, P1199##USTINOV E. A., 1992, COSMIC RESEARCH, V30, P170##USTINOV E. A., 1991, COSMIC RESEARCH, V29, P785##USTINOV E. A., 1991, COSMIC RESEARCH, V29, P519##WALTER HH, 2005, J QUANT SPECTROSC RA, V95, P175, DOI 10.1016/J.JQSRT.2004.08.043",8,2020-11-20,NA
J,WOS:000243108100002,2006,LATERAL ENTRAPMENT OF SEDIMENT IN TIDAL ESTUARIES: AN IDEALIZED MODEL STUDY,"[ 1] TWO PHYSICAL MECHANISMS LEADING TO LATERAL ACCUMULATION OF SEDIMENT IN TIDALLY DOMINATED ESTUARIES ARE INVESTIGATED, INVOLVING CORIOLIS FORCING AND LATERAL DENSITY GRADIENTS. AN IDEALIZED MODEL IS USED THAT CONSISTS OF THE THREE-DIMENSIONAL SHALLOW WATER EQUATIONS AND SEDIMENT MASS BALANCE. CONDITIONS ARE ASSUMED TO BE UNIFORM IN THE ALONG-ESTUARY DIRECTION. A SEMIDIURNAL TIDAL DISCHARGE AND TIDALLY AVERAGED DENSITY GRADIENTS ARE PRESCRIBED. THE EROSIONAL SEDIMENT FLUX AT THE BED DEPENDS BOTH ON THE BED SHEAR STRESS AND ON THE AMOUNT OF SEDIMENT AVAILABLE IN MUD REACHES FOR RESUSPENSION. THE DISTRIBUTION OF MUD REACHES OVER THE BED IS SELECTED SUCH THAT SEDIMENT TRANSPORT IS IN MORPHODYNAMIC EQUILIBRIUM, THAT IS, TIDALLY AVERAGED EROSION AND DEPOSITION OF SEDIMENT AT THE BED BALANCE. ANALYTICAL SOLUTIONS ARE OBTAINED BY USING PERTURBATION ANALYSIS. RESULTS SUGGEST THAT IN MOST ESTUARIES LATERAL DENSITY GRADIENTS INDUCE MORE SEDIMENT TRANSPORT THAN CORIOLIS FORCING. WHEN FRICTIONAL FORCES ARE SMALL (EKMAN NUMBER E < 0.02), THE CORIOLIS MECHANISM DOMINATES AND ACCUMULATES SEDIMENT ON THE RIGHT BANK ( LOOKING UP-ESTUARY IN THE NORTHERN HEMISPHERE). ON THE OTHER HAND, WHEN FRICTIONAL FORCES ARE MODERATE TO HIGH ( E > 0.02), THE LATERAL DENSITY GRADIENT MECHANISM DOMINATES AND ENTRAPS SEDIMENT IN AREAS WITH FRESHER WATER. RESULTS ALSO SHOW THAT THE LATERAL SEDIMENT TRANSPORT INDUCED BY THE SEMIDIURNAL TIDAL FLOW IS SIGNIFICANT WHEN FRICTIONAL FORCES ARE SMALL ( E SIMILAR TO 0.02). MODEL PREDICTIONS ARE IN GOOD AGREEMENT WITH OBSERVATIONS FROM THE JAMES RIVER ESTUARY.",TURBIDITY MAXIMUM; CIRCULATION; VARIABILITY; PATTERNS; STRAIGHT,NA,JOURNAL OF GEOPHYSICAL RESEARCH-OCEANS,"HUIJTS, KMH##SCHUTTELAARS, HM##DE SWART, HE##VALLE-LEVINSON, A","UNIV UTRECHT, INST MARINE & ATMOSPHER RES UTRECHT, NL-3584 CC UTRECHT, NETHERLANDS. DELFT UNIV TECHNOL, DELFT INST APPL MATH, NL-2600 GA DELFT, NETHERLANDS. UNIV FLORIDA, DEPT CIVIL & COASTAL ENGN, GAINESVILLE, FL 32611 USA.",OCEANOGRAPHY,OCEANOGRAPHY,"BATTISTO GM, 2003, COASTAL SEDIMENTS 20##BOWDEN KF, 1959, GEOPHYS J ROY ASTR S, V2, P288, DOI 10.1111/J.1365-246X.1959.TB05801.X##DYER K.R., 1973, ESTUARIES PHYS INTRO##DYER KR, 1986, COASTAL ESTUARINE SE##FESTA JF, 1978, ESTUAR COAST MAR SCI, V7, P347, DOI 10.1016/0302-3524(78)90087-7##FESTA JF, 1976, ESTUAR COAST MAR SCI, V4, P309, DOI 10.1016/0302-3524(76)90063-3##FISCHER H.B., 1979, MIXING INLAND COASTA##FRIEDRICHS CT, 1994, J GEOPHYS RES-OCEANS, V99, P3321, DOI 10.1029/93JC03219##FRIEDRICHS CT, 1998, PHYSICS OF ESTUARIES AND COASTAL SEAS, P315##FRIEDRICHS CT, 2003, COASTAL SEDIMENTS 20##GEYER WR, 2001, ESTUARIES, V24, P670, DOI 10.2307/1352875##GEYER WR, 1998, PHYSICS OF ESTUARIES AND COASTAL SEAS, P115##GEYER WR, 1993, ESTUARIES, V16, P113, DOI 10.2307/1352769##GILL AE, 1982, INT GEOPHYS SER, V30##HANSEN DONALD V., 1965, J MAR RES, V23, P104##JAY DA, 1990, J GEOPHYS RES-OCEANS, V95, P733, DOI 10.1029/JC095IC01P00733##JAY DA, 1994, J GEOPHYS RES-OCEANS, V99, P20445, DOI 10.1029/94JC00971##KAPPENBERG J, 2001, ESTUARIES, V24, P699, DOI 10.2307/1352878##KASAI A, 2000, J GEOPHYS RES-OCEANS, V105, P16961, DOI 10.1029/2000JC900058##LERCZAK JA, 2004, J PHYS OCEANOGR, V34, P1410, DOI 10.1175/1520-0485(2004)034<1410:MTLCIS>2.0.CO;2##LIN J, 2001, ESTUARIES, V24, P707, DOI 10.2307/1352879##MUNK WH, 1948, J MAR RES, V7, P276##NICHOLS M. M., 1972, GEOLOGICAL SOC AM ME, V133, P169##NORTH EW, 2004, ESTUARIES, V27, P132, DOI 10.1007/BF02803567##OFFICER C.B., 1976, PHYS OCEANOGRAPHY ES##PRANDLE D, 2004, ESTUAR COAST SHELF S, V59, P385, DOI 10.1016/J.ECSS.2003.10.001##SANFORD LP, 2001, ESTUARIES, V24, P655, DOI 10.2307/1352874##SCHRAMKOWSKI GP, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2000JC000693##UNCLES RJ, 1993, ESTUARIES, V16, P126, DOI 10.2307/1352770##VALLE-LEVINSON A, 2003, J PHYS OCEANOGR, V33, P2375, DOI 10.1175/1520-0485(2003)033<2375:EOBFAR>2.0.CO;2##VALLE-LEVINSON A, 2000, J GEOPHYS RES-OCEANS, V105, P3413, DOI 10.1029/1999JC900307##VALLE-LEVINSON A, 2001, ESTUAR COAST SHELF S, V53, P825, DOI 10.1006/ECSS.2000.0813##VALLE-LEVINSON A, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2003JC001786##VALLELEVINSON A, 1997, J MARINE SYST, V12, P221, DOI 10.1016/S0924-7963(96)00099-1##VAN RIJN L.C., 1993, PRINCIPLES SEDIMENT##VANDEKREEKE J, 1990, SEA A, V9, P495##WINTERWERP JC, 2002, CONT SHELF RES, V22, P1339, DOI 10.1016/S0278-4343(02)00010-9##WOODRUFF JD, 2001, MAR GEOL, V179, P105, DOI 10.1016/S0025-3227(01)00182-7",63,2020-11-20,NA
J,WOS:000242825400034,2006,TETRAPYRROLE SINGLET EXCITED STATE QUENCHING BY CAROTENOIDS IN AN ARTIFICIAL PHOTOSYNTHETIC ANTENNA,"TWO ARTIFICIAL PHOTOSYNTHETIC ANTENNA MODELS CONSISTING OF A SI PHTHALOCYANINE ( PC) BEARING TWO AXIALLY ATTACHED CAROTENOID MOIETIES HAVING EITHER 9 OR 10 CONJUGATED DOUBLE BONDS ARE USED TO ILLUSTRATE SOME OF THE FUNCTION OF CAROTENOIDS IN PHOTOSYNTHETIC MEMBRANES. BOTH MODELS STUDIED IN TOLUENE, METHYLTETRAHYDROFURAN, AND BENZONITRILE EXHIBITED CHARGE SEPARATED STATES OF THE TYPE C.+- PC.- CONFIRMING THAT THE QUENCHING OF THE PC S-1 STATE IS DUE TO PHOTOINDUCED ELECTRON TRANSFER. IN HEXANE, THE PC S1 STATE OF THE 10 DOUBLE BOND CAROTENOID-PC MODEL WAS SLIGHTLY QUENCHED BUT THE C.+- PC.- TRANSIENT WAS NOT SPECTROSCOPICALLY DETECTED. A SEMICLASSICAL ANALYSIS OF THE DATA IN HEXANE AT TEMPERATURES RANGING FROM 180 TO 320 K WAS USED TO DEMONSTRATE THAT PHOTOINDUCED ELECTRON TRANSFER COULD OCCUR. THE MODEL BEARING THE 10 DOUBLE BOND CAROTENOIDS EXHIBITS BIEXPONENTIAL FLUORESCENCE DECAY IN TOLUENE AND IN HEXANE, WHICH IS INTERPRETED IN TERMS OF AN EQUILIBRIUM MIXTURE OF TWO ISOMERS COMPRISING S-CIS AND S-TRANS CONFORMERS OF THE CAROTENOID. THE SHORTER FLUORESCENCE LIFETIME IS ASSOCIATED WITH AN S-CIS CAROTENOID CONFORMER WHERE THE CLOSE APPROACH BETWEEN THE DONOR AND ACCEPTOR MOIETIES PROVIDES THROUGH-SPACE ELECTRONIC COUPLING IN ADDITION TO THE THROUGH-BOND COMPONENT.",NUCLEAR MAGNETIC-RESONANCE; GREEN PLANTS; ELECTRON-TRANSFER; GERMANIUM PHTHALOCYANINES; CHLOROPHYLL FLUORESCENCE; XANTHOPHYLL CYCLE; ENERGY-TRANSFER; SHIFT REAGENTS; HEMIPORPHYRAZINES; ELECTROCHEMISTRY,NA,JOURNAL OF PHYSICAL CHEMISTRY B,"PALACIOS, RE##KODIS, G##HERRERO, C##OCHOA, EM##GERVALDO, M##GOULD, SL##KENNIS, JTM##GUST, D##MOORE, TA##MOORE, AL","ARIZONA STATE UNIV, CTR STUDY EARLY EVENTS PHOTOSYNTH, DEPT CHEM & BIOCHEM, TEMPE, AZ 85287 USA. VRIJE UNIV AMSTERDAM, DEPT BIOPHYS, DIV PHYS & ASTRON, FAC SCI, NL-1081 HV AMSTERDAM, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"BARBARA PF, 1996, J PHYS CHEM-US, V100, P13168##BERERA R, 2006, P NATL ACAD SCI USA, V103, P5343, DOI 10.1073/PNAS.0508530103##DREUW A, 2003, PHYS CHEM CHEM PHYS, V5, P3247, DOI 10.1039/B304944B##DREUW A, 2003, J PHYS CHEM B, V107, P6500, DOI 10.1021/JP034562R##ESPOSITO JN, 1967, INORG CHEM, V6, P1116, DOI 10.1021/IC50052A011##FREIBERG A, 1998, J PHYS CHEM B, V102, P10974, DOI 10.1021/JP982265U##FUNGO F, 2003, PHYS CHEM CHEM PHYS, V5, P469, DOI 10.1039/B209694C##GILMORE AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/J.1399-3054.1997.990127.X##GOULD SL, 2004, J PHYS CHEM B, V108, P10566, DOI 10.1021/JP040143Y##HERMANT RM, 1993, J AM CHEM SOC, V115, P2080, DOI 10.1021/JA00058A088##HOLT NE, 2005, SCIENCE, V307, P433, DOI 10.1126/SCIENCE.1105833##HOLT NE, 2004, BIOCHEMISTRY-US, V43, P8281, DOI 10.1021/BI0494020##HORTON P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/ANNUREV.ARPLANT.47.1.655##JANSON TR, 1969, J AM CHEM SOC, V91, P5210, DOI 10.1021/JA01047A004##JORTNER J, 1980, J AM CHEM SOC, V102, P6676, DOI 10.1021/JA00542A004##JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142##KANE AR, 1968, INORG CHEM, V7, P2588, DOI 10.1021/IC50070A025##KODIS G, 2004, J PHYS CHEM B, V108, P414, DOI 10.1021/JP036139O##KOYAMA T, 1994, INORG CHIM ACTA, V218, P41, DOI 10.1016/0020-1693(93)03783-7##KURNIKOV IV, 1997, J AM CHEM SOC, V119, P5690, DOI 10.1021/JA970309R##LIDE D. R., 2003, CRC HDB CHEM PHYS, DOI [10.1136/OEM.53.7.504, DOI 10.1136/OEM.53.7.504]##LIU YP, 1995, J PHYS CHEM-US, V99, P12382, DOI 10.1021/J100033A004##MA YZ, 2003, P NATL ACAD SCI USA, V100, P4377, DOI 10.1073/PNAS.0736959100##MARINO-OCHOA E, 2002, PHOTOCHEM PHOTOBIOL, V76, P116, DOI 10.1562/0031-8655(2002)076<0116:HEETFC>2.0.CO;2##MARINOOCHOA E, 2002, THESIS ARIZONA STATE##MASKASKY JE, 1972, J AM CHEM SOC, V94, P2132, DOI 10.1021/JA00761A068##MASKASKY JE, 1973, J AM CHEM SOC, V95, P1443, DOI 10.1021/JA00786A016##NIEDZWIEDZKI D, 2005, CHEM PHYS LETT, V415, P308, DOI 10.1016/J.CPLETT.2005.09.010##POLIVKA T, 2004, CHEM REV, V104, P2021, DOI 10.1021/CR020674N##RACKETT HG, 1970, J CHEM ENG DATA, V15, P514, DOI 10.1021/JE60047A012##RIAZI MR, 1999, CHEM ENG COMMUN, V176, P175, DOI 10.1080/00986449908912152##SALTIEL J, 2001, J PHYS CHEM A, V105, P7569, DOI 10.1021/JP011493C##SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/ANNUREV.BB.19.060190.001505##SILVER J, 2001, INORG CHEM, V40, P5434, DOI 10.1021/IC001120A##SILVER J, 1998, INORG CHEM, V37, P411, DOI 10.1021/IC970934X##SUTTON LE, 1967, INORG CHEM, V6, P1869, DOI 10.1021/IC50056A023##VAN AMERONGEN H, 2001, J PHYS CHEM B, V105, P604, DOI 10.1021/JP0028406##WASIELEWSKI MR, 1988, J AM CHEM SOC, V110, P7219, DOI 10.1021/JA00229A050##WOHLFARTH C, 1991, STAT DIELECTRIC CONS, V6, P521",14,2020-11-20,NA
J,WOS:000242963900017,2006,CIRCUIT DEPENDENCE OF THE DIAMETER OF PULSED POSITIVE STREAMERS IN AIR,"THE DIAMETER AND BRANCHING STRUCTURE OF POSITIVE STREAMERS IN AMBIENT AIR ARE INVESTIGATED WITH A FAST ICCD CAMERA. WE USE DIFFERENT PULSED POWER CIRCUITS AND FIND THAT THEY GENERATE DIFFERENT SPATIAL STREAMER STRUCTURES. THE ELECTRODES HAVE A POINT-PLANE GEOMETRY AND A DISTANCE OF 40 OR 80 MM, AND THE PEAK VOLTAGES OVER THE DISCHARGE GAP ARE UP TO 60 KV. DEPENDING ON CIRCUIT AND PEAK VOLTAGE, WE OBSERVE STREAMERS WITH DIAMETERS VARYING GRADUALLY BETWEEN 0.2 AND 2.5 MM. THE STREAMER VELOCITY INCREASES WITH THE DIAMETER, RANGING FROM 0.07 TO 1.5 MM NS(-1), WHILE THE CURRENT DENSITY WITHIN THE STREAMERS STAYS ALMOST CONSTANT. THE THICKER STREAMERS EXTEND MUCH FURTHER BEFORE THEY BRANCH THAN THE THINNER ONES. THE PULSED POWER SUPPLIES ARE A SWITCHED CAPACITOR SUPPLY WITH AN INTERNAL RESISTANCE OF 1 K OMEGA AND A TRANSMISSION LINE TRANSFORMER SUPPLY WITH AN IMPEDANCE OF 200 OMEGA; ADDITIONAL RESISTORS CHANGE THE IMPEDANCE AS WELL AS THE VOLTAGE RISE TIME IN THE CASE OF THE CAPACITOR SUPPLY. WE OBSERVE THAT SHORT RISE TIMES AND LOW IMPEDANCE CREATE THICK STREAMERS CLOSE TO THE POINTED ELECTRODE, WHILE A LONGER RISE TIME AS WELL AS A HIGHER IMPEDANCE CREATE THINNER STREAMERS AT THE SAME PEAK VOLTAGE OVER THE DISCHARGE.",NEGATIVE STREAMERS; HIGH-VOLTAGE; DISCHARGE; PROPAGATION; TRANSITION; CORONA; PHOTOIONIZATION; REACTOR; SPRITES; FIELD,NA,JOURNAL OF PHYSICS D-APPLIED PHYSICS,"BRIELS, TMP##KOS, J##VAN VELDHUIZEN, EM##EBERT, U","TECH UNIV EINDHOVEN, DEPT APPL PHYS, NL-5600 MB EINDHOVEN, NETHERLANDS. CENT WISKUNDE & INFORMAT, NL-1090 GB AMSTERDAM, NETHERLANDS.","PHYSICS, APPLIED",PHYSICS,"ARRAYAS M, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.174502##BASTIEN F, 1979, J PHYS D APPL PHYS, V12, P249, DOI 10.1088/0022-3727/12/2/010##BLOM P, 1994, GASEOUS DIELECTRICS, V7##BRIELS TMP, 2005, 17 ICPIG EINDH NETH##CREYGHTON YLM, 1993, NATO ASI SERIES G A, V34, P205##CUMMER SA, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024969##D'YAKONOV M. I., 1988, SOVIET PHYSICS - JETP, V67, P1049##DAWSON GA, 1965, Z PHYS, V183, P159, DOI 10.1007/BF01380792##EBERT U, 2006, PLASMA SOURCES SCI T, V15, PS118, DOI 10.1088/0963-0252/15/2/S14##GERKEN EA, 2002, GEOPHYS RES LETT, V29, P82##GRABOWSKI LR, 2006, PLASMA CHEM PLASMA P, V26, P3, DOI 10.1007/S11090-005-8721-8##GRABOWSKI LR, 2005, 17 ICPIG EINDH NETH##GRAVENDEEL B, 1987, THESIS EINDHOVEN U T##KULIKOVSKY AA, 1998, PHYS REV E, V57, P7066, DOI 10.1103/PHYSREVE.57.7066##LIU N, 2006, J PHYS D APPL PHYS, V39, P327, DOI 10.1088/0022-3727/39/2/013##LIU NY, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2003JA010064##LUQUE A, 2006, PHYSICS0609247##MEEK J. M., 1953, ELECT BREAKDOWN GASE##MONTIJN C, 2006, J COMPUT PHYS, V219, P801, DOI 10.1016/J.JCP.2006.04.017##MONTIJN C, 2006, PHYS REV E, V73, DOI 10.1103/PHYSREVE.73.065401##MONTIJN C, 2006, J PHYS D APPL PHYS, V39, P2979, DOI 10.1088/0022-3727/39/14/017##PANCHESHNYI S, 2005, PHYS REV E, V71, DOI 10.1103/PHYSREVE.71.016407##PANCHESHNYI SV, 2003, J PHYS D APPL PHYS, V36, P2683, DOI 10.1088/0022-3727/36/21/014##PASKO VP, 2002, NATURE, V416, P152, DOI 10.1038/416152A##RAETHER H, 1939, Z PHYS, V112, P464, DOI 10.1007/BF01340229##RAIZER YP, 1998, PLASMA PHYS REP, V24, P700##ROCCO A, 2002, PHYS REV E, V66, DOI 10.1103/PHYSREVE.66.035102##SENTMAN DD, 1995, GEOPHYS RES LETT, V22, P1205, DOI 10.1029/95GL00583##VAN VELDHUIZEN EM, 2002, J PHYS D APPL PHYS, V35, P2169, DOI 10.1088/0022-3727/35/17/313##VAN VELDHUIZEN EM, 2002, IEEE T PLASMA SCI, V30, P162, DOI 10.1109/TPS.2002.1003974##VANVELDHUIZEN EM, 2000, ELECT DISCHARGES ENV, P420##WATERS RT, 1964, PHILOS TR R SOC S-A, V256, P185, DOI 10.1098/RSTA.1964.0003##WINANDS GJJ, 2006, J PHYS D APPL PHYS, V39, P3010, DOI 10.1088/0022-3727/39/14/020##YAN K, 2001, REV SCI INSTRUM, V72, P2443, DOI 10.1063/1.1367358##ZHELEZNYAK MB, 1982, HIGH TEMP+, V20, P357",87,2020-11-20,NA
J,WOS:000242963900019,2006,A STUDY OF STARK EFFECTS OF RYDBERG P STATES OF NOBLE GAS ATOMS,WE HAVE STUDIED THE STARK EFFECT FOR RYDBERG P STATES OF NOBLE GAS ATOMS USING LASER OPTOGALVANIC SPECTROSCOPY. THE MEASUREMENTS WERE PERFORMED IN THE SHEATH REGION OF NOBLE GAS GLOW DISCHARGES. LASER EXCITATION FROM METASTABLE STATES TO NP STATES WAS MONITORED BY OPTOGALVANIC SPECTROSCOPY. CLEAR STARK SHIFTS WERE OBSERVED AND THE EXPERIMENTAL RESULTS WERE COMPARED WITH A THEORETICAL CALCULATION BASED ON SOLVING THE SCHRODINGER EQUATION OF NOBLE GAS ATOMS IN AN ELECTRIC FIELD. THERE WAS GOOD AGREEMENT BETWEEN THE CALCULATION RESULTS AND THE EXPERIMENTAL RESULTS. THE ANALYSIS SHOWS THAT THE STARK SHIFT OF NP STATES OF NOBLE GAS ATOMS CAN BE USED FOR ELECTRIC FIELD MEASUREMENTS. THIS METHOD CAN BE A USEFUL ALTERNATIVE TO ELECTRIC FIELD METHODS BASED ON EXCITATION TO NF STATES BECAUSE OF THE HIGHER TRANSITION PROBABILITY OF NP STATES.,ELECTRIC-FIELDS; LASER SPECTROSCOPY; KRYPTON; XENON; SERIES,NA,JOURNAL OF PHYSICS D-APPLIED PHYSICS,"JIANG, T##BOWDEN, MD##WAGENAARS, E##STOFFELS, E##KROESEN, GMW","EINDHOVEN UNIV TECHNOL, DEPT APPL PHYS, NL-5600 MB EINDHOVEN, NETHERLANDS. OPEN UNIV, DEPT PHYS & ASTRON, MILTON KEYNES MK7 6AA, BUCKS, ENGLAND.","PHYSICS, APPLIED",PHYSICS,"BOUNAKHLA M, 1993, J PHYS B-AT MOL OPT, V26, P345, DOI 10.1088/0953-4075/26/3/009##BREVET PF, 1990, PHYS REV A, V42, P1460, DOI 10.1103/PHYSREVA.42.1460##DELSART C, 1981, J PHYS B-AT MOL OPT, V14, P4241, DOI 10.1088/0022-3700/14/22/010##DELSART C, 1983, PHYS REV A, V28, P845, DOI 10.1103/PHYSREVA.28.845##DOUGHTY DK, 1984, PHYS LETT A, V103, P41, DOI 10.1016/0375-9601(84)90045-8##ERNST WE, 1988, PHYS REV A, V37, P4172, DOI 10.1103/PHYSREVA.37.4172##GAVRILENKO VP, 2000, PHYS REV E, V62, P7201, DOI 10.1103/PHYSREVE.62.7201##JIANG T, 2006, NEW J PHYS, V8, DOI 10.1088/1367-2630/8/9/202##KELLEHER DE, 1987, PHYS REV A, V35, P3327, DOI 10.1103/PHYSREVA.35.3327##KNIGHT RD, 1985, PHYS REV A, V32, P896, DOI 10.1103/PHYSREVA.32.896##LABASTIE P, 1982, J PHYS B-AT MOL OPT, V15, P2595, DOI 10.1088/0022-3700/15/16/010##LITTMAN MG, 1978, PHYS REV LETT, V41, P103, DOI 10.1103/PHYSREVLETT.41.103##LITTMAN MG, 1976, PHYS REV LETT, V36, P788, DOI 10.1103/PHYSREVLETT.36.788##PELLARIN M, 1988, J PHYS B-AT MOL OPT, V21, P3833, DOI 10.1088/0953-4075/21/23/005##RACAH G, 1942, PHYS REV, V61, P537, DOI 10.1103/PHYSREV.61.537##RAIZER Y P, 1991, GAS DISCHARGE PHYS##SOBELMAN II, 1979, ATMOIC SPECTRA RAD T##ZIMMERMAN ML, 1979, PHYS REV A, V20, P2251, DOI 10.1103/PHYSREVA.20.2251",1,2020-11-20,NA
J,WOS:000243059000016,2006,FALLS IN PATIENTS WITH NEUROMUSCULAR DISORDERS,WE MONITORED THE INCIDENCE AND CONSEQUENCES OF FALLS DURING A 3-MONTH FOLLOW-UP IN 66 PATIENTS WITH A VARIETY OF NEUROMUSCULAR DISORDERS AND IN 44 AGE-MATCHED CONTROLS. PATIENTS FELL MORE OFTEN THAN CONTROLS (27% VERSUS 5%). FALLS FREQUENTLY CAUSED INJURIES (MINOR IN 79% OF SUBJECTS AND MAJOR IN 5%) AND WERE OFTEN ACCOMPANIED BY FEAR OF FALLING (58%) AND REDUCED ACTIVITIES (48%). WE CONCLUDE THAT FALLING IS A CLINICALLY IMPORTANT PROBLEM IN PATIENTS WITH NEUROMUSCULAR DISORDERS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.,PARKINSONS-DISEASE; COMMUNITY; PEOPLE; RISK; PREDICTORS,ACCIDENTAL FALLS; RISK FACTORS; NEUROMUSCULAR DISEASE,JOURNAL OF THE NEUROLOGICAL SCIENCES,"PIETERSE, AJ##LUTTIKHOLD, TB##DE LAAT, K##BLOEM, BR##VAN ENGELEN, BG##MUNNEKE, M","RADBOUD UNIV NIJMEGEN, MED CTR, DEPT NEUROL 935, INST NEUROL, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, DEPT PHYS THERAPY, RES CTR ALLIED HLTH CARE, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, NEUROMUSCULAR CTR NIJMEGEN, NL-6500 HB NIJMEGEN, NETHERLANDS.",CLINICAL NEUROLOGY; NEUROSCIENCES,NEUROSCIENCES & NEUROLOGY,"ASHBURN A, 2001, AGE AGEING, V30, P47, DOI 10.1093/AGEING/30.1.47##BLOEM BR, 2004, MOVEMENT DISORD, V19, P359##BLOEM BR, 2001, J NEUROL, V248, P950, DOI 10.1007/S004150170047##BLOEM BR, 2004, CLIN DISORDERS BALAN, P173##BUCHNER DM, 1997, J GERONTOL A-BIOL, V52, PM218, DOI 10.1093/GERONA/52A.4.M218##CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/J.1532-5415.1988.TB06155.X##DE WARRENBURG BPC, 2005, MOVEMENT DISORD, V20, P497, DOI 10.1002/MDS.20375##HYNDMAN D, 2003, DISABIL REHABIL, V25, P817, DOI 10.1080/0963828031000122221##LORD SR, 2002, ARCH PHYS MED REHAB, V83, P757, DOI 10.1053/APMR.2002.32827##MAKI BE, 1994, J GERONTOL, V49, PM72, DOI 10.1093/GERONJ/49.2.M72##RICHARDSON JK, 1992, J AM GERIATR SOC, V40, P1008, DOI 10.1111/J.1532-5415.1992.TB04477.X##RYAN JW, 1993, J GERONTOL NURS, V49, P23##STEINBERG M, 2000, J EPIDEMIOL COMMUN H, V54, P227, DOI 10.1136/JECH.54.3.227##STOLZE H, 2004, J NEUROL, V251, P79, DOI 10.1007/S00415-004-0276-8##TROMP AM, 2001, J CLIN EPIDEMIOL, V54, P837, DOI 10.1016/S0895-4356(01)00349-3##VISSER M, 2003, ARCH PHYS MED REHAB, V84, P1669, DOI 10.1053/S0003-9993(03)00348-4",29,2020-11-20,NA
J,WOS:000243153000020,2006,"THE 6C** SAMPLE OF STEEP-SPECTRUM RADIO SOURCES - I. RADIO DATA, NEAR-INFRARED IMAGING AND OPTICAL SPECTORSCOPY","WE PRESENT BASIC OBSERVATIONAL DATA ON THE 6C** SAMPLE. THIS IS A NEW SAMPLE OF RADIO SOURCES DRAWN FROM THE 151-MHZ 6C SURVEY, WHICH WAS FILTERED WITH RADIO CRITERIA CHOSEN TO OPTIMIZE THE CHANCES OF FINDING RADIO GALAXIES AT Z > 4. THE FILTERING CRITERIA ARE A STEEP-SPECTRAL INDEX AND A SMALL ANGULAR SIZE. THE FINAL SAMPLE CONSISTS OF 68 SOURCES FROM A REGION OF SKY COVERING 0.421 SR. WE PRESENT VERY LARGE ARRAY RADIO MAPS, AND THE RESULTS OF K-BAND IMAGING AND OPTICAL SPECTROSCOPY. NEAR-INFRARED COUNTERPARTS ARE IDENTIFIED FOR 66 OF THE 68 SOURCES, DOWN TO A 3 SIGMA LIMITING MAGNITUDE OF K SIMILAR TO 22 MAG IN A 3-ARCSEC APERTURE. EIGHT OF THESE IDENTIFICATIONS ARE SPATIALLY COMPACT, IMPLYING AN UNRESOLVED NUCLEAR SOURCE. THE K-MAGNITUDE DISTRIBUTION PEAKS AT A MEDIAN K APPROXIMATE TO 18.7 MAG, AND IS FOUND TO BE STATISTICALLY INDISTINGUISHABLE FROM THAT OF THE SIMILARLY SELECTED 6C* SAMPLE, IMPLYING THAT THE REDSHIFT DISTRIBUTION COULD EXTEND TO Z GREATER THAN OR SIMILAR TO 4. REDSHIFTS DETERMINED FROM SPECTROSCOPY ARE AVAILABLE FOR 22 (32 PER CENT) OF THE SOURCES, OVER THE RANGE OF 0.2 LESS THAN OR SIMILAR TO Z LESS THAN OR SIMILAR TO 3.3. WE MEASURE 15 OF THESE, WHEREAS THE OTHER SEVEN WERE PREVIOUSLY KNOWN. SIX SOURCES ARE AT Z > 2.5. FOUR SOURCES SHOW BROAD EMISSION LINES IN THEIR SPECTRA AND ARE CLASSIFIED AS QUASARS. THREE OF THESE SHOW ALSO AN UNRESOLVED K-BAND IDENTIFICATION. I I SOURCES FAIL TO SHOW ANY DISTINCTIVE EMISSION AND/OR ABSORPTION FEATURES IN THEIR SPECTRA. WE SUGGEST THAT THESE COULD BE (I) IN THE SO-CALLED 'REDSHIFT DESERT' REGION OF 1.2 < Z < 1.8 OR (II) AT A GREATER REDSHIFT, BUT FEATURE WEAK EMISSION-LINE SPECTRA.",7C REDSHIFT SURVEY; ALPHA EMISSION-LINES; NORTH ECLIPTIC CAP; K-Z RELATION; FIND OBJECTS; LUMINOSITY FUNCTION; ABSORBING HALOES; SKY SURVEY; 6C SURVEY; GALAXIES,GALAXIES : ACTIVE; GALAXIES : EVOLUTION; GALAXIES : HIGH-REDSHIFT; RADIO CONTINUUM : GALAXIES,MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY,"CRUZ, MJ##JARVIS, MJ##BLUNDELL, KM##RAWLINGS, S##CROFT, S##KLOCKNER, HR##MCLURE, RJ##SIMPSON, C##TARGETT, TA##WILLOTT, CJ","DEPT PHYS, OXFORD OX1 3RH, ENGLAND. LEIDEN UNIV, NL-2300 RA LEIDEN, NETHERLANDS. LAWRENCE LIVERMORE NATL LAB, INST GEOPHYS & PLANETARY PHYS, LIVERMORE, CA 94550 USA. UNIV CALIF MERCED, SCH NAT SCI, MERCED, CA 95344 USA. UNIV EDINBURGH, ROYAL OBSERV, ASTRON INST, EDINBURGH EH9 3HJ, MIDLOTHIAN, SCOTLAND. LIVERPOOL JOHN MOORES UNIV, ASTROPHYS RES INST, BIRKENHEAD CH41 1LD, MERSEYSIDE, ENGLAND. NATL RES COUNCIL CANADA, HERZBERG INST ASTROPHYS, VICTORIA, BC V9E 2E7, CANADA.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ALLINGTONSMITH JR, 1985, MON NOT R ASTRON SOC, V213, P243, DOI 10.1093/MNRAS/213.2.243##BARTHEL PD, 1988, NATURE, V333, P319, DOI 10.1038/333319A0##BECKER RH, 1995, ASTROPHYS J, V450, P559, DOI 10.1086/176166##BECKER RH, 2001, ASTRON J, V122, P2850, DOI 10.1086/324231##BICKNELL GV, 2002, NEW ASTRON REV, V46, P365, DOI 10.1016/S1387-6473(01)00210-X##BLUNDELL KM, 1999, ASTRON J, V117, P677, DOI 10.1086/300721##BLUNDELL KM, 1999, NATURE, V399, P330, DOI 10.1038/20612##BLUNDELL KM, 1998, MON NOT R ASTRON SOC, V295, P265, DOI 10.1046/J.1365-8711.1998.01143.X##BLUNDELL KM, 2000, PERSPECTIVES RADIO A, P1131##BRINKMANN W, 2000, ASTRON ASTROPHYS, V356, P445##CARILLI CL, 2002, ASTROPHYS J, V577, P22, DOI 10.1086/342179##CHAMBERS KC, 1996, ASTROPHYS J SUPPL S, V106, P215, DOI 10.1086/192337##COHEN AS, 2004, ASTROPHYS J SUPPL S, V150, P417, DOI 10.1086/380783##CONDON JJ, 1998, ASTRON J, V115, P1693, DOI 10.1086/300337##DE BREUCK C, 2000, ASTRON ASTROPHYS SUP, V143, P303, DOI 10.1051/AAS:2000181##DE BREUCK C, 1998, ASTRON J, V116, P13, DOI 10.1086/300421##DE BREUCK C, 2002, ASTRON J, V123, P637, DOI 10.1086/324632##DE BREUCK C, 2001, ASTRON J, V121, P1241, DOI 10.1086/319392##DE BREUCK C, 2000, ASTRON ASTROPHYS, V362, P519##DEY A, 1995, ASTROPHYS J, V440, P515, DOI 10.1086/175293##DUNLOP JS, 2003, MON NOT R ASTRON SOC, V340, P1095, DOI 10.1046/J.1365-8711.2003.06333.X##EDGE AC, 2003, MON NOT R ASTRON SOC, V339, P913, DOI 10.1046/J.1365-8711.2003.06270.X##FOSBURY RAE, 1999, P ESO WORKSH CHEM EV, P227##FURLANETTO SR, 2006, MON NOT R ASTRON SOC, V365, P1012, DOI 10.1111/J.1365-2966.2005.09785.X##GARDNER JP, 1993, APJ, V415, P9##GOOCH R, 1996, ASTR SOC P, V101, P80##GUNN JE, 1965, ASTROPHYS J, V142, P1633, DOI 10.1086/148444##HAIMAN Z, 2002, ASTROPHYS J, V576, PL1, DOI 10.1086/343101##HALES SEG, 1988, MON NOT R ASTRON SOC, V234, P919, DOI 10.1093/MNRAS/234.4.919##HALES SEG, 1990, MON NOT R ASTRON SOC, V246, P256##HAWARDEN TG, 2001, MON NOT R ASTRON SOC, V325, P563, DOI 10.1046/J.1365-8711.2001.04460.X##HILL GJ, 2003, NEW ASTRON REV, V47, P373, DOI 10.1016/S1387-6473(03)00048-4##JARVIS MJ, 2003, MON NOT R ASTRON SOC, V338, P263, DOI 10.1046/J.1365-8711.2003.06053.X##JARVIS MJ, 2001, MON NOT R ASTRON SOC, V326, P1585, DOI 10.1111/J.1365-2966.2001.04730.X##JARVIS MJ, 2001, MON NOT R ASTRON SOC, V326, P1563, DOI 10.1111/J.1365-2966.2001.04726.X##KURK JD, 2004, ASTRON ASTROPHYS, V428, P817, DOI 10.1051/0004-6361:20041819##KURK JD, 2002, REV MEX AST ASTR, V13, P191##LACY M, 1999, MON NOT R ASTRON SOC, V308, P1096, DOI 10.1046/J.1365-8711.1999.02790.X##LACY M, 1999, MON NOT R ASTRON SOC, V308, P1087, DOI 10.1046/J.1365-8711.1999.02789.X##LAING RA, 1983, MON NOT R ASTRON SOC, V204, P151, DOI 10.1093/MNRAS/204.1.151##MCCARTHY PJ, 1991, ASTRON J, V102, P518, DOI 10.1086/115890##MCCARTHY PJ, 1993, ANNU REV ASTRON ASTR, V31, P639##MCLURE RJ, 2004, MON NOT R ASTRON SOC, V353, PL45, DOI 10.1111/J.1365-2966.2004.08305.X##MILEY GK, 2004, NATURE, V427, P47, DOI 10.1038/NATURE02125##MONET DBA, 1998, 1252 VIZIER ONL DAT##NESSER NJ, 1995, ASTROPHYS J, V451, P76, DOI 10.1086/176201##RAWLINGS S, 2001, MON NOT R ASTRON SOC, V322, P523, DOI 10.1046/J.1365-8711.2001.04151.X##RAWLINGS S, 1996, NATURE, V383, P502, DOI 10.1038/383502A0##RAWLINGS S, 1990, MNRAS, V243, P14##REULAND M, 2003, APJ, V582, P71##ROTTGERING HJA, 1994, ASTRON ASTROPHYS SUP, V108, P79##ROWANROBINSON M, 1991, NATURE, V351, P719, DOI 10.1038/351719A0##SANTOS MR, 2004, MON NOT R ASTRON SOC, V349, P1137, DOI 10.1111/J.1365-2966.2004.07594.X##SKRUTSKIE MF, 2006, ASTRON J, V131, P1163, DOI 10.1086/498708##TADHUNTER CN, 2002, REV MEX AST ASTR, V13, P213##VANOJIK R, 1997, ASTRON ASTROPHYS, V317, P358##VANOJIK R, 1994, ASTRON ASTROPHYS, V289, P54##VENEMANS BP, 2005, ASTRON ASTROPHYS, V431, P793, DOI 10.1051/0004-6361:20042038##VENEMANS BP, 2004, ASTRON ASTROPHYS, V4424, P617##VERNET J, 2001, ASTRON ASTROPHYS, V366, P7, DOI 10.1051/0004-6361:20000076##VIGOTTI M, 1990, ASTRON ASTROPHYS SUP, V83, P205##VILLAR-MARTIN M, 1999, ASTRON ASTROPHYS, V351, P47##WILLOTT CJ, 1998, MON NOT R ASTRON SOC, V300, P625##WILLOTT CJ, 1999, MON NOT R ASTRON SOC, V309, P1017, DOI 10.1046/J.1365-8711.1999.02907.X##WILLOTT CJ, 2003, MON NOT R ASTRON SOC, V339, P173, DOI 10.1046/J.1365-8711.2003.06172.X##WILLOTT CJ, 2002, MON NOT R ASTRON SOC, V331, P435, DOI 10.1046/J.1365-8711.2002.05209.X##WILLOTT CJ, 2001, MON NOT R ASTRON SOC, V322, P536, DOI 10.1046/J.1365-8711.2001.04101.X##WILMAN RJ, 2004, MON NOT R ASTRON SOC, V351, P1109, DOI 10.1111/J.1365-2966.2004.07857.X##ZIRM AW, 2003, ASTROPHYS J, V585, P90, DOI 10.1086/346021",21,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [ST/G002630/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242971100047,2006,A NEW PROGEROID SYNDROME REVEALS THAT GENOTOXIC STRESS SUPPRESSES THE SOMATOTROPH AXIS,"XPF-ERCC1 ENDONUCLEASE IS REQUIRED FOR REPAIR OF HELIX-DISTORTING DNA LESIONS AND CYTOTOXIC DNA INTERSTRAND CROSSLINKS. MILD MUTATIONS IN XPF CAUSE THE CANCER-PRONE SYNDROME XERODERMA PIGMENTOSUM. A PATIENT PRESENTED WITH A SEVERE XPF MUTATION LEADING TO PROFOUND CROSSLINK SENSITIVITY AND DRAMATIC PROGEROID SYMPTOMS. IT IS NOT KNOWN HOW UNREPAIRED DNA DAMAGE ACCELERATES AGEING OR ITS RELEVANCE TO NATURAL AGEING. HERE WE SHOW A HIGHLY SIGNIFICANT CORRELATION BETWEEN THE LIVER TRANSCRIPTOME OF OLD MICE AND A MOUSE MODEL OF THIS PROGEROID SYNDROME. EXPRESSION DATA FROM XPF-ERCC1-DEFICIENT MICE INDICATE INCREASED CELL DEATH AND ANTI-OXIDANT DEFENCES, A SHIFT TOWARDS ANABOLISM AND REDUCED GROWTH HORMONE/INSULIN-LIKE GROWTH FACTOR 1 (IGF1) SIGNALLING, A KNOWN REGULATOR OF LIFESPAN. SIMILAR CHANGES ARE SEEN IN WILD-TYPE MICE IN RESPONSE TO CHRONIC GENOTOXIC STRESS, CALORIC RESTRICTION, OR WITH AGEING. WE CONCLUDE THAT UNREPAIRED CYTOTOXIC DNA DAMAGE INDUCES A HIGHLY CONSERVED METABOLIC RESPONSE MEDIATED BY THE IGF1/INSULIN PATHWAY, WHICH RE-ALLOCATES RESOURCES FROM GROWTH TO SOMATIC PRESERVATION AND LIFE EXTENSION. THIS HIGHLIGHTS A CAUSAL CONTRIBUTION OF DNA DAMAGE TO AGEING AND DEMONSTRATES THAT AGEING AND END-OF-LIFE FITNESS ARE DETERMINED BOTH BY STOCHASTIC DAMAGE, WHICH IS THE CAUSE OF FUNCTIONAL DECLINE, AND GENETICS, WHICH DETERMINES THE RATES OF DAMAGE ACCUMULATION AND DECLINE.",PIGMENTOSUM GROUP-F; DNA-REPAIR DEFECTS; XERODERMA-PIGMENTOSUM; LIFE-SPAN; GROWTH-HORMONE; NUCLEAR ABNORMALITIES; GENOMIC INSTABILITY; CALORIC RESTRICTION; GENE; MICE,NA,NATURE,"NIEDERNHOFER, LJ##GARINIS, GA##RAAMS, A##LALAI, AS##ROBINSON, AR##APPELDOORN, E##ODIJK, H##OOSTENDORP, R##AHMAD, A##VAN LEEUWEN, W##THEIL, AF##VERMEULEN, W##VAN DER HORST, GTJ##MEINECKE, P##KLEIJER, WJ##VIJG, J##JASPERS, NGJ##HOEIJMAKERS, JHJ","ERASMUS UNIV, MED CTR, CTR BIOMED GENET MED GENET CTR, DEPT CELL BIOL & GENET, NL-3000 DR ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT EXPT RADIOL, NL-3000 DR ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT CLIN GENET, NL-3000 DR ROTTERDAM, NETHERLANDS. UNIV PITTSBURGH, SCH MED, INST CANC, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15213 USA. ALTONAER KINDERKRANKENHAUS, ABT MED GENET, D-22763 HAMBURG, GERMANY. BUCK INST AGE RES, NOVATO, CA 94945 USA.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"BARTKE A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/EN.2005-0411##BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/J.1460-2075.1993.TB06043.X##BOOTSMA D., 2001, METABOLIC MOL BASES, P677##CAMPISI J, 2005, MECH AGEING DEV, V126, P51, DOI 10.1016/J.MAD.2004.09.024##CAO SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/PNAS.191313598##CARTER CS, 2002, TRENDS GENET, V18, P295, DOI 10.1016/S0168-9525(02)02696-3##DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169A0##DOLLE MET, 2006, MUTAT RES-FUND MOL M, V596, P22, DOI 10.1016/J.MRFMMM.2005.11.008##ENZLIN JH, 2002, EMBO J, V21, P2045, DOI 10.1093/EMBOJ/21.8.2045##GHOSHAL AK, 2000, P SOC EXP BIOL MED, V225, P128, DOI 10.1046/J.1525-1373.2000.22516.X##GUPTA S, 2000, SEMIN CANCER BIOL, V10, P161##HANSEN M, 2005, PLOS GENET, V1, P119, DOI 10.1371/JOURNAL.PGEN.0010017##HASTY P, 2004, AGING CELL, V3, P55, DOI 10.1111/J.1474-9728.2004.00082.X##HASTY P, 2003, SCIENCE, V299, P1355, DOI 10.1126/SCIENCE.1079161##HERBIG U, 2006, SCIENCE, V311, P1257, DOI 10.1126/SCIENCE.1122446##HUANG Q, 2001, TOXICOL SCI, V63, P196, DOI 10.1093/TOXSCI/63.2.196##KASAI H, 1998, CARCINOGENESIS, V19, P1459, DOI 10.1093/CARCIN/19.8.1459##KENYON C, 2005, CELL, V120, P449, DOI 10.1016/J.CELL.2005.02.002##KIPLING D, 2004, SCIENCE, V305, P1426, DOI 10.1126/SCIENCE.1102587##KIRKWOOD TBL, 2000, HUM EXP TOXICOL, V19, P338, DOI 10.1191/096032700678816025##KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/RSPB.1979.0083##KIRKWOOD TBL, 2005, CELL, V120, P437, DOI 10.1016/J.CELL.2005.01.027##LEE CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/SCIENCE.285.5432.1390##LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4##LOMBARD DB, 2005, CELL, V120, P497, DOI 10.1016/J.CELL.2005.01.028##LOMBARDI G, 2005, J ENDOCRINOL INVEST, V28, P99##MACCORMICK RE, 2006, MED HYPOTHESES, V67, P212, DOI 10.1016/J.MEHY.2006.01.045##MAIER B, 2004, GENE DEV, V18, P306, DOI 10.1101/GAD.1162404##MATSUMURA Y, 1998, HUM MOL GENET, V7, P969, DOI 10.1093/HMG/7.6.969##MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/NG1193-217##MILLER RA, 2005, SCIENCE, V310, P441, DOI 10.1126/SCIENCE.310.5747.441##MITCHELL JR, 2003, CURR OPIN CELL BIOL, V15, P232, DOI 10.1016/S0955-0674(03)00018-8##MOSTOSLAVSKY R, 2006, CELL, V124, P315, DOI [10.1016/J.CELL.2005.11.044, 10.1016/J.CEL.2005.11.044]##MULLER EE, 1999, PHYSIOL REV, V79, P511##NIEDERNHOFER LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004##NIEDERNHOFER LJ, 2003, J BIOL CHEM, V278, P31426, DOI 10.1074/JBC.M212549200##PINKSTON JM, 2006, SCIENCE, V313, P971, DOI 10.1126/SCIENCE.1121908##PRASHER JM, 2005, EMBO J, V24, P861, DOI 10.1038/SJ.EMBOJ.7600542##SIJBERS AM, 1998, J INVEST DERMATOL, V110, P832, DOI 10.1046/J.1523-1747.1998.00171.X##SIJBERS AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5##SONNTAG WE, 2005, ENDOCRINOLOGY, V146, P2920, DOI 10.1210/EN.2005-0058##SPINDLER SR, 2005, MECH AGEING DEV, V126, P960, DOI 10.1016/J.MAD.2005.03.016##TAKAHASHI Y, 2003, BBA-MOL CELL BIOL L, V1631, P265, DOI 10.1016/S1388-1981(03)00038-6##TIAN M, 2004, MOL CELL BIOL, V24, P1200, DOI 10.1128/MCB.24.3.1200-1205.2004##TSODIKOV OV, 2005, P NATL ACAD SCI USA, V102, P11236, DOI 10.1073/PNAS.0504341102##VANDERPLUIJM I, IN PRESS PLOS BIOL, DOI DOI 10.1037/JOURNAL.PBIO.0050002##WEEDA G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4##WYLLIE FS, 2000, NAT GENET, V24, P16##ZHU XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7",465,2020-11-20,"NATIONAL CANCER INSTITUTEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL CANCER INSTITUTE (NCI) [K22CA111525, K22CA111525, K22CA111525] FUNDING SOURCE: NIH REPORTER; NCI NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL CANCER INSTITUTE (NCI) [K22 CA111525] FUNDING SOURCE: MEDLINE"
J,WOS:000242971100049,2006,NO SUPERNOVAE ASSOCIATED WITH TWO LONG-DURATION GAMMA-RAY BURSTS,"IT IS NOW ACCEPTED THAT LONG-DURATION GAMMA-RAY BURSTS (GRBS) ARE PRODUCED DURING THE COLLAPSE OF A MASSIVE STAR(1,2). THE STANDARD 'COLLAPSAR' MODEL(3) PREDICTS THAT A BROAD-LINED AND LUMINOUS TYPE IC CORE-COLLAPSE SUPERNOVA ACCOMPANIES EVERY LONG- DURATION GRB(4). THIS ASSOCIATION HAS BEEN CONFIRMED IN OBSERVATIONS OF SEVERAL NEARBY GRBS(5-9). HERE WE REPORT THAT GRB 060505 ( REF. 10) AND GRB 060614 ( REF. 11) WERE NOT ACCOMPANIED BY SUPERNOVA EMISSION DOWN TO LIMITS HUNDREDS OF TIMES FAINTER THAN THE ARCHETYPAL SUPERNOVA SN 1998BW THAT ACCOMPANIED GRB 980425, AND FAINTER THAN ANY TYPE IC SUPERNOVA EVER OBSERVED(12). MULTI-BAND OBSERVATIONS OF THE EARLY AFTERGLOWS, AS WELL AS SPECTROSCOPY OF THE HOST GALAXIES, EXCLUDE THE POSSIBILITY OF SIGNIFICANT DUST OBSCURATION AND SHOW THAT THE BURSTS ORIGINATED IN ACTIVELY STAR-FORMING REGIONS. THE ABSENCE OF A SUPERNOVA TO SUCH DEEP LIMITS IS QUALITATIVELY DIFFERENT FROM ALL PREVIOUS NEARBY LONG- DURATION GRBS AND SUGGESTS A NEW PHENOMENOLOGICAL TYPE OF MASSIVE STELLAR DEATH.",EMISSION; COLLAPSE; LIGHT; DISKS; HST,NA,NATURE,"FYNBO, JPU##WATSON, D##THONE, CC##SOLLERMAN, J##BLOOM, JS##DAVIS, TM##HJORTH, J##JAKOBSSON, P##JORGENSEN, UG##GRAHAM, JF##FRUCHTER, AS##BERSIER, D##KEWLEY, L##CASSAN, A##CERON, JMC##FOLEY, S##GOROSABEL, J##HINSE, TC##HORNE, KD##JENSEN, BL##KLOSE, S##KOCEVSKI, D##MARQUETTE, JB##PERLEY, D##RAMIREZ-RUIZ, E##STRITZINGER, MD##VREESWIJK, PM##WIJERS, RAM##WOLLER, KG##XU, D##ZUB, M","UNIV COPENHAGEN, DARK COSMOL CTR, DK-2100 COPENHAGEN, DENMARK. UNIV COPENHAGEN, NIELS BOHR INST, DK-2100 COPENHAGEN, DENMARK. UNIV STOCKHOLM, ALBANOVA, DEPT ASTRON, S-10691 STOCKHOLM, SWEDEN. UNIV CALIF BERKELEY, DEPT ASTRON, BERKELEY, CA 94720 USA. UNIV HERTFORDSHIRE, CTR ASTROPHYS RES, HATFIELD AL10 9AB, HERTS, ENGLAND. SPACE TELESCOPE SCI INST, BALTIMORE, MD 21218 USA. LIVERPOOL JOHN MOORES UNIV, ASTROPHYS RES INST, BIRKENHEAD CH41 1LD, MERSEYSIDE, ENGLAND. UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA. UNIV HEIDELBERG ZAH, ZENTRUM ASTRON, ARI, D-69120 HEIDELBERG, GERMANY. UNIV COLL DUBLIN, SCH PHYS, DUBLIN 4, IRELAND. CSIC, INST ASTROFIS ANDALUCIA, E-18080 GRANADA, SPAIN. UNIV ST ANDREWS, SUPA PHYS ASTRON, ST ANDREWS KY16 9SS, FIFE, SCOTLAND. THURINGER LANDESSTERNWARTE TAUTENBURG, D-07778 TAUTENBURG, GERMANY. UNIV PARIS 06, CNRS, UMR 70951, INST ASTROPHYS PARIS, F-75014 PARIS, FRANCE. INST ADV STUDY, PRINCETON, NJ 08540 USA. UNIV CALIF SANTA CRUZ, DEPT ASTRON & ASTROPHYS, SANTA CRUZ, CA 95064 USA. UNIV CHILE, DEPT ASTRON, SANTIAGO, CHILE. UNIV AMSTERDAM, ASTRON INST ANTON PANNEKOEK, FAC SCI, NL-1098 SJ AMSTERDAM, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"FERRERO P, 2006, ASTRON ASTROPHYS, V457, P857, DOI 10.1051/0004-6361:20065530##FRUCHTER AS, 2006, NATURE, V441, P463, DOI 10.1038/NATURE04787##FRYER CL, 2006, ASTROPHYS J, V650, P1028, DOI 10.1086/506250##FYNBO JPU, 2004, ASTROPHYS J, V609, P962, DOI 10.1086/421260##GALAMA TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150##HEGER A, 2003, ASTROPHYS J, V591, P288, DOI 10.1086/375341##HJORTH J, 2003, NATURE, V423, P847, DOI 10.1038/NATURE01750##HOLLAND ST, 2006, 5255 GCN##HULLINGER D, 2006, 5142 GCN##LEVAN A, 2005, ASTROPHYS J, V622, P977, DOI 10.1086/426938##MACFADYEN AI, 2003, AIP CONF PROC, V662, P202##MACFADYEN AI, 1999, ASTROPHYS J, V524, P262, DOI 10.1086/307790##MALESANI D., 2004, APJ, V609, P5##OFEK EO, 2006, 5123 GCN##PEDERSEN H, 1998, ASTROPHYS J, V496, P311, DOI 10.1086/305385##PIAN E, 2006, NATURE, V442, P1011, DOI 10.1038/NATURE05082##RICHARDSON D, 2006, ASTRON J, V131, P2233, DOI 10.1086/500578##SCHLEGEL DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772##SCHMIDT BP, 2006, 5258 GCN##SODERBERG AM, 2006, ASTROPHYS J, V636, P391, DOI 10.1086/498009##SODERBERG AM, 2005, ASTROPHYS J, V627, P877, DOI 10.1086/430405##SOLLERMAN J, 2006, ASTRON ASTROPHYS, V454, P503, DOI 10.1051/0004-6361:20065226##SOLLERMAN J, 2005, NEW ASTRON, V11, P103, DOI 10.1016/J.NEWAST.2005.06.004##STANEK KZ, 2003, ASTROPHYS J, V591, PL17, DOI 10.1086/376976##WOOSLEY SE, 2006, ANNU REV ASTRON ASTR, V44, P507, DOI 10.1146/ANNUREV.ASTRO.43.072103.150558##WOOSLEY SE, 1993, ASTROPHYS J, V405, P273, DOI 10.1086/172359##ZEH A, 2004, ASTROPHYS J, V609, P952, DOI 10.1086/421100",334,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/D000890/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242956200016,2006,"OVERWEIGHT, OBESITY, AND MORTALITY",NA,NA,NA,NEW ENGLAND JOURNAL OF MEDICINE,"APPELS, CWY##VANDENBROUCKE, JP","LEIDEN UNIV, MED CTR, NL-2300 RC LEIDEN, NETHERLANDS.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"ADAMS KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMOA055643##FLEGAL KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/JAMA.293.15.1861",6,2020-11-20,NA
J,WOS:000243193900018,2006,THEORETICAL MODELING OF ENERGY REDISTRIBUTION AND STEREODYNAMICS IN CF SCATTERING FROM SI(100) UNDER GRAZING INCIDENCE,"WE HAVE SIMULATED CF SCATTERING FROM SI(100) USING THE MOLECULAR DYNAMICS METHOD. TRANSLATIONAL ENERGY LOSS SPECTRA ARE PRESENTED. THE SHAPE OF THE ENERGY LOSS DISTRIBUTION AS A RESULT OF INTERNAL ENERGY RELEASE IS ANALYZED. AT THE CLASSICAL TURNING POINT, THE INTERNAL ENERGY OF THE MOLECULE IS MAINLY IN THE FORM OF ROTATIONAL ENERGY. THE STRONG ROTATIONAL EXCITATION RESULTS IN ADDITIONAL MOLECULE-SURFACES INTERACTIONS DURING THE LATTER HALF OF THE COLLISION. THESE ADDITIONAL COLLISIONS PERMIT SOME MOLECULES THAT INITIALLY GAIN INTERNAL ENERGY EXCEEDING THE BOND STRENGTH TO ULTIMATELY SURVIVE THE COLLISION PROCESS VIA ROTATIONAL DE-EXCITATION. THE ROTATIONAL MOTION EXHIBITED BY SURVIVING MOLECULES IS DETERMINED BY THE COMBINATION OF THE MOLECULAR AXIS ORIENTATION AND THE LOCAL SURFACE STRUCTURE DURING THE COLLISION PROCESS. THE ROTATION PLANES OF THE SURVIVING MOLECULES ARE PREFERENTIALLY ALIGNED WITH THE SURFACE NORMAL (CARTWHEEL-LIKE AND PROPELLER-LIKE MOTIONS). IN THIS STUDY, PROPELLER-LIKE MOTION OF THE SURVIVING MOLECULES IS PREDICTED. THE MAJORITY OF SURVIVING MOLECULES EXHIBIT A CARTWHEEL-LIKE MOTION. HOWEVER, MOLECULES THAT GAIN A PROPELLER-LIKE ROTATION EXHIBIT A MUCH BETTER ALIGNMENT OF THEIR PLANES-OF-ROTATION COMPARED WITH MOLECULES EXHIBITING CARTWHEEL-LIKE MOTION.",MOLECULAR-DYNAMICS SIMULATION; DISSOCIATIVE SCATTERING; DIATOMIC-MOLECULES; POLYATOMIC IONS; LIQUID SURFACE; SOLID-SURFACES; FAST N-2; COLLISIONS; AG(111); POTENTIALS,NA,PHYSICAL CHEMISTRY CHEMICAL PHYSICS,"GOU, F##GLEESON, MA##KLEYN, AW","LEIDEN UNIV, LEIDEN INST CHEM, GORLAEUS LABS, NL-2300 RA LEIDEN, NETHERLANDS. EURATOM, FOM, INST PLASMA PHYS RIJNHUIZEN, NL-3430 BE NIEUWEGEIN, NETHERLANDS.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"ALLEN M. P., 1987, COMPUTER SIMULATION##BRUNING K, 2000, J CHEM PHYS, V113, P2456, DOI 10.1063/1.482063##CHANG JP, 2003, J VAC SCI TECHNOL A, V21, PS145, DOI 10.1116/1.1600452##DARLING GR, 1995, REP PROG PHYS, V58, P1595, DOI 10.1088/0034-4885/58/12/001##ELBER R, 1983, J CHEM PHYS, V79, P4087, DOI 10.1063/1.446283##GERBER RB, 1986, J PHYS CHEM-US, V90, P4483, DOI 10.1021/J100410A005##GERBER RB, 1981, J CHEM PHYS, V74, P4709, DOI 10.1063/1.441617##GOU F, 2006, NUCL INSTRUM METH B, V247, P244, DOI 10.1016/J.NIMB.2006.02.009##GREELEY JN, 1995, J CHEM PHYS, V102, P4996, DOI 10.1063/1.469550##HEILAND W, 1987, NUCL INSTRUM METH B, V27, P167, DOI 10.1016/0168-583X(87)90017-6##KLEYN AW, 1992, J PHYS-CONDENS MAT, V4, P8375, DOI 10.1088/0953-8984/4/44/003##KOPPERS WR, 1997, J CHEM PHYS, V107, P10736, DOI 10.1063/1.474189##KOPPERS WR, 1998, INT J MASS SPECTROM, V174, P11, DOI 10.1016/S0168-1176(97)00287-5##KOPPERS WR, 1996, PHYS REV B, V53, P11207, DOI 10.1103/PHYSREVB.53.11207##KOPPERS WR, 1999, J CHEM PHYS, V110, P2588, DOI 10.1063/1.477979##LAHAYE RJWE, 1995, SURF SCI, V338, P169, DOI 10.1016/0039-6028(95)00698-2##MARTIN JS, 1996, J PHYS CHEM-US, V100, P1689, DOI 10.1021/JP943073B##MOLIERE G, 1947, Z NATURFORSCH A, V2, P133##MORSE PM, 1929, PHYS REV, V33, P0932, DOI 10.1103/PHYSREV.33.932##PETERSON JR, 1984, PHYS REV A, V30, P2807, DOI 10.1103/PHYSREVA.30.2807##POLANYI JC, 1982, BER BUNSEN PHYS CHEM, V86, P356, DOI 10.1002/BBPC.19820860506##REIJNEN PHF, 1989, SURF SCI, V221, P427, DOI 10.1016/0039-6028(89)90480-9##SCHLATHOLTER T, 1997, J CHEM PHYS, V106, P4723, DOI 10.1063/1.473471##TANAKA J, 2000, J VAC SCI TECHNOL A, V18, P938, DOI 10.1116/1.582279##TERSOFF J, 1988, PHYS REV LETT, V61, P2879, DOI 10.1103/PHYSREVLETT.61.2879##TERSOFF J, 1988, PHYS REV B, V38, P9902, DOI 10.1103/PHYSREVB.38.9902##TERSOFF J, 1989, PHYS REV B, V39, P5566, DOI 10.1103/PHYSREVB.39.5566##VANDENHOEK PJ, 1989, J CHEM PHYS, V91, P4318, DOI 10.1063/1.457623##VANDENHOEK PJ, 1988, SURF SCI, V198, PL335, DOI 10.1016/0039-6028(88)90466-9##WINTER H, 2002, PHYS REP, V367, P387, DOI 10.1016/S0370-1573(02)00010-8",11,2020-11-20,NA
J,WOS:000242955000005,2006,DERIVATIVE-FREE GENERATION AND INTERPOLATION OF CONVEX PARETO OPTIMAL IMRT PLANS,"IN INVERSE TREATMENT PLANNING FOR INTENSITY-MODULATED RADIATION THERAPY (IMRT), BEAMLET INTENSITY LEVELS IN FLUENCE MAPS OF HIGH-ENERGY PHOTON BEAMS ARE OPTIMIZED. TREATMENT PLAN EVALUATION CRITERIA ARE USED AS OBJECTIVE FUNCTIONS TO STEER THE OPTIMIZATION PROCESS. FLUENCE MAP OPTIMIZATION CAN BE CONSIDERED A MULTI-OBJECTIVE OPTIMIZATION PROBLEM, FOR WHICH A SET OF PARETO OPTIMAL SOLUTIONS EXISTS: THE PARETO EFFICIENT FRONTIER (PEF). IN THIS PAPER, A CONSTRAINED OPTIMIZATION METHOD IS PURSUED TO ITERATIVELY ESTIMATE THE PEF UP TO SOME PREDEFINED ERROR. WE USE THE PROPERTY THAT THE PEF IS CONVEX FOR A CONVEX OPTIMIZATION PROBLEM TO CONSTRUCT PIECEWISE-LINEAR UPPER AND LOWER BOUNDS TO APPROXIMATE THE PEF FROM A SMALL INITIAL SET OF PARETO OPTIMAL PLANS. A DERIVATIVE-FREE SANDWICH ALGORITHM IS PRESENTED IN WHICH THESE BOUNDS ARE USED WITH THREE STRATEGIES TO DETERMINE THE LOCATION OF THE NEXT PARETO OPTIMAL SOLUTION SUCH THAT THE UNCERTAINTY IN THE ESTIMATED PEF IS MAXIMALLY REDUCED. WE SHOW THAT AN INTELLIGENT INITIAL SOLUTION FOR A NEW PARETO OPTIMAL PLAN CAN BE OBTAINED BY INTERPOLATION OF FLUENCE MAPS FROM NEIGHBOURING PARETO OPTIMAL PLANS. THE METHOD HAS BEEN APPLIED TO A SIMPLIFIED CLINICAL TEST CASE USING TWO CONVEX OBJECTIVE FUNCTIONS TO MAP THE TRADE-OFF BETWEEN TUMOUR DOSE HETEROGENEITY AND CRITICAL ORGAN SPARING. ALL THREE STRATEGIES PRODUCE REPRESENTATIVE ESTIMATES OF THE PEF. THE NEW ALGORITHM IS PARTICULARLY SUITABLE FOR DYNAMIC GENERATION OF PARETO OPTIMAL PLANS IN INTERACTIVE TREATMENT PLANNING.",INTENSITY-MODULATED RADIOTHERAPY; DOSE-VOLUME CONSTRAINTS; MULTIPLE LOCAL MINIMA; RADIATION-THERAPY; OPTIMIZATION; APPROXIMATION; ALGORITHM; SYSTEM; CANCER,NA,PHYSICS IN MEDICINE AND BIOLOGY,"HOFFMANN, AL##D SIEM, AY##DEN HERTOG, D##KAANDERS, JHAM##HUIZENGA, H","UNIV NIJMEGEN, RADBOUD MED CTR, DEPT RADIAT ONCOL, NL-6500 HB NIJMEGEN, NETHERLANDS. TILBURG UNIV, CENTER, DEPT ECONOMETR & OPERAT RES, NL-5000 LE TILBURG, NETHERLANDS.","ENGINEERING, BIOMEDICAL; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ENGINEERING; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ALBER M, 2002, PHYS MED BIOL, V47, PN265, DOI 10.1088/0031-9155/47/19/402##AMOLS HI, 1997, INT J RADIAT ONCOL, V38, P455, DOI 10.1016/S0360-3016(97)00093-X##BORTFELD T, 1995, THESIS R CAROLA U HE##BOYD S, 2004, CONVEX OPTIMIZATION##BRAHME A, 1995, RAD THERAPY PHYSICS, P209##BURKARD RE, 1991, NAV RES LOG, V38, P911, DOI 10.1002/NAV.3800380609##CHANKONG V, 1983, LARGE SCALE SYST, V5, P1##CHANKONG V, 1983, MULTIOBJECTIVE DECIS##CHOI B, 2002, PHYS MED BIOL, V47, P3579, DOI 10.1088/0031-9155/47/20/302##CRAFT D, 2005, PHYS MED BIOL, V50, P5857, DOI 10.1088/0031-9155/50/24/007##CRAFT DL, 2006, MED PHYS, V33, P3399, DOI 10.1118/1.2335486##DEASY JO, 1997, MED PHYS, V24, P1157, DOI 10.1118/1.598017##EISBRUCH A, 1999, INT J RADIAT ONCOL, V45, P577, DOI 10.1016/S0360-3016(99)00247-3##FRUHWIRTH B, 1989, EUR J OPER RES, V42, P326, DOI 10.1016/0377-2217(89)90443-8##GRAEME S, 2005, PSYCHOL SCI, V16, P70##GUSTAFSSON A, 1994, MED PHYS, V21, P343, DOI 10.1118/1.597302##HAIMES YY, 1971, IEEE T SYST MAN CYB, VSMC1, P296##HAMACHER HW, 2002, DISCRETE APPL MATH, V118, P145, DOI 10.1016/S0166-218X(01)00261-X##HUNT MA, 2002, INT J RADIAT ONCOL, V54, P953, DOI 10.1016/S0360-3016(02)03004-3##KUFER KH, 2003, OR SPECTRUM, V25, P223, DOI 10.1007/S00291-003-0125-7##LLACER J, 2003, PHYS MED BIOL, V48, P183, DOI 10.1088/0031-9155/48/2/304##MARLER RT, 2004, STRUCT MULTIDISCIP O, V26, P369, DOI 10.1007/S00158-003-0368-6##MESSAC A, 2003, STRUCT MULTIDISCIP O, V25, P86, DOI 10.1007/S00158-002-0276-1##MIETTINEN K., 1999, NONLINEAR MULTIOBJEC##NIEMIERKO A, 1999, MED PHYS, V26, P1100, DOI DOI 10.1118/1.598063##PARETO V, 1971, MANUAL POLITICAL EC##REEMTSEN R, 2004, CONTINUOUS OPTIMIZAT##ROMEIJN HE, 2004, PHYS MED BIOL, V49, P1991, DOI 10.1088/0031-9155/49/10/011##ROTE G, 1992, COMPUTING, V48, P337, DOI 10.1007/BF02238642##SIEM AYD, 2006, LECT NOTES COMPUT SC, V3982, P812##SIEM AYD, 2006, UNPUB EUR J OPER RES##THIEKE C, 2003, THESIS U HEIDELBERG##VAN TOL-GEERDINK JJ, 2006, INT J RADIAT ONCOL, V66, P1105, DOI 10.1016/J.IJROBP.2006.07.001##WEBB S, 2001, SERIES MED PHYS BIOM##YANG XQ, 1997, EUR J OPER RES, V97, P205, DOI 10.1016/0377-2217(95)00368-1",41,2020-11-20,NA
J,WOS:000243112100003,2006,A MONTHLY INTERCEPTION EQUATION BASED ON THE STATISTICAL CHARACTERISTICS OF DAILY RAINFALL,"[1] THIS PAPER PRESENTS A SIMPLE ANALYTICAL EQUATION FOR MONTHLY INTERCEPTION ON THE BASIS OF THE COMBINATION OF A DAILY THRESHOLD MODEL WITH THE PROBABILITY DISTRIBUTION OF DAILY RAINFALL. IN THIS PAPER, INTERCEPTION HAS A WIDER DEFINITION THAN MERELY CANOPY INTERCEPTION. IT IS THE PART OF THE RAINFALL THAT EVAPORATES AFTER IT HAS BEEN STORED ON THE WETTED SURFACE, WHICH INCLUDES THE CANOPY, THE UNDERSTORY, THE BOTTOM VEGETATION, THE LITTER LAYER, THE SOIL, AND THE HARD SURFACE. INTERCEPTION IS DEFINED AS THE PROCESS OF EVAPORATION FROM INTERCEPTED RAINFALL. IT IS SHOWN THAT THIS PROCESS HAS A TYPICAL TIMESCALE OF 1 DAY. MONTHLY INTERCEPTION MODELS CAN BE IMPROVED BY TAKING THE STATISTICAL CHARACTERISTICS OF DAILY RAINFALL INTO ACCOUNT. THESE CHARACTERISTICS APPEAR TO BE LESS VARIABLE IN SPACE THAN THE RAINFALL ITSELF. WITH THE STATISTICAL CHARACTERISTICS OF DAILY RAINFALL OBTAINED AT A FEW LOCATIONS WHERE RELIABLE RECORDS ARE AVAILABLE ( FOR EXAMPLE, AIRPORTS) MONTHLY MODELS CAN BE IMPROVED AND APPLIED TO LARGER AREAS ( 20 - 200 KM). THE EQUATION CAN BE REGIONALIZED, MAKING USE OF THE MARKOV PROPERTY OF DAILY RAINFALL. THE EQUATION OBTAINED FOR MONTHLY INTERCEPTION IS SIMILAR TO BUDYKO'S CURVE.",DAILY PRECIPITATION; MODEL; VARIABILITY; FOREST,NA,WATER RESOURCES RESEARCH,"DE GROEN, MM##SAVENIJE, HHG","ARCADIS, NL-3006 AE ROTTERDAM, NETHERLANDS. DELFT UNIV TECHNOL, WATER RESOURCES SECT, NL-2600 GA DELFT, NETHERLANDS.",ENVIRONMENTAL SCIENCES; LIMNOLOGY; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; MARINE & FRESHWATER BIOLOGY; WATER RESOURCES,"ARORA VK, 2002, J HYDROL, V265, P164, DOI 10.1016/S0022-1694(02)00101-4##BUCKLE C., 1996, WEATHER CLIMATE AFRI##BUDYKO M., 1974, CLIMATE LIFE##BUDYKO M, 1951, PROB FIZ GEOGR, V16##BUDYKO M., 1948, EVAPORATION NATURAL##CALDER I.R., 1990, EVAPORATION UPLANDS##CLARKE D, 1998, CROPWAT WINDOWS USER##CLARKE RT, 1998, STOCHASTIC PROCESSES##DEGROEN MM, 2002, MODELLING INTERCEPTI##DOOGE JCI, 1997, REFLECTIONS HYDROLOG, P85##FALKENMARK M, 2005, HYDROL EARTH SYST SC, V9, P15, DOI 10.5194/HESS-9-15-2005##FALKENMARK M., 2004, BALANCING WATER HUMA##*FAO, 1977, 24 FA3##*FAO, 1979, 33 FAO##GABRIEL KR, 1962, Q J ROY METEOR SOC, V88, P90, DOI 10.1002/QJ.49708837511##GERMER S, 2006, HYDROL EARTH SYST SC, V10, P383, DOI 10.5194/HESS-10-383-2006##GERRITS AMJ, 2006, HYDROL EARTH SYST SC, V3, P2323, DOI DOI 10.5194/HESSD-3-2323-2006##MATARIRA CH, 1992, INT J CLIMATOL, V12, P165, DOI 10.1002/JOC.3370120205##PITMAN WV, 1973, 273 U WITW DEP CIV E##RUTTER A J, 1972, AGRICULTURAL METEOROLOGY, V9, P367, DOI 10.1016/0002-1571(71)90034-3##SAVENIJE HHG, 2004, HYDROL PROCESS, V18, P1507, DOI 10.1002/HYP.5563##SCHELLEKENS J, 1999, J HYDROL, V225, P168, DOI 10.1016/S0022-1694(99)00157-2##SCHREIBER P., 1904, Z METEOROL, V21, P441##SIVAPALAN M, 1998, J HYDROL, V204, P150, DOI 10.1016/S0022-1694(97)00117-0##STERN RD, 1982, AGR METEOROL, V26, P35, DOI 10.1016/0002-1571(82)90056-5##TAYLOR CM, 1997, MON WEATHER REV, V125, P2211, DOI 10.1175/1520-0493(1997)125<2211:IBTLSA>2.0.CO;2##TODOROVIC P, 1975, J APPL METEOROL, V14, P17, DOI 10.1175/1520-0450(1975)014<0017:ASMODP>2.0.CO;2##TORRANCE J. D., 1981, CLIMATE HDB ZIMBABWE##WINSEMIUS HC, 2006, HYDROL EARTH SYST SC, V10, P339, DOI 10.5194/HESS-10-339-2006##WOOLHISER DA, 1993, WATER RESOUR RES, V29, P1287, DOI 10.1029/92WR02536##WOOLHISER DA, 1979, J APPL METEOROL, V18, P34, DOI 10.1175/1520-0450(1979)018<0034:MLEOFC>2.0.CO;2##ZENG N, 2000, J HYDROL, V228, P228, DOI 10.1016/S0022-1694(00)00140-2##ZUCCHINI W, 1992, S AFR J SCI, V88, P103",41,2020-11-20,NA
J,WOS:000243036000009,2006,BONE MORPHOGENETIC PROTEIN-2 IS A NEGATIVE REGULATOR OF HEPATOCYTE PROLIFERATION DOWNREGULATED IN THE REGENERATING LIVER,"AIM: TO CHARACTERIZE THE EXPRESSION AND DYNAMIC CHANGES OF BONE MORPHOGENETIC PROTEIN (BMP)-2 IN HEPATOCYTES IN THE REGENERATING LIVER IN RATS AFTER PARTIAL HEPATECTOMY (PH), AND EXAMINE THE EFFECTS OF BMP-2 ON PROLIFERATION OF HUMAN HUH7 HEPATOMA CELLS. METHODS: FIFTY-FOUR ADULT MALE WISTAR RATS WERE RANDOMLY DIVIDED INTO THREE GROUPS: A NORMAL CONTROL (NC) GROUP, A PARTIAL HEPATECTOMIZED (PH) GROUP AND A SHAM OPERATED (SO) GROUP. TO STUDY THE EFFECT OF LIVER REGENERATION ON BMP-2 EXPRESSION, RATS WERE SACRIFICED BEFORE AND AT DIFFERENT TIME POINTS AFTER PH OR THE SHAM INTERVENTION (6, 12, 24 AND 48 H). FOR EACH TIME POINT, SIX RATS WERE USED IN PARALLEL. EXPRESSION AND DISTRIBUTION OF BMP-2 PROTEIN WERE DETERMINED IN REGENERATING LIVER TISSUE BY WESTERN BLOT ANALYSIS AND IMMUNOHISTOCHEMISTRY. EFFECTS OF BMP-2 ON CELL PROLIFERATION OF HUMAN HUH7 HEPATOMA CELL LINE WERE ASSESSED USING AN MTT ASSAY. RESULTS: IN THE NORMAL LIVER STRONG BMP-2 EXPRESSION WAS OBSERVED AROUND THE CENTRAL AND PORTAL VEINS. THE EXPRESSION OF BMP-2 DECREASED RAPIDLY AS MEASURED BY BOTH IMMUNOHISTOCHEMISTRY AND WESTERN BLOT ANALYSIS. THIS DECREASE WAS AT A MAXIMUM OF 3.22 FOLD AFTER 12 H AND RETURNED TO NORMAL LEVELS AT 48 H AFTER PH. NO SIGNIFICANT CHANGES IN BMP-2 IMMUNOREACTIVITY WERE OBSERVED IN THE SO GROUP. BMP-2 INHIBITED SERUM INDUCED HUH7 CELL PROLIFERATION. CONCLUSION: BMP-2 IS EXPRESSED IN NORMAL ADULT RAT LIVER AND NEGATIVELY REGULATES HEPATOCYTE PROLIFERATION. THE OBSERVED DOWN REGULATION OF BMP-2 FOLLOWING PARTIAL HEPATECTOMY SUGGESTS THAT SUCH DOWN REGULATION MAY BE NECESSARY FOR HEPATOCYTE PROLIFERATION. (C) 2006 THE WJG PRESS. ALL RIGHTS RESERVED.",TRANSFORMING-GROWTH-FACTOR; GENE-EXPRESSION; GROWTH-FACTOR-BETA-1; CELLS; BETA; HEPATOGENESIS,BONE MORPHOGENETIC PROTEIN-2; PARTIAL HEPATECTOMY; LIVER REGENERATION; HEPATOCELLULAR CARCINOMA,WORLD JOURNAL OF GASTROENTEROLOGY,"XU, CP##JI, WM##VAN DEN BRINK, GR##PEPPELENBOSCH, MP","SHANXI MED UNIV, CLIN COLL 1, DEPT DIGEST DIS, TAIYUAN 030001, SHANXI, PEOPLES R CHINA. LEIDEN UNIV, MED CTR, DEPT GASTROENTEROL & HEPATOL, LEIDEN, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, FAC MED SCI, DEPT CELL BIOL, GRONINGEN, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,"AZARI K, 2001, EXPERT OPIN INV DRUG, V10, P1677, DOI 10.1517/13543784.10.9.1677##BACHNER D, 1999, BIOFACTORS, V9, P11##BLACK D, 2004, J SURG RES, V117, P306, DOI 10.1016/J.JSS.2003.10.026##CARR BI, 1986, CANCER RES, V46, P2330##IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/JBC.270.10.5476##JIRTLE RL, 1991, J BIOL CHEM, V266, P22444##KNITTEL T, 1997, EXP CELL RES, V232, P263, DOI 10.1006/EXCR.1997.3504##NAKABAYASHI H, 1982, CANCER RES, V42, P3858##ROMERO-GALLO J, 2005, ONCOGENE, V24, P3028, DOI 10.1038/SJ.ONC.1208475##ROSSI JM, 2001, GENE DEV, V15, P1998, DOI 10.1101/GAD.904601##SAKOU T, 1998, BONE, V22, P591, DOI 10.1016/S8756-3282(98)00053-2##SHEN H, 2003, AM J PHYSIOL-GASTR L, V285, PG539, DOI 10.1152/AJPGI.00436.2002##SHEN H, 2003, WORLD J GASTROENTERO, V9, P784, DOI 10.3748/WJG.V9.I4.784##SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/EN.136.10.4293##TAUB R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/NRM1489##URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/SCIENCE.150.3698.893##WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/SCIENCE.3201241##WOZNEY JM, 1998, CLIN ORTHOP RELAT R, P26##ZHANG WJ, 2004, DEV BIOL, V268, P312, DOI 10.1016/J.YDBIO.2004.01.019",20,2020-11-20,NA
J,WOS:000243669500009,2006,LOW-FREQUENCY MODULATION OF THE ATMOSPHERIC SURFACE LAYER OVER AMAZONIAN RAIN FOREST AND ITS IMPLICATION FOR SIMILARITY RELATIONSHIPS,"THE APPLICATION OF MONIN-OBUKHOV SIMILARITY THEORY (MOS) IS BASED ON EMPIRICAL RELATIONSHIPS DERIVED OVER UNIFORM SURFACES IN FLAT TERRAIN. IT IS NOT CLEAR TO WHAT EXTENT THESE RELATIONSHIPS HOLD FOR COMPLEX SURFACES SUCH AS TROPICAL FOREST OR HILLY TERRAIN. THIS STUDY INVESTIGATES THE INFLUENCE OF LOW-FREQUENCY MOTIONS IN THE STRUCTURE OF THE ATMOSPHERIC SURFACE LAYER OVER AMAZONIAN FOREST AND ITS IMPLICATION FOR THE APPLICATION OF MOS THEORY. WE TEST THE ESTIMATION OF HEAT FLUXES BY THE FLUX-VARIANCE METHOD, WHICH IS BASED ON MOS THEORY, FOR MEASUREMENTS IN UNSTABLE CONDITIONS IN THE K34 FOREST SITE IN CENTRAL AMAZONIA, NORTH OF MANAUS, BRAZIL. IT IS FOUND THAT THE MOS RELATIONSHIPS AND THE FLUX-VARIANCE METHOD PROVIDE REASONABLE RESULTS ONLY WHEN THE W - T CORRELATION (R(WT)) IS ABOVE 0.5. EXAMINING THE SCALE DEPENDENCE OF R(WT) AND OF U - W CORRELATION (R(UW)) REVEALED THAT W VARIATIONS TEND TO BE NOT WELL CORRELATED WITH FLUCTUATIONS IN U OR TAT LOW FREQUENCIES. IN THIS SENSE, A GREATER INFLUENCE OF LOW-FREQUENCY PROCESSES TENDS TO CAUSE R(WT) AND R(UW) TO DECREASE, AND IN THESE CONDITIONS THE SURFACE LAYER CANNOT BE CHARACTERIZED BY THE 'TEXTBOOK' DESCRIPTIONS OF THE SURFACE LAYER OBSERVED OVER UNIFORM TERRAIN. AS AN ALTERNATIVE TO THE CONVENTIONAL MOS SCALING, WE TEST THE USE OF THE 'DISSIPATION VELOCITY' U(EPSILON), = (KZE)(1/3), PROPOSED BY MCNAUGHTON [MCNAUGHTON, K.G., 2006. ON THE KINETIC ENERGY BUDGET OF THE UNSTABLE ATMOSPHERIC SURFACE LAYER. BOUNDARY-LAYER METEOROL. 118, 83-107], TO SCALE THE STANDARD DEVIATIONS AND PARAMETERIZE THE MODULATION OF LOW-FREQUENCY MOTIONS. THE SYSTEMATIC VARIATION WITH STABILITY IS TAKEN OUT BY THE USE OF THE NEW PARAMETERS, AND THE SCALED VARIABLES BECOME INDEPENDENT OF THE MOS STABILITY PARAMETER. THIS RESULT IS CONSISTENT WITH THE SELF-ORGANIZING NATURE OF THE TURBULENT STRUCTURE IN THE MODULATED SURFACE LAYER. THE RESULTS HIGHLIGHT THE COMPLEXITIES OF THE SURFACE LAYER ABOVE VEGETATION SUCH AS AMAZONIAN FOREST. ESTIMATIONS OF THE PARAMETER V(*)/U(*), WHICH REPRESENT THE MODULATION OF THE OUTER-LAYER MOTIONS ON THE SURFACE LAYER, INDICATE THAT DURING ROUGHLY 20% OF THE TIME THE UNSTABLE SURFACE LAYER ABOVE THE FOREST DEVIATES FROM THE 'CLASSICAL' DESCRIPTION. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",MONIN-OBUKHOV SIMILARITY; TURBULENT KINETIC-ENERGY; EDDY-CORRELATION; BOUNDARY-LAYER; CONVECTIVE CONDITIONS; SENSIBLE HEAT; STRUCTURE PARAMETER; DISSIPATION RATE; CARBON-DIOXIDE; WATER-VAPOR,TURBULENCE; SURFACE LAYER; SIMILARITY THEORY; LOW FREQUENCY; AMAZONIAN FOREST,AGRICULTURAL AND FOREST METEOROLOGY,"VON RANDOW, C##KRUIJT, B##HOLTSLAG, AAM","UNIV WAGENINGEN & RES CTR, ALTERRA, NL-6700 AA WAGENINGEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, METROL & AIR QUAL GRP, NL-6701 AP WAGENINGEN, NETHERLANDS.",AGRONOMY; FORESTRY; METEOROLOGY & ATMOSPHERIC SCIENCES,AGRICULTURE; FORESTRY; METEOROLOGY & ATMOSPHERIC SCIENCES,"ALBERTSON JD, 1997, J GEOPHYS RES-ATMOS, V102, P13423, DOI 10.1029/96JD03346##ANDREAS EL, 2002, J ATMOS SCI, V59, P2605##ARAUJO AC, J GEOPHYS RES, V107, P8090, DOI DOI 10.1029/2001D000676##AUBINET M, 2000, ADV ECOL RES, V30, P113, DOI 10.1016/S0065-2504(08)60018-5##BAAS P, 2006, J ATMOS SCI, V63, P3045, DOI 10.1175/JAS3778.1##CULF AD, 2000, HYDROL EARTH SYST SC, V4, P193, DOI 10.5194/HESS-4-193-2000##DEBRUIN HAR, 1993, BOUND-LAY METEOROL, V63, P231, DOI 10.1007/BF00710461##DEBRUIN HAR, 1991, LAND SURFACE EVAPORA, P157##FINNIGAN JJ, 2003, BOUND-LAY METEOROL, V107, P1, DOI 10.1023/A:1021554900225##FITZJARRALD DR, 1990, J GEOPHYS RES-ATMOS, V95, P16825, DOI 10.1029/JD095ID10P16825##HARTOGENSIS O.K., 2006, THESIS WAGENINGEN U##HARTOGENSIS OK, 2005, BOUND-LAY METEOROL, V116, P253, DOI 10.1007/S10546-004-2817-1##HICKS B. B., 1978, BOUNDARY-LAYER METEOROLOGY, V14, P567##HICKS BB, 1981, BOUND-LAY METEOROL, V21, P389, DOI 10.1007/BF00119281##HILL RJ, 1989, J ATMOS SCI, V46, P2236, DOI 10.1175/1520-0469(1989)046<2236:IOMSTF>2.0.CO;2##HOGSTROM U, 1990, J ATMOS SCI, V47, P1949, DOI 10.1175/1520-0469(1990)047<1949:AOTSIT>2.0.CO;2##HOLTSLAG AAM, 1991, J ATMOS SCI, V48, P1690, DOI 10.1175/1520-0469(1991)048<1690:EDACTI>2.0.CO;2##HOWELL JF, 1997, BOUND-LAY METEOROL, V83, P117, DOI 10.1023/A:1000210427798##JOHANSSON C, 2002, J ATMOS SCI, V59, P2608, DOI 10.1175/1520-0469(2002)059<2608:R>2.0.CO;2##JOHANSSON C, 2001, J ATMOS SCI, V58, P1549, DOI 10.1175/1520-0469(2001)058<1549:CTOTVO>2.0.CO;2##KAIMAL J C, 1994, ATMOSPHERIC BOUNDARY##KATUL GG, 1994, J ATMOS SCI, V51, P2181, DOI 10.1175/1520-0469(1994)051<2181:OTAROT>2.0.CO;2##KAYS WM, 1994, J HEAT TRANS-T ASME, V116, P284, DOI 10.1115/1.2911398##KOLMOGOROV A., 1941, DOKL AKAD NAUK SSSR, V30, P299, DOI DOI 10.1098/RSPA.1991.0075##KRUIJT B, 2000, BOUND-LAY METEOROL, V94, P297, DOI 10.1023/A:1002401829007##KRUIJT B, 2004, ECOL APPL, V14, PS101##LLOYD CR, 1991, BOUND-LAY METEOROL, V57, P311, DOI 10.1007/BF00120051##MAHRT L, 1991, Q J ROY METEOR SOC, V117, P151, DOI 10.1256/SMSQJ.49707##MALHI Y, 2004, HDB MICROMETEOROLOGY, P101##MCBEAN GA, 1972, Q J ROY METEOR SOC, V98, P383, DOI 10.1256/SMSQJ.41609##MCMILLEN RT, 1988, BOUND-LAY METEOROL, V43, P231, DOI 10.1007/BF00128405##MCNAUGHTON KG, 2000, BOUND-LAY METEOROL, V96, P143, DOI 10.1023/A:1002477120507##MCNAUGHTON KG, 2006, BOUND-LAY METEOROL, V118, P83, DOI 10.1007/S10546-005-3779-7##MCNAUGHTON KG, 2004, BOUND-LAY METEOROL, V112, P199, DOI 10.1023/B:BOUN.0000027906.28627.49##MCNAUGHTON KG, 2002, BOUND-LAY METEOROL, V102, P161, DOI 10.1023/A:1013171312407##MONCRIEFF JB, 1997, J HYDROL, V188, P589##MONIN A. S., 1971, STAT FLUID MECH, V1##MONIN AS, 1975, STAT FLUID MECH MECH, V2, P874##PANOFSKY H A, 1984, ATMOSPHERIC TURBULEN##RAUPACH MR, 1981, ANNU REV FLUID MECH, V13, P97, DOI 10.1146/ANNUREV.FL.13.010181.000525##SAKAI RK, 2001, J APPL METEOROL, V40, P2178, DOI 10.1175/1520-0450(2001)040<2178:IOLFCT>2.0.CO;2##SCHOTANUS P, 1983, BOUND-LAY METEOROL, V26, P81, DOI 10.1007/BF00164332##TENNEKES H, 1970, J ATMOS SCI, V27, P1027, DOI 10.1175/1520-0469(1970)027<1027:FCITTE>2.0.CO;2##TILLMAN J. E., 1972, JOURNAL OF APPLIED METEOROLOGY, V11, P783, DOI 10.1175/1520-0450(1972)011<0783:TIDOSH>2.0.CO;2##TOWNSEND AA, 1961, J FLUID MECH, V11, P97, DOI 10.1017/S0022112061000883##TWINE TE, 2000, AGR FOREST METEOROL, V103, P279, DOI 10.1016/S0168-1923(00)00123-4##VICKERS D, 2003, J ATMOS OCEAN TECH, V20, P660, DOI 10.1175/1520-0426(2003)20<660:TCGATF>2.0.CO;2##VON RANDOW C, 2004, THEOR APPL CLIMATOL, V78, P5, DOI 10.1007/S00704-004-0041-Z##VON RANDOW C, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000379##WEAVER HL, 1990, BOUND-LAY METEOROL, V53, P77, DOI 10.1007/BF00122464##WYNGAARD J. C., 1971, J OPT SOC AM, V15, P1177##ZHUANG YH, 1995, J ATMOS SCI, V52, P1712, DOI 10.1175/1520-0469(1995)052<1712:DAEOCP>2.0.CO;2",20,2020-11-20,NA
J,WOS:000243669500012,2006,A METHOD FOR ASSESSING FROST DAMAGE RISK IN SWEET CHERRY ORCHARDS OF SOUTH PATAGONIA,"QUANTIFICATION OF FROST DAMAGE RISK IS IMPORTANT IN PLANNING THE DEVELOPMENT OF NEW ORCHARD AREAS AND FOR DECISION-MAKING ON DESIGN AND INSTALLATION OF FROST CONTROL SYSTEMS. THE OBJECTIVE OF THIS STUDY WAS TO DEVELOP A COMPREHENSIVE METHOD TO QUANTIFY FROST DAMAGE RISK IN DIFFERENT SWEET CHERRY PRODUCTION AREAS OF SOUTH PATAGONIA AND TO ESTIMATE THE POTENTIAL IMPACT OF FROST CONTROL SYSTEMS ON RISK REDUCTION. LACK OF HISTORICAL WEATHER DATA REQUIRED A THEORETICAL-EMPIRICAL APPROACH. FROST DAMAGE FOR ANY SPECIFIC DAY OF THE SEASON WAS ASSUMED TO OCCUR WHEN THE MINIMUM TEMPERATURE ON THAT DAY WAS BELOW THE SPECIFIC LETHAL TEMPERATURE FOR THE PHENOLOGICAL STAGE PREDICTED AT THAT MOMENT (BASED ON PHENOLOGICAL MODELS). FROST DAMAGE PROBABILITY WAS ESTIMATED FOR EACH PRODUCTION LOCATION OF SOUTH PATAGONIA AS THE FREQUENCY OF SEASONS IN WHICH AT LEAST ONE DAMAGING FROST (DAMAGING >= 90% OF THE REPRODUCTIVE ORGANS) OCCURS, AT ANY TIME DURING THE GROWING SEASON UNTIL HARVEST. FROST DAMAGE RISK WAS COMPARED AMONG CULTIVARS AND LOCATIONS. FINALLY, THE EFFECT OF ACTIVE FROST CONTROL METHODS ON FROST DAMAGE RISK REDUCTION WAS ANALYZED. THERE WAS VERY LITTLE DIFFERENCE IN FROST DAMAGE RISK AMONG CULTIVARS, ALTHOUGH 'SUNBURST' WAS THE CULTIVAR WITH THE LOWEST RISK. THE MOST RISKY LOCATIONS WERE LOS ANTIGUOS AND ESQUEL, WHILE COMODORO RIVADAVIA WAS THE SAFEST LOCATION. THE FREQUENCY OF YEARS WITH AT LEAST ONE KILLING FROST DECREASED DRAMATICALLY WHEN THE MINIMUM TEMPERATURE WAS INCREASED BY 3 DEGREES C, USING ACTIVE FROST CONTROL SYSTEMS. THE METHODOLOGY PRESENTED APPEARS USEFUL TO IDENTIFY THE MAIN AND SECONDARY VARIABLES AFFECTING FROST DAMAGE RISK. THUS, THIS TYPE OF QUANTITATIVE ANALYSIS CAN SUPPORT GROWERS IN DECISION-MAKING ON REQUIRED INVESTMENTS AND OPERATIONAL COSTS OF THE EQUIPMENT FOR FROST CONTROL, ON THE BASIS OF POTENTIAL IMPACT OF A PARTICULAR CONTROL SYSTEM ON MEAN YIELDS AND YIELD STABILITY. IT MAY ALSO BE A GUIDE TO PRIORITISE RESEARCH ISSUES TO FILL KNOWLEDGE-GAPS WITH REGARD TO FROST RISK ASSESSMENT. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",AFRICA,LETHAL TEMPERATURE; FROST CONTROL; DAMAGE LEVEL; PHENOLOGY,AGRICULTURAL AND FOREST METEOROLOGY,"CITTADINI, ED##DE RIDDER, N##PERI, PL##VAN KEULEN, H","INST NACL TECNOL AGROPECUARIA, ESTAC EXPT AGROPECUARIA CHUBUT, TRELEW, ARGENTINA. UNIV WAGENINGEN & RES CTR, PLANT PROD SYST GRP, NL-6700 AA WAGENINGEN, NETHERLANDS. UNIV NACL PATAGONIA AUSTRAL, INST NACL TECNOL AGROPECUARIA, ESTAC EXPT AGROPECUARIA SANTA CRUZ, BUENOS AIRES, DF, ARGENTINA. CONSEJO NACL INVEST CIENT & TECN, COMIS NACL INVEST CIENTIF & TECN, RIO GALLEGOS, ARGENTINA. UNIV WAGENINGEN & RES CTR, PLANT RES INT, NL-6700 AA WAGENINGEN, NETHERLANDS.",AGRONOMY; FORESTRY; METEOROLOGY & ATMOSPHERIC SCIENCES,AGRICULTURE; FORESTRY; METEOROLOGY & ATMOSPHERIC SCIENCES,"BALLARD J.K, 1997, CRITICAL TEMPERATURE##BERTOLI D, 2005, 12 C LAT 28 C ARG HO, P68##BRUNO AMP, 1998, FENOLOGIA ESPECIES F##CITTADINI E. D., 2005, P 5 INT CHERR S BURS, P122##CITTADINI E. D., 2005, P 5 INT CHERR S BURS, P124##CITTADINI ED, 2005, P 5 INT CHERR S BURS, P161##DE PERRAUDIN G, 1965, AGR ROMANDE, V4, P70##IEZZONI A.F., 1985, ACTA HORTIC, V169, P123##JONES P, 2002, MARKSIM COMPUTER TOO##JONES PG, 2003, GLOBAL ENVIRON CHANG, V13, P51, DOI 10.1016/S0959-3780(02)00090-0##JONES PG, 2000, AGRON J, V92, P445, DOI 10.2134/AGRONJ2000.923445X##LINDKVIST L, 1999, CLIMATE RES, V12, P65, DOI 10.3354/CR012065##LINDKVIST L, 2000, AGR FOREST METEOROL, V102, P51, DOI 10.1016/S0168-1923(99)00087-8##LONGSTROTH M., 1996, P203##MAVROMATIS T, 2001, AGR FOREST METEOROL, V109, P283, DOI 10.1016/S0168-1923(01)00272-6##MEINKE H, 2001, AGR SYST, V70, P493, DOI 10.1016/S0308-521X(01)00057-9##PASCALE A. J., 1997, REVISTA DE LA FACULTAD DE AGRONOMIA (UNIVERSIDAD DE BUENOS AIRES), V17, P25##PROEBSTING EL, 1978, J AM SOC HORTIC SCI, V103, P192##PUGH AB, 2001, FENOLOGIA ESPECIES F##PUGH EO, 2002, FENOLOGIA ESPECIES F##PUGH EO, 2001, FENOLOGIA ESPECIES F##TASSARA M, 2005, DEFENSA HELADAS, V45, P20##THOMPSON M., 1996, P223##WHITING MD, 2004, J AM SOC HORTIC SCI, V129, P407, DOI 10.21273/JASHS.129.3.0407",30,2020-11-20,NA
J,WOS:000242955200024,2006,THE MID-INFRARED PROPERTIES OF STARBURST GALAXIES FROM SPITZER-IRS SPECTROSCOPY,"WE PRESENT 5-38 MU M MID-INFRARED SPECTRA AT A SPECTRAL RESOLUTION OF R APPROXIMATE TO 65-130 OF A LARGE SAMPLE OF 22 STARBURST NUCLEI TAKEN WITH THE INFRARED SPECTROGRAPH ( IRS) ON BOARD THE SPITZER SPACE TELESCOPE. THE SPECTRA SHOW A VAST RANGE OF STARBURST SEDS. THE SILICATE ABSORPTION RANGES FROM ESSENTIALLY NO ABSORPTION TO HEAVILY OBSCURED SYSTEMS WITH AN OPTICAL DEPTH OF TAU(9.8 MU M) SIMILAR TO 5. THE SPECTRAL SLOPES CAN BE USED TO DISCRIMINATE BETWEEN STARBURST AND AGN POWERED SOURCES. THE MONOCHROMATIC CONTINUUM FLUXES AT 15 AND 30 MU M ENABLE A REMARKABLY ACCURATE ESTIMATE OF THE TOTAL INFRARED LUMINOSITY OF THE STARBURST. WE FIND THAT THE PAH EQUIVALENT WIDTH IS INDEPENDENT OF THE TOTAL STARBURST LUMINOSITY L-IR AS BOTH CONTINUUM AND PAH FEATURE SCALE PROPORTIONALLY. HOWEVER, THE LUMINOSITY OF THE 6.2 MU M FEATURE SCALES WITH L-IR AND CAN BE USED TO APPROXIMATE THE TOTAL INFRARED LUMINOSITY OF THE STARBURST. ALTHOUGH OUR STARBURST SAMPLE COVERS ABOUT A FACTOR OF 10 DIFFERENCE IN THE [NE II]/[NE II] RATIO, WE FOUND NO SYSTEMATIC CORRELATION BETWEEN THE RADIATION FIELD HARDNESS AND THE PAH EQUIVALENT WIDTH OR THE 7.7 MU M/11.3 MU M PAH RATIO. THESE RESULTS ARE BASED ON SPATIALLY INTEGRATED DIAGNOSTICS OVER AN ENTIRE STARBURST REGION, AND LOCAL VARIATIONS MAY BE ""AVERAGED OUT.'' IT IS PRESUMABLY DUE TO THIS EFFECT THAT UNRESOLVED STARBURST NUCLEI WITH SIGNIFICANTLY DIFFERENT GLOBAL PROPERTIES APPEAR SPECTRALLY AS RATHER SIMILAR MEMBERS OF ONE CLASS OF OBJECTS.",STAR-FORMATION HISTORY; INFRARED SPECTROGRAPH; EMISSION FEATURES; BENDING MODES; SPECTRA; NUCLEAR; EVOLUTION; CONTINUUM; RADIO; DUST,GALAXIES : STARBURST; INFRARED : GALAXIES,ASTROPHYSICAL JOURNAL,"BRANDL, BR##BERNARD-SALAS, J##SPOON, HWW##DEVOST, D##SLOAN, GC##GUILLES, S##WU, Y##HOUCK, JR##WEEDMAN, DW##ARMUS, L##APPLETON, PN##SOIFER, BT##CHARMANDARIS, V##HAO, L##MARSHALL, JA##HIGDON, SJ##HERTER, TL","LEIDEN UNIV, NL-2300 RA LEIDEN, NETHERLANDS. CORNELL UNIV, DEPT ASTRON, ITHACA, NY 14853 USA. CALTECH, SPITZER SCI CTR, PASADENA, CA 91125 USA. UNIV CRETE, DEPT PHYS, GR-71003 IRAKLION, GREECE. CORNELL UNIV, DEPT ASTRON, ITHACA, NY 14853 USA.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ALONSO-HERRERO A, 2001, ASTROPHYS J, V546, P952, DOI 10.1086/318282##ARMUS L, 2006, ASTROPHYS J, V640, P204, DOI 10.1086/500040##ARMUS L, 2007, IN PRESS APJ, V655##ASHBY MLN, 1995, ASTROPHYS J, V447, P545, DOI 10.1086/175898##BAKES ELO, 1994, ASTROPHYS J, V427, P822, DOI 10.1086/174188##BALZANO VA, 1983, ASTROPHYS J, V268, P602, DOI 10.1086/160983##BEIRAO P, 2006, ASTROPHYS J, V643, PL1, DOI 10.1086/505027##BENDO GJ, 2004, ASTRON J, V127, P3338, DOI 10.1086/420712##BESWICK RJ, 2003, MON NOT R ASTRON SOC, V346, P424, DOI 10.1046/J.1365-2966.2003.07104.X##BRANDL BR, 2004, ASTROPHYS J SUPPL S, V154, P188, DOI 10.1086/422101##CESARSKY D, 1996, ASTRON ASTROPHYS, V315, PL309##CHARMANDARIS V, 2001, ASTROPHYS SPACE SCI, V277, P55, DOI 10.1023/A:1012767308774##CHARY R, 2001, ASTROPHYS J, V556, P562, DOI 10.1086/321609##CHIAR JE, 2000, ASTROPHYS J, V537, P749, DOI 10.1086/309047##COHEN M, 2003, ASTRON J, V125, P2645, DOI 10.1086/374362##DALE DA, 2006, ASTROPHYS J, V646, P161, DOI 10.1086/504835##DALE DA, 2000, ASTRON J, V120, P583, DOI 10.1086/301478##DALE DA, 2005, ASTROPHYS J, V633, P857, DOI 10.1086/491642##DEVEREUX NA, 1989, ASTROPHYS J, V346, P126, DOI 10.1086/167991##DRAINE BT, 1989, ESA SP PUBL, V290, P93##FRITZEVONALVENSLEBEN U, 1994, ASTRON ASTROPHYS, V285, P775##GAO Y, 2004, ASTROPHYS J, V606, P271, DOI 10.1086/382999##GEBALLE TR, 1989, ASTROPHYS J, V341, P278, DOI 10.1086/167491##GENZEL R, 2000, ANNU REV ASTRON ASTR, V38, P761, DOI 10.1146/ANNUREV.ASTRO.38.1.761##GONZALEZDELGADO RM, 1999, APJ, V513, P707##HECKMAN TM, 1998, ASTROPHYS J, V503, P646, DOI 10.1086/306035##HELOU G, 2000, ASTROPHYS J, V532, PL21, DOI 10.1086/312549##HIGDON SJU, 2004, PUBL ASTRON SOC PAC, V116, P975, DOI 10.1086/425083##HO LC, 1997, ASTROPHYS J SUPPL S, V112, P315, DOI 10.1086/313041##HONY S, 2001, ASTRON ASTROPHYS, V370, P1030, DOI 10.1051/0004-6361:20010242##HOUCK JR, 2004, ASTROPHYS J SUPPL S, V154, P18, DOI 10.1086/423134##IWASAWA K, 1993, ASTROPHYS J, V409, P155, DOI 10.1086/172651##JOSEPH RD, 1985, MON NOT R ASTRON SOC, V214, P87, DOI 10.1093/MNRAS/214.2.87##KEEL WC, 1984, ASTROPHYS J, V282, P75, DOI 10.1086/162177##KENNICUTT RC, 1998, ANNU REV ASTRON ASTR, V36, P189, DOI 10.1146/ANNUREV.ASTRO.36.1.189##KETO E, 1992, ASTROPHYS J, V389, P223, DOI 10.1086/171199##LAURENT O, 2000, ASTRON ASTROPHYS, V359, P887##LEVENSON NA, 2001, ASTROPHYS J SUPPL S, V133, P269, DOI 10.1086/320355##LIU CT, 1995, ASTROPHYS J, V450, P547, DOI 10.1086/176165##LONSDALE CJ, 1984, ASTROPHYS J, V287, P95, DOI 10.1086/162666##LU NY, 2003, ASTROPHYS J, V588, P199, DOI 10.1086/374043##LUTZ D, 1998, ASTRON ASTROPHYS, V333, PL75##LUTZ D, 1999, ESA SPEC PUBL, V427, P623##MADDEN SC, 2006, ASTRON ASTROPHYS, V446, P877, DOI 10.1051/0004-6361:20053890##MATHIS JS, 1977, ASTROPHYS J, V217, P425, DOI 10.1086/155591##MAYYA YD, 2004, ASTROPHYS J, V600, P188, DOI 10.1086/379707##MILLER BW, 1997, ASTRON J, V114, P2381, DOI 10.1086/118655##MOURI H, 1997, ASTROPHYS J, V484, P222, DOI 10.1086/304308##OSMER PS, 1974, ASTROPHYS J, V192, P279, DOI 10.1086/153058##OSTERBROCK DE, 1983, ASTROPHYS J, V273, P478, DOI 10.1086/161385##PEETERS E, 2004, ASTROPHYS J, V613, P986, DOI 10.1086/423237##PEETERS E, 2002, ASTRON ASTROPHYS, V390, P1089, DOI 10.1051/0004-6361:20020773##RIGOPOULOU D, 1999, ASTRON J, V118, P2625, DOI 10.1086/301146##RIGOPOULOU D, 1996, ASTRON ASTROPHYS, V315, PL125##ROBERTS TP, 2004, MON NOT R ASTRON SOC, V349, P1193, DOI 10.1111/J.1365-2966.2004.07626.X##SANDERS DB, 2003, ASTRON J, V126, P1607, DOI 10.1086/376841##SANDERS DB, 1996, ANNU REV ASTRON ASTR, V34, P749, DOI 10.1146/ANNUREV.ASTRO.34.1.749##SCHREIBER NAF, 2003, ASTRON ASTROPHYS, V399, P833, DOI 10.1051/0004-6361:20021719##SCHREIBER NAF, 2004, ASTRON ASTROPHYS, V419, P501, DOI 10.1051/0004-6361:20040963##SMITH DA, 1998, ASTROPHYS J, V494, P150, DOI 10.1086/305175##*SPITZ SCI CTR, 2005, SPITZ OBS MAN VERS 6##SPOON HWW, 2006, ASTROPHYS J, V638, P759, DOI 10.1086/498566##SPOON HWW, 2000, ASTRON ASTROPHYS, V357, P898##SPOON HWW, 2002, ASTRON ASTROPHYS, V385, P1022, DOI 10.1051/0004-6361:20020147##STORCHI-BERGMANN T, 2003, ASTROPHYS J, V598, P956, DOI 10.1086/378938##STURM E, 2000, ASTRON ASTROPHYS, V358, P481##TACCONI-GARMAN LE, 2005, ASTRON ASTROPHYS, V432, P91, DOI 10.1051/0004-6361:20035738##TAKEUCHI TT, 2005, ASTRON ASTROPHYS, V432, P423, DOI 10.1051/0004-6361:20042189##THORNLEY MD, 2000, ASTROPHYS J, V539, P641, DOI 10.1086/309261##TIELENS AGGM, 1985, ASTROPHYS J, V291, P722, DOI 10.1086/163111##TRAN D, 1998, THESIS U PARIS 11##UCHIDA KI, 1998, ASTROPHYS J, V493, PL109, DOI 10.1086/311136##VAN KERCKHOVEN C, 2000, ASTRON ASTROPHYS, V357, P1013##VERMA A, 2003, ASTRON ASTROPHYS, V403, P829, DOI 10.1051/0004-6361:20030408##VERMEIJ R, 2002, ASTRON ASTROPHYS, V382, P1042, DOI 10.1051/0004-6361:20011628##VERON P, 1980, ASTRON ASTROPHYS, V87, P245##VERSTRAETE L, 1996, ASTRON ASTROPHYS, V315, PL337##WANG G, 1992, ACTA ASTROPHYS SINIC, V11, P311##WEEDMAN DW, 1981, ASTROPHYS J, V248, P105, DOI 10.1086/159133##WEEDMAN DW, 2005, ASTROPHYS J, V633, P706, DOI 10.1086/466520##WERNER MW, 2004, ASTROPHYS J SUPPL S, V154, P1, DOI 10.1086/422992##WU YL, 2006, ASTROPHYS J, V639, P157, DOI 10.1086/499226",327,2020-11-20,NA
J,WOS:000242955200029,2006,EJECTION OF HIGH-VELOCITY STARS FROM THE GALACTIC CENTER BY AN INSPIRALING INTERMEDIATE-MASS BLACK HOLE,"THE PRESENCE OF YOUNG STARS NEAR SGR A* REMAINS UNEXPLAINED. ONE IDEA FOR THEIR ORIGIN POSITS THAT THE STARS WERE BROUGHT IN BY AN INTERMEDIATE- MASS BLACK HOLE (IMBH) THAT INSPIRALED INTO THE GALACTIC CENTER A FEW MILLION YEARS AGO. YU & TREMAINE HAVE ARGUED THAT IN THIS CASE SOME OLD STARS IN THE SGR A* CUSP WOULD BE EJECTED BY HARD GRAVITATIONAL COLLISIONS WITH THE IMBH. WE DERIVE A GENERAL EXPRESSION FOR THE PHASE-SPACE DISTRIBUTION OF THE EJECTED HIGHVELOCITY STARS, GIVEN THE DISTRIBUTION FUNCTION OF THE STARS IN THE CUSP. WE COMPUTE IT EXPLICITLY FOR THE PEEBLES-YOUNG DISTRIBUTION FUNCTION OF THE CUSP AND MODEL THE TIME-DEPENDENT EJECTION OF STARS DURING THE IMBH INSPIRAL. WE FIND THAT (1) THE STARS ARE EJECTED IN A BURST LASTING A FEW DYNAMICAL FRICTION TIMESCALES; IF GAIA DETECTS THE EJECTED STARS, THEY ARE LIKELY TO BE PRODUCED BY A SINGLE INSPIRAL EVENT. (2) IF THE INSPIRAL IS CIRCULAR, THEN IN THE BEGINNING OF THE BURST THE VELOCITY VECTORS OF THE EJECTED STARS CLUSTER AROUND THE INSPIRAL PLANE BUT RAPIDLY ISOTROPIZE AS THE BURST PROCEEDS. (3) IF THE INSPIRAL IS ECCENTRIC, THEN THE STARS ARE EJECTED IN A BROAD JET ROUGHLY PERPENDICULAR TO THE IMBH ORBIT'S RUNGE-LENZ VECTOR. IN A TYPICAL CUSP THE ORBIT WILL PRECESS WITH A PERIOD OF SIMILAR TO 10(5) YR, AND THE RATE OF EJECTION INTO OUR PART OF THE GALAXY (AS DEFINED BY GAIA VISIBILITY) WILL BE MODULATED PERIODICALLY. GAIA, TOGETHER WITH GROUND-BASED FOLLOW-UP OBSERVATIONS, WILL BE ABLE TO CLOCK MANY HIGH-VELOCITY STARS BACK TO THEIR EJECTION, THUS MEASURING SOME OF THE ABOVE PHENOMENA. THIS WOULD PROVIDE A CLEAR SIGNATURE OF THE IMBH INSPIRAL IN THE PAST 10-20 MYR.",HYPERVELOCITY STARS; CLUSTERS; DYNAMICS; HALO,BLACK HOLE PHYSICS; GALAXY : CENTER; GALAXY : NUCLEUS,ASTROPHYSICAL JOURNAL,"LEVIN, Y","CANADIAN INST THEORET ASTROPHYS, TORONTO, ON M5S 3H8, CANADA. LEIDEN OBSERV, NL-2300 RA LEIDEN, NETHERLANDS.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ARTYMOWICZ P, 1993, ASTROPHYS J, V409, P592, DOI 10.1086/172690##BROWN WR, 2005, ASTROPHYS J, V622, PL33, DOI 10.1086/429378##DANBY J, 1988, FUNDAMENTALS CELESTI##GENZEL R, 2003, ASTROPHYS J, V594, P812, DOI 10.1086/377127##GERHARD O, 2001, ASTROPHYS J, V546, PL39, DOI 10.1086/318054##GNEDIN OY, 2005, ASTROPHYS J, V634, P344, DOI 10.1086/496958##GOODMAN J, 2004, ASTROPHYS J, V608, P108, DOI 10.1086/386360##GOULD A, 2003, ASTROPHYS J, V592, P935, DOI 10.1086/375840##GUALANDRIS A, 2005, MON NOT R ASTRON SOC, V363, P223, DOI 10.1111/J.1365-2966.2005.09433.X##GURKAN MA, 2004, ASTROPHYS J, V604, P632, DOI 10.1086/381968##HANSEN BMS, 2003, ASTROPHYS J, V593, PL77, DOI 10.1086/378182##HENON M., 1960, ANNALES D'ASTROPHYSIQUE, V23, P467##HENON M, 1969, ASTRON ASTROPHYS, V2, P151##HENON M., 1960, ANNALES D'ASTROPHYSIQUE, V23, P668##LEVIN Y, 2003, ASTROPHYS J, V590, PL33, DOI 10.1086/376675##LEVIN Y, 2005, ASTROPHYS J, V635, P341, DOI 10.1086/497286##LEVIN Y, 2003, ASTROPH0307084##LIN DNC, 1980, ASTROPHYS J, V242, P789, DOI 10.1086/158513##MORRIS M, 1993, ASTROPHYS J, V408, P496, DOI 10.1086/172607##MUNYANEZA F, 1999, ASTROPHYS J, V526, P744, DOI 10.1086/308026##PERRYMAN MAC, 2001, ASTRON ASTROPHYS, V369, P339, DOI 10.1051/0004-6361:20010085##PHINNEY E. S., 1989, IAU S, V136, P543##SANDERS RH, 1992, NATURE, V359, P131, DOI 10.1038/359131A0##YOUNG P, 1980, ASTROPHYS J, V242, P1232, DOI 10.1086/158553##YU QJ, 2003, ASTROPHYS J, V599, P1129, DOI 10.1086/379546##ZWART SFP, 2004, NATURE, V428, P724, DOI 10.1038/NATURE02448",50,2020-11-20,NA
J,WOS:000242955200050,2006,DISCOVERY OF TWIN KHZ QPOS IN THE PECULIAR X-RAY BINARY CIRCINUS X-1,"WE REPORT THE DISCOVERY WITH THE RXTE PCA OF TWIN KHZ QPOS IN THE PECULIAR X-RAY BINARY CIRCINUS X-1. ELEVEN CASES OF SIMULTANEOUS DOUBLE QPOS OCCURRED, WITH SIGNIFICANCES OF UP TO 6.3 AND 5.5 SIGMA AND CENTROID FREQUENCIES RANGING BETWEEN APPROXIMATELY 56 AND 225 AND 230 AND 500 HZ FOR THE TWO QPO PEAKS, RESPECTIVELY, I.E., FOR THE MOST PART AT FREQUENCIES WELL BELOW THOSE OF OTHER SOURCES. THE QPO PROPERTIES CLEARLY INDICATE THAT THESE DOUBLE PEAKS ARE THE KHZ QPOS KNOWN FROM LOW MAGNETIC FIELD NEUTRON STARS, AND NOT BLACK HOLE HIGH-FREQUENCY QPOS, CONFIRMING THAT CIR X-1 IS A NEUTRON STAR, AS SUSPECTED SINCE THE DETECTION OF TYPE I X-RAY BURSTS FROM THE FIELD OF THE SOURCE 20 YEARS AGO. THE KHZ QPO PEAK SEPARATION VARIES OVER A WIDE RANGE, SIMILAR TO 175-340 HZ, AND INCREASES AS A FUNCTION OF KHZ QPO FREQUENCY. THIS IS CONTRARY TO WHAT HAS BEEN OBSERVED IN OTHER SOURCES BUT IN GOOD AGREEMENT WITH PREDICTIONS OF THE RELATIVISTIC PRECESSION MODEL AND ALFVEN WAVE MODELS; BEAT-FREQUENCY MODELS REQUIRE MODIFICATION TO ACCOMMODATE THIS. IN OTHER OBSERVATIONS, SINGLE KHZ QPOS CAN BE SEEN DOWN TO FREQUENCIES AS LOW AS SIMILAR TO 12HZ, AS WELL AS A STRONG LOW-FREQUENCY QUASI-PERIODIC OSCILLATION (LF QPO) BETWEEN 1 AND 30 HZ. THE RELATIONS BETWEEN THE KHZ QPOS AND THE LF QPO ARE IN GOOD AGREEMENT WITH THOSE FOUND PREVIOUSLY IN Z SOURCES, CONFIRMING THAT CIR X-1 MAY BE A PECULIAR Z SOURCE. WE SUGGEST THAT THE LOW-FREQUENCY RANGE OVER WHICH THE KHZ QPOS OCCUR IN CIR X-1 AND TO A LESSER EXTENT IN (OTHER) Z SOURCES, MIGHT BE DUE TO A STRONGER RADIAL ACCRETION FLOW RELATIVE TO THE DISK FLOW THAN IN OTHER KHZ QPO SOURCES, POSSIBLY RELATED TO THE NATURE OF THE COMPANION STAR.",QUASI-PERIODIC OSCILLATIONS; NEUTRON-STAR; CIR X-1; TIMING-EXPLORER; BRIGHTNESS OSCILLATIONS; 4U 1608-52; FREQUENCY; BEHAVIOR; MODEL; SPECTRUM,X-RAYS : BINARIES; X-RAYS : INDIVIDUAL (CIRCINUS X-1),ASTROPHYSICAL JOURNAL,"BOUTLOUKOS, S##VAN DER KLIS, M##ALTAMIRANO, D##KLEIN-WOLT, M##WIJNANDS, R##JONKER, PG##FENDER, RP","UNIV AMSTERDAM, ASTRON INST ANTON PANNEKOEK, NL-1098 SJ AMSTERDAM, NETHERLANDS. CTR HIGH ENERGY ASTROPHYS, NL-1098 SJ AMSTERDAM, NETHERLANDS. UNIV TUBINGEN, D-72076 TUBINGEN, GERMANY. NETHERLANDS INST SPACE RES, SRON, NL-3584 CA UTRECHT, NETHERLANDS. HARVARD SMITHSONIAN CTR ASTROPHYS, CAMBRIDGE, MA 02138 USA. UNIV UTRECHT, INST ASTRON, NL-3508 TA UTRECHT, NETHERLANDS. UNIV SOUTHAMPTON, SCH PHYS & ASTRON, SOUTHAMPTON SO17 1BJ, HANTS, ENGLAND.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ALTAMIRANO D, 2005, ASTROPHYS J, V633, P358, DOI 10.1086/447761##BELLONI T, 2005, ASTRON ASTROPHYS, V437, P209, DOI 10.1051/0004-6361:20041377##BELLONI T, 2002, ASTROPHYS J, V572, P392, DOI 10.1086/340290##DING GQ, 2003, ASTROPHYS J, V596, PL219, DOI 10.1086/379338##DONE C, 2003, MON NOT R ASTRON SOC, V342, P1041, DOI 10.1046/J.1365-8711.2003.06614.X##FENDER R, 2004, NATURE, V427, P222, DOI 10.1038/NATURE02137##FENDER R, 2005, ASTRON TEL, V563, P1##GLASS IS, 1994, MON NOT R ASTRON SOC, V268, P742, DOI 10.1093/MNRAS/268.3.742##GOSS WM, 1977, MON NOT R ASTRON SOC, V181, P255, DOI 10.1093/MNRAS/181.2.255##HASINGER G, 1989, ASTRON ASTROPHYS, V225, P79##HOMAN J, 2002, ASTROPHYS J, V568, P878, DOI 10.1086/339057##IARIA R, 2005, ASTROPHYS J, V619, P503, DOI 10.1086/426422##IARIA R, 2001, ASTROPHYS J, V547, P412, DOI 10.1086/318366##JAHODA K, 2006, ASTROPHYS J SUPPL S, V163, P401, DOI 10.1086/500659##JOHNSTON HM, 1999, MON NOT R ASTRON SOC, V308, P415, DOI 10.1046/J.1365-8711.1999.02702.X##JONES C, 1974, ASTROPHYS J, V191, PL71, DOI 10.1086/181551##JONKER PG, 2002, MON NOT R ASTRON SOC, V333, P665, DOI 10.1046/J.1365-8711.2002.05442.X##JONKER PG, 2004, MON NOT R ASTRON SOC, V354, P355, DOI 10.1111/J.1365-2966.2004.08193.X##JONKER PG, 2006, IN PRESS MNRAS##KLEIN-WOLT M, 2004, NUCL PHYS B-PROC SUP, V132, P381, DOI 10.1016/J.NUCLPHYSBPS.2004.04.067##KLUZNIAK W, 2003, ASTROPH0304345##KLUZNIAK W, 2001, ASTROPH0105057##KUULKERS E, 1994, ASTRON ASTROPHYS, V289, P795##LAMB FK, 2001, ASTROPHYS J, V554, P1210, DOI 10.1086/323148##LAMB FK, 2003, ASTROPH0308179##LINARES M, 2005, ASTROPHYS J, V634, P1250, DOI 10.1086/497025##MAISACK M, 1995, ADV SPACE RES, V16, P91, DOI 10.1016/0273-1177(95)00051-F##MCCLINTOCK J.E., 2006, COMPACT STELLAR XRAY, P157, DOI DOI 10.2277/0521826594##MENDEZ M, 2001, ASTROPHYS J, V561, P1016, DOI 10.1086/323486##MIGLIARI S, 2003, MON NOT R ASTRON SOC, V345, PL35, DOI 10.1046/J.1365-8711.2003.07186.X##MILLER MC, 1998, ASTROPHYS J, V508, P791, DOI 10.1086/306408##MURDIN P, 1980, ASTRON ASTROPHYS, V87, P292##OOSTERBROEK T, 1995, ASTRON ASTROPHYS, V297, P141##PSALTIS D, 1998, ASTROPHYS J, V501, PL95, DOI 10.1086/311455##PSALTIS D, 1999, ASTROPHYS J, V520, P262, DOI 10.1086/307436##PSALTIS D, 1995, ASTROPHYS J, V454, PL137, DOI 10.1086/309780##REVNIVTSEV M, 2000, ASTRON ASTROPHYS, V363, P1013##REZANIA V, 2005, ASTRON ASTROPHYS, V436, P999, DOI 10.1051/0004-6361:20041796##SAMIMI J, 1979, NATURE, V278, P434, DOI 10.1038/278434A0##SHIREY RE, 1998, ASTROPHYS J, V506, P374, DOI 10.1086/306247##SHIREY RE, 1999, ASTROPHYS J, V517, P472, DOI 10.1086/307188##SHIREY RE, 1996, ASTROPHYS J, V469, PL21, DOI 10.1086/310264##STELLA L, 1999, PHYS REV LETT, V82, P17, DOI 10.1103/PHYSREVLETT.82.17##STROHMAYER TE, 2001, ASTROPHYS J, V552, PL49, DOI 10.1086/320258##TENNANT A. F., 1986, MNRAS, V221, P27##TENNANT AF, 1987, MON NOT R ASTRON SOC, V226, P971, DOI 10.1093/MNRAS/226.4.971##VAN DER KLIS M, 2001, ASTROPHYS J, V561, P943, DOI 10.1086/323378##VAN DER KLIS M., 2006, COMPACT STELLAR XRAY, P39##VAN STRAATEN S, 2003, ASTROPHYS J, V596, P1155, DOI 10.1086/378155##VAN STRAATEN S, 2005, ASTROPHYS J, V619, P455, DOI 10.1086/426183##VAN STRAATEN S, 2002, ASTROPHYS J, V568, P912, DOI 10.1086/338948##ZHANG C, 2004, ASTRON ASTROPHYS, V423, P401, DOI 10.1051/0004-6361:20035808##ZHANG CM, 2005, ASTROPH0502102##ZHANG W, 1996, ASTROPHYS J, V469, PL29, DOI 10.1086/310259##ZHANG W, 1995, ASTROPHYS J, V449, P930, DOI 10.1086/176111",75,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/D001013/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242118800003,2006,CHARACTERIZATION OF AN EXPERIMENTAL MINIATURE BIOREACTOR FOR CELLULAR PERTURBATION STUDIES,"A MINI BIOREACTOR (3.0 ML VOLUME) HAS BEEN DEVELOPED AND SHOWN TO BE A VERSATILE TOOL FOR RAPIDLY SCREENING AND QUANTIFYING THE RESPONSE OF ORGANISMS ON ENVIRONMENTAL PERTURBATIONS. THE MINI BIOREACTOR IS ESSENTIALLY A PLUG FLOW DEVICE TRANSFORMED INTO A WELL-MIXED REACTOR BY A RECYCLE FLOW OF THE BROTH. THE GAS AND LIQUID PHASES ARE SEPARATED BY A SILICONE MEMBRANE. DYNAMIC MASS TRANSFER EXPERIMENTS WERE PERFORMED TO DETERMINE THE MASS TRANSFER CAPACITIES FOR OXYGEN AND CARBON DIOXIDE. THE MASS TRANSFER COEFFICIENTS FOR OXYGEN AND CARBON DIOXIDE WERE FOUND TO BE 1.55 +/- 0.17 X 10(-5) M/S AND 4.52 +/- 0.60 X 10(-6) M/S, RESPECTIVELY. CULTIVATION EXPERIMENTS WITH THE 3.0 ML BIOREACTOR SHOW THAT (I) IT CAN MAINTAIN BIOMASS IN THE SAME PHYSIOLOGICAL STATE AS THE 4.0 L LAB SCALE BIOREACTOR, (II) REPRODUCIBLE PERTURBATION EXPERIMENTS SUCH AS CHANGING SUBSTRATE UPTAKE RATE CAN BE READILY PERFORMED AND THE PHYSIOLOGICAL RESPONSE MONITORED QUANTITATIVELY IN TERMS OF THE O-2 AND CO2 UPTAKE AND PRODUCTION RATES. (C) 2006 WILEY PERIODICALS, INC.",IN-VIVO KINETICS; METABOLISM; DESIGN; SYSTEM,MINI BIOREACTOR; PERTURBATION; QUANTITATIVE RESPONSE IN O-2 AND CO2; SCREENING; RTD; MASS TRANSFER,BIOTECHNOLOGY AND BIOENGINEERING,"ABOKA, FO##YANG, HL##DE JONGE, LP##KERSTE, R##VAN WINDEN, WA##VAN GULIK, WM##HOOGENDIJK, R##OUDSHOORN, A##HEIJNEN, JJ","DELFT UNIV TECHNOL, DEPT BIOTECHNOL, NL-2628 BC DELFT, NETHERLANDS. APPLIKON BV, NL-AE SCHIEDAM, NETHERLANDS.",BIOTECHNOLOGY & APPLIED MICROBIOLOGY,BIOTECHNOLOGY & APPLIED MICROBIOLOGY,"ALPER H, 2004, CHEM ENG SCI, V59, P5009, DOI 10.1016/J.CES.2004.09.027##BAILEY JE, 1980, CHEM ENG SCI, V35, P1854, DOI 10.1016/0009-2509(80)80134-5##BEEK JWM, 1999, TRANSPORT PHENOMENA##BLOEMEN HHJ, 2003, AICHE J, V49, P1895, DOI 10.1002/AIC.690490725##BUFFHAM BA, 1975, CHEM ENG SCI, V30, P1519, DOI 10.1016/0009-2509(75)85030-5##COTE P, 1989, J MEMBRANE SCI, V47, P91, DOI 10.1016/S0376-7388(00)80862-5##GMATI D, 2005, BIOTECHNOL BIOENG, V89, P138, DOI 10.1002/BIT.20293##HATZIMANIKATIS V, 1998, BIOTECHNOL BIOENG, V58, P154, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<154::AID-BIT7>3.0.CO;2-K##KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633A0##LEE JY, 1994, BIOTECHNOL BIOENG, V43, P1146, DOI 10.1002/BIT.260431120##LEVENSPIEL O., 1999, CHEM REACTION ENG##LINEK V, 1987, CHEM ENG J BIOCH ENG, V34, P11, DOI 10.1016/0300-9467(87)85003-7##MASHEGO RM, 2005, THESIS TU DELFT NETH##NGUYEN VT, 1995, WATER RES, V29, P2520, DOI 10.1016/0043-1354(95)00076-W##PERRY R.H, 1997, PERRYS CHEM ENG HDB, V7##RIZZI M, 1996, BIOTECHNOL BIOENG, V55, P305##TRAMPER J, 1991, BASIC BIOREACTOR DES##VAILLEJOS JR, 2006, BIOTECHNOL BIOENG, V93, P906, DOI 10.1002/BIT.20785##VALLEJOS JR, 2005, BIOTECHNOL PROGR, V21, P1531, DOI 10.1021/BP050117X##VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/YEA.320080703##VILLENEUVE EP, 1992, ADV SPACE RES, V12, P237##VISSER D, 2004, METAB ENG, V6, P378, DOI 10.1016/J.YMBEN.2004.07.001##VISSER D, 2002, BIOTECHNOL BIOENG, V79, P674, DOI 10.1002/BIT.10328##VISSER D, 2004, BIOTECHNOL BIOENG, V88, P157, DOI 10.1002/BIT.20235##YOUNG J, 2004, CHEM ENG SCI, V59, P5041, DOI 10.1016/J.CES.2004.09.037",11,2020-11-20,NA
J,WOS:000243120300005,2006,POLYMORPHISM VERSUS SPECIES RICHNESS-SYSTEMATICS OF LARGE DENDROBATES FROM THE EASTERN GUIANA SHIELD (AMPHIBIA : DENDROBATIDAE),"A MOLECULAR PHYLOGENY BASED ON A FRAGMENT OF THE MITOCHONDRIAL 16 S RRNA GENE AND MORPHOLOGICAL COMPARISONS SUGGESTS THAT ONLY ONE POLYMORPHIC: SPECIES OF LARGE DENDROBATES, COMMONLY ASSIGNED TO D. TINCTORIUS, OCCURS ON THE EASTERN GUIANA SHIELD AND ITS VICINITIES. THE OLDEST AVAILABLE NAME FOR THIS TAXON IS D. TINCTORIUS (SCHNEIDER, 1799). WE PLACE D. AZUREUS HOOGMOED, 1969 AS ITS JUNIOR SYNONYM. DATA FOR D. MACHADOI BOKERMANN, 1958 ARE NOT AVAILABLE, BUT WE SUSPECT THAT THIS NAME HAS TO BE TREATED IN THE SAME WAY. DENDROBATES TINCTORIUS EXHIBITS NUMEROUS VARIANTS DIFFERING IN COLOR AND PATTERN.",POISON FROGS; EVOLUTION; MODEL,NA,COPEIA,"WOLLENBERG, KC##VEITH, M##NOONAN, BP##LOTTERS, S","UNIV AMSTERDAM, INST BIODIVERS & ECOSYST DYNAM, NL-1098 SM AMSTERDAM, NETHERLANDS. BRIGHAM YOUNG UNIV, DEPT INTEGRAT BIOL, PROVO, UT 84602 USA. UNIV MAINZ, DEPT ZOOL, D-55099 MAINZ, GERMANY.",ZOOLOGY,ZOOLOGY,"AVISE J.C., 1990, OXFORD SURVEYS IN EVOLUTIONARY BIOLOGY, V7, P45##DE QUEIROZ K, 1998, ENDLESS FORMS, P57##FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/J.1558-5646.1985.TB00420.X##HOOGMOED MS, 1969, ZOOL MEDEDEL, V12, P133##JUNGFER KARL-HEINZ, 2004, SALAMANDRA, V40, P99##KLUGE AG, 1969, SYST ZOOL, V18, P1, DOI 10.2307/2412407##LEVITON AE, 1985, COPEIA S, V1, P802##LOTTERS S, IN PRESS PFEILGIFTFR##LOTTERS STEFAN, 1999, HERPETOZOA, V12, P23##NOONAN BP, 2006, J BIOGEOGR, V33, P1007, DOI 10.1111/J.1365-2699.2006.01483.X##PALUMBI S.R., 1991, SIMPLE FOOLS GUIDE P##POSADA D, 2004, SYST BIOL, V53, P793, DOI 10.1080/10635150490522304##POSADA D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/BIOINFORMATICS/14.9.817##SANTOS JC, 2003, P NATL ACAD SCI USA, V100, P12792, DOI 10.1073/PNAS.2133521100##SILVERSTONE P., 1975, NAT HIST MUS LOS ANG, V21, P1##SIMPSON G.G, 1961, PRINCIPLES ANIMAL TA##SUMMERS K, 2003, J BIOGEOGR, V30, P35, DOI 10.1046/J.1365-2699.2003.00795.X##SYMULA R, 2001, P ROY SOC B-BIOL SCI, V268, P2415, DOI 10.1098/RSPB.2001.1812##VENCES M, 2003, ORG DIVERS EVOL, V3, P215, DOI 10.1078/1439-6092-00076##WALLS J.G., 1994, JEWELS RAINFOREST PO##WILEY EO, 1981, PHYLOGENETICS THEORY",22,2020-11-20,NA
J,WOS:000242786200053,2006,ENERGY CONSUMPTION AND NET CO2 SEQUESTRATION OF AQUEOUS MINERAL CARBONATION,"AQUEOUS MINERAL CARBONATION IS A POTENTIALLY ATTRACTIVE SEQUESTRATION TECHNOLOGY TO REDUCE CO2 EMISSIONS. THE ENERGY CONSUMPTION OF THIS TECHNOLOGY, HOWEVER, REDUCES THE NET AMOUNT OF CO2 SEQUESTERED. THEREFORE, THE ENERGETIC CO2 SEQUESTRATION EFFICIENCY OF AQUEOUS MINERAL CARBONATION WAS STUDIED IN DEPENDENCE OF VARIOUS PROCESS VARIABLES USING EITHER WOLLASTONITE (CASIO3) OR STEEL SLAG AS FEEDSTOCK. FOR WOLLASTONITE, THE MAXIMUM ENERGETIC CO2 SEQUESTRATION EFFICIENCY WITHIN THE RANGES OF PROCESS CONDITIONS STUDIED WAS 75% AT 200 DEGREES C, 20 BAR CO2, AND A PARTICLE SIZE OF < 38 MU M. THE MAIN ENERGY-CONSUMING PROCESS STEPS WERE THE GRINDING OF THE FEEDSTOCK AND THE COMPRESSION OF THE CO2 FEED. AT THESE PROCESS CONDITIONS, A SIGNIFICANTLY LOWER EFFICIENCY WAS DETERMINED FOR STEEL SLAG (69%), MAINLY BECAUSE OF THE LOWER CA CONTENT OF THE FEEDSTOCK. THE CO2 SEQUESTRATION EFFICIENCY MIGHT BE IMPROVED SUBSTANTIALLY FOR BOTH TYPES OF FEEDSTOCK BY, E. G., REDUCING THE AMOUNT OF PROCESS WATER APPLIED AND FURTHER GRINDING OF THE FEEDSTOCK. THE CALCULATED ENERGETIC EFFICIENCIES WARRANT A FURTHER ASSESSMENT OF THE (ENERGETIC) FEASIBILITY OF CO2 SEQUESTRATION BY AQUEOUS MINERAL CARBONATION ON THE BASIS OF A PILOT-SCALE PROCESS.",STEEL SLAG; DIOXIDE; MECHANISMS; DISPOSAL; PRODUCTS,NA,INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH,"HUIJGEN, WJJ##RUIJG, GJ##COMANS, RNJ##WITKAMP, GJ","ENERGY RES CTR NETHERLANDS, NL-1755 ZG PETTEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, DEPT SOIL QUAL, NL-6700 EC WAGENINGEN, NETHERLANDS. DELFT UNIV TECHNOL, LAB PROC EQUIPMENT, NL-2628 CA DELFT, NETHERLANDS.","ENGINEERING, CHEMICAL",ENGINEERING,"BOND F.C., 1961, BRIT CHEM ENG, V6, P378##CARLSON EC, 1996, CHEM ENG PROG, V92, P35##HUIJGEN W. J. J., 2005, CARBON DIOXIDE STORA##HUIJGEN WJJ, 2005, ENVIRON SCI TECHNOL, V39, P9676, DOI 10.1021/ES050795F##HUIJGEN WJJ, 2006, ENVIRON SCI TECHNOL, V40, P2790, DOI 10.1021/ES052534B##HUIJGEN WJJ, 2006, CHEM ENG SCI, V61, P4242, DOI 10.1016/J.CES.2006.01.048##IIZUKA A, 2004, IND ENG CHEM RES, V43, P7880, DOI 10.1021/IE0496176##*IPCC, 2005, IPCC SPEC REP CARB C##KAKIZAWA M, 2001, ENERGY, V26, P341, DOI 10.1016/S0360-5442(01)00005-6##LACKNER KS, 1995, ENERGY, V20, P1153, DOI 10.1016/0360-5442(95)00071-N##NILSEN DN, 2001, DOEARCTR01015 ALB RE##O'CONNOR WK, 2002, MINER METALL PROC, V19, P95, DOI 10.1007/BF03403262##OCONNOR WK, 2005, ARCTR04002##PERRY R. H., 1998, PERRYS CHEM ENG HDB##RUBIN ES, 2005, P 7 INT C GREENH GAS, V1, P285##TEIR S, 2005, ENERG CONVERS MANAGE, V46, P2954, DOI 10.1016/J.ENCONMAN.2005.02.009##WU JCS, 2001, IND ENG CHEM RES, V40, P3902, DOI 10.1021/IE010222L",88,2020-11-20,NA
J,WOS:000243237100036,2006,MAPPING REACTION PATHS IN PHASE-SPACE,"GIVEN A DYNAMICS IN CONFIGURATION OR PHASE-SPACE, IT IS OFTEN IMPORTANT TO MAP THE BARRIERS, THE SEPARATRICES EMANATING FROM THEM, AND THE CURRENT DISTRIBUTIONS OF THE REACTION PATHS. WE DESCRIBE A STRATEGY TO DO THIS EFFICIENTLY.",NA,REACTION; SEPARATRIX; BARRIER,INTERNATIONAL JOURNAL OF MODERN PHYSICS B,"TRAILLEUR, J##TANASE-NICOLA, S##KURCHAN, J","ECOLE SUPER PHYS & CHIM IND VILLE PARIS, CNRS, UMR 7636, F-75231 PARIS, FRANCE. FOM, INST ATOM & MOL PHYS, NL-1098 SJ AMSTERDAM, NETHERLANDS.","PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER; PHYSICS, MATHEMATICAL",PHYSICS,"MILNOR J, 1963, MORSE THEORY, P75302##TAILLEUR J, IN PRESS J STAT PHYS, P75302##TANASE-NICOLA S, 2004, J STAT PHYS, V116, P1201, DOI 10.1023/B:JOSS.0000041739.53068.6A##WALES DJ, 2003, ENERGY LANDSCAPES, P75302##WITTEN E, 1982, J DIFFER GEOM, V17, P661, DOI 10.4310/JDG/1214437492",0,2020-11-20,NA
J,WOS:000242973400010,2006,COST-UTILITY ANALYSIS OF SHORT-VERSUS LONG-COURSE PALLIATIVE RADIOTHERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER,"BACKGROUND: RADIOTHERAPY CAN EFFECTIVELY PALLIATE THE SYMPTOMS OF POOR-PROGNOSIS PATIENTS WITH NON-SMALL-CELL LUNG CANCER. HOWEVER, CONTROVERSY REMAINS ABOUT WHETHER SHORT-COURSE OR MORE PROTRACTED RADIOTHERAPY SCHEDULES PROVIDE BETTER VALUE FOR THE MONEY. WE CONDUCTED A SOCIETAL COST-UTILITY ANALYSIS OF A DUTCH MULTICENTER RANDOMIZED TRIAL WITH 1-YEAR FOLLOW-UP THAT COMPARED THE EFFICACY OF RADIOTHERAPY SCHEDULES CONSISTING OF 10 FRACTIONS OF 3 GY (10 X 3 GY) VERSUS TWO FRACTIONS OF 8 GY (2 X 8 GY) IN 297 PATIENTS WITH INOPERABLE STAGE IIIA/B OR STAGE IV NON-SMALL-CELL LUNG CANCER. THIS TRIAL FOUND THAT THE 10 X 3-GY GROUP HAD BETTER SURVIVAL THAN THE 2 X 8-GY GROUP. METHODS: LIFETIME QUALITY-ADJUSTED LIFE-YEARS (QALYS) WERE ESTIMATED USING THE EUROQOL QUESTIONNAIRE. LIFETIME SOCIETAL COSTS WERE ESTIMATED USING A MODEL ESTIMATED BASED ON DATA FROM COST QUESTIONNAIRES FILLED OUT BY A SUBSET OF PATIENTS (N = 56). DIFFERENCES WERE ANALYZED STATISTICALLY USING TWO-SIDED NONPARAMETRIC BOOTSTRAPPING. RESULTS: COMPARED WITH THE 2 X 8-GY GROUP, THE 10 X 3-GY GROUP ACCRUED STATISTICALLY SIGNIFICANTLY MORE QALYS (20.0 VERSUS 13.2 WEEKS; DIFFERENCE = 6.8 WEEKS, 95% CONFIDENCE INTERVAL [CI] = 0.1 TO 13.5 WEEKS, P = .05), WHICH WAS MAINLY DUE TO THE STATISTICALLY SIGNIFICANTLY BETTER SURVIVAL (38.1 VERSUS 27.4 WEEKS; DIFFERENCE = 10.7 WEEKS, 95% CI = 0.9 TO 20.6 WEEKS, P = .03) WITHOUT A STATISTICALLY SIGNIFICANT DIFFERENCE WITH RESPECT TO THE AVERAGE VALUATION OF HEALTH (P = .27). TOTAL RADIOTHERAPY AND RADIOTHERAPY-RELATED COSTS WERE ESTIMATED AT $5236 FOR THE 10 X 3-GY GROUP AND $2512 FOR THE 2 X 8-GY GROUP (DIFFERENCE = $2724, 95% CI = $2501 TO $2947, P < .001). THE 39% INCREASE IN LIFE EXPECTANCY IN THE 10 X 3-GY GROUP AS COMPARED WITH THE 2 X 8-GY GROUP WAS ASSOCIATED WITH A 30% INCREASE IN SURVIVAL-RELATED NONRADIOTHERAPY COSTS ($11254 VERSUS $8651, DIFFERENCE $2602, 95% CI = -$357 TO $5562, P = .09). THE COST-UTILITY RATIO FOR THE 10 X 3-GY SCHEDULE VERSUS THE 2 X 8-GY SCHEDULE WAS ESTIMATED AT $40900 PER QALY (95% CI = $19400 TO $1100000 PER QALY). CONCLUSIONS: IN THESE POOR-PROGNOSIS NON-SMALL-CELL LUNG CANCER PATIENTS, THE ESTIMATED COST-UTILITY RATIO FOR THE PALLIATIVE 10 X 3-GY SCHEDULE WAS ACCEPTABLE ACCORDING TO CURRENT ECONOMIC STANDARDS. HOWEVER, THE ADDITIONAL COSTS FOR THE PROTRACTED SCHEDULE WERE JUSTIFIED NOT BY IMPROVED QUALITY OF LIFE BUT BY LONGER SURVIVAL.",CARE; RADIATION; SINGLE; TIME; LIFE,NA,JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE,"VAN DEN HOUT, WB##KRAMER, GWPM##NOORDIJK, EM##LEER, JWH","LEIDEN UNIV, MED CTR, DEPT MED DECIS MAKING, NL-2300 RC LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT CLIN ONCOL, NL-2300 RC LEIDEN, NETHERLANDS. ARNHEM NIJMEGEN RADIAN, JOINT CTR RADIAT ONCOL, ARNHEM, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"ALBERTI W, 1995, BRIT MED J, V311, P899##BEZJAK A, 2002, INT J RADIAT ONCOL, V54, P719, DOI 10.1016/S0360-3016(02)02989-9##BLEEHEN NM, 1992, BRIT J CANCER, V65, P934, DOI 10.1038/BJC.1992.196##BRUNDAGE M D, 1996, CAN J ONCOL, V6 SUPPL 1, P25##DESGAGNE A, 1998, PHARMACOECONOMICS, V13, P487, DOI 10.2165/00019053-199813050-00002##DOLAN P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002##*DUTCH HLTH INS EX, 2000, PHARM COMP 2000 2001##EARLE CC, 2000, J CLIN ONCOL, V18, P3302, DOI 10.1200/JCO.2000.18.18.3302##GANDJOUR A, 2005, J HEALTH ECON, V24, P715, DOI 10.1016/J.JHEALECO.2004.11.009##GIRLING DJ, 1991, BRIT J CANCER, V63, P265##GOLD MR, 1996, COST EFFECTIVENESS H##KONSKI A, 2005, SEMIN ONCOL, V32, P156, DOI 10.1053/J.SEMINONCOL.2004.11.013##KRAMER GWPM, 2005, J CLIN ONCOL, V23, P2962, DOI 10.1200/JCO.2005.01.685##MACBETH F, 2001, COCHRANE DB SYST REV##MACBETH F R, 1996, CLIN ONCOL (R COLL RADIOL), V8, P167, DOI 10.1016/S0936-6555(96)80041-0##MELTZER D, 1997, J HEALTH ECON, V16, P33, DOI 10.1016/S0167-6296(96)00507-3##MOUNTAIN CF, 1997, CHEST, V111, P1710, DOI 10.1378/CHEST.111.6.1710##NYMAN JA, 2004, HEALTH ECON, V13, P417, DOI 10.1002/HEC.850##OOSTENBRINK JB, 2002, PHARMACOECONOMICS, V20, P443, DOI 10.2165/00019053-200220070-00002##OOSTENBRINK JB, 2000, MANUAL COST ANAL MET##REES G J, 1997, CLIN ONCOL (R COLL RADIOL), V9, P90, DOI 10.1016/S0936-6555(05)80446-7##SESHAMANI M, 2004, J HEALTH ECON, V23, P217, DOI 10.1016/J.JHEALECO.2003.08.004##SINGER PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/JAMA.281.2.163##SOMERFIELD MR, 1997, J CLIN ONCOL, V15, P2996##STIGGELBOUT AM, 1996, INT J TECHNOL ASSESS, V12, P291, DOI 10.1017/S0266462300009648##TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2##UBEL PA, 2003, ARCH INTERN MED, V163, P1637, DOI 10.1001/ARCHINTE.163.14.1637##*US BUR LAB STAT, CONS EXP 2003 ANN RE##VAN DEN BERG B, 2005, HEALTH ECON, V14, P169, DOI 10.1002/HEC.893##VAN DEN BRINK M, 2005, INT J TECHNOL ASSESS, V21, P298, DOI 10.1017/S0266462305050397##VAN DEN HOUT WB, 2003, JNCI-J NATL CANCER I, V95, P222, DOI 10.1093/JNCI/95.3.222##WILLIAMS A, 1990, HEALTH POLICY, V16, P199##ZETHRAEUS N, 2003, PHARMACOECONOMICS, V21, P39, DOI 10.2165/00019053-200321010-00003",38,2020-11-20,NA
J,WOS:000242994400027,2006,CHILDHOOD PAPILLARY THYROID CARCINOMA WITH MILIARY PULMONARY METASTASES,NA,NA,NA,JOURNAL OF CLINICAL ONCOLOGY,"VERMEER-MENS, JCJ##GOEMAERE, NNT##KUENEN-BOUMEESTER, V##KEIZER-SCHRAMA, SMPFD##ZWAAN, CM##DEVOS, AS##DE KRIJGER, RR","ERASMUS MC UNIV MED CTR, DEPT PATHOL, ROTTERDAM, NETHERLANDS. ERASMUS MC UNIV MED CTR, DEPT PEDIAT ENDOCRINOL, ROTTERDAM, NETHERLANDS. ERASMUS MC UNIV MED CTR, DEPT PEDIAT ONCOL, ROTTERDAM, NETHERLANDS. ERASMUS MC UNIV MED CTR, DEPT PEDIAT RADIOL, ROTTERDAM, NETHERLANDS. ERASMUS MC SOPHIA, ROTTERDAM, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"ADENIRAN AJ, 2006, AM J SURG PATHOL, V30, P216, DOI 10.1097/01.PAS.0000176432.73455.1B##CASTRO P, 2006, J CLIN ENDOCR METAB, V91, P213, DOI 10.1210/JC.2005-1336##CHU KC, 1995, CANC PREVENTION CONT, P37##COLLINI P, 2006, PEDIATR BLOOD CANCER, V46, P300, DOI 10.1002/PBC.20474##DELELLIS RA, 2004, WHO CLASSIFICATION T, P51##GIORDANO TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/SJ.ONC.1208822##MILLMAN B, 1995, ARCH OTOLARYNGOL, V121, P1261##OKADA T, 2006, EUR J PEDIATR SURG, V16, P8, DOI 10.1055/S-2006-923795",14,2020-11-20,NA
J,WOS:000242637500003,2006,"DISTRIBUTION OF MT1 MELATONIN RECEPTOR IMMUNOREACTIVITY IN THE HUMAN HYPOTHALAMUS AND PITUITARY GLAND: COLOCALIZATION OF MT1 WITH VASOPRESSIN, OXYTOCIN, AND CORTICOTROPIN-RELEASING HORMONE","MELATONIN IS IMPLICATED IN NUMEROUS PHYSIOLOGICAL PROCESSES, INCLUDING CIRCADIAN RHYTHMS, STRESS, AND REPRODUCTION, MANY OF WHICH ARE MEDIATED BY THE HYPOTHALAMUS AND PITUITARY. THE PHYSIOLOGICAL ACTIONS OF MELATONIN ARE MAINLY MEDIATED BY MELATONIN RECEPTORS. WE HERE DESCRIBE THE DISTRIBUTION OF THE MELATONIN RECEPTOR MT1 IN THE HUMAN HYPOTHALAMUS AND PITUITARY BY IMMUNOCYTOCHEMISTRY. MT1 IMMUNOREACTIVITY SHOWED A WIDESPREAD PATTERN IN THE HYPOTHALAMUS. IN ADDITION TO THE AREA OF THE SUPRACHIASMATIC NUCLEUS (SCN), A NUMBER OF NOVEL SITES, INCLUDING THE PARAVENTRICULAR NUCLEUS (PVN), PERIVENTRICULAR NUCLEUS, SUPRAOPTIC NUCLEUS (SON), SEXUALLY DIMORPHIC NUCLEUS, THE DIAGONAL BAND OF BROCA, THE NUCLEUS BASALIS OF MEYNERT, INFUNDIBULAR NUCLEUS, VENTROMEDIAL AND DORSOMEDIAL NUCLEUS, TUBEROMAMILLARY NUCLEUS, MAMILLARY BODY, AND PARAVENTRICULAR THALAMIC NUCLEUS WERE OBSERVED TO HAVE NEURONAL MT1 RECEPTOR EXPRESSION. NO STAINING WAS OBSERVED IN THE NUCLEUS TUBERALIS LATERALIS AND BED NUCLEUS OF THE STRIA TERMINALIS. THE MT1 RECEPTOR WAS COLOCALIZED WITH SOME VASOPRESSIN (AV-P) NEURONS IN THE SCN, COLOCALIZED WITH SOME PARVOCELLULAR AND MAGNOCELLULAR AVP AND OXYTOCINE (OXT) NEURONS IN THE PVN AND SON, AND COLOCALIZED WITH SOME PARVOCELLULAR CORTICOTROPIN-RELEASING HORMONE (CRH) NEURONS IN THE PVN. IN THE PITUITARY, STRONG MT1 EXPRESSION WAS OBSERVED IN THE PARS TUBERALIS, WHILE A WEAK STAINING WAS FOUND IN THE POSTERIOR AND ANTERIOR PITUITARY. THESE FINDINGS PROVIDE A NEUROBIOLOGICAL BASIS FOR THE PARTICIPATION OF MELATONIN IN THE REGULATION OF VARIOUS HYPOTHALAMIC AND PITUITARY FUNCTIONS. THE COLOCALIZATION OF MT1 AND CRH SUGGESTS THAT MELATONIN MIGHT DIRECTLY MODULATE THE HYPOTHALAMUS-PITUITARY-ADRENAL AXIS IN THE PVN, WHICH MAY HAVE IMPLICATIONS FOR STRESS CONDITIONS SUCH AS DEPRESSION.",ALZHEIMERS-DISEASE; SUPRACHIASMATIC NUCLEUS; ARGININE-VASOPRESSIN; CIRCADIAN RESPONSES; MONOCLONAL-ANTIBODY; PINEAL MELATONIN; MAMILLARY BODIES; ENDOCRINE STATUS; BASAL FOREBRAIN; MESSENGER-RNAS,MELATONIN RECEPTOR; MT1; HYPOTHALAMUS; HUMAN; IMMUNOCYTOCHEMISTRY; COLOCALIZATION; VASOPRESSIN; CORTICOTROPIN-RELEASING HORMONE,JOURNAL OF COMPARATIVE NEUROLOGY,"WU, YH##ZHOU, JN##BALESAR, R##UNMEHOPA, U##BAO, AM##JOCKERS, R##VAN HEERIKHUIZE, J##SWAAB, DF","NETHERLANDS INST NEUROSCI, NL-1105 BA AMSTERDAM, NETHERLANDS. UNIV SCI & TECHNOL CHINA, DEPT NEUROBIOL, SCH LIFE SCI, HEFEI 230026, PEOPLES R CHINA. INSERM, U567, F-75014 PARIS, FRANCE. INST COCHIN, DEPT CELL BIOL, F-75014 PARIS, FRANCE. CNRS, UMR 8104, F-75014 PARIS, FRANCE. UNIV PARIS DESCARTES, FAC MED RENE DESCARTES, F-75014 PARIS, FRANCE.",NEUROSCIENCES; ZOOLOGY,NEUROSCIENCES & NEUROLOGY; ZOOLOGY,"ADAMS JC, 1992, J HISTOCHEM CYTOCHEM, V40, P1457, DOI 10.1177/40.10.1527370##AOYAMA H, 1987, ACTA PATHOL JAPON, V37, P1143##ARENDT J, 2005, SLEEP MED REV, V9, P25, DOI 10.1016/J.SMRV.2004.05.002##BALIK A, 2004, PHYSIOL RES, V53, PS153##BAXTER MG, 1999, CURR OPIN NEUROBIOL, V9, P178, DOI 10.1016/S0959-4388(99)80024-5##BENLOUCIF S, 1997, AM J PHYSIOL-REG I, V273, PR1855##BRAAK H, 1991, BRAIN PATHOL, V1, P213, DOI 10.1111/J.1750-3639.1991.TB00661.X##BRUSCO LI, 1999, BIOL SIGNAL RECEPT, V8, P126##BRYDON L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/ME.13.12.2025##CARDINALI DP, 2002, NEUROENDOCRINOL LETT, V23, P20##CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V##CLAES SJ, 2004, ANN MED, V36, P50, DOI 10.1080/07853890310017044##DAI JP, 1998, J COMP NEUROL, V400, P87, DOI 10.1002/(SICI)1096-9861(19981012)400:1<87::AID-CNE6>3.0.CO;2-P##DAI JP, 1997, J COMP NEUROL, V383, P397, DOI 10.1002/(SICI)1096-9861(19970714)383:4<397::AID-CNE1>3.0.CO;2-Y##DARDENTE H, 2003, J NEUROENDOCRINOL, V15, P778, DOI 10.1046/J.1365-2826.2003.01060.X##DEBREE FM, 1994, BIOCHIMIE, V76, P315, DOI 10.1016/0300-9084(94)90165-1##FISCHER S, 2003, J CLIN ENDOCR METAB, V88, P5315, DOI 10.1210/JC.2003-030540##FORSLING ML, 1999, CLIN ENDOCRINOL, V51, P637, DOI 10.1046/J.1365-2265.1999.00820.X##FORSLING ML, 1998, EXP PHYSIOL, V83, P409, DOI 10.1113/EXPPHYSIOL.1998.SP004124##FORSLING ML, 2002, CLIN ENDOCRINOL, V57, P615, DOI 10.1046/J.1365-2265.2002.01644.X##GIBBS RB, 1998, HORM BEHAV, V34, P98, DOI 10.1006/HBEH.1998.1451##HAWTHORN J, 1985, BRAIN RES, V346, P51, DOI 10.1016/0006-8993(85)91093-5##HOUYU A, 1986, NEUROENDOCRINOLOGY, V44, P235, DOI 10.1159/000124651##HOUYU A, 1982, J HISTOCHEM CYTOCHEM, V30, P1249, DOI 10.1177/30.12.6185560##HUSSON I, 2002, ANN NEUROL, V51, P82, DOI 10.1002/ANA.10072##HUSTON JP, 1997, BEHAV BRAIN RES, V83, P97, DOI 10.1016/S0166-4328(97)86052-4##JEAN-LOUIS G, 1998, J PINEAL RES, V25, P177, DOI 10.1111/J.1600-079X.1998.TB00557.X##JUSZCZAK M, 2001, NEUROENDOCRINOL LETT, V22, P169##KONAKCHIEVA R, 1998, NEUROENDOCRINOLOGY, V67, P171, DOI 10.1159/000054312##KONAKCHIEVA R, 1997, BIOL CELL, V89, P587, DOI 10.1016/S0248-4900(98)80163-9##KRAUCHI K, 2001, NEUROPSYCHOPHARMACOL, V25, PS92, DOI 10.1016/S0893-133X(01)00315-3##KRUIJVER FPM, 2002, J COMP NEUROL, V454, P115, DOI 10.1002/CNE.10416##KRUIJVER FPM, 2001, J CLIN ENDOCR METAB, V86, P818, DOI 10.1210/JC.86.2.818##LAUDON M, 1988, NEUROENDOCRINOLOGY, V48, P577, DOI 10.1159/000125066##LIU C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5##LOESCH DV, 1995, J NEUROSURG, V83, P354, DOI 10.3171/JNS.1995.83.2.0354##MASANA MI, 2000, J PINEAL RES, V28, P185, DOI 10.1034/J.1600-079X.2001.280309.X##MATSUBARA E, 2003, J NEUROCHEM, V85, P1101, DOI 10.1046/J.1471-4159.2003.01654.X##MAYO JC, 2002, CELL MOL LIFE SCI, V59, P1706, DOI 10.1007/PL00012498##MAZZUCCHELLI C, 1996, MOL BRAIN RES, V39, P117, DOI 10.1016/0169-328X(96)00017-4##MISHIMA K, 2000, CHRONOBIOL INT, V17, P419, DOI 10.1081/CBI-100101055##MONTI JM, 2000, BIOL SIGNAL RECEPT, V9, P328##PACCHIEROTTI C, 2001, FRONT NEUROENDOCRIN, V22, P18, DOI 10.1006/FRNE.2000.0202##PANG SF, 1998, J CHEM NEUROANAT, V14, P157, DOI 10.1016/S0891-0618(98)00029-5##PAPPOLLA MA, 2002, J PINEAL RES, V32, P135, DOI 10.1034/J.1600-079X.2002.1O838.X##PARKER A, 1997, EUR J NEUROSCI, V9, P2423, DOI 10.1111/J.1460-9568.1997.TB01659.X##PASQUALETTI P, 1998, NEPHRON, V78, P33, DOI 10.1159/000044879##PIERPAOLI W, 1987, IMMUNOL LETT, V16, P355, DOI 10.1016/0165-2478(87)90169-6##POIREL VJ, 2002, BRAIN RES, V946, P64, DOI 10.1016/S0006-8993(02)02824-X##RAADSHEER FC, 1993, BRAIN RES, V615, P50, DOI 10.1016/0006-8993(93)91113-7##RAZ N, 1992, NEUROREPORT, V3, P713, DOI 10.1097/00001756-199208000-00016##REITER RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5##REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/EDRV-12-2-151##REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8##REPPERT SM, 1988, SCIENCE, V242, P78, DOI 10.1126/SCIENCE.2845576##SATOH K, 2001, CLIN NEUROPHARMACOL, V24, P334, DOI 10.1097/00002826-200111000-00004##SAVASKAN E, 2002, J PINEAL RES, V32, P59, DOI 10.1034/J.1600-079X.2002.00841.X##SAVASKAN E, 2001, NEUROSCI LETT, V308, P9, DOI 10.1016/S0304-3940(01)01967-X##SONG CK, 2000, J NEUROENDOCRINOL, V12, P627, DOI 10.1046/J.1365-2826.2000.00479.X##SWAAB DF, 2003, HUMAN HYPOTHALAMUS 1##TAN DX, 2000, NEUROENDOCRINOL LETT, V21, P361##THOMAS L, 1998, INT J MOL MED, V1, P539##THOMAS L, 2002, J PINEAL RES, V33, P218, DOI 10.1034/J.1600-079X.2002.02921.X##VANDERSLUIS PJ, 1988, ELECTROPHORESIS, V9, P654, DOI 10.1002/ELPS.1150091006##VANECEK J, 1988, NEUROENDOCRINOLOGY, V48, P201, DOI 10.1159/000125008##VANECEK J, 1999, ADV EXP MED BIOL, V460, P191##VANOERS JWAM, 1989, ENDOCRINOLOGY, V124, P1239, DOI 10.1210/ENDO-124-3-1239##VON GALL C, 2002, CELL TISSUE RES, V309, P151, DOI 10.1007/S00441-002-0581-4##WADA H, 1991, TRENDS NEUROSCI, V14, P415, DOI 10.1016/0166-2236(91)90034-R##WATANABE K, 1998, BRAIN RES, V801, P216, DOI 10.1016/S0006-8993(98)00543-5##WEAVER DR, 1993, J CLIN ENDOCR METAB, V76, P295, DOI 10.1210/JC.76.2.295##WEAVER DR, 1996, NEUROREPORT, V8, P109, DOI 10.1097/00001756-199612200-00022##WEAVER DR, 1996, MOL ENDOCRINOL, V10, P1478, DOI 10.1210/ME.10.11.1478##WEAVER DR, 2001, J BIOL RHYTHM, V16, P216, DOI 10.1177/074873001129001926##WETTERBERG L, 1999, REPROD NUTR DEV, V39, P367, DOI 10.1051/RND:19990309##WILLIAMS LM, 1991, ENDOCRINOLOGY, V128, P2083, DOI 10.1210/ENDO-128-4-2083##WILLIAMS LM, 1997, J NEUROENDOCRINOL, V9, P639, DOI 10.1046/J.1365-2826.1997.00625.X##WITT-ENDERBY PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5##WU YH, 2003, J CLIN ENDOCR METAB, V88, P5898, DOI 10.1210/JC.2003-030833##WU YH, 2005, J PINEAL RES, V38, P145, DOI 10.1111/J.1600-079X.2004.00196.X##YASIN SA, 1993, ENDOCRINOLOGY, V132, P1329, DOI 10.1210/EN.132.3.1329",121,2020-11-20,NA
J,WOS:000242637500005,2006,ONTOGENY OF HIPPOCAMPAL CORTICOSTEROID RECEPTORS: EFFECTS OF ANTENATAL GLUCOCORTICOIDS IN HUMAN AND MOUSE,"WOMEN AT RISK FOR PRETERM DELIVERY ARE TREATED WITH SYNTHETIC GLUCOCORTICOIDS (GCS) TO ENHANCE FETAL LUNG MATURATION. GCS CAN BIND TO TWO INTRACELLULAR RECEPTORS, THE GLUCOCORTICOID RECEPTOR (GR) AND THE MINERALOCORTICOID RECEPTOR (MR), WHICH FUNCTION AS TRANSCRIPTION FACTORS. BOTH ARE HIGHLY EXPRESSED IN THE HIPPOCAMPUS. SEVERAL STUDIES HAVE FOCUSED ON ADVERSE SIDE EFFECTS OF ANTENATAL GC TREATMENT. HOWEVER, RELATIVELY LITTLE IS KNOWN ABOUT THE ONTOGENY OF GR AND MR, ESPECIALLY IN HUMAN. THEREFORE, WE STUDIED THE ONTOGENY OF BOTH RECEPTORS IN THE HUMAN AND MOUSE HIPPOCAMPUS AND INVESTIGATED THE EFFECTS OF ANTENATAL DEXAMETHASONE (DEX) TREATMENT, A SYNTHETIC GLUCOCORTICOID, ON MR AND GR MRNA LEVELS DURING HIPPOCAMPAL DEVELOPMENT. THE RESULTS DEMONSTRATE THAT MR MRNA WAS FIRST EXPRESSED IN MOUSE HIPPOCAMPUS AT EMBRYONIC DAY (E)15.5, AT THE TIMEPOINT WHEN DEX WAS ADMINISTERED. IN CONTRAST, GR MRNA EXPRESSION WAS FIRST OBSERVED AFTER BIRTH AT POSTNATAL DAY (P)5. HOWEVER, IN THE HUMAN HIPPOCAMPUS BOTH RECEPTORS ARE EXPRESSED AT 24 WEEKS OF GESTATION, WHEN ANTENATAL GCS ARE ADMINISTERED IN CLINICAL PRACTICE. QUANTITATIVE IN SITU HYBRIDIZATION DEMONSTRATED THAT MR MRNA LEVELS WERE REDUCED ONLY SHORTLY AFTER DEX TREATMENT AT E16, BUT WERE UNAFFECTED FROM E18 ONWARDS. THESE FINDINGS INDICATE THAT A SINGLE ANTENATAL DEX ADMINISTRATION AT E15.5 TRANSIENTLY AFFECTS MR MRNA LEVELS IN THE MOUSE HIPPOCAMPUS. NO EFFECT OF ANTENATAL DEX TREATMENT WAS FOUND ON THE HUMAN HIPPOCAMPUS AT THE THIRD TRIMESTER OF PREGNANCY. THESE DATA ON THE PRENATAL ONTOGENY OF BOTH CORTICOSTEROID RECEPTORS IN THE HUMAN HIPPOCAMPUS IS IMPORTANT FOR UNDERSTANDING THE SIGNIFICANCE OF FETAL GLUCOCORTICOID OR STRESS EXPOSURE AND ITS POTENTIAL EFFECTS ON HEALTH AND DISEASE.",PITUITARY-ADRENOCORTICAL AXIS; GUINEA-PIG BRAIN; MINERALOCORTICOID RECEPTOR; MESSENGER-RNA; DEXAMETHASONE-TREATMENT; GENE-EXPRESSION; ADRENAL AXIS; MATERNAL DEXAMETHASONE; POSTNATAL ONTOGENY; HORMONAL-CONTROL,HIPPOCAMPUS; DEXAMETHASONE; MINERALOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR,JOURNAL OF COMPARATIVE NEUROLOGY,"NOORLANDER, CW##DE GRAAN, PNE##MIDDELDORP, J##VAN BEERS, JJBC##VISSER, GHA","UNIV UTRECHT, CTR MED, RUDOLF MAGNUS INST NEUROSCI, NL-3584 CG UTRECHT, NETHERLANDS. UNIV UTRECHT, CTR MED, DEPT OBSTET NEONATOL & GYNAECOL, NL-3584 CG UTRECHT, NETHERLANDS.",NEUROSCIENCES; ZOOLOGY,NEUROSCIENCES & NEUROLOGY; ZOOLOGY,"BAKKER JM, 1995, J NEUROIMMUNOL, V63, P183, DOI 10.1016/0165-5728(95)00152-2##BALLARD PL, 1989, BAILLIERE CLIN ENDOC, V3, P723, DOI 10.1016/S0950-351X(89)80051-5##BALLARD R A, 1996, J PERINATOL, V16, P390##BEERS MF, 2000, AM J RESP CELL MOL, V22, P380, DOI 10.1165/AJRCMB.22.3.3645##BROWN SD, 1996, J CRIT CARE, V11, P2, DOI 10.1016/S0883-9441(96)90014-3##CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8##DALLMAN MF, 1987, ANN NY ACAD SCI, V512, P402, DOI 10.1111/J.1749-6632.1987.TB24976.X##DASILVA SL, 1995, MOL BRAIN RES, V30, P131, DOI 10.1016/0169-328X(94)00289-Q##DE KLOET ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/ER.19.3.269##DEAN F, 1999, BRAIN RES, V846, P253, DOI 10.1016/S0006-8993(99)02064-8##DEAN F, 2001, NEUROENDOCRINOLOGY, V73, P194, DOI 10.1159/000054636##DIAZ R, 1998, J NEUROSCI, V18, P2570##ERDELJAN P, 2001, BRAIN RES, V896, P130, DOI 10.1016/S0006-8993(01)02075-3##HERMAN JP, 1996, CRIT REV NEUROBIOL, V10, P371, DOI 10.1615/CRITREVNEUROBIOL.V10.I3-4.50##HERMAN JP, 1989, MOL ENDOCRINOL, V3, P1886, DOI 10.1210/MEND-3-11-1886##JACOBSON L, 2005, ENDOCRIN METAB CLIN, V34, P271, DOI 10.1016/J.ECL.2005.01.003##JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/EDRV-12-2-118##JONGEN-RELO AL, 2002, BRAIN RES, V953, P223, DOI 10.1016/S0006-8993(02)03293-6##KELLENDONK C, 2002, BRAIN RES BULL, V57, P73, DOI 10.1016/S0361-9230(01)00638-4##LEVITT NS, 1996, NEUROENDOCRINOLOGY, V64, P412, DOI 10.1159/000127146##LIU D, 1997, SCIENCE, V277, P1659, DOI 10.1126/SCIENCE.277.5332.1659##MATTHEWS SG, 2000, PEDIATR RES, V47, P291, DOI 10.1203/00006450-200003000-00003##MATTHEWS SG, 1998, DEV BRAIN RES, V107, P123, DOI 10.1016/S0165-3806(98)00008-X##MEANEY M.J., 1985, BRAIN RES, V350, P159, DOI DOI 10.1016/0165-3806(85)90259-7##MEIJER OC, 1998, CRIT REV NEUROBIOL, V12, P1##MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/ANNUREV.PHYSIOL.53.1.415##PRYCE CR, 2005, EUR J NEUROSCI, V21, P1521, DOI 10.1111/J.1460-9568.2005.04003.X##RAUBENHEIMER PJ, 2006, CLIN ENDOCRINOL, V65, P22, DOI 10.1111/J.1365-2265.2006.02540.X##ROSENFELD P, 1988, DEV BRAIN RES, V42, P113, DOI 10.1016/0165-3806(88)90206-4##SANCHEZ MM, 2000, J NEUROSCI, V20, P4657, DOI 10.1523/JNEUROSCI.20-12-04657.2000##SCHELLHASE DE, 1991, AM J RESP CELL MOL, V4, P304, DOI 10.1165/AJRCMB/4.4.304##SCHMIDT M, 2003, INT J DEV NEUROSCI, V21, P125, DOI 10.1016/S0736-5748(03)00030-3##SHOENER JA, 2006, AM J PHYSIOL-REG I, V290, PR1366, DOI 10.1152/AJPREGU.00757.2004##SMIDT MP, 2004, DEVELOPMENT, V131, P1145, DOI 10.1242/DEV.01022##SPEIRS HJL, 2004, J ENDOCRINOL, V181, P105, DOI 10.1677/JOE.0.1810105##UNO H, 1994, HORM BEHAV, V28, P336, DOI 10.1006/HBEH.1994.1030##VANEEKELEN JAM, 1988, J NEUROSCI RES, V21, P88, DOI 10.1002/JNR.490210113##VANEEKELEN JAM, 1991, DEV BRAIN RES, V61, P33, DOI 10.1016/0165-3806(91)90111-U##VELDHUIS HD, 1982, ENDOCRINOLOGY, V110, P2044, DOI 10.1210/ENDO-110-6-2044##VELLUCCI SV, 2002, NEUROPEPTIDES, V36, P291, DOI 10.1016/S0143-4179(02)00048-3",61,2020-11-20,NA
J,WOS:000243079600012,2006,PARALLELIZATION OF AN EULER-LAGRANGE MODEL USING MIXED DOMAIN DECOMPOSITION AND A MIRROR DOMAIN TECHNIQUE: APPLICATION TO DISPERSED GAS-LIQUID TWO-PHASE FLOW,"WE REPORT A PARALLEL ALGORITHM APPLICABLE TO A EULER-LAGRANGE MODEL EMBEDDING FOUR-WAY COUPLING. THE MODEL DESCRIBING THE DISPERSED PHASE DYNAMICS ACCOUNTS FOR BUBBLE-BUBBLE COLLISIONS AND IS PARALLELIZED USING A MIRROR DOMAIN TECHNIQUE WHILE THE PRESSURE POISSON EQUATION FOR THE CONTINUOUS PHASE IS SOLVED USING A DOMAIN DECOMPOSITION TECHNIQUE IMPLEMENTED IN THE PETSC LIBRARY [S. BALAY, K. BUSCHELMAN, W.D. GROPP, D. KAUSHIK, M.G. KNEPLEY, L.C. MCINNES, B.F. SMITH, H. ZHANG, PETSC WEB PAGE: HTTP://WWW.MCS.ANL.GOV/PETSC, 2001]. THE PARALLEL ALGORITHM IS VERIFIED AND IT IS FOUND THAT IT GIVES THE SAME RESULTS FOR BOTH PHASES AS COMPARED TO THE SERIAL ALGORITHM. FURTHERMORE THE ALGORITHM SHOWS GOOD SCALABILITY UP TO 32 PROCESSORS. USING THE PROPOSED METHOD, A HOMOGENEOUS BUBBLY FLOW IN A LABORATORY SCALE BUBBLE COLUMN CAN BE SIMULATED AT VERY HIGH GAS HOLD-UP (37%) WHILE CONSUMING A REASONABLE AMOUNT OF CALCULATION WALL TIME. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",DISCRETE BUBBLE MODEL; FLUIDIZED-BED; SIMULATION; COALESCENCE; COLUMNS; HYDRODYNAMICS; REACTORS; BREAKUP; MASS; CFD,BUBBLE COLUMN; DISCRETE BUBBLE MODEL; FOUR-WAY COUPLING; DIRECT BUBBLE-BUBBLE INTERACTION; COLLISION MODEL; COALESCENCE MODEL; COMPUTATIONAL FLUID DYNAMICS; PARALLEL COMPUTATION,JOURNAL OF COMPUTATIONAL PHYSICS,"DARMANA, D##DEEN, NG##KUIPERS, JAM","UNIV TWENTE, FAC SCI & TECHNOL, POB 217, NL-7500 AE ENSCHEDE, NETHERLANDS.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; PHYSICS, MATHEMATICAL",COMPUTER SCIENCE; PHYSICS,"ALLEN M. P., 1987, COMPUTER SIMULATION##AUTON TR, 1987, J FLUID MECH, V183, P199, DOI 10.1017/S002211208700260X##BALAY S, 1997, MODERN SOFTWARE TOOLS FOR SCIENTIFIC COMPUTING, P163##BALAY S, 2004, ANL9511##BURNS G., 1994, P SUP S, P379##CENTRELLA J, 1984, ASTROPHYS J SUPPL S, V54, P229, DOI 10.1086/190927##CHESTERS A. K., 1991, T I CHEM ENG-LOND, V69A, P259##CHESTERS AK, 1982, APPL SCI RES, V38, P353, DOI 10.1007/BF00385965##DARMANA D, 2005, CHEM ENG SCI, V60, P3383, DOI 10.1016/J.CES.2005.01.025##DEEN NG, 2004, CHEM ENG SCI, V59, P1853, DOI 10.1016/J.CES.2004.01.038##DEEN NG, 2001, CHEM ENG SCI, V56, P6341, DOI 10.1016/S0009-2509(01)00249-4##DELNOIJ E, 1999, CHEM ENG SCI, V54, P2217, DOI 10.1016/S0009-2509(98)00362-5##DELNOIJ E, 1997, CHEM ENG SCI, V52, P1429, DOI 10.1016/S0009-2509(96)00515-5##DENG GB, 2001, COMPUT FLUIDS, V30, P445, DOI 10.1016/S0045-7930(00)00025-6##ENWALD H, 1999, CHEM ENG SCI, V54, P311, DOI 10.1016/S0009-2509(98)00186-9##FERZIGER J. H., 1999, COMPUTATIONAL METHOD##GROPP WD, 2001, PARALLEL COMPUT, V27, P337, DOI 10.1016/S0167-8191(00)00075-2##HARTEVELD W. K, 2004, P CHISA 16 INT C CHE##HOOMANS BPB, 1996, CHEM ENG SCI, V51, P99, DOI 10.1016/0009-2509(95)00271-5##HOOMANS BPB, 1999, THESIS U TWENTE##JAKOBSEN HA, 2005, IND ENG CHEM RES, V44, P5107, DOI 10.1021/IE049447X##JAKOBSEN HA, 1997, IND ENG CHEM RES, V36, P4052, DOI 10.1021/IE970276O##KIRKPATRICK RD, 1974, CHEM ENG SCI, V29, P2363, DOI 10.1016/0009-2509(74)80013-8##KITAGAWA A, 2001, INT J MULTIPHAS FLOW, V27, P2129, DOI 10.1016/S0301-9322(01)00040-4##KUIPERS JAM, 1993, COMPUT CHEM ENG, V17, P839, DOI 10.1016/0098-1354(93)80067-W##LEE CH, 1987, CHEM ENG COMMUN, V59, P65, DOI 10.1080/00986448708911986##LINDBORG H, 2004, COMPUT CHEM ENG, V28, P1585, DOI 10.1016/J.COMPCHEMENG.2003.12.009##MAGNAUDET J, 2000, ANNU REV FLUID MECH, V32, P659, DOI 10.1146/ANNUREV.FLUID.32.1.659##PAN Y, 2000, AICHE J, V46, P434, DOI 10.1002/AIC.690460303##PATANKAR SV, 1972, INT J HEAT MASS TRAN, V15, P1787, DOI 10.1016/0017-9310(72)90054-3##PESKIN CS, 1977, J COMPUT PHYS, V25, P220, DOI 10.1016/0021-9991(77)90100-0##PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/AIC.690361004##SMAGORINSKY J., 1963, MON WEATHER REV, V91, P99, DOI [DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091]##SOKOLICHIN A, 1994, CHEM ENG SCI, V49, P5735, DOI 10.1016/0009-2509(94)00289-4##SOMMERFELD M, 2003, CAN J CHEM ENG, V81, P508, DOI 10.1002/CJCE.5450810324##SOMMERFELD M, 2000, LECT SERIES, V2000, P1##SQUYRES JM, 2003, LECT NOTES COMPUT SC, V2840, P379##TOMIYAMA A, 1997, NUCL ENG DES, V175, P77, DOI 10.1016/S0029-5493(97)00164-7##TOMIYAMA A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4##TOMIYAMA A, 1995, MULTIPHASE FLOW 1995, P241##VAN DEN HENGEL EIV, 2005, IND ENG CHEM RES, V44, P5233, DOI 10.1021/IE0492449##VAN WACHEM BGM, 2002, AICHE J, V48, P2744, DOI 10.1002/AIC.690481205##WANG P, 1999, SPE 15 RES SIM S SOC, P63##WELLEK RM, 1966, AICHE J, V12, P854, DOI 10.1002/AIC.690120506",73,2020-11-20,NA
J,WOS:000243132500014,2006,MAGNETIC PROPERTIES AND MAGNETOCALORIC EFFECTS IN MN1.2FE0.8P1-XGEX COMPOUNDS,"WE HAVE STUDIED THE MAGNETIC PROPERTIES AND MAGNETOCALORIC EFFECTS IN THE MN1.2FE0.8P1-XGEX COMPOUNDS WITH X = 0.2, 0.22, 0.3, 0.4 AND 0.5. X-RAY DIFFRACTION PATTERNS SHOW THAT THE MN1.2FE0.8P1-XGEX COMPOUNDS CRYSTALLIZE IN THE HEXAGONAL FE2P-TYPE CRYSTAL STRUCTURE. THE MAGNETIC MOMENTS OF THE MN1.2FE0.8P1-XGEX COMPOUNDS MEASURED AT 5 K AND 5 T INCREASE WITH INCREASING GE CONTENT. THE CURIE TEMPERATURE INCREASES STRONGLY AND THE MAGNETIC ENTROPY CHANGE HAS A MAXIMUM AROUND 233 K FOR THE COMPOUND WITH X = 0.22, WHICH IS ABOUT 19 AND 31 J KG(-1) K-1 FOR A FIELD CHANGE OF 2 AND 5 T, RESPECTIVELY.",ENTROPY CHANGE; TRANSITION,NA,JOURNAL OF PHYSICS-CONDENSED MATTER,"OU, ZQ##WANG, GF##LIN, S##TEGUS, O##BRUCK, E##BUSCHOW, KJ","INNER MONGOLIA NORMAL UNIV, KEY LAB MAGNET MAT, HOHHOT 010022, PEOPLES R CHINA. UNIV AMSTERDAM, WAALS ZEEMAN INST, NL-1018 XE AMSTERDAM, NETHERLANDS.","PHYSICS, CONDENSED MATTER",PHYSICS,"DAGULA W, 2006, J APPL PHYS, V99, DOI 10.1063/1.2158969##DAGULA W, 2005, IEEE T MAGN, V41, P2778, DOI 10.1109/TMAG.2005.854774##FUJITA A, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.104416##GSCHNEIDNER KA, 2000, ANNU REV MATER SCI, V30, P387, DOI 10.1146/ANNUREV.MATSCI.30.1.387##HORI T, 1992, J MAGN MAGN MATER, V104, P2045, DOI 10.1016/0304-8853(92)91661-C##HU FX, 2001, APPL PHYS LETT, V78, P3675, DOI 10.1063/1.1375836##PECHARSKY VK, 1997, PHYS REV LETT, V78, P4494, DOI 10.1103/PHYSREVLETT.78.4494##TEGUS O, 2005, J ALLOY COMPD, V396, P6, DOI 10.1016/J.JALLCOM.2004.12.001##TEGUS O, 2002, NATURE, V415, P150, DOI 10.1038/415150A##TEGUS O, 2002, PHYSICA B, V319, P174, DOI 10.1016/S0921-4526(02)01119-5##TEGUS O, 2006, IN PRESS J APPL PHYS##WADA H, 2001, APPL PHYS LETT, V79, P3302, DOI 10.1063/1.1419048",37,2020-11-20,NA
J,WOS:000242825600034,2006,AMINO ACIDS LABELED WITH [TC-99M(CO)(3)](+) AND RECOGNIZED BY THE L-TYPE AMINO ACID TRANSPORTER LAT1,NA,IN-VITRO CHARACTERIZATION; HEAVY-CHAIN; EXPRESSION; TRACER,NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"LIU, Y##PAK, JK##SCHMUTZ, P##BAUWENS, M##MERTENS, J##KNIGHT, H##ALBERTO, R","UNIV ZURICH, INST INORGAN CHEM, CH-8057 ZURICH, SWITZERLAND. VRIJE UNIV BRUSSEL VIB, B-1090 BRUSSELS, BELGIUM. MALLINCKRODT MED BV, NL-1755 ZG PETTEN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"BANERJEE SR, 2006, INORG CHIM ACTA, V359, P1603, DOI 10.1016/J.ICA.2005.11.022##BANERJEE SR, 2005, NUCL MED BIOL, V32, P1, DOI 10.1016/J.NUCMEDBIO.2004.09.001##FUCHS BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/J.SEMCANCER.2005.04.005##KANAI Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/JBC.273.37.23629##KERSEMANS V, 2006, EUR J NUCL MED MOL I, V33, P919, DOI 10.1007/S00259-005-0043-9##LAHOUTTE T, 2004, J NUCL MED, V45, P1591##MARX V, 2005, CHEM ENG NEWS, V83, P25, DOI 10.1021/CEN-V083N030.P025##MEIER C, 2002, EMBO J, V21, P580, DOI 10.1093/EMBOJ/21.4.580##MERTENS J, 2004, NUCL MED BIOL, V31, P739, DOI 10.1016/J.NUCMEDBIO.2004.03.003##OHKAME H, 2001, J SURG ONCOL, V78, P265, DOI 10.1002/JSO.1165##SCHIBLI R, 2005, BIOCONJUGATE CHEM, V16, P105, DOI 10.1021/BC049774L##SHIKANO N, 2003, NUCL MED BIOL, V30, P31, DOI 10.1016/S0969-8051(02)00350-5##STORR T, 2005, CHEM-EUR J, V11, P195, DOI 10.1002/CHEM.200400719##UCHINO H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/MOL.61.4.729##YANAGIDA O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4",52,2020-11-20,NA
J,WOS:000242825600059,2006,"EXIGUAMINE A, AN INDOLEAMINE-2,3-DIOXYGENASE (IDO) INHIBITOR ISOLATED FROM THE MARINE SPONGE NEOPETROSIA EXIGUA",NA,"INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN CATABOLISM; CHEMOTHERAPY; CANCER; TARGET",NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"BRASTIANOS, HC##VOTTERO, E##PATRICK, BO##VAN SOEST, R##MATAINAHO, T##MAUK, AG##ANDERSEN, RJ","UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOL BIOL, VANCOUVER, BC V6T 1Z1, CANADA. UNIV BRITISH COLUMBIA, DEPT EARTH & OCEAN SCI & CHEM, VANCOUVER, BC V6T 1Z1, CANADA. UNIV BRITISH COLUMBIA, DEPT CHEM, VANCOUVER, BC V6T 1Z1, CANADA. UNIV AMSTERDAM, INST SYSTEMAT & ECOL, NL-1090 GT AMSTERDAM, NETHERLANDS. UNIV PAPUA NEW GUINEA, DISCIPLINE PHARMACOL, NCD, PAPUA N GUINEA.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"MULLER AJ, 2005, CANCER RES, V65, P8065, DOI 10.1158/0008-5472.CAN-05-2213##MULLER AJ, 2005, EXPERT OPIN THER TAR, V9, P831, DOI 10.1517/14728222.9.4.831##MULLER AJ, 2005, NAT MED, V11, P312, DOI 10.1038/NM1196##MUNN DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/SCIENCE.281.5380.1191##MUNN DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/JEM.189.9.1363##PEREIRA A, 2006, J NAT PROD, V69, P1496, DOI 10.1021/NP060111X##SHIMIZU T, 1978, J BIOL CHEM, V253, P4700##UYTTENHOVE C, 2003, NAT MED, V9, P1269, DOI 10.1038/NM934##VOTTERO EDUARDO, 2006, BIOTECHNOLOGY JOURNAL, V1, P282, DOI 10.1002/BIOT.200600001",93,2020-11-20,NA
J,WOS:000242825600071,2006,CHIRAL ALIGNMENT OF OPV CHROMOPHORES: EXPLOITATION OF THE UREIDOPHTHALIMIDE-BASED FOLDAMER,"THE ABILITY OF FOLDAMERS TO ADOPT A SECONDARY STRUCTURE IN SOLUTION HAS BEEN EXPLOITED TO ORGANIZE PERIPHERAL FUNCTIONALITY. OUR PREVIOUSLY REPORTED POLY(UREIDOPHTHALIMIDE) FOLDAMER PROVED TO BE AN EXCELLENT SCAFFOLD FOR THE CHIRAL ORGANIZATION OF PERIPHERALLY POSITIONED OLIGO(P-PHENYLENEVINYLENE) (OPV) CHROMOPHORES. FACILE HIGH-YIELDING SYNTHESIS GAVE ACCESS TO THE REQUIRED OPV-DECORATED BUILDING BLOCKS. A CONDENSATION POLYMERIZATION PROVIDED POLYMERS OF SUFFICIENT LENGTH TO ALLOW CONSTRUCTION OF A HELICAL ARCHITECTURE COMPRISING SEVERAL TURNS. SHORT AND LONG CHAINS WERE SEPARATED BY CHROMATOGRAPHY. CIRCULAR DICHROISM STUDIES IN THF OF THE LONGER CHAINS INDICATE THE PRESENCE OF HELICALLY ARRANGED OPVS. HOWEVER, SUCH AN EFFECT IS NOT OBSERVED IN CHCL3. REMARKABLE ARE THE MEASUREMENTS OF THE OPV FOLDAMERS IN HEPTANE. A BISIGNATE COTTON EFFECT IS OBSERVED IN HEPTANE OF A SAMPLE WITH A THF HISTORY. NO COTTON EFFECT IS OBSERVED IN HEPTANE OF A SAMPLE WITH A CHCL3 HISTORY. IN THIS EXAMPLE OF SUPRAMOLECULAR SYNTHESIS, THE SOLVENT DICTATES THE EXPRESSION OF SUPRAMOLECULAR CHIRALITY IN A SECONDARY STRUCTURE. THE SHORT-CHAIN OLIGOMERIC FRACTIONS THAT ARE UNABLE TO CREATE A FULL TURN REVEALED ON SCANNING TUNNELING MICROSCOPY ANALYSIS THE PRESENCE OF CIRCULAR ARCHITECTURES AT THE GRAPHITE/1-PHENYLOCTANE INTERFACE. THIS IS IN FULL AGREEMENT WITH THE PROPOSED CONFORMATION OF THE DECORATED FOLDAMERS.",PHENYLENE ETHYNYLENE FOLDAMERS; PHOTOINDUCED ELECTRON-TRANSFER; ORGANIC SOLAR-CELLS; ENERGY-TRANSFER; COLUMNAR STACKS; HELIX FORMATION; OLIGOMERS; RECOGNITION; COMBINATION; FAMILY,NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"SINKELDAM, RW##HOEBEN, FJM##POUDEROIJEN, MJ##DE CAT, I##ZHANG, J##FURUKAWA, S##DE FEYTER, S##VEKEMANS, JAJM##MEIJER, EW","EINDHOVEN UNIV TECHNOL, LAB MACROMOL & ORGAN CHEM, NL-5600 MB EINDHOVEN, NETHERLANDS. KATHOLIEKE UNIV LEUVEN, LAB PHOTOCHEM & SPECTROSCOPY, DEPT CHEM, DIV MOL & NANO MAT, B-3001 HEVERLEE, BELGIUM.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"AJAYAGHOSH A, 2003, ANGEW CHEM INT EDIT, V42, P332, DOI 10.1002/ANIE.200390109##APPELLA DH, 1996, J AM CHEM SOC, V118, P13071, DOI 10.1021/JA963290L##BECKERS EHA, 2002, J MATER CHEM, V12, P2054, DOI 10.1039/B201186G##BERL V, 2001, CHEM-EUR J, V7, P2798, DOI 10.1002/1521-3765(20010702)7:13<2798::AID-CHEM2798>3.0.CO;2-L##BLATCHLY RA, 2003, J ORG CHEM, V68, P8780, DOI 10.1021/JO034827Y##BLOCK MAB, 2005, TOP CURR CHEM, V245, P89, DOI 10.1007/B98167##BRUNSVELD L, 2001, J AM CHEM SOC, V123, P7978, DOI 10.1021/JA010751G##CORBIN PS, 2001, J AM CHEM SOC, V123, P10475, DOI 10.1021/JA010638Q##DAVYDOV AS, 1948, ZH EKSP TEOR FIZ+, V18, P210##DOBABALAPUR A, 1996, ADV MATER, V8, P853##DOLAIN C, 2005, CHEM-EUR J, V11, P6135, DOI 10.1002/CHEM.200500395##DOLAIN C, 2005, J AM CHEM SOC, V127, P12943, DOI 10.1021/JA0527828##ETTER MC, 1990, J AM CHEM SOC, V112, P8415, DOI 10.1021/JA00179A028##ETTER MC, 1988, J AM CHEM SOC, V110, P5896, DOI 10.1021/JA00225A049##GARRIC J, 2005, ANGEW CHEM INT EDIT, V44, P1954, DOI 10.1002/ANIE.200462898##GELLMAN SH, 1998, ACCOUNTS CHEM RES, V31, P173, DOI 10.1021/AR960298R##GOTO K, 2005, ORG LETT, V7, P1683, DOI 10.1021/OL0500721##HAMURO Y, 1996, J AM CHEM SOC, V118, P7529, DOI 10.1021/JA9539857##HAMURO Y, 1997, J AM CHEM SOC, V119, P10587, DOI 10.1021/JA963449U##HILL DJ, 2001, CHEM REV, V101, P3893, DOI 10.1021/CR990120T##HOEBEN FJM, 2004, ANGEW CHEM INT EDIT, V43, P1976, DOI 10.1002/ANIE.200353451##HOPPE H, 2004, J MATER RES, V19, P1924, DOI 10.1557/JMR.2004.0252##HOROWITZ G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U##HOU JL, 2004, J AM CHEM SOC, V126, P12386, DOI 10.1021/JA047436P##HUC I, 2004, EUR J ORG CHEM, V2004, P17, DOI 10.1002/EJOC.200300495##HUNTER CA, 2005, CHEM COMMUN, P3691, DOI 10.1039/B506093A##JONES TV, 2003, ORG LETT, V5, P3297, DOI 10.1021/OL0352254##JONKHEIJM P, 2004, ANGEW CHEM INT EDIT, V43, P74, DOI 10.1002/ANIE.200352790##JONKHEIJM P, 2003, J AM CHEM SOC, V125, P15941, DOI 10.1021/JA0383118##KATAYAMA H, UNPUB##KRAFT A, 2001, CHEMPHYSCHEM, V2, P163, DOI 10.1002/1439-7641(20010316)2:3<163::AID-CPHC163>3.0.CO;2-V##MATSUDA K, 2002, J AM CHEM SOC, V124, P11836, DOI 10.1021/JA027437M##MATTHEWS JR, 2005, CHEM COMMUN, P5503, DOI 10.1039/B512119A##MAURIZOT V, 2004, CHEM COMMUN, P924, DOI 10.1039/B317078K##MIURA A, 2005, SMALL, V1, P131, DOI 10.1002/SMLL.200400008##NAKANO T, 2003, J AM CHEM SOC, V125, P15474, DOI 10.1021/JA037836X##NELSON JC, 1997, SCIENCE, V277, P1793, DOI 10.1126/SCIENCE.277.5333.1793##NGUYEN JQ, 1999, J AM CHEM SOC, V121, P2639, DOI 10.1021/JA9838920##PEETERS E, 2002, CHEM-EUR J, V8, P4470, DOI 10.1002/1521-3765(20021004)8:19<4470::AID-CHEM4470>3.0.CO;2-F##PRINCE RB, 1999, J AM CHEM SOC, V121, P3114, DOI 10.1021/JA983995I##PRINCE RB, 2000, ANGEW CHEM INT EDIT, V39, P228, DOI 10.1002/(SICI)1521-3773(20000103)39:1<228::AID-ANIE228>3.0.CO;2-B##PRINCE RB, 2000, J AM CHEM SOC, V122, P2758, DOI 10.1021/JA993830P##SANDFORD AR, 2004, EUR J BIOCHEM, V271, P1416##SCHENNING APHJ, 2002, J AM CHEM SOC, V124, P10252, DOI 10.1021/JA020378S##SCHENNING APHJ, 2001, J AM CHEM SOC, V123, P409, DOI 10.1021/JA0033180##SCHMUCK C, 2003, ANGEW CHEM INT EDIT, V42, P2448, DOI 10.1002/ANIE.200201625##SCHUSTER GB, 2000, ACCOUNTS CHEM RES, V33, P253, DOI 10.1021/AR980059Z##SEGURA JL, 2005, CHEM SOC REV, V34, P31, DOI 10.1039/B402417F##SINKELDAM RW, 2006, CHEM-EUR J, V12, P6129, DOI 10.1002/CHEM.200600476##SINKELDAM RW, 2006, ORG LETT, V8, P383, DOI 10.1021/OL0524757##STONE MT, 2004, ORG LETT, V6, P469, DOI 10.1021/OL036238K##SUN YM, 2005, J MATER CHEM, V15, P53, DOI 10.1039/B411245H##SYAMAKUMARI A, 2002, CHEM-EUR J, V8, P3353, DOI 10.1002/1521-3765(20020802)8:15<3353::AID-CHEM3353>3.0.CO;2-X##TANATANI A, 2005, J AM CHEM SOC, V127, P8553, DOI 10.1021/JA0455291##TANATANI A, 2002, ANGEW CHEM INT EDIT, V41, P325, DOI 10.1002/1521-3773(20020118)41:2<325::AID-ANIE325>3.0.CO;2-1##VAN GORP JJ, 2004, CHEM COMMUN, P60, DOI 10.1039/B312407J##VANGORP JJ, 2004, THESIS EINDHOVEN U T##VERSTEEGEN RM, 2005, MACROMOLECULES, V38, P3176, DOI 10.1021/MA0478207##WOLFFS M, 2005, J AM CHEM SOC, V127, P13484, DOI 10.1021/JA054406T##YANG XW, 2004, J AM CHEM SOC, V126, P3148, DOI 10.1021/JA039416D##YUAN LH, 2004, J AM CHEM SOC, V126, P16528, DOI 10.1021/JA046858W##ZHANG AM, 2006, ORG LETT, V8, P803, DOI 10.1021/OL0526322",54,2020-11-20,NA
J,WOS:000242825600099,2006,STERIC COMMUNICATION OF CHIRAL INFORMATION OBSERVED IN DENDRONIZED POLYACETYLENES,"STRUCTURAL AND RETROSTRUCTURAL ANALYSIS OF HELICAL DENDRONIZED POLYACETYLENES (I.E., SELF-ORGANIZABLE POLYACETYLENES CONTAINING FIRST GENERATION DENDRONS OR MINIDENDRONS AS SIDE GROUPS) SYNTHESIZED BY THE POLYMERIZATION OF MINIDENDRITIC ACETYLENES WITH [RH(NBD)CL](2) (NBD = 2,5-NORBORNADIENE) REVEALS AN SIMILAR TO 10% CHANGE IN THE AVERAGE COLUMN STRATUM THICKNESS (I) OF THE CYLINDRICAL MACROMOLECULES WITH A CHIRAL PERIPHERY, THROUGH WHICH A STRONG PREFERENCE FOR A SINGLE-HANDED SCREW-SENSE IS COMMUNICATED. THE CYLINDRICAL MACROMOLECULES REVERSIBLY INTERCONVERT BETWEEN A THREE-DIMENSIONAL (3D) CENTERED RECTANGULAR LATTICE (PHI(R-C,K)) EXHIBITING LONG-RANGE INTRACOLUMNAR HELICAL ORDER AT LOWER TEMPERATURES AND A TWO-DIMENSIONAL (2D) HEXAGONAL COLUMNAR LATTICE (PHI(H)) WITH SHORT-RANGE HELICAL ORDER AT HIGHER TEMPERATURES. A POLYMER CONTAINING CHIRAL, NONRACEMIC PERIPHERAL ALKYL TAILS IS FOUND TO HAVE A LARGER I AS COMPARED TO THE ACHIRAL POLYMERS. IN METHYL CYCLOHEXANE SOLUTION, THE SAME POLYMER EXHIBITS AN INTENSE SIGNAL IN CIRCULAR DICHROISM (CD) SPECTRA, WHOSE INTENSITY DECREASES UPON HEATING. THE OBSERVED CHANGE IN I INDICATES THAT THE CHIRAL TAILS ALTER THE POLYMER CONFORMATION FROM THAT OF THE CORRESPONDING POLYMER WITH ACHIRAL SIDE CHAINS. THIS CHANGE IN CONFORMATION RESULTS IN A RELATIVELY LARGE FREE ENERGY DIFFERENCE (DELTA G(H)) FAVORING ONE HELIX-SENSE OVER THE OTHER (PER MONOMER RESIDUE). THE CAPACITY TO DISTORT THE POLYMER CONFORMATION AND CORRESPONDING FREE ENERGY IS RELATED TO THE POPULATION OF BRANCHES IN THE CHIRAL TAILS AND THEIR DISTANCE FROM THE POLYMER BACKBONE BY COMPARISON TO RECENTLY REPORTED FIRST AND SECOND GENERATION DENDRONIZED POLYPHENYLACETYLENES.",POLY(PHENYLACETYLENE) DERIVATIVES BEARING; CONSTITUTIONAL ISOMERIC AB(2); SELF-ASSEMBLING DENDRONS; STRUCTURAL-ANALYSIS; LIVING POLYMERIZATION; LIQUID-CRYSTAL; LIBRARIES; AB(3); MACROMOLECULES; VISUALIZATION,NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"PERCEC, V##AQAD, E##PETERCA, M##RUDICK, JG##LEMON, L##RONDA, JC##DE, BB##HEINEY, PA##MEIJER, EW","UNIV PENN, DEPT CHEM, ROY & DIANA VAGELOS LABS, PHILADELPHIA, PA 19104 USA. UNIV PENN, DEPT PHYS & ASTRON, PHILADELPHIA, PA 19104 USA. EINDHOVEN UNIV TECHNOL, LAB MACROMOL & ORGAN CHEM, NL-5600 MB EINDHOVEN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"CORNELISSEN JJLM, 2001, CHEM REV, V101, P4039, DOI 10.1021/CR990126I##DUAN H, 2001, CHEM-EUR J, V7, P4134, DOI 10.1002/1521-3765(20011001)7:19<4134::AID-CHEM4134>3.0.CO;2-W##FRAUENRATH H, 2005, PROG POLYM SCI, V30, P325, DOI 10.1016/J.PROGPOLYMSCI.2005.01.011##GREEN MM, 1995, SCIENCE, V268, P1860, DOI 10.1126/SCIENCE.268.5219.1860##GREEN MM, 2001, ACCOUNTS CHEM RES, V34, P672, DOI 10.1021/AR010009L##GREEN MM, 1989, J AM CHEM SOC, V111, P6452, DOI 10.1021/JA00198A084##HASEGAWA T, 2006, MACROMOLECULES, V39, P482, DOI 10.1021/MA052206W##HILL DJ, 2001, CHEM REV, V101, P3893, DOI 10.1021/CR990120T##HOEBEN FJM, 2005, CHEM REV, V105, P1491, DOI 10.1021/CR030070Z##HUDSON SD, 1997, SCIENCE, V278, P449, DOI 10.1126/SCIENCE.278.5337.449##JONKHEIJM P, 2006, SCIENCE, V313, P80, DOI 10.1126/SCIENCE.1127884##KISHIMOTO Y, 1994, J AM CHEM SOC, V116, P12131, DOI 10.1021/JA00105A095##KISHIMOTO Y, 1999, J AM CHEM SOC, V121, P12035, DOI 10.1021/JA991903Z##LEMON L, 1996, THESIS CASE W RESERV##LI YY, 2004, J AM CHEM SOC, V126, P1872, DOI 10.1021/JA038617E##MORINO K, 2002, CHEM-EUR J, V8, P5112, DOI 10.1002/1521-3765(20021115)8:22<5112::AID-CHEM5112>3.0.CO;2-S##NAKAKO H, 2000, MACROMOLECULES, V33, P3978, DOI 10.1021/MA000191Q##NAKANO T, 2001, CHEM REV, V101, P4013, DOI 10.1021/CR0000978##NOMURA R, 2000, J AM CHEM SOC, V122, P8830, DOI 10.1021/JA000877Y##PERCEC V, 2006, SCIENCE, V313, P55, DOI 10.1126/SCIENCE.1129512##PERCEC V, 1983, POLYM BULL, V10, P1, DOI 10.1007/BF00263230##PERCEC V, 1983, POLYM BULL, V9, P548##PERCEC V, 2005, J AM CHEM SOC, V127, P15257, DOI 10.1021/JA055406W##PERCEC V, 2005, MACROMOLECULES, V38, P7241, DOI 10.1021/MA051060Y##PERCEC V, 2005, MACROMOLECULES, V38, P7205, DOI 10.1021/MA051536D##PERCEC V, 2004, NATURE, V430, P764, DOI 10.1038/NATURE02770##PERCEC V, 1993, J CHEM SOC PERK T 1, P2799, DOI 10.1039/P19930002799##PERCEC V, 1998, NATURE, V391, P161, DOI 10.1038/34384##PERCEC V, 2004, J AM CHEM SOC, V126, P6078, DOI 10.1021/JA049846J##PERCEC V, 2002, CHEM-EUR J, V8, P1106, DOI 10.1002/1521-3765(20020301)8:5<1106::AID-CHEM1106>3.0.CO;2-G##PERCEC V, 2001, J AM CHEM SOC, V123, P1302, DOI 10.1021/JA0037771##PERCEC V, 1998, J AM CHEM SOC, V120, P8619, DOI 10.1021/JA981211V##PERCEC V, 2002, J POLYM SCI POL CHEM, V40, P3509, DOI 10.1002/POLA.10458##PERCEC V, 2002, NATURE, V419, P384, DOI 10.1038/NATURE01072##PERCEC V, 2001, BIOMACROMOLECULES, V2, P729, DOI 10.1021/BM015559L##PERCEC V, 2001, BIOMACROMOLECULES, V2, P706, DOI 10.1021/BM015550J##PERCEC V, 2006, J AM CHEM SOC, V128, P3324, DOI 10.1021/JA060062A##PERCEC V, 1999, CHEM-EUR J, V5, P1070, DOI 10.1002/(SICI)1521-3765(19990301)5:3<1070::AID-CHEM1070>3.0.CO;2-9##PERCEC V, 1997, J AM CHEM SOC, V119, P12978, DOI 10.1021/JA9727878##PERCEC V, 2002, J POLYM SCI POL CHEM, V40, P3212, DOI 10.1002/POLA.10421##PERCEC V, 2006, CHEM-EUR J, V12, P6216, DOI 10.1002/CHEM.200600178##PERCEC V, 2006, CHEM-EUR J, V12, P6298, DOI 10.1002/CHEM.200501195##PERCEC V, 2006, PHILOS T R SOC A, V364, P2709, DOI 10.1098/RSTA.2006.1848##PERCEC V, 2006, CHEM-EUR J, V12, P5731, DOI 10.1002/CHEM.200600009##ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425A0##SCHENNING APHJ, 2002, MACROMOL RAPID COMM, V23, P266##SCHLUTER AD, 2005, TOP CURR CHEM, V245, P151, DOI 10.1007/B98168##SEDLACEK J, 2003, COLLECT CZECH CHEM C, V68, P1745, DOI 10.1135/CCCC20031745##SIMIONESCU CI, 1979, J POLYM SCI POL LETT, V17, P421, DOI 10.1002/POL.1979.130170705##SIMIONESCU CI, 1977, J POLYM SCI POL CHEM, V15, P2497, DOI 10.1002/POL.1977.170151018##SIMIONESCU CI, 1980, J POLYM SCI POL CHEM, V18, P147, DOI 10.1002/POL.1980.170180114##TANG HZ, 2004, J AM CHEM SOC, V126, P3722, DOI 10.1021/JA049937G##UNGAR G, 2003, SCIENCE, V299, P1208, DOI 10.1126/SCIENCE.1078849##YASHIMA E, 1995, MACROMOLECULES, V28, P4184, DOI 10.1021/MA00116A020##YASHIMA E, 2004, CHEM-EUR J, V10, P42, DOI 10.1002/CHEM.200305295##YEARDLEY DJP, 2000, J AM CHEM SOC, V122, P1684, DOI 10.1021/JA993915Q##ZENG XB, 2004, NATURE, V428, P157, DOI 10.1038/NATURE02368",128,2020-11-20,NA
J,WOS:000242825600101,2006,ALKYL CHAIN BARRIERS FOR KINETIC OPTIMIZATION IN DYE-SENSITIZED SOLAR CELLS,"THE OPTIMIZATION OF INTERFACIAL CHARGE TRANSFER IS CRUCIAL TO THE DESIGN OF DYE-SENSITIZED SOLAR CELLS. IN THIS PAPER WE ADDRESS THE DYNAMICS OF THE CHARGE SEPARATION AND RECOMBINATION IN LIQUID-ELECTROLYTE AND SOLID-STATE CELLS EMPLOYING A SERIES OF AMPHIPHILIC RUTHENIUM DYES WITH VARYING HYDROCARBON CHAIN LENGTHS, ACTING AS AN INSULATING BARRIER FOR ELECTRON-HOLE RECOMBINATION. DYNAMICS OF ELECTRON INJECTION, MONITORED BY TIME-RESOLVED EMISSION SPECTROSCOPY, AND OF CHARGE RECOMBINATION AND REGENERATION, MONITORED BY TRANSIENT OPTICAL ABSORPTION SPECTROSCOPY, ARE CORRELATED WITH DEVICE PERFORMANCE. WE FIND THAT INCREASING DYE ALKYL CHAIN LENGTH RESULTS IN SLOWER CHARGE RECOMBINATION DYNAMICS TO BOTH THE DYE CATION AND THE REDOX ELECTROLYTE OR SOLID-STATE HOLE CONDUCTOR (SPIRO-OMETAD). THESE SLOWER RECOMBINATION DYNAMICS ARE HOWEVER PARALLELED BY REDUCED RATES FOR BOTH ELECTRON INJECTION INTO THE TIO2 ELECTRODE AND DYE REGENERATION BY THE I-/I-3(-) REDOX COUPLE OR SPIRO-OMETAD. KINETIC COMPETITION BETWEEN ELECTRON RECOMBINATION WITH DYE CATIONS AND DYE GROUND STATE REGENERATION BY THE IODIDE ELECTROLYTE IS FOUND TO BE A KEY FACTOR FOR LIQUID ELECTROLYTE CELLS, WITH OPTIMUM DEVICE PERFORMANCE BEING OBTAINED WHEN THE DYE REGENERATION IS JUST FAST ENOUGH TO COMPETE WITH ELECTRON-HOLE RECOMBINATION. THESE RESULTS ARE DISCUSSED IN TERMS OF THE MINIMIZATION OF KINETIC REDUNDANCY IN SOLID-STATE AND LIQUID-ELECTROLYTE DYE-SENSITIZED PHOTOVOLTAIC DEVICES.",NANOCRYSTALLINE TIO2 FILMS; ELECTRON-TRANSFER PROCESSES; CHARGE SEPARATION; TRANSFER DYNAMICS; STATE; RECOMBINATION; OXIDE; EFFICIENCY; INJECTION; ENERGY,NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"KROEZE, JE##HIRATA, N##KOOPS, S##NAZEERUDDIN, MK##SCHMIDT-MENDE, L##GRATZEL, M##DURRANT, JR","UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, CTR ELECT MAT & DEVICES, LONDON SW7 2AY, ENGLAND. SWISS FED INST TECHNOL, INST CHEM SCI & ENGN, LAB PHOTON & INTERFACES, CH-1015 LAUSANNE, SWITZERLAND.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"ANDERSON NA, 2005, ANNU REV PHYS CHEM, V56, P491, DOI 10.1146/ANNUREV.PHYSCHEM.55.091602.094347##BACH U, 1999, J AM CHEM SOC, V121, P7445, DOI 10.1021/JA9915403##BARBE CJ, 1997, J AM CERAM SOC, V80, P3157##BAUER C, 2002, J PHYS CHEM B, V106, P12693, DOI 10.1021/JP0200268##CAZZANTI S, 2006, J AM CHEM SOC, V128, P9996, DOI 10.1021/JA062087F##CLIFFORD JN, 2004, J AM CHEM SOC, V126, P5670, DOI 10.1021/JA049705H##DURRANT JR, 2004, COORDIN CHEM REV, V248, P1247, DOI 10.1016/J.CCR.2004.03.014##GRATZEL M, 2001, NATURE, V414, P338, DOI 10.1038/35104607##GREEN ANM, 2005, J PHYS CHEM B, V109, P12525, DOI 10.1021/JP050145Y##GREEN ANM, 2005, J PHYS CHEM B, V109, P142, DOI 10.1021/JP047414P##GREGG BA, 2001, J PHYS CHEM B, V105, P1422, DOI 10.1021/JP003000U##HAGFELDT A, 2000, ACCOUNTS CHEM RES, V33, P269, DOI 10.1021/AR980112J##HAQUE SA, 2004, ADV MATER, V16, P1177, DOI 10.1002/ADMA.200400327##HAQUE SA, 2005, ANGEW CHEM INT EDIT, V44, P5740, DOI 10.1002/ANIE.200500363##HAQUE SA, 2003, CHEMPHYSCHEM, V4, P89, DOI 10.1002/CPHC.200390014##HAQUE SA, 2005, J AM CHEM SOC, V127, P3456, DOI 10.1021/JA0460357##HIRATA N, 2006, CHEM COMMUN, P535, DOI 10.1039/B513180D##HIRATA N, 2004, CHEM-EUR J, V10, P595, DOI 10.1002/CHEM.200305408##HUANG SY, 1997, J PHYS CHEM B, V101, P2576, DOI 10.1021/JP962377Q##ITO S, 2004, J MATER CHEM, V14, P385, DOI 10.1039/B311090G##KAY A, 1994, J PHYS CHEM-US, V98, P952, DOI 10.1021/J100054A035##KAY A, 2002, CHEM MATER, V14, P2930, DOI 10.1021/CM0115968##KROEZE JE, 2006, ADV FUNCT MATER, V16, P1832, DOI 10.1002/ADFM.200500748##KRUGER J, 2001, APPL PHYS LETT, V79, P2085, DOI 10.1063/1.1406148##MEYER GJ, 2005, INORG CHEM, V44, P6852, DOI 10.1021/IC0505908##MONTANARI I, 2002, J PHYS CHEM B, V106, P12203, DOI 10.1021/JP025824C##NAZEERUDDIN MK, 1999, INORG CHEM, V38, P6298, DOI 10.1021/IC990916A##NAZEERUDDIN MK, 2005, J AM CHEM SOC, V127, P16835, DOI 10.1021/JA052467L##NAZEERUDDIN MK, 2004, COORDIN CHEM REV, V248, P1317, DOI 10.1016/J.CCR.2004.03.012##NELSON J, 2001, PHYS REV B, V63, DOI 10.1103/PHYSREVB.63.205321##NOGUEIRA AF, 2001, J PHYS CHEM B, V105, P7517, DOI 10.1021/JP010420Q##PALOMARES E, 2003, J AM CHEM SOC, V125, P475, DOI 10.1021/JA027945W##REDMOND G, 1993, J PHYS CHEM-US, V97, P6951, DOI 10.1021/J100129A005##SCHMIDT-MENDE L, 2005, NANO LETT, V5, P1315, DOI 10.1021/NL050555Y##SCHMIDT-MENDE L, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1844032##SNAITH HJ, 2005, ANGEW CHEM INT EDIT, V22, P2##TACHIBANA Y, 1996, J PHYS CHEM-US, V100, P20056, DOI 10.1021/JP962227F##TACHIBANA Y, 2001, J PHYS CHEM B, V105, P7424, DOI 10.1021/JP010173Q##TACHIBANA Y, 2002, CHEM PHYS, V285, P127, DOI 10.1016/S0301-0104(02)00695-X##TENNAKONE K, 1999, CHEM COMMUN, P15, DOI 10.1039/A806801A##TRIBUTSCH H, 2006, CR CHIM, V9, P584, DOI 10.1016/J.CRCI.2005.09.002##YUM JH, 2006, J PHYS CHEM B, V110, P3215, DOI 10.1021/JP0564593##ZABAN A, 2000, CHEM COMMUN, P2231, DOI 10.1039/B005921H##ZAKEERUDDIN SM, 2002, LANGMUIR, V18, P952, DOI 10.1021/LA0110848",237,2020-11-20,NA
J,WOS:000243289600003,2006,"ISLAND-TERMINUS EVOLUTION RELATED TO CHANGING EBB-TIDAL-DELTA CONFIGURATION: TEXEL, THE NETHERLANDS","HISTORICAL MAPS OF SOUTHWEST TEXEL AND THE ADJACENT EBB-TIDAL DELTA, SUPPLEMENTED WITH QUARTZ OSL (OPTICALLY STIMULATED LUMINESCENCE) AGES OF DUNE SAND, SPAN FOUR CENTURIES AND SHOW SEVERAL LINKS BETWEEN COASTAL DEVELOPMENT AND EBB-TIDAL-DELTA BEHAVIOR. UPDRIFT INLET MIGRATION GOVERNED RECURVED-SPIT FORMATION, AND CHANGES IN EBB-TIDAL-DETTA SIZE AND SHAPE RESULTED IN THE FORMATION OF A BULGE AT THE ISLAND TERMINUS. SUSTAINED UPDRIFT MIGRATION OF THE EBB-TIDAL DELTA RESULTED IN A COMMENSURATE POSITION SHIFT OF THE BULGE AND EVENTUALLY IN FLATTENING OF THE COASTLINE. REGIONAL COASTAL-MANAGEMENT MEASURES HAVE HAD A STRONG INFLUENCE ON TIDAL-INLET AND EBB-TIDAL-DELTA BEHAVIOR, AND THEREFORE ALSO ON THE CHANGING SHAPE OF SOUTHWEST TEXEL. IDENTIFICATION OF RELATIONSHIPS BETWEEN EBB-TIDAL-DELTA BEHAVIOR AND CHANGING BARRIER-TERMINUS EROSION-AND-ACCRETION PATTERNS ON A DECADAL TO CENTURY TIME SCALE CONTRIBUTES TO OUR UNDERSTANDING OF COASTAL-SYSTEM DYNAMICS. ANY BARRIER TERMINUS WITH PRESERVED SETS OF DUNE RIDGES HOLDS A POTENTIAL RECORD ON PAST EBB-TIDAL-DELTA ORIENTATIONS, WHICH PROVIDE CLUES ON PAST CHANGES IN TIDAL PRISMS AND WAVE VERSUS TIDE DOMINANCE. UNDER THE CURRENT EBB-TIDAL-DELTA CONFIGURATION, THE ENTIRE WESTWARD-ORIENTED COAST OF SOUTHWEST TEXEL IS TOO EXPOSED FOR LASTING ACCRETION. BULGES RESULTING FROM FUTURE MERGER OF SHOALS WITH THE COAST IN THIS AREA WILL BE ERODED RAPIDLY. (C) 2006 PUBLISHED BY ELSEVIER B.V.",EAST FRISIAN-ISLANDS; DOSE-RATES; LUMINESCENCE; GERMANY; GRAINS; INLET; WEST,BARRIER ISLAND; BEACH RIDGE; COASTAL PROCESSES; DUNE RIDGE; LUMINESCENCE DATING,MARINE GEOLOGY,"VAN HETEREN, S##OOST, AP##VAN DER SPEK, AJF##ELIAS, EPL","GEOL SURVEY NETHERLANDS, TNO, BUILT ENVIRONM & GEOSCI, NL-3508 TA UTRECHT, NETHERLANDS. NETHERLANDS CTR LUMINESCENCE DATING, NL-2629 JB DELFT, NETHERLANDS. NATL INST COASTAL & MARINE MANAGEMENT, RIKZ, NL-9750 AE HAREN, NETHERLANDS. DELFT UNIV TECHNOL, NETHERLANDS CTR COASTAL RES, NL-2600 GA DELFT, NETHERLANDS. DELFT UNIV TECHNOL, FAC CIVIL ENGN & GEOSCI, NL-2600 GA DELFT, NETHERLANDS.","GEOSCIENCES, MULTIDISCIPLINARY; OCEANOGRAPHY",GEOLOGY; OCEANOGRAPHY,"BALLARINI M, 2003, QUATERNARY SCI REV, V22, P1011, DOI 10.1016/S0277-3791(03)00043-X##BOTTER-JENSEN L, 1999, RADIAT PROT DOSIM, V84, P307##CLEVERINGA J, 2001, RIZKOS2001031##COWELL PJ, 2003, J COASTAL RES, V19, P812##ELIAS EPL, 2006, MAR GEOL, V225, P5, DOI 10.1016/J.MARGEO.2005.09.008##FITZGERALD D.M., 1984, J SEDIMENT PETROL, V54, P1301##FITZGERALD D.M, 1996, J COASTAL RES, V23, P47, DOI DOI 10.2307/25736068##FITZGERALD DM, 1984, MAR GEOL, V60, P355, DOI 10.1016/0025-3227(84)90157-9##FITZGERALD DM, 1958, HYDRODYNAMICS SEDIME, P269##HALLEWAS DP, 1984, GEOL MIJNBOUW, V63, P299##HAYES M.O., 1979, BARRIER ISLANDS GULF, P1##HUBBARD D.K., 1975, ESTUARINE RES, V2, P253##JOUSTRA DS, 1973, GEULBEWEGING BUITEND, P71##MEJDAHL V, 1979, ARCHAEOMETRY, V21, P61, DOI 10.1111/J.1475-4754.1979.TB00241.X##MURRAY AS, 1987, J RADIOAN NUCL CH AR, V115, P263, DOI 10.1007/BF02037443##MURRAY AS, 2000, RADIAT MEAS, V32, P57, DOI 10.1016/S1350-4487(99)00253-X##OLLEY JM, 1996, QUATERNARY SCI REV, V15, P751, DOI 10.1016/0277-3791(96)00026-1##PRESCOTT JR, 1994, RADIAT MEAS, V23, P497, DOI 10.1016/1350-4487(94)90086-8##RIDDERNKHOF H, 1999, P EUR C ROM IT##SCHOORL H, 1999, CONVEXE KUSTBOOG DEE, P189##SCHOORL H., 1973, ZESHONDERD JAAR WATE##SCHOUTEN L, 1999, CONVEXE KUSTBOOG DEE, P1##SHA LP, 1989, MAR GEOL, V89, P11, DOI 10.1016/0025-3227(89)90025-X##SHA LP, 1990, THESIS UTRECHT U UTR##SHA LP, 1996, MEDEDELINGEN RIJKS G, V57, P79##TER WEE M. W., 1962, MEDEDELINGEN GEOLOGI, V15, P57##ZIMMERMA.DW, 1971, ARCHAEOMETRY, V13, P29, DOI 10.1111/J.1475-4754.1971.TB00028.X",16,2020-11-20,NA
J,WOS:000243241300046,2006,GATE SIMULATIONS FOR OPTIMIZATION OF PINHOLE IMAGING,"WE VALIDATED THE MONTE CARLO PACKAGE, GATE, FOR MULTI-PINHOLE GAMMA-RAY IMAGING SIMULATIONS USING CALCULATIONS AND MEASUREMENTS. FOR THESE STUDIES REQUIRING LARGE AMOUNT OF PHOTON HISTORIES, THE NEWLY DESIGNED CLUSTER VERSION OF GATE WAS USED. ACCORDINGLY THAT VALIDATED SIMULATOR ALLOWED US THEN TO EVALUATE DESIGN PARAMETERS FOR I-123-EXPERIMENTS ON A PROTOTYPE MULTI-PINHOLE SPELT CAMERA FOR WHICH ANALYTICAL CALCULATIONS WERE FAILING DUE TO SCATTER OF HIGH-ENERGY PHOTONS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NA,MONTE CARLO; GATE; OBLIQUE PINHOLE; I-123,NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT,"STAELENS, S##VUNCKX, K##DE BEENHOUWER, J##BEEKMAN, F##D'ASSELER, Y##NUYTS, J##LEMAHIEU, I","UGENT ELIS, B-9000 GHENT, BELGIUM. UZLEUVEN, B-3000 LOUVAIN, BELGIUM. UMCUTRECHT, NL-3584 CG UTRECHT, NETHERLANDS.","INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS, NUCLEAR; PHYSICS, PARTICLES & FIELDS",INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS,"BEEKMAN FJ, 2005, J NUCL MED, V46, P1194##BEEKMAN FJ, 2002, EUR J NUCL MED MOL I, V29, P933, DOI 10.1007/S00259-002-0805-6##BEQUE D, 2005, THESIS CATHOLIC U LE##DE BEENHOUWER J, 2005, IEEE NUCL SCI CONF R, P2437##ICHIHARA T, 1993, J NUCL MED, V34, P2216##JAN S, 2004, PHYS MED BIOL, V49, P4543, DOI 10.1088/0031-9155/49/19/007##PAUWELS EKJ, 2005, DRUG FUTURE, V30, P311, DOI 10.1358/DOF.2005.030.03.886980##SCHRAMM NU, 2003, IEEE T NUCL SCI, V50, P315, DOI 10.1109/TNS.2003.812437",13,2020-11-20,NA
J,WOS:000207443600055,2006,MONITORING THE T-CELL RECEPTOR REPERTOIRE AT SINGLE-CLONE RESOLUTION,"THE ADAPTIVE IMMUNE SYSTEM RECOGNIZES BILLIONS OF UNIQUE ANTIGENS USING HIGHLY VARIABLE T-CELL RECEPTORS. THE ALPHA BETA T-CELL RECEPTOR REPERTOIRE INCLUDES AN ESTIMATED 10(6) DIFFERENT REARRANGED BETA CHAINS PER INDIVIDUAL. THIS PAPER DESCRIBES A NOVEL MICROARRAY BASED METHOD THAT MONITORS THE BETA CHAIN REPERTOIRE WITH A RESOLUTION OF A SINGLE T-CELL CLONE. THESE T-ARRAYS ARE QUANTITATIVE AND DETECT T-CELL CLONES AT A FREQUENCY OF LESS THAN ONE T CELL IN A MILLION, WHICH IS 2 LOGS MORE SENSITIVE THAN SPECTRATYPING (IMMUNOSCOPE), THE CURRENT STANDARD IN REPERTOIRE ANALYSIS. USING T-ARRAYS WE DETECTED CMV-SPECIFIC CD4+ AND CD8+ T-CELL CLONES THAT EXPANDED EARLY AFTER VIRAL ANTIGEN STIMULATION IN VITRO AND IN VIVO. THIS APPROACH WILL BE USEFUL IN MONITORING INDIVIDUAL T-CELL CLONES IN DIVERSE EXPERIMENTAL SETTINGS, AND IN IDENTIFICATION OF T-CELL CLONES ASSOCIATED WITH INFECTIOUS DISEASE, AUTOIMMUNE DISEASE AND CANCER.",NA,NA,PLOS ONE,"BONARIUS, HPJ##BAAS, F##REMMERSWAAL, EBM##VAN LIER, RAW##TEN BERGE, IJM##TAK, PP##DE VRIES, N","[BONARIUS, HENDRIK P. J.; BAAS, FRANK; TAK, PAUL P.; DE VRIES, NIEK] UNIV AMSTERDAM, ACAD MED CTR, DIV CLIN IMMUNOL & RHEUMATOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. [BAAS, FRANK] UNIV AMSTERDAM, ACAD MED CTR, DEPT NEUROGENET, NL-1105 AZ AMSTERDAM, NETHERLANDS. [REMMERSWAAL, ESTER B. M.; VAN LIER, RENE A. W.] UNIV AMSTERDAM, ACAD MED CTR, DEPT EXPT IMMUNOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. [TEN BERGE, INEKE J. M.] UNIV AMSTERDAM, ACAD MED CTR, DEPT INTERNAL MED, DIV NEPHROL, NL-1105 AZ AMSTERDAM, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"ARDEN BERNHARD, 1995, IMMUNOGENETICS, V42, P455##ARSTILA T P, 2000, SCIENCE, V288, P1135##ARSTILA TP, 1999, SCIENCE, V286, P958, DOI 10.1126/SCIENCE.286.5441.958##BETTS MR, 2005, P NATL ACAD SCI USA, V102, P4512, DOI 10.1073/PNAS.0408773102##DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395A0##DOUEK DC, 2002, J IMMUNOL, V168, P3099, DOI 10.4049/JIMMUNOL.168.6.3099##DOUMAID K, 2000, TRANSPL IMMUNOL, V8, P83, DOI 10.1016/S0966-3274(00)00008-3##HACEIN-BEY-ABINA S, 2003, SCIENCE, V302, P415, DOI 10.1126/SCIENCE.1088547##HOHLFELD R, 2003, BRAIN, V126, P2, DOI 10.1093/BRAIN/AWG001##JAMES KD, 1998, NUCLEIC ACIDS RES, V26, P5203, DOI 10.1093/NAR/26.22.5203##JANEWAY C, 2004, IMMUNOBIOLOGY##KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/ANNUREV.IY.04.040186.002525##KUHN K, 2004, GENOME RES, V14, P2347, DOI 10.1101/GR.2739104##MURARO PA, 2003, BRAIN, V126, P20, DOI 10.1093/BRAIN/AWG021##PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/PNAS.90.9.4319##PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0##PRICE DA, 2005, J EXP MED, V202, P1349, DOI 10.1084/JEM.20051357##PRICE DA, 2004, IMMUNITY, V21, P793, DOI 10.1016/J.IMMUNI.2004.10.010##ROHRLICH PS, 2005, P NATL ACAD SCI USA, V102, P12855, DOI 10.1073/PNAS.0502309102##ROTH ME, 2004, NAT BIOTECHNOL, V22, P418, DOI 10.1038/NBT948##RUIZ M, 2000, NUCLEIC ACIDS RES, V28, P219, DOI 10.1093/NAR/28.1.219##VANLEEUWEN EM, 2006, BLOOD    IN PRESS, DOI DOI 10.1182/BLOOD-2006-03-006809##WILLS MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996##YEE C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/PNAS.242600099##ZANDERS ED, 1983, NATURE, V303, P625, DOI 10.1038/303625A0##ZHU YY, 2001, BIOTECHNIQUES, V30, P892, DOI 10.2144/01304PF02",14,2020-11-20,THE NETHERLANDS GENOMICS INITIATIVE
J,WOS:000207443600090,2006,"HUMAN CORONARY ARTERY REMODELING, BEGINNING AND END OF THE ATHEROSCLEROTIC PROCESS","BACKGROUND, AIMS OF THE STUDY. THE OBJECTIVE OF THE STUDY WAS TO RELATE THE PROGRESS OF CORONARY ARTERY REMODELING TO THE EARLIEST STAGES OF THE ATHEROSCLEROTIC PROCESS. FOR THIS PURPOSE, A MATHEMATICAL MODEL FOR DESCRIPTION OF DIMENSIONAL CHANGE OF THE CORONARY ARTERY WALL AND ITS CONSTITUENT COMPONENTS WAS DEVELOPED AND APPLIED. MATERIALS AND METHODS. THE STUDY USED CORONARY ARTERY SAMPLES RANDOMLY TAKEN FROM EACH OF 83 CONSECUTIVE, UNSELECTED POSTMORTEMS. ALL SAMPLES WERE ROUTINELY FIXED AND PROCESSED TO PARAFFIN FOR THE PREPARATION OF RIGHT-ANGLED, 5-MICRON SECTIONS, ROUTINELY STAINED AND MOUNTED FOR SUBSEQUENT ANALYSIS. COMPUTER ASSISTED IMAGE ANALYSIS, USING 32 SYSTEMATIC RANDOM, RADIAL SAMPLING LINES, WAS USED FOR INTERACTIVE MEASUREMENTS OF DISTANCE FROM CENTRE OF LUMEN TO POINTS DEFINING INTIMA, MEDIA AND ADVENTITIA THICKNESS ALONG THE RADIAL INTERCEPT, WHICH WERE SUBSEQUENTLY TABLED FOR ANALYSIS OF VARIANCE, CALCULATIONS OF (GROUP-VESSEL) MEANS, AND RELATED TO STAGE OF PATHOLOGY. RESULTS. PRE-ATHEROSCLEROTIC CHANGES, BEFORE ANY LOCALISED CHANGES IN ESPECIALLY INTIMA DIMENSIONS, ARE FOUND, CONSISTING OF A PROCESS OF GRADUAL VASCULAR WIDENING, ASSOCIATED WITH TEMPORALLY AT LEAST PARTLY DISSOCIATED INCREASES IN WIDTH, WHICH AS A FRACTION OF TOTAL VESSEL RADIUS SHOW A PHASED PROCESS. IN THESE, THE INTIMA FIRST INCREASES, SUBSEQUENTLY REMAINS STABLE, AND FINALLY REDUCES IN WIDTH PROPORTIONALLY TO THE INCREASING DIAMETER. THE MEDIA SHOWS A SIMILAR INITIAL INCREASE, ON AVERAGE STABILISING IN THE THIRD PHASE AFTER REACHING A PLATEAU VALUE IN THE SECOND. THE ADVENTITIA, ALREADY INCREASING IN PHASE 1, CONTINUES TO INCREASE IN PHASE 2, ACCELERATING IN PHASE 3. THE COMPLEX PROCESS, AS FOUND, OCCURS SYSTEMATICALLY IN ALL VESSELS, IS DISTRIBUTED CIRCUMFERENTIALLY, AND PRECEDES THE DEVELOPMENT OF LOCALISED LESIONS OF THE INTIMA. CONCLUSIONS. THE FINDINGS SUGGEST THE EXISTENCE OF A DIFFUSE COMPLEX OF CHANGES, CONSISTING OF A GRADUAL VASCULAR WIDENING FOLLOWED BY NARROWING, WITH ASSOCIATED MURAL CHANGES REFLECTING THE ATHEROSCLEROTIC PROCESS.",NA,NA,PLOS ONE,"DE GROOT, P##VELDHUIZEN, RW","[DE GROOT, PAUL] MCH HOSP, DEPT CARDIOL, THE HAGUE, NETHERLANDS. [VELDHUIZEN, R. W.] MCH HOSP, DEPT PATHOL, THE HAGUE, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"BOND MG, 1981, ARTERY, V9, P21##CLARIJS JAGM, 1997, ARTERIOSCL THROM VAS, V17, P2617, DOI 10.1161/01.ATV.17.11.2617##DEGROOT P, 1994, THESIS LEIDEN U##GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204##HERITY NA, 1999, J CARDIOVASC ELECTR, V10, P1016, DOI 10.1111/J.1540-8167.1999.TB01273.X##LABROPOULOS N, 1998, AM J SURG, V176, P140, DOI 10.1016/S0002-9610(98)00135-4##VARNAVA AM, 2001, HEART, V86, P207, DOI 10.1136/HEART.86.2.207##ZARINS CK, 1988, J VASC SURG, V7, P386, DOI 10.1067/MVA.1988.AVS0070386",4,2020-11-20,NA
J,WOS:000207443600012,2006,THE EFFECTIVENESS OF CONTACT TRACING IN EMERGING EPIDEMICS,"BACKGROUND. CONTACT TRACING PLAYS AN IMPORTANT ROLE IN THE CONTROL OF EMERGING INFECTIOUS DISEASES, BUT LITTLE IS KNOWN YET ABOUT ITS EFFECTIVENESS. HERE WE DEDUCE FROM A GENERIC MATHEMATICAL MODEL HOW EFFECTIVENESS OF TRACING RELATES TO VARIOUS ASPECTS OF TIME, SUCH AS THE COURSE OF INDIVIDUAL INFECTIVITY, THE (VARIABILITY IN) TIME BETWEEN INFECTION AND SYMPTOM-BASED DETECTION, AND DELAYS IN THE TRACING PROCESS. IN ADDITION, THE POSSIBILITY OF ITERATIVELY TRACING OF YET ASYMPTOMATIC INFECTEDS IS CONSIDERED. WITH THESE INSIGHTS WE EXPLAIN WHY CONTACT TRACING WAS AND WILL BE EFFECTIVE FOR CONTROL OF SMALLPOX AND SARS, ONLY PARTIALLY EFFECTIVE FOR FOOT-AND-MOUTH DISEASE, AND LIKELY NOT EFFECTIVE FOR INFLUENZA. METHODS AND FINDINGS. WE INVESTIGATE CONTACT TRACING IN A MODEL OF AN EMERGING EPIDEMIC THAT IS FLEXIBLE ENOUGH TO USE FOR MOST INFECTIONS. WE CONSIDER ISOLATION OF SYMPTOMATIC INFECTEDS AS THE BASIC SCENARIO, AND EXPRESS EFFECTIVENESS AS THE PROPORTION OF CONTACTS THAT NEED TO BE TRACED FOR A REPRODUCTION RATIO SMALLER THAN 1. WE OBTAIN GENERAL RESULTS FOR SPECIAL CASES, WHICH ARE INTERPRETED WITH RESPECT TO THE LIKELY SUCCESS OF TRACING FOR INFLUENZA, SMALLPOX, SARS, AND FOOT-AND-MOUTH DISEASE EPIDEMICS. CONCLUSIONS. WE CONCLUDE THAT (1) THERE IS NO GENERAL PREDICTIVE FORMULA FOR THE PROPORTION TO BE TRACED AS THERE IS FOR THE PROPORTION TO BE VACCINATED; (2) VARIABILITY IN TIME TO DETECTION IS FAVOURABLE FOR EFFECTIVE TRACING; (3) TRACING EFFECTIVENESS NEED NOT BE SENSITIVE TO THE DURATION OF THE LATENT PERIOD AND TRACING DELAYS; (4) ITERATIVE TRACING PRIMARILY IMPROVES EFFECTIVENESS WHEN SINGLE-STEP TRACING IS ON THE BRINK OF BEING EFFECTIVE.",NA,NA,PLOS ONE,"KLINKENBERG, D##FRASER, C##HEESTERBEEK, H","[KLINKENBERG, DON; HEESTERBEEK, HANS] UNIV UTRECHT, FAC VET MED, DEPT FARM ANIM HLTH, UTRECHT, NETHERLANDS. [FRASER, CHRISTOPHE] UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT INFECT DIS EPIDEMIOL, LONDON, ENGLAND.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"ALDIS GK, 2005, MATH BIOSCI, V195, P1, DOI 10.1016/J.MBS.2005.01.006##BECKER NG, 2005, MATH BIOSCI, V193, P205, DOI 10.1016/J.MBS.2004.07.006##BELL D, 2006, EMERG INFECT DIS, V12, P81##DIEKMANN O., 2000, MATH EPIDEMIOLOGY IN##DONNELLY CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1##EAMES KTD, 2003, P ROY SOC B-BIOL SCI, V270, P2565, DOI 10.1098/RSPB.2003.2554##EICHNER M, 2003, AM J EPIDEMIOL, V158, P118, DOI 10.1093/AJE/KWG104##FENNER FH, 1988, SMALLPOX ITS ERADICA##FERGUSON NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116##FERGUSON NM, 2005, NATURE, V437, P209, DOI 10.1038/NATURE04017##FRASER C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/PNAS.0307506101##KISS IZ, 2005, P ROY SOC B-BIOL SCI, V272, P1407, DOI 10.1098/RSPB.2005.3092##LLOYD-SMITH JO, 2003, P ROY SOC B-BIOL SCI, V270, P1979, DOI 10.1098/RSPB.2003.2481##MULLER J, 2000, MATH BIOSCI, V164, P39, DOI 10.1016/S0025-5564(99)00061-9##PORCO TC, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-34",57,2020-11-20,EU SIXTH FRAMEWORK PROGRAMMEEUROPEAN UNION (EU) [SP22-CT-2004-511066]; NETHERLANDS ORGANISATION FOR SCIENTIFIC RESEARCH (NWO)NETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCH (NWO) [918.56.620]
J,WOS:000207443600086,2006,MODULATION OF T CELL FUNCTION BY COMBINATION OF EPITOPE SPECIFIC AND LOW DOSE ANTICYTOKINE THERAPY CONTROLS AUTOIMMUNE ARTHRITIS,"INNATE AND ADAPTIVE IMMUNITY CONTRIBUTE TO THE PATHOGENESIS OF AUTOIMMUNE ARTHRITIS BY GENERATING AND MAINTAINING INFLAMMATION, WHICH LEADS TO TISSUE DAMAGE. CURRENT BIOLOGICAL THERAPIES TARGET INNATE IMMUNITY, EMINENTLY BY INTERFERING WITH SINGLE PRO-INFLAMMATORY CYTOKINE PATHWAYS. THIS APPROACH HAS SHOWN EXCELLENT EFFICACY IN A GOOD PROPORTION OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA), BUT IS LIMITED BY COST AND SIDE EFFECTS. ADAPTIVE IMMUNITY, PARTICULARLY T CELLS WITH A REGULATORY FUNCTION, PLAYS A FUNDAMENTAL ROLE IN CONTROLLING INFLAMMATION IN PHYSIOLOGIC CONDITIONS. A GROWING BODY OF EVIDENCE SUGGESTS THAT MODULATION OF T CELL FUNCTION IS IMPAIRED IN AUTOIMMUNITY. RESTORATION OF SUCH FUNCTION COULD BE OF SIGNIFICANT THERAPEUTIC VALUE. WE HAVE RECENTLY DEMONSTRATED THAT EPITOPE-SPECIFIC THERAPY CAN RESTORE MODULATION OF T CELL FUNCTION IN RA PATIENTS. HERE, WE TESTED THE HYPOTHESIS THAT A COMBINATION OF ANTI-CYTOKINE AND EPITOPE-SPECIFIC IMMUNOTHERAPY MAY FACILITATE THE CONTROL OF AUTOIMMUNE INFLAMMATION BY GENERATING ACTIVE T CELL REGULATION. THIS NOVEL COMBINATION OF MUCOSAL TOLERIZATION TO A PATHOGENIC T CELL EPITOPE AND SINGLE LOW DOSE ANTI-TNF ALPHA WAS AS THERAPEUTICALLY EFFECTIVE AS FULL DOSE ANTI-TNFA TREATMENT. ANALYSIS OF THE UNDERLYING IMMUNOLOGICAL MECHANISMS SHOWED INDUCTION OF T CELL IMMUNE DEVIATION.",NA,NA,PLOS ONE,"ROORD, STA##ZONNEVELD-HUIJSSOON, E##LE, T##YUNG, GP##KOFFEMAN, E##RONAGHY, A##GHAHRAMANI, N##LANZA, P##BILLETTA, R##PRAKKEN, BJ##ALBANI, S","[ROORD, SARAH T. A.; LE, THO; YUNG, GISELLA PUGA; KOFFEMAN, EVA; RONAGHY, ARASH; ALBANI, SALVATORE] UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA. [ROORD, SARAH T. A.; LE, THO; YUNG, GISELLA PUGA; KOFFEMAN, EVA; ALBANI, SALVATORE] UNIV CALIF SAN DIEGO, DEPT PEDIAT, LA JOLLA, CA 92093 USA. [ROORD, SARAH T. A.; ZONNEVELD-HUIJSSOON, EVELIEN; PRAKKEN, BERENT J.] WILHELMINA CHILDRENS HOSP, UNIV MED CTR UTRECHT, DEPT PEDIAT IMMUNOL, UTRECHT, NETHERLANDS. [GHAHRAMANI, NEGAR; LANZA, PAOLA; BILLETTA, ROSARIO; ALBANI, SALVATORE] ANDROCLUS THERAPEUT, SAN DIEGO, CA USA. [ROORD, SARAH T. A.; ZONNEVELD-HUIJSSOON, EVELIEN; LE, THO; YUNG, GISELLA PUGA; KOFFEMAN, EVA; PRAKKEN, BERENT J.; ALBANI, SALVATORE] EUREKA INST TRANSLAT MED, IMMUNOL ADV CTR, PRECLIN IMMUNOGENOM PROJECT, SIRACUSA, ITALY.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"ALBANI S, 1994, J PEDIATR-US, V124, P561, DOI 10.1016/S0022-3476(05)83134-8##ALBANI S, 1996, IMMUNOL TODAY, V17, P466, DOI 10.1016/0167-5699(96)20029-G##ALBANI S, 1995, NAT MED, V1, P448, DOI 10.1038/NM0595-448##ALBANI S, 1994, CLIN EXP RHEUMATOL, V12, PS35##ANDERSON PO, 2006, EUR J IMMUNOL, V36, P1374, DOI 10.1002/EJI.200635883##ANDERTON SM, 1995, J EXP MED, V181, P943, DOI 10.1084/JEM.181.3.943##BACH JF, 2003, NAT REV IMMUNOL, V3, P189, DOI 10.1038/NRI1026##BAECHER-ALLAN C, 2004, SEMIN IMMUNOL, V16, P89, DOI 10.1016/J.SMIM.2003.12.005##BANCHEREAU J, 2004, IMMUNITY, V20, P539, DOI 10.1016/S1074-7613(04)00108-6##BENDELE AM, 1999, CLIN EXP RHEUMATOL, V17, P553##BLOOM BJ, 2000, ARTHRITIS RHEUM, V43, P2606, DOI 10.1002/1529-0131(200011)43:11<2606::AID-ANR31>3.0.CO;2-X##BLUESTONE JA, 2006, SEMIN IMMUNOL, V18, P77, DOI 10.1016/J.SMIM.2006.01.003##BLUESTONE JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/NRI1032##BRESSON D, 2006, J CLIN INVEST, V116, P1371, DOI 10.1172/JCI27191##COPE AP, 2004, CURR OPIN IMMUNOL, V16, P780, DOI 10.1016/J.COI.2004.09.005##DE KLEER I, 2006, BLOOD, V107, P1696, DOI 10.1182/BLOOD-2005-07-2800##DE KLEER IM, 2003, ARTHRITIS RHEUM, V48, P2001, DOI 10.1002/ART.11174##DEKKER L, 2004, CLIN EXP RHEUMATOL, V22, P252##DIECKMANN D, 2001, J EXP MED, V193, P1303, DOI 10.1084/JEM.193.11.1303##EHRENSTEIN MR, 2004, J EXP MED, V200, P277, DOI 10.1084/JEM.20040165##GARROOD T, 2006, ARTHRITIS RHEUM-US, V54, P1055, DOI 10.1002/ART.21720##JOHNSON MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/ABIO.1999.4461##JONULEIT H, 2001, J EXP MED, V193, P1285, DOI 10.1084/JEM.193.11.1285##KAMPHUIS S, 2005, LANCET, V366, P50, DOI 10.1016/S0140-6736(05)66827-4##KEANE J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMOA011110##LACAVA A, 1997, J CLIN INVEST, V100, P658, DOI 10.1172/JCI119577##LARCHE M, 2006, IMMUNOL ALLERGY CLIN, V26, P321, DOI 10.1016/J.IAC.2006.02.005##MALOY KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/NI0901-816##MASTELLER EL, 2006, SEMIN IMMUNOL, V18, P103, DOI 10.1016/J.SMIM.2006.01.004##NOLTE-'T HOEN ENM, 2004, EUR J IMMUNOL, V34, P3016, DOI 10.1002/EJI.200324725##OLSEN NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMRA032906##PRAKKEN ABJ, 1996, ARTHRITIS RHEUM-US, V39, P1826, DOI 10.1002/ART.1780391108##PRAKKEN BJ, 2001, CURR DIRECT AUTOIMMU, V3, P51##PRAKKEN BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/PNAS.0400061101##PRAKKEN BJ, 2003, SPRINGER SEMIN IMMUN, V25, P47, DOI 10.1007/S00281-003-0128-7##PRAKKEN BJ, 1997, P NATL ACAD SCI USA, V94, P3284, DOI 10.1073/PNAS.94.7.3284##PRAKKEN BJ, 2002, ARTHRITIS RHEUM, V46, P1937, DOI 10.1002/ART.10366##SAKAGUCHI S, 2003, J CLIN INVEST, V112, P1310, DOI 10.1172/JCI200320274##SCHOTTE H, 2004, RHEUMATOLOGY, V43, P960, DOI 10.1093/RHEUMATOLOGY/KEH178##TARZI M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/J.1365-2222.2006.02469.X##TAYLOR PC, 2001, CURR OPIN RHEUMATOL, V13, P164, DOI 10.1097/00002281-200105000-00003##VALENCIA X, 2006, BLOOD, V108, P253, DOI 10.1182/BLOOD-2005-11-4567##VAN EDEN W, 1998, IMMUNOL TODAY, V19, P303, DOI 10.1016/S0167-5699(98)01283-3##VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117##VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171A0##VIGLIETTA V, 2004, J EXP MED, V199, P971, DOI 10.1084/JEM.20031579##WALKER MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441##ZANIN-ZHOROV A, 2006, J CLIN INVEST, V116, P2022, DOI 10.1172/JCI28423##ZOU J, 2003, ANN RHEUM DIS, V62, P561, DOI 10.1136/ARD.62.6.561",31,2020-11-20,"ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES; DUTCH SOCIETY OF SCIENTIFIC RESEARCH (NWO)NETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCH (NWO); NIAMS AND NIAD, NIHUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES (NIAMS)"
J,WOS:000207443600042,2006,A UNIFORM GENOMIC MINOR HISTOCOMPATIBILITY ANTIGEN TYPING METHODOLOGY AND DATABASE DESIGNED TO FACILITATE CLINICAL APPLICATIONS,"BACKGROUND. MINOR HISTOCOMPATIBILITY (H) ANTIGEN MISMATCHES SIGNIFICANTLY INFLUENCE THE OUTCOME OF HLA-MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION. THE MOLECULAR IDENTIFICATION OF HUMAN H ANTIGENS IS INCREASING RAPIDLY. IN PARALLEL, CLINICAL APPLICATION OF MINOR H ANTIGEN TYPING HAS GAINED INTEREST. SO FAR, RELEVANT AND SIMPLE TOOLS TO ANALYZE THE MINOR H ANTIGENS IN A QUICK AND RELIABLE WAY ARE LACKING. METHODOLOGY AND FINDINGS. WE DEVELOPED A UNIFORM PCR WITH SEQUENCE-SPECIFIC PRIMERS (PCR-SSP) FOR 10 DIFFERENT AUTOSOMAL MINOR H ANTIGENS AND H-Y. THIS GENOMIC MINOR H ANTIGEN TYPING METHODOLOGY ALLOWS EASY INCORPORATION IN THE ROUTINE HLA TYPING PROCEDURES. DNA FROM PREVIOUSLY TYPED EBV-LCL WAS USED TO VALIDATE THE METHODOLOGY. TO FACILITATE EASY INTERPRETATION FOR CLINICAL PURPOSES, A MINOR H DATABASE NAMED DBMINOR (HTTP://WWW.LUMC.NL/DBMINOR) WAS DEVELOPED. INPUT OF THE MINOR H ANTIGEN TYPING RESULTS SUBSEQUENTLY PROVIDES ALL RELEVANT INFORMATION FOR A GIVEN PATIENT/DONOR PAIR AND ADDITIONAL INFORMATION ON THE PUTATIVE GRAFT-VERSUS-HOST, GRAFT-VERSUS-TUMOR AND HOST-VERSUS-GRAFT REACTIVITIES. SIGNIFICANCE. A SIMPLE, UNIFORM AND RAPID METHODOLOGY WAS DEVELOPED ENABLING DETERMINATION OF MINOR H ANTIGEN GENOTYPES OF ALL CURRENTLY IDENTIFIED MINOR H ANTIGENS. A DBMINOR DATABASE WAS DEVELOPED TO INTERPRET THE GENOMIC TYPING FOR ITS POTENTIAL CLINICAL RELEVANCE. THE COMBINATION OF THE MINOR H ANTIGEN GENOMIC TYPING METHODOLOGY WITH THE ONLINE DBMINOR DATABASE AND APPLICATIONS FACILITATES THE CLINICAL APPLICATION OF MINOR H ANTIGENS ANTI-TUMOR TARGETS AFTER STEM CELL TRANSPLANTATION.",NA,NA,PLOS ONE,"SPIERINGS, E##DRABBELS, J##HENDRIKS, M##POOL, J##SPRUYT-GERRITSE, M##CLAAS, F##GOULMY, E","[SPIERINGS, ERIC; DRABBELS, JOS; HENDRIKS, MATTHIJS; POOL, JOS; SPRUYT-GERRITSE, MARIJKE; CLAAS, FRANS; GOULMY, ELS] LEIDEN UNIV, MED CTR, DEPT IMMUNOHEMATOL & BLOOD TRANSFUS, LEIDEN, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"AKATSUKA Y, 2003, J EXP MED, V197, P1489, DOI 10.1084/JEM.20021925##BRICKNER AG, 2006, BLOOD, V107, P3779, DOI 10.1182/BLOOD-2005-08-3501##BRICKNER AG, 2001, J EXP MED, V193, P195, DOI 10.1084/JEM.193.2.195##CAI JC, 2004, J EXP MED, V199, P1017, DOI 10.1084/JEM.20031012##DEBUEGER M, 1992, J IMMUNOL, V149, P1788##DEN HAAN JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/SCIENCE.279.5353.1054##DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/SCIENCE.7539551##DOLSTRA H, 2002, EUR J IMMUNOL, V32, P2748, DOI 10.1002/1521-4141(2002010)32:10<2748::AID-IMMU2748>3.0.CO;2-T##DOLSTRA H, 1999, J EXP MED, V189, P301, DOI 10.1084/JEM.189.2.301##FUJII N, 2002, TRANSPLANTATION, V73, P1137, DOI 10.1097/00007890-200204150-00022##GOULMY E, 1976, LANCET, V2, P1206##GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159A0##GOULMY E, 1996, CURR OPIN IMMUNOL, V8, P75, DOI 10.1016/S0952-7915(96)80108-7##GOULMY E, 1997, IMMUNOL REV, V157, P125, DOI 10.1111/J.1600-065X.1997.TB00978.X##GOULMY E, 2006, HUM IMMUNOL, V67, P433, DOI 10.1016/J.HUMIMM.2006.03.012##HAMBACH L, 2005, CURR OPIN IMMUNOL, V17, P202, DOI 10.1016/J.COI.2005.01.010##IVANOV R, 2005, CLIN CANCER RES, V11, P1694, DOI 10.1158/1078-0432.CCR-04-1772##KLEIN CA, 2002, J EXP MED, V196, P359, DOI 10.1084/JEM.20011838##LO YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800##MEADOWS L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1##MOMMAAS B, 2002, J IMMUNOL, V169, P3131, DOI 10.4049/JIMMUNOL.169.6.3131##MURATA M, 2003, J EXP MED, V197, P1279, DOI 10.1084/JEM.20030044##NISHIDA T, 2004, BRIT J HAEMATOL, V124, P629, DOI 10.1111/J.1365-2141.2004.04823.X##OLERUP O, 1991, TISSUE ANTIGENS, V37, P197, DOI 10.1111/J.1399-0039.1991.TB01872.X##PIERCE RA, 1999, J IMMUNOL, V163, P6360##RIJKE BC, 2005, J CLIN INVEST, V115, P3506, DOI 10.1172/JCI24832##SHERRY ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/NAR/29.1.308##SPIERINGS E, 2005, J CLIN INVEST, V115, P3397, DOI 10.1172/JCI27094##SPIERINGS E, 2003, LANCET, V362, P610, DOI 10.1016/S0140-6736(03)14191-8##SPIERINGS E, 2003, BLOOD, V102, P621, DOI 10.1182/BLOOD-2003-01-0260##TORIKAI H, 2004, J IMMUNOL, V173, P7046, DOI 10.4049/JIMMUNOL.173.11.7046##TSENG LH, 1998, TISSUE ANTIGENS, V52, P305, DOI 10.1111/J.1399-0039.1998.TB03052.X##VOGT MHJ, 2000, BLOOD, V96, P3126, DOI 10.1182/BLOOD.V96.9.3126.H8003126_3126_3132##VOGT MHJ, 2000, BLOOD, V95, P1100, DOI 10.1182/BLOOD.V95.3.1100.003K42_1100_1105##VOGT MHJ, 2002, BLOOD, V99, P3027, DOI 10.1182/BLOOD.V99.8.3027##WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/SCIENCE.7667640##WARREN EH, 2006, SCIENCE, V313, P1444, DOI 10.1126/SCIENCE.1130660##WARREN EH, 2000, J IMMUNOL, V164, P2807, DOI 10.4049/JIMMUNOL.164.5.2807##WARREN EH, 1998, BLOOD, V91, P2197, DOI 10.1182/BLOOD.V91.6.2197##WILKE M, 2002, TISSUE ANTIGENS, V59, P304, DOI 10.1034/J.1399-0039.2002.590408.X##WILKE M, 1998, TISSUE ANTIGENS, V52, P312, DOI 10.1111/J.1399-0039.1998.TB03053.X##WILKE MARTINA, 2003, HEMATOL J, V4, P315, DOI 10.1038/SJ.THJ.6200318##ZORN E, 2004, J EXP MED, V199, P1133, DOI 10.1084/JEM.20031560",41,2020-11-20,"EUROPEAN COMMISSIONEUROPEAN COMMISSIONEUROPEAN COMMISSION JOINT RESEARCH CENTRE; LEIDEN UNIVERSITY MEDICAL CENTER, THE NETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCH (NWO)NETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCH (NWO); MACROPA FOUNDATION"
J,WOS:000207443600022,2006,GENETIC INFLUENCES ON EXERCISE PARTICIPATION IN 37.051 TWIN PAIRS FROM SEVEN COUNTRIES,"BACKGROUND. A SEDENTARY LIFESTYLE REMAINS A MAJOR THREAT TO HEALTH IN CONTEMPORARY SOCIETIES. TO GET MORE INSIGHT IN THE RELATIVE CONTRIBUTION OF GENETIC AND ENVIRONMENTAL INFLUENCES ON INDIVIDUAL DIFFERENCES IN EXERCISE PARTICIPATION, TWIN SAMPLES FROM SEVEN COUNTRIES PARTICIPATING IN THE GENOMEUTWIN PROJECT WERE USED. METHODOLOGY. SELF-REPORTED DATA ON LEISURE TIME EXERCISE BEHAVIOR FROM AUSTRALIA, DENMARK, FINLAND, NORWAY, THE NETHERLANDS, SWEDEN AND UNITED KINGDOM WERE USED TO CREATE A COMPARABLE INDEX OF EXERCISE PARTICIPATION IN EACH COUNTRY (60 MINUTES WEEKLY AT A MINIMUM INTENSITY OF FOUR METABOLIC EQUIVALENTS). PRINCIPAL FINDINGS. MODEST GEOGRAPHICAL VARIATION IN EXERCISE PARTICIPATION WAS REVEALED IN 85,198 SUBJECTS, AGED 19-40 YEARS. MODELING OF MONOZYGOTIC AND DIZYGOTIC TWIN RESEMBLANCE SHOWED THAT GENETIC EFFECTS PLAY AN IMPORTANT ROLE IN EXPLAINING INDIVIDUAL DIFFERENCES IN EXERCISE PARTICIPATION IN EACH COUNTRY. SHARED ENVIRONMENTAL EFFECTS PLAYED NO ROLE EXCEPT FOR NORWEGIAN MALES. HERITABILITY OF EXERCISE PARTICIPATION IN MALES AND FEMALES WAS SIMILAR AND RANGED FROM 48% TO 71% (EXCLUDING NORWEGIAN MALES). CONCLUSIONS. GENETIC VARIATION IS IMPORTANT IN INDIVIDUAL EXERCISE BEHAVIOR AND MAY INVOLVE GENES INFLUENCING THE ACUTE MOOD EFFECTS OF EXERCISE, HIGH EXERCISE ABILITY, HIGH WEIGHT LOSS ABILITY, AND PERSONALITY. THIS COLLABORATIVE STUDY SUGGESTS THAT ATTEMPTS TO FIND GENES INFLUENCING EXERCISE PARTICIPATION CAN POOL EXERCISE DATA ACROSS MULTIPLE COUNTRIES AND DIFFERENT INSTRUMENTS.",NA,NA,PLOS ONE,"STUBBE, JH##BOOMSMA, DI##VINK, JM##CORNES, BK##MARTIN, NG##SKYTTHE, A##KYVIK, KO##ROSE, RJ##KUJALA, UM##KAPRIO, J##HARRIS, JR##PEDERSEN, NL##HUNKIN, J##SPECTOR, TD##DE GEUS, EJC","[STUBBE, JANINE H.; BOOMSMA, DORRET I.; VINK, JACQUELINE M.; HUNKIN, JANICE; SPECTOR, TIM D.; DE GEUS, ECO J. C.] VRIJE UNIV AMSTERDAM, DEPT BIOL PSYCHOL, AMSTERDAM, NETHERLANDS. [ROSE, RICHARD J.; KAPRIO, JAAKKO] UNIV HELSINKI, DEPT PUBL HLTH, HELSINKI, FINLAND. [SKYTTHE, AXEL; KYVIK, KIRSTEN O.] UNIV SO DENMARK, INST PUBL HLTH, ODENSE, DENMARK. [CORNES, BELINDA K.; MARTIN, NICHOLAS G.] QUEENSLAND INST MED RES, BRISBANE, QLD 4006, AUSTRALIA. [PEDERSEN, NANCY L.] KAROLINSKA INST, DEPT MED EPIDEMIOL & BIOSTAT, STOCKHOLM, SWEDEN. [HARRIS, JENNIFER R.] NORWEGIAN INST PUBL HLTH, OSLO, NORWAY. ST THOMAS HOSP, TWIN RES & GENET EPIDEMIOL UNIT, LONDON, ENGLAND. [KAPRIO, JAAKKO] NATL PUBL HLTH INST, DEPT MENTAL HLTH & ALCOHOL RES, HELSINKI, FINLAND. [ROSE, RICHARD J.] INDIANA UNIV, DEPT PSYCHOL, BLOOMINGTON, IN USA. [KUJALA, URHO M.] UNIV JYASKYLA, DEPT HLTH SCI, JYASKYLA, FINLAND.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"AARNIO M, 1997, INT J SPORTS MED, V18, P549, DOI 10.1055/S-2007-972680##BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/OXFORDJOURNALS.AJE.A115704##BEUNEN G, 1999, INT J OBESITY, V23, PS55, DOI 10.1038/SJ.IJO.0800885##BLAIR SN, 1995, B WORLD HEALTH ORGAN, V73, P135##BOOMSMA D, 2002, NAT REV GENET, V3, P872, DOI 10.1038/NRG932##BOOMSMA DI, 2002, TWIN RES, V5, P401, DOI 10.1375/136905202320906174##BOOMSMA DI, 1989, BEHAV GENET, V19, P123, DOI 10.1007/BF01065888##BOUCHARD C, 1999, J APPL PHYSIOL, V87, P1003##CAMACHO TC, 1991, AM J EPIDEMIOL, V134, P220, DOI 10.1093/OXFORDJOURNALS.AJE.A116074##CASPERSEN CJ, 2000, MED SCI SPORT EXER, V32, P1601##COLCOMBE S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.T01-1-01430##DAVIS JM, 1997, MED SCI SPORT EXER, V29, P45, DOI 10.1097/00005768-199701000-00008##DISHMAN RK, 1985, PUBLIC HEALTH REP, V100, P158##ETNIER JL, 1997, J SPORT EXERCISE PSY, V19, P249, DOI 10.1123/JSEP.19.3.249##FALCONER DS, 1996, INTRO QUANTITATIVE G, P311##FARMER ME, 1988, AM J EPIDEMIOL, V128, P1340, DOI 10.1093/OXFORDJOURNALS.AJE.A115087##GAUVIN L, 1996, NUTR REV, V54, PS53##HAASE A, 2004, PREV MED, V39, P182, DOI 10.1016/J.YPMED.2004.01.028##HALLIWILL J R, 2001, EXERC SPORT SCI REV, V29, P65, DOI 10.1097/00003677-200104000-00005##HARRIS JR, 2002, TWIN RES, V5, P415, DOI 10.1375/TWIN.5.5.415##HILLMAN CH, 2004, RES Q EXERCISE SPORT, V75, P176, DOI 10.1080/02701367.2004.10609149##KAPLAN GA, 1991, AM J PREV MED, V7, P12##KAPLAN GA, 1996, AM J EPIDEMIOL, V144, P793, DOI 10.1093/OXFORDJOURNALS.AJE.A009003##KAPRIO J, 2002, TWIN RES, V5, P366, DOI 10.1375/TWIN.5.5.366##KAPRIO J, 1981, PROG CLIN BIOL RES, V69 PT C, P37##KESANIEMI YA, 2001, MED SCI SPORT EXER, V33, PS351##KING AC, 1992, MED SCI SPORT EXER, V24, PS221##KOOPMANS JR, 1994, GENETIC FACTORS CORO, P217##KUJALA UM, 2002, AM J EPIDEMIOL, V156, P985, DOI 10.1093/AJE/KWF151##KUPPER N, 2005, PSYCHOPHYSIOLOGY, V42, P202, DOI 10.1111/J.1469-8986.2005.00276.X##LAUDERDALE DS, 1997, MED SCI SPORT EXER, V29, P1062, DOI 10.1097/00005768-199708000-00012##LICHTENSTEIN P, 2002, J INTERN MED, V252, P184, DOI 10.1046/J.1365-2796.2002.01032.X##MAIA JAR, 2002, AM J PREV MED, V23, P87, DOI 10.1016/S0749-3797(02)00478-6##MARTINEZ-GONZALEZ MA, 2001, MED SCI SPORT EXER, V33, P1142, DOI 10.1097/00005768-200107000-00011##MATSON-KOFFMAN DM, 2005, AM J HEALTH PROMOT, V19, P167, DOI 10.4278/0890-1171-19.3.167##MULDER EJ, 2003, TWIN RES, V6, P422, DOI 10.1375/136905203770326420##NEALE MC, 1992, METHODOLOGY GENETICS##ORLEANS CT, 2003, ANN BEHAV MED, V25, P77, DOI 10.1207/S15324796ABM2502_02##PAYNE N, 2005, BRIT J HEALTH PSYCH, V10, P115, DOI 10.1348/135910704X14636##PERUSSE L, 1989, AM J EPIDEMIOL, V129, P1012, DOI 10.1093/OXFORDJOURNALS.AJE.A115205##PLOMIN R., 2000, BEHAV GENETICS##RANKINEN T, 2004, MED SCI SPORT EXER, V36, P1451, DOI 10.1249/01.MSS.0000139902.42385.5F##RICHARDS M, 2003, SOC SCI MED, V56, P785, DOI 10.1016/S0277-9536(02)00075-8##ROWLAND TW, 1998, MED SCI SPORT EXER, V30, P392, DOI 10.1097/00005768-199803000-00009##SALLIS JF, 1988, J BEHAV MED, V11, P31, DOI 10.1007/BF00846167##SCHOUSBOE K, 2003, TWIN RES, V6, P409, DOI 10.1375/136905203770326411##SEEFELDT V, 2002, SPORTS MED, V32, P143, DOI 10.2165/00007256-200232030-00001##SHEPHARD RJ, 1985, SPORTS MED, V2, P348, DOI 10.2165/00007256-198502050-00004##SHERWOOD NE, 2000, ANNU REV NUTR, V20, P21, DOI 10.1146/ANNUREV.NUTR.20.1.21##SILVENTOINEN K, 2003, TWIN RES, V6, P399, DOI 10.1375/136905203770326402##SIMONEN R, 2004, MED SCI SPORT EXER, V36, P1559, DOI 10.1249/01.MSS.0000074670.03001.98##SIMONEN RL, 2003, PHYSIOL BEHAV, V78, P751, DOI 10.1016/S0031-9384(03)00084-2##SIMONEN RL, 2002, MED SCI SPORT EXER, V34, P1137, DOI 10.1097/00005768-200207000-00014##SIRARD JR, 2001, SPORTS MED, V31, P439, DOI 10.2165/00007256-200131060-00004##STEPTOE A, 1996, LANCET, V347, P1789, DOI 10.1016/S0140-6736(96)91616-5##STUBBE JH, 2005, MED SCI SPORT EXER, V37, P563, DOI 10.1249/01.MSS.0000158181.75442.8B##TERGERSON JL, 2002, J SCHOOL HEALTH, V72, P374, DOI 10.1111/J.1746-1561.2002.TB03562.X##THOMIS MA, 1997, J APPL PHYSIOL, V82, P959##THORBURN A W, 2000, OBES REV, V1, P87, DOI 10.1046/J.1467-789X.2000.00018.X##TOU JCL, 2002, EXP BIOL MED, V227, P587##VAN LOON AJM, 2000, INT J EPIDEMIOL, V29, P785, DOI 10.1093/IJE/29.5.785##VARO JJ, 2003, INT J EPIDEMIOL, V32, P138, DOI 10.1093/IJE/DYG116##WEYERER S, 1992, INT J SPORTS MED, V13, P492, DOI 10.1055/S-2007-1021304##WILMORE JH, 1999, AM J CLIN NUTR, V70, P346##WOLFARTH B, 2005, MED SCI SPORT EXER, V37, P881, DOI 10.1249/01.MSS.0000168663.55604.1D##YEUNG RR, 1996, J PSYCHOSOM RES, V40, P123, DOI 10.1016/0022-3999(95)00554-4",171,2020-11-20,"NETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCHNETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCH (NWO) [NWO-MW 904-61-193]; EUROPEAN COMMISSIONEUROPEAN COMMISSIONEUROPEAN COMMISSION JOINT RESEARCH CENTRE [QLG2-CT-2002-01254]; NIAA (USA) [AA07535, AA013320, AA013326]; NHMRC (AUSTRALIA)NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL OF AUSTRALIA [941177, 951023, 950998, 981339, 241916, 941944]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE ON ALCOHOL ABUSE & ALCOHOLISM (NIAAA) [AA08315, AA12502]; ACADEMY OF FINLANDACADEMY OF FINLAND [44069, 100499]; WELLCOME TRUSTWELLCOME TRUST; ARTHRITIS & RHEUMATISM CAMPAIGN; NORWEGIAN RESEARCH COUNCILRESEARCH COUNCIL OF NORWAY; NORWEGIAN FOUNDATION FOR HEALTH AND REHABILITATION; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE ON ALCOHOL ABUSE & ALCOHOLISM (NIAAA) [R01AA013326, R37AA012502, R01AA008315, R37AA012502, R01AA007535, R01AA012502, R37AA012502, R01AA013320, R01AA013326, R37AA012502, R01AA012502, R37AA012502, R01AA008315, R01AA012502, R37AA012502, R01AA012502, R01AA007535, R01AA007535, R37AA012502, R01AA007535, R01AA008315, R01AA007535, R01AA007535, R01AA013320, R01AA013326, R01AA007535, R01AA008315, R01AA013320, R01AA013326, R37AA012502, R01AA013320, R01AA013320, R37AA012502, R37AA012502, R01AA007535, R01AA013320, R01AA007535, R01AA008315, R01AA012502, R01AA013326, R01AA007535] FUNDING SOURCE: NIH REPORTER"
J,WOS:000243149700016,2006,COMBINED PRE-ANNEALING AND PRE-OXIDATION TREATMENT FOR THE PROCESSING OF THERMAL BARRIER COATINGS ON NICOCRALY BOND COATINGS,"A COMBINED PRE-ANNEALING AND PRE-OXIDATION TREATMENT WAS DEVELOPED FOR THE PROCESSING OF PARTIALLY YTTRIA STABILIZED (PYSZ) THERMAL BARRIER COATINGS (TBC) ON TOP OF NICOCRALY BOND COATINGS (BC). TO DEVELOP THIS PRE-TREATMENT, THE INFLUENCE OF THE OXYGEN POTENTIAL DURING PRE-ANNEALING AND PRE-OXIDATION ON THE LIFE SPAN AND FAILURE MECHANISMS OF THE ENTIRE HIGH TEMPERATURE COATING SYSTEM UPON THERMAL CYCLING WAS INVESTIGATED. THE RESULTS OF THIS STUDY SHOWED THAT THE SERVICE LIFE OF THE COATING SYSTEM DEPENDED STRONGLY ON THE COMPOSITION AND MICROSTRUCTURE OF THE THERMALLY GROWN OXIDE (TGO) AFTER PRE-OXIDATION. THE LONGER LIFE SPANS WERE OBTAINED IF THE TGO THICKENED VERY SLOWLY DURING THERMAL CYCLING DUE TO A LARGE ALPHA-AL2O3 GRAIN SIZE. SUCH A SLOW-GROWING TGO CORRESPONDED WITH A PRE-TREATMENT FOR WHICH THETA-AL2O3 WAS FORMED DURING PRE-OXIDATION AND FOR WHICH THE YTTRIUM WAS LOCATED WITHIN A HIGH DENSITY OF PEGS ALONG THE TGO/BC INTERFACE AFTER PRE-OXIDATION. IF THE YTTRIUM WAS PRESENT ON TOP OF THE TGO AFTER PRE-OXIDATION, A THICK MIXED ALUMINA-ZIRCONIA LAYER FORMED UPON THERMAL CYCLING. THIS MIXED OXIDE LAYER CONTRIBUTED SIGNIFICANTLY TO THE TOTAL OXIDE LAYER THICKNESS, RESULTING IN SHORT LIFE SPANS. THE FORMATION OF NIAL2O4 SPINEL IN BETWEEN THE TBC AND THE ALPHA-AL2O3 SHOULD BE AVOIDED, SINCE THIS CAN LEAD TO PREMATURE FAILURE ALONG THE SPINEL/ALPHA-AL2O3 INTERFACE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",HIGH-TEMPERATURE OXIDATION; MICROSTRUCTURE; DURABILITY; DEPOSITION; MECHANISMS; FAILURE; ALLOYS; GROWTH,THERMAL BARRIER COATINGS; MCRALY BOND COATINGS; OXIDATION; ALUMINA; PRE-TREATMENTS,SURFACE & COATINGS TECHNOLOGY,"NIJDAM, TJ##SLOOF, WG","DELFT UNIV TECHNOL, DEPT MAT SCI & ENGN, NL-2628 CD DELFT, NETHERLANDS. NETHERLANDS INST MET RES, NL-2628 CD DELFT, NETHERLANDS.","MATERIALS SCIENCE, COATINGS & FILMS; PHYSICS, APPLIED",MATERIALS SCIENCE; PHYSICS,"BRAUE W, 2004, MATER SCI FORUM, V461-464, P899, DOI 10.4028/WWW.SCIENTIFIC.NET/MSF.461-464.899##EVANS AG, 2001, PROG MATER SCI, V46, P505, DOI 10.1016/S0079-6425(00)00020-7##GIGGINS CS, 1971, J ELECTROCHEM SOC, V118, P1782, DOI 10.1149/1.2407837##GRABKE HJ, 1999, INTERMETALLICS, V7, P1153, DOI 10.1016/S0966-9795(99)00037-0##LEVI CG, 2003, J AM CERAM SOC, V86, P676, DOI 10.1111/J.1151-2916.2003.TB03357.X##LEYENS C, 2001, Z METALLKD, V92, P762##MONCEAU D, 2000, J MATER RES, V15, P665, DOI 10.1557/JMR.2000.0099##NIJDAM TJ, 2005, MATER HIGH TEMP, V22, P551, DOI 10.3184/096034005782744010##NIJDAM TJ, 2006, METALL MATER TRANS A, V37A, P683, DOI 10.1007/S11661-006-0040-Z##NIJDAM TJ, 2005, OXID MET, V64, P355, DOI 10.1007/S11085-005-8532-6##NIJDAM TJ, 2005, ACTA MATER, V53, P1643, DOI 10.1016/J.ACTAMAT.2004.12.014##NIJDAM TJ, IN PRESS OXID MET##PADTURE NP, 2002, SCIENCE, V296, P280, DOI 10.1126/SCIENCE.1068609##PRESCOTT R, 1992, OXID MET, V38, P233, DOI 10.1007/BF00666913##SCHULZ U, 2001, SURF COAT TECH, V146, P117, DOI 10.1016/S0257-8972(01)01481-5##SPITSBERG I, 2006, MAT SCI ENG A-STRUCT, V417, P322, DOI 10.1016/J.MSEA.2005.11.014##SPITSBERG IT, 2005, MAT SCI ENG A-STRUCT, V394, P176, DOI 10.1016/J.MSEA.2004.11.038##STIGER MJ, 1999, Z METALLKD, V90, P1069##TANIGUCHI S, 2002, OXID MET, V58, P545, DOI 10.1023/A:1020577107126##TOLPYGO VK, 2001, SURF COAT TECH, V146, P124, DOI 10.1016/S0257-8972(01)01482-7",55,2020-11-20,NA
J,WOS:000243149700086,2006,"DENSITY, STRESS, HARDNESS AND REDUCED YOUNG'S MODULUS OF W-C : H COATINGS","DENSITY, HARDNESS AND COMPRESSIVE STRESS OF TUNGSTEN CONTAINED IN AN AMORPHOUS-HYDROGENATED-CARBON MATRIX (W-C:H) HAVE BEEN STUDIED AS A FUNCTION OF COMPOSITION AND BIAS VOLTAGE. W-C:H COATINGS WERE DEPOSITED BY REACTIVE SPUTTER DEPOSITION FROM A TUNGSTEN-CARBIDE (WC TARGET ON SILICON SUBSTRATE IN AN ARGON-ACETYLENE PLASMA. W-C:H COATINGS OBTAINED AT DIFFERENT ACETYLENE FLOW RATES AND SUBSTRATE BIAS VOLTAGES, WERE CHARACTERIZED BY SCANNING ELECTRON MICROSCOPY, X-RAY DIFFRACTION, NANOINDENTATION AND SUBSTRATE CURVATURE METHOD. IT HAS BEEN OBSERVED THAT COMPRESSIVE STRESS, HARDNESS AND REDUCED YOUNG'S MODULUS DECREASE WHEN THE ACETYLENE FLOW IS INCREASED FROM 0 TO 10 SEEM. ALSO, COMPRESSIVE STRESS AND HARDNESS INCREASES WITH THE SUBSTRATE BIAS VOLTAGE. IN PARTICULAR, FOR W-C:H COATINGS OBTAINED AT 5 SEEM OF ACETYLENE FLOW, THE COMPRESSIVE STRESS AND HARDNESS INCREASE FROM - 1.6 GPA TO - 3.2 GPA AND FROM 19 GPA TO 24 GPA, RESPECTIVELY, WHEN INCREASING THE SUBSTRATE BIAS FROM 0 TO 200 V. THE VARIATION OF THE INTERNAL STRESS, HARDNESS AND DENSITY OF THE COATINGS IS DISCUSSED IN TERMS OF COMPOSITION AND STRUCTURE OF THE W-C:H COATINGS. (C) 2006 ELSEVIER B.V ALL RIGHTS RESERVED.",DIAMOND-LIKE CARBON; TUNGSTEN CARBIDE; ION-BOMBARDMENT; FILMS; MICROSTRUCTURE; DEPOSITION,SPUTTER DEPOSITION; DIAMOND-LIKE CARBON COATINGS; COMPRESSIVE STRESS,SURFACE & COATINGS TECHNOLOGY,"PUJADA, BR##JANSSEN, GCAM","NETHERLANDS INST MET RES, NL-2600 GA DELFT, NETHERLANDS. DELFT UNIV TECHNOL, DEPT MAT SCI & ENGN, NL-2628 CD DELFT, NETHERLANDS.","MATERIALS SCIENCE, COATINGS & FILMS; PHYSICS, APPLIED",MATERIALS SCIENCE; PHYSICS,"ABDELOUAHDI K, 2006, J PHYS-CONDENS MAT, V18, P1913, DOI 10.1088/0953-8984/18/6/008##BEWILOGUA K, 1993, SURF COAT TECH, V61, P144, DOI 10.1016/0257-8972(93)90217-C##CALLISTER W.D., 2003, MAT SCI ENG INTRO, P530##CARVALHO NJM, 2001, THIN SOLID FILMS, V388, P150, DOI 10.1016/S0040-6090(01)00842-2##CZYZNIEWSKI A, 2004, J MATER PROCESS TECH, V157, P274, DOI 10.1016/J.JMATPROTEC.2004.09.044##DHEURLE FM, 1989, THIN SOLID FILMS, V171, P81, DOI 10.1016/0040-6090(89)90035-7##JANSSEN GCAM, 2003, APPL PHYS LETT, V83, P3287, DOI 10.1063/1.1619561##JIANG X, 1994, PHYS REV B, V49, P13815, DOI 10.1103/PHYSREVB.49.13815##MENG WJ, 1998, J APPL PHYS, V84, P4314, DOI 10.1063/1.368650##OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564##PEI YT, 2005, ACTA MATER, V53, P4505, DOI 10.1016/J.ACTAMAT.2005.05.045##PETROV I, 1989, THIN SOLID FILMS, V169, P299, DOI 10.1016/0040-6090(89)90713-X##STRONDL C, 2005, SURF COAT TECH, V200, P1142, DOI 10.1016/J.SURFCOAT.2005.02.182##STRONDL C, 2003, SURF COAT TECH, V162, P288, DOI 10.1016/S0257-8972(02)00497-8##STRONDL C, 2001, SURF COAT TECH, V142, P707, DOI 10.1016/S0257-8972(01)01179-3##WANG M, 1992, J MATER RES, V7, P1465, DOI 10.1557/JMR.1992.1465",18,2020-11-20,NA
J,WOS:000243149700091,2006,INTERFACE FRACTURE BEHAVIOR OF ZINC COATINGS ON STEEL: EXPERIMENTS AND FINITE ELEMENT CALCULATIONS,"HOT-DIPPED GALVANIZED STEELS ARE WIDELY USED IN THE AUTOMOTIVE INDUSTRY. THE FORMABILITY AND DAMAGE RESISTANCE OF ZINC COATINGS DEPEND STRONGLY ON THEIR MICROSTRUCTURE AND ADHESION TO THE STEEL SUBSTRATE. IN ORDER TO IMPROVE THE MECHANICAL PERFORMANCE OF ZINC COATINGS, THE INFLUENCE OF THEIR THICKNESS, GRAIN ORIENTATION AND GRAIN SIZE ON THE ZINC COATING/STEEL SUBSTRATE INTERFACE CRACKING BEHAVIOR WAS STUDIED. TO THIS END, SCANNING ELECTRON MICROSCOPIC OBSERVATIONS DURING IN SITU TENSILE TESTING OF ZINC COATED IF STEEL SHEETS WERE PERFORMED. AFTER PARTIAL DELAMINATION OF THE ZINC COATING, CROSS SECTIONS OF ZINC COATED STEEL WERE PREPARED TO DETERMINE THE LOCATION AND EXTENT OF THE INTERFACE CRACKING AND THE CRYSTALLOGRAPHIC ORIENTATION OF THE DELAMINATED ZINC GRAINS. A TWO-GRAIN MODEL USING A FINITE ELEMENT METHOD IS PROPOSED TO ANALYZE THE ZINC COATING/STEEL SUBSTRATE INTERFACE CRACKING BEHAVIOR. IN ADDITION, THE COATING ADHESION STRENGTH CAN BE ESTIMATED BASED ON THIS MODEL. BOTH CALCULATIONS AND EXPERIMENTAL OBSERVATIONS SHOW THAT: (I) A PREFERENTIAL ZINC GRAIN ORIENTATION WITH THE [0001] DIRECTION PARALLEL TO THE INTERFACE AND (II) A SMALL GRAIN SIZE MITIGATE ZINC COATING/STEEL SUBSTRATE INTERFACE CRACKING. (C) 2006 ELSEVIER B.V ALL RIGHTS RESERVED.",DEFORMATION; STRENGTH; CRACKING,INTERFACE FRACTURE; ZINC COATINGS; ADHESION STRENGTH; MECHANICAL ANISOTROPY; FINITE ELEMENT MODELING,SURFACE & COATINGS TECHNOLOGY,"SONG, GM##SLOOF, WG##PEI, YT##DE HOSSON, JTM","DELFT UNIV TECHNOL, DEPT MAT SCI & ENGN, NL-2628 CD DELFT, NETHERLANDS. NETHERLANDS INST MET RES, NL-2628 CD DELFT, NETHERLANDS. UNIV GRONINGEN, CTR MAT SCI, DEPT APPL PHYS, NL-9747 AG GRONINGEN, NETHERLANDS.","MATERIALS SCIENCE, COATINGS & FILMS; PHYSICS, APPLIED",MATERIALS SCIENCE; PHYSICS,"DAO M, 2001, ACTA MATER, V49, P3899, DOI 10.1016/S1359-6454(01)00295-6##DE BRUYCKER E, 2004, STEEL RES INT, V75, P147, DOI 10.1002/SRIN.200405940##FLUHRER J, 2004, DEFORM 2D 8 1 VERSIO##FREUND L. B., 2003, THIN FILM MAT STRESS##HERTVELDT I, 1999, ISIJ INT, V39, P1280, DOI 10.2355/ISIJINTERNATIONAL.39.1280##HUTCHINSON JW, 1992, ADV APPL MECH, V29, P63, DOI 10.1016/S0065-2156(08)70164-9##LIDE DR, 1995, HDB CHEM PHYS##MICHAL G. M., 2004, GALVATECH 04 C P APR, P517##NUNOMURA Y, 2003, ISIJ INT, V43, P454, DOI 10.2355/ISIJINTERNATIONAL.43.454##OCHIAI S, 2005, METALL MATER TRANS A, V36A, P1807, DOI 10.1007/S11661-005-0044-0##PARISOT R, 2004, METALL MATER TRANS A, V35A, P797, DOI 10.1007/S11661-004-0007-X##SONG GM, IN PRESS EVALUATION##XHOFFER C, 2004, ELECTROCHIM ACTA, V49, P2825, DOI 10.1016/J.ELECTACTA.2004.01.072",37,2020-11-20,NA
J,WOS:000242792700010,2006,DEVELOPMENT OF A REAL TIME PCR FOR THE DETECTION OF TAYLORELLA EQUIGENITALIS DIRECTLY FROM GENITAL SWABS AND DISCRIMINATION FROM TAYLORELLA ASINIGENITALIS,"A DISCRIMINATORY REAL TIME PCR FOR THE DETECTION OF TAYLORELLA EQUIGENITALIS, THE CAUSATIVE AGENT OF CONTAGIOUS EQUINE METRITIS (CEM), AND THE RELATED SPECIES T ASINIGENITALIS WAS DEVELOPED FOR THE DIRECT EXAMINATION OF GENITAL SWABS. THE 112 BP AMPLICONS PRODUCED FROM THE TWO SPECIES WERE DISCRIMINATED FROM EACH OTHER USING TAQMAN (R) PROBES LABELLED WITH DIFFERENT FLUOROPHORES. THE TAQMAN (R) PCR WAS SHOWN TO BE SPECIFIC FOR THE 16S RIBOSOMAL DNA OF THE TWO SPECIES OF TAYLORELLA AND DID NOT CROSS-HYBRIDISE WITH THE 16S FIBOSOMAL DNA OF OTHER BACTERIA TESTED. DIRECT AMPLIFICATION FROM GENITAL SWABS WAS SHOWN TO BE EQUALLY SENSITIVE TO THAT OF CULTURE METHODS. PREVALENCE IN A SAMPLE SET FROM THE NETHERLANDS WAS SHOWN TO BE EQUIVALENT TO THAT DEMONSTRATED BY CULTURE. A COMPANION REAL TIME PCR THAT AMPLIFIED A FRAGMENT OF THE 16S RDNA GENE OF EQUINE COMMENSAL BACTERIA WAS DEVELOPED TO ENSURE BACTERIAL DNA WAS EXTRACTED FROM SWAB MATERIAL SUPPLIED FOR TESTING. THE USE OF A RAPID AND RELIABLE REAL TIME PCR FOR THE ORGANISM CAUSING CEM SHOULD AID THE CONTROL OF THIS DISEASE. CROWN COPYRIGHT (C) 2006 PUBLISHED BY ELSEVIER B.V. ALL RIGHTS RESERVED.",CONTAGIOUS EQUINE METRITIS; POLYMERASE-CHAIN-REACTION; ORGANISM; CEM; MISIDENTIFICATION; DIAGNOSIS; TRACT,CONTAGIOUS EQUINE METRITIS; TAYLORELLA EQUIGENITALIS; TAYLORELLA ASINIGENITALIS; DIRECT PCR AMPLIFICATION,VETERINARY MICROBIOLOGY,"WAKELEY, PR##ERRINGTON, J##HANNON, S##ROEST, HIJ##CARSON, T##HUNT, B##SAWYER, J##HEATH, P","VET LABS AGCY, TECHNOL TRANSFER UNIT, DEPT BIOTECHNOL, WEYBRIDGE KT15 3NB, SURREY, ENGLAND. CENT INST ANIM DIS CONTROL LELYSTAD, LELYSTAD, NETHERLANDS.",MICROBIOLOGY; VETERINARY SCIENCES,MICROBIOLOGY; VETERINARY SCIENCES,"ANZAI T, 1999, J VET MED SCI, V61, P1287, DOI 10.1292/JVMS.61.1287##ARATA AB, 2001, J VET DIAGN INVEST, V13, P263, DOI 10.1177/104063870101300316##ATHERTON JG, 1983, VET REC, V113, P299, DOI 10.1136/VR.113.13.299##BLEUMINKPLUYM NMC, 1993, INT J SYST BACTERIOL, V43, P618##BLEUMINKPLUYM NMC, 1994, J CLIN MICROBIOL, V32, P893, DOI 10.1128/JCM.32.4.893-896.1994##CROWHURST RC, 1979, VET REC, V104, P465, DOI 10.1136/VR.104.20.465##FERNIE DS, 1980, RES VET SCI, V28, P362, DOI 10.1016/S0034-5288(18)32723-1##JACKSON G, 2002, VET REC, V151, P582##JANG SS, 2001, INT J SYST EVOL MICR, V51, P971, DOI 10.1099/00207713-51-3-971##MITSUHASHI M, 1996, J CLIN LAB ANAL, V10, P285, DOI 10.1002/(SICI)1098-2825(1996)10:5<285::AID-JCLA9>3.3.CO;2-H##MOORE JE, 2000, J EQUINE VET SCI, V20, P479, DOI 10.1016/S0737-0806(00)70204-8##MOORE JE, 2001, VET RES, V32, P611, DOI 10.1051/VETRES:2001149##POWELL DG, 1981, ADV VET SCI COMP MED, V25, P161##PREMANANDH J, 2003, VET MICROBIOL, V95, P229, DOI 10.1016/S0378-1135(03)00065-8##RIDEOUT M I, 1982, J REPROD FERTIL SUPPL, V32, P35##RUPF S, 1999, J DENT RES, V78, P850, DOI 10.1177/00220345990780040501##SCHLUTER H, 1991, PRAKT TIERARZT, V72, P503##SUGIMOTO C, 1983, CURR MICROBIOL, V9, P155, DOI 10.1007/BF01567289##SWERCZEK TW, 1978, VET REC, V103, P125, DOI 10.1136/VR.103.6.125-A##TIMONEY PJ, 1982, VET REC, V111, P107, DOI 10.1136/VR.111.5.107##2003, VET REC, V152, P311",33,2020-11-20,NA
J,WOS:000242792400014,2006,STUDY ON SMALL RUMINANT LUNGWORMS IN NORTHEASTERN ETHIOPIA,"A CROSS-SECTIONAL STUDY OF LUNGWORM INFECTION WAS CARRIED OUT WITH THE AIM OF DETERMINING THE PREVALENCE OF LUNGWORM INFECTION OF SMALL RUMINANTS AND IDENTIFYING THE SPECIES OF THE RESPIRATORY HELMINTHES CIRCULATING IN SIX DISTRICTS OF NORTHEASTERN ETHIOPIA: DEBRESINA, LEGAMBO, HABRU, KALU, CHAFFA-DAWI AND ARTUMANA-FERSEJELLE. FAECAL AND POSTMORTEM EXAMINATION WERE CONDUCTED FROM 1162 AND 104 ANIMALS, RESPECTIVELY. AN OVERALL INFECTION RATE OF 53.6% AND 66.3% WAS FOUND BY FAECAL AND POSTMORTEM EXAMINATIONS, RESPECTIVELY. SIGNIFICANT DIFFERENCE (P < 0.05) WAS FOUND BETWEEN AREAS OF DIFFERENT ALTITUDE WITH AN INFECTION RATE OF 30.4%, 32.5% AND 71.3% AT LOW, MEDIUM AND HIGH ALTITUDE AREAS, RESPECTIVELY. PREVALENCE ON THE DIFFERENT MONTHS WAS INSIGNIFICANT (P > 0.05). THE PREVALENCE OF DICTYOCAULUS FILARIA AND MUELLERIUS CAPILLARIS INFECTION SHOWED A SIGNIFICANT DIFFERENCE (P < 0.05) BETWEEN YOUNG, ADULT AND OLD AGE GROUPS. THE PREVALENCE OF D. FILARIA DECREASES AND THAT OF M. CAPILLARIS INCREASE WITH INCREASING AGE OF THE ANIMAL. ANIMALS UNDER RELATIVELY GOOD MANAGEMENT SYSTEM HAVE BEEN FOUND LESS AFFECTED WITH SIGNIFICANT DIFFERENCE (P > 0.05) THAN THEIR COUNTERPARTS AT RELATIVELY POOR MANAGEMENT SYSTEM. THE INFECTION RATE BETWEEN MALE AND FEMALE ANIMALS SHOWED SIGNIFICANT DIFFERENCE (P < 0.05) WITH PREVALENCE RATE OF 44.4% AND 59.3%, RESPECTIVELY. A SIGNIFICANT DIFFERENCE BETWEEN SHEEP AND GOATS WAS ALSO NOTED WITH INFECTION RATE OF 24.4% AND 50.7%, RESPECTIVELY. MONTHLY WORM BURDEN OF D. FILARIA INFECTION SHOWED SIGNIFICANT DIFFERENCE (P > 0.05) WHILE IT WAS INSIGNIFICANT IN CASE OF M. CAPILLARIS. DUE TO ITS IMPACT ON PRODUCTION, EMPHASIS SHOULD BE GIVEN FOR THE CONTROL AND PREVENTION OF LUNGWORM INFECTION IN HIGHLAND AREAS. (C) 2006 PUBLISHED BY ELSEVIER B.V.",INFECTION; SHEEP,DICTYOCAULUS FILARIA; MUELLERIUS CAPILLARIS; PROTOSTRONGYLUS RUFESCENS; LUNGWORMS; SMALL RUMINANT; ETHIOPIA,VETERINARY PARASITOLOGY,"ALEMU, S##LEYKUN, EG##AYELET, G##ZELEKE, A","MINIST AGR, N WOLLO, ETHIOPIA. NATL VET INST, DEBRE ZEIT, ETHIOPIA.",PARASITOLOGY; VETERINARY SCIENCES,PARASITOLOGY; VETERINARY SCIENCES,"BEKELE M, 1981, ETHIO J AGR SCI, V3, P75##CRAIG TM, 1998, SMALL RUM MIX AN PRA##DHAR DN, 1978, INDIAN J ANIM SCI, V48, P29##DURANT AJ, 1960, DAIRY GOAT J, V38, P6##FRASER CM, 1991, MERK VET MANUAL HDB, P714##HANSEN J, 1994, EPIDEMIOLOGY DIAGNOS##*INT LIV CTR AFR I, 1990, ANN REP 1989, P37##KIMBERLING CV, 1988, DIS SHEEP, P29##MEZGEBU M, 1995, THESIS AAUFVM DEBRE##MICHEL JF, 1965, RES VET SCI, V6, P344##ROSS CV, 1965, J ANIM SCI, V24, P910##SCHANZEL H, 1959, VET B, V29, P569##SISSAY A, 1996, THESIS AAUFVM DEBRE##THOMSON EF, 1988, TROP ANIM HEALTH PRO, V20, P187, DOI 10.1007/BF02240092##TORNCY PM, 1989, MANUAL TROPICAL VET, P81##UQBAZGHI K, 1990, THESIS AAU FVM DEBRE##URQUHART GM, 1994, VET PARASITOLGOY, P39##WILSON GI, 1970, RES VET SCI, V2, P7",11,2020-11-20,NA
J,WOS:000243057400013,2006,QUESTIONNAIRE TO DISTINGUISH BETWEEN STRESS AND URGE URINARY INCONTINENCE,NA,NA,NA,ANNALS OF INTERNAL MEDICINE,"MOONS, KGM","JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, NL-3508 GA UTRECHT, NETHERLANDS.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"BROWN JS, 2006, ANN INTERN MED, V144, P715, DOI 10.7326/0003-4819-144-10-200605160-00005##BROWN JS, 1999, OBSTET GYNECOL, V94, P66, DOI 10.1016/S0029-7844(99)00263-X##MOONS KGM, 1999, EPIDEMIOLOGY, V10, P276, DOI 10.1097/00001648-199905000-00015##MOONS KGM, 2004, CLIN CHEM, V50, P473, DOI 10.1373/CLINCHEM.2003.024752",0,2020-11-20,NA
J,WOS:000242771000019,2006,"THERMODYNAMICS OF THE ATPASE CYCLE OF GLCV, THE NUCLEOTIDE-BINDING DOMAIN OF THE GLUCOSE ABC TRANSPORTER OF SULFOLOBUS SOLFATARICUS","ATP-BINDING CASSETTE TRANSPORTERS DRIVE THE TRANSPORT OF SUBSTRATES ACROSS THE MEMBRANE BY THE HYDROLYSIS OF ATP. THEY TYPICALLY HAVE A CONSERVED DOMAIN STRUCTURE WITH TWO MEMBRANE-SPANNING DOMAINS THAT FORM THE TRANSPORT CHANNEL AND TWO CYTOSOLIC NUCLEOTIDE-BINDING DOMAINS ( NBDS) THAT ENERGIZE THE TRANSPORT REACTION. BINDING OF ATP TO THE NBD MONOMER RESULTS IN FORMATION OF A NBD DIMER. HYDROLYSIS OF THE ATP DRIVES THE DISSOCIATION OF THE DIMER. THE THERMODYNAMICS OF DISTINCT STEPS IN THE ATPASE CYCLE OF GLCV, THE NBD OF THE GLUCOSE ABC TRANSPORTER OF THE EXTREME THERMOACIDOPHILE SULFOLOBUS SOLFATARICUS, WERE STUDIED BY ISOTHERMAL TITRATION CALORIMETRY USING THE WILD-TYPE PROTEIN AND TWO MUTANTS, WHICH ARE ARRESTED AT DIFFERENT STEPS IN THE ATP HYDROLYTIC CYCLE. THE G144A MUTANT IS UNABLE TO DIMERIZE, WHILE THE E166A MUTANT IS DEFECTIVE IN DIMER DISSOCIATION. THE ATP, ADP, AND AMP-PNP BINDING AFFINITIES, STOICHIOMETRIES, AND ENTHALPIES OF BINDING WERE DETERMINED AT DIFFERENT TEMPERATURES. FROM THESE DATA, THE THERMODYNAMIC PARAMETERS OF NUCLEOTIDE BINDING, NBD DIMERIZATION, AND ATP HYDROLYSIS WERE CALCULATED. THE DATA DEMONSTRATE THAT THE ATP HYDROLYSIS CYCLE OF ISOLATED NBDS CONSISTS OF CONSECUTIVE STEPS WHERE ONLY THE FINAL STEP OF ADP RELEASE IS ENERGETICALLY UNFAVORABLE.",P-GLYCOPROTEIN; MALTOSE TRANSPORTER; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; TRANSITION-STATE; CATALYTIC CYCLE; CASSETTE DIMER; ACTIVE-SITE; HYDROLYSIS; SUBUNIT,NA,BIOCHEMISTRY,"PRETZ, MG##ALBERS, SV##SCHUURMAN-WOLTERS, G##TAMPE, R##DRIESSEN, AJM##VAN DER DOES, C","UNIV GRONINGEN, DEPT BIOCHEM, GRONINGEN, NETHERLANDS. GOETHE UNIV FRANKFURT, INST BIOCHEM, FRANKFURT, GERMANY. UNIV GRONINGEN, DEPT MOL MICROBIOL, GRONINGEN, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"AL-SHAWI MK, 2003, J BIOL CHEM, V278, P52629, DOI 10.1074/JBC.M308175200##ALBERS SV, 1999, J BACTERIOL, V181, P4285, DOI 10.1128/JB.181.14.4285-4291.1999##AUSTERMUHLE MI, 2004, J BIOL CHEM, V279, P28243, DOI 10.1074/JBC.M403508200##BOHM A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/JBC.M107905200##CALISKAN G, 2004, J CHEM PHYS, V121, P1978, DOI 10.1063/1.1764491##CHEN J, 2003, MOL CELL, V12, P651, DOI 10.1016/J.MOLCEL.2003.08.004##DAVIDSON AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/ANNUREV.BIOCHEM.73.011303.073626##DE LA TORRE JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6##DEN BLAAUWEN T, 1999, FEBS LETT, V458, P145, DOI 10.1016/S0014-5793(99)01139-4##GAUDET R, 2001, EMBO J, V20, P4964, DOI 10.1093/EMBOJ/20.17.4964##HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/ANNUREV.CELLBIO.8.1.67##HIGGINS CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/NSMB836##HOPFNER KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9##HORN C, 2003, J MOL BIOL, V334, P403, DOI 10.1016/J.JMB.2003.09.079##JANAS E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/JBC.M301227200##JONES PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/S00018-003-3336-9##JONES PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1016/S0378-1097(99)00411-5##KARPOWICH N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7##KODAMA T, 1976, J BIOL CHEM, V251, P7499##LIU RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/BI9627119##LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/BI00231A019##LOCHER KP, 2004, CURR OPIN STRUC BIOL, V14, P426, DOI 10.1016/J.SBI.2004.06.005##LU G, 2005, P NATL ACAD SCI USA, V102, P17969, DOI 10.1073/PNAS.0506039102##MOODY JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/JBC.C200228200##NIKAIDO K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/JBC.272.44.27745##PANAGIOTIDIS CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/J.1365-2958.1998.01084.X##SCHMITT L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8##SENIOR AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8##SHARMA S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000##SMITH PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2##SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/BI00131A009##STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/PNAS.74.6.2236##URBATSCH IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/JBC.M301957200##URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/JBC.270.33.19383##VAN DER DOES C, 2006, J BIOL CHEM, V281, P5694, DOI 10.1074/JBC.M511730200##VAN DER DOES C, 2004, BIOL CHEM, V385, P927, DOI 10.1515/BC.2004.121##VERDON G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8##VERDON G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/J.JMB.2003.08.065##VERDON G, 2002, ACTA CRYSTALLOGR D, V58, P362, DOI 10.1107/S0907444901020765##WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3##YUAN YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/JBC.M100758200##ZAITSEVA J, 2005, BIOCHEMISTRY-US, V44, P9680, DOI 10.1021/BI0506122##ZAITSEVA J, 2005, EMBO J, V24, P1901, DOI 10.1038/SJ.EMBOJ.7600657",13,2020-11-20,NA
J,WOS:000243522300014,2006,INHIBITION OF COMPLEMENT COMPONENT C3 REDUCES VEIN GRAFT ATHEROSCLEROSIS IN APOLIPOPROTEIN E3-LEIDEN TRANSGENIC MICE,"BACKGROUND - VENOUS BYPASS GRAFTS MAY FAIL BECAUSE OF DEVELOPMENT OF INTIMAL HYPERPLASIA AND ACCELERATED ATHEROSCLEROSIS. INFLAMMATION PLAYS A MAJOR ROLE IN THESE PROCESSES. COMPLEMENT IS AN IMPORTANT PART OF THE IMMUNE SYSTEM AND PARTICIPATES IN THE REGULATION OF INFLAMMATION. THE EXACT ROLE OF COMPLEMENT IN THE PROCESS OF ACCELERATED ATHEROSCLEROSIS OF VEIN GRAFTS HAS NOT YET BEEN EXPLORED, HOWEVER. METHODS AND RESULTS - TO ASSESS THE ROLE OF COMPLEMENT IN THE DEVELOPMENT OF VEIN GRAFT ATHEROSCLEROSIS, A MOUSE MODEL, IN WHICH A VENOUS INTERPOSITION WAS PLACED IN THE COMMON CAROTID ARTERY, WAS USED. IN THIS MODEL, VEIN GRAFT THICKENING APPEARED WITHIN 4 WEEKS. THE EXPRESSION OF COMPLEMENT COMPONENTS WAS STUDIED WITH THE USE OF IMMUNOHISTOCHEMISTRY ON SECTIONS OF THE THICKENED VEIN GRAFT. C1Q, C3, C9, AND THE REGULATORY PROTEINS CD59 AND COMPLEMENT RECEPTOR-RELATED GENE Y COULD BE DETECTED IN THE LESIONS 4 WEEKS AFTER SURGERY. QUANTITATIVE MRNA ANALYSIS FOR C1Q, C3, CD59, AND COMPLEMENT RECEPTOR-RELATED GENE Y REVEALED EXPRESSION OF THESE MOLECULES IN THE THICKENED VEIN GRAFT, WHEREAS C9 DID NOT SHOW LOCAL MRNA EXPRESSION. FURTHERMORE, INTERFERENCE WITH C3 ACTIVATION WITH COMPLEMENT RECEPTOR-RELATED GENE Y-IG WAS ASSOCIATED WITH REDUCED VEIN GRAFT THICKENING, REDUCED C3 AND C9 DEPOSITION, AND REDUCED INFLAMMATION AS ASSESSED BY ANALYSIS OF INFLUX OF INFLAMMATORY CELLS, SUCH AS LEUKOCYTES, T CELLS, AND MONOCYTES. IN ADDITION, CHANGES IN APOPTOSIS AND PROLIFERATION WERE OBSERVED. WHEN C3 WAS INHIBITED BY COBRA VENOM FACTOR, A SIMILAR REDUCTION IN VEIN GRAFT THICKENING WAS OBSERVED. CONCLUSIONS - THE COMPLEMENT CASCADE IS INVOLVED IN VEIN GRAFT THICKENING AND MAY BE A TARGET FOR THERAPY IN VEIN GRAFT FAILURE DISEASE.",ACCELERATED ATHEROSCLEROSIS; ISCHEMIA-REPERFUSION; 2 PARTS; ACTIVATION; PATHWAY; INJURY; GLOMERULONEPHRITIS; ARTERIOSCLEROSIS; IMMUNOLOGY; EXPRESSION,ATHEROSCLEROSIS; BYPASS; IMMUNOLOGY; COMPLEMENT SYSTEM PROTEINS,CIRCULATION,"SCHEPERS, A##DE VRIES, MR##VAN LEUVEN, CJ##GRIMBERGEN, JM##HOLERS, VM##DAHA, MR##VAN BOCKEL, JH##QUAX, PHA","TNO QUAL LIFE, GAUBIUS LAB, DEPT BIOMED RES, NL-2301 CE LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT VASC SURG, LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT RENAL DIS, LEIDEN, NETHERLANDS. UNIV COLORADO, HLTH SCI CTR, DEPT RHEUMATOL, DENVER, CO 80202 USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/JEM.182.6.1959##BULKLEY BH, 1977, CIRCULATION, V55, P163, DOI 10.1161/01.CIR.55.1.163##BUSH HL, 1986, J VASC SURG, V3, P204, DOI 10.1067/MVA.1986.AVS0030204##CHAN RK, 2003, BRIT J SURG, V90, P1470, DOI 10.1002/BJS.4408##CHRISTIANSEN JF, 2004, ANN THORAC SURG, V77, P1575, DOI 10.1016/J.ATHORACSUR.2003.10.107##DAVIES MG, 1995, EUR J VASC ENDOVASC, V9, P7, DOI 10.1016/S1078-5884(05)80218-7##ESLAMI MH, 2001, J VASC SURG, V34, P923, DOI 10.1067/MVA.2001.118590##FITZMAURICE M, 1990, ARCH PATHOL LAB MED, V114, P388##HOCH JR, 1994, SURGERY, V116, P463##KAUL M, 2001, FEBS LETT, V500, P91, DOI 10.1016/S0014-5793(01)02592-3##LARDENOYE JHP, 2000, CIRC RES, V87, P248, DOI 10.1161/01.RES.87.3.248##LARDENOYE JHP, 2002, CIRC RES, V91, P577, DOI 10.1161/01.RES.0000036901.58329.D7##LIBBY P, 2002, NAT MED, V8, P1257, DOI 10.1038/NM1102-1257##MATSUO S, 1994, KIDNEY INT, V46, P191, DOI 10.1038/KI.1994.259##NAUTA AJ, 2002, EUR J IMMUNOL, V32, P1726, DOI 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R##NICULESCU F, 2004, IMMUNOL RES, V30, P73, DOI 10.1385/IR:30:1:073##OKSJOKI R, 2003, CURR OPIN LIPIDOL, V14, P477, DOI 10.1097/00041433-200310000-00008##PARK P, 2001, J AM SOC NEPHROL, V12, P1383##QUIGG RJ, 1998, J IMMUNOL, V160, P4553##RATLIFF NB, 1989, ARCH PATHOL LAB MED, V113, P772##SEIFERT PS, 1990, J EXP MED, V172, P547, DOI 10.1084/JEM.172.2.547##STAHL GL, 2003, AM J PATHOL, V162, P449, DOI 10.1016/S0002-9440(10)63839-4##THURMAN JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/JIMMUNOL.170.3.1517##TORZEWSKI M, 1998, ARTERIOSCL THROM VAS, V18, P369, DOI 10.1161/01.ATV.18.3.369##TROUW LA, 2005, MOL IMMUNOL, V42, P731, DOI 10.1016/J.MOLIMM.2004.09.024##TSUJI S, 1994, J BIOCHEM-TOKYO, V116, P794, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A124598##VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540##WALPORT MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406##WALPORT MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506##XU QB, 2004, AM J PATHOL, V165, P1, DOI 10.1016/S0002-9440(10)63270-1##ZOU YP, 1998, AM J PATHOL, V153, P1301, DOI 10.1016/S0002-9440(10)65675-1",39,2020-11-20,NA
J,WOS:000243039800007,2006,SOCIAL-INSECT FUNGUS FARMING,NA,GROWING ANTS; MUTUALISM; SYMBIOSIS; EVOLUTION; TERMITES; CONFLICT; BACTERIA,NA,CURRENT BIOLOGY,"AANEN, DK##BOOMSMA, JJ","UNIV WAGENINGEN & RES CTR, GENET LAB, NL-6703 BD WAGENINGEN, NETHERLANDS. UNIV COPENHAGEN, INST BIOL, DEPT POPULAT BIOL, DK-2100 COPENHAGEN, DENMARK.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOLOGY; CELL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS; CELL BIOLOGY,"AANEN DK, 2002, P NATL ACAD SCI USA, V99, P14887, DOI 10.1073/PNAS.222313099##AANEN DK, 2006, INSECT SYMBIOSIS, V2##AANEN DK, 2006, BIOL LETT-UK, V2, P209, DOI 10.1098/RSBL.2005.0424##BOURKE AFG, 2005, INSECT EVOLUTIONARY##CURRIE CR, 2006, SCIENCE, V311, P81, DOI 10.1126/SCIENCE.1119744##CURRIE CR, 1999, NATURE, V398, P701, DOI 10.1038/19519##CURRIE CR, 2003, SCIENCE, V299, P386, DOI 10.1126/SCIENCE.1078155##FOSTER KR, 2006, J EVOLUTION BIOL, V19, P1283, DOI 10.1111/J.1420-9101.2005.01073.X##FRANK SA, 1996, P ROY SOC B-BIOL SCI, V263, P339, DOI 10.1098/RSPB.1996.0052##GREEN AM, 2002, MOL ECOL, V11, P191, DOI 10.1046/J.1365-294X.2002.01433.X##KIERS ET, 2003, NATURE, V425, P78, DOI 10.1038/NATURE01931##MIKHEYEV AS, 2006, P NATL ACAD SCI USA, V103, P10702, DOI 10.1073/PNAS.0601441103##MUELLER UG, 2002, AM NAT, V160, PS67, DOI 10.1086/342084##MUELLER UG, 2005, ANNU REV ECOL EVOL S, V36, P563, DOI 10.1146/ANNUREV.ECOLSYS.36.102003.152626##POULSEN M, 2005, SCIENCE, V307, P741, DOI 10.1126/SCIENCE.1106688",8,2020-11-20,NA
J,WOS:000243105700007,2006,FIBER OPTICS OPENS WINDOW ON STREAM DYNAMICS,"A NEW APPROACH TO MONITORING SURFACE WATERS USING DISTRIBUTED FIBER OPTIC TEMPERATURE SENSING IS PRESENTED, ALLOWING RESOLUTIONS OF TEMPERATURE OF 0.01 DEGREES C EVERY METER ALONG A FIBER OPTIC CABLE OF UP TO 10,000 M IN LENGTH. WE ILLUSTRATE THE POTENTIAL OF THIS APPROACH BY QUANTIFYING BOTH STREAM TEMPERATURE DYNAMICS AND GROUNDWATER INFLOWS TO THE MAISBICH, A FIRST-ORDER STREAM IN LUXEMBOURG ( 49 DEGREES 47'N, 6 DEGREES 02'E). THE TECHNIQUE PROVIDES A VERY RICH DATASET, WHICH MAY BE OF INTEREST TO MANY TYPES OF ENVIRONMENTAL RESEARCH, NOTABLY THAT OF STREAM ECOSYSTEMS.",NA,NA,GEOPHYSICAL RESEARCH LETTERS,"SELKER, J##VAN DE GIESEN, N##WESTHOFF, M##LUXEMBURG, W##PARLANGE, MB","DELFT UNIV TECHNOL, FAC CIVIL ENGN & GEOSCI, DEPT WATER MANAGEMENT, NL-2628 CN DELFT, NETHERLANDS. OREGON STATE UNIV, DEPT BIOL & ECOL ENGN, CORVALLIS, OR 97331 USA. ECOLE POLYTECH FED LAUSANNE, SCH ARCHITECTURE CIVIL & ENVIRONM ENGN, CH-1015 LAUSANNE, SWITZERLAND.","GEOSCIENCES, MULTIDISCIPLINARY",GEOLOGY,"BOYD M., 2003, ANAL METHODS DYNAMIC##CONSTANTZ J, 1998, WATER RESOUR RES, V34, P1609, DOI 10.1029/98WR00998##KOBAYASHI D, 1985, J HYDROL, V76, P155, DOI 10.1016/0022-1694(85)90096-4##SELKER JS, 2006, WATER RESOUR RES, V42, DOI 10.1029/2006WR005326##SHANLEY J. B., 1988, JOURNAL OF CONTAMINANT HYDROLOGY, V3, P349, DOI 10.1016/0169-7722(88)90040-X##TORGERSEN CE, 1999, ECOL APPL, V9, P301, DOI 10.2307/2641187",183,2020-11-20,NA
J,WOS:000242916100003,2006,"RANDOMIZED DOUBLE-BLIND COMPARISON OF SIROLIMUS-ELUTING STENT VERSUS BARE-METAL STENT IMPLANTATION IN DISEASED SAPHENOUS VEIN GRAFTS - SIX-MONTH ANGIOGRAPHIC, INTRAVASCULAR ULTRASOUND, AND CLINICAL FOLLOW-UP OF THE RRISC TRIAL","OBJECTIVES WE SOUGHT TO COMPARE, IN A RANDOMIZED FASHION, SIROLIMUS-ELUTING STENTS (SES) VERSUS BARE-METAL STENTS (BMS) IN SAPHENOUS VEIN GRAFTS (SVGS). BACKGROUND SIROLIMUS-ELUTING STENTS REDUCE RESTENOSIS AND REPEATED REVASCULARIZATION IN NATIVE CORONARY ARTERIES COMPARED WITH BMS. HOWEVER, RANDOMIZED DATA IN SVG ARE ABSENT. METHODS PATIENTS WITH SVG LESIONS WERE RANDOMIZED TO SES OR BMS. ALL WERE SCHEDULED TO UNDERGO 6-MONTH CORONARY ANGIOGRAPHY. THE PRIMARY END POINT WAS 6-MONTH ANGIOGRAPHIC IN-STENT LATE LUMEN LOSS. SECONDARY END POINTS INCLUDED BINARY ANGIOGRAPHIC RESTENOSIS, NEOINTIMAL VOLUME BY INTRAVASCULAR ULTRASOUND AND MAJOR ADVERSE CLINICAL EVENTS (DEATH, MYOCARDIAL INFARCTION, TARGET LESION, AND VESSEL REVASCULARIZATION). RESULTS A TOTAL OF 75 PATIENTS WITH 96 LESIONS LOCALIZED IN 80 DISEASED SVGS WERE INCLUDED: 38 PATIENTS RECEIVED 60 SES FOR 47 LESIONS, WHEREAS 37 PATIENTS RECEIVED 54 BMS FOR 49 LESIONS. IN-STENT LATE LOSS WAS SIGNIFICANTLY REDUCED IN SES (0.38 +/- 0.51 MM VS. 0.79 +/- 0.66 MM IN BMS, P = 0.001). BINARY IN-STENT AND IN-SEGMENT RESTENOSIS WERE REDUCED, 11.3% VERSUS 30.6% (RELATIVE RISK [RR] 0.37; 95% CONFIDENCE INTERVAL [CI] 0.15 TO 0.97, P = 0.024) AND 13.6% VERSUS 32.6% (RR 0.42; 95% CI 0.18 TO 0.97, P = 0.031), RESPECTIVELY. MEDIAN NEOINTIMAL VOLUME WAS 1 MM(3) (INTERQUARTILE RANGE 0 TO 13) IN SES VERSUS 24 (INTERQUARTILE RANGE 8 TO 34) IN BMS (P < 0.001). TARGET LESION AND VESSEL REVASCULARIZARION RATES WERE SIGNIFICANTLY REDUCED, 5.3% VERSUS 21.6% (RR 0.24; 95% CI 0.05 TO 1.0, P = 0.047) AND 5.3% VERSUS 27% (RR 0.19; 95% CI 0.05 TO 0.83, P = 0.012), RESPECTIVELY. DEATH AND MYOCARDIAL INFARCTION RATES WERE NOT DIFFERENT. CONCLUSIONS SIROLIMUS-ELUTING STENTS SIGNIFICANTLY REDUCE LATE LOSS IN SVG AS OPPOSED TO BMS. THIS IS ASSOCIATED WITH A REDUCTION IN RESTENOSIS RATE AND REPEATED TARGET LESION AND VESSEL REVASCULARIZATION PROCEDURES.",MEMBRANE-COVERED STENTS; SMALL CORONARY-ARTERIES; BYPASS GRAFTS; BALLOON ANGIOPLASTY; MYOCARDIAL-INFARCTION; EUROPEAN-SOCIETY; STANDARD STENT; RESTENOSIS; LESIONS; PREVENTION,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,"VERMEERSCH, P##AGOSTONI, P##VERHEYE, S##VAN DEN HEUVEL, P##CONVENS, C##BRUINING, N##VAN DEN BRANDEN, F##VAN LANGENHOVE, G","ANTWERP CARDIOVASC INST MIDDELHEIM, AZ MIDDELHEIM, B-2020 ANTWERP, BELGIUM. ERASMUS MC, THORAXCTR, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ALEXANDER JH, 2005, JAMA-J AM MED ASSOC, V294, P2446##ALPERT JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/EUHJ.2000.2305##ARDISSINO D, 2004, JAMA-J AM MED ASSOC, V292, P2727, DOI 10.1001/JAMA.292.22.2727##BALDUS S, 2000, CIRCULATION, V102, P2024, DOI 10.1161/01.CIR.102.17.2024##BRUINING N, 1998, CATHETER CARDIO DIAG, V43, P254, DOI 10.1002/(SICI)1097-0304(199803)43:3<254::AID-CCD3>3.0.CO;2-8##BRYAN AJ, 1994, CURR OPIN CARDIOL, V9, P641, DOI 10.1097/00001573-199411000-00002##CHU WW, 2006, AM J CARDIOL, V97, P34, DOI 10.1016/J.AMJCARD.2005.08.018##DE WINTER SA, 2004, CATHETER CARDIO INTE, V61, P84, DOI 10.1002/CCD.10693##DEPRE C, 1998, AM J CLIN PATHOL, V110, P378, DOI 10.1093/AJCP/110.3.378##FITZGIBBON GM, 1996, J AM COLL CARDIOL, V28, P616, DOI 10.1016/0735-1097(96)00206-9##GE L, 2005, J AM COLL CARDIOL, V45, P989, DOI 10.1016/J.JACC.2004.11.060##HAMERS R, 2001, COMPUT CARDIOL, V28, P589, DOI 10.1109/CIC.2001.977724##HANEKAMP CEE, 2003, CATHETER CARDIO INTE, V60, P452, DOI 10.1002/CCD.10692##HOYE ANGELA, 2004, J INVASIVE CARDIOL, V16, P230##IAKOVOU I, 2005, JAMA-J AM MED ASSOC, V293, P2126, DOI 10.1001/JAMA.293.17.2126##KASTRATI A, 2005, JAMA-J AM MED ASSOC, V293, P165, DOI 10.1001/JAMA.293.2.165##KEREIAKES DJ, 2005, J AM COLL CARDIOL, V45, P1206, DOI 10.1016/J.JACC.2005.01.005##LANSKY AJ, 2002, J AM COLL CARDIOL, V39, P274, DOI 10.1016/S0735-1097(01)01745-4##LEE MS, 2005, CATHETER CARDIO INTE, V66, P507, DOI 10.1002/CCD.20498##MAURI L, 2005, CIRCULATION, V111, P3435, DOI 10.1161/CIRCULATIONAHA.104.513952##MCFADDEN EP, 2004, LANCET, V364, P1519, DOI 10.1016/S0140-6736(04)17275-9##MEHRAN R, 1999, CIRCULATION, V100, P1872, DOI 10.1161/01.CIR.100.18.1872##MORICE M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMOA012843##MOSES JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMOA035071##ONG ATL, 2005, J AM COLL CARDIOL, V45, P2088, DOI 10.1016/J.JACC.2005.02.086##PRICE MJ, 2005, CATHETER CARDIO INTE, V65, P208, DOI 10.1002/CCD.20369##SABATE M, 2005, CIRCULATION, V112, P2175, DOI 10.1161/CIRCULATIONAHA.105.562421##SALOMON NW, 1990, J THORAC CARDIOV SUR, V100, P250##SAVAGE MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103##SCHACHINGER V, 2003, J AM COLL CARDIOL, V42, P1360, DOI 10.1016/S0735-1097(03)01038-6##SCHAMPAERT E, 2004, J AM COLL CARDIOL, V43, P1110, DOI 10.1016/J.JACC.2004.01.024##SCHOFER J, 2003, LANCET, V362, P1093, DOI 10.1016/S0140-6736(03)14462-5##SILBER S, 2005, EUR HEART J, V26, P804, DOI 10.1093/EURHEARTJ/EHI138##STANKOVIC G, 2003, CIRCULATION, V108, P37, DOI 10.1161/01.CIR.0000079106.71097.1C##SUTTORP MJ, 2006, CIRCULATION, V114, P921, DOI 10.1161/CIRCULATIONAHA.106.613588##TURCO MA, 2006, CATHETER CARDIO INTE, V68, P379, DOI 10.1002/CCD.20873##VALGIMIGLI M, 2005, JAMA-J AM MED ASSOC, V293, P2109, DOI 10.1001/JAMA.293.17.2109##VAN LANGENHOVE G, 1999, J INVASIVE CARDIOL, V11, P274##VAN LANGENHOVE G, 2000, CAN J CARDIOL, V16, P473##VANBEUSEKOM HMM, 1993, J AM COLL CARDIOL, V21, P45, DOI 10.1016/0735-1097(93)90715-D##VANDERZWET PMJ, 1994, J AM COLL CARDIOL, V24, P216, DOI 10.1016/0735-1097(94)90566-5##VONBIRGELEN C, 1997, CIRCULATION, V96, P2944, DOI 10.1161/01.CIR.96.9.2944##WAKSMAN R, 2002, NEW ENGL J MED, V346, P1194, DOI 10.1056/NEJMOA012579##WEINTRAUB WS, 1997, CIRCULATION, V95, P868##WESSELY R, 2005, ANN INTERN MED, V143, P392, DOI 10.7326/0003-4819-143-5-200509060-00119",196,2020-11-20,NA
J,WOS:000242916100015,2006,RELATIONSHIP BETWEEN NONINVASIVE CORONARY ANGIOGRAPHY WITH MULTI-SLICE COMPUTED TOMOGRAPHY AND MYOCARDIAL PERFUSION IMAGING,"OBJECTIVES THE AIM OF THIS STUDY WAS TO PERFORM A HEAD-TO-HEAD COMPARISON BETWEEN MULTI-SLICE COMPUTED TOMOGRAPHY (MSCT) AND MYOCARDIAL PERFUSION IMAGING (MPI) IN PATIENTS WITH AN INTERMEDIATE LIKELIHOOD OF CORONARY ARTERY DISEASE (CAD) AND TO COMPARE NON-INVASIVE FINDINGS TO INVASIVE CORONARY ANGIOGRAPHY. BACKGROUND MULTI-SLICE COMPUTED TOMOGRAPHY DETECTS ATHEROSCLEROSIS, WHEREAS MPI DETECTS ISCHEMIA; HOW THESE 2 TECHNIQUES COMPARE IN PATIENTS WITH AN INTERMEDIATE LIKELIHOOD OF CAD IS UNKNOWN. METHODS A TOTAL OF 114 PATIENTS, MAINLY WITH INTERMEDIATE LIKELIHOOD OF CAD, UNDER-WENT BOTH MSCT AND MPI. THE MSCT STUDIES WERE CLASSIFIED AS HAVING NO CAD, NONOBSTRUCTIVE (< 50% LUMINAL NARROWING) CAD, OR OBSTRUCTIVE CAD. MYOCARDIAL PERFUSION IMAGING EXAMINATIONS WERE CLASSIFIED AS SHOWING NORMAL OR ABNORMAL (REVERSIBLE AND/OR FIXED DEFECTS). IN A SUBSET OF 58 PATIENTS, INVASIVE CORONARY ANGIOGRAPHY WAS PERFORMED. RESULTS ON THE BASIS OF THE MSCT DATA, 41 PATIENTS (36%) WERE CLASSIFIED AS HAVING NO CAD, OF WHOM 90% HAD NORMAL MPI. A TOTAL OF 33 PATIENTS (29%) SHOWED NOM-OBSTRUCTIVE CAD, WHEREAS AT LEAST I SIGNIFICANT (>= 50% LUMINAL NARROWING) LESION WAS OBSERVED IN THE REMAINING 40 PATIENTS (35%). ONLY 45% OF PATIENTS WITH AN ABNORMAL MSCT HAD ABNORMAL MPI; EVEN IN PATIENTS WITH OBSTRUCTIVE CAD ON MSCT, 50% STILL HAD A NORMAL MPI. IN THE SUBSET OF PATIENTS UNDERGOING INVASIVE ANGIOGRAPHY, THE AGREEMENT WITH MSCT WAS EXCELLENT (90%). CONCLUSIONS MYOCARDIAL PERFUSION IMAGING AND MSCT PROVIDE DIFFERENT AND COMPLEMENTARY INFORMATION ON CAD, NAMELY, DETECTION OF ATHEROSCLEROSIS VERSUS DETECTION OF ISCHEMIA. AS COMPARED TO INVASIVE ANGIOGRAPHY, MSCT HAS A HIGH ACCURACY FOR DETECTING CAD IN PATIENTS WITH AN INTERMEDIATE LIKELIHOOD OF CAD.",LEFT-VENTRICULAR FUNCTION; ARTERY-DISEASE; DIAGNOSTIC-ACCURACY; ATHEROSCLEROSIS; CARDIOLOGY; LESIONS; SPECT,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,"SCHUIJF, JD##WIJNS, W##JUKEMA, W##ATSMA, DE##DE ROOS, A##LAMB, HJ##STOKKEL, MPM##DIBBETS-SCHNEIDER, P##DECRAMER, I##DE BONDT, P##VAN DER WALL, EE##VANHOENACKER, PK##BAX, JJ","LEIDEN UNIV, MED CTR, DEPT CARDIOL, NL-2333 ZA LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT RADIOL, LEIDEN, NETHERLANDS. INTERUNIV INST NETHERLANDS, UTRECHT, NETHERLANDS. CARDIOVASC CTR, AALST, BELGIUM. LEIDEN UNIV, MED CTR, DEPT NUCL MED, LEIDEN, NETHERLANDS. OLV, DEPT RADIOL & MED IMAGING, AALST, BELGIUM. OLV, DIV NUCL MED, AALST, BELGIUM.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ABIDOV A, 2005, NEW ENGL J MED, V353, P1889, DOI 10.1056/NEJMOA042741##BAVELAAR-CROON CDL, 2001, J NUCL CARDIOL, V8, P10, DOI 10.1067/MNC.2001.109862##BERGER A, 2005, J AM COLL CARDIOL, V46, P438, DOI 10.1016/J.JACC.2005.04.041##BERMAN DS, 2004, J AM COLL CARDIOL, V44, P923, DOI 10.1016/J.JACC.2004.06.042##CERQUEIRA MD, 2002, CIRCULATION, V105, P539, DOI 10.1161/HC0402.102975##CORTIGIANI L, 2006, J AM COLL CARDIOL, V47, P605, DOI 10.1016/J.JACC.2005.09.035##DE BRUYNE B, 2001, CIRCULATION, V104, P2401, DOI 10.1161/HC4501.099316##DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402##HACHAMOVITCH R, 2004, J AM COLL CARDIOL, V43, P200, DOI 10.1016/J.JACC.2003.07.043##HACKER M, 2005, J NUCL MED, V46, P1294##HELLER LI, 1997, CIRCULATION, V96, P484##LEBER AW, 2005, J AM COLL CARDIOL, V46, P147, DOI 10.1016/J.JACC.2005.03.071##LESCHKA S, 2005, EUR HEART J, V26, P1482, DOI 10.1093/EURHEARTJ/EHI261##MOLLET NR, 2005, CIRCULATION, V112, P2318, DOI 10.1161/CIRCULATIONAHA.105.533471##PUGLIESE F, 2006, EUR RADIOL, V16, P575, DOI 10.1007/S00330-005-0041-0##RAFF GL, 2005, J AM COLL CARDIOL, V46, P552, DOI 10.1016/J.JACC.2005.05.056##ROPERS D, 2006, AM J CARDIOL, V97, P343, DOI 10.1016/J.AMJCARD.2005.08.050##SALM LP, 2005, J NUCL CARDIOL, V12, P545, DOI 10.1016/J.NUCLCARD.2005.04.015##SCHUIJF JD, 2006, AM HEART J, V151, P404, DOI 10.1016/J.AHJ.2005.03.022##SCHUIJF JD, 2005, AM J CARDIOL, V95, P571, DOI 10.1016/J.AMJCARD.2004.11.002##SMANIO PEP, 1997, J AM COLL CARDIOL, V30, P1687, DOI 10.1016/S0735-1097(97)00363-X##UNDERWOOD SR, 2004, EUR J NUCL MED MOL I, V31, P261, DOI 10.1007/S00259-003-1344-5",345,2020-11-20,NA
J,WOS:000242916100017,2006,STRUCTURAL ABNORMALITIES OF THE INFEROSEPTAL LEFT VENTRICULAR WALL DETECTED BY CARDIAC MAGNETIC RESONANCE IMAGING IN CARRIERS OF HYPERTROPHIC CARDIOMYOPATHY MUTATIONS,"OBJECTIVES THE PURPOSE OF THIS STUDY WAS TO EVALUATE WHETHER STRUCTURAL LEFT VENTRICULAR (LV) ABNORMALITIES CAN BE OBSERVED IN HYPERTROPHIC CARDIOMYOPATHY (HCM) MUTATION CARRIERS WHO HAVE NOT YET DEVELOPED ECHOCARDIOGRAPHIC SIGNS OF HYPERTROPHY BY USING CARDIAC MAGNETIC RESONANCE IMAGING (CMR). BACKGROUND HYPERTROPHIC CARDIOMYOPATHY IS CAUSED BY MUTATIONS OF GENES ENCODING FOR SARCOMERIC PROTEINS. MYOCYTE DISARRAY AND INTERSTITIAL FIBROSIS PRECEDE THE DEVELOPMENT OF REGIONAL HYPERTROPHY IN HCM MUTATION CARRIERS (CARRIERS). NO MACROSCOPIC LV STRUCTURAL ABNORMALITIES HAVE BEEN OBSERVED IN CARRIERS WITHOUT LV HYPERTROPHY. METHODS A CMR, ECHOCARDIOGRAM, AND ELECTROCARDIOGRAM (ECG) WERE PERFORMED IN 16 CARRIERS. DELAYED CONTRAST ENHANCEMENT IMAGING WAS USED WITH CMR TO DETECT FIBROSIS. IN 16 AGE- AND GENDER-MATCHED CONTROL SUBJECTS, CMR AND ECG WERE PERFORMED AND AN ECHOCARDIOGRAM WAS MADE WHEN STRUCTURAL ABNORMALITIES WERE DETECTED WITH CMR. ALL CARRIERS HAD AN LV WALL THICKNESS < 13 MM IN THE YEAR BEFORE THE STUDY, MEASURED BY ECHOCARDIOGRAPHY. RESULTS LIT 13 CARRIERS (81%), CRYPTS WERE DISCERNED WITH CMR IN THE BASAL AND MID INFEROSEPTAL LV WALL, NOT DETECTED BY ROUTINE ECHOCARDIOGRAPHY AND NOT OBSERVED IN HEALTHY VOLUNTEERS. IN 4 OF THE CRYPT-POSITIVE CARRIERS, BOTH THE ECHOCARDIOGRAM AND ECG WERE NORMAL. TWO HCM CARRIERS REVEALED REGIONAL HYPERTROPHY OF THE INFEROSEPTUM NOT DETECTED BY ECHOCARDIOGRAPHY, AND IN BOTH CARRIERS, FOCAL FIBROSIS WAS PRESENT. CONCLUSIONS IN CARRIERS WHO HAVE NOT YET DEVELOPED FRANK HYPERTROPHY, CRYPTS CAN BE DETECTED WITH CMR IN THE INFEROSEPTAL LV WALL, EVEN WHEN ECHOCARDIOGRAPHY AND ECG ARE NORMAL. THE CRYPTS MIGHT REPRESENT ONE OF THE EARLY PATHOLOGICAL ALTERATIONS OF MYOCARDIUM IN CARRIERS THAT ULTIMATELY PROGRESS INTO MANIFEST HCM.",DELAYED CONTRAST ENHANCEMENT; SUDDEN-DEATH; MRI; DIAGNOSIS; YOUNG; MODEL; RISK; GENE,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,"GERMANS, T##WILDE, AAM##DIJKMANS, PA##CHAI, W##KAMP, O##PINTO, YM##VAN ROSSUM, AC","VU UNIV, MED CTR, DEPT CARDIOL, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT CARDIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV HOSP MAASTRICHT, DEPT CARDIOL, MAASTRICHT, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ALDERS M, 2003, EUR HEART J, V24, P1848, DOI 10.1016/S0195-668X(03)00466-4##ALFAKIH K, 2003, J MAGN RESON IMAGING, V17, P323, DOI 10.1002/JMRI.10262##BASSO C, 2000, HUM PATHOL, V31, P988, DOI 10.1053/HUPA.2000.16659##BOTTINI PB, 1995, AM J HYPERTENS, V8, P221, DOI 10.1016/0895-7061(94)00178-E##GEISTERFERLOWRANCE AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/SCIENCE.272.5262.731##JONGBLOED RJ, 2003, J AM COLL CARDIOL, V41, P981, DOI 10.1016/S0735-1097(02)03005-X##KIM RJ, 1999, CIRCULATION, V100, P1992, DOI 10.1161/01.CIR.100.19.1992##MARCUS JT, 1999, J CARDIOV MAGN RESON, V1, P1, DOI 10.3109/10976649909080828##MARIAN AJ, 2003, CIRCULATION, V107, P2171, DOI 10.1161/01.CIR.0000068686.12195.C2##MARON BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/JAMA.287.10.1308##MOON JC, 2005, HEART, V91, P1036, DOI 10.1136/HRT.2004.041384##MOON JCC, 2004, J AM COLL CARDIOL, V43, P2260, DOI 10.1016/J.JACC.2004.03.035##MOON JCC, 2003, J AM COLL CARDIOL, V41, P1561, DOI 10.1016/S0735-1097(03)00189-X##NAGUEH SF, 2003, CIRCULATION, V108, P395, DOI 10.1161/01.CIR.0000084500.72232.8D##RICKERS C, 2005, CIRCULATION, V112, P855, DOI 10.1161/CIRCULATIONAHA.104.507723##ROMHILT DW, 1969, CIRCULATION, V40, P185, DOI 10.1161/01.CIR.40.2.185##SHIRANI J, 2000, J AM COLL CARDIOL, V35, P36, DOI 10.1016/S0735-1097(99)00492-1##SPIRITO P, 2000, NEW ENGL J MED, V342, P1778, DOI 10.1056/NEJM200006153422403##SUTTON MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981##TERAOKA K, 2004, MAGN RESON IMAGING, V22, P155, DOI 10.1016/J.MRI.2003.08.009##USYK TP, 2001, AM J PHYSIOL-HEART C, V281, PH506",115,2020-11-20,NA
J,WOS:000242771200018,2006,ON THE BINDING OF CALCIUM BY MICELLES COMPOSED OF CARBOXY-MODIFIED PLURONICS MEASURED BY MEANS OF DIFFERENTIAL POTENTIOMETRIC TITRATION AND MODELED WITH A SELF-CONSISTENT-FIELD THEORY,"WE PERFORM DIFFERENTIAL POTENTIOMETRIC TITRATION MEASUREMENTS FOR THE BINDING OF CA2+ IONS TO MICELLES COMPOSED OF THE CARBOXYLIC ACID END-STANDING PLURONIC P85 BLOCK COPOLYMER (I.E., CAE-85 (COOH-(EO)(26)-(PO)(39)-(EO)(26)-COOH)). TWO DIFFERENT ION-SELECTIVE ELECTRODES (ISES) ARE USED TO DETECT THE FREE CALCIUM CONCENTRATION; THE FIRST ISE IS AN INDICATOR ELECTRODE, AND THE SECOND IS A REFERENCE ELECTRODE. THE TITRATION IS DONE BY ADDING THE BLOCK COPOLYMERS TO A KNOWN SOLUTION OF CA2+ AT NEUTRAL PH AND HIGH ENOUGH TEMPERATURE (ABOVE THE CRITICAL MICELLIZATION TEMPERATURE CMT) AND VARIOUS AMOUNT OF ADDED MONOVALENT SALT. BY MEASURING THE DIFFERENCE IN THE ELECTROMOTIVE FORCE BETWEEN THE TWO ISES, THE AMOUNT OF CA2+ THAT IS BOUND BY THE MICELLES IS CALCULATED. THIS IS THEN USED TO DETERMINE THE BINDING CONSTANT OF CA2+ WITH THE MICELLES, WHICH IS A MISSING PARAMETER NEEDED TO PERFORM MOLECULAR REALISTIC SELF-CONSISTENT-FIELD (SCF) CALCULATIONS. IT TURNS OUT THAT THE MICELLES FROM BLOCK COPOLYMER CAE-85 BIND CA2+ IONS BOTH ELECTROSTATICALLY AND SPECIFICALLY. THE SPECIFIC BINDING BETWEEN CA2+ AND CARBOXYLIC GROUPS IN THE CORONA OF THE MICELLES IS MODELED THROUGH THE REACTION EQUILIBRIUM -COOCA+ REVERSIBLE ARROW -COO- + CA2+ WITH PK(CA) = 1.7 +/- 0.06.",BLOCK-COPOLYMER MICELLES; INTERACTING CHAIN MOLECULES; OXIDE) TRIBLOCK COPOLYMERS; STATISTICAL-THEORY; AQUEOUS-SOLUTIONS; ION-EXCHANGE; ADSORPTION; MICELLIZATION; SURFACTANTS; TEMPERATURE,NA,LANGMUIR,"LAUW, Y##LEERMAKERS, FAM##STUART, MAC","WAGENINGEN UNIV, LAB PHYS CHEM & COLLOID SCI, NL-6700 EK WAGENINGEN, NETHERLANDS. UNIV ALGARVE, DEPT CHEM & BIOCHEM, P-8005139 FARO, PORTUGAL. EINDHOVEN UNIV TECHNOL, PROC DEV GRP, NL-5600 MB EINDHOVEN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CHEMISTRY, PHYSICAL; MATERIALS SCIENCE, MULTIDISCIPLINARY",CHEMISTRY; MATERIALS SCIENCE,"ALEXANDRIDIS P, 1995, COLLOID SURFACE A, V96, P1, DOI 10.1016/0927-7757(94)03028-X##BJORLING M, 1990, J PHYS CHEM-US, V94, P471##BOHMER MR, 1990, MACROMOLECULES, V23, P2288, DOI 10.1021/MA00210A027##BOHMER MR, 1992, LANGMUIR, V8, P1594, DOI 10.1021/LA00042A017##CHRISTENSEN T, 2003, J AM CHEM SOC, V125, P7357, DOI 10.1021/JA021240C##CUSTERS JPA, 2005, J AM CHEM SOC, V127, P1594, DOI 10.1021/JA0432362##DE BRUIJN VG, 2002, LANGMUIR, V18, P10467, DOI 10.1021/LA0206312##GERSTNER JA, 1994, BIOPHYS CHEM, V52, P97, DOI 10.1016/0301-4622(94)00006-9##GIBBS J.W., 1993, SCI PAPERS JW GIBBS, V1##GOLDMINTS I, 1999, LANGMUIR, V15, P1651, DOI 10.1021/LA9807006##HALL DG, 1967, NONIONIC SURFACTANTS, PCH16##HENDRIX T, 2000, BIOPHYS CHEM, V84, P27, DOI 10.1016/S0301-4622(99)00140-4##HILL T.L., 1994, THERMODYNAMICS SMA 1##HILL T.L., 1994, THERMODYNAMICS SMA 2##HUANG K, 2002, BIOMACROMOLECULES, V3, P397, DOI 10.1021/BM015650P##HURTER PN, 1993, MACROMOLECULES, V26, P5592, DOI 10.1021/MA00073A010##ISRAELS R, 1994, MACROMOLECULES, V27, P3087, DOI 10.1021/MA00089A028##KINOSIAN HJ, 1998, BIOPHYS J, V75, P3101, DOI 10.1016/S0006-3495(98)77751-3##LAU BK, 2004, J POLYM SCI POL PHYS, V42, P2014, DOI 10.1002/POLB.20105##LAUW Y, 2006, J PHYS CHEM B, V110, P465, DOI 10.1021/JP053795A##LEEMAKERS FAM, 2005, FUNDAMENTALS INTERFA, V5, PCH4##LI JT, 1996, BIOCONJUGATE CHEM, V7, P592, DOI 10.1021/BC960048V##MALOVIKOVA A, 1994, BIOPOLYMERS, V34, P1059, DOI 10.1002/BIP.360340809##MARCUS Y, 1988, CHEM REV, V88, P1475, DOI 10.1021/CR00090A003##MARCUS Y, 1985, ION SOLVATION##MORTENSEN K, 1993, MACROMOLECULES, V26, P805, DOI 10.1021/MA00056A035##POCHARD I, 1999, COLLOID POLYM SCI, V277, P818, DOI 10.1007/S003960050458##SCHEUTJENS JMHM, 1980, J PHYS CHEM-US, V84, P178, DOI 10.1021/J100439A011##SCHEUTJENS JMHM, 1979, J PHYS CHEM-US, V83, P1619, DOI 10.1021/J100475A012##SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551##SINN CG, 2004, MACROMOLECULES, V37, P3444, DOI 10.1021/MA030550S##SU YL, 2002, LANGMUIR, V18, P5370, DOI 10.1021/LA020007P##TACKETT SL, 1969, ANAL CHEM, V41, P1703, DOI 10.1021/AC60281A026##TAMURA T, 1998, POLYM INT, V46, P353, DOI 10.1002/(SICI)1097-0126(199808)46:4<353::AID-PI38>3.0.CO;2-6##TANFORD C., 1973, HYDROPHOBIC EFFECT F##*THERM EL CORP, 2003, CALC EL INSTR MAN OR",6,2020-11-20,NA
J,WOS:000243166600031,2006,ATMOSPHERIC NITROGEN DEPOSITION PROMOTES CARBON LOSS FROM PEAT BOGS,"PEAT BOGS HAVE HISTORICALLY REPRESENTED EXCEPTIONAL CARBON (C) SINKS BECAUSE OF THEIR EXTREMELY LOW DECOMPOSITION RATES AND CONSEQUENT ACCUMULATION OF PLANT REMNANTS AS PEAT. AMONG THE FACTORS FAVORING THAT PEAT ACCUMULATION, A MAJOR ROLE IS PLAYED BY THE CHEMICAL QUALITY OF PLANT LITTER ITSELF, WHICH IS POOR IN NUTRIENTS AND CHARACTERIZED BY POLYPHENOLS WITH A STRONG INHIBITORY EFFECT ON MICROBIAL BREAKDOWN. BECAUSE BOGS RECEIVE THEIR NUTRIENT SUPPLY SOLELY FROM ATMOSPHERIC DEPOSITION, THE GLOBAL INCREASE OF ATMOSPHERIC NITROGEN (N) INPUTS AS A CONSEQUENCE OF HUMAN ACTIVITIES COULD POTENTIALLY ALTER THE LITTER CHEMISTRY WITH IMPORTANT, BUT STILL UNKNOWN, EFFECTS ON THEIR C BALANCE. HERE WE PRESENT DATA SHOWING THE DECOMPOSITION RATES OF RECENTLY FORMED LITTER PEAT SAMPLES COLLECTED IN NINE EUROPEAN COUNTRIES UNDER A NATURAL GRADIENT OF ATMOSPHERIC N DEPOSITION FROM APPROXIMATE TO 0.2 TO 2 G CENTER DOT M(-2)CENTER DOT YR(-1). WE FOUND THAT ENHANCED DECOMPOSITION RATES FOR MATERIAL ACCUMULATED UNDER HIGHER ATMOSPHERIC N SUPPLIES RESULTED IN HIGHER CARBON DIOXIDE (CO2) EMISSIONS AND DISSOLVED ORGANIC CARBON RELEASE. THE INCREASED IN AVAILABILITY FAVORED MICROBIAL DECOMPOSITION (I) BY REMOVING N CONSTRAINTS ON MICROBIAL METABOLISM AND (II) THROUGH A CHEMICAL AMELIORATION OF LITTER PEAT QUALITY WITH A POSITIVE FEEDBACK ON MICROBIAL ENZYMATIC ACTIVITY. ALTHOUGH SOME UNCERTAINTY REMAINS ABOUT WHETHER DECAY-RESISTANT SPHAGNUM WILL CONTINUE TO DOMINATE LITTER PEAT, OUR DATA INDICATE THAT, EVEN WITHOUT SUCH CHANGES, INCREASED N DEPOSITION POSES A SERIOUS RISK TO OUR VALUABLE PEATLAND C SINKS.",N DEPOSITION; SOIL CARBON; NUTRITIONAL CONSTRAINTS; OMBROTROPHIC BOGS; LITTER QUALITY; ORGANIC-MATTER; CLIMATE-CHANGE; SPHAGNUM; DECOMPOSITION; PEATLANDS,DECOMPOSITION; GLOBAL CHANGE; LITTER PEAT; CO2,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,"BRAGAZZA, L##FREEMAN, C##JONES, T##RYDIN, H##LIMPENS, J##FENNER, N##ELLIS, T##GERDOL, R##HAJEK, M##HAJEK, T##LACUMIN, P##KUTNAR, L##TAHVANAINEN, T##TOBERMAN, H","UNIV FERRARA, DEPT BIOL & EVOLUT, I-44100 FERRARA, ITALY. UNIV WALES, SCH BIOL SCI, BANGOR LL57 2UW, GWYNEDD, WALES. UPPSALA UNIV, EVOLUTIONARY BIOL CTR, DEPT PLANT ECOL, SE-75236 UPPSALA, SWEDEN. UNIV WAGENINGEN & RES CTR, NAT CONSERVAT & PLANT ECOL GRP, NL-6708 PD WAGENINGEN, NETHERLANDS. MASARYK UNIV, FAC SCI, INST BOT & ZOOL, CZ-61137 BRNO, CZECH REPUBLIC. ACAD SCI CZECH REPUBL, INST BOT, DEPT ECOL, CZ-60300 BRNO, CZECH REPUBLIC. ACAD SCI CZECH REPUBL, INST BOT, CZ-37982 TREBON, CZECH REPUBLIC. UNIV S BOHEMIA, FAC BIOL SCI, CZ-37005 CESKE BUDEJOVICE, CZECH REPUBLIC. UNIV PARMA, DEPT EARTH SCI, I-43100 PARMA, ITALY. SLOVENIAN FORESTRY INST, DEPT FOREST ECOL, SI-1000 LJUBLJANA, SLOVENIA. UNIV JOENSUU, DEPT BIOL, FIN-80101 JOENSUU, FINLAND.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"AERTS R, 2001, J ECOL, V89, P292, DOI 10.1046/J.1365-2745.2001.00539.X##ALLISON SD, 2005, SOIL BIOL BIOCHEM, V37, P937, DOI 10.1016/J.SOILBIO.2004.09.014##ANDERSSON S, 2000, SOIL BIOL BIOCHEM, V32, P1, DOI 10.1016/S0038-0717(99)00103-0##BERENDSE F, 2001, GLOBAL CHANGE BIOL, V7, P591, DOI 10.1046/J.1365-2486.2001.00433.X##BRAGAZZA L, 2005, GLOBAL CHANGE BIOL, V11, P106, DOI 10.1111/J.1365-2486.2004.00886.X##BRAGAZZA L, 2004, NEW PHYTOL, V163, P609, DOI 10.1111/J.1469-8137.2004.01154.X##BRIDGHAM SD, 2003, BIOGEOCHEMISTRY, V65, P151, DOI 10.1023/A:1026026212581##DIJKSTRA FA, 2004, ECOL LETT, V7, P1192, DOI 10.1111/J.1461-0248.2004.00679.X##DORREPAAL E, 2005, J ECOL, V93, P817, DOI 10.1111/J.1365-2745.2005.01024.X##FENNER N, 2005, SOIL BIOL BIOCHEM, V37, P1814, DOI 10.1016/J.SOILBIO.2005.02.032##FREEMAN C, 2004, SOIL BIOL BIOCHEM, V36, P1663, DOI 10.1016/J.SOILBIO.2004.07.012##FREEMAN C, 2001, NATURE, V409, P149, DOI 10.1038/35051650##GALLO ME, 2005, GLOBAL CHANGE BIOL, V11, P1514, DOI 10.1111/J.1365-2486.2005.01001.X##GALLOWAY JN, 2004, BIOGEOCHEMISTRY, V70, P153, DOI 10.1007/S10533-004-0370-0##GUNNARSSON U, 2000, NEW PHYTOL, V147, P527, DOI 10.1046/J.1469-8137.2000.00717.X##HENRY HAL, 2005, GLOBAL CHANGE BIOL, V11, P1808, DOI 10.1111/J.1365-2486.2005.001007.X##HU S, 2001, NATURE, V409, P188, DOI 10.1038/35051576##JANDL R, 1997, BIOL FERT SOILS, V25, P196, DOI 10.1007/S003740050303##JONES CG, 1999, OIKOS, V86, P27, DOI 10.2307/3546567##KNORR M, 2005, ECOLOGY, V86, P3252, DOI 10.1890/05-0150##LIMPENS J, 2003, NEW PHYTOL, V157, P339, DOI 10.1046/J.1469-8137.2003.00667.X##LIMPENS J, 2003, OIKOS, V103, P537, DOI 10.1034/J.1600-0706.2003.12707.X##MACK MC, 2004, NATURE, V431, P440, DOI 10.1038/NATURE02887##MALMER N, 1988, OIKOS, V53, P105, DOI 10.2307/3565670##MOORE PD, 2002, ENVIRON CONSERV, V29, P3, DOI 10.1017/S0376892902000024##MOORE T, 2005, GLOBAL CHANGE BIOL, V11, P356, DOI 10.1111/J.1365-2486.2004.00882.X##NEFF JC, 2002, NATURE, V419, P915, DOI 10.1038/NATURE01136##OLANDER LP, 2000, BIOGEOCHEMISTRY, V49, P175, DOI 10.1023/A:1006316117817##OSBURN CL, 2001, BIOGEOCHEMISTRY, V54, P251, DOI 10.1023/A:1010657428418##PAINTER TJ, 1991, CARBOHYD POLYM, V15, P123, DOI 10.1016/0144-8617(91)90028-B##RUDOLPH H, 1985, PHYTOCHEMISTRY, V24, P745, DOI 10.1016/S0031-9422(00)84888-8##SCHOLES RJ, 2001, SCIENCE, V294, P1012, DOI 10.1126/SCIENCE.1065307##SINSABAUGH RL, 1994, BIOL FERT SOILS, V17, P69, DOI 10.1007/BF00418675##SINSABAUGH RL, 2002, BIOGEOCHEMISTRY, V60, P1, DOI 10.1023/A:1016541114786##SMITH LC, 2004, SCIENCE, V303, P353, DOI 10.1126/SCIENCE.1090553##TURNER BL, 2002, ENVIRON POLLUT, V120, P313, DOI 10.1016/S0269-7491(02)00147-1##TURUNEN J, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002154##VANBREEMEN N, 1995, TRENDS ECOL EVOL, V10, P270, DOI 10.1016/0169-5347(95)90007-1##VERHOEVEN JTA, 1997, ACTA BOT NEERL, V46, P117##VITT DH, 2003, BRYOLOGIST, V106, P235, DOI 10.1639/0007-2745(2003)106[0235:ROSFTN]2.0.CO;2##WALDROP MP, 2004, ECOL APPL, V14, P1172, DOI 10.1890/03-5120",308,2020-11-20,NA
J,WOS:000243415200016,2006,NONCRITICAL PHASE-MATCHED LITHIUM TRIBORATE OPTICAL PARAMETRIC OSCILLATOR FOR HIGH RESOLUTION COHERENT ANTI-STOKES RAMAN SCATTERING SPECTROSCOPY AND MICROSCOPY,"AN EFFICIENT, WIDELY TUNABLE, NARROW-BANDWIDTH, GREEN-PUMPED, NONCRITICAL PHASE-MATCHED LITHIUM TRIBORATE BASED OPTICAL PARAMETRIC OSCILLATOR (OPO) IS APPLIED TO COHERENT ANTI-STOKES RAMAN SCATTERING (CARS) SPECTROSCOPY AND MICROSCOPY. THE TUNABLE SIGNAL BEAM (740-930 NM) OF THE OPO IS COMBINED WITH THE FUNDAMENTAL OF A ND:YVO(4) PUMP LASER (1064 NM, 15 PS) TO OBTAIN HIGH RESOLUTION VIBRATIONAL SPECTRA OF MOLECULES AROUND THE CH VIBRATIONAL STRETCH (2700-3100 CM(-1)). THE STRAIGHTFORWARD AND CONVENIENT TUNABILITY OF THE OPO IS DEMONSTRATED BY CARS MICROSCOPY FOR THE IDENTIFICATION OF DIFFERENT POLYMER MICROPARTICLES ON THE SAME SUBSTRATE. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",LIGHT-SOURCE,NA,APPLIED PHYSICS LETTERS,"JURNA, M##KORTERIK, JP##OFFERHAUS, HL##OTTO, C","UNIV TWENTE, OPT TECH GRP, NL-7500 AE ENSCHEDE, OVERIJSSEL, NETHERLANDS. UNIV TWENTE, DEPT SCI & TECHNOL, MESA INST NANOTECHNOL, NL-7500 AE ENSCHEDE, OVERIJSSEL, NETHERLANDS. UNIV TWENTE, BIOPHYS ENGN GRP, NL-7500 AE ENSCHEDE, OVERIJSSEL, NETHERLANDS.","PHYSICS, APPLIED",PHYSICS,"AKHMANOV S. A., 1974, JOURNAL OF RAMAN SPECTROSCOPY, V2, P239, DOI 10.1002/JRS.1250020303##BETZIG E, 2006, SCIENCE, V313, P1642, DOI 10.1126/SCIENCE.1127344##CHENG JX, 2004, J PHYS CHEM B, V108, P827, DOI 10.1021/JP035693V##CHENG JX, 2002, J OPT SOC AM B, V19, P1363, DOI 10.1364/JOSAB.19.001363##CHENG JX, 2001, OPT LETT, V26, P1341, DOI 10.1364/OL.26.001341##GANIKHANOV F, 2006, OPT LETT, V31, P1292, DOI 10.1364/OL.31.001292##KANO H, 2006, OPT EXPRESS, V14, P2798, DOI 10.1364/OE.14.002798##NAVRATIL M, 2006, ANAL CHEM, V78, P4005, DOI 10.1021/AC0606756##PETROV GI, 2005, OPT EXPRESS, V13, P1299, DOI 10.1364/OPEX.13.001299##POTMA EO, 2006, OPT LETT, V31, P241, DOI 10.1364/OL.31.000241##POTMA EO, 2002, OPT LETT, V27, P1168, DOI 10.1364/OL.27.001168##TUKKER TW, 1998, J OPT SOC AM B, V15, P2455, DOI 10.1364/JOSAB.15.002455##TUKKER TW, 1998, OPT COMMUN, V154, P83, DOI 10.1016/S0030-4018(98)00315-0##VAN MANEN HJ, 2005, P NATL ACAD SCI USA, V102, P10159, DOI 10.1073/PNAS.0502746102##VOROSHILOV A, 1996, APPL SPECTROSC, V50, P78, DOI 10.1366/0003702963906690##XIE XS, 2006, UNPUB CARS WORKSH XI",45,2020-11-20,NA
J,WOS:000242746200008,2006,"HISTAMINE, A VASOACTIVE AGENT WITH VASCULAR DISRUPTING POTENTIAL, IMPROVES TUMOUR RESPONSE BY ENHANCING LOCAL DRUG DELIVERY","TUMOUR NECROSIS FACTOR (TNF)-BASED ISOLATED LIMB PERFUSION (ILP) IS AN APPROVED AND REGISTERED TREATMENT FOR SARCOMAS CONFINED TO THE LIMBS IN EUROPE SINCE 1998, WITH LIMB SALVAGE INDEXES OF 76%. TNF IMPROVES DRUG DISTRIBUTION IN SOLID TUMOURS AND SECONDARILY DESTROYS THE TUMOUR-ASSOCIATED VASCULATURE (TAV). HERE WE EXPLORE THE SYNERGISTIC ANTITUMOUR EFFECT OF ANOTHER VASOACTIVE AGENT, HISTAMINE ( HI), IN DOXORUBICIN (DXR)-BASED ILP AND EVALUATE ITS ANTIVASCULAR EFFECTS ON TAV. WE USED OUR WELL-ESTABLISHED RAT ILP MODEL FOR IN VIVO STUDIES LOOKING AT TUMOUR RESPONSE, DRUG DISTRIBUTION AND EFFECTS ON TUMOUR VESSELS. IN VITRO STUDIES EXPLORED DRUG INTERACTIONS AT CELLULAR LEVEL ON TUMOUR CELLS (BN-175) AND HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS ( HUVEC). THERE WAS A 17% PARTIAL RESPONSE AND A 50% ARREST IN TUMOUR GROWTH WHEN HI WAS COMBINED TO DXR, WITHOUT IMPORTANT SIDE EFFECTS, AGAINST 100% PROGRESSIVE DISEASE WITH DXR ALONE AND 29% ARREST IN TUMOUR GROWTH FOR HI ALONE. HISTOLOGY DOCUMENTED AN INCREASED DXR LEAKAGE IN TUMOUR TISSUE COMBINED TO A DESTRUCTION OF THE TAV, WHEN HI WAS ADDED TO THE ILP. IN VITRO NO SYNERGY BETWEEN THE DRUGS WAS OBSERVED. IN CONCLUSION, HI IS A VASOACTIVE DRUG, TARGETING PRIMARILY THE TAV AND SYNERGISES WITH DIFFERENT CHEMOTHERAPEUTIC AGENTS.",ISOLATED LIMB PERFUSION; NECROSIS-FACTOR-ALPHA; SOFT-TISSUE SARCOMAS; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; MELPHALAN; COMBINATION; DOXORUBICIN; MODEL,REGIONAL TREATMENT; HISTAMINE; DOXORUBICIN; TAV; SOFT-TISSUE SARCOMAS,BRITISH JOURNAL OF CANCER,"BRUNSTEIN, F##RENS, J##VAN TIEL, ST##EGGERMONT, AMM##TEN HAGEN, TLM","DR DANIEL DEN HOED CANC CTR, LAB EXPT SURG ONCOL, ERASMUS MC, DEPT SURG ONCOL, NL-3000 DR ROTTERDAM, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"BANCROFT J.D., 1984, MANUAL HISTOLOGICAL##BICKELS J, 1999, EUR J SURG ONCOL, V25, P509, DOI 10.1053/EJSO.1999.0687##BRUNSTEIN F, 2004, JNCI-J NATL CANCER I, V96, P1603, DOI 10.1093/JNCI/DJH300##CARSON MR, 1989, AM J PHYSIOL, V257, PL259##DE WILT JHW, 2000, BRIT J CANCER, V82, P1000, DOI 10.1054/BJOC.1999.1032##DE WILT JHW, 1999, BRIT J CANCER, V80, P161, DOI 10.1038/SJ.BJC.6990335##DENEKAMP J, 1984, ACTA RADIOL ONCOL, V23, P217, DOI 10.3109/02841868409136015##EGGERMONT AMM, 1996, ANN SURG, V224, P756, DOI 10.1097/00000658-199612000-00011##EGGERMONT AMM, 1996, J CLIN ONCOL, V14, P2653, DOI 10.1200/JCO.1996.14.10.2653##EGGERMONT AMM, 2003, LANCET ONCOL, V4, P429, DOI 10.1016/S1470-2045(03)01141-0##HOVING S, 2005, CANCER RES, V65, P4300, DOI 10.1158/0008-5472.CAN-04-2214##HOVING S, 2006, ANTI-CANCER DRUG, V17, P949, DOI 10.1097/01.CAD.0000224450.54447.B3##KORT WJ, 1984, J NATL CANCER I, V72, P709##LIENARD D, 1992, WORLD J SURG, V16, P234, DOI 10.1007/BF02071526##NOOIJEN PTGA, 1996, BRIT J CANCER, V74, P1908, DOI 10.1038/BJC.1996.652##O'BYRNE K, 1999, ONCOLOGY-BASEL, V56, P13, DOI 10.1159/000011924##OLIEMAN AFT, 1999, ARCH SURG-CHICAGO, V134, P303, DOI 10.1001/ARCHSURG.134.3.303##PRIMEAU AJ, 2005, CLIN CANCER RES, V11, P8782, DOI 10.1158/1078-0432.CCR-05-1664##RESINK TJ, 1987, BIOCHEM BIOPH RES CO, V144, P438, DOI 10.1016/S0006-291X(87)80529-6##REVTYAK GE, 1992, BIOCHIM BIOPHYS ACTA, V1123, P216, DOI 10.1016/0005-2760(92)90114-B##ROSSI CR, 2005, ANN SURG ONCOL, V12, P398, DOI 10.1245/ASO.2005.12.038##ROSSI CR, 1999, CANCER, V86, P1742, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1742::AID-CNCR16>3.0.CO;2-G##SANTORO A, 1995, J CLIN ONCOL, V13, P1537, DOI 10.1200/JCO.1995.13.7.1537##SEYNHAEVE ALB, 2006, CELL BIOCHEM BIOPHYS, V44, P157, DOI 10.1385/CBB:44:1:157##SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/JNCI/82.13.1107##TAKEMOTO M, 2003, INT J HYPERTHER, V19, P193, DOI 10.1080/0265673021000035235##THOMPSON JF, 1998, SEMIN SURG ONCOL, V14, P238##VANDEWIEL PA, 1992, IMMUNOPHARMACOLOGY, V23, P49, DOI 10.1016/0162-3109(92)90008-Z##WANG LX, 1990, J LIPID RES, V31, P2265##WU NZ, 1992, MICROVASC RES, V44, P334, DOI 10.1016/0026-2862(92)90092-4",16,2020-11-20,NA
J,WOS:000242746200010,2006,VERY LOW PREVALENCE OF GERMLINE MSH6 MUTATIONS IN HEREDITARY NON-POLYPOSIS COLORECTAL CANCER SUSPECTED PATIENTS WITH COLORECTAL CANCER WITHOUT MICROSATELLITE INSTABILITY,"HEREDITARY NON-POLYPOSIS COLORECTAL CANCER (HNPCC) IS CAUSED BY MUTATIONS IN ONE OF THE MISMATCH REPAIR GENES MLH1, MSH2, MSH6, OR PMS2 AND RESULTS IN HIGH-LEVEL MICROSATELLITE INSTABILITY (MSI-HIGH) IN TUMOURS OF HNPCC PATIENTS. THE MSI TEST IS CONSIDERED RELIABLE FOR INDICATING MUTATIONS IN MLH1 AND MSH2, BUT IS QUESTIONED FOR MSH6. GERMLINE MUTATION ANALYSIS WAS PERFORMED IN 19 PATIENTS WITH AN MSI-HIGH TUMOUR AND ABSENCE OF MSH2 AND/OR MSH6 PROTEIN AS DETERMINED BY IMMUNOHISTOCHEMISTRY (IHC), WITHOUT AN MLH1 OR MSH2 MUTATION, AND IN 76 OUT OF 295 PATIENTS SUSPECTED OF HNPCC, WITH A NON-MSI-HIGH COLORECTAL CANCER (CRC). ALL 295 NON-MSI-HIGH CRCS WERE ANALYSED FOR PRESENCE OF MSH6 PROTEIN BY IHC. IN 10 PATIENTS WITH AN MSI-HIGH TUMOUR WITHOUT MSH2 AND/ OR MSH6 EXPRESSION, A PATHOGENIC MSH6 MUTATION WAS DETECTED, WHEREAS NO PATHOGENIC MSH6 MUTATION WAS DETECTED IN 76 PATIENTS WITH A NON-MSI-HIGH CRC AND NORMAL MSH6 PROTEIN EXPRESSION. IN NONE OF THE 295 CRCS LOSS OF MSH6 PROTEIN EXPRESSION WAS DETECTED. THE PREVALENCE OF A GERMLINE MSH6 MUTATION IS VERY LOW IN HNPCC SUSPECTED PATIENTS WITH NON-MSI-HIGH CRC. MICROSATELLITE INSTABILITY ANALYSIS IN CRCS IS HIGHLY SENSITIVE TO SELECT PATIENTS FOR MSH6 GERMLINE MUTATION ANALYSIS.",LYNCH-SYNDROME; BETHESDA GUIDELINES; FAMILY-HISTORY; CARRIERS; ONSET; DISEASE; RISK,MSI; HNPCC; HEREDITARY CANCER; MSH6,BRITISH JOURNAL OF CANCER,"KETS, CM##VAN KRIEKEN, JHJM##HEBEDA, KM##WEZENBERG, SJ##GOOSSENS, M##BRUNNER, HG##LIGTENBERG, MJL##HOOGERBRUGGE, N","RADBOUD UNIV NIJMEGEN MED CTR, DEPT HUMAN GENET, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, DEPT PATHOL, NL-6500 HB NIJMEGEN, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"BARNETSON RA, 2006, NEW ENGL J MED, V354, P2751, DOI 10.1056/NEJMOA053493##BERENDS MJW, 2002, AM J HUM GENET, V70, P26, DOI 10.1086/337944##BOLAND CR, 1998, CANCER RES, V58, P5248##HAMPEL H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMOA043146##HENDRIKS YMC, 2004, GASTROENTEROLOGY, V127, P17, DOI 10.1053/J.GASTRO.2004.03.068##HOOGERBRUGGE N, 2003, CLIN GENET, V63, P64, DOI 10.1034/J.1399-0004.2003.630110.X##KOLODNER RD, 1999, CANCER RES, V59, P5068##LYNCH HT, 2005, NEW ENGL J MED, V352, P1920, DOI 10.1056/NEJME058058##NIESSEN RC, 2006, GUT       0424, DOI DOI 10.1136/GUT.2005.090159##PARC YR, 2000, CANCER RES, V60, P2225##PINTO C, 2006, BRIT J CANCER, V95, P752, DOI 10.1038/SJ.BJC.6603318##PLASCHKE J, 2004, J CLIN ONCOL, V22, P4486, DOI 10.1200/JCO.2004.02.033##RODRIGUEZBIGAS MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/JNCI/89.23.1758##UMAR A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/JNCI/DJH034##VERMA L, 1999, J MED GENET, V36, P678##WIJNEN J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773##WU Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612",11,2020-11-20,NA
J,WOS:000243099800017,2006,NEURAL CREST-DERIVED CELLS WITH STEM CELL FEATURES CAN BE TRACED BACK TO MULTIPLE LINEAGES IN THE ADULT SKIN,"GIVEN THEIR ACCESSIBILITY, MULTIPOTENT SKIN-DERIVED CELLS MIGHT BE USEFUL FOR FUTURE CELL REPLACEMENT THERAPIES. WE DESCRIBE THE ISOLATION OF MULTIPOTENT STEM CELL-LIKE CELLS FROM THE ADULT TRUNK SKIN OF MICE AND HUMANS THAT EXPRESS THE NEURAL CREST STEM CELL MARKERS P75 AND SOX10 AND DISPLAY EXTENSIVE SELF-RENEWAL CAPACITY IN SPHERE CULTURES. TO DETERMINE THE ORIGIN OF THESE CELLS, WE GENETICALLY MAPPED THE FATE OF NEURAL CREST CELLS IN FACE AND TRUNK SKIN OF MOUSE. IN WHISKER FOLLICLES OF THE FACE, MANY MESENCHYMAL STRUCTURES ARE NEURAL CREST DERIVED AND APPEAR TO CONTAIN CELLS WITH SPHERE-FORMING POTENTIAL. IN THE TRUNK SKIN, HOWEVER, SPHERE-FORMING NEURAL CREST-DERIVED CELLS ARE RESTRICTED TO THE GLIAL AND MELANOCYTE LINEAGES. THUS, SELF-RENEWING CELLS IN THE ADULT SKIN CAN BE OBTAINED FROM SEVERAL NEURAL CREST DERIVATIVES, AND THESE ARE OF DISTINCT NATURE IN FACE AND TRUNK SKIN. THESE FINDINGS ARE RELEVANT FOR THE DESIGN OF THERAPEUTIC STRATEGIES BECAUSE THE POTENTIAL OF STEM AND PROGENITOR CELLS IN VIVO LIKELY DEPENDS ON THEIR NATURE AND ORIGIN.",TRANSCRIPTION FACTOR SOX10; PERIPHERAL NERVOUS-SYSTEM; HAIR-FOLLICLE; SELF-RENEWAL; PROGENITOR CELLS; IN-VIVO; FUNCTIONAL-INTEGRATION; NESTIN EXPRESSION; PRECURSOR CELLS; NEURONS,NA,JOURNAL OF CELL BIOLOGY,"WONG, CE##PARATORE, C##DOURS-ZIMMERMANN, MT##ROCHAT, A##PIETRI, T##SUTER, U##ZIMMERMANN, DR##DUFOUR, S##THIERY, JP##MEIJER, D##BEERMANN, F##BARRANDON, Y##SOMMER, L","ETH, SWISS FED INST TECHNOL, DEPT BIOL, INST CELL BIOL, CH-8093 ZURICH, SWITZERLAND. UNIV ZURICH HOSP, DEPT PATHOL, MOL BIOL LAB, CH-8091 ZURICH, SWITZERLAND. ECOLE POLYTECH FED LAUSANNE, LAB STEM CELL DYNAM, SCH LIFE SCI, CH-1015 LAUSANNE, SWITZERLAND. UNIV LAUSANNE HOSP, CH-1015 LAUSANNE, SWITZERLAND. INST CURIE, CNRS, UMR144, F-75248 PARIS 05, FRANCE. ERASMUS UNIV, MED CTR, DEPT CELL BIOL & GENET, NL-3000 DR ROTTERDAM, NETHERLANDS. SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND.",CELL BIOLOGY,CELL BIOLOGY,"ALONSO L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/PNAS.1734203100##AMOH Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/PNAS.0501263102##BELICCHI M, 2004, J NEUROSCI RES, V77, P475, DOI 10.1002/JNR.20151##BENNINGER F, 2003, J NEUROSCI, V23, P7075, DOI 10.1523/JNEUROSCI.23-18-07075.2003##BIXBY S, 2002, NEURON, V35, P643, DOI 10.1016/S0896-6273(02)00825-5##BJORKLUND LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/PNAS.022438099##BLANPAIN C, 2004, CELL, V118, P635, DOI 10.1016/J.CELL.2004.08.012##BOTCHKAREV VA, 1997, J COMP NEUROL, V386, P379, DOI 10.1002/(SICI)1096-9861(19970929)386:3<379::AID-CNE4>3.0.CO;2-Z##BOTCHKAREVA NV, 1999, DEV BIOL, V216, P135, DOI 10.1006/DBIO.1999.9464##BRAULT V, 2001, DEVELOPMENT, V128, P1253##BRITSCH S, 2001, GENE DEV, V15, P66, DOI 10.1101/GAD.186601##BRUSTLE O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/PNAS.94.26.14809##CLAUDINOT S, 2005, P NATL ACAD SCI USA, V102, P14677, DOI 10.1073/PNAS.0507250102##DUPIN E, 2000, P NATL ACAD SCI USA, V97, P7882, DOI 10.1073/PNAS.97.14.7882##DUTT S, 2006, J BIOL CHEM, V281, P12123, DOI 10.1074/JBC.M510834200##DYCE PW, 2004, BIOCHEM BIOPH RES CO, V316, P651, DOI 10.1016/J.BBRC.2004.02.093##FERNANDES KJL, 2006, EXP NEUROL, V201, P32, DOI 10.1016/J.EXPNEUROL.2006.03.018##FERNANDES KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/NCB1181##GAMBARDELLA L, 2003, CURR OPIN CELL BIOL, V15, P771, DOI 10.1016/J.CEB.2003.10.011##GUYONNEAU L, 2002, PIGM CELL RES, V15, P305, DOI 10.1034/J.1600-0749.2002.02039.X##HAGEDORN L, 1999, DEVELOPMENT, V126, P3781##JAEGLE M, 2003, GENE DEV, V17, P1380, DOI 10.1101/GAD.258203##JIANG XB, 2000, DEVELOPMENT, V127, P1607##JOANNIDES A, 2004, LANCET, V364, P172, DOI 10.1016/S0140-6736(04)16630-0##KAWAGUCHI A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/MCNE.2000.0925##KLEBER M, 2004, CURR OPIN CELL BIOL, V16, P681, DOI 10.1016/J.CEB.2004.08.006##KLEBER M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/JCB.200411095##KOBAYASHI K, 1993, P NATL ACAD SCI USA, V90, P7391, DOI 10.1073/PNAS.90.15.7391##KRUGER GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9##LE DOUARIN NM, 2003, CURR OPIN GENET DEV, V13, P529, DOI 10.1016/J.GDE.2003.08.002##LEE HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/SCIENCE.1091611##LI LN, 2003, P NATL ACAD SCI USA, V100, P9958, DOI 10.1073/PNAS.1733025100##LUTOLF S, 2002, DEVELOPMENT, V129, P373##NISHIMURA EK, 2002, NATURE, V416, P854, DOI 10.1038/416854A##OSAWA M, 2005, DEVELOPMENT, V132, P5589, DOI 10.1242/DEV.02161##OSHIMA H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2##PARATORE C, 2002, HUM MOL GENET, V11, P3075, DOI 10.1093/HMG/11.24.3075##PARATORE C, 2001, DEVELOPMENT, V128, P3949##PARDAL R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/NRC1232##PETERS EMJ, 2003, J INVEST DERMATOL, V121, P976, DOI 10.1046/J.1523-1747.2003.12478.X##PETERS EMJ, 2002, J HISTOCHEM CYTOCHEM, V50, P751, DOI 10.1177/002215540205000602##PIETRI T, 2003, DEV BIOL, V259, P176, DOI 10.1016/S0012-1606(03)00175-1##PLUCHINO S, 2003, NATURE, V422, P688, DOI 10.1038/NATURE01552##RENDL M, 2005, PLOS BIOL, V3, P1910, DOI 10.1371/JOURNAL.PBIO.0030331##REYNOLDS BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/NMETH758##SANTAGATI F, 2003, NAT REV NEUROSCI, V4, P806, DOI 10.1038/NRN1221##SHIH DTB, 2005, STEM CELLS, V23, P1012, DOI 10.1634/STEMCELLS.2004-0125##SIEBER-BLUM M, 2004, DEV DYNAM, V231, P258, DOI 10.1002/DVDY.20129##SIEBER-BLUM MAYA, 2004, BIRTH DEFECTS RES C EMBRYO TODAY, V72, P162, DOI 10.1002/BDRC.20008##SLACK J, 2001, NAT CELL BIOL, V3, PE205, DOI 10.1038/NCB0901-E205##SOMMER L, 2001, CELL TISSUE RES, V305, P211, DOI 10.1007/S004410000331##SOMMER L, 2005, SCI STKE, PPE42##SRINIVAS S, 2001, BMC DEV BIOL, V1, P4, DOI 10.1186/1471-213X-1-4##STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q##TAYLOR G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7##TOMA JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/NCB0901-778##TOMA JG, 2005, STEM CELLS, V23, P727, DOI 10.1634/STEMCELLS.2004-0134##TRENTIN A, 2004, P NATL ACAD SCI USA, V101, P4495, DOI 10.1073/PNAS.0400629101##WAGERS AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9##WANG Y, 2006, CELL BIOL INT, V30, P144, DOI 10.1016/J.CELLBI.2005.09.005##WERNIG M, 2004, J NEUROSCI, V24, P5258, DOI 10.1523/JNEUROSCI.0428-04.200##WURDAK H, 2005, GENE DEV, V19, P530, DOI 10.1101/GAD.317405",234,2020-11-20,NA
J,WOS:000243253100009,2006,SEDIMENT BUDGET OF THE RHONE DELTA SHOREFACE SINCE THE MIDDLE OF THE 19TH CENTURY,"THIS STUDY ANALYSES LONG-TEEN (1841-1872-1895-1974) CHANGES IN THE GRAND RHONE PRODELTAIC LOBE TO (1) QUANTIFY THE ACCUMULATION, (2) DETERMINE THE EVOLUTION OF RELICT PRODELTAIC LOBES AND (3) ESTABLISH LONG-TERM RELATIONSHIPS BETWEEN RIVER SEDIMENT DISCHARGE, THE SHOREFACE AND THE CONTINENTAL SHELF. OUR RESULTS SHOW A REDUCTION OF THE SEDIMENTATION OF THE PRODELTAIC LOBE AT THE MAIN RIVER MOUTH, SINCE 150 YR BY A FACTOR OF 3.7 (12.63 TO 3.41 X 10(6) M(3) YR(-1)). AT THE MINOR MOUTH OF THE RIVER, EROSION DOMINATES AND SPEEDS UP DURING THE SAME PERIOD (-0.53 TO -1.34 X 10(6) M(3) YR(-1)). THESE CHANGES ARE FOUND TO DIRECTLY RESULT FROM THE RIVER SEDIMENT INPUT DECREASE RELATED TO THE NATURAL DECREASING OF THE FREQUENCY OF MAJOR FLOODS (END OF THE LITTLE ICE,AGE), THE REFORESTATION IN THE CATCHMENT AREA, THE DAM CONSTRUCTION AND THE DREDGING ACTIVITIES (SINCE THE 1950S). OUR RESULTS INDICATE THAT WHILE THERE IS LARGE SEDIMENT ACCUMULATION IN THE AREA AROUND A GROWING PRODELTAIC LOBE, THERE IS ALSO A REDUCED CONTRIBUTION OF THE RIVER SEDIMENTS TO THE NON-ADJACENT BEACHES OF THE MOUTH. FOLLOWING A SHIFT IN THE RIVER CHANNEL AND MOUTH, THE RELICT PRODELTAIC LOBES (PETIT RHONE-ST FERREOL, BRAS DE FER AND PEGOULIER) ARE REWORKED BY WAVES AND THEIR SEDIMENTS CONTRIBUTE PARTIALLY TO THE GROWTH OF THE SPITS (ESPIGUETTE, BEAUDUC AND GRACIEUSE). THIS SUGGESTS THAT THERE IS A ""TIME-SHIFT"" BETWEEN THE INPUT OF RIVER SEDIMENT TO THE SEA AND THE BUILD UP OF A BEACH. THE CHRONIC EROSION OF THE COASTLINE IS LIKELY TO CONTINUE IN THE FUTURE SINCE (I) A RIVER SHIFT IS NOT POSSIBLE, BECAUSE THE RIVER CHANNELS ARE CONTROLLED BY DYKES AND HUMAN INTERVENTION, (2) THE DECREASE OF LIVER SEDIMENT INPUT AND (3) THE RELICT PRODELTAIC LOBES CONSTITUTE SEDIMENTARY RESERVOIRS THAT ARE GRADUALLY BEING USED UP. (C) 2006 PUBLISHED BY ELSEVIER B.V.",EBRO DELTA; CHANNEL CHANGES; SOUTHERN FRANCE; ICE-AGE; RIVER; EVOLUTION; COAST; TRANSPORT; DELIVERY; WATER,BATHYMETRY; RIVER SEDIMENTS INPUT; PRODELTAIC LOBE; LARGE SCALE COASTAL BEHAVIOUR,MARINE GEOLOGY,"SABATIER, F##MAILLET, G##PROVANSAL, M##FLEURY, TJ##SUANEZ, S##VELLA, C","CNRS, CTR EUROPEEN RECH & ENSEIGNEMENT GEOSCI & ENVIRON, UMR 6635, F-13545 AIX EN PROVENCE 04, FRANCE. DELFT UNIV TECHNOL, FAC CIVIL ENGN, HYDRAUL ENGN SECT, NL-2628 CN DELFT, NETHERLANDS. UNIV ANGERS, LAB PAYSAGES & BIODIVERS, UFR SCI, F-49045 ANGERS 1, FRANCE. CNRS, UMR 6554, IUEM, F-29280 PLOUZANE, FRANCE.","GEOSCIENCES, MULTIDISCIPLINARY; OCEANOGRAPHY",GEOLOGY; OCEANOGRAPHY,"ALOISI, 1977, B SOC GEOL FR, V19, P183##ANTONELLI C, 2004, GEOMORPHOLOGY, V57, P385, DOI 10.1016/S0169-555X(03)00167-3##ANTONELLI C, 2002, P INT C FLUV HYDR LO, V2, P587##ANTONELLI C, 2002, GEOMORPHOLOGY EXPERT##ARNAUD-FASSETTA G, 1999, HYDROBIOLOGIA, V410, P241, DOI 10.1023/A:1003865428112##ARNAUD-FASSETTA G, 2003, CATENA, V51, P141, DOI 10.1016/S0341-8162(02)00093-0##ARNAUDFASSETTA G, 1997, GEOMORPHOLOGIE, V3, P237, DOI DOI 10.3406/MORFO.1997.922##ARNAUDFASSETTA G, 1998, THESIS U PROVENCE AI##BLANC J, 1977, PUBL CENT NATL EXPLO, V75##BRAVARD J. P., 1989, B SOC GEOGRAPHIQUE L, V25, P145##BRAVARD JP, 1993, Z GEOMORPHOLOGIE S, V88, P67##CENCINI C, 1998, J COASTAL RES, V14, P774##CONSIDERE RP, 1956, 4 JOURN HYDR EN MER, P289##DE MADRON XD, 2000, OCEANOL ACTA, V23, P717##DUGAS SF, 1989, ETUDE TRANSIT SEDIME##ELHABR H, 1987, REV SCI EAU, V6, P395##GALLOWAY W.E., 1975, DELTAS MODELS EXPLOR, P87##GAUTIER E, 1994, REV GEOGRAPHIE LYON, V69, P57, DOI DOI 10.3406/GEOCA.1994.4238##GIOSAN L, 1999, J COASTAL RES, V15, P859##GUILLEN J, 1993, MAR GEOL, V115, P239, DOI 10.1016/0025-3227(93)90053-X##GUILLEN J, 1997, J COASTAL RES, V13, P867##HEQUETTE A, 1993, MAR GEOL, V113, P283, DOI 10.1016/0025-3227(93)90023-O##HEQUETTE A, 2001, J COASTAL RES, V17, P507##*IRS, 2000, ET GLOB STRAT RED RI, V3##JIMENEZ JA, 1999, MAR GEOL, V157, P219, DOI 10.1016/S0025-3227(98)00153-4##JIMENEZ JA, 1993, MAR GEOL, V114, P105, DOI 10.1016/0025-3227(93)90042-T##KLINGEMAN PC, 1994, REV GEOGRAPHIE LYON, V69, P73, DOI 10.3406/GEOCA.1994.4240##KOLB C. R., 1966, DELTAS THEIR GEOLOGI, P17##KOMAR P.D., 1998, BEACH PROCESSES SEDI##KRUIT C, 1955, SEDIMENTS RHONE DELT##LHOMER A, 1981, OCEANIS, V7, P389##LI GX, 2000, MAR GEOL, V168, P129, DOI 10.1016/S0025-3227(00)00053-0##MASSELINK G, 1992, J COASTAL RES, V8, P286##MILLIMAN JD, 1983, J GEOL, V91, P1, DOI 10.1086/628741##MILLIMAN JD, 1997, NATURE, V386, P325, DOI 10.1038/386325A0##MIRAMONT C, 1997, GEOMORPHOLOGIE, V4, P235##MORGAN J.P., 1970, DELTAIC SEDIMENTATIO, V15, P198##PARDE M, 1925, THESIS U GRENOBLE##PAUC HE, 1976, B SOC HIST NATURELLE, V67, P151##PICHARD G., 1995, MEDITERRANEE, V3-4, P105, DOI DOI 10.3406/MEDIT.1995.2908##POINSARD D, 1992, THESIS LYON 3 U##PONT D, 2002, ESTUAR COAST SHELF S, V54, P1, DOI 10.1006/ECSS.2001.0829##PONT D, 1995, 7 RENC AG REG ENV PA, P283##PONT D, 1996, WORKSH MEDDELT VEN I, V1##PRANZINI E, 2001, GEOMORPHOLOGY, V38, P125, DOI 10.1016/S0169-555X(00)00076-3##PROBST J-L, 1989, HIST CHANGE LARGE AL, P41##RADAKOVITCH O, 1999, ESTUAR COAST SHELF S, V48, P77, DOI 10.1006/ECSS.1998.0405##RODITIS JC, 1993, MEDITERRANEE, P5##RUSSELL RJ, 1942, ANN ASSOC AM GEOGR, V32, P149, DOI 10.2307/2561087##SABATIER F, 2001, THESIS U AIXMARSEILL##SABATIER F., 2003, GEOMORPHOLOGIE, V4, P283, DOI DOI 10.3406/M0RF0.2003.1191##SAVEY P, 1967, INTL ASS SCI HYDR PU, V75, P462##STANLEY DJ, 1998, J COASTAL RES, V14, P794##STIVE MJF, 1995, MAR GEOL, V126, P235, DOI 10.1016/0025-3227(95)00080-I##STONE GW, 1998, J COASTAL RES, V14, P695##SUANEZ S, 1997, CR ACAD SCI II A, V324, P639##SUANEZ S, 1998, J COASTAL RES, V14, P493##SUANEZ S, 1998, GEOMORPHOLOGIE, V4, P291##SUANEZ S, 1997, PHOTOINTERPRETATION, V3, P147##SUANEZ SERGE, 1999, JOURNAL OF COASTAL CONSERVATION, V5, P1, DOI 10.1007/BF02802734##SURELL M, 1847, MEMOIRE AMELIORATION, P1##THIELER ER, 2000, J COASTAL RES, V16, P48##TOUZANI A, 2002, J COASTAL RES, V18, P102##VAN STRAATEN L.M.J.U, 1959, P 2 COAST GEOGR C CO, P233##VELLA C, 2005, MAR GEOL, V222, P235, DOI 10.1016/J.MARGEO.2005.06.028##VELLA C, 2000, MAR GEOL, V170, P27, DOI 10.1016/S0025-3227(00)00063-3##VERNIER E, 1976, B BRGM, V4, P103##WARNER RF, 2000, REGUL RIVER, V16, P141, DOI 10.1002/(SICI)1099-1646(200003/04)16:2&LT;141::AID-RRR574&GT;3.0.CO;2-2##WELLS JT, 1987, ESTUAR COAST SHELF S, V25, P111, DOI 10.1016/0272-7714(87)90029-1##WRIGHT LD, 1984, MAR GEOL, V56, P93, DOI 10.1016/0025-3227(84)90008-2##WRIGHT LD, 1991, MAR GEOL, V96, P19, DOI 10.1016/0025-3227(91)90200-N##ZEILER M, 2000, MAR GEOL, V170, P363, DOI 10.1016/S0025-3227(00)00089-X##ZUO Z, 1997, DEEP-SEA RES PT II, V44, P597, DOI 10.1016/S0967-0645(96)00083-5##1999, 550470JLRR3",65,2020-11-20,NA
J,WOS:000243253100014,2006,INVERSE MODELING OF POST LAST GLACIAL MAXIMUM TRANSGRESSIVE SEDIMENTATION USING 2D-SEDFLUX: APPLICATION TO THE NORTHERN ADRIATIC SEA,"A COUPLED SIMULATION OF THE HYDROLOGIC MODEL HYDROTREND AND THE STRATIGRAPHIC MODEL 2D-SEDFLUX IS APPLIED TO TRANSGRESSIVE DEPOSITS IN THE NORTH ADRIATIC SEA AREA OVER THE LAST 21,000YEARS. SYNTHETIC SEDIMENT DISCHARGE FROM THE PO RIVER, WHICH INCREASES MORE THAN 70% DURING LATE PLEISTOCENE COMPARED TO THOSE DURING HOLOCENE DUE TO GLACIER MELT AND ENLARGED DRAINAGE AREA, IS EMPLOYED IN THE SIMULATION OF SEDIMENT DEPOSITION BY THE PROCESS BASED, FORWARD MODEL, 2D-SEDFLUX. PALEO-MORPHOLOGY IS RECONSTRUCTED IN A PSEUDO-INVERSE MANNER BY COMPARING THE PREDICTED DEPOSIT DISTRIBUTION AND THE MODERN MORPHOLOGY. ACCOMMODATION FOR THICK, PROGRADING DEPOSITS IN THE MODERN PO DELTA AND THE PO LOWSTAND DELTA ARE CREATED BY DRAWING BACK THE MODERN BATHYMETRIC PROFILE. THE BATHYMETRIC PROFILE IS THEN ADJUSTED FOR AGGRADATIONAL DEPOSITS. THESE SEQUENTIAL SIMULATIONS PRODUCED A LIKELY PROFILE OF THE PALEO-MORPHOLOGY, WHICH HAD ACCOMMODATION MATCHING WITH THE SEDIMENT SUPPLY. EVALUATION OF EFFECTS OF WAVES, HOWEVER, SUGGESTED THAT THE PREDICTED RATE OF SEDIMENT INPUT WAS TOO LOW TO PRODUCE A PROGRADING DELTA. A GOOD MATCH WITH THE OBSERVATION OF THE MODERN PO DELTA WAS ACHIEVED WHEN FURTHER ADJUSTMENTS IN BASIN WIDTH WAS PROPERLY MADE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",FLUX; VARIABILITY; DEPOSITION; TRANSPORT; EROSION; IMPACT; SHELF,NUMERICAL MODEL; TRANSGRESSIVE SEDIMENTS; ADRIATIC SEA; PALEO-MORPHOLOGY,MARINE GEOLOGY,"KUBO, Y##SYVITSKI, JPM##HUTTON, EWH##KETTNER, AJ","UNIV TOKYO, OCEAN RES INST, NAKANO KU, TOKYO 1648639, JAPAN. UNIV COLORADO, INST ARCTIC & ALPINE RES, BOULDER, CO 80309 USA. DELFT UNIV TECHNOL, NL-2628 RX DELFT, NETHERLANDS.","GEOSCIENCES, MULTIDISCIPLINARY; OCEANOGRAPHY",GEOLOGY; OCEANOGRAPHY,"AMOROSI A, 2003, J GEOL, V111, P39, DOI 10.1086/344577##BAGNOLD RA, 1966, APPROACH SEDIMENT TR, P37##CAVALERI L, 1997, NUOVO CIMENTO C, V20, P103##COCO G, 1999, THESIS U PLYMOUTH##CROSS T., 1999, SEPM SPECIAL PUBLICA, V62, DOI DOI 10.2110/PEC.99.62.0069##CUSHMAN-ROISIN B., 2001, PHYS OCEANOGRAPHY AD##GUYMON GL, 1974, J HYDR ENG DIV-ASCE, V100, P41##HALLET B, 1996, GLOBAL PLANET CHANGE, V12, P213, DOI 10.1016/0921-8181(95)00021-6##HUTTON EWH, 2004, MAR GEOL, V203, P367, DOI 10.1016/S0025-3227(03)00316-5##KETTNER AJ, IN PRESS IAS SPECIAL##KOMAR P.D., 1998, BEACH PROCESSES SEDI##KRAFT BJ, 2006, IEEE J OCEANIC ENG, V31, P266, DOI 10.1109/JOE.2006.875235##KUBO Y, 2005, SEDIMENT GEOL, V178, P187, DOI 10.1016/J.SEDGEO.2005.04.005##LAMBECK K, 2000, EARTH PLANET SC LETT, V175, P203, DOI 10.1016/S0012-821X(99)00289-7##LAWSON DE, 1993, MONOGRAM##MOREHEAD MD, 2003, GLOBAL PLANET CHANGE, V39, P95, DOI 10.1016/S0921-8181(03)00019-5##MOREHEAD MK, 2001, GLOBAL PLANET CHANGE, V28, P107, DOI 10.1016/S0921-8181(00)00068-0##NICHOLLS RJ, 1998, MAR GEOL, V148, P179, DOI 10.1016/S0025-3227(98)00011-5##OVEREEM I, 2005, MAR GEOL, V224, P23, DOI 10.1016/J.MARGEO.2005.06.044##READING HG, 1996, SEDIMENTARY ENV PROC##SHERWOOD C.R., 2004, OCEANOGRAPHY, V17, P58, DOI DOI 10.5670/0CEAN0G.2004.04##SWENSON JB, 2005, J GEOPHYS RES-EARTH, V110, P1, DOI 10.1029/2004JF000265##SYVITSKI JP, 1998, COMPUT GEOSCI, V24, P51, DOI 10.1016/S0098-3004(97)00083-6##SYVITSKI JP, 1998, COMPUT GEOSCI, V24, P159, DOI 10.1016/S0098-3004(97)00084-8##SYVITSKI JPM, 2005, MAR GEOL, V222, P75, DOI 10.1016/J.MARGEO.2005.06.030##SYVITSKI JPM, 2003, SEDIMENT GEOL, V162, P5, DOI 10.1016/S0037-0738(03)00232-X##SYVITSKI JPM, 2005, SCIENCE, V308, P376, DOI 10.1126/SCIENCE.1109454##SYVITSKI JPM, 2005, J COASTAL RES, V21, P580, DOI 10.2112/04-702A.1##SYVITSKI JPM, 2001, COMPUT GEOSCI-UK, V27, P731, DOI 10.1016/S0098-3004(00)00139-4##SYVITSKI JPM, 1993, COMPUT GEOSCI, V19, P399##SYVITSKI JPM, 2004, OCEANOGRAPHY, V17, P14, DOI DOI 10.5670/0CEAN0G.2004.18##TRINCARDI F, 1994, GEO-MAR LETT, V14, P41, DOI 10.1007/BF01204470##TRINCARDI FABIO, 1996, MEMORIE DELL'ISTITUTO ITALIANO DI IDROBIOLOGIA, V55, P39##WANG XH, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2001JC001303",19,2020-11-20,NA
J,WOS:000242738000004,2006,"ORIENTIFOLDS, HYPERCHARGE EMBEDDINGS AND THE STANDARD MODEL","THE EMBEDDING OF THE SM HYPERCHARGE INTO AN ORIENTIFOLD GAUGE GROUP IS STUDIED. POSSIBLE EMBEDDINGS ARE CLASSIFIED, AND A SYSTEMATIC CONSTRUCTION OF BOTTOM-UP CONFIGURATIONS AND TOP-DOWN ORIENTIFOLD VACUA IS ACHIEVED, SOLVING THE TADPOLE CONDITIONS IN THE CONTEXT OF GEPNER ORIENTIFOLDS. SOME HYPERCHARGE EMBEDDINGS ARE STRONGLY PREFERRED COMPARED TO OTHERS. CONFIGURATIONS WITH CHIRAL ANTI-SYMNIETRIC TENSORS ARE SUPPRESSED. WE FIND AMONG OTHERS, GENUINE EXAMPLES OF SUPERSYMMETRIC SU(5), FLIPPED SU(5), PATI-SALAM AND TRINIFICATION VACUA WITH NO CHIRAL EXOTICS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",D-BRANES; SPECTRA; GRAVITY; VACUA,NA,NUCLEAR PHYSICS B,"ANASTASOPOULOS, P##DIJKSTRA, T##KIRITSIS, E##SCHELLEKENS, B","UNIV ATHENS, DEPT PHYS, GR-15784 ATHENS, GREECE. NIKHEF, NL-1009 DB AMSTERDAM, NETHERLANDS. CNRS, CPHT, ECOLE POLYTECH, UMR 7644, F-91128 PALAISEAU, FRANCE. UNIV CRETE, DEPT PHYS, IRAKLION 71003, GREECE. RADBOUD UNIV NIJMEGEN, IMAPP, NIJMEGEN, NETHERLANDS.","PHYSICS, PARTICLES & FIELDS",PHYSICS,"ACHIMAN Y, 1979, NEW PHENOMENA LEPTON##ALDAZABAL G, 2004, J HIGH ENERGY PHYS##ALDAZABAL G, 2000, J HIGH ENERGY PHYS##ALDAZABAL G, 2003, JHEP, V309, P67##ALDAZABAL G, HEPTH0603217##ANGELANTONJ C, 1996, PHYS LETT B, V385, P96, DOI 10.1016/0370-2693(96)00869-6##ANGELANTONJ C, 1996, PHYS LETT B, V387, P743, DOI 10.1016/0370-2693(96)01124-0##ANTEBI YE, 2006, PHYS REV D, V73, DOI 10.1103/PHYSREVD.73.075009##ANTONIADIS I, 2003, NUCL PHYS B, V660, P81, DOI 10.1016/S0550-3213(03)00256-6##ANTONIADIS I, 2000, PHYS LETT B, V486, P186, DOI 10.1016/S0370-2693(00)00733-4##ANTONIADIS I, 2005, NUCL PHYS B, V715, P120, DOI 10.1016/J.NUCLPHYSB.2005.03.005##ANTONIADIS I, 2001, FORTSCHR PHYS, V49, P573, DOI 10.1002/1521-3978(200105)49:4/6<573::AID-PROP573>3.3.CO;2-1##ANTONIADIS I, 2002, NUCL PHYS B, V637, P92, DOI 10.1016/S0550-3213(02)00458-3##AXENIDES M, 2003, JHEP, V310, P6##BERENSTEIN D, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.071602##BERENSTEIN D, HEPTH0603103, P73004##BLUMENHAGEN R, 2003, J HIGH ENERGY PHYS##BLUMENHAGEN R, 1998, PHYS LETT B, V438, P52, DOI 10.1016/S0370-2693(98)00959-9##BLUMENHAGEN R, 2001, NUCL PHYS B, V616, P3, DOI 10.1016/S0550-3213(01)00423-0##BLUMENHAGEN R, 2004, JHEP, V402##BLUMENHAGEN R, HEPTH0502005##BRUNNER I, HEPTH0401137##CARDY JL, 1989, NUCL PHYS B, V324, P581, DOI 10.1016/0550-3213(89)90521-X##CHEN CM, 2005, PHYS LETT B, V625, P96, DOI 10.1016/J.PHYSLETB.2005.08.042##CHEN CM, HEPTH0604107##CORIANO C, HEPPH0510332##CVETIC M, 2004, NUCL PHYS B, V696, P298, DOI 10.1016/J.NUCLPHYSB.2004.06.041##CVETIC M, 2004, NUCL PHYS B, V698, P163, DOI 10.1016/J.NUCLPHYSB.2004.07.036##CVETIC M, 2003, NUCL PHYS B, V659, P193, DOI 10.1016/S0550-3213(03)00222-0##DENEF F, HEPTH0602072##DENT T, 2005, PHYS LETT B, V605, P399, DOI 10.1016/J.PHYSLETB.2004.11.032##DIJKSTRA TPT, 2005, NUCL PHYS B, V710, P3, DOI 10.1016/J.NUCLPHYSB.2004.12.032##DIJKSTRA TPT, 2005, PHYS LETT B, V609, P408, DOI 10.1016/J.PHYSLETB.2004.04.094##ELLIS J, 2002, NUCL PHYS B, V647, P235, DOI 10.1016/S0550-3213(02)00935-5##FUCHS J, 2000, PHYS LETT B, V495, P427, DOI 10.1016/S0370-2693(00)01271-5##GATO-RIVERA B, 2006, PHYS LETT B, V632, P728, DOI 10.1016/J.PHYSLETB.2005.11.037##GATORIVERA B, 1992, COMMUN MATH PHYS, V145, P85, DOI 10.1007/BF02099282##GEORGI H., 1984, 5 WORKSH GRAND UN WO##GMEINER F, 2006, J HIGH ENERGY PHYS##HONECKER G, 2003, NUCL PHYS B, V666, P175, DOI 10.1016/S0550-3213(03)00540-6##HONECKER G, 2004, PHYS REV D, V70, DOI 10.1103/PHYSREVD.70.126010##HONECKER G, 2005, PHYS REV D, V71, DOI 10.1103/PHYSREVD.71.069902##IBANEZ LE, 2001, J HIGH ENERGY PHYS##KIRITSIS E, 2005, PHYS REP, V421, P105, DOI 10.1016/J.PHYSREP.2005.09.001##KIRITSIS E, 2004, FORTSCHR PHYS, V52, P200, DOI 10.1002/PROP.200310120##KORS B, 2004, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2004/12/005##KORS B, 2004, PHYS LETT B, V586, P366, DOI 10.1016/J.PHYSLETB.2004.02.051##KORS B, HEPPH0503208##KREUZER M, 1994, NUCL PHYS B, V411, P97, DOI 10.1016/0550-3213(94)90055-8##LEONTARIS GK, 2001, PHYS LETT B, V510, P295, DOI 10.1016/S0370-2693(01)00592-5##LEONTARIS GK, 2006, PHYS LETT B, V632, P710, DOI 10.1016/J.PHYSLETB.2005.11.045##LEONTARIS GK, HEPPH0603203##LI LF, 1974, PHYS REV D, V9, P1723, DOI 10.1103/PHYSREVD.9.1723##SCHELLEKENS AN, PHYSICS0604134##SUSSKIND L., HEPTH0302219##URANGA AM, 2001, NUCL PHYS B, V598, P225, DOI 10.1016/S0550-3213(00)00787-2",120,2020-11-20,NA
J,WOS:000423838100001,2006,LONGITUDINAL DOUBLE-SPIN ASYMMETRY AND CROSS SECTION FOR INCLUSIVE JET PRODUCTION IN POLARIZED PROTON COLLISIONS AT ROOT S=200 GEV,WE REPORT A MEASUREMENT OF THE LONGITUDINAL DOUBLE-SPIN ASYMMETRY A(LL) AND THE DIFFERENTIAL CROSS SECTION FOR INCLUSIVE MIDRAPIDITY JET PRODUCTION IN POLARIZED PROTON COLLISIONS AT ROOT S = 200 GEV. THE CROSS SECTION DATA COVER TRANSVERSE MOMENTA 5 < P(T) < 50 GEV/C AND AGREE WITH NEXT-TO-LEADING ORDER PERTURBATIVE QCD EVALUATIONS. THE A(LL) DATA COVER 5 < P(T) < 17 GEV/C AND DISFAVOR AT 98% C.L. MAXIMAL POSITIVE GLUON POLARIZATION IN THE POLARIZED NUCLEON.,NA,NA,PHYSICAL REVIEW LETTERS,"ABELEV, BI##AGGARWAL, MM##AHAMMED, Z##AMONETT, J##ANDERSON, BD##ANDERSON, M##ARKHIPKIN, D##AVERICHEV, GS##BAI, Y##BALEWSKI, J##BARANNIKOVA, O##BARNBY, LS##BAUDOT, J##BEKELE, S##BELAGA, VV##BELLINGERI-LAURIKAINEN, A##BELLWIED, R##BENEDOSSO, F##BHARDWAJ, S##BHASIN, A##BHATI, AK##BICHSEL, H##BIELCIK, J##BIELCIKOVA, J##BLAND, LC##BLYTH, SL##BONNER, BE##BOTJE, M##BOUCHET, J##BRANDIN, AV##BRAVAR, A##BURTON, TP##BYSTERSKY, M##CADMAN, RV##CAI, XZ##CAINES, H##SANCHEZ, MCDLB##CASTILLO, J##CATU, O##CEBRA, D##CHAJECKI, Z##CHALOUPKA, P##CHATTOPADHYAY, S##CHEN, HF##CHEN, JH##CHENG, J##CHERNEY, M##CHIKANIAN, A##CHRISTIE, W##COFFIN, JP##CORMIER, TM##COSENTINO, MR##CRAMER, JG##CRAWFORD, HJ##DAS, D##DAS, S##DASH, S##DAUGHERITY, M##DE MOURA, MM##DEDOVICH, TG##DEPHILLIPS, M##DEREVSCHIKOV, AA##DIDENKO, L##DIETEL, T##DJAWOTHO, P##DOGRA, SM##DONG, WJ##DONG, X##DRAPER, JE##DU, F##DUNIN, VB##DUNLOP, JC##MAZUMDAR, MRD##ECKARDT, V##EDWARDS, WR##EFIMOV, LG##EMELIANOV, V##ENGELAGE, J##EPPLEY, G##ERAZMUS, B##ESTIENNE, M##FACHINI, P##FATEMI, R##FEDORISIN, J##FILIP, P##FINCH, E##FINE, V##FISYAK, Y##FU, J##GAGLIARDI, CA##GAILLARD, L##GANTI, MS##GHAZIKHANIAN, V##GHOSH, P##GONZALEZ, JE##GORBUNOV, YG##GOS, H##GREBENYUK, O##GROSNICK, D##GUERTIN, SM##GUIMARAES, KSFF##GUPTA, N##GUTIERREZ, TD##HAAG, B##HALLMAN, TJ##HAMED, A##HARRIS, JW##HE, W##HEINZ, M##HENRY, TW##HEPPLEMANN, S##HIPPOLYTE, B##HIRSCH, A##HJORT, E##HOFFMAN, AM##HOFFMANN, GW##HORNER, MJ##HUANG, HZ##HUANG, SL##HUGHES, EW##HUMANIC, TJ##IGO, G##JACOBS, P##JACOBS, WW##JAKL, P##JIA, F##JIANG, H##JONES, PG##JUDD, EG##KABANA, S##KANG, K##KAPITAN, J##KAPLAN, M##KEANE, D##KECHECHYAN, A##KHODYREV, VY##KIM, BC##KIRYLUK, J##KISIEL, A##KISLOV, EM##KLEIN, SR##KOCOLOSKI, A##KOETKE, DD##KOLLEGGER, T##KOPYTINE, M##KOTCHENDA, L##KOUCHPIL, V##KOWALIK, KL##KRAMER, M##KRAVTSOV, P##KRAVTSOV, VI##KRUEGER, K##KUHN, C##KULIKOV, AI##KUMAR, A##KUZNETSOV, AA##LAMONT, MAC##LANDGRAF, JM##LANGE, S##LAPOINTE, S##LAUE, F##LAURET, J##LEBEDEV, A##LEDNICKY, R##LEE, CH##LEHOCKA, S##LEVINE, MJ##LI, C##LI, Q##LI, Y##LIN, G##LIN, X##LINDENBAUM, SJ##LISA, MA##LIU, F##LIU, H##LIU, J##LIU, L##LIU, Z##LJUBICIC, T##LLOPE, WJ##LONG, H##LONGACRE, RS##LOVE, WA##LU, Y##LUDLAM, T##LYNN, D##MA, GL##MA, JG##MA, YG##MAGESTRO, D##MAHAPATRA, DP##MAJKA, R##MANGOTRA, LK##MANWEILER, R##MARGETIS, S##MARKERT, C##MARTIN, L##MATIS, HS##MATULENKO, YA##MCCLAIN, CJ##MCSHANE, TS##MELNICK, Y##MESCHANIN, A##MILLANE, J##MILLER, ML##MINAEV, NG##MIODUSZEWSKI, S##MIRONOV, C##MISCHKE, A##MISHRA, DK##MITCHELL, J##MOHANTY, B##MOLNAR, L##MOORE, CF##MOROZOV, DA##MUNHOZ, MG##NANDI, BK##NATTRASS, C##NAYAK, TK##NELSON, JM##NETRAKANTI, PK##NOGACH, LV##NURUSHEV, SB##ODYNIEC, G##OGAWA, A##OKOROKOV, V##OLDENBURG, M##OLSON, D##PACHR, M##PAL, SK##PANEBRATSEV, Y##PANITKIN, SY##PAVLINOV, AI##PAWLAK, T##PEITZMANN, T##PEREVOZTCHIKOV, V##PERKINS, C##PERYT, W##PHATAK, SC##PICHA, R##PLANINIC, M##PLUTA, J##POLJAK, N##PORILE, N##PORTER, J##POSKANZER, AM##POTEKHIN, M##POTREBENIKOVA, E##POTUKUCHI, BVKS##PRINDLE, D##PRUNEAU, C##PUTSCHKE, J##RAKNESS, G##RANIWALA, R##RANIWALA, S##RAY, RL##RAZIN, SV##REINNARTH, J##RELYEA, D##RIDIGER, A##RITTER, HG##ROBERTS, JB##ROGACHEVSKIY, OV##ROMERO, JL##ROSE, A##ROY, C##RUAN, L##RUSSCHER, MJ##SAHOO, R##SAKUMA, T##SALUR, S##SANDWEISS, J##SARSOUR, M##SAZHIN, PS##SCHAMBACH, J##SCHARENBERG, RP##SCHMITZ, N##SEGER, J##SELYUZHENKOV, I##SEYBOTH, P##SHABETAI, A##SHAHALIEV, E##SHAO, M##SHARMA, M##SHEN, WQ##SHIMANSKIY, SS##SICHTERMANN, EP##SIMON, F##SINGARAJU, RN##SMIRNOV, N##SNELLINGS, R##SOOD, G##SORENSEN, P##SOWINSKI, J##SPELTZ, J##SPINKA, HM##SRIVASTAVA, B##STADNIK, A##STANISLAUS, TDS##STOCK, R##STOLPOVSKY, A##STRIKHANOV, M##STRINGFELLOW, B##SUAIDE, AAP##SUGARBAKER, E##SUMBERA, M##SUN, Z##SURROW, B##SWANGER, M##SYMONS, TJM##DE TOLEDO, AS##TAI, A##TAKAHASHI, J##TANG, AH##TARNOWSKY, T##THEIN, D##THOMAS, JH##TIMMINS, AR##TIMOSHENKO, S##TOKAREV, M##TRAINOR, TA##TRENTALANGE, S##TRIBBLE, RE##TSAI, OD##ULERY, J##ULLRICH, T##UNDERWOOD, DG##VAN BUREN, G##VAN DER KOLK, N##VAN LEEUWEN, M##MOLEN, AMV##VARMA, R##VASILEVSKI, IM##VASILIEV, AN##VERNET, R##VIGDOR, SE##VIYOGI, YP##VOKAL, S##VOLOSHIN, SA##WAGGONER, WT##WANG, F##WANG, G##WANG, JS##WANG, XL##WANG, Y##WATSON, JW##WEBB, JC##WESTFALL, GD##WETZLER, A##WHITTEN, C##WIEMAN, H##WISSINK, SW##WITT, R##WOOD, J##WU, J##XU, N##XU, QH##XU, Z##YEPES, P##YOO, IK##YUREVICH, VI##ZHAN, W##ZHANG, H##ZHANG, WM##ZHANG, Y##ZHANG, ZP##ZHAO, Y##ZHONG, C##ZOULKARNEEV, R##ZOULKARNEEVA, Y##ZUBAREV, AN##ZUO, JX","[CADMAN, R. V.; KRUEGER, K.; MCCLAIN, C. J.; SPINKA, H. M.; UNDERWOOD, D. G.] ARGONNE NATL LAB, ARGONNE, IL 60439 USA. [BARNBY, L. S.; BURTON, T. P.; GAILLARD, L.; JONES, P. G.; NELSON, J. M.; TIMMINS, A. R.] UNIV BIRMINGHAM, BIRMINGHAM, W MIDLANDS, ENGLAND. [BLAND, L. C.; BRAVAR, A.; CHRISTIE, W.; DEPHILLIPS, M.; DIDENKO, L.; DUNLOP, J. C.; FACHINI, P.; FINE, V.; FISYAK, Y.; HALLMAN, T. J.; LANDGRAF, J. M.; LAUE, F.; LAURET, J.; LEBEDEV, A.; LEVINE, M. J.; LJUBICIC, T.; LONGACRE, R. S.; LOVE, W. A.; LUDLAM, T.; LYNN, D.; OGAWA, A.; PANITKIN, S. Y.; PEREVOZTCHIKOV, V.; POTEKHIN, M.; SORENSEN, P.; TANG, A. H.; ULLRICH, T.; VAN BUREN, G.; XU, Z.; ZHANG, H.] BROOKHAVEN NATL LAB, UPTON, NY 11973 USA. [HUGHES, E. W.; RELYEA, D.] CALTECH, PASADENA, CA 91125 USA. [CRAWFORD, H. J.; ENGELAGE, J.; JUDD, E. G.; PERKINS, C.] UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. [ANDERSON, M.; SANCHEZ, M. CALDERON DE LA BARCA; CEBRA, D.; DRAPER, J. E.; GUTIERREZ, T. D.; HAAG, B.; PICHA, R.; ROMERO, J. L.] UNIV CALIF DAVIS, DAVIS, CA 95616 USA. [DONG, W. J.; GHAZIKHANIAN, V.; GONZALEZ, J. E.; GUERTIN, S. M.; HUANG, H. Z.; IGO, G.; JIANG, H.; LONG, H.; MA, J. G.; TAI, A.; THEIN, D.; TRENTALANGE, S.; TSAI, O. D.; WANG, G.; WHITTEN, C., JR.; WOOD, J.] UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90095 USA. [KAPLAN, M.] CARNEGIE MELLON UNIV, PITTSBURGH, PA 15213 USA. [BARANNIKOVA, O.] UNIV ILLINOIS, CHICAGO, IL USA. [CHERNEY, M.; GORBUNOV, Y. G.; MCSHANE, T. S.; SEGER, J.; SWANGER, M.; WAGGONER, W. T.] CREIGHTON UNIV, OMAHA, NE 68178 USA. [BYSTERSKY, M.; CHALOUPKA, P.; JAKL, P.; KAPITAN, J.; KOUCHPIL, V.; PACHR, M.; SUMBERA, M.] NUCL PHYS INST AS CR, PRAGUE 25068, CZECH REPUBLIC. [AVERICHEV, G. S.; BELAGA, V. V.; DEDOVICH, T. G.; DUNIN, V. B.; EFIMOV, L. G.; FEDORISIN, J.; KECHECHYAN, A.; KISLOV, E. M.; KULIKOV, A. I.; KUZNETSOV, A. A.; LEHOCKA, S.; PANEBRATSEV, Y.; POTREBENIKOVA, E.; RAZIN, S. V.; ROGACHEVSKIY, O. V.; SAZHIN, P. S.; SHAHALIEV, E.; SHIMANSKIY, S. S.; STADNIK, A.; TOKAREV, M.; VOKAL, S.; YUREVICH, V. I.; ZUBAREV, A. N.] LAB HIGH ENERGY JINR, DUBNA, RUSSIA. [ARKHIPKIN, D.; FILIP, P.; LEDNICKY, R.; VASILEVSKI, I. M.; ZOULKARNEEV, R.; ZOULKARNEEVA, Y.] PARTICLE PHYS LAB JINR, DUBNA, RUSSIA. [DIETEL, T.; KOLLEGGER, T.; LANGE, S.; STOCK, R.] GOETHE UNIV FRANKFURT, FRANKFURT, GERMANY. [DASH, S.; MAHAPATRA, D. P.; MISHRA, D. K.; PHATAK, S. C.; SAHOO, R.; VIYOGI, Y. P.] INST PHYS, BHUBANESWAR 751005, ORISSA, INDIA. [NANDI, B. K.; VARMA, R.] INDIAN INST TECHNOL, MUMBAI, MAHARASHTRA, INDIA. [BALEWSKI, J.; DJAWOTHO, P.; HE, W.; JACOBS, W. W.; SOWINSKI, J.; VIGDOR, S. E.; WISSINK, S. W.] INDIANA UNIV, BLOOMINGTON, IN 47408 USA. [BAUDOT, J.; COFFIN, J. P.; ESTIENNE, M.; HIPPOLYTE, B.; KUHN, C.; SPELTZ, J.; VERNET, R.] INST RECHERCHES SUBATOM, STRASBOURG, FRANCE. [BHASIN, A.; DOGRA, S. M.; GUPTA, N.; MANGOTRA, L. K.; POTUKUCHI, B. V. K. S.] UNIV JAMMU, JAMMU 180001, INDIA. [AMONETT, J.; ANDERSON, B. D.; KEANE, D.; KOPYTINE, M.; MARGETIS, S.; MIRONOV, C.; SHABETAI, A.; WATSON, J. W.; ZHANG, W. M.] KENT STATE UNIV, KENT, OH 44242 USA. [JIA, F.; SUN, Z.; WANG, J. S.; ZHAN, W.] INST MODERN PHYS, LANZHOU, PEOPLES R CHINA. [BLYTH, S-L.; EDWARDS, W. R.; HJORT, E.; HORNER, M. J.; JACOBS, P.; KLEIN, S. R.; KOWALIK, K. L.; MATIS, H. S.; ODYNIEC, G.; OLDENBURG, M.; OLSON, D.; POSKANZER, A. M.; PUTSCHKE, J.; RITTER, H. G.; ROSE, A.; RUAN, L.; SICHTERMANN, E. P.; SYMONS, T. J. M.; THOMAS, J. H.; VAN LEEUWEN, M.; WETZLER, A.; WIEMAN, H.; XU, N.; XU, Q. H.] LAWRENCE BERKELEY NATL LAB, BERKELEY, CA 94720 USA. [FATEMI, R.; HOFFMAN, A. M.; KIRYLUK, J.; KOCOLOSKI, A.; MILLANE, J.; MILLER, M. L.; SAKUMA, T.; SIMON, F.; SURROW, B.] MIT, CAMBRIDGE, MA 02139 USA. [ECKARDT, V.; SCHMITZ, N.; SEYBOTH, P.] MAX PLANCK INST PHYS & ASTROPHYS, MUNICH, GERMANY. [MOLEN, A. M. VANDER; WESTFALL, G. D.] MICHIGAN STATE UNIV, E LANSING, MI 48824 USA. [BRANDIN, A. V.; EMELIANOV, V.; KOTCHENDA, L.; KRAVTSOV, P.; OKOROKOV, V.; RIDIGER, A.; STRIKHANOV, M.; TIMOSHENKO, S.] MOSCOW ENGN PHYS INST, MOSCOW, RUSSIA. [KRAMER, M.; LINDENBAUM, S. J.] CUNY CITY COLL, NEW YORK, NY 10031 USA. [BAI, Y.; BENEDOSSO, F.; BOTJE, M.; CASTILLO, J.; GREBENYUK, O.; MISCHKE, A.; PEITZMANN, T.; RUSSCHER, M. J.; SNELLINGS, R.; VAN DER KOLK, N.] NIKHEF, AMSTERDAM, NETHERLANDS. [BAI, Y.; BENEDOSSO, F.; BOTJE, M.; CASTILLO, J.; GREBENYUK, O.; MISCHKE, A.; PEITZMANN, T.; RUSSCHER, M. J.; SNELLINGS, R.; VAN DER KOLK, N.] UNIV UTRECHT, AMSTERDAM, NETHERLANDS. [BEKELE, S.; CHAJECKI, Z.; HUMANIC, T. J.; LISA, M. A.; MAGESTRO, D.; SUGARBAKER, E.] OHIO STATE UNIV, COLUMBUS, OH 43210 USA. [AGGARWAL, M. M.; BHATI, A. K.; KUMAR, A.; SHARMA, M.] PANJAB UNIV, CHANDIGARH 160014, INDIA. [HEPPLEMANN, S.; RAKNESS, G.] PENN STATE UNIV, UNIVERSITY PK, PA 16802 USA. [DEREVSCHIKOV, A. A.; KHODYREV, V. YU.; KRAVTSOV, V. I.; MATULENKO, YU. A.; MELNICK, YU.; MESCHANIN, A.; MINAEV, N. G.; MOROZOV, D. A.; NOGACH, L. V.; NURUSHEV, S. B.; VASILIEV, A. N.] INST HIGH ENERGY PHYS, PROTVINO, RUSSIA. [HIRSCH, A.; MOLNAR, L.; PORILE, N.; SCHARENBERG, R. P.; SRIVASTAVA, B.; STRINGFELLOW, B.; TARNOWSKY, T.; ULERY, J.; WANG, F.] PURDUE UNIV, WEST LAFAYETTE, W LAFAYETTE, IN 47907 USA. [KIM, B. C.; LEE, C. -H.] PUSAN NATL UNIV, PUSAN, SOUTH KOREA. [BHARDWAJ, S.; RANIWALA, R.; RANIWALA, S.; YOO, I. -K.] UNIV RAJASTHAN, JAIPUR 302004, RAJASTHAN, INDIA. [BONNER, B. E.; EPPLEY, G.; LIU, J.; LLOPE, W. J.; MITCHELL, J.; ROBERTS, J. B.; YEPES, P.] RICE UNIV, HOUSTON, TX 77251 USA. [COSENTINO, M. R.; DE MOURA, M. M.; GUIMARAES, K. S. F. F.; MUNHOZ, M. G.; SUAIDE, A. A. P.; DE TOLEDO, A. SZANTO; TAKAHASHI, J.] UNIV SAO PAULO, SAO PAULO, BRAZIL. [CHEN, H. F.; DONG, X.; HUANG, S. L.; LI, C.; LIU, H.; SHAO, M.; WANG, X. L.; WU, J.; ZHANG, Y.; ZHANG, Z. P.; ZHAO, Y.] UNIV SCI TECHNOL CHINA, HEFEI 230026, ANHUI, PEOPLES R CHINA. [CAI, X. Z.; CHEN, J. H.; MA, G. L.; MA, Y. G.; SHEN, W. Q.; ZHONG, C.; ZUO, J. X.] SHANGHAI INST APPL PHYS, SHANGHAI 201800, PEOPLES R CHINA. [BELLINGERI-LAURIKAINEN, A.; BOUCHET, J.; ERAZMUS, B.; KABANA, S.; MARTIN, L.; REINNARTH, J.; ROY, C.] SUBATECH, NANTES, FRANCE. [GAGLIARDI, C. A.; HENRY, T. W.; MIODUSZEWSKI, S.; SARSOUR, M.; TRIBBLE, R. E.] TEXAS A&M UNIV, COLLEGE STN, TX 77843 USA. [DAUGHERITY, M.; HOFFMANN, G. W.; MARKERT, C.; MOORE, C. F.; RAY, R. L.; SCHAMBACH, J.] UNIV TEXAS, AUSTIN, TX 78712 USA. [CHENG, J.; KANG, K.; LI, Y.; WANG, Y.] TSINGHUA UNIV, BEIJING 100084, PEOPLES R CHINA. [GROSNICK, D.; KOETKE, D. D.; MANWEILER, R.; SOOD, G.; STANISLAUS, T. D. S.; WEBB, J. C.] VALPARAISO UNIV, VALPARAISO, IN 46383 USA. [AHAMMED, Z.; CHATTOPADHYAY, S.; DAS, D.; DAS, S.; MAZUMDAR, M. R. DUTTA; GANTI, M. S.; GHOSH, P.; MOHANTY, B.; NAYAK, T. K.; NETRAKANTI, P. K.; PAL, S. K.; SINGARAJU, R. N.] CTR VARIABLE ENERGY CYCLOTRON, KOLKATA 700064, INDIA. [GOS, H.; KISIEL, A.; PAWLAK, T.; PERYT, W.; PLUTA, J.] WARSAW UNIV TECHNOL, WARSAW, POLAND. [BICHSEL, H.; CRAMER, J. G.; PORTER, J.; PRINDLE, D.; TRAINOR, T. A.] UNIV WASHINGTON, SEATTLE, WA 98195 USA. [BELLWIED, R.; CORMIER, T. M.; HAMED, A.; LAPOINTE, S.; LI, Q.; PAVLINOV, A. I.; PRUNEAU, C.; SELYUZHENKOV, I.; STOLPOVSKY, A.; VOLOSHIN, S. A.] WAYNE STATE UNIV, DETROIT, MI 48201 USA. [FU, J.; LIN, X.; LIU, F.; LIU, L.; LIU, Z.; LU, Y.] INST PARTICLE PHYS, CCNU HZNU, WUHAN 430079, HUBEI, PEOPLES R CHINA. [ABELEV, B. I.; BIELCIK, J.; BIELCIKOVA, J.; CAINES, H.; CATU, O.; CHIKANIAN, A.; DU, F.; FINCH, E.; HARRIS, J. W.; HEINZ, M.; LAMONT, M. A. C.; LIN, G.; MAJKA, R.; NATTRASS, C.; SALUR, S.; SANDWEISS, J.; SMIRNOV, N.; WITT, R.] YALE UNIV, NEW HAVEN, CT 06520 USA. [PLANINIC, M.; POLJAK, N.] UNIV ZAGREB, HR-10002 ZAGREB, CROATIA.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"ADAMS DL, 1994, PHYS LETT B, V336, P269, DOI 10.1016/0370-2693(94)00998-8##ADAMS J, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.172302##ADEVA B, 2004, PHYS REV D, V70, DOI 10.1103/PHYSREVD.70.012002##ADEVA B, 1998, PHYS REV D, V58, DOI 10.1103/PHYSREVD.58.112002##ADLER SS, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.202002##AGEEV ES, 2006, PHYS LETT B, V633, P25, DOI 10.1016/J.PHYSLETB.2005.11.049##AIRAPETIAN A, 2000, PHYS REV LETT, V84, P2584, DOI 10.1103/PHYSREVLETT.84.2584##ALTARELLI G, 1988, PHYS LETT B, V212, P391, DOI 10.1016/0370-2693(88)91335-4##ASHMAN J, 1989, NUCL PHYS B, V328, P1, DOI 10.1016/0550-3213(89)90089-8##BLAZEY GC, HEPEX0005012##BUNCE G, 2000, ANNU REV NUCL PART S, V50, P525, DOI 10.1146/ANNUREV.NUCL.50.1.525##CORCELLA G, 2001, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2001/01/010##FIELD R, HEPPH0510198##FILIPPONE BW, 2001, ADV NUCL PHYS, V26, P1##GLUCK M, 2001, PHYS REV D, V63, DOI 10.1103/PHYSREVD.63.094005##HARRISON M, 2003, NUCL INSTRUM METHO A, V499##HIRAI M, 2004, PHYS REV D, V69, DOI 10.1103/PHYSREVD.69.054021##JAGER B, 2004, PHYS REV D, V70, DOI 10.1103/PHYSREVD.70.034010##JINNOUCHI O, 2004, 171 RHICCAD##KARLITZ R. D., 1988, PHYS LETT B, V214, P229##KIRYLUK J., HEPEX0501072##MEYER HO, 1998, PHYS REV LETT, V81, P3096, DOI 10.1103/PHYSREVLETT.81.3096##OKADA H., PHYS LETT B IN PRESS##PUMPLIN J, 2002, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2002/07/012##SJOSTRAND T, 2001, COMPUT PHYS COMMUN, V135, P238, DOI 10.1016/S0010-4655(00)00236-8",134,2020-11-20,"RHIC OPERATIONS GROUP; RCF AT BNL; NERSC CENTER AT LBNL; OFFICE OF NP WITHIN THE US. DOE OFFICE OF SCIENCEUNITED STATES DEPARTMENT OF ENERGY (DOE); OFFICE OF HEP WITHIN THE US. DOE OFFICE OF SCIENCEUNITED STATES DEPARTMENT OF ENERGY (DOE); U.S. NSFNATIONAL SCIENCE FOUNDATION (NSF); BMBF OF GERMANYFEDERAL MINISTRY OF EDUCATION & RESEARCH (BMBF); CNRS/IN2P3 OF FRANCE; RA OF FRANCE; RPL OF FRANCE; EMN OF FRANCE; EPSRC OF THE UNITED KINGDOMENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL (EPSRC); FAPESP OF BRAZILFUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO (FAPESP); RUSSIAN MINISTRY OF SCIENCE AND TECHNOLOGY; MINISTRY OF EDUCATION OF CHINAMINISTRY OF EDUCATION, CHINA; NNSFC OF CHINANATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (NSFC); IRP OF THE CZECH REPUBLIC; GA OF THE CZECH REPUBLIC; FOM OF THE NETHERLANDSFOM (THE NETHERLANDS); DAE OF THE GOVERNMENT OF INDIA; DST OF THE GOVERNMENT OF INDIA; CSIR OF THE GOVERNMENT OF INDIACOUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (CSIR) - INDIA; SWISS NSFSWISS NATIONAL SCIENCE FOUNDATION (SNSF); POLISH STATE COMMITTEE FOR SCIENTIFIC RESEARCHPOLISH STATE COMMITTEE FOR SCIENTIFIC RESEARCH; SRDA OF SLOVAKIA; KOREA SCI. & ENG. FOUNDATION"
J,WOS:000242874300002,2006,CLASSICAL OSCILLATOR DRIVEN BY AN OSCILLATING CHIRPED FORCE,"THE MOTION OF A CLASSICAL (HARMONIC) OSCILLATOR IS STUDIED IN THE CASE WHERE THE OSCILLATOR IS DRIVEN BY A PULSED OSCILLATING FORCE WITH A FREQUENCY VARYING IN TIME (FREQUENCY CHIRP). THE AMPLITUDE AND PHASE OF THE OSCILLATIONS LEFT AFTER THE PULSED FORCE IN DEPENDENCE ON THE PROFILE AND STRENGTH OF CHIRP, FREQUENCY AND DURATION OF THE FORCE IS INVESTIGATED. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",LASER; SCATTERING; PULSES; RAMAN,CLASSICAL OSCILLATOR; DRIVING FORCE; FREQUENCY CHIRP,PHYSICS LETTERS A,"KHACHATRYAN, AG##VAN GOOR, FA##BOLLER, KJ","UNIV TWENTE, FAC SCI & TECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"DJOTYAN GP, 2004, PHYS REV A, V70, DOI 10.1103/PHYSREVA.70.063406##DODD ES, 2001, PHYS PLASMAS, V8, P3531, DOI 10.1063/1.1382820##GORDON DF, 2003, PHYS REV LETT, V90, DOI 10.1103/PHYSREVLETT.90.215001##HARTEMANN FV, 1999, PHYS PLASMAS, V6, P4104, DOI 10.1063/1.873718##KHACHATRYAN AG, 2004, PHYS REV E, V70, DOI 10.1103/PHYSREVE.70.067601##KIBBLE TWB, 2004, CLASSICAL MECH, PCH2##LEE DG, 2001, PHYS REV LETT, V87, DOI 10.1103/PHYSREVLETT.87.243902##SCHROEDER CB, 2003, PHYS PLASMAS, V10, P2039, DOI 10.1063/1.1560614##SINGH KP, 2006, PHYS PLASMAS, V13, DOI 10.1063/1.2187449##STRICKLAND D, 1985, OPT COMMUN, V56, P219, DOI 10.1016/0030-4018(85)90120-8##YAU TW, 2002, PHYS PLASMAS, V9, P391, DOI 10.1063/1.1430251",2,2020-11-20,NA
J,WOS:000242874300030,2006,A DATA ANALYSIS METHOD FOR IDENTIFYING DETERMINISTIC COMPONENTS OF STABLE AND UNSTABLE TIME-DELAYED SYSTEMS WITH COLORED NOISE,"A METHOD IS PROPOSED TO IDENTIFY DETERMINISTIC COMPONENTS OF STABLE AND UNSTABLE TIME-DELAYED SYSTEMS SUBJECTED TO NOISE SOURCES WITH FINITE CORRELATION TIMES (COLORED NOISE). BOTH NEUTRAL AND RETARDED DELAY SYSTEMS ARE CONSIDERED. FOR VANISHING CORRELATION TIMES IT IS SHOWN HOW TO DETERMINE THEIR NOISE AMPLITUDES BY MINIMIZING APPROPRIATELY DEFINED KULLBACK MEASURES. THE METHOD IS ILLUSTRATED BY APPLYING IT TO SIMULATED DATA FROM STOCHASTIC TIME-DELAYED SYSTEMS REPRESENTING DELAY-INDUCED BIFURCATIONS, POSTURAL SWAY AND SHIP ROLLING. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",INDUCED OSCILLATIONS; RECONSTRUCTION; DYNAMICS; CHAOS,NA,PHYSICS LETTERS A,"PATANARAPEELERT, K##FRANK, TD##FRIEDRICH, R##BEEK, PJ##TANG, IM","UNIV MUNSTER, INST THEORET PHYS, D-48149 MUNSTER, GERMANY. MAHIDOL UNIV, FAC SCI, DEPT MATH, BANGKOK 10400, THAILAND. FREE UNIV AMSTERDAM, FAC HUMAN MOVEMENT SCI, NL-1081 BT AMSTERDAM, NETHERLANDS. FREE UNIV AMSTERDAM, INST FUNDAMENTAL & CLIN HUMAN MOVEMENT SCI, NL-1081 BT AMSTERDAM, NETHERLANDS. MAHIDOL UNIV, FAC SCI, DEPT PHYS, BANGKOK 10400, THAILAND.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"ABELES M, 1991, CORTICONICS NEURAL C, V1##ABELES M, 1991, CORTICONICS NEURAL C, V2##ALEXANDROV AV, 2005, BIOL CYBERN, V93, P309, DOI [10.1007/S00422-005-0004-1, 10.1007/S00422-005-0004-L]##BAKER CTH, 1998, J MATH BIOL, V37, P341, DOI 10.1007/S002850050133##BALANOV AG, 2004, PHYSICA D, V199, P1, DOI 10.1016/J.PHYSD.2004.05.008##BOCHAROV GA, 2000, J COMPUT APPL MATH, V125, P183, DOI 10.1016/S0377-0427(00)00468-4##BRUNNER J, 1996, PHYS REV E, V54, PR3082##CABRERA JL, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.158702##COURTEMANCHE M, 1993, PHYS REV LETT, V70, P2182, DOI 10.1103/PHYSREVLETT.70.2182##CUSHING JM, 1977, INTEGRODIFFERENTIAL##DAFFERTSHOFER A, 2004, CLIN BIOMECH, V19, P415, DOI 10.1016/J.CLINBIOMECH.2004.01.005##DE GENNES P.-G., 1993, PHYS LIQUID CRYSTALS##DORF RC, 1995, MODERN CONTROL SYSTE##DRIVER R. D., 1977, ORDINARY DELAY DIFFE, V20##EBELING W., 2004, STAT THERMODYNAMICS##EINSTEIN A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/ANDP.19053220806##ENGBERT R, 1997, PHYS REV E, V56, P5823, DOI 10.1103/PHYSREVE.56.5823##FRANK TD, 2005, J PHYS A-MATH GEN, V38, PL485, DOI 10.1088/0305-4470/38/28/L01##FRANK TD, 2003, PHYS REV E, V68, DOI 10.1103/PHYSREVE.68.021912##FRANK TD, 2005, PHYS LETT A, V338, P74, DOI 10.1016/J.PHYSLETA.2005.01.091##FRANK TD, 2004, PHYS LETT A, V328, P219, DOI 10.1016/J.PHYSLETA.2004.06.012##FRIEDRICH R, 1997, PHYS REV LETT, V78, P863, DOI 10.1103/PHYSREVLETT.78.863##FRIEDRICH R, 1996, PHYSICA D, V98, P171, DOI 10.1016/0167-2789(96)00059-0##GRADISEK J, 2002, PHYS LETT A, V294, P234, DOI 10.1016/S0375-9601(02)00060-9##HAKEN H., 1996, PRINCIPLES BRAIN FUN##HAKEN H, 2002, BRAIN DYNAMICS##HAKEN H., 2004, SYNERGETICS INTRO AD##HALE J., 1977, THEORY FUNCTIONAL DI##HANGGI P, 2005, ANN PHYS-BERLIN, V14, P51, DOI 10.1002/ANDP.200410121##HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/REVMODPHYS.62.251##HAW M, 2005, PHYS WORLD, V18, P19##HORBELT W, 2002, PHYS LETT A, V299, P513, DOI 10.1016/S0375-9601(02)00748-X##JANSON NB, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.010601##JIRSA VK, 1995, PHYSICA D, V89, P100, DOI 10.1016/0167-2789(95)00226-X##KELSO J. A. S., 1995, DYNAMIC PATTERNS SEL##KLEINHANS D, 2005, PHYS LETT A, V346, P42, DOI 10.1016/J.PHYSLETA.2005.07.077##KUANG Y, 1993, DELAY DIFFERENTIAL E##KULLBACK S, 1968, INFORM THEORY STAT##LONGTIN A, 1990, PHYS REV A, V41, P6992, DOI 10.1103/PHYSREVA.41.6992##MACKEY MC, 1977, SCIENCE, V197, P287, DOI 10.1126/SCIENCE.267326##MANTEGNA R. N., 2000, INTRO ECONOPHYSICS##MINORSKY N, 1947, T ASME, V69, P735##NEWELL K. M., 1993, VARIABILITY MOTOR CO##OHIRA T, 1999, PHYS REV LETT, V82, P2811, DOI 10.1103/PHYSREVLETT.82.2811##OKUBO A, 2001, DIFFUSION ECOLOGICAL##ORTIN S, 2005, PHYSICA A, V351, P133, DOI 10.1016/J.PHYSA.2004.12.015##OTTINGER H.C., 1996, STOCHASTIC PROCESSES##PARISI G, 2005, NATURE, V433, P221, DOI 10.1038/433221A##PATANARAPEELERT K, 2006, PHYS REV E, V73, DOI 10.1103/PHYSREVE.73.021901##PETERKA RJ, 2002, J NEUROPHYSIOL, V88, P1097, DOI 10.1152/JN.2002.88.3.1097##POMPLUN J, 2005, EUROPHYS LETT, V71, P366, DOI 10.1209/EPL/I2005-10100-9##PONOMARENKO VI, 2002, PHYS REV E, V66, DOI 10.1103/PHYSREVE.66.026215##PYRAGAS K, 1992, PHYS LETT A, V170, P421, DOI 10.1016/0375-9601(92)90745-8##REIMANN P, 2002, PHYS REP, V361, P57, DOI 10.1016/S0370-1573(01)00081-3##SCHWEITZER F., 2003, SPRINGER SERIES SYNE##SERVANT F, 2000, SOLID STATE COMMUN, V116, P489, DOI 10.1016/S0038-1098(00)00364-1##SIEGERT S, 2001, PHYS REV E, V64, DOI 10.1103/PHYSREVE.64.041107##SIEGERT S, 1998, PHYS LETT A, V243, P275, DOI 10.1016/S0375-9601(98)00283-7##SOUTHWORTH RW, 1965, DIGITAL COMPUTATION##STEPAN G., 1989, RETARDED DYNAMICAL S##TASS P. A., 1999, PHASE RESETTING MED##VAN KAMPEN N. G., 1981, STOCHASTIC PROCESSES##VASILAKOS K, 1993, J THEOR BIOL, V165, P389, DOI 10.1006/JTBI.1993.1196##VOSS H, 1999, CHAOS SOLITON FRACT, V10, P805",9,2020-11-20,NA
J,WOS:000242633400002,2006,QUANTIFICATION OF THE CONTACT STRUCTURE IN A FERAL CATTLE POPULATION AND ITS HYPOTHETICAL EFFECT ON THE TRANSMISSION OF BOVINE HERPESVIRUS 1,"THE ORGANISATION OF ANIMAL POPULATIONS IN SOCIAL GROUPINGS MAY PLAY A CRUCIAL ROLE IN THE TRANSMISSION OF ANY INFECTIOUS DISEASE THAT REQUIRES CLOSE CONTACT. THE OBJECTIVE OF THIS STUDY WAS TO QUANTIFY THE CONTACT STRUCTURE OF PART OF THE HECK CATTLE POPULATION IN A DUTCH NATURE RESERVE AND ITS HYPOTHETICAL EFFECT ON THE TRANSMISSION OF BOVINE HERPESVIRUS 1 (BHV1). THE CONTACT STRUCTURE WAS QUANTIFIED BY OBSERVING THE NUMBER OF DIFFERENT ANIMALS WITH WHOM CONTACT WAS MADE (I.E. THE NUMBER OF CONTACTEES) WITHIN A FIXED TIME PERIOD. TWO TYPES OF BEHAVIOUR SAMPLING METHODS, NAMELY FOCAL SAMPLING AND SCAN SAMPLING WERE USED TO OBSERVE THE CONTACT STRUCTURE. IN THIS STUDY ONLY THOSE CONTACTS BETWEEN INDIVIDUALS WERE OBSERVED THAT WERE ASSUMED TO BE A PROXY MEASURE OF AN AT-RISK EVENT FOR BHV1-INFECTION. TWO REPRODUCTION RATIOS (R), I.E. THE AVERAGE NUMBER OF NEW CASES CAUSED BY A TYPICAL INFECTED INDIVIDUAL, WERE ESTIMATED, ONE FOR THE OBSERVED CONTACT STRUCTURE AND ANOTHER FOR A RANDOM MIXING CONTACT STRUCTURE. THE TWO REPRODUCTION RATIOS WERE THEN COMPARED TO STUDY THE HYPOTHETICAL EFFECT ON BHV1 TRANSMISSION. THE OVERALL NUMBER OF CONTACTEES WAS HIGHEST DURING SUMMER AND LOWEST DURING WINTER-SPRING. THE CONTACT STRUCTURE OF THE HOMOGENEOUS POPULATION DID DIFFER SIGNIFICANTLY FROM A RANDOM MIXING CONTACT STRUCTURE, RESULTING IN THAT THE VARIATION IN THE NUMBER OF CONTACTEES WAS HIGHER THAN UNDER RANDOM MIXING. BULLS, YOUNG BULLS AND COWS HAD THE HIGHEST NUMBER OF CONTACTEES DURING, RESPECTIVELY, SUMMER, AUTUMN AND WINTER-SPRING. FROM THE ANALYSIS OF THE CONTINGENCY TABLES IT WAS CLEAR THAT CONTACTS BETWEEN ANIMAL TYPES DID NOT OCCUR AT RANDOM DURING SUMMER AND AUTUMN. FOR EXAMPLE, DURING SUMMER MORE CONTACTS THAN EXPECTED OCCURRED BETWEEN BULLS AND COWS. THIS HETEROGENEITY AT ANIMAL TYPE LEVEL WAS TAKEN INTO ACCOUNT IN THE CALCULATION FOR R, WHICH RESULTED FOR THE OBSERVED CONTACT STRUCTURE IN HIGHER ESTIMATES FOR R THAN FOR THE HOMOGENEOUS POPULATION. WHEN LOOKING AT HETEROGENEITY AT INDIVIDUAL LEVEL IT WAS FOUND THAT DURING SUMMER ALMOST ALL INDIVIDUALS WERE OBSERVED TOGETHER DIRECT OR INDIRECT IN THE SAME GROUP EXCEPT FOR CERTAIN BULL GROUPS. DURING AUTUMN AND WINTER-SPRING ALMOST ALL INDIVIDUALS WERE SEEN TOGETHER IN THE SAME GROUP WHEN CONSIDERING A LONG CONTACT PERIOD OF 14 DAYS BUT THE GROUPS WERE FALLEN APART IN SMALLER GROUPS AND SOLITARY INDIVIDUALS FOR A SHORT CONTACT PERIOD OF 5 DAYS. IT COULD BE CONCLUDED THAT BASED ON THE OBSERVED CONTACT STRUCTURE TRANSMISSION WOULD BE FAVOURED MOST DURING SUMMER. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",MODEL,CONTACT STRUCTURE; WHO MIXES WITH WHOM; FERAL CATTLE; REPRODUCTION RATIO; BOVINE HERPESVIRUS 1,PREVENTIVE VETERINARY MEDICINE,"MOLLEMA, L##KOENE, P##DE JONG, MCM","UNIV WAGENINGEN & RES CTR, ANIM SCI GRP, NL-6700 AH WAGENINGEN, NETHERLANDS. ANIM SCI GRP, NL-8200 AB LELYSTAD, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,"BISHOP YMM, 1975, DISCRETE MULTIVARIAT, P136##BOSCH JC, 1997, THESIS U UTRECHT NET##DE GROOT J, 1999, J NEUROIMMUNOL, V95, P143, DOI 10.1016/S0165-5728(99)00005-3##DEKOEIJER AA, 2003, THESIS U UTRECHT NET##DIEKMANN O, 1998, J APPL PROBAB, V35, P448, DOI 10.1017/S0021900200015072##DIEKMANN O, 1990, J MATH BIOL, V28, P365##DIEKMANN O, 2000, MATH EPIDEMIOLOGY IN, P153##GIBBS E. P. J., 1977, VETERINARY BULLETIN, V47, P317##HUBER S, 2003, GEN COMP ENDOCR, V130, P48, DOI 10.1016/S0016-6480(02)00535-X##KAHRS RF, 1977, J AM VET MED ASSOC, V171, P1055##LAZO A, 1994, ANIM BEHAV, V48, P1133, DOI 10.1006/ANBE.1994.1346##MARS MH, 2000, THESIS U UTRECHT NET##MARTIN P., 1993, MEASURING BEHAV INTR, P84##METHA C, 1998, STATXACT 4 WINDOWS##MOLLEMA L, 2005, EPIDEMIOL INFECT, V133, P137, DOI 10.1017/S0950268804003097##MORRIS M, 1993, NATURE, V365, P437, DOI 10.1038/365437A0##PAYNE RW, 2000, GUIDE GENSTAT##SINCLAIR ARE, 1977, AFRICAN BUFFALO STUD, P101##VANVUURE C, 2005, RETRACING AUROCHS HI, P431##VULINK JT, 2001, THESIS U GRONINGEN N##WENTINK GH, 1993, VET QUART, V15, P30, DOI 10.1080/01652176.1993.9694365##WOLFRAM S, 1999, MATH BOOK",5,2020-11-20,NA
J,WOS:000242633400004,2006,"EFFECT OF NEOSPORA CANINUM-SEROSTATUS ON CULLING, REPRODUCTIVE PERFORMANCE AND MILK PRODUCTION IN DUTCH DAIRY HERDS WITH AND WITHOUT A HISTORY OF NEOSPORA CANINUM-ASSOCIATED ABORTION EPIDEMICS","WE QUANTIFIED THE EFFECT OF NEOSPORA CANINUM (NC)-SEROSTATUS ON CULLING AND (RE)PRODUCTION IN 83 HERDS RANDOMLY SELECTED FROM THE DUTCH DAIRY HERD POPULATION (RANDOM GROUP) AND IN 17 HERDS THAT HAD EXPERIENCED AN ABORTION EPIDEMIC ASSOCIATED WITH NC INFECTION (EPIDEMIC-ABORTION GROUP). IN THE RANDOM GROUP, A SINGLE WHOLE-HERD BLOOD SAMPLING WAS DONE DURING THE SPRING OF 2003, WHILE IN THE EPIDENTIC-ABORTION GROUP WHOLE-HERD BLOOD SAMPLING WAS DONE REPEATEDLY AT LEAST ONCE A YEAR STARTING AFTER THE ABORTION EPIDEMIC DURING THE PERIOD 1997-2000 UNTIL THE SUMMER OF 2004. SEROLOGICAL TEST-RESULTS FOR NC WERE GIVEN AS 'NEGATIVE' (N), 'LOW-POSITIVE' (LP) AND 'HIGH-POSITIVE' (HP). FOR ANALYSING THE TIME TO CULLING, CALVING INTERVAL AND AGE OF FIRST CALVING, SURVIVAL ANALYSIS WAS USED. FOR CATEGORICAL REPRODUCTION PARAMETERS EITHER A LOGISTIC-REGRESSION MODEL (ABORTION, NON-RETURN AFTER 1ST INSEMINATION) OR A POISSON-REGRESSION MODEL (NUMBER OF INSEMINATIONS PER PREGNANCY) WAS USED. FOR MILK PRODUCTION A LINEAR-MIXED MODEL WAS USED. ALL MODELS WERE CONTROLLED, IF APPLICABLE, FOR CONFOUNDING VARIABLES LIKE PARITY, PRODUCTION, SEASON, YEAR AND ABORTION AND ADJUSTED FOR WITHIN-HERD CLUSTERING. IN RANDOM HERDS, HP SEROSTATUS INCREASED THE HAZARD FOR CULLING 1.73-FOLD (95% CI: 1.37-2.19) COMPARED TO N AND LP SEROSTATUS. COMPARED TO N SEROSTATUS, LP AND HP SEROSTATUS IN EPIDEMIC-ABORTION HERDS INCREASED THE ODDS FOR ABORTION 1.88-FOLD (95% CI: 1.41-2.52) AND 1.72-FOLD (95% CI: 1.38-2.14), RESPECTIVELY. NO OTHER REPRODUCTION PARAMETERS WERE ASSOCIATED WITH NC-SEROSTATUS IN THE RANDOM OR EPIDEMIC-ABORTION HERDS. WE FOUND NO EFFECT OF SEROSTATUS ON MILK PRODUCTION IN THE RANDOM GROUP. IN CONTRAST, MILK PRODUCTION OF LP AND HP SEROSTATUS IN THE EPIDEMIC-ABORTION GROUP WAS RESPECTIVELY, 0.72 KG MILK/DAY (95% CI: 0.15-1.03) AND 0.59 KG MILK/DAY (95% CI: 0.13-1.30), LESS DURING THE FIRST 100 DAYS OF LACTATION IN THE FIRST YEAR AFTER THE ABORTION EPIDEMIC COMPARED WITH N SEROSTATUS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",LINKED IMMUNOSORBENT ASSAYS; HOLSTEIN CATTLE; INFECTION; COWS; SEROPOSITIVITY; NETHERLANDS; ANTIBODIES; PREGNANCY; LACTATION,NEOSPORA CANINUM; EPIDEMIOLOGICAL EFFECTS; MILK PRODUCTION; REPRODUCTIVE PERFORMANCE; CULLING,PREVENTIVE VETERINARY MEDICINE,"BARTELS, CJM##VAN SCHAIK, G##VELDHUISEN, JP##VAN DEN BORNE, BHP##WOUDA, W##DIJKSTRA, T","ANIM HLTH SERV LTD, NL-7400 AA DEVENTER, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,"BARTELS CJM, 2006, VET PARASITOL, V137, P17, DOI 10.1016/J.VETPAR.2005.12.016##BARTELS CJM, 2005, VET PARASITOL, V131, P235, DOI 10.1016/J.VETPAR.2005.05.011##BJORKMAN C, 1996, J AM VET MED ASSOC, V208, P1441##CRAMER G, 2002, J AM VET MED ASSOC, V221, P1165, DOI 10.2460/JAVMA.2002.221.1165##DAVISON HC, 1999, INT J PARASITOL, V29, P1189, DOI 10.1016/S0020-7519(99)00094-6##DIJKSTRA T, 2003, VET PARASITOL, V110, P161, DOI 10.1016/S0304-4017(02)00323-0##DIJKSTRA T, 2001, INT J PARASITOL, V31, P209, DOI 10.1016/S0020-7519(00)00160-0##DIJKSTRA T, 2005, 20 INT C WORLD ASS A##DOHOO I, 2003, VET EPIDEMIOLOGIC RE, PCH19##DUBEY J.P., 2003, J PARASITOL S, V89, P42, DOI [10.1016/J.CVFA.2005.03.004., DOI 10.1016/J.CVFA.2005.03.004]##HERNANDEZ J, 2001, J AM VET MED ASSOC, V219, P632, DOI 10.2460/JAVMA.2001.219.632##HOBSON JC, 2002, J AM VET MED ASSOC, V221, P1160, DOI 10.2460/JAVMA.2002.221.1160##INNES EA, 2002, TRENDS PARASITOL, V18, P497, DOI 10.1016/S1471-4922(02)02372-3##JENSEN AM, 1999, PREV VET MED, V40, P151, DOI 10.1016/S0167-5877(99)00048-3##KEEFE G, 2000, AM ASS BOVINE PRACTI, V33, P150##LOPEZ-GATIUS F, 2005, J VET MED B, V52, P51, DOI 10.1111/J.1439-0450.2004.00811.X##LOPEZ-GATIUS F, 2004, THERIOGENOLOGY, V62, P606, DOI 10.1016/J.THERIOGENOLOGY.2003.11.002##MOEN AR, 1998, THERIOGENOLOGY, V49, P1301, DOI 10.1016/S0093-691X(98)00077-6##ROMERO JJ, 2005, THERIOGENOLOGY, V64, P1928, DOI 10.1016/J.THERIOGENOLOGY.2005.03.023##THURMOND MC, 1996, AM J VET RES, V57, P1559##THURMOND MC, 1997, J AM VET MED ASSOC, V210, P672##TIWARI A, 2005, VET MICROBIOL, V109, P147, DOI 10.1016/J.VETMIC.2005.05.011##TREES AJ, 1999, INT J PARASITOL, V29, P1195, DOI 10.1016/S0020-7519(99)00093-4##VON BLUMRODER D, 2004, VET PARASITOL, V120, P11, DOI 10.1016/J.VETPAR.2003.12.010##WALDNER CL, 1998, J AM VET MED ASSOC, V213, P685##WILMINK JBM, 1987, LIVEST PROD SCI, V16, P335, DOI 10.1016/0301-6226(87)90003-0##WOUDA W, 1998, CLIN DIAGN LAB IMMUN, V5, P711, DOI 10.1128/CDLI.5.5.711-716.1998##WOUDA W, 1999, THERIOGENOLOGY, V52, P233, DOI 10.1016/S0093-691X(99)00125-9",29,2020-11-20,NA
J,WOS:000243569000005,2006,ASYMMETRIC ORGANOCATALYTIC SYNTHESIS OF CIS-SUBSTITUTED DIHYDROBENZOFURANOLS VIA INTRAMOLECULAR ALDOL REACTIONS,THE DIASTEREO- AND ENANTIOSELECTIVE SYNTHESIS OF 3-HYDROXY 2.3-DIHYDROBENZOFURANS VIA AN INTRAMOLECULAR CIS-SELECTIVE ALDOL REACTION EMPLOYING PROLINE-TYPE ORGANOCATALYSTS IS DESCRIBED ENABLING A NEW ENTRY TO COUMARINE NATURAL PRODUCTS.,DE-NOVO SYNTHESIS; TRANSITION-STATES; PROLINE; COUMARINS; INDUCTION; MANNICH; CATALYSIS; ALDEHYDES; MICHAEL; ENTRY,ORGANOCATALYSIS; ALDOL REACTION; ASYMMETRIC SYNTHESIS; PROLINE; DIHYDROBENZOFURAN,SYNLETT,"ENDERS, D##NIEMEIER, O##STRAVER, L","UNIV AACHEN, RHEIN WESTFAL TH AACHEN, INST ORGAN CHEM, D-52074 AACHEN, GERMANY. BRUKER AXS BV, APPLICAT SCD, NL-2600 AV DELFT, NETHERLANDS.","CHEMISTRY, ORGANIC",CHEMISTRY,"APPENDINO G, 2004, J NAT PROD, V67, P532, DOI 10.1021/NP0340652##BAHMANYAR S, 2003, J AM CHEM SOC, V125, P2475, DOI 10.1021/JA028812D##BAHMANYAR S, 2001, J AM CHEM SOC, V123, P12911, DOI 10.1021/JA011714S##BAHMANYAR S, 2001, J AM CHEM SOC, V123, P11273, DOI 10.1021/JA011403H##BERKESSEL A, 2005, ASYMMETRIC ORGANOCATALYSIS: FROM BIOMIMETIC CONCEPTS TO APPLICATIONS IN ASYMMETRIC SYNTHESIS, P1, DOI 10.1002/3527604677##CHRISTMANN M, 2005, ANGEW CHEM INT EDIT, V44, P2632, DOI 10.1002/ANIE.200500761##COHEN N, 1976, ACCOUNTS CHEM RES, V9, P412, DOI 10.1021/AR50107A005##CORDOVA A, 2002, J ORG CHEM, V67, P301, DOI 10.1021/JO015881M##DALKO PI, 2001, ANGEW CHEM INT EDIT, V40, P3726, DOI 10.1002/1521-3773(20011015)40:20<3726::AID-ANIE3726>3.0.CO;2-D##DALKO PI, 2004, ANGEW CHEM INT EDIT, V43, P5138, DOI 10.1002/ANIE.200400650##DRAUZ K, 1982, ANGEW CHEM INT EDIT, V21, P584, DOI 10.1002/ANIE.198205841##EDER U, 1971, ANGEW CHEM INT EDIT, V10, P496, DOI 10.1002/ANIE.197104961##EDER U., 1971, GERMAN PATENT, PATENT NO. 2014757##ENDERS D, 2006, ANGEW CHEM INT EDIT, V45, P1463, DOI 10.1002/ANIE.200503885##ENDERS D, 2006, CHEM COMMUN, P655, DOI 10.1039/B515007H##ENDERS D, 2005, ANGEW CHEM INT EDIT, V44, P4079, DOI 10.1002/ANIE.200500810##ENDERS D, 2005, SYNLETT, P991, DOI 10.1055/S-2005-864813##ENDERS D, 2005, ANGEW CHEM INT EDIT, V44, P1210, DOI 10.1002/ANIE.200462428##ENDERS D, 2004, SYNLETT, P2111, DOI 10.1055/S-2004-831306##ENDERS D, 2004, ACCOUNTS CHEM RES, V37, P534, DOI 10.1021/AR030050J##ENDERS D, 2002, SYNLETT, P26##ENDERS D, 2002, ANGEW CHEM INT EDIT, V41, P1743, DOI 10.1002/1521-3773(20020517)41:10<1743::AID-ANIE1743>3.0.CO;2-Q##ENDERS D, 2006, IN PRESS ENANTIOSELE##ENDERS D, 2006, SYNLETT, P2431, DOI 10.1055/S-2006-950403##ENDERS D, 2006, SYNTHESIS-STUTTGART, P2155, DOI 10.1055/S-2006-942413##ENDERS D, 2006, NATURE, V441, P861, DOI 10.1038/NATURE04820##GRONDAL C, 2006, TETRAHEDRON, V62, P329, DOI 10.1016/J.TET.2005.09.060##GUPTA BD, 1976, PHYTOCHEMISTRY, V15, P576, DOI 10.1016/S0031-9422(00)88988-8##HAJOS Z. G., 1971, GERMAN PATENT, PATENT NO. [DE 2102623, 2102623, DE2102623]##HAJOS ZG, 1974, J ORG CHEM, V39, P1615, DOI 10.1021/JO00925A003##HOANG L, 2003, J AM CHEM SOC, V125, P16, DOI 10.1021/JA028634O##ITAGAKI N, 2005, ORG LETT, V7, P4185, DOI 10.1021/OL051569D##JARVO ER, 2002, TETRAHEDRON, V58, P2481, DOI 10.1016/S0040-4020(02)00122-9##JIMENEZ B, 2000, PHYTOCHEMISTRY, V53, P1025, DOI 10.1016/S0031-9422(99)00524-5##KHANUM SA, 2003, J CHEM RES, P463##LEMMICH J, 1983, PHYTOCHEMISTRY, V22, P553, DOI 10.1016/0031-9422(83)83044-1##LIST B, 2004, P NATL ACAD SCI USA, V101, P5839, DOI 10.1073/PNAS.0307979101##LIST B, 2002, TETRAHEDRON, V58, P5573, DOI 10.1016/S0040-4020(02)00516-1##LIST B, 2000, J AM CHEM SOC, V122, P2395, DOI 10.1021/JA994280Y##LIST B, 2001, SYNLETT, P1675, DOI 10.1055/S-2001-18074##LIST B, 2004, ACCOUNTS CHEM RES, V37, P548, DOI 10.1021/AR0300571##MAHRWALD R, 1999, CHEM REV, V99, P1095, DOI 10.1021/CR980415R##MAHRWALD R., 2004, MODERN ALDOL REACTIO##NORTHRUP AB, 2002, J AM CHEM SOC, V124, P6798, DOI 10.1021/JA0262378##NOTZ W, 2004, ACCOUNTS CHEM RES, V37, P580, DOI 10.1021/AR0300468##NOTZ W, 2000, J AM CHEM SOC, V122, P7386, DOI 10.1021/JA001460V##PALOMO C, 2004, CHEM SOC REV, V33, P65, DOI 10.1039/B202901D##PIDATHALA C, 2003, ANGEW CHEM INT EDIT, V42, P2785, DOI 10.1002/ANIE.200351266##SEAYAD J, 2005, ORG BIOMOL CHEM, V3, P719, DOI 10.1039/B415217B##SESHADRI TR, 1971, INDIAN J CHEM, V9, P418##SHIMOMURA H, 1982, PHYTOCHEMISTRY, V21, P2213, DOI 10.1016/0031-9422(82)85180-7##STORER RI, 2004, TETRAHEDRON, V60, P7705, DOI 10.1016/J.TET.2004.04.089##VILEGAS W, 1993, J NAT PROD, V56, P416, DOI 10.1021/NP50093A015##ZOU YF, 2005, J ORG CHEM, V70, P1761, DOI 10.1021/JO047974K",42,2020-11-20,NA
J,WOS:000242483100020,2006,THE FIRST TOTAL SYNTHESIS OF (R)-CONVOLUTAMYDINE A,"THE FIRST TOTAL SYNTHESIS OF (R)-CONVOLUTAMYDINE A HAS BEEN ACHIEVED BY THE ORGANOCATALYTIC ADDITION OF ACETONE TO 4,6-DIBRO-MOISATIN. THE ABSOLUTE CONFIGURATION WAS DETERMINED BY SINGLE CRYSTAL X-RAY DIFFRACTION. DFT STUDIES WERE USED TO MODEL THE TRANSITION STATES FOR THE ALDOL REACTION AND EQUILIBRIUM GEOMETRIES OF THE POST-ALDOL REACTION INTERMEDIATES. THE DFT STUDY REVEALED THAT THE ALDOL BOND FORMING REACTION WAS CONSIDERABLY ENDOTHERMIC. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",ASYMMETRIC ALDOL REACTIONS; OPTICALLY-ACTIVE STEROIDS; DENSITY-FUNCTIONAL THEORY; CONVOLUTAMYDINE; STEREOSELECTIVITIES; ALKALOIDS; MECHANISM; MANNICH; ORIGIN,CONVOLUTAMYDINE A; ALDOL REACTION; ORGANOCATALYSIS; DFT CALCULATIONS,TETRAHEDRON,"LUPPI, G##MONARI, M##CORREA, RJ##VIOLANTE, FD##PINTO, AC##KAPTEIN, B##BROXTERMAN, QB##GARDEN, SJ##TOMASINI, C","UNIV BOLOGNA, DIPARTIMENTO CHIM G CIAMICIAN, ALMA MATER STUDIORUM, I-40126 BOLOGNA, ITALY. UNIV FED RIO DE JANEIRO, INST QUIM, DEPT QUIM ORGAN, BR-21945090 RIO DE JANEIRO, BRAZIL. DSM RES & PATENTS, NL-6160 MD GELEEN, NETHERLANDS.","CHEMISTRY, ORGANIC",CHEMISTRY,"ALLEMANN C, 2004, ACCOUNTS CHEM RES, V37, P558, DOI 10.1021/AR0300524##ARNO M, 2005, TETRAHEDRON-ASYMMETR, V16, P2764, DOI 10.1016/J.TETASY.2005.06.034##ARNO M, 2002, THEOR CHEM ACC, V108, P232, DOI 10.1007/S00214-002-0381-7##BAHMANYAR S, 2003, J AM CHEM SOC, V125, P2475, DOI 10.1021/JA028812D##BAHMANYAR S, 2003, ORG LETT, V5, P1249, DOI 10.1021/OL034198E##BAHMANYAR S, 2001, J AM CHEM SOC, V123, P12911, DOI 10.1021/JA011714S##BASSAN A, 2005, ANGEW CHEM INT EDIT, V44, P7028, DOI 10.1002/ANIE.200502388##BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913##BURGI HB, 1983, ACCOUNTS CHEM RES, V16, P153, DOI 10.1021/AR00089A002##BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/JA00796A058##BURGI HB, 1974, TETRAHEDRON, V30, P1563, DOI 10.1016/S0040-4020(01)90678-7##CANNIZZARO CE, 2002, J AM CHEM SOC, V124, P7163, DOI 10.1021/JA012417Q##CHEONG PHY, 2006, ORG LETT, V8, P811, DOI 10.1021/OL052861O##CHEONG PHY, 2004, ADV SYNTH CATAL, V346, P1111, DOI 10.1002/ADSC.200404127##CLEMENTE FR, 2005, J AM CHEM SOC, V127, P11294, DOI 10.1021/JA0507620##CLEMENTE FR, 2004, ANGEW CHEM INT EDIT, V43, P5766, DOI 10.1002/ANIE.200460916##CORDOVA A, 2005, CHEM COMMUN, P3586, DOI 10.1039/B507968N##CORDOVA A, 2002, J ORG CHEM, V67, P301, DOI 10.1021/JO015881M##EDER U, 1971, ANGEW CHEM INT EDIT, V10, P496, DOI 10.1002/ANIE.197104961##EDER U., 1971, GERMAN PATENT, PATENT NO. 2014757##FORMAGGIO F, 2004, J PEPT RES, V63, P161, DOI 10.1111/J.1399-3011.2003.00123.X##FRISCH M.J., 1998, GAUSSIAN 98 REVISION##GARDEN SJ, 1997, TETRAHEDRON LETT, V38, P1501, DOI 10.1016/S0040-4039(97)00140-8##HAJOS Z. G., 1971, GERMAN PATENT, PATENT NO. [DE 2102623, 2102623, DE2102623]##HAJOS ZG, 1974, J ORG CHEM, V39, P1615, DOI 10.1021/JO00925A003##HAMMOND GS, 1955, J AM CHEM SOC, V77, P334, DOI 10.1021/JA01607A027##HOANG L, 2003, J AM CHEM SOC, V125, P16, DOI 10.1021/JA028634O##JNANESHWAR GK, 1999, J CHEM RES, P632, DOI 10.1039/A904205I##JNANESHWARA GK, 1999, SYNTHETIC COMMUN, V29, P3627, DOI 10.1080/00397919908085998##JUNG ME, 1976, TETRAHEDRON, V32, P3, DOI 10.1016/0040-4020(76)80016-6##KAMANO Y, 1995, TETRAHEDRON LETT, V36, P2783, DOI 10.1016/0040-4039(95)00395-S##KAPTEIN B, 1993, TETRAHEDRON-ASYMMETR, V4, P1113, DOI 10.1016/S0957-4166(00)80217-7##KAWASAKI T, 2004, TETRAHEDRON, V60, P3493, DOI 10.1016/J.TET.2004.02.031##KRUIZINGA WH, 1988, J ORG CHEM, V53, P1826, DOI 10.1021/JO00243A049##LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PHYSREVB.37.785##LIST B, 2004, P NATL ACAD SCI USA, V101, P5839, DOI 10.1073/PNAS.0307979101##LIST B, 2000, J AM CHEM SOC, V122, P2395, DOI 10.1021/JA994280Y##LIST B, 2001, SYNLETT, P1675, DOI 10.1055/S-2001-18074##LOZA E, 1995, J CHROMATOGR A, V708, P231##LUPPI G, 2005, J ORG CHEM, V70, P7418, DOI 10.1021/JO050257L##MASE N, 2006, J AM CHEM SOC, V128, P734, DOI 10.1021/JA0573312##NAKAMURA T, 2006, ORG LETT, V8, P677, DOI 10.1021/OL052871P##NOTZ W, 2000, J AM CHEM SOC, V122, P7386, DOI 10.1021/JA001460V##PIHKO PM, 2006, TETRAHEDRON, V62, P317, DOI 10.1016/J.TET.2005.09.070##RANKIN KN, 2002, J PHYS CHEM A, V106, P5155, DOI 10.1021/JP020079P##RUPPERT J, 1973, CHEM BER-RECL, V106, P3636, DOI 10.1002/CBER.19731061123##SAKTHIVEL K, 2001, J AM CHEM SOC, V123, P5260, DOI 10.1021/JA010037Z##STEPHANI R, 1998, J CHROMATOGR A, V813, P79, DOI 10.1016/S0021-9673(98)00339-2##TAKAYAMA H, 1999, TETRAHEDRON, V55, P6841, DOI 10.1016/S0040-4020(99)00337-3##ZHANG HP, 1994, TETRAHEDRON, V50, P10201, DOI 10.1016/S0040-4020(01)81752-X##ZHANG HP, 1995, TETRAHEDRON, V51, P5523, DOI 10.1016/0040-4020(95)00241-Y",104,2020-11-20,NA
J,WOS:000243715100002,2006,"DESIGN OF THE DUTCH OBESITY INTERVENTION IN TEENAGERS (NRG-DOIT): SYSTEMATIC DEVELOPMENT, IMPLEMENTATION AND EVALUATION OF A SCHOOL-BASED INTERVENTION AIMED AT THE PREVENTION OF EXCESSIVE WEIGHT GAIN IN ADOLESCENTS","BACKGROUND: ONLY LIMITED DATA ARE AVAILABLE ON THE DEVELOPMENT, IMPLEMENTATION, AND EVALUATION PROCESSES OF WEIGHT GAIN PREVENTION PROGRAMS IN ADOLESCENTS. TO BE ABLE TO LEARN FROM SUCCESSES AND FAILURES OF SUCH INTERVENTIONS, INTEGRAL WRITTEN AND PUBLISHED REPORTS ARE NEEDED. METHODS: APPLYING THE INTERVENTION MAPPING (IM) PROTOCOL, THIS PAPER DESCRIBES THE DEVELOPMENT, IMPLEMENTATION, AND EVALUATION OF THE DUTCH OBESITY INTERVENTION IN TEENAGERS (DOIT), A SCHOOL-BASED INTERVENTION PROGRAM AIMED AT THE PREVENTION OF EXCESSIVE WEIGHT GAIN. THE INTERVENTION FOCUSSED ON THE FOLLOWING HEALTH BEHAVIOURS: ( 1) REDUCTION OF THE CONSUMPTION OF SUGAR-SWEETENED BEVERAGES, ( 2) REDUCTION OF ENERGY INTAKE DERIVED FROM SNACKS, ( 3) DECREASE OF LEVELS OF SEDENTARY BEHAVIOUR, AND ( 4) INCREASE OF LEVELS OF PHYSICAL ACTIVITY (I.E. ACTIVE TRANSPORT BEHAVIOUR AND SPORTS PARTICIPATION). THE INTERVENTION PROGRAM CONSISTED OF AN INDIVIDUAL CLASSROOM-BASED COMPONENT (I.E. AN EDUCATIONAL PROGRAM, COVERING 11 LESSONS OF BOTH BIOLOGY AND PHYSICAL EDUCATION CLASSES), AND AN ENVIRONMENTAL COMPONENT (I.E. ENCOURAGING AND SUPPORTING CHANGES AT THE SCHOOL CANTEENS, AS WELL AS OFFERING ADDITIONAL PHYSICAL EDUCATION CLASSES). WE EVALUATED THE EFFECTIVENESS OF THE INTERVENTION PROGRAM USING A RANDOMISED CONTROLLED TRIAL DESIGN. WE ASSESSED THE EFFECTS OF THE INTERVENTION ON BODY COMPOSITION ( PRIMARY OUTCOME MEASURE), AS WELL AS ON BEHAVIOUR, BEHAVIOURAL DETERMINANTS, AND AEROBIC FITNESS ( SECONDARY OUTCOME MEASURES). FURTHERMORE, WE CONDUCTED A PROCESS EVALUATION. DISCUSSION: THE DEVELOPMENT OF THE DOIT-INTERVENTION RESULTED IN A COMPREHENSIVE SCHOOLBASED WEIGHT GAIN PREVENTION PROGRAM, TAILORED TO THE NEEDS OF DUTCH ADOLESCENTS FROM LOW SOCIOECONOMIC BACKGROUND.",BALANCE-RELATED BEHAVIORS; CSA ACTIVITY MONITOR; PHYSICAL-ACTIVITY; CHILDHOOD OBESITY; DIABETES-MELLITUS; RANDOMIZED-TRIALS; COMPUTER-SCIENCE; FOOD-CONSUMPTION; FAT DISTRIBUTION; DIETARY-INTAKE,NA,BMC PUBLIC HEALTH,"SINGH, AS##PAW, MJCA##KREMERS, SPJ##VISSCHER, TLS##BRUG, J##VAN MECHELEN, W","VRIJE UNIV AMSTERDAM MED CTR, EMGO INST, AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM MED CTR, DEPT PUBL & OCCUPAT HLTH, AMSTERDAM, NETHERLANDS. UNIV MAASTRICHT, DEPT HLTH EDUC & HLTH PROMOT, MAASTRICHT, NETHERLANDS. VRIJE UNIV AMSTERDAM, INST HLTH SCI, AMSTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR ROTTERDAM, DEPT PUBL HLTH, ROTTERDAM, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","AARTS H, 1997, HEALTH EDUC RES, V12, P363, DOI 10.1093/HER/12.3.363##AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T##ALTMAN DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012##ANDERSEN RE, 1998, JAMA-J AM MED ASSOC, V279, P938, DOI 10.1001/JAMA.279.12.938##ARMITAGE CJ, 2004, HEALTH PSYCHOL, V23, P319, DOI 10.1037/0278-6133.23.3.319##BARANOWSKI T, 1999, ANNU REV NUTR, V19, P17, DOI 10.1146/ANNUREV.NUTR.19.1.17##BARTHOLOMEW LK, 2001, INTERVENTION MAPPING##BAUMAN AE, 2002, AM J PREV MED, V23, P5, DOI 10.1016/S0749-3797(02)00469-5##BEGG C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/JAMA.276.8.637##BILLINGTON CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/ARCHINTE.160.7.898##BRUG J, 2005, INT J BEHAV NUTR PHY, V2, P2, DOI DOI 10.1186/1479-5868-2-2##CAREY VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/OXFORDJOURNALS.AJE.A009158##CHAIKEN S, 1999, DUAL PROCESS THEORY##CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/DIACARE.17.9.961##COUNCIL OF EUROPE, 1988, EUR HDB EUR TESTS PH##DETERDING D, 2001, J PHONETICS, V29, P217, DOI 10.1006/JPHO.2001.0138##DOAK CM, 2006, OBES REV, V7, P111, DOI 10.1111/J.1467-789X.2006.00234.X##DONAHUE RP, 1990, HORM METAB RES, V22, P46##DURNIN JVG, 1967, BRIT J NUTR, V21, P681, DOI 10.1079/BJN19670070##EGGER G, 1997, BRIT MED J, V315, P477, DOI 10.1136/BMJ.315.7106.477##FLODMARK CE, 2006, INT J OBESITY, V30, P579, DOI 10.1038/SJ.IJO.0803290##FRENN MARILYN, 2003, J PEDIATR NURS, V18, P36, DOI 10.1053/JPDN.2003.6##GIAMMATTEI J, 2003, ARCH PEDIAT ADOL MED, V157, P882, DOI 10.1001/ARCHPEDI.157.9.882##GOLLWITZER PM, 1999, AM PSYCHOL, V54, P493, DOI 10.1037//0003-066X.54.7.493##GORDON-LARSEN P, 2000, PEDIATRICS, V105, DOI 10.1542/PEDS.105.6.E83##GORELY T, 2004, INT J BEHAV MED, V11, P152, DOI 10.1207/S15327558IJBM1103_4##HALFORD JCG, 2004, APPETITE, V42, P221, DOI 10.1016/J.APPET.2003.11.006##HARDEMAN W, 2000, INT J OBESITY, V24, P131, DOI 10.1038/SJ.IJO.0801100##HILL JO, 2003, SCIENCE, V299, P853, DOI 10.1126/SCIENCE.1079857##*HLTH COUNC NETH C, 2002, VOL PUBL##HOLLIS S, 1999, BRIT MED J, V319, P670, DOI 10.1136/BMJ.319.7211.670##HULSHOF KFAM, 2003, EUR J CLIN NUTR, V57, P128, DOI 10.1038/SJ.EJCN.1601503##JAMES J, 2004, BMJ-BRIT MED J, V328, P1237, DOI 10.1136/BMJ.38077.458438.EE##JANSEN J, 2002, VOLUME 270555004##KILLEN JD, 1989, HEALTH EDUC QUART, V16, P263, DOI 10.1177/109019818901600210##KOK G, 2004, J HEALTH PSYCHOL, V9, P85, DOI 10.1177/1359105304038379##KREMERS SPJ, 2005, EUR J CLIN NUTR, V59, P498, DOI 10.1038/SJ.EJCN.1602100##KREMERS SPJ, 2004, PSYCHOL HEALTH, V19, P595, DOI 10.1080/08870440412331279630##KREMERS SPJ, 2006, INT J BEHAV NUTR PHY, V3, DOI 10.1186/1479-5868-3-9##KROEZE W, 2006, ANN BEHAV MED, V31, P205, DOI 10.1207/S15324796ABM3103_2##KVAAVIK E, 2003, ARCH PEDIAT ADOL MED, V157, P1212, DOI 10.1001/ARCHPEDI.157.12.1212##LEGER LA, 1988, J SPORT SCI, V6, P93, DOI 10.1080/02640418808729800##LIEN N, 2001, PREV MED, V33, P217, DOI 10.1006/PMED.2001.0874##LOBSTEIN T, 2004, OBES REV S1, V5, P4, DOI DOI 10.1111/J.1467-789X.2004.00133.X##LONG BJ, 1996, AM J PREV MED, V12, P73##LUDWIG DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1##MALIK VS, 2006, AM J CLIN NUTR, V84, P274##MARTENS MK, 2006, IN PRESS HLTH ED RES##MELANSON EL, 1995, MED SCI SPORT EXER, V27, P934##METCALF BS, 2002, MED SCI SPORT EXER, V34, P1533, DOI 10.1097/00005768-200209000-00022##MIKKILA V, 2004, EUR J CLIN NUTR, V58, P1038, DOI 10.1038/SJ.EJCN.1601929##MILNE S, 2002, BRIT J HEALTH PSYCH, V7, P163, DOI 10.1348/135910702169420##MUST A, 2005, INT J OBESITY, V29, PS84, DOI 10.1038/SJ.IJO.0803064##NICKLAS TA, 2001, J AM COLL NUTR, V20, P599, DOI 10.1080/07315724.2001.10719064##NIELSEN SJ, 2002, PREV MED, V35, P107, DOI 10.1006/PMED.2002.1037##OENEMA A, 2005, ANN BEHAV MED, V29, P54, DOI 10.1207/S15324796ABM2901_8##PEREZ-RODRIGO C, 2005, ANN NUTR METAB, V49, P267, DOI 10.1159/000087249##POPPITT SD, 1998, INT J OBESITY, V22, P303, DOI 10.1038/SJ.IJO.0800584##PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/BMJ.311.7002.437##PUYAU MR, 2002, OBES RES, V10, P150, DOI 10.1038/OBY.2002.24##RENNIE KL, 2005, BEST PRACT RES CL EN, V19, P343, DOI 10.1016/J.BEEM.2005.04.003##RESNICOW K, 1993, ANN NY ACAD SCI, V699, P154, DOI 10.1111/J.1749-6632.1993.TB18847.X##REXRODE KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/JAMA.280.21.1843##RIDDOCH CJ, 2004, MED SCI SPORT EXER, V36, P86, DOI 10.1249/01.MSS.0000106174.43932.92##ROBINSON TN, 2001, PEDIATR CLIN N AM, V48, P1017, DOI 10.1016/S0031-3955(05)70354-0##ROBINSON TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/JAMA.282.16.1561##ROGERS E. M, 1995, DIFFUSION INNOVATION##SALLIS JF, 2000, MED SCI SPORT EXER, V32, P963, DOI 10.1097/00005768-200009000-00012##SEIDELL JC, 2000, PHYS ACTIVITY OBESIT##SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/PMED.1993.1014##STEINBECK K, 2005, BEST PRACT RES CL EN, V19, P455, DOI 10.1016/J.BEEM.2005.04.010##STORY M, 1999, INT J OBESITY, V23, PS43, DOI 10.1038/SJ.IJO.0800859##SUMMERBELL CD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001871.PUB2##SWINBURN B, 1999, PREV MED, V29, P563, DOI 10.1006/PMED.1999.0585##TAMMELIN T, 2003, AM J PREV MED, V24, P22, DOI 10.1016/S0749-3797(02)00575-5##TORDOFF MG, 1990, AM J CLIN NUTR, V51, P963##TROST S G, 2001, EXERC SPORT SCI REV, V29, P32, DOI 10.1097/00003677-200101000-00007##TROST SG, 1998, MED SCI SPORT EXER, V30, P629, DOI 10.1097/00005768-199804000-00023##VAN ASSEMA P, 2001, J HUM NUTR DIET, V14, P377, DOI 10.1046/J.1365-277X.2001.00310.X##VAN ASSEMA PATRICIA, 2002, NUTRITION AND HEALTH (BICESTER), V16, P85##VAN MECHELEN W, 2000, MED SCI SPORT EXER, V32, P1610##VAN SLUIJS EM, 2004, FAM PRACT, V21, P429, DOI 10.1093/FAMPRA/CMH414##VANDER HK, 2006, HLTH ED RES##VANMECHELEN W, 1986, EUR J APPL PHYSIOL O, V55, P503, DOI 10.1007/BF00421645##VERPLANKEN B, 1999, EUR J SOC PSYCHOL, V29, P591, DOI 10.1002/(SICI)1099-0992(199908/09)29:5/6<591::AID-EJSP948>3.0.CO;2-H##WANG YF, 2001, INT J EPIDEMIOL, V30, P1129, DOI 10.1093/IJE/30.5.1129##*WHO, 2003, VOL WHO TECHN REP, V916##ZEIJL E, 2003, RAPPORTAGE JEUGD 200##ZIMMERMAN BJ, 2000, HDB SELF REGULATION, P13, DOI DOI 10.1016/B978-012109890-2/50031-7",76,2020-11-20,NA
J,WOS:000242698600010,2006,"PARAMETERIZING, EVALUATING AND COMPARING METAPOPULATION MODELS WITH DATA FROM INDIVIDUAL-BASED SIMULATIONS","DUE TO THE LACK OF SUFFICIENT DATA AND APPROPRIATE ECOLOGICAL INFORMATION PARAMETERIZING PREDICTIVE POPULATION DYNAMICAL MODELS USUALLY IS A DIFFICULT TASK. THE APPROACH PROPOSED IN THIS STUDY IS MEANT TO OVERCOME THIS PROBLEM BY USING DETAILED INDIVIDUAL-BASED SIMULATIONS TO GENERATE ARTIFICIAL DATA. WITH SHORT-TERM DATA SAMPLES, THE MODELS TO BE INVESTIGATED CAN BE PARAMETERIZED AND THEIR PREDICTIONS BE COMPARED. THE FLEXIBILITY OF INDIVIDUAL-BASED SIMULATIONS AS EXPERIMENTAL TOOLS ALSO FACILITATES THE EVALUATION AND COMPARISON OF DIFFERENT (AGGREGATED) MODEL TYPES. THE PRESENTED APPROACH IS A STEP TOWARDS UNIFYING MODELS OF DIFFERENT COMPLEXITY. AS AN EXAMPLE WE APPLIED IT TO TWO METAPOPULATION MODELS OF INSECT SPECIES IN A HIGHLY FRAGMENTED LANDSCAPE: THE WELL-KNOWN INCIDENCE FUNCTION MODEL WITH A PATCH-BASED REPRESENTATION OF SPACE AND A GRID-BASED ANALOGUE. THE MODELS ARE TESTED WITH RESPECT TO THEIR DATA REQUIREMENT AND RECOMMENDATIONS FOR A BETTER DATA SAMPLING ARE DERIVED. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",PATCH OCCUPANCY MODELS; ECOLOGICAL THEORY; POPULATION; DYNAMICS; DISPERSAL; PATTERN; HETEROGENEITY; OPTIMIZATION; PERSISTENCE; EXTINCTION,MODEL COMPARISON; PARAMETERIZATION; METAPOPULATION; INDIVIDUAL-BASED MODEL; INCIDENCE FUNCTION MODEL; GRID-BASED,ECOLOGICAL MODELLING,"HILKER, FM##HINSCH, M##POETHKE, HJ","UNIV OSNABRUCK, DEPT MATH & COMP SCI, INST ENVIRONM SYST RES, D-49069 OSNABRUCK, GERMANY. UNIV GRONINGEN, CEES, NL-9751 NN HAREN, NETHERLANDS. UNIV WURZBURG, FIELD STN FABRIKSCHLEICHACH, D-96181 RAUHENEBRACH, GERMANY.",ECOLOGY,ENVIRONMENTAL SCIENCES & ECOLOGY,"ADLER FR, 1994, THEOR POPUL BIOL, V45, P41, DOI 10.1006/TPBI.1994.1003##APPELT M, 1997, J INSECT CONSERV, V1, P205, DOI 10.1023/A:1018468017604##BASCOMPTE J, 1998, DYNAMICS ECOLOGY##BERGER U, 1999, ECOL MODEL, V115, P119, DOI 10.1016/S0304-3800(98)00187-2##BOUNDS DG, 1987, NATURE, V329, P215, DOI 10.1038/329215A0##BOYCE MS, 1992, ANNU REV ECOL SYST, V23, P481, DOI 10.1146/ANNUREV.ES.23.110192.002405##BROWN JH, 1977, ECOLOGY, V58, P445, DOI 10.2307/1935620##CASAGRANDI R, 1999, NATURE, V400, P560##CASAGRANDI R, 2002, THEOR POPUL BIOL, V61, P127, DOI 10.1006/TPBI.2001.1559##CZARAN T, 1998, SPATIOTEMPORAL MODEL##DEANGELIS D. L., 1992, INDIVIDUAL BASED MOD##FAHSE L, 1998, AM NAT, V152, P838, DOI 10.1086/286212##FRANK K, 2002, AM NAT, V159, P530, DOI 10.1086/338991##GOSSELIN F, 1998, B MATH BIOL, V60, P955, DOI 10.1006/BULM.1998.0052##GOSSELIN F, 1999, MATH BIOSCI, V159, P21, DOI 10.1016/S0025-5564(99)00018-8##GRIMM V, 1999, ECOL MODEL, V115, P129, DOI 10.1016/S0304-3800(98)00188-4##GRIMM V, 1996, SCI TOTAL ENVIRON, V183, P151, DOI 10.1016/0048-9697(95)04966-5##GRIMM V, 1999, ECOL MODEL, V115, P275, DOI 10.1016/S0304-3800(98)00186-0##GRIMM V., 2005, PRINCETON SERIES THE##GYLLENBERG MATS, 1997, P93, DOI 10.1016/B978-012323445-2/50008-0##HANSKI I, 1994, J ANIM ECOL, V63, P151, DOI 10.2307/5591##HANSKI I, 2000, NATURE, V404, P755, DOI 10.1038/35008063##HANSKI I, 1996, CONSERV BIOL, V10, P578, DOI 10.1046/J.1523-1739.1996.10020578.X##HANSKI I, 2001, NATURWISSENSCHAFTEN, V88, P372, DOI 10.1007/S001140100246##HANSKI I., 1999, METAPOPULATION ECOLO##HARRISON S, 1991, BIOL J LINN SOC, V42, P73, DOI 10.1111/J.1095-8312.1991.TB00552.X##HARRISON SUSAN, 1994, P111##HEIN S, 2004, ECOL MODEL, V174, P411, DOI 10.1016/J.ECOLMODEL.2003.10.005##HOKIT DG, 2001, CONSERV BIOL, V15, P1102, DOI 10.1046/J.1523-1739.2001.0150041102.X##JEPSEN JU, 2005, ECOL MODEL, V181, P445, DOI 10.1016/J.ECOLMODEL.2003.11.019##KEELING MJ, 2002, J ANIM ECOL, V71, P270, DOI 10.1046/J.1365-2656.2002.00594.X##KINDVALL O, 1999, J ANIM ECOL, V68, P172, DOI 10.1046/J.1365-2656.1999.00273.X##KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/SCIENCE.220.4598.671##LEVINS R, 1969, BULLETIN OF THE ENTOMOLOGICAL SOCIETY OF AMERICA, V15, P237##MCCARTHY MA, 2003, CONSERV BIOL, V17, P982, DOI 10.1046/J.1523-1739.2003.01570.X##MOILANEN A, 2004, ECOL MODEL, V179, P533, DOI 10.1016/J.ECOLMODEL.2004.04.019##MOILANEN A, 2002, OIKOS, V96, P516, DOI 10.1034/J.1600-0706.2002.960313.X##MOILANEN A, 1998, AM NAT, V152, P530, DOI 10.1086/286188##MOILANEN A, 1999, ECOLOGY, V80, P1031, DOI 10.2307/177036##MOILANEN A, 2000, J ANIM ECOL, V69, P143, DOI 10.1046/J.1365-2656.2000.00381.X##OVASKAINEN O, 2004, AM NAT, V164, P364, DOI 10.1086/423151##OVASKAINEN O, 2002, AM NAT, V160, P612, DOI 10.1086/342818##OVASKAINEN O, 2001, THEOR POPUL BIOL, V60, P281, DOI 10.1006/TPBI.2001.1548##PECK SL, 2004, TRENDS ECOL EVOL, V19, P530, DOI 10.1016/J.TREE.2004.07.019##POETHKE HANS JOACHIM, 1996, ZEITSCHRIFT FUER OEKOLOGIE UND NATURSCHUTZ, V5, P229##REVILLA E, 2004, AM NAT, V164, PE130, DOI 10.1086/424767##SETTELE J, 1998, METAPOPULATIONSANALY##SJOGREN-GULVE PER, 2000, ECOLOGICAL BULLETINS, V48, P53##TER BRAAK CJF, 1998, ENVIRONM INTELL UNIT, P167##THOMAS CD, 1994, TRENDS ECOL EVOL, V9, P300, DOI 10.1016/0169-5347(94)90039-6##TILMAN D., 1997, SPATIAL ECOLOGY ROLE##TURCHIN P, 1998, QUANTITATIVE ANAL MO##UEBERHUBER CW, 1997, NUMERICAL COMPUTATIO, V2##WAHLBERG N, 1996, SCIENCE, V273, P1536, DOI 10.1126/SCIENCE.273.5281.1536##WIEGAND T, 2003, OIKOS, V100, P209, DOI 10.1034/J.1600-0706.2003.12027.X##WILSON WG, 1998, AM NAT, V151, P116, DOI 10.1086/286106",16,2020-11-20,NA
J,WOS:000240782200006,2006,THE EQUIVALENCE PROBLEM FOR DETERMINISTIC MSO TREE TRANSDUCERS IS DECIDABLE,IT IS DECIDABLE FOR DETERMINISTIC MSO DEFINABLE GRAPH-TO-STRING OR GRAPH-TO-TREE TRANSDUCERS WHETHER THEY ARE EQUIVALENT ON A CONTEXT-FREE SET OF GRAPHS. (C) 2006 PUBLISHED BY ELSEVIER B.V.,TRANSLATIONS; LANGUAGES,FORMAL LANGUAGES; AUTOMATA THEORY; EQUIVALENCE PROBLEM; TRANSDUCER,INFORMATION PROCESSING LETTERS,"ENGELFRIET, J##MANETH, S","ECOLE POLYTECH FED LAUSANNE, CH-1015 LAUSANNE, SWITZERLAND. LEIDEN UNIV, LIACS, NL-2300 RA LEIDEN, NETHERLANDS.","COMPUTER SCIENCE, INFORMATION SYSTEMS",COMPUTER SCIENCE,"AHO AV, 1971, INFORM CONTROL, V19, P439, DOI 10.1016/S0019-9958(71)90706-6##BLOEM R, 2000, J COMPUT SYST SCI, V61, P1, DOI 10.1006/JCSS.1999.1684##COURCELLE B, 1982, INFORM CONTROL, V52, P275, DOI 10.1016/S0019-9958(82)90786-0##COURCELLE B, 1994, THEOR COMPUT SCI, V126, P53, DOI 10.1016/0304-3975(94)90268-2##COURCELLE B., 1997, HDB GRAPH GRAMMARS C, V1, P313, DOI DOI 10.1142/9789812384720_##CULIK K, 1987, SIAM J COMPUT, V16, P221##ENGELFRIET J, 1980, J COMPUT SYST SCI, V20, P150, DOI 10.1016/0022-0000(80)90058-6##ENGELFRIET J, 2005, LECT NOTES COMPUT SC, V3821, P495##ENGELFRIET J, 2003, ACTA INFORM, V39, P613, DOI 10.1007/S00236-003-0120-0##ENGELFRIET J, 2003, SIAM J COMPUT, V32, P950, DOI 10.1137/S0097539701394511##ENGELFRIET J, 1999, INFORM COMPUT, V154, P34, DOI 10.1006/INCO.1999.2807##ENGELFRIET J., 1980, FORMAL LANGUAGE THEO##ENGELFRIET J, 1997, HDB FORMAL LANGUAGES, V3, P125##ENGELFRIET J., 2001, ACM T COMPUT LOG, V2, P216, DOI DOI 10.1145/371316.371512##ESIK Z, 1980, ACTA CYBERNETICA##FULOP Z, 1998, EATCS MONOGRAPHS THE##GINSBURG S, 1964, T AM MATH SOC, V113, P333, DOI 10.2307/1994067##GINSBURG S, 1966, MATH THEORY CONTEXT##GRIFFITHS TV, 1968, J ACM, V15, P409, DOI 10.1145/321466.321473##GURARI EM, 1982, SIAM J COMPUT, V11, P448, DOI 10.1137/0211035##IBARRA OH, 1982, THEOR COMPUT SCI, V19, P219, DOI 10.1016/0304-3975(82)90061-5##MANETH S, 2003, LECT NOTES COMPUT SC, V2914, P326##MANETH S, 2005, PODS, P283, DOI DOI 10.1145/1065167.1065203##MILO T, 2003, J COMPUT SYST SCI, V66, P66, DOI 10.1016/S0022-0000(02)00030-2##PARIKH RJ, 1966, J ACM, V13, P570, DOI 10.1145/321356.321364##ZACHAR Z, 1980, ACTA CYBERNET, V4, P167",22,2020-11-20,NA
J,WOS:000242953400003,2006,SIMULATING HOLOCENE CARBON ACCUMULATION IN A WESTERN SIBERIAN WATERSHED MIRE USING A THREE-DIMENSIONAL DYNAMIC MODELING APPROACH,"THE VAST UNDISTURBED MIRES IN WESTERN SIBERIA FORMED A SIGNIFICANT SINK OF ATMOSPHERIC CARBON DIOXIDE DURING THE HOLOCENE. HOWEVER, THE LACK OF SPATIALLY RESOLVED SIMULATION MODELS HAMPERS THE QUANTIFICATION OF HOLOCENE CARBON ACCUMULATION OF THE ENTIRE MIRE SYSTEMS. HERE WE DEVELOPED A THREE-DIMENSIONAL DYNAMIC MODEL, BASED ON A HYDROLOGICAL APPROACH. WE APPLIED THE MODEL TO A LARGE MIRE COMPLEX IN WESTERN SIBERIA TO SIMULATE ITS HOLOCENE DEVELOPMENT AND TO QUANTIFY THE LONG-TERM CARBON ACCUMULATION RATE (LORCA). OUR MODEL SIMULATED A LORCA WITH A SPATIAL VARIATION OF 10-85 G C M(-2) YR(-1). THE AVERAGE OVER THE HOLOCENE WAS 16.2 G C M(-2) YR(-1). SIMULATION SCENARIOS FOR THE 21ST CENTURY SHOW THAT THE AVERAGE LORCA DROPPED TO 5.2 G C M(-2) YR(-1) BECAUSE OF OXIDATION AND DECOMPOSITION OF PEAT FOLLOWING MIRE DRAINAGE AFTER THE 1950S. EVEN IN THE UNDRAINED PARTS OF THE MIRE COMPLEX THE LORCA IS LOWERED SUBSTANTIALLY BECAUSE OF THE DROPPED WATER TABLE AND RESULTING DECREASE IN PEAT GROWTH. OUR RESULTS SHOW THAT CARBON ACCUMULATION IN WESTERN SIBERIAN WATERSHED MIRES WILL CONTINUE IN THE FUTURE. THUS THESE MIRES MIGHT REMAIN A SIGNIFICANT SINK OF CARBON.",HYDRAULIC CONDUCTIVITY; RAISED MIRE; PEAT BOG; PEATLANDS; CALIBRATION; HYDROLOGY; PROGRAM; FLOW,NA,WATER RESOURCES RESEARCH,"BORREN, W##BLEUTEN, W","UNIV UTRECHT, PHYS GEOG RES INST, NL-3508 TC UTRECHT, NETHERLANDS.",ENVIRONMENTAL SCIENCES; LIMNOLOGY; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; MARINE & FRESHWATER BIOLOGY; WATER RESOURCES,"BECKWITH CW, 2003, HYDROL PROCESS, V17, P89, DOI 10.1002/HYP.1116##BLEUTEN W., 2001, CARBON STORAGE ATMOS##BORREN W, 2004, QUATERNARY RES, V61, P42, DOI 10.1016/J.YQRES.2003.09.002##BOTCH MS, 1995, GLOBAL BIOGEOCHEM CY, V9, P37, DOI 10.1029/94GB03156##CAMPBELL DI, 1997, J HYDROL, V193, P142, DOI 10.1016/S0022-1694(96)03149-6##CLYMO RS, 1984, PHILOS T ROY SOC B, V303, P605, DOI 10.1098/RSTB.1984.0002##CLYMO RS, 2004, HYDROL PROCESS, V18, P261, DOI 10.1002/HYP.1374##DOHERTY J, 2003, PEST MODEL INDEPENDE##FETTER CW, 2001, APPL HYDROGEOLOGY##HARBAUGH AW, 2000, 0092 US GEOL SURV, P121##HEMOND HF, 1985, J ECOL, V73, P579, DOI 10.2307/2260495##HOLDEN J, 2003, HYDROL PROCESS, V17, P1227, DOI 10.1002/HYP.1182##INGRAM HAP, 1967, J ECOL, V55, P711, DOI 10.2307/2258420##INGRAM HAP, 1982, NATURE, V297, P300, DOI 10.1038/297300A0##IVANOV KE, 1981, WATER MOVEMENT MIREL##KLIMANOV VA, 1984, LATE QUATERNARY ENV, P297##KORHOLA A, 1996, J QUATERNARY SCI, V11, P161, DOI 10.1002/(SICI)1099-1417(199603/04)11:2<161::AID-JQS248>3.0.CO;2-J##KREMENETSKI KV, 2003, QUATERNARY SCI REV, V22, P703, DOI 10.1016/S0277-3791(02)00196-8##LAPSHINA ED, 2001, CARBON STORAGE ATMOS, P23##MEHL SW, 2001, 01177 US GEOL SURV##PEBESMA EJ, 1998, COMPUT GEOSCI-UK, V24, P17, DOI 10.1016/S0098-3004(97)00082-4##RAMSEY CB, 1995, RADIOCARBON, V37, P425, DOI 10.1017/S0033822200030903##REEVE AS, 2000, J HYDROL, V227, P207, DOI 10.1016/S0022-1694(99)00183-3##RYCROFT DW, 1975, J ECOL, V63, P535, DOI 10.2307/2258734##SHENG YW, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002190##STUIVER M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123##TURUNEN J, 2001, GLOBAL BIOGEOCHEM CY, V15, P285, DOI 10.1029/2000GB001312##WESSELING C.G., 1996, T GIS, V1, P40, DOI DOI 10.1111/J.1467-9671.1996.TB00032.X##WINSTON RB, 1994, GEOL SOC AM BULL, V106, P1594, DOI 10.1130/0016-7606(1994)106&LT;1594:MOTGHA&GT;2.3.CO;2##YEFREMOV SP, 2001, CARBON STORAGE ATMOS, P73##YU ZC, 2001, ECOL MODEL, V145, P197, DOI 10.1016/S0304-3800(01)00391-X",14,2020-11-20,NA
J,WOS:000242466200024,2006,"FRONTOMETAPHYSEAL DYSPLASIA: MUTATIONS IN FLNA AND PHENOTYPIC DIVERSITY (VOL 140A, PG 1726, 2006)",NA,NA,NA,AMERICAN JOURNAL OF MEDICAL GENETICS PART A,"ROBERTSON, SP##JENKINS, ZA##MORGAN, T##ADES, L##AFTIMOS, S##BOUTE, O##FISKERSTRAND, T##GARCIA-MINAUR, S##GRIX, A##GREEN, A##KALOUISTIAN, VD##LEWKONIA, R##MCINNES, B##VAN HAELST, MM##MACINI, G##ILLES, T##MORTIER, G##NEWBURY-ECOB, R##NICHOLSON, L##SCOTT, CI##OCHMAN, K##BROZEK, I##SHEARS, DJ##SUPERTI-FURGA, A##SURI, M##WHITEFORD, M##WILKIE, AOM##KRAKOW, D","DUNEDIN SCH MED, DEPT PAEDIAT & CHILD HLTH, DUNEDIN, NEW ZEALAND. CHILDRENS HOSP WESTMEAD, DEPT MED GENET, SYDNEY, NSW, AUSTRALIA. UNIV SYDNEY, DISCIPLINE PAEDIAT & CHILD HLTH, SYDNEY, NSW 2006, AUSTRALIA. NO REG GENET SERV, AUCKLAND, NEW ZEALAND. JEANNE FLANDRE HOSP, GENET SERV, LILLE, FRANCE. HAUKELAND HOSP, CTR MED GENET & MOL MED, N-5021 BERGEN, NORWAY. WESTERN GEN HOSP, GENET SERV, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND. PERMANENTE MED GRP INC, SACRAMENTO, CA USA. OUR LADYS HOSP SICK CHILDREN, DEPT MED GENET, DUBLIN 12, IRELAND. MCGILL UNIV, MONTREAL CHILDRENS HOSP, DIV MED GENET, MONTREAL, PQ H3H 1P3, CANADA. ALBERTA CHILDRENS PROV GEN HOSP, DEPT MED GENET, CALGARY, AB, CANADA. ERASMUS UNIV, MED CTR, DEPT CLIN GENET, ROTTERDAM, NETHERLANDS. UNIV PECS, DEPT ORTHOPED SURG, PECS, HUNGARY. STATE UNIV GHENT HOSP, CTR MED GENET, B-9000 GHENT, BELGIUM. UNITED BRISTOL HOSP TRUST, CLIN GENET SERV, BRISTOL, AVON, ENGLAND. DUPONT HOSP CHILDREN, DIV MED GENET, WILMINGTON, DE USA. MED UNIV GDANSK, DEPT BIOL & GENET, GDANSK, POLAND. INST CHILD HLTH, CLIN & MOL GENET UNIT, LONDON, ENGLAND. UNIV FREIBURG, DEPT PAEDIAT & ADOLESCENT MED, FREIBURG, GERMANY. CITY HOSP, CLIN GENET SERV, NOTTINGHAM NG5 1PB, ENGLAND. FERGUSON SMITH CTR MED GENET, GLASGOW, LANARK, SCOTLAND. WEATHERALL INST MOL MED, OXFORD, ENGLAND. CEDARS SINAI MED RES INST, LOS ANGELES, CA USA.",GENETICS & HEREDITY,GENETICS & HEREDITY,"ROBERTSON SP, 2006, AM J MED GENET A, V140A, P1726, DOI 10.1002/AJMG.A.31322",0,2020-11-20,NA
J,WOS:000242889400001,2006,TO WHEEZE OR NOT TO WHEEZE - PROSPECTIVE FE-NO-TYPING IN EARLY INFANCY,NA,EXHALED NITRIC-OXIDE; INHALED CORTICOSTEROIDS; YOUNG-CHILDREN; ASTHMA; RISK,NA,AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,"DE JONGSTE, JC","ERASMUS UNIV, MED CTR, SOPHIA CHILDRENS HOSP, ROTTERDAM, NETHERLANDS.",CRITICAL CARE MEDICINE; RESPIRATORY SYSTEM,GENERAL & INTERNAL MEDICINE; RESPIRATORY SYSTEM,"AMERICAN THORACIC SOCIETY, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/RCCM.200406-710ST##BARALDI E, 1999, AM J RESP CRIT CARE, V159, P1284, DOI 10.1164/AJRCCM.159.4.9807084##BISGAARD H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMOA054692##BRUSSEE JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604##CASTRO-RODRIGUEZ JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/AJRCCM.162.4.9912111##FREY U, 2004, AM J RESP CRIT CARE, V170, P260, DOI 10.1164/RCCM.200307-1002OC##GABRIELE C, IN PRESS PEDIAT ALLE##GABRIELE C, 2006, PEDIATR RES, V60, P461, DOI 10.1203/01.PDR.0000238242.39881.64##GUILBERT TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMOA051378##HALL GL, 2002, J APPL PHYSIOL, V92, P59##LATZIN P, 2006, AM J RESP CRIT CARE, V174, P1292, DOI 10.1164/RCCM.200606-782OC##LEX C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/RCCM.200603-352OC##MURRAY CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4##POHUNEK P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/J.1399-3038.2005.00239.X##SAGLANI S, 2006, EUR RESPIR J, V27, P29, DOI 10.1183/09031936.06.00030605##TAYLOR DR, 2006, THORAX, V61, P817, DOI 10.1136/THX.2005.056093",5,2020-11-20,NA
J,WOS:000242467700004,2006,MODIFYING MILK COMPOSITION THROUGH FORAGE,"THE FATTY ACID (FA) COMPOSITION OF COWS MILK HAS BECOME LESS FAVORABLE TO HUMAN HEALTH IN THE LAST FOUR DECADES DUE TO CHANGED FEEDING AND MANAGEMENT PRACTICES, NOTABLY HIGHER PROPORTIONS OF CONCENTRATES AND SILAGES IN DIETS WITH LESS GRAZING. ESSENTIAL FA AND CONJUGATED LINOLEIC ACID (CLA) CONCENTRATIONS HAVE GENERALLY DECLINED AND, WITH MORE 'LOW-FAT' DAIRY PRODUCTS, HUMAN INTAKE OF THESE FA HAS DECLINED EVEN FURTHER SINCE RUMINANT FOOD PRODUCTS ARE THE MAIN SOURCE OF HUMAN CLA INTAKE. CHANGING SOCIETAL DRIVERS AND CONSUMER DEMANDS REQUIRE DAIRY PRODUCTION SYSTEMS THAT PROVIDE FOOD PRODUCTS THROUGH SUSTAINABLE PRODUCTION SYSTEMS. MILK FA WERE EXAMINED IN MILK PRODUCED IN DIFFERENT REGIONS OF THE WORLD, IN THE DIFFERENT SEASONS OF THE YEAR, AND UNDER DIFFERENT FEEDING SYSTEMS. FA LEVELS WERE EXAMINED IN FORAGES, CONCENTRATES AND MILK. MILK FROM COWS FED FRESH GREEN FORAGE, ESPECIALLY THOSE GRAZING GRASS, HAD A MUCH HIGHER UNSATURATED: SATURATED FA PROPORTION, WITH MORE POLYUNSATURATED FA AND MORE CLA (IN PARTICULAR C 18:2 CIS-9, TRANS-11), THAN MILK FROM SILAGE-FED COWS. FARMERS FROM SOME DAIRY COOPERATIVES IN THE NETHERLANDS THAT PRODUCE MILK FROM GRAZED GRASS NOW RECEIVE A PREMIUM PAYMENT IN ADDITION TO THE BASE MILK PRICE, SO THAT PRIMARY PRODUCERS CAN BENEFIT FROM THE HIGHER MARKET VALUE AT THE END OF THE PRODUCTION CHAIN. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",CONJUGATED LINOLEIC-ACID; TRANS-FATTY-ACIDS; REDUCES CANCER-RISK; PERENNIAL RYEGRASS; VACCENIC ACID; BOVINE-MILK; FISH-OIL; DUODENAL FLOW; LINSEED OIL; FRESH GRASS,FORAGE; SILAGE; FEEDING SYSTEM; SEASONAL CHANGE; MILK FATTY ACIDS,ANIMAL FEED SCIENCE AND TECHNOLOGY,"ELGERSMA, A##TAMMINGA, S##ELLEN, G","WAGENINGEN UNIV, CROP & WEED ECOL GRP, GRAD SCH PE&RC, NL-6709 RZ WAGENINGEN, NETHERLANDS. WAGENINGEN UNIV, ANIM SCI GRP, GRAD SCH WIAS, NL-6709 PG WAGENINGEN, NETHERLANDS. NIZO FOOD RES, NL-6710 BA EDE, NETHERLANDS.","AGRICULTURE, DAIRY & ANIMAL SCIENCE",AGRICULTURE,"ARO A, 2000, NUTR CANCER, V38, P151, DOI 10.1207/S15327914NC382_2##ASCHERIO A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/BMJ.313.7049.84##AULDIST MJ, 1998, J DAIRY RES, V65, P401, DOI 10.1017/S0022029998002970##BANNI S, 2001, NUTR CANCER, V41, P91, DOI 10.1207/S15327914NC41-1&AMP;2_12##BAUCHART D, 1984, CAN J ANIM SCI, V64, P330, DOI 10.4141/CJAS84-285##BAUMAN D. E., 2001, RECENT ADVANCES IN ANIMAL NUTRITION: 2001, P221##BELURY MA, 2002, ANNU REV NUTR, V22, P505, DOI 10.1146/ANNUREV.NUTR.22.021302.121842##BERNARD L, 2000, REPROD NUTR DEV, V40, P89, DOI 10.1051/RND:2000122##BOUFAIED H, 2003, CAN J ANIM SCI, V83, P501, DOI 10.4141/A02-098##CHILLIARD Y, 2001, LIVEST PROD SCI, V70, P31, DOI 10.1016/S0301-6226(01)00196-8##CHOW TT, 2004, ANIM FEED SCI TECH, V117, P1, DOI 10.1016/J.ANIFEEDSCI.2004.08.008##COLLOMB M, 2002, INT DAIRY J, V12, P649, DOI 10.1016/S0958-6946(02)00061-4##CORL BA, 2003, J NUTR, V133, P2893##DEWHURST RJ, 1998, GRASS FORAGE SCI, V53, P219, DOI 10.1046/J.1365-2494.1998.00130.X##DEWHURST RJ, 2003, P NUTR SOC, V62, P329, DOI 10.1079/PNS2003241##DEWHURST RJ, 2003, J DAIRY SCI, V86, P2598, DOI 10.3168/JDS.S0022-0302(03)73855-7##DEWHURST RJ, 2003, FATTY ACIDS MILK FAT, P111##DHIMAN TR, 1999, J DAIRY SCI, V82, P2146, DOI 10.3168/JDS.S0022-0302(99)75458-5##DHIMAN TR, 1999, J DAIRY SCI, V82, P412, DOI 10.3168/JDS.S0022-0302(99)75247-1##ELGERSMA A, 2003, GRASS FORAGE SCI, V58, P323, DOI 10.1046/J.1365-2494.2003.00384.X##ELGERSMA A, 2005, ANN APPL BIOL, V147, P145, DOI 10.1111/J.1744-7348.2005.00020.X##ELGERSMA A, 2004, ANIM FEED SCI TECH, V117, P13, DOI 10.1016/J.ANIFEEDSCI.2004.08.003##ELGERSMA A, 2003, ANIM FEED SCI TECH, V108, P191, DOI 10.1016/S0377-8401(03)00134-2##ELGERSMA A., 2003, GRASSLAND SCI EUR, V8, P271##ELGERSMA A, 2003, ASP APPL BIOL, V70, P107##ELGERSMA A, 2004, GRASSLAND SCI EUR, V9, P1136##ELLEN G., 2003, VOEDINGSMAGAZINE, V16, P12##ELLEN G, 2001, ZUIVELZICHT, V93, P26##GRIINARI JM, 2000, J NUTR, V130, P2285##GRUNDY SM, 1988, AM J CLIN NUTR, V47, P822##HAVEL RJ, 1997, BIOTECHN AG, P13##HAWKE J. C., 1973, CHEMISTRY AND BIOCHEMISTRY OF HERBAGE. VOLUME 1., P213##INNOCENTE N, 2002, ITAL J FOOD SCI, V14, P217##IP C, 1999, J NUTR, V129, P2135##ITABASHI H, 2001, B INT DAIRY FED, V366, P9##JAHREIS G, 1997, NUTR RES, V17, P1479, DOI 10.1016/S0271-5317(97)00138-3##JENSEN RG, 2002, J DAIRY SCI, V85, P295, DOI 10.3168/JDS.S0022-0302(02)74079-4##KALSCHEUR KF, 1997, J DAIRY SCI, V80, P2104, DOI 10.3168/JDS.S0022-0302(97)76156-3##KELLY ML, 1998, J DAIRY SCI, V81, P1630, DOI 10.3168/JDS.S0022-0302(98)75730-3##KELSEY JA, 2003, J DAIRY SCI, V86, P2588, DOI 10.3168/JDS.S0022-0302(03)73854-5##KENNELLY JJ, 2001, B INT DIARY FED, V366, P28##KHANAL R. C., 2004, PAKISTAN JOURNAL OF NUTRITION, V3, P82##LAVILLONNIERE F, 1998, J AM OIL CHEM SOC, V75, P343, DOI 10.1007/S11746-998-0051-6##LAWLESS F, 1998, J DAIRY SCI, V81, P3259, DOI 10.3168/JDS.S0022-0302(98)75890-4##LEE MRF, 2004, J SCI FOOD AGR, V84, P1639, DOI 10.1002/JSFA.1854##LEE MRF, 2003, ANIM SCI, V76, P491, DOI 10.1017/S1357729800058719##LIN H, 1995, J DAIRY SCI, V78, P2358, DOI 10.3168/JDS.S0022-0302(95)76863-1##LOCK AL, 2004, J NUTR, V134, P2698##LOCK AL, 2002, ANIM SCI, V74, P163, DOI 10.1017/S1357729800052334##LOCK AL, 2003, LIVEST PROD SCI, V79, P47, DOI 10.1016/S0301-6226(02)00118-5##LOOR JJ, 2004, J DAIRY SCI, V87, P2472, DOI 10.3168/JDS.S0022-0302(04)73372-X##LOOR JJ, 2004, J DAIRY SCI, V87, P2468, DOI 10.3168/JDS.S0022-0302(04)73371-8##MACGIBBON AKH, 2001, AUST J DAIRY TECHNOL, V56, P158##MATTSSON S, 1949, P 12 INT DAIR C STOC, P308##NALECZTARWACKA T, THESIS WARSAW Y POLA##PRECHT D, 1995, NAHRUNG, V39, P343, DOI 10.1002/FOOD.19950390503##PRECHT D, 2000, MILCHWISSENSCHAFT, V55, P687##REKLEWSKA B, 2003, ZESZYTY NAUKOWE PRZE, V65, P85##RIEL RR, 1963, J DAIRY SCI, V46, P102, DOI 10.3168/JDS.S0022-0302(63)88981-X##SALMINEN I, 1998, J NUTR BIOCHEM, V9, P93, DOI 10.1016/S0955-2863(97)00173-3##SANTORA JE, 2000, J NUTR, V130, P208##SCOLLAN ND, 2005, GRASSLAND: A GLOBAL RESOURCE, P41##SHINGFIELD KJ, 2006, J DAIRY SCI, V89, P714, DOI 10.3168/JDS.S0022-0302(06)72134-8##STADHOUDERS J, 1955, MILK DAIRY J, V9, P182##TAMMINGA S, 2001, B INT DAIRY FED, V366, P15##TAWEEL HZ, 2005, ANIM FEED SCI TECH, V121, P243, DOI 10.1016/J.ANIFEEDSCI.2005.02.024##THOMSON N. A., 2000, PROCEEDINGS OF THE NEW ZEALAND SOCIETY OF ANIMAL PRODUCTION, V60, P314##TURPEINEN AM, 2002, AM J CLIN NUTR, V76, P504##VANDENPOLVANDAS.A, 2005, GRAZING TRANSITION, V81, P127##WHITE SL, 2001, J DAIRY SCI, V84, P2295, DOI 10.3168/JDS.S0022-0302(01)74676-0##WILLIAMS CM, 2000, ANN ZOOTECH, V49, P165, DOI 10.1051/ANIMRES:2000116##WITKOWSKA IC, 2006, UNPUB EUR J AGRON##ZEGARSKA A, 2001, POL J FOOD NUTR, V4, P41##ZEGARSKA Z, 1988, MILCHWISSENSCHAFT, V43, P777",156,2020-11-20,NA
J,WOS:000242782100001,2006,ASSESSING THE HUMAN-ANIMAL RELATIONSHIP IN FARMED SPECIES: A CRITICAL REVIEW,"THE PRESENT PAPER FOCUSES ON SIX MAIN ISSUES. FIRST, WE BRIEFLY EXPLAIN WHY AN INCREASED UNDERSTANDING OF THE HUMAN-ANIMAL RELATIONSHIP (HAR) IS AN ESSENTIAL COMPONENT OF ANY STRATEGY INTENDED TO IMPROVE THE WELFARE OF FARMED ANIMALS AND THEIR STOCKPERSONS. SECOND, WE LIST THE MAIN INTERNAL AND EXTERNAL FACTORS THAT CAN INFLUENCE THE NATURE OF THE RELATIONSHIP AND THE INTERACTIONS BETWEEN HUMAN BEINGS AND FARM ANIMALS. THIRD, WE ARGUE THAT THE NUMEROUS TESTS THAT HAVE BEEN USED TO ASSESS THE HAR FALL INTO THREE MAIN CATEGORIES (STATIONARY HUMAN, MOVING HUMAN, HANDLING/ RESTRAINT), ACCORDING TO THE DEGREE OF HUMAN INVOLVEMENT. FOURTH, THE REQUIREMENTS THAT ANY TEST OF HAR MUST FULFIL BEFORE IT CAN BE CONSIDERED EFFECTIVE, AND THE WAYS IN WHICH THE TESTS CAN BE VALIDATED ARE DISCUSSED. FIFTH, THE VARIOUS TYPES OF TEST PROCEDURES THAT HAVE BEEN USED TO ASSESS THE HAR IN A RANGE OF FARMED SPECIES ARE REVIEWED AND CRITICALLY DISCUSSED. FINALLY, SOME RESEARCH PERSPECTIVES THAT MERIT FURTHER ATTENTION ARE SHOWN. THE PRESENT REVIEW EMBRACES A RANGE OF FARMED ANIMALS. OUR PRIMARY REASONS FOR INCLUDING A PARTICULAR SPECIES WERE: WHETHER OR NOT GENERAL INTEREST HAS BEEN EXPRESSED IN ITS WELFARE AND ITS RELATIONSHIP WITH HUMANS, WHETHER RELEVANT LITERATURE WAS AVAILABLE, AND WHETHER IT IS FARMED IN AT LEAST SOME EUROPEAN COUNTRIES. THEREFORE, WE INCLUDE LARGE AND SMALL RUMINANTS (CATTLE, SHEEP, GOATS), PIGS, POULTRY (CHICKENS), FUR ANIMALS (FOXES, MINK) AND HORSES. ALTHOUGH HORSES ARE PRIMARILY USED FOR SPORT, LEISURE OR THERAPY THEY ARE FARMED AS DRAUGHT, FOOD OR BREEDING ANIMALS IN MANY COUNTRIES. LITERATURE ON THE HAR IN OTHER SPECIES WAS RELATIVELY SCARCE SO THEY RECEIVE NO FURTHER MENTION HERE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",OPEN-FIELD BEHAVIOR; JAPANESE-QUAIL CHICKS; MINIATURE PIGS DISCRIMINATE; HEART-RATE-VARIABILITY; HUMAN-BEINGS; DAIRY-COWS; INDIVIDUAL-DIFFERENCES; DOMESTIC CHICKS; FEAR REACTIONS; LAYING HENS,HUMAN-ANIMAL RELATIONSHIPS; FARM ANIMALS; TESTS; ASSESSMENT; WELFARE,APPLIED ANIMAL BEHAVIOUR SCIENCE,"WAIBLINGER, S##BOIVIN, X##PEDERSEN, V##TOSI, MV##JANCZAK, AM##VISSER, EK##JONES, RB","UNIV VET MED, DEPT VET PUBL HLTH & FOOD SCI, INST ANIM HUSB & WELF, A-1210 VIENNA, AUSTRIA. INRA, F-63122 ST GENES CHAMPANELLE, FRANCE. UNIV COPENHAGEN, INST BIOL, ANIM BEHAV GRP, COPENHAGEN 2200 N, DENMARK. UNIV MILAN, FAC MED VET, IST ZOOTECN, I-20133 MILAN, ITALY. NORWEGIAN UNIV LIFE SCI, DEPT ANIM & AQUACULTURAL SCI, N-1432 AS, NORWAY. UNIV WAGENINGEN & RES CTR, ANIM SCI GRP, NL-8200 AB LELYSTAD, NETHERLANDS.","AGRICULTURE, DAIRY & ANIMAL SCIENCE; BEHAVIORAL SCIENCES; VETERINARY SCIENCES",AGRICULTURE; BEHAVIORAL SCIENCES; VETERINARY SCIENCES,"AHOLA L, 2000, P 7 INT SCI C FUR AN, V24, P132##AJZEN I, 1988, ATTITUEDES PERSONALI##BAKKEN M, 1998, APPL ANIM BEHAV SCI, V56, P309, DOI 10.1016/S0168-1591(97)00088-9##BAKKEN M, 1999, APPL ANIM BEHAV SCI, V64, P141, DOI 10.1016/S0168-1591(99)00022-2##BAKKEN M, 1998, NJF SEM BERG NORG 7##BAKKEN M, 1993, P INT C APPL ETH BER, P591##BAKKEN M, 1992, NORW J AGR SCI S, V9, P520##BAKKEN M, 1988, AKTUELT STATENS FAGT, V1, P440##BANK L, 1996, STRESS RESPONSE ACUT##BARNETT JL, 1994, APPL ANIM BEHAV SCI, V41, P87, DOI 10.1016/0168-1591(94)90054-X##BARNETT JL, 1993, APPL ANIM BEHAV SCI, V37, P139, DOI 10.1016/0168-1591(93)90106-Y##BARNETT JL, 1992, BRIT POULTRY SCI, V33, P699, DOI 10.1080/00071669208417510##BARNETT JL, 1989, BRIT POULTRY SCI, V30, P497, DOI 10.1080/00071668908417174##BATESON P, 1979, ANIM BEHAV, V27, P470, DOI 10.1016/0003-3472(79)90184-2##BECKER BG, 1997, APPL ANIM BEHAV SCI, V53, P219, DOI 10.1016/S0168-1591(96)01091-X##BERTELSEN N, 1995, THESIS U COPENHAGEN##BESSEI W, 1983, ARCH GEFLUGELKD, V47, P134##BEUVING G, 1978, GEN COMP ENDOCR, V35, P153, DOI 10.1016/0016-6480(78)90157-0##BOISSY A, 1998, PHYSIOL BEHAV, V63, P489, DOI 10.1016/S0031-9384(97)00466-6##BOISSY A, 1998, GENETICS AND THE BEHAVIOR OF DOMESTIC ANIMALS, P67##BOISSY A, 1997, PHYSIOL BEHAV, V61, P693, DOI 10.1016/S0031-9384(96)00521-5##BOISSY A, 1988, APPL ANIM BEHAV SCI, V20, P259, DOI 10.1016/0168-1591(88)90051-2##BOISSY A, 1995, Q REV BIOL, V70, P165, DOI 10.1086/418981##BOISSY A, 2002, 7 WORLD C GEN APPL L, P32##BOIVIN X, 1996, APPL ANIM BEHAV SCI, V48, P61, DOI 10.1016/0168-1591(95)01019-X##BOIVIN X, 1998, APPL ANIM BEHAV SCI, V61, P1, DOI 10.1016/S0168-1591(98)00170-1##BOIVIN X, 1997, J ANIM SCI, V75, P2892##BOIVIN X, 1992, APPL ANIM BEHAV SCI, V32, P313, DOI 10.1016/S0168-1591(05)80024-3##BOIVIN X, 1994, APPL ANIM BEHAV SCI, V39, P115, DOI 10.1016/0168-1591(94)90131-7##BOIVIN X, 1992, APPL ANIM BEHAV SCI, V32, P325, DOI 10.1016/S0168-1591(05)80025-5##BOIVIN X, 2003, ANIM WELFARE, V12, P479##BOIVIN X, 2002, APPL ANIM BEHAV SCI, V77, P311, DOI 10.1016/S0168-1591(02)00084-9##BOIVIN X, 2001, APPL ANIM BEHAV SCI, V72, P89, DOI 10.1016/S0168-1591(00)00201-X##BOIVIN X, 1998, APPL ANIM BEHAV SCI, V55, P245, DOI 10.1016/S0168-1591(97)00050-6##BOIVIN X, 2000, J ANIM SCI, V78, P879##BOUISSOU MF, 1995, BEHAV PROCESS, V34, P81, DOI 10.1016/0376-6357(94)00056-M##BRAASTAD BO, 1998, APPL ANIM BEHAV SCI, V57, P157, DOI 10.1016/S0168-1591(97)00114-7##BREUER K, 2003, APPL ANIM BEHAV SCI, V84, P3, DOI 10.1016/S0168-1591(03)00146-1##BREUER K, 2000, APPL ANIM BEHAV SCI, V66, P273, DOI 10.1016/S0168-1591(99)00097-0##BURROW H. M., 1997, ANIMAL BREEDING ABSTRACTS, V65, P477##BURROW HM, 2000, AUST J AGR RES, V51, P155, DOI 10.1071/AR99053##BURROW HM, 2001, LIVEST PROD SCI, V70, P213, DOI 10.1016/S0301-6226(01)00178-6##CARMICHAEL NL, 1999, BRIT POULTRY SCI, V40, P148, DOI 10.1080/00071669988006##CHAMOVE AS, 2002, ANTHROZOOS, V15, P323, DOI 10.2752/089279302786992423##COLEMAN GJ, 2003, APPL ANIM BEHAV SCI, V82, P189, DOI 10.1016/S0168-1591(03)00057-1##COLEMAN GJ, 1998, APPL ANIM BEHAV SCI, V58, P63, DOI 10.1016/S0168-1591(96)01168-9##COLEMAN GJ, 2000, APPL ANIM BEHAV SCI, V66, P11, DOI 10.1016/S0168-1591(99)00073-8##COSTA PT, 1986, CLIN PSYCHOL REV, V6, P407, DOI 10.1016/0272-7358(86)90029-2##CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/H0040957##DAVIES H, 2001, BR POULT SCI, V42, P267##DENENBERG VH, 1962, BEHAVIOUR DOMESTIC A, PCH6##DEPASSILLE AM, 1996, J ANIM SCI, V74, P969##DESIRE L, 2002, BEHAV PROCESS, V60, P165, DOI 10.1016/S0376-6357(02)00081-5##DUNCAN IJH, 1990, CURR T VET, V53, P121##DYCKHOFF B, 1998, THESIS TIERARZTLICHE##EIBLEIBESFELDT I, 1999, GRUNDRISS VERGLEICHE, P932##ENGLISH, 1992, STOCKMANSHIP IMPROVI##ERHARD HW, 1999, APPL ANIM BEHAV SCI, V64, P31, DOI 10.1016/S0168-1591(99)00028-3##ERHARD HW, 2003, ANIM WELFARE, V12, P349##ESTEP D.Q., 1992, INEVITABLE BOND EXAM, P6##FAURE J. M., 2003, POULTRY GENETICS, BREEDING AND BIOTECHNOLOGY, P221, DOI 10.1079/9780851996608.0221##FELL LR, 1989, APPL ANIM BEHAV SCI, V22, P283, DOI 10.1016/0168-1591(89)90023-3##FISHBEIN M., 1975, BELIEF ATTITUDE INTE##FORDYCE G, 1985, AUST J EXP AGR, V25, P283, DOI 10.1071/EA9850283##FORDYCE G., 1982, PROCEEDINGS OF THE AUSTRALIAN SOCIETY OF ANIMAL PRODUCTION, V14, P329##GALLUP GG, 1972, ANIM BEHAV, V20, P166, DOI 10.1016/S0003-3472(72)80187-8##GAULY M, 2001, APPL ANIM BEHAV SCI, V74, P109, DOI 10.1016/S0168-1591(01)00151-4##GODDARD PJ, 2000, APPL ANIM BEHAV SCI, V66, P305, DOI 10.1016/S0168-1591(99)00091-X##GONYOU HW, 1986, APPL ANIM BEHAV SCI, V16, P269, DOI 10.1016/0168-1591(86)90119-X##GRANDIN T, 1995, APPL ANIM BEHAV SCI, V46, P117, DOI 10.1016/0168-1591(95)00638-9##GRANDIN T, 1993, APPL ANIM BEHAV SCI, V36, P1, DOI 10.1016/0168-1591(93)90094-6##GRANDIN T, 1984, VET MED SM ANIM CLIN, V79, P827##GRANDIN T, 2000, J AM VET MED ASSOC, V216, P848, DOI 10.2460/JAVMA.2000.216.848##GRANDIN T, 1998, GENETICS AND THE BEHAVIOR OF DOMESTIC ANIMALS, P1##GRANDIN T, 1987, JOURNAL OF ANIMAL SCIENCE, V65, P230##GRANDIN T, 1989, APPL ANIM BEHAV SCI, V23, P257, DOI 10.1016/0168-1591(89)90116-0##GRANDIN T, 1994, APPL ANIM BEHAV SCI, V39, P21, DOI 10.1016/0168-1591(94)90012-4##GRANDIN T, 1987, VET CLIN N AM-FOOD A, V3, P323, DOI 10.1016/S0749-0720(15)31155-5##GRANDIN T, 1983, OBJECTIVE MEASUREMEN##GRIGNARD L, 2000, APPL ANIM BEHAV SCI, V68, P1, DOI 10.1016/S0168-1591(00)00085-X##GRIGNARD L, 2001, APPL ANIM BEHAV SCI, V71, P263, DOI 10.1016/S0168-1591(00)00187-8##GROSS WB, 1982, AM J VET RES, V43, P2010##HAGEDORN T. K., 1996, POULTRY SCIENCE, V75, P120##HAMA H, 1996, JPN PSYCHOL RES, V38, P66, DOI 10.1111/J.1468-5884.1996.TB00009.X##HANSEN SW, 1996, APPL ANIM BEHAV SCI, V49, P137, DOI 10.1016/0168-1591(96)01045-3##HARESIGN W, 1995, ANIM SCI, V61, P77, DOI 10.1017/S1357729800013540##HARGREAVES AL, 1990, APPL ANIM BEHAV SCI, V26, P243, DOI 10.1016/0168-1591(90)90140-9##HARRI M, 2000, P 7 INT SCI C FUR AN, V24, P118##HAUSBERGER A, 2002, APPL ANIM BEHAV SCI, V76, P339##HAUSER J, 2004, APPL ANIM BEHAV SCI, V85, P65, DOI 10.1016/J.APPLANIM.2003.09.006##HEARNSHAW H, 1981, P AUST ASS AN BREED, P164##HEDIGER H, 1965, MENSCH TIER ZOO##HEMSWORTH PH, 1989, BRIT POULTRY SCI, V30, P505, DOI 10.1080/00071668908417175##HEMSWORTH PH, 1990, APPL ANIM BEHAV SCI, V25, P85, DOI 10.1016/0168-1591(90)90072-L##HEMSWORTH PH, 1996, APPL ANIM BEHAV SCI, V50, P71, DOI 10.1016/0168-1591(96)01065-9##HEMSWORTH PH, 1994, APPL ANIM BEHAV SCI, V40, P129, DOI 10.1016/0168-1591(94)90077-9##HEMSWORTH PH, 1992, APPL ANIM BEHAV SCI, V35, P83, DOI 10.1016/0168-1591(92)90018-7##HEMSWORTH PH, 1996, APPL ANIM BEHAV SCI, V50, P43, DOI 10.1016/0168-1591(96)01067-2##HEMSWORTH PH, 1987, APPL ANIM BEHAV SCI, V18, P247, DOI 10.1016/0168-1591(87)90220-6##HEMSWORTH PH, 2003, APPL ANIM BEHAV SCI, V81, P185, DOI 10.1016/S0168-1591(02)00280-0##HEMSWORTH PH, 2000, BIOLOGY OF ANIMAL STRESS, P309, DOI 10.1079/9780851993591.0309##HEMSWORTH PH, 2002, J ANIM SCI, V80, P68##HEMSWORTH PH, 1987, APPL ANIM BEHAV SCI, V17, P245, DOI 10.1016/0168-1591(87)90149-3##HEMSWORTH PH, 1987, VET CLIN N AM-FOOD A, V3, P339, DOI 10.1016/S0749-0720(15)31156-7##HEMSWORTH PH, 1993, ANIM WELFARE, V2, P33##HEMSWORTH PH, 1991, APPL ANIM BEHAV SCI, V30, P61, DOI 10.1016/0168-1591(91)90085-C##HEMSWORTH PH, 1999, APPL ANIM BEHAV SCI, V65, P43, DOI 10.1016/S0168-1591(99)00047-7##HEMSWORTH PH, 1994, APPL ANIM BEHAV SCI, V39, P349, DOI 10.1016/0168-1591(94)90168-6##HEMSWORTH PH, 1989, APPL ANIM BEHAV SCI, V22, P313, DOI 10.1016/0168-1591(89)90026-9##HEMSWORTH PH, 1986, APPL ANIM BEHAV SCI, V15, P303, DOI 10.1016/0168-1591(86)90123-1##HEMSWORTH PH, 1989, APPL ANIM BEHAV SCI, V23, P301, DOI 10.1016/0168-1591(89)90099-3##HEMSWORTH PH, 1981, HORM BEHAV, V15, P396, DOI 10.1016/0018-506X(81)90004-0##HEMSWORTH PH, 1981, LIVEST PROD SCI, V8, P67, DOI 10.1016/0301-6226(81)90031-2##HEMSWORTH PH, 2000, J ANIM SCI, V78, P2821##HEMSWORTH PH, 1993, APPL ANIM BEHAV SCI, V36, P197, DOI 10.1016/0168-1591(93)90010-M##HEMSWORTH PH, 1998, HUMAN LIVESTOCK INTE##HENNESSY MB, 1997, PHYSIOL BEHAV, V62, P485, DOI 10.1016/S0031-9384(97)80328-9##HENNESSY MB, 1998, APPL ANIM BEHAV SCI, V61, P63, DOI 10.1016/S0168-1591(98)00179-8##HESSING MJC, 1993, APPL ANIM BEHAV SCI, V37, P285, DOI 10.1016/0168-1591(93)90118-9##HINRICHSEN JK, 1979, KTBL SCHRIFT, V254, P103##HUTSON GD, 1982, ANIM PROD, V35, P231, DOI 10.1017/S0003356100027409##JAGO JG, 1999, APPL ANIM BEHAV SCI, V62, P137, DOI 10.1016/S0168-1591(98)00219-6##JANCZAK AM, 2003, APPL ANIM BEHAV SCI, V82, P121, DOI 10.1016/S0168-1591(03)00055-8##JEPPESEN LL, 1998, NJF SEM BERG NORG 7##JEZIERSKI T, 1999, APPL ANIM BEHAV SCI, V62, P1, DOI 10.1016/S0168-1591(98)00209-3##JOHN OP, 2000, HDB RES METHODS SOCI, P339##JONES R. B., 1997, ANIMAL WELFARE., P75##JONES R. B., 1995, INT J COMP PSYCHOL, V8, P88##JONES RB, 1994, PHYSIOL BEHAV, V56, P379, DOI 10.1016/0031-9384(94)90210-0##JONES RB, 1987, BIOL BEHAV, V12, P100##JONES RB, 1981, BEHAV PROCESS, V6, P121, DOI 10.1016/0376-6357(81)90031-0##JONES RB, 1990, BIOL BEHAV, V15, P93##JONES RB, 1985, APPL ANIM BEHAV SCI, V14, P63, DOI 10.1016/0168-1591(85)90038-3##JONES RB, 1993, ANIM BEHAV, V46, P991, DOI 10.1006/ANBE.1993.1280##JONES RB, 2004, POULT SCI S, V27, P215, DOI 10.1079/9780851998138.0215##JONES RB, 1996, WORLD POULTRY SCI J, V52, P131, DOI 10.1079/WPS19960013##JONES RB, 1991, J COMP PSYCHOL, V105, P15, DOI 10.1037/0735-7036.105.1.15##JONES RB, 1986, WORLD POULTRY SCI J, V42, P82, DOI 10.1079/WPS19860008##JONES RB, 1995, APPL ANIM BEHAV SCI, V42, P261, DOI 10.1016/0168-1591(94)00544-O##JONES RB, 1994, APPL ANIM BEHAV SCI, V42, P129, DOI 10.1016/0168-1591(94)90153-8##JONES RB, 1999, ANIM WELFARE, V8, P343##JONES RB, 1999, POULT AVIAN BIOL REV, V10, P213##JONES RB, 1993, APPL ANIM BEHAV SCI, V36, P185, DOI 10.1016/0168-1591(93)90009-E##JONES RB, 1992, HORM BEHAV, V26, P385, DOI 10.1016/0018-506X(92)90008-J##JONES RB, 1992, POULTRY SCI, V71, P1403, DOI 10.3382/PS.0711403##JONES RB, 1987, COGNITIVE ASPECTS SO, P40##JONES RB, 1993, P 4 EUR S POULTR WEL, P292##KEERKEER S, 1996, APPL ANIM BEHAV SCI, V49, P321, DOI 10.1016/0168-1591(96)01055-6##KENDRICK KM, 1995, ANIM BEHAV, V49, P1665, DOI 10.1016/0003-3472(95)90088-8##KENDRICK KM, 1998, APPL ANIM BEHAV SCI, V57, P213, DOI 10.1016/S0168-1591(98)00098-7##KENTTAMIES H, 2000, P 7 C FUR AN PROD 3B, V24, P107##KNIERIM U., 1993, PROCEEDINGS OF THE INTERNATIONAL CONGRESS ON APPLIED ETHOLOGY BERLIN 1993: 3RD JOINT MEETING., P169##KOBA Y, 1999, APPL ANIM BEHAV SCI, V61, P239, DOI 10.1016/S0168-1591(98)00192-0##KOBA Y, 2001, APPL ANIM BEHAV SCI, V73, P45, DOI 10.1016/S0168-1591(01)00106-X##KOMAI T, 1960, POULTRY SCI, V39, P817, DOI 10.3382/PS.0390817##KORFF J, 1997, P 31 INT C INT SOC A, P87##KORHONEN H, 1996, J ANIM BREED GENET, V113, P209, DOI 10.1111/J.1439-0388.1996.TB00606.X##KORHONEN H, 2000, PHYSIOL BEHAV, V69, P571, DOI 10.1016/S0031-9384(00)00215-8##KORTE SM, 1997, PHYSIOL BEHAV, V62, P437, DOI 10.1016/S0031-9384(97)00149-2##KORTE SM, 1999, PHYSIOL BEHAV, V65, P649##KOSTARCZYK E, 1992, INEVITABLE BOND EXAM, P109##KRAEMER GW, 1992, BEHAV BRAIN SCI, V15, P493, DOI 10.1017/S0140525X00069752##KRISTENSEN MP, 1988, SCIENTIFUR, V12, P199##KROHN CC, 2003, APPL ANIM BEHAV SCI, V80, P263, DOI 10.1016/S0168-1591(02)00230-7##KROHN CC, 2001, APPL ANIM BEHAV SCI, V74, P121, DOI 10.1016/S0168-1591(01)00161-7##LANKIN V, 1997, GENET SEL EVOL, V29, P73, DOI 10.1051/GSE:19970105##LANKIN VS, 2001, RUSS J GENET+, V37, P783, DOI 10.1023/A:1016751010678##LANSADE L, 2004, APPL ANIM BEHAV SCI, V87, P131, DOI 10.1016/J.APPLANIM.2003.12.011##LEHNER PN, 1996, HDB ETHOLOGICAL METH##LENEINDRE P, 1996, APPL ANIM BEHAV SCI, V49, P73, DOI 10.1016/0168-1591(95)00669-9##LENEINDRE P, 1995, J ANIM SCI, V73, P2249##LENEINDRE P, 1993, GENET SEL EVOL, V25, P447, DOI 10.1051/GSE:19930504##LENEINDRE P, 1998, P 6 WORLD C GEN APPL, V27, P23##LENSINK BJ, 2000, J ANIM SCI, V78, P1219##LENSINK BJ, 2000, J ANIM SCI, V78, P1213##LENSINK BJ, 2001, ANIM SCI, V72, P105, DOI 10.1017/S1357729800055600##LENSINK BJ, 2001, J ANIM SCI, V79, P642##LENSINK BJ, 2001, APPL ANIM BEHAV SCI, V70, P187, DOI 10.1016/S0168-1591(00)00152-0##LENSINK J, 2000, ANN ZOOTECH, V49, P313, DOI 10.1051/ANIMRES:2000122##LEVINE S, 1958, J COMP PHYSIOL PSYCH, V51, P230, DOI 10.1037/H0042437##LEWIS NJ, 1998, APPL ANIM BEHAV SCI, V58, P213, DOI 10.1016/S0168-1591(97)00150-0##LORENZ K., 1935, JOURNAL FUR ORNITHOLOGIE, V83, P137, DOI 10.1007/BF01905355##LOTT DF, 1979, APPL ANIM ETHOL, V5, P309, DOI 10.1016/0304-3762(79)90102-0##LYNCH JJ, 1974, PSYCHOPHYSIOLOGY, V11, P472, DOI 10.1111/J.1469-8986.1974.TB00575.X##LYONS DM, 1988, PHYSIOL BEHAV, V43, P451, DOI 10.1016/0031-9384(88)90119-9##LYONS DM, 1988, ANIM BEHAV, V36, P1323, DOI 10.1016/S0003-3472(88)80201-X##LYONS DM, 1987, APPL ANIM BEHAV SCI, V18, P363, DOI 10.1016/0168-1591(87)90230-9##LYONS DM, 1989, APPL ANIM BEHAV SCI, V22, P269, DOI 10.1016/0168-1591(89)90022-1##MAL ME, 1994, APPL ANIM BEHAV SCI, V40, P187, DOI 10.1016/0168-1591(94)90060-4##MAL ME, 1996, APPL ANIM BEHAV SCI, V50, P115, DOI 10.1016/0168-1591(96)01083-0##MALMKVIST J, 2001, ANIM WELFARE, V10, P41##MALMKVIST J, 1996, ANIMAL PRODUCTION RE, V29, P9##MALMKVIST J, 2001, THESIS U COPENHAGEN##MARCHANT JN, 2001, APPL ANIM BEHAV SCI, V72, P23, DOI 10.1016/S0168-1591(00)00190-8##MARCHANT JN, 1997, P 31 INT C INT SOC A, P182##MARCHANT-FORDE JN, 2003, APPL ANIM BEHAV SCI, V80, P287, DOI 10.1016/S0168-1591(02)00229-0##MARCHANT-FORDE JN, 2002, APPL ANIM BEHAV SCI, V75, P115, DOI 10.1016/S0168-1591(01)00170-8##MARIN RH, 2001, APPL ANIM BEHAV SCI, V71, P57, DOI 10.1016/S0168-1591(00)00167-2##MARKOWITZ TM, 1998, ANIM BEHAV, V55, P573, DOI 10.1006/ANBE.1997.0640##MARTIN P., 1993, MEASURING BEHAV INTR, DOI [10.1017/CBO9781139168342, DOI 10.1017/CBO9781139168342]##MATEO JM, 1991, APPL ANIM BEHAV SCI, V32, P45, DOI 10.1016/S0168-1591(05)80162-5##MCCANN JS, 1988, APPL ANIM BEHAV SCI, V19, P215, DOI 10.1016/0168-1591(88)90002-0##MCMILLAN FD, 1999, J AM VET MED ASSOC, V215, P1592##MEARS GJ, 1999, CAN J ANIM SCI, V79, P35, DOI 10.4141/A98-013##MILLOT JL, 1987, APPL ANIM BEHAV SCI, V19, P189, DOI 10.1016/0168-1591(87)90216-4##MILLS AD, 1990, CURR T VET, V53, P248##MIURA A, 1996, APPL ANIM BEHAV SCI, V49, P247, DOI 10.1016/0168-1591(95)00658-3##MOE RO, 1996, THESIS NORWEGIAN COL##MUNKSGAARD L, 1997, J DAIRY SCI, V80, P1106, DOI 10.3168/JDS.S0022-0302(97)76036-3##MUNKSGAARD L, 2001, APPL ANIM BEHAV SCI, V73, P15, DOI 10.1016/S0168-1591(01)00119-8##MUNKSGAARD L, 1999, APPL ANIM BEHAV SCI, V65, P1, DOI 10.1016/S0168-1591(99)00055-6##MURPHEY RM, 1981, BEHAV GENET, V11, P37, DOI 10.1007/BF01065826##MURPHEY RM, 1980, BEHAV GENET, V10, P171, DOI 10.1007/BF01066267##MURPHY LB, 1977, APPL ANIM ETHOL, V3, P321, DOI 10.1016/0304-3762(77)90057-8##NIKULA S, 2000, P 7 INT SCI C FUR AN, V24, P99##NOL E, 1996, ANIM BEHAV, V52, P813, DOI 10.1006/ANBE.1996.0226##NORDRUM NV, 2000, P 7 INT SCI C FUR AN, V24, P98##O'CONNOR C E, 1985, PROCEEDINGS OF THE NEW ZEALAND SOCIETY OF ANIMAL PRODUCTION, V45, P159##PAJOR EA, 2003, APPL ANIM BEHAV SCI, V80, P93, DOI 10.1016/S0168-1591(02)00119-3##PAJOR EA, 2000, APPL ANIM BEHAV SCI, V69, P89, DOI 10.1016/S0168-1591(00)00119-2##PATERSON AM, 1992, APPL ANIM BEHAV SCI, V34, P315, DOI 10.1016/S0168-1591(05)80092-9##PAUL ES, 1993, ANIM WELFARE, V2, P321##PEDERSEN V, 1994, APPL ANIM BEHAV SCI, V40, P285, DOI 10.1016/0168-1591(94)90069-8##PEDERSEN V, 1990, APPL ANIM BEHAV SCI, V26, P383, DOI 10.1016/0168-1591(90)90037-E##PEDERSEN V, 2002, APPL ANIM BEHAV SCI, V77, P139, DOI 10.1016/S0168-1591(02)00043-6##PEDERSEN V, 1998, ANIM WELFARE, V7, P137##PEDERSEN V, 1993, APPL ANIM BEHAV SCI, V37, P239, DOI 10.1016/0168-1591(93)90114-5##PEDERSEN V, 1993, THESIS U COPENHAGEN##PEDERSEN V, 1992, NORW J AGR SCI S, V9, P529##PINCHBECK GL, 2004, EQUINE VET J, V36, P384, DOI 10.2746/0425164044868387##PLYUSNINA IZ, 1996, ANIMAL PRODUCTION RE, V29, P17##POLLARD JC, 1994, APPL ANIM BEHAV SCI, V39, P63, DOI 10.1016/0168-1591(94)90016-7##PRICE EO, 1980, APPL ANIM ETHOL, V6, P331, DOI 10.1016/0304-3762(80)90133-9##PRICE EO, 1984, Q REV BIOL, V59, P1, DOI 10.1086/413673##REALE D, 2000, ANIM BEHAV, V60, P589, DOI 10.1006/ANBE.2000.1530##REKILA T, 1997, PHYSIOL BEHAV, V62, P805, DOI 10.1016/S0031-9384(97)00241-2##REKILA T, 1999, NATURAL ENV SCI C, V92##ROMEYER A, 1992, APPL ANIM BEHAV SCI, V34, P93, DOI 10.1016/S0168-1591(05)80060-7##ROSALES A. G., 1994, JOURNAL OF APPLIED POULTRY RESEARCH, V3, P199, DOI 10.1093/JAPR/3.2.199##ROUSING T, 2004, APPL ANIM BEHAV SCI, V85, P215, DOI 10.1016/J.APPLANIM.2003.09.014##RUSHEN J, 1999, APPL ANIM BEHAV SCI, V65, P285, DOI 10.1016/S0168-1591(99)00089-1##RUSHEN J, 1998, APPL ANIM BEHAV SCI, V55, P259, DOI 10.1016/S0168-1591(97)00053-1##RUSHEN J, 1999, J DAIRY SCI, V82, P720, DOI 10.3168/JDS.S0022-0302(99)75289-6##RUSHEN J, 2001, APPL ANIM BEHAV SCI, V73, P1, DOI 10.1016/S0168-1591(01)00105-8##RUSHEN J, 1986, APPL ANIM BEHAV SCI, V16, P363, DOI 10.1016/0168-1591(86)90008-0##RYBARCZYK P, 2003, APPL ANIM BEHAV SCI, V81, P307, DOI 10.1016/S0168-1591(02)00273-3##RYBARCZYK P, 2001, APPL ANIM BEHAV SCI, V74, P175, DOI 10.1016/S0168-1591(01)00162-9##SAMBRAUS H H, 1975, ZEITSCHRIFT FUER TIERPSYCHOLOGIE, V38, P1##SAMBRAUS HH, 1974, DTSCH TIERARZTL WSCH, V81, P29##SATTERLEE DG, 1997, POULTRY SCI, V76, P469, DOI 10.1093/PS/76.3.469##SCHALLER GEORGE B., 1962, ANIMAL BEHAVIOUR, V10, P370, DOI 10.1016/0003-3472(62)90060-X##SCHWARTZKOPFGENSWEIN KS, 1997, J ANIM SCI, V75, P2064##SCOTT JP, 1992, INEVITABLE BOND EXAM, P72##SEABROOK M. F., 1972, JOURNAL OF AGRICULTURAL LABOUR SCIENCE, V1, P45##SEABROOK MF, 1992, FARM ANIMALS AND THE ENVIRONMENT, P111##SEABROOK MF, 1984, VET REC, V115, P84, DOI 10.1136/VR.115.4.84##SEABROOK MF, 1990, J EUR VET TIERPRODUK, V41, P452##SEABROOK MF, 1995, J BR PIG VET SOC, V34, P31##SEABROOK MF, 2001, P 3 NAHWOA WORKSH U, P23##SHABALINA AT, 1984, BRIT POULTRY SCI, V25, P297, DOI 10.1080/00071668408454870##SLUCKIN W, 1972, IMPRINTING EARLY LEA##SONDERGAARD E, 2003, APPL ANIM BEHAV SCI, V84, P265, DOI 10.1016/J.APPLANIM.2003.08.011##SUAREZ SD, 1982, J COMP PHYSIOL PSYCH, V96, P432, DOI 10.1037/H0077886##SYME LA, 1981, ANIM BEHAV, V29, P283, DOI 10.1016/S0003-3472(81)80176-5##TANIDA H, 1995, APPL ANIM BEHAV SCI, V42, P249, DOI 10.1016/0168-1591(94)00545-P##TANIDA H, 1998, APPL ANIM BEHAV SCI, V56, P149, DOI 10.1016/S0168-1591(97)00095-6##TAYLOR AA, 1998, APPL ANIM BEHAV SCI, V58, P13, DOI 10.1016/S0168-1591(97)00061-0##TILBROOK AJ, 1989, APPL ANIM BEHAV SCI, V23, P107, DOI 10.1016/0168-1591(89)90011-7##TULLOH N. M., 1961, ANIMAL BEHAVIOUR, V9, P25, DOI 10.1016/0003-3472(61)90046-X##VANDENHEEDE M, 1993, APPL ANIM BEHAV SCI, V37, P39, DOI 10.1016/0168-1591(93)90069-2##VANDENHEEDE M, 1994, BEHAV PROCESS, V32, P17, DOI 10.1016/0376-6357(94)90024-8##VANDERWERT W, 1985, J ANIM SCI, V61, P310##VEISSIER I, 1989, BIOL BEHAV, V14, P66##VIERIN M, 2002, APPL ANIM BEHAV SCI, V75, P307, DOI 10.1016/S0168-1591(01)00201-5##VISSER EK, 2002, PHYSIOL BEHAV, V76, P289, DOI 10.1016/S0031-9384(02)00698-4##VISSER EK, 2001, APPL ANIM BEHAV SCI, V74, P241, DOI 10.1016/S0168-1591(01)00177-0##VOISINET BD, 1997, MEAT SCI, V46, P367, DOI 10.1016/S0309-1740(97)00031-4##VOISINETBARTLET.BD, 1996, J ANIM SCI S, V1, P74##WAIBLINGER S, 2004, APPL ANIM BEHAV SCI, V85, P31, DOI 10.1016/J.APPLANIM.2003.07.002##WAIBLINGER S, 2003, APPL ANIM BEHAV SCI, V84, P23, DOI 10.1016/S0168-1591(03)00148-5##WAIBLINGER S, 1999, ANTHROZOOS, V12, P240, DOI 10.2752/089279399787000156##WAIBLINGER S, 2002, APPL ANIM BEHAV SCI, V79, P195, DOI 10.1016/S0168-1591(02)00155-7##WAIBLINGER S., 2001, P 3 WORKSH INT NETW, P64##WAIBLINGER S, 1996, MENSCH TIER BEZIEHUN, V24##WAIBLINGER S, 2003, AKTUELLE ARBEITEN AN, P125##WARAN N, 2002, ANIMAL WEL, V1, P151##WATTS JM, 2000, APPL ANIM BEHAV SCI, V67, P15, DOI 10.1016/S0168-1591(99)00108-2##WEBB ML, 1984, BRIT POULTRY SCI, V25, P425, DOI 10.1080/00071668408454883##WEMELSFELDER F, 2001, ACTA AGR SCAND A-AN, V51, P21, DOI 10.1080/090647001300004763##WEMELSFELDER F, 2001, ANIM BEHAV, V62, P209, DOI 10.1006/ANBE.2001.1741##WEMELSFELDER F, 2000, APPL ANIM BEHAV SCI, V67, P193, DOI 10.1016/S0168-1591(99)00093-3##WILLIAMS JL, 2002, APPL ANIM BEHAV SCI, V77, P105, DOI 10.1016/S0168-1591(02)00047-3##WOLFF A, 1997, BEHAV PROCESS, V40, P209, DOI 10.1016/S0376-6357(97)00784-5",338,2020-11-20,NA
J,WOS:000242782100012,2006,A NOTE ON REWARD-RELATED BEHAVIOUR AND EMOTIONAL EXPRESSIONS IN FARMED SILVER FOXES (VULPES VULPES) - BASIS FOR A NOVEL TOOL TO STUDY ANIMAL WELFARE,"THE PRESENT STUDY AIMED TO INVESTIGATE THE PROFILE AND QUANTITATIVE ASPECTS OF REWARD-RELATED BEHAVIOUR AND EMOTIONAL EXPRESSIONS DURING ANTICIPATION OF POSITIVE (PREDICTABLE OR VARIOUS UNPREDICTABLE) OR NEGATIVE (PREDICTABLE) REWARDS IN A PAVLOVIAN TRACE CONDITIONING PARADIGM IN FARMED SILVER FOXES. WHEN ANTICIPATING A POSITIVE REWARD, SILVER FOXES WERE MORE ACTIVE, PERFORMED MORE STEREOTYPICAL BEHAVIOUR, HAD MORE ERECTED EARS AND SPENT MORE TIME IN THE FRONT OF THE CAGE COMPARED TO ANTICIPATING AVERSIVE STIMULI. FOXES WERE ONLY TO A MINOR DEGREE ABLE TO DISCRIMINATE THE TWO DIFFERENT POSITIVE PARADIGMS. IN CONCLUSION, STUDIES RELATED TO ANTICIPATORY BEHAVIOUR MAY BE USEFUL FOR THE DEVELOPMENT OF INDICATORS OF POSITIVE EMOTIONAL STATES AND, THUS, POSITIVE WELFARE, IN FARMED SILVER FOXES. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",ANTICIPATORY BEHAVIOR; SYSTEMS; RATS,REWARD-RELATED BEHAVIOUR; EMOTIONS; ANIMAL WELFARE; POSITIVE WELFARE; FUR ANIMALS; CONDITIONED LEARNING; PREDICTABILITY; STEREOTYPIES,APPLIED ANIMAL BEHAVIOUR SCIENCE,"MOE, RO##BAKKEN, M##KITTILSEN, S##KINGSLEY-SMITH, H##SPRUIJT, BM","NORWEGIAN UNIV LIFE SCI, DEPT ANIM & AQUACULTURAL SCI, N-1432 AS, NORWAY. UNIV UTRECHT, FAC VET MED, DEPT ANIM SCI & SOC, NL-3584 CL UTRECHT, NETHERLANDS.","AGRICULTURE, DAIRY & ANIMAL SCIENCE; BEHAVIORAL SCIENCES; VETERINARY SCIENCES",AGRICULTURE; BEHAVIORAL SCIENCES; VETERINARY SCIENCES,"BAKKEN M., 1994, SCIENTIFUR, V18, P233##BAKKEN M, 1993, P INT C APPL ETH BER, P591##DAWKINS MS, 2001, COPING CHALLENGE WEL, P63##DESIRE L, 2002, BEHAV PROCESS, V60, P165, DOI 10.1016/S0376-6357(02)00081-5##FOX MW, 1970, BEHAVIOUR, V36, P49, DOI 10.1163/156853970X00042##FOX MW, 1975, WILD CANIDS THEIR SY##LEVINE S, 1976, PHYSIOL BEHAV, V17, P35, DOI 10.1016/0031-9384(76)90265-1##MARTIN P., 1993, MEASURING BEHAV INTR##MASON G, 1997, APPL ANIM BEHAV SCI, V53, P45, DOI 10.1016/S0168-1591(96)01150-1##SPRUIJT BM, 2001, APPL ANIM BEHAV SCI, V72, P145, DOI 10.1016/S0168-1591(00)00204-5##VAN DEN BOS R, 2003, BEHAV BRAIN RES, V141, P83, DOI 10.1016/S0166-4328(02)00318-2##VAN DER HARST JE, 2003, BEHAV BRAIN RES, V142, P151, DOI 10.1016/S0166-4328(02)00403-5##VINKE CM, 2004, APPL ANIM BEHAV SCI, V89, P145, DOI 10.1016/J.APPLANIM.2004.06.002##WIEPKEMA PR, 1990, NATO ADV SCI I D-BEH, V54, P1",35,2020-11-20,NA
J,WOS:000242892400015,2006,EFFECTIVENESS OF BEHAVIORAL GRADED ACTIVITY IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEE: A RANDOMIZED CLINICAL TRIAL,"OBJECTIVE: TO DETERMINE THE EFFECTIVENESS OF A BEHAVIORAL GRADED ACTIVITY PROGRAM (BGA) COMPARED WITH USUAL CARE (UC; EXERCISE THERAPY AND ADVICE) ACCORDING TO THE DUTCH GUIDELINES FOR PHYSIOTHERAPY IN PATIENTS WITH OSTEOARTHRITIS (OA) OF THE HIP AND/OR KNEE. THE BGA INTERVENTION IS INTENDED TO INCREASE ACTIVITY IN THE LONG TERM AND CONSISTS OF AN EXERCISE PROGRAM WITH BOOSTER SESSIONS, USING OPERANT TREATMENT PRINCIPLES. METHODS. WE CONDUCTED A CLUSTER RANDOMIZED TRIAL INVOLVING 200 PATIENTS WITH HIP AND/OR KNEE OA. PRIMARY OUTCOME MEASURES WERE PAIN (VISUAL ANALOG SCALE [VAS] AND WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX [WOMAC]), PHYSICAL FUNCTION (WOMAC), AND PATIENT GLOBAL ASSESSMENT, ASSESSED AT WEEKS 0, 13, 39, AND 65. SECONDARY OUTCOME MEASURES COMPRISED TIREDNESS (VAS), PATIENT-ORIENTED PHYSICAL FUNCTION (MCMASTER TORONTO ARTHRITIS PATIENT PREFERENCE DISABILITY QUESTIONNAIRE [MACTAR]), 5-METER WALKING TIME, MUSCLE STRENGTH, AND RANGE OF MOTION. DATA WERE ANALYZED ACCORDING TO INTENT-TO-TREAT PRINCIPLE. RESULTS. BOTH TREATMENTS SHOWED SHORT-TERM AND LONG-TERM BENEFICIAL WITHIN-GROUP EFFECTS. THE MEAN DIFFERENCES BETWEEN THE 2 GROUPS FOR PAIN AND FUNCTIONAL STATUS WERE NOT STATISTICALLY SIGNIFICANT. SIGNIFICANT DIFFERENCES IN FAVOR OF BGA WERE FOUND FOR THE MACTAR FUNCTIONAL SCALE AND 5-METER WALKING TEST AT WEEK 65. CONCLUSION. BECAUSE BOTH INTERVENTIONS RESULTED IN BENEFICIAL LONG-TERM EFFECTS, THE SUPERIORITY OF BGA OVER UC HAS NOT BEEN DEMONSTRATED. THEREFORE, BGA SEEMS TO BE AN ACCEPTABLE METHOD TO TREAT PATIENTS WITH HIP AND/OR KNEE OA, WITH EQUIVALENT RESULTS COMPARED WITH UC.",LOW-BACK-PAIN; EXERCISE THERAPY; DISABILITY; REHABILITATION; GUIDELINES; STRENGTH; PROGRAM; WOMAC; RECOMMENDATIONS; CLASSIFICATION,OSTEOARTHRITIS; PHYSIOTHERAPY; BEHAVIORAL TREATMENT; GRADED ACTIVITY; EXERCISE THERAPY; BOOSTER SESSIONS; RANDOMIZED CONTROLLED TRIAL,ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH,"VEENHOF, C##KOKE, AJA##DEKKER, J##OOSTENDORP, RA##BIJLSMA, JWJ##VAN TULDER, MW##VAN DEN ENDE, CHM","NETHERLANDS INST HLTH SERV RES, UTRECHT, NETHERLANDS. UNIV HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS. HOENSBROEK REHABIL CTR, HOENSBROEK, NETHERLANDS. VRIJE UNIV AMSTERDAM MED CTR, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, NIJMEGEN, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.",RHEUMATOLOGY,RHEUMATOLOGY,"ALBRIGHT J, 2001, PHYS THER, V81, P1675##ALEXANDER NB, 2001, J AM GERIATR SOC, V49, P1418, DOI 10.1046/J.1532-5415.2001.4911232.X##ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/ART.1780340502##ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/ART.1780290816##ANGST F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0##BEKKERING GE, 2005, QUAL SAF HEALTH CARE, V14, P107, DOI 10.1136/QSHC.2003.009357##BELLAMY N, 1997, J RHEUMATOL, V24, P799##BELLAMY N, 1988, J RHEUMATOL, V15, P1833##BIJLSMA JW, 2005, NED T REUM, V1, P27##BOHANNON RW, 1990, MUSCLE STRENGTH TEST, P69##BRYK AS, 1992, HIERARCHICAL LINEAR##COHEN J, 1976, STAT POWER ANAL BEHA##DE VREEDE PL, 2005, J AM GERIATR SOC, V53, P2, DOI 10.1111/J.1532-5415.2005.53003.X##DEKKER J, 1992, J BEHAV MED, V15, P189, DOI 10.1007/BF00848325##FORDYCE WE, 1973, ARCH PHYS MED REHAB, V54, P399##FRANSEN M, 2002, J RHEUMATOL, V29, P1737##GERAETS JJXR, 2005, AUST J PHYSIOTHER, V51, P87, DOI 10.1016/S0004-9514(05)70037-4##GOLDSTEIN H., 1995, MULTILEVEL STAT MODE##HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/ART.1780381104##JETTE AM, 1997, PHYS THER, V77, P145, DOI 10.1093/PTJ/77.2.145##JORDAN KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ARD.2003.011742##KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ARD.16.4.494##KETELAAR M, 2001, PHYS THER, V81, P1534, DOI 10.1093/PTJ/81.9.1534##KING M, 2002, BRIT MED J, V324, P947, DOI 10.1136/BMJ.324.7343.947##LEQUESNE MG, 1987, SCAND J RHEUMATOL, P85##LINDSTROM I, 1992, SPINE, V17, P641, DOI 10.1097/00007632-199206000-00003##LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/PTJ/72.4.279##LINTON SJ, 1993, PAIN, V54, P353, DOI 10.1016/0304-3959(93)90037-P##NORKIN C, 1986, MEASUREMENT JOINT MO##OSTELO RWJG, 2003, EUR SPINE J, V12, P637, DOI 10.1007/S00586-003-0560-9##RAVAUD P, 1997, J RHEUMATOL, V24, P786##ROORDA LD, 2004, ANN RHEUM DIS, V63, P36, DOI 10.1136/ARD.2002.001784##SMIDT N, 2005, AUST J PHYSIOTHER, V51, P71, DOI 10.1016/S0004-9514(05)70036-2##STAAL JB, 2004, ANN INTERN MED, V140, P77, DOI 10.7326/0003-4819-140-2-200401200-00007##STEULTJENS MPM, 2000, RHEUMATOLOGY, V39, P955, DOI 10.1093/RHEUMATOLOGY/39.9.955##STEULTJENS MPM, 2001, CLIN REHABIL, V15, P331, DOI 10.1191/026921501673178408##TAN J. C., 1998, PRACTICAL MANUAL PHY##TUBACH F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ARD.2004.022905##TUGWELL P, 1987, J RHEUMATOL, V14, P446##VAN BAAR ME, 2001, ANN RHEUM DIS, V60, P1123, DOI 10.1136/ARD.60.12.1123##VAN BAAR ME, 1998, J RHEUMATOL, V25, P2432##VAN BAAR ME, 1999, ARTHRITIS RHEUM, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9##VAN BAAR ME, 1998, J RHEUMATOL, V25, P125##VANDERHEIJDEN GJM, 1996, SHOULDER DISORDER TR##VEENHOF C, 2005, ARTHRIT RHEUM-ARTHR, V53, P375, DOI 10.1002/ART.21171##VLAEYEN JWS, 1995, BRIT J CLIN PSYCHOL, V34, P95, DOI 10.1111/J.2044-8260.1995.TB01443.X##VOGELS EMH, 2001, CLIN PRACTICE GUIDEL##WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002##WENDEL-VOS GCW, 2003, J CLIN EPIDEMIOL, V56, P1163, DOI 10.1016/S0895-4356(03)00220-8",74,2020-11-20,NA
J,WOS:000242892400016,2006,USING INTERNET TECHNOLOGY TO DELIVER A HOME-BASED PHYSICAL ACTIVITY INTERVENTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED CONTROLLED TRIAL,"OBJECTIVE. TO COMPARE THE EFFECTIVENESS OF 2 INTERNET-BASED PHYSICAL ACTIVITY INTERVENTIONS FOR PATIENTS WITH RHEUMATOID ARTHRITIS (RA). METHODS. A TOTAL OF 160 PHYSICALLY INACTIVE PATIENTS WITH RA WHO HAD A COMPUTER WITH INTERNET ACCESS WERE RANDOMLY ASSIGNED TO AN INTERNET-BASED PHYSICAL ACTIVITY PROGRAM WITH INDIVIDUAL GUIDANCE, A BICYCLE ERGOMETER, AND GROUP CONTACTS (INDIVIDUALIZED TRAINING [IT] GROUP; N = 82) OR TO AN INTERNET-BASED PROGRAM PROVIDING ONLY GENERAL INFORMATION ON EXERCISES AND PHYSICAL ACTIVITY (GENERAL TRAINING [GT] GROUP; N = 78). OUTCOME MEASURES INCLUDED QUANTITY OF PHYSICAL ACTIVITY (QUESTIONNAIRE AND ACTIVITY MONITOR), FUNCTIONAL ABILITY, QUALITY OF LIFE, AND DISEASE ACTIVITY (BASELINE, 3, 6, 9, AND 12 MONTHS). RESULTS. THE PROPORTION OF PHYSICALLY ACTIVE PATIENTS WAS SIGNIFICANTLY GREATER IN THE IT THAN IN THE GT GROUP AT 6 (38% VERSUS 22%) AND 9 MONTHS (35% VERSUS 11%; BOTH P < 0.05) REGARDING A MODERATE INTENSITY LEVEL FOR 30 MINUTES IN SUCCESSION ON AT LEAST 5 DAYS A WEEK, AND AT 6 (35% VERSUS 13%), 9 (40% VERSUS 14%), AND 12 MONTHS (34% VERSUS 10%; ALL P < 0.005) REGARDING A VIGOROUS INTENSITY LEVEL FOR 20 MINUTES IN SUCCESSION ON AT LEAST 3 DAYS A WEEK. IN GENERAL, THERE WERE NO STATISTICALLY SIGNIFICANT DIFFERENCES REGARDING CHANGES IN PHYSICAL ACTIVITY AS MEASURED WITH AN ACTIVITY MONITOR, FUNCTIONAL ABILITY, QUALITY OF LIFE, OR DISEASE ACTIVITY. CONCLUSION. AN INTERNET-BASED PHYSICAL ACTIVITY INTERVENTION WITH INDIVIDUALLY TAILORED SUPERVISION, EXERCISE EQUIPMENT, AND GROUP CONTACTS IS MORE EFFECTIVE WITH RESPECT TO THE PROPORTION OF PATIENTS WHO REPORT MEETING PHYSICAL ACTIVITY RECOMMENDATIONS THAN AN INTERNET-BASED PROGRAM WITHOUT THESE ADDITIONAL ELEMENTS IN PATIENTS WITH RA. NO DIFFERENCES WERE FOUND REGARDING THE TOTAL AMOUNT OF PHYSICAL ACTIVITY MEASURED WITH AN ACTIVITY MONITOR.",CHRONIC-FATIGUE-SYNDROME; ACTIVITY PROGRAMS; PUBLIC-HEALTH; OLDER-ADULTS; PORTABLE ACCELEROMETER; ENERGY-EXPENDITURE; CLINICAL-TRIALS; PRIMARY-CARE; EXERCISE; WALKING,PHYSICAL ACTIVITY; EXERCISE; INTERNET; RHEUMATOID ARTHRITIS,ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH,"VAN DEN BERG, MH##RONDAY, HK##PEETERS, AJ##LE CESSIE, S##VAN DER GIESEN, FJ##BREEDVELD, FC##VLIELAND, TPMV","LEIDEN UNIV, MED CTR, DEPT RHEUMATOL, NL-2300 RC LEIDEN, NETHERLANDS. HAGA LEYENBURG TEACHING HOSP, THE HAGUE, NETHERLANDS. REINIER GRAAF GASTHUIS, DELFT, NETHERLANDS.",RHEUMATOLOGY,RHEUMATOLOGY,"ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315##BORG G, 1978, SCAND J REHABIL MED SUPPL, V6, P105##BOUTAUGH ML, 2003, ARTHRIT RHEUM-ARTHR, V49, P463, DOI 10.1002/ART.11050##CHAO D, 2000, CONTROL CLIN TRIALS, V21, P212S, DOI 10.1016/S0197-2456(00)00081-7##DE JONG Z, 2005, CURR OPIN RHEUMATOL, V17, P177, DOI 10.1097/01.BOR.0000151400.33899.88##DEJONG Z, 1997, BRIT J RHEUMATOL, V36, P878##EURENIUS E, 2005, ARTHRIT RHEUM-ARTHR, V53, P48, DOI 10.1002/ART.20924##FONTAINE KR, 2004, ARTHRITIS RHEUM-US, V50, P624, DOI 10.1002/ART.20057##FONTAINE KR, 2005, ARTHRIT RHEUM-ARTHR, V53, P279, DOI 10.1002/ART.21073##FRANSEN M, 2003, COCHRANE DB SYST REV, V3##FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/ART.1780230202##GORDON MM, 2002, RHEUMATOLOGY, V41, P1402, DOI 10.1093/RHEUMATOLOGY/41.12.1402##HAGEMAN PATRICIA A, 2005, J GERIATR PHYS THER, V28, P28##HALBERT J, 2001, ARTHRIT RHEUM-ARTHR, V45, P228, DOI 10.1002/1529-0131(200106)45:3<228::AID-ART253>3.0.CO;2-2##HARLAND J, 1999, BRIT MED J, V319, P828, DOI 10.1136/BMJ.319.7213.828##HAYS R D, 1993, HEALTH ECON, V2, P217, DOI 10.1002/HEC.4730020305##HOOTMAN JM, 2003, ARTHRIT RHEUM-ARTHR, V49, P129, DOI 10.1002/ART.10911##IVERSEN MD, 2004, ARTHRIT RHEUM-ARTHR, V51, P63, DOI 10.1002/ART.20168##JAN MH, 2004, ARCH PHYS MED REHAB, V85, P1943, DOI 10.1016/J.APMR.2004.02.011##KLESGES RC, 1990, MED SCI SPORT EXER, V22, P690, DOI 10.1249/00005768-199010000-00022##LESLIE E, 2005, PREV MED, V40, P54, DOI 10.1016/J.YPMED.2004.05.002##LOMBARD DN, 1995, HEALTH PSYCHOL, V14, P164, DOI 10.1037/0278-6133.14.2.164##LOWTHER M, 1999, BRIT J SPORT MED, V33, P244, DOI 10.1136/BJSM.33.4.244##MACERA CA, 2003, ARTHRIT RHEUM-ARTHR, V49, P122, DOI 10.1002/ART.10907##MARSHALL A L, 2004, J SCI MED SPORT, V7, P74, DOI 10.1016/S1440-2440(04)80281-0##MARSHALL AL, 2003, AM J PREV MED, V25, P88, DOI 10.1016/S0749-3797(03)00111-9##MATTHEWS CE, 2002, MED SCI SPORT EXER, V34, P1376, DOI 10.1097/00005768-200208000-00021##MCKAY HG, 2001, DIABETES CARE, V24, P1328, DOI 10.2337/DIACARE.24.8.1328##MEIJER GA, 1989, MED SCI SPORT EXER, V21, P343##MONTOYE HJ, 1983, MED SCI SPORT EXER, V15, P403##NAPOLITANO MA, 2003, ANN BEHAV MED, V25, P92, DOI 10.1207/S15324796ABM2502_04##OOIJENDIJK WTM, 2002, TRENDRAPPORT BEWEGEN, P7##PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/JAMA.273.5.402##PLOTNIKOFF RC, 2005, AM J HEALTH PROMOT, V19, P422, DOI 10.4278/0890-1171-19.6.422##PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/ART.1780380107##PROPER KI, 2003, AM J PREV MED, V24, P218, DOI 10.1016/S0749-3797(02)00645-1##REGER B, 2002, PREV MED, V35, P285, DOI 10.1006/PMED.2002.1074##RICHTER JG, 2004, Z RHEUMATOL, V63, P216, DOI 10.1007/S00393-004-0571-X##RIEMSMA RP, 1996, BRIT J RHEUMATOL, V35, P755##SEMANIK P, 2004, ARTHRIT RHEUM-ARTHR, V51, P246, DOI 10.1002/ART.20245##STENSTROM CH, 2003, ARTHRIT RHEUM-ARTHR, V49, P428, DOI 10.1002/ART.11051##TALBOT LA, 2003, J AM GERIATR SOC, V51, P387, DOI 10.1046/J.1532-5415.2003.51113.X##TUGWELL P, 1987, J RHEUMATOL, V14, P446##VAN BAAR ME, 1999, ARTHRITIS RHEUM, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9##VAN DER WERF SP, 2000, J PSYCHOSOM RES, V49, P373, DOI 10.1016/S0022-3999(00)00197-5##VERCOULEN JHMM, 1997, J PSYCHIAT RES, V31, P661, DOI 10.1016/S0022-3956(97)00039-3##WASHBURN RA, 1999, J SPORT MED PHYS FIT, V39, P336##WESTBY MD, 2000, J RHEUMATOL, V27, P1674##WILBUR J, 2005, NURS RES, V54, P33##2003, ARTHRITIS RHEUM, V49, P477",81,2020-11-20,NA
J,WOS:000242892400018,2006,JOINT LAXITY AND THE RELATIONSHIP BETWEEN MUSCLE STRENGTH AND FUNCTIONAL ABILITY IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE,"OBJECTIVE. TO ESTABLISH THE IMPACT OF KNEE JOINT LAXITY ON THE RELATIONSHIP BETWEEN MUSCLE STRENGTH AND FUNCTIONAL ABILITY IN OSTEOARTHRITIS (OA) OF THE KNEE. METHODS. A CROSS-SECTIONAL STUDY OF 86 PATIENTS WITH OA OF THE KNEE WAS CONDUCTED. TESTS WERE PERFORMED TO DETERMINE VARUS-VALGUS LAXITY, MUSCLE STRENGTH, AND FUNCTIONAL ABILITY. LAXITY WAS ASSESSED USING A DEVICE THAT MEASURES THE ANGULAR DEVIATION OF THE KNEE IN THE FRONTAL PLANE. MUSCLE STRENGTH WAS MEASURED USING A COMPUTER-DRIVEN ISOKINETIC DYNAMOMETER. FUNCTIONAL ABILITY WAS ASSESSED BY OBSERVATION (100-METER WALKING TEST) AND SELF REPORT (WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX [WOMAC]). REGRESSION ANALYSES WERE PERFORMED TO ASSESS THE IMPACT OF JOINT LAXITY ON THE RELATIONSHIP BETWEEN MUSCLE STRENGTH AND FUNCTIONAL ABILITY. RESULTS. IN REGRESSION ANALYSES, THE INTERACTION BETWEEN MUSCLE STRENGTH AND JOINT LAXITY CONTRIBUTED TO THE VARIANCE IN BOTH WALKING TIME (P = 0.002) AND WOMAC SCORE (P = 0.080). THE SLOPE OF THE REGRESSION LINES INDICATED THAT THE RELATIONSHIP BETWEEN MUSCLE STRENGTH AND FUNCTIONAL ABILITY (WALKING TIME, WOMAC) WAS STRONGER IN PATIENTS WITH HIGH KNEE JOINT LAXITY. CONCLUSION. PATIENTS WITH KNEE OA AND HIGH KNEE JOINT LAXITY SHOW A STRONGER RELATIONSHIP BETWEEN MUSCLE STRENGTH AND FUNCTIONAL ABILITY THAN PATIENTS WITH OA AND LOW KNEE JOINT LAXITY. PATIENTS WITH OA, HIGH KNEE JOINT LAXITY, AND LOW MUSCLE STRENGTH ARE MOST AT RISK OF BEING DISABLED.",ANTERIOR CRUCIATE LIGAMENT; HIP OSTEOARTHRITIS; PHYSICAL FUNCTION; DISABILITY; WOMAC; EXERCISE; THERAPY; HEALTHY; UPDATE; PAIN,OSTEOARTHRITIS; KNEE; DISABILITY; LAXITY; MUSCLE STRENGTH,ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH,"VAN DER ESCH, M##STEULTJENS, M##KNOL, DL##DINANT, H##DEKKER, J","JAN VAN BREEMEN INST, CTR REHABIL & RHEUMATOL, NL-1056 AB AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS.",RHEUMATOLOGY,RHEUMATOLOGY,"AIKEN LS, 1991, MULTIPLE REGRESSION##ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/ART.1780290816##ALTMAN RD, 2000, ARTHRITIS RHEUM-US, V43, P1905##ALTMAN RD, 1995, OSTEOARTHR CARTILAGE, V3, P3##BELLAMY N, 1988, J RHEUMATOL, V15, P1833##COOPER C., 1998, RHEUMATOLOGY, P1##DOORENBOSCH CAM, 2003, CLIN BIOMECH, V18, P142, DOI 10.1016/S0268-0033(02)00183-3##FELSON DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9##FRANSEN M, 2002, J RHEUMATOL, V29, P1737##HORTOBAGYI T, 2005, CLIN BIOMECH, V20, P97, DOI 10.1016/J.CLINBIOMECH.2004.08.004##KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ARD.16.4.494##LIN YC, 2001, SCAND J MED SCI SPOR, V11, P280, DOI 10.1034/J.1600-0838.2001.110505.X##MCALINDON TE, 1993, ANN RHEUM DIS, V52, P258, DOI 10.1136/ARD.52.4.258##MCCONNELL S, 2001, ARTHRIT RHEUM-ARTHR, V45, P453, DOI 10.1002/1529-0131(200110)45:5<453::AID-ART365>3.0.CO;2-W##MCNAIR PJ, 1994, ARCH PHYS MED REHAB, V75, P584##ROORDA LD, 2004, ANN RHEUM DIS, V63, P36, DOI 10.1136/ARD.2002.001784##SHARMA L, 2003, ARTHRITIS RHEUM-US, V48, P3359, DOI 10.1002/ART.11420##SHARMA L, 1999, ARTHRITIS RHEUM, V42, P861, DOI 10.1002/1529-0131(199905)42:5<861::AID-ANR4>3.0.CO;2-N##SHARMA L, 1999, ARTHRITIS RHEUM-US, V42, P25, DOI 10.1002/1529-0131(199901)42:1<25::AID-ANR3>3.0.CO;2-G##SHARMA L, 2003, OSTEOARTHRITIS, V2, P177##STEULTJENS MPM, 2001, CLIN REHABIL, V15, P331, DOI 10.1191/026921501673178408##VAN BAAR ME, 1999, ARTHRITIS RHEUM, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9##VAN BAAR ME, 1998, J RHEUMATOL, V25, P125##VAN DER ESCH M, 2005, SCAND J RHEUMATOL, V34, P298, DOI 10.1080/03009740510018651##VAN DER ESCH M, 2006, RHEUMATOLOGY, V45, P595, DOI 10.1093/RHEUMATOLOGY/KEI243",44,2020-11-20,NA
J,WOS:000242892400020,2006,"COMPARISON OF EFFICACY OF ARTHROSCOPIC LAVAGE PLUS ADMINISTRATION OF CORTICOSTEROIDS, ARTHROSCOPIC LAVAGE PLUS ADMINISTRATION OF PLACEBO, AND JOINT ASPIRATION PLUS ADMINISTRATION OF CORTICOSTEROIDS IN ARTHRITIS OF THE KNEE: A RANDOMIZED CONTROLLED TRIAL","OBJECTIVE. TO COMPARE THE EFFICACY OF ARTHROSCOPIC LAVAGE PLUS ADMINISTRATION OF CORTICOSTEROIDS (ALC), ARTHROSCOPIC LAVAGE PLUS ADMINISTRATION OF PLACEBO (ALP), AND JOINT ASPIRATION PLUS ADMINISTRATION OF CORTICOSTEROIDS (JAC) IN KNEE ARTHRITIS, AND TO EVALUATE WHETHER CLINICAL OR HISTOLOGIC CHARACTERISTICS DETERMINE OUTCOME. METHODS. PATIENTS WITH KNEE ARTHRITIS (NOT DUE TO GOUT, OSTEOARTHRITIS, OR SEPTIC ARTHRITIS) WERE RANDOMIZED OVER 3 TREATMENT ARMS: ALC, ALP, AND JAC. THE PRIMARY END POINT WAS EVENT-FREE SURVIVAL, WITH EVENTS DEFINED AS 1) RECURRENCE OR PERSISTENCE OF SYMPTOMATIC KNEE SWELLING NECESSITATING LOCAL RE-TREATMENT, OR 2) NONIMPROVEMENT OF THE KNEE JOINT SCORE. SYNOVIAL TISSUE SPECIMENS WERE COLLECTED AND ANALYZED HISTOLOGICALLY TO IDENTIFY PREDICTIVE FACTORS OF RESPONSIVENESS. RESULTS. A TOTAL OF 78 PATIENTS WERE ENROLLED; 3 PATIENTS DID NOT RECEIVE THEIR ALLOCATED THERAPY AND 3 WERE LOST TO FOLLOWUP. THE MEDIAN TIME UNTIL RECURRENCE WAS 9.6 MONTHS AFTER ALC, 3.0 MONTHS AFTER JAC, AND 1.0 MONTH AFTER ALP, CORRESPONDING TO A RELATIVE RISK (RR) OF ARTHRITIS RECURRENCE OF 2.2 FOR JAC (95% CONFIDENCE INTERVAL [95% CI] 1.2-4.2, P = 0.02) AND 4.7 FOR ALP (95% CI 2.3-9.4, P < 0.0001) COMPARED WITH ALC. A HIGH VERSUS LOW SYNOVIAL EXTENT OF FIBROSIS CONFERRED AN RR FOR RECURRENCE OF 5.7 (95% CI 1.6-20.5, P < 0.01) AFTER ALC. CONCLUSION. ARTHROSCOPIC LAVAGE PLUS ADMINISTRATION OF CORTICOSTEROIDS WAS MORE EFFECTIVE THAN ARTHROSCOPIC LAVAGE PLUS ADMINISTRATION OF PLACEBO OR JOINT ASPIRATION PLUS INJECTION OF CORTICOSTEROIDS. THE ABSENCE OF FIBROSIS WAS A HISTOLOGIC PREDICTOR OF A BENEFICIAL RESPONSE.",RHEUMATOID-ARTHRITIS; INTRAARTICULAR CORTICOSTEROIDS; DISEASE-ACTIVITY; SYNOVITIS; INFLAMMATION; OSTEOARTHRITIS; INJECTIONS; PLACEMENT; TISSUE; MODEL,ARTHROSCOPIC LAVAGE; CORTICOSTEROIDS; ARTHRITIS,ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH,"VAN OOSTERHOUT, M##SONT, JK##BAJEMA, IM##BREEDVELD, FC##VAN LAAR, JM","LEIDEN UNIV, MED CTR, DEPT RHEUMATOL, NL-2300 RC LEIDEN, NETHERLANDS.",RHEUMATOLOGY,RHEUMATOLOGY,"ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315##BIRD HA, 1978, ANN RHEUM DIS, V37, P78, DOI 10.1136/ARD.37.1.78##BLIDDAL H, 1999, ANN RHEUM DIS, V58, P641, DOI 10.1136/ARD.58.10.641##CHAKRAVARTY K, 1994, BRIT J RHEUMATOL, V33, P464##FITZGERALD O, 1985, BRIT J RHEUMATOL, V24, P6##HARAOUI B, 1991, ARTHRITIS RHEUM, V34, P153, DOI 10.1002/ART.1780340205##JONES A, 1993, BRIT MED J, V307, P1329, DOI 10.1136/BMJ.307.6915.1329##KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ARD.16.4.494##LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085##LOEUILLE D, 2005, ARTHRITIS RHEUM-US, V52, P3492, DOI 10.1002/ART.21373##MCCARTY DJ, 1991, J RHEUMATOL, V18, P1091##PATERSON J, 1978, ANN RHEUM DIS, V37, P48, DOI 10.1136/ARD.37.1.48##POPERT J, 1985, BRIT J RHEUMATOL, V24, P1##PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/ART.1780380107##SANCHEZ-PERNAUTE O, 2003, ANN RHEUM DIS, V62, P1135, DOI 10.1136/ARD.2003.011767##SHARMA A, 1996, J RHEUMATOL, V23, P1872##SMITH MD, 2003, RHEUMATOLOGY, V42, P1477, DOI 10.1093/RHEUMATOLOGY/KEG398##SRINIVASAN A, 1995, BRIT J RHEUMATOL, V34, P771##TAK PP, 1997, ARTHRITIS RHEUM, V40, P217, DOI 10.1002/ART.1780400206##TANAKA N, 2002, CLIN RHEUMATOL, V21, P4, DOI 10.1007/S100670200002##VAN DER POUW KRAAN TCTM, 2003, GENES IMMUN, V4, P187, DOI 10.1038/SJ.GENE.6363975##VAN OOSTERHOUT M, 2003, RHEUMATOLOGY, V42, P102, DOI 10.1093/RHEUMATOLOGY/KEG042##VERBURG RJ, 2005, ANN RHEUM DIS, V64, P1397, DOI 10.1136/ARD.2004.033332##WEITOFT T, 2000, ANN RHEUM DIS, V59, P233, DOI 10.1136/ARD.59.3.233##YOUSSEF PP, 1998, ARTHRITIS RHEUM, V41, P663, DOI 10.1002/1529-0131(199804)41:4<663::AID-ART13>3.0.CO;2-L",19,2020-11-20,NA
J,WOS:000242680000022,2006,"COCAINE STRONGLY REDUCES PREPULSE INHIBITION IN APOMORPHINE-SUSCEPTIBLE RATS, BUT NOT IN APOMORPHINE-UNSUSCEPTIBLE RATS: REGULATION BY DOPARNINE D2 RECEPTORS","DOPAMINERGIC AGONISTS, SUCH AS APOMORPHINE AND AMPHETAMINE, HAVE BEEN SHOWN TO DRASTICALLY REDUCE PREPULSE INHIBITION OF THE ACOUSTIC STARTLE REFLEX. THE EFFECTS OF THE INDIRECT DOPAMINE AGONIST COCAINE ON PREPULSE INHIBITION HAVE ONLY BEEN DESCRIBED IN A FEW REPORTS AND HAVE YIELDED CONFLICTING RESULTS, POSSIBLY DUE TO INDIVIDUAL DIFFERENCES WITHIN AND BETWEEN RAT STRAINS. IN THIS STUDY WE THEREFORE USED APOMORPHINE-SUSCEPTIBLE AND APOMORPHINE-UNSUSCEPTIBLE RATS, AS AN ANIMAL MODEL FOR INDIVIDUAL DIFFERENCES, TO STUDY THE EFFECTS OF COCAINE (20, 30 MG/KG I.P.) ON PREPULSE INHIBITION. IN ADDITION WE TESTED WHETHER THE COCAINE-INDUCED DEFICIT IN PREPULSE INHIBITION COULD BE REVERSED BY THE D-2-ANTAGONIST REMOXIPRIDE (5 MG/KG I.P.), THE ALPHA-I ADRENOCEPTOR ANTAGONIST PRAZOSIN (2.5 MG/KG I.P.) AND THE 5-HT2 -ANTAGONIST KETANSERIN (2.0 MG/KG I.P.). COCAINE STRONGLY REDUCED PREPULSE INHIBITION IN APOMORPHINE-SUSCEPTIBLE RATS, BUT HAD NO EFFECT AT ALL ON APOMORPHINE-UNSUSCEPTIBLE RATS. REMOXIPRIDE HAD NO EFFECT ON PREPULSE INHIBITION, BUT PRAZOSIN AND KETANSERIN INCREASED PREPULSE INHIBITION. BOTH REMOXIPRIDE AND PRAZOSIN REVERSED THE COCAINE-INDUCED DEFICIT IN PREPULSE INHIBITION, WHEREAS KETANSERIN DID NOT. WE CONCLUDE THAT APOMORPHINE-SUSCEPTIBLE RATS ARE EXTREMELY SENSITIVE TO THE EFFECTS OF COCAINE ON PREPULSE INHIBITION, WHILE APOMORPHINE-UNSUSCEPTIBLE RATS ARE NOT. THE EFFECTS OF COCAINE ON PREPULSE INHIBITION IN APOMORPHINE-SUSCEPTIBLE RATS WERE MEDIATED BY D-2-RECEPTORS, BUT NOT BY 5-HT2-RECEPTORS OR ALPHA-I ADRENOCEPTORS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",SENSORIMOTOR GATING DEFICITS; ACOUSTIC STARTLE RESPONSE; NUCLEUS-ACCUMBENS; MONOAMINE TRANSPORTERS; ANTIPSYCHOTIC ACTIVITY; DOPAMINERGIC SYSTEM; STRAIN DIFFERENCES; LOCOMOTOR-ACTIVITY; ANIMAL-MODELS; WISTAR RATS,DOPAMINE; COCAINE; REMOXIPRIDE; KETANSERIN; PRAZOSIN,BEHAVIOURAL BRAIN RESEARCH,"VAN DER ELST, MCJ##ELLENBROEK, BA##COOLS, AR","UNIV NIJMEGEN, RADBOUD MED CTR, MOL NEUROBIOL SECT, DEPT COGNIT NEUROSCI, NIJMEGEN, NETHERLANDS.",BEHAVIORAL SCIENCES; NEUROSCIENCES,BEHAVIORAL SCIENCES; NEUROSCIENCES & NEUROLOGY,"ANGRIST B M, 1970, BIOL PSYCHIATRY, V2, P95##BAKSHI VP, 1997, J PHARMACOL EXP THER, V283, P666##BRAFF DL, 1992, ARCH GEN PSYCHIAT, V49, P206##BRODERICK PA, 2003, PROG NEURO-PSYCHOPH, V27, P1037, DOI 10.1016/S0278-5846(03)00176-3##BYRNES JJ, 2000, NEUROPSYCHOPHARMACOL, V22, P551, DOI 10.1016/S0893-133X(99)00151-7##CARASSO BS, 1998, NEUROPHARMACOLOGY, V37, P401, DOI 10.1016/S0028-3908(98)00051-3##CASTELLANOS FX, 1996, BIOL PSYCHIAT, V39, P33, DOI 10.1016/0006-3223(95)00101-8##COOLS AR, 1990, BRAIN RES BULL, V24, P49, DOI 10.1016/0361-9230(90)90288-B##DEPOORTERE R, 1997, PSYCHOPHARMACOLOGY, V132, P366, DOI 10.1007/S002130050357##DEPOORTERE R, 1997, BEHAV PHARMACOL, V8, P51##ELLENBROEK BA, 2002, BEHAV GENET, V32, P349, DOI 10.1023/A:1020214322065##ELLENBROEK BA, 2001, J PHARMACOL EXP THER, V298, P386##ELLENBROEK BA, 2000, PSYCHOPHARMACOLOGY, V148, P124, DOI 10.1007/S002130050033##FEIFEL D, 1999, NEUROPSYCHOPHARMACOL, V20, P141, DOI 10.1016/S0893-133X(98)00041-4##GEYER MA, 2001, PSYCHOPHARMACOLOGY, V156, P117, DOI 10.1007/S002130100811##GINGRAS MA, 1997, PHARMACOL BIOCHEM BE, V57, P857, DOI 10.1016/S0091-3057(96)00320-6##HOOKS MS, 1991, PHARMACOL BIOCHEM BE, V38, P467, DOI 10.1016/0091-3057(91)90308-O##HURD YL, 1989, SYNAPSE, V3, P48, DOI 10.1002/SYN.890030107##JOHANSSON C, 1995, PHARMACOL BIOCHEM BE, V52, P649, DOI 10.1016/0091-3057(95)00160-X##KINNEY GG, 1999, J NEUROSCI, V19, P5644##LEVIEL V, 2001, NEUROCHEM INT, V38, P83, DOI 10.1016/S0197-0186(00)00076-0##MANSBACH RS, 1988, PSYCHOPHARMACOLOGY, V94, P507, DOI 10.1007/BF00212846##MARTINEZ ZA, 1999, PSYCHOPHARMACOLOGY, V142, P253, DOI 10.1007/S002130050887##MOGHADDAM B, 1989, SYNAPSE, V4, P156, DOI 10.1002/SYN.890040209##RITZ MC, 1988, PROG NEURO-PSYCHOPH, V12, P233, DOI 10.1016/0278-5846(88)90040-1##ROTHMAN RB, 2003, EUR J PHARMACOL, V479, P23, DOI 10.1016/J.EJPHAR.2003.08.054##ROTS NY, 1996, BRAIN RES, V710, P189, DOI 10.1016/0006-8993(95)01379-2##SIPES TA, 1994, NEUROPHARMACOLOGY, V33, P441, DOI 10.1016/0028-3908(94)90074-4##SWERDLOW NR, 2000, J NEUROSCI, V20, P4325##SWERDLOW NR, 1998, NEUROPSYCHOPHARMACOL, V18, P50##SWERDLOW NR, 1995, J NEUROL NEUROSUR PS, V58, P192, DOI 10.1136/JNNP.58.2.192##SWERDLOW NR, 1993, BIOL PSYCHIAT, V33, P298, DOI 10.1016/0006-3223(93)90300-3##SWERDLOW NR, 1993, PHARMACOL BIOCHEM BE, V44, P741, DOI 10.1016/0091-3057(93)90193-W##UHL GR, 2002, MOL PSYCHIATR, V7, P21, DOI 10.1038/SJ/MP/4000964##VAN DER ELST MCJ, 2005, EXP BRAIN RES, V160, P418, DOI 10.1007/S00221-004-2025-8##VAN DER ELST MCJ, 2005, LIFE SCI, V76, P1391, DOI 10.1016/J.LFS.2004.10.023##VANDERELST MCJ, IN PRESS PSYCHOPHARM##VARTY GB, 1998, BEHAV PHARMACOL, V9, P445, DOI 10.1097/00008877-199809000-00008##VARTY GB, 1995, EUR J PHARMACOL, V287, P201, DOI 10.1016/0014-2999(95)00660-5##WEISS IC, 2000, BEHAV NEUROSCI, V114, P364, DOI 10.1037/0735-7044.114.2.364##WILLIAMSON S, 1997, DRUG ALCOHOL DEPEN, V44, P87, DOI 10.1016/S0376-8716(96)01324-5##ZHANG JH, 2000, PSYCHOPHARMACOLOGY, V149, P181, DOI 10.1007/S002130000369",11,2020-11-20,NA
J,WOS:000242983200003,2006,SPATIAL SEGREGATION OF TRANSPORT AND SIGNALLING FUNCTIONS BETWEEN HUMAN ENDOTHELIAL CAVEOLAE AND LIPID RAFT PROTEOMES,"LIPID RAFTS AND CAVEOLAE ARE BIOCHEMICALLY SIMILAR, SPECIALIZED DOMAINS OF THE PM (PLASMA MEMBRANE) THAT CLUSTER SPECIFIC PROTEINS. HOWEVER, THEY ARE MORPHOLOGICALLY DISTINCT, IMPLYING DIFFERENT, POSSIBLY COMPLEMENTARY FUNCTIONS. TWO-DIMENSIONAL GEL ELECTROPHORESIS PRECEDING IDENTIFICATION OF PROTEINS BY MS WAS USED TO COMPARE THE RELATIVE ABUNDANCE OF PROTEINS IN DRMS (DETERGENT-RESISTANT MEMBRANES) ISOLATED FROM HUVEC (HUMAN UMBILICAL-VEIN ENDOTHELIAL CELLS), AND CAVEOLAE IMMUNOPURIFIED FROM DRM FRACTIONS. VARIOUS SIGNALLING AND TRANSPORT PROTEINS WERE IDENTIFIED AND ADDITIONAL CELL-SURFACE BIOTINYLATION REVEALED THE MAJORITY TO BE EXPOSED, DEMONSTRATING THEIR PRESENCE AT THE PM. IN RESTING ENDOTHELIAL CELLS, THE SCAFFOLD OF IMMUNOISOLATED CAVEOLAE CONSISTS OF ONLY FEW RESIDENT PROTEINS, RELATED TO STRUCTURE [CAV 1 (CAVEOLIN-1), VIMENTIN] AND TRANSPORT (V-ATPASE), AS WELL AS THE GPI (GLYCOSYLPHOSPHATIDYLINOSITOL)-LINKED, SURFACE-EXPOSED PROTEIN CD59. FURTHER QUANTITATIVE CHARACTERIZATION BY IMMUNOBLOTTING AND CONFOCAL MICROSCOPY OF WELL-KNOWN [ENOS (ENDOTHELIAL NITRIC OXIDE SYNTHASE) AND CAV 1], LESS KNOWN [SNAP-23 (23 KDA SYNAPTOSOME-ASSOCIATED PROTEIN) AND BASP1 (BRAIN ACID SOLUBLE PROTEIN 1)] AND NOVEL [C80RF2 (CHROMOSOME 8 OPEN READING FRAME 2)] PROTEINS SHOWED DIFFERENT SUBCELLULAR DISTRIBUTIONS WITH NONE OF THESE PROTEINS BEING EXCLUSIVE TO EITHER CAVEOLAE OR DRM. HOWEVER, THE DRM-ASSOCIATED FRACTION OF THE NOVEL PROTEIN C80RF2 (SIMILAR TO 5% OF TOTAL PROTEIN) ASSOCIATED WITH IMMUNOSEPARATED CAVEOLAE, IN CONTRAST WITH THE RAFT PROTEIN SNAP-23. THE SEGREGATION OF CAVEOLAE FROM LIPID RAFTS WAS VISUALLY CONFIRMED IN PROLIFERATING CELLS, WHERE CAV1 WAS SPATIALLY SEPARATED FROM ENOS, SNAP-23 AND BASP1. THESE RESULTS PROVIDE DIRECT EVIDENCE FOR THE PREVIOUSLY SUGGESTED SEGREGATION OF TRANSPORT AND SIGNALLING FUNCTIONS BETWEEN SPECIALIZED DOMAINS OF THE ENDOTHELIAL PLASMA MEMBRANE.",GPI-ANCHORED PROTEINS; LINKED PROTEINS; ATPASE; INTERNALIZATION; SEQUESTRATION; RECEPTOR-1; MEMBRANES; SURFACE; CELLS,CAVEOLAE; DETERGENT-RESISTANT MEMBRANE (DRM); HUMAN UMBILICAL-VEIN ENDOTHELIAL CELLS (HUVEC); LIPID RAFT; SUB-PROTEOMICS; VESICULAR TRANSPORT,BIOCHEMICAL JOURNAL,"SPRENGER, RR##FONTIJN, RD##VAN MARLE, J##PANNEKOEK, H##HORREVOETS, AJG","UNIV AMSTERDAM, ACAD MED CTR, DEPT MED BIOCHEM, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT CELL BIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"BAUER PM, 2005, P NATL ACAD SCI USA, V102, P204, DOI 10.1073/PNAS.0406092102##BLAGOEV B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/NBT790##BLONDER J, 2004, ELECTROPHORESIS, V25, P1307, DOI 10.1002/ELPS.200405891##BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J##COHEN AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/PHYSREV.00046.2003##D'ALESSIO A, 2005, AM J PATHOL, V166, P1273, DOI 10.1016/S0002-9440(10)62346-2##DI GUGLIELMO GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/NCB975##DRAB M, 2001, SCIENCE, V293, P2449, DOI 10.1126/SCIENCE.1062688##DURR E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/NBT993##EPAND RM, 2001, BIOCHEMISTRY-US, V40, P10514, DOI 10.1021/BI010897S##FOSTER LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/PNAS.0631608100##FRANK PG, 2003, ARTERIOSCL THROM VAS, V23, P1161, DOI 10.1161/01.ATV.0000070546.16946.3A##GRATTON JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17##HENLEY JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/JCB.141.1.85##JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470##KORTY PE, 1991, J IMMUNOL, V146, P4092##LEE WC, 2001, ATHEROSCLEROSIS, V155, P307, DOI 10.1016/S0021-9150(00)00578-5##LEGLER DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X##LI N, 2004, PROTEOMICS, V4, P3156, DOI 10.1002/PMIC.200400832##LICHTENBERG D, 2005, TRENDS BIOCHEM SCI, V30, P430, DOI 10.1016/J.TIBS.2005.06.004##MAEKAWA S, 2003, BBA-BIOMEMBRANES, V1610, P261, DOI 10.1016/S0005-2736(03)00023-3##MANES S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/NRI1129##MATVEEV SV, 2002, AM J PHYSIOL-CELL PH, V282, PC935, DOI 10.1152/AJPCELL.00349.2001##MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/SCIENCE.7516582##MCMAHON KA, 2006, PROTEOMICS, V6, P143, DOI 10.1002/PMIC.200500208##MINEO C, 1996, EXP CELL RES, V224, P237, DOI 10.1006/EXCR.1996.0133##MOSEVITSKY MI, 1997, BIOCHIMIE, V79, P373, DOI 10.1016/S0300-9084(97)80032-6##MUNRO S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1##NAVARRO A, 2004, FASEB J, V18, P1801, DOI 10.1096/FJ.04-2516REV##OH P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/JBC.274.33.23144##PARTON RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/NRM1017##POLISHCHUK R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/NCB1109##RAIMONDO F, 2005, EXPERT REV PROTEOMIC, V2, P793, DOI 10.1586/14789450.2.5.793##RAZANI B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/PR.54.3.431##RAZANI B, 2001, J BIOL CHEM, V276, P38121##RAZZAQ TM, 2004, IMMUNOLOGY, V113, P413, DOI 10.1111/J.1365-2567.2004.01998.X##SALAUN C, 2004, BBA-MOL CELL RES, V1693, P81, DOI 10.1016/J.BBAMCR.2004.05.008##SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/JCB.122.4.789##SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/SCIENCE.7660128##SCHUCK S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/PNAS.0631579100##SHEVCHENKO A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/AC950914H##SHOGOMORI H, 2003, BIOL CHEM, V384, P1259, DOI 10.1515/BC.2003.139##SIMONS K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052##SIMONS K, 1997, NATURE, V387, P569, DOI 10.1038/42408##SOTGIA F, 2002, MOL CELL BIOL, V22, P3905, DOI 10.1128/MCB.22.11.3905-3926.2002##SPRENGER RR, 2004, ELECTROPHORESIS, V25, P156, DOI 10.1002/ELPS.200305675##SUN-WADA GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/J.BBABIO.2004.04.013##SUN-WADA GH, 2003, CELL STRUCT FUNCT, V28, P455, DOI 10.1247/CSF.28.455##TAVERNARAKIS N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X##VISENTIN L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145",56,2020-11-20,NA
J,WOS:000242675300021,2006,LEVELS OF INTRINSIC COAGULATION FACTORS AND THE RISK OF MYOCARDIAL INFARCTION AMONG MEN: OPPOSITE AND SYNERGISTIC EFFECTS OF FACTORS XI AND YII,"THE ROLE OF THE INTRINSIC COAGULATION SYSTEM ON THE RISK OF MYOCARDIAL INFARCTION IS UNCLEAR. IN THE STUDY OF MYOCARDIAL INFARCTIONS LEIDEN (SMILE) THAT INCLUDED 560 MEN YOUNGER THAN AGE 70 WITH A FIRST MYOCARDIAL INFARCTION AND 646 CONTROL SUBJECTS, WE INVESTIGATED THE RISK OF MYOCARDIAL INFARCTION FOR LEVELS OF FACTOR XI (FACTOR XIC) AND FACTOR XII (FACTOR XIIC). FURTHERMORE, THE RISKS FOR FACTOR VIII ACTIVITY (FACTOR VIIIC) AND FACTOR IX ACTIVITY (FACTOR IXC) WERE ASSESSED. FACTOR XIC WAS 113.0% IN PATIENTS COMPARED WITH 109.8% IN CONTROL SUBJECTS (DIFFERENCE, 3.2%; 95% CL, 1.1%-5.4%). THE RISK OF 6.4; 95% CL, 2.2-18.0). FACTOR VILIC INCREASED THE RISK OF MYOCARDIAL INFARCTION ALTHOUGH NOT DOSE DEPENDENTLY. FACTOR IXC INCREASED THE RISK; ODDS RATIO OF MYOCARDIAL INFARCTION FOR MEN IN THE HIGHEST QUINTILE VERSUS THOSE IN THE LOWEST QUINTILE WAS 3.2 (ORADJ, 3.2; 95% CL, 2.0-5.1). THUS, FACTORS XIC AND XIIC HAVE OPPOSITE AND SYNERGISTIC EFFECTS ON THE RISK OF MYOCARDIAL INFARCTION IN MEN; FACTOR VILIC AND FACTOR IXC INCREASE THE RISK.",CORONARY-HEART-DISEASE; MOLECULAR-WEIGHT KININOGEN; MIDDLE-AGED MEN; HAGEMAN-FACTOR; HEMOSTATIC FACTORS; VENOUS THROMBOSIS; FACTOR-VIII; ACTIVATION; DEFICIENCY; FIBRINOLYSIS,NA,BLOOD,"DOGGEN, CJM##ROSENDAAL, FR##MEIJERS, JCM","LEIDEN UNIV, MED CTR, DEPT CLIN EPIDEMIOL, NL-2300 RA LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, THROMBOSIS & HAEMOSTASIS RES CTR, NL-2300 RA LEIDEN, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT VASC MED, NL-1012 WX AMSTERDAM, NETHERLANDS.",HEMATOLOGY,HEMATOLOGY,"ALTIERI P, 2005, THROMB RES, V115, P65, DOI 10.1016/J.THROMRES.2004.08.011##BOUMA BN, 1999, THROMB HAEMOSTASIS, V82, P243##COOPER JA, 2000, CIRCULATION, V102, P2816##DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/BI00107A001##DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601##DOGGEN CJM, 1998, CIRCULATION, V97, P1037, DOI 10.1161/01.CIR.97.11.1037##FOLSOM AR, 1997, CIRCULATION, V96, P1102, DOI 10.1161/01.CIR.96.4.1102##GALLIMORE MJ, 2004, THROMB RES, V114, P91, DOI 10.1016/J.THROMRES.2004.05.005##GHEBREHIWET B, 1981, J EXP MED, V153, P665, DOI 10.1084/JEM.153.3.665##GRUBER A, 2003, BLOOD, V102, P953, DOI 10.1182/BLOOD-2003-01-0324##HALBMAYER WM, 1994, CORONARY ARTERY DIS, V5, P451, DOI 10.1097/00019501-199405000-00012##HERWALD H, 1998, NAT MED, V4, P298, DOI 10.1038/NM0398-298##KELLEHER CC, 1992, ATHEROSCLEROSIS, V97, P67, DOI 10.1016/0021-9150(92)90052-I##KOSTER T, 1994, BRIT J HAEMATOL, V87, P422, DOI 10.1111/J.1365-2141.1994.TB04937.X##KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/BI00548A011##LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659##LEITCH JW, 1989, MED J AUSTRALIA, V150, P6, DOI 10.5694/J.1326-5377.1989.TB136310.X##LODI S, 1984, SCAND J HAEMATOL, V33, P80##LOWE GDO, 2004, ARTERIOSCL THROM VAS, V24, P1529, DOI 10.1161/01.ATV.0000135995.39488.6C##MEADE TW, 1994, BRIT J HAEMATOL, V88, P601, DOI 10.1111/J.1365-2141.1994.TB05079.X##MEIJERS JCM, 2000, NEW ENGL J MED, V342, P696, DOI 10.1056/NEJM200003093421004##MERLO C, 2002, ATHEROSCLEROSIS, V161, P261, DOI 10.1016/S0021-9150(01)00666-9##MILLER GJ, 1997, ARTERIOSCL THROM VAS, V17, P2103, DOI 10.1161/01.ATV.17.10.2103##MINNEMA MC, 1998, J CLIN INVEST, V101, P10, DOI 10.1172/JCI781##PENNY WJ, 1985, BRIT HEART J, V53, P230##RENNE T, 2005, J EXP MED, V202, P271, DOI 10.1084/JEM.20050664##RUMLEY A, 1999, BRIT J HAEMATOL, V105, P110, DOI 10.1111/J.1365-2141.1999.01317.X##SALOMON O, 2003, J THROMB HAEMOST, V1, P658, DOI 10.1046/J.1538-7836.2003.00195.X##TANIS B, 2006, EUR J HAEMATOL, V77, P67, DOI 10.1111/J.1600-0609.2006.00656.X##VONDEMBORNE PAK, 1995, BLOOD, V86, P3035##VONDEMBORNE PAK, 1997, J CLIN INVEST, V99, P2323, DOI 10.1172/JCI119412##WANG X, 2005, J THROMB HAEMOST, V3, P695, DOI 10.1111/J.1538-7836.2005.01236.X##ZITO F, 2000, CIRCULATION, V102, P2058, DOI 10.1161/01.CIR.102.17.2058",160,2020-11-20,NA
J,WOS:000242675300053,2006,CONTINUOUS IN VIVO INFUSION OF INTERFERON-GAMMA (IFN-GAMMA) ENHANCES ENGRAFTMENT OF SYNGENEIC WILD-TYPE CELLS IN FANCA(-/-) AND FANCG(-/-) MICE,"FANCONI ANEMIA (FA) IS A HETEROGENEOUS GENETIC DISORDER CHARACTERIZED BY BONE MARROW (BM) FAILURE AND CANCER SUSCEPTIBILITY. IDENTIFICATION OF THE CDNAS OF FA COMPLEMENTATION TYPES ALLOWS THE POTENTIAL OF USING GENE TRANSFER TECHNOLOGY TO INTRODUCE FUNCTIONAL CDNAS AS TRANSGENES INTO AUTOLOGOUS STEM CELLS AND PROVIDE A CURE FOR THE BM FAILURE IN FA PATIENTS. HOWEVER, STRATEGIES TO ENHANCE THE MOBILIZATION, TRANSDUCTION, AND ENGRAFTMENT OF EXOGENOUS STEM CELLS ARE REQUIRED TO OPTIMIZE EFFICACY PRIOR TO WIDE-SPREAD CLINICAL USE. HYPERSENSITIVITY OF FANCC(-/-) CELLS TO INTERFERON-GAMMA (IFN-GAMMA), A NONGENOTOXIC IMMUNE-REGULATORY CYTOKINE, ENHANCES ENGRAFTMENT OF SYNGENEIC WILD-TYPE (WT) CELLS IN FANCC(-/-) MICE. HOWEVER, WHETHER THIS PHENOTYPE IS OF BROAD RELEVANCE IN OTHER FA COMPLEMENTATION GROUPS IS UNRESOLVED. HERE WE SHOW THAT PRIMITIVE AND MATURE MYELOID PROGENITORS IN FANCA(-/-) AND FANCG(-/-) MICE ARE HYPERSENSITIVE TO IFN-GAMMA AND THAT IN VIVO INFUSION OF IFN-GAMMA AT CLINICALLY RELEVANT CONCENTRATIONS WAS SUFFICIENT TO ALLOW CONSISTENT LONG-TERM ENGRAFTMENT OF ISOGENIC WT REPOPULATING STEM CELLS. GIVEN THAT FANCA, FANCC, AND FANCG COMPLEMENTATION GROUPS ACCOUNT FOR MORE THAN 90% OF ALL FA PATIENTS, THESE DATA PROVIDE EVIDENCE THAT IFN-GAMMA CONDITIONING MAY BE A USEFUL NONGENOTOXIC STRATEGY FOR MYELO-PREPARATION IN FA PATIENTS.",GROUP C GENE; BONE-MARROW-TRANSPLANTATION; HEMATOPOIETIC STEM-CELLS; FANCONI-ANEMIA; TARGETED DISRUPTION; PROGENITOR CELLS; APLASTIC-ANEMIA; CD34(+) CELLS; EXPRESSION; MURINE,NA,BLOOD,"SI, Y##CICCONE, S##YANG, FC##YUAN, J##ZENG, D##CHEN, S##VAN DE VRUGT, HJ##CRITSER, J##ARWERT, F##HANELINE, LS##CLAPP, DW","INDIANA UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, INDIANAPOLIS, IN 46202 USA. INDIANA UNIV, SCH MED, DEPT PEDIAT, HERMAN B WELLS CTR PEDIAT RES, INDIANAPOLIS, IN 46202 USA. UNIV MISSOURI, DEPT LAB PATHOL, COMPARAT MED CTR, ST LOUIS, MO 63121 USA. UNIV AMSTERDAM, DEPT CLIN GENET & HUMAN GENET, MED CTR, AMSTERDAM, NETHERLANDS.",HEMATOLOGY,HEMATOLOGY,"ALTER BP, 2003, BLOOD, V101, P2072, DOI 10.1182/BLOOD-2002-11-3597##ALTER BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M##BAGBY GROVER C, 2004, HEMATOLOGY AM SOC HEMATOL EDUC PROGRAM, P318##BORDEN EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/SCBI.2000.0315##BROXMEYER HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/JEM.20041385##CHENG NC, 2000, HUM MOL GENET, V9, P1805, DOI 10.1093/HMG/9.12.1805##CROOP JM, 2001, BLOOD, V98, P2917, DOI 10.1182/BLOOD.V98.10.2917##D'ANDREA AD, 2003, GENE DEV, V17, P1933, DOI 10.1101/GAD.1128303##DEEG HJ, 1996, BLOOD, V87, P386, DOI 10.1182/BLOOD.V87.1.386.BLOODJOURNAL871386##ERNSTOFF MS, 1987, J CLIN ONCOL, V5, P1804, DOI 10.1200/JCO.1987.5.11.1804##GLUCKMAN E, 1995, BLOOD, V86, P2856##GUARDIOLA P, 1998, BONE MARROW TRANSPL, V21, PS24##HANELINE LS, 2003, BLOOD, V101, P1299, DOI 10.1182/BLOOD-2002-08-2404##HANELINE LS, 1999, BLOOD, V94, P1##HANELINE LS, 1998, BLOOD, V91, P4092##JETMORE A, 2002, BLOOD, V99, P1585, DOI 10.1182/BLOOD.V99.5.1585##JOENJE H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590##KOOK H, 2005, HEMATOLOGY, V10, P108, DOI 10.1080/10245330512331390096##KUTLER DI, 2003, BLOOD, V101, P1249, DOI 10.1182/BLOOD-2002-07-2170##LEVITUS M, 2004, BLOOD, V103, P2498, DOI 10.1182/BLOOD-2003-08-2915##LEVITUS M, 2005, NAT GENET, V37, P934, DOI 10.1038/NG1625##LEVRAN O, 2005, NAT GENET, V37, P931, DOI 10.1038/NG1624##LI XX, 2005, BLOOD, V105, P3465, DOI 10.1182/BLOOD-2004-06-2483##LI XX, 2004, BLOOD, V104, P1204, DOI 10.1182/BLOOD-2004-03-1094##LILES W C, 2001, SEMIN RESPIR INFECT, V16, P11##LIU JM, 1999, HUM GENE THER, V10, P2337, DOI 10.1089/10430349950016988##MEETEI AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003##MEETEI AR, 2005, NAT GENET, V37, P958, DOI 10.1038/NG1626##NOLL M, 2002, EXP HEMATOL, V30, P679, DOI 10.1016/S0301-472X(02)00838-X##ORSCHELL-TRAYCOFF CM, 2000, BLOOD, V96, P1380, DOI 10.1182/BLOOD.V96.4.1380.H8001380_1380_1387##PANG QS, 2001, EMBO J, V20, P4478, DOI 10.1093/EMBOJ/20.16.4478##QUESENBERRY PJ, 2005, EXP HEMATOL, V33, P9, DOI 10.1016/J.EXPHEM.2004.10.012##RATHBUN RK, 1997, BLOOD, V90, P974, DOI 10.1182/BLOOD.V90.3.974.974_974_985##ROSENBERG PS, 2005, BLOOD, V105, P67, DOI 10.1182/BLOOD-2004-04-1652##SCHROEDER TM, 1976, HUM GENET, V32, P257, DOI 10.1007/BF00295817##SOCIE G, 1998, BRIT J HAEMATOL, V103, P249, DOI 10.1046/J.1365-2141.1998.00968.X##SOCIE G, 1998, TRANSPLANTATION, V66, P667, DOI 10.1097/00007890-199809150-00023##SZILVASSY SJ, 1999, BLOOD, V93, P1557, DOI 10.1182/BLOOD.V93.5.1557##TANIGUCHI T, 2002, INT J HEMATOL, V75, P123, DOI 10.1007/BF02982016##THOMPSON LH, 2005, NAT GENET, V37, P921, DOI 10.1038/NG0905-921##TOWER PA, 1998, EXP HEMATOL, V26, P19##YANG Y, 2001, BLOOD, V98, P3435, DOI 10.1182/BLOOD.V98.12.3435##ZHANG XL, 2004, J BIOL CHEM, V279, P43910, DOI 10.1074/JBC.M403884200##ZHANG YY, 1998, J EXP MED, V187, P1893, DOI 10.1084/JEM.187.11.1893",30,2020-11-20,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL HEART LUNG & BLOOD INSTITUTE (NHLBI) [P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586, P01HL053586] FUNDING SOURCE: NIH REPORTER; NHLBI NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL HEART LUNG & BLOOD INSTITUTE (NHLBI) [P01 HL053586, P01HL053586] FUNDING SOURCE: MEDLINE"
J,WOS:000242838600005,2006,METASTATIC DISEASE OF SCREEN-DETECTED PROSTATE CANCER - CHARACTERISTICS AT DIAGNOSIS,"BACKGROUND. SCREENING FOR PROSTATE CANCER HAS NOT ONLY LED TO A STAGE MIGRATION, BUT ALSO TO A HIGHER INCIDENCE OF THE DISEASE. A DECREASE IN MORTALITY HAS OCCURRED IN SEVERAL COUNTRIES DURING THE SAME TIME PERIOD. RISK STRATIFICATION OF SCREEN-DETECTED CANCERS AT DIAGNOSIS HAS BECOME MORE IMPORTANT FOR THE ANTICIPATION AND INTERPRETATION OF CHANGING INCIDENCE/MORTALITY RATIOS. METHODS. FROM 1993 TO 1998, 633 MEN WERE DIAGNOSED WITH NONMETASTATIC PROSTATE CANCER IN THE PREVALENCE SCREEN OF THE ROTTERDAM SECTION OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC). THE CHARACTERISTICS AT DIAGNOSIS OF MEN WHO DEVELOPED METASTATIC DISEASE WERE COMPARED WITH MEN WITHOUT EVIDENCE OF METASTASES DURING FOLLOW-TIP. RESULTS. DURING THE MEDIAN FOLLOW-TIP OF 7.5 YEARS, 41 MEN DEVELOPED METASTATIC DISEASE. AFTER 10 YEARS THE METASTASIS-FREE SURVIVAL RATE WAS 89.6%, THE OVERALL SURVIVAL 64.7%. IN A COX-MODEL 2LOGPSA (PROSTATE-SPECIFIC ANTIGEN), BIOPSY GLEASON SCORE AND THE NUMBER OF BIOPSY CORES WITH PROSTATE CANCER WERE INDEPENDENT PREDICTORS FOR THE DEVELOPMENT OF METASTASES; THE LATTER ONLY PREDICTED METASTASES THAT PRESENTED WITHIN 60 MONTHS OF FOLLOW-UP. CONCLUSION. THE METASTASIS-FREE SURVIVAL OF MEN WITH PROSTATE CANCER DETECTED IN A PREVALENCE SCREENING WAS VERY HIGH. WHETHER THIS WAS RELATED TO THE BENEFICIAL EFFECTS OF SCREENING OR TO OVERDIAGNOSIS DUE TO SCREENING (OR BOTH) REMAINS UNCLEAR. THE PROGNOSTIC FACTORS KNOWN FOR CLINICALLY DIAGNOSED DISEASE ALSO HOLD FOR SCREEN-DETECTED DISEASE.",CARCINOMA; RADIOTHERAPY,PROSTATE CANCER; MASS SCREENING; NEOPLASM METASTASIS; PROGNOSTIC FACTORS; SURVIVAL,CANCER,"ROEMELING, S##KRANSE, R##VIS, AN##GOSSELAAR, C##VAN DER KWAST, TH##SCHRODER, FH","UNIV MED CTR, DEPT UROL, ERASMUS MC, NL-3000 CA ROTTERDAM, NETHERLANDS. CTR COMPREHENS CANC, ROTTERDAM, NETHERLANDS. UNIV MED CTR, DEPT PATHOL, ERASMUS MC, ROTTERDAM, NETHERLANDS. MT SINAI HOSP, DEPT PATHOL & LAB MED, TORONTO, ON M5G 1X5, CANADA.",ONCOLOGY,ONCOLOGY,"D'AMICO AV, 2002, CANCER, V95, P281, DOI 10.1002/CNCR.10657##DE KONING HJ, 2003, BJU INT, V92, P71, DOI 10.1111/J.1465-5101.2003.04402.X##DONOVAN J, 2003, HEALTH TECHNOL ASSESS, V7, P1##DRAISMA G, 2003, J NATL CANCER I, V95, P868, DOI 10.1093/JNCI/95.12.868##ESKEW LA, 1997, J UROLOGY, V157, P202##FRANSSON P, 1999, CANCER, V85, P678, DOI 10.1002/(SICI)1097-0142(19990201)85:3<678::AID-CNCR18>3.0.CO;2-E##JEMAL A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/CANJCLIN.56.2.106##PENSON DF, 2003, J UROLOGY, V169, P1653, DOI 10.1097/01.JU.0000061964.49961.55##POLLACK A, 2000, J CLIN ONCOL, V18, P3904, DOI 10.1200/JCO.2000.18.23.3904##POSTMA R, 2004, CANCER-AM CANCER SOC, V100, P968, DOI 10.1002/CNCR.20048##ROOBOL MJ, 2003, BJU INT, V92, P117, DOI 10.1111/J.1464-410X.2003.4698X.X",0,2020-11-20,NA
J,WOS:000242838600028,2006,ADULT SURVIVORS OF CHILDHOOD CANCER AND UNEMPLOYMENT - A METAANALYSIS - AUTHOR REPLY,NA,NA,NA,CANCER,"DE BOER, AGEM##VERBEEK, JHAM##VAN DIJK, FJH","CORONEL INST, CORONEL INST OCCUPAT HLTH, AMSTERDAM, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"DE BOER AGEM, 2006, CANCER, V107, P1, DOI 10.1002/CNCR.21974##SHORT PF, 2005, CANCER, V103, P1292, DOI 10.1002/CNCR.20912",0,2020-11-20,NA
J,WOS:000242915600007,2006,ADRENAL HYPERPLASIA AND ADENOMAS ARE ASSOCIATED WITH INHIBITION OF PHOSPHODIESTERASE 11A IN CARRIERS OF PDE11A SEQUENCE VARIANTS THAT ARE FREQUENT IN THE POPULATION,"SEVERAL TYPES OF ADRENOCORTICAL TUMORS THAT LEAD TO CUSHING SYNDROME MAY BE CAUSED BY ABERRANT CYCLIC AMP (CAMP) SIGNALING. WE RECENTLY IDENTIFIED PATIENTS WITH MICRONODULAR ADRENOCORTICAL HYPERPLASIA WHO WERE CARRIERS OF INACTIVATING MUTATIONS IN THE 2Q-LOCATED PHOSPHODIESTERASE 11A (PDE11A) GENE. WE NOW STUDIED THE FREQUENCY OF TWO MISSENSE SUBSTITUTIONS, R804H AND R867G, IN CONSERVED REGIONS OF THE ENZYME IN SEVERAL SETS OF NORMAL CONTROLS, INCLUDING 745 INDIVIDUALS ENROLLED IN A LONGITUDINAL COHORT STUDY, THE NEW YORK CANCER PROJECT. IN THE LATTER, WE ALSO SCREENED FOR THE PRESENCE OF THE PREVIOUSLY IDENTIFIED PDE11A NONSENSE MUTATIONS. R804H AND R867G WERE FREQUENT AMONG PATIENTS WITH ADRENOCORTICAL TUMORS; ALTHOUGH STATISTICAL SIGNIFICANCE WAS NOT REACHED, THESE VARIANTS AFFECTED SIGNIFICANTLY ENZYMATIC FUNCTION IN VITRO WITH VARIABLE INCREASES IN CAMP AND/OR CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE LEVELS IN HELA AND HEK293 CELLS. ADRENOCORTICAL TISSUES CARRYING THE R804H MUTATION SHOWED 2Q ALLELIC LOSSES AND HIGHER CYCLIC NUCLEOTIDE LEVELS AND CAMP-RESPONSIVE ELEMENT BINDING PROTEIN PHOSPHORYLATION. WE CONCLUDE THAT MISSENSE MUTATIONS OF THE PDE11A GENE THAT AFFECT ENZYMATIC ACTIVITY IN VITRO ARE PRESENT IN THE GENERAL POPULATION; PROTEIN-TRUNCATING PDE11A MUTATIONS MAY ALSO CONTRIBUTE TO A PREDISPOSITION TO OTHER TUMORS, IN ADDITION TO THEIR ASSOCIATION WITH ADRENOCORTICAL HYPERPLASIA. WE SPECULATE THAT PDE11A GENETIC DEFECTS MAY BE ASSOCIATED WITH ADRENAL PATHOLOGY IN A WIDER THAN PREVIOUSLY SUSPECTED CLINICAL SPECTRUM THAT INCLUDES ASYMPTOMATIC INDIVIDUALS.",NODULAR ADRENOCORTICAL DISEASE; CARNEY COMPLEX; GENOMIC ORGANIZATION; CUSHING-SYNDROME; HUMAN TISSUES; PRKAR1A GENE; MUTATIONS; EXPRESSION; LOCALIZATION,NA,CANCER RESEARCH,"HORVATH, A##GIATZAKIS, C##ROBINSON-WHITE, A##BOIKOS, S##LEVINE, E##GRIFFIN, K##STEIN, E##KAMVISSI, V##SONI, P##BOSSIS, I##DE HERDER, W##CARNEY, JA##BERTHERAT, J##GREGERSEN, PK##REMMERS, EF##STRATAKIS, CA","NICHHD, SECT ENDOCRINOL & GENET, PEDIAT ENDOCRINOL TRAINING PROGRAM, DEB,NIH, BETHESDA, MD 20892 USA. NIAMSD, GENET & GENOM BRANCH, NIH, BETHESDA, MD 20892 USA. ERASMUS MC, DEPT INTERNAL MED, ROTTERDAM, NETHERLANDS. MAYO CLIN, DEPT LAB MED & PATHOL, ROCHESTER, MN USA. INST COCHIN, INSERM U567, DEPT ENDOCRINOL METAB & CANC, GENET MOL, F-75014 PARIS, FRANCE. UNIV PARIS 05, CNRS, UMR 8104, PARIS, FRANCE. UNIV PARIS 05, CTR REFERENCE MALAD RARES SURRENALE, SERV ENDOCRINOL, HOP COCHIN, PARIS, FRANCE. N SHORE LIJ HLTH SYST, FEINSTEIN INST MED RES, MANHASSET, NY USA.",ONCOLOGY,ONCOLOGY,"BARZON L, 2003, EUR J ENDOCRINOL, V149, P273, DOI 10.1530/EJE.0.1490273##BERTHERAT J, 2003, CANCER RES, V63, P5308##BOURDEAU I, 2002, ANN NY ACAD SCI, V968, P240, DOI 10.1111/J.1749-6632.2002.TB04339.X##D'ANDREA MR, 2005, J HISTOCHEM CYTOCHEM, V53, P895, DOI 10.1369/JHC.5A6625.2005##GBEKOR E, 2002, J UROLOGY, V167, P246##GROUSSIN L, 2002, J CLIN ENDOCR METAB, V87, P4324, DOI 10.1210/JC.2002-020592##GUNTHER DF, 2004, J CLIN ENDOCR METAB, V89, P3173, DOI 10.1210/JC.2003-032247##HORVATH A, 2006, NAT GENET, V38, P794, DOI 10.1038/NG1809##KIRSCHNER LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/HMG/9.20.3037##KIRSCHNER LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238##LOUGHNEY K, 2005, INT J IMPOT RES, V17, P320, DOI 10.1038/SJ.IJIR.3901317##MICHIBATA H, 2001, BBA-GENE STRUCT EXPR, V1517, P278, DOI 10.1016/S0167-4781(00)00293-1##MITCHELL MK, 2004, J URBAN HEALTH, V81, P301, DOI 10.1093/JURBAN/JTH116##STRATAKIS CA, 2001, J CLIN ENDOCR METAB, V86, P4041, DOI 10.1210/JC.86.9.4041##STRATAKIS CA, 1998, HORM METAB RES, V30, P456, DOI 10.1055/S-2007-978914##TING JC, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-25##YUASA K, 2001, EUR J BIOCHEM, V268, P168, DOI 10.1046/J.1432-1327.2001.01866.X",77,2020-11-20,"EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [Z01HD000642, Z01HD000642, Z01HD000642, Z01HD000642, Z01HD000642, Z01HD000642, Z01HD000642, Z01HD000642, Z01HD000642, Z01HD000642, Z01HD000642] FUNDING SOURCE: NIH REPORTER; INTRAMURAL NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USA FUNDING SOURCE: MEDLINE; NICHD NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [Z01-HD-000642-04] FUNDING SOURCE: MEDLINE"
J,WOS:000242915600014,2006,COMPARISON OF KINOME PROFILES OF BARRETT'S ESOPHAGUS WITH NORMAL SQUAMOUS ESOPHAGUS AND NORMAL GASTRIC CARDIA,"THE PRECURSOR METAPLASTIC MUCOSAL LESION THAT PREDISPOSES FOR ESOPHAGEAL ADENOCARCINOMA IS BARRETT'S ESOPHAGUS. BECAUSE THE SIGNAL TRANSDUCTION EVENTS THAT OCCUR IN BARRETT'S ESOPHAGUS ARE POORLY UNDERSTOOD, THIS STUDY AIMED AT GENERATING A COMPREHENSIVE DESCRIPTION OF CELLULAR KINASE ACTIVITY IN BARRETT'S ESOPHAGUS, NORMAL SQUAMOUS ESOPHAGUS, AND GASTRIC CARDIA TO GAIN MORE INSIGHT INTO THE PATHOGENESIS OF BARRETT'S ESOPHAGUS. PEPTIDE ARRAYS, EXHIBITING 1,176 SPECIFIC CONSENSUS SEQUENCES FOR PROTEIN KINASES, WERE USED TO PRODUCE A GLOBAL ANALYSIS OF CELLULAR KINASE ACTIVITY IN BIOPSIES OF BARRETT'S ESOPHAGUS, AND RESULTS WERE COMPARED WITH THE NEIGHBORING CARDIA AND SQUAMOUS EPITHELIA. SEVERAL DIFFERENCES IN KINASE ACTIVITY USING IMMUNOBLOT ANALYSIS AND ENZYME ACTIVITY ASSAYS WERE VALIDATED IN BIOPSIES OF 27 BARRETT'S ESOPHAGUS PATIENTS. THREE UNIQUE KINOME PROFILES ARE DESCRIBED AND COMPARED. WE IDENTIFIED CASCADES OF ACTIVATED KINASES SHOWING THAT MITOGEN-ACTIVATED PROTEIN KINASE AND EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVITY ARE BOTH SIGNIFICANTLY ALTERED IN BARRETT'S ESOPHAGUS COMPARED WITH SQUAMOUS AND GASTRIC CARDIA EPITHELIA. ANOTHER NOVEL FINDING IS THAT THE GLYCOLYSIS PATHWAY IS SIGNIFICANTLY UP-REGULATED IN BARRETT'S ESOPHAGUS, WHICH IS ILLUSTRATED BY AN UP-REGULATED PYRUVATE KINASE ACTIVITY. HERE, THE UNIQUE KINOME PROFILE OF BARRETT'S ESOPHAGUS IS MADE AVAILABLE AS A COMPREHENSIVE DATABASE. SEVERAL SIGNALING PATHWAYS ARE REVEALED AS SPECIFICALLY EXPRESSED IN BARRETT'S ESOPHAGUS WHEN COMPARED WITH THE ADJACENT NORMAL EPITHELIA. THESE UNIQUE FINDINGS PROVIDE NOVEL INSIGHT IN THE PATHOGENESIS OF BARRETT'S ESOPHAGUS THAT WILL ULTIMATELY HELP TO RESOLVE THE INCREASING PROBLEM OF BARRETT'S ESOPHAGUS AND PREVENTION OF ESOPHAGEAL ADENOCARCINOMA.",DYSPLASIA-ADENOCARCINOMA SEQUENCE; COLUMNAR EPITHELIUM; GENE-EXPRESSION; PYRUVATE-KINASE; METAPLASIA; CELLS; PROLIFERATION; PATTERNS,NA,CANCER RESEARCH,"VAN BAAL, JWPM##DIKS, SH##WANDERS, RJA##RYGIEL, AM##MILANO, F##JOORE, J##BERGMAN, JJGHM##PEPPELENBOSCH, MP##KRISHNADATH, KK","UNIV AMSTERDAM, ACAD MED CTR, LAB EXPT INTERNAL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, LAB GENET METAB DIS, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT GASTROENTEROL & HEPATOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. PEPSCAN SYST, LELYSTAD, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT CELL BIOL, GRONINGEN, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"BARRETT MT, 2002, NEOPLASIA, V4, P121, DOI 10.1038/SJ.NEO.7900221##BLUME-JENSEN P, 2001, NATURE, V411, P355, DOI 10.1038/35077225##BYTZER P, 1999, AM J GASTROENTEROL, V94, P86##COHEN P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/NRD773##DEMEESTER SR, 2001, CURR PROB SURG, V38, P554##DEVESA SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.3.CO;2-U##DIKS SH, 2004, J BIOL CHEM, V279, P49206, DOI 10.1074/JBC.M405028200##DREWITZ DJ, 1997, AM J GASTROENTEROL, V92, P212##HAGGITT RC, 1978, AM J CLIN PATHOL, V70, P1##HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3##HARDWICK JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/J.GASTRO.2003.10.067##HUNTER T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8##IRISH JM, 2004, CELL, V118, P217, DOI 10.1016/J.CELL.2004.06.028##JAISWAL K, 2004, SURGERY, V136, P160, DOI 10.1016/J.SURG.2004.04.008##JANKOWSKI J, 1992, GUT, V33, P439, DOI 10.1136/GUT.33.4.439##KOSS K, 2004, J CLIN PATHOL, V57, P1156, DOI 10.1136/JCP.2004.018150##KUMBLE S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/GAST.1997.V112.PM9024288##LEVINE DS, 1989, LAB INVEST, V60, P418##LOWENBERG M, 2005, BLOOD, V106, P1703, DOI 10.1182/BLOOD-2004-12-4790##LOWENBERG M, 2006, ENDOCRINOLOGY, V147, P3555, DOI 10.1210/EN.2005-1602##MANN NS, 1989, AM J GASTROENTEROL, V84, P1494##MANNING G, 2002, SCIENCE, V298, P1912, DOI 10.1126/SCIENCE.1075762##MOORE JH, 1994, INT J CANCER, V56, P487, DOI 10.1002/IJC.2910560406##PRACH AT, 1997, LANCET, V350, P933, DOI 10.1016/S0140-6736(05)63269-2##RANSFORD RAJ, 2000, ACTA GASTRO-ENT BELG, V63, P18##REGALADO SP, 1998, MOL CARCINOGEN, V22, P182, DOI 10.1002/(SICI)1098-2744(199807)22:3<182::AID-MC6>3.3.CO;2-N##SHAHEEN NJ, 2000, GASTROENTEROLOGY, V119, P333, DOI 10.1053/GAST.2000.9302##SOUZA RF, 2004, AM J PHYSIOL-GASTR L, V287, PG743, DOI 10.1152/AJPGI.00144.2004##SOUZA RF, 2002, GASTROENTEROLOGY, V122, P299, DOI 10.1053/GAST.2002.30993##SPECHLER SJ, 1994, LANCET, V344, P1533, DOI 10.1016/S0140-6736(94)90349-2##STREITZ JM, 2005, DIS ESOPHAGUS, V18, P170, DOI 10.1111/J.1442-2050.2005.00488.X##VALENTIN G, 2000, J BIOL CHEM, V275, P18145, DOI 10.1074/JBC.M001870200##VAN BAAL JWPM, 2005, GASTROENTEROLOGY, V129, P1274, DOI 10.1053/J.GASTRO.2005.07.026##VONA-DAVIS L, 2004, J GASTROINTEST SURG, V8, P1018, DOI 10.1016/J.GASSUR.2004.08.014##WINTERS C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X##WU GD, 1993, GASTROENTEROLOGY, V105, P837, DOI 10.1016/0016-5085(93)90902-O",64,2020-11-20,NA
J,WOS:000242915600034,2006,ENFORCED EXPRESSION OF NUP98-HOXA9 IN HUMAN CD34(+) CELLS ENHANCES STEM CELL PROLIFERATION,"THE T(7;11)(P15:P15) TRANSLOCATION, OBSERVED IN ACUTE MYELOGENOUS LEUKEMIA AND MYELODYSPLASTIC SYNDROME, GENERATES A CHIMERIC GENE WHERE THE 5' PORTION OF THE SEQUENCE ENCODING THE HUMAN NUCLEOPORIN NUP98 PROTEIN IS FUSED TO THE 3' REGION OF HOXA9. HERE, WE SHOW THAT RETROVIRAL-MEDIATED ENFORCED EXPRESSION OF THE NUP98-HOXA9 FUSION PROTEIN IN CORD BLOODDERIVED CD34(+) CELLS CONFERS A PROLIFERATIVE ADVANTAGE IN BOTH CYTOKINE-STIMULATED SUSPENSION CULTURES AND STROMAL COCULTURE. THIS ADVANTAGE IS REFLECTED IN THE SELECTIVE EXPANSION OF HEMATOPOIETIC STEM CELLS AS MEASURED IN VITRO BY COBBLESTONE AREA-FORMING CELL ASSAYS AND IN VIVO BY COMPETITIVE REPOPULATION OF NONOBESE DIABETIC/SEVERE COMBINED IMMUNODEFICIENT MICE. N1UP98-HOXA9 EXPRESSION INHIBITED ERYTHROID PROGENITOR DIFFERENTIATION AND DELAYED NEUTROPHIL MATURATION IN TRANSDUCED PROGENITORS BUT STRONGLY ENHANCED THEIR SERIAL REPLATING EFFICIENCY. ANALYSIS OF THE TRANSCRIPTOSOME OF TRANSDUCED CELLS REVEALED TIP-REGULATION OF SEVERAL HOMEOBOX GENES OF THE A AND B CLUSTER AS WELL AS OF MEIS1 AND PIM-1 AND DOWN-MODULATION OF GLOBIN GENES AND OF CAAT/ENHANCER BINDING PROTEIN A. THE LATTER GENE, WHEN COEXPRESSED WITH AIUP98-HOXA9, REVERSED THE ENHANCED PROLIFERATION OF TRANSDUCED CD34(+) CELLS. UNLIKE HOXA9, THE NUP98-HOXA9 FUSION WAS PROTECTED FROM UBIQUITINATION MEDIATED BY CULLIN-4A AND SUBSEQUENT PROTEASOME-DEPENDENT DEGRADATION. THE RESULTING PROTEIN STABILIZATION MAY CONTRIBUTE TO THE LEUKEMOGENIC ACTIVITV OF THE FUSION PROTEIN.",ACUTE MYELOID-LEUKEMIA; MESSENGER-RNA EXPORT; GENE-EXPRESSION; SELF-RENEWAL; HOMEOBOX GENES; HOXA9; NUP98; NUCLEOPORIN; MEIS1; TRANSCRIPTION,NA,CANCER RESEARCH,"CHUNG, KY##MORRONE, G##SCHURINGA, JJ##PLASILOVA, M##SHIEH, JH##ZHANG, Y##ZHOU, PB##MOORE, MAS","CORNELL UNIV, MOORE LAB, CELL BIOL PROGRAM, MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA. CORNELL UNIV, DEPT MED, CELL BIOL PROGRAM, MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA. CORNELL UNIV, DEPT PATHOL & LAB MED, WEILL MED COLL, NEW YORK, NY 10021 USA. CORNELL UNIV, GRAD SCH MED SCI, NEW YORK, NY 10021 USA. UNIV CATANZARO MAGNA GRAECIA, DEPT EXPT & CLIN MED GAETANO SALVATORE, CATANZARO, ITALY. UNIV GRONINGEN, DEPT HEMATOL, MED CTR, GRONINGEN, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"AYTON PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/GAD.1111603##BERNASSOLA F, 2004, J EXP MED, V199, P1545, DOI 10.1084/JEM.20031943##BLEVINS MB, 2003, J BIOL CHEM, V278, P20979, DOI 10.1074/JBC.M302061200##BORROW J, 1996, NAT GENET, V12, P159, DOI 10.1038/NG0296-159##BULLINGER L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMOA031046##CALVO KR, 2002, ONCOGENE, V21, P4247, DOI 10.1038/SJ.ONC.1205516##CALVO KR, 2001, P NATL ACAD SCI USA, V98, P13120, DOI 10.1073/PNAS.231115398##CHUNG KY, 2005, BLOOD, V105, P77, DOI 10.1182/BLOOD-2003-12-4445##CRONSHAW JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/JCB.200206106##CROOKS GM, 1999, BLOOD, V94, P519, DOI 10.1182/BLOOD.V94.2.519.414K20_519_528##ENNINGA J, 2002, SCIENCE, V295, P1523, DOI 10.1126/SCIENCE.1067861##FONTOURA BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/JCB.144.6.1097##FROHLING S, 2004, NEW ENGL J MED, V351, P2370, DOI 10.1056/NEJMP048241##FULLER JF, 1999, BLOOD, V93, P3391, DOI 10.1182/BLOOD.V93.10.3391.410K26_3391_3400##GHANNAM G, 2004, J BIOL CHEM, V279, P866, DOI 10.1074/JBC.M307280200##GILLILAND DG, 2002, BLOOD, V100, P1532, DOI 10.1182/BLOOD-2002-02-0492##GOLUB TR, 1999, SCIENCE, V286, P531, DOI 10.1126/SCIENCE.286.5439.531##GRONROOS E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1##IWASAKI M, 2005, BLOOD, V105, P784, DOI 10.1182/BLOOD-2004-04-1508##JO DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954##KASPER LH, 1999, MOL CELL BIOL, V19, P764##KAWAGOE H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/SJ.LEU.2401410##KIM KT, 2005, BLOOD, V105, P1759, DOI 10.1182/BLOOD-2004-05-2006##KROON E, 2001, EMBO J, V20, P350, DOI 10.1093/EMBOJ/20.3.350##KRSKOVA-HONZATKOVA L, 2001, LEUKEMIA RES, V25, P45, DOI 10.1016/S0145-2126(00)00086-2##KUMAR AR, 2004, BLOOD, V103, P1823, DOI 10.1182/BLOOD-2003-07-2582##LAWRENCE HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/SJ.LEU.2401578##LAWRENCE HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/BLOOD.V89.6.1922##MAYOTTE N, 2002, BLOOD, V100, P4177, DOI 10.1182/BLOOD-2002-04-1244##MOORE MAS, 2005, EXP HEMATOL, V33, P719, DOI 10.1016/J.EXPHEM.2005.04.011##MOORE MAS, 2006, IN PRESS EXP HEMATOL##NEBEN K, 2005, ONCOGENE, V24, P1580, DOI 10.1038/SJ.ONC.1208344##PEARSON M, 2000, NATURE, V406, P207##PINEAULT N, 2005, LEUKEMIA, V19, P636, DOI 10.1038/SJ.LEU.2403696##PLASILOVA M, 2005, BLOOD, V106, P197A##PRITCHARD CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/JCB.145.2.237##RADOMSKA HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301##SCHURINGA JJ, 2004, J EXP MED, V200, P623, DOI 10.1084/JEM.20041024##SCHWIEGER M, 2004, BLOOD, V103, P2744, DOI 10.1182/BLOOD-2003-07-2280##SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X##SHAMSHER MK, 2002, P NATL ACAD SCI USA, V99, P14195, DOI 10.1073/PNAS.212518199##SHEN WF, 1999, MOL CELL BIOL, V19, P3051##SHOJAEI F, 2005, DEV CELL, V8, P651, DOI 10.1016/J.DEVCEL.2005.03.004##SLAPE C, 2004, LEUKEMIA LYMPHOMA, V45, P1341, DOI 10.1080/10428190310001659325##THORSTEINSDOTTIR U, 1997, HEMATOL ONCOL CLIN N, V11, P1221, DOI 10.1016/S0889-8588(05)70491-3##WEISEL KC, 2005, ANN NY ACAD SCI, V1044, P51, DOI 10.1196/ANNALS.1349.007##WIERENGA ATJ, 2006, BLOOD, V107, P4326, DOI 10.1182/BLOOD-2005-11-4608##ZHANG P, 2004, IMMUNITY, V21, P853, DOI 10.1016/J.IMMUNI.2004.11.006##ZHANG Y, 2003, EMBO J, V22, P6057, DOI 10.1093/EMBOJ/CDG577",53,2020-11-20,"NCI NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL CANCER INSTITUTE (NCI) [CA092210, CA118085] FUNDING SOURCE: MEDLINE; NATIONAL CANCER INSTITUTEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL CANCER INSTITUTE (NCI) [R01CA118085, R01CA118085, R01CA118085, R01CA118085, R01CA118085] FUNDING SOURCE: NIH REPORTER"
J,WOS:000242898100001,2006,CLASPIN - TIMING THE CELL CYCLE ARREST WHEN THE GENOME IS DAMAGED,"DNA DAMAGE CHECKPOINTS MAINTAIN GENOMIC INTEGRITY BY DELAYING CELL CYCLE PROGRESSION IN RESPONSE TO GENOTOXIC STRESS AND STALLED REPLICATION FORKS. ONE CENTRAL PATHWAY IN THE CHECKPOINT RESPONSE IS THE ATR-CHK1 PATHWAY, IN WHICH, UPON DNA DAMAGE, ATR PHOSPHORYLATES AND ACTIVATES THE EFFECTOR KINASE CHK1. THIS PROCESS DEPENDS ON THE ADAPTOR PROTEIN CLASPIN THAT BRIDGES ATR AND CHK1. ONCE THE DAMAGE IS REPAIRED, THIS PATHWAY MUST SOMEHOW BE SWITCHED OFF TO ALLOW THE CELL TO CONTINUE THE CELL DIVISION PROCESS, AN EVENT KNOWN AS CHECKPOINT RECOVERY. POLO-LIKE KINASE 1 (PLK1) PLAYS A CENTRAL ROLE DURING CHECKPOINT RECOVERY. INTERESTINGLY, THE XENOPUS HOMOLOGUE OF PLK1, PLX1, IS ABLE TO BIND AND PHOSPHORYLATE CLASPIN, RELEASING IT FROM DNA AND THEREBY CONTRIBUTING TO CHK1 INACTIVATION. MOREOVER, IT WAS RECENTLY DEMONSTRATED THAT CLASPIN LEVELS ARE CONTROLLED BY PROTEASOMAL DEGRADATION, AND THIS IS REGULATED BY PLK1. IMPORTANTLY, PLK1-MEDIATED PROTEOSOMAL DEGRADATION OF CLASPIN APPEARS TO BE ESSENTIAL FOR CHECK POINT RECOVERY. HERE WE REVIEW THESE RECENT FINDINGS AND DISCUSS THE MECHANISMS OF CHECKPOINT REGULATION BY CLASPIN.",REPLICATION CHECKPOINT RESPONSE; SCF-BETA-TRCP; REPEATED PHOSPHOPEPTIDE MOTIFS; DOUBLE-STRAND BREAK; POLO-LIKE KINASE-1; DNA-DAMAGE; SIGNALING PATHWAYS; CHK1; RECOVERY; PROTEIN,CLASPIN; CHK1; PLK1; DNA DAMAGE CHECKPOINT; CHECKPOINT RECOVERY; MITOSIS; PROTEASOME; BETA-TRCP-SCF; F-BOX PROTEIN; PHOSPHO-DEGRON,CELL CYCLE,"FREIRE, R##VAN VUGT, MATM##MAMELY, I##MEDEMA, RH","HOSP UNIV CANARIAS, UNIDAD INVEST, E-38320 TENERIFE, SPAIN. MIT, CANC RES CTR, CAMBRIDGE, MA 02139 USA. UNIV UTRECHT, MED CTR, DEPT MED ONCOL, UTRECHT, NETHERLANDS.",CELL BIOLOGY,CELL BIOLOGY,"ALCASABAS AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/NCB1101-958##AMERIK AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/J.BBAMCR.2004.10.003##BARTKOVA J, 2005, NATURE, V434, P864, DOI 10.1038/NATURE03482##BENNETT LN, 2006, FEBS LETT, V580, P4176, DOI 10.1016/J.FEBSLET.2006.06.071##BUSINO L, 2003, NATURE, V426, P87, DOI 10.1038/NATURE02082##CHINI C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/SJ.ONC.1209447##CHINI CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/J.DNAREP.2004.03.001##CHINI CCS, 2006, J BIOL CHEM, V281, P33276, DOI 10.1074/JBC.M604373200##CHOWDHURY D, 2005, MOL CELL, V20, P801, DOI 10.1016/J.MOLCEL.2005.10.003##CHRISTIANO C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/JBC.M301136200##CLARKE CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966##DEN ELZEN N, 2004, CELL CYCLE, V3, P529##DEN ELZEN NR, 2004, EMBO J, V23, P908, DOI 10.1038/SJ.EMBOJ.7600105##FISCELLA M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/PNAS.94.12.6048##GORGOULIS VG, 2005, NATURE, V434, P907, DOI 10.1038/NATURE03485##JAZAYERI A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/NCB1337##KEOGH MC, 2006, NATURE, V439, P497, DOI 10.1038/NATURE04384##KUMAGAI A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4##KUMAGAI A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/NCB921##LEROY C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3##LIU QH, 2000, GENE DEV, V14, P1448##LU XB, 2005, CELL CYCLE, V4, P1060##LU XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/GAD.1291305##MAILAND N, 2006, MOL CELL, V23, P307, DOI 10.1016/J.MOLCEL.2006.06.016##MAMELY I, 2006, CURR BIOL##MANIATIS T, 1999, GENE DEV, V13, P505, DOI 10.1101/GAD.13.5.505##MATSUOKA S, 1998, SCIENCE, V282, P1893, DOI 10.1126/SCIENCE.282.5395.1893##OSBORN AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/GAD.1098303##PELLICIOLI A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0##PESCHIAROLI A, 2006, MOL CELL, V23, P319, DOI 10.1016/J.MOLCEL.2006.06.013##SAR F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/JBC.M405793200##SHREERAM S, 2006, MOL CELL, V23, P757, DOI 10.1016/J.MOLCEL.2006.07.010##SMITS VAJ, 2000, NAT CELL BIOL, V2, P672##TANAKA K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/NCB1101-966##VAN DE WEERDT BCM, 2006, CELL CYCLE, V5, P853, DOI 10.4161/CC.5.8.2692##VAN VUGT MATM, 2004, CELL CYCLE, V3, P1383, DOI 10.4161/CC.3.11.1248##VAN VUGT MATM, 2005, CANCER RES, V65, P7037, DOI 10.1158/0008-5472.CAN-05-1054##VAN VUGT MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/J.MOLCEL.2004.07.015##WATANABE N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/PNAS.0307700101##YOO HY, 2006, GENE DEV, V20, P772, DOI 10.1101/GAD.1398806##YOO HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9##ZHANG D, 2006, CELL, V126, P529, DOI 10.1016/J.CELL.2006.06.039##ZOU L, 2002, GENE DEV, V16, P198, DOI 10.1101/GAD.950302",33,2020-11-20,NA
J,WOS:000242898100012,2006,NUCLEOTIDE EXCISION REPAIR DISORDERS AND THE BALANCE BETWEEN CANCER AND AGING,"CANCER INCIDENCE INCREASES WITH AGE AND IS DRIVEN BY ACCUMULATION OF MUTATIONS IN THE DNA. IN MANY SO-CALLED PREMATURE AGING DISORDERS, CANCER APPEARS EARLIER AND AT ELEVATED RATES. THESE DISEASES ARE PREDOMINANTLY CAUSED BY GENOME INSTABILITY AND PRESENT WITH SYMPTOMS, INCLUDING CANCER, RESEMBLING ""SEGMENTS"" OF AGING AND ARE THUS OFTEN REFERRED TO AS ""SEGMENTAL PROGERIAS"". TWO RELATED SEGMENTAL PROGERIAS, COCKAYNE SYNDROME (CS) AND TRICHOTHIODYSTROPHY (TTD), DON'T FIT THIS PATTERN. ALTHOUGH CAUSED BY DEFECTS IN GENOME MAINTENANCE VIA THE NUCLEOTIDE EXCISION DNA REPAIR (NER) PATHWAY AND DISPLAYING SEVERE PROGEROID SYMPTOMS, CS AND TTD PATIENTS APPEAR TO LACK ANY CANCER PREDISPOSITION. MORE STRIKINGLY, GENETIC DEFECTS IN THE SAME NER PATHWAY, AND IN SOME CASES EVEN WITHIN THE SAME GENE, XPD, CAN ALSO GIVE RISE TO DISORDERS WITH GREATLY ELEVATED CANCER RATES BUT WITHOUT PROGERIA (XERODERMA PIGMENTOSUM). IN THIS REVIEW, WE WILL DISCUSS THE CONNECTION BETWEEN GENOME MAINTENANCE, AGING AND CANCER IN LIGHT OF A NEW MOUSE MODEL OF XPD DISEASE.",MAMMALIAN LIFE-SPAN; COCKAYNE-SYNDROME; DNA-REPAIR; XERODERMA-PIGMENTOSUM; COMBINED FEATURES; IGF-I; MICE; TRANSCRIPTION; GENOME; DAMAGE,NUCLEOTIDE EXCISION REPAIR; XERODERMA PIGMENTOSUM; COCKAYNE SYNDROME; AGING; CANCER; INSULIN-LIKE GROWTH FACTOR 1,CELL CYCLE,"ANDRESSOO, JO##HOEIJMAKERS, JHJ##MITCHELL, JR","ERASMUS MC, CTR GENET MED, DEPT CELL BIOL & GENET, CTR BIOMED GENET, NL-3000 DR ROTTERDAM, NETHERLANDS. UNIV HELSINKI, INST BIOTECHNOL, HELSINKI, FINLAND.",CELL BIOLOGY,CELL BIOLOGY,"ANDRESSOO JO, 2006, CANCER CELL, V10, P121, DOI 10.1016/J.CCR.2006.05.027##BERGINK S, 2006, GENE DEV, V20, P1343, DOI 10.1101/GAD.373706##BERNEBURG M, 2000, EMBO J, V19, P1157, DOI 10.1093/EMBOJ/19.5.1157##BOOTSMA D, 2002, GENETIC BASE HUMAN C##CAMPISI J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/NRC1073##COMPE E, 2005, MOL CELL BIOL, V25, P6065, DOI 10.1128/MCB.25.14.6065-6076.2005##DE BOER J, 2002, SCIENCE, V296, P1276, DOI 10.1126/SCIENCE.1070174##GRUBE K, 1992, P NATL ACAD SCI USA, V89, P11759, DOI 10.1073/PNAS.89.24.11759##HOEIJMAKERS JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232##ITIN PH, 2001, J AM ACAD DERMATOL, V44, P891, DOI 10.1067/MJD.2001.114294##JENKINS PJ, 2004, EUR J ENDOCRINOL, V151, PS17, DOI 10.1530/EJE.0.151S017##KAPAHI P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2##LINDENBAUM Y, 2001, EUR J PAEDIATR NEUROL, V5, P225, DOI 10.1053/EJPN.2001.0523##LJUNGMAN M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/NRC1435##MAIER B, 2004, GENE DEV, V18, P306, DOI 10.1101/GAD.1162404##MCKAY BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/SJ.ONC.1204901##MITCHELL JR, 2003, CURR OPIN CELL BIOL, V15, P232, DOI 10.1016/S0955-0674(03)00018-8##MIYAMOTO S, 2005, CLIN CANCER RES, V11, P3494, DOI 10.1158/1078-0432.CCR-04-1701##MURAI M, 2001, P NATL ACAD SCI USA, V98, P13379, DOI 10.1073/PNAS.231329598##NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/AJMG.1320420115##NIEDERNHOFER LJ, IN PRESS NATURE##O'DRISCOLL M, 2003, NAT GENET, V33, P497, DOI 10.1038/NG1129##PROMISLOW DEL, 1994, J THEOR BIOL, V170, P291, DOI 10.1006/JTBI.1994.1190##RAPIN I, 2000, NEUROLOGY, V55, P1442, DOI 10.1212/WNL.55.10.1442##SPIVAK G, 2006, DNA REPAIR, V5, P13, DOI 10.1016/J.DNAREP.2005.06.017##THERON T, 2005, MOL CELL BIOL, V25, P8368, DOI 10.1128/MCB.25.18.8368-8378.2005##TYNER SD, 2002, NATURE, V415, P45, DOI 10.1038/415045A##VAN DE VEN MARIEKE, 2006, PLOS GENET, V2, PE192, DOI 10.1371/JOURNAL.PGEN.0020192##VAN DER PLUIJM I, 2007, PLOS BIOL, V5, P23, DOI 10.1371/JOURNAL.PBIO.0050002##VOGELSTEIN B, 2004, NAT MED, V10, P789, DOI 10.1038/NM1087##WIJNHOVEN SWP, 2005, DNA REPAIR, V4, P1314, DOI 10.1016/J.DNAREP.2005.07.002##YAKAR S, 2005, ENDOCRIN DEV, V9, P11, DOI 10.1159/000085718##YU H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/JNCI/92.18.1472",60,2020-11-20,NA
J,WOS:000242126300003,2006,TUBERCULIN SKIN TESTING IS USEFUL IN THE SCREENING FOR NONTUBERCULOUS MYCOBACTERIAL CERVICOFACIAL LYMPHADENITIS IN CHILDREN,"BACKGROUND. WE EVALUATED THE DIAGNOSTIC USEFULNESS OF TUBERCULIN SKIN TESTING IN THE SCREENING FOR NONTUBERCULOUS MYCOBACTERIAL (NTM) INFECTION IN CHILDREN. METHODS. WE ENROLLED 180 CHILDREN WHO HAD CHRONIC CERVICOFACIAL LYMPHADENITIS IN OUR STUDY. SKIN TESTING WAS DONE USING ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS, MYCOBACTERIUM AVIUM, MYCOBACTERIUM KANSASII, AND MYCOBACTERIUM SCROPHULACEUM. THE REFERENCE STANDARD FOR NTM INFECTION WAS A POSITIVE CULTURE RESULT, IDENTIFICATION BY PCR, OR BOTH. RECEIVER OPERATING CHARACTERISTIC ANALYSIS WAS USED TO IDENTIFY THE OPTIMAL CUTOFF POINT IN SKIN INDURATION FOR THE DETECTION OF NTM INFECTION. ACCURACY OF THE MYCOBACTERIAL SKIN TESTS WAS QUANTIFIED USING SENSITIVITY AND SPECIFICITY RATES AND POSITIVE AND NEGATIVE PREDICTIVE VALUES AT THE OPTIMAL SKIN INDURATION CUTOFF. RESULTS. A TOTAL OF 112 NTM INFECTIONS WERE IDENTIFIED, OF WHICH 83 WERE CAUSED BY M. AVIUM, 21 BY MYCOBACTERIUM HAEMOPHILUM, AND 8 BY OTHER NTM SPECIES. AT THE OPTIMAL CUTOFF FOR A POSITIVE TEST (5 MM), TUBERCULIN SKIN TESTING HAD A SENSITIVITY AND SPECIFICITY OF 70% AND 98%, RESPECTIVELY, AND A POSITIVE PREDICTIVE VALUE AND A NEGATIVE PREDICTIVE VALUE OF 98% AND 64%, RESPECTIVELY, COMPARED WITH A SENSITIVITY AND A SPECIFICITY OF 93% AND 97%, RESPECTIVELY; M. AVIUM SENSITIN, THE BEST-PERFORMING SKIN TEST, HAD POSITIVE AND NEGATIVE PREDICTIVE VALUES OF 98% AND 90%, RESPECTIVELY. CONCLUSION. TUBERCULIN SKIN TESTING COULD BE VALUABLE AS A FIRST STEP IN THE DIAGNOSTIC ANALYSIS OF CERVICOFACIAL LYMPHADENITIS IN CHILDREN WITHOUT A HISTORY OF TB EXPOSURE OR BACILLE CALMETTE-GUERIN VACCINATION.",AVIUM COMPLEX INFECTION; SENSITIN; LYMPHADENOPATHY; MANAGEMENT; DIAGNOSIS; ANTIGENS; DISEASE,NA,CLINICAL INFECTIOUS DISEASES,"LINDEBOOM, JA##KUIJPER, EJ##PRINS, JM##VAN COPPENRAET, ESB##LINDEBOOM, R","UNIV AMSTERDAM, ACAD MED CTR, DEPT ORAL & MAXILLOFACIAL SURG, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT INTERNAL MED, DIV INFECT DIS TROP MED & AIDS, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, CTR INFECT & IMMUN AMSTERDAM, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD CTR DENT, NL-1105 AZ AMSTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT MED MICROBIOL, NL-2300 RA LEIDEN, NETHERLANDS.",IMMUNOLOGY; INFECTIOUS DISEASES; MICROBIOLOGY,IMMUNOLOGY; INFECTIOUS DISEASES; MICROBIOLOGY,"*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, PS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_##BERGMANS AMC, 1995, J INFECT DIS, V171, P916, DOI 10.1093/INFDIS/171.4.916##BIERRENBACH AL, 2003, INT J TUBERC LUNG D, V7, P312##CHAPARAS SD, 1994, CLIN INFECT DIS, V19, P24, DOI 10.1093/CLINIDS/19.1.24##DAVIDSON M, 2002, AUST J PHYSIOTHER, V48, P227, DOI 10.1016/S0004-9514(14)60228-2##HAIMI-COHEN Y, 2001, CLIN INFECT DIS, V33, P1786, DOI 10.1086/323984##HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/RADIOLOGY.143.1.7063747##HAVERKAMP MH, 2004, CLIN INFECT DIS, V39, P450, DOI 10.1086/422319##HUEBNER RE, 1992, PEDIATR INFECT DIS J, V11, P450, DOI 10.1097/00006454-199206000-00006##*KNCV TUB, REP TUB NETH 2003 20##LINDEBOOM JA, 2005, CLIN INFECT DIS, V41, P1569, DOI 10.1086/497834##MALTEZOU HC, 1999, PEDIATR INFECT DIS J, V18, P968, DOI 10.1097/00006454-199911000-00006##MARGILETH AM, 1984, AM J DIS CHILD, V138, P917, DOI 10.1001/ARCHPEDI.1984.02140480019007##POUCHOT J, 1997, ANN INTERN MED, V126, P210, DOI 10.7326/0003-4819-126-3-199702010-00005##SCHAAD UB, 1979, J PEDIATR-US, V95, P356, DOI 10.1016/S0022-3476(79)80506-5##VAN COPPENRAET ESB, 2004, J CLIN MICROBIOL, V42, P2644, DOI 10.1128/JCM.42.6.2644-2650.2004##VAN COPPENRAET LES, 2005, EMERG INFECT DIS, V11, P62, DOI 10.3201/EID1101.040589##VON REYN CF, 1998, J INFECT DIS, V177, P730, DOI 10.1086/514225##VONREYN CF, 1994, CLIN INFECT DIS, V19, P15, DOI 10.1093/CLINIDS/19.1.15##VONREYN CF, 1993, J INFECT DIS, V168, P1553, DOI 10.1093/INFDIS/168.6.1553##WOLINSKY E, 1995, CLIN INFECT DIS, V20, P954, DOI 10.1093/CLINIDS/20.4.954##YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3",29,2020-11-20,NA
J,WOS:000242873900002,2006,"OVERCHARGING, CHARGE REVERSAL: CHEMISTRY OR PHYSICS?","OVERCHARGING, ALSO CALLED CHARGE REVERSAL OR CHARGE INVERSION, IS THE OCCURRENCE OF ELECTRIC DOUBLE LAYERS IN WHICH, AS MEASURED BY ELECTROKINETICS OR INTERACTION, THERE IS MORE COUNTERCHARGE THAN CHARGE ON THE SURFACE. THE TREND IS THAT THE PROPENSITY OF OVERCHARGING INCREASES WITH THE VALENCY OF THE COUNTERION. FOR THE INTERPRETATION OF THIS PHENOMENON, DISPARATE EXPLANATIONS HAVE BEEN FORWARDED AND ELABORATED THAT, BRIEFLY, CAN BE DISTINGUISHED AS ""CHEMICAL"" (SPECIFIC ADSORPTION,...) AND ""PHYSICAL"" (ION CORRELATIONS,...). IN THE PRESENT PAPER, AN ANALYSIS OF THIS DISPARITY WILL BE GIVEN. IN PARTICULAR, TYPES OF EXPERIMENTS WILL BE PROPOSED WHICH CAN HELP TO DISCRIMINATE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",ELECTRIC DOUBLE-LAYERS; ELECTROLYTE-SOLUTIONS; AQUEOUS-SOLUTIONS; PRIMITIVE MODEL; INVERSION; COUNTERIONS; ADSORPTION; SURFACES; COLLOIDS; HYDROLYSIS,CHARGE REVERSAL; OVERCHARGING; ELECTROKINETIC CHARGE; SURFACE CHARGE; POINT OF ZERO CHARGE; CAPACITANCE; SPECIFIC ADSORPTION; ION CORRELATIONS; SUPEREQUIVALENT ADSORPTION,COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS,"LYKLEMA, J","UNIV WAGENINGEN & RES CTR, DEPT AGROTECHNOL & FOOD SCI, LAB PHYS CHEM & COLLOID SCI, NL-6703 HB WAGENINGEN, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"ATTARD P, 2001, CURR OPIN COLLOID IN, V6, P366, DOI 10.1016/S1359-0294(01)00102-9##BARRINGER EA, 1985, LANGMUIR, V1, P420, DOI 10.1021/LA00064A006##BESTEMAN K, 2005, PHYS REV E, V72, DOI 10.1103/PHYSREVE.72.061501##BESTEMAN K, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.170802##BESTEMAN K, COMMUNICATION##BONEKAMP BC, 1986, J COLLOID INTERF SCI, V113, P67, DOI 10.1016/0021-9797(86)90206-7##BOSTROM M, 2001, LANGMUIR, V17, P4475, DOI 10.1021/LA0102298##BOURIKAS K, 2001, LANGMUIR, V17, P749, DOI 10.1021/LA000806C##CARNIE SL, 1981, J CHEM PHYS, V74, P1472, DOI 10.1063/1.441161##CASIMIR HBG, 1944, S STERK EL EL DUBB N, P6##DELGADO AV, 2005, PURE APPL CHEM, V77, P1753, DOI 10.1351/PAC200577101753##FLEER G., 1993, POLYM INTERFACES##FUERSTENAU DW, 1981, ADSORPTION AQUEOUS S##GREBERG H, 1998, J CHEM PHYS, V108, P2940, DOI 10.1063/1.475681##GROSBERG AY, 2002, REV MOD PHYS, V74, P329, DOI 10.1103/REVMODPHYS.74.329##GUERRERO-GARCIA GI, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1949168##JAMES RO, 1972, J COLLOID INTERF SCI, V40, P53, DOI 10.1016/0021-9797(72)90173-7##KIRKWOOD JG, 1934, J CHEM PHYS, V2, DOI 10.1063/1.1749393##KJELLANDER R, 1985, J CHEM PHYS, V82, P2122, DOI 10.1063/1.448350##KRUYT H. R., 1943, KOLLOID BEIHEFTE, V54, P262##KUNZ W, 2004, CURR OPIN COLLOID IN, V9, P1, DOI 10.1016/J.COCIS.2004.05.004##LOZADA-CASSOU M, 2001, J COLLOID INTERF SCI, V239, P285, DOI 10.1006/JCIS.2001.7680##LOZADA-CASSOU M, 2001, J COLLOID INTERF SCI, V240, P644, DOI 10.1006/JCIS.2001.7804##LYKLEMA J, 1998, LANGMUIR, V14, P5659, DOI 10.1021/LA980399T##LYKLEMA J, 2003, ADV COLLOID INTERFAC, V100, P1, DOI 10.1016/S0001-8686(02)00075-1##LYKLEMA J, 2005, FUND INTERFACE COLL, V4, P1##LYKLEMA J, 1995, ELECT DOUBLE LAYERS, V2, PCH3##LYKLEMA J, 1961, J COLLOID SCI, V16, P502##LYKLMEA J, 1995, ELECT DOUBLE LAYERS, V2##MARTIN-MOLINA A, 2003, J PHYS-CONDENS MAT, V15, PS3475, DOI 10.1088/0953-8984/15/48/008##MARTIN-MOLINA A, 2002, J PHYS CHEM B, V106, P6881, DOI 10.1021/JP020777+##MATIJEVIC E, 1960, J PHYS CHEM-US, V64, P1157, DOI 10.1021/J100838A013##MATUBAYASHI N, 1999, J COLLOID INTERF SCI, V209, P398, DOI 10.1006/JCIS.1998.5928##MCQUARRIE D.A., 1973, STAT MECH##MESSINA R, 2002, EUROPHYS LETT, V60, P383, DOI 10.1209/EPL/I2002-00275-Y##NINHAM BW, 1997, LANGMUIR, V13, P2097, DOI 10.1021/LA960974Y##OVERBEEK JTG, 1952, COLLOID SCIENCE, V1, PCH8##QUESADA-PEREZ M, 2005, LANGMUIR, V21, P9231, DOI 10.1021/LA0505925##QUESADA-PEREZ M, 2005, COLLOID SURFACE A, V267, P24, DOI 10.1016/J.COLSURFA.2005.06.034##QUESADA-PEREZ M, 2004, J CHEM PHYS, V121, P8618, DOI 10.1063/1.1798932##SHKLOVSKII BI, 1999, PHYS REV E, V60, P5802, DOI 10.1103/PHYSREVE.60.5802##TROELSTRA SA, 1941, THESIS STATE U UTREC##WIESE GR, 1975, J COLLOID INTERF SCI, V51, P434, DOI 10.1016/0021-9797(75)90140-X##YANG C, 2001, J COLLOID INTERF SCI, V243, P128, DOI 10.1006/JCIS.2001.7842",135,2020-11-20,NA
J,WOS:000242873900003,2006,"SURFACE CHARGE REGULATION UPON POLYELECTROLYTE ADSORPTION, HEMATITE, POLYSTYRENE SULFONATE, SURFACE CHARGE REGULATION - THEORETICAL CALCULATIONS AND HEMATITE-POLY(STYRENE SULFONATE) SYSTEM","THE CHARGE REGULATION OF A MINERAL SURFACE UPON ADSORPTION OF A STRONG POLYELECTROLYTE IS STUDIED THEORETICALLY AND EXPERIMENTALLY. SELF-CONSISTENT-FIELD CALCULATIONS WERE DONE TO EVALUATE THE CHARGE CHARACTERISTICS OF A MODEL OXIDE SURFACE IN THE ABSENCE AND PRESENCE OF A LINEAR STRONG POLYELECTROLYTE. THE CALCULATIONS SHOW HIGH AFFINITY ADSORPTION ISOTHERMS FOR THE POLYELECTROLYTE AT DIFFERENT PH. AT THE ADSORPTION PLATEAU THE SURFACE CHARGE IS OVERCOMPENSATED BY THE CHARGE OF THE ADSORBED POLYELECTROLYTE. THE INCREASE IN SURFACE CHARGE UPON POLYELECTROLYTE ADSORPTION IS SUBSTANTIAL. FOR A BARE SURFACE A SIMILAR ADJUSTMENT WOULD REQUIRE A PH CHANGE BY ABOUT THREE UNITS. AT A GIVEN PH AND SALT CONCENTRATION THE PROTON CO-ADSORPTION RATIO INCREASES WITH THE ADSORBED POLYELECTROLYTE CHARGE TILL THE CHARGE COMPENSATION POINT IS REACHED AND THEN IT DECREASES AGAIN. THE MEASURED ADSORPTION ISOTHERMS OF LINEAR POLY(STYRENE SULFONATE) (PSS) ON HEMATITE DO NOT SHOW A HIGH AFFINITY CHARACTER. THIS MIGHT BE DUE TO FAST FLOCCULATION AND A NON-EQUILIBRIUM POLYMER CONFORMATION AT THE SURFACE. AT PH 7 THE ADSORPTION PLATEAU IS REACHED AND THE SURFACE CHARGE IS OVERCOMPENSATED BY THE ADSORBED POLYELECTROLYTE CHARGE. THE ADSORPTION OF PSS INCREASES THE SURFACE CHARGE, SIMILARLY AS IN THE CALCULATIONS. THE INCREASE OF THE SURFACE CHARGE WITH INCREASING PSS ADSORPTION IS ABOUT LINEAR UP TO THE CHARGE COMPENSATION POINT AND DECREASES BEYOND THE CHARGE COMPENSATION POINT. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",ION ADSORPTION; HUMIC-ACID; CATIONIC SURFACTANTS; ANIONIC SURFACTANTS; OXIDE; PARTICLES; GOETHITE; HOMODISPERSE; AGGREGATION; ADJUSTMENTS,METAL OXIDE SURFACE; SURFACE CHARGE ADAPTATION; SURFACE CHARGE COMPENSATION; PROTON CO-ADSORPTION; SALT CONCENTRATION EFFECTS; PH EFFECTS; SELF-CONSISTENT-FIELD THEORY,COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS,"WOLTERINK, JK##KOOPAL, LK##STUART, MAC##VAN RIEMSDIJK, WH","UNIV WAGENINGEN & RES CTR, LAB PHYS CHEM & COLLOID SCI, NL-6703 HB WAGENINGEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, DEPT SOIL QUAL, NL-6703 HB WAGENINGEN, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"BARJA BC, 1999, LANGMUIR, V15, P2316, DOI 10.1021/LA980540Y##BOHMER MR, 1992, LANGMUIR, V8, P2649, DOI 10.1021/LA00047A014##BOHMER MR, 1991, J PHYS CHEM-US, V95, P9569, DOI 10.1021/J100176A095##BOHMER MR, 1990, MACROMOLECULES, V23, P2288, DOI 10.1021/MA00210A027##BOLT GH, 1982, DEV SOIL SCI B, V5, PCH13##BONEKAMP BC, 1986, J COLLOID INTERF SCI, V113, P67, DOI 10.1016/0021-9797(86)90206-7##BOURIKAS K, 2001, LANGMUIR, V17, P749, DOI 10.1021/LA000806C##BREEUWSMA A, 1971, DISCUSS FARADAY SOC, P324##CHARLOT G, 1964, COLORIMETRICS DETERM, P458##FILIUS JD, 1997, J COLLOID INTERF SCI, V195, P368, DOI 10.1006/JCIS.1997.5152##FLORY P. J., 1964, PRINCIPLES POLYM CHE##FOKKINK LGJ, 1987, J COLLOID INTERF SCI, V118, P454, DOI 10.1016/0021-9797(87)90481-4##GEBHARDT JE, 1983, COLLOID SURFACE, V7, P221, DOI 10.1016/0166-6622(83)80048-1##GOLOUB TP, 1996, LANGMUIR, V12, P3188, DOI 10.1021/LA9505475##GOLOUB TP, 1997, LANGMUIR, V13, P673, DOI 10.1021/LA960690D##GUNNARSSON M, 2001, J COLLOID INTERF SCI, V240, P448, DOI 10.1006/JCIS.2001.7725##HIEMSTRA T, 1996, J COLLOID INTERF SCI, V179, P488, DOI 10.1006/JCIS.1996.0242##HIEMSTRA T, 1999, LANGMUIR, V15, P5942##HIEMSTRA T, 1999, LANGMUIR, V15, P8045, DOI 10.1021/LA9903604##HOOGENDAM CW, 1998, LANGMUIR, V14, P3825, DOI 10.1021/LA9800046##ISRAELS R, 1994, MACROMOLECULES, V27, P3087, DOI 10.1021/MA00089A028##KIK RA, 2005, PHYS CHEM CHEM PHYS, V7, P1996, DOI 10.1039/B501893E##KINNIBURGH DG, 1998, WE9323 BRIT GEOL SUR##KOOPAL LK, 1979, J ELECTROANAL CHEM, V100, P895, DOI 10.1016/0368-1874(79)85159-X##KOOPAL LK, 1975, FARADAY DISCUSS, V59, P230, DOI 10.1039/DC9755900230##KOOPAL LK, 1996, ELECTROCHIM ACTA, V41, P2293, DOI 10.1016/0013-4686(96)00059-X##KOOPAL LK, 1995, J COLLOID INTERF SCI, V170, P85, DOI 10.1006/JCIS.1995.1075##LEE EM, 1996, J COLLOID INTERF SCI, V177, P478, DOI 10.1006/JCIS.1996.0061##LEERMAKERS FAM, 2005, LANGMUIR, V21, P11534, DOI 10.1021/LA051569M##LEERMAKERS FAM, 1997, LANGMUIR, V13, P5751, DOI 10.1021/LA9702704##LYKLEMA J, 2005, ADV COLLOID INTERFAC, V114, P27, DOI 10.1016/J.CIS.2004.05.002##PAPENHUIJZEN J, 1985, J COLLOID INTERF SCI, V104, P530, DOI 10.1016/0021-9797(85)90060-8##PEFFERKORN E, 2001, COLLOID POLYM SCI, V279, P498, DOI 10.1007/S003960100484##PENNERS NHG, 1987, COLLOID SURFACE, V28, P67, DOI 10.1016/0166-6622(87)80167-1##PENNERS NHG, 1986, COLLOID SURFACE, V21, P457, DOI 10.1016/0166-6622(86)80109-3##PENNERS NHG, 1986, COLLOID SURFACE, V19, P337##RIETRA RPJJ, 1999, J COLLOID INTERF SCI, V218, P511, DOI 10.1006/JCIS.1999.6408##RIETRA RPJJ, 1999, GEOCHIM COSMOCHIM AC, V63, P3009, DOI 10.1016/S0016-7037(99)00228-8##SAITO T, 2004, LANGMUIR, V20, P689, DOI 10.1021/LA034806Z##SCHEUTJENS JMHM, 1979, J PHYS CHEM-US, V83, P1619, DOI 10.1021/J100475A012##SCHUDEL M, 1997, J COLLOID INTERF SCI, V196, P241, DOI 10.1006/JCIS.1997.5207##SHIN Y, 2002, MACROMOLECULES, V35, P4090, DOI 10.1021/MA0115390##SHIN YW, 2002, J COLLOID INTERF SCI, V247, P220, DOI 10.1006/JCIS.2001.8100##SHUBIN V, 1997, MACROMOLECULES, V30, P5944, DOI 10.1021/MA970334H##SIDOROVA M, 1993, ADV COLLOID INTERFAC, V43, P1, DOI 10.1016/0001-8686(93)80003-T##TIJSSEN R, 1993, J CHROMATOGR A, V656, P135, DOI 10.1016/0021-9673(93)80801-E##VANDERSCHEE HA, 1982, EFFECT POLYM DISPERS, P81##VANMALE J, 2003, THESIS WAGENINGEN U##VANMALE J, 2001, SFBOX COMPUTER PROGR##VENEMA P, 1996, J COLLOID INTERF SCI, V183, P515, DOI 10.1006/JCIS.1996.0575##VENEMA P, 1998, J COLLOID INTERF SCI, V198, P282, DOI 10.1006/JCIS.1997.5245##VERMEER AWP, 1999, J COLLOID INTERF SCI, V212, P176, DOI 10.1006/JCIS.1998.6050##VERMEER AWP, 1997, LANGMUIR, V13, P4413, DOI 10.1021/LA9701440##VERMEER AWP, 1998, LANGMUIR, V14, P2810, DOI 10.1021/LA970624R##VERMOHLEN K, 2000, COLLOID SURFACE A, V163, P45, DOI 10.1016/S0927-7757(99)00429-X##WOLTERINK JK, 1999, MACROMOLECULES, V32, P2365",19,2020-11-20,NA
J,WOS:000242875600001,2006,SPECIAL ISSUE ON NONLINEAR MODELLING AND FINANCIAL ECONOMETRICS,NA,WILD BOOTSTRAP,NA,COMPUTATIONAL STATISTICS & DATA ANALYSIS,"AMENDOLA, A##FRANCQ, C##KOOPMAN, SJ","UNIV SALERNO, DEPT ECON & STAT, I-84084 FISCIANO, SA, ITALY. UNIV LILLE 3, F-59653 VILLENEUVE DASCQ, FRANCE. VRIJE UNIV AMSTERDAM, DEPT ECON, FEWEB, NL-1081 HV AMSTERDAM, NETHERLANDS.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; STATISTICS & PROBABILITY",COMPUTER SCIENCE; MATHEMATICS,"BARAGONA R, 2004, COMPUT STAT DATA AN, V47, P277, DOI 10.1016/J.CSDA.2003.11.003##BARONE-ADESI G, 2005, COMPUT STAT DATA AN, V49, P287, DOI 10.1016/J.CSDA.2004.05.014##BRAHIM-BELHOUARI S, 2004, COMPUT STAT DATA AN, V47, P705, DOI 10.1016/J.CSDA.2004.02.006##BROTO C, 2006, COMPUT STAT DATA AN, V50, P2146, DOI 10.1016/J.CSDA.2004.12.009##CUBADDA G, 2005, COMPUT STAT DATA AN, V49, P333, DOI 10.1016/J.CSDA.2004.05.016##DE GOOIJER JG, 2003, COMPUT STAT DATA AN, V42, P73, DOI 10.1016/S0167-9473(02)00123-8##FLACHAIRE E, 2005, COMPUT STAT DATA AN, V49, P361, DOI 10.1016/J.CSDA.2004.05.018##GODFREY LG, 2005, COMPUT STAT DATA AN, V49, P377, DOI 10.1016/J.CSDA.2004.05.020##JEWITT G, 2005, COMPUT STAT DATA AN, V49, P397, DOI 10.1016/J.CSDA.2004.05.021##PASCUAL L, 2006, COMPUT STAT DATA AN, V50, P2293, DOI 10.1016/J.CSDA.2004.12.008##POLLOCK DSG, 2006, COMPUT STAT DATA AN, V50, P2268, DOI 10.1016/J.CSDA.2005.07.010##PROIETTI T, 2005, COMPUT STAT DATA AN, V49, P477, DOI 10.1016/J.CSDA.2004.05.024##SWAMY PAVB, 2005, COMPUT STAT DATA AN, V49, P575, DOI 10.1016/J.CSDA.2004.05.028##XEKALAKI E, 2005, COMPUT STAT DATA AN, V49, P611, DOI 10.1016/J.CSDA.2004.05.030",6,2020-11-20,NA
J,WOS:000242875600010,2006,NONLINEAR DYNAMICS IN NASDAQ DEALER QUOTES,"A NONLINEAR DYNAMIC MODEL FOR THE QUOTES ISSUED BY NASDAQ DEALERS IS CONSIDERED. THE MODEL FOCUSSES ON THE TOP TWO ELECTRONIC COMMUNICATION NETWORKS (ECNS), ISLAND AND INSTINCT, AND THE THREE MOST ACTIVE MARKET MAKERS FOR A SAMPLE OF TWENTY STOCKS. THE MODEL EXTENDS THE STANDARD LINEAR VECTOR ERROR CORRECTION MODEL FOR PRICE DISCOVERY IN THREE DIFFERENT WAYS. FIRST, QUOTE ADJUSTMENTS ARE SET RELATIVE TO THE INSIDE QUOTE, I.E. THE BEST BID AND ASK IN THE MARKET. SECOND, DEALERS REACT TO THE INSIDE SPREAD. THIRD, ADJUSTMENTS DIFFER ACCORDING TO WHICH DEALER IS CURRENTLY AT THE INSIDE. ADJUSTMENTS ARE DIFFERENT IF AN ECN IS CURRENTLY AT THE INSIDE COMPARED TO AN INDIVIDUAL DEALER. THIS DIFFERENCE IS ATTRIBUTED TO THE ASYMMETRIC INFORMATION AMONG DEALERS. PRICE DISCOVERY DYNAMICS ARE STUDIED USING GENERALIZED IMPULSE RESPONSE FUNCTIONS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",MARKET; MICROSTRUCTURE,HIGH FREQUENCY DATA; DEALER MARKETS; ERROR CORRECTION MODELS; NONLINEAR IMPULSE-RESPONSE FUNCTIONS,COMPUTATIONAL STATISTICS & DATA ANALYSIS,"FRIJNS, B##SCHOTMAN, PC","RADBOUD UNIV NIJMEGEN, NIJMEGEN SCH MANAGEMENT, NL-6500 HK NIJMEGEN, NETHERLANDS. MAASTRICHT UNIV, LIFE, NL-6200 MD MAASTRICHT, NETHERLANDS.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; STATISTICS & PROBABILITY",COMPUTER SCIENCE; MATHEMATICS,"BREUSCH TS, 1979, ECONOMETRICA, V47, P1287, DOI 10.2307/1911963##CHAN KC, 1995, J BUS, V68, P35, DOI 10.1086/296652##CHRISTIE WG, 1994, J FINANC, V49, P1813, DOI 10.2307/2329272##CHRISTIE WG, 1994, J FINANC, V49, P1841, DOI 10.2307/2329273##CHUNG KH, 2003, J FINANC RES, V26, P191##ENGLE RF, 2004, J FINANC MARK, V7, P1, DOI 10.1016/S1386-4181(03)00018-1##EUN CS, 2003, J FINANC, V58, P549, DOI 10.1111/1540-6261.00537##HARRIS FHD, 1995, J BANK FINANC, V19, P323##HASBROUCK J, 1995, J FINANC, V50, P1175, DOI 10.2307/2329348##HASBROUCK J, 1991, J FINANC, V46, P179, DOI 10.2307/2328693##HASBROUCK J, 1999, J FINANC, V54, P2109, DOI 10.1111/0022-1082.00183##HUANG RD, 2002, J FINANC, V57, P1285, DOI 10.1111/1540-6261.00461##JANG HS, 1991, J FINANC, V46, P433, DOI 10.2307/2328704##KOOP G, 1996, J ECONOMETRICS, V74, P119, DOI 10.1016/0304-4076(95)01753-4##KYLE AS, 1985, ECONOMETRICA, V53, P1315, DOI 10.2307/1913210##PEIERS B, 1997, J FINANC, V52, P1589, DOI 10.2307/2329448##SCHULTZ P, 2003, J FINANC MARK, V6, P49, DOI 10.1016/S1386-4181(02)00022-8##STOLL HR, 1989, J FINANC, V44, P115, DOI 10.2307/2328278##WANG JX, 2001, J INT FINANC MARK I, V11, P115",6,2020-11-20,NA
J,WOS:000242215100011,2006,NOVEL BINDING PARTNERS OF LDB1 ARE REQUIRED FOR HAEMATOPOIETIC DEVELOPMENT,"LDB1, A UBIQUITOUSLY EXPRESSED LIM DOMAIN BINDING PROTEIN, IS ESSENTIAL IN A NUMBER OF TISSUES DURING DEVELOPMENT. IT INTERACTS WITH GATA1, TAL1, E2A AND LMO2 TO FORM A TRANSCRIPTION FACTOR COMPLEX REGULATING LATE ERYTHROID GENES. WE IDENTIFY A NUMBER OF NOVEL LDB1 INTERACTING PROTEINS IN ERYTHROLEUKAEMIC CELLS, IN PARTICULAR THE REPRESSOR PROTEIN ETO-2 (AND ITS FAMILY MEMBER MTGR1), THE CYCLIN-DEPENDENT KINASE CDK9, AND THE BRIDGING FACTOR LMO4. MO-MEDIATED KNOCKDOWNS IN ZEBRAFISH SHOW THESE FACTORS TO BE ESSENTIAL FOR DEFINITIVE HAEMATOPOIESIS. IN ACCORDANCE WITH THE ZEBRAFISH RESULTS THESE FACTORS ARE COEXPRESSED IN PREHAEMATOPOIETIC CELLS OF THE EARLY MOUSE EMBRYO, ALTHOUGH WE ORIGINALLY IDENTIFIED THE COMPLEX IN LATE ERYTHROID CELLS. BASED ON THE CHANGE IN SUBCELLULLAR LOCALISATION OF ETO-2 WE POSTULATE THAT IT PLAYS A CENTRAL ROLE IN THE TRANSITION FROM THE MIGRATION AND EXPANSION PHASE OF THE PREHAEMATOPOIETIC CELLS TO THE ESTABLISHMENT OF DEFINITIVE HAEMATOPOIETIC STEM CELLS.",NEURAL-TUBE CLOSURE; STEM-CELLS; MICE LACKING; YOLK-SAC; ERYTHROID-DIFFERENTIATION; HOMEODOMAIN PROTEINS; ZEBRAFISH EMBRYOS; TRANSGENIC MICE; SMALL-INTESTINE; GLOBIN GENE,LDB1; TRANSCRIPTION FACTOR COMPLEXES; HAEMATOPOIETIC STEM CELLS; HAEMATOPOIESIS,DEVELOPMENT,"MEIER, N##KRPIC, S##RODRIGUEZ, P##STROUBOULIS, J##MONTI, M##KRIJGSVELD, J##GERING, M##PATIENT, R##HOSTERT, A##GROSVELD, F","ERASMUS MC, DEPT CELL BIOL & GENET, NL-3000 CA ROTTERDAM, NETHERLANDS. UNIV UTRECHT, DEPT BIOMOL MASS SPECT, BIJVOET CTR BIOMOL RES, NL-3584 CA UTRECHT, NETHERLANDS. UNIV UTRECHT, UTRECHT INST PHARMACEUT SCI, NL-3584 CA UTRECHT, NETHERLANDS. UNIV OXFORD, WEATHERALL INST MOL MED, MRC MOL HAEMATOL UNIT, OXFORD OX3 9DS, ENGLAND.",DEVELOPMENTAL BIOLOGY,DEVELOPMENTAL BIOLOGY,"AGULNICK AD, 1996, NATURE, V384, P270, DOI 10.1038/384270A0##AMANN JM, 2005, MOL CELL BIOL, V25, P9576, DOI 10.1128/MCB.25.21.9576-9585.2005##ANGUITA E, 2004, EMBO J, V23, P2841, DOI 10.1038/SJ.EMBOJ.7600274##ANTONIOU M, 1991, METHODS MOL BIOL, V7, P421, DOI 10.1385/0-89603-178-0:421##BAGELLA L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.0.CO;2-R##BETTENCOURT-DIAS M, 2004, NATURE, V432, P980, DOI 10.1038/NATURE03160##BRAND M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/NSMB713##CANTOR AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4##CHEN L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/PNAS.212532399##CUMANO A, 2001, IMMUNITY, V15, P477, DOI 10.1016/S1074-7613(01)00190-X##DAVIS JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1##DAVIS JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/SJ.ONC.1202412##DE BOER E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/PNAS.1332608100##DE BRUIJN MFTR, 2000, EMBO J, V19, P2465, DOI 10.1093/EMBOJ/19.11.2465##DE BRUIJN MFTR, 2002, IMMUNITY, V16, P673, DOI 10.1016/S1074-7613(02)00313-8##DE LA CALLE-MUSTIENES E, 2003, DEV BIOL, V264, P564, DOI 10.1016/J.YDBIO.2003.09.002##DURAND C, 2005, HAEMATOLOGICA, V90, P100##GARRIGA J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003##GEKAS C, 2005, DEV CELL, V8, P365, DOI 10.1016/J.DEVCEL.2004.12.016##GELMETTI V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185##GERING M, 2005, DEV CELL, V8, P389, DOI 10.1016/J.DEVCEL.2005.01.010##GIRAUD S, 2004, ONCOGENE, V23, P7391, DOI 10.1038/SJ.ONC.1207972##GOARDON N, 2006, EMBO J, V25, P357, DOI 10.1038/SJ.EMBOJ.7600934##GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/PNAS.91.9.3834##GUYOT B, 2004, BLOOD, V104, P89, DOI 10.1182/BLOOD-2004-01-0108##HAHM KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004##JOWETT T, 1996, TRENDS GENET, V12, P387, DOI 10.1016/S0168-9525(96)90091-8##KALEV-ZYLINSKA ML, 2002, DEVELOPMENT, V129, P2015##KENNY DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/PNAS.95.19.11257##KORINEK V, 1998, NAT GENET, V19, P379##LAHLIL R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004##LANE MARY ELLEN, 2002, GENE EXPRESSION PATTERNS, V2, P207, DOI 10.1016/S1567-133X(02)00061-3##LEE SK, 2005, MOL CELL NEUROSCI, V28, P205, DOI 10.1016/J.MCN.2004.04.010##LIU HB, 2005, J CELL PHYSIOL, V203, P251, DOI 10.1002/JCP.20224##LUTTERBACH B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176##MARSHALL NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/JBC.271.43.27176##MCDEVITT MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/PNAS.94.15.7976##MEDVINSKY A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8##MORCILLO P, 1997, GENE DEV, V11, P2729, DOI 10.1101/GAD.11.20.2729##MUKHOPADHYAY M, 2003, DEVELOPMENT, V130, P495, DOI 10.1242/DEV.00225##NASEVICIUS A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951##NISHIOKA N, 2005, DEVELOPMENT, V132, P2535, DOI 10.1242/DEV.01844##ONODERA K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/PNAS.94.9.4487##OTTERSBACH K, 2005, DEV CELL, V8, P377, DOI 10.1016/J.DEVCEL.2005.02.001##PALSTRA RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/NG1244##PATRINOS GP, 2004, GENE DEV, V18, P1495, DOI 10.1101/GAD.289704##QUINKERTZ A, 1999, DEV GENES EVOL, V209, P126, DOI 10.1007/S004270050235##RAMAIN P, 2000, MOL CELL, V6, P781, DOI 10.1016/S1097-2765(00)00077-0##ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/PNAS.92.15.7075##RODRIGUEZ P, 2005, EMBO J, V24, P2354, DOI 10.1038/SJ.EMBOJ.7600702##SCHUH AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005##SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432A0##SHORE SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9##TOLHUIS B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5##TORIGOI E, 2000, P NATL ACAD SCI USA, V97, P2686, DOI 10.1073/PNAS.050586397##TSE E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004##VAN MEYEL DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/DEV.00389##WADMAN IA, 1997, EMBO J, V16, P3145, DOI 10.1093/EMBOJ/16.11.3145##WANG L, 1998, EUR T ELECTR POWER, V8, P21##WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1##WESTERFIELD M., 1993, ZEBRAFISH BOOK GUIDE##WHYATT DAVID J., 1997, GENES AND FUNCTION, V1, P11##YODER MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6##ZHU YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/GAD.11.20.2622##ZHUANG Y, 1996, MOL CELL BIOL, V16, P2898",106,2020-11-20,MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [MC_U137981013] FUNDING SOURCE: MEDLINE
J,WOS:000243220100024,2006,"SCA-1 NEGATIVELY REGULATES PROLIFERATION AND DIFFERENTIATION OF MUSCLE CELLS (VOL 283, PG 240, 2005)",NA,NA,NA,DEVELOPMENTAL BIOLOGY,"MITCHELL, PO##MILLS, T##O'CONNOR, RS##KLINE, ER##GRAUBERT, T##DZIERZAK, E##PAVLATH, GK","EMORY UNIV, SCH MED, DEPT PHARMACOL, OW ROLLINS RES CTR, ATLANTA, GA 30322 USA. EMORY UNIV, GRAD PROGRAM MOL & SYST PHARMACOL, ATLANTA, GA 30322 USA. WASHINGTON UNIV, DEPT INTERNAL MED, DIV ONCOL, STEM CELL BIOL SECT,SCH MED, ST LOUIS, MO 63110 USA. ERASMUS UNIV, DEPT CELL BIOL & GENET, NL-3000 DR ROTTERDAM, NETHERLANDS.",DEVELOPMENTAL BIOLOGY,DEVELOPMENTAL BIOLOGY,"MITCHELL PO, 2005, DEV BIOL, V283, P240, DOI 10.1016/J.YDBIO.2005.04.016",0,2020-11-20,NA
J,WOS:000242793400008,2006,MODELING METAL-PARTICLE INTERACTIONS WITH AN EMPHASIS ON NATURAL ORGANIC MATTER,NA,BIOTIC LIGAND MODEL; NICA-DONNAN MODEL; ION-BINDING; HUMIC SUBSTANCES; FRESH-WATERS; HEAVY-METALS; ADSORPTION; ACID; CHARGE; COMPLEXATION,NA,ENVIRONMENTAL SCIENCE & TECHNOLOGY,"MERDY, P##HUCLIER, S##KOOPAL, LK","UNIV TOULON & VAR, DEPT CHEM, PROTEE LAB, TOULON, FRANCE. UNIV WAGENINGEN & RES CTR, LAB PHYS CHEM & COLLOID SCI, NL-6700 HB WAGENINGEN, NETHERLANDS.","ENGINEERING, ENVIRONMENTAL; ENVIRONMENTAL SCIENCES",ENGINEERING; ENVIRONMENTAL SCIENCES & ECOLOGY,"AU KK, 1999, GEOCHIM COSMOCHIM AC, V63, P2903, DOI 10.1016/S0016-7037(99)00268-9##BENEDETTI MF, 2006, J GEOCHEM EXPLOR, V88, P81, DOI 10.1016/J.GEXPLO.2005.08.018##BENEDETTI MF, 1996, GEOCHIM COSMOCHIM AC, V60, P2503, DOI 10.1016/0016-7037(96)00113-5##DI TORO DM, 2001, ENVIRON TOXICOL CHEM, V20, P2383, DOI 10.1002/ETC.5620201034##DIJKSTRA JJ, 2004, ENVIRON SCI TECHNOL, V38, P4390, DOI 10.1021/ES049885V##DILL K, 2003, MOL DRIVING FORCES S##DUDAL Y, 2004, EARTH-SCI REV, V66, P199, DOI 10.1016/J.EARSCIREV.2004.01.002##DZOMBAK D.A., 1990, SURFACE COMPLEXATION##FEIN JB, 1997, GEOCHIM COSMOCHIM AC, V61, P3319, DOI 10.1016/S0016-7037(97)00166-X##GUSTAFSSON JP, 2001, J COLLOID INTERF SCI, V244, P102, DOI 10.1006/JCIS.2001.7871##HIEMSTRA T, 1989, J COLLOID INTERF SCI, V133, P91, DOI 10.1016/0021-9797(89)90284-1##HIEMSTRA T, 1996, J COLLOID INTERF SCI, V179, P488, DOI 10.1006/JCIS.1996.0242##JONES MN, 1998, ADV COLLOID INTERFAC, V78, P1, DOI 10.1016/S0001-8686(98)00058-X##KIM JI, 1996, RADIOCHIM ACTA, V73, P5##KINNIBURGH DG, 1999, COLLOID SURFACE A, V151, P147, DOI 10.1016/S0927-7757(98)00637-2##KOOPAL LK, 2005, COLLOID SURFACE A, V265, P40, DOI 10.1016/J.COLSURFA.2004.11.050##KOOPAL LK, 1996, ELECTROCHIM ACTA, V41, P2293, DOI 10.1016/0013-4686(96)00059-X##KOSTER M, 2006, SOIL BIOL BIOCHEM, V38, P1788, DOI 10.1016/J.SOILBIO.2005.11.033##LOCK K, 2006, SOIL BIOL BIOCHEM, V38, P1924, DOI 10.1016/J.SOILBIO.2005.12.014##MACDONALD JD, 2006, ENVIRON POLLUT, V143, P228, DOI 10.1016/J.ENVPOL.2005.11.031##MARTELL AE, 2004, NIST CRITICALLY SELE##MEIMA JA, 2001, ENVIRON SCI TECHNOL, V35, P2049##MILNE CJ, 2003, ENVIRON SCI TECHNOL, V37, P958, DOI 10.1021/ES0258879##MILNE CJ, 2001, ENVIRON SCI TECHNOL, V35, P2049, DOI 10.1021/ES000123J##MONTAVON G, 2002, RADIOCHIM ACTA, V90, P689, DOI 10.1524/RACT.2002.90.9-11_2002.689##PINHEIRO JP, 2000, ENVIRON SCI TECHNOL, V34, P5137, DOI 10.1021/ES0000899##RABUNG T, 1998, RADIOCHIM ACTA, V82, P243##SAITO T, 2005, COLLOID SURFACE A, V265, P104, DOI 10.1016/J.COLSURFA.2004.10.139##SAITO T, 2005, ENVIRON SCI TECHNOL, V39, P4886, DOI 10.1021/ES0500308##SVERJENSKY DA, 2005, GEOCHIM COSMOCHIM AC, V69, P225, DOI 10.1016/J.GCA.2004.05.040##TAKAHASHI Y, 2002, GEOCHIM COSMOCHIM AC, V66, P1, DOI 10.1016/S0016-7037(01)00748-7##TESSIER A, 1996, GEOCHIM COSMOCHIM AC, V60, P387, DOI 10.1016/0016-7037(95)00413-0##TIPPING E, 2006, ENVIRON POLLUT, V141, P139, DOI 10.1016/J.ENVPOL.2005.08.019##TIPPING E, 1998, AQUAT GEOCHEM, V4, P3, DOI 10.1023/A:1009627214459##TIPPING E, 2002, CAMBRIDGE NEV CHEM S, V12##TIPPING E, 1996, J HYDROL, V174, P304##UNSWORTH ER, 2006, ENVIRON SCI TECHNOL, V40, P1942, DOI 10.1021/ES051246C##VERMEER AWP, 1999, ENVIRON SCI TECHNOL, V33, P3892, DOI 10.1021/ES990260K##VERMEER AWP, 1998, LANGMUIR, V14, P2810, DOI 10.1021/LA970624R##VOIGT A, 2006, ENVIRON TOXICOL CHEM, V25, P692, DOI 10.1897/04-619R.1##WENG LP, 2006, J COLLOID INTERF SCI, V302, P442, DOI 10.1016/J.JCIS.2006.07.005##WENG LP, 2006, LANGMUIR, V22, P389, DOI 10.1021/LA051730T##ZHANG H, 2004, ENVIRON SCI TECHNOL, V38, P1421, DOI 10.1021/ES034654U##IUPAC STABILITY CONS",37,2020-11-20,NA
J,WOS:000242793400009,2006,"MODELING THE INTERACTIONS BETWEEN HUMICS, IONS, AND MINERAL SURFACES","MODEL VI AND THE NICA-DONNAN MODEL ARE TWO SUCCESSFUL MODELS PRESENTLY AVAILABLE FOR DESCRIBING METAL ION BINDING BY HUMIC MATERIALS. BOTH MODELS DEAL WITH THE COMPLEXITY OF THE UNDERLYING PROCESSES (INTRINSIC HETEROGENEITY, PARTIAL CORRELATION BETWEEN AFFINITY DISTRIBUTIONS, VARIABLE STOICHIOMETRY, ELECTROSTATICS) IN A PRAGMATIC WAY. THE PARAMETERS OF THE NICA-DONNAN MODEL AND THEIR DETERMINATION ARE DISCUSSED. THE CURRENT INTERPRETATION OF THE ION-SPECIFIC ""NON-IDEALITY"" PARAMETERS, N(I), FOUND IN THE NICA-DONNAN MODEL, EMPHASIZES THEIR ROLE IN DETERMINING THE STOICHIOMETRY FOR THE COMPETITIVE BINDING OF IONS. THE RATIO N(M)/N(H) IS REFLECTED IN THE CORRESPONDING EXCHANGE RATIOS AND THE PH DEPENDENCE OF THE METAL ION BINDING. EXPERIMENTAL COMPLICATIONS OCCUR IN TESTING MODELS. ALTHOUGH MODEL VI AND THE NICA-DONNAN MODELS HAVE MUCH IN COMMON, THERE ARE DIFFERENCES THAT MAY BECOME MORE APPARENT AS THE MODELS ARE MORE WIDELY TESTED. RECENTLY ION BINDING TO COMPLEXES OF HUMICS AND OXIDES HAS BEEN DESCRIBED BY COMBINING THE NICA-DONNAN MODEL (ION BINDING TO HUMICS) WITH THE CD-MUSIC MODEL (ION BINDING TO OXIDES). THE IMPACT OF HUMIC TO OXIDE BINDING ON BOTH CATION AND ANION BINDING IS BRIEFLY DISCUSSED.",DONNAN MEMBRANE TECHNIQUE; NATURAL ORGANIC-MATTER; CHEMICAL-EQUILIBRIUM MODELS; SITE BINDING MODELS; FULVIC-ACID; HETEROGENEOUS SURFACES; PROTON BINDING; AFFINITY DISTRIBUTIONS; COPPER-BINDING; TRACE-METALS,NA,ENVIRONMENTAL SCIENCE & TECHNOLOGY,"VAN RIEMSDIJK, WH##KOOPAL, LK##KINNIBURGH, DG##BENEDETTI, MF##WENG, LP","UNIV WAGENINGEN & RES CTR, SOIL QUAL DEPT, NL-6700 EC WAGENINGEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, LAB PHYS CHEM & COLLOID SCI, NL-6703 HB WAGENINGEN, NETHERLANDS. BRITISH GEOL SURVEY, WALLINGFORD OX10 8BB, OXON, ENGLAND. UNIV PARIS 07, CNRS, UMR 7154, LAB GEOCHIM EAUX, F-75251 PARIS 05, FRANCE.","ENGINEERING, ENVIRONMENTAL; ENVIRONMENTAL SCIENCES",ENGINEERING; ENVIRONMENTAL SCIENCES & ECOLOGY,"ADAMSON A., 1976, PHYS CHEM SURFACES##ALLARD T, 2004, GEOCHIM COSMOCHIM AC, V68, P3079, DOI 10.1016/J.GCA.2004.01.014##AVENA MJ, 1999, J COLLOID INTERF SCI, V217, P37, DOI 10.1006/JCIS.1999.6317##BENEDETTI MF, 1995, ENVIRON SCI TECHNOL, V29, P446, DOI 10.1021/ES00002A022##BENEDETTI MF, 1996, ENVIRON SCI TECHNOL, V30, P1805, DOI 10.1021/ES950012Y##CHRISTL I, 2001, ENVIRON SCI TECHNOL, V35, P2505, DOI 10.1021/ES0002518##CHRISTL I, 2001, GEOCHIM COSMOCHIM AC, V65, P3435, DOI 10.1016/S0016-7037(01)00695-0##CHRISTL I, 2005, ENVIRON SCI TECHNOL, V39, P5319, DOI 10.1021/ES050018F##CROUE JP, 2003, ENVIRON SCI TECHNOL, V37, P328, DOI 10.1021/ES020676P##DAHLQVIST R, 2004, GEOCHIM COSMOCHIM AC, V68, P4059, DOI 10.1016/J.GCA.2004.04.007##DILL K, 2003, MOL DRIVING FORCES S##DUDAL Y, 2004, EARTH-SCI REV, V66, P199, DOI 10.1016/J.EARSCIREV.2004.01.002##FILIUS JD, 2000, GEOCHIM COSMOCHIM AC, V64, P51, DOI 10.1016/S0016-7037(99)00176-3##GARCES JL, 2004, J CHEM PHYS, V120, P9266, DOI 10.1063/1.1710857##HEALY TW, 1978, ADV COLLOID INTERFAC, V9, P303, DOI 10.1016/0001-8686(78)85002-7##HIEMSTRA T, 1999, J COLLOID INTERF SCI, V210, P182, DOI 10.1006/JCIS.1998.5904##JARONIEC M, 1983, ADV COLLOID INTERFAC, V18, P149, DOI 10.1016/0001-8686(83)87002-X##KALIS EJJ, 2006, ENVIRON SCI TECHNOL, V40, P955, DOI 10.1021/ES051435V##KINNIBURGH DG, 1999, COLLOID SURFACE A, V151, P147, DOI 10.1016/S0927-7757(98)00637-2##KOOPAL LK, 2005, COLLOID SURFACE A, V265, P40, DOI 10.1016/J.COLSURFA.2004.11.050##KOOPAL LK, 1994, J COLLOID INTERF SCI, V166, P51, DOI 10.1006/JCIS.1994.1270##LUMSDON DG, 2005, ENVIRON SCI TECHNOL, V39, P6624, DOI 10.1021/ES050180I##MARANG L, UNPUB ENV SCI TECHNO##MEEUSSEN JCL, 2003, ENVIRON SCI TECHNOL, V37, P1175, DOI 10.1021/ES025597S##MILNE CJ, 2003, ENVIRON SCI TECHNOL, V37, P958, DOI 10.1021/ES0258879##MILNE CJ, 2001, ENVIRON SCI TECHNOL, V35, P2049, DOI 10.1021/ES000123J##NEDERLOF MM, 1993, ENVIRON SCI TECHNOL, V27, P846, DOI 10.1021/ES00042A006##OSTE LA, 2002, ENVIRON SCI TECHNOL, V36, P208, DOI 10.1021/ES0100571##RIETRA RPJJ, 2001, ENVIRON SCI TECHNOL, V35, P3369, DOI 10.1021/ES000210B##RUSCH U, 1997, J COLLOID INTERF SCI, V191, P247, DOI 10.1006/JCIS.1997.4904##SAITO T, 2005, COLLOID SURFACE A, V265, P104, DOI 10.1016/J.COLSURFA.2004.10.139##SAITO T, 2005, ENVIRON SCI TECHNOL, V39, P4886, DOI 10.1021/ES0500308##SAITO T, 2004, LANGMUIR, V20, P689, DOI 10.1021/LA034806Z##SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922##SPOSITO G, 2004, SURFACE CHEM NATURAL##STIGTER D, 1989, J PHYS CHEM-US, V93, P6737, DOI 10.1021/J100355A033##TEMMINGHOFF EJM, 2000, ANAL CHIM ACTA, V417, P149, DOI 10.1016/S0003-2670(00)00935-1##TIPPING E, 1988, WATER RES, V22, P597, DOI 10.1016/0043-1354(88)90061-9##TIPPING E, 1992, GEOCHIM COSMOCHIM AC, V56, P3627, DOI 10.1016/0016-7037(92)90158-F##TIPPING E, 1998, AQUAT GEOCHEM, V4, P3, DOI 10.1023/A:1009627214459##TIPPING E., 2002, CATION BINDING HUMIC##UNSWORTH ER, 2006, ENVIRON SCI TECHNOL, V40, P1942, DOI 10.1021/ES051246C##VANRIEMSDIJK WH, 1996, J COLLOID INTERF SCI, V183, P35, DOI 10.1006/JCIS.1996.0516##VANRIEMSDIJK WH, 1987, J COLLOID INTERF SCI, V116, P511, DOI 10.1016/0021-9797(87)90147-0##VENEMA P, 1996, J COLLOID INTERF SCI, V181, P45, DOI 10.1006/JCIS.1996.0355##VERMEER AWP, 1999, ENVIRON SCI TECHNOL, V33, P3892, DOI 10.1021/ES990260K##WENG L, 2002, EUR J SOIL SCI, V53, P575, DOI 10.1046/J.1365-2389.2002.00455.X##WENG L, 2001, EUR J SOIL SCI, V52, P629, DOI 10.1046/J.1365-2389.2001.00416.X##WENG LP, 2006, ENVIRON SCI TECHNOL, V40, P7494, DOI 10.1021/ES060777D##WENG LP, 2002, ENVIRON SCI TECHNOL, V36, P4804, DOI 10.1021/ES0200084##WENG LP, 2002, ENVIRON SCI TECHNOL, V36, P1699, DOI 10.1021/ES010283A##WENG LP, 2006, LANGMUIR, V22, P389, DOI 10.1021/LA051730T##WENG LP, 2001, ENVIRON SCI TECHNOL, V35, P4436, DOI 10.1021/ES010085J##WENG LP, 2005, GEOCHIM COSMOCHIM AC, V69, P325, DOI 10.1016/J.GCA.2004.07.002##WENG LP, 2005, ANAL CHEM, V77, P2852, DOI 10.1021/AC0485435##WENG LP, IN PRESS J COLLOID I",53,2020-11-20,NATURAL ENVIRONMENT RESEARCH COUNCILNERC NATURAL ENVIRONMENT RESEARCH COUNCIL [BGS03002] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242793400012,2006,ADSORPTION OF HUMIC SUBSTANCES ON GOETHITE: COMPARISON BETWEEN HUMIC ACIDS AND FULVIC ACIDS,"THE ADSORPTION OF HUMIC ACIDS (HA) TO GOETHITE (AT PH 3 - 11) AND THE PROTON CO-ADSORPTION (AT PH 4.0, 5.5, AND 7.0) WERE MEASURED, AND THE RESULTS WERE COMPARED TO THOSE OF FULVIC ACIDS (FA). COMPARED TO FA, THE ADSORPTION OF HA IS STRONGER AND MORE IONIC STRENGTH DEPENDENT. THE ADSORPTION OF BOTH HA AND FA DECREASES WITH INCREASING PH. THE RELATIVE CHANGE OF THE ADSORPTION WITH PH IS BIGGER FOR HA THAN FOR FA AT RELATIVELY LOW PH. AT RELATIVELY HIGH PH, IT IS THE OPPOSITE. PROTONS ARE RELEASED AT PH 4.0 AND CO-ADSORBED AT PH 5.5 AND 7.0 UPON THE ADSORPTION OF BOTH HA AND FA. THE OBSERVED PH DEPENDENCY OF HA AND FA ADSORPTION IS IN AGREEMENT WITH THE PROTON CO- ADSORPTION DATA. MODEL CALCULATIONS SHOW THAT THE ADSORBED FA PARTICLES ARE ON AVERAGE LOCATED IN THE STERN LAYER, WHEREAS THE ADSORBED HA PARTICLES PROTRUDE BEYOND THE STERN LAYER. THE CLOSER LOCATION TO THE SURFACE OF THE ADSORBED FA LEADS TO STRONGER ELECTROSTATIC INTERACTIONS BETWEEN THE FA PARTICLES AND THE SURFACE, WHICH EXPLAINS THE LARGER AMOUNT OF PROTONS RELEASED AT LOW PH AND CO- ADSORBED AT HIGH PH WITH EACH MASS UNIT OF FA ADSORBED THAN THAT WITH HA ADSORBED. THE MODEL ALSO REVEALS THAT FOR FA A MEAN-FIELD (SMEARED-OUT) APPROXIMATION IS REASONABLE, BUT FOR HA A PATCHWISE APPROACH IS MORE APPROPRIATE AT RELATIVELY LOW LOADING.",NATURAL ORGANIC-MATTER; NICA-DONNAN MODEL; ALUMINUM-OXIDE; ION-BINDING; WATER INTERFACE; CLAY-MINERALS; FRACTIONATION; SURFACES; STOICHIOMETRY; ISOTHERMS,NA,ENVIRONMENTAL SCIENCE & TECHNOLOGY,"WENG, LP##VAN RIEMSDIJK, WH##KOOPAL, LK##HIEMSTRA, T","UNIV WAGENINGEN & RES CTR, DEPT SOIL QUAK, NL-6700 EC WAGENINGEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, LAB PHYS CHEM & COLLOID SCI, NL-6700 EK WAGENINGEN, NETHERLANDS.","ENGINEERING, ENVIRONMENTAL; ENVIRONMENTAL SCIENCES",ENGINEERING; ENVIRONMENTAL SCIENCES & ECOLOGY,"AIKEN GR, 1979, ANAL CHEM, V51, P1799, DOI 10.1021/AC50047A044##DAVIS JA, 1982, GEOCHIM COSMOCHIM AC, V46, P2381, DOI 10.1016/0016-7037(82)90209-5##DAVIS JA, 1981, ENVIRON SCI TECHNOL, V15, P1223, DOI 10.1021/ES00092A012##DEWIT JCM, 1990, ANAL CHIM ACTA, V232, P189, DOI 10.1016/S0003-2670(00)81235-0##FILIUS JD, 2003, GEOCHIM COSMOCHIM AC, V67, P1463, DOI 10.1016/S0016-7037(02)01042-6##FILIUS JD, 2000, GEOCHIM COSMOCHIM AC, V64, P51, DOI 10.1016/S0016-7037(99)00176-3##GU BH, 1994, ENVIRON SCI TECHNOL, V28, P38, DOI 10.1021/ES00050A007##HIEMSTRA T, 1989, J COLLOID INTERF SCI, V133, P91, DOI 10.1016/0021-9797(89)90284-1##HIEMSTRA T, 1996, J COLLOID INTERF SCI, V179, P488, DOI 10.1006/JCIS.1996.0242##HIEMSTRA T, 2002, ENCY SURFACE COLLOID##HUR J, 2006, J ENVIRON SCI HEAL A, V41, P343, DOI 10.1080/10934520500423485##KINNIBURGH DG, 1995, SOIL SCI SOC AM J, V59, P417, DOI 10.2136/SSSAJ1995.03615995005900020021X##KINNIBURGH DG, 1999, COLLOID SURFACE A, V151, P147, DOI 10.1016/S0927-7757(98)00637-2##KO I, 2005, CHEM SPEC BIOAVAILAB, V17, P41, DOI 10.3184/095422905782774928##KOOPAL LK, 2005, COLLOID SURFACE A, V265, P40, DOI 10.1016/J.COLSURFA.2004.11.050##KOOPAL LK, 1994, J COLLOID INTERF SCI, V166, P51, DOI 10.1006/JCIS.1994.1270##MEEUSSEN JCL, 2003, ENVIRON SCI TECHNOL, V37, P1175, DOI 10.1021/ES025597S##MILNE CJ, 2001, ENVIRON SCI TECHNOL, V35, P2049, DOI 10.1021/ES000123J##NAMJESNIK-DEJANOVIC K, 2000, SOIL SCI, V165, P545, DOI 10.1097/00010694-200007000-00003##PARFITT RL, 1977, J SOIL SCI, V28, P289, DOI 10.1111/J.1365-2389.1977.TB02237.X##PERONA MJ, 1985, J COLLOID INTERF SCI, V106, P64, DOI 10.1016/0021-9797(85)90381-9##REILLER P, 2006, ENVIRON SCI TECHNOL, V40, P2235, DOI 10.1021/ES0520518##RIETRA RPJJ, 2000, J COLLOID INTERF SCI, V229, P199, DOI 10.1006/JCIS.2000.6982##SAITO T, 2004, LANGMUIR, V20, P689, DOI 10.1021/LA034806Z##SCHLAUTMAN MA, 1994, GEOCHIM COSMOCHIM AC, V58, P4293, DOI 10.1016/0016-7037(94)90334-4##SCHULTHESS CP, 1991, SOIL SCI SOC AM J, V55, P34, DOI 10.2136/SSSAJ1991.03615995005500010006X##SPECHT CH, 2000, WATER RES, V34, P4063, DOI 10.1016/S0043-1354(00)00148-2##SWIFT R.S, 1996, METHODS SOIL ANAL 3##TIPPING E, 1981, GEOCHIM COSMOCHIM AC, V45, P191, DOI 10.1016/0016-7037(81)90162-9##VAN ZOMEREN A, 2004, ENVIRON SCI TECHNOL, V38, P3927, DOI 10.1021/ES035266V##VERMEER AWP, 1998, LANGMUIR, V14, P2810, DOI 10.1021/LA970624R##VREYSEN S, 2006, APPL CLAY SCI, V32, P190, DOI 10.1016/J.CLAY.2006.03.007##WENG LP, 2005, GEOCHIM COSMOCHIM AC, V69, P325, DOI 10.1016/J.GCA.2004.07.002##WENG LP, IN PRESS J COLLOID I",172,2020-11-20,NA
J,WOS:000242793400064,2006,STRUGGLE FOR QUALITY IN DETERMINATION OF PERFLUORINATED CONTAMINANTS IN ENVIRONMENTAL AND HUMAN SAMPLES,"THE FIRST WORLDWIDE INTERLABORATORY STUDY ON THE ANALYSES OF 13 PERFLUORINATED COMPOUNDS (PFCS) IN THREE ENVIRONMENTAL AND TWO HUMAN SAMPLES INDICATES A VARYING DEGREE OF ACCURACY IN RELATION TO THE MATRIX OR ANALYTE DETERMINED. THE ABILITY OF 38 PARTICIPATING LABORATORIES FROM 13 COUNTRIES TO DETERMINE THE ANALYTES IN THE VARIOUS MATRICES WAS EVALUATED BY CALCULATION OF Z-SCORES ACCORDING TO THE COFINO MODEL. THE PFCS WHICH WERE REPORTED MOST FREQUENTLY BY THE LABORATORIES, AND ASSESSED WITH THE MOST SATISFACTORY AGREEMENT, WERE PERFLUOROOCTANE SULFONATE (PFOS) AND PERFLUOROOCTANOIC ACID (PFOA). IN GENERAL, THE LEVEL OF AGREEMENT BETWEEN THE PARTICIPATING LABORATORIES DECREASED IN THE FOLLOWING ORDER: PFC STANDARD SOLUTION (76% SATISFACTORY Z-SCORES OF <VERTICAL BAR 2 VERTICAL BAR FOR PFOS) < HUMAN BLOOD (67%)< HUMAN PLASMA (63%)< FISH LIVER EXTRACT (55%) < WATER (31%) < FISH TISSUE (17%). THIS SHOWS THAT RELATIVE GOOD AGREEMENT BETWEEN LABORATORIES WAS OBTAINED FOR THE STUDY OF STANDARD AND HUMAN MATRICES. FOR THE FISH EXTRACT, MOST LABORATORIES UNDERESTIMATED THE ACTUAL PFOS CONCENTRATION DUE TO MATRIX EFFECTS. THE RESULTS FOR THE FISH TISSUE AND WATER ARE ALSO POOR, INDICATING THAT THE EXTRACTION AND CLEANUP STEPS REQUIRE FURTHER IMPROVEMENT. IT WAS CONCLUDED THAT THE PFC DETERMINATIONS IN VARIOUS MATRICES ARE NOT YET FULLY MASTERED.",MASS-SPECTROMETRY; ACIDS; FLUOROCHEMICALS; SUBSTANCES; CHAIN; BLOOD; BIOTA,NA,ENVIRONMENTAL SCIENCE & TECHNOLOGY,"VAN LEEUWEN, SPJ##KARRMAN, A##VAN BAVEL, B##DE BOER, J##LINDSTROM, G","FREE UNIV AMSTERDAM, INST ENVIRONM STUDIES, IVM, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV OREBRO, MAN TECHNOL ENVIRONM RES CTR MTM, SE-70182 OREBRO, SWEDEN.","ENGINEERING, ENVIRONMENTAL; ENVIRONMENTAL SCIENCES",ENGINEERING; ENVIRONMENTAL SCIENCES & ECOLOGY,"BERGER U, 2005, J CHROMATOGR A, V1081, P210, DOI 10.1016/J.CHROMA.2005.05.064##COFINO WP, 2000, CHEMOMETR INTELL LAB, V53, P37, DOI 10.1016/S0169-7439(00)00093-9##DE BOER J, 2006, TRAC-TREND ANAL CHEM, V25, P364, DOI 10.1016/J.TRAC.2006.01.008##DEBOER J, 2002, CHEMOSPHERE, P46##HANSEN KJ, 2001, ENVIRON SCI TECHNOL, V35, P766, DOI 10.1021/ES001489Z##HOFF PT, 2003, ENVIRON TOXICOL CHEM, V22, P608, DOI 10.1002/ETC.5620220320##KANNAN K, 2005, ARCH ENVIRON CON TOX, V48, P559, DOI 10.1007/S00244-004-0133-X##KANNAN K, 2004, ENVIRON SCI TECHNOL, V38, P4489, DOI 10.1021/ES0493446##KARRMAN A, 2005, ANAL CHEM, V77, P864, DOI 10.1021/AC049023C##MARTIN JW, 2004, ENVIRON SCI TECHNOL, V38, P373, DOI 10.1021/ES034727+##MARTIN JW, 2004, ENVIRON SCI TECHNOL, V38, P248A, DOI 10.1021/ES0405528##QUEVAUVILLER P, 1999, INTERLABORATORY STUD, V22##VERREAULT J, 2005, ENVIRON SCI TECHNOL, V39, P7439, DOI 10.1021/ES051097Y##WELLS DE, 1997, MAR POLLUT BULL, V35, P18, DOI 10.1016/S0025-326X(97)00120-3##YAMASHITA N, 2004, ENVIRON SCI TECHNOL, V38, P5522, DOI 10.1021/ES0492541##YAMASHITA N, 2005, MAR POLLUT BULL, V51, P658, DOI 10.1016/J.MARPOLBUL.2005.04.026",108,2020-11-20,NA
J,WOS:000242827700005,2006,STABILITY OF SITTING POSTURES: THE INFLUENCE OF DEGREES OF FREEDOM,"OBSERVATIONAL STUDIES OF SITTING HAVE SHOWN THAT, DURING SPONTANEOUS SITTING, PEOPLE ADOPT A VARIETY OF POSTURES. VARIOUS RESEARCHERS HAVE FORMULATED THEORIES TO EXPLAIN WHY PEOPLE ADOPT THEIR SITTING POSTURES. BRANTON (1969) HYPOTHESIZED THAT THERE IS CONTINUAL NEED FOR POSTURAL STABILITY WHILE SITTING. DEMPSTER (1955) STATED THAT ADDITIONAL STABILITY COULD BE OBTAINED THROUGH TEMPORARILY CLOSING CHAINS OF BODY SEGMENTS, OR, IN OTHER WORDS, THROUGH DECREASING THE NUMBER OF DEGREES OF FREEDOM OF THE BODY. THE PRESENT STUDY ELABORATES ON DEMPSTER'S THEORY. THE AIM OF THIS STUDY WAS TO DETERMINE THE INFLUENCE OF THE DEGREES OF FREEDOM OF THE BODY ON POSTURAL STABILITY IN SITTING POSTURES. FOR 21 DIFFERENT SITTING POSTURES, THE TOTAL NUMBER OF DEGREES OF FREEDOM WAS DETERMINED. POSTURAL SWAY, A MEASURE FOR POSTURAL STABILITY, WAS DETERMINED USING A 3D MOTION AND POSITION MEASUREMENT SYSTEM WITH TEN HEALTHY SUBJECTS. THIS STUDY SHOWS THAT THE MEAN PATH LENGTH AT THE LEVEL OF THE SECOND THORACIC VERTEBRA (PL0.05), A MEASURE DERIVED FROM POSTURAL SWAY, INCREASES SIGNIFICANTLY (P < 0.0001) WITH AN INCREASE OF THE NUMBER OF DEGREES OF FREEDOM OF THE BODY (DOF(B)). CLOSER EXAMINATION OF THE DATA SHOWED THAT A MODEL TAKING INTO ACCOUNT ONLY THE DEGREES OF FREEDOM OF THE LUMBAR AND THORACIC SPINE AND PELVIS SEEMS TO BE A BETTER PREDICTOR OF POSTURAL SWAY THAN THE TOTAL NUMBER OF DEGREES OF FREEDOM OF THE BODY.",BEHAVIOUR; TRUNK,POSTURAL STABILITY; POSTURAL SWAY; CLOSED-CHAIN THEORY; DEGREES OF FREEDOM; SITTING BEHAVIOUR; OBSERVATIONAL STUDIES,ERGONOMICS,"HENDRIKS, HM##SPOORX, CW##DE JONG, AM##GOOSSENS, RHM","DELFT UNIV TECHNOL, FAC IND DESIGN ENGN, SECT APPL ERGONOM & DESIGN, NL-2628 CE DELFT, NETHERLANDS. ERASMUS UNIV, SCH MANAGEMENT, DEPT MANAGEMENT TECHNOL & INNOVAT, NL-3000 DR ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT BIOMED PHYS & TECHNOL, NL-3015 GE ROTTERDAM, NETHERLANDS.","ENGINEERING, INDUSTRIAL; ERGONOMICS; PSYCHOLOGY, APPLIED; PSYCHOLOGY",ENGINEERING; PSYCHOLOGY,"AKERBLOM B, 1988, POSTURE SITTING STAN, P51##ANDERSSON G B J, 1979, SPINE, V4, P52, DOI 10.1097/00007632-197901000-00009##BHATTACHARYA A, 1987, ANN BIOMED ENG, V15, P533, DOI 10.1007/BF02364247##BRANTON P, 1969, ERGONOMICS, V12, P316, DOI 10.1080/00140136908931055##BRANTON P, 1967, ERGONOMICS, V10, P35, DOI 10.1080/00140136708930838##BRANTON P, 1966, POSTURE SITTING STAN, P70##CARON O, 2003, NEUROSCI LETT, V340, P83, DOI 10.1016/S0304-3940(02)01455-6##CHOLEWICKI J, 2000, J BIOMECH, V33, P1733, DOI 10.1016/S0021-9290(00)00126-3##COE JB, 1983, P 20 ANN C ERG SOC A, P119##COERMANN R, 1964, INT Z ANGEW PHYSIOL, V20, P376##DEMPSTER WT, 1955, ANN NY ACAD SCI, V63, P559, DOI 10.1111/J.1749-6632.1955.TB32112.X##GRANDJEAN E, 1977, APPL ERGON, V8, P135, DOI 10.1016/0003-6870(77)90002-3##HARRISON DD, 1999, J MANIP PHYSIOL THER, V22, P594, DOI 10.1016/S0161-4754(99)70020-5##HASAN SS, 1992, IEEE ENG MED BIOL, V11, P35, DOI 10.1109/51.256956##HASAN SS, 1996, GAIT POSTURE, V4, P11##HASAN SS, 1990, 12TH ANN INT C IEEE, V12, P2105##HELBIG K, 1978, ANTHROPOL ANZ, V36, P194##HOOGVLIET P., 1997, THESIS ERASMUS U ROT##KAMPER DG, 2000, J REHABIL RES DEV, V37, P81##KERR HM, 2002, CLIN BIOMECH, V17, P555, DOI 10.1016/S0268-0033(02)00068-2##KINCL LAUREL D, 2002, APPL OCCUP ENVIRON HYG, V17, P256, DOI 10.1080/10473220252826565##LIN F, 2006, ARCH PHYS MED REHAB, V87, P504, DOI 10.1016/J.APMR.2005.11.031##MAYAGOITIA RE, 2002, GAIT POSTURE, V16, P55, DOI 10.1016/S0966-6362(01)00199-0##MOE-NILSSEN R, 2002, GAIT POSTURE, V16, P60, DOI 10.1016/S0966-6362(01)00200-4##MOLLOY CA, 2003, J AUTISM DEV DISORD, V33, P643, DOI 10.1023/B:JADD.0000006001.00667.4C##REINECKE S, 1994, HARD FACTS SOFT MACH, P193##RIEDEL SA, 1992, IEEE ENG MED BIOL, V11, P42, DOI 10.1109/51.256958##SACKLEY CM, 2005, CLIN REHABIL, V19, P746, DOI 10.1191/0269215505CR863OA##SNIJDERWS CJ, 1995, BIOMECHANICA SPIERSK##WEBBER A, 2004, EXP BRAIN RES, V155, P450, DOI 10.1007/S00221-003-1743-7##WINTER D., 1990, BIOMECHANICS MOTOR C##YASUKOUCHI AKIRA, 1995, APPLIED HUMAN SCIENCE, V14, P15",3,2020-11-20,NA
J,WOS:000242827700006,2006,THE EFFECTS OF SHOULDER LOAD AND PINCH FORCE ON ELECTROMYOGRAPHIC ACTIVITY AND BLOOD FLOW IN THE FOREARM DURING A PINCH TASK,"THE OBJECT OF THE CURRENT STUDY WAS TO DETERMINE WHETHER STATIC CONTRACTION OF PROXIMAL MUSCULATURE HAS AN EFFECT ON THE BLOOD FLOW MORE DISTALLY IN THE UPPER EXTREMITY. STATIC CONTRACTIONS OF MUSCLES IN THE NECK SHOULDER REGION AT THREE LEVELS (RELAXED, SHOULDERS ELEVATED AND SHOULDERS ELEVATED LOADED WITH 4.95 KG EACH) WERE COMBINED WITH INTERMITTENT PINCH FORCES AT 0, 10 AND 25% OF THE MAXIMUM VOLUNTARY CONTRACTION (MVC). BLOOD FLOW TO THE FOREARM WAS MEASURED WITH DOPPLER ULTRASOUND. MYOELECTRIC ACTIVITY OF THE FOREARM AND NECK-SHOULDER MUSCLES WAS RECORDED TO CHECK FOR THE WORKLOAD LEVELS. ACROSS ALL LEVELS OF SHOULDER LOAD, BLOOD FLOW INCREASED SIGNIFICANTLY WITH INCREASING PINCH FORCE (21% AT 10% MVC AND BY 44% AT 25% MVC). BLOOD FLOW WAS SIGNIFICANTLY AFFECTED BY SHOULDER LOAD, WITH THE LOWEST BLOOD FLOW AT THE HIGHEST SHOULDER LOAD. INTERACTIONS OF PINCH FORCE AND SHOULDER LOAD WERE NOT SIGNIFICANT. THE MYOELECTRIC ACTIVITY OF FOREARM MUSCLES INCREASED WITH INCREASING PINCH FORCE. THE ACTIVATION OF THE TRAPEZIUS MUSCLE DECREASED WITH INCREASING PINCH FORCE AND INCREASED WITH INCREASING SHOULDER LOAD. THE PRECISE MECHANISMS ACCOUNTING FOR THE INFLUENCE OF SHOULDER LOAD REMAINS UNCLEAR. THE RESULTS OF THIS STUDY INDICATE THAT SHOULDER LOAD MIGHT INFLUENCE BLOOD FLOW TO THE FOREARM.",INTRAMUSCULAR PRESSURE; UPPER-EXTREMITY; MUSCLE-ACTIVITY; EXERCISE; WORK; ARM; DISORDERS; ONSET; PAIN,UPPER EXTREMITY MUSCULOSKELETAL DISORDERS; ELECTROMYOGRAPHY; BLOOD FLOW; COMPUTER WORK,ERGONOMICS,"VISSER, B##NIELSEN, PK##DE KRAKER, H##SMITS, M##JENSEN, BR##VEEGER, D##VAN DIEEN, JH","VRIJE UNIV AMSTERDAM, FAC HUMAN MOVEMENT SCI, INST FUNDAMENTAL & CLIN HUMAN MOVEMENT SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. TNO, VUMC, RES CTR PHYS ACTIVITY, AMSTERDAM, NETHERLANDS. NATL INST OCCUPAT HLTH, DEPT PHYSIOL, COPENHAGEN, DENMARK. DELFT UNIV TECHNOL, LAB MEASUREMENT & CONTROL, DELFT, NETHERLANDS. UNIV COPENHAGEN, INST EXERCISE & SPORT SCI, DEPT HUMAN PHYSIOL, COPENHAGEN, DENMARK.","ENGINEERING, INDUSTRIAL; ERGONOMICS; PSYCHOLOGY, APPLIED; PSYCHOLOGY",ENGINEERING; PSYCHOLOGY,"BERNARD B., 1997, MUSCULOSKELETAL DISO##BUCKLE P, 1999, WORK RELATED NECK UP##BYSTROM S, 1998, SCAND J CLIN LAB INV, V58, P569, DOI 10.1080/00365519850186193##BYSTROM SEG, 1990, EUR J APPL PHYSIOL O, V60, P457, DOI 10.1007/BF00705037##CARAYON P, 1999, HUM FACTORS, V41, P644, DOI 10.1518/001872099779656743##COLETTA JM, 2001, CARDIOVASC SURG, V9, P11, DOI 10.1016/S0967-2109(00)00092-2##EDWARDS RHT, 1988, EUR J APPL PHYSIOL O, V57, P275, DOI 10.1007/BF00635985##GRUCZA R, 1989, EUR J APPL PHYSIOL O, V59, P184, DOI 10.1007/BF02386185##HARMS CA, 2000, MED SCI SPORT EXER, V32, P94##HISDAL J, 2004, EUR J APPL PHYSIOL, V91, P336, DOI 10.1007/S00421-003-0982-4##HUGHSON RL, 1996, J APPL PHYSIOL, V81, P1619##JARVHOLM U, 1988, EUR J APPL PHYSIOL, V58, P219, DOI 10.1007/BF00417252##JEKA JJ, 1994, EXP BRAIN RES, V100, P495, DOI 10.1007/BF02738408##JENSEN BR, 1993, ACTA PHYSIOL SCAND, V147, P203, DOI 10.1111/J.1748-1716.1993.TB09490.X##JENSEN BR, 1995, EUR J MORPHOL, V33, P205##JENSEN BR, 1997, ADV OCCUPATIONAL MED, V3, P21##JONSSON B, 1988, EUR J APPL PHYSIOL, V57, P305, DOI 10.1007/BF00635988##KADEFORS R, 1999, ERGONOMICS, V42, P359, DOI 10.1080/001401399185711##KAGAYA A, 1994, EUR J APPL PHYSIOL, V68, P252, DOI 10.1007/BF00376774##KAGAYA A, 1992, J EXERC SCI, V2, P5##KELLER K, 1998, J HAND THER, V11, P9##KILBOM A, 1976, EUR J APPL PHYSIOL, V36, P7, DOI 10.1007/BF00421629##KROEMER KHE, 1989, APPL ERGON, V20, P274, DOI 10.1016/0003-6870(89)90190-7##KUORINKA I, 1987, APPL ERGON, V18, P233, DOI 10.1016/0003-6870(87)90010-X##LARSSON SE, 2003, CHRONIC WORK RELATED, P111##MUGGLETON JM, 1999, ERGONOMICS, V42, P714, DOI 10.1080/001401399185405##MURTHY G, 1997, J ORTHOPAED RES, V15, P507, DOI 10.1002/JOR.1100150405##OGITA F, 1996, EUR J APPL PHYSIOL O, V73, P511, DOI 10.1007/BF00357672##PRITCHARD MH, 1999, RHEUMATOLOGY, V38, P636, DOI 10.1093/RHEUMATOLOGY/38.7.636##RADEGRAN G, 1998, AM J PHYSIOL-HEART C, V274, PH314##RAYAN GM, 1998, J SHOULDER ELB SURG, V7, P440, DOI 10.1016/S1058-2746(98)90042-8##ROE C, 2002, INT J IND ERGONOM, V30, P251, DOI 10.1016/S0169-8141(02)00129-4##SAITO M, 1992, ACTA PHYSIOL SCAND, V146, P449, DOI 10.1111/J.1748-1716.1992.TB09446.X##SJOGAARD G, 2000, EUR J APPL PHYSIOL, V83, P99, DOI 10.1007/S004210000285##SJOGAARD G, 1998, CLIN ORTHOP RELAT R, P21##SLUITER JK, 2001, SCAND J WORK ENV HEA, V27, P1##VAN GALEN GP, 2002, AM J IND MED, V41, P406, DOI 10.1002/AJIM.10051##VISSER B, 2000, CLIN BIOMECH, V15, PS34, DOI 10.1016/S0268-0033(00)00058-9##VISSER B, 2003, J ELECTROMYOGR KINES, V13, P149, DOI 10.1016/S1050-6411(02)00108-6##WESTGAARD RH, 1996, ELECTROMYOGRAPHY ERG, P227##WILLIAMS CA, 1991, J PHYSIOL-LONDON, V435, P573, DOI 10.1113/JPHYSIOL.1991.SP018526",5,2020-11-20,NA
J,WOS:000243230900020,2006,AUTOCORRELATED GROWTH OF TROPICAL FOREST TREES: UNRAVELING PATTERNS AND QUANTIFYING CONSEQUENCES,"TROPICAL TREES SHOW CONSIDERABLE VARIATION IN GROWTH RATES. OFTEN THIS VARIATION IS NOT RANDOM, AS SOME TREES PERFORM BETTER THAN OTHERS AND AS GROWTH MAY BE TEMPORALLY CORRELATED. USING LONG-TERM GROWTH DATA OBTAINED FROM TREE RING ANALYSIS, WE STUDIED THE DEGREE TO WHICH GROWTH RATES OF FOUR BOLIVIAN RAINFOREST TREE SPECIES WERE AUTOCORRELATED AND HOW THIS AFFECTED THE OUTPUT OF GROWTH SIMULATIONS. AUTOCORRELATED GROWTH IS COMMONLY DEFINED AS THE CORRELATION BETWEEN GROWTH IN ONE TIME INTERVAL WITH THAT IN A SUBSEQUENT INTERVAL CALCULATED OVER ALL INDIVIDUALS OF THE POPULATION. WE TERMED THIS TOTAL AUTOCORRELATED GROWTH AND IDENTIFIED ITS TWO COMPONENTS: TEMPORALLY COT-RELATED GROWTH RATES OF INDIVIDUAL TREES (WITHIN-TREE AUTOCORRELATED GROWTH) AND PERSISTENT GROWTH DIFFERENCES BETWEEN TREES (AMONG-TREE AUTOCORRELATED GROWTH). TOTAL AUTOCORRELATED GROWTH WAS HIGH (PEARSON'S R SIMILAR TO 0.75) BETWEEN GROWTH RATES OF SUBSEQUENT YEARS AND DECREASED GRADUALLY AT LARGER TIME LAGS. AT TIME LAGS OF 20 YEARS GROWTH RATES WERE STILL POSITIVELY AUTOCORRELATED IN SOME SPECIES. JUVENILE TREES TEND TO HAVE STRONG WITHIN-TREE AUTOCORRELATED GROWTH (PEARSON'S R SIMILAR TO 0.4-0.5), PROBABLY MAINLY CAUSED BY TEMPORALLY CORRELATED VARIATION IN LIGHT AVAILABILITY DUE TO CANOPY DYNAMICS. THE WITHIN-TREE AUTOCORRELATION WAS CONSIDERABLY LOWER IN LARGER TREES (PEARSON'S R < 0.2), AND DID - IN CONTRAST TO JUVENILE TREES - NOT CONTRIBUTE MUCH TO TOTAL AUTOCORRELATION. IN LARGER TREES TOTAL AUTOCORRELATION ORIGINATED MOSTLY FROM PERSISTENT GROWTH DIFFERENCES AMONG TREES, CAUSED BY FACTORS AS SITE-SPECIFIC DIFFERENCES OR DIFFERENCES AMONG TREES IN CROWN AREA OR LIANA INFESTATIONS. AMONG-TREE AUTOCORRELATED GROWTH WAS STRONG AND LONG-LASTING: DIFFERENCES BETWEEN FAST AND SLOW GROWING TREES WERE MAINTAINED FOR LONG PERIODS. INCORPORATION OF AUTOCORRELATED GROWTH IN BOOTSTRAP SIMULATION MODELS LED TO HIGHER VARIATION IN AGE ESTIMATES COMPARED TO SIMULATIONS WITHOUT AUTOCORRELATION. STILL, THIS VARIATION WAS LOWER THAN THAT OBSERVED IN TREE RINGS. BY USING 5-YEAR GROWTH STEPS INSTEAD OF THE I-YEAR GROWTH STEPS THE OBSERVED VARIATION INCREASED AND CLOSELY MATCHED THOSE IN TREE RINGS. OUR FINDINGS EMPHASIZE THE IMPORTANCE OF INCORPORATING AUTOCORRELATED GROWTH IN TREE GROWTH SIMULATION MODELS, FOR OBTAINING MORE REALISTIC ESTIMATES OF LONG-TERM GROWTH AND TREE AGES. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NEOTROPICAL RAIN-FOREST; TIME-SERIES ANALYSES; POPULATION-DYNAMICS; RING ANALYSIS; CANOPY; HISTORY; RECRUITMENT; STORAGE; HEIGHT; CURVES,BOOTSTRAPPED SIMULATIONS; SIZE-DEPENDENT GROWTH; SIZE VARIABILITY; TREE AGE; TEMPORAL AUTOCORRELATION,FOREST ECOLOGY AND MANAGEMENT,"BRIENEN, RJW##ZUIDEMA, PA##DURING, HJ","UNIV UTRECHT, DEPT PLANT ECOL, NL-3508 TB UTRECHT, NETHERLANDS. PROGRAMA MANEJO BOSQUES AMAZONIA BOLIVIANA, PROMAB, RIBERALTA, BOLIVIA.",FORESTRY,FORESTRY,"ARETS EJM, 2005, TROPENBOS GUYANA SER, V13, P191##BOX G. E. P., 1976, TIME SERIES ANAL##BRIENEN RJW, 2006, J ECOL, V94, P481, DOI 10.1111/J.1365-2745.2005.01080.X##BRIENEN RJW, 2005, OECOLOGIA, V146, P1, DOI 10.1007/S00442-005-0160-Y##BULLOCK SH, 2004, ECOLOGY, V85, P2114, DOI 10.1890/03-3115##CANHAM CD, 1985, B TORREY BOT CLUB, V112, P145##CASPER BB, 1997, ANNU REV ECOL SYST, V28, P545, DOI 10.1146/ANNUREV.ECOLSYS.28.1.545##CHAPIN FS, 1990, ANNU REV ECOL SYST, V21, P423, DOI 10.1146/ANNUREV.ECOLSYS.21.1.423##CLARK DA, 2001, ECOLOGY, V82, P1460, DOI 10.1890/0012-9658(2001)082[1460:GTTCTH]2.0.CO;2##CLARK DA, 1999, ECOL APPL, V9, P981, DOI 10.1890/1051-0761(1999)009[0981:ATGOTR]2.0.CO;2##CLARK DA, 1992, ECOL MONOGR, V62, P315, DOI 10.2307/2937114##CLARK DB, 1990, J TROP ECOL, V6, P321, DOI 10.1017/S0266467400004570##CONDIT R, 1993, FOREST ECOL MANAG, V62, P123, DOI 10.1016/0378-1127(93)90046-P##CONDIT R, 1995, ECOL MONOGR, V65, P419, DOI 10.2307/2963497##DEANGELIS DL, 1993, AM NAT, V142, P604, DOI 10.1086/285560##FOX JC, 2001, FOREST ECOL MANAG, V154, P261, DOI 10.1016/S0378-1127(00)00632-0##FRITTS H.C., 1976, TREE RINGS CLIMATE##FUJIWARA M, 2004, ECOL LETT, V7, P106, DOI 10.1046/J.1461-0248.2003.00556.X##KAMMESHEIDT L, 2003, FOREST ECOL MANAG, V174, P437, DOI 10.1016/S0378-1127(02)00077-4##KOBE RK, 1997, OIKOS, V80, P226, DOI 10.2307/3546590##KOHYAMA T, 1989, ANN BOT-LONDON, V64, P47, DOI 10.1093/OXFORDJOURNALS.AOB.A087807##KOHYAMA T, 2005, ECOL RES, V20, P11, DOI 10.1007/S11284-004-0007-8##LANDIS RM, 2005, ECOLOGY, V86, P63, DOI 10.1890/03-0848##LANDIS RM, 1999, THESIS DARTMOUTH COL, P111##LAURANCE WF, 2004, FOREST ECOL MANAG, V190, P131, DOI 10.1016/J.FORECO.2003.09.011##LIEBERMAN D, 1985, J ECOL, V73, P915, DOI 10.2307/2260157##LIEBERMAN M, 1985, ECOLOGY, V66, P632, DOI 10.2307/1940415##LUSK CH, 1998, ECOLOGY, V79, P795, DOI 10.1890/0012-9658(1998)079[0795:LHDATS]2.0.CO;2##MONSERUD RA, 1986, FOREST SCI, V32, P349##OBRIEN ST, 1995, ECOLOGY, V76, P1926, DOI 10.2307/1940724##ORWIG DA, 1994, CAN J FOREST RES, V24, P2141, DOI 10.1139/X94-276##PACIOREK CJ, 2000, J ECOL, V88, P765, DOI 10.1046/J.1365-2745.2000.00494.X##PFISTER CA, 2003, ECOLOGY, V84, P496, DOI 10.1890/0012-9658(2003)084[0496:IVAESI]2.0.CO;2##PFISTER CA, 2002, ECOLOGY, V83, P59##PUTZ FE, 1984, ECOLOGY, V65, P1713, DOI 10.2307/1937767##SHEIL D, 1995, FOREST ECOL MANAG, V77, P11, DOI 10.1016/0378-1127(95)03583-V##SWAINE MD, 1987, J TROP ECOL, V3, P331, DOI 10.1017/S0266467400002315##SWAINE MD, 1988, VEGETATIO, V75, P81, DOI 10.1007/BF00044629##TERBORGH J., 1997, JOURNAL OF TROPICAL ECOLOGY, V13, P833, DOI 10.1017/S0266467400011020##VANDERMEER PJ, 1996, VEGETATIO, V126, P167, DOI 10.1007/BF00045602##WOOLLONS RC, 1990, NEW ZEAL J ECOL, V13, P9##ZAGT R. J., 1997, TREE DEMOGRAPHY IN THE TROPICAL RAIN FOREST OF GUYANA.##ZUIDEMA PA, 2002, J TROP ECOL, V18, P1, DOI 10.1017/S0266467402002018##1999, SUPERINTENDENCIA FOR",56,2020-11-20,NA
J,WOS:000243230900025,2006,"EFFECTS OF LIMING, SOD-CUTTING AND FERTILIZATION AT AMBIENT AND DECREASED NITROGEN DEPOSITION ON THE SOIL SOLUTION CHEMISTRY IN A SCOTS PINE FOREST IN THE NETHERLANDS","THE DUTCH GOVERNMENT HAS COMMITTED ITSELF TO REDUCE NITROGEN DEPOSITION TO FORESTS IN 2010 TO THE TARGET (CRITICAL LOAD) VALUE OF 15-20 KG N HA(-1) YEAR(-1), WHILE AT PRESENT THE N INPUT IS ABOUT 45 KG N HA(-1) YEAR(-1). IN 2001, A FIELD EXPERIMENT WAS STARTED BELOW A ROOF WITH THE REDUCED N INPUT, INCLUDING THREE MANAGEMENT OPTIONS (LIMING, SOD-CUTTING AND FERTILIZATION). OUTSIDE THE ROOF THE SAME TREATMENTS WERE APPLIED AT AMBIENT DEPOSITION. IN THIS WAY THE EFFECTIVENESS OF THESE TREATMENTS CAN BE EVALUATED AT TWO N INPUT LEVELS, SINCE THESE MANAGEMENT OPTIONS WERE DEVELOPED IN TIMES WHEN THE N DEPOSITION WAS VERY HIGH. THREE YEARS AFTER THE START OF THE TREATMENT IT IS CONCLUDED THAT REDUCING THE N INPUT IS A KEY FACTOR IN RESTORING THE SOIL SOLUTION CHEMISTRY. ESPECIALLY IN THE LOW DEPOSITION SOD-CUT AND FERTILIZER TREATMENTS THE AMMONIUM AND NITRATE CONCENTRATIONS HAVE DECREASED SIGNIFICANTLY. AT ALL LOW DEPOSITION TREATMENTS THE NUTRITIONAL BALANCE IN THE SOIL SOLUTION HAS IMPROVED. AT 90 CM DEPTH LEACHING OF NITRATE TO THE GROUND WATER HAS DIMINISHED, JUST LIKE THE LEACHING OF K, MG AND CA AS COMPANYING BASE CATIONS. REMOVING N FROM THE ECOSYSTEM BY SOD-CUTTING IN COMBINATION WITH A DEPOSITION REDUCTION SEEMS AT THIS MOMENT THE MOST FAVOURABLE SOLUTION. SINCE LIMING AND FERTILIZATION ARE AIMED TO HAVE EFFECTS FOR AT LEAST 20 AND 10 YEARS, RESPECTIVELY, IT IS INTERESTING TO MONITOR ECOSYSTEM RESPONSE FOR A LONGER TIME. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",VEGETATION; ECOSYSTEMS,FERTILIZATION; FOREST MANAGEMENT; LIRNMG; NITROGEN DEPOSITION; SCOTS PINE; SOD-CUTTING; SOIL SOLUTION CHEMISTRY,FOREST ECOLOGY AND MANAGEMENT,"BOXMAN, AW##ROELOFS, JGM","RADBOUD UNIV NIJMEGEN, DEPT ECOL, NL-6500 GL NIJMEGEN, NETHERLANDS.",FORESTRY,FORESTRY,"ABER JD, 1989, BIOSCIENCE, V39, P378, DOI 10.2307/1311067##BINKLEY D, 1986, FOREST NUTR MANAGEME, P304##BOBBINK R, 1992, CRITICAL LOADS NITRO, P11##BOXMAN AW, 1998, FOREST ECOL MANAG, V101, P65, DOI 10.1016/S0378-1127(97)00126-6##BOXMAN AW, 1998, FOREST ECOL MANAG, V101, P155, DOI 10.1016/S0378-1127(97)00132-1##DISE NB, 1995, FOREST ECOL MANAG, V71, P153, DOI 10.1016/0378-1127(94)06092-W##DORLAND E, 2004, PLANT SOIL, V265, P267, DOI 10.1007/S11104-005-0363-3##GUNDERSEN P, 1998, FOREST ECOL MANAG, V101, P37, DOI 10.1016/S0378-1127(97)00124-2##HUTTL RF, 1993, FOREST ECOL MANAG, V61, P325##KOOPMANS CJ, 1998, SOIL BIOL BIOCHEM, V30, P141, DOI 10.1016/S0038-0717(97)00116-8##KREUTZER K, 1995, PLANT SOIL, V168, P447, DOI 10.1007/BF00029358##MINDERMA.G, 1968, PLANT SOIL, V28, P61, DOI 10.1007/BF01349178##MINDRUP M., 1995, AFZ, ALLGEMEINE FORST ZEITSCHRIFT, V50, P928##REHFUESS KE, 1990, WALDBODEN ENTWICKLUN##ROELOFS JGM, 1985, PLANT SOIL, V42, P372##TAMM C.O., 1991, ECOL STUD, V81, P116##VANDENBURG J, 1995, RICHTLIJNEN MINERALE",6,2020-11-20,NA
J,WOS:000243230900037,2006,"MYCORRHIZAL FUNGAL DIVERSITY IN WILLOW FORESTS OF DIFFERENT AGE ALONG THE RIVER WAAL, THE NETHERLANDS","IN THE NETHERLANDS, RIPARIAN EDGE FORESTS ARE OFTEN DOMINATED BY SALIX SPECIES BECAUSE THEY ARE WELL ADAPTED TO ANAEROBIC SOIL CONDITIONS. WILLOWS PLAY THEREFORE AN IMPORTANT ROLE IN REHABILITATION OF NATURAL RIPARIAN EDGE FORESTS. THEY ASSOCIATE WITH BOTH ARBUSCULAR MYCORRHIZAL (AM) AND ECTOMYCORRHIZAL (EM) FUNGI WHICH ARE ESSENTIAL FOR SUCCESSFUL RESTORATION OF NATURAL ECOSYSTEMS, BUT IT IS STILL UNKNOWN WHAT COMMUNITIES OF MYCORRHIZAL FUNGI DEVELOP ON SALIX SPECIES IN THIS ENVIRONMENT. SALIX ALBA L. (WHITE WILLOW) FORESTS OF THREE DIFFERENT AGES (10, 20 AND 60 YEARS OLD) UNDER RESTORATION MANAGEMENT ALONG THE RIVER WAAL WERE STUDIED BY MOLECULAR TECHNIQUES TO DESCRIBE SPECIES COMPOSITION OF MYCORRHIZAL FUNGI IN ROOTS AND SOIL SURROUNDING THE TREES. PRESENCE OF AM COLONIZATION WAS NOT DETERMINED IN THE ROOTS OF S. ALBA AND ONLY EM FUNGI WERE OBSERVED. FREQUENCIES OF EM ROOT TIPS WERE BELOW 9% AT ALL SITES. TWELVE TYPES OF MYCORRHIZAT FUNGI WERE DISTINGUISHED IN THE ROOTS. THE MYCORRHIZAL BELOW-GROUND COMMUNITIES WERE DOMINATED BY TUBER SPECIES AND TO OUR BEST KNOWLEDGE, THIS IS THE FIRST MOLECULAR INDICATION THAT TUBER SPP. ARE ASSOCIATED WITH ROOTS OF SALIX SPECIES. THE BASIDIOMYCETOUS FUNGI INCLUDING HEBELOMA AND THELEPHOROID SPP. WERE FOUND MAINLY IN THE 20-YEAR-OLD FOREST WITH THE LOWEST SOIL NUTRIENT CONCENTRATIONS AND WERE APPARENTLY ABLE TO WITHSTAND FLOODING. A TENDENCY WAS OBSERVED FOR HIGHER FREQUENCIES OF MYCORRHIZAL ROOTS WITH LOWER NUTRIENT CONCENTRATIONS AND HIGHER SOIL PH AMONG THE SITES OF DIFFERENT AGE. THE RESULTS DEMONSTRATE THAT ONLY A LIMITED NUMBER OF MYCORRHIZAL FUNGI CAN RESIST THE HARSH CONDITIONS CAUSED BY FLOODING AND DROUGHT. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",ARBUSCULAR MYCORRHIZAL; ECTOMYCORRHIZAL FUNGI; SALIX-VIMINALIS; COLONIZATION; ENVIRONMENT; COMMUNITIES; SEEDLINGS; L.,ASCOMYCETOUS; BASIDIOMYCETOUS; FLOODPLAIN; MOLECULAR ANALYSIS; ECTOMYCORRHIZA; RIPARIAN EDGE FOREST; SALIX ALBA L.,FOREST ECOLOGY AND MANAGEMENT,"PARADI, I##BAAR, J","EOTVOS LORAND UNIV, DEPT PLANT PHYSIOL & MOL PLANT BIOL, H-1117 BUDAPEST, HUNGARY. UNIV WAGENINGEN & RES CTR, MUSHROOM UNIT, NL-5960 AA HORST, NETHERLANDS.",FORESTRY,FORESTRY,"AANEN DK, 2000, MYCOLOGIA, V92, P269, DOI 10.2307/3761560##AGERER R, 1987, COLOUR ATLAS ECTOMYC##ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/NAR/25.17.3389##ARGUS G. W., 1997, SYST BOT MONOGR, V52, P1, DOI DOI 10.2307/25096638##ARNOLDS E, 1991, AGR ECOSYST ENVIRON, V35, P209, DOI 10.1016/0167-8809(91)90052-Y##BAAR J, 2000, PLANT BIOLOGY, V2, P505, DOI 10.1055/S-2000-7468##BAAR J, 2002, MYCORRHIZA, V12, P147, DOI 10.1007/S00572-002-0158-9##BAAR J, 1997, MYCORRHIZA, V7, P94##BAUM C, 2002, FOREST ECOL MANAG, V160, P35, DOI 10.1016/S0378-1127(01)00470-4##ERLAND S, 2002, ECOL STU AN, V157, P163##GARDES M, 1993, MOL ECOL, V2, P113, DOI 10.1111/J.1365-294X.1993.TB00005.X##HASHIMOTO YASUSHI, 2003, MYCOSCIENCE, V44, P339, DOI 10.1007/S10267-003-0117-0##HOUBA VJG, 1990, COMMUN SOIL SCI PLAN, V21, P2281, DOI 10.1080/00103629009368380##JONES MD, 1990, NEW PHYTOL, V115, P259, DOI 10.1111/J.1469-8137.1990.TB00451.X##KARRENBERG S, 2002, FRESHWATER BIOL, V47, P733, DOI 10.1046/J.1365-2427.2002.00894.X##KOLJALG U, 2000, MOL ECOL, V9, P1985, DOI 10.1046/J.1365-294X.2000.01105.X##KOSKE RE, 1989, MYCOL RES, V92, P466##KUITERS AT, 2005, LEVENDE NATUUR, V106, P40##KUZOVKINA YA, 2005, WATER AIR SOIL POLL, V162, P183, DOI 10.1007/S11270-005-6272-5##MALANSON G.P., 1993, RIPARIAN LANDSCAPES##MCGONIGLE TP, 1990, NEW PHYTOL, V115, P495, DOI 10.1111/J.1469-8137.1990.TB00476.X##PUTTSEPP U, 2004, FOREST ECOL MANAG, V196, P413, DOI 10.1016/J.FORECO.2004.04.003##SASAKI A, 2001, ECOL RES, V16, P165, DOI 10.1046/J.1440-1703.2001.00382.X##SCHRODER P, 1989, GAERTN ANN SCI FOR S, V46, PS310##SMITH SE, 1997, MYCORRHIZAL SYMBIOSI##SOKAL R.R., 1995, BIOMETRY##STENSTROM E, 1991, PLANT SOIL, V131, P247, DOI 10.1007/BF00009455##SZEMERE L, 1965, UNTERIRDISCHEN PILZE##VAN DER HEIJDEN EW, 2001, MYCORRHIZA, V10, P185, DOI 10.1007/S005720000077##WHITE TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1",24,2020-11-20,NA
J,WOS:000243080400040,2006,"SPACE-TIME KALMAN FILTERING OF SOIL REDISTRIBUTION GEODERMA (VOL 133, PG 124, 2006)",NA,NA,NA,GEODERMA,"HEUVELINK, GBM##SCHOORL, JM##VELDKAMP, A##PENNOCK, DJ","UNIV WAGENINGEN & RES CTR, ENVIRONM SCI GRP, NL-6700 AA WAGENINGEN, NETHERLANDS. UNIV SASKATCHEWAN, DEPT SOIL SCI, SASKATOON, SK S7N 5A8, CANADA.",SOIL SCIENCE,AGRICULTURE,"HEUVELINK GBM, 2006, GEODERMA, V133, P124, DOI 10.1016/J.GEODERMA.2006.03.041",0,2020-11-20,NA
J,WOS:000242307800036,2006,NO MAJOR IMPACT OF MAMMOGRAPHY SCREENING ON THE AGE SPECIFIC INCIDENCE RATES OF BREAST CANCER IN THE NETHERLANDS,NA,NA,NA,INTERNATIONAL JOURNAL OF CANCER,"VERKOOIJEN, HM##FIORETTA, G##VAN DER HEIDEN, M##KOOT, VCM##BOUCHARDY, C","UNIV GENEVA, INST SOCIAL & PREVENT MED, GENEVA CANC REGISTRY, CH-1250 GENEVA, SWITZERLAND. COMPREHENS CANC CTR MIDDLE NETHERLANDS, UTRECHT, NETHERLANDS. ASSOC COMPREHENS CANC CTR, UTRECHT, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"BOUCHARDY C, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-78##HEMMINKI K, 2005, INT J CANCER, V117, P145, DOI 10.1002/IJC.21149",0,2020-11-20,NA
J,WOS:000242307800039,2006,HELICOBACTER PYLORI INFECTION APPEARS THE PRIME RISK FACTOR FOR STOMACH CANCER - REPLY TO THE LETTER TO THE EDITOR,NA,GASTRIC-CANCER,NA,INTERNATIONAL JOURNAL OF CANCER,"GONZALEZ, CA##PERA, G##AGUDO, A##PALLI, D##LINSEISEN, J##BOEING, H##JENAB, M##BUENO-DE-MESQUITA, HB##NUMANS, ME##RIBOLI, E","IDIBELL, CATALAN INST ONCOL, DEPT EPIDEMIOL, BARCELONA, SPAIN. CSPO, SCI INST TUSCANY, MOL & NUTRIT EPIDEMIOL UNIT, FLORENCE, ITALY. DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV CLIN EPIDEMIOL, D-6900 HEIDELBERG, GERMANY. GERMAN INST HUMAN NUTR, POTSDAM, GERMANY. INT AGCY RES CANC, NUTR & HORMONES GRP, F-69372 LYON, FRANCE. NATL INST PUBL HLTH & ENVIRONM, CTR NUTR & HLTH, NL-3720 BA BILTHOVEN, NETHERLANDS. UNIV UTRECHT, CTR MED, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS. UNIV LONDON IMPERIAL COLL SCI & TECHNOL, FAC MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON, ENGLAND.",ONCOLOGY,ONCOLOGY,"BLASER MJ, 2000, NAT MED, V6, P376, DOI 10.1038/74627##CORREA P, 1994, CANCER RES, V54, PS1941##GONZALEZ CA, 2003, INT J CANCER, V107, P629, DOI 10.1002/IJC.11426##GONZALEZ CA, 2006, JNCI-J NATL CANCER I, V98, P345, DOI 10.1093/JNCI/DJJ071##PARKIN DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/IJC.21731##WONG BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/JAMA.291.2.187",0,2020-11-20,NA
J,WOS:000242797700025,2006,"AGREEMENT BETWEEN COMPUTED TOMOGRAPHY, MAGNETIC RESONANCE IMAGING, AND SURGICAL FINDINGS IN DOGS WITH DEGENERATIVE LUMBOSACRAL STENOSIS","OBJECTIVE-TO ASSESS THE EXTENT OF AGREEMENT BETWEEN COMPUTED TOMOGRAPHY (CT), MAGNETIC RESONANCE IMAGING (MRI), AND SURGICAL FINDINGS IN DOGS WITH DEGENERATIVE LUMBOSACRAL STENOSIS. DESIGN-OBSERVATIONAL STUDY. ANIMALS-35 DOGS WITH DEGENERATIVE LUMBOSACRAL STENOSIS. PROCEDURES-RESULTS OF PREOPERATIVE CT AND MRI WERE COMPARED WITH SURGICAL FINDINGS WITH RESPECT TO DEGREE AND LOCATION OF DISK PROTRUSION, POSITION OF THE DURAL SAC, AMOUNT OF EPIDURAL FAT, AND SWELLING OF SPINAL NERVE ROOTS. RESULTS-A LUMBOSACRAL STEP WAS SEEN ON RADIOGRAPHIC IMAGES FROM 22 OF 32 (69%) DOGS, ON CT IMAGES FROM 23 OF 35 (66%) DOGS, AND ON MR IMAGES FROM 21 OF 35 (60%) DOGS. MOST DOGS HAD SLIGHT OR MODERATE DISK PROTRUSION THAT WAS CENTRALLY LOCATED. THERE WAS SUBSTANTIAL OR NEAR PERFECT AGREEMENT BETWEEN CT AND MRI FINDINGS IN REGARD TO DEGREE OF DISK PROTRUSION (KAPPA, 0.88), LOCATION OF DISK PROTRUSION (0.63), POSITION OF THE DURAL SAC (0.89), AMOUNT OF EPIDURAL FAT (0.72), AND SWELLING OF SPINAL NERVE ROOTS (0.60). THE DEGREE OF AGREEMENT BETWEEN CT AND SURGICAL FINDINGS AND BETWEEN MRI AND SURGICAL FINDINGS WAS MODERATE IN REGARD TO DEGREE AND LOCATION OF DISK PROTRUSION (KAPPA, 0.44 TO 0.56) AND SWELLING OF SPINAL NERVE ROOTS (0.40 AND 0.50). CONCLUSIONS AND CLINICAL RELEVANCE-RESULTS INDICATE THAT THERE IS A HIGH DEGREE OF AGREEMENT BETWEEN CT AND MRI FINDINGS IN DOGS WITH DEGENERATIVE LUMBOSACRAL STENOSIS BUT THAT THE DEGREE OF AGREEMENT BETWEEN DIAGNOSTIC IMAGING FINDINGS AND SURGICAL FINDINGS IS LOWER.",CAUDA-EQUINA SYNDROME; LARGE-BREED DOGS; RADIOGRAPHIC EVALUATION; INTERVERTEBRAL DISC; VACUUM PHENOMENON; SPINE; DIAGNOSIS; LUMBAR; ABNORMALITIES; ASSOCIATION,NA,JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION,"SUWANKONG, N##VOORHOUT, G##HAZEWINKEL, HAW##MEIJ, BP","CHIANG MAI UNIV, FAC VET MED, SMALL ANIM CLIN, CHIANG MAI 50100, THAILAND. UNIV UTRECHT, FAC VET MED, DEPT CLIN SCI COMPAN ANIM, NL-3508 TD UTRECHT, NETHERLANDS. UNIV UTRECHT, FAC VET MED, DIV DIAGNOST IMAGING, NL-3508 TD UTRECHT, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,"ADAMS WH, 1995, VET RADIOL ULTRASOUN, V36, P3, DOI 10.1111/J.1740-8261.1995.TB00204.X##AXLUND TW, 2003, VET RADIOL ULTRASOUN, V44, P630, DOI 10.1111/J.1740-8261.2003.TB00521.X##BENNETT D, 1981, J SMALL ANIM PRACT, V22, P539, DOI 10.1111/J.1748-5827.1981.TB00640.X##BRAY JP, 1998, J AM ANIM HOSP ASSOC, V34, P135, DOI 10.5326/15473317-34-2-135##CHAMBERS JN, 1997, J AM ANIM HOSP ASSOC, V33, P296, DOI 10.5326/15473317-33-4-296##DANIELSSON F, 1999, VET SURG, V28, P91, DOI 10.1053/JVET.1999.0091##DAVIDSON A.P., 2000, HEREDITARY BONE JOIN, P209##DE RISIO L, 2000, VET CLIN N AM-SMALL, V30, P111, DOI 10.1016/S0195-5616(00)50005-9##DEHAAN JJ, 1993, VET SURG, V22, P1, DOI 10.1111/J.1532-950X.1993.TB00359.X##DOHOO I., 2003, VET EPIDEMIOLOGIC RE, P85##HATHCOCK JT, 1994, VET RADIOL ULTRASOUN, V35, P285, DOI 10.1111/J.1740-8261.1994.TB02043.X##INDRIERI RJ, 1988, VET CLIN N AM-SMALL, V18, P697, DOI 10.1016/S0195-5616(88)50062-1##JONES JC, 1994, VET RADIOL ULTRASOUN, V35, P339, DOI 10.1111/J.1740-8261.1994.TB02051.X##JONES JC, 1999, VET RADIOL ULTRASOUN, V40, P108, DOI 10.1111/J.1740-8261.1999.TB01892.X##JONES JC, 1996, VET RADIOL ULTRASOUN, V37, P247, DOI 10.1111/J.1740-8261.1996.TB01226.X##JONES JC, 1995, AM J VET RES, V56, P1125##JONES JC, 1995, VET RADIOL ULTRASOUN, V36, P91, DOI 10.1111/J.1740-8261.1995.TB00223.X##JONES JC, 2000, J AM VET MED ASSOC, V216, P1769, DOI 10.2460/JAVMA.2000.216.1769##JONES JC, 2000, VET RADIOL ULTRASOUN, V41, P19, DOI 10.1111/J.1740-8261.2000.TB00421.X##KARKKAINEN M, 1993, VET RADIOL ULTRASOUN, V34, P399, DOI 10.1111/J.1740-8261.1993.TB02028.X##MATTOON JS, 1993, VET RADIOL ULTRASOUN, V34, P194, DOI 10.1111/J.1740-8261.1993.TB02005.X##MAYHEW PD, 2002, J AM ANIM HOSP ASSOC, V38, P555, DOI 10.5326/0380555##MORGAN JP, 1993, J AM VET MED ASSOC, V202, P1877##MORGAN JP, 1999, J SMALL ANIM PRACT, V40, P167, DOI 10.1111/J.1748-5827.1999.TB03784.X##MORGAN JP, 1990, J SMALL ANIM PRACT, V31, P69, DOI 10.1111/J.1748-5827.1990.TB00724.X##NESS MG, 1994, J SMALL ANIM PRACT, V35, P185, DOI 10.1111/J.1748-5827.1994.TB01683.X##QUIST JJ, 1998, J BONE JOINT SURG BR, V80B, P520, DOI 10.1302/0301-620X.80B3.8010##RAMIREZ O, 1998, VET RADIOL ULTRASOUN, V39, P283, DOI 10.1111/J.1740-8261.1998.TB01608.X##SCHMID V, 1993, J SMALL ANIM PRACT, V34, P437, DOI 10.1111/J.1748-5827.1993.TB03897.X##SCHWARZ T, 2000, J AM VET MED ASSOC, V217, P862, DOI 10.2460/JAVMA.2000.217.862##SEILER G, 2003, VET RADIOL ULTRASOUN, V44, P179, DOI 10.1111/J.1740-8261.2003.TB01268.X##SISSON AF, 1992, J VET INTERN MED, V6, P253, DOI 10.1111/J.1939-1676.1992.TB00349.X##STIKEL RL, 1993, VET CLIN N AM-SMALL, V23, P417##TAGA A, 1998, J VET MED SCI, V60, P1345, DOI 10.1292/JVMS.60.1345##TARVIN G, 1980, J AM VET MED ASSOC, V177, P154##TERTTI M, 1991, SPINE, V16, P629, DOI 10.1097/00007632-199106000-00006##WATT PR, 1991, J SMALL ANIM PRACT, V32, P125, DOI 10.1111/J.1748-5827.1991.TB00527.X##WEBER WJ, 1995, VET RADIOL ULTRASOUN, V36, P493, DOI 10.1111/J.1740-8261.1995.TB00301.X##WHEELER SJ, 1992, VET CLIN N AM-SMALL, V22, P937, DOI 10.1016/S0195-5616(92)50085-7",43,2020-11-20,NA
J,WOS:000243157900107,2006,REMOVAL OF BIOFILMS BY IMPINGING WATER DROPLETS,"THE PROCESS OF IMPINGING WATER DROPLETS ON STREPTOCOCCUS MUTANS BIOFILMS WAS STUDIED EXPERIMENTALLY AND NUMERICALLY. DROPLETS WERE EXPERIMENTALLY PRODUCED BY NATURAL BREAKUP OF A CYLINDRICAL LIQUID JET. DROPLET DIAMETER AND VELOCITY WERE VARIED BETWEEN 20 AND 200 MU M AND BETWEEN 20 AND 100 M/S, RESPECTIVELY. THE RESULTING EROSION PROCESS OF THE BIOFILM WAS DETERMINED EXPERIMENTALLY WITH HIGH-SPEED RECORDING TECHNIQUES AND A QUANTITATIVE RELATIONSHIP BETWEEN THE REMOVAL RATE, DROPLET SIZE, AND VELOCITY WAS DETERMINED. THE SHEAR STRESS AND THE PRESSURE ON THE SURFACE DURING DROPLET IMPACT WERE DETERMINED BY NUMERICAL SIMULATIONS, AND A QUALITATIVE AGREEMENT BETWEEN THE EXPERIMENT AND THE SIMULATION WAS OBTAINED. FURTHERMORE, IT WAS SHOWN THAT THE STRESSES ON THE SURFACE ARE STRONGLY REDUCED WHEN A WATER FILM IS PRESENT. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",IMPACT; SURFACE; JET,NA,JOURNAL OF APPLIED PHYSICS,"CENSE, AW##VAN DONGEN, MEH##GOTTENBOS, B##NUIJS, AM##SHULEPOV, SY","EINDHOVEN UNIV TECHNOL, NL-5600 MB EINDHOVEN, NETHERLANDS. PHILIPS RES LABS, NL-5656 AE EINDHOVEN, NETHERLANDS. PHILIPS RES LABS, NL-5656 AG EINDHOVEN, NETHERLANDS.","PHYSICS, APPLIED",PHYSICS,"ADLER W. F., 1979, TREATISE MATERIALS S, P127##BOURNE NK, 2005, P ROY SOC A-MATH PHY, V461, P1129, DOI 10.1098/RSPA.2004.1440##*CD AD GROUP, 2004, METH STAR CD V 3 20##CENSE A, 2005, THESIS TU EINDHOVEN##CENSE AW, 2006, J MICROBIOL METH, V67, P463, DOI 10.1016/J.MIMET.2006.04.023##COAD E, 1997, P ROY SOC LOND A MAT, V454, P213##DEAR JP, 1988, J APPL PHYS, V63, P1015, DOI 10.1063/1.340000##FERZIGER J.H, 2002, COMPUTATIONAL METHOD##FIELD JE, 1999, WEAR, V233, P1, DOI 10.1016/S0043-1648(99)00189-1##HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5##KENNEDY CF, 2000, J MATER SCI, V35, P5331, DOI 10.1023/A:1004842828161##LESSER MB, 1981, P ROY SOC LOND A MAT, V377, P289, DOI 10.1098/RSPA.1981.0125##LIN SP, 1998, ANNU REV FLUID MECH, V30, P85, DOI 10.1146/ANNUREV.FLUID.30.1.85##MIDDLEMAN S, 1995, MODELLING AXISYMMETR##PASANDIDEHFARD M, 1996, PHYS FLUIDS, V8, P650, DOI 10.1063/1.868850##SEWARD CR, 1994, P SOC PHOTO-OPT INS, V2286, P285, DOI 10.1117/12.187350##VAN DAM DB, 2004, PHYS FLUIDS, V16, P3403, DOI 10.1063/1.1773551",10,2020-11-20,NA
J,WOS:000243157900030,2006,INFLUENCE OF CAPPING LAYERS ON THE CRYSTALLIZATION OF DOPED SBXTE FAST-GROWTH PHASE-CHANGE FILMS,"ISOTHERMAL CRYSTALLIZATION OF DOPED SBXTE FAST-GROWTH PHASE-CHANGE FILMS, WITH AND WITHOUT CAPPING LAYERS, WAS INVESTIGATED USING TRANSMISSION ELECTRON MICROSCOPY, WHICH PROVIDED DIRECT AND QUANTITATIVE INFORMATION ON NUCLEATION AND GROWTH PROCESSES SEPARATELY. TWO TYPES OF AMORPHOUS DIELECTRIC LAYERS, ZNS-SIO2 AND GECRN, WERE USED FOR SANDWICHING THE SBXTE FILMS TO FORM TYPICAL TRILAYER STACKS, WHICH ARE THE ACTIVE PART IN APPLICATIONS. THE NUCLEATION AND GROWTH PARAMETERS OF SBXTE FILMS WERE FOUND TO BE INFLUENCED BY THE DIELECTRIC CAPPING LAYERS. THE CRYSTAL GROWTH RATE IS TEMPERATURE DEPENDENT AND IT REDUCES WHEN THE FILM IS SANDWICHED BETWEEN THE DIELECTRIC LAYERS. THE REDUCTION IN GROWTH RATE DIFFERS WITH THE CAPPING LAYER TYPE. THE CAPPING LAYER INFLUENCE ON THE GROWTH RATE IS PRONOUNCED AT LOWER TEMPERATURES SIMILAR TO 160 DEGREES C, BUT TENDS TO VANISH AT HIGHER TEMPERATURES SIMILAR TO 200 DEGREES C. THE ACTIVATION ENERGY FOR CRYSTAL GROWTH IS 2.4 +/- 0.3 EV FOR AN UNCAPPED FILM AND IT INCREASES SIMILAR TO 40% WHEN THE CAPPING LAYERS, GECRN OR ZNS-SIO2, ARE ADDED. A TEMPERATURE AND TIME DEPENDENT NUCLEATION RATE IS FOUND AND IT IS ACCELERATED SIMILAR TO 1.7 TIMES BY GECRN LAYERS, WHEREAS IT IS RETARDED SIMILAR TO 5 TIMES BY ZNS-SIO2 LAYERS. THE ACTIVATION ENERGY FOR CRYSTAL NUCLEATION IS 6.1 +/- 0.4 EV FOR AN UNCAPPED FILM AND IT IS NOT NOTICEABLY ALTERED BY THE CAPPING LAYERS. THESE VARIATIONS OBSERVED IN THE CRYSTALLIZATION KINETICS ARE ATTRIBUTED TO VARIATIONS IN INTERFACE ENERGY BETWEEN THE PHASE-CHANGE FILM AND THE CAPPING LAYERS OR VACUUM AND THE CONFINEMENT EFFECT BY THE CAPPING LAYERS ON THE PHASE-CHANGE FILM. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",TRANSMISSION ELECTRON-MICROSCOPY; THIN-FILMS; CRYSTAL NUCLEATION; OPTICAL-PROPERTIES; GE2SB2TE5; GE; KINETICS; TRANSITION; SPEED; BEHAVIOR,NA,JOURNAL OF APPLIED PHYSICS,"PANDIAN, R##KOOI, BJ##DE HOSSON, JTM##PAUZA, A","UNIV GRONINGEN, DEPT APPL PHYS, CTR MAT SCI, NL-9747 AG GRONINGEN, NETHERLANDS. UNIV GRONINGEN, NETHERLAND INST MET RES, NL-9747 AG GRONINGEN, NETHERLANDS. PLASMON DATA SYST LTD, MELBOURN ROYSTON SG8 6EN, HERTS, ENGLAND.","PHYSICS, APPLIED",PHYSICS,"AVRAMOV I, 2005, J NON-CRYST SOLIDS, V351, P3163, DOI 10.1016/J.JNONCRYSOL.2005.08.021##AVRAMOV I, 2005, J NON-CRYST SOLIDS, V351, P472, DOI 10.1016/J.JNONCRYSOL.2005.01.044##BORG H, 2001, MAT RES SOC S P, V674##BORG HJ, 2001, JPN J APPL PHYS 1, V40, P1592, DOI 10.1143/JJAP.40.1592##CHANG D, 2003, JPN J APPL PHYS 1, V42, P754, DOI 10.1143/JJAP.42.754##CHEN M, 1986, APPL PHYS LETT, V49, P502, DOI 10.1063/1.97617##CHENG HY, 2005, SEMICOND SCI TECH, V20, P1111, DOI 10.1088/0268-1242/20/11/002##FONTANA M, 2000, PHILOS MAG B, V80, P1833, DOI 10.1080/13642810008216509##FRIEDRICH I, 2000, J APPL PHYS, V87, P4130, DOI 10.1063/1.373041##GILL M, P 2002 IEEE INT SOL, P158##GIRAUD V, 2005, J APPL PHYS, V98, DOI 10.1063/1.1944910##HELLMIG J, 2003, JPN J APPL PHYS 1, V42, P848, DOI 10.1143/JJAP.42.848##HER YC, 2003, JPN J APPL PHYS 1, V42, P804, DOI 10.1143/JJAP.42.804##HER YC, 2003, J APPL PHYS, V93, P10097, DOI 10.1063/1.1575493##HORIE M, 1996, THIN SOLID FILMS, V278, P74, DOI 10.1016/0040-6090(95)08184-4##HYOT B, 2002, J MAGN MAGN MATER, V249, P504, DOI 10.1016/S0304-8853(02)00470-5##HYOT B, 2004, P EPCOS##JEONG TH, 1999, J APPL PHYS, V86, P774, DOI 10.1063/1.370803##KALB J, 2004, APPL PHYS LETT, V84, P5240, DOI 10.1063/1.1764591##KALB J, 2003, J APPL PHYS, V94, P4908, DOI 10.1063/1.1610775##KALB JA, 2005, J APPL PHYS, V98, DOI 10.1063/1.2034655##KALB JA, 2005, J APPL PHYS, V98, DOI 10.1063/1.2037870##KHULBE PK, 2002, APPL OPTICS, V41, P6220, DOI 10.1364/AO.41.006220##KOOI BJ, 2005, J MATER RES, V20, P1825, DOI 10.1557/JMR.2005.0228##KOOI BJ, 2004, J APPL PHYS, V95, P4714, DOI 10.1063/1.1690112##KOOI BJ, 2004, J APPL PHYS, V95, P924, DOI 10.1063/1.1636259##LAI S, 2001, IEDM, P803##LANKHORST MHR, 2005, NAT MATER, V4, P347, DOI 10.1038/NMAT1350##LANKHORST MHR, 2003, JPN J APPL PHYS 1, V42, P863, DOI 10.1143/JJAP.42.863##LEE TY, 2002, APPL PHYS LETT, V80, P3313, DOI 10.1063/1.1476705##MAIMON J, 2002, UNPUB P NON VOL MEM##MARTENS HCF, 2004, J APPL PHYS, V95, P3977, DOI 10.1063/1.1667606##NAKAYAMA K, 2003, JPN J APPL PHYS 1, V42, P404, DOI 10.1143/JJAP.42.404##NAKAYAMA K, 2000, JPN J APPL PHYS 1, V39, P6157, DOI 10.1143/JJAP.39.6157##NJOROGE WK, 2004, J APPL PHYS, V96, P2624, DOI 10.1063/1.1774265##OHSHIMA N, 1996, J APPL PHYS, V79, P8357, DOI 10.1063/1.362548##OHSHIMA N, 1998, J APPL PHYS, V83, P5244, DOI 10.1063/1.367346##OOMACHI N, 2002, JPN J APPL PHYS 1, V41, P1695, DOI 10.1143/JJAP.41.1695##OVSHINSKY SR, 1968, PHYS REV LETT, V21, P1450, DOI 10.1103/PHYSREVLETT.21.1450##PANDIAN R, UNPUB##PELLIZZER F, 2004, 2004 SYMPOSIUM ON VLSI TECHNOLOGY, DIGEST OF TECHNICAL PAPERS, P18##PRIVITERA S, 2004, MATER RES SOC SYMP P, V803, P83##RAULT J, 2000, J NON-CRYST SOLIDS, V271, P177, DOI 10.1016/S0022-3093(00)00099-5##RIVERA-RODRIGUEZ C, 2004, J APPL PHYS, V96, P1040, DOI 10.1063/1.1756223##RUITENBERG G, 2002, J APPL PHYS, V92, P3116, DOI 10.1063/1.1503166##SENKADER S, 2004, J APPL PHYS, V95, P504, DOI 10.1063/1.1633984##SHARAF K. A., 2000, FIZIKA A, V9, P67##TOMINAGA J, 1998, JPN J APPL PHYS 1, V37, P1852, DOI 10.1143/JJAP.37.1852##UHLMANN D. R., 1972, JOURNAL OF NON-CRYSTALLINE SOLIDS, V7, P337, DOI 10.1016/0022-3093(72)90269-4##YAMADA N, 1991, J APPL PHYS, V69, P2849, DOI 10.1063/1.348620##YEUNG F, 2005, JPN J APPL PHYS 1, V44, P2691, DOI 10.1143/JJAP.44.2691##ZHOU GF, 2001, MAT SCI ENG A-STRUCT, V304, P73, DOI 10.1016/S0921-5093(00)01448-9##ZHOU GF, 1997, MAT SCI ENG A-STRUCT, V226, P1069, DOI 10.1016/S0921-5093(97)80105-0",40,2020-11-20,NA
J,WOS:000241593800107,2006,EPDM RUBBER RECLAIM FROM DEVULCANIZED EPDM,"TWO TYPES OF ETHYLENE-PROPYLENE-DIENE MONOMER (EPDM) RUBBERS, NAMELY AN EFFICIENT VULCANIZED (EV) AND A SERNIEFFICIENT VULCANIZED (SEV), HAVE BEEN USED TO PRODUCE DEVULCANIZATES IN A CONTINUOUS SETUP. THE DEVULCANIZATES ARE RE-CURED USING THE SAME RECIPES AS FOR THE VIRGIN RUBBER. THE INFLUENCE OF MIXING IT WITH VIRGIN RUBBER COMPOUND, THE ADDITION OF EXTRA SULFUR, THE OPERATING DEVULCANIZATION CONDITIONS, AND THE EXCESS OF DEVULCANIZING AGENT ON THE MECHANICAL PROPERTIES (HARDNESS, TENSILE STRENGTH, AND COMPRESSION SET) OF THE RECLAIM RUBBERS ARE STUDIED. MOST OF THE RECLAIMS PRODUCED SHOW SLIGHTLY INFERIOR MECHANICAL PROPERTIES COMPARED TO THE VIRGIN RUBBER. SURFACE IMPERFECTION WAS OBSERVED ON THE DEVULCANIZATE WITH HIGH DEVULCANIZING AGENT CONTENT. EXCELLENT MECHANICAL PROPERTIES (ALL ABOVE THE STANDARDS) OF THE RECLAIM WERE FOUND WHEN THE DEVULCANIZED PROFILE MATERIAL WAS USED (EV-EPDM) TO REPLACE THE VIRGIN ONE FOR APPLICATION AS A ROOFING SHEET MATERIAL (SEV-EPDM). (C) 2006 WILEY PERIODICALS, INC.",MECHANICAL-PROPERTIES; CARBON-BLACK; CURE CHARACTERISTICS; WASTE; BLENDS; VULCANIZATE; COMPOUND; PHOTO,RECYCLING; RUBBER; PROCESSING; ETHYLENE-PROPYLENE-DIENE MONOMER; MECHANICAL PROPERTIES,JOURNAL OF APPLIED POLYMER SCIENCE,"SUTANTO, P##PICCHIONI, F##JANSSEN, LPBM##DIJKHUIS, KAJ##DIERKES, WK##NOORDERMEER, JWM","UNIV GRONINGEN, DEPT CHEM ENGN, NL-9747 AG GRONINGEN, NETHERLANDS.",POLYMER SCIENCE,POLYMER SCIENCE,"DELOR F, 1998, POLYM DEGRAD STABIL, V60, P321, DOI 10.1016/S0141-3910(97)00087-6##DELOR-JESTIN F, 2000, POLYM DEGRAD STABIL, V67, P469, DOI 10.1016/S0141-3910(99)00147-0##DIKLAND HG, 1993, POLYM BULL, V30, P477, DOI 10.1007/BF00338483##DIKLAND HG, 1992, THESIS U TWENTE##FLORY P. J., 1953, PRINCIPLES POLYM CHE, P432##HOFFMANN W, 1989, RUBBER TECHNOLOGY HD##JACOB C, 2003, RUBBER CHEM TECHNOL, V76, P36, DOI 10.5254/1.3547740##JACOB C, 2003, J APPL POLYM SCI, V87, P2204, DOI 10.1002/APP.11474##JACOB C, 2001, J APPL POLYM SCI, V82, P3304, DOI 10.1002/APP.2189.ABS##JACOB C, 2001, J APPL POLYM SCI, V82, P3293, DOI 10.1002/APP.2188.ABS##KIM JK, 2000, J APPL POLYM SCI, V78, P1573, DOI 10.1002/1097-4628(20001121)78:8<1573::AID-APP150>3.0.CO;2-P##LANDI VR, 1978, POLYM ENG SCI, V8, P1135##RATTANASOM N, 2005, POLYM TEST, V24, P728, DOI 10.1016/J.POLYMERTESTING.2005.04.008##SOMBATSOMPOP N, 2003, J APPL POLYM SCI, V87, P1723, DOI 10.1002/APP.11698##SREEJA TD, 2000, POLYM-PLAST TECHNOL, V39, P501, DOI 10.1081/PPT-100100043##SUTANTO P, UNPUB J APPL POLYM S##SUTANTO P, UNPUB CHEM ENG SCI##TANTAYANON S, 2004, J APPL POLYM SCI, V91, P510, DOI 10.1002/APP.13182##WANG WZ, 2003, POLYM DEGRAD STABIL, V81, P531, DOI 10.1016/S0141-3910(03)00154-X##YUN J, 2004, J APPL POLYM SCI, V91, P1646, DOI 10.1002/APP.13320##YUN JS, 2004, J APPL POLYM SCI, V92, P132, DOI 10.1002/APP.13668",33,2020-11-20,NA
J,WOS:000242995900001,2006,GRANZYMES AT A GLANCE,NA,PERFORIN; CYTOTOXICITY; LYMPHOCYTES; DNA,NA,JOURNAL OF CELL SCIENCE,"BOTS, M##MEDEMA, JP","ACAD MED CTR, LAB EXPT ONCOL & RADIOBIOL, CTR EXPT & MOL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CELL BIOLOGY,CELL BIOLOGY,"ADRAIN C, 2005, J BIOL CHEM, V280, P4663, DOI 10.1074/JBC.M410915200##BARRY M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/NRI819##BOTS M, 2005, BLOOD, V105, P1153, DOI 10.1182/BLOOD-2004-03-0791##BOTS M, 2006, BLOOD, V107, P4974, DOI 10.1182/BLOOD-2006-01-0291##BREDEMEYER AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/PNAS.0402353101##BUZZA MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/JBC.M412001200##CATALFAMO M, 2003, CURR OPIN IMMUNOL, V15, P522, DOI 10.1016/S0952-7915(03)00114-6##CHOWDHURY D, 2006, MOL CELL, V23, P133, DOI 10.1016/J.MOLCEL.2006.06.005##DAVIS JE, 2001, EUR J IMMUNOL, V31, P39, DOI 10.1002/1521-4141(200101)31:1<39::AID-IMMU39>3.0.CO;2-1##GROSSMAN WJ, 2003, CURR OPIN IMMUNOL, V15, P544, DOI 10.1016/S0952-7915(03)00099-2##JOHNSON H, 2003, BLOOD, V101, P3093, DOI 10.1182/BLOOD-2002-08-2485##KEEFE D, 2005, IMMUNITY, V23, P249, DOI 10.1016/J.IMMUNI.2005.08.001##KELLY JM, 2004, J BIOL CHEM, V279, P22236, DOI 10.1074/JBC.M401670200##LIEBERMAN J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0##MACDONALD G, 1999, J EXP MED, V189, P131, DOI 10.1084/JEM.189.1.131##MARTINVALET D, 2005, IMMUNITY, V22, P355, DOI 10.1016/J.IMMUNI.2005.02.004##MEDEMA JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/PNAS.201398198##MENASCHE G, 2005, IMMUNOL REV, V203, P165, DOI 10.1111/J.0105-2896.2005.00224.X##METKAR SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8##PARDO J, 2002, EUR J IMMUNOL, V32, P2881, DOI 10.1002/1521-4141(2002010)32:10<2881::AID-IMMU2881>3.0.CO;2-K##RUSSELL JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/ANNUREV.IMMUNOL.20.100201.131730##SILVA VV, 2001, COMPOS SCI TECHNOL, V61, P301, DOI 10.1016/S0266-3538(00)00222-0##SMYTH MJ, 2003, J IMMUNOL, V171, P515, DOI 10.4049/JIMMUNOL.171.2.515##TRAPANI JA, 2003, CURR OPIN IMMUNOL, V15, P533, DOI 10.1016/S0952-7915(03)00107-9##WATERHOUSE NJ, 2006, IMMUNOL CELL BIOL, V84, P72, DOI 10.1111/J.1440-1711.2005.01416.X",94,2020-11-20,NA
J,WOS:000242995900003,2006,"KASH-DOMAIN PROTEINS IN NUCLEAR MIGRATION, ANCHORAGE AND OTHER PROCESSES","THE NUCLEUS IN EUKARYOTIC CELLS CAN MOVE WITHIN THE CYTOPLASM, AND ITS POSITION IS CRUCIAL FOR MANY CELLULAR EVENTS, INCLUDING MIGRATION AND DIFFERENTIATION. NUCLEAR ANCHORAGE AND MOVEMENT CAN BE ACHIEVED THROUGH ASSOCIATION OF OUTER NUCLEAR MEMBRANE (ONM) PROTEINS WITH THE THREE CYTOSKELETAL SYSTEMS. TWO DECADES AGO STUDIES DESCRIBED C. ELEGANS MUTANTS WITH DEFECTS IN SUCH EVENTS, BUT ONLY RECENTLY HAS IT BEEN SHOWN THAT THE STRATEGIES FOR NUCLEAR POSITIONING ARE INDEED CONSERVED IN C. ELEGANS, DROSOPHILA, MAMMALS AND POTENTIALLY ALL EUKARYOTES. THE INTEGRAL ONM PROTEINS IMPLICATED IN THESE PROCESSES THUS FAR ALL CONTAIN A CONSERVED KLARSICHT/ANC1/SYNE HOMOLOGY (KASH) DOMAIN AT THEIR C-TERMINUS THAT CAN ASSOCIATE WITH SAD1P/UNC-84 (SUN)-DOMAIN PROTEINS OF THE INNER NUCLEAR MEMBRANE WITHIN THE PERIPLASMIC SPACE OF THE NUCLEAR ENVELOPE ( NE). THE COMPLEX THUS FORMED IS RESPONSIBLE NOT ONLY FOR ASSOCIATION WITH CYTOPLASMIC ELEMENTS BUT ALSO FOR THE INTEGRITY OF THE NE ITSELF.",MEMBRANE PROTEIN; SPECTRIN-REPEAT; DEPENDENT LOCALIZATION; CELL LINEAGES; MEMBER SYNE-1; LAMIN-A; ENVELOPE; NEMATODE; FAMILY; TRANSPORT,NUCLEAR ENVELOPE; OUTER NUCLEAR MEMBRANE; KASH DOMAIN; NESPRIN,JOURNAL OF CELL SCIENCE,"WILHELMSEN, K##KETEMA, M##TRUONG, H##SONNENBERG, A","NETHERLANDS CANC INST, DIV CELL BIOL, NL-1066 CX AMSTERDAM, NETHERLANDS.",CELL BIOLOGY,CELL BIOLOGY,"APEL ED, 2000, J BIOL CHEM, V275, P31986, DOI 10.1074/JBC.M004775200##BERS DR, 1999, CARDIOVASC RES, V42, P339, DOI 10.1016/S0008-6363(99)00038-3##COTTRELL JR, 2004, NEURON, V44, P677, DOI 10.1016/J.NEURON.2004.10.025##CRISP M, 2006, J CELL BIOL, V172, P41, DOI 10.1083/JCB.200509124##DJINOVIC-CARUGO K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X##DREGER M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/PNAS.211201898##FAN J, 2004, J CELL SCI, V117, P619, DOI 10.1242/JCS.00892##FISCHER JA, 2004, GENETICS, V168, P1385, DOI 10.1534/GENETICS.104.028662##FISCHERVIZE JA, 1994, DEVELOPMENT, V120, P2609##FRIDKIN A, 2004, P NATL ACAD SCI USA, V101, P6987, DOI 10.1073/PNAS.0307880101##FUCHS E, 2001, GENE DEV, V15, P1, DOI 10.1101/GAD.861501##GEIGER B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066##GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/ANNUREV.CB.04.110188.002003##GOUGH LL, 2004, BBA-MOL CELL RES, V1693, P29, DOI 10.1016/J.BBAMCR.2004.04.004##GOUGH LL, 2003, MOL BIOL CELL, V14, P2410, DOI 10.1091/MBC.E02-07-0446##GRADY RM, 2005, P NATL ACAD SCI USA, V102, P4359, DOI 10.1073/PNAS.0500711102##GRUENBAUM Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/NRM1550##GUILD GM, 1997, J CELL BIOL, V138, P783, DOI 10.1083/JCB.138.4.783##GUO Y, 2005, MOL BIOL CELL, V16, P1406, DOI 10.1091/MBC.E04-10-0920##HAQUE F, 2006, MOL CELL BIOL, V26, P3738, DOI 10.1128/MCB.26.10.3738-3751.2006##HASAN S, 2006, FEBS LETT, V580, P1263, DOI 10.1016/J.FEBSLET.2006.01.039##HEDGECOCK EM, 1982, CELL, V30, P321, DOI 10.1016/0092-8674(82)90038-1##HODZIC DM, 2004, J BIOL CHEM, V279, P25805, DOI 10.1074/JBC.M313157200##HORVITZ HR, 1980, GENETICS, V96, P435##INGBER DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/JCS.00360##INGBER DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/JCS.00359##INGBER DE, 2006, FASEB J, V20, P811, DOI 10.1096/FJ.05-5424REV##KAPILOFF MS, 2001, J CELL SCI, V114, P3167##KOBAYASHI Y, 2006, EXP CELL RES, V312, P3152, DOI 10.1016/J.YEXCR.2006.06.026##KRAMER H, 1999, GENETICS, V151, P675##KRAMER H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/JCB.133.6.1205##LEE KK, 2002, MOL BIOL CELL, V13, P892, DOI 10.1091/MBC.01-06-0294##LEUNG CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8##LIBOTTE T, 2005, MOL BIOL CELL, V16, P3411, DOI 10.1091/MBC.E04-11-1009##LIU J, 2003, DEV CELL, V5, P487, DOI 10.1016/S1534-5807(03)00262-4##MALONE CJ, 1999, DEVELOPMENT, V126, P3171##MALONE CJ, 2003, CELL, V115, P825, DOI 10.1016/S0092-8674(03)00985-1##MANIOTIS AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/PNAS.94.3.849##MCGEE MD, 2006, MOL BIOL CELL, V17, P1790, DOI 10.1091/MBC.E05-09-0894##MISLOW JMK, 2002, FEBS LETT, V525, P135, DOI 10.1016/S0014-5793(02)03105-8##MISLOW JMK, 2002, J CELL SCI, V115, P61##MORRIS NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/JCB.148.6.1097##MOSLEY-BISHOP KL, 1999, CURR BIOL, V9, P1211, DOI 10.1016/S0960-9822(99)80501-6##NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718A0##NICKEL W, 2002, J CELL SCI, V115, P3235##PADMAKUMAR VC, 2005, J CELL SCI, V118, P3419, DOI 10.1242/JCS.02471##PADMAKUMAR VC, 2004, EXP CELL RES, V295, P330, DOI 10.1016/J.YEXCR.2004.01.014##PARE GC, 2005, EXP CELL RES, V303, P388, DOI 10.1016/J.YEXCR.2004.10.009##PATTERSON K, 2004, MOL BIOL CELL, V15, P600, DOI 10.1091/MBC.E03-06-0374##REINSCH S, 1998, J CELL SCI, V111, P2283##ROSENBERGHASSON Y, 1996, MECH DEVELOP, V60, P83, DOI 10.1016/S0925-4773(96)00602-8##SIMPSON F, 2005, TRAFFIC, V6, P442, DOI 10.1111/J.1600-0854.2005.00289.X##SPRADLING ALLAN C., 1993, P1##STARR DA, 2003, J CELL SCI, V116, P211, DOI 10.1242/JCS.00248##STARR DA, 2002, SCIENCE, V298, P406, DOI 10.1126/SCIENCE.1075119##STARR DA, 2001, DEVELOPMENT, V128, P5039##SULSTON JE, 1976, PHILOS T ROY SOC B, V275, P287, DOI 10.1098/RSTB.1976.0084##SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0##SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4##SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9##VOLK T, 1992, DEVELOPMENT, V116, P721##WALENTA JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/JCB.152.5.923##WELTE MA, 1998, CELL, V92, P547, DOI 10.1016/S0092-8674(00)80947-2##WICHE G, 1998, J CELL SCI, V111, P2477##WILHELMSEN K, 2005, J CELL BIOL, V171, P799, DOI 10.1083/JCB.200506083##WILLIAMS-MASSON EM, 1998, DEV BIOL, V204, P263, DOI 10.1006/DBIO.1998.9048##WINDER SJ, 2005, J CELL SCI, V118, P651, DOI 10.1242/JCS.01670##YU JH, 2006, DEV BIOL, V289, P336, DOI 10.1016/J.YDBIO.2005.10.027##ZHANG QP, 2005, J CELL SCI, V118, P673, DOI 10.1242/JCS.01642##ZHANG QP, 2002, GENOMICS, V80, P473, DOI 10.1006/GENO.2002.6859##ZHANG QP, 2001, J CELL SCI, V114, P4485##ZHEN YY, 2002, J CELL SCI, V115, P3207",106,2020-11-20,NA
J,WOS:000242995900009,2006,PLANT G PROTEIN HETEROTRIMERS REQUIRE DUAL LIPIDATION MOTIFS OF G ALPHA AND G GAMMA AND DO NOT DISSOCIATE UPON ACTIVATION,"IN PLANTS ONE BONA FIDE G ALPHA SUBUNIT HAS BEEN IDENTIFIED, AS WELL AS A SINGLE G BETA AND TWO G GAMMA SUBUNITS. TO STUDY THE ROLES OF LIPIDATION MOTIFS IN THE REGULATION OF SUBCELLULAR LOCATION AND HETEROTRIMER FORMATION IN LIVING PLANT CELLS, GFP-TAGGED VERSIONS OF THE ARABIDOPSIS THALIANA HETEROTRIMERIC G PROTEIN SUBUNITS WERE CONSTRUCTED. MUTATIONAL ANALYSIS SHOWED THAT THE ARABIDOPSIS G ALPHA SUBUNIT, GP ALPHA 1, CONTAINS TWO LIPIDATION MOTIFS THAT WERE ESSENTIAL FOR PLASMA MEMBRANE LOCALIZATION. THE ARABIDOPSIS G BETA SUBUNIT, AG BETA 1, AND THE G GAMMA SUBUNIT, AGG1, WERE DEPENDENT UPON EACH OTHER FOR TETHERING TO THE PLASMA MEMBRANE. THE SECOND G GAMMA SUBUNIT, AGG2, DID NOT REQUIRE AG BETA 1 FOR LOCALIZATION TO THE PLASMA MEMBRANE. LIKE AGG1, AGG2 CONTAINS TWO PUTATIVE LIPIDATION MOTIFS, BOTH OF WHICH WERE NECESSARY FOR MEMBRANE LOCALIZATION. INTERACTION BETWEEN THE SUBUNITS WAS STUDIED USING FLUORESCENCE RESONANCE ENERGY TRANSFER ( FRET) IMAGING BY MEANS OF FLUORESCENCE LIFETIME IMAGING MICROSCOPY (FLIM). THE RESULTS SUGGEST THAT AG BETA 1 AND AGG1 OR AG BETA 1 AND AGG2 CAN FORM HETERODIMERS INDEPENDENT OF LIPIDATION. IN ADDITION, FLIM-FRET REVEALED THE EXISTENCE OF GP ALPHA 1-AG BETA 1-AGG1 HETEROTRIMERS AT THE PLASMA MEMBRANE. IMPORTANTLY, RENDERING GP ALPHA 1 CONSTITUTIVELY ACTIVE DID NOT CAUSE A FRET DECREASE IN THE HETEROTRIMER, SUGGESTING NO DISSOCIATION UPON GP ALPHA 1 ACTIVATION.",G-BETA-GAMMA; PHEROMONE-RESPONSE PATHWAY; PLASMA-MEMBRANE LOCALIZATION; LIFETIME IMAGING MICROSCOPY; GTP-BINDING PROTEINS; ARABIDOPSIS-THALIANA; N-MYRISTOYLATION; FLUORESCENT PROTEINS; SUBUNIT DISSOCIATION; SIGNAL-TRANSDUCTION,HETEROTRIMERIC G PROTEIN; ARABIDOPSIS THALIANA; GFP; LIPID MODIFICATION; FRET; FRAP,JOURNAL OF CELL SCIENCE,"ADJOBO-HERMANS, MJW##GOEDHART, J##GADELLA, TWJ","UNIV AMSTERDAM, SWAMMERDAM INST LIFE SCI, SECT MOL CYTOL, CTR ADV MICROSCOPY, NL-1098 SM AMSTERDAM, NETHERLANDS.",CELL BIOLOGY,CELL BIOLOGY,"ASSMANN SM, 2002, PLANT CELL, V14, PS355, DOI 10.1105/TPC.001792##BASTIAENS PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X##BOEVINK P, 1998, PLANT J, V15, P441, DOI 10.1046/J.1365-313X.1998.00208.X##BOISSON B, 2003, J BIOL CHEM, V278, P43418, DOI 10.1074/JBC.M307321200##BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117A0##BRACHA K, 2002, J BIOL CHEM, V277, P29856, DOI 10.1074/JBC.M202916200##BUNEMANN M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/PNAS.2536719100##CABRERA-VERA TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/ER.2000-0026##CADINANOS J, 2003, J BIOL CHEM, V278, P42091, DOI 10.1074/JBC.M306700200##CHEN JG, 2003, SCIENCE, V301, P1728, DOI 10.1126/SCIENCE.1087790##CHEN JG, 2006, PLANT PHYSIOL, V141, P887, DOI 10.1104/PP.106.079202##CLANCY SM, 2005, MOL CELL NEUROSCI, V28, P375, DOI 10.1016/J.MCN.2004.10.009##CLAPHAM DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/ANNUREV.PHARMTOX.37.1.167##CLEGG R.M., 1996, FLUORESCENCE IMAGING, P179##CROWELL DN, 2000, PROG LIPID RES, V39, P393, DOI 10.1016/S0163-7827(00)00010-2##EVANKO DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/JBC.M101154200##FISHBURN CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/JBC.274.26.18793##FRANK M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/JBC.M414630200##FUJISAWA Y, 2001, PLANT CELL PHYSIOL, V42, P789, DOI 10.1093/PCP/PCE111##GADELLA TWJ, 1999, TRENDS PLANT SCI, V4, P287, DOI 10.1016/S1360-1385(99)01426-0##GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/BJ3030697##GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/BJ3020913##HIRSCHMAN JE, 1997, J BIOL CHEM, V272, P240##HUANG J, 2006, PLANT CELL, V18, P1226, DOI 10.1105/TPC.105.037259##IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164A0##JONES AM, 2004, EMBO REP, V5, P572, DOI 10.1038/SJ.EMBOR.7400174##JONES AM, 2003, PLANT PHYSIOL, V131, P1623, DOI 10.1104/PP.102.017624##KATADA T, 1984, J BIOL CHEM, V259, P3578##KATO C, 2004, PLANT J, V38, P320, DOI 10.1111/J.1365-313X.2004.02046.X##KAYDAMOV C, 2000, BBA-GENE STRUCT EXPR, V1491, P143, DOI 10.1016/S0167-4781(00)00039-7##KLEIN S, 2000, P NATL ACAD SCI USA, V97, P3219, DOI 10.1073/PNAS.050015797##KLEUSS C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/PNAS.94.12.6116##KLEUSS C, 2003, EMBO J, V22, P826, DOI 10.1093/EMBOJ/CDG095##KOROLEVA OA, 2005, PLANT J, V41, P162, DOI 10.1111/J.1365-313X.2004.02281.X##KREMERS GJ, 2006, BIOCHEMISTRY-US, V45, P6570, DOI 10.1021/BI0516273##LIPPINCOTT-SCHWARTZ J, 2003, SCIENCE, V300, P87, DOI 10.1126/SCIENCE.1082520##MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/PNAS.87.10.3821##MA H, 1994, PLANT MOL BIOL, V26, P1611, DOI 10.1007/BF00016493##MANAHAN CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/MBC.11.3.957##MASON MG, 2001, BBA-GENE STRUCT EXPR, V1520, P147, DOI 10.1016/S0167-4781(01)00262-7##MASON MG, 2000, P NATL ACAD SCI USA, V97, P14784, DOI 10.1073/PNAS.97.26.14784##MAURER-STROH S, 2002, J MOL BIOL, V317, P523, DOI 10.1006/JMBI.2002.5425##MICHAELSON D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/MBC.E02-02-0095##MUNTZ KH, 1992, MOL BIOL CELL, V3, P49##MURRAY D, 2001, J BIOL CHEM, V276, P45153, DOI 10.1074/JBC.M101784200##OBRDLIK P, 2000, FEBS LETT, V476, P208, DOI 10.1016/S0014-5793(00)01706-3##OFFERMANNS S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X##PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/BJ2910349##PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/BI00023A019##PELLEGRINO S, 1997, J BIOL CHEM, V272, P25360, DOI 10.1074/JBC.272.40.25360##PERFUS-BARBEOCH L, 2004, CURR OPIN PLANT BIOL, V7, P719, DOI 10.1016/J.PBI.2004.09.013##PONIMASKIN E, 1998, FEBS LETT, V429, P370, DOI 10.1016/S0014-5793(98)00638-3##PONIMASKIN E, 2000, FEBS LETT, V478, P173, DOI 10.1016/S0014-5793(00)01845-7##QANBAR R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5##ROCKS O, 2005, SCIENCE, V307, P1746, DOI 10.1126/SCIENCE.1105654##RODRIGUEZ-CONCEPCION M, 2000, PLANT J, V24, P775, DOI 10.1046/J.1365-313X.2000.00924.X##ROLLAND N, 2006, J EXP BOT, V57, P1579, DOI 10.1093/JXB/ERJ162##RUIZ-VELASCO V, 2001, J PHYSIOL-LONDON, V537, P679##SANFORD J, 1991, J BIOL CHEM, V266, P9570##SCHROEDER H, 1996, J CELL BIOL, V134, P647, DOI 10.1083/JCB.134.3.647##SHANER NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/NBT1037##SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/SCIENCE.1902986##SMOTRYS JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/ANNUREV.BIOCHEM.73.011303.073954##SONDEK J, 1996, NATURE, V379, P369, DOI 10.1038/379369A0##SONG JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/JBC.271.34.20273##SONG JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/BI961846B##SPRANG SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/ANNUREV.BIOCHEM.66.1.639##SVOBODA P, 2002, CELL MOL LIFE SCI, V59, P501, DOI 10.1007/S00018-002-8441-7##SWARTHOUT JT, 2005, J BIOL CHEM, V280, P31141, DOI 10.1074/JBC.M504113200##TAKIDA S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/JBC.M213239200##TSIEN RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/ANNUREV.BIOCHEM.67.1.509##ULLAH H, 2003, PLANT CELL, V15, P393, DOI 10.1105/TPC.006148##UTSUMI T, 2004, EUR J BIOCHEM, V271, P863, DOI 10.1111/J.1432-1033.2004.03991.X##VAN MUNSTER EB, 2004, J MICROSC-OXFORD, V213, P29, DOI 10.1111/J.1365-2818.2004.01249.X##VAN MUNSTER EB, 2004, CYTOM PART A, V58A, P185, DOI 10.1002/CYTO.A.20013##VANBOKHOVEN H, 1993, J GEN VIROL, V74, P2233, DOI 10.1099/0022-1317-74-10-2233##VERMEER JEM, 2004, J MICROSC-OXFORD, V214, P190, DOI 10.1111/J.0022-2720.2004.01318.X##WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001##WEISS CA, 1993, PLANT CELL, V5, P1513##WEISS CA, 1994, P NATL ACAD SCI USA, V91, P9554, DOI 10.1073/PNAS.91.20.9554##WEISS CA, 1997, FEBS LETT, V407, P361, DOI 10.1016/S0014-5793(97)00378-5##WHITEWAY MS, 1994, GENETICS, V137, P967##WILLARD FS, 2004, METHOD ENZYMOL, V389, P320##WILLUMSEN BM, 1996, ONCOGENE, V13, P1901##WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/JBC.270.16.9667##WISE A, 1997, PLANT MOL BIOL, V33, P723, DOI 10.1023/A:1005732423622##WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/ABIO.1994.1134##YALOVSKY S, 1999, TRENDS PLANT SCI, V4, P439, DOI 10.1016/S1360-1385(99)01492-2##YANG ZH, 1992, J BIOL CHEM, V267, P23197##YU JZ, 2002, MOL PHARMACOL, V61, P352, DOI 10.1124/MOL.61.2.352##ZHANG FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/ANNUREV.BI.65.070196.001325##ZHAO J, 2004, J BIOL CHEM, V279, P1794, DOI 10.1074/JBC.M309529200",100,2020-11-20,NA
J,WOS:000242122500007,2006,DIFFERENTIAL EFFECTS OF MATRIX AND GROWTH FACTORS ON ENDOTHELIAL AND FIBROBLAST MOTILITY: APPLICATION OF A MODIFIED CELL MIGRATION ASSAY,"CELL MIGRATION IS CRUCIAL IN VIRTUALLY EVERY BIOLOGICAL PROCESS AND STRONGLY DEPENDS ON THE NATURE OF THE SURROUNDING MATRIX. AN ASSAY THAT ENABLES REAL-TIME STUDIES ON THE EFFECTS OF DEFINED MATRIX COMPONENTS AND GROWTH FACTORS ON CELL MIGRATION IS NOT AVAILABLE. WE HAVE SET UP A NOVEL, QUANTITATIVE MIGRATION ASSAY, WHICH ENABLES UNHARMED CELLS TO MIGRATE ALONG A DEFINED MATRIX. HERE, WE USED THIS SO-CALLED BARRIER-ASSAY TO DEFINE THE CONTRIBUTION OF FIBRONECTIN (FN) AND COLLAGEN-I (COL-I) TO VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BASIC FIBROBLAST GROWTH FACTOR (BFGF), AND LYSOPHOSPHATIDIC ACID (LPA)-INDUCED CELL MIGRATION OF ENDOTHELIAL CELLS (EC) AND FIBROBLASTS. IN EC, BOTH FN AND COL-I STIMULATED MIGRATION, BUT FN-INDUCED MOTILITY WAS RANDOM, WHILE NET MOVEMENT WAS INHIBITED. ADDITION OF BFGF AND VEGF OVERCAME THE EFFECT OF FN, WITH VEGF CAUSING DIRECTIONAL MOVEMENT. IN CONTRAST, IN 3T3 FIBROBLASTS, FN STIMULATED MOTILITY AND THIS EFFECT WAS ENHANCED BY BFGF. THIS MOTILITY WAS MORE EFFICIENT AND MORPHOLOGICALLY COMPLETELY DIFFERENT COMPARED TO LPA STIMULATION. STRIKINGLY, DIRECTIONAL MIGRATION OF EC WAS NOT PARALLELED BY HIGHER AMOUNTS OF STABLE MICROTUBULES (MT) OR AN INCREASED REORIENTATION OF THE MICROTUBULE-ORGANIZING CENTRE (MTOC). FOR EC, THE FN EFFECT APPEARED CONCENTRATION DEPENDENT; HIGH FN WAS ABLE TO INDUCE MIGRATION, WHILE FOR FIBROBLASTS BOTH LOW AND HIGH CONCENTRATIONS OF FN INDUCED MOTILITY. BESIDES SHOWING DISTINCT RESPONSES OF THE DIFFERENT CELLS TO THE SAME FACTORS, THESE RESULTS ADDRESS CONTRADICTIVE REPORTS ON FN AND SHOW THAT THE INTERPLAY BETWEEN MATRIX COMPONENTS AND GROWTH FACTORS DETERMINES BOTH PATTERN AND REGULATION OF CELL MIGRATION.",EXTRACELLULAR-MATRIX; SELECTIVE STABILIZATION; LYSOPHOSPHATIDIC ACID; 3T3 FIBROBLASTS; IV COLLAGEN; MICROTUBULES; FIBRONECTIN; ANGIOGENESIS; ACTIN; RHO,CELL MIGRATION; EXTRA CELLULAR MATRIX; GROWTH FACTOR; FIBRONECTIN,JOURNAL OF CELLULAR BIOCHEMISTRY,"VAN HORSSEN, R##GALJART, N##RENS, JAP##EGGERMONT, AMM##TEN HAGEN, TLM","ERASMUS MC, DR DANIEL DEN HOED CANC CTR, LAB EXPT SURG ONCOL, NL-3000 DR ROTTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; CELL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; CELL BIOLOGY,"AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N##BERGERS G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/NRC1093##BERNATCHEZ PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/JBC.274.43.31047##BERVEN LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/J.YEXER.2003.12.032##BUSSOLINO F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8##CARMELIET P, 2003, NAT MED, V9, P653, DOI 10.1038/NM0603-653##CHON JH, 1998, ANN BIOMED ENG, V26, P1091, DOI 10.1114/1.139##CLARK RAF, 2003, J INVEST DERMATOL, V121, P695, DOI 10.1046/J.1523-1747.2003.12484.X##CONRAD PA, 1989, CELL MOTIL CYTOSKEL, V14, P527, DOI 10.1002/CM.970140410##COOK TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/JCB.141.1.175##CROSS MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X##DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/PNAS.91.9.4082##DANEN EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/JCP.1137##DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/JCB.122.3.729##FISCHER RS, 2003, J CELL BIOL, V161, P371, DOI 10.1083/JCB.200209057##FONG TAT, 1999, CANCER RES, V59, P99##GOTLIEB AI, 1983, J CELL BIOL, V96, P1266, DOI 10.1083/JCB.96.5.1266##GUNDERSEN GG, 1994, J CELL SCI, V107, P645##GUNDERSEN GG, 1988, P NATL ACAD SCI USA, V85, P5946, DOI 10.1073/PNAS.85.16.5946##GUPTON SL, 2005, J CELL BIOL, V168, P619, DOI 10.1083/JCB.200406063##HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/JCB.106.4.1365##HORWITZ AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/SCIENCE.286.5442.1102##HOTCHKISS KA, 2002, MOL CANCER THER, V1, P1191##JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470##LAUFFENBURGER DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5##LEE TYJ, 1999, CELL TISSUE RES, V297, P435, DOI 10.1007/S004410051370##MADRI JA, 1991, J CELL BIOCHEM, V45, P123, DOI 10.1002/JCB.240450202##MCCARTHY JB, 1984, J CELL BIOL, V98, P1474, DOI 10.1083/JCB.98.4.1474##MCDONALD DM, 2004, J IMMUNOTHER, V27, P161, DOI 10.1097/00002371-200403000-00010##NAGASAKI T, 1996, J CELL SCI, V109, P2461##NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4##OHTAKA K, 1996, BIOCHEM BIOPH RES CO, V220, P346, DOI 10.1006/BBRC.1996.0408##PALAZZO AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035##PALAZZO AF, 2004, SCIENCE, V303, P836, DOI 10.1126/SCIENCE.1091325##PALAZZO AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4##POSTLETHWAITE AE, 1981, J EXP MED, V153, P494, DOI 10.1084/JEM.153.2.494##PRATT BM, 1984, AM J PATHOL, V117, P349##SCHOR SL, 1996, J CELL SCI, V109, P2581##SMALL JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1##SMALL JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/NRM971##TOTSUKAWA G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/JCB.200306172##UEDA M, 1997, P NATL ACAD SCI USA, V94, P9674, DOI 10.1073/PNAS.94.18.9674##VARANI J, 1978, AM J PATHOL, V90, P159##WATERMAN-STORER CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018##WEN Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/NCB1160##YOUNG WC, 1985, J CELL SCI, V73, P19",48,2020-11-20,NA
J,WOS:000242791500007,2006,CAPILLARY SCALE MONOLITHIC TRAP COLUMN FOR DESALTING AND PRECONCENTRATION OF PEPTIDES AND PROTEINS IN ONE- AND TWO-DIMENSIONAL SEPARATIONS,"MONOLITHIC COLUMNS BASED ON POLY-(STYRENE-DIVINYLBENZENE) (PS-DVB) WERE UTILIZED BOTH FOR PRECONCENTRATION (IN 10 MM X 0.20 MM I.D. FORMAT) AND ANALYTICAL SEPARATION (IN 60 MM X 0.20 AND 0.10 MM I.D. FORMAT) OF PEPTIDES AND PROTEINS IN COLUMN SWITCHING MICRO-SCALE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY. A SPECIAL HOLDER FOR SHORT MONOLITHIC PRECONCENTRATION COLUMNS WAS DESIGNED AND PRESSURE DURABILITY TESTS APPROVED LONG-TERM STABILITY UP TO 400 BAR. AN 11-20% DECREASE IN THE AVERAGE PEAK WIDTHS OF NINE PEPTIDES WAS OBTAINED UPON COMBINING A PRECONCENTRATION COLUMN WITH AN ANALYTICAL COLUMN AS COMPARED WITH A SETUP USING AN ANALYTICAL COLUMN ONLY. TRAPPING EFFICIENCY, ESPECIALLY FOR SMALL AND HYDROPHILIC PEPTIDES, WAS OPTIMIZED BY USING 0.10% HEPTAFLUOROBUTYRIC ACID INSTEAD OF 0.050% TRIFLUOROACETIC ACID AS SOLVENT ADDITIVE DURING SAMPLE LOADING. USING A 10 MM X 0.20 MM I.D. PRECONCENTRATION COLUMN, LOADABILITIES BETWEEN 0.5 AND 1.6 MU G WERE DETERMINED BY FRONTAL ANALYSIS OF PROTEINS AND BIOACTIVE PEPTIDES, RESPECTIVELY. A 100-FOLD CONCENTRATION FOLLOWED BY DIRECT ON-LINE INTACT MASS DETERMINATION IS DEMONSTRATED FOR DILUTED (3 MU MOL L-1) PROTEIN SOLUTIONS. THE APPLICABILITY OF THE MONOLITHIC PRECONCENTRATION COLUMN FOR MULTIDIMENSIONAL CHROMATOGRAPHY WAS TESTED BY OFF-LINE TWO-DIMENSIONAL SEPARATION, COMBINING STRONG CATION-EXCHANGE CHROMATOGRAPHY AND ION-PAIR REVERSED-PHASE CHROMATOGRAPHY. PEPTIDE IDENTIFICATION DATA FROM DIGESTED PROTEIN MIXTURES DEMONSTRATED REPRODUCIBILITIES OF 46-75% IN TRIPLICATE ANALYSES, AND CONFIDENT PEPTIDE IDENTIFICATIONS OF LOW ABUNDANT PEPTIDES EVEN IN THE PRESENCE OF A 650-FOLD MOLAR EXCESS OF HIGH ABUNDANT PEPTIDES. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",PERFORMANCE LIQUID-CHROMATOGRAPHY; IONIZATION MASS-SPECTROMETRY; SOLID-PHASE EXTRACTION; NUCLEIC-ACIDS; IDENTIFICATION; MS; TECHNOLOGY; MS/MS; ROD,MONOLITHIC COLUMN; POLY-(STYRENE-DIVINYLBENZENE); COLUMN SWITCHING; PRECONCENTRATION COLUMN; TRAPPING; MULTIDIMENSIONAL CHROMATOGRAPHY; PEPTIDES; PROTEINS,JOURNAL OF CHROMATOGRAPHY A,"SCHLEY, C##SWART, R##HUBER, CG","UNIV SAARLAND, DEPT CHEM INSTRUMENTAL ANAL & BIOANAL, D-66041 SAARBRUCKEN, GERMANY. LC PACKINGS A DIONEX CO, NL-1046 AA AMSTERDAM, NETHERLANDS.","BIOCHEMICAL RESEARCH METHODS; CHEMISTRY, ANALYTICAL",BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY,"ASPERGER A, 2002, J CHROMATOGR A, V960, P109, DOI 10.1016/S0021-9673(01)01392-9##CHELIUS D, 2003, ANAL CHEM, V75, P6658, DOI 10.1021/AC034607K##DAVIS MT, 2001, J CHROMATOGR B, V752, P281, DOI 10.1016/S0378-4347(00)00547-8##FREI RW, 1988, SELECTIVE SAMPLE HAN##GUSEV I, 1999, J CHROMATOGR A, V855, P273, DOI 10.1016/S0021-9673(99)00697-4##HAGEMEIER E, 1983, J CHROMATOGR, V268, P291, DOI 10.1016/S0021-9673(01)95418-4##HENION J, 1998, ANAL CHEM, V70, P650A, DOI 10.1021/AC981991Q##HUANG XA, 2002, ANAL CHEM, V74, P2336, DOI 10.1021/AC011202W##HUBER CG, 2004, PROTEOMICS, V4, P3909, DOI 10.1002/PMIC.200400823##HUBER CG, 2001, J BIOCHEM BIOPH METH, V47, P5, DOI 10.1016/S0165-022X(00)00147-0##IVANOV AR, 2003, ANAL CHEM, V75, P5306, DOI 10.1021/AC030163G##MCDONALD WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8##MITULOVIC G, 2004, PROTEOMICS, V4, P2545, DOI 10.1002/PMIC.200300806##OBERACHER H, 2002, TRAC-TREND ANAL CHEM, V21, P166, DOI 10.1016/S0165-9936(02)00304-7##OBERACHER H, 2004, J CHROMATOGR A, V1030, P201, DOI 10.1016/J.CHROMA.2004.01.009##OPITECK GJ, 1997, ANAL CHEM, V69, P1518, DOI 10.1021/AC961155L##PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T##PERKINS DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2##PREMSTALLER A, 2000, ANAL CHEM, V72, P4386, DOI 10.1021/AC000283D##PREMSTALLER A, 2001, ANAL CHEM, V73, P2390, DOI 10.1021/AC010046Q##RIVASSEAU C, 2000, J MICROCOLUMN SEP, V12, P323, DOI 10.1002/(SICI)1520-667X(2000)12:5<323::AID-MCS7>3.0.CO;2-M##SHEN Y, 2004, ANAL CHEM, V76, P144, DOI 10.1021/AC030096Q##SHEN YF, 2003, ANAL CHEM, V75, P3596, DOI 10.1021/AC0300690##SOUVERAIN S, 2004, J CHROMATOGR B, V801, P141, DOI 10.1016/J.JCHROMB.2003.11.043##TOLL H, 2005, J SEP SCI##VEUTHEY JL, 2004, THER DRUG MONIT, V26, P161, DOI 10.1097/00007691-200404000-00013##VISSERS JPC, 1997, J CHROMATOGR A, V779, P1, DOI 10.1016/S0021-9673(97)00422-6##WALCHER W, 2004, J CHROMATOGR A, V1053, P107, DOI 10.1016/J.CHROMA.2004.06.047##WANG QC, 1993, ANAL CHEM, V65, P2243, DOI 10.1021/AC00065A013##WANG QC, 1994, J CHROMATOGR A, V669, P230, DOI 10.1016/0021-9673(94)80352-8##WOLTERS DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/AC010617E##XIE S, 1999, J CHROMATOGR A, V865, P169, DOI 10.1016/S0021-9673(99)00981-4",38,2020-11-20,NA
J,WOS:000242399500015,2006,CONTROL OF THE ELECTRICAL CONDUCTIVITY OF COMPOSITES OF ANTIMONY DOPED TIN OXIDE (ATO) NANOPARTICLES AND ACRYLATE BY GRAFTING OF 3-METHACRYLOXYPROPYLTRIMETHOXYSILANE (MPS),"THE EFFECT OF THE ADDITION OF ANTIMONY DOPED TIN OXIDE (ATO) NANOPARTICLES ON THE ELECTRICAL CONDUCTIVITY OF ACRYLATE FILMS IS DESCRIBED. TO ENABLE DISPERSING OF ATO IN ACRYLATE MATRICES, 3-METHACRYLOXYPROPYLTRIMETHOXYSILANE (MPS) WAS GRAFTED ON THE SURFACE OF THE FILLER. THE AMOUNT OF MPS USED FOR THIS SURFACE MODIFICATION WAS FOUND TO STRONGLY AFFECT THE ELECTRICAL CONDUCTIVITY. SURFACE MODIFICATION WITH A LARGE AMOUNT OF MPS RESULTED IN COLLOIDALLY STABLE DISPERSIONS OF ATO, LEADING TO A HOMOGENEOUS DISTRIBUTION. SURFACE MODIFICATION WITH SMALL AMOUNTS OF MPS LED TO INSTABLE ATO DISPERSIONS AND AGGREGATION OF ATO INTO A FRACTAL TYPE NETWORK, WHICH GIVES A MUCH HIGHER CONDUCTIVITY ESPECIALLY AT LOW-VOLUME FRACTIONS. FOR COMPOSITES WITH A FRACTAL TYPE ATO NETWORK A SECOND EFFECT WAS FOUND. DECREASING THE AMOUNT OF ON ATO GRAFTED MPS RESULTED IN AN INCREASE OF THE ELECTRICAL CONDUCTION BETWEEN THE ATO PARTICLES. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",FILLED POLYMERS; FILMS; AGGREGATION; TRANSPORT; BEHAVIOR; SYSTEMS; MODELS; GELS,NANOPARTICLES; GRAFTING WITH METHACRYLOXYPROPYLTRIMETHOXYSILANE; ELECTRICAL CONDUCTIVITY; FRACTAL AGGREGATE; EBECRYL 745; PEGDA; TMPTA,JOURNAL OF COLLOID AND INTERFACE SCIENCE,"POSTHUMUS, W##LAVEN, J##DE WITH, G##VAN DER LINDE, R","EINDHOVEN UNIV TECHNOL, DEPT CHEM ENGN & CHEM, LAB MAT & INTERFACE CHEM SMG, NL-5600 MB EINDHOVEN, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"ANDRADE JS, 1998, PHYSICA A, V248, P227, DOI 10.1016/S0378-4371(97)00568-2##BREMER L. G. B., 1992, FRACTAL AGGREGATION##BROWN WD, 1987, THESIS U CAMBRIDGE U##BUNDE A, 1996, FRACTALS DISORDERS S, P37##CARMONA F, 2002, CARBON, V40, P151, DOI 10.1016/S0008-6223(01)00166-X##CHOPRA KL, 1983, THIN SOLID FILMS, V102, P1, DOI 10.1016/0040-6090(83)90256-0##DICKINSON E, 2000, J COLLOID INTERF SCI, V225, P2, DOI 10.1006/JCIS.1999.6662##EVANS DF, 1994, COLL DOM WHER PHYS C##GUL' VE, 1996, STRUCTURE PROPERTIES##HAMILTON WC, 1964, STAT PHYS SCI ESTIMA, P109##HUNTER R. J., 1996, INTRO MODERN COLLOID##KJEMS JK, 1992, PHYSICA A, V191, P328, DOI 10.1016/0378-4371(92)90547-4##KOLB M, 2001, ADV SOLID STATE PHYS, V41, P381, DOI 10.1007/3-540-44946-9_31##KULKARNI AM, 2002, LANGMUIR, V18, P3090, DOI 10.1021/LA011282Z##LEE SI, 1986, PHYS REV B, V34, P6719, DOI 10.1103/PHYSREVB.34.6719##LUX F, 1993, J MATER SCI, V28, P285, DOI 10.1007/BF00357799##MILLER KT, 1996, STUD SURF SCI CATAL, V103, P23##NINHAM BW, 1999, ADV COLLOID INTERFAC, V83, P1, DOI 10.1016/S0001-8686(99)00008-1##POSTHUMUS W, 2004, J COLLOID INTERF SCI, V269, P109, DOI 10.1016/J.JCIS.2003.07.008##RADHAKRISHNAN S, 1985, POLYM COMMUN, V26, P153##ROLDUGHIN VI, 2000, PROG ORG COAT, V39, P81, DOI 10.1016/S0300-9440(00)00140-5##SAHIMI M, 2003, HETEROGENEOUS MAT, V1, P37##SHERMAN RD, 1983, POLYM ENG SCI, V23, P36, DOI 10.1002/PEN.760230109##SHIH WH, 1990, PHYS REV A, V42, P4772, DOI 10.1103/PHYSREVA.42.4772##STRUMPLER R, 1999, J ELECTROCERAM, V3, P329, DOI 10.1023/A:1009909812823##SUN J, 2003, J POLYM SCI POL PHYS, V41, P1744, DOI 10.1002/POLB.10532##TEXTER J, 1999, LANGMUIR, V15, P654, DOI 10.1021/LA980526L##WANG YC, 1999, MACROMOLECULES, V32, P6172, DOI 10.1021/MA990207G##WEITZ DA, 1985, PHYS REV LETT, V54, P1416, DOI 10.1103/PHYSREVLETT.54.1416##YOSHIZUMI M, ANTISTATIC TRANSPARE",26,2020-11-20,NA
J,WOS:000242947300003,2006,"ORIGIN AND MECHANICAL SIGNIFICANCE OF FOLIATED CATACLASTIC ROCKS IN THE CORES OF CRUSTAL-SCALE FAULTS: EXAMPLES FROM THE MEDIAN TECTONIC LINE, JAPAN","THE MEDIAN TECTONIC LINE (MTL) IS JAPAN'S LARGEST ONSHORE FAULT AND HAS BEEN ACTIVE SINCE THE MID-CRETACEOUS. FOLIATED CATACLASTIC FAULT ROCKS ARE EXCEPTIONALLY WELL EXPOSED IN THE FAULT CORE AT ANKO, NAGANO PREFECTURE. FOLLOWING AN EARLY PHASE OF MYLONITIZATION AND EXHUMATION DURING LEFT-LATERAL SHEARING, BRITTLE FRACTURE AND CATACLASIS OCCURRED LEADING TO THE DEVELOPMENT OF CENTIMETER- TO SUBMILLIMETER-SPACED, FAULT ZONE PARALLEL FRACTURE SYSTEMS. THESE FRACTURE SYSTEMS ESTABLISHED AN INITIAL ARCHITECTURAL HIERARCHY THAT INFLUENCED THE SUBSEQUENT DEVELOPMENT OF FOLIATED CATACLASITES AND GOUGE. INITIALLY, FRACTURE SYSTEMS COALESCED TO FORM INTERCONNECTED ZONES OF FINE-GRAINED ULTRACATACLASITE. FLUID INFLUX AT THE ONSET OF GRAIN-SCALE BRITTLE DEFORMATION LED TO PRECIPITATION OF FIBROUS CHLORITE WITHIN THE ULTRACATACLASITES, ULTIMATELY LEADING TO THE DEVELOPMENT OF AN INTERCONNECTED NETWORK OF FOLIATED, PHYLLOSILICATE-RICH CATACLASITES AND GOUGES IN THE CORE OF THE MTL. THE BRITTLE REDUCTION OF GRAIN SIZE AND INGRESS OF A CHEMICALLY ACTIVE FLUID PHASE SIMULTANEOUSLY PROMOTED REACTION SOFTENING AND DIFFUSIVE MASS TRANSFER IN THE FOLIATED ULTRACATACLASITES, LEADING TO RATE-DEPENDENT ""FRICTIONAL-VISCOUS"" FLOW AT SUB-BYERLEE FRICTION VALUES. ASSOCIATED WEAKENING IS INDICATED BY THE PREFERENTIAL LOCALIZATION OF DEFORMATION WITHIN THE ULTRACATACLASITES. A PROTRACTED SEQUENCE OF CARBONATE MINERALIZATION AND CEMENTATION EVENTS IS ALSO RECOGNIZED DURING THE FAULT ROCK EVOLUTION AND SUGGESTS EPISODIC PERIODS OF FLUID OVERPRESSURING. A CRUSTAL-SCALE FAULT ZONE MODEL IS PROPOSED, SUGGESTING THAT THE FOLIATED CATACLASITES/GOUGES ARE WEAK IN THE LONG TERM AND REPRESENT SHALLOWER CRUSTAL EQUIVALENTS OF PHYLLONITIC FAULT ROCKS EXPOSED IN MORE DEEPLY EXHUMED FAULT ZONES, INCLUDING OTHER PARTS OF THE MTL.",BRITTLE-DUCTILE TRANSITION; FRICTIONAL-VISCOUS FLOW; GOUGE-BEARING FAULTS; EXPERIMENTAL DEFORMATION; WEAKENING MECHANISMS; INTERNAL STRUCTURE; PRESSURE SOLUTION; SOUTHWEST JAPAN; ZONE; SLIP,NA,JOURNAL OF GEOPHYSICAL RESEARCH-SOLID EARTH,"JEFFERIES, SP##HOLDSWORTH, RE##SHIMAMOTO, T##TAKAGI, H##LLOYD, GE##SPIERS, CJ","UNIV DURHAM, DEPT EARTH SCI, REACTIVAT RES GRP, DURHAM DH1 3LE, ENGLAND. KYOTO UNIV, GRAD SCH SCI, DEPT GEOL & MINERAL, KYOTO 6068501, JAPAN. WASEDA UNIV, DEPT EARTH SCI, SHINJUKU KU, TOKYO 1698050, JAPAN. UNIV LEEDS, DEPT EARTH SCI, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND. UNIV UTRECHT, DEPT EARTH SCI, HPT LAB, NL-3508 TA UTRECHT, NETHERLANDS.",GEOCHEMISTRY & GEOPHYSICS,GEOCHEMISTRY & GEOPHYSICS,"BEELER NM, 1996, J GEOPHYS RES-SOL EA, V101, P8697, DOI 10.1029/96JB00411##BOS B, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000301##BOS B, 2000, TECTONOPHYSICS, V327, P173, DOI 10.1016/S0040-1951(00)00168-2##BOS B, 2000, EARTH PLANET SC LETT, V184, P199, DOI 10.1016/S0012-821X(00)00304-6##BOS B, 2000, J GEOPHYS RES-SOL EA, V105, P16699, DOI 10.1029/2000JB900089##CHESTER FM, 1986, PURE APPL GEOPHYS, V124, P79, DOI 10.1007/BF00875720##CHESTER FM, 1985, TECTONOPHYSICS, V111, P139, DOI 10.1016/0040-1951(85)90071-X##CHESTER FM, 1995, J GEOPHYS RES-SOL EA, V100, P13033, DOI 10.1029/95JB00313##CHESTER FM, 1993, J GEOPHYS RES-SOL EA, V98, P771, DOI 10.1029/92JB01866##COLLETTINI C, 2004, J GEOL SOC LONDON, V161, P1039, DOI 10.1144/0016-764903-179##DIETERICH JH, 1979, J GEOPHYS RES, V84, P2162, DOI DOI 10.1029/JB084IB05P02151##EVANS JP, 1995, J GEOPHYS RES-SOL EA, V100, P13007, DOI 10.1029/94JB02625##GUEYDAN F, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000611##HANDY MR, 1990, J GEOPHYS RES-SOLID, V95, P8647, DOI 10.1029/JB095IB06P08647##HANDY MR, 1994, J STRUCT GEOL, V16, P287, DOI 10.1016/0191-8141(94)90035-3##HARA I, 1980, MEM GEOL SOC JPN, V18, P27##HAYAMA Y, 1980, MEM GEOL SOC JPN, V18, P5##HAYAMA Y, 1963, EARTH SCI, V66, P23##HOLDSWORTH RE, 2004, SCIENCE, V303, P181, DOI 10.1126/SCIENCE.1092491##HOLDSWORTH RE, 2001, GEOL SOC SPEC PUBL, V184, P115, DOI 10.1144/GSL.SP.2001.184.01.07##ICHIKAWA K., 1980, MEMOIRS GEOL SOC JAP, V18, P187##IMBER J, 2001, TECTONICS, V20, P601, DOI 10.1029/2000TC001250##ITO M, 1978, MTL, V3, P99##JEFFERIES SP, 2006, J STRUCT GEOL, V28, P220, DOI 10.1016/J.JSG.2005.10.008##LUAN FC, 1992, J GEOPHYS RES-SOL EA, V97, P301, DOI 10.1029/91JB01748##MARES VM, 1993, J STRUCT GEOL, V15, P1061, DOI 10.1016/0191-8141(93)90156-5##MARIANI E, 2006, J STRUCT GEOL, V28, P1569, DOI 10.1016/J.JSG.2006.06.009##NIEMEIJER AR, 2005, GEOL SOC SPEC PUBL, V245, P303, DOI 10.1144/GSL.SP.2005.245.01.15##OHTOMO Y., 1993, J SCI HIROSHIMA U C, V9, P611##OKADA A, 1980, MEM GEOL SOC JPN, V18, P79##SCHMID S.M., 1991, CONTROVERSIES MODERN, P339##SIBSON RH, 1977, J GEOL SOC LONDON, V133, P191, DOI [10.1144/GSJGS.133.3.0191, DOI 10.1144/GSJGS.133.3.0191]##SNOKE A. W., 1998, FAULT RELATED ROCKS##STEWART M, 2000, J STRUCT GEOL, V22, P543, DOI 10.1016/S0191-8141(99)00164-9##SUZUKI K, 1998, J METAMORPH GEOL, V16, P23, DOI 10.1111/J.1525-1314.1998.00057.X##TAKAGI H, 1986, J STRUCT GEOL, V8, P3, DOI 10.1016/0191-8141(86)90013-1##TAKAGI H., 1992, J GEOLOGICAL SOC JAP, V98, P1069##TAKAGI H., 1984, J GEOL SOC JPN, V90, P81##TANAKA H, 1996, J TECTONIC RES GROUP, V41, P31##WIBBERLEY CAJ, 2005, GEOL SOC SPEC PUBL, V245, P347, DOI 10.1144/GSL.SP.2005.245.01.17##WIBBERLEY CAJ, 2003, J STRUCT GEOL, V25, P59, DOI 10.1016/S0191-8141(02)00014-7##WINTSCH RP, 1995, J GEOPHYS RES-SOL EA, V100, P13021, DOI 10.1029/94JB02622##YAMAMOTO H, 1994, J STRUCT GEOL, V16, P61, DOI 10.1016/0191-8141(94)90018-3##YUNG RA, 1990, J GEOPHYS RES-SOLID, V95, P15589, DOI 10.1029/JB095IB10P15589",48,2020-11-20,"GRANTS-IN-AID FOR SCIENTIFIC RESEARCHMINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE AND TECHNOLOGY, JAPAN (MEXT)JAPAN SOCIETY FOR THE PROMOTION OF SCIENCEGRANTS-IN-AID FOR SCIENTIFIC RESEARCH (KAKENHI) [17654097] FUNDING SOURCE: KAKEN"
J,WOS:000243416800067,2006,ADENOVIRUS-SPECIFIC CD4(+) T CELL CLONES RECOGNIZING ENDOGENOUS ANTIGEN INHIBIT VIRAL REPLICATION IN VITRO THROUGH COGNATE INTERACTION,"HUMAN ADENOVIRUS (HADV) INFECTION IS A FREQUENT AND POTENTIALLY SEVERE COMPLICATION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN. BECAUSE TREATMENT WITH ANTIVIRAL DRUGS IS OFTEN INEFFECTIVE, ADOPTIVE TRANSFER OF DONOR-DERIVED HADV-SPECIFIC T CELLS ABLE TO CONTROL VIRAL REPLICATION OF HADV OF MULTIPLE SEROTYPES MAY BE AN OPTION FOR THERAPY. IN HEALTHY DONORS, PREDOMINANTLY HADV-SPECIFIC T CELLS EXPRESSING CD4 ARE DETECTED. IN THIS STUDY, A PRECLINICAL IN VITRO MODEL WAS USED TO MEASURE THE ANTIVIRAL EFFECT OF HADV-SPECIFIC CD4(+) T CELLS. CD4(+) HADV-SPECIFIC T CELL CLONES RESTRICTED BY HLA CLASS 11 MOLECULES WERE GENERATED AND MOST OF THESE CLONES RECOGNIZED CONSERVED PEPTIDES DERIVED FROM THE HEXON PROTEIN. THESE CROSS-REACTIVE T CELL CLONES WERE ABLE TO CONTROL VIRAL REPLICATION OF MULTIPLE SEROTYPES OF HADV IN EBV-TRANSFORMED B CELLS (B-LCL), MELANOMA CELLS (MJS) AND PRIMARY BRONCHIAL EPITHELIAL CELLS THROUGH COGNATE INTERACTION. THE HADV-SPECIFIC CD4(+) T CELL CLONES WERE ABLE TO SPECIFICALLY LYSE INFECTED TARGET CELLS USING A PERFORIN-DEPENDENT MECHANISM. ANTIGENIC PEPTIDES WERE ALSO PRESENTED TO THE CD4(+) T CELL CLONES WHEN DERIVED FROM ENDOGENOUSLY PRODUCED HEXON PROTEIN. TOGETHER, THESE RESULTS SHOW THAT CROSS-REACTIVE HADV-SPECIFIC CD4(+) T CELLS CAN CONTROL REPLICATION OF HADV IN VITRO AND PROVIDE A RATIONALE FOR THE USE OF HADV-SPECIFIC T CELLS IN ADOPTIVE IMMUNOTHERAPY PROTOCOLS FOR CONTROL OF LIFE-THREATENING HADV-INFECTIONS IN IMMUNOCOMPROMISED PATIENTS.",MHC CLASS-II; BONE-MARROW-TRANSPLANTATION; EXTENSIVE CROSS-REACTIVITY; IMMUNOCOMPROMISED HOST; MEDIATED CYTOTOXICITY; IMMUNE RECOVERY; INFECTED CELLS; EX-VIVO; B-CELLS; RESPONSES,NA,JOURNAL OF IMMUNOLOGY,"HEEMSKERK, B##VAN VREESWIJK, T##VELTROP-DUITS, LA##SOMBROEK, CC##FRANKEN, K##VERHOOSEL, RM##HIEMSTRA, PS##VAN LEEUWEN, D##RESSING, ME##TOES, REM##VAN TOL, MJD##SCHILHAM, MW","LEIDEN UNIV, MED CTR, DEPT PEDIAT, NL-2300 RC LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT IMMUNOHEMATOL & BLOODTRANSFUS, NL-2300 RC LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT PULMONOL, NL-2300 RC LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT MED MICROBIOL, NL-2300 RC LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT RHEUMATOL, NL-2300 RC LEIDEN, NETHERLANDS.",IMMUNOLOGY,IMMUNOLOGY,"ADHIKARY D, 2006, J EXP MED, V203, P995, DOI 10.1084/JEM.20051287##APPAY V, 2002, J IMMUNOL, V168, P5954, DOI 10.4049/JIMMUNOL.168.11.5954##BALDWIN A, 2000, BONE MARROW TRANSPL, V26, P1333, DOI 10.1038/SJ.BMT.1702716##BOSS JM, 2003, CURR OPIN IMMUNOL, V15, P105, DOI 10.1016/S0952-7915(02)00015-8##BROWN IWM, 2004, CURR APPL PHYS, V4, P171, DOI 10.1016/J.CAP.2003.11.001##CARRIGAN DONALD R., 1997, AMERICAN JOURNAL OF MEDICINE, V102, P71, DOI 10.1016/S0002-9343(97)00015-6##CHAKRABARTI S, 2000, BONE MARROW TRANSPL, V26, P305, DOI 10.1038/SJ.BMT.1702508##CHAKRABARTI S, 2002, BLOOD, V100, P1619, DOI 10.1182/BLOOD-2002-02-0377##DANI A, 2004, J CELL SCI, V117, P4219, DOI 10.1242/JCS.01288##DE JONG JC, 1999, J CLIN MICROBIOL, V37, P3940, DOI 10.1128/JCM.37.12.3940-3945.1999##ECHAVARRIA M, 2001, LANCET, V358, P384, DOI 10.1016/S0140-6736(01)05580-5##EINSELE H, 2002, BLOOD, V99, P3916, DOI 10.1182/BLOOD.V99.11.3916##FLOMENBERG P, 1995, J INFECT DIS, V171, P1090, DOI 10.1093/INFDIS/171.5.1090##FLOMENBERG P, 1994, J INFECT DIS, V169, P775, DOI 10.1093/INFDIS/169.4.775##HALE GA, 1999, BONE MARROW TRANSPL, V23, P277, DOI 10.1038/SJ.BMT.1701563##HEEMSKERK B, 2005, J INFECT DIS, V191, P520, DOI 10.1086/427513##HEEMSKERK B, 2003, J VIROL, V77, P6562, DOI 10.1128/JVI.77.11.6562-6566.2003##HEEMSKERK MHM, 1995, IMMUNOLOGY, V84, P521##HEGDE NR, 2005, J EXP MED, V202, P1109, DOI 10.1084/JEM.20050162##HESLOP HE, 1997, IMMUNOL REV, V157, P217, DOI 10.1111/J.1600-065X.1997.TB00984.X##HIERHOLZER JC, 1992, CLIN MICROBIOL REV, V5, P262, DOI 10.1128/CMR.5.3.262-274.1992##HORWITZ MS, 2001, FIELDS VIROLOGY, P2301##HROMAS R, 1994, BLOOD, V84, P1689, DOI 10.1182/BLOOD.V84.5.1689.BLOODJOURNAL8451689##KATAOKA T, 1996, J IMMUNOL, V156, P3678##KAYAGAKI N, 1999, J IMMUNOL, V162, P2639##KHANOLKAR A, 2001, VIROLOGY, V287, P79, DOI 10.1006/VIRO.2001.1020##KINSELLA TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/HUM.1996.7.12-1405##KOJAOGHLANIAN T, 2003, REV MED VIROL, V13, P155, DOI 10.1002/RMV.386##LANDAIS E, 2005, J IMMUNOL, V175, P7939, DOI 10.4049/JIMMUNOL.175.12.7939##LANKESTER AC, 2002, CLIN INFECT DIS, V34, P864, DOI 10.1086/339073##LAVERY D, 1987, J VIROL, V61, P1466, DOI 10.1128/JVI.61.5.1466-1472.1987##LE ROY E, 2002, J IMMUNOL, V169, P1293, DOI 10.4049/JIMMUNOL.169.3.1293##LEEN AM, 2004, BLOOD, V104, P2432, DOI 10.1182/BLOOD-2004-02-0646##LEEN AM, 2004, BLOOD, V103, P1011, DOI 10.1182/BLOOD-2003-07-2449##LERUEZ-VILLE M, 2004, CLIN INFECT DIS, V38, P45, DOI 10.1086/380450##LICH JD, 2000, J EXP MED, V191, P1513, DOI 10.1084/JEM.191.9.1513##LION T, 2003, BLOOD, V102, P1114, DOI 10.1182/BLOOD-2002-07-2152##LJUNGMAN P, 2004, EUR J CLIN MICROBIOL, V23, P583, DOI 10.1007/S10096-004-1165-X##LJUNGMAN PER, 1997, AMERICAN JOURNAL OF MEDICINE, V102, P44, DOI 10.1016/S0002-9343(97)00010-7##MOORE ML, 2004, J VIROL, V78, P5584, DOI 10.1128/JVI.78.11.5584-5590.2004##MOORE ML, 2003, J VIROL, V77, P10060, DOI 10.1128/JVI.77.18.10060-10070.2003##MUKHERJEE P, 2001, J IMMUNOL, V167, P2632, DOI 10.4049/JIMMUNOL.167.5.2632##NIKIFOROW S, 2003, J VIROL, V77, P12088, DOI 10.1128/JVI.77.22.12088-12104.2003##OLIVE M, 2002, HUM GENE THER, V13, P1167, DOI 10.1089/104303402320138952##OLIVE M, 2001, VIRAL IMMUNOL, V14, P403, DOI 10.1089/08828240152716646##PALUDAN C, 2005, SCIENCE, V307, P593, DOI 10.1126/SCIENCE.1104904##REGN S, 2001, BONE MARROW TRANSPL, V27, P53, DOI 10.1038/SJ.BMT.1702752##RUNDE V, 2001, BONE MARROW TRANSPL, V28, P51, DOI 10.1038/SJ.BMT.1703083##RUX JJ, 2000, MOL THER, V1, P18, DOI 10.1006/MTHE.1999.0001##SCHAGEN FHE, 1999, GENE THER, V6, P873, DOI 10.1038/SJ.GT.3300897##SCHILHAM MW, 2002, CLIN INFECT DIS, V35, P526, DOI 10.1086/341770##SCHOTTE H, 2001, RHEUMATOLOGY, V40, P393, DOI 10.1093/RHEUMATOLOGY/40.4.393##SCOTTTAYLOR TH, 1992, J CLIN MICROBIOL, V30, P1703, DOI 10.1128/JCM.30.7.1703-1710.1992##SESTER M, 2002, J INFECT DIS, V185, P1379, DOI 10.1086/340502##SHRESTA S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6##SMITH CA, 1998, HUM GENE THER, V9, P1419, DOI 10.1089/HUM.1998.9.10-1419##SMITH CA, 1996, J VIROL, V70, P6733, DOI 10.1128/JVI.70.10.6733-6740.1996##SMYTH MJ, 2001, J LEUKOCYTE BIOL, V70, P18##SOUBERBIELLE BE, 1995, J INFECT DIS, V172, P1421, DOI 10.1093/INFDIS/172.5.1421-A##TANG J, 2006, VIROLOGY, V350, P312, DOI 10.1016/J.VIROL.2006.01.024##TANG J, 2004, GENE THER, V11, P1408, DOI 10.1038/SJ.GT.3302316##TEWARI MK, 2005, NAT IMMUNOL, V6, P287, DOI 10.1038/NI1171##TOLLEFSON AE, 1998, NATURE, V392, P726, DOI 10.1038/33712##VAN LIER RAW, 2003, NAT REV IMMUNOL, V3, P931, DOI 10.1038/NRI1228##VAN TOL MJD, 2005, BONE MARROW TRANSPL, V36, P39, DOI 10.1038/SJ.BMT.1705003##VAN WETERING S, 2000, J INVEST MED, V48, P359##VELTROP-DUITS LA, 2006, EUR J IMMUNOL, V36, P2410, DOI 10.1002/EJI.200535786##WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603##WOLD WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8##YANAI F, 2003, J IMMUNOL, V170, P2205, DOI 10.4049/JIMMUNOL.170.4.2205##YASUKAWA M, 1999, J IMMUNOL, V162, P6100",28,2020-11-20,NA
J,WOS:000242988100007,2006,STABILITY AND OXYGEN PERMEATION BEHAVIOR OF CE0.8SM0.2O2-DELTA-LA0.8SR0.2CRC3-DELTA COMPOSITE MEMBRANE UNDER LARGE OXYGEN PARTIAL PRESSURE GRADIENTS,"THE STABILITY AND OXYGEN PERMEATION BEHAVIOR OF THE CE0.8SM0.2-DELTA-LA0.8SR0.2CRO3-DELTA DUAL-PHASE COMPOSITE WERE INVESTIGATED UNDER A LARGE OXYGEN GRADIENT WITH ONE SIDE OF IT EXPOSED TO AIR AND THE OTHER SIDE TO CO, CH4 OR H-2 AT ELEVATED TEMPERATURES. AN OXYGEN PERMEATION FLUX OF 8.6 X 10(-7) MOL CM(-2) S(-1) WAS OBTAINED WITH A 1.1 MM THICK MEMBRANE TUBE UNDER AIR/CO GRADIENT AT 950 DEGREES C, AND NO DECREASE IN THE FLUX WAS OBSERVED WITHIN A PERIOD OF 110 H. THE OXYGEN FLUX UNDER AIR/CO GRADIENT WAS FOUND TO BE ABOUT TWICE THAT UNDER AIR/CH4 OR AIR/H-2 GRADIENTS, WHICH MAY BE ATTRIBUTED TO THE HIGHER CATALYTIC ACTIVITY OF THE MEMBRANE TOWARDS THE OXIDATION OF CO. THE MEMBRANE TUBE REMAINED INTACT AFTER HIGH TEMPERATURE OPERATION FOR OVER 1000 IT, AND NO SIGNIFICANT CHANGE IN THE PHASE COMPOSITION AND MICROSTRUCTURE OCCURRED. THE DUAL-PHASE COMPOSITE MAY SATISFY THE STABILITY REQUIREMENT UNDER THE STRINGENT MEMBRANE REACTOR CONDITIONS. (C) 2006 PUBLISHED BY ELSEVIER B.V.",OXIDE FUEL-CELL; PEROVSKITE-TYPE OXIDES; PARTIAL OXIDATION; METHANE; SYNGAS; CERIA; REACTOR; PERMEABILITY; CONVERSION; CATALYSTS,OXYGEN PERMEATION; STABILITY; LANTHANUM CHROMITE; CERIA; COMPOSITE; MEMBRANE,JOURNAL OF MEMBRANE SCIENCE,"WANG, B##YI, JX##WINNUBST, L##CHEN, CS","UNIV SCI & TECHNOL CHINA, DEPT MAT SCI & ENGN, LAB ADV FUNCT MAT & DEVICES, HEFEI 230026, ANHUI, PEOPLES R CHINA. UNIV TWENTE, FAC SCI & TECHNOL, MESA RES INST NANOTECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS.","ENGINEERING, CHEMICAL; POLYMER SCIENCE",ENGINEERING; POLYMER SCIENCE,"BADWAL SPS, 1999, SOLID STATE IONICS, V121, P253, DOI 10.1016/S0167-2738(99)00044-2##BALACHANDRAN U, 1997, CATAL TODAY, V36, P265, DOI 10.1016/S0920-5861(96)00229-5##CHEN C. S., 1994, THESIS U TWENTE NETH##CHEN CS, 2003, ANGEW CHEM INT EDIT, V42, P5196, DOI 10.1002/ANIE.200351085##DOSHI R, 1993, J CATAL, V140, P557, DOI 10.1006/JCAT.1993.1105##FERGUS JW, 2004, SOLID STATE IONICS, V171, P1, DOI 10.1016/J.SSI.2004.04.010##HENDRIKSEN PV, 2000, CATAL TODAY, V56, P283, DOI 10.1016/S0920-5861(99)00286-2##ISHIHARA T, 2003, J ELECTROCHEM SOC, V150, PE17, DOI 10.1149/1.1524174##KHARTON VV, 2000, J ELECTROCHEM SOC, V147, P2814, DOI 10.1149/1.1393611##KRUIDHOF H, 1993, SOLID STATE IONICS, V63-5, P816, DOI 10.1016/0167-2738(93)90202-E##MAZANEC TJ, 1992, SOLID STATE IONICS, V53, P111, DOI 10.1016/0167-2738(92)90372-V##MOGENSEN M, 2000, SOLID STATE IONICS, V129, P63, DOI 10.1016/S0167-2738(99)00318-5##NAKAMURA T, 1979, MATER RES BULL, V14, P649, DOI 10.1016/0025-5408(79)90048-5##PEI S, 1995, CATAL LETT, V30, P201, DOI 10.1007/BF00813686##SFEIR J, 2001, J CATAL, V202, P229, DOI 10.1006/JCAT.2001.3286##TAKAMURA H, 2006, J ALLOY COMPD, V408, P1084, DOI 10.1016/J.JALLCOM.2004.12.139##TAO SW, 2003, NAT MATER, V2, P320, DOI 10.1038/NMAT871##TERAOKA Y, 1985, CHEM LETT, P1743, DOI 10.1246/CL.1985.1743##WANG HH, 2003, CATAL TODAY, V82, P157, DOI 10.1016/S0920-5861(03)00228-1##YAHIRO H, 1989, SOLID STATE IONICS, V36, P71, DOI 10.1016/0167-2738(89)90061-1##YI JX, UNPUB J MEMBR SCI##YOKOKAWA H, 1992, SOLID STATE IONICS, V52, P43, DOI 10.1016/0167-2738(92)90090-C##ZHU DC, 2003, CATAL TODAY, V82, P151, DOI 10.1016/S0920-5861(03)00224-4",39,2020-11-20,NA
J,WOS:000242769200010,2006,"MOSAIC STRUCTURE OF HUMAN CORONAVIRUS NL63, ONE THOUSAND YEARS OF EVOLUTION","BEFORE THE SARS OUTBREAK ONLY TWO HUMAN CORONAVIRUSES (HCOV) WERE KNOWN: HCOV-OC43 AND HCOV-229E. WITH THE DISCOVERY OF SARS-COV IN 2003, A THIRD FAMILY MEMBER WAS IDENTIFIED. SOON THEREAFTER, WE DESCRIBED THE FOURTH HUMAN CORONAVIRUS (HCOV-NL63), A VIRUS THAT HAS SPREAD WORLDWIDE AND IS ASSOCIATED WITH CROUP IN CHILDREN. WE REPORT HERE THE COMPLETE GENOME SEQUENCE OF TWO HCOV-NL63 CLINICAL ISOLATES, DESIGNATED AMSTERDAM 57 AND AMSTERDAM 496. THE GENOMES ARE 27,538 AND 27,550 NUCLEOTIDES LONG, RESPECTIVELY, AND SHARE THE SAME GENOME ORGANIZATION. WE IDENTIFIED TWO VARIABLE REGIONS, ONE WITHIN THE LA AND ONE WITHIN THE S GENE, WHEREAS THE 1B AND N GENES WERE MOST CONSERVED. PHYLOGENETIC ANALYSIS REVEALED THAT HCOV-NL63 GENOMES HAVE A MOSAIC STRUCTURE WITH MULTIPLE RECOMBINATION SITES. ADDITIONALLY, EMPLOYING THREE DIFFERENT ALGORITHMS, WE ASSESSED THE EVOLUTIONARY RATE FOR THE S GENE OF GROUP 1B CORONAVIRUSES TO BE SIMILAR TO 3 X 10(-4) SUBSTITUTIONS PER SITE PER YEAR. USING THIS EVOLUTIONARY RATE WE DETERMINED THAT HCOV-NL63 DIVERGED IN THE 11TH CENTURY FROM. ITS CLOSEST RELATIVE HCOV-229E. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",INFECTIOUS-BRONCHITIS VIRUS; MURINE HEPATITIS-VIRUS; RESPIRATORY SYNDROME CORONAVIRUS; KAWASAKI-DISEASE; RNA RECOMBINATION; NATURAL RECOMBINATION; VIRAL REPLICATION; CHILDREN; SEQUENCE; ASSOCIATION,CORONAVIRUS; HCOV-NL63; RECOMBINATION; EVOLUTION; MOLECULAR CLOCK,JOURNAL OF MOLECULAR BIOLOGY,"PYRC, K##DIJKMAN, R##DENG, L##JEBBINK, MF##ROSS, HA##BERKHOUT, B##VAN DER HOEK, L","UNIV AMSTERDAM, LAB EXPT VIROL, DEPT MED MICROBIOL, CTR INFECT & IMMUN AMSTERDAM,ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AUCKLAND, SCH BIOL SCI, AUCKLAND 1, NEW ZEALAND. UNIV AUCKLAND, BIOINFORMAT INST, AUCKLAND 1, NEW ZEALAND.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"ARDEN KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/JMV.20288##BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3##BASTIEN N, 2005, J CLIN MICROBIOL, V43, P4567, DOI 10.1128/JCM.43.9.4567-4573.2005##BASTIEN N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869##BROCKWAY SM, 2005, VIROLOGY, V340, P209, DOI 10.1016/J.VIROL.2005.06.035##CAVANAGH D, 1993, ADV EXP MED BIOL, V342, P255##CHANG LY, 2006, J INFECT DIS, V193, P283, DOI 10.1086/498875##CHIU SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301##DRUMMOND A, 2001, MOL BIOL EVOL, V18, P1365, DOI 10.1093/OXFORDJOURNALS.MOLBEV.A003920##DRUMMOND A, 2000, MOL BIOL EVOL, V17, P1807, DOI 10.1093/OXFORDJOURNALS.MOLBEV.A026281##DRUMMOND AJ, 2002, GENETICS, V161, P1307##EBIHARA T, 2005, J INFECT DIS, V192, P351, DOI 10.1086/430797##EBIHARA T, 2005, J MED VIROL, V75, P463, DOI 10.1002/JMV.20289##ESPER F, 2005, J INFECT DIS, V191, P499, DOI 10.1086/428291##FOUCHIER RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/PNAS.0400762101##GOODE M, 2004, CURRENT PROTOCOLS BI##GRAHAM RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005##GUY JS, 2000, J CLIN MICROBIOL, V38, P4523, DOI 10.1128/JCM.38.12.4523-4526.2000##HERREWEGH AAPM, 1998, J VIROL, V72, P4508, DOI 10.1128/JVI.72.5.4508-4514.1998##HOFMANN H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/PNAS.0409465102##JIA W, 1995, ARCH VIROL, V140, P259, DOI 10.1007/BF01309861##KAISER L, 2005, PEDIATR INFECT DIS J, V24, P1015, DOI 10.1097/01.INF.0000183773.80217.12##KECK JG, 1988, J VIROL, V62, P1810, DOI 10.1128/JVI.62.5.1810-1813.1988##KOTIER SA, 1995, VIROLOGY, V213, P569, DOI 10.1006/VIRO.1995.0029##KUSTERS JG, 1990, VACCINE, V8, P605, DOI 10.1016/0264-410X(90)90018-H##LAI MM, 2005, FIELDS VIROLOGY, P1163##LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985##LOLE KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999##MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986##MOES E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6##NIELSEN R, 1998, GENETICS, V148, P929##POON LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005##PYRC K, 2006, ANTIMICROB AGENTS CH, V50, P2000, DOI 10.1128/AAC.01598-05##PYRC K, 2004, VIROL J, V1, DOI 10.1186/1743-422X-1-7##RISCO C, 1995, J VIROL, V69, P5269, DOI 10.1128/JVI.69.9.5269-5277.1995##SANCHEZ CM, 1992, VIROLOGY, V190, P92, DOI 10.1016/0042-6822(92)91195-Z##SHARP PM, 1985, J MOL EVOL, V21, P150, DOI 10.1007/BF02100089##SHI ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999##SHIMIZU C, 2005, J INFECT DIS, V192, P1767, DOI 10.1086/497170##SMITS SL, 2003, J VIROL, V77, P9567, DOI 10.1128/JVI.77.17.9567-9577.2003##SUZUKI A, 2005, PEDIATR INFECT DIS J, V24, P645, DOI 10.1097/01.INF.0000168846.71517.EE##TIJMS MA, 2001, P NATL ACAD SCI USA, V98, P1889, DOI 10.1073/PNAS.041390398##VABRET A, 2005, EMERG INFECT DIS, V11, P1225, DOI 10.3201/EID1108.050110##VAN DER HOEK L, 2005, PLOS MED, V2, P764, DOI 10.1371/JOURNAL.PMED.0020240##VAN DER HOEK L, 2004, NAT MED, V10, P368, DOI 10.1038/NM1024##VIJGEN L, 2005, J VIROL, V79, P3223, DOI 10.1128/JVI.79.5.3223-3225.2005##VIJGEN L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005##VIJGEN L, 2006, J VIROL, V80, P7270, DOI 10.1128/JVI.02675-05##WANG L, 1993, VIROLOGY, V192, P710, DOI 10.1006/VIRO.1993.1093##WOO PCY, 2006, J VIROL, V80, P7136, DOI 10.1128/JVI.00509-06##WOO PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005##YANG ZH, 1997, COMPUT APPL BIOSCI, V13, P555",88,2020-11-20,NA
J,WOS:000242327500011,2006,ZR-TUD-1: A NOVEL HETEROGENEOUS CATALYST FOR THE MEERWEIN-PONNDORF-VERLEY REACTION,"A NEW, THREE-DIMENSIONAL, AMORPHOUS MESOPOROUS SILICATE CONTAINING ZIRCONIUM, ZR-TUD-1, WAS SYNTHESISED VIA A DIRECT HYDROTHERMAL TREATMENT METHOD USING TRIETHANOLAMINE AS THE TEMPLATE. THE MESOPOROSITY OF ZR-TUD-1 WAS CONFIRMED BY XRD, N-2 SORPTION AND HR-TEM STUDIES. THE ACID SITES PRESENT IN ZR-TUD-1 WERE EVALUATED BY FT-IR STUDIES OF PYRIDINE ADSORPTION AND SHOWN TO BE PREDOMINATELY LEWIS ACIDIC. THE NATURE OF ZIRCONIUM IN ZR-TUD-1 WAS ESTABLISHED BY FT-IR, XPS AND UV-VIS STUDIES. ZR-TUD-1 WAS TESTED IN THE MEERWEIN-PONNDORF-VERLEY REDUCTION. IT SHOWED A PROMISING ACTIVITY, IN PARTICULAR FOR THE STEREOSELECTIVE REDUCTION OF STEROIDS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",ZR-ZEOLITE-BETA; OPPENAUER REACTIONS; CYCLOHEXANE OXIDATION; SELECTIVE CATALYST; MESOPOROUS SILICA; REDUCTION; ZIRCONIUM; ALDEHYDES; HYDROGENATION; ALCOHOLS,MESOPOROUS SILICA; MEERWEIN-PONNDORF-VERLEY; PRINS-REACTION; ZIRCONIUM,JOURNAL OF MOLECULAR CATALYSIS A-CHEMICAL,"RAMANATHAN, A##KLOMP, D##PETERS, JA##HANEFELD, U","DELFT UNIV TECHNOL, NL-2628 BL DELFT, NETHERLANDS. KRICT, ADV CHEM TECHNOL DIV, TAEJON 305600, SOUTH KOREA.","CHEMISTRY, PHYSICAL",CHEMISTRY,"ANAND R, 2004, CATAL LETT, V95, P113, DOI 10.1023/B:CATL.0000027283.70453.1A##ARAMENDIA MA, 2003, APPL CATAL A-GEN, V249, P1, DOI 10.1016/S0926-860X(03)00163-7##ASTORINO E, 1995, J CATAL, V157, P482, DOI 10.1006/JCAT.1995.1313##ATTYGALLE AB, 2001, J CHEM SOC PERK T 2, P498, DOI 10.1039/B009019K##CAMBLOR MA, 1993, J CHEM SOC CHEM COMM, P557, DOI 10.1039/C39930000557##CAMPBELL EJ, 2001, ORG LETT, V3, P2391, DOI 10.1021/OL0162116##COHEN R, 2004, J AM CHEM SOC, V126, P14796, DOI 10.1021/JA047613M##CORMA A, 2003, J CATAL, V215, P294, DOI 10.1016/S0021-9517(03)00014-9##CREYGHTON EJ, 1997, J MOL CATAL A-CHEM, V115, P457, DOI 10.1016/S1381-1169(96)00351-2##DEGRAAUW JF, 1994, SYNTHESIS-STUTTGART, P1007##HAMDY MS, 2006, CHEM-EUR J, V12, P1782, DOI 10.1002/CHEM.200500166##HAMDY MS, 2005, CATAL TODAY, V110, P264, DOI 10.1016/J.CATTOD.2005.09.026##HAMDY MS, 2005, CATAL TODAY, V100, P255, DOI 10.1016/J.CATTOD.2004.10.018##INFANTES-MOLINA A, 2004, MICROPOR MESOPOR MAT, V75, P23, DOI 10.1016/J.MICROMESO.2004.06.025##ISHII Y, 1986, J ORG CHEM, V51, P240, DOI 10.1021/JO00352A021##IVANOV VA, 1994, J MOL CATAL, V91, P45, DOI 10.1016/0304-5102(94)00017-4##JANSEN JC, 2001, CHEM COMMUN, P713, DOI 10.1039/B101000J##JYOTHI TM, 2000, J MOL CATAL A-CHEM, V157, P193, DOI 10.1016/S1381-1169(99)00439-2##KLOMP D, 2005, ORG BIOMOL CHEM, V3, P483, DOI 10.1039/B413944E##KLOMP D, 2004, CHEM-EUR J, V10, P2088, DOI 10.1002/CHEM.200305460##KNAVER B, 1995, LIEBIGS ANN, P677##LIU SH, 2002, J CATAL, V206, P321, DOI 10.1006/JCAT.2001.3480##LIU YC, 2002, ORGANOMETALLICS, V21, P2066, DOI 10.1021/OM0200454##NAMY JL, 1984, J ORG CHEM, V49, P2045, DOI 10.1021/JO00185A053##NIE YT, 2006, CHEM COMMUN, P790, DOI 10.1039/B513430G##NISHIDE K, 2002, CHIRALITY, V14, P759, DOI 10.1002/CHIR.10142##NOYORI R, 2003, ADV SYNTH CATAL, V345, P15, DOI 10.1002/ADSC.200390002##OKANO T, 1987, CHEM LETT, P181, DOI 10.1246/CL.1987.181##OOI T, 2002, SYNTHESIS-STUTTGART, P279##RAKSHE B, 1997, CATAL LETT, V45, P41, DOI 10.1023/A:1019078520445##RODRIGUEZ-CASTELLON E, 2003, J SOLID STATE CHEM, V175, P159, DOI 10.1016/S0022-4596(03)00218-4##SHAN Z, 2001, CHEM-EUR J, V7, P1437, DOI 10.1002/1521-3765(20010401)7:7<1437::AID-CHEM1437>3.3.CO;2-D##SIMONS C, 2004, CHEM-EUR J, V10, P5829, DOI 10.1002/CHEM.200400528##VAN DER WAAL JC, 1997, TOP CATAL, V4, P261, DOI 10.1023/A:1019160827175##WEI MD, 2004, CATAL COMMUN, V5, P597, DOI 10.1016/J.CATCOM.2004.07.014##YONGZHONG Z., 2005, J CATAL, V229, P404##ZHU YZ, 2006, J CATAL, V241, P25, DOI 10.1016/J.JCAT.2006.04.008##ZHU YZ, 2004, J CATAL, V227, P1, DOI 10.1016/J.JCAT.2004.05.037##ZHU YZ, 2003, J CATAL, V218, P396, DOI 10.1016/S0021-9517(03)00160-X##ZHU YZ, 2003, CHEM COMMUN, P2734, DOI 10.1039/B309191K",37,2020-11-20,NA
J,WOS:000242327500022,2006,"IMMOBILIZATION AND ACTIVATION OF 2,6-BIS(IMINO)PYRIDYL FE, CR AND V PRECATALYSTS USING A MGCL2/ALRN(OET)(3-N) SUPPORT: EFFECTS ON POLYETHYLENE MOLECULAR WEIGHT AND MOLECULAR WEIGHT DISTRIBUTION","ETHYLENE POLYMERIZATIONS CARRIED OUT WITH VARIOUS BIS(IMINO)PYRIDYL IRON, CHROMIUM AND VANADIUM COMPLEXES IMMOBILIZED ON A MGCL2/AIR(N)(OET)(3-N) SUPPORT GAVE RELATIVELY BROAD POLYETHYLENE MOLECULAR WEIGHT DISTRIBUTIONS IN THE CASE OF IRON, BUT HIGH MOLECULAR WEIGHT AND A VERY NARROW MOLECULAR WEIGHT DISTRIBUTION WITH VANADIUM, INDICATIVE OF A SINGLE ACTIVE SPECIES. THE NARROW MWD WAS CONFIRMED BY MELT RHEOMETRY. SIMILAR RESULTS WERE OBTAINED AFTER REACTION OF THE BIS(IMINO)PYRIDYL COMPLEX LVCL3 (6) WITH MELI OR ALET3, WHERE ALKYLATION OF THE PYRIDINE RING GIVES A COMPLEX L'VCL2 (7). IN THE CASE OF CHROMIUM, A BIMODAL DISTRIBUTION WAS OBTAINED, WITH EVIDENCE OF INCOMPLETE CATALYST IMMOBILIZATION. THE POLYETHYLENE MOLECULAR WEIGHTS OBTAINED WITH THE IRON COMPLEXES WERE STRONGLY DEPENDENT ON THE SUBSTIMENTS IN THE BIS(IMINO)PYRIDYL LIGAND, AND WERE SOMEWHAT HIGHER THAN HAVE BEEN OBTAINED IN HOMOGENEOUS POLYMERIZATION. IN CONTRAST, THE MOLECULAR WEIGHTS OBTAINED WITH THE BIS(IMINO)PYRIDYL CHROMIUM AND VANADIUM COMPLEXES WERE MUCH HIGHER THAT THOSE PREVIOUSLY OBTAINED UNDER HOMOGENEOUS CONDITIONS. IN ALL CASES, THE ACTIVITIES OF THE IMMOBILIZED CATALYSTS WERE HIGHER THAN THOSE FOUND IN HOMOGENEOUS POLYMERIZATION. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",SINGLE-SITE CATALYSTS; OLEFIN POLYMERIZATION CATALYSTS; NICKEL DIIMINE CATALYSTS; LINEAR ALPHA-OLEFINS; ETHYLENE POLYMERIZATION; MGCL2-BASED ACTIVATORS; COBALT COMPLEXES; CHAIN GROWTH; IRON; METAL,CATALYSIS; ETHYLENE; IMMOBILIZATION; MAGNESIUM CHLORIDE; POLYMERIZATION,JOURNAL OF MOLECULAR CATALYSIS A-CHEMICAL,"HUANG, RB##KUKALYEKAR, N##KONING, CE##CHADWICK, JC","EINDHOVEN UNIV TECHNOL, POLYMER CHEM LAB, NL-5600 MB EINDHOVEN, NETHERLANDS. DUTCH POLYMER INST, NL-5600 AX EINDHOVEN, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"BARABANOV AA, 2005, MACROMOL CHEM PHYS, V206, P2292, DOI 10.1002/MACP.200500310##BLACKMORE IJ, 2005, J AM CHEM SOC, V127, P6012, DOI 10.1021/JA042657G##BRITOVSEK GJP, 2004, J AM CHEM SOC, V126, P10701, DOI 10.1021/JA0485560##BRITOVSEK GJP, 1998, CHEM COMMUN, P849, DOI 10.1039/A801933I##BRITOVSEK GJP, 1999, J AM CHEM SOC, V121, P8728, DOI 10.1021/JA990449W##BRITOVSEK GJP, 2002, ANGEW CHEM INT EDIT, V41, P489, DOI 10.1002/1521-3773(20020201)41:3<489::AID-ANIE489>3.0.CO;2-C##CHEN YF, 2003, ORGANOMETALLICS, V22, P4312, DOI 10.1021/OM0302894##DEVORE DD, 2000, PATENT NO. 0069923##ESTERUELAS MA, 2003, ORGANOMETALLICS, V22, P395, DOI 10.1021/OM020561U##GAMBAROTTA S, 2003, COORDIN CHEM REV, V237, P229, DOI 10.1016/S0010-8545(02)00298-9##HAGEN H, 2002, CHEM SOC REV, V31, P357, DOI 10.1039/B205238E##HLATKY GG, 2000, CHEM REV, V100, P1347, DOI 10.1021/CR9902401##HUANG RB, 2005, J MOL CATAL A-CHEM, V233, P91, DOI 10.1016/J.MOLCATA.2005.02.004##HUANG RB, 2004, MACROMOL CHEM PHYS, V205, P966, DOI 10.1002/MACP.200300213##KAUL FAR, 2002, ORGANOMETALLICS, V21, P74, DOI 10.1021/OM000939T##KIM I, 2003, MACROMOLECULES, V36, P6689, DOI 10.1021/MA0347060##KNIJNENBURG Q, 2006, ORGANOMETALLICS, V25, P1036, DOI 10.1021/OM050936M##KUMAR KR, 2000, MACROMOL CHEM PHYS, V201, P1513##MARKS TJ, 1992, ACCOUNTS CHEM RES, V25, P57, DOI 10.1021/AR00014A001##MIKENAS TB, 2005, J POLYM SCI POL CHEM, V43, P2128, DOI 10.1002/POLA.20687##NAKAYAMA Y, 2004, J MOL CATAL A-CHEM, V213, P141, DOI 10.1016/J.MOLCATA.2003.11.025##NAKAYAMA Y, 2004, B CHEM SOC JPN, V77, P617, DOI 10.1246/BCSJ.77.617##NAKAYAMA Y, 2003, CHEM LETT, V32, P766, DOI 10.1246/CL.2003.766##NAKAYAMA Y, 2003, J CATAL, V215, P171, DOI 10.1016/S0021-9517(02)00046-5##PELASCINI F, 2005, EUR POLYM J, V41, P1288, DOI 10.1016/J.EURPOLYMJ.2004.12.004##QUIJADA R, 2001, MACROMOLECULES, V34, P2411, DOI 10.1021/MA0012088##RADHAKRISHNAN K, 2003, MACROMOL RAPID COMM, V24, P251, DOI 10.1002/MARC.200390036##REARDON D, 1999, J AM CHEM SOC, V121, P9318, DOI 10.1021/JA990263X##SCHMIDT R, 2004, J MOL CATAL A-CHEM, V222, P17, DOI 10.1016/J.MOLCATA.2004.07.015##SCHMIDT R, 2002, J MOL CATAL A-CHEM, V179, P155, DOI 10.1016/S1381-1169(01)00333-8##SCOTT J, 2005, J AM CHEM SOC, V127, P13019, DOI 10.1021/JA054152B##SCOTT J, 2005, J AM CHEM SOC, V127, P17204, DOI 10.1021/JA056135S##SEVERN JR, 2005, CHEM REV, V105, P4073, DOI 10.1021/CR040670D##SEVERN JR, 2004, MACROMOLECULES, V37, P6258, DOI 10.1021/MA049247X##SEVERN JR, 2005, POLYM INT, V54, P837, DOI 10.1002/PI.1779##SEVERN JR, 2005, MACROMOL RAPID COMM, V26, P150, DOI 10.1002/MARC.200400500##SEVERN JR, 2004, MACROMOL CHEM PHYS, V205, P1987, DOI 10.1002/MACP.200400270##SEVERN JR, 2004, MACROMOL RAPID COMM, V25, P1024, DOI 10.1002/MARC.200400093##SEVERN JR, 2005, PATENT NO. 2005092935##SEVERN JR, 2005, PATENT NO. 2005077989##SMALL BL, 2004, MACROMOLECULES, V37, P4375, DOI 10.1021/MA035554B##SMALL BL, 1998, J AM CHEM SOC, V120, P7143, DOI 10.1021/JA981317Q##SMALL BL, 1998, J AM CHEM SOC, V120, P4049, DOI 10.1021/JA9802100##SOUANE R, 2002, CR CHIM, V5, P43, DOI 10.1016/S1631-0748(02)01329-2##SUGIYAMA H, 2002, J AM CHEM SOC, V124, P12268, DOI 10.1021/JA020485M##VEGA JF, 2004, J RHEOL, V48, P663, DOI 10.1122/1.1718367##WANG Q, 2005, EUR POLYM J, V41, P1170, DOI 10.1016/J.EURPOLYMJ.2005.01.008##WANG Q, 2004, J POLYM SCI POL CHEM, V42, P1093, DOI 10.1002/POLA.11078##XU RW, 2006, MACROMOL CHEM PHYS, V207, P779, DOI 10.1002/MACP.200500582##1995, PATENT NO. 5698487",37,2020-11-20,NA
J,WOS:000242919300019,2006,COOPERATIVE AND NON-COOPERATIVE DYNAMICS IN ULTRA-THIN FILMS OF POLYSTYRENE STUDIED BY DIELECTRIC SPECTROSCOPY AND CAPACITIVE DILATOMETRY,"THE EFFECT OF THICKNESS REDUCTIONS ON THE GLASS TRANSITION DYNAMICS IN ULTRATHIN. FILMS OF POLYSTYRENE HAS BEEN STUDIED BY DIELECTRIC SPECTROSCOPY (DS) AND CAPACITIVE DILATOMETRY (M). UPON REDUCTION OF THE FILM THICKNESS, A SYSTEMATIC DECREASE IN THE DILATOMETRIC GLASS TRANSITION TEMPERATURES, T-G (DIL), WAS OBSERVED VIA CD, WHILE DS REVEALED A CONTINUOUS SPEED-UP AND BROADENING OF THE ALPHA-PROCESS, ACCOMPANIED BY ONLY MINOR REDUCTIONS IN THE FRAGILITY INDEX. A GOOD AGREEMENT BETWEEN 'SPECTROSCOPIC' AND THE DILATOMETRIC GLASS TRANSITION TEMPERATURES WAS FOUND FOR FILMS THICKER THAN 20 NM, WHILE FOR THINNER FILMS BOTH QUANTITIES DIVERGE INCREASINGLY. A LIKELY EXPLANATION FOR THIS DISCREPANCY IS THE PRESENCE OF ANOTHER DYNAMIC PROCESS SHOWING ARRHENIUS-BEHAVIOR (E-A SIMILAR TO 72 KJ/MOL) WITH A PRE-EXPONENTIAL FACTOR OF 10(-12) S BEING INDICATIVE FOR NON-COOPERATIVE DYNAMICS. SUCH A NEW PROCESS MIGHT BE ASSIGNED TO DISTINCT SURFACE DYNAMICS IN POLYSTYRENE FILMS AS SUGGESTED IN RECENT PAPERS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",GLASS-TRANSITION TEMPERATURE; POLYMER-FILMS; POLY(METHYL METHACRYLATE); RELAXATIONS; CONFINEMENT; VISCOSITY; INTERFACE; SPECTRA,DIELECTRIC PROPERTIES; RELAXATION; ELECTRIC MODULUS; FILMS AND COATINGS; GLASS TRANSITION; FRAGILITY; STRUCTURAL RELAXATION,JOURNAL OF NON-CRYSTALLINE SOLIDS,"LUPASCU, V##PICKEN, SJ##WUBBENHORST, M","DELFT UNIV TECHNOL, DEPT CHEM TECHNOL, NL-2628 BL DELFT, NETHERLANDS. KATHOLIEKE UNIV LEUVEN, DEPT PHYS & ASTRON, B-3001 HEVERLEE, BELGIUM.","MATERIALS SCIENCE, CERAMICS; MATERIALS SCIENCE, MULTIDISCIPLINARY",MATERIALS SCIENCE,"BOHMER R, 1993, J CHEM PHYS, V99, P4201, DOI 10.1063/1.466117##CECCHETTO E, 2000, J PHYS IV, V10, P247, DOI 10.1051/JP4:2000749##DALNOKI-VERESS K, 2001, PHYS REV E, V63, DOI 10.1103/PHYSREVE.63.031801##DEMAGGIO GB, 1997, PHYS REV LETT, V78, P1524, DOI 10.1103/PHYSREVLETT.78.1524##EFREMOV MY, 2003, THERMOCHIM ACTA, V403, P37, DOI 10.1016/S0040-6031(03)00122-9##ELLISON CJ, 2002, EUR PHYS J E, V8, P155, DOI 10.1140/EPJE/I2001-10057-Y##FAUPEL F, 1998, MAT SCI ENG R, V22, P1, DOI 10.1016/S0927-796X(97)00020-X##FORREST JA, 1996, PHYS REV LETT, V77, P2002, DOI 10.1103/PHYSREVLETT.77.2002##FORREST JA, 2000, PHYS REV E, V61, PR53, DOI 10.1103/PHYSREVE.61.R53##FORREST JA, 2001, ADV COLLOID INTERFAC, V94, P167, DOI 10.1016/S0001-8686(01)00060-4##FORREST JA, 1997, PHYS REV E, V56, P5705, DOI 10.1103/PHYSREVE.56.5705##FORREST JA, 1998, PHYS REV E, V58, P6109, DOI 10.1103/PHYSREVE.58.6109##FRYER DS, 2000, MACROMOLECULES, V33, P6439, DOI 10.1021/MA0003349##FUKAO K, 2001, PHYS REV E, V64, DOI 10.1103/PHYSREVE.64.051807##FUKAO K, 2000, PHYS REV E, V61, P1743, DOI 10.1103/PHYSREVE.61.1743##FUKAO K, 1999, EUROPHYS LETT, V46, P649, DOI 10.1209/EPL/I1999-00309-6##FUKAO K, 2002, J NON-CRYST SOLIDS, V307, P517, DOI 10.1016/S0022-3093(02)01479-5##FUKAO K, 2000, J PHYS IV, V10, P243, DOI 10.1051/JP4:2000748##FULCHER GS, 1925, J AM CERAM SOC, V8, P339, DOI 10.1111/J.1151-2916.1925.TB16731.X##HARTMANN L, 2002, EUR PHYS J E, V8, P145, DOI 10.1140/EPJE/I2001-10073-Y##HAVRILIA.S, 1967, POLYMER, V8, P161, DOI 10.1016/0032-3861(67)90021-3##KAWANA S, 2001, PHYS REV E, V63, DOI 10.1103/PHYSREVE.63.021501##KEDDIE JL, 1994, EUROPHYS LETT, V27, P59, DOI 10.1209/0295-5075/27/1/011##LUPASCU V, 2005, THERMOCHIM ACTA, V432, P222, DOI 10.1016/J.TCA.2005.04.022##LUPASCU V, 2006, UNPUB##ROTH CB, 2003, EUR PHYS J E, V12, PS103, DOI 10.1140/EPJED/E2003-01-024-2##SERGHEI A, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.165702##SHARP JS, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.235701##SILLS S, 2004, J CHEM PHYS, V120, P5334, DOI 10.1063/1.1647047##STRUNSKUS T, 2000, ADV ENG MATER, V2, P489, DOI 10.1002/1527-2648(200008)2:8<489::AID-ADEM489>3.0.CO;2-T##TAMMANN G, 1926, Z ANORG ALLG CHEM, V156, P245, DOI [DOI 10.1002/ZAAC.19261560121, 10.1002/ZAAC.19261560121]##VAN TURNHOUT J, 2002, J NON-CRYST SOLIDS, V305, P50, DOI 10.1016/S0022-3093(02)01120-1##VOGEL H, 1921, PHYS Z, V22, P645##WALLACE WE, 1995, PHYS REV E, V52, PR3329, DOI 10.1103/PHYSREVE.52.R3329##WUBBENHORST M, 2002, 11TH INTERNATIONAL SYMPOSIUM ON ELECTRETS (ISE 11), P401, DOI 10.1109/ISE.2002.1043027##WUBBENHORST M, 2003, EUR PHYS J E, V12, PS109, DOI 10.1140/EPJED/E2003-01-025-1##WUBBENHORST M, 2002, J NON-CRYST SOLIDS, V305, P40, DOI 10.1016/S0022-3093(02)01086-4##WUBBENHORST M, 2005, ISE 12, P4",60,2020-11-20,NA
J,WOS:000242870400013,2006,NMDA RECEPTORS TRIGGER NEUROSECRETION OF 5-HT WITHIN DORSAL RAPHE NUCLEUS OF THE RAT IN THE ABSENCE OF ACTION POTENTIAL FIRING,"ACTIVITY AND CALCIUM-DEPENDENT RELEASE OF NEUROTRANSMITTERS FROM THE SOMATODENDRITIC COMPARTMENT IS AN IMPORTANT SIGNALLING MECHANISM BETWEEN NEURONES THROUGHOUT THE BRAIN. NMDA RECEPTORS AND VESICLES FILLED WITH NEUROTRANSMITTERS OCCUR IN CLOSE PROXIMITY IN MANY BRAIN AREAS. IT IS UNKNOWN WHETHER CALCIUM INFLUX THROUGH THESE RECEPTORS CAN TRIGGER THE RELEASE OF SOMATODENDRITIC VESICLES DIRECTLY, OR WHETHER POSTSYNAPTIC ACTION POTENTIAL FIRING IS NECESSARY FOR RELEASE OF THESE VESICLES. HERE WE ADDRESSED THIS QUESTION BY STUDYING LOCAL RELEASE OF SEROTONIN (5-HT) FROM DORSAL RAPHE NUCLEUS (DRN) NEURONES. WE PERFORMED CAPACITANCE MEASUREMENTS TO MONITOR THE SECRETION OF VESICLES IN GIANT SOMA PATCHES, IN RESPONSE TO SHORT DEPOLARIZATIONS AND ACTION POTENTIAL WAVEFORMS. AMPEROMETRIC MEASUREMENTS CONFIRMED THAT SECRETED VESICLES CONTAINED 5-HT. SURPRISINGLY, TWO-PHOTON IMAGING OF DRN NEURONES IN SLICES REVEALED THAT DENDRITIC CALCIUM CONCENTRATION CHANGES IN RESPONSE TO SOMATIC FIRING WERE RESTRICTED TO PROXIMAL DENDRITIC AREAS. THIS IMPLIED THAT ALTERNATIVE CALCIUM ENTRY PATHWAYS MAY DOMINATE THE INDUCTION OF VESICLE SECRETION FROM DISTAL DENDRITES. IN LINE WITH THIS, TRANSIENT NMDA RECEPTOR ACTIVATION, IN THE ABSENCE OF ACTION POTENTIAL FIRING, WAS SUFFICIENT TO INDUCE CAPACITANCE CHANGES. BY MONITORING GABAERGIC TRANSMISSION ONTO DRN 5-HT NEURONES IN SLICES, WE SHOW THAT ENDOGENOUS NMDA RECEPTOR ACTIVATION, IN THE ABSENCE OF POSTSYNAPTIC FIRING, INDUCED RELEASE OF 5-HT, WHICH IN TURN INCREASED THE FREQUENCY OF GABAERGIC INPUTS THROUGH ACTIVATION OF 5-HT2 RECEPTORS. WE PROPOSE HERE THAT CALCIUM INFLUX THROUGH NMDA RECEPTORS CAN DIRECTLY INDUCE POSTSYNAPTIC 5-HT RELEASE FROM DRN NEURONES, WHICH IN TURN MAY FACILITATE GABAERGIC INPUT ONTO THESE CELLS.",SOMATODENDRITIC DOPAMINE RELEASE; SUBSTANTIA-NIGRA NEURONS; MEDIAL PREFRONTAL CORTEX; VENTRAL TEGMENTAL AREA; D-ASPARTATE RECEPTORS; GABA RELEASE; SEROTONERGIC NEURONS; OLFACTORY-BULB; IN-VITRO; ANTIDEPRESSANT TREATMENTS,NA,JOURNAL OF PHYSIOLOGY-LONDON,"DE KOCK, CPJ##CORNELISSE, LN##BURNASHEV, N##LODDER, JC##TIMMERMAN, AJ##COUEY, JJ##MANSVELDER, HD##BRUSSAARD, AB","FREE UNIV AMSTERDAM, CNCR, DEPT EXPT NEUROPHYSIOL, NL-1081 HV AMSTERDAM, NETHERLANDS.",NEUROSCIENCES; PHYSIOLOGY,NEUROSCIENCES & NEUROLOGY; PHYSIOLOGY,"ADELL A, 2002, BRAIN RES REV, V39, P154, DOI 10.1016/S0165-0173(02)00182-0##ANGLESON JK, 1997, TRENDS NEUROSCI, V20, P281, DOI 10.1016/S0166-2236(97)01083-7##ARANGO V, 2001, NEUROPSYCHOPHARMACOL, V25, P892, DOI 10.1016/S0893-133X(01)00310-4##ARTIGAS F, 1996, TRENDS NEUROSCI, V19, P378, DOI 10.1016/S0166-2236(96)10037-0##ARTIGAS F, 1996, ADV EXP MED BIOL, V398, P51##BECQUET D, 1993, J NEUROCHEM, V61, P1692, DOI 10.1111/J.1471-4159.1993.TB09805.X##BEKKERS JM, 2000, J PHYSIOL-LONDON, V525, P593, DOI 10.1111/J.1469-7793.2000.T01-1-00593.X##BLIER P, 1998, ANN NY ACAD SCI, V861, P204, DOI 10.1111/J.1749-6632.1998.TB10192.X##BLIER P, 2003, BIOL PSYCHIAT, V53, P193, DOI 10.1016/S0006-3223(02)01643-8##BUNIN MA, 1998, J NEUROSCI, V18, P4854##BUNIN MA, 1999, TRENDS NEUROSCI, V22, P377, DOI 10.1016/S0166-2236(99)01410-1##BURNASHEV N, 1995, J PHYSIOL-LONDON, V485, P403, DOI 10.1113/JPHYSIOL.1995.SP020738##CELADA P, 2001, J NEUROSCI, V21, P9917, DOI 10.1523/JNEUROSCI.21-24-09917.2001##CELADA P, 2002, NEUROTOX RES, V4, P409, DOI 10.1080/10298420290030550##CHAZAL G, 1987, J COMP NEUROL, V259, P317, DOI 10.1002/CNE.902590302##CHEN BT, 2002, J NEUROCHEM, V81, P158, DOI 10.1046/J.1471-4159.2002.00811.X##CHEN BT, 2001, J NEUROSCI, V21, P7841##CHEN WR, 2000, NEURON, V25, P625, DOI 10.1016/S0896-6273(00)81065-X##COMMONS KG, 2005, EUR J NEUROSCI, V21, P1577, DOI 10.1111/J.1460-9568.2005.03991.X##DE KOCK CPJ, 2003, J NEUROSCI, V23, P2726##DE KOCK CPJ, 2004, J PHYSIOL-LONDON, V561, P53, DOI 10.1113/JPHYSIOL.2004.069005##DESCARRIES L, 1982, J COMP NEUROL, V207, P239, DOI 10.1002/CNE.902070305##DUGUID IC, 2004, NAT NEUROSCI, V7, P525, DOI 10.1038/NN1227##GOVINDAIAH, 2004, NEURON, V41, P611, DOI 10.1016/S0896-6273(04)00013-3##GRILLNER P, 2002, BEHAV BRAIN RES, V130, P149, DOI 10.1016/S0166-4328(01)00418-1##HAJOS M, 1999, BRIT J PHARMACOL, V126, P1741, DOI 10.1038/SJ.BJP.0702510##HAJOS M, 2003, NEUROPHARMACOLOGY, V45, P72, DOI 10.1016/S0028-3908(03)00139-4##HALABISKY B, 2000, J NEUROSCI, V20, P5124##HAUSSER M, 1995, NEURON, V15, P637, DOI 10.1016/0896-6273(95)90152-3##HOFFMAN AF, 1999, J PHARMACOL EXP THER, V289, P455##ISAACSON JS, 2001, P NATL ACAD SCI USA, V98, P337, DOI 10.1073/PNAS.021445798##JAFFE EH, 1998, J NEUROSCI, V18, P3548##JANKOWSKI MP, 2004, J COMP NEUROL, V468, P518, DOI 10.1002/CNE.10976##KAPADIA SE, 1985, NEUROSCIENCE, V15, P729, DOI 10.1016/0306-4522(85)90075-2##KLYACHKO VA, 2002, NATURE, V418, P89, DOI 10.1038/NATURE00852##KOMBIAN SB, 1996, J NEUROPHYSIOL, V76, P1166##KOMBIAN SB, 1997, NEURON, V19, P903, DOI 10.1016/S0896-6273(00)80971-X##LI YQ, 2001, BRAIN RES, V900, P110, DOI 10.1016/S0006-8993(01)02272-7##LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306##LIPOSITS Z, 1985, J HISTOCHEM CYTOCHEM, V33, P604, DOI 10.1177/33.6.3889144##LIU RJ, 2000, BRAIN RES, V873, P34, DOI 10.1016/S0006-8993(00)02468-9##LIU RJ, 2005, EUR J NEUROSCI, V21, P945, DOI 10.1111/J.1460-9568.2005.03930.X##LOZOVAYA NA, 2004, J PHYSIOL-LONDON, V558, P451, DOI 10.1113/JPHYSIOL.2004.063792##LUDWIG M, 2002, NATURE, V418, P85, DOI 10.1038/NATURE00822##LUDWIG M, 2002, PROG BRAIN RES, V139, P247##MENNINI T, 1986, BRAIN RES, V371, P372, DOI 10.1016/0006-8993(86)90378-1##MUNSCH T, 2003, P NATL ACAD SCI USA, V100, P16065, DOI 10.1073/PNAS.2535311100##NEDERGAARD S, 1988, NATURE, V333, P174, DOI 10.1038/333174A0##PALLOTTA M, 1998, BRAIN RES, V783, P173, DOI 10.1016/S0006-8993(97)01333-4##PAUL IA, 2003, ANN NY ACAD SCI, V1003, P250, DOI 10.1196/ANNALS.1300.016##PAUL IA, 1994, J PHARMACOL EXP THER, V269, P95##PIOMELLI D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/NRN1247##PUIG MV, 2005, CEREB CORTEX, V15, P1, DOI 10.1093/CERCOR/BHH104##RALSTON HJ, 1971, NATURE, V230, P585, DOI 10.1038/230585A0##RICE ME, 1997, J NEUROPHYSIOL, V77, P853##ROZOV A, 1998, J PHYSIOL-LONDON, V511, P361, DOI 10.1111/J.1469-7793.1998.361BH.X##SABATINI BL, 1995, NEUROPHARMACOLOGY, V34, P1453, DOI 10.1016/0028-3908(95)00129-T##SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/JPHYSIOL.1992.SP019148##SKOLNICK P, 1996, PHARMACOPSYCHIATRY, V29, P23, DOI 10.1055/S-2007-979537##STAMFORD JA, 2000, TRENDS NEUROSCI, V23, P459, DOI 10.1016/S0166-2236(00)01631-3##STOCKMEIER CA, 1998, J NEUROSCI, V18, P7394##STOLTENBERG SF, 2005, BEHAV GENET, V35, P199, DOI 10.1007/S10519-004-1019-4##STUART G, 1997, TRENDS NEUROSCI, V20, P125, DOI 10.1016/S0166-2236(96)10075-8##SUTTON MA, 2004, SCIENCE, V304, P1979, DOI 10.1126/SCIENCE.1096202##TOLLE TR, 1993, J NEUROSCI, V13, P5009##ZOLI M, 1999, TRENDS PHARMACOL SCI, V20, P142, DOI 10.1016/S0165-6147(99)01343-7",37,2020-11-20,NA
J,WOS:000243012200011,2006,REDUCED WORK CAPACITY AFTER LUMBAR DISC SURGERY: THE ROLE OF COGNITIVE-BEHAVIORAL AND WORK-RELATED RISK FACTORS,"A SIGNIFICANT NUMBER OF PATIENTS WHO HAVE HAD SURGERY FOR LUMBOSACRAL RADICULAR SYNDROME STILL HAVE A REDUCED WORK CAPACITY SEVERAL MONTHS LATER. IN A PROSPECTIVE COHORT STUDY OF 182 PEOPLE WHO UNDERWENT LUMBAR DISC SURGERY, WE DETERMINED THE PREDICTIVE VALUE OF PREOPERATIVELY MEASURED COGNITIVE-BEHAVIORAL AND WORK-RELATED FACTORS ON WORK CAPACITY 6 MONTHS AFTER SURGERY. LOGISTIC REGRESSION ANALYSES INDICATED THAT THESE FACTORS INDEPENDENTLY PREDICTED WORK CAPACITY 6 MONTHS AFTER SURGERY. SPECIFICALLY, FEAR OF MOVEMENT/(RE)INJURY, MORE PASSIVE PAIN COPING, AND HIGHER PHYSICAL WORK-LOAD PREDICTED REDUCED WORK CAPACITY IN MULTIPLE LOGISTIC REGRESSION ANALYSES, TAKING INTO ACCOUNT THE ROLE OF A WIDE RANGE OF CONTROL VARIABLES INCLUDING DEMOGRAPHIC VARIABLES, PREOPERATIVE DISABILITY AND PAIN INTENSITY, NEUROLOGICAL DEFICITS, INTAKE OF ANALGESICS, DURATION OF COMPLAINTS, AND PAIN INTENSITY 3 DAYS POSTOPERATIVELY. THE STUDY SUPPORTS THE NEED TO DEVELOP AND EVALUATE PREOPERATIVE RISK SCREENING MEASURES THAT INCLUDE BOTH COGNITIVE-BEHAVIORAL AND WORK-RELATED FACTORS AND TO EVALUATE THE EFFECTIVENESS OF COGNITIVE-BEHAVIORAL AND WORK-RELATED INTERVENTIONS IN PATIENTS AT RISK OF REDUCED WORK CAPACITY AFTER SURGERY FOR LRS. (C) 2006 INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN. PUBLISHED BY ELSEVIER B.V. ALL RIGHTS RESERVED.",LOW-BACK-PAIN; PRIMARY-CARE; DISABILITY; PREDICTORS; BELIEFS; SCALE; MODEL,LUMBAR DISC SURGERY; FEAR AVOIDANCE BEHAVIOUR; PAIN COPING; PHYSICAL WORK LOAD; COGNITIVE-BEHAVIORAL RISK FACTOR; WORK-RELATED RISK FACTOR,PAIN,"DEN BOER, JJ##OOSTENDORP, RAB##BEEMS, T##MUNNEKE, M##EVERS, AWM","RADBOUD UNIV NIJMEGEN MED CTR, DEPT PHYS THERAPY, NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, CTR QUAL CARE RES, NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, DEPT NEUROSURG, NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, DEPT PSYCHOL MED, NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, RES CTR ALLIED HLTH SCI, NIJMEGEN, NETHERLANDS. DUTCH INST ALLIED HLTH CARE, AMERSFOORT, NETHERLANDS.",ANESTHESIOLOGY; CLINICAL NEUROLOGY; NEUROSCIENCES,ANESTHESIOLOGY; NEUROSCIENCES & NEUROLOGY,"COLE DC, 2002, CAN MED ASSOC J, V166, P749##CROOK J, 2002, J OCCUP REHABIL, V12, P277, DOI 10.1023/A:1020278708861##DEN BOER JJ, 2006, EUR SPINE J, V15, P527, DOI 10.1007/S00586-005-0910-X##DENBOER JJ, 2006, PAIN, V22##DEYO RA, 1996, SPINE, V21, P2826, DOI 10.1097/00007632-199612150-00003##DONCEEL P, 1999, SCAND J WORK ENV HEA, V25, P264, DOI 10.5271/SJWEH.433##ELDERS LAM, 2003, SPINE, V28, P1340, DOI 10.1097/00007632-200306150-00021##EVERS AWM, 2003, BEHAV RES THER, V41, P1295, DOI 10.1016/S0005-7967(03)00036-6##FORDYCE WE, 1982, J BEHAV MED, V5, P405, DOI 10.1007/BF00845370##FRITZ JM, 2001, PAIN, V94, P7, DOI 10.1016/S0304-3959(01)00333-5##GEHLDOR ELM, 2005, PAIN, V113, P71##GIBSON JNA, 1999, SPINE, V24, P1820, DOI 10.1097/00007632-199909010-00012##GIEZEN AM, 2000, PAIN, P285##GOMMERMANS MW, 1997, NED TIJDSCHR FYSIOTH, V107, P28##GOUBERT L, 2004, CLIN J PAIN, V20, P103, DOI 10.1097/00002508-200403000-00007##HASHEMI L, 1997, J OCCUP MED, V32, P13##HILDEBRANDT V, 1991, VOORBURG##KOES BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022##KRAAIMAAT FW, 2003, INT J BEHAV MED, V41, P1292##LETHEM J, 1983, BEHAV RES THER, V21, P401, DOI 10.1016/0005-7967(83)90009-8##MAYER TG, 1989, CLIN ORTHOPAEDICS, V244, P147##PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4##SCHADE V, 1999, PAIN, V80, P239, DOI 10.1016/S0304-3959(98)00210-3##SCHULTZ IZ, 2004, PAIN, V107, P77, DOI 10.1016/J.PAIN.2003.09.019##SPITZER WO, 1987, SPINE S, V2, P1##STAM J, 1996, NED TIJDSCHR GENEESKD, V140, P2621##SYMONDS TL, 1996, OCCUP MED-OXFORD, V46, P25, DOI 10.1093/OCCMED/46.1.25##TUBACH F, 2002, J OCCUP ENVIRON MED, V44, P451, DOI 10.1097/00043764-200205000-00013##WADDELL G, 1996, SPINE, V21, P2820, DOI 10.1097/00007632-199612150-00002##WICKSTROM GJ, 1998, SCAND J WORK ENV HEA, V24, P145, DOI 10.5271/SJWEH.292##WILLIAMS DA, 1998, SPINE, V23, P2329, DOI 10.1097/00007632-199811010-00016",22,2020-11-20,NA
J,WOS:000243012200019,2006,PAIN ASSESSMENT IN PROFOUND COGNITIVE IMPAIRED CHILDREN USING THE CHECKLIST PAIN BEHAVIOR; IS ITEM REDUCTION VALID?,"THERE ARE BOTH COMMONALITIES AND IDIOSYNCRATIC FEATURES IN THE REACTION OF PAIN CHILDREN WITH PROFOUND COGNITIVE IMPAIRMENT (CI), AND THAT THERE IS NO EVIDENCE TO SUGGEST THAT IDIOSYNCRATIC BEHAVIOR IS MORE CHARACTERISTIC OF THIS POPULATION THAN OF ANY OTHER POPULATION. THE MAIN OBJECTIVE OF THIS STUDY WAS TO IDENTIFY WHETHER THE 23-ITEM VERSION OF THE CHECKLIST PAIN BEHAVIOR COULD BE REDUCED TO 10 ITEMS. PREVIOUS RESEARCH DEMONSTRATED THAT ONLY THESE 10 ITEMS DISCRIMINATED BETWEEN ABSENCE AND PRESENCE OF PAIN. SECOND, WE WANTED TO EXPLORE THE UNDERLYING STRUCTURE OF THESE 10 SELECTED ITEMS INCLUDING ITS PERFORMANCE. DATA OF 477 OBSERVATIONS IN 73 CHILDREN WERE USED. ALL THESE CHILDREN WERE VIDEO-TAPED WHILE THEY WERE ADMITTED TO THE SOPHIA CHILDREN'S HOSPITAL FOR SURGERY, TWICE BEFORE AND FIVE TIMES AFTER SURGERY. THESE VIDEO-TAPES WERE SCORED BY AN INDEPENDENT OBSERVER. A VISUAL ANALOGUE SCALE (VAS) BY A RESEARCHER WAS USED TO ASSESS THE PRESENCE OF PAIN. WE TESTED WHETHER THE UNDERLYING STRUCTURE WAS UNIDIMENSIONAL, AND WHETHER IT HAD DIFFERENTIAL QUALITIES BETWEEN PAIN AND NO PAIN, AND TO WHICH DEGREE. USING A MODERN PSYCHOMETRIC METHOD, I.E., MOKKEN SCALING MODEL, WE UNRAVELED THE INTERDEPENDENCY OF THE PAIN RESPONSE IN CI-CHILDREN, IN THAT THE STRUCTURE TURNED OUT TO BE UNIDIMENSIONAL. IN ADDITION, THESE BEHAVIORS COULD BE HIERARCHICALLY ORDERED IN TERMS OF FREQUENCY OF OCCURRENCES. FINALLY, THESE BEHAVIORS HAD TO A HIGH DEGREE THE POTENTIALITIES TO ESTIMATE THE LIKELIHOOD OF OCCURRENCE OF PAIN. (C) 2006 INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN. PUBLISHED BY ELSEVIER B.V. ALL RIGHTS RESERVED.",DEVELOPMENTAL DELAYS; PEDIATRIC PAIN; EXPRESSION; RESPONSES; INFANTS; PARENTS; IRT,PAIN BEHAVIOR; ITEM RESPONSE THEORY; MOKKEN SCALING MODEL,PAIN,"DUIVENVOORDEN, HJ##TIBBOEL, D##KOOT, HM##VAN DIJK, M##PETERS, JWB","ERASMUS UNIV, MED CTR, NIHES, DEPT MED PSYCHOL & PSYCHOTHERAPY, ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR SOPHIA, DEPT PEDIAT SURG, ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT ANESTHESIOL, ROTTERDAM, NETHERLANDS. FREE UNIV AMSTERDAM, DEPT DEV PSYCHOL, AMSTERDAM, NETHERLANDS.",ANESTHESIOLOGY; CLINICAL NEUROLOGY; NEUROSCIENCES,ANESTHESIOLOGY; NEUROSCIENCES & NEUROLOGY,"BIRNBAUM A., 1968, STAT THEORIES MENTAL, P397##BREAU LM, 2002, ANESTHESIOLOGY, V96, P528, DOI 10.1097/00000542-200203000-00004##CAMPBELL PH, 1989, COMMUNICATION PROGRA##CHAMBERS CT, 1998, CLIN J PAIN, V14, P336, DOI 10.1097/00002508-199812000-00011##CHAMBERS CT, 1999, PAIN, V83, P25, DOI 10.1016/S0304-3959(99)00086-X##COLLIGNON P, 2001, EUR J PAIN-LONDON, V5, P433, DOI 10.1053/EUJP.2001.0265##EMBRETSON S., 2000, ITEM RESPONSE THEORY, P13##GILBERT-MACLEOD CA, 2000, J PEDIATR PSYCHOL, V25, P301, DOI 10.1093/JPEPSY/25.5.301##GRUNAU RVE, 1987, PAIN, V28, P395, DOI 10.1016/0304-3959(87)90073-X##HUNT A, 2004, DEV MED CHILD NEUROL, V46, P9, DOI 10.1017/S0012162204000039##LACHAPELLE DL, 1999, CLIN J PAIN, V15, P13, DOI 10.1097/00002508-199903000-00004##MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272##MEIJER RR, 1990, APPL PSYCH MEAS, V14, P283, DOI 10.1177/014662169001400306##MERCER K, 2004, CHILD CARE HLTH DEV, V30, P353, DOI 10.1111/J.1365-2214.2004.00430.X##MOKKEN R. J., 1997, HDB MODERN ITEM RESP, P351, DOI DOI 10.1007/978-1-4757-2691-6##MOKKEN RJ, 1982, APPL PSYCH MEAS, V6, P417, DOI 10.1177/014662168200600404##MOKKEN RJ, 1971, THEORY PROCEDURE SCA##MOLENAAR IW, 1997, HDB MODERN ITEM RESP, P369##NADER R, 2004, CLIN J PAIN, V20, P88, DOI 10.1097/00002508-200403000-00005##NOVICK MR, 1967, PSYCHOMETRIKA, V32, P1, DOI 10.1007/BF02289400##OBERLANDER TF, 1999, CLIN J PAIN, V15, P201, DOI 10.1097/00002508-199909000-00007##PETERS JWB, 2003, CLIN J PAIN, V19, P353, DOI 10.1097/00002508-200311000-00003##RASCH G., 1960, PROBABILISTIC MODELS##SAMEJIMA F, 1973, PSYCHOMETRIKA, V39, P221##SAMEJIMA F, 1969, PSYCHOMETRIKA MONOGR, P17##SIJTSMA K, 1998, APPL PSYCH MEAS, V22, P3, DOI 10.1177/01466216980221001##SINGER AJ, 2002, ACAD EMERG MED, V9, P609, DOI 10.1111/J.1553-2712.2002.TB02298.X##STALLARD P, 2002, PAIN, V98, P145, DOI 10.1016/S0304-3959(02)00038-6##TERSTEGEN C, 2003, PAIN, V103, P187, DOI 10.1016/S0304-3959(02)00453-0",15,2020-11-20,NA
J,WOS:000243012200025,2006,THE PSYCHOMETRIC QUALITY AND CLINICAL USEFULNESS OF THREE PAIN ASSESSMENT TOOLS FOR ELDERLY PEOPLE WITH DEMENTIA,"IN VIEW OF THE NEED FOR VALID, RELIABLE, AND CLINICALLY USEFUL SCALES TO ASSESS PAIN IN ELDERLY PEOPLE WITH DEMENTIA, THIS STUDY EVALUATED THE PSYCHOMETRIC PROPERTIES OF TRANSLATED VERSIONS OF THE PAINAD, PACSLAC, AND DOLOPLUS-2 SCALES. IN AN OBSERVATIONAL STUDY DESIGN, TWO RATERS SIMULTANEOUSLY ASSESSED THE NURSING HOME RESIDENTS (N = 128) FOR PAIN DURING INFLUENZA VACCINATION AND CARE SITUATIONS. THE PACSLAC WAS VALUED AS THE MOST USEFUL SCALE BY NURSES. CRONBACH'S ALPHA WAS HIGH (>.80) FOR THE TOTAL SCALE AT T2 AND T3 AND ADEQUATE FOR THE 'FACIAL EXPRESSION' AND 'SOCIAL/PERSONALITY/MOOD' SUBSCALES. IC SCORES FOR THE 'ACTIVITY/BODY MOVEMENT' AND 'PHYSIOLOGICAL INDICATORS/EATING/SLEEPING CHANGES/VOCAL BEHAVIORS' SUBSCALES WERE LOW. IT DEMONSTRATED GOOD VALIDITY AND RELIABILITY, ALTHOUGH THE SCALE SHOULD BE FURTHER REFINED. THIS REFINEMENT SHOULD INCREASE HOMOGENEITY. THE PAINAD SHOWED GOOD PSYCHOMETRIC QUALITIES IN TERMS OF RELIABILITY, VALIDITY, AND HOMOGENEITY (ALPHA RANGED.69-74 AT T2 AND T3) (EXCEPT FOR THE 'BREATHING' ITEM). THE PAINAD SCALE HAD LOWER SCORES FOR CLINICAL USEFULNESS IN THIS SAMPLE. THE DUTCH VERSION OF THE DOLOPLUS-2 WAS CONSIDERED MORE DIFFICULT TO USE BUT SHOWED ACCEPTABLE PSYCHOMETRIC QUALITIES IN TERMS OF THE ISSUES ASSESSED, EXCEPT FOR THE 'PSYCHOSOCIAL REACTIONS' SUBSCALE. IC OF THE DOLOPLUS WERE ADEQUATE FOR THE TOTAL SCALE (ALPHA RANGED .74-75) AND ALMOST ALL SUBSCALES (ALPHA RANGED .58-80). FINDINGS OF THIS STUDY PROVIDE EVIDENCE OF VALIDITY AND RELIABILITY OF THE THREE PAIN ASSESSMENT SCALES. NOW THAT A PAIN SCALE IS AVAILABLE, FUTURE STUDIES ALSO NEED TO FOCUS ON ITS IMPLEMENTATION IN NURSING PRACTICE. (C) 2006 INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN. PUBLISHED BY ELSEVIER B.V. ALL RIGHTS RESERVED.",MINI-MENTAL-STATE; VALIDATION; MANAGEMENT; SCALE,NURSING HOMES; DEMENTIA; ELDERLY RESIDENTS; PAIN ASSESSMENT; PSYCHOMETRIC,PAIN,"ZWAKHALEN, SMG##HAMERS, JPH##BERGER, MRF","MAASTRICHT UNIV, SECT NURSING SCI, DEPT HLTH CARE STUDIES, MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, DEPT METHODOL & STAT, MAASTRICHT, NETHERLANDS.",ANESTHESIOLOGY; CLINICAL NEUROLOGY; NEUROSCIENCES,ANESTHESIOLOGY; NEUROSCIENCES & NEUROLOGY,"BREAU LM, 2001, CLIN J PAIN, V17, P178, DOI 10.1097/00002508-200106000-00011##CLOSS SJ, 2004, J PAIN SYMPTOM MANAG, V27, P196, DOI 10.1016/J.JPAINSYMMAN.2003.12.010##CRAIG K, 2001, HDB PAIN ASSESSMENT, P153##FARRELL MJ, 1996, PAIN, V67, P7, DOI 10.1016/0304-3959(96)03041-2##FERRELL BA, 1995, ANN INTERN MED, V123, P681, DOI 10.7326/0003-4819-123-9-199511010-00007##FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6##FUCHS S, 2002, IASP SAN DIEG##FUCHS-LACELLE S, 2004, PAIN MANAG NURS, V5, P37, DOI 10.1016/J.PMN.2003.10.001##HADJISTAVROPOULOS T, 2000, CLIN J PAIN, V16, P54, DOI 10.1097/00002508-200003000-00009##HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, PM128, DOI 10.1093/GERONA/50A.2.M128##HELME RD, 2001, CLIN GERIATR MED, V17, P417, DOI 10.1016/S0749-0690(05)70078-1##HOLEN JC, 2005, PALLIATIVE MED, V19, P411, DOI 10.1191/0269216305PM1031OA##HURLEY AC, 1992, RES NURS HEALTH, V15, P369, DOI 10.1002/NUR.4770150506##JENSEN MP, 1997, PROG PAIN RES MANAG, V8, P637##JENSEN MP, 2001, HDB PAIN ASSESSMENT, P14##LANE PATRICIA, 2003, HOME HEALTHC NURSE, V21, P32, DOI 10.1097/00004045-200301000-00007##LANSBURY G, 2000, DISABIL REHABIL, V22, P2, DOI 10.1080/096382800297079-1##LEFEBVRE-CHAPIRO S., 2001, EUR J PALLIAT CARE, V8, P191, DOI DOI 10.1186/1471-2318-7-29##LEONG IY, 2006, AGE AGEING, V23, P1##MCGRATH P, 1996, PAIN, V64, P435, DOI 10.1016/0304-3959(95)00171-9##MCGRATH PJ, 1998, DEV MED CHILD NEUROL, V40, P340##MICHEL M, 2000, REV GERIATRIE, V25, P155##MORRIS JN, 1994, J GERONTOL, V49, PM174, DOI 10.1093/GERONJ/49.4.M174##NUNNALLY JC, 1978, PSYCHOMETRIC THEORY##OBERLANDER TF, 1999, CLIN J PAIN, V15, P201, DOI 10.1097/00002508-199909000-00007##POLIT DF, 2004, NURSING RES PRINCIPL##SCHERDER E, 2005, BMJ-BRIT MED J, V330, P461, DOI 10.1136/BMJ.330.7489.461##SCHERDER EJA, 2003, PSYCHIATRY, V66, P133, DOI 10.1521/PSYC.66.2.133.20618##SERBOUTI S, 2002, IASP SAN DIEG##STREINER D, 2003, HLTH MEASUREMENT SCA##WARDEN VICTORIA, 2003, J AM MED DIR ASSOC, V4, P9, DOI 10.1016/S1525-8610(04)70258-3##WARY B, 1999, SOINS GERONTOL, P25##WARY B, 2001, DOULEURS, V2, P35##WEISSMAN DE, 1999, THEOR MED BIOETH, V20, P31, DOI 10.1023/A:1009923907285##ZWAKHALEN SANDRA M G, 2006, BMC GERIATR, V6, P3, DOI 10.1186/1471-2318-6-3",138,2020-11-20,NA
J,WOS:000242888700012,2006,MEASUREMENT OF THE B-S(0) LIFETIME USING SEMILEPTONIC DECAYS,"WE REPORT A MEASUREMENT OF THE B-S(0) LIFETIME IN THE SEMILEPTONIC DECAY CHANNEL B-S(0)-> D-S(-)MU(+)NU X (AND ITS CHARGE CONJUGATE), USING APPROXIMATELY 0.4 FB(-1) OF DATA COLLECTED WITH THE D0 DETECTOR DURING 2002-2004. USING 5176 RECONSTRUCTED D-S(-)MU(+) SIGNAL EVENTS, WE HAVE MEASURED THE B-S(0) LIFETIME TO BE TAU(B-S(0))=1.398 +/- 0.044(STAT)(-0.025)(+0.028)(SYST) PS. THIS IS THE MOST PRECISE MEASUREMENT OF THE B-S(0) LIFETIME TO DATE.",DETECTOR; PHYSICS,NA,PHYSICAL REVIEW LETTERS,"ABAZOV, VM##ABBOTT, B##ABOLINS, M##ACHARYA, BS##ADAMS, M##ADAMS, T##AGELOU, M##AGRAM, JL##AHN, SH##AHSAN, M##ALEXEEV, GD##ALKHAZOV, G##ALTON, A##ALVERSON, G##ALVES, GA##ANASTASOAIE, M##ANDEEN, T##ANDERSON, S##ANDRIEU, B##ANZELC, MS##ARNOUD, Y##AROV, M##ASKEW, A##ASMAN, B##JESUS, ACSA##ATRAMENTOV, O##AUTERMANN, C##AVILA, C##AY, C##BADAUD, F##BADEN, A##BAGBY, L##BALDIN, B##BANDURIN, DV##BANERJEE, P##BANERJEE, S##BARBERIS, E##BARGASSA, P##BARINGER, P##BARNES, C##BARRETO, J##BARTLETT, JF##BASSLER, U##BAUER, D##BEAN, A##BEGALLI, M##BEGEL, M##BELANGER-CHAMPAGNE, C##BELLAVANCE, A##BENITEZ, JA##BERI, SB##BERNARDI, G##BERNHARD, R##BERNTZON, L##BERTRAM, I##BESANCON, M##BEUSELINCK, R##BEZZUBOV, VA##BHAT, PC##BHATNAGAR, V##BINDER, M##BISCARAT, C##BLACK, KM##BLACKLER, I##BLAZEY, G##BLEKMAN, F##BLESSING, S##BLOCH, D##BLOOM, K##BLUMENSCHEIN, U##BOEHNLEIN, A##BOERIU, O##BOLTON, TA##BORCHERDING, F##BORISSOV, G##BOS, K##BOSE, T##BRANDT, A##BROCK, R##BROOIJMANS, G##BROSS, A##BROWN, D##BUCHANAN, NJ##BUCHHOLZ, D##BUEHLER, M##BUESCHER, V##BURDIN, S##BURKE, S##BURNETT, TH##BUSATO, E##BUSZELLO, CP##BUTLER, JM##CALVET, S##CAMMIN, J##CARON, S##CARRASCO-LIZARRAGA, MA##CARVALHO, W##CASEY, BCK##CASON, NM##CASTILLA-VALDEZ, H##CHAKRABARTI, S##CHAKRABORTY, D##CHAN, KM##CHANDRA, A##CHAPIN, D##CHARLES, F##CHEU, E##CHEVALLIER, F##CHO, DK##CHOI, S##CHOUDHARY, B##CHRISTOFEK, L##CLAES, D##CLEMENT, B##CLEMENT, C##COADOU, Y##COOKE, M##COOPER, WE##COPPAGE, D##CORCORAN, M##COUSINOU, MC##COX, B##CREPE-RENAUDIN, S##CUTTS, D##CWIOK, M##DA MOTTA, H##DAS, A##DAS, M##DAVIES, B##DAVIES, G##DAVIS, GA##DE, K##DE JONG, P##DE JONG, SJ##DE LA CRUZ-BURELO, E##MARTINS, CD##DEGENHARDT, JD##DELIOT, F##DEMARTEAU, M##DEMINA, R##DEMINE, P##DENISOV, D##DENISOV, SP##DESAI, S##DIEHL, HT##DIESBURG, M##DOIDGE, M##DOMINGUEZ, A##DONG, H##DUDKO, LV##DUFLOT, L##DUGAD, SR##DUPERRIN, A##DYER, J##DYSHKANT, A##EADS, M##EDMUNDS, D##EDWARDS, T##ELLISON, J##ELMSHEUSER, J##ELVIRA, VD##ENO, S##ERMOLOV, P##ESTRADA, J##EVANS, H##EVDOKIMOV, A##EVDOKIMOV, VN##FATAKIA, SN##FELIGIONI, L##FERAPONTOV, AV##FERBEL, T##FIEDLER, F##FILTHAUT, F##FISHER, W##FISK, HE##FLECK, I##FORD, M##FORTNER, M##FOX, H##FU, S##FUESS, S##GADFORT, T##GALEA, CF##GALLAS, E##GALYAEV, E##GARCIA, C##GARCIA-BELLIDO, A##GARDNER, J##GAVRILOV, V##GAY, A##GAY, P##GELE, D##GELHAUS, R##GERBER, CE##GERSHTEIN, Y##GILLBERG, D##GINTHER, G##GOLLUB, N##GOMEZ, B##GOUNDER, K##GOUSSIOU, A##GRANNIS, PD##GREENLEE, H##GREENWOOD, ZD##GREGORES, EM##GRENIER, G##GRIS, P##GRIVAZ, JF##GRUNENDAHL, S##GRUNEWALD, MW##GUO, F##GUO, J##GUTIERREZ, G##GUTIERREZ, P##HAAS, A##HADLEY, NJ##HAEFNER, P##HAGOPIAN, S##HALEY, J##HALL, I##HALL, RE##HAN, L##HANAGAKI, K##HARDER, K##HAREL, A##HARRINGTON, R##HAUPTMAN, M##HAUSER, R##HAYS, J##HEBBEKER, T##HEDIN, D##HEGEMAN, JG##HEINMILLER, JM##HEINSON, AP##HEINTZ, U##HENSEL, C##HESKETH, G##HILDRETH, MD##HIROSKY, R##HOBBS, JD##HOENEISEN, B##HOHLFELD, M##HONG, SJ##HOOPER, R##HOUBEN, P##HU, Y##HYNEK, V##IASHVILI, I##ILLINGWORTH, R##ITO, AS##JABEEN, S##JAFFRE, M##JAIN, S##JAKOBS, K##JARVIS, C##JENKINS, A##JESIK, R##JOHNS, K##JOHNSON, C##JOHNSON, M##JONCKHEERE, A##JONSSON, P##JUSTE, A##KAFER, D##KAHN, S##KAJFASZ, E##KALININ, AM##KALK, JM##KALK, JR##KAPPLER, S##KARMANOV, D##KASPER, J##KATSANOS, I##KAU, D##KAUR, R##KEHOE, R##KERMICHE, S##KESISOGLOU, S##KHANOV, A##KHARCHILAVA, A##KHARZHEEV, YM##KHATIDZE, D##KIM, H##KIM, TJ##KIRBY, MH##KLIMA, B##KOHLI, JM##KONRATH, JP##KOPAL, M##KORABLEV, VM##KOTCHER, J##KOTHARI, B##KOUBAROVSKY, A##KOZELOV, AV##KOZMINSKI, J##KRYEMADHI, A##KRZYWDZINSKI, S##KUHL, T##KUMAR, A##KUNORI, S##KUPCO, A##KURCA, T##KVITA, J##LAGER, S##LAMMERS, S##LANDSBERG, G##LAZOFLORES, J##LE BIHAN, AC##LEBRUN, P##LEE, WM##LEFLAT, A##LEHNER, F##LEONIDOPOULOS, C##LESNE, V##LEVEQUE, J##LEWIS, P##LI, J##LI, QZ##LIMA, JGR##LINCOLN, D##LINNEMANN, J##LIPAEV, VV##LIPTON, R##LIU, Z##LOBO, L##LOBODENKO, A##LOKAJICEK, M##LOUNIS, A##LOVE, P##LUBATTI, HJ##LYNKER, M##LYON, AL##MACIEL, AKA##MADARAS, RJ##MATTIG, P##MAGASS, C##MAGERKURTH, A##MAGNAN, AM##MAKOVEC, N##MAL, PK##MALBOUISSON, HB##MALIK, S##MALYSHEV, VL##MAO, HS##MARAVIN, Y##MARTENS, M##MATTINGLY, SEK##MCCARTHY, R##MCCROSKEY, R##MEDER, D##MELNITCHOUK, A##MENDES, A##MENDOZA, L##MERKIN, M##MERRITT, KW##MEYER, A##MEYER, J##MICHAUT, M##MIETTINEN, H##MILLET, T##MITREVSKI, J##MOLINA, J##MONDAL, NK##MONK, J##MOORE, RW##MOULIK, T##MUANZA, GS##MULDERS, M##MULHEARN, M##MUNDIM, L##MUTAF, YD##NAGY, E##NAIMUDDIN, M##NARAIN, M##NAUMANN, NA##NEAL, HA##NEGRET, JP##NELSON, S##NEUSTROEV, P##NOEDING, C##NOMEROTSKI, A##NOVAES, SF##NUNNEMANN, T##O'DELL, V##O'NEIL, DC##OBRANT, G##OGURI, V##OLIVEIRA, N##OSHIMA, N##OTEC, R##GARZON, GJOY##OWEN, M##PADLEY, P##PARASHAR, N##PARK, SJ##PARK, SK##PARSONS, J##PARTRIDGE, R##PARUA, N##PATWA, A##PAWLOSKI, G##PEREA, PM##PEREZ, E##PETERS, K##PETROFF, P##PETTENI, M##PIEGAIA, R##PLEIER, MA##PODESTA-LERMA, PLM##PODSTAVKOV, VM##POGORELOV, Y##POL, ME##POMPOS, A##POPE, BG##POPOV, V##DA SILVA, WLP##PROSPER, HB##PROTOPOPESCU, S##QIAN, J##QUADT, A##QUINN, B##RANI, KJ##RANJAN, K##RAPIDIS, PA##RATOFF, PN##RENKEL, P##REUCROFT, S##RIJSSENBEEK, M##RIPP-BAUDOT, I##RIZATDINOVA, F##ROBINSON, S##RODRIGUES, RF##ROYON, C##RUBINOV, P##RUCHTI, R##RUD, VI##SAJOT, G##SANCHEZ-HERNANDEZ, A##SANDERS, MP##SANTORO, A##SAVAGE, G##SAWYER, L##SCANLON, T##SCHAILE, D##SCHAMBERGER, RD##SCHEGLOV, Y##SCHELLMAN, H##SCHIEFERDECKER, P##SCHMITT, C##SCHWANENBERGER, C##SCHWARTZMAN, A##SCHWIENHORST, R##SENGUPTA, S##SEVERINI, H##SHABALINA, E##SHAMIM, M##SHARY, V##SHCHUKIN, AA##SHEPHARD, WD##SHIVPURI, RK##SHPAKOV, D##SICCARDI, V##SIDWELL, RA##SIMAK, V##SIROTENKO, V##SKUBIC, P##SLATTERY, P##SMITH, RP##SNOW, GR##SNOW, J##SNYDER, S##SOLDNER-REMBOLD, S##SONG, X##SONNENSCHEIN, L##SOPCZAK, A##SOSEBEE, M##SOUSTRUZNIK, K##SOUZA, M##SPURLOCK, B##STARK, J##STEELE, J##STEVENSON, K##STOLIN, V##STONE, A##STOYANOVA, DA##STRANDBERG, J##STRANG, MA##STRAUSS, M##STROHMER, R##STROM, D##STROVINK, M##STUTTE, L##SUMOWIDAGDO, S##SZNAJDER, A##TALBY, M##TAMBURELLO, P##TAYLOR, W##TELFORD, P##TEMPLE, J##TILLER, B##TITOV, M##TOKMENIN, VV##TOMOTO, M##TOOLE, T##TORCHIANI, I##TOWERS, S##TREFZGER, T##TRINCAZ-DUVOID, S##TSYBYCHEV, D##TUCHMING, B##TULLY, C##TURCOT, AS##TUTS, PM##UNALAN, R##UVAROV, L##UVAROV, S##UZUNYAN, S##VACHON, B##VAN DEN BERG, PJ##VAN KOOTEN, R##VAN LEEUWEN, WM##VARELAS, N##VARNES, EW##VARTAPETIAN, A##VASILYEV, IA##VAUPEL, M##VERDIER, P##VERTOGRADOV, LS##VERZOCCHI, M##VILLENEUVE-SEGUIER, F##VINT, P##VLIMANT, JR##VON TOERNE, E##VOUTILAINEN, M##VREESWIJK, M##WAHL, HD##WANG, L##WARCHOL, J##WATTS, G##WAYNE, M##WEBER, M##WEERTS, H##WERMES, N##WETSTEIN, M##WHITE, A##WICKE, D##WILSON, GW##WIMPENNY, SJ##WOBISCH, M##WOMERSLEY, J##WOOD, DR##WYATT, TR##XIE, Y##XUAN, N##YACOOB, S##YAMADA, R##YAN, M##YASUDA, T##YATSUNENKO, YA##YIP, K##YOO, HD##YOUN, SW##YU, C##YU, J##YURKEWICZ, A##ZATSERKLYANIY, A##ZEITNITZ, C##ZHANG, D##ZHAO, T##ZHAO, Z##ZHOU, B##ZHU, J##ZIELINSKI, M##ZIEMINSKA, D##ZIEMINSKI, A##ZUTSHI, V##ZVEREV, EG","JOINT INST NUCL RES, DUBNA, RUSSIA. UNIV BUENOS AIRES, BUENOS AIRES, DF, ARGENTINA. CTR BRASILEIRO PESQUISAS FIS, LAFEX, RIO DE JANEIRO, BRAZIL. UNIV ESTADO RIO DE JANEIRO, RIO DE JANEIRO, BRAZIL. UNIV ESTADUAL PAULISTA, INST FIS TEOR, BR-01405 SAO PAULO, BRAZIL. UNIV ALBERTA, EDMONTON, AB, CANADA. YORK UNIV, TORONTO, ON M3J 2R7, CANADA. SIMON FRASER UNIV, BURNABY, BC V5A 1S6, CANADA. MCGILL UNIV, MONTREAL, PQ, CANADA. INST HIGH ENERGY PHYS, BEIJING 100039, PEOPLES R CHINA. UNIV SCI & TECHNOL CHINA, HEFEI 230026, PEOPLES R CHINA. UNIV LOS ANDES, BOGOTA, COLOMBIA. CHARLES UNIV PRAGUE, CTR PARTICLE PHYS, PRAGUE, CZECH REPUBLIC. CZECH TECH UNIV, CR-16635 PRAGUE, CZECH REPUBLIC. ACAD SCI CZECH REPUBLIC, INST PHYS, CTR PARTICLE PHYS, PRAGUE, CZECH REPUBLIC. UNIV SAN FRANCISCO, QUITO, ECUADOR. UNIV CLERMONT FERRAND, CNRS, IN2P3, LAB PHYS CORPUSCULAIRE, CLERMONT FERRAND, FRANCE. UNIV GRENOBLE 1, CNRS, IN2P3, LAB PHYS SUBATOM & COSMOL, GRENOBLE, FRANCE. UNIV AIX MARSEILLE 2, CNRS, IN2P3, CPPM, MARSEILLE, FRANCE. CNRS, IN2P3, LAB ACCELERATEUR LINEAIRE, F-91405 ORSAY, FRANCE. UNIV PARIS 06, CNRS, IN2P3, LPNHE, PARIS, FRANCE. UNIV PARIS 07, CNRS, IN2P3, LPNHE, PARIS, FRANCE. CEA, DAPNIA, SERV PHYS PARTICULES, SACLAY, FRANCE. UNIV STRASBOURG, CNRS, IN2P3, IRES, STRASBOURG, FRANCE. UNIV HAUTE ALSACE, MULHOUSE, FRANCE. UNIV LYON 1, CNRS, INST PHYS NUCL LYON, IN2P3, F-69622 VILLEURBANNE, FRANCE. RHEIN WESTFAL TH AACHEN, PHYS INST 3A, D-5100 AACHEN, GERMANY. UNIV BONN, INST PHYS, D-5300 BONN, GERMANY. UNIV FREIBURG, INST PHYS, FREIBURG, GERMANY. JOHANNES GUTENBERG UNIV MAINZ, INST PHYS, D-6500 MAINZ, GERMANY. UNIV MUNICH, MUNICH, GERMANY. UNIV WUPPERTAL, FACHBEREICH PHYS, WUPPERTAL, GERMANY. PANJAB UNIV, CHANDIGARH 160014, INDIA. UNIV DELHI, DELHI 110007, INDIA. TATA INST FUNDAMENTAL RES, BOMBAY 400005, MAHARASHTRA, INDIA. UNIV COLL DUBLIN, DUBLIN 2, IRELAND. KOREA UNIV, KOREA DECTOR LAB, SEOUL 136701, SOUTH KOREA. SUNGKYUNKWAN UNIV, SUWON, SOUTH KOREA. CINVESTAV, MEXICO CITY 14000, DF, MEXICO. UNIV AMSTERDAM, NIKHEF H, AMSTERDAM, NETHERLANDS. NIKHEF H, FOM INST, NL-1009 DB AMSTERDAM, NETHERLANDS. RADBOUD UNIV NIJMEGEN, NIKHEF H, NIJMEGEN, NETHERLANDS. INST THEORET & EXPT PHYS, MOSCOW 117259, RUSSIA. MOSCOW MV LOMONOSOV STATE UNIV, MOSCOW, RUSSIA. INST HIGH ENERGY PHYS, PROTVINO, RUSSIA. PETERSBURG NUCL PHYS INST, ST PETERSBURG, RUSSIA. ROYAL INST TECHNOL, STOCKHOLM, SWEDEN. LUND UNIV, LUND, SWEDEN. STOCKHOLM UNIV, S-10691 STOCKHOLM, SWEDEN. UPPSALA UNIV, UPPSALA, SWEDEN. UNIV ZURICH, INST PHYS, ZURICH, SWITZERLAND. UNIV LANCASTER, LANCASTER, ENGLAND. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON, ENGLAND. UNIV MANCHESTER, MANCHESTER, LANCS, ENGLAND. UNIV ARIZONA, TUCSON, AZ 85721 USA. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. LAWRENCE BERKELEY NAT LAB, BERKELEY, CA 94720 USA. CALIF STATE UNIV FRESNO, FRESNO, CA 93740 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. FLORIDA STATE UNIV, TALLAHASSEE, FL 32306 USA. FERMILAB NATL ACCELERATOR LAB, BATAVIA, IL 60510 USA. UNIV ILLINOIS, CHICAGO, IL 60607 USA. NO ILLINOIS UNIV, DE KALB, IL 60115 USA. NORTHWESTERN UNIV, EVANSTON, IL 60208 USA. INDIANA UNIV, BLOOMINGTON, IN 47405 USA. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. PURDUE UNIV CALUMET, HAMMOND, IN 46323 USA. IOWA STATE UNIV, AMES, IA 50011 USA. UNIV KANSAS, LAWRENCE, KS 66045 USA. KANSAS STATE UNIV, MANHATTAN, KS 66506 USA. LOUISIANA TECH UNIV, RUSTON, LA 71272 USA. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. BOSTON UNIV, BOSTON, MA 02215 USA. NORTHEASTERN UNIV, BOSTON, MA 02115 USA. UNIV MICHIGAN, ANN ARBOR, MI 48109 USA. MICHIGAN STATE UNIV, E LANSING, MI 48824 USA. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV NEBRASKA, LINCOLN, NE 68588 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. SUNY BUFFALO, BUFFALO, NY 14260 USA. COLUMBIA UNIV, NEW YORK, NY 10027 USA. UNIV ROCHESTER, ROCHESTER, NY 14627 USA. SUNY STONY BROOK, STONY BROOK, NY 11794 USA. BROOKHAVEN NATL LAB, UPTON, NY 11973 USA. LANGSTON UNIV, LANGSTON, OK 73050 USA. UNIV OKLAHOMA, NORMAN, OK 73019 USA. OKLAHOMA STATE UNIV, STILLWATER, OK 74078 USA. BROWN UNIV, PROVIDENCE, RI 02912 USA. UNIV TEXAS, ARLINGTON, TX 76019 USA. SO METHODIST UNIV, DALLAS, TX 75275 USA. RICE UNIV, HOUSTON, TX 77005 USA. UNIV VIRGINIA, CHARLOTTESVILLE, VA 22901 USA. UNIV WASHINGTON, SEATTLE, WA 98195 USA.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"ABACHI S, 1994, NUCL INSTRUM METH A, V338, P185, DOI 10.1016/0168-9002(94)91312-9##ABAZOV VM, 2006, NUCL INSTRUM METH A, V565, P463, DOI 10.1016/J.NIMA.2006.05.248##ABAZOV VM, 2005, PHYS REV LETT, V94, DOI [10.1103/PHYSREVLETT.94.042001, 10.1103/PHYSREVLETT.94.232001, 10.1103/PHYSREVLETT.94.102001]##ABAZOVA VM, 2005, NUCL INSTRUM METH A, V552, P372, DOI 10.1016/J.NIMA.2005.07.008##ABDALLAH J, 2004, EUR PHYS J C, V32, P145, DOI 10.1140/EPJC/S2003-01394-X##ABE F, 1999, PHYS REV D, V59, DOI 10.1103/PHYSREVD.59.032004##ABREU P, 2000, EUR PHYS J C, V16, P555, DOI 10.1007/S100520000415##ACKERSTAFF K, 1998, PHYS LETT B, V426, P161, DOI 10.1016/S0370-2693(98)00289-5##ANIKEEV K, HEPEX0505100##BIGI II, 1994, B DECAYS##BRUN R., 1984, DDEE841 CERN##BUSKULIC D, 1996, PHYS LETT B, V377, P205, DOI 10.1016/0370-2693(96)00451-0##EIDELMAN S, 2004, PHYS LETT B, V592, P1, DOI 10.1016/J.PHYSLETB.2004.06.001##LANGE DJ, 2001, NUCL INSTRUM METH A, V462, P152, DOI 10.1016/S0168-9002(01)00089-4##SJOSTRAND T, 2001, COMPUT PHYS COMMUN, V135, P238, DOI 10.1016/S0010-4655(00)00236-8",25,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/E000487/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242888700037,2006,DROP FORMATION BY THERMAL FLUCTUATIONS AT AN ULTRALOW SURFACE TENSION,"WE PRESENT EXPERIMENTAL EVIDENCE THAT DROP BREAKUP IS CAUSED BY THERMAL NOISE IN A SYSTEM WITH A SURFACE TENSION THAT IS MORE THAN 10(6) TIMES SMALLER THAN THAT OF WATER. WE OBSERVE THAT AT VERY SMALL SCALES CLASSICAL HYDRODYNAMICS BREAKS DOWN AND THE CHARACTERISTIC SIGNATURES OF PINCH-OFF DUE TO THERMAL NOISE ARE OBSERVED. SURPRISINGLY, THE NOISE MAKES THE DROP SIZE DISTRIBUTION MORE UNIFORM, BY SUPPRESSING THE FORMATION OF SATELLITE DROPLETS OF THE SMALLEST SIZES. THE CROSSOVER BETWEEN DETERMINISTIC HYDRODYNAMIC MOTION AND STOCHASTIC THERMALLY DRIVEN MOTION HAS REPERCUSSIONS FOR OUR UNDERSTANDING OF SMALL-SCALE HYDRODYNAMICS, IMPORTANT IN MANY PROBLEMS SUCH AS MICRO- OR NANOFLUIDICS AND INTERFACIAL SINGULARITIES.",THIN-FILM FLOW; BREAKUP; DYNAMICS; FLUID,NA,PHYSICAL REVIEW LETTERS,"HENNEQUIN, Y##AARTS, DGAL##VAN DER WIEL, JH##WEGDAM, G##EGGERS, J##LEKKERKERKER, HNW##BONN, D","UNIV AMSTERDAM, WAALS ZEEMAN INST, COMPLEX FLUIDS GRP, NL-1018 XE AMSTERDAM, NETHERLANDS. UNIV UTRECHT, VANT HOFF LAB, NL-3584 CH UTRECHT, NETHERLANDS. ECOLE NORMALE SUPER, LAB PHYS STAT, F-75231 PARIS 05, FRANCE. UNIV BRISTOL, SCH MATH, BRISTOL BS8 1TW, AVON, ENGLAND.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"AARTS DGA, 2005, THESIS U UTRECHT, P59801##AARTS DGAL, 2004, SCIENCE, V304, P847, DOI 10.1126/SCIENCE.1097116##AARTS DGAL, 2003, J PHYS-CONDENS MAT, V15, PS245, DOI 10.1088/0953-8984/15/1/332##ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347##BERGERON V, 2000, NATURE, V405, P772, DOI 10.1038/35015525##BRENNER MP, 1994, PHYS REV LETT, V73, P3391, DOI 10.1103/PHYSREVLETT.73.3391##COHEN I, 1999, PHYS REV LETT, V83, P1147, DOI 10.1103/PHYSREVLETT.83.1147##DAVIDOVITCH B, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.244505##DE GENNES P.G., 1979, SCALING CONCEPTS POL##DOSHI P, 2003, SCIENCE, V302, P1185, DOI 10.1126/SCIENCE.1089272##EGGERS J, 1993, PHYS REV LETT, V71, P3458, DOI 10.1103/PHYSREVLETT.71.3458##EGGERS J, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.084502##EGGERS J, 1997, REV MOD PHYS, V69, P865, DOI 10.1103/REVMODPHYS.69.865##*EPAPS, EPRLTAO97013650##GRUN G, 2006, J STAT PHYS, V122, P1261, DOI 10.1007/S10955-006-9028-8##HENDERSON D, 2000, PHYS FLUIDS, V12, P550, DOI 10.1063/1.870261##LISTER JR, 1998, PHYS FLUIDS, V10, P2758, DOI 10.1063/1.869799##MARMOTTANT PH, 2004, J FLUID MECH, V498, P73, DOI 10.1017/S0022112003006529##MECKE K, 2005, J PHYS-CONDENS MAT, V17, PS3515, DOI 10.1088/0953-8984/17/45/042##MOSELER M, 2000, SCIENCE, V289, P1165, DOI 10.1126/SCIENCE.289.5482.1165##PEREGRINE DH, 1990, J FLUID MECH, V212, P25, DOI 10.1017/S0022112090001835##ROWLINSON JS, 1982, MOL THEORY CAPILLARI##SHI XD, 1994, SCIENCE, V265, P219, DOI 10.1126/SCIENCE.265.5169.219##VRIJ A, 1976, PURE APPL CHEM, V48, P471, DOI 10.1351/PAC197648040471",39,2020-11-20,NA
J,WOS:000242473300008,2006,"CONTINUUM REMOVED BAND DEPTH ANALYSIS FOR DETECTING THE EFFECTS OF NATURAL GAS, METHANE AND ETHANE ON MAIZE REFLECTANCE","IT IS KNOWN THAT NATURAL GAS IN THE SOIL AFFECTS VEGETATION HEALTH, WHICH MAY BE DETECTED THROUGH ANALYSIS OF REFLECTANCE SPECTRA. SINCE NATURAL GAS IS INVISIBLE, CHANGES IN THE VEGETATION COULD POTENTIALLY INDICATE GAS LEAKAGE. ALTHOUGH IT IS KNOWN THAT GAS IN SOIL AFFECTS PLANT REFLECTANCE, THE RELATIONSHIP BETWEEN NATURAL GAS AND THE DEVELOPMENT AND REFLECTANCE PROPERTIES OF PLANTS HAS NOT BEEN STUDIED. THE OBJECTIVE OF THIS STUDY WAS TO TEST WHETHER NATURAL GAS AND ITS TWO MAIN COMPONENTS, METHANE AND ETHANE, AFFECT VEGETATION REFLECTANCE IN THE CHLOROPHYLL AND WATER ABSORPTION REGIONS. AN EXPERIMENT WAS CARRIED OUT IN WHICH MAIZE (ZEA MAYS) PLANTS WERE GROWN IN POTS THAT WERE FLUSHED WITH 10 1 OF GAS PER DAY FOR 39 4 DAYS. LEAF REFLECTANCE WAS MEASURED ONCE A WEEK WITH A SPECTROPHOTOMETER. THE REFLECTANCE WAS ANALYSED USING CONTINUUM REMOVAL OF THE BLUE (400-550 NM), RED (550-750 NM) AND TWO WATER ABSORPTION FEATURES (1370-1570 NM AND 1870-2170 NM), AFTER WHICH THE BAND DEPTHS AND NORMALIZED BAND DEPTHS WERE ANALYZED FOR EACH TREATMENT. THE BAND DEPTH ANALYSIS SHOWED THAT ETHANE CAUSED AN INITIAL INCREASE OF 10% IN REFLECTANCE BETWEEN 560 AND 590 NM, FOLLOWED BY A DECREASE DURING THE COURSE OF THE EXPERIMENT. NORMALIZED BAND DEPTH ANALYSIS SHOWED THAT ETHANE CAUSED A REFLECTANCE SHIFT OF I TO 5 NM TOWARDS LONGER WAVELENGTHS COMPARED TO THE CONTROL REFLECTANCE IN THE VISIBLE REGION. ALL GASES CAUSED AN INCREASE IN REFLECTANCE IN THE WATER ABSORPTION BANDS. THE PHYSIOLOGICAL REFLECTANCE INDEX, PRI, WHICH HAS PREVIOUSLY LINKED WATER STRESS TO PHOTOSYNTHETIC ACTIVITY, SUGGESTED THAT THE HYDROCARBON GASES (PARTICULARLY ETHANE) DECREASED THE PHOTOSYNTHETIC ACTIVITY OF THE PLANTS. THE COMBINATION OF REDUCED BAND DEPTHS IN THE CHLOROPHYLL AND WATER ABSORPTION REGIONS AND THE INCREASED PRI SUGGESTS THAT ETHANE GAS IN THE SOIL HAMPERED A NORMAL WATER UPTAKE BY MAIZE PLANTS IN AN EARLY STAGE OF THEIR GROWTH. ALTHOUGH FURTHER RESEARCH IS NECESSARY TO UPSCALE THE RESULTS FROM THE LABORATORY TO THE FIELD, THE INCREASED REFLECTANCE IN THE 560-590 NM REGION CAUSED BY ETHANE TOGETHER WITH THE INCREASED PRI ARE PROMISING INDICATORS FOR GAS LEAKAGE. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",LEAF WATER-CONTENT; SPECTRAL REFLECTANCE; ABSORPTION FEATURES; RED-EDGE; PASTURE QUALITY; PLANT STRESS; VEGETATION; LEAVES; RESOLUTION; RESPONSES,NATURAL GAS; METHANE; ETHANE; ZEA MAYS; REFLECTANCE; CONTINUUM REMOVAL; PRI,REMOTE SENSING OF ENVIRONMENT,"NOOMEN, MF##SKIDMORE, AK##VAN DER MEER, FD##PRINS, HHT","INST INST GEOINFORMAT SCI & EARTH OBSERV, NL-7500 AA ENSCHEDE, NETHERLANDS. UNIV WAGENINGEN & RES CTR, DEPT RESOURCE ECOL, NL-6708 PD WAGENINGEN, NETHERLANDS.",ENVIRONMENTAL SCIENCES; REMOTE SENSING; IMAGING SCIENCE & PHOTOGRAPHIC TECHNOLOGY,ENVIRONMENTAL SCIENCES & ECOLOGY; REMOTE SENSING; IMAGING SCIENCE & PHOTOGRAPHIC TECHNOLOGY,"ADAMS ML, 1999, INT J REMOTE SENS, V20, P3663, DOI 10.1080/014311699211264##ADAMSE AD, 1972, MICROBIOLOGISCHE ACT, P15##ARTHUR JJ, 1985, J ENVIRON SCI HEAL A, V20, P913, DOI 10.1080/10934528509375267##BAMMEL BH, 1994, PHOTOGRAMM ENG REM S, V60, P87##BANNINGER C, 1991, PHYS MEASUREMENTS SI, V1, P155##BENEDICT HM, 1961, SCIENCE, V133, P2015, DOI 10.1126/SCIENCE.133.3469.2015##BOOCHS F, 1990, INT J REMOTE SENS, V11, P1741, DOI 10.1080/01431169008955127##BORU G, 2003, ANN BOT-LONDON, V91, P447, DOI 10.1093/AOB/MCG040##BRAVERMAN MM, 1962, GAS AGE, V129, P23##CARTER GA, 1993, AM J BOT, V80, P239, DOI 10.2307/2445346##CARTER GA, 1991, AM J BOT, V78, P916, DOI 10.2307/2445170##CECCATO P, 2001, REMOTE SENS ENVIRON, V77, P22, DOI 10.1016/S0034-4257(01)00191-2##CIBULA WG, 1992, INT J REMOTE SENS, V13, P1869, DOI 10.1080/01431169208904236##CLARK RN, 1984, J GEOPHYS RES, V89, P6329, DOI 10.1029/JB089IB07P06329##COCHRAN WG, 1992, EXPT DESIGNS, P611##CURRAN PJ, 1989, REMOTE SENS ENVIRON, V30, P271, DOI 10.1016/0034-4257(89)90069-2##CURRAN PJ, 2001, REMOTE SENS ENVIRON, V76, P349, DOI 10.1016/S0034-4257(01)00182-1##DANSON FM, 1992, INT J REMOTE SENS, V13, P461, DOI 10.1080/01431169208904049##DEMETRIADESSHAH TH, 1990, REMOTE SENS ENVIRON, V33, P55, DOI 10.1016/0034-4257(90)90055-Q##DEOLIVEIRA WJ, 1997, 12 INT C WORKSH APPL, P1##DREW MC, 1983, PLANT SOIL, V75, P179, DOI 10.1007/BF02375564##EVAIN S, 2004, REMOTE SENS ENVIRON, V91, P175, DOI 10.1016/J.RSE.2004.03.012##GAMON JA, 1992, REMOTE SENS ENVIRON, V41, P35, DOI 10.1016/0034-4257(92)90059-S##GATES DM, 1965, APPL OPTICS, V4, P11, DOI 10.1364/AO.4.000011##GITELSON A., 1998, ADV SPACE RES, V22, P609##GUSTAFSON FG, 1944, PLANT PHYSIOL, V19, P551, DOI 10.1104/PP.19.3.551##HANSON RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996##HENDERSHOT W. H., 1993, SOIL SAMPLING METHOD, P141, DOI DOI 10.1007/BF02990926##HOEKS J, 1972, TECHNICAL B I LAND W, V82, P46##HOEKS J, 1972, THESIS WAGENINGEN U, P120##HORLER DNH, 1983, INT J REMOTE SENS, V4, P273, DOI 10.1080/01431168308948546##HUANG B, 1997, CROP SCI, V37, P812, DOI 10.2135/CROPSCI1997.0011183X003700030020X##HUNT ER, 1989, REMOTE SENS ENVIRON, V30, P43, DOI 10.1016/0034-4257(89)90046-1##JONES VT, 1996, AAPG MEMOIR, V66, P203##KOKALY RF, 1999, REMOTE SENS ENVIRON, V67, P267, DOI 10.1016/S0034-4257(98)00084-4##LEOPOLD A. C., 1975, PLANT GROWTH AND DEVELOPMENT.##LICHTENTHALER HK, 1996, J PLANT PHYSL, V148, P8##LYNCH J, 1995, PLANT PHYSIOL, V109, P7, DOI 10.1104/PP.109.1.7##MARACCI G, 1991, P INT GEOSC REM SENS, P2303##MILLER R, 1985, ENCY STAT SCI, P679##MUTANGA O, 2005, INT J REMOTE SENS, V26, P1093, DOI 10.1080/01431160512331326738##MUTANGA O, 2004, REMOTE SENS ENVIRON, V89, P393, DOI 10.1016/J.RSE.2003.11.001##*NAT TRANSP SAF BO, 2001, NAT GAS EXPL FIR S R##NATIONAL TRANSPORTATION SAFETY BOARD, 2000, NAT GAS PIP RUPT FIR##NICODEMUS FE, 1977, NATL BUREAU STANDARD, V160, P42##OLAH G. A., 2003, HYDROCARBON CHEM, P871##PYSEK P, 1989, WEED RES, V29, P193, DOI 10.1111/J.1365-3180.1989.TB00859.X##RADIN J W, 1969, PLANT PHYSIOLOGY (ROCKVILLE), V44, P1584, DOI 10.1104/PP.44.11.1584##REID N, 1988, P 6 THEM C REM SENS, V1, P213##SANDMEIER S, 1999, REMOTE SENS ENVIRON, V69, P281, DOI 10.1016/S0034-4257(99)00032-2##SCHUMACHER D, 1996, AAPG MEMOIR, V66, P71##SIMS DA, 2003, REMOTE SENS ENVIRON, V84, P526, DOI 10.1016/S0034-4257(02)00151-7##SMITH KL, 2004, REMOTE SENS ENVIRON, V92, P207, DOI 10.1016/J.RSE.2004.06.002##SMITH KL, 2004, INT J REMOTE SENS, V25, P4395, DOI 10.1080/01431160410001729172##STEVEN MD, 2006, EUROPEAN J SOIL SCI##STRACHAN IB, 2002, REMOTE SENS ENVIRON, V80, P213, DOI 10.1016/S0034-4257(01)00299-1##THENOT F, 2002, INT J REMOTE SENS, V23, P5135, DOI 10.1080/01431160210163100##TUCKER CJ, 1980, REMOTE SENS ENVIRON, V10, P23, DOI 10.1016/0034-4257(80)90096-6##WELLBURN AR, 1994, J PLANT PHYSIOL, V144, P307, DOI 10.1016/S0176-1617(11)81192-2##YANG H, 1999, INT J REMOTE SENS, V20, P807, DOI 10.1080/014311699213226",69,2020-11-20,NA
J,WOS:000242887700015,2006,"EVALUATION OF METHODS FOR QUANTIFYING AGRICULTURAL EMISSIONS OF AIR, WATER AND SOIL POLLUTANTS","INTEGRATED ASSESSMENTS THAT ANALYZE GLOBAL WARMING, ACIDIFICATION, EUTROPHICATION AND OZONE RELATED PROBLEMS SIMULTANEOUSLY, NEED COMPLETE, DETAILED AND CONSISTENT EMISSION ESTIMATES THAT CONSIDER POSSIBLE INTERRELATIONS BETWEEN DIFFERENT POLLUTANTS. WE DISCUSS THREE TYPES OF EMISSION ESTIMATION METHODS: EMISSION FACTOR, REGRESSION ANALYSES AND PROCESS-BASED METHODS. SELECTED EXAMPLES OF THESE ARE REVIEWED TO ILLUSTRATE THE LARGE VARIETY IN METHODS AVAILABLE. WE PRESENT AN APPROACH FOR THE EVALUATION OF EMISSION ESTIMATION METHODS WHICH FOLLOWS THREE STEPS: (1) COMPARISON, (2) SCORING AND (3) MULTI-CRITERIA ANALYSIS (MCA). WE DEMONSTRATE THE USEFULNESS OF THIS APPROACH BY APPLYING IT TO A CASE STUDY FOR THE CZECH REPUBLIC. FIRSTLY WE COMPARE SELECTED METHODS WITH RESPECT TO CHARACTERISTICS WHICH WE CONSIDER AS REQUIREMENTS TO QUANTIFY EMISSIONS OF AIR, WATER AND SOIL POLLUTANTS IN AN INTEGRATED WAY. WE OBSERVE THAT NONE OF THE SELECTED METHODS FULLY MEET OUR DEFINED CHARACTERISTICS. SECONDLY, WE SCORE THE METHODS WITH RESPECT TO THREE TYPES OF CRITERIA. THIS EVALUATION REVEALS LARGE DIFFERENCES BETWEEN THE METHODS. WE CONCLUDE THAT THE FOLLOWING METHODS BEST MEET OUR CRITERIA: THE IPCC GUIDELINES, METHODS FROM INITIATOR, AND THE DETAILED METHOD OF THE EMEP/CORINAIR GUIDEBOOK. FINALLY, WE PERFORM A MULTI-CRITERIA ANALYSIS TO ANALYZE HOW OUR CONCLUSIONS CHANGE IF ONE CONSIDERS CERTAIN CRITERIA AS MORE IMPORTANT THAN OTHERS. BASED ON THIS ANALYSIS WE SUGGEST THAT COMBINING PARTS OF EACH OF THE THREE METHODS FORMS A SOUND BASIS FOR A NEW EMISSION ESTIMATION METHOD FOR QUANTIFYING AGRICULTURAL EMISSIONS OF AIR, WATER AND SOIL POLLUTION SIMULTANEOUSLY. (C) 2006 ELSEVIER B.V ALL RIGHTS RESERVED.",NITROUS-OXIDE EMISSIONS; AMMONIA EMISSIONS; GAS EMISSIONS; MODEL; EUROPE; TEMPERATE,AGRICULTURE; EMISSION ESTIMATE; MULTI-CRITERIA ANALYSIS,SCIENCE OF THE TOTAL ENVIRONMENT,"HAVLIKOVA, M##KROEZE, C","CZECH HYDROMETEOROL INST, PRAGUE 14306 4, CZECH REPUBLIC. UNIV WAGENINGEN & RES CTR, ENVIRONM SYST ANAL GRP, NL-6700 DD WAGENINGEN, NETHERLANDS.",ENVIRONMENTAL SCIENCES,ENVIRONMENTAL SCIENCES & ECOLOGY,"AMANN M, 2005, CAFE SCENARIO ANAL R, V6##AMANN M, 1998, COST EFFECTIVE CONTR##BRINK JC, 2003, THESIS WAGENINGEN U, P141##BROWN L, 2001, NUTR CYCL AGROECOSYS, V60, P149, DOI 10.1023/A:1012659801484##BROWN L, 2002, ATMOS ENVIRON, V36, P917, DOI 10.1016/S1352-2310(01)00512-X##DE VRIES W, 2003, NUTR CYCL AGROECOSYS, V66, P71, DOI 10.1023/A:1023354109910##DE VRIES W, 2005, ENV SCI, V2, P217##DE VRIES W., 2004, P 13 CLEAN AIR ENV P##DEVRIES W, 2001, P 2 INT NITR C SCI P##DEVRIES W, UNPUB INITIATOR2 INS##*EEA, 2005, EMEP CORINAIR EM INV##*EPA, 2004, COMP AIR POLL EM FAC, V1##ERISMAN JW, 2004, ENVIRON POLLUT, V129, P159, DOI 10.1016/J.ENVPOL.2003.08.042##*FAO IFA, 2001, GLOB EST GAS EM NH3, P106##FOY B, 2004, P 4 INT PHOSPH WORKS##FREIBAUER A, 2003, EUR J AGRON, V19, P135, DOI 10.1016/S1161-0301(02)00020-5##FREIBAUER A, 2003, BIOGEOCHEMISTRY, V63, P93, DOI 10.1023/A:1023398108860##FROLKING SE, 1998, NUTR CYCL AGROECOSYS, V52, P77, DOI 10.1023/A:1009780109748##IGNACIUK A, 2002, WORLD RESOUR REV, V14, P25##*IPCC, 2001, GOOD PRACT GUID UNC##KLAASSEN G, 1994, EUR REV AGRIC ECON, V21, P219, DOI 10.1093/ERAE/21.2.219##KLAASSEN G, 2004, IR04015 IIASA##KLIMONT Z, 2001, MODELLING PARTICULAT##KROEZE C, 1994, SCI TOTAL ENVIRON, V143, P193, DOI 10.1016/0048-9697(94)90457-X##KROEZE C, 1998, NUTR CYCL AGROECOSYS, V52, P195, DOI 10.1023/A:1009780608708##LAEGREID M., 1999, AGR FERTILIZERS ENV##LI CS, 2000, NUTR CYCL AGROECOSYS, V58, P259, DOI 10.1023/A:1009859006242##MAYERHOFER P, 2001, WATER AIR SOIL POLL, V130, P1151, DOI 10.1023/A:1013992025515##MENZI H, 1998, ATMOS ENVIRON, V32, P301, DOI 10.1016/S1352-2310(97)00239-2##MONTENY GJ, 2001, NUTR CYCL AGROECOSYS, V60, P123, DOI 10.1023/A:1012602911339##NEUFELDT H, 2006, AGR ECOSYST ENVIRON, V112, P233, DOI 10.1016/J.AGEE.2005.08.024##*ODPM, 2004, MULT AN MAN, P145##PINDER RW, 2004, ATMOS ENVIRON, V38, P1357, DOI 10.1016/J.ATMOSENV.2003.11.024##SCHOPP W, 2005, ENVIRON SCI POLICY, V8, P601, DOI 10.1016/J.ENVSCI.2005.06.008##SILGRAM M, 2001, NUTR CYCL AGROECOSYS, V60, P189, DOI 10.1023/A:1012695413780##SOGAARD HT, 2002, ATMOS ENVIRON, V36, P3309, DOI 10.1016/S1352-2310(02)00300-X##VANAARDENNE JA, 2002, THESIS WAGENINGEN U, P145##VANIERLAND EC, 2002, GLOBAL CHANGE##WEBB J, 2004, ATMOS ENVIRON, V38, P2163, DOI 10.1016/J.ATMOSENV.2004.01.023##2003, MEA MILLENNIUM ECOSY, P138",6,2020-11-20,NA
J,WOS:000241591200005,2006,"IN VITRO CHARACTERIZATION OF SLV308 (7-[4-METHYL-1-PIPERAZINYL]-2(3H)-BENZOXAZOLONE, MONOHYDROCHLORIDE): A NOVEL PARTIAL DOPAMINE D-2 AND D-3 RECEPTOR AGONIST AND SEROTONIN 5-HT1A RECEPTOR AGONIST","PRESENT PARKINSON'S DISEASE TREATMENT STRATEGIES ARE FAR FROM IDEAL FOR A VARIETY OF REASONS; IT HAS THEREFORE BEEN SUGGESTED THAT PARTIAL DOPAMINE RECEPTOR AGONISM MIGHT BE A POTENTIAL THERAPEUTIC APPROACH WITH POTENTIALLY FEWER SIDE EFFECTS. IN THE PRESENT STUDY, WE DESCRIBE THE IN VITRO CHARACTERIZATION OF THE NONERGOT LIGAND SLV308 (7-[4-METHYL-1-PIPERAZINYL]-2(3H)-BENZOXAZOLONEMONOHYDROCHLORIDE). SLV308 BINDS TO DOPAMINE D-2, D-3, AND D-4 RECEPTORS AND 5-HT1A RECEPTORS AND IS A PARTIAL AGONIST AT DOPAMINE D-2 AND D-3 RECEPTORS AND A FULL AGONIST AT SEROTONIN 5-HT1A RECEPTORS. AT CLONED HUMAN DOPAMINE D-2, L RECEPTORS, SLV308 ACTED AS A POTENT BUT PARTIAL D-2 RECEPTOR AGONIST (PEC(50) = 8.0 AND PA(2) = 8.4) WITH AN EFFICACY OF 50% ON FORSKOLIN STIMULATED CAMP ACCUMULATION. AT HUMAN RECOMBINANT DOPAMINE D-3 RECEPTORS, SLV308 ACTED AS A PARTIAL AGONIST IN THE INDUCTION OF [S-35]GTP GAMMA S BINDING (INTRINSIC ACTIVITY OF 67%; PEC(50) = 9.2) AND ANTAGONIZED THE DOPAMINE INDUCTION OF [S-35]GTR GAMMA S BINDING (PA(2) = 9-0). SLV308 ACTED AS A FULL 5-HT1A RECEPTOR AGONIST ON FORSKOLIN INDUCED CAMP ACCUMULATION AT CLONED HUMAN 5-HT1A RECEPTORS BUT WITH LOW POTENCY (PEC(50) = 6.3). IN RAT STRIATAL SLICES SLV308 CONCENTRATION-DEPENDENTLY ATTENUATED FORSKOLIN STIMULATED ACCUMULATION OF CAMP, AS EXPECTED FOR A DOPAMINE D-2 AND D-3 RECEPTOR AGONIST. SLV308 ANTAGONIZED THE INHIBITORY EFFECT OF QUINPIROLE ON K+-STIMULATED [3 HI-DOPAMINE RELEASE FROM RAT STRIATAL SLICES (PA(2) = 8.5). IN THE SAME PARADIGM, SLV308 HAD ANTAGONIST PROPERTIES IN THE PRESENCE OF QUINPIROLE (PA2 = 8.5), BUT THE PARTIAL D-2 AGONIST TERGURIDE HAD MUCH STRONGER ANTAGONISTIC PROPERTIES. IN CONCLUSION, SLV308 COMBINES HIGH POTENCY PARTIAL AGONISM AT DOPAMINE D-2 AND D-3 RECEPTORS WITH FULL EFFICACY LOW POTENCY SEROTONIN 5-HT1A RECEPTOR AGONISM AND IS WORTHY OF PROFILING IN IN VIVO MODELS OF PARKINSON'S DISEASE.",MONOAMINERGIC RECEPTOR; ANTIPARKINSON AGENTS; DIFFERENTIAL ACTIONS; PARKINSONS-DISEASE; MULTIPLE CLASSES; ANTAGONIST PROPERTIES; HIGH-AFFINITY; ACTIVATION; VIVO; MULTICENTER,PARTIAL AGONIST; RECEPTOR BINDING; NEUROCHEMISTRY; PARKINSON'S DISEASE; SEROTONIN; D-2; D-3; 5-HT1A,SYNAPSE,"GLENNON, JC##VAN SCHARRENBURG, G##RONKEN, E##HESSELINK, MB##REINDERS, JH##VAN DER NEUT, M##LONG, SK##FEENSTRA, RW##MCCREARY, AC","SOLVAY PHARMACEUT RES LABS, NL-1380 DA WEESP, NETHERLANDS.",NEUROSCIENCES,NEUROSCIENCES & NEUROLOGY,"AHLENIUS S, 2000, EUR J PHARMACOL, V394, P247, DOI 10.1016/S0014-2999(00)00158-8##BARA-JIMENEZ W, 2005, MOVEMENT DISORD, V20, P932, DOI 10.1002/MDS.20370##BARTOSZYK GD, 2004, J NEURAL TRANSM, V111, P113, DOI 10.1007/S00702-003-0094-7##BENNETT JP, 1999, J NEUROL SCI, V163, P25, DOI 10.1016/S0022-510X(98)00307-4##BIBBIANI F, 2001, NEUROLOGY, V57, P1829, DOI 10.1212/WNL.57.10.1829##BLANDINI F, 2000, PROG NEUROBIOL, V62, P63, DOI 10.1016/S0301-0082(99)00067-2##BROOKS DJ, 2001, CURR OPIN NEUROL, V14, P465, DOI 10.1097/00019052-200108000-00006##BURRIS KD, 2002, J PHARMACOL EXP THER, V302, P381, DOI 10.1124/JPET.102.033175##CHRISTOFFERSEN CL, 1998, NEUROPSYCHOPHARMACOL, V18, P399##CUSSAC D, 2002, MOL PHARMACOL, V62, P578, DOI 10.1124/MOL.62.3.578##FILIPOVA M, 1988, EUR ARCH PSY CLIN N, V237, P298, DOI 10.1007/BF00450549##GAINETDINOV RR, 1996, EUR J PHARMACOL, V308, P261, DOI 10.1016/0014-2999(96)00300-7##GOBERT A, 1995, J PHARMACOL EXP THER, V275, P899##HAGAN JJ, 1997, TRENDS PHARMACOL SCI, V18, P310, DOI 10.1016/S0165-6147(97)90651-9##JANKOVIC J, 1993, NEUROLOGY, V43, P14##JENNER P, 2002, NEUROLOGY, V58, PS1, DOI 10.1212/WNL.58.SUPPL_1.S1##JOHNSON CK, 2005, PHYSIOLOGY, V20, P10, DOI 10.1152/PHYSIOL.00037.2004##KANNARI KAZUYA, 2002, NO TO SHINKEI, V54, P133##KULKARNI SK, 2000, FUNDAM CLIN PHARM, V14, P529, DOI 10.1111/J.1472-8206.2000.TB00437.X##LE FOLL B, 2005, LIFE SCI, V76, P1281, DOI 10.1016/J.LFS.2004.09.018##LLEDO A, 2000, PARKINSONISM RELAT D, V7, P51, DOI 10.1016/S1353-8020(00)00038-9##LOZANO AM, 1998, CURR OPIN NEUROBIOL, V8, P783, DOI 10.1016/S0959-4388(98)80122-0##MCCREARY AC, 2006, MOVEMENT DISORD, V21, PP92##MCCREARY AC, 2006, NEUROPSYCHOPHARMACOL##MCCREARY AC, 2006, IN PRESS MOV DISORD##MCCREARY AC, 2006, MOVEMENT DISORD, V21, PS13##MCCREARY AC, 2003, 10 INT M NEUR METH S##MELTZER HY, 2003, PROG NEURO-PSYCHOPH, V27, P1159, DOI 10.1016/J.PNPBP.2003.09.010##METMAN LV, 1994, MOVEMENT DISORD, V9, P577, DOI 10.1002/MDS.870090512##MILLAN MJ, 2000, J PHARMACOL EXP THER, V295, P853##MILLAN MJ, 2000, J PHARMACOL EXP THER, V293, P1063##MILLAN MJ, 2004, J PHARMACOL EXP THER, V311, P190, DOI 10.1124/JPET.104.069625##MILLAN MJ, 2002, J PHARMACOL EXP THER, V303, P791, DOI 10.1124/JPET.102.039867##NEWMAN-TANCREDI A, 2002, J PHARMACOL EXP THER, V303, P815, DOI 10.1124/JPET.102.039883##NEWMAN-TANCREDI A, 1999, MOL PHARMACOL, V55, P564##NEWMAN-TANCREDI A, 2002, J PHARMACOL EXP THER, V303, P805, DOI 10.1124/JPET.102.039875##OAK JN, 2000, EUR J PHARMACOL, V405, P303, DOI 10.1016/S0014-2999(00)00562-8##OLANOW CW, 2004, CLIN NEUROPHARMACOL, V27, P58, DOI 10.1097/00002826-200403000-00003##PACCHETTI C, 1993, MOVEMENT DISORD, V8, P463, DOI 10.1002/MDS.870080408##RASCOL O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004##REAVILL C, 2000, J PHARMACOL EXP THER, V294, P1154##ROBERTSON RG, 1990, BRAIN RES, V531, P95, DOI 10.1016/0006-8993(90)90762-Z##ROBINSON DS, 1989, PSYCHOPATHOLOGY, V22, P27, DOI 10.1159/000284624##SUMIYOSHI T, 2004, AM J PSYCHIAT, V161, P1505, DOI 10.1176/APPI.AJP.161.8.1505##TANG L, 1994, J PHARMACOL EXP THER, V270, P475##TUNNICLIFF G, 1991, PHARMACOL TOXICOL, V69, P149, DOI 10.1111/J.1600-0773.1991.TB01289.X##WERKMAN T. R., 2006, CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, V5, P3, DOI 10.2174/187152706784111614",38,2020-11-20,NA
J,WOS:000243462000002,2006,NEONATAL DIARRHOEA IN PIGS: ALPHA- AND BETA(2)-TOXIN PRODUCED BY CLOSTRIDIUM PERFRINGENS,"SINCE 2001 THE PIG HEALTH UNIT OF UTRECHT UNIVERSITY HAS BEEN CONSULTED BY VARIOUS PIG FARMS REGARDING NEONATAL DIARRHOEA. WHEN PREVENTIVE MEASURES AGAINST E. COLI-INDUCED DIARRHOEA HAD NO OR LIMITED RESULTS, THE DIARRHOEIC PIGLETS WERE INVESTIGATED FURTHER THE MICROBIOLOGICAL AND PATHOLOGICAL FINDINGS WERE INDICATIVE OF INFECTION WITH CLOSTRIDIUM PERFRINGENS. TOXIN TYPING BY POLYMERASE CHAIN REACTION LED TO THE DETECTION OF GENES ENCODING ALPHA-TOXIN (CPA) AND BETA(2)-TOXIN (CPB2). SURPRISINGLY, ALPHA- AND BETA(2)-TOXIN-PRODUCING C. PERFRINGENS WAS ISOLATED FROM ALL TESTED HERDS WITH PIGLETS WITH NEONATAL DIARRHOEA. FROM OUR OBSERVATIONS, IT IS LIKELY THAT MANY HERDS IN THE NETHERLANDS ARE INFECTED WITH BETA(2)-TOXIN-PRODUCING C. PERFRINGENS STRAINS. AS PRESENT VACCINES LACK BETA(2)-TOXOID AND THUS DO NOT PROVIDE PIGLETS WITH PROTECTION AGAINST BETA(2)-INDUCED DIARRHOEA.",BETA2 TOXIN; ANIMALS; PREVALENCE; PIGLETS; GENE,NA,TIJDSCHRIFT VOOR DIERGENEESKUNDE,"HENDRIKSEN, SWM##VAN LEENGOED, LAMG##ROEST, HIJ##VAN NES, A","UNIV UTRECHT, FAC DIERGENEESKUNDE, DEPT GEZONDHEIDSZORG LANDBOUWHUISDIEREN, AFDELING VARKENSGEZOND HEIDSZORG, NL-3584 CL UTRECHT, NETHERLANDS. WAGENINGEN UR, DIV BACTERIOL TSES, CIDC, WAGENINGEN, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,"BRAUN M, 2000, FEMS MICROBIOL LETT, V184, P29, DOI 10.1111/J.1574-6968.2000.TB08985.X##BUESCHEL DM, 2003, VET MICROBIOL, V94, P121, DOI 10.1016/S0378-1135(03)00081-6##BUOGO C, 1995, J VET MED B, V42, P51, DOI 10.1111/J.1439-0450.1995.TB00681.X##GARMORY HS, 2000, EPIDEMIOL INFECT, V124, P61, DOI 10.1017/S0950268899003295##GIBERT M, 1997, GENE, V203, P65, DOI 10.1016/S0378-1119(97)00493-9##HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990##HERHOLZ C, 1999, J CLIN MICROBIOL, V37, P358, DOI 10.1128/JCM.37.2.358-361.1999##HOLMGREN N, 2004, 18 INT PIG VET SOC C, P828##KLAASEN HLBM, 1999, FEMS IMMUNOL MED MIC, V24, P325, DOI 10.1111/J.1574-695X.1999.TB01301.X##ROOD JI, 1991, MICROBIOL REV, V55, P621, DOI 10.1128/MMBR.55.4.621-648.1991##ROOD JI, 1998, ANNU REV MICROBIOL, V52, P333, DOI 10.1146/ANNUREV.MICRO.52.1.333##SCHMIDT AS, 2004, 18 INT PIG VET SOC C, P330##SCHOTTE U, 2004, J VET MED B, V51, P423, DOI 10.1111/J.1439-0450.2004.00802.X##SHIMIZU T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/PNAS.022493799##SONGER JG, 1996, CLIN MICROBIOL REV, V9, P216, DOI 10.1128/CMR.9.2.216##SPRINGER S, 1999, FEMS IMMUNOL MED MIC, V24, P333, DOI 10.1111/J.1574-695X.1999.TB01302.X##ZIZLAVSKY M, 2004, 18 INT PIG VET SOC C, P296",5,2020-11-20,NA
J,WOS:000243462000003,2006,SPOROTRICHOSIS IN A CAT AND ITS OWNER,NA,NA,NA,TIJDSCHRIFT VOOR DIERGENEESKUNDE,"HUGEN, L##KOUMANS, H","VERBONDEN DIERENKLIN HUGEN, NIEUWEGEIN, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,NA,0,2020-11-20,NA
J,WOS:000243462000007,2006,EXAMINATIONS PRIORITIES IN VIEW OF THE MRSA PROBLEM IN DUTCH ANIMAL OWNERSHIP,NA,NA,NA,TIJDSCHRIFT VOOR DIERGENEESKUNDE,"MEVIUS, D##VERBRUGH, H","CIDC, LELYSTAD, NETHERLANDS. ERASMUS UMC, ROTTERDAM, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,"DENEELING AJ, 2006, VWA CLB SURVEY VOORK",2,2020-11-20,NA
J,WOS:000242948600018,2006,EVEROLIMUS INTERFERES WITH HEALING OF EXPERIMENTAL INTESTINAL ANASTOMOSES,"BACKGROUND. ALTHOUGH CLINICAL DATA SUGGEST ITS EXISTENCE, LITTLE IS KNOWN ABOUT THE EFFECT OF RAPAMYCIN DERIVATIVES ON WOUND REPAIR. THIS STUDY AIMS TO DELINEATE THE INFLUENCE OF THE MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR EVEROLIMUS ON WOUND HEALING IN THE RAT INTESTINE. METHODS. FOUR GROUPS OF 26 MALE WISTAR RATS RECEIVED EVEROLIMUS IN DAILY ORAL DOSAGES OF 0 (CONTROLS), 0.5 (GROUP E-0.5), 1.0 (GROUP E-1), AND 3.0 (GROUP E-3) MG/KG EVERY 24 HOURS, RESPECTIVELY, STARTING FOUR HOURS BEFORE THE OPERATION UNTIL KILLING. AFTER RESECTION OF 1-CM SEGMENTS OF COLON AND ILEUM, INTESTINAL ANASTOMOSES WERE CONSTRUCTED. THE ANIMALS WERE KILLED AT DAYS THREE OR SEVEN AFTER OPERATION. WOUND HEALING WAS ASSESSED BY MECHANICAL (BURSTING PRESSURE, BREAKING STRENGTH), BIOCHEMICAL (COLLAGEN CONTENT, GELATINASE ACTIVITY), AND HISTOLOGIC PARAMETERS. RESULTS. NO DIFFERENCES BETWEEN GROUPS WERE RECORDED FOR ANY OF THE PARAMETERS ON DAY THREE. ON DAY SEVEN, A DOSE-DEPENDENT REDUCTION IN BREAKING STRENGTH (P < 0.05) WAS MEASURED. THE LARGEST EFFECTS WERE FOUND IN GROUP E-3 IN WHICH THE BREAKING STRENGTH WAS REDUCED BY 56% AND 73% IN COLONIC AND ILEAL ANASTOMOSES, RESPECTIVELY. A SIMILAR PATTERN WAS OBSERVED WITH THE BURSTING PRESSURE. LOSS OF STRENGTH WAS ACCOMPANIED BY A REDUCTION IN HYDROXYPROLINE CONTENT AND BY A LESSENED COLLAGEN DEPOSITION IN THE WOUND AREA BUT NOT BY AN INCREASED GELATINASE ACTIVITY. NO FURTHER HISTOLOGIC ABNORMALITIES WERE FOUND. CONCLUSION. EVEROLIMUS CAUSES A MASSIVE REDUCTION IN ANASTOMOTIC STRENGTH SUCH AS NORMALLY OBSERVED IN THE PROLIFERATIVE PHASE OF REPAIR. THE DATA SUGGEST THIS TO BE CAUSED BY AN IMPAIRED DEPOSITION OF COLLAGEN IN THE ANASTOMOTIC AREA.",MATRIX-METALLOPROTEINASE ACTIVITY; ENDOTHELIAL GROWTH-FACTOR; MYCOPHENOLATE-MOFETIL; TRANSPLANT RECIPIENTS; KIDNEY-TRANSPLANTATION; SDZ RAD; SIROLIMUS; RAPAMYCIN; COMPLICATIONS; STRENGTH,IMMUNOSUPPRESSION; EVEROLIMUS; WOUND HEALING,TRANSPLANTATION,"VLIET, JAD##WILLEMS, MCM##DE MAN, BM##LOMME, RMLM##HENDRIKS, T","RADBOUD UNIV NIJMEGEN, MED CTR, DEPT SURG, DIV VASC & TRANSPLANT SURG, NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, SURG RES LAB, NIJMEGEN, NETHERLANDS.",IMMUNOLOGY; SURGERY; TRANSPLANTATION,IMMUNOLOGY; SURGERY; TRANSPLANTATION,"AZZOLA A, 2004, TRANSPLANTATION, V77, P275, DOI 10.1097/01.TP.0000101822.50960.AB##BYRNE AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/J.1582-4934.2005.TB00379.X##DE HINGH IHJT, 2003, BRIT J SURG, V90, P981, DOI 10.1002/BJS.4146##DEAN PG, 2004, TRANSPLANTATION, V77, P1555, DOI 10.1097/01.TP.0000123082.31092.53##DEHINGH IH, 2003, BRIT J SURG, V93, P489##DEWAARD JWD, 1995, BRIT J CANCER, V72, P456, DOI 10.1038/BJC.1995.355##DEWAARD JWD, 1995, ARCH SURG-CHICAGO, V130, P959##DOSSARBASSOV D, 2005, CURR OPIN CELL BIOL, V17, P596##DUTLY AE, 2003, EUR J CARDIO-THORAC, V24, P154, DOI 10.1016/S1010-7940(03)00182-9##EASTON JB, 2004, EXPERT OPIN THER TAR, V8, P551, DOI 10.1517/14728222.8.6.551##FISHBEIN TM, 2002, TRANSPLANTATION, V73, P1538, DOI 10.1097/00007890-200205270-00004##FLECHNER SM, 2003, TRANSPLANTATION, V76, P1729, DOI 10.1097/01.TP.0000093502.26208.42##HAUSEN B, 1999, TRANSPLANTATION, V67, P956, DOI 10.1097/00007890-199904150-00005##HENDRIKS T, 1990, DIS COLON RECTUM, V33, P891, DOI 10.1007/BF02051930##HOEBEN A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/PR.56.4.3##JOHNSON S, 2003, MICROSURG, V23, P476, DOI 10.1002/MICR.10167##KAHN D, 2005, TRANSPLANT P, V37, P832, DOI 10.1016/J.TRANSPROCEED.2004.12.164##KAHN D, 2005, TRANSPLANT P, V37, P830, DOI 10.1016/J.TRANSPROCEED.2004.12.156##KNEISSEL M, 2004, BONE, V35, P1144, DOI 10.1016/J.BONE.2004.07.013##KOBASHIGAWA JA, 2006, AM J TRANSPLANT, V6, P1377, DOI 10.1111/J.1600-6143.2006.01290.X##KOVARIK JM, 2002, TRANSPLANTATION, V73, P920, DOI 10.1097/00007890-200203270-00016##KUPPAHALLY S, 2006, AM J TRANSPLANT, V6, P986, DOI 10.1111/J.1600-6143.2006.01282.X##LORBER MI, 2005, TRANSPLANTATION, V80, P244, DOI 10.1097/01.TP.0000164352.65613.24##MAASILTA PK, 2001, TRANSPLANTATION, V72, P998, DOI 10.1097/00007890-200109270-00004##POSMA LAE, 2006, SURGERY, V139, P671, DOI 10.1016/J.SURG.2005.10.014##RAVANTI L, 2000, INT J MOL MED, V6, P391##ROWINSKY EK, 2004, CURR OPIN ONCOL, V16, P564, DOI 10.1097/01.CCO.0000143964.74936.D1##SCHAFFR M, 1998, BRIT J SURG, V85, P345##SEIFERT WF, 1996, GUT, V39, P114, DOI 10.1136/GUT.39.1.114##STARLING RC, 2004, AM J TRANSPLANT, V4, P2126, DOI 10.1046/J.1600-6143.2004.00601.X##TROTTER JF, 2001, LIVER TRANSPLANT, V7, P343, DOI 10.1053/JLTS.2001.23012##VALENTE JF, 2003, AM J TRANSPLANT, V3, P1128, DOI 10.1034/J.1600-6143.2003.00185.X##VAN DER KOLK BM, 1999, BRIT J CANCER, V79, P545, DOI 10.1038/SJ.BJC.6690086##VERHOFSTAD MHJ, 2001, DIS COLON RECTUM, V44, P423, DOI 10.1007/BF02234744##VITKO S, 2005, AM J TRANSPLANT, V5, P2521, DOI 10.1111/J.1600-6143.2005.01063.X##WITTE MB, 2003, CRIT CARE MED, V31, PS538, DOI 10.1097/01.CCM.0000081436.09826.A4##YOUNG DA, 2005, CURR OPIN PHARMACOL, V5, P418, DOI 10.1016/J.COPH.2005.03.004",26,2020-11-20,NA
J,WOS:000242527400005,2006,GENE EXPRESSION RESPONSES TO A SALMONELLA INFECTION IN THE CHICKEN INTESTINE DIFFER BETWEEN LINES,"POULTRY PRODUCTS ARE AN IMPORTANT SOURCE OF SALMONELLA ENTERICA. AN EFFECTIVE WAY TO REDUCE FOOD POISONING DUE TO SALMONELLA WOULD BE TO BREED CHICKENS MORE RESISTANT TO SALMONELLA. UNFORTUNATELY HOST RESPONSES TO SALMONELLA ARE COMPLEX WITH MANY FACTORS INVOLVED. TO LEARN MORE ABOUT RESPONSES TO SALMONELLA IN YOUNG CHICKENS, A CDNA MICROARRAY ANALYSIS WAS PERFORMED TO COMPARE GENE EXPRESSION PROFILES BETWEEN TWO CHICKEN LINES UNDER CONTROL AND SALMONELLA INFECTED CONDITIONS. NEWLY HATCHED CHICKENS WERE ORALLY INFECTED WITH S. ENTERICA SEROVAR ENTERITIDIS. SINCE THE INTESTINE IS THE FIRST BARRIER THE BACTERIA ENCOUNTER AFTER ORAL INOCULATION, INTESTINAL GENE EXPRESSION WAS INVESTIGATED AT DIFFERENT TIMEPOINTS. DIFFERENCES IN GENE EXPRESSION BETWEEN THE TWO CHICKEN LINES WERE FOUND IN CONTROL AS WELL AS SALMONELLA INFECTED CONDITIONS. IN RESPONSE TO THE SALMONELLA INFECTION A FAST GROWING CHICKEN BROILER LINE INDUCED GENES THAT AFFECT T-CELL ACTIVATION, WHEREAS IN A SLOW GROWING BROILER LINE GENES INVOLVED IN MACROPHAGE ACTIVATION SEEMED TO BE MORE AFFECTED AT DAY I POST-INFECTION. AT DAYS 7 AND 9 MOST GENE EXPRESSION DIFFERENCES BETWEEN THE TWO CHICKEN LINES WERE IDENTIFIED UNDER CONTROL CONDITIONS, INDICATING A DIFFERENCE IN THE INTESTINAL DEVELOPMENT BETWEEN THE TWO CHICKEN LINES WHICH MIGHT BE LINKED TO THE DIFFERENCE IN SALMONELLA SUSCEPTIBILITY. THE FINDINGS IN THIS STUDY HAVE LEAD TO THE IDENTIFICATION OF NOVEL GENES AND POSSIBLE CELLULAR PATHWAYS, WHICH ARE HOST DEPENDENT. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",MESSENGER-RNA EXPRESSION; NATURAL-RESISTANCE; IMMUNE-RESPONSE; HOST RESPONSES; BROILER LINES; ENTERITIDIS; POULTRY; MACROPHAGE; MICE; POLYMORPHISMS,CDNA MICROARRAY; CHICKEN; DISEASE SUSCEPTIBILITY; SMALL INTESTINE,VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY,"VAN HEMERT, S##HOEKMAN, AJW##SMITS, MA##REBEL, JMJ","WAGENINGEN UR, ANIM SCI GRP, ANIM RESOURCES DEV, NL-8200 AB LELYSTAD, NETHERLANDS.",IMMUNOLOGY; VETERINARY SCIENCES,IMMUNOLOGY; VETERINARY SCIENCES,"BERTILSSON PM, 2001, J PHARM SCI, V90, P638, DOI 10.1002/1520-6017(200105)90:5<638::AID-JPS1020>3.0.CO;2-L##BRYAN FL, 1995, J FOOD PROTECT, V58, P326, DOI 10.4315/0362-028X-58.3.326##BUMSTEAD N, 1993, AVIAN DIS, V37, P189, DOI 10.2307/1591473##CHEEMA MA, 2003, POULTRY SCI, V82, P1519, DOI 10.1093/PS/82.10.1519##CHU DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/J.1600-065X.1998.TB01238.X##GEYRA A, 2001, POULTRY SCI, V80, P776, DOI 10.1093/PS/80.6.776##GUILLOT JF, 1995, VET RES, V26, P81##HONJO K, 1993, J VET MED SCI, V55, P895, DOI 10.1292/JVMS.55.895##ISHIJIMA SA, 1995, CELL IMMUNOL, V165, P278, DOI 10.1006/CIMM.1995.1214##KARSTEN SL, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/NAR/30.2.E4##KRAMER J, 2003, BRIT POULTRY SCI, V44, P577, DOI [10.1080/00071660310001616174, NO_DOI]##KRAMER J, 2003, ANIM GENET, V34, P339, DOI 10.1046/J.1365-2052.2003.01027.X##KRAMER J, 2001, VET IMMUNOL IMMUNOP, V79, P219, DOI 10.1016/S0165-2427(01)00261-6##KUO CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/ANNUREV.IMMUNOL.17.1.149##LAMONT SJ, 1998, POULTRY SCI, V77, P1111, DOI 10.1093/PS/77.8.1111##LAMONT SJ, 2002, VET IMMUNOL IMMUNOP, V87, P423, DOI 10.1016/S0165-2427(02)00064-8##LIU W, 2003, POULTRY SCI, V82, P259, DOI 10.1093/PS/82.2.259##MALEK M, 2004, POULTRY SCI, V83, P544, DOI 10.1093/PS/83.4.544##MALEK M, 2003, GENET SEL EVOL, V35, PS99, DOI 10.1051/GSE:2003019##MASTROENI P, 2004, MICROBES INFECT, V6, P398, DOI 10.1016/J.MICINF.2003.12.009##MEAD PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/EID0505.990502##NOCENTINI G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/EJI.200425818##RABSCH W, 2001, MICROBES INFECT, V3, P237, DOI 10.1016/S1286-4579(01)01375-2##REHLI M, 1995, J BIOL CHEM, V270, P15644, DOI 10.1074/JBC.270.26.15644##RICHTER G, 2004, ONKOLOGIE, V27, P91, DOI 10.1159/000075612##ROSENBERGER CM, 2001, MICROBES INFECT, V3, P1353, DOI 10.1016/S1286-4579(01)01497-6##ROY MF, 2002, GENES IMMUN, V3, P381, DOI 10.1038/SJ.GENE.6363924##SADEYEN JR, 2004, MICROBES INFECT, V6, P1278, DOI 10.1016/J.MICINF.2004.07.005##SANTOS RL, 2003, BRAZ J MED BIOL RES, V36, P3, DOI 10.1590/S0100-879X2003000100002##SHEELA RR, 2003, CLIN DIAGN LAB IMMUN, V10, P670, DOI 10.1128/CDLI.10.4.670-679.2003##SHIN HH, 2002, FEBS LETT, V514, P275, DOI 10.1016/S0014-5793(02)02379-7##SMITH MW, 1990, COMP BIOCHEM PHYS A, V97, P57, DOI 10.1016/0300-9629(90)90722-5##SWAGGERTY CL, 2004, IMMUNOLOGY, V113, P139, DOI 10.1111/J.1365-2567.2004.01939.X##TSEUNG SLY, 2003, CELL MICROBIOL, V5, P299##TUSHER VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/PNAS.091062498##VAN HEMERT S, 2003, ANIM BIOTECHNOL, V14, P133, DOI 10.1081/ABIO-120026483##VAN HEMERT S, 2004, POULTRY SCI, V83, P1675, DOI 10.1093/PS/83.10.1675##VREUGDENHIL ACE, 2000, J IMMUNOL, V165, P4561, DOI 10.4049/JIMMUNOL.165.8.4561##WAN Y, 2001, P NATL ACAD SCI USA, V98, P13066, DOI 10.1073/PNAS.231487598##WIGLEY P, 2004, RES VET SCI, V76, P165, DOI 10.1016/S0034-5288(03)00117-6##WITHANAGE GSK, 2004, INFECT IMMUN, V72, P2152, DOI 10.1128/IAI.72.4.2152-2159.2004##YOSHIDA A, 1999, GLYCOBIOLOGY, V9, P303, DOI 10.1093/GLYCOB/9.3.303",45,2020-11-20,NA
J,WOS:000242942800001,2006,ISOTOPIC COMPOSITION OF H-2 FROM CH4 OXIDATION IN THE STRATOSPHERE AND THE TROPOSPHERE,"[1] ENRICHMENT IN DEUTERIUM (D) OF STRATOSPHERIC H-2 IS INVESTIGATED USING NEW AND PUBLISHED DATA. APPLYING A RAYLEIGH MODEL TO ACCOUNT FOR THE ISOTOPIC FRACTIONATIONS IN THE PHOTOCHEMICAL CHAIN REACTIONS FROM CH4 TO THE FINAL PRODUCT H2O VIA H-2 REVEALS A STRONG ENRICHMENT OF PHOTOCHEMICALLY PRODUCED H-2. THIS IS CONSISTENT WITH PREVIOUS STUDIES, BUT THE DEGREE OF ENRICHMENT OBTAINED IN THIS STUDY APPEARS TO BE 100 - 120% LARGER THAN THE PREVIOUS ESTIMATES ON AVERAGE. THE DISCREPANCY PRIMARILY STEMS FROM THE FORMER USE OF EITHER AN ISOTOPIC FRACTIONATION FACTOR OF H-2 THAT DOES NOT TAKE INTO ACCOUNT THE EFFECT OF STRATOSPHERIC TRANSPORT OR AN H-2 YIELD FROM CH2O PHOTOLYSIS THAT IS NOT APPLICABLE TO STRATOSPHERIC CONDITIONS. WE FURTHER INVESTIGATE THE SAME ISOTOPIC FRACTIONATION PROCESS UNDER TROPOSPHERIC CONDITIONS BY CONSIDERING THE DIFFERENCES IN BOTH THE SPECIES AND AMOUNTS OF OXIDIZING AGENTS AND THE WAVELENGTHS THAT ARE EFFECTIVE IN THE PHOTOLYSIS OF CH2O. THESE WERE NOT CONSIDERED IN THE FORMER STUDIES WHEN THEY DERIVED THE DELTA D VALUE UNDER THE TROPOSPHERIC CONDITIONS. WE THEREBY ANTICIPATE THE DELTA D VALUE OF H-2 FROM PHOTOCHEMICAL OXIDATION OF CH4 IN THE TROPOSPHERE TO BE 190 ( +/- 50)%.",MOLECULAR-HYDROGEN; ATMOSPHERIC METHANE; RATE COEFFICIENTS; RADICAL REACTIONS; NITROUS-OXIDE; WATER-VAPOR; CARBON; BUDGET; RATIO; ENRICHMENT,NA,JOURNAL OF GEOPHYSICAL RESEARCH-ATMOSPHERES,"RHEE, TS##BRENNINKMEIJER, CAM##BRASS, M##BRUHL, C","KOREA POLAR RES INST, ANSAN 426744, SOUTH KOREA. MAX PLANCK INST CHEM, DIV ATMOSPHER CHEM, D-55020 MAINZ, GERMANY. UNIV UTRECHT, INST MARINE & ATMOSPHER RES UTRECHT, NL-3508 TC UTRECHT, NETHERLANDS.",METEOROLOGY & ATMOSPHERIC SCIENCES,METEOROLOGY & ATMOSPHERIC SCIENCES,"BERGAMASCHI P, 2000, J GEOPHYS RES-ATMOS, V105, P14531, DOI 10.1029/1999JD901176##BERGAMASCHI P, 1996, GEOPHYS RES LETT, V23, P2227, DOI 10.1029/96GL02139##BIGELEISEN J, 1959, J CHEM PHYS, V30, P1340, DOI 10.1063/1.1730183##BRASS M, 2006, THESIS RUPRECHT KARL##BRASSEUR G, 1986, AERONOMY MIDDLE ATMO##BRENNINKMEIJER CAM, 1999, J ATMOS OCEAN TECH, V16, P1373, DOI 10.1175/1520-0426(1999)016<1373:CCAFGM>2.0.CO;2##DEMORE W. B., 1997, JPL PUBL, V97-4##EHHALT DH, 1989, J GEOPHYS RES-ATMOS, V94, P9831, DOI 10.1029/JD094ID07P09831##ENGEL A, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000584##ENGEL A, 2003, 16 ESA S EUR ROCK BA##ERIKSSON E, 1965, TELLUS, V18, P498##FEILBERG KL, 2004, J PHYS CHEM A, V108, P7393, DOI 10.1021/JP048329K##GERST S, 2001, J GEOPHYS RES-ATMOS, V106, P5021, DOI 10.1029/2000JD900593##GIERCZAK T, 1997, J PHYS CHEM A, V101, P3125, DOI 10.1021/JP963892R##GROOSS JU, 1998, ATMOS ENVIRON, V32, P3173, DOI 10.1016/S1352-2310(98)00016-8##HAGEMANN R, 1970, TELLUS, V22, P712##HARTECK P, 1949, NATURWISSENSCHAFTEN, V36, P218, DOI 10.1007/BF00590320##JOCKEL P, 2005, ATMOS CHEM PHYS, V5, P433##KAISER J, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001506##KAYE JA, 1987, REV GEOPHYS, V25, P1609, DOI 10.1029/RG025I008P01609##LASSEY KR, 2000, GLOBAL BIOGEOCHEM CY, V14, P41, DOI 10.1029/1999GB900094##LETEXIER H, 1988, Q J ROY METEOR SOC, V114, P281, DOI 10.1002/QJ.49711448002##LEVIN I, 1999, J GEOPHYS RES-ATMOS, V104, P3447, DOI 10.1029/1998JD100064##MCCARTHY MC, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003183##MCQUIGG RD, 1969, J AM CHEM SOC, V91, P1590, DOI 10.1021/JA01035A002##MELANDER L., 1980, REACTION RATES ISOTO##MOORTGAT GK, 1983, J CHEM PHYS, V78, P1185, DOI 10.1063/1.444911##MORGAN CG, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003402##NOVELLI PC, 1999, J GEOPHYS RES-ATMOS, V104, P30427, DOI 10.1029/1999JD900788##PARK M, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003706##PARK SY, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003731##PERSKY A, 1966, J CHEM PHYS, V44, P3617, DOI 10.1063/1.1727273##QUAY P, 1999, GLOBAL BIOGEOCHEM CY, V13, P445, DOI 10.1029/1998GB900006##RAHN T, 1997, SCIENCE, V278, P1776, DOI 10.1126/SCIENCE.278.5344.1776##RAHN T, 2003, NATURE, V424, P918, DOI 10.1038/NATURE01917##RAHN T, 2002, GEOCHIM COSMOCHIM AC, V66, P2475, DOI 10.1016/S0016-7037(02)00858-X##RAVISHANKARA AR, 1988, ANNU REV PHYS CHEM, V39, P367, DOI 10.1146/ANNUREV.PC.39.100188.002055##RAYLEIGH L, 1902, PHILOS MAG, V4, P521##RHEE TS, 2006, ATMOS CHEM PHYS, V6, P1611, DOI 10.5194/ACP-6-1611-2006##RHEE TS, 2004, RAPID COMMUN MASS SP, V18, P299, DOI 10.1002/RCM.1309##RICE AL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003042##ROCKMANN T, 2003, ATMOS CHEM PHYS, V3, P2015##ROCKMANN T, 2001, J GEOPHYS RES-ATMOS, V106, P10403, DOI 10.1029/2000JD900822##ROLSTON JH, 1976, J PHYS CHEM-US, V80, P1064, DOI 10.1021/J100551A008##SAUERESSIG G, 2001, J GEOPHYS RES-ATMOS, V106, P23127, DOI 10.1029/2000JD000120##SAUERESSIG G, 1996, GEOPHYS RES LETT, V23, P3619, DOI 10.1029/96GL03292##SCHMIDT U, 1987, PLANET SPACE SCI, V35, P647, DOI 10.1016/0032-0633(87)90131-0##SUESS HE, 1953, ECO T AGU, V34, P343##SUGAWARA S, 1997, GEOPHYS RES LETT, V24, P2989, DOI 10.1029/97GL03044##TAATJES CA, 1999, CHEM PHYS LETT, V306, P33, DOI 10.1016/S0009-2614(99)00420-0##TALUKDAR RK, 1996, CHEM PHYS LETT, V253, P177, DOI 10.1016/0009-2614(96)00203-5##TALUKDAR RK, 1996, J PHYS CHEM-US, V100, P3037, DOI 10.1021/JP9518724##TOYODA S, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004316##WAHLEN M, 1989, EOS T AGU, V70, P1017##WETTER T, 1998, MESSUNGEN CO H2 MISC",19,2020-11-20,NA
J,WOS:000242625900001,2006,SUPERABSORBING FULLERENES: SPECTRAL AND KINETIC CHARACTERIZATION OF PHOTOINDUCED INTERACTIONS IN PERYLENEDIIMIDE-FULLERENE-C-60 DYADS,"TWO N-TYPE MOLECULAR MATERIALS ARE COVALENTLY COMBINED INTO A NEW PHOTOVOLTAIC COMPONENT FOR POLYMER SOLAR CELLS. LIGHT HARVESTING BY THE PERYLENEDIIMIDE RESULTS IN VERY FAST ENERGY TRANSFER TO THE FULLERENE UNIT, AS SHOWN WITH FEMTOSECOND TRANSIENT ABSORPTION SPECTROSCOPY IN TOLUENE SOLUTION. TWO ENERGY TRANSFER RATES ARE OBSERVED OF 2.5 X 10(12) S(-1) (53%) AND 2 X 10(11) S(-1) (47%), ATTRIBUTED TO TWO CONFORMATIONS. THE FINAL EXCITED STATE THAT IS POPULATED IS A PERYLENEDIIMIDE-BASED TRIPLET STATE THAT IS FORMED ON THE NANOSECOND TIME SCALE WITH A HIGH YIELD.",EXCITED-STATE PROPERTIES; ELECTRON-TRANSFER; PHOTOVOLTAIC CELLS; BUILDING-BLOCKS; TARGET ANALYSIS; PERYLENE DYE; SOLAR-CELLS; MORPHOLOGY; EFFICIENT; POLYMER,NA,JOURNAL OF PHYSICAL CHEMISTRY A,"BAFFREAU, J##LEROY-LHEZ, S##HUDHOMME, P##GROENEVELD, MM##VAN STOKKUM, IHM##WILLIAMS, RM","UNIV AMSTERDAM, VANT HOFF INST MOL SCI, MOL PHOTON GRP, NL-1018 WV AMSTERDAM, NETHERLANDS. CNRS, UMR 6200, GRP SYNTHESE ORGAN & MAT FONCT, CHIM INGN MOL & MAT ANGERS, F-49045 ANGERS, FRANCE. VRIJE UNIV AMSTERDAM, DEPT PHYS & ASTRON, NL-1081 HV AMSTERDAM, NETHERLANDS.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"BAFFREAU J, 2005, TETRAHEDRON LETT, V46, P4599, DOI 10.1016/J.TETLET.2005.04.132##BINGEL C, 1993, CHEM BER-RECL, V126, P1957, DOI 10.1002/CBER.19931260829##EBBESEN TW, 1991, CHEM PHYS LETT, V181, P501, DOI 10.1016/0009-2614(91)80302-E##FORD WE, 1987, J PHYS CHEM-US, V91, P6373, DOI 10.1021/J100309A012##GOMEZ R, 2005, ORG LETT, V7, P717, DOI 10.1021/OL047451Z##HOPPE H, 2006, J MATER CHEM, V16, P45, DOI 10.1039/B510618B##HUA JL, 2004, CHINESE CHEM LETT, V15, P1373##HUA JL, 2004, CHEM LETT, V33, P432, DOI 10.1246/CL.2004.432##HUA JL, 2004, J MATER CHEM, V14, P1849, DOI 10.1039/B316996K##KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162A0##LANGHALS H, 1995, HETEROCYCLES, V40, P477, DOI 10.3987/REV-94-SR2##LIU Y, 2005, MACROMOLECULES, V38, P4880, DOI 10.1021/MA050434K##MA WL, 2005, ADV FUNCT MATER, V15, P1617, DOI 10.1002/ADFM.200500211##ONEIL MP, 1992, SCIENCE, V257, P63, DOI 10.1126/SCIENCE.257.5066.63##PRODI A, 2005, J AM CHEM SOC, V127, P1454, DOI 10.1021/JA045379U##SARICIFTCI NS, 1992, SCIENCE, V258, P1474, DOI 10.1126/SCIENCE.258.5087.1474##SAUTTER A, 2005, J AM CHEM SOC, V127, P6719, DOI 10.1021/JA0448216##TANG CW, 1986, APPL PHYS LETT, V48, P183, DOI 10.1063/1.96937##VAN DER BOOM T, 2002, J AM CHEM SOC, V124, P9582, DOI 10.1021/JA026286K##VAN DUREN JKJ, 2004, ADV FUNCT MATER, V14, P425, DOI 10.1002/ADFM.200305049##VAN STOKKUM IHM, 2004, BBA-BIOENERGETICS, V1657, P82, DOI 10.1016/J.BBABIO.2004.04.011##VAN STOKKUM IHM, 2002, J PHYS CHEM B, V106, P3477, DOI 10.1021/JP0127723##WANG N, 2006, TETRAHEDRON, V62, P1216, DOI 10.1016/J.TET.2005.10.061##WEISS EA, 2005, J AM CHEM SOC, V127, P11842, DOI 10.1021/JA052901J##WEISS EA, 2004, J AM CHEM SOC, V126, P5577, DOI 10.1021/JA0398215##WIENK MM, 2003, ANGEW CHEM INT EDIT, V42, P3371, DOI 10.1002/ANIE.200351647##WILLIAMS RM, 1995, J AM CHEM SOC, V117, P4093, DOI 10.1021/JA00119A025##WURTHNER F, 2004, CHEM COMMUN, P1564, DOI 10.1039/B401630K##YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/SCIENCE.270.5243.1789",34,2020-11-20,NA
J,WOS:000242625900005,2006,"ULTRAFAST INTERSYSTEM CROSSING IN 9,10-ANTHRAQUINONES AND INTRAMOLECULAR CHARGE SEPARATION IN AN ANTHRAQUINONE-BASED DYAD","FEMTOSECOND TRANSIENT ABSORPTION SPECTROSCOPY WAS EMPLOYED TO DETERMINE QUANTITATIVELY THE ULTRAFAST S-1-T-1 INTERSYSTEM CROSSING IN A 2-SUBSTITUTED 9,10-ANTHRAQUINONE DERIVATIVE (3), K(ISC) = 2.5 X 10(12) S(-1). NOTWITHSTANDING THIS RAPID PROCESS, PHOTOEXCITATION OF DYAD 1 IS FOLLOWED BY COMPETITION BETWEEN INTERSYSTEM CROSSING AND INTRAMOLECULAR CHARGE SEPARATION, THE LATTER LEADING TO A SHORT-LIVED (2 PS) SINGLET CHARGE-TRANSFER (CT) STATE. THE LOCAL TRIPLET STATE ITSELF UNDERGOES SLOWER CHARGE SEPARATION TO POPULATE A RELATIVELY LONG-LIVED (130 NS) TRIPLET CT STATE. AN EARLIER REPORT ABOUT THE FORMATION OF AN EXTREMELY LONG-LIVED CT STATE (> 900 MU S) IN 1 WAS FOUND TO BE ERRONEOUS AND WAS RELATED TO THE SACRIFICIAL PHOTO-OXIDATION OF THE DIMETHYLSULFOXIDE SOLVENT USED IN THAT STUDY. FINALLY, SOME IMPORTANT CRITERIA HAVE BEEN FORMULATED FOR FUTURE EXPERIMENTAL VALIDATION OF ""UNUSUALLY LONG-LIVED"" CT STATES.",POLARIZABLE CONTINUUM MODEL; ELECTRON-TRANSFER; TRANSFER STATES; ABSORPTION; IONS; TETRACYANOETHYLENE; SPECTROSCOPY; DERIVATIVES; OXIDATION; CLUSTERS,NA,JOURNAL OF PHYSICAL CHEMISTRY A,"VAN RAMESDONK, HJ##BAKKER, BH##GROENEVELD, MM##VERHOEVEN, JW##ALLEN, BD##ROSTRON, JP##HARRIMAN, A","UNIV AMSTERDAM, HIMS, DEPT CHEM, NL-1018 WS AMSTERDAM, NETHERLANDS. UNIV NEWCASTLE UPON TYNE, SCH NAT SCI, MOL PHOTON LAB, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"ALLEN NS, 1995, J PHOTOCH PHOTOBIO A, V91, P73, DOI 10.1016/1010-6030(95)04120-5##ARMITAGE B, 1994, J AM CHEM SOC, V116, P9847, DOI 10.1021/JA00101A005##BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913##BENNISTON AC, 2005, J AM CHEM SOC, V127, P16054, DOI 10.1021/JA052967E##BENNISTON AC, 2005, CHEM COMMUN, P2701, DOI 10.1039/B501262G##BREZOVA V, 1996, J PHYS CHEM-US, V100, P16232, DOI 10.1021/JP960547T##BRODARD P, 2001, J PHYS CHEM A, V105, P6594, DOI 10.1021/JP010808L##CAMMI R, 1999, J PHYS CHEM A, V103, P9100, DOI 10.1021/JP991564W##COSSI M, 1999, J CHEM PHYS, V111, P5295, DOI 10.1063/1.479788##COSSI M, 2000, J CHEM PHYS, V112, P2427, DOI 10.1063/1.480808##COURTOTC.J, 1967, B SOC CHIM FR, P4744##GARRIDO EM, 2001, ANAL CHIM ACTA, V434, P35, DOI 10.1016/S0003-2670(01)00817-0##HAMANOUE K, 1993, J CHEM SOC FARADAY T, V89, P3243, DOI 10.1039/FT9938903243##HAMANOUE K, 1987, J CHEM PHYS, V86, P6654, DOI 10.1063/1.452412##HUBIG SM, 1997, J AM CHEM SOC, V119, P2926, DOI 10.1021/JA963907Z##KONCKA M, 1995, ELECTROANAL, V7, P1010, DOI 10.1002/ELAN.1140071103##KUSHIBIKI N, 1977, B CHEM SOC JPN, V50, P349, DOI 10.1246/BCSJ.50.349##MENNUCCI B, 1997, J CHEM PHYS, V106, P5151, DOI 10.1063/1.473558##MUROV S. L., 1993, HDB PHOTOCHEMISTRY##OKAMOTO K, 2005, J PHYS CHEM A, V109, P4662, DOI 10.1021/JP045042E##OOSTERBAAN WD, 2001, J PHYS CHEM A, V105, P5984, DOI 10.1021/JP0044983##SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/JCC.540141112##SCHUSTER GB, 2000, ACCOUNTS CHEM RES, V33, P253, DOI 10.1021/AR980059Z##SHIDA T., 1988, ELECT ABSORPTION SPE, V34##STEWART FE, 1966, J CHEM PHYS, V44, P2866, DOI 10.1063/1.1727146##TANIMOTO Y, 1988, B CHEM SOC JPN, V61, P3121, DOI 10.1246/BCSJ.61.3121##VERGEER FW, 2002, INORG CHIM ACTA, V327, P126, DOI 10.1016/S0020-1693(01)00678-8##VERHOEVEN JW, 2006, J PHOTOCH PHOTOBIO C, V7, P40, DOI 10.1016/J.JPHOTOCHEMREV.2006.04.001##VERHOEVEN JW, 2005, INT J PHOTOENERGY, V7, P103, DOI 10.1155/S1110662X05000152##VERHOEVEN JW, 2005, CHEMPHYSCHEM, P2251##VOIGT EM, 1964, J AM CHEM SOC, V86, P3930, DOI 10.1021/JA01073A005##ZWEIG A, 1964, J AM CHEM SOC, V86, P4124, DOI 10.1021/JA01073A043",47,2020-11-20,NA
J,WOS:000242625700035,2006,HEXAMERIZATION OF THE BACTERIOPHAGE T4 CAPSID PROTEIN GP23 AND ITS W13V MUTANT STUDIED BY TIME-RESOLVED TRYPTOPHAN FLUORESCENCE,"THE BACTERIOPHAGE T4 CAPSID PROTEIN GP23 WAS STUDIED USING TIME-RESOLVED AND STEADY-STATE FLUORESCENCE OF THE INTRINSIC PROTEIN FLUOROPHORE TRYPTOPHAN. IN-VITRO GP23 CONSISTS MOSTLY OF MONOMERS AT LOW TEMPERATURE BUT FORMS HEXAMERS AT ROOM TEMPERATURE. TO EXTEND OUR KNOWLEDGE OF THE STRUCTURE AND HEXAMERIZATION CHARACTERISTICS OF GP23, THE TEMPERATURE-DEPENDENT FLUORESCENCE PROPERTIES OF A TRYPTOPHAN MUTANT (W13V) WERE COMPARED TO THOSE OF WILD-TYPE GP23. THE W13V MUTATION IS LOCATED IN THE N-TERMINAL PART OF THE PROTEIN, WHICH IS CLEAVED OFF AFTER PROHEAD FORMATION IN THE LIVE BACTERIOPHAGE. RESULTS SHOW THAT W13 PLAYS A ROLE IN THE HEXAMERIZATION PROCESS BUT IS NOT NEEDED TO STABILIZE THE HEXAMER ONCE IT IS FORMED. FURTHERMORE, BESIDES THE MONOMER-TO-HEXAMER TEMPERATURE TRANSITION (15-23 DEGREES C AND 12-43 DEGREES C FOR WILD-TYPE AND W13V GP23, RESPECTIVELY), WE WERE ABLE TO OBSERVE DENATURATION OF THE N-TERMINUS IN HEXAMERIC WILD-TYPE GP23 AROUND 40 DEGREES C. IN ADDITION, WITH THE AID OF A RECENTLY PUBLISHED HOMOLOGY MODEL OF GP23, THE LIFETIMES OBTAINED FROM TIME-RESOLVED FLUORESCENCE MEASUREMENTS COULD TENTATIVELY BE ASSIGNED TO SPECIFIC TRYPTOPHAN RESIDUES.",MECHANISMS; DECAY; CHAPERONINS; TRANSITIONS; SPECTRA; ORIGIN; GENES; HEAD,NA,JOURNAL OF PHYSICAL CHEMISTRY B,"STORTELDER, A##HENDRIKS, J##BUIJS, JB##BULTHUIS, J##GOOIJER, C##VAN DER VIES, SM##VAN DER ZWAN, G","FREE UNIV AMSTERDAM, DEPT ANALYT CHEM & APPL SPECT, LASER CTR VU, FAC SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. FREE UNIV AMSTERDAM, DEPT BIOCHEM & MOL BIOL, FAC SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. FREE UNIV AMSTERDAM, DEPT PHYS CHEM, FAC SCI, NL-1081 HV AMSTERDAM, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"AIJRICH LG, 2002, BIOCHEMISTRY-MOSCOW+, V67, P815, DOI 10.1023/A:1016361027033##AKSOY S, 1984, J BACTERIOL, V157, P363, DOI 10.1128/JB.157.2.363-367.1984##ALCALA JR, 1987, BIOPHYS J, V51, P597, DOI 10.1016/S0006-3495(87)83384-2##BAKKES PJ, 2005, THESIS VRIJE U AMSTE##BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37##BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/ANNUREV.BI.54.070185.000355##BEN-ZVI AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/JSBI.2001.4352##BERMAN HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/NAR/28.1.235##BHUTANI N, 2002, CURR SCI INDIA, V83, P1337##BLACK LINDSAY W., 1994, P218##BROWN AM, 2001, COMPUT METH PROG BIO, V65, P191, DOI 10.1016/S0169-2607(00)00124-3##BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/J.1751-1097.1973.TB06422.X##CALLIS PR, 2004, J PHYS CHEM B, V108, P4248, DOI 10.1021/JP0310551##CALLIS PR, 1997, METHOD ENZYMOL, V278, P113##DEUERLING E, 2004, CRIT REV BIOCHEM MOL, V39, P261, DOI 10.1080/10409230490892496##EDGAR RS, 1964, GENETICS, V49, P635##EFTINK MR, 1998, BIOCHEMISTRY-MOSCOW+, V63, P276##EISERLING FREDERICK A., 1994, P209##ENGELBORGHS Y, 2003, J FLUORESC, V13, P9, DOI 10.1023/A:1022398329107##ENGELBORGHS Y, 2001, SPECTROCHIM ACTA A, V57, P2255, DOI 10.1016/S1386-1425(01)00485-1##FOKINE A, 2005, P NATL ACAD SCI USA, V102, P7163, DOI 10.1073/PNAS.0502164102##FOKINE A, 2004, P NATL ACAD SCI USA, V101, P6003, DOI 10.1073/PNAS.0400444101##GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7##KIRBY E.P., 1970, J PHYS CHEM-US, V74, P4480, DOI [DOI 10.1021/J100720A004, 10.1021/J100720A004]##KORADI R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4##LAKOWICZ J. R., 1983, PRINCIPLES FLUORESCE, P341, DOI 10.1007/978-1-4615-7658-7_11##LAKOWICZ JR, 2000, PHOTOCHEM PHOTOBIOL, V72, P421, DOI 10.1562/0031-8655(2000)072<0421:OSRIP>2.0.CO;2##LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/BI00793A015##LIU TQ, 2005, J AM CHEM SOC, V127, P4104, DOI 10.1021/JA043154D##MAYER MP, 1995, GENE, V163, P41, DOI 10.1016/0378-1119(95)00389-N##NAGRADOVA NK, 2004, BIOCHEMISTRY-MOSCOW+, V69, P830, DOI 10.1023/B:BIRY.0000040214.43943.9A##PETRICH JW, 1983, J AM CHEM SOC, V105, P3824, DOI 10.1021/JA00350A014##RESHETNYAK YK, 2001, BIOPHYS J, V81, P1735, DOI 10.1016/S0006-3495(01)75825-0##ROSS PD, 1985, J MOL BIOL, V183, P353, DOI 10.1016/0022-2836(85)90006-3##SLAVOTINEK AM, 2001, TRENDS GENET, V17, P528, DOI 10.1016/S0168-9525(01)02413-1##STEVEN AC, 1976, J MOL BIOL, V102, P373, DOI 10.1016/0022-2836(76)90323-5##STORTELDER A, 2005, J PHOTOCH PHOTOBIO B, V78, P53, DOI 10.1016/J.JPHOTOBIOL.2004.09.007##STORTELDER A, 2004, APPL SPECTROSC, V58, P705, DOI 10.1366/000370204872908##SZABO AG, 1980, J AM CHEM SOC, V102, P554, DOI 10.1021/JA00522A020##VAN DUIJN E, 2005, NAT METHODS, V2, P371, DOI 10.1038/NMETH753##VIVIAN JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8",6,2020-11-20,NA
J,WOS:000242625700037,2006,HOW ENERGY FUNNELS FROM THE PHYCOERYTHRIN ANTENNA COMPLEX TO PHOTOSYSTEM I AND PHOTOSYSTEM II IN CRYPTOPHYTE RHODOMONAS CS24 CELLS,"WE REPORT AN INVESTIGATION OF ENERGY MIGRATION DYNAMICS IN INTACT CELLS OF THE PHOTOSYNTHETIC CRYPTOPHYTE RHODOMONAS CS24 USING ANALYSES OF STEADY-STATE AND TIME-RESOLVED FLUORESCENCE ANISOTROPY MEASUREMENTS. BY FITTING A SPECIFIC MODEL TO THE FLUORESCENCE DATA, WE OBTAIN THREE TIME SCALES (17, 58, AND 113 PS) BY WHICH THE ENERGY IS TRANSFERRED FROM PHYCOERYTHRIN 545 (PE545) TO THE MEMBRANE-ASSOCIATED CHLOROPHYLLS (CHLS). WE PROPOSE THAT THESE TIME SCALES REFLECT BOTH AN ANGULAR DISTRIBUTION OF PE545 AROUND THE PHOTOSYSTEMS AND THE RELATIVE ORIENTATIONS OF THE DONOR DIHYDROBILIVERDIN (DBV) BILIN AND THE ACCEPTOR CHL. CONTRARY TO INVESTIGATIONS OF THE ISOLATED ANTENNA COMPLEX, IT IS DEMONSTRATED THAT ENERGY TRANSFER FROM PE545 DOES NOT OCCUR FROM A SINGLE-EMITTING BILIN, BUT RATHER BOTH THE PERIPHERAL DIHYDROBILIVERDIN (DBV) CHROMOPHORES IN PE545 APPEAR TO BE VIABLE DONORS OF EXCITATION ENERGY TO THE MEMBRANE-BOUND PROTEINS. THE MODEL SHOWS AN ALMOST EQUAL DISTRIBUTION OF EXCITATION ENERGY FROM PE545 TO BOTH PHOTOSYSTEM I (PSI) AND PHOTOSYSTEM II (PSII), WHOSE TRAP TIMES CORRESPOND WELL TO THOSE OBTAINED FROM EXPERIMENTS ON ISOLATED PHOTOSYSTEMS.",LIGHT-HARVESTING PROTEIN; CRYPTOMONAS-RUFESCENS; FLUORESCENCE; ORGANIZATION; DYNAMICS; PARTICLES; PIGMENT; ALGA,NA,JOURNAL OF PHYSICAL CHEMISTRY B,"VAN DER WEIJ-DE WIT##DOUST, AB##VAN STOKKUM, IHM##DEKKER, JP##WILK, KE##CURMI, PMG##SCHOLES, GD##VAN GRONDELLE, R","FREE UNIV AMSTERDAM, FAC SCI, DEPT PHYS & ASTRON, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV TORONTO, INST OPT SCI, TORONTO, ON M5S 3H6, CANADA. UNIV TORONTO, CTR QUANTUM INFORMAT & QUANTUM CONTROL, TORONTO, ON M5S 3H6, CANADA. LASH MILLER CHEM LABS, TORONTO, ON M5S 3H6, CANADA. UNIV NEW S WALES, SCH PHYS, SYDNEY, NSW 2052, AUSTRALIA. UNIV NEW S WALES, CTR IMMUNOL, SYDNEY, NSW 2052, AUSTRALIA. UNIV TORONTO, DEPT CHEM, TORONTO, ON M5S 3H6, CANADA.","CHEMISTRY, PHYSICAL",CHEMISTRY,"ANDRIZHIYEVSKAYA EG, 2005, PHOTOSYNTH RES, V84, P173, DOI 10.1007/S11120-005-0478-7##ANDRIZHIYEVSKAYA EG, 2004, PHYS CHEM CHEM PHYS, V6, P4810, DOI 10.1039/B411977K##BATHKE L, 1999, PLANT BIOLOGY, V1, P516, DOI 10.1111/J.1438-8677.1999.TB00777.X##BERGMANN TI, 2004, THESIS STATE U NEW J, P66##BRUCE D, 1986, PHOTOCHEM PHOTOBIOL, V44, P519, DOI 10.1111/J.1751-1097.1986.TB04702.X##DEKKER JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/J.BBABIO.2004.09.009##DOUST AB, 2005, J PHYS CHEM B, V109, P14219, DOI 10.1021/JP051173J##DOUST AB, 2004, J MOL BIOL, V344, P135, DOI 10.1016/J.JMB.2004.09.044##DOUST AB, 2006, J PHOTOCH PHOTOBIO A, V184, P1, DOI 10.1016/J.JPHOTOCHEM.2006.06.006##FLEMING GR, 2004, NATURE, V431, P256, DOI 10.1038/431256A##GERVAIS F, 1997, J PHYCOL, V33, P18, DOI 10.1111/J.0022-3646.1997.00018.X##GOBETS B, 2001, BBA-BIOENERGETICS, V1507, P80, DOI 10.1016/S0005-2728(01)00203-1##GOBETS B, 2001, BIOPHYS J, V81, P407, DOI 10.1016/S0006-3495(01)75709-8##GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229, DOI 10.1139/M62-029##HARNISCHFEGER G, 1981, BER DEUT BOT GES, V94, P65##HILL DRA, 1989, PHYCOLOGIA, V28, P455, DOI 10.2216/I0031-8884-28-4-455.1##HILLER RG, 1992, BIOCHIM BIOPHYS ACTA, V1102, P360, DOI 10.1016/0167-4838(92)90522-F##IHALAINEN JA, 2002, BIOPHYS J, V83, P2190, DOI 10.1016/S0006-3495(02)73979-9##INGRAM K, 1983, BIOCHIM BIOPHYS ACTA, V722, P310, DOI 10.1016/0005-2728(83)90078-6##KIRK JTO, 1994, LIGHT PHOTOSYNTHESIS##LICHTLE C, 1980, BIOCHIM BIOPHYS ACTA, V591, P104, DOI 10.1016/0005-2728(80)90224-8##LICHTLE C, 1986, PHOTOBIOCH PHOTOBIOP, V11, P159##LICHTLE C, 1987, BIOCHIM BIOPHYS ACTA, V894, P76, DOI 10.1016/0005-2728(87)90214-3##MACCOLL R., 1987, PHYCOBILIPROTEINS##MIMURO MAMORU, 1998, PHYCOLOGICAL RESEARCH, V46, P155, DOI 10.1111/J.1440-1835.1998.TB00108.X##SCHOLES GD, 2006, ADV CHEM PHYS, V132, P57##SIDLER WA, 1994, ADV PHOTOSYNTHESIS, V1##SNYDER UK, 1987, BIOCHIM BIOPHYS ACTA, V892, P48, DOI 10.1016/0005-2728(87)90246-5##SPEARBERNSTEIN L, 1989, J PHYCOL, V25, P412, DOI 10.1111/J.1529-8817.1989.TB00245.X##STON J, 2002, J APPL PHYCOL, V14, P205, DOI 10.1023/A:1019928411436##SUNDSTROM V, 1999, J PHYS CHEM B, V103, P2327, DOI 10.1021/JP983722+##TOOLE CM, 2003, RED CRYPTOMONAD GLAU, P305##VAN AMERONGEN H., 2003, LIGHT HARVESTING ANT, P219##VAN GRONDELLE R, 2006, PHYS CHEM CHEM PHYS, V8, P793, DOI 10.1039/B514032C##VAN STOKKUM IHM, 2004, BBA-BIOENERGETICS, V1658, P262, DOI 10.1016/J.BBABIO.2004.08.005##VAN STOKKUM IHM, 2004, BBA-BIOENERGETICS, V1657, P82, DOI 10.1016/J.BBABIO.2004.04.011##VANGRONDELLE R, 1985, BIOCHIM BIOPHYS ACTA, V811, P147, DOI 10.1016/0304-4173(85)90017-5##VANGRONDELLE R, 1994, BBA-BIOENERGETICS, V1187, P1, DOI 10.1016/0005-2728(94)90166-X##VANMIEGHEM FJE, 1992, BIOCHIM BIOPHYS ACTA, V1100, P198##WILK KE, 1999, P NATL ACAD SCI USA, V96, P8901, DOI 10.1073/PNAS.96.16.8901",29,2020-11-20,NA
J,WOS:000242598200001,2006,FOCUSED ION BEAM MILLING OF NANOCAVITIES IN SINGLE COLLOIDAL PARTICLES AND SELF-ASSEMBLED OPALS,"WE PRESENT A NEW METHOD OF REALIZING SINGLE NANOCAVITIES IN INDIVIDUAL COLLOIDAL PARTICLES ON THE SURFACE OF SILICON DIOXIDE ARTIFICIAL OPALS USING A FOCUSED ION BEAM MILLING TECHNIQUE. WE SHOW THAT BOTH THE RADIUS AND THE POSITION OF THE NANOCAVITY CAN BE CONTROLLED WITH NANOMETRE PRECISION, TO RADII AS SMALL AS 40 NM. THE RELATION BETWEEN THE DEFECT SIZE AND THE MILLING TIME HAS BEEN ESTABLISHED. WE CONFIRMED THAT MILLING NOT ONLY OCCURS ON THE SURFACE OF THE SPHERES, BUT INTO AND THROUGH THEM AS WELL. WE ALSO SHOW THAT AN ARRAY OF NANOCAVITIES CAN BE FASHIONED. STRUCTURALLY MODIFIED COLLOIDS HAVE INTERESTING POTENTIAL APPLICATIONS IN NANOLITHOGRAPHY, AS WELL AS IN CHEMICAL SENSING AND SOLAR CELLS, AND AS PHOTONIC CRYSTAL CAVITIES.",3-DIMENSIONAL PHOTONIC CRYSTALS; FABRICATION; MONOLAYER; SPHERES; SILICA; FILMS,NA,NANOTECHNOLOGY,"WOLDERING, LA##OTTER, AM##HUSKEN, BH##VOS, WL","UNIV TWENTE, INST NANOTECHNOL & DEV, MESA, COMPEX PHOTON SYST,COPS, NL-7500 AE ENSCHEDE, NETHERLANDS. FOM, INST ATOM & MOL PHYS, NL-1098 SJ AMSTERDAM, NETHERLANDS.","NANOSCIENCE & NANOTECHNOLOGY; MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED",SCIENCE & TECHNOLOGY - OTHER TOPICS; MATERIALS SCIENCE; PHYSICS,"ARRIAGADA FJ, 1995, J COLLOID INTERF SCI, V170, P8, DOI 10.1006/JCIS.1995.1064##BAIN CD, 1988, SCIENCE, V240, P62, DOI 10.1126/SCIENCE.240.4848.62##BURMEISTER F, 1997, LANGMUIR, V13, P2983, DOI 10.1021/LA9621123##FERRAND P, 2004, MICROELECTRON ENG, V73-4, P362, DOI 10.1016/J.MEE.2004.02.068##GARCIA-SANTAMARIA F, 2002, ADV MATER, V14, P1144, DOI 10.1002/1521-4095(20020816)14:16<1144::AID-ADMA1144>3.0.CO;2-I##GEISSLER M, 2004, ADV MATER, V16, P1249, DOI 10.1002/ADMA.200400835##GRATZEL M, 2001, NATURE, V414, P338, DOI 10.1038/35104607##JIANG P, 1999, CHEM MATER, V11, P2132, DOI 10.1021/CM990080+##LEE WM, 2002, ADV MATER, V14, P271, DOI 10.1002/1521-4095(20020219)14:4<271::AID-ADMA271>3.3.CO;2-P##LOPEZ C, 2003, ADV MATER, V15, P1679, DOI 10.1002/ADMA.200300386##REYNTJENS S, 2001, J MICROMECH MICROENG, V11, P287, DOI 10.1088/0960-1317/11/4/301##SCHAEFER DM, 1995, APPL PHYS LETT, V66, P1012, DOI 10.1063/1.113589##SIGAL GB, 1996, ANAL CHEM, V68, P490, DOI 10.1021/AC9504023##STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5##VAN BLAADEREN A, 2006, NATURE, V439, P545, DOI 10.1038/439545A##WIJNHOVEN JEGJ, 2001, CHEM MATER, V13, P4486, DOI 10.1021/CM0111581##XIA YN, 2000, ADV MATER, V12, P693, DOI 10.1002/(SICI)1521-4095(200005)12:10<693::AID-ADMA693>3.0.CO;2-J##YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PHYSREVLETT.58.2059##YOUNG RJ, 1993, J VAC SCI TECHNOL B, V11, P234, DOI 10.1116/1.586708",15,2020-11-20,NA
J,WOS:000242906900002,2006,STUDY OF LEADING HADRONS IN GLUON AND QUARK FRAGMENTATION,"THE STUDY OF QUARK JETS IN E(+)E(-) REACTIONS AT LEP HAS DEMONSTRATED THAT THE HADRONISATION PROCESS IS REPRODUCED WELL BY THE LUND STRING MODEL. HOWEVER. OUR UNDERSTANDING OF GLUON FRAGMENTATION IS LESS COMPLETE. IN THIS STUDY ENRICHED QUARK AND GLUON JET SAMPLES OF DIFFERENT PURITIES ARE SELECTED IN THREE-JET EVENTS FROM HADRONIC DECAYS OF THE Z COLLECTED BY THE DELPHI EXPERIMENT IN THE LEP RUNS DURING 1994 AND 1995. THE LEADING SYSTEMS OF THE TWO KINDS OF JETS ARE DEFINED BY REQUIRING A RAPIDITY GAP AND THEIR SUM OF CHARGES IS STUDIED. AN EXCESS OF LEADING SYSTEMS WITH TOTAL CHARGE ZERO IS FOUND FOR GLUON JETS IN ALL CASES, WHEN COMPARED TO MONTE CARLO SIMULATIONS WITH JETSET (WITH AND WITHOUT BOSE-EINSTEIN CORRELATIONS INCLUDED) AND ARIADNE. THE CORRESPONDING LEADING SYSTEMS OF QUARK JETS DO NOT EXHIBIT SUCH AN EXCESS. THE INFLUENCE OF THE GAP SIZE AND OF THE GLUON PURITY ON THE EFFECT IS STUDIED AND A CONCENTRATION OF THE EXCESS OF NEUTRAL LEADING SYSTEMS AT LOW INVARIANT MASSES (LESS THAN OR SIMILAR TO 2 GEV/C(2)) IS OBSERVED, INDICATING THAT GLUON JETS MIGHT HAVE AN ADDITIONAL HITHERTO UNDETECTED FRAGMENTATION MODE VIA A TWO-GLUON SYSTEM. THIS COULD BE AN INDICATION OF A POSSIBLE PRODUCTION OF GLUONIC STATES AS PREDICTED BY QCD. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",SCALAR GLUEBALL; Z(0) DECAYS; DELPHI DETECTOR; QCD; JETS; MASS; RESONANCES; PHYSICS; MODELS; MESONS,NA,PHYSICS LETTERS B,"ABDALLAH, J##ABREU, P##ADAM, W##ADZIC, P##ALBRECHT, T##ALEMANY-FERNANDEZ, R##ALLMENDINGER, T##ALLPORT, PP##AMALDI, U##AMAPANE, N##AMATO, S##ANASHKIN, E##ANDREAZZA, A##ANDRINGA, S##ANJOS, N##ANTILOGUS, P##APEL, WD##ARNOUD, Y##ASK, S##ASMAN, B##AUGUSTIN, JE##AUGUSTINUS, A##BAILLON, P##BALLESTRERO, A##BAMBADE, P##BARBIER, R##BARDIN, D##BARKER, GJ##BARONCELLI, A##BATTAGLIA, M##BAUBILLIER, M##BECKS, KH##BEGALLI, M##BEHRMANN, A##BEN-HAIM, E##BENEKOS, N##BENVENUTI, A##BERAT, C##BERGGREN, M##BERNTZON, L##BERTRAND, D##BESANCON, M##BESSON, N##BLOCH, D##BLOM, M##BLUJ, M##BONESINI, M##BOONEKAMP, M##BOOTH, PSL##BORISOV, G##BOTNER, O##BOUQUET, B##BOWCOCK, TJV##BOYKO, I##BRACKO, M##BRENNER, R##BRODET, E##BRUCKMAN, P##BRUNET, JM##BUSCHBECK, B##BUSCHMANN, P##CALVI, M##CAMPORESI, T##CANALE, V##CARENA, F##CASTRO, N##CAVALLO, F##CHAPKIN, M##CHARPENTIER, P##CHECCHIA, P##CHIERICI, R##CHLIAPNIKOV, P##CHUDOBA, J##CHUNG, SU##CIESLIK, K##COLLINS, P##CONTRI, R##COSME, G##COSSUTTI, F##COSTA, MJ##CRENNELL, D##CUEVAS, J##D'HONDT, J##DALMAU, J##DA SILVA, T##DA SILVA, W##DELLA RICCA, G##DE ANGELIS, A##DE BOER, W##DE CLERCQ, C##DE LOTTO, B##DE MARIA, N##DE MIN, A##DE PAULA, L##DI CIACCIO, L##DI SIMONE, A##DOROBA, K##DREES, J##EIGEN, G##EKELOF, T##ELLERT, M##ELSING, M##SANTO, MCE##FANOURAKIS, G##FASSOULIOTIS, D##FEINDT, M##FERNANDEZ, J##FERRER, A##FERRO, F##FLAGMEYER, U##FOETH, H##FOKITIS, E##FULDA-QUENZER, F##FUSTER, J##GANDELMAN, M##GARCIA, C##GAVILLET, P##GAZIS, E##GOKIELI, R##GOLOB, B##GOMEZ-CEBALLOS, G##GONCALVES, P##GRAZIANI, E##GROSDIDIER, G##GRZELAK, K##GUY, J##HAAG, C##HALLGREN, A##HAMACHER, K##HAMILTON, K##HAUG, S##HAULER, F##HEDBERG, V##HENNECKE, M##HERR, H##HOFFMAN, J##HOLMGREN, SO##HOLT, PJ##HOULDEN, MA##JACKSON, JN##JARLSKOG, G##JARRY, P##JEANS, D##JOHANSSON, EK##JOHANSSON, PD##JONSSON, P##JORAM, C##JUNGERMANN, L##KAPUSTA, F##KATSANEVAS, S##KATSOUFIS, E##KERNEL, G##KERSEVAN, BP##KERZEL, U##KING, BT##KJAER, NJ##KLUIT, P##KOKKINIAS, P##KOURKOUMELIS, C##KOUZNETSOV, O##KRUMSTEIN, Z##KUCHARCZYK, M##LAMSA, J##LEDER, G##LEDROIT, F##LEINONEN, L##LEITNER, R##LEMONNE, J##LEPELTIER, V##LESIAK, T##LIEBIG, W##LIKO, D##LIPNIACKA, A##LOPES, JH##LOPEZ, JM##LOUKAS, D##LUTZ, P##LYONS, L##MACNAUGHTON, J##MALEK, A##MALTEZOS, S##MANDL, F##MARCO, J##MARCO, R##MARECHAL, B##MARGONI, M##MARIN, JC##MARIOTTI, C##MARKOU, A##MARTINEZ-RIVERO, C##MASIK, J##MASTROYIANNOPOULOS, N##MATORRAS, F##MATTEUZZI, C##MAZZUCATO, F##MAZZUCATO, M##MC NULTY, R##MERONI, C##MIGLIORE, E##MITAROFF, W##MJOERNMARK, U##MOA, T##MOCH, M##MOENIG, K##MONGE, R##MONTENEGRO, J##MORAES, D##MORENO, S##MORETTINI, P##MUELLER, U##MUENICH, K##MULDERS, M##MUNDIM, L##MURRAY, W##MURYN, B##MYATT, G##MYKLEBUST, T##NASSIAKOU, M##NAVARRIA, F##NAWROCKI, K##NICOLAIDOU, R##NIKOLENKO, M##OBLAKOWSKA-MUCHA, A##OBRAZTSOV, V##OLSHEVSKI, A##ONOFRE, A##ORAVA, R##OSTERBERG, K##OURAOU, A##OYANGUREN, A##PAGANONI, M##PAIANO, S##PALACIOS, JP##PALKA, H##PAPADOPOULOU, TD##PAPE, L##PARKES, C##PARODI, F##PARZEFALL, U##PASSERI, A##PASSON, O##PERALTA, L##PEREPELITSA, V##PERROTTA, A##PETROLINI, A##PIEDRA, J##PIERI, L##PIERRE, F##PIMENTA, M##PIOTTO, E##PODOBNIK, T##POIREAU, V##POL, ME##POLOK, G##POZDNIAKOV, V##PUKHAEVA, N##PULLIA, A##RAMES, J##READ, A##REBECCHI, P##REHN, J##REID, D##REINHARDT, R##RENTON, P##RICHARD, F##RIDKY, J##RIVERO, M##RODRIGUEZ, D##ROMERO, A##RONCHESE, P##ROUDEAU, P##ROVELLI, T##RUHLMANN-KLEIDER, V##RYABTCHIKOV, D##SADOVSKY, A##SALMI, L##SALT, J##SANDER, C##SAVOY-NAVARRO, A##SCHWICKERATH, U##SEKULIN, R##SIEBEL, M##SISAKIAN, A##SMADJA, G##SMIRNOVA, O##SOKOLOV, A##SOPCZAK, A##SOSNOWSKI, R##SPASSOV, T##STANITZKI, M##STOCCHI, A##STRAUSS, J##STUGU, B##SZCZEKOWSKI, M##SZEPTYCKA, M##SZUMLAK, T##TABARELLI, T##TAFFARD, AC##TEGENFELDT, F##TIMMERMANS, J##TKATCHEV, L##TOBIN, M##TODOROVOVA, S##TOME, B##TONAZZO, A##TORTOSA, P##TRAVNICEK, P##TREILLE, D##TRISTRAM, G##TROCHIMCZUK, M##TRONCON, C##TURLUER, ML##TYAPKIN, IA##TYAPKIN, P##TZAMARIAS, S##UVAROV, V##VALENTI, G##VAN DAM, P##VAN ELDIK, J##VAN REMORTEL, N##VAN VULPEN, I##VEGNI, G##VELOSO, F##VENUS, W##VERDIER, P##VERZI, V##VILANOVA, D##VITALE, L##VRBA, V##WAHLEN, H##WASHBROOK, AJ##WEISER, C##WICKE, D##WICKENS, J##WILKINSON, G##WINTER, M##WITEK, M##YUSHCHENKO, O##ZALEWSKA, A##ZALEWSKI, P##ZAVRTANIK, D##ZHURAVLOV, V##ZIMIN, NI##ZINTCHENKO, A##ZUPAN, M","IOWA STATE UNIV, DEPT PHYS & ASTRON, AMES, IA 50011 USA. VRIJE UNIV BRUSSEL, ULB, IIHE, B-1050 BRUSSELS, BELGIUM. UNIV ATHENS, PHYS LAB, GR-10680 ATHENS, GREECE. UNIV BERGEN, DEPT PHYS, NO-5007 BERGEN, NORWAY. UNIV BOLOGNA, DIPARTIMENTO FIS, IT-40126 BOLOGNA, ITALY. IST NAZL FIS NUCL, IT-40126 BOLOGNA, ITALY. CTR BRASILEIRO PESQUISAS FIS, BR-22290 RIO DE JANEIRO, BRAZIL. UNIV ESTADO RIO DE JANEIRO, INST FIS, RIO DE JANEIRO, BRAZIL. COLL FRANCE, CNRS, IN2P3, PHYS CORPUSCULAIRE LAB, FR-75231 PARIS 05, FRANCE. CERN, CH-1211 GENEVA 23, SWITZERLAND. ULP, CNRS, IN2P3, INST RECH SUBATOM, FR-67037 STRASBOURG, FRANCE. NCSR DEMOKRITOS, INST NUCL PHYS, GR-15310 ATHENS, GREECE. ACAD SCI CZECH REPUBLIC, INST PHYS, FZU, DIV HIGH ENERGY PHYS, CZ-18040 PRAGUE 8, CZECH REPUBLIC. UNIV GENOA, DIPARTIMENTO FIS, IT-16146 GENOA, ITALY. IST NAZL FIS NUCL, IT-16146 GENOA, ITALY. UNIV GRENOBLE 1, CNRS, IN2P3, INST SCI NUCL, FR-38026 GRENOBLE, FRANCE. UNIV HELSINKI, HELSINKI INST PHYS, FIN-00014 HELSINKI, FINLAND. UNIV HELSINKI, DEPT PHYS SCI, FIN-00014 HELSINKI, FINLAND. JOINT INST NUCL RES DUBNA, RU-101000 MOSCOW, RUSSIA. UNIV KARLSRUHE, INST EXPT KERNPHYS, DE-76128 KARLSRUHE, GERMANY. PAN, INST NUCL PHYS, PL-31142 KRAKOW, POLAND. UNIV MIN & MET KRAKOW, FAC PHYS & NUCL TECH, PL-30055 KRAKOW, POLAND. UNIV PARIS 11, CNRS, IN2P3, LAB ACCELERATEUR LINEAIRE, FR-91405 ORSAY, FRANCE. UNIV LANCASTER, SCH PHYS & CHEM, LANCASTER LA1 4YB, ENGLAND. FCUL, IST, LIP, PT-1000 LISBON, PORTUGAL. UNIV LIVERPOOL, DEPT PHYS, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND. UNIV GLASGOW, DEPT PHYS & ASTRON, GLASGOW G12 8QQ, LANARK, SCOTLAND. UNIV PARIS 06, CNRS, IN2P3, LPNHE, FR-75252 PARIS 05, FRANCE. UNIV PARIS 07, CNRS, IN2P3, LPNHE, FR-75252 PARIS 05, FRANCE. LUND UNIV, DEPT PHYS, SE-22363 LUND, SWEDEN. UNIV LYON 1, CNRS, IN2P3, IPNL, FR-69622 VILLEURBANNE, FRANCE. UNIV MILAN, DIPARTIMENTO FIS, IT-20133 MILAN, ITALY. IST NAZL FIS NUCL, IT-20133 MILAN, ITALY. UNIV MILAN, DIPARTIMENTO FIS, IT-20126 MILAN, ITALY. IST NAZL FIS NUCL, IT-20126 MILAN, ITALY. CHARLES UNIV PRAGUE, MFF, IPNP, AREAL MFF, CZ-18000 PRAGUE 8, CZECH REPUBLIC. NIKHEF H, NL-1009 DB AMSTERDAM, NETHERLANDS. NATL TECH UNIV ATHENS, DEPT PHYS, GR-15773 ZOGRAFOS, GREECE. UNIV OSLO, DEPT PHYS, NO-0316 OSLO, NORWAY. UNIV OVIEDO, DEPT FIS, ES-33007 OVIEDO, SPAIN. UNIV OXFORD, DEPT PHYS, OXFORD OX1 3RH, ENGLAND. UNIV PADUA, DEPT PHYS, IT-35131 PADUA, ITALY. IST NAZL FIS NUCL, IT-35131 PADUA, ITALY. RUTHERFORD APPLETON LAB, DIDCOT OX11 0QX, OXON, ENGLAND. UNIV ROMA TOR VERGATA, DIPARTIMENTO FIS, IT-00173 ROME, ITALY. IST NAZL FIS NUCL, IT-00173 ROME, ITALY. CEA SACLAY, DAPNIA, SERV PHYS PARTICULES, FR-91191 GIF SUR YVETTE, FRANCE. UC, CSIC, INST FIS CANTABRIA, ES-39006 SANTANDER, SPAIN. INST HIGH ENERGY PHYS, PROTVINO, MOSCOW REGION, RUSSIA. JOZEF STEFAN INST, SI-1000 LJUBLJANA, SLOVENIA. UNIV NOVA GORICA, LAB ASTROPARTICLE PHYS, SI-5000 NOVA GORICA, SLOVENIA. UNIV LJUBLJANA, DEPT PHYS, SI-1000 LJUBLJANA, SLOVENIA. STOCKHOLM UNIV, FYSIKUM, SE-11385 STOCKHOLM, SWEDEN. UNIV TURIN, DIPARTIMENTO FIS SPERIMENTALE, IT-10125 TURIN, ITALY. IST NAZL FIS NUCL, SEZ TORINO, IT-10125 TURIN, ITALY. UNIV TURIN, DIPARTIMENTO FIS TEOR, IT-10125 TURIN, ITALY. UNIV TRIESTE, IST FIS, IT-34127 TRIESTE, ITALY. IST NAZL FIS NUCL, IT-34127 TRIESTE, ITALY. UNIV UDINE, IST FIS, IT-33100 UDINE, ITALY. IST NAZL FIS NUCL, IT-33100 UDINE, ITALY. UNIV FED RIO DE JANEIRO, BR-21945970 RIO DE JANEIRO, BRAZIL. UPPSALA UNIV, DEPT RADIAT SCI, SE-75121 UPPSALA, SWEDEN. UNIV VALENCIA, CSIC, IFIC, ES-46100 BURJASSOT, VALENCIA, SPAIN. UNIV VALENCIA, DFAMN, ES-46100 BURJASSOT, VALENCIA, SPAIN. AUSTRIAN ACAD SCI, INST HOCHENERGIEPHYS, AT-1050 VIENNA, AUSTRIA. INST NUCL STUDIES, PL-00681 WARSAW, POLAND. UNIV WARSAW, PL-00681 WARSAW, POLAND. UNIV GESAMTHSCH WUPPERTAL, FACHBEREICH PHYS, DE-42097 WUPPERTAL, GERMANY.","ASTRONOMY & ASTROPHYSICS; PHYSICS, NUCLEAR; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"ABBIENDI G, 2004, EUR PHYS J C, V35, P293, DOI 10.1140/EPJC/S2004-01809-2##ABDALLAH J, 2002, PHYS LETT B, V533, P243, DOI 10.1016/S0370-2693(02)01658-1##ABREU P, 1998, PHYS LETT B, V416, P247, DOI 10.1016/S0370-2693(97)01380-4##ABREU P, 2000, PHYS LETT B, V490, P61, DOI 10.1016/S0370-2693(00)00868-6##ABREU P, 1996, Z PHYS C PART FIELDS, V73, P11, DOI 10.1007/S002880050298##ABREU P, 1997, PHYS LETT B, V407, P174, DOI 10.1016/S0370-2693(97)11783-X##ABREU P, 1996, NUCL INSTRUM METH A, V378, P57, DOI 10.1016/0168-9002(96)00463-9##ABREU P, 1996, Z PHYS C PART FIELDS, V70, P179, DOI 10.1007/S002880050099##ABREU P, 1998, EUR PHYS J C, V4, P1, DOI 10.1007/S100520050182##ABREU P, 2000, EUR PHYS J C, V13, P573, DOI 10.1007/S100520000313##ABREU P, 1995, PHYS LETT B, V355, P415, DOI 10.1016/0370-2693(95)00711-S##ALEXANDER G, 1996, Z PHYS C PART FIELDS, V69, P543, DOI 10.1007/S002880050059##AMSLER C, 1995, PHYS LETT B, V353, P385, DOI 10.1016/0370-2693(95)00579-A##AMSLER C, 1996, PHYS REV D, V53, P295, DOI 10.1103/PHYSREVD.53.295##ANDERSON B, 2002, P 31 S MULT DYN DAT, P471##ANISOVICH VV, 1996, PHYS LETT B, V389, P388, DOI 10.1016/S0370-2693(96)01317-2##BENTVELSEN S, 2003, P 31 INT C HIGH EN P, P377##BETHKE S, 1998, NUCL PHYS B, V523, P681, DOI 10.1016/S0550-3213(98)00219-3##BETHKE S, 1992, NUCL PHYS B, V370, P310, DOI 10.1016/0550-3213(92)90289-N##BORISOV G, 1996, NUCL INSTRUM METH A, V372, P181, DOI 10.1016/0168-9002(95)01287-7##BUSCHBECK B., 2002, PROCEEDINGS OF THE 31ST INTERNATIONAL SYMPOSIUM ON MULTIPARTICLE DYNAMICS, P50##CATANI S, 1991, PHYS LETT B, V269, P432, DOI 10.1016/0370-2693(91)90196-W##COLLINS P, 2004, DYNAM SYST, V19, P1, DOI 10.1080/14689360310001623421##FRITZSCH H, 1975, NUOVO CIMENTO A, V30, P393, DOI 10.1007/BF02730295##GARY JW, 2004, ACTA PHYS POL B, V35, P365##GUSTAFSON G, 1988, PHYS LETT B, V209, P90, DOI 10.1016/0370-2693(88)91836-9##KHOZE VA, 1994, Z PHYS C, V62, P281##KLEMPT E, 2000, MESON SPECTROSCOPY, P2001##LONNBLAD L, 1995, PHYS LETT B, V351, P293, DOI 10.1016/0370-2693(95)00393-Y##LONNBLAD L, 1992, COMPUT PHYS COMMUN, V71, P15, DOI 10.1016/0010-4655(92)90068-A##LONNBLAD L, 1998, EUR PHYS J C, V2, P165, DOI 10.1007/S100520050131##MINKOWSKI P., 2001, PROCEEDINGS OF THE 30TH INTERNATIONAL SYMPOSIUM ON MULTIPARTICLE DYNAMICS. FROM E+E- TO HEAVY ION COLLISIONS, P183##MINKOWSKI P, 1999, EUR PHYS J C, V9, P283, DOI 10.1007/S100530050441##MINKOWSKI P, 2000, PHYS LETT B, V485, P139, DOI 10.1016/S0370-2693(00)00678-X##MINKOWSKI P, 2004, P RINGB WORKSH NEW T, P169##MONTVAY I, 1979, PHYS LETT B, V84, P331, DOI 10.1016/0370-2693(79)90052-2##NARISON S, 2003, NUCL PHYS B-PROC SUP, V121, P131, DOI 10.1016/S0920-5632(03)01828-0##NARISON S, 1998, NUCL PHYS B, V509, P312, DOI 10.1016/S0550-3213(97)00562-2##OCHS W, HEPPH0111408##OCHS W, 2000, P 29 INT S QCD MULT, P64##PETERSON C, 1980, PHYS LETT B, V91, P455, DOI 10.1016/0370-2693(80)91019-9##SCHAEL S, CERNPHEP2006020##SEXTON J, 1995, PHYS REV LETT, V75, P4563, DOI 10.1103/PHYSREVLETT.75.4563##SJOSTRAND T, 1994, PHYS REV LETT, V72, P28, DOI 10.1103/PHYSREVLETT.72.28##SJOSTRAND T, 1994, COMPUT PHYS COMMUN, V82, P74, DOI 10.1016/0010-4655(94)90132-5##SPIESBERGER H, 2000, PHYS LETT B, V481, P236, DOI 10.1016/S0370-2693(00)00449-4##SUDAKOV V, 1956, ZH EKSP TEOR FIZ, V3, P65",7,2020-11-20,NA
J,WOS:000243800600004,2006,PREDICTION OF THE VISCOSITY REDUCTION DUE TO DISSOLVED CO2 OF AND AN ELEMENTARY APPROACH IN THE SUPERCRITICAL CO2 ASSISTED CONTINUOUS PARTICLE PRODUCTION OF A POLYESTER RESIN,"THE DISSOLUTION OF CO2 IN A POLYMER CAUSES PLASTICIZATION OF THE POLYMER AND HENCE, ITS VISCOSITY IS REDUCED. A MODEL BASED ON THE FREE VOLUME THEORY HAS BEEN USED FOR A POLYESTER RESIN, WHICH SHOWS A CONSIDERABLE REDUCTION IN THE VISCOSITY DUE TO DISSOLVED M. THEREFORE, SUPERCTITICAL CO2 HAS BEEN USED AS A PROCESSING SOLVENT IN THE CONTINUOUS PRODUCTION OF MICRON SIZE PARTICLES OF THE RESIN. DESPITE THE VISCOSITY REDUCTION CAUSED BY THE DISSOLVED CO2, AN EXCESS QUANTITY OF CO2 WITH RESPECT TO ITS SOLUBILITY LIMIT HAS BEEN USED FOR MICRONISATION OF THE POLYMER DUE TO ITS HIGH VISCOSITY. THE MIXING OF CO2 AND THE POLYMER HAS NOT BEEN POSSIBLE IN AN EXTRUDER AT HIGH GAS TO POLYMER MASS RATIOS AND CONSEQUENTLY, A SIMPLIFIED KENICS TYPE STATIC MIXER HAS BEEN USED FOR THE MIXING PURPOSE. IN THIS STUDY, THE EFFECT OF VARIOUS PARAMETERS SUCH AS TEMPERATURE, PRESSURE, NOZZLE DIAMETER AND GAS TO POLYMER MASS RATIO ON THE PARTICLE MORPHOLOGY AND SIZE HAS BEEN STUDIED. THE EXPERIMENTAL RESULTS MANIFEST THE TECHNOLOGICAL AS WELL AS THE THEORETICAL INSIGHT INTO THE PARTICLES PRODUCTION FROM A HIGH VISCOSITY MATERIAL. (C) 2006 ELSEVIER B.V. ALL FIGHTS RESERVED.",GLASS-TRANSITION TEMPERATURE; HIGH-PRESSURE RHEOLOGY; DEPENDENCE; MELTS; EXTRUSION; BLENDS; FLUIDS; FOAMS,SUPERCRITICAL CO2; VISCOSITY; FREE VOLUME THEORY; EXTRUDER; STATIC MIXER; NOZZLE,POWDER TECHNOLOGY,"NALAWADE, SP##NIEBORG, VHJ##PICCHIONI, F##JANSSEN, LPBM","UNIV GRONINGEN, DEPT CHEM ENGN, NL-9747 AG GRONINGEN, NETHERLANDS.","ENGINEERING, CHEMICAL",ENGINEERING,"CHIOU JS, 1985, J APPL POLYM SCI, V30, P11##CHOW TS, 1980, MACROMOLECULES, V13, P362, DOI 10.1021/MA60074A029##CHRISTANTI Y, 2001, J NON-NEWTON FLUID, V100, P9, DOI 10.1016/S0377-0257(01)00135-5##DOOLITTLE AK, 1951, J APPL PHYS, V22, P1471, DOI 10.1063/1.1699894##DOOLITTLE AK, 1951, J APPL PHYS, V22, P9##GERHARDT LJ, 1998, J POLYM SCI POL PHYS, V36, P1911, DOI 10.1002/(SICI)1099-0488(199808)36:11<1911::AID-POLB12>3.0.CO;2-A##HAN XM, 2003, POLYM ENG SCI, V43, P1261, DOI 10.1002/PEN.10107##HIEBER CA, 1992, POLYM ENG SCI, V32, P931, DOI 10.1002/PEN.760321404##JUNG J, 2001, J SUPERCRIT FLUID, V20, P179, DOI 10.1016/S0896-8446(01)00064-X##KAPPLER P, 2003, P 6 INT S SUP FLUIDS, V3, P1891##KELLEY FN, 1961, J POLYM SCI, V50, P549, DOI 10.1002/POL.1961.1205015421##KUKOVA E, 2003, P 6 ISSF MAT PROC, V3, P1547##KWAG C, 2001, IND ENG CHEM RES, V40, P3048, DOI 10.1021/IE000680E##LEE MH, 1998, POLYM ENG SCI, V38, P1112, DOI 10.1002/PEN.10278##MANLY BFJ, 1998, MULTIVARIATE STAT ME##MANSOUR A, 1995, J NON-NEWTON FLUID, V58, P161, DOI 10.1016/0377-0257(95)01356-Z##PARK CB, 1995, POLYM ENG SCI, V35, P432, DOI 10.1002/PEN.760350509##PARK CB, 1996, J MANUF SCI E-T ASME, V118, P639, DOI 10.1115/1.2831079##PEARSON K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720##ROYER JR, 2000, J POLYM SCI POL PHYS, V38, P3168, DOI 10.1002/1099-0488(20001201)38:23<3168::AID-POLB170>3.0.CO;2-E##ROYER JR, 2001, J POLYM SCI POL PHYS, V39, P3055, DOI 10.1002/POLB.10057##SIRIPURAPU S, 2002, POLYMER, V43, P5511, DOI 10.1016/S0032-3861(02)00407-X##WILLIAMS ML, 1955, J AM CHEM SOC, V77, P3701, DOI 10.1021/JA01619A008##WISSINGER RG, 1987, J POLYM SCI POL PHYS, V25, P2497, DOI 10.1002/POLB.1987.090251206##YEO SD, 2005, J SUPERCRIT FLUID, V34, P287, DOI 10.1016/J.SUPFLU.2004.10.006",18,2020-11-20,NA
J,WOS:000243076100001,2006,COPING WITH METHODOLOGICAL DILEMMAS; ABOUT ESTABLISHING THE EFFECTIVENESS OF INTERVENTIONS IN ROUTINE MEDICAL PRACTICE,"BACKGROUND: THE AIM OF THIS PAPER IS TO SHOW HOW RESEARCHERS BALANCE BETWEEN SCIENTIFIC RIGOUR AND LOCALISATION IN CONDUCTING PRAGMATIC TRIAL RESEARCH. OUR CASE IS THE QUATTRO STUDY, A PRAGMATIC TRIAL ON THE EFFECTIVENESS OF MULTIDISCIPLINARY PATIENT CARE TEAMS USED IN PRIMARY HEALTH CARE CENTRES IN DEPRIVED NEIGHBOURHOODS OF TWO MAJOR CITIES IN THE NETHERLANDS FOR INTENSIFIED SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES. METHODS: FOR THIS STUDY AN ETHNOGRAPHIC DESIGN WAS USED. WE OBSERVED AND INTERVIEWED THE RESEARCHERS AND THE PRACTICE NURSES. ALL GATHERED RESEARCH DOCUMENTS, TRANSCRIBED OBSERVATIONS AND INTERVIEWS WERE ANALYSED THEMATICALLY. RESULTS: CONDUCTING A PRAGMATIC TRIAL IS A CONTINUOUS BALANCING ACT BETWEEN MEETING METHODOLOGICAL DEMANDS AND IMPLEMENTING A COMPLEX INTERVENTION IN ROUTINE PRIMARY HEALTH CARE. AS AN EFFECT, THE RESEARCH DESIGN HAD TO BE ADJUSTED PRAGMATICALLY SEVERAL TIMES AND THE INTERVENTION THAT WAS MEANT TO BE TAILOR-MADE BECAME A RATHER STRINGENT PROCEDURE. CONCLUSION: A PRAGMATIC TRIAL RESEARCH IS A DYNAMIC PROCESS THAT, IN ORDER TO BE ABLE TO ASSESS THE VALIDITY AND RELIABILITY OF ANY EFFECTS OF INTERVENTIONS MUST ALSO HAVE A CONTINUOUS PROCESS OF METHODOLOGICAL AND PRACTICAL REFLECTION. ETHNOGRAPHIC ANALYSIS, AS WE SHOW, IS THEREFORE OF COMPLEMENTARY VALUE.",RANDOMIZED CONTROLLED-TRIALS; HEALTH-PROMOTION; ATTITUDES; SERVICES; POLICY,NA,BMC HEALTH SERVICES RESEARCH,"JANSEN, YJFM##BAL, R##BRUIJNZEELS, M##FOETS, M##FRENKEN, R##DE BONT, A","ERASMUS MC, INST HLTH POLICY & MANAGEMENT, NL-3000 DR ROTTERDAM, NETHERLANDS. STICHTING LIJN HAAGLANDEN 1, NL-2270 AC VOORBURG, NETHERLANDS.",HEALTH CARE SCIENCES & SERVICES,HEALTH CARE SCIENCES & SERVICES,"ANDERSON LM, 2005, AM J PREV MED, V28, P226, DOI 10.1016/J.AMEPRE.2005.02.014##ARMITAGE P, 1998, STAT MED, V17, P2675##BARNES J, 1999, ARCH DIS CHILD, V80, P280, DOI 10.1136/ADC.80.3.280##BLACK N, 1996, BRIT MED J, V312, P1215##BLAIR E, 2004, J CLIN EPIDEMIOL, V57, P1219, DOI 10.1016/J.JCLINEPI.2004.06.003##CALLON M., 2002, COMPLEXITIES SOCIAL, P191##CAMPBELL M, 2000, BRIT MED J, V321, P694, DOI 10.1136/BMJ.321.7262.694##CRESWELL J. W., 2003, RES DESIGN QUALITATI##DRUSS B, 2005, BMJ-BRIT MED J, V330, P92, DOI 10.1136/BMJ.330.7482.92##EL FAKIRI F, 2006, HEART, V92, P741, DOI 10.1136/HRT.2005.068114##GARFINKEL H, 2003, STUDIES ETHNOMETHODO##HOTOPF M, 2002, ADV PSYCHIAT TREATME, V8, P326, DOI DOI 10.1192/APT.8.5.326##LEYS M, 2003, HEALTH POLICY, V65, P217, DOI 10.1016/S0168-8510(02)00209-9##MACPHERSON H, 2004, COMPLEMENT THER MED, V12, P136, DOI 10.1016/J.CTIM.2004.07.043##MARKS HM, 1997, PROGR EXPT SCI THERA##MCQUEEN DV, 2000, HEALTH PROMOT INT, V15, P95, DOI 10.1093/HEAPRO/15.2.95##NUTBEAM D, 1999, HEALTH PROMOT INT, V14, P99, DOI 10.1093/HEAPRO/14.2.99##OAKLEY A, 2006, BRIT MED J, V332, P413, DOI 10.1136/BMJ.332.7538.413##PADKIN A, 2001, BRIT MED J, V323, P923, DOI 10.1136/BMJ.323.7318.923##ROLAND M, 1998, BRIT MED J, V316, P285, DOI 10.1136/BMJ.316.7127.285##SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0##SPRATLEY JP, 1980, PARTICIPATION OBSERV##TONES K, 2000, PATIENT EDUC COUNS, V39, P227, DOI 10.1016/S0738-3991(99)00035-X##VISSER A, 2000, PATIENT EDUC COUNS, V39, P147##WARD E, 1999, BRIT J GEN PRACT, V49, P919",12,2020-11-20,NA
J,WOS:000243251200013,2006,EFFECTS OF TIME PRESSURE ON VERBAL SELF-MONITORING: AN ERP STUDY,"THE ERROR-RELATED NEGATIVITY (ERN) IS A COMPONENT OF THE EVENT-RELATED BRAIN POTENTIAL (ERP) THAT IS ASSOCIATED WITH ACTION MONITORING AND ERROR DETECTION. THE PRESENT STUDY ADDRESSED THE QUESTION WHETHER OR NOT AN ERN OCCURS AFTER VERBAL ERROR DETECTION, E.G., DURING PHONEME MONITORING. WE OBTAINED AN ERN FOLLOWING VERBAL ERRORS WHICH SHOWED A TYPICAL DECREASE IN AMPLITUDE UNDER SEVERE TIME PRESSURE. THIS RESULT DEMONSTRATES THAT THE FUNCTIONING OF THE VERBAL SELF-MONITORING SYSTEM IS COMPARABLE TO OTHER PERFORMANCE MONITORING, SUCH AS ACTION MONITORING. FURTHERMORE, WE FOUND THAT PARTICIPANTS MADE MORE ERRORS IN PHONEME MONITORING UNDER TIME PRESSURE THAN IN A CONTROL CONDITION. THIS MAY SUGGEST THAT TIME PRESSURE DECREASES THE AMOUNT OF RESOURCES AVAILABLE TO A CAPACITY-LIMITED SELF-MONITOR THEREBY LEADING TO MORE ERRORS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",ANTERIOR CINGULATE CORTEX; ERROR-DETECTION; SPEECH PRODUCTION; BRAIN POTENTIALS; NEURAL SYSTEM; COMPONENTS; COMPENSATION; PERFORMANCE; ACTIVATION; MECHANISMS,SPEECH PRODUCTION; VERBAL SELF-MONITORING; PHONEME MONITORING; ERN; TIME PRESSURE,BRAIN RESEARCH,"GANUSHCHAK, LY##SCHILLER, NO","MAASTRICHT UNIV, FAC PSYCHOL, DEPT COGNIT NEUROSCI, NL-6200 MD MAASTRICHT, NETHERLANDS. LEIDEN UNIV, LIBC, LEIDEN, NETHERLANDS.",NEUROSCIENCES,NEUROSCIENCES & NEUROLOGY,"ANDERER P, 1987, METHOD FIND EXP CLIN, V9, P371##BAARS BJ, 1992, EXPT SLIPS HUMAN ERR, P129, DOI DOI 10.1007/978-1-4899-1164-3_6##BAAYEN R. H., 1995, CELEX LEXICAL DATABA##BERNSTEIN PS, 1995, J EXP PSYCHOL HUMAN, V21, P1312, DOI 10.1037/0096-1523.21.6.1312##BOTVINICK MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624##CARTER CS, 1998, SCIENCE, V280, P747, DOI 10.1126/SCIENCE.280.5364.747##CARTER CS, 2001, AM J PSYCHIAT, V158, P1423, DOI 10.1176/APPI.AJP.158.9.1423##COLES MGH, 2001, BIOL PSYCHOL, V56, P173, DOI 10.1016/S0301-0511(01)00076-X##DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/J.1467-9280.1994.TB00630.X##DESMURGET M, 2000, TRENDS COGN SCI, V4, P423, DOI 10.1016/S1364-6613(00)01537-0##FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9##FALKENSTEIN M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9##FORMAN SD, 2004, BIOL PSYCHIAT, V55, P531, DOI 10.1016/J.BIOPSYCH.2003.09.011##GEHRING WJ, 2000, PSYCHOL SCI, V11, P1, DOI 10.1111/1467-9280.00206##GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/J.1467-9280.1993.TB00586.X##HAJCAK G, 2003, PSYCHOPHYSIOLOGY, V40, P895, DOI 10.1111/1469-8986.00107##HOLROYD CB, 2003, TRENDS NEUROSCI, V26, P402, DOI 10.1016/S0166-2236(03)00175-9##HOLROYD CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]##LEVELT W. J. M., 1989, SPEAKING INTENTION A##LEVELT WJM, 1999, BEHAV BRAIN SCI, V22, P1##LEVELT WJM, 1983, COGNITION, V14, P41, DOI 10.1016/0010-0277(83)90026-4##LICKLEY RJ, 2005, LANG SPEECH, V48, P299, DOI 10.1177/00238309050480030301##LUU P, 2000, J NEUROSCI, V20, P464, DOI 10.1523/JNEUROSCI.20-01-00464.2000##MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163##MASAKI H, 2001, NEUROREPORT, V12, P1851, DOI 10.1097/00001756-200107030-00018##MOLLER J, IN PRESS CEREB CORTE##MORGAN JL, 2003, J PSYCHOLINGUIST RES, V32, P269, DOI 10.1023/A:1023591518131##MOTLEY MT, 1982, J VERB LEARN VERB BE, V21, P578, DOI 10.1016/S0022-5371(82)90791-5##OOMEN CCE, 2001, CORTEX, V37, P627, DOI 10.1016/S0010-9452(08)70610-5##OOMEN CCE, 2001, J PSYCHOLINGUIST RES, V30, P163, DOI 10.1023/A:1010377828778##OSMAN A, 2000, BIOL PSYCHOL, V51, P173, DOI 10.1016/S0301-0511(99)00045-9##POSTMA A, 2000, COGNITION, V77, P97, DOI 10.1016/S0010-0277(00)00090-1##POSTON T, 1996, COMMUN ACM, V39, P37, DOI 10.1145/229459.229464##RABBIT P.M.A., 1981, HUMAN SKILLS, P153##RODRIGUEZ-FORNELLS A, 2002, J NEUROSCI, V22, P9990##ROELOFS A, 1992, COGNITION, V42, P107, DOI 10.1016/0010-0277(92)90041-F##SCHEFFERS MK, 1996, PSYCHOPHYSIOLOGY, V33, P42, DOI 10.1111/J.1469-8986.1996.TB02107.X##SCHILLER NO, 2006, LANG COGNITIVE PROC, V21, P112, DOI 10.1080/01690960400001861##SCHILLER NO, 2005, TWENTY-FIRST CENTURY PSYCHOLINGUISTICS: FOUR CORNERSTONES, P245##SCLIFFLER NO, 2006, BRAIN RES, V1112, P201, DOI 10.1016/J.BRAINRES.2006.07.027##SEAL MARC L, 2004, COGN NEUROPSYCHIATRY, V9, P43, DOI 10.1080/13546800344000156##SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127##WHEELDON LR, 1995, J MEM LANG, V34, P311, DOI 10.1006/JMLA.1995.1014##WHEELDON LR, 2002, LANG COGNITIVE PROC, V17, P503, DOI 10.1080/01690960143000308",39,2020-11-20,NA
J,WOS:000243087400007,2006,ORBITAL OVERLAP AND CHEMICAL BONDING,"THE CHEMICAL BONDS IN THE DIATOMIC MOLECULES LI-2-F-2 AND NA-2-CL-2 AT DIFFERENT BOND LENGTHS HAVE BEEN ANALYZED BY THE ENERGY DECOMPOSITION ANALYSIS (EDA) METHOD USING DFT CALCULATIONS AT THE BP86/TZ2P LEVEL. THE INTERATOMIC INTERACTIONS ARE DISCUSSED IN TERMS OF QUASICLASSICAL ELECTROSTATIC INTERACTIONS DELTA E-ELSTAT, PAULI REPULSION DELTA E-PAULI AND ATTRACTIVE ORBITAL INTERACTIONS DELTA E-PAULI. THE ENERGY TERMS ARE COMPARED WITH THE ORBITAL OVERLAPS AT DIFFERENT INTERATOMIC DISTANCES. THE QUASICLASSICAL ELECTROSTATIC INTERACTIONS BETWEEN TWO ELECTRONS OCCUPYING 1S, 2S, 2P(SIGMA), AND 2P(PI) ORBITALS HAVE BEEN CALCULATED AND THE RESULTS ARE ANALYZED AND DISCUSSED. IT IS SHOWN THAT THE EQUILIBRIUM DISTANCES OF THE COVALENT BONDS ARE NOT DETERMINED BY THE MAXIMUM OVERLAP OF THE SIGMA VALENCE ORBITALS, WHICH NEARLY ALWAYS HAS ITS LARGEST VALUE AT CLEARLY SHORTER DISTANCES THAN THE EQUILIBRIUM BOND LENGTH. THE CRUCIAL INTERACTION THAT PREVENTS SHORTER BONDS IS NOT THE LOSS OF ATTRACTIVE INTERACTIONS, BUT A SHARP INCREASE IN THE PAULI REPULSION BETWEEN ELECTRONS IN VALENCE ORBITALS. THE ATTRACTIVE INTERACTIONS OF DELTA E-ORB AND THE REPULSIVE INTERACTIONS OF DELTA E-ORB ARE BOTH DETERMINED BY THE ORBITAL OVERLAP. THE NET EFFECT OF THE TWO TERMS DEPENDS ON THE OCCUPATION OF THE VALENCE ORBITALS, BUT THE ONSET OF ATTRACTIVE ORBITAL INTERACTIONS OCCURS AT LONGER DISTANCES THAN PAULI REPULSION, BECAUSE OVERLAP OF OCCUPIED ORBITALS WITH VACANT ORBITALS STARTS EARLIER THAN OVERLAP BETWEEN OCCUPIED ORBITALS. THE CONTRIBUTION OF DELTA E-ELSLAT IN MOST NONPOLAR COVALENT BONDS IS STRONGLY ATTRACTIVE. THIS COMES FROM THE DEVIATION OF QUASICLASSICAL ELECTRON-ELECTRON REPULSION AND NUCLEAR-ELECTRON ATTRACTION FROM COULOMB'S LAW FOR POINT CHARGES. THE ACTUAL STRENGTH OF DELTA E-ELSTAT DEPENDS ON THE SIZE AND SHAPE OF THE OCCUPIED VALENCE ORBITALS. THE ATTRACTIVE ELECTROSTATIC CONTRIBUTIONS IN THE DIATOMIC MOLECULES LI-2-F-2 COME FROM THE S AND P(SIGMA) ELECTRONS, WHILE THE P(PI) ELECTRONS DO NOT COMPENSATE FOR NUCLEAR-NUCLEAR REPULSION. IT IS THE INTERPLAY OF THE THREE TERMS DELTA E-ORB, DELTA E-PAULI, AND DELTA E-ELSTAT THAT DETERMINES THE BOND ENERGIES AND EQUILIBRIUM DISTANCES OF COVALENTLY BONDED MOLECULES. MOLECULES LIKE N-2 AND O-2, WHICH ARE USUALLY CONSIDERED AS COVALENTLY BONDED, WOULD NOT BE BONDED WITHOUT THE QUASICLASSICAL ATTRACTION DELTA E-ELSTAT.",ENERGY-PARTITIONING ANALYSIS; ELECTRONIC-STRUCTURE; TOPOLOGICAL ANALYSES; HYDROGEN-BONDS; SILICON ANALOG; STATE; APPROXIMATION; COMPLEXES; MOLECULES; ALKYNE,BOND ENERGY; BOND THEORY; DENSITY FUNCTIONAL CALCULATIONS; ENERGY DECOMPOSITION ANALYSIS; MAIN GROUP ELEMENTS,CHEMISTRY-A EUROPEAN JOURNAL,"KRAPP, A##BICKELHAUPT, FM##FRENKING, G","VRIJE UNIV AMSTERDAM, AFDELING THEORET CHEM, SCHEIKUNDIG LAB, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV MARBURG, FACHBEREICH CHEM, D-35043 MARBURG, GERMANY.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"ALBRIGHT T, 1985, ORBITAL INTERACTIONS##ARNOLD CC, 1993, J CHEM PHYS, V99, P766, DOI 10.1063/1.465757##BADER RFW, 2006, CHEM-EUR J, V12, P2896, DOI 10.1002/CHEM.200501589##BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PHYSREVA.38.3098##BICKELHAUPT FM, 1998, J PHYS CHEM A, V102, P9549, DOI 10.1021/JP9820830##BICKELHAUPT FM, 1999, CHEM-EUR J, V5, P162, DOI 10.1002/(SICI)1521-3765(19990104)5:1<162::AID-CHEM162>3.0.CO;2-4##BICKELHAUPT FM, 1996, ORGANOMETALLICS, V15, P1477, DOI 10.1021/OM950560K##BICKELHAUPT FM, 2002, J AM CHEM SOC, V124, P1500, DOI 10.1021/JA0117837##BICKELHAUPT FM, 1992, J PHYS CHEM-US, V96, P4864, DOI 10.1021/J100191A027##BICKELHAUPT FM, 2000, REV COMP CH, V15, P1, DOI 10.1002/9780470125922.CH1##DIEFENBACH A, 2000, J AM CHEM SOC, V122, P6449, DOI 10.1021/JA000663G##DUPUIS M, 1978, J CHEM PHYS, V68, P2902, DOI 10.1063/1.436088##ESTERHUYSEN C, 2004, THEOR CHEM ACC, V111, P381, DOI 10.1007/S00214-003-0535-2##FRENKING G, 2002, ORGANOMETALLICS, V21, P2921, DOI 10.1021/OM020311D##FRENKING G, 2006, CHEMPHYSCHEM, V7, P799, DOI 10.1002/CPHC.200500689##FRENKING G, 2003, ANGEW CHEM, V115, P152##FRENKING G., 2003, COORDIN CHEM REV, P238##FRENKING G, 2003, ANGEW CHEM, V115, P3456##FUKUI K., 1975, THEORY ORIENTATION S##GALBRAITH JM, 2000, CHEM-EUR J, V6, P2425##GILLESPIE R. J., 2001, CHEM BONDING MOL GEO##GILLESPIE RJ, 2003, ANGEW CHEM, V115, P3452##GILLESPIE RJ, 2003, ANGEW CHEM INT EDIT, V42, P3331##GUERRA CF, 2002, ANGEW CHEM INT EDIT, V41, P2092##GUERRA CF, 2002, ANGEW CHEM, V114, P2194##HACHEY M, 1992, J PHYS B-AT MOL OPT, V25, P1119, DOI 10.1088/0953-4075/25/6/004##HEITLER W, 1927, Z PHYS, V46, P47, DOI 10.1007/BF02055757##HERZBERG G., 1989, MOL SPECTRA MOL STRU##HUCKEL E, 1930, Z PHYS, V60, P423, DOI 10.1007/BF01341254##HUCKEL E, 1931, Z PHYS, V70, P204, DOI 10.1007/BF01339530##HUET TR, 1990, J MOL SPECTROSC, V144, P32, DOI 10.1016/0022-2852(90)90306-B##KITSOPOULOS TN, 1991, J CHEM PHYS, V95, P1441, DOI 10.1063/1.461057##KOVACS A, 2005, CHEM-EUR J, V11, P1813, DOI 10.1002/CHEM.200400525##KRIJN J., 1984, FIT FUNCTIONS HFS ME##KUTZELNIGG W, 1990, CONCEPT CHEM BOND, V1, P1##KUTZELNIGG W, 1984, ANGEW CHEM, V96, P262##LEIN M, 2003, ANGEW CHEM INT EDIT, V42, P1303, DOI 10.1002/ANIE.200390336##LEIN M., 2005, THEORY APPL COMPUTAT, P367##LENNARD--JONES JE, 1929, T FARADAY SOC, V25, P0668, DOI 10.1039/TF9292500668##MOROKUMA K, 1971, J CHEM PHYS, V55, P1236, DOI 10.1063/1.1676210##PAULING L., 1931, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, V53, P1367, DOI 10.1021/JA01355A027##PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PHYSREVB.33.8822##PIGNEDOLI CA, 2006, CHEMPHYSCHEM, V7, P801, DOI 10.1002/CPHC.200600025##POATER J, 2006, CHEM-EUR J, V12, P2902, DOI 10.1002/CHEM.200600057##RUEDENBERG K, 1962, REV MOD PHYS, V34, P326, DOI 10.1103/REVMODPHYS.34.326##SCHWARZ WHE, 1989, ANGEW CHEM INT EDIT, V28, P597, DOI 10.1002/ANIE.198905971##SCHWARZ WHE, 1989, ANGEW CHEM, V101, P605##SHAIK S, 2001, CHEM REV, V101, P1501, DOI 10.1021/CR990363L##SHAIK S, 2004, REV COMP CH, V20, P1, DOI 10.1002/0471678856.CH1##SNIJDERS J.G., 1981, ATOM DATA NUCL DATA, V26, P483, DOI DOI 10.1016/0092-640X(81)90004-8##SPACKMAN MA, 1986, J PHYS CHEM-US, V90, P2020, DOI 10.1021/J100401A010##TE VELDE G, 2001, J COMPUT CHEM, V22, P931, DOI 10.1002/JCC.1056##VERBRAAK H, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2039083##WOODWARD R. B., 1970, CONSERVATION ORBITAL##ZIEGLER T, 1979, INORG CHEM, V18, P1558, DOI 10.1021/IC50196A034",219,2020-11-20,NA
J,WOS:000242891100004,2006,GSK-3 BETA-REGULATED INTERACTION OF BICD WITH DYNEIN IS INVOLVED IN MICROTUBULE ANCHORAGE AT CENTROSOME,"MICROTUBULE ARRAYS DIRECT INTRACELLULAR ORGANIZATION AND DEFINE CELLULAR POLARITY. HERE, WE SHOW A NOVEL FUNCTION OF GLYCOGEN SYNTHASE KINASE-3B (GSK-3B) IN THE ORGANIZATION OF MICROTUBULE ARRAYS THROUGH THE INTERACTION WITH BICAUDAL-D (BICD). BICD IS KNOWN TO FORM A COMPLEX WITH DYNEIN-DYNACTIN AND TO FUNCTION IN THE INTRACELLULAR VESICLE TRAFFICKING. OUR DATA REVEALED THAT GSK-3B IS REQUIRED FOR THE BINDING OF BICD TO DYNEIN BUT NOT TO DYNACTIN. KNOCKDOWN OF GSK-3B OR BICD REDUCED CENTROSOMALLY FOCUSED MICROTUBULES AND INDUCED THE MISLOCALIZATION OF CENTROSOMAL PROTEINS. THE UNFOCUSED MICROTUBULES IN GSK-3B KNOCKDOWN CELLS WERE RESCUED BY THE EXPRESSION OF THE DYNEIN INTERMEDIATE CHAIN-BICD FUSION PROTEIN. MICROTUBULE REGROWTH ASSAYS SHOWED THAT GSK-3B AND BICD ARE REQUIRED FOR THE ANCHORING OF MICROTUBULES TO THE CENTROSOME. THESE RESULTS IMPLY THAT GSK-3B MAY FUNCTION IN TRANSPORTING CENTROSOMAL PROTEINS TO THE CENTROSOME BY STABILIZING THE BICD1 AND DYNEIN COMPLEX, RESULTING IN THE REGULATION OF A FOCUSED MICROTUBULE ORGANIZATION.",GLYCOGEN-SYNTHASE KINASE-3; ADENOMATOUS POLYPOSIS-COLI; BICAUDAL-D; BETA-CATENIN; DROSOPHILA; CELLS; DYNACTIN; DYNAMICS; PHOSPHORYLATION; ACCUMULATION,ANCHORING; BICD; CENTROSOME; GSK-3; MICROTUBULE,EMBO JOURNAL,"FUMOTO, K##HOOGENRAAD, CC##KIKUCHI, A","HIROSHIMA UNIV, GRAD SCH BIOMED SCI, DEPT BIOCHEM, MINAMI KU, HIROSHIMA 7348551, JAPAN. ERASMUS MC, DEPT NEUROSCI, ROTTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; CELL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; CELL BIOLOGY,"ABAL M, 2002, J CELL BIOL, V159, P731, DOI 10.1083/JCB.200207076##AKHMANOVA A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4##BOBINNEC Y, 2006, CELL MOTIL CYTOSKEL, V63, P313, DOI 10.1002/CM.20128##BORNENS M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3##COHEN P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075##DAMMERMANN A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/JCB.200204023##DAMMERMANN A, 2003, CURR BIOL, V13, PR614, DOI 10.1016/S0960-9822(03)00530-X##DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608##DELGEHYR N, 2005, J CELL SCI, V118, P1565, DOI 10.1242/JCS.02302##DOXSEY S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575##ETIENNE-MANNEVILLE S, 2003, NATURE, V421, P753, DOI 10.1038/NATURE01423##HINO S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/JBC.M213265200##HOLLAND PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/JBC.M108662200##HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7##HOOGENRAAD CC, 2001, EMBO J, V20, P4041, DOI 10.1093/EMBOJ/20.15.4041##HOOGENRAAD CC, 2003, EMBO J, V22, P6004, DOI 10.1093/EMBOJ/CDG592##HOUALLA T, 2005, MECH DEVELOP, V122, P97, DOI 10.1016/J.MOD.2004.08.005##IKEDA S, 1998, EMBO J, V17, P1371, DOI 10.1093/EMBOJ/17.5.1371##JOPE RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/J.TIBS.2003.12.004##MAHJOUB MR, 2005, J AM SOC NEPHROL, V16, P3485, DOI 10.1681/ASN.2005080824##MATANIS T, 2002, NAT CELL BIOL, V4, P986, DOI 10.1038/NCB891##MEADS T, 1995, CELL MOTIL CYTOSKEL, V32, P273, DOI 10.1002/CM.970320404##MITCHISON TJ, 1986, METHOD ENZYMOL, V134, P261##MOGENSEN MM, 2000, J CELL SCI, V113, P3013##PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N##QUINTYNE NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/JCB.147.2.321##RIOS RM, 2004, CELL, V118, P323##RODIONOV V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/PNAS.96.1.115##SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/GAD.3.12A.1957##THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4##VOROBJEV IA, 1997, J CELL SCI, V110, P2635##WAKEFIELD JG, 2003, J CELL SCI, V116, P637, DOI 10.1242/JCS.00273##YAMAMOTO H, 2003, EMBO J, V22, P2047, DOI 10.1093/EMBOJ/CDG204##YOUNG J, 2005, MOL BIOL CELL, V16, P162, DOI 10.1091/MBC.E04-03-0260##ZUMBRUNN J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1",64,2020-11-20,NA
J,WOS:000242575300006,2006,OXIDIZED GOLD AS AN ULTRATHIN ETCH RESIST APPLIED IN MICROCONTACT PRINTING,NA,SELF-ASSEMBLED MONOLAYERS; LITHOGRAPHY; OXIDE; NANOLITHOGRAPHY; ELLIPSOMETRY; RESOLUTION; OXIDATION,NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"SHARPE, RBA##BURDINSKI, D##HUSKENS, J##ZANDVLIET, HJW##REINHOUDT, DN##POELSEMA, B","PHILIPS RES, NL-5656 AE EINDHOVEN, NETHERLANDS. UNIV TWENTE, MESA INST NANOTECHNOL, MESA STRATEG RES ORIENTAT NANOFABRICT MOL NANOFAB, NL-7500 AE ENSCHEDE, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"CAVALLINI M, 2003, APPL PHYS LETT, V83, P5286, DOI 10.1063/1.1633685##CHAO F, 1977, J ELECTROANAL CHEM, V83, P65, DOI 10.1016/S0022-0728(77)80501-9##DELAMARCHE E, 2002, J AM CHEM SOC, V124, P3834, DOI 10.1021/JA017854J##GEISSLER M, 2002, LANGMUIR, V18, P2374, DOI 10.1021/LA0155909##HOEPPENER S, 2003, NANO LETT, V3, P761, DOI 10.1021/NL034176L##KIM YT, 1990, SURF SCI, V233, P341, DOI 10.1016/0039-6028(90)90647-Q##KRYSINSKI P, 2005, BIOELECTROCHEMISTRY, V66, P71, DOI 10.1016/J.BIOELECHEM.2004.03.012##KUMAR A, 1992, J AM CHEM SOC, V114, P9188, DOI 10.1021/JA00049A061##KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/LA00017A030##MACHALETT F, 2000, APPL PHYS A-MATER, V71, P331, DOI 10.1007/S003390000598##MICHEL B, 2001, IBM J RES DEV, V45, P697, DOI 10.1147/RD.455.0697##QUATE CF, 1997, SURF SCI, V386, P259, DOI 10.1016/S0039-6028(97)00305-1##ROZKIEWICZ DI, 2006, ANGEW CHEM INT EDIT, V45, P5292, DOI 10.1002/ANIE.200601090##SHARPE RBA, 2005, J AM CHEM SOC, V127, P10344, DOI 10.1021/JA052139L##TIEN J, 1998, THIN FILMS, V24, P227##TSENG AA, 2005, J VAC SCI TECHNOL B, V23, P877, DOI 10.1116/1.1926293",3,2020-11-20,NA
J,WOS:000242575300012,2006,COPPER CATALYZED ASYMMETRIC SYNTHESIS OF CHIRAL ALLYLIC ESTERS,NA,ENANTIOSELECTIVE CONJUGATE ADDITION; GRIGNARD-REAGENTS; PHOSPHORAMIDITE LIGANDS; KINETIC RESOLUTION; ALKYLATION; ETHERIFICATION; SUBSTITUTIONS; CARBONATES; ALDEHYDES; ALCOHOLS,NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"GEURTS, K##FLETCHER, SP##FERINGA, BL","UNIV GRONINGEN, DEPT ORGAN CHEM & MOL INORGAN CHEM, STRATINGH INST, NL-9747 AG GRONINGEN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"ALEXAKIS A, 2006, CHIMIA, V60, P124, DOI 10.2533/000942906777674994##ANDERSON CE, 2003, J AM CHEM SOC, V125, P12412, DOI 10.1021/JA037086R##BALMER E, 1993, J CHEM SOC PERK T 1, P399, DOI 10.1039/P19930000399##CARREA G, 2000, ANGEW CHEM INT EDIT, V39, P2226##CHA JK, 1995, CHEM REV, V95, P1761, DOI 10.1021/CR00038A003##FALLER JW, 2004, ORG LETT, V6, P1301, DOI 10.1021/OL0497382##FERINGA BL, 2000, ACCOUNTS CHEM RES, V33, P346, DOI 10.1021/AR990084K##FERINGA BL, 2004, P NATL ACAD SCI USA, V101, P5834, DOI 10.1073/PNAS.0308008101##FISCHER C, 2004, J AM CHEM SOC, V126, P1628, DOI 10.1021/JA0390707##JIANG L, 2002, ORG LETT, V4, P3411, DOI 10.1021/OL026504E##JOHNSON R. A., 2000, CATALYTIC ASYMMETRIC##KINGSBURY JS, 1999, J AM CHEM SOC, V121, P791, DOI 10.1021/JA983222U##KIRSCH SF, 2005, J AM CHEM SOC, V127, P2866, DOI 10.1021/JA0425583##KLINGLER FD, 1993, PATENT NO. 4219510##LI HM, 2005, J AM CHEM SOC, V127, P8355, DOI 10.1021/JA0425740##LOPEZ F, 2003, J AM CHEM SOC, V125, P3426, DOI 10.1021/JA029790Y##LOPEZ F, 2004, J AM CHEM SOC, V126, P12784, DOI 10.1021/JA046632T##LOPEZ F, 2005, ANGEW CHEM INT EDIT, V44, P2752, DOI 10.1002/ANIE.200500317##LOPEZ F, 2006, CHEM COMMUN, P409, DOI 10.1039/B513887F##MALDA H, 2001, ORG LETT, V3, P1169, DOI 10.1021/OL0156289##MAZERY RD, 2005, J AM CHEM SOC, V127, P9966, DOI 10.1021/JA053020F##OPPOLZER W, 1992, HELV CHIM ACTA, V75, P170, DOI 10.1002/HLCA.19920750114##PU L, 2001, CHEM REV, V101, P757, DOI 10.1021/CR000411Y##SHU CT, 2004, ANGEW CHEM INT EDIT, V43, P4794, DOI 10.1002/ANIE.200460214##TAKAYAMA H, 2003, ORG LETT, V5, P2967, DOI 10.1021/OL035128A##TOMITA D, 2006, CHEM-ASIAN J, V1, P161, DOI 10.1002/ASIA.200600068##TRNKA TM, 2001, ACCOUNTS CHEM RES, V34, P18, DOI 10.1021/AR000114F##TROST BM, 2006, J AM CHEM SOC, V128, P6745, DOI 10.1021/JA060812G##TROST BM, 2006, J AM CHEM SOC, V128, P3931, DOI 10.1021/JA0578348##TROST BM, 2001, J AM CHEM SOC, V123, P12191, DOI 10.1021/JA0118338##TROST BM, 1998, J AM CHEM SOC, V120, P12702, DOI 10.1021/JA983238K##TROST BM, 2001, J AM CHEM SOC, V123, P3671, DOI 10.1021/JA003774O##TROST BM, 2000, J AM CHEM SOC, V122, P3534, DOI 10.1021/JA994326N##TROST BM, 1999, J AM CHEM SOC, V121, P4545, DOI 10.1021/JA9828713##TROST BM, 2003, CHEM REV, V103, P2921, DOI 10.1021/CR020027W##VAN ZIJL AW, 2004, ADV SYNTH CATAL, V346, P413, DOI 10.1002/ADSC.200303207##WOOD JL, 1997, J AM CHEM SOC, V119, P9641, DOI 10.1021/JA9713035##YORIMITSU H, 2005, ANGEW CHEM INT EDIT, V44, P4435, DOI 10.1002/ANIE.200500653",73,2020-11-20,NA
J,WOS:000242575300027,2006,NUCLEOPHILIC CATALYSIS OF HYDRAZONE FORMATION AND TRANSIMINATION: IMPLICATIONS FOR DYNAMIC COVALENT CHEMISTRY,NA,MECHANISM; BASE; OXIME,NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"DIRKSEN, A##DIRKSEN, S##HACKENG, TM##DAWSON, PE","SCRIPPS RES INST, SKAGGS INST CHEM BIOL, DEPT CELL BIOL, LA JOLLA, CA 92037 USA. SCRIPPS RES INST, SKAGGS INST CHEM BIOL, DEPT CHEM, LA JOLLA, CA 92037 USA. UNIV MAASTRICHT, CARDIOVASC RES INST MAASTRICHT, NL-6200 MD MAASTRICHT, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/JA00741A013##CORBETT PT, 2006, CHEM REV, V106, P3652, DOI 10.1021/CR020452P##CORDES EH, 1962, J AM CHEM SOC, V84, P826, DOI 10.1021/JA00864A030##CORDES EH, 1962, J AM CHEM SOC, V84, P832, DOI 10.1021/JA00864A031##DIRKSEN A, 2006, ANGEW CHEM INT EDIT, V45, P7581, DOI 10.1002/ANIE.200602877##ERLANSON DA, 2004, ANNU REV BIOPH BIOM, V33, P199, DOI 10.1146/ANNUREV.BIOPHYS.33.110502.140409##GIUSEPPONE N, 2005, J AM CHEM SOC, V127, P5528, DOI 10.1021/JA042469Q##JENCKS W. P., 1986, CATALYSIS CHEM ENZYM, P467##JENCKS WP, 1959, J AM CHEM SOC, V81, P475, DOI 10.1021/JA01511A053##JENCKS WP, 1986, CATALYSIS CHEM ENZYM, P72##LAM RTS, 2005, SCIENCE, V308, P667, DOI 10.1126/SCIENCE.1109999##MICHEEL F, 1964, ANGEW CHEM INT EDIT, V3, P320, DOI 10.1002/ANIE.196403202##NELSON KL, 1964, J AM CHEM SOC, V86, P684, DOI 10.1021/JA01058A028##NGUYEN R, 2003, CHEM COMMUN, P942, DOI 10.1039/B211645F##POLYAKOV VA, 1999, J PHYS ORG CHEM, V12, P357, DOI 10.1002/(SICI)1099-1395(199905)12:5<357::AID-POC129>3.0.CO;2-Y##RAMSTROM O, 2002, NAT REV DRUG DISCOV, V1, P26, DOI 10.1038/NRD704##ROWAN SJ, 2002, ANGEW CHEM INT EDIT, V41, P898, DOI 10.1002/1521-3773(20020315)41:6<898::AID-ANIE898>3.0.CO;2-E##SAYER JM, 1973, J AM CHEM SOC, V95, P4277, DOI 10.1021/JA00794A600",302,2020-11-20,"NIGMS NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) [GM059380] FUNDING SOURCE: MEDLINE; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) [R01GM059380, R01GM059380, R01GM059380, R01GM059380, R01GM059380, R01GM059380, R01GM059380, R01GM059380, R01GM059380, R01GM059380, R01GM059380] FUNDING SOURCE: NIH REPORTER"
J,WOS:000242991200001,2006,DETECTION AND CLINICAL MANIFESTATION OF PLACENTAL MALARIA IN SOUTHERN GHANA,"BACKGROUND: PLASMODIUM FALCIPARUM CAN BE DETECTED BY MICROSCOPY, HISTIDINE-RICH-PROTEIN-2 (HRP2) CAPTURE TEST OR PCR BUT THE RESPECTIVE CLINICAL RELEVANCE OF THE THEREBY DIAGNOSED INFECTIONS IN PREGNANT WOMEN IS NOT WELL ESTABLISHED. METHODS: IN A CROSS-SECTIONAL, YEAR-ROUND STUDY AMONG 839 DELIVERING WOMEN IN AGOGO, GHANA, P. FALCIPARUM WAS SCREENED FOR IN BOTH, PERIPHERAL AND PLACENTAL BLOOD SAMPLES, AND ASSOCIATIONS WITH MATERNAL ANAEMIA, LOW BIRTH WEIGHT ( LBW) AND PRETERM DELIVERY (PD) WERE ANALYSED. RESULTS: IN PERIPHERAL BLOOD, P. FALCIPARUM WAS OBSERVED IN 19%, 34%, AND 53% BY MICROSCOPY, HRP2 TEST, AND PCR, RESPECTIVELY. FOR PLACENTAL SAMPLES, THESE FIGURES WERE 35%, 41%, AND 59%. IRRESPECTIVE OF DIAGNOSTIC TOOL, P. FALCIPARUM INFECTION INCREASED THE RISK OF ANAEMIA. POSITIVE PERIPHERAL BLOOD RESULTS OF MICROSCOPY AND PCR WERE NOT ASSOCIATED WITH LBW OR PD. IN CONTRAST, THE HRP2 TEST PERFORMED WELL IN IDENTIFYING WOMEN AT INCREASED RISK OF POOR PREGNANCY OUTCOME, PARTICULARLY IN CASE OF A NEGATIVE PERIPHERAL BLOOD FILM. ADJUSTING FOR AGE, PARITY, AND ANTENATAL VISITS, PLACENTAL HRP2 WAS THE ONLY MARKER OF INFECTION ASSOCIATED WITH LBW ( ADJUSTED ODDS RATIO (AOR), 1.5 (95% CI, 1.0 - 2.2)) AND, AT BORDERLINE STATISTICAL SIGNIFICANCE, PD ( AOR, 1.4 ( 1.0 - 2.1)) IN ADDITION TO ANAEMIA ( AOR, 2.3 ( 1.7 - 3.2)). LIKEWISE, HRP2 IN PERIPHERAL BLOOD OF SEEMINGLY APARASITAEMIC WOMEN WAS ASSOCIATED WITH PD ( AOR, 1.7 ( 1.0 - 2.7)) AND ANAEMIA ( AOR, 2.1 ( 1.4 - 3.2)). CONCLUSION: PERIPHERAL BLOOD FILM MICROSCOPY NOT ONLY UNDERESTIMATES PLACENTAL MALARIA. IN THIS HIGHLY ENDEMIC SETTING, IT ALSO FAILS TO IDENTIFY MALARIA AS A CAUSE OF FOETAL IMPAIRMENT. SUB- MICROSCOPIC INFECTIONS DETECTED BY A HRP2 TEST IN SEEMINGLY APARASITAEMIC WOMEN INCREASE THE RISKS OF ANAEMIA AND PD. THESE FINDINGS INDICATE THAT THE BURDEN OF MALARIA IN PREGNANCY MAY BE EVEN LARGER THAN THOUGHT AND ACCENTUATE THE NEED FOR EFFECTIVE ANTI-MALARIAL INTERVENTIONS IN PREGNANCY.",PLASMODIUM-FALCIPARUM INFECTIONS; LOW-BIRTH-WEIGHT; INTRAUTERINE GROWTH-RETARDATION; POLYMERASE-CHAIN-REACTION; RAPID DIAGNOSTIC-TEST; GESTATIONAL-AGE; PREGNANCY OUTCOMES; PRETERM DELIVERY; INFANT-MORTALITY; HIGH-SENSITIVITY,NA,MALARIA JOURNAL,"MOCKENHAUPT, FP##BEDU-ADDO, G##VON GAERTNER, C##BOYE, R##FRICKE, K##HANNIBAL, I##KARAKAYA, F##SCHALLER, M##ULMEN, U##ACQUAH, PA##DIETZ, E##EGGELTE, TA##BIENZLE, U","CHARITE UNIV MED BERLIN, INST TROP MED & INT HLTH, BERLIN, GERMANY. KWAME NKRUMAH UNIV SCI & TECHNOL, SCH MED SCI, KOMFO ANOYKE TEACHING HOSP, DEPT MED, KUMASI, GHANA. PRESBYTERIAN MISSION HOSP, AGOGO, GHANA. CHARITE UNIV MED BERLIN, INST SOCIAL MED EPIDEMIOL & HLTH ECON, DIV INT HLTH, BERLIN, GERMANY. UNIV AMSTERDAM, ACAD MED CTR, DIV INFECT DIS TROP MED & AIDS, NL-1105 AZ AMSTERDAM, NETHERLANDS.",INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,"ADAM I, 2005, ANN TROP MED PARASIT, V99, P339, DOI 10.1179/136485905X36244##ASHDOWN-LAMBERT JR, 2005, J R SOC PROMO HEALTH, V125, P76, DOI 10.1177/146642400512500211##BELL DR, 2005, AM J TROP MED HYG, V73, P199, DOI 10.4269/AJTMH.2005.73.199##BRABIN BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/J.PLACENTA.2003.10.019##BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005##BROCKLEHURST P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/J.1471-0528.1998.TB10227.X##BROWNE ENL, 2000, ANN TROP MED PARASIT, V94, P15, DOI 10.1080/00034980057572##BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/J.1365-2559.1993.TB00110.X##CASALS-PASCUAL C, 2006, BLOOD, V108, P2569, DOI 10.1182/BLOOD-2006-05-018697##DUFFY PE, 2003, INFECT IMMUN, V71, P6620, DOI 10.1128/IAI.71.11.6620-6623.2003##FINNSTROM O, 1977, ACTA PAEDIATR SCAND, V66, P601, DOI 10.1111/J.1651-2227.1977.TB07954.X##FRIED M, 1998, J IMMUNOL, V160, P2523##FRIED M, 1998, NATURE, V395, P851, DOI 10.1038/27570##*GHAN AIDS COMM, 2005, HIV SENT SURV REP##HUMAR A, 1997, AM J TROP MED HYG, V56, P44, DOI 10.4269/AJTMH.1997.56.44##KAIN KC, 1994, J INFECT DIS, V170, P1626, DOI 10.1093/INFDIS/170.6.1626##KAMWENDO DD, 2002, T ROY SOC TROP MED H, V96, P145, DOI 10.1016/S0035-9203(02)90284-1##KASSAM SN, 2006, INT J GYNECOL OBSTET, V93, P225, DOI 10.1016/J.IJGO.2006.02.021##KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663##KRAMER MS, 2000, JAMA-J AM MED ASSOC, V284, P843, DOI 10.1001/JAMA.284.7.843##LEKE RFG, 1999, J CLIN MICROBIOL, V37, P2992, DOI 10.1128/JCM.37.9.2992-2996.1999##LONE FW, 2004, TROP MED INT HEALTH, V9, P486, DOI 10.1111/J.1365-3156.2004.01222.X##MALHOTRA I, 2005, J CLIN MICROBIOL, V43, P3630, DOI 10.1128/JCM.43.8.3630-3635.2005##MANKHAMBO L, 2002, J CLIN MICROBIOL, V40, P155, DOI 10.1128/JCM.40.1.155-158.2002##MAYENGUE PI, 2004, TROP MED INT HEALTH, V9, P949, DOI 10.1111/J.1365-3156.2004.01294.X##MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204##MCGREADY R, 2002, T ROY SOC TROP MED H, V96, P644, DOI 10.1016/S0035-9203(02)90339-1##MENENDEZ C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449##MOCKENHAUPT FP, 2000, TROP MED INT HEALTH, V5, P167, DOI 10.1046/J.1365-3156.2000.00532.X##MOCKENHAUPT FP, 2002, J CLIN MICROBIOL, V40, P306, DOI 10.1128/JCM.40.1.306-308.2002##MOCKENHAUPT FP, 2001, AM J TROP MED HYG, V65, P21, DOI 10.4269/AJTMH.2001.65.21##MOCKENHAUPT FP, 2006, J INFECT DIS, V194, P184, DOI 10.1086/505152##MOORMANN AM, 1999, J INFECT DIS, V180, P1987, DOI 10.1086/315135##ROGERSON SJ, 2003, J CLIN MICROBIOL, V41, P1370, DOI 10.1128/JCM.41.4.1370-1374.2003##SARR D, 2006, AM J TROP MED HYG, V75, P171, DOI 10.4269/AJTMH.2006.75.171##SAUTE F, 2002, TROP MED INT HEALTH, V7, P19, DOI 10.1046/J.1365-3156.2002.00831.X##SCHOLL TO, 1992, AM J CLIN NUTR, V55, P985##SINGER LM, 2004, AM J TROP MED HYG, V70, P481##SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B##STEKETEE RW, 1996, AM J TROP MED HYG, V55, P33, DOI 10.4269/AJTMH.1996.55.33##STEKETEE RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/AJTMH.2001.64.28##SULLIVAN AD, 2000, PLACENTA, V21, P417, DOI 10.1053/PLAC.1999.0479##SULLIVAN AD, 1999, J INFECT DIS, V179, P1580, DOI 10.1086/314752##TAKO EA, 2005, AM J TROP MED HYG, V72, P236, DOI 10.4269/AJTMH.2005.72.236##VAN GEERTRUYDEN JP, 2004, AM J TROP MED HYG, V71, P35, DOI 10.4269/AJTMH.2004.71.35##WALKER-ABBEY A, 2005, AM J TROP MED HYG, V72, P229, DOI 10.4269/AJTMH.2005.72.229##WITTE AMC, 1990, T ROY SOC TROP MED H, V84, P521, DOI 10.1016/0035-9203(90)90024-9",54,2020-11-20,NA
J,WOS:000242786500013,2006,PHASE-CORRELATED NONDIRECTIONAL LASER EMISSION FROM THE END FACETS OF A ZNO NANOWIRE,"WE INVESTIGATED THE LASER EMISSION FROM INDIVIDUAL ZNO NANOWIRES AND OBSERVED AN INTERFERENCE PATTERN DUE TO COHERENT LASER EMISSION FROM THE WIRE END FACETS. COMPARISON WITH NUMERICAL SIMULATIONS SHOWS THAT THE LASER LIGHT IS EMITTED NEARLY SPHERICALLY FROM THE WIRE ENDS. THE ENERGY SPACING BETWEEN SHARP LASING MODES SCALES WITH THE INVERSE LENGTH OF THE NANOWIRE; THUS, LASER EMISSION PEAKS CORRESPOND TO FABRY-PEROT MODES OF THE NANOWIRE CAVITY.",SUBWAVELENGTH PHOTONICS INTEGRATION; ROOM-TEMPERATURE; WAVE-GUIDES,NA,NANO LETTERS,"VAN VUGT, LK##RUHLE, S##VANMAEKELBERGH, D","UNIV UTRECHT, DEBYE INST, NL-3508 TA UTRECHT, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CHEMISTRY, PHYSICAL; NANOSCIENCE & NANOTECHNOLOGY; MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",CHEMISTRY; SCIENCE & TECHNOLOGY - OTHER TOPICS; MATERIALS SCIENCE; PHYSICS,"AGARWAL R, 2005, NANO LETT, V5, P917, DOI 10.1021/NL050440U##BAYER M, 2002, PHYS STATUS SOLIDI A, V191, P3, DOI 10.1002/1521-396X(200205)191:1<3::AID-PSSA3>3.0.CO;2-M##BORN M., 1933, OPTIK, P235##CHIN AH, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2198017##DING JX, 2004, APPL PHYS LETT, V85, P2361, DOI 10.1063/1.1791326##DUAN XF, 2003, NATURE, V421, P241, DOI 10.1038/NATURE01353##GRADECAK S, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2115087##HAUSCHILD R, 2006, PHYS STATUS SOLIDI B, V243, P853, DOI 10.1002/PSSB.200564718##HUANG MH, 2001, SCIENCE, V292, P1897, DOI 10.1126/SCIENCE.1060367##HUANG MH, 2001, ADV MATER, V13, P113, DOI 10.1002/1521-4095(200101)13:2<113::AID-ADMA113>3.0.CO;2-H##HUANG Y, 2005, SMALL, V1, P142, DOI 10.1002/SMLL.200400030##JOHNSON JC, 2003, J PHYS CHEM B, V107, P8816, DOI 10.1021/JP034482N##LAW M, 2004, SCIENCE, V305, P1269, DOI 10.1126/SCIENCE.1100999##MASLOV AV, 2004, OPT LETT, V29, P572, DOI 10.1364/OL.29.000572##MASLOV AV, 2006, J APPL PHYS, V99, DOI 10.1063/1.2164538##NOBIS T, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.103903##PAN AL, 2005, J PHYS CHEM B, V109, P24268, DOI 10.1021/JP055164M##PETTERSSON H, 2006, NANO LETT, V6, P229, DOI 10.1021/NL052170L##PRASANTH R, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2200230##SIRBULY DJ, 2005, J PHYS CHEM B, V109, P15190, DOI 10.1021/JP051813I##TONG LM, 2003, NATURE, V426, P816, DOI 10.1038/NATURE02193##WANG D, 2006, J APPL PHYS, V99, DOI 10.1063/1.2196148",129,2020-11-20,NA
J,WOS:000242786500049,2006,BENDING-MODE VIBRATION OF A SUSPENDED NANOTUBE RESONATOR,"WE HAVE USED A SUSPENDED CARBON NANOTUBE AS A FREQUENCY MIXER TO DETECT ITS OWN MECHANICAL MOTION. A SINGLE GATE-DEPENDENT RESONANCE IS OBSERVED, WHICH WE ATTRIBUTE TO THE FUNDAMENTAL BENDING MODE VIBRATION OF THE SUSPENDED CARBON NANOTUBES. A CONTINUUM MODEL IS USED TO FIT THE GATE DEPENDENCE OF THE RESONANCE FREQUENCY, FROM WHICH WE OBTAIN VALUES FOR THE FUNDAMENTAL FREQUENCY, THE RESIDUAL AND GATE-INDUCED TENSION IN THE NANOTUBE. THIS ANALYSIS SHOWS THAT THE NANOTUBES IN OUR DEVICES HAVE NO SLACK AND THAT, BY APPLYING A GATE VOLTAGE, THE NANOTUBE CAN BE TUNED FROM A REGIME WITHOUT STRAIN TO A REGIME WHERE IT BEHAVES AS A VIBRATING STRING UNDER TENSION.",NA,NA,NANO LETTERS,"WITKAMP, B##POOT, M##VAN DER ZANT, HSJ","DELFT UNIV TECHNOL, KAVLI INST NANOSCI, NL-2600 GA DELFT, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CHEMISTRY, PHYSICAL; NANOSCIENCE & NANOTECHNOLOGY; MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",CHEMISTRY; SCIENCE & TECHNOLOGY - OTHER TOPICS; MATERIALS SCIENCE; PHYSICS,"BABIC B, 2003, NANO LETT, V3, P1577, DOI 10.1021/NL0344716##BABIC B, 2003, NANOTECHNOLOGY, V14, P327, DOI 10.1088/0957-4484/14/2/344##CLELAND AN, 2003, FDN NANOMECHANICS##KNOBEL RG, 2003, NATURE, V424, P291, DOI 10.1038/NATURE01773##KRISHNAN A, 1998, PHYS REV B, V58, P14013, DOI 10.1103/PHYSREVB.58.14013##LEFEVRE R, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.185504##LEROY BJ, 2004, NATURE, V432, P371, DOI 10.1038/NATURE03046##MEYER JC, 2005, SCIENCE, V309, P1539, DOI 10.1126/SCIENCE.1115067##PENG HB, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.087203##POSTMA HWC, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1929098##REULET B, 2000, PHYS REV LETT, V85, P2829, DOI 10.1103/PHYSREVLETT.85.2829##SAPMAZ S, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.026801##SAPMAZ S, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.235414##SAZONOVA V, 2004, NATURE, V431, P284, DOI 10.1038/NATURE02905##USTUNEL H, 2005, NANO LETT, V5, P523, DOI 10.1021/NL0481371##WALTERS DA, 1999, APPL PHYS LETT, V74, P3803, DOI 10.1063/1.124185",150,2020-11-20,NA
J,WOS:000242786500069,2006,"COMMENT ON ""DIRECT AND REAL-TIME VISUALIZATION OF THE DISASSEMBLY OF A SINGLE RECA-DNA-ATP GAMMA S COMPLEX USING AFM IMAGING IN FLUID""",NA,PROTEIN; POLYMERIZATION; MOLECULE; REPAIR,NA,NANO LETTERS,"VAN DER HEIJDEN, T##MORENO-HERRERO, F##KANAAR, R##WYMAN, C##DEKKER, C","DELFT UNIV TECHNOL, KAVLI INST NANOSCI, NL-2628 CJ DELFT, NETHERLANDS. ERASMUS MC, DEPT CELL BIOL & GENET, NL-3000 CA ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT RADIAT ONCOL, NL-3000 CA ROTTERDAM, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CHEMISTRY, PHYSICAL; NANOSCIENCE & NANOTECHNOLOGY; MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",CHEMISTRY; SCIENCE & TECHNOLOGY - OTHER TOPICS; MATERIALS SCIENCE; PHYSICS,"JANICIJEVIC A, 2003, J MICROSC-OXFORD, V212, P264, DOI 10.1111/J.1365-2818.2003.01254.X##LI BS, 2006, NANO LETT, V6, P1474, DOI 10.1021/NL060862J##LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043##MOLLER C, 1999, BIOPHYS J, V77, P1150, DOI 10.1016/S0006-3495(99)76966-3##RATCLIFF GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/JA005750N##ROCA AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3##SHIVASHANKAR GV, 1999, P NATL ACAD SCI USA, V96, P7916, DOI 10.1073/PNAS.96.14.7916##VAN DER HEIJDEN T, 2005, NUCLEIC ACIDS RES, V33, P2099, DOI 10.1093/NAR/GKI512",7,2020-11-20,NA
J,WOS:000242515600008,2006,HIGH OPEN-CIRCUIT VOLTAGE POLY(ETHYNYLENE BITHIENYLENE): FULLERENE SOLAR CELLS,NA,CHARGE-TRANSPORT; POLYTHIOPHENE; DESIGN,NA,CHEMISTRY OF MATERIALS,"CREMER, J##BAUERLE, P##WIENK, MM##JANSSEN, RAJ","UNIV ULM, DEPT ORGAN CHEM ORGAN MAT & COMBINATORIAL CHEM 2, D-89081 ULM, GERMANY. EINDHOVEN UNIV TECHNOL, NL-5600 MB EINDHOVEN, NETHERLANDS. DUTCH POLYMER INST, NL-5600 MB EINDHOVEN, NETHERLANDS.","CHEMISTRY, PHYSICAL; MATERIALS SCIENCE, MULTIDISCIPLINARY",CHEMISTRY; MATERIALS SCIENCE,"CREMER J, 2005, THESIS U ULM ULM GER##EGBE DAM, 2005, POLYMER, V46, P9585, DOI 10.1016/J.POLYMER.2005.08.008##EGBE DAM, 2006, THIN SOLID FILMS, V511, P486, DOI 10.1016/J.TSF.2005.12.090##GADISA A, 2004, APPL PHYS LETT, V84, P1609, DOI 10.1063/1.1650878##GREVE DR, 2001, EUR J ORG CHEM, V2001, P3437##HOPPE H, 2004, J MATER CHEM, V14, P3462, DOI 10.1039/B407794F##KIM Y, 2006, NAT MATER, V5, P197, DOI 10.1038/NMAT1574##KIM Y, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1861123##LI G, 2005, NAT MATER, V4, P864, DOI 10.1038/NMAT1500##MA WL, 2005, ADV FUNCT MATER, V15, P1617, DOI 10.1002/ADFM.200500211##MCCULLOUGH RD, 1993, J ORG CHEM, V58, P904, DOI 10.1021/JO00056A024##MIHAILETCHI VD, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.126602##MIHAILETCHI VD, 2006, ADV FUNCT MATER, V16, P699, DOI 10.1002/ADFM.200500420##MIHAILETCHI VD, 2003, J APPL PHYS, V94, P6849, DOI 10.1063/1.1620683##PADINGER F, 2003, ADV FUNCT MATER, V13, P85, DOI 10.1002/ADFM.200390011##REYES-REYES M, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2006986##RUGHOOPUTH SDDV, 1987, J POLYM SCI POL PHYS, V25, P1071, DOI 10.1002/POLB.1987.090250508##SCHARBER MC, 2006, ADV MATER, V18, P789, DOI 10.1002/ADMA.200501717##SCHIKORA M, IN PRESS##SCHILINSKY P, 2002, APPL PHYS LETT, V81, P3885, DOI 10.1063/1.1521244##SHAHEEN SE, 2001, APPL PHYS LETT, V78, P841, DOI 10.1063/1.1345834##SIRRINGHAUS H, 1999, NATURE, V401, P685, DOI 10.1038/44359##SVENSSON M, 2003, ADV MATER, V15, P988, DOI 10.1002/ADMA.200304150##YANG XN, 2005, NANO LETT, V5, P579, DOI 10.1021/NL048120I",87,2020-11-20,NA
J,WOS:000243477800008,2006,OVERLAP SYNDROME OF CARDIAC SODIUM CHANNEL DISEASE IN MICE CARRYING THE EQUIVALENT MUTATION OF HUMAN SCN5A-1795INSD,"BACKGROUND - PATIENTS CARRYING THE CARDIAC SODIUM CHANNEL (SCN5A) MUTATION 1795INSD SHOW SUDDEN NOCTURNAL DEATH AND SIGNS OF MULTIPLE ARRHYTHMIA SYNDROMES INCLUDING BRADYCARDIA, CONDUCTION DELAY, QT PROLONGATION, AND RIGHT PRECORDIAL ST-ELEVATION. WE INVESTIGATED THE ELECTROPHYSIOLOGICAL CHARACTERISTICS OF A TRANSGENIC MODEL OF THE MURINE EQUIVALENT MUTATION 1798INSD. METHODS AND RESULTS - ON 24-HOUR CONTINUOUS TELEMETRY AND SURFACE ECG RECORDINGS, SCN5A(1798INSD/+) HETEROZYGOUS MICE SHOWED SIGNIFICANTLY LOWER HEART RATES, MORE BRADYCARDIC EPISODES ( PAUSES >= 500 MS), AND INCREASED PQ INTERVAL, QRS DURATION, AND QTC INTERVAL COMPARED WITH WILD-TYPE MICE. THE SODIUM CHANNEL BLOCKER FLECAINIDE INDUCED MARKED SINUS BRADYCARDIA AND/OR SINUS ARREST IN THE MAJORITY OF SCN5A(1798INSD/+) MICE, BUT NOT IN WILD-TYPE MICE. EPICARDIAL MAPPING USING A MULTIELECTRODE GRID ON EXCISED, LANGENDORFF-PERFUSED HEARTS SHOWED PREFERENTIAL CONDUCTION SLOWING IN THE RIGHT VENTRICLE OF SCN5A(1798INSD/+) HEARTS. ON WHOLE-CELL PATCH-CLAMP ANALYSIS, VENTRICULAR MYOCYTES ISOLATED FROM SCN5A(1798INSD/+) HEARTS DISPLAYED ACTION POTENTIAL PROLONGATION, A 39% REDUCTION IN PEAK SODIUM CURRENT DENSITY AND A SIMILAR REDUCTION IN ACTION POTENTIAL UPSTROKE VELOCITY. SCN5A(1798INSD/+) MYOCYTES DISPLAYED A SLOWER TIME COURSE OF SODIUM CURRENT DECAY WITHOUT SIGNIFICANT DIFFERENCES IN VOLTAGE-DEPENDENCE OF ACTIVATION AND STEADY-STATE INACTIVATION, SLOW INACTIVATION, OR RECOVERY FROM INACTIVATION. FURTHERMORE, SCN5A(1798INSD/+) MYOCYTES SHOWED A LARGER TETRODOTOXIN-SENSITIVE PERSISTENT INWARD CURRENT COMPARED WITH WILD-TYPE MYOCYTES. CONCLUSIONS - MICE CARRYING THE MURINE EQUIVALENT OF THE SCN5A-1795INSD MUTATION DISPLAY BRADYCARDIA, RIGHT VENTRICULAR CONDUCTION SLOWING, AND QT PROLONGATION, SIMILAR TO THE HUMAN PHENOTYPE. THESE RESULTS DEMONSTRATE THAT THE PRESENCE OF A SINGLE SCN5A MUTATION IS INDEED SUFFICIENT TO CAUSE AN OVERLAP SYNDROME OF CARDIAC SODIUM CHANNEL DISEASE.",LONG-QT SYNDROME; SINUS NODE DYSFUNCTION; BRUGADA-SYNDROME; NA+ CHANNEL; GENE SCN5A; TARGETED DISRUPTION; MOLECULAR-MECHANISM; CONDUCTION DISEASE; ARRHYTHMIAS; CONTRIBUTES,"CONDUCTION; DEATH, SUDDEN; ELECTROPHYSIOLOGY; GENETICS; ION CHANNELS; LONG-QT SYNDROME; SODIUM",CIRCULATION,"REMME, CA##VERKERK, AO##NUYENS, D##VAN GINNEKEN, ACG##VAN BRUNSCHOT, S##BELTERMAN, CNW##WILDERS, R##VAN ROON, MA##TAN, HL##WILDE, AAM##CARMELIET, P##DE BAKKER, JMT##VELDKAMP, MW##BEZZINA, CR","UNIV AMSTERDAM, ACAD MED CTR, EXPT & MOL CARDIOL GRP, DEPT CARDIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT PHYSIOL, FACIL GENET MODIFIED MICE, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN GENET, NL-1105 AZ AMSTERDAM, NETHERLANDS. KATHOLIEKE UNIV LEUVEN VIB, CTR GENE TRANSGENE TECHNOL & GENE THERAPY, LOUVAIN, BELGIUM. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ANTZELEVITCH C, 1999, J ELECTROCARDIOL, V32, P158, DOI 10.1016/S0022-0736(99)90074-2##BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683A0##BENSON DW, 2003, J CLIN INVEST, V112, P1019, DOI 10.1172/JCI200318062##BEZZINA C, 1999, CIRC RES, V85, P1206##BEZZINA CR, 2005, CARDIOVASC RES, V67, P343, DOI 10.1016/J.CARDIORES.2005.06.004##CHEN QY, 1998, NATURE, V392, P293##CLANCY CE, 2002, CIRCULATION, V105, P1208, DOI 10.1161/HC1002.105183##COHEN CJ, 1984, CIRC RES, V54, P636, DOI 10.1161/01.RES.54.6.636##CORONEL R, 2005, CIRCULATION, V112, P2769, DOI 10.1161/CIRCULATIONAHA.105.532614##GRANT AO, 2002, J CLIN INVEST, V110, P1201, DOI 10.1172/JCI200215570##IZUMIDA N, 2004, INT J CARDIOL, V95, P261, DOI 10.1016/J.IJCARD.2003.05.025##KYNDT F, 2001, CIRCULATION, V104, P3081, DOI 10.1161/HC5001.100834##LEI M, 2005, J PHYSIOL-LONDON, V567, P387, DOI 10.1113/JPHYSIOL.2005.083188##MITCHELL GF, 1998, AM J PHYSIOL-HEART C, V274, PH747##NAGASE S, 2002, J AM COLL CARDIOL, V39, P1992, DOI 10.1016/S0735-1097(02)01888-0##NUYENS D, 2001, NAT MED, V7, P1021, DOI 10.1038/NM0901-1021##PAPADATOS GA, 2002, P NATL ACAD SCI USA, V99, P6210, DOI 10.1073/PNAS.082121299##PRIORI SG, 2000, CIRCULATION, V102, P945, DOI 10.1161/01.CIR.102.9.945##ROSSENBACKER T, 2004, HEART RHYTHM, V1, P610, DOI 10.1016/J.HRTHM.2004.07.001##SCHALIJ MJ, 2000, CIRCULATION, V102, P2650##SCHOTT JJ, 1999, NAT GENET, V23, P20, DOI 10.1038/12618##SMITS JPP, 2005, J MOL CELL CARDIOL, V38, P969, DOI 10.1016/J.YJMCC.2005.02.024##TAN HL, 2003, CARDIOVASC RES, V57, P961, DOI 10.1016/S0008-6363(02)00714-9##TUKKIE R, 2004, CIRCULATION, V109, P1272, DOI 10.1161/01.CIR.0000118467.53182.D1##VAN DEN BERG MP, 2001, J CARDIOVASC ELECTR, V12, P630##VAN VEEN TAB, 2005, CIRCULATION, V112, P1927, DOI 10.1161/CIRCULATIONAHA.105.539072##VELDKAMP MW, 2003, CIRC RES, V92, P976, DOI 10.1161/01.RES.0000069689.09869.A8##VELDKAMP MW, 2000, CIRC RES, V86, PE91, DOI 10.1161/01.RES.86.9.E91",124,2020-11-20,NA
J,WOS:000243477800031,2006,"RESPONSE TO LETTER REGARDING ARTICLE, ""REPERFUSION STARTS IN THE AMBULANCE""",NA,ACUTE MYOCARDIAL-INFARCTION; INSULIN-POTASSIUM INFUSION; N-ACETYLCYSTEINE,NA,CIRCULATION,"VERHEUGT, FWA","UNIV NIJMEGEN, CTR MED, HEART LUNG CTR, DEPT CARDIOL, NIJMEGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ARSTALL MA, 1995, CIRCULATION, V92, P2855, DOI 10.1161/01.CIR.92.10.2855##MARENZI G, 2006, NEW ENGL J MED, V354, P2773, DOI 10.1056/NEJMOA054209##MEHTA SR, 2005, JAMA-J AM MED ASSOC, V293, P437##TIMMER JR, 2006, J AM COLL CARDIOL, V47, P1730, DOI 10.1016/J.JACC.2006.01.040##VERHEUGT FWA, 2006, CIRCULATION, V113, P2377, DOI 10.1161/CIRCULATIONAHA.106.626713",0,2020-11-20,NA
J,WOS:000241056500002,2006,MODELLING THE EFFECTS OF EXPOSURE TO WHOLE-BODY VIBRATION ON LOW-BACK PAIN AND ITS LONG-TERM CONSEQUENCES FOR SICKNESS ABSENCE AND ASSOCIATED WORK DISABILITY,"BACKGROUND: EXPOSURE TO WHOLE-BODY VIBRATION (WBV) IS A WELL-KNOWN RISK FACTOR FOR THE OCCURRENCE OF LOW-BACK PAIN (LBP). LITTLE IS KNOWN ABOUT THE LONG-TERM COURSE OF BACK PAIN IN WORKERS EXPOSED TO WBV AND THE CONSEQUENCES FOR (TEMPORARY) DISABILITY, DUE TO LACK OF COHORT STUDIES WITH SUFFICIENTLY LONG FOLLOW-UP PERIODS. METHODS: A SYSTEMATIC REVIEW OF THE LITERATURE WAS PERFORMED TO ASSESS ASSOCIATIONS BETWEEN EXPOSURE TO WBV AND LBP, SICKNESS ABSENCE DUE TO LOW-BACK DISORDERS AND PERMANENT DISABILITY. A META-ANALYSIS WAS USED TO ESTIMATE THE PREVALENCES OF LBP AND SICKNESS ABSENCE DUE TO LOW-BACK DISORDERS IN OCCUPATIONAL POPULATIONS, DEPENDING ON RELEVANT EXPOSURE CHARACTERISTICS. THESE PREVALENCES WERE CONVERTED INTO PROBABILITIES FOR TRANSITIONS BETWEEN NO COMPLAINTS, LBP, SICKNESS DUE TO LBP, AND DISABILITY. A MARKOV MODEL WAS APPLIED TO EVALUATE A HYPOTHETICAL COHORT OF WORKERS WITHOUT LBP AT THE START OF THE COHORT AND A FOLLOW-UP OF 40 YEARS (40 CYCLES OF I YEAR) TO REFLECT A LONG-LIFE CAREER WITH CONTINUOUS EXPOSURE TO WBV. RESULTS: IN THIS HYPOTHETICAL COHORT IT WAS ESTIMATED THAT AMONG WORKERS WITH THE HIGHEST EXPOSURE TO WBV ON AVERAGE ABOUT 47 WEEKS OF THEIR WORKING LIFE WERE LOST DUE TO SICK LEAVE BECAUSE OF LBP, WHICH IS APPROXIMATELY 2.5% OF THEIR WORKING LIFE. WHEN ALL WORKERS ON PROLONGED SICK LEAVE FOR 52 WEEKS WOULD REMAIN DISABLED FOR THE REST OF THEIR WORKING LIFE, A MAXIMUM OF 23.4% OF THEIR WORKING LIFE COULD BE LOST DUE TO HIGH WBV EXPOSURE. AMONG WORKERS WITHOUT OR LOW EXPOSURE TO WBV THE CORRESPONDING LOSSES WERE 0.8% AND 7.8%, RESPECTIVELY. CONCLUSION: THE APPROACH TO ASSESS YEARS OF WORK LOST DUE TO AN OCCUPATIONAL EXPOSURE MAY PROVIDE A MORE ADEQUATE DESCRIPTION FOR STAKEHOLDERS THAN THE TRADITIONAL MEASURES OF RELATIVE RISK OR ATTRIBUTABLE RISK FRACTION. THE CONCEPT OF WORK YEARS LOST MAY ALSO FACILITATE A BETTER APPRECIATION OF THE POTENTIAL BENEFITS OF PREVENTIVE MEASURES. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",RISK-FACTORS; DRIVERS; DISORDERS; POPULATION; PREVALENCE; OPERATORS; DISEASE; NURSES; NECK,NA,JOURNAL OF SOUND AND VIBRATION,"BURDORF, A##HULSHOF, CTJ","UNIV ROTTERDAM, ERASMUS MC, CTR MED, DEPT PUBL HLTH, ROTTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, CORONEL INST OCCUPAT & ENVIRONM HLTH, NL-1105 AZ AMSTERDAM, NETHERLANDS.","ACOUSTICS; ENGINEERING, MECHANICAL; MECHANICS",ACOUSTICS; ENGINEERING; MECHANICS,"ALCOUFFE J, 1999, OCCUP ENVIRON MED, V56, P696, DOI 10.1136/OEM.56.10.696##BONGERS PM, 1988, INT ARCH OCC ENV HEA, V60, P129, DOI 10.1007/BF00381494##BONGERS PM, 1990, ACADEMISCH PROEFSCHR, P205##BOSHUIZEN HC, 1992, SPINE, V17, P59, DOI 10.1097/00007632-199201000-00010##BOSHUIZEN HC, 1990, INT ARCH OCC ENV HEA, V62, P109, DOI 10.1007/BF00383586##BOVENZI M, 1994, APPL ERGON, V25, P231, DOI 10.1016/0003-6870(94)90004-3##BOVENZI M, 1992, SPINE, V17, P1048, DOI 10.1097/00007632-199209000-00007##BOVENZI M, 2002, J SOUND VIB, V253, P3, DOI 10.1006/JSVI.2001.4246##BOVENZI M, 1999, INT ARCH OCC ENV HEA, V72, P351, DOI 10.1007/S004200050387##BRENDSTRUP T, 1987, SCAND J WORK ENV HEA, V13, P442##BURDORF A, 1991, ERGONOMICS, V34, P909, DOI 10.1080/00140139108964834##BURDORF A, 1993, J OCCUP ENVIRON MED, V35, P1213##BURDORF A, 1997, SCAND J WORK ENV HEA, V23, P243, DOI 10.5271/SJWEH.217##COLE DC, 2002, J OCCUP REHABIL, V12, P163, DOI 10.1023/A:1016842611591##ELDERS LAM, 2004, SPINE, V29, PE101, DOI 10.1097/01.BRS.0000115125.60331.72##*EUR PARL COUNC EU, 2002, OFFICIAL J EUROPEA L, V177, P13##FRANK JW, 1996, SPINE, V21, P2918, DOI 10.1097/00007632-199612150-00025##HARTVIGSEN J, 2000, SCAND J PUBLIC HEALT, V28, P230, DOI 10.1177/14034948000280030201##HESTBAEK L, 2003, EUR SPINE J, V12, P149, DOI 10.1007/S00586-002-0508-5##HOOGENDOORN WE, 2002, OCCUP ENVIRON MED, V59, P459, DOI 10.1136/OEM.59.7.459##HULSHOF CTJ, 2002, J SOUND VIB, V253, P185, DOI 10.1006/JSVI.2001.4255##INTERNATIONAL ORGANIZATION FOR STANDARDIZATION, 1997, 26311 ISO##JANSEN JP, 2004, OCCUP ENVIRON MED, V61, P972, DOI 10.1136/OEM.2003.012245##KUMAR A, 1999, SPINE, V24, P2506, DOI 10.1097/00007632-199912010-00013##LINGS S, 2000, INT ARCH OCC ENV HEA, V73, P290, DOI 10.1007/S004200000118##LINTON SJ, 1990, WORK STRESS, V4, P41, DOI 10.1080/02678379008256963##LOTTERS F, 2003, SCAND J WORK ENV HEA, V29, P431##MAGNUSSON ML, 1996, SPINE, V21, P710, DOI 10.1097/00007632-199603150-00010##MAUL I, 2003, OCCUP ENVIRON MED, V60, P497, DOI 10.1136/OEM.60.7.497##MOLDANO SM, 2001, AM J IND MED, V40, P275##NURMINEN M, 2004, SCAND J WORK ENV HEA, V30, P339, DOI 10.5271/SJWEH.821##PALMER KT, 2000, OCCUP ENVIRON MED, V57, P229, DOI 10.1136/OEM.57.4.229##PENGEL LHM, 2003, BMJ-BRIT MED J, V327, P323, DOI 10.1136/BMJ.327.7410.323##PIETRI F, 1992, SCAND J WORK ENV HEA, V18, P52, DOI 10.5271/SJWEH.1614##SARASTE H, 1987, SCAND J REHABIL MED, V19, P109##SCHWARZE S, 1998, J SOUND VIB, V215, P613, DOI 10.1006/JSVI.1998.1602##SMEDLEY J, 1998, SPINE, V23, P2422, DOI 10.1097/00007632-199811150-00012##SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409##*TREEAGE SOFTW INC, 1998, DATAT TREEAGE VERS 3##VIIKARI-JUNTURA E, 2001, OCCUP ENVIRON MED, V58, P345, DOI 10.1136/OEM.58.5.345##VONKORFF M, 1994, SPINE, V19, PS2041##XU Y, 1997, OCCUP ENVIRON MED, V54, P741, DOI 10.1136/OEM.54.10.741",10,2020-11-20,NA
J,WOS:000242515800025,2006,"EPDM/PP THERMOPLASTIC VULCANIZATES AS STUDIED BY PROTON NMR RELAXATION: PHASE COMPOSITION, MOLECULAR MOBILITY, NETWORK STRUCTURE IN THE RUBBERY PHASE, AND NETWORK HETEROGENEITY","PROTON SOLID-STATE NMR T-2 RELAXATION ANALYSIS IS USED TO STUDY MODEL OIL-EXTENDED ETHYLENE-PROPYLENE-DIENE RUBBER (EPDM) AND THERMOPLASTIC VULCANIZATES (TPV) COMPOSED OF POLYPROPYLENE (PP), EPDM AND OIL. IT IS SHOWN THAT THE METHOD ALLOWS SELECTIVE CHARACTERIZATION OF CRYSTALLINE AND AMORPHOUS PHASES OF PP, CROSS-LINKED EPDM, AND OIL IN TPVS. THE NETWORK DENSITY IN THE RUBBERY (EPDM) PHASE IS DETERMINED IN A WIDE RANGE OF THE TPV COMPOSITIONS, AS WELL AS IN THE OIL-EXTENDED EPDM VULCANIZATES CONTAINING DIFFERENT AMOUNT OF OIL. THE ENTANGLEMENT DENSITY DECREASES WITH INCREASING OIL CONTENT IN OIL-EXTENDED EPDM. THIS DECREASE CAN BE DESCRIBED USING A SCALING APPROACH. MOLECULAR MOBILITY OF OIL MOLECULES DECREASES WITH INCREASING EPDM NETWORK DENSITY AND IS SIGNIFICANTLY LOWER THAN THAT OF PURE OIL DUE TO PHYSICAL INTERACTIONS WITH THE HOST MATRIX. IT IS SHOWN THAT THE NETWORK DENSITY IN THE RUBBERY PHASE OF TPV IS COMPOSED OF CHEMICAL CROSS-LINKS, PHYSICAL JUNCTIONS AT THE EPDM/PP INTERFACE, AND TEMPORARY AND TRAPPED CHAIN ENTANGLEMENTS. THE DENSITY OF CHEMICAL CROSS-LINKS INCREASES WITH THE AMOUNT OF CROSS-LINKER PER WEIGHT UNIT OF EPDM. THE DENSITY OF THE PHYSICAL JUNCTIONS INCREASES WITH INCREASING PP CONTENT. CRYSTALLINITY OF PP IN TPV IS HARDLY AFFECTED BY THE TPV COMPOSITION. A SMALL FRACTION OF OIL MOLECULES PLASTICIZES THE AMORPHOUS PHASE OF PP AND THE PLASTICIZATION EFFECT IS PROPORTIONAL TO AN OIL: PP MASS RATIO IN THE TPV COMPOSITION. TWO NMR METHODS FOR IMPROVING THE SELECTIVITY OF THE T-2 RELAXATION ANALYSIS TO DIFFERENT PHASES OF TPV ARE EVALUATED. THE METHODS ARE BASED ON THE INVERSION-RECOVERY EXPERIMENT AND DOUBLE-QUANTUM (DQ) FILTERING OF THE DECAY OF THE TRANSVERSE MAGNETIZATION RELAXATION. THE DQ FILTERED T-2 RELAXATION EXPERIMENT IMPROVES THE SELECTIVITY OF THE METHOD AND COULD OPEN NEW POSSIBILITIES FOR CHARACTERIZATION OF THE NETWORK HETEROGENEITY IN RUBBERY MATERIALS. SOME RELATIONSHIPS BETWEEN THE TPV COMPOSITION, NETWORK DENSITY, AND MECHANICAL PROPERTIES ARE SHORTLY DISCUSSED.",MULTIPLE-QUANTUM NMR; RESIDUAL DIPOLAR COUPLINGS; NUCLEAR-MAGNETIC-RESONANCE; FREE INDUCTION DECAY; SOLID-STATE H-1-NMR; CROSS-LINK DENSITY; SPUN NYLON-6 FIBERS; SPIN-DIFFUSION; ISOTACTIC POLYPROPYLENE; POLYMER-CHAINS,NA,MACROMOLECULES,"LITVINOV, VM","DSM RES BV, NL-6160 MD GELEEN, NETHERLANDS.",POLYMER SCIENCE,POLYMER SCIENCE,"ALUAS M, 2005, SOLID STATE NUCL MAG, V27, P165, DOI 10.1016/J.SSNMR.2004.10.001##ANDERSON SL, 1995, MACROMOLECULES, V28, P2944, DOI 10.1021/MA00112A047##BA Y, 1998, J CHEM PHYS, V108, P8589, DOI 10.1063/1.476288##BERTMER M, 2004, MACROMOL CHEM PHYSIC, V205, P83, DOI 10.1002/MACP.200300027##BILSKI P, 2003, MOL PHYS, V101, P335, DOI 10.1080/0026897021000018178##BILSKI P, 2000, MOLECUL PHYS REP, V29, P55##BRERETON MG, 1991, MACROMOLECULES, V24, P2068, DOI 10.1021/MA00008A055##BRERETON MG, 1990, MACROMOLECULES, V23, P1119, DOI 10.1021/MA00206A034##BUDA A, 2003, J PHYS CHEM B, V107, P5357, DOI 10.1021/JP021684V##BUDA A, 2004, CHEMPHYSCHEM, V5, P876, DOI 10.1002/CPHC.200301071##BUDA A, 2003, SOLID STATE NUCL MAG, V24, P39, DOI 10.1016/S0926-2040(03)00020-1##CHEN Z, 2002, MACROMOLECULES, V35, P3296, DOI 10.1021/MA012048I##CHERRY BR, 2005, MACROMOLECULES, V38, P1201, DOI 10.1021/MA047885+##COHENADDAD JP, 1983, POLYMER, V24, P400, DOI 10.1016/0032-3861(83)90025-3##COHENADDAD JP, 1992, MACROMOLECULES, V25, P593, DOI 10.1021/MA00028A017##COHENADDAD JP, 1993, PROGR NUCLEAR MAGNET, V25, P1##COHENADDAD JP, 2002, SPECTROSCOPY RUBBERY, P291##COLBY RH, 1991, MACROMOLECULES, V24, P3873, DOI 10.1021/MA00013A021##COLBY RH, 1992, MACROMOLECULES, V25, P996, DOI 10.1021/MA00028A076##CORAN AY, 1980, RUBBER CHEM TECHNOL, V53, P141, DOI 10.5254/1.3535023##DADAYLI D, 1994, POLYMER, V35, P4083, DOI 10.1016/0032-3861(94)90579-7##DE GENNES P.G., 1979, SCALING CONCEPTS POL##DE SK, 1990, THERMOPLASTIC ELASTO##DELOCHE B., 2002, SPECTROSCOPY RUBBERS, P557##DERISI FR, UNPUB##DUJOURDY L, 1999, POLYM INT, V48, P558, DOI 10.1002/(SICI)1097-0126(199907)48:7<558::AID-PI196>3.0.CO;2-4##ELLUL MD, 2004, POLYMER, V45, P3351, DOI 10.1016/J.POLYMER.2004.03.029##ELLUL MD, 1998, RUBBER CHEM TECHNOL, V71, P244, DOI 10.5254/1.3538482##FECHETE R, 2004, J MAGN RESON, V169, P19, DOI 10.1016/J.JMR.2004.03.026##FEDOTOV V, 1989, STRUCTURE DYNAMICS B##FRY CG, 1988, MACROMOLECULES, V21, P1292, DOI 10.1021/MA00183A019##GERGEN WP, 1987, THERMOPLASTIC ELASTO##GOTLIB Y.Y., 1976, POLYM SCI USSR, V18, DOI [10.1016/0032-3950(76)90192-1, DOI 10.1016/0032-3950(76)90192-1]##GRAF R, 1997, J CHEM PHYS, V106, P885, DOI 10.1063/1.473169##GRAF R, 1998, SOLID STATE NUCL MAG, V12, P139, DOI 10.1016/S0926-2040(98)00058-7##HANSEN EW, 1998, J PHYS CHEM B, V102, P5444, DOI 10.1021/JP981753Z##HEDESIU C, UNPUB POLYMER##IWATA K, 1989, J CHEM PHYS, V90, P4567, DOI 10.1063/1.456617##JAYARAMAN K, 2004, J APPL POLYM SCI, V93, P113, DOI 10.1002/APP.20414##KAVASSALIS TA, 1989, MACROMOLECULES, V22, P2709, DOI 10.1021/MA00196A031##KAWABATA S, 1992, J APPL POLYM SCI APP, V50, P245##KENWRIGHT AM, 1993, NMR SPECTROSCOPY POL, P231##KIKUCHI Y, 1992, J APPL POLYM SCI APP, V50, P261##KIMMICH R, 1991, J POLYM SCI POL PHYS, V29, P1025, DOI 10.1002/POLB.1991.090290813##KIMMICH R., 1997, NMR TOMOGRAPHY DIFFU##KRISTIANSEN PE, 1999, J PHYS CHEM B, V103, P3552, DOI 10.1021/JP984539J##KULAGINA TP, 1993, J POLYM SCI POL PHYS, V31, P241, DOI 10.1002/POLB.1993.090310301##LEGGE NR, 1987, THERMOPLASTIC ELASTO##LIENIN SF, 1998, J MAGN RESON, V131, P184, DOI 10.1006/JMRE.1998.1368##LITVINOV V. M., 2002, SPECTROSCOPY RUBBERS, P353##LITVINOV VM, 2004, MACROMOL CHEM PHYSIC, V205, P1721, DOI 10.1002/MACP.200400089##LITVINOV VM, 1998, RUBBER CHEM TECHNOL, V71, P105, DOI 10.5254/1.3538466##LITVINOV VM, 2005, POLYMER, V46, P3077, DOI 10.1016/J.POLYMER.2005.01.074##LITVINOV VM, 2001, MACROMOLECULES, V34, P4051, DOI 10.1021/MA010066U##LITVINOV VM, 2001, MACROMOLECULES, V34, P489, DOI 10.1021/MA001478Q##LITVINOV VM, 2001, MACROMOLECULES, V34, P8468, DOI 10.1021/MA010208K##LITVINOV VM, 1999, MACROMOLECULES, V32, P8476, DOI 10.1021/MA9910080##MARINOVIC T, 1998, KAUT GUMMI KUNSTST, V51, P189##MCBRIERTY VJ, 1993, NUCL MAGNETIC RESONA##MUNOWITZ M, 1987, ADV CHEM PHYS, V66, P1##OHLSSON B, 1996, POLYM ENG SCI, V36, P501, DOI 10.1002/PEN.10436##ORZA RA, 2005, MACROMOL SYMP, V230, P144, DOI 10.1002/MASY.200551153##RICHTER D, 1993, MACROMOLECULES, V26, P795, DOI 10.1021/MA00056A034##RIES ME, 1998, MACROMOLECULES, V31, P4950, DOI 10.1021/MA971860B##SAALWACHTER K, 2006, MACROMOLECULES, V39, P3291, DOI 10.1021/MA052567B##SAALWACHTER K, 2005, MACROMOLECULES, V38, P9650, DOI 10.1021/MA051238G##SAALWACHTER K, 2005, MACROMOLECULES, V38, P4040, DOI 10.1021/MA050182N##SAALWACHTER K, 2004, APPL MAGN RESON, V27, P401, DOI 10.1007/BF03166740##SAALWACHTER K, 2005, MACROMOLECULES, V38, P1508, DOI 10.1021/MA0478005##SAALWACHTER K, 2004, MACROMOLECULES, V37, P8556, DOI 10.1021/MA048803K##SAALWACHTER K, 2003, J CHEM PHYS, V119, P3468, DOI 10.1063/1.1589000##SCHNEIDER M, 1999, J CHEM PHYS, V111, P402, DOI 10.1063/1.479291##SCHREURS S, 1999, J PHYS CHEM B, V103, P1393, DOI 10.1021/JP9829694##SENGERS WGF, 2005, POLYMER, V46, P6391, DOI 10.1016/J.POLYMER.2005.04.094##SENGUPTA P, 2005, MACROMOL RAPID COMM, V26, P542, DOI 10.1002/MARC.200400589##SENGUPTA P, 2004, THESIS U TWENTE ENSC##SOTTA P, 1998, MACROMOLECULES, V31, P8417, DOI 10.1021/MA980987D##SOTTA P, 1990, MACROMOLECULES, V23, P1999, DOI 10.1021/MA00209A021##SPIESS HW, 1983, COLLOID POLYM SCI, V261, P193, DOI 10.1007/BF01469664##STEENBRINK AC, 1998, POLYMER, V39, P4817, DOI 10.1016/S0032-3861(97)10103-3##STERN SA, 1990, ACS SYM SER, V423, P22##TANAKA H, 1993, POLYM INT, V31, P9, DOI 10.1002/PI.4990310103##TAO H, 1999, MACROMOLECULES, V32, P1212, DOI 10.1021/MA981468D##VALIC S, 2003, POLYMER, V44, P5263, DOI 10.1016/S0032-3861(03)00475-0##VALIC S, 1999, POLYMER, V40, P989, DOI 10.1016/S0032-3861(98)00305-X##VANDUIN M, 1995, RUBBER CHEM TECHNOL, V68, P717, DOI 10.5254/1.3538768##VENNEMANN N, 2001, KAUT GUMMI KUNSTST, V54, P362##VODA MA, 2005, J MAGN RESON, V172, P98, DOI 10.1016/J.JMR.2004.10.001##WANG MF, 2003, MACROMOLECULES, V36, P4411, DOI 10.1021/MA0217534##WEGLARZ WP, 2000, J POLYM SCI POL PHYS, V38, P2487, DOI 10.1002/1099-0488(20001001)38:19<2487::AID-POLB10>3.0.CO;2-X##WESTERMANN S, 2000, MACROMOL CHEM PHYS, V201, P500##WINTERS R, 2001, POLYMER, V42, P9745, DOI 10.1016/S0032-3861(01)00504-3##WOUTERS MEL, 2003, MACROMOLECULES, V36, P1147, DOI 10.1021/MA020358A##YANG Y, 1998, POLYMER, V39, P3365, DOI 10.1016/S0032-3861(97)10119-7",79,2020-11-20,NA
J,WOS:000242515800029,2006,OLIGO(TRIMETHYLENE CARBONATE)-BASED SUPRAMOLECULAR BIOMATERIALS,"A SUPRAMOLECULAR POLYMER SYSTEM IS PRESENTED IN WHICH RELATIVELY SHORT TRIMETHYLENE CARBONATE (TMC) PREPOLYMERS ARE LINKED VIA REVERSIBLE QUADRUPLE HYDROGEN BONDING UREIDOPYRIMIDINONE (UPY) MOIETIES. SEVERAL UPY-MODIFIED BIFUNCTIONAL AND TRIFUNCTIONAL TMC POLYMERS WERE SYNTHESIZED. TUNABILITY OF THE MECHANICAL AND THERMAL PROPERTIES WAS ACHIEVED BY MIXING DIFFERENT TRIFUNCTIONAL UPY-TMC WITH BIFUNCTIONAL UPY-TMC POLYMERS. THE CONCENTRATION OF UPY GROUPS INFLUENCED THE CRYSTALLIZATION BEHAVIOR OF THE MATERIALS. THE UPY-MODIFIED TMC POLYMERS DISPLAYED MELTING ENDOTHERMS, WHICH ARE CAUSED BY AGGREGATION OF THE UPY UNITS INTO SMALL CRYSTALLITES. IT IS ASSUMED THAT THE UPY DIMERS STACK IN THE LATERAL DIRECTION DUE TO URETHANE HYDROGEN BONDING. ATOMIC FORCE MICROSCOPY CONFIRMED THE PRESENCE OF FIBERLIKE STACKS. THESE CRYSTALLITES GIVE THE MATERIAL ITS MECHANICAL STRENGTH AND PREVENT FLOWING OF THE MATERIAL AFTER PROCESSING INTO 3D SCAFFOLDS. MORE IMPORTANTLY, THESE POLYMERS CAN BE PROCESSED QUITE EASILY AT SLIGHTLY ELEVATED TEMPERATURES. BECAUSE OF THE STRONG TEMPERATURE DEPENDENCE OF THE REVERSIBLE NATURE OF THE HYDROGEN BONDS, THEIR MELT VISCOSITIES ARE LOW, WHILE AT TEMPERATURES BELOW 50 C EXCELLENT MECHANICAL PROPERTIES ARE FOUND AS A RESULT OF SUPRAMOLECULAR, PHYSICAL CROSS-LINKING. THE UPY-TMC POLYMERS ARE SHOWN TO BE BIOCOMPATIBLE AND FIBROBLASTS PROLIFERATE WELL ON DROP CAST FILMS OF UPY-TMC. THUS, THESE NOVEL SUPRAMOLECULAR UPY-TMC POLYMERS ARE VERY PROMISING, BIOCOMPATIBLE, TUNABLE, AND EASILY PROCESSABLE BIOMATERIALS FOR APPLICATIONS SUCH AS TISSUE ENGINEERING.","RING-OPENING POLYMERIZATION; 1,3-TRIMETHYLENE CARBONATE; TRIMETHYLENE CARBONATE; POLY(TRIMETHYLENE CARBONATE); EPSILON-CAPROLACTONE; THERMOPLASTIC ELASTOMERS; MECHANICAL-PROPERTIES; TRIBLOCK COPOLYMERS; POLYMERS; SCAFFOLDS",NA,MACROMOLECULES,"DANKERS, PYW##ZHANG, Z##WISSE, E##GRIJPMA, DW##SIJBESMA, RP##FEIJEN, J##MEIJER, EW","EINDHOVEN UNIV TECHNOL, LAB MACROMOL & ORGAN CHEM, NL-5600 MB EINDHOVEN, NETHERLANDS. UNIV TWENTE, DEPT POLYMER CHEM & BIOMAT, NL-7500 AE ENSCHEDE, NETHERLANDS.",POLYMER SCIENCE,POLYMER SCIENCE,"BEIJER FH, 1998, J AM CHEM SOC, V120, P6761, DOI 10.1021/JA974112A##DANKERS PYW, 2005, NAT MATER, V4, P568, DOI 10.1038/NMAT1418##FOLMER BJB, 2000, ADV MATER, V12, P874, DOI 10.1002/1521-4095(200006)12:12<874::AID-ADMA874>3.3.CO;2-3##GRIJPMA DW, 2005, BIOMATERIALS, V26, P2795, DOI 10.1016/J.BIOMATERIALS.2004.08.002##HUTMACHER DW, 2001, J BIOMED MATER RES, V55, P203, DOI 10.1002/1097-4636(200105)55:2<203::AID-JBM1007>3.3.CO;2-Z##HUTMACHER DW, 2001, J BIOMAT SCI-POLYM E, V12, P107, DOI 10.1163/156856201744489##KAUTZ H, 2006, MACROMOLECULES, V39, P4265, DOI 10.1021/MA060706Z##KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0##KRICHELDORF HR, 2004, MACROMOL CHEM PHYSIC, V205, P1602, DOI 10.1002/MACP.200300188##KRICHELDORF HR, 1995, J POLYM SCI POL CHEM, V33, P2193, DOI 10.1002/POLA.1995.080331313##MATSUMURA S, 1997, MACROMOLECULES, V30, P3122, DOI 10.1021/MA961862G##NEDERBERG F, 2005, POLYM ADVAN TECHNOL, V16, P108, DOI 10.1002/PAT.556##NEDERBERG F, 2004, J AM CHEM SOC, V126, P15350, DOI 10.1021/JA0457314##PEGO AP, 2003, J BIOMED MATER RES A, V67A, P1044, DOI 10.1002/JBM.A.10121##PEGO AP, 2003, J BIOMED MATER RES A, V67A, P876, DOI 10.1002/JBM.A.10074##PEGO AP, 2003, J CONTROL RELEASE, V87, P69, DOI 10.1016/S0168-3659(02)00351-6##PEGO AP, 2003, TISSUE ENG, V9, P981, DOI 10.1089/107632703322495628##PEGO AP, 2003, POLYMER, V44, P6495, DOI 10.1016/S0032-3861(03)00668-2##POSPIECH D, 2005, BIOMACROMOLECULES, V6, P439, DOI 10.1021/BM049393A##SIJBESMA RP, 1997, SCIENCE, V278, P1601, DOI 10.1126/SCIENCE.278.5343.1601##SONTJENS S. H. M., 2002, THESIS##SONTJENS SHM, 2000, J AM CHEM SOC, V122, P7487, DOI 10.1021/JA000435M##ZHANG Z, 2004, J MATER SCI-MATER M, V15, P381, DOI 10.1023/B:JMSM.0000021105.02301.FF##ZHANG Z, 2004, MACROMOL CHEM PHYS, V205, P867, DOI 10.1002/MACP.200300184",74,2020-11-20,NA
J,WOS:000242750900021,2006,DYNAMOMETRY OF INTRINSIC HAND MUSCLES IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE,"BACKGROUND: SEVERAL PROBLEMS ARE ASSOCIATED WITH MANUAL MUSCLE TESTING AND DYNAMOMETRY IN THE HANDS OF PATIENTS WITH CHARCOT-MARIE-TOOTH (CMT) DISEASE. OBJECTIVE: TO EVALUATE THE EFFICACY OF THE ROTTERDAM INTRINSIC HAND MYOMETER (RIHM) TO DIRECTLY MEASURE INTRINSIC HAND MUSCLE STRENGTH IN CMT DISEASE. METHODS: WE MEASURED HAND MUSCLE STRENGTH AND HAND FUNCTION IN 41 PATIENTS WITH CMT DISEASE. RESULTS: RIHM MEASUREMENT OF INTRINSIC STRENGTH HAD EXCELLENT RELIABILITY. WE FOUND OVERLAPPING RIHM STRENGTH VALUES IN MEDICAL RESEARCH COUNCIL GRADES 3 TO 5. HIGH GRIP AND PINCH STRENGTH COULD BE FOUND IN PATIENTS WITH SEVERE INTRINSIC MUSCLE WEAKNESS. RIHM MEASUREMENTS WERE MORE STRONGLY CORRELATED WITH FINE MOTOR SKILLS OF THE HAND THAN GRIP AND PINCH STRENGTH. CONCLUSIONS: THE ROTTERDAM INTRINSIC HAND MYOMETER IS A RELIABLE INSTRUMENT TO MEASURE INTRINSIC HAND MUSCLES STRENGTH IN PATIENTS WITH CHARCOT MARIE-TOOTH DISEASE, PROVIDING MORE DETAILED INFORMATION THAN MANUAL MUSCLE TESTING AND A MORE DIRECT ASSESSMENT OF INTRINSIC MUSCLE LOSS THAN GRIP AND PINCH DYNAMOMETERS.",SENSORY NEUROPATHY; FORCE MEASUREMENTS; HEREDITARY MOTOR; PINCH STRENGTH; RELIABILITY; GRIP; ULNAR; INJURIES,NA,NEUROLOGY,"SELLES, RW##VAN GINNEKEN, BTJ##SCHREUDERS, TAR##JANSSEN, WGM##STAM, HJ","ERASMUS UNIV, MED CTR, DEPT REHABIL MED, NL-3000 CA ROTTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"AITKENS S, 1989, MUSCLE NERVE, V12, P173, DOI 10.1002/MUS.880120302##[ANONYMOUS], 1992, CLIN ASSESSMENT RECO, P41##BEATON D E, 2001, J HAND THER, V14, P128##BEATON DE, 2001, J HAND THER, V6, P109, DOI DOI 10.1177/175899830100600401##BOHANNON RW, 2005, PERCEPT MOTOR SKILL, V100, P795, DOI 10.2466/PMS.100.3.795-798##BOHANNON RW, 2005, CLIN REHABIL, V19, P662, DOI 10.1191/0269215505CR873OA##BRANDSMA J W, 2001, J HAND THER, V14, P273##BRANDSMA J W, 1995, J HAND THER, V8, P185##CARTER GT, 1995, AM J PHYS MED REHAB, V74, PS140, DOI 10.1097/00002060-199509001-00008##DVIR Z, 1997, CLIN REHABIL, V11, P36, DOI 10.1177/026921559701100106##FOWLER WM, 1995, AM J PHYS MED REHAB, V74, PS62, DOI 10.1097/00002060-199509001-00002##JESTER A, 2005, J HAND SURG-AM, V30A, P1074, DOI 10.1016/J.JHSA.2005.04.009##KILMER DD, 1997, ARCH PHYS MED REHAB, V78, P1364, DOI 10.1016/S0003-9993(97)90311-7##KOZIN SH, 1999, J HAND SURG-AM, V24A, P64##NOREAU L, 1998, SPINAL CORD, V36, P716, DOI 10.1038/SJ.SC.3100646##PRONK CNA, 1981, MED BIOL ENG COMPUT, V19, P127, DOI 10.1007/BF02443858##ROEBROECK ME, 1993, PHYS THER, V73, P386, DOI 10.1093/PTJ/73.6.386##ROSEN B, 2000, J HAND SURG-AM, V25A, P535, DOI 10.1053/JHSU.2000.6458##SCHREUDERS TAR, 2003, PHYS THER, V83, P806, DOI 10.1093/PTJ/83.9.806##SCHREUDERS TAR, 2004, J REHABIL MED, V36, P273, DOI 10.1080/16501970410033677##SCHREUDERS TAR, 2004, J HAND SURG-AM, V29A, P318, DOI 10.1016/J.JHSA.2003.10.024##SCHREUDERS TAR, 2000, J HAND SURG-BRIT EUR, V25B, P560, DOI 10.1054/JHSB.2000.0415##SCHULZ L A, 1998, J HAND THER, V11, P200##SCHWARTZ S, 1992, ARCH PHYS MED REHAB, V73, P1063##SOLLERMAN C, 1995, SCAND J PLAST RECONS, V29, P167, DOI 10.3109/02844319509034334##STRICKLAND JW, 1991, OPERATIVE NERVE REPA##VAN DER PLOEG R J, 2001, NED TIJDSCHR GENEESKD, V145, P19##VANDERPLOEG RJO, 1984, J NEUROL, V231, P200##VIDELER AJ, 2002, ARCH PHYS MED REHAB, V83, P1274, DOI 10.1053/APMR.2002.34282",30,2020-11-20,NA
J,WOS:000242750900035,2006,PERIPHERAL AND CENTRAL HYPOMYELINATION WITH HYPOGONADOTROPIC HYPOGONADISM AND HYPODONTIA,"WE IDENTIFIED FOUR UNRELATED PATIENTS (THREE FEMALE, ONE MALE) AGED 20 TO 30 YEARS WITH HYPOMYELINATION, PITUITARY HYPOGONADOTROPIC HYPOGONADISM, AND HYPODONTIA. ELECTRON MICROSCOPY AND MYELIN PROTEIN IMMUNOHISTOCHEMISTRY OF SURAL NERVES SHOWED GRANULAR DEBRIS-LINED CLEFTS, EXPANDED ABAXONAL SPACE, OUTPOCKETING WITH VACUOLAR DISRUPTION, AND LOSS OF NORMAL MYELIN PERIODICITY. REDUCED GALACTOCEREBROSIDE, SPHINGOMYELIN, AND GM1-N-ACETYLGLUCOSAMINE AND INCREASED ESTERIFIED CHOLESTEROL WERE FOUND. THIS IS A CLINICALLY HOMOGENEOUS PROGRESSIVE HYPOMYELINATING DISORDER. THE TERM 4H SYNDROME IS SUGGESTED.",SCHWANN-CELLS; ATAXIA,NA,NEUROLOGY,"TIMMONS, M##TSOKOS, M##ABU ASAB, M##SEMINARA, SB##ZIRZOW, GC##KANESKI, CR##HEISS, JD##VAN DER KNAAP, MS##VANIER, MT##SCHIFFMANN, R##WONG, K","NINDS, DEV & METAB NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA. NINDS, SURG NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA. NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA. MASSACHUSETTS GEN HOSP, REPROD ENDOCRINE UNIT, BOSTON, MA 02114 USA. HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA. VRIJE UNIV AMSTERDAM, DEPT CHILD NEUROL, MED CTR, NL-1081 HV AMSTERDAM, NETHERLANDS. LYON SUD UNIV HOSP, LYON SUD MED SCH, PIERRE BENITE, FRANCE. LYON SUD UNIV HOSP, FDN GILLET MERIEUX, PIERRE BENITE, FRANCE. WILFORD HALL USAF MED CTR, DIV NEUROPATHOL, SAN ANTONIO, TX 78236 USA.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"BENMESSAHEL Y, 2002, ANN NY ACAD SCI, V973, P83, DOI 10.1111/J.1749-6632.2002.TB04611.X##BERCIANO MT, 2000, GLIA, V29, P246, DOI 10.1002/(SICI)1098-1136(20000201)29:3<246::AID-GLIA6>3.0.CO;2-L##CHAPPELL PE, 1997, ENDOCRINOLOGY, V138, P4147, DOI 10.1210/EN.138.10.4147##LI YT, 1973, J BIOL CHEM, V248, P2634##QUARLES RH, 1997, J MOL NEUROSCI, V8, P1, DOI 10.1007/BF02736858##SEMINARA SB, 2002, J CLIN ENDOCR METAB, V87, P1607, DOI 10.1210/JC.87.4.1607##SILVEIRA LFG, 2002, SEMIN REPROD MED, V20, P327, DOI 10.1055/S-2002-36707##VITAL C, 2002, ULTRASTRUCT PATHOL, V26, P9, DOI 10.1080/01913120252934279##WOLF NI, 2005, NEUROLOGY, V64, P1461, DOI 10.1212/01.WNL.0000158615.56071.E3##ZHU XY, 2005, CURR OPIN GENET DEV, V15, P332, DOI 10.1016/J.GDE.2005.04.011",58,2020-11-20,"INTRAMURAL NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USA [Z01 NS002984-09, Z01 NS002984] FUNDING SOURCE: MEDLINE; NICHD NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [R01 HD043341] FUNDING SOURCE: MEDLINE; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE (NINDS) [Z01NS002984, Z01NS002984, Z01NS002984, Z01NS002984, Z01NS002984, Z01NS002984, Z01NS002984, Z01NS002984, Z01NS002984, Z01NS002984] FUNDING SOURCE: NIH REPORTER"
J,WOS:000242750900038,2006,NEUROLOGIC AND HEMATOLOGIC RESPONSE TO FLUDARABINE TREATMENT IN IGM MGUS POLYNEUROPATHY,"WE STUDIED THE EFFICACY OF FLUDARABINE IN 16 PATIENTS WITH IMMUNOGLOBULIN M MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE POLYNEUROPATHY IN A PROSPECTIVE UNCONTROLLED TRIAL. THE MODIFIED RANKIN SCALE IMPROVED IN 5/16 PATIENTS, ALL OF WHOM HAD A DEMYELINATING POLYNEUROPATHY. THE MOTOR CONDUCTION VELOCITY IMPROVED BY MORE THAN 10% IN TWO OR MORE NERVES FOR FOUR OF FIVE OF THESE PATIENTS. HEMATOLOGIC RESPONSE IN BONE MARROW OCCURRED IN THREE OF FIVE OF THESE PATIENTS, WHEREAS TWO OF FIVE ALREADY HAD SMALL POLYCLONAL B CELL POPULATIONS. THERE WERE NO SERIOUS SIDE EFFECTS.",MONOCLONAL GAMMOPATHY; INTRAVENOUS IMMUNOGLOBULIN; UNDETERMINED SIGNIFICANCE; DEMYELINATING NEUROPATHY,NA,NEUROLOGY,"NIERMEIJER, JMF##EURELINGS, M##LOKHORST, H##FRANSSEN, H##FIJNHEER, R##WOKKE, JHJ##NOTERMANS, NC","UNIV UTRECHT, MED CTR, DEPT NEUROL & NEUROSURG, RUDOLF MAGNUS INST NEUROSCI, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT NEUROL, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT CLIN NEUROPHYSIOL, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT HEMATOL, NL-3508 GA UTRECHT, NETHERLANDS.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"BRIL V, 1998, MUSCLE NERVE, V21, P1368, DOI 10.1002/(SICI)1097-4598(199811)21:11<1368::AID-MUS2>3.0.CO;2-7##COMI G, 2002, J NEUROL, V249, P1370, DOI 10.1007/S00415-002-0808-Z##DALAKAS MC, 1996, ANN NEUROL, V40, P792, DOI 10.1002/ANA.410400516##DYCK PJ, 1991, NEW ENGL J MED, V325, P1482, DOI 10.1056/NEJM199111213252105##DYCK PJ, 1990, NEUROLOGY, V40, P327##LUNN M.P., 2003, COCHRANE DB SYST REV##NOTERMANS NC, 1994, BRAIN, V117, P1385, DOI 10.1093/BRAIN/117.6.1385##NOTERMANS NC, 1996, NEUROLOGY, V47, P1227, DOI 10.1212/WNL.47.5.1227##SHERMAN WH, 1994, ANN NEUROL, V36, P326##WILSON HC, 1999, J NEUROL NEUROSUR PS, V66, P575, DOI 10.1136/JNNP.66.5.575",20,2020-11-20,NA
J,WOS:000242785800001,2006,MAGNETIZATION OF BILAYER TWO-DIMENSIONAL ELECTRON SYSTEMS,"WE HAVE MEASURED THE MAGNETIZATION OF STRONGLY COUPLED BILAYER TWO-DIMENSIONAL ELECTRON SYSTEMS. WHEN SWEEPING THE MAGNETIC FIELD STEPS APPEAR IN THE MAGNETIZATION WHENEVER A TRANSITION BETWEEN DISCRETE ENERGY LEVELS TAKES PLACE. AT MAGNETIC FIELDS FOR WHICH THE LANDAU-LEVEL SPLITTING DOMINATES, THE STEPS OCCURRING AT TOTAL FILLING FACTORS NU(T) = 4J ARE RELATED TO TRANSITIONS BETWEEN ADJACENT LANDAU LEVELS J - 1 AND J; SUCH STEPS CAN ALSO BE OBSERVED IN SINGLE LAYERS. ADDITIONAL MAGNETIZATION STEPS SHOWING UP IN BILAYERS AT HALF LANDAU-LEVEL FILLING NU(T) = 4J + 2 ARE ASSOCIATED WITH TRANSITIONS FROM A SYMMETRIC TO AN ANTISYMMETRIC STATE INSIDE THE SAME LANDAU LEVEL J. THE OBSERVED SIZE OF THE LANDAU-LEVEL STEPS IN BILAYERS IS CONSIDERABLY LOWER THAN EXPECTED THEORETICALLY. THESE FINDINGS ARE EXPLAINED USING A MODEL WITH A LARGE BACKGROUND DENSITY OF STATES.",GAS; MAGNETOMETER,NA,NEW JOURNAL OF PHYSICS,"BOMINAAR-SILKENS, IMA##SCHAAPMAN, MR##ZEITLER, U##CHRISTIANEN, PCM##MAAN, JC##REUTER, D##WIECK, AD##SCHUH, D##BICHLER, M","RADBOUD UNIV NIJMEGEN, INST MOL & MAT, HIGH FIELD MAGNET LAB, NL-6525 ED NIJMEGEN, NETHERLANDS. RUHR UNIV BOCHUM, LEHRSTUHL ANGEW FESTKORPERPHYS, D-44780 BOCHUM, GERMANY. TECH UNIV MUNICH, WALTER SCHOTTKY INST, D-85748 GARCHING, GERMANY.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"BOMINAAR-SILKENS IMA, 2004, INT J MOD PHYS B, V18, P3665, DOI 10.1142/S0217979204027256##DAVIES AG, 1996, PHYS REV B, V54, P17331, DOI 10.1103/PHYSREVB.54.R17331##EISENSTEIN JP, 1985, PHYS REV LETT, V55, P875, DOI 10.1103/PHYSREVLETT.55.875##JONES CL, 1996, SOLID STATE COMMUN, V97, P763, DOI 10.1016/0038-1098(95)00738-5##MEINEL I, 1997, APPL PHYS LETT, V70, P3305, DOI 10.1063/1.119145##POTTS A, 1996, J PHYS-CONDENS MAT, V8, P5189, DOI 10.1088/0953-8984/8/28/004##SCHAAPMAN MR, 2003, PHYS REV B, V68, DOI 10.1103/PHYSREVB.68.193308##SCHAAPMAN MR, 2004, PHYSICA E, V22, P86, DOI 10.1016/J.PHYSE.2003.11.222##SCHAAPMAN MR, 2002, APPL PHYS LETT, V81, P1041, DOI 10.1063/1.1498152##SCHWARZ MP, 2002, PHYS REV B, V65, DOI 10.1103/PHYSREVB.65.245315##SCHWARZ MP, 2000, APPL PHYS LETT, V76, P3564, DOI 10.1063/1.126708##WIEGERS SAJ, 1997, PHYS REV LETT, V79, P3238, DOI 10.1103/PHYSREVLETT.79.3238##WILDE MA, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.125325##WILDE MA, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.165429##ZHU M, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.155329",3,2020-11-20,NA
J,WOS:000242884200015,2006,SOLUTION STRUCTURE AND DYNAMICS OF THE COMPLEX BETWEEN CYTOCHROME C AND CYTOCHROME C PEROXIDASE DETERMINED BY PARAMAGNETIC NMR,"THE PHYSIOLOGICAL COMPLEX OF YEAST CYTOCHROME C PEROXIDASE AND ISO-1-CYTOCHROME C IS A PARADIGM FOR BIOLOGICAL ELECTRON TRANSFER. USING PARAMAGNETIC NMR SPECTROSCOPY, WE HAVE DETERMINED THE CONFORMATION OF THE PROTEIN COMPLEX IN SOLUTION, WHICH IS SHOWN TO BE VERY SIMILAR TO THAT OBSERVED IN THE CRYSTAL STRUCTURE [PELLETIER H, KRAUT J (1992) SCIENCE 258:1748-1755]. OUR RESULTS SUPPORT THE VIEW THAT THIS TRANSIENT ELECTRON TRANSFER COMPLEX IS DYNAMIC. THE SOLUTION STRUCTURE REPRESENTS THE DOMINANT PROTEIN-PROTEIN ORIENTATION, WHICH, ACCORDING TO OUR ESTIMATES, IS OCCUPIED FOR > 70% OF THE LIFETIME OF THE COMPLEX, WITH THE REST OF THE TIME SPENT IN THE DYNAMIC ENCOUNTER STATE. BASED ON THE OBSERVED PARAMAGNETIC EFFECTS, WE HAVE DELINEATED THE CONFORMATIONAL SPACE SAMPLED BY THE PROTEIN MOLECULES DURING THE DYNAMIC PART OF THE INTERACTION, PROVIDING EXPERIMENTAL SUPPORT FOR THE THEORETICAL PREDICTIONS OF THE CLASSICAL BROWNIAN DYNAMICS STUDY [NORTHRUP SH, BOLES JO, REYNOLDS JCL (1988) SCIENCE 241:67-70]. OUR FINDINGS CORROBORATE THE DYNAMIC BEHAVIOR OF THIS COMPLEX AND OFFER AN INSIGHT INTO THE MECHANISM OF THE PROTEIN COMPLEX FORMATION IN SOLUTION.",PROTEIN-PROTEIN ASSOCIATION; NUCLEAR-MAGNETIC-RESONANCE; GLOBAL FOLD DETERMINATION; ELECTRON-TRANSFER COMPLEX; SITE-DIRECTED SPIN; RELAXATION ENHANCEMENT; YEAST ISO-1-CYTOCHROME-C; BROWNIAN DYNAMICS; CRYSTAL-STRUCTURE; BINDING,ELECTRON TRANSFER; ENCOUNTER STATE; TRANSIENT COMPLEX; SPIN LABEL; PARAMAGNETIC RELAXATION ENHANCEMENT,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,"VOLKOV, AN##WORRALL, JAR##HOLTZMANN, E##UBBINK, M","LEIDEN UNIV, LEIDEN INST CHEM, GORLAEUS LABS, NL-2300 RA LEIDEN, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"ADAM G., 1968, STRUCTURAL CHEM MOL, P198##BATTISTE JL, 2000, BIOCHEMISTRY-US, V39, P5355, DOI 10.1021/BI000060H##BENDALL D. S., 1996, P43##BERGHUIS AM, 1992, J MOL BIOL, V223, P959, DOI 10.1016/0022-2836(92)90255-I##BONAGURA CA, 2003, BIOCHEMISTRY-US, V42, P5600, DOI 10.1021/BI034058C##CAVANAGH J, 1995, PROTEIN NMR SPECTROS, P17##ERMAN JE, 2002, BBA-PROTEIN STRUCT M, V1597, P193, DOI 10.1016/S0167-4838(02)00317-5##GABDOULLINE RR, 2001, J MOL BIOL, V306, P1139, DOI 10.1006/JMBI.2000.4404##GAPONENKO V, 2000, PROTEIN SCI, V9, P302##GILLESPIE JR, 1997, J MOL BIOL, V268, P158, DOI 10.1006/JMBI.1997.0954##GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/BI00234A017##GUEX N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/ELPS.1150181505##GUO ML, 2004, P NATL ACAD SCI USA, V101, P5940, DOI 10.1073/PNAS.0306708101##HELGSTRAND M, 2000, J BIOMOL NMR, V18, P329, DOI 10.1023/A:1026729404698##HOFFMAN BM, 2005, P NATL ACAD SCI USA, V102, P3564, DOI 10.1073/PNAS.0408767102##IWAHARA J, 2006, NATURE, V440, P1227, DOI 10.1038/NATURE04673##IWAHARA J, 2004, J AM CHEM SOC, V126, P12800, DOI 10.1021/JA046246B##IWAHARA J, 2004, J AM CHEM SOC, V126, P5879, DOI 10.1021/JA031580D##JENG MF, 1994, NAT STRUCT BIOL, V1, P234, DOI 10.1038/NSB0494-234##KANG SA, 2005, P NATL ACAD SCI USA, V102, P15465, DOI 10.1073/PNAS.0505176102##KANG SA, 2004, J AM CHEM SOC, V126, P10836, DOI 10.1021/JA049230U##KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399##KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3##MATHEWS FS, 2000, PROTEIN PROTEIN RECO, P60##MAUK MR, 1994, BIOCHEMISTRY-US, V33, P12609, DOI 10.1021/BI00208A011##MCLENDON G, 1993, J AM CHEM SOC, V115, P3665, DOI 10.1021/JA00062A035##MCLENDON G, 1991, STRUCT BOND, V75, P159##MERRITT EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9##MOENCH SJ, 1992, BIOCHEMISTRY-US, V31, P3661, DOI 10.1021/BI00129A015##MOORE GR, 1998, BIOCHEM J, V332, P439, DOI 10.1042/BJ3320439##MORAR AS, 1999, J BIOL INORG CHEM, V4, P220, DOI 10.1007/S007750050307##NOCEK JM, 1996, CHEM REV, V96, P2459, DOI 10.1021/CR9500444##NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/SCIENCE.2838904##PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/SCIENCE.1334573##PIELAK GJ, 2001, BIOCHEMISTRY-US, V40, P422, DOI 10.1021/BI002124U##POLLOCK WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/BI972188D##SCHWIETERS CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9##UBBINK M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5##VOLKOV AN, 2005, PROTEIN SCI, V14, P799, DOI 10.1110/PS.041150205##WANG XM, 1999, BIOCHEMISTRY-US, V38, P16876, DOI 10.1021/BI992005I##WORRALL JAR, 2001, BIOCHEMISTRY-US, V40, P7069, DOI 10.1021/BI0025823##WORRALL JAR, 2002, BIOCHEMISTRY-US, V41, P11721, DOI 10.1021/BI026296Y##YI Q, 1994, BIOCHEMISTRY-US, V33, P12032, DOI 10.1021/BI00206A004##ZHOU JS, 1994, SCIENCE, V265, P1693, DOI 10.1126/SCIENCE.8085152##ZHOU JS, 1995, SCIENCE, V269, P204, DOI 10.1126/SCIENCE.7618081",210,2020-11-20,NA
J,WOS:000242886500149,2006,"NANOIMPRINT LITHOGRAPHY COMBINED WITH DIRECT BONDING: A POSSIBILITY TO CONSTRUCT QUANTUM DOTS, WIRES, AND PLANES IN VERTICAL CASCADE","RELATIVELY CHEAP NANOIMPRINT TECHNOLOGY, DIRECT BONDING, AND MODERN SEMICONDUCTOR TECHNOLOGIES CREATE POSSIBILITIES TO CONSTITUTE SINGLE QUANTUM ELEMENTS: DOTS, WIRES, AND PLANES (WELLS AND BOXES). THESE FUNCTIONAL ELEMENTARY SPECIALITIES CAN BE MADE UP IN VERTICAL CASCADE BY SUBSEQUENT DIRECT BONDING. THIS LETTER PRESENTS THREE EXAMPLES OF THESE POSSIBILITIES. HEREIN THE DOTS AND WIRES, SITUATED IN DEPTH, MAY FINALLY FULFILL A SOURCE/MEMORY INTERPLAY FUNCTION WHILE THE (QUANTUM) PLANE MAY PLAY A DETECTING/TRANSMITTING ROLE. IN THIS SENSE THEY MIGHT REPRESENT A DIGITAL ELEMENTARY CELL AND THAT OF THE SMALLEST ACHIEVABLE LEVEL AS TO A FUNCTIONAL (NOT PER SE TECHNOLOGICAL) LIMIT OF MOORE'S LAW. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",IMPRINT LITHOGRAPHY; TECHNOLOGY; FUTURE,NA,APPLIED PHYSICS LETTERS,"HAISMA, J","PHILIPS RES LABS, NL-5656 AE EINDHOVEN, NETHERLANDS.","PHYSICS, APPLIED",PHYSICS,"BRUEL M, 1997, JPN J APPL PHYS 1, V36, P1636, DOI 10.1143/JJAP.36.1636##BUKOWSKI TJ, 2002, CRIT REV SOLID STATE, V27, P119, DOI 10.1080/10408430208500496##CHAN KK, 2002, PATENT NO. 6365465##CHEN W, 1998, PATENT NO. 5714766##CHOU SY, 1997, MICROELECTRON ENG, V35, P237, DOI 10.1016/S0167-9317(96)00097-4##DAUKSHER WJ, 2006, MICROELECTRON ENG, V83, P929, DOI 10.1016/J.MEE.2006.01.075##HAISMA J, 1996, J VAC SCI TECHNOL B, V14, P4124, DOI 10.1116/1.588604##HAISMA J, 2003, APPL PHYS LETT, V83, P3323, DOI 10.1063/1.1620672##HAISMA J, 2002, MAT SCI ENG R, V37, P1, DOI 10.1016/S0927-796X(02)00003-7##KASTNER MA, 2000, ANN PHYS-BERLIN, V9, P885, DOI 10.1002/1521-3889(200011)9:11/12<885::AID-ANDP885>3.0.CO;2-8##KHAN SM, 2006, PATENT NO. 5687114##LIU HI, 1993, J VAC SCI TECHNOL B, V11, P2532, DOI 10.1116/1.586661##MOORE GE, 1995, P SOC PHOTO-OPT INS, V2438, P2, DOI 10.1117/12.209244##TONG QY, 1999, SEMICONDUCTOR WAFER, P1",3,2020-11-20,NA
J,WOS:000243289400017,2006,MOLASSES AS C SOURCE FOR HETEROTROPHIC BACTERIA PRODUCTION ON SOLID FISH WASTE,"THE DRUMFILTER EFFLUENT FROM A RECIRCULATION AQUACULTURE SYSTEM (RAS) CAN BE USED AS SUBSTRATE FOR HETEROTROPHIC BACTERIA PRODUCTION. THESE BACTERIA CAN BE REUSED AS AQUATIC FEED. IN RAS DRUMFILTER EFFLUENTS ARE ORGANIC CARBON DEFICIENT FOR BACTERIA PRODUCTION. THIS IS DUE TO NITROGEN ACCUMULATION IN THE SYSTEM WATER. IN THE PRESENT EXPERIMENT, A BACTERIA GROWTH REACTOR (3.51) WAS CONNECTED TO THE DRUMFILTER (FILTER MESH SIZE 60 GM) OUTLET OF A RECIRCULATION SYSTEM. TO COUNTERACT CARBON DEFICIENCY, DIFFERENT SUPPLEMENTATION LEVELS OF MOLASSES (ORGANIC CARBON) WERE TESTED (CARBON FLUXES OF 0.0, 3.2, 5.8, 7.8, 9.7 GC MOLASSES/L/D; C:N RATIOS: 3.4, 6.4, 9.4, 13.0 AND 16.5). THE HYDRAULIC RETENTION TIME IN THE BACTERIA REACTOR WAS 6 IT. FOR THE MAXIMUM FLUX, THE VSS AND CRUDE PROTEIN PRODUCTIONS WERE ABOUT 168 GVSS AND 95 G CRUDE PROTEIN PER KG FEED. THE MAXIMUM CONVERSION OF NITRATE AND ORTHO-PHOSPHATE WAS 24 G NO3-N AND 4 GP/KG FEED. THIS EQUALS A CONVERSION OF 90% OF THE INORGANIC NITROGENOUS WASTE AND 98% OF THE ORTHO-PHOSPHATE-P. FURTHERMORE THE MAXIMUM SUBSTRATE REMOVAL RATE AND THE K, FOR MOLASSES WERE DETERMINED (1.62 GC/L/H AND 0.097 GC/L RESPECTIVELY). THE MAXIMUM SPECIFIC REMOVAL RATE WAS 0.31 GC/GVSS/H AND THE RELATED HALF SATURATION CONSTANT WAS 0.008 GC/L. THE OBSERVED GROWTH RATE REACHED A MAXIMUM FOR C FLUXES HIGHER THAN 8 G/L/D. THE PRESENT INTEGRATION OF HETEROTROPHIC BACTERIA PRODUCTION IN RAS REPRESENTS, THEREFORE, AN INNOVATIVE OPTION TO REDUCE WASTE DISCHARGE BY CONVERSION. IF THE BACTERIA ARE REUSED AS FEED, SYSTEM'S ECOLOGICAL SUSTAINABILITY INCREASES. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",EXCHANGE; NITROGEN; CULTURE; BIOMASS; REACTOR; WATER; BIOFILMS; SYSTEMS; STREAMS; PONDS,BACTERIA; FISH WASTE; CONVERSION; NUTRIENTS; MOLASSES,AQUACULTURE,"SCHNEIDER, O##SERETI, V##EDING, EH##VERRETH, JAJ","UNIV WAGENINGEN, AQUACULTURE & FISHERIES GRP, NL-6700 AH WAGENINGEN, NETHERLANDS.",FISHERIES; MARINE & FRESHWATER BIOLOGY,FISHERIES; MARINE & FRESHWATER BIOLOGY,"ATKINSON B, 1991, BIOCH ENG BIOTECHNOL##AULENTA F, 2003, WATER RES, V37, P2764, DOI 10.1016/S0043-1354(03)00059-9##AVNIMELECH Y, 1992, AQUACULT ENG, V11, P157, DOI 10.1016/0144-8609(92)90002-F##AVNIMELECH Y, 1999, AQUACULTURE, V176, P227, DOI 10.1016/S0044-8486(99)00085-X##BERISTAIN B. T., 2005, ORGANIC MATTER DECOMPOSITION IN SIMULATED AQUACULTURE PONDS##BURFORD MA, 2003, AQUACULTURE, V219, P393, DOI 10.1016/S0044-8486(02)00575-6##CABIB G, 1983, J CHEM TECH BIOT B, V33, P21##CLESCERI L, 1998, STANDARD METHODS EXA##CURTIN L, 1993, MOLASSES GEN CONSIDE##FROLUND B, 1996, WATER RES, V30, P1749, DOI 10.1016/0043-1354(95)00323-1##HARI B, 2004, AQUACULTURE, V241, P179, DOI 10.1016/J.AQUACULTURE.2004.07.002##HENZE M, 1996, WASTE WATER TREATMEN##JAHN A, 1998, WATER SCI TECHNOL, V37, P17, DOI 10.1016/S0273-1223(97)00751-8##JIMENEZ AM, 2004, BIOCHEM ENG J, V18, P121, DOI 10.1016/S1369-703X(03)00198-0##KARGI F, 1980, BIOTECHNOL BIOENG, V22, P1567, DOI 10.1002/BIT.260220805##LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P857, DOI 10.1128/AEM.57.3.857-862.1991##LIU F, 2004, AQUACULTURE, V230, P281, DOI 10.1016/J.AQUACULTURE.2003.09.033##MARAZIOTI C, 2003, WATER RES, V37, P1239, DOI 10.1016/S0043-1354(02)00463-3##MCINTOSH D, 2000, AQUACULT ENG, V21, P215, DOI 10.1016/S0144-8609(99)00030-8##NASS, 2005, AGR PRIC 2004 SUMM##POZNANSKI S, 1983, AGR WASTES, V6, P77, DOI 10.1016/0141-4607(83)90060-4##QUAN ZX, 2005, BIORESOURCE TECHNOL, V96, P1690, DOI 10.1016/J.BIORTECH.2004.12.033##RITTMANN B.E., 2001, ENV BIOTECHNOLOGY PR##SCHNEIDER O, 2007, AQUACULT ENG, V36, P24, DOI 10.1016/J.AQUAENG.2006.05.002##SCHNEIDER O, 2006, WATER RES, V40, P2684, DOI 10.1016/J.WATRES.2006.05.008##TCHOBANOGLOUS G., 2003, WASTEWATER ENG TREAT##TIJHUIS L, 1994, BIOTECHNOL BIOENG, V44, P595, DOI 10.1002/BIT.260440506##UGALDE UO, 2002, AGR FOOD PRODUCTION, P360##VANDERWESTHUIZEN TH, 1996, WATER SCI TECHNOL, V33, P31, DOI 10.1016/0273-1223(96)00258-2##VELASCO M, 2000, GLOBAL AQUACULTURE A, V3, P60",31,2020-11-20,NA
J,WOS:000242701600015,2006,MOLECULAR RECOGNITION IN POLY(EPSILON-CAPROLACTONE)-BASED THERMOPLASTIC ELASTOMERS,"THE MOLECULAR RECOGNITION PROPERTIES OF THE HYDROGEN BONDING SEGMENTS IN BIODEGRADABLE THERMOPLASTIC ELASTOMERS WERE EXPLORED, AIMING AT THE FURTHER FUNCTIONALIZATION OF THESE POTENTIALLY INTERESTING BIOMATERIALS. A POLY(EPSILON-CAPROLACTONE)-BASED POLY(UREA) 2 WAS SYNTHESIZED AND CHARACTERIZED IN TERMS OF MECHANICAL PROPERTIES, PROCESSIBILITY AND HISTOCOMPATIBILITY. COMPARISON OF THE DATA WITH THOSE OBTAINED FROM THE STRUCTURALLY RELATED POLY( URETHANE UREA) 1 REVEALED THAT THE DIFFERENCE IN HARD SEGMENT STRUCTURE DOES NOT SIGNIFICANTLY AFFECT THE POTENCY FOR APPLICATION AS A BIOMATERIAL. NEVERTHELESS, THE SMALL DIFFERENCES IN HARD BLOCK COMPOSITION HAD A STRONG EFFECT ON THE MOLECULAR RECOGNITION PROPERTIES OF THE HYDROGEN BONDING SEGMENTS. HIGH SELECTIVITY WAS FOUND FOR POLY(UREA) 2 IN WHICH BISUREIDOBUTYLENE-FUNCTIONALIZED AZOBENZENE DYE 3 WAS SELECTIVELY INCORPORATED WHILE BISUREIDOPENTYLENE-FUNCTIONALIZED AZOBENZENE DYE 4 WAS COMPLETELY RELEASED. IN CONTRAST, THE INCORPORATION OF BOTH DYES IN POLY(URETHANE UREA) 1 LED IN BOTH CASES TO THEIR GRADUAL RELEASE IN TIME. THERMAL ANALYSIS OF THE POLYMERS IN COMBINATION WITH VARIABLE TEMPERATURE INFRARED EXPERIMENTS INDICATED THAT THE HARD BLOCKS IN 1 SHOWED A SHARP MELTING POINT, WHEREAS THOSE IN 2 SHOWED A VERY BROAD MELTING TRAJECTORY. THIS SUGGESTS A MORE PRECISE ORGANIZATION OF THE HYDROGEN BONDING SEGMENTS IN THE HARD BLOCKS OF POLY(UREA) 2 COMPARED TO POLY(URETHANE UREA) 1 AND EXPLAINS THE RESULTS FROM THE MOLECULAR RECOGNITION EXPERIMENTS. PRELIMINARY RESULTS REVEALED THAT A BISUREIDOBUTYLENE-FUNCTIONALIZED GRGDS PEPTIDE SHOWED MORE SUPRAMOLECULAR INTERACTION WITH THE PCL-BASED POLY(UREA), CONTAINING THE BISUREIDOBUTYLENE RECOGNITION UNIT, AS COMPARED TO HMW PCL, LACKING THIS RECOGNITION UNIT.",INFRARED TEMPERATURE; POLYMERS; BLENDS; BULK,NA,BIOMACROMOLECULES,"WISSE, E##SPIERING, AJH##VAN LEEUWEN, ENM##RENKEN, RAE##DANKERS, PYW##BROUWER, LA##VAN LUYN, MJA##HARMSEN, MC##SOMMERDIJK, NAJM##MEIJER, EW","EINDHOVEN UNIV TECHNOL, LAB MACROMOL & ORGAN CHEM, NL-5600 MB EINDHOVEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, MED BIOL SECT, DEPT PATHOL & LAB MED, NL-9713 GZ GRONINGEN, NETHERLANDS.","BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY, ORGANIC; POLYMER SCIENCE",BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY; POLYMER SCIENCE,"BROWN N, 1988, POLYMER, V29, P463, DOI 10.1016/0032-3861(88)90363-1##CAMACHO-ZUNIGA C, 2003, IND ENG CHEM RES, V42, P1530, DOI 10.1021/IE0205389##CHEBOTAREVA N, 2005, CHEM COMMUN, P4967, DOI 10.1039/B507171B##COLEMAN MM, 1988, MACROMOLECULES, V21, P59, DOI 10.1021/MA00179A014##COLEMAN MM, 1997, MACROMOL CHEM PHYSIC, V198, P117, DOI 10.1002/MACP.1997.021980110##COLEMAN MM, 1986, MACROMOLECULES, V19, P2149, DOI 10.1021/MA00162A008##DANKERS PYW, 2005, NAT MATER, V4, P568, DOI 10.1038/NMAT1418##FROMSTEIN JD, 2002, J BIOMAT SCI-POLYM E, V13, P391, DOI 10.1163/156856202320253929##GARRETT JT, 2001, MACROMOLECULES, V34, P7066, DOI 10.1021/MA0102114##GUAN JJ, 2002, J BIOMED MATER RES, V61, P493, DOI 10.1002/JBM.10204##HERSEL U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142-9612(03)00343-0##KOEVOETS RA, 2005, J AM CHEM SOC, V127, P2999, DOI 10.1021/JA0451160##KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0##LI D, 2004, ADV MATER, V16, P1151, DOI 10.1002/ADMA.200400719##MOORE JS, 1990, MACROMOLECULES, V23, P65, DOI 10.1021/MA00203A013##NIKLASON LE, 1999, SCIENCE, V284, P489, DOI 10.1126/SCIENCE.284.5413.489##PARK H, 2005, BIOMATERIALS, V26, P7095, DOI 10.1016/J.BIOMATERIALS.2005.05.083##PARRISH B, 2005, J AM CHEM SOC, V127, P7404, DOI 10.1021/JA050310N##PFAU A, 1999, SURF INTERFACE ANAL, V27, P410, DOI 10.1002/(SICI)1096-9918(199905/06)27:5/6<410::AID-SIA542>3.3.CO;2-5##PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030A0##SHAH JH, 1995, J MED CHEM, V38, P4284, DOI 10.1021/JM00021A018##SHETH JP, 2005, MACROMOLECULES, V38, P5681, DOI 10.1021/MA048222V##SPAANS CJ, 1998, POLYM BULL, V41, P131, DOI 10.1007/S002890050343##TAI NRM, 1999, J VASC SURG, V30, P936, DOI 10.1016/S0741-5214(99)70020-0##THUBRIKAR M., 1990, AORTIC VALVE##VAN ESCH J, 1999, CHEM-EUR J, V5, P937##VOS MRJ, 2005, J AM CHEM SOC, V127, P16768, DOI 10.1021/JA055075N##WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/SCIENCE.2934816##WU W, 2005, LANGMUIR, V21, P9721, DOI 10.1021/LA051130U##YAMAGUCHI N, 2005, BIOMACROMOLECULES, V6, P1921, DOI 10.1021/BM050003+",54,2020-11-20,NA
J,WOS:000242701600017,2006,CO- AND TERPOLYESTERS BASED ON ISOSORBIDE AND SUCCINIC ACID FOR COATING APPLICATIONS: SYNTHESIS AND CHARACTERIZATION,"CO- AND TERPOLYESTERS BASED ON SUCCINIC ACID AND ISOSORBIDE IN COMBINATION WITH OTHER RENEWABLE MONOMERS SUCH AS 2,3-BUTANEDIOL, 1,3-PROPANEDIOL, AND CITRIC ACID WERE SYNTHESIZED AND CHARACTERIZED. LINEAR POLYESTERS WERE OBTAINED VIA MELT POLYCONDENSATION OF NONACTIVATED DICARBOXYLIC ACIDS WITH OH FUNCTIONAL MONOMERS. POLYMER END FUNCTIONALITY (I.E., HYDROXYL OR CARBOXYLIC ACID) WAS CONTROLLED BY ADJUSTING THE MONOMER STOICHIOMETRY. THE GLASS TRANSITION TEMPERATURES OF THE RESULTING POLYESTERS COULD BE EFFECTIVELY ADJUSTED BY VARYING THE POLYMER COMPOSITION AND MOLAR MASS. BY ADDING POLYFUNCTIONAL MONOMERS SUCH AS TRIMETHYLOLPROPANE OR CITRIC ACID, POLYESTERS WITH ENHANCED FUNCTIONALITY WERE OBTAINED. THESE BIOBASED POLYESTERS DISPLAYED FUNCTIONALITIES AND T-G VALUES IN THE APPROPRIATE RANGE FOR (POWDER) COATING APPLICATIONS. THE POLYESTERS WERE CROSS-LINKED USING CONVENTIONAL CURING AGENTS. COATINGS FROM BRANCHED POLYESTERSSHYDROXYL AS WELL AS ACID FUNCTIONALS-SHOWED SIGNIFICANTLY IMPROVED MECHANICAL AND CHEMICAL RESISTANCE COMPARED TO THOSE FORMULATED FROM LINEAR POLYMERS. THESE RENEWABLE POLYESTERS PROVED TO BE SUITABLE MATERIALS FOR COATING APPLICATIONS WITH RESPECT TO SOLVENT RESISTANCE, IMPACT RESISTANCE, AND HARDNESS.","POLYESTERS; ESTERIFICATION; POLY(ETHYLENE-TEREPHTHALATE); 1,4/3,6-DIANHYDRO-D-GLUCITOL; UV",NA,BIOMACROMOLECULES,"NOORDOVER, BAJ##VAN STAALDUINEN, VG##DUCHATEAU, R##KONING, CE##VAN BENTHEM, RATM##MAK, M##HEISE, A##FRISSEN, AE##VAN HAVEREN, J","EINDHOVEN UNIV TECHNOL, POLYMER CHEM LAB, NL-5600 MB EINDHOVEN, NETHERLANDS. EINDHOVEN UNIV TECHNOL, LAB MAT & INTERFACE CHEM, NL-5600 MB EINDHOVEN, NETHERLANDS. DSM RES BV, NL-6160 MD GELEEN, NETHERLANDS. AGROTECHNOL & FOOD INNOVAT, NL-6700 AA WAGENINGEN, NETHERLANDS.","BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY, ORGANIC; POLYMER SCIENCE",BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY; POLYMER SCIENCE,"ABENHAIM D, 1994, CARBOHYD RES, V261, P255, DOI 10.1016/0008-6215(94)84022-9##ALICATA R, 2002, RAPID COMMUN MASS SP, V16, P248, DOI 10.1002/RCM.573##ALLEN NS, 1993, POLYM DEGRAD STABIL, V41, P191, DOI 10.1016/0141-3910(93)90043-I##BENGS H., 2002, US PATENT, PATENT NO. [6342300, 6,342,300 B1]##BRANDENBURG C. J., 2003, US PATENT, PATENT NO. [2,003,204,029, 2003204029]##BRAUN D, 1992, ANGEW MAKROMOL CHEM, V199, P191, DOI 10.1002/APMC.1992.051990115##CARROCCIO S, 2000, RAPID COMMUN MASS SP, V14, P1513, DOI 10.1002/1097-0231(20000830)14:16<1513::AID-RCM57>3.3.CO;2-3##CECUTTI C, 1998, BIORESOURCE TECHNOL, V66, P63, DOI 10.1016/S0960-8524(97)00082-5##COGNETGEORJON E, 1996, MACROMOL CHEM PHYSIC, V197, P3593, DOI 10.1002/MACP.1996.021971109##COURTAULDS LTD, 1964, PATENT NO. 6405497##DECKER C, 1991, J POLYM SCI POL CHEM, V29, P739, DOI 10.1002/POLA.1991.080290516##DEVAUX J, 1982, POLYM ENG SCI, V22, P229, DOI 10.1002/PEN.760220403##FOX TG, 1950, J APPL PHYS, V21, P581, DOI 10.1063/1.1699711##HULT A, 1984, POLYM DEGRAD STABIL, V8, P75, DOI 10.1016/0141-3910(84)90087-9##KAMOUN W, 2005, E-POLYMERS, P1##KHANARIAN G, 1999, PATENT NO. 5958581##KOUTINAS AA, 2004, IND CROP PROD, V20, P75, DOI 10.1016/J.INDCROP.2003.12.013##KRICHELDORF HR, 1997, J MACROMOL SCI R M C, VC37, P599, DOI 10.1080/15321799708009650##KRICHELDORF HR, 2001, PATENT NO. 6291629##LIMOUSIN C, 1998, TETRAHEDRON, V54, P13567, DOI 10.1016/S0040-4020(98)00834-5##LUDA MP, 2000, EUR COAT J, V10, P74##MAJDOUB M, 1994, EUR POLYM J, V30, P1431, DOI 10.1016/0014-3057(94)90274-7##MISEV T. A., 1991, POWDER COATINGS CHEM##MISEV TA, 1998, PROG ORG COAT, V34, P160, DOI 10.1016/S0300-9440(98)00029-0##MORRISON JG, 1962, PATENT NO. 3041300##OKADA M, 2002, PROG POLYM SCI, V27, P87, DOI 10.1016/S0079-6700(01)00039-9##OKADA M, 1995, J POLYM SCI POL CHEM, V33, P2813, DOI 10.1002/POLA.1995.080331615##OTTON J, 1988, J POLYM SCI POL CHEM, V26, P2183, DOI 10.1002/POLA.1988.080260815##SHEKHAWAT D, 2002, APPL CATAL A-GEN, V223, P261, DOI 10.1016/S0926-860X(01)00762-1##SMITH WA, 1981, J APPL POLYM SCI, V26, P4233, DOI 10.1002/APP.1981.070261223##STORBECK R, 1996, J APPL POLYM SCI, V59, P1199, DOI 10.1002/(SICI)1097-4628(19960214)59:7<1199::AID-APP19>3.0.CO;2-0##VAN DAM JEG, 2005, IND CROP PROD, V21, P129, DOI 10.1016/J.INDCROP.2004.02.003##WILLIAMS JB, 1997, MACROMOLECULES, V30, P3781, DOI 10.1021/MA970123C",148,2020-11-20,NA
J,WOS:000242701600027,2006,STRONG IMPACT OF IONIC STRENGTH ON THE KINETICS OF FIBRILAR AGGREGATION OF BOVINE BETA-LACTOGLOBULIN,"WE INVESTIGATE THE EFFECT OF IONIC STRENGTH ON THE KINETICS OF HEAT-INDUCED FIBRILAR AGGREGATION OF BOVINE BETA-LACTOGLOBULIN AT PH 2.0. USING IN SITU LIGHT SCATTERING WE FIND AN APPARENT CRITICAL PROTEIN CONCENTRATION BELOW WHICH THERE IS NO SIGNIFICANT FIBRIL FORMATION FOR ALL IONIC STRENGTHS STUDIED. THIS IS AN INDEPENDENT CONFIRMATION OF OUR PREVIOUS OBSERVATION OF AN APPARENT CRITICAL CONCENTRATION FOR 13 MM IONIC STRENGTH BY PROTON NMR SPECTROSCOPY. IT IS ALSO THE FIRST REPORT OF SUCH A CRITICAL CONCENTRATION FOR THE HIGHER IONIC STRENGTHS. THE CRITICAL CONCENTRATION DECREASES WITH INCREASING IONIC STRENGTH. BELOW THE CRITICAL CONCENTRATION MAINLY ""DEAD-END"" SPECIES THAT CANNOT AGGREGATE ANYMORE ARE FORMED. WE PROVE THAT FOR THE LOWEST IONIC STRENGTH THIS SPECIES CONSISTS OF IRREVERSIBLY DENATURED PROTEIN. ATOMIC FORCE MICROSCOPY STUDIES OF THE MORPHOLOGY OF THE FIBRILS FORMED AT DIFFERENT IONIC STRENGTHS SHOW SHORTER AND CURVIER FIBRILS AT HIGHER IONIC STRENGTH. THE FIBRIL LENGTH DISTRIBUTION CHANGES NON-MONOTONICALLY WITH INCREASING IONIC STRENGTH. AT ALL IONIC STRENGTHS STUDIED, THE FIBRILS HAD SIMILAR THICKNESSES OF ABOUT 3.5 NM AND A PERIODIC STRUCTURE WITH A PERIOD OF ABOUT 25 NM.",HEAT-INDUCED GELATION; ATOMIC-FORCE MICROSCOPY; GLOBULAR-PROTEINS; INDUCED DENATURATION; LIGHT-SCATTERING; GELS; PH; TEMPERATURE; GROWTH; MODEL,NA,BIOMACROMOLECULES,"ARNAUDOV, LN##DE VRIES, R","WAGENINGEN UNIV, LAB PHYS CHEM & COLLOID SCI, NL-6700 EK WAGENINGEN, NETHERLANDS. WAGENINGEN UNIV, FOOD PHYS GRP, NL-6703 HD WAGENINGEN, NETHERLANDS.","BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY, ORGANIC; POLYMER SCIENCE",BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY; POLYMER SCIENCE,"ARNAUDOV LN, 2005, BIOPHYS J, V88, P515, DOI 10.1529/BIOPHYSJ.104.048819##ARNAUDOV LN, 2003, BIOMACROMOLECULES, V4, P1614, DOI 10.1021/BM034096B##ARNAUDOV LN, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2171418##AYMARD P, 1996, INT J BIOL MACROMOL, V19, P213, DOI 10.1016/0141-8130(96)01130-0##AYMARD P, 1999, MACROMOLECULES, V32, P2542, DOI 10.1021/MA981689J##BERNE B.J., 2000, DYNAMIC LIGHT SCATTE##CHAMBERLAIN AK, 2000, BIOPHYS J, V79, P3282, DOI 10.1016/S0006-3495(00)76560-X##DOBSON CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/RSTB.2000.0758##FERRONE F, 1999, METHOD ENZYMOL, V309, P256##GIMEL JC, 1994, MACROMOLECULES, V27, P583, DOI 10.1021/MA00080A037##GOSAL WS, 2002, LANGMUIR, V18, P7174, DOI 10.1021/LA025531A##HAMADA D, 2002, PROTEIN SCI, V11, P2417, DOI 10.1110/PS.0217702##HARWALKAR VR, 1985, MILCHWISSENSCHAFT, V40, P665##HOFFMANN MAM, 1999, J AGR FOOD CHEM, V47, P1898, DOI 10.1021/JF980886E##HOFFMANN MAM, 1996, J DAIRY RES, V63, P423, DOI 10.1017/S0022029900031939##HOFFMANN MAM, 1997, J AGR FOOD CHEM, V45, P2942, DOI 10.1021/JF960789Q##IKEDA S, 2002, BIOMACROMOLECULES, V3, P382, DOI 10.1021/BM0156429##IKEDA S, 2003, SPECTROSC-INT J, V17, P195, DOI 10.1155/2003/920321##KAVANAGH GM, 2000, INT J BIOL MACROMOL, V28, P41, DOI 10.1016/S0141-8130(00)00144-6##KAVANAGH GM, 2000, LANGMUIR, V16, P9584, DOI 10.1021/LA0004698##KOIKE A, 1996, POLYMER, V37, P587, DOI 10.1016/0032-3861(96)83145-4##LANGTON M, 1992, FOOD HYDROCOLLOID, V5, P523, DOI 10.1016/S0268-005X(09)80122-7##LE BON C, 1999, MACROMOLECULES, V32, P6120, DOI 10.1021/MA9905775##LE BON C, 1999, INT J FOOD SCI TECH, V34, P451, DOI 10.1046/J.1365-2621.1999.00310.X##LEFEBVRE J, 1998, RHEOL ACTA, V37, P345, DOI 10.1007/S003970050121##LEFEVRE T, 2000, BIOPOLYMERS, V54, P578, DOI 10.1002/1097-0282(200012)54:7<578::AID-BIP100>3.0.CO;2-2##LOMAKIN A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/PNAS.93.3.1125##OOSAWA F., 1975, THERMODYNAMICS POLYM##POUZOT M, 2005, FOOD HYDROCOLLOID, V19, P231, DOI 10.1016/J.FOODHYD.2004.06.003##RENARD D, 1992, INT J BIOL MACROMOL, V14, P287, DOI 10.1016/S0141-8130(05)80042-X##SCHOKKER EP, 2000, INT DAIRY J, V10, P233, DOI 10.1016/S0958-6946(00)00047-9##TOBITANI A, 1997, MACROMOLECULES, V30, P4855, DOI 10.1021/MA970113B##TOBITANI A, 1997, MACROMOLECULES, V30, P4845, DOI 10.1021/MA970112J##VEERMAN C, 2002, BIOMACROMOLECULES, V3, P869, DOI 10.1021/BM025533+##VERHEUL M, 1998, J AGR FOOD CHEM, V46, P896, DOI 10.1021/JF970751T##VERHEUL M, 1999, BIOPOLYMERS, V49, P11, DOI 10.1002/(SICI)1097-0282(199901)49:1<11::AID-BIP2>3.3.CO;2-T##WONG DWS, 1996, CRIT REV FOOD SCI, V36, P807, DOI 10.1080/10408399609527751",54,2020-11-20,NA
J,WOS:000242933000001,2006,ABNORMAL SUSCEPTIBILITY TO DISTRACTERS HINDERS PERCEPTION IN EARLY STAGE PARKINSON'S DISEASE: A CONTROLLED STUDY,"BACKGROUND: ONE OF THE PERCEPTUAL ABNORMALITIES OBSERVED IN PARKINSON'S DISEASE (PD) IS A DEFICIT IN THE SUPPRESSION OF REFLEXIVE SACCADES THAT ARE AUTOMATICALLY TRIGGERED BY THE ONSET OF A PERIPHERAL TARGET. IMPAIRMENT OF SUBSTANTIA NIGRA FUNCTION IS THOUGHT TO LEAD TO THIS REDUCED ABILITY TO SUPPRESS REFLEXIVE SACCADES. METHODS: THE PRESENT STUDY EXAMINED WHETHER THIS PERCEPTUAL DEFICIT IS ALSO PRESENT IN EARLY STAGE PD WHEN USING HARDLY NOTICEABLE TASK-IRRELEVANT STIMULI. ELEVEN NON-DEMENTED DE NOVO, UNTREATED PD PATIENTS ( MEAN AGE 57 YR, RANGE 44 - 70) PARTICIPATED IN THE STUDY AS WELL AS 12 AGE-MATCHED CONTROLS. PERFORMANCE ON AN 'OCULOMOTOR CAPTURE' TASK, IN WHICH IN HALF OF THE TRIALS AN IRRELEVANT STIMULUS WITH SUDDEN ONSET WAS ADDED TO THE DISPLAY, WAS COMPARED BETWEEN PATIENTS AND CONTROLS. ANALYSIS OF VARIANCE ( ANOVA) WAS PERFORMED WITH GROUP (PATIENTS/CONTROLS) AND AGE (< 61 YRS/>= 61 YRS) AS INDEPENDENT FACTORS AND TYPE OF TRIAL (CONTROL/DISTRACTER) AS REPEATED MEASUREMENTS FACTOR. THE FACTOR SEX WAS USED AS COVARIATE. RESULTS: WITH RESPECT TO REACTION TIME (RT), A SIGNIFICANT INTERACTION BETWEEN GROUP AND CONDITION WAS FOUND. RTS INCREASED UNDER THE 'IRRELEVANT STIMULUS' CONDITION IN BOTH GROUPS, THE PATIENTS EXHIBITING A SIGNIFICANTLY LARGER INCREASE IN RTS THAN THE CONTROL GROUP. ALSO, A SIGNIFICANT INTERACTION EFFECT BETWEEN GROUP AND CONDITION FOR NUMBER OF CORRECT RESPONSES WAS FOUND. THE NUMBER OF CORRECT RESPONSES WAS REDUCED IN THE ONSET DISTRACTER CONDITION, THE REDUCTION BEING LARGER IN THE PATIENTS. IN THE PATIENT GROUP, CONTRARY TO THE CONTROL GROUP, A HIGHER AGE WAS ASSOCIATED WITH FEWER CORRECT RESPONSES AT BASELINE AND IN THE ONSET DISTRACTER CONDITION, SUGGESTING THAT PERCEPTUAL FUNCTIONS IN PD ARE HIGHLY SUSCEPTIBLE TO THE EFFECTS OF AGEING. THE INCREASED REACTION TIMES AND LARGER NUMBER OF INCORRECT RESPONSES OF THE PD PATIENTS IN THE ONSET DISTRACTER CONDITION MAY BE RELATED TO IMPAIRMENTS OF SUBSTANTIA NIGRA FUNCTION AND LOWER BRAIN STEM. CONCLUSION: THE CAPTURE TASK SEEMS TO BE A SENSITIVE INSTRUMENT TO DETECT EARLY PERCEPTUAL DEFICITS IN PD. THE MAGNITUDE OF THE OBSERVED DEFICITS SUGGESTS THAT PERCEPTUAL FUNCTIONS IN EARLY STAGE PD ARE SO SUBSTANTIALLY IMPAIRED THAT THIS MAY INTERFERE WITH DAILY ACTIVITIES.",EYE-MOVEMENT CONTROL; SUPERIOR COLLICULUS; SACCADES; DOPAMINE; DEPLETION; FIXATION; DEFICITS; CORTEX,NA,BMC NEUROLOGY,"DEIJEN, JB##STOFFERS, D##BERENDSE, HW##WOLTERS, EC##THEEUWES, J","VRIJE UNIV AMSTERDAM, DEPT CLIN NEUROPSYCHOL, NL-1081 BT AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM MED CTR, DEPT NEUROL, INST CLIN & EXPT NEUROSCI, NL-1007 MB AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, DEPT COGNIT PSYCHOL, NL-1081 BT AMSTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"ALEXANDER GE, 1994, J CLIN NEUROPHYSIOL, V11, P420, DOI 10.1097/00004691-199407000-00004##BASSO MA, 1996, J NEUROSCI, V16, P7308, DOI 10.1523/JNEUROSCI.16-22-07308.1996##BODIS-WOLLNER I G, 1999, ADV NEUROL, V80, P383##BRONSTEIN AM, 1985, BRAIN, V108, P925, DOI 10.1093/BRAIN/108.4.925##*CENTR BUR STAT, 2000, SAND OND SOI 1978 AF##CHAN F, 2005, NEUROPSYCHOLOGIA, V43, P784, DOI 10.1016/J.NEUROPSYCHOLOGIA.2004.06.026##CRAWFORD TJ, 1989, BRAIN, V112, P1573, DOI 10.1093/BRAIN/112.6.1573##DEL TREDICI K, 2002, J NEUROPATH EXP NEUR, V61, P413, DOI 10.1093/JNEN/61.5.413##DENG S. Y., 1986, ADAPTIVE PROCESSES V, P201##DJAMGOZ MBA, 1997, VISION RES, V37, P3509, DOI 10.1016/S0042-6989(97)00129-6##FLOWERS KA, 1995, PERCEPTION, V24, P1201, DOI 10.1068/P241201##GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/JNNP.51.6.745##GODIJN R, 2002, J EXP PSYCHOL HUMAN, V28, P1039, DOI 10.1037//0096-1523.28.5.1039##KATO M, 1995, J NEUROSCI, V15, P912##KEMPS E, 2005, PARKINSONISM RELAT D, V11, P181, DOI 10.1016/J.PARKRELDIS.2004.10.010##KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402##KITAGAWA M, 1994, NEUROLOGY, V44, P2285, DOI 10.1212/WNL.44.12.2285##KRAMER AF, 2000, PSYCHOL SCI, V11, P210, DOI 10.1111/1467-9280.00243##LEVY G, 2005, ARCH NEUROL-CHICAGO, V62, P467, DOI 10.1001/ARCHNEUR.62.3.467##MESTRE DR, 1996, ADV NEUROL, V69, P503##MIYATA Y, 1998, NIHON RONEN IGAKKAI ZASSHI, V35, P464##MUNOZ DP, 1992, J NEUROPHYSIOL, V67, P1000##MUNOZ DP, 1993, J NEUROPHYSIOL, V70, P576##NAKAMURA T, 1994, BRAIN, V117, P1423, DOI 10.1093/BRAIN/117.6.1423##NETTER FH, 1996, CIBA COLLECTION MED, V1, P173##PIERROT-DESEILLIGNY C, 2004, CURR OPIN NEUROL, V17, P17, DOI 10.1097/00019052-200402000-00005##RASCOL O, 1989, BRAIN, V112, P1193, DOI 10.1093/BRAIN/112.5.1193##SCHALL JD, 1995, J NEUROSCI, V15, P4464##THEEUWES J, 1998, PSYCHOL SCI, V9, P379, DOI 10.1111/1467-9280.00071##TYCHSEN L, 1989, ANN NEUROL, V25, P444, DOI 10.1002/ANA.410250505##VENTRE J, 1992, BRAIN, V115, P1147, DOI 10.1093/BRAIN/115.4.1147##WINK B, 2000, VISION RES, V40, P1937, DOI 10.1016/S0042-6989(00)00036-5",14,2020-11-20,NA
J,WOS:000243233400022,2006,NI 3S-HOLE STATES IN NIO BY NON-ORTHOGONAL CONFIGURATION INTERACTION,"THE ORIGIN OF THE FEATURES IN THE NI 3S X-RAY PHOTOELECTRON SPECTRUM OF NIO IS INVESTIGATED USING A NON-ORTHOGONAL CONFIGURATION INTERACTION APPROACH FOR AN EMBEDDED [NIO6] CLUSTER. WE STUDY THE INTERPLAY OF INTER-ATOMIC SCREENING WITH THE METAL CORE HOLE AND INTRA-ATOMIC EXCHANGE AND ELECTRON CORRELATION EFFECTS. WE SHOW THAT THE SPECTRUM CAN BE DESCRIBED IN TERMS OF ONLY FEW KEY CONFIGURATIONS, PROVIDED THAT ORBITAL RELAXATION EFFECTS ARE EXPLICITLY TAKEN INTO ACCOUNT FOR THE EXCITED CHARGE TRANSFER CONFIGURATIONS. THE STRENGTH OF THIS APPROACH HAS BEEN DEMONSTRATED EARLIER FOR THOSE FINAL STATES THAT HAVE A HIGH-SPIN COUPLING. IN THE PRESENT CONTRIBUTION THE ANALYSIS IS EXTENDED TO INCLUDE LOW-SPIN COUPLED 3S-HOLE STATES. THE EFFECTS OF ENLARGING THE EMBEDDED CLUSTER AND OF AN IMPROVED REPRESENTATION OF THE NEAREST CLUSTER SURROUNDINGS WERE STUDIED FOR THE HIGH-SPIN FINAL STATES. WE FOUND ONLY MINOR EFFECTS ON THE COMPUTED PEAK SEPARATIONS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",ELECTRON BINDING ENERGIES; MOLECULAR WAVE-FUNCTIONS; BROKEN ORBITAL-SYMMETRY; TRANSITION-METAL IONS; 1S HOLE STATES; ANO BASIS-SETS; PHOTOELECTRON-SPECTRA; BAND-GAP; PHOTOEMISSION; CRYSTALS,NON-ORTHOGONAL CI; X-RAY PHOTOELECTRON SPECTROSCOPY; NIO,CHEMICAL PHYSICS,"HOZOI, L##DE VRIES, AH##BROER, R##DE GRAAF, C##BAGUS, PS","UNIV ROVIRA & VIRGILI, DEPT PHYS & INORGAN CHEM, TARRAGONA 43007, SPAIN. UNIV GRONINGEN, CTR MAT SCI, NL-9747 AG GRONINGEN, NETHERLANDS. UNIV N TEXAS, DEPT CHEM, DENTON, TX 76203 USA.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"ABERG T, 1967, PHYS REV, V156, P35, DOI 10.1103/PHYSREV.156.35##ANDERSSON K, 2002, MOLCAS VERSION 5 4##BAGUS PS, 2000, PHYS REV LETT, V84, P2259, DOI 10.1103/PHYSREVLETT.84.2259##BAGUS PS, 1993, CHEM PHYS LETT, V207, P569, DOI 10.1016/0009-2614(93)89049-N##BAGUS PS, 1973, PHYS REV LETT, V30, P850, DOI 10.1103/PHYSREVLETT.30.850##BAGUS PS, 2004, CHEM PHYS LETT, V394, P150, DOI 10.1016/J.CPLETT.2004.06.120##BAGUS PS, 1972, J CHEM PHYS, V56, P224, DOI 10.1063/1.1676850##BAGUS PS, 1999, J ELECTRON SPECTROSC, V98, P303, DOI 10.1016/S0368-2048(98)00295-3##BAGUS PS, 1996, CHEM PHYS LETT, V251, P90, DOI 10.1016/0009-2614(96)00070-X##BARANDIARAN Z, 1988, J CHEM PHYS, V89, P5739, DOI 10.1063/1.455549##BARR TL, 1994, MODERN ESCA PRINCIPL##BROER R, 1988, THEOR CHIM ACTA, V73, P405, DOI 10.1007/BF00527744##BROER R, 1981, CHEM PHYS, V54, P291, DOI 10.1016/0301-0104(81)85107-5##BROER R, 1981, GNOME##BROER R, 1991, REV SOLID STATE SCI, V5, P79##BROUGHTON JQ, 1987, PHYS REV B, V36, P2813, DOI 10.1103/PHYSREVB.36.2813##DE GRAAF C, 1999, J MOL STRUC-THEOCHEM, V458, P53##DE VRIES AH, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.035108##DEGRAAF C, 1997, CHEM PHYS LETT, V272, P341, DOI 10.1016/S0009-2614(97)00508-3##EVJEN HM, 1932, PHYS REV, V39, P675, DOI 10.1103/PHYSREV.39.675##FADLEY CS, 1969, PHYS REV LETT, V23, P1397, DOI 10.1103/PHYSREVLETT.23.1397##FREUND HJ, 1996, REP PROG PHYS, V59, P283, DOI 10.1088/0034-4885/59/3/001##GELEIJNS M, 1999, SURF SCI, V421, P106, DOI 10.1016/S0039-6028(98)00835-8##JANSSEN GJM, 1988, PHYS REV B, V38, P3449, DOI 10.1103/PHYSREVB.38.3449##JANSSEN GJM, 1988, INT J QUANTUM CHEM, P679##LOWDIN PO, 1955, PHYS REV, V97, P1474, DOI 10.1103/PHYSREV.97.1474##MALMQVIST PA, 1989, CHEM PHYS LETT, V155, P189, DOI 10.1016/0009-2614(89)85347-3##MCKAY JM, 1984, PHYS REV LETT, V53, P2343, DOI 10.1103/PHYSREVLETT.53.2343##PASCUAL JL, 1993, J CHEM PHYS, V98, P9715, DOI 10.1063/1.464350##POUAMERIGO R, 1995, THEOR CHIM ACTA, V92, P149, DOI 10.1007/S002140050119##SANGALETTI L, 1995, CHEM PHYS LETT, V245, P463, DOI 10.1016/0009-2614(95)01011-W##SAWATZKY GA, 1984, PHYS REV LETT, V53, P2339, DOI 10.1103/PHYSREVLETT.53.2339##SEIJO L, 1993, J CHEM PHYS, V98, P4041, DOI 10.1063/1.464034##SNYDER LC, 1971, J CHEM PHYS, V55, P95, DOI 10.1063/1.1675565##VANDERVELDE GA, 1974, SYMOL##VEAL BW, 1983, PHYS REV LETT, V51, P1995, DOI 10.1103/PHYSREVLETT.51.1995##VIINIKKA EK, 1975, PHYS REV B, V11, P4168, DOI 10.1103/PHYSREVB.11.4168##WIDMARK PO, 1990, THEOR CHIM ACTA, V77, P291, DOI 10.1007/BF01120130##WYCKOFF RWG, 1963, CRYSTAL STRUCTURE, V1",9,2020-11-20,NA
J,WOS:000243067000011,2006,FREE CARRIER PHOTOGENERATION IN POLYTHIOPHENE VERSUS POLY(PHENYLENE VINYLENE) STUDIED WITH THZ SPECTROSCOPY,"USING THZ TIME DOMAIN SPECTROSCOPY, WE INVESTIGATE ULTRAFAST PHOTOCONDUCTIVITY IN TWO CONJUGATED POLYMERS, DERIVATIVES OF POLY(PHENYLENE VINYLENE) (MEH-PPV) AND POLYTHIOPHENE (RR-P3HT), TO INVESTIGATE FREE CHARGE CARRIER DYNAMICS. WE FIND THAT THE ULTRAFAST PHOTO-CONDUCTIVITY DUE TO FREE CHARGES IS LARGER IN THE RR-P3HT THAN IN THE MEH-PPV SAMPLE. THESE CHARGES ARE LONG-LIVED, REMAINING MOBILE FOR SEVERAL NANOSECONDS, IN CONTRAST TO THE PICOSECOND DECAY OF FREE CHARGES IN MEH-PPV. BY COMPARING OUR MEASURED CONDUCTIVITIES TO CHARGE MOBILITIES INFERRED FROM MICROWAVE ABSORPTION MEASUREMENTS, WE MAKE ESTIMATES FOR THE FREE CARRIER QUANTUM YIELDS. (C) 2006 PUBLISHED BY ELSEVIER B.V.",CONJUGATED POLYMER-CHAINS; CHARGE-TRANSPORT; MOLECULAR MATERIALS; PHOTOLUMINESCENCE; PHOTOCONDUCTIVITY; SEMICONDUCTORS; KINETICS,NA,CHEMICAL PHYSICS LETTERS,"HENDRY, E##KOEBERG, M##SCHINS, JM##SIEBBELES, LDA##BONN, M","FOM, INST ATOM & MOL PHYS, NL-1098 SJ AMSTERDAM, NETHERLANDS. UNIV EXETER, SCH PHYS, ELECTROMAGNET MAT GRP, EXETER EX4 4QL, DEVON, ENGLAND. DELFT UNIV TECHNOL, FAC SCI APPL, DELFCHEMTECH, NL-2628 BL DELFT, NETHERLANDS.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"ARKHIPOV VI, 1999, PHYS REV LETT, V82, P1321, DOI 10.1103/PHYSREVLETT.82.1321##BARBARELLA G, 2005, ADV MATER, V17, P1581, DOI 10.1002/ADMA.200402020##BARBEC C, 2003, ORGANIC PHOTOVOLTAIC##BASCO DM, 2002, PHYS REV B, V66, P5210##BEARD MC, 2002, J PHYS CHEM B, V106, P7146, DOI 10.1021/JP020579I##BLYTHE T., 2002, ELECT PROPERTIES POL##BROWN PJ, 2001, PHYS REV B, V63, DOI 10.1103/PHYSREVB.63.125204##CHUA LL, 2005, NATURE, V434, P194, DOI 10.1038/NATURE03376##DICKER G, 2004, J PHYS CHEM B, V108, P17818, DOI 10.1021/JP046853L##DICKER G, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.045203##FRIEND RH, 1999, NATURE, V397, P121, DOI 10.1038/16393##GELINCK GH, 1997, CHEM PHYS LETT, V277, P361, DOI 10.1016/S0009-2614(97)00909-3##GROZEMA FC, 2002, J PHYS CHEM B, V106, P7791, DOI 10.1021/JP021114V##HADZIIOANNOU G, 2000, SEMICONDUCTING POLYM##HAYES GR, 1995, PHYS REV B, V52, P11569, DOI 10.1103/PHYSREVB.52.R11569##HENDRY E, 2005, PHYS REV B, V71, DOI 10.1103/PHYSREVB.71.125201##HENDRY E, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.196601##HOOFMAN RJOM, 1998, NATURE, V392, P54, DOI 10.1038/32118##KOHLER A, 1998, NATURE, V392, P903, DOI 10.1038/31901##MOSES D, 1996, PHYS REV B, V54, P4748, DOI 10.1103/PHYSREVB.54.4748##PRINS P, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.045204##PRINS P, 2006, J PHYS CHEM B, V110, P14659, DOI 10.1021/JP0626115##REDDINGER JL, 1999, ADV POLYM SCI, V145, P57##SCHWARTZ BJ, 2003, ANNU REV PHYS CHEM, V54, P141, DOI 10.1146/ANNUREV.PHYSCHEM.54.011002.103811##SILVA C, 2001, PHYS REV B, V64, DOI 10.1103/PHYSREVB.64.125211##TAN CH, 2002, ORG ELECTRON, V3, P81, DOI 10.1016/S1566-1199(02)00037-X##TANASE C, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.216601##TESSLER N, 1996, NATURE, V382, P695, DOI 10.1038/382695A0##VAN DER HORST JW, 2001, CHEM PHYS LETT, V334, P303, DOI 10.1016/S0009-2614(00)01476-7##WARMAN JM, 2002, J PHYS-CONDENS MAT, V14, P9935, DOI 10.1088/0953-8984/14/42/308##WARMAN JM, 1997, P SOC PHOTO-OPT INS, V3145, P142, DOI 10.1117/12.279275",40,2020-11-20,NA
J,WOS:000244334000023,2006,FIRST PRINCIPLES AND EXPERIMENTAL H-1 NMR SIGNATURES OF SOLVATED IONS: THE CASE OF HCI(AQ),"A COMBINED EXPERIMENTAL AND AB INITIO STUDY IS PRESENTED OF THE H-1 NMR CHEMICAL SHIFT DISTRIBUTION OF AQUEOUS HYDROGEN CHLORIDE SOLUTION AS A FUNCTION OF ACID CONCENTRATION, BASED ON CAR-PARRINELLO MOLECULAR DYNAMICS SIMULATIONS AND FULLY PERIODIC NMR CHEMICAL-SHIFT CALCULATIONS. THE AGREEMENT OF COMPUTED AND EXPERIMENTAL SPECTRA IS VERY GOOD. FROM FIRST-PRINCIPLES CALCULATIONS, WE CAN SHOW THAT THE INDIVDUAL CONTRIBUTIONS OF EIGEN AND ZUNDEL IONS, REGULAR WATER MOLECULES, AND THE CHLORINE SALVATION SHELL TO THE NMR LINE ARE VERY DISTINCT AND ALMOST INDEPENDENT OF THE ACID CONCENTRATION. FROM THE COMPUTED INSTANTANEOUS NMR DISTRIBUTIONS, IT IS FURTHER POSSIBLE TO CHARACTERIZE THE AVERAGE VARIATION IN HYDROGEN-BOND STRENGTH OF THE DIFFERENT COMPLEXES.",INITIO MOLECULAR-DYNAMICS; NMR CHEMICAL-SHIFTS; HYDROGEN-BOND NETWORK; SPACE GAUSSIAN PSEUDOPOTENTIALS; DENSITY-FUNCTIONAL THEORY; LIQUID WATER; AB-INITIO; TEMPERATURE-DEPENDENCE; INFRARED-SPECTRUM; QUANTUM NATURE,AB INITIO CALCULATIONS; HYDROCHLORIC ACID; MOLECULAR DYNAMICS; NMIR SPECTROSCOPY; SOLVATION,CHEMPHYSCHEM,"MURAKHTINA, T##HEUFT, J##MEIJER, EJ##SEBASTIANI, D","MAX PLANCK INST POLYMER RES, D-55128 MAINZ, GERMANY. UNIV AMSTERDAM, VANT HOFF INST MOL SCI, NL-1018 WV AMSTERDAM, NETHERLANDS.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PHYSREVA.38.3098##BOERO M, 2005, CHEMPHYSCHEM, V6, P1775, DOI 10.1002/CPHC.200400572##BUHL M, 1999, J COMPUT CHEM, V20, P91##COLTHUP N.B., 1975, INTRO INFRARED RAMAN##FENN MD, 1984, J PHYS CHEM-US, V88, P3993, DOI 10.1021/J150662A026##GAIGEOT MP, 2003, J PHYS CHEM B, V107, P10344, DOI 10.1021/JP034788U##GERVAIS C, 2005, J PHYS CHEM A, V109, P6960, DOI 10.1021/JP0513925##GOEDECKER S, 1996, PHYS REV B, V54, P1703, DOI 10.1103/PHYSREVB.54.1703##GOWARD GR, 2003, J AM CHEM SOC, V125, P5792, DOI 10.1021/JA029059R##GREGOR T, 1999, J CHEM PHYS, V111, P1815, DOI 10.1063/1.479451##GROSSMAN JC, 2004, J CHEM PHYS, V120, P300, DOI 10.1063/1.1630560##HARTWIGSEN C, 1998, PHYS REV B, V58, P3641, DOI 10.1103/PHYSREVB.58.3641##HENDERSON MA, 2002, SURF SCI REP, V46, P1, DOI 10.1016/S0167-5729(01)00020-6##HETENYI B, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2171966##HETENYI B, 2004, J CHEM PHYS, V120, P8632, DOI 10.1063/1.1703526##HEUFT JM, 2006, PHYS CHEM CHEM PHYS, V8, P3116, DOI 10.1039/B603059A##HUTTER J, 2005, CHEMPHYSCHEM, V6, P1788, DOI 10.1002/CPHC.200500059##HUTTER J, 1990, COMPUTER CODE CPMD V##JAMESON CJ, 2004, NUCL MAGN RESON, V33, P47##KAUPP M, 2004, CALCULATIONS NMR EPR##KLEIN RA, 2004, J PHYS CHEM A, V108, P5851, DOI 10.1021/JP0487408##KUO IFW, 2004, J PHYS CHEM B, V108, P12990, DOI 10.1021/JP047788I##LAASONEN K, 1993, J CHEM PHYS, V99, P9080, DOI 10.1063/1.465574##LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PHYSREVB.37.785##LIGHTSTONE FC, 2005, CHEMPHYSCHEM, V6, P1745, DOI 10.1002/CPHC.200500053##LUDWIG R, 2003, ANGEW CHEM INT EDIT, V42, P3458, DOI 10.1002/ANIE.200301658##MURAKHTINA T, 2006, CHEMPHYSCHEM, V7, P1215, DOI 10.1002/CPHC.200500642##NILSSON A, 2005, SCIENCE, V308, P793A, DOI 10.1126/SCIENCE.1108864##PFROMMER BG, 2000, J AM CHEM SOC, V122, P123, DOI 10.1021/JA991961K##PINES E, 2004, CHEMPHYSCHEM, V5, P1315, DOI 10.1002/CPHC.200301004##PUTRINO A, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.176401##RAUGEI S, 2004, CHEMPHYSCHEM, V5, P1569, DOI 10.1002/CPHC.200400198##RAUGEI S, 2002, J CHEM PHYS, V116, P196, DOI 10.1063/1.1421366##ROSSANO S, 2005, J PHYS CHEM B, V109, P7245, DOI 10.1021/JP044251W##SCHMIDT J, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2000241##SCHULZ-DOBRICK M, 2005, CHEMPHYSCHEM, V6, P315, DOI 10.1002/CPHC.200400338##SEBASTIANI D, 2006, CHEMPHYSCHEM, V7, P164, DOI 10.1002/CPHC.200500438##SEBASTIANI D, 2005, J CHEM THEORY COMPUT, V1, P78, DOI 10.1021/CT049955O##SEBASTIANI D, 2003, MOD PHYS LETT B, V17, P1301, DOI 10.1142/S0217984903006372##SEBASTIANI D, 2003, J MOL STRUC-THEOCHEM, V625, P283, DOI 10.1016/S0166-1280(03)00030-7##SEBASTIANI D, 2002, CHEMPHYSCHEM, V3, P675, DOI 10.1002/1439-7641(20020816)3:8<675::AID-CPHC675>3.0.CO;2-O##SEBASTIANI D, 2001, J PHYS CHEM A, V105, P1951, DOI 10.1021/JP002807J##SHARMA M, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.187401##SILLANPAA AJ, 2002, J PHYS CHEM B, V106, P11315, DOI 10.1021/JP0260088##SILVESTRELLI PL, 1997, CHEM PHYS LETT, V277, P478, DOI 10.1016/S0009-2614(97)00930-5##SILVESTRELLI PL, 1999, J CHEM PHYS, V111, P3572, DOI 10.1063/1.479638##SIMON C, 2005, CHEMPHYSCHEM, V6, P148, DOI 10.1002/CPHC.200400284##SMITH JD, 2005, SCIENCE, V308, P793B, DOI 10.1126/SCIENCE.1108945##SMITH JD, 2004, SCIENCE, V306, P851, DOI 10.1126/SCIENCE.1102560##SOPER AK, 2000, CHEM PHYS, V258, P107, DOI 10.1016/S0301-0104(00)00187-7##SPRIK M, 1996, J CHEM PHYS, V105, P1142, DOI 10.1063/1.471957##TUCKERMAN ME, 1996, J CHEM PHYS, V104, P5579, DOI 10.1063/1.471771##TUCKERMAN ME, 1997, SCIENCE, V275, P817, DOI 10.1126/SCIENCE.275.5301.817##UMARI P, 2005, DIAM RELAT MATER, V14, P1255, DOI 10.1016/J.DIAMOND.2004.12.007##VANDEVONDELE J, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1828433##VIDOSSICH P, 2006, J AM CHEM SOC, V128, P7215, DOI 10.1021/JA0577903##VON ROSENVINGE T, 1997, FARADAY DISCUSS, V106, P273, DOI 10.1039/A702374J##WARREN B. E., 1990, XRAY DIFFRACTION##WERNET P, 2004, SCIENCE, V304, P995, DOI 10.1126/SCIENCE.1096205##YATES JR, 2005, PHYS CHEM CHEM PHYS, V7, P1402, DOI 10.1039/B500674K##YATES JR, 2005, J AM CHEM SOC, V127, P10216, DOI 10.1021/JA051019A",43,2020-11-20,NA
J,WOS:000242946200006,2006,ALTERED BETA-SECRETASE ENZYME KINETICS AND LEVELS OF BOTH BACE1 AND BACE2 IN THE ALZHEIMER'S DISEASE BRAIN,"BETA-SECRETASE IS THE RATE LIMITING ENZYMATIC ACTIVITY IN THE PRODUCTION OF AMYLOID-BETA PEPTIDE, THE PRIMARY COMPONENT OF SENILE PLAQUE PATHOLOGY IN ALZHEIMER'S DISEASE (AD). THIS STUDY PERFORMED THE FIRST COMPARATIVE ANALYSIS OF BETA-SECRETASE ENZYME KINETICS IN AD AND CONTROL BRAIN TISSUE. RESULTS FOUND V-MAX VALUES FOR BETA-SECRETASE TO BE SIGNIFICANTLY INCREASED, AND K-M VALUES UNCHANGED IN AD TEMPORAL CORTEX COMPARED TO MATCHED CONTROL TEMPORAL CORTEX. THE INCREASED V-MAX IN AD CASES, DID NOT CORRELATE WITH LEVELS OF BACE1, AND DECREASED BACE1 AND BACE2 LEVELS CORRELATED WITH THE SEVERITY OF NEUROFIBRILLARY PATHOLOGY (I-VI), AND SYNAPTIC LOSS IN AD. THESE RESULTS INDICATE THAT INCREASED V-MAX FOR BETA-SECRETASE IS A FEATURE OF AD PATHOGENESIS AND THIS INCREASE DOES NOT CORRELATE DIRECTLY WITH LEVELS OF BACE1, THE PRINCIPAL BETA-SECRETASE IN BRAIN. (C) 2006 PUBLISHED BY ELSEVIER B.V. ON BEHALF OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES.",AMYLOID PRECURSOR PROTEIN; CLEAVING ENZYME; PEPTIDE GENERATION; ALPHA-SECRETASE; DOWN-SYNDROME; LIPID RAFTS; SITE; EXPRESSION; CLEAVAGE; CHOLESTEROL,BETA-SECRETASE KINETICS; BACE1; BACE2; NEUROFIBRILLARY TANGLES; ALZHEIMER'S DISEASE; AMYLOID-BETA-PEPTIDE,FEBS LETTERS,"STOCKLEY, JH##RAVID, R##O'NEILL, C","NATL UNIV IRELAND UNIV COLL CORK, BIOSCI INST, DEPT BIOCHEM, CORK, IRELAND. NETHERLANDS BRAIN BANK, NL-1005 AZ AMSTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS; CELL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS; CELL BIOLOGY,"AUGUSTINACK JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/S004010100423##BARBIERO L, 2003, EXP NEUROL, V182, P335, DOI 10.1016/S0014-4886(03)00049-9##BASI G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/JBC.M300169200##BECKMAN M, 2006, BIOCHEMISTRY-US, V45, P6703, DOI 10.1021/BI052498T##BENNETT BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/JBC.M002688200##BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809##CAI HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064##CAPELL A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/JBC.M003202200##CIRRITO JR, 2005, NEURON, V48, P913, DOI 10.1016/J.NEURON.2005.10.028##CORDY JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/PNAS.1635130100##ERMOLIEFF J, 2000, BIOCHEMISTRY-US, V39, P16263, DOI 10.1021/BI005122I##FARZAN M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/PNAS.160115697##FLUHRER R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/J.1471-4159.2002.00908.X##FUKUMOTO H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/ARCHNEUR.59.9.1381##GHRIBI O, 2006, EXP NEUROL, V200, P460, DOI 10.1016/J.EXPNEUROL.2006.03.019##GRUNINGER-LEITCH F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/JBC.M109266200##HAASS C, 2004, EMBO J, V23, P483, DOI 10.1038/SJ.EMBOJ.7600061##HATTORI C, 2006, J NEUROSCI RES, V84, P912, DOI 10.1002/JNR.20981##HE WX, 2004, NAT MED, V10, P959, DOI 10.1038/NM1088##HOLSINGER RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ANA.10208##HUSE JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/JBC.M004175200##HUSSAIN I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/MCNE.2000.0884##HUSSAIN I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/MCNE.1999.0811##JOHNSTON JA, 2005, BIOCHEM SOC T, V33, P1096, DOI 10.1042/BST0331096##KALVODOVA L, 2005, J BIOL CHEM, V280, P36815, DOI 10.1074/JBC.M504484200##KAMENETZ F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7##KELLIHER M, 1999, NEUROSCIENCE, V92, P499, DOI 10.1016/S0306-4522(99)00042-1##LI R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/PNAS.0205689101##LIN XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/PNAS.97.4.1456##LUO Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059##MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9##MASLIAH E, 1991, AM J PATHOL, V138, P235##MASLIAH E, 2001, NEUROLOGY, V56, P127, DOI 10.1212/WNL.56.1.127##MOTONAGA K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2##MURAYAMA KS, 2006, EUR J NEUROSCI, V24, P1237, DOI 10.1111/J.1460-9568.2006.05005.X##ROBERDS SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/HMG/10.12.1317##SCHOLEFIELD Z, 2003, J CELL BIOL, V163, P97, DOI 10.1083/JCB.200303059##SINHA S, 1999, NATURE, V402, P537, DOI 10.1038/990114##SUN AY, 2002, EXP NEUROL, V175, P10, DOI 10.1006/EXNR.2002.7875##SUN XL, 2006, FASEB J, V20, P1369, DOI 10.1096/FJ.05-5632COM##TUN H, 2002, J MOL NEUROSCI, V19, P31, DOI 10.1007/S12031-002-0007-5##TYLER SJ, 2002, BIOCHEM BIOPH RES CO, V299, P373, DOI 10.1016/S0006-291X(02)02635-9##VASSAR R, 2002, ADV DRUG DELIVER REV, V54, P1589, DOI 10.1016/S0169-409X(02)00157-6##VASSAR R, 1999, SCIENCE, V286, P735, DOI 10.1126/SCIENCE.286.5440.735##VERHEIJEN JH, 2006, CLIN CHEM, V52, P1168, DOI 10.1373/CLINCHEM.2006.066720##WALTER J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1##WEN Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/J.BRAINRES.2003.09.086##WESTMEYER GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/JBC.M410378200##XIE J, 2005, J BIOL CHEM, V280, P13824, DOI 10.1074/JBC.M411933200##YAN RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/JBC.M105583200##YAN RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107##YANG LB, 2003, NAT MED, V9, P3, DOI 10.1038/NM0103-3##ZOHAR O, 2003, MOL BRAIN RES, V115, P63, DOI 10.1016/S0169-328X(03)00182-7",35,2020-11-20,NA
J,WOS:000242946200013,2006,METHYLATION OF SMAD6 BY PROTEIN ARGININE N-METHYLTRANSFERASE 1,"SIGNAL TRANSDUCTION PATHWAYS UTILIZE POSTTRANSLATIONAL MODIFICATIONS TO REGULATE THE ACTIVITY OF THEIR COMPONENTS IN A TEMPORAL-SPATIAL AND EFFICIENT FASHION. ARGININE METHYLATION IS ONE OF THE POSTTRANSLATIONAL MODIFICATIONS THAT CAN RESULT IN MONOMETHYLATED-, ASYMMETRIC DIMETHYLATED- AND/OR SYMMETRIC DIMETHYLATED-ARGININE RESIDUES IN PROTEINS. HERE WE DEMONSTRATE THAT INHIBITORY-SMADS (SMAD6 AND SMAD7), BUT NOT RECEPTOR-REGULATED- (R-)SMADS AND THE COMMON-PARTNER SMAD4, CAN BE METHYLATED BY PROTEIN ARGININE N-METHYLTRANSFERASE (PRMT)1. USING MASS-SPECTROMETRIC ANALYSIS, WE FOUND THAT PRMT1 DIMETHYLATES ARGININE(74) (ARG(74)) IN MOUSE SMAD6. PRMT1 INTERACTS WITH THE N-TERMINAL DOMAIN OF SMAD6 IN WHICH ARG(74) RESIDUE IS LOCATED. ASSAYS EXAMINED SO FAR HAVE SHOWN NO SIGNIFICANT DIFFERENCES BETWEEN THE FUNCTIONS OF SMAD6 AND THOSE OF METHYLATION-DEFECTIVE SMAD6 (SMAD6R74A). BOTH WILD-TYPE AND SMAD6R74A WERE EQUALLY EFFICIENT IN BLOCKING BMP-INDUCED GROWTH ARREST UPON THEIR ECTOPIC EXPRESSION IN HS-72 MOUSE B-CELL HYBRIDOMA CELLS. (C) 2006 FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES. PUBLISHED BY ELSEVIER B.V. ALL RIGHTS RESERVED.",BONE MORPHOGENETIC PROTEIN; GROWTH-FACTOR-BETA; GENE-EXPRESSION; CELL-MEMBRANE; I RECEPTOR; METHYLTRANSFERASE; TRANSCRIPTION; BINDING; INHIBITION; SUBSTRATE,BMP; I-SMAD; PRMT1; SMAD6; SMAD7,FEBS LETTERS,"INAMITSU, M##ITOH, S##HELLMAN, U##TEN DIJKE, P##KATO, M","UNIV TSUKUBA, GRAD SCH COMPREHENS HUMAN SCI, DEPT EXPT PATHOL, TSUKUBA, IBARAKI 3058575, JAPAN. UPPSALA UNIV, LUDWIG INST CANC RES, BIOMED CTR, S-75124 UPPSALA, SWEDEN. LEIDEN UNIV, MED CTR, DEPT MOL CELL BIOL, NL-2300 RC LEIDEN, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS; CELL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS; CELL BIOLOGY,"BEDFORD MT, 2005, MOL CELL, V18, P263, DOI 10.1016/J.MOLCEL.2005.04.003##BLANCHET F, 2006, CURR OPIN IMMUNOL, V18, P321, DOI 10.1016/J.COI.2006.03.001##BOISVERT FM, 2005, GENE DEV, V19, P671, DOI 10.1101/GAD.1279805##BRANSCOMBE TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/JBC.M105412200##CHEN DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/SCIENCE.284.5423.2174##COOK JR, 2006, BIOCHEM BIOPH RES CO, V342, P472, DOI 10.1016/J.BBRC.2006.01.167##COTE J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/MBC.E02-08-0484##DENNLER S, 1998, EMBO J, V17, P3091, DOI 10.1093/EMBOJ/17.11.3091##EBISAWA T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/JBC.C100008200##FRANKEL A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/JBC.M108786200##GLESNE D, 2006, ONCOGENE, V25, P4086, DOI 10.1038/SJ.ONC.1209436##GOLDMAN LA, 1996, BIOTECHNIQUES, V21, P1013##GRONROOS E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1##HANYU A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/JCB.200106023##HATA A, 1998, GENE DEV, V12, P186, DOI 10.1101/GAD.12.2.186##HELDIN CH, 1997, NATURE, V390, P465, DOI 10.1038/37284##HELLMAN U, 2000, EXS, V88, P43##IMAMURA T, 1997, NATURE, V389, P622, DOI 10.1038/39355##ISHISAKI A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/JBC.274.19.13637##ITOH F, 2001, EMBO J, V20, P4132, DOI 10.1093/EMBOJ/20.15.4132##ITOH S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/JBC.M208258200##ITOH S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/NAR/28.21.4291##JONK LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/JBC.273.33.21145##KAVSAK P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9##KAWABATA M, 1998, EMBO J, V17, P4056, DOI 10.1093/EMBOJ/17.14.4056##KOINUMA D, 2003, EMBO J, V22, P6458, DOI 10.1093/EMBOJ/CDG632##LEE DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/ER.2004-0008##LIN X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003##MASSAGUE J, 2005, GENE DEV, V19, P2783, DOI 10.1101/GAD.1350705##MASSAGUE J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5##MCBRIDE AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8##MOWEN KA, 2004, MOL CELL, V15, P559, DOI 10.1016/J.MOLCEL.2004.06.042##MOWEN KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6##MURAKAMI G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/MBC.E02-07-0441##PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5##PARK SH, 2005, J BIOCHEM MOL BIOL, V38, P9##PAWLAK MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000##PERSSON U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5##PULASKI L, 2001, J BIOL CHEM, V276, P14344, DOI 10.1074/JBC.M011019200##REZAI-ZADEH N, 2003, GENE DEV, V17, P1019, DOI 10.1101/GAD.1068003##ROBERTS AB, 1990, HDB EXPT PHARM, V95, P419##SHI WB, 2004, J CELL BIOL, V164, P291, DOI 10.1083/JCB.200307151##SHI YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X##SIMONSSON M, 2005, J BIOL CHEM, V280, P21797, DOI 10.1074/JBC.M503134200##TAMAKI K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8##YADAV N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/PNAS.1232272100",22,2020-11-20,"GRANTS-IN-AID FOR SCIENTIFIC RESEARCHMINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE AND TECHNOLOGY, JAPAN (MEXT)JAPAN SOCIETY FOR THE PROMOTION OF SCIENCEGRANTS-IN-AID FOR SCIENTIFIC RESEARCH (KAKENHI) [18012009, 17390073] FUNDING SOURCE: KAKEN"
J,WOS:000242946200031,2006,FERREDOXIN/FERREDOXIN-THIOREDOXIN REDUCTASE COMPLEX: COMPLETE NMR MAPPING OF THE INTERACTION SITE ON FERREDOXIN BY GALLIUM SUBSTITUTION,"THE REDUCTION OF FERREDOXIN-THIOREDOXIN REDUCTASE (FTR) BY PLANT-TYPE FERREDOXIN PLAYS AN IMPORTANT ROLE IN REDOX REGULATION IN PLANTS AND CYANOBACTERIA. NUCLEAR MAGNETIC RESONANCE (NMR) WAS USED TO MAP THE BINDING SITES ON SYNECHOCYSTIS FERREDOXIN FOR FTR. A GALLIUM-SUBSTITUTED STRUCTURAL ANALOG OF THIS [2FE-2S] FERREDOXIN WAS OBTAINED BY RECONSTITUTING THE APOPROTEIN IN A REFOLDING BUFFER CONTAINING GALLIUM. FOR THE FIRST TIME, THE COMPLETE INTERACTION INTERFACE OF A [2FE-2S] FERREDOXIN WITH A TARGET ENZYME HAS BEEN MAPPED BY NMR CHEMICAL SHIFT PERTURBATION WITH THIS DIAMAGNETIC STRUCTURAL ANALOG. (C) 2006 FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES.",ELECTRON-TRANSFER COMPLEX; PROTEIN INTERACTIONS; GLUTAMATE SYNTHASE; PLANT FERREDOXIN; REDOX PROTEINS; ASSIGNMENT; BINDING,[2FE-2S] FERREDOXIN; FERREDOXIN-THIOREDOXIN REDUCTASE; CHEMICAL SHIFT PERTURBATION,FEBS LETTERS,"XU, XF##KIM, SK##SCHURMANN, P##HIRASAWA, M##TRIPATHY, JN##SMITH, J##KNAFF, DB##UBBINK, M","LEIDEN UNIV, GORLAEUS LABS, LEIDEN INST CHEM, NL-2300 RA LEIDEN, NETHERLANDS. TEXAS TECH UNIV, DEPT CHEM & BIOCHEM, LUBBOCK, TX 79409 USA. UNIV NEUCHATEL, BIOL CELLULAIRE & MOL LAB, CH-2009 NEUCHATEL, SWITZERLAND. TEXAS TECH UNIV, CTR BIOTECHNOL & GENOM, LUBBOCK, TX 79409 USA.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS; CELL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS; CELL BIOLOGY,"BERTINI I, 1996, COORDIN CHEM REV, V150, P1##BLANKENSHIP RE, 2001, NAT STRUCT BIOL, V8, P94, DOI 10.1038/84191##CROWLEY PB, 2003, ACCOUNTS CHEM RES, V36, P723, DOI 10.1021/AR0200955##DAI SD, 2000, SCIENCE, V287, P655, DOI 10.1126/SCIENCE.287.5453.655##DAI SD, 2004, PHOTOSYNTH RES, V79, P233, DOI 10.1023/B:PRES.0000017194.34167.6D##DAI SHAODONG, 2006, V23, P221##DEPASCALIS AR, 1994, FEBS LETT, V337, P217, DOI 10.1016/0014-5793(94)80194-0##FUKUYAMA K, 2004, PHOTOSYNTH RES, V81, P289, DOI 10.1023/B:PRES.0000036882.19322.0A##GLAUSER DA, 2004, J BIOL CHEM, V279, P16662, DOI 10.1074/JBC.M313851200##GUEX N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/ELPS.1150181505##GUILLOUARD I, 2000, BIOCHEM BIOPH RES CO, V271, P647, DOI 10.1006/BBRC.2000.2687##HASE T, 2006, PHOTOSYSTEM, V1, P333##HELGSTRAND M, 2000, J BIOMOL NMR, V18, P329, DOI 10.1023/A:1026729404698##HIRASAWA M, 1988, BIOCHIM BIOPHYS ACTA, V935, P1, DOI 10.1016/0005-2728(88)90101-6##JACQUOT JP, 1997, FEBS LETT, V400, P293, DOI 10.1016/S0014-5793(96)01407-X##KAZANIS S, 1995, J AM CHEM SOC, V117, P6625, DOI 10.1021/JA00129A040##KURISU G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097##LELONG C, 1995, BIOCHEMISTRY-US, V34, P14462, DOI 10.1021/BI00044A024##MORALES R, 2000, EMBO REP, V1, P271, DOI 10.1093/EMBO-REPORTS/KVD057##PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/PRO.5560041120##PERVUSHIN K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/PNAS.94.23.12366##POCHAPSKY TC, 1998, J BIOMOL NMR, V12, P407, DOI 10.1023/A:1008354113765##PRUDENCIO M, 2004, J MOL RECOGNIT, V17, P524, DOI 10.1002/JMR.686##RUBIO LM, 2002, PHOTOSYNTH RES, V72, P13, DOI 10.1023/A:1016078700839##SAITOH T, 2006, J BIOL CHEM, V281, P10482, DOI 10.1074/JBC.M510530200##SCHMITZ S, 1996, BBA-BIOENERGETICS, V1277, P135, DOI 10.1016/S0005-2728(96)00095-3##SCHURMANN P, 2003, ANTIOXID REDOX SIGN, V5, P69, DOI 10.1089/152308603321223559##STAPLES CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/BI961007P##UBBINK M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5##UBBINK M, 2004, PHOTOSYNTH RES, V81, P277, DOI 10.1023/B:PRES.0000036880.67124.E7##VAN DEN HEUVEL RHH, 2003, J MOL BIOL, V330, P113, DOI 10.1016/S0022-2836(03)00522-9##VO E, 1997, J AM CHEM SOC, V119, P1934, DOI 10.1021/JA961330F##WORRALL JAR, 2003, BIOCHEMISTRY-US, V42, P7068, DOI 10.1021/BI0342968",20,2020-11-20,NA
J,WOS:000242479700049,2006,"SYNTHESIS, CHARACTERIZATION, AND DNA-BINDING STUDIES OF NITRO(OLIGOPYRIDINE) RUTHENIUM(II) COMPLEXES","THE COMPLEXES OF GENERAL FORMULAS [RU-II(TERPY)(4-CO2H-4'-MEBPY)(X)](N+) (X = NO (N = 3) AND NO2 (N = 1); 1, 2) AND [RU-II(TERPY)(4-COGHK-4'-MEBPY)(X)] (X = NO (N = 3) AND NO2 (N = 1); 3, 4) WERE SYNTHESIZED AND CHARACTERIZED. THE COMPLEX [RU-II(TERPY)(4-CO2-4'-MEBPY)(NO2)](-)7.5H(2)O HAS ALSO BEEN CHARACTERIZED BY X-RAY CRYSTALLOGRAPHIC STUDIES. IT CRYSTALLIZES IN THE TRICLINIC SYSTEM: A = 9.4982(1) ANGSTROM, B = 13.1330(1) ANGSTROM, C = 14.2498(2) ANGSTROM; ALPHA = 110.5870(6)XBC, BETA = 98.4048(5)XBC, GAMMA = 106.4353(5), P (1) OVER BAR, Z = 2. THE CRYSTAL STRUCTURE REVEALS AN EXTENDED HYDROGEN-BONDING NETWORK. TWO WATER MOLECULES FORM STRONG HYDROGEN BONDS WITH THE NITRO AND THE CARBOXYLIC OXYGEN ATOMS OF TWO SEPARATE UNITS OF THE COMPLEX, RESULTING IN A DIMERIC UNIT. THE DIMERS ARE BRIDGED BY A (H2O)(15) CLUSTER, CONSISTING OF TWO CYCLO-(H2O)(6) SPECIES, WHILE AN EXO-H2O(8) CONNECTS THEM. TWO MORE EXO-H2O MOLECULES ARE JOINED TOGETHER AND CONNECT THE CYCLO-(H2O)(6) UNITS WITH THE H2O(1) OF THE DIMERIC UNIT. IT WAS FOUND THAT COMPLEXES 1 AND 3 CAN BE TRANSFORMED INTO THEIR NITRO DERIVATIVES IN AQUEOUS MEDIA AT NEUTRAL PH. PHOTORELEASE OF NO IN DRY MECN SOLUTIONS WAS OBSERVED FOR COMPLEXES 1 AND 3. ALSO, COMPLEX 2 PARTIALLY RELEASES (NO2)(-) IN MECN UPON VISIBLE LIGHT IRRADIATION. COMPLEX 2 INTERACTS WITH SHORT FRAGMENTS (70-300 BP) OF CALF THYMUS DNA SHORTENING SLIGHTLY THE APPARENT POLYNUCLEOTIDE LENGTH, WHILE THE CONJUGATION OF THE PEPTIDE GHK TO IT (2) AFFECTS ITS DNA-BINDING MODE. THE PEPTIDE MOIETY OF COMPLEX 4 WAS FOUND TO INTERACT WITH THE DNA HELIX IN A SYNERGISTIC WAY WITH THE WHOLE COMPLEX. PRELIMINARY RESULTS OF PHOTOCLEAVAGE OF DNA BY COMPLEX 2 ARE ALSO REPORTED.",CALF THYMUS DNA; CRYSTAL-STRUCTURE; NITRIC-OXIDE; DEOXYNUCLEOTIDE DUPLEX; NITROSYL COMPLEXES; ELECTRON-TRANSFER; POLYPYRIDINE COMPLEXES; STEREOSPECIFIC BINDING; CIRCULAR-DICHROISM; ANCILLARY LIGANDS,NA,INORGANIC CHEMISTRY,"KARIDI, K##GAROUFIS, A##HADJILIADIS, N##LUTZ, M##SPEK, AL##REEDIJK, J","UNIV IOANNINA, LAB INORGAN & GEN CHEM, DEPT CHEM, GR-45110 IOANNINA, GREECE. UNIV UTRECHT, BIJVOET CTR BIOMOL CTR CRYSTAL & STRUCT CHEM, NL-3584 CH UTRECHT, NETHERLANDS. LEIDEN UNIV, GORLAEUS LABS, LEIDEN INST CHEM, NL-2300 RA LEIDEN, NETHERLANDS.","CHEMISTRY, INORGANIC & NUCLEAR",CHEMISTRY,"ALTOMARE A, 1999, J APPL CRYSTALLOGR, V32, P115, DOI 10.1107/S0021889898007717##BLESSING RH, 1997, J APPL CRYSTALLOGR, V30, P421, DOI 10.1107/S0021889896014628##BORDINI J, 2002, INORG CHEM, V41, P5410, DOI 10.1021/IC011273D##BRYANT GM, 1971, AUST J CHEM, V24, P257, DOI 10.1071/CH9710257##CALLAHAN RW, 1977, INORG CHEM, V16, P574, DOI 10.1021/IC50169A015##CATTE A, 2002, J BIOMOL STRUCT DYN, V20, P99, DOI 10.1080/07391102.2002.10506827##CHANDA N, 2005, INORG CHEM, V44, P3499, DOI 10.1021/IC048184W##CHANDA N, 2004, INORG CHEM, V43, P5128, DOI 10.1021/IC049605C##CHANDA N, 2004, INORG CHEM, V43, P1056, DOI 10.1021/IC034902N##COPELAND KD, 2002, BIOCHEMISTRY-US, V41, P343, DOI 10.1021/BI011793K##COPELAND KD, 2002, BIOCHEMISTRY-US, V41, P12785, DOI 10.1021/BI020407B##ERKKILA KE, 1999, CHEM REV, V99, P2777, DOI 10.1021/CR9804341##ERSHOV AY, 2004, RUSS J GEN CHEM+, V74, P651, DOI 10.1023/B:RUGC.0000039071.51270.43##FORD PC, 2005, COORDIN CHEM REV, V249, P391, DOI 10.1016/J.CCR.2004.04.006##FORD PC, 2002, CHEM REV, V102, P993, DOI 10.1021/CR0000271##FORD PC, 2005, COORDIN CHEM REV, V249, P1382, DOI 10.1016/J.CCR.2004.10.022##GARCIAFRESNADILLO D, 1996, HELV CHIM ACTA, V79, P1222, DOI 10.1002/HLCA.19960790428##GHOSH SK, 2005, INORG CHEM, V44, P3856, DOI 10.1021/IC050102W##GHOSH SK, 2003, INORG CHEM, V42, P8250, DOI 10.1021/IC034976Z##GODWIN JB, 1971, INORG CHEM, V10, P471##HARTSHORN CM, 2001, INORG CHEM, V40, P601, DOI 10.1021/IC9911724##HERGUETA-BRAVO A, 2002, J PHYS CHEM B, V106, P4010, DOI 10.1021/JP013542R##IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/BIP.1973.360120109##JI LN, 2001, COORDIN CHEM REV, V216, P513, DOI 10.1016/S0010-8545(01)00338-1##KANE-MAGUIRE NAP, 2001, COORDIN CHEM REV, V211, P145, DOI 10.1016/S0010-8545(00)00280-0##KANKIA BI, 2001, NUCLEIC ACIDS RES, V29, P2795, DOI 10.1093/NAR/29.13.2795##KANKIA BI, 2000, BIOPHYS CHEM, V84, P227, DOI 10.1016/S0301-4622(00)00125-3##KAR S, 2005, CHEM-EUR J, V11, P4901, DOI 10.1002/CHEM.200500202##KARIDI K, 2005, DALTON T, P1176, DOI 10.1039/B418838A##KARIDI K, 2005, DALTON T, P728, DOI 10.1039/B410402A##KUMAR CV, 1985, J AM CHEM SOC, V107, P5518, DOI 10.1021/JA00305A032##LANG DR, 2000, INORG CHEM, V39, P2294, DOI 10.1021/IC9912979##LASEY RC, 2000, INORG CHIM ACTA, V300, P822, DOI 10.1016/S0020-1693(99)00589-7##LEISING RA, 1990, INORG CHEM, V29, P1306, DOI 10.1021/IC00332A004##LOPES LGF, 2001, INORG CHIM ACTA, V312, P15, DOI 10.1016/S0020-1693(00)00341-8##LUO Y, 1996, INORG CHEM, V35, P5445, DOI 10.1021/IC950694Q##MCCLEVERTY JA, 2004, CHEM REV, V104, P403, DOI 10.1021/CR020623Q##MONDAL B, 2001, J CHEM SOC DALTON, P481, DOI 10.1039/B007975H##MYARI A, 2005, BIOINORG CHEM APPL, V3, P109, DOI 10.1155/BCA.2005.109##MYARI A, 2005, J INORG BIOCHEM, V99, P616, DOI 10.1016/J.JINORGBIO.2004.11.010##MYARI A, 2004, EUR J INORG CHEM, P1427, DOI 10.1002/EJIC.200300725##ONEILL MA, 2004, LONG RANGE CHARGE TR, V236##PATEL DJ, 1976, BIOPOLYMERS, V15, P533, DOI 10.1002/BIP.1976.360150310##PATRA AK, 2003, INORG CHEM, V42, P7363, DOI 10.1021/IC030110H##PEEK BM, 1991, INT J PEPT PROT RES, V38, P114##PIPES DW, 1984, INORG CHEM, V23, P2466, DOI 10.1021/IC00184A021##ROBINSON K, 1971, SCIENCE, V172, P567, DOI 10.1126/SCIENCE.172.3983.567##SARDESAI NY, 1995, BIOCONJUGATE CHEM, V6, P302, DOI 10.1021/BC00033A011##SARDESAI NY, 1994, J AM CHEM SOC, V116, P7502, DOI 10.1021/JA00096A005##SARKAR S, 2005, INORG CHEM, V44, P6092, DOI 10.1021/IC050533E##SHELDRICK G. M., 1997, SHELXL97 PROGRAM CRY##SLOCIK JM, 2000, INORG CHIM ACTA, V311, P80, DOI 10.1016/S0020-1693(00)00309-1##SPEEDY RJ, 1987, J PHYS CHEM-US, V91, P909, DOI 10.1021/J100288A029##SPEK AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112##SULLIVAN BP, 1980, INORG CHEM, V19, P1404, DOI 10.1021/IC50207A066##WILSON WD, 1982, NUCLEIC ACIDS RES, V10, P1399, DOI 10.1093/NAR/10.4.1399##XIONG Y, 1999, COORDIN CHEM REV, V185-6, P711, DOI 10.1016/S0010-8545(99)00019-3##YAMAGISHI A, 1983, J CHEM SOC CHEM COMM, P572, DOI 10.1039/C39830000572##YAMAGISHI A, 1984, J PHYS CHEM-US, V88, P5709, DOI 10.1021/J150667A050##YE BH, 2004, INORG CHEM, V43, P6866, DOI 10.1021/IC049232F",25,2020-11-20,NA
J,WOS:000242707300004,2006,THE EFFECT OF CARRIER SURFACE TREATMENT ON DRUG PARTICLE DETACHMENT FROM CRYSTALLINE CARRIERS IN ADHESIVE MIXTURES FOR INHALATION,"IN THIS STUDY, THE EFFECT OF LACTOSE CARRIER SURFACE TREATMENT ON DRUG PARTICLE DETACHMENT DURING INHALATION HAS BEEN INVESTIGATED. CRYSTALS OF MARKETED BRANDS OF ALPHA LACTOSE MONOHYDRATE BRANDS NORMALLY EXHIBIT A CERTAIN SURFACE RUGOSITY AND CONTAIN NATURAL FINES AND IMPURITIES ON THEIR SURFACE, WHICH INFLUENCE THE DRUG-TO-CARRIER INTERACTION IN ADHESIVE MIXTURES FOR INHALATION. SUBMERSION TREATMENT MAY CHANGE THESE SURFACE CHARACTERISTICS. TWO DIFFERENT SIEVE FRACTIONS (63-90 AND 250-355 MU M) WERE SUBMERGED IN MIXTURES OF ETHANOL AND WATER (96 AND 80% V/V, RESPECTIVELY). MICROSCOPIC OBSERVATION AND LASER DIFFRACTION ANALYSIS REVEALED THAT NEITHER THE SHAPE NOR THE SIZE OF THE CARRIER PARTICLES WAS CHANGED BY THE SUBMERSION TREATMENT. HOWEVER, THE SPECIFIC SURFACE AREA AND THE AMOUNT OF IMPURITIES APPEARED TO DECREASE SUBSTANTIALLY AFTER SUBMERSION, AND THE MAGNITUDE OF THE DECREASE WAS DIFFERENT FOR THE DIFFERENT ETHANOL-WATER MIXTURES. THE REDUCTION IN SPECIFIC SURFACE AREA WAS ATTRIBUTED PARTICULARLY TO THE REMOVAL OF THE ADHERING LACTOSE FINES FROM THE CARRIER SURFACE. MIXTURES WITH BUDESONIDE (IN A WIDE RANGE OF CARRIER PAYLOADS) WERE PREPARED BEFORE AND AFTER TREATMENT. DRUG PARTICLE DETACHMENT FROM THE VARIOUS MIXTURES WAS STUDIED WITH A SIEVE TEST AND WITH A CASCADE IMPACTOR ANALYSIS AT 30 AND 601/MIN. TWO DIFFERENT TYPES OF INHALERS WERE USED, ONE GENERATING LIFT- AND DRAG-FORCES (ISF INHALER) AND ONE GENERATING INERTIAL FORCES (TEST INHALER), RESPECTIVELY. THE CASCADE IMPACTOR AND SIEVE TEST EXPERIMENTS SHOWED THAT AN INCREASE IN CARRIER SURFACE SMOOTHNESS RESULTS IN A REDUCED DRUG PARTICLE DETACHMENT DURING INHALATION, WHICH WAS INDEPENDENT OF THE TYPE OF INHALER USED. THIS REDUCTION COULD BE ATTRIBUTED TO THE REMOVAL OF THE ADHERING LACTOSE FINES WHICH MAY PROVIDE SHELTER FOR THE DRUG PARTICLES FROM PRESS-ON FORCES DURING MIXING. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",DRY POWDER INHALATION; IN-VITRO DEPOSITION; LACTOSE CARRIER; SIZE; MONOHYDRATE; MORPHOLOGY; ROUGHNESS; DELIVERY,ADHESION; BUDESONIDE; CARRIER LACTOSE; DRY POWDER INHALER; SURFACE TREATMENT; RUGOSITY,INTERNATIONAL JOURNAL OF PHARMACEUTICS,"DICKHOFF, BHJ##DE BOER, AH##LAMBREGTS, D##FRIJLINK, HW","UNIV GRONINGEN, INST DRUG EXPLORAT, DEPT PHARMACEUT TECHNOL & BIOPHARM, NL-9713 AV GRONINGEN, NETHERLANDS. DMV INT, NL-5460 BA VEGHEL, NETHERLANDS.",PHARMACOLOGY & PHARMACY,PHARMACOLOGY & PHARMACY,"COLOMBO P, 2000, RESP DRUG DELIVERY, V7, P629##DE BOER AH, 2003, INT J PHARM, V260, P201, DOI 10.1016/S0378-5173(03)00264-3##DE BOER AH, 2005, INT J PHARMACEUT, V294, P173, DOI 10.1016/J.IJPHARM.2005.01.035##DICKHOFF BHJ, 2005, EUR J PHARM BIOPHARM, V59, P197, DOI 10.1016/J.EJPB.2004.07.005##DICKHOFF BHJ, 2003, EUR J PHARM BIOPHARM, V56, P291, DOI 10.1016/S0939-6411(03)00109-7##DICKHOFF BHJ, UNPUB INT J PHARM##ELSABAWI D, 2004, RDD, V9, P733##FLAMENT MP, 2004, INT J PHARMACEUT, V275, P201, DOI 10.1016/J.IJPHARM.2004.02.002##HENG PWS, 2000, CHEM PHARM BULL, V48, P393, DOI 10.1248/CPB.48.393##HICKEY AJ, 1994, PHARM TECH, V18, P58##IIDA K, 2003, CHEM PHARM BULL, V51, P1, DOI 10.1248/CPB.51.1##KASSEM NM, 1990, J PHARM PHARMACOL, V42, P11##KAWASHIMA Y, 1998, INT J PHARM, V172, P179, DOI 10.1016/S0378-5173(98)00202-6##KULVANICH P, 1987, J PHARM PHARMACOL, V39, P673, DOI 10.1111/J.2042-7158.1987.TB06968.X##LERK CF, 1983, J PHARM PHARMACOL, V35, P747, DOI 10.1111/J.2042-7158.1983.TB02883.X##LERK CF, 1987, PHARM Z, V2, P39##PODCZECK F, 1998, INT J PHARM, V160, P119, DOI 10.1016/S0378-5173(97)00313-X##PODCZECK F, 1999, AEROSOL SCI TECH, V31, P301, DOI 10.1080/027868299304174##PRICE R, 2002, INT J PHARM, V246, P47, DOI 10.1016/S0378-5173(02)00359-9##SALVATORE C, 1976, PATENT NO. 3991761##STECKEL H, 1997, INT J PHARM, V154, P31, DOI 10.1016/S0378-5173(97)00115-4##TIMSINA MP, 1994, INT J PHARM, V101, P1, DOI 10.1016/0378-5173(94)90070-1##VISSER J, 1989, POWDER TECHNOL, V58, P1, DOI 10.1016/0032-5910(89)80001-4##YOUNG PM, 2002, J PHARM PHARMACOL, V54, P1339, DOI 10.1211/002235702760345400##ZENG XM, 2001, EUR J PHARM BIOPHARM, V51, P55##ZENG XM, 2000, INT J PHARM, V200, P93, DOI 10.1016/S0378-5173(00)00347-1##ZENG XM, 2001, J PHARM SCI, V90, P1424, DOI 10.1002/JPS.1094##ZENG XM, 2000, INT J PHARM, V197, P41, DOI 10.1016/S0378-5173(99)00400-7",34,2020-11-20,NA
J,WOS:000243152900002,2006,THE SAURON PROJECT - VIII. OASIS/CFHT INTEGRAL-FIELD SPECTROSCOPY OF ELLIPTICAL AND LENTICULAR GALAXY CENTRES,"WE PRESENT HIGH SPATIAL RESOLUTION INTEGRAL-FIELD SPECTROSCOPY OF 28 ELLIPTICAL (E) AND LENTICULAR (SO) GALAXIES FROM THE SAURON REPRESENTATIVE SURVEY OBTAINED WITH THE OASIS SPECTROGRAPH DURING ITS OPERATION AT THE CANADA-FRANCE-HAWAII TELESCOPE. THESE SEEING-LIMITED OBSERVATIONS EXPLORE THE CENTRAL 8 X 10 ARCSEC(2) (TYPICALLY 1 KPC DIAMETER) REGIONS OF THESE GALAXIES USING A SPATIAL SAMPLING FOUR TIMES HIGHER THAN SAURON (0.27-ARCSEC VERSUS 0.94-ARCSEC SPATIAL ELEMENTS), RESULTING IN ALMOST A FACTOR OF 2 IMPROVEMENT IN THE MEDIAN POINT SPREAD FUNCTION. THESE DATA ALLOW ACCURATE STUDY OF THE CENTRAL REGIONS TO COMPLEMENT THE LARGE-SCALE VIEW PROVIDED BY SAURON. HERE WE PRESENT THE STELLAR AND GAS KINEMATICS, STELLAR ABSORPTION-LINE STRENGTHS AND NEBULAR EMISSION-LINE STRENGTHS FOR THIS SAMPLE. WE ALSO CHARACTERIZE THE STELLAR VELOCITY MAPS USING THE 'KINEMETRY' TECHNIQUE, AND DERIVE MAPS OF THE LUMINOSITY-WEIGHTED STELLAR AGE, METALLICITY AND ABUNDANCE RATIO VIA STELLAR POPULATION MODELS. WE GIVE A BRIEF REVIEW OF THE STRUCTURES FOUND IN OUR MAPS, LINKING ALSO TO LARGER-SCALE STRUCTURES MEASURED WITH SAURON. WE PRESENT TWO PREVIOUSLY UNREPORTED KINEMATICALLY DECOUPLED COMPONENTS (KDCS) IN THE CENTRES OF NGC 3032 AND NGC 4382. WE COMPARE THE INTRINSIC SIZE AND LUMINOSITY-WEIGHTED STELLAR AGE OF ALL THE VISIBLE KDCS IN THE FULL SAURON SAMPLE, AND FIND TWO TYPES OF COMPONENTS: KILOPARSEC-SCALE KDCS, WHICH ARE OLDER THAN 8 GYR, AND ARE FOUND IN GALAXIES WITH LITTLE NET ROTATION; AND COMPACT KDCS, WHICH HAVE INTRINSIC DIAMETERS OF LESS THAN A FEW HUNDRED PARSEC, SHOW A RANGE OF STELLAR AGES FROM 0.5 TO 15 GYR (WITH 5/6 YOUNGER THAN 5 GYR), ARE FOUND EXCLUSIVELY IN FAST-ROTATING GALAXIES, AND ARE CLOSE TO COUNTER-ROTATING AROUND THE SAME AXIS AS THEIR HOST. OF THE SEVEN GALAXIES IN THE SAURON SAMPLE WITH INTEGRATED LUMINOSITY-WEIGHTED AGES LESS THAN 5 GYR, FIVE SHOW SUCH COMPACT KDCS, SUGGESTING A LINK BETWEEN COUNTER-ROTATION AND RECENT STAR FORMATION. WE SHOW THAT THIS MAY BE DUE TO A COMBINATION OF SMALL SAMPLE SIZE AT YOUNG AGES, AND AN OBSERVATIONAL BIAS, SINCE YOUNG KDCS ARE EASIER TO DETECT THAN THEIR OLDER AND/OR COROTATING COUNTERPARTS.",HUBBLE-SPACE-TELESCOPE; OLD STELLAR POPULATIONS; ABSORPTION-LINE SPECTRA; SIGHT VELOCITY DISTRIBUTIONS; DWARF SEYFERT NUCLEI; BLACK-HOLE; SPIRAL GALAXIES; GLOBULAR-CLUSTERS; SURFACE PHOTOMETRY; CENTRAL REGIONS,GALAXIES : ELLIPTICAL AND LENTICULAR; CD; GALAXIES : EVOLUTION; GALAXIES : FORMATION; GALAXIES : ISM; GALAXIES : KINEMATICS AND DYNAMICS; GALAXIES : STRUCTURE,MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY,"MCDERMID, RM##EMSELLEM, E##SHAPIRO, KL##BACON, R##BUREAU, M##CAPPELLARI, M##DAVIES, RL##DE ZEEUW, T##FALCON-BARROSO, J##KRAJNOVIC, D##KUNTSCHNER, H##PELETIER, RF##SARZI, M","LEIDEN UNIV, LEIDEN OBSERV, NL-2300 RA LEIDEN, NETHERLANDS. UNIV LYON 1, CRAL, OBSERV LYON, F-69230 ST GENIS LAVAL, FRANCE. ENS LYON, CNRS, UMR 5574, LYON, FRANCE. UNIV CALIF BERKELEY, DEPT ASTRON, BERKELEY, CA 94720 USA. UNIV OXFORD, OXFORD, ENGLAND. EUROPEAN SPACE TECHNOL CTR, NL-2200 AG NOORDWIJK, NETHERLANDS. EUROPEAN SO OBSERV, SPACE TELESCOPE EUROPEAN COORDINATING FACIL, D-85748 GARCHING, GERMANY. UNIV GRONINGEN, KAPTEYN ASTRON INST, NL-9700 AV GRONINGEN, NETHERLANDS. UNIV HERTFORDSHIRE, CTR ASTROPHYS RES, SCI & TECHNOL RES INST, HATFIELD AL10 9AB, HERTS, ENGLAND.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"BACON R, 1995, ASTRON ASTROPHYS SUP, V113, P347##BACON R, 2001, MON NOT R ASTRON SOC, V326, P23, DOI 10.1046/J.1365-8711.2001.04612.X##BENDER R, 1992, ASTROPHYS J, V399, P462, DOI 10.1086/171940##BENDER R, 1992, ASTRON ASTROPHYS, V258, P250##BENDER R, 1988, ASTRON ASTROPHYS, V202, PL5##BERNARDI M, 2003, ASTRON J, V125, P1866, DOI 10.1086/367794##BERNARDI M, 1998, ASTROPHYS J, V508, PL143, DOI 10.1086/311742##BERNARDI M, 2005, ASTRON J, V129, P61, DOI 10.1086/426336##BINNEY J, 2004, MON NOT R ASTRON SOC, V347, P1093, DOI 10.1111/J.1365-2966.2004.07277.X##BINNEY J, 1978, MON NOT R ASTRON SOC, V183, P501, DOI 10.1093/MNRAS/183.3.501##BOHLIN RC, 2000, ASTRON J, V120, P437, DOI 10.1086/301431##BOHLIN RC, 2001, ASTRON J, V122, P2118, DOI 10.1086/323137##BRODIE JP, 2005, ASTRON J, V129, P2643, DOI 10.1086/429889##BROWN RJN, 2000, MON NOT R ASTRON SOC, V317, P406, DOI 10.1046/J.1365-8711.2000.03595.X##BROWN TM, 1998, ASTROPHYS J, V504, P113, DOI 10.1086/306079##BRUZUAL G, 2003, MON NOT R ASTRON SOC, V344, P1000, DOI 10.1046/J.1365-8711.2003.06897.X##BURSTEIN D, 1984, ASTROPHYS J, V287, P586, DOI 10.1086/162718##BUSARELLO G, 1996, ASTRON ASTROPHYS, V314, P32##CAPPELLARI M, 2005, CLASSICAL QUANT GRAV, V22, PS347, DOI 10.1088/0264-9381/22/10/028##CAPPELLARI M, 2004, PUBL ASTRON SOC PAC, V116, P138, DOI 10.1086/381875##CAPPELLARI M, 2003, MON NOT R ASTRON SOC, V342, P345, DOI 10.1046/J.1365-8711.2003.06541.X##CAPPELLARI M, 2002, ASTROPHYS J, V578, P787, DOI 10.1086/342653##CAROLLO CM, 1997, ASTROPHYS J, V491, P545, DOI 10.1086/304979##CAROLLO CM, 1999, ASTROPHYS J, V523, P566, DOI 10.1086/307753##CAROLLO CM, 2002, ASTRON J, V123, P159, DOI 10.1086/324725##CAROLLO CM, 1997, ASTRON J, V114, P2366, DOI 10.1086/118654##CAROLLO CM, 1997, ASTROPHYS J, V481, P710, DOI 10.1086/304060##CAROLLO CM, 1993, MON NOT R ASTRON SOC, V265, P553, DOI 10.1093/MNRAS/265.3.553##CAROLLO CM, 1994, MON NOT R ASTRON SOC, V270, P523, DOI 10.1093/MNRAS/270.3.523##CAROLLO CM, 1994, MON NOT R ASTRON SOC, V270, P743, DOI 10.1093/MNRAS/270.4.743##CAROLLO CM, 1998, ASTRON J, V116, P68, DOI 10.1086/300407##COLLESS M, 1999, MON NOT R ASTRON SOC, V303, P813, DOI 10.1046/J.1365-8711.1999.02292.X##COTE P, 2006, ASTROPHYS J SUPPL S, V165, P57, DOI 10.1086/504042##COWIE LL, 1996, ASTRON J, V112, P839, DOI 10.1086/118058##DAVIES R, 2001, ASTROPHYS J LETT, V548, P33##DAVIES RL, 1983, ASTROPHYS J, V266, P41, DOI 10.1086/160757##DE VAUCOULEURS G., 1991, 3 REFERENCE CATALOGU##DE ZEEUW PT, 2002, MON NOT R ASTRON SOC, V329, P513##DELGADO RMG, 1998, ASTROPHYS J, V505, P174, DOI 10.1086/306154##DI MATTEO T, 2005, NATURE, V433, P604, DOI 10.1038/NATURE03335##DRESSLER A, 1983, ASTROPHYS J, V270, P7, DOI 10.1086/161093##EMSELLEM E, 2004, MON NOT R ASTRON SOC, V352, P721, DOI 10.1111/J.1365-2966.2004.07948.X##EMSELLEM E, 2003, MON NOT R ASTRON SOC, V345, P1297, DOI 10.1046/J.1365-2966.2003.07050.X##FABER SM, 1997, ASTRON J, V114, P1771, DOI 10.1086/118606##FALCON-BARROSO J, 2004, MON NOT R ASTRON SOC, V350, P35, DOI 10.1111/J.1365-2966.2004.07704.X##FERRARESE L, 2000, ASTROPHYS J, V539, PL9, DOI 10.1086/312838##FILIPPENKO AV, 1982, PUBL ASTRON SOC PAC, V94, P715, DOI 10.1086/131052##FORBES DA, 1996, ASTROPHYS J, V467, P126, DOI 10.1086/177589##FORD HC, 1994, ASTROPHYS J, V435, PL27, DOI 10.1086/187586##FRANX M, 1988, ASTROPHYS J, V327, PL55, DOI 10.1086/185139##FRANX M, 1989, ASTRON J, V98, P538, DOI 10.1086/115157##GEBHARDT K, 2000, ASTROPHYS J, V539, PL13, DOI 10.1086/312840##GERHARD OE, 1993, MON NOT R ASTRON SOC, V265, P213, DOI 10.1093/MNRAS/265.1.213##GOUDFROOIJ P, 1996, A A, V306, P45##GRANATO GL, 2004, ASTROPHYS J, V600, P580, DOI 10.1086/379875##HARMS RJ, 1994, ASTROPHYS J, V435, PL35, DOI 10.1086/187588##HECKMAN TM, 1997, ASTROPHYS J, V482, P114, DOI 10.1086/304139##HERNQUIST L, 1991, NATURE, V354, P210, DOI 10.1038/354210A0##HO LC, 1997, ASTROPHYS J SUPPL S, V112, P315, DOI 10.1086/313041##HO LC, 1993, ASTROPHYS J, V417, P63, DOI 10.1086/173291##HO LC, 1995, ASTROPHYS J SUPPL S, V98, P477, DOI 10.1086/192170##HOAGLIN D., 1983, UNDERSTANDING ROBUST##HOLLEY-BOCKELMANN K, 2000, ASTROPHYS J, V531, P232, DOI 10.1086/308447##HORNE K, 1986, PUBL ASTRON SOC PAC, V98, P609, DOI 10.1086/131801##JAFFE W, 1994, ASTRON J, V108, P1567, DOI 10.1086/117178##JEDRZEJEWSKI RI, 1987, MON NOT R ASTRON SOC, V226, P747, DOI 10.1093/MNRAS/226.4.747##JONES LA, 1997, THESIS N CAROLINA##KAPFERER W, 2005, ASTRON ASTROPHYS, V438, P87, DOI 10.1051/0004-6361:20052753##KORMENDY J, 1984, ASTROPHYS J, V287, P577, DOI 10.1086/162717##KORMENDY J, 1995, ANNU REV ASTRON ASTR, V33, P581, DOI 10.1146/ANNUREV.AA.33.090195.003053##KRAJNOVIC D, 2006, MON NOT R ASTRON SOC, V366, P787, DOI 10.1111/J.1365-2966.2005.09902.X##KRAJNOVIC D, 2005, MON NOT R ASTRON SOC, V357, P1113, DOI 10.1111/J.1365-2966.2005.08715.X##KRAJNOVIC D, 2004, ASTRON ASTROPHYS, V428, P877, DOI 10.1051/0004-6361:20040359##KUNTSCHNER H, 2004, ASTRON ASTROPHYS, V426, P737, DOI 10.1051/0004-6361:20041414##KUNTSCHNER H, 2001, MON NOT R ASTRON SOC, V323, P615, DOI 10.1046/J.1365-8711.2001.04263.X##KUNTSCHNER H, 2006, MON NOT R ASTRON SOC, V369, P497, DOI 10.1111/J.1365-2966.2006.10153.X##LAINE S, 2003, ASTRON J, V125, P478, DOI 10.1086/345823##LAUER TR, 1998, ASTRON J, V116, P2263, DOI 10.1086/300617##LAUER TR, 2005, ASTRON J, V129, P2138, DOI 10.1086/429565##MACCHETTO F, 1997, ASTROPHYS J, V489, P579, DOI 10.1086/304823##MAOZ D, 1996, ASTRON J, V111, P2248, DOI 10.1086/117960##MATTEUCCI F, 1994, ASTRON ASTROPHYS, V288, P57##MCDERMID R, 2004, ASTRON NACHR, V325, P100, DOI 10.1002/ASNA.200310184##MORELLI L, 2004, MON NOT R ASTRON SOC, V354, P753, DOI 10.1111/J.1365-2966.2004.08236.X##OKE JB, 1990, ASTRON J, V99, P1621, DOI 10.1086/115444##OOSTERLOO T, 1994, MON NOT R ASTRON SOC, V266, PL10, DOI 10.1093/MNRAS/266.1.L10##PROCTOR RN, 2004, MON NOT R ASTRON SOC, V355, P1327, DOI 10.1111/J.1365-2966.2004.08415.X##PROCTOR RN, 2002, MON NOT R ASTRON SOC, V333, P517, DOI 10.1046/J.1365-8711.2002.05391.X##REST A, 2001, ASTRON J, V121, P2431, DOI 10.1086/320370##RIX HW, 1992, MON NOT R ASTRON SOC, V254, P389, DOI 10.1093/MNRAS/254.3.389##ROUSSET A, 1992, THESIS U J MONNET SA##SARZI M, 2006, MON NOT R ASTRON SOC, V366, P1151, DOI 10.1111/J.1365-2966.2005.09839.X##SARZI M, 2005, ASTROPHYS J, V628, P169, DOI 10.1086/428637##SHAPIRO KL, 2006, MON NOT R ASTRON SOC, V370, P559, DOI 10.1111/J.1365-2966.2006.10537.X##SILK J, 1998, ASTRON ASTROPHYS, V331, PL1##SMAIL I, 2002, MON NOT R ASTRON SOC, V331, P495, DOI 10.1046/J.1365-8711.2002.05203.X##SOFUE Y, 1998, PUBL ASTRON SOC JPN, V50, P427, DOI 10.1093/PASJ/50.5.427##STATLER TS, 2004, MON NOT R ASTRON SOC, V353, P1, DOI 10.1111/J.1365-2966.2004.08062.X##STATLER TS, 1991, ASTROPHYS J, V382, PL11, DOI 10.1086/186202##SURMA P, 1995, ASTRON ASTROPHYS, V298, P405##THOMAS D, 2005, ASTROPHYS J, V621, P673, DOI 10.1086/426932##THOMAS D, 2003, MON NOT R ASTRON SOC, V339, P897, DOI 10.1046/J.1365-8711.2003.06248.X##TOMITA A, 2000, ASTRON J, V120, P123, DOI 10.1086/301440##TONRY JL, 2001, ASTROPHYS J, V546, P681, DOI 10.1086/318301##TRAGER SC, 1998, ASTROPHYS J SUPPL S, V116, P1, DOI 10.1086/313099##TRAGER SC, 2000, ASTRON J, V119, P1645, DOI 10.1086/301299##TREMAINE S, 1995, ASTRON J, V110, P628, DOI 10.1086/117548##VANDERMAREL RP, 1993, ASTROPHYS J, V407, P525, DOI 10.1086/172534##VANDERMAREL RP, 1994, MON NOT R ASTRON SOC, V270, P271, DOI 10.1093/MNRAS/270.2.271##VANDEVEN G, 2004, P IAU S, V220, P179##VANDOKKUM PG, 1995, ASTRON J, V110, P2027, DOI 10.1086/117667##VAZDEKIS A, 1999, ASTROPHYS J, V513, P224, DOI 10.1086/306843##VEROLME EK, 2003, LECT NOTES PHYS, V626, P279##VEROLME EK, 2002, MON NOT R ASTRON SOC, V335, P517, DOI 10.1046/J.1365-8711.2002.05664.X##WEIL ML, 1993, ASTROPHYS J, V405, P142, DOI 10.1086/172347##WERNLI F, 2002, ASTRON ASTROPHYS, V396, P73, DOI 10.1051/0004-6361:20021333##WORTHEY G, 1994, ASTROPHYS J SUPPL S, V94, P687, DOI 10.1086/192087##WORTHEY G, 2003, ASTROPHYS J, V586, P17, DOI 10.1086/367607##WORTHEY G, 1997, ASTROPHYS J SUPPL S, V111, P377, DOI 10.1086/313021##YANG YJ, 2004, ASTROPHYS J, V607, P258, DOI 10.1086/383259##ZABLUDOFF AI, 1996, ASTROPHYS J, V466, P104, DOI 10.1086/177495",154,2020-11-20,NA
J,WOS:000243152900022,2006,CONSTRAINTS ON THE NATURE OF DUST PARTICLES BY INFRARED OBSERVATIONS,"THE FAR-INFRARED (FIR) EMISSIVITY OF DUST IS AN IMPORTANT PARAMETER CHARACTERIZING THE PHYSICAL PROPERTIES OF THE GRAINS. WITH THE AVAILABILITY OF STELLAR DATA BASES AND FIR DATA FROM INFRARED SPACE OBSERVATORY (ISO), IT IS POSSIBLE TO COMPARE THE OPTICAL AND INFRARED PROPERTIES OF DUST, AND DERIVE THE FIR EMISSIVITY WITH RESPECT TO THE OPTICAL EXTINCTION. IN THIS PAPER, WE PRESENT THE RESULTS OF A SYSTEMATIC ANALYSIS OF THE FIR EMISSIVITY OF INTERSTELLAR CLOUDS OBSERVED WITH ISOPHOT (THE PHOTOMETER ONBOARD ISO) AT LEAST AT TWO INFRARED WAVELENGTHS, ONE CLOSE TO SIMILAR TO 100 MU M AND THE OTHER AT 200 MU M. WE CONSTRUCTED FIR EMISSION MAPS, DETERMINED DUST TEMPERATURES, CREATED EXTINCTION MAPS USING TWO-MICRON ALL-SKY SURVEY DATA AND CALCULATED FIR EMISSIVITY FOR EACH OF THESE CLOUDS. WE PRESENT THE LARGEST HOMOGENEOUSLY REDUCED DATA BASE CONSTRUCTED SO FAR FOR THIS PURPOSE. DURING THE DATA ANALYSIS, SPECIAL CARE WAS TAKEN ON POSSIBLE SYSTEMATIC ERRORS. WE FIND THAT FIR EMISSIVITY HAS A CLEAR DEPENDENCE ON TEMPERATURE. THE EMISSIVITY IS ENHANCED BY A FACTOR OF USUALLY LESS THAN 2 IN THE LOW DUST TEMPERATURE REGIME OF 12 K <= T-D <= 14 K. THIS RESULT SUGGESTS LARGER GRAIN SIZES IN THOSE REGIONS. HOWEVER, THE EMISSIVITY INCREASE OF TYPICALLY BELOW 2 RESTRICTS THE POSSIBLE GRAIN GROWTH PROCESSES TO ICE MANTLE FORMATION AND COAGULATION OF SILICATE GRAINS, AND EXCLUDES THE COAGULATION OF CARBONACEOUS PARTICLES ON THE SCALES OF THE REGIONS WE INVESTIGATED. IN THE TEMPERATURE RANGE 14K <= T-D <= 16 K, A SYSTEMATIC DECREASE OF EMISSIVITY IS OBSERVED WITH RESPECT TO THE VALUES OF THE DIFFUSE INTERSTELLAR MATTER. POSSIBLE SCENARIOS FOR THIS BEHAVIOUR ARE DISCUSSED IN THIS PAPER.",BACKGROUND EXPERIMENT SEARCH; OPTICAL-PROPERTIES; TRANSLUCENT CLOUD; ISO OBSERVATIONS; MOLECULAR CLOUD; STAR COUNTS; COLD DUST; EXTINCTION; LATITUDE; EMISSION,ISM : CLOUDS; DUST; EXTINCTION; INFRARED : ISM,MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY,"KISS, C##ABRAHAM, P##LAUREIJS, RJ##MOOR, A##BIRKMANN, SM","HUNGARIAN ACAD SCI, KONKOLY OBSERV BUDAPEST, H-1525 BUDAPEST, HUNGARY. EUROPEAN SPACE AGCY, DIV ASTROPHYS, NL-2201 AZ NOORDWIJK, NETHERLANDS. MAX PLANCK INST ASTRON, D-69117 HEIDELBERG, GERMANY.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ARENDT RG, 1998, ASTROPHYS J, V508, P74, DOI 10.1086/306381##BERNARD JP, 1999, ASTRON ASTROPHYS, V347, P640##BIANCHI S, 2003, ASTRON ASTROPHYS, V399, PL43, DOI 10.1051/0004-6361:20030078##BOULANGER F, 1996, ASTRON ASTROPHYS, V312, P256##CAMBRESY L, 1997, ASTRON ASTROPHYS, V324, PL5##CAMBRESY L, 2002, ASTRON J, V123, P2559, DOI 10.1086/339830##CAMBRESY L, 2001, ASTRON ASTROPHYS, V375, P999, DOI 10.1051/0004-6361:20010930##CARDELLI JA, 1989, ASTROPHYS J, V345, P245, DOI 10.1086/167900##CUTRI R.M, 2003, 2MASS ALL SKY CATALO##DEL BURGO C, 2005, MON NOT R ASTRON SOC, V360, P901, DOI 10.1111/J.1365-2966.2005.09044.X##DEL BURGO C, 2003, MON NOT R ASTRON SOC, V346, P403, DOI 10.1046/J.1365-2966.2003.07081.X##DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480##DUPAC X, 2003, ASTRON ASTROPHYS, V404, PL11, DOI 10.1051/0004-6361:20030575##DWEK E, 1997, ASTROPHYS J, V484, P779, DOI 10.1086/304370##GABRIEL C, 1997, ASTR SOC P, V125, P108##GEZARI DY, 1973, ASTROPHYS J, V179, PL67, DOI 10.1086/181118##HAUSER M. G., 1998, COBE DIFFUSE INFRARE##HAUSER MG, 1998, ASTROPHYS J, V508, P25, DOI 10.1086/306379##JUVELA M, 2002, ASTRON ASTROPHYS, V382, P583, DOI 10.1051/0004-6361:20011539##KISS ZT, 2006, ASTRON ASTROPHYS, V453, P923, DOI 10.1051/0004-6361:20053235##KLAAS U, 2003, ESA, P19##LADA CJ, 1994, ASTROPHYS J, V429, P694, DOI 10.1086/174354##LAGACHE G, 1998, ASTRON ASTROPHYS, V333, P709##LAUREIJS RJ, 2003, ISO HDB, V5##LEHTINEN K, 1998, ASTRON ASTROPHYS, V333, P702##LEHTINEN K, 2004, ASTRON ASTROPHYS, V423, P975, DOI 10.1051/0004-6361:20047087##LEMKE D, 1996, ASTRON ASTROPHYS, V315, P64##LOMBARDI M, 2001, ASTRON ASTROPHYS, V377, P1023, DOI 10.1051/0004-6361:20011099##MONET D, 1998, USNO A2 0 CATALOGUE##MONET DG, 2003, ASTRON J, V125, P984, DOI 10.1086/345888##MOOR A, 2004, FAR INFRARED OBSERVA##MOOR A, 2003, FAR INFRARED OBSERVA##MOOR A, 2005, FAR INFRARED OBSERVA##PAGANI L, 2003, ASTRON ASTROPHYS, V406, PL59, DOI 10.1051/0004-6361:20030903##RAWLINGS MG, 2005, MON NOT R ASTRON SOC, V356, P810, DOI 10.1111/J.1365-2966.2004.08527.X##RIDDERSTAD M, 2006, ASTRON ASTROPHYS, V451, P961, DOI 10.1051/0004-6361:20053467##SALAMA A, 2004, ASTR SOC P, V314, P26##SALAMA A, 2004, COSPAR SCI ASS REC H, P4681##SCHLEGEL DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772##STEPNIK B, 2003, ASTRON ASTROPHYS, V398, P551, DOI 10.1051/0004-6361:20021309##STOGNIENKO R, 1995, ASTRON ASTROPHYS, V296, P797##WHITTET DCB, 2001, ASTROPHYS J, V547, P872, DOI 10.1086/318421##WOLF M., 1923, ASTRON NACHR, V219, P109, DOI 10.1002/ASNA.19232190702",20,2020-11-20,NA
J,WOS:000242964300049,2006,MID-INFRARED WAVELENGTH- AND FREQUENCY-MODULATION SPECTROSCOPY WITH A PUMP-MODULATED SINGLY-RESONANT OPTICAL PARAMETRIC OSCILLATOR,"WE DESCRIBE THE IMPLEMENTATION OF THE WAVELENGTH- AND FREQUENCY-MODULATION SPECTROSCOPY TECHNIQUES USING A SINGLY-RESONANT OPTICAL PARAMETRIC OSCILLATOR (OPO) PUMPED BY A FIBER-AMPLIFIED DIODE LASER. FREQUENCY MODULATION OF THE DIODE LASER WAS TRANSFERRED TO THE OPO'S MID-INFRARED IDLER OUTPUT, AVOIDING THE NEED FOR EXTERNAL MODULATION DEVICES. THIS APPROACH THUS PROVIDES A MEANS OF IMPLEMENTING THESE IMPORTANT TECHNIQUES WITH POWERFUL, WIDELY TUNABLE, MID-INFRARED SOURCES WHILE RETAINING THE SIMPLE, FLEXIBLE MODULATION PROPERTIES OF DIODE LASERS. (C) 2006 OPTICAL SOCIETY OF AMERICA.",DIODE-LASER; CONTINUOUS-WAVE; PHOTOACOUSTIC-SPECTROSCOPY,NA,OPTICS EXPRESS,"LINDSAY, ID##GROSS, P##LEE, CJ##ADHIMOOLAM, B##BOLLER, KJ","UNIV TWENTE, FAC SCI & TECHNOL, LASER PHYS & NONLINEAR OPT GRP, NL-7500 AE ENSCHEDE, NETHERLANDS.",OPTICS,OPTICS,"BJORKLUND GC, 1983, APPL PHYS B-PHOTO, V32, P145, DOI 10.1007/BF00688820##BOMSE DS, 1992, APPL OPTICS, V31, P718, DOI 10.1364/AO.31.000718##BORRI S, 2006, APPL PHYS B-LASERS O, V85, P223, DOI 10.1007/S00340-006-2343-6##HENDERSON A, 2006, OPT EXPRESS, V14, P767, DOI 10.1364/OPEX.14.000767##KLEIN ME, 2003, OPT LETT, V28, P920, DOI 10.1364/OL.28.000920##KOPLOW JP, 2000, OPT LETT, V25, P442, DOI 10.1364/OL.25.000442##KOSTEREV AA, 2002, OPT LETT, V27, P1902, DOI 10.1364/OL.27.001902##LI HJ, 2006, APPL OPTICS, V45, P1052, DOI 10.1364/AO.45.001052##LINDSAY ID, 2005, OPT EXPRESS, V13, P1234, DOI 10.1364/OPEX.13.001234##MADDALONI P, 2005, APPL PHYS B-LASERS O, V80, P141, DOI 10.1007/S00340-004-1714-0##NG J, 2004, OPT LETT, V29, P1206, DOI 10.1364/OL.29.001206##PAVONE FS, 1993, APPL PHYS B-PHOTO, V56, P118, DOI 10.1007/BF00325250##ROTHMAN LS, 2005, J QUANT SPECTROSC RA, V96, P139, DOI 10.1016/J.JQSRT.2004.10.008##VAN HERPEN MMJW, 2004, APPL PHYS B-LASERS O, V78, P281, DOI 10.1007/S00340-003-1384-3",22,2020-11-20,NA
J,WOS:000242642700023,2006,GAIN MEASUREMENTS OF FABRY-PEROT INP/INGAASP LASERS USING AN ULTRAHIGH-RESOLUTION SPECTROMETER,"MEASUREMENTS OF THE OPTICAL GAIN IN A SEMICONDUCTOR LASER USING A 20 MHZ RESOLUTION OPTICAL SPECTRUM ANALYZER ARE PRESENTED FOR WHAT IS BELIEVED TO BE THE FIRST TIME. THE HIGH RESOLUTION ALLOWS FOR ACCURATE GAIN MEASUREMENTS CLOSE TO THE LASING THRESHOLD. THIS IS DEMONSTRATED BY GAIN MEASUREMENTS ON A BULK INGAASP 1.5 MU M FABRY-PEROT LASER. COMBINED WITH DIRECT MEASUREMENT OF TRANSPARENCY CARRIER DENSITY VALUES, PARAMETERS WERE DETERMINED FOR CHARACTERIZING THE GAIN AT A RANGE OF WAVELENGTHS AND TEMPERATURES. THE NECESSITY OF THE USE OF A LOGARITHMIC GAIN MODEL IS SHOWN. (C) 2006 OPTICAL SOCIETY OF AMERICA.",SEMICONDUCTOR OPTICAL AMPLIFIERS; SPECTRA,NA,APPLIED OPTICS,"BARBARIN, Y##BENTE, EAJM##SERVANTON, G##MUSSARD, L##OEI, YS##NOTZEL, R##SMIT, MK","EINDHOVEN UNIV TECHNOL, INST COMMUN TECHNOL BASIC RES & APPLICAT, NL-5600 MB EINDHOVEN, NETHERLANDS.",OPTICS,OPTICS,"AGRAWAL GP, 1993, SEMICONDUCTOR LASERS, P142##CASSIDY DT, 1984, J APPL PHYS, V56, P3096, DOI 10.1063/1.333867##DETEMPLE TA, 1993, IEEE J QUANTUM ELECT, V29, P1246, DOI 10.1109/3.236138##DURHUUS T, 1992, J LIGHTWAVE TECHNOL, V10, P1056, DOI 10.1109/50.156845##GORDON EI, 1964, BELL SYST TECH J, V43, P507, DOI 10.1002/J.1538-7305.1964.TB04076.X##GUO WH, 2003, IEEE J QUANTUM ELECT, V39, P716, DOI 10.1109/JQE.2003.810776##HADER J, 1999, IEEE J QUANTUM ELECT, V35, P1878, DOI 10.1109/3.806602##HAKKI BW, 1975, J APPL PHYS, V46, P1299, DOI 10.1063/1.321696##OCCHI L, 2003, IEEE J SEL TOP QUANT, V9, P788, DOI 10.1109/JSTQE.2003.818346##WANG HL, 2005, IEEE J QUANTUM ELECT, V41, P532, DOI 10.1109/JQE.2005.843925",11,2020-11-20,NA
J,WOS:000242913800005,2006,"GALAXIES AT Z SIMILAR TO 6: THE UV LUMINOSITY FUNCTION AND LUMINOSITY DENSITY FROM 506 HUDF, HUDF PARALLEL ACS FIELD, AND GOODS I-DROPOUTS","WE HAVE DETECTED 506 I-DROPOUTS (Z SIMILAR TO 6 GALAXIES) IN DEEP, WIDE-AREA HSTACS FIELDS: HUDF, ENHANCED GOODS, AND HUDF PARALLEL ACS FIELDS (HUDF-PS). THE CONTAMINATION LEVELS ARE LESS THAN OR SIMILAR TO 8% (I.E., GREATER THAN OR SIMILAR TO 92% ARE AT Z SIMILAR TO 6). WITH THESE SAMPLES, WE PRESENT THE MOST COMPREHENSIVE, QUANTITATIVE ANALYSES OF Z SIMILAR TO 6 GALAXIES YET AND PROVIDE OPTIMAL MEASURES OF THE UV LUMINOSITY FUNCTION (LF) AND LUMINOSITY DENSITY AT Z SIMILAR TO 6, AND THEIR EVOLUTION TO Z SIMILAR TO 3. WE REDETERMINE THE SIZE AND COLOR EVOLUTION FROM Z SIMILAR TO 6 TO Z SIMILAR TO 3. FIELD-TO-FIELD VARIATIONS (COSMIC VARIANCE), COMPLETENESS, FLUX, AND CONTAMINATION CORRECTIONS ARE MODELED SYSTEMATICALLY AND QUANTITATIVELY. AFTER CORRECTIONS, WE DERIVE A REST-FRAME CONTINUUM UV (SIMILAR TO 1350 ANGSTROM) LF AT Z SIMILAR TO 6 THAT EXTENDS TO M-1350,M-AB SIMILAR TO -17.5 (0.04L(Z=3)*). THERE IS STRONG EVIDENCE FOR EVOLUTION OF THE LF BETWEEN Z SIMILAR TO 6 AND Z SIMILAR TO 3, MOST LIKELY THROUGH A BRIGHTENING (0.6 +/- 0.2 MAG) OF M* (AT 99.7% CONFIDENCE), ALTHOUGH THE DEGREE DEPENDS ON THE FAINT-END SLOPE. AS EXPECTED FROM HIERARCHICAL MODELS, THE MOST LUMINOUS GALAXIES ARE DEFICIENT AT Z SIMILAR TO 6. DENSITY EVOLUTION (PHI*) IS RULED OUT AT > 99.99% CONFIDENCE. DESPITE LARGE CHANGES IN THE LF, THE LUMINOSITY DENSITY AT Z SIMILAR TO 6 IS SIMILAR TO (0.82 +/- 0.21 TIMES) THAT AT Z SIMILAR TO 3. CHANGES IN THE MEAN UV COLOR OF GALAXIES FROM Z - 6 TO Z - 3 SUGGEST AN EVOLUTION IN DUST CONTENT, INDICATING THAT THE TRUE EVOLUTION IS SUBSTANTIALLY LARGER: AT Z SIMILAR TO 6 THE STAR FORMATION RATE DENSITY IS JUST SIMILAR TO 30% OF THE Z SIMILAR TO 3 VALUE. OUR UV LF IS CONSISTENT WITH Z SIMILAR TO 6 GALAXIES PROVIDING THE NECESSARY UV FLUX TO REIONIZE THE UNIVERSE.",LYMAN-BREAK GALAXIES; ULTRA-DEEP-FIELD; STAR-FORMING GALAXIES; LY-ALPHA EMITTERS; HIGH-REDSHIFT; ADVANCED CAMERA; CONTINUUM EMISSION; L-DWARF; INFRARED PHOTOMETRY; SIZE EVOLUTION,GALAXIES : EVOLUTION; GALAXIES : HIGH-REDSHIFT,ASTROPHYSICAL JOURNAL,"BOUWENS, RJ##ILLINGWORTH, GD##BLAKESLEE, JP##FRANX, M","UNIV CALIF SANTA CRUZ, DEPT ASTRON, SANTA CRUZ, CA 95064 USA. WASHINGTON STATE UNIV, DEPT PHYS & ASTRON, PULLMAN, WA 99164 USA. LEIDEN OBSERV, NL-2300 RA LEIDEN, NETHERLANDS.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ADELBERGER KL, 2000, ASTROPHYS J, V544, P218, DOI 10.1086/317183##AJIKI M, 2003, ASTRON J, V126, P2091, DOI 10.1086/378481##ARNOUTS S, 2005, ASTROPHYS J, V619, PL43, DOI 10.1086/426733##ARNOUTS S, 2001, ASTRON ASTROPHYS, V379, P740, DOI 10.1051/0004-6361:20011341##BARDEEN JM, 1986, ASTROPHYS J, V304, P15, DOI 10.1086/164143##BECKER RH, 2001, ASTRON J, V122, P2850, DOI 10.1086/324231##BECKWITH SVW, 2006, ASTRON J, V132, P1729, DOI 10.1086/507302##BERTIN E, 1996, ASTRON ASTROPHYS SUP, V117, P393, DOI 10.1051/AAS:1996164##BINNEY J, 2004, MON NOT R ASTRON SOC, V347, P1093, DOI 10.1111/J.1365-2966.2004.07277.X##BIRNBOIM Y, 2003, MON NOT R ASTRON SOC, V345, P349, DOI 10.1046/J.1365-8711.2003.06955.X##BLAKESLEE J.P., 2003, ASP C SER, V295, P257##BLAKESLEE JP, 2004, ASTROPHYS J, V602, PL9, DOI 10.1086/382505##BOUWENS R, 1998, ASTROPHYS J, V506, P579, DOI 10.1086/306289##BOUWENS R, 2003, ASTROPHYS J, V593, P640, DOI 10.1086/376588##BOUWENS R, 1998, ASTROPHYS J, V506, P557, DOI 10.1086/306258##BOUWENS RJ, 2004, ASTROPHYS J, V611, DOI 10.1086/423786##BOUWENS RJ, 2005, ASTROPHYS J, V624, PL5, DOI 10.1086/430302##BOUWENS RJ, 2004, ASTROPHYS J, V616, PL79, DOI 10.1086/426503##BOUWENS RJ, 2004, ASTROPHYS J, V606, PL25, DOI 10.1086/421016##BOUWENS RJ, 2003, ASTROPHYS J, V595, P589, DOI 10.1086/377477##BOUWENS RJ, 2006, UNPUB APJ##BUNKER AJ, 2004, MON NOT R ASTRON SOC, V355, P374, DOI 10.1111/J.1365-2966.2004.08326.X##CIMATTI A, 2002, ASTRON ASTROPHYS, V381, PL68, DOI 10.1051/0004-6361:20011696##COE D, 2006, ASTRON J, V132, P926, DOI 10.1086/505530##COLEMAN GD, 1980, ASTROPHYS J SUPPL S, V43, P393, DOI 10.1086/190674##COORAY A, 2005, MON NOT R ASTRON SOC, V364, P303, DOI 10.1111/J.1365-2966.2005.09564.X##CROTON DJ, 2006, MON NOT R ASTRON SOC, V365, P11, DOI 10.1111/J.1365-2966.2005.09675.X##DEHARVENG JM, 2001, ASTRON ASTROPHYS, V375, P805, DOI 10.1051/0004-6361:20010920##DEJONG RS, 2006, P 2005 HST CAL WORKS, P121##DI MATTEO T, 2005, NATURE, V433, P604, DOI 10.1038/NATURE03335##DICKINSON M, 2004, ASTROPHYS J, V600, PL99, DOI 10.1086/381119##DOWHYGELUND C, 2006, UNPUB APJ##FAN XH, 2002, ASTRON J, V123, P1247, DOI 10.1086/339030##FERGUSON HC, 2004, ASTROPHYS J, V600, PL107, DOI 10.1086/378578##FERNANDEZ-SOTO A, 2003, MON NOT R ASTRON SOC, V342, P1215, DOI 10.1046/J.1365-8711.2003.06622.X##GABASCH A, 2004, ASTRON ASTROPHYS, V421, P41, DOI 10.1051/0004-6361:20035909##GEBALLE TR, 2002, ASTROPHYS J, V564, P466, DOI 10.1086/324078##GIALLONGO E, 2002, ASTROPHYS J, V568, PL9, DOI 10.1086/340254##GIAVALISCO M, 2004, ASTROPHYS J, V600, PL103, DOI 10.1086/381244##GIAVALISCO M, 2004, ASTROPHYS J, V600, PL93, DOI 10.1086/379232##GRANATO GL, 2004, ASTROPHYS J, V600, P580, DOI 10.1086/379875##HU EM, 2004, ASTRON J, V127, P563, DOI 10.1086/381302##HURWITZ M, 1997, ASTROPHYS J, V481, PL31, DOI 10.1086/310649##INOUE AK, 2005, ASTRON ASTROPHYS, V435, P471, DOI 10.1051/0004-6361:20041769##IWATA I, 2003, PUBL ASTRON SOC JPN, V55, P415, DOI 10.1093/PASJ/55.2.415##KNAPP GR, 2004, ASTRON J, V127, P3553, DOI 10.1086/420707##KNEIB JP, 2004, ASTROPHYS J, V607, P697, DOI 10.1086/386281##KODAIRA K, 2003, PUBL ASTRON SOC JPN, V55, PL17, DOI 10.1093/PASJ/55.2.L17##KRON RG, 1980, ASTROPHYS J SUPPL S, V43, P305, DOI 10.1086/190669##LEGGETT SK, 2002, ASTROPHYS J, V564, P452, DOI 10.1086/324037##LEHMER BD, 2005, ASTRON J, V129, P1, DOI 10.1086/426335##LEHNERT MD, 2003, ASTROPHYS J, V593, P630, DOI 10.1086/376729##LEITHERER C, 1999, ASTROPHYS J SUPPL S, V123, P3, DOI 10.1086/313233##LEITHERER C, 1995, APJ, V454, P19##MADAU P, 1998, ASTROPHYS J, V498, P106, DOI 10.1086/305523##MADAU P, 1999, ASTROPHYS J, V514, P648, DOI 10.1086/306975##MALHOTRA S, 2005, ASTROPHYS J, V626, P666, DOI 10.1086/430047##MALKAN M, 2003, ASTROPHYS J, V598, P878, DOI 10.1086/379117##MARTIN DC, 2005, ASTROPHYS J, V619, PL59, DOI 10.1086/425496##MEURER GR, 1999, ASTROPHYS J, V521, P64, DOI 10.1086/307523##MO HJ, 1996, MON NOT R ASTRON SOC, V282, P347, DOI 10.1093/MNRAS/282.2.347##NAGAO T, 2004, ASTROPHYS J, V613, PL9, DOI 10.1086/424965##NIGHT C, 2006, MON NOT R ASTRON SOC, V366, P705, DOI 10.1111/J.1365-2966.2005.09730.X##OUCHI M, 2004, ASTROPHYS J, V611, P660, DOI 10.1086/422207##PIRZKAL N, 2004, ASTROPHYS J SUPPL S, V154, P501, DOI 10.1086/422582##REDDY NA, 2004, ASTROPHYS J, V603, PL13, DOI 10.1086/383087##RIX HW, 2004, ASTROPHYS J SUPPL S, V152, P163, DOI 10.1086/420885##RYAN RE, 2005, ASTROPHYS J, V631, PL159, DOI 10.1086/497368##SANDAGE A, 1979, ASTROPHYS J, V232, P352, DOI 10.1086/157295##SAWICKI M, 2005, ASTROPHYS J, V635, P100, DOI 10.1086/497562##SCANNAPIECO E, 2005, ASTROPHYS J, V635, PL13, DOI 10.1086/499271##SCANNAPIECO E, 2004, ASTROPHYS J, V608, P62, DOI 10.1086/386542##SCHAERER D, 2005, MON NOT R ASTRON SOC, V362, P1054, DOI 10.1111/J.1365-2966.2005.09373.X##SCHAERER D, 2003, ASTRON ASTROPHYS, V397, P527, DOI 10.1051/0004-6361:20021525##SCHECHTER P, 1976, ASTROPHYS J, V203, P297, DOI 10.1086/154079##SCHIMINOVICH D, 2005, ASTROPHYS J, V619, PL47, DOI 10.1086/427077##SCHLEGEL DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772##SHETH RK, 1999, MON NOT R ASTRON SOC, V308, P119, DOI 10.1046/J.1365-8711.1999.02692.X##SHIMASAKU K, 2005, PUBL ASTRON SOC JPN, V57, P447, DOI 10.1093/PASJ/57.3.447##SIRIANNI M, 2005, PUBL ASTRON SOC PAC, V117, P1049, DOI 10.1086/444553##SKRUTSKIE MF, 1997, ASTROPHYS SPACE SC L, V210, P25##SOMERVILLE RS, 2004, ASTROPHYS J, V600, PL171, DOI 10.1086/378628##SPERGEL DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226##STANWAY ER, 2004, ASTROPHYS J, V604, PL13, DOI 10.1086/383523##STANWAY ER, 2005, MON NOT R ASTRON SOC, V359, P1184, DOI 10.1111/J.1365-2966.2005.08977.X##STANWAY ER, 2004, ASTROPHYS J, V607, P704, DOI 10.1086/383531##STANWAY ER, 2003, MON NOT R ASTRON SOC, V342, P439, DOI 10.1046/J.1365-8711.2003.06546.X##STEIDEL CC, 1999, ASTROPHYS J, V519, P1, DOI 10.1086/307363##STEIDEL CC, 2001, ASTROPHYS J, V546, P665, DOI 10.1086/318323##STIAVELLI M, 2004, ASTROPHYS J, V610, PL1, DOI 10.1086/423198##STIAVELLI M, 2004, ASTROPHYS J, V600, P508, DOI 10.1086/380110##THOMPSON RI, 2005, ASTRON J, V130, P1, DOI 10.1086/430528##TRIMBLE V, 2005, PUBL ASTRON SOC PAC, V117, P311, DOI 10.1086/429117##WANG BQ, 1996, ASTROPHYS J, V457, P645, DOI 10.1086/176760##WHITE RL, 2003, ASTRON J, V126, P1, DOI 10.1086/375547##WILLIAMS RE, 1996, ASTRON J, V112, P1335, DOI 10.1086/118105##WILLIAMS RE, 2000, ASTRON J, V120, P2735, DOI 10.1086/316854##YAN HJ, 2005, ASTROPHYS J, V634, P109, DOI 10.1086/491695##YAN HJ, 2004, ASTROPHYS J, V612, PL93, DOI 10.1086/424690##YAN HJ, 2004, ASTROPHYS J, V600, PL1, DOI 10.1086/381573",284,2020-11-20,NA
J,WOS:000242913800012,2006,"LINE STRENGTHS IN EARLY-TYPE CLUSTER GALAXIES AT Z=0.33: IMPLICATIONS FOR ALPHA/FE, NITROGEN, AND THE HISTORIES OF E/S0S","IN THIS PAPER WE ANALYZE PREVIOUSLY PUBLISHED SPECTRA WITH HIGH SIGNAL-TO-NOISE RATIOS OF E/S0S IN THE RICH CLUSTER CL 1358+62 AT Z = 0.33. INTRODUCING TECHNIQUES FOR FITTING STELLAR POPULATION MODELS TO THE DATA, WE FOCUS ON THE 19 ES AND SOS WITH A HOMOGENEOUS SET OF EIGHT BLUE LICK INDICES. WE EXPLORE THE GALAXY PROPERTIES USING SIX-PARAMETER STELLAR POPULATION MODELS FROM THE LITERATURE AND DESCRIBE AN APPROACH FOR FITTING THE MODELS DIFFERENTIALLY, SUCH THAT THE LARGEST SYSTEMATIC ERRORS ARE AVOIDED. THE RESULTS OF THE MODEL FITTING ARE ACCURATE RELATIVE MEASURES OF THE STELLAR POPULATION PARAMETERS. WE FIND (1) NO DIFFERENCE BETWEEN THE BEST-FIT STELLAR POPULATION PARAMETERS OF ES AND S0S AT FIXED OR; (2) THE STARS IN ES AND S0S ARE UNIFORMLY OLD, CONSISTENT WITH PREVIOUSLY PUBLISHED RESULTS USING THE FUNDAMENTAL PLANE; (3) A CORRELATION OF [Z/H] WITH SIGMA, IN A MANNER CONSISTENT WITH THE OBSERVED B-V COLORS OF THE GALAXIES; (4) NO STRONG CORRELATION OF [ALPHA/FE] WITH SIGMA, DISCREPANT WITH THE CORRELATION INFERRED FROM DATA ON NEARBY GALAXIES AT THE < 3 SIGMA OR LEVEL; AND (5) A SIGNIFICANT ANTICORRELATION OF [ALPHA/N] WITH SIGMA, WHICH WE INTERPRET AS A CORRELATION OF THE ABUNDANCE OF SECONDARY NITROGEN WITH MEAN METALLICITY. WHILE THE DIFFERENCES BETWEEN OUR CONCLUSIONS AND THE CURRENT VIEW OF STELLAR POPULATIONS MAY POINT TO SERIOUS DEFICIENCIES, OUR DEDUCED CORRELATION OF MEAN METALLICITY WITH VELOCITY DISPERSION DOES REPRODUCE THE OBSERVED COLORS OF THE GALAXIES AND THE SLOPE OF THE LOCAL MG-SIGMA RELATION. MORE SPECIFICALLY, OUR DATA CONCLUSIVELY SHOW THAT CLUSTER S0S DID NOT FORM THEIR STARS AT SIGNIFICANTLY LATER EPOCHS THAN CLUSTER ELLIPTICAL GALAXIES OF THE SAME MASS, AND THE PRESENCE OF SECONDARY NITROGEN INDICATES THAT BOTH ES AND S0S FORMED FROM SELF-ENRICHING PROGENITORS, PRESUMABLY WITH EXTENDED STAR FORMATION HISTORIES.",OLD STELLAR POPULATIONS; COLOR-MAGNITUDE RELATION; MORPHOLOGY-DENSITY RELATION; STAR-FORMATION HISTORIES; RED GIANT BRANCH; ELLIPTIC GALAXIES; FUNDAMENTAL-PLANE; DISTANT CLUSTERS; CL 1358+62; VELOCITY DISPERSIONS,"GALAXIES : CLUSTERS : INDIVIDUAL; (CL 1358+62); GALAXIES : ELLIPTICAL AND LENTICULAR, CD; GALAXIES : EVOLUTION; GALAXIES : STELLAR CONTENT",ASTROPHYSICAL JOURNAL,"KELSON, DD##ILLINGWORTH, GD##FRANX, M##VAN DOKKUM, PG","CARNEGIE INST SCI, CARNEGIE OBSERV, PASADENA, CA 91101 USA. UNIV CALIF SANTA CRUZ, UNIV CALIF OBSERV, LICK OBSERV, SANTA CRUZ, CA 95065 USA. LEIDEN OBSERV, NL-2300 RA LEIDEN, NETHERLANDS. YALE UNIV, DEPT ASTRON, NEW HAVEN, CT 06520 USA.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"AOKI W, 1997, ASTRON ASTROPHYS, V328, P175##BARR J, 2005, ASTRON J, V130, P445, DOI 10.1086/431745##BAUM WA, 1959, PUBL ASTRON SOC PAC, V71, P106, DOI 10.1086/127346##BEERS TC, 1990, ASTRON J, V100, P32, DOI 10.1086/115487##BELLMAN S, 2001, PUBL ASTRON SOC PAC, V113, P326, DOI 10.1086/319336##BENSBY T, 2004, ASTRON ASTROPHYS, V415, P155, DOI 10.1051/0004-6361:20031655##BLAKESLEE JP, 2006, ASTROPHYS J, V644, P30, DOI 10.1086/503539##BOOTHROYD AI, 1999, ASTROPHYS J, V510, P232, DOI 10.1086/306546##BRILEY MM, 2004, ASTRON J, V127, P1579, DOI 10.1086/382100##BRILEY MM, 2004, ASTRON J, V127, P1588, DOI 10.1086/381912##BRILEY MM, 2002, ASTROPHYS J, V579, PL17, DOI 10.1086/345095##BRUZUAL G, 2003, MON NOT R ASTRON SOC, V344, P1000, DOI 10.1046/J.1365-8711.2003.06897.X##BURBIDGE EM, 1961, ASTROPHYS J, V133, P393, DOI 10.1086/147042##BURKE JA, 1968, MON NOT R ASTRON SOC, V140, P241, DOI 10.1093/MNRAS/140.2.241##BURSTEIN D, 1984, ASTROPHYS J, V287, P586, DOI 10.1086/162718##BURSTEIN D, 1986, ASTRON J, V91, P1130, DOI 10.1086/114090##CALDWELL N, 2003, ASTRON J, V125, P2891, DOI 10.1086/375308##CALDWELL N, 1997, ASTRON J, V113, P492, DOI 10.1086/118271##CARDIEL N, 2003, ASTRON ASTROPHYS, V409, P511, DOI 10.1051/0004-6361:20031096##CARDIEL N, 1998, ASTRON ASTROPHYS SUP, V127, P597, DOI 10.1051/AAS:1998123##CARRETERO C, 2004, ASTROPHYS J, V609, PL45, DOI 10.1086/422749##CENARRO AJ, 2003, MON NOT R ASTRON SOC, V339, PL12, DOI 10.1046/J.1365-8711.2003.06360.X##CENARRO AJ, 2004, APJ, V614, P101##CHARBONNEL C, 1994, ASTRON ASTROPHYS, V282, P811##DJORGOVSKI S, 1987, ASTROPHYS J, V313, P59, DOI 10.1086/164948##DRESSLER A, 1987, ASTROPHYS J, V313, P42, DOI 10.1086/164947##DRESSLER A, 1997, ASTROPHYS J, V490, P577, DOI 10.1086/304890##FABER SM, 1976, ASTROPHYS J, V204, P668, DOI 10.1086/154215##FABER SM, 1972, ASTRON ASTROPHYS, V20, P361##FABER SM, 1985, ASTROPHYS J SUPPL S, V57, P711, DOI 10.1086/191024##FABRICANT D, 2000, ASTROPHYS J, V539, P577, DOI 10.1086/309269##FALCON-BARROSO J, 2003, ASTROPHYS J, V588, PL17, DOI 10.1086/375391##FISHER D, 1998, ASTROPHYS J, V498, P195, DOI 10.1086/305553##FRANX M, 1989, ASTRON J, V98, P538, DOI 10.1086/115157##GALLAZZI A, 2005, MON NOT R ASTRON SOC, V362, P41, DOI 10.1111/J.1365-2966.2005.09321.X##GARBOW BS, 1980, MINPACK ROUTINES NET##GONZALEZ J, 1993, THESIS U CALIFORNIA##GORGAS J, 1993, ASTROPHYS J SUPPL S, V86, P153, DOI 10.1086/191774##GRATTON R, 2004, ANNU REV ASTRON ASTR, V42, P385, DOI 10.1146/ANNUREV.ASTRO.42.053102.133945##HENRY RBC, 2000, ASTROPHYS J, V541, P660, DOI 10.1086/309471##HENRY RBC, 1999, PUBL ASTRON SOC PAC, V111, P919, DOI 10.1086/316403##HOLDEN BP, 2006, ASTROPHYS J, V642, PL123, DOI 10.1086/504714##HOLDEN BP, 2005, ASTROPHYS J, V620, PL83, DOI 10.1086/428663##HOLDEN BP, 2004, ASTRON J, V127, P2484, DOI 10.1086/382722##HOLDEN BP, 1999, MNRAS, V306, P607##JORGENSEN I, 2005, ASTRON J, V129, P1249, DOI 10.1086/427857##JORGENSEN I, 2006, ASTROPHYS J, V639, PL9, DOI 10.1086/501348##JORGENSEN I, 1997, MON NOT R ASTRON SOC, V288, P161, DOI 10.1093/MNRAS/288.1.161##JORGENSEN I, 1995, MON NOT R ASTRON SOC, V276, P1341##JUNEAU S, 2005, ASTROPHYS J, V619, PL135, DOI 10.1086/427937##KAUFFMANN G, 1993, MON NOT R ASTRON SOC, V264, P201, DOI 10.1093/MNRAS/264.1.201##KAUFFMANN G, 1999, MON NOT R ASTRON SOC, V303, P188, DOI 10.1046/J.1365-8711.1999.02202.X##KAVIRAJ S, 2005, MON NOT R ASTRON SOC, V360, P60, DOI 10.1111/J.1365-2966.2005.08883.X##KELSON DD, 2000, ASTROPHYS J, V531, P159, DOI 10.1086/308445##KELSON DD, 2000, ASTROPHYS J, V531, P184, DOI 10.1086/308440##KELSON DD, 2000, ASTROPHYS J, V531, P137, DOI 10.1086/308460##KELSON DD, 2001, ASTROPHYS J, V552, PL17, DOI 10.1086/320252##KELSON DD, 1997, APJ, V478, P13##KOPPEN J, 1999, MON NOT R ASTRON SOC, V306, P317, DOI 10.1046/J.1365-8711.1999.02584.X##KOPPEN J, 2005, ASTRON ASTROPHYS, V434, P531, DOI 10.1051/0004-6361:20042266##KORN AJ, 2005, ASTRON ASTROPHYS, V438, P685, DOI 10.1051/0004-6361:20042126##KUNTSCHNER H, 2000, MON NOT R ASTRON SOC, V315, P184, DOI 10.1046/J.1365-8711.2000.03377.X##KUNTSCHNER H, 2001, MON NOT R ASTRON SOC, V323, P615, DOI 10.1046/J.1365-8711.2001.04263.X##KUNTSCHNER H, 1998, THESIS U DURHAM##LANZONI B, 2005, MON NOT R ASTRON SOC, V361, P369, DOI 10.1111/J.1365-2966.2005.09252.X##MARIGO P, 1998, ASTRON ASTROPHYS, V331, P564##MEHLERT D, 2003, ASTRON ASTROPHYS, V407, P423, DOI 10.1051/0004-6361:20030886##MICHIELSEN D, 2003, ASTROPHYS J, V597, PL21, DOI 10.1086/379658##MINKOWSKI R, 1962, IAU S, V15, P112##MORAN SM, 2005, ASTROPHYS J, V634, P977, DOI 10.1086/497024##MORGAN WW, 1957, PUBL ASTRON SOC PAC, V69, P291, DOI 10.1086/127075##NELAN JE, 2005, ASTROPHYS J, V632, P137, DOI 10.1086/431962##OKE JB, 1995, PUBL ASTRON SOC PAC, V107, P375, DOI 10.1086/133562##POGGIANTI BM, 2001, ASTROPHYS J, V562, P689, DOI 10.1086/323217##POSTMAN M, 2005, ASTROPHYS J, V623, P721, DOI 10.1086/428881##PROCTOR RN, 2004, MON NOT R ASTRON SOC, V355, P1327, DOI 10.1111/J.1365-2966.2004.08415.X##PROCTOR RN, 2004, MON NOT R ASTRON SOC, V349, P1381, DOI 10.1111/J.1365-2966.2004.07617.X##RIX HW, 1992, MON NOT R ASTRON SOC, V254, P389, DOI 10.1093/MNRAS/254.3.389##ROMEO AD, 2005, MON NOT R ASTRON SOC, V361, P983, DOI 10.1111/J.1365-2966.2005.09239.X##ROOD HJ, 1969, ASTROPHYS J, V158, P657, DOI 10.1086/150227##SAGLIA RP, 2002, APJ, V579, P13##SANCHEZBLAZQUEZ P, 2004, THESIS U COMPLUTENSE##SCHIAVON RP, 2004, ASTRON J, V127, P1513, DOI 10.1086/381950##SCHIAVON RP, 2002, ASTROPHYS J, V580, P850, DOI 10.1086/343788##SCHIAVON RP, 2005, UNPUB APJS##STANFORD SA, 1998, ASTROPHYS J, V492, P461, DOI 10.1086/305050##TERLEVICH R, 1981, MON NOT R ASTRON SOC, V196, P381, DOI 10.1093/MNRAS/196.2.381##THOMAS D, 2005, ASTROPHYS J, V621, P673, DOI 10.1086/426932##THOMAS D, 2003, MON NOT R ASTRON SOC, V343, P279, DOI 10.1046/J.1365-8711.2003.06659.X##THOMAS D, 2003, MON NOT R ASTRON SOC, V339, P897, DOI 10.1046/J.1365-8711.2003.06248.X##THOMAS W, 2004, ATHEROSCLEROSIS SUPP, V5, P19##TONRY J, 1979, ASTRON J, V84, P1511, DOI 10.1086/112569##TRAGER SC, 2000, ASTRON J, V120, P165, DOI 10.1086/301442##TRAGER SC, 1998, ASTROPHYS J SUPPL S, V116, P1, DOI 10.1086/313099##TRAGER SC, 2000, ASTRON J, V119, P1645, DOI 10.1086/301299##TRAN KVH, 2005, ASTROPHYS J, V627, PL25, DOI 10.1086/432090##TRIPICCO MJ, 1995, ASTRON J, V110, P3035, DOI 10.1086/117744##VAN DOKKUM PG, 2003, ASTROPHYS J, V585, P78, DOI 10.1086/345989##VAN DOKKUM PG, 1998, ASTROPHYS J, V500, P714, DOI 10.1086/305762##VAN DOKKUM PG, 1998, ASTROPHYS J, V504, PL17, DOI 10.1086/311567##VAZDEKIS A, 1999, ASTROPHYS J, V513, P224, DOI 10.1086/306843##WORTHEY G, 1994, ASTROPHYS J SUPPL S, V94, P687, DOI 10.1086/192087##WORTHEY G, 1994, ASTROPHYS J SUPPL S, V95, P107, DOI 10.1086/192096##WORTHEY G, 2003, ASTROPHYS J, V586, P17, DOI 10.1086/367607##WORTHEY G, 1997, ASTROPHYS J SUPPL S, V111, P377, DOI 10.1086/313021##WORTHEY G, 1998, PUBL ASTRON SOC PAC, V110, P888, DOI 10.1086/316203##WUYTS S, 2004, ASTROPHYS J, V605, P677, DOI 10.1086/381746##ZIEGLER BL, 2005, ASTRON ASTROPHYS, V433, P519, DOI 10.1051/0004-6361:20042471##ZIEGLER BL, 1997, MON NOT R ASTRON SOC, V291, P527, DOI 10.1093/MNRAS/291.3.527",54,2020-11-20,NA
J,WOS:000242913800035,2006,SYNCHROTRON EMISSION IN SMALL-SCALE MAGNETIC FIELDS AS A POSSIBLE EXPLANATION FOR PROMPT EMISSION SPECTRA OF GAMMA-RAY BURSTS,"SYNCHROTRON EMISSION IS BELIEVED TO BE A MAJOR RADIATION MECHANISM DURING GAMMA-RAY BURSTS' (GRBS) PROMPT EMISSION PHASE. A SIGNIFICANT DRAWBACK OF THIS ASSUMPTION IS THAT THE THEORETICAL PREDICTED SPECTRUM, CALCULATED WITHIN THE FRAMEWORK OF THE ""INTERNAL SHOCKS"" SCENARIO USING THE STANDARD ASSUMPTION THAT THE MAGNETIC FIELD MAINTAINS A STEADY VALUE THROUGHOUT THE SHOCKED REGION, LEADS TO A SLOPE F-V PROPORTIONAL TO NU(-1/2) BELOW 100 KEV, WHICH IS IN CONTRADICTION TO THE MUCH HARDER SPECTRA OBSERVED. THIS IS DUE TO THE ELECTRON COOLING TIME BEING MUCH SHORTER THAN THE DYNAMICAL TIME. IN ORDER TO OVERCOME THIS PROBLEM, WE PROPOSE HERE THAT THE MAGNETIC FIELD CREATED BY THE INTERNAL SHOCKS DECAYS ON A LENGTH SCALE MUCH SHORTER THAN THE COMOVING WIDTH OF THE PLASMA. WE SHOW THAT UNDER THIS ASSUMPTION SYNCHROTRON RADIATION CAN REPRODUCE THE OBSERVED PROMPT EMISSION SPECTRA OF THE MAJORITY OF THE BURSTS. WE CALCULATE THE REQUIRED DECAY LENGTH OF THE MAGNETIC FIELD, AND FIND IT TO BE SIMILAR TO 10(4)-10(5) CM (EQUIVALENT TO 10(5)-10(6) SKIN DEPTHS), MUCH SHORTER THAN THE CHARACTERISTIC COMOVING WIDTH OF THE PLASMA, SIMILAR TO 3 X 10(9) CM. WE IMPLEMENT OUR MODEL TO THE CASE OF GRB 050820A, WHERE A BREAK AT 4 KEV WAS OBSERVED, AND SHOW THAT THIS BREAK CAN BE EXPLAINED BY SYNCHROTRON SELF-ABSORPTION. WE DISCUSS THE CONSEQUENCES OF THE SMALL-SCALE MAGNETIC FIELD SCENARIO ON CURRENT MODELS OF MAGNETIC FIELD GENERATION IN SHOCK WAVES.",PHYSICAL PARAMETERS; RELATIVISTIC SHOCKS; GRB 970508; GENERATION; AFTERGLOW; MODEL; ENERGY; ACCELERATION; PHOTOSPHERES; CATALOG,GAMMA RAYS : BURSTS; GAMMA RAYS : THEORY; MAGNETIC FIELDS; PLASMAS; RADIATION MECHANISMS : NONTHERMAL,ASTROPHYSICAL JOURNAL,"PE'ER, A##ZHANG, B","ASTRON INST ANTON PANNEKOEK, NL-1098 SJ AMSTERDAM, NETHERLANDS. UNIV NEVADA, DEPT PHYS, LAS VEGAS, NV 89154 USA.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"CHEVALIER RA, 1992, NATURE, V355, P617, DOI 10.1038/355617A0##COHEN E, 1997, ASTROPHYS J, V488, P330, DOI 10.1086/304699##CRIDER A, 1997, ASTROPHYS J, V479, PL39, DOI 10.1086/310574##DERISHEV EV, 2001, ASTRON ASTROPHYS, V372, P1071, DOI 10.1051/0004-6361:20010586##DHAWAN V, 2000, ASTROPHYS J, V543, P373, DOI 10.1086/317088##FENDER R. P., 2006, COMPACT STELLAR XRAY, P381, DOI DOI 10.1017/CBO9780511536281##FRAIL DA, 2000, ASTROPHYS J, V537, P191, DOI 10.1086/309024##FREDERIKSEN JT, 2004, ASTROPHYS J, V608, PL13, DOI 10.1086/421262##FREEDMAN DL, 2001, ASTROPHYS J, V547, P922, DOI 10.1086/318386##FRONTERA F, 2000, ASTROPHYS J SUPPL S, V127, P59, DOI 10.1086/313316##GHIRLANDA G, 2003, ASTRON ASTROPHYS, V406, P879, DOI 10.1051/0004-6361:20030803##GHISELLINI G, 1999, ASTROPHYS J, V511, PL93, DOI 10.1086/311845##GHISELLINI G, 2000, MON NOT R ASTRON SOC, V313, PL1, DOI 10.1046/J.1365-8711.2000.03354.X##GRUZINOV A, 2001, ASTROPHYS J, V563, PL15, DOI 10.1086/324223##HEDEDAL CB, 2004, ASTROPHYS J, V617, PL107, DOI 10.1086/427387##JAROSCHEK CH, 2004, ASTROPHYS J, V616, P1065, DOI 10.1086/424923##KANEKO Y, 2006, ASTROPHYS J SUPPL S, V166, P298, DOI 10.1086/505911##KATZ JI, 1994, ASTROPHYS J, V432, PL107, DOI 10.1086/187523##KAZIMURA Y, 1998, ASTROPHYS J, V498, PL183, DOI 10.1086/311316##KUMAR P, 2006, MON NOT R ASTRON SOC, V367, PL52, DOI 10.1111/J.1745-3933.2006.00138.X##LAZZATI D, 2000, ASTROPHYS J, V529, PL17, DOI 10.1086/312452##LIANG E, 1997, ASTROPHYS J, V479, PL35, DOI 10.1086/310568##LIANG EP, 1997, ASTROPHYS J, V491, PL15, DOI 10.1086/311046##LLOYD NM, 2000, ASTROPHYS J, V543, P722, DOI 10.1086/317125##LLOYD-RONNING NM, 2002, ASTROPHYS J, V565, P182, DOI 10.1086/324484##MEDVEDEV MV, 1999, ASTROPHYS J, V526, P697, DOI 10.1086/308038##MESZAROS P, 1993, ASTROPHYS J, V405, P278, DOI 10.1086/172360##MESZAROS P, 1993, ASTROPHYS J, V415, P181, DOI 10.1086/173154##MESZAROS P, 1994, ASTROPHYS J, V432, P181, DOI 10.1086/174559##MESZAROS P, 2000, ASTROPHYS J, V530, P292, DOI 10.1086/308371##MESZAROS P, 2002, ASTROPHYS J, V578, P812, DOI 10.1086/342611##MESZAROS P, 1993, ASTROPHYS J, V418, PL59, DOI 10.1086/187116##MESZAROS P, 1997, ASTROPHYS J, V476, P232, DOI 10.1086/303625##NISHIKAWA KI, 2005, ASTROPHYS J, V622, P927, DOI 10.1086/428394##PAGE M, 2005, 3830 GCN##PANAITESCU A, 2002, ASTROPHYS J, V571, P779, DOI 10.1086/340094##PANAITESCU A, 2001, ASTROPHYS J, V560, PL49, DOI 10.1086/324061##PANAITESCU A, 2000, ASTROPHYS J, V544, PL17, DOI 10.1086/317301##PANAITESCU A, 1998, ASTROPHYS J, V501, P772, DOI 10.1086/305856##PE'ER A, 2005, ASTROPHYS J, V635, P476, DOI 10.1086/497360##PE'ER A, 2004, ASTROPHYS J, V613, P448, DOI 10.1086/422989##PE'ER A, 2006, ASTROPHYS J, V642, P995, DOI 10.1086/501424##PE'ER A, 2006, ASTROPHYS J, V643, P1036, DOI 10.1086/500969##PIRAN T, 2005, AIP CONF PROC, V784, P164##PREECE RD, 1998, ASTROPHYS J, V506, PL23, DOI 10.1086/311644##PREECE RD, 2000, ASTROPHYS J SUPPL S, V126, P19, DOI 10.1086/313289##PREECE RD, 2002, ASTROPHYS J, V581, P1248, DOI 10.1086/344252##REES MJ, 1994, ASTROPHYS J, V430, PL93, DOI 10.1086/187446##REES MJ, 1992, MON NOT R ASTRON SOC, V258, PP41, DOI 10.1093/MNRAS/258.1.41P##ROMANO P, 2006, ASTRON ASTROPHYS, V456, P917, DOI 10.1051/0004-6361:20065071##ROSSI E, 2003, MON NOT R ASTRON SOC, V339, P881, DOI 10.1046/J.1365-8711.2003.06242.X##RYBICKI G. B., 1979, RAD PROCESSES ASTROP##SARI R, 1997, MON NOT R ASTRON SOC, V287, P110, DOI 10.1093/MNRAS/287.1.110##SARI R, 1996, ASTROPHYS J, V473, P204, DOI 10.1086/178136##SARI R, 1998, ASTROPHYS J, V497, PL17, DOI 10.1086/311269##SCHAEFER BE, 1998, ASTROPHYS J, V492, P696, DOI 10.1086/305058##SILVA LO, 2003, ASTROPHYS J, V596, PL121, DOI 10.1086/379156##TAVANI M, 1996, ASTROPHYS J, V466, P768, DOI 10.1086/177551##TAVANI M, 1996, PHYS REV LETT, V76, P3478, DOI 10.1103/PHYSREVLETT.76.3478##WAXMAN E, 1997, ASTROPHYS J, V489, PL33, DOI 10.1086/310960##WAXMAN E, 1997, ASTROPHYS J, V485, PL5, DOI 10.1086/310809##WIERSMA J, 2004, ASTRON ASTROPHYS, V428, P365, DOI 10.1051/0004-6361:20041882##WIJERS RAMJ, 1999, ASTROPHYS J, V523, P177, DOI 10.1086/307705##ZHANG B, 2002, ASTROPHYS J, V581, P1236, DOI 10.1086/344338##ZHANG B, 2004, INT J MOD PHYS A, V19, P2385, DOI 10.1142/S0217751X0401746X",65,2020-11-20,NA
J,WOS:000242913800036,2006,JET BREAKS IN SHORT GAMMA-RAY BURSTS. I. THE UNCOLLIMATED AFTERGLOW OF GRB 050724,"WE REPORT THE RESULTS OF THE CHANDRA OBSERVATIONS OF THE SWIFT-DISCOVERED SHORT GAMMA-RAY BURST GRB 050724. CHANDRA OBSERVED THIS BURST TWICE, ABOUT 2 DAYS AFTER THE BURST AND A SECOND TIME 3 WEEKS LATER. THE FIRST CHANDRA POINTING OCCURRED AT THE END OF A STRONG LATE-TIME FLARE. ABOUT 150 PHOTONS WERE DETECTED DURING THIS 49.3 KS OBSERVATION IN THE 0.4-10.0 KEV RANGE. THE SPECTRAL FIT IS IN GOOD AGREEMENT WITH SPECTRAL ANALYSIS OF EARLIER SWIFT XRT DATA. IN THE SECOND CHANDRA POINTING THE AFTERGLOW WAS CLEARLY DETECTED WITH EIGHT BACKGROUND-SUBTRACTED PHOTONS IN 44.6 KS. FROM THE COMBINED SWIFT XRT AND CHANDRA-ACIS-S LIGHT CURVE WE FIND SIGNIFICANT FLARING SUPERPOSED ON AN UNDERLYING POWER-LAW DECAY SLOPE OF ALPHA = 0.98(-0.09)(+0.11). THERE IS NO EVIDENCE FOR A BREAK BETWEEN ABOUT 1 KS AFTER THE BURST AND THE LAST CHANDRA POINTING ABOUT 3 WEEKS AFTERTHE BURST. THE TIONDETECTION OF AJET BREAK PLACES A LOWER LIMIT OF 25 DEGREES ON THE JET OPENING ANGLE, INDICATING THAT THE OUTFLOW IS LESS STRONGLY COLLIMATED THAN MOST PREVIOUSLY REPORTED LONG GRBS. THIS IMPLIES THAT THE BEAMING CORRECTED ENERGY OF GRB 050724 IS AT LEAST 4 X 1049 ERGS.",HOST GALAXY; ENGINE ACTIVITY; LIGHT CURVES; BLACK-HOLES; TELESCOPE; ENERGETICS; FLARES; ORIGIN; DISCOVERY; MISSION,GAMMA RAYS : BURSTS; X-RAYS : INDIVIDUAL (GRB 050724),ASTROPHYSICAL JOURNAL,"GRUPE, D##BURROWS, DN##PATEL, SK##KOUVELIOTOU, C##ZHANG, B##MESZAROS, P##WIJERS, RAM##GEHRELS, N","PENN STATE UNIV, DEPT ASTRON & ASTROPHYS, UNIVERSITY PK, PA 16802 USA. UNIV SPACE RES ASSOC, COLUMBIA, MD 21044 USA. NASA, GEORGE C MARSHALL SPACE FLIGHT CTR, NATL SPACE SCI TECHNOL CTR, HUNTSVILLE, AL 35805 USA. UNIV NEVADA, DEPT PHYS, LAS VEGAS, NV 89154 USA. PENN STATE UNIV, DEPT PHYS, UNIVERSITY PK, PA 16802 USA. UNIV AMSTERDAM, ASTRON INST ANTON PANNEKOEK, NL-1098 SJ AMSTERDAM, NETHERLANDS. NASA, GODDARD SPACE FLIGHT CTR, GREENBELT, MD 20771 USA.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ALOY MA, 2005, ASTRON ASTROPHYS, V436, P273, DOI 10.1051/0004-6361:20041865##ARNAUD KA, 1996, ASTR SOC P, V101, P17##BARTHELMY SD, 2005, SPACE SCI REV, V120, P143, DOI 10.1007/S11214-005-5096-3##BARTHELMY SD, 2005, NATURE, V438, P994, DOI 10.1038/NATURE04392##BERGER E, 2005, NATURE, V438, P988, DOI 10.1038/NATURE04238##BLOOM JS, 2003, ASTROPHYS J, V594, P674, DOI 10.1086/377125##BLOOM JS, 2006, ASTROPHYS J, V638, P354, DOI 10.1086/498107##BURROWS DN, 2005, SCIENCE, V309, P1833, DOI 10.1126/SCIENCE.1116168##BURROWS DN, 2005, SPACE SCI REV, V120, P165, DOI 10.1007/S11214-005-5097-2##BURROWS DN, 2005, 3697 GCN##BURROWS DN, 2006, APJ, V653, P469##CAMPANA S, 2006, ASTRON ASTROPHYS, V454, P113, DOI 10.1051/0004-6361:20064856##CHESTER M, 2005, 3670 GCN##COSTA E, 1997, NATURE, V387, P783, DOI 10.1038/42885##COVINO S, 2005, 3665 GCN##DAI ZG, 2006, SCIENCE, V311, P1127, DOI 10.1126/SCIENCE.1123606##DICKEY JM, 1990, ANNU REV ASTRON ASTR, V28, P215, DOI 10.1146/ANNUREV.AA.28.090190.001243##EICHLER D, 1989, NATURE, V340, P126, DOI 10.1038/340126A0##FABER JA, 2006, ASTROPHYS J, V641, PL93, DOI 10.1086/504111##FALCONE AD, 2006, ASTROPHYS J, V641, P1010, DOI 10.1086/500655##FOX DB, 2005, NATURE, V437, P845, DOI 10.1038/NATURE04189##FRAIL DA, 2001, ASTROPHYS J, V562, PL55, DOI 10.1086/338119##GEHRELS N, 2004, ASTROPHYS J, V611, P1005, DOI 10.1086/422091##GEHRELS N, 2005, NATURE, V437, P851, DOI 10.1038/NATURE04142##HILL JE, 2004, P SOC PHOTO-OPT INS, V5165, P217, DOI 10.1117/12.505728##HJORTH J, 2005, NATURE, V437, P859, DOI 10.1038/NATURE04174##HOGG D. W., 1999, ASTROPH9905116##KOUVELIOTOU C, 1993, APJ, V413, P101, DOI DOI 10.1086/186969)##LIANG EW, 2006, ASTROPHYS J, V646, P351, DOI 10.1086/504684##MESZAROS P, 1997, ASTROPHYS J, V476, P232, DOI 10.1086/303625##MESZAROS P, 1999, NEW ASTRON, V4, P303, DOI 10.1016/S1384-1076(99)00013-5##NOUSEK JA, 2006, ASTROPHYS J, V642, P389, DOI 10.1086/500724##PACIESAS WS, 1999, ASTROPHYS J SUPPL S, V122, P465, DOI 10.1086/313224##PACZYNSKI B., 1991, ACTA ASTRONOMICA, V41, P257##PANAITESCU A, 2006, MON NOT R ASTRON SOC, V367, PL42, DOI 10.1111/J.1745-3933.2005.00134.X##PERNA R, 2006, ASTROPHYS J, V636, PL29, DOI 10.1086/499775##POPHAM R, 1999, ASTROPHYS J, V518, P356, DOI 10.1086/307259##PROCHASKA JX, 2006, ASTROPHYS J, V642, P989, DOI 10.1086/501160##PROGA D, 2006, MON NOT R ASTRON SOC, V370, PL61, DOI 10.1111/J.1745-3933.2006.00189.X##RHOADS JE, 1999, ASTROPHYS J, V525, P737, DOI 10.1086/307907##ROMANO P, 2006, ASTRON ASTROPHYS, V450, P59, DOI 10.1051/0004-6361:20054172##ROMANO P, 2005, 3685 GCN##ROMING PWA, 2005, SPACE SCI REV, V120, P95, DOI 10.1007/S11214-005-5095-4##SARI R, 1999, ASTROPHYS J, V519, PL17, DOI 10.1086/312109##SODERBERG AM, 2006, ASTROPHYS J, V650, P261, DOI 10.1086/506429##SODERBERG AM, 2005, 3696 GCN##VAUGHAN S, 2006, ASTROPHYS J, V639, P323, DOI 10.1086/499353##VILLASENOR JS, 2005, NATURE, V437, P855, DOI 10.1038/NATURE04213##WOOSLEY SE, 1993, ASTROPHYS J, V405, P273, DOI 10.1086/172359##ZHANG B, 2006, ASTROPHYS J, V642, P354, DOI 10.1086/500723##ZHANG B, 2004, INT J MOD PHYS A, V19, P2385, DOI 10.1142/S0217751X0401746X##ZHANG WQ, 2004, ASTROPHYS J, V608, P365, DOI 10.1086/386300",89,2020-11-20,NA
J,WOS:000242913800037,2006,JET BREAKS IN SHORT GAMMA-RAY BURSTS. II. THE COLLIMATED AFTERGLOW OF GRB 051221A,"WE REPORT THE BEST EVIDENCE TO DATE OF A JET BREAK IN A SHORT GAMMA-RAY BURST (GRB) AFTERGLOW, USING CHANDRA AND SWIFT XRT OBSERVATIONS OF THE X-RAY AFTERGLOW OF GRB 051221A. THE COMBINED X-RAY LIGHT CURVE, WHICH HAS THREE BREAKS, IS SIMILAR TO THOSE COMMONLY OBSERVED IN SWIFT OBSERVATIONS OF LONG GRBS. A FLAT SEGMENT OF THE LIGHT CURVE AT SIMILAR TO 0.1 DAYS AFTER THE BURST REPRESENTS THE FIRST CLEAR CASE OF STRONG ENERGY INJECTION IN THE EXTERNAL SHOCK OF A SHORT GRB AFTERGLOW. THE LAST BREAK IN THE LIGHT CURVE OCCURS AT SIMILAR TO 4 DAYS POSTBURST AND BREAKS TO A POWER-LAW DECAY INDEX OF SIMILAR TO 2. WE INTERPRET THIS AS A JET BREAK, WITH IMPORTANT IMPLICATIONS FOR MODELS OF SHORT GRBS, SINCE IT REQUIRES COLLIMATION OF THE AFTERGLOW INTO A JET WITH AN INITIAL OPENING ANGLE THETA(0) SIMILAR TO 4 DEGREES-8 DEGREES AND IMPLIES A TOTAL JET KINETIC ENERGY OF E-JET SIMILAR TO (1-5) X 10(49) ERGS. COMBINED WITH THE LACK OF A JET BREAK IN GRB 050724, THIS SUGGESTS A WIDE RANGE IN JET COLLIMATION IN SHORT GRBS, WITH AT LEAST SOME HAVING COLLIMATION SIMILAR TO THAT FOUND IN LONG GRBS, ALTHOUGH WITH SIGNIFICANTLY LOWER JET ENERGIES.",NEUTRON-STARS; HOST GALAXY; TELESCOPE; GRB-050709; ENERGETICS; NUCLEOSYNTHESIS; CONSTRAINTS; EMISSION; BINARIES; OUTFLOWS,GAMMA RAYS : BURSTS,ASTROPHYSICAL JOURNAL,"BURROWS, DN##GRUPE, D##CAPALBI, M##PANAITESCU, A##PATEL, SK##KOUVELIOTOU, C##ZHANG, B##MESZAROS, P##CHINCARINI, G##GEHRELS, N##WIJERS, RAM","PENN STATE UNIV, DEPT ASTRON & ASTROPHYS, UNIVERSITY PK, PA 16802 USA. ASI, SCI DATA CTR, I-00044 FRASCATI, ITALY. LOS ALAMOS NATL LAB, LOS ALAMOS, NM 87545 USA. UNIV SPACE RES ASSOC, COLUMBIA, MD 21044 USA. NASA, NATL SPACE SCI TECHNOL CTR, MARSHALL SPACE FLIGHT CTR, HUNTSVILLE, AL 35805 USA. UNIV NEVADA, DEPT PHYS, LAS VEGAS, NV 89154 USA. PENN STATE UNIV, DEPT PHYS, UNIVERSITY PK, PA 16802 USA. OSSERV ASTRON BRERA, INAF, MERATE 23807, ITALY. UNIV MILAN, DIPARTIMENTO FIS, I-20126 MILAN, ITALY. NASA, GODDARD SPACE FLIGHT CTR, GREENBELT, MD 20771 USA. UNIV AMSTERDAM, ASTRON INST ANTON PANNEKOEK, NL-1098 SJ AMSTERDAM, NETHERLANDS.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"BARTHELMY SD, 2005, SPACE SCI REV, V120, P143, DOI 10.1007/S11214-005-5096-3##BARTHELMY SD, 2005, NATURE, V438, P994, DOI 10.1038/NATURE04392##BLOOM JS, 2003, ASTROPHYS J, V594, P674, DOI 10.1086/377125##BLOOM JS, 2006, ASTROPHYS J, V638, P354, DOI 10.1086/498107##BURROWS DN, 2005, SPACE SCI REV, V120, P165, DOI 10.1007/S11214-005-5097-2##BURROWS DN, 2005, 4366 GCN##CAMPANA S, 2006, ASTRON ASTROPHYS, V454, P113, DOI 10.1051/0004-6361:20064856##CUMMINGS J, 2005, 4365 GCN##DICKEY JM, 1990, ANNU REV ASTRON ASTR, V28, P215, DOI 10.1146/ANNUREV.AA.28.090190.001243##EICHLER D, 1989, NATURE, V340, P126, DOI 10.1038/340126A0##FOX DB, 2005, NATURE, V437, P845, DOI 10.1038/NATURE04189##FRAIL DA, 2001, ASTROPHYS J, V562, PL55, DOI 10.1086/338119##GEHRELS N, 2004, ASTROPHYS J, V611, P1005, DOI 10.1086/422091##GEHRELS N, 2005, NATURE, V437, P851, DOI 10.1038/NATURE04142##GOLENETSKII S, 2005, 4394 GCN##GRUPE D, 2005, 4389 GCN##GRUPE D, 2006, APJ, V653, P463##HILL JE, 2004, P SOC PHOTO-OPT INS, V5165, P217, DOI 10.1117/12.505728##HJORTH J, 2005, NATURE, V437, P859, DOI 10.1038/NATURE04174##HJORTH J, 2005, ASTROPHYS J, V630, PL117, DOI 10.1086/491733##LATTIMER JM, 1976, ASTROPHYS J, V210, P549, DOI 10.1086/154860##NOUSEK JA, 2006, ASTROPHYS J, V642, P389, DOI 10.1086/500724##PACZYNSKI B, 1986, ASTROPHYS J, V308, PL43, DOI 10.1086/184740##PACZYNSKI B., 1991, ACTA ASTRONOMICA, V41, P257##PAGANI C, 2006, ASTROPHYS J, V645, P1315, DOI 10.1086/504518##PANAITESCU A, 2006, MON NOT R ASTRON SOC, V366, P1357, DOI 10.1111/J.1365-2966.2005.09900.X##PANAITESCU A, 2006, MON NOT R ASTRON SOC, V367, PL42, DOI 10.1111/J.1745-3933.2005.00134.X##PANAITESCU A, 2005, MON NOT R ASTRON SOC, V363, P1409, DOI 10.1111/J.1365-2966.2005.09532.X##PANAITESCU A, 2003, ASTROPHYS J, V592, P390, DOI 10.1086/375563##PARSONS A, 2005, 4363 GCN##ROMANO P, 2006, ASTRON ASTROPHYS, V456, P917, DOI 10.1051/0004-6361:20065071##ROSSWOG S, 2005, ASTROPHYS J, V634, P1202, DOI 10.1086/497062##ROSSWOG S, 2003, MON NOT R ASTRON SOC, V345, P1077, DOI 10.1046/J.1365-2966.2003.07032.X##SODERBERG AM, 2006, ASTROPHYS J, V650, P261, DOI 10.1086/506429##VAUGHAN S, 2006, ASTROPHYS J, V638, P920, DOI 10.1086/499069##VILLASENOR JS, 2005, NATURE, V437, P855, DOI 10.1038/NATURE04213##ZHANG B, 2006, ASTROPHYS J, V642, P354, DOI 10.1086/500723##ZHANG B, 2004, INT J MOD PHYS A, V19, P2385, DOI 10.1142/S0217751X0401746X",116,2020-11-20,NA
J,WOS:000242913800042,2006,"A LONG, HARD LOOK AT THE LOW/HARD STATE IN ACCRETING BLACK HOLES","WE PRESENT THE FIRST RESULTS OF COORDINATED MULTIWAVELENGTH OBSERVATIONS OF THE GALACTIC BLACK HOLE GX 339-4 IN A CANONICAL LOW/HARD STATE, OBTAINED DURING ITS 2004 OUTBURST. XMM-NEWTON OBSERVED THE SOURCE FOR TWO REVOLUTIONS, OR APPROXIMATELY 280 KS; RXTE MONITORED THE SOURCE THROUGHOUT THIS LONG STARE. THE RESULTING DATA OFFER THE BEST VIEW YET OBTAINED OF THE INNER ACCRETION FLOW GEOMETRY IN THE LOW/HARD STATE, WHICH IS THOUGHT TO BE ANALOGOUS TO THE GEOMETRY IN LOW-LUMINOSITY ACTIVE GALACTIC NUCLEI. THE XMM-NEWTON SPECTRA CLEARLY REVEAL THE PRESENCE OF A COOL ACCRETION DISK COMPONENT AND A RELATIVISTIC FE K EMISSION LINE. THE RESULTS OF FITS MADE TO BOTH COMPONENTS STRONGLY SUGGEST THAT A STANDARD THIN DISK REMAINS AT OR NEAR TO THE INNERMOST STABLE CIRCULAR ORBIT, AT LEAST IN BRIGHT PHASES OF THE LOW/HARD STATE. THESE FINDINGS INDICATE THAT POTENTIAL LINKS BETWEEN THE INNER DISK RADIUS AND THE ONSET OF A STEADY COMPACT JET, AND THE PARADIGM OF A RADIALLY RECESSED DISK IN THE LOW/HARD STATE, DO NOT HOLD UNIVERSALLY. THE RESULTS OF OUR OBSERVATIONS CAN BEST BE EXPLAINED IF A STANDARD THIN ACCRETION DISK FUELS A CORONA THAT IS CLOSELY RELATED TO, OR CONSISTENT WITH, THE BASE OF A COMPACT JET. IN A BRIEF EXAMINATION OF ARCHIVAL DATA, WE SHOW THAT CYGNUS X-1 SUPPORTS THIS PICTURE OF THE LOW/HARD STATE. WE DISCUSS OUR RESULTS WITHIN THE CONTEXT OF DISK-JET CONNECTIONS AND PREVAILING MODELS FOR ACCRETION ONTO BLACK HOLES.",ADVECTION-DOMINATED ACCRETION; XMM-NEWTON/EPIC-PN; X-RAY TRANSIENTS; ASCA OBSERVATIONS; RADIO-EMISSION; XTE J1118+480; IRON-LINE; CANDIDATE; GX-339-4; EVOLUTION,"ACCRETION, ACCRETION DISKS; BLACK HOLE PHYSICS; RELATIVITY; X-RAYS : BINARIES; X-RAYS : INDIVIDUAL (GX 339-4)",ASTROPHYSICAL JOURNAL,"MILLER, JM##HOMAN, J##STEEGHS, D##RUPEN, M##HUNSTEAD, RW##WIJNANDS, R##CHARLES, PA##FABIAN, AC","UNIV MICHIGAN, DEPT ASTRON, ANN ARBOR, MI 48109 USA. MIT, KAVLI INST ASTROPHYS & SPACE RES, CAMBRIDGE, MA 02139 USA. HARVARD SMITHSONIAN CTR ASTROPHYS, CAMBRIDGE, MA 02138 USA. NATL RADIO ASTRON OBSERV, ARRAY OPERAT CTR, SOCORRO, NM 87801 USA. UNIV SYDNEY, SCH PHYS, SYDNEY, NSW 2006, AUSTRALIA. UNIV AMSTERDAM, ASTRON INST ANTON PANNEKOEK, NL-1098 SJ AMSTERDAM, NETHERLANDS. UNIV SOUTHAMPTON, SCH PHYS & ASTRON, SOUTHAMPTON SO17 1BJ, HANTS, ENGLAND. S AFRICAN ASTRON OBSERV, ZA-7935 CAPE TOWN, SOUTH AFRICA. UNIV CAMBRIDGE, ASTRON INST, CAMBRIDGE CB3 0HA, ENGLAND.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"BAGANOFF FK, 2003, ASTROPHYS J, V591, P891, DOI 10.1086/375145##BALLANTYNE DR, 2001, MON NOT R ASTRON SOC, V323, P506, DOI 10.1046/J.1365-8711.2001.04234.X##BALUCINSKA M, 1991, ASTRON ASTROPHYS, V241, P439##BARR P, 1990, ASTROPHYS J, V352, PL41, DOI 10.1086/185689##BELLONI T, 1990, ASTRON ASTROPHYS, V227, PL33##BELLONI T, 2005, ASTRON ASTROPHYS, V440, P207, DOI 10.1051/0004-6361:20042457##BELLONI T, 1997, ASTROPHYS J, V479, PL145, DOI 10.1086/310595##BELOBORODOV AM, 1999, ASTROPHYS J, V510, PL123, DOI 10.1086/311810##BRANDT WN, 1996, MON NOT R ASTRON SOC, V283, P1071, DOI 10.1093/MNRAS/283.3.1071##CORBEL S, 2000, ASTRON ASTROPHYS, V359, P251##DONE C, 2006, IN PRESS MNRAS##EBISAWA K, 1996, ASTROPHYS J, V467, P419, DOI 10.1086/177616##ESIN AA, 1997, ASTROPHYS J, V489, P865, DOI 10.1086/304829##FABIAN AC, 1995, MON NOT R ASTRON SOC, V277, PL11##FENDER RP, 2004, MON NOT R ASTRON SOC, V355, P1105, DOI 10.1111/J.1365-2966.2004.08384.X##FENDER RP, 2005, COMPACT STELLAR XRAY##FRANK J., 2002, ACCRETION POWER ASTR##GALLO E, 2004, MON NOT R ASTRON SOC, V347, PL52, DOI 10.1111/J.1365-2966.2004.07435.X##GIERLINSKI M, 1997, MON NOT R ASTRON SOC, V288, P958, DOI 10.1093/MNRAS/288.4.958##GREISEN E, 2005, AIPS COOKBOOK##HERRERO A, 1995, ASTRON ASTROPHYS, V297, P556##HERRNSTEIN JR, 1998, ASTROPHYS J, V497, PL69, DOI 10.1086/311284##HOMAN J, 2005, ASTROPHYS J, V624, P295, DOI 10.1086/428722##HOMAN J, 2001, ASTROPHYS J SUPPL S, V132, P377, DOI 10.1086/318954##HOMAN J, 2005, ASTROPHYS SPACE SCI, V300, P107, DOI 10.1007/S10509-005-1197-4##HYNES RI, 2004, ASTROPHYS J, V609, P317, DOI 10.1086/421014##HYNES RI, 2003, ASTROPHYS J, V583, PL95, DOI 10.1086/368108##HYNES RI, 2005, ASTROPHYS J, V623, P1026, DOI 10.1086/428445##KLEIN-WOLT M, 2004, NUCL PHYS B-PROC SUP, V132, P381, DOI 10.1016/J.NUCLPHYSBPS.2004.04.067##MACCARONE TJ, 2002, MON NOT R ASTRON SOC, V336, P1371, DOI 10.1046/J.1365-8711.2002.05876.X##MAGDZIARZ P, 1995, MON NOT R ASTRON SOC, V273, P837, DOI 10.1093/MNRAS/273.3.837##MAOZ D, 2005, ASTROPHYS J, V625, P699, DOI 10.1086/429795##MARKOFF S, 2003, ASTRON ASTROPHYS, V397, P645, DOI 10.1051/0004-6361:20021497##MARKOFF S, 2004, ASTROPHYS J, V609, P972, DOI 10.1086/421099##MARKOFF S, 2001, ASTRON ASTROPHYS, V372, PL25, DOI 10.1051/0004-6361:20010420##MARKOWITZ A, 2005, ASTROPHYS J, V625, PL39, DOI 10.1086/430762##MCCLINTOCK JE, 1995, ASTROPHYS J, V442, P358, DOI 10.1086/175445##MCCLINTOCK JE, 2001, ASTROPHYS J, V555, P477, DOI 10.1086/321449##MCCLINTOCK JE, 2005, COMPACT STELLAR XRAY, P157##MERLONI A, 2000, MON NOT R ASTRON SOC, V313, P193, DOI 10.1046/J.1365-8711.2000.03226.X##MERLONI A, 2002, MON NOT R ASTRON SOC, V332, P165, DOI 10.1046/J.1365-8711.2002.05288.X##MEYER-HOFMEISTER E, 1999, ASTRON ASTROPHYS, V348, P154##MILLER JM, 2006, ASTROPHYS J, V652, PL113, DOI 10.1086/510015##MILLER JM, 2002, MON NOT R ASTRON SOC, V335, P865, DOI 10.1046/J.1365-8711.2002.05636.X##MILLER JM, 2004, ASTROPHYS J, V606, PL131, DOI 10.1086/421263##MILLER JM, 2002, ASTROPHYS J, V570, PL69, DOI 10.1086/341099##MILLER JM, 2002, ASTROPHYS J, V578, P348, DOI 10.1086/342466##MILLER JM, 2004, ASTROPHYS J, V601, P450, DOI 10.1086/380196##MIYAMOTO S, 1991, ASTROPHYS J, V383, P784, DOI 10.1086/170837##MIYAMOTO S, 1995, APJ, V442, P13##PARK SQ, 2004, ASTROPHYS J, V610, P378, DOI 10.1086/421511##REYNOLDS CS, 2000, ASTROPHYS J, V533, P821, DOI 10.1086/308712##ROSSI S, 2005, MON NOT R ASTRON SOC, V360, P763, DOI 10.1111/J.1365-2966.2005.09069.X##SAULT R, 2004, MIRIAD USERS GUIDE##SHRADER CR, 1999, ASTROPHYS J, V521, PL121, DOI 10.1086/312194##TANAKA Y, 1995, NATURE, V375, P659, DOI 10.1038/375659A0##TITARCHUK L, 2003, ASTROPHYS J, V598, P411, DOI 10.1086/378701##VADAWALE SV, 2003, ASTROPHYS J, V597, P1023, DOI 10.1086/378672##VAUGHAN S, 2004, MON NOT R ASTRON SOC, V348, P1415, DOI 10.1111/J.1365-2966.2004.07456.X##ZDZIARSKI AA, 2004, MON NOT R ASTRON SOC, V351, P791, DOI 10.1111/J.1365-2966.2004.07830.X##ZIMMERMAN ER, 2005, ASTROPHYS J, V618, P832, DOI 10.1086/426071",194,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/D001013/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242914000015,2006,BINARITY AS A KEY FACTOR IN PROTOPLANETARY DISK EVOLUTION: SPITZER DISK CENSUS OF THE ETA CHAMAELEONTIS CLUSTER,"THE FORMATION OF PLANETS IS DIRECTLY LINKED TO THE EVOLUTION OF THE CIRCUMSTELLAR (CS) DISK FROM WHICH THEY ARE BORN. THE DISSIPATION TIMESCALES OF CS DISKS ARE THEREFORE OF DIRECT ASTROPHYSICAL IMPORTANCE IN EVALUATING THE TIME AVAILABLE FOR PLANET FORMATION. WE EMPLOY SPITZER SPACE TELESCOPE SPECTRA TO COMPLETE THE CS DISK CENSUS FOR THE LATE-TYPE MEMBERS OF THE SIMILAR OR EQUAL TO 8 MYR OLD ETA CHAMAELEONTIS STAR CLUSTER. OF THE 15 K- AND M-TYPE MEMBERS, EIGHT SHOW EXCESS EMISSION. WE FIND THAT THE PRESENCE OF A CS DISK IS ANTICORRELATED WITH BINARITY, WITH ALL BUT ONE DISK ASSOCIATED WITH SINGLE STARS. WITH NINE SINGLE STARS IN TOTAL, ABOUT 80% RETAIN A CS DISK. OF THE SIX KNOWN OR SUSPECTED CLOSE BINARIES, THE ONLY CS DISK IS ASSOCIATED WITH THE PRIMARY OF RECX 9. NO CIRCUMBINARY DISKS HAVE BEEN DETECTED. WE ALSO FIND THAT STARS WITH DISKS ARE SLOW ROTATORS WITH SURFACE VALUES OF SPECIFIC ANGULAR MOMENTUM J= 2-15 J(CIRCLE DOT). ALL HIGH SPECIFIC ANGULAR MOMENTUM SYSTEMS WITH J=20-30J(CIRCLE DOT) ARE CONFINED TO THE PRIMARY STARS OF BINARIES. THIS PROVIDES NOVEL EMPIRICAL EVIDENCE FOR ROTATIONAL DISK LOCKING AND AGAIN DEMONSTRATES THE MUCH SHORTER DISK LIFETIMES IN CLOSE BINARY SYSTEMS COMPARED TO SINGLE-STAR SYSTEMS. WE ESTIMATE THE CHARACTERISTIC MEAN DISK DISSIPATION TIMESCALE TO BE SIMILAR TO 5 AND APPROXIMATE TO 9 MYR FOR THE BINARY AND SINGLE-STAR SYSTEMS, RESPECTIVELY.",PRE-MAIN-SEQUENCE; INFRARED SPECTROGRAPH; STAR; ACCRETION; SKY,BINARIES : GENERAL; INFRARED : STARS; OPEN CLUSTERS AND ASSOCIATIONS : INDIVIDUAL (ETA CHAMAELEONTIS); PLANETARY SYSTEMS : FORMATION; PLANETARY SYSTEMS : PROTOPLANETARY DISKS; STARS : PRE-MAIN SEQUENCE,ASTROPHYSICAL JOURNAL,"BOUWMAN, J##LAWSON, WA##DOMINIK, C##FEIGELSON, ED##HENNING, T##TIELENS, AGGM##WATERS, LBFM","MAX PLANCK INST ASTRON, D-69117 HEIDELBERG, GERMANY. UNIV NEW S WALES, SCH PHYS ENVIRONM & MATH SCI, AUSTRALIAN DEF FORCE ACAD, CANBERRA, ACT 2600, AUSTRALIA. UNIV AMSTERDAM, ASTRON INST ANTON PANNEKOEK, NL-1098 SJ AMSTERDAM, NETHERLANDS. PENN STATE UNIV, DEPT ASTRON & ASTROPHYS, UNIVERSITY PK, PA 16802 USA. UNIV GRONINGEN, KAPTEYN ASTRON INST, NL-9700 AV GRONINGEN, NETHERLANDS.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ARTYMOWICZ P, 1994, ASTROPHYS J, V421, P651, DOI 10.1086/173679##BOUVIER J, 1997, ASTRON ASTROPHYS, V326, P1023##BRANDEKER A, 2006, IN PRESS APJ##COVINO E, 1997, ASTRON ASTROPHYS, V328, P187##GULLBRING E, 1998, ASTROPHYS J, V492, P323, DOI 10.1086/305032##HAISCH KE, 2001, ASTROPHYS J, V553, PL153, DOI 10.1086/320685##HERBST W, 2005, ASTROPHYS J, V633, P967, DOI 10.1086/491577##HIGDON SJU, 2004, PUBL ASTRON SOC PAC, V116, P975, DOI 10.1086/425083##HOUCK JR, 2004, ASTROPHYS J SUPPL S, V154, P18, DOI 10.1086/423134##JAYAWARDHANA R, 2006, IN PRESS APJ##KLEY W, 2001, IAU S, V200, P511##KOHLER R, 2002, ASTRON J, V124, P2899, DOI 10.1086/344081##KUKER M, 2003, ASTROPHYS J, V589, P397, DOI 10.1086/374408##LAHUIS F, 2003, CHEMISTRY AS A DIAGNOSTIC OF STAR FORMATION, P335##LAWSON WA, 2004, MON NOT R ASTRON SOC, V351, PL39, DOI 10.1111/J.1365-2966.2004.07959.X##LAWSON WA, 2002, MON NOT R ASTRON SOC, V329, PL29, DOI 10.1046/J.1365-8711.2002.05093.X##LAWSON WA, 2001, MON NOT R ASTRON SOC, V321, P57, DOI 10.1046/J.1365-8711.2001.03967.X##LUHMAN KL, 2004, ASTROPHYS J, V609, P917, DOI 10.1086/421291##LYO AR, 2004, MON NOT R ASTRON SOC, V355, P363, DOI 10.1111/J.1365-2966.2004.08318.X##LYO AR, 2004, MON NOT R ASTRON SOC, V347, P246, DOI 10.1111/J.1365-2966.2004.07194.X##LYO AR, 2003, MON NOT R ASTRON SOC, V338, P616, DOI 10.1046/J.1365-8711.2003.06084.X##MAMAJEK EE, 1999, ASTROPHYS J, V516, PL77, DOI 10.1086/312005##MAYER L, 2005, MON NOT R ASTRON SOC, V363, P641, DOI 10.1111/J.1365-2966.2005.09468.X##MEGEATH ST, 2005, ASTROPHYS J, V634, PL113, DOI 10.1086/498503##RAGHAVAN D, 2006, ASTROPHYS J, V646, P523, DOI 10.1086/504823##SICILIA-AGUILAR A, 2006, ASTROPHYS J, V638, P897, DOI 10.1086/498085",75,2020-11-20,NA
J,WOS:000242914300002,2006,CONTROVERSIES IN THE MANAGEMENT OF CLINICAL STAGE I TESTIS CANCER,"DURING THE LAST TWO DECADES, DEFINITIVE PRIMARY TREATMENTS AND SURVEILLANCE WITH DEFINITIVE TREATMENT DEFERRED UNTIL RELAPSE HAVE DEMONSTRATED 98% TO 99% CURE RATES IN PATIENTS WITH STAGE I TESTIS CANCER, AND THESE OPTIONS HAVE OBTAINED FIRM POSITIONS IN STANDARD MANAGEMENT. THE DEVELOPMENT OF OPTIMAL MANAGEMENT STRATEGIES IN VARIOUS COUNTRIES WERE AT LEAST PARTLY GUIDED BY AVAILABLE SURGICAL EXPERTISE IN RETROPENTONEAL LYMPH NODE DISSECTION IN THE UNITED STATES, AND EASY ACCESS TO REFERENCE HOSPITALS IN DENSELY POPULATED COUNTRIES IN WESTERN EUROPE THAT FACILITATED CLOSE SURVEILLANCE PROGRAMS, HENCE, TREATMENT PREFERENCES DIFFER ON THE TWO SIDES OF THE ATLANTIC. THE SUCCESS OF BOTH APPROACHES IS HIGHLY DEPENDENT ON THE SKILLS OF THE PRACTITIONER, PARTICULARLY OF SURGERY AND OF SCRUTINIZED SURVEILLANCE. AS A RESULT, LOCAL EXPERTISE AND FAMILIARITY WITH A CHOSEN MODALITY HAS STRENGTHENED OVER THE YEARS, AND INVESTIGATORS HAVE BEEN RELUCTANT TO EMBARK ON RANDOMIZED TRIALS DESIGNED TO COMPARE ONE MODALITY WITH ANOTHER. SUCH EXPERTISE WITH ONE PARTICULAR TECHNIQUE, WITH THE OTHER APPROACH BEING LESS FAMILIAR TERRITORY, HAS CREATED CONTROVERSY, BECAUSE BOTH PHYSICIANS AND PATIENTS SEEK EVIDENCE-BASED DATA COMING FROM RANDOMIZED CLINICAL TRIALS ON WHICH TO MAKE MANAGEMENT DECISIONS. MOREOVER, THE REDUCED RISK OF RELAPSE RESULTING FROM THE USE OF RADIOTHERAPY OR CARBOPLATIN IN STAGE I SEMINOMA AND OF CISPLATIN-BASED CHEMOTHERAPY IN STAGE I NONSEMINOMA MUST BE BALANCED AGAINST THE POTENTIAL LONG-TERM ADVERSE EFFECTS IN THIS POPULATION OF PATIENTS WITH A NORMAL LIFE EXPECTANCY. THE PURPOSE OF THIS REVIEW IS TO PRESENT THE CURRENTLY AVAILABLE DATA AND DISCUSS THE MERITS AND THE DISADVANTAGES OF THE VARIOUS APPROACHES, YIELDING TO THE POSSIBLE CONCLUSION THAT ALL OPTIONS APPEAR TO BE EQUAL IN TERMS OF EFFICACY, BUT THAT MODALITY-ASSOCIATED ADVERSE EFFECTS DIFFER.",GERM-CELL TUMORS; MEDICAL-RESEARCH-COUNCIL; SINGLE-AGENT CARBOPLATIN; LYMPH-NODE DISSECTION; NONSEMINOMATOUS TESTICULAR CANCER; POSITRON-EMISSION-TOMOGRAPHY; LONG-TERM SURVIVORS; RISK-ADAPTED TREATMENT; ADJUVANT CHEMOTHERAPY; FOLLOW-UP,NA,JOURNAL OF CLINICAL ONCOLOGY,"DE WIT, R##FIZAZI, K","ERASMUS UNIV, MED CTR, DEPT MED ONCOL, ROTTERDAM, NETHERLANDS. ROTTERDAM CANC INST, ROTTERDAM, NETHERLANDS. INST GUSTAVE ROUSSY, DEPT MED, VILLEJUIF, FRANCE.",ONCOLOGY,ONCOLOGY,"AASS N, 1992, INT J RADIAT ONCOL, V22, P1057, DOI 10.1016/0360-3016(92)90808-U##ABOUASSALY R, 2005, UROL ONCOL-SEMIN ORI, V23, P447, DOI 10.1016/J.UROLONC.2005.06.006##ALEXANDRE J, 2001, EUR J CANCER, V37, P576, DOI 10.1016/S0959-8049(00)00442-1##AMATO RJ, 2004, UROLOGY, V63, P144, DOI 10.1016/J.UROLOGY.2003.08.045##APARICIO J, 2003, ANN ONCOL, V14, P867, DOI 10.1093/ANNONC/MDG241##APARICIO J, 2005, J CLIN ONCOL, V23, P8717, DOI 10.1200/JCO.2005.01.9810##BANIEL J, 1994, J UROLOGY, V152, P424, DOI 10.1016/S0022-5347(17)32754-4##BERRINGTON DE GONZALEZ A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0##BODEN G, 1951, LANCET, V261, P1195##BOHLEN D, 1999, J UROLOGY, V161, P1148, DOI 10.1016/S0022-5347(01)61615-X##BOKEMEYER C, 1995, J CLIN ONCOL, V13, P283, DOI 10.1200/JCO.1995.13.1.283##BOKEMEYER C, 2004, BRIT J CANCER, V91, P683, DOI 10.1038/SJ.BJC.6602020##BOSL GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406##BRAY F, 2006, INT J CANCER, V118, P3099, DOI 10.1002/IJC.21747##BRENNER DJ, 2004, RADIOLOGY, V232, P735, DOI 10.1148/RADIOL.2323031095##BRYDOY M, 2005, JNCI-J NATL CANCER I, V97, P1580, DOI 10.1093/JNCI/DJI339##CARVER BS, 2005, UROL ONCOL-SEMIN ORI, V23, P441, DOI 10.1016/J.UROLONC.2005.06.003##CHEVREAU C, 2004, EUR UROL, V46, P209, DOI 10.1016/J.EURURO.2004.03.022##CHOO R, 2005, INT J RADIAT ONCOL, V61, P736, DOI 10.1016/J.IJROBP.2004.06.209##COLLETTE L, 1999, JNCI-J NATL CANCER I, V91, P839, DOI 10.1093/JNCI/91.10.839##COLLS BM, 1999, J UROLOGY, V162, P169, DOI 10.1097/00005392-199907000-00056##CREMERIUS U, 1998, J NUCL MED, V39, P815##CULLEN MH, 1996, J CLIN ONCOL, V14, P1106, DOI 10.1200/JCO.1996.14.4.1106##DAUGAARD G, 2003, APMIS, V111, P76, DOI 10.1034/J.1600-0463.2003.11101111.X##DE SANTIS M, 2004, WORLD J UROL, V22, P41, DOI 10.1007/S00345-004-0403-2##DE WIT M, 2005, J CLIN ONCOL, V23, P379S##DE WIT R, 2001, J CLIN ONCOL, V19, P1629, DOI 10.1200/JCO.2001.19.6.1629##DE WIT R, 1999, SEMIN SURG ONCOL, V17, P250, DOI 10.1002/(SICI)1098-2388(199912)17:4<250::AID-SSU5>3.0.CO;2-M##DEARNALEY DP, 2005, BRIT J CANCER, V92, P2107, DOI 10.1038/SJ.BJC.6602624##DIECKMANN KP, 2000, UROLOGY, V55, P102, DOI 10.1016/S0090-4295(99)00376-3##DONOHUE JP, 1993, J UROLOGY, V149, P237, DOI 10.1016/S0022-5347(17)36046-9##DROZ JP, 1993, EUR J CANCER, V29A, P1038, DOI 10.1016/S0959-8049(05)80220-5##ERNST D SCOTT, 2005, CAN J UROL, V12, P2575##FERNANDEZ E, 1994, UROLOGY, V44, P548, DOI 10.1016/S0090-4295(94)80056-1##FOSSA SD, 1990, BRIT J CANCER, V61, P639, DOI 10.1038/BJC.1990.142##FOSSA SD, 1989, CANCER, V64, P404, DOI 10.1002/1097-0142(19890715)64:2<404::AID-CNCR2820640211>3.0.CO;2-7##FOSSA SD, 1999, J CLIN ONCOL, V17, P1146, DOI 10.1200/JCO.1999.17.4.1146##FRANCIS R, 2000, EUR J CANCER, V36, P1925, DOI 10.1016/S0959-8049(00)00140-4##FREEDMAN LS, 1987, LANCET, V2, P294##GELS ME, 1995, J CLIN ONCOL, V13, P1188, DOI 10.1200/JCO.1995.13.5.1188##GEORGE DW, 2003, J CLIN ONCOL, V21, P113, DOI 10.1200/JCO.2003.03.019##GERMA LLUCH J R, 1993, BR J UROL, V71, P473##GIACCHETTI S, 1993, INT J RADIAT ONCOL, V27, P3, DOI 10.1016/0360-3016(93)90414-Q##HAO D, 1998, J UROLOGY, V160, P768, DOI 10.1016/S0022-5347(01)62782-4##HEIDENREICH A, 1998, CANCER, V83, P1002, DOI 10.1002/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.3.CO;2-F##HERMANS BP, 2000, J UROLOGY, V163, P1721, DOI 10.1016/S0022-5347(05)67528-3##HILTON S, 1997, AM J ROENTGENOL, V169, P521, DOI 10.2214/AJR.169.2.9242768##HORWICH A, 1994, RADIOTHER ONCOL, V30, P193, DOI 10.1016/0167-8140(94)90457-X##HORWICH A, 1994, WORLD J UROL, V12, P148##HORWICH A, 1997, J CLIN ONCOL, V15, P1844, DOI 10.1200/JCO.1997.15.5.1844##HORWICH A, 1992, BRIT J CANCER, V65, P775, DOI 10.1038/BJC.1992.164##HUDDART RA, 2005, BRIT J CANCER, V93, P200, DOI 10.1038/SJ.BJC.6602677##HUDDART RA, 2003, J CLIN ONCOL, V21, P1513, DOI 10.1200/JCO.2003.04.173##JONES WG, 2005, J CLIN ONCOL, V23, P1200, DOI 10.1200/JCO.2005.08.003##KARAPETIS CS, 2003, INTERN MED J, V33, P427, DOI 10.1046/J.1445-5994.2003.00456.X##KLEPP O, 1997, EUR J CANCER, V33, P1038, DOI 10.1016/S0959-8049(97)00041-5##KLEPP OH, 2003, P AN M AM SOC CLIN, V22, P399##KONDAGUNTA GV, 2005, J CLIN ONCOL, V23, P9290, DOI 10.1200/JCO.2005.03.6616##KONDAGUNTA GV, 2004, J CLIN ONCOL, V22, P464, DOI 10.1200/JCO.2004.07.178##KREGE S, 2006, ANN ONCOL, V17, P276, DOI 10.1093/ANNONC/MDJ039##KREGE S, 1997, EUR UROL, V31, P405##LEEUWEN FE, 2005, EJC SUPPL, P152##LEIBOVITCH I, 1995, J UROLOGY, V154, P1759, DOI 10.1016/S0022-5347(01)66778-8##LOEHRER PJ, 1986, J UROLOGY, V135, P1183, DOI 10.1016/S0022-5347(17)46031-9##LOEHRER PJ, 2005, J CLIN ONCOL, V23, P8566, DOI 10.1200/JCO.2005.03.0361##MADEJ G, 1991, CLIN ONCOL (R COLL RADIOL), V3, P270, DOI 10.1016/S0936-6555(05)80880-5##MEINARDI MT, 2000, J CLIN ONCOL, V18, P1725, DOI 10.1200/JCO.2000.18.8.1725##MIZUTANI Y, 2002, BJU INT, V89, P454, DOI 10.1046/J.1464-4096.2001.01794.X##*NETH ASS COMPR CA, 2002, NAT CONS BAS ONC GUI##NICOLAI N, 1995, J UROLOGY, V154, P1045, DOI 10.1016/S0022-5347(01)66972-6##NICOLAI N, 2004, J UROLOGY, V171, P172, DOI 10.1097/01.JU.0000101513.64777.F2##OLDENBURG J, 2003, J CLIN ONCOL, V21, P3310, DOI 10.1200/JCO.2003.03.184##OLIVER RTD, 2005, LANCET, V366, P293, DOI 10.1016/S0140-6736(05)66984-X##OLIVER RTD, 2004, UROLOGY, V63, P556, DOI 10.1016/J.UROLOGY.2003.10.023##OLIVER RTD, 1994, INT J RADIAT ONCOL, V29, P3, DOI 10.1016/0360-3016(94)90219-4##ORWICH A, 2006, LANCET, V367, P754##PECTASIDES D, 2003, ANTICANCER RES, V23, P4239##PIKETTY AC, 2005, BRIT J CANCER, V93, P909, DOI 10.1038/SJ.BJC.6602791##PONT J, 1996, J CLIN ONCOL, V14, P441, DOI 10.1200/JCO.1996.14.2.441##RAMAKRISHNAN S, 1992, CLIN ONCOL (R COLL RADIOL), V4, P284, DOI 10.1016/S0936-6555(05)81100-8##READ G, 1992, J CLIN ONCOL, V10, P1762, DOI 10.1200/JCO.1992.10.11.1762##REITER WJ, 2001, J CLIN ONCOL, V19, P101, DOI 10.1200/JCO.2001.19.1.101##ROELEVELD TA, 2001, J UROLOGY, V166, P2166, DOI 10.1016/S0022-5347(05)65527-9##RONNEN EA, 2005, J CLIN ONCOL, V23, P6999, DOI 10.1200/JCO.2005.21.956##SCHMOLL HJ, 2004, ANN ONCOL, V15, P1377, DOI 10.1093/ANNONC/MDH301##SHARIR S, 1999, J UROLOGY, V161, P472, DOI 10.1016/S0022-5347(01)61926-8##SHEINFELD J, 2006, COMPEHENSIVE TXB GEN, P616##SLEIJFER S, 2006, COMPREHENSIVE TXB GE, P639##SOGANI PC, 1998, J UROLOGY, V159, P855, DOI 10.1016/S0022-5347(01)63753-4##SPERMON J ROAN, 2002, CURR OPIN UROL, V12, P419, DOI 10.1097/00042307-200209000-00009##SPERMON JR, 2002, BJU INT, V89, P549, DOI 10.1046/J.1464-410X.2002.02641.X##STEINER H, 2002, UROLOGY, V60, P324, DOI 10.1016/S0090-4295(02)01708-9##STEPHENSON AJ, 2005, J UROLOGY, V174, P557, DOI 10.1097/01.JU.0000165163.03805.37##STEPHENSON ANDREW J, 2005, CURR TREAT OPTIONS ONCOL, V6, P367, DOI 10.1007/S11864-005-0040-Z##STIGGELBOUT AM, 1996, EUR J CANCER, V32A, P2267, DOI 10.1016/S0959-8049(96)00279-1##STURGEON JFG, 1992, J CLIN ONCOL, V10, P564, DOI 10.1200/JCO.1992.10.4.564##TONER GC, 1990, J CLIN ONCOL, V8, P1683, DOI 10.1200/JCO.1990.8.10.1683##TRAVIS LB, 1997, JNCI-J NATL CANCER I, V89, P1429, DOI 10.1093/JNCI/89.19.1429##TRAVIS LB, 2005, JNCI-J NATL CANCER I, V97, P1354, DOI 10.1093/JNCI/DJI278##TRAVIS LB, 2000, JNCI-J NATL CANCER I, V92, P1165, DOI 10.1093/JNCI/92.14.1165##VAN DEN BELT-DUSEBOUT AW, 2006, J CLIN ONCOL, V24, P467, DOI 10.1200/JCO.2005.02.7193##VANLEEUWEN FE, 1993, J CLIN ONCOL, V11, P415, DOI 10.1200/JCO.1993.11.3.415##VERGOUWE Y, 2003, J CLIN ONCOL, V21, P4092, DOI 10.1200/JCO.2003.01.094##VERGOUWE Y, 2003, BRIT J CANCER, V88, P843, DOI 10.1038/SJ.BJC.6600759##WARDE P, 2005, LANCET, V366, P267, DOI 10.1016/S0140-6736(05)66959-0##WARDE P, 2002, J CLIN ONCOL, V20, P4448, DOI 10.1200/JCO.2002.01.038##WARDE PR, 2005, J CLIN ONCOL, V23, P382S##ZAGARS GK, 2004, J CLIN ONCOL, V22, P640, DOI 10.1200/JCO.2004.05.205",69,2020-11-20,NA
J,WOS:000242816800005,2006,DENSITY DISTRIBUTION FOR A DENSE HARD-SPHERE GAS IN MICRO/NANO-CHANNELS: ANALYTICAL AND SIMULATION RESULTS,"WE STUDY THE PROPERTIES OF A HARD-SPHERE DENSE GAS NEAR THE HARD WALLS OF MICRO AND NANO-CHANNELS. ANALYTICAL TECHNIQUES, MONTE CARLO (MC) METHODS AND MOLECULAR DYNAMICS (MD) SIMULATION METHODS HAVE BEEN USED TO CHARACTERIZE THE INFLUENCE OF THE CHARACTERISTIC PARAMETERS SUCH AS NUMBER DENSITY, REDUCED DENSITY, WIDTH OF THE SYSTEM AND MOLECULAR DIAMETER, ON THE EQUILIBRIUM PROPERTIES OF THE GAS NEAR THE HARD WALLS OF MICRO AND NANO-CHANNELS. A MATHEMATICAL MODEL HAS BEEN DEVELOPED TO CHARACTERIZE THE DENSITY OSCILLATIONS AS THE RESULT OF PACKING OF MOLECULES IN CASE OF A DENSE GAS NEAR THE MICRO AND NANO-CHANNELS WALLS. THE HEIGHT AND THE POSITION OF THE DENSITY OSCILLATION PEAKS NEAR THE WALL ARE CHARACTERIZED. THESE RESULTS ARE ALSO CONFIRMED BY THE MD AND MC SIMULATION RESULTS. COMPARISONS BETWEEN MD AND MC SIMULATION RESULTS FOR PARTICLES HAVING DIFFERENT DIAMETER ARE ALSO PRESENTED. FOR THE SAME SIZE OF THE PARTICLES AND MODERATELY DENSE GAS, MC AND MD RESULTS ARE SIMILAR, DIFFERENCES IN THE DENSITY PROFILES BEING LIMITED ONLY TO THE OSCILLATORY REGION. FOR DIFFERENT PARTICLE SIZES, MD AND MC RESULTS ARE LIMITED TO A SHORT DISTANCE NEAR THE WALL FOR LONG SIZE SYSTEMS AND MODERATELY DENSE FLUIDS. THE EFFECT OF THE BOUNDARY (PARTICLE SIZE) ON THE SIMULATION RESULTS IS FOUND TO INCREASE WITH ETA (REDUCED DENSITY) AND IT IS VERY SMALL IN CASE OF A DILUTE GAS. FOR SMALL ETA AND SMALL PARTICLE SIZE (R) RELATIVE TO THE WIDTH OF THE SYSTEM L, THE HEIGHT OF THE OSCILLATION PEAKS IS SLOWLY INCREASING WITH R/L, AND FOR HIGH DENSITIES IS ALWAYS DECREASING WITH R/L. THE POSITION OF THESE PEAKS DEPENDS ONLY ON THE SIZE OF THE PARTICLES AND WHEN R IS MUCH SMALLER THAN L, IT SHOWS A SMALL DEPENDENCE ON L. THE DEVIATIONS IN THE OSCILLATORY REGION FOR THE PURE MC SIMULATION RESULTS COMPARED TO PURE MD SIMULATION RESULTS ARE QUANTIFIED, AND MORE EFFICIENT HYBRID MC-MD SIMULATIONS ARE PERFORMED TO REDUCE THESE DEVIATIONS. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",MONTE-CARLO-SIMULATION; ENSKOG; EQUATION,MICRO FLUIDICS; SOLID-GAS INTERFACE; ANALYTICAL MODELING; HARD-SPHERE GAS BEHAVIOUR; MICRO AND NANO-CHANNELS; PARTICLE SIMULATION METHODS; MONTE CARLO AND MOLECULAR DYNAMICS; HYBRID SIMULATIONS,JOURNAL OF COMPUTATIONAL PHYSICS,"NEDEA, SV##FRIJNS, AJH##VAN STEENHOVEN, AA##JANSEN, APJ##MARKVOORT, AJ##HILBERS, PAJ","EINDHOVEN UNIV TECHNOL, DEPT MECH ENGN, NL-5600 MB EINDHOVEN, NETHERLANDS. EINDHOVEN UNIV TECHNOL, DEPT CHEM ENGN, NL-5600 MB EINDHOVEN, NETHERLANDS. EINDHOVEN UNIV TECHNOL, DEPT BIOMED ENGN, NL-5600 MB EINDHOVEN, NETHERLANDS.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; PHYSICS, MATHEMATICAL",COMPUTER SCIENCE; PHYSICS,"ALEXANDER FJ, 1995, PHYS REV LETT, V74, P5212, DOI 10.1103/PHYSREVLETT.74.5212##ALEXANDER FJ, 1997, COMPUTER SIMULATION, V11, P196##ALEXANDER FJ, 1997, PHYSICA A, V240, P588##BIRD GA, 1994, MOL GAS DYNAMICS DIR##CARNAHAN NF, 1969, J CHEM PHYS, V51, P635, DOI 10.1063/1.1672048##CERCIGNANI C, 1990, MATH METHODS KINETIC##CHAPMAN S, 1960, MATH THEORY NONUNIFO##ENSKOG D, 1922, KUNGL SVENSKA VETENS, V63, P3##FRENKEL D., 1996, UNDERSTANDING MOL SI##FREZZOTTI A, 1997, PHYS FLUIDS, V9, P1329, DOI 10.1063/1.869247##FREZZOTTI A, 1999, EUR J MECH B-FLUID, V18, P103, DOI 10.1016/S0997-7546(99)80008-9##FRIJNS AJH, 2004, P WORKSH MOD SIM M 4, P666##GARCIA AL, 1994, NUMERICAL METHODS PH, PCH10##ISRAELACHVILI J, 1991, INTERMOLECULAR SURFA, V68, P437##MONTANERO JM, 1996, PHYS REV E, V54, P438, DOI 10.1103/PHYSREVE.54.438##MONTANERO JM, 1997, PHYS FLUIDS, V9, P2057, DOI 10.1063/1.869325##NANBU K, 1986, P 15 INT S RAR GAS D##NEDEA SV, 2005, PHYS REV E, V72, DOI 10.1103/PHYSREVE.72.016705##RESIBOIS P., 1977, CLASSICAL KINETIC TH##SCHMIDT RR, 2002, IBM J RES DEV, V46, P739, DOI 10.1147/RD.466.0739##VANBEIJE.H, 1973, PHYSICA, V68, P437, DOI 10.1016/0031-8914(73)90372-8",10,2020-11-20,NA
J,WOS:000242816800009,2006,PSEUDO-TIME STEPPING METHODS FOR SPACE-TIME DISCONTINUOUS GALERKIN DISCRETIZATIONS OF THE COMPRESSIBLE NAVIER-STOKES EQUATIONS,"THE SPACE-TIME DISCONTINUOUS GALERKIN DISCRETIZATION OF THE COMPRESSIBLE NAVIER-STOKES EQUATIONS RESULTS IN A NON-LINEAR SYSTEM OF ALGEBRAIC EQUATIONS, WHICH WE SOLVE WITH PSEUDO-TIME STEPPING METHODS. WE SHOW THAT EXPLICIT RUNGE-KUTTA METHODS DEVELOPED FOR THE EULER EQUATIONS SUFFER FROM A SEVERE STABILITY CONSTRAINT LINKED TO THE VISCOUS PART OF THE EQUATIONS AND PROPOSE AN ALTERNATIVE TO RELIEVE THIS CONSTRAINT WHILE PRESERVING LOCALITY. TO EVALUATE ITS EFFECTIVENESS, WE COMPARE WITH AN IMPLICIT-EXPLICIT RUNGE-KUTTA METHOD WHICH DOES NOT SUFFER FROM THE VISCOUS STABILITY CONSTRAINT. WE ANALYZE THE STABILITY OF THE METHODS AND ILLUSTRATE THEIR PERFORMANCE BY COMPUTING THE FLOW AROUND A 2D AIRFOIL AND A 3D DELTA WING AT LOW AND MODERATE REYNOLDS NUMBERS. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",FINITE-ELEMENT-METHOD; NUMERICAL-SOLUTION; ELLIPTIC PROBLEMS,COMPRESSIBLE NAVIER-STOKES EQUATIONS; DISCONTINUOUS GALERKIN FINITE ELEMENT METHODS; PSEUDO-TIME INTEGRATION; IMPLICIT-EXPLICIT RUNGE-KUTTA METHODS,JOURNAL OF COMPUTATIONAL PHYSICS,"KLAIJ, CM##VAN DER VEGT, JJW##VAN DER VEN, H","UNIV TWENTE, DEPT APPL MATH, NL-7500 AE ENSCHEDE, NETHERLANDS. NATL AEROSP LAB, NLR, NL-1006 BM AMSTERDAM, NETHERLANDS.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; PHYSICS, MATHEMATICAL",COMPUTER SCIENCE; PHYSICS,"ARNOLD DN, 2002, SIAM J NUMER ANAL, V39, P1749, DOI 10.1137/S0036142901384162##BASSI F, 2002, INT J NUMER METH FL, V40, P197, DOI 10.1002/FLD.338##BASSI F, 1997, J COMPUT PHYS, V131, P267, DOI 10.1006/JCPH.1996.5572##BASSI F, 2005, COMPUT FLUIDS, V34, P507, DOI 10.1016/J.COMPFLUID.2003.08.004##BASSI F, 2000, LECT NOTES COMP SCI, V11, P197##BAUMANN CE, 1999, INT J NUMER METH FL, V31, P79, DOI 10.1002/(SICI)1097-0363(19990915)31:1<79::AID-FLD956>3.0.CO;2-C##BREZZI F, 2000, NUMER METH PART D E, V16, P365, DOI 10.1002/1098-2426(200007)16:4<365::AID-NUM2>3.0.CO;2-Y##BRISTEAU MO, 1987, NUMERICAL SIMULATION##COCKBURN B, 1998, SIAM J NUMER ANAL, V35, P2440, DOI 10.1137/S0036142997316712##COCKBURN B., 2001, JOURNAL OF SCIENTIFIC COMPUTING, V16, P173, DOI 10.1023/A:1012873910884##DOLEJSI V, 2004, INT J NUMER METH FL, V45, P1083, DOI 10.1002/FLD.730##HAIRER E., 2002, SOLVING ORDINARY DIF##HARTMANN R, 2006, INT J NUMER ANAL MOD, V3, P1##KLAIJ CM, UNPUB J COMPUT PHYS##KLAIJ CM, IN PRESS J COMPUT PH##KLEB W.L., 1999, AIAA J, V99, P181##KOK J, 1998, THESIS DELFT U TECHN##MELSON N. D., 1993, P 6 COPP MOUNT C MUL##OSTERMANN A, 2002, APPL NUMER MATH, V42, P353, DOI 10.1016/S0168-9274(01)00160-X##POPE SB, 2000, TURBULENT FLOWS##SUDIRHAM JJ, IN PRESS APPL NUMER##VAN DER VEGT JJW, 2002, J COMPUT PHYS, V182, P546, DOI 10.1006/JCPH.2002.7185##VAN DER VEN H, 2002, COMPUT METHOD APPL M, V191, P4747, DOI 10.1016/S0045-7825(02)00403-6##WESSELING P., 2000, PRINCIPLES COMPUTATI",31,2020-11-20,NA
J,WOS:000242816800018,2006,AN ADAPTIVE GRID REFINEMENT STRATEGY FOR THE SIMULATION OF NEGATIVE STREAMERS,"THE EVOLUTION OF NEGATIVE STREAMERS DURING ELECTRIC BREAKDOWN OF A NON-ATTACHING GAS CAN BE DESCRIBED BY A TWO-FLUID MODEL FOR ELECTRONS AND POSITIVE IONS. IT CONSISTS OF CONTINUITY EQUATIONS FOR THE CHARGED PARTICLES INCLUDING DRIFT, DIFFUSION AND REACTION IN THE LOCAL ELECTRIC FIELD, COUPLED TO THE POISSON EQUATION FOR THE ELECTRIC POTENTIAL. THE MODEL GENERATES FIELD ENHANCEMENT AND STEEP PROPAGATING IONIZATION FRONTS AT THE TIP OF GROWING IONIZED FILAMENTS. AN ADAPTIVE GRID REFINEMENT METHOD FOR THE SIMULATION OF THESE STRUCTURES IS PRESENTED. IT USES FINITE VOLUME SPATIAL DISCRETIZATIONS AND EXPLICIT TIME STEPPING, WHICH ALLOWS THE DECOUPLING OF THE GRIDS FOR THE CONTINUITY EQUATIONS FROM THOSE FOR THE POISSON EQUATION. STANDARD REFINEMENT METHODS IN WHICH THE REFINEMENT CRITERION IS BASED ON LOCAL ERROR MONITORS FAIL DUE TO THE PULLED CHARACTER OF THE STREAMER FRONT THAT PROPAGATES INTO A LINEARLY UNSTABLE STATE. WE PRESENT A REFINEMENT METHOD WHICH DEALS WITH ALL THESE FEATURES. TESTS ON ONE-DIMENSIONAL STREAMER FRONTS AS WELL AS ON THREE-DIMENSIONAL STREAMERS WITH CYLINDRICAL SYMMETRY (HENCE EFFECTIVELY 2D FOR NUMERICAL PURPOSES) ARE CARRIED OUT SUCCESSFULLY. RESULTS ON FINE GRIDS ARE PRESENTED, THEY SHOW THAT SUCH AN ADAPTIVE GRID METHOD IS NEEDED TO CAPTURE THE STREAMER CHARACTERISTICS WELL. THIS REFINEMENT STRATEGY ENABLES US TO ADEQUATELY COMPUTE NEGATIVE STREAMERS IN PURE GASES IN THE PARAMETER REGIME WHERE A PHYSICAL INSTABILITY APPEARS: BRANCHING STREAMERS. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",PARTIAL-DIFFERENTIAL-EQUATIONS; CATHODE-DIRECTED STREAMER; PLASMA FLUID EQUATIONS; ELECTRICAL-DISCHARGE; NUMERICAL-SOLUTION; HIGH-VOLTAGE; PROPAGATION; PHOTOIONIZATION; SPRITES; CORONA,ADAPTIVE GRID REFINEMENTS; FINITE VOLUMES; ELLIPTIC-PARABOLIC SYSTEM; NEGATIVE STREAMERS; PULLED FRONT,JOURNAL OF COMPUTATIONAL PHYSICS,"MONTIJN, C##HUNDSDORFER, W##EBERT, U","CWI, NL-1090 GB AMSTERDAM, NETHERLANDS. TECH UNIV EINDHOVEN, DEPT PHYS, NL-5600 MB EINDHOVEN, NETHERLANDS.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; PHYSICS, MATHEMATICAL",COMPUTER SCIENCE; PHYSICS,"ABOU-GHAZALA A, 2002, IEEE T PLASMA SCI, V30, P1449, DOI 10.1109/TPS.2002.804193##ARRAYAS M, 2004, PHYS REV E, V69, DOI 10.1103/PHYSREVE.69.036214##ARRAYAS M, 2002, PHYS REV LETT, V88, P1##BARNES M, 1986, J APPL PHYS, V61, P81##BAZELYAN E. M., 2000, LIGHTNING PHYS LIGHT##BLOM JG, 1996, ACM T MATH SOFTWARE, V22, P302, DOI 10.1145/232826.232850##BOBROV YK, 1998, COMP MATH MATH PHYS, V38, P1652##BOEUF J, 2005, P 27 INT C PHEN ION##BOTTA EFF, 1997, APPL NUMER MATH, V24, P439, DOI 10.1016/S0168-9274(97)00041-X##CLEMENTS JS, 1989, IEEE T IND APPL, V25, P62, DOI 10.1109/28.18870##COLELLA P, 1999, J COMPUT PHYS, V152, P550, DOI 10.1006/JCPH.1999.6245##COLELLA P, 1999, J COMPUT PHYS, V149, P168, DOI 10.1006/JCPH.1998.6136##DHALI SK, 1987, J APPL PHYS, V62, P4696, DOI 10.1063/1.339020##DUTTON J, 1975, J PHYS CHEM REF DATA, V4, P664##EBERT U, 2000, PHYSICA D, V146, P1, DOI 10.1016/S0167-2789(00)00068-3##EBERT U, 2006, PLASMA SOURCES SCI T, V15, PS118, DOI 10.1088/0963-0252/15/2/S14##EBERT U, 1997, PHYS REV E, V55, P1530, DOI 10.1103/PHYSREVE.55.1530##EBERT U, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.229402##FRANZ RC, 1990, SCIENCE, V249, P48, DOI 10.1126/SCIENCE.249.4964.48##GERKEN EA, 2000, GEOPHYS RES LETT, V27, P2637, DOI 10.1029/2000GL000035##GOLUB G.H., 1996, MATRIX COMPUTATIONS##GOTTLIEB S, 2001, SIAM REV, V43, P89, DOI 10.1137/S003614450036757X##HUNDSDORFER W, 2003, SERIES COMPUTATIONAL, V33##KULIKOVSKY AA, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.229401##KULIKOVSKY AA, 2000, J PHYS D APPL PHYS, V33, PL5, DOI 10.1088/0022-3727/33/1/102##LANG J, 2000, THEORY ALGORITHM APP, V16##LI ST, 1998, SIAM J SCI COMPUT, V20, P719, DOI 10.1137/S1064827596302011##LIU N, 2006, J PHYS D APPL PHYS, V39, P327, DOI 10.1088/0022-3727/39/2/013##LIU NY, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2003JA010064##MEULENBROEK B, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.195004##MEULENBROEK B, 2004, PHYS REVB, V69, DOI UNSP 067402(1-4)##MONTIJN C, 2006, J PHYS D APPL PHYS, V39, P2979, DOI 10.1088/0022-3727/39/14/017##NAIR SA, 2004, J ELECTROSTAT, V61, P117, DOI 10.1016/J.ELSTAT.2004.02.002##PANCHESHNYI SV, 2003, J PHYS D APPL PHYS, V36, P2683, DOI 10.1088/0022-3727/36/21/014##PANCHESHNYI SV, 2001, J PHYS D APPL PHYS, V34, P105, DOI 10.1088/0022-3727/34/1/317##PASKO VP, 2002, NATURE, V416, P152, DOI 10.1038/416152A##QUI Y, 1998, J COMPUT PHYS, V146, P726##RAIZER Y P, 1991, GAS DISCHARGE PHYS##ROCCO A, 2002, PHYS REV E, V66, DOI 10.1103/PHYSREVE.66.035102##SATO M, 1996, IEEE T IND APPL, V32, P106, DOI 10.1109/28.485820##SCHUMANN U, 1976, J COMPUT PHYS, V20, P171, DOI 10.1016/0021-9991(76)90062-0##SENTMAN DD, 1995, GEOPHYS RES LETT, V22, P1205, DOI 10.1029/95GL00583##TROMPERT RA, 1991, APPL NUMER MATH, V8, P65, DOI 10.1016/0168-9274(91)90098-K##VAN VELDHUIZEN EM, 2002, IEEE T PLASMA SCI, V30, P162, DOI 10.1109/TPS.2002.1003974##VITELLO PA, 1994, PHYS REV E, V49, P5574, DOI 10.1103/PHYSREVE.49.5574##VNAVELDHUIZEN E, 2000, ELECT DISCHARGES ENV##WACKERS J, 2005, J COMPUT APPL MATH, V180, P1, DOI 10.1016/J.CAM.2004.09.054##WESSELING P, 2001, PRINCIPLES COMPUTATI, V29",91,2020-11-20,NA
J,WOS:000242566600006,2006,MICROFLUIDICS WITH ULTRASOUND-DRIVEN BUBBLES,"MICROSTREAMING FROM OSCILLATING BUBBLES IS KNOWN TO INDUCE VIGOROUS VORTEX FLOW. HERE WE SHOW HOW TO HARNESS THE POWER OF BUBBLE STREAMING IN AN EXPERIMENT TO ACHIEVE DIRECTED TRANSPORT FLOW OF HIGH VELOCITY, ALLOWING DESIGN AND MANUFACTURE OF MICROFLUIDIC MEMS DEVICES. BY COMBINING OSCILLATING BUBBLES WITH SOLID PROTRUSIONS POSITIONED ON A PATTERNED SUBSTRATE, SOLID BEADS AND LIPID VESICLES ARE GUIDED IN DESIRED DIRECTIONS WITHOUT MICROCHANNELS. SIMULTANEOUSLY, THE FLOW EXERTS CONTROLLED LOCALIZED FORCES CAPABLE OF OPENING AND RECLOSING LIPID MEMBRANES.",FLOW; BOUNDARY; SCALE,NA,JOURNAL OF FLUID MECHANICS,"MARMOTTANT, P##RAVEN, JP##GARDENIERS, H##BOMER, JG##HILGENFELDT, S","UNIV TWENTE, DEPT SCI & TECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV TWENTE, MESA RES INST, NL-7500 AE ENSCHEDE, NETHERLANDS.","MECHANICS; PHYSICS, FLUIDS & PLASMAS",MECHANICS; PHYSICS,"AMIN N, 1990, J FLUID MECH, V210, P459, DOI 10.1017/S0022112090001367##BEEBE DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047##BLAKE JR, 1974, J ENG MATH, V8, P23, DOI 10.1007/BF02353701##BRENNEN C E, 1995, CAVITATION BUBBLE DY##DE BOER MJ, 2002, J MICROELECTROMECH S, V11, P385, DOI 10.1109/JMEMS.2002.800928##HANSEN D, 2006, UNPUB STEADY STREAMI##HILGENFELDT S, 1996, PHYS FLUIDS, V8, P2808, DOI 10.1063/1.869131##JACKEL JL, 1990, OPT LETT, V15, P1470, DOI 10.1364/OL.15.001470##KOPP MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/SCIENCE.280.5366.1046##LIGHTHILL J, 1978, J SOUND VIB, V61, P391##LONGUET-HIGGINS MS, 1998, P ROY SOC A-MATH PHY, V454, P725, DOI 10.1098/RSPA.1998.0183##LUTZ BR, 2003, P NATL ACAD SCI USA, V100, P4395, DOI 10.1073/PNAS.0831077100##MARMOTTANT P, 2004, P NATL ACAD SCI USA, V101, P9523, DOI 10.1073/PNAS.0307007101##MARMOTTANT P, 2003, NATURE, V423, P153, DOI 10.1038/NATURE01613##MARMOTTANT P, 2006, EXP FLUIDS, V41, P147, DOI 10.1007/S00348-005-0080-Y##MILLER DL, 2000, ULTRASOUND MED BIOL, V26, P661, DOI 10.1016/S0301-5629(99)00170-2##NYBORG WL, 1958, J ACOUST SOC AM, V30, P329, DOI 10.1121/1.1909587##PAPAVASILIOU AP, 2001, P 11 INT C SOL STAT, P940##POZRIKIDIS C, 1992, BOUNDARY INTEGRAL SI##SHI XG, 2002, J ACOUST SOC AM, V111, P1110, DOI 10.1121/1.1428544##SOLOMON TH, 2003, NATURE, V425, P376, DOI 10.1038/NATURE01993##SQUIRES TM, 2005, REV MOD PHYS, V77, P977, DOI 10.1103/REVMODPHYS.77.977##STONE HA, 2001, AICHE J, V47, P1250, DOI 10.1002/AIC.690470602##STROOCK AD, 2002, SCIENCE, V295, P647, DOI 10.1126/SCIENCE.1066238##THORSEN T, 2002, SCIENCE, V298, P580, DOI 10.1126/SCIENCE.1076996##YUAN H, 1999, J MICROMECH MICROENG, V9, P402, DOI 10.1088/0960-1317/9/4/318",76,2020-11-20,NA
J,WOS:000242566600009,2006,AXIAL STABILITY OF TAYLOR BUBBLES,"LONG GAS BUBBLES RISING IN A VERTICAL TUBE ARE OBSERVED TO LOSE AXIAL SYMMETRY AND BECOME UNSTABLE IN A DOWNWARD LIQUID FLOW. IN THIS PAPER AN APPROXIMATE LINEAR STABILITY ANALYSIS OF THIS PHENOMENON IS PRESENTED. IT IS FOUND THAT, UNDER THE COMBINED EFFECT OF GRAVITY AND THE PRESSURE GRADIENT WHICH DRIVES THE LIQUID FLOW, THE RELATIVE VELOCITY BETWEEN THE BUBBLE AND THE LIQUID DECREASES WITH INCREASING DOWNFLOW, WHICH DIMINISHES THE STABILIZING EFFECT OF CONVECTION. THE DECREASE OF THE RELATIVE VELOCITY IS ACCOMPANIED BY A FLATTENING OF THE BUBBLE NOSE, WHICH ALSO HAS A DESTABILIZING EFFECT BY STRENGTHENING THE RAYLEIGH-TAYLOR INSTABILITY AT THE BUBBLE NOSE.",LARGE GAS BUBBLE; 2 PHASE FLOW; SURFACE-TENSION; LONG BUBBLES; VERTICAL TUBES; RISING BUBBLE; RISE VELOCITY; CLOSED TUBES; MOTION; INSTABILITY,NA,JOURNAL OF FLUID MECHANICS,"LU, X##PROSPERETTI, A","JOHNS HOPKINS UNIV, DEPT MECH ENGN, BALTIMORE, MD 21218 USA. UNIV TWENTE, FAC APPL PHYS, TWENTE INST MECH, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV TWENTE, BURGERSCENTRUM, NL-7500 AE ENSCHEDE, NETHERLANDS.","MECHANICS; PHYSICS, FLUIDS & PLASMAS",MECHANICS; PHYSICS,"ABARZHI SI, 1998, PHYS REV LETT, V81, P337, DOI 10.1103/PHYSREVLETT.81.337##BARNEA D, 1982, CHEM ENG SCI, V37, P735, DOI 10.1016/0009-2509(82)85033-1##BATCHELOR GK, 1987, J FLUID MECH, V184, P399, DOI 10.1017/S0022112087002945##BAUMBACH V, 2005, J FLUID MECH, V524, P131, DOI 10.1017/S0022112004001995##BENDIKSEN KH, 1984, INT J MULTIPHAS FLOW, V10, P467, DOI 10.1016/0301-9322(84)90057-0##BENDIKSEN KH, 1985, INT J MULTIPHAS FLOW, V11, P797, DOI 10.1016/0301-9322(85)90025-4##BENSIMON D, 1987, J PHYS-PARIS, V48, P2081, DOI 10.1051/JPHYS:0198700480120208100##CLANET C, 2004, J FLUID MECH, V519, P359, DOI 10.1017/S0022112004001296##COLLINS R, 1978, J FLUID MECH, V89, P497, DOI 10.1017/S0022112078002700##DAVIES RM, 1950, PROC R SOC LON SER-A, V200, P375, DOI 10.1098/RSPA.1950.0023##DUMITRESCU DT, 1943, Z ANGEW MATH MECH, V23, P139, DOI 10.1002/ZAMM.19430230303##EPSTEIN R, 2004, PHYS PLASMAS, V11, P5114, DOI 10.1063/1.1790496##FABRE J, 1992, ANNU REV FLUID MECH, V24, P21, DOI 10.1146/ANNUREV.FL.24.010192.000321##FRANKEL I, 1987, J FLUID MECH, V185, P361, DOI 10.1017/S0022112087003215##FUNADA T, 2005, INT J MULTIPHAS FLOW, V31, P473, DOI 10.1016/J.IJMULTIPHASEFLOW.2004.11.010##GARABEDIAN PR, 1957, PROC R SOC LON SER-A, V241, P423, DOI 10.1098/RSPA.1957.0137##GRIFFITH P, 1961, T ASME       C, V83, P307##HANGOC H, 2004, MULTIPHASE SCI TECHN, V16, P191##HARTUNIAN RA, 1957, J FLUID MECH, V3, P27, DOI 10.1017/S0022112057000464##KAWANISHI K, 1990, NUCL ENG DES, V120, P447, DOI 10.1016/0029-5493(90)90394-D##LAMB H., 1932, HYDRODYNAMICS##LAYZER D, 1955, ASTROPHYS J, V122, P1, DOI 10.1086/146048##LEVINE H, 1990, PHYS FLUIDS A-FLUID, V2, P542, DOI 10.1063/1.857754##LU X, 2006, UNPUB INT J MULTIPHA##MARTIN C. S., 1976, TRANSACTIONS OF THE ASME. SERIES I, JOURNAL OF FLUIDS ENGINEERING, V98, P715##MEIRON DI, 1989, J FLUID MECH, V198, P101, DOI 10.1017/S0022112089000054##MUKHERJEE H, 1985, INT J MULTIPHAS FLOW, V11, P299, DOI 10.1016/0301-9322(85)90060-6##NICKENS HV, 1987, INT J MULTIPHAS FLOW, V13, P57, DOI 10.1016/0301-9322(87)90007-3##NICKLIN D.J., 1962, T I CHEM ENG-LOND, V40, P61##NICKLIN DJ, 1962, CHEM ENG SCI, V17, P693, DOI 10.1016/0009-2509(62)85027-1##NIE Q, 1995, PHYS FLUIDS, V7, P1292, DOI 10.1063/1.868518##NIGMATULIN TR, 2001, DOKL PHYS, V46, P803, DOI 10.1134/1.1424376##PLESSET MS, 1954, J APPL PHYS, V25, P96, DOI 10.1063/1.1721529##PLESSET MS, 1977, ANNU REV FLUID MECH, V9, P145, DOI 10.1146/ANNUREV.FL.09.010177.001045##POLONSKY S, 1999, INT J MULTIPHAS FLOW, V25, P957, DOI 10.1016/S0301-9322(99)00037-3##SAFFMAN PG, 1986, J FLUID MECH, V173, P73, DOI 10.1017/S0022112086001088##SPEDDING PL, 1980, CHEM ENG SCI, V35, P779, DOI 10.1016/0009-2509(80)85062-7##TANVEER S, 1987, PHYS FLUIDS, V30, P2318, DOI 10.1063/1.866122##TAYLOR G, 1959, Q J MECH APPL MATH, V12, P265, DOI [DOI 10.1093/QJMAM/12.3.265, 10.1093/QJMAM/12.3.265]##TUNG KW, 1976, ACTA MECH, V24, P313, DOI 10.1007/BF01190380##VANDENBROECK JM, 1991, PHYS FLUIDS A-FLUID, V3, P258, DOI 10.1063/1.858133##VANDENBROECK JM, 1984, PHYS FLUIDS, V27, P2604, DOI 10.1063/1.864560##VANDENBROECK JM, 1984, PHYS FLUIDS, V27, P1090, DOI 10.1063/1.864754##VIANA F, 2003, J FLUID MECH, V494, P379, DOI 10.1017/S0022112003006165##WHITE ET, 1962, CHEM ENG SCI, V17, P351, DOI 10.1016/0009-2509(62)80036-0##ZELDOVICH YB, 1980, COMBUST SCI TECHNOL, V24, P1##ZUKOSKI EE, 1966, J FLUID MECH, V25, P821, DOI 10.1017/S0022112066000442",10,2020-11-20,NA
J,WOS:000242924000002,2006,BABAR SILICON VERTEX TRACKER: STATUS AND PROSPECTS,"THE BABAR SILICON VERTEX TRACKER (SVT) HAS BEEN EFFICIENTLY OPERATED FOR SIX YEARS SINCE THE START OF DATA TAKING IN 1999. DUE TO HIGHER THAN EXPECTED BACKGROUND LEVELS SOME UNFORESEEN EFFECTS HAVE APPEARED. WE DISCUSS: A SHIFT IN THE PEDESTAL FOR THE CHANNELS OF THE ATOM READOUT CHIPS THAT ARE MOST EXPOSED TO RADIATION; AN ANOMALOUS INCREASE IN THE BIAS LEAKAGE CURRENT FOR THE MODULES IN THE OUTER LAYERS. ESTIMATES OF FUTURE RADIATION DOSES AND OCCUPANCIES ARE SHOWN TOGETHER WITH THE EXTRAPOLATED DETECTOR PERFORMANCE AND LIFETIME, IN LIGHT OF THE NEW OBSERVATIONS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NA,SILICON DETECTOR; RADIATION DAMAGE; CHARGE ACCUMULATION,NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT,"RE, V##BONDIOLI, M##BRUINSMA, M##CURRY, S##KIRKBY, D##BERRYHILL, J##BURKE, S##CALLAHAN, D##CAMPAGNARI, C##CUNHA, A##DAHMES, B##HALE, D##KYRE, S##RICHMAN, J##STONER, J##VERKERKE, W##BECK, T##EISNER, AM##KROSEBERG, J##LOCKMAN, WS##NESOM, G##SEIDEN, A##SPRADLIN, P##WILSON, M##WINSTROM, L##BOZZI, C##CIBINETTO, G##PIEMONTESE, L##BROWN, D##CHARLES, E##DARDIN, S##GOOZEN, F##GRITSAN, A##KERTH, LT##LYNCH, G##ROE, NA##CHEN, C##LAE, CK##ROBERTS, D##SIMI, G##LAZZARO, A##PALOMBO, F##SNOEK, HL##RATTI, L##ANGELINI, C##BATIGNANI, G##BETTARINI, S##BOSI, F##BUCCI, F##CALDERINI, G##CARPINELLI, M##CECCANTI, M##FORTI, F##CENCI, R##GIORGI, MA##LUSIANI, A##MAMMINI, P##MANFREDI, PF##MARCHIORI, G##MAZUR, M##MORGANTI, M##MORSANI, F##NERI, N##PAOLONI, E##PROFETI, A##RAMA, M##RIZZO, G##WALSH, J##ELMER, P##LONG, O##PERAZZO, A##BURCHAT, P##EDWARDS, AJ##MAJEWSKI, S##PETERSEN, BA##BONA, M##BIANCHI, F##GAMBA, D##TRAPANI, P##BOMBEN, M##BOSISIO, L##CARTARO, C##COSSUTTI, F##DELLA RICCA, G##DITTONGO, S##LANCERI, L##VITALE, L##DATTA, M##MIHALYI, A","STANFORD LINEAR ACCELERATOR CTR, STANFORD, CA 94309 USA. UNIV BERGAMO, BERGAMO, ITALY. UNIV CALIF IRVINE, IRVINE, CA USA. UNIV CALIF SANTA BARBARA, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA CRUZ, SANTA CRUZ, CA 95064 USA. IST NAZL FIS NUCL, FERRARA, ITALY. UNIV FERRARA, I-44100 FERRARA, ITALY. LAWRENCE BERKELEY NATL LAB, BERKELEY, CA USA. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. UNIV MILAN, MILAN, ITALY. IST NAZL FIS NUCL, I-20133 MILAN, ITALY. NATL INST NUCL & HIGH ENERGY PHYS, NIKHEF, NL-1009 DB AMSTERDAM, NETHERLANDS. UNIV PAVIA, I-27100 PAVIA, ITALY. IST NAZL FIS NUCL, I-27100 PAVIA, ITALY. IST NAZL FIS NUCL, PISA, ITALY. UNIV PISA, PISA, ITALY. PRINCETON UNIV, PRINCETON, NJ 08544 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. STANFORD UNIV, STANFORD, CA 94305 USA. IST NAZL FIS NUCL, I-10125 TURIN, ITALY. UNIV TURIN, TURIN, ITALY. UNIV TRIESTE, TRIESTE, ITALY. IST NAZL FIS NUCL, TRIESTE, ITALY. UNIV WISCONSIN, MADISON, WI USA.","INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS, NUCLEAR; PHYSICS, PARTICLES & FIELDS",INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS,"AUBERT B, 2002, NUCL INSTRUM METH A, V479, P1, DOI 10.1016/S0168-9002(01)02012-5##BARBIERI D, 1999, NUOVO CIMENTO A, V112, P113##BETTARINI S, 2004, 2004 NUCL SCI S ROM##RE V, 1998, NUCL INSTRUM METH A, V409, P354, DOI 10.1016/S0168-9002(97)01298-9##RE V, 2004, NUCL SCI S P, V2, P1048##1995, SLACR95457",5,2020-11-20,NA
J,WOS:000242924000009,2006,THE ALICE VERTEX DETECTOR: FOCUS ON THE MICRO-STRIP LAYERS,"THE ALICE EXPERIMENT, WHICH IS BEING INSTALLED AT THE LARGE HADRON COLLIDER AT CERN, IS DESIGNED TO OPERATE IN A HIGH-TRACK DENSITY ENVIRONMENT WHICH IS TYPICAL OF RELATIVISTIC HEAVY IONS PHYSICS. THIS PAPER REPORTS THE MAIN CHARACTERISTICS OF THE INNER TRACKING SYSTEM (ITS) OF ALICE AND DESCRIBES THE SILICON STRIP DETECTOR, WHICH FORMS THE TWO OUTERMOST LAYERS OF THE ITS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NA,ALICE ITS; DOUBLE-SIDED AC SILICON STRIP DETECTOR,NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT,"BREGANT, M##BORYSOV, O##BOSISIO, L##CAMERINI, P##CONTIN, G##FALESCHINI, F##FRAGIACOMO, E##GRION, N##MARGAGLIOTTI, GV##PIANO, S##RACHEVSKAIA, I##RUI, R##DE HAAS, AP##KLUIT, R##KUIJER, PG##NOOREN, GJL##OSKAMP, CJ##SOKOLOV, AN##VAN DEN BRINK, A##AGNESE, F##BONNET, D##CLAUSSE, O##IMHOFF, M##KUHN, C##LITTEL, F##LUTZ, JR##PLUMERI, S##SIGWARD, MH##WABNITZ, C##ZETER, V##OINONEN, M##AALTONEN, J##KASSAMAKOV, I##NIKKINEN, S##RADIVOJEVIC, Z##SEPPANEN, H##OSTERBERG, M##ANTONOVA, V##BORSHCHOV, V##LISTRATENKO, A##PROTSENKO, M##KOSTYSHIN, J##TYMCHUK, I##ZINOVJEV, G","IST NAZL FIS NUCL, SEZ TRIESTE, TRIESTE, ITALY. UNIV TRIESTE, DIPARTIMENTO FIS, TRIESTE, ITALY. UNIV UTRECHT, UTRECHT, NETHERLANDS. CNRS, INST RECH SUBATOM, IN2P3, STRASBOURG, FRANCE. UNIV HELSINKI, HELSINKI INST PHYS, HELSINKI, FINLAND. UNIV HELSINKI, DEPT PHYS SCI, ELECT RES UNIT, HELSINKI, FINLAND. NOKIA RES CTR, HELSINKI, FINLAND. NATL ACAD SCI UKRAINE, DEPT HIGH ENERGY DENS PHYS, BAGOLYUBOV INST THEORET PHYS, KIEV, UKRAINE. SCI & TECHNOL RES INST INSTRUMENT ENGN, KHARKOV, UKRAINE.","INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS, NUCLEAR; PHYSICS, PARTICLES & FIELDS",INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS,"BORSHCHOV V., 2002, P 8 WORKSH EL LHC EX##BORSHCHOV V, 2002034 CERNLHCC##*CERN LHCC, 200001 CERNLHCC##*CERN LHCC, 9912 CERNLHCC##*CERN LHCC, 2005030 CERNLHCC, V2##CORTESE P, 2004, J PHYS G NUCL PARTIC, V30, P1517, DOI 10.1088/0954-3899/30/11/001##HUGUO C, 2002, P 8 WORKSH EL LHC EX##HUGUO C, 2001, P 7 WORKSH EL LHC EX##*LEPSI, IN2P3 ULP##LUTZ JR, 2003, P 9 WORKSH EL LHC EX##SOKOLOV A, 2004, ALICEINT2004028",4,2020-11-20,NA
J,WOS:000242924000023,2006,OBSERVATIONS OF SENSOR BIAS DEPENDENT CLUSTER CENTROID SHIFTS IN A PROTOTYPE SENSOR FOR THE LHCB VERTEX LOCATOR DETECTOR,"WE PRESENT RESULTS FROM A RECENT BEAM TEST OF A PROTOTYPE SENSOR FOR THE LHCB VERTEX LOCATOR DETECTOR, READ OUT WITH THE BECTLE1.3 FRONT-END CHIP. WE HAVE STUDIED THE EFFECT OF THE SENSOR BIAS VOLTAGE ON THE RECONSTRUCTED CLUSTER POSITIONS IN A SENSOR PLACED IN A 120 GEV PION BEAM AT A 10 DEGREES INCIDENCE ANGLE. WE FIND AN UNEXPLAINED SYSTEMATIC SHIFT IN THE RECONSTRUCTED CLUSTER CENTROID WHEN INCREASING THE BIAS VOLTAGE ON AN ALREADY OVERDEPLETED SENSOR. THE SHIFT IS INDEPENDENT OF STRIP PITCH AND SENSOR THICKNESS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NA,VERTEX DETECTOR; SILICON MICRO STRIP; BALLISTIC DEFICIT; BEAM TEST; DETECTOR ALIGNMENT,NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT,"PAPADELIS, A","NATL INST NUCL & HIGH ENERGY PHYS, NL-1009 DB AMSTERDAM, NETHERLANDS.","INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS, NUCLEAR; PHYSICS, PARTICLES & FIELDS",INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS,"[ANONYMOUS], 2003030 CERNLHCC##BARTALINI P, LCHB2000099##JAMES F, MINUIT REFERENCE MAN##PARKES C, LCHB2001038 VELO##VANBAKEL N, LHCB2001046##2001011 CERNLHCC",0,2020-11-20,NA
J,WOS:000243310500010,2006,A NEW TECHNIQUE FOR IN VIVO IMAGING OF SPECIFIC GLP-1 BINDING SITES: FIRST RESULTS IN SMALL RODENTS,"EXPERIMENTAL OBJECTIVES: IN VIVO IMAGING OF GLP-1 RECEPTOR-POSITIVE TISSUES MAY ALLOW EXAMINATION OF PHYSIOLOGIC AND PATHOPHYSIOLOGIC PROCESSES. BASED ON THE GLP-1 ANALOG EXENDIN 4, WE HAVE DEVELOPED A RADIOLABELED COMPOUND SPECIFICALLY TARGETING THE GLP-1 RECEPTOR (DTPA-LYS(40)-EXENDIN 4). THIS WORK AIMS TO DETECT GLP-1 RECEPTOR-POSITIVE TISSUES BY BIODISTRIBUTION STUDIES AND IN VIVO SMALL ANIMAL IMAGING STUDIES. FOR IN VIVO IMAGING, A HIGH-RESOLUTION MULTI-PINHOLE SPECT (SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY) SYSTEM WAS USED IN CONJUNCTION WITH AN MRI (MAGNETIC RESONANCE IMAGING) SYSTEM FOR IMAGE FUSION. RESULTS: DTPA-LYS40-EXENDIN 4 CAN BE LABELED WITH IN-111 TO HIGH SPECIFIC ACTIVITY (40 GBQ/MU MOL). THE RADIOCHEMICAL PURITY RELIABLY EXCEEDED 95%. USING THIS COMPOUND FOR IN VIVO SMALL ANIMAL IMAGING OF RATS AND MICE AS WELL AS FOR BIODISTRIBUTION STUDIES, SPECIFIC GLP-1 BINDING SITES COULD BE DETECTED IN STOMACH, PANCREAS, LUNG, ADRENALS, AND PITUITARY. RECEPTOR-POSITIVE TISSUES WERE VISUALIZED WITH A HIGH-RESOLUTION SPECT SYSTEM WITH A RESOLUTION OF LESS THAN 1 MM. CONCLUSIONS: THE NEW TECHNIQUE USING DTPA-LYS(40)-EXENDIN 4 ALLOWS HIGHLY SENSITIVE IMAGING OF GLP-1 RECEPTOR-POSITIVE TISSUES IN VIVO. THEREFORE, INTRA-INDIVIDUAL FOLLOW-UP STUDIES OF GLP-1 RECEPTOR-POSITIVE TISSUE COULD BE CONDUCTED IN VIVO. (C) 2006 ELSEVIER B.V ALL RIGHTS RESERVED.",GLUCAGON-LIKE PEPTIDE-1; MOLECULAR-BASIS; CELL RECEPTOR; 7-36 AMIDE; EXENDIN-4; EXPRESSION; CLONING; BRAIN; ACINI,GLP-1; RECEPTOR IMAGING; SMALL ANIMAL IMAGING; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; MAGNETIC RESONANCE IMAGING; EXENDIN 4,REGULATORY PEPTIDES,"GOTTHARDT, M##LALYKO, G##VAN EERD-VISMALE, J##KEIL, B##SCHURRAT, T##HOWER, M##LAVERMAN, P##BEHR, TM##BOERMAN, OC##GOKE, B##BEHE, M","RADBOUD UNIV NIJMEGEN, MED CTR, DEPT NUCL MED, NL-6500 HB NIJMEGEN, NETHERLANDS. UNIV MARBURG, DEPT NUCL MED, D-35043 MARBURG, GERMANY. UNIV MARBURG, DEPT DIAGNOST RADIOL, D-35043 MARBURG, GERMANY. UNIV MUNICH, DEPT INTERNAL MED, D-81377 MUNICH, GERMANY.",ENDOCRINOLOGY & METABOLISM; PHYSIOLOGY,ENDOCRINOLOGY & METABOLISM; PHYSIOLOGY,"BEHE M, 2003, EUR J NUCL MED MOL I, V30, P1140, DOI 10.1007/S00259-003-1178-1##BEHR TM, 2002, NUKLEARMED-NUCL MED, V41, P71##BOCK T, 1999, APMIS, V107, P791, DOI 10.1111/J.1699-0463.1999.TB01474.X##BULLOCK BP, 1996, ENDOCRINOLOGY, V137, P2968, DOI 10.1210/EN.137.7.2968##CHICK RR, 2003, AM J PHYSIOL, V284, PR1427##DE JONG M, 2005, J NUCL MED, V46, P1696##EDWARDS CMB, 2001, AM J PHYSIOL-ENDOC M, V281, PE155##ENG J, 1992, J BIOL CHEM, V267, P7402##GOKE R, 1995, EUR J NEUROSCI, V7, P2294, DOI 10.1111/J.1460-9568.1995.TB00650.X##GOTTHARDT M, 2004, CURR PHARM DESIGN, V10, P2951, DOI 10.2174/1381612043383502##GOTTHARDT M, 2002, EUR J NUCL MED MOL I, V29, P597, DOI 10.1007/S00259-002-0761-1##GOTTHARDT M, 2005, J NUCL MED, V46, PP91##HASSAN M, 1999, NUCL MED BIOL, V26, P413, DOI 10.1016/S0969-8051(98)00121-8##HOROWITZ M, 2002, DIABETIC MED, V19, P177, DOI 10.1046/J.1464-5491.2002.00658.X##KASTIN AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07##LANKATBUTTGEREIT B, 1994, EXP CLIN ENDOCRINOL, V102, P341, DOI 10.1055/S-0029-1211301##LANKATBUTTGEREIT B, 1994, DIGESTION, V55, P29, DOI 10.1159/000201119##MEIER JJ, 2005, DIABETES-METAB RES, V21, P91, DOI 10.1002/DMRR.538##MEIER JJ, 2002, EUR J PHARMACOL, V440, P269, DOI 10.1016/S0014-2999(02)01434-6##MELIS M, 2005, EUR J NUCL MED MOL I, V32, P1136, DOI 10.1007/S00259-005-1793-0##NIELSEN LL, 2004, REGUL PEPTIDES, V117, P77, DOI 10.1016/J.REGPEP.2003.10.028##ORSKOV C, 1996, DIABETES, V45, P832, DOI 10.2337/DIABETES.45.6.832##ORSKOV C, 1991, DIABETES, V40, P1292, DOI 10.2337/DIABETES.40.10.1292##REUBI JC, 2003, EUR J NUCL MED MOL I, V30, P781, DOI 10.1007/S00259-003-1184-3##REUBI JC, 1995, J NUCL MED, V36, P1825##RICHTER G, 1990, FEBS LETT, V267, P78, DOI 10.1016/0014-5793(90)80292-Q##SANDHU H, 1999, DIABETES, V48, P1045, DOI 10.2337/DIABETES.48.5.1045##SCHEPP W, 1994, EUR J PHARM-MOLEC PH, V269, P183, DOI 10.1016/0922-4106(94)90085-X##SCHMIDTLER J, 1994, AM J PHYSIOL, V267, PG423##SCHRAMM NU, 2003, IEEE T NUCL SCI, V50, P315, DOI 10.1109/TNS.2003.812437##SINGH G, 1994, REGUL PEPTIDES, V53, P47, DOI 10.1016/0167-0115(94)90158-9##THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/PNAS.89.18.8641##TURTON MD, 1996, NATURE, V379, P69, DOI 10.1038/379069A0##VALVERDE I, 1993, ENDOCRINOLOGY, V132, P75, DOI 10.1210/EN.132.1.75##WILD D, 2005, MOL IMAGING, V4, P328",75,2020-11-20,NA
J,WOS:000243009600014,2006,EFFECTIVENESS OF EARLY SWITCH FROM INTRAVENOUS TO ORAL ANTIBIOTICS IN SEVERE COMMUNITY ACQUIRED PNEUMONIA: MULTICENTRE RANDOMISED TRIAL,"OBJECTIVES TO COMPARE THE EFFECTIVENESS OF AN EARLY SWITCH TO ORAL ANTIBIOTICS WITH THE STANDARD 7 DAY COURSE OF INTRAVENOUS ANTIBIOTICS IN SEVERE COMMUNITY ACQUIRED PNEUMONIA. DESIGN MULTICENTRE RANDOMISED CONTROLLED TRIAL. SETTING FIVE TEACHING HOSPITALS AND 2 UNIVERSITY MEDICAL CENTRES IN THE NETHERLANDS. PARTICIPANTS 302 PATIENTS IN NON-INTENSIVE CARE WARDS WITH SEVERE COMMUNITY ACQUIRED PNEUMONIA. 265 PATIENTS FULFILLED THE STUD), REQUIREMENTS. INTERVENTION THREE DAYS OF TREATMENT WITH INTRAVENOUS ANTIBIOTICS FOLLOWED, WHEN CLINICALLY STABLE, BY ORAL ANTIBIOTICS OR BY 7 DAYS OF INTRAVENOUS ANTIBIOTICS. MAIN OUTCOME MEASURES CLINICAL CURE AND LENGTH OF HOSPITAL STAYS RESULTS 302 PATIENTS WERE RANDOMISED. (MEAN AGE 69.5 (STANDARD DEVIATION 14.0), MEAN PNEUMONIA SEVERITY SCORE 112.7 (26.0)). 37 PATIENTS WERE EXCLUDED FROM ANALYSIS BECAUSE OF EARLY DROPOUT BEFORE DAY 3, LEAVING 265 PATIENTS FOR INTENTION TO TREAT ANALYSIS. MORTALITY AT CLAY 28 WAS 4% IN THE INTERVENTION GROUP AND 6% IN THE CONTROL GROUP (MEAN DIFFERENCE 2%,95% CONFIDENCE INTERVAL - 3% TO 8%). CLINICAL CURE WAS 83% IN THE INTERVENTION GROUP AND 85% IN THE CONTROL GROUP (2%, - 7% TO 10%). DURATION OF INTRAVENOUS TREATMENT AND LENGTH OF HOSPITAL STAY WERE REDUCED IN THE INTERVENTION GROUP, WITH MEAN DIFFERENCES OF 3.4 DAYS (3.6 (1.5) V 7.0 (2.0) DAYS; 2.8 TO 3.9) AND 1.9 DAYS (9.6 (5.0) V 11.5 (4.9) DAYS; 0.6 TO 3.2), RESPECTIVELY CONCLUSIONS EARLY SWITCH FROM INTRAVENOUS TO ORAL ANTIBIOTICS IN PATIENTS WITH SEVERE COMMUNITY ACQUIRED PNEUMONIA IS SAFE AND DECREASES LENGTH OF HOSPITAL STAY BY 2 DAYS.",HOSPITALIZED-PATIENTS; PRACTICE GUIDELINE; THERAPY; DISCHARGE; INFECTIONS; DIAGNOSIS; DURATION; OUTCOMES; COST; RISK,NA,BMJ-BRITISH MEDICAL JOURNAL,"OOSTERHEERT, JJ##BONTEN, MJM##SCHNEIDER, MME##BUSKENS, E##LAMMERS, JWJ##HUSTINX, WMN##KRAMER, MHH##PRINS, JM##SLEE, PHTJ##KAASJAGER, K##HOEPELMAN, AIM","UNIV MED CTR, DEPT INTERNAL MED & INFECT DIS, NL-3508 GA UTRECHT, NETHERLANDS. UNIV MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 GA UTRECHT, NETHERLANDS. UNIV MED CTR, DEPT PULMONOL, NL-3508 GA UTRECHT, NETHERLANDS. DIAKONESSEN HOSP, DEPT INTERNAL MED, UTRECHT, NETHERLANDS. MEANDER MED CTR, DEPT INTERNAL MED, AMERSFOORT, NETHERLANDS. ACAD MED CTR, DEPT INTERNAL MED, DIV INFECT DIS & TROP MED & AIDS, AMSTERDAM, NETHERLANDS. ST ANTONIUS HOSP, DEPT INTERNAL MED, NIEUWEGEIN, NETHERLANDS. RIJNSTATE HOSP, DEPT INTERNAL MED, ARNHEM, NETHERLANDS.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"CASTRO-GUARDIOLA A, 2001, AM J MED, V111, P367, DOI 10.1016/S0002-9343(01)00868-3##CHOW AW, 1992, CLIN INFECT DIS, V15, PS62, DOI 10.1093/CLIND/15.SUPPLEMENT_1.S62##FINE MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402##GUEST JF, 1997, EUR RESPIR J, V10, P1530, DOI 10.1183/09031936.97.10071530##HALM EA, 2002, ARCH INTERN MED, V162, P1278, DOI 10.1001/ARCHINTE.162.11.1278##JACOBS E, 1993, CLIN INFECT DIS, V17, PS79, DOI 10.1093/CLINIDS/17.SUPPLEMENT_1.S79##MARRIE TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/JAMA.283.6.749##MARSTON BARBARA J., 1997, ARCHIVES OF INTERNAL MEDICINE, V157, P1709, DOI 10.1001/ARCHINTE.157.15.1709##NIEDERMAN MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/AJRCCM.163.7.AT1010##OMIDVARI K, 1998, RESP MED, V92, P1032, DOI 10.1016/S0954-6111(98)90351-1##PINNER RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/JAMA.275.3.189##RAMIREZ JA, 2001, ARCH INTERN MED, V161, P848, DOI 10.1001/ARCHINTE.161.6.848##RAMIREZ JA, 1999, ARCH INTERN MED, V159, P2449, DOI 10.1001/ARCHINTE.159.20.2449##RAMIREZ JA, 1995, ARCH INTERN MED, V155, P1273, DOI 10.1001/ARCHINTE.155.12.1273##RHEW DC, 2001, MED CLIN N AM, V85, P1427, DOI 10.1016/S0025-7125(05)70389-8##RHEW DC, 1998, CHEST, V114, P115, DOI 10.1378/CHEST.114.1.115##SIEGEL RE, 1996, CHEST, V110, P965, DOI 10.1378/CHEST.110.4.965##STOUT JE, 1997, NEW ENGL J MED, V337, P682, DOI 10.1056/NEJM199709043371006##VAN DER EERDEN MM, 2004, CLIN THER, V26, P294, DOI 10.1016/S0149-2918(04)90028-8##VAN KASTEREN M E, 1998, NED TIJDSCHR GENEESKD, V142, P952##WEINGARTEN SR, 1996, AM J RESP CRIT CARE, V153, P1110, DOI 10.1164/AJRCCM.153.3.8630553",118,2020-11-20,NA
J,WOS:000243009600015,2006,COMMUNITY BASED OCCUPATIONAL THERAPY FOR PATIENTS WITH DEMENTIA AND THEIR CARE GIVERS: RANDOMISED CONTROLLED TRIAL,"OBJECTIVE TO DETERMINE THE EFFECTIVENESS OF COMMUNITY BASED OCCUPATIONAL THERAPY ON DAILY FUNCTIONING OF PATIENTS WITH DEMENTIA AND THE SENSE OF COMPETENCE OF THEIR CARE GIVERS. DESIGN SINGLE BLIND RANDOMISED CONTROLLED TRIAL. ASSESSORS WERE BLINDED FOR TREATMENT ALLOCATION. SETTING MEMORY CLINIC AND DAY CLINIC OF A GERIATRICS DEPARTMENT AND PARTICIPANTS' HOMES. PARTICIPANTS 135 PATIENTS AGED >= 65 WITH MILD TO MODERATE DEMENTIA LIVING IN THE COMMUNITY AND THEIR PRIMARY CARE GIVERS. INTERVENTIONS 10 SESSIONS OF OCCUPATIONAL THERAPY OVER FIVE WEEKS, INCLUDING COGNITIVE AND BEHAVIOURAL INTERVENTIONS, TO TRAIN PATIENTS IN THE USE OF AIDS TO COMPENSATE FOR COGNITIVE DECLINE AND CARE GIVERS IN COPING BEHAVIOURS AND SUPERVISION. MAIN OUTCOME MEASURES PATIENTS' DAILY FUNCTIONING ASSESSED WITH THE ASSESSMENT OF MOTOR AND PROCESS SKILLS (AMPS) AND INTERVIEW OF DETERIORATION IN DAILY ACTIVITIES IN DEMENTIA (IDDD). CARE GIVER BURDEN ASSESSED WITH THE SENSE OF COMPETENCE QUESTIONNAIRE (SCQ). PARTICIPANTS WERE EVALUATED AT BASELINE, SIX WEEKS, AND THREE MONTHS. RESULTS SCORES IMPROVED SIGNIFICANTLY RELATIVE TO BASELINE IN PATIENTS AND CARE GIVERS IN THE INTERVENTION GROUP COMPARED WITH THE CONTROLS (DIFFERENCES WERE 1.5 (95% CONFIDENCE INTERVAL 1.3 TO 1.7) FOR THE PROCESS SCALE; - 11.7 (- 13.6 TO - 9.7) FOR THE PERFORMANCE SCALE; AND 0 1.0; 9.2 TO 12.8) FOR THE COMPETENCE SCALE). THIS IMPROVEMENT WAS STILL SIGNIFICANT AT THREE MONTHS. THE NUMBER NEEDED TO TREAT TO REACH A CLINICALLY RELEVANT IMPROVEMENT IN MOTOR AND PROCESS SKILLS SCORE WAS 1.3 (1.2 TO 1.4) AT SIX WEEKS. EFFECT SIZES WERE 2.5, 2.3, AND 1.2, RESPECTIVELY, AT SIX WEEKS AND 2.7, 2.4, AND 0.8, RESPECTIVELY, AT 12 WEEKS. CONCLUSIONS OCCUPATIONAL THERAPY IMPROVED PATIENTS' DAILY FUNCTIONING AND REDUCED THE BURDEN ON THE CARE GIVER, DESPITE THE PATIENTS' LIMITED LEARNING ABILITY. EFFECTS WERE STILL PRESENT AT 12 WEEKS, WHICH JUSTIFIES IMPLEMENTATION OF THIS INTERVENTION.",ALZHEIMERS-DISEASE; RATING-SCALE; CAREGIVERS; HOME; INTERVENTION; INDIVIDUALS; PROGRAM,NA,BMJ-BRITISH MEDICAL JOURNAL,"GRAFF, MJL##VERNOOIJ-DASSEN, MJM##THIJSSEN, M##DEKKER, J##HOEFNAGELS, WHL##RIKKERT, MGMO","RADBOUD UNIV NIJMEGEN MED CTR, RES GRP ALLIED HLTH CARE, DEPT ALLIED HLTH CARE DISCIPLINES, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, CTR QUAL CARE RES, ALZHEIMER CTR NIJMEGEN, NL-6525 JV NIJMEGEN, NETHERLANDS. VRIJE UNIV AMSTERDAM MED CTR, EMGO INST, DEPT REHABIL MED, NL-1007 MB AMSTERDAM, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, DEPT GERIATR, ALZHEIMER CTR NIJMEGEN, NL-6500 HB NIJMEGEN, NETHERLANDS.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"APA, 1994, DIAGN STAT MAN MENT##BRINK T., 1982, CLIN GERONTOLOGIST, V1, P37, DOI DOI 10.1300/J018V01N01_06##BURGENER SC, 1998, GERIATR NURS, V19, P121, DOI 10.1016/S0197-4572(98)90055-6##COEN J, 1998, J HLTH GAIN, V2, P5##CORCORAN MA, 1992, AM J OCCUP THER, V46, P801, DOI 10.5014/AJOT.46.9.801##FISHER AG, 2003, ASSESSMENT MOTOR POR##FISHER AG., 2003, ASSESSMENT MOTOR PRO##FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6##FOSSEY J, 2006, BMJ-BRIT MED J, V332, P756, DOI 10.1136/BMJ.38782.575868.7C##GITLIN LN, 2005, J GERONTOL A-BIOL, V60, P368, DOI 10.1093/GERONA/60.3.368##GITLIN LN, 2001, GERONTOLOGIST, V41, P4, DOI 10.1093/GERONT/41.1.4##GRAFF M. J. L., 2000, NED TIJDSCHR ERGOTHE, V28, P169##GRAFF MJL, 2003, OTJR-OCCUP PART HEAL, V23, P155, DOI 10.1177/153944920302300403##GRAFF MJL, 2006, DEMENTIA, V5, P503, DOI DOI 10.1177/1471301206069918##HASSELKUS BR, 1990, OCCUPATIONAL THERAPY, V2, P9##JEPSON C, 1999, IMAGE J NURS SCH, V31, P115, DOI 10.1111/J.1547-5069.1999.TB00444.X##JEPSON G, 1999, IMAGE J NURS SCH, V31, P115##LAW M, 1996, CANADIAN OCCUPATIONA##LUIJPEN MW, 2003, REV NEUROSCIENCE, V14, P343##MILLER G. S., 1906, P BIOL SOC WASH, V19, P41##MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N##RADLOFF L S, 1977, APPLIED PSYCHOLOGICAL MEASUREMENT, V1, P385, DOI 10.1177/014662167700100306##REISBERG B, 1983, PSYCHOPHARMACOL BULL, V19, P702##RIOPELSMITH R, 1998, OCCUPATIONAL PERFORM, V2##ROCKWOOD K, 2006, TRIAL DESIGNS OUTCOM##SIEMONSMA PC, 1997, CLIN REHABIL, V11, P273, DOI 10.1177/026921559701100402##STEULTJENS EMJ, 2004, AGE AGEING, V33, P453, DOI 10.1093/AGEING/AFH174##TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622##TEUNISSE S., 1997, CLINIMETRICS DEMENTI##VERNOOIJDASSEN MJFJ, 1996, SOC SCI MED, V43, P41, DOI 10.1016/0277-9536(95)00332-0##VERNOOJ-DASSEN M, 2000, INT J AGING HUM DEV, V51, P259, DOI 10.2190/P8L1-N8QD-VTJ4-EURT##WALKER MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5##WIMO A, 2006, DEMENT GERIATR COGN, V21, P175, DOI 10.1159/000090733##WITLACH CJ, 1991, GERONTOLOGISTS, V31, P9",260,2020-11-20,NA
J,WOS:000243009600016,2006,MANAGEMENT OF HYPERGLYCAEMIA IN TYPE 2 DIABETES,NA,MICROVASCULAR COMPLICATIONS; INSULIN GLARGINE; GLYCEMIC CONTROL; THERAPY; METFORMIN; SULFONYLUREAS; ASSOCIATION; PROGRESSION; TRIAL,NA,BMJ-BRITISH MEDICAL JOURNAL,"HEINE, RJ##DIAMANT, M##MBANYA, JC##NATHAN, DM","VU UNIV MED CTR AMSTERDAM, DEPT ENDOCRINOL, CTR DIABET, AMSTERDAM, NETHERLANDS. UNIV YAOUNDE, DEPT INTERNAL MED & SPECIALTIES, DIABET & ENDOCRINE UNIT, YAOUNDE, CAMEROON. HARVARD UNIV, SCH MED, MASSACHUSETTS GEN HOSP, CTR DIABET, BOSTON, MA USA.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"*AM DIAB ASS, 2005, DIABETES CARE S1, V28, PS15##[ANONYMOUS], 1999, DIABET MED, V16, P716##COOK MN, 2005, DIABETES CARE, V28, P995, DOI 10.2337/DIACARE.28.5.995##DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902##DORMANDY JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9##DRUCKER DJ, 2005, NAT CLIN PRACT ENDOC, V1, P22, DOI 10.1038/NCPENDMET0017##GROOP LC, 1992, DIABETES CARE, V15, P737, DOI 10.2337/DIACARE.15.6.737##HEINE RJ, 2005, ANN INTERN MED, V143, P559, DOI 10.7326/0003-4819-143-8-200510180-00006##HOLST JJ, 2006, DIABETOLOGIA, V49, P253, DOI 10.1007/S00125-005-0107-1##HOLSTEIN A, 2001, DIABETES-METAB RES, V17, P467, DOI 10.1002/DMRR.235##MALAISSE WILLY J, 2003, TREAT ENDOCRINOL, V2, P401, DOI 10.2165/00024677-200302060-00004##MATSCHINSKY FM, 2006, DIABETES, V55, P1##MOLLER DE, 2001, NATURE, V414, P821, DOI 10.1038/414821A##MOORE H, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004097.PUB3##NATHAN DM, 2006, DIABETOLOGIA, V49, P1711, DOI 10.1007/S00125-006-0316-2##NATHAN DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/NEJMOA052187##OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K##OSEI-HYIAMAN D, 2006, INT J OBESITY, V30, PS33, DOI 10.1038/SJ.IJO.0803276##ROSENSTOCK J, 2005, ANN INTERN MED, V143, P549, DOI 10.7326/0003-4819-143-8-200510180-00005##SALPETER S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002967.PUB2##SJOSTROM L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMOA035622##STRATTON IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/BMJ.321.7258.405##STUMVOLL M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X##TURNER RC, 1998, LANCET, V352, P854, DOI 10.1016/S0140-6736(98)07037-8##TURNER RC, 1998, LANCET, V352, P837, DOI 10.1016/S0140-6736(98)07019-6##VAN DE LAAR FA, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003639.PUB2##VIBERTI G, 2002, DIABETES CARE, V25, P1737, DOI 10.2337/DIACARE.25.10.1737##YKI-JARVINEN H, 2006, DIABETOLOGIA, V49, P442, DOI 10.1007/S00125-005-0132-0##YKI-JARVINEN H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMRA041001##ZIMMET P, 2001, NATURE, V414, P782, DOI 10.1038/414782A",47,2020-11-20,NA
J,WOS:000242752800007,2006,OBSERVED TIMESCALES OF EVAPOTRANSPIRATION RESPONSE TO SOIL MOISTURE,"THE SENSITIVITY OF EVAPOTRANSPIRATION ( ET) TO SOIL MOISTURE STORAGE PLAYS AN IMPORTANT ROLE IN THE LAND-ATMOSPHERE SYSTEM. YET LITTLE IS KNOWN ABOUT ITS MAGNITUDE, OR ITS DEPENDENCE ON VEGETATION, SOIL, AND/OR CLIMATE CHARACTERISTICS. HERE WE RELATE THE SENSITIVITY TO THE TIMESCALE OF ET DECAY IN ABSENCE OF RAINFALL, AND SHOW THAT IT CAN THUS BE DERIVED FROM TIME SERIES OF ET ALONE. WE ANALYZE ET OBSERVATIONS FROM 15 VEGETATED SITES COVERING A RANGE OF CLIMATES CONDITIONS, YIELDING TIMESCALES OF 15-35 DAYS. LONGER TIMESCALES ( WEAKER ET SENSITIVITY) ARE FOUND IN REGIONS WITH SEASONAL DROUGHTS, OR AT SITES WITH WOODY VEGETATION. WE COMPARE OBSERVED VALUES WITH OUTPUT OF DIFFERENT LAND SURFACE MODELS (LSMS) FROM THE SECOND GLOBAL SOIL WETNESS PROJECT, REVEALING LARGE INTER-MODEL DIFFERENCES AND SIGNIFICANT DIFFERENCES WITH OBSERVATIONS. OUR METHODOLOGY CAN LEAD TO IMPROVED REPRESENTATION OF SOIL MOISTURE EFFECTS ON ET IN LSMS.",ATMOSPHERE COUPLING EXPERIMENT; LAND-SURFACE; WATER; FLUXES; DROUGHT; PRECIPITATION; GRASSLAND; SAVANNA; MODELS; MEMORY,NA,GEOPHYSICAL RESEARCH LETTERS,"TEULING, AJ##SENEVIRATNE, SI##WILLIAMS, C##TROCH, PA","WAGENINGEN UNIV, HYDROL & QUANTITAT WATER MANAGEMENT GRP, NL-6708 PB WAGENINGEN, NETHERLANDS. ETH, INST ATMOSPHER & CLIMATE SCI, CH-8092 ZURICH, SWITZERLAND. UNIV ARIZONA, DEPT HYDROL & WATER RESOURCES, TUCSON, AZ 85721 USA. COLORADO STATE UNIV, NAT RESOURCE ECOL LAB, FT COLLINS, CO 80523 USA.","GEOSCIENCES, MULTIDISCIPLINARY",GEOLOGY,"BALDOCCHI DD, 2004, AGR FOREST METEOROL, V123, P13, DOI 10.1016/J.AGRFORMET.2003.11.006##BRUNO RD, 2006, HYDROL PROCESS, V20, P2477, DOI 10.1002/HYP.6211##BRUTSAERT W, 1995, WATER RESOUR RES, V31, P1305, DOI 10.1029/95WR00323##DARDANELLI JL, 2004, FIELD CROP RES, V87, P59, DOI 10.1016/J.FCR.2003.09.008##DIRMEYER PA, 2006, B AM METEOROL SOC, V87, P1381, DOI 10.1175/BAMS-87-10-1381##FALGE E, 2005, FLUXNET MARC C GAP F##HUNT JE, 2002, AGR FOREST METEOROL, V111, P65, DOI 10.1016/S0168-1923(02)00006-0##KOSTER RD, 2006, J HYDROMETEOROL, V7, P590, DOI 10.1175/JHM510.1##KOSTER RD, 2004, SCIENCE, V305, P1138, DOI 10.1126/SCIENCE.1100217##KOSTER RD, 2001, J HYDROMETEOROL, V2, P558, DOI 10.1175/1525-7541(2001)002<0558:SMMICM>2.0.CO;2##LOHMANN D, 2003, GLOBAL PLANET CHANGE, V38, P81, DOI 10.1016/S0921-8181(03)00007-9##MEYERS TP, 2001, AGR FOREST METEOROL, V106, P205, DOI 10.1016/S0168-1923(00)00213-6##NEPSTAD DC, 1994, NATURE, V372, P666, DOI 10.1038/372666A0##RODRIGUEZ-ITURBE I., 2004, ECOHYDROLOGY WATER C##SALVUCCI GD, 2001, WATER RESOUR RES, V37, P1357, DOI 10.1029/2000WR900336##SCHENK HJ, 2002, ECOL MONOGR, V72, P311, DOI 10.1890/0012-9615(2002)072[0311:TGBOR]2.0.CO;2##SCHUTTEMEYER D, 2006, BOUND-LAY METEOROL, V118, P583, DOI 10.1007/S10546-005-9028-2##SENEVIRATNE SI, 2006, NATURE, V443, P205, DOI 10.1038/NATURE05095##SENEVIRATNE SI, 2006, J HYDROMETEOROL, V7, P1090, DOI 10.1175/JHM533.1##TEULING AJ, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025019##VERHOEF A, 1999, INT J CLIMATOL, V19, P1267, DOI 10.1002/(SICI)1097-0088(199909)19:11&LT;1267::AID-JOC418&GT;3.0.CO;2-S##WILLIAMS CA, 2004, WATER RESOUR RES, V40, DOI 10.1029/2004WR003208##XU CY, 2005, HYDROL PROCESS, V19, P3717, DOI 10.1002/HYP.5853",77,2020-11-20,NA
J,WOS:000242663700014,2006,THE DREAM TRIAL,NA,NA,NA,LANCET,"LUBSEN, J##POOLE-WILSON, PA","UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, LONDON SW3 6LY, ENGLAND. ERASMUS MC, DEPT EPIDEMIOL & BIOSTAT, ROTTERDAM, NETHERLANDS.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"BOSCH J, 2006, NEW ENGL J MED, V355, P1551##GERSTEIN HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8",2,2020-11-20,NA
J,WOS:000243172700014,2006,QUESTIONNAIRE SURVEY OF DISEASE PREVALENCE AND VETERINARY TREATMENTS IN ORGANIC PIG HUSBANDRY IN THE NETHERLANDS,NA,LIVESTOCK PRODUCTION; WELFARE; HEALTH,NA,VETERINARY RECORD,"VAN DER MEULEN, J##VAN DER WERF, JTN##KIJLSTRA, A","WAGENINGEN UR, ANIM SCI GRP, NL-8200 AB LELYSTAD, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,"BAUMGARTNER J, 2001, POSITIVE HLTH PREVEN, P126##BENNETEAU E, 2001, B GROUPEMENTS TECHNI##CARSTENSEN L, 2002, VET PARASITOL, V106, P253, DOI 10.1016/S0304-4017(02)00080-8##DAY JEL, 2003, ANIM WELFARE, V12, P637##DE GROOT J, 2004, TIJDSCHR DIERGENEESK, V129, P252##*EC, 2004, 18041999 EC##EIJCK IAJM, 2005, VET RES COMMUN, V29, P407, DOI 10.1007/S11259-005-1201-Z##FEENSTRA AA, 2000, P NIF, P107##HAMEENOJA P, 2001, ACTA VET SCAND, P33##HANSSON I, 2000, J VET MED B, V47, P111, DOI 10.1046/J.1439-0450.2000.00313.X##HOVI M, 2003, LIVEST PROD SCI, V80, P41, DOI 10.1016/S0301-6226(02)00320-2##LOKEN T, 2001, ACTA VET SCAND, P47##NANSEN P, 1999, INT J PARASITOL, V29, P877, DOI 10.1016/S0020-7519(99)00048-X##VAARST M, 2000, P NIF, P77",2,2020-11-20,NA
J,WOS:000243656700001,2006,EXOSOMES RELEASED BY EBV-INFECTED NASOPHARYNGEAL CARCINOMA CELLS CONVEY THE VIRAL LATENT MEMBRANE PROTEIN 1 AND THE IMMUNOMODULATORY PROTEIN GALECTIN 9,"BACKGROUND: NASOPHARYNGEAL CARCINOMAS (NPC) ARE CONSISTENTLY ASSOCIATED WITH THE EPSTEIN-BARR VIRUS (EBV). THEIR MALIGNANT EPITHELIAL CELLS CONTAIN THE VIRAL GENOME AND EXPRESS SEVERAL ANTIGENIC VIRAL PROTEINS. HOWEVER, THE MECHANISMS OF IMMUNE ESCAPE IN NPCS ARE STILL POORLY UNDERSTOOD. EBV-TRANSFORMED B-CELLS HAVE BEEN REPORTED TO RELEASE EXOSOMES CARRYING THE EBV-ENCODED LATENT MEMBRANE PROTEIN 1 (LMP1) WHICH HAS T-CELL INHIBITORY ACTIVITY. ALTHOUGH THIS REPORT SUGGESTED THAT NPC CELLS COULD ALSO PRODUCE EXOSOMES CARRYING IMMUNOSUPPRESSIVE PROTEINS, THIS HYPOTHESIS HAS REMAINED SO FAR UNTESTED. METHODS: MALIGNANT EPITHELIAL CELLS DERIVED FROM NPC XENOGRAFTS - LMP1- POSITIVE (C15) OR NEGATIVE (C17) - WERE USED TO PREPARE CONDITIONED CULTURE MEDIUM. VARIOUS MICROPARTICLES AND VESICLES RELEASED IN THE CULTURE MEDIUM WERE COLLECTED AND FRACTIONATED BY DIFFERENTIAL CENTRIFUGATION. EXOSOMES COLLECTED IN THE LAST CENTRIFUGATION STEP WERE FURTHER PURIFIED BY IMMUNOMAGNETIC CAPTURE ON BEADS CARRYING ANTIBODY DIRECTED TO HLA CLASS II MOLECULES. PURIFIED EXOSOMES WERE VISUALIZED BY ELECTRON MICROSCOPY AND ANALYSED BY WESTERN BLOTTING. THE T-CELL INHIBITORY ACTIVITIES OF RECOMBINANT LMP1 AND GALECTIN 9 WERE ASSESSED ON PERIPHERAL BLOOD MONONUCLEAR CELLS ACTIVATED BY CD3/CD28 CROSS-LINKING. RESULTS: HLA-CLASS II-POSITIVE EXOSOMES PURIFIED FROM C15 AND C17 CELL SUPERNATANTS WERE CONTAINING EITHER LMP1 AND GALECTIN 9 ( C15) OR GALECTIN 9 ONLY ( C17). RECOMBINANT LMP1 INDUCED A STRONG INHIBITION OF T-CELL PROLIFERATION (IC50 = 0.17 NM). IN CONTRAST RECOMBINANT GALECTIN 9 HAD A WEAKER INHIBITORY EFFECT (IC50 = 46 NM) WITH NO SYNERGY WITH LMP1. CONCLUSION: THIS STUDY PROVIDES THE PROOF OF CONCEPT THAT NPC CELLS CAN RELEASE HLA CLASS-II POSITIVE EXOSOMES CONTAINING GALECTIN 9 AND/OR LMP1. IT CONFIRMS THAT THE LMP1 MOLECULE HAS INTRINSIC T-CELL INHIBITORY ACTIVITY. THESE FINDINGS WILL ENCOURAGE INVESTIGATIONS OF TUMOR EXOSOMES IN THE BLOOD OF NPC PATIENTS AND ASSESSMENT OF THEIR EFFECTS ON VARIOUS TYPES OF TARGET CELLS.",LATENT MEMBRANE-PROTEIN; ANTIGEN-PROCESSING FUNCTION; HODGKINS-DISEASE; T-LYMPHOCYTES; MONOCLONAL-ANTIBODIES; DISTINCT EXPRESSION; DENDRITIC CELLS; TUMOR; APOPTOSIS; INTERLEUKIN-1,NA,BMC CANCER,"KERYER-BIBENS, C##PIOCHE-DURIEU, C##VILLEMANT, C##SOUQUERE, S##NISHI, N##HIRASHIMA, M##MIDDELDORP, J##BUSSON, P","INST GUSTAVE ROUSSY, CNRS, UMR 8126, VILLEJUIF, FRANCE. INST ANDRE LWOFF, CNRS, UPR 1983, VILLEJUIF, FRANCE. KAGAWA UNIV, FAC MED, DEPT ENDOCRINOL, TAKAMATSU, KAGAWA 760, JAPAN. KAGAWA UNIV, FAC MED, DEPT IMMUNOPATHOL, TAKAMATSU, KAGAWA 760, JAPAN. VRIJE UNIV AMSTERDAM MED CTR, DEPT PATHOL, NL-1081 HV AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM MED CTR, CTR CANC, NL-1081 HV AMSTERDAM, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"BECK A, 2001, J PATHOL, V194, P145, DOI 10.1002/PATH.867##BUSSON P, 2004, TRENDS MICROBIOL, V12, P356, DOI 10.1016/J.TIM.2004.06.005##BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/IJC.2910420422##BUSSON P, 1987, P NATL ACAD SCI USA, V84, P6262, DOI 10.1073/PNAS.84.17.6262##CHARRIN S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/JBC.M011297200##DAI SY, 2005, J IMMUNOL, V175, P2974, DOI 10.4049/JIMMUNOL.175.5.2974##DELSOL G, 1992, AM J PATHOL, V140, P247##DEVI BCR, 2004, CANCER EPIDEM BIOMAR, V13, P482##DUKERS DF, 2000, J IMMUNOL, V165, P663, DOI 10.4049/JIMMUNOL.165.2.663##FLANAGAN J, 2003, J GEN VIROL, V84, P1871, DOI 10.1099/VIR.0.18944-0##HEUSSINGER N, 2004, J PATHOL, V203, P696, DOI 10.1002/PATH.1569##HIRASHIMA M, 2002, GLYCOCONJUGATE J, V19, P593, DOI 10.1023/B:GLYC.0000014090.63206.2F##HO SY, 2004, HEAD NECK-J SCI SPEC, V26, P977, DOI 10.1002/HED.20090##HUANG YT, 1999, CANCER RES, V59, P1599##HUGEL B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/PHYSIOL.00029.2004##KASHIO Y, 2003, J IMMUNOL, V170, P3631, DOI 10.4049/JIMMUNOL.170.7.3631##KHANNA R, 1998, CANCER RES, V58, P310##LEE SP, 2000, J IMMUNOL, V165, P573, DOI 10.4049/JIMMUNOL.165.1.573##MEIJ P, 2000, J VIROL METHODS, V90, P193, DOI 10.1016/S0166-0934(00)00233-0##MUNZ C, 2004, J EXP MED, V199, P1301, DOI 10.1084/JEM.20040730##NICHOLLS JM, 1997, J PATHOL, V183, P164##OZYAR E, 2004, CANCER INVEST, V22, P483, DOI 10.1081/CNV-200026386##PALACIOS R, 1985, P NATL ACAD SCI USA, V82, P6652, DOI 10.1073/PNAS.82.19.6652##PELLETIER I, 2003, J BIOL CHEM, V278, P22223, DOI 10.1074/JBC.M302693200##PERONE MJ, 2006, J IMMUNOL, V176, P7207, DOI 10.4049/JIMMUNOL.176.12.7207##PIOCHE-DURIEU C, 2005, J VIROL, V79, P13326, DOI 10.1128/JVI.79.21.13326-13337.2005##RAAB-TRAUB N, 2005, EPSTEIN-BARR VIRUS, P71##ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575##SBIH-LAMMALI F, 1999, CANCER RES, V59, P924##SETO E, 2005, J MED VIROL, V76, P82, DOI 10.1002/JMV.20327##TANG KF, 2001, HUM PATHOL, V32, P42, DOI 10.1053/HUPA.2001.20886##TAYLOR DD, 2005, BRIT J CANCER, V92, P305, DOI 10.1038/SJ.BJC.6602316##TEICHMANN M, 2005, J PATHOL, V206, P68, DOI 10.1002/PATH.1745##THERY C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/JIMMUNOL.166.12.7309##THERY C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/NRI855##TSUKUDA M, 1993, J CANCER RES CLIN, V120, P115, DOI 10.1007/BF01200735##TURECI O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/JBC.272.10.6416##VICAT JM, 2003, BIOCHEM PHARMACOL, V65, P423, DOI 10.1016/S0006-2952(02)01449-1##WHITNEY BM, 2002, J MED VIROL, V67, P359, DOI 10.1002/JMV.10073##ZANUSSI S, 2003, CANCER IMMUNOL IMMUN, V52, P28, DOI 10.1007/S00262-002-0333-Z##ZHU C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/NI1271",156,2020-11-20,NA
J,WOS:000243407200015,2006,INDUCTION OF HEAT SHOCK RESPONSE PROTECTS THE HEART AGAINST ATRIAL FIBRILLATION,"THERE IS EVIDENCE SUGGESTING THAT HEAT SHOCK PROTEINS (HSPS) MAY PROTECT AGAINST CLINICAL ATRIAL FIBRILLATION (AF). WE EVALUATED THE EFFECT OF HSP INDUCTION IN AN IN VITRO ATRIAL CELL LINE (HL-1) MODEL OF TACHYCARDIA REMODELING AND IN TACHYPACED ISOLATED CANINE ATRIAL CARDIOMYOCYTES. WE ALSO EVALUATED THE EFFECT OF HSP INDUCTION ON IN VIVO AF PROMOTION BY ATRIAL TACHYCARDIA-INDUCED REMODELING IN DOGS. TACHYPACING (3 HZ) SIGNIFICANTLY AND PROGRESSIVELY REDUCED CA2+ TRANSIENTS AND CELL SHORTENING OF HL-1 MYOCYTES OVER 4 HOURS. THESE REDUCTIONS WERE PREVENTED BY HSP-INDUCING PRETREATMENTS: MILD HEAT SHOCK, GERANYLGERANYLACETONE (GGA), AND TRANSFECTION WITH HUMAN HSP27 OR THE PHOSPHORYLATION-MIMICKING HSP27-DDD. HOWEVER, TREATMENT WITH HSP70 OR THE PHOSPHORYLATION-DEFICIENT MUTANT HSP27-AAA FAILED TO ALTER TACHYCARDIA-INDUCED CA2+ TRANSIENT AND CELL-SHORTENING REDUCTIONS, AND DOWNREGULATION (SHORT INTERFERING RNA) OF HSP27 PREVENTED GGA-MEDIATED PROTECTION. TACHYPACING (3 HZ) FOR 24 HOURS IN VITRO SIGNIFICANTLY REDUCED L-TYPE CA2+ CURRENT AND ACTION POTENTIAL DURATION IN CANINE ATRIAL CARDIOMYOCYTES; THESE EFFECTS WERE PREVENTED WHEN TACHYPACING WAS PERFORMED IN CELLS EXPOSED TO GGA. IN VIVO TREATMENT WITH GGA INCREASED HSP EXPRESSION AND SUPPRESSED REFRACTORINESS ABBREVIATION AND AF PROMOTION IN DOGS SUBJECTED TO 1-WEEK ATRIAL TACHYCARDIA-INDUCED REMODELING. IN CONCLUSION, OUR FINDINGS INDICATE THAT (1) HSP INDUCTION PROTECTS AGAINST ATRIAL TACHYCARDIA-INDUCED REMODELING, (2) THE PROTECTIVE EFFECT IN HL-1 MYOCYTES REQUIRES HSP27 INDUCTION AND PHOSPHORYLATION, AND (3) THE ORALLY ADMINISTERED HSP INDUCER GGA PROTECTS AGAINST AF IN A CLINICALLY RELEVANT ANIMAL MODEL. THESE FINDINGS ADVANCE OUR UNDERSTANDING OF THE BIOCHEMICAL DETERMINANTS OF AF AND SUGGEST THE POSSIBILITY THAT HSP INDUCTION MAY BE AN INTERESTING NOVEL APPROACH TO PREVENTING CLINICAL AF.",OXIDATIVE STRESS; CONTRACTILE DYSFUNCTION; SMOOTH-MUSCLE; TACHYCARDIA; PROTEINS; EXPRESSION; CELLS; PHOSPHORYLATION; PREVENTS; MYOCYTES,ATRIAL FIBRILLATION; HEAT SHOCK PROTEIN; REMODELING,CIRCULATION RESEARCH,"BRUNDEL, BJJM##SHIROSHITA-TAKESHITA, A##QI, XY##YEH, YH##CHARTIER, D##VAN GELDER, IC##HENNING, RH##KAMPINGA, HH##NATTEL, S","MONTREAL HEART INST, DEPT MED, MONTREAL, PQ H1T 1C8, CANADA. MONTREAL HEART INST, RES CTR, MONTREAL, PQ H1T 1C8, CANADA. UNIV MONTREAL, MONTREAL, PQ H3C 3J7, CANADA. UNIV GRONINGEN, MED CTR, DEPT RADIAT & STRESS CELL BIOL, NL-9700 AB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT CARDIOL, NL-9700 AB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT CLIN PHARMACOL, NL-9700 AB GRONINGEN, NETHERLANDS. CHANG GUNG UNIV, CHANG GUNG MEM HOSP, CARDIOVASC DIV 1, TAO YUAN, TAIWAN.",CARDIAC & CARDIOVASCULAR SYSTEMS; HEMATOLOGY; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY; HEMATOLOGY,"AN SS, 2004, J APPL PHYSIOL, V96, P1701, DOI 10.1152/JAPPLPHYSIOL.01129.2003##BENJAMIN IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117##BRUMMELKAMP TR, 2002, SCIENCE, V296, P550, DOI 10.1126/SCIENCE.1068999##BRUNDEL BJJM, 2006, J MOL CELL CARDIOL, V41, P555, DOI 10.1016/J.YJMCC.2006.06.068##BRUNDEL BJJM, 2004, CARDIOVASC RES, V62, P521, DOI 10.1016/J.CARDIORES.2004.02.007##BRUNDEL BJJM, 2001, CIRCULATION, V103, P684##CARNES CA, 2001, CIRC RES, V89, PE32, DOI 10.1161/HH1801.097644##CLAYCOMB WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/PNAS.95.6.2979##DERNELLIS J, 2004, EUR HEART J, V25, P1100, DOI 10.1016/J.EHJ.2004.04.025##DOBREV D, 2003, BASIC RES CARDIOL, V98, P137, DOI 10.1007/S00395-003-0409-8##DOHKE T, 2006, J CARD FAIL, V12, P77, DOI 10.1016/J.CARDFAIL.2005.07.006##DUDLEY SC, 2005, CIRCULATION, V112, P1266, DOI 10.1161/CIRCULATIONAHA.105.538108##FAREH S, 1999, CIRCULATION, V100, P2191, DOI 10.1161/01.CIR.100.21.2191##FAREH S, 1998, CIRCULATION, V98, P2202, DOI 10.1161/01.CIR.98.20.2202##GAITANAKI C, 2003, J EXP BIOL, V206, P2759, DOI 10.1242/JEB.00483##HIRAKAWA T, 1996, GASTROENTEROLOGY, V111, P345, DOI 10.1053/GAST.1996.V111.PM8690199##JOYEUX M, 1997, J MOL CELL CARDIOL, V29, P3285, DOI 10.1006/JMCC.1997.0554##KATSUNO M, 2005, P NATL ACAD SCI USA, V102, P16801, DOI 10.1073/PNAS.0506249102##KIERAN D, 2004, NAT MED, V10, P402, DOI 10.1038/NM1021##KIM YM, 2005, CIRC RES, V97, P629, DOI 10.1161/01.RES.0000183735.09871.61##LEACH RN, 2005, CELL CALCIUM, V38, P515, DOI 10.1016/J.CECA.2005.07.006##MANDAL K, 2005, ANN THORAC SURG, V79, P865, DOI 10.1016/J.ATHORACSUR.2004.08.018##NATTEL S, 2002, NATURE, V415, P219, DOI 10.1038/415219A##OOIE T, 2001, CIRCULATION, V104, P1837, DOI 10.1161/HC3901.095771##OZAYDIN M, 2006, AM J CARDIOL, V97, P1490, DOI 10.1016/J.AMJCARD.2005.11.082##ROGALLA T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/JBC.274.27.18947##SCHAFLER AE, 2002, BASIC RES CARDIOL, V97, P258, DOI 10.1007/S003950200019##SHINAGAWA K, 2003, CIRCULATION, V107, P1440, DOI 10.1161/01.CIR.0000055316.35552.74##SHINAGAWA K, 2003, PACE, V26, P752, DOI 10.1046/J.1460-9592.2003.00128.X##SHIROSHITA-TAKESHITA A, 2006, CARDIOVASC RES, V69, P865, DOI 10.1016/J.CARDIORES.2005.11.028##SHIROSHITA-TAKESHITA A, 2004, CIRCULATION, V110, P2313, DOI 10.1161/01.CIR.0000145163.56529.D1##SOMARA S, 2004, AM J PHYSIOL-CELL PH, V286, PC1290, DOI 10.1152/AJPCELL.00458.2003##SOTI C, 2005, BRIT J PHARMACOL, V146, P769, DOI 10.1038/SJ.BJP.0706396##SUN H, 2001, CARDIOVASC RES, V49, P751, DOI 10.1016/S0008-6363(00)00294-7##SUN H, 1998, CIRCULATION, V98, P719, DOI 10.1161/01.CIR.98.7.719##VAN GELDER IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMOA021375##VENKATAKRISHNAN CD, 2006, AM J PHYSIOL-HEART C, V291, PH2680, DOI 10.1152/AJPHEART.00395.2006##VIGH L, 1997, NAT MED, V3, P1150, DOI 10.1038/NM1097-1150##VITADELLO M, 2001, CIRCULATION, V103, P2201##YAMAGAMI K, 2000, J LAB CLIN MED, V135, P465, DOI 10.1067/MLC.2000.106806##YAMANAKA K, 2003, J MOL CELL CARDIOL, V35, P785, DOI 10.1016/S0022-2828(03)00133-0##YANG ZHENJIANG, 2005, J MOL CELL CARDIOL, V38, P299, DOI 10.1016/J.YJMCC.2004.11.015##YUE LX, 1996, AM J PHYSIOL-HEART C, V270, PH2157##YUE LX, 1997, CIRC RES, V81, P512, DOI 10.1161/01.RES.81.4.512",130,2020-11-20,NA
J,WOS:000242752500005,2006,MULTIMODEL STUDY OF TROPICAL ATLANTIC VARIABILITY AND CHANGE,"[1] INTERANNUAL VARIABILITY ASSOCIATED WITH THE ZONAL AND THE MERIDIONAL MODE IN THE TROPICAL ATLANTIC IS STUDIED IN NINE COUPLED OCEAN-ATMOSPHERE MODELS FOR TWENTIETH CENTURY CLIMATE CONDITIONS (TC) AND THE SRES-A1B SCENARIO FOR FUTURE GREENHOUSE GAS CONCENTRATIONS. FOR TC, THE SUBTROPICAL PART OF THE MERIDIONAL MODE IS REASONABLY WELL SIMULATED, IN CONTRAST TO THE DEEP TROPICAL PART OF THE MERIDIONAL MODE AND THE ZONAL MODE. A COMMON MODEL BIAS IS THAT THE ONSET OF THE MERIDIONAL MODE IS PRECEDED BY THE PRESENCE OF A ZONAL MODE IN BOREAL FALL THAT EXTENDS TOWARDS THE WESTERN BOUNDARY OF THE ATLANTIC BASIN AND WHICH INITIATES A WIND-EVAPORATION-SST FEEDBACK. AS A RESULT OF THIS, THERE IS A SPURIOUSLY STRONG INTERACTION BETWEEN THE ZONAL AND THE MERIDIONAL MODE. THE MODELS THAT SEEM TO BEST REPRESENT THE MERIDIONAL MODE SHOW A WEAKENING FOR FUTURE CLIMATE CONDITIONS. BIASES IN THE ZONAL MODE ARE TOO STRONG TO ASSESS CHANGES.",COUPLED MODEL; CLIMATE VARIABILITY; OCEAN; CIRCULATION; SECTOR; TEMPERATURES; MECHANISMS; SIMULATION; DYNAMICS; SST,NA,GEOPHYSICAL RESEARCH LETTERS,"BREUGEM, WP##HAZELEGER, W##HAARSMA, RJ","ROYAL NETHERLANDS METEOROL INST, NL-3730 AE DE BILT, NETHERLANDS.","GEOSCIENCES, MULTIDISCIPLINARY",GEOLOGY,"BIASUTTI M, 2006, J CLIMATE, V19, P935, DOI 10.1175/JCLI3673.1##BREUGEM WP, 2006, IN PRESS J CLIM##CARTON JA, 1996, J PHYS OCEANOGR, V26, P1165, DOI 10.1175/1520-0485(1996)026<1165:DAISVI>2.0.CO;2##CHANG P, 2000, J CLIMATE, V13, P2195, DOI 10.1175/1520-0442(2000)013<2195:TEOLSS>2.0.CO;2##CHANG P, 2006, J CLIMATE, V19, P5122, DOI 10.1175/JCLI3903.1##CHANG P, 1997, NATURE, V385, P516, DOI 10.1038/385516A0##COLLINS WD, 2006, J CLIMATE, V19, P2122, DOI 10.1175/JCLI3761.1##DAVEY MK, 2002, CLIM DYNAM, V18, P403, DOI 10.1007/S00382-001-0188-6##DELWORTH TL, 2006, J CLIMATE, V19, P643, DOI 10.1175/JCLI3629.1##FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602A0##GORDON C, 2000, CLIM DYNAM, V16, P147, DOI 10.1007/S003820050010##GORDON HB, 2002, 60 CISRO MAR ATM RES##HASUMI H, 2004, 1 K1 U TOK CENT CLIM##HIRST AC, 1983, J PHYS OCEANOGR, V13, P1146, DOI 10.1175/1520-0485(1983)013<1146:AOMOCA>2.0.CO;2##JOHNSON RS, 2001, J VAC SCI TECHNOL A, V19, P1353, DOI 10.1116/1.1379316##JUNGCLAUS JH, 2006, J CLIMATE, V19, P3952, DOI 10.1175/JCLI3827.1##MOURA AD, 1981, J ATMOS SCI, V38, P2653, DOI 10.1175/1520-0469(1981)038<2653:OTDODI>2.0.CO;2##OKAJIMA H, 2003, J METEOROL SOC JPN, V81, P1371, DOI 10.2151/JMSJ.81.1371##RUIZ-BARRADAS A, 2000, J CLIMATE, V13, P3285, DOI 10.1175/1520-0442(2000)013<3285:SOITDC>2.0.CO;2##SERVAIN J, 2000, INT J CLIMATOL, V20, P939, DOI 10.1002/1097-0088(200007)20:9<939::AID-JOC511>3.0.CO;2-V##UPPALA SM, 2005, Q J ROY METEOR SOC, V131, P2961, DOI 10.1256/QJ.04.176##VON STORCH H., 2001, STAT ANAL CLIMATE RE##XIE SP, 2004, GEOPHYS MONOGR SER, V147, P121##XIE SP, 1999, J CLIMATE, V12, P64, DOI 10.1175/1520-0442-12.1.64##ZEBIAK SE, 1993, J CLIMATE, V6, P1567, DOI 10.1175/1520-0442(1993)006<1567:AIITEA>2.0.CO;2",39,2020-11-20,NA
J,WOS:000242752500001,2006,ARCTIC WINTER 2005: IMPLICATIONS FOR STRATOSPHERIC OZONE LOSS AND CLIMATE CHANGE,"[1] THE ARCTIC POLAR VORTEX EXHIBITED WIDESPREAD REGIONS OF LOW TEMPERATURES DURING THE WINTER OF 2005, RESULTING IN SIGNIFICANT OZONE DEPLETION BY CHLORINE AND BROMINE SPECIES. WE SHOW THAT CHEMICAL LOSS OF COLUMN OZONE (DELTA O(3)) AND THE VOLUME OF ARCTIC VORTEX AIR COLD ENOUGH TO SUPPORT THE EXISTENCE OF POLAR STRATOSPHERIC CLOUDS (V(PSC)) BOTH EXCEED LEVELS FOUND FOR ANY OTHER ARCTIC WINTER DURING THE PAST 40 YEARS. COLD CONDITIONS AND OZONE LOSS IN THE LOWERMOST ARCTIC STRATOSPHERE (E.G., BETWEEN POTENTIAL TEMPERATURES OF 360 TO 400 K) WERE PARTICULARLY UNUSUAL COMPARED TO PREVIOUS YEARS. MEASUREMENTS INDICATE DELTA O(3) = 121 +/- 20 DU AND THAT DELTA O(3) VERSUS V(PSC) LIES ALONG AN EXTENSION OF THE COMPACT, NEAR LINEAR RELATION OBSERVED FOR PREVIOUS ARCTIC WINTERS. THE MAXIMUM VALUE OF V(PSC) DURING FIVE TO TEN YEAR INTERVALS EXHIBITS A STEADY, MONOTONIC INCREASE OVER THE PAST FOUR DECADES, INDICATING THAT THE COLDEST ARCTIC WINTERS HAVE BECOME SIGNIFICANTLY COLDER, AND HENCE ARE MORE CONDUCIVE TO OZONE DEPLETION BY ANTHROPOGENIC HALOGENS.",DEPLETION,NA,GEOPHYSICAL RESEARCH LETTERS,"REX, M##SALAWITCH, RJ##DECKELMANN, H##VON DER GATHEN, P##HARRIS, NRP##CHIPPERFIELD, MP##NAUJOKAT, B##REIMER, E##ALLAART, M##ANDERSEN, SB##BEVILACQUA, R##BRAATHEN, GO##CLAUDE, H##DAVIES, J##DE BACKER, H##DIER, H##DOROKHOV, V##FAST, H##GERDING, M##GODIN-BEEKMANN, S##HOPPEL, K##JOHNSON, B##KYRO, E##LITYNSKA, Z##MOORE, D##NAKANE, H##PARRONDO, MC##RISLEY, AD##SKRIVANKOVA, P##STUBI, R##VIATTE, P##YUSHKOV, V##ZEREFOS, C","ALFRED WEGENER INST POLAR & MARINE RES, RES UNIT POTSDAM, D-14401 POTSDAM, GERMANY. CALTECH, JET PROP LAB, PASADENA, CA 91109 USA. UNIV CAMBRIDGE, EUROPEAN OZONE RES COORDINATING UNIT, CAMBRIDGE CB2 1EW, ENGLAND. UNIV LEEDS, SCH EARTH & ENVIRONM, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND. FREE UNIV BERLIN, INST METEOROL, D-12165 BERLIN, GERMANY. ROYAL NETHERLANDS METEOROL INST, NL-3730 AE DE BILT, NETHERLANDS. DANISH METEOROL INST, DK-20100 COPENHAGEN, DENMARK. USN, RES LAB, WASHINGTON, DC 20375 USA. NORWEGIAN INST AIR RES, KJELLER, NORWAY. GERMAN WEATHER SERV, METEOROL OBSERV HOHENPEISSENBERG, D-82383 HOHENPEISSENBERG, GERMANY. METEOROL SERV CANADA, TORONTO, ON M3H 5T4, CANADA. ROYAL METEOROL INST BELGIUM, B-01180 BRUSSELS, BELGIUM. METEOROL OBSERV LINDENBERG, LINDENBERG, GERMANY. CENT AEROL OBSERV, MOSCOW, RUSSIA. LEIBNIZ INST ATMOSPHARENPHYS, D-18225 KUHLUNGSBORN, GERMANY. CNRS, INST PIERRE SIMON LAPLACE, SERV AERON, F-75252 PARIS 05, FRANCE. NOAA, EARTH SYST RES LAB, BOULDER, CO 80305 USA. SODANKYLA METEOROL OBSERV, SODANKYLA, FINLAND. CTR AEROL, INST METEOROL & WATER MANAGEMENT, PL-05119 LEGIONOWO, POLAND. MET OFF, EXETER EX1 3PB, DEVON, ENGLAND. NATL INST ENVIRONM STUDIES, ASIAN ENVIRONM RES GRP, TSUKUBA, IBARAKI 3058506, JAPAN. INST NACL TECN AEROSPACIAL, E-28850 MADRID, SPAIN. SCI APPLICAT INT CORP, HAMPTON, VA 23666 USA. CZECH HYDROMETEOROL INST, PRAGUE 14306 4, CZECH REPUBLIC. SWISS METEOROL AEROL STN, CH-1530 PAYERNE, SWITZERLAND. METEOSWISS, FED OFF METEOROL & CLIMATOL, CH-1530 PAYERNE, SWITZERLAND. UNIV ATHENS, LAB CLIMATOL & ATMOSPHER ENVIRONM, GR-15784 ATHENS, GREECE.","GEOSCIENCES, MULTIDISCIPLINARY",GEOLOGY,"AUSTIN J, 1992, NATURE, V360, P221, DOI 10.1038/360221A0##HOPPEL K, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000476##KNUDSEN BM, 2004, ATMOS CHEM PHYS, V4, P1849, DOI 10.5194/ACP-4-1849-2004##KNUDSEN BM, 1998, GEOPHYS RES LETT, V25, P627, DOI 10.1029/98GL00300##MANNEY GL, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024494##MANNEY GL, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005367##RANDALL CE, 2005, J ATMOS SCI, V62, P748, DOI 10.1175/JAS-3336.1##REX M, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018844##REX M, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000533##REX M, 1999, J ATMOS CHEM, V32, P35, DOI 10.1023/A:1006093826861##SCHNADT C, 2002, CLIM DYNAM, V18, P501, DOI 10.1007/S00382-001-0190-Z##SHINDELL DT, 1998, NATURE, V392, P589, DOI 10.1038/33385##TILMES S, 2004, ATMOS CHEM PHYS, V4, P2181, DOI 10.5194/ACP-4-2181-2004",111,2020-11-20,NA
J,WOS:000242477100047,2006,RETINOL DEHYDROGENASE (RDH12) PROTECTS PHOTORECEPTORS FROM LIGHT-INDUCED DEGENERATION IN MICE,"RDH12 HAS BEEN SUGGESTED TO BE ONE OF THE RETINOL DEHYDROGENASES (RDH) INVOLVED IN THE VITAMIN A RECYCLING SYSTEM (VISUAL CYCLE) IN THE EYE. LOSS OF FUNCTION MUTATIONS IN THE RDH12 GENE WERE RECENTLY REPORTED TO BE ASSOCIATED WITH AUTOSOMAL RECESSIVE CHILDHOOD-ONSET SEVERE RETINAL DYSTROPHY. HERE WE SHOW THAT RDH12 LOCALIZES TO THE PHOTORECEPTOR INNER SEGMENTS AND THAT DELETION OF THIS GENE IN MICE SLOWS THE KINETICS OF ALL-TRANS-RETINAL REDUCTION, DELAYING DARK ADAPTATION. HOWEVER, ACCELERATED 11-CIS-RETINAL PRODUCTION AND INCREASED SUSCEPTIBILITY TO LIGHT-INDUCED PHOTORECEPTOR APOPTOSIS WERE ALSO OBSERVED IN RDH12(-/-) MICE, SUGGESTING THAT RDH12 PLAYS A UNIQUE, NON-REDUNDANT ROLE IN THE PHOTORECEPTOR INNER SEGMENTS TO REGULATE THE FLOW OF RETINOIDS IN THE EYE. THUS, SEVERE VISUAL IMPAIRMENTS OF INDIVIDUALS WITH NULL MUTATIONS IN RDH12 MAY LIKELY BE CAUSED BY LIGHT DAMAGE(1).",LEBER CONGENITAL AMAUROSIS; COUPLED RECEPTOR RHODOPSIN; ALL-TRANS-RETINOL; VISUAL CYCLE; PIGMENT EPITHELIUM; VERTEBRATE RETINA; DARK-ADAPTATION; IN-VIVO; SUBSTRATE-SPECIFICITY; RPE65,NA,JOURNAL OF BIOLOGICAL CHEMISTRY,"MAEDA, A##MAEDA, T##IMANISHI, Y##SUN, WY##JASTRZEBSKA, B##HATALA, DA##WINKENS, HJ##HOFMANN, KP##JANSSEN, JJ##BAEHR, W##DRIESSEN, CA##PALCZEWSKI, K","CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA. CASE WESTERN RESERVE UNIV, SCH MED, DEPT OPHTHALMOL, CLEVELAND, OH 44106 USA. UNIV NIJMEGEN, DEPT OPHTHALMOL, NL-6525 EX NIJMEGEN, NETHERLANDS. UNIV NIJMEGEN, DEPT BIOCHEM, NL-6525 EX NIJMEGEN, NETHERLANDS. HUMBOLDT UNIV, UNIV KLINIKUM CHARITE, INST MED PHYS & BIOPHYS, D-10098 BERLIN, GERMANY. UNIV UTAH, DEPT OPHTHALMOL & VISUAL SCI, SALT LAKE CITY, UT 84112 USA. UNIV UTAH, DEPT NEUROBIOL & ANAT, SALT LAKE CITY, UT 84112 USA.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"ALPERN M, 1971, J PHYSIOL-LONDON, V217, P447, DOI 10.1113/JPHYSIOL.1971.SP009580##BATTEN ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/JBC.M312410200##BELYAEVA OV, 2005, BIOCHEMISTRY-US, V44, P7035, DOI 10.1021/BI050226K##BISWAS MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/JBC.272.25.15959##DRIESSEN C, 2003, VISION RES, V43, P3075, DOI 10.1016/S0042-6989(03)00483-8##DRIESSEN CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000##FAIN G L, 2001, PROG BRAIN RES, V131, P383##FAIN GL, 2001, PHYSIOL REV, V81, P117##FILIPEK S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/ANNUREV.PHYSIOL.65.092101.142611##GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/JBC.270.37.22029##GREEN DG, 1975, J GEN PHYSIOL, V65, P483, DOI 10.1085/JGP.65.4.483##GRIMM C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614##HAESELEER F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/JBC.M208882200##HORRIGAN DM, 2005, J GEN PHYSIOL, V126, P453, DOI 10.1085/JGP.200509387##IMANISHI Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/JCB.200311079##JANECKE AR, 2004, NAT GENET, V36, P850, DOI 10.1038/NG1394##JANG GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/JBC.M104949200##JANG GF, 2000, J BIOL CHEM, V275, P28128##JEON CJ, 1998, J NEUROSCI, V18, P8936##JIN MH, 2005, CELL, V122, P449, DOI 10.1016/J.CELL.2005.06.042##KIM TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/JBC.M413172200##LAMB TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/J.PRETEYERES.2004.03.001##MAEDA A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/JBC.M501757200##MAEDA T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/J.1471-4159.2003.01741.X##MARTRAS S, 2004, EUR J BIOCHEM, V271, P1660, DOI 10.1111/J.1432-1033.2004.04058.X##MATA NL, 2001, INVEST OPHTH VIS SCI, V42, P1685##MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/JGP.47.2.215##MCBEE JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7##MCCABE SL, 2004, J GEN PHYSIOL, V123, P521, DOI 10.1085/JGP.200409011##MOISEYEV G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/PNAS.0503460102##OHGURO H, 1993, P NATL ACAD SCI USA, V90, P3241, DOI 10.1073/PNAS.90.8.3241##PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/BI00250A027##PALCZEWSKI K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3##PALCZEWSKI K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/ANNUREV.BIOCHEM.75.103004.142743##PARISH CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/PNAS.95.25.14609##PERRAULT I, 2004, AM J HUM GENET, V75, P639, DOI 10.1086/424889##RATTNER A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/JBC.275.15.11034##REDMOND TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813##REDMOND TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/PNAS.0504167102##ROHRER B, 2003, INVEST OPHTH VIS SCI, V44, P310, DOI 10.1167/IOVS.02-0567##SAARI JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3##SONG MS, 2003, J BIOL CHEM, V278, P40079, DOI 10.1074/JBC.M304910200##THOMPSON DA, 2005, HUM MOL GENET, V14, P3865, DOI 10.1093/HMG/DDI411##THOMPSON DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X##TRAVIS G.H., 2007, ANN REV PHARM TOXICO, V47, P1##WENG J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9##WENZEL A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001##WU BX, 2004, INVEST OPHTH VIS SCI, V45, P3857, DOI 10.1167/IOVS.03-1302##XIAO M, 2000, J COMP NEUROL, V425, P545##YZER S, 2006, INVEST OPHTH VIS SCI, V47, P1167, DOI 10.1167/IOVS.05-0848",75,2020-11-20,"NEI NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL EYE INSTITUTE (NEI) [K08 EY019031-01, R01 EY009339, P30 EY11373, P30 EY011373, EY09339, R01 EY022658, K08 EY019031] FUNDING SOURCE: MEDLINE; NATIONAL EYE INSTITUTEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL EYE INSTITUTE (NEI) [P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, R01EY009339, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, R01EY009339, P30EY011373, P30EY011373, R01EY022658, P30EY011373, R01EY009339, P30EY011373, P30EY011373, R01EY009339, P30EY011373, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, R01EY022658, R01EY009339, P30EY011373, P30EY011373, R01EY009339, K08EY019031, K08EY019031, P30EY011373, R01EY009339, P30EY011373, K08EY019031, P30EY011373, P30EY011373, R01EY009339, P30EY011373, P30EY011373, R01EY009339, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, R01EY022658, R01EY009339, R01EY022658, R01EY022658, R01EY009339, P30EY011373, R01EY009339, P30EY011373, K08EY019031, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, K08EY019031, P30EY011373, R01EY009339, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, P30EY011373, R01EY009339, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, R01EY009339, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, R01EY009339, K08EY019031, P30EY011373, P30EY011373, P30EY011373, R01EY009339, P30EY011373, R01EY009339, P30EY011373, R01EY009339, R01EY009339, P30EY011373, R01EY009339, R01EY009339, P30EY011373, R01EY009339, R01EY009339, P30EY011373, P30EY011373, P30EY011373, P30EY011373, P30EY011373, R01EY009339] FUNDING SOURCE: NIH REPORTER"
J,WOS:000242477100078,2006,STRUCTURAL CHARACTERIZATION OF SPO0E-LIKE PROTEIN-ASPARTIC ACID PHOSPHATASES THAT REGULATE SPORULATION IN BACILLI,"SPORE FORMATION IS AN EXTREME RESPONSE OF MANY BACTERIAL SPECIES TO STARVATION. IN THE CASE OF PATHOGENIC SPECIES OF BACILLUS AND CLOSTRIDIUM, IT IS ALSO A COMPONENT OF DISEASE TRANSMISSION. ENTRY INTO THE PATHWAY OF SPORULATION IN BACILLUS SUBTILIS AND ITS RELATIVES IS CONTROLLED BY AN EXPANDED TWO-COMPONENT SYSTEM IN WHICH STARVATION SIGNALS LEAD TO THE ACTIVATION OF SENSOR KINASES AND PHOSPHORYLATION OF THE MASTER SPORULATION RESPONSE REGULATOR SPO0A. ACCUMULATION OF THRESHOLD CONCENTRATIONS OF SPO0A SIMILAR TO P HERALDS THE COMMITMENT TO SPORULATION. COUNTERING THE ACTIVITIES OF THE SENSOR KINASES ARE PHOSPHATASES SUCH AS SPO0E, WHICH DEPHOSPHORYLATE SPO0A SIMILAR TO P AND INHIBIT SPORULATION. SPO0E-LIKE PROTEIN-ASPARTIC ACID-PHOSPHATE PHOSPHATASES, CONSISTING OF 50-90 RESIDUES, ARE CONSERVED IN SPOREFORMING BACTERIA AND UNRELATED IN SEQUENCE TO PROTEINS OF KNOWN STRUCTURE. HERE WE DETERMINED THE STRUCTURES OF THE SPO0A SIMILAR TO P PHOSPHATASES BA1655 AND BA5174 FROM BACILLUS ANTHRACIS USING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. EACH IS COMPOSED OF TWO ANTI-PARALLEL ALPHA-HELICES FLANKED BY FLEXIBLE REGIONS AT THE TERMINI. THE SIGNATURE SQELD MOTIF (SRDLD IN BA1655) IS SITUATED IN THE MIDDLE OF HELIX ALPHA 2 WITH ITS POLAR RESIDUES PROJECTING OUTWARD. BA5174 IS A MONOMER, WHEREAS BA1655 IS A DIMER. THE FOUR-HELIX BUNDLE STRUCTURE IN THE DIMER IS REMINISCENT OF THE PHOSPHOTRANSFERASE SPO0B AND THE CHEMOTAXIS PHOSPHATASE CHEZ, ALTHOUGH IN CONTRAST TO THESE SYSTEMS, THE SUBUNITS IN BA1655 ARE IN HEAD-TO-TAIL RATHER THAN HEAD-TO-HEAD APPOSITION. THE IMPLICATIONS OF THE STRUCTURES FOR INTERACTIONS BETWEEN THE PHOSPHATASES AND THEIR SUBSTRATE SPO0A SIMILAR TO P ARE DISCUSSED.",TRANSCRIPTION FACTOR SPO0A; TORSION ANGLE DYNAMICS; RESPONSE REGULATOR; MOLECULAR RECOGNITION; SUBTILIS SPORULATION; HISTIDINE KINASES; ESCHERICHIA-COLI; PHOSPHORELAY; ASSIGNMENT; MECHANISM,NA,JOURNAL OF BIOLOGICAL CHEMISTRY,"GRENHA, R##RZECHORZEK, NJ##BRANNIGAN, JA##DE JONG, RN##AB, E##DIERCKS, T##TRUFFAULT, V##LADDS, JC##FOGG, MJ##BONGIORNI, C##PEREGO, M##KAPTEIN, R##WILSON, KS##FOLKERS, GE##WILKINSON, AJ","UNIV UTRECHT, BIJVOET CTR, NMR DEPT, NL-3584 CH UTRECHT, NETHERLANDS. UNIV YORK, DEPT CHEM, STRUCT BIOL LAB, YORK YO10 5YW, N YORKSHIRE, ENGLAND. SCRIPPS RES INST, DIV CELLULAR BIOL, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W##BRUNGER AT, 1997, CRYSTALLOGRAPHY NMR##BRUNSING RL, 2005, J BACTERIOL, V187, P6972, DOI 10.1128/JB.187.20.6972-6981.2005##BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T##CORNILESCU G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740##DAUMKE O, 2004, NATURE, V429, P197, DOI 10.1038/NATURE02505##DELANO W. L., 2002, PYMOL MOL GRAPHICS S##DIERCKS T, 1999, J BIOMOL NMR, V15, P177, DOI 10.1023/A:1008367912535##FERRARI E, 1986, J BACTERIOL, V166, P173, DOI 10.1128/JB.166.1.173-179.1986##FOLKERS G. E., 2004, JOURNAL OF STRUCTURAL AND FUNCTIONAL GENOMICS, V5, P119, DOI 10.1023/B:JSFG.0000029200.66197.0C##GODDARD TD, 2006, SPARKY 3##GOUET P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/BIOINFORMATICS/15.4.305##GUNTERT P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/JMBI.1997.1284##HERRMANN T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3##JANSSON M, 1996, J BIOMOL NMR, V7, P131##JIANG M, 2000, MOL MICROBIOL, V38, P535, DOI 10.1046/J.1365-2958.2000.02148.X##KOBAYASHI K, 1995, J BACTERIOL, V177, P176, DOI 10.1128/JB.177.1.176-182.1995##KOEHLER TM, 1994, J BACTERIOL, V176, P586, DOI 10.1128/JB.176.3.586-595.1994##KORADI R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4##LANDAU M, 2005, NUCLEIC ACIDS RES, V33, PW299, DOI 10.1093/NAR/GKI370##LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944##LEDEAUX JR, 1995, J BACTERIOL, V177, P166, DOI 10.1128/JB.177.1.166-175.1995##LEE SY, 2001, NAT STRUCT BIOL, V8, P52##LEUTNER M, 1998, J BIOMOL NMR, V11, P31, DOI 10.1023/A:1008298226961##LEWIS RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/JMBI.1999.3261##LEWIS RJ, 2002, J MOL BIOL, V316, P235, DOI 10.1006/JMBI.2001.5331##LO CONTE L, 1999, J MOL BIOL, V285, P2177##MADHUSUDAN, 1996, STRUCTURE, V4, P679, DOI 10.1016/S0969-2126(96)00074-3##MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/PROT.340120407##MUCHOVA K, 2004, MOL MICROBIOL, V53, P829, DOI 10.1111/J.1365-2958.2004.04171.X##NEDERVEEN AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/PROT.20408##OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/PNAS.91.5.1756##PARK SY, 2004, MOL CELL, V16, P563, DOI 10.1016/J.MOLCEL.2004.10.018##PEREGO M, 1997, P NATL ACAD SCI USA, V94, P8612, DOI 10.1073/PNAS.94.16.8612##PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3##PEREGO M, 2001, PEPTIDES, V22, P1541, DOI 10.1016/S0196-9781(01)00490-9##PEREGO M, 2001, MOL MICROBIOL, V42, P133, DOI 10.1046/J.1365-2958.2001.02611.X##PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/JB.173.8.2514-2520.1991##PIGGOT PJ, 2004, CURR OPIN MICROBIOL, V7, P579, DOI 10.1016/J.MIB.2004.10.001##PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976##POTTERTON L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716##POYART C, 1997, FEMS MICROBIOL LETT, V156, P193, DOI 10.1111/J.1574-6968.1997.TB12726.X##SATTLER M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9##SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/PNAS.54.3.704##STEPHENSON K, 2002, MOL MICROBIOL, V46, P297, DOI 10.1046/J.1365-2958.2002.03186.X##STEPHENSON SJ, 2002, MOL MICROBIOL, V44, P1455, DOI 10.1046/J.1365-2958.2002.02974.X##VARUGHESE KI, 1998, MOL CELL, V2, P485, DOI 10.1016/S1097-2765(00)80148-3##VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V##WHITEHEAD B, 1997, J BIOMOL NMR, V9, P313, DOI 10.1023/A:1018687127330##ZAPF J, 2000, STRUCTURE, V8, P851, DOI 10.1016/S0969-2126(00)00174-X##ZAPF JW, 1996, BIOCHEMISTRY-US, V35, P2926, DOI 10.1021/BI9519361##ZHAO R, 2002, NAT STRUCT BIOL, V9, P570##ZIMMERMAN DE, 1997, J MOL BIOL, V269, P592, DOI 10.1006/JMBI.1997.1052",12,2020-11-20,"NIAID NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES (NIAID) [AI52289] FUNDING SOURCE: MEDLINE; NIGMS NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) [GM55594] FUNDING SOURCE: MEDLINE; WELLCOME TRUSTWELLCOME TRUST FUNDING SOURCE: MEDLINE; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES (NIAID) [R01AI052289, R01AI052289, R01AI052289, R01AI052289, R01AI052289] FUNDING SOURCE: NIH REPORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) [R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594] FUNDING SOURCE: NIH REPORTER"
J,WOS:000242708900015,2006,OBSERVATION OF AN EXCITED CHARM BARYON OMEGA(*)(C) DECAYING TO OMEGA(0)(C)GAMMA,"WE REPORT THE FIRST OBSERVATION OF AN EXCITED SINGLY CHARMED BARYON OMEGA(*)(C) (CSS) IN THE RADIATIVE DECAY OMEGA(0)(C)GAMMA, WHERE THE OMEGA(0)(C) BARYON IS RECONSTRUCTED IN THE DECAYS TO THE FINAL STATES OMEGA(-)PI(+), OMEGA(-)PI(+)PI(0), OMEGA(-)PI(+)PI(-)PI(+), AND XI K--(-)PI(+)PI(+). THIS ANALYSIS IS PERFORMED USING A DATA SET OF 230.7 FB(-1) COLLECTED BY THE BABAR DETECTOR AT THE PEP-II ASYMMETRIC-ENERGY B FACTORY AT THE STANFORD LINEAR ACCELERATOR CENTER. THE MASS DIFFERENCE BETWEEN THE OMEGA(*)(C) AND THE OMEGA(0)(C) BARYONS IS MEASURED TO BE 70.8 +/- 1.0(STAT) +/- 1.1(SYST) MEV/C(2). WE ALSO MEASURE THE RATIO OF INCLUSIVE PRODUCTION CROSS SECTIONS OF OMEGA(*)(C) AND OMEGA(0)(C) IN E(+)E(-) ANNIHILATION.",MASSES; PHYSICS,NA,PHYSICAL REVIEW LETTERS,"AUBERT, B##BONA, M##BOUTIGNY, D##COUDERC, F##KARYOTAKIS, Y##LEES, JP##POIREAU, V##TISSERAND, V##ZGHICHE, A##GRAUGES, E##PALANO, A##CHEN, JC##QI, ND##RONG, G##WANG, P##ZHU, YS##EIGEN, G##OFTE, I##STUGU, B##ABRAMS, GS##BATTAGLIA, M##BROWN, DN##BUTTON-SHAFER, J##CAHN, RN##CHARLES, E##GILL, MS##GROYSMAN, Y##JACOBSEN, RG##KADYK, JA##KERTH, LT##KOLOMENSKY, YG##KUKARTSEV, G##LYNCH, G##MIR, LM##ORIMOTO, TJ##PRIPSTEIN, M##ROE, NA##RONAN, MT##WENZEL, WA##SANCHEZ, PD##BARRETT, M##FORD, KE##HART, AJ##HARRISON, TJ##HAWKES, CM##WATSON, AT##HELD, T##KOCH, H##LEWANDOWSKI, B##PELIZAEUS, M##PETERS, K##SCHROEDER, T##STEINKE, M##BOYD, JT##BURKE, JP##COTTINGHAM, WN##WALKER, D##ASGEIRSSON, DJ##CUHADAR-DONSZELMANN, T##FULSOM, BG##HEARTY, C##KNECHT, NS##MATTISON, TS##MCKENNA, JA##KHAN, A##KYBERD, P##SALEEM, M##SHERWOOD, DJ##TEODORESCU, L##BLINOV, VE##BUKIN, AD##DRUZHININ, VP##GOLUBEV, VB##ONUCHIN, AP##SEREDNYAKOV, SI##SKOVPEN, YI##SOLODOV, EP##TODYSHEV, KY##BONDIOLI, M##BRUINSMA, M##CHAO, M##CURRY, S##ESCHRICH, I##KIRKBY, D##LANKFORD, AJ##LUND, P##MANDELKERN, M##MOMMSEN, RK##ROETHEL, W##STOKER, DP##ABACHI, S##BUCHANAN, C##FOULKES, SD##GARY, JW##LONG, O##SHEN, BC##WANG, K##ZHANG, L##HADAVAND, HK##HILL, EJ##PAAR, HP##RAHATLOU, S##SHARMA, V##BERRYHILL, JW##CAMPAGNARI, C##CUNHA, A##DAHMES, B##HONG, TM##KOVALSKYI, D##RICHMAN, JD##BECK, TW##EISNER, AM##FLACCO, CJ##HEUSCH, CA##KROSEBERG, J##LOCKMAN, WS##NESOM, G##SCHALK, T##SCHUMM, BA##SEIDEN, A##SPRADLIN, P##WILLIAMS, DC##WILSON, MG##ALBERT, J##CHEN, E##DVORETSKII, A##FANG, F##HITLIN, DG##NARSKY, I##PIATENKO, T##PORTER, FC##RYD, A##MANCINELLI, G##MEADOWS, BT##MISHRA, K##SOKOLOFF, MD##BLANC, F##BLOOM, PC##CHEN, S##FORD, WT##HIRSCHAUER, JF##KREISEL, A##NAGEL, M##NAUENBERG, U##OLIVAS, A##RUDDICK, WO##SMITH, JG##ULMER, KA##WAGNER, SR##ZHANG, J##CHEN, A##ECKHART, EA##SOFFER, A##TOKI, WH##WILSON, RJ##WINKLMEIER, F##ZENG, Q##ALTENBURG, DD##FELTRESI, E##HAUKE, A##JASPER, H##MERKEL, J##PETZOLD, A##SPAAN, B##BRANDT, T##KLOSE, V##LACKER, HM##MADER, WF##NOGOWSKI, R##SCHUBERT, J##SCHUBERT, KR##SCHWIERZ, R##SUNDERMANN, JE##VOLK, A##BERNARD, D##BONNEAUD, GR##LATOUR, E##THIEBAUX, C##VERDERI, M##CLARK, PJ##GRADL, W##MUHEIM, F##PLAYFER, S##ROBERTSON, AI##XIE, Y##ANDREOTTI, M##BETTONI, D##BOZZI, C##CALABRESE, R##CIBINETTO, G##LUPPI, E##NEGRINI, M##PETRELLA, A##PIEMONTESE, L##PRENCIPE, E##ANULLI, F##BALDINI-FERROLI, R##CALCATERRA, A##DE SANGRO, R##FINOCCHIARO, G##PACETTI, S##PATTERI, P##PERUZZI, IM##PICCOLO, M##RAMA, M##ZALLO, A##BUZZO, A##CONTRI, R##LO VETERE, M##MACRI, MM##MONGE, MR##PASSAGGIO, S##PATRIGNANI, C##ROBUTTI, E##SANTRONI, A##TOSI, S##BRANDENBURG, G##CHAISANGUANTHUM, KS##MORII, M##WU, J##DUBITZKY, RS##MARKS, J##SCHENK, S##UWER, U##BHIMJI, W##BOWERMAN, DA##DAUNCEY, PD##EGEDE, U##FLACK, RL##NASH, JA##NIKOLICH, MB##VAZQUEZ, WP##BARD, DJ##BEHERA, PK##CHAI, X##CHARLES, MJ##MALLIK, U##MEYER, NT##ZIEGLER, V##COCHRAN, J##CRAWLEY, HB##DONG, L##EYGES, V##MEYER, WT##PRELL, S##ROSENBERG, EI##RUBIN, AE##GRITSAN, AV##DENIG, AG##FRITSCH, M##SCHOTT, G##ARNAUD, N##DAVIER, M##GROSDIDIER, G##HOCKER, A##LE DIBERDER, F##LEPELTIER, V##LUTZ, AM##OYANGUREN, A##PRUVOT, S##RODIER, S##ROUDEAU, P##SCHUNE, MH##STOCCHI, A##WANG, WF##WORMSER, G##CHENG, CH##LANGE, DJ##WRIGHT, DM##CHAVEZ, CA##FORSTER, IJ##FRY, JR##GABATHULER, E##GAMET, R##GEORGE, KA##HUTCHCROFT, DE##PAYNE, DJ##SCHOFIELD, KC##TOURAMANIS, C##BEVAN, AJ##DI LODOVICO, F##MENGES, W##SACCO, R##COWAN, G##FLAECHER, HU##HOPKINS, DA##JACKSON, PS##MCMAHON, TR##RICCIARDI, S##SALVATORE, F##WREN, AC##BROWN, DN##DAVIS, CL##ALLISON, J##BARLOW, NR##BARLOW, RJ##CHIA, YM##EDGAR, CL##LAFFERTY, GD##NAISBIT, MT##WILLIAMS, JC##YI, JI##CHEN, C##HULSBERGEN, WD##JAWAHERY, A##LAE, CK##ROBERTS, DA##SIMI, G##BLAYLOCK, G##DALLAPICCOLA, C##HERTZBACH, SS##LI, X##MOORE, TB##SAREMI, S##STAENGLE, H##COWAN, R##SCIOLLA, G##SEKULA, SJ##SPITZNAGEL, M##TAYLOR, F##YAMAMOTO, RK##KIM, H##MCLACHLIN, SE##PATEL, PM##ROBERTSON, SH##LAZZARO, A##LOMBARDO, V##PALOMBO, F##BAUER, JM##CREMALDI, L##ESCHENBURG, V##GODANG, R##KROEGER, R##SANDERS, DA##SUMMERS, DJ##ZHAO, HW##BRUNET, S##COTE, D##SIMARD, M##TARAS, P##VIAUD, FB##NICHOLSON, H##CAVALLO, N##DE NARDO, G##FABOZZI, F##GATTO, C##LISTA, L##MONORCHIO, D##PAOLUCCI, P##PICCOLO, D##SCIACCA, C##BAAK, MA##RAVEN, G##SNOEK, HL##JESSOP, CP##LOSECCO, JM##ALLMENDINGER, T##BENELLI, G##CORWIN, LA##GAN, KK##HONSCHEID, K##HUFNAGEL, D##JACKSON, PD##KAGAN, H##KASS, R##RAHIMI, AM##REGENSBURGER, JJ##TER-ANTONYAN, R##WONG, QK##BLOUNT, NL##BRAU, J##FREY, R##IGONKINA, O##KOLB, JA##LU, M##RAHMAT, R##SINEV, NB##STROM, D##STRUBE, J##TORRENCE, E##GAZ, A##MARGONI, M##MORANDIN, M##POMPILI, A##POSOCCO, M##ROTONDO, M##SIMONETTO, F##STROILI, R##VOCI, C##BENAYOUN, M##BRIAND, H##CHAUVEAU, J##DAVID, P##DEL BUONO, L##DE LA VAISSIERE, C##HAMON, O##HARTFIEL, BL##LERUSTE, P##MALCLES, J##OCARIZ, J##ROOS, L##THERIN, G##GLADNEY, L##BIASINI, M##COVARELLI, R##ANGELINI, C##BATIGNANI, G##BETTARINI, S##BUCCI, F##CALDERINI, G##CARPINELLI, M##CENCI, R##FORTI, F##GIORGI, MA##LUSIANI, A##MARCHIORI, G##MAZUR, MA##MORGANTI, M##NERI, N##PAOLONI, E##RIZZO, G##WALSH, JJ##HAIRE, M##JUDD, D##WAGONER, DE##BIESIADA, J##DANIELSON, N##ELMER, P##LAU, YP##LU, C##OLSEN, J##SMITH, AJS##TELNOV, AV##BELLINI, F##CAVOTO, G##D'ORAZIO, A##DEL RE, D##DI MARCO, E##FACCINI, R##FERRAROTTO, F##FERRONI, F##GASPERO, M##GIOI, LL##MAZZONI, MA##MORGANTI, S##PIREDDA, G##POLCI, F##TEHRANI, FS##VOENA, C##EBERT, M##SCHRODER, H##WALDI, R##ADYE, T##DE GROOT, N##FRANEK, B##OLAIYA, EO##WILSON, FF##ALEKSAN, R##EMERY, S##GAIDOT, A##GANZHUR, SF##DE MONCHENAULT, GH##KOZANECKI, W##LEGENDRE, M##VASSEUR, G##YECHE, C##ZITO, M##CHEN, XR##LIU, H##PARK, W##PUROHIT, MV##WILSON, JR##ALLEN, MT##ASTON, D##BARTOLDUS, R##BECHTLE, P##BERGER, N##CLAUS, R##COLEMAN, JP##CONVERY, MR##CRISTINZIANI, M##DINGFELDER, JC##DORFAN, J##DUBOIS-FELSMANN, GP##DUJMIC, D##DUNWOODIE, W##FIELD, RC##GLANZMAN, T##GOWDY, SJ##GRAHAM, MT##GRENIER, P##HALYO, V##HAST, C##HRYN'OVA, T##INNES, WR##KELSEY, MH##KIM, P##LEITH, DWGS##LI, S##LUITZ, S##LUTH, V##LYNCH, HL##MACFARLANE, DB##MARSISKE, H##MESSNER, R##MULLER, DR##O'GRADY, CP##OZCAN, VE##PERAZZO, A##PERL, M##PULLIAM, T##RATCLIFF, BN##ROODMAN, A##SALNIKOV, AA##SCHINDLER, RH##SCHWIENING, J##SNYDER, A##STELZER, J##SU, D##SULLIVAN, MK##SUZUKI, K##SWAIN, SK##THOMPSON, JM##VA'VRA, J##VAN BAKEL, N##WEAVER, M##WEINSTEIN, AJR##WISNIEWSKI, WJ##WITTGEN, M##WRIGHT, DH##YARRITU, AK##YI, K##YOUNG, CC##BURCHAT, PR##EDWARDS, AJ##MAJEWSKI, SA##PETERSEN, BA##ROAT, C##WILDEN, L##AHMED, S##ALAM, MS##BULA, R##ERNST, JA##JAIN, V##PAN, B##SAEED, MA##WAPPLER, FR##ZAIN, SB##BUGG, W##KRISHNAMURTHY, M##SPANIER, SM##ECKMANN, R##RITCHIE, JL##SATPATHY, A##SCHILLING, CJ##SCHWITTERS, RF##IZEN, JM##LOU, XC##YE, S##BIANCHI, F##GALLO, F##GAMBA, D##BOMBEN, M##BOSISIO, L##CARTARO, C##COSSUTTI, F##DELLA RICCA, G##DITTONGO, S##LANCERI, L##VITALE, L##AZZOLINI, V##LOPEZ-MARCH, N##MARTINEZ-VIDAL, F##BANERJEE, S##BHUYAN, B##BROWN, CM##FORTIN, D##HAMANO, K##KOWALEWSKI, R##NUGENT, IM##RONEY, JM##SOBIE, RJ##BACK, JJ##HARRISON, PF##LATHAM, TE##MOHANTY, GB##PAPPAGALLO, M##BAND, HR##CHEN, X##CHENG, B##DASU, S##DATTA, M##FLOOD, KT##HOLLAR, JJ##KUTTER, PE##MELLADO, B##MIHALYI, A##PAN, Y##PIERINI, M##PREPOST, R##WU, SL##YU, Z##NEAL, H","CNRS, PHYS PARTICULES LAB, IN2P3, F-74941 ANNECY LE VIEUX, FRANCE. UNIV SAVOIE, F-74941 ANNECY LE VIEUX, FRANCE. UNIV BARCELONA, FAC FIS, DEPT ECM, E-08028 BARCELONA, SPAIN. UNIV BARI, DIPARTMENTO FIS, I-70126 BARI, ITALY. UNIV BARI, IST NAZL FIS NUCL, I-70126 BARI, ITALY. INST HIGH ENERGY PHYS, BEIJING 100039, PEOPLES R CHINA. UNIV BERGEN, INST PHYS, N-5007 BERGEN, NORWAY. UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA. UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. RUHR UNIV BOCHUM, INST EXPT PHYS 1, D-44780 BOCHUM, GERMANY. UNIV BRISTOL, BRISTOL BS8 1TL, AVON, ENGLAND. UNIV BRITISH COLUMBIA, VANCOUVER, BC V6T 1Z1, CANADA. BRUNEL UNIV, UXBRIDGE UB8 3PH, MIDDX, ENGLAND. BUDKER INST NUCL PHYS, NOVOSIBIRSK 630090, RUSSIA. UNIV CALIF IRVINE, IRVINE, CA 92697 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA. UNIV CALIF SANTA BARBARA, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA CRUZ, INST PARTICLE PHYS, SANTA CRUZ, CA 95064 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CINCINNATI, CINCINNATI, OH 45221 USA. UNIV COLORADO, BOULDER, CO 80309 USA. COLORADO STATE UNIV, FT COLLINS, CO 80523 USA. UNIV DORTMUND, INST PHYS, D-44221 DORTMUND, GERMANY. TECH UNIV DRESDEN, INST KERN & TEILCHENPHYS, D-01062 DRESDEN, GERMANY. ECOLE POLYTECH, CNRS, LAB LABPRINCE RINGUET, IN2P3, F-91128 PALAISEAU, FRANCE. UNIV EDINBURGH, EDINBURGH EH9 3JZ, MIDLOTHIAN, SCOTLAND. UNIV FERRARA, DIPARTMENTO FIS, I-44100 FERRARA, ITALY. UNIV FERRARA, IST NAZL FIS NUCL, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, LAB NAZL FRASCATI, I-00044 FRASCATI, ITALY. UNIV GENOA, DIPARTIMENTO FIS, I-16146 GENOA, ITALY. UNIV GENOA, IST NAZL FIS NUCL, I-16146 GENOA, ITALY. HARVARD UNIV, CAMBRIDGE, MA 02138 USA. HEIDELBERG UNIV, INST PHYS, D-69120 HEIDELBERG, GERMANY. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AZ, ENGLAND. UNIV IOWA, IOWA CITY, IA 52242 USA. IOWA STATE UNIV, AMES, IA 50011 USA. JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA. UNIV KARLSRUHE, INST EXPT KERNPHYS, D-76021 KARLSRUHE, GERMANY. CNRS, LAB ACCELERATEUR LINEAIRE, IN2P3, F-91898 ORSAY, FRANCE. UNIV PARIS 11, CTR SCI ORSAY, F-91898 ORSAY, FRANCE. LAWRENCE LIVERMORE NATL LAB, LIVERMORE, CA 94550 USA. UNIV LIVERPOOL, LIVERPOOL L69 7ZE, MERSEYSIDE, ENGLAND. QUEEN MARY UNIV LONDON, LONDON E1 4NS, ENGLAND. UNIV LONDON ROYAL HOLLOWAY & BEDFORD NEW COLL, EGHAM TW20 0EX, SURREY, ENGLAND. UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA. UNIV MANCHESTER, MANCHESTER M13 9PL, LANCS, ENGLAND. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. UNIV MASSACHUSETTS, AMHERST, MA 01003 USA. MIT, NUCL SCI LAB, CAMBRIDGE, MA 02139 USA. MCGILL UNIV, MONTREAL, PQ H3A 2T8, CANADA. UNIV MILAN, DIPARTIMENTO FIS, I-20133 MILAN, ITALY. UNIV MILAN, IST NAZL FIS NUCL, I-20133 MILAN, ITALY. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV MONTREAL, MONTREAL, PQ H3C 3J7, CANADA. MT HOLYOKE COLL, S HADLEY, MA 01075 USA. UNIV NAPLES FEDERICO II, DIPARTIMENTO SCI FIS, I-80126 NAPLES, ITALY. UNIV NAPLES FEDERICO II, IST NAZL FIS NUCL, I-80126 NAPLES, ITALY. NIKHEF H, NATL INST NUCL PHYS & HIGH ENERGY PHYS, NL-1009 DB AMSTERDAM, NETHERLANDS. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. UNIV OREGON, EUGENE, OR 97403 USA. UNIV PADUA, DIPARTIMENTO FIS, I-35131 PADUA, ITALY. UNIV PADUA, IST NAZL FIS NUCL, I-35131 PADUA, ITALY. UNIV PARIS 06, CNRS, LAB PHYS NUCL & HAUTES ENERGIES, IN2P3, F-75252 PARIS, FRANCE. UNIV PARIS 07, F-75252 PARIS, FRANCE. UNIV PENN, PHILADELPHIA, PA 19104 USA. UNIV PERUGIA, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. UNIV PERUGIA, IST NAZL FIS NUCL, I-06100 PERUGIA, ITALY. UNIV PISA, DIPARTIMENTO FIS, SCUOLA NORMALE SUPER PISA, I-56127 PISA, ITALY. UNIV PISA, IST NAZL FIS NUCL, I-56127 PISA, ITALY. PRIARIE VIEW A&M UNIV, PRAIRIE VIEW, TX 77446 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. UNIV ROMA LA SAPIENZA, DIPARTIMENTO FIS, I-00185 ROME, ITALY. UNIV ROMA LA SAPIENZA, IST NAZL FIS NUCL, I-00185 ROME, ITALY. UNIV ROSTOCK, D-18051 ROSTOCK, GERMANY. RUTHERFORD APPLETON LAB, DIDCOT OX11 0QX, OXON, ENGLAND. CEA SACLAY, DSM DAPNIA, F-91191 GIF SUR YVETTE, FRANCE. UNIV S CAROLINA, COLUMBIA, SC 29208 USA. STANFORD LINEAR ACCELERATOR CTR, STANFORD, CA 94309 USA. STANFORD UNIV, STANFORD, CA 94305 USA. SUNY ALBANY, ALBANY, NY 12222 USA. UNIV TENNESSEE, KNOXVILLE, TN 37996 USA. UNIV TEXAS, AUSTIN, TX 78712 USA. UNIV TEXAS, RICHARDSON, TX 75083 USA. UNIV TURIN, DIPARTIMENTO FIS SPERIMENTALE, I-10125 TURIN, ITALY. UNIV TURIN, IST NAZL FIS NUCL, I-10125 TURIN, ITALY. UNIV TRIESTE, DIPARTIMENTO FIS, I-34127 TRIESTE, ITALY. UNIV TRIESTE, IST NAZL FIS NUCL, I-34127 TRIESTE, ITALY. UNIV POLITECN VALENCIA, CSIC, IFIC, E-46071 VALENCIA, SPAIN. UNIV VICTORIA, VICTORIA, BC V8W 3P6, CANADA. UNIV WARWICK, DEPT PHYS, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND. UNIV WISCONSIN, MADISON, WI 53706 USA. YALE UNIV, NEW HAVEN, CT 06511 USA.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"AGOSTINELLI S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8##ANTREASYAN D, 1983, CRYSTAL BALL NOTE, P321##AUBERT B, 2002, NUCL INSTRUM METH A, V479, P1, DOI 10.1016/S0168-9002(01)02012-5##BURAKOVSKY L, 1997, PHYS REV D, V56, P7124, DOI 10.1103/PHYSREVD.56.7124##EIDELMAN S, 2004, PHYS LETT B, V592, P1, DOI 10.1016/J.PHYSLETB.2004.06.001##GLOZMAN LY, 1996, NUCL PHYS A, V603, P326, DOI 10.1016/0375-9474(96)80005-C##JENKINS E, 1996, PHYS REV D, V54, P4515, DOI 10.1103/PHYSREVD.54.4515##LICHTENBERG DB, 1996, PHYS REV D, V53, P6678, DOI 10.1103/PHYSREVD.53.6678##MATHUR N, 2002, PHYS REV D, V66, DOI 10.1103/PHYSREVD.66.014502##RONCAGLIA R, 1995, PHYS REV D, V52, P1722, DOI 10.1103/PHYSREVD.52.1722##ROSNER JL, 1995, PHYS REV D, V52, P6461, DOI 10.1103/PHYSREVD.52.6461##SAVAGE MJ, 1995, PHYS LETT B, V359, P189, DOI 10.1016/0370-2693(95)01060-4##SJOSTRAND T, 1994, COMPUT PHYS COMMUN, V82, P74, DOI 10.1016/0010-4655(94)90132-5##WOLOSHYN RM, 2001, NUCL PHYS B-PROC SUP, V93, P38, DOI 10.1016/S0920-5632(00)01055-0##ZALEWSKA A., HEPPH9608240",95,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/E000444/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242708900013,2006,OPEN M5-BRANES,"WE SHOW HOW, IN HETEROTIC M THEORY, AN M5-BRANE IN THE 11-DIMENSIONAL BULK MAY END ON AN ""M9-BRANE"" BOUNDARY, THE M5-BRANE BOUNDARY BEING A YANG-MONOPOLE 4-BRANE. THIS POSSIBILITY SUGGESTS VARIOUS NOVEL 5-BRANE CONFIGURATIONS OF HETEROTIC M THEORY, IN PARTICULAR, A STATIC M5-BRANE SUSPENDED BETWEEN THE TWO M9-BRANE BOUNDARIES, FOR WHICH WE FIND THE ASYMPTOTIC HETEROTIC SUPERGRAVITY SOLUTION.",P-BRANES; SOLITONS; SUPERGRAVITY; INSTANTONS; DIMENSIONS,NA,PHYSICAL REVIEW LETTERS,"BERGSHOEFF, EA##GIBBONS, GW##TOWNSEND, PK","UNIV GRONINGEN, CTR THEORET PHYS, NL-9747 AG GRONINGEN, NETHERLANDS. UNIV CAMBRIDGE, DEPT APPL MATH & THEORET PHYS, CTR MATH SCI, CAMBRIDGE CB3 0WA, ENGLAND.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"BERGMAN O, HEPTH0606216##CALLAN CG, 1991, NUCL PHYS B, V359, P611, DOI 10.1016/0550-3213(91)90074-8##CALLAN CG, 1991, NUCL PHYS B, V367, P60, DOI 10.1016/0550-3213(91)90041-U##DUFF MJ, 1991, NUCL PHYS B, V354, P141, DOI 10.1016/0550-3213(91)90180-6##DUFF MJ, 1994, PHYS LETT B, V332, P321, DOI 10.1016/0370-2693(94)91260-2##GANOR OJ, 1996, NUCL PHYS B, V474, P122, DOI 10.1016/0550-3213(96)00243-X##GIBBONS GW, 2006, CLASSICAL QUANT GRAV, V23, P4873, DOI 10.1088/0264-9381/23/15/007##GIBBONS GW, 1993, PHYS REV LETT, V71, P3754, DOI 10.1103/PHYSREVLETT.71.3754##HORAVA P, 1996, NUCL PHYS B, V475, P94, DOI 10.1016/0550-3213(96)00308-2##HORAVA P, 1996, NUCL PHYS B, V460, P506, DOI 10.1016/0550-3213(95)00621-4##POLCHINSKI J, 1995, PHYS REV LETT, V75, P4724, DOI 10.1103/PHYSREVLETT.75.4724##POLCHINSKI J, 2006, J HIGH ENERGY PHYS##STROMINGER A, 1991, NUCL PHYS B, V353, P565##STROMINGER A, 1996, PHYS LETT B, V383, P44, DOI 10.1016/0370-2693(96)00712-5##STROMINGER A, 1990, NUCL PHYS B, V343, P167, DOI 10.1016/0550-3213(90)90599-9##TOWNSEND PK, 1996, PHYS LETT B, V373, P68, DOI 10.1016/0370-2693(96)00104-9##YANG CN, 1978, J MATH PHYS, V19, P320, DOI 10.1063/1.523506",11,2020-11-20,ENGINEERING AND PHYSICAL SCIENCES RESEARCH COUNCILENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL (EPSRC) [EP/C544951/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242708900055,2006,COMPOSITE TO TILTED VORTEX LATTICE TRANSITION IN BI(2)SR(2)CACU(2)O(8+DELTA) IN OBLIQUE FIELDS,"PRECISION MEASUREMENTS OF THE VORTEX PHASE DIAGRAM IN SINGLE CRYSTALS OF THE LAYERED SUPERCONDUCTOR BI(2)SR(2)CACU(2)O(8+DELTA) IN OBLIQUE MAGNETIC FIELDS CONFIRM THE EXISTENCE OF A SECOND PHASE TRANSITION, IN ADDITION TO THE USUAL FIRST-ORDER VORTEX-LATTICE MELTING LINE H(M)(T). THE TRANSITION HAS A STRONG FIRST-ORDER CHARACTER, IS ACCOMPANIED BY STRONG HYSTERESIS, AND INTERSECTS THE MELTING LINE IN A TRICRITICAL POINT (H(M)(PERPENDICULAR TO), H(CR)(PARALLEL TO)). ITS FIELD DEPENDENCE AND THE CHANGING CHARACTER OF THE MELTING LINE AT THE TRICRITICAL POINT STRONGLY SUGGEST THAT THE GROUND STATE FOR MAGNETIC FIELDS CLOSELY ALIGNED WITH THE SUPERCONDUCTING LAYERS IS A LATTICE OF UNIFORMLY TILTED VORTEX LINES.",LAYERED SUPERCONDUCTORS; ANISOTROPIC SUPERCONDUCTORS; MELTING TRANSITION; SINGLE-CRYSTALS; FLUX LATTICES; CHAIN STATE; BARRIERS; BSCCO; PHASE; LINE,NA,PHYSICAL REVIEW LETTERS,"KONCZYKOWSKI, M##VAN DER BEEK, CJ##KOSHELEV, AE##MOSSER, V##DODGSON, M##KES, PH","ECOLE POLYTECH, SOLIDES IRRADIES LAB, CNRS, UMR 7642, PALAISEAU, FRANCE. ECOLE POLYTECH, CEA, DSM, DRECAM, PALAISEAU, FRANCE. ARGONNE NATL LAB, DIV SCI MAT, ARGONNE, IL 60439 USA. ITRON, F-92240 MALAKOFF, FRANCE. UCL, DEPT PHYS & ASTRON, LONDON WC1E 6BT, ENGLAND. LEIDEN UNIV, KAMERLINGH ONNES LAB, NL-2300 RA LEIDEN, NETHERLANDS.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"BENDING SJ, 2005, J PHYS-CONDENS MAT, V17, PR955, DOI 10.1088/0953-8984/17/35/R01##BLATTER G, 1992, PHYS REV LETT, V68, P875, DOI 10.1103/PHYSREVLETT.68.875##BLATTER G, 1964, PHYS REV LETT, V12, P14##BOLLE CA, 1991, PHYS REV LETT, V66, P112, DOI 10.1103/PHYSREVLETT.66.112##GILCHRIST J, 1993, PHYSICA C, V212, P43, DOI 10.1016/0921-4534(93)90484-8##GOLDIN TR, 1998, PHYS REV B, V58, P9524, DOI 10.1103/PHYSREVB.58.9524##GRIGORENKO A, 2001, NATURE, V414, P728, DOI 10.1038/414728A##GRIGORIEVA IV, 1995, PHYS REV B, V51, P3765, DOI 10.1103/PHYSREVB.51.3765##INDENBOM MV, 1996, J LOW TEMP PHYS, V105, P1117, DOI 10.1007/BF00753849##KONCZYKOWSKI M, 2000, PHYSICA C, V341, P1213, DOI 10.1016/S0921-4534(00)01110-2##KOSHELEV AE, 1999, PHYS REV LETT, V83, P187, DOI 10.1103/PHYSREVLETT.83.187##KOSHELEV AE, 1999, PHYS REV B, V59, P4358, DOI 10.1103/PHYSREVB.59.4358##KOSHELEV AE, 2003, PHYS REV B, V68, DOI 10.1103/PHYSREVB.68.094520##KOSHELEV AE, 1998, PHYS REV B, V57, P8026, DOI 10.1103/PHYSREVB.57.8026##KOSHELEV AE, UNPUB##LI M, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.024502##MIRKOVIC J, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.132505##MIRKOVIC J, 2001, PHYS REV LETT, V86, P886, DOI 10.1103/PHYSREVLETT.86.886##MOROZOV N, 1996, PHYS REV B, V54, PR3784, DOI 10.1103/PHYSREVB.54.R3784##MOROZOV N, 1997, PHYSICA C, V291, P113, DOI 10.1016/S0921-4534(97)01666-3##OOI S, 1999, PHYS REV LETT, V82, P4308, DOI 10.1103/PHYSREVLETT.82.4308##SAVEL'EV SE, 2001, PHYS REV B, V64, DOI 10.1103/PHYSREVB.64.094521##SCHILLING A, 2000, PHYS REV B, V61, P3592, DOI 10.1103/PHYSREVB.61.3592##SCHMIDT B, 1997, PHYS REV B, V55, PR8705, DOI 10.1103/PHYSREVB.55.R8705##TOKUNAGA M, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.220501##TOKUNAGA M, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.060507##VLASKO-VLASOV VK, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.014523##ZELDOV E, 1995, NATURE, V375, P373, DOI 10.1038/375373A0##ZELDOV E, 1994, PHYS REV LETT, V73, P1428, DOI 10.1103/PHYSREVLETT.73.1428",16,2020-11-20,NA
J,WOS:000242708900027,2006,MECHANISM OF POLYMER DRAG REDUCTION USING A LOW-DIMENSIONAL MODEL,"USING A RETARDED-MOTION EXPANSION TO DESCRIBE THE POLYMER STRESS, WE DERIVE A LOW-DIMENSIONAL MODEL TO UNDERSTAND THE EFFECTS OF POLYMER ELASTICITY ON THE SELF-SUSTAINING PROCESS THAT MAINTAINS THE COHERENT WAVY STREAMWISE VORTICAL STRUCTURES UNDERLYING WALL-BOUNDED TURBULENCE. OUR ANALYSIS SHOWS THAT AT SMALL WEISSENBERG NUMBERS, WI, ELASTICITY ENHANCES THE COHERENT STRUCTURES. AT HIGHER WI, HOWEVER, POLYMER STRESSES SUPPRESS THE STREAMWISE VORTICES (ROLLS) BY CALMING DOWN THE INSTABILITY OF THE STREAKS THAT REGENERATES THE ROLLS. WE SHOW THAT THIS BEHAVIOR CAN BE ATTRIBUTED TO THE NONMONOTONIC DEPENDENCE OF THE BIAXIAL EXTENSIONAL VISCOSITY ON WI, AND IDENTIFY IT AS THE KEY RHEOLOGICAL PROPERTY CONTROLLING DRAG REDUCTION.",TURBULENT CHANNEL FLOW; SHEAR FLOWS; ADDITIVES; DYNAMICS,NA,PHYSICAL REVIEW LETTERS,"ROY, A##MOROZOV, A##VAN SAARLOOS, W##LARSON, RG","UNIV MICHIGAN, DEPT CHEM ENGN, ANN ARBOR, MI 48109 USA. LEIDEN UNIV, INST LORENTZ, NL-2300 RA LEIDEN, NETHERLANDS.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"BAGGETT JS, 1997, PHYS FLUIDS, V9, P1043, DOI 10.1063/1.869199##BENZI R, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.194502##BIRD R. B., 1987, DYNAMICS POLYM LIQUI, V1##HOF B, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.214502##HOF B, 2004, SCIENCE, V305, P1594, DOI 10.1126/SCIENCE.1100393##HOUSIADAS KD, 2003, PHYS FLUIDS, V15, P2369, DOI 10.1063/1.1589484##LARSON R. G., 1988, CONSTITUTIVE EQUATIO##LUMLEY JL, 1969, ANNU REV FLUID MECH, V1, P367, DOI 10.1146/ANNUREV.FL.01.010169.002055##MIN T, 2003, J FLUID MECH, V486, P213, DOI 10.1017/S0022112003004610##MOEHLIS J, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/056##PTASINSKI PK, 2003, J FLUID MECH, V490, P251, DOI 10.1017/S0022112003005305##ROY A, 2005, APPL RHEOL, V15, P370, DOI 10.1515/ARH-2005-0018##ROY A, 2006, THESIS U MICHIGAN AN##STONE PA, 2004, PHYS FLUIDS, V16, P3470, DOI 10.1063/1.1775192##STONE PA, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.208301##STONE PA, 2003, PHYS FLUIDS, V15, P1247, DOI 10.1063/1.1563258##TERRAPON VE, 2004, J FLUID MECH, V504, P61, DOI 10.1017/S0022112004008250##VIRK PS, 1975, AICHE J, V21, P625, DOI 10.1002/AIC.690210402##WALEFFE F, 1997, PHYS FLUIDS, V9, P883, DOI 10.1063/1.869185##WALEFFE F, 1998, PHYS REV LETT, V81, P4140, DOI 10.1103/PHYSREVLETT.81.4140",24,2020-11-20,NA
J,WOS:000242708900026,2006,UNIFIED GREEN'S FUNCTION RETRIEVAL BY CROSS CORRELATION,"IT HAS BEEN SHOWN BY MANY AUTHORS THAT THE CROSS CORRELATION OF TWO RECORDINGS OF A DIFFUSE WAVE FIELD AT DIFFERENT RECEIVERS YIELDS THE GREEN'S FUNCTION BETWEEN THESE RECEIVERS. RECENTLY THE THEORY HAS BEEN EXTENDED FOR SITUATIONS WHERE TIME-REVERSAL INVARIANCE DOES NOT HOLD (E.G., IN ATTENUATING MEDIA) AND WHERE SOURCE-RECEIVER RECIPROCITY BREAKS DOWN (IN MOVING FLUIDS). HERE WE PRESENT A UNIFIED THEORY FOR GREEN'S FUNCTION RETRIEVAL THAT CAPTURES ALL THESE SITUATIONS AND, BECAUSE OF THE UNIFIED FORM, READILY EXTENDS TO MORE COMPLEX SITUATIONS, SUCH AS ELECTROKINETIC GREEN'S FUNCTION RETRIEVAL IN POROELASTIC OR PIEZOELECTRIC MEDIA. THE UNIFIED THEORY HAS A WIDE RANGE OF APPLICATIONS IN ""REMOTE SENSING WITHOUT A SOURCE.""",DIFFUSE FIELD; EMERGENCE; RECIPROCITY; ACOUSTICS,NA,PHYSICAL REVIEW LETTERS,"WAPENAAR, K##SLOB, E##SNIEDER, R","DELFT UNIV TECHNOL, DEPT GEOTECHNOL, NL-2600 GA DELFT, NETHERLANDS. COLORADO SCH MINES, CTR WAVE PHENOMENA, GOLDEN, CO 80401 USA.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"AULD B. A, 1973, ACOUSTIC FIELDS WAVE##BIOT MA, 1956, J ACOUST SOC AM, V28, P168, DOI 10.1121/1.1908239##CAMPILLO M, 2003, SCIENCE, V299, P547, DOI 10.1126/SCIENCE.1078551##DE HOOP MV, 2000, P ROY SOC A-MATH PHY, V456, P641, DOI 10.1098/RSPA.2000.0534##DEHOOP AT, 1966, APPL SCI RES, V16, P39##DERODE A, 2003, APPL PHYS LETT, V83, P3054, DOI 10.1063/1.1617373##DRAGANOV D, 2006, GEOPHYSICS, V71, PSI61, DOI 10.1190/1.2209947##FOKKEMA J. T., 1993, SEISMIC APPL ACOUSTI##GODIN OA, 1992, ACOUSTICS LAYERED ME##GODIN OA, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.054301##LOBKIS OI, 2001, J ACOUST SOC AM, V110, P3011, DOI 10.1121/1.1417528##LYAMSHEV LM, 1961, DOKL AKAD NAUK SSSR+, V138, P575##MALCOLM AE, 2004, PHYS REV E, V70, DOI 10.1103/PHYSREVE.70.015601##PRIDE S, 1994, PHYS REV B, V50, P15678, DOI 10.1103/PHYSREVB.50.15678##PRIDE SR, 1996, J ACOUST SOC AM, V100, P1301, DOI 10.1121/1.416018##ROUX P, 2005, J ACOUST SOC AM, V117, P79, DOI 10.1121/1.1830673##SANCHEZ-SESMA FJ, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026454##SLOB E, 2006, P 11 INT C GROUND PE##SLOB E, IN PRESS GEOPHYS J I##SLOB E, IN PRESS##SNIEDER R, 2004, PHYS REV E, V69, DOI 10.1103/PHYSREVE.69.046610##SNIEDER R, IN PRESS J ACOUST SO##SNIEDER R, IN PRESS##SNIEDER R, 2006, PHYS REV E, V74, DOI 10.1103/PHYSREVE.74.046620##VAN MANEN DJ, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.164301##VAN TIGGELEN BA, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.243904##WAPENAAR K, 2004, J APPL MECH-T ASME, V71, P145, DOI 10.1115/1.1636792##WAPENAAR K, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.254301##WAPENAAR K., 2002, 72 ANN INT M SEG, P2269##WAPENAAR K, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027747##WAPENAAR K, 2006, GEOPHYSICS, V71, PSI33, DOI 10.1190/1.2213955##WAPENAAR K, 2006, J ACOUST SOC AM, V120, PEL7, DOI 10.1121/1.2208153##WEAVER R, 2002, ULTRASONICS, V40, P435, DOI 10.1016/S0041-624X(02)00156-7##WEAVER RL, 2005, J ACOUST SOC AM, V117, P3432, DOI 10.1121/1.1898683##WEAVER RL, 2004, J ACOUST SOC AM, V116, P2731, DOI 10.1121/1.1810232##WEAVER RL, 2001, PHYS REV LETT, V87, DOI 10.1103/PHYSREVLETT.87.134301",91,2020-11-20,NA
J,WOS:000243044400015,2006,ORIENTATIONAL ORDER AND MECHANICAL PROPERTIES OF POLY(AMIDE-BLOCK-ARAMID) ALTERNATING BLOCK COPOLYMER FILMS AND FIBERS,"MECHANICAL PROPER-TIES AND ORIENTATIONAL ORDER OF A SERIES OF UNIAXIALLY ORIENTED BLOCK COPOLYMER FILMS AND FIBERS COMPRISED OF ALTERNATING RIGID ARAMID BLOCKS OF POLY(P-PHENYLENE TEREPHTHALAMIDE) (PPTA) AND FLEXIBLE BLOCKS OF POLYAMIDE 6,6 (PA 6,6) HAVE BEEN INVESTIGATED. THE PREPARED BLOCK COPOLYMER FILMS DIFFER IN ARAMID CONTENT AND AVERAGE BLOCK LENGTH. THE FILMS WERE PREPARED BY SHEARING THE POLYMER SOLUTIONS (IN SULPHURIC ACID) FOLLOWED BY RAPID COAGULATION OF THE SOLUTIONS IN WATER. FROM WIDE ANGLE X-RAY SCATTERING (WAXS) AND OPTICAL POLARISATION MICROSCOPY (OPM) IT WAS FOUND THAT FILMS WITH A MOLE FRACTION OF PPTA OF AT LEAST 0.5 SHOW A LIQUID CRYSTALLINE (LC) PHASE. IT WAS FOUND THAT THE MECHANICAL PROPERTIES OF LC BLOCK COPOLYMER FILMS ARE SIMILAR TO THE PROPERTIES OF ISOTROPIC FILMS, AS DETERMINED WITH DYNAMICAL MECHANICAL ANALYSES (DMAS) AND FROM TENSILE TESTS. THIS WAS ATTRIBUTED TO THE RELATIVE LOW < P-2 > PARAMETER OF THE LC FILMS OBTAINED BY USING WAXS. COPOLYMERISATION OF THE PPTA BLOCKS WITH THE FLEXIBLE POLYAMIDE BLOCKS RESULTED IN AN INCREASE OF STORAGE AND YOUNG'S MODULUS, A DECREASE OF THE ELONGATION AT BREAK WHILE THE TENSILE STRENGTH WAS UNAFFECTED COMPARED TO NORMAL PA 6,6. BLOCK COPOLYMER FIBERS HAVE BEEN SPUN FROM LIQUID CRYSTALLINE SOLUTIONS BY MEANS OF A DRY-JET WET SPINNING PROCESS. THE ONLY VARIABLE PARAMETER WAS THE IMPOSED DRAW-RATIO IN THE AIR-GAP OF THE SPINNING PROCESS. INCREASING THE DRAW-RATIO RESULTED IN AN INCREASED MOLECULAR ORIENTATION, YOUNG'S MODULUS AND TENSILE STRENGTH OF THE FIBERS WHILE ITS EFFECT ON THE MAXIMUM ELONGATION AT BREAK WAS SMALL. HEAT TREATMENT AT 300 DEGREES C OF THE FIBERS RESULTED IN AN INCREASE OF THE YOUNG'S MODULUS, A MINOR INCREASE OF THE STRENGTH AND A DECREASE OF THE ELONGATION AT BREAK. SCANNING ELECTRON MICROSCOPIC (SEM) PHOTOGRAPHS OF THE FRACTURED SURFACES OF THE BLOCK COPOLYMER FIBERS DO NOT SHOW A FIBRILLAR FRACTURE SURFACE, WHICH IS TYPICALLY OBSERVED FOR PURE PPTA FIBERS. (C) 2006 PUBLISHED BY ELSEVIER LTD.",POLY(P-PHENYLENE TEREPHTHALAMIDE) FIBERS; FLEXIBLE BLOCK; POLY(PARA-PHENYLENE; STRENGTH; BEHAVIOR; UNITS,BLOCK COPOLYMERS; LIQUID CRYSTALLINE POLYMERS; FIBERS,POLYMER,"DE RUIJTER, C##MENDES, E##BOERSTOEL, H##PICKEN, SJ","DELFT UNIV TECHNOL, FAC SCI APPL, NL-2628 BL DELFT, NETHERLANDS. TEIJIN TWARON BV, RES INST, NL-6800 SB ARNHEM, NETHERLANDS.",POLYMER SCIENCE,POLYMER SCIENCE,"BAIR TI, 1977, MACROMOLECULES, V10, P1396, DOI 10.1021/MA60060A042##BUNN CW, 1947, PROC R SOC LON SER-A, V189, P39, DOI 10.1098/RSPA.1947.0028##CAVALLERI P, 1998, MACROMOL CHEM PHYSIC, V199, P2087, DOI 10.1002/(SICI)1521-3935(19981001)199:10<2087::AID-MACP2087>3.0.CO;2-Y##CAVALLERI P, 1997, MACROMOLECULES, V30, P3513, DOI 10.1021/MA9618282##DE RUIJTER C, 2006, MACROMOLECULES, V39, P4411, DOI 10.1021/MA052230+##DE RUIJTER C, 2006, MACROMOLECULES, V39, P3824, DOI 10.1021/MA052228I##DETERESA SJ, 1984, J MATER SCI, V19, P57, DOI 10.1007/BF02403111##FISCHER H, 1994, ACTA POLYM, V45, P88, DOI 10.1002/ACTP.1994.010450205##GOTO T, 1989, J APPL POLYM SCI, V37, P867, DOI 10.1002/APP.1989.070370402##HARAGUCHI K, 1979, J APPL POLYM SCI, V23, P915, DOI 10.1002/APP.1979.070230326##HELGEE B, 1992, POLYMER, V33, P3616, DOI 10.1016/0032-3861(92)90645-D##HINDELEH AM, 1984, J MACROMOL SCI PHYS, VB23, P289, DOI 10.1080/00222348408219461##KRIGBAUM WR, 1987, J POLYM SCI POL PHYS, V25, P1043, DOI 10.1002/POLB.1987.090250506##KRIGBAUM WR, 1987, J POLYM SCI POL CHEM, V25, P653, DOI 10.1002/POLA.1987.080250217##KWOLEK SL, 1977, MACROMOLECULES, V10, P1390, DOI 10.1021/MA60060A041##MAGAT EE, 1975, J POLYM SCI POLYM S, V51, P203##MAIER W, 1961, Z NATURFORSCH   A, V16, P816##NORTHOLT MG, 2005, ADV POLYM SCI, V178, P1, DOI 10.1007/B104207##NORTHOLT MG, 1985, POLYMER, V26, P310, DOI 10.1016/0032-3861(85)90047-3##NORTHOLT MG, 1980, POLYMER, V21, P1199, DOI 10.1016/0032-3861(80)90088-9##NORTHOLT MG, 1974, EUR POLYM J, V10, P799, DOI 10.1016/0014-3057(74)90131-1##PICKEN SJ, 1992, POLYMER, V33, P2998, DOI 10.1016/0032-3861(92)90087-D##ROERDINK E, 1985, POLYMER, V26, P1582, DOI 10.1016/0032-3861(85)90098-9##YANG HH, 1993, KEVLAR ARAMID FIBER, P95##ZANNONI C, 1979, MOL PHYSICS LIQUID C, PCH3",19,2020-11-20,NA
J,WOS:000243293500017,2006,KU-BAND HIGH-POWER LOWPASS FILTER WITH SPURIOUS REJECTION,A KU-BAND HIGH-POWER LOWPASS FILTER WITH SPURIOUS PASSBAND SUPPRESSION UP TO 40 GHZ IS PROPOSED IN RECTANGULAR WAVEGUIDE TECHNOLOGY. THE NEW DESIGN CONSISTS OF A CONVENTIONAL E-PLANE CORRUGATED LOWPASS FILTER CASCADED WITH A QUASI-PERIODIC STRUCTURE TUNED TO REJECT THE UNDESIRED SPURIOUS PASSBANDS. THIS NEW DESIGN TECHNIQUE ALLOWS THE MINIMUM GAP OF THE ORIGINAL CORRUGATED FILTER TO BE KEPT WIDE ENOUGH TO PERMIT HIGH-POWER OPERATION.,NA,NA,ELECTRONICS LETTERS,"ARNEDO, I##GIL, J##ORTIZ, N##LOPETEGI, T##LASO, MAG##SOROLLA, M##THUMM, M##SCHMITT, D##GUGLIELMI, M","PUBL UNIV NAVARRE, DEPT ELECT ENGN, E-31006 PAMPLONA, SPAIN. KARLSRUHE RES CTR, INST PULSE POWER & MICROWAVE TECHNOL, D-76344 KARLSRUHE, GERMANY. EUROPEAN SPACE AGCY, ESTEC, NL-2200 AG NOORDWIJK, NETHERLANDS. UNIV KARLSRUHE, KARLSRUHE, GERMANY.","ENGINEERING, ELECTRICAL & ELECTRONIC",ENGINEERING,"BUNGER R, 1999, IEEE MTT S INT MICR, P1691, DOI 10.1109/MWSYM.1999.780296##CAPUTO J, 1965, IEEE T MICROW THEORY, VMT13, P701, DOI 10.1109/TMTT.1965.1126068##GIL J, 2005, PATENT NO. 513##KATSENELENBAUM BZ, 1998, WAVES SERIES IEE, V44##LOPETCGI T, IEEE T MICROW THEORY, V49, P1593##UBER J., 1993, WAVEGUIDE COMPONENTS",10,2020-11-20,NA
J,WOS:000242752100004,2006,CASSINI OBSERVATIONS OF PLANETARY-PERIOD OSCILLATIONS OF SATURN'S MAGNETOPAUSE,"EXAMINATION OF CASSINI MAGNETIC FIELD AND PLASMA DATA IN THE OUTER BOUNDARY REGIONS OF SATURN'S MAGNETOSPHERE SHOWS THAT MAGNETOPAUSE OSCILLATIONS AT THE PLANETARY PERIOD COMMONLY OCCUR, IN PHASE WITH PLASMA PRESSURE VARIATIONS INSIDE THE MAGNETOSPHERE. THE PEAK-TO-TROUGH AMPLITUDE OF THE BOUNDARY OSCILLATIONS MAPPED TO THE PLANET-SUN LINE IS ESTIMATED TO BE TYPICALLY SIMILAR TO 2 R-S, CORRESPONDING TO A SIMILAR TO 10% CHANGE IN THE BOUNDARY RADIUS. THE CHANGE IN INTERNAL PRESSURE REQUIRED TO PRODUCE SUCH MOTIONS IS ESTIMATED TO BE SIMILAR TO 40% OF THE BACKGROUND VALUES. A QUALITATIVE PHYSICAL PICTURE IS PROPOSED IN WHICH A COMPRESSIVE WAVE PROPAGATES OUTWARD THROUGH THE SUB-COROTATING OUTER MAGNETOSPHERIC PLASMA, ORIGINATING FROM A COROTATING SOURCE IN THE NEARER-PLANET REGION.",JOVIAN MAGNETOPAUSE; BOW SHOCK; LOCATIONS; VOYAGER; SHAPE,NA,GEOPHYSICAL RESEARCH LETTERS,"CLARKE, KE##ANDRE, N##ANDREWS, DJ##COATES, AJ##COWLEY, SWH##DOUGHERTY, MK##LEWIS, GR##MCANDREWS, HJ##NICHOLS, JD##ROBINSON, TR##WRIGHT, DM","UNIV LEICESTER, DEPT PHYS & ASTRON, LEICESTER LE1 7RH, LEICS, ENGLAND. EUROPEAN SPACE AGCY, RES & SCI SUPPORT DEPT, NL-2200 AG NOORDWIJK, NETHERLANDS. UCL, MULLARD SPACE SCI LAB, DORKING RH5 6NT, SURREY, ENGLAND. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, BLACKETT LAB, LONDON SW7 2AZ, ENGLAND.","GEOSCIENCES, MULTIDISCIPLINARY",GEOLOGY,"ARRIDGE CS, 2006, J GEOPHYS RES-SPACE, V111, DOI 10.1029/2005JA011574##COWLEY SWH, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025522##DOUGHERTY MK, 2004, SPACE SCI REV, V114, P331, DOI 10.1007/S11214-004-1432-2##DOUGHERTY MK, 2005, SCIENCE, V307, P1266, DOI 10.1126/SCIENCE.1106098##ESPINOSA SA, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2001JA005084##ESPINOSA SA, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2001JA005083##GIAMPIERI G, 2006, NATURE, V441, P62, DOI 10.1038/NATURE04750##HUDDLESTON DE, 1998, J GEOPHYS RES-PLANET, V103, P20075, DOI 10.1029/98JE00394##JOY SP, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA009146##KAISER ML, 1980, SCIENCE, V209, P1238, DOI 10.1126/SCIENCE.209.4462.1238##KIVELSON MG, 2003, PLANET SPACE SCI, V51, P891, DOI 10.1016/S0032-0633(03)00075-8##SHUE JH, 1997, J GEOPHYS RES-SPACE, V102, P9497, DOI 10.1029/97JA00196##SLAVIN JA, 1983, GEOPHYS RES LETT, V10, P9, DOI 10.1029/GL010I001P00009##YOUNG DT, 2004, SPACE SCI REV, V114, P1, DOI 10.1007/S11214-004-1406-4",50,2020-11-20,UK SPACE AGENCY [PP/D00084X/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242428200004,2006,BAND GAP VARIATION IN PRUSSIAN BLUE VIA CATION-INDUCED STRUCTURAL DISTORTION,"THE CHARGE-TRANSFER BAND GAP OF THE IRON CYANIDE FRAMEWORK MATERIAL PRUSSIAN BLUE AND ITS DEPENDENCE ON THE TYPE AND LOCATION OF THE CHARGE-COMPENSATING INTERSTITIAL CATIONS (K+, RB+, CS+) ARE INVESTIGATED VIA PERIODIC DENSITY FUNCTIONAL (DF) CALCULATIONS. THE CALCULATED VARIATION IN THE BAND GAP MAGNITUDE WITH RESPECT TO CATION TYPE CONFIRMS RECENT EXPERIMENTAL RESULTS ON CATION-INDUCED SPECTRAL SHIFTS. THE ROLE OF BOTH THE CATION INTERACTION WITH THE FRAMEWORK AND THE CATION-INDUCED LATTICE EXPANSION ARE EXAMINED WITH RESPECT TO THEIR INFLUENCE ON THE BAND GAP. THE GAP MAGNITUDE IS RELATED TO THE CATION TYPE BUT IS FOUND TO BE MORE STRONGLY AFFECTED BY CATION-INDUCED LATTICE DISTORTION AS THE CATION PASSES THROUGH THE MATERIAL. OUR RESULTS SUPPORT THE POSSIBILITY OF ENGINEERING THE ELECTRONIC STRUCTURE OF PRUSSIAN BLUE TYPE MATERIALS THROUGH GUEST-INDUCED HOST-FRAMEWORK DISTORTION.",SUBSTITUTIONAL SOLID-SOLUTIONS; NICKEL HEXACYANOFERRATE; MAGNETIC-PROPERTIES; X-RAY; COPPER; ELECTROCHEMISTRY; ELECTROCHROMISM; TEMPERATURES; DIFFRACTION; FABRICATION,NA,JOURNAL OF PHYSICAL CHEMISTRY B,"WOJDEL, JC##BROMLEY, ST","UNIV BARCELONA & PARC CIENTIF, DEPT QUIM FIS, E-08028 BARCELONA, SPAIN. UNIV BARCELONA & PARC CIENTIF, CTR ESPECIAL RECERCA, E-08028 BARCELONA, SPAIN. DELFT UNIV TECHNOL, DELFTCHEMTECH, CERAM MEMBRANE CTR PORE, NL-2628 BL DELFT, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"CHEH LC, 2002, J NEW MAT ELECTR SYS, V5, P203##DE TACCONI NR, 2003, CHEM MATER, V15, P3046, DOI 10.1021/CM0341540##DELONGCHAMP DM, 2004, CHEM MATER, V16, P4799, DOI 10.1021/CM0496624##DUNBAR KR, 1997, PROG INORG CHEM, V45, P283##EFTEKHARI A, 2004, J POWER SOURCES, V126, P221, DOI 10.1016/J.JPOWSOUR.2003.08.007##HAMMER B, 1999, PHYS REV B, V59, P7413, DOI 10.1103/PHYSREVB.59.7413##HERREN F, 1980, INORG CHEM, V19, P956, DOI 10.1021/IC50206A032##JAYALAKSHMI M, 2000, J POWER SOURCES, V91, P217, DOI 10.1016/S0378-7753(00)00475-4##JAYALAKSHMI M, 2000, J POWER SOURCES, V87, P212, DOI 10.1016/S0378-7753(99)00488-7##JEERAGE KM, 2002, CHEM MATER, V14, P530, DOI 10.1021/CM010156D##JEERAGE KM, 2000, SEPAR SCI TECHNOL, V35, P2375, DOI 10.1081/SS-100102344##JOHANSSON A, 2005, NANO LETT, V5, P1603, DOI 10.1021/NL050964U##KULESZA PJ, 1996, J ELECTROCHEM SOC, V143, PL10, DOI 10.1149/1.1836374##LUNEAU D, 2001, CURR OPIN SOLID ST M, V5, P123, DOI 10.1016/S1359-0286(00)00043-7##MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PHYSREVB.13.5188##MOORE JG, 2003, ANGEW CHEM INT EDIT, V42, P2741, DOI 10.1002/ANIE.200250409##NAKANISHI S, 2003, J AM CHEM SOC, V125, P14998, DOI 10.1021/JA0381151##NISHINO M, 1998, CHEM PHYS LETT, V297, P51, DOI 10.1016/S0009-2614(98)01081-1##OHKOSHI S, 1999, PHYS REV LETT, V82, P1285, DOI 10.1103/PHYSREVLETT.82.1285##PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PHYSREVB.46.6671##PYRASCH M, 2003, CHEM MATER, V15, P245, DOI 10.1021/CM021230A##RICCI F, 2005, BIOSENS BIOELECTRON, V21, P389, DOI 10.1016/J.BIOS.2004.12.001##ROSSEINSKY DR, 2003, INORG CHEM, V42, P6015, DOI 10.1021/IC020575S##ROSSEINSKY DR, 2002, CHEM COMMUN, P2988, DOI 10.1039/B209708G##SCHWUDKE D, 2000, ELECTROCHEM COMMUN, V2, P301, DOI 10.1016/S1388-2481(00)00028-X##TAGUCHI M, 2005, CHEM MATER, V17, P4554, DOI 10.1021/CM051060C##TENNAKONE K, 1983, J PHYS C SOLID STATE, V16, P5633, DOI 10.1088/0022-3719/16/29/017##WIDMANN A, 2002, INORG CHEM, V41, P5706, DOI 10.1021/IC0201654##WOJDEL JC, 2005, J MOL MODEL, V11, P288, DOI 10.1007/S00894-005-0247-8##WOJDEL JC, 2004, CHEM PHYS LETT, V397, P154, DOI 10.1016/J.CPLETT.2004.08.107##ZAKHARCHUK NF, 1999, J SOLID STATE ELECTR, V3, P264, DOI 10.1007/S100080050157##ZHOU PH, 2002, NANO LETT, V2, P845, DOI 10.1021/NL0256154",26,2020-11-20,NA
J,WOS:000242428200018,2006,PHOTOISOMERIZATION OF AZOBENZENE DERIVATIVES IN NANOSTRUCTURED SILICA,"A SERIES OF DERIVATIZED AZOBENZENE MOLECULES ARE SYNTHESIZED SUCH THAT ONE OF THE PHENYL GROUPS CAN BE CHEMICALLY BONDED TO MESOSTRUCTURED SILICA AND THE OTHER, DERIVATIZED WITH DENDRONS, IS FREE TO UNDERGO LARGE-AMPLITUDE LIGHT-DRIVEN MOTION. THE SILICA FRAMEWORKS ON WHICH THE MOTION TAKES PLACE ARE EITHER 150 NM THICK FILMS CONTAINING ORDERED HEXAGONAL ARRAYS OF TUBES (INNER DIAMETER ABOUT 2 NM) CONTAINING THE BONDED AZOBENZENES, OR PARTICLES (ABOUT 500 NM IN DIAMETER) CONTAINING THE SAME ORDERED ARRAYS OF FUNCTIONALIZED TUBES. THE PHOTOISOMERIZATION YIELDS AND THE RATE CONSTANTS FOR THE THERMAL CIS TO TRANS BACK-REACTION OF THE AZOBENZENES IN THE TUBES ARE MEASURED AND COMPARED TO THOSE OF THE MOLECULES IN SOLUTION. THE RATE CONSTANTS DECREASE WITH INCREASING SIZE OF THE DENDRONS. FLUORESCENCE SPECTRA OF THE CIS AND TRANS ISOMERS IN THE PORES SHOW THAT THE PHOTOISOMERIZATION IN THE NANOSTRUCTURED MATERIALS IS SELECTIVELY DRIVEN BY SPECIFIC WAVELENGTHS OF LIGHT AND IS REVERSIBLE.",GEL THIN-FILMS; LUMINESCENT MOLECULES; DATA-STORAGE; FLUORESCENCE; POLYMERS; SPECTROSCOPY; PLACEMENT; MATRICES; SYSTEMS; SURFACE,NA,JOURNAL OF PHYSICAL CHEMISTRY B,"SIEROCKI, P##MAAS, H##DRAGUT, P##RICHARDT, G##VOGTLE, F##COLA, L##BROUWER, FAM##ZINK, JI","UNIV BONN, KEKULE INST ORGAN CHEM & BIOCHEM, D-53121 BONN, GERMANY. UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA. UNIV AMSTERDAM, VANT HOFF INST MOL SCI, NL-1018 WV AMSTERDAM, NETHERLANDS.","CHEMISTRY, PHYSICAL",CHEMISTRY,"[ANONYMOUS], 2003, ANGEW CHEM, V115, P1773##ARCHUT A, 1998, CHEM-EUR J, V4, P699, DOI 10.1002/(SICI)1521-3765(19980416)4:4<699::AID-CHEM699>3.3.CO;2-0##AZUMA J, 1998, MOL CRYST LIQ CRYS A, V314, P83, DOI 10.1080/10587259808042460##BERG RH, 1996, NATURE, V383, P505, DOI 10.1038/383505A0##CALZAFERRI G, 2003, ANGEW CHEM INT EDIT, V42, P3732, DOI 10.1002/ANIE.200300570##CHIA SY, 2000, J AM CHEM SOC, V122, P6488, DOI 10.1021/JA0011515##CHIA SY, 2001, ANGEW CHEM INT EDIT, V40, P2447, DOI 10.1002/1521-3773(20010702)40:13<2447::AID-ANIE2447>3.0.CO;2-P##DAVE BC, 1997, J SOL-GEL SCI TECHN, V8, P629, DOI 10.1023/A:1018316108875##DUNN B, 1998, ACTA MATER, V46, P737, DOI 10.1016/S1359-6454(97)00254-1##FRECHET J. M. J., 2001, DENDRIMERS DENDRITIC##GRUN M, 1997, ADV MATER, V9, P254, DOI 10.1002/ADMA.19970090317##HALLER I, 1978, J AM CHEM SOC, V100, P8050, DOI 10.1021/JA00494A003##HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/JA00177A027##HELLER HG, 1981, J CHEM SOC P2, V2, P341##HERNANDEZ R, 2004, J AM CHEM SOC, V126, P3370, DOI 10.1021/JA039424U##HERNANDEZ R, 2001, J AM CHEM SOC, V123, P1248, DOI 10.1021/JA003634E##HUANG MH, 2000, J AM CHEM SOC, V122, P3739, DOI 10.1021/JA993882E##HUANG MH, 1998, LANGMUIR, V14, P7331, DOI 10.1021/LA981298Y##ICHIMURA K, 2000, SCIENCE, V288, P1624, DOI 10.1126/SCIENCE.288.5471.1624##IKEDA T, 1995, SCIENCE, V268, P1873, DOI 10.1126/SCIENCE.268.5219.1873##JUNGE DM, 1999, J AM CHEM SOC, V121, P4912, DOI 10.1021/JA990387+##JUNGE DM, 1997, J CHEM SOC CHEM COMM, P857##KIM I, 2000, COLLOID SURFACE A, V171, P167, DOI 10.1016/S0927-7757(99)00560-9##KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710A0##LIU NG, 2003, ANGEW CHEM INT EDIT, V42, P1731, DOI 10.1002/ANIE.200250189##LIU NG, 2004, NANO LETT, V4, P551, DOI 10.1021/NL0350783##LIU ZF, 1990, NATURE, V347, P658, DOI 10.1038/347658A0##LU YF, 1997, NATURE, V389, P364, DOI 10.1038/38699##MILLER JM, 1996, J NON-CRYST SOLIDS, V202, P279, DOI 10.1016/0022-3093(96)00191-3##MINOOFAR PN, 2005, J AM CHEM SOC, V127, P2656, DOI 10.1021/JA045185E##MINOOFAR PN, 2002, J AM CHEM SOC, V124, P14388, DOI 10.1021/JA020817N##NGUYEN TD, 2005, P NATL ACAD SCI USA, V102, P10029, DOI 10.1073/PNAS.0504109102##RAU H., 1990, STUDIES ORGANIC CHEM, P165##SCHWYZER R, 1958, HELV CHIM ACTA, V60, P491##SEKKAT Z, 1992, APPL PHYS B-PHOTO, V54, P486, DOI 10.1007/BF00325395##SHIMOMURA M, 1987, J AM CHEM SOC, V109, P5175, DOI 10.1021/JA00251A022##TAIT KM, 2003, CHEM PHYS LETT, V374, P372, DOI 10.1016/S0009-2614(03)00670-5##TAIT KM, 2003, J PHOTOCH PHOTOBIO A, V154, P179, DOI 10.1016/S1010-6030(02)00347-7##VAN TENDELOO G, 2003, J PHYS-CONDENS MAT, V15, PS3037##VICTOR JG, 1987, MACROMOLECULES, V20, P2241, DOI 10.1021/MA00175A032##WANG J, 2004, ADV FUNCT MATER, V14, P409, DOI 10.1002/ADFM.200400032##WATSON SJ, 1999, MOL CRYST LIQ CRYS A, V331, P2235##WILLETT KL, 2000, J CHEM EDUC, V77, P900, DOI 10.1021/ED077P900##WIRNSBERGER G, 2001, CHEM COMMUN, P119, DOI 10.1039/B003995K##ZIMMERMAN G, 1958, J AM CHEM SOC, V80, P3528, DOI 10.1021/JA01547A010",63,2020-11-20,NA
J,WOS:000242373300007,2006,EVOLUTION OF TALKING PLANTS IN A TRITROPHIC CONTEXT: CONDITIONS FOR UNINFESTED PLANTS TO ATTRACT PREDATORS PRIOR TO HERBIVORE ATTACK,"HERBIVORY INDUCES PLANTS TO EMIT VOLATILE CHEMICALS THAT ATTRACT ENEMIES OF THE HERBIVORES (BODYGUARDS OF PLANTS). IN THIS WAY, THE PLANT ACQUIRES PROTECTION AND THE BODYGUARDS GAIN FOOD. THESE PLANT SIGNALS CAUSE NEIGHBORING PLANTS, NOT UNDER ATTACK, TO RELEASE SIGNALS AS WELL. WE HYPOTHESIZE THAT SUCH ""SECONDARY"" SIGNALS HELP TO REDUCE DAMAGE FROM FUTURE HERBIVORE ATTACKS BY THE PROTECTION RECEIVED FROM THE BODYGUARDS. BY MODELING WE EXPLORE THE CONDITIONS FOR SUCH SECONDARY SIGNALS TO EVOLVE. THREE KINDS OF STRATEGIES ARE CONSIDERED: PLANTS OF THE FIRST STRATEGY ALWAYS EMIT A SIGNAL, THOSE OF THE SECOND STRATEGY EMIT A SIGNAL ONLY WHEN INFESTED, AND THOSE OF THE THIRD STRATEGY EMIT A SIGNAL NOT ONLY WHEN INFESTED, BUT ALSO WHEN A CERTAIN NUMBER OF NEIGHBORS ARE INFESTED (I.E. SECONDARY SIGNALING). WHEN SIGNALING IS MUCH LESS (MUCH MORE) COSTLY THAN DAMAGE FROM HERBIVORY, THE FIRST (SECOND) STRATEGY WILL BE FAVORED BY SELECTION, WHEREAS FOR INTERMEDIATE COSTS THE THIRD STRATEGY, I.E. SECONDARY SIGNALING, WILL EVOLVE. HOWEVER, SECONDARY SIGNALING WILL NOT EVOLVE WHEN THE PRIMARY SIGNALS LURE THE BODYGUARDS TOO EFFECTIVELY. THIS IS BECAUSE THE UNDAMAGED PLANT GAINS ASSOCIATIONAL DEFENSE WHEN THE INFESTED INDIVIDUAL IS DEFENDING VERY WELL; THEREFORE, THE NEED FOR SECONDARY SIGNALING DECREASES. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",LIMA-BEAN LEAVES; WILD TOBACCO; CONSPECIFIC PLANTS; VOLATILES; COMMUNICATION; DEFENSE; RESISTANCE; EMISSION; EXPOSURE; SIGNALS,PLANT-PLANT COMMUNICATION; INDUCED DEFENSE; PLANT VOLATILE; HERBIVORE; NATURAL ENEMY,JOURNAL OF THEORETICAL BIOLOGY,"KOBAYASHI, Y##YAMAMURA, N##SABELIS, MW","KYOTO UNIV, CTR ECOL RES, OTSU, SHIGA 5202113, JAPAN. UNIV AMSTERDAM, INST BIODIVERS & ECOSYST DYNAM, NL-1090 GB AMSTERDAM, NETHERLANDS.",BIOLOGY; MATHEMATICAL & COMPUTATIONAL BIOLOGY,LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS; MATHEMATICAL & COMPUTATIONAL BIOLOGY,"ARIMURA G, 2000, NATURE, V406, P512, DOI 10.1038/35020072##ARIMURA G, 2002, PLANT J, V29, P87, DOI 10.1046/J.1365-313X.2002.01198.X##ARIMURA G, 2001, BIOCHEM SYST ECOL, V29, P1049, DOI 10.1016/S0305-1978(01)00049-7##BALDWIN IT, 1983, SCIENCE, V221, P277, DOI 10.1126/SCIENCE.221.4607.277##BIRKETT MA, 2000, P NATL ACAD SCI USA, V97, P9329, DOI 10.1073/PNAS.160241697##BRUIN J, 1992, EXPERIENTIA, V48, P525, DOI 10.1007/BF01928181##BRUIN J, 1995, TRENDS ECOL EVOL, V10, P167, DOI 10.1016/S0169-5347(00)89033-3##CHAMBERLAIN K, 2001, BIOCHEM SYST ECOL, V29, P1063, DOI 10.1016/S0305-1978(01)00050-3##CHOH Y, 2006, OECOLOGIA, V147, P455, DOI 10.1007/S00442-005-0289-8##CHOH Y, 2004, J CHEM ECOL, V30, P1305, DOI 10.1023/B:JOEC.0000037741.13402.19##CHOH Y, 2005, THESIS KYOTO U##DICKE M, 1999, HERBIVORES: BETWEEN PLANTS AND PREDATORS, P483##DICKE M, 1990, J CHEM ECOL, V16, P3091, DOI 10.1007/BF00979614##DICKE M, 2003, TRENDS PLANT SCI, V8, P403, DOI 10.1016/S1360-1385(03)00183-3##DICKE M, 2001, BIOCHEM SYST ECOL, V29, P981, DOI 10.1016/S0305-1978(01)00045-X##DICKE M, 2001, BIOCHEM SYST ECOL, V29, P1075, DOI 10.1016/S0305-1978(01)00051-5##DICKE M., 1989, CAUSES CONSEQUENCES, P341##DOLCH R, 2000, OECOLOGIA, V125, P504, DOI 10.1007/S004420000482##ENGELBERTH J, 2004, P NATL ACAD SCI USA, V101, P1781, DOI 10.1073/PNAS.0308037100##FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/PNAS.87.19.7713##FRITZSCHEHOBALL.ME, 2001, EVOLUTIONARY ECOLOGY, V3, P533##GERITZ SAH, 1998, EVOL ECOL, V12, P35, DOI 10.1023/A:1006554906681##GLINWOOD R, 2004, ECOL ENTOMOL, V29, P188, DOI 10.1111/J.0307-6946.2004.00582.X##GLINWOOD R, 2003, J CHEM ECOL, V29, P261, DOI 10.1023/A:1022687025416##GODFRAY HCJ, 1995, OIKOS, V72, P367, DOI 10.2307/3546122##GUERRIERI E, 2002, J CHEM ECOL, V28, P1703, DOI 10.1023/A:1020553531658##HAUKIOJA E, 1985, OECOLOGIA, V65, P363, DOI 10.1007/BF00378910##HEIL M, 2004, J CHEM ECOL, V30, P1289, DOI 10.1023/B:JOEC.0000030299.59863.69##HORIUCHI JI, 2003, APPL ENTOMOL ZOOL, V38, P365, DOI 10.1303/AEZ.2003.365##JAREMO J, 1998, ECOLOGY AND EVOLUTION OF INDUCIBLE DEFENSES, P33##KARBAN R, 2000, OECOLOGIA, V125, P66, DOI 10.1007/PL00008892##KARBAN R, 2003, OIKOS, V100, P325, DOI 10.1034/J.1600-0706.2003.12075.X##KARBAN R, 2002, ECOLOGY, V83, P1209, DOI 10.1890/0012-9658(2002)083[1209:TFCOIE]2.0.CO;2##KARBAN R, 2001, BIOCHEM SYST ECOL, V29, P995, DOI 10.1016/S0305-1978(01)00046-1##KOBAYASHI Y, 2003, J THEOR BIOL, V223, P489, DOI 10.1016/S0022-5193(03)00124-3##NINKOVIC V, 2003, AGRIC FOR ENTOMOL, V5, P27, DOI 10.1046/J.1461-9563.2003.00159.X##NINKOVIC V, 2002, ENTOMOL EXP APPL, V102, P177, DOI 10.1023/A:1015851430481##PFISTER CA, 1988, OECOLOGIA, V77, P118, DOI 10.1007/BF00380934##RHOADES DF, 1983, ACS SYM SER, V208, P55##RHOADES DF, 1985, CHEM MEDIATED INTERA, P195##SABELIS M, 1999, INDUCED PLANT DEFENSES AGAINST PATHOGENS AND HERBIVORES, P269##SABELIS MW, 2002, CA ST AD DY, V2, P297, DOI 10.1017/CBO9780511525728.028##SABELIS MW, 1988, OIKOS, V53, P247, DOI 10.2307/3566070##SABELIS MW, 1999, HERBIVORES: BETWEEN PLANTS AND PREDATORS, P109##SHULAEV V, 1997, NATURE, V385, P718, DOI 10.1038/385718A0##SMITH JM, 1982, EVOLUTION THEORY GAM##TAKABAYASHI J, 1996, TRENDS PLANT SCI, V1, P109, DOI 10.1016/S1360-1385(96)90004-7##VAN LOON JJA, 2000, ENTOMOL EXP APPL, V97, P219##WACKERS F.L., 2005, PLANT PROVIDED FOOD##ZERINGUE HJ, 1987, PHYTOCHEMISTRY, V26, P1357, DOI 10.1016/S0031-9422(00)81812-9",9,2020-11-20,"GRANTS-IN-AID FOR SCIENTIFIC RESEARCHMINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE AND TECHNOLOGY, JAPAN (MEXT)JAPAN SOCIETY FOR THE PROMOTION OF SCIENCEGRANTS-IN-AID FOR SCIENTIFIC RESEARCH (KAKENHI) [18570018] FUNDING SOURCE: KAKEN"
J,WOS:000242373300015,2006,ARTIFICIAL NEURAL NETWORKS CAN LEARN TO ESTIMATE EXTINCTION RATES FROM MOLECULAR PHYLOGENIES,"MOLECULAR PHYLOGENIES TYPICALLY CONSIST OF ONLY EXTANT SPECIES, YET THEY ALLOW INFERENCE OF PAST RATES OF EXTINCTION, BECAUSE. RECENTLY ORIGINATED SPECIES ARE LESS LIKELY TO BE EXTINCT THAN ANCIENT SPECIES. DESPITE THE SIMPLE STRUCTURE OF THE ASSUMED UNDERLYING SPECIATION-EXTINCTION PROCESS, PARAMETRIC FUNCTIONS TO ESTIMATE EXTINCTION RATES FROM PHYLOGENIES TURNED OUT TO BE COMPLEX AND OFTEN DIFFICULT TO DERIVE. MOREOVER, THESE PARAMETRIC FUNCTIONS ARE SPECIFIC TO A PARTICULAR PROCESS (E.G. COMPLETE SPECIES LEVEL PHYLOGENY WITH CONSTANT BIRTH AND DEATH RATES) AND A PARTICULAR TYPE OF DATA (E.G. TIMES BETWEEN BIFURCATIONS). HERE, IT IS SHOWN THAT ARTIFICIAL NEURAL NETWORKS CAN SUBSTITUTE FOR PARAMETRIC ESTIMATION FUNCTIONS ONCE THEY HAVE BEEN SUFFICIENTLY TRAINED ON SIMULATED DATA. THIS TECHNIQUE CAN IN PRINCIPLE BE USED FOR DIFFERENT PROCESSES AND DATA TYPES, AND BECAUSE IT CIRCUMVENTS THE TIME-CONSUMING AND DIFFICULT TASK OF DERIVING PARAMETRIC ESTIMATION FUNCTIONS, IT MAY GREATLY EXTEND THE POSSIBILITIES TO MAKE MACRO-EVOLUTIONARY INFERENCES FROM MOLECULAR PHYLOGENIES. THIS NOVEL APPROACH IS EXPLAINED, APPLIED TO ESTIMATE SPECIATION AND EXTINCTION RATES FROM A MOLECULAR PHYLOGENY OF THE REEF FISH GENUS NASO (ACANTURIDAE), AND ITS PERFORMANCE IS COMPARED TO THAT OF MAXIMUM LIKELIHOOD ESTIMATION. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",DIVERSIFICATION,ARTIFICIAL INTELLIGENCE; MACROEVOLUTION; MODELLING; PARAMETER ESTIMATION; SPECIATION,JOURNAL OF THEORETICAL BIOLOGY,"BOKMA, F","GRONINGEN BIOINFORMAT CTR, GRONINGEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, GRONINGEN, NETHERLANDS.",BIOLOGY; MATHEMATICAL & COMPUTATIONAL BIOLOGY,LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS; MATHEMATICAL & COMPUTATIONAL BIOLOGY,"ATHREYA K., 1972, BRANCHING PROCESSES##BAILEY N. T. J., 1964, ELEMENTS STOCHASTIC##BOKMA F, 2003, EVOLUTION, V57, P2469##HARVEY PH, 1994, EVOLUTION, V48, P523, DOI 10.1111/J.1558-5646.1994.TB01341.X##HAYKIN S., 1999, NEURAL NETWORKS COMP##JAGERS P., 1975, BRANCHING PROCESSES##KENDALL DG, 1948, ANN MATH STAT, V19, P1, DOI 10.1214/AOMS/1177730285##KENDALL DG, 1966, J LONDON MATH SOC, V41, P385, DOI 10.1112/JLMS/S1-41.1.385##KLANTEN SO, 2004, MOL PHYLOGENET EVOL, V32, P221, DOI 10.1016/J.YMPEV.2003.11.008##KOZA JR, 1993, GENETIC PROGRAMMING##KOZA JR, 1991, P INT JOINT C NEUR N, V2, P397##KUBO T, 1995, EVOLUTION, V49, P694, DOI 10.1111/J.1558-5646.1995.TB02306.X##NEE S, 1994, PHILOS T ROY SOC B, V344, P77, DOI 10.1098/RSTB.1994.0054##NEE S, 1994, PHILOS T ROY SOC B, V344, P305, DOI 10.1098/RSTB.1994.0068##PARADIS E, 2003, P ROY SOC B-BIOL SCI, V270, P2499, DOI 10.1098/RSPB.2003.2513##PYBUS OG, 2000, P ROY SOC B-BIOL SCI, V267, P2267, DOI 10.1098/RSPB.2000.1278",6,2020-11-20,NA
J,WOS:000242581100021,2006,CLAIM OF BIAS AGAINST CRITICS IS REFUTED BY PUBLICATION,NA,NA,NA,NATURE,"DE JONG, G##KORTHOF, G","UNIV UTRECHT, NL-3584 CH UTRECHT, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"GIERTYCH M, 2006, NATURE, V444, P265, DOI 10.1038/444265D",0,2020-11-20,NA
J,WOS:000242581100053,2006,ACTIVE GALACTIC NUCLEI AS SCALED-UP GALACTIC BLACK HOLES,"A LONG-STANDING QUESTION IS WHETHER ACTIVE GALACTIC NUCLEI (AGN) VARY LIKE GALACTIC BLACK HOLE SYSTEMS WHEN APPROPRIATELY SCALED UP BY MASS(1-3). IF SO, WE CAN THEN DETERMINE HOW AGN SHOULD BEHAVE ON COSMOLOGICAL TIMESCALES BY STUDYING THE BRIGHTER AND MUCH FASTER VARYING GALACTIC SYSTEMS. AS X-RAY EMISSION IS PRODUCED VERY CLOSE TO THE BLACK HOLES, IT PROVIDES ONE OF THE BEST DIAGNOSTICS OF THEIR BEHAVIOUR. A CHARACTERISTIC TIMESCALE - WHICH POTENTIALLY COULD TELL US ABOUT THE MASS OF THE BLACK HOLE - IS FOUND IN THE X-RAY VARIATIONS FROM BOTH AGN AND GALACTIC BLACK HOLES(1-6), BUT WHETHER IT IS PHYSICALLY MEANINGFUL TO COMPARE THE TWO HAS BEEN QUESTIONED(7). HERE WE REPORT THAT, AFTER CORRECTING FOR VARIATIONS IN THE ACCRETION RATE, THE TIMESCALES CAN BE PHYSICALLY LINKED, REVEALING THAT THE ACCRETION PROCESS IS EXACTLY THE SAME FOR SMALL AND LARGE BLACK HOLES. STRONG SUPPORT FOR THIS LINKAGE COMES, PERHAPS SURPRISINGLY, FROM THE PERMITTED OPTICAL EMISSION LINES IN AGN WHOSE WIDTHS ( IN BOTH BROAD-LINE AGN AND NARROW-EMISSION-LINE SEYFERT 1 GALAXIES) CORRELATE STRONGLY WITH THE CHARACTERISTIC X-RAY TIMESCALE, EXACTLY AS EXPECTED FROM THE AGN BLACK HOLE MASSES AND ACCRETION RATES. SO AGN REALLY ARE JUST SCALED-UP GALACTIC BLACK HOLES.",X-RAY VARIABILITY; LONG-TERM VARIABILITY; SEYFERT 1 GALAXIES; POWER SPECTRA; CYGNUS X-1; STATES; LUMINOSITY; EVOLUTION; NGC-5506; RXTE,NA,NATURE,"MCHARDY, IM##KOERDING, E##KNIGGE, C##UTTLEY, P##FENDER, RP","UNIV SOUTHAMPTON, SCH PHYS & ASTRON, SOUTHAMPTON SO17 1BJ, HANTS, ENGLAND. UNIV AMSTERDAM, ASTRON INST ANTON PANNEKOEK, NL-1098 SJ AMSTERDAM, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"AXELSSON M, 2005, ASTRON ASTROPHYS, V438, P999, DOI 10.1051/0004-6361:20042362##BENTZ MC, 2006, ASTROPHYS J, V644, P133, DOI 10.1086/503537##BRANDT WN, 1999, MNRAS, V303, P53##DONE C, 2005, MON NOT R ASTRON SOC, V364, P208, DOI 10.1111/J.1365-2966.2005.09555.X##EDELSON R, 1999, ASTROPHYS J, V514, P682, DOI 10.1086/306980##FALCKE H, 2004, ASTRON ASTROPHYS, V414, P895, DOI 10.1051/0004-6361:20031683##HARDY M, 1987, NATURE, V325, P696##KOLLATSCHNY W, 2006, ASTRON ASTROPHYS, V454, P459, DOI 10.1051/0004-6361:20054357##LAWRENCE A, 1987, NATURE, V325, P694, DOI 10.1038/325694A0##LEIGHLY KM, 1999, ASTROPHYS J SUPPL S, V125, P297, DOI 10.1086/313277##LIU BF, 1999, APJ, V527, P17##LYUBARSKII YE, 1997, MON NOT R ASTRON SOC, V292, P679, DOI 10.1093/MNRAS/292.3.679##MARKOWITZ A, 2003, ASTROPHYS J, V593, P96, DOI 10.1086/375330##MCCLINTOCK J.E., 2006, COMPACT STELLAR XRAY, P157, DOI DOI 10.2277/0521826594##MCHARDY I., 1988, MEMORIE DELLA SOCIETA ASTRONOMICA ITALIANA, V59, P239##MCHARDY IM, 2004, MON NOT R ASTRON SOC, V348, P783, DOI 10.1111/J.1365-2966.2004.07376.X##MCHARDY IM, 2005, MON NOT R ASTRON SOC, V359, P1469, DOI 10.1111/J.1365-2966.2005.08992.X##MERLONI A, 2003, MON NOT R ASTRON SOC, V345, P1057, DOI 10.1046/J.1365-2966.2003.07017.X##MIGLIARI S, 2005, MON NOT R ASTRON SOC, V363, P112, DOI 10.1111/J.1365-2966.2005.09412.X##NAGAR NM, 2002, ASTRON ASTROPHYS, V391, PL21, DOI 10.1051/0004-6361:20021039##NOWAK MA, 2000, MON NOT R ASTRON SOC, V318, P361, DOI 10.1046/J.1365-8711.2000.03668.X##PAPADAKIS IE, 2004, MON NOT R ASTRON SOC, V348, P207, DOI 10.1111/J.1365-2966.2004.07351.X##PETERSON BM, 2004, ASTROPHYS J, V613, P682, DOI 10.1086/423269##PETERSON BM, 2000, ASTROPHYS J, V542, P161, DOI 10.1086/309518##POTTTSCHMIDT K, 2003, ASTRON ASTROPHYS, V407, P1039, DOI 10.1051/0004-6361:20030906##TRUDOLYUBOV SP, 2001, ASTROPHYS J, V558, P276, DOI 10.1086/322466##TURNER TJ, 1999, ASTROPHYS J, V524, P667, DOI 10.1086/307834##UTTLEY P, 2005, MON NOT R ASTRON SOC, V363, P586, DOI 10.1111/J.1365-2966.2005.09475.X##UTTLEY P, 2002, MON NOT R ASTRON SOC, V332, P231, DOI 10.1046/J.1365-8711.2002.05298.X##WILMS J, 2006, ASTRON ASTROPHYS, V447, P245, DOI 10.1051/0004-6361:20053938",409,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/D001013/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242581400002,2006,EXPLORING THE USES OF RNAI - GENE KNOCKDOWN AND THE NOBEL PRIZE,NA,INTERFERENCE,NA,NEW ENGLAND JOURNAL OF MEDICINE,"BERNARDS, R","NETHERLANDS CANC INST, DIV MOL CARCINOGENESIS, AMSTERDAM, NETHERLANDS.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"FIRE A, 1998, NATURE, V391, P806, DOI 10.1038/35888##MORRIS KV, 2006, BIOTECHNIQUES, V40, P7, DOI 10.2144/000112166##NGO VN, 2006, NATURE, V441, P106, DOI 10.1038/NATURE04687##ROTTMANN S, 2005, P NATL ACAD SCI USA, V102, P15195, DOI 10.1073/PNAS.0505114102",22,2020-11-20,NA
J,WOS:000242581400005,2006,FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IMATINIB FOR CHRONIC MYELOID LEUKEMIA,"BACKGROUND: THE CAUSE OF CHRONIC MYELOID LEUKEMIA (CML) IS A CONSTITUTIVELY ACTIVE BCR-ABL TYROSINE KINASE. IMATINIB INHIBITS THIS KINASE, AND IN A SHORT-TERM STUDY WAS SUPERIOR TO INTERFERON ALFA PLUS CYTARABINE FOR NEWLY DIAGNOSED CML IN THE CHRONIC PHASE. FOR 5 YEARS, WE FOLLOWED PATIENTS WITH CML WHO RECEIVED IMATINIB AS INITIAL THERAPY. METHODS: WE RANDOMLY ASSIGNED 553 PATIENTS TO RECEIVE IMATINIB AND 553 TO RECEIVE INTERFERON ALFA PLUS CYTARABINE AND THEN EVALUATED THEM FOR OVERALL AND EVENT-FREE SURVIVAL; PROGRESSION TO ACCELERATED-PHASE CML OR BLAST CRISIS; HEMATOLOGIC, CYTOGENETIC, AND MOLECULAR RESPONSES; AND ADVERSE EVENTS. RESULTS: THE MEDIAN FOLLOW-UP WAS 60 MONTHS. KAPLAN-MEIER ESTIMATES OF CUMULATIVE BEST RATES OF COMPLETE CYTOGENETIC RESPONSE AMONG PATIENTS RECEIVING IMATINIB WERE 69% BY 12 MONTHS AND 87% BY 60 MONTHS. AN ESTIMATED 7% OF PATIENTS PROGRESSED TO ACCELERATED-PHASE CML OR BLAST CRISIS, AND THE ESTIMATED OVERALL SURVIVAL OF PATIENTS WHO RECEIVED IMATINIB AS INITIAL THERAPY WAS 89% AT 60 MONTHS. PATIENTS WHO HAD A COMPLETE CYTOGENETIC RESPONSE OR IN WHOM LEVELS OF BCR-ABL TRANSCRIPTS HAD FALLEN BY AT LEAST 3 LOG HAD A SIGNIFICANTLY LOWER RISK OF DISEASE PROGRESSION THAN DID PATIENTS WITHOUT A COMPLETE CYTOGENETIC RESPONSE (P<0.001). GRADE 3 OR 4 ADVERSE EVENTS DIMINISHED OVER TIME, AND THERE WAS NO CLINICALLY SIGNIFICANT CHANGE IN THE PROFILE OF ADVERSE EVENTS. CONCLUSIONS: AFTER 5 YEARS OF FOLLOW-UP, CONTINUOUS TREATMENT OF CHRONIC-PHASE CML WITH IMATINIB AS INITIAL THERAPY WAS FOUND TO INDUCE DURABLE RESPONSES IN A HIGH PROPORTION OF PATIENTS.",CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; COMPLETE CYTOGENETIC REMISSION; ALPHA PLUS CYTARABINE; INTERFERON-ALPHA; CHRONIC-PHASE; BLAST CRISIS; CHROMOSOME; RESPONSES; CELLS,NA,NEW ENGLAND JOURNAL OF MEDICINE,"DRUKER, BJ##GUILHOT, F##O'BRIEN, SG##GATHMANN, I##KANTARJIAN, H##GATTERMANN, N##DEININGER, MWN##SILVER, RT##GOLDMAN, JM##STONE, RM##CERVANTES, F##HOCHHAUS, A##POWELL, BL##GABRILOVE, JL##ROUSSELOT, P##REIFFERS, J##CORNELISSEN, JJ##HUGHES, T##AGIS, H##FISCHER, T##VERHOEF, G##SHEPHERD, J##SAGLIO, G##GRATWOHL, A##NIELSEN, JL##RADICH, JP##SIMONSSON, B##TAYLOR, K##BACCARANI, M##SO, C##LETVAK, L##LARSON, RA","OREGON HLTH & SCI UNIV, INST CANC, PORTLAND, OR 97239 USA. CHU, POITIERS, FRANCE. UNIV NEWCASTLE, NEWCASTLE UPON TYNE, TYNE & WEAR, ENGLAND. NOVARTIS, BASEL, SWITZERLAND. UNIV TEXAS, MD ANDERSON CANC CTR, HOUSTON, TX 77030 USA. UNIV DUSSELDORF, D-4000 DUSSELDORF, GERMANY. UNIV LEIPZIG, D-7010 LEIPZIG, GERMANY. WEILL CORNELL MED CTR, NEW YORK, NY USA. NHLBI, BETHESDA, MD 20892 USA. DANA FARBER CANC INST, BOSTON, MA 02115 USA. HOSP CLIN BARCELONA, BARCELONA, SPAIN. HEIDELBERG UNIV, D-6800 MANNHEIM, GERMANY. WAKE FOREST UNIV, BAPTIST MED CTR, WINSTON SALEM, NC 27109 USA. MT SINAI SCH MED, NEW YORK, NY USA. HOP ST LOUIS, PARIS, FRANCE. CHU BORDEAUX, PESSAC, FRANCE. ERASMUS MC, ROTTERDAM, NETHERLANDS. ROYAL ADELAIDE HOSP, ADELAIDE, SA 5000, AUSTRALIA. UNIV VIENNA, INNERE MED KLIN 1, VIENNA, AUSTRIA. JOHANNES GUTENBERG UNIV MAINZ, D-6500 MAINZ, GERMANY. UNIV HOSP GASTHUISBERG, B-3000 LOUVAIN, BELGIUM. VANCOVER HOSP, VANCOUVER, BC, CANADA. AZIENDA OSPED S LUIGI GONZAGA, ORBASSANO, ITALY. UNIV BASEL HOSP, CH-4031 BASEL, SWITZERLAND. AARHUS KOMMUNE HOSP, DK-8000 AARHUS, DENMARK. FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA. AKAD SJUKHUSET, UPPSALA, SWEDEN. MATER HOSP, BRISBANE, QLD, AUSTRALIA. POLICLIN O ORSOLA MALPIGHI, BOLOGNA, ITALY. NOVARITS, FLORHAM PK, NJ USA. UNIV CHICAGO, CHICAGO, IL 60637 USA.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"BACCARANI M, 2002, BLOOD, V99, P1527, DOI 10.1182/BLOOD.V99.5.1527##BONIFAZI F, 2001, BLOOD, V98, P3074, DOI 10.1182/BLOOD.V98.10.3074##BRECCIA M, 2006, LEUKEMIA RES, V30, P1577, DOI 10.1016/J.LEUKRES.2006.03.011##CHU S, 2005, BLOOD, V105, P2093, DOI 10.1182/BLOOD-2004-03-1114##COPLAND M, 2006, BLOOD, V107, P4532, DOI 10.1182/BLOOD-2005-07-2947##CORTES J, 2004, BLOOD, V104, P2204, DOI 10.1182/BLOOD-2004-04-1335##DRUKER BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402##DRUKER BJ, 1996, NAT MED, V2, P561, DOI 10.1038/NM0596-561##DRUKER BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401##DRUKER BJ, 2001, NEW ENGL J MED, V345, P232##GRAHAM SM, 2002, BLOOD, V99, P319, DOI 10.1182/BLOOD.V99.1.319##GRISWOLD IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05##GUILHOT F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402##HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758A0##HUGHES TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMOA030513##KANTARJIAN H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMOA011573##KANTARJIAN H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMOA055104##KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0##MAURO MJ, 2004, LEUKEMIA RES, V28, PS71, DOI 10.1016/J.LEUKRES.2003.10.017##MERANTE S, 2005, HAEMATOLOGICA, V90, P979##NOWELL PC, 1960, SCIENCE, V132, P1497##O'BRIEN SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMOA022457##ROCHE-LESTIENNE C, 2003, SEMIN HEMATOL, V40, P80, DOI 10.1053/SHEM.2003.50046##ROUSSELOT P, IN PRESS BLOOD##ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290A0##ROY L, 2006, BLOOD, V108, P1478, DOI 10.1182/BLOOD-2006-02-001495##SAWYERS CL, 2002, BLOOD, V99, P3530, DOI 10.1182/BLOOD.V99.10.3530##SHAH NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/SJ.ONC.1206942##SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550A0##SILVER RT, 1999, BLOOD, V94, P1517##SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/BLOOD.V63.4.789.789##TALPAZ M, 2002, BLOOD, V99, P1928, DOI 10.1182/BLOOD.V99.6.1928##TALPAZ M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMOA055229##THOMAS J, 2004, BLOOD, V104, P3739, DOI 10.1182/BLOOD-2003-12-4276##WILLIS SG, 2005, BLOOD, V106, P2128, DOI 10.1182/BLOOD-2005-03-1036",2526,2020-11-20,NA
J,WOS:000242581400019,2006,DRUG-ELUTING STENTS IN PRIMARY PCI - REPLY,NA,NA,NA,NEW ENGLAND JOURNAL OF MEDICINE,"LAARMAN, GJ","ONZE LIEVE VROUW HOSP, NL-1217 NJ AMSTERDAM, NETHERLANDS.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,NA,0,2020-11-20,NA
J,WOS:000242619200014,2006,CELL MODEL FOR EFFICIENT SIMULATION OF WAVE PROPAGATION IN HUMAN VENTRICULAR TISSUE UNDER NORMAL AND PATHOLOGICAL CONDITIONS,"IN THIS PAPER, WE FORMULATE A MODEL FOR HUMAN VENTRICULAR CELLS THAT IS EFFICIENT ENOUGH FOR WHOLE ORGAN ARRHYTHMIA SIMULATIONS YET DETAILED ENOUGH TO CAPTURE THE EFFECTS OF CELL LEVEL PROCESSES SUCH AS CURRENT BLOCKS AND CHANNELOPATHIES. THE MODEL IS OBTAINED FROM OUR DETAILED HUMAN VENTRICULAR CELL MODEL BY USING MATHEMATICAL TECHNIQUES TO REDUCE THE NUMBER OF VARIABLES FROM 19 TO NINE. WE CAREFULLY COMPARE OUR FULL AND REDUCED MODEL AT THE SINGLE CELL, CABLE AND 2D TISSUE LEVEL AND SHOW THAT THE REDUCED MODEL HAS A VERY SIMILAR BEHAVIOUR. IMPORTANTLY, THE NEW MODEL CORRECTLY PRODUCES THE EFFECTS OF CURRENT BLOCKS AND CHANNELOPATHIES ON AP AND SPIRAL WAVE BEHAVIOUR, PROCESSES AT THE CORE OF CURRENT DAY ARRHYTHMIA RESEARCH. THE NEW MODEL IS WELL OVER FOUR TIMES MORE EFFICIENT THAN THE FULL MODEL. WE CONCLUDE THAT THE NEW MODEL CAN BE USED FOR EFFICIENT SIMULATIONS OF THE EFFECTS OF CURRENT CHANGES ON ARRHYTHMIAS IN THE HUMAN HEART.",RECTIFIER K+ CURRENT; LONG-QT SYNDROME; TRANSIENT OUTWARD CURRENT; ELECTRICAL RESTITUTION; BRUGADA-SYNDROME; CARDIAC RESTITUTION; SPIRAL BREAKUP; HEART-FAILURE; DIADIC SPACE; 2 COMPONENTS,NA,PHYSICS IN MEDICINE AND BIOLOGY,"TEN TUSSCHER, KHWJ##PANFILOV, AV","UNIV UTRECHT, DEPT THEORET BIOL, NL-3584 CH UTRECHT, NETHERLANDS.","ENGINEERING, BIOMEDICAL; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ENGINEERING; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ALIEV RR, 1996, CHAOS SOLITON FRACT, V7, P293, DOI 10.1016/0960-0779(95)00089-5##ANTZELEVITCH C, 1999, CURR OPIN CARDIOL, V14, P274, DOI 10.1097/00001573-199905000-00013##BOSCH RF, 1998, CARDIOVASC RES, V38, P441, DOI 10.1016/S0008-6363(98)00021-2##BOYETT MR, 1988, J THEOR BIOL, V132, P15, DOI 10.1016/S0022-5193(88)80187-5##CAO JM, 1999, CIRC RES, V84, P1318, DOI 10.1161/01.RES.84.11.1318##CHERRY EM, 2004, AM J PHYSIOL-HEART C, V286, PH2332, DOI 10.1152/AJPHEART.00747.2003##CLANCY CE, 2002, CIRCULATION, V105, P1208, DOI 10.1161/HC1002.105183##COURTEMANCHE M, 1998, AM J PHYSIOL-HEART C, V275, PH301##DROUIN E, 1995, J AM COLL CARDIOL, V26, P185, DOI 10.1016/0735-1097(95)00167-X##DUMAINE R, 1999, CIRC RES, V85, P803, DOI 10.1161/01.RES.85.9.803##FENTON F, 1998, CHAOS, V8, P20, DOI 10.1063/1.166311##FISH JM, 2003, J ELECTROCARDIOL, V36, P173, DOI 10.1016/J.JELECTROCARD.2003.09.054##FITZHUGH R, 1961, BIOPHYS J, V1, P445, DOI 10.1016/S0006-3495(61)86902-6##FITZHUGH R, 1960, J GEN PHYSIOL, V43, P867, DOI 10.1085/JGP.43.5.867##GARFINKEL A, 2000, P NATL ACAD SCI USA, V97, P6061, DOI 10.1073/PNAS.090492697##GRANT AO, 2001, AM J MED, V110, P296, DOI 10.1016/S0002-9343(00)00714-2##IOST N, 1998, CARDIOVASC RES, V40, P508, DOI 10.1016/S0008-6363(98)00204-1##IYER V, 2004, BIOPHYS J, V87, P1507, DOI 10.1529/BIOPHYSJ.104.043299##KARMA A, 1993, PHYS REV LETT, V71, P1103, DOI 10.1103/PHYSREVLETT.71.1103##KARMA A, 1994, CHAOS, V4, P461, DOI 10.1063/1.166024##KEENER J., 1998, MATH PHYSL##KELLER DI, 2003, J MOL CELL CARDIOL, V35, P1513, DOI 10.1016/J.YJMCC.2003.08.007##KOLLER ML, 2000, AM J PHYSIOL-HEART C, V279, PH2665##LI GR, 1998, AM J PHYSIOL-HEART C, V275, PH369##LI GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689##LUO CH, 1991, CIRC RES, V68, P1501, DOI 10.1161/01.RES.68.6.1501##LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071##NABAUER M, 1996, CIRCULATION, V93, P168, DOI 10.1161/01.CIR.93.1.168##NAGUMO J, 1962, P IRE, V50, P2061, DOI 10.1109/JRPROC.1962.288235##NASH MP, 2006, EXP PHYSIOL, V91, P339, DOI 10.1113/EXPPHYSIOL.2005.031070##NOBLE D, 1998, CAN J CARDIOL, V14, P123##PANFILOV AV, 1990, PHYS LETT A, V147, P463, DOI 10.1016/0375-9601(90)90607-P##PEREON Y, 2000, AM J PHYSIOL-HEART C, V278, PH1908##PRIEBE L, 1998, CIRC RES, V82, P1206, DOI 10.1161/01.RES.82.11.1206##QU ZL, 1999, AM J PHYSIOL-HEART C, V276, PH269##RICCIO ML, 1999, CIRC RES, V84, P955##RICE JJ, 1999, BIOPHYS J, V77, P1871, DOI 10.1016/S0006-3495(99)77030-X##RIVOLTA I, 2001, J BIOL CHEM, V276, P30623, DOI 10.1074/JBC.M104471200##RUSH S, 1978, IEEE T BIO-MED ENG, V25, P389, DOI 10.1109/TBME.1978.326270##TAGGART P, 2000, J MOL CELL CARDIOL, V32, P621, DOI 10.1006/JMCC.2000.1105##TEN TUSSCHER KHWJ, 2006, AM J PHYSIOL-HEART C, V291, PH1088, DOI 10.1152/AJPHEART.00109.2006##TEN TUSSCHER KHWJ, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.108106##TEN TUSSCHER KHWJ, 2004, AM J PHYSIOL-HEART C, V286, PH1573, DOI 10.1152/AJPHEART.00794.2003##WEI J, 1999, CIRCULATION, V99, P3165, DOI 10.1161/01.CIR.99.24.3165##WETTWER E, 1994, CIRC RES, V75, P473, DOI 10.1161/01.RES.75.3.473##WINSLOW RL, 1999, CIRC RES, V84, P571, DOI 10.1161/01.RES.84.5.571##XIE F, 2001, AM J PHYSIOL-HEART C, V280, PH1667##ZENG JL, 1995, CIRC RES, V77, P140, DOI 10.1161/01.RES.77.1.140##ZHANG H, 2000, AM J PHYSIOL-HEART C, V279, PH397",120,2020-11-20,NA
J,WOS:000242915500012,2006,PLASMA PTERINS AND FOLATE IN LATE LIFE DEPRESSION: THE ROTTERDAM STUDY,"TETRAHYDROBIOPTERIN IS A COFACTOR IN THE SYNTHESIS OF MONOAMINE NEUROTRANSMITTERS. HIGH NEOPTERIN LEVELS GENERALLY SIGNAL INCREASED IMMUNE ACTIVATION. BOTH PTERINS HAVE BEEN INVESTIGATED IN SEVERAL SMALL CLINICAL STUDIES OF DEPRESSED PATIENTS WITH CONFLICTING RESULTS. THEREFORE, WE EXAMINED THE RELATION OF PLASMA BIOPTERIN AND NEOPTERIN WITH DEPRESSION IN A POPULATION-BASED STUDY. WE ALSO STUDIED THE ASSOCIATION OF PTERINS WITH FOLATES IN DEPRESSED PERSONS AS THIS VITAMIN IS REQUIRED FOR PTERIN BIOSYNTHESIS. WE SCREENED 3884 ADULTS AGED 60 YEARS AND OVER FOR DEPRESSIVE SYMPTOMS. SCREEN POSITIVE SUBJECTS HAD A PSYCHIATRIC INTERVIEW TO DIAGNOSE DSM-LV DISORDER. PLASMA PTERINS AND SERUM FOLATE WERE DETERMINED IN ALL PERSONS WITH DEPRESSIVE SYMPTOMS (11 238) AND RANDOMLY SELECTED NON-DEPRESSED PERSONS (N = 357). WE FOUND NO ASSOCIATION BETWEEN THE CONCENTRATION OF BIOPTERIN OR NEOPTERIN WITH DEPRESSIVE SYMPTOMS OR DEPRESSIVE DISORDERS. HOWEVER, IN DEPRESSED PERSONS THE RELATION BETWEEN PTERINS AND FOLATES WAS DIFFERENT THAN IN THE NON-DEPRESSED, I.E. NEOPTERIN CONCENTRATIONS INCREASED WITH FOLATE LEVELS IN PERSONS WITH DEPRESSIVE SYMPTOMS (0.09 PER LOG(NMOL/L FOLATE); 95% CI=0.01, 0.18, P=0.03), BUT NOT IN NON-DEPRESSED PERSONS (-0.07 PER LOG(NMOL/L FOLATE); 95% CI=-0.17, 0.03, P=0.18). THE INTERACTION BETWEEN DEPRESSIVE SYMPTOMS, FOLATE AND NEOPTERIN WAS SIGNIFICANT (P=0.03). THE STUDY SUGGESTS THAT THE RELATION BETWEEN FOLATE AND PTERINS IS ALTERED IN THE DEPRESSED ELDERLY. (C) 006 ELSEVIER IRELAND LTD. ALL RIGHTS RESERVED.",IMMUNE-SYSTEM ACTIVATION; MAJOR DEPRESSION; TETRAHYDROBIOPTERIN BIOSYNTHESIS; MONOAMINE METABOLISM; AFFECTIVE-DISORDERS; OXIDATIVE STRESS; BIOPTERIN LEVELS; NEOPTERIN; VITAMIN-B-12; HOMOCYSTEINE,DEPRESSION; FOLATES; PTERINS; POPULATION-BASED; ELDERLY; MONOAMINE SYNTHESIS,PSYCHIATRY RESEARCH,"TIEMEIER, H##FEKKES, D##HOFMAN, A##VAN TUIJL, HR##KILIAAN, AJ##BRETELER, MMB","ERASMUS UNIV, CTR MED, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS. ERASMUS UNIV, CTR MED, DEPT PSYCHIAT, NL-3000 DR ROTTERDAM, NETHERLANDS. ERASMUS UNIV, CTR MED, DEPT NEUROSCI, NL-3000 DR ROTTERDAM, NETHERLANDS. RADBOUD UNIV NIJMEGEN, NIJMEGEN MED CTR, DEPT ANAT & EMBRYOL, NIJMEGEN, NETHERLANDS. NIMICO RES, WAGENINGEN, NETHERLANDS.",PSYCHIATRY,PSYCHIATRY,"ABOU-SALEH MT, 1999, EUR NEUROPSYCHOPHARM, V9, P295##ABOUSALEH MT, 1995, BIOL PSYCHIAT, V38, P458, DOI 10.1016/0006-3223(94)00323-U##ALMEIDA OP, 2005, NEUROBIOL AGING, V26, P251, DOI 10.1016/J.NEUROBIOLAGING.2004.03.007##ALPERT JE, 2000, NUTRITION, V16, P544, DOI 10.1016/S0899-9007(00)00327-0##*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, V4##BARFORD PA, 1984, J NEUROL NEUROSUR PS, V47, P736, DOI 10.1136/JNNP.47.7.736##BEEKMAN ATF, 1997, PSYCHOL MED, V27, P231, DOI 10.1017/S0033291796003510##BJELLAND I, 2003, ARCH GEN PSYCHIAT, V60, P618, DOI 10.1001/ARCHPSYC.60.6.618##BLAU N, 2001, METABOLIC MOL BASES, P1726##BLAZER D, 1991, J GERONTOL, V46, P210##BONACCORSO S, 1998, J AFFECT DISORDERS, V48, P75, DOI 10.1016/S0165-0327(97)00144-4##BOTTIGLIERI T, 1992, PSYCHOL MED, V22, P871, DOI 10.1017/S0033291700038447##BOTTIGLIERI T, 2000, J NEUROL NEUROSUR PS, V69, P228, DOI 10.1136/JNNP.69.2.228##COPPEN A, 1989, J AFFECT DISORDERS, V16, P103, DOI 10.1016/0165-0327(89)90062-1##DI RM, 1990, BIOCHEM BIOPH RES CO, V172, P1246##DUNBAR PR, 1992, PSYCHOL MED, V22, P1051, DOI 10.1017/S0033291700038629##FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/ART.1780230202##FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X##HAMON CGB, 1986, J MENT DEFIC RES, V30, P179##HASHIMOTO R, 1988, NEUROPSYCHOBIOLOGY, V19, P61, DOI 10.1159/000118435##HASHIMOTO R, 1987, NEUROPSYCHOBIOLOGY, V17, P176, DOI 10.1159/000118360##HASHIMOTO R, 1990, BIOL PSYCHIAT, V28, P526, DOI 10.1016/0006-3223(90)90487-M##HOEKSTRA R, 2001, PSYCHIAT RES, V103, P115, DOI 10.1016/S0165-1781(01)00282-7##HOFFMANN G, 2003, INFLAMM RES, V52, P313, DOI 10.1007/S00011-003-1181-9##HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007##KNAPP S, 1989, BIOL PSYCHIAT, V26, P156, DOI 10.1016/0006-3223(89)90019-X##MAES M, 1999, ADV EXP MED BIOL, V461, P25##MAES M, 1994, PSYCHIAT RES, V54, P143, DOI 10.1016/0165-1781(94)90003-5##MURR C, 2002, CURR DRUG METAB, V3, P175, DOI 10.2174/1389200024605082##O'TOOLE SM, 1998, PSYCHIAT RES, V79, P21, DOI 10.1016/S0165-1781(98)00019-5##OETTL K, 2002, CURR DRUG METAB, V3, P203, DOI 10.2174/1389200024605127##ORDWAY GA, 2002, NEUROPSYCHOPHARMACOL, P1051##PENNINX BWJH, 2000, AM J PSYCHIAT, V157, P715, DOI 10.1176/APPI.AJP.157.5.715##PLOTSKY PM, 1998, PSYCHIAT CLIN N AM, V21, P293, DOI 10.1016/S0193-953X(05)70006-X##RADLOFF LS, 1977, APPL PSYCH MEAS, V1, P385, DOI [10.1177/014662167700100306, DOI 10.1177/014662167700100306]##SURTEES R, 1990, LANCET, V335, P619, DOI 10.1016/0140-6736(90)90409-X##THONY B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001##TIEMEIER H, 2002, AM J PSYCHIAT, V159, P2099, DOI 10.1176/APPI.AJP.159.12.2099##VANPRAAG HM, 1982, LANCET, V2, P1259##VERMEER SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMOA022066##WERNER-FELMAYER G, 2002, CURR DRUG METAB, V3, P159, DOI 10.2174/1389200024605073##*WHO DIV MENT HLTH, 1997, SCAN SCHED CLIN ASS##WIDNER B, 2002, CURR DRUG METAB, V3, P225, DOI 10.2174/1389200024605091##ZORRILLA EP, 2001, BRAIN BEHAV IMMUN, V15, P199, DOI 10.1006/BRBI.2000.0597",19,2020-11-20,NA
J,WOS:000243205000003,2006,SENSITIVITY OF WATER AND CARBON FLUXES TO CLIMATE CHANGES FROM 1960 TO 2100 IN EUROPEAN FOREST ECOSYSTEMS,"THE EFFECTS OF CLIMATE CHANGES OIL CARBON AND WATER FLUXES ARE QUANTIFIED USING A PHYSIOLOGICALLY MULTI-LAYER, PROCESS-BASED MODEL CONTAINING A CARBON ALLOCATION MODEL AND COUPLED WITH A SOIL MODEL (CASTANEA). THE MODEL IS FIRST EVALUATED ON FOUR EUROFLUX SITES USING EDDY COVARIANCE DATA, WHICH PROVIDE ESTIMATES OF CARBON AND WATER FLUXES AT THE ECOSYSTEM SCALE. IT CORRECTLY REPRODUCES THE DIURNAL FLUXES AND THE SEASONAL PATTERN. THEREAFTER SIMULATIONS WERE CONDUCTED ON SIX FRENCH FOREST ECOSYSTEMS REPRESENTATIVE OF THREE CLIMATIC AREAS (OCEANIC. CONTINENTAL AND MEDITERRANEAN AREAS) DOMINATED BY DECIDUOUS SPECIES (FAGUS SYLVATICA, QUERCUS ROBUR), CONIFEROUS SPECIES (PINUS PINASTER, PINUS SYLVESTRIS) OR SCLEROPHYLLOUS EVERGREEN SPECIES (QUERCUS HEX). THE MODEL IS DRIVEN BY THE RESULTS OF A METEOROLOGICAL MODEL (ARPEGE) FOLLOWING THE B2 SCENARIO OF IPCC. FROM 1960 TO 2100, THE AVERAGE TEMPERATURE INCREASES BY 3.1 DEGREES C (30%) AND THE RAINFALL DURING SUMMER DECREASES BY 68 MM (-27%). FOR ALL THE SITES, BETWEEN THE TWO PERIODS, THE SIMULATIONS PREDICT ON AVERAGE A GROSS PRIMARY PRODUCTION (GPP) INCREASE OF 513 G(C) M(-2) (+38%). THIS INCREASE IS RELATIVELY STEEP UNTIL 2020, FOLLOWED BY A SLOWING DOWN OF THE GPP RISE DUE TO AN INCREASE OF THE EFFECT OF WATER STRESS. CONTRARY TO GPP, THE ECOSYSTEM RESPIRATION (R-ECO) RAISES AT A CONSTANT RATE (350 G(C) M(-2) I.E. 31% FROM 1960 TO 2100). THE DYNAMICS OF THE NET ECOSYSTEM PRODUCTIVITY (GPP MINUS R-ECO) IS THE CONSEQUENCE OF THE EFFECT ON BOTH GPP AND R-ECO AND DIFFERS PER SITE. THE ECOSYSTEMS ALWAYS REMAIN CARBON SINKS; HOWEVER THE SINK STRENGTH GLOBALLY DECREASES FOR CONIFEROUS (-8%), INCREASES FOR SCLEROPHYLLOUS EVERGREEN (+34%) AND STRONGLY INCREASES FOR DECIDUOUS FOREST (+67%) THAT LARGELY BENEFITS BY THE LENGTHENING OF THE FOLIATED PERIOD. THE SEPARATELY QUANTIFIED EFFECTS OF THE MAIN VARIABLES (TEMPERATURE, LENGTH OF FOLIATED SEASON, CO2 FERTILIZATION, DROUGHT EFFECT), SHOW THAT THE MAGNITUDE OF THESE EFFECTS DEPENDS ON THE SPECIES AND THE CLIMATIC ZONE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",MODELING CANOPY PHOTOSYNTHESIS; TEMPERATURE RESPONSE; CO2 CONCENTRATION; GLOBAL RADIATION; DIRECT COMPONENT; ATMOSPHERIC CO2; INCREASING CO2; NET CARBON; H2O FLUXES; EXCHANGE,FOREST ECOSYSTEMS; CARBON SINK; CLIMATE CHANGE; CANOPY SCALE; PHENOLOGY,AGRICULTURAL AND FOREST METEOROLOGY,"DAVI, H##DUFRENE, E##FRANCOIS, C##LE MAIRE, G##LOUSTAU, D##BOSC, A##RAMBAL, S##GRANIER, A##MOORS, E","INRA, UR629, RECH FORESTIERES MEDITERRANEENNES, F-84914 AVIGNON 9, FRANCE. CNRS, LAB ECOL SYSTEMAT & EVOLUT, F-91405 ORSAY, FRANCE. UNIV PARIS 11, F-91405 ORSAY, FRANCE. INRA PIERROTON, LAB ECOPHYSIOL & NUTR, STN RECH FORESTIERES, F-33611 GAZINET, FRANCE. INRA, UHP ECOL & ECOPHYSIOL FORESTIERES, UMR, F-54280 SEICHAMPS, FRANCE. ALTERRA, NL-6700 AA WAGENINGEN, NETHERLANDS.",AGRONOMY; FORESTRY; METEOROLOGY & ATMOSPHERIC SCIENCES,AGRICULTURE; FORESTRY; METEOROLOGY & ATMOSPHERIC SCIENCES,"AUBINET M, 2000, ADV ECOL RES, V30, P113, DOI 10.1016/S0065-2504(08)60018-5##BADECK FW, 2004, NEW PHYTOL, V162, P295, DOI 10.1111/J.1469-8137.2004.01059.X##BALDOCCHI D, 2005, NATURE, V437, P483, DOI 10.1038/437483A##BALDOCCHI DD, 1996, TREE PHYSIOL, V16, P5##BALDOCCHI DD, 2003, GLOBAL CHANGE BIOL, V9, P479, DOI 10.1046/J.1365-2486.2003.00629.X##BALL J.T., 1987, PROGR PHOTOSYNTHESIS, P221, DOI DOI 10.1007/978-94-017-0519-6_48##BARBAROUX C, 2002, THESIS U PARIS SUD##BECKER T, 1994, APPL ALGEBR ENG COMM, V5, P1, DOI 10.1007/BF01196621##BEERLING DJ, 1997, AM J BOT, V84, P1572, DOI 10.2307/2446619##BEERLING DJ, 1999, GLOB CHANGE BIOL, V5, P55, DOI 10.1046/J.1365-2486.1998.00209.X##BERBIGIER P, 2001, AGR FOREST METEOROL, V108, P183, DOI 10.1016/S0168-1923(01)00240-4##BERNACCHI CJ, 2001, PLANT CELL ENVIRON, V24, P253, DOI 10.1111/J.1365-3040.2001.00668.X##BOSC A, 2003, TREE PHYSIOL, V23, P227, DOI 10.1093/TREEPHYS/23.4.227##BOURIAUD O, 2003, THESIS##BRADLEY RS, 1987, SCIENCE, V237, P171, DOI 10.1126/SCIENCE.237.4811.171##CANNELL MGR, 1998, FORESTRY, V71, P277, DOI 10.1093/FORESTRY/71.4.277##CIAIS P, 2005, NATURE, V437, P529, DOI 10.1038/NATURE03972##COOPS NC, 2001, GLOBAL CHANGE BIOL, V7, P15, DOI 10.1046/J.1365-2486.2001.00385.X##COURTIER P, 1991, P ECMWF WORKSH NUM M, V2, P193##CRAMER W, 1999, GLOBAL CHANGE BIOL, V5, P1, DOI 10.1046/J.1365-2486.1999.00009.X##CRAMER W, 2001, GLOBAL CHANGE BIOL, V7, P357, DOI 10.1046/J.1365-2486.2001.00383.X##CURTIS PS, 1996, PLANT CELL ENVIRON, V19, P127, DOI 10.1111/J.1365-3040.1996.TB00234.X##DAMESIN C, 2002, NEW PHYTOL, V153, P159, DOI 10.1046/J.0028-646X.2001.00296.X##DARRIGO R, 1987, NATURE, V329, P321, DOI 10.1038/329321A0##DAVI, 2004, THESIS U PARIS SUD 1##DAVI H, 2005, ECOL MODEL, V185, P387, DOI 10.1016/J.ECOLMODEL.2005.01.003##DEQUE M, 1998, CLIM DYNAM, V14, P173, DOI 10.1007/S003820050216##DEQUE M, 1995, CLIM DYNAM, V11, P321, DOI 10.1007/BF00215735##DEQUE M, 1994, CLIM DYNAM, V10, P249, DOI 10.1007/BF00208992##DEVRIES FWT, 1974, J THEOR BIOL, V45, P339, DOI DOI 10.1016/0022-5193(74)90119-2##DEVRIES FWT, 1975, PHOTOSYNTHESIS PRODU, P459##DEVRIES FWT, 1975, ANN BOTANY, V39, P77##DOLMAN AJ, 2002, AGR FOREST METEOROL, V111, P157, DOI 10.1016/S0168-1923(02)00024-2##DREYER E, 2001, TREE PHYSIOL, V21, P223, DOI 10.1093/TREEPHYS/21.4.223##DUFRENE E, 2005, ECOL MODEL, V185, P407, DOI 10.1016/J.ECOLMODEL.2005.01.004##EHLERINGER J, 1977, PLANT PHYSIOL, V59, P86, DOI 10.1104/PP.59.1.86##ENJALBAL M, 1994, ETUDE ACCROISSEMENT##EPRON D, 2001, TREE PHYSIOL, V21, P145, DOI 10.1093/TREEPHYS/21.2-3.145##FALGE E, 2002, AGR FOREST METEOROL, V113, P53, DOI 10.1016/S0168-1923(02)00102-8##FARQUHAR GD, 1980, PLANTA, V149, P78, DOI 10.1007/BF00386231##FRANCOIS C, 2002, REMOTE SENS ENVIRON, V80, P122, DOI 10.1016/S0034-4257(01)00293-0##GIBELIN AL, 2003, CLIM DYNAM, V20, P327, DOI 10.1007/S00382-002-0277-1##GRANIER A, 1999, ECOL MODEL, V116, P269, DOI 10.1016/S0304-3800(98)00205-1##GRANIER A, 2000, FUNCT ECOL, V14, P312, DOI 10.1046/J.1365-2435.2000.00434.X##GRANIER A, 2000, ANN FOR SCI, V57, P755, DOI 10.1051/FOREST:2000158##GRANT RF, 2000, GLOBAL CHANGE BIOL, V6, P183, DOI 10.1046/J.1365-2486.2000.00288.X##GUYON D, 2003, CAN J REMOTE SENS, V29, P336, DOI 10.5589/M03-008##HAGER C, 1999, TELLUS B, V51, P385, DOI 10.1034/J.1600-0889.1999.00019.X##HOFF C, 2002, FOREST ECOL MANAG, V164, P121, DOI 10.1016/S0378-1127(01)00605-3##IDSO SB, 1981, WATER RESOUR RES, V17, P295, DOI 10.1029/WR017I002P00295##IPCC CLIMATE CHANGE, 2001, CLIMATE CHANGE 2001, P881, DOI DOI 10.1002/JOC.763##JOOS F, 2002, GLOBAL CHANGE BIOL, V8, P299, DOI 10.1046/J.1354-1013.2002.00505.X##KAUPPI PE, 1992, SCIENCE, V256, P70, DOI 10.1126/SCIENCE.256.5053.70##KICKLIGHTER DW, 1999, TELLUS B, V51, P343, DOI 10.1034/J.1600-0889.1999.00017.X##KIRSCHBAUM MUF, 1998, GLOB CHANGE BIOL, V4, P23, DOI 10.1046/J.1365-2486.1998.00103.X##KIRSCHBAUM MUF, 1999, TELLUS B, V51, P871, DOI 10.1034/J.1600-0889.1999.T01-4-00002.X##KORNER C, 1994, WHOLE PLANT PERSPECT, P173##KRAMER K, 2002, GLOBAL CHANGE BIOL, V8, P213, DOI 10.1046/J.1365-2486.2002.00471.X##LAW BE, 2002, AGR FOREST METEOROL, V113, P97, DOI 10.1016/S0168-1923(02)00104-1##LE MAIRE G, 2005, TREE PHYSIOL, V25, P859, DOI 10.1093/TREEPHYS/25.7.859##LEUNING R, 1990, BOUND-LAY METEOROL, V53, P63, DOI 10.1007/BF00122463##LEUNING R, 1997, J EXP BOT, V48, P345, DOI 10.1093/JXB/48.2.345##LIOZON R, 2000, TREE PHYSIOL, V20, P239##LONG SP, 1991, PLANT CELL ENVIRON, V14, P729, DOI 10.1111/J.1365-3040.1991.TB01439.X##LOUSTAU D, 2005, TREE PHYSIOL, V25, P813, DOI 10.1093/TREEPHYS/25.7.813##MEDLYN BE, 1999, ECOL MODEL, V124, P69, DOI 10.1016/S0304-3800(99)00148-9##MEDLYN BE, 2002, PLANT CELL ENVIRON, V25, P1155, DOI 10.1046/J.1365-3040.2002.00890.X##MEDLYN BE, 2001, NEW PHYTOL, V149, P247, DOI 10.1046/J.1469-8137.2001.00028.X##MEIRESONNE L, 2003, J HYDROL, V270, P230, DOI 10.1016/S0022-1694(02)00284-6##MINKKINEN K, 2002, GLOBAL CHANGE BIOL, V8, P785, DOI 10.1046/J.1365-2486.2002.00504.X##MONTCRIEFF JB, 1996, CHANGE BIOL, V2, P231##MONTEITH J L, 1965, SYMP SOC EXP BIOL, V19, P205##MYNENI RB, 2001, P NATL ACAD SCI USA, V98, P14784, DOI 10.1073/PNAS.261555198##NABUURS GJ, 2003, GLOBAL CHANGE BIOL, V9, P152, DOI 10.1046/J.1365-2486.2003.00570.X##NABUURS GJ, 2002, GLOBAL CHANGE BIOL, V8, P304, DOI 10.1046/J.1354-1013.2001.00470.X##NOLAN WG, 1976, BIOCHIM BIOPHYS ACTA, V440, P461, DOI 10.1016/0005-2728(76)90034-7##OGEE J, 2003, GLOBAL CHANGE BIOL, V9, P697, DOI 10.1046/J.1365-2486.2003.00628.X##PARTON WJ, 1987, SOIL SCI SOC AM J, V51, P1173, DOI 10.2136/SSSAJ1987.03615995005100050015X##PORTE A, 1999, THESIS U ORSAY PARIS##RAMBAL S, 2003, GLOBAL CHANGE BIOL, V9, P1813, DOI 10.1111/J.1365-2486.2003.00687.X##RAPP M, 1978, PROBLEMES ECOLOGIE, P129##REICHSTEIN M, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003430##REICHSTEIN M, 2002, GLOBAL CHANGE BIOL, V8, P999, DOI 10.1046/J.1365-2486.2002.00530.X##RYAN MG, 1991, ECOL APPL, V1, P157, DOI 10.2307/1941808##SALA A, 1996, AGR FOREST METEOROL, V78, P203, DOI 10.1016/0168-1923(95)02250-3##SELLERS PJ, 1997, SCIENCE, V275, P502, DOI 10.1126/SCIENCE.275.5299.502##SPITTERS CJT, 1986, AGR FOREST METEOROL, V38, P231, DOI 10.1016/0168-1923(86)90061-4##SPITTERS CJT, 1986, AGR FOREST METEOROL, V38, P217, DOI 10.1016/0168-1923(86)90060-2##STERNBERG P, 2000, AGR FOREST METEOROL, V79, P1##VALENTINI R, 1999, GREENHOUSE GASES THE, P1##VERHOEF W, 1985, REMOTE SENS ENVIRON, V17, P165, DOI 10.1016/0034-4257(85)90072-0##VERHOEF W, 1984, REMOTE SENS ENVIRON, V16, P125, DOI 10.1016/0034-4257(84)90057-9##WHITE A, 2000, GLOBAL CHANGE BIOL, V6, P227, DOI 10.1046/J.1365-2486.2000.00302.X##WHITE A, 2000, GLOBAL CHANGE BIOL, V6, P817, DOI 10.1046/J.1365-2486.2000.00358.X##WULLSCHLEGER SD, 1993, J EXP BOT, V44, P907, DOI 10.1093/JXB/44.5.907",82,2020-11-20,NA
J,WOS:000243235100001,2006,A PREDICTION RULE FOR SHOULDER PAIN RELATED SICK LEAVE: A PROSPECTIVE COHORT STUDY,"BACKGROUND: SHOULDER PAIN IS COMMON IN PRIMARY CARE, AND HAS AN UNFAVOURABLE OUTCOME IN MANY PATIENTS. INFORMATION ABOUT PREDICTORS OF SHOULDER PAIN RELATED SICK LEAVE IN WORKERS IS SCARCE AND INCONSISTENT. THE OBJECTIVE WAS TO DEVELOP A CLINICAL PREDICTION RULE FOR CALCULATING THE RISK OF SHOULDER PAIN RELATED SICK LEAVE FOR INDIVIDUAL WORKERS, DURING THE 6 MONTHS FOLLOWING FIRST CONSULTATION IN GENERAL PRACTICE. METHODS: A PROSPECTIVE COHORT STUDY WITH 6 MONTHS FOLLOW-UP WAS CONDUCTED AMONG 350 WORKERS WITH A NEW EPISODE OF SHOULDER PAIN. POTENTIAL PREDICTORS INCLUDED THE RESULTS OF A PHYSICAL EXAMINATION, SOCIODEMOGRAPHIC VARIABLES, DISEASE CHARACTERISTICS (DURATION OF SYMPTOMS, SICK LEAVE IN THE 2 MONTHS PRIOR TO CONSULTATION, PAIN INTENSITY, DISABILITY, COMORBIDITY), PHYSICAL ACTIVITY, PHYSICAL WORK LOAD, PSYCHOLOGICAL FACTORS, AND THE PSYCHOSOCIAL WORK ENVIRONMENT. THE MAIN OUTCOME MEASURE WAS SICK LEAVE DURING 6 MONTHS FOLLOWING FIRST CONSULTATION IN GENERAL PRACTICE. RESULTS: RESPONSE RATE TO THE FOLLOW-UP QUESTIONNAIRE AT 6 MONTHS WAS 85%. DURING THE 6 MONTHS AFTER FIRST CONSULTATION 30% (89/298) OF THE WORKERS REPORTED SICK LEAVE. 16% (47) REPORTED 10 DAYS SICK LEAVE OR MORE. SICK LEAVE DURING THIS PERIOD WAS PREDICTED IN A MULTIVARIABLE MODEL BY A LONGER DURATION OF SICK LEAVE PRIOR TO CONSULTATION, MORE SHOULDER PAIN, A PERCEIVED CAUSE OF STRAIN OR OVERUSE DURING REGULAR ACTIVITIES, AND CO-EXISTING PSYCHOLOGICAL COMPLAINTS. THE DISCRIMINATIVE ABILITY OF THE PREDICTION MODEL WAS SATISFACTORY WITH AN AREA UNDER THE CURVE OF 0.70 (95% CI 0.64-0.76). CONCLUSION: ALTHOUGH 30% OF ALL WORKERS WITH SHOULDER PAIN REPORTED SICK LEAVE DURING FOLLOW-UP, THE DURATION OF SICK LEAVE WAS LIMITED TO A FEW DAYS IN MOST WORKERS. WE DEVELOPED A PREDICTION RULE AND A SCORE CHART THAT CAN BE USED BY GENERAL PRACTITIONERS AND OCCUPATIONAL HEALTH CARE PROVIDERS TO CALCULATE THE ABSOLUTE RISK OF SICK LEAVE IN INDIVIDUAL WORKERS WITH SHOULDER PAIN, WHICH MAY HELP TO IDENTIFY WORKERS WHO NEED ADDITIONAL ATTENTION. THE PERFORMANCE AND APPLICABILITY OF OUR MODEL NEEDS TO BE TESTED IN OTHER WORKING POPULATIONS WITH SHOULDER PAIN TO ENABLE VALID AND RELIABLE USE OF THE SCORE CHART IN EVERYDAY PRACTICE.",LOW-BACK-PAIN; ACTIVE MOTOR TESTS; GENERAL-PRACTICE; FUNCTIONAL STATUS; PRIMARY-CARE; DISORDERS; COMPLAINTS; POPULATION; PREVALENCE; ABSENCE,NA,BMC MUSCULOSKELETAL DISORDERS,"KUIJPERS, T##VAN DER WINDT, DAWM##VAN DER HEIJDEN, GJMG##TWISK, JWR##VERGOUWE, Y##BOUTER, LM","VU UNIV MED CTR, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS. AMSTERDAM SCH ALLIED HLTH CARE EDUC, DEPT ALLIED HLTH CARE RES, AMSTERDAM, NETHERLANDS. MAASTRICHT UNIV, CARE & PUBL HLTH RE INST, MAASTRICHT, NETHERLANDS. KEELE UNIV, PRIMARY CARE MUSCULOSKELETAL RES CTR, KEELE, STAFFS, ENGLAND. UNIV MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS. VU UNIV MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, AMSTERDAM, NETHERLANDS.",ORTHOPEDICS; RHEUMATOLOGY,ORTHOPEDICS; RHEUMATOLOGY,"BERG SGM, 2001, INSTRUMENTS MEASUR 2##BERGMAN GJD, 2004, ANN INTERN MED, V141, P432, DOI 10.7326/0003-4819-141-6-200409210-00008##BERGMAN GJD, 2004, MANIPULATIVE THERAPY##BEURSKENS AJ, 1999, J MANIP PHYSIOL THER, V22, P144, DOI 10.1016/S0161-4754(99)70127-2##BOT SD, 2005, PREDICTORS OUTCOME N, V30, P459##BOT SDM, 2005, ANN RHEUM DIS, V64, P118, DOI 10.1136/ARD.2003.019349##CROFT P, 1996, BRIT MED J, V313, P601##DE JONGE J, 2000, J OCCUP HEALTH PSYCHOL, V5, P256, DOI 10.1037/1076-8998.5.2.256##EFRON B, 1993, INTRO BOOTSTRAP MONO##HARRELL FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4##HOOZEMANS MJM, 2002, OCCUP ENVIRON MED, V59, P696, DOI 10.1136/OEM.59.10.696##HOSMER DW, 1989, APPL LOGISTIC REGRES, P135##IJZELENBERG W, 2004, OCCUP ENVIRON MED, V61, P806, DOI 10.1136/OEM.2003.011635##JUSTICE AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016##KARASEK R. A., 1985, JOB CONTENT QUESTION##KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498##KUIJPERS T, 2004, PAIN, V109, P420, DOI 10.1016/J.PAIN.2004.02.017##LOTTERS F, 2005, SCAND J WORK ENV HEA, V31, P367##LUIME JJ, 2004, SCAND J RHEUMATOL, V33, P73, DOI 10.1080/03009740310004667##MIRANDA H, 2001, OCCUP ENVIRON MED, V58, P528, DOI 10.1136/OEM.58.8.528##NEER CS, 1983, CLIN ORTHOP RELAT R, P70##*NHG, 2003, PRACT GUID##SOLEMBERTOFT E, 1996, SCAND J REHABIL MED, V28, P71##TERLUIN B, 2004, WORK STRESS, V18, P187, DOI 10.1080/0267837042000297535##VAN DER HEIJDEN GJMG, 1999, BEST PRACT RES CL RH, V13, P287, DOI 10.1053/BERH.1999.0021##VAN DER HEIJDEN GJMG, 2000, J CLIN EPIDEMIOL, V53, P29, DOI 10.1016/S0895-4356(99)00078-5##VAN DER LINDEN M, 2005, COMPLAINTS DISORDERS##VAN DER WINDT DAWM, 1998, BRIT MED J, V317, P1292, DOI 10.1136/BMJ.317.7168.1292##VAN DER WINDT DAWM, 2000, OCCUP ENVIRON MED, V57, P433, DOI 10.1136/OEM.57.7.433##VANDERWINDT DAWM, 1996, BRIT J GEN PRACT, V46, P519##VENDRIG A, 1998, NEDERLANDS TIJDSCHRI, V18, P11##VLAEYEN JWS, 1999, PAIN, V82, P297, DOI 10.1016/S0304-3959(99)00054-8##WEEVERS HJA, 2005, FAM PRACT, V22, P197, DOI 10.1093/FAMPRA/CMH727##WESTERBERG CE, 1996, SCAND J REHABIL MED, V28, P63##WINTERS JC, 1999, RHEUMATOLOGY, V38, P160, DOI 10.1093/RHEUMATOLOGY/38.2.160##WINTERS JC, 1999, HUISARTS WET, V42, P222",33,2020-11-20,NA
J,WOS:000242933800002,2006,DETERMINANTS OF DAILY SMOKING IN TURKISH YOUNG ADULTS IN THE NETHERLANDS,"BACKGROUND: AS LITTLE IS KNOWN ABOUT THE DETERMINANTS OF SMOKING IN LARGE ETHNIC MINORITIES IN THE NETHERLANDS AND OTHER WESTERN EUROPEAN COUNTRIES, WE STUDIED THE DETERMINANTS OF SMOKING YOUNG ADULT OFFSPRING OF TURKISH MIGRANTS TO THE NETHERLANDS. METHODS: CROSS-SECTIONAL SURVEY OF 439 TURKISH ADULTS ( 18 - 28 Y) IN 2003. SMOKERS WERE COMPARED WITH NEVER SMOKERS FOR FIVE GROUPS OF DETERMINANTS: DEMOGRAPHIC AND SOCIOECONOMIC FACTORS, BEHAVIORAL AND EMOTIONAL PROBLEMS, PSYCHOSOCIAL FACTORS, AND CULTURAL FACTORS. ASSOCIATIONS WERE MEASURED BY PREVALENCE RATE RATIOS. RESULTS: PREVALENCES FOR MEN WERE 51% FOR DAILY SMOKING, 12% FOR FORMER SMOKING, AND 38% FOR NEVER SMOKING. FOR WOMEN THEY WERE 44%, 11%, AND 47%, RESPECTIVELY. WITHOUT ADJUSTMENT FOR OTHER DETERMINANTS, HIGHER PREVALENCE WAS ASSOCIATED WITH: EMOTIONAL PROBLEMS, BOREDOM, LIFE EVENTS, AND BEING MALE; AND, SPECIFICALLY AMONG WOMEN, WITH LOW SELF-ESTEEM AND HAVING CHILDREN. THE STRONGEST DETERMINANTS OF DAILY SMOKING IN MULTIVARIATE MODELS WERE ALCOHOL USE AND DEMOGRAPHIC AND SOCIO-ECONOMIC FACTORS. OF THE CULTURAL FACTORS ONLY STRONG MUSLIM IDENTIFICATION WAS ASSOCIATED WITH LOWER SMOKING PREVALENCE. CONCLUSION: THE HIGH PREVALENCE OF SMOKING WARRANTS ACTION. MANY OF THE WELL-KNOWN DETERMINANTS OF SMOKING IN WESTERN COUNTRIES WERE ALSO IMPORTANT AMONG YOUNG ADULTS FROM ETHNIC MINORITIES. WOMEN WITH CHILDREN AND PEOPLE OF A LOW EDUCATIONAL LEVEL DESERVE SPECIAL ATTENTION.",CIGARETTE-SMOKING; MOROCCAN IMMIGRANTS; NICOTINE DEPENDENCE; EUROPEAN COUNTRIES; HEALTH BEHAVIOR; WOMENS SMOKING; UNITED-STATES; RISK-FACTORS; PREVALENCE; ACCULTURATION,NA,BMC PUBLIC HEALTH,"VAN OORT, FVA##VAN DER ENDE, J##CRIJNEN, AAM##VERHULST, FC##MACKENBACH, JP##JOUNG, IMA","UNIV MED CTR, ERASMUS MC, DEPT PUBL HLTH, ROTTERDAM, NETHERLANDS. UNIV MED CTR, ERASMUS MC SOPHIA, DEPT CHILD & ADOLESCENT PSYCHIAT, ROTTERDAM, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","ACEVEDO-GARCIA D, 2005, SOC SCI MED, V61, P1223, DOI 10.1016/J.SOCSCIMED.2005.01.027##ACHENBACH T.M., 2003, MANUAL ASEBA ADULT F##BENGIARSLAN L, 1997, SOC PSYCH PSYCH EPID, V32, P477, DOI 10.1007/BF00789143##BERRY JW, 1992, CROSS CULTURAL PSYCH, V14, P459##BHOPAL R, 2004, BMJ-BRIT MED J, V328, PA76##BRESLAU N, 2004, BIOL PSYCHIAT, V55, P69, DOI 10.1016/S0006-3223(03)00317-2##BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P1069##BUSH J, 2003, BRIT MED J, V326, P962, DOI 10.1136/BMJ.326.7396.962##DIFRANZA JR, 2004, PEDIATRICS, V113, P1007##GEORGIADES K, 2006, J ADOLESCENT HEALTH, V38, P443E1##GISKES K, 2005, J EPIDEMIOL COMMUN H, V59, P395, DOI 10.1136/JECH.2004.025684##GRAHAM H, 2006, J EPIDEMIOL COMMUN H, V60, P228, DOI 10.1136/JECH.2005.039784##GRIESLER PAMELA C, 2002, NICOTINE TOB RES, V4, P79, DOI 10.1080/14622200110103197##GRITZ ER, 1998, PREV MED, V27, P365, DOI 10.1006/PMED.1998.0300##HU MC, 2006, AM J PUBLIC HEALTH, V96, P299, DOI 10.2105/AJPH.2004.057232##HUISMAN M, 2005, TOB CONTROL, V14, P106, DOI 10.1136/TC.2004.008573##JUN HJ, 2004, AM J PUBLIC HEALTH, V94, P2170, DOI 10.2105/AJPH.94.12.2170##KANDEL DB, 2004, AM J PUBLIC HEALTH, V94, P128, DOI 10.2105/AJPH.94.1.128##KOYCU B, 1997, NED TIJDSCHR GENEESKD, V141, P882##LAAKSONEN M, 2001, EUR J PUBLIC HEALTH, V11, P294, DOI 10.1093/EURPUB/11.3.294##LANDRINE H, 2004, J BEHAV MED, V27, P527, DOI 10.1007/S10865-004-0002-0##LINDSTROM M, 2002, EUR J PUBLIC HEALTH, V12, P287, DOI 10.1093/EURPUB/12.4.287##LOPEZ AD, 1994, TOB CONTROL, V3, P242, DOI DOI 10.1136/TC.3.3.242##MA GX, 2002, AM J PUBLIC HEALTH, V92, P1013, DOI 10.2105/AJPH.92.6.1013##MURRAY CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8##NICHOLS TR, 2006, J ADOLESCENT HEALTH, V38, P369, DOI 10.1016/J.JADOHEALTH.2005.04.016##NIERKENS V, 2005, HEALTH EDUC RES, V20, P622, DOI 10.1093/HER/CYH026##NIERKENS V, 2006, THESIS U AMSTERDAM A##OGEL K, 2003, BAGIMLILIK DERGISI, V4, P105##PEARLIN LI, 1981, J HEALTH SOC BEHAV, V22, P337, DOI 10.2307/2136676##PEREZ-STABLE EJ, 2001, AM J PUBLIC HEALTH, V91, P1424, DOI 10.2105/AJPH.91.9.1424##PHALET K, 2000, ISLAM MULTICULTURAL##PIERCE JP, 1989, AM J PUBLIC HEALTH, V79, P152, DOI 10.2105/AJPH.79.2.152##REIJNEVELD SA, 1998, J EPIDEMIOL COMMUN H, V52, P298, DOI 10.1136/JECH.52.5.298##REINE I, 2004, PUBLIC HEALTH, V118, P337, DOI 10.1016/J.PUHE.2003.10.008##ROGERS E. M., 1971, COMMUNICATION INNOVA##ROSENBERG M., 1989, SOC ADOLESCENT SELF##SALANT T, 2003, SOC SCI MED, V57, P71, DOI 10.1016/S0277-9536(02)00300-3##SATMAN I, 2002, DIABETES CARE, V25, P1551, DOI 10.2337/DIACARE.25.9.1551##SONG YJ, 2004, PREV MED, V39, P147, DOI 10.1016/J.YPMED.2004.01.013##SPIEGELMAN D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/AJE/KWI188##STEPTOE A, 2001, BRIT J PSYCHOL, V92, P659, DOI 10.1348/000712601162400##TUCKER JS, 2003, J ADOLESCENT HEALTH, V32, P314, DOI 10.1016/S1054-139X(02)00709-7##TYAS SL, 1998, TOB CONTROL, V7, P409, DOI 10.1136/TC.7.4.409##UITEWAAL PJM, 2004, PREV MED, V39, P1068, DOI 10.1016/J.YPMED.2004.04.009##VAN OORT FVA, 2006, ETHNIC HEALTH, V11, P133, DOI 10.1080/13557850500460280##VANLEEST LAT, 2002, CARDIOVASCULAR DIS N##WEDEN MM, 2006, SOC SCI MED, V62, P303, DOI 10.1016/J.SOCSCIMED.2005.06.009##WILLIAMS DR, 2003, AM J PUBLIC HEALTH, V93, P200, DOI 10.2105/AJPH.93.2.200##WILLIAMS JM, 2004, ADDICT BEHAV, V29, P1067, DOI 10.1016/J.ADDBEH.2004.03.009",18,2020-11-20,NA
J,WOS:000242933800001,2006,STUDY PROTOCOL OF A CLUSTER RANDOMISED CONTROLLED TRIAL INVESTIGATING THE EFFECTIVENESS OF A TAILORED ENERGY BALANCE PROGRAMME FOR RECENT RETIREES,"BACKGROUND: PEOPLE IN TRANSITIONAL LIFE STAGES, SUCH AS OCCUPATIONAL RETIREMENT, ARE LIKELY TO GAIN WEIGHT AND ACCUMULATE ABDOMINAL FAT MASS CAUSED BY CHANGES IN PHYSICAL ACTIVITY AND DIET. HENCE, RETIREES ARE AN IMPORTANT TARGET GROUP FOR WEIGHT GAIN PREVENTION PROGRAMMES, AS DESCRIBED IN THE PRESENT PAPER. METHODS/DESIGN: A SYSTEMATIC AND STEPWISE APPROACH ( INTERVENTION MAPPING) IS USED TO DEVELOP A LOW-INTENSITY ENERGY BALANCE INTERVENTION PROGRAMME FOR RECENT RETIREES. THIS ONE-YEAR, LOW-INTENSITY MULTIFACETED PROGRAMME AIMS TO PREVENT ACCUMULATION OF ABDOMINAL FAT MASS AND GENERAL WEIGHT GAIN BY INCREASING AWARENESS OF ENERGY BALANCE AND INFLUENCING RELATED BEHAVIOURS OF PARTICIPANTS' PREFERENCE. THESE BEHAVIOURS ARE PHYSICAL ACTIVITY, FIBRE INTAKE, PORTION SIZE AND FAT CONSUMPTION. THE EFFECTIVENESS OF THE INTERVENTION PROGRAMME IS TESTED IN A CLUSTER RANDOMISED CONTROLLED TRIAL. MEASUREMENTS OF ANTHROPOMETRY, PHYSICAL ACTIVITY, ENERGY INTAKE, AND RELATED PSYCHOSOCIAL DETERMINANTS ARE PERFORMED AT BASELINE AND REPEATED AT 6 MONTHS FOR INTERMEDIATE EFFECT, AT 12 MONTHS TO EVALUATE SHORT-TERM INTERVENTION EFFECTS AND AT 24 MONTHS TO TEST THE SUSTAINABILITY OF THE EFFECTS. DISCUSSION: THIS INTERVENTION PROGRAMME IS UNIQUE IN ITS FOCUS ON RETIREES AND ENERGY BALANCE. IT AIMS AT INCREASING AWARENESS AND TAKES INTO ACCOUNT PERSONAL PREFERENCES OF THE USERS BY OFFERING SEVERAL OPTIONS FOR BEHAVIOUR CHANGE. MOREOVER, THE INTERVENTION PROGRAMME IS EVALUATED AT SHORT-TERM AND LONG-TERM AND INCLUDES CONSECUTIVE OUTCOME MEASURES ( DETERMINANTS, BEHAVIOUR AND BODY COMPOSITION).",FOOD-FREQUENCY QUESTIONNAIRE; PHYSICAL-ACTIVITY SCALE; LOW-FAT DIETS; WEIGHT-GAIN; WAIST CIRCUMFERENCE; OBESITY PREVENTION; RELATIVE VALIDITY; ELDERLY PASE; RISK-FACTORS; FIBER,NA,BMC PUBLIC HEALTH,"WERKMAN, A##SCHUIT, AJ##KWAK, L##KREMERS, SPJ##VISSCHER, TLS##KOLK, FJ##SCHOUTEN, EG","UNIV WAGENINGEN & RES CTR, DEPT HUMAN NUTR, NL-6700 EV WAGENINGEN, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, NL-3720 BA BILTHOVEN, NETHERLANDS. MAASTRICHT UNIV, DEPT HUMAN BIOL, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, DEPT HLTH EDUC & PROMOT, NL-6200 MD MAASTRICHT, NETHERLANDS. VRIJE UNIV AMSTERDAM, INST HLTH SCI, NL-1081 HV AMSTERDAM, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","AARTS H, 1997, HEALTH EDUC RES, V12, P363, DOI 10.1093/HER/12.3.363##ANDERSON JW, 2001, AM J CLIN NUTR, V74, P579##ASTRUP A, 2000, INT J OBESITY, V24, P1545, DOI 10.1038/SJ.IJO.0801453##ASTRUP A, 2002, P NUTR SOC, V61, P299, DOI 10.1079/PNS2002149##ASTRUP A, 2001, PUBLIC HEALTH NUTR, V4, P499##BARANOWSKI T, 1999, ANNU REV NUTR, V19, P17, DOI 10.1146/ANNUREV.NUTR.19.1.17##BARTHOLOMEW LK, 2000, INTERVENTION MAPPING##BRUG J, 1997, AM J HEALTH PROMOT, V12, P25, DOI 10.4278/0890-1171-12.1.25##BRUG J, 2003, AM J CLIN NUTR, V77, P1028S, DOI 10.1093/AJCN/77.4.1028S##BRUG J, 2000, APPETITE, V34, P285, DOI 10.1006/APPE.2000.0322##BRUG J, 1995, APPETITE, V25, P285, DOI 10.1006/APPE.1995.0062##BRUG J, 1999, PATIENT EDUC COUNS, V36, P145, DOI 10.1016/S0738-3991(98)00131-1##CAMPBELL MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/BMJ.328.7441.702##CARRARO R, 2003, EUR J CLIN NUTR, V57, PS94, DOI 10.1038/SJ.EJCN.1601808##DAVEY RC, 2004, BRIT J SPORT MED, V38, P360, DOI 10.1136/BJSM.2003.007443##DE VRIES H, 1998, PSYCHOL HEALTH, V13, P369, DOI 10.1080/08870449808406757##FEUNEKES GIJ, 1993, AM J CLIN NUTR, V58, P489##FOGELHOLM M, 2000, OBES REV, V1, P95, DOI 10.1046/J.1467-789X.2000.00016.X##FRENCH SA, 2001, ANNU REV PUBL HEALTH, V22, P309, DOI 10.1146/ANNUREV.PUBLHEALTH.22.1.309##GILL T, 2005, P NUTR SOC, V64, P255, DOI 10.1079/PNS2005425##HARDEMAN W, 2000, INT J OBESITY, V24, P131, DOI 10.1038/SJ.IJO.0801100##HILL JO, 2000, J NUTR, V130, P284S##HILL JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/SCIENCE.280.5368.1371##HOWARTH NC, 2001, NUTR REV, V59, P129, DOI 10.1111/J.1753-4887.2001.TB07001.X##HOWARTH NC, 2005, J AM DIET ASSOC, V105, P1365, DOI 10.1016/J.JADA.2005.06.001##JAKICIC JM, 2005, AM J CLIN NUTR, V82, P226S, DOI 10.1093/AJCN/82.1.226S##KIM S, 2006, INT J EPIDEMIOL, V35, P60, DOI 10.1093/IJE/DYI255##KREBSSMITH SM, 1995, AM J HEALTH PROMOT, V10, P98, DOI 10.4278/0890-1171-10.2.98##KREMERS SPJ, 2005, SPORTS MED, V35, P923, DOI 10.2165/00007256-200535110-00001##KREMERS SPJ, 2005, EUR J CLIN NUTR, V59, P498, DOI 10.1038/SJ.EJCN.1602100##KREMERS SPJ, 2006, INT J BEHAV NUTR PHY, V3, DOI 10.1186/1479-5868-3-9##KUMANYIKA S, 2002, INT J OBESITY, V26, P425, DOI 10.1038/SJ.IJO.0801938##LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/BMJ.311.6998.158##LECHNER L, 1997, J NUTR EDUC, V29, P313, DOI 10.1016/S0022-3182(97)70245-0##LEDIKWE JH, 2005, J NUTR, V135, P905##LUDWIG DS, 1999, JAMA-J AM MED ASSOC, V282, P1539, DOI 10.1001/JAMA.282.16.1539##MCCRORY MA, 2002, J NUTR, V132, P3830S##MULLIS RM, 2004, CIRCULATION, V110, PE484, DOI 10.1161/01.CIR.0000140072.49273.6B##NOOYENS ACJ, 2005, PUBLIC HEALTH NUTR, V8, P1266, DOI 10.1079/PHN2005756##O'BRIEN A, 2000, J BEHAV MED, V23, P465, DOI 10.1023/A:1005525115828##OCKE MC, 1997, INT J EPIDEMIOL, V26, PS37, DOI 10.1093/IJE/26.SUPPL_1.S37##OCKE MC, 1997, INT J EPIDEMIOL, V26, PS49, DOI 10.1093/IJE/26.SUPPL_1.S49##PI-SUNYER X, 2003, SCIENCE, V299, P859, DOI 10.1126/SCIENCE.1082319##PROCHASKA JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38##RITZ P, 2001, PUBLIC HEALTH NUTR, V4, P561##ROBERTS SB, 2002, J AM COLL NUTR, V21, P140S, DOI 10.1080/07315724.2002.10719211##ROGERS E. M, 1995, DIFFUSION INNOVATION##ROLLS BJ, 2000, J NUTR, V130, P268S, DOI 10.1093/JN/130.2.268S##ROLLS BJ, 2002, AM J CLIN NUTR, V76, P1207##RONDA G, 2001, HEALTH PROMOT INT, V16, P305, DOI 10.1093/HEAPRO/16.4.305##SCHUIT AJ, 1997, J CLIN EPIDEMIOL, V50, P541, DOI 10.1016/S0895-4356(97)00010-3##SEIDELL JC, 2000, EUR J CLIN NUTR, V54, PS33, DOI 10.1038/SJ.EJCN.1601023##SLAVIN JL, 2005, NUTRITION, V21, P411, DOI 10.1016/J.NUT.2004.08.018##SMITH AT, 2003, P NUTR SOC, V62, P455, DOI 10.1079/PNS2003260##ST-ONGE MP, 2005, CURR OPIN CLIN NUTR, V8, P523##STAFLEU A, 2003, VOEDING NU, V5, P21##VAN ASSEMA P, 2001, J HUM NUTR DIET, V14, P377, DOI 10.1046/J.1365-277X.2001.00310.X##VANDELANOTTE C, 2005, ANN BEHAV MED, V29, P138, DOI 10.1207/S15324796ABM2902_8##VERPLANKEN B, 2003, J APPL SOC PSYCHOL, V33, P1313, DOI 10.1111/J.1559-1816.2003.TB01951.X##VISSCHER TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/ANNUREV.PUBLHEALTH.22.1.355##WARDLE J, 2000, APPETITE, V34, P269, DOI 10.1006/APPE.1999.0311##WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4##WEARS RL, 2002, ACAD EMERG MED, V9, P330, DOI 10.1197/AEMJ.9.4.330##WEBBER J, 2003, P NUTR SOC, V62, P539, DOI 10.1079/PNS2003256##WEINSTEIN ND, 1998, HEALTH PSYCHOL, V17, P290, DOI 10.1037/0278-6133.17.3.290##WEINSTEIN ND, 1992, HEALTH PSYCHOL, V11, P170, DOI 10.1037/0278-6133.11.3.170##WING RR, 2001, ANNU REV NUTR, V21, P323, DOI 10.1146/ANNUREV.NUTR.21.1.323##YAO MJ, 2001, NUTR REV, V59, P247",3,2020-11-20,NA
J,WOS:000242575100012,2006,CHANGE IN THE MORPHOLOGY OF RBTIOPO4 INTRODUCED BY THE PRESENCE OF NB,"RBTIOPO4 CRYSTALS DOPED WITH NB SHOW AN IMPORTANT FLATTENING OF THE MORPHOLOGY THAT MAKES THEIR USE DIFFICULT IN NONLINEAR OPTICS APPLICATIONS. HERE, WE IDENTIFY THE POSSIBLE CAUSES OF THIS MORPHOLOGICAL CHANGE: NB ACTS AS AN IMPURITY THAT BRAKES THE VELOCITY OF GROWTH OF THE {100} FACES AND MODIFIES THE GROWTH MECHANISM OF {201} FACES OF THE CRYSTALS. WE ALSO PROPOSE A WAY OF OBTAINING ISOMETRIC CRYSTALS BY FORCING CRYSTAL GROWTH IN THE A CRYSTALLOGRAPHIC DIRECTION. THIS CAUSES A NEW CHANGE IN MORPHOLOGY WITH BENEFITS FOR LATER NONLINEAR OPTICS APPLICATIONS DUE TO THE LARGER USEFUL AREA OBTAINED IN THE X-Y PLANE.",POTASSIUM TITANYL PHOSPHATE; SEEDED SOLUTION GROWTH; KTP SINGLE-CRYSTALS; KTIOPO4; NIOBIUM,NA,CRYSTAL GROWTH & DESIGN,"CARVAJAL, JJ##WOENSDREGT, CF##SOLE, R##DIAZ, F##AGUILO, M","UNIV ROVIRA & VIRGILI, TARRAGONA 43007, SPAIN. UNIV UTRECHT, DEPT PETROL, FAC GEOSCI, NL-3508 TA UTRECHT, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CRYSTALLOGRAPHY; MATERIALS SCIENCE, MULTIDISCIPLINARY",CHEMISTRY; CRYSTALLOGRAPHY; MATERIALS SCIENCE,"BOLT RJ, 1992, J CRYST GROWTH, V19, P329##CARVAJAL JJ, 2000, CHEM MATER, V12, P3171, DOI 10.1021/CM000305C##CARVAJAL JJ, 2003, CHEM MATER, V15, P2730, DOI 10.1021/CM0340936##CARVAJAL JJ, 2001, CRYST GROWTH DES, V1, P479, DOI 10.1021/CG015528##CARVAJAL JJ, 2003, CHEM MATER, V15, P2338, DOI 10.1021/CM034044T##CARVAJAL JJ, 2002, CHEM MATER, V14, P3136, DOI 10.1021/CM0200745##CARVAJAL JJ, UNPUB##CARVAJAL JJ, 2001, J ALLOY COMPD, V231, P323##CHENG L. K., 1993, FERROELECTRICS, V142, P209, DOI 10.1080/00150199308237899##CHENG LT, 1994, APPL PHYS LETT, V64, P155, DOI 10.1063/1.111549##DOWTY E, 1995, SHAPE WINDOWS VERSIO##HAGERMAN ME, 1995, CHEM MATER, V7, P602, DOI 10.1021/CM00052A004##ILIEV K, 1990, J CRYST GROWTH, V100, P225, DOI 10.1016/0022-0248(90)90626-V##KIM JH, 1995, J CRYST GROWTH, V147, P343, DOI 10.1016/0022-0248(94)00637-7##MOORTHY SG, 1999, MAT SCI ENG B-SOLID, V60, P88, DOI 10.1016/S0921-5107(99)00031-8##OSELEDCHIK YS, 1994, OPT MATER, V3, P237, DOI 10.1016/0925-3467(94)90035-3##PAVLOVA N. I., 1986, SOVIET PHYSICS - CRYSTALLOGRAPHY, V31, P87##PUOCHOU JL, 1984, RECH AEROSPATIALE, V3, P13##RICO M, 1998, J PHYS-CONDENS MAT, V10, P10101, DOI 10.1088/0953-8984/10/44/015##SATYANARAYAN MN, 1999, CRIT REV SOLID STATE, V24, P103, DOI 10.1080/10408439991329189##SOLE R, 1997, CHEM MATER, V9, P2745, DOI 10.1021/CM960644Z##THOMAS PA, 1992, ACTA CRYSTALLOGR B, V48, P401, DOI 10.1107/S0108768192002465##VORONKOVA V. I., 1986, SOVIET PHYSICS - CRYSTALLOGRAPHY, V31, P123##VORONKOVA VI, 2005, CRYSTALLOGR REP+, V50, P137, DOI 10.1134/1.1857260##WANG JY, 1997, CRYST RES TECHNOL, V32, P319, DOI 10.1002/CRAT.2170320216",12,2020-11-20,NA
J,WOS:000242575100014,2006,CRYSTAL STRUCTURE OF ASPARTAME ANHYDRATE FROM POWDER DIFFRACTION DATA. STRUCTURAL ASPECTS OF THE DEHYDRATION PROCESS OF ASPARTAME,"ASPARTAME HAS THREE PSEUDO-POLYMORPHIC FORMS, TWO HYDRATES AND A HEMI-HYDRATE, FOR WHICH CRYSTAL STRUCTURES WERE DETERMINED FROM SINGLE-CRYSTAL DIFFRACTION DATA. THIS PAPER PRESENTS THE CRYSTAL STRUCTURE OF THE ANHYDRATE, WHICH WAS OBTAINED BY DEHYDRATING THE HEMI-HYDRATE. THE CRYSTAL STRUCTURE OF ASPARTAME ANHYDRATE, L-ASPARTYL-L-PHENYLALANINE METHYL ESTER, WAS DETERMINED FROM X-RAY POWDER DIFFRACTION DATA. ASPARTAME ANHYDRATE CRYSTALLIZES IN THE MONOCLINIC SYSTEM WITH SPACE GROUP P2(1) AND CELL PARAMETERS: A = 19.4078( 10) ANGSTROM, B = 4.9605(2) ANGSTROM, C = 15.6547(9) ANGSTROM, BETA = 94.876( 2), V = 1501.65(14) ANGSTROM(3). FINAL RIETVELD REFINEMENT RESULTED IN R-WP = 2.26 AND A GOOF OF 2.30. COMPARING THE HYDRATES OF ASPARTAME AND USING MOLECULAR MODELING PROVIDE A COMPLETE AND CLEAR PICTURE OF THE DEHYDRATION BEHAVIOR OF ASPARTAME AT THE MOLECULAR LEVEL.",PREFERRED ORIENTATION; HEMIHYDRATE; SWEETENER; BEHAVIOR; MODEL; FORM,NA,CRYSTAL GROWTH & DESIGN,"GUGUTA, C##MEEKES, H##DE GELDER, R","RADBOUD UNIV NIJMEGEN, INST MOL & MAT, NL-6525 ED NIJMEGEN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CRYSTALLOGRAPHY; MATERIALS SCIENCE, MULTIDISCIPLINARY",CHEMISTRY; CRYSTALLOGRAPHY; MATERIALS SCIENCE,"*ACC INC, 2002, CER 2 US GUID##BOULTIF A, 1991, J APPL CRYSTALLOGR, V24, P987, DOI 10.1107/S0021889891006441##BRUKER AXS, 2003, TOPAS V2 1 GEN PROF##*CAMBR CRYST DAT C, 2005, CAMBR STRUCT DAT##CHEARY RW, 1992, J APPL CRYSTALLOGR, V25, P109, DOI 10.1107/S0021889891010804##CUPPEN HM, 2005, CRYST GROWTH DES, V5, P917, DOI 10.1021/CG049676M##CUPPEN HM, 2004, CRYST GROWTH DES, V4, P989, DOI 10.1021/CG049975B##DAVID W. I. F., 2004, DASH VERSION 3 0##DOLLASE WA, 1986, J APPL CRYSTALLOGR, V19, P267, DOI 10.1107/S0021889886089458##FLORENCE AJ, 2005, J APPL CRYSTALLOGR, V38, P249, DOI 10.1107/S0021889804032662##HATADA M, 1985, J AM CHEM SOC, V107, P4279, DOI 10.1021/JA00300A034##HOWARD CJ, 2000, J APPL CRYSTALLOGR, V33, P1434, DOI 10.1107/S0021889800012267##LEUNG SS, 1998, J PHARM SCI, V87, P508, DOI 10.1021/JS970250M##LEUNG SS, 1997, J PHARM SCI, V86, P64, DOI 10.1021/JS960228D##LEUNG SS, 1998, J PHARM SCI-US, V87, P501, DOI 10.1021/JS970249N##MEGURO T, 2000, J PEPT RES, V56, P97, DOI 10.1034/J.1399-3011.2000.00732.X##PAWLEY GS, 1981, J APPL CRYSTALLOGR, V14, P357, DOI 10.1107/S0021889881009618##YOUNG RA, 1996, RIETVELD REFINEMENT",24,2020-11-20,NA
J,WOS:000242276000008,2006,"SELF-DUAL, NOT SELF-POLAR","THE SMALLEST NUMBER OF POINTS OF AN INCIDENCE STRUCTURE WHICH IS SELF-DUAL BUT NOT SELF-POLAR IS 7. FOR NON-BINARY STRUCTURES (WHERE A ""POINT"" MAY OCCUR MORE THAN ONCE IN A ""BLOCK"") THE NUMBER IS 6. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NA,INCIDENCE STRUCTURE; SELF-DUAL; SELF-POLAR,DISCRETE MATHEMATICS,"BROUWER, AE##CAMERON, PJ##HAEMERS, WH##PREECE, DA","UNIV LONDON QUEEN MARY & WESTFIELD COLL, SCH MATH SCI, LONDON E1 4NS, ENGLAND. EINDHOVEN UNIV TECHNOL, DEPT MATH, NL-5600 MB EINDHOVEN, NETHERLANDS. TILBURG UNIV, DEPT ECONOMETR & OPERAT RES, NL-5000 LE TILBURG, NETHERLANDS. UNIV KENT, INST MATH STAT & ACTUARIAL SCI, CANTERBURY CT2 7NF, KENT, ENGLAND.",MATHEMATICS,MATHEMATICS,"CAMERON PJ, 1991, QMW MATHS NOTES, V13##JENDROL S, 1989, DISCRETE MATH, V74, P325, DOI 10.1016/0012-365X(89)90144-1##STARKE EP, 1976, AM MATH MONTHLY, V83, P201",1,2020-11-20,NA
J,WOS:000242276000013,2006,5-CHROMATIC STRONGLY REGULAR GRAPHS,"IN THIS PAPER, WE BEGIN THE DETERMINATION OF ALL PRIMITIVE STRONGLY REGULAR GRAPHS WITH CHROMATIC NUMBER EQUAL TO 5. USING EIGENVALUE TECHNIQUES, WE SHOW THAT THERE ARE AT MOST 43 POSSIBLE PARAMETER SETS FOR SUCH A GRAPH. FOR EACH PARAMETER SET, WE MUST DECIDE WHICH STRONGLY REGULAR GRAPHS, IF ANY, POSSESSING THE SET ARE 5-CHROMATIC. IN THIS WAY, WE DEAL COMPLETELY WITH 34 OF THESE PARAMETER SETS USING EIGENVALUE TECHNIQUES AND COMPUTER ENUMERATIONS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",UNIQUENESS,STRONGLY REGULAR GRAPHS; CHROMATIC NUMBER,DISCRETE MATHEMATICS,"FIALA, NC##HAEMERS, WH","ST CLOUD STATE UNIV, DEPT MATH, ST CLOUD, MN 56301 USA. TILBURG UNIV, DEPT ECONOMETR & OPERAT RES, TILBURG, NETHERLANDS.",MATHEMATICS,MATHEMATICS,"BROUWER A. E., 1996, CRC DISCR MATH APPL, P667##BROUWER AE, 1983, J GRAPH THEOR, V7, P455, DOI 10.1002/JGT.3190070411##BROUWER AE, 1993, EUR J COMBIN, V14, P397, DOI 10.1006/EUJC.1993.1044##BROUWER AE, 1992, DISCRETE MATH, V106, P77, DOI 10.1016/0012-365X(92)90532-K##BROUWER AE, 2003, DISCRETE MATH, V264, P13, DOI 10.1016/S0012-365X(02)00546-0##BROUWER AE, 1984, ENUMERATION DESIGN, P85##BUSSEMAKER FC, 1989, EUR J COMBIN, V10, P413, DOI 10.1016/S0195-6698(89)80014-9##BUSSEMAKER FC, 2000, DESIGN CODE CRYPTOGR, V21, P77, DOI 10.1023/A:1008379409579##CAMERON P. J., 1978, SELECTED TOPICS GRAP, P337##CAMERON PJ, 1972, MATH Z, V128, P1, DOI 10.1007/BF01111509##CAMERON PJ, 1991, DESIGNS GRAPHS CODES##COOLSAET K, 2006, ELECTRON J COMB, V13##CVETKOVI D.M, 1971, PUB ELEK FAK U BEOGR, V354/356, P1##FIALA NC, 2002, THESIS OHIO STATE U##GEWIRTZ A, 1969, T NEW YORK ACAD SCI, V31, P656, DOI 10.1111/J.2164-0947.1969.TB01990.X##GEWIRTZ A, 1970, CAN J MATH, V21, P915##GODSIL C, 2001, ALGEBRAIC GRAPH THEO##GOETHALS JM, 1970, CANADIAN J MATH, V22, P597, DOI 10.4153/CJM-1970-067-9##HAEMERS W, 1993, LONDON MATH SOC LECT, V191, P175##HAEMERS W. H., 1996, DESIGNS, CODES AND CRYPTOGRAPHY, V8, P145, DOI 10.1023/A:1018037025910##HAEMERS WH, 1995, LINEAR ALGEBRA APPL, V226, P593, DOI 10.1016/0024-3795(95)00199-2##HAEMERS WH, 2001, EUR J COMBIN, V22, P839, DOI 10.1006/EUJC.2001.0507##HAEMERS WH, 1979, THESIS EINDHOVEN U T##HIGMAN DG, 1968, MATH Z, V105, P110, DOI 10.1007/BF01110435##HOFFMAN A., 1970, GRAPH THEORY ITS APP, P79##HOFFMAN AJ, 1963, AM MATH MON, V70, P30, DOI 10.2307/2312780##HOFFMAN AJ, 1960, IBM J RES DEV, V4, P497, DOI 10.1147/RD.45.0497##MARCUS M., 1964, SURVEY MATRIX THEORY##MATHON R., 1981, ARS COMBINATORIA, V11, P131##MCKAY B.D., 2001, AUSTRALAS J COMBIN, V24, P293##PAULUS AJL, 1983, C MATR GRAPHS ORD 26##PAYNE SE, 1984, FINITE GEN QUADRANGL##ROZENFEL'D M.Z., 1973, USP MAT NAUK, V28, P197##SEIDEL J. J., 1968, LINEAR ALGEBRA APPL, V1, P281, DOI DOI 10.1016/0024-3795(68)90008-6##SEIDEL JJ, 1979, LONDON MATH SOC LECT, V38, P157##SOICHER LH, 1993, DIMACS SERIES DISCRE, V11, P287##SPENCE E., 2000, ELECT J COMBIN, V7##VAN DAM ER, 1999, J ALGEBR COMB, V10, P69, DOI 10.1023/A:1018628204156##VANLINT JH, 1992, COURSE COMBINATORICS##WILBRINK HA, 1983, INDAG MATH, V45, P117##WOLFRAM S, 1991, MATHEMATICA",5,2020-11-20,NA
J,WOS:000242367000038,2006,SELF-ORGANIZED MONOLAYER OF MESO-TETRADODECYLPORPHYRIN COORDINATED TO AU(111),"THE STRUCTURE OF MOLECULAR MONOLAYERS FORMED AT THE INTERFACE BETWEEN ATOMICALLY FLAT SURFACES AND A SOLUTION OF FREE-BASE MESO-TETRADODECYLPORPHYRINS (H(2)PS) WAS EXAMINED BY SCANNING TUNNELING MICROSCOPY (STM) AT THE LIQUID/SOLID INTERFACE. ON THE SURFACE OF GRAPHITE (HOPG), H(2)PS FORM A WELL-ORDERED MONOLAYER CHARACTERIZED BY AN OBLIQUE UNIT CELL. ON AU(111), H(2)PS FORM A SELF-ORGANIZED MONOLAYER COMPRISED OF TWO DISTINCT DOMAIN TYPES. IN BOTH TYPES OF DOMAINS, THE DENSITY OF THE PORPHYRIN CORES IS INCREASED IN COMPARISON TO THE ARRANGEMENT OBSERVED ON HOPG. ALSO, HIGH-RESOLUTION STM IMAGES REVEAL THAT, IN CONTRAST TO WHAT IS OBSERVED ON HOPG, PHYSISORPTION ON AU(111) INDUCES A DISTORTION OF THE PORPHYRIN MACROCYCLE OUT OF PLANARITY. BY USING X-RAY PHOTOELECTRON SPECTROSCOPY, WE DEMONSTRATE THAT THIS IS LIKELY TO BE DUE TO THE COORDINATION OF THE LONE PAIRS OF THE IMINIC (-C=N-) NITROGEN ATOMS OF THE PORPHYRIN MACROCYCLE TO AU(111).",SCANNING-TUNNELING-MICROSCOPY; RAY PHOTOELECTRON-SPECTROSCOPY; ASSEMBLED MONOLAYERS; N-ALKANES; PORPHYRINS; SURFACE; FULLERENES; ADSORPTION; GRAPHITE; NETWORK,NA,JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,"KATSONIS, N##VICARIO, J##KUDERNAC, T##VISSER, J##POLLARD, MM##FERINGA, BL","UNIV GRONINGEN, DEPT ORGAN & MOL INORGAN CHEM, STRATINGH INST, NL-9747 AG GRONINGEN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"DE FEYTER S, 2003, CHEM SOC REV, V32, P139, DOI 10.1039/B206566P##GASSMAN PG, 1992, J AM CHEM SOC, V114, P9990, DOI 10.1021/JA00051A035##GOLL JG, 1996, J AM CHEM SOC, V118, P8344, DOI 10.1021/JA9610904##GOTTFRIED JM, 2006, J AM CHEM SOC, V128, P5644, DOI 10.1021/JA0610333##HULSKEN B, 2006, JPN J APPL PHYS 1, V45, P1953, DOI 10.1143/JJAP.45.1953##IANCU V, 2006, NANO LETT, V6, P820, DOI 10.1021/NL0601886##IKEDA T, 2004, LANGMUIR, V20, P5454, DOI 10.1021/LA049577A##KATSONIS N, 2004, SYNTHETIC MET, V147, P73, DOI 10.1016/J.SYNTHMET.2004.06.045##KATSONIS N, 2003, J AM CHEM SOC, V125, P13682, DOI 10.1021/JA0375737##KIEBELE A, 2006, CHEMPHYSCHEM, V7, P1462, DOI 10.1002/CPHC.200600186##LI WS, 2005, J AM CHEM SOC, V127, P7700, DOI 10.1021/JA0513335##MARCHENKO A, 2002, PHYS REV B, V65, DOI 10.1103/PHYSREVB.65.045414##MARCHENKO A, 2002, LANGMUIR, V18, P1171, DOI 10.1021/LA010827M##MENDOZA SM, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2137694##OTSUKI J, 2005, J AM CHEM SOC, V127, P10400, DOI 10.1021/JA0531778##POIRIER GE, 1997, CHEM REV, V97, P1117, DOI 10.1021/CR960074M##QIU XH, 2000, J AM CHEM SOC, V122, P5550, DOI 10.1021/JA994271P##QIU XH, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.196806##RABE JP, 1991, SCIENCE, V253, P424, DOI 10.1126/SCIENCE.253.5018.424##SCHUURMANS N, 2004, J AM CHEM SOC, V126, P13884, DOI 10.1021/JA046124J##SCUDIERO L, 2000, J PHYS CHEM B, V104, P11899, DOI 10.1021/JP002292W##SCUDIERO L, 2001, J AM CHEM SOC, V123, P4073, DOI 10.1021/JA0100726##SENGE MO, 2006, CHEM COMMUN, P243, DOI 10.1039/B511389J##SPILLMANN H, 2006, ADV MATER, V18, P275, DOI 10.1002/ADMA.200501734##WATEL G, 1993, SURF SCI, V281, PL297, DOI 10.1016/0039-6028(93)90843-9##XIE ZX, 2002, LANGMUIR, V18, P3113, DOI 10.1021/LA010869A##YOKOYAMA T, 2001, NATURE, V413, P619, DOI 10.1038/35098059##YOKOYAMA T, 2004, J CHEM PHYS, V121, P11993, DOI 10.1063/1.1819877##YOSHIMOTO S, 2004, J AM CHEM SOC, V126, P8540, DOI 10.1021/JA0485210##ZHOU YS, 2005, CHEM PHYS LETT, V403, P140, DOI 10.1016/J.CPLETT.2005.01.006",72,2020-11-20,NA
J,WOS:000242808200013,2006,PHARMACOGENETICS OF ABCG2 AND ADVERSE REACTIONS TO GEFITINIB,"GEFITINIB IS AN INHIBITOR OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE WITH ACTIVITY IN NON-SMALL-CELL LUNG CANCER. DIARRHEA AND SKIN TOXICITY ARE PROMINENT GEFITINIB-RELATED ADVERSE EVENTS THAT POTENTIALLY LIMIT ITS USE. GEFITINIB IS A SUBSTRATE FOR ABCG2 (ABCP, BCRP, MXR), A POLYMORPHIC EFFLUX TRANSPORTER PROTEIN THAT IS HIGHLY EXPRESSED IN THE INTESTINES AND LIVER. HERE WE INVESTIGATED ASSOCIATIONS BETWEEN ALLELIC VARIANTS OF EGFR, ABCG2, AND THE TRANSPORTER PROTEIN ABCB1 WITH DIARRHEA AND SKIN TOXICITY IN GEFITINIB-TREATED PATIENTS. ONE VARIANT, A COMMON FUNCTIONAL SINGLE-NUCLEOTIDE POLYMORPHISM (SNP) IN THE ABCG2 GENE, WAS ASSOCIATED WITH DIARRHEA IN 124 PATIENTS TREATED WITH ORAL GETITINIB 250 MG ONCE DAILY; SEVEN (44%) OF 16 PATIENTS HETEROZYGOUS FOR ABCG2 421C > A (Q141K) DEVELOPED DIARRHEA, VERSUS ONLY 13 (12%) OF 108 PATIENTS HOMOZYGOUS FOR THE WILD-TYPE SEQUENCE (P = .0046). HOWEVER, THIS SNP WAS NOT ASSOCIATED WITH SKIN TOXICITY (P = .99). THE FINDING SUGGESTS THAT PATIENTS WITH REDUCED ABCG2 ACTIVITY DUE TO A COMMON GENETIC VARIANT ARE AT INCREASED RISK FOR SUBSTRATE DRUG-INDUCED DIARRHEA, WITH IMPLICATIONS FOR OPTIMIZING TREATMENT WITH SUCH AGENTS.",GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE; MULTIDRUG TRANSPORTER; DRUG-RESISTANCE; INTRON 1; INHIBITOR; IRESSA; POLYMORPHISM; EXPRESSION,NA,JOURNAL OF THE NATIONAL CANCER INSTITUTE,"CUSATIS, G##GREGORC, V##LI, J##SPREAFICO, A##INGERSOLL, RG##VERWEIJ, J##LUDOVINI, V##VILLA, E##HIDALGO, M##SPARREBOOM, A##BAKER, SD","ST JUDE CHILDRENS HOSP, PHARMACEUT SCI DEPT, MEMPHIS, TN 38105 USA. JOHNS HOPKINS UNIV, SIDNEY KIMMEL COMPREHENS CANC CTR, BALTIMORE, MD USA. UNIV HOSP SAN RAFFAELE, SCI INST, DIV MED ONCOL, MILAN, ITALY. POLICLIN MONTELUCE HOSP, DIV MED ONCOL, PERUGIA, ITALY. JOHNS HOPKINS UNIV, SCH MED, INST GENET MED, BALTIMORE, MD USA. ERAMUS MD DANIEL HOED CANC CTR, DEPT MED ONCOL, ROTTERDAM, NETHERLANDS. NCI, BETHESDA, MD USA.",ONCOLOGY,ONCOLOGY,"AMADOR ML, 2004, CANCER RES, V64, P9139, DOI 10.1158/0008-5472.CAN-04-1036##BUERGER H, 2000, CANCER RES, V60, P854##BURGER H, 2004, BLOOD, V104, P2940, DOI 10.1182/BLOOD-2004-04-1398##ELKIND NB, 2005, CANCER RES, V65, P1770, DOI 10.1158/0008-5472.CAN-04-3303##FUKUOKA M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038##GARDNER ER, 2006, IN PRESS CURR PHARMA, P4##GEBHARDT F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/JBC.274.19.13176##GREGORC V, 2004, CLIN CANCER RES, V10, P6006, DOI 10.1158/1078-0432.CCR-03-0770##HINTZE J, 2004, NUMBER CRUCHER STAT##IMAI Y, 2002, MOL CANCER THER, V1, P611##JANNE PA, 2005, J CLIN ONCOL, V23, P3227, DOI 10.1200/JCO.2005.09.985##JOHNSON BE, 2005, J CLIN ONCOL, V23, P6813, DOI 10.1200/JCO.2005.97.008##KRIS MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/JAMA.290.16.2149##LEPPER ER, 2005, PHARMACOGENOMICS, V6, P115, DOI 10.1517/14622416.6.2.115##LI J, 2005, CLIN CANC RES S, V11S, P120##LI J, 2005, P AM SOC CLIN ONCOL, V41##LIU WQ, 2005, CANCER RES, V65, P46##MOHAMED MK, 2005, ANN ONCOL, V16, P780, DOI 10.1093/ANNONC/MDI157##NAKAMURA Y, 2005, CANCER RES, V65, P1541, DOI 10.1158/0008-5472.CAN-03-2417##OZVEGY-LACZKA C, 2004, MOL PHARMACOL, V65, P1485, DOI 10.1124/MOL.65.6.1485##PEREZ-SOLER R, 2005, J CLIN ONCOL, V23, P5235, DOI 10.1200/JCO.2005.00.6916##RAZIS E, 2005, ANTI-CANCER DRUG, V16, P191, DOI 10.1097/00001813-200502000-00011##SCHUETTE W, 2005, ONKOLOGIE, V28, P195, DOI 10.1159/000084204##SONG PF, 2006, J CLIN PHARMACOL, V46, P373, DOI 10.1177/0091270005284387##STEWART CF, 2004, CANCER RES, V64, P7491, DOI 10.1158/0008-5472.CAN-04-0096##WANG DX, 2005, PHARMACOGENET GENOM, V15, P693, DOI 10.1097/01.FPC.0000178311.02878.83",188,2020-11-20,NA
J,WOS:000242808200014,2006,CHANGE IN COGNITIVE FUNCTION AFTER CHEMOTHERAPY: A PROSPECTIVE LONGITUDINAL STUDY IN BREAST CANCER PATIENTS,"SOME BREAST CANCER SURVIVORS EXPERIENCE COGNITIVE DECLINE FOLLOWING CHEMOTHERAPY. WE PROSPECTIVELY EXAMINED CHANGES IN COGNITIVE PERFORMANCE AMONG HIGH-RISK BREAST CANCER PATIENTS WHO HAD RECEIVED HIGH-DOSE CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN (CTC GROUP; N = 28) OR STANDARD-DOSE CHEMOTHERAPY WITH 5-FLUOROURACIL, EPIRUBICIN, AND CYCLOPHOSPHAMIDE (FEC GROUP; N = 39); STAGE-I BREAST CANCER PATIENTS WHO HAD RECEIVED NO SYSTEMIC CHEMOTHERAPY (NO-CT GROUP; N = 57); AND HEALTHY CONTROL SUBJECTS (N = 60). ALL PATIENTS UNDERWENT NEUROPSYCHOLOGIC TESTING BEFORE AND 6 MONTHS AFTER TREATMENT (12-MONTH INTERVAL); CONTROL SUBJECTS UNDERWENT REPEATED TESTING OVER A 6-MONTH INTERVAL. NO DIFFERENCES IN COGNITIVE FUNCTIONING BETWEEN THE FOUR GROUPS WERE OBSERVED AT THE FIRST ASSESSMENT. MORE OF THE CTC GROUP THAN THE CONTROL SUBJECTS EXPERIENCED A DETERIORATION IN COGNITIVE PERFORMANCE OVER TIME (25% VERSUS 6.7%; ODDS RATIO [OR] = 5.3, 95% CONFIDENCE INTERVAL [CI] = 1.3 TO 21.2, P = .02). NO SUCH DIFFERENCE WAS OBSERVED FOR THE FEC OR THE NO-CT GROUPS (FEC VERSUS CONTROL: OR = 2.2, 95% CI = 0.5 TO 9.1, P = .27; NO-CT VERSUS CONTROL: OR = 2.2,95% CL = 0.6 TO 8.0; P=.21). SOME CYTOTOXIC TREATMENT FOR BREAST CANCER AFFECTS COGNITION IN A SUBSET OF WOMEN.",RECEIVING ADJUVANT CHEMOTHERAPY; AGE-RELATED DIFFERENCES; MENOPAUSAL SYMPTOMS; DOSE CHEMOTHERAPY; WOMEN; PERFORMANCE; IMPAIRMENT; CARCINOMA; FATIGUE; INVENTORY,NA,JOURNAL OF THE NATIONAL CANCER INSTITUTE,"SCHAGEN, SB##MULLER, MJ##BOOGERD, W##MELLENBERGH, GJ##VAN DAM, FSAM","ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT PSYCHOSOCIAL RES & EPIDEMIOL, NL-1066 CX AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, DEPT PSYCHOL, AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT NEUROONCOL, AMSTERDAM, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"AHLES TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485##ALPHERTS W, 1994, FEPSY IRON PSYCHE HE##AMERICAN PSYCHIATRIC ASSOCIATION, 2004, DIAGN STAT MAN MENT, P6##BENDER CM, 2006, PSYCHO-ONCOLOGY, V15, P422, DOI 10.1002/PON.964##BREZDEN CB, 2000, J CLIN ONCOL, V18, P2695, DOI 10.1200/JCO.2000.18.14.2695##CASTELLON SA, 2004, J CLIN EXP NEUROPSYC, V26, P955, DOI 10.1080/13803390490510905##DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/BS.3830190102##FAN HGM, 2005, J CLIN ONCOL, V23, P8025, DOI 10.1200/JCO.2005.01.6550##HAMMES J, 1978, STROOP KLEUR WOORD T##JENKINS V, 2006, BRIT J CANCER, V94, P828, DOI 10.1038/SJ.BJC.6603029##LUTEIJN F, 1973, GIT GRONINGER INTELL##MAASSEN GH, 2000, J CLIN EXP NEUROPSYC, V22, P622, DOI 10.1076/1380-3395(200010)22:5;1-9;FT622##REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271##RODENHUIS S, 2003, NEW ENGL J MED, V349, P7, DOI 10.1056/NEJMOA022794##SCHAGEN SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G##SCHMAND B., 1992, NEDERLANDSE LEESTEST##SHILLING V, 2005, BREAST, V14, P142, DOI 10.1016/J.BREAST.2004.10.004##SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O##TANNOCK IF, 2004, J CLIN ONCOL, V22, P2233, DOI 10.1200/JCO.2004.08.094##TCHEN N, 2003, J CLIN ONCOL, V21, P4175, DOI 10.1200/JCO.2003.01.119##TEMKIN NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068##VAN DAM FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/JNCI/90.3.210##VANDERLINDEN M, 1994, BRIT J PSYCHOL, V85, P145##WECHSLER D., 1987, WECHSLER MEMORY SCAL##WEFEL JS, 2004, CANCER-AM CANCER SOC, V101, P466, DOI 10.1002/CNCR.20393##WEFEL JS, 2004, CANCER-AM CANCER SOC, V100, P2292, DOI 10.1002/CNCR.20272##WIENEKE MH, 1995, PSYCHO-ONCOL, V4, P61, DOI 10.1002/PON.2960040108##ZEEF EJ, 1993, PSYCHOPHYSIOLOGY, V30, P138, DOI 10.1111/J.1469-8986.1993.TB01727.X",196,2020-11-20,NA
J,WOS:000242759000002,2006,DISTRIBUTED FIBER-OPTIC TEMPERATURE SENSING FOR HYDROLOGIC SYSTEMS,"[ 1] INSTRUMENTS FOR DISTRIBUTED FIBER-OPTIC MEASUREMENT OF TEMPERATURE ARE NOW AVAILABLE WITH TEMPERATURE RESOLUTION OF 0.01 DEGREES C AND SPATIAL RESOLUTION OF 1 M WITH TEMPORAL RESOLUTION OF FRACTIONS OF A MINUTE ALONG STANDARD FIBER-OPTIC CABLES USED FOR COMMUNICATION WITH LENGTHS OF UP TO 30,000 M. WE DISCUSS THE SPECTRUM OF FIBER-OPTIC TOOLS THAT MAY BE EMPLOYED TO MAKE THESE MEASUREMENTS, ILLUMINATING THE POTENTIAL AND LIMITATIONS OF THESE METHODS IN HYDROLOGIC SCIENCE. THERE ARE TRADE-OFFS BETWEEN PRECISION IN TEMPERATURE, TEMPORAL RESOLUTION, AND SPATIAL RESOLUTION, FOLLOWING THE SQUARE ROOT OF THE NUMBER OF MEASUREMENTS MADE; THUS BRIEF, SHORT MEASUREMENTS ARE LESS PRECISE THAN MEASUREMENTS TAKEN OVER LONGER SPANS IN TIME AND SPACE. FIVE ILLUSTRATIVE APPLICATIONS DEMONSTRATE CONFIGURATIONS WHERE THE DISTRIBUTED TEMPERATURE SENSING (DTS) APPROACH COULD BE USED: ( 1) LAKE BOTTOM TEMPERATURES USING EXISTING COMMUNICATION CABLES, ( 2) TEMPERATURE PROFILE WITH DEPTH IN A 1400 M DEEP DECOMMISSIONED MINE SHAFT, ( 3) AIR-SNOW INTERFACE TEMPERATURE PROFILE ABOVE A SNOW-COVERED GLACIER, ( 4) AIR-WATER INTERFACIAL TEMPERATURE IN A LAKE, AND ( 5) TEMPERATURE DISTRIBUTION ALONG A FIRST-ORDER STREAM. IN EXAMPLES 3 AND 4 IT IS SHOWN THAT BY WINDING THE FIBER AROUND A CYLINDER, VERTICAL SPATIAL RESOLUTION OF MILLIMETERS CAN BE ACHIEVED. THESE TOOLS MAY BE OF EXCEPTIONAL UTILITY IN OBSERVING A BROAD RANGE OF HYDROLOGIC PROCESSES, INCLUDING EVAPORATION, INFILTRATION, LIMNOLOGY, AND THE LOCAL AND OVERALL ENERGY BUDGET SPANNING SCALES FROM 0.003 TO 30,000 M. THIS RANGE OF SCALES CORRESPONDS WELL WITH MANY OF THE AREAS OF GREATEST OPPORTUNITY FOR DISCOVERY IN HYDROLOGIC SCIENCE.",AQUIFER; FIBERS,NA,WATER RESOURCES RESEARCH,"SELKER, JS##THEVENAZ, L##HUWALD, H##MALLET, A##LUXEMBURG, W##DE GIESEN, NV##STEJSKAL, M##ZEMAN, J##WESTHOFF, M##PARLANGE, MB","OREGON STATE UNIV, DEPT BIOL & ECOL ENGN, CORVALLIS, OR 97331 USA. ECOLE POLYTECH FED LAUSANNE, SCH ARCHITECTURE CIVIL & ENVIRONM ENGN, CH-1015 LAUSANNE, SWITZERLAND. ECOLE POLYTECH FED LAUSANNE, LAB NANOPHOTON & METROL, CH-1015 LAUSANNE, SWITZERLAND. DELFT UNIV TECHNOL, FAC CIVIL ENGN & GEOSCI, NL-2628 CN DELFT, NETHERLANDS. MASARYK UNIV, FAC SCI, INST GEOL SCI, BRNO 60177, CZECH REPUBLIC.",ENVIRONMENTAL SCIENCES; LIMNOLOGY; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; MARINE & FRESHWATER BIOLOGY; WATER RESOURCES,"HENNINGES J, 2003, 7 FKPE WORKSH BOHRL##KALOUS J, 2005, 20 WORLD MIN C EXP 2##KASHYAP R, 1999, FIBER BRAGG GRATINGS##KURASHIMA T, 1990, OPT LETT, V15, P1038, DOI 10.1364/OL.15.001038##LOHEIDE SP, 2006, ENVIRON SCI TECHNOL, V40, P3336, DOI 10.1021/ES0522074##MACFARLANE PA, 2002, HYDROGEOL J, V10, P662, DOI 10.1007/S10040-002-0223-7##MEASURES R.M., 2001, STRUCTURAL MONITORIN##NIKLES M, 1997, J LIGHTWAVE TECHNOL, V15, P1842, DOI 10.1109/50.633570##OTHONOS A, 1997, REV SCI INSTRUM, V68, P4309, DOI 10.1063/1.1148392##PINZON JE, 1995, BOUND-LAY METEOROL, V76, P323, DOI 10.1007/BF00709237##RAO YJ, 1997, J LIGHTWAVE TECHNOL, V15, P779, DOI 10.1109/50.580812##SCHMUGGE TJ, 2002, ADV WATER RESOUR, V25, P1367, DOI 10.1016/S0309-1708(02)00065-9##SCHULTZ GA, 1988, J HYDROL, V100, P239, DOI 10.1016/0022-1694(88)90187-4##WEHR A, 1999, ISPRS J PHOTOGRAMM, V54, P68, DOI 10.1016/S0924-2716(99)00011-8",326,2020-11-20,NA
J,WOS:000242759000001,2006,ASSESSMENT OF GRAVITY RECOVERY AND CLIMATE EXPERIMENT (GRACE) TEMPORAL SIGNATURE OVER THE UPPER ZAMBEZI,"[1] THE TEMPORAL SIGNATURE OF TERRESTRIAL STORAGE CHANGES INFERRED FROM THE GRAVITY RECOVERY AND CLIMATE EXPERIMENT ( GRACE) HAS BEEN ASSESSED BY COMPARISON WITH OUTPUTS FROM A CALIBRATED HYDROLOGICAL MODEL ( LUMPED ELEMENTARY WATERSHED (LEW)) OF THE UPPER ZAMBEZI AND SURROUNDINGS AND AN INSPECTION OF THE WITHIN-MONTH GROUND TRACK COVERAGE OF GRACE TOGETHER WITH SPATIAL-TEMPORAL RAINFALL PATTERNS. THE COMPARISON OF THE HYDROLOGICAL MODEL WITH GRACE REVEALS TEMPORAL INCONSISTENCIES BETWEEN BOTH DATA SETS. BECAUSE THE LEW MODEL HAS BEEN CALIBRATED AND VALIDATED WITH INDEPENDENT DATA SOURCES, WE BELIEVE THAT THIS IS A GRACE ARTIFACT. THE WITHIN-MONTH GROUND TRACK COVERAGE SHOWS AN IRREGULAR ORBIT BEHAVIOR WHICH MAY WELL CAUSE ALIASING IN THE GRACE MONTHLY DECONVOLUTIONS. THIS ALIASING IS THE MOST PROBABLE CAUSE OF OBSERVED TEMPORAL INCONSISTENCIES BETWEEN GRACE AND OTHER DATA SETS.",DATA ASSIMILATION; WATER-BALANCE; RIVER-BASIN; EVAPOTRANSPIRATION; VARIABILITY; EVAPORATION; SYSTEMS; SCALE,NA,WATER RESOURCES RESEARCH,"WINSEMIUS, HC##SAVENIJE, HHG##VAN DE GIESEN, NC##VAN DEN HURK, BJJM##ZAPREEVA, EA##KLEES, R","DELFT UNIV TECHNOL, DEPT WATER MANAGEMENT, NL-2600 GA DELFT, NETHERLANDS. DELFT UNIV TECHNOL, DEPT PHYS & SPACE GEODESY, NL-2600 GA DELFT, NETHERLANDS. ROYAL NETHERLANDS METEOROL INST, NL-3730 AE DE BILT, NETHERLANDS.",ENVIRONMENTAL SCIENCES; LIMNOLOGY; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; MARINE & FRESHWATER BIOLOGY; WATER RESOURCES,"ANDERSEN OB, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023574##BERBERY EH, 1999, MON WEATHER REV, V127, P2654, DOI 10.1175/1520-0493(1999)127<2654:MMBORS>2.0.CO;2##BEVEN K, 1992, HYDROL PROCESS, V6, P279, DOI 10.1002/HYP.3360060305##BEVEN K, 2001, J HYDROL, V249, P11, DOI 10.1016/S0022-1694(01)00421-8##HAN SC, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022382##HERMAN A, 1997, INT J REMOTE SENS, V18, P2147, DOI 10.1080/014311697217800##MOHAMED YA, 2005, THESIS UNESCO IHE I##NEW M, 2002, CLIMATE RES, V21, P1, DOI 10.3354/CR021001##RODELL M, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020873##RODELL M, 2004, B AM METEOROL SOC, V85, P381, DOI 10.1175/BAMS-85-3-381##ROWLANDS DD, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021908##SAVENIJE HHG, 2004, HYDROL PROCESS, V18, P1507, DOI 10.1002/HYP.5563##SAVENIJE HHG, 1997, HYDROL EARTH SYST SC, V1, P93, DOI 10.5194/HESS-1-93-1997##SCHMIDT M, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025509##SENEVIRATNE SI, 2004, J CLIMATE, V17, P2039, DOI [10.1175/1520-0442(2004)017<2039:ICITWS>2.0.CO;2, 10.1175/1520-0442(2004)017&LT;2039:ICITWS&GT;2.0.CO;2]##SWENSON S, 2003, WATER RESOUR RES, V39, DOI 10.1029/2002WR001808##SWENSON S, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000576##SWENSON SC, 2006, WATER RESOUR RES, V42, DOI 10.1029/2005WR004628##TAPLEY BD, 2004, SCIENCE, V305, P503, DOI 10.1126/SCIENCE.1099192##TRENBERTH KE, 1995, TELLUS A, V47, P287, DOI 10.1034/J.1600-0870.1995.T01-1-00001.X##TRENBERTH KE, 2001, J CLIMATE, V14, P1499, DOI 10.1175/1520-0442(2001)014<1499:QORITT>2.0.CO;2##VAN DEN HURK B, 2005, J CLIMATE, V18, P3536, DOI 10.1175/JCLI3471.1##WAHR J, 1998, J GEOPHYS RES-SOL EA, V103, P30205, DOI 10.1029/98JB02844##WINSEMIUS HC, 2006, HYDROL EARTH SYST SC, V10, P339, DOI 10.5194/HESS-10-339-2006##YEH PJF, 1998, J GEOPHYS RES-ATMOS, V103, P19823, DOI 10.1029/98JD01721",35,2020-11-20,NA
J,WOS:000242546400020,2006,CHMP2B MUTATIONS ARE NOT A CAUSE OF DEMENTIA IN DUTCH PATIENTS WITH FAMILIAL AND SPORADIC FRONTOTEMPORAL DEMENTIA,"MUTATIONS IN THE CHMP2B GENE HAVE BEEN RECENTLY IDENTIFIED IN A LARGE DANISH PEDIGREE WITH AUTOSOMAL DOMINANT FRONTOTEMPORAL DEMENTIA (FTD) LINKED TO CHROMOSOME 3 (FTD3). WE REPORT THE FREQUENCY OF CHMP2B MUTATIONS IN 162 FTD PATIENTS RECRUITED FROM A LARGE POPULATION-BASED STUDY OF FTD CARRIED OUT IN THE NETHERLANDS. OUR RESULTS SUGGEST THAT MUTATIONS IN CHMP2B ARE A RARE CAUSE OF FTD AS COMPARED TO MAPT MUTATIONS. (C) 2006 WILEY-LISS, INC.",COMPLEX,FRONTOTEMPORAL DEMENTIA; CHMP2B; MAPT; MUTATION FREQUENCY,AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS,"RIZZU, P##VAN MIL, SE##ANAR, B##ROSSO, SM##KAAT, LD##HEUTINK, P##VAN SWIETEN, JC","VRIJE UNIV AMSTERDAM, DEPT HUMAN GENET, SECT MED GENOM, MED CTR, NL-1081 BT AMSTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT NEUROL, ROTTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, CTR NEUROGENOM & COGNIT RES, MED CTR, NL-1081 BT AMSTERDAM, NETHERLANDS.",GENETICS & HEREDITY; PSYCHIATRY,GENETICS & HEREDITY; PSYCHIATRY,"BABST M, 2005, TRAFFIC, V6, P2, DOI 10.1111/J.1600-0854.2004.00246.X##BROWN J, 1998, CELL MOL LIFE SCI, V54, P925, DOI 10.1007/S000180050222##BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416##CANNON A, 2006, NEUROSCI LETT, V398, P83, DOI 10.1016/J.NEULET.2005.12.056##HOSLER BA, 2000, JAMA-J AM MED ASSOC, V284, P1664, DOI 10.1001/JAMA.284.13.1664##RADEMAKERS R, 2004, HUM MUTAT, V24, P277, DOI 10.1002/HUMU.20086##ROSSO SM, 2003, BRAIN, V126, P2016, DOI 10.1093/BRAIN/AWG204##SKIBINSKI G, 2005, NAT GENET, V37, P806, DOI 10.1038/NG1609##WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159",30,2020-11-20,NA
J,WOS:000242677300002,2006,THE PATHOGENESIS OF VENOUS THROMBOEMBOLISM: EVIDENCE FOR MULTIPLE INTERRELATED CAUSES,"BACKGROUND: VENOUS THROMBOEMBOLISM (VTE) IS THOUGHT TO RESULT FROM INTERACTIONS BETWEEN MULTIPLE GENETIC AND ENVIRONMENTAL RISK FACTORS. OBJECTIVE: TO ASSESS THE CONTRIBUTION OF MULTIPLE THROMBOPHILIC DEFECTS AND EXOGENOUS RISK FACTORS TO THE ABSOLUTE RISK FOR VTE. DESIGN: RETROSPECTIVE FAMILY COHORT STUDY. SETTING: SINGLE UNIVERSITY HOSPITAL. PARTICIPANTS: 468 RELATIVES OF 91 PROBANDS WITH A SYMPTOMATIC HEREDITARY DEFICIENCY OF PROTEIN S, PROTEIN C, OR ANTITHROMBIN. MEASUREMENTS: ALL RELATIVES WERE TESTED FOR 10 THROMBOPHILIC DEFICIENCIES AND DEFECTS IN ADDITION TO THE INDEX DEFICIENCY AND WERE ASSESSED FOR EXOGENOUS RISK FACTORS (SURGERY, TRAUMA, IMMOBILIZATION, USE OF ORAL CONTRACEPTIVES, AND PREGNANCY). THE AUTHORS COMPARED ANNUAL INCIDENCES AND RELATIVE RISKS FOR VTE IN DEFICIENT AND NONDEFICIENT RELATIVES. RESULTS: ANNUAL INCIDENCES OF VTE IN RELATIVES WITH 0, 1, AND 2 OR MORE ADDITIONAL THROMBOPHILIC DEFICIENCIES OR DEFECTS WERE 1.16 (95% CL, 0.60 TO 2.03), 1.75 (CL, 1.17 TO 2.53), AND 2.64 (CL, 1.67 TO 3.96) PER 100 PERSON-YEARS, RESPECTIVELY, COMPARED WITH 0.06 (CI, 0.002 TO 0.33) PER 100 PERSON-YEARS IN NONDEFICIENT RELATIVES WITHOUT ADDITIONAL DEFICIENCIES OR DEFECTS. ADJUSTED RELATIVE RISKS WERE 16.3 (CI, 2.0 TO 131.0), 50.3 (6.5 TO 389.7), AND 102.8 (12.5 TO 843.4). OF DEFICIENT RELATIVES, 38% WITH NO ADDITIONAL DEFECT, 57% WITH 1 ADDITIONAL DEFECT, AND 81 % WITH 2 OR MORE ADDITIONAL DEFECTS HAD VTE AT AGE 65 YEARS COMPARED WITH 5% OF NONDEFICIENT RELATIVES (P < 0.001). IN DEFICIENT RELATIVES WITH ADDITIONAL DEFICIENCIES OR DEFECTS, EXOGENOUS RISK FACTORS INCREASED THE RISK FOR VTE FROM 1.20% TO 2.51% PER YEAR (RELATIVE RISK, 2.1 [CI, 1.1 TO 4.2]). LIMITATIONS: THIS WAS A RETROSPECTIVE STUDY WITHOUT THE ABILITY TO DISTINGUISH INTERACTIONS BETWEEN SPECIFIC THROMBOPHILIC DEFICIENCIES AND DEFECTS. CONCLUSION: ADDITIONAL THROMBOPHILIC DEFECTS AND EXOGENOUS RISK FACTORS INCREASE THE RISK FOR VTE IN PERSONS WITH HEREDITARY DEFICIENCIES OF PROTEIN S, PROTEIN C, OR ANTITHROMBIN AND PROVIDE EVIDENCE THAT MULTIPLE GENETIC AND ENVIRONMENTAL RISK FACTORS CONTRIBUTE TO VTE.",PROTEIN-S DEFICIENCY; DEEP-VEIN THROMBOSIS; FACTOR-V-LEIDEN; PROSPECTIVE COHORT; RISK-FACTOR; INHERITED THROMBOPHILIA; ANTITHROMBIN-III; FAMILIES; PROTHROMBIN; RESISTANCE,NA,ANNALS OF INTERNAL MEDICINE,"BROUWER, JLP##VEEGER, NJGM##KLUIN-NELEMANS, HC##VAN DER MEER, J","UNIV GRONINGEN, MED CTR, DEPT HEMATOL, DIV HAMEOSTASIS THROMBOSIS & RHEOL, NL-9713 GZ GRONINGEN, NETHERLANDS.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"ALLAART CF, 1995, BRIT MED J, V311, P910##ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/ARCHINTE.151.5.933##ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3##BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064A0##BROUWER JLP, 2005, BRIT J HAEMATOL, V128, P703, DOI 10.1111/J.1365-2141.2005.05371.X##CAPRINI JA, 2004, CIRCULATION, V109, PI4, DOI 10.1161/01.CIR.0000122869.59485.36##CASTAMAN G, 2000, BLOOD COAGUL FIBRIN, V11, P321, DOI 10.1097/00001721-200006000-00002##DANNEBERG J, 1998, CLIN CHEM, V44, P349##DENHEIJER M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203##DESTEFANO V, 1994, THROMB HAEMOSTASIS, V72, P352##EXNER T, 1991, THROMB HAEMOSTASIS, V65, P320##FREZZATO M, 1996, AM J EPIDEMIOL, V143, P1257##KOELEMAN BPC, 1994, BLOOD, V84, P1031##NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/J.1365-2796.1992.TB00565.X##PABINGER I, 1994, THROMB HAEMOSTASIS, V71, P441##REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5##ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O##ROSENDAAL FR, 1999, LANCET, V353, P1167, DOI 10.1016/S0140-6736(98)10266-0##ROSENDAAL FR, 1998, THROMB HAEMOSTASIS, V79, P706##ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P247##SANSON BJ, 1999, BLOOD, V94, P3702##SIMIONI P, 1999, THROMB HAEMOSTASIS, V81, P198##TIRADO I, 2001, HAEMATOLOGICA, V86, P1200##VANBOVEN HH, 1996, THROMB HAEMOSTASIS, V75, P417##VANDENBELT AGM, 1996, CLIN APPL THROMB-HEM, V2, P227, DOI 10.1177/107602969600200402##VOSSEN CY, 2005, J THROMB HAEMOST, V3, P459, DOI 10.1111/J.1538-7836.2005.01197.X##ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/BLOOD.V85.12.3518.BLOODJOURNAL85123518",63,2020-11-20,NA
J,WOS:000242646800003,2006,THE ASSET INTERCOMPARISON OF OZONE ANALYSES: METHOD AND FIRST RESULTS,"THIS PAPER AIMS TO SUMMARISE THE CURRENT PERFORMANCE OF OZONE DATA ASSIMILATION (DA) SYSTEMS, TO SHOW WHERE THEY CAN BE IMPROVED, AND TO QUANTIFY THEIR ERRORS. IT EXAMINES 11 SETS OF OZONE ANALYSES FROM 7 DIFFERENT DA SYSTEMS. TWO ARE NUMERICAL WEATHER PREDICTION (NWP) SYSTEMS BASED ON GENERAL CIRCULATION MODELS (GCMS); THE OTHER FIVE USE CHEMISTRY TRANSPORT MODELS (CTMS). THE SYSTEMS EXAMINED CONTAIN EITHER LINEARISED OR DETAILED OZONE CHEMISTRY, OR NO CHEMISTRY AT ALL. IN MOST ANALYSES, MIPAS (MICHELSON INTERFEROMETER FOR PASSIVE ATMOSPHERIC SOUNDING) OZONE DATA ARE ASSIMILATED; TWO ASSIMILATE SCIAMACHY (SCANNING IMAGING ABSORPTION SPECTROMETER FOR ATMOSPHERIC CHARTOGRAPHY) OBSERVATIONS INSTEAD. ANALYSES ARE COMPARED TO INDEPENDENT OZONE OBSERVATIONS COVERING THE TROPOSPHERE, STRATOSPHERE AND LOWER MESOSPHERE DURING THE PERIOD JULY TO NOVEMBER 2003. BIASES AND STANDARD DEVIATIONS ARE LARGEST, AND SHOW THE LARGEST DIVERGENCE BETWEEN SYSTEMS, IN THE TROPOSPHERE, IN THE UPPER-TROPOSPHERE/LOWER-STRATOSPHERE, IN THE UPPER-STRATOSPHERE AND MESOSPHERE, AND THE ANTARCTIC OZONE HOLE REGION. HOWEVER, IN ANY PARTICULAR AREA, APART FROM THE TROPOSPHERE, AT LEAST ONE SYSTEM CAN BE FOUND THAT AGREES WELL WITH INDEPENDENT DATA. IN GENERAL, NONE OF THE DIFFERENCES CAN BE LINKED TO THE ASSIMILATION TECHNIQUE (KALMAN FILTER, THREE OR FOUR DIMENSIONAL VARIATIONAL METHODS, DIRECT INVERSION) OR THE SYSTEM (CTM OR NWP SYSTEM). WHERE RESULTS DIVERGE, A MAIN EXPLANATION IS THE WAY OZONE IS MODELLED. IT IS IMPORTANT TO CORRECTLY MODEL TRANSPORT AT THE TROPICAL TROPOPAUSE, TO AVOID POSITIVE BIASES AND EXCESSIVE STRUCTURE IN THE OZONE FIELD. IN THE SOUTHERN HEMISPHERE OZONE HOLE, ONLY THE ANALYSES WHICH CORRECTLY MODEL HETEROGENEOUS OZONE DEPLETION ARE ABLE TO REPRODUCE THE NEAR-COMPLETE OZONE DESTRUCTION OVER THE POLE. IN THE UPPER-STRATOSPHERE AND MESOSPHERE (ABOVE 5 HPA), SOME OZONE PHOTOCHEMISTRY SCHEMES CAUSED LARGE BUT EASILY REMEDIED BIASES. THE DIURNAL CYCLE OF OZONE IN THE MESOSPHERE IS NOT CAPTURED, EXCEPT BY THE ONE SYSTEM THAT INCLUDES A DETAILED TREATMENT OF MESOSPHERIC CHEMISTRY. THESE RESULTS INDICATE THAT WHEN GOOD OBSERVATIONS ARE AVAILABLE FOR ASSIMILATION, THE FIRST PRIORITY FOR IMPROVING OZONE DA SYSTEMS IS TO IMPROVE THE MODELS. THE ANALYSES BENEFIT STRONGLY FROM THE GOOD QUALITY OF THE MIPAS OZONE OBSERVATIONS. USING THE ANALYSES AS A TRANSFER STANDARD, IT IS SEEN THAT MIPAS IS SIMILAR TO 5% HIGHER THAN HALOE (HALOGEN OCCULTATION EXPERIMENT) IN THE MID AND UPPER STRATOSPHERE AND MESOSPHERE (ABOVE 30 HPA), AND OF ORDER 10% HIGHER THAN OZONESONDE AND HALOE IN THE LOWER STRATOSPHERE (100 HPA TO 30 HPA). ANALYSES BASED ON SCIAMACHY TOTAL COLUMN ARE ALMOST AS GOOD AS THE MIPAS ANALYSES; ANALYSES BASED ON SCIAMACHY LIMB PROFILES ARE WORSE IN SOME AREAS, DUE TO PROBLEMS IN THE SCIAMACHY RETRIEVALS.",GENERAL-CIRCULATION MODEL; 4-DIMENSIONAL VARIATIONAL ASSIMILATION; STRATOSPHERIC OZONE; 3-DIMENSIONAL MODEL; SEQUENTIAL ASSIMILATION; SATELLITE-OBSERVATIONS; 3-D MODELS; CHEMISTRY; TRANSPORT; PROFILES,NA,ATMOSPHERIC CHEMISTRY AND PHYSICS,"GEER, AJ##LAHOZ, WA##BEKKI, S##BORMANN, N##ERRERA, Q##ESKES, HJ##FONTEYN, D##JACKSON, DR##JUCKES, MN##MASSART, S##PEUCH, VH##RHARMILI, S##SEGERS, A","UNIV READING, DATA ASSIMILAT RES CTR, READING, BERKS, ENGLAND. UNIV PARIS 06, CNRS, SERV AERON, PARIS, FRANCE. INST AERON SPATIALE BELGIQUE, B-1180 BRUSSELS, BELGIUM. ROYAL NETHERLANDS METEOROL INST, NL-3730 AE DE BILT, NETHERLANDS. MET OFF, EXETER, DEVON, ENGLAND. RUTHERFORD APPLETON LAB, BRITISH ATMOSPHER DATA CTR, DIDCOT OX11 0QX, OXON, ENGLAND. CERFACS, F-31057 TOULOUSE, FRANCE. METEO FRANCE, CNRM, GAME, TOULOUSE, FRANCE. CNRS, URA 1357, TOULOUSE, FRANCE.",ENVIRONMENTAL SCIENCES; METEOROLOGY & ATMOSPHERIC SCIENCES,ENVIRONMENTAL SCIENCES & ECOLOGY; METEOROLOGY & ATMOSPHERIC SCIENCES,"ANDERSSON E, 1999, Q J ROY METEOR SOC, V125, P697, DOI 10.1256/SMSQJ.55415##AUSTIN J, 2003, ATMOS CHEM PHYS, V3, P1, DOI 10.5194/ACP-3-1-2003##BHARTIA PK, 1996, J GEOPHYS RES-ATMOS, V101, P18793, DOI 10.1029/96JD01165##BHATT PP, 1999, J GEOPHYS RES-ATMOS, V104, P9261, DOI 10.1029/1999JD900058##BREGMAN A, 2001, J GEOPHYS RES-ATMOS, V106, P17479, DOI 10.1029/2000JD900752##BREGMAN B, 2006, ATMOS CHEM PHYS DISC, V6, P4375##CARIOLLE D, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025597##CARIOLLE D, 1986, J GEOPHYS RES-ATMOS, V91, P825, DOI 10.1029/JD091ID10P10825##CARSLAW KS, 1995, GEOPHYS RES LETT, V22, P1877, DOI 10.1029/95GL01668##CATHALA ML, 2003, TELLUS B, V55, P1, DOI 10.1034/J.1600-0889.2003.00002.X##CHIPPERFIELD MP, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002110##COURTIER P., 1991, WORKSH NUM METH ATM, P193##DAERDEN F, 2006, ATMOS CHEM PHYS DISC, V6, P8511##DAVIES T, 2005, Q J ROY METEOR SOC, V131, P1759, DOI 10.1256/QJ.04.101##DETHOF A, 2004, Q J ROY METEOR SOC, V130, P2851, DOI 10.1256/QJ.03.196##DETHOF A, 2003, MONITORING RETRIEVAL##DETHOF A, 2003, ASSIMILATION OZONE R, P428##DETHOF A, 2004, MONITORING ASSIMILAT##DUFOUR A, 2005, ATMOS RES, V74, P161, DOI 10.1016/J.ATMOSRES.2004.04.013##EL AMRAOUI L, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004796##ELBERN H, 2001, J GEOPHYS RES-ATMOS, V106, P3569, DOI 10.1029/2000JD900448##ERRERA Q, 2001, J GEOPHYS RES-ATMOS, V106, P12253, DOI 10.1029/2001JD900010##ESKES H, 2005, J ATMOS SCI, V62, P812, DOI 10.1175/JAS-3337.1##ESKES H. J, 2005, ATMOS CHEM PHYS DISC, V5, P4429, DOI [10.5194/ACPD-5-4429-2005, DOI 10.5194/ACPD-5-4429-2005]##ESKES HJ, 2003, Q J ROY METEOR SOC, V129, P1663, DOI 10.1256/QJ.02.14##*EUR SPACE AG, 2004, MIPAC PROD HDB##FIERLI F, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014272##FISCHER H, 1996, APPL OPTICS, V35, P2787, DOI 10.1364/AO.35.002787##FISCHER H, 2004, P 2 WORKSH ATM CHEM##FISHER M, 1995, Q J ROY METEOR SOC, V121, P1681, DOI 10.1002/QJ.49712152709##FISHER M., 2003, P ECMWF SEM REC DEV, P45##FISHER M., 2001, 347 ECMWF##FORTUIN J. P. F., 1995, P SOC PHOTO-OPT INS, V2311, P207, DOI DOI 10.1117/12.198578##FORTUIN JPF, 1998, J GEOPHYS RES-ATMOS, V103, P31709, DOI 10.1029/1998JD200008##GATES WL, 1992, B AM METEOROL SOC, V73, P1962, DOI 10.1175/1520-0477(1992)073<1962:ATAMIP>2.0.CO;2##GAUTHIER P, 2003, QUALITY CONTROL METH, P177##GEER AJ, 2006, Q J ROY METEOR SOC, V132, P231, DOI 10.1256/QJ.04.181##GEER AJ, 2006, ATMOS CHEM PHYS DISC, V6, P7427##HERVIG M, 1999, GEOPHYS RES LETT, V26, P719, DOI 10.1029/1999GL900069##HUDSON RD, 2003, J ATMOS SCI, V60, P1669, DOI 10.1175/1520-0469(2003)060<1669:TTOFSI>2.0.CO;2##JACKSON D. R., 2004, 454 MET OFF FOR RES##JACKSON DR, 2002, 394 MET OFF FOR RES##JOSSE B, 2004, TELLUS B, V56, P339, DOI 10.1111/J.1600-0889.2004.00112.X##JUCKES MN, 2006, ATMOS CHEM PHYS, V6, P1549, DOI 10.5194/ACP-6-1549-2006##JUCKES MN, 2006, ATMOS CHEM PHYS DISC, V6, P9389##KALNAY E., 2003, ATMOSPHERIC MODELING##KHATTATOV BV, 2000, J GEOPHYS RES-ATMOS, V105, P29135, DOI 10.1029/2000JD900466##KOMHYR WD, 1995, J GEOPHYS RES-ATMOS, V100, P9231, DOI 10.1029/94JD02175##LAGARDE T, 2001, Q J ROY METEOR SOC, V127, P189, DOI 10.1256/SMSQJ.57110##LAHOZ WA, 2006, Q J ROY METEOR SOC, V132, P1985, DOI 10.1256/QJ.05.221##LARSEN N, 2000, 0006 DAN MET I##LEFEVRE F, 1994, J GEOPHYS RES-ATMOS, V99, P8183, DOI 10.1029/93JD03476##LEFEVRE F, 1998, GEOPHYS RES LETT, V25, P2425, DOI 10.1029/98GL51812##LI D, 1995, 35 UGAMP##LOGAN JA, 1999, J GEOPHYS RES-ATMOS, V104, P16115, DOI 10.1029/1998JD100096##LORENC AC, 2000, Q J ROY METEOR SOC, V126, P2991, DOI 10.1256/SMSQJ.57001##MASSART S, 2005, C R GEOSCIENCES, V15, P1305##MCCORMACK JP, 2004, ATMOS CHEM PHYS, V4, P2401, DOI 10.5194/ACP-4-2401-2004##MCLINDEN CA, 2000, J GEOPHYS RES-ATMOS, V105, P14653, DOI 10.1029/2000JD900124##MCPETERS RD, 1998, NASA TECHNICAL PUBLI##MIGLIORINI S, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004988##MORCRETTE JJ, 2003, 375 ECMWF##PAWSON S, 2000, B AM METEOROL SOC, V81, P781, DOI 10.1175/1520-0477(2000)081<0781:TGIPFS>2.3.CO;2##PEUCH A, 2000, Q J ROY METEOR SOC, V126, P1641, DOI 10.1256/SMSQJ.56605##PLUMB RA, 2002, J METEOROL SOC JPN, V80, P793, DOI 10.2151/JMSJ.80.793##RABIER F, 2000, Q J ROY METEOR SOC, V126, P1143, DOI 10.1256/SMSQJ.56414##RANDEL W, 2004, J CLIMATE, V17, P986, DOI 10.1175/1520-0442(2004)017<0986:TSIOMC>2.0.CO;2##RASPOLLINI P, 2006, ATMOS CHEM PHYS, V6, P5605, DOI 10.5194/ACP-6-5605-2006##RIISHOJGAARD LP, 1996, Q J ROY METEOR SOC, V122, P1545, DOI 10.1002/QJ.49712253505##RODGERS C., 2000, INVERSE METHODS ATMO##ROELOFS GJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003462##RUSSELL JM, 1993, J GEOPHYS RES-ATMOS, V98, P10777, DOI 10.1029/93JD00799##SASSI F, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL022131##SCHEELE MP, 2005, ATMOS CHEM PHYS, V5, P1, DOI 10.5194/ACP-5-1-2005##SCHOEBERL MR, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002652##SEGERS AJ, 2005, ATMOS CHEM PHYS, V5, P3045, DOI 10.5194/ACP-5-3045-2005##SEGERS AJ, 2005, Q J ROY METEOR SOC, V131, P477, DOI 10.1256/QJ.04.92##SPIEGEL MR, 1999, SCHAUMS OUTLINE THEO##STAJNER I, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004118##STAJNER I, 2001, Q J ROY METEOR SOC, V127, P1069, DOI 10.1002/QJ.49712757320##STOHL A, 2004, J ATMOS SCI, V61, P1446, DOI 10.1175/1520-0469(2004)061<1446:ACNOTU>2.0.CO;2##STRUTHERS H, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000957##TALAGRAND O, 2003, NATO SCI S SS IV EAR, V26, P85##TAN WW, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004057##THOMPSON AM, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2001JD000967##THOMPSON AM, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002241##UPPALA SM, 2005, Q J ROY METEOR SOC, V131, P2961, DOI 10.1256/QJ.04.176##WARGAN K, 2005, Q J ROY METEOR SOC, V131, P2713, DOI 10.1256/QJ.04.184##WEAVER A, 2001, Q J ROY METEOR SOC, V127, P1815, DOI 10.1256/SMSQJ.57517##*WORLD MET ORG, 2003, 47 WORLD MET ORG##ZAGAR N, 2004, J ATMOS SCI, V61, P1877, DOI 10.1175/1520-0469(2004)061<1877:AOEWBL>2.0.CO;2",80,2020-11-20,NA
J,WOS:000242642300024,2006,CITIES CHANGE THE SONGS OF BIRDS,"WORLDWIDE URBANIZATION AND THE ONGOING RISE OF URBAN NOISE LEVELS FORM A MAJOR THREAT TO LIVING CONDITIONS IN AND AROUND CITIES [1-4]. URBAN ENVIRONMENTS TYPICALLY HOMOGENIZE ANIMAL COMMUNITIES, AND THIS RESULTS, FOR EXAMPLE, IN THE SAME FEW BIRD SPECIES' BEING FOUND EVERYWHERE [5, 6]. INSIGHT INTO THE BEHAVIORAL STRATEGIES OF THE URBAN SURVIVORS MAY EXPLAIN THE SENSITIVITY OF OTHER SPECIES TO URBAN SELECTION PRESSURES. HERE, WE SHOW THAT SONGS THAT ARE IMPORTANT TO MATE ATTRACTION AND TERRITORY DEFENSE HAVE SIGNIFICANTLY DIVERGED IN GREAT TITS (PARUS MAJOR), A VERY SUCCESSFUL URBAN SPECIES. URBAN SONGS WERE SHORTER AND SUNG FASTER THAN SONGS IN FORESTS, AND OFTEN CONCERNED ATYPICAL SONG TYPES. FURTHERMORE, WE FOUND CONSISTENTLY HIGHER MINIMUM FREQUENCIES IN TEN OUT OF TEN CITY-FOREST COMPARISONS FROM LONDON TO PRAGUE AND FROM AMSTERDAM TO PARIS. ANTHROPOGENIC NOISE IS MOST LIKELY A DOMINANT FACTOR DRIVING THESE DRAMATIC CHANGES [7-9]. THESE DATA PROVIDE THE MOST CONSISTENT EVIDENCE SUPPORTING THE ACOUSTIC-ADAPTATION HYPOTHESIS SINCE IT WAS POSTULATED IN THE EARLY SEVENTIES [10-12]. AT THE SAME TIME, THEY REVEAL A BEHAVIORAL PLASTICITY THAT MAY BE KEY TO URBAN SUCCESS AND THE LACK OF WHICH MAY EXPLAIN DETRIMENTAL EFFECTS ON BIRD COMMUNITIES THAT LIVE IN NOISY URBANIZED AREAS OR ALONG HIGHWAYS.",TIT PARUS-MAJOR; GREAT TIT; URBAN NOISE; TRAFFIC NOISE; HOMOGENIZATION; COMMUNICATION; URBANIZATION; CONSEQUENCES; DISPERSAL; EVOLUTION,NA,CURRENT BIOLOGY,"SLABBEKOORN, H##DEN BOER-VISSER, A","LEIDEN UNIV, INST BIOL, NL-2300 RA LEIDEN, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOLOGY; CELL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS; CELL BIOLOGY,"BABISCH WF, 2005, EPIDEMIOLOGY, V16, P33, DOI 10.1097/01.EDE.0000147104.84424.24##BERGMAN G., 1982, ORNIS FENNICA, V57, P97##BRUMM H, 2005, ADV STUD BEHAV, V35, P151, DOI 10.1016/S0065-3454(05)35004-2##BRUMM H, 2002, ANIM BEHAV, V63, P891, DOI 10.1006/ANBE.2001.1968##BRUMM H, 2004, J ANIM ECOL, V73, P434, DOI 10.1111/J.0021-8790.2004.00814.X##CHAPUIS C, 1971, TERRE ET LA VIE, V118, P183##CLERGEAU P, 2006, BIOL CONSERV, V127, P336, DOI 10.1016/J.BIOCON.2005.06.035##DAWKINS R, 1976, SELFISH GENE##ELLERS J, 2003, ANIM BEHAV, V65, P671, DOI 10.1006/ANBE.2003.2081##ENDLER JA, 1992, AM NAT, V139, P1##FERNANDEZ-JURICIC ESTEBAN, 2005, URBAN HABITATS, V3, P49##GREENWOOD PJ, 1979, J ANIM ECOL, V48, P123, DOI 10.2307/4105##HORAK P, 1994, ORNIS FENNICA, V71, P47##HUNTER ML, 1979, J ANIM ECOL, V48, P759, DOI 10.2307/4194##JOHNSRUDE IS, 1994, J COMP PSYCHOL, V108, P172, DOI 10.1037/0735-7036.108.2.172##KELCEY J. G., 2005, BIRDS EUROPEAN CITIE##KLUMP GEORG M., 1996, P321##KREBS J, 1978, NATURE, V271, P539, DOI 10.1038/271539A0##KVIST L, 1999, HEREDITY, V82, P495, DOI 10.1038/SJ.HDY.6885130##LEHTONEN L, 1983, ORNIS FENNICA, V60, P16##LENGAGNE T, 2000, J ACOUST SOC AM, V107, P508, DOI 10.1121/1.428319##MARZLUFF J, 2001, AVIAN ECOLOGY CONSER##MCGREGOR PK, 1989, BEHAVIOUR, V108, P139, DOI 10.1163/156853989X00105##MCKINNEY ML, 2006, BIOL CONSERV, V127, P247, DOI 10.1016/J.BIOCON.2005.09.005##MORTON ES, 1975, AM NAT, V109, P17, DOI 10.1086/282971##PATRICELLI GL, 2006, AUK, V123, P639, DOI 10.1642/0004-8038(2006)123[639:ACIUNC]2.0.CO;2##PODOS J, 2004, ANNU REV ECOL EVOL S, V35, P55, DOI 10.1146/ANNUREV.ECOLSYS.35.021103.105719##POSTMA E, 2005, NATURE, V433, P65, DOI 10.1038/NATURE03083##RIDDINGTON R, 1995, IBIS, V137, P371, DOI 10.1111/J.1474-919X.1995.TB08035.X##SLABBEKOOM H, 2004, J ACOUST SOC AM, V116, P3727, DOI 10.1121/1.1811121##SLABBEKOORN H, 2003, NATURE, V424, P267, DOI 10.1038/424267A##SLABBEKOORN H, 2002, PHILOS T R SOC B, V357, P493, DOI 10.1098/RSTB.2001.1056##SLABBEKOORN H, 1999, ETHOLOGY, V105, P377, DOI 10.1046/J.1439-0310.1999.00420.X##SLABBEKOORN HANS, 2004, P178, DOI 10.1016/B978-012473070-0/50009-8##SLAGSVOLD T, 1994, BEHAVIOUR, V131, P115, DOI 10.1163/156853994X00244##SNOW DW, 1954, EVOLUTION, V8, P19, DOI 10.1111/J.1558-5646.1954.TB00105.X##STANSFELD SA, 2005, LANCET, V365, P1942, DOI 10.1016/S0140-6736(05)66660-3##WARREN PS, 2006, ANIM BEHAV, V71, P491, DOI 10.1016/J.ANBEHAV.2005.07.014##WESTERN D, 2001, P NATL ACAD SCI USA, V98, P5458, DOI 10.1073/PNAS.101093598##WOOD WE, 2006, AUK, V123, P650, DOI 10.1642/0004-8038(2006)123[650:SSMMSV]2.0.CO;2",278,2020-11-20,NA
J,WOS:000242642300025,2006,THE SCOPE AND LIMITS OF TOP-DOWN ATTENTION IN UNCONSCIOUS VISUAL PROCESSING,"ATTENTIONAL SELECTION PLAYS A CRITICAL ROLE IN CONSCIOUS PERCEPTION. WHEN ATTENTION IS DIVERTED, EVEN SALIENT STIMULI FAIL TO REACH VISUAL AWARENESS [1, 2]. ATTENTION CAN BE VOLUNTARILY DIRECTED TO A SPATIAL LOCATION [3-9] OR A VISUAL FEATURE [9-14] FOR FACILITATING THE PROCESSING OF INFORMATION RELEVANT TO CURRENT GOALS. IN EVERYDAY SITUATIONS, ATTENTION AND AWARENESS ARE TIGHTLY COUPLED. THIS HAS LED SOME TO SUGGEST THAT ATTENTION AND AWARENESS MIGHT BE BASED ON A COMMON NEURAL FOUNDATION [15, 16], WHEREAS OTHERS ARGUE THAT THEY ARE MEDIATED BY DISTINCT MECHANISMS [17-19]. A BODY OF EVIDENCE SHOWS THAT VISUAL STIMULI CAN BE PROCESSED AT MULTIPLE STAGES OF THE VISUAL-PROCESSING STREAMS WITHOUT EVOKING VISUAL AWARENESS [20-22]. TO ILLUMINATE THE RELATIONSHIP BETWEEN VISUAL ATTENTION AND CONSCIOUS PERCEPTION, WE INVESTIGATED WHETHER TOP-DOWN ATTENTION CAN TARGET AND MODULATE THE NEURAL REPRESENTATIONS OF UNCONSCIOUSLY PROCESSED VISUAL STIMULI. OUR EXPERIMENTS SHOW THAT SPATIAL ATTENTION CAN TARGET ONLY CONSCIOUSLY PERCEIVED STIMULI, WHEREAS FEATURE-BASED ATTENTION CAN MODULATE THE PROCESSING OF INVISIBLE STIMULI. THE ATTENTIONAL MODULATION OF UNCONSCIOUS SIGNALS IMPLIES THAT ATTENTION AND AWARENESS CAN BE DISSOCIATED, CHALLENGING A SIMPLISTIC VIEW OF THE BOUNDARY BETWEEN CONSCIOUS AND UNCONSCIOUS VISUAL PROCESSING.",LATERAL GENICULATE-NUCLEUS; BINOCULAR-RIVALRY; SELECTIVE ATTENTION; NEURAL MECHANISMS; AREAS V1; CORTEX; V4; ORIENTATION; ADAPTATION; AWARENESS,NA,CURRENT BIOLOGY,"KANAI, R##TSUCHIYA, N##VERSTRATEN, FAJ","UNIV UTRECHT, HELMHOLTZ INST, DEPT EXPT PSYCHOL, NL-3584 CS UTRECHT, NETHERLANDS. CALTECH, DIV BIOL, PASADENA, CA 91125 USA. CALTECH, DIV HUMANITIES & SOCIAL SCI, PASADENA, CA 91125 USA.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOLOGY; CELL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS; CELL BIOLOGY,"CLIFFORD CWG, 2000, P ROY SOC B-BIOL SCI, V267, P1705, DOI 10.1098/RSPB.2000.1198##DEHAENE S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/J.TICS.2006.03.007##DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/ANNUREV.NEURO.18.1.193##GIBSON JJ, 1937, J EXP PSYCHOL, V20, P453, DOI 10.1037/H0059826##HAYDEN BY, 2005, NEURON, V47, P637, DOI 10.1016/J.NEURON.2005.07.020##HAYNES JD, 2005, NATURE, V438, P496, DOI 10.1038/NATURE04169##HAYNES JD, 2005, NAT NEUROSCI, V8, P686, DOI 10.1038/NN1445##HE S, 2001, NATURE, V411, P473, DOI 10.1038/35078072##HUK AC, 2001, NEURON, V32, P161, DOI 10.1016/S0896-6273(01)00452-4##JIN DZ, 2005, J NEUROPHYSIOL, V94, P4038, DOI 10.1152/JN.00571.2004##JOSEPH JS, 1997, NATURE, V387, P805, DOI 10.1038/42940##KASTNER S, 1999, NEURON, V22, P751, DOI 10.1016/S0896-6273(00)80734-5##KENTRIDGE RW, 1999, P ROY SOC B-BIOL SCI, V266, P1805, DOI 10.1098/RSPB.1999.0850##KOCH C, IN PRESS TRENDS COGN##KOHN A, 2004, NAT NEUROSCI, V7, P764, DOI 10.1038/NN1267##LAMME VAF, 2003, TRENDS COGN SCI, V7, P12, DOI 10.1016/S1364-6613(02)00013-X##LAMME VAF, 2000, TRENDS NEUROSCI, V23, P571, DOI 10.1016/S0166-2236(00)01657-X##LEOPOLD DA, 1996, NATURE, V379, P549, DOI 10.1038/379549A0##LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/SCIENCE.2772635##LUCK SJ, 1997, J NEUROPHYSIOL, V77, P24##MACK A., 1998, INATTENTIONAL BLINDN##MARTINEZ-TRUJILLO JC, 2004, CURR BIOL, V14, P744, DOI 10.1016/J.CUB.2004.04.028##MCADAMS CJ, 2000, J NEUROPHYSIOL, V83, P1751##MEHTA SD, 2000, CEREB CORTEX, V10, P343, DOI 10.1093/CERCOR/10.4.343##MELCHER D, 2005, NEURON, V46, P723, DOI 10.1016/J.NEURON.2005.04.023##MITCHELL JF, 2004, NATURE, V429, P410, DOI 10.1038/NATURE02584##MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/SCIENCE.4023713##MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909##NACCACHE L, 2002, PSYCHOL SCI, V13, P416, DOI 10.1111/1467-9280.00474##O'REGAN JK, 2001, BEHAV BRAIN SCI, V24, P939, DOI 10.1017/S0140525X01000115##RAJIMEHR R, 2004, NEURON, V41, P663, DOI 10.1016/S0896-6273(04)00041-8##REYNOLDS JH, 1999, J NEUROSCI, V19, P1736##REYNOLDS JH, 2000, NEURON, V26, P703, DOI 10.1016/S0896-6273(00)81206-4##ROSSI AF, 1995, VISION RES, V35, P621, DOI 10.1016/0042-6989(94)00156-G##SAENZ M, 2002, NAT NEUROSCI, V5, P631, DOI 10.1038/NN876##SPIVEY MJ, 2000, PERCEPT PSYCHOPHYS, V62, P1525, DOI 10.3758/BF03212153##SUMNER P, 2006, P NATL ACAD SCI USA, V103, P10520, DOI 10.1073/PNAS.0601974103##TONG F, 2001, NATURE, V411, P195, DOI 10.1038/35075583##TOOTELL RBH, 1998, NEURON, V21, P1409, DOI 10.1016/S0896-6273(00)80659-5##TREUE S, 1999, NATURE, V399, P575, DOI 10.1038/21176##TREUE S, 1996, NATURE, V382, P539, DOI 10.1038/382539A0##TSUCHIYA N, 2005, NAT NEUROSCI, V8, P1096, DOI 10.1038/NN1500##WUNDERLICH K, 2005, NAT NEUROSCI, V8, P1595, DOI 10.1038/NN1554",93,2020-11-20,NA
J,WOS:000241593700016,2006,"RECYCLING OF NR BASED CURED LATEX MATERIAL RECLAIMED WITH 2,2 '-DIBENZAMIDODIPHENYLDISULPHIDE IN A TRUCK TIRE TREAD COMPOUND","IT IS OBSERVED THAT RECLAMATION OF NATURAL RUBBER LATEX BASED RUBBER USING 2,2'-DIBENZAMIDODIPHENYLDISULPHIDE AS RECLAIMING AGENT IS AN OPTIONAL METHODOLOGY FOR RECYCLING OF WASTE LATEX RUBBER (WLR). FOR PROGRESSIVE REPLACEMENT OF VIRGIN NATURAL RUBBER BY THE RECLAIM, TWO ALTERNATIVES CURING SYSTEM WERE INVESTIGATED: ADJUSTMENT OR REDUCTION OF THE CURING SYSTEM WITH INCREASING RECLAIM CONTENT, TO COMPENSATE FOR THE EXTRA AMOUNT OF CURATIVES BROUGHT ALONG BY THE RECLAIM. FOR FIXED CURING SYSTEM, AS IF THE RECLAIM WERE EQUIVALENT TO VIRGIN NR. THE CURE BEHAVIOR, FINAL CROSSLINK DENSITY AND DISTRIBUTION, MECHANICAL PROPERTIES, AND DYNAMIC VISCOELASTIC PROPERTIES OF THE BLENDS WITH RECLAIMED WLR ARE MEASURED AND COMPARED WITH THE VIRGIN COMPOUND. THE MORPHOLOGY OF THE BLENDS, SULFUR MIGRATION, AND FINAL DISTRIBUTION ARE ANALYZED. THE MECHANICAL AND DYNAMIC VISCOELASTIC PROPERTIES DETERIORATE FOR BOTH CURING SYSTEMS, BUT TO A LESSER EXTENT FOR FIXED CURING SYSTEM COMPARED TO ADJUSTED CURING SYSTEM. WITH THE FIXED CURE SYSTEM, MANY PROPERTIES LIKE TENSILE STRENGTH AND COMPRESSION SET DO STILL DETERIORATE, BUT TAN DELTA AND M300/M100, REPRESENTATIVE FOR THE ROLLING RESISTANCE OF TIRES ARE IMPROVED. ON THE OTHER HAND, WITH THE ADJUSTED CURE SYSTEM BOTH MECHANICAL AND DYNAMIC PROPERTIES STILL DETERIORATE. (C) 2006 WILEY PERIODICALS, INC.",RUBBER; DEVULCANIZATION; RHEOLOGY,RECYCLING; RUBBER; COMPOUNDING; TIRE TREAD; DIPHENYLDISULPHIES,JOURNAL OF APPLIED POLYMER SCIENCE,"RAJAN, VV##DIERKES, WK##JOSEPH, R##NOORDERMEER, JWM","UNIV TWENTE, FAC SCI & TECHNOL, DEPT RUBBER TECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. COCHIN UNIV SCI & TECHNOL, DEPT POLYMER SCI & RUBBERT TECHNOL, KOCHI, KERALA, INDIA.",POLYMER SCIENCE,POLYMER SCIENCE,"BURGOYNE MD, 1976, RUBBER CHEM TECHNOL, V49, P375, DOI DOI 10.5254/1.3534972##CAMPBELL DS, 1969, J APPL POLYM SCI, V13, P1201, DOI 10.1002/APP.1969.070130609##CAMPBELL DS, 1967, P INT RUBB C BRIGHT, P1##CORAN AY, 1978, SCI TECHNOLOGY RUBBE##FESUS E, 1991, RUBBER WORLD, V203, P23##FLORY PJ, 1950, J CHEM PHYS, V18, P108, DOI 10.1063/1.1747424##FUJIMOTO K, 1981, INT POLYM SCI TECHN, V8, P30##ISAYEV AI, 1995, RUBBER CHEM TECHNOL, V68, P267, DOI 10.5254/1.3538741##KNORR K, 1994, KAUT GUMMI KUNSTST, V47, P54##KOHLER R, 1997, RUBBER WORLD, V216, P32##KRAUS G., 1963, J APPL POLYM SCI, V7, P861, DOI [10.1002/APP.1963.070070306, DOI 10.1002/APP.1963.070070306]##MYHRE MJ, 1996, RUBBER WORLD, V214, P42##RAJAN VV, 2005, RUBBER CHEM TECHNOL, V78, P572, DOI 10.5254/1.3547898##SCURACCHIO CH, 2004, J ELASTOM PLAST, V36, P45, DOI 10.1177/0095244304039913##SEKHAR B. C., 1996, EUR PAT., PATENT NO. [EP 0748837, 0748837]##SOMBATSOMPOP N, 2003, J APPL POLYM SCI, V87, P1723, DOI 10.1002/APP.11698##TAPALE M, 1998, J APPL POLYM SCI, V70, P2007, DOI 10.1002/(SICI)1097-4628(19981205)70:10<2007::AID-APP17>3.3.CO;2-4##TUKACHINSKY A, 1996, RUBBER CHEM TECHNOL, V69, P92, DOI 10.5254/1.3538362##WANG MJ, 1998, RUBBER CHEM TECHNOL, V71, P520, DOI 10.5254/1.3538492##YUN J, 2003, RUBBER CHEM TECHNOL, V76, P253, DOI 10.5254/1.3547738##1980, EUR RUBBER J, V162, P36",29,2020-11-20,NA
J,WOS:000241593700124,2006,THE USE OF EXPERIMENTAL DESIGN TO STUDY THE RESPONSES OF CONTINUOUS DEVULCANIZATION PROCESSES,"THIS PAPER PRESENTS THE USE OF STATISTICAL ANALYSIS FOR STUDYING THE RESPONSES OF TWO CONTINUOUS DEVULCANIZATION PROCESSES (OF THE EPDM ROOFING SHEET AND THE EPDM PROFILE) IN THE EXTRUDER. THE RESPONSE IS REPRESENTED BY THE REACTION CONVERSION, WHICH IS DENOTED AS THE RELATIVE DECREASE IN CROSSLINK DENSITY. EXPERIMENTAL DESIGN IS CONSIDERED AS A USEFUL TOOL WHEN THE KINETIC DATA FOR THE PHYSICAL MODELING ARE NOT AVAILABLE. THE MODELS DERIVED SHOW SIMILAR TENDENCY OF BOTH PROCESSES WITH RESPECT TO THE TEMPERATURE AND THE SCREW SPEED. A DIFFERENCE IS OBSERVED IN THEIR RESPONSES TO THE FEED RATE, WHICH MIGHT BE THE CONSEQUENCE OF THEIR DIFFERENT DEVULCANIZATION RATES. (C) 2006 WILEY PERIODICALS, INC.",ULTRASONIC DEVULCANIZATION; RUBBER,RECYCLING; RUBBER; PROCESSING; ETHYLENE-PROPYLENE-DIENE MONOMER; EXTRUSION; MODELING,JOURNAL OF APPLIED POLYMER SCIENCE,"SUTANTO, P##PICCHIONI, F##JANSSEN, LPBM","UNIV GRONINGEN, DEPT CHEM ENGN, GRONINGEN, NETHERLANDS.",POLYMER SCIENCE,POLYMER SCIENCE,"BIRD R.B., 1994, TRANSPORT PHENOMENA##BOOY ML, 1978, POLYM ENG SCI, V18, P973, DOI 10.1002/PEN.760181212##BOOY ML, 1980, POLYM ENG SCI, V20, P1220, DOI 10.1002/PEN.760201808##BURRIDGE E, 2003, EUR CHEM NEWS, V10, P15##BURRIDGE E., 2005, EUR CHEM NEWS, V82, P16##CHANG YK, 1999, BRAZ J CHEM ENG, V16, P285, DOI 10.1590/S0104-66321999000300007##FLORY PJ, 1950, J CHEM PHYS, V18, P108, DOI 10.1063/1.1747424##*INT I SYNTH RUBB, 2003, REPORT##MONTGOMERY DC, 2001, DESIGN ANAL EXPT##MOURI M, 2000, INT POLYM SCI TECH, V27##NOORDERMEER JWM, 1993, KIRKOTHMER CONCISE E, V8##RAUWENDAAL C, 1994, POLYM EXTRUSION##SATO N, 1999, INT RUBB C IRC P SEO##SUTANTO P, 2006, CHEM ENG SCI, V61, P6442, DOI 10.1016/J.CES.2006.05.024##SUTANTO P, IN PRESS CHEM ENG SC##SUZUKI Y., 1998, TOYOTA TECH REV, V48, P53##VANDUIN M, 2003, PATENT NO. 2003013776##YUN J, 2004, J APPL POLYM SCI, V91, P1646, DOI 10.1002/APP.13320##YUN J, 2002, RUBB DIV M AM CHEM S##YUN JS, 2003, POLYM ENG SCI, V43, P809, DOI 10.1002/PEN.10067",25,2020-11-20,NA
J,WOS:000242520900001,2006,PROTECTIVE EFFECTS OF ERYTHROPOIETIN IN CARDIAC ISCHEMIA - FROM BENCH TO BEDSIDE,"ERYTHROPOIETIN (EPO) IS A HYPOXIA-INDUCED HORMONE PRODUCED IN THE KIDNEYS THAT STIMULATES HEMATOPOIESIS IN THE BONE MARROW. HOWEVER, RECENT STUDIES HAVE ALSO SHOWN IMPORTANT NONHEMATOPOIETIC EFFECTS OF EPO. A FUNCTIONAL EPO RECEPTOR IS FOUND IN THE CARDIOVASCULAR SYSTEM, INCLUDING ENDOTHELIAL CELLS AND CARDIOMYOCYTES. IN ANIMAL STUDIES, TREATMENT WITH EPO DURING ISCHEMIA/REPERFUSION IN THE HEART HAS BEEN SHOWN TO LIMIT THE INFARCT SIZE AND THE EXTENT OF APOPTOSIS. IN THE LONGER TERM, EPO MAY PROMOTE ISCHEMIA-INDUCED NEOVASCULARIZATION, EITHER BY STIMULATING ENDOTHELIAL CELLS IN SITU OR BY MOBILIZING ENDOTHELIAL PROGENITOR CELLS FROM BONE MARROW. THE EFFECTS OF EPO IN THE ISCHEMIC HEART SUPPORT THE CONCEPT OF EPO AS A PLEIOTROPIC, TISSUE-PROTECTIVE AGENT FOR OTHER ORGANS EXPRESSING THE EPO RECEPTOR. WE RECENTLY PERFORMED A FIRST RANDOMIZED CLINICAL STUDY SHOWING THE SAFETY AND FEASIBILITY OF EPO ADMINISTRATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. FUTURE CLINICAL STUDIES ARE WARRANTED TO TRANSLATE THE BENEFICIAL EFFECTS OF EPO FROM BASIC EXPERIMENTS TO CARDIAC PATIENTS.",ENDOTHELIAL PROGENITOR CELLS; ACUTE MYOCARDIAL-INFARCTION; CHRONIC HEART-FAILURE; ANALOG DARBEPOETIN-ALPHA; REPERFUSION INJURY; IN-VIVO; DEPENDENT PATHWAY; RENAL-FAILURE; ANEMIA; RATS,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,"LIPSIC, E##SCHOEMAKER, RG##VAN DER MEER, P##VOORS, AA##VAN VELDHUISEN, DJ##VAN GILST, WH","UNIV GRONINGEN, DEPT CLIN PHARMACOL, MED CTR, GRONINGEN, NETHERLANDS. UNIV GRONINGEN, DEPT CARDIOL, MED CTR, GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/PNAS.91.9.3974##AYUS JC, 2005, KIDNEY INT, V68, P788, DOI 10.1111/J.1523-1755.2005.00458.X##BAHLMANN FH, 2004, CIRCULATION, V110, P1006, DOI 10.1161/01.CIR.0000139335.04152.F3##BAHLMANN FH, 2004, BLOOD, V103, P921, DOI 10.1182/BLOOD-2003-04-1284##BESARAB A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903##BOKEMEYER C, 2004, EUR J CANCER, V40, P2201, DOI 10.1016/J.EJCA.2004.07.015##BRINES M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/PNAS.0406491101##BRINES ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/PNAS.97.19.10526##BULLARD AJ, 2005, BASIC RES CARDIOL, V100, P397, DOI 10.1007/S00395-005-0537-4##CAI ZQ, 2004, CIRCULATION, V109, P2050, DOI 10.1161/01.CIR.0000127954.98131.23##CAI ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A##CALVILLO L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/PNAS.0630444100##CHONG ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F##DEPPING R., 2005, J THORAC CARDIOVASC, V130##FIORDALISO F, 2005, P NATL ACAD SCI USA, V102, P2046, DOI 10.1073/PNAS.0409329102##FISHER JW, 2003, EXP BIOL MED, V228, P1##FOLEY RN, 1996, AM J KIDNEY DIS, V28, P53, DOI 10.1016/S0272-6386(96)90130-4##GRIMM C, 2002, NAT MED, V8, P718, DOI 10.1038/NM723##HANLON PR, 2005, FASEB J, V19, P1323, DOI 10.1096/FJ.04-3545FJE##HEESCHEN C, 2003, BLOOD, V102, P1340, DOI 10.1182/BLOOD-2003-01-0223##HENRY DH, 2004, ARCH INTERN MED, V164, P262, DOI 10.1001/ARCHINTE.164.3.262##HIRATA A, 2005, CARDIOVASC DRUG THER, V19, P33, DOI 10.1007/S10557-005-6895-1##JAQUET K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/MVRE.2002.2426##JELKMANN W, 2004, ANN HEMATOL, V83, P673, DOI 10.1007/S00277-004-0911-6##LEIST M, 2004, SCIENCE, V305, P239, DOI 10.1126/SCIENCE.1098313##LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/PNAS.82.22.7580##LIPSIC E, 2006, J AM COLL CARDIOL, V47, P74A##LIPSIC E, 2004, J CARDIOVASC PHARM, V44, P473, DOI 10.1097/01.FJC.0000140209.04675.C3##LIPSIC E, 2006, CARDIOVASC DRUG THER, V20, P135, DOI 10.1007/S10557-006-7680-5##MANCINI DM, 2003, CIRCULATION, V107, P294, DOI 10.1161/01.CIR.0000044914.42696.6A##MCMAHON LP, 2000, NEPHROL DIAL TRANSPL, V15, P1425, DOI 10.1093/NDT/15.9.1425##MEYER GP, 2006, CIRCULATION, V113, P1287, DOI 10.1161/CIRCULATIONAHA.105.575118##MIX TCH, 2005, AM HEART J, V149, P408, DOI 10.1016/J.AHJ.2004.09.047##MOON C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/PNAS.1930406100##MURRY CE, 2004, NATURE, V428, P664, DOI 10.1038/NATURE02446##NAMIUCHI S, 2005, J AM COLL CARDIOL, V45, P1406, DOI 10.1016/J.JACC.2005.01.043##OPASICH C, 2005, EUR HEART J, V26, P2232, DOI 10.1093/EURHEARTJ/EHI388##PARSA CJ, 2004, J BIOL CHEM, V279, P20655, DOI 10.1074/JBC.M314099200##PARSA CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200##PATEL NSA, 2004, KIDNEY INT, V66, P983, DOI 10.1111/J.1523-1755.2004.00847.X##PORAT O, 1996, J PHARMACOL EXP THER, V276, P1162##RATAJCZAK J, 2001, BRIT J HAEMATOL, V115, P195, DOI 10.1046/J.1365-2141.2001.03058.X##RIBATTI D, 1999, BLOOD, V93, P2627, DOI 10.1182/BLOOD.V93.8.2627.408K21_2627_2636##RODRIGUEZ M, 2002, ANN MED, V34, P470, DOI 10.1080/078538902321012414##RUI T, 2005, CARDIOVASC RES, V65, P719, DOI 10.1016/J.CARDIORES.2004.11.019##SHI Y, 2004, BASIC RES CARDIOL, V99, P173, DOI 10.1007/S00395-004-0455-X##SHINTANI S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/HC2301.092122##SILVERBERG DS, 2001, J AM COLL CARDIOL, V37, P1775, DOI 10.1016/S0735-1097(01)01248-7##SQUADRITO F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/SJ.BJP.0702521##TRAMONTANO AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1##VAN DER MEER P, 2005, CIRCULATION, V112, P1743, DOI 10.1161/CIRCULATIONAHA.105.549121##VAN DER MEER P, 2005, J AM COLL CARDIOL, V46, P125, DOI 10.1016/J.JACC.2005.03.044##VAN DER MEER P, 2004, EUR J HEART FAIL, V6, P853, DOI 10.1016/J.EJHEART.2004.03.012##VAN DER MEER P, 2004, J AM COLL CARDIOL, V44, P63, DOI 10.1016/J.JACC.2004.03.052##VAN DER MEER P, 2004, EUR HEART J, V25, P285, DOI 10.1016/J.EHJ.2003.11.017##VAN VELDHUISEN DJ, 2006, J AM COLL CARDIOL, V47, P61A##WALD M, 1995, NEPHRON, V71, P190, DOI 10.1159/000188711##WANG L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.A4##WERNER N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMOA043814##WOLLERT KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9##WRIGHT GL, 2004, FASEB J, V18, P1031, DOI 10.1096/FJ.03-1289FJE",150,2020-11-20,NA
J,WOS:000242520900002,2006,"MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY EVOLVING AS A CLINICALLY FEASIBLE TECHNIQUE FOR ACCURATE, RAPID, AND SAFE ASSESSMENT OF MYOCARDIAL PERFUSION - THE EVIDENCE SO FAR","INTRAVENOUS MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY (MCE) IS A RECENTLY DEVELOPED TECHNIQUE FOR ASSESSMENT OF MYOCARDIAL PERFUSION. UP TO NOW, MANY STUDIES HAVE DEMONSTRATED THAT THE SENSITIVITY AND SPECIFICITY OF QUALITATIVE ASSESSMENT OF MYOCARDIAL PERFUSION BY MCE IN PATIENTS WITH ACUTE AND CHRONIC ISCHEMIC HEART DISEASE ARE COMPARABLE WITH OTHER TECHNIQUES SUCH AS CARDIAC SCINTIGRAPHY AND DOBUTAMINE STRESS ECHOCARDIOGRAPHY. FURTHERMORE, QUANTITATIVE PARAMETERS OF MYOCARDIAL PERFUSION DERIVED FROM MCE CORRELATE WELL WITH THE CURRENT CLINICAL STANDARD FOR THIS PURPOSE, POSITRON EMISSION TOMOGRAPHY. MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY PROVIDES A PROMISING AND VALUABLE TOOL FOR ASSESSMENT OF MYOCARDIAL PERFUSION. ALTHOUGH MCE HAS BEEN PRIMARILY PERFORMED FOR MEDICAL RESEARCH, ITS IMPLEMENTATION IN ROUTINE CLINICAL CARE IS EVOLVING. THIS ARTICLE IS INTENDED TO GIVE AN OVERVIEW OF THE CURRENT STATUS OF MCE.",DOBUTAMINE STRESS ECHOCARDIOGRAPHY; LEFT-VENTRICULAR FUNCTION; CORONARY-ARTERY STENOSIS; EMISSION COMPUTED-TOMOGRAPHY; REAL-TIME; FUNCTIONAL RECOVERY; PREDICTS RECOVERY; WALL-MOTION; BLOOD-FLOW; INCREMENTAL VALUE,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,"DIJKMANS, PA##SENIOR, R##BECHER, H##PORTER, TR##WEI, K##VISSER, CA##KAMP, O","VRIJE UNIV AMSTERDAM, MED CTR, DEPT CARDIOL 6D 120, NL-1007 MB AMSTERDAM, NETHERLANDS. NORTHWICK PK HOSP & CLIN RES CTR, DEPT CARDIOVASC MED, HARROW HA1 3UJ, MIDDX, ENGLAND. JOHN RADCLIFFE HOSP, DEPT CARDIOL, OXFORD OX3 9DU, ENGLAND. UNIV NEBRASKA, MED CTR, DEPT INTERNAL MED, CARDIOL SECT, OMAHA, NE USA. OREGON HLTH & SCI UNIV, PORTLAND, OR USA.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ABE Y, 2005, HEART, V91, P1578, DOI 10.1136/HRT.2004.057521##AGATI L, 1997, EUR HEART J, V18, P771##BALCELLS E, 2003, J AM COLL CARDIOL, V41, P827, DOI 10.1016/S0735-1097(02)02962-5##BIAGINI E, 2006, AM J CARDIOL, V97, P361, DOI 10.1016/J.AMJCARD.2005.08.053##BOLOGNESE L, 2004, CIRCULATION, V109, P1121, DOI 10.1161/01.CIR.0000118496.44135.A7##BOLOGNESE L, 1996, J AM COLL CARDIOL, V28, P1677, DOI 10.1016/S0735-1097(96)00400-7##CHAPMAN S, 2005, J ULTRAS MED, V24, P1099, DOI 10.7863/JUM.2005.24.8.1099##DIJKMANS P A, 2005, EUR J ECHOCARDIOGR, V6, P363, DOI 10.1016/J.EUJE.2005.02.003##ELHENDY A, 2004, J AM COLL CARDIOL, V44, P2185, DOI 10.1016/J.JACC.2004.08.059##FIRSCHKE C, 1997, CIRCULATION, V96, P959##HAGENDORFF A, 2004, EUR J ECHOCARDIOGR, V5, P132, DOI 10.1016/S1525-2167(03)00055-6##HEINLE SK, 2000, CIRCULATION, V102, P55, DOI 10.1161/01.CIR.102.1.55##HILLIS GS, 2003, J AM SOC ECHOCARDIOG, V16, P638, DOI 10.1016/S0894-7317(03)00212-8##HUANG WC, 2005, INT J CARDIOL, V104, P81, DOI 10.1016/J.IJCARD.2004.12.022##ISMAIL S, 1995, CIRCULATION, V91, P821, DOI 10.1161/01.CIR.91.3.821##ITO H, 1992, CIRCULATION, V85, P1699, DOI 10.1161/01.CIR.85.5.1699##IWAKURA K, 2001, J AM COLL CARDIOL, V38, P472, DOI 10.1016/S0735-1097(01)01405-X##JANARDHANAN R, 2003, AM J CARDIOL, V92, P493, DOI 10.1016/S0002-9149(03)00713-6##JANARDHANAN R, 2005, AM HEART J, V149, P355, DOI 10.1016/J.AHJ.2004.06.018##JAYAWEERA AR, 1994, CIRC RES, V74, P1157, DOI 10.1161/01.RES.74.6.1157##JEETLEY P, 2006, J AM COLL CARDIOL, V47, P141, DOI 10.1016/J.JACC.2005.08.054##KAMP O, 2001, EUR HEART J, V22, P1485, DOI 10.1053/EUHJ.2001.2604##KAUL S, 1997, CIRCULATION, V96, P785##KLONER RA, 1993, J AM COLL CARDIOL, V21, P537, DOI 10.1016/0735-1097(93)90700-B##KONTOS MC, 2003, AM J CARDIOL, V91, P1099, DOI 10.1016/S0002-9149(03)00156-5##KOROSOGLOU G, 2006, AM HEART J, V151, P131, DOI 10.1016/J.AHJ.2005.02.046##KOROSOGLOU G, 2005, AM J CARDIOL, V95, P1033, DOI 10.1016/J.AMJCARD.2004.12.055##LAFITTE S, 2002, J AM COLL CARDIOL, V39, P1546, DOI 10.1016/S0735-1097(02)01771-0##LEPPER W, 2000, CIRCULATION, V101, P2368, DOI 10.1161/01.CIR.101.20.2368##LEPPER W, 2001, AM J CARDIOL, V88, P1358, DOI 10.1016/S0002-9149(01)02113-0##LINDNER JR, 2000, CIRCULATION, V102, P2745, DOI 10.1161/01.CIR.102.22.2745##LINKA AZ, 1998, CIRCULATION, V98, P1912, DOI 10.1161/01.CIR.98.18.1912##MAIN ML, 2001, J AM COLL CARDIOL, V38, P1390, DOI 10.1016/S0735-1097(01)01574-1##MASUGATA H, 2000, CIRCULATION, V102, P1427, DOI 10.1161/01.CIR.102.12.1427##MASUGATA H, 2001, CIRCULATION, V104, P1550, DOI 10.1161/HC3801.095694##MOIR S, 2004, CIRCULATION, V110, P1108, DOI 10.1161/01.CIR.0000139905.47128.9F##MOIR S, 2004, AM J CARDIOL, V93, P1212, DOI 10.1016/J.AMJCARD.2004.02.010##MOR-AVI V, 2001, CIRCULATION, V104, P352##OLSZOWSKA M, 2003, INT J CARDIOL, V90, P49, DOI 10.1016/S0167-5273(02)00475-8##ORABY MA, 2002, AM J CARDIOL, V89, P640, DOI 10.1016/S0002-9149(01)02317-7##PELTIER M, 2004, J AM COLL CARDIOL, V43, P257, DOI 10.1016/J.JACC.2003.07.040##PORTER TR, 1998, AM J CARDIOL, V82, P1173, DOI 10.1016/S0002-9149(98)00597-9##RAGOSTA M, 1994, CIRCULATION, V89, P2562, DOI 10.1161/01.CIR.89.6.2562##ROCCHI G, 2003, CORONARY ARTERY DIS, V14, P239, DOI 10.1097/01.MCA.0000065924.30342.38##ROCCHI G, 2001, AM J CARDIOL, V87, P278, DOI 10.1016/S0002-9149(00)01358-8##SAKUMA T, 1998, J AM COLL CARDIOL, V32, P890, DOI 10.1016/S0735-1097(98)00342-8##SBANO JCN, 2005, ECHOCARDIOGR-J CARD, V22, P496, DOI 10.1111/J.1540-8175.2005.04007.X##SCHUMANN PA, 2002, INVEST RADIOL, V37, P587, DOI 10.1097/00004424-200211000-00001##SENIOR R, 2005, CIRCULATION, V112, P1587, DOI 10.1161/CIRCULATIONAHA.104.530089##SENIOR R, 2004, AM HEART J, V147, P1100, DOI 10.1016/J.AHJ.2003.12.030##SENIOR R, 2003, AM J CARDIOL, V91, P397, DOI 10.1016/S0002-9149(02)03232-0##SHIMONI S, 2003, CIRCULATION, V107, P538, DOI 10.1161/01.CIR.0000047211.53448.12##SHIMONI S, 2001, J AM COLL CARDIOL, V37, P741, DOI 10.1016/S0735-1097(00)01179-7##SIESWERDA GERTJAN TJ, 2004, EUR J ECHOCARDIOGR, V5, P41, DOI 10.1016/J.EUJE.2003.08.005##SIESWERDA GT, 2003, ECHOCARDIOGR-J CARD, V20, P545, DOI 10.1046/J.1540-8175.2003.03093.X##SOMAN P, 2000, HEART, V84, P634, DOI 10.1136/HEART.84.6.634##SWINBURN JMA, 2001, J AM COLL CARDIOL, V38, P19, DOI 10.1016/S0735-1097(01)01317-1##TOLEDO E, 2006, J AM COLL CARDIOL, V47, P146, DOI 10.1016/J.JACC.2005.08.053##TONG KL, 2005, J AM COLL CARDIOL, V46, P920, DOI 10.1016/J.JACC.2005.03.076##TSUTSUI JM, 2005, ECHOCARDIOGR-J CARD, V22, P487, DOI 10.1111/J.1540-8175.2005.40037.X##TSUTSUI JM, 2005, J AM COLL CARDIOL, V45, P1235, DOI 10.1016/J.JACC.2005.01.024##TSUTSUI JM, 2005, CIRCULATION, V112, P1444, DOI 10.1161/CIRCULATIONAHA.105.537134##TSUTSUI JM, 2005, AM J CARDIOL, V95, P565, DOI 10.1016/J.AMJCARD.2004.10.035##VILLANUEVA FS, 1998, CIRCULATION, V98, P1, DOI 10.1161/01.CIR.98.1.1##VOGEL R, 2005, J AM COLL CARDIOL, V45, P754, DOI 10.1016/J.JACC.2004.11.044##WEI K, 2001, CIRCULATION, V103, P2560##WEI K, 1998, CIRCULATION, V97, P473##WEI K, 2003, AM J CARDIOL, V91, P1293, DOI 10.1016/S0002-9149(03)00316-3##WEI K, 2002, CIRCULATION, V105, P218, DOI 10.1161/HC0202.101986##WEI K, 1998, J AM COLL CARDIOL, V32, P252, DOI 10.1016/S0735-1097(98)00212-5##WINTER REIDAR, 2005, EUR J ECHOCARDIOGR, V6, P31, DOI 10.1016/J.EUJE.2004.06.003##XIE F, 2005, AM J CARDIOL, V96, P506, DOI 10.1016/J.AMJCARD.2005.04.010##YU EHC, 2004, J AM COLL CARDIOL, V43, P1807, DOI 10.1016/J.JACC.2003.09.073",77,2020-11-20,NA
J,WOS:000242520900003,2006,VALUE OF PLATELET REACTIVITY IN PREDICTING RESPONSE TO TREATMENT AND CLINICAL OUTCOME IN PATIENTS UNDERGOING PRIMARY CORONARY INTERVENTION - INSIGHTS INTO THE STRATEGY STUDY,"OBJECTIVES THE PURPOSE OF THIS STUDY WAS TO EVALUATE THE VALUE OF PLATELET REACTIVITY (PR) IN PREDICTING THE RESPONSE TO TREATMENT AND OUTCOME IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION ASSISTED BY GLYCOPROTEIN (GP) IIB/IIIA INHIBITION. BACKGROUND THERE IS LIMITED PROGNOSTIC INFORMATION ON THE ROLE OF SPONTANEOUS OR DRUG-MODULATED PR IN STEMI PATIENTS. METHODS THE PR WAS MEASURED WITH PLATELET FUNCTION ANALYZER (PFA)-100 AND LIGHT TRANSMISSION AGGREGOMETRY (LTA) USING ADENOSINE DIPHOSPHATE AS AGONIST IN 70 CONSECUTIVE STEMI PATIENTS AT ENTRY (PR-TO), 10 MIN AFTER GP ILB/IIIA BOLUS (PR-T1), AND DISCHARGE (PR-T2) AND IN 30 STABLE ANGINA (SA) PATIENTS (PR-SA). COMPLETE PLATELET INHIBITION (CPI) WAS BASED ON CLOSURE TIME > 300 S BY PFA-100 AND PERCENTAGE INHIBITION OF PLATELET AGGREGATION > 95% BY LTA. CLINICAL, ELECTROCARDIOGRAPHIC, AND ANGIOGRAPHIC RESPONSES TO TREATMENT DURING 1-YEAR FOLLOW-UP WERE COLLECTED. RESULTS ACCORDING TO BOTH TECHNIQUES, PR-TO WAS HIGHER THAN: 1) PR-T2 AND PR-SA; 2) IN THOSE WITHOUT CPI AT T1; AND 3) IN PATIENTS WITH FINAL THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) FLOW GRADE < 3. THE PR-TO ASSESSED WITH PFA-100 CORRELATED WITH: 1) CORRECTED TIMI FRAME COUNT (R = -0.6, P < 0.001); 2) ST-SEGMENT RESOLUTION (R = 45, P < 0.001); AND 3) CREATINE KINASE-MB (R = -0.47, P < 0.001). AT 1 YEAR, PATIENTS WITH HIGH PR-TO SHOWED AN ADJUSTED 5- TO 11-FOLD INCREASE IN THE RISK OF DEATH, REINFARCTION, AND TARGET VESSEL REVASCULARIZATION (HAZARD RATIO [HR] 11, 95% CONFIDENCE INTERVAL [CI] 1.5 TO 78 [P = 0.02] IN PFA-100; HR 5.2, 95% CI 1.1 TO 23 [P = 0.03] IN LTA). CONCLUSIONS THE PR AT ENTRY AFFECTS RESPONSE TO GP ILB/IIIA INHIBITION, MECHANICAL TREATMENT, AND LONG-TERM OUTCOME IN STEMI PATIENTS UNDERGOING PRIMARY INTERVENTION.",ACUTE MYOCARDIAL-INFARCTION; SIROLIMUS-ELUTING STENT; BARE-METAL STENT; CLOPIDOGREL; AGGREGATION; ANGIOPLASTY; REPERFUSION; INHIBITION; THROMBOSIS; TIROFIBAN,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,"CAMPO, G##VALGIMIGLI, M##GEMMATI, D##PERCOCO, G##TOGNAZZO, S##CICCHITELLI, G##CATOZZI, L##MALAGUTTI, P##ANSELMI, M##VASSANELLI, C##SCAPOLI, G##FERRARI, R","UNIV FERRARA, DEPT CARDIOL, I-44100 FERRARA, ITALY. UNIV FERRARA, CTR STUDY HEMOSTASIS & THROMBOSIS, I-44100 FERRARA, ITALY. IRCCS, SALVATORE MAUGERI FDN, CARDIOVASC RES CTR, GUSSAGO, ITALY. ERASMUS MC, THORAXCTR, ROTTERDAM, NETHERLANDS. DIPARTIMENTO SCI BIOMED & CHIRURG CARDIOL, VERONA, ITALY.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"AJZENBERG N, 2005, J AM COLL CARDIOL, V45, P1753, DOI 10.1016/J.JACC.2004.10.079##ANGIOLILLO DJ, 2005, DIABETES, V54, P2430, DOI 10.2337/DIABETES.54.8.2430##ANGIOLILLO DJ, 2005, THROMB RES, V115, P101, DOI 10.1016/J.THROMRES.2004.07.007##ANTONIUCCI D, 2003, J AM COLL CARDIOL, V42, P1879, DOI 10.1016/J.JACC.2003.07.017##BOERSMA E, 2002, LANCET, V359, P189, DOI 10.1016/S0140-6736(02)07442-1##FROSSARD M, 2004, CIRCULATION, V110, P1392, DOI 10.1161/01.CIR.0000141575.92958.9C##GIBSON CM, 1996, CIRCULATION, V93, P879, DOI 10.1161/01.CIR.93.5.879##GURBEL PA, 2005, J AM COLL CARDIOL, V46, P1820, DOI 10.1016/J.JACC.2005.07.041##GURBEL PA, 2003, CIRCULATION, V107, P2908, DOI 10.1161/01.CIR.0000072771.11429.83##KABBANI SS, 2001, CIRCULATION, V104, P181, DOI 10.1161/01.CIR.104.2.181##MADAN M, 2002, AM HEART J, V144, P151, DOI 10.1067/MHJ.2002.123581##MADAN M, 2001, AM HEART J, V141, P226, DOI 10.1067/MHJ.2001.112489##MAMMEN EF, 1998, SEMIN THROMB HEMOST, V24, P195, DOI 10.1055/S-2007-995840##MORISHIMA I, 2000, J AM COLL CARDIOL, V36, P1202, DOI 10.1016/S0735-1097(00)00865-2##PASSAMANI E, 1985, NEW ENGL J MED, V312, P932##STEINHUBL SR, 2001, CIRCULATION, V103, P2572##TOPOL EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1##TOPOL EJ, 2003, J AM COLL CARDIOL, V42, P1886, DOI 10.1016/J.JACC.2003.09.010##VALGIMIGLI M, 2005, JAMA-J AM MED ASSOC, V293, P2109, DOI 10.1001/JAMA.293.17.2109##VALGIMIGLI M, 2004, CARDIOVASC DRUG THER, V18, P225, DOI 10.1023/B:CARD.0000033644.91126.F7##VAN'T HOF AWJ, 1998, CIRCULATION, V97, P2302, DOI 10.1161/01.CIR.97.23.2302##WENAWESER P, 2005, J AM COLL CARDIOL, V45, P1748, DOI 10.1016/J.JACC.2005.01.058",126,2020-11-20,NA
J,WOS:000242520900007,2006,ONLY INCIDENT DEPRESSIVE EPISODES AFTER MYOCARDIAL INFARCTION ARE ASSOCIATED WITH NEW CARDIOVASCULAR EVENTS,"OBJECTIVES THE PURPOSE OF THIS RESEARCH WAS TO STUDY WHETHER INCIDENT AND NON-INCIDENT DEPRESSION AFTER MYOCARDIAL INFARCTION (MI) ARE DIFFERENTIALLY ASSOCIATED WITH PROSPECTIVE FATAL AND NON-FATAL CARDIOVASCULAR EVENTS. BACKGROUND POST-MI DEPRESSION IS DEFINED AS THE PRESENCE OF DEPRESSION AFTER MI. HOWEVER, ONLY ABOUT ONE-HALF OF POST-MI DEPRESSIONS REPRESENT AN INCIDENT EPISODE, WHEREAS THE OTHER HALF ARE ONGOING OR RECURRENT DEPRESSIONS. WE INVESTIGATED WHETHER THESE SUBTYPES DIFFER IN CARDIOVASCULAR PROGNOSIS. METHODS A TOTAL OF 468 MI PATIENTS WERE ASSESSED FOR THE PRESENCE OF AN INTERNATIONAL CLASSIFICATION OF DISEASES-10 DEPRESSIVE DISORDER DURING THE YEAR AFTER INDEX MI. A COMPARISON WAS MADE ON NEW CARDIOVASCULAR EVENTS (MEAN FOLLOW UP: 2.5 YEARS) BETWEEN PATIENTS WITH NO, INCIDENT, AND NON-INCIDENT POST-MI DEPRESSION BY SURVIVAL ANALYSIS. RESULTS COMPARED WITH NON-DEPRESSED PATIENTS, THOSE WITH AN INCIDENT DEPRESSION HAD AN INCREASED RISK OF CARDIOVASCULAR EVENTS (HAZARD RATIO [HR] 1.65; 95% CONFIDENCE INTERVAL [CI] 1.02 TO 2.65), BUT NOT THOSE WITH A NON-INCIDENT DEPRESSION (HR 1.12; 95% CL 0.61 TO 2.06), WHICH REMAINED AFTER CONTROLLING FOR CONFOUNDERS (HR 1.76; 9S% C1 1.06 TO 2.93 AND HR 1.39; 95% CL 0.74 TO 2.61, RESPECTIVELY). CONCLUSIONS ONLY PATIENTS WITH INCIDENT POST-MI DEPRESSION HAVE AN IMPAIRED CARDIOVASCULAR PROGNOSIS. A MORE DETAILED SUBTYPING OF POST-MI DEPRESSION IS NEEDED, BASED ON AN INTEGRATION OF RECENT FINDINGS ON THE DIFFERENTIAL IMPACT OF DEPRESSION SYMPTOM PROFILES AND PERSONALITY ON CARDIAC OUTCOMES.",CORONARY-HEART-DISEASE; D PERSONALITY; MAJOR DEPRESSION; SYMPTOMS; MORTALITY; RISK; VALIDITY; ILLNESS; MI,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,"DE JONGE, P##VAN DEN BRINK, RHS##SPIJKERMAN, TA##ORMEL, J","UNIV GRONINGEN, MED CTR, DEPT PSYCHIAT, NL-9700 RB GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"BERKMAN LF, 2003, JAMA-J AM MED ASSOC, V289, P3106##BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/JAMA.264.19.2524##BUSH DE, 2001, AM J CARDIOL, V88, P337, DOI 10.1016/S0002-9149(01)01675-7##COLE MG, 2003, AM J PSYCHIAT, V160, P1147, DOI 10.1176/APPI.AJP.160.6.1147##DE JONGE P, 2006, PSYCHOSOMATICS, V47, P33, DOI 10.1176/APPI.PSY.47.1.33##DE JONGE P, 2006, AM J PSYCHIAT, V163, P138, DOI 10.1176/APPI.AJP.163.1.138##DENOLLET J, 2000, CIRCULATION, V102, P630, DOI 10.1161/01.CIR.102.6.630##DUSSELDORP E, 1999, HEALTH PSYCHOL, V18, P506, DOI 10.1037/0278-6133.18.5.506##EYSENCK SBG, 1985, PERS INDIV DIFFER, V6, P21, DOI 10.1016/0191-8869(85)90026-1##FREEDLAND KE, 1992, PSYCHOSOM MED, V54, P416, DOI 10.1097/00006842-199207000-00004##GLASSMAN AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/JAMA.288.6.701##GRACE SL, 2005, AM J CARDIOL, V96, P1179, DOI 10.1016/J.AMJCARD.2005.06.052##LLOYD GG, 1983, BRIT J PSYCHIAT, V142, P120, DOI 10.1192/BJP.142.2.120##MCCAFFERY JM, 2006, PSYCHOSOM MED, V68, P187, DOI 10.1097/01.PSY.0000208630.79271.A0##PEDERSEN SS, 2004, J PSYCHOSOM RES, V57, P265, DOI 10.1016/S0022-3999(03)00614-7##PEDERSEN SS, 2004, J AM COLL CARDIOL, V44, P997, DOI 10.1016/J.JACC.2004.05.064##SPIJKERMAN T, 2005, GEN HOSP PSYCHIAT, V27, P411, DOI 10.1016/J.GENHOSPPSYCH.2005.05.007##STRIK JJMH, 2003, J AM COLL CARDIOL, V42, P1801, DOI 10.1016/J.JACC.2003.07.007##VAN MELLE JP, 2004, PSYCHOSOM MED, V66, P814, DOI 10.1097/01.PSY.0000146294.82810.9C##WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1",102,2020-11-20,NA
J,WOS:000242520900008,2006,BETA-BLOCKERS AND DEPRESSION AFTER MYOCARDIAL INFARCTION - A MULTICENTER PROSPECTIVE STUDY,"OBJECTIVES THE PURPOSE OF THIS RESEARCH WAS TO EXPLORE THE PROSPECTIVE RELATIONSHIP BETWEEN THE USE OF BETA-BLOCKERS AND DEPRESSION IN MYOCARDIAL INFARCTION (MI) PATIENTS. BACKGROUND BETA-BLOCKER USE HAS BEEN REPORTED TO BE ASSOCIATED WITH THE DEVELOPMENT OF DEPRESSION, BUT THE METHODOLOGICAL QUALITY OF STUDIES IN THIS FIELD IS WEAK. METHODS IN A MULTICENTER STUDY, MI PATIENTS (N = 127 NON-BETA-BLOCKER USERS AND N = 254 BETA-BLOCKER USERS) WERE ASSESSED FOR DEPRESSIVE SYMPTOMS (USING THE BECK DEPRESSION INVENTORY [BDI] AT BASELINE AND T = 3, 6, AND 12 MONTHS POST-MI) AND INTERNATIONAL CLASSIFICATION OF DISEASES-10 DEPRESSIVE DISORDER (COMPOSITE INTERNATIONAL DIAGNOSTIC INTER-VIEW). PATIENTS WERE MATCHED USING THE FREQUENCY MATCHING PROCEDURE ACCORDING TO AGE, GENDER, HOSPITAL OF ADMISSION, PRESENCE OF BASELINE DEPRESSIVE SYMPTOMS, AND LEFT VENTRICULAR FUNCTION. RESULTS NO SIGNIFICANT DIFFERENCES WERE FOUND BETWEEN NON-BETA-BLOCKER USERS AND BETA-BLOCKER USERS ON THE PRESENCE OF DEPRESSIVE SYMPTOMS (P > 0.10 AT ANY OF THE TIME POINTS) OR DEPRESSIVE DISORDER (P = 0.86). CONTROLLING FOR CONFOUNDERS DID NOT ALTER THESE FINDINGS. A TREND TOWARD INCREASING BDI SCORES WAS SEEN IN PATIENTS WITH LONG-TERM USE OF BETA-BLOCKERS AND PATIENTS WITH HIGHER BETA-BLOCKER DOSE. CONCLUSIONS IN POST-MI PATIENTS, PRESCRIPTION OF BETA-BLOCKERS IS NOT ASSOCIATED WITH AN INCREASE IN DEPRESSIVE SYMPTOMS OR DEPRESSIVE DISORDERS IN THE FIRST YEAR AFTER MI. HOWEVER, LONG-TERM AND HIGH-DOSAGE EFFECTS CANNOT BE RULED OUT.",RANDOMIZED TRIAL; PROPRANOLOL; HYPERTENSION; BLOCKADE; ASSOCIATION; MORTALITY; THERAPY; USERS,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,"VAN MELLE, JP##VERBEEK, DEP##VAN DEN BERG, MP##ORMEL, J##VAN DER LINDE, MR##DE JONGE, P","UNIV GRONINGEN, MED CTR, DEPT CARDIOL, THORAXCTR, NL-9700 RB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT PSYCHIAT, NL-9700 RB GRONINGEN, NETHERLANDS. NIJ SMELLINGHE HOSP, DEPT CARDIOL, DRACHTEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ADLER L, 1988, PSYCHOPHARMACOL BULL, V24, P232##[ANONYMOUS], 1990, COMP INT DIAGN INT C##AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/JAMA.255.3.357##BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/ARCHPSYC.1961.01710120031004##BRIGHT RA, 1992, JAMA-J AM MED ASSOC, V267, P1783##CARNEY RM, 1987, AM J MED, V83, P223, DOI 10.1016/0002-9343(87)90689-9##COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/BMJ.293.6555.1145##EVERLY MJ, 2004, ANN PHARMACOTHER, V38, P286, DOI 10.1345/APH.1C472##FODOR JG, 1987, J CLIN PHARMACOL, V27, P892, DOI 10.1002/J.1552-4604.1987.TB05585.X##FREEMANTLE N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/BMJ.318.7200.1730##FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707##GERSTMAN BB, 1996, J CLIN EPIDEMIOL, V49, P809, DOI 10.1016/0895-4356(96)00017-0##GOLDSTEIN G, 1990, HYPERTENSION, V15, P361, DOI 10.1161/01.HYP.15.4.361##GRIFFIN SJ, 1986, J CLIN PSYCHIAT, V47, P453##HALLAS J, 1996, EPIDEMIOLOGY, V7, P478, DOI 10.1097/00001648-199609000-00005##HEAD A, 1996, BRIT J SPORT MED, V30, P238, DOI 10.1136/BJSM.30.3.238##JULIAN DG, 1982, LANCET, V1, P1142##LOPEZ-SENDON J, 2004, EUR HEART J, V25, P1341, DOI 10.1016/J.EHJ.2004.06.002##MELLE JP, 2006, IN J CARDIOL, V109, P88##SCHLEIFER SJ, 1991, AM HEART J, V121, P1397, DOI 10.1016/0002-8703(91)90144-7##SORGI P, 1992, J NEUROPSYCH CLIN N, V4, P187##SPIJKERMAN T, 2005, GEN HOSP PSYCHIAT, V27, P411, DOI 10.1016/J.GENHOSPPSYCH.2005.05.007##STRIK JJMH, 2001, PSYCHOSOMATICS, V42, P423, DOI 10.1176/APPI.PSY.42.5.423##THIESSEN BQ, 1990, ARCH INTERN MED, V150, P2286, DOI 10.1001/ARCHINTE.150.11.2286##VAN DEN BRINK RHS, 2002, AM HEART J, V144, P219, DOI 10.1067/MHJ.2002.123580##VAN MELLE JP, 2004, PSYCHOSOM MED, V66, P814, DOI 10.1097/01.PSY.0000146294.82810.9C##WAAL HJ, 1967, BRIT MED J, V2, P50, DOI 10.1136/BMJ.2.5543.50",38,2020-11-20,NA
J,WOS:000242520900015,2006,CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH A NARROW QRS COMPLEX,"OBJECTIVES THE PURPOSE OF THIS STUDY WAS TO EVALUATE THE EFFECTS OF CARDIAC RESYNCHRONIZATION THERAPY (CRT) IN HEART FAILURE PATIENTS WITH NARROW QRS COMPLEX (< 120 MS) AND EVIDENCE OF LEFT VENTRICULAR (LV) DYSSYNCHRONY ON TISSUE DOPPLER IMAGING (TDI). BACKGROUND CARDIAC RESYNCHRONIZATION THERAPY IS BENEFICIAL IN SELECTED HEART FAILURE PATIENTS WITH WIDE QRS COMPLEX (>= 120 MS). PATIENTS WITH NARROW QRS COMPLEX ARE CURRENTLY NOT ELIGIBLE FOR CRT, AND THE POTENTIAL EFFECTS OF CRT ARE NOT WELL STUDIED. METHODS THIRTY-THREE CONSECUTIVE PATIENTS WITH NARROW QRS COMPLEX AND 33 CONSECUTIVE PATIENTS WITH WIDE QRS COMPLEX (CONTROL GROUP) WERE PROSPECTIVELY INCLUDED. ALL PATIENTS NEEDED TO HAVE LV DYSSYNCHRONY >= 65 MS ON TDI, NEW YORK HEART ASSOCIATION (NYHA) FUNCTIONAL CLASS III/IV HEART FAILURE, AND LV EJECTION FRACTION <= 35%. RESULTS BASELINE CHARACTERISTICS, PARTICULARLY LV DYSSYNCHRONY, WERE COMPARABLE BETWEEN PATIENTS WITH NARROW AND WIDE QRS COMPLEX (110 +/- 8 MS VS. 175 +/- 22 MS; P = NS). NO SIGNIFICANT RELATIONSHIP WAS OBSERVED BETWEEN BASELINE QRS DURATION AND LV DYSSYNCHRONY (R = 0.21; P = NS). THE IMPROVEMENT IN CLINICAL SYMPTOMS AND LV REVERSE REMODELING WAS COMPARABLE BETWEEN PATIENTS WITH NARROW AND WIDE QRS COMPLEX (MEAN NYHA FUNCTIONAL CLASS REDUCTION 0.9 +/- 0.6 VS. 1.1 +/- 0.6 [P = NS] AND MEAN LV END-SYSTOLIC VOLUME REDUCTION 39 +/- 34 ML VS. 44 +/- 46 ML [P = NS]). CONCLUSIONS CARDIAC RESYNCHRONIZATION THERAPY APPEARS TO BE BENEFICIAL IN PATIENTS WITH NARROW QRS COMPLEX AND SEVERE LV DYSSYNCHRONY ON TDI, WITH SIMILAR IMPROVEMENT IN SYMPTOMS AND COMPARABLE LV REVERSE REMODELING TO PATIENTS WITH WIDE QRS COMPLEX. THE CURRENT RESULTS NEED CONFIRMATION IN LARGER PATIENT COHORTS.",LEFT-VENTRICULAR DYSSYNCHRONY; CHRONIC HEART-FAILURE; DURATION; ASYNCHRONY; PREDICTS; BENEFIT; DELAY,NA,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,"BLEEKER, GB##HOLMAN, ER##STEENDIJK, P##BOERSMA, E##VAN DER WALL, EE##SCHALIJ, MJ##BAX, JJ","LEIDEN UNIV, MED CTR, DEPT CARDIOL, NL-2333 ZA LEIDEN, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS. ERASMUS UNIV, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ABRAHAM WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMOA013168##ACHILLI A, 2003, J AM COLL CARDIOL, V42, P2117, DOI 10.1016/J.JACC.2003.08.024##BADER H, 2004, J AM COLL CARDIOL, V43, P248, DOI 10.1016/J.JACC.2003.08.038##BAX JJ, 2003, AM J CARDIOL, V92, P1238, DOI 10.1016/J.AMJCARD.2003.06.016##BAX JJ, 2004, J AM COLL CARDIOL, V44, P1834, DOI 10.1016/J.JACC.2004.08.016##BLEEKER GB, 2006, CIRCULATION, V113, P969, DOI 10.1161/CIRCULATIONAHA.105.543678##BLEEKER GB, 2005, AM J CARDIOL, V95, P140, DOI 10.1016/J.AMJCARD.2004.08.082##BLEEKER GB, 2004, J CARDIOVASC ELECTR, V15, P544, DOI 10.1046/J.1540-8167.2004.03604.X##BORDONI A, 2004, CINEFORUM, V44, P2##BREITHARDT OA, 2002, J AM COLL CARDIOL, V40, P536, DOI 10.1016/S0735-1097(02)01987-3##BRISTOW MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMOA032423##CAZEAU S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202##CLELAND JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMOA050496##FREUDENBERGER R, 2004, CLIN CARDIOL, V27, P151, DOI 10.1002/CLC.4960270311##GHIO S, 2004, EUR HEART J, V25, P571, DOI 10.1016/J.EHJ.2003.09.030##KASHANI A, 2005, J AM COLL CARDIOL, V46, P2183, DOI 10.1016/J.JACC.2005.01.071##ROULEAU F, 2001, PACE, V24, P1500, DOI 10.1046/J.1460-9592.2001.01500.X##SCHILLER N B, 1989, J AM SOC ECHOCARDIOGR, V2, P358##STRICKBERGER SA, 2005, CIRCULATION, V111, P2146, DOI 10.1161/01.CIR.0000161276.09685.4A##SUTTON MGS, 2003, CIRCULATION, V107, P1985, DOI 10.1161/01.CIR.0000065226.24159.E9##SWEDBERG K, 2005, EUR HEART J, V26, P1115, DOI 10.1093/EURHEARTJ/EHI204##TURNER MS, 2004, HEART, V90, P502, DOI 10.1136/HRT.2003.011759##YU CM, 2003, AM J CARDIOL, V91, P684, DOI 10.1016/S0002-9149(02)03404-5##YU CM, 2003, HEART, V89, P54, DOI 10.1136/HEART.89.1.54",194,2020-11-20,NA
J,WOS:000242564300001,2006,BIOGEOCHEMICAL SPECIATION OF FE IN OCEAN WATER,"THE BIOGEOCHEMICAL SPECIATION OF FE IN SEAWATER HAS BEEN EVALUATED USING THE CONSISTENT NON-IDEAL COMPETITIVE ADSORPTION MODEL (NICA-DONNAN MODEL). TWO TYPES OF DATA SETS WERE USED, I.E. FE-HYDROXIDE SOLUBILITY DATA AND COMPETITIVE LIGAND EQUILIBRATION/CATHODIC STRIPPING VOLTAMMETRY (CLE/CSV) FE TITRATION DATA. THE DIFFERENCE IN SOLUBILITY OF FE-HYDROXIDE IN 0.7 M NACL AND SEAWATER WAS USED TO EVALUATE THE SPECIATION OF INORGANIC FE(III) AND WAS USED TO PARAMETERIZE THE NICA-DORMAN MODEL FOR FE COMPLEXATION BY THE MARINE DOM FRACTION (< 0.025 MU M), RELYING FOR COMPETITIVE IONS ON GENERIC PARAMETERS DERIVED FOR FULVIC ACID. MARINE DOM BEHAVES HETEROGENEOUSLY WITH RESPECT TO FE COMPLEXATION. THIS IS ALSO OBSERVED FOR CU(II) COMPLEXATION. FOR CU2+, THE COMPLEXATION IN SEAWATER CAN BE PREDICTED WITH THE NICA-DONNAN MODEL USING A GENERIC PARAMETER SET DERIVED FOR FULVIC ACIDS. THE FE-BINDING DECREASES WITH INCREASING PH DUE TO FE(ILL) HYDROLYSIS AND DECREASING FE-HYDROXIDE SOLUBILITY. MG(II) AND CA(II) IONS ARE GOOD COMPETITORS, REDUCING THE FE(III) COMPLEXATION BY A FACTOR OF ABOUT 4 IN SEAWATER AT PH 8.1. TRACE METALS LIKE AI(HI) AND CU2+ HAVE ALMOST NO EFFECT ON FE(III) COMPLEXATION AND VICE VERSA. INTERPRETATION OF THE NON-IDEALITY PARAMETERS OF FE(III) AS STOICHIOMETRY COEFFICIENTS POINTS TO AN INTERACTION OF FE3+ WITH TWO LIGANDS IN THE LOW PH RANGE AND WITH THREE LIGANDS IN HIGH PH RANGE (SEAWATER). THE FE COMPLEXATION BY DOM IS ALMOST TEMPERATURE INDEPENDENT IN CONTRAST TO THE DISSOLUTION OF FE-HYDROXIDE (DELTA H-R = -78 KJ/MOL). THE FE COMPLEXATION OF MARINE DOM (FRACTION < 0.2/0.4 MU M) HAS ALSO BEEN EVALUATED USING FE TITRATION DATA OF SEAWATER MEASURED WITH CLE/CSV. IN MOST CASES, THE SAME CHEMICAL HETEROGENEITY IS OBSERVED, BUT VARIATION IN FE BINDING (MOL/KG DOM) EXISTS. THE DIFFERENCE IS DISCUSSED IN RELATION TO THE VARIATION IN THE MOLECULAR SIZE (HMW/LMW) AND COMPOSITION (REFRACTORY/LABILE OR HUMIC-LIKE/PROTEIN-LIKE) OF MARINE DOC. ANALYSIS OF THE FE BINDING DURING BLOOMING OF PHYTOPLANKTON SHOWS THAT IN SUCH SITUATIONS THE FE-COMPLEXATION CAN BE ENHANCED BY A FACTOR 3 COMPARED TO NON-PRODUCTIVE SEAWATER AT THE SAME FREE INORGANIC FE CONCENTRATION. INTERESTINGLY, THE CHARACTERISTICS REMAIN SIMILAR TO THAT OF DOM, WHICH MIGHT IMPLY THAT THE NEWLY GENERATED ORGANIC LIGANDS DO NOT REACT ACCORDING TO A SIMPLE SINGLE SITE LANGMUIR MODEL. IF THE INCREASE IN FE COMPLEXATION IS DUE TO NEWLY GENERATED LIGANDS, THESE LIGANDS HAVE A MUCH HIGHER AFFINITY ON A MASS BASIS COMPARED TO DOM, SUGGESTING COMPOUNDS LIKE SIDEROPHORES OR PRODUCTS OF CELL LYSIS. THE DATA CAN BE DESCRIBED WITH THE NICA MODEL, ONLY ADJUSTING THE AVERAGE AFFINITY. ANALYSIS OF THE SPECIATION IN THE WATER COLUMN OF LOCATIONS IN DIFFERENT OCEANS SHOWS THAT DEEPWATER IN THE HNLC AREAS OF THE SOUTHERN HEMISPHERE IS GENERALLY UNDERSATURATED WITH RESPECT TO FE-HYDROXIDE. IN HIGHLY PRODUCTIVE AREAS, THE DISSOLVED FE CONCENTRATION EQUALS ABOUT 0.6-0.7 NM IN AGREEMENT WITH THE EXPECTED FE-HYDROXIDE SOLUBILITY AT 5 DEGREES C AND DOC CONTENT OF ABOUT 40 MU M. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",IRON(III) HYDROXIDE SOLUBILITY; DISSOLVED ORGANIC-MATTER; EQUATORIAL PACIFIC-OCEAN; METAL-ION BINDING; HUMIC SUBSTANCES; SOUTHERN-OCEAN; NORTH PACIFIC; ADSORPTION-ISOTHERMS; IRON CONCENTRATIONS; ATLANTIC-OCEAN,NICA; CLE/CSV; DOC; FULVIC ACID; SIDEROPHORE; PHYTO-PLANKTON; COPPER; IRON,MARINE CHEMISTRY,"HIEMSTRA, T##VAN RIEMSDIJK, WH","UNIV WAGENINGEN & RES CTR, DEPT SOIL QUAL, NL-6700 EC WAGENINGEN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; OCEANOGRAPHY",CHEMISTRY; OCEANOGRAPHY,"ARCHER DE, 2000, GLOBAL BIOGEOCHEM CY, V14, P269, DOI 10.1029/1999GB900053##BAES JR C. F., 1976, HYDROLYSIS CATIONS##BENEDETTI MF, 1995, ENVIRON SCI TECHNOL, V29, P446, DOI 10.1021/ES00002A022##BENEDETTI MF, 1996, ENVIRON SCI TECHNOL, V30, P1805, DOI 10.1021/ES950012Y##BENNER R, 1992, SCIENCE, V255, P1561, DOI 10.1126/SCIENCE.255.5051.1561##BOYD PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500##BOYE M, 2001, DEEP-SEA RES PT I, V48, P1477, DOI 10.1016/S0967-0637(00)00099-6##BUCK KN, 2005, MAR CHEM, V96, P185, DOI 10.1016/J.MARCHEM.2005.01.001##BYRNE RH, 2000, MAR CHEM, V70, P23, DOI 10.1016/S0304-4203(00)00012-8##CARLSON CA, 1995, DEEP-SEA RES PT II, V42, P639, DOI 10.1016/0967-0645(95)00023-J##CARLSON DJ, 1985, MAR CHEM, V16, P155, DOI 10.1016/0304-4203(85)90020-9##CHESTER R., 2003, MARINE GEOCHEMISTRY##COALE KH, 1996, NATURE, V383, P495, DOI 10.1038/383495A0##COALE KH, 2004, SCIENCE, V304, P408, DOI 10.1126/SCIENCE.1089778##DAFHER EV, 2002, J ENVIRON MONITOR, V4, P55, DOI 10.1039/B107279J##DAVIS JA, 1978, J COLLOID INTERF SCI, V67, P90, DOI 10.1016/0021-9797(78)90217-5##DRUFFEL ERM, 1989, J GEOPHYS RES, V97, P15639##FILIUS JD, 2000, GEOCHIM COSMOCHIM AC, V64, P51, DOI 10.1016/S0016-7037(99)00176-3##GLEDHILL M, 1994, MAR CHEM, V47, P41, DOI 10.1016/0304-4203(94)90012-4##HANSELL DA, 1997, DEEP-SEA RES PT I, V44, P843, DOI 10.1016/S0967-0637(96)00128-8##HIEMSTRA T., 2002, ENCY SURFACE COLLOID, P3773##HUDSON RJM, 2003, ENVIRON SCI TECHNOL, V37, P1553, DOI 10.1021/ES025751A##JOHNSON KS, 1997, MAR CHEM, V57, P137, DOI 10.1016/S0304-4203(97)00043-1##KAHLER P, 2001, DEEP-SEA RES PT I, V48, P49, DOI 10.1016/S0967-0637(00)00034-0##KEIZER M. G., 1998, ECOSAT TECHNICAL REP##KINNIBURGH D.G., 1993, WD9323 BRIT GEOL SUR##KINNIBURGH DG, 1983, J COLLOID INTERF SCI, V95, P370, DOI 10.1016/0021-9797(83)90197-2##KINNIBURGH DG, 1999, COLLOID SURFACE A, V151, P147, DOI 10.1016/S0927-7757(98)00637-2##KUMA K, 1996, LIMNOL OCEANOGR, V41, P396, DOI 10.4319/LO.1996.41.3.0396##LINDSAY WL, 1979, CHEM EQUILIBRIA SOIL##LIU XW, 2002, MAR CHEM, V77, P43, DOI 10.1016/S0304-4203(01)00074-3##LIU XW, 1999, GEOCHIM COSMOCHIM AC, V63, P3487, DOI 10.1016/S0016-7037(99)00270-7##MACRELLIS HM, 2001, MAR CHEM, V76, P175, DOI 10.1016/S0304-4203(01)00061-5##MARTIN JH, 1991, LIMNOL OCEANOGR, V36, P1793, DOI 10.4319/LO.1991.36.8.1793##MILLERO FJ, 1998, EARTH PLANET SC LETT, V154, P323, DOI 10.1016/S0012-821X(97)00179-9##MILNE CJ, 1995, GEOCHIM COSMOCHIM AC, V59, P1101, DOI 10.1016/0016-7037(95)00027-W##MILNE CJ, 2003, ENVIRON SCI TECHNOL, V37, P958, DOI 10.1021/ES0258879##MOPPER K, 1993, MAR CHEM, V41, P229, DOI 10.1016/0304-4203(93)90124-7##NOLTING RF, 1998, MAR CHEM, V62, P335, DOI 10.1016/S0304-4203(98)00046-2##PAREKH P, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002061##PERERA WN, 2003, INORG CHEM, V42, P5917, DOI 10.1021/IC034087B##PERONA MJ, 1985, J COLLOID INTERF SCI, V106, P64, DOI 10.1016/0021-9797(85)90381-9##RUE EL, 1995, MAR CHEM, V50, P117, DOI 10.1016/0304-4203(95)00031-L##RUE EL, 1997, LIMNOL OCEANOGR, V42, P901, DOI 10.4319/LO.1997.42.5.0901##RUSCH U, 1997, J COLLOID INTERF SCI, V191, P247, DOI 10.1006/JCIS.1997.4904##SCHULZ KG, 2004, NATURE, V430, P673, DOI 10.1038/NATURE02631##SIGG L, 2003, ENVIRON SCI TECHNOL, V40, P1934##SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922##SUNDA W, 2003, MAR CHEM, V84, P35, DOI 10.1016/S0304-4203(03)00101-4##SUNDA WG, 1997, NATURE, V390, P389, DOI 10.1038/37093##TAKATA H, 2004, MAR CHEM, V86, P139, DOI 10.1016/J.MARCHEM.2003.12.007##TANI H, 2003, DEEP-SEA RES PT I, V50, P1063, DOI 10.1016/S0967-0637(03)00098-0##TIPPING E, 2002, GEOCHIM COSMOCHIM AC, V66, P3211, DOI 10.1016/S0016-7037(02)00930-4##TUPAS LM, 1994, MAR CHEM, V45, P207, DOI 10.1016/0304-4203(94)90004-3##VAN DEN BERG CMG, 1995, MAR CHEM, V50, P139, DOI 10.1016/0304-4203(95)00032-M##VANRIEMSDIJK WH, 1986, J COLLOID INTERF SCI, V109, P219, DOI 10.1016/0021-9797(86)90296-1##WEBER L, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002340##WITTER AE, 2000, MAR CHEM, V69, P1, DOI 10.1016/S0304-4203(99)00087-0##WITTER AE, 1998, MAR CHEM, V62, P241, DOI 10.1016/S0304-4203(98)00044-9##WU JF, 1994, LIMNOL OCEANOGR, V39, P1119, DOI 10.4319/LO.1994.39.5.1119##WU JF, 2001, SCIENCE, V293, P847, DOI 10.1126/SCIENCE.1059251",56,2020-11-20,NA
J,WOS:000242564300008,2006,AN OPTIMIZED METHOD FOR AUTOMATED ANALYSIS OF ALGAL PIGMENTS BY HPLC,"A RECENT DEVELOPMENT IN ALGAL PIGMENT ANALYSIS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) IS THE APPLICATION OF AUTOMATION. AN OPTIMIZATION OF A COMPLETE SAMPLING AND ANALYSIS PROTOCOL APPLIED SPECIFICALLY IN AUTOMATION HAS NOT YET BEEN PERFORMED. IN THIS PAPER WE SHOW THAT AUTOMATION CAN ONLY BE SUCCESSFUL IF THE VARIOUS METHODOLOGICAL ASPECTS OF THE SAMPLING AND ANALYSIS PROTOCOL ARE CONSIDERED IN COHERENCE. WE INTRODUCE AN OPTIMIZED PROTOCOL THAT INVOLVES FREEZE-DRYING OF THE SAMPLE, SUBSEQUENT EXTRACTION IN 90% ACETONE AND THE APPLICATION OF WATER-PACKING DURING ANALYSIS. THE METHOD WAS EVALUATED ON BOTH NATURAL PLANKTON POPULATIONS AND A BROAD SPECTRUM OF MICROALGAL CULTURES: THALASSIOSIRA WEISFLOGII (BACILLARIOPHYCEAE), EMILIANIA HUXLEYI (PRYMNESIOPHYCEAE), PHAEOCYSTIS GLOBOSA AND PHAEOCYSTIS ANTARCTICA (PRYRYMESIOPHYCEAC) AND PYRAMIMONAS SP. (PRASINOPHYCEAE). WHEREAS PIGMENT EXTRACTS WERE UNSTABLE IN METHANOL, WITH RECORDED CHLOROPHYLL A LOSSES FROM 10% TO 60% PER DAY, PIGMENT DEGRADATION RATES IN ACETONE WERE GENERALLY LESS THAN 1% OVER 18 H STORAGE IN THE AUTOSAMPLER (4 DEGREES C). IN ADDITION, IT WAS FOUND THAT THE EXTRACTION EFFICIENCY OF ACETONE SIGNIFICANTLY INCREASED UPON FREEZE-DRYING PRIOR TO EXTRACTION. INCREASES AS HIGH AS 50-60% WERE MEASURED IN P. ANTARCTICA. THE APPLICATION OF WATER-PACKING OF THE SAMPLE DURING INJECTION RESULTED IN IMPROVED PEAK SHAPE AND PEAK SEPARATION, WITHOUT DILUTING THE PIGMENT CONCENTRATIONS. AUTOMATION IS ESPECIALLY BENEFICIAL FOR APPLICATION IN THE FIELD, WHEN MIXED ALGAL ASSEMBLAGES AND LOW BIOMASS PUT A HIGH DEMAND ON THE SENSITIVITY AS WELL AS REPRODUCIBILITY OF THE METHOD. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",PHOTOSYNTHETIC PIGMENTS; MARINE-PHYTOPLANKTON; CHLOROPHYLL-ALPHA; SEPARATION; EXTRACTION; MECHANISM; PHOSPHATE; IRON,AUTOMATION; FREEZE-DRYING; HPLC PIGMENT ANALYSES; MICROALGAE; WATER-PACKING,MARINE CHEMISTRY,"VAN LEEUWE, MA##VILLERIUS, LA##ROGGEVELD, J##VISSER, RJW##STEFELS, J","UNIV GRONINGEN, CTR BIOL, DEPT MARINE BIOL, NL-9750 AA HAREN, NETHERLANDS. NATL INST COASTAL & MARINE ENVIRONM, NL-9750 AE HAREN, NETHERLANDS. UNIV GRONINGEN, CTR BIOL, LAB PLANT PHYSIOL, NL-9750 AA HAREN, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT CLIN PHARMACOL, NL-9700 AD GRONINGEN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; OCEANOGRAPHY",CHEMISTRY; OCEANOGRAPHY,"ADMIRAAL W, 1983, J PLANKTON RES, V5, P495, DOI 10.1093/PLANKT/5.4.495##BARRETT J, 1964, PLANT PHYSIOL, V39, P44, DOI 10.1104/PP.39.1.44##BOWLES ND, 1985, CAN J FISH AQUAT SCI, V42, P1127, DOI 10.1139/F85-139##BRERETON RG, 1994, PHOTOCHEM PHOTOBIOL, V59, P99, DOI 10.1111/J.1751-1097.1994.TB05007.X##BUFFAN-DUBAU E, 2000, MAR ECOL PROG SER, V204, P293, DOI 10.3354/MEPS204293##CHEN NH, 2003, GEOCHIM COSMOCHIM AC, V67, P2027, DOI 10.1016/S0016-7037(02)01297-8##CLAUSTRE H, 2004, MAR CHEM, V85, P41, DOI 10.1016/J.MARCHEM.2003.09.002##DRAZKIEWICZ M, 1994, PHOTOSYNTHETICA, V30, P321##GEIDER RJ, 1993, J PHYCOL, V29, P755, DOI 10.1111/J.0022-3646.1993.00755.X##GIBB SW, 2001, DEEP-SEA RES PT II, V48, P795, DOI 10.1016/S0967-0645(00)00098-9##JEFFREY S.W., 1997, PHYTOPLANKTON PIGMEN##JEFFREY SW, 1974, MAR BIOL, V26, P101, DOI 10.1007/BF00388879##JEFFREY SW, 1987, MAR ECOL PROG SER, V35, P293, DOI 10.3354/MEPS035293##KOWALEWSKA G, 2001, OCEANOLOGIA, V43, P315##KRAAY GW, 1992, J PHYCOL, V28, P708, DOI 10.1111/J.0022-3646.1992.00708.X##LASATA M, 1996, MAR CHEM, V51, P315##MANTOURA RFC, 1997, PHYTOPLANKTON PIGMEN, P283##NAKAMURA A, 2001, ANAL SCI, V17, P503, DOI 10.2116/ANALSCI.17.503##NELSON JR, 1993, J MAR RES, V51, P155, DOI 10.1357/0022240933223837##STOCK R, 1967, CHROMATOGRAPHIC METH##VAN LEEUWE MA, 1998, J PHYCOL, V34, P496, DOI 10.1046/J.1529-8817.1998.340496.X##VAN LEEUWE MA, 1998, POLAR BIOL, V19, P348, DOI 10.1007/S003000050257##WRIGHT S. W., 1997, PHYTOPLANKTON PIGMEN, V10, P261, DOI DOI 10.1007/S00300-009-0582-9##WRIGHT SW, 1991, MAR ECOL PROG SER, V77, P183, DOI 10.3354/MEPS077183##WRIGHT SW, 1996, MAR ECOL PROG SER, V144, P285, DOI 10.3354/MEPS144285##WRIGHT SW, 1987, MAR ECOL PROG SER, V38, P259, DOI 10.3354/MEPS038259##ZAPATA M, 2004, MAR ECOL PROG SER, V270, P83, DOI 10.3354/MEPS270083##ZAPATA M, 1991, CHROMATOGRAPHIA, V31, P589, DOI 10.1007/BF02279480",65,2020-11-20,NA
J,WOS:000242564300009,2006,CO-VARIANCE OF DISSOLVED FE-BINDING LIGANDS WITH PHYTOPLANKTON CHARACTERISTICS IN THE CANARY BASIN,"DISSOLVED FE AND LIGAND CONCENTRATIONS AND THE FE-BINDING STRENGTH OF THE ORGANIC LIGANDS WERE MEASURED IN SAMPLES FROM THE UPPER WATER COLUMN (150 M) OF THE OLIGOTROPHIC WATERS OF THE CANARY BASIN (EASTERN NORTH ATLANTIC OCEAN). CONCENTRATIONS OF MAJOR NUTRIENTS, PHYTOPLANKTON ABUNDANCE AND PHOTOSYNTHETIC CHARACTERISTICS WERE ALSO MEASURED IN THE SAME SAMPLES. THE CONCENTRATIONS OF DISSOLVED FE AND DISSOLVED ORGANIC LIGANDS WERE LOW WITH MEAN VALUES OF 0.31 +/- 0.18 NM FE AND 1.79 +/- 0.73 NEQ OF M FE(N =47), RESPECTIVELY. THE CONDITIONAL BINDING CONSTANT VARIED BETWEEN 10(19.8)-10(22.7) (N = 47). THE LARGEST VARIATION WITH DEPTH IN THE LIGAND CONCENTRATIONS (BETWEEN 4.78 AND 1.1 NEQ OF M FE) WAS OBSERVED IN THE UPPER LAYER, ABOVE THE DEEP CHLOROPHYLL MAXIMUM (DCM LOCATED BETWEEN 80 AND 100 IN), WITH HIGH SURFACE VALUES IN STATIONS AT 18 AND 34. AT THE DCM WHERE FE WAS DEPLETED, THE LIGAND CONCENTRATIONS WERE STILL RELATIVELY HIGH SHOWING THE SAME TREND WITH DEPTH AS THE AMOUNT OF PHYTOPLANKTON CELLS. HERE 62% OF THE VERTICAL VARIATION IN LIGAND CONCENTRATIONS CAN BE EXPLAINED BY PARAMETERS DESCRIBING PHYTOPLANKTON CELL ABUNDANCE OR BIOMASS AND ORTHOSILICIC ACID CONCENTRATION, WHICH COULD REFLECT DIATOM GROWTH. LIGAND CONCENTRATIONS BELOW THE MAXIMUM OF THE DCM (N=4) SHOWED GOOD LINEAR POSITIVE RELATIONSHIPS WITH THE TOTAL PHYTOPLANKTON BIOMASS AS WELL AS WITH 2 OUT OF 4 DISTINGUISHED GROUPS OF PHYTOPLANKTON (SYNECHOCOCCUS AND PICO-EUKARYOTE I). IN THE MAXIMUM OF THE DCM AND BELOW THIS MAXIMUM THE PHYTOPLANKTON ORIGIN OF THE DISSOLVED ORGANIC LIGANDS OF FE IS VERY PROBABLE. DATA SUGGEST A RELEASE OF LIGANDS BY CELL LYSIS AND NOT BY AN ACTIVE PRODUCTION. HOWEVER, THE ORIGIN IN THE SURFACE LAYER IS MORE DIFFICULT TO EXPLAIN. ALTHOUGH THE AMOUNT OF PHYTOPLANKTON CELLS IN THE SURFACE LAYER IS REDUCED, IT IS STILL SIMILAR TO 25% OF THE CELL CONCENTRATION OBSERVED IN THE DCM. HIGH CONCENTRATIONS OF ORGANIC LIGANDS COULD THEN BE A REMNANT OF PAST BLOOMS OR PRESENT PRODUCTION UNDER NUTRIENT DEPLETED CONDITIONS. INPUT OF SAHARA DUST CAN BE ANOTHER SOURCE OF LIGANDS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NATURAL ORGANIC-LIGANDS; SIDEROPHORE PRODUCTION; DIATOM THALASSIOSIRA; MARINE-PHYTOPLANKTON; SOUTHERN-OCEAN; COMPLEXING LIGANDS; IRON AVAILABILITY; ATLANTIC-OCEAN; NORTH PACIFIC; SURFACE-WATER,NA,MARINE CHEMISTRY,"GERRINGA, LJA##VELDHUIS, MJW##TIMMERMANS, KR##SARTHOU, G##DE BAAR, HJW","ROYAL NETHERLANDS INST SEA RES, NL-1790 AB DEN BURG, NETHERLANDS. UBO, CNRS, IUEM, LEMAR,UMR6539, F-29280 PLOUZANE, FRANCE. UNIV GRONINGEN, CTR ECOL & EVOLUTIONARY SCI, NL-9750 AA HAREN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; OCEANOGRAPHY",CHEMISTRY; OCEANOGRAPHY,"ANDERSON MA, 1982, LIMNOL OCEANOGR, V27, P789, DOI 10.4319/LO.1982.27.5.0789##ARMBRUST EV, 2004, SCIENCE, V306, P79, DOI 10.1126/SCIENCE.1101156##BENDERLIEV KM, 1994, PLANTA, V193, P163##BOWIE AR, 2003, MAR CHEM, V84, P19, DOI 10.1016/S0304-4203(03)00091-4##BOYE M, 2005, MAR CHEM, V96, P257, DOI 10.1016/J.MARCHEM.2005.02.002##BOYE M, 2001, DEEP-SEA RES PT I, V48, P1477, DOI 10.1016/S0967-0637(00)00099-6##BOYE M, 2000, MAR CHEM, V70, P277, DOI 10.1016/S0304-4203(00)00032-3##BRULAND KW, 2003, LECT IGBP OC OP SCI##BUCCIARELLI E, 2001, MAR CHEM, V73, P21, DOI 10.1016/S0304-4203(00)00070-0##COALE KH, 1996, NATURE, V383, P495, DOI 10.1038/383495A0##CROOT PL, 2001, GEOPHYS RES LETT, V28, P3425, DOI 10.1029/2001GL013023##CROOT PL, 2000, ELECTROANAL, V12, P565, DOI 10.1002/(SICI)1521-4109(200005)12:8<565::AID-ELAN565>3.0.CO;2-L##DE BAAR HJW, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002601##DEBAAR HJW, 1990, MAR ECOL PROG SER, V65, P105, DOI 10.3354/MEPS065105##DEBAAR HJW, 1995, NATURE, V373, P412, DOI 10.1038/373412A0##DEBAAR HJW, 2000, DYNAMIC OCEAN CARBON, P61##FRANCK VM, 2000, TOP STUD OCEANOGR, V47, P3315##FUSE H, 1993, BIOSCI BIOTECH BIOCH, V57, P509, DOI 10.1271/BBB.57.509##GEIDER RJ, 1994, PHOTOSYNTH RES, V39, P275, DOI 10.1007/BF00014588##GERRINGA LJA, 1995, MAR CHEM, V48, P131, DOI 10.1016/0304-4203(94)00041-B##GLEDHILL M, 2004, MAR CHEM, V88, P75, DOI 10.1016/J.MARCHEM.2004.03.003##GLEDHILL M, 1994, MAR CHEM, V47, P41, DOI 10.1016/0304-4203(94)90012-4##GRASSHOFF K., 1983, METHODS SEAWATER ANA, P263##HONG HS, 1986, LIMNOL OCEANOGR, V31, P512, DOI 10.4319/LO.1986.31.3.0512##HUDSON RJM, 1990, LIMNOL OCEANOGR, V35, P1002, DOI 10.4319/LO.1990.35.5.1002##HUTCHINS DA, 1999, NATURE, V400, P858, DOI 10.1038/23680##JONES GJ, 1988, PLANT PHYSIOL, V87, P143, DOI 10.1104/PP.87.1.143##KRAMER J, 2004, MAR CHEM, V88, P85, DOI 10.1016/J.MARCHEM.2004.03.009##KUMA K, 1992, MAR CHEM, V37, P15, DOI 10.1016/0304-4203(92)90054-E##KUMA K, 2000, LIMNOL OCEANOGR, V45, P1235, DOI 10.4319/LO.2000.45.6.1235##MALDONADO MT, 1999, DEEP-SEA RES PT II, V46, P2447, DOI 10.1016/S0967-0645(99)00071-5##MALDONADO MT, 2000, LIMNOL OCEANOGR, V45, P814, DOI 10.4319/LO.2000.45.4.0814##MALDONADO MT, 1999, DEEP-SEA RES PT II, V46, P2475, DOI 10.1016/S0967-0645(99)00072-7##MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123A0##MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341A0##MARTINEZ JS, 2001, LIMNOL OCEANOGR, V46, P420, DOI 10.4319/LO.2001.46.2.0420##MCCORMACK P, 2003, ANAL CHEM, V75, P2647, DOI 10.1021/AC0340105##MILLER WL, 1994, J MAR RES, V52, P325, DOI 10.1357/0022240943077136##NAKASHIBA T, 2002, MECH DEVELOP, V111, P47, DOI 10.1016/S0925-4773(01)00600-1##NOLTING RF, 1998, MAR CHEM, V62, P335, DOI 10.1016/S0304-4203(98)00046-2##OBATA H, 1993, ANAL CHEM, V65, P1524, DOI 10.1021/AC00059A007##REID RT, 1993, NATURE, V366, P455, DOI 10.1038/366455A0##RIJKENBERG MJA, 2005, MAR CHEM, V93, P119, DOI 10.1016/J.MARCHEM.2004.03.021##RUE EL, 1995, MAR CHEM, V50, P117, DOI 10.1016/0304-4203(95)00031-L##RUE EL, 1997, LIMNOL OCEANOGR, V42, P901, DOI 10.4319/LO.1997.42.5.0901##SARTHOU G, 2003, DEEP-SEA RES PT I, V50, P1339, DOI 10.1016/S0967-0637(03)00126-2##SARTHOU G, 2005, J SEA RES, V53, P25, DOI 10.1016/J.SEARES.2004.01.007##SARTHOU G, UNPUB MAR CHEM##SATHYENDRANATH S, 1995, DEEP-SEA RES PT I, V42, P1773, DOI 10.1016/0967-0637(95)00059-F##SAYDAM AC, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013562##SUNDA WG, 1995, MAR CHEM, V50, P189, DOI 10.1016/0304-4203(95)00035-P##SUNDA WG, 1991, NATURE, V351, P55, DOI 10.1038/351055A0##SUNDA WG, 2001, IUPAC SERIES ANAL PH, V7##TAKATA H, 2004, MAR CHEM, V86, P139, DOI 10.1016/J.MARCHEM.2003.12.007##TIMMERMANS KR, 2004, LIMNOL OCEANOGR, V49, P2141, DOI 10.4319/LO.2004.49.6.2141##TIMMERMANS KR, 2001, MAR ECOL PROG SER, V217, P287, DOI 10.3354/MEPS217287##TIMMERMANS KR, 2001, LIMNOL OCEANOGR, V46, P260, DOI 10.4319/LO.2001.46.2.0260##TRICK CG, 1983, MAR BIOL, V75, P9, DOI 10.1007/BF00392625##VAN DEN BERG CMG, 1982, MAR CHEM, V11, P307, DOI 10.1016/0304-4203(82)90028-7##VAN DEN BERG CMG, 1995, MAR CHEM, V50, P139, DOI 10.1016/0304-4203(95)00032-M##VELDHUIS MJW, 2004, DEEP-SEA RES PT I, V51, P507, DOI 10.1016/J.DSR.2003.12.002##VELDHUIS MJW, 2001, EUR J PHYCOL, V36, P167, DOI 10.1080/09670260110001735318##VELDHUIS MJW, 2000, SCI MAR, V64, P121, DOI 10.3989/SCIMAR.2000.64N2121##VINK S, 2001, DEEP-SEA RES PT II, V48, P2787, DOI 10.1016/S0967-0645(01)00018-2##VISSER F, 2003, J PHYCOL, V39, P1085, DOI 10.1111/J.0022-3646.2003.03-023.X##WATSON A.J., 2001, BIOGEOCHEMISTRY IRON, P9##WELLS ML, 1991, DEEP-SEA RES, V38, P1379, DOI 10.1016/0198-0149(91)90012-5##WELLS ML, 2004, MAR CHEM, V86, P1, DOI 10.1016/J.MARCHEM.2003.10.003##WILHELM SW, 1996, LIMNOL OCEANOGR, V41, P89, DOI 10.4319/LO.1996.41.1.0089##WILHELM SW, 1994, LIMNOL OCEANOGR, V39, P1979, DOI 10.4319/LO.1994.39.8.1979##WU JF, 1995, MAR CHEM, V50, P159, DOI 10.1016/0304-4203(95)00033-N",42,2020-11-20,NA
J,WOS:000242689800009,2006,EFFECT OF UREA ON THE STRUCTURAL DYNAMICS OF WATER,"WE USE POLARIZATION-RESOLVED MID-INFRARED PUMP-PROBE SPECTROSCOPY TO STUDY THE EFFECT OF UREA ON THE STRUCTURE AND DYNAMICS OF WATER. SURPRISINGLY, WE FIND THAT, EVEN AT HIGH CONCENTRATIONS OF UREA (8 M), THE ORIENTATIONAL DYNAMICS OF MOST WATER MOLECULES ARE THE SAME AS IN PURE LIQUID WATER, SHOWING THAT UREA HAS A NEGLIGIBLE EFFECT ON THE HYDROGEN-BOND DYNAMICS OF THESE MOLECULES. HOWEVER, A SMALL FRACTION OF THE WATER MOLECULES (APPROXIMATELY ONE WATER MOLECULE PER UREA MOLECULE) TURNS OUT TO BE STRONGLY IMMOBILIZED BY UREA, DISPLAYING ORIENTATIONAL DYNAMICS THAT ARE MORE THAN SIX TIMES SLOWER THAN IN BULK WATER. A LIKELY EXPLANATION IS THAT THESE WATER MOLECULES ARE TIGHTLY ASSOCIATED WITH UREA, FORMING SPECIFIC UREA-WATER COMPLEXES. WE DISCUSS THESE RESULTS IN LIGHT OF THE PROTEIN DENATURING ABILITY OF AQUEOUS UREA.",AQUEOUS UREA; MOLECULAR-DYNAMICS; LIQUID WATER; SIMULATIONS; SPECTROSCOPY; DERIVATIVES; RELAXATION; DENATURANT; SOLVENT; MODEL,HYDROGEN BONDING; INFRARED PUMP-PROBE SPECTROSCOPY; ORIENTATIONAL DYNAMICS; PROTEIN DENATURATION,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,"REZUS, YLA##BAKKER, HJ","INST ATOM & MOL PHYS, FDN FUNDAMENTAL RES MATTER, NL-1098 SJ AMSTERDAM, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"ASTRAND PO, 1994, J PHYS CHEM-US, V98, P8224##BARONE G, 1970, J PHYS CHEM-US, V74, P2230, DOI 10.1021/J100909A037##BEAUREGARD DV, 1968, J CHEM PHYS, V49, P5241, DOI 10.1063/1.1670040##FINER EG, 1972, J AM CHEM SOC, V94, P4424, DOI 10.1021/JA00768A004##FRANK HS, 1968, J CHEM PHYS, V48, P4746, DOI 10.1063/1.1668057##GODRALLA B. C., 1986, MOL PHYS, V59, P817##HARDY EH, 2001, J CHEM PHYS, V114, P3174, DOI 10.1063/1.1340584##IDRISSI A, 2005, SPECTROCHIM ACTA A, V61, P1, DOI 10.1016/J.SAA.2004.02.039##IDRISSI A, 2001, J CHEM PHYS, V114, P6774, DOI 10.1063/1.1355019##IDRISSI A, 2000, J CHEM PHYS, V112, P9479, DOI 10.1063/1.481566##ISHIDA T, 2004, J PHYS CHEM B, V108, P17583, DOI 10.1021/JP0473218##KAATZE U, 1986, J PHYS CHEM-US, V90, P5464, DOI 10.1021/J100412A113##KALLIES B, 2002, PHYS CHEM CHEM PHYS, V4, P86, DOI 10.1039/B105836N##KRESHECK GC, 1965, J PHYS CHEM-US, V69, P1704, DOI 10.1021/J100889A043##LEE C, 1995, J PHYS CHEM-US, V99, P17737, DOI 10.1021/J100050A011##LOPARO JJ, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.180201##PILETIC IR, 2006, J PHYS CHEM A, V110, P4985, DOI 10.1021/JP061065C##REZUS YLA, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2009729##SHARP KA, 2001, J CHEM PHYS, V114, P1791, DOI 10.1063/1.1334678##SHELLMAN JA, 1955, C R TRAV LAB CARLSBE, V29, P223##SHIMIZU A, 2000, J MOL LIQ, V85, P269, DOI 10.1016/S0167-7322(00)00106-9##SOPER AK, 2003, BIOPHYS CHEM, V105, P649, DOI 10.1016/S0301-4622(03)00095-4##STEINEL T, 2004, J PHYS CHEM A, V108, P10957, DOI 10.1021/JP046711R##STOKES RH, 1967, AUST J CHEM, V20, P2087, DOI 10.1071/CH9672087##VANZI F, 1998, J AM CHEM SOC, V120, P10748, DOI 10.1021/JA981529N##WALRAFEN GE, 1966, J CHEM PHYS, V44, P3726, DOI 10.1063/1.1726526",142,2020-11-20,NA
J,WOS:000242689800040,2006,DYNAMIC ASSEMBLY OF END-JOINING COMPLEXES REQUIRES INTERACTION BETWEEN KU70/80 AND XRCC4,"DNA DOUBLE-STRAND BREAK (DSB) REPAIR BY NONHOMOLOGOUS END JOINING (NHEJ) REQUIRES THE ASSEMBLY OF SEVERAL PROTEINS ON DNA ENDS. ALTHOUGH BIOCHEMICAL STUDIES HAVE ELUCIDATED SEVERAL ASPECTS OF THE NHEJ REACTION MECHANISM, MUCH LESS IS KNOWN ABOUT NHEJ IN LIVING CELLS, MAINLY BECAUSE OF THE INABILITY TO VISUALIZE NHEJ REPAIR PROTEINS AT DNA DAMAGE. HERE WE PROVIDE EVIDENCE THAT A PULSED NEAR IR LASER CAN PRODUCE DSBS WITHOUT ANY VISIBLE ALTERATIONS IN THE NUCLEUS, AND WE SHOW THAT NHEJ PROTEINS ACCUMULATE IN THE IRRADIATED AREAS. THE LEVELS OF DSBS AND KU ACCUMULATION DIMINISHED IN TIME, SHOWING THAT THIS APPROACH ALLOWS US TO STUDY DNA REPAIR KINETICS IN VIVO. REMARKABLY, THE KU HETERODIMERS ON DNA ENDS WERE IN DYNAMIC EQUILIBRIUM WITH KU70/80 IN SOLUTION, SHOWING THAT NHEJ COMPLEX ASSEMBLY IS REVERSIBLE. ACCUMULATION OF XRCC4/LIGASE IV ON DSBS DEPENDED ON THE PRESENCE OF KU70/80, BUT NOT DNA-PKCS. WE DETECTED A DIRECT INTERACTION BETWEEN KU70 AND XRCC4 THAT COULD EXPLAIN THESE REQUIREMENTS. OUR RESULTS SUGGEST THAT THIS ASSEMBLY CONSTITUTES THE CORE OF THE NHEJ REACTION AND THAT XRCC4 MAY SERVE AS A FLEXIBLE TETHER BETWEEN KU70/80 AND LIGASE IV.",DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; DNA-LIGASE-IV; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; POLYNUCLEOTIDE KINASE; AUTOPHOSPHORYLATION; SYNAPSIS; DAMAGE,DNA REPAIR; DNA-DEPENDENT PROTEIN KINASE; DOUBLE-STRAND BREAK REPAIR; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; LIVE CELL IMAGING,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,"MARI, PO##FLOREA, BI##PERSENGIEV, SP##VERKAIK, NS##BRUEGGENWIRTH, HT##MODESTI, M##GIGLIA-MARI, G##BEZSTAROSTI, K##DEMMERS, JAA##LUIDER, TM##HOUTSMULLER, AB##VAN GENT, DC","ERASMUS UNIV, MED CTR, ERASMUS MC, DEPT CELL BIOL & GENET, NL-3000 CA ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, ERASMUS MC, DEPT NEUROL, NL-3000 CA ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, ERASMUS MC, DEPT PATHOL, NL-3000 CA ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, ERASMUS MC, DEPT BIOCHEM,CTR BIOM, NL-3000 CA ROTTERDAM, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"AHNESORG P, 2006, CELL, V124, P301, DOI 10.1016/J.CELL.2005.12.031##BEKKER-JENSEN S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/JCB.200510130##BRADSHAW PS, 2005, NAT GENET, V37, P193, DOI 10.1038/NG1506##BUCK D, 2006, CELL, V124, P287, DOI 10.1016/J.CELL.2005.12.030##CALSOU P, 2003, J MOL BIOL, V326, P93, DOI 10.1016/S0022-2836(02)01328-1##CHAN DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/GAD.1015202##CHAN DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/JBC.271.15.8936##CRITCHLOW SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2##DEFAZIO LG, 2002, EMBO J, V21, P3192, DOI 10.1093/EMBOJ/CDF299##DING Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003##DUNDR M, 2002, J STRUCT BIOL, V140, P92, DOI 10.1016/S1047-8477(02)00521-X##ERRAMI A, 1998, NUCLEIC ACIDS RES, V26, P3146, DOI 10.1093/NAR/26.13.3146##ERRAMI A, 1996, MOL CELL BIOL, V16, P1519##FRANK KM, 1998, NATURE, V396, P173, DOI 10.1038/24172##GAO YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6##GRAWUNDER U, 1997, NATURE, V388, P492, DOI 10.1038/41358##HERRMANN G, 1998, EMBO J, V17, P4188, DOI 10.1093/EMBOJ/17.14.4188##HOUTSMULLER AB, 2001, HISTOCHEM CELL BIOL, V115, P13, DOI 10.1007/S004180000234##HSU HL, 2002, DNA REPAIR, V1, P225, DOI 10.1016/S1568-7864(01)00018-0##KIM JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/JCB.200411083##KOCH CA, 2004, EMBO J, V23, P3874, DOI 10.1038/SJ.EMBOJ.7600375##LI ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3##LUKAS C, 2005, CHROMOSOMA, V114, P146, DOI 10.1007/S00412-005-0011-Y##LUKAS C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/NCB945##MELDRUM RA, 2003, EMBO REP, V4, P1144, DOI 10.1038/SJ.EMBOR.7400028##MODESTI M, 1999, EMBO J, V18, P2008, DOI 10.1093/EMBOJ/18.7.2008##ONO M, 1996, MOL IMMUNOL, V33, P787, DOI 10.1016/0161-5890(96)00030-2##RASBAND WS, 1997, IMAGE4##REDDY YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/JBC.M406432200##RIBALLO E, 2004, MOL CELL, V16, P715, DOI 10.1016/J.MOLCEL.2004.10.029##RODGERS W, 2002, J IMMUNOL, V168, P2348, DOI 10.4049/JIMMUNOL.168.5.2348##SMITH GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/GAD.13.8.916##TEO SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1##TIRLAPUR UK, 2001, CELL MOL BIOL NOISY, V47, DOI UNSP OL131-OL134##VAN DER BURG M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121##VAN GENT DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049##VAN HEEMST D, 2004, DNA REPAIR, V3, P43, DOI 10.1016/J.DNAREP.2003.09.004##VERKAIK NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T##WETERINGS E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/J.DNAREP.2004.06.003##WETERINGS E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/NAR/GKG889##WHITEHOUSE CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7##ZHENG PP, 2003, FRONT BIOSCI-LANDMRK, V8, PD451, DOI 10.2741/1008",272,2020-11-20,NA
J,WOS:000242689800071,2006,SENSORY INTEGRATION DOES NOT LEAD TO SENSORY CALIBRATION,"ONE GENERALLY HAS THE IMPRESSION THAT ONE FEELS ONE'S HAND AT THE SAME LOCATION AS ONE SEES IT. HOWEVER, BECAUSE OUR BRAIN DEALS WITH POSSIBLY CONFLICTING VISUAL AND PROPRIOCEPTIVE INFORMATION ABOUT HAND POSITION BY COMBINING IT INTO AN OPTIMAL ESTIMATE OF THE HAND'S LOCATION, MUTUAL CALIBRATION IS NOT NECESSARY TO ACHIEVE SUCH A COHERENT PERCEPT. DOES SENSORY INTEGRATION NEVERTHELESS ENTAIL SENSORY CALIBRATION? WE ASKED SUBJECTS TO MOVE THEIR HAND BETWEEN VISUAL TARGETS. BLOCKS OF TRIALS WITHOUT ANY VISUAL FEEDBACK ABOUT THEIR HAND'S POSITION WERE ALTERNATED WITH BLOCKS WITH VERIDICAL VISUAL FEEDBACK. WHENEVER VISION WAS REMOVED, INDIVIDUAL SUBJECTS' HANDS SLOWLY DRIFTED TOWARD THE SAME POSITION TO WHICH THEY HAD DRIFTED ON PREVIOUS BLOCKS WITHOUT VISUAL FEEDBACK. THE TIME COURSE OF THE OBSERVED DRIFT DEPENDED IN A PREDICTABLE MANNER (ASSUMING OPTIMAL SENSORY COMBINATION) ON THE VARIABLE ERRORS IN THE BLOCKS WITH AND WITHOUT VISUAL FEEDBACK. WE CONCLUDE THAT THE OPTIMAL USE OF UNALIGNED SENSORY INFORMATION, RATHER THAN CHANGES WITHIN EITHER OF THE SENSES OR AN ACCUMULATION OF EXECUTION ERRORS, IS THE CAUSE OF THE FREQUENTLY OBSERVED MOVEMENT DRIFT. THE CONCLUSION THAT SEEING ONE'S HAND DOES NOT LEAD TO AN ALIGNMENT BETWEEN VISION AND PROPRIOCEPTION HAS IMPORTANT CONSEQUENCES FOR THE INTERPRETATION OF PREVIOUS WORK ON VISUOMOTOR ADAPTATION.",PROPRIOCEPTION; INFORMATION; REPRESENTATION; ADAPTATION; FRAMES; DRIFT,ADAPTATION; MOTOR CONTROL; VISION; PROPRIOCEPTION; DRIFT,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,"SMEETS, JBJ##VAN DEN DOBBELSTEEN, JJ##DE GRAVE, DDJ##VAN BEERS, RJ##BRENNER, E","ERASMUS MC, AFD NEUROWETENSCHAPPEN, NL-3000 DR ROTTERDAM, NETHERLANDS. VRIJE UNIV, FAC HUMAN MOVEMENT SCI, NL-1081 BT AMSTERDAM, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"AVILLAC M, 2005, NAT NEUROSCI, V8, P941, DOI 10.1038/NN1480##BEDFORD FL, 1999, TRENDS COGN SCI, V3, P4, DOI 10.1016/S1364-6613(98)01266-2##BRENNER E, 2003, SPATIAL VISION, V16, P365, DOI 10.1163/156856803322467581##BROWN LE, 2003, J NEUROPHYSIOL, V90, P3105, DOI 10.1152/JN.00013.2003##BROWN LE, 2003, EXP BRAIN RES, V153, P266, DOI 10.1007/S00221-003-1601-7##CARROZZO M, 1999, EXP BRAIN RES, V129, P201, DOI 10.1007/S002210050890##CHOE CS, 1974, J EXP PSYCHOL, V102, P1076, DOI 10.1037/H0036325##CLOWER DM, 2000, J NEUROPHYSIOL, V84, P2703##COHEN YE, 2002, NAT REV NEUROSCI, V3, P553, DOI 10.1038/NRN873##CUIJPERS RH, 2003, J MATH PSYCHOL, V47, P278, DOI 10.1016/S0022-2496(03)00004-X##DE GRAVE DDJ, 2004, EXP BRAIN RES, V155, P56, DOI 10.1007/S00221-003-1708-X##DENEVE S, 2004, J PHYSIOLOGY-PARIS, V98, P249, DOI 10.1016/J.JPHYSPARIS.2004.03.011##DESMURGET M, 1998, NEUROSCI BIOBEHAV R, V22, P761, DOI 10.1016/S0149-7634(98)00004-9##DESMURGET M, 2000, EXP BRAIN RES, V134, P363, DOI 10.1007/S002210000473##ERNST MO, 2000, NAT NEUROSCI, V3, P69, DOI 10.1038/71140##FITTS PM, 1954, J EXP PSYCHOL, V47, P381, DOI 10.1037/H0055392##FOX D, 2003, IEEE PERVAS COMPUT, V2, P24, DOI 10.1109/MPRV.2003.1228524##GRAZIANO MSA, 1999, P NATL ACAD SCI USA, V96, P10418, DOI 10.1073/PNAS.96.18.10418##JACOBS RA, 2002, TRENDS COGN SCI, V6, P345, DOI 10.1016/S1364-6613(02)01948-4##KNILL DC, 2004, TRENDS NEUROSCI, V27, P712, DOI 10.1016/J.TINS.2004.10.007##LACKNER JR, 2000, TRENDS COGN SCI, V4, P279, DOI 10.1016/S1364-6613(00)01493-5##MARAVITA A, 2003, CURR BIOL, V13, PR531, DOI 10.1016/S0960-9822(03)00449-4##MEDENDORP WP, 2005, J NEUROPHYSIOL, V93, P954, DOI 10.1152/JN.00725.2004##REDDING GM, 2005, NEUROSCI BIOBEHAV R, V29, P431, DOI 10.1016/J.NEUBIOREV.2004.12.004##SMITH RC, 1986, INT J ROBOT RES, V5, P56, DOI 10.1177/027836498600500404##SOBER SJ, 2005, NAT NEUROSCI, V8, P490, DOI 10.1038/NN1427##VAN BEERS RJ, 2002, CURR BIOL, V12, P834, DOI 10.1016/S0960-9822(02)00836-9##VAN BEERS RJ, 1999, J NEUROPHYSIOL, V81, P1355##VAN BEERS RJ, 2004, J NEUROPHYSIOL, V91, P1050, DOI 10.1152/JN.00652.2003##VAN BEERS RJ, 1998, EXP BRAIN RES, V122, P367, DOI 10.1007/S002210050525##VAN DEN DOBBELSTEEN JJ, 2004, J NEUROPHYSIOL, V92, P416, DOI 10.1152/JN.00764.2003##VAN DEN DOBBELSTEEN JJ, 2003, EXP BRAIN RES, V148, P471, DOI 10.1007/S00221-002-1321-4##VANBEERS RJ, 1996, EXP BRAIN RES, V111, P253, DOI 10.1007/BF00227302##WANN JP, 1992, EXP BRAIN RES, V91, P162",144,2020-11-20,NA
J,WOS:000242689800080,2006,GENETIC BASIS FOR NATURAL VARIATION IN SEED VITAMIN E LEVELS IN ARABIDOPSIS THALIANA,"VITAMIN E IS AN ESSENTIAL NUTRIENT FOR HUMANS AND IS OBTAINED PRIMARILY FROM FOOD, ESPECIALLY OIL, DERIVED FROM THE SEED OF PLANTS. GENES ENCODING THE COMMITTED STEPS IN VITAMIN E SYNTHESIS IN PLANTS (VTE, LOCI 1-5) HAVE BEEN ISOLATED AND USED FOR TOCOPHEROL PATHWAY ENGINEERING WITH VARIOUS DEGREES OF SUCCESS. AS A COMPLEMENT TO SUCH APPROACHES WE HAVE USED QUANTITATIVE TRAIT LOCI ANALYSIS WITH TWO SETS OF ARABIDOPSIS THALIANA RECOMBINANT INBRED LINES AND HAVE IDENTIFIED 14 QVE (QUANTITATIVE VITAMIN E) LOCI AFFECTING TOCOPHEROL CONTENT AND COMPOSITION IN SEEDS. FIVE QVE INTERVALS CONTAIN VTE LOCI THAT ARE LIKELY QVE GENE CANDIDATES. NINE QVE INTERVALS DO NOT CONTAIN VTE LOCI AND THEREFORE IDENTIFY NOVEL LOCI AFFECTING SEED TOCOPHEROL CONTENT AND COMPOSITION. SEVERAL NEAR-ISOGENIC LINES CONTAINING INTROGRESSIONS OF THE ACCESSION WITH INCREASED VITAMIN E LEVELS WERE SHOWN TO CONFER SIGNIFICANTLY ELEVATED TOCOPHEROL LEVELS COMPARED WITH THE RECURRENT PARENT. FINE-MAPPING HAS NARROWED QVE7 (A GAMMA-TOCOPHEROL QUANTITATIVE TRAIT LOCI) TO AN 8.5-KB INTERVAL ENCOMPASSING TWO GENES. UNDERSTANDING THE BASIS OF THE QVE LOCI IN ARABIDOPSIS PROMISES TO PROVIDE INSIGHT INTO THE REGULATION AND/OR METABOLISM OF VITAMIN E IN PLANTS AND HAS CLEAR RAMIFICATIONS FOR IMPROVING THE NUTRITIONAL CONTENT OF CROPS THROUGH MARKER-ASSISTED SELECTION AND METABOLIC ENGINEERING.",TOCOPHEROL BIOSYNTHESIS; ENVIRONMENT INTERACTIONS; PLANTS; MUTANT; PATHWAY; LOCI; ACCUMULATION; MANIPULATION; DISSECTION; PROGRESS,BIOFORTIFICATION; QUANTITATIVE TRAIT LOCI; SEED METABOLISM; TOCOPHEROL,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,"GILLILAND, LU##MAGALLANES-LUNDBACK, M##HEMMING, C##SUPPLEE, A##KOORNNEEF, M##BENTSINK, L##DELLAPENNA, D","MICHIGAN STATE UNIV, DEPT BIOCHEM & MOL BIOL, E LANSING, MI 48824 USA. WAGENINGEN UNIV, GENET LAB, NL-6703 BD WAGENINGEN, NETHERLANDS. MAX PLANCK INST PLANT BREEDING RES, D-50829 COLOGNE, GERMANY.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"AJJAWI I, 2004, TRENDS BIOTECHNOL, V22, P104, DOI 10.1016/J.TIBTECH.2004.01.008##ALONSO JM, 2003, SCIENCE, V301, P653, DOI 10.1126/SCIENCE.1086391##ALONSO-BLANCO C, 1998, GENETICS, V149, P749##BENTSINK L, 2003, THEOR APPL GENET, V106, P1234, DOI 10.1007/S00122-002-1177-9##CHENG ZG, 2003, PLANT CELL, V15, P2343, DOI 10.1105/TPC.013656##COLLAKOVA E, 2003, PLANT PHYSIOL, V133, P930, DOI 10.1104/PP.103.026138##DE LA GARZA RD, 2004, P NATL ACAD SCI USA, V101, P13720, DOI 10.1073/PNAS.0404208101##DELLAPENNA D, 2006, PHYSIOL PLANTARUM, V126, P356, DOI 10.1111/J.1399-3054.2006.00611.X##DELLAPENNA D, 2005, TRENDS PLANT SCI, V10, P574, DOI 10.1016/J.TPLANTS.2005.10.007##DELLAPENNA D, 2006, ANNU REV PLANT BIOL, V57, P711, DOI 10.1146/ANNUREV.ARPLANT.56.032604.144301##GALLIHER HL, 1985, CROP SCI, V25, P547, DOI 10.2135/CROPSCI1985.0011183X002500030028X##GILLILAND LU, 1998, GENETICS, V149, P717##HOSSAIN T, 2004, P NATL ACAD SCI USA, V101, P5158, DOI 10.1073/PNAS.0401342101##JANDER GEORG, 2006, V323, P115##KANWISCHER M, 2005, PLANT PHYSIOL, V137, P713, DOI 10.1104/PP.104.054908##LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/J.1365-313X.1993.04040745.X##LOUDET O, 2003, PLANT PHYSIOL, V131, P345, DOI 10.1104/PP.102.010785##MARWEDE V, 2005, PLANT BREEDING, V124, P20, DOI 10.1111/J.1439-0523.2004.01050.X##MARWEDE V, 2004, CROP SCI, V44, P728, DOI 10.2135/CROPSCI2004.0728##PAINE JA, 2005, NAT BIOTECHNOL, V23, P482, DOI 10.1038/NBT1082##PINON V, 2005, PLANT PHYSIOL, V139, P1666, DOI 10.1104/PP.105.070144##PORFIROVA S, 2002, P NATL ACAD SCI USA, V99, P12495, DOI 10.1073/PNAS.182330899##SATTLER SE, 2004, PLANT CELL, V16, P1419, DOI 10.1105/TPC.021360##SHINTANI D, 1998, SCIENCE, V282, P2098, DOI 10.1126/SCIENCE.282.5396.2098##TIAN L, 2003, PLANT CELL, V15, P1320, DOI 10.1105/TPC.011403##TIAN L, 2001, PLANT MOL BIOL, V47, P379, DOI 10.1023/A:1011623907959##TSEGAYE Y, 2002, PLANT PHYSIOL BIOCH, V40, P913, DOI 10.1016/S0981-9428(02)01461-4##UNGERER MC, 2003, GENETICS, V165, P353##UTZ H. F., 1996, JOURNAL OF AGRICULTURAL GENOMICS, V2, P1##VALENTIN HE, 2006, PLANT CELL, V18, P212, DOI 10.1105/TPC.105.037077##VAN EENENNAAM AL, 2003, PLANT CELL, V15, P3007, DOI 10.1105/TPC.015875##VREUGDENHIL D, 2004, PLANT CELL ENVIRON, V27, P828, DOI 10.1111/J.1365-3040.2004.01189.X##WONG JC, 2003, CROP SCI, V43, P2257, DOI 10.2135/CROPSCI2003.2257##YE XD, 2000, SCIENCE, V287, P303, DOI 10.1126/SCIENCE.287.5451.303##ZHANG ZY, 2006, PLANT CELL, V18, P1524, DOI 10.1105/TPC.105.039602",62,2020-11-20,NA
J,WOS:000242758900001,2006,EXPERIMENTAL EVIDENCE OF LATERAL FLOW IN UNSATURATED HOMOGENEOUS ISOTROPIC SLOPING SOIL DUE TO RAINFALL,"[ 1] THIS PAPER DESCRIBES LABORATORY EXPERIMENTAL EVIDENCE FOR LATERAL FLOW IN THE TOP LAYER OF UNSATURATED SLOPING SOIL DUE TO RAINFALL. WATER WAS APPLIED UNIFORMLY ON HORIZONTAL AND V-SHAPED SURFACES OF FINE SAND, AT RATES ABOUT 100 TIMES SMALLER THAN THE SATURATED HYDRAULIC CONDUCTIVITY. FLOW REGIMES NEAR THE SURFACE AND IN THE SOIL BULK WERE STUDIED BY USING DYES. STREAMLINES AND STREAK LINES AND WETTING FRONTS WERE VISUALLY STUDIED AND PHOTOGRAPHED THROUGH A VERTICAL GLASS WALL. NEAR WETTING FRONTS THE FLOW DIRECTION WAS ALWAYS PERPENDICULAR TO THE FRONTS OWING TO DOMINANT MATRIX POTENTIAL GRADIENTS. THUS, DURING EARLY WETTING OF DRY SLOPING SAND, THE FLOW DIRECTION IS DIRECTED UPSLOPE. FAR ABOVE A WETTING FRONT THE FLOW WAS VERTICAL DUE TO THE DOMINANCE OF GRAVITY. DOWNSLOPE FLOW WAS OBSERVED DURING DECREASING RAINFALL AND DRY PERIODS. THE LATERAL MOVEMENT WAS LARGEST NEAR THE SOIL SURFACE AND DECAYED WITH SOIL DEPTH. UNSTABLE DOWNSLOPE LATERAL FLOW CLOSE TO THE SOIL SURFACE WAS ATTRIBUTED TO NON-DARCIAN FLOW DUE TO VARIABLE TEMPORAL AND SPATIAL RAINDROP DISTRIBUTIONS. THE EXPERIMENTS VERIFY THE THEORY THAT PREDICTS UNSATURATED DOWNSLOPE LATERAL FLOW IN SLOPING SOIL DUE TO RAINFALL DYNAMICS ONLY, WITHOUT APPARENT SOIL TEXTURE DIFFERENCE OR ANISOTROPY. THIS PHENOMENON COULD HAVE SIGNIFICANT IMPLICATIONS FOR HILLSIDE HYDROLOGY, DESERT AGRICULTURE, IRRIGATION MANAGEMENT, ETC., AS WELL AS FOR THE BASIC MECHANISMS OF SURFACE RUNOFF AND EROSION.",DOWNWARD WATER-FLOW; SURFACE HYDROLOGY; HILLSLOPE INFILTRATION; MOISTURE FLOW; VADOSE ZONE; ANISOTROPY; TRANSIENT; DYNAMICS; RUNOFF; LAYERS,NA,WATER RESOURCES RESEARCH,"SINAI, G##DIRKSEN, C","TECHNION ISRAEL INST TECHNOL, DEPT CIVIL & ENVIRONM ENGN, IL-32000 HAIFA, ISRAEL. UNIV WAGENINGEN & RES CTR, DEPT WATER RESOURCES, WAGENINGEN, NETHERLANDS.",ENVIRONMENTAL SCIENCES; LIMNOLOGY; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; MARINE & FRESHWATER BIOLOGY; WATER RESOURCES,"[ANONYMOUS], 1991, J ANTIMICROB CHEMOTHER, V27 SUPPL D, P1##BEAR J., 1972, DYNAMICS FLUID POROU##BEAR J., 1972, HYDRAULICS GROUNDWAT##BODHINAYAKE W, 2004, VADOSE ZONE J, V3, P964, DOI 10.2113/3.3.964##BRONSTERT A, 1997, J HYDROL, V198, P177, DOI 10.1016/S0022-1694(96)03306-9##DIRKSEN C, 1978, T ASAE, V21, P913##DIRKSEN C, 1978, WATER RESOUR RES, V14, P611, DOI 10.1029/WR014I004P00611##FREEZE RA, 1972, WATER RESOUR RES, V8, P1272, DOI 10.1029/WR008I005P01272##HEWLETT JD, 1963, J GEOPHYS RES, V68, P1081, DOI 10.1029/JZ068I004P01081##JACKSON CR, 1992, WATER RESOUR RES, V28, P2533, DOI 10.1029/92WR00664##JACKSON CR, 1993, WATER RESOUR RES, V29, P4169, DOI 10.1029/93WR02322##MCCORD JT, 1987, HYDROL PROCESS, V1, P225, DOI 10.1002/HYP.3360010302##MCCORD JT, 1991, WATER RESOUR RES, V27, P1501, DOI 10.1029/91WR00880##MIYAZAKI T, 1988, J HYDROL, V102, P201, DOI 10.1016/0022-1694(88)90098-4##NIEBER JL, 1981, WATER RESOUR RES, V17, P1722, DOI 10.1029/WR017I006P01722##PAN LH, 1997, J HYDROL, V199, P36, DOI 10.1016/S0022-1694(96)03317-3##PHILIP JR, 1991, WATER RESOUR RES, V27, P1041, DOI 10.1029/91WR00129##PHILIP JR, 1993, WATER RESOUR RES, V29, P4167, DOI 10.1029/93WR02321##SILLIMAN SE, 2002, GROUND WATER, V40, P76, DOI 10.1111/J.1745-6584.2002.TB02493.X##SINAI G, 1981, SOIL SCI, V132, P367, DOI 10.1097/00010694-198111000-00007##SU NH, 2002, WATER RESOUR RES, V38, DOI 10.1029/2001WR000373##THORENZ C, 2002, WATER RESOUR RES, V38, DOI 10.1029/2001WR000364##TORRES R, 1998, WATER RESOUR RES, V34, P1865, DOI 10.1029/98WR01140##WALLACH R, 1989, WATER RESOUR RES, V25, P1989, DOI 10.1029/WR025I009P01989##WALLACH R, 1991, WATER RESOUR RES, V27, P1665, DOI 10.1029/91WR00778##WALTER MT, 2004, FUNNELED FLOW MECH S##WARRICK AW, 1997, J HYDROL, V192, P321, DOI 10.1016/S0022-1694(96)03080-6##ZASLAVSKY D, 1969, SOIL SCI SOC AM PRO, V33, P594, DOI 10.2136/SSSAJ1969.03615995003300040031X##ZASLAVSKY D, 1981, J HYDR ENG DIV-ASCE, V107, P1##ZASLAVSKY D, 1981, J HYDR ENG DIV-ASCE, V107, P65##ZASLAVSKY D, 1981, J HYDR ENG DIV-ASCE, V107, P37##ZASLAVSKY D, 1981, J HYDR ENG DIV-ASCE, V107, P53##ZASLAVSKY D, 1970, 41157 USDA AGR RES S",20,2020-11-20,NA
J,WOS:000243183700020,2006,A KINETIC TWO-PHASE AND EQUILIBRIUM SOLID SOLUTION IN SPINEL LI4+XTI5O12,"THE ZERO STRAIN LI4+XTI5O12 MATERIAL AS A TWO-PHASE SYSTEM IS, IN CONTRAST TO COMMON KNOWLEDGE, UNSTABLE AT ROOM TEMPERATURE (SEE FIGURE), AND IT IS FAST LI INSERTION THAT LEADS TO A KINETICALLY INDUCED EFFECTIVE TWO-PHASE REACTION. THE SOLID-SOLUTION-INDUCED DISORDER, RESULTING FROM THE MIXED 8A/16C OCCUPATION, IS MOST LIKELY RESPONSIBLE FOR THE HIGH RATE CAPABILITIES IN LI4+XTI5O12.",X LESS-THAN; LITHIUM INSERTION; TRANSPORT; ANATASE,NA,ADVANCED MATERIALS,"WAGEMAKER, M##SIMON, DR##KELDER, EM##SCHOONMAN, J##RINGPFEIL, C##HAAKE, U##LUTZENKIRCHEN-HECHT, D##FRAHM, R##MULDER, FM","DELFT UNIV TECHNOL, FAC SCI APPL, DEPT RADIAT RADIONUCLIDES & REACTORS, NL-2629 JB DELFT, NETHERLANDS. DELFT UNIV TECHNOL, DELFCHEMTECH, FAC SCI APPL, NL-2628 BL DELFT, NETHERLANDS. DELFT UNIV TECHNOL, FAC SCI APPL, DELF INST SUSTAINABLE ENERGY, NL-2628 BL DELFT, NETHERLANDS. BERG UNIV WUPPERTAL, FACBEREICH PHYS C, D-42097 WUPPERTAL, GERMANY.","CHEMISTRY, MULTIDISCIPLINARY; CHEMISTRY, PHYSICAL; NANOSCIENCE & NANOTECHNOLOGY; MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",CHEMISTRY; SCIENCE & TECHNOLOGY - OTHER TOPICS; MATERIALS SCIENCE; PHYSICS,"ALDON L, 2004, CHEM MATER, V16, P5721, DOI 10.1021/CM0488837##AMATUCCI GG, 2001, J ELECTROCHEM SOC, V148, PA930, DOI 10.1149/1.1383553##COLBOW KM, 1989, J POWER SOURCES, V26, P397, DOI 10.1016/0378-7753(89)80152-1##DELACOURT C, 2005, NAT MATER, V4, P254, DOI 10.1038/NMAT1335##DESCHANV.A, 1971, MATER RES BULL, V6, P699, DOI 10.1016/0025-5408(71)90103-6##FERG E, 1994, J ELECTROCHEM SOC, V141, PL147, DOI 10.1149/1.2059324##HARRISON MR, 1985, PHILOS MAG B, V52, P679, DOI 10.1080/13642818508240629##HUANG H, 2000, 198 M EL SOC PHON OC##JOHNSTON DC, 1976, J LOW TEMP PHYS, V25, P145, DOI 10.1007/BF00654827##KAVAN L, 2003, J ELECTROCHEM SOC, V150, PA1000, DOI 10.1149/1.1581262##LARSON AC, 1994, NM87545 LOS AL NAT L##LEONIDOV IA, 2003, PHYS SOLID STATE+, V45, P2183, DOI 10.1134/1.1626760##MAIER J, 2005, NAT MATER, V4, P805, DOI 10.1038/NMAT1513##MURPHY DW, 1982, REV CHIM MINER, V19, P441##OHZUKU T, 1995, J ELECTROCHEM SOC, V142, P1431, DOI 10.1149/1.2048592##PECHARROMAN C, 2000, PHYS REV B, V62, P12062, DOI 10.1103/PHYSREVB.62.12062##SCHARNER S, 1999, J ELECTROCHEM SOC, V146, P857, DOI 10.1149/1.1391692##WAGEMAKER M, 2003, J AM CHEM SOC, V125, P840, DOI 10.1021/JA028165Q##WAGEMAKER M, 2002, NATURE, V418, P397, DOI 10.1038/NATURE00901##WAGEMAKER M, 2001, J AM CHEM SOC, V123, P11454, DOI 10.1021/JA0161148##WHITTINGHAM MS, 1977, J ELECTROCHEM SOC, V124, P1387, DOI 10.1149/1.2133659##YAMADA A, 2006, NAT MATER, V5, P357, DOI 10.1038/NMAT1634",163,2020-11-20,NA
J,WOS:000242709200076,2006,"MAGNETIZATION REVERSAL, ASYMMETRY, AND ROLE OF UNCOMPENSATED SPINS IN PERPENDICULAR EXCHANGE COUPLED SYSTEMS","SOFT X-RAY RESONANT MAGNETIC SCATTERING HAS BEEN USED TO INVESTIGATE THE ELEMENT-SELECTIVE MICROSCOPIC MAGNETIZATION REVERSAL BEHAVIOR OF ROOM TEMPERATURE PERPENDICULAR EXCHANGE COUPLED FERROMAGNETIC/ANTIFERROMAGNETIC (F/AF) SYSTEMS AND TO STUDY THE ROLE OF THE INTERFACIAL COUPLING STRENGTH ON IT. DIFFERENT NUCLEATION PROCESSES AND DOMAIN SIZE DISTRIBUTIONS ALONG THE DECREASING AND INCREASING BRANCHES OF THE REVERSAL HAVE BEEN FOUND. THE SIZE OF THE MAGNETIC DOMAINS DURING REVERSAL DEPENDS ON BOTH THE F ANISOTROPY AND F/AF COUPLING STRENGTH, DECREASING WHEN ONE OF THEM INCREASES. EVIDENCE OF THE EXCHANGE BIAS (COERCIVITY ENHANCEMENT) BEING INDUCED BY PINNED (UNPINNED) UNCOMPENSATED AF INTERFACIAL SPINS IS ALSO SHOWN. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",BIAS; ANISOTROPY; MULTILAYERS,NA,APPLIED PHYSICS LETTERS,"CAMARERO, J##MIGUEL, J##GOEDKOOP, JB##VOGEL, J##ROMANENS, F##PIZZINI, S##GARCIA, F##SORT, J##DIENY, B##BROOKES, NB","UNIV AUTONOMA MADRID, DEPT FIS MAT CONDENSADA, E-28049 MADRID, SPAIN. UNIV AMSTERDAM, VAN DER WAALS ZEEMAN INST, NL-1018 XE AMSTERDAM, NETHERLANDS. CNRS, LAB LOUIS NEEL, F-38042 GRENOBLE, FRANCE. CEA, SPINTEC, URA2512, CNRS, F-38054 GRENOBLE 9, FRANCE.","PHYSICS, APPLIED",PHYSICS,"CAMARERO J, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.057204##CAMARERO J, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.020413##CAMARERO J, UNPUB##CHOE SB, 1999, J APPL PHYS, V85, P5651, DOI 10.1063/1.369829##GARCIA F, 2002, J APPL PHYS, V91, P6905, DOI 10.1063/1.1447870##GARCIA F, 2002, IEEE T MAGN, V38, P2730, DOI 10.1109/TMAG.2002.803176##HELLWIG O, 2002, PHYS REV B, V65, DOI 10.1103/PHYSREVB.65.144418##KAGERER B, 2000, J MAGN MAGN MATER, V217, P139, DOI 10.1016/S0304-8853(00)00315-2##KIRILYUK A, 2002, J APPL PHYS, V91, P7745, DOI 10.1063/1.1454978##MAAT S, 2001, PHYS REV LETT, V87, DOI 10.1103/PHYSREVLETT.87.087202##MEIKLEJOHN WH, 1956, PHYS REV, V102, P1413, DOI 10.1103/PHYSREV.102.1413##NOGUES J, 1999, J MAGN MAGN MATER, V192, P203, DOI 10.1016/S0304-8853(98)00266-2##OHLDAG H, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.017203##ROMANENS F, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.134410##SKUMRYEV V, 2003, NATURE, V423, P850, DOI 10.1038/NATURE01687",19,2020-11-20,NA
J,WOS:000242709200069,2006,LARGE CONE ANGLE MAGNETIZATION PRECESSION OF AN INDIVIDUAL NANOPATTERNED FERROMAGNET WITH DC ELECTRICAL DETECTION,"THE ON-CHIP RESONANT DRIVING OF LARGE CONE-ANGLE MAGNETIZATION PRECESSION OF AN INDIVIDUAL NANOSCALE PERMALLOY ELEMENT IS DEMONSTRATED. STRONG DRIVING IS REALIZED BY LOCATING THE ELEMENT IN CLOSE PROXIMITY TO THE SHORTED END OF A COPLANAR STRIP WAVEGUIDE, WHICH GENERATES A MICROWAVE MAGNETIC FIELD. A FREQUENCY MODULATION METHOD IS USED TO ACCURATELY MEASURE RESONANT CHANGES OF THE DC ANISOTROPIC MAGNETORESISTANCE. PRECESSION CONE ANGLES UP TO 9 DEGREES ARE DETERMINED WITH BETTER THAN 1 DEGREES OF RESOLUTION. THE RESONANCE PEAK SHAPE IS WELL DESCRIBED BY THE LANDAU-LIFSHITZ-GILBERT EQUATION. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",NA,NA,APPLIED PHYSICS LETTERS,"COSTACHE, MV##WATTS, SM##SLADKOV, M##VAN DER WAL, CH##VAN WEES, BJ","UNIV GRONINGEN, CTR MAT SCI, NL-9747 AG GRONINGEN, NETHERLANDS.","PHYSICS, APPLIED",PHYSICS,"BRATAAS A, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.060404##COSTACHE MV, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.216603##COSTACHE MV, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2385405##GROLLIER J, 2006, J APPL PHYS, V100, DOI 10.1063/1.2218464##KAKA S, 2002, APPL PHYS LETT, V80, P2958, DOI 10.1063/1.1470704##SANKEY JC, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.227601##TSOI M, 2000, NATURE, V406, P46, DOI 10.1038/35017512##TULAPURKAR AA, 2005, NATURE, V438, P339, DOI 10.1038/NATURE04207##YAMAGUCHI A, CONDMAT0606305",61,2020-11-20,NA
J,WOS:000242709200036,2006,INVESTIGATIONS OF GAN SURFACE QUANTUM WELL IN ALGAN/GAN TRANSISTOR HETEROSTRUCTURES BY CONTACTLESS ELECTROREFLECTANCE SPECTROSCOPY,"ALGAN/GAN TRANSISTOR HETEROSTRUCTURES, CAPED BY SIMILAR TO 2 NM GAN LAYER, WERE INVESTIGATED BY CONTACTLESS ELECTROREFLECTANCE (CER) SPECTROSCOPY AT ROOM TEMPERATURE. BELOW THE ALGAN-RELATED TRANSITION CER SPECTRA HAVE SHOWN A CLEAR RESONANCE AT THE ENERGY OF SIMILAR TO 3.7 EV, I.E., AT MUCH HIGHER ENERGY THAN THE GAN BAND GAP ENERGY. THE OBSERVED FEATURE HAS BEEN CONNECTED WITH THE OPTICAL TRANSITION WITHIN THE GAN CAP LAYER. IT WAS CONCLUDED THAT A SURFACE GAN QUANTUM WELL HAS BEEN CREATED BY THE DEPOSITION OF NOMINALLY UNDOPED (OR SI-DOPED) GAN CAP LAYER ON ALGAN/GAN TRANSISTOR HETEROSTRUCTURES. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",2-DIMENSIONAL ELECTRON-GAS; STATES,NA,APPLIED PHYSICS LETTERS,"MOTYKA, M##SYPEREK, M##KUDRAWIEC, R##MISIEWICZ, J##RUDZINSKI, M##HAGEMAN, PR##LARSEN, PK","WROCLAW UNIV TECHNOL, INST PHYS, PL-50370 WROCLAW, POLAND. RADBOUD UNIV NIJMEGEN, INST MOL & MAT, NL-6525 ED NIJMEGEN, NETHERLANDS.","PHYSICS, APPLIED",PHYSICS,"BAUR J, 1994, APPL PHYS LETT, V65, P2211, DOI 10.1063/1.112764##BERMUDEZ VM, 1996, J APPL PHYS, V79, P110, DOI 10.1063/1.360917##BOGATU V, 1999, PHYS STATUS SOLIDI B, V212, P89, DOI 10.1002/(SICI)1521-3951(199903)212:1<89::AID-PSSB89>3.0.CO;2-A##COHEN RM, 1987, APPL PHYS LETT, V50, P1675, DOI 10.1063/1.97764##DREYBRODT J, 1993, PHYS REV B, V48, P14741, DOI 10.1103/PHYSREVB.48.14741##HEIKMAN S, 2003, J APPL PHYS, V93, P10114, DOI 10.1063/1.1577222##JOGAI B, 2003, J APPL PHYS, V93, P1631, DOI 10.1063/1.1530729##KISHIMOTO Y, 1998, THIN SOLID FILMS, V321, P81, DOI 10.1016/S0040-6090(98)00452-0##KUDRAWIEC R, 2006, J APPL PHYS, V100, DOI 10.1063/1.2206707##KUDRAWIEC R, 2006, APPL SURF SCI, V253, P80, DOI 10.1016/J.APSUSC.2006.05.073##MIAO ZL, 2000, PHYS LETT A, V273, P271, DOI 10.1016/S0375-9601(00)00504-1##MISIEWICZ J, 2003, MATER SCI-POLAND, V21, P263##MOISON JM, 1990, PHYS REV B, V41, P12945, DOI 10.1103/PHYSREVB.41.12945##MORKOC H, 1999, SOLID STATE ELECT, V43, P1753, DOI 10.1016/S0038-1101(99)00146-X##MOTYKA M, IN PRESS THIN SOLID##MUTH JF, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2123396##POLLAK FH, 1994, HDB SEMICONDUCTORS, V2, P527##SHEN L, 2001, IEEE ELECTR DEVICE L, V22, P457, DOI 10.1109/55.954910##SMORCHKOVA IP, 2001, J APPL PHYS, V90, P5196, DOI 10.1063/1.1412273##STRITE S, 1992, J VAC SCI TECHNOL B, V10, P1237, DOI 10.1116/1.585897##YABLONOVITCH E, 1988, APPL PHYS LETT, V52, P1002, DOI 10.1063/1.99226",21,2020-11-20,NA
J,WOS:000242709200108,2006,GIANT OPTICAL BIREFRINGENCE IN ENSEMBLES OF SEMICONDUCTOR NANOWIRES,"GIANT BIREFRINGENCE IS DEMONSTRATED IN ENSEMBLES OF RANDOMLY GROWN, VERTICALLY ALIGNED SEMICONDUCTOR NANOWIRES. BOTTOM-UP FABRICATION OF EPITAXIAL SEMICONDUCTOR NANOWIRES GROWN USING THE VAPOR-LIQUID-SOLID MECHANISM YIELDS A HIGHLY ANISOTROPIC PHOTONIC METAMATERIAL. THE BIREFRINGENCE IN THE MATERIAL IS SHOWN TO DEPEND ON THE NANOWIRE LENGTH. SHORT NANOWIRES WITH A VOLUME FILLING FRACTION AROUND 50% EXHIBIT THE STRONGEST BIREFRINGENCE, IN AGREEMENT WITH EFFECTIVE MEDIUM THEORIES. A LARGE DIFFERENCE IS FOUND BETWEEN THE IN-PLANE AND OUT-OF-PLANE REFRACTIVE INDICES OF DELTA N=0.8, EXCEEDING BY A FACTOR OF 75 THE NATURAL BIREFRINGENCE OF QUARTZ AND BY MORE THAN A FACTOR OF 2 THAT OF INVERTED ARTIFICIAL MATERIALS. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",PHOTOLUMINESCENCE,NA,APPLIED PHYSICS LETTERS,"MUSKENS, OL##BORGSTROM, MT##BAKKERS, EPAM##RIVAS, JG","PHILIPS RES EINDHOVEN, FOM, INST ATOM & MOL PHYS, AMOLF, NL-5656 AE EINDHOVEN, NETHERLANDS.","PHYSICS, APPLIED",PHYSICS,"ARTIGAS D, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.013901##BRAGG WL, 1953, ACTA CRYSTALLOGR, V6, P865, DOI 10.1107/S0365110X53002519##DEHEER WA, 1995, SCIENCE, V268, P845, DOI 10.1126/SCIENCE.268.5212.845##DIEDENHOFEN SL, UNPUB##GENEREUX F, 2001, PHYS REV B, V63, DOI 10.1103/PHYSREVB.63.161101##GERARDOT BD, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.137403##KIRCHNER A, 1998, PHYS REV B, V57, P277, DOI 10.1103/PHYSREVB.57.277##KOTLYAR MV, 2005, OPT EXPRESS, V13, P5040, DOI 10.1364/OPEX.13.005040##KUNZNER N, 2001, OPT LETT, V26, P1265, DOI 10.1364/OL.26.001265##LEVY O, 1997, PHYS REV B, V56, P8035, DOI 10.1103/PHYSREVB.56.8035##LIN VSY, 1997, SCIENCE, V278, P840, DOI 10.1126/SCIENCE.278.5339.840##MARKHAM ML, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1844035##MUSKENS OL, UNPUB##PALIK E. D., 1985, HDB OPTICAL CONSTANT, VI, P445##PETTERSSON H, 2006, NANO LETT, V6, P229, DOI 10.1021/NL052170L##QI ZM, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2171490##VAN VUGT LK, 2005, J AM CHEM SOC, V127, P12357, DOI 10.1021/JA051860O##WAGNER RS, 1964, APPL PHYS LETT, V4, P89, DOI 10.1063/1.1753975##WANG JF, 2001, SCIENCE, V293, P1455, DOI 10.1126/SCIENCE.1062340##WANG WU, 2005, P NATL ACAD SCI USA, V102, P3208, DOI 10.1073/PNAS.0406368102",61,2020-11-20,NA
J,WOS:000242979400002,2006,COLLABORATION WITH GENERAL PRACTITIONERS: PREFERENCES OF MEDICAL SPECIALISTS - A QUALITATIVE STUDY,"BACKGROUND: COLLABORATION BETWEEN GENERAL PRACTITIONERS (GPS) AND SPECIALISTS HAS BEEN THE FOCUS OF MANY COLLABORATIVE CARE PROJECTS DURING THE PAST DECADE. UNFORTUNATELY, QUITE A NUMBER OF THESE PROJECTS FAILED. THIS RAISES THE QUESTION OF WHAT MOTIVATES MEDICAL SPECIALISTS TO INITIATE AND CONTINUE PARTICIPATING WITH GPS IN NEW COLLABORATIVE CARE MODELS. THE FOLLOWING QUESTION IS ADDRESSED IN THIS STUDY: WHAT MOTIVATES MEDICAL SPECIALISTS TO INITIATE AND SUSTAIN NEW MODELS FOR COLLABORATING WITH GPS? METHODS: WE CONDUCTED SEMI-STRUCTURED INTERVIEWS WITH EIGHTEEN MEDICAL SPECIALISTS IN THE PROVINCE OF GRONINGEN, IN THE NORTH OF THE NETHERLANDS. THE SAMPLING CRITERIA WERE AGE, GENDER, TYPE OF HOSPITAL IN WHICH THEY WERE PRACTICING, AND SPECIALTY. THE INTERVIEWS WERE RECORDED, FULLY TRANSCRIBED, AND ANALYSED BY THREE RESEARCHERS WORKING INDEPENDENTLY. THE RESULTING MOTIVATIONAL FACTORS WERE GROUPED INTO CATEGORIES. RESULTS: ' TEACHING GPS' AND ' REGULATING PATIENT FLOW' ( REFERRALS) APPEARED TO DOMINATE WHEN THE MOTIVATIONAL FACTORS WERE CONSIDERED. IN ADDITION, SPECIALISTS WANT TO DEVELOP RELATIONSHIPS WITH THE GPS ON A MORE PERSONAL LEVEL. MOST SPECIALISTS BELIEVE THAT THERE IS NOT MUCH THEY CAN LEARN FROM GPS. ' LACK OF TIME', ' NO FINANCIAL COMPENSATION', AND ' NO SUPPORT FROM COLLEAGUES' WERE CONSIDERED TO BE THE MAIN CONCERNS TO ESTABLISHING COLLABORATIVE CARE PRACTICES. ADDITIONALLY, PROJECTS WERE OFTEN EXPERIENCED AS TOO COMPLEX AND TIME CONSUMING WHEREAS GUIDELINES WERE EXPERIENCED AS TOO RESTRICTIVE. CONCLUSION: SPECIALISTS ARE PARTICULARLY INTERESTED IN COLLABORATING BECAUSE THE GP IS THE GATEKEEPER FOR ACCESS TO SECONDARY HEALTH CARE RESOURCES. SPECIALISTS FEEL THAT THEY ARE ABLE TO TEACH THE GPS SOMETHING, BUT THEY DO NOT FEEL THAT THEY HAVE ANYTHING TO LEARN FROM THE GPS. WITH RESPECT TO PROFESSIONAL EXPERTISE, THEREFORE, SPECIALISTS DO NOT CONSIDER GPS AS EQUALS. ONCE PERSONAL RELATIONSHIPS WITH THE GPS HAVE BEEN ESTABLISHED, AN INFORMAL NETWORK WITH INCIDENTAL PROFESSIONAL CONTACT SEEMS TO BE SUFFICIENT TO SATISFY THE COLLABORATIVE NEEDS OF THE SPECIALIST. THE CONCERNS SEEM TO OUTWEIGH ANY POSITIVE MOTIVATIONAL FORCES TO DEVELOPING NEW MODELS OF COLLABORATIVE PRACTICE.",HOSPITAL CONSULTANTS WORK; PROFESSIONAL RELATIONSHIP; TREATMENT GUIDELINES; SECONDARY CARE; NETHERLANDS; PHYSICIANS; VIEWS; BARRIERS; WELL; GPS,NA,BMC HEALTH SERVICES RESEARCH,"BERENDSEN, AJ##BENNEKER, WHGM##SCHULING, J##RIJKERS-KOORN, N##SLAETS, JPJ##MEYBOOM-DE JONG, B","UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT GEN PRACTICE, NL-9713 AV GRONINGEN, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT INTERNAL MED, NL-9713 AV GRONINGEN, NETHERLANDS.",HEALTH CARE SCIENCES & SERVICES,HEALTH CARE SCIENCES & SERVICES,"BERENDSEN AJ, 2006, UNPUB BMC HLTH SERV##BOWLING A, 2000, BRIT J GEN PRACT, V50, P116##BRENNAN T, 2002, LANCET, V359, P520, DOI 10.1016/S0140-6736(02)07684-5##DIJKSTRA RF, 2000, NETH J MED, V56, P80, DOI 10.1016/S0300-2977(99)00123-0##DONOHOE MT, 1998, ARCH INTERN MED, V158, P1596, DOI 10.1001/ARCHINTE.158.15.1596##EZEKOWITZ JA, 2005, CAN MED ASSOC J, V172, P189, DOI 10.1503/CMAJ.1032017##HARDY B, 1999, HEALTH POLICY, V48, P87, DOI 10.1016/S0168-8510(99)00037-8##HORNE R, 2001, BRIT J GEN PRACT, V51, P187##KASJE WN, 2004, INT J QUAL HEALTH C, V16, P229, DOI 10.1093/INTQHC/MZH038##KVAMME OJ, 2001, QUAL HEALTH CARE, V10, P33, DOI 10.1136/QHC.10.1.33##MARSHALL MN, 1998, BRIT J GEN PRACT, V48, P1379##MARSHALL MN, 1998, BRIT MED J, V316, P442, DOI 10.1136/BMJ.316.7129.442##MARSHALL MN, 1999, PROF GEOGR, V51, P274, DOI 10.1111/0033-0124.00164##MARSHALL MN, 1999, FAM PRACT, V16, P33, DOI 10.1093/FAMPRA/16.1.33##MOL PGM, 2004, EMERG INFECT DIS, V10, P522, DOI 10.3201/EID1003.030292##O'CATHAIN A, 1999, J HEALTH SERV RES POLICY, V4, P154##PENA-DOLHUN E, 2001, J FAM PRACTICE, V50, P1032##POLLEMANS M C, 1996, NED TIJDSCHR GENEESKD, V140, P2040##POPE C, 2002, QUAL SAF HEALTH CARE, V11, P148, DOI 10.1136/QHC.11.2.148##RITCHIE J, 1994, ANAL QUALITATIVE DAT##WAGNER EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/BMJ.320.7234.569##WYNIA MK, 1999, NEW ENGL J MED, V341, P1612, DOI 10.1056/NEJM199911183412112",43,2020-11-20,NA
J,WOS:000242745800007,2006,THE ROLE OF SUPEROXIDE ANIONS IN THE DEVELOPMENT OF DISTANT TUMOUR RECURRENCE,"WE HYPOTHESISE THAT REACTIVE OXYGEN SPECIES (ROS) RELEASED FROM ACTIVATED POLYMORPHONUCLEAR LEUCOCYTES DURING SURGERY PLAY A CRUCIAL ROLE IN ENHANCED TUMOUR RECURRENCE SEEN AFTER SURGERY. THEREFORE, THE EFFECT OF ROS ON ADHESION OF TUMOUR CELLS TO MICROVASCULAR ENDOTHELIUM IN A REPRODUCIBLE HUMAN IN VITRO MODEL WAS STUDIED. PREINCUBATION OF MICROVASCULAR ENDOTHELIAL CELLS WITH THE SUPEROXIDE ANION PRODUCING XANTHINE-XANTHINE OXIDASE COMPLEX SIGNIFICANTLY INCREASED ADHESION OF THE HUMAN COLON CARCINOMA CELLS HT29 (167% VS CONTROL, P < 0.01), CACO2 (164% VS CONTROL, P < 0.01) AND OF THE PANCREAS CARCINOMA CELLS PANC1 (180% VS CONTROL, P < 0.01). ADDITION OF THE ANTIOXIDANT ENZYMES SUPEROXIDE DISMUTASE OR CATALASE SIGNIFICANTLY DECREASED TUMOUR CELL ADHESION (P < 0.01). EXPOSURE OF ENDOTHELIAL CELLS TO SUPEROXIDE ANIONS INCREASED THE APOPTOTIC RATE TO 7.9 TIMES THE NORMAL RATE. ADDITIONALLY, EXPOSURE INCREASED EXPRESSION OF THE ENDOTHELIAL ADHESION MOLECULES E-SELECTIN, ICAM-1, AND VCAM-1 OF MAXIMALLY 170% VS CONTROL (P < 0.01). IN CONCLUSION, THIS STUDY SHOWS THAT SUPEROXIDE ANIONS PROMOTE THE ADHERENCE OF TUMOUR CELLS TO THE MICROVASCULATURE BY INDUCING ENDOTHELIAL APOPTOSIS THAT SUBSEQUENTLY INDUCES THE EXPRESSION OF VARIOUS ADHESION MOLECULES FOR TUMOUR CELLS. THIS INDICATES THAT BY TACKLING THE PRODUCTION OF ROS PREVENTING TUMOUR RECURRENCE AT DISTANT SITES MIGHT BE FEASIBLE.",ENDOTHELIAL CELL-INTERACTION; SURGICAL STRESS; COLORECTAL-CANCER; ADHESION MOLECULES; SURGERY; METASTASIS; PERITONEAL; GROWTH; MODEL; NEUTROPHILS,SURGICAL TRAUMA; ROS; TUMOUR CELL; MICROVASCULAR ENDOTHELIUM; ADHESION,BRITISH JOURNAL OF CANCER,"TEN KATE, M##VAN DER WAL, JBC##SLUITER, W##HOFLAND, LJ##JEEKEL, J##SONNEVELD, P##VAN EIJCK, CHJ","ERASMUS MC, DEPT SURG, NL-3015 GD ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT BIOCHEM, NL-3015 GD ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT INTERNAL MED, NL-3015 GD ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT HEMATOL, NL-3015 GD ROTTERDAM, NETHERLANDS.",ONCOLOGY,ONCOLOGY,"AOSASA S, 2000, WORLD J SURG, V24, P10, DOI 10.1007/S002689910003##AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457##BAIGRIE RJ, 1992, BRIT J SURG, V79, P757, DOI 10.1002/BJS.1800790813##BOUVY ND, 1997, BRIT J SURG, V84, P358##BRADLEY JR, 1993, AM J PATHOL, V142, P1598##BUSCH ORC, 1993, NEW ENGL J MED, V328, P1372, DOI 10.1056/NEJM199305133281902##CATTERALL JB, 1994, CANCER LETT, V87, P199, DOI 10.1016/0304-3835(94)90223-2##CHANDRA D, 2003, CHEM-BIOL INTERACT, V143, P605, DOI 10.1016/S0009-2797(02)00191-6##CHIRIVI RGS, 1994, CELL ADHES COMMUN, V2, P219, DOI 10.3109/15419069409004440##FOSSE E, 1987, ACTA ANAESTH SCAND, V31, P33, DOI 10.1111/J.1399-6576.1987.TB02516.X##GIAVAZZI R, 1996, CURR TOP MICROBIOL, V213, P13##HEBERT MJ, 1998, AM J PATHOL, V152, P523##HILDEBRANDT U, 2003, SURG ENDOSC, V17, P242, DOI 10.1007/S00464-001-9148-9##HOFLAND LJ, 1990, EUR J CANCER, V26, P37, DOI 10.1016/0277-5379(90)90254-Q##LINK KH, 2005, ANN SURG, V242, P178, DOI 10.1097/01.SLA.0000171033.65639.A9##LO SK, 1993, AM J PHYSIOL, V264, PL406##MARKERT M, 1984, METHOD ENZYMOL, V105, P358##MIDGLEY R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X##MIYAOKA K, 2005, J SURG RES, V125, P144, DOI 10.1016/J.JSS.2004.12.001##NOSHIMA S, 1997, SURG TODAY, V27, P135, DOI 10.1007/BF02385902##OKA Y, 1994, AM J SURG, V167, P405, DOI 10.1016/0002-9610(94)90125-2##ORR FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P##PROSS M, 2002, WORLD J SURG, V26, P49, DOI 10.1007/S00268-001-0180-7##SHIROMIZU A, 2000, SURGERY, V128, P799, DOI 10.1067/MSY.2000.108047##TEN KATE M, 2004, INT J CANCER, V112, P943, DOI 10.1002/IJC.20506##TERADA LS, 1997, J APPL PHYSIOL, V82, P866##URE BM, 2002, SURG ENDOSC, V16, P836, DOI 10.1007/S00464-001-9093-7##VAN DEN TOL RM, 1998, ANN SURG, V227, P242, DOI 10.1097/00000658-199802000-00014##VAN ROSSEN MEE, 1999, BRIT J SURG, V86, P509##VAN ROSSEN MEE, 2000, CANCER RES, V60, P5625##VARGA G, 1997, ACTA CHIR HUNG, V36, P368##WAYNE JD, 2002, ONCOLOGIST, V7, P34, DOI 10.1634/THEONCOLOGIST.7-1-34##WEESE JL, 1986, SURGERY, V100, P273##WEISS L., 1985, PRINCIPLES METASTASI##YOKOTA KI, 1995, SURG TODAY, V25, P579, DOI 10.1007/BF00311429",18,2020-11-20,NA
J,WOS:000242745800021,2006,"HUMAN PAPILLOMAVIRUS INFECTION IN SHENYANG CITY, PEOPLE'S REPUBLIC OF CHINA: A POPULATION-BASED STUDY","TO INVESTIGATE THE PREVALENCE OF, AND RISK FACTORS FOR, CERVICAL INFECTION WITH HUMAN PAPILLOMAVIRUS (HPV) IN SHENYANG CITY, PEOPLE'S REPUBLIC OF CHINA, WE INTERVIEWED AND OBTAINED CERVICAL CELL SAMPLES FROM 685 WOMEN AGED 15-59 YEARS ENUMERATED FROM LOCAL POPULATION LISTS. HUMAN PAPILLOMAVIRUS DNA WAS DETECTED IN CERVICAL CELL SAMPLES USING A GP5 +/6 + -BASED PCR ASSAY FOR 44 HPV TYPES. HUMAN PAPILLOMAVIRUS PREVALENCE WAS 16.8% OVERALL AND 13.6% AMONG WOMEN WITHOUT CERVICAL ABNORMALITIES (16.6% AND 12.4%, RESPECTIVELY, AGE-STANDARDISED TO THE WORLD STANDARD POPULATION), WITH NO SIGNIFICANT TRENDS IN HPV PREVALENCE BY AGE GROUP. OF THE 32 TYPES IDENTIFIED, HIGH-RISK HPV TYPES PREDOMINATED IN ALL AGE GROUPS, HPV16 BEING THE MOST COMMON (3.4% OF ALL WOMEN), FOLLOWED BY HPV52 (2.5%) AND 58 (1.9%). MULTIPLE-TYPE INFECTIONS ACCOUNTED FOR 31.3% OF ALL INFECTED WOMEN. NOT BEING MARRIED, REPORTING MULTIPLE SEXUAL PARTNERS AND HUSBAND'S EXTRAMARITAL SEXUAL RELATIONSHIPS WERE ALL SIGNIFICANTLY ASSOCIATED WITH BEING HPV-POSITIVE. THE DISCLOSURE OF A RELATIVELY HIGH HPV PREVALENCE IN SHENYANG, IN COMPARISON WITH OTHER WORLDWIDE POPULATIONS, RAISES IMPORTANT QUESTIONS CONCERNING THE PREVENTION OF CERVICAL CANCER IN CHINA, ESPECIALLY GIVEN THE PROMISING EFFICACY OF PROPHYLACTIC HPV VACCINES.",COLOMBIAN WOMEN; HPV INFECTION; PREVALENCE; DETERMINANTS; WORLDWIDE; TRENDS,HUMAN PAPILLOMAVIRUS; CERVICAL NEOPLASIA; CHINA; EPIDEMIOLOGY,BRITISH JOURNAL OF CANCER,"LI, LK##DAI, M##CLIFFORD, GM##YAO, WQ##ARSLAN, A##LI, N##SHI, JF##SNIJDERS, PJF##MEIJER, CJLM##QIAO, YL##FRANCESCHI, S","INT AGCY RES CANC, F-69372 LYON 08, FRANCE. LIAONING PROVINCIAL TUMOR HOSP, DEPT CANC EPIDEMIOL, SHENYANG 110042, LIAONING, PEOPLES R CHINA. CHINESE ACAD MED SCI, CANC INST HOSP, BEIJING 100021, PEOPLES R CHINA. VRIJE UNIV AMSTERDAM, MED CTR, NL-1007 MB AMSTERDAM, NETHERLANDS. LIAONING PROVINCIAL TUMOR HOSP, DEPT GYNECOL ONCOL, SHENYANG 110042, LIAONING, PEOPLES R CHINA.",ONCOLOGY,ONCOLOGY,"ANH PTH, 2003, INT J CANCER, V104, P213, DOI 10.1002/IJC.10936##CHEN XS, 2000, SEX TRANSM DIS, V27, P138, DOI 10.1097/00007435-200003000-00003##CLIFFORD G, 2005, PAPILLOMAVIRUS REP, V16, P322, DOI [DOI 10.1179/095741905X49089, 10.1179/095741905X49089]##CLIFFORD GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/SJ.BJC.6600688##CLIFFORD GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9##DAI M, 2006, BRIT J CANCER, V95, P96, DOI 10.1038/SJ.BJC.6603208##DOLL R, 1966, CANC INCIDENCE 5 CON##FERRECCIO C, 2004, CANCER EPIDEM BIOMAR, V13, P2271##FRANCESCHI S, 2005, BRIT J CANCER, V92, P601, DOI 10.1038/SJ.BJC.6602348##FRANCESCHI S, 2006, INT J CANC   0921##JACOBS MV, 2000, INT J CANCER, V87, P221, DOI 10.1002/1097-0215(20000715)87:2&LT;221::AID-IJC11&GT;3.0.CO;2-2##MATOS E, 2003, SEX TRANSM DIS, V30, P593, DOI 10.1097/01.OLQ.0000085181.25063.6C##MOLANO M, 2003, AM J EPIDEMIOL, V158, P486, DOI 10.1093/AJE/KWG171##MOLANO M, 2002, BRIT J CANCER, V87, P324, DOI 10.1038/SJ.BJC.6600442##PARKIN D, 2002, IARC SCI PUBLICATION, VVIII##PETO J, 2004, BRIT J CANCER, V91, P942, DOI 10.1038/SJ.BJC.6602049##SUKVIRACH S, 2003, J INFECT DIS, V187, P1246, DOI 10.1086/373901##THOMAS JO, 2004, BRIT J CANCER, V90, P638, DOI 10.1038/SJ.BJC.6601515##VACCARELLA S, 2006, CANCER EPIDEM BIOMAR, V15, P326, DOI 10.1158/1055-9965.EPI-05-0577##VAN DEN BRULE AJC, 2002, J CLIN MICROBIOL, V40, P779, DOI 10.1128/JCM.40.3.779-787.2002##YANG L, 2003, INT J CANCER, V106, P771, DOI 10.1002/IJC.11300##YANG LING, 2003, ZHONGGUO YI XUE KE XUE YUAN XUE BAO, V25, P386",112,2020-11-20,NA
J,WOS:000242520100063,2006,VARIATIONAL COLLAPSE OF THE OPTIMIZED EFFECTIVE POTENTIAL METHOD WITH AN ORBITAL-DEPENDENT EXCHANGE-CORRELATION FUNCTIONAL BASED ON SECOND ORDER PERTURBATION THEORY,"IT IS WELL KNOWN, THAT SECOND-ORDER PERTURBATION THEORY (PT2) BREAKS DOWN WHEN THE GAP BETWEEN THE HIGHEST OCCUPIED MOLECULAR ORBITAL (HOMO) AND THE LOWEST UNOCCUPIED MO (LUMO) BECOMES TOO LOW. IT IS DEMONSTRATED THAT WHEN THE LOCAL KOHN-SHAM (KS) POTENTIAL VS IS APPROXIMATED BY AN EXPANSION IN A SET OF BASIS FUNCTIONS, EXACT HOMO-LUMO DEGENERACY OCCURS, IF A FINITE ORBITAL BASIS SET IS USED. NUMERICAL EVIDENCE IS GIVEN FOR THE HE ATOM, WHICH UNTIL NOW STOOD OUT AS A 'SAFE' SIMPLE CASE. VARIATIONAL COLLAPSE OF THE OPTIMIZED EFFECTIVE POTENTIAL (OEP) METHOD WITH THE PT2 FUNCTIONAL IN A FINITE ORBITAL BASIS MAY BE EXPECTED TO BE A COMMON PHENOMENON. WE ALSO SHOW VARIATIONAL BREAKDOWN WITH A NON-PERTURBATIVE FUNCTIONAL WHEN THE HOMO-LUMO GAP IS USED TO REGULATE THE CONTRIBUTION OF VIRTUAL ORBITALS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",GAUSSIAN-BASIS SETS; MOLECULAR CALCULATIONS; CORRELATION-ENERGY; DENSITY; (HYPER)POLARIZABILITIES; APPROXIMATION; CONNECTION; EXPLICIT,NA,CHEMICAL PHYSICS LETTERS,"ROHR, D##GRITSENKO, O##BAERENDS, EJ","VRIJE UNIV AMSTERDAM, AFDELING THEORET CHEM, NL-1081 HV AMSTERDAM, NETHERLANDS.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"BAERENDS EJ, 2001, PHYS REV LETT, V87, DOI 10.1103/PHYSREVLETT.87.133004##BAERENDS EJ, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1904566##BARTLETT RJ, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1904585##BUIJSE MA, 2002, MOL PHYS, V100, P401, DOI 10.1080/00268970110070243##BUIJSE MA, 1991, THESIS VRIJE U AMSTE##COLLE R, 2001, J PHYS B-AT MOL OPT, V34, P2475, DOI 10.1088/0953-4075/34/12/312##CSANYI G, 2000, PHYS REV B, V61, P7348, DOI 10.1103/PHYSREVB.61.7348##DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153##ENGEL E, 2000, PHYS REV A, V61, DOI 10.1103/PHYSREVA.61.032502##ENGEL E, 1998, PHYS REV A, V58, P964, DOI 10.1103/PHYSREVA.58.964##ENGEL E, 1999, J COMPUT CHEM, V20, P31, DOI 10.1002/(SICI)1096-987X(19990115)20:1<31::AID-JCC6>3.0.CO;2-P##ERNZERHOF M, 1996, CHEM PHYS LETT, V263, P499, DOI 10.1016/S0009-2614(96)01225-0##FRITSCHE L, 1998, PHYS REV A, V57, P3425, DOI 10.1103/PHYSREVA.57.3425##GORLING A, 1994, PHYS REV A, V50, P196, DOI 10.1103/PHYSREVA.50.196##GORLING A, 1992, PHYS REV A, V46, P3753, DOI 10.1103/PHYSREVA.46.3753##GORLING A, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1904583##GRITSENKO OV, 2001, PHYS REV A, V64, DOI 10.1103/PHYSREVA.64.042506##GRUNING M, 2003, J CHEM PHYS, V118, P7183, DOI 10.1063/1.1562197##GRUNING M, 2002, J CHEM PHYS, V116, P6435, DOI 10.1063/1.1463444##GRUNING M, 2001, J CHEM PHYS, V114, P652, DOI 10.1063/1.1327260##HIRATA S, 2001, J CHEM PHYS, V115, P1635, DOI 10.1063/1.1381013##MORI-SANCHEZ P, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1904584##MULLER AMK, 1984, PHYS LETT A, V105, P446, DOI 10.1016/0375-9601(84)91034-X##PERDEW JP, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1904565##ROHR DR, 2006, J MOL STRUC-THEOCHEM, V762, P193, DOI 10.1016/J.THEOCHEM.2005.10.020##ROSE JH, 1975, SOLID STATE COMMUN, V17, P327, DOI 10.1016/0038-1098(75)90304-X##SCHIPPER PRT, 2000, J CHEM PHYS, V112, P1344, DOI 10.1063/1.480688##STAROVEROV VN, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2194546##TALMAN JD, 1976, PHYS REV A, V14, P36, DOI 10.1103/PHYSREVA.14.36##WOON DE, 1994, J CHEM PHYS, V100, P2975, DOI 10.1063/1.466439##YANG WT, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.143002",17,2020-11-20,NA
J,WOS:000242520100070,2006,CORRECTLY VALIDATING RESULTS FROM SINGLE MOLECULE DATA: THE CASE OF STRETCHED EXPONENTIAL DECAY IN THE CATALYTIC ACTIVITY OF SINGLE LIPASE B MOLECULES,"THE QUESTION OF HOW TO VALIDATE AND INTERPRET CORRECTLY THE WAITING TIME PROBABILITY DENSITY FUNCTIONS (WT-PDFS) FROM SINGLE MOLECULE DATA IS ADDRESSED. IT IS SHOWN BY SIMULATION THAT WHEN A STRETCHED EXPONENTIAL WT-PDF, PHI(OFF) (T) = PHI(0)E(-(IOTA/TAU)ALPHA), GENERATES THE OFF PERIODS OF A TWO-STATE TRAJECTORY, A RELIABLE RECOVERY OF THE INPUT PHI(OFF)(T) FROM THE TRAJECTORY IS OBTAINED EVEN WHEN THE BIN SIZE USED TO DEFINE THE TRAJECTORY, DT, IS MUCH LARGER THAN THE PARAMETER TAU. THIS HOLDS TRUE AS LONG AS THE FIRST MOMENT OF THE WT-PDF IS MUCH LARGER THAN DT. OUR RESULTS VALIDATE THE RESULTS IN AN EARLIER STUDY OF THE ACTIVITY OF SINGLE LIPASE B MOLECULES AND DISPROVE RECENT RELATED CRITIQUE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",AGGREGATED MARKOV-MODELS; CONFORMATIONAL DYNAMICS; ENZYME KINETICS,NA,CHEMICAL PHYSICS LETTERS,"FLOMENBOM, O##HOFKENS, J##VELONIA, K##DE SCHRYVER, FC##ROWAN, AE##NOLTE, RJM##KLAFTER, J##SILBEY, RJ","KATHOLIEKE UNIV LEUVEN, DEPT CHEM, B-3001 HEVERLEE, BELGIUM. MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA. UNIV GENEVA, DEPT ORGAN CHEM, CH-1211 GENEVA 4, SWITZERLAND. RADBOUD UNIV NIJMEGEN, DEPT ORGAN CHEM, NL-6525 ED NIJMEGEN, NETHERLANDS. TEL AVIV UNIV, SACKLER FAC EXACT SCI, SCH CHEM, IL-69978 TEL AVIV, ISRAEL.","CHEMISTRY, PHYSICAL; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; PHYSICS,"AGMON N, 2000, J PHYS CHEM B, V104, P7830, DOI 10.1021/JP0012911##BAUER RJ, 1987, BIOPHYS J, V52, P961, DOI 10.1016/S0006-3495(87)83289-7##BOKINSKY G, 2003, P NATL ACAD SCI USA, V100, P9302, DOI 10.1073/PNAS.1133280100##BRUNO WJ, 2005, P NATL ACAD SCI USA, V102, P6326, DOI 10.1073/PNAS.0409110102##CAO JS, 2000, CHEM PHYS LETT, V327, P38, DOI 10.1016/S0009-2614(00)00809-5##COLQUHOUN D, 1982, PHILOS T ROY SOC B, V300, P1, DOI 10.1098/RSTB.1982.0156##EDMAN L, 1999, CHEM PHYS, V247, P11, DOI 10.1016/S0301-0104(99)00098-1##FLOMENBOM O, 2005, BIOPHYS J, V88, P3780, DOI 10.1529/BIOPHYSJ.104.055905##FLOMENBOM O, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.098105##FLOMENBOM O, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1979489##FLOMENBOM O, 2005, ACTA PHYS POL B, V36, P1527##FLOMENBOM O, 2006, P NATL ACAD SCI USA, V103, P10907, DOI 10.1073/PNAS.0604546103##FRAUENFELDER H, 1999, REV MOD PHYS, V71, PS419, DOI 10.1103/REVMODPHYS.71.S419##FREDKIN DR, 1986, J APPL PROBAB, V23, P208, DOI 10.2307/3214130##GRANEK R, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.098106##HA TJ, 1999, P NATL ACAD SCI USA, V96, P893, DOI 10.1073/PNAS.96.3.893##KIENKER P, 1989, PROC R SOC SER B-BIO, V236, P269, DOI 10.1098/RSPB.1989.0024##LU HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/SCIENCE.282.5395.1877##MOLSKI A, 2006, CHEM PHYS LETT, V428, P196, DOI 10.1016/J.CPLETT.2006.07.038##NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799A0##PRESS WH, 1986, NUMERICAL RECIPES##QIAN H, 2002, BIOPHYS CHEM, V101, P565, DOI 10.1016/S0301-4622(02)00145-X##QIN F, 2000, BIOPHYS J, V79, P1915, DOI 10.1016/S0006-3495(00)76441-1##RHOADES E, 2003, P NATL ACAD SCI USA, V100, P3197, DOI 10.1073/PNAS.2628068100##RICHTERDYN N, 1974, STOCHASTIC MODELS BI##VELONIA K, 2005, ANGEW CHEM INT EDIT, V44, P560, DOI 10.1002/ANIE.200460625##WITKOSKIE JB, 2004, J CHEM PHYS, V121, P6373, DOI 10.1063/1.1785784##YANG H, 2003, SCIENCE, V302, P262, DOI 10.1126/SCIENCE.1086911##YERAMIAN E, 1987, NATURE, V326, P169, DOI 10.1038/326169A0",11,2020-11-20,NA
J,WOS:000242793500007,2006,REVERSIBLE CHAIN TRANSFER BETWEEN ORGANOYTTRIUM CATIONS AND ALUMINUM: SYNTHESIS OF ALUMINUM-TERMINATED POLYETHYLENE WITH EXTREMELY NARROW MOLECULAR-WEIGHT DISTRIBUTION,"AMINOPYRIDINATO-LIGAND-STABILIZED ORGANOYTTRIUM CATIONS ARE ACCESSIBLE IN VERY GOOD YIELD THROUGH ALKANE ELIMINATION FROM TRIALKYL YTTRIUM COMPLEXES WITH STERICALLY DEMANDING AMINOPYRIDINES, FOLLOWED BY ABSTRACTION OF ONE OF THE TWO ALKYL FUNCTIONS USING AMMONIUM BORATES. AT 80 DEGREES C AND IN THE PRESENCE OF SMALL AMOUNTS OF ALUMINUM ALKYL COMPOUNDS, VERY HIGH ETHYLENE POLYMERIZATION ACTIVITIES ARE OBSERVED IF VERY BULKY AMINOPYRIDINATO LIGANDS ARE USED. DURING THESE POLYMERIZATIONS A REVERSIBLE POLYETHYLENE CHAIN TRANSFER IS OBSERVED BETWEEN THE ORGANOYTTRIUM CATIONS AND ALUMINUM ALKYLS. THE CHAIN-TRANSFER CATALYST SYSTEM DESCRIBED HERE IS ABLE TO PRODUCE RELATIVELY LONG-CHAIN (UP TO 4000 GMOL(-1)) AL-TERMINATED POLYETHYLENE WITH A MOLECULAR-WEIGHT DISTRIBUTION < 1.1. IN THE SYNTHESIS OF HIGHER MOLECULAR PE A SLIGHT INCREASE IN POLYDISPERSITY WITH INCREASING CHAIN LENGTH (15600 GMOL(-1), -1.4) IS OBSERVED OWING TO REDUCED REVERSIBILITY CAUSED BY HIGHER VISCOSITY AND PRECIPITATION OF POLYMER CHAINS (TEMPERATURE OF 80-100 DEGREES C).",RARE-EARTH-METALS; OLEFIN POLYMERIZATION CATALYSTS; LANTHANIDE-ALKYL COMPLEXES; STRUCTURAL-CHARACTERIZATION; AMINOPYRIDINATO LIGANDS; COORDINATION; REACTIVITY; CARBOXYLATE; ACTIVATION; ETHYLENE,ALUMINUM; CHAIN TRANSFER; LANTHANIDES; POLYMERIZATION; YTTRIUM,CHEMISTRY-A EUROPEAN JOURNAL,"KRETSCHMER, WP##MEETSMA, A##HESSEN, B##SCHMALZ, T##QAYYUM, S##KEMPE, R","UNIV GRONINGEN, CTR CALAYT OLEFIN POLYMERIZAT, STRATINGH INST CHEM & CHEM ENGN, NL-9747 AG GRONINGEN, NETHERLANDS. UNIV BAYREUTH, LEHRSTUHL ANORGAN CHEM 2, D-95440 BAYREUTH, GERMANY. LEIBNIZ INST KATALYSE, D-18059 ROSTOCK, GERMANY.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"[ANONYMOUS], 2005, ANGEW CHEM, V117, P7640##[ANONYMOUS], 2005, ANGEW CHEM, V117, P5437##ARNDT S, 2005, ADV SYNTH CATAL, V347, P339, DOI 10.1002/ADSC.200404269##ARNDT S, 2002, CHEM COMMUN, P896, DOI 10.1039/B201613N##ARNDT S, 2003, DALTON T, P3622, DOI 10.1039/B305964B##ARNDT S, 2005, ANGEW CHEM INT EDIT, V44, P7473, DOI 10.1002/ANIE.200502915##ARNDT S, 2003, ORGANOMETALLICS, V22, P775, DOI 10.1021/OM0207010##BAMBIRRA S, 2004, J AM CHEM SOC, V126, P9182, DOI 10.1021/JA0475297##BAMBIRRA S, 2001, CHEM COMMUN, P637, DOI 10.1039/B101012N##BAZAN GC, 2001, ORGANOMETALLICS, V20, P2059, DOI 10.1021/OM001048O##BRITOVSEK G. J. P, 2002, ANGEW CHEM, V114, P507##BRITOVSEK GJP, 2004, J AM CHEM SOC, V126, P10701, DOI 10.1021/JA0485560##BRITOVSEK GJP, 2002, ANGEW CHEM INT EDIT, V41, P489, DOI 10.1002/1521-3773(20020201)41:3<489::AID-ANIE489>3.0.CO;2-C##BRITOVSEK GJP, 1999, ANGEW CHEM INT EDIT, V38, P428, DOI 10.1002/(SICI)1521-3773(19990215)38:4<428::AID-ANIE428>3.0.CO;2-3##BRITOVSEK GJP, 1999, ANGEW CHEM, V111, P448, DOI DOI 10.1002/(ISSN)1521-3757##CAMERON TM, 2003, CHEM COMMUN, P2282, DOI 10.1039/B306889G##CRANE FE, 1956, ANAL CHEM, V28, P1794, DOI 10.1021/AC60119A052##DIETRICH HM, 2006, J AM CHEM SOC, V128, P1458, DOI 10.1021/JA057618Z##DIETRICH HM, 2005, ORGANOMETALLICS, V24, P5767, DOI 10.1021/OM0506163##DIETRICH HM, 2005, ANGEW CHEM INT EDIT, V44, P5303, DOI 10.1002/ANIE.200463109##EVANS WJ, 2006, INORG CHEM, V45, P424, DOI 10.1021/IC0515610##EVANS WJ, 2005, CHEM COMMUN, P5925, DOI 10.1039/B511714C##EVANS WJ, 2005, ORGANOMETALLICS, V24, P4882, DOI 10.1021/OM050270W##EVANS WJ, 2005, ORGANOMETALLICS, V24, P570, DOI 10.1021/OM049484O##FISCHBACH A, 2006, ORGANOMETALLICS, V25, P1626, DOI 10.1021/OM060052I##FISCHBACH A, 2003, ORGANOMETALLICS, V22, P499, DOI 10.1021/OM020784K##HAJELA S, 1997, J ORGANOMET CHEM, V532, P45, DOI 10.1016/S0022-328X(96)06768-X##HAN CJ, 2002, MACROMOLECULES, V35, P8923, DOI 10.1021/MA025565P##HAYES PG, 2005, ORGANOMETALLICS, V24, P1173, DOI 10.1021/OM050007V##HAYES PG, 2003, ORGANOMETALLICS, V22, P1577, DOI 10.1021/OM030157A##KANEYOSHI H, 2005, MACROMOLECULES, V38, P5425, DOI 10.1021/MA050263J##KEMPE R, 2003, EUR J INORG CHEM, P791##KEMPE R, 2002, J ORGANOMET CHEM, V647, P12, DOI 10.1016/S0022-328X(01)01475-9##LAPPERT MF, 1973, J CHEM SOC CHEM COMM, P126, DOI 10.1039/C39730000126##LAWRENCE SC, 2003, CHEM COMMUN, P2880, DOI 10.1039/B310867H##LOPEZ RG, 2006, MACROMOL RAPID COMM, V27, P173, DOI 10.1002/MARC.200500670##MANI G., 2004, ANGEW CHEM, V116, P2313, DOI DOI 10.1002/ANGE.200353040##PELLETIER J. F., 1998, US PAT., PATENT NO. 5779942##PELLETIER J.-F., 1996, ANGEW CHEM, V108, P1980##PELLETIER JF, 1996, ANGEW CHEM INT EDIT, V35, P1854, DOI 10.1002/ANIE.199618541##ROGERS JS, 2000, CHEM COMMUN, P1209, DOI 10.1039/B002146F##SAITO J, 2005, MACROMOLECULES, V38, P4955, DOI 10.1021/MA050289A##SCHAVERIEN CJ, 1992, ORGANOMETALLICS, V11, P3476, DOI 10.1021/OM00046A060##SCHREMS MG, 2005, CHEM COMMUN, P5922, DOI 10.1039/B512047K##SCOTT NM, 2005, EUR J INORG CHEM, P1319, DOI 10.1002/EJIC.200400823##SCOTT NM, 2004, EUR J INORG CHEM, P3297, DOI 10.1002/EJIC.200400228##TAZELAAR CGJ, 2004, ORGANOMETALLICS, V23, P936, DOI 10.1021/OM034403U##VAN MEURS M, 2005, J AM CHEM SOC, V127, P9913, DOI 10.1021/JA050100A##VANBAAR JF, 2000, PATENT NO. 2000035974##WARD BD, 2005, ANGEW CHEM INT EDIT, V44, P1668, DOI 10.1002/ANIE.200462804##WARD BD, 2005, ANGEW CHEM, V117, P1696##ZIEGLER K, 1955, ANGEW CHEM INT EDIT, V67, P541, DOI 10.1002/ANGE.19550671902##ZIEGLER K, 1952, ANGEW CHEM-GER EDIT, V64, P323, DOI 10.1002/ANGE.19520641202##ZIEGLER K., 1954, BRENNST CHEM, V35, P321",130,2020-11-20,NA
J,WOS:000242793500008,2006,HIGHLY SELECTIVE HYDROAMINOMETHYLATION OF INTERNAL ALKENES TO GIVE LINEAR AMINES,"THE APPLICATION OF PHENOXAPHOSPHINO-MODIFIED XANTPHOS-TYPE LIGANDS (1-9) IN THE RHODIUM-CATALYZED HYDROAMINOMETHYLATION OF INTERNAL OLEFINS TO GIVE LINEAR AMINES IS REPORTED. EXCELLENT CHEMO- AND REGIOSELECTIVITIES HAVE BEEN OBTAINED THROUGH THE USE OF 0.1 MOL% [RH(COD)(2)]BF4/0.4 MOL% XANTPHENOXAPHOS (1), PROVIDING A PRACTICAL AND ENVIRONMENTALLY ATTRACTIVE SYNTHETIC ROUTE FOR THE PREPARATION OF AMINES FROM INTERNAL ALKENES. FOR THE FIRST TIME, BOTH FUNCTIONALIZED INTERNAL OLEFINS AND MIXTURES OF INTERNAL AND TERMINAL OLEFINS HAVE BEEN CONVERTED HIGHLY SELECTIVELY INTO LINEAR AMINES. INVESTIGATIONS OF THE EFFECTS OF THE CALCULATED NATURAL BITE ANGLES OF LIGANDS ON HYDROAMINOMETHYLATION SHOWS THAT THE REGIOSELECTIVITY FOR THE LINEAR PRODUCT FOLLOWS A SIMILAR TREND TO THAT SEEN IN THE HYDROFORMYLATION OF INTERNAL ALKENES WITH THE AID OF THESE LIGANDS. HYDROAMINOMETHYLATION AND EACH OF ITS INDIVIDUAL STEPS WERE MONITORED BY HIGH-PRESSURE INFRARED SPECTROSCOPY. THE RESULTS SUGGEST THAT HYDROAMINOMETHYLATIONS TAKE PLACE BY A SEQUENTIAL ISOMERIZATION/HYDROFORMYLATION/AMINATION/HYDROGENATION PATHWAY.",ONE-POT SYNTHESIS; HYDROFORMYLATION/REDUCTIVE AMINATION; CATALYTIC AMINOMETHYLATION; ORGANIC-SYNTHESIS; CARBON-MONOXIDE; METAL-CATALYSTS; BITE ANGLE; RHODIUM; OLEFINS; SECONDARY,AMINES; HOMOGENEOUS CATALYSIS; HYDROAMINOMETHYLATION; RHODIUM; XANTPHOS-TYPE LIGANDS,CHEMISTRY-A EUROPEAN JOURNAL,"AHMED, M##BRONGER, RPJ##JACKSTELL, R##KAMER, PCL##VAN LEEUWEN, PWNM##BELLER, M","UNIV ROSTOCK EV, LEIBNIZ INST KATALYSE, D-18059 ROSTOCK, GERMANY. UNIV AMSTERDAM, VANT HOFF INST MOL SCI, NL-1018 WV AMSTERDAM, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"AHLBRECHT H, 1984, TETRAHEDRON LETT, V25, P1353, DOI 10.1016/S0040-4039(01)80155-6##AHMED M, 2004, TETRAHEDRON LETT, V45, P869, DOI 10.1016/J.TETLET.2003.11.044##AHMED M, 2003, ANGEW CHEM INT EDIT, V42, P5615, DOI 10.1002/ANIE.200352320##AHMED M, 2003, J AM CHEM SOC, V125, P10311, DOI 10.1021/JA030143W##AHMED M, 2003, ANGEW CHEM, V115, P5773##ALI B, 2000, SYNLETT, V6, P161##ANGELOVSKI G, 2005, TETRAHEDRON-ASYMMETR, V16, P1919, DOI 10.1016/J.TETASY.2005.03.035##ANGELOVSKI G, 2003, TETRAHEDRON, V59, P8265, DOI 10.1016/J.TET.2003.08.012##BAIG T, 1993, J ORGANOMET CHEM, V455, P219, DOI 10.1016/0022-328X(93)80402-W##BAIG T, 1992, J CHEM SOC CHEM COMM, P1373, DOI 10.1039/C39920001373##BARFACKER L, 1999, TETRAHEDRON, V55, P7177, DOI 10.1016/S0040-4020(99)00350-6##BEHR A, 2004, CHEM-ING-TECH, V76, P904, DOI 10.1002/CITE.200400069##BEHR A, 2000, EUR J LIPID SCI TECH, V102, P467, DOI 10.1002/1438-9312(200008)102:7<467::AID-EJLT467>3.3.CO;2-A##BELLER M, 2004, ANGEW CHEM INT EDIT, V43, P3368, DOI 10.1002/ANIE.200300616##BELLER M, 1999, CHEM-EUR J, V5, P1301, DOI 10.1002/(SICI)1521-3765(19990401)5:4<1301::AID-CHEM1301>3.0.CO;2-Y##BELLER M, 2004, ANGEW CHEM, V116, P26##BELLER M., 2004, TRANSITION METALS OR##BENINCORI T, 2005, J ORG CHEM, V70, P5436, DOI 10.1021/JO050390D##BILLIG E, 1988, PATENT NO. 213639##BOTTEGHI C, 1985, SYNTHESIS-STUTTGART, P592##BREIT B, 1998, TETRAHEDRON LETT, V39, P5163, DOI 10.1016/S0040-4039(98)01038-7##BRONGER RPJ, 2003, ORGANOMETALLICS, V22, P5358, DOI 10.1021/OM034012F##BROUSSARD ME, 1993, SCIENCE, V260, P1784, DOI 10.1126/SCIENCE.260.5115.1784##BRUNET JJ, 1994, J MOL CATAL, V87, P223, DOI 10.1016/0304-5102(93)E0231-5##BRUNET JJ, 2001, CATALYTIC HETEROFUNC, P98##BRUNO W, 1934, J AM CHEM SOC, V56, P2419##BURKE PM, 1997, PATENT NO. 9733854##CASEY CP, 1990, ISRAEL J CHEM, V30, P299##DEBENNEVILLE PL, 1950, J AM CHEM SOC, V72, P3073, DOI 10.1021/JA01163A074##DIEKHAUS G, 1993, PATENT NO. 334809##DOI T, 1999, SYNLETT, P1751##DRENT E, 1992, PATENT NO. 457386##EILBRACHT P, 1999, EUR J ORG CHEM, V1999, P1907##EILBRACHT P, 1999, CHEM REV, V99, P3329, DOI 10.1021/CR970413R##FREDERICK H, 2002, PATENT NO. 6489512##HELLER D, 2002, ANGEW CHEM INT EDIT, V41, P777, DOI 10.1002/1521-3773(20020301)41:5<777::AID-ANIE777>3.0.CO;2-7##HELLER D, 2001, J ORG CHEM, V66, P6816, DOI 10.1021/JO010445L##HELLER D, 2002, ANGEW CHEM, V114, P814##IQBAL AFM, 1971, HELV CHIM ACTA, V54, P1440, DOI 10.1002/HLCA.19710540526##JACHIMOWICZ F, 1982, J ORG CHEM, V47, P445, DOI 10.1021/JO00342A013##JONES MD, 1989, J ORGANOMET CHEM, V366, P403, DOI 10.1016/0022-328X(89)87190-6##KAMER PCJ, 2004, COORDIN CHEM REV, V248, P2409, DOI 10.1016/J.CCR.2004.06.006##KLEIN H, 2005, CHEM COMMUN, P2283, DOI 10.1039/B418350A##KLEIN H, 2001, ANGEW CHEM INT EDIT, V40, P3408, DOI 10.1002/1521-3773(20010917)40:18<3408::AID-ANIE3408>3.0.CO;2-A##KLEIN H, 2001, ANGEW CHEM, V113, P3505##KOC F, 2005, J ORG CHEM, V70, P2021, DOI 10.1021/JO0481304##KRANEMANN CL, 1999, TETRAHEDRON LETT, V40, P7773, DOI 10.1016/S0040-4039(99)01661-5##KRANEMANN CL, 1999, TETRAHEDRON, V55, P4721, DOI 10.1016/S0040-4020(99)00162-3##LAINE RM, 1980, J ORG CHEM, V45, P3370, DOI 10.1021/JO01304A053##MACENTIRE E, 1987, PATENT NO. 2410933##MULLER TE, 1998, CHEM REV, V98, P675, DOI 10.1021/CR960433D##MURATA K, 1984, J MOL CATAL, V23, P121, DOI 10.1016/0304-5102(84)85063-4##PHILIP MJ, 1940, J AM CHEM SOC, V626, P1450##PINE SH, 1974, J ORG CHEM, V39, P130, DOI 10.1021/JO00916A002##REETZ MT, 2004, TETRAHEDRON-ASYMMETR, V15, P2165, DOI 10.1016/J.TETASY.2004.04.038##REPPE W, 1949, EXPERIENTIA, V5, P93, DOI 10.1007/BF02145295##RISCHE T, 1998, TETRAHEDRON, V54, P8441, DOI 10.1016/S0040-4020(98)00428-1##RISCHE T, 1999, EUR J ORG CHEM, V1999, P653##RISCHE T, 1999, TETRAHEDRON, V55, P7841, DOI 10.1016/S0040-4020(99)00414-7##RISCHE T, 1999, TETRAHEDRON, V55, P1915, DOI 10.1016/S0040-4020(98)01224-1##RISCHE T, 1998, TETRAHEDRON, V54, P2723, DOI 10.1016/S0040-4020(98)83008-1##RISCHE T, 1999, TETRAHEDRON, V55, P9801, DOI 10.1016/S0040-4020(99)00536-0##RISCHE T, 1999, TETRAHEDRON, V55, P3917, DOI 10.1016/S0040-4020(99)00111-8##ROUTABOUL L, 2005, TETRAHEDRON LETT, V46, P7401, DOI 10.1016/J.TETLET.2005.08.107##SANDEE AJ, 2001, J AM CHEM SOC, V123, P8468, DOI 10.1021/JA010150P##SCHAFFRATH H, 1999, J MOL CATAL A-CHEM, V140, P107, DOI 10.1016/S1381-1169(98)00230-1##SCHMIDT A, 2004, TETRAHEDRON, V60, P11487, DOI 10.1016/J.TET.2004.09.058##SEAYAD A, 2002, SCIENCE, V297, P1676, DOI 10.1126/SCIENCE.1074801##SEAYAD AM, 2003, TETRAHEDRON LETT, V44, P1679, DOI 10.1016/S0040-4039(03)00008-X##SEAYAD J, 2002, ADV SYNTH CATAL, V344, P795, DOI 10.1002/1615-4169(200209)344:8<795::AID-ADSC795>3.0.CO;2-Q##SEAYAD J, 2004, ANGEW CHEM, V116, P3448##SELENT D, 2001, ANGEW CHEM INT EDIT, V40, P1696, DOI 10.1002/1521-3773(20010504)40:9<1696::AID-ANIE16960>3.0.CO;2-2##SELENT D, 2001, ANGEW CHEM, V113, P1739##SHELDON RA, 1994, CHEMTECH, V24, P38##SHINICHI I, 1992, J ORG CHEM, V57, P2##SOLOVEV VM, 1961, J GEN CHEM USSR, V31, P2405##TARAROV VI, 2003, ADV SYNTH CATAL, V345, P239, DOI 10.1002/ADSC.200390018##TOROS S, 1992, J CHEM SOC CHEM COMM, P858, DOI 10.1039/C39920000858##TROST B. M., 1995, ANGEW CHEM, V107, P285, DOI DOI 10.1002/ANGE.19951070304##TROST BM, 2002, ACCOUNTS CHEM RES, V35, P695, DOI 10.1021/AR010068Z##TROST BM, 1995, ANGEW CHEM INT EDIT, V34, P259, DOI 10.1002/ANIE.199502591##TUNDO P, 1999, GREEN CHEM CHALLENGI##VAN DER VEEN LA, 1999, ORGANOMETALLICS, V18, P4765, DOI 10.1021/OM990523J##VAN DER VEEN LA, 1999, ANGEW CHEM INT EDIT, V38, P336, DOI 10.1002/(SICI)1521-3773(19990201)38:3<336::AID-ANIE336>3.0.CO;2-P##VANDERVEEN LA, 1999, ANGEW CHEM, V111, P349##WITTMANN K, 2001, CHEM-EUR J, V7, P4584, DOI 10.1002/1521-3765(20011105)7:21<4584::AID-CHEM4584>3.0.CO;2-P##YANKEP E, 1987, TETRAHEDRON LETT, V28, P427, DOI 10.1016/S0040-4039(00)95746-0##ZIMMERMANN B, 1999, ANGEW CHEM INT EDIT, V38, P2372, DOI 10.1002/(SICI)1521-3773(19990816)38:16<2372::AID-ANIE2372>3.0.CO;2-H##ZIMMERMANN B., 1999, ANGEW CHEM, V111, P2515",71,2020-11-20,NA
J,WOS:000242793500015,2006,WATER-SOLUBLE IONIC LIQUIDS AS NOVEL STABILIZERS IN SUSPENSION POLYMERIZATION REACTIONS: ENGINEERING POLYMER BEADS,"AQUEOUS SOLUTIONS OF IONIC LIQUIDS HAVE BEEN USED AS NOVEL AND ENVIRONMENTALLY FRIENDLY REACTION MEDIA TO SYNTHESIZE AND ""CONTROL"" THE SIZE OF DIFFERENT CROSS-LINKED POLYMER BEADS BY SUSPENSION POLYMERIZATION REACTIONS. IT WAS FOUND THAT THE INVESTIGATED IONIC LIQUIDS CAN ACT AS NOVEL STABILIZING AGENTS OF THE SUSPENSIONS AS A RESULT OF THEIR SURFACE-ACTIVE PROPERTIES. THE RESULTS HAVE DEMONSTRATED THAT THE AVERAGE SIZE OF POLYMER BEADS CAN BE VARIED FROM THE MACRO- TO THE NANOSCALE AND THEIR SURFACE AREA CAN ALSO BE ""ADJUSTED"" BY THIS SYNTHETIC APPROACH. FURTHERMORE, THE USE OF A COMBINATION OF IONIC LIQUIDS AND WATER FOR THE SYNTHESIS OF POLYMERS, THE SIMPLE ISOLATION OF THE PRODUCTS FORMED IN THIS POLYMERIZATION PROCEDURE, AS WELL AS THE RECYCLING OF THE CONTINUOUS MEDIUM FOR FURTHER REACTIONS OPEN UP POSSIBILITIES FOR THE DEVELOPMENT OF ""NEW AND GREEN"" POLYMERIZATION PROCESSES.",INTRINSIC MICROPOROSITY; PARTICLE-SIZE; MICROSPHERES; DISPERSION,COMBINATORIAL CHEMISTRY; CROSS-LINKED POLYMER BEADS; GREEN CHEMISTRY; IONIC LIQUIDS; IONIC SURFACTANTS; SUSPENSION POLYMERIZATION,CHEMISTRY-A EUROPEAN JOURNAL,"GUERRERO-SANCHEZ, C##ERDMENGER, T##SEREDA, P##WOUTERS, D##SCHUBERT, US","EINDHOVEN UNIV TECHNOL, LAB MACROMOL CHEM & NANOSCI, NL-5600 MB EINDHOVEN, NETHERLANDS. DPI, NL-5600 MB EINDHOVEN, NETHERLANDS. EINDHOVEN UNIV TECHNOL, DEPT BIOMED ENGN, BIOMIM IMAGE ANAL & INTERPRETAT, NL-5612 AZ EINDHOVEN, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"ALLEN T., 1997, PARTICLE SIZE MEASUR##BAGNO A, 2005, ORG BIOMOL CHEM, V3, P1624, DOI 10.1039/B502654G##BILGIC T, 1993, ANGEW MAKROMOL CHEM, V213, P33, DOI 10.1002/APMC.1993.052130105##BOWERS J, 2004, LANGMUIR, V20, P2191, DOI 10.1021/LA035940M##BRAZEL CS, 2005, ACS S SER, V913##BUDD PM, 2004, CHEM COMMUN, P230, DOI 10.1039/B311764B##CORMA A, 1997, CHEM REV, V97, P2373, DOI 10.1021/CR960406N##DEETLEFS M, 2003, GREEN CHEM, V5, P181, DOI 10.1039/B300071K##GIUSTI P, 1994, J MATER SCI-MATER M, V5, P858, DOI 10.1007/BF01172025##GONZALEZMELCHOR M, 2005, J CHEM PHYS, V122##GREGG SJ, 1982, ADSORPTION SURFACE A##GUERRERO-SANCHEZ C, 2006, APPL SURF SCI, V252, P2555, DOI 10.1016/J.APSUSC.2005.05.088##GUERRERO-SANCHEZ C, 2005, MACROMOLECULES, V38, P10185, DOI 10.1021/MA051544U##GUERRERO-SANCHEZ C, 2006, CHEM COMMUN, P3797, DOI 10.1039/B608364A##GUERREROSANCHEZ C, 2005, ACS SYM SER, V913, P37##GUERREROSANCHEZ C, UNPUB##HATATE Y, 1995, J CHEM ENG JPN, V28, P656, DOI 10.1252/JCEJ.28.656##HOFFMANN D., 2001, MAGNETOHYDRODYNAMICS, V37, P217##JAHANZAD F, 2005, IND ENG CHEM RES, V44, P4112, DOI 10.1021/IE048827F##KARA A, 2004, J HAZARD MATER, V106, P93, DOI 10.1016/J.JHAZMAT.2003.08.016##KAWAGUCHI H, 2000, PROG POLYM SCI, V25, P1171, DOI 10.1016/S0079-6700(00)00024-1##KUBISA P, 2004, PROG POLYM SCI, V29, P3, DOI 10.1016/J.PROGPOLYMSCI.2003.10.002##LAW G, 2001, LANGMUIR, V17, P6138, DOI 10.1021/LA010629V##MCKEOWN N. B., 2006, ANGEW CHEM, V118, P1836##MCKEOWN NB, 2006, ANGEW CHEM INT EDIT, V45, P1804, DOI 10.1002/ANIE.200504241##PEKEL N, 2004, POLYM BULL, V51, P307, DOI 10.1007/S00289-004-0224-X##QUINA FH, 1995, J CHEM PHYS, V102, P17028##SCHEIRS J., 2003, MODERN STYRENIC POLY##SNEDDEN P, 2003, MACROMOLECULES, V36, P4549, DOI 10.1021/MA021710N##SNEDDEN P, 2005, ACS SYM SER, V913, P133, DOI DOI 10.1021/BK-2005-0913.CH009##SUNG J, 2005, CHEM PHYS LETT, V406, P495, DOI 10.1016/J.CPLETT.2005.03.036##WOODS HM, 2005, MACROMOLECULES, V38, P3271, DOI 10.1021/MA048406+##YAN F, 2006, CHEM COMMUN, P2696, DOI 10.1039/B605287H##YEUM JH, 2005, MACROMOL MATER ENG, V290, P78, DOI 10.1002/MAME.200400313##ZANG SL, 2005, FLUID PHASE EQUILIBR, V230, P192, DOI 10.1016/J.FLUID.2005.02.012##ZHOU Y, 2004, CHEM MATER, V16, P544, DOI 10.1021/CM034442W",48,2020-11-20,NA
J,WOS:000242793500016,2006,HYDROGEN-BONDED OLIGO(P-PHENYLENEVINYLENE) FUNCTIONALIZED WITH PERYLENE BISIMIDE: SELF-ASSEMBLY AND ENERGY TRANSFER,"WE DESCRIBE THE SYNTHESIS, SUPRAMOLECULAR ORDERING ON SURFACES AND IN SOLUTION, AND PHOTOPHYSICAL CHARACTERIZATION OF OPV4UT-PERY, AN OLIGO(P-PHENYLENEVINYLENE) (OPV) WITH A COVALENTLY ATTACHED PERYLENE BISIMIDE MOIETY. IN CHLOROFORM, THE MOLECULE FORMS DIMERS THROUGH QUADRUPLE HYDROGEN BONDING OF THE UREIDO-S-TRIAZINC ARRAY. THIS IS SUPPORTED BY SCANNING TUNNELING MICROSCOPY (STM) STUDIES, WHICH REVEAL DIMER FORMATION AT THE LIQUID (1,2,4-TRICHLOROBENZENE)/SOLID (GRAPHITE) INTERFACE. MOREOVER, CON- TRAST REVERSAL IN BIAS-DEPENDENT STM IMAGING PROVIDES INFORMATION ON THE ORDERING AND DIFFERENT ELECTRONIC PROPERTIES OF THE OLIGO(P-PHENYLENEVINYLENE) AND PERYLENE BISIMIDE MOIETIES. IN DODECANE, THE MOLECULE SELF-ASSEMBLES INTO H-TYPE AGGREGATES THAT ARE STILL SOLUBLE AS A RESULT OF THE HYDROPHOBIC SHELL FORMED BY THE DODECYLOXY WEDGES. THE DONOR-ACCEPTOR MOLECULE IS CHARACTERIZED BY EFFICIENT ENERGY TRANSFER FROM THE PHOTOEXCITED OPV TO THE PERYLENE BISIMIDE. MIXED ASSEMBLIES WITH ANALOGOUS OPVS LACKING THE PERYLENE BISIMIDE UNIT HAVE BEEN PREPARED IN DODECANE SOLUTION AND ENERGY TRANSFER TO THE INCORPORATED PERYLENE BISIMIDES HAS BEEN STUDIED BY FLUORESCENCE SPECTROSCOPY.",PHOTOINDUCED ELECTRON-TRANSFER; SUPRAMOLECULAR ASSEMBLIES; ORDERED ARCHITECTURES; STM INVESTIGATIONS; COLUMNAR STACKS; ACCEPTOR; VINYLENE); ORGANIZATION; TRANSPORT; GRAPHITE,ENERGY TRANSFER; OLIGO(P-PHENYLENEVINYLENE); PERYLENE BISIMIDES; SCANNING TUNNELING MICROSCOPY; SELF-ASSEMBLY; SUPRAMOLECULAR CHEMISTRY,CHEMISTRY-A EUROPEAN JOURNAL,"ZHANG, H##HOEBEN, FJM##POUDEROIJEN, MJ##SCHENNING, APHL##MEIJER, EW##SCHRYVER, FC##DE FEYTER, S","EINDHOVEN UNIV TECHNOL, LAB MACROMOL & ORGAN CHEM, NL-5600 MB EINDHOVEN, NETHERLANDS. KATHOLIEKE UNIV LEUVEN, DIV MOL & NANOMAT, LAB PHOTOCHEM & SPECT, B-3001 HEVERLEE, BELGIUM.","CHEMISTRY, MULTIDISCIPLINARY",CHEMISTRY,"AHRENS MJ, 2004, J AM CHEM SOC, V126, P8284, DOI 10.1021/JA039820C##[ANONYMOUS], 2000, ANGEW CHEM, V112, P1285##BARTH JV, 2000, ANGEW CHEM INT EDIT, V39, P1230, DOI 10.1002/(SICI)1521-3773(20000403)39:7<1230::AID-ANIE1230>3.0.CO;2-I##BECKERS EHA, 2004, J PHYS CHEM A, V108, P6933, DOI 10.1021/JP048980N##BREEZE AJ, 2002, APPL PHYS LETT, V81, P3085, DOI 10.1063/1.1515362##CORMIER RA, 1997, J PHYS CHEM B, V101, P11004, DOI 10.1021/JP9732064##CORMIER RA, 1998, CHEM MATER, V10, P1309, DOI 10.1021/CM970695B##DE FEYTER S, 2003, CHEM SOC REV, V32, P139, DOI 10.1039/B206566P##DE FEYTER S, 2005, NANO LETT, V5, P77, DOI 10.1012/NL048360Y##DE FEYTER S, 2005, TOP CURR CHEM, V258, P205, DOI 10.1007/B136670##GESQUIERE A, 2003, J MATER CHEM, V13, P2164, DOI 10.1039/B304517J##GESQUIERE A, 2004, NANO LETT, V4, P1175, DOI 10.1021/NL049842C##HERZ LM, 2003, PHYS REV B, V68, DOI 10.1103/PHYSREVB.68.045203##HOEBEN F. J. M., 2004, ANGEW CHEM, V116, P2010##HOEBEN FJM, 2005, CHEM REV, V105, P1491, DOI 10.1021/CR030070Z##HOEBEN FJM, 2004, ANGEW CHEM INT EDIT, V43, P1976, DOI 10.1002/ANIE.200353451##JACKEL F, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.188303##JONKHEIJM P, 2004, ANGEW CHEM INT EDIT, V43, P74, DOI 10.1002/ANIE.200352790##JONKHEIJM P, 2003, J AM CHEM SOC, V125, P15941, DOI 10.1021/JA0383118##JONKHEIJM P, 2004, ANGEW CHEM, V116, P76##KANEDA Y, 2001, LANGMUIR, V17, P6185, DOI 10.1021/LA0100587##LI ADQ, 2003, CHEM-EUR J, V9, P4594, DOI 10.1002/CHEM.200305025##LUDWIG C, 1994, Z PHYS B CON MAT, V93, P365, DOI 10.1007/BF01312708##MARTIN RE, 1999, ANGEW CHEM INT EDIT, V38, P1350, DOI 10.1002/(SICI)1521-3773(19990517)38:10<1350::AID-ANIE1350>3.0.CO;2-6##MENA-OSTERITZ E, 2006, ADV MATER, V18, P447, DOI 10.1002/ADMA.200501575##MIURA A, 2005, SMALL, V1, P131, DOI 10.1002/SMLL.200400008##MIURA A, 2003, J AM CHEM SOC, V125, P14968, DOI 10.1021/JA037407Z##NEUTEBOOM EE, 2004, CHEM-EUR J, V10, P3907, DOI 10.1002/CHEM.200400097##NEUTEBOOM EE, 2003, ORG BIOMOL CHEM, V1, P198, DOI 10.1039/B208824J##PARK LY, 2003, J AM CHEM SOC, V125, P10586, DOI 10.1021/JA036540O##PEERLINGS HWI, 1999, TETRAHEDRON LETT, V40, P1021, DOI 10.1016/S0040-4039(98)02515-5##PEETERS E, 2002, CHEM-EUR J, V8, P4470, DOI 10.1002/1521-3765(20021004)8:19<4470::AID-CHEM4470>3.0.CO;2-F##PRINS L. J., 2001, ANGEW CHEM, V113, P2446##ROHR U, 2001, J MATER CHEM, V11, P1789, DOI 10.1039/B009708J##SAMORI P, 2004, J AM CHEM SOC, V126, P3567, DOI 10.1021/JA038648+##SAMORI P, 2006, ADV MATER, V18, P1317, DOI 10.1002/ADMA.200502391##SCHENNING APHJ, 2002, J AM CHEM SOC, V124, P10252, DOI 10.1021/JA020378S##SCHENNING APHJ, 2001, J AM CHEM SOC, V123, P409, DOI 10.1021/JA0033180##SCHMIDT-MENDE L, 2001, SCIENCE, V293, P1119, DOI 10.1126/SCIENCE.293.5532.1119##STEINER T, 2002, ANGEW CHEM INT EDIT, V41, P48, DOI 10.1002/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U##STEINER T., 2002, ANGEW CHEM, V114, P50##STRUIJK CW, 2000, J AM CHEM SOC, V122, P11057, DOI 10.1021/JA000991G##SWARBRICK JC, 2005, J PHYS CHEM B, V109, P12167, DOI 10.1021/JP0508305##SYAMAKUMARI A, 2002, CHEM-EUR J, V8, P3353, DOI 10.1002/1521-3765(20020802)8:15<3353::AID-CHEM3353>3.0.CO;2-X##TANG CW, 1986, APPL PHYS LETT, V48, P183, DOI 10.1063/1.96937##TCHEBOTAREVA N, 2003, J AM CHEM SOC, V125, P9734, DOI 10.1021/JA028609I##UJI-I H, 2005, CHEMPHYSCHEM, V6, P2389, DOI 10.1002/CPHC.200500241##VAN DER BOOM T, 2002, J AM CHEM SOC, V124, P9582, DOI 10.1021/JA026286K##WANG W, 2003, J AM CHEM SOC, V125, P1120, DOI 10.1021/JA027186H##WARD MD, 1997, CHEM SOC REV, V26, P365, DOI 10.1039/CS9972600365##WU J, 2004, ANGEW CHEM, V116, P5445##WU JS, 2004, ANGEW CHEM INT EDIT, V43, P5331, DOI 10.1002/ANIE.200460174##WURTHNER F, 2004, J AM CHEM SOC, V126, P10611, DOI 10.1021/JA0475353##WURTHNER F, 2004, J ORG CHEM, V69, P7933, DOI 10.1021/JO048880D##WURTHNER F, 2005, TOP CURR CHEM, V258, P1##WURTHNER F, 2003, ORG BIOMOL CHEM, V1, P240, DOI 10.1039/B208582H##WURTHNER F, 2000, CHEM-EUR J, V6, P3871, DOI 10.1002/1521-3765(20001103)6:21<3871::AID-CHEM3871>3.3.CO;2-W##WURTHNER F, 1999, ADV MATER, V11, P754, DOI 10.1002/(SICI)1521-4095(199906)11:9<754::AID-ADMA754>3.0.CO;2-5##WURTHNER F, 2001, CHEM-EUR J, V7, P2245, DOI 10.1002/1521-3765(20010518)7:10<2245::AID-CHEM2245>3.0.CO;2-W",52,2020-11-20,NA
J,WOS:000242691900001,2006,THE CLUSTER SIZE DISTRIBUTION FOR A FOREST-FIRE PROCESS ON Z,"CONSIDER THE FOLLOWING FOREST-FIRE MODEL WHERE TREES ARE LOCATED ON SITES OF Z. A SITE CAN BE VACANT OR BE OCCUPIED BY A TREE. EACH VACANT SITE BECOMES OCCUPIED AT RATE 1, INDEPENDENTLY OF THE OTHER SITES. EACH SITE IS HIT BY LIGHTNING WITH RATE LAMBDA, WHICH BURNS DOWN THE OCCUPIED CLUSTER OF THAT SITE INSTANTANEOUSLY. AS LAMBDA DOWN ARROW 0 THIS PROCESS IS BELIEVED TO DISPLAY SELF-ORGANISED CRITICAL BEHAVIOUR. THIS PAPER IS MAINLY CONCERNED WITH THE CLUSTER SIZE DISTRIBUTION IN STEADY-STATE. DROSSEL, CLAR AND SCHWABL ( 3) CLAIMED THAT THE CLUSTER SIZE DISTRIBUTION HAS A CERTAIN POWER LAW BEHAVIOUR WHICH HOLDS FOR CLUSTER SIZES THAT ARE NOT TOO LARGE COMPARED TO SOME EXPLICIT CLUSTER SIZE S(MAX). THE LATTER CAN BE WRITTEN IN TERMS OF LAMBDA APPROXIMATELY AS S(MAX) LN(S(MAX)) = 1/LAMBDA. HOWEVER, VAN DEN BERG AND JARAI ( 1) SHOWED THAT THIS CLAIM IS NOT CORRECT FOR CLUSTER SIZES OF ORDER S(MAX), WHICH LEFT THE QUESTION FOR WHICH CLUSTER SIZES THE POWER LAW BEHAVIOUR DOES HOLD. OUR MAIN RESULT IS A RIGOROUS PROOF OF THE POWER LAW BEHAVIOUR UP TO CLUSTER SIZES OF THE ORDER S(MAX)(1/3). FURTHER, IT PROVES THE EXISTENCE OF A STATIONARY TRANSLATION INVARIANT DISTRIBUTION, WHICH WAS ALWAYS ASSUMED BUT NEVER SHOWN RIGOROUSLY IN THE LITERATURE",MODEL,FOREST-FIRES; SELF-ORGANISED CRITICALITY; CLUSTER SIZE DISTRIBUTION,ELECTRONIC JOURNAL OF PROBABILITY,"BROUWER, R##PENNANEN, J","UNIV HELSINKI, HELSINKI, FINLAND. CWI, NL-1009 AB AMSTERDAM, NETHERLANDS.",STATISTICS & PROBABILITY,MATHEMATICS,"DROSSEL B, 1992, PHYS REV LETT, V69, P1629, DOI 10.1103/PHYSREVLETT.69.1629##DROSSEL B, 1993, PHYS REV LETT, V71, P3739, DOI 10.1103/PHYSREVLETT.71.3739##DURRE M, 2005, EXISTENCE MULTIDIMEN##DURRETT R., 1988, LECT NOTES PARTICLE##LIGGETT T, 1985, INTERACTING PARTICLE##PENNANEN J, 2000, THESIS U HELSINKI##VAN DEN BERG J, 2005, COMMUN MATH PHYS, V253, P633, DOI 10.1007/S00220-004-1200-X",4,2020-11-20,NA
J,WOS:000412819200006,2006,"A STRUCTURAL MODEL OF SELF-CONCEPT, AUTONOMOUS MOTIVATION AND ACADEMIC PERFORMANCE IN CROSS-CULTURAL PERSPECTIVE",NA,NA,NA,ELECTRONIC JOURNAL OF RESEARCH IN EDUCATIONAL PSYCHOLOGY,"AHMED, W##BRUINSMA, M","[AHMED, WONDIMU] UNIV GRONINGEN, INST INVEST EDUC, GRONINGEN, NETHERLANDS. [BRUINSMA, MARJON] UNIV GRONINGEN, CTR DOCENCIA & APRENDIZAJE, GRONINGEN, NETHERLANDS.","PSYCHOLOGY, EDUCATIONAL",PSYCHOLOGY,NA,33,2020-11-20,NA
J,WOS:000243077400011,2006,NICKEL THIOLATE COMPLEXES AS LIGANDS FOR COPPER AND ZINC: NOVEL ADDITIONS TO A LIBRARY OF BINDING MODES,"THE REACTIVITY OF THE TWO NICKEL COMPLEXES [NI(XBSMS)] AND [NI(BSMS)(2)] [H(2)XBSMS = ALPHA,ALPHA'-BIS(4-MERCAPTO-3,3-DIMETHYL-2-THIABUTYL)-O-XYLENE; HBSMS = 4-MERCAPTO-3,3-DIMETHYL-LPHENYL-2-THIABUTANE] TOWARDS COPPER IODIDE AND ZINC BROMIDE HAS BEEN INVESTIGATED. THE REACTIONS YIELD NOVEL AGGREGATES OF HIGHER NUCLEARITY WITH TOPOLOGIES THAT ARE DIFFERENT FROM PREVIOUS REPORTS; THE NICKEL COMPLEXES IN ALL CASES CAN BE CONSIDERED AS DIDENTATE S LIGANDS. THE X-RAY STRUCTURE OF THE NOVEL OCTANUCLEAR CLUSTER [{NI(BSMS)(2)}(3)(CUI)(5)] SHOWS A UNIQUE ARRANGEMENT IN WHICH THE CIS-NIS2S'(2) UNITS ACT AS DIDENTATE LIGANDS TO A TRIGONAL-BIPYRAMIDAL ARRAY OF FIVE CU-I IONS. THE TETRANUCLEAR STRUCTURE OF [{NI(XBSMS)CUI}(2)] SHOWS UNPRECEDENTED ASYMMETRIC BRIDGING OF THE THIOLATE SULFUR ATOMS, WITH ONE OF THE THIOLATE GROUPS BINDING TO ONE COPPER ION AND THE OTHER ONE MU(3)-BRIDGING TO TWO COPPER IONS. THE COMPLEX IS LOCATED ON A CRYSTALLOGRAPHIC TWOFOLD AXIS AND THE COMPLEX IN A SINGLE CRYSTAL IS ENANTIOMERICALLY PURE. THE TRINUCLEAR COMPLEX [NI-2(BSMS)(3)ZNBR3] IS FORMED AS A RESULT OF DISSOCIATION OF THE DIDENTATE BSMS LIGAND FROM PART OF THE MONONUCLEAR COMPLEX AND REASSEMBLY TO FORM A DINUCLEAR CORE TO WHICH THE ZNBR3- UNIT IS COORDINATED TO A SINGLE THIOLATE SULFUR ATOM. A COMPLEX OF STOICHIOMETRY [NI-3(XBSMS)(2)-(ZNBR3)(2)] HAS ALSO BEEN ISOLATED AND A STRUCTURE PROPOSAL BASED ON SPECTROSCOPIC PROPERTIES IS GIVEN. ALL COMPLEXES HAVE BEEN CHARACTERISED BY ANALYTICAL AND SPECTROSCOPIC METHODS. (C) WILEY-VCH VERLAG GMBH & CO.",COENZYME-A SYNTHASE; DEHYDROGENASE/ACETYL-COA SYNTHASE; CRYSTAL-STRUCTURES; CATALYTIC SITE; ACTIVE-SITE; CLUSTER; CU; HYDROGENASES; REFINEMENT; REACTIVITY,NICKEL; COPPER; ZINC; S LIGANDS; CLUSTER COMPOUNDS,EUROPEAN JOURNAL OF INORGANIC CHEMISTRY,"VERHAGEN, JAW##TOCK, C##LUTZ, M##SPEK, AL##BOUWMAN, E","LEIDEN UNIV, GORLAEUS LABS, LEIDEN INST CHEM, NL-2300 RA LEIDEN, NETHERLANDS. UNIV UTRECHT, BIJVOET CTR BIOMOL RES CRYSTAL & STRUCT CHEM, NL-3508 TC UTRECHT, NETHERLANDS.","CHEMISTRY, INORGANIC & NUCLEAR",CHEMISTRY,"ALTOMARE A, 1999, J APPL CRYSTALLOGR, V32, P115, DOI 10.1107/S0021889898007717##AMOROSO AJ, 2003, CHEM COMMUN, P2020, DOI 10.1039/B303851C##BAUMGARTNER M, 1993, INORG CHIM ACTA, V208, P135, DOI 10.1016/S0020-1693(00)85113-0##BOUWMAN E, 1999, EUR J INORG CHEM, P217##BOWMAKER GA, 1984, POLYHEDRON, V3, P535, DOI 10.1016/S0277-5387(00)88084-5##CHALBOT MU, 2003, EUR J INORG CHEM, P453##DARNAULT C, 2003, NAT STRUCT BIOL, V10, P271, DOI 10.1038/NSB912##DOUKOV TI, 2002, SCIENCE, V298, P567, DOI 10.1126/SCIENCE.1075843##DRENNAN CL, 2004, J BIOL INORG CHEM, V9, P511, DOI 10.1007/S00775-004-0563-Y##DUISENBERG AJM, 2003, J APPL CRYSTALLOGR, V36, P220, DOI 10.1107/S0021889802022628##GOLDEN ML, 2003, CHEM COMMUN, P1824, DOI 10.1039/B304884P##GOLDEN ML, 2004, EUR J INORG CHEM, P231, DOI 10.1002/EJIC.200300675##GOLDEN ML, 2005, INORG CHEM, V44, P875, DOI 10.1021/IC0489701##HARROP TC, 2004, J AM CHEM SOC, V126, P14714, DOI 10.1021/JA045284S##HERBST-IRMER R, 1998, ACTA CRYSTALLOGR B, V54, P443, DOI 10.1107/S0108768197018454##KAASJAGER VE, 2002, INORG CHEM, V41, P1837, DOI 10.1021/IC010784X##KAASJAGER VE, 1998, ANGEW CHEM INT EDIT, V37, P1668, DOI 10.1002/(SICI)1521-3773(19980703)37:12<1668::AID-ANIE1668>3.0.CO;2-J##KAASJAGER VE, 2001, INORG CHIM ACTA, V316, P99, DOI 10.1016/S0020-1693(01)00393-0##KAASJAGER VE, 2000, INORG CHIM ACTA, V310, P183, DOI 10.1016/S0020-1693(00)00285-1##KONNO T, 2004, CHEM COMMUN, P2296, DOI 10.1039/B404512B##KRISHNAN R, 2003, J AM CHEM SOC, V125, P4422, DOI 10.1021/JA0346577##KRISHNAN R, 2004, J AM CHEM SOC, V126, P4484, DOI 10.1021/JA038086U##LINCK RC, 2003, J AM CHEM SOC, V125, P8700, DOI 10.1021/JA035606C##MILLER ML, 2003, INORG CHEM, V42, P2999, DOI 10.1021/IC0262684##RAO CP, 1986, INORG CHEM, V25, P428, DOI 10.1021/IC00224A011##RAO PV, 2004, INORG CHEM, V43, P5833, DOI 10.1021/IC040055S##SPEK AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112##VERHAGEN JAW, 2004, INORG CHIM ACTA, V357, P2687, DOI 10.1016/J.ICA.2004.02.003##VERHAGEN JAW, 2003, EUR J INORG CHEM, P3968, DOI 10.1002/EJIC.200300285##VERHAGEN JAW, 2002, J CHEM SOC DALTON, P1275, DOI 10.1039/B110332F##VERHAGEN JAW, 2004, THESIS LEIDEN U LEID##WANG Q, 2004, CHEM-EUR J, V10, P3384, DOI 10.1002/CHEM.200305738##WANG Q, 2003, CHEM COMMUN, P3012, DOI 10.1039/B310183E##WINGE DR, 1993, BIOINORGANIC CHEM CO, V1, P110",7,2020-11-20,NA
J,WOS:000242770000002,2006,CRACKING UP: SYMMETRY BREAKING IN CELLULAR SYSTEMS,"THE SHAPE OF ANIMAL CELLS IS, TO A LARGE EXTENT, DETERMINED BY THE CORTICAL ACTIN NETWORK THAT UNDERLIES THE CELL MEMBRANE. BECAUSE OF THE PRESENCE OF MYOSIN MOTORS, THE ACTIN CORTEX IS UNDER TENSION, AND LOCAL RELAXATION OF THIS TENSION CAN RESULT IN CORTICAL FLOWS THAT LEAD TO DEFORMATION AND POLARIZATION OF THE CELL. CORTEX RELAXATION IS OFTEN REGULATED BY POLARIZING SIGNALS, BUT THE CORTEX CAN ALSO RUPTURE AND RELAX SPONTANEOUSLY. A SIMILAR TENSION-INDUCED POLARIZATION IS OBSERVED IN ACTIN GELS GROWING AROUND BEADS, AND WE PROPOSE THAT A COMMON MECHANISM GOVERNS ACTIN GEL RUPTURE IN BOTH SYSTEMS.",CORTICAL TENSION; MYOSIN-II; SURFACE-RECEPTORS; EUKARYOTIC CELLS; CLEAVAGE FURROW; ANIMAL-CELLS; ACTIN; CYTOKINESIS; DYNAMICS; PHOSPHORYLATION,NA,JOURNAL OF CELL BIOLOGY,"PALUCH, E##VAN DER GUCHT, J##SYKES, C","UNIV PARIS 06, INST CURIE, CTR NATL RECH SCI, UNITE MIXTE RECH 168, F-75231 PARIS, FRANCE. UNIV PARIS 07, INST CURIE, CTR NATL RECH SCI, UNITE MIXTE RECH 168, F-75231 PARIS, FRANCE. MAX PLANCK INST MOL CELL BIOL & GENET, D-01307 DRESDEN, GERMANY. INT INST MOL CELL BIOL, PL-02109 WARSAW, POLAND. UNIV WAGENINGEN & RES CTR, LAB PHYS CHEM & COLLOID SCI, NL-6701 BH WAGENINGEN, NETHERLANDS.",CELL BIOLOGY,CELL BIOLOGY,"BEMENT WM, 2005, J CELL BIOL, V170, P91, DOI 10.1083/JCB.200501131##BEREITERHAHN J, 1990, J CELL SCI, V96, P171##BERNHEIM-GROSWASSER A, 2002, NATURE, V417, P308, DOI 10.1038/417308A##BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/SCIENCE.3277283##BRETSCHNEIDER T, 2004, CURR BIOL, V14, P1, DOI 10.1016/J.CUB.2003.12.005##BRINGMANN H, 2005, NATURE, V436, P731, DOI 10.1038/NATURE03823##BURGESS DR, 2005, TRENDS CELL BIOL, V15, P156, DOI 10.1016/J.TCB.2005.01.006##BURTON K, 1997, NATURE, V385, P450, DOI 10.1038/385450A0##CAO LG, 1990, J CELL BIOL, V111, P1905, DOI 10.1083/JCB.111.5.1905##CHARRAS GT, 2005, NATURE, V435, P365, DOI 10.1038/NATURE03550##CHUNG CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X##COSGROVE DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/NRM1746##COWAN CR, 2004, NATURE, V431, P92, DOI 10.1038/NATURE02825##CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/JCB.129.6.1589##DA SILVA JS, 2003, J CELL BIOL, V162, P1267, DOI 10.1083/JCB.200304021##DA SILVA JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/NRN918##DAI JW, 1999, BIOPHYS J, V77, P1168, DOI 10.1016/S0006-3495(99)76968-7##DEAN SO, 2005, P NATL ACAD SCI USA, V102, P13473, DOI 10.1073/PNAS.0506810102##DEBIASIO RL, 1996, MOL BIOL CELL, V7, P1259##DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/ANNUREV.CB.04.110188.003245##DOMB C, 1983, PHASE TRANSITIONS CR, V8##EVANS E, 1989, BIOPHYS J, V56, P151, DOI 10.1016/S0006-3495(89)82660-8##FUTTERER C, 2003, EUROPHYS LETT, V64, P137, DOI 10.1209/EPL/I2003-00148-Y##HAROLD FM, 2002, FUNGAL GENET BIOL, V37, P271, DOI 10.1016/S1087-1845(02)00528-5##JUNGBLUTH A, 1994, J CELL SCI, V107, P117##KELLER H, 2002, EXP CELL RES, V277, P161, DOI 10.1006/EXCR.2002.5552##LECHLER T, 2001, J CELL BIOL, V155, P261, DOI 10.1083/JCB.200104094##MATZKE R, 2001, NAT CELL BIOL, V3, P607, DOI 10.1038/35078583##MEDALIA O, 2002, SCIENCE, V298, P1209, DOI 10.1126/SCIENCE.1076184##MILLS JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/JCB.140.3.627##MIYOSHI H, 1996, GASTROENTEROLOGY, V110, P1897, DOI 10.1053/GAST.1996.V110.PM8964416##MOGILNER A, 2006, CURR OPIN CELL BIOL, V18, P32, DOI 10.1016/J.CEB.2005.11.001##MORONE N, 2006, J CELL BIOL, V174, P851, DOI 10.1083/JCB.200606007##MUNRO E, 2004, DEV CELL, V7, P413, DOI 10.1016/J.DEVCEL.2004.08.001##NOIREAUX V, 2000, BIOPHYS J, V78, P1643, DOI 10.1016/S0006-3495(00)76716-6##PALUCH E, 2005, BIOPHYS J, V89, P724, DOI 10.1529/BIOPHYSJ.105.060590##PALUCH E, 2006, TRENDS CELL BIOL, V16, P5, DOI 10.1016/J.TCB.2005.11.003##PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549A0##PASTERNAK C, 1985, J CELL BIOL, V100, P860, DOI 10.1083/JCB.100.3.860##PLASTINO J, 2005, CURR OPIN CELL BIOL, V17, P62, DOI 10.1016/J.CEB.2004.12.001##SAHAI E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/NCB1019##SEKIMOTO K, 2004, EUR PHYS J E, V13, P247, DOI 10.1140/EPJE/I2003-10073-Y##SHEETZ MP, 2006, ANNU REV BIOPH BIOM, V35, P417, DOI 10.1146/ANNUREV.BIOPHYS.35.040405.102017##SOHRMANN M, 2003, TRENDS CELL BIOL, V13, P526, DOI 10.1016/J.TCB.2003.08.006##STRAIGHT AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/SCIENCE.1081412##VAN DER GUCHT J, 2005, P NATL ACAD SCI USA, V102, P7847, DOI 10.1073/PNAS.0502121102##WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/SCIENCE.7684161##WEDLICH-SOLDNER R, 2003, SCIENCE, V299, P1231, DOI 10.1126/SCIENCE.1080944##WEDLICH-SOLDNER R, 2003, NAT CELL BIOL, V5, P267, DOI 10.1038/NCB0403-267##YOSHIDA K, 2006, J CELL SCI, V119, P3833, DOI 10.1242/JCS.03152",50,2020-11-20,NA
J,WOS:000243388600025,2006,VEGEMITE AND CHOCOLATE SPRINKLES: DUTCH MEDICAL STUDENTS IN RURAL AUSTRALIA,"THE PRIMARY HEALTH CARE (PHC) WORKING GROUP OF THE DEPARTMENT OF GENERAL PRACTICE OF MAASTRICHT UNIVERSITY IN THE NETHERLANDS WAS FOUNDED IN 1998 SPECIFICALLY TO INTRODUCE STUDENTS TO PATIENT CARE, RESEARCH,AND EDUCATION IN PRIMARY HEALTH CARE SETTINGS OUTSIDE THE NETHERLANDS. RURAL HEALTH CARE IN AUSTRALIA IS APPEALING TO INTERNATIONAL MEDICAL STUDENTS BECAUSE OF ITS UNIQUE SETTING. IN THE PAST 5 YEARS, 42 MEDICAL STUDENTS FROM MAASTRICHT UNIVERSITY HAVE PURSUED A MEDICAL ELECTIVE IN RURAL AUSTRALIA, SUPERVISED BY THE PHC WORKING GROUP. DOCTORS AND COORDINATORS IN PRIMARY CARE CLINICS ACROSS AUSTRALIA HAVE WELCOMED AND SUPERVISED STUDENTS FROM MAASTRICHT CARE. FUTURE COLLABORATION WITH OTHER AUSTRALIAN PRIMARY CARE CLINICS IS WELCOMED.",NA,NA,MEDICAL JOURNAL OF AUSTRALIA,"CALS, J##JOYNER, P##TUFFLEY, RJ##DINANT, GJ","MAASTRICHT UNIV, DEPT GEN PRACTICE, PHC WORKING GRP, MAASTRICHT, NETHERLANDS. MANNUM MED CTR, MANNUM, SA, AUSTRALIA. GYMPIE CLIN, GYMPIE, QLD, AUSTRALIA.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,NA,1,2020-11-20,NA
J,WOS:000242681200007,2006,"CRYSTAL STRUCTURE, MAGNETISM AND SPECTROSCOPY OF TWO STRONGLY ANTIFERROMAGNETICALLY COUPLED DINUCLEAR CU(II) PADDLEWHEEL-LIKE COMPOUNDS WITH 4-AZABENZIMIDAZOLE AS A LIGAND","TWO DINUCLEAR COMPOUNDS, [CU-2(AZAB)(4)CL-2]CL-2(CH3OH)(3) (1) AND [CU-2(AZAB)(4)BR-2]BR-2(H2O)(1/2) (2) (IN WHICH AZAB = 4-AZABENZIMIDAZOLE), HAVE BEEN SYNTHESIZED AND CHARACTERIZED BY INFRARED SPECTROSCOPY AND EPR. ALSO THE X-RAY STRUCTURES OF BOTH COMPOUNDS AND THE MAGNETIC SUSCEPTIBILITY HAVE BEEN INVESTIGATED, AND THE DINUCLEAR STRUCTURAL DETAILS ARE PRESENTED. THE GEOMETRIES OF BOTH STRUCTURES ARE SIMILAR. EACH COPPER(II) ION HAS A SQUARE PYRAMIDAL GEOMETRY WITH THE BASAL PLANE FORMED BY FOUR NITROGEN ATOMS OF FOUR BISCHELATING AZAB MOLECULES IN A PADDLEWHEEL-LIKE FASHION. THE APICAL POSITION IS OCCUPIED BY A CHLORIDE OR BROMIDE ANION, RESPECTIVELY. THE EPR SPECTRA SHOW A RESOLVED TRIPLET, S = 1, SPECTRUM FOR BOTH COMPOUNDS (INCLUDING THE DELTA MS = +/- 2 TRANSITION SPLITTED INTO SEVEN LINES AT 77 K) WITH A ZERO-FIELD SPLITTING (D) OF 0.124 CM(-1). THE MAGNETIC SUSCEPTIBILITY MEASUREMENTS (FROM 5 TO 300 K) AGREE WITH A STRONG OVERALL ANTIFERROMAGNETIC INTERACTION WITH A LARGE SINGLET-TRIPLET SPLITTING OF J = -329 AND -349 CM(-1), FOR COMPOUNDS 1 AND 2, RESPECTIVELY. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",BINUCLEAR COPPER(II) COMPLEX; NUCLEOTIDE BASE COMPLEXES; COORDINATION-COMPOUNDS; CATALYTIC-OXIDATION; MOLECULAR-STRUCTURE; EXCHANGE; ADENINE; 7-AZAINDOLE; HYPOXANTHINE; EPR,COPPER; STRUCTURE; MAGNETISM; EPR; DINUCLEAR,POLYHEDRON,"VAN ALBADA, GA##MUTIKAINEN, I##TURPEINEN, U##REEDIJK, J","LEIDEN UNIV, GORLAEUS LABS, LEIDEN INST CHEM, NL-2300 RA LEIDEN, NETHERLANDS. UNIV HELSINKI, DEPT CHEM, LAB INORGANCHEM, HELSINKI 00014, FINLAND.","CHEMISTRY, INORGANIC & NUCLEAR; CRYSTALLOGRAPHY",CHEMISTRY; CRYSTALLOGRAPHY,"ACEVEDOCHAVEZ R, 1996, INORG CHEM, V35, P7430, DOI 10.1021/IC9602005##ASAKAWA T, 1972, B CHEM SOC JPN, V45, P1054, DOI 10.1246/BCSJ.45.1054##BOUWMAN E, 1990, COORDIN CHEM REV, V104, P143, DOI 10.1016/0010-8545(90)80042-R##BROOKES RW, 1975, INORG CHEM, V14, P528, DOI 10.1021/IC50145A016##CASANOVA J, 1997, INORG CHEM, V36, P2052, DOI 10.1021/IC960968P##CEJUDO-MARIN R, 2004, INORG CHEM, V43, P6805, DOI 10.1021/IC049718W##DE MEESTER P., 1971, J CHEM SOC A, V13, P2167##DEMEESTER P, 1971, NATURE, V229, P191, DOI 10.1038/229191A0##DUERST RW, 1969, NATURE, V222, P665, DOI 10.1038/222665A0##GARCIA-TERAN JP, 2004, INORG CHEM, V43, P4549, DOI 10.1021/IC049512V##GONZALEZ-PEREZ JM, 2006, INORG CHEM, V45, P877, DOI 10.1021/IC051965S##GOODGAME DM, 1971, BIOCHEM BIOPH RES CO, V42, P63, DOI 10.1016/0006-291X(71)90362-7##GOODGAME DM, 1968, NATURE, V220, P783, DOI 10.1038/220783A0##GUTIERREZ L, 2001, INORG CHEM, V40, P3089, DOI 10.1021/IC000869I##HAJ MA, 2002, EUR J INORG CHEM, P811##HATHAWAY B. J., 1987, COMPREHENSIVE COORDI, V5##KAHN O., 1993, MOL MAGNETISM##MINAKATA S, 1997, CHEM LETT, P311, DOI 10.1246/CL.1997.311##MINAKATA S, 1996, CHEM LETT, P19, DOI 10.1246/CL.1996.19##*NON BV, 2002, COLLECT##OBRIEN P, 1984, COORDIN CHEM REV, V58, P169, DOI 10.1016/0010-8545(84)85049-3##PENG SM, 1986, ACTA CRYSTALLOGR C, V42, P1725, DOI 10.1107/S0108270186090789##REEDIJK J., 1987, COMPREHENSIVE COORDI, V2, P73##RETTIG SJ, 2000, J CHEM SOC DALTON, P3931, DOI 10.1039/B002574G##RZEPKA M, 1996, POL J CHEM, V70, P19##SHELDRICK G.M., 1997, SHELXS 97 PROGRAM CR##SHELDRICK G. M., 1997, SHELXL 97 PROGRAM RE##SLETTEN E, 1970, ACTA CRYSTALL B-STRU, VB 26, P1609, DOI 10.1107/S0567740870004545##SLETTEN E, 1967, CHEM COMMUN, P1119, DOI 10.1039/C19670001119##SLETTEN E, 1969, ACTA CRYSTALL B-STRU, VB 25, P1480, DOI 10.1107/S0567740869004237##SONNENFROH D, 1980, INORG CHEM, V19, P1259, DOI 10.1021/IC50207A030##TERZIS A, 1973, INORG CHEM, V12, P1166, DOI 10.1021/IC50123A039##VANNIEKERK JN, 1953, ACTA CRYSTALLOGR, V6, P227, DOI 10.1107/S0365110X53000715##WASSON JR, 1968, INORG CHEM, V7, P469, DOI 10.1021/IC50061A017",19,2020-11-20,NA
J,WOS:000243002800001,2006,"ONSET OF RELIEF OF DYSPNOEA WITH BUDESONIDE/FORMOTEROL OR SALBUTAMOL FOLLOWING METHACHOLINE-INDUCED SEVERE BRONCHOCONSTRICTION IN ADULTS WITH ASTHMA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY","BACKGROUND: THE LONG-ACTING BETA(2)-AGONIST ( LABA) FORMOTEROL HAS AN ONSET OF EFFECT COMPARABLE TO THAT OF SALBUTAMOL. CONSEQUENTLY, THE COMBINATION OF FORMOTEROL AND BUDESONIDE IN ONE INHALER, APPROVED FOR MAINTENANCE USE, CAN POTENTIALLY BE USED FOR RELIEVER THERAPY. THIS STUDY COMPARED THE ONSET OF RELIEF FROM INDUCED BRONCHOSPASM WITH A SINGLE DOSE OF BUDESONIDE/ FORMOTEROL VERSUS STANDARD SALBUTAMOL THERAPY IN PATIENTS WITH ASTHMA. METHODS: IN THIS RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY, 32 PATIENTS WITH ASTHMA UNDERWENT A METHACHOLINE PROVOCATION TEST LEADING TO A FALL IN FORCED EXPIRATORY VOLUME IN 1 SECOND (FEV1) OF >= 30% AT ENROLMENT ( VISIT 1) AND THREE SUBSEQUENT STUDY VISITS ( VISITS 2 - 4). IMMEDIATELY AFTER EACH PROVOCATION AT VISITS 2 - 4, PATIENTS RECEIVED ONE OF THREE TEST TREATMENTS: ONE INHALATION OF BUDESONIDE/ FORMOTEROL 160/4.5 MU G ( VIA TURBUHALER(R)), TWO INHALATIONS OF SALBUTAMOL 100 MU G ( VIA A PRESSURISED METERED-DOSE INHALER [PMDI]) OR PLACEBO. ALL PATIENTS RECEIVED EACH OF THE TEST TREATMENTS IN A RANDOMISED ORDER, AFTER SEPARATE METHACHOLINE PROVOCATIONS. THE EFFECT OF TREATMENT ON FEV1 AND BREATHLESSNESS ( USING THE BORG SCALE) WAS MEASURED AT 1, 3, 5, 10, 15, 20, 25 AND 30 MINUTES AFTER TEST TREATMENT. RESULTS: FOLLOWING METHACHOLINE PROVOCATION, BORG SCORE INCREASED FROM A BASELINE VALUE OF BELOW 0.5 TO 3.03, 3.31 AND 3.50 BEFORE TREATMENT WITH BUDESONIDE/ FORMOTEROL, SALBUTAMOL AND PLACEBO, RESPECTIVELY. BUDESONIDE/FORMOTEROL AND SALBUTAMOL REVERSED METHACHOLINE-INDUCED DYSPNOEA ( BREATHLESSNESS) RAPIDLY. AT 1 MINUTE AFTER INHALATION, STATISTICALLY SIGNIFICANT DECREASES IN BORG SCORE WERE OBSERVED FOR BUDESONIDE/ FORMOTEROL AND SALBUTAMOL ( P = 0.0233 AND P < 0.0001, RESPECTIVELY, VERSUS PLACEBO), WITH SIMILAR RAPID INCREASES IN FEV1 ( BOTH ACTIVE TREATMENTS P < 0.0001 VERSUS PLACEBO). THE MEDIAN TIME TO 50% RECOVERY IN BORG SCORE AFTER METHACHOLINE PROVOCATION WAS 3 MINUTES WITH BUDESONIDE/ FORMOTEROL, 2 MINUTES WITH SALBUTAMOL AND 10 MINUTES WITH PLACEBO. ALL TREATMENTS AND PROCEDURES WERE WELL TOLERATED. CONCLUSION: SINGLE DOSES OF BUDESONIDE/ FORMOTEROL AND SALBUTAMOL BOTH PROVIDED RAPID RELIEF OF DYSPNOEA AND REVERSAL OF SEVERE AIRWAY OBSTRUCTION IN PATIENTS WITH ASTHMA WITH EXPERIMENTALLY INDUCED BRONCHOCONSTRICTION. THE PERCEPTION OF RELIEF, AS CONFIRMED BY OBJECTIVE LUNG FUNCTION ASSESSMENT, PROVIDES EVIDENCE THAT BUDESONIDE/ FORMOTEROL CAN BE USED AS RELIEVER MEDICATION IN ASTHMA.",SINGLE INHALER; FORMOTEROL; THERAPY; MODERATE; BUDESONIDE; MEDICATION; SAFETY; TURBUHALER(R); MAINTENANCE; COMBINATION,NA,RESPIRATORY RESEARCH,"JONKERS, RE##BANTJE, TA##AALBERS, R","UNIV AMSTERDAM, ACAD MED CTR, DEPT PULM DIS, NL-1105 AZ AMSTERDAM, NETHERLANDS. AMPHIA ZIEKENHUIS, DEPT PULM DIS, BREDA, NETHERLANDS. MARTINI HOSP, DEPT PULM DIS, GRONINGEN, NETHERLANDS.",RESPIRATORY SYSTEM,RESPIRATORY SYSTEM,"[ANONYMOUS], 1987, AM REV RESPIR DIS, V136, P225##BALANAG VM, 2006, PULM PHARMACOL THER, V19, P139, DOI 10.1016/J.PUPT.2005.04.009##BARNES PJ, 2005, AM J RESP CRIT CARE, V171, P95, DOI 10.1164/RCCM.2410004##BATEMAN ED, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-13##BATEMAN ERIC D, 2003, AM J RESPIR MED, V2, P275##BOONSAWAT W, 2003, RESP MED, V97, P1067, DOI 10.1016/S0954-6111(03)00139-2##BUHL R, 2003, RESP MED, V97, P323, DOI 10.1053/RMED.2002.1427##CHEUNG D, 2006, EUR RESPIR J, V27, P504, DOI 10.1183/09031936.06.00006805##CRAPO RO, 2000, AM J RESP CRIT CARE, V161, P309##GIBSON PG, 2005, EUR RESPIR J, V25, P397, DOI 10.1183/09031936.05.00002805##*GLOB IN ASTHM, 2005, GLOB STRAT ASTHM MAN##GREMBIALE RD, 2002, PULM PHARMACOL THER, V15, P463, DOI 10.1006/PUPT.2002.0387##KENDRICK K R, 2000, J EMERG NURS, V26, P216##LALLOO UG, 2003, CHEST, V123, P1480, DOI 10.1378/CHEST.123.5.1480##O'BYRNE PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/RCCM.200407-884OC##PAUWELS RA, 2003, EUR RESPIR J, V22, P787, DOI 10.1183/09031936.03.00055803##POLITIEK MJ, 1999, EUR RESPIR J, V13, P988, DOI 10.1034/J.1399-3003.1999.13E10.X##QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005S1693##RABE KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2##RUBINFELD AR, 2006, EUR RESPIR J, V27, P735, DOI 10.1183/09031936.06.00027405##SCICCHITANO R, 2004, CURR MED RES OPIN, V20, P1403, DOI 10.1185/030079904X2051##SEBEROVA E, 2000, RESP MED, V94, P607, DOI 10.1053/RMED.2000.0788##TATTERSFIELD AE, 2001, LANCET, V357, P257, DOI 10.1016/S0140-6736(00)03611-4##VAN DER WOUDE HJ, 2004, RESP MED, V98, P816, DOI 10.1016/J.RMED.2004.03.001##VAN DER WOUDE HJ, 2004, PULM PHARMACOL THER, V17, P89, DOI 10.1016/J.PUPT.2003.11.001##VAN NOORD JA, 1998, RESP MED, V92, P1346, DOI 10.1016/S0954-6111(98)90140-8##VOGELMEIER C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305##WILSON RC, 1989, CLIN SCI, V76, P277, DOI 10.1042/CS0760277##ZETTERSTROM O, 2001, EUR RESPIR J, V18, P262, DOI 10.1183/09031936.01.00065801",10,2020-11-20,NIEHS NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS) [27398C0007] FUNDING SOURCE: MEDLINE
J,WOS:000242478400003,2006,DIFFERENTIAL EFFECT OF TRANSPIRATION AND CA SUPPLY ON GROWTH AND CA CONCENTRATION OF TOMATO PLANTS,"TO DETERMINE THE EXTENT TO WHICH TRANSPIRATION AND CA CONCENTRATION IN THE NUTRIENT SOLUTION AFFECT THE REGULATION OF GROWTH, TWO INDEPENDENT EXPERIMENTS WITH YOUNG TOMATO PLANTS WERE CARRIED OUT UNDER FULLY CONTROLLED CLIMATE CONDITIONS AND GROWN HYDROPONICALLY. THE FIRST EXPERIMENT CONSISTED OF THE REGULATION OF TRANSPIRATION BY THREE LEVELS OF RELATIVE AIR HUMIDITY (RH): 50%, 70% (CONTROL) AND 95% (CORRESPONDING TO 1.32, 0.79 AND 0.13 KPA, RESPECTIVELY) DURING 7 DAYS. THE SECOND EXPERIMENT INVOLVED FOUR PERIODS OF 1, 3, 7 OR 14 DAYS OF LOW-CALCIUM (0.5 MEQ L-1) COMPARED WITH THE NUTRIENT STANDARD SOLUTION (9 MEQ L-1). THE RESULTS SHOW THAT PLANT GROWTH WAS AFFECTED MORE BY RH THAN BY THE REDUCTION OF CA IN THE NUTRIENT SOLUTION. HIGH HUMIDITY REDUCED THE TOTAL PLANT DRY MATTER AND TOTAL LEAF AREA, INCREASING THE DRY MATTER PARTITIONING INTO THE STEMS AND REDUCING IT INTO THE LEAVES. HOWEVER, THE LOW-CA SUPPLY DID NOT AFFECT THOSE PARAMETERS. PLANT CA CONCENTRATION WAS SIGNIFICANTLY REDUCED BY LOW-CA SUPPLY AS WELL AS BY HIGH RH, BUT TO A MUCH GREATER EXTENT BY THE CA SUPPLY THAN BY HIGH RH. CA CONCENTRATIONS IN LEAVES, STEM, AND ROOTS WERE QUICKLY REDUCED ALREADY AFTER 1 DAY OF LOW-CA. AFTER 14 DAYS, CA CONCENTRATION IN ALL PLANT ORGANS (LEAVES, STEMS AND ROOTS) WAS REDUCED BY APPROXIMATELY 70% COMPARED TO CONTROL PLANTS. OUR DATA SHOW THAT CALCIUM SUPPLY, AND CONSEQUENTLY CA CONCENTRATION IN THE TOMATO PLANT CAN BE REDUCED DRASTICALLY FOR SHORT-TERM PERIODS DURING THE VEGETATIVE GROWTH STAGE WITHOUT ANY ADVERSE EFFECT ON GROWTH WHILST HIGHER HUMIDITY REDUCE BOTH GROWTH AND CA CONCENTRATION IN YOUNG VEGETATIVE TOMATO PLANTS. CONSEQUENTLY, REDUCED CA UPTAKE AT HIGH AIR HUMIDITY IS NOT THE CAUSE FOR THE REDUCTION IN GROWTH. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",RELATIVE-HUMIDITY; CALCIUM; ACCUMULATION; TRANSPORT; SALINITY; LEAVES; FRUIT; YIELD,CALCIUM; TRANSPIRATION; DRY MATTER PARTITIONING; LEAF EXPANSION; LYCOPERSICON ESCULENTUM MILL.,SCIENTIA HORTICULTURAE,"DEL AMOR, FM##MARCELIS, LFM","INST MURCIANO & INVEST & DESARROLLO AGRARIO & ALI, MURCIA 30150, SPAIN. PLANT RES INT, NL-6700 AA WAGENINGEN, NETHERLANDS.",HORTICULTURE,AGRICULTURE,"ADAMS P, 1992, J HORTIC SCI, V67, P137, DOI 10.1080/00221589.1992.11516230##ARMSTRONG MJ, 1979, PLANT SOIL, V52, P427, DOI 10.1007/BF02185585##BAKKER JC, 1990, J HORTIC SCI, V65, P323##BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/ANNUREV.PP.46.060195.000523##DEL AMOR FM, 2003, J HORTIC SCI BIOTECH, V78, P343##EPSTEIN E., 1972, MINERAL NUTR PLANTS##EVANS G.C., 1972, QUANTITATIVE ANAL PL##GAUTIER H, 1999, ACTA HORTIC, V507, P77##GRANGE RI, 1987, J HORTIC SCI, V62, P125, DOI 10.1080/14620316.1987.11515760##GUICHARD S, 1999, ACTA HORTIC, P223, DOI 10.17660/ACTAHORTIC.1999.507.26##HAYNES RJ, 1980, BOT REV, V46, P75, DOI 10.1007/BF02860867##HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/ANNUREV.PP.36.060185.002145##HOFFMAN GJ, 1979, CONTROLLED ENV GUIDE##HOLDER R, 1990, J HORTIC SCI, V65, P31, DOI 10.1080/00221589.1990.11516025##HURD RG, 1981, GROWER GUIDE, V20, P55##KORNER O, 2003, COMPUT ELECTRON AGR, V39, P173, DOI 10.1016/S0168-1699(03)00079-6##LI YL, 2004, J HORTIC SCI BIOTECH, V79, P211, DOI 10.1080/14620316.2004.11511750##NELSON PV, 2003, SCI HORTIC-AMSTERDAM, V98, P409, DOI 10.1016/S0304-4238(03)00034-7##POORTER H, 1990, OECOLOGIA, V83, P553, DOI 10.1007/BF00317209##REDDY ASN, 2001, PLANT SCI, V160, P381, DOI 10.1016/S0168-9452(00)00386-1##ROBSON AD, 1983, INORGANIC PLANT NUTR##ROMEROARANDA R, 1995, J HORTIC SCI, V70, P423, DOI 10.1080/14620316.1995.11515312##SALIM M, 1989, NEW PHYTOL, V113, P13, DOI 10.1111/J.1469-8137.1989.TB02390.X##STANGHELLINI C, 1987, THESIS AGR U WAGENIN##STEBBINS RL, 1972, J AM SOC HORTIC SCI, V97, P471##TANNER W, 1990, PLANT CELL ENVIRON, V13, P745, DOI 10.1111/J.1365-3040.1990.TB01089.X##TANNER W, 2001, P NATL ACAD SCI USA, V98, P9443, DOI 10.1073/PNAS.161279898##TROMP J, 1993, PHYSIOL PLANTARUM, V89, P149, DOI [10.1034/J.1399-3054.1993.890121.X, 10.1111/J.1399-3054.1993.TB01798.X]",11,2020-11-20,NA
J,WOS:000244831800057,2006,EFFECT OF PRIOR PLASMA NITRIDING APPLIED TO A HOT-WORK TOOL STEEL ON THE SCRATCH-RESISTANT PROPERTIES OF PACVD TIBN AND TICN COATINGS,"TERNARY TIBN AND TICN COATINGS ON A HOT-WORK TOOL STEEL SUBSTRATE WITH AND WITHOUT PLASMA NITRIDING (PN) PRIOR TO PLASMA-ASSISTED CHEMICAL VAPOUR DEPOSITION (PACVD) WERE INVESTIGATED. COMPOSITIONAL ANALYSIS WITH A RADIO FREQUENCY GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPE (RF-GDOES) SHOWED MIXTURES OF TIBN+TIN AND TICN+TIN IN THE PACVD TIBN AND TICN COATINGS, RESPECTIVELY. EACH COATING LAYER HAD A COMPOSITIONAL GRADIENT ACROSS THE COATING DEPTH AND SLIGHTLY INTO THE SUBSTRATE. THE MICROHARDNESS PROFILES (HV0.1) OF THE SUBSTRATE WITH AND WITHOUT PN FROM THE INTERFACE WITH THE COATING TO THE SUBSTRATE CORE WERE DETERMINED. THE DEPTH OF THE EFFECTIVE NITRIDED DIFFUSION LAYER WAS CONFIRMED FROM THE EXAMINATION OF ITS OPTICAL MICROSTRUCTURE. THE ADHESION OF THESE TWO COATINGS TO THE SUBSTRATE WAS EVALUATED THROUGH SCRATCH TESTS IN THE PROGRESSIVE MODE. IT WAS FOUND THAT WITH INCREASING LOAD, BOTH OF THE COATINGS ON THE SUBSTRATE WITH AND WITHOUT PRIOR NITRIDING DETERIORATED IN THE SAME FAILURE MODES. CRITICAL LOADS CORRESPONDING TO THE FIRST MICROCRACKING RELATED TO COHESIVE FAILURE, SPALLATION RELATED TO ADHESIVE FAILURE, BREAKTHROUGH AND WORN OUT WERE DETERMINED AND USED TO QUANTIFY THE SCRATCH RESISTANCE OF THESE COATINGS. WITH PN PRIOR TO PACVD, BOTH THE COHESION AND ADHESION PROPERTIES OF THE TIBN AND TICN COATINGS WERE REMARKABLY IMPROVED. THIS IMPROVEMENT WAS ATTRIBUTED TO A FUNCTIONALLY GRADIENT HARDNESS CONFIGURATION FROM THE COATING THROUGH THE NITRIDED DIFFUSION LAYER TO THE SUBSTRATE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.","B-N COATINGS; HARD COATINGS; TRIBOLOGICAL PROPERTIES; WEAR BEHAVIOR; TIN COATINGS; MICROSTRUCTURE; TI(B,N)",PACVD; PLASMA NITRIDING; SCRATCH TEST; TIBN; TICN,SURFACE & COATINGS TECHNOLOGY,"HE, Y##APACHITEI, I##ZHOU, J##WALSTOCK, T##DUSZCZYK, J","DELFT UNIV TECHNOL, DEPT MAT SCI & ENGN, NL-2628 CD DELFT, NETHERLANDS. ADEX BV, NL-5928 PZ VENLO, NETHERLANDS.","MATERIALS SCIENCE, COATINGS & FILMS; PHYSICS, APPLIED",MATERIALS SCIENCE; PHYSICS,"BADISCH E, 2003, SURF COAT TECH, V174, P450, DOI 10.1016/S0257-8972(03)00401-8##BERG M, 2000, SURF COAT TECH, V124, P25, DOI 10.1016/S0257-8972(99)00472-7##BRESSAN JD, 2001, WEAR, V250, P561, DOI 10.1016/S0043-1648(01)00638-X##BULL SJ, 2006, TRIBOL INT, V39, P99, DOI 10.1016/J.TRIBOINT.2005.04.013##BULL SJ, 2003, SURF COAT TECH, V163, P507, DOI 10.1016/S0257-8972(02)00651-5##DORFEL I, 1999, SURF COAT TECH, V116, P898, DOI 10.1016/S0257-8972(99)00153-X##GISSLER W, 1994, SURF COAT TECH, V68, P556, DOI 10.1016/0257-8972(94)90217-8##HEIM D, 1999, SURF COAT TECH, V116, P530, DOI 10.1016/S0257-8972(99)00104-8##KAMMINGA JD, 2004, SURF COAT TECH, V177, P284, DOI 10.1016/J.SURFCOAT.2003.09.006##KLIMEK KS, 2003, SURF COAT TECH, V174, P677, DOI 10.1016/S0257-8972(03)00365-7##KULLMER R, 2003, SURF COAT TECH, V174, P1229, DOI 10.1016/S0257-8972(03)00532-2##MA SL, 2005, SURF COAT TECH, V191, P201, DOI 10.1016/J.SURFCOAT.2004.03.048##MATTHES B, 1990, SURF COAT TECH, V43-4, P721, DOI 10.1016/0257-8972(90)90015-5##MAYRHOFER PH, 2005, SCRIPTA MATER, V53, P241, DOI 10.1016/J.SCRIPTAMAT.2005.03.031##MITTERER C, 1999, SURF COAT TECH, V120, P405, DOI 10.1016/S0257-8972(99)00489-2##MITTERER C, 2003, SURF COAT TECH, V163, P716, DOI 10.1016/S0257-8972(02)00685-0##MITTERER C, 2001, SURF COAT TECH, V142, P1005, DOI 10.1016/S0257-8972(01)01065-9##PARK B, 2005, SURF COAT TECH, V200, P726, DOI 10.1016/J.SURFCOAT.2005.01.064##PFOHL C, 2001, SURF COAT TECH, V142, P1116, DOI 10.1016/S0257-8972(01)01224-5##PFOHL C, 1999, SURF COAT TECH, V116, P911, DOI 10.1016/S0257-8972(99)00141-3##RIE KT, 1995, SURF COAT TECH, V76-77, P425, DOI 10.1016/0257-8972(95)02513-8##STOIBER M, 2004, SURF COAT TECH, V177, P348, DOI 10.1016/J.SURFCOAT.2003.09.025##STOIBER M, 2003, SURF COAT TECH, V174, P687, DOI 10.1016/S0257-8972(03)00353-0##STOIBER M, 2001, SURF COAT TECH, V142, P117, DOI 10.1016/S0257-8972(01)01220-8##TARFA TN, 2004, P 8 INT AL EXTR TECH, V2, P357##VETTER J, 1999, SURF COAT TECH, V111, P210, DOI 10.1016/S0257-8972(98)00809-3##WIEDEMANN R, 1999, SURF COAT TECH, V116, P302, DOI 10.1016/S0257-8972(99)00130-9",49,2020-11-20,NA
J,WOS:000242864100010,2006,CARPAL MYXOSARCOMA AND FORELIMB AMPUTATION IN A FERRET (MUSTELA PUTORIUS FURO),NA,SURGICAL EXCISION; VACCINATION; PROGNOSIS; TUMORS,NA,VETERINARY RECORD,"VAN ZEELAND, YRA##HERNANDEZ-DIVERS, SJ##BLASIER, MW##VILA-GARCIA, G##DELONG, D##STEDMAN, NL","UNIV UTRECHT, FAC VET MED, DEPT SMALL ANIM MED, NL-3508 TC UTRECHT, NETHERLANDS. UNIV GEORGIA, DEPT SMALL ANIM MED & SURG, COLL VET MED, ATHENS, GA 30602 USA. UNIV GEORGIA, DEPT PATHOL, COLL VET MED, ATHENS, GA 30602 USA. UNIV LONDON ROYAL VET COLL, LONDON NW1 0TU, ENGLAND. AVALON ANIM HOSP, LAWRENCEVILLE, GA 30044 USA.",VETERINARY SCIENCES,VETERINARY SCIENCES,"BEACH JE, 1993, J COMP PATHOL, V108, P133, DOI 10.1016/S0021-9975(08)80217-4##BOSTOCK DE, 1980, VET PATHOL, V17, P581, DOI 10.1177/030098588001700507##BRIGGS OM, 1997, J S AFR VET ASSOC, V68, P144##BRISCOE CM, 1998, J VET DIAGN INVEST, V10, P79, DOI 10.1177/104063879801000114##BROWN SA, 1997, FERRETS RABBITS RODE, P99##COUTO CG, 1998, J AM VET MED ASSOC, V213, P1426##CRAIG LE, 2002, VET PATHOL, V39, P66, DOI 10.1354/VP.39-1-66##DAVIDSON EB, 1997, VET SURG, V26, P265, DOI 10.1111/J.1532-950X.1997.TB01497.X##FUDGE AM, 2000, LAB MED AVIAN EXOTIC, P375##GOAD MEP, 1998, BIOL DIS FERRET, P274##GOLDSCHMIDT M. H., 2002, TUMORS IN DOMESTIC ANIMALS, P45, DOI 10.1002/9780470376928.CH2##HERSHEY AE, 2000, J AM VET MED ASSOC, V216, P58, DOI 10.2460/JAVMA.2000.216.58##KASS PH, 1993, J AM VET MED ASSOC, V203, P396##MACKENZIE DH, 1981, AM J SURG PATHOL, V5, P443, DOI 10.1097/00000478-198107000-00004##MADEWELL BR, 1987, VET CANCER MED, P233##MUNDAY JS, 2003, VET PATHOL, V40, P288, DOI 10.1354/VP.40-3-288##MURRAY J, 1998, J AM VET MED ASSOC, V213, P955##PARKER GA, 1993, VET PATHOL, V30, P499, DOI 10.1177/030098589303000602##RICHTER M, 2003, VET OPHTHALMOL, V6, P183, DOI 10.1046/J.1463-5224.2003.00289.X##STANNARD AA, 1978, TUMOURS DOMESTIC ANI, P48##WEIGEL JP, 2002, TXB SMALL ANIMAL SUR, P2180",7,2020-11-20,NA
J,WOS:000242746100002,2006,"MULTIVARIATE SEQUENCE STRATIGRAPHY: TACKLING COMPLEXITY AND UNCERTAINTY WITH STRATIGRAPHIC FORWARD MODELING, MULTIPLE SCENARIOS, AND CONDITIONAL FREQUENCY MAPS","SEQUENCE-STRATIGRAPHIC CONCEPTUAL MODELS TYPICALLY FOCUS ON ACCOMMODATION AS A DOMINANT CONTROL. ALTHOUGH USEFUL IN MANY WAYS, THIS APPROACH MAY NOT ADDRESS THE FULL RANGE OF POSSIBLE CONTROLS ON STRATAL PATTERNS, NOR IS IT LIKELY TO FULLY ADDRESS UNCERTAINTY IN THE IDENTIFICATION AND QUANTIFICATION OF CONTROLLING PROCESSES. CONSEQUENTLY, PREDICTIONS FROM SEQUENCE-STRATIGRAPHIC CONCEPTUAL MODELS MAY BE MORE LIMITED THAN GENERALLY STATED. PROGRESS IN ADDRESSING THIS PROBLEM CAN BE ACHIEVED BY APPLYING THE LATEST GENERATION THREE-DIMENSIONAL STRATIGRAPHIC FORWARD MODELING TO (1) INVESTIGATE AND INCLUDE MORE OF THE PARAMETERS THAT MAY CONTROL STRATAL ARCHITECTURES AND (2) CONSIDER MULTIPLE SCENARIOS TO HELP DETERMINE THE IMPACT OF UNCERTAINTY IN OPERATING PROCESSES AND THEIR PARAMETER VALUES. RESULTS FROM A THREE-DIMENSIONAL DIFFUSIONAL STRATIGRAPHIC FORWARD MODEL ILLUSTRATE THIS APPROACH, SUGGESTING THAT RELATIVE SEA LEVEL CHANGE, SHELF WIDTH, AND SEDIMENT-TRANSPORT EFFICIENCY ARE IMPORTANT LARGE-SCALE CONTROLS ON THE SPATIAL AND TEMPORAL DISTRIBUTION OF DEEP-MARINE STRATAL VOLUMES. IF THIS RESULT IS SUFFICIENTLY INDEPENDENT OF MODEL ASSUMPTIONS AND CAN BE REPLICATED IN OTHER MODELS, IT SUGGESTS THAT ALL THREE CONTROLLING FACTORS SHOULD BE INCLUDED IN INTERPRETATIONS AND PREDICTIONS OF OUTCROP AND SUBSURFACE DEEP-MARINE STRATA. MODELING RESULTS ALSO SUGGEST THAT COMBINING MULTIPLE FORWARD-MODEL SCENARIOS TO FORM CONDITIONAL FREQUENCY MAPS MAY BE A USEFUL, PRACTICAL METHOD TO PRESENT AND ANALYZE MULTIPLE SCENARIOS. THE USE OF MULTIPLE FORWARD-MODELING SCENARIOS TO CONSIDER MULTIPLE CONTROLS ON STRATAL ARCHITECTURE COULD BEGIN TO ACCOUNT MORE FULLY FOR UNCERTAINTY IN CONTROLLING PROCESSES AND PARAMETER VALUES, IN SEQUENCE STRATIGRAPHY GENERALLY, AND EVALUATION OF SUBSURFACE UNCERTAINTY SPECIFICALLY.",SEA-LEVEL; BASIN; ARCHITECTURE; TEXAS; CLIMATE; EUSTASY; EXAMPLE,NA,AAPG BULLETIN,"BURGESS, PM##LAMMERS, H##VAN OOSTERHOUT, C##GRANJEON, D","SHELL INT EXPLORAT & PROD BV, RES & DEV, NL-2280 GS RIJSWIJK, NETHERLANDS. IFP ENERGIES NOUVELLES, F-92506 RUEIL MALMAISON, FRANCE.","GEOSCIENCES, MULTIDISCIPLINARY",GEOLOGY,"ALLEN PA, 2005, BASIN ANAL PRINCIPLE##ANDERSON JB, 1996, GEOL SOC SPEC PUBL, V117, P95, DOI 10.1144/GSL.SP.1996.117.01.06##ARMENTROUT JM, 2004, AAPG PACIFIC SECTION##ATCHLEY SC, 2004, J SEDIMENT RES, V74, P391, DOI 10.1306/102203740391##BAGIROV E, 1999, SEPM SPEC PUBL, V62, P35, DOI DOI 10.2110/PEC.99.62.0035##BLUM MD, 2001, J SEDIMENT RES, V71, P581, DOI 10.1306/112100710581##BURGESS PM, 1998, J GEOL SOC LONDON, V155, P217, DOI 10.1144/GSJGS.155.2.0217##BURGESS PM, 2001, GEOLOGY, V29, P1127, DOI 10.1130/0091-7613(2001)029<1127:MCSDWR>2.0.CO;2##BURTON R, 1987, EARTH-SCI REV, V24, P237, DOI 10.1016/0012-8252(87)90062-6##CARROLL AR, 2006, GEOLOGY, V34, P197, DOI 10.1130/G22148.1##COE A.L., 2003, SEDIMENTARY RECORD S, P57##CROSS T., 1999, SEPM SPECIAL PUBLICA, V62, DOI DOI 10.2110/PEC.99.62.0069##DE WET CB, 1998, J SEDIMENT RES, V68, P653, DOI 10.2110/JSR.68.653##DEUTSCH C, 2002, GEOSTATISTICAL RESER##EWING TE, 2002, ASS GEOLOGICAL SOC T, V52, P257##GAWTHORPE RL, 1994, MAR PETROL GEOL, V11, P642, DOI 10.1016/0264-8172(94)90021-3##GRANJEON D, 2002, AAPG ANN M PROGRAM, V11, PA66##GRANJEON D., 1999, SPECIAL PUBLICATION, V62, P197, DOI DOI 10.2110/PEC.99.62.0197##HELLER PL, 1993, GEOLOGY, V21, P747, DOI 10.1130/0091-7613(1993)021<0747:SSSFDT>2.3.CO;2##JERVEY M.T., 1988, SEPM SPEC PUBL, V42, P47, DOI DOI 10.2110/PEC.88.01.0047##JORDAN TE, 1991, J GEOPHYS RES-SOLID, V96, P6681, DOI 10.1029/90JB01399##KARNER GD, 1997, J GEOL SOC LONDON, V154, P443, DOI 10.1144/GSJGS.154.3.0443##LAWRENCE DT, 1990, AAPG BULL, V74, P273##LEEDER MR, 1998, BASIN RES, V10, P7, DOI 10.1046/J.1365-2117.1998.00054.X##MARTINEZ P., 1993, SIMULATING NEARSHORE##MEIJER XD, 2002, BASIN RES, V14, P361, DOI 10.1046/J.1365-2117.2002.00187.X##MIALL AD, 1997, GEOLOGY STRATIGRAPHI##MITCHUM JR. R. M., 1990, AAPG METHODS EXPLORA, V7##MODICA CJ, 2004, AAPG BULL, V88, P923, DOI 10.1306/01220403043##PAOLA C, 2000, SEDIMENTOLOGY, V47, P121, DOI 10.1046/J.1365-3091.2000.00006.X##PERLMUTTER M., 1999, SEPM SPECIAL PUBLICA, V62, P25##PINOUS OV, 2001, AAPG BULL, V85, P1713##POSAMENTIER H.W., 1988, SEPM SPECIAL PUBLICA, V26, P109, DOI DOI 10.2110/PEC.88.01.0109##POSAMENTIER HW, 2003, J SEDIMENT RES, V73, P367, DOI 10.1306/111302730367##POSAMENTIER HW, 1993, SEDIMENT GEOL, V86, P91, DOI 10.1016/0037-0738(93)90135-R##POSAMENTIER HW, 2000, GEOL SOC SPEC PUBL, V172, P19, DOI 10.1144/GSL.SP.2000.172.01.02##PRATHER BE, 2003, MAR PETROL GEOL, V20, P529, DOI 10.1016/J.MARPETGEO.2003.03.009##RASMUSSEN ES, 2005, SEDIMENTOLOGY, V52, P25, DOI 10.1111/J.1365-3091.2004.00681.X##READING HG, 1994, AAPG BULL, V78, P792##SALTELLI A., 2000, SENSITIVITY ANAL##SCHLAGER W, 1993, SEDIMENT GEOL, V86, P111, DOI 10.1016/0037-0738(93)90136-S##SCHROEDER FW, 1993, AAPG BULL, V77, P638##SCHUMM SA, 1991, INTERPRET EARTH 10 Y##SHEETS BA, 2002, BASIN RES, V14, P287, DOI 10.1046/J.1365-2117.2002.00185.X##SMITH R, 2004, GEOL SOC SPEC PUBL, V222, P23, DOI 10.1144/GSL.SP.2004.222.01.03##SWIFT DJP, 1991, SPECIAL PUBLICATION, V14, P3##SYVITSKI JPM, 1999, NUMERICAL EXPT STRAT, V62, P219##THORNE JA, 1992, AAPG MEMOIR, V53, P375##THORNE JA, 1991, SPECIAL PUBLICATION, V14, P33##VAIL P.R., 1977, AAPG BULL, V26, P83, DOI DOI 10.1306/M26490C6##VAN HEIJST MWIM, 2001, BASIN RES, V13, P269, DOI 10.1046/J.1365-2117.2001.00149.X##WANDEBOURG J, 2002, MULTIDIMENSIONAL BAS, V7, P1##WHITE DA, 1988, AAPG BULL, V72, P944",71,2020-11-20,NA
J,WOS:000209485400007,2006,INFORMATION TRADING BY CORPORATE INSIDERS BASED ON ACCOUNTING ACCRUALS: FORECASTING ECONOMIC PERFORMANCE,"IN THIS PAPER, WE TEST WHETHER DIRECTORS' (CORPORATE INSIDERS) TRADING IN AUSTRALIA, BASED ON ACCOUNTING ACCRUALS, PROVIDES INCREMENTAL INFORMATION IN FORECASTING A FIRM'S ECONOMIC PERFORMANCE. WE DETERMINE THAT DIRECTORS' TRADING ON NEGATIVE ACCRUALS IN LARGER FIRMS HAS GREATER FORECASTING CONTENT AND IS ASSOCIATED WITH 1-YEAR-AHEAD BULL MARKET PHASES. MOREOVER, ARBITRAGE PORTFOLIOS SET UP TO MIMIC INSIDER TRADING CAN EARN 1-YEAR-AHEAD EXCESS SIZE-ADJUSTED ARBITRAGE RETURNS OF UP TO 12.2 PER CENT. RESULTS ARE CONSISTENT WITH DIRECTORS HIDING THEIR TRADES IN LIQUID WELL-TRADED FIRMS AND IN PROVIDING INCREMENTAL INFORMATION ABOVE THAT SUPPLIED BY A CONTINUOUS INFORMATION REGIME.",EARNINGS,INSIDER TRADING; ACCRUAL QUALITY; INSIDER ARBITRAGE RETURNS; CONTINUOUS INFORMATION REPORTING,ACCOUNTING AND FINANCE,"HODGSON, A##VAN PRAAG, B","[HODGSON, ALLAN; VAN PRAAG, BART] AMSTERDAM BUSINESS SCH, NL-1018 WB AMSTERDAM, NETHERLANDS.","BUSINESS, FINANCE",BUSINESS & ECONOMICS,"ABOODY D, 2000, J FINANC, V55, P2747, DOI 10.1111/0022-1082.00305##AMIHUD Y, 1991, J FINANC, V46, P1765, DOI 10.2307/2328572##ANAND A., 2002, WORKING PAPER##BAESEL JB, 1979, J FINANC QUANT ANAL, V14, P553, DOI 10.2307/2330188##BASU S, 1997, J ACCOUNT ECON, V24, P3, DOI 10.1016/S0165-4101(97)00014-1##BENEISH MD, 2002, ACCOUNT REV, V77, P755, DOI 10.2308/ACCR.2002.77.4.755##BETTIS JC, 2000, J FINANC ECON, V57, P191, DOI 10.1016/S0304-405X(00)00055-6##BROWN P., 1997, WORKING PAPER##BROWN P., 1998, WORKING PAPER##FINNERTY JE, 1976, J FINANC, V31, P1141, DOI 10.2307/2326279##HAMILL P., 2002, J MANAG GOV, V6, P215##HAY MANAGEMENT CONSULTANTS, 1998, SHORT TERM INC REP 1##HILLIER D., 2002, J BUSINESS FINANCE A, V29, P77, DOI [10.1111/1468-5957.00424_29_1-2, DOI 10.1111/1468-5957.00424_29_1-2]##JENG LA, 2003, REV ECON STAT, V85, P453, DOI 10.1162/003465303765299936##JOHN K, 1991, J FINANC, V46, P1361, DOI 10.2307/2328862##KE B, 2003, J ACCOUNT ECON, V35, P315, DOI 10.1016/S0165-4101(03)00036-3##LAKONISHOK J, 2001, REV FINANC STUD, V14, P79, DOI 10.1093/RFS/14.1.79##MEULBROEK LK, 1992, J FINANC, V47, P1661, DOI 10.2307/2328992##NOE CF, 1999, J ACCOUNT ECON, V27, P305, DOI 10.1016/S0165-4101(99)00014-2##NUNN KP, 1983, J PORTFOLIO MANAGE, V9, P18##SEYHUN HN, 1986, J FINANC ECON, V16, P189, DOI 10.1016/0304-405X(86)90060-7##SEYHUN HN, 1992, J LAW ECON, V35, P149, DOI 10.1086/467248##SEYHUN N., 1998, INVESTMENT INTELLIGE##SIVAKUMAR K, 1994, FINANC MANAGE, V23, P23, DOI 10.2307/3666053##SLOAN RG, 1996, ACCOUNT REV, V71, P289##SUMMERS SL, 1998, ACCOUNT REV, V73, P131##TOMASIC R, 1991, CASINO CAPITALISM IN##VUONG QH, 1989, ECONOMETRICA, V57, P307, DOI 10.2307/1912557##WATSON I., 1998, WORKING PAPER",10,2020-11-20,ARCAUSTRALIAN RESEARCH COUNCIL [LGA00104218]
J,WOS:000202972700005,2006,DESIGN AND IMPLEMENTATION OF A GUI FOR THE TLC MODEL CHECKER,"FOR SOME TIME NOW, THE TLC MODEL CHECKER [1] HAS BEEN ACCEPTED AS A VERY USEFUL TOOL FOR CHECKING SPECIFICATIONS WRITTEN IN THE LANGUAGE TLA+ [1]. THE MODEL CHECKER HELPS THE SYSTEM DESIGNER TO FIND ERRORS IN A SPECIFICATION BEFORE STARTING ON AN IMPLEMENTATION. ONE FACILITY THAT TLA+/TLC LACKS HOWEVER, IS A GUI PROVIDING THE USER WITH MORE OPERATIONAL COMFORT. THIS ARTICLE PRESENTS OUR DESIGN AND IMPLEMENTATION OF A GUI FOR THE TLA+/TLC-SYSTEM, CALLED THE GTLA SYSTEM. GTLA PROVIDES THE USER WITH THREE MAIN FACILITIES: A SYSTEM EDITOR, A SIMULATOR AND A VERIFIER (THE TLC MODEL CHECKER) OPERABLE THROUGH A GUI. THIS ARTICLE ALSO DISCUSSES THE TOOLS WHICH HAVE BEEN USED FOR CONSTRUCTING THE GTLA SYSTEM.",NA,TLA; TEMPORAL LOGIC; TLC; MODEL CHECKING; GUI; SML; GRAPHVIZ,ACM SIGPLAN NOTICES,"WANG, B##PRONK, C","DELFT UNIV TECHNOL, DEPT ELECT ENGN MATH & COMP SCI, NL-2628 CD DELFT, NETHERLANDS.","COMPUTER SCIENCE, SOFTWARE ENGINEERING",COMPUTER SCIENCE,"BIRD R., 1988, SERIES COMPUTER SCI##ENGBERG U, 1996, BRICS DISSERTATION S, P1396##FUCHS NE, 1989, SOFTWARE ENG J, V4, P320##GANSNER E, 2002, DRAWING GRAPHS DOT##GRAVELL A, EXECUTING FORMAL SPE##HAYES IJ, 1989, SOFTWARE ENG J, V4, P320##LAMPORT L, 147 SRC##LAMPORT L., 2002, SPECIFYING SYSTEMS T##MOKHTARI Y, 1999, ANIMATING TLA SPECIF, P92##WANG B, 2002, THESIS DELFT U TECHN",0,2020-11-20,NA
J,WOS:000243396000001,2006,EXPRESSIVE POWER OF AN ALGEBRA FOR DATA MINING,"THE RELATIONAL DATA MODEL HAS SIMPLE AND CLEAR FOUNDATIONS ON WHICH SIGNIFICANT THEORETICAL AND SYSTEMS RESEARCH HAS FLOURISHED. BY CONTRAST, MOST RESEARCH ON DATA MINING HAS FOCUSED ON ALGORITHMIC ISSUES. A MAJOR OPEN QUESTION IS: WHAT'S AN APPROPRIATE FOUNDATION FOR DATA MINING, WHICH CAN ACCOMMODATE DISPARATE MINING TASKS? WE ADDRESS THIS PROBLEM BY PRESENTING A DATABASE MODEL AND AN ALGEBRA FOR DATA MINING. THE DATABASE MODEL IS BASED ON THE 3W-MODEL INTRODUCED BY JOHNSON ET AL. [ 2000]. THIS MODEL RELIED ON BLACK BOX MINING OPERATORS. A MAIN CONTRIBUTION OF THIS ARTICLE IS TO OPEN UP THESE BLACK BOXES, BY USING GENERIC OPERATORS IN A DATA MINING ALGEBRA. TWO KEY OPERATORS IN THIS ALGEBRA ARE REGIONIZE, WHICH CREATES REGIONS ( OR MODELS) FROM DATA TUPLES, AND A RESTRICTED FORM OF LOOPING CALLED MINING LOOP. THEN THE RESULTING DATA MINING ALGEBRA MA IS STUDIED AND PROPERTIES CONCERNING EXPRESSIVE POWER AND COMPLEXITY ARE ESTABLISHED. WE PRESENT RESULTS IN THREE DIRECTIONS: ( 1) EXPRESSIVENESS OF THE MINING ALGEBRA; ( 2) RELATIONS WITH ALTERNATIVE FRAMEWORKS, AND ( 3) INTERACTIONS BETWEEN REGIONIZE AND MINING LOOP.",COMPLEXITY,LANGUAGES; THEORY; ALGEBRA; EXPRESSIVE POWER; DATA MINING,ACM TRANSACTIONS ON DATABASE SYSTEMS,"CALDERS, T##LAKSHMANAN, LVS##NG, RT##PAREDAENS, J","EINDHOVEN UNIV TECHNOL, DEPT MATH & COMP SCI, NL-5600 MB EINDHOVEN, NETHERLANDS. UNIV BRITISH COLUMBIA, DEPT COMP SCI, VANCOUVER, BC V6T 1Z4, CANADA. UNIV ANTWERP, DEPT MATH & COMP SCI, B-2020 ANTWERP, BELGIUM.","COMPUTER SCIENCE, INFORMATION SYSTEMS; COMPUTER SCIENCE, SOFTWARE ENGINEERING",COMPUTER SCIENCE,"ABITEBOUL S, 1995, LECT NOTES COMPUT SC, V893, P439##ABITEBOUL S, 1995, FDN DATABASES##AGRAWAL A, 1994, P 20 INT C VER LARG, P487##AGRAWAL R., 1993, SIGMOD RECORD, V22, P207, DOI 10.1145/170035.170072##BOULICAUT JF, 1999, LNCS, V1676, P293##BREIMAN L., 1984, CLASSIFICATION REGRE##CALDERS T, 2006, LECT NOTES COMPUTER, V3848##CHAUDHURI S, 2002, PROC INT CONF DATA, P529, DOI 10.1109/ICDE.2002.994772##CONSENS MP, 1993, THEOR COMPUT SCI, V116, P95, DOI 10.1016/0304-3975(93)90221-E##DANTZIG GB, 1963, LINEAR PROGRAMMING E##GAREY M. R., 1979, COMPUTER INTRACTABIL##GEIST I, 2002, P DBFUSION INT WORKS, V124##GUTTMAN A., 1984, P ACM SIGMOD INT C M, P47, DOI DOI 10.1145/602259.602266##HAN J, 2000, P 2000 ACM SIGMOD IN, P1, DOI DOI 10.1145/342009.335372##HAN J, 1996, P SIGMOD 96 WORKSH R, P27##HAND D. J., 2001, PRINCIPLES DATA MINI##IMIELINSKI T, 1996, COMMUN ACM, V39, P58, DOI 10.1145/240455.240472##IMIELINSKI T, 1999, DATA MIN KNOWL DISC, V3, P373, DOI 10.1023/A:1009816913055##JOHNSON T, 2000, P 26 INT C VER LARG, P21##KENNEDY K, 1994, P 6 INT WORKSH LANG, P301##LAW YN, 2004, P 30 INT C VER LARG, P492##LIBKIN L, 1998, LECT NOTES COMPUT SC, V1369, P260##MANNILA H, 1996, P KDD INT C KNOWL DI##MEO R, 1996, PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON VERY LARGE DATA BASES, P122##MURTY KG, 1983, LINEAR PROGRAMMING##NETZ A, 2001, PROC INT CONF DATA, P379, DOI 10.1109/ICDE.2001.914850##PARADAENS J, 1998, P PODS INT C PRINC D, P29##PARADAENS J, 1994, P 13 ACM S PRINC DAT, P279##SARAWAGI S, 1998, P ACM SIGMOD INT C M, P343##TSUR D, 1998, P ACM SIGMOD INT C M, P1##VAN DEN BUSSCHE J, 2001, THEOR COMPUT SCI, V254, P363, DOI 10.1016/S0304-3975(99)00301-1##WANG H, 2003, P 3 SIAM INT C DAT M##WANG HX, 2000, SPRINGER INT SER ENG, V597, P523##ZANIOLO C, 2005, LECT NOTES COMPUTER, V3933",15,2020-11-20,NA
J,WOS:000247210200002,2006,THE ECLIPSE OF SPECIES RANGES,"THIS PAPER DISTINGUISHES FOUR RECOGNISABLY DIFFERENT GEOGRAPHICAL PROCESSES IN PRINCIPLE CAUSING SPECIES TO DIE OUT. ONE OF THESE PROCESSES, THE ONE WE DUB ""RANGE ECLIPSE"", HOLDS THAT ONE RANGE EXPANDS AT THE EXPENSE OF ANOTHER ONE, THEREBY USURPING IT. CHANNELL AND LOMOLINO (2000A, JOURNAL OF BIOGEOGRAPHY 27: 169-179; 2000B, NATURE 403: 84-87; SEE ALSO LOMOLINO AND CHANNELL, 1995, JOURNAL OF MAMMALOGY 76: 335-347) MEASURED THE COURSE OF THIS PROCESS IN TERMS OF THE PROPORTION OF THE TOTAL RANGE REMAINING IN ITS ORIGINAL CENTRE, THEREBY ESSENTIALLY ASSUMING A HOMOGENEOUS DISTRIBUTION OF ANIMALS OVER THE RANGE. HOWEVER, PART OF THEIR MEASURE SEEMS MISTAKEN. BY GIVING A GENERAL, ANALYTICAL FORMULATION OF ECLIPSING RANGES, WE ESTIMATE THE EXACT COURSE OF THIS PROCESS. ALSO, OUR FORMULATION DOES NOT PARTITION A RANGE INTO TWO SPATIALLY EQUAL PARTS, ITS CORE AND ITS EDGE, BUT IT ASSUMES CONTINUITY. FOR APPLYING THIS MODEL TO DATA ON THE TIME EVOLUTION OF SPECIES, INDIVIDUAL TIME SERIES SHOULD BE AVAILABLE FOR EACH OF THEM. FOR PRACTICAL PURPOSES WE GIVE AN ALTERNATIVE WAY OF PLOTTING AND INTERPRETING SUCH TIME SERIES. OUR APPROACH, BEING MORE SENSITIVE THAN CHANNELL AND LOMOLINO'S, GIVES A LESS OPTIMISTIC INDICATION OF RANGE ECLIPSES THAN THEIRS ONCE THESE HAVE STARTED.",GEOGRAPHICAL RANGES; CONTRACTION; PATTERNS; EXTINCTION; EXPANSION; VELOCITY; DYNAMICS,RANGE; BIOGEOGRAPHY; CONSERVATION; EXTINCTION,ACTA BIOTHEORETICA,"HEMERIK, L##HENGEVELD, R##LIPPE, E","UNIV WAGENINGEN & RES CTR, DEPT MATH & STAT METHODS, NL-6700 AC WAGENINGEN, NETHERLANDS. FREE UNIV AMSTERDAM, INST ECOL SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. ALTERRA, DEPT ECOL & ENVIRONM, NL-6700 AA WAGENINGEN, NETHERLANDS.",MATHEMATICAL & COMPUTATIONAL BIOLOGY,MATHEMATICAL & COMPUTATIONAL BIOLOGY,"CASE TJ, 2005, OIKOS, V108, P28, DOI 10.1111/J.0030-1299.2005.13148.X##CAUGHLEY G, 1988, J ANIM ECOL, V57, P771, DOI 10.2307/5092##CHANNELL R, 2000, J BIOGEOGR, V27, P169, DOI 10.1046/J.1365-2699.2000.00382.X##CHANNELL R, 2000, NATURE, V403, P84, DOI 10.1038/47487##DONALD PF, 2001, IBIS, V143, P593, DOI 10.1111/J.1474-919X.2001.TB04887.X##FISHER DO, 2003, P ROY SOC B-BIOL SCI, V270, P1801, DOI 10.1098/RSPB.2003.2447##HAECK J, 1981, BIOL CONSERV, V19, P189, DOI 10.1016/0006-3207(81)90034-3##HENGEVELD R, 1982, J BIOGEOGR, V9, P309##HENGEVELD R, 1990, DYNAMIC BIOGEOGRAPHY##HENGEVELD R, 2002, DISPERSAL ECOLOGY##LALIBERTE AS, 2004, BIOSCIENCE, V54, P123, DOI 10.1641/0006-3568(2004)054[0123:RCONAC]2.0.CO;2##LOMOLINO MV, 1995, J MAMMAL, V76, P335, DOI 10.2307/1382345##RODRIGUEZ A, 2002, ECOGRAPHY, V25, P314, DOI 10.1034/J.1600-0587.2002.250308.X##RODRIGUEZ JP, 2002, ECOL APPL, V12, P238##RODRIGUEZ JP, 1999, THESIS PRINCETON U P##SAGARIN RD, 2002, ECOL LETT, V5, P137, DOI 10.1046/J.1461-0248.2002.00297.X##VANDENBOSCH F, 1992, J BIOGEOGR, V19, P135, DOI 10.2307/2845500##VANDENBOSCH F, 1990, J MATH BIOL, V28, P529, DOI 10.1007/BF00164162##WILLIAMS CK, 2003, ECOLOGY, V84, P2654, DOI 10.1890/03-0038",12,2020-11-20,NA
J,WOS:000247210200003,2006,DIETS AND CIRCADIAN RHYTHMS: CHALLENGES FROM BIOLOGY FOR MEDICINE,"AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS AND GASTROINTESTINAL DISORDERS SUCH AS STOMACH ULCERS ARE OFTEN TREATED WITH DRUGS. NSAIDS, A COMMON TREATMENT IN RHEUMATOID ARTHRITIS, MAY CAUSE STOMACH ULCERS WHICH CALL FOR ADDITIONAL MEDICATIONS, NOTABLY ANTACIDS IN THE SENSE OF DRUGS THAT SUPPRESS ACID SECRETION BY THE STOMACH. INFECTION WITH HELICOBACTER PYLORI ALSO PLAYS A ROLE IN THE ULCERS. THE INFECTION IS TYPICALLY TREATED WITH ANTIBIOTICS ADDED TO ANTACIDS. CONSIDERING NSAIDS AND ANTACIDS, WE SUSPECT THAT OVERMEDICATION IS COMMON TO THE EXTENT THAT PARTICULAR DIETS ARE A BETTER OPTION. CURRENT RESEARCH AND CURRENT TREATMENTS WITH THESE DRUGS ARE ALSO PROBLEMATIC SINCE CIRCADIAN RHYTHMS ARE MOSTLY DISREGARDED. ALL THE PROCESSES INVOLVED IN THE DISORDERS TREATED SHOW MARKED VARIATIONS IN THE COURSE OF THE DAY. HENCE EXPERIMENTS CONFORMING TO THE GUIDELINES OF EVIDENCE-BASED MEDICINE, AND TREATMENTS IN LINE WITH THEM, HAVE OUTCOMES STRONGLY DEPENDING ON THE TIME FACTOR. THIS CALLS FOR REFORMS IN MEDICINE WITH FRESH INPUTS FROM BIOLOGY.",NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HELICOBACTER-PYLORI INFECTION; CYCLOOXYGENASE-2 INHIBITORS; PHILOSOPHY; MELATONIN; EFFICACY; DAMAGE,CIRCADIAN RHYTHMS; EVIDENCE-BASED MEDICINE; RHEUMATOID ARTHRITIS; STOMACH ULCERS; NSAIDS; ANTACIDS; COXIBS; HELICOBACTER PYLORI; OVERMEDICATION; DIETS; OMEGA-3 FATTY ACIDS,ACTA BIOTHEORETICA,"VAN DER STEEN, WJ##HO, VKY","COMPREHENS CANC CTR MIDDLE NETHERLANDS, DEPT REGISTRAT & RES, NL-3501 DB UTRECHT, NETHERLANDS.",MATHEMATICAL & COMPUTATIONAL BIOLOGY,MATHEMATICAL & COMPUTATIONAL BIOLOGY,"ADEBAYO D, 2006, IS NONSTEROIDAL ANTI, V82, P186##AHRENS N, 2006, MISDIANGNOSIS PATIEN, V81, P128##ALI US, 2006, PEDIATR NEPHROL, V21, P274, DOI 10.1007/S00467-005-2089-0##ARJONA A, 2006, EVIDENCE SUPPORTING, V20, P469##BANNWARTH B, 2005, EXPERT OPIN INV DRUG, V14, P521, DOI 10.1517/13543784.14.4.521##BRZOZOWSKI T, 2005, J PINEAL RES, V39, P375, DOI 10.1111/J.1600-079X.2005.00264.X##BURIAN RM, 1996, STUD HIST PHILOS SCI, V27, P1, DOI 10.1016/0039-3681(95)00034-8##CANTER PH, 2006, SYSTEMATIC REV RANDO, V13, P371##CAPONE ML, 2005, CLIN PHARM ETORICOXI, V1, P269##CARRILLOVICO A, 2006, MODULATORY ROLE MELA, V7, P423##CHAN FKL, 2005, DRUG SAFETY, V28, P287, DOI 10.2165/00002018-200528040-00002##CHENG HF, 2005, CURR PHARM DESIGN, V11, P1795, DOI 10.2174/1381612053764922##CUTOLO M, 2005, AUTOIMMUN REV, V4, P497, DOI 10.1016/J.AUTREV.2005.04.019##CUTOLO M, 2006, CIRCADIAN RHYTHMS GL, V1069, P289##DENG WG, 2006, MELATONIN SUPPRESSES, V108, P518##ESTEVE JB, 2005, CLIN NEPHROL, V63, P385##FLOCKHART DA, 2000, CLIN PHARMACOKINET, V39, P295, DOI 10.2165/00003088-200039040-00005##GIACCHETTI S, 2006, PHASE 3 TRIAL COMP 4, V24, P3562##GRIFFIN MR, 1998, EPIDEMIOLOGY NONSTER, V104, PS23##HALBERG FRANZ, 2003, J CIRCADIAN RHYTHMS, V1, P2, DOI 10.1186/1740-3391-1-2##HARRIS RC, 2006, COX 2 KIDNEY, V47, PS37##JAINU M, 2005, ATTENUATION NEUTROPH, V5, P33##JAMES MJ, 2006, CURR OPIN CLIN NUTR, V9, P89, DOI 10.1097/01.MCO.0000214565.67439.83##JOHNS CE, 2005, AM J GASTROENTEROL, V100, P1491, DOI 10.1111/J.1572-0241.2005.41859.X##KONTUREK SJ, 2005, PROSTAGLANDINS ULCER, V56, PS5##KOUKKARI W.L., 2006, INTRO BIOL RHYTHMS P##KRAUSE I, 2005, PEDIATR NEPHROL, V20, P1295, DOI 10.1007/S00467-005-1966-X##LEE SKM, 2006, CURRENT CLIN APPL OM, V21, P323##LIU J, 2006, CIRCADIAN CLOCK PERI, V74, P4750##MAHMOUD F, 2005, THERAPEUTIC APPL MEL, V22, P295##MAYO JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/J.JNEUROIM.2005.05.002##NOLDIN VF, 2005, Z NATURFORSCH C, V60, P701##PAN YS, 2005, CLIN ENDOSCOPIC FEAT, V104, P804##REFINETTI R., 2006, CIRCADIAN PHYSL##SAITOH T, 2001, INTRAGASTRIC ACIDITY, V55, PS138##SAITOH T, 2002, EFFECT H2 BLOCKERS C, V56, PS349##SETTY AR, 2005, SEMIN ARTHRITIS RHEU, V34, P773, DOI 10.1016/J.SEMARTHRIT.2005.01.011##SOHAIL MT, 2005, PHYTOTHER RES, V19, P365, DOI 10.1002/PTR.1680##SOLANKAR AK, 2005, CHRONOBIOLOGICAL CHR, V43, P46##STAMP DH, 2006, BILE ACIDS AIDED ACI, V66, P154##TUGWELL P, 2005, J CLIN EPIDEMIOL, V58, P785, DOI 10.1016/J.JCLINEPI.2004.11.028##VAN DER STEEN WJ, 2005, CURRENT THEMES IN THEORETICAL BIOLOGY: A DUTCH PERSPECTIVE, P71##VAN DER STEEN WJ, 2003, ACTA BIOTHEOR, V51, P151, DOI 10.1023/A:1025119821313##VAN DER STEEN WJ, 2001, ACTA BIOTHEOR, V49, P125, DOI 10.1023/A:1010240129648##VAN DER STEEN WJ, 1993, PRACTICAL PHILOS LIF##VANDERSTEEN WJ, 1991, BRIT J PHILOS SCI, V42, P445, DOI 10.1093/BJPS/42.4.445##VANDERSTEEN WJ, 2003, BEYOND BOUNDARIES BI##WALDUM HL, 2005, ANTIULCER DRUGS GAST, V50, PS39##WOLFE MM, 1996, HOSP PRACT, V31, P37, DOI 10.1080/21548331.1996.11443389##YANG PY, 2004, J LIPID RES, V45, P1030, DOI 10.1194/JLR.M300455-JLR200##YOUNGSTEDT SD, 2001, J PINEAL RES, V31, P264, DOI 10.1034/J.1600-079X.2001.310311.X##YU WEN-YA, 2005, CHIN J INTEGR MED, V11, P255##YUAN Y, 2006, PEPTIC ULCER DIS TOD, V3, P80",0,2020-11-20,NA
J,WOS:000243430900031,2006,THEODOR BILLROTH 1829-1894,NA,NA,NA,ACTA CHIRURGICA BELGICA,"BUSMAN, DC",NA,SURGERY,SURGERY,"BILLROTH T, PUBLICATION LIST",9,2020-11-20,NA
J,WOS:000241992300022,2006,STRUCTURES OF MONO-UNSATURATED TRIACYLGLYCEROLS. I. THE BETA(1) POLYMORPH,"THE CRYSTAL STRUCTURES OF THE BETA(1) POLYMORPHS OF MONOUNSATURATED TRIACYLGLYCEROLS HAVE BEEN SOLVED FROM HIGH-RESOLUTION LABORATORY AND SYNCHROTRON POWDER DIFFRACTION DATA FOR FIVE PURE COMPOUNDS, THE 1,3-DIMYRISTOYL-2-OLEOYLGLYCEROL (BETA 1-MOM), 1,3-DIPALMITOYL-2-OLEOYLGLYCEROL (BETA(1)-POP), 1,3-DISTEAROYL-2-OLEOYLGLYCEROL (BETA(1)-SOS), 1-PALMITOYL-2-OLEOYL-3-STEAROYLGLYCEROL (BETA(1)-POS), 1-STEAROYL-2-OLEOYL-3-ARACHIDOYLGLYCEROL (BETA 1-SOA) AND THREE MIXTURES: THE CO-CRYSTALLIZED 1:1 MOLAR MIXTURE OF SOS AND POP [BETA(1)-SOS/POP (1:1)] AND TWO COCOA BUTTERS FROM BAHIA AND IVORY COAST, BOTH IN THEIR BETA-VI (= BETA 1) POLYMORPH. ALL EIGHT BETA 1 STRUCTURES CRYSTALLIZED IN THE SPACE GROUP (P2(1)/N) AND HAVE TWO SHORT CELL AXES (5.44-5.46 AND 8.18-8.22 A), AS WELL AS A VERY LONG B AXIS (112-135 A). THE DOMINANT-ZONE PROBLEM IN THE INDEXING OF THE POWDER PATTERNS WAS SOLVED WITH THE SPECIAL BRUTE-FORCE INDEXING ROUTINE LSQDETC FROM THE POWSIM PROGRAM. STRUCTURES WERE SOLVED USING THE DIRECT-SPACE PARALLEL-TEMPERING METHOD FOX AND REFINED WITH GSAS. ALONG THE B AXIS, ALTERNATIONS OF INVERSION-CENTRE- RELATED 'THREE- PACKS' CAN BE DISCERNED. EACH 'THREE-PACK' HAS A CENTRAL OLEIC ZONE, WITH OLEIC ACYL CHAINS OF THE MOLECULES BEING PACKED TOGETHER, THAT IS SANDWICHED BETWEEN TWO SATURATED-CHAIN ZONES. THE CONFORMATION OF THE TRIACYLGLYCEROL MOLECULES IS RELATIVELY 'FLAT' BECAUSE THE LEAST-SQUARE PLANES THROUGH THE SATURATED CHAINS AND THOSE THROUGH THE SATURATED PARTS OF THE OLEIN CHAIN ARE PARALLEL. THE SOLUTION OF THE BETA 1 STRUCTURES IS A STEP FORWARD TOWARDS UNDERSTANDING THE MECHANISM OF FAT-BLOOM FORMATION IN DARK CHOCOLATE AND HAS LED TO A REEXAMINATION OF THE BETA(2) STRUCTURAL MODEL.",CRYSTAL-STRUCTURE; COCOA BUTTER; BEHAVIOR; FORM,NA,ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE CRYSTAL ENGINEERING AND MATERIALS,"VAN MECHELEN, JB##PESCHAR, R##SCHENK, H","UNIV AMSTERDAM, HIMS FNWI KRISTALLOG, NL-1018 XE AMSTERDAM, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CRYSTALLOGRAPHY",CHEMISTRY; CRYSTALLOGRAPHY,"ABRAHAMSSON S, 1978, PROG CHEM FATS OTHER LIPIDS, V16, P125, DOI 10.1016/0079-6832(78)90039-3##ALLEN FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890##ARISHIMA T, 1991, J AM OIL CHEM SOC, V68, P710, DOI 10.1007/BF02662157##BECKETT S. T., 1999, IND CHOCOLATE MANUFA##CULOT C, 2000, ACTA CRYSTALLOGR B, V56, P317, DOI 10.1107/S0108768199014020##DEJONG S, 1991, J AM OIL CHEM SOC, V68, P371, DOI 10.1007/BF02663752##DOLLASE WA, 1986, J APPL CRYSTALLOGR, V19, P267, DOI 10.1107/S0021889886089458##DOYNE TH, 1968, J AM OIL CHEM SOC, V45, P333, DOI 10.1007/BF02667104##FAVRE-NICOLIN V, 2002, J APPL CRYSTALLOGR, V35, P734, DOI 10.1107/S0021889802015236##FILER LJ, 1946, J AM CHEM SOC, V68, P167, DOI 10.1021/JA01206A002##GIBON V, 1984, B SOC CHIM BELG, V93, P27##GOTO M, 1992, P NATL ACAD SCI USA, V89, P8083, DOI 10.1073/PNAS.89.17.8083##HELMHOLDT RB, 2002, ACTA CRYSTALLOGR B, V58, P134, DOI 10.1107/S0108768101016330##JENSEN LH, 1966, ACTA CRYSTALLOGR, V21, P770, DOI 10.1107/S0365110X66003839##LARSON AC, 1987, LAUR86748 GSAS##LARSSON K, 1965, ARK KEMI, V23, P1##LARSSON K, 1972, FETTE SEIFEN ANSTR V, V74, P136, DOI 10.1002/LIPI.19720740302##LAUGIER J, 2001, CHEKCELL##MARCH A, 1932, Z KRISTALLOGR, V81, P285##PESCHAR R, 2004, J PHYS CHEM B, V108, P15450, DOI 10.1021/JP046723C##PESCHAR R, 2002, STRUCTURE DETERMINAT, PCH10##SATO K, 2001, J LIPID RES, V42, P338##SATO K, 2001, CRYSTALLIZATION PROC, PCH5##SCHLENK W, 1965, J AM OIL CHEM SOC, V42, P945, DOI 10.1007/BF02632453##TAKAGI T, 1995, J AM OIL CHEM SOC, V72, P1203, DOI 10.1007/BF02540989##VAN LANGEVELDE A, 1999, ACTA CRYSTALLOGR B, V55, P114, DOI 10.1107/S0108768198009392##VAN LANGEVELDE A, 2000, ACTA CRYSTALLOGR B, V56, P1103, DOI 10.1107/S0108768100009927##VAN LANGEVELDE A, 2001, ACTA CRYSTALLOGR B, V57, P372, DOI 10.1107/S0108768100019121##VAN LANGEVELDE A, 2001, CHEM MATER, V13, P1089, DOI 10.1021/CM001190F##VAN MALSSEN K, 1999, J AM OIL CHEM SOC, V76, P669, DOI 10.1007/S11746-999-0158-4##VAN MECHELEN JB, 2006, ACTA CRYSTALLOGR B, V62, P1131, DOI 10.1107/S0108768106037086##VAND V, 1951, ACTA CRYSTALLOGR, V4, P465, DOI 10.1107/S0365110X5100146X##VANMALSSEN K, 1996, J AM OIL CHEM SOC, V73, P1217, DOI 10.1007/BF02525449##WILLE RL, 1966, J AM OIL CHEM SOC, V43, P491, DOI 10.1007/BF02641273##YANO J, 1993, J PHYS CHEM-US, V97, P12967, DOI 10.1021/J100151A053",41,2020-11-20,NA
J,WOS:000241992300023,2006,STRUCTURES OF MONO-UNSATURATED TRIACYLGLYCEROLS. II. THE BETA(2) POLYMORPH,"AN IMPROVED CRYSTAL STRUCTURE MODEL HAS BEEN ESTABLISHED FOR THE BETA(2) POLYMORPH OF THE SYMMETRIC MONO-UNSATURATED TRIACYLGLYCEROL 1,3-DISTEAROYL-2-OLEOYLGLYCEROL (SOS) AND THE EQUIVALENT BETA-V POLYMORPH OF IVORY COAST COCOA BUTTER. IN ADDITION, THE CRYSTAL STRUCTURES OF THE BETA(2) POLYMORPHS ARE REPORTED FOR THE TRIACYLGLYCEROLS 1,3-DIPALMITOYL-2-OLEOYLGLYCEROL (POP) AND 1-PALMITOYL-2-OLEOYL-3-STEAROYLGLYCEROL (POS), WHICH ARE, TOGETHER WITH SOS, THE MAJOR COMPONENTS OF COCOA BUTTER, AND THAT OF 1-STEAROYL-2-OLEOYL-3-ARACHIDOYLGLYCEROL (SOA). THE EXISTENCE OF BETA 2-POS AND BETA 2-SOA HAS NOT BEEN PREVIOUSLY REPORTED IN THE LITERATURE. ALL STRUCTURES HAVE BEEN SOLVED FROM HIGH-RESOLUTION LABORATORY OR SYNCHROTRON POWDER DIFFRACTION DATA WITH THE DIRECT-SPACE PARALLEL-TEMPERING PROGRAM FOX AND REFINED WITH THE RIETVELD MODULE OF GSAS. ALL COMPOUNDS CRYSTALLIZE IN SIMILAR MONOCLINIC UNIT CELLS (CC) WITH VERY LONG B AXES (> 127 A). THE OLEIC CHAINS ARE PACKED TOGETHER AND SANDWICHED BETWEEN SATURATED CHAIN LAYERS, FORMING ACYL-CHAIN THREE-PACKS. AN ANALYSIS OF THE BETA(2) POLYMORPHS AND BETA(1) POLYMORPHS [VAN MECHELEN ET AL. (2006). ACTA CRYST. B62, 1121-1130] SHOWS THAT THEY CONTAIN THE SAME THREE-PACKS AND DIFFER ONLY IN THE SYMMETRY RELATION BETWEEN THE THREE-PACKS. THE THREE- PACK BUILD- UP PROVIDES AN EXPLANATION OF THE MECHANISM OF THE PHASE TRANSITION THAT CAUSES THE FORMATION OF FAT BLOOM ON DARK CHOCOLATE.",FAT BLOOM; CRYSTAL-STRUCTURES; MELTING-POINTS; CHOCOLATE; SOS; POP,NA,ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE CRYSTAL ENGINEERING AND MATERIALS,"VAN MECHELEN, JB##PESCHAR, R##SCHENK, H","UNIV AMSTERDAM, HIMS FNWI KRISTALLOG, NL-1018 XE AMSTERDAM, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CRYSTALLOGRAPHY",CHEMISTRY; CRYSTALLOGRAPHY,"DEJONG S, 1991, J AM OIL CHEM SOC, V68, P371, DOI 10.1007/BF02663752##DOLLASE WA, 1986, J APPL CRYSTALLOGR, V19, P267, DOI 10.1107/S0021889886089458##FAVRE-NICOLIN V, 2002, J APPL CRYSTALLOGR, V35, P734, DOI 10.1107/S0021889802015236##HELMHOLDT RB, 2002, ACTA CRYSTALLOGR B, V58, P134, DOI 10.1107/S0108768101016330##KOYANO T, 1990, FOOD STRUCT, V9, P231##LARSON AC, 1987, LAUR86748 GSAS##LAUGIER J, 2001, CHEKCELL##LONCHAMPT P, 2004, EUR J LIPID SCI TECH, V106, P241, DOI 10.1002/EJLT.200400938##LOVEGREN NV, 1976, J AM OIL CHEM SOC, V53, P519, DOI 10.1007/BF02586251##LOVEGREN NV, 1978, J AM OIL CHEM SOC, V55, P310, DOI 10.1007/BF02669918##MARCH A, 1932, Z KRISTALLOGR, V81, P285##*MOL SIM INC, 2000, CER REL 4 2##PESCHAR R, 2004, J PHYS CHEM B, V108, P15450, DOI 10.1021/JP046723C##SATO K, 1989, J AM OIL CHEM SOC, V66, P664, DOI 10.1007/BF02669949##SPRUNT JC, 2000, PHYS CHEM CHEM PHYS, V2, P4299, DOI 10.1039/B003894F##VAN LANGEVELDE A, 2001, J AM OIL CHEM SOC, V78, P919, DOI 10.1007/S11746-001-0364-2##VAN LANGEVELDE A, 2001, CHEM MATER, V13, P1089, DOI 10.1021/CM001190F##VANMECHELAN HB, 2006, ACTA CRYSTALLOGR B, V62, P1121##YANO J, 1993, J PHYS CHEM-US, V97, P12967, DOI 10.1021/J100151A053",42,2020-11-20,NA
J,WOS:000242434600079,2006,"GAMMA-TRIS(2,4-PENTANEDIONATO-KAPPA O-2,O ')ALUMINIUM(III) AT 110 K","THE TITLE COMPOUND, [AL(C5H7O2)(3)], WAS REINVESTIGATED AT 110 K TO PROVIDE INFORMATION ON THERMAL VIBRATIONS IN THE STRUCTURE, COMPARING IT TO THE PREVIOUSLY PUBLISHED STRUCTURE BY MCCLELLAND [ACTA CRYST. (1975), B31, 2496-2498] BASED ON ROOM-TEMPERATURE DATA. THE GAMMA-POLYMORPH CONTAINS FOUR INDEPENDENT MOLECULES IN THE ASYMMETRIC UNIT WITH THEIR CENTERS OF GRAVITY AT PSEUDO-SPECIAL POSITIONS.",PROGRAM,NA,ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS,"VON CHRZANOWSKI, LS##LUTZ, M##SPEK, AL","UNIV UTRECHT, BIJVOET CTR BIOMOL RES CRYSTAL & STRUCT CHEM, NL-3584 CH UTRECHT, NETHERLANDS.",CRYSTALLOGRAPHY,CRYSTALLOGRAPHY,"ABRAHAMS SC, 1971, ACTA CRYSTALL A-CRYS, VA 27, P157, DOI 10.1107/S0567739471000305##DUISENBERG AJM, 2003, J APPL CRYSTALLOGR, V36, P220, DOI 10.1107/S0021889802022628##FLACK HD, 2000, J APPL CRYSTALLOGR, V33, P1143, DOI 10.1107/S0021889800007184##FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762##HUMMEL W, 1990, J MOL GRAPHICS, V8, P214, DOI 10.1016/0263-7855(90)80006-2##MCCLELLAND BW, 1975, ACTA CRYSTALLOGR B, V31, P2496, DOI 10.1107/S056774087500787X##NONIUS, 1999, COLLECT##PILATI T, 1998, J APPL CRYSTALLOGR, V31, P503, DOI 10.1107/S0021889898002180##SCHOMAKER V, 1998, ACTA CRYSTALLOGR B, V54, P507, DOI 10.1107/S0108768198003243##SCHREURS AMM, 2005, PEAKREF##SHELDRICK G. M., 1997, SHELXL97##SHELDRICK G.M., 2002, SADABS##SPEK AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112",8,2020-11-20,NA
J,WOS:000242434600175,2006,CHLORODIETHYL[4-(4-NITROPHENYL)PIPERAZINE-1-CARBODITHIOATO]TIN(IV),"THE MOLECULE OF THE TITLE COMPOUND, [SN(C2H5)(2)(C11H12N3O2S2)CL], FEATURES AN ASYMMETRICALLY CHELATING THIOCARBOXYLATE LIGAND. THE SN ATOM IS FIVE-COORDINATE WITHIN A C2CLS2 DONOR SET THAT IS BEST DESCRIBED AS TRIGONAL BIPYRAMIDAL WITH S AND CL ATOMS IN AXIAL POSITIONS, DEFINING A BOND ANGLE OF 156.58 (2)DEGREES.",NA,NA,ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE,"ZIA-UR-RAHMAN##ALI, S##MUHAMMAD, N##MEETSMA, A","QUAID I AZAM UNIV, DEPT CHEM, ISLAMABAD 45320, PAKISTAN. UNIV GRONINGEN, CRYSTAL STRUCT CTR, CTR MAT SCI, NL-9747 AG GRONINGEN, NETHERLANDS.",CRYSTALLOGRAPHY,CRYSTALLOGRAPHY,"BEURSKENS P.T., 1999, DIRDIF99 PROGRAM SYS##*BRUK AXS INC, 2000, SMART VERS 5 624 SAI##SHELDRICK G. M., 1997, SHELXL97##SHELDRICK GM, 2001, SADABS VERSION 2 03##SPEK AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112##STIEFEL E.I., 1995, ACS SYM SER, V653, P2##TIEKINK ERT, 1992, MAIN GROUP MET CHEM, V15, P161, DOI DOI 10.1002/CHIN.199321265",2,2020-11-20,NA
J,WOS:000242429700033,2006,CRYSTALLIZATION AND PRELIMINARY X-RAY ANALYSIS OF AN ALDITOL OXIDASE FROM STREPTOMYCES COELICOLOR A3(2),"ALDITOL OXIDASE IS A 45 KDA ENZYME CONTAINING A COVALENTLY BOUND FAD COFACTOR. THIS OXIDASE EFFICIENTLY OXIDIZES A RANGE OF ALDITOLS TO THE CORRESPONDING ALDOSES. OWING TO ITS SUBSTRATE RANGE AND REGIOSELECTIVITY, THIS ENZYME IS AN INTERESTING CANDIDATE FOR BIOTECHNOLOGICAL APPLICATIONS. CRYSTALS OF ALDITOL OXIDASE FROM STREPTOMYCES COELICOLOR A3(2) WERE OBTAINED BY THE HANGING-DROP VAPOUR-DIFFUSION METHOD AND DIFFRACTED TO 1.1 ANGSTROM RESOLUTION. THE CRYSTALS BELONG TO SPACE GROUP C2, WITH UNIT-CELL PARAMETERS A = 107, B = 68, C = 58 ANGSTROM, BETA = 94 DEGREES. CRYSTALS OF SELENO-L-METHIONINE-LABELLED ALDITOL OXIDASE WERE OBTAINED AFTER SEEDING THE CRYSTALLIZATION DROPS WITH NATIVE MICROCRYSTALS AND SHOWED A DIFFRACTION LIMIT OF 2.4 ANGSTROM.",NA,NA,ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS,"FORNERIS, F##ROVIDA, S##HEUTS, DPHM##FRAAIJE, MW##MATTEVI, A","UNIV PAVIA, DEPT GENET & MICROBIOL, I-27100 PAVIA, ITALY. UNIV GRONINGEN, BIOCHEM LAB, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, NL-9747 AG GRONINGEN, NETHERLANDS.",BIOCHEMICAL RESEARCH METHODS; BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS; CRYSTALLOGRAPHY,BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS; CRYSTALLOGRAPHY,"COLLABORATIVE COMPUTATIONAL PROJECT, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112##DOUBLIE S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0##DUCRUIX A., 1992, CRYSTALLIZATION NUCL, P73##FRAAIJE MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9##HEUTS DPH, 2007, UNPUB##LESLIE AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X##MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2##STURA EA, 1992, CRYSTALLIZATION NUCL, P99",2,2020-11-20,NA
J,WOS:000242779300023,2006,MICROSTRUCTURAL MODIFICATIONS INDUCED BY HYDROGEN ABSORPTION IN MG5GA2 AND MG6PD,WE HAVE RECENTLY PROPOSED A NEW METHOD TO DESIGN ONE-DIMENSIONAL STRUCTURES OF MGH2 IN THE NANO- AND MICROMETER RANGES BY HYDROGEN-INDUCED DISPROPORTIONATION OF BULK MG24Y5. THE PRESENT STUDY CONFIRMS THE SAME BEHAVIOR IN HYDROGENATED MG5GA2 AND MG6PD. SINGLE-CRYSTALLINE ONE-DIMENSIONAL STRUCTURES AND MICROPARTICLES OF MGH2 ARE FORMED BY HYDROGEN ABSORPTION AND SUBSEQUENT PARTIAL DISPROPORTIONATION OF MG5GA2 AND MG6PD. THE MGH2 WHISKERS AND PARTICLES GROW WITH DIFFERENT MORPHOLOGIES FOR DIFFERENT ALLOYING PARTNERS. GROWTH MECHANISMS ARE PROPOSED IN RELATION TO THE MORPHOLOGY AND THE CHEMICAL SURFACE COMPOSITION OF ORIGINAL COMPOUNDS. (C) 2006 ACTA MATERIALIA INC. PUBLISHED BY ELSEVIER LTD. ALL RIGHTS RESERVED.,SURFACE-ANALYSIS; MAGNESIUM; ALLOYS,MAGNESIUM INTERMETALLICS; HYDRIDE; MICROSTRUCTURE; SURFACE PROPERTIES,ACTA MATERIALIA,"ZLOTEA, C##ANDERSSON, Y","EUROPEAN COMMISS, JOINT RES CTR, INST ENERGY, NL-1755 ZG PETTEN, NETHERLANDS. UPPSALA UNIV, DEPT CHEM MAT, S-75121 UPPSALA, SWEDEN.","MATERIALS SCIENCE, MULTIDISCIPLINARY; METALLURGY & METALLURGICAL ENGINEERING",MATERIALS SCIENCE; METALLURGY & METALLURGICAL ENGINEERING,"*AMS INT, 1996, BIN ALL PHAS DIAGR##[ANONYMOUS], 1996, SOLID STATE PHENOMEN, V49-50##DICK KA, 2004, NAT MATER, V3, P380, DOI 10.1038/NMAT1133##FERRO R, 1959, J LESS-COMMON MET, V1, P424, DOI 10.1016/0022-5088(59)90060-8##FESCHOTTE P, 1990, J LESS-COMMON MET, V158, P89, DOI 10.1016/0022-5088(90)90434-L##HERLEY PJ, 1985, J APPL PHYS, V58, P292, DOI 10.1063/1.335674##IWAMURA E, 1999, THIN SOLID FILMS, V349, P191, DOI 10.1016/S0040-6090(99)00220-5##KUME Y, 1987, J LESS-COMMON MET, V136, P51, DOI 10.1016/0022-5088(87)90008-7##LEWIS FA, 2000, SOLID STATE PHENOMEN, V73-75, P207, DOI 10.4028/WWW.SCIENTIFIC.NET/SSP.73-75.207##MIEDEMA AR, 1978, Z METALLKD, V69, P287##REILLY JJ, 1968, INORG CHEM, V7, P2254, DOI 10.1021/IC50069A016##SAMSON S, 1972, ACTA CRYSTALL B-STRU, VB 28, P936##SCHLAPBACH L, 1979, MATER RES BULL, V14, P1235, DOI 10.1016/0025-5408(79)90220-4##SCHUBERT K, 1963, Z METALLKD, V54, P422##SEILER A, 1980, J LESS-COMMON MET, V73, P193, DOI 10.1016/0022-5088(80)90360-4##SELVAM P, 1986, INT J HYDROGEN ENERG, V11, P169, DOI 10.1016/0360-3199(86)90082-0##SELVAM P, 1990, J LESS-COMMON MET, V163, P89, DOI 10.1016/0022-5088(90)90088-2##SMOGUNOV AN, 1997, SURF SCI, V391, P245, DOI 10.1016/S0039-6028(97)00488-3##TAKESHITA T, 1993, J ALLOY COMPD, V193, P231, DOI 10.1016/0925-8388(93)90356-R##WAGMAN DD, 1982, J PHYS CHEM REF DATA, V11, P1##WAGNER CD, 1979, HDBH XRAY PHOTOELECT##ZALUSKA A, 2001, APPL PHYS A-MATER, V72, P157, DOI 10.1007/S003390100783##ZLOTEA C, 2006, J ALLOY COMPD, V426, P357, DOI 10.1016/J.JALLCOM.2006.02.024##ZUTTEL A, 2003, MATER TODAY, V6, P24, DOI DOI 10.1016/S1369-7021(03)00922-2",12,2020-11-20,NA
J,WOS:000242623300004,2006,UNILATERAL PALLIDOTOMY VERSUS BILATERAL SUBTHALAMIC NUCLEUS STIMULATION IN PARKINSON'S DISEASE: ONE YEAR FOLLOW-UP OF A RANDOMISED OBSERVER-BLIND MULTI CENTRE TRIAL,"BACKGROUND. TO INVESTIGATE WHETHER STN STIMULATION IS MORE EFFICACIOUS THAN UNILATERAL PALLIDOTOMY IN ADVANCED PARKINSON'S DISEASE (PD) ONE YEAR AFTER SURGERY. METHOD. THIRTY-FOUR PATIENTS WITH ADVANCED PD WERE RANDOMLY ASSIGNED TO UNILATERAL PALLIDOTOMY OR BILATERAL STN STIMULATION. OUTCOME MEASURES WERE PARKINSONIAN SYMPTOMS IN OFF AND ON PHASES (UPDRS 3), DYSKINESIAS, FUNCTIONAL STATUS, PARKINSON'S DISEASE QUALITY OF LIFE QUESTIONNAIRE, THE EFFECTS ON SEPARATE SYMPTOMS, TIMED TESTS, PATIENT DIARIES, DOPAMINERGIC DRUGS CHANGES, ADVERSE EFFECTS, AND GLOBAL OUTCOME SCALE. PATIENTS WERE ASSESSED BEFORE SURGERY, SIX MONTHS AND ONE YEAR AFTER SURGERY. THE PRIMARY OUTCOME MEASURE WAS THE OFF PHASE UPDRS 3 AT SIX MONTHS FOLLOW-UP. FINDINGS. THE OFF PHASE UPDRS 3 SCORE IMPROVED FROM 46.5 TO 32 POINTS IN THE PALLIDOTOMY PATIENTS AND FROM 51.5 TO 24 IN THE STN STIMULATION PATIENTS (P = 0.002). ON PHASE UPDRS 3 AND OFF PHASE SCHWAB AND ENGLAND FUNCTIONAL SCALE IMPROVED SIGNIFICANTLY IN FAVOUR OF THE STN STIMULATION PATIENTS. DOPAMINERGIC DRUGS REDUCTION WAS LARGER IN THE STN GROUP ALTHOUGH THE DIFFERENCE BETWEEN THE TREATMENT GROUPS WAS NOT SIGNIFICANT. ONE PATIENT IN EACH GROUP HAD A MAJOR ADVERSE EFFECT. CONCLUSIONS. BILATERAL STN STIMULATION IS MORE EFFICACIOUS THAN UNILATERAL PALLIDOTOMY IN ADVANCED PD UP TO ONE YEAR AFTER SURGERY.",DEEP-BRAIN-STIMULATION; PD; MULTICENTER,PARKINSON'S DISEASE; PALLIDOTOMY; SUBTHALAMIC NUCLEUS STIMULATION; RANDOMISED CONTROLLED TRIAL,ACTA NEUROCHIRURGICA,"ESSELINK, RAJ##DE BIE, RMA##DE HAAN, RJ##STEUR, ENHJ##BEUTE, GN##PORTMAN, AT##SCHUURMAN, PR##BOSCH, DA##SPEELMAN, JD","UNIV AMSTERDAM, ACAD MED CTR, DEPT NEUROL, NL-1100 DD AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, NL-1100 DD AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT NEUROSURG, NL-1100 DD AMSTERDAM, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, DEPT NEUROL & GERIATR, NIJMEGEN, NETHERLANDS. MED SPECTRUM TWENTE, DEPT NEUROL, ENSCHEDE, NETHERLANDS. ST ELIZABETH HOSP, DEPT NEUROSURG, TILBURG, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT NEUROL, GRONINGEN, NETHERLANDS.",CLINICAL NEUROLOGY; SURGERY,NEUROSCIENCES & NEUROLOGY; SURGERY,"ANDERSON VC, 2005, ARCH NEUROL-CHICAGO, V62, P554, DOI 10.1001/ARCHNEUR.62.4.554##CHARLES PD, 2002, NEUROLOGY, V59, P932, DOI 10.1212/WNL.59.6.932##DE BIE RMA, 1999, LANCET, V354, P1665, DOI 10.1016/S0140-6736(99)03556-4##DE BIE RMA, 2001, J NEUROL NEUROSUR PS, V71, P375, DOI 10.1136/JNNP.71.3.375##DEBOER AGEM, 1996, J NEUROL NEUROSUR PS, V61, P70, DOI 10.1136/JNNP.61.1.70##DEFER GL, 1999, MOVEMENT DISORD, V14, P572, DOI 10.1002/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C##ESSELINK RAJ, 2004, NEUROLOGY, V62, P201, DOI 10.1212/01.WNL.0000103235.12621.C3##FAHN S, 1987, RECENT DEV PARKINSON, V2, P153##FRAIX V, 2006, J NEUROL NEUROSUR PS, V77, P443, DOI 10.1136/JNNP.2005.077677##FUNKIEWIEZ A, 2003, MOVEMENT DISORD, V18, P524, DOI 10.1002/MDS.10441##GELB DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/ARCHNEUR.56.1.33##HAGELL P, 1999, MOVEMENT DISORD, V14, P448, DOI 10.1002/1531-8257(199905)14:3<448::AID-MDS1010>3.0.CO;2-0##HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427##HOUETO JL, 2000, ARCH NEUROL-CHICAGO, V57, P461, DOI 10.1001/ARCHNEUR.57.4.461##KRACK P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMOA035275##KRACK P, 1998, BRAIN, V121, P451, DOI 10.1093/BRAIN/121.3.451##KUMAR R, 1999, NEUROLOGY, V53, P561, DOI 10.1212/WNL.53.3.561##LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/JNS.1992.76.1.0053##LANG AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503##LIMOUSIN P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603##MATTIS S, 1976, GERIATRIC PSYCHIAT, P77##MEISSNER W, 2005, J NEUROL, V252, P218, DOI 10.1007/S00415-005-0640-3##OBESO JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/NEJMOA000827##RODRIGUEZ-OROZ MC, 2005, BRAIN, V128, P2240, DOI 10.1093/BRAIN/AWH571##SCHUPBACH WMM, 2005, J NEUROL NEUROSUR PS, V76, P1640, DOI 10.1136/JNNP.2005.063206##SMEDING HMM, 2006, NEUROLOGY, V66, P1830, DOI 10.1212/01.WNL.0000234881.77830.66##VOLKMANN J, 2001, NEUROLOGY, V56, P548, DOI 10.1212/WNL.56.4.548",27,2020-11-20,NA
J,WOS:000242623300012,2006,RELATION BETWEEN SIZE OF ANEURYSMS AND RISK OF REBLEEDING IN PATIENTS WITH SUBARACHNOID HAEMORRHAGE,"BACKGROUND AND PURPOSE. FEW RISK FACTORS HAVE BEEN IDENTIFIED FOR REBLEEDING IN PATIENTS WITH SUBARACHNOID HAEMORRHAGE. WE STUDIED WHETHER SIZE OF ANEURYSM AFTER RUPTURE IS A RISK FACTOR FOR REBLEEDING. SINCE INTRACRANIAL ANEURYSMS DEVELOP DURING LIFE AND MAY THEREFORE BE LARGER AT AN OLDER AGE, WE ALSO ASSESSED WHETHER AGE CONFOUNDS A RELATION BETWEEN SIZE AND REBLEEDING. METHODS. WE STUDIED ALL PATIENTS WITH ANEURYSMAL SUBARACHNOID HAEMORRHAGE ADMITTED BETWEEN 1995 AND 2000. SINCE 1995 CT-ANGIOGRAPHY IS OBTAINED IN ALL PATIENTS ON ADMISSION. PATIENTS WERE FOLLOWED UNTIL REBLEEDING, OPERATION, DISCHARGE OR DEATH. FOR THE RELATION BETWEEN SIZE AND RISK OF REBLEEDING WE USED COX PROPORTIONAL HAZARDS MODELLING. RESULTS. WE INCLUDED 354 PATIENTS. REBLEEDING OCCURRED IN 22 (30%) OF THE 73 PATIENTS WITH A LARGE (> 10 MM) ANEURYSM, AND IN 68 (24%) OF THE 281 PATIENTS WITH A SMALL (<= 10 MM) ANEURYSM (HAZARD RATIO FOR LARGE ANEURYSMS 1.6 (95% CONFIDENCE INTERVAL [CI] 1.0-2.6)). WITHIN THE FIRST THREE DAYS REBLEEDING OCCURRED IN 14 (19.2%) PATIENTS WITH A LARGE ANEURYSM AND IN 25 (8.9%) PATIENTS WITH A SMALL ANEURYSM (HAZARD RATIO 2.4 (95% CI 1.2-4.5)). AFTER ADJUSTMENT FOR AGE, ALL HAZARD RATIOS REMAINED ESSENTIALLY THE SAME. CONCLUSION. PATIENTS WITH LARGE ANEURYSMS HAVE A HIGHER RISK FOR REBLEEDING, IN PARTICULAR WITHIN THE FIRST THREE DAYS AFTER THE INITIAL HAEMORRHAGE. THIS INCREASED RISK IS INDEPENDENT OF AGE.",INTRACRANIAL ANEURYSMS,ANEURYSM; SUBARACHNOID HAEMORRHAGE; COMPLICATION; AGE,ACTA NEUROCHIRURGICA,"PLEIZIER, CM##ALGRA, A##VELTHUIS, BK##RINKEL, GJE","UNIV UTRECHT, MED CTR, DEPT NEUROL, RUDOLF MAGNUS INST NEUROSCI, NL-3500 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3500 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT RADIOL, NL-3500 GA UTRECHT, NETHERLANDS.",CLINICAL NEUROLOGY; SURGERY,NEUROSCIENCES & NEUROLOGY; SURGERY,"DRAKE CG, 1988, J NEUROSURG, V68, P985##JUVELA S, 2001, STROKE, V32, P485, DOI 10.1161/01.STR.32.2.485##LANZINO G, 1996, J NEUROSURG, V85, P410, DOI 10.3171/JNS.1996.85.3.0410##LINN FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625##POCOCK SJ, 2002, LANCET, V359, P1686, DOI 10.1016/S0140-6736(02)08594-X##RINKEL GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251##ROOS EJ, 2000, NEUROLOGY, V54, P2334, DOI 10.1212/WNL.54.12.2334##ROOS YBWEM, 2000, J NEUROL NEUROSUR PS, V68, P337, DOI 10.1136/JNNP.68.3.337##WIEBERS D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3",16,2020-11-20,NA
J,WOS:000242623300024,2006,BASILAR IMPRESSION IN OSTEOGENESIS IMPERFECTA: CAN IT BE TREATED WITH HALO TRACTION AND POSTERIOR FUSION?,"BASILAR IMPRESSION (BI) AND HYDROCEPHALUS COMPLICATING OSTEOGENESIS IMPERFECTA (OI) IS USUALLY TREATED BY ANTERIOR TRANSORAL DECOMPRESSION AND POSTERIOR FIXATION. NEVERTHELESS, IT MAY BE QUESTIONED IF POSTERIOR FUSION FOLLOWING AXIAL HALO TRACTION IS ADEQUATE IN PATIENTS WITH SYMPTOMATIC BI COMPLICATING OI. WE REPORT ON A CASE WITH PROGRESSIVE SYMPTOMATIC HYDROCEPHALUS AND BI COMPLICATING OI THAT WAS SUCCESSFULLY TREATED BY HALO TRACTION FOLLOWED BY POSTERIOR OCCIPITOCERVICAL FUSION. HOWEVER, AFTER A SYMPTOM FREE INTERVAL OF 2 YEARS THE PATIENT SUFFERED FROM RECURRENCE OF SYMPTOMATIC HYDROCEPHALUS NEEDING ADDITIONAL VENTRICULOPERITONEAL(VP) SHUNT PLACEMENT. IN CONCLUSION, POSTERIOR FUSION WITHOUT ADDITIONAL VP SHUNT PLACEMENT MAY NOT BE EFFECTIVE IN THE LONG TERM FOR AMELIORATING SYMPTOMS AND SIGNS AND HALTING PROGRESSIVE HYDROCEPHALUS IN BI COMPLICATING OI.",PIN-SITE COMPLICATIONS; HYDROCEPHALUS; INVAGINATION; MANAGEMENT; NECK,OSTEOGENESIS IMPERFECTA; BASILAR IMPRESSION; HYDROCEPHALUS; HALO TRACTION; OCCIPITOCERVICAL FUSION,ACTA NEUROCHIRURGICA,"NOSKE, DP##VAN ROYEN, BJ##BRON, JL##VANDERTOP, WP","VRIJE UNIV AMSTERDAM, MED CTR, DEPT ORTHOPAED SURG, NL-1007 MB AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, DEPT NEUROSURG, NL-1007 MB AMSTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY; SURGERY,NEUROSCIENCES & NEUROLOGY; SURGERY,"BHANGOO RS, 1999, CLIN ORTHOP RELAT R, P115##CHARNAS LR, 1993, NEUROLOGY, V43, P2603, DOI 10.1212/WNL.43.12.2603##COPPERMAN SM, 1984, JAMA-J AM MED ASSOC, V252, P3367, DOI 10.1001/JAMA.1984.03350240017021##ENGELBERT RHH, 1998, ACTA ORTHOP SCAND, V69, P283, DOI 10.3109/17453679809000931##FRANK E, 1982, SURG NEUROL, V17, P116, DOI 10.1016/S0090-3019(82)80033-5##HANLO PW, 2003, J NEUROSURG, V99, P52, DOI 10.3171/JNS.2003.99.1.0052##HARKEY HL, 1990, NEUROSURGERY, V27, P782##HAYES M, 1999, J NEUROL NEUROSUR PS, V66, P357, DOI 10.1136/JNNP.66.3.357##JANUS GJM, 2003, EUR J RADIOL, V47, P19, DOI 10.1016/S0720-048X(02)00179-1##MCBRIDE DQ, 1985, NEW ENGL J MED, V312, P186##MCNEIL SL, 1987, ANN EMERG MED, V16, P114, DOI 10.1016/S0196-0644(87)80300-1##MENEZES ARNOLD H., 1996, P2729##NAKAMURA MASAHIRO, 2002, SPINE (PHILA PA 1976), V27, PE224, DOI 10.1097/00007632-200204150-00025##NEMETH JA, 2001, J BONE JOINT SURG AM, V83A, P377, DOI 10.2106/00004623-200103000-00009##POZO JL, 1984, J BONE JOINT SURG BR, V66, P233##PRIMORAC D, 2001, CROAT MED J, V42, P393##RAMIREZ B, 1984, JAMA-J AM MED ASSOC, V252, P3366, DOI 10.1001/JAMA.1984.03350240016019##SAWIN PD, 1997, J NEUROSURG, V86, P950, DOI 10.3171/JNS.1997.86.6.0950##SILLENCE D, 1981, CLIN ORTHOP RELAT R, P11##SILLENCE DO, 1994, PEDIATR RADIOL, V24, P427, DOI 10.1007/BF02011910##TUITE GF, 1996, J NEUROSURG, V84, P573, DOI 10.3171/JNS.1996.84.4.0573##VERTULLO CJ, 1997, SPINE, V22, P2514, DOI 10.1097/00007632-199711010-00010",6,2020-11-20,NA
J,WOS:000242623300034,2006,UNTITLED,NA,CARPAL-TUNNEL-SYNDROME,NA,ACTA NEUROCHIRURGICA,"VERHAGEN, WIM##BARTELS, RHMA","CANISISUS WILHELMINA HOSP, DEPT NEUROL, NL-6532 SZ NIJMEGEN, NETHERLANDS. NEUROSURG CTR NIJMEGEN, NL-6532 SZ NIJMEGEN, NETHERLANDS.",CLINICAL NEUROLOGY; SURGERY,NEUROSCIENCES & NEUROLOGY; SURGERY,"HAIR JR J.F., 1998, MULTIVAR DATA ANAL, P166##PADUA L, 2001, CLIN NEUROPHYSIOL, V112, P1946, DOI 10.1016/S1388-2457(01)00637-X##PAZZAGLIA C, 2005, ACT NEUR S, V92, P35",0,2020-11-20,NA
J,WOS:000244297800006,2006,"A LONGITUDINAL TWIN STUDY ON IQ, EXECUTIVE FUNCTIONING, AND ATTENTION PROBLEMS DURING CHILDHOOD AND EARLY ADOLESCENCE","VARIATION IN HUMAN BEHAVIOR MAY BE CAUSED BY DIFFERENCES IN GENOTYPE AND BY NON-GENETIC DIFFERENCES (""ENVIRONMENT"") BETWEEN INDIVIDUALS. THE RELATIVE CONTRIBUTIONS OF GENOTYPE (G) AND ENVIRONMENT (E) TO PHENOTYPIC VARIATION CAN BE ASSESSED WITH THE CLASSICAL TWIN DESIGN. WE ILLUSTRATE THIS APPROACH WITH LONGITUDINAL DATA COLLECTED IN 5 AND 12-YEAR-OLD DUTCH TWINS. AT AGE 5 DATA ON COGNITIVE ABILITIES AS ASSESSED WITH A STANDARD INTELLIGENCE TEST (IQ), WORKING MEMORY, SELECTIVE AND SUSTAINED ATTENTION, AND ATTENTION PROBLEMS WERE COLLECTED IN 237 TWIN PAIRS. SEVEN YEARS LATER 172 TWIN PAIRS PARTICIPATED AGAIN WHEN THEY WERE 12 YEARS OLD AND UNDERWENT A SIMILAR PROTOCOL. RESULTS SHOWED THAT VARIATION IN ALL PHENOTYPES WAS INFLUENCED BY GENETIC FACTORS. FOR IQ THE HERITABILITY ESTIMATES INCREASED FROM 30% AT AGE 5, TO 80% AT AGE 12. FOR EXECUTIVE FUNCTIONING PERFORMANCE GENETIC FACTORS ACCOUNTED FOR AROUND 50% OF THE VARIANCE AT BOTH AGES. ATTENTION PROBLEMS SHOWED HIGH HERITABILITIES (ABOVE 60%) AT BOTH AGES, FOR MATERNAL AND TEACHER RATINGS. LONGITUDINAL ANALYSES REVEALED THAT EXECUTIVE FUNCTIONING DURING CHILDHOOD WAS WEAKLY CORRELATED WITH IQ SCORES AT AGE 12. ATTENTION PROBLEMS DURING CHILDHOOD, AS RATED BY THE MOTHER AND THE TEACHER WERE STRONGER PREDICTORS (R = -0.28 AND -0.36, RESPECTIVELY). THIS ASSOCIATION COULD BE ATTRIBUTED TO A PARTLY OVERLAPPING SET OF GENES INFLUENCING ATTENTION PROBLEMS AT AGE 5 AND IQ AT AGE 12. IQ PERFORMANCE AT AGE 5 WAS THE BEST PREDICTOR OF IQ AT AGE 12. IQ AT BOTH AGES WAS INFLUENCED BY THE SAME GENES, WHOSE INFLUENCE WAS AMPLIFIED DURING DEVELOPMENT.",DEFICIT HYPERACTIVITY DISORDER; WORKING-MEMORY; PROCESSING SPEED; ADHD SYMPTOMATOLOGY; CHILDREN; HERITABILITY; INTELLIGENCE; INHIBITION; BEHAVIOR; BRAIN,CHILDREN; HERITABILITY; COGNITIVE DEVELOPMENT; ADHD; INTELLIGENCE,ACTA NEUROLOGICA BELGICA,"POLDERMAN, TJC##GOSSO, MF##POSTHUMA, D##BEIJSTERVELDT, TCEM##HEUTINK, P##VERHULST, FC##BOOMSMA, DI","FREE UNIV AMSTERDAM, DEPT BIOL PSYCHOL, NL-1081 BT AMSTERDAM, NETHERLANDS. ERASMUS UNIV, DEPT CHILD & ADOLESCENT PSYCHIAT, ROTTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, CNCR, NL-1081 HV AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, DEPT CLIN GENET & ANTHROPOGENET, MED GENET SECT, NL-1081 HV AMSTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY; NEUROSCIENCES,NEUROSCIENCES & NEUROLOGY,"ACHENBACH T. M., 1991, MANUAL CHILD BEHAV C##ACHENBACH TM, 1991, MANUAL TEACHERS REPO##ANDO J, 2001, BEHAV GENET, V31, P615, DOI 10.1023/A:1013353613591##BADDELEY A, 2010, CURR BIOL, V20, PR136, DOI 10.1016/J.CUB.2009.12.014##BARKLEY RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65##BARTELS A, 2004, DEV PSYCHOL, V40, P852, DOI 10.1037/0012-1649.40.5.852##BARTELS M, 2002, BEHAV GENET, V32, P237, DOI 10.1023/A:1019772628912##BAYLISS DM, 2005, DEV PSYCHOL, V41, P579, DOI 10.1037/0012-1649.41.4.579##BLEICHRODT N, 1984, REVISIE AMSTERDAMS K##BONAFINA MA, 2000, J LEARN DISABIL-US, V33, P297, DOI 10.1177/002221940003300307##BOOMSMA D, 2002, NAT REV GENET, V3, P872, DOI 10.1038/NRG932##BOOMSMA D I, 1998, TWIN RES, V1, P34, DOI 10.1375/136905298320566465##BOOMSMA DI, 2002, TWIN RES, V5, P401, DOI 10.1375/136905202320906174##BOOMSMA DI, 1998, DEV NEUROPSYCHOL, V14, P115, DOI 10.1080/87565649809540702##BOUCHARD TJ, 1981, SCIENCE, V212, P1055, DOI 10.1126/SCIENCE.7195071##BROWN RT, 2001, PEDIATRICS, V107, DOI 10.1542/PEDS.107.3.E43##CARROL J. B., 1993, HUMAN COGNITIVE ABIL##CASEY BJ, 2006, AM J PSYCHIAT, V163, P957, DOI 10.1176/APPI.AJP.163.6.957##CASTELLANOS FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/J.TICS.2006.01.011##CASTELLANOS FX, 2003, AM J PSYCHIAT, V160, P1693, DOI 10.1176/APPI.AJP.160.9.1693##CASTELLANOS FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/NRN896##COHEN NJ, 2000, J CHILD PSYCHOL PSYC, V41, P353, DOI 10.1111/1469-7610.00619##COWAN N, 2005, COGNITIVE PSYCHOL, V51, P42, DOI 10.1016/J.COGPSYCH.2004.12.001##CROSBIE J, 2001, AM J PSYCHIAT, V158, P1884, DOI 10.1176/APPI.AJP.158.11.1884##DAVIDSON MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/J.NEUROPSYCHOLOGIA.2006.02.006##DE SONNEVILLE LMJ, 1999, COMP PSYCH, V6, P187##DEMPSTER FN, 1981, PSYCHOL BULL, V89, P63, DOI 10.1037/0033-2909.89.1.63##DERKS EM, 2006, COMPR PSYCHIAT, V47, P116, DOI 10.1016/J.COMPPSYCH.2005.05.006##DERKS EM, 2006, IN PRESS HDB BEHAV G##DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/ANNUREV.NEURO.18.1.193##DOYLE AE, 2005, J CHILD PSYCHOL PSYC, V46, P774, DOI 10.1111/J.1469-7610.2005.01476.X##DURSTON S, 2006, IN PRESS BIOL PSYCHI##FARAONE S, 2002, CHILD ADOLESC PSYCHI, V10, P299##FARAONE STEPHEN V, 2003, WORLD PSYCHIATRY, V2, P104##FRY AF, 2000, BIOL PSYCHOL, V54, P1, DOI 10.1016/S0301-0511(00)00051-X##GROOT AS, 2004, J CHILD PSYCHOL PSYC, V45, P306, DOI 10.1111/J.1469-7610.2004.00222.X##HALL JG, 2003, LANCET, V362, P735, DOI 10.1016/S0140-6736(03)14237-7##HUDZIAK JJ, 2004, J CHILD PSYCHOL PSYC, V45, P1299, DOI 10.1111/J.1469-7610.2004.00314.X##HUDZIAK JJ, 2000, J AM ACAD CHILD PSY, V39, P469, DOI 10.1097/00004583-200004000-00016##HUMPHREYS LG, 1985, HDB INTELLIGENCE THE##JENSEN A. R., 1998, G FACTOR SCI MENTAL##JONSDOTTIR S, 2006, ARCH CLIN NEUROPSYCH, V21, P383, DOI 10.1016/J.ACN.2006.05.003##KAIL R, 1994, ACTA PSYCHOL, V86, P199, DOI 10.1016/0001-6918(94)90003-5##KASIUS MC, 1997, J CHILD PSYCHOL PSYC, V38, P625, DOI 10.1111/J.1469-7610.1997.TB01689.X##KUNTSI J, 2004, AM J MED GENET B, V124B, P41, DOI 10.1002/AJMG.B.20076##LEVY F, 1997, J AM ACAD CHILD PSY, V36, P737, DOI 10.1097/00004583-199706000-00009##LUCIANO M, 2001, BEHAV GENET, V31, P581, DOI 10.1023/A:1013397428612##MANNUZZA S, 2004, J ABNORM CHILD PSYCH, V32, P565, DOI 10.1023/B:JACP.0000037784.80885.1A##MANNUZZA S, 2000, CHILD ADOL PSYCH CL, V9, P711##MARTIN N, 1997, NAT GENET, V17, P387, DOI 10.1038/NG1297-387##MEULENBELT I, 1995, AM J HUM GENET, V57, P1252##MILLER EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/ANNUREV.NEURO.24.1.167##MIN JL, 2006, TWIN RES HUM GENET, V9, P501, DOI 10.1375/TWIN.9.4.501##MIYAKE A, 2006, MODELS WORKING MEMOR##NADDER TS, 1998, BEHAV GENET, V28, P83, DOI 10.1023/A:1021686906396##NADDER TS, 2001, J CHILD PSYCHOL PSYC, V42, P475, DOI 10.1111/1469-7610.00741##NEALE MC, 1992, METHODOLOGY GENETIC##NEALE MC, 2003, MX STAT MODELING COM##OBERAUER K, 2003, INTELLIGENCE, V31, P167, DOI 10.1016/S0160-2896(02)00115-0##PENNINGTON BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/J.1469-7610.1996.TB01380.X##PETRILL SA, 2004, DEV PSYCHOL, V40, P805, DOI 10.1037/0012-1649.40.5.805##PLOMIN R, 1999, NATURE, V402, PC25, DOI 10.1038/35011520##POLDERMAN TJC, 2006, INTELLIGENCE, V34, P549, DOI 10.1016/J.INTELL.2006.03.010##POSTHUMA D, 2003, TWIN RES, V6, P361, DOI 10.1375/136905203770326367##POSTHUMA D, 2002, NAT NEUROSCI, V5, P83, DOI 10.1038/NN0202-83##POSTHUMA D, 2001, BEHAV GENET, V31, P593, DOI 10.1023/A:1013349512683##RAZ A, 2006, NAT REV NEUROSCI, V7, P367, DOI 10.1038/NRN1903##RIETVELD MJH, 2004, J CHILD PSYCHOL PSYC, V45, P577, DOI 10.1111/J.1469-7610.2004.00247.X##RIETVELD MJH, 2003, AM J MED GENET B, V117B, P102, DOI 10.1002/AJMG.B.10024##RUCKLIDGE JJ, 2001, J AM ACAD CHILD PSY, V40, P530, DOI 10.1097/00004583-200105000-00012##SATTLER J., 1992, ASSESSMENT CHILDREN##SATTLER JM, 1982, ASSESSMENT CHILDRENS##SCHMITZ S, 1998, BEHAV GENET, V28, P357, DOI 10.1023/A:1021669602220##SHAW P, 2006, ARCH GEN PSYCHIAT, V63, P540, DOI 10.1001/ARCHPSYC.63.5.540##SHAW P, 2006, NATURE, V440, P676, DOI 10.1038/NATURE04513##SPEARMAN C, 1904, AM J PSYCHOL, V15, P201, DOI 10.2307/1412107##SPIVACK G, 1966, DEVEREUX CHILD BEHAV##STINS JF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-49##STINS JF, 2005, BEHAV GENET, V35, P407, DOI 10.1007/S10519-004-3875-3##TANNOCK R, 1998, J CHILD PSYCHOL PSYC, V39, P65, DOI 10.1111/1469-7610.00304##THAPAR A, 2000, J AM ACAD CHILD PSY, V39, P1528, DOI 10.1097/00004583-200012000-00015##THAPAR A, 1995, BEHAV GENET, V25, P537, DOI 10.1007/BF02327577##THURSTONE LL, 1938, PSYCHOMETRIC MONOGRA, V1##VAN BEIJSTERVELDT CEM, 2004, BEHAV GENET, V34, P229, DOI 10.1023/B:BEGE.0000017869.30151.FD##VAN DER ENDE J, 2005, EUR CHILD ADOLES PSY, V14, P117, DOI 10.1007/S00787-005-0438-Y##VAN HAASEN P. P, 1986, WECHSLER INTELLIGENC##VAN MOURIK R, 2005, J CHILD PSYCHOL PSYC, V46, P150, DOI 10.1111/J.1469-7610.2004.00345.X##VERHULST FC, 1997, ACTA PSYCHIAT SCAND, V96, P75, DOI 10.1111/J.1600-0447.1997.TB09909.X",90,2020-11-20,NA
J,WOS:000241762500017,2006,THE KEY ROLE OF ELECTROPHYSIOLOGY IN THE DIAGNOSIS OF VISUALLY IMPAIRED CHILDREN,"PURPOSE: TO DESCRIBE THE OUTCOME OF SPECIALIZED ELECTROPHYSIOLOGY IN VISUALLY IMPAIRED CHILDREN. METHODS: WE CARRIED OUT A RETROSPECTIVE EVALUATION OF 340 ELECTROPHYSIOLOGICAL EXAMINATIONS PERFORMED IN 298 CHILDREN OVER A 3-YEAR PERIOD (2001-2003), WITH REGARD TO DEMOGRAPHIC DATA, REFERRAL PATTERN, DEGREE OF COMPLIANCE, AND DIAGNOSTIC RESULTS. ELECTROPHYSIOLOGY WAS PERFORMED WITHOUT SEDATION OR ANAESTHESIA. IN ELECTRORETINOGRAMS, DTL ELECTRODES WERE USED IN COMBINATION WITH ONLINE SELECTION OF RESPONSES. VISUAL EVOKED POTENTIALS TESTING WAS PERFORMED WITH SEVEN ACTIVE OCCIPITAL ELECTRODES. RESULTS: THE MEAN AGE OF THE CHILDREN WAS 7 +/- 5 YEARS; 72 (24%) OF THE CHILDREN WERE MENTALLY AS WELL AS VISUALLY IMPAIRED. MAIN REASONS FOR REFERRAL WERE SUSPECTED POSTERIOR SEGMENT DISEASE, ABNORMAL VISUAL DEVELOPMENT, UNEXPLAINED LOW VISION, HIGH MYOPIA, AND SUSPECTED ALBINISM. COMPLIANCE WAS GOOD IN 302/340 (88%), PARTIAL IN 24/340 (7%), AND ABSENT IN 14/340 (4%) OF THE EXAMINATIONS. OF THE 326 SUCCESSFUL PROCEDURES, 215 (66%) SHOWED ABNORMAL RESULTS. TAPETORETINAL DYSTROPHY (22%), OPTICOPATHY (16%), CONGENITAL STATIONARY NIGHT BLINDNESS (13%), AND CONE DYSTROPHY (11%) WERE THE MOST FREQUENTLY ESTABLISHED DIAGNOSES. ALBINISM WAS CONFIRMED IN 14 OF 24 SUSPECTED PATIENTS; ADDITIONALLY, UNSUSPECTED MISROUTING WAS FOUND IN SIX. IN 26 (9%) OF THE PATIENTS, A PREVIOUSLY ESTABLISHED DIAGNOSIS WAS CHANGED. CONCLUSIONS: IN A SPECIALIZED SETTING, ELECTROPHYSIOLOGICAL EXAMINATIONS CAN BE PERFORMED SUCCESSFULLY IN VISUALLY IMPAIRED CHILDREN. THE RESULTS ARE ESSENTIAL FOR THE FINAL OPHTHALMOLOGICAL DIAGNOSIS AND HAVE IMPORTANT CONSEQUENCES FOR REHABILITATION.",STATIONARY NIGHT BLINDNESS; ERG RESPONSES; DYSFUNCTION; MATURATION; CHILDHOOD; ACUITY; MATURE,ELECTRORETINOGRAPHY; VISUAL EVOKED POTENTIALS; VISUALLY IMPAIRED CHILDREN; CHILDHOOD BLINDNESS; DTL ELECTRODES; MISROUTING,ACTA OPHTHALMOLOGICA SCANDINAVICA,"VAN GENDEREN, M##RIEMSLAG, F##JORRITSMA, F##HOEBEN, F##MEIRE, F##STILMA, J","BARTIMEUS INST VISUALLY IMPAIRED, ZEIST, NETHERLANDS. UNIV CHILDRENS HOSP KONINGIN FABIOLA, BRUSSELS, BELGIUM. GHENT UNIV HOSP, B-9000 GHENT, BELGIUM. UNIV UTRECHT, MED CTR, DEPT OPHTHALMOL, UTRECHT, NETHERLANDS.",OPHTHALMOLOGY,OPHTHALMOLOGY,"ALAGARATNAM J, 2002, EYE, V16, P557, DOI 10.1038/SJ.EYE.6700149##ALTMAN DG, 1997, PRACTICAL STAT MED R, P60##APKARIAN P, 1984, EXP BRAIN RES, V53, P285##BLOHME J, 1997, ACTA OPHTHALMOL SCAN, V75, P681##BRECELJ J, 2003, DOC OPHTHALMOL, V107, P215, DOI 10.1023/B:DOOP.0000005330.62543.9C##BRECELJ J, 2004, CLIN NEUROPHYSIOL, V115, P461, DOI 10.1016/J.CLINPH.2003.10.011##DAWSON WW, 1979, INVEST OPHTH VIS SCI, V18, P988##DUTTON G N, 2001, SEMIN NEONATOL, V6, P477, DOI 10.1053/SINY.2001.0078##FLANAGAN NM, 2003, CHILD CARE HLTH DEV, V29, P493, DOI 10.1046/J.1365-2214.2003.00369.X##FLITCROFT DI, 2005, BRIT J OPHTHALMOL, V89, P484, DOI 10.1136/BJO.2004.045328##FULTON AB, 2003, DOC OPHTHALMOL, V107, P235, DOI 10.1023/B:DOOP.0000005332.88367.B8##HANSEN E, 1992, ACTA OPHTHALMOL, V70, P597##HENNESSY MP, 1995, DOC OPHTHALMOL, V89, P235, DOI 10.1007/BF01203377##JACOBSON LK, 2000, SURV OPHTHALMOL, V45, P1, DOI 10.1016/S0039-6257(00)00134-X##KELLY JP, 2003, DOC OPHTHALMOL, V106, P289, DOI 10.1023/A:1022909328103##KOCUR I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/BJO.86.7.716##KRISS A, 1994, INT J PSYCHOPHYSIOL, V16, P137, DOI 10.1016/0167-8760(89)90040-8##LOEWERSIEGER DH, 1975, CHILD CARE HLTH DEV, V1, P275, DOI 10.1111/J.1365-2214.1975.TB00207.X##LORENZ B, 2001, KLIN MONATSBL AUGENH, V218, P3, DOI 10.1055/S-2001-11254##MANAHILOV V, 1992, ELECTROEN CLIN NEURO, V82, P220, DOI 10.1016/0013-4694(92)90171-D##MARMOR MF, 1995, DOC OPHTHALMOL, V89, P199, DOI 10.1007/BF01203373##MARR JE, 2001, EYE, V15, P70, DOI 10.1038/EYE.2001.17##MCCULLOCH DL, 1997, DOC OPHTHALMOL, V94, P327, DOI 10.1007/BF02580858##MICHAELIDES M, 2005, PEDIAT OPHTHALMOLOGY, P531##MIYAKE Y, 1987, INVEST OPHTH VIS SCI, V28, P1816##PONJAVIC V, 1999, OPHTHALMIC GENET, V20, P251, DOI 10.1076/OPGE.20.4.251.2270##RAHI JS, 2003, LANCET, V362, P1359, DOI 10.1016/S0140-6736(03)14631-4##ROSENBERG T, 1996, BRIT J OPHTHALMOL, V80, P49, DOI 10.1136/BJO.80.1.49##SALOMAO SR, 1995, INVEST OPHTH VIS SCI, V36, P657##SPEKREIJSE H, 1999, VISION RES, P216##SUNDIN OH, 2000, NAT GENET, V25, P289, DOI 10.1038/77162##TELLER DY, 1974, VISION RES, V14, P1433, DOI 10.1016/0042-6989(74)90018-2##TREMBLAY F, 2003, DOC OPHTHALMOL, V107, P271, DOI 10.1023/B:DOOP.0000005336.08147.FC##WELEBER RG, 1987, ARCH OPHTHALMOL-CHIC, V105, P360##WESTALL CA, 1999, DOC OPHTHALMOL, V96, P355, DOI 10.1023/A:1001856911730##*WHO, 1992, 457 WHO##YZER S, 2003, J MED GENET, V40, P709, DOI 10.1136/JMG.40.9.709##ZEITZ C, 2005, INVEST OPHTH VIS SCI, V46, P4328, DOI 10.1167/IOVS.05-0526",15,2020-11-20,NA
J,WOS:000243586300009,2006,PERFORMANCE OF 3 GELATINE-BASED RESORBABLE CEMENT PLUGS - A STUDY ON 15 SYNTHETIC FEMURS AND A PROSPECTIVE RANDOMIZED STUDY ON 103 PATIENTS,"BACKGROUND INTRAMEDULLARY PLUGS ARE KEY FACTORS IN IMPROVING CEMENT FIXATION OF THE FEMORAL COMPONENT. WE INVESTIGATED THE PERFORMANCE OF 3 COMMERCIALLY AVAILABLE RESORBABLE CEMENT RESTRICTORS IN VITRO AND IN VIVO. METHODS WE MEASURED THE MIGRATION OF THE SEM H, THE C-PLUG, AND THE REX PLUG IN 15 SAWBONES SYNTHETIC FEMURS AND IN 103 PATIENTS DURING TOTAL HIP SURGERY. CEMENT PRESSURES WERE ALSO MEASURED DISTALLY AND PROXIMALLY IN VITRO. RESULTS AND INTERPRETATION OUR IN VITRO RESULTS SHOWED POOR PERFORMANCE OF THE C-PLUG COMPARED WITH THE REX AND SEM H PLUGS. IN VIVO, THE MEAN MIGRATION WAS LEAST FOR THE SEM PLUG AND MOST FOR THE C-PLUG. THE SMALLER SIZES PERFORMED SIGNIFICANTLY BETTER THAN THE LARGER ONES FOR ALL 3 PLUG TYPES. THE OVERALL IN VIVO PERFORMANCE OF ALL 3 PLUG TYPES WAS UNSATISFACTORY. DIFFERENCES BETWEEN THE SEM II AND REX PLUGS WERE SMALL AND THEREFORE NOT SIGNIFICANT. THE SEM II PERFORMED BETTER THAN THE REX, THE FORMER BEING MUCH CHEAPER AND EASIER TO INSERT. THE REX PLUG LOOKS PROMISING; HOWEVER, THE INSERTION DEVICE MUST BE IMPROVED FOR BETTER RESULTS. THE C-PLUG PROVED TO BE UNSTABLE.",TOTAL HIP-ARTHROPLASTY; FOLLOW-UP; IN-VITRO; PRESSURIZATION; RESTRICTORS; OCCLUSION,NA,ACTA ORTHOPAEDICA,"KROON, M##VISSER, CPJ##MOOTANAH, R##BRAND, R","LEIDEN UNIV, MED CTR, DEPT BIOSTAT, LEIDEN, NETHERLANDS.",ORTHOPEDICS,ORTHOPEDICS,"BULSTRA SK, 1996, J BONE JOINT SURG BR, V78B, P892, DOI 10.1302/0301-620X78B6.6806##FREUND KG, 2003, ACTA ORTHOP SCAND, V74, P37, DOI 10.1080/00016470310013626##HEISEL C, 2003, ORTHOPADE, V32, P541, DOI 10.1007/S00132-002-0416-8##HEISEL C, 2003, J BIOMECH, V36, P835, DOI 10.1016/S0021-9290(03)00017-4##KAPOOR B, 2004, ACTA ORTHOP SCAND, V75, P708, DOI 10.1080/00016470410004076##MALTRY JA, 1995, J ARTHROPLASTY, V10, P492, DOI 10.1016/S0883-5403(05)80151-2##MOOTANAH R, 2003, P INT SOC BIOMECH, P19##NOBLE PC, 1998, CLIN ORTHOP RELAT R, P77##NORTHMORE-BALL M D, 1991, J ARTHROPLASTY, V6, P199, DOI 10.1016/S0883-5403(06)80165-8##SONG Y, 1994, CLIN ORTHOP RELAT R, P297##SUOMINEN S, 1996, ARCH ORTHOP TRAUM SU, V115, P276, DOI 10.1007/BF00439053##VISSER CPJ, 2002, J ARTHROPLASTY, V17, P576, DOI 10.1054/ARTH.2002.33273",1,2020-11-20,NA
J,WOS:000241216100016,2006,DEVELOPMENT AND EVALUATION OF A NOVEL TRACHEOSTOMA BUTTON AND FIXATION SYSTEM (PROVOX LARYBUTTON AND LARYCLIP ADHESIVE) TO FACILITATE HANDS-FREE TRACHEOESOPHAGEAL SPEECH,"CONCLUSION. THIS NEWLY DEVELOPED TRACHEOSTOMA BUTTON AND FIXATION SYSTEM WAS APPRECIATED BY THE MAJORITY OF THE PATIENTS IN THIS STUDY AND LED TO AN INCREASED USE OF AUTOMATIC SPEAKING VALVES (ASVS). OBJECTIVE. DEVELOPMENT AND PROSPECTIVE CLINICAL EVALUATION OF A NEW TRACHEOSTOMA BUTTON AND FIXATION SYSTEM TO ENHANCE HANDS-FREE SPEECH IN LARYNGECTOMIZED PATIENTS. PATIENTS AND METHODS. THE PROVOX(R) LARYBUTTON(TM) AND LARYCLIP(TM) ADHESIVE SYSTEM WERE PROSPECTIVELY EVALUATED IN 11 PATIENTS: 10 MALE, 1 FEMALE; MEAN AGE 60.5 YEARS, RANGE 46 - 80 YEARS; MEDIAN FOLLOW-UP SINCE LARYNGECTOMY 4.9 YEARS, RANGE 9 MONTHS TO 21 YEARS. A STUDY-SPECIFIC QUESTIONNAIRE WAS USED AND THE OBSERVATION PERIOD WAS 3 WEEKS. RESULTS. EIGHT PATIENTS WERE COMPLIANT, THREE DROPPED OUT OF THE STUDY. THE LARYCLIP ADHESIVE SYSTEM WAS TRIED BY SEVEN OF THESE COMPLIANT PATIENTS, AND ULTIMATELY USED BY SIX. AT THE START OF THE STUDY TWO PATIENTS USED AN ASV ON A DAILY BASIS, THREE ALTERNATED BETWEEN AN ASV AND REGULAR, MANUALLY OPERATED HEAT AND MOISTURE EXCHANGERS (HME), THREE ONLY USED A HME. AT THE END OF THE STUDY, THREE USED THE ASV DAILY, FIVE ALTERNATED BETWEEN ASV AND HME. SEVEN PATIENTS INDICATED THAT THEY WOULD CONTINUE USING THE NEW SYSTEM, SIX WITH CLIPS AND ONE WITH THE BUTTON ONLY.",PULMONARY REHABILITATION; MOISTURE EXCHANGER; VALVE; LARYNGECTOMY; STOMAFILTER; HEAT,TRACHEOSTOMA; BUTTON; FIXATION; VOICE PROSTHESIS; HANDS-FREE SPEECH,ACTA OTO-LARYNGOLOGICA,"HILGERS, FJM##ACKERSTAFF, AH","ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT HEAD & NECK ONCOL & SURG, NL-1066 CX AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, INST PHONET SCI, AMSTERDAM CTR LANGUAGE & COMMUN, NL-1012 WX AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT OTOLARYNGOL, NL-1012 WX AMSTERDAM, NETHERLANDS.",OTORHINOLARYNGOLOGY,OTORHINOLARYNGOLOGY,"ACKERSTAFF AH, 1998, LARYNGOSCOPE, V108, P257, DOI 10.1097/00005537-199802000-00018##BARTON D, 1988, OTOLARYNG HEAD NECK, V99, P38, DOI 10.1177/019459988809900106##HILGERS FJM, 1996, CLIN OTOLARYNGOL, V21, P414, DOI 10.1046/J.1365-2273.1996.00817.X##HILGERS FJM, 2003, ACTA OTO-LARYNGOL, V123, P91, DOI 10.1080/0036554021000028083##LEWIN JS, 2000, HEAD NECK-J SCI SPEC, V22, P142, DOI 10.1002/(SICI)1097-0347(200003)22:2<142::AID-HED5>3.0.CO;2-G##OP DE COUL BMR, 2005, ACTA OTO-LARYNGOL, V125, P629, DOI 10.1080/00016480510031515##TEN HALLERS EJO, 2005, ACTA OTO-LARYNGOL, V125, P804, DOI 10.1080/00016480510031506",14,2020-11-20,NA
J,WOS:000242103700001,2006,FUNCTIONAL IMAGING OF THE CENTRAL AUDITORY SYSTEM USING PET,"IN THE LAST FEW DECADES FUNCTIONAL NEUROIMAGING TOOLS HAVE EMERGED TO STUDY THE FUNCTION OF THE HUMAN BRAIN IN VIVO. THESE TECHNIQUES HAVE INCREASED THE KNOWLEDGE OF HOW THE BRAIN PROCESSES STIMULI OF DIFFERENT SENSORY MODALITIES, INCLUDING AUDITORY PROCESSING. POSITRON EMISSION TOMOGRAPHY (PET) HAS BEEN USED FOR NEARLY 20 YEARS TO STUDY CHANGES IN CEREBRAL BLOOD FLOW ASSOCIATED WITH AUDITORY STIMULATION IN NORMAL AND HEARING IMPAIRED SUBJECTS. PET STUDIES GAVE INSIGHT INTO THE NEURAL BASE OF PROCESSING BASIC SOUND FEATURES SUCH AS FREQUENCY AND INTENSITY, BUT COMPLEX STIMULI SUCH AS SPEECH AND MUSIC HAVE ALSO BEEN INVESTIGATED EXTENSIVELY. KNOWLEDGE OF THE NORMAL AUDITORY FUNCTION OF THE BRAIN HELPS US TO UNDERSTAND THE NEURAL BASE OF HEARING DEFICITS AND PROVIDES IDEAS FOR POSSIBLE TREATMENTS. ALTHOUGH FUNCTIONAL MAGNETIC RESONANCE IMAGING (FMRI) IS REPLACING PET IN MANY NEUROIMAGING STUDIES NOWADAYS, PET STILL HOLDS UNIQUE ADVANTAGES AND CAN GIVE US VALUABLE KNOWLEDGE ABOUT THE AUDITORY CORTEX AND AUDITORY PERCEPTION.",POSITRON-EMISSION-TOMOGRAPHY; TRANSCRANIAL MAGNETIC STIMULATION; PRIMATE PREFRONTAL CORTEX; CROSS-MODAL PLASTICITY; TONOTOPIC ORGANIZATION; ELECTRICAL-STIMULATION; PLANUM TEMPORALE; MACAQUE MONKEYS; RHESUS-MONKEY; HUMAN BRAIN,FUNCTIONAL NEUROIMAGING; AUDITORY CORTEX; HEARING; POSITRON EMISSION TOMOGRAPHY; HUMAN,ACTA OTO-LARYNGOLOGICA,"RUYTJENS, L##WILLEMSEN, ATM##VAN DIJK, P##WIT, HP##ALBERS, FWJ","UNIV MED CTR UTRECHT, DEPT OTORHINOLARYNGOL, NL-3508 GA UTRECHT, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT OTORHINOLARYNGOL, GRONINGEN, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT NUCL MED & MOL IMAGING, GRONINGEN, NETHERLANDS.",OTORHINOLARYNGOLOGY,OTORHINOLARYNGOLOGY,"ARNOTT SR, 2004, NEUROIMAGE, V22, P401, DOI 10.1016/J.NEUROIMAGE.2004.01.014##BELIN P, 2000, NAT NEUROSCI, V3, P965, DOI 10.1038/79890##BERNSTEIN LE, 2002, NEUROREPORT, V13, P311, DOI 10.1097/00001756-200203040-00013##BINDER JR, 2000, CEREB CORTEX, V10, P512, DOI 10.1093/CERCOR/10.5.512##BRODMANN K., 1909, VERGLEICHENDE LOKALI##BUSHARA KO, 1999, NAT NEUROSCI, V2, P759##CALVERT GA, 1997, SCIENCE, V276, P593, DOI 10.1126/SCIENCE.276.5312.593##CAPLAN D, 1999, NEUROIMAGE, V9, P343, DOI 10.1006/NIMG.1998.0412##COHEN LG, 1997, NATURE, V389, P180, DOI 10.1038/38278##DE RIDDER D, 2005, OTOL NEUROTOL, V26, P616, DOI 10.1097/01.MAO.0000178146.91139.3C##DE RIDDER D, 2004, J NEUROSURG, V100, P560, DOI 10.3171/JNS.2004.100.3.0560##DEMONET JF, 2005, PHYSIOL REV, V85, P49, DOI 10.1152/PHYSREV.00049.2003##DIERKS T, 1999, NEURON, V22, P615, DOI 10.1016/S0896-6273(00)80715-1##FINNEY EM, 2001, NAT NEUROSCI, V4, P1171, DOI 10.1038/NN763##FORMISANO E, 2003, NEURON, V40, P859, DOI 10.1016/S0896-6273(03)00669-X##GIFFORD GW, 2005, EXP BRAIN RES, V162, P509, DOI 10.1007/S00221-005-2220-2##GIRAUD AL, 2001, NEURON, V30, P657, DOI 10.1016/S0896-6273(01)00318-X##GIRAUD AL, 2000, J NEUROPHYSIOL, V84, P1588##GRIFFITHS TD, 2000, BRAIN, V123, P2065, DOI 10.1093/BRAIN/123.10.2065##GUSNARD DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500##HACKETT TA, 1999, BRAIN RES, V817, P45, DOI 10.1016/S0006-8993(98)01182-2##HALPERN AR, 1999, CEREB CORTEX, V9, P697, DOI 10.1093/CERCOR/9.7.697##HOLM AF, 2005, OTOL NEUROTOL, V26, P425, DOI 10.1097/01.MAO.0000169784.15083.61##JANCKE L, 1998, NEUROPSYCHOLOGIA, V36, P875, DOI 10.1016/S0028-3932(98)00019-0##JANCKE L, 2002, HEARING RES, V170, P166, DOI 10.1016/S0378-5955(02)00488-4##JOHNSRUDE IS, 2002, AUDIOL NEURO-OTOL, V7, P251, DOI 10.1159/000064446##KAAS JH, 1998, AUDIOL NEURO-OTOL, V3, P73, DOI 10.1159/000013783##KANNO I, 1991, J NUCL MED, V32, P1931##LANGERS DRM, 2005, NEUROIMAGE, V28, P490, DOI 10.1016/J.NEUROIMAGE.2005.06.024##LAUREYS S, 2000, BRAIN, V123, P1589, DOI 10.1093/BRAIN/123.8.1589##LAUTER JL, 1985, HEARING RES, V20, P199, DOI 10.1016/0378-5955(85)90024-3##LOCKWOOD AH, 1999, CEREB CORTEX, V9, P65, DOI 10.1093/CERCOR/9.1.65##MAZOYER BM, 1993, J COGNITIVE NEUROSCI, V5, P467, DOI 10.1162/JOCN.1993.5.4.467##MCGURK H, 1976, NATURE, V264, P746, DOI 10.1038/264746A0##MELCHER JR, 2000, J NEUROPHYSIOL, V83, P1058##MERZENICH MM, 1973, BRAIN RES, V50, P275, DOI 10.1016/0006-8993(73)90731-2##MIDDLEBROOKS JC, 2002, NAT NEUROSCI, V5, P824, DOI 10.1038/NN0902-824##MIRZ F, 1999, SCAND AUDIOL, V28, P161, DOI 10.1080/010503999424734##MOORE CJ, 2004, HUMAN NERVOUS SYSTEM##MOREL A, 1993, J COMP NEUROL, V335, P437, DOI 10.1002/CNE.903350312##MOREL A, 1992, J COMP NEUROL, V318, P27, DOI 10.1002/CNE.903180104##MOROSAN P, 2001, NEUROIMAGE, V13, P684, DOI 10.1006/NIMG.2000.0715##PANTEV C, 1989, SCIENCE, V246, P486, DOI 10.1126/SCIENCE.2814476##PATEL AD, 2003, NAT NEUROSCI, V6, P674, DOI 10.1038/NN1082##PAULESU E, 2003, J NEUROPHYSIOL, V90, P2005, DOI 10.1152/JN.00926.2002##PLEWNIA C, 2003, ANN NEUROL, V53, P263, DOI 10.1002/ANA.10468##PUGH KR, 1996, NEUROIMAGE, V4, P159, DOI 10.1006/NIMG.1996.0067##RADEMACHER J, 2001, NEUROIMAGE, V13, P669, DOI 10.1006/NIMG.2000.0714##RAICHLE ME, 1998, P NATL ACAD SCI USA, V95, P765, DOI 10.1073/PNAS.95.3.765##RAUSCHECKER JP, 1997, J COMP NEUROL, V382, P89##RAUSCHECKER JP, 2000, P NATL ACAD SCI USA, V97, P11800, DOI 10.1073/PNAS.97.22.11800##ROMANSKI LM, 1999, NAT NEUROSCI, V2, P1131, DOI 10.1038/16056##ROMANSKI LM, 2002, NAT NEUROSCI, V5, P15, DOI 10.1038/NN781##ROMANSKI LM, 1999, J COMP NEUROL, V403, P141, DOI 10.1002/(SICI)1096-9861(19990111)403:2<141::AID-CNE1>3.0.CO;2-V##SADATO N, 1996, NATURE, V380, P526, DOI 10.1038/380526A0##SCHONWIESNER M, 2002, NEUROIMAGE, V17, P1144, DOI 10.1006/NIMG.2002.1250##SHAPLESKE J, 1999, BRAIN RES REV, V29, P26, DOI 10.1016/S0165-0173(98)00047-2##STRAINER JC, 1997, AM J NEURORADIOL, V18, P601##SYKA J, 2002, PHYSIOL REV, V82, P601, DOI 10.1152/PHYSREV.00002.2002##TANAKA H, 2000, NEUROREPORT, V11, P2045, DOI 10.1097/00001756-200006260-00047##TRUY E, 1999, INT J PEDIATR OTORHI, V47, P131, DOI 10.1016/S0165-5876(98)00131-1##TRUY E, 1995, HEARING RES, V86, P34, DOI 10.1016/0378-5955(95)00052-6##TZOURIO N, 1997, NEUROIMAGE, V5, P63, DOI 10.1006/NIMG.1996.0252##UNGERLEIDER LESLIE G., 1994, CURRENT OPINION IN NEUROBIOLOGY, V4, P157, DOI 10.1016/0959-4388(94)90066-3##WEEKS R, 2000, J NEUROSCI, V20, P2664##WEEKS RA, 1999, NEUROSCI LETT, V262, P155, DOI 10.1016/S0304-3940(99)00062-2##WESSINGER CM, 2001, J COGNITIVE NEUROSCI, V13, P1, DOI 10.1162/089892901564108##WESTBURY CF, 1999, CEREB CORTEX, V9, P392, DOI 10.1093/CERCOR/9.4.392##ZATORRE RJ, 2001, ANN NY ACAD SCI, V930, P193, DOI 10.1111/J.1749-6632.2001.TB05734.X##ZATORRE RJ, 1994, J NEUROSCI, V14, P1908, DOI 10.1523/JNEUROSCI.14-04-01908.1994##ZATORRE RJ, 1999, NEUROIMAGE, V10, P544, DOI 10.1006/NIMG.1999.0491##ZATORRE RJ, 2003, TRENDS NEUROSCI, V26, P229, DOI 10.1016/S0166-2236(03)00074-2##ZATORRE RJ, 2002, NAT NEUROSCI, V5, P905, DOI 10.1038/NN904##ZATORRE RJ, 2001, CEREB CORTEX, V11, P946, DOI 10.1093/CERCOR/11.10.946##ZATORRE RJ, 2002, TRENDS COGN SCI, V6, P37, DOI 10.1016/S1364-6613(00)01816-7",13,2020-11-20,NA
J,WOS:000242103700012,2006,THE PSYCHOLOGICAL IMPACT OF ANNUAL CHEST X-RAY FOLLOW-UP IN HEAD AND NECK CANCER,"CONCLUSION. ANNUAL POST-TREATMENT SCREENING OF HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) PATIENTS FOR SECOND PRIMARY LUNG CANCER AND METASTATIC RECURRENCE APPEARED TO FORM NO MAJOR BURDEN FOR HEAD AND NECK CANCER PATIENTS. A MAJORITY OF PATIENTS REGARD THE ANNUAL CHEST X-RAY AS A REASSURANCE. GIVEN THESE RESULTS A MORE INTENSIVE SCREENING PROGRAM SEEMS PSYCHOLOGICALLY JUSTIFIABLE FOR THIS GROUP. OBJECTIVE. TO ASSESS THE PSYCHOLOGICAL IMPACT OF ANNUAL POST-TREATMENT SCREENING FOR SECOND PRIMARY LUNG CANCER AND METASTASES IN HNSCC PATIENTS. PATIENTS AND METHODS. IN A COHORT OF 106 PATIENTS, 68 MEN AND 38 WOMEN, WITH A MEAN AGE OF 56, THE IMPACT OF THE YEARLY CHEST RADIOGRAPH WAS EVALUATED BY MEANS OF A NINE-ITEM QUESTIONNAIRE. RESULTS. IN ALL, 90% OF THE PATIENTS WERE IN FAVOR OF ANNUAL POST-TREATMENT SCREENING, 2% WOULD NOT LIKE TO RECEIVE THIS SCREENING, AND 8% HAD NO PREFERENCE. A MAJORITY (98%) CONSIDERED THE SCREENING AS AN EXTRA MEDICAL CHECK AND 76% FELT REASSURED. ALTHOUGH 21% OF THE PATIENTS WERE VERY NERVOUS ABOUT THE OUTCOME OF THE SCREENING, ONLY 3% WANTED TO AVOID THE YEARLY CHEST X-RAY FOR THIS REASON.",SQUAMOUS-CELL CARCINOMA; QUALITY-OF-LIFE; LUNG-CANCER; BREAST-CANCER; PULMONARY METASTASES; PROSTATE-CANCER; TUMOR SIZE; CURABILITY; RESECTION; SURVIVAL,HNSCC; PSYCHOLOGICAL FACTORS,ACTA OTO-LARYNGOLOGICA,"GEURTS, TW##ACKERSTAFF, AH##VAN ZANDWIJK, N##HART, AAM##HILGERS, FJM##BALM, AJM","ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT HEAD NECK ONCOL & SURG, NL-1066 CX AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT THORAC ONCOL, NL-1066 CX AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT RADIOTHERAPY, NL-1066 CX AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT ORL, NL-1105 AZ AMSTERDAM, NETHERLANDS.",OTORHINOLARYNGOLOGY,OTORHINOLARYNGOLOGY,"ATABEK U, 1987, AM J SURG, V154, P434, DOI 10.1016/0002-9610(89)90019-6##BACH PB, 2003, CHEST, V123, P72S, DOI 10.1378/CHEST.123.1_SUPPL.72S##BUWALDA J, 1999, NED TIJDSCHR GENEESKD, V143, P1517##ESSINK-BOT ML, 1998, J NATL CANCER I, V90, P925, DOI 10.1093/JNCI/90.12.925##FERLITO A, 2001, ORL-J OTO-RHIN-LARYN, V63, P202, DOI 10.1159/000055740##FINLEY RK, 1992, AM J SURG, V164, P594, DOI 10.1016/S0002-9610(05)80714-7##FONTANA RS, 2000, CANCER, V89, P2352, DOI 10.1002/1097-0142(20001201)89:11+<2352::AID-CNCR7>3.0.CO;2-5##FORD ME, 2003, CANCER EPIDEM BIOMAR, V12, P28##GEURTS TW, 2005, CLIN CANCER RES, V11, P6608, DOI 10.1158/1078-0432.CCR-05-0257##HENSCHKE CI, 2003, LUNG CANCER-J IASLC, V39, P327, DOI 10.1016/S0169-5002(02)00503-2##HENSCHKE CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6##LEON X, 1999, HEAD NECK-J SCI SPEC, V21, P204, DOI 10.1002/(SICI)1097-0347(199905)21:3<204::AID-HED4>3.0.CO;2-7##LIBBY DM, 2004, CHEST, V125, P1522, DOI 10.1378/CHEST.125.4.1522##MULSHINE JL, 2005, NEW ENGL J MED, V352, P2714, DOI 10.1056/NEJMCP042630##NIJS HGT, 2000, J PUBLIC HEALTH MED, V22, P312, DOI 10.1093/PUBMED/22.3.312##OKAMOTO N, 2000, CANCER, V89, P2489, DOI 10.1002/1097-0142(20001201)89:11+<2489::AID-CNCR29>3.0.CO;2-E##PASTORINO U, 2003, LANCET, V362, P593, DOI 10.1016/S0140-6736(03)14188-8##PATZ EF, 2000, CHEST, V117, P1568, DOI 10.1378/CHEST.117.6.1568##RIJNSBURGER AJ, 2004, BRIT J CANCER, V91, P69, DOI 10.1038/SJ.BJC.6601912##RITOE SC, 2002, LARYNGOSCOPE, V112, P2002, DOI 10.1097/00005537-200211000-00017##SOBIN LH, 2002, TNM CLASSIFICATION##SUTTON S, 1995, J EPIDEMIOL COMMUN H, V49, P413, DOI 10.1136/JECH.49.4.413##VAN DOOREN S, 2005, EUR J CANCER, V41, P1416, DOI 10.1016/J.EJCA.2005.03.020##WEDMAN J, 1996, HEAD NECK-J SCI SPEC, V18, P311##WISNIVESKY JP, 2004, CHEST, V126, P761, DOI 10.1378/CHEST.126.3.761",4,2020-11-20,NA
J,WOS:000243125800027,2006,DETERMINANTS OF COMPLIANCE WITH METHYLPHENIDATE THERAPY IN CHILDREN,"AIM: TO GET MORE INSIGHT INTO FACTORS THAT INFLUENCE COMPLIANCE WITH THE USE OF METHYLPHENIDATE. METHODS: 22 PHARMACIES DETECTED CHILDREN WHO USED METHYLPHENIDATE. THEIR PARENTS WERE SENT A QUESTIONNAIRE ON THE USE OF METHYLPHENIDATE. IN A CASE-CONTROL STUDY, THE INFLUENCE OF PATIENT- AND DRUG-RELATED FACTORS ON COMPLIANCE, AS REPORTED BY PARENTS, WAS DETERMINED. RESULTS: PARENTS RETURNED 117 (75%) OF 157 QUESTIONNAIRES SENT OUT. OF THESE, 47.8% OF THE CHILDREN MISSED A DOSE TWO TIMES A MONTH OR MORE. FORGETTING TO TAKE THE MEDICATION (87.9%) WAS THE MOST IMPORTANT REASON. THE CASE-CONTROL STUDY SHOWED THAT CHILDREN OF 16-18 Y WERE MORE LIKELY TO MISS DOSES. OTHER PATIENT- AND DRUG-RELATED FACTORS DID NOT INFLUENCE THE MISSING OF DOSES. CONCLUSION: A NUMBER OF KNOWN DETERMINANTS FOR COMPLIANCE DO NOT INFLUENCE THE MISSING OF DOSES OF METHYLPHENIDATE. WITH ABOUT 80% OF THE PARENTS REPORTING THAT THEIR CHILD MISSED DOSES OF METHYLPHENIDATE LESS THAN 5 TIMES PER MONTH, COMPLIANCE WAS QUITE GOOD FOR THE MAJORITY OF THE CHILDREN.",ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; TRIAL,CASE-CONTROL STUDY; CHILDREN; COMPLIANCE; DETERMINANTS; EFFICACY; METHYLPHENIDATE; SIDE EFFECTS,ACTA PAEDIATRICA,"HUGTENBURG, JG##WITTE, I##HEERDINK, ER","VRIJE UNIV AMSTERDAM, MED CTR, DEPT MED PHARMACOL, NL-1081 BT AMSTERDAM, NETHERLANDS. UNIV UTRECHT, FAC PHARMACEUT SCI, DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY, NL-3508 TC UTRECHT, NETHERLANDS.",PEDIATRICS,PEDIATRICS,"BARKLEY RA, 1990, PEDIATRICS, V86, P184##BROWN RT, 1987, J AM ACAD CHILD PSY, V26, P521, DOI 10.1097/00004583-198707000-00010##DIMATTEO MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.MLR.0000114908.90348.F9##EFRON D, 1997, PEDIATRICS, V100, P662, DOI 10.1542/PEDS.100.4.662##EPSTEIN LH, 1984, HEALTH PSYCHOL, V3, P385, DOI 10.1037/0278-6133.3.4.385##FIRESTONE P, 1982, AM J ORTHOPSYCHIAT, V21, P474##*GEZ, 2000, PUBL GEZ##GREENHILL LL, 1999, J AM ACAD CHILD PSY, V38, P503, DOI 10.1097/00004583-199905000-00011##HUGTENBURG JG, 2005, PHARM WORLD SCI, V27, P197, DOI 10.1007/S11096-004-2848-1##JENSEN PS, 1999, ARCH GEN PSYCHIAT, V56, P1073##PAES AHP, 1997, DIABETES CARE, V20, P1512, DOI 10.2337/DIACARE.20.10.1512##PULLAR T, 1988, CLIN PHARMACOL THER, V44, P540, DOI 10.1038/CLPT.1988.191##SCHACHTER HA, 2001, CAN MED ASSOC J, V165, P1475##SWANSON J, 2003, CNS DRUGS, V17, P117, DOI 10.2165/00023210-200317020-00004##WEINTRAUB M, 1973, JAMA-J AM MED ASSOC, V224, P481, DOI 10.1001/JAMA.224.4.481",4,2020-11-20,NA
J,WOS:000242221300003,2006,KINETIC CHANGES AND MODULATION BY CARBAMAZEPINE ON VOLTAGE-GATED SODIUM CHANNELS IN RAT CA1 NEURONS AFTER EPILEPSY,"AIM: TO STUDY WHETHER THE FUNCTIONAL PROPERTIES OF SODIUM CHANNELS, AND SUBSEQUENTLY THE CHANNEL MODULATION BY CARBAMAZEPINE (CBZ) IN HIPPOCAMPAL CA1 NEURONS CAN BE CHANGED AFTER EPILEPTIC SEIZURES. METHODS: WE USED THE ACUTELY DISSOCIATED HIPPOCAMPAL CA1 PYRAMIDAL CELLS FROM EPILEPSY MODEL RATS 3 WEEKS AND 3 MONTHS RESPECTIVELY AFTER KAINATE INJECTION, AND WHOLE-CELL VOLTAGE-CLAMP TECHNIQUES. RESULTS: AFTER LONG-TERM EPILEPTIC SEIZURES, BOTH SODIUM CHANNEL VOLTAGE-DEPENDENCE OF ACTIVATION AND STEADY-STATE INACTIVATION SHIFTED TO MORE HYPERPOLARIZING POTENTIALS, WHICH RESULTED IN THE ENLARGED WINDOW CURRENT; THE MEMBRANE DENSITY OF SODIUM CURRENT DECREASED AND THE TIME CONSTANT OF RECOVERY FROM INACTIVATION INCREASED. CBZ DISPLAYED UNCHANGED EFFICACY ON SODIUM CHANNELS, WITH A SIMILAR BINDING RATE TO THEM, EXCEPT THAT AT HIGHER CONCENTRATIONS, THE VOLTAGE SHIFT OF INACTIVATION WAS REDUCED. FOR THE SHORT-TERM KAINATE MODEL RATS, NO DIFFERENCES WERE DETECTED BETWEEN THE CONTROL AND EPILEPSY GROUPS. CONCLUSION: THESE RESULTS INDICATE THAT THE PROPERTIES OF SODIUM CHANNELS IN ACUTELY DISSOCIATED HIPPOCAMPAL NEURONS COULD BE CHANGED FOLLOWING LONG-TERM EPILEPSY, BUT THE ALTERNATION MIGHT NOT BE ENOUGH TO INDUCE THE CHANNEL RESISTANCE TO CBZ.",KAINATE-INDUCED SEIZURES; TEMPORAL-LOBE EPILEPSY; MESSENGER-RNAS; STATUS-EPILEPTICUS; NA+ CHANNELS; BRAIN; CURRENTS; SUBUNIT; LAMOTRIGINE; HIPPOCAMPUS,SODIUM CHANNEL; VOLTAGE CLAMP; KAINATE MODEL; EPILEPSY; HIPPOCAMPUS; CARBAMAZEPINE,ACTA PHARMACOLOGICA SINICA,"SUN, GC##WERKMAN, TR##WADMAN, WJ","GUIYAND MED COLL, DEPT PHARMACOL, GUIYANG 550004, PEOPLES R CHINA. UNIV AMSTERDAM, SWAMMERDAM INST LIFE SCI, AMSTERDAM, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; PHARMACOLOGY & PHARMACY",CHEMISTRY; PHARMACOLOGY & PHARMACY,"ARONICA E, 2003, ACTA NEUROPATHOL, V105, P515, DOI 10.1007/S00401-003-0677-2##ARONICA E, 2001, EUR J NEUROSCI, V13, P1261, DOI 10.1046/J.0953-816X.2001.01502.X##BARTOLOMEI F, 1997, J NEUROCYTOL, V26, P667, DOI 10.1023/A:1018549928277##BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4##BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W##BROWNE TR, 2001, NEW ENGL J MED, V344, P1145, DOI 10.1056/NEJM200104123441507##CATTERALL W A, 1999, ADV NEUROL, V79, P441##CATTERALL WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2##CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/ANNUREV.BIOCHEM.64.1.493##CLARE JJ, 2000, DRUG DISCOV TODAY, V5, P506, DOI 10.1016/S1359-6446(00)01570-1##GASTALDI M, 1998, NEUROSCI LETT, V249, P53, DOI 10.1016/S0304-3940(98)00394-2##GASTALDI M, 1997, MOL BRAIN RES, V44, P179, DOI 10.1016/S0169-328X(96)00199-4##GORTER JA, 2003, EPILEPSIA, V44, P647, DOI 10.1046/J.1528-1157.2003.53902.X##HEINEMANN U, 1994, EPILEPSIA, V35, PS10, DOI 10.1111/J.1528-1157.1994.TB05959.X##HELLIER JL, 1999, EPILEPSY RES, V35, P47, DOI 10.1016/S0920-1211(98)00127-2##HILLE B, 1992, IONIC CHANNELS EXCIT##JEUB M, 2002, NEUROPHARMACOLOGY, V42, P107, DOI 10.1016/S0028-3908(01)00148-4##JOHNSTON D, 1995, FDN CELL NEUROPHYSIO##KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8##KUO CC, 1998, MOL PHARMACOL, V54, P712##KUO CC, 1997, BRIT J PHARMACOL, V121, P1231, DOI 10.1038/SJ.BJP.0701221##LOTHMAN E W, 1996, EPILEPSY RES SUPPL, V11, P9##NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826A0##RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0##RAGSDALE DS, 1998, BRAIN RES REV, V26, P16, DOI 10.1016/S0165-0173(97)00054-4##REGESTA G, 1999, EPILEPSY RES, V34, P109, DOI 10.1016/S0920-1211(98)00106-5##SCHALLER KL, 1995, J NEUROSCI, V15, P3231##VREUGDENHIL M, 1998, NEUROSCIENCE, V86, P99, DOI 10.1016/S0306-4522(98)00041-4##WHITAKER WRJ, 1999, ANN NY ACAD SCI, V868, P88, DOI 10.1111/J.1749-6632.1999.TB11278.X##WHITAKER WRJ, 2000, J COMP NEUROL, V422, P123, DOI 10.1002/(SICI)1096-9861(20000619)422:1<123::AID-CNE8>3.0.CO;2-X##WHITAKER WRJ, 2001, NEUROSCIENCE, V106, P275, DOI 10.1016/S0306-4522(01)00212-3##WUARIN JP, 1996, J NEUROSCI, V16, P4438",12,2020-11-20,NA
J,WOS:000243750000013,2006,ONSET OF DECONFINEMENT IN PB+PB COLLISIONS AT THE CERN SPS,THE NA49 FIXED-TARGET EXPERIMENT STUDIED HIGH ENERGY-DENSITY MATTER PRODUCED IN NUCLEUS-NUCLEUS REACTIONS AT THE CERN SPS. IN CENTRAL PB+PB COLLISIONS AT 158A GEV THE ENERGY DENSITY AT THE EARLY STAGE SUBSTANTIALLY EXCEEDS THE THRESHOLD FOR QUARK DECONFINEMENT PREDICTED BY LATTICE QCD. THE PRODUCED MATTER SHOWS STRONG TRANSVERSE AND LONGITUDINAL FLOW. RATIOS OF YIELDS OF PRODUCED PARTICLES ARE APPROXIMATELY CONSISTENT WITH STATISTICAL EQUILIBRATION. AN ENERGY SCAN THROUGH THE SPS RANGE REVEALED STRUCTURE IN THE ENERGY DEPENDENCE OF PI AND K YIELDS AS WELL AS OF THE INVERSE SLOPES OF TRANSVERSE MASS DISTRIBUTIONS. THESE FEATURES SUGGEST THAT A DECONFINED PHASE STARTS TO BE PRODUCED AT AROUND 30A GEV IN CENTRAL PB+PB COLLISIONS. THE ANALYSIS OF FLUCTUATIONS AND CORRELATIONS HAS NOT YET PROVIDED EVIDENCE FOR THE PREDICTED CRITICAL POINT OF OCD.,NUCLEUS-NUCLEUS COLLISIONS; BY-EVENT FLUCTUATIONS; QUARK-GLUON PLASMA; HEAVY-ION COLLISIONS; TRANSVERSE-MOMENTUM; CHARGE FLUCTUATIONS; BALANCE FUNCTIONS; PHASE-TRANSITION; PB COLLISIONS; FREEZE-OUT,NA,ACTA PHYSICA POLONICA B,"SEYBOTH, P##ALT, C##ANTICIC, T##BAATAR, B##BARNA, D##BARTKE, J##BETEV, L##BIALKOWSKA, H##BLUME, C##BOIMSKA, B##BOTJE, M##BRACINIK, J##BRAMM, R##BUNCIC, P##CERNY, V##CHRISTAKOGLOU, P##CHUNG, P##CHVALA, O##CRAMER, JG##CSATO, P##DINKELAKER, P##ECKARDT, V##FLIERL, D##FODOR, Z##FOKA, P##FRIESE, V##GAL, J##GAZDZICKI, M##GENCHEV, V##GEORGOPOULOS, G##GLADYSZ, E##GREBIESZKOW, K##HEGYI, S##HOHNE, C##KADIJA, K##KAREV, A##KIKOLA, D##KLIEMANT, M##KNIEGE, S##KOLESNIKOV, VI##KORNAS, E##KORUS, R##KOWALSKI, M##KRAUS, I##KREPS, M##LASZLO, A##LACEY, R##VAN LEEUWEN, M##LEVAI, P##LITOV, L##LUNGWITZ, B##MAKARIEV, M##MALAKHOV, AI##MATEEV, M##MELKUMOV, GL##MISCHKE, A##MITROVSKI, M##MOLNAR, J##MROWCZYNSKI, S##NICOLIC, V##PALLA, G##PANAGIOTOU, AD##PANAYOTOV, D##PETRIDIS, A##PERYT, W##PIKNA, M##PLUTA, J##PRINDLE, D##PUHLHOFER, F##RENFORDT, R##ROLAND, C##ROLAND, G##RYBCZYNSKI, M##RYBICKI, A##SANDOVAL, A##SCHMITZ, N##SCHUSTER, T##SIKLER, F##SITAR, B##SKRZYPCZAK, E##SLODKOWSKI, M##STEFANEK, G##STOCK, R##STRABEL, C##STROBELE, H##SUSA, T##SZENTPETERY, I##SZIKLAI, J##SZUBA, M##SZYMANSKI, P##TRUBNIKOV, V##VARGA, D##VASSILIOU, M##VERES, GI##VESZTERGOMBI, G##VRANIC, D##WETZLER, A##WLODARCZYK, Z##YOO, IK##ZIMANYI, J","MAX PLANCK INST PHYS & ASTROPHYS, D-80805 MUNICH, GERMANY. NIKHEF, AMSTERDAM, NETHERLANDS. UNIV ATHENS, DEPT PHYS, GR-10679 ATHENS, GREECE. COMENIUS UNIV, BRATISLAVA 81806, SLOVAKIA. KFKI, RES INST PARTICLE & NUCL PHYS, BUDAPEST, HUNGARY. MIT, CAMBRIDGE, MA 02139 USA. INST NUCL PHYS, KRAKOW, POLAND. GESELL SCHWERIONENFORSCH MBH, GSI, DARMSTADT, GERMANY. JOINT INST NUCL RES, DUBNA, RUSSIA. GOETHE UNIV FRANKFURT, FACHBEREICH PHYS, D-6000 FRANKFURT, GERMANY. CERN, CH-1211 GENEVA 23, SWITZERLAND. JAN KOCHANOWSKI UNIV HUMANITIES & SCI, INST PHYS, KIELCE, POLAND. UNIV MARBURG, FACHBEREICH PHYS, D-3550 MARBURG, GERMANY. CHARLES UNIV PRAGUE, INST NUCL & PARTICLE PHYS, CR-11636 PRAGUE 1, CZECH REPUBLIC. PUSAN NATL UNIV, DEPT PHYS, PUSAN 609735, SOUTH KOREA. UNIV WASHINGTON, PHYS NUCL LAB, SEATTLE, WA 98195 USA. UNIV SOFIA, DEPT ATOM PHYS, ST KLIMENT OHRIDSKI, BU-1126 SOFIA, BULGARIA. BULGARIAN ACAD SCI, INST NUCL RES & NUCL ENERGY, SOFIA, BULGARIA. SUNY STONY BROOK, DEPT CHEM, STONY BROOK, NY 11794 USA. INST NUCL STUDIES, PL-00681 WARSAW, POLAND. UNIV WARSAW, INST EXPT PHYS, PL-00325 WARSAW, POLAND. WARSAW UNIV TECHNOL, FAC PHYS, PL-00661 WARSAW, POLAND. RUDJER BOSKOVIC INST, ZAGREB, CROATIA.","PHYSICS, MULTIDISCIPLINARY",PHYSICS,"ADAMOVA D, 2003, NUCL PHYS A, V727, P97, DOI 10.1016/J.NUCLPHYSA.2003.07.018##ADAMS J, 2005, PHYS REV C, V71, DOI 10.1103/PHYSREVC.71.064906##ADAMS J, 2003, PHYS REV LETT, V90, DOI 10.1103/PHYSREVLETT.90.172301##AFANASIEV S, 1999, NUCL INSTRUM METH A, V430, P210, DOI 10.1016/S0168-9002(99)00239-9##AFANASIEV SV, 2002, PHYS REV C, V66, DOI 10.1103/PHYSREVC.66.054902##ALBER T, 1995, PHYS REV LETT, V75, P3814, DOI 10.1103/PHYSREVLETT.75.3814##ALT C, 2004, PHYS REV C, V70, DOI 10.1103/PHYSREVC.70.064903##ALT C, 2005, PHYS REV C, V71, DOI 10.1103/PHYSREVC.71.034903##ALT C, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.192301##ALT C, 2003, PHYS REV C, V68, DOI 10.1103/PHYSREVC.68.034903##ALT C, 2004, J PHYS G, V30, PS119##ANTICIC T, 2004, PHYS REV C, V70, DOI 10.1103/PHYSREVC.70.034902##ANTICIC T, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.022302##ANTINORI F, 2004, J PHYS G NUCL PARTIC, V30, P823, DOI 10.1088/0954-3899/30/6/011##ANTONIOU NG, CERNSPSC2006001##APPELHAUSER H, 1998, PHYS LETT B, V444, P523, DOI 10.1016/S0370-2693(98)01399-9##APPELSHAUSER H, 1998, EUR PHYS J C, V2, P661, DOI 10.1007/S100520050168##APPELSHAUSER H, 1999, PHYS LETT B, V459, P679, DOI 10.1016/S0370-2693(99)00673-5##BARTKE J, 2004, VILL WORKSH##BASS SA, 2000, PHYS REV LETT, V85, P2689, DOI 10.1103/PHYSREVLETT.85.2689##BECATTINI F, 2004, PHYS REV C, V69, DOI 10.1103/PHYSREVC.69.024905##BIALAS A, 2004, PHYS LETT B, V579, P31, DOI 10.1016/J.PHYSLETB.2003.10.106##BIALAS A, 2002, PHYS LETT B, V532, P249, DOI 10.1016/S0370-2693(02)01550-2##BORYSOVA MS, 2006, PHYS REV C, V73, DOI 10.1103/PHYSREVC.73.024903##CLEYMANS J, 1998, PHYS REV LETT, V81, P5284, DOI 10.1103/PHYSREVLETT.81.5284##CLEYMANS J, 2005, PHYS LETT B, V615, P50, DOI 10.1016/J.PHYSLETB.2005.03.074##COLLINS JC, 1975, PHYS REV LETT, V34, P1353, DOI 10.1103/PHYSREVLETT.34.1353##DAS S, NUCLEX0503023##FODOR Z, 2004, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2004/04/050##GAZDZICKI M, 2004, J PHYS G NUCL PARTIC, V30, PS701, DOI 10.1088/0954-3899/30/8/008##GAZDZICKI M, 1999, ACTA PHYS POL B, V30, P2705##GORENSTEIN MI, 2004, PHYS LETT B, V585, P237, DOI 10.1016/J.PHYSLETB.2004.01.080##GORENSTEIN MI, 2003, PHYS LETT B, V567, P175, DOI 10.1016/J.PHYSLETB.2003.06.043##HAMA Y, 2004, ACTA PHYS POL B, V35, P179##HARRIS JW, 1996, ANNU REV NUCL PART S, V46, P71, DOI 10.1146/ANNUREV.NUCL.46.1.71##HEINZ U, 2000, PHYS REV C, V65##JEON S, 2000, PHYS REV LETT, V85, P2076, DOI 10.1103/PHYSREVLETT.85.2076##KARSCH F, 2002, NUCL PHYS B, V605, P290##MROWCZYNSKI S, 2004, PHYS REV C, V70, DOI 10.1103/PHYSREVC.70.054906##RETIERE F, 2004, PHYS REV C, V70, DOI 10.1103/PHYSREVC.70.044907##RITTER HG, 2004, J PHYS G, V30, PS633##ROLAND C, 2004, J PHYS G NUCL PARTIC, V30, PS1381, DOI 10.1088/0954-3899/30/8/132##STEFANEK G, 2006, NUCL PHYS A, V774, P499, DOI 10.1016/J.NUCLPHYSA.2006.06.074##STEPHANOV M, 1998, PHYS REV LETT, V81, P4816, DOI 10.1103/PHYSREVLETT.81.4816##TEANEY D, 2001, PHYS REV LETT, V86, P4783, DOI 10.1103/PHYSREVLETT.86.4783##WANG F, 2000, PHYS REV C, V61, DOI 10.1103/PHYSREVC.61.064904##WEBER H, 2002, PHYS LETT B, V545, P285, DOI 10.1016/S0370-2693(02)02623-0##ZARANEK J, 2002, PHYS REV C, V66, DOI 10.1103/PHYSREVC.66.024905##P RIKEN BNL WORKSH C",6,2020-11-20,NA
J,WOS:000242612800001,2006,"NEWS, POLITICAL KNOWLEDGE AND PARTICIPATION: THE DIFFERENTIAL EFFECTS OF NEWS MEDIA EXPOSURE ON POLITICAL KNOWLEDGE AND PARTICIPATION","THIS CROSS-NATIONAL STUDY INVESTIGATES THE RELATIONSHIP BETWEEN MEDIA AND POLITICAL KNOWLEDGE AND PARTICIPATION. DRAWING ON PANEL SURVEYS AND NEWS MEDIA CONTENT ANALYSES THE STUDY LINKS EXPOSURE AND ATTENTION TO SPECIFIC MEDIA CONTENTS TO CHANGES IN POLITICAL KNOWLEDGE AND PARTICIPATION. WHILE THE LITERATURE ON THIS ISSUE IS DIVIDED, THIS STUDY SHOWS THAT THE POSITIVE EFFECTS OF NEWS MEDIA EXPOSURE OUTWEIGH THE NEGATIVE EFFECTS AND THAT THE EFFECTS ARE CONDITIONAL UPON ACTUAL CONTENT. EXPOSURE TO NEWS OUTLETS WITH HIGH LEVELS OF POLITICAL CONTENT (SUCH AS PUBLIC TELEVISION NEWS AND BROADSHEET NEWSPAPERS) CONTRIBUTES THE MOST TO KNOWLEDGE GAINS AND INCREASES THE PROPENSITY TO TURN OUT TO VOTE. EXPOSURE TO NEWS OUTLETS WITH LESS POLITICAL CONTENT HAS EITHER NO EFFECTS OR SLIGHTLY POSITIVE EFFECTS, DEPENDING ON THE TYPE OF CONTENT. IN OTHER WORDS, THE EFFECTS OF NEWS MEDIA USE ON KNOWLEDGE AND PARTICIPATION ARE RATHER 'VIRTUOUS' THAN 'VICIOUS'. THE RESULTS ARE DISCUSSED IN THE LIGHT OF RESEARCH ON MEDIA EFFECTS AND POLITICAL PARTICIPATION.",MASS-MEDIA; TELEVISION; COMMUNICATION; IMPACT; MOBILIZATION; INFORMATION; GROWTH,POLITICAL KNOWLEDGE; POLITICAL PARTICIPATION; TURNOUT; NEWS MEDIA EFFECTS,ACTA POLITICA,"DE VREESE, CH##BOOMGAARDEN, H","UNIV AMSTERDAM, AMSTERDAM SCH COMMUN RES, AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, DEPT COMMUN SCI, NESCOR, NETHERLANDS SCH COMMUN RES, NL-1012 CX AMSTERDAM, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"AARTS K, 2003, J POLIT, V65, P759, DOI 10.1111/1468-2508.00211##AIKEN LR, 1988, PSYCHOL TESTING ASSE##BARTELS LM, 1993, AM POLIT SCI REV, V87, P267, DOI 10.2307/2939040##BECK PA, 2002, AM POLIT SCI REV, V96, P57, DOI 10.1017/S0003055402004239##BELLI RF, 1999, PUBLIC OPIN QUART, V63, P90, DOI 10.1086/297704##BERNSTEIN R, 2001, PUBLIC OPIN QUART, V65, P22, DOI 10.1086/320036##BLUMLER JG, 1997, POLIT COMMUN, V14, P395, DOI 10.1080/105846097199191##BRANTS K., 2004, MEDIA EUROPE EUROMED, P145##CAPPELLA J. N., 1997, SPIRAL CYNICISM PRES##CARPINI MXD, 1996, AM KNOW POLITICS WHY##CHAFFEE SH, 1986, HUM COMMUN RES, V13, P76, DOI 10.1111/J.1468-2958.1986.TB00096.X##CHAFFEE SH, 1977, JOURNALISM QUART, V54, P466, DOI 10.1177/107769907705400304##DALTON RUSSELL J., 2002, CITIZEN POLITICS PUB##DE VREESE CH, 2002, COMMUN RES, V29, P615, DOI 10.1177/009365002237829##DEVREESE CH, 2007, IN PRESS SCANDINAVIA##DEVREESE CH, 2006, J COMMON MARKET STUD, V44, P139##DILLMAN DA, 2000, MAIL INTERNET SURVEY##GRABER D., 1988, PROCESSING NEWS PEOP##GRABER DA, 1990, J COMMUN, V40, P134, DOI 10.1111/J.1460-2466.1990.TB02275.X##GRABER DORIS A., 2001, PROCESSING POLITICS##GRANBERG D, 1991, AM J POLIT SCI, V35, P448, DOI 10.2307/2111370##HOLTZ-BACHA C, 2001, POLIT COMMUN, V18, P123, DOI 10.1080/105846001750322943##HOOGHE M, 2002, HARV INT J PRESS-POL, V7, P84, DOI 10.1177/1081180X02007002006##KEETER S, 1986, COMMUN RES, V13, P37##KINDER D. R., 1996, DIVIDED COLOR RACIAL##KROSNICK JA, 1993, AM POLIT SCI REV, V87, P963, DOI 10.2307/2938828##KROSNICK JA, 1990, AM POLIT SCI REV, V84, P173##LAUF E, 2001, EUR J COMMUN, V16, P233, DOI 10.1177/0267323101016002005##LEMERT JB, 1981, DOES MASS COMMUNICAT##MARKUS G.B., 1979, ANAL PANEL DATA##MCLEOD JM, 1999, POLIT COMMUN, V16, P315, DOI 10.1080/105846099198659##MONDAK JJ, 2001, AM J POLIT SCI, V45, P224, DOI 10.2307/2669369##MONDAK JJ, 1995, AM J POLIT SCI, V39, P513, DOI 10.2307/2111623##MORTENSEN F, 2004, MEDIA EUROPE EUROMED, P43##NELSON TE, 1997, AM POLIT SCI REV, V91, P567, DOI 10.2307/2952075##NEUMAN WR, 1992, COMMON KNOWLEDGE NEW##NEUMAN WR, 1986, PARADOX MASS POLITIC##NEWTON K, 1999, BRIT J POLIT SCI, V29, P577, DOI 10.1017/S0007123499000289##NORRIS P., 2000, VIRTUOUS CIRCLE POLI##PETER J, 2004, HARV INT J PRESS-POL, V9, P3, DOI 10.1177/1081180X04270597##PFETSCH B, 1996, EUR J COMMUN, V11, P427, DOI 10.1177/0267323196011004002##PRICE V, 1993, PUBLIC OPIN QUART, V57, P133, DOI 10.1086/269363##PRIOR M, 2003, POLIT COMMUN, V20, P149, DOI 10.1080/10584600390211172##PRIOR M, 2003, NEWS VS ENTERTAINMEN##PUTNAM R. D., 2000, BOWLING ALONE COLLAP##ROBINSON JP, 1990, J COMMUN, V40, P106, DOI 10.1111/J.1460-2466.1990.TB02273.X##ROBINSON MJ, 1976, AM POLIT SCI REV, V70, P409, DOI 10.2307/1959647##ROSENSTONE S. J., 1993, MOBILIZATION PARTICI##SCHEUFELE DA, 2002, COMMUN RES, V29, P46, DOI 10.1177/009365020202900103##SCHMITT-BECK R, 2003, BRIT J POLIT SCI, V33, P233, DOI 10.1017/S0007123403000103##SCHUDSON M., 1998, GOOD CITIZEN HIST AM##SCHULZ W, 1998, EUROPEAN J COMMUNICA, V23, P527##SEMETKO H. A., 2000, DEMOCRACY MEDIA COMP, P343##SEMETKO HA, 2003, BRIT J POLIT SCI, V33, P621, DOI 10.1017/S0007123403000280##SLATER MD, 2004, J MASS COMMUN Q, V81, P168, DOI 10.1177/107769900408100112##TAN AS, 1980, PUBLIC OPIN QUART, V44, P241, DOI 10.1086/268588##TICHENOR PJ, 1970, PUBLIC OPIN QUART, V34, P159, DOI 10.1086/267786##VANPRAAG P, 2000, TUSSEN BEELD INHOUD##VERBA S, 1997, J POLIT, V59, P1051, DOI 10.2307/2998592##VERBA S, 1995, VOICE EQUALITY CIVIC",134,2020-11-20,NA
J,WOS:000242612800004,2006,COALITION GOVERNANCE IN BELGIUM AND THE NETHERLANDS: RISING GOVERNMENT STABILITY AGAINST ALL ELECTORAL ODDS,NA,CABINET; DELEGATION,COALITION GOVERNMENT; COALITION AGREEMENTS; ENFORCEMENT; CONFLICT RESOLUTION; BELGIAN POLITICS; DUTCH POLITICS,ACTA POLITICA,"TIMMERMANS, A##MOURY, C","UNIV TWENTE, DEPT POLIT SCI, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV LUXEMBOURG, LUXEMBOURG, LUXEMBOURG. UNIV SIENA, I-53100 SIENA, ITALY.",POLITICAL SCIENCE,GOVERNMENT & LAW,"ANDEWEG R, 2000, PARLIAMENTARY PARTY, P89##ANDEWEG RB, 1988, EUR J POLIT RES, V16, P125, DOI 10.1111/J.1475-6765.1988.TB00146.X##ANDEWEG RB, 2000, EUR J POLIT RES, V37, P377, DOI 10.1111/1475-6765.00518##ANDEWEG RB, IN PRESS COALITION G##AXELROD R., 1984, EVOLUTION COOPERATIO##DEPAUW S, 2002, REBELLEN PARLEMENT##DERIDDER MM, 1986, W EUROPEAN POLITICS, V3, P376##DESCHOUWER K, 1994, RES PUBLICA, V36, P43##DEWINTER L, 2002, POLITICAL PARTIES DE##DEWINTER L, 1996, RES PUBLICA, V48, P325##DEWINTER L, 2001, LEGISLATURES POLICIE##DEWINTER L, 1999, COURIER HEBDOMADAIRE, V1664##DRUCKMAN JN, 2002, AM J POLIT SCI, V46, P760, DOI 10.2307/3088432##ERALY A, 2002, POUVOIR ENCHAINE MIN##GILBERT M, 1993, ETHICS, V103, P679, DOI 10.1086/293548##HUBER JD, 2001, AM POLIT SCI REV, V95, P345, DOI 10.1017/S0003055401002052##KEMAN H, 2002, POLITICAL I EUROPE##KLINGEMANN HD, 1994, PARTIES POLICY DEMOC##LAVER M., 1994, CABINET MINISTERS PA##LAVER MICHAEL, 1992, PARTY POLICY COALITI##LAVER MICHAEL, 1990, MULTIPARTY GOVT POLI##LUEBBERT G.M., 1986, COMP DEMOCRACY POLIC##LUPIA A, 1995, AM POLIT SCI REV, V89, P648, DOI 10.2307/2082980##MAIR PETER, 2002, COMP DEMOCRACIES, P88##MOURY C., 2004, REV INT POLITIQUE CO, V11, P10##MULLER WOLFGANG, 2000, COALITION GOVT W EUR, P559##PETERSON RL, 1983, RES PUBLICA, P49##ROYED TJ, 1996, BRIT J POLIT SCI, V26, P45, DOI 10.1017/S0007123400007419##SHEPSLE KENNETH A., 1996, MAKING BREAKING GOVT##STROM K, 2001, AM POL SCI ASS SAN F##STROM K, IN PRESS COALITION G##STROM K, 2003, DELEGATION ACCOUNTAB##THIES MF, 2001, AM J POLIT SCI, V45, P580, DOI 10.2307/2669240##THOMSON R, 2001, EUR J POLIT RES, V40, P171, DOI 10.1023/A:1012987522904##TIMMERMANS A, IN PRESS EUROPEAN J##TIMMERMANS A., 2000, COALITION GOVT W EUR, P356##TIMMERMANS A., 1998, ACTA POLIT, V33, P409##TIMMERMANS A, 1990, MINISTER MINISTERRAA, P175##TIMMERMANS AI, 2003, HIGH POLITICS LOW CO##WOLDENDORP J., 2000, PARTY GOVT 48 DEMOCR",25,2020-11-20,NA
J,WOS:000242612800008,2006,THE RATIONAL DESIGN OF INTERNATIONAL INSTITUTIONS,NA,NA,NA,ACTA POLITICA,"GROENLEER, MLP","LEIDEN UNIV, DEPT PUBL ADM, LEIDEN, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"KOREMENOS BARBARA, 2004, RATIONAL DESIGN INT",0,2020-11-20,NA
J,WOS:000242612800009,2006,"PROCEDURAL POLITICS. ISSUES, INFLUENCE, AND INSTITUTIONAL CHOICE IN THE EUROPEAN UNION",NA,NA,NA,ACTA POLITICA,"HAGE, FM","LEIDEN UNIV, DEPT PUBL ADM, LEIDEN, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"JUPILLE JOSEPH, 2004, PROCEDURAL POLITICS",0,2020-11-20,NA
J,WOS:000242612800010,2006,"CAPITALISM, DEMOCRACY AND WELFARE",NA,NA,NA,ACTA POLITICA,"BECKER, U","UNIV AMSTERDAM, DEPT POLIT SCI, AMSTERDAM, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"IVERSEN T., 2005, CAPITALISM DEMOCRACY",0,2020-11-20,NA
J,WOS:000242612800011,2006,EUROPEAN UNION ENLARGEMENT,NA,NA,NA,ACTA POLITICA,"VLIEGENTHART, A","VRIJE UNIV AMSTERDAM, FAC SOCIAL SCI, DEPT POLIT SCI, AMSTERDAM, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"NUGENT N., 2004, EUROPEAN UNION ENLAR",0,2020-11-20,NA
J,WOS:000242612800012,2006,THE SOURCES OF DEMOCRATIC CONSOLIDATION,NA,NA,NA,ACTA POLITICA,"DE RAADT, J","VRIJE UNIV AMSTERDAM, FAC SOCIAL SCI, DEPT POLIT SCI, NL-1081 HV AMSTERDAM, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"ALEXANDER GERARD, 2002, SOURCES DEMOCRATIC C",0,2020-11-20,NA
J,WOS:000242612800013,2006,THE POLITICS OF CRISIS MANAGEMENT. PUBLIC LEADERSHIP UNDER PRESSURE,NA,NA,NA,ACTA POLITICA,"VERBEEK, B","RADBOUD UNIV NIJMEGEN, NIJMEGEN SCH MANAGEMENT, NIJMEGEN, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"BOIN A., 2005, POLITICS CRISIS MANA",0,2020-11-20,NA
J,WOS:000242612800014,2006,POLITICAL EMPOWERMENT OF WOMEN: THE NETHERLANDS AND OTHER COUNTRIES,NA,NA,NA,ACTA POLITICA,"OLDERSMA, J","LEIDEN UNIV, DEPT PUBL ADM, LEIDEN, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"LEIJENAAR M., 2004, POLITICAL EMPOWERMEN",0,2020-11-20,NA
J,WOS:000242612800015,2006,THE FUTURE OF THE WELFARE STATE. CRISIS MYTHS AND CRISIS REALITIES,NA,NA,NA,ACTA POLITICA,"VIS, B","VRIJE UNIV AMSTERDAM, DEPT POLIT SCI, NL-1081 HV AMSTERDAM, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"CASTLES FRANCIS G., 2004, FUTURE WELFARE STATE",0,2020-11-20,NA
J,WOS:000242612800016,2006,ENDING EMPIRE. CONTESTED SOVEREIGNTY AND TERRITORIAL PARTITION,NA,NA,NA,ACTA POLITICA,"SEGERS, M","RADBOUD UNIV NIJMEGEN, DEPT POLIT SCI & PUBL ADM, NIJMEGEN, NETHERLANDS.",POLITICAL SCIENCE,GOVERNMENT & LAW,"SPRUYT H., 2005, ENDING EMPIRE CONTES",0,2020-11-20,NA
J,WOS:000241832900004,2006,THE PERSISTENCE OF DEPRESSION SCORE,"OBJECTIVE: TO CONSTRUCT A SCORE THAT ALLOWS PREDICTION OF MAJOR DEPRESSIVE EPISODE (MDE) PERSISTENCE IN INDIVIDUALS WITH MDE USING DETERMINANTS OF PERSISTENCE IDENTIFIED IN PREVIOUS RESEARCH. METHOD: DATA WERE DERIVED FROM 250 SUBJECTS FROM THE GENERAL POPULATION WITH NEW MDE ACCORDING TO DSM-III-R. THESE SUBJECTS WERE RECRUITED FROM THE NETHERLANDS MENTAL HEALTH SURVEY AND INCIDENCE STUDY (NEMESIS), USING THE COMPOSITE INTERNATIONAL DIAGNOSTIC INTERVIEW. DETERMINANTS FOR PERSISTENCE WERE TRANSFORMED INTO A PRACTICAL RISK SCORE USING PROPORTIONAL HAZARDS MODELS AND BOOTSTRAPPING TECHNIQUES. RESULTS: THE RISK OF MDE PERSISTENCE AFTER 12 MONTHS WAS 23%. THE SCORE COMPRISED MEASURES OF PHYSICAL ILLNESS, SOCIAL SUPPORT, DEPRESSION SEVERITY AND RECURRENCY, AND DURATION OF PREVIOUS EPISODES. WITH INCREASING CATEGORIES OF THESE MEASURES, THE PREDICTED RISKS INCREASED FROM 7 TO 40%. CONCLUSION: WE CONSTRUCTED THE PERSISTENCE OF DEPRESSION SCORE (PDS) SHOWING REASONABLE PERFORMANCE. THE PDS COULD BE OF IMPORTANCE IN CLINICAL PRACTICE TO SUPPORT TREATMENT DECISIONS.",MENTAL-HEALTH SURVEY; GENERAL-POPULATION; MAJOR DEPRESSION; PRIMARY-CARE; NEMESIS; EPISODES; PSYCHOPATHOLOGY; DISABILITY; DISORDERS; INTERVIEW,DEPRESSION; PROGNOSIS; RISK ASSESSMENT; GENERAL POPULATION,ACTA PSYCHIATRICA SCANDINAVICA,"SPIJKER, J##DE GRAAF, R##ORMEL, J##NOLEN, WA##GROBBEE, DE##BURGER, H","NETHERLANDS INST MENTAL HLTH & ADDICT, TRIMBOS INST, NL-3500 AS UTRECHT, NETHERLANDS. INST MENTAL HLTH CARE, WOLFHEZE, NETHERLANDS. UNIV GRONINGEN, DEPT PSYCHIAT, MED CTR, GRONINGEN, NETHERLANDS. UNIV UTRECHT, JULIUS CTR HLTH SCI & PRIMARY CARE, MED CTR, UTRECHT, NETHERLANDS.",PSYCHIATRY,PSYCHIATRY,"AMERICAN PSYCHIATRIC ASSOCIATION, 1987, DIAGN STAT MAN MENT##BIJL RV, 1998, SOC PSYCH PSYCH EPID, V33, P581, DOI 10.1007/S001270050097##DE GRAAF R, 2000, AM J EPIDEMIOL, V152, P1039, DOI 10.1093/AJE/152.11.1039##EFRON B, 1993, MONOGRAPHS STAT APPL, V57##FURUKAWA TA, 2000, BRIT J PSYCHIAT, V177, P331, DOI 10.1192/BJP.177.4.331##GILMER WS, 2005, ACTA PSYCHIAT SCAND, V112, P425, DOI 10.1111/J.1600-0447.2005.00633.X##HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/RADIOLOGY.143.1.7063747##HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/JAMA.247.18.2543##HARRELL FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4##JUDD LL, 1997, ARCH GEN PSYCHIAT, V54, P989##KALKMAN CJ, 2003, PAIN, V105, P415, DOI 10.1016/S0304-3959(03)00252-5##KELLER MB, 1994, BRIT J PSYCHIAT, V165, P9, DOI 10.1192/S0007125000293239##LYKETSOS CG, 1994, INT J METHOD PSYCH, V4, P143##NASSER EH, 2005, ACTA PSYCHIAT SCAND, V111, P125, DOI 10.1111/J.1600-0447.2004.00423.X##*NAT I CLIN EXC, 2004, CLIN GUID NAT I CLIN, V23##ORMEL J, 1993, ARCH GEN PSYCHIAT, V50, P759##PAYKEL ES, 1996, PSYCHOL MED, V26, P121, DOI 10.1017/S0033291700033766##RAMANA R, 1995, PSYCHOL MED, V25, P1161, DOI 10.1017/S0033291700033134##SARGEANT JK, 1990, ARCH GEN PSYCHIAT, V47, P519##SMEETS R., 1993, COMPOSITE INT DIAGNO##SPIJKER J, 2004, J AFFECT DISORDERS, V81, P231, DOI 10.1016/J.JAD.2003.08.005##SPIJKER J, 2004, ACTA PSYCHIAT SCAND, V110, P208, DOI 10.1111/J.1600-0447.2004.00335.X##SPIJKER J, 2002, BRIT J PSYCHIAT, V181, P208, DOI 10.1192/BJP.181.3.208##SPIJKER J, 2001, ACTA PSYCHIAT SCAND, V104, P19, DOI 10.1034/J.1600-0447.2001.00363.X##TIEMENS BG, 1996, AM J PSYCHIAT, V153, P636##VAN DEN BRINK RHS, 2001, BRIT J PSYCHIAT, V178, P18##VERGOUWE YVONNE, 2002, SEMIN UROL ONCOL, V20, P96, DOI 10.1053/SURO.2002.32521##*WHO, 1990, COMP DIAGN INT CIDI##WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1",7,2020-11-20,NA
J,WOS:000242452300009,2006,QUANTIFICATION OF GLOBAL LEFT VENTRICULAR FUNCTION: COMPARISON OF MULTIDETECTOR COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING. A META-ANALYSIS AND REVIEW OF THE CURRENT LITERATURE,"CARDIAC MORBIDITY AND MORTALITY ARE CLOSELY RELATED TO CARDIAC VOLUMES AND GLOBAL LEFT VENTRICULAR (LV) FUNCTION, EXPRESSED AS LEFT VENTRICULAR EJECTION FRACTION. ACCURATE ASSESSMENT OF THESE PARAMETERS IS REQUIRED FOR THE PREDICTION OF PROGNOSIS IN INDIVIDUAL PATIENTS AS WELL AS IN ENTIRE COHORTS. THE CURRENT STANDARD OF REFERENCE FOR LEFT VENTRICULAR FUNCTION IS ANALYSIS BY SHORT-AXIS MAGNETIC RESONANCE IMAGING. IN RECENT YEARS, MAJOR EXTENSIVE TECHNOLOGICAL IMPROVEMENTS HAVE BEEN ACHIEVED IN COMPUTED TOMOGRAPHY. THE MOST MARKED DEVELOPMENT HAS BEEN THE INTRODUCTION OF THE MULTIDETECTOR CT (MDCT), WHICH HAS SIGNIFICANTLY IMPROVED TEMPORAL AND SPATIAL RESOLUTIONS. IN ORDER TO ASSESS THE CURRENT STATUS OF MDCT FOR ANALYSIS OF LV FUNCTION, THE CURRENT AVAILABLE LITERATURE ON THIS SUBJECT WAS REVIEWED. THE DATA PRESENTED IN THIS REVIEW INDICATE THAT THE GLOBAL LEFT VENTRICULAR FUNCTIONAL PARAMETERS MEASURED BY CONTEMPORARY MULTI-DETECTOR ROW SYSTEMS COMBINED WITH ADEQUATE RECONSTRUCTION ALGORITHMS AND POST-PROCESSING TOOLS SHOW A NARROW DIAGNOSTIC WINDOW AND ARE INTERCHANGEABLE WITH THOSE OBTAINED BY MRI.",16-SLICE SPIRAL-CT; CARDIAC EJECTION FRACTION; ROW CT; 3-DIMENSIONAL ECHOCARDIOGRAPHY; INTERSTUDY REPRODUCIBILITY; MYOCARDIAL-INFARCTION; INITIAL-EXPERIENCE; STROKE VOLUME; 1.5 T; MRI,CMR; GLOBAL LEFT VENTRICULAR FUNCTION; LEFT VENTRICULAR EJECTION FRACTION; MDCT; MRI,ACTA RADIOLOGICA,"VAN DER VLEUTEN, PA##WILLEMS, TP##GOTTE, MJW##TIO, RA##GREUTER, MJW##ZIJLSTRA, F##OUDKERK, M","UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT CARDIOL, CTR THORAX, NL-9700 RB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT RADIOL, NL-9700 RB GRONINGEN, NETHERLANDS.","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ALLISON JD, 1993, MAGN RESON IMAGING, V11, P329, DOI 10.1016/0730-725X(93)90065-L##BARGER AV, 2000, MAGNET RESON MED, V44, P821, DOI 10.1002/1522-2594(200012)44:6<821::AID-MRM1>3.0.CO;2-S##BELLENGER NG, 2000, J CARDIOV MAGN RESON, V2, P271, DOI 10.3109/10976640009148691##BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/S0140-6736(86)90837-8##BORNSTEDT A, 2001, J MAGN RESON IMAGING, V14, P300, DOI 10.1002/JMRI.1186##CAIANI EG, 2005, J AM SOC ECHOCARDIOG, V18, P779, DOI 10.1016/J.ECHO.2004.12.015##COHNEN M, 2003, EUR RADIOL, V13, P1148, DOI 10.1007/S00330-002-1614-9##CULHAM JAG, 1988, J CAN ASSOC RADIOL, V39, P247##DEBATIN JF, 1992, INVEST RADIOL, V27, P198, DOI 10.1097/00004424-199203000-00003##DEBATIN JF, 1992, JMRI-J MAGN RESON IM, V2, P135, DOI 10.1002/JMRI.1880020205##EHRHARD K, 2002, ROFO-FORTSCHR RONTG, V174, P1566, DOI 10.1055/S-2002-35946##EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645##ERBEL R, 1984, AM J CARDIOL, V53, P590, DOI 10.1016/0002-9149(84)90036-5##FLOHR TG, 2006, EUR RADIOL, V16, P256, DOI 10.1007/S00330-005-2919-2##FUNABASHI N, 2006, INT J CARDIOL##GRUDE M, 2003, INVEST RADIOL, V38, P653, DOI 10.1097/01.RLI.0000077070.40713.76##GUTBERLET M, 2005, EUR RADIOL, V15, P1586, DOI 10.1007/S00330-005-2768-Z##GUTBERLET M, 2004, ROFO-FORTSCHR RONTG, V176, P801, DOI 10.1055/S-2004-813220##HALLIBURTON SS, 2003, INT J CARDIOVAS IMAG, V19, P73, DOI 10.1023/A:1021793420007##HENDEE WR, 1992, JAMA-J AM MED ASSOC, V268, P620, DOI 10.1001/JAMA.268.5.620##HEUSCHMID M, 2005, ROFO-FORTSCHR RONTG, V177, P60, DOI 10.1055/S-2004-813768##HIGGINS CB, 1992, J AM COLL CARDIOL, V19, P1608, DOI 10.1016/0735-1097(92)90626-X##HOFMANN T, 1988, AM HEART J, V116, P1455, DOI 10.1016/0002-8703(88)90728-4##HUNOLD P, 2003, RADIOLOGY, V226, P145, DOI 10.1148/RADIOL.2261011365##JUERGENS KU, 2004, RADIOLOGY, V230, P403, DOI 10.1148/RADIOL.2302030042##JUNG BA, 2002, MAGNET RESON MED, V48, P921, DOI 10.1002/MRM.10280##KOCH K, 2004, ROFO-FORTSCHR RONTG, V176, P1786, DOI 10.1055/S-2004-813730##KONDO C, 1991, AM J ROENTGENOL, V157, P9, DOI 10.2214/AJR.157.1.2048544##KOPP AF, 2005, EUR RADIOL, V15, PD15, DOI 10.1007/S10406-005-0133-6##KRONIK G, 1979, CIRCULATION, V60, P1308, DOI 10.1161/01.CIR.60.6.1308##LONGMORE DB, 1985, LANCET, V1, P1360##MAHNKEN AH, 2005, EUR RADIOL, V15, P714, DOI 10.1007/S00330-004-2592-X##MAHNKEN AH, 2003, ACTA RADIOL, V44, P604, DOI 10.1080/02841850312331287799##MAHNKEN AH, 2004, ROFO-FORTSCHR RONTG, V176, P1365, DOI 10.1055/S-2004-813562##MAHNKEN AH, 2003, ROFO-FORTSCHR RONTG, V175, P83, DOI 10.1055/S-2003-36598##MARKIEWICZ W, 1987, J AM COLL CARDIOL, V10, P170, DOI 10.1016/S0735-1097(87)80176-6##MICHAELY HJ, 2006, INVEST RADIOL, V41, P133, DOI 10.1097/01.RLI.0000192023.96494.AF##MOGELVANG J, 1986, EUR HEART J, V7, P1016, DOI 10.1093/OXFORDJOURNALS.EURHEARTJ.A062010##OTA T, 2001, J CARDIOL, V37 SUPPL 1, P93##PESHOCK R M, 1996, MAGN RESON IMAGING CLIN N AM, V4, P287##PUJADAS S, 2004, J MAGN RESON IMAGING, V19, P789, DOI 10.1002/JMRI.20079##REICHEK N, 1991, MAGNETIC RESONANCE QUARTERLY, V7, P255##ROELANDT JRTC, 1998, ACTA CARDIOL, V53, P323##ROGUIN A, 2004, CIRCULATION, V110, P475, DOI 10.1161/01.CIR.0000137121.28722.33##ROZENMAN Y, 1984, CLIN CARDIOL, V7, P349, DOI 10.1002/CLC.4960070606##SALEM R, 2006, EUR RADIOL##SCHLOSSER T, 2005, AM J ROENTGENOL, V184, P765, DOI 10.2214/AJR.184.3.01840765##SECHTEM U, 1987, CARDIOVASC INTER RAD, V10, P365, DOI 10.1007/BF02577347##SEMELKA RC, 1990, AM HEART J, V119, P1367, DOI 10.1016/S0002-8703(05)80187-5##SEMELKA RC, 1990, RADIOLOGY, V174, P763, DOI 10.1148/RADIOLOGY.174.3.2305059##TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4##THIELE H, 2002, J CARDIOV MAGN RESON, V4, P327, DOI 10.1081/JCMR-120013298##WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44##YAMAMURO M, 2005, RADIOLOGY, V234, P381, DOI 10.1148/RADIOL.2342031271",65,2020-11-20,NA
J,WOS:000242063700007,2006,EXCUSES TO CONTINUE SMOKING: THE ROLE OF DISENGAGEMENT BELIEFS IN SMOKING CESSATION,"BACKGROUND: THE AIM OF THE PRESENT STUDY WAS TO INVESTIGATE THE ROLE OF DISENGAGEMENT BELIEFS IN SMOKING CESSATION. THE ASSOCIATION OF DISENGAGEMENT BELIEFS WITH FORWARD TRANSITION THROUGH THE TRANSTHEORETICAL STAGES OF CHANGE AND SELF-REPORTED QUITTING WERE EXAMINED, WITH AND WITHOUT ADJUSTING FOR PROCESSES OF CHANGE. METHODS: A LONGITUDINAL SURVEY WAS CONDUCTED AMONG DUTCH SMOKERS, RESULTING IN 367 RESPONDENTS WHO COMPLETED TWO QUESTIONNAIRES, ONE AT BASELINE AND ONE AT 8 MONTHS FOLLOW-UP. DISENGAGEMENT BELIEFS, INTENTION TO QUIT, ACTUAL QUITTING, AND THE PROCESSES OF CHANGE WERE ASSESSED. RESULTS: THE FINDINGS SHOWED THAT DISENGAGEMENT BELIEFS WERE NEGATIVELY ASSOCIATED WITH FORWARD STAGE TRANSITION AND ACTUAL QUITTING. PROCESSES OF CHANGE ONLY PARTLY MEDIATED THESE ASSOCIATIONS. CONCLUSIONS: ADHERING TO DISENGAGEMENT BELIEFS SEEMS TO BE AN INHIBITOR OF PROGRESSION TOWARDS SMOKING CESSATION AND ACTUAL QUITTING, ALSO AFTER ADJUSTMENT FOR PROCESSES OF CHANGE. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",SELF-EXEMPTING BELIEFS; TRANSTHEORETICAL MODEL; COGNITIVE-DISSONANCE; FEAR APPEALS; SMOKERS; HEALTH; STAGE; PREDICT; METAANALYSIS; TRANSITION,DISENGAGEMENT BELIEFS; STAGES OF CHANGE; PROCESSES OF CHANGE; SMOKING CESSATION,ADDICTIVE BEHAVIORS,"KLEINJAN, M##VAN DEN EIJNDEN, RJJM##DIJKSTRA, A##BRUG, J##ENGELS, RCME","UNIV GRONINGEN, NL-9712 TS GRONINGEN, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT PUBL HLTH, NL-3000 CA ROTTERDAM, NETHERLANDS. RADBOUD UNIV NIJMEGEN, INST BEHAV SCI, NL-6500 HE NIJMEGEN, NETHERLANDS.","PSYCHOLOGY, CLINICAL; SUBSTANCE ABUSE",PSYCHOLOGY; SUBSTANCE ABUSE,"BANDURA A, 1996, J PERS SOC PSYCHOL, V71, P364, DOI 10.1037/0022-3514.71.2.364##BANDURA A., 1986, SOCIAL FDN THOUGHT A##BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173##CHAPMAN S, 1993, AM J PUBLIC HEALTH, V83, P215, DOI 10.2105/AJPH.83.2.215##CONNERS G. J., 2001, SUBSTANCE ABUSE TREA##DAS EHHJ, 2003, PERS SOC PSYCHOL B, V29, P650, DOI 10.1177/0146167203029005009##DIJKSTRA A, 1997, ADDICT BEHAV, V22, P327, DOI 10.1016/S0306-4603(96)00054-8##DIJKSTRA A, 1998, ADDICT BEHAV, V23, P339, DOI 10.1016/S0306-4603(97)00070-1##DIJKSTRA A, 2003, BRIT J HEALTH PSYCH, V8, P423, DOI 10.1348/135910703770238284##DIJKSTRA A, 2003, BEHAV RES THER, V41, P1081, DOI 10.1016/S0005-7967(02)00244-9##DIJKSTRA A, 1999, PSYCHOL HEALTH, V14, P747, DOI 10.1080/08870449908410762##DIJKSTRA A, 2003, GEDRAG GEZONDHEID, V31, P30##FESTINGER L., 1957, THEORY COGNITIVE DIS##HERZOG TA, 1999, HEALTH PSYCHOL, V18, P369, DOI 10.1037/0278-6133.18.4.369##JOHNSON RE, 1968, J PERS SOC PSYCHOL, V9, P260, DOI 10.1037/H0025901##KRISTELLER J L, 1992, J SUBST ABUSE, V4, P263, DOI 10.1016/0899-3289(92)90035-V##MCMASTER C, 1991, ADDICT BEHAV, V16, P349, DOI 10.1016/0306-4603(91)90028-G##OAKES W, 2004, PREV MED, V39, P776, DOI 10.1016/J.YPMED.2004.03.001##OCONNOR EA, 1996, J CONSULT CLIN PSYCH, V64, P130, DOI 10.1037/0022-006X.64.1.130##OLSHAVSKY RW, 1974, J CONSUM RES, V1, P63, DOI 10.1086/208582##PROCHASKA JO, 1992, ADDICT BEHAV, V17, P35, DOI 10.1016/0306-4603(92)90051-V##PROCHASKA JO, 1988, J CONSULT CLIN PSYCH, V56, P520, DOI 10.1037/0022-006X.56.4.520##PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102##ROSEN CS, 2000, HEALTH PSYCHOL, V19, P593, DOI 10.1037/0278-6133.19.6.593##SEGAN CJ, 2002, PSYCHOL HEALTH, V17, P417, DOI 10.1080/0887044022000004911##SEGAN CJ, 2004, HEALTH PSYCHOL, V23, P86, DOI 10.1037/0278-6133.23.1.86##STEPHENS S, 2004, ADDICT BEHAV, V29, P759, DOI 10.1016/J.ADDBEH.2004.02.004##STIVOROROOKVRIJ, 2005, ROKEN HARDE FEITEN V##VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI 10.1037/0033-2909.111.1.23##VOETEN MJM, 2003, LINEAIRE REGRESSIEAN##WICKLUND ROBERT A., 1976, PERSPECTIVES COGNITI##WITTE K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506",31,2020-11-20,NA
J,WOS:000242063700011,2006,WHEN CHILDREN OF PROBLEM DRINKERS GROW OLD: DOES THE INCREASED RISK OF MENTAL DISORDERS PERSIST?,"IT IS WELL ESTABLISHED THAT CHILDREN OF PROBLEM DRINKERS HAVE AN INCREASED RISK OF DEVELOPING MENTAL HEALTH PROBLEMS, NOT ONLY DURING CHILDHOOD BUT ALSO WHEN THEY GROW UP INTO ADOLESCENTS AND ADULTS. HOWEVER, IT HAS NOT BEEN EXAMINED WHETHER THIS RISK IS ALSO PRESENT DURING THE OLD AGE OF THESE CHILDREN. IN THIS STUDY, WE EXAMINE THE QUESTION WHETHER THIS INCREASED RISK IS PRESENT IN INHABITANTS OF ELEVEN RESIDENTIAL HOMES (MEAN AGE 85 YEARS). A TOTAL OF 355 RESIDENTS INDICATED WHETHER ONE OF THEIR PARENTS EVER HAD PROBLEMS WITH ALCOHOL. WE ALSO USED THE MINI DIAGNOSTIC INTERVIEW TO ASSESS THE PRESENCE OF MENTAL DISORDERS. WE FOUND THAT PARENTAL PROBLEM DRINKING WAS SIGNIFICANTLY ASSOCIATED WITH HAVING A MAJOR DEPRESSION (CURRENT AND LIFETIME), AND WITH THE NUMBER OF DRINKS IN THE PAST WEEK. NO SIGNIFICANT RELATIONSHIP WAS FOUND WITH ALCOHOL-RELATED DISORDERS AND ANXIETY DISORDERS. IT WAS ALREADY KNOWN THAT PARENTAL PROBLEM DRINKING RESULTS IN MENTAL HEALTH PROBLEMS IN CHILDREN. WE FOUND CLEAR INDICATIONS THAT THESE PROBLEMS DO NOT DISAPPEAR WHEN THESE CHILDREN GROW OLD. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",SCALE CES-D; PSYCHIATRIC-DISORDERS; PARENTAL ALCOHOLISM; ADULT CHILDREN; DEPRESSION,CHILDREN OF PROBLEM DRINKERS; CHILDREN OF ALCOHOLICS; MAJOR DEPRESSION; OLDER ADULTS; RESIDENTIAL HOMES,ADDICTIVE BEHAVIORS,"CUIJPERS, P##STEUNENBERG, B##VAN STRATEN, A","FREE UNIV AMSTERDAM, DEPT CLIN PSYCHOL, NL-1081 BT AMSTERDAM, NETHERLANDS.","PSYCHOLOGY, CLINICAL; SUBSTANCE ABUSE",PSYCHOLOGY; SUBSTANCE ABUSE,"ADAMS WL, 1990, J AM GERIATR SOC, V38, P211, DOI 10.1111/J.1532-5415.1990.TB03493.X##BEEKMAN A T, 1994, TIJDSCHR GERONTOL GERIATR, V25, P95##BOUMA J, 1995, METEN DEPRESSIE MET##*CENTR BUR STAT, 1989, HLTH INT QUEST##CUIJPERS P, 1999, ADDICTION, V94, P1489, DOI 10.1046/J.1360-0443.1999.941014895.X##CUIJPERS P, 2001, ADDICT BEHAV, V26, P741, DOI 10.1016/S0306-4603(00)00155-6##FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6##GREENFIELD SF, 1993, AM J PSYCHIAT, V150, P608##HARINGSMA R, 2004, INT J GERIATR PSYCH, V19, P558, DOI 10.1002/GPS.1130##JOHNSON DH, 2001, ONCOLOGY-NY, V15, P33##LAKHANI N, 1997, J ADV NURS, V25, P1227, DOI 10.1046/J.1365-2648.1997.19970251227.X##LEWINSOHN PM, 1997, PSYCHOL AGING, V12, P277, DOI 10.1037/0882-7974.12.2.277##MATHEW RJ, 1993, AM J PSYCHIAT, V150, P793##MERIKANGAS KR, 1990, PSYCHOL MED, V20, P11, DOI 10.1017/S0033291700013192##OVERBEEK T., 1999, MINI INT NEUROPSYCHI##RADLOFF L S, 1977, APPLIED PSYCHOLOGICAL MEASUREMENT, V1, P385, DOI 10.1177/014662167700100306##RUIZCABALLERO JA, 1994, COGNITION EMOTION, V8, P555, DOI 10.1080/02699939408408959##SEARLES JS, 1988, J ABNORM PSYCHOL, V97, P153, DOI 10.1037/0021-843X.97.2.153##SHEEHAN DV, 1998, J CLIN PSYCHIAT, V59, P34, DOI 10.4088/JCP.09M05305WHI##VANSTEINHAUSEN H, 1995, EUROPEAN CHILD ADOLE, V4, P143##VONKNORRING AL, 1991, J CHILD PSYCHOL PSYC, V32, P411##WEST MO, 1987, PSYCHOL BULL, V102, P204, DOI 10.1037/0033-2909.102.2.204##ZEITLIN H, 1994, BRIT MED BULL, V50, P139, DOI 10.1093/OXFORDJOURNALS.BMB.A072872",6,2020-11-20,NA
J,WOS:000243281600009,2006,NITRILE HYDRATASE ACTIVITY OF A RECOMBINANT NITRILASE,"APPRECIABLE AMOUNTS OF AMIDE ARE FORMED IN THE COURSE OF NITRILE HYDROLYSIS IN THE PRESENCE OF RECOMBINANT NITRILASE FROM PSEUDOMONAS FLUORESCENS EBC 191, DEPENDING ON THE ALPHA-SUBSTITUENT AND THE REACTION CONDITIONS. THE RATIO OF THE NITRILASE AND NITRILE HYDRATASE ACTIVITIES OF THE ENZYME IS PROFOUNDLY INFLUENCED BY THE ELECTRONIC AND STERIC PROPERTIES OF THE REACTANT. IN GENERAL, AMIDE FORMATION INCREASED WHEN THE A-SUBSTITUENT WAS ELECTRON-DEFICIENT; 2-CHLORO-2-PHENYLACETONITRILE, FOR EXAMPLE, AFFORDED 89% AMIDE. WE FOUND, MOREOVER, THAT (R)-MANDELONITRILE WAS HYDROLYSED WITH 11% OF AMIDE FORMATION WHEREAS 55% AMIDE WAS FORMED FROM THE (S)-ENANTIOMER; A SIMILAR EFFECT WAS FOUND FOR THE O-ACETYL DERIVATIVES. A MECHANISM THAT ACCOMODATES OUR RESULTS IS PROPOSED.",SITE-DIRECTED MUTAGENESIS; AMINO-ACID AMIDOHYDROLASE; CRYSTAL-STRUCTURE; ENANTIOSELECTIVE HYDROLYSIS; PURIFICATION; CATALYSIS; REVEALS,AMIDE FORMATION; ENANTIOMER SELECTIVITY; MECHANISM; NITRILASE; PSEUDOMONAS FLUORESCENS EBC 191; SELECTIVITY,ADVANCED SYNTHESIS & CATALYSIS,"FERNANDES, BCM##MATEO, C##KIZIAK, C##CHMURA, A##WACKER, J##VAN RANTWIJK, F##STOLZ, A##SHELDON, RA","DELFT UNIV TECHNOL, LAB BIOCATALYSIS & ORGAN CHEM, NL-2628 BL DELFT, NETHERLANDS. UNIV STUTTGART, INST MIKROBIOL, D-70550 STUTTGART, GERMANY.","CHEMISTRY, APPLIED; CHEMISTRY, ORGANIC",CHEMISTRY,"BRENNER C, 2002, CURR OPIN STRUC BIOL, V12, P775, DOI 10.1016/S0959-440X(02)00387-1##BREUER M, 2004, ANGEW CHEM INT EDIT, V43, P788, DOI 10.1002/ANIE.200300599##CHATURVEDI RK, 1967, J AM CHEM SOC, V89, P6984, DOI 10.1021/JA01002A029##DUFOUR E, 1995, BIOCHEMISTRY-US, V34, P16382, DOI 10.1021/BI00050A019##EFFENBERGER F, 2001, TETRAHEDRON-ASYMMETR, V12, P279, DOI 10.1016/S0957-4166(01)00034-9##FORSTER S, 1996, ANGEW CHEM INT EDIT, V35, P437, DOI 10.1002/ANIE.199604371##GOLDLUST A, 1989, BIOTECHNOL APPL BIOC, V11, P581##HARPER DB, 1977, BIOCHEM J, V165, P309, DOI 10.1042/BJ1650309##HEINEMANN U, 2003, APPL MICROBIOL BIOT, V63, P274, DOI 10.1007/S00253-003-1382-8##HOOK RH, 1964, J BIOL CHEM, V239, P4263##KIZIAK C, 2005, MICROBIOL-SGM, V151, P3639, DOI 10.1099/MIC.0.28246-0##KOBAYASHI M, 1998, BIOCHEM BIOPH RES CO, V253, P662, DOI 10.1006/BBRC.1998.9834##KUMARAN D, 2003, PROTEINS, V52, P283, DOI 10.1002/PROT.10417##LAYH N, 1992, ARCH MICROBIOL, V158, P405##NAGASAWA T, 1989, TRENDS BIOTECHNOL, V7, P153, DOI 10.1016/0167-7799(89)90026-7##NAKAI T, 2000, STRUCTURE, V8, P729, DOI 10.1016/S0969-2126(00)00160-X##NOVO C, 2002, BIOCHEM J, V365, P731, DOI 10.1042/BJ20011714##OSSWALD S, 2002, EUR J BIOCHEM, V269, P680, DOI 10.1046/J.0014-2956.2001.02702.X##PACE HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7##PACE HC, 2001, GENOME BIOL, V2##PIOTROWSKI M, 2001, J BIOL CHEM, V276, P2616, DOI 10.1074/JBC.M007890200##SCHMIDT M, 1999, TOP CURR CHEM, V200, P193##STEVENSON DE, 1992, BIOTECHNOL APPL BIOC, V15, P283##VAN LANGEN LM, 2005, ORG LETT, V7, P327, DOI 10.1021/OL047647Z##VEUM L, 2005, ADV SYNTH CATAL, V347, P1015, DOI 10.1002/ADSC.200505031##WANG WC, 2001, J MOL BIOL, V306, P251, DOI 10.1006/JMBI.2000.4380##WINKLER M, 2006, CHEM COMMUN, P1298, DOI 10.1039/B516937B##YAMAMOTO K, 1991, APPL ENVIRON MICROB, V57, P3028, DOI 10.1128/AEM.57.10.3028-3032.1991##ZERVOS C, 1971, J ORG CHEM, V36, P1661",70,2020-11-20,NA
J,WOS:000421183000002,2006,LIKELIHOOD-BASED INFERENCE FOR SERIES SYSTEM RELIABILITY,"IN THIS ARTICLE WE EMPLOY LIKELIHOOD-BASED METHODS TO DRAW LIKELIHOOD INFERENCE ON THE RELIABILITY OF A SERIES SYSTEM COMPOSED OF K INDEPENDENT SUBSYSTEMS. THE DATA ON EACH SUBSYSTEM IS BASED ON TYPE-2 CENSORED SAMPLE (FAILURE CENSORING). IT IS ASSUMED THAT THE PARENT DISTRIBUTION FROM WHICH THE CENSORED SAMPLE OF THE I-TH SUBSYSTEM IS GENERATED IS EXPONENTIAL WITH UNKNOWN MEAN.I, I = 1,..., K. TWO LIKELIHOOD-BASED METHODS ARE USED; NAMELY, THE PROFILE AND CONDITIONAL LIKELIHOODS. NUMERICAL EXAMPLES ARE PROVIDED AND A COMPARISON IS MADE WITH RESPECT TO RESULTS OBTAINED BY THE CLASSICAL, FREQUENCY-BASED, APPROACH.",NA,TYPE-2 CENSORING; RELIABILITY; SERIES SYSTEM; PROFILE LIKELIHOOD; CONDITIONAL LIKELIHOOD,ADVANCES AND APPLICATIONS IN STATISTICS,"BAR-LEV, SK##SCHOUTEN, FAVDD","[BAR-LEV, SHAUL K.] UNIV HAIFA, DEPT STAT, IL-31905 HAIFA, ISRAEL. TILBURG UNIV, CTR ECON RES, NL-5000 LE TILBURG, NETHERLANDS.",STATISTICS & PROBABILITY,MATHEMATICS,"BAR-LEV S. K., 2005, J APPL STAT SCI, V14, P2005##BAR-LEV SK, 2004, LIFETIME DATA ANAL, V10, P293, DOI 10.1023/B:LIDA.0000036394.66861.9E##BARNARD GA, 1983, ANN STAT, V11, P104, DOI 10.1214/AOS/1176346061##BASU D, 1977, J AM STAT ASSOC, V72, P355, DOI 10.2307/2286800##BERGER JO, 1988, LIKELIHOOD PRINCIPLE##FISHER RA, 1934, P R SOC LOND A-CONTA, V144, P0285, DOI 10.1098/RSPA.1934.0050##FISHER RA, 1956, STAT METHODS SCI INF##GHOSH J. K., 1988, LECT NOTES STAT, V45##KALBFLEI.JD, 1970, J ROY STAT SOC B, V32, P175##KALBFLEISCH J. D., 1970, NEW DEV SURVEY SAMPL##KALBFLEISH JD, 1973, SANKHYA SER A, V35, P311##LAWLESS J.F., 2003, STAT MODELS METHODS##LENTNER M. M., 1963, TECHNOMETRICS, V5, P670##MEEKER W. Q., 1998, STAT METHODS RELIABI##NELSON W, 1990, ACCELERATED TESTING##PACE L., 1997, PRINCIPLES STAT INFE##ROYALL R. M., 1997, STAT EVIDENCE##SEVERINI T.A., 2000, LIKELIHOOD METHODS S##SPROTT DA, 1975, BIOMETRIKA, V62, P599, DOI 10.1093/BIOMET/62.3.599##SPROTT DA, 1969, J AM STAT ASSOC, V64, P468, DOI 10.2307/2283633##ZHU YL, 1994, CAN J STAT, V22, P111, DOI 10.2307/3315827",0,2020-11-20,NA
J,WOS:000243579100003,2006,MAXIMUM LIKELIHOOD ESTIMATION FOR RANDOM SEQUENTIAL ADSORPTION,THE EXISTENCE AND UNIQUENESS OF MAXIMUM LIKELIHOOD ESTIMATORS FOR THE TIME AND RANGE PARAMETERS IN RANDOM SEQUENTIAL ADSORPTION MODELS ARE INVESTIGATED.,COMPLETE PACKING; SIMULATION; MODELS,MAXIMUM LIKELIHOOD ESTIMATION; RANDOM SEQUENTIAL ADSORPTION; SEQUENTIAL SPATIAL PROCESS; SIMPLE SEQUENTIAL INHIBITION,ADVANCES IN APPLIED PROBABILITY,"VAN LIESHOUT, MNM","CWI, NL-1090 GB AMSTERDAM, NETHERLANDS. EURANDOM, EINDHOVEN, NETHERLANDS.",STATISTICS & PROBABILITY,MATHEMATICS,"CRESSIE N. A. C., 1991, STAT SPATIAL DATA##DALEY D.J., 1988, INTRO THEORY POINT P##DIGGLE P. J., 1983, STAT ANAL SPATIAL PO##DIGGLE PJ, 1976, BIOMETRICS, V32, P659, DOI 10.2307/2529754##DOGE G, 2001, J STAT COMPUT SIM, V69, P141, DOI 10.1080/00949650108812087##DVORETZKY A, 1964, PUBL MATH I HUNG, V9, P209##EVANS JW, 1993, REV MOD PHYS, V65, P1281, DOI 10.1103/REVMODPHYS.65.1281##FEDER J, 1980, J THEOR BIOL, V87, P237, DOI 10.1016/0022-5193(80)90358-6##FELLER W., 1970, INTRO PROBABILITY TH, VII##HALL P., 1988, INTRO THEORY COVERAG##LOTWICK HW, 1982, J STAT COMPUT SIM, V15, P295, DOI 10.1080/00949658208810596##MATHAI AM, 1982, ANN I STAT MATH, V34, P591, DOI 10.1007/BF02481056##PENROSE MD, 2001, COMMUN MATH PHYS, V218, P153, DOI 10.1007/S002200100387##PREKOPA A., 1973, ACTA SCI MATH, V34, P335##RENYI A, 1958, PUBL MATH I HUNG, V3, P109##RIPLEY B.D., 1988, STAT INFERENCE SPATI##SENGER B, 2000, COLLOID SURFACE A, V165, P255, DOI 10.1016/S0927-7757(99)00413-6##STOYAN D, 1998, INT STAT REV, V66, P1##TANEMURA M, 1979, ANN I STAT MATH, V31, P351, DOI 10.1007/BF02480293##UPTON G. J. G., 1985, SPATIAL DATA ANAL EX, V1##VAN LIESHOUT M, 2006, P PRAG STOCH 2006, P215##VANLIESHOUT MNM, 2006, LECT NOTES MONOGRAPH, V48, P154",8,2020-11-20,NA
J,WOS:000243579100012,2006,ESTIMATION IN BRANCHING PROCESSES WITH RESTRICTED OBSERVATIONS,"WE CONSIDER AN EPIDEMIC MODEL WHERE THE SPREAD OF THE EPIDEMIC CAN BE DESCRIBED BY A DISCRETE-TIME GALTON-WATSON BRANCHING PROCESS. BETWEEN TIMES N AND N + 1, ANY INFECTED INDIVIDUAL IS DETECTED WITH UNKNOWN PROBABILITY PI AND THE NUMBERS OF THESE DETECTED INDIVIDUALS ARE THE ONLY OBSERVATIONS WE HAVE. DETECTED INDIVIDUALS PRODUCE A REDUCED NUMBER OF OFFSPRING IN THE TIME INTERVAL OF DETECTION, AND NO OFFSPRING AT ALL THEREAFTER. IF ONLY THE GENERATION SIZES OF A GALTON-WATSON PROCESS ARE OBSERVED, IT IS KNOWN THAT ONE CAN ONLY ESTIMATE THE FIRST TWO MOMENTS OF THE OFFSPRING DISTRIBUTION CONSISTENTLY ON THE EXPLOSION SET OF THE PROCESS (AND, APART FROM SOME LATTICE PARAMETERS, NO PARAMETERS THAT ARE NOT DETERMINED BY THOSE MOMENTS). SOMEWHAT SURPRISINGLY, IN OUR CONTEXT, WHERE WE OBSERVE A BINOMIALLY DISTRIBUTED SUBSET OF EACH GENERATION, WE ARE ABLE TO ESTIMATE THREE FUNCTIONS OF THE PARAMETERS CONSISTENTLY. IN CONCRETE SITUATIONS, THIS OFTEN ENABLES US TO ESTIMATE PI CONSISTENTLY, AS WELL AS THE MEAN NUMBER OF OFFSPRING. WE APPLY THE ESTIMATORS TO DATA FOR A REAL EPIDEMIC OF CLASSICAL SWINE FEVER.",NA,GALTON-WATSON BRANCHING PROCESS; CONSISTENT ESTIMATION; PARTIAL OBSERVATION; EPIDEMIC; REAL-TIME ESTIMATION,ADVANCES IN APPLIED PROBABILITY,"MEESTER, R##TRAPMAN, P","VRIJE UNIV AMSTERDAM, DEPT MATH, NL-1081 HV AMSTERDAM, NETHERLANDS.",STATISTICS & PROBABILITY,MATHEMATICS,"ANDERSSON H, 2000, LECT NOTES STAT, V151##BECKER NG, 1997, J ROY STAT SOC B MET, V59, P415, DOI 10.1111/1467-9868.00076##DIEKMANN O., 2000, MATH EPIDEMIOLOGY IN##GUTTORP P, 1991, STAT INFERENCE BRANC##HALL P, 1980, MARTINGALE LIMIT THE##JACOB C, 1998, ADV APPL PROBAB, V30, P948, DOI 10.1017/S0001867800008740##KLINKENBERG D, 2003, THESIS UTRECHT U##MEESTER R, 2002, BIOMETRICS, V58, P178, DOI 10.1111/J.0006-341X.2002.00178.X##TRAPMAN P, 2004, J MATH BIOL, V49, P553, DOI 10.1007/S00285-004-0267-5##TRAPMAN P, 2006, THESIS VRIJE U AMSTE",8,2020-11-20,NA
J,WOS:000243030100003,2006,"FEASIBILITY STUDY ON AUTOMATED RECOGNITION OF ALLERGENIC POLLEN: GRASS, BIRCH AND MUGWORT","QUANTIFICATION OF AIRBORNE POLLEN IS AN IMPORTANT TOOL IN SCIENTIFIC RESEARCH AND PATIENT CARE IN ALLERGY. THE CURRENTLY AVAILABLE METHOD RELIES ON MICROSCOPIC EXAMINATION OF POLLEN SLIDES, PERFORMED BY QUALIFIED RESEARCHERS. ALTHOUGH HIGHLY RELIABLE, THE METHOD IS LABOR INTENSIVE AND REQUIRES EXTENSIVE TRAINING OF THE RESEARCHERS INVOLVED. IN AN APPROACH TO DEVELOP ALTERNATIVE DETECTION METHODS, WE PERFORMED A FEASIBILITY STUDY ON THE AUTOMATED RECOGNITION OF THE ALLERGENIC RELEVANT POLLEN, GRASS, BIRCH, AND MUGWORT, BY UTILIZING DIGITAL IMAGE ANALYSIS AND PATTERN RECOGNITION TOOLS. OF A TOTAL OF 254 POLLEN SAMPLES (INCLUDING 79 OF GRASS, 79 OF BIRCH AND 96 OF MUGWORT), 97.2% WERE RECOGNIZED CORRECTLY. THIS ENCOURAGING RESULT PROVIDES A PROMISING PROSPECT FOR FUTURE DEVELOPMENTS.",NA,AIRBORNE POLLEN; AUTOMATED RECOGNITION; IMAGE ANALYSIS; PORE/COLPUS; SHAPE FEATURES; STATISTICAL GRAY-LEVEL FEATURES,AEROBIOLOGIA,"CHEN, C##HENDRIKS, EA##DUIN, RPW##REIBER, JHC##HIEMSTRA, PS##DE WEGER, LA##STOEL, BC","LEIDEN UNIV, MED CTR, DEPT RADIOL, DIV IMAGE PROC, NL-2300 RC LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT PULMONOL, NL-2300 RC LEIDEN, NETHERLANDS. DELFT UNIV TECHNOL, INFORMAT & COMMUN THEORY GRP, NL-2600 GA DELFT, NETHERLANDS.",BIOLOGY; ENVIRONMENTAL SCIENCES,LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS; ENVIRONMENTAL SCIENCES & ECOLOGY,"BONTON P, 2001, IMAGE ANAL STEREOL, V20, P527##BOUCHER ALAIN, 2002, AEROBIOLOGIA, V18, P195, DOI 10.1023/A:1021322813565##COSTA LF, 2001, SHAPE ANAL CLASSIFIC, P422##COSTA LF, 2001, SHAPE ANAL CLASSIFIC, P376##DASARATHY BV, 1991, NEAREST NEIGHBOUR NO##EGAN J., 1975, SIGNAL DETECTION THE##HOUGH P. V. C., 1962, U.S. PATENT, PATENT NO. [3,069,654, 3069654]##ILLINGWORTH J, 1988, COMPUT VISION GRAPH, V44, P87, DOI 10.1016/S0734-189X(88)80033-1##KITTLER J, 1975, INT J MAN MACH STUD, V7, P609, DOI 10.1016/S0020-7373(75)80023-X##LACHENBR.PA, 1968, TECHNOMETRICS, V10, P1, DOI 10.2307/1266219##LI P, 1999, GRANA, V38, P59, DOI 10.1080/001731300750044717##MCLACHLAN G., 1992, DISCRIMINANT ANAL ST##PRATT WK, 1978, DIGITAL IMAGE PROCES, P651##RODRIGUEZ-DAMIAN M, 2004, INT C PATT RECOG, P212, DOI 10.1109/ICPR.2004.1334098##RONNEBERGER OLAF, 2002, AEROBIOLOGIA, V18, P107, DOI 10.1023/A:1020623724584##STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/J.2517-6161.1974.TB00994.X##WEBB A, 2002, STAT PATTERN RECOGNI, P34##WEBB AR, 2002, STAT PATTERN RECOGNI, P362##WEBER RW, 1998, ANN ALLERG ASTHMA IM, V80, P141, DOI 10.1016/S1081-1206(10)62947-X##YOUNG IT, 1998, DIGIT SIGNAL PROCESS, V51, P33##YOUNG IT, 1998, DIGIT SIGNAL PROCESS, V51, P63##ZHANG Y, 2004, INT C COMP SCI ICC 1, P416",28,2020-11-20,NA
J,WOS:000242887300005,2006,GHANAIAN INTERWEAVING IN THE NINETEENTH CENTURY - A NEW PERSPECTIVE ON EWE AND ASANTE TEXTILE HISTORY,NA,NA,NA,AFRICAN ARTS,"KRAAMER, M","ERASMUS UNIV, NL-3000 DR ROTTERDAM, NETHERLANDS. UNIV E ANGLIA, SAINSBURY RES UNIT, NORWICH NR4 7TJ, NORFOLK, ENGLAND.",ART,ART,"AMENUMEY DEK, 1989, EWE UNIFICATION MOUV##BOWDICH TE, 1966, MISSION CAPE COAST C##CHRISTALLER JG, 1881, DICT ASANTE FANTI LA##CLARKE D, 1999, THESIS U LONDON LOND##COLLIER K, 2002, THESIS U BIRMINGHAM##FREEMAN RA, 1998, TRAVELS LIFE ASHANTI##GABUS J, 1955, SAHARA HOMMES LEURS##GABUS JEAN., 1958, SAHARA ARTS SYMBOLES##HIAMEY TB, 1981, THESIS U SCI TECHNOL##ISERT PE, FONTES HIST AFRICANA, V7##KASFIR SIDNEY LITTLEFIELD, 1984, HIST AFR, V11, P163, DOI DOI 10.2307/3171633##KLEIN A, 1998, THESIS U LONDON LOND##KRAAMER M, 2005, THESIS U LONDON LOND##KRAAMER M, 2005, HDB EWELAND, V3, P293##LAMB VENICE, 1975, W AFRICAN WEAVING##MCLEOD MD, 1981, THE ASANTE##MEYER B, 2002, J RELIG AFR, V32, P167##NUGENT PC, 1991, THESIS U LONDON##OGBECHI SO, 2005, AFR ARTS, V36, P62##PICTON J, 1991, AFR ARTS, V24, P83, DOI 10.2307/3336929##PICTON JOHN, 1992, HIST DESIGN CRAFT W, P13##PICTON JOHN, 1989, AFRICAN TEXTILES##RATTRAY RS, 1927, REL ART ASHANTI##ROBERTS A.F., 1995, ANIMALS AFRICAN ART##ROMER LF, 1965, COAST GUINEA##ROSS DH, 1998, UCLA FOWLER MUSEUM C, V2##SPIETH J., 1906, EWE STAMME MAT KUNDE##SPRIGGE R. G. S., 1969, T HIST SOC GHANA, V10, P87##VAN DANTZIG A., 1978, DUTCH GUINEA COAST 1##VANSINA J, 1984, ART HIST AFRICA INT",5,2020-11-20,NA
J,WOS:000242887300006,2006,DAK'ART 2006 - POSITIONS AND PERSPECTIVES - DAK'ART SPACES OF EXPRESSION,NA,NA,NA,AFRICAN ARTS,"ROBERTS, PN##HUGHES, HM##BROWN, C##DIBA, V##NELSON, S##VAN RENSBURG, SJ","UNIV CALIF LOS ANGELES, FOWLER MUSEUM, LOS ANGELES, CA 90024 USA. UNIV CALIF LOS ANGELES, DEPT WORLD ARTS & CULTURE, LOS ANGELES, CA 90024 USA. AICA, PARIS, FRANCE. IRM, AMSTERDAM, NETHERLANDS. DURBAN ART GALLERY, DURBAN, SOUTH AFRICA.",ART,ART,"FATMI M, GETTING OUT OF HISTO##LO N, 2005, REFUS DE ROSA PARKS##MWANGI I, 1999, WILDLIFE##OKUDZETO S, 2006, CAPITALISME ET SCHIZ##SERLE B, 2005, ABOUT TO FORGET##TSIMBA R, 2005, SILHOUTTE EFFACEE",1,2020-11-20,NA
J,WOS:000242198700006,2006,HAEMATOPOIETIC STEM CELLS AND ENDOTHELIAL PROGENITOR CELLS IN HEALTHY MEN: EFFECT OF AGING AND TRAINING,"THE NUMBER OF HEMATOPOIETIC STEM CELLS (HSC) AND ENDOTHELIAL PROGENITOR CELLS (EPC) IS THOUGHT TO BE A MARKER FOR NEOVASCULARIZATION AND VASCULAR REPAIR. BECAUSE PHYSICAL INACTIVITY AND AGING ARE RISK FACTORS FOR CARDIOVASCULAR DISEASES, THESE FACTORS MAY INFLUENCE THE NUMBERS OF HSCS AND EPCS. THEREFORE, WE EXAMINED BASELINE AND EXERCISE-INDUCED LEVELS OF HSCS AND EPCS IN SEDENTARY AND TRAINED YOUNG AND OLDER MEN. TO STUDY THE ROLE OF AGING IN EIGHT SEDENTARY YOUNG (19-28 YEARS) AND EIGHT SEDENTARY OLDER MEN (67-76 YEARS), BASELINE AND ACUTE EXERCISE-INDUCED NUMBERS OF HSCS (CD34(+)-CELLS) AND EPCS (CD34(+)/VEGFR-2(+)-CELLS) WERE QUANTIFIED BY FLUORESCENCE-ACTIVATED CELL SORTER (FACS) ANALYSIS. TO EXAMINE THE EFFECT OF CHRONIC TRAINING, EIGHT AGE-MATCHED TRAINED YOUNG MEN (18-28 YEARS) WERE COMPARED WITH SEDENTARY YOUNG MEN, WHEREAS OLDER MEN PERFORMED AN 8-WEEK ENDURANCE TRAINING. OLDER MEN SHOWED SIGNIFICANTLY LOWER BASELINE AND EXERCISE-INDUCED LEVELS OF HSCS/EPCS THAN THE YOUNG MEN (P < 0.05). IN YOUNG AND OLDER MEN, ACUTE EXERCISE SIGNIFICANTLY INCREASED HSCS (P < 0.01), BUT NOT EPCS. THE ABSOLUTE INCREASE IN NUMBERS OF HSCS WAS ATTENUATED IN OLDER MEN (P = 0.03). APART FROM THE LOWER BASELINE NUMBERS OF EPCS AFTER CHRONIC TRAINING IN OLDER MEN, TRAINING STATUS DID NOT ALTER BASELINE OR EXERCISE-INDUCED LEVELS OF HSCS/EPCS IN YOUNG AND OLDER MEN. WE CONCLUDED THAT ADVANCING AGE RESULTS IN LOWER CIRCULATING NUMBERS OF HSCS AND EPCS AND ATTENUATES THE ACUTE EXERCISE-INDUCED INCREASE IN HSCS. INTERESTINGLY, IN YOUNG AS WELL AS IN OLDER MEN CHRONIC ENDURANCE TRAINING DOES NOT AFFECT BASELINE AND EXERCISE-INDUCED NUMBERS OF HSCS AND EPCS.",CENTRAL ARTERIAL COMPLIANCE; REGULAR AEROBIC EXERCISE; GROWTH-FACTOR; HABITUAL EXERCISE; PHYSICAL-ACTIVITY; VASCULAR FUNCTION; AGE; MOBILIZATION; INCREASES; SEDENTARY,AGING; ENDOTHELIAL PROGENITOR CELL; ENDURANCE TRAINING; HAEMATOPOIETIC STEM CELL; SINGLE EXERCISE BOUT,AGING CELL,"THIJSSEN, DHJ##VOS, JB##VERSEYDEN, C##VAN ZONNEVELD, AJ##SMITS, P##SWEEP, FCGJ##HOPMAN, MTE##DE BOER, HC","RADBOUD UNIV NIJMEGEN, MED CTR, DEPT PHYSIOL, INST FUNDAMENTAL & CLIN MOVEMENT SCI, NL-6525 EZ NIJMEGEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT NEPHROL, LEIDEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, DEPT PHARMACOL & TOXICOL, NL-6525 EZ NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, DEPT CHEM ENDOCRINOL, NL-6525 EZ NIJMEGEN, NETHERLANDS.",CELL BIOLOGY; GERIATRICS & GERONTOLOGY,CELL BIOLOGY; GERIATRICS & GERONTOLOGY,"ADAMS V, 2004, ARTERIOSCL THROM VAS, V24, P684, DOI 10.1161/01.ATV.0000124104.23702.A0##ASAHARA T, 1997, SCIENCE, V275, P964, DOI 10.1126/SCIENCE.275.5302.964##ASAHARA T, 1999, EMBO J, V18, P3964, DOI 10.1093/EMBOJ/18.14.3964##CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P471, DOI 10.1016/0735-1097(94)90305-0##CHEN MC, 2006, INT HEART J, V47, P95, DOI 10.1536/IHJ.47.95##DESOUZA CA, 2000, CIRCULATION, V102, P1351, DOI 10.1161/01.CIR.102.12.1351##ESKURZA I, 2004, J PHYSIOL-LONDON, V556, P315, DOI 10.1113/JPHYSIOL.2003.057042##FRANZONI F, 2004, BIOMED PHARMACOTHER, V58, P432, DOI 10.1016/J.BIOPHA.2004.08.009##GAVIN TP, 2004, J APPL PHYSIOL, V96, P19, DOI 10.1152/JAPPLPHYSIOL.00748.2003##GREEN DJ, 2004, J APPL PHYSIOL, V97, P749, DOI 10.1152/JAPPLPHYSIOL.00109.2004##HEISS C, 2005, J AM COLL CARDIOL, V45, P1441, DOI 10.1016/J.JACC.2004.12.074##HILL JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMOA022287##ISHIZAWA K, 2004, BIOCHEM BIOPH RES CO, V324, P276, DOI 10.1016/J.BBRC.2004.09.049##KRAUS RM, 2004, J APPL PHYSIOL, V96, P1445, DOI 10.1152/JAPPLPHYSIOL.01031.2003##LAUFS U, 2005, EUR J CARDIOV PREV R, V12, P407, DOI 10.1097/01.HJR.0000174823.87269.2E##LAUFS U, 2004, CIRCULATION, V109, P220, DOI 10.1161/01.CIR.0000109141.48980.37##MIYACHI M, 2004, CIRCULATION, V110, P2858, DOI 10.1161/01.CIR.0000146380.08401.99##MONAHAN KD, 2001, CIRCULATION, V104, P1627, DOI 10.1161/HC3901.096670##MORICI G, 2005, AM J PHYSIOL-REG I, V289, PR1496, DOI 10.1152/AJPREGU.00338.2005##ORLIC D, 2001, NATURE, V410, P701, DOI 10.1038/35070587##OZUYAMAN B, 2005, THROMB HAEMOSTASIS, V94, P770, DOI 10.1160/TH05-01-0038##PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003##PALANGE P, 2006, EUR RESPIR J, V27, P529, DOI 10.1183/09031936.06.00120604##RAUSCHER FM, 2003, CIRCULATION, V108, P457, DOI 10.1161/01.CIR.0000082924.75945.48##REHMAN J, 2004, J AM COLL CARDIOL, V43, P2314, DOI 10.1016/J.JACC.2004.02.049##RYAN NA, 2006, J APPL PHYSIOL, V100, P178, DOI 10.1152/JAPPLPHYSIOL.00827.2005##SANDRI M, 2005, CIRCULATION, V111, P3391, DOI 10.1161/CIRCULATIONAHA.104.527135##SCHMIDT-LUCKE C, 2005, CIRCULATION, V111, P2981, DOI 10.1161/CIRCULATIONAHA.104.504340##SHAFFER RG, 2006, CYTOM PART B-CLIN CY, V70B, P56, DOI 10.1002/CYTO.B.20085##SHINTANI S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/HC2301.092122##SPAN PN, 2000, INT J BIOL MARKER, V15, P184##STEINER S, 2005, ATHEROSCLEROSIS, V181, P305, DOI 10.1016/J.ATHEROSCLEROSIS.2005.01.006##TADDEI S, 2000, CIRCULATION, V101, P2896, DOI 10.1161/01.CIR.101.25.2896##TANAKA H, 2002, J APPL PHYSIOL, V92, P1458, DOI 10.1152/JAPPLPHYSIOL.00824.2001##TANAKA H, 2000, CIRCULATION, V102, P1270, DOI 10.1161/01.CIR.102.11.1270##URBICH C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78##VASA M, 2001, CIRC RES, V89, PE1, DOI 10.1161/HH1301.093953##WERNER N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMOA043814",115,2020-11-20,NA
J,WOS:000242542800002,2006,FACTORS AFFECTING SOIL QUALITY CHANGES IN THE NORTH CHINA PLAIN: A CASE STUDY OF QUZHOU COUNTY,"AT THE END OF THE 1970S THERE WERE 3,300,000 HA OF SALT-AFFECTED LAND IN THE NORTH CHINA PLAIN. AFTER THE SUCCESSFUL REMOVAL OF THE SALT IN THE 1980S, THE LAND HAS GRADUALLY BEEN USED FOR INCREASING INTENSIVE FORMS OF AGRICULTURE. THE HOUSEHOLD RESPONSIBILITY SYSTEM (HRS) WAS ADOPTED IN CHINESE RURAL AREAS AT THE TIME OF THE ECONOMIC REFORM OF THE EARLY 1980S. FARM HOUSEHOLDS BECAME THE BASIC DECISION-MAKING UNITS THAT COULD DIRECTLY CONTROL SOIL QUALITY. THIS PAPER DESCRIBES THE CHANGE IN SOIL FERTILITY AFTER 20 YEARS OF INTENSIVE AGRICULTURE AND THE DRIVING FACTORS OF SOIL FERTILITY CHANGE. QUZHOU COUNTY WAS SELECTED AS IT IS REPRESENTATIVE FOR THE NORTH CHINA PLAIN. THE SOIL FERTILITY STATUS AND NUTRIENT FLOWS OF THE SALT-AFFECTED LAND FOR 1980-1981 AND 1999 IN QUZHOU COUNTY WERE EVALUATED. OVER 20 YEARS, THE TOTAL NITROGEN (N), THE EXTRACTABLE PHOSPHORUS (P) AND THE SOIL ORGANIC MATTER (SOM) IN SALT-AFFECTED LAND INCREASED BY 127%, 601% AND 51% RESPECTIVELY; BUT EXCHANGEABLE POTASSIUM DECREASED BY 31%. THE N, P, K AND SOM BALANCE IN 1980-1981 WAS -15, -2, -29 AND -24 KG HA(-1) Y(-1), BUT IN 1999 THE N AND P BALANCE HAD CHANGED TO 24 KG HA(-1) Y(-1) AND 25 KG HA(-1) Y-1 AS A RESULT OF THE WIDESPREAD USE OF N AND P FERTILIZER. WITH THE RAPID INCREASE IN CROP PRODUCTION AND THE SPARSE USE OF K FERTILIZER, THE K BALANCE CONTINUES TO BE NEGATIVE. STRAW PRODUCTION INCREASED ALONG WITH CROP YIELDS AND THERE WAS A DEVELOPMENT OF STOCK BREEDING. TOGETHER WITH BETTER STRAW RESTITUTION PRACTICES, THE SOM BALANCE INCREASED TO A POSITIVE 613 KG HA(-1) Y(-1). THE ANALYSIS OF FARM HOUSEHOLD LAND-USE AND INPUTS INDICATED THAT THERE WERE SIGNIFICANT DIFFERENCES IN BEHAVIOUR BETWEEN ALMOST TOTALLY OFF-FARM HOUSEHOLDS AND OTHER HOUSEHOLD TYPES. THESE DIFFERENCES WERE IN THE CHOICE OF LAND-USE TYPE, THE USE OF FERTILIZERS AND CROP RESIDUE MANAGEMENT. HOWEVER, THERE WAS NO SIGNIFICANT RELATIONSHIP BETWEEN SOCIO-ECONOMIC FACTORS AND FERTILIZER INPUTS. CURRENT NUTRIENT MANAGEMENT IS NOT OPTIMAL. THEREFORE, IT IS IMPORTANT TO ESTABLISH A BETTER SYSTEM FOR BOTTOM-UP KNOWLEDGE COLLECTION AND TRANSFER OF SCIENTIFIC INFORMATION TO FARMERS. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",AGRICULTURAL LAND-USE; NUTRIENT BALANCES; INDICATORS; MANAGEMENT; FLOWS; AFRICA,CHINA; SOIL QUALITY; SOIL FERTILITY; HOUSEHOLD; FARMER BEHAVIOUR; INTEGRATED NUTRIENT MANAGEMENT,AGRICULTURAL SYSTEMS,"CHEN, J##YU, ZR##OUYANG, JL##VAN MENSVOORT, MEF","CHINA AGR UNIV, COLL AGR RESOURCES & ENVIRONM SCI, BEIJING 100094, PEOPLES R CHINA. UNIV WAGENINGEN & RES CTR, LAB SOIL SCI & GEOL, NL-6700 AA WAGENINGEN, NETHERLANDS.","AGRICULTURE, MULTIDISCIPLINARY",AGRICULTURE,"BATIONO A, 1998, AGR ECOSYST ENVIRON, V71, P19, DOI 10.1016/S0167-8809(98)00129-7##BAUDRY J, 1999, CRIT REV PLANT SCI, V18, P373, DOI 10.1016/S0735-2689(99)00371-8##BINDRABAN PS, 2000, AGR ECOSYST ENVIRON, V81, P103, DOI 10.1016/S0167-8809(00)00184-5##BOUMA J, 1998, GEODERMA, V85, P103, DOI 10.1016/S0016-7061(98)00031-7##BURESH RJ, 1997, SSSA SPECIAL PUBLICA, P251##DORAN JW, 1994, SSSA SPEC PUBL, P3##DUMANSKI J, 2000, AGR ECOSYST ENVIRON, V81, P93, DOI 10.1016/S0167-8809(00)00183-3##GAO X Z, 2000, PLANT NUTR FERTILIZE, V6, P363##GEURTS PMH, 1999, NUTRIENT DISEQUILIBRIA IN AGROECOSYSTEMS: CONCEPTS AND CASE STUDIES, P191##HAO JM, 2002, DEV INTEGRATED AGR N, P45##HARRIS FMA, 1998, AGR ECOSYST ENVIRON, V71, P201, DOI 10.1016/S0167-8809(98)00141-8##*ISS, 1979, PHYS CHEM AN SOIL, P539##JANSEN DM, 1995, NETH J AGR SCI, V43, P61##JANSSEN BH, 1999, NUTRIENT DISEQUILIBRIA IN AGROECOSYSTEMS: CONCEPTS AND CASE STUDIES, P27##JIANG YH, 2001, CHINESE J SOIL SCI, V32, P209##JIN J, 1990, P INT S BAL FERT SOI, P111##JIN J, 1998, P IFA REG C AS PAC H, P21##LI YM, 1984, THESIS CHINA AGR U B##LU R.K., 1996, CHINESE J SOIL SCI, V27, P145##LU RK, 1996, CHINESE J SOIL SCI, V27, P152##LU RUKUN, 2000, SCIENTIA AGRICULTURA SINICA, V33, P63##NANDWA SM, 1998, AGR ECOSYST ENVIRON, V71, P5, DOI 10.1016/S0167-8809(98)00128-5##*NCO, 1997, STAT AN INC CHANG HO##NIU LA, 2003, J CHINA AGR U, V6, P23##OENEMA O, 2003, EUR J AGRON, V20, P3, DOI 10.1016/S1161-0301(03)00067-4##OENEMA O, 1999, NUTRIENT DISEQUILIBRIA IN AGROECOSYSTEMS: CONCEPTS AND CASE STUDIES, P75##OLDEMAN LR, 1990, WORLD MAP HUMAN INDU##ONEMA Q, 2005, PLANT NUTR FOOD SECU, P70##OUYANG JL, 2001, THESIS CHINA AGR U B##PENG SB, 2002, AGR SCI CHINA, V35, P1095##SCOONES I, 1998, AGR ECOSYST ENVIRON, V71, P255, DOI 10.1016/S0167-8809(98)00145-5##SHELDRICK WF, 2003, AGR ECOSYST ENVIRON, V94, P341, DOI 10.1016/S0167-8809(02)00038-5##SHI YC, 1983, MOVEMENT WATER SALT##SMALING E.M.A., 1999, NUTR DISEQUILIBRIA A, P322##SMALING E.M.A., 1997, SSSA SPECIAL PUBLICA, P47##SMALING EMA, 1993, GEODERMA, V60, P235, DOI 10.1016/0016-7061(93)90029-K##SMALING EMA, 1996, AMBIO, V25, P492##STOORVOGEL JJ, 1993, FERT RES, V35, P227, DOI 10.1007/BF00750641##STOORVOGEL JJ, 1998, NUTR CYCL AGROECOSYS, V50, P151, DOI 10.1023/A:1009732126336##SUI YY, 2005, J SOIL WATER CONSERV, V6, P190##TIAN SM, 2000, THESIS CHINA AGR U B##VAN DER HOEK KW, 1999, NUTRIENT DISEQUILIBRIA IN AGROECOSYSTEMS: CONCEPTS AND CASE STUDIES, P57##VANHAAFTEN EH, 1998, HUMAN RESILIENCE DEG##WANG JW, 1998, THESIS CHINA AGR U B##XIE JC, 1998, NUTRIENT MANAGEMENT FOR SUSTAINABLE CROP PRODUCTION IN ASIA, P267##XIN DH, 1990, COMPREHENSIVE CONTRO##XIN G., 2002, CHINESE J SOIL SCI, V33, P332##YU ZR, 1995, INTEGRATED AGR TECHN, P24##YU ZR, 1997, J RURAL ECOENVIRONME, V3, P1##ZACCHEO P, 1997, AGR ECOSYST ENVIRON, V66, P231, DOI 10.1016/S0167-8809(97)00106-0##ZAINAB MS, 2000, LAND USE POLICY, V17, P321##ZHANG F.S., 2003, PHOSPHATE COMPOUND F, V18, P1##ZHANG F.S., 2005, PLANT NUTR FOOD SECU, P13##ZHANG FS, 2000, SOIL ENV SCI, V9, P154, DOI 1008-181X(2000)02-0154-04##ZHANG SR, 2002, ACTA ECOLOGICAL SINI, V12, P2041##ZHENG DM, 2002, J TARIM U AGR RECLAM, V2, P5##ZHU ZL, 2002, NUTR CYCL AGROECOSYS, V63, P117, DOI 10.1023/A:1021107026067##1997, CHINA LONG TERM FOOD, P193",41,2020-11-20,NA
J,WOS:000243379400006,2006,SYSTEMATIC DEVELOPMENT OF A SELF-HELP AND MOTIVATIONAL ENHANCEMENT INTERVENTION TO PROMOTE SEXUAL HEALTH IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN,"THE OBJECTIVE OF THIS STUDY WAS TO DESCRIBE THE APPLICATION OF A SYSTEMATIC PROCESS - INTERVENTION MAPPING - TO DEVELOPING A THEORY- AND EVIDENCE-BASED INTERVENTION TO PROMOTE SEXUAL HEALTH IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN ( MSM). INTERVENTION MAPPING PROVIDES A FRAMEWORK THAT GIVES PROGRAM PLANNERS A SYSTEMATIC METHOD FOR DECISION- MAKING IN EACH PHASE OF INTERVENTION DEVELOPMENT. IN STEP 1, WE FOCUSED ON THE IMPROVEMENT OF TWO HEALTH-PROMOTING BEHAVIORS: SATISFACTORY SEXUAL FUNCTIONING AND SAFER SEXUAL BEHAVIOR. THESE BEHAVIORS WERE THEN LINKED WITH SELECTED PERSONAL AND EXTERNAL DETERMINANTS, SUCH AS ATTITUDES AND SOCIAL SUPPORT, TO PRODUCE A SET OF PROXIMAL PROGRAM OBJECTIVES. IN STEP 2, THEORETICAL METHODS WERE IDENTIFIED TO INFLUENCE THE PROXIMAL PROGRAM OBJECTIVES AND WERE TRANSLATED INTO PRACTICAL STRATEGIES. ALTHOUGH THEORETICAL METHODS WERE DERIVED FROM VARIOUS THEORIES, SELF-REGULATION THEORY AND A COGNITIVE MODEL OF BEHAVIOR CHANGE PROVIDED THE MAIN FRAMEWORK FOR SELECTING THE INTERVENTION METHODS. THE MAIN STRATEGIES CHOSEN WERE BIBLIOTHERAPY ( I.E., THE USE OF WRITTEN MATERIAL TO HELP PEOPLE SOLVE PROBLEMS OR CHANGE BEHAVIOR) AND MOTIVATIONAL INTERVIEWING. IN STEP 3, THE THEORETICAL METHODS AND PRACTICAL STRATEGIES WERE APPLIED IN A PROGRAM THAT COMPRISED A SELF-HELP GUIDE, A MOTIVATIONAL INTERVIEWING SESSION AND A MOTIVATIONAL INTERVIEWING TELEPHONE CALL, BOTH DELIVERED BY SPECIALIST NURSES IN HIV TREATMENT CENTERS. IN STEP 4, IMPLEMENTATION WAS ANTICIPATED BY DEVELOPING A LINKAGE GROUP TO ENSURE INVOLVEMENT OF PROGRAM USERS IN THE PLANNING PROCESS AND CONDUCTING ADDITIONAL RESEARCH TO UNDERSTAND HOW TO IMPLEMENT OUR PROGRAM BETTER. IN STEP 5, PROGRAM EVALUATION WAS ANTICIPATED BASED ON THE PLANNING PROCESS FROM THE PREVIOUS INTERVENTION MAPPING STEPS.",RISK BEHAVIOR; SILDENAFIL USE; PREVENTION; THERAPY; PROGRAM; PEOPLE; BIBLIOTHERAPY; INFECTION; PATIENT; CARE,NA,AIDS PATIENT CARE AND STDS,"VAN KESTEREN, NMC##KOK, G##HOSPERS, HJ##SCHIPPERS, J##DE WILDT, W","MAASTRICHT UNIV, DEPT EXPT PSYCHOL, RESHAPE, NL-6200 MD MAASTRICHT, NETHERLANDS. HAGAHOSP, OUTPATIENT CLIN MED SEXOL, THE HAGUE, NETHERLANDS. TRAINING CTR MOTIVAT INTEVIEWING & COGNIT BEHAV T, HABIT PRO, AMSTERDAM, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; INFECTIOUS DISEASES","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; INFECTIOUS DISEASES","ASPINWALL LG, 2001, BLACKWELL HDB SOCIAL, P591##BANDURA A, 2005, APPL PSYCHOL-INT REV, V54, P245, DOI 10.1111/J.1464-0597.2005.00208.X##BANDURA A., 1986, SOCIAL FDN THOUGHT A##BANDURA A., 1997, SELF EFFICACY EXERCI##BARTHOLOMEW L, 2006, PLANNING HLTH PROMOT##BARTHOLOMEW LK, 2000, PATIENT EDUC COUNS, V39, P253, DOI 10.1016/S0738-3991(99)00045-2##BARTHOLOMEW LK, 2001, INTERVENTION MAPPING##BATSON CD, 1997, PERS SOC PSYCHOL B, V23, P751, DOI 10.1177/0146167297237008##BELCHER L, 1998, J CONSULT CLIN PSYCH, V66, P856, DOI 10.1037/0022-006X.66.5.856##BLACKARD JT, 2002, CLIN INFECT DIS, V34, P1108, DOI 10.1086/339547##BLAGYS MD, 2002, CLIN PSYCHOL REV, V22, P671, DOI 10.1016/S0272-7358(01)00117-9##BROOKS RA, 2005, AIDS PATIENT CARE ST, V19, P737, DOI 10.1089/APC.2005.19.737##CACHAY E, 2004, AIDS PATIENT CARE ST, V18, P349, DOI 10.1089/1087291041444050##CLARK N M, 1990, HEALTH EDUCATION RESEARCH, V5, P371, DOI 10.1093/HER/5.3.371##COATES TJ, 1989, AM J PUBLIC HEALTH, V79, P885, DOI 10.2105/AJPH.79.7.885##CREPAZ N, 2002, AIDS, V16, P135, DOI 10.1097/00002030-200201250-00002##CROWTHER MR, 1999, J CLIN PSYCHOL, V55, P961##CULLEN KW, 1998, J BEHAV MED, V21, P241, DOI 10.1023/A:1018764932609##DIAZ R. M., 1998, LATINO GAY MEN HIV C##ELLIS A, 1975, COUNS PSYCHOL, V5, P14, DOI 10.1177/001100007500500106##EVANS RI, 1984, J APPL SOC PSYCHOL, V14, P289, DOI 10.1111/J.1559-1816.1984.TB02237.X##GLASGOW RE, 1978, PSYCHOL BULL, V85, P1, DOI 10.1037/0033-2909.85.1.1##GOULD RA, 1993, CLIN PSYCHOL REV, V13, P169, DOI 10.1016/0272-7358(93)90039-O##GRAS L, 2005, SCI REPORT 2005 MONI##HEANEY CA, 2002, HLTH BEHAV HLTH ED T, P185##HEINEN MM, 2006, PATIENT EDUC COUNS, V61, P279, DOI 10.1016/J.PEC.2005.04.007##HERBST JH, 2005, JAIDS-J ACQ IMM DEF, V39, P228##HOSPERS H, 1998, SOC AS AIDS, P40##JOST S, 2002, NEW ENGL J MED, V347, P731, DOI 10.1056/NEJMOA020263##KALICHMAN SC, 1996, ANN BEHAV MED, V18, P6, DOI 10.1007/BF02903934##KEGELES S M, 1998, AIDS, V12 SUPPL A, PS209##KELLY JA, 1991, HOSP COMMUNITY PSYCH, V42, P239##KELLY JA, 2000, AIDS, V14, PS34##KING-SPOONER S, 1999, INT J STD AIDS, V10, P141, DOI 10.1258/0956462991913763##KOK G, 1999, PATIENT EDUC COUNS, V36, P239, DOI 10.1016/S0738-3991(98)00141-4##KOTSES H, 1990, J ASTHMA, V27, P375, DOI 10.3109/02770909009073354##LOCKE EA, 1991, THEORY GOAL SETTING##MASTERS WH, 1970, HUMAN SEXUAL INADEQU##MAYER KH, 2004, JAIDS-J ACQ IMM DEF, V37, PS130, DOI 10.1097/01.QAI.0000140613.66887.0C##MILLER W, 2002, MOTIVATIONAL INTERVI##MILLER WR, 1991, MOTIVATIONAL INTERVI##PROCHASKA J. O., 2002, HLTH BEHAV HLTH ED T, V3, P99##RICHARD R, 1995, BRIT J SOC PSYCHOL, V34, P9, DOI 10.1111/J.2044-8309.1995.TB01045.X##ROGERS T, 1995, DIFFUSION INNOVATION##ROLLNICK S., 1999, HLTH BEHAV CHANGE GU##ROSEN RC, 1994, J SEX MARITAL THER, V20, P67, DOI 10.1080/00926239408403419##ROSEN RC, 1995, J CONSULT CLIN PSYCH, V63, P877, DOI 10.1037/0022-006X.63.6.877##ROSS M, 2000, PSYCHOL PERSPECTIVES, P383##RUTLEDGE SE, 2001, CLIN SOC WORK J, V29, P291, DOI 10.1023/A:1010463813593##SCHILTZ MA, 2000, SOC SCI MED, V50, P1571, DOI 10.1016/S0277-9536(99)00466-9##SCHIPPERS J, 2004, HIV SEKS ZELFHULPGID##SILVERBERG LAWRENCE I., 2003, JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, V103, P131##SNIEHOTTA FF, 2005, EUR J SOC PSYCHOL, V35, P565, DOI 10.1002/EJSP.258##STALL R, 2000, AIDS BEHAV, V4, P181, DOI DOI 10.1023/A:1009516608672##STECKLER A, 2002, HLTH BEHAV HLTH ED T, P312##SWEARINGEN SG, 2005, AM J MED, V118, P571, DOI 10.1016/J.AMJMED.2005.01.042##THORESEN CE, 1983, J ALLERGY CLIN IMMUN, V72, P596, DOI 10.1016/0091-6749(83)90487-6##TORTOLERO SR, 2005, HEALTH PROMOT PRACT, V6, P286, DOI 10.1177/1524839904266472##VAN EMPELEN P, 2003, SOC SCI MED, V57, P1593, DOI 10.1016/S0277-9536(02)00557-9##VAN EMPELEN PEPIJN, 2003, HEALTH PROMOT PRACT, V4, P402, DOI 10.1177/1524839903255421##VAN KESTEREN NMC, 2005, QUAL HEALTH RES, V15, P145, DOI 10.1177/1049732304270817##VAN LANKVELD JJDM, 1998, J CONSULT CLIN PSYCH, V66, P702, DOI 10.1037/0022-006X.66.4.702##VANDENHOEK C, 2005, TSG, V83, P159##VANKESTEREN NMC, IN PRESS PATIENT ED##VANKESTEREN NMC, IN PRESS ARCH SEX BE##VERDULT F, 2005, HIVNIEUWS, V93, P14##WEINER B, 1986, ATTRIBUTIONAL THEORY",26,2020-11-20,NA
J,WOS:000242636200011,2006,DOES CDX2 EXPRESSION PREDICT BARRETT'S METAPLASIA IN OESOPHAGEAL COLUMNAR EPITHELIUM WITHOUT GOBLET CELLS?,"BACKGROUND INTESTINAL METAPLASIA (BARRETT'S OESOPHAGUS), BUT NOT CARDIAC-TYPE MUCOSA IN COLUMNAR-LINED OESOPHAGUS, IS REGARDED AS PREMALIGNANT. AS INTESTINAL METAPLASIA AND CARDIAC-TYPE MUCOSA ARE ENDOSCOPICALLY INDISCERNIBLE, IT IS DIFFICULT TO TAKE TARGETED SAMPLES FROM COLUMNAR-LINED OESOPHAGUS WITH CONSEQUENTLY A RISK OF HAVING UNDETECTED INTESTINAL METAPLASIA. AIM TO INVESTIGATE WHETHER THE INTESTINAL MARKERS CDX2, MUC2 AND VILLIN CAN PREDICT THE PRESENCE OF UNDETECTED INTESTINAL METAPLASIA IN COLUMNAR-LINED OESOPHAGUS. METHODS PRESENCE OF INTESTINAL METAPLASIA OR CARDIAC-TYPE MUCOSA WAS IDENTIFIED IN 122 BIOPSY SETS OF COLUMNAR-LINED OESOPHAGUS FROM 61 PATIENTS, COLLECTED AT TWO SUBSEQUENT FOLLOW-UP UPPER ENDOSCOPIES. CDX2, MUC2 AND VILLIN EXPRESSION WERE DETERMINED BY IMMUNOHISTOCHEMISTRY. RESULTS ALL INTESTINAL METAPLASIA SAMPLES (55) WERE POSITIVE FOR CDX2 AND MUC2 AND 32 OF 55 FOR VILLIN. CDX2 EXPRESSION WAS DETECTED IN 23 OF 67 (34%) SAMPLES WITH ONLY CARDIAC-TYPE MUCOSA. DETECTION OF CDX2 IN CARDIAC-TYPE MUCOSA INCREASED THE LIKELIHOOD OF FINDING INTESTINAL METAPLASIA IN ANOTHER BIOPSY SET OF COLUMNAR-LINED OESOPHAGUS (ODDS RATIO 3.5, 95% CI=1.2-10, P=0.02). MUC2 WAS POSITIVE IN 13 OF 23 (57%) OF CDX2-POSITIVE CARDIAC-TYPE MUCOSA SAMPLES, WHEREAS VILLIN WAS DETECTED IN SEVEN OF 23 (30%). CONCLUSIONS CDX2 EXPRESSION IN CARDIAC-TYPE MUCOSA MIGHT BE ABLE TO PREDICT THE PRESENCE OF UNDETECTED INTESTINAL METAPLASIA IN COLUMNAR-LINED OESOPHAGUS, AND THUS MAY BE A PUTATIVE MARKER FOR THE PRESENCE OF INTESTINAL METAPLASIA IN THE ABSENCE OF GOBLET CELLS.",GASTROESOPHAGEAL-REFLUX DISEASE; HOMEODOMAIN PROTEIN CDX2; INTESTINAL METAPLASIA; GENE-EXPRESSION; LINED ESOPHAGUS; CARDIAC MUCOSA; GASTRIC-TYPE; DIFFERENTIATION; ADENOCARCINOMA; DYSPLASIA,NA,ALIMENTARY PHARMACOLOGY & THERAPEUTICS,"KERKHOF, M##BAX, DA##MOONS, LMG##VAN VUUREN, AJ##VAN DEKKEN, H##STEYERBERG, EW##KUIPERS, EJ##KUSTERS, JG##SIERSEMA, PD","ERASMUS UNIV, MED CTR, DEPT GASTROENTEROL & HEPATOL, NL-3000 CA ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT PATHOL, NL-3000 CA ROTTERDAM, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY; PHARMACOLOGY & PHARMACY,GASTROENTEROLOGY & HEPATOLOGY; PHARMACOLOGY & PHARMACY,"AVIDAN B, 2002, AM J GASTROENTEROL, V97, P1930, DOI 10.1111/J.1572-0241.2002.05902.X##BAX DA, 2004, J CLIN PATHOL, V57, P1267, DOI 10.1136/JCP.2004.017020##BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/AJA.1002040302##BUTTAR NS, 2004, NAT CLIN PRACT GASTR, V1, P106, DOI 10.1038/NCPGASTHEP0057##CASSARO M, 1999, HUM PATHOL, V30, P741, DOI 10.1016/S0046-8177(99)90133-8##CHANDRASOMA P, 2005, HISTOPATHOLOGY, V46, P361, DOI 10.1111/J.1365-2559.2005.02088.X##CHANDRASOMA PT, 2000, AM J SURG PATHOL, V24, P344, DOI 10.1097/00000478-200003000-00002##CHANDRASOMA PT, 2001, AM J SURG PATHOL, V25, P1188, DOI 10.1097/00000478-200109000-00010##CHINYAMA CN, 1999, HISTOPATHOLOGY, V35, P517##CORFIELD AP, 2000, GUT, V47, P589, DOI 10.1136/GUT.47.4.589##EDA A, 2003, J GASTROENTEROL, V38, P14, DOI 10.1007/S005350300001##FALK GW, 2002, GASTROENTEROLOGY, V122, P1569, DOI 10.1053/GAST.2002.33427##FITZGERALD RC, 1996, J CLIN INVEST, V98, P2120, DOI 10.1172/JCI119018##GLICKMAN JN, 2003, AM J SURG PATHOL, V27, P1357, DOI 10.1097/00000478-200310000-00008##GROISMAN GM, 2004, MODERN PATHOL, V17, P1282, DOI 10.1038/MODPATHOL.3800182##GUILLEM P, 2000, INT J CANCER, V88, P856, DOI 10.1002/1097-0215(20001215)88:6<856::AID-IJC3>3.0.CO;2-D##GUILLEM PG, 2005, DIGEST DIS SCI, V50, P415, DOI 10.1007/S10620-005-2451-X##HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4##HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3##HAMILTON SR, 1977, GASTROENTEROLOGY, V72, P669##HAMILTON SR, 1987, AM J CLIN PATHOL, V87, P301, DOI 10.1093/AJCP/87.3.301##HOUDE M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/JBC.M100236200##KUMBLE S, 1996, INT J CANCER, V66, P48, DOI 10.1002/(SICI)1097-0215(19960328)66:1<48::AID-IJC9>3.3.CO;2-G##MOONS LMG, 2004, J CLIN PATHOL, V57, P1063, DOI 10.1136/JCP.2003.015727##NIWA T, 2005, J HISTOCHEM CYTOCHEM, V53, P75, DOI 10.1369/JHC.4A6443.2005##OBERG S, 1997, ANN SURG, V226, P522, DOI 10.1097/00000658-199710000-00013##OBERG S, 2001, ANN SURG, V234, P619, DOI 10.1097/00000658-200111000-00006##PAULL A, 1976, NEW ENGL J MED, V295, P476, DOI 10.1056/NEJM197608262950904##PHILLIPS RW, 2003, AM J SURG PATHOL, V27, P1442, DOI 10.1097/00000478-200311000-00006##REGALADO SP, 1998, MOL CARCINOGEN, V22, P182, DOI 10.1002/(SICI)1098-2744(199807)22:3<182::AID-MC6>3.3.CO;2-N##SAMPLINER RE, 2002, AM J GASTROENTEROL, V97, P1888##SHIELDS HM, 2001, AM J GASTROENTEROL, V96, P3268##SILBERG DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/GAST.2000.18142##SILBERG DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/GAST.2002.31902##STEININGER H, 2005, PATHOL RES PRACT, V201, P573, DOI 10.1016/J.PRP.2005.03.010##WARSON C, 2002, HUM PATHOL, V33, P660, DOI 10.1053/HUPA.2002.124907##YAMAMOTO H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2",24,2020-11-20,NA
J,WOS:000243238500027,2006,"INEQUALITY AVERSION, EFFICIENCY, AND MAXIMIN PREFERENCES IN SIMPLE DISTRIBUTION EXPERIMENTS: REPLY",NA,COOPERATION,NA,AMERICAN ECONOMIC REVIEW,"ENGELMANN, D##STROBEL, M","UNIV LONDON ROYAL HOLLOWAY & BEDFORD NEW COLL, DEPT ECON, EGHAM TW20 0EX, SURREY, ENGLAND. UNIV MAASTRICHT, DEPT ECON, NL-6200 MD MAASTRICHT, NETHERLANDS. UNIV MAASTRICHT, INT INST INFORMAT, NL-6200 MD MAASTRICHT, NETHERLANDS.",ECONOMICS,BUSINESS & ECONOMICS,"BLANCO M, 2006, UNPUB WITHIN SUBJECT##BOLTON G. E., 1998, EXPT EC, V1, P207, DOI DOI 10.1023/A:1009951108693##BOLTON GE, 2006, AM ECON REV, V96, P1906, DOI 10.1257/AER.96.5.1906##CHARNESS G, 2002, Q J ECON, V117, P817, DOI 10.1162/003355302760193904##COX JC, 2004, GAME ECON BEHAV, V46, P260, DOI 10.1016/S0899-8256(03)00119-2##CXO JC, 2006, 200613 EXP EC CTR A##ENGELMANN D, 2004, AM ECON REV, V94, P857, DOI 10.1257/0002828042002741##ENGELMANN D, 2002, 2002013 MERIT##ENGELMANN D, 2005, UNPUB FAINRESS INTER##ENGELMANND, PUBLIC FINANCE REV##FEHR E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151##FEHR E, 2006, AM ECON REV, V96, P1912, DOI 10.1257/AER.96.5.1912##GUTH W, 1982, J ECON BEHAV ORGAN, V3, P367, DOI 10.1016/0167-2681(82)90011-7##GUTH W, 2001, GAME ECON BEHAV, V37, P161, DOI 10.1006/GAME.2000.0829##ROTH AE, 1991, AM ECON REV, V81, P1068##YEZER AM, 1996, J ECON PERSPECT, V10, P177, DOI 10.1257/JEP.10.1.177",24,2020-11-20,NA
J,WOS:000243110400026,2006,COMPARISON OF SIROLIMUS-ELUTING AND BARE METAL STENTS IN CORONARY BIFURCATION LESIONS: SUBGROUP ANALYSIS OF THE STENTING CORONARY ARTERIES IN NON-STRESS/BENESTENT DISEASE TRIAL (SCANDSTENT),"BACKGROUND SIROLIMUS-ELUTING STENT IMPLANTATION IMPROVES THE OUTCOME IN SIMPLE CORONARY ARTERY LESIONS COMPARED WITH BARE METAL STENTS, BUT THERE IS LIMITED EVIDENCE OF THEIR SAFETY AND EFFICACY WHEN IMPLANTED IN COMPLEX LESIONS LIKE CORONARY BIFURCATIONS. METHODS SCANDSTENT WAS A RANDOMIZED CONTROLLED STUDY COMPARING IMPLANTATION OF SIROLIMUS-ELUTING STENTS WITH BARE-METAL STENTS IN PATIENTS WITH COMPLEX CORONARY ARTERY DISEASE. THIS SUBSTUDY EVALUATES THE ANGIOGRAPHIC AND CLINICAL OUTCOME OF 126 PATIENTS WITH LESIONS LOCATED IN A CORONARY BIFURCATION. RESULTS THE BASELINE CHARACTERISTICS OF THE PATIENTS WERE COMPARABLE: 15% HAD DIABETES, AND 1.7 STENTS WERE IMPLANTED PER LESION. AT FOLLOW-UP, THE MINIMUM LUMEN DIAMETER OF THE MAIN BRANCH WAS 2.35 MM IN PATIENTS WHO RECEIVED SIROLIMUS-ELUTING STENTS COMPARED WITH 1.68 MM IN THOSE WHO RECEIVED BARE-METAL STENTS, AND THAT OF THE SIDE BRANCH WAS 1.70 VERSUS 1.19 MM (BOTH P < .001). THE LATE LUMEN LOSS IN THE MAIN BRANCH WAS 0.12 MM IN THE SIROLIMUS-ELUTING STENT GROUP VERSUS 0.99 MM IN THE BARE-METAL STENT GROUP AND 0.03 VERSUS 0.56 MM IN THE SIDE BRANCH (BOTH P < .001). THUS, SIROLIMUS-ELUTING STENTS REDUCED THE RESTENOSIS RATE FROM 28.3% TO 4.9% IN THE MAIN BRANCH AND FROM 43.4% TO 14.8% IN THE SIDE BRANCHES (BOTH P < .001). MAJOR ADVERSE CARDIAC EVENTS OCCURRED IN 9% WITH SIROLIMUS-ELUTING STENTS VERSUS 28% WITH BARE-METAL STENTS (P = .01), AND STENT THROMBOSIS WAS OBSERVED IN 0% VERSUS 9% (P = .02). CONCLUSION SIROLIMUS-ELUTING STENT IMPLANTATION IMPROVES BOTH THE ANGIOGRAPHIC AND CLINICAL OUTCOMES CONSIDERABLY COMPARED WITH THAT OF BARE-METAL STENTS IN PATIENTS WITH STENOSES LOCATED IN CORONARY BIFURCATIONS.",STANDARD STENT; THROMBOSIS; INTERVENTION; IMPLANTATION; REVASCULARIZATION; OUTCOMES; REGISTRY; RISK,NA,AMERICAN HEART JOURNAL,"THUESEN, L##KELBAEK, H##KLOVGAARD, L##HELQVIST, S##JORGENSEN, E##ALJABBARI, S##KRUSELL, LR##JENSEN, GVH##BOTKER, HE##SAUNAMAKI, K##LASSEN, JF##VAN WEERT, A","RIGSHOSP, CARDIAC CATH LAB 2013, DK-2100 COPENHAGEN, DENMARK. SKEJBY SYGEHUS, SKEJBY, DENMARK. ROSKILDE AMTSSYGEHUS, ROSKILDE, DENMARK. HEART CORE, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"BAVRY AA, 2005, AM J CARDIOL, V95, P1469, DOI 10.1016/J.AMJCARD.2005.02.015##BAVRY AA, 2005, J AM COLL CARDIOL, V45, P941, DOI 10.1016/J.JACC.2004.11.064##COLOMBO A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6##COLOMBO A, 2004, CIRCULATION, V109, P1244, DOI 10.1161/01.CIR.0000118474.71662.E3##COSTA RA, 2005, J AM COLL CARDIOL, V46, P599, DOI 10.1016/J.JACC.2005.05.034##GAROT P, 2005, J AM COLL CARDIOL, V46, P606, DOI 10.1016/J.JACC.2005.01.065##GE L, 2005, J AM COLL CARDIOL, V46, P613, DOI 10.1016/J.JACC.2005.05.032##HELQVIST S, 2006, HEART, V92, P981, DOI 10.1136/HRT.2005.072967##JEREMIAS A, 2004, CIRCULATION, V109, P1930, DOI 10.1161/01.CIR.0000127105.99982.21##KELBAEK H, 2006, J AM COLL CARDIOL, V47, P449, DOI 10.1016/J.JACC.2005.10.045##KUCHULAKANTI PK, 2006, CIRCULATION, V113, P1108, DOI 10.1161/CIRCULATIONAHA.105.600155##LEFEVRE T, 2005, J AM COLL CARDIOL, V46, P592, DOI 10.1016/J.JACC.2005.05.033##LOUVARD Y, 2004, HEART, V90, P713, DOI 10.1136/HRT.2002.007682##MORENO R, 2005, J AM COLL CARDIOL, V45, P954, DOI 10.1016/J.JACC.2004.11.065##MORICE M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMOA012843##MOSES JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMOA035071##ONG ATL, 2005, J AM COLL CARDIOL, V45, P947, DOI 10.1016/J.JACC.2004.09.079##SABATE M, 2005, CIRCULATION, V112, P2175, DOI 10.1161/CIRCULATIONAHA.105.562421##SILBER S, 2005, EUR HEART J, V26, P804, DOI 10.1093/EURHEARTJ/EHI138##STONE GW, 2005, JAMA-J AM MED ASSOC, V294, P1215, DOI 10.1001/JAMA.294.10.1215##STONE GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMOA032441##VAN WEERT ANTON W. M., 2001, HEARTDRUG, V1, P44, DOI 10.1159/000022710##WILLIAMS DO, 2005, J AM COLL CARDIOL, V46, P621, DOI 10.1016/J.JACC.2005.05.035",70,2020-11-20,NA
J,WOS:000242775800089,2006,TINKERING: CONSUMERS REINVENT THE EARLY AUTOMOBILE.,NA,NA,NA,AMERICAN HISTORICAL REVIEW,"MOM, G","EINDHOVEN UNIV TECHNOL, NL-5600 MB EINDHOVEN, NETHERLANDS.",HISTORY,HISTORY,"FRANZ K, 2005, TINKERING: CONSUMERS REINVENT THE EARLY AUTOMOBILE, P1",0,2020-11-20,NA
J,WOS:000242775800183,2006,MAKING SENSE OF SUFFERING: HOLOCAUST AND HOLODOMOR IN UKRAINIAN CULTURE,NA,NA,NA,AMERICAN HISTORICAL REVIEW,"BERKHOFF, KC","CTR HOLOCAUST & GENOCIDE STUDIES, AMSTERDAM, NETHERLANDS.",HISTORY,HISTORY,"DIETSCH JOHAN, 2006, MAKING SENSE SUFFERI",0,2020-11-20,NA
J,WOS:000242106200006,2006,PREDICTING THE SUPPLY OF ECOSYSTEM SERVICES FROM AGRICULTURE,NA,SPATIAL HETEROGENEITY; CARBON SEQUESTRATION; POLICY; EFFICIENCY; MANAGEMENT,NA,AMERICAN JOURNAL OF AGRICULTURAL ECONOMICS,"ANTLE, JM##STOORVOGEL, JJ","MONTANA STATE UNIV, BOZEMAN, MT USA. UNIV WAGENINGEN & RES CTR, NL-6700 HB WAGENINGEN, NETHERLANDS.",AGRICULTURAL ECONOMICS & POLICY; ECONOMICS,AGRICULTURE; BUSINESS & ECONOMICS,"ANTLE J, 2003, J ENVIRON ECON MANAG, V46, P231, DOI 10.1016/S0095-0696(02)00038-4##ANTLE JM, 2006, AUST J AGR RESOUR EC, V50, P1, DOI 10.1111/J.1467-8489.2006.00315.X##ANTLE JM, 2002, J AGR RESOUR ECON, V27, P1##ANTLE JM, 2001, ECOSYSTEMS, V4, P723, DOI 10.1007/S10021-001-0041-0##ANTLE JM, 2007, IN PRESS CLIMATIC CH, V80##ANTLE JM, 2006, ENVIRON DEV ECON, V11, P39, DOI 10.1017/S1355770X05002639##FUGLIE K. O., 2001, REVIEW OF AGRICULTURAL ECONOMICS, V23, P386, DOI 10.1111/1467-9353.00068##*GEN ACC OFF, 2006, GAO06312##GRACE PR, 2001, NET ECOSYSTEM EXCHAN, P89##LUBOWKI RN, 2005, WORKING PAPER SERIES##MCCARL BA, 2001, SCIENCE, V294, P2481, DOI 10.1126/SCIENCE.1064193##OGLE SM, 2003, GLOBAL CHANGE BIOL, V9, P1521, DOI 10.1046/J.1365-2486.2003.00683.X##PAUSTIAN K, 2006, IN PRESS AGR ROLE GR##PAUTSCH GR, 2001, CONTEMP ECON POLICY, V19, P123, DOI 10.1093/CEP/19.2.123##PLANTINGA AJ, 2003, LAND ECON, V79, P74, DOI 10.2307/3147106##SANCHIRICO JN, 2005, J ENVIRON ECON MANAG, V50, P23, DOI 10.1016/J.JEEM.2004.11.001##SUNDING D, 2001, HANDB ECON, V18, P207##WU JJ, 2004, AM J AGR ECON, V86, P26, DOI 10.1111/J.0092-5853.2004.00560.X",31,2020-11-20,NA
J,WOS:000242106200009,2006,COEXISTENCE RULES AND REGULATIONS IN THE EUROPEAN UNION,NA,LIABILITY,NA,AMERICAN JOURNAL OF AGRICULTURAL ECONOMICS,"BECKMANN, V##SOREGAROLI, C##WESSELER, J","HUMBOLDT UNIV, DEPT AGR ECON, D-1086 BERLIN, GERMANY. UNIV SACRED HEART, OSSERVATORIO LATTE, I-20123 MILAN, ITALY. UNIV WAGENINGEN & RES CTR, SOCIAL SCI DEPT, ENVIRONM ECON & NAT RESOURCES GRP, NL-6700 HB WAGENINGEN, NETHERLANDS.",AGRICULTURAL ECONOMICS & POLICY; ECONOMICS,AGRICULTURE; BUSINESS & ECONOMICS,"BECKMANN V, 2006, 122006 HUMB U DIV RE##BIJMAN J, 2000, SCI PUBL POLICY, V29, P245##*COMM EUR COMM, 2003, OFFICIAL J EUROPEA L, V189##*COMM EUR COMM, 2003, OFFICIAL J EUROPEA L, V286##COMMISSION OF THE EUROPEAN COMMUNITIES, 2006, ANN COMM COMM COUNC##KOLSTAD CD, 1990, AM ECON REV, V80, P888##MESSEAN A, 2006, 22102 EN EUR I PROSP##SOREGAROLI C, 2005, WAG UR FRON, V7, P165",70,2020-11-20,NA
J,WOS:000242595300001,2006,RELATION BETWEEN PLAQUE PROGRESSION AND LOW-DENSITY LIPOPRIOTEIN CHOLESTEROL DURING AGING AS ASSESSED WITH SERIAL LONG-TERM (>= 12 MONTHS). FOLLOW-UP INTRAVASCULAR ULTRASOUND OF THE LEFT MAIN CORONARY ARTERY,"BECAUSE OF THE CLINICAL BENEFIT OF LIPID LOWERING IN OLDER PATIENTS, WE HYPOTHESIZED THAT THE RELATION BETWEEN LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL SERUM LEVELS AND CORONARY PLAQUE PROGRESSION MAY PERSIST THROUGHOUT AGING. WE ANALYZED SERIAL INTRAVASCULAR ULTRASOUND (IVUS) DATA OF 60 LEFT MAIN STEMS (1 8 +/- 9.MONTHS APART) AND EVALUATED THE RELATION BETWEEN LDL CHOLESTEROL LEVELS AND CORONARY PLAQUE PROGRESSION AT DIFFERENT AGES. THE POPULATION (N = 60) WAS DIVIDED INTO 3 GROUPS ACCORDING TO AGE: TERTILE I (N = 20) WAS A MEAN AGE OF 48 +/- 6 YEARS (MEDIAN 51, RANGE 33 TO 55), TERTILE 2 (N = 20) WAS A MEAN AGE OF 58 +/- 2 YEARS (MEDIAN 59, RANGE 55 TO 61), AND TERTILE 3 (N = 20) WAS A MEAN AGE OF 66 +/- 6 YEARS (MEDIAN 65, RANGE 61 TO 83). BETWEEN GROUPS, THERE WAS NO SIGNIFICANT DIFFERENCE IN NON-AGE-RELATED DEMOGRAPHICS, CLINICAL DATA, LIPID PROFILES, OR MEDICATIONS (E.G., STATINS). THERE WAS A POSITIVE LINEAR RELATION BETWEEN LDL CHOLESTEROL AND ANNUAL CHANGES IN PLAQUE PLUS MEDIA AREA IN ALL AGE TERTILES, WHICH WAS STATISTICALLY SIGNIFICANT IN TERTILES 2 AND 3 (R = 0.56, P.< 0.01; R = 0.50, P < 0.02) AND SHOWED A STRONG TREND IN TERTILE 1 (R = 0.41, P = 0.07). THE ESTIMATED LDL CHOLESTEROL THRESHOLDS, WHICH, AS DETERMINED BY REGRESSION ANALYSIS,. WOULD CORRESPOND TO NO PLAQUE PROGRESSION, WERE 74, 60, AND 78 MG/DL, RESPECTIVELY, IN TERTILES 1, 2, AND 3. IN CONCLUSION, SERIAL IVUS DATA IN LEFT MAIN CORONARY ARTERIES SUGGEST THAT THE RELATION BETWEEN LDL CHOLESTEROL SERUM LEVELS AND PLAQUE PROGRESSION PERSISTS DURING AGING. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",RANDOMIZED CONTROLLED-TRIAL; LIPID-LOWERING THERAPY; HEART-DISEASE; RISK; PRAVASTATIN; EVENTS; ATHEROSCLEROSIS; SIMVASTATIN; PREVENTION; REGRESSION,NA,AMERICAN JOURNAL OF CARDIOLOGY,"HARTMANN, M##BIRGELEN, C##MINTZ, GS##VAN HOUWELINGEN, GK##EGGEBRECHT, H##BOSE, D##WIENEKE, H##VERHORST, PMJ##ERBEL, R","MED SPECTRUM TWENTE, DEPT CARDIOL, ENSCHEDE, NETHERLANDS. CARDIOVASC RES FDN, NEW YORK, NY USA. ESSEN UNIV, DEPT CARDIOL, ESSEN, GERMANY.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"BAUMGART D, 1996, CATHETER CARDIO DIAG, V39, P328, DOI 10.1002/(SICI)1097-0304(199611)39:3<328::AID-CCD28>3.0.CO;2-9##CANNON CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMOA040583##COLLINS R, 2002, LANCET, V360, P1618, DOI 10.1016/S0140-6736(02)11650-3##COLLINS R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3##CURB JD, 2004, J AM GERIATR SOC, V52, P1975, DOI 10.1111/J.1532-5415.2004.52551.X##DEVEREUX RB, 1993, CIRCULATION, V88, P1444, DOI 10.1161/01.CIR.88.4.1444##DOWNS JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/JAMA.279.20.1615##GRUNDY SCOTT M, 2004, J AM COLL CARDIOL, V44, P720, DOI 10.1016/J.JACC.2004.07.001##HUNT D, 2001, ANN INTERN MED, V134, P931, DOI 10.7326/0003-4819-134-10-200105150-00007##JENSEN LO, 2004, CIRCULATION, V110, P265, DOI 10.1161/01.CIR.0000135215.75876.41##KAWASAKI M, 2005, J AM COLL CARDIOL, V45, P1946, DOI 10.1016/J.JACC.2004.09.081##LAROSA JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMOA050461##LLOYD-LONES DM, 2003, ARCH INTERN MED, V163, P1966, DOI 10.1001/ARCHINTE.163.16.1966##MARON DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207##MINTZ GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5##NISSEN SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/JAMA.291.9.1071##PEDERSEN TR, 1994, LANCET, V344, P1383##SACKS FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401##SCHARTL M, 2001, CIRCULATION, V104, P387, DOI 10.1161/HC2901.093188##SHEPHERD J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X##SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001##TAYLOR A, 2005, ATHEROSCLEROSIS, V180, P1, DOI 10.1016/J.ATHEROSCLEROSIS.2004.12.024##VON BIRGELEN C, 2003, CIRCULATION, V108, P2757, DOI 10.1161/01.CIR.0000103664.47406.49##VON BIRGELEN C, 2006, J AM COLL CARDIOL, V47, P1363, DOI 10.1016/J.JACC.2005.11.055##VON BIRGELEN C, 2004, CIRCULATION, V110, P1579, DOI 10.1161/01.CIR.0000142048.94084.CA##VONBIRGELEN C, 1997, CIRCULATION, V96, P2944, DOI 10.1161/01.CIR.96.9.2944##WATERS D, 1993, CIRCULATION, V88, P1356##WILLIAMS MA, 2002, CIRCULATION, V105, P1735, DOI 10.1161/01.CIR.0000013074.73995.6C",11,2020-11-20,NA
J,WOS:000242595300021,2006,IMPACT OF GLOMERULAR FILTRATION RATE MINOR TROPONIN T ELEVATIONS FOR RISK ASSESSMENT IN PATIENTS UNDERGOING OPERATION FOR ABDOMINAL AORTIC ANEURYSM OR LOWER EXTREMITY ARTERIAL OBSTRUCTION,"DEBATE SURROUNDS THE IMPACT OF RENAL FUNCTION ON THE PROGNOSTIC VALUE OF MINOR TROPONIN T RELEASE IN VASCULAR SURGERY PATIENTS. THE OBJECTIVE OF THIS STUDY WAS TO ASSESS THE LONG-TERM PROGNOSTIC VALUE OF MINOR DEGREES OF TROPONIN T RELEASE IN PATIENTS WHO UNDERGO MAJOR VASCULAR SURGERY, ESPECIALLY THOSE WITH CONCOMITANT RENAL DYSFUNCTION. SURVIVORS OF MAJOR NONCARDIAC VASCULAR SURGERY (N = 558) WERE PREOPERATIVELY SCREENED FOR CARDIAC RISK FACTORS AND RENAL FUNCTION. SERIAL TROPONIN T WAS MEASURED ON DAYS 1, 3, AND 7 AFTER SURGERY, USING A THRESHOLD OF 0.03 NG/ML. ALL-CAUSE MORTALITY AND MAJOR ADVERSE CARDIAC EVENTS (MACES) WERE NOTED DURING FOLLOW-UP (MEAN 3.5 +/- 2.0 YEARS). MINOR (0.03 TO 0.09 NG/ML) AND MAJOR (>= 0.1 NG/ML) RELEASE OF TROPONIN T WAS OBSERVED IN 5% AND 8%, RESPECTIVELY. DURING FOLLOW-UP, 21% OF THE PATIENTS DIED AND 15% EXPERIENCED MACES. AFTER ADJUSTMENT FOR THE ESTIMATED GLOMERULAR FILTRATION RATE, PATIENTS WITH MINOR AND MAJOR TROPONIN T RELEASE WERE AT COMPARABLE INCREASED RISK FOR LATE MORTALITY (HAZARD RATIO [HR] 3.43, 95% CONFIDENCE INTERVAL [CI] 1.79 TO 6.58, AND HR 3.72, 95% CI 2.37 TO 5.85, RESPECTIVELY), AND. MACES (HR 5.47, 95% CI 2.60 TO 11.48, AND HR 6.32, 95% CI 3.82 TO 10.48, RESPECTIVELY) COMPARED WITH PATIENTS WITH TROPONIN T RELEASE < 0.03 NG/ML. TESTS FOR HETEROGENEITY REVEALED THAT MINOR AND MAJOR TROPONIN T RELEASE HAVE PROGNOSTIC VALUE ACROSS THE ENTIRE SPECTRUM OF RENAL FUNCTION. IN CONCLUSION, MARGINAL ELEVATIONS OF TROPONIN T STRONGLY PREDICT LATE MORTALITY AND MACES AFTER MAJOR VASCULAR SURGERY, IRRESPECTIVE OF RENAL FUNCTION. A CURRENTLY UNDERESTIMATED HIGH-RISK SUBGROUP OF PATIENTS MAY BE IDENTIFIED USING A LOWER TROPONIH T THRESHOLD. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",MYOCARDIAL-INFARCTION; PRACTICE GUIDELINES; NONCARDIAC SURGERY; CARDIAC TROPONIN; CK-MB; ASSOCIATION; PREDICTION; COMMITTEE; COLLEGE,NA,AMERICAN JOURNAL OF CARDIOLOGY,"FERINGA, HHH##BAX, JJ##DE JONGE, R##ELHENDY, A##VAN DOMBURG, RT##DUNKELGRUN, M##SCHOUTEN, O##KARAGIANNIS, SE##VIDAKOVIC, R##POLDERMANS, D","ERASMUS MC, DEPT ANAESTHESIOL, ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT CARDIOL, ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT CLIN CHEM, ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT VASC SURG, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT CARDIOL, LEIDEN, NETHERLANDS. UNIV NEBRASKA, DEPT INTERNAL MED, CARDIOL SECT, OMAHA, NE 68182 USA.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ALPERT JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4##EAGLE KA, 2002, CIRCULATION, V105, P1257, DOI 10.1161/HC1002.104956##HENRIKSON CA, 2004, AM J CARDIOL, V93, P275, DOI 10.1016/J.AMJCARD.2003.10.004##LANDESBERG G, 2003, J AM COLL CARDIOL, V42, P1547, DOI 10.1016/J.JACC.2003.05.001##LEE TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043##LEVEY AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013##LEVEY AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002##MANGANO DT, 1994, ANESTHESIOLOGY, V81, P1317, DOI 10.1097/00000542-199412000-00003##PANTEGHINI M, 2004, CLIN CHEM, V50, P327, DOI 10.1373/CLINCHEM.2003.026815",4,2020-11-20,NA
J,WOS:000242776800001,2006,PUBLIC HEALTH SUCCESS IN RECENT DECADES MAY BE IN DANGER IF LIFESTYLES OF THE ELDERLY ARE NEGLECTED,NA,OLDER-ADULTS; WEIGHT-LOSS; OBESITY; WOMEN,NA,AMERICAN JOURNAL OF CLINICAL NUTRITION,"VAN BAAK, MA##VISSCHER, TLS","MAASTRICHT UNIV, DEPT HUMAN BIOL, NUTR & TOXICOL RES INST MAASTRICHT, NL-6200 MD MAASTRICHT, NETHERLANDS. VRIJE UNIV AMSTERDAM, INST HLTH SCI, AMSTERDAM, NETHERLANDS.",NUTRITION & DIETETICS,NUTRITION & DIETETICS,"CHAO D, 2000, J AM GERIATR SOC, V48, P753, DOI 10.1111/J.1532-5415.2000.TB04749.X##MANINI TM, 2006, JAMA-J AM MED ASSOC, V296, P171, DOI 10.1001/JAMA.296.2.171##NOOYENS ACJ, 2005, OBES REV, V6, P5##PEETERS A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008##SEIDELL JC, 2005, P NUTR SOC, V64, P1, DOI 10.1079/PNS2004402##VILLAREAL DT, 2006, AM J CLIN NUTR, V84, P1317##VILLAREAL DT, 2006, ARCH INTERN MED, V166, P860, DOI 10.1001/ARCHINTE.166.8.860##VISSCHER TLS, 2004, ARCH INTERN MED, V164, P1413, DOI 10.1001/ARCHINTE.164.13.1413##VISSER M, 1998, AM J CLIN NUTR, V68, P584",8,2020-11-20,NA
J,WOS:000242776800009,2006,EFFECT OF GARLIC POWDER ON C-REACTIVE PROTEIN AND PLASMA LIPIDS IN OVERWEIGHT AND SMOKING SUBJECTS,"BACKGROUND: EPIDERNIOLOGIC STUDIES SUGGEST THAT GARLIC MAY HAVE BENEFICIAL EFFECTS ON RISK FACTORS ASSOCIATED WITH CARDIOVASCULAR DISEASE (CVD). HOWEVER, THESE FINDINGS ARE NOT UNAMBIGUOUSLY SUPPORTED BY RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIALS. OBJECTIVE: WE SOUGHT TO INVESTIGATE THE EFFECTS OF A CHEMICALLY WELL-CHARACTERIZED GARLIC PREPARATION ON BIOMARKERS FOR INFLAMMATION, ENCLOTHELIAL FUNCTION, AND LIPID METABOLISM IN SUBJECTS WITH RISK FACTORS FOR CVD. DESIGN: THIS WAS A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN 90 OVERWEIGHT [BODY MASS INDEX (IN KG/M(2)) > 24.5] SUBJECTS AGED 40-75 Y WHO SMOKED > 10 CIGARETTES/D. THE SUBJECTS WERE RANDOMLY ASSIGNED TO 3 PARALLEL TREATMENT GROUPS: GARLIC POWDER (2.1 G/D), ATORVASTATIN (40 MG/D), OR PLACEBO. DUPLICATE MEASUREMENTS WERE PERFORMED AT BASELINE AND AFTER 1 AND 3 MO OF TREATMENT. TREATMENTS WERE COMPARED WITH ANALYSIS OF COVARIANCE WITH BASELINE AS THE COVARIATE, AND DIFFERENCES BETWEEN THE TREATMENTS WERE REPORTED AS MEAN PERCENTAGE DIFFERENCE AND CORRESPONDING 97.5% CI. RESULTS: NONE OF THE VARIABLES SHOWED SIGNIFICANT DIFFERENCES BETWEEN THE GARLIC-TREATED AND THE PLACEBO GROUPS. IN CONTRAST, COMPARED WITH THE PLACEBO GROUP, ATORVASTATIN TREATMENT RESULTED IN SIGNIFICANTLY LOWER PLASMA CONCENTRATIONS OF C-REACTIVE PROTEIN (20.2%; 1.7%,35.3%), TOTAL CHOLESTEROL (37.2%; 33.1%,41.1%), LDL CHOLESTEROL (52.7%; 47.9%, 57.1%) TRIACYLGLYCEROLS (31.9%; 20.8%, 41.5%), AND TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA; 41.9%; 19.0%, 58.3%) AND INCREASED THE RATIO OF EX VIVO WHOLE BLOOD LIPOPOLYSACCHARIDE-STIMULATED TO NONSTIMULATED TNF-ALPHA CONCENTRATIONS (109.7%; 37.9%, 218.9%). CONCLUSION: WE CONCLUDE THAT A CHEMICALLY WELL-CHARACTERIZED GARLIC PREPARATION HAS NO SIGNIFICANT EFFECT ON INFLAMMATORY BIOMARKERS, ENDOTHELIAL FUNCTION, OR LIPID PROFILE IN NORMOLIPIDEMIC SUBJECTS WITH RISK FACTORS FOR CVD.",SERUM-LIPIDS; BLOOD-PRESSURE; DOUBLE-BLIND; LIPOPROTEINS; ATORVASTATIN; ALLICIN; RELEASE; HEALTHY; DISEASE; RISK,GARLIC; C-REACTIVE PROTEIN; CRP; LIPIDS; ENDOTHELIAL FUNCTION; HUMANS,AMERICAN JOURNAL OF CLINICAL NUTRITION,"VAN DOORN, MBA##SANTO, SME##MEIJER, P##KAMERLING, IM##SCHOEMAKER, RC##DIRSCH, V##VOLLMAR, A##HAFFNER, T##GEBHARDT, R##COHEN, AF##PRINCEN, HM##BURGGRAAF, J","CTR HUMAN DRUG RES, NL-2333 CL LEIDEN, NETHERLANDS. TNO PREVENT & HLTH, GAUBIUS LAB, LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT GEN INTERNAL MED, LEIDEN, NETHERLANDS. UNIV MUNICH, DEPT PHARM, MUNICH, GERMANY. LICHTWER AG, BERLIN, GERMANY. FAC MED, INST BIOCHEM, LEIPZIG, GERMANY.",NUTRITION & DIETETICS,NUTRITION & DIETETICS,"ARNAULT I, 2003, J CHROMATOGR A, V991, P69, DOI 10.1016/S0021-9673(03)00214-0##ARNAULT I, 2005, J PHARMACEUT BIOMED, V37, P963, DOI 10.1016/J.JPBA.2004.09.032##BANERJEE SK, 2002, NUTR J, V1, DOI 10.1186/1475-2891-1-4##BERTHOLD HK, 1998, JAMA-J AM MED ASSOC, V279, P1900, DOI 10.1001/JAMA.279.23.1900##BREITHAUPTGROGLER K, 1997, CIRCULATION, V96, P2649, DOI 10.1161/01.CIR.96.8.2649##CHAN DC, 2002, CLIN CHEM, V48, P877##CHERNYAD'EVA IF, 2003, B EXP BIOL MED+, V135, P436, DOI 10.1023/A:1024955023300##CURB JD, 2003, CIRCULATION, V107, P2016, DOI 10.1161/01.CIR.0000065228.20100.F7##GARDNER CD, 2001, ATHEROSCLEROSIS, V154, P213, DOI 10.1016/S0021-9150(00)00466-4##HAVERKATE F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5##HODGE G, 2002, CYTOMETRY, V48, P209, DOI 10.1002/CYTO.10133##HOUSE D, 2002, J INFECT DIS, V186, P240, DOI 10.1086/341298##IDE N, 2001, J NUTR, V131, P1020S, DOI 10.1093/JN/131.3.1020S##INGERSLEV J, 1987, SCAND J CLIN LAB INV, V47, P143##ISAACSOHN JL, 1998, ARCH INTERN MED, V158, P1189, DOI 10.1001/ARCHINTE.158.11.1189##JAIN AK, 1993, AM J MED, V94, P632, DOI 10.1016/0002-9343(93)90216-C##JAIN RC, 1977, AM J CLIN NUTR, V30, P1380##KEISS HP, 2003, J NUTR, V133, P2171##LAUFS U, 2001, AM J CARDIOL, V88, P1306, DOI 10.1016/S0002-9149(01)02095-1##LAWSON LD, 2001, J AGR FOOD CHEM, V49, P2592, DOI 10.1021/JF001287M##MCMAHON FG, 1993, PHARMACOTHERAPY, V13, P406##OREKHOV AN, 1997, NUTRITION, V13, P656, DOI 10.1016/S0899-9007(97)83010-9##PELEG A, 2003, ISR MED ASSOC J, V5, P637##RIDKER PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202##SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S##STEINER M, 1996, AM J CLIN NUTR, V64, P866##TURNER B, 2004, BRIT J NUTR, V92, P701, DOI 10.1079/BJN20041255##VAN DE REE MA, 2003, ATHEROSCLEROSIS, V166, P129, DOI 10.1016/S0021-9150(02)00316-7",46,2020-11-20,NA
J,WOS:000242776800034,2006,DEPRESSION AND CARDIOVASCULAR MORTALITY: A ROLE FOR N-3 FATTY ACIDS?,"BACKGROUND: RECENT STUDIES INDICATE THAT DEPRESSION PLAYS AN IMPORTANT ROLE IN THE OCCURRENCE OF CARDIOVASCULAR DISEASES (CVDS). THE UNDERLYING MECHANISMS ARE NOT WELL UNDERSTOOD. OBJECTIVE: WE INVESTIGATED WHETHER DIETARY INTAKE OF THE N-3 FATTY ACIDS (FAS) EICOSAPENTAENIC ACID AND DOCOSAHEXAENOIC ACID COULD EXPLAIN THE RELATION BETWEEN DEPRESSIVE SYMPTOMS AND CARDIOVASCULAR MORTALITY. DESIGN: THE ZUTPHEN ELDERLY STUDY IS A PROSPECTIVE COHORT STUDY CONDUCTED IN THE NETHERLANDS. DEPRESSIVE SYMPTOMS WERE MEASURED IN 1990 WITH THE ZUNG SELF-RATING DEPRESSION SCALE IN 332 MEN AGED 70-90 Y AND FREE FROM CVD AND DIABETES. DIETARY FACTORS WERE ASSESSED WITH A CROSS-CHECK DIETARY HISTORY METHOD IN 1990. MORTALITY DATA WERE COLLECTED BETWEEN 1990 AND 2000. LOGISTIC AND COX REGRESSION ANALYSES WERE PERFORMED, WITH ADJUSTMENT FOR DEMOGRAPHICS AND CVD RISK FACTORS. RESULTS: COMPARED WITH A LOW INTAKE ((X) OVER BAR: 21 MG/D), A HIGH INTAKE ((X) OVER BAR: 407 MG/D) OF N-3 FAS WAS ASSOCIATED WITH FEWER DEPRESSIVE SYMPTOMS [ODDS RATIO: 0.46; 95% CI: 0.22, 0.95; P FOR TREND = 0.04] AT BASELINE AND NO SIGNIFICANT REDUCED RISK OF 10-Y CVD MORTALITY [HAZARD RATIO (HR): 0.88; 95% CI: 0.51, 1.50]. THE ADJUSTED HR FOR AN INCREASE IN DEPRESSIVE SYMPTOMS WITH 1 SD FOR CVD MORTALITY WAS 1.28 (95% CI: 1.03, 1.57) AND DID NOT CHANGE AFTER ADDITIONAL ADJUSTMENT FOR THE INTAKE OF N-3 FAS. CONCLUSION: AN AVERAGE INTAKE OF APPROXIMATE TO 400 MG N-3 FA/D MAY REDUCE THE RISK OF DEPRESSION. OUR RESULTS, HOWEVER, DO NOT SUPPORT THE HYPOTHESIS THAT THE INTAKE OF N-3 FAS EXPLAINS THE RELATION BETWEEN DEPRESSION AND CVD.",PRELIMINARY DOUBLE-BLIND; CORONARY-HEART-DISEASE; FISH CONSUMPTION; DIETARY-INTAKE; RISK-FACTOR; OMEGA-3-FATTY-ACIDS; SYMPTOMS; FINLAND; SCALE; METAANALYSIS,DEPRESSIVE SYMPTOMS; N-3 FATTY ACIDS; CARDIOVASCULAR DISEASE; MORTALITY; EPIDEMIOLOGY,AMERICAN JOURNAL OF CLINICAL NUTRITION,"KAMPHUIS, MH##GEERLINGS, MI##TIJHUIS, MAR##KALMIJN, S##GROBBEE, DE##KROMHOUT, D","UNIV UTRECHT, CTR MED, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 GA UTRECHT, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, CTR PREVENT & HLTH SERV RES, NL-3720 BA BILTHOVEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, DIV HUMAN NUTR, WAGENINGEN, NETHERLANDS.",NUTRITION & DIETETICS,NUTRITION & DIETETICS,"BIGGS JT, 1978, BRIT J PSYCHIAT, V132, P381, DOI 10.1192/BJP.132.4.381##BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/OXFORDJOURNALS.AJE.A115405##CARNEY RM, 2005, ARCH INTERN MED, V165, P1486, DOI 10.1001/ARCHINTE.165.13.1486##CARNEY RM, 2005, PSYCHOSOM MED, V67, PS29, DOI 10.1097/01.PSY.0000162254.61556.D5##CARNEY RM, 2002, J PSYCHOSOM RES, V53, P897, DOI 10.1016/S0022-3999(02)00311-2##DEFORGE BR, 1988, INT J PSYCHIAT MED, V18, P325##DUNN VK, 1989, PSYCHOL AGING, V4, P125, DOI 10.1037/0882-7974.4.1.125##FESKENS EJM, 1993, NETHERLANDS J CARDIO, V6, P200##FRASURE-SMITH N, 2004, BIOL PSYCHIAT, V55, P891, DOI 10.1016/J.BIOPSYCH.2004.01.021##FRASURE-SMITH N, 2005, PSYCHOSOM MED, V67, PS19, DOI 10.1097/01.PSY.0000162253.07959.DB##HAAG M, 2003, CAN J PSYCHIAT, V48, P195##HAKKARAINEN R, 2004, AM J PSYCHIAT, V161, P567, DOI 10.1176/APPI.AJP.161.3.567##HE K, 2004, CIRCULATION, V109, P2705, DOI 10.1161/01.CIR.0000132503.19410.6B##HE K, 2004, STROKE, V35, P1538, DOI 10.1161/01.STR.0000130856.31468.47##HEMINGWAY H, 1999, BMJ-BRIT MED J, V318, P1460, DOI 10.1136/BMJ.318.7196.1460##HIBBELN JR, 1998, BIOL PSYCHIAT, V44, P235, DOI 10.1016/S0006-3223(98)00141-3##HIBBELN JR, 1995, AM J CLIN NUTR, V62, P1##HIBBELN JR, 1998, LANCET, V351, P1213, DOI 10.1016/S0140-6736(05)79168-6##JACKA E, 2004, NUTR NEUROSCI, V7, P101, DOI 10.1080/10284150410001710438##KALMIJN S, 1997, AM J EPIDEMIOL, V145, P33, DOI 10.1093/OXFORDJOURNALS.AJE.A009029##KAMPHUIS MH, 2006, EUR J CARDIOV PREV R, V13, P199, DOI 10.1097/01.HJR.0000188242.64590.92##KEYS A, 1980, 7 COUNTRIES MULTIVAR##KIVELA SL, 1986, PSYCHOL REP, V59, P587, DOI 10.2466/PR0.1986.59.2.587##KROMHOUT D, 1990, AM J EPIDEMIOL, V131, P855, DOI 10.1093/OXFORDJOURNALS.AJE.A115576##MAMALAKIS G, 2004, PROSTAG LEUKOTR ESS, V70, P495, DOI 10.1016/J.PLEFA.2003.10.005##MEYER BJ, 2003, LIPIDS, V38, P391, DOI 10.1007/S11745-003-1074-0##MURRAY CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2##MUSSELMAN DL, 1998, ARCH GEN PSYCHIAT, V55, P580, DOI 10.1001/ARCHPSYC.55.7.580##PENNINX BWJH, 2003, BIOL PSYCHIAT, V54, P566, DOI 10.1016/S0006-3223(02)01811-5##ROSE GA, 1968, WHO MONOGR SER, V56, P1##ROSS R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207##SAS INSTITUTE, 2004, STAT AN SYST VERS 9##SEVERUS WE, 2001, HARVARD REV PSYCHIAT, V9, P280, DOI 10.1093/HRP/9.6.280##STOLL AL, 1999, ARCH GEN PSYCHIAT, V56, P407, DOI 10.1001/ARCHPSYC.56.5.407##SU KP, 2003, EUR NEUROPSYCHOPHARM, V13, P267, DOI 10.1016/S0924-977X(03)00032-4##TANSKANEN A, 2001, PSYCHIATR SERV, V52, P529, DOI 10.1176/APPI.PS.52.4.529##TIEMEIER H, 2003, EPIDEMIOLOGY, V14, P103, DOI 10.1097/00001648-200301000-00025##TIEMEIER H, 2003, AM J CLIN NUTR, V78, P40##TIMONEN M, 2004, J AFFECT DISORDERS, V82, P447, DOI 10.1016/J.JAD.2004.02.002##WESTERTERP KR, 1992, MED SCI SPORTS EXERC, V24, P68##WILLETT WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/AJCN/65.4.1220S##ZUNG WWK, 1969, AM J PSYCHIAT, V126, P116, DOI 10.1176/AJP.126.1.116##ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V13, P508, DOI 10.1001/ARCHPSYC.1965.01730060026004##ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/ARCHPSYC.1965.01720310065008",41,2020-11-20,NA
J,WOS:000242776800042,2006,SATURATED FAT DOES NOT AFFECT BLOOD CHOLESTEROL - REPLY TO U RAVNSKOV,NA,CORONARY-HEART-DISEASE; HYPOTHESIS; ATHEROSCLEROSIS; FREQUENCY; MORTALITY; CITATION; CAUSAL; ACIDS,NA,AMERICAN JOURNAL OF CLINICAL NUTRITION,"KATAN, MB","INST HLTH SCI, FAC EARTH & LIFE SCI, NL-1081 HV AMSTERDAM, NETHERLANDS.",NUTRITION & DIETETICS,NUTRITION & DIETETICS,"RAVNSHOV U, 1999, BRIT MED J, V319, P255##RAVNSKOV T, 2001, LANCET, V358, P1907, DOI 10.1016/S0140-6736(01)06912-4##RAVNSKOV U, 2005, NEW ENGL J MED, V353, P94##RAVNSKOV U, 1991, LAKARTIDNINGEN, V88, P1060##RAVNSKOV U, 1992, UGESKR LAEGER, V154, P1716##RAVNSKOV U, 1993, LAKARTIDNINGEN, V90, P4587##RAVNSKOV U, 1993, UGESKR LAEGER, V155, P3679##RAVNSKOV U, 1993, CIRCULATION, V88, P1358, DOI 10.1161/01.CIR.88.3.1358##RAVNSKOV U, 1993, LAKARTIDNINGEN, V90, P2528##RAVNSKOV U, 1993, BRIT MED J, V307, P125, DOI 10.1136/BMJ.307.6896.125-A##RAVNSKOV U, 1993, UGESKR LAEGER, V155, P1886##RAVNSKOV U, 1994, LANCET, V344, P1297, DOI 10.1016/S0140-6736(94)90783-8##RAVNSKOV U, 1994, CIRCULATION, V90, P2572, DOI 10.1161/01.CIR.90.5.2572##RAVNSKOV U, 1994, CIRCULATION, V90, P2568, DOI 10.1161/CIRC.90.5.7832874##RAVNSKOV U, 1994, UGESKR LAEGER, V156, P4479##RAVNSKOV U, 1994, LAKARTIDNINGEN, V91, P2308##RAVNSKOV U, 1995, BRIT MED J, V311, P1436, DOI 10.1136/BMJ.311.7017.1436C##RAVNSKOV U, 1995, UGESKR LAEGER, V157, P1534##RAVNSKOV U, 1996, ANN INTERN MED, V125, P1010, DOI 10.7326/0003-4819-125-12-199612150-00023##RAVNSKOV U, 1996, LAKARTIDNINGEN, V93, P2040##RAVNSKOV U, 1998, LAKARTIDNINGEN, V95, P4966##RAVNSKOV U, 1998, LAKARTIDNINGEN, V95, P4749##RAVNSKOV U, 1998, J CLIN EPIDEMIOL, V51, P443, DOI 10.1016/S0895-4356(98)00018-3##RAVNSKOV U, 1998, LAKARTIDNINGEN, V95, P1022##RAVNSKOV U, 1999, LAKARTIDNINGEN, V96, P1949##RAVNSKOV U, 2001, LAKARTIDNINGEN, V98, P4897##RAVNSKOV U, 2001, LAKARTIDNINGEN, V98, P4574##RAVNSKOV U, 1991, MED HYPOTHESES, V36, P238, DOI 10.1016/0306-9877(91)90140-T##RAVNSKOV U, 1992, BRIT MED J, V305, P717, DOI 10.1136/BMJ.305.6855.717##RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/BMJ.305.6844.15##RAVNSKOV U, 1994, NEPHRON, V66, P356, DOI 10.1159/000187838##RAVNSKOV U, 1995, LANCET, V346, P181##RAVNSKOV U, 1995, J CLIN EPIDEMIOL, V48, P713, DOI 10.1016/0895-4356(94)00222-C##RAVNSKOV U, 2000, BRIT MED J, V320, P1470##RAVNSKOV U, 2002, J CLIN EPIDEMIOL, V55, P1057, DOI 10.1016/S0895-4356(02)00504-8##RAVNSKOV U, 2002, QJM-INT J MED, V95, P397, DOI 10.1093/QJMED/95.6.397##RAVNSKOV U, 2002, SCIENCE, V295, P1464##RAVNSKOV U, 2003, BRIT MED J, V327, P1348, DOI 10.1136/BMJ.327.7427.1348-B##RAVNSKOV U, 2003, QJM-INT J MED, V96, P927, DOI 10.1093/QJMED/HCG150##RAVNSKOV U, 2003, LANCET, V361, P1988, DOI 10.1016/S0140-6736(03)13565-9##RAVNSKOV U, 2003, LANCET, V361, P1986, DOI 10.1016/S0140-6736(03)13559-3##RAVNSKOV U, 2004, JAMA-J AM MED ASSOC, V291, P1833, DOI 10.1001/JAMA.291.15.1833##RAVNSKOV U, 2004, JAMA-J AM MED ASSOC, V292, P38, DOI 10.1001/JAMA.292.1.38-A##RAVNSKOV U, 2005, BRIT MED J, V331, P906, DOI 10.1136/BMJ.331.7521.906-B##RAVNSKOV U, 2002, BMJ-BRIT MED J, V324, P238, DOI 10.1136/BMJ.324.7331.238##RAVNSKOV U, 2006, JAMA-J AM MED ASSOC, V295, P2478##RAVNSKOV U, 2004, LAKARTIDNINGEN, V101, P1218##RAVNSKOV U, 2004, LAKARTIDNINGEN, V101, P1221##RAVNSKOV U, 1994, BRIT MED J, V308, P103##RAVNSKOV UFFE, 2002, LAKARTIDNINGEN, V99, P2673##RAVNSKOV UFFE, 2002, LAKARTIDNINGEN, V99, P1507##RAVNSKOV UFFE, 2004, TIDSSKR NOR LAEGEFOREN, V124, P2153##RAVNSKOV UFFE, 2004, LAKARTIDNINGEN, V101, P1215##RAVNSKOV UFFE, 2005, LAKARTIDNINGEN, V102, P2583##RAVNSKOV UFFE, 2006, UGESKR LAEGER, V168, P1665##RAVNSKOV UFFE, 2006, LAKARTIDNINGEN, V103, P569##RAVNSKOV U, 2006, JAMA-J AM MED ASSOC, V295, P2476, DOI 10.1001/JAMA.295.21.2476-A##RAVNSKOV U, 2006, BMJ-BRIT MED J, V332, P1330, DOI 10.1136/BMJ.332.7553.1330##RAVNSKOV UFFE, 2003, LAKARTIDNINGEN, V100, P3255##UNDERSTRUP AG, 2005, J CHEM ECOL, V31, P1205, DOI 10.1007/S10886-005-4257-X",0,2020-11-20,NA
J,WOS:000242776800045,2006,EFFECTS OF N-3 FATTY ACIDS ON ARRHYTHMIC EVENTS AND MORTALITY IN THE SOFA IMPLANTABLE CARDIOVERTER DEFIBRILLATOR TRIAL,NA,NA,NA,AMERICAN JOURNAL OF CLINICAL NUTRITION,"BROUWER, IA##KATAN, MB##ZOCK, PL","WAGENINGEN CTR FOOD SCI, WAGENINGEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, DIV HUMAN NUTR, NL-6703 HD WAGENINGEN, NETHERLANDS. VRIJE UNIV AMSTERDAM, INST HLTH SCI, AMSTERDAM, NETHERLANDS. UNILEVER FOOD & HLTH RES INST, VLAARDINGEN, NETHERLANDS.",NUTRITION & DIETETICS,NUTRITION & DIETETICS,"BROUWER IA, 2006, JAMA-J AM MED ASSOC, V2959, P2613##WANG CC, 2006, AM J CLIN NUTR, V84, P5",2,2020-11-20,NA
J,WOS:000242681900002,2006,FRACTURE BEHAVIOR OF STRUCTURALLY COMPROMISED NON-VITAL MAXILLARY PREMOLARS RESTORED USING EXPERIMENTAL FIBER REINFORCED COMPOSITE CROWNS,"PURPOSE: TO STUDY THE FRACTURE BEHAVIOR OF DIRECT RESIN COMPOSITE CROWNS WITH OR WITHOUT EXPERIMENTAL FIBER REINFORCEMENT. METHODS: CLINICAL CROWNS OF SINGLE-ROOTED MAXILLARY PREMOLARS WERE CUT OFF AT THE CEMENTO-ENAMEL JUNCTION. CANALS WERE PREPARED WITH GATES GLIDDEN DRILLS UP TO SIZE 4. NO ADDITIONAL POST-SPACE PREPARATIONS WERE MADE. ROOTS WERE EMBEDDED IN ACRYLIC AND CANAL ENTRANCES WERE STANDARDIZED (DEPTH 2 NUN, DIAMETER 1.75 MM). THREE GROUPS OF 14 SAMPLES WERE TREATED AS FOLLOWS: (1) CUSTOM-MADE GLASS FRC POST (EVERSTICK POST); FIBERS 5 MM DEEP IN THE CANAL, (2) SIMILAR POST-SYSTEM AS (1) WITH INCORPORATION OF A NEW TYPE OF GLASS FIBER FABRIC, (3) NO FIBER REINFORCEMENT (CONTROL). POSTS WERE CEMENTED WITH RESIN CEMENT (PANAVIA F). RESIN COMPOSITE CROWNS (FILTEK Z250) WERE MADE USING AN ANATOMICALLY FORMED MOLD. STATIC LOAD UNTIL FRACTURE WAS APPLIED USING A UNIVERSAL LOADING DEVICE WITH A CYLINDRICAL BAR (DIAMETER 2 MM) WITH A CROSSHEAD SPEED OF 5 MM/MINUTE (LOADING ANGLE: 30 DEGREES TO THE TOOTH LONG-AXIS). FAILURE MODES WERE CATEGORIZED AS FAVORABLE AND UNFAVORABLE FAILURES. RESULTS: THERE WAS NO SIGNIFICANT DIFFERENCE IN MEAN FAILURE LOADS AMONG THE FOUR GROUPS (P> 0.05). FAVORABLE FAILURES OCCURRED SIGNIFICANTLY MORE OFTEN IN GROUP 2 THAN IN THE OTHER GROUPS (P< 0.05). THE RESULTS SUGGEST THAT AN INCORPORATED GLASS FIBER FABRIC DOES NOT AFFECT THE LOAD-BEARING CAPACITY OF RESIN COMPOSITE COMPLETE CROWNS ON STRUCTURALLY COMPROMISED AND NON-VITAL PREMOLARS. INCORPORATION OF A GLASS FIBER FABRIC, HOWEVER, HAS A BENEFICIAL EFFECT ON THE FAILURE MODE.",DIFFERENT POST SYSTEMS; TOOTH-COLORED POSTS; IN-VITRO EVALUATION; CROSS-HEAD SPEED; ROOT-CANAL POSTS; CORE SYSTEMS; PULPLESS TEETH; RESTORATIVE MATERIALS; FLEXURAL PROPERTIES; ENDODONTIC POSTS,NA,AMERICAN JOURNAL OF DENTISTRY,"FOKKINGA, WA##KREULEN, CM##LE BELL-RONNLOF, AM##LASSILA, LVJ##VALLITTU, PK##CREUGERS, NHJ","UNIV NIJMEGEN, RADBOUD MED CTR, COLL DENT SCI, DEPT ORAL FUNCT & PROSTHET DENT, NL-6500 HB NIJMEGEN, NETHERLANDS. UNIV TURKU, DEPT PROSTHET DENT & BIOMAT RES, INST DENT, SF-20500 TURKU, FINLAND.","DENTISTRY, ORAL SURGERY & MEDICINE","DENTISTRY, ORAL SURGERY & MEDICINE","AKKAYAN B, 2002, J PROSTHET DENT, V87, P431, DOI 10.1067/MPR.2002.123227##ASMUSSEN E, 1999, J DENT, V27, P275, DOI 10.1016/S0300-5712(98)00066-9##BOLHUIS HPB, 2001, AM J DENT, V14, P286##BOLHUIS P, 2004, QUINTESSENCE INT, V35, P657##BRUNTON PA, 1999, J PROSTHET DENT, V82, P167, DOI 10.1016/S0022-3913(99)70151-4##CORMIER C J, 2001, J PROSTHODONT, V10, P26, DOI 10.1053/JPRO.2001.23777##CREUGERS NHJ, 2005, INT J PROSTHODONT, V18, P40##CREUGERS NHJ, 2005, INT J PROSTHODONT, V18, P34##DEAN JP, 1998, J ENDODONT, V24, P807, DOI 10.1016/S0099-2399(98)80007-1##DECLEEN MJH, 1993, INT ENDOD J, V26, P53, DOI 10.1111/J.1365-2591.1993.TB00542.X##DRUMMOND JL, 1999, EUR J ORAL SCI, V107, P220, DOI 10.1046/J.0909-8836.1999.EOS1070310.X##EMILSON CG, 2004, J DENT RES, P83##ESKITASCIOGLU G, 2002, J ENDODONT, V28, P629, DOI 10.1097/00004770-200209000-00001##FENNIS WMM, 2005, DENT MATER, V21, P565, DOI 10.1016/J.DENTAL.2004.07.019##FOKKINGA WA, 2005, INT ENDOD J, V38, P230, DOI 10.1111/J.1365-2591.2005.00941.X##FOKKINGA WA, 2004, INT J PROSTHODONT, V17, P476##FUSS Z, 2001, J ENDODONT, V27, P46, DOI 10.1097/00004770-200101000-00017##HARA AT, 2001, DENT MATER, V17, P165, DOI 10.1016/S0109-5641(00)00060-9##ISAAC DH, 1999, 1 S FIBR REINF PLAST##KESKI-NIKKOLA M S, 2004, EUR J PROSTHODONT RESTOR DENT, V12, P80##KING PA, 1990, J ORAL REHABIL, V17, P599, DOI 10.1111/J.1365-2842.1990.TB01431.X##KLOCKE A, 2005, DENT MATER, V21, P139, DOI 10.1016/J.DENTAL.2004.03.004##KREJCI I, 2003, OPER DENT, V28, P127##KREJCI I, 1994, J DENT RES, V73, P1228, DOI 10.1177/00220345940730061501##LASSILA LVJ, 2004, DENT MATER, V20, P29, DOI 10.1016/S0109-5641(03)00065-4##LE BELL AM, 2003, INT J PROSTHODONT, V16, P403##MANNOCCI F, 2002, J PROSTHET DENT, V88, P297, DOI 10.1067/MPR.2002.128492##MARTINEZ-INSUA A, 1998, J PROSTHET DENT, V80, P527, DOI 10.1016/S0022-3913(98)70027-7##NISSAN J, 2001, J PROSTHET DENT, V86, P304, DOI 10.1067/MPR.2001.114759##PURTON DG, 2003, QUINTESSENCE INT, V34, P366##QUALTROUGH AJE, 2003, QUINTESSENCE INT, V34, P199##REID LC, 2003, J ENDODONT, V29, P125, DOI 10.1097/00004770-200302000-00010##ROETERS J J, 2001, J ADHES DENT, V3, P81##ROSENTRITT M, 2000, J ORAL REHABIL, V27, P595, DOI 10.1046/J.1365-2842.2000.00548.X##SIDOLI GE, 1997, J PROSTHET DENT, V78, P5, DOI 10.1016/S0022-3913(97)70080-5##SIRIMAI S, 1999, J PROSTHET DENT, V81, P262, DOI 10.1016/S0022-3913(99)70267-2##SORENSEN JA, 1984, J PROSTHET DENT, V52, P28, DOI 10.1016/0022-3913(84)90176-8##TORBJORNER A, 2004, INT J PROSTHODONT, V17, P369##TROPE M, 1985, ENDODONTICS AND DENTAL TRAUMATOLOGY, V1, P108##VALLITTU PK, 1999, J PROSTHET DENT, V81, P318, DOI 10.1016/S0022-3913(99)70276-3##VALLITTU PK, 1 S FIBR REINF PLAST##YANG HS, 2001, J PROSTHET DENT, V85, P558, DOI 10.1067/MPR.2001.115504##YANG HS, 2001, J PROSTHET DENT, V86, P74, DOI 10.1067/MPR.2001.115503",9,2020-11-20,NA
J,WOS:000242681900003,2006,EFFECT OF THE SEATING PRESSURE ON THE ADHESIVE BONDING OF INDIRECT RESTORATIONS,"PURPOSE: TO EVALUATE THE EFFECT OF TWO DIFFERENT TECHNIQUES OF SEATING PRESSURE APPLICATION ON THE ADHESIVE-DENTIN BOND OF INDIRECT RESTORATIONS. METHODS: EIGHT NON-CARIOUS HUMAN THIRD MOLARS WERE RANDOMLY DIVIDED IN TWO TREATMENT GROUPS (FOUR TEETH EACH). CYLINDRICAL COMPOSITE BLOCKS WERE LUTED WITH A RESIN CEMENT (PANAVIA F). IN GROUP 1, THE SEATING PRESSURE WAS APPLIED FOR 5 SECONDS. IN GROUP 2, THE RESIN CYLINDER WAS MAINTAINED UNDER CONSTANT PRESSURE DURING THE ENTIRE 3-MINUTE POLYMERIZATION PERIOD OF THE RESIN CEMENT. AFTER STORING IN DISTILLED WATER FOR 24 HOURS, 0.9 X 0.9 MM STICKS WERE PRODUCED FROM THESE LUTED SPECIMENS FOR MICROTENSILE BOND TESTING AND SEM EXAMINATION. RESULTS: THE STUDENT T-TEST SHOWED A SIGNIFICANT DIFFERENCE (P< 0.05) IN BOND STRENGTH BETWEEN GROUPS 1 AND 2. SEM REVEALED THE PRESENCE OF STRUCTURAL DEFECTS AND RESIN GLOBULES ON THE SEATING SURFACE OF THE COMPOSITES. THESE FEATURES WERE EXCLUSIVELY IDENTIFIED FROM GROUP I SPECIMENS AND WERE PROBABLY CAUSED BY FLUID TRANSUDATION FROM THE UNDERLYING DENTIN THROUGH THE SIMPLIFIED SELF-ETCH ADHESIVE (ED PRIMER).",RESIN CEMENTS; SINGLE-STEP; DENTIN; STRENGTH; FORCE; POLYMERIZATION; DESIGN,NA,AMERICAN JOURNAL OF DENTISTRY,"CHIEFFI, N##CHERSONI, S##PAPACCHINI, F##VANO, M##GORACCI, C##DAVIDSON, CL##TAY, FR##FERRARI, M","UNIV SIENA, DEPT RESTORAT DENT & DENT MAT, I-53100 SIENA, ITALY. UNIV BOLOGNA, DEPT DENT SCI, BOLOGNA, ITALY. UNIV PISA, DEPT ORAL SURG, PISA, ITALY. UNIV AMSTERDAM, NL-1012 WX AMSTERDAM, NETHERLANDS. UNIV HONG KONG, DEPT PEDIAT DENT & ORTHODONT, HONG KONG, HONG KONG, PEOPLES R CHINA. TUFTS UNIV, BOSTON, MA 02111 USA.","DENTISTRY, ORAL SURGERY & MEDICINE","DENTISTRY, ORAL SURGERY & MEDICINE","BURKE F J, 1994, QUINTESSENCE INT, V25, P269##CARVALHO RM, 2004, J DENT, V32, P55, DOI 10.1016/J.JDENT.2003.08.003##DE MUNCK J, 2004, DENT MATER, V20, P963, DOI 10.1016/J.DENTAL.2004.03.002##EL ZOHAIRY AA, 2004, DENT MATER, V20, P778, DOI 10.1016/J.DENTAL.2003.05.010##EL ZOHAIRY AA, 2003, DENT MATER, V19, P575, DOI 10.1016/S0109-5641(02)00107-0##FEILZER AJ, 1989, J DENT RES, V68, P48, DOI 10.1177/00220345890680010701##FURUKAWA K, 2002, DENT MATER, V18, P136, DOI 10.1016/S0109-5641(01)00032-X##HASHIMOTO M, 2000, J DENT RES, V79, P1385, DOI 10.1177/00220345000790060601##JAYASOORIYA PRIMALI R, 2003, J ESTHET RESTOR DENT, V15, P105, DOI 10.1111/J.1708-8240.2003.TB00325.X##KRAMER N, 2000, AM J DENT, V13, P60D##MAK YF, 2002, DENT MATER, V18, P609, DOI 10.1016/S0109-5641(02)00005-2##MONTES MAJR, 2003, OPER DENT, V28, P378##NIKAIDO T, 2003, AM J DENT, V16, P41A##NYUNT M M, 1996, DENT MATER J, V15, P175##OGAWA T, 2001, J PROSTHET DENT, V85, P170, DOI 10.1067/MPR.2001.113354##OKUDA M, 2002, OPER DENT, V27, P289##PIEMJAI MM, 2001, INT J PROSTHODONT, V14, P412##SANARES AME, 2001, DENT MATER, V17, P542, DOI 10.1016/S0109-5641(01)00016-1##SHONO Y, 1999, J DENT RES, V78, P699, DOI 10.1177/00220345990780021001##STEWART GP, 2002, J PROSTHET DENT, V88, P277, DOI 10.1067/MPR.2002.128034##TAY FR, 2002, J DENT, V30, P371, DOI 10.1016/S0300-5712(02)00064-7##TAY FR, 2004, AM J DENT, V17, P271##TAY FRANKLIN R, 2003, J CAN DENT ASSOC, V69, P726##TYAS MJ, 2000, INT DENT J, V50, P1, DOI 10.1111/J.1875-595X.2000.TB00540.X##VERSLUIS A, 1996, J DENT RES, V75, P871, DOI 10.1177/00220345960750030301##WANG CJ, 1992, J PROSTHET DENT, V67, P786, DOI 10.1016/0022-3913(92)90583-V##WHITE SN, 1992, J PROSTHET DENT, V68, P476, DOI 10.1016/0022-3913(92)90414-6##WHITE SN, 1993, J PROSTHET DENT, V69, P28, DOI 10.1016/0022-3913(93)90235-G##YU Z, 1995, J PROSTHODONT, V4, P251, DOI 10.1111/J.1532-849X.1995.TB00351.X",11,2020-11-20,NA
J,WOS:000242681900008,2006,SURVIVAL OF SELF-ETCH ADHESIVE CLASS II COMPOSITE RESTORATIONS USING ART AND CONVENTIONAL CAVITY PREPARATIONS IN PRIMARY MOLARS,"PURPOSE : TO TEST THE NULL-HYPOTHESIS THAT THERE WAS NO DIFFERENCE IN THE SURVIVAL PERCENTAGES OF CLASS II COMPOSITE RESTORATIONS IN PRIMARY TEETH PRODUCED THROUGH EITHER ART OR CONVENTIONAL APPROACHES AFTER 2 YEARS. METHODS: 157 CHILDREN WITH 325 CLASS II CAVITATED DENTIN LESIONS WERE INCLUDED IN A SPLIT-MOUTH STUDY DESIGN. A COMPUTER PROGRAM RANDOMLY ASSIGNED CAVITATED DENTIN LESIONS TO TREATMENT GROUPS STRATIFIED FOR GENDER, OPERATOR, UPPER/LOWER JAW AND LEFT/RIGHT SIDE OF THE MOUTH. THREE OPERATORS PLACED RESIN COMPOSITE (PERTAC II) RESTORATIONS USING A SELF-ETCH ADHESIVE (PROMPT L-POP). TWO INDEPENDENT EXAMINERS EVALUATED THE RESTORATIONS AFTER 0.5, 1 AND 2 YEARS USING THE MODIFIED RYGE CRITERIA. A MODIFICATION OF THE ACTUARIAL SURVIVAL METHOD WAS APPLIED TO ESTIMATE SURVIVAL PERCENTAGES. RESULTS: THERE WAS NO STATISTICALLY SIGNIFICANT DIFFERENCE (P> 0.05) OBSERVED BETWEEN THE CUMULATIVE SURVIVAL PERCENTAGES OF CLASS II COMPOSITE RESTORATIONS IN PRIMARY TEETH PRODUCED BY THE TWO APPROACHES AFTER 2 YEARS (ART: 34.9% +/- 4.7%; CONVENTIONAL: 35.1% +/- 4.7%). THE CUMULATIVE SURVIVAL PERCENTAGES OF ART AND CONVENTIONAL CLASS II RESTORATIONS OF ONE OF THE OPERATORS WERE LOWER THAN FOR ART RESTORATIONS OF THE OTHER TWO OPERATORS AND FOR CONVENTIONAL RESTORATIONS OF ONE OF THE OPERATORS (P <= 0.001). THE MAIN REASON FOR CLASS II COMPOSITE RESTORATIONS TO FAIL OVER THE 2-YEAR PERIOD WAS COMPLETE LOSS OF RETENTION; ART:75%; CONVENTIONAL: 77%. THE NULL-HYPOTHESIS WAS ACCEPTED AS THERE WAS NO DIFFERENCE IN THE CUMULATIVE SURVIVAL PERCENTAGES OF ART AND CONVENTIONAL CLASS II COMPOSITE RESTORATIONS IN PRIMARY TEETH AFTER 2 YEARS. IT APPEARS THAT THE LOW SURVIVAL RESULTS OBTAINED MAY HAVE BEEN CAUSED BY POOR BONDING OF THE SELF-ETCH ADHESIVE.",GLASS-IONOMER; CLINICAL-EVALUATION; PRIMARY TEETH; RESIN; DURABILITY; CHILDREN; AMALGAM; LESIONS,NA,AMERICAN JOURNAL OF DENTISTRY,"EDEN, E##TOPALOGLU-AK, A##FRENCKEN, JE##VAN'T HOF, M","EGE UNIV, DEPT PAEDIAT DENT, SCH DENT, IZMIR, TURKEY. RADBOUD UNIV MED CTR, WHO, COLLABORATING CTR ORAL HLTH CARE PLANNING & FUTUR, COLL DENT SCI, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV MED CTR, DEPT PREVENT & RESTORAT DENT, COLL DENT SCI, NL-6500 HB NIJMEGEN, NETHERLANDS.","DENTISTRY, ORAL SURGERY & MEDICINE","DENTISTRY, ORAL SURGERY & MEDICINE","ALTMAN DG, 1999, PRACTICAL STAT MED R, P379##ATTIN T, 2000, OPER DENT, V25, P259##ATTIN T, 1996, QUINTESSENCE INT, V27, P203##BRACKETT WW, 2002, OPER DENT, V27, P218##BURKE FJT, 2005, BRIT DENT J, V199, P365, DOI 10.1038/SJ.BDJ.4812696##EFFRON B, 1979, ANN STAT, V7, P1##ERNST CLAUS-PETER, 2002, J ADHES DENT, V4, P223##EWOLDSEN N, 1997, SPEC CARE DENTIST, V17, P19, DOI 10.1111/J.1754-4505.1997.TB00531.X##FRENCKEN JE, 1996, J PUBLIC HEALTH DENT, V56, P135, DOI 10.1111/J.1752-7325.1996.TB02423.X##FRENCKEN JO E, 2004, DENT UPDATE, V31, P295##HO TFT, 1999, COMMUNITY DENT ORAL, V27, P195##HONKALA E, 2000, INT J PAEDIAT DENT, V13, P172##HONKALA S, 2002, J ORAL REHABIL, V29, P435, DOI 10.1046/J.1365-2842.2002.00903.X##ISSA M H, 2000, DENT UPDATE, V27, P484##KANELLIS MJ, 1998, JSSPD, V4, P22##KILPATRICK NM, 1993, J DENT, V21, P67, DOI 10.1016/0300-5712(93)90148-J##LO ECM, 2001, CARIES RES, V35, P458, DOI 10.1159/000047490##MACHADO MAAM, 2001, PEDIAT DENT, V23, P315##MJOR IA, 2002, ACTA ODONTOL SCAND, V60, P25, DOI 10.1080/000163502753471961##MOUNT G J, 1997, QUINTESSENCE INT, V28, P301##MOUNT GJ, 1999, OPER DENT, V24, P115##OSTLUND J, 1992, SWED DENT J, V16, P81##PAPATHANASSIOU AG, 2000, PEDIAT DENT, V22, P479##RAHIMTOOLA S, 2000, J DENT CHILD, V67, P123##RYGE G, 1980, INT DENT J, V30, P347##SCHRIKS MCM, 2003, COMMUNITY DENT ORAL, V31, P15, DOI 10.1034/J.1600-0528.2003.00021.X##SEALE NS, 2003, J AM DENT ASSOC, V134, P1630, DOI 10.14219/JADA.ARCHIVE.2003.0110##TAIFOUR D, 2002, CARIES RES, V36, P437, DOI 10.1159/000066531##VAN DIJKEN JWV, 2004, AM J DENT, V17, P27##VENKER DJ, 2004, J PUBLIC HEALTH DENT, V64, P191##*WHO, 1997, OR HLTH SURV BAS MET##YU C, 2004, INT DENT J, V54, P42, DOI 10.1111/J.1875-595X.2004.TB00251.X##ZIRAPS A, 2002, MED PRIN PRACT, V11, P44, DOI 10.1159/000057778",26,2020-11-20,NA
J,WOS:000242245000009,2006,ETHANOL INTAKE AND RISK OF LUNG CANCER IN THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION (EPIC),"WITHIN THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION (EPIC), THE AUTHORS EXAMINED THE ASSOCIATION OF ETHANOL INTAKE AT RECRUITMENT (1,119 CASES) AND MEAN LIFELONG ETHANOL INTAKE (887 CASES) WITH LUNG CANCER. INFORMATION ON BASELINE AND PAST ALCOHOL CONSUMPTION, LIFETIME TOBACCO SMOKING, DIET, AND THE ANTHROPOMETRIC CHARACTERISTICS OF 478,590 PARTICIPANTS WAS COLLECTED BETWEEN 1992 AND 2000. COX PROPORTIONAL HAZARDS REGRESSION WAS USED TO CALCULATE MULTIVARIATE-ADJUSTED HAZARD RATIOS AND 95% CONFIDENCE INTERVALS. OVERALL, NEITHER ETHANOL INTAKE AT RECRUITMENT NOR MEAN LIFELONG ETHANOL INTAKE WAS SIGNIFICANTLY ASSOCIATED WITH LUNG CANCER. HOWEVER, MODERATE INTAKE (5-14.9 G/DAY) AT RECRUITMENT (HAZARD RATIO (HR) = 0.76, 95% CONFIDENCE INTERVAL (CI): 0.63, 0.90) AND MODERATE MEAN LIFELONG INTAKE (HR = 0.80, 95% CI: 0.66, 0.97) WERE ASSOCIATED WITH A LOWER LUNG CANCER RISK IN COMPARISON WITH LOW CONSUMPTION (0.1-4.9 G/DAY). COMPARED WITH LOW INTAKE, A HIGH (>= 60 G/DAY) MEAN LIFELONG ETHANOL INTAKE TENDED TO BE RELATED TO A HIGHER RISK OF LUNG CANCER (HR = 1.29, 95% CI: 0.93, 1.74), BUT HIGH INTAKE AT RECRUITMENT WAS NOT. ALTHOUGH THERE WAS NO OVERALL ASSOCIATION BETWEEN ETHANOL INTAKE AND RISK OF LUNG CANCER, THE AUTHORS CANNOT RULE OUT A LOWER RISK FOR MODERATE CONSUMPTION AND A POSSIBLY INCREASED RISK FOR HIGH LIFELONG CONSUMPTION.",ALCOHOLIC BEVERAGE CONSUMPTION; MORTALITY; COHORT; TOBACCO; 8-HYDROXYDEOXYGUANOSINE; DRINKING; SMOKING; BOWEL; BEER; DIET,ALCOHOL DRINKING; COHORT STUDIES; ETHANOL; LUNG NEOPLASMS,AMERICAN JOURNAL OF EPIDEMIOLOGY,"ROHRMANN, S##LINSEISEN, J##BOSHUIZEN, HC##WHITTAKER, J##AGUDO, A##VINEIS, P##BOFFETTA, P##JENSEN, MK##OLSEN, A##OVERVAD, K##TJONNELAND, A##BOUTRON-RUAULT, MC##CLAVEL-CHAPELON, F##BERGMANN, MM##BOEING, H##ALLEN, N##KEY, T##BINGHAM, S##KHAW, KT##KYRIAZI, G##SOUKARA, S##TRICHOPOULOU, A##PANICO, S##PALLI, D##SIERI, S##TUMINO, R##PEETERS, PHM##BUENO-DE-MESQUITA, HB##BUCHNER, FL##GRAM, IT##LUND, E##ARDANAZ, E##CHIRLAQUE, MD##DORRONSORO, M##PEREZ, MJS##QUIROS, JR##BERGLUND, G##JANZON, L##RASMUSON, T##WEINEHALL, L##FERRARI, P##JENAB, M##NORAT, T##RIBOLI, E","DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV CLIN EPIDEMIOL, GERMAN CANC RES CTR, D-69120 HEIDELBERG, GERMANY. NATL INST PUBL HLTH & ENVIRONM, CTR INFORMAT TECHNOL & METHODOL, NL-3720 BA BILTHOVEN, NETHERLANDS. LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT HLTH, LONDON WC1, ENGLAND. CATALAN INST ONCOL, DEPT EPIDEMIOL, BARCELONA, SPAIN. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AY, ENGLAND. INT AGCY RES CANC, UNIT NUTR, LYON, FRANCE. AARHUS UNIV HOSP, AALBORG HOSP, DEPT CLIN EPIDEMIOL, DK-8000 AARHUS, DENMARK. DANISH CANC SOC, INST CANC EPIDEMIOL, COPENHAGEN, DENMARK. INST GUSTAVE ROUSSY, INSERM, E3N EPIC GRP, F-94805 VILLEJUIF, FRANCE. GERMAN INST HUMAN NUTR, DEPT EPIDEMIOL, POTSDAM, GERMANY. UNIV OXFORD, CANC RES UK EPIDEMIOL UNIT, OXFORD OX1 2JD, ENGLAND. UNIV CAMBRIDGE, INST PUBL HLTH, STRANGEWAYS RES LAB, CAMBRIDGE CB2 1TN, ENGLAND. UNIV ATHENS, SCH MED, DEPT HYG & EPIDEMIOL, GR-10679 ATHENS, GREECE. UNIV NAPLES FEDERICO II, DEPT CLIN & EXPT MED, NAPLES, ITALY. GSPO SCI INST TUSCANY, MOL & NUTR EPIDEMIOL UNIT, FLORENCE, ITALY. ITALIAN NATL CANC INST, EPIDEMIOL UNIT, MILAN, ITALY. AZIENDA OSPED CIVILE MP AREZZO, CANC REGISTRY, RAGUSA, ITALY. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 TA UTRECHT, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, CTR NUTR & HLTH, NL-3720 BA BILTHOVEN, NETHERLANDS. UNIV TROMSO, INST COMMUNITY MED, N-9001 TROMSO, NORWAY. INST PUBL HLTH, PAMPLONA, SPAIN. MURCIA HLTH COUNCIL, DEPT EPIDEMIOL, MURCIA, SPAIN. PUBL HLTH DIV GIPUZKOA, SAN SEBASTIAN, SPAIN. ANDALUSIAN SCH PUBL HLTH, GRANADA, SPAIN. PUBL HLTH & HLTH PLANNING DIRECTORATE, ASTURIAS, SPAIN. LUND UNIV, DEPT CLIN SCI MALMO, S-22100 LUND, SWEDEN. UMEA UNIV, DEPT RADIAT SCI, S-90187 UMEA, SWEDEN. UMEA UNIV, DEPT PUBL HLTH & CLIN MED, S-90187 UMEA, SWEDEN. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON SW7 2AZ, ENGLAND.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","ALBERG AJ, 2003, CHEST S1, V123, P21##BALDER HF, 2005, CANCER EPIDEM BIOMAR, V14, P483, DOI 10.1158/1055-9965.EPI-04-0353##BANDERA EV, 1997, CANCER CAUSE CONTROL, V8, P828, DOI 10.1023/A:1018456127018##BANDERA EV, 2001, CANCER EPIDEM BIOMAR, V10, P813##BIANCHINI F, 2003, EUR J CANCER PREV, V12, P417, DOI 10.1097/00008469-200310000-00011##BIANCHINI F, 2001, CARCINOGENESIS, V22, P885, DOI 10.1093/CARCIN/22.6.885##BRESLOW RA, 2000, CANCER CAUSE CONTROL, V11, P419, DOI 10.1023/A:1008996208313##CARPENTER CL, 1998, J NUTR, V128, P694##DJOUSSE L, 2002, J NATL CANCER I, V94, P1877, DOI 10.1093/JNCI/94.24.1877##DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/BMJ.309.6959.911##DOSEMECI M, 1997, CANCER CAUSE CONTROL, V8, P729, DOI 10.1023/A:1018479304728##FREUDENHEIM JL, 2005, AM J CLIN NUTR, V82, P657##FREUDENHEIM JL, 2003, J NUTR, V133, P3619##FRIESEMA IHM, 2004, AM J EPIDEMIOL, V159, P809, DOI 10.1093/AJE/KWH102##GORDON T, 1984, AM J EPIDEMIOL, V120, P97, DOI 10.1093/OXFORDJOURNALS.AJE.A113879##HEINZL H, 1997, COMPUT METH PROG BIO, V54, P201, DOI 10.1016/S0169-2607(97)00043-6##IMHOF A, 2004, EUR HEART J, V25, P2092, DOI 10.1016/J.EHJ.2004.09.032##*INT AG RES CANC, 1999, IARC MON EV CARC RIS, V71##KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139##KLIPSTEIN-GROBUSCHL K, 2002, PUBLIC HEALTH NUTR, V5, P1297, DOI 10.1079/PHN2002406##KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/IJE/15.4.527##KORTE JE, 2002, AM J EPIDEMIOL, V155, P496, DOI 10.1093/AJE/155.6.496##KVALE G, 1983, INT J CANCER, V31, P397, DOI 10.1002/IJC.2910310402##LIEBER CS, 2004, DRUG METAB REV, V36, P511, DOI 10.1081/DMR-200033441##MURATA M, 1996, CANCER DETECT PREV, V20, P557##NACHIAPPAN V, 1994, ALCOHOL ALCOHOLISM, V29, P565##POLLACK ES, 1984, NEW ENGL J MED, V310, P617, DOI 10.1056/NEJM198403083101003##POTTER J D, 1992, ANN EPIDEMIOL, V2, P587, DOI 10.1016/1047-2797(92)90003-9##POTTER JD, 1982, J CHRON DIS, V35, P833, DOI 10.1016/0021-9681(82)90048-0##PRESCOTT E, 1999, AM J EPIDEMIOL, V149, P463, DOI 10.1093/OXFORDJOURNALS.AJE.A009834##RIBOLI E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394##SEITZ HK, 1981, EUR J CLIN INVEST, V11, P33, DOI 10.1111/J.1365-2362.1981.TB01762.X##STEENLAND K, 2004, EPIDEMIOLOGY, V15, P63, DOI 10.1097/01.EDE.0000100287.45004.E7##STEMMERMANN GN, 1990, DIGEST DIS SCI, V35, P1414, DOI 10.1007/BF01536750##WHITE IR, 1999, J CLIN EPIDEMIOL, V52, P967, DOI 10.1016/S0895-4356(99)00076-1##*WHO FAO EXP CONS, 2001, DIET NUTR PREV CHR D##WOODSON K, 1999, JNCI-J NATL CANCER I, V91, P1738, DOI 10.1093/JNCI/91.20.1738##YONG LC, 1997, AM J EPIDEMIOL, V146, P231, DOI 10.1093/OXFORDJOURNALS.AJE.A009258##YOSHIDA R, 2001, IND HEALTH, V39, P322, DOI 10.2486/INDHEALTH.39.322##ZANG EA, 2001, PREV MED, V32, P359, DOI 10.1006/PMED.2000.0818",25,2020-11-20,MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [G0401527] FUNDING SOURCE: MEDLINE; WELLCOME TRUSTWELLCOME TRUST FUNDING SOURCE: MEDLINE
J,WOS:000242372800018,2006,PSYCHOLOGICAL FACTORS AFFECT THE FREQUENCY OF BELCHING IN PATIENTS WITH AEROPHAGIA,"BACKGROUND: IN PATIENTS WITH AEROPHAGIA AND EXCESSIVE BELCHING AN ORGANIC CAUSE IS SELDOM FOUND AND A PSYCHOGENIC CAUSE IS OFTEN SUSPECTED. AIM: TO INVESTIGATE THE EFFECTS OF ATTENTION AND DISTRACTION ON THE FREQUENCY OF BELCHING IN PATIENTS WITH AEROPHAGIA. METHODS: IN 10 PATIENTS WITH AEROPHAGIA, COMBINED ESOPHAGEAL MANOMETRY AND IMPEDANCE MONITORING WAS PERFORMED FOR 2 H, CONSISTING OF FOUR 30-MINUTE RECORDING PERIODS. PERIOD I: PATIENT UNAWARE THAT RECORDING HAD COMMENCED. PERIOD II: PATIENT INFORMED OF RECORDING IN PROGRESS. PERIOD III: DISTRACTION BY FILLING IN QUESTIONNAIRES. PERIOD IV: NO DISTRACTION. RESULTS: A TOTAL OF 1,258 BELCHES WAS MEASURED, 51 OF WHICH WERE THE RESULT OF AIR THAT ESCAPED FROM THE STOMACH (GASTRIC BELCHES). A TOTAL OF 1,207 BELCHES (96%) WERE EVENTS DURING WHICH AIR WAS EXPELLED IN THE ORAL DIRECTION ALMOST IMMEDIATELY AFTER ENTERING THE ESOPHAGUS FROM THERE (SUPRAGASTRIC BELCHES). GASTRIC BELCHES WERE DISTRIBUTED EQUALLY OVER THE FIRST (1.5 [0.5-2.0]), SECOND (1.5 [0.5-2.0]), THIRD (1.0 [0-2.0]), AND FOURTH (1.0 [0-2.0]) RECORDING PERIODS. IN CONTRAST, THE INCIDENCE OF SUPRAGASTRIC BELCHES INCREASED SIGNIFICANTLY FROM 0 (0-32) IN PERIOD 1 TO 30 (18-60) IN PERIOD II, AFTER PATIENTS WERE TOLD THAT RECORDING WAS STARTED. DURING PERIOD III (QUESTIONNAIRES) THE INCIDENCE OF SUPRAGASTRIC BELCHES DECREASED TO 14 (4-30). IN PERIOD IV THE INCIDENCE OF SUPRAGASTRIC BELCHES INCREASED TO 21 (10-49). CONCLUSIONS: WHEN PATIENTS WITH EXCESSIVE BELCHING ARE UNAWARE THAT THEY ARE BEING STUDIED OR WHEN THEY ARE DISTRACTED, THE INCIDENCE OF BELCHING IS SIGNIFICANTLY REDUCED. THESE FINDINGS UNDERLINE THE IMPORTANCE OF PSYCHOLOGICAL FACTORS AND PROVIDE RATIONALE FOR BEHAVIORAL THERAPY.",INTRALUMINAL ELECTRICAL-IMPEDANCE; DISORDERS; DYSPEPSIA; THERAPY; DISEASE; REFLUX,NA,AMERICAN JOURNAL OF GASTROENTEROLOGY,"BREDENOORD, AJ##WEUSTEN, BLAM##TIMMER, R##SMOUT, AJPM","ST ANTONIUS HOSP, DEPT GASTROENTEROL, NL-3430 EM NIEUWEGEIN, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT GASTROENTEROL, GASTROINTESTINAL RES UNIT, NL-3508 TA UTRECHT, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,"BREDENOORD AJ, 2004, NEUROGASTROENT MOTIL, V16, P713, DOI 10.1111/J.1365-2982.2004.00575.X##BREDENOORD AJ, 2004, GUT, V53, P1561, DOI 10.1136/GUT.2004.042945##CAMILLERI M, 2005, CLIN GASTROENTEROL H, V3, P543, DOI 10.1016/S1542-3565(05)00153-9##CHITKARA DK, 2005, ALIMENT PHARM THER, V22, P855, DOI 10.1111/J.1365-2036.2005.02651.X##DAMSTE PH, 1975, LARYNGOSCOPE, V85, P649, DOI 10.1288/00005537-197504000-00006##DMELLO D, 1983, J CLIN PSYCHIAT, V44, P387##DROSSMAN DA, 2003, GASTROENTEROLOGY, V125, P19, DOI 10.1016/S0016-5085(03)00669-3##HU MTM, 1998, MOVEMENT DISORD, V13, P363, DOI 10.1002/MDS.870130232##KENNEDY T, 2005, BRIT MED J, V331, P435, DOI 10.1136/BMJ.38545.505764.06##LIN M, 2003, AM J GASTROENTEROL, V98, P2139, DOI 10.1016/S0002-9270(03)00538-0##ROTH JLA, 1973, EMOTIONAL FACTORS GA, P16##SIFRIM D, 1999, GUT, V44, P47, DOI 10.1136/GUT.44.1.47##ZELLA SJ, 1998, PSYCHOSOMATICS, V39, P299, DOI 10.1016/S0033-3182(98)71352-0",42,2020-11-20,NA
J,WOS:000242719000010,2006,INCIDENCE AND OUTCOME OF DEPRESSIVE SYMPTOMS IN NURSING HOME PATIENTS IN THE NETHERLANDS,"OBJECTIVES: TO ASSESS INCIDENCE AND OUTCOME OF DEPRESSIVE SYMPTOMS AMONG NURSING HOME (NH) PATIENTS AND TO IDENTIFY CLINICAL CHARACTERISTICS PREDICTING ONSET AND PERSISTENCE OF DEPRESSIVE SYMPTOMS. METHODS: DEPRESSIVE SYMPTOMS (GDS > 10) AND RELEVANT CORRELATES WERE ASSESSED AT BASELINE AND AT FOLLOW-UP (6 MONTHS) IN 350 NH-PATIENTS OF 14 DUTCH NH'S WITH THE GERIATRIC DEPRESSION SCALE (GDS). PREDICTORS OF ONSET AND PERSISTENCE WERE STUDIED USING CHI-SQUARE STATISTICS AND MULTIPLE LOGISTIC REGRESSION ANALYSES. RESULTS: THE PREVALENCE OF DEPRESSIVE SYMPTOMS DECREASED FROM 41.3% TO 28.9% DURING SIX MONTHS FOLLOW-UP. THE ONSET OF DEPRESSIVE SYMPTOMS IN THOSE WITHOUT DEPRESSIVE SYMPTOMS AT BASELINE WAS 4.7%, WHILE THE RATE OF PERSISTENCE WAS 63.3%. PERSISTENCE OF DEPRESSIVE SYMPTOMS WAS MORE FREQUENT IN PATIENTS WITH HIGHER GDS-SCORES (18-30) AT BASELINE. NO BASELINE CHARACTERISTICS WERE ASSOCIATED WITH ONSET OF DEPRESSIVE SYMPTOMS. PERSISTENCE OF DEPRESSIVE SYMPTOMS WAS ONLY ASSOCIATED WITH MORE YEARS OF EDUCATION. CONCLUSIONS: PRE-ADMISSION FACTORS AND TRANSITION MAY LARGELY BE RESPONSIBLE FOR DEPRESSIVE SYMPTOMS AMONG NURSING HOME PATIENTS. THE OBSERVED SUBSTANTIAL DECREASE IN PREVALENCE OF DEPRESSIVE SYMPTOMS OVER SIX MONTHS IS LARGELY DUE TO REMISSION OF DEPRESSIVE SYMPTOMS PRESENT AT BASELINE. ADAPTATION OF NURSING HOME PATIENTS TO PRE-ADMISSION FACTORS, FACILITATED BY THE NURSING HOME ENVIRONMENT, MAY EXPLAIN THIS OBSERVED DECREASE OF DEPRESSIVE SYMPTOMS. FUTURE STUDIES SHOULD EVALUATE INTERVENTIONS TARGETED AT PATIENTS WITH HIGHER GDS-SCORES.",LONG-TERM-CARE; SICKNESS IMPACT PROFILE; OLDER-ADULTS; LONGITUDINAL RELATIONSHIP; DISABILITY; PREVALENCE; HEALTH; LIFE,DEPRESSIVE SYMPTOMS; INCIDENCE; OUTCOME; LONG-TERM CARE; ELDERLY,AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY,"SMALBRUGGE, M##JONGENELIS, L##POT, AM##EEFSTING, JA##RIBBE, MW##BEEKMAN, ATF","VRIJE UNIV AMSTERDAM, MED CTR, DEPT NURSING HOME MED, NL-1081 BT AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, INST EXTRAMURAL MED, NL-1081 BT AMSTERDAM, NETHERLANDS. NETHERLANDS INST MENTAL HLTH & ADDICT, TRIMBOS INST, UTRECHT, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, DEPT PSYCHIAT, NL-1081 BT AMSTERDAM, NETHERLANDS.",GERIATRICS & GERONTOLOGY; GERONTOLOGY; PSYCHIATRY,GERIATRICS & GERONTOLOGY; PSYCHIATRY,"ACHTERBERG WP, 2004, THESIS VU U MED CTR##BEEKMAN ATF, 1995, J AFFECT DISORDERS, V34, P41, DOI 10.1016/0165-0327(94)00103-G##BEEKMAN ATF, 2001, J AFFECT DISORDERS, V65, P131, DOI 10.1016/S0165-0327(00)00243-3##BEEKMAN ATF, 2002, ACTA PSYCHIAT SCAND, V105, P20, DOI 10.1034/J.1600-0447.2002.10078.X##BEEKMAN ATF, 1997, PSYCHOL MED, V27, P1397, DOI 10.1017/S0033291797005734##COHEN J., 1988, STAT POWER ANAL BEHA##DE JONG GIERVELD J., 1999, MANUAL LONELINESS SC##DEBRUIN AF, 1996, THESIS STATE U LIMBU##ERDMAN RAM, 1994, GEDRAG GEZONDHEID TI, V22, P309##FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198##FOSTER JR, 1991, INT J GERIATR PSYCH, V6, P13, DOI 10.1002/GPS.930060104##GEERLINGS SW, 2002, SOC PSYCH PSYCH EPID, V37, P23, DOI 10.1007/S127-002-8210-2##GERETY MB, 1994, J GERONTOL, V49, PM2, DOI 10.1093/GERONJ/49.1.M2##GERETY MB, 1994, J AM GERIATR SOC, V42, P1103, DOI 10.1111/J.1532-5415.1994.TB06217.X##HOEK JF, 2003, INT J GERIATR PSYCH, V18, P244, DOI 10.1002/GPS.816##JONGENELIS K, 2004, J AFFECT DISORDERS, V83, P135, DOI 10.1016/J.JAD.2004.06.001##JONGENELIS K, 2003, TIJDSCHR GERONTOL GERIATR, V34, P52##KATZ I R, 1989, INT PSYCHOGERIATR, V1, P5, DOI 10.1017/S1041610289000025##LESHER E L, 1986, CLINICAL GERONTOLOGIST, V4, P21, DOI 10.1300/J018V04N04_04##MCGIVNEY SA, 1994, J AM GERIATR SOC, V42, P490, DOI 10.1111/J.1532-5415.1994.TB04969.X##MULROW CD, 1994, J AM GERIATR SOC, V42, P374, DOI 10.1111/J.1532-5415.1994.TB07484.X##PARMELEE PA, 1992, J GERONTOL, V47, PM189, DOI 10.1093/GERONJ/47.6.M189##POT AM, 2005, GERONTOLOGIST, V45, P359, DOI 10.1093/GERONT/45.3.359##RIBBE M W, 1993, INT PSYCHOGERIATR, V5, P213, DOI 10.1017/S1041610293001541##ROTHMAN ML, 1989, MED CARE, V27, PS157, DOI 10.1097/00005650-198903001-00013##ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/JAMA.265.8.993##ROZZINI R, 1996, INT J GERIATR PSYCH, V11, P629, DOI 10.1002/(SICI)1099-1166(199607)11:7<629::AID-GPS360>3.0.CO;2-X##VAN EIJK L M, 1994, TIJDSCHR GERONTOL GERIATR, V25, P192##VANCAMPEN C, 1998, TIJDSCHR GERONTOL GE, V9, P11##WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/JAMA.262.7.914##YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4",50,2020-11-20,NA
J,WOS:000242131600006,2006,HLA AND GENOMEWIDE ALLELE SHARING IN DIZYGOTIC TWINS,"GAMETIC SELECTION DURING FERTILIZATION OR THE EFFECTS OF SPECIFIC GENOTYPES ON THE VIABILITY OF EMBRYOS MAY CAUSE A SKEWED TRANSMISSION OF CHROMOSOMES TO SURVIVING OFFSPRING. A RECENT ANALYSIS OF TRANSMISSION DISTORTION IN HUMANS REPORTED SIGNIFICANT EXCESS SHARING AMONG FULL SIBLINGS. DIZYGOTIC (DZ) TWIN PAIRS ARE A SPECIAL CASE OF THE SIMULTANEOUS SURVIVAL OF TWO GENOTYPES, AND THERE HAVE BEEN REPORTS OF DZ PAIRS WITH EXCESS ALLELE SHARING AROUND THE HLA LOCUS, A CANDIDATE LOCUS FOR EMBRYO SURVIVAL. WE PERFORMED AN ALLELE-SHARING STUDY OF 1,592 DZ TWIN PAIRS FROM TWO INDEPENDENT AUSTRALIAN COHORTS, OF WHICH 1,561 PAIRS WERE INFORMATIVE FOR LINKAGE ON CHROMOSOME 6. WE ALSO ANALYZED ALLELE SHARING IN 336 DZ TWIN PAIRS FROM THE NETHERLANDS. WE FOUND NO EVIDENCE OF EXCESS ALLELE SHARING, EITHER AT THE HLA LOCUS OR IN THE REST OF THE GENOME. IN CONTRAST, WE FOUND EVIDENCE OF A SMALL BUT SIGNIFICANT (P = .003 FOR THE AUSTRALIAN SAMPLE) GENOMEWIDE DEFICIT IN THE PROPORTION OF TWO ALLELES SHARED IDENTICAL BY DESCENT AMONG DZ TWIN PAIRS. WE RECONCILED CONFLICTING EVIDENCE IN THE LITERATURE FOR EXCESS GENOMEWIDE ALLELE SHARING BY PERFORMING A SIMULATION STUDY THAT SHOWS HOW UNDETECTED GENOTYPING ERRORS CAN LEAD TO AN APPARENT DEFICIT OR EXCESS OF ALLELE SHARING AMONG SIBLING PAIRS, DEPENDENT ON WHETHER PARENTAL GENOTYPES ARE KNOWN. OUR RESULTS IMPLY THAT GENE-MAPPING STUDIES BASED ON AFFECTED SIBLING PAIRS THAT INCLUDE DZ PAIRS WILL NOT SUFFER FROM FALSE-POSITIVE RESULTS DUE TO LOCI INVOLVED IN EMBRYO SURVIVAL.",RECURRENT PREGNANCY LOSS; INCREASED OVULATION RATE; VANISHING TWIN; PAIRS; FAMILIES; RISK; HERITABILITY; CONCEPTIONS; SIMILARITY; DEPENDENCE,NA,AMERICAN JOURNAL OF HUMAN GENETICS,"MONTGOMERY, GW##ZHU, G##HOTTENGA, JJ##DUFFY, DL##HEATH, AC##BOOMSMA, DI##MARTIN, NG##VISSCHER, PM","QUEENSLAND INST MED RES, MOL & GENET EPIDEMIOL LABS, BRISBANE, QLD 4029, AUSTRALIA. VRIJE UNIV AMSTERDAM, DEPT BIOL PSYCHOL, AMSTERDAM, NETHERLANDS. WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, ST LOUIS, MO 63110 USA.",GENETICS & HEREDITY,GENETICS & HEREDITY,"ABECASIS GR, 2002, NAT GENET, V30, P97, DOI 10.1038/NG786##ABECASIS GR, 2001, BIOINFORMATICS, V17, P742, DOI 10.1093/BIOINFORMATICS/17.8.742##BEEKMAN M, 2003, TWIN RES, V6, P322, DOI 10.1375/TWIN.6.4.322##BOKLAGE CE, 1990, INT J FERTIL, V35, P75##BOOMSMA D, 2002, NAT REV GENET, V3, P872, DOI 10.1038/NRG932##BOOMSMA D I, 2000, TWIN RES, V3, P323, DOI 10.1375/136905200320565300##BOOMSMA DI, 1996, GENET EPIDEMIOL, V13, P49, DOI 10.1002/(SICI)1098-2272(1996)13:1<49::AID-GEPI5>3.0.CO;2-1##CHOUDHURY SR, 2001, HUM REPROD UPDATE, V7, P135, DOI 10.1093/HUMUPD/7.2.135##CORNES BK, 2005, TWIN RES HUM GENET, V8, P616##DAHER S, 2003, J REPROD IMMUNOL, V58, P69, DOI 10.1016/S0165-0378(02)00059-1##DE VILLENA FPM, 2000, TRENDS GENET, V16, P573, DOI 10.1016/S0168-9525(00)02134-X##DE VILLENA FPM, 2001, MAMM GENOME, V12, P331, DOI 10.1007/S003350040003##DUFFY DL, 1998, AM J RESP CRIT CARE, V157, P840, DOI 10.1164/AJRCCM.157.3.9702070##EDMONDS DK, 1982, FERTIL STERIL, V38, P447##EDWARDS JH, 2003, CLIN GENET, V63, P1, DOI 10.1034/J.1399-0004.2003.630101.X##EWEN KR, 2000, AM J HUM GENET, V67, P727, DOI 10.1086/303048##GALLOWAY SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033##HALL J, 1997, CURRENT PROTOCOLS HU, DOI UNSP 2.8.1-2.8.19##HANRAHAN JP, 2004, BIOL REPROD, V70, P900, DOI 10.1095/BIOLREPROD.103.023093##HEATH AC, 1997, PSYCHOL MED, V27, P1381, DOI 10.1017/S0033291797005643##HEIJMANS BT, 2005, EUR J HUM GENET, V13, P1143, DOI 10.1038/SJ.EJHG.5201466##JAWAHEER D, 1996, J MED GENET, V33, P1015, DOI 10.1136/JMG.33.12.1015##KIRK K M, 2000, TWIN RES, V3, P299, DOI 10.1375/136905200320565274##KONG A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592##KONG A, 2004, NAT GENET, V36, P1203, DOI 10.1038/NG1445##KONG X, 2004, AM J HUM GENET, V75, P1143, DOI 10.1086/426405##LANDY HJ, 1986, AM J OBSTET GYNECOL, V155, P14, DOI 10.1016/0002-9378(86)90068-2##LANDY HJ, 1982, ACTA GENET MED GEMEL, V31, P179, DOI 10.1017/S0001566000008278##MARTIN N, 1997, NAT GENET, V17, P387, DOI 10.1038/NG1297-387##NIELSEN LS, 1990, TISSUE ANTIGENS, V36, P141, DOI 10.1111/J.1399-0039.1990.TB01820.X##NIELSEN PE, 1990, BIOCONJUGATE CHEM, V2, P1##ROBERTS CJ, 1975, LANCET, V1, P498##RUBIO C, 2005, AM J REPROD IMMUNOL, V53, P159, DOI 10.1111/J.1600-0897.2005.00260.X##SATA F, 2003, MOL HUM REPROD, V9, P725, DOI 10.1093/MOLEHR/GAG089##SHORT R V, 1978, CIBA FOUND SYMP, P377##SNIEDER H, 1997, AM J HUM GENET, V60, P638##SULLIVAN PF, 2006, TWIN RES HUM GENET, V9, P600, DOI 10.1375/183242706778025026##TITLESTAD IL, 2002, TWIN RES, V5, P287, DOI 10.1375/TWIN.5.4.287##TONG S, 2002, NATURE, V416, P142, DOI 10.1038/416142A##VINK J, 2005, BEHAV GENET, V35, P397, DOI 10.1007/S10519-004-1327-8##VISSCHER PM, 2006, PLOS GENET, V2, P316, DOI 10.1371/JOURNAL.PGEN.0020041##WILSON T, 2001, BIOL REPROD, V64, P1225, DOI 10.1095/BIOLREPROD64.4.1225##ZETTERBERG H, 2002, EUR J HUM GENET, V10, P113, DOI 10.1038/SJ.EJHG.5200767##ZHU G, 2004, TWIN RES, V7, P197, DOI 10.1375/TWIN.7.2.197##ZOLLNER S, 2004, AM J HUM GENET, V74, P62, DOI 10.1086/381131",6,2020-11-20,"NHGRI NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI) [N01HG65403] FUNDING SOURCE: MEDLINE; NIAAA NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE ON ALCOHOL ABUSE & ALCOHOLISM (NIAAA) [R01 AA014041, AA013320, R01 AA013320, R01 AA007535, AA11998, AA014041, P50 AA011998, R37 AA007728, R01 AA007728, R01 AA013326, AA013326, AA07728, R01 AA010249] FUNDING SOURCE: MEDLINE; NICHD NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [R01 HD042157, HD042157] FUNDING SOURCE: MEDLINE; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [R01HD042157, R01HD042157, R01HD042157, R01HD042157, R01HD042157] FUNDING SOURCE: NIH REPORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI) [N01HG065403, N01HG065403, N01HG065403, N01HG065403, N01HG065403, N01HG065403] FUNDING SOURCE: NIH REPORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE ON ALCOHOL ABUSE & ALCOHOLISM (NIAAA) [R01AA013320, P50AA011998, P50AA011998, R01AA010249, R01AA013326, R01AA007728, R37AA007728, R01AA007535, R01AA007535, P60AA011998, R01AA010249, R01AA013326, P50AA011998, P50AA011998, R01AA007535, R01AA007728, R37AA007728, R37AA007728, R01AA013320, P50AA011998, P60AA011998, R01AA007728, R01AA007535, P50AA011998, P60AA011998, P60AA011998, R37AA007728, R01AA007535, P50AA011998, P50AA011998, R01AA007728, P60AA011998, P50AA011998, R37AA007728, P50AA011998, P60AA011998, P60AA011998, P60AA011998, R01AA007728, P60AA011998, P60AA011998, P50AA011998, P50AA011998, P50AA011998, P50AA011998, P60AA011998, P50AA011998, R01AA014041, P60AA011998, R01AA007728, R01AA013326, P60AA011998, P50AA011998, P50AA011998, P50AA011998, R37AA007728, R01AA007728, R01AA013326, P50AA011998, P50AA011998, P60AA011998, P50AA011998, P60AA011998, P50AA011998, R01AA007728, P60AA011998, R01AA007535, P60AA011998, P50AA011998, P50AA011998, R37AA007728, P60AA011998, P60AA011998, P60AA011998, P50AA011998, P50AA011998, P50AA011998, P60AA011998, P60AA011998, P50AA011998, P60AA011998, R01AA010249, R01AA010249, P60AA011998, R01AA014041, R01AA007535, R01AA007728, R01AA014041, P60AA011998, P50AA011998, P50AA011998, P50AA011998, R01AA007535, P50AA011998, P60AA011998, P60AA011998, R37AA007728, P50AA011998, R01AA013326, P60AA011998, P50AA011998, P50AA011998, P60AA011998, P60AA011998, R01AA013320, P60AA011998, P60AA011998, P60AA011998, R01AA013320, P60AA011998, P50AA011998, R01AA013320, R01AA014041, R37AA007728, P50AA011998, P50AA011998, R01AA007535, P60AA011998, P60AA011998, P60AA011998, P60AA011998, P50AA011998, P50AA011998, P50AA011998, P50AA011998, R01AA007535, R01AA007728, P60AA011998, P50AA011998, P50AA011998, P50AA011998, P60AA011998, R01AA013320, P50AA011998, P50AA011998, P50AA011998, P50AA011998, P50AA011998, R37AA007728, P50AA011998, P50AA011998, P50AA011998, P50AA011998, P50AA011998, R01AA007728, P60AA011998, P50AA011998, P60AA011998, P60AA011998, R01AA014041, P60AA011998, P50AA011998, P60AA011998, P50AA011998, P50AA011998, P50AA011998] FUNDING SOURCE: NIH REPORTER"
J,WOS:000242131600012,2006,MUTATIONS IN THE GENE ENCODING THE WNT-SIGNALING COMPONENT R-SPONDIN 4 (RSPO4) CAUSE AUTOSOMAL RECESSIVE ANONYCHIA,"ANONYCHIA IS AN AUTOSOMAL RECESSIVE DISORDER CHARACTERIZED BY THE CONGENITAL ABSENCE OF FINGER- AND TOENAILS. IN A LARGE GERMAN NONCONSANGUINEOUS FAMILY WITH FOUR AFFECTED AND FIVE UNAFFECTED SIBLINGS WITH ISOLATED TOTAL CONGENITAL ANONYCHIA, WE PERFORMED GENOMEWIDE MAPPING AND SHOWED LINKAGE TO 20P13. ANALYSIS OF THE RSPO4 GENE WITHIN THIS INTERVAL REVEALED A FRAMESHIFT AND A NONCONSERVATIVE MISSENSE MUTATION IN EXON 2 AFFECTING THE HIGHLY CONSERVED FIRST FURIN-LIKE CYSTEINE-RICH DOMAIN. BOTH MUTATIONS WERE NOT PRESENT AMONG CONTROLS AND WERE SHOWN TO SEGREGATE WITH THE DISEASE PHENOTYPE. RSPO4 IS A MEMBER OF THE RECENTLY DESCRIBED R-SPONDIN FAMILY OF SECRETED PROTEINS THAT PLAY A MAJOR ROLE IN ACTIVATING THE WNT/BETA-CATENIN SIGNALING PATHWAY. WNT SIGNALING IS EVOLUTIONARILY CONSERVED AND PLAYS A PIVOTAL ROLE IN EMBRYONIC DEVELOPMENT, GROWTH REGULATION OF MULTIPLE TISSUES, AND CANCER DEVELOPMENT. OUR FINDINGS ADD TO THE INCREASING BODY OF EVIDENCE INDICATING THAT MESENCHYMAL-EPITHELIAL INTERACTIONS ARE CRUCIAL IN NAIL DEVELOPMENT AND PUT ANONYCHIA ON THE GROWING LIST OF CONGENITAL MALFORMATION SYNDROMES CAUSED BY WNT-SIGNALING-PATHWAY DEFECTS. TO THE BEST OF OUR KNOWLEDGE, THIS IS THE FIRST GENE KNOWN TO BE RESPONSIBLE FOR AN ISOLATED, NONSYNDROMIC NAIL DISORDER.",NAIL-PATELLA SYNDROME; EXPRESSION; FAMILY; LMX1B; RECEPTORS; PROTEINS,NA,AMERICAN JOURNAL OF HUMAN GENETICS,"BERGMANN, C##SENDEREK, J##ANHUF, D##THIEL, CT##EKICI, AB##POBLETE-GUTIERREZ, P##VAN STEENSEL, M##SEELOW, D##NURNBERG, G##SCHILD, HH##NURNBERG, P##REIS, A##FRANK, J##ZERRES, K","UNIV AACHEN, DEPT HUMAN GENET, D-52074 AACHEN, GERMANY. UNIV ERLANGEN NURNBERG, INST HUMAN GENET, D-8520 ERLANGEN, GERMANY. UNIV HOSP MAASTRICHT, DEPT DERMATOL, MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, UNIV HOSP MAASTRICHT, CTR MOL DERMATOL, MAASTRICHT, NETHERLANDS. UNIV COLOGNE, COLOGNE CTR GENOM, D-5000 COLOGNE, GERMANY. UNIV BONN, DEPT RADIOL, D-5300 BONN, GERMANY.",GENETICS & HEREDITY,GENETICS & HEREDITY,"CHEN HX, 2002, INT J DEV BIOL, V46, P937##DERKALOUSTIAN VM, 1979, GENETIC DIS SKIN, P196##DREYER SD, 2000, HUM MOL GENET, V9, P1067, DOI 10.1093/HMG/9.7.1067##DREYER SD, 1998, NAT GENET, V19, P47, DOI 10.1038/NG0598-47##KATOH M, 2005, INT J MOL MED, V16, P1103##KAZANSKAYA O, 2004, DEV CELL, V7, P525, DOI 10.1016/J.DEVCEL.2004.07.019##KELSELL DP, 2005, 14 C EUR AC DERM VEN##KIM KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/CC.5.1.2305##KIRIKOSHI H, 2001, INT J ONCOL, V19, P767##KRAUS P, 2001, DERMATOLOGY ONLINE J, V7, P23D##KRUPNIK VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0##LITTMAN A, 1964, J INVEST DERMATOL, V42, P177, DOI 10.1038/JID.1964.37##LOGAN CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/ANNUREV.CELLBIO.20.010403.113126##MULHOLLAND DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/ER.2003-0034##NAM JS, 2006, J BIOL CHEM, V281, P13247, DOI 10.1074/JBC.M508324200##ROEBROEK AJM, 1994, BIOCHIMIE, V76, P210, DOI 10.1016/0300-9084(94)90148-1##SEITZ CS, 2005, BRIT J DERMATOL, V152, P1339, DOI 10.1111/J.1365-2133.2005.06509.X##STRANDSKOV HH, 1939, J HERED, V30, P53, DOI 10.1093/OXFORDJOURNALS.JHERED.A104670##ZAIAS N, 1963, ARCH DERMATOL, V87, P37, DOI 10.1001/ARCHDERM.1963.01590130043010",71,2020-11-20,NA
J,WOS:000242131600015,2006,LEIGH SYNDROME WITH NEPHROPATHY AND COQ(10) DEFICIENCY DUE TO DECAPRENYL DIPHOSPHATE SYNTHASE SUBUNIT 2 (PDSS2) MUTATIONS,"COENZYME Q(10) (COQ(10)) IS A VITAL LIPOPHILIC MOLECULE THAT TRANSFERS ELECTRONS FROM MITOCHONDRIAL RESPIRATORY CHAIN COMPLEXES I AND II TO COMPLEX III. DEFICIENCY OF COQ(10) HAS BEEN ASSOCIATED WITH DIVERSE CLINICAL PHENOTYPES, BUT, IN MOST PATIENTS, THE MOLECULAR CAUSE IS UNKNOWN. THE FIRST DEFECT IN A COQ(10) BIOSYNTHETIC GENE, COQ2, WAS IDENTIFIED IN A CHILD WITH ENCEPHALOMYOPATHY AND NEPHROTIC SYNDROME AND IN A YOUNGER SIBLING WITH ONLY NEPHROPATHY. HERE, WE DESCRIBE AN INFANT WITH SEVERE LEIGH SYNDROME, NEPHROTIC SYNDROME, AND COQ(10) DEFICIENCY IN MUSCLE AND FIBROBLASTS AND COMPOUND HETEROZYGOUS MUTATIONS IN THE PDSS2 GENE, WHICH ENCODES A SUBUNIT OF DECAPRENYL DIPHOSPHATE SYNTHASE, THE FIRST ENZYME OF THE COQ(10) BIOSYNTHETIC PATHWAY. BIOCHEMICAL ASSAYS WITH RADIOLABELED SUBSTRATES INDICATED A SEVERE DEFECT IN DECAPRENYL DIPHOSPHATE SYNTHASE IN THE PATIENT'S FIBROBLASTS. THIS IS THE FIRST DESCRIPTION OF PATHOGENIC MUTATIONS IN PDSS2 AND CONFIRMS THE MOLECULAR AND CLINICAL HETEROGENEITY OF PRIMARY COQ(10) DEFICIENCY.",COENZYME Q(10) DEFICIENCY; CEREBELLAR-ATAXIA; MITOCHONDRIAL ENCEPHALOMYOPATHY; MYOPATHY; PROTEIN,NA,AMERICAN JOURNAL OF HUMAN GENETICS,"LOPEZ, LC##SCHUELKE, M##QUINZII, CM##KANKI, T##RODENBURG, RJT##NAINI, A##DIMAURO, S##HIRANO, M","COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL, NEW YORK, NY 10032 USA. VIRCHOW UNIV HOSP BERLIN, CHARITE, DEPT NEUROPEDIAT, BERLIN, GERMANY. UNIV NIJMEGEN, RADBOUD MED CTR, CTR MITOCHONDRIAL DISORDERS, NIJMEGEN, NETHERLANDS.",GENETICS & HEREDITY,GENETICS & HEREDITY,"ARTUCH R, 2006, J NEUROL SCI, V246, P153, DOI 10.1016/J.JNS.2006.01.021##BARROS MH, 2005, J BIOL CHEM, V280, P42627, DOI 10.1074/JBC.M510768200##BOITIER E, 1998, J NEUROL SCI, V156, P41, DOI 10.1016/S0022-510X(98)00006-9##COLLINS JS, 2002, AM J HUM GENET, V71, P1251, DOI 10.1086/344344##HORVATH R, 2006, NEUROLOGY, V66, P253, DOI 10.1212/01.WNL.0000194241.35115.7C##KAWAMUKAI M, 2002, J BIOSCI BIOENG, V94, P511, DOI 10.1016/S1389-1723(02)80188-8##LALANI SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/ARCHNEUR.62.2.317##LAMPERTI C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC##MUSUMECI O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849##NAINI A, 2003, BIOFACTORS, V18, P145, DOI 10.1002/BIOF.5520180217##OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/PNAS.86.7.2379##QUINZII C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092##QUINZII CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58##RAHMAN S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/MPD.2001.117575##ROTIG A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9##SAIKI R, 2005, FEBS J, V272, P5606, DOI 10.1111/J.1742-4658.2005.04956.X##SAIKI R, 2003, EUR J BIOCHEM, V270, P4113, DOI 10.1046/J.1432-1033.2003.03804.X##SALVIATI L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.WNL.0000172859.55579.A7##SOBREIRA C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238##TURUNEN M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/J.BBAMEM.2003.11.012##VAN MALDERGEM L, 2002, ANN NEUROL, V52, P750, DOI 10.1002/ANA.10371",253,2020-11-20,"EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [P01HD032062, P01HD032062, P01HD032062, P01HD032062, R01HD057543, R01HD057543, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062] FUNDING SOURCE: NIH REPORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [P01HD032062, R01HD057543, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, R01HD057543, R01HD057543, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, R01HD057543, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, R01HD057543, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062, P01HD032062] FUNDING SOURCE: NIH REPORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE (NINDS) [P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P50NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766, P01NS011766] FUNDING SOURCE: NIH REPORTER; NICHD NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [R01 HD057543, HD32062, P01 HD032062] FUNDING SOURCE: MEDLINE; NINDS NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE (NINDS) [NS11766, P01 NS011766] FUNDING SOURCE: MEDLINE"
J,WOS:000242277800008,2006,IMMUNOTOXIC EFFECTS OF CHEMICALS: A MATRIX FOR OCCUPATIONAL AND ENVIRONMENTAL EPIDEMIOLOGICAL STUDIES,"BACKGROUND MANY BIOLOGICAL AND CHEMICAL AGENTS HAVE THE CAPACITY TO ALTER THE WAY THE IMMUNE SYSTEM FUNCTIONS IN HUMAN AND ANIMALS. THIS STUDY EVALUATES THE IMMUNOTOXICITY OF 20 SUBSTANCES USED WIDELY IN WORK ENVIRONMENTS. METHODS A SYSTEMATIC LITERATURE SEARCH ON THE IMMUNOTOXICITY OF 20 CHEMICALS WAS PERFORMED. THE FIRST STEP WAS TO REVIEW LITERATURE ON IMMUNOTOXICITY TESTING AND TESTING SCHEMES ADOPTED FOR ESTABLISHING IMMUNOTOXICITY IN HUMANS. THE SECOND STEP CONSISTED OF PROVIDING A DOCUMENTATION ON IMMUNOTOXICITY OF SUBSTANCES THAT ARE WIDELY USED IN WORK ENVIRONMENT, BY BUILDING TABLES FOR EACH CHEMICAL OF INTEREST (BENZENE, TRICHLOROETHYLENE, PAHS, CRYSTALLINE SILICA, DIESEL EXHAUSTS, WELDING FUMES, ASBESTOS, STYRENE,FORMALDEHYDE, TOLUENE, VINYL CHLORIDE MONOMER, TETRACHLOROETHYLENE, CHLOROPHENOLS, 1,3-BUTADIENE, MINERAL OILS, P-DICHLOROBENZENE, DICHLOROMETHANE, XYLENE, 1,1,1-TRICHLOROETHANE, ETHYLENE OXIDE). THE THIRD STEP WAS THE CLASSIFICATION OF SUBSTANCES; AN INDEX (STRONG, INTERMEDIATE, WEAK, NIL) WAS ASSIGNED ON THE BASIS OF THE EVIDENCE OF TOXICITY AND TYPE OF IMMUNOTOXIC EFFECTS (IMMUNOSUPPRESSION, AUTOIMMUNITY, HYPERSENSITIVITY) ON THE BASIS OF THE IMMUNE RESPONSES. FINALLY SUBSTANCES WERE ASSIGNED A SCORE OF IMMUNOTOXIC POWER RESULTS TABLES HAVE BEEN PRODUCED THAT INCLUDE INFORMATION FOR THE 20 SUBSTANCES OF INTEREST, BASED ON 227 ANIMAL STUDIES AND 94 HUMAN STUDIES. EACH SUBSTANCE WAS ASSIGNED AN INDEX OF IMMUNOTOXIC EVIDENCE, A SCORE OF IMMUNOTOXIC POWER AND TYPE OF IMMUNOTOXIC EFFECT. CONCLUSIONS THIS MATRIX CAN REPRESENT A TOOL TO IDENTIFY CHEMICALS WITH SIMILAR PROPERTIES CONCERNING THE TOXICITY FOR THE IMMUNE SYSTEM, AND TO INTERPRET EPIDEMIOLOGICAL STUDIES ON IMMUNE-RELATED DISEASES.",BONE-MARROW; BENZENE INHALATION; IMMUNE-RESPONSE; INHALED BENZENE; ORAL-EXPOSURE; LYMPHOCYTE-B; STEM-CELLS; MICE; WORKERS; HEMATOTOXICITY,IMMUNOTOXICITY; IMMUNE EFFECTS; IMMUNOSTIMULATION; IMMUNOSUPPRESSION; AUTOIMMUNITY; HYPERSENSITIVITY; CHEMICALS; EPIDEMIOLOGICAL STUDIES,AMERICAN JOURNAL OF INDUSTRIAL MEDICINE,"VERALDI, A##COSTANTINI, AS##BOLEJACK, V##MILIGI, L##VINEIS, P##VAN LOVEREN, H","CTR STUDIO & PREVENZ ONCOL, UNIT ENVIRONM & OCCUPAT EPIDEMIOL, I-50135 FLORENCE, ITALY. UNIV TURIN, DEPT BIOMED SCI & HUMAN ONCOL, TURIN, ITALY. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AZ, ENGLAND. DUTCH NATL INST PUBL HLTH & ENVIRONM, RIVM, BILTHOVEN, NETHERLANDS. MAASTRICHT UNIV, DEPT HLTH RISK ANALY & TOXICOL, MAASTRICHT, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","AKSOY M, 1974, BLOOD, V44, P837, DOI 10.1182/BLOOD.V44.6.837.837##AKSOY M, 1972, BRIT J IND MED, V29, P56##AKSOY M, 1983, BR J IND MED, V44, P785##AOYAMA K, 1986, TOXICOL APPL PHARM, V85, P92, DOI 10.1016/0041-008X(86)90390-X##ARANYI C, 1986, FUND APPL TOXICOL, V6, P713, DOI 10.1016/0272-0590(86)90184-3##BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2##BIGAZZI PE, 1988, J TOXICOL-CLIN TOXIC, V26, P125, DOI 10.3109/15563658809000343##BOGADI-SARE A, 2000, INT ARCH OCC ENV HEA, V73, P397, DOI 10.1007/S004200000126##BOWLER RM, 1997, ENVIRON RES, V72, P93, DOI 10.1006/ENRS.1996.3721##CHERTKOV JL, 1992, J LAB CLIN MED, V119, P412##CHIU BCH, 2003, CLIN LYMPHOMA, V4, P161, DOI 10.3816/CLM.2003.N.025##CODY RP, 1993, J OCCUP ENVIRON MED, V35, P776, DOI 10.1097/00043764-199308000-00013##COLOSIO C, 1999, TOXICOL LETT, V108, P285, DOI 10.1016/S0378-4274(99)00100-9##COSTANTINI AS, 2001, EPIDEMIOLOGY, V12, P78##CRONKITE EP, 1986, BLOOD CELLS, V12, P129##CRONKITE EP, 1985, AM J IND MED, V7, P447, DOI 10.1002/AJIM.4700070509##CRONKITE EP, 1982, J TOXICOL ENV HEALTH, V9, P411, DOI 10.1080/15287398209530174##DAYAN AD, 1998, TOXICOLOGY, V125, P183##DEAN JH, 1979, DRUG CHEM TOXICOL, V2, P5, DOI 10.3109/01480547908993178##FAN X H, 1992, NIHON IKA DAIGAKU ZASSHI, V59, P393##FARRIS GM, 1997, FUND APPL TOXICOL, V36, P119, DOI 10.1006/FAAT.1997.2293##FROOM P, 1994, SCAND J WORK ENV HEA, V20, P306, DOI 10.5271/SJWEH.1393##GILL DP, 1980, TOXICOLOGY, V16, P163, DOI 10.1016/0300-483X(80)90046-3##GOLDWATER LJ, 1941, J LAB CLIN MED, V26, P957##GREEN JD, 1981, TOXICOL APPL PHARM, V58, P492, DOI 10.1016/0041-008X(81)90102-2##GREENBURG LEONARD, 1939, JOUR INDUST HYG AND TOXICOL, V21, P395##HOOVER R, 1973, LANCET, V2, P55##HSIEH GC, 1991, IMMUNOPHARMACOLOGY, V21, P23, DOI 10.1016/0162-3109(91)90004-I##HSIEH GC, 1990, ARCH TOXICOL, V64, P320, DOI 10.1007/BF01972993##HSIEH GC, 1988, ARCH ENV CONTAM TOXI, V17, P131##KAMMULLER ME, 1989, AUTOIMMUNITY TOXICOL##KIPEN HM, 1989, ENVIRON HEALTH PERSP, V82, P199, DOI 10.2307/3430776##KLAN MJ, 1990, TOXICOL APPL PHARM, V103, P198, DOI 10.1016/0041-008X(90)90222-G##LANGE A, 1973, INT ARCH ARBEITSMED, V31, P37, DOI 10.1007/BF00538971##LANGE A, 1973, INT ARCH ARBEITSMED, V31, P45, DOI 10.1007/BF00538972##LIL, 1992, BIOMED ENV SCI, V5, P349##LUSTER MI, 1988, FUND APPL TOXICOL, V10, P2, DOI 10.1016/0272-0590(88)90247-3##MACEACHERN L, 1992, TOXICOL APPL PHARM, V117, P147, DOI 10.1016/0041-008X(92)90231-G##NEUN DJ, 1992, ARCH TOXICOL, V66, P11, DOI 10.1007/BF02307264##NICULESCU R, 1995, ARCH TOXICOL, V69, P141, DOI 10.1007/S002040050150##OBRAMS GI, 1991, CANCER SURV, V10, P91##PLAPPERT U, 1994, ARCH TOXICOL, V68, P284, DOI 10.1007/S002040050070##ROBINSON SN, 1997, TOXICOLOGY, V119, P227, DOI 10.1016/S0300-483X(97)03621-4##ROSENTHAL GJ, 1987, TOXICOL APPL PHARM, V88, P35, DOI 10.1016/0041-008X(87)90267-5##ROSENTHAL GJ, 1985, TOXICOL APPL PHARM, V80, P502, DOI 10.1016/0041-008X(85)90395-3##ROZEN MG, 1985, TOXICOLOGY, V37, P13, DOI 10.1016/0300-483X(85)90109-X##ROZEN MG, 1984, TOXICOL LETT, V20, P343, DOI 10.1016/0378-4274(84)90170-X##RUIZ MA, 1994, PATHOL RES PRACT, V190, P151##SNYDER CA, 1980, TOXICOL APPL PHARM, V54, P323, DOI 10.1016/0041-008X(80)90202-1##SNYDER CA, 1978, J TOXICOL ENV HLTH, V4, P605##TRYPHONAS H, 2001, ENVIRON HEALTH PERSP, V109, P877, DOI 10.2307/3454650##TRYPHONAS HELEN, 2001, P193##*USDHHS, 1986, TOX CARC STUD BENZ##VAN LOVEREN H., 1999, BIOMARKERS, V4, P135, DOI 10.1080/135475099230949##VANLOVEREN H, 1989, IMMUNOTOXICOLOGICAL, P143##VOS J G, 1980, ARCH TOXICOL SUPPL, V4, P95##WELLMAN CL, 1991, BEHAV NEURAL BIOL, V56, P1, DOI 10.1016/0163-1047(91)90243-J##*WHO, 1996, ENV HLTH CRIT 180 PR##*WHO, 1999, ENV HLTH CRIT 212 PR##XIA Z L, 1995, BIOMED ENVIRON SCI, V8, P30##YARDLEYJONES A, 1988, BRIT J IND MED, V45, P516##YIN S, 1982, REGUL TOXICOL PHARM, V2, P209##1984, LANCET, V17, P601",35,2020-11-20,NA
J,WOS:000248541000008,2006,NOVEL OCRL1 MUTATIONS IN PATIENTS WITH THE PHENOTYPE OF DENT DISEASE,"BACKGROUND: DENT DISEASE IS AN X-LINKED TUBULOPATHY FREQUENTLY CAUSED BY MUTATIONS AFFECTING THE VOLTAGE-GATED CHLORIDE CHANNEL AND CHLORIDE/PROTON ANTIPORTER CIC-5. A RECENT STUDY SHOWED THAT DEFECTS IN OCRL1, ENCODING A PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE (OCRL) AND USUALLY FOUND MUTATED IN PATIENTS WITH LOWE SYNDROME, ALSO CAN PROVOKE A DENT-LIKE PHENOTYPE (DENT 2 DISEASE). METHODS: WE INVESTIGATED 20 CLCN5-NEGATIVE MALES FROM 17 FAMILIES WITH A PHENOTYPE RESEMBLING DENT DISEASE FOR DEFECTS IN OCRL1. RESULTS: IN OUR COMPLETE SERIES OF 35 FAMILIES WITH A PHENOTYPE OF DENT DISEASE, A MUTATION IN THE OCRL 1 GENE WAS DETECTED IN 6 KINDREDS. ALL WERE NOVEL FRAMESHIFT (Q70RFSX88 AND T121NFSX122, DETECTED TWICE) OR MISSENSE MUTATIONS (1257T AND R476W). NONE OF OUR PATIENTS HAD COGNITIVE OR BEHAVIORAL IMPAIRMENT OR CATARACTS, 2 CLASSIC HALLMARKS OF LOWE SYNDROME. ALL PATIENTS HAD MILD INCREASES IN LACTATE DEHYDROGENASE AND/OR CREATINE KINASE LEVELS, WHICH RARELY IS OBSERVED IN CLCN5-POSITIVE PATIENTS, BUT FREQUENTLY FOUND IN PATIENTS WITH LOWE SYNDROME. TO EXPLAIN THE PHENOTYPIC HETEROGENEITY CAUSED BY OCRL1 MUTATIONS, WE PERFORMED EXTENSIVE DATA-BANK MINING AND EXTENDED REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION ANALYSIS, WHICH PROVIDED NO EVIDENCE FOR YET UNKNOWN (TISSUE-SPECIFIC) ALTERNATIVE OCRL1 TRANSCRIPTS. CONCLUSION: MUTATIONS IN THE OCRL1 GENE ARE FOUND IN APPROXIMATELY 23% OF KINDREDS WITH A DENT PHENOTYPE. DEFECTIVE PROTEIN SORTING/TARGETING OF OCRL MIGHT BE THE REASON FOR MILDLY ELEVATED CREATINE KINASE AND LACTATE DEHYDROGENASE SERUM CONCENTRATIONS IN THESE PATIENTS AND A CLUE TO SUSPECT DENT DISEASE UNRELATED TO CLCN5 MUTATIONS. IT REMAINS TO BE ELUCIDATED WHY THE VARIOUS OCRL1 MUTATIONS FOUND IN PATIENTS WITH DENT 2 DISEASE DO NOT CAUSE CATARACTS.",LOWE OCULOCEREBRORENAL SYNDROME; INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; CHLORIDE CHANNEL; CLC PROTEINS; GENE; IDENTIFICATION; DEFICIENCY; FAMILIES; CELLS; NEPHROLITHIASIS,DENT DISEASE; LOWE SYNDROME; VOLTAGE-GATED CHLORIDE CHANNEL AND CHLORIDE/PROTON ANTIPORTER 5-; -GENE (CLCN5); OCULOCEREBRORENAL SYNDROME OF LOWE GENE (OCRL1); TUBULOPATHY; CATARACT; MENTAL RETARDATION; CREATINE KINASE (CK); LACTATE CLEHYDROGENASE (LDH).,AMERICAN JOURNAL OF KIDNEY DISEASES,"UTSCH, B##BOKENKAMP, A##BENZ, MR##BESBAS, N##DOTSCH, J##FRANKE, I##FRUND, S##GOK, F##HOPPE, B##KARLE, S##KUWERTZ-BROKING, E##LAUBE, G##NEB, M##NUUTINEN, M##OZALTIN, F##RASCHER, W##RING, T##TASIC, V##VAN WIJK, JAE##LUDWIG, M","UNIV KLINIKUM BONN, INST KLIN BIOCHEM, D-53105 BONN, GERMANY. UNIV ERLANGEN NURNBERG, KLIN POLIKLIN KINDER & JUGENDLICHE, ERLANGEN, GERMANY. KLINIKUM UNIV MUNCHEN, DR VON HAUNERSCHES KINDERSPITAL, MUNICH, GERMANY. UNIV KLINIKUM BONN, INST KLIN BIOCHEM, BONN, GERMANY. KFH NIERENZENTRUM KINDER & JUGENDLICHE, MUNSTER, GERMANY. UNIV KINDERKLIN, ABT PADIATR NEPHROL, COLOGNE, GERMANY. VRIJE UNIV AMSTERDAM, MED CTR, DEPT PEDIAT, AMSTERDAM, NETHERLANDS. HACETTEPE UNIV, FAC MED, DEPT PEDIAT NEPHROL, ANKARA, TURKEY. GULHANE MIL MED ACAD, PEDIAT NEPHROL UNIT, ANKARA, TURKEY. UNIV KINDERKLIN, KINDERNEPHROL, ZURICH, SWITZERLAND. OULU UNIV HOSP, DEPT PEDIAT & ADOLESCENCE, OULU, FINLAND. AALBORG HOSP, DEPT NEPHROL, AALBORG, DENMARK. UNIV CHILDRENS HOSP, DEPT PEDIAT NEPHROL, SKOPJE, MACEDONIA.",UROLOGY & NEPHROLOGY,UROLOGY & NEPHROLOGY,"ADDIS MARIA, 2004, HUM MUTAT, V23, P524, DOI 10.1002/HUMU.9239##ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239A0##BESBAS N, 2005, NEPHROL DIAL TRANSPL, V20, P1476, DOI 10.1093/NDT/GFH799##*CDCP, 1933, 2 20 YEARS BOYS STAT##CHABAA L, 2006, ANN BIOL CLIN-PARIS, V64, P53##CHARNAS LR, 1991, NEW ENGL J MED, V324, P1318, DOI 10.1056/NEJM199105093241904##CHOU YEN-YIN, 2005, ACTA PAEDIATRICA TAIWANICA, V46, P226##DENT CE, 1964, ARCH DIS CHILD, V39, P240, DOI 10.1136/ADC.39.205.240##DEVUYST O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/HMG/8.2.247##DRESSMAN MA, 2000, J HISTOCHEM CYTOCHEM, V48, P179, DOI 10.1177/002215540004800203##ENDRIS V, 2002, P NATL ACAD SCI USA, V99, P11754, DOI 10.1073/PNAS.162241099##FERREIRA-CORNWELL MC, 2000, EXP CELL RES, V256, P237, DOI 10.1006/EXCR.2000.4819##FISHER SE, 1995, GENOMICS, V29, P598, DOI 10.1006/GENO.1995.9960##GROPMAN A, 2000, AM J MED GENET, V95, P461, DOI 10.1002/1096-8628(20001218)95:5<461::AID-AJMG10>3.0.CO;2-D##GUERRERO ML, 1997, AM J PHYSIOL, V272, PC687##GUNTHER W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/PNAS.95.14.8075##HEILBRON DC, 1991, PEDIATR NEPHROL, V5, P5, DOI 10.1007/BF00852829##HOOPES RR, 2005, AM J HUM GENET, V76, P260, DOI 10.1086/427887##HOOPES RR, 2004, KIDNEY INT, V65, P1615, DOI 10.1111/J.1523-1755.2004.00571.X##JANNE PA, 1998, J CLIN INVEST, V101, P2042, DOI 10.1172/JCI2414##JOHNSON JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/SCIENCE.1090100##KAWANO T, 1998, AM J MED GENET, V77, P348, DOI 10.1002/(SICI)1096-8628(19980605)77:5<348::AID-AJMG2>3.3.CO;2-H##KENWORTHY L, 1993, AM J MED GENET, V46, P297, DOI 10.1002/AJMG.1320460312##KUBOTA T, 1998, CLIN GENET, V54, P199##LEAHEY AM, 1993, HUM MOL GENET, V2, P461, DOI 10.1093/HMG/2.4.461##LIN T, 1998, MOL GENET METAB, V64, P58, DOI 10.1006/MGME.1998.2687##LIN T, 1997, AM J HUM GENET, V60, P1384, DOI 10.1086/515471##LLOYD SE, 1996, NATURE, V379, P445, DOI 10.1038/379445A0##LOWE CU, 1952, AMA AM J DIS CHILD, V83, P164, DOI 10.1001/ARCHPEDI.1952.02040060030004##LUDWIG M, 2005, HUM GENET, V117, P228, DOI 10.1007/S00439-005-1303-2##LUDWIG M, 2003, KIDNEY BLOOD PRESS R, V26, P176, DOI 10.1159/000071883##LUDWIG M, 2006, PEDIATR NEPHROL, V21, P1241, DOI 10.1007/S00467-006-0172-9##MONNIER N, 2000, HUM MUTAT, V16, P157, DOI 10.1002/1098-1004(200008)16:2<157::AID-HUMU8>3.0.CO;2-9##NICHOLSON JF, 2000, NELSON TXB PEDIAT, P2181##NORDEN AGW, 2002, J AM SOC NEPHROL, V13, P125##NUSSBAUM RL, 1997, HUM GENET, V99, P145, DOI 10.1007/S004390050329##NUSSBAUM RL, 2001, METABOLIC MOL BASES, P6257##OLIVOSGLANDER IM, 1995, AM J HUM GENET, V57, P817##PEVERALL J, 2000, CLIN GENET, V58, P479, DOI 10.1034/J.1399-0004.2000.580609.X##PICOLLO A, 2005, NATURE, V436, P420, DOI 10.1038/NATURE03720##PIWON N, 2000, NATURE, V408, P369, DOI 10.1038/35042597##PONTING CP, 2006, BIOINFORMATICS, V22, P1031, DOI 10.1093/BIOINFORMATICS/BTL022##RAUCHER D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3##ROSCHINGER W, 2000, MOL GENET METAB, V69, P213, DOI 10.1006/MGME.1999.2955##SATRE V, 1999, AM J HUM GENET, V65, P68, DOI 10.1086/302443##SCHEEL O, 2005, NATURE, V436, P424, DOI [10.1038/NATURE03860, 10.1038/NATURE0386O]##SCHNEIDER JF, 2001, NEUROPEDIATRICS, V32, P45, DOI 10.1055/S-2001-12221##SCHRAMM L, 2004, AM J KIDNEY DIS, V43, P538, DOI 10.1053/J.AJKD.2003.11.013##SUCHY SF, 2002, AM J HUM GENET, V71, P1420, DOI 10.1086/344517##UNGEWICKELL A, 2004, P NATL ACAD SCI USA, V101, P13501, DOI 10.1073/PNAS.0405664101##UNGEWICKELL AJ, 1999, P NATL ACAD SCI USA, V96, P13342, DOI 10.1073/PNAS.96.23.13342##WANG SS, 2000, HUM MOL GENET, V9, P2937, DOI 10.1093/HMG/9.20.2937##WRONG OM, 1994, Q J MED, V87, P473##ZHANG XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/JBC.273.3.1574##ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/PNAS.92.11.4853",58,2020-11-20,NA
J,WOS:000242466100017,2006,HUTCHINSON-GIFFORD PROGERIA SYNDROME: REVIEW OF THE PHENOTYPE,"HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) IS A RARE BUT WELL KNOWN ENTITY CHARACTERIZED BY EXTREME SHORT STATURE LOW BODY WEIGHT, EARLY LOSS OF HAIR, LIPODYSTROPHY, SCLERODERMA, DECREASED JOINT MOBILITY, OSTEOLYSIS, AND FACIAL FEATURES THAT RESEMBLE AGED PERSONS. CARDIOVASCULAR COMPROMISE LEADS TO EARLY DEMISE. COGNITIVE DEVELOPMENT IS NORMAL. DATA ON 10 OF OUR OWN CASES AND 132 CASES FROM LITERATURE ARE PRESENTED. THE INCIDENCE IN THE LAST CENTURY IN THE NETHERLANDS WAS 1:4,000,000. SEX RATIO WAS 1.2:1. MAIN FIRST SYMPTOMS WERE FAILURE TO THRIVE (55%), HAIR LOSS (40%), SKIN PROBLEMS (28%), AND LIPODYSTROPHY (20%). MEAN AGE AT DIAGNOSIS WAS 2.9 YEARS. GROWTH IN WEIGHT WAS MORE DISTURBED THAN GROWTH IN HEIGHT, AND GROWTH DELAY STARTED ALREADY PRENATALLY. MEAN HEIGHT > 13 YEARS WAS 109.0 CM, MEAN WEIGHT WAS 14.5 KG. OSTEOLYSIS WAS WIDE-SPREAD BUT NOT EXPRESSED, EXCEPT IN THE VISCEROCRANIUM, AND REMAINED LIMITED TO MEMBRANOUS FORMED BONE. LIPODYSTROPHY IS GENERALIZED, ONLY INTRA-ABDOMINAL FAR DEPOSITIONS REMAIN PRESENT. CARDIOVASCULAR PROBLEMS ARE EXTREMELY VARIABLE, BOTH IN AGE OF ONSET AND NATURE. STROKE AND CORONARY DYSFUNCTIONING ARE MOST FREQUENT. PATHOLOGIC FINDINGS IN CORONARIES AND AORTA RESEMBLE SOMETIMES THE FINDINGS IN ELDERLY PERSONS, BUT CAN ALSO BE MUCH MORE LIMITED. LOSS OF SMOOTH MUSCLE CELLS SEEMS THE MOST IMPORTANT FINDING. MEAN AGE OF DEMISE WAS 12.6 YEARS. PATIENTS CAN HE SUBDIVIDED IN PATIENTS WITH CLASSICAL HGPS, WHICH FOLLOWS AN AUTOSOMAL DOMINANT PATTERN OF INHERITANCE, (ALMOST) ALL CASES REPRESENTING SPONTANEOUS MUTATIONS, AND IN NON-CLASSICAL PROGERIA, IN WHOM GROWTH CAN BE LESS RETARDED, SCALP HAIR REMAINS PRESENT FOR A LONGER TIME, LIPODYSTROPHY IS MORE SLOWLY PROGRESSIVE, OSTEOLYSIS IS MORE EXPRESSED EXCEPT IN THE FACE, AND SURVIVAL WELL INTO ADULTHOOD IS NOT UNCOMMON. PATTERN OF INHERITANCE OF NON-CLASSICAL PROGERIA IS MOST PROBABLY AUTOSOMAL RECESSIVE. THE CAUSE OF HGPS IS M ABNORMALLY FORMED LAMIN A, EITHER DIRECTLY BY A MUTATED LMNA GENE, OR THROUGH ABNORMAL POSTTRANSLATIONAL PROCESSING (ZMPSTE24 GENE MUTATIONS). OF 34 LMNA MUTATIONS FOUND IN PROGERIA PATIENTS, THERE WERE 26 CLASSICAL P.G608G MUTATIONS (76%). PATHOGENESIS IS MOST LIKELY TO FOLLOW SEVERAL DIFFERENT PATHWAYS. POTENTIAL THERAPEUTIC STRATEGIES ARE DEVELOPED ALONG THESE LINES AND INCLUDE RNA INTERFERENCE TECHNIQUES AND INHIBITION OF THE DOMINANT-NEGATIVE INFLUENCE OF ABNORMALLY FORMED LAMIN A ON POLYMERIZATION WITH NORMALLY FORMED LAMIN A. (C) 2006 WILEY-LISS, INC.",AUTOSOMAL RECESSIVE INHERITANCE; GILFORD-PROGERIA; LAMIN-A; PATHOLOGIC FINDINGS; MANDIBULOACRAL DYSPLASIA; CEREBRAL INFARCTION; PATERNAL ORIGIN; DISEASE; ZMPSTE24; MUTATION,LAMINOPATHY; NATURAL HISTORY; MANAGEMENT; LAMIN A/C; NUCLEAR ENVELOPE,AMERICAN JOURNAL OF MEDICAL GENETICS PART A,"HENNEKAM, RCM","GREAT ORMOND ST HOSP SICK CHILDREN, CLIN & MOL GENET UNIT, INST CHILD HLTH, LONDON, ENGLAND. ACAD MED CTR, DEPT PAEDIAT, AMSTERDAM, NETHERLANDS.",GENETICS & HEREDITY,GENETICS & HEREDITY,"ACKERMAN J, 2002, PEDIATR PATHOL MOL M, V21, P1, DOI 10.1080/15227950252774110##AGARWAL AK, 2003, HUM MOL GENET, V12, P1995, DOI 10.1093/HMG/DDG213##ALGHAMDI SA, 1995, ANN SAUDI MED, V15, P631, DOI 10.5144/0256-4947.1995.631##ATKINS L, 1954, NEW ENGL J MED, V250, P1065, DOI 10.1056/NEJM195406242502503##BAKER PB, 1981, ARCH PATHOL LAB MED, V105, P384##BATSTONE M D, 2002, INT J PAEDIATR DENT, V12, P429, DOI 10.1046/J.1365-263X.2002.00401.X##BERGO MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/PNAS.192460799##BHAKOO ON, 1964, INDIAN PEDIATR, V2, P164##BISWAS A C, 1997, INDIAN PEDIATR, V34, P945##BROC R, 1935, PRESSE MED, V39, P786##BROERS JLV, 2004, HUM MOL GENET, V13, P2567, DOI 10.1093/HMG/DDH295##BROWN W T, 1985, BASIC LIFE SCI, V35, P375##BROWN WT, 1990, AM J HUM GENET, V47, P175##BRUNE THOMAS, 2004, PEDIATR ENDOCRINOL REV, V2, P39##BURKE B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/NRM879##CADINANOS J, 2005, CELL CYCLE, V4, P1732, DOI 10.4161/CC.4.12.2202##CAO HN, 2003, J HUM GENET, V48, P271, DOI 10.1007/S10038-003-0025-3##CEBALLOS EL, 1999, REV CUB ORTOP TRAUMA, V13, P129##CHAWLA V, 1986, E AFR MED J, V63, P749##COOKE JV, 1953, J PEDIATR-US, V42, P26, DOI 10.1016/S0022-3476(53)80106-X##CORCOY R, 1989, AM J MED SCI, V297, P383, DOI 10.1097/00000441-198906000-00010##CURTIN VT, 1929, AM J DIS CHILD, V38, P993, DOI 10.1001/ARCHPEDI.1929.01930110092012##D'APICE MR, 2004, CLIN GENET, V65, P52, DOI 10.1111/J..2004.00181.X##DE SANDRE-GIOVANNOLI A, 2003, SCIENCE, V300, P2055, DOI 10.1126/SCIENCE.1084125##DEBUSK FL, 1972, J PEDIATR-US, V80, P697, DOI 10.1016/S0022-3476(72)80229-4##DEMARTINVILLE B, 1980, ARCH FR PEDIATR, V37, P679##DERSPEK FBD, 1993, NED TIJDSCHR DERMATO, V3, P183##DOUB H P, 1953, MED RADIOGR PHOTOGR, V29, P60##DYCK JD, 1987, J PEDIATR-US, V111, P407, DOI 10.1016/S0022-3476(87)80466-3##ELSIBAIE B, 1954, GAZ EGYPT PEDIATR AS, V2, P337##ERDEM N, 1994, DERMATOLOGY, V188, P318, DOI 10.1159/000247175##ERECINSKI KAZIMIERZ, 1961, POLSKI TYGODNIK LEKARSKI, V16, P806##ERIKSSON M, 2003, NATURE, V423, P293, DOI 10.1038/NATURE01629##EXCHAQUET L, 1935, REV FRANC PEDIAT, V11, P467##FAIVRE L, 1999, AM J MED GENET, V87, P450, DOI 10.1002/(SICI)1096-8628(19991222)87:5<450::AID-AJMG16>3.0.CO;2-T##FATUNDE OJ, 1990, AM J HUM GENET, V47, PA55##FEINGOLD M, 1971, AM J DIS CHILD, V122, P61, DOI 10.1001/ARCHPEDI.1971.02110010097018##FERNANDEZPALAZZI F, 1992, EUR J PEDIATR SURG, V2, P378, DOI 10.1055/S-2008-1063486##FLEISCHMAJER R, 1973, ARCH DERMATOL, V107, P253, DOI 10.1001/ARCHDERM.107.2.253##FRANKLYN PP, 1976, CLIN RADIOL, V27, P327, DOI 10.1016/S0009-9260(76)80082-7##FUKUCHI K, 2004, J MED GENET, V41, DOI 10.1136/JMG.2003.014688##GABR M, 1960, J PEDIATR-US, V57, P70, DOI 10.1016/S0022-3476(60)80213-2##GAMBLE JG, 1984, J PEDIATR ORTHOPED, V4, P585##GARCIA-BLANCO MA, 2005, CURR OPIN MOL THER, V7, P476##GILFORD H, 1897, MED CHIR TRANS, V80, P17##GILFORD H., 1904, PRACTITIONER, V73, P188##GILLAR PJ, 1991, PEDIATR DERMATOL, V8, P199, DOI 10.1111/J.1525-1470.1991.TB00859.X##GLYNN MW, 2005, HUM MOL GENET, V14, P2959, DOI 10.1093/HMG/DDI326##GOLDMAN RD, 2002, GENE DEV, V16, P533, DOI 10.1101/GAD.960502##GORLIN RJ, 1968, MOD MED, V46, P62##GRAAF MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/J.CTRV.2004.06.010##GUPTE S, 1976, INDIAN J PEDIATR, V43, P319, DOI 10.1007/BF02749070##GUPTE S, 1983, INDIAN PEDIATR, V20, P694##HARJACEK M, 1990, EUR J PEDIATR, V150, P40, DOI 10.1007/BF01959478##HASTY M F, 1988, PEDIATRIC DENTISTRY, V10, P314##HUANG SR, 2005, HUM GENET, V118, P444, DOI 10.1007/S00439-005-0051-7##HUTCHINSON J, 1886, T MED CHIR SOC EDINB, V69, P473##ISHII T, 1976, J AM GERIATR SOC, V24, P193, DOI 10.1111/J.1532-5415.1976.TB06779.X##JIMBOW K, 1988, ARCH DERMATOL, V124, P1261, DOI 10.1001/ARCHDERM.124.8.1261##JONES KL, 1975, J PEDIATR-US, V86, P84, DOI 10.1016/S0022-3476(75)80709-8##KHALIFA MM, 1989, CLIN GENET, V35, P125##KING CR, 1978, J MED GENET, V15, P481, DOI 10.1136/JMG.15.6.481##KIRSCHNER J, 2005, ANN NEUROL, V57, P148, DOI 10.1002/ANA.20359##KOZLOWSK.K, 1965, ANN RADIOL-RADIOL CL, V8, PR92##LABEILLE B, 1987, ANN DERMATOL VENER, V114, P233##LIESSMANN CD, 2001, PAEDIATR ANAESTH, V11, P611, DOI 10.1046/J.1460-9592.2001.00721.X##LIVNEH H, 1995, DEATH STUD, V19, P433, DOI 10.1080/07481189508253392##LUENGO WD, 2002, AM J MED GENET, V113, P298, DOI 10.1002/AJMG.10753##MACIEL AT, 1988, AM J MED GENET, V31, P483, DOI 10.1002/AJMG.1320310302##MACNAMARA BG, 1970, ARCH DIS CHILD, V45, P553##MAKOUS N, 1962, AM HEART J, V64, P334, DOI 10.1016/0002-8703(62)90148-5##MANDERA M, 2003, CHILD NERV SYST, V19, P63, DOI 10.1007/S00381-002-0679-8##MANSCHOT WA, 1940, NED TIJDSCHR GENEES, V84, P3774##MATSUO S, 1994, PEDIATR NEUROL, V10, P237, DOI 10.1016/0887-8994(94)90030-2##MITCHELL EC, 1940, AM J DIS CHILD, V59, P379, DOI 10.1001/ARCHPEDI.1940.01990130162013##MOEN C, 1982, J BONE JOINT SURG AM, V64, P542, DOI 10.2106/00004623-198264040-00009##MONU JUV, 1990, SKELETAL RADIOL, V19, P585##MOSTAFA A H, 1954, ARCH PEDIATR, V71, P163##MOUNKES L, 2003, CURR OPIN GENET DEV, V13, P223, DOI 10.1016/S0959-437X(03)00058-3##NAGANUMA Y, 1990, NO TO HATTATSU, V22, P71##NAVARRO CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/HMG/DDI159##NELSON M, 1962, ARCH PEDIATR, V79, P87##NOLTENIUS G, 1960, BILD DIENST ROCHE, V10, P3##NOVELLI G, 2002, AM J HUM GENET, V71, P426, DOI 10.1086/341908##OGIHARA T, 1986, AM J MED, V81, P135, DOI 10.1016/0002-9343(86)90196-8##ORRICO J, 1927, ARCH MED ENFANTS, V30, P385##OZONOFF MB, 1967, AMER J ROENTGENOL RA, V100, P75, DOI 10.2214/AJR.100.1.75##PLASILOVA M, 2004, J MED GENET, V41, P609, DOI 10.1136/JMG.2004.019661##PLUNKETT ER, 1954, J CLIN ENDOCR METAB, V14, P735, DOI 10.1210/JCEM-14-7-735##RAMESH V, 1987, AUSTRALAS J DERMATOL, V23, P33##RANDACCIO M, 1972, MINERVA PEDIATRICA, V24, P599##RANNAN-ELIYA SV, 2004, HUM GENET, V115, P200, DOI 10.1007/S00439-004-1151-5##RAVA G, 1967, MINERVA MED, V58, P1502##REICHEL W, 1970, AM J CLIN PATHOL, V53, P243##RODRIGUES GHD, 2002, ANN GENET-PARIS, V45, P151, DOI 10.1016/S0003-3995(02)01119-X##RODRIGUEZ JI, 1999, AM J MED GENET, V82, P242, DOI 10.1002/(SICI)1096-8628(19990129)82:3<242::AID-AJMG9>3.3.CO;2-5##ROSENBLOOM AL, 1983, J PEDIATR-US, V102, P400, DOI 10.1016/S0022-3476(83)80660-X##ROSENTHAL IM, 1956, PEDIATRICS, V18, P565##ROSMAN NP, 2001, J CHILD NEUROL, V16, P212, DOI 10.1177/088307380101600309##SAINT-MARC T, 2000, AIDS, V14, P37, DOI 10.1097/00002030-200001070-00005##SCAFFIDI P, 2005, NAT MED, V11, P440, DOI 10.1038/NM1204##SCHIPPERS JC, 1916, NED TIJDSCHR GENEES, V2, P2274##SCHWARTZ AS, 1945, BIOL S, V11, P96##SCHWARZ E, 1962, RADIOLOGY, V79, P411, DOI 10.1148/79.3.411##SEVENANTS L, 2005, EUR J PEDIATR, V164, P283, DOI 10.1007/S00431-005-1635-X##SHACKLETON S, 2005, J MED GENET, V42, DOI 10.1136/JMG.2004.029751##SHIRAISHI I, 2001, PEDIATR CARDIOL, V22, P530, DOI 10.1007/S002460010292##SIVARAMAN, 1999, JOURNAL OF DERMATOLOGY (TOKYO), V26, P324##SMITH AS, 1993, AM J NEURORADIOL, V14, P441##SOARES LRM, 1984, CIENCIA CULTURA, V36, P849##SOOD S, 1991, ACTA RADIOL, V32, P67##SORET J, 2005, P NATL ACAD SCI USA, V102, P8764, DOI 10.1073/PNAS.0409829102##STEHBENS WE, 1999, CARDIOVASC PATHOL, V8, P29, DOI 10.1016/S1054-8807(98)00023-4##STRUNZ F, 1929, Z KINDERHEILKD, V47, P401##TALBOT NB, 1945, AM J DIS CHILD, V69, P267##THOMSON J, 1950, ARCH DIS CHILD, V25, P224, DOI 10.1136/ADC.25.123.224##TOTH JI, 2005, P NATL ACAD SCI USA, V102, P12873, DOI 10.1073/PNAS.0505767102##UNGER RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6##VALDISERRI L, 1974, CHIR ORGANI MOV, V61, P291##VARELA I, 2005, NATURE, V437, P564, DOI 10.1038/NATURE04019##VARIOT G, 1910, B SOC PEDIATR PARIS, V12, P307##VERSTRAETEN VLR, 2006, IN PRESS HUM MOL GEN##VIEGAS J, 1974, J MED GENET, V11, P384, DOI 10.1136/JMG.11.4.384##WAGLE WA, 1992, PEDIATR NEUROL, V8, P476, DOI 10.1016/0887-8994(92)90014-P##WESLEY RK, 1979, J DENT CHILD, V46, P55##WUYTS W, 2005, AM J MED GENET A, V135A, P66, DOI 10.1002/AJMG.A.30663##XUEZHE Z, 1979, CHINESE MEDICAL JOURNAL (ENGLISH EDITION), V92, P853##ZANOLA G, 1961, LATTANTE, V32, P553##ZASTROW MS, 2004, J CELL SCI, V117, P979, DOI 10.1242/JCS.01102##ZEDER ERNST, 1940, MONATSSCHR KINDERHEILK, V81, P167",310,2020-11-20,NA
J,WOS:000242466100018,2006,PATCHED MUTATIONS AND HAIRY SKIN PATCHES: A NEW SIGN IN GORLIN SYNDROME,"WE REPORT ON THE OCCURRENCE OF DISCRETE PATCHES OF UNUSUALLY LONG PIGMENTED HAIR ON THE SKIN OF THREE PATIENTS WITH GORLIN SYNDROME FROM TWO UNRELATED FAMILIES WITH CONFIRMED HETEROZYGONS MUTATIONS IN THE PATCHED (PTCH) GENE. THE PTCH PROTEIN IS A NEGATIVE REGULATOR OF HEDGEHOG SIGNALING, AND THE SONIC HEDGEHOG (SHH)-PTCH PATHWAY IS KNOWN TO PLAY AN IMPORTANT ROLE IN THE FORMATION AND CYCLING OF THE HAIR FOLLICLE. WE BELIEVE THAT THE PATCHES REPRESENT A GENUINE PHYSICAL SIGN ASSOCIATED WITH GORLIN SYNDROME, AND DISCUSS MOLECULAR MECHANISMS BY WHICH THEY MIGHT ARISE. (C) 2006 WILEY-LISS, INC.",BASAL-CELL CARCINOMA; SONIC-HEDGEHOG; FOLLICLE; INDUCTION; PATHWAY,NEVOID BASAL CELL CARCINOMA SYNDROME; BASAL CELL NEVUS SYNDROME; HAIR FOLLICLE; HYPERTRICHOSIS,AMERICAN JOURNAL OF MEDICAL GENETICS PART A,"WILSON, LC##AJAYI-OBE, E##BERNHARD, B##MAAS, SM","GREAT ORMOND STREET HOSP, LONDON WC1E 3JH, ENGLAND. INST CHILD HLTH, CLIN & MOL GENET UNIT, LONDON, ENGLAND. HAMMERSMITH HOSP, DEPT PAEDIAT, LONDON, ENGLAND. NW THAMES REG GENET SERV, HARROW, MIDDX, ENGLAND. UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN GENET, NL-1105 AZ AMSTERDAM, NETHERLANDS.",GENETICS & HEREDITY,GENETICS & HEREDITY,"BALE AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/HMG/10.7.757##BOUTET N, 2003, J INVEST DERMATOL, V121, P478, DOI 10.1046/J.1523-1747.2003.12423.X##CALLAHAN CA, 2001, CURR OPIN GENET DEV, V11, P541, DOI 10.1016/S0959-437X(00)00230-6##CHIANG C, 1999, DEV BIOL, V205, P1, DOI 10.1006/DBIO.1998.9103##COHEN MM, 2003, AM J MED GENET A, V123A, P5, DOI 10.1002/AJMG.A.20495##DLUGOSZ A, 1999, J CLIN INVEST, V104, P851, DOI 10.1172/JCI8416##GORLIN RJ, 2004, GENET MED, V6, P530, DOI 10.1097/01.GIM.0000144188.15902.C4##HAHN H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4##LAM CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/SJ.ONC.1202360##LING G, 2001, ONCOGENE, V20, P7770, DOI 10.1038/SJ.ONC.1204946##MILLAR SE, 2002, J INVEST DERMATOL, V118, P216, DOI 10.1046/J.0022-202X.2001.01670.X##ORO AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8##PASTORINO L, 2005, HUM MUTAT, V25, DOI 10.1002/HUMU.9317##PAUS R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706##REIFENBERGER J, 1998, CANCER RES, V58, P1798##REYNOLDS AJ, 1999, NATURE, V402, P33##SATO N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691##ST-JACQUES B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9##WANG LC, 2000, J INVEST DERMATOL, V114, P901, DOI 10.1046/J.1523-1747.2000.00951.X##WICKING C, 2001, CANCER LETT, V173, P1, DOI 10.1016/S0304-3835(01)00676-0##WICKING C, 1997, AM J HUM GENET, V60, P21##XIE JW, 1998, NATURE, V391, P90",17,2020-11-20,NA
J,WOS:000242819400014,2006,WATER IMMERSION IN PREECLAMPSIA,"OBJECTIVE: PREECLAMPSIA IS ASSOCIATED WITH PROFOUND VASOCONSTRICTION IN MOST ORGAN SYSTEMS AND REDUCED PLASMA VOLUME. BECAUSE WATER IMMERSION PRODUCES A MARKED CENTRAL REDISTRIBUTION OF BLOOD VOLUME AND SUPPRESSES THE RENIN-ANGIOTENSIN SYSTEM RESPONSE AND SYMPATHETIC ACTIVITY, WE HYPOTHESIZED THAT WATER IMMERSION MIGHT BE USEFUL IN THE TREATMENT OF PREECLAMPSIA. STUDY DESIGN: THE EFFECTS OF THERMONEUTRAL WATER IMMERSION FOR 3 HOURS ON CENTRAL AND PERIPHERAL HEMODYNAMICS WERE EVALUATED IN 7 PREECLAMPTIC PATIENTS, 7 NORMAL PREGNANT CONTROL PATIENTS, AND 7 NONPREGNANT WOMEN. FINGER PLETHYSMOGRAPHY WAS USED TO DETERMINE HEMODYNAMIC MEASUREMENTS (CARDIAC OUTPUT AND TOTAL PERIPHERAL RESISTANCE), AND FOREARM BLOOD FLOW WAS MEASURED BY STRAIN GAUGE PLETHYSMOGRAPHY. POSTISCHEMIC HYPEREMIA WAS USED TO DETERMINE ENDOTHELIUM-DEPENDENT VASODILATION. ANALYSIS WAS BY ANALYSIS OF VARIANCE FOR REPEATED MEASUREMENTS. RESULTS: DURING WATER IMMERSION CARDIAC OUTPUT INCREASED WHILE DIASTOLIC BLOOD PRESSURE AND HEART RATE DECREASED, ALTHOUGH SYSTOLIC BLOOD PRESSURE REMAINED UNCHANGED IN EACH GROUP. FOREARM BLOOD FLOW INCREASED SIGNIFICANTLY IN THE NORMAL PREGNANT AND PREECLAMPTIC SUBJECTS. TOTAL PERIPHERAL RESISTANCE DECREASED IN ALL GROUPS, BUT VALUES IN PREECLAMPTIC PATIENTS REMAINED ABOVE THOSE. OF NORMOTENSIVE PREGNANT WOMEN. WATER IMMERSION HAD NO EFFECT ON ENDOTHELIUM-DEPENDENT VASODILATION IN THE PREECLAMPTIC GROUP, AND MOST HEMODYNAMIC CHANGES THAT WERE OBSERVED REVERSED TO BASELINE WITHIN 2 HOURS OF COMPLETION OF THE PROCEDURE. CONCLUSION: ALTHOUGH WATER IMMERSION RESULTS IN HEMODYNAMIC ALTERATIONS IN A MANNER THAT IS THEORETICALLY THERAPEUTIC FOR WOMEN WITH PREECLAMPSIA, THE EFFECT WAS LIMITED AND SHORT-LIVED. IN ADDITION WATER IMMERSION HAD NO EFFECT ON ENDOTHELIUM-DEPENDENT VASODILATION IN WOMEN WITH PREECLAMPSIA. THE THERAPEUTIC POTENTIAL FOR WATER IMMERSION IN PREECLAMPSIA APPEARS TO BE LIMITED. (C) 2006 MOSBY, INC. ALL RIGHTS RESERVED.",BLOOD-PRESSURE MONITOR; NITRIC-OXIDE; PREGNANCY; FLOW; HUMANS; PLASMA; VASODILATION; ALDOSTERONE; VALIDATION; FOREARM,WATER IMMERSION; PREECLAMPSIA; VASODILATION,AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,"ELVAN-TASPINAR, A##FRANX, A##DELPRAT, CC##BRUINSE, HW##KOOMANS, HA","UNIV UTRECHT, MED CTR, DEPT PERINATOL & GYNECOL, NL-3508 AB UTRECHT, NETHERLANDS. SINT ELISABETH HOSP, DEPT OBSTET & GYNECOL, TILBURG, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT HYPERTENS & NEPHROL, NL-3508 AB UTRECHT, NETHERLANDS.",OBSTETRICS & GYNECOLOGY,OBSTETRICS & GYNECOLOGY,"BARDEN A, 2001, HYPERTENSION, V38, P803, DOI 10.1161/HY1101.092969##BOWYER L, 2003, BJOG-INT J OBSTET GY, V110, P383, DOI 10.1016/S1470-0328(02)02930-0##BROWN MA, 1994, CLIN SCI, V86, P575, DOI 10.1042/CS0860575##COCKELL AP, 1997, HYPERTENSION, V30, P247, DOI 10.1161/01.HYP.30.2.247##DAWES GS, 1991, J PERINAT MED, V19, P47, DOI 10.1515/JPME.1991.19.1-2.47##DIJKHORST-OEI LT, 2000, J AM SOC NEPHROL, V11, P1293##ELSHEIKH A, 2001, ARCH GYNECOL OBSTET, V264, P182, DOI 10.1007/S004040000104##ELVAN-TASPINAR A, 2003, J HYPERTENS, V21, P2053, DOI 10.1097/01.HJH.0000098138.70956.68##EPSTEIN M, 1992, PHYSIOL REV, V72, P563##FISCHER T, 2000, AM J OBSTET GYNECOL, V183, P1489, DOI 10.1067/MOB.2000.107323##FRANX A, 1997, HYPERTENS PREGNANCY, V16, P187, DOI 10.3109/10641959709031636##GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462##HARMS MPM, 1999, CLIN SCI, V97, P291, DOI 10.1042/CS19990061##JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314##KATZ VL, 1990, OBSTET GYNECOL, V75, P147##KOKOT F, 1983, P EUR DIAL TRANS, V20, P557##KWEE A, 2000, BRIT J OBSTET GYNAEC, V107, P663, DOI 10.1111/J.1471-0528.2000.TB13310.X##LINDHEIMER MD, 1999, CHESLEYS HYPERTENSIV##MCKINNEY ET, 2000, AM J OBSTET GYNECOL, V183, P874, DOI 10.1067/MOB.2000.108877##MEREDITH IT, 1996, AM J PHYSIOL-HEART C, V270, PH1435##NIJHUIS IJM, 1998, PRENAT NEONAT MED, V3, P314##PENAZ J, INT C MED BIOL ENG D, P104##RABELINK AJ, 1989, AM J PHYSIOL, V257, PF375##ROBERTS JM, 2003, HYPERTENSION, V41, P437, DOI 10.1161/01.HYP.0000054981.03589.E9##ROBERTS JM, 2002, PLACENTA, V23, P359, DOI 10.1053/PLAC.2002.0819##ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0##SHENNAN AH, 1993, BRIT J OBSTET GYNAEC, V100, P904, DOI 10.1111/J.1471-0528.1993.TB15104.X##STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X##WESSELING KH, 1995, HOMEOSTASIS HLTH DIS, V36, P67##WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566##WILLIAMS DJ, 1997, AM J PHYSIOL, V272, P748##YOSHIDA A, 2000, HYPERTENSION, V36, P400, DOI 10.1161/01.HYP.36.3.400",7,2020-11-20,NA
J,WOS:000242819400063,2006,DAMAGE TO OVARIAN RESERVE ASSOCIATED WITH TAPAROSCOPIC EXCISION OF ENDOMETRIOMAS: A QUANTITATIVE RATHER THAN QUALITATIVE INJURY,NA,NA,NA,AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,"VAN DER WEIDEN, RMF","ST FRANCISCUS GASTHUIS, DEPT OBSTET & GYNECOL, NL-3045 PM ROTTERDAM, NETHERLANDS.",OBSTETRICS & GYNECOLOGY,OBSTETRICS & GYNECOLOGY,"RAGNI G, 2005, AM J OBSTET GYNECOL, V193, P1908, DOI 10.1016/J.AJOG.2005.05.056",1,2020-11-20,NA
J,WOS:000242834500523,2006,COGNITIVE IMPAIRMENT IN FORMERLY ECLAMPTIC WOMEN,NA,NA,NA,AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,"AUKES, A##DUBOIS, A##WESSEL, I##AARNOUDSE, J##ZEEMAN, G","UNIV GRONINGEN, MED CTR, GRONINGEN, NETHERLANDS. RIJKSUNIVERSITEIT GRONINGEN, GRONINGEN, NETHERLANDS.",OBSTETRICS & GYNECOLOGY,OBSTETRICS & GYNECOLOGY,NA,0,2020-11-20,NA
J,WOS:000242834500468,2006,ENDOTHELIUM-DEPENDENT AND -INDEPENDENT VASODILATATION IN PREECLAMPSIA AND HELLP SYNDROME,NA,NA,NA,AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,"BLAAUW, J##VAN PAMPUS, MG##RAKHORST, G##AARNOUDSE, JG","UNIV GRONINGEN, UNIV MED CTR GRONINGEN, GRONINGEN, NETHERLANDS.",OBSTETRICS & GYNECOLOGY,OBSTETRICS & GYNECOLOGY,NA,0,2020-11-20,NA
J,WOS:000242834500314,2006,THROMBOELASTOMETRY AS AN ADJUNCTIVE TEST IN THROMBOPHILIA SCREENING FOR ADVERSE PREGNANCY OUTCOME,NA,NA,NA,AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,"FLACH, L##LENGLET, J##VAN GEIJN, H##BOLTE, A","VRIJE UNIV AMSTERDAM, CTR MED, AMSTERDAM, NETHERLANDS.",OBSTETRICS & GYNECOLOGY,OBSTETRICS & GYNECOLOGY,NA,0,2020-11-20,NA
J,WOS:000242834500164,2006,LUNG-TO-HEAD RATIO AND LIVER POSITION TO PREDICT NEONATAL MORBIDITY IN FETUSES WITH ISOLATED CONGENITAL DIAPHRAGMATIC HERNIA: A MULTICENTER STUDY,NA,NA,NA,AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,"JANI, J##BENACHI, A##MITANCHEZ, D##ALLEGAERT, K##TIBBOEL, D##MORENO, O##EISENBERG, V##NICOLAIDES, K##GRATACOS, E##VAN HEIJST, A##STORME, L##MATIS, J##DEPREST, J","UNIV HOSP LEUVEN, LOUVAIN WC2R 2LS, BELGIUM. HOP NECKER ENFANTS MALAD, PARIS, FRANCE. ERASMUS UNIV CHILDRENS HOSP, ROTTERDAM, NETHERLANDS. HOSP & CLIN, BARCELONA, SPAIN. BEN GURION UNIV NEGEV, JERUSALEM, ISRAEL. KINGS COLL LONDON, HARRIS BIRTHRIGHT RES CTR, LONDON, ENGLAND. RADBOUD UNIV NIJMEGEN MED CTR, NIJMEGEN, NETHERLANDS. CHRU LILLE, DEPT PERINATOL, LILLE, FRANCE. CHRU STRASBOURG, SCHILTIGHEIM, FRANCE.",OBSTETRICS & GYNECOLOGY,OBSTETRICS & GYNECOLOGY,NA,0,2020-11-20,NA
J,WOS:000242834500659,2006,GENETIC INFLUENCE ON PARTURITION IN A TWIN SAMPLE: EXAMINATION OF PARENTAL EFFECT ON BIRTH TIMING,NA,NA,NA,AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,"KISTKA, Z##DEFRANCO, E##LIGTHART, L##BOOMSMA, DI##MUGLIA, LJ","WASHINGTON UNIV, ST LOUIS, MO USA. VRIJE UNIV AMSTERDAM, DEPT BIOL PSYCHOL, AMSTERDAM, NETHERLANDS.",OBSTETRICS & GYNECOLOGY,OBSTETRICS & GYNECOLOGY,NA,0,2020-11-20,NA
J,WOS:000242834500561,2006,ENDOTHELIUM-DEPENDENT AND -INDEPENDENT MICROVASCULAR REACTIVITY IN PREGNANCIES COMPLICATED BY INTRAUTERINE GROWTH RESTRICTION,NA,NA,NA,AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,"KOOPMANS, C##BLAAUW, J##VAN PAMPUS, M##RAKHORST, G##AARNOUDSE, JG","UNIV MEWD CTR GRONINGEN, GRONINGEN, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT OBSTET & GYNECOL, GRONINGEN, NETHERLANDS.",OBSTETRICS & GYNECOLOGY,OBSTETRICS & GYNECOLOGY,NA,0,2020-11-20,NA
J,WOS:000242834500219,2006,EN CAUL DELIVERY OF EXTREMELY PRETERM INFANTS: DOES IT MAKE A DIFFERENCE?,NA,NA,NA,AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY,"STOELINGA, B##BIENSTOCK, J##GOODWIN, C##HUEPPCHEN, N","ERASMUS UNIV, MED CTR ROTTERDAM, ROTTERDAM, NETHERLANDS. JOHNS HOPKINS UNIV, BALTIMORE, MD USA.",OBSTETRICS & GYNECOLOGY,OBSTETRICS & GYNECOLOGY,NA,2,2020-11-20,NA
J,WOS:000242135400028,2006,HEPATIC GLUCOSE PRODUCTION IS MORE SENSITIVE TO INSULIN-MEDIATED INHIBITION THAN HEPATIC VLDL-TRIGLYCERIDE PRODUCTION,"HEPATIC GLUCOSE PRODUCTION IS MORE SENSITIVE TO INSULIN-MEDIATED INHIBITION THAN HEPATIC VLDL-TRIGLYCERIDE PRODUCTION. AM J PHYSIOL ENDOCRINOL METAB 291: E1360-E1364, 2006. FIRST PUBLISHED JULY 18, 2006; DOI:10.1152/AJPENDO.00188.2006.-INSULIN IS AN IMPORTANT INHIBITOR OF BOTH HEPATIC GLUCOSE OUTPUT AND HEPATIC VLDL-TRIGLYCERIDE (VLDL-TG) PRODUCTION. WE INVESTIGATED WHETHER BOTH PROCESSES ARE EQUALLY SENSITIVE TO INSULIN-MEDIATED INHIBITION. TO TEST THIS, WE USED EUGLYCEMIC CLAMP STUDIES WITH FOUR INCREASING PLASMA CONCENTRATIONS OF INSULIN IN WILD-TYPE C57B1/6 MICE. BY EXTRAPOLATION, WE ESTIMATED THAT HALF-MAXIMAL INHIBITION OF HEPATIC GLUCOSE OUTPUT AND HEPATIC VLDL-TG PRODUCTION BY INSULIN WERE OBTAINED AT PLASMA INSULIN LEVELS OF SIMILAR TO 3.6 AND SIMILAR TO 6.8 NG/ML, RESPECTIVELY. IN THE SAME EXPERIMENTS, WE MEASURED THAT HALF-MAXIMAL DECREASE OF PLASMA FREE FATTY ACID LEVELS AND HALF-MAXIMAL STIMULATION OF PERIPHERAL GLUCOSE UPTAKE WERE REACHED AT PLASMA INSULIN LEVELS OF SIMILAR TO 3.0 AND SIMILAR TO 6.0 NG/ML, RESPECTIVELY. WE CONCLUDE THAT, COMPARED WITH INSULIN SENSITIVITY OF HEPATIC GLUCOSE OUTPUT, PERIPHERAL GLUCOSE UPTAKE AND HEPATIC VLDL-TG PRODUCTION ARE LESS SENSITIVE TO INSULIN.",DENSITY LIPOPROTEIN PRODUCTION; FREE FATTY-ACIDS; RAT-LIVER; APOLIPOPROTEIN-B; TRANSFER PROTEIN; SKELETAL-MUSCLE; BETA-OXIDATION; C57BL/6J MICE; EXPRESSION; PLASMA,VERY-LOW-DENSITY LIPOPROTEIN; FATTY ACID; EUGLYCEMIC HYPERINSULINEMIC CLAMP; LIVER,AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM,"DEN BOER, MAM##VOSHOL, PJ##KUIPERS, F##ROMIJN, JA##HAVEKES, LM","LEIDEN UNIV, MED CTR, DEPT ENDOCRINOL & METAB, NL-2333 ZA LEIDEN, NETHERLANDS. NETHERLANDS ORG APPL SCI RES QUAL LIFE, GAUBIUS LAB, LEIDEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT PEDIAT, NL-9700 AB GRONINGEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT CARDIOL, NL-2300 RA LEIDEN, NETHERLANDS.",ENDOCRINOLOGY & METABOLISM; PHYSIOLOGY,ENDOCRINOLOGY & METABOLISM; PHYSIOLOGY,"AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066##ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/JCB.69.2.241##AU CS, 2004, METABOLISM, V53, P228, DOI 10.1016/J.METABOL.2003.09.011##BARTHEL A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/J.TEM.2005.03.010##BROWN AM, 2001, ARTERIOSCL THROM VAS, V21, P1656, DOI 10.1161/HQ1001.096640##CARPENTIER A, 2002, DIABETES, V51, P1867, DOI 10.2337/DIABETES.51.6.1867##DE FRONZO RA, 1979, AM J PHYSIOL, V237, P214##DUIVENVOORDEN I, 2005, J LIPID RES, V46, P988, DOI 10.1194/JLR.M400505-JLR200##FISHER EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/JBC.M008885200##FOSTER JD, 1997, P SOC EXP BIOL MED, V215, P314##FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776##GREFHORST A, 2005, AM J PHYSIOL-ENDOC M, V289, PE829, DOI 10.1152/AJPENDO.00165.2005##GREFHORST A, 2005, AM J PHYSIOL-GASTR L, V289, PG592, DOI 10.1152/AJPGI.00063.2005##GUZMAN M, 1989, BIOCHEM J, V264, P107, DOI 10.1042/BJ2640107##HAGAN DL, 1994, J BIOL CHEM, V269, P28737##HOLM C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/ANNUREV.NUTR.20.1.365##KIM JK, 2003, DIABETES, V52, P1311, DOI 10.2337/DIABETES.52.6.1311##KRONES A, 2000, BIOCHEM J, V348, P433, DOI 10.1042/0264-6021:3480433##LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/BBRC.1994.1702##LEWIS GF, 1995, J CLIN INVEST, V95, P158, DOI 10.1172/JCI117633##LEWIS GF, 1997, CURR OPIN LIPIDOL, V8, P146, DOI 10.1097/00041433-199706000-00004##OBRIEN RM, 1990, DIABETES CARE, V13, P327, DOI 10.2337/DIACARE.13.3.327##RIZZA RA, 1981, AM J PHYSIOL, V240, P630##SURWIT RS, 1991, DIABETES, V40, P82, DOI 10.2337/DIABETES.40.1.82##SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/DIABETES.37.9.1163##VOSHOL PJ, 2003, ENDOCRINOLOGY, V144, P3456, DOI 10.1210/EN.2002-0036##VOSHOL PJ, 2001, DIABETES, V50, P2585, DOI 10.2337/DIABETES.50.11.2585##WETTERAU JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3##ZAMBON A, 1993, J LIPID RES, V34, P1021",21,2020-11-20,NA
J,WOS:000241855700003,2006,INHIBITION OF MATRIX METALLOPROTEINASES INCREASES PPAR-ALPHA AND IL-6 AND PREVENTS DIETARY-INDUCED HEPATIC STEATOSIS AND INJURY IN A MURINE MODEL,"STEATOSIS IS A PROMINENT FEATURE OF NONALCOHOLIC FATTY LIVER DISEASE AND A POTENTIAL PROMOTER OF INFLAMMATION. INJURY LEADING TO CIRRHOSIS IS PARTLY MEDIATED BY DYSREGULATION OF MATRIX PROTEIN TURNOVER. MATRIX METALLOPROTEINASE (MMP) INHIBITORS PROTECT MICE FROM LETHAL TNF-ALPHA INDUCED LIVER INJURY. WE HYPOTHESIZED THAT MARIMASTAT, A BROAD-SPECTRUM MMP AND TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITOR, MIGHT MODULATE THIS INJURY THROUGH INTERRUPTION OF INFLAMMATORY PATHWAYS. TRIGLYCERIDE AND PHOSPHOLIPID LEVELS (LIVER, SERUM) AND FATTY ACID PROFILES WERE USED TO ASSESS ESSENTIAL FATTY ACID STATUS AND DE NOVO LIPOGENESIS AS MECHANISMS FOR HEPATIC STEATOSIS. MICE RECEIVING A FAT-FREE, HIGH-CARBOHYDRATE DIET (HCD) FOR 19 DAYS DEVELOPED SEVERE FATTY LIVER INFILTRATION, DEMONSTRATED BY HISTOLOGY, MAGNETIC RESONANCE SPECTROSCOPY, AND ELEVATED LIVER FUNCTION TESTS. ANIMALS RECEIVING HCD PLUS MARIMASTAT (HCD+MAR) WERE COMPARABLE TO CONTROL ANIMALS. INCREASED TISSUE LEVELS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA (PPAR-ALPHA), HIGHER LEVELS OF SERUM IL-6, AND DECREASED LEVELS OF SERUM TNF-ALPHA RECEPTOR II WERE ALSO SEEN IN THE HCD+MAR GROUP COMPARED WITH HCD-ONLY. IN ADDITION, THERE WAS INCREASED PHOSPHORYLATION, AND LIKELY ACTIVATION, OF PPAR-ALPHA IN THE HCD+MAR GROUP. PPAR-ALPHA IS A TRANSCRIPTION FACTOR INVOLVED IN BETA-OXIDATION OF FATTY ACIDS, AND IL-6 IS A HEPATOPROTECTIVE CYTOKINE. LIVER TRIGLYCERIDE LEVELS WERE HIGHER AND SERUM TRIGLYCERIDE AND PHOSPHOLIPID LEVELS LOWER WITH HCD-ONLY BUT IMPROVED WITH MARIMASTAT TREATMENT. HCD-ONLY AND HCD+MAR GROUPS WERE ESSENTIAL FATTY ACID DEFICIENT AND HAD ELEVATED RATES OF DE NOVO LIPOGENESIS. WE THEREFORE CONCLUDE THAT MARIMASTAT REDUCES LIVER TRIGLYCERIDE ACCUMULATION BY INCREASING FAT OXIDATION AND/OR LIVER CLEARANCE OF TRIGLYCERIDES. THIS MAY BE RELATED TO INCREASED EXPRESSION AND ACTIVATION OF PPAR-ALPHA OR IL-6, RESPECTIVELY.",NONALCOHOLIC FATTY LIVER; TUMOR-NECROSIS-FACTOR; TOTAL PARENTERAL-NUTRITION; ACTIVATED-RECEPTOR-ALPHA; TNF-ALPHA; INSULIN-RESISTANCE; ACID DEFICIENCY; NATURAL-HISTORY; RISK-FACTORS; OBESE MICE,MATRIX METALLOPROTEINASE; NONALCOHOLIC FATTY LIVER DISEASE; TNF-ALPHA; PPAR-ALPHA,AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY,"ALWAYN, IPJ##ANDERSSON, C##LEE, S##ARSENAULT, DA##BISTRIAN, BR##GURA, KM##NOSE, V##ZAUSCHER, B##MOSES, M##PUDER, M","CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA. CHILDRENS HOSP, VASC BIOL PROGRAM, BOSTON, MA 02115 USA. CHILDRENS HOSP, DEPT PHARM, BOSTON, MA 02115 USA. CHILDRENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA. BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA. BETH ISRAEL DEACONESS MED CTR, DEPT MED, BOSTON, MA 02115 USA. ERASMUS MC, DEPT SURG, ROTTERDAM, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY; PHYSIOLOGY,GASTROENTEROLOGY & HEPATOLOGY; PHYSIOLOGY,"ALVAREZ JG, 1992, J CHROMATOGR-BIOMED, V577, P142, DOI 10.1016/0378-4347(92)80609-T##ALWAYN IPJ, 2005, PEDIATR RES, V57, P445, DOI 10.1203/01.PDR.0000153672.43030.75##ALWAYN IPJ, 2004, HEPATOLOGY, V39, P1176, DOI 10.1002/HEP.20189##ANGULO P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMRA011775##ARMSTRONG L, 2006, AM J RESP CELL MOL, V34, P219, DOI 10.1165/RCMB.2005-0087OC##BELLENTANI S, 2000, ANN INTERN MED, V132, P112, DOI 10.7326/0003-4819-132-2-200001180-00004##BENJAMIN DR, 1981, AM J CLIN PATHOL, V76, P276##BROWN MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5##CHOI KC, 2005, BIOCHEM BIOPH RES CO, V336, P747, DOI 10.1016/J.BBRC.2005.08.203##CLARK JEANNE M, 2002, CURR DIAB REP, V2, P210, DOI 10.1007/S11892-002-0085-3##CLARK JM, 2003, GASTROENTEROLOGY, V124, P248, DOI 10.1053/GAST.2003.50032##CLARK JM, 2002, GASTROENTEROLOGY, V122, P1649, DOI 10.1053/GAST.2002.33573##CLARK JM, 2003, AM J GASTROENTEROL, V98, P960, DOI [10.1016/S0002-9270(03)00265-X, 10.1111/J.1572-0241.2003.07486.X]##CURSIO R, 2001, FASEB J, V15, P93, DOI 10.1096/FJ.01-0279FJE##DANDONA P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/J.IT.2003.10.013##DAY CP, 2002, BEST PRACT RES CL GA, V16, P663, DOI 10.1053/BEGA.2002.0333##DAY CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2##DEKKERS PEP, 1999, BLOOD, V94, P2252, DOI 10.1182/BLOOD.V94.7.2252.419K25_2252_2258##DENG QG, 2005, HEPATOLOGY, V42, P905, DOI 10.1002/HEP.20877##DESVERGNE B, 1998, J STEROID BIOCHEM, V65, P65, DOI 10.1016/S0960-0760(97)00182-9##FEINGOLD KR, 1988, BIOCHEM BIOPH RES CO, V153, P576, DOI 10.1016/S0006-291X(88)81134-3##FELDSTEIN AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7##FELDSTEIN AE, 2003, J HEPATOL, V39, P978, DOI 10.1016/S0168-8278(03)00460-4##FERNANDES JC, 2002, BIORHEOLOGY, V39, P237##GLASER KB, 1999, BIOCHEM PHARMACOL, V57, P291, DOI 10.1016/S0006-2952(98)00300-1##HARUYAMA T, 2000, BIOCHEM BIOPH RES CO, V272, P681, DOI 10.1006/BBRC.2000.2837##HONG F, 2004, HEPATOLOGY, V40, P933, DOI 10.1002/HEP.20400##HORTON JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593##HUGHES CA, 1983, GUT, V24, P241, DOI 10.1136/GUT.24.3.241##IIMURO Y, 1997, HEPATOLOGY, V26, P1530##JAVID PJ, 2005, J PEDIATR SURG, V40, P1446, DOI 10.1016/J.JPEDSURG.2005.05.045##KEIM NL, 1984, J NUTR, V114, P1807##KERSTEN S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223##KIM TH, 2000, HEPATOLOGY, V31, P75, DOI 10.1002/HEP.510310114##KNITTEL T, 2000, HISTOCHEM CELL BIOL, V113, P443##KOOBY DA, 2003, J GASTROINTEST SURG, V7, P1034, DOI 10.1016/J.GASSUR.2003.09.012##KOTEISH A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/S-2001-12932##LEBER TM, 1998, BRIT J CANCER, V78, P724, DOI 10.1038/BJC.1998.568##LI ZP, 2003, HEPATOLOGY, V37, P343, DOI 10.1053/JHEP.2003.50048##MATTEONI CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8##MCMILLAN JI, 1996, INT J CANCER, V67, P523, DOI 10.1002/(SICI)1097-0215(19960807)67:4<523::AID-IJC11>3.0.CO;2-8##NAGASE H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/JBC.274.31.21491##PAPPO I, 1995, JPEN-PARENTER ENTER, V19, P80, DOI 10.1177/014860719501900180##PASSILLY P, 1999, BIOCHEM PHARMACOL, V58, P1001, DOI 10.1016/S0006-2952(99)00182-3##POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/HEP.1840110114##RATZIU V, 2000, GASTROENTEROLOGY, V118, P1117, DOI 10.1016/S0016-5085(00)70364-7##ROY R, 2006, EXP CELL RES, V312, P608, DOI 10.1016/J.YEXCR.2005.11.022##RUAN H, 2003, CYTOKINE GROWTH F R, V14, P447, DOI 10.1016/S1359-6101(03)00052-2##RUDERMAN N, 1998, DIABETES, V47, P699, DOI 10.2337/DIABETES.47.5.699##SAHOO S, 2003, SEMIN LIVER DIS, V23, P295##SANTUCCI MB, 2003, INT IMMUNOPHARMACOL, V3, P1657, DOI 10.1016/S1567-5769(03)00202-9##SAX HC, 1988, JPEN-PARENTER ENTER, V12, P615, DOI 10.1177/0148607188012006615##SAX HC, 1986, SURGERY, V100, P697##SEKIYA M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/J.HEP.2003.09.028##SHIMANO H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248##SHIMANO H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8##SUN ZL, 2003, GASTROENTEROLOGY, V125, P202, DOI 10.1016/S0016-5085(03)00696-6##TELI MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/HEP.1840220616##TILG H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007##WANLESS IR, 1990, HEPATOLOGY, V12, P1106, DOI 10.1002/HEP.1840120505##WATANABE Y, 2003, BIOL PHARM BULL, V26, P564##WERNER A, 2005, AM J PHYSIOL-GASTR L, V288, PG1150, DOI 10.1152/AJPGI.00456.2004##WHALEN GF, 1990, J PEDIATR SURG, V25, P622, DOI 10.1016/0022-3468(90)90348-D##WIELOCKX B, 2001, NAT MED, V7, P1202, DOI 10.1038/NM1101-1202##XU JH, 2005, J NEUROSCI RES, V81, P403, DOI 10.1002/JNR.20518##YAHAGI N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/JBC.M201584200",28,2020-11-20,"NATIONAL CANCER INSTITUTEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL CANCER INSTITUTE (NCI) [R01CA083106, R01CA083106, R01CA083106, R01CA083106] FUNDING SOURCE: NIH REPORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES (NIDDK) [P30DK040561, P30DK040561, P30DK040561, K08DK069621, P30DK040561, P50DK065298, P50DK065298, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P50DK065298, K08DK069621, P50DK065298, P50DK065298, P50DK065298, P30DK040561, P50DK065298, P50DK065298, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P50DK065298, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, K08DK069621, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P50DK065298, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, K08DK069621, P50DK065298, P30DK040561, P50DK065298, P30DK040561, P50DK065298, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P50DK065298, P50DK065298, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P50DK065298, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P50DK065298, P50DK065298, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, K08DK069621, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P30DK040561, P50DK065298, P30DK040561, P50DK065298, P30DK040561, P50DK065298, P30DK040561] FUNDING SOURCE: NIH REPORTER; NCI NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL CANCER INSTITUTE (NCI) [CA-83106] FUNDING SOURCE: MEDLINE; NIDDK NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES (NIDDK) [DK-065298, P30 DK040561-11, P30 DK040561, DK-069621-01] FUNDING SOURCE: MEDLINE"
J,WOS:000241855900013,2006,THE DIASTOLIC FLOW VELOCITY-PRESSURE GRADIENT RELATION AND DP(V50) TO ASSESS THE HEMODYNAMIC SIGNIFICANCE OF CORONARY STENOSES,"TO EVALUATE THE HEMODYNAMIC IMPACT OF CORONARY STENOSES, THE FRACTIONAL (FFR) OR CORONARY FLOW VELOCITY RESERVE (CFVR) USUALLY IS MEASURED. THE COMBINED MEASUREMENT OF INSTANTANEOUS FLOW VELOCITY AND PRESSURE GRADIENT (V-DP RELATION) IS RARELY USED IN HUMANS. WE DERIVED FROM THE V-DP RELATION A NEW INDEX, DPV50 (PRESSURE GRADIENT AT FLOW VELOCITY OF 50 CM/S), AND COMPARED THE DIAGNOSTIC PERFORMANCE OF DPV50, CFVR, AND FFR. BEFORE CORONARY ANGIOGRAPHY WAS PERFORMED, PATIENTS UNDERWENT NONINVASIVE STRESS TESTING. IN ALL CORONARY VESSELS WITH AN INTERMEDIATE OR SEVERE STENOSIS, THE FLOW VELOCITY, AORTIC, AND DISTAL CORONARY PRESSURE WERE MEASURED SIMULTANEOUSLY WITH A DOPPLER AND PRESSURE GUIDEWIRE AFTER INDUCTION OF HYPEREMIA. AFTER REGRESSION ANALYSIS OF ALL MIDDIASTOLIC FLOW VELOCITY AND PRESSURE GRADIENT DATA, THE DPV50 WAS CALCULATED. WITH THE USE OF THE RESULTS OF NONINVASIVE STRESS TESTING, THE DPV50 CUTOFF VALUE WAS ESTABLISHED AT 22.4 MMHG. IN 77 PATIENTS, 124 CORONARY VESSELS WITH A MEAN 39% (SD 19) DIAMETER STENOSIS WERE ANALYZED. IN 43 STENOSES, ISCHEMIA WAS DETECTED. WE FOUND A SENSITIVITY, SPECIFICITY, AND ACCURACY OF 56%, 86%, AND 76% FOR CFVR; 77%, 99%, AND 91% FOR FFR; AND 95%, 95%, AND 95% FOR DPV50. TO ESTABLISH THAT DPV50 IS NOT DEPENDENT ON MAXIMAL HYPEREMIA, DPV50 WAS RECALCULATED AFTER OMISSION OF THE HIGHEST QUARTILE OF FLOW VELOCITY DATA, SHOWING A DIFFERENCE OF 3%. WE FOUND THAT DPV50 PROVIDED THE HIGHEST SENSITIVITY AND ACCURACY COMPARED WITH FFR AND CFVR IN THE ASSESSMENT OF CORONARY STENOSES. IN CONTRAST TO CFVR AND FFR, ASSESSMENT OF DPV50 IS NOT DEPENDENT ON MAXIMAL HYPEREMIA.",ADENOSINE 5'-TRIPHOSPHATE; INTRACORONARY ADENOSINE; MYOCARDIAL-ISCHEMIA; ARTERY STENOSES; TASK-FORCE; RESERVE; HUMANS; VASOCONSTRICTION; HYPEREMIA; DYNAMICS,CORONARY DISEASE; PHYSIOLOGY; CATHETERIZATION; CORONARY BLOOD FLOW,AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY,"MARQUES, KMJ##VAN EENIGE, MJ##SPRUIJT, HJ##WESTERHOF, N##TWISK, J##VISSER, CA##VISSER, FC","VRIJE UNIV AMSTERDAM, MED CTR, DEPT CARDIOL, NL-1007 MB AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, DEPT PHYSIOL, CARDIOVASC RES INST, NL-1007 MB AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PHYSIOLOGY; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY; PHYSIOLOGY,"CHAMULEAU SAJ, 2001, J AM COLL CARDIOL, V37, P1316, DOI 10.1016/S0735-1097(01)01173-1##DE BRUYNE B, 2003, CIRCULATION, V107, P1877, DOI 10.1161/01.CIR.0000061950.24940.88##DEBRUYNE B, 1996, CIRCULATION, V94, P1842, DOI 10.1161/01.CIR.94.8.1842##DEBRUYNE B, 1995, CIRCULATION, V92, P39, DOI 10.1161/01.CIR.92.1.39##DOUCETTE JW, 1992, CIRCULATION, V85, P1899, DOI 10.1161/01.CIR.85.5.1899##FEIGENBAUM H, 1993, INT J CARD IMAGING, V9 SUPPL 2, P55, DOI 10.1007/BF01143180##GOULD KL, 1978, CIRC RES, V43, P242, DOI 10.1161/01.RES.43.2.242##GOULD KL, 1974, AM J CARDIOL, V34, P48, DOI 10.1016/0002-9149(74)90092-7##GOULD KL, 1974, AM J CARDIOL, V33, P87, DOI 10.1016/0002-9149(74)90743-7##GREGORINI L, 1994, CIRCULATION, V90, P895, DOI 10.1161/01.CIR.90.2.895##GREGORINI L, 2002, CIRCULATION, V106, P2901, DOI 10.1161/01.CIR.0000040998.88272.A7##HEUSCH G, 2000, CIRCULATION, V101, P689, DOI 10.1161/01.CIR.101.6.689##JEREMIAS A, 2000, AM HEART J, V140, P651, DOI 10.1067/MHJ.2000.109920##JEREMIAS A, 2000, CIRCULATION, V101, P318, DOI 10.1161/01.CIR.101.3.318##LORENZONI R, 1996, AM J PHYSIOL-HEART C, V271, PH1302##MARQUES KMJ, 2002, J AM COLL CARDIOL, V39, P1630, DOI 10.1016/S0735-1097(02)01834-X##MATES RE, 1978, CIRC RES, V42, P152, DOI 10.1161/01.RES.42.1.152##MILLER DD, 1994, CIRCULATION, V89, P2150, DOI 10.1161/01.CIR.89.5.2150##MURTAGH B, 2003, AM HEART J, V146, P99, DOI 10.1016/S0002-8703(03)00120-0##PIJLS NHJ, 1995, CIRCULATION, V92, P3183, DOI 10.1161/01.CIR.92.11.3183##PIJLS NHJ, 2000, CATHETER CARDIO INTE, V49, P1##PIJLS NHJ, 1996, NEW ENGL J MED, V334, P1703, DOI 10.1056/NEJM199606273342604##QUINONES MA, 2003, CIRCULATION, V107, P1068, DOI 10.1161/01.CIR.0000061708.42540.47##RITCHIE JL, 1995, CIRCULATION, V91, P1278##TRON C, 1995, AM HEART J, V130, P723, DOI 10.1016/0002-8703(95)90070-5##YOUNG DF, 1975, CIRC RES, V36, P735, DOI 10.1161/01.RES.36.6.735##YOUNG DF, 1977, CIRC RES, V41, P99, DOI 10.1161/01.RES.41.1.99",19,2020-11-20,NA
J,WOS:000241855900069,2006,SYMPATHETIC NERVOUS SYSTEM CONTRIBUTES TO THE AGE-RELATED IMPAIRMENT OF FLOW-MEDIATED DILATION OF THE SUPERFICIAL FEMORAL ARTERY,"THE PHYSIOLOGICAL AGING PROCESS IS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION, AS ASSESSED BY FLOW-MEDIATED DILATION (FMD). AGING IS ALSO CHARACTERIZED BY INCREASED SYMPATHETIC TONE. THEREFORE, THE AIM OF THE PRESENT STUDY IS TO ASSESS WHETHER ACUTE CHANGES IN SYMPATHETIC ACTIVITY ALTER FMD IN THE LEG. FOR THIS PURPOSE, THE FMD OF THE SUPERFICIAL FEMORAL ARTERY WAS DETERMINED IN 10 HEALTHY YOUNG (22 +/- 1 YR) AND 8 HEALTHY OLDER (69 +/- 1 YR) MEN IN THREE DIFFERENT CONDITIONS: 1) AT BASELINE, 2) DURING REDUCTION OF SYMPATHETIC ACTIVITY, AND 3) DURING SYMPATHETIC STIMULATION. REDUCTION OF SYMPATHETIC ACTIVITY WAS ACHIEVED BY PERFORMING A MAXIMAL CYCLING EXERCISE, LEADING TO POSTEXERCISE ATTENUATION OF THE SYMPATHETIC RESPONSIVENESS IN THE EXERCISED LIMB. A COLD PRESSOR TEST WAS USED TO INCREASE SYMPATHETIC ACTIVITY. NITROGLYCERIN (NTG) WAS USED TO ASSESS ENDOTHELIUM-INDEPENDENT VASODILATION IN ALL THREE CONDITIONS. OUR RESULTS SHOWED THAT, IN OLDER MEN, THE FMD AND NTG RESPONSES WERE SIGNIFICANTLY LOWER COMPARED WITH YOUNG MEN (P = 0.001 AND P = 0.02, RESPECTIVELY). IN OLDER MEN, SYMPATHETIC ACTIVITY SIGNIFICANTLY AFFECTED THE FMD RESPONSE [REPEATED-MEASURES (RM) ANOVA: P = 0.01], WITH A NEGATIVE CORRELATION BETWEEN THE LEVEL OF SYMPATHETIC ACTIVITY AND FMD (R = 0.41, P = 0.049). THIS WAS NOT THE CASE FOR NTG RESPONSES (ANOVA; P = 0.48). FMD AND NTG RESPONSES IN YOUNG MEN DID NOT DIFFER AMONG THE THREE CONDITIONS (RM-ANOVA: P = 0.32 AND P = 0.31, RESPECTIVELY). IN CONCLUSION, IN OLDER MEN, FMD OF THE FEMORAL ARTERY IS IMPAIRED. LOCAL ATTENUATION OF THE SYMPATHETIC RESPONSIVENESS PARTLY RESTORES THE FMD IN THESE SUBJECTS. IN CONTRAST, IN YOUNG SUBJECTS, ACUTE MODULATION OF THE SYMPATHETIC NERVOUS SYSTEM ACTIVITY DOES NOT ALTER FLOW-MEDIATED VASODILATION IN THE LEG.",COLD PRESSOR TEST; ENDOTHELIUM-DEPENDENT VASODILATION; BRACHIAL-ARTERY; VASCULAR CONDUCTANCE; MENTAL STRESS; HUMAN LIMBS; BLOOD-FLOW; MUSCLE; DYSFUNCTION; VASOCONSTRICTION,ENDOTHELIUM-DEPENDENT DILATION; COLD PRESSOR TEST; EXERCISE,AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY,"THIJSSEN, DHJ##DE GROOT, P##KOOIJMAN, M##SMITS, P##HOPMAN, MTE","RADBOUD UNIV NIJMEGEN MED CTR, DEPT PHYSIOL, NIJMEGEN MED CTR, INST FUNDAMENTAL & CLIN MOVEMENT SCI, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, DEPT PHARMACOL TOXICOL, NL-6500 HB NIJMEGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PHYSIOLOGY; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY; PHYSIOLOGY,"ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4##CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F##CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P471, DOI 10.1016/0735-1097(94)90305-0##CORRETTI MC, 2002, J AM COLL CARDIOL, V39, P257, DOI 10.1016/S0735-1097(01)01746-6##DE GROOT PCE, 2004, AM J PHYSIOL-HEART C, V287, PH374, DOI 10.1152/AJPHEART.00958.2003##DESOUZA CA, 2000, CIRCULATION, V102, P1351, DOI 10.1161/01.CIR.102.12.1351##DINENNO FA, 2001, J PHYSIOL-LONDON, V536, P977, DOI 10.1111/J.1469-7793.2001.00977.X##DREXLER H, 1992, AM J CARDIOL, V69, P1596, DOI 10.1016/0002-9149(92)90710-G##DYSON KS, 2006, AM J PHYSIOL-HEART C, V290, PH1446, DOI 10.1152/AJPHEART.00771.2005##FAGIUS J, 1989, ACTA PHYSIOL SCAND, V137, P325, DOI 10.1111/J.1748-1716.1989.TB08760.X##FERGUSON DW, 1990, J AM COLL CARDIOL, V16, P1125, DOI 10.1016/0735-1097(90)90544-Y##GREEN D, 2005, J APPL PHYSIOL, V99, P1233, DOI 10.1152/JAPPLPHYSIOL.00601.2005##GROOTHUIS JT, 2003, J APPL PHYSIOL, V95, P342, DOI 10.1152/JAPPLPHYSIOL.00022.2003##HALLIWILL JR, 1996, J PHYSIOL-LONDON, V495, P279, DOI 10.1113/JPHYSIOL.1996.SP021592##HARRIS CW, 2000, AM HEART J, V139, P405, DOI 10.1016/S0002-8703(00)90083-8##HARVEY PJ, 2005, J HYPERTENS, V23, P285, DOI 10.1097/00004872-200502000-00010##HIJMERING ML, 2002, J AM COLL CARDIOL, V39, P683, DOI 10.1016/S0735-1097(01)01786-7##KELLER DM, 2004, J PHYSIOL-LONDON, V561, P273, DOI 10.1113/JPHYSIOL.2004.071993##KOCH DW, 2003, J PHYSIOL-LONDON, V551, P337, DOI 10.1113/JPHYSIOL.2003.042747##KOOIJMAN M, 2003, CIRCULATION, V108, P2361, DOI 10.1161/01.CIR.0000096480.55857.3C##LEVENSON J, 2001, J AM COLL CARDIOL, V38, P1668, DOI 10.1016/S0735-1097(01)01604-7##LIGTENBERG G, 1997, CIRCULATION, V95, P2271, DOI 10.1161/01.CIR.95.9.2271##LIND L, 2002, BLOOD PRESSURE, V11, P22, DOI 10.1080/080370502753543927##MIZUSHIMA T, 1998, STROKE, V29, P607, DOI 10.1161/01.STR.29.3.607##MULLER-DELP JM, 2002, AM J PHYSIOL-HEART C, V283, PH1662, DOI 10.1152/AJPHEART.00004.2002##NEUNTEUFL T, 1997, ATHEROSCLEROSIS, V129, P111, DOI 10.1016/S0021-9150(96)06018-2##NEWCOMER SC, 2005, AM J PHYSIOL-HEART C, V289, PH308, DOI 10.1152/AJPHEART.01151.2004##NEWCOMER SC, 2004, J PHYSIOL-LONDON, V556, P1001, DOI 10.1113/JPHYSIOL.2003.059717##NG AV, 1993, HYPERTENSION, V21, P498, DOI 10.1161/01.HYP.21.4.498##PAWELCZYK JA, 2002, J APPL PHYSIOL, V92, P2105, DOI 10.1152/JAPPLPHYSIOL.00979.2001##PROCTOR DN, 2005, J APPL PHYSIOL, V98, P193, DOI 10.1152/JAPPLPHYSIOL.00704.2004##RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, PS1, DOI 10.1097/00005344-199304000-00002##SEALS DR, 2004, AM J PHYSIOL-HEART C, V287, PH1895, DOI 10.1152/AJPHEART.00486.2004##STEINBERG HO, 1997, CIRCULATION, V96, P3287##TADDEI S, 1995, CIRCULATION, V91, P1981, DOI 10.1161/01.CIR.91.7.1981##TADDEI S, 2000, CIRCULATION, V101, P2896, DOI 10.1161/01.CIR.101.25.2896##THIJSSEN DHJ, 2005, CLIN SCI, V108, P151, DOI 10.1042/CS20040177##TSCHAKOVSKY, 2005, J APPL PHYSIOL, V99, P1237##TSCHAKOVSKY ME, 2005, J APPL PHYSIOL, V99, P1235, DOI 10.1152/JAPPLPHYSIOL.00607.2005##VICTOR RG, 1987, HYPERTENSION, V9, P429, DOI 10.1161/01.HYP.9.5.429##WOLF S, 1941, J CLIN INVEST, V20, P521, DOI 10.1172/JCI101245",48,2020-11-20,NA
J,WOS:000241855900040,2006,TIME COURSE ANALYSIS OF BAROREFLEX SENSITIVITY DURING POSTURAL STRESS,"POSTURAL STRESS REQUIRES IMMEDIATE AUTONOMIC NERVOUS ACTION TO MAINTAIN BLOOD PRESSURE. WE DETERMINED TIME-DOMAIN CARDIAC BAROREFLEX SENSITIVITY (BRS) AND TIME DELAY (TAU) BETWEEN SYSTOLIC BLOOD PRESSURE AND INTERBEAT INTERVAL VARIATIONS DURING STEPWISE CHANGES IN THE ANGLE OF VERTICAL BODY AXIS (ALPHA). THE ASSUMPTION WAS THAT WITH INCREASING POSTURAL STRESS, BRS BECOMES ATTENUATED, ACCOMPANIED BY A SHIFT IN TAU TOWARD HIGHER VALUES. IN 10 HEALTHY YOUNG VOLUNTEERS, ALPHA INCLUDED 20 DEGREES HEAD-DOWN TILT (-20 DEGREES), SUPINE (0 DEGREES), 30 AND 70 DEGREES HEAD-UP TILT (30 DEGREES, 70 DEGREES), AND FREE STANDING (90 DEGREES). NONINVASIVE BLOOD PRESSURES WERE ANALYZED OVER 6-MIN PERIODS BEFORE AND AFTER EACH CHANGE IN ALPHA. THE BRS WAS DETERMINED BY FREQUENCY-DOMAIN ANALYSIS AND WITH XBRS, A CROSS-CORRELATION TIME-DOMAIN METHOD. ON AVERAGE, BETWEEN 28 (-20 DEGREES) TO 45 (90 DEGREES) XBRS ESTIMATES PER MINUTE BECAME AVAILABLE. FOLLOWING A CHANGE IN ALPHA, XBRS REACHED A DIFFERENT MEAN LEVEL IN THE FIRST MINUTE IN 78% OF THE CASES AND IN 93% AFTER 6 MIN. WITH INCREASING ALPHA, BRS DECREASED: BRS = -10.1 CENTER DOT SIN(ALPHA) + 18.7 (R(2) = 0.99) WITH TIGHT CORRELATION BETWEEN XBRS AND CROSS-SPECTRAL GAIN (R(2) SIMILAR TO 0.97). DELAY TAU SHIFTED TOWARD HIGHER VALUES. IN CONCLUSION, IN HEALTHY SUBJECTS THE SENSITIVITY OF THE CARDIAC BAROREFLEX OBTAINED FROM TIME DOMAIN DECREASES LINEARLY WITH SIN(ALPHA), AND THE START OF BAROREFLEX ADAPTATION TO A PHYSIOLOGICAL PERTURBATION LIKE POSTURAL STRESS OCCURS RAPIDLY. THE DECREASES OF BRS AND REDUCTION OF SHORT TAU MAY BE THE RESULT OF REDUCED VAGAL ACTIVITY WITH INCREASING ALPHA.",HEAD-UP TILT; BLOOD-PRESSURE; BARORECEPTOR REFLEX; CARDIAC BAROREFLEX; SPECTRAL-ANALYSIS; ARTERIAL-PRESSURE; HEALTHY-SUBJECTS; HUMANS; RESPONSES; VARIABILITY,BLOOD PRESSURE REGULATION; TILT; SEQUENTIAL AND SPECTRAL ANALYSIS; VAGAL AND SYMPATHETIC TONE,AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY,"WESTERHOF, BE##GISOLF, J##KAREMAKER, JM##WESSELING, KH##SECHER, NH##VAN LIESHOUT, JJ","UNIV AMSTERDAM, ACAD MED CTR, BNEYE, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT PHYSIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT INTERNAL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV COPENHAGEN, RIGSHOSP, DEPT ANESTHESIA, DK-2100 COPENHAGEN, DENMARK.",CARDIAC & CARDIOVASCULAR SYSTEMS; PHYSIOLOGY; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY; PHYSIOLOGY,"BAHJAOUI-BOUHADDI M, 1998, PHYSIOL RES, V47, P227##BERTINIERI G, 1988, AM J PHYSIOL, V254, PH377##BORST C, 1983, J AUTONOM NERV SYST, V9, P399, DOI 10.1016/0165-1838(83)90004-8##BOS WJW, 1996, CIRCULATION, V94, P1870, DOI 10.1161/01.CIR.94.8.1870##CASTIGLIONI P, 1999, CLIN SCI, V97, P129, DOI 10.1042/CS19980405##COOKE WH, 1999, J PHYSIOL-LONDON, V517, P617, DOI 10.1111/J.1469-7793.1999.0617T.X##COOPER VL, 2002, CLIN SCI, V103, P221, DOI 10.1042/CS1030221##DEBOER RW, 1986, AM J PHYSIOL, V251, PH685##DEBOER RW, 1987, AM J PHYSIOL, V253, PH680##DEMAREES H, 1973, BASIC RES CARDIOL, V69, P462##DI RIENZO M, 2001, AM J PHYSIOL-REG I, V280, PR744##DI RIENZO M., 1985, MED BIOL ENG COMP S1, VSUPPL##DIRIENZO M, 1997, IEEE ENG MED BIOL, V16, P86, DOI 10.1109/51.620499##ECKBERG DL, 2005, J PHYSIOL-LONDON, V567, P1011, DOI 10.1113/JPHYSIOL.2005.091090##ECKBERG DL, 1997, CIRCULATION, V96, P3224, DOI 10.1161/01.CIR.96.9.3224##ECKBERG DL, 1975, J LAB CLIN MED, V85, P167##ECKBERG DL, 1976, J APPL PHYSIOL, V41, P383##ECKBERG DL, 1992, HUMAN BAROREFLEXES H##FADEL PJ, 2003, AM J PHYSIOL-HEART C, V284, PH735, DOI 10.1152/AJPHEART.00246.2002##GISOLF J, 2005, J APPL PHYSIOL, V98, P1682, DOI 10.1152/JAPPLPHYSIOL.01219.2004##GISOLF J, 2004, J AM COLL CARDIOL, V44, P588, DOI 10.1016/J.JACC.2004.04.038##GIZDULICH P, 1997, CARDIOVASC RES, V33, P698, DOI 10.1016/S0008-6363(97)00003-5##GULLI G, 2005, CLIN AUTON RES, V15, P207, DOI 10.1007/S10286-005-0273-8##IWASE S, 1987, PHYSIOLOGIST S, V30, P62##JANSEN JRC, 2001, BRIT J ANAESTH, V87, P212, DOI 10.1093/BJA/87.2.212##JOYNER MJ, 1993, CLIN AUTONOMIC DISOR, P55##JULU POO, 2003, J PHYSIOL-LONDON, V549, P299, DOI 10.1113/JPHYSIOL.2002.036715##KARDOS A, 1997, CLIN AUTON RES, V7, P143, DOI 10.1007/BF02308842##KATONA PG, 1975, J APPL PHYSIOL, V39, P801##KESELBRENER L, 1996, IEEE T BIO-MED ENG, V43, P789, DOI 10.1109/10.508542##KEYL C, 2001, J APPL PHYSIOL, V91, P283##LAUDE D, 2004, AM J PHYSIOL-REG I, V286, PR226, DOI 10.1152/AJPREGU.00709.2002##LIPMAN RD, 2003, HYPERTENSION, V42, P481, DOI 10.1161/01.HYP.0000091370.83602.E6##LUCINI D, 2000, J HYPERTENS, V18, P281, DOI 10.1097/00004872-200018030-00007##MALLIANI A, 2004, HYPERTENSION, V43, PE24, DOI 10.1161/01.HYP.0000120966.82562.90##MUKAI S, 1995, J APPL PHYSIOL, V78, P212##O'LEARY DD, 2003, EXP PHYSIOL, V88, P769, DOI 10.1113/EPH8802632##OGOH S, 2005, J PHYSIOL-LONDON, V566, P599, DOI 10.1113/JPHYSIOL.2005.084541##OGOH S, 2003, J PHYSIOL-LONDON, V551, P601, DOI 10.1113/JPHYSIOL.2003.046029##PARATI G, 2004, J HYPERTENS, V22, P1259, DOI 10.1097/01.HJH.0000125469.35523.32##PARATI G, 2004, HYPERTENSION, V43, PE32, DOI 10.1161/01.HYP.0000126689.12940.CD##PARATI G, 2006, J APPL PHYSIOL, V101, P676, DOI 10.1152/JAPPLPHYSIOL.00446.2006##PARLOW J, 1995, HYPERTENSION, V25, P1058, DOI 10.1161/01.HYP.25.5.1058##PAWELCZYK JA, 1989, AM J PHYSIOL, V257, PH1389##PEDERSEN M, 1995, ACTA PHYSIOL SCAND, V155, P435, DOI 10.1111/J.1748-1716.1995.TB09993.X##PICKERING TG, 1973, CARDIOVASC RES, V7, P213, DOI 10.1093/CVR/7.2.213##PITZALIS M, 2003, J AM COLL CARDIOL, V41, P1167, DOI 10.1016/S0735-1097(03)00050-0##RAY CA, 2003, ACTA PHYSIOL SCAND, V177, P313, DOI 10.1046/J.1365-201X.2003.01084.X##ROBBE HWJ, 1987, HYPERTENSION, V10, P538, DOI 10.1161/01.HYP.10.5.538##SMIT AAJ, 2002, CIRCULATION, V105, P1329, DOI 10.1161/HC1102.105744##SMYTH HS, 1969, CIRC RES, V24, P109, DOI 10.1161/01.RES.24.1.109##STEPTOE A, 1990, CARDIOVASC RES, V24, P627, DOI 10.1093/CVR/24.8.627##TAYLOR JA, 1995, J PHYSIOL-LONDON, V483, P289, DOI 10.1113/JPHYSIOL.1995.SP020585##VAN LIESHOUT JJ, 2005, ACTA ANAESTH SCAND, V49, P1287, DOI 10.1111/J.1399-6576.2005.00841.X##WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566##WESTERHOF BE, 2004, J HYPERTENS, V22, P1371, DOI 10.1097/01.HJH.0000125439.28861.ED##WESTERHOF BE, 2002, J HYPERTENS, V20, P1981, DOI 10.1097/00004872-200210000-00017##ZELEN M, 1965, HDB MATH FUNCTIONS",63,2020-11-20,NA
J,WOS:000241768400006,2006,LOW-CARBOHYDRATE DIETS AFFECT ENERGY BALANCE AND FUEL HOMEOSTASIS DIFFERENTIALLY IN LEAN AND OBESE RATS,"IN PARALLEL WITH INCREASED PREVALENCE OF OVERWEIGHT PEOPLE IN AFFLUENT SOCIETIES ARE INDIVIDUALS TRYING TO LOSE WEIGHT, OFTEN USING LOW-CARBOHYDRATE DIETS. NEVERTHELESS, LONG-TERM METABOLIC CONSEQUENCES OF THOSE DIETS, USUALLY HIGH IN (SATURATED) FAT, REMAIN UNCLEAR. THEREFORE, WE INVESTIGATED LONG-TERM EFFECTS OF HIGH-FAT DIETS WITH DIFFERENT CARBOHYDRATE/PROTEIN RATIOS ON ENERGY BALANCE AND FUEL HOMEOSTASIS IN OBESE (FA/FA) ZUCKER AND LEAN WISTAR RATS. ANIMALS WERE FED HIGH-CARBOHYDRATE (HC), HIGH-FAT (HSF), OR LOW-CARBOHYDRATE, HIGH-FAT, HIGH-PROTEIN (LC-HSF-HP) DIETS FOR 60 DAYS. BOTH LINES FED THE LC-HSF-HP DIET DISPLAYED REDUCED ENERGY INTAKE COMPARED WITH THOSE FED THE HSF DIET (ZUCKER, -3.7%) OR THE HC DIET (WISTAR RATS, -12.4%). THIS WAS NOT ASSOCIATED WITH LOWER WEIGHT GAIN RELATIVE TO HC FED RATS, BECAUSE OF INCREASED FOOD EFFICIENCIES IN EACH LINE FED HSF AND PARTICULARLY LC-HSF-HP FOOD. ZUCKER RATS WERE LESS GLUCOSE TOLERANT THAN WISTAR RATS. LOWEST GLUCOSE TOLERANCES WERE FOUND IN HSF AND PARTICULARLY IN LC-HSF-HP FED ANIMALS IRRESPECTIVE OF LINE, BUT THIS PARALLELED REDUCED PLASMA ADIPONECTIN LEVELS, ELEVATED PLASMA RESISTIN LEVELS, HIGHER RETROPERITONEAL FAT MASSES, AND REDUCED INSULIN SENSITIVITY (INDEXED BY INSULIN-INDUCED HYPOGLYCEMIA) ONLY IN WISTAR RATS. IN ZUCKER RATS, HOWEVER, IMPROVED INSULIN RESPONSES DURING GLUCOSE TOLERANCE TESTING AND TENDENCY TOWARD INCREASED INSULIN SENSITIVITIES WERE OBSERVED WITH HSF OR LC-HSF-HP FEEDING RELATIVE TO HC FEEDING. THUS, DESPITE ADVERSE CONSEQUENCES OF LC-HSF DIETS ON BLOOD GLUCOSE HOMEOSTASIS, PRINCIPAL DIFFERENCES EXIST IN THE UNDERLYING HORMONAL REGULATORY MECHANISMS, WHICH COULD HAVE BENEFITS FOR B-CELL FUNCTIONING AND INSULIN ACTION IN THE OBESE STATE BUT NOT IN THE LEAN STATE.",HIGH-PROTEIN DIETS; HIGH-FAT; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; BODY-WEIGHT; LEPTIN; HYPERPHAGIA; INFUSION; ATKINS; BLOOD,FA/FA ZUCKER RATS; GLUCOSE TOLERANCE; INSULIN SENSITIVITY,AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY,"MORENS, C##SIROT, V##SCHEURINK, AJW##VAN DIJK, G","UNIV GRONINGEN, CTR BEHAV & NEUROSCI, DEPT NEUROENDOCRINOL, NL-9750 AA HAREN, NETHERLANDS.",PHYSIOLOGY,PHYSIOLOGY,"ALBARAZANJI KA, 1997, OBES RES, V5, P387, DOI 10.1002/J.1550-8528.1997.TB00660.X##ASTRUP A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9##BELOBRAJDIC DP, 2004, J NUTR, V134, P1454##BRAY GA, 2005, ANN INTERN MED, V142, P469, DOI 10.7326/0003-4819-142-6-200503150-00013##CHALKLEY SM, 2002, AM J PHYSIOL-ENDOC M, V282, PE1231, DOI 10.1152/AJPENDO.00173.2001##CLELAND R, 1998, COMMERCIAL WEIGHT LO##CLEMENT KARINE, 2002, AM J PHARMACOGENOMICS, V2, P177, DOI 10.2165/00129785-200202030-00003##FOSTER GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMOA022207##HARA KAZUO, 2005, CURR DIAB REP, V5, P136, DOI 10.1007/S11892-005-0041-0##HILL JO, 1983, LIFE SCI, V33, P141, DOI 10.1016/0024-3205(83)90406-X##HOFFMAN WS, 1937, J BIOL CHEM, V120, P51##HUANG BW, 2004, DIABETES OBES METAB, V6, P120, DOI 10.1111/J.1462-8902.2004.00323.X##IIDA M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/BBRC.1996.1070##*INT ASS STUD OB, 2005, AB OB##LAFONTAN M, 2005, ANNU REV PHARMACOL, V45, P119, DOI 10.1146/ANNUREV.PHARMTOX.45.120403.095843##LARA-CASTRO C, 2004, J CLIN ENDOCR METAB, V89, P4197, DOI 10.1210/JC.2004-0683##MCAULEY KA, 2005, DIABETOLOGIA, V48, P8, DOI 10.1007/S00125-004-1603-4##MORENS C, 2005, AM J PHYSIOL-REG I, V289, PRU56##MU H, 2006, CARDIOVASC RES, V70, P146, DOI 10.1016/J.CARDIORES.2006.01.015##*NIH NAT HEART LUN, 2005, PRACT GUID ID EV TRE##PATEL L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3##PERET J, 1984, METABOLISM, V33, P200, DOI 10.1016/0026-0495(84)90036-2##SEELEY RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/S-2007-979874##SERDULA MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/JAMA.282.14.1353##SHAFRIR E, 1999, ANN NY ACAD SCI, V892, P223, DOI 10.1111/J.1749-6632.1999.TB07798.X##STEFFENS AB, 1969, PHYSIOL BEHAV, V4, P833, DOI 10.1016/0031-9384(69)90126-7##STERN L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007##STORLIEN LH, 1996, DIABETOLOGIA, V39, P621, DOI 10.1007/BF00418533##TOME D, 2004, BRIT J NUTR, V92, PS27, DOI 10.1079/BJN20041138##TREMBLAY F, 2003, DIABETES, V52, P29, DOI 10.2337/DIABETES.52.1.29##TRISCARI J, 1982, METABOLISM, V31, P223, DOI 10.1016/0026-0495(82)90057-9##UHLEY VE, 1989, INT J OBESITY, V13, P849##VASSELLI JR, 1990, PHYSIOL BEHAV, V48, P805, DOI 10.1016/0031-9384(90)90231-R##VASSELLI JR, 1992, AM J PHYSIOL, V262, PR33##WHO CONSULTATION, 2000, WHO TECH REP SER, V894, P1##WINZELL MS, 2004, DIABETES, V53, PS215, DOI 10.2337/DIABETES.53.SUPPL_3.S215##WOLF G, 2004, NUTR REV, V62, P389, DOI 10.1301/NR.2004.OCT.389-394##YANCY WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006##ZIMMET P, 1999, ANN NY ACAD SCI, V892, P25, DOI 10.1111/J.1749-6632.1999.TB07783.X",13,2020-11-20,NA
J,WOS:000241755600009,2006,AGE-DEPENDENT ALTERATIONS IN CA2+ HOMEOSTASIS: ROLE OF TRPV5 AND TRPV6,"AGING IS ASSOCIATED WITH ALTERATIONS IN CA2+ HOMEOSTASIS, WHICH PREDISPOSES ELDER PEOPLE TO HYPERPARATHYROIDISM AND OSTEOPOROSIS. INTESTINAL CA2+ ABSORPTION DECREASES WITH AGING AND, IN PARTICULAR, ACTIVE TRANSPORT OF CA2+ BY THE DUODENUM. IN ADDITION, THERE ARE AGE-RELATED CHANGES IN RENAL CA2+ HANDLING. TO EXAMINE AGE-RELATED CHANGES IN EXPRESSION OF THE RENAL AND INTESTINAL EPITHELIAL CA2+ CHANNELS, CONTROL (TRPV5(+/+)) AND TRPV5 KNOCKOUT (TRPV5(-/-)) MICE AGED 10, 30, AND 52 WK WERE STUDIED. AGING OF TRPV5(+/+) MICE RESULTED IN A TENDENCY TOWARD INCREASED RENAL CA2+ EXCRETION AND SIGNIFICANTLY DECREASED INTESTINAL CA2+ ABSORPTION, WHICH WAS ACCOMPANIED BY REDUCED EXPRESSION OF TRPV5 AND TRPV6, RESPECTIVELY, DESPITE INCREASED SERUM 1,25(OH)(2)D-3 LEVELS. SIMILARLY, IN TRPV5(-/-) MICE THE EXISTING RENAL CA2+ LOSS WAS MORE PRONOUNCED IN ELDER ANIMALS, WHEREAS THE COMPENSATORY INTESTINAL CA2+ ABSORPTION AND TRPV6 EXPRESSION DECLINED WITH AGING. IN BOTH MICE STRAINS, AGING RESULTED IN A RESISTANCE TO 1,25( OH) 2D3 AND DIMINISHED RENAL VITAMIN D RECEPTOR MRNA LEVELS, WHEREAS SERUM CA2+ LEVELS REMAINED CONSTANT. FURTHERMORE, 52-WK-OLD TRPV5(-/-) MICE SHOWED SEVERE HYPERPARATHYROIDISM, WHEREAS PTH LEVELS IN ELDER TRPV5(+/+) MICE REMAINED NORMAL. IN 52-WK-OLD TRPV5(-/-) MICE, SERUM OSTEOCALCIN LEVELS WERE INCREASED IN ACCORDANCE WITH THE ELEVATED PTH LEVELS, SUGGESTING AN INCREASED BONE TURNOVER IN THESE MICE. IN CONCLUSION, DOWNREGULATION OF TRPV5 AND TRPV6 IS LIKELY INVOLVED IN THE IMPAIRED CA2+ (RE)ABSORPTION DURING AGING. MOREOVER, TRPV5(-/-) MICE LIKELY DEVELOP AGE-RELATED HYPERPARATHYROIDISM AND OSTEOPOROTIC CHARACTERISTICS BEFORE TRPV5(+/+) MICE, DEMONSTRATING THE IMPORTANCE OF THE EPITHELIAL CA2+ CHANNELS IN CA2+ HOMEOSTASIS.","INTESTINAL CALCIUM-ABSORPTION; PARATHYROID-HORMONE; VITAMIN-D; DIETARY CALCIUM; 1,25-DIHYDROXYVITAMIN D-3; KNOCKOUT MICE; GENE-EXPRESSION; RABBIT KIDNEY; WISTAR RATS; RENAL-CELLS","ECAC; CAT1; VDR; PTH; 1,25(OH)(2)D-3; AGING; OSTEOPOROSIS",AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY,"VAN ABEL, M##HUYBERS, S##HOENDEROP, JGJ##VAN DER KEMP, AWCM##VAN LEEUWEN, JPTM##BINDELS, RJM","UNIV NIJMEGEN, RADBOUD MED CTR, NIJMEGEN CTR MOL LIFE SCI, DEPT PHYSIOL, NL-6500 HB NIJMEGEN, NETHERLANDS. ERASMUS MED CTR, DEPT INTERNAL MED, ROTTERDAM, NETHERLANDS.",PHYSIOLOGY; UROLOGY & NEPHROLOGY,PHYSIOLOGY; UROLOGY & NEPHROLOGY,"AGUS ZS, 1973, AM J PHYSIOL, V224, P1143##ARMBRECHT HJ, 1979, AM J PHYSIOL, V236, PE769##ARMBRECHT HJ, 1989, ENDOCRINOLOGY, V125, P2950, DOI 10.1210/ENDO-125-6-2950##ARMBRECHT HJ, 2003, ARCH BIOCHEM BIOPHYS, V420, P194, DOI 10.1016/J.ABB.2003.09.025##ARMBRECHT HJ, 1999, AM J PHYSIOL-GASTR L, V277, PG41##ARMBRECHT HJ, 1980, AM J PHYSIOL, V239, PE322##ARMBRECHT HJ, 1984, AM J PHYSIOL, V246, PE266##BECK L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/PNAS.95.9.5372##BINDELS RJM, 1991, AM J PHYSIOL, V261, PF799##BINDELS RJM, 1994, AM J PHYSIOL, V266, PF620##BROWN AJ, 2005, ARCH BIOCHEM BIOPHYS, V437, P51, DOI 10.1016/J.ABB.2005.02.007##CHAPUY MC, 1983, J GERONTOL, V38, P19, DOI 10.1093/GERONJ/38.1.19##COLIN EM, 1999, J BONE MINER RES, V14, P57, DOI 10.1359/JBMR.1999.14.1.57##GALLAGHER JC, 1979, J CLIN INVEST, V64, P729, DOI 10.1172/JCI109516##GENTILI C, 2003, J CELL BIOCHEM, V88, P1157, DOI 10.1002/JCB.10472##HANAI H, 1990, AM J PHYSIOL, V259, PF444##HANAI H, 1986, J BIOL CHEM, V261, P5419##HANAI H, 1989, J CLIN INVEST, V83, P268, DOI 10.1172/JCI113869##HOENDEROP JGJ, 2000, J AM SOC NEPHROL, V11, P1171##HOENDEROP JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826##HOENDEROP JGJ, 2002, FASEB J, V16, P1398, DOI 10.1096/FJ.02-0225COM##HOENDEROP JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/ANNUREV.PHYSIOL.64.081501.155921##HOENDEROP JGJ, 2001, J AM SOC NEPHROL, V12, P1342##HOENDEROP JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/JBC.274.13.8375##HORST RL, 1990, ENDOCRINOLOGY, V126, P1053, DOI 10.1210/ENDO-126-2-1053##JOHNSON JA, 1995, EXP GERONTOL, V30, P631, DOI 10.1016/0531-5565(95)00014-3##KEENAN MJ, 1991, ANN NUTR METAB, V35, P315, DOI 10.1159/000177664##LI YC, 2001, AM J PHYSIOL-ENDOC M, V281, PE558##LIANG CT, 1994, EXP GERONTOL, V29, P179, DOI 10.1016/0531-5565(94)90049-3##MASSHEIMER V, 2000, J CELL PHYSIOL, V182, P429, DOI 10.1002/(SICI)1097-4652(200003)182:3<429::AID-JCP14>3.0.CO;2-S##MELTON LJ, 1993, J BONE MINER RES, V8, P1227##MONTELL C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3##NAVEHMANY T, 1995, J CLIN INVEST, V96, P1786, DOI 10.1172/JCI118224##NIJENHUIS T, 2003, J AM SOC NEPHROL, V14, P2731, DOI 10.1097/01.ASN.0000094081.78893.E8##NORDIN BEC, 1994, CLIN ENDOCRINOL, V41, P41, DOI 10.1111/J.1365-2265.1994.TB03782.X##ORWOLL ES, 1986, J CLIN ENDOCR METAB, V63, P1262, DOI 10.1210/JCEM-63-6-1262##PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/JCB.240550308##PENG JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/JBC.274.32.22739##PICOTTO G, 1997, AM J PHYSIOL-CELL PH, V273, PC1349##RENKEMA KY, 2005, J AM SOC NEPHROL, V16, P3188, DOI 10.1681/ASN.2005060632##SCHAPIRA D, 1995, BONE, V16, P575, DOI 10.1016/8756-3282(95)00088-U##SHERMAN SS, 1992, J BONE MINER RES, V7, P1123##TAKAMOTO S, 1990, BIOCHIM BIOPHYS ACTA, V1034, P22, DOI 10.1016/0304-4165(90)90148-P##TEITELBAUM SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/SCIENCE.289.5484.1504##VAN ABEL M, 2005, KIDNEY INT, V68, P1708, DOI 10.1111/J.1523-1755.2005.00587.X##VAN ABEL M, 2003, AM J PHYSIOL-GASTR L, V285, PG78, DOI 10.1152/AJPGI.00036.2003##VAN ABEL M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022423.34922.2A##VAN CROMPHAUT SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/PNAS.231474698##VANBAAL J, 1996, AM J PHYSIOL-RENAL, V271, PF985##VERHAEGHE J, 1989, J ENDOCRINOL, V120, P143, DOI 10.1677/JOE.0.1200143##YANG TX, 1997, AM J PHYSIOL-RENAL, V272, PF751",35,2020-11-20,NA
J,WOS:000243039200010,2006,REVISITING KURT LEWIN - HOW TO GAIN INSIGHT INTO ENVIRONMENTAL CORRELATES OF OBESOGENIC BEHAVIORS,"OVERWEIGHT AND OBESITY ARE IMPORTANT DETERMINANTS OF POPULATION HEALTH. PREVENTION OF WEIGHT GAIN IS DEPENDENT ON THE SUCCESSFUL BALANCING OF EATING AND PHYSICAL ACTIVITY BEHAVIORS. PLANNED PROMOTION OF HEALTHFUL BEHAVIOR REQUIRES INSIGHTS INTO IMPORTANT AND CHANGEABLE DETERMINANTS AND CORRELATES OF BEHAVIOR CHANGE. THE MODEST EFFECTS OF HEALTH EDUCATION HAVE INDUCED A SHIFT IN FOCUS FROM PERSONAL TO ENVIRONMENTAL CORRELATED OF EATING AND PHYSICAL ACTIVITY BEHAVIORS. SIX SYSTEMATIC REVIEWS WERE CONDUCTED IN 2005 OF OBSERVATIONAL STUDIES OF ENVIRONMENTAL CORRELATES AND ENVIRONMENTAL INTERVENTIONS FOR WEIGHT-RELATED EATING BEHAVIORS AND PHYSICAL ACTIVITY FOR CHILDREN, ADOLESCENTS, AND ADULTS. THE REVIEWS OF 297 OBSERVATIONAL STUDIES SHOWED THAT FEW INVESTIGATIONS OF ENVIRONMENTAL ASSOCIATIONS HAVE BEEN REPLICATED, AND THAT MOST STUDIES USED WEAK RESEARCH DESIGNS AND NONVALIDATED SELF-REPORT MEASURES, WERE RESTRICTED TO MICRO-ENVIRONMENTAL FACTORS, AND FAILED TO APPLY MULTILEVEL ANALYSES. THERE IS, THEREFORE, VERY LITTLE EVIDENCE FOR AN ASSOCIATION BETWEEN ENVIRONMENTAL FACTORS AND WEIGHT-RELATED BEHAVIORS. HOWEVER, THE REVIEWS OF 112 INTERVENTION STUDIES INDICATED MUCH STRONGER EVIDENCE FOR POSITIVE EFFECTS OF MICRO-PHYSICAL AND SOCIOCULTURAL ENVIRONMENTAL CHANGES ON EATING AND PHYSICAL ACTIVITY BEHAVIORS. INSPIRED BY QUOTES FROM KURT LEWIN, WE ARGUE THAT BEFORE LARGE-SCALE ENVIRONMENTAL CHANGE INTERVENTIONS ARE LAUNCHED, BETTER-DESIGNED AND -CONDUCTED RESEARCH ON THE TRUE IMPORTANCE OF ENVIRONMENTAL FACTORS, INCLUDING MACROLEVEL FACTORS, FOR OBESOGENIC BEHAVIORAL CHANGE IS NEEDED. SUCH RESEARCH SHOULD (1) DEVELOP BETTER MEASURES OF ENVIRONMENTAL EXPOSURE, (2) ATTEMPT TO INTEGRATE PERSONAL AND ENVIRONMENTAL CORRELATES OF OBESOGENIC BEHAVIORS, (3) TAKE A SOLUTION-ORIENTED, RATHER THEN A PROBLEM-ORIENTED APPROACH, AND (4) IDENTIFY ACCESS POINTS FOR INDUCING BEHAVIOR CHANGE INSTEAD OF FINDING EXPLANATIONS FOR EXISTING BEHAVIORAL PATTERNS. (AM J PREV MED 2006;31(6):525-529) (C) 2006 AMERICAN JOURNAL OF PREVENTIVE MEDICINE",FOOD-INTAKE; OBESITY; HEALTH; FRAMEWORK,NA,AMERICAN JOURNAL OF PREVENTIVE MEDICINE,"BRUG, J##VAN LENTHE, FJ##KREMERS, SPJ","ERASMUS UNIV, MED CTR, DEPT PUBL HLTH, NL-3000 CA ROTTERDAM, NETHERLANDS. MAASTRICHT UNIV, DEPT HLTH EDUC & HLTH PROMOT, MAASTRICHT, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICINE, GENERAL & INTERNAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; GENERAL & INTERNAL MEDICINE","AARTS H, 1997, HEALTH EDUC RES, V12, P363, DOI 10.1093/HER/12.3.363##BANDURA A, 1986, SOCIAL FDN THOUGHT A##BRAY GA, 2004, PHYSIOL BEHAV, V82, P115, DOI 10.1016/J.PHYSBEH.2004.04.033##BRUG J, 2005, INT J BEHAV NUTR PHY, V2, P2, DOI DOI 10.1186/1479-5868-2-2##BRUG J, 2005, ENV DETERMINANTS INT##EGGER G, 1997, BRIT MED J, V315, P477, DOI 10.1136/BMJ.315.7106.477##FERREIRA I, IN PRESS OBES REV##FLAY BR, 1994, ADV MED SOCIOL, V4, P4##GREEN LW, 1999, HLTH PROMOTION PLANN##KREMERS SPJ, 2005, SPORTS MED, V35, P923, DOI 10.2165/00007256-200535110-00001##KREMERS SPJ, 2006, INT J BEHAV NUTR PHY, V3, DOI 10.1186/1479-5868-3-9##LEWIN K, 1951, FIELD THEORY SOCIAL##MAYOR S, 2004, BRIT MED J, V328, P363, DOI 10.1136/BMJ.328.7436.363##POLLARD T, 2003, AM J HEALTH PROMOT, V18, P109, DOI 10.4278/0890-1171-18.1.109##ROBINSON TN, 2005, AM J PREV MED, V28, P194, DOI 10.1016/J.AMEPRE.2004.10.030##ROTHMAN ALEXANDER J, 2004, INT J BEHAV NUTR PHYS ACT, V1, P11, DOI 10.1186/1479-5868-1-11##ROTHSCHILD ML, 1999, J MARKETING, V63, P24, DOI 10.2307/1251972##SCHWARTZ M B, 2003, OBES REV, V4, P57, DOI 10.1046/J.1467-789X.2003.00093.X##STOKOLS D, 2003, AM J HEALTH PROMOT, V18, P4, DOI 10.4278/0890-1171-18.1.4##SWINBURN B, 1999, PREV MED, V29, P563, DOI 10.1006/PMED.1999.0585##SWINBURN BA, 2004, PUBLIC HEALTH NUTR, V7, P123, DOI 10.1079/PHN2003585##WAMMES BM, 2003, POSSIBLE DETERMINANT##WANSINK B, 2004, ANNU REV NUTR, V24, P455, DOI 10.1146/ANNUREV.NUTR.24.012003.132140",75,2020-11-20,NA
J,WOS:000242626000030,2006,IN VIVO H-1-MAGNETIC RESONANCE SPECTROSCOPY STUDY OF AMYGDALA-HIPPOCAMPAL AND PARIETAL REGIONS IN AUTISM,"OBJECTIVE: THE NEURAL BASIS FOR AUTISTIC SPECTRUM DISORDERS IS UNCLEAR, BUT ABNORMALITIES IN THE DEVELOPMENT OF LIMBIC AREAS AND OF GLUTAMATE HAVE BEEN SUGGESTED. PROTON MAGNETIC RESONANCE SPECTROSCOPY (H-1-MRS) CAN BE USED TO MEASURE THE CONCENTRATION OF BRAIN METABOLITES. HOWEVER, THE CONCENTRATION OF GLUTAMATE/GLUTAMINE IN BRAIN REGIONS IMPLICATED IN AUTISTIC SPECTRUM DISORDERS HAS NOT YET BEEN EXAMINED IN VIVO. METHOD: THE AUTHORS USED 1H-MRS TO INVESTIGATE THE NEURONAL INTEGRITY OF THE AMYGDALA-HIPPOCAMPAL COMPLEX AND A PARIETAL CONTROL REGION IN ADULTS WITH AUTISTIC SPECTRUM DISORDERS AND HEALTHY SUBJECTS. RESULTS: PEOPLE WITH AUTISTIC SPECTRUM DISORDERS HAD A SIGNIFICANTLY HIGHER CONCENTRATION OF GLUTAMATE/GLUTAMINE AND CREATINE/PHOSPHOCREATINE IN THE AMYGDALA-HIPPOCAMPAL REGION BUT NOT IN THE PARIETAL REGION. CONCLUSIONS: ABNORMALITIES IN GLUTAMATE/GLUTAMINE MAY PARTIALLY UNDERPIN THE PATHOPHYSIOLOGY OF AUTISTIC SPECTRUM DISORDERS, AND THE AUTHORS CONFIRM EARLIER REPORTS THAT LIMBIC AREAS ARE METABOLICALLY ABERRANT IN THESE DISORDERS.",GLUTAMATE-RECEPTOR-6 GENE; ASSOCIATION; LINKAGE; BRAIN,NA,AMERICAN JOURNAL OF PSYCHIATRY,"PAGE, LA##DALY, E##SCHMITZ, N##SIMMONS, A##TOAL, F##DEELEY, Q##AMBERY, F##MCALONAN, GM##MURPHY, KC##MURPHY, DGM","INST PSYCHIAT, DIV PSYCHOL MED, SECT BRAIN MATURAT, LONDON SE5 8AF, ENGLAND. LEIDEN UNIV, MED CTR, DEPT RADIOL, LEIDEN, NETHERLANDS. INST PSYCHIAT, NEUROIMAGING RES GRP, LONDON, ENGLAND. ROYAL COLL SURGEONS IRELAND, BEAUMONT HOSP, DUBLIN 2, IRELAND. UNIV HONG KONG, DEPT PSYCHIAT, HONG KONG, HONG KONG, PEOPLES R CHINA.",PSYCHIATRY,PSYCHIATRY,"CHAKRABARTI S, 2001, JAMA-J AM MED ASSOC, V285, P3093, DOI 10.1001/JAMA.285.24.3093##CRITCHLEY HD, 2000, BRAIN, V123, P2203, DOI 10.1093/BRAIN/123.11.2203##FATEMI SH, 2002, BIOL PSYCHIAT, V52, P805, DOI 10.1016/S0006-3223(02)01430-0##JAMAIN S, 2002, MOL PSYCHIATR, V7, P302, DOI 10.1038/SJ.MP.4000979##JARBRINK K, 2001, AUTISM, V5, P7, DOI 10.1177/1362361301005001002##KEMPER TL, 1993, NEUROL CLIN, V11, P175##MURPHY DGM, 2002, ARCH GEN PSYCHIAT, V59, P885, DOI 10.1001/ARCHPSYC.59.10.885##ONEILL J, 2003, 11 SCI M TOR ISMRM##POLLEUX F, 2004, MENT RETARD DEV D R, V10, P303, DOI 10.1002/MRDD.20044##PURCELL AE, 2001, NEUROLOGY, V57, P1618, DOI 10.1212/WNL.57.9.1618##RAMOZ N, 2004, AM J PSYCHIAT, V161, P662, DOI 10.1176/APPI.AJP.161.4.662##SERAJEE FJ, 2003, J MED GENET, V40, DOI 10.1136/JMG.40.4.E42##SHUANG M, 2004, AM J MED GENET B, V131B, P48, DOI 10.1002/AJMG.B.30025",119,2020-11-20,MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [G0400061] FUNDING SOURCE: MEDLINE
J,WOS:000243315200004,2006,COMMISSION ERRORS BUT NOT CRITICAL LURES DECREASE WHEN YOU HAVE TO PAY A PRICE FOR THEM,"USING THE DEESE-ROEDIGER-MCDERMOTT PARADIGM, WE EXPLORED THE EFFECT OF MONETARY PENALTY ON FALSE MEMORIES. PARTICIPANTS WERE PRESENTED 6 15-WORD LISTS OF SEMANTIC ASSOCIATES THAT ALL CONVERGED ON A NONPRESENTED CRITICAL LURE. NEXT, HALF OF THE PARTICIPANTS RECEIVED A MONETARY REWARD (0.10 EURO; ABOUT $0.10) FOR EACH CORRECTLY RECALLED WORD, WHEREAS THEY LOST MONEY (0.20 EURO; ABOUT $0.20) FOR EACH INCORRECT RESPONSE. COMPARED WITH CONTROL PARTICIPANTS WHO RECEIVED A FIXED FINANCIAL COMPENSATION, PARTICIPANTS IN THE EXPERIMENTAL GROUP REPORTED FEWER COMMISSIONS (I.E., INCORRECT RESPONSES OTHER THAN THE CRITICAL LURE). NUMBER OF HITS AND CRITICAL LURES DID NOT DIFFER BETWEEN THE GROUPS.",FALSE MEMORIES; RECALL; RECOGNITION; WORDS; LISTS,NA,AMERICAN JOURNAL OF PSYCHOLOGY,"CANDEL, I##MERCKELBACH, H##JELICIC, M##JENTJENS, K","MAASTRICHT UNIV, DEPT EXPT PSYCHOL, NL-6200 MD MAASTRICHT, NETHERLANDS.","PSYCHOLOGY, MULTIDISCIPLINARY",PSYCHOLOGY,"DEESE J, 1959, J EXP PSYCHOL, V58, P17, DOI 10.1037/H0046671##GALLO DA, 2001, PSYCHON B REV, V8, P579, DOI 10.3758/BF03196194##ISRAEL L, 1997, PSYCHON B REV, V4, P577, DOI 10.3758/BF03214352##JOHNSON MK, 1981, PSYCHOL REV, V88, P67, DOI 10.1037/0033-295X.88.1.67##KORIAT A, 1994, J EXP PSYCHOL GEN, V123, P297, DOI 10.1037/0096-3445.123.3.297##MCDERMOTT KB, 2001, J MEM LANG, V45, P160, DOI 10.1006/JMLA.2000.2771##NILSSON LG, 1987, PSYCHOL RES-PSYCH FO, V49, P183, DOI 10.1007/BF00308685##PETERS MJV, 2006, INT J NEUROSCI, V116, P1065, DOI 10.1080/00207450600808768##ROEDIGER HL, 1995, J EXP PSYCHOL LEARN, V21, P803, DOI 10.1037/0278-7393.21.4.803##ROEDIGER HL, 2001, PSYCHON B REV, V8, P385, DOI 10.3758/BF03196177##ROEDIGER HL, 1993, PSYCHOL LEARNING MOT##SCHWARTZ BL, 1998, MEMORY, V6, P257, DOI 10.1080/741942362##SEAMON JG, 2002, MEMORY, V10, P225, DOI 10.1080/09658210143000344##STADLER MA, 1999, MEM COGNITION, V27, P494, DOI 10.3758/BF03211543",0,2020-11-20,NA
J,WOS:000242743500008,2006,MUSCLE WASTING AND IMPAIRED MUSCLE REGENERATION IN A MURINE MODEL OF CHRONIC PULMONARY INFLAMMATION,"MUSCLE WASTING AND INCREASED CIRCULATING LEVELS OF INFLAMMATORY CYTOKINES, INCLUDING TNF-ALPHA, ARE COMMON FEATURES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. TO INVESTIGATE WHETHER INFLAMMATION OF THE LUNG IS RESPONSIBLE FOR SYSTEMIC INFLAMMATION AND MUSCLE WASTING, WE ADOPTED A MOUSE MODEL OF PULMONARY INFLAMMATION RESULTING FROM DIRECTED OVEREXPRESSION OF A TNF-ALPHA TRANSGENE CONTROLLED BY THE SURFACTANT PROTEIN C (SP-C) PROMOTER. COMPARED WITH WILD-TYPE MICE, SP-C/TNF-ALPHA MICE EXHIBITED INCREASED LEVELS OF TNF-ALPHA IN THE CIRCULATION AND INCREASED ENDOGENOUS TNF-ALPHA EXPRESSION IN SKELETAL MUSCLE, POTENTIALLY REFLECTING AN AMPLIFICATORY RESPONSE TO CIRCULATING TNF-ALPHA. DECREASED MUSCLE AND BODY WEIGHTS OBSERVED IN SP-C/TNF-ALPHA MICE WERE INDICATIVE OF MUSCLE WASTING. FURTHER EVALUATION OF THE SP-C/TNF-ALPHA MOUSE MUSCULATURE REVEALED A DECREASED MUSCLE REGENERATIVE CAPACITY, SHOWN BY ATTENUATED MYOBLAST PROLIFERATION AND DIFFERENTIATION IN RESPONSE TO RELOADING OF DISUSE-ATROPHIED MUSCLE, WHICH MAY CONTRIBUTE TO SKELETAL MUSCLE WASTING. IMPORTANTLY, INCUBATION OF CULTURED MYOBLASTS WITH TNF-ALPHA ALSO RESULTED IN ELEVATED TNF-ALPHA. MRNA LEVELS AND INHIBITION OF MYOBLAST DIFFERENTIATION. COLLECTIVELY, OUR RESULTS DEMONSTRATE THAT CHRONIC PULMONARY INFLAMMATION RESULTS IN MUSCLE WASTING AND IMPAIRED MUSCLE REGENERATION IN SP-C/TNF-ALPHA MICE, POSSIBLY AS A CONSEQUENCE OF AN AMPLIFICATORY TNF-ALPHA EXPRESSION CIRCUIT EXTENDING FROM THE LUNG TO SKELETAL MUSCLE.",NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVATION; FAT-FREE MASS; MYOGENIC DIFFERENTIATION; SATELLITE CELLS; OVEREXPRESSION; MODULATION; EXPRESSION; CYTOKINES; INCREASE,MUSCLE REGENERATION; PULMONARY INFLAMMATION; SKELETAL MUSCLE ATROPHY; TNF-ALPHA,AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY,"LANGEN, RCJ##SCHOLS, AMWJ##KELDERS, MCJM##VAN DER VELDEN, JLJ##WOUTERS, EFM##JANSSEN-HEININGER, YMW","MAASTRICHT UNIV, DEPT RESP MED, NL-6202 AZ MAASTRICHT, NETHERLANDS. UNIV VERMONT, DEPT PATHOL, BURLINGTON, VT 05405 USA.",BIOCHEMISTRY & MOLECULAR BIOLOGY; CELL BIOLOGY; RESPIRATORY SYSTEM,BIOCHEMISTRY & MOLECULAR BIOLOGY; CELL BIOLOGY; RESPIRATORY SYSTEM,"ALLEN DL, 1999, MUSCLE NERVE, V22, P1350, DOI 10.1002/(SICI)1097-4598(199910)22:10<1350::AID-MUS3>3.0.CO;2-8##BEMELMANS MHA, 1994, CYTOKINE, V6, P608, DOI 10.1016/1043-4666(94)90048-5##BODINE SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/SCIENCE.1065874##BOLTON CE, 2004, AM J RESP CRIT CARE, V170, P1286, DOI 10.1164/RCCM.200406-754OC##BUCK M, 1996, EMBO J, V15, P1753, DOI 10.1002/J.1460-2075.1996.TB00524.X##CAI DS, 2004, CELL, V119, P285, DOI 10.1016/J.CELL.2004.09.027##DE ROSSI M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/INTIMM/12.9.1329##DIFRANCIA M, 1994, AM J RESP CRIT CARE, V150, P1453, DOI 10.1164/AJRCCM.150.5.7952575##DUGUEZ S, 2003, AM J PHYSIOL-ENDOC M, V285, PE206, DOI 10.1152/AJPENDO.00331.2002##EID AA, 2001, AM J RESP CRIT CARE, V164, P1414, DOI 10.1164/AJRCCM.164.8.2008109##FONG Y, 1989, AM J PHYSIOL, V256, PR659##FUJITA M, 2001, AM J PHYSIOL-LUNG C, V280, PL39##GLASS DJ, 2003, TRENDS MOL MED, V9, P344, DOI 10.1016/S1471-4914(03)00138-2##GOMES MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/PNAS.251541198##GUTTRIDGE DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/SCIENCE.289.5488.2363##GUTTRIDGE DC, 1999, MOL CELL BIOL, V19, P5785##HAWKE TJ, 2001, J APPL PHYSIOL, V91, P534##HUNTER RB, 2004, J CLIN INVEST, V114, P1504, DOI 10.1172/JCI200421696##KAMI K, 2002, J HISTOCHEM CYTOCHEM, V50, P1579, DOI 10.1177/002215540205001202##KEATINGS VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/AJRCCM.153.2.8564092##LANGEN RCJ, 2003, IN VITRO CELL DEV-AN, V39, P163##LANGEN RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/FJ.03-0251COM##LANGEN RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/FJ.00-0463##LI YP, 1998, FASEB J, V12, P871##LUNDBLAD LKA, 2005, AM J RESP CRIT CARE, V171, P1363, DOI 10.1164/RCCM.200410-1349OC##MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295##MITCHELL PO, 2001, AM J PHYSIOL-CELL PH, V281, PC1076##MIYAZAKI Y, 1995, J CLIN INVEST, V96, P250, DOI 10.1172/JCI118029##PAHL HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/SJ.ONC.1203239##PAUWELS ROMAIN A., 2001, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, V163, P1256##SCHOLS AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791, DOI 10.1164/AJRCCM.157.6.9705017##SCHOLS AMWJ, 1996, THORAX, V51, P819, DOI 10.1136/THX.51.8.819##SMITH TH, 1992, DEV BIOL, V149, P16, DOI 10.1016/0012-1606(92)90260-N##SOLOMON V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/PNAS.95.21.12602##TAKABATAKE N, 2000, AM J RESP CRIT CARE, V161, P1179, DOI 10.1164/AJRCCM.161.4.9903022##VANITALLIE TB, 1990, AM J CLIN NUTR, V52, P953##VARY TC, 1996, SHOCK, V6, P13, DOI 10.1097/00024382-199607000-00004##WANEK LJ, 2000, ANAT REC, V258, P176##WUNSCH AM, 1987, DEV BIOL, V119, P94, DOI 10.1016/0012-1606(87)90210-7",82,2020-11-20,NA
J,WOS:000242718200015,2006,MAGNETIC RESONANCE IMAGING ABNORMALITIES IN SYMPTOMATIC AND CONTRALATERAL KNEES - PREVALENCE AND ASSOCIATIONS WITH TRAUMATIC HISTORY IN GENERAL PRACTICE,"BACKGROUND: AFTER TRAUMA, INTERNAL KNEE LESIONS ARE FOUND IN APPROXIMATELY TWO THIRDS OF PATIENTS. HOWEVER, MAGNETIC RESONANCE IMAGING ABNORMALITIES HAVE ALSO BEEN DESCRIBED IN ASYMPTOMATIC VOLUNTEERS. HYPOTHESIS: NOT ALL VISUALIZED LESIONS IN SYMPTOMATIC POSTTRAUMATIC KNEES ARE THE RESULT OF RECENT TRAUMA; THERE ARE SUBGROUPS OF LESIONS THAT MAY BE PREEXISTENT. STUDY DESIGN: CROSS-SECTIONAL STUDY (PREVALENCE); LEVEL OF EVIDENCE, 2. METHODS: PATIENTS VISITING THEIR GENERAL PRACTITIONERS AFTER KNEE TRAUMA WERE INVITED FOR MAGNETIC RESONANCE IMAGING OF BOTH KNEES. PREVALENCE OF KNEE ABNORMALITIES WAS COMPARED BETWEEN SYMPTOMATIC AND ASYMPTOMATIC KNEES. MULTIVARIABLE ANALYSIS WAS PERFORMED TO INVESTIGATE THE ASSOCIATION BETWEEN LESIONS THAT WERE SEEN IN SYMPTOMATIC AND ASYMPTOMATIC KNEES (IE, EFFUSION AND MENISCAL TEARS) AND RECENT TRAUMA, HISTORY OF OLD TRAUMA, AGE, AND OSTEOARTHRITIS. RESULTS: IN 134 PARTICIPANTS, LIGAMENT LESIONS WERE FOUND ALMOST EXCLUSIVELY IN SYMPTOMATIC KNEES. MENISCAL LESIONS AND EFFUSION WERE ALMOST EQUALLY FOUND IN SYMPTOMATIC AND ASYMPTOMATIC KNEES. EFFUSION WAS RELATED TO RECENT TRAUMA (ODDS RATIO, 14.0; 95% CONFIDENCE INTERVAL, 5.0-39.6) AND OSTEOARTHRITIS (ODDS RATIO, 4.7; 95% CONFIDENCE INTERVAL, 1.4-15.5) BUT NOT TO HISTORY OF OLD TRAUMA AND AGE. MENISCAL TEARS WERE MORE COMMON IN OLDER PATIENTS (ODDS RATIO, 1.09; 95% CONFIDENCE INTERVAL, 1.05-1.12) BUT WERE NOT RELATED TO OSTEOARTHRITIS. HISTORY OF OLD TRAUMA WAS MORE STRONGLY RELATED TO THE GROUP OF RADIAL, LONGITUDINAL, AND COMPLEX MENISCAL TEARS (ODDS RATIO, 8.6; 95% CONFIDENCE INTERVAL, 3.3-22.5) THAN TO HORIZONTAL TEARS (ODDS RATIO, 2.3; 95% CONFIDENCE INTERVAL, 0.9-5.6). RECENT TRAUMA WAS NOT RELATED TO HORIZONTAL MENISCAL TEARS BUT WAS STRONGLY RELATED TO OTHER TYPES OF MENISCAL TEARS (ODDS RATIO, 3.2; 95% CONFIDENCE INTERVAL, 1.4-6.9). CONCLUSION: LIGAMENT KNEE LESIONS ARE MOST PROBABLY THE RESULT OF RECENT TRAUMA. RADIAL, LONGITUDINAL, AND COMPLEX MENISCAL TEARS ARE STRONGLY RELATED TO TRAUMA, WHEREAS HORIZONTAL MENISCAL TEARS AND EFFUSION MAY BE PREEXISTENT IN MANY CASES.",ASYMPTOMATIC KNEES; JOINT; OSTEOARTHRITIS; MRI; IMPACT,KNEE; TRAUMA; MAGNETIC RESONANCE IMAGING (MRI); GENERAL PRACTICE,AMERICAN JOURNAL OF SPORTS MEDICINE,"BOKS, SS##VROEGINDEWEIJ, D##KOES, BW##HUNINK, MMGM##BIERMA-ZEINSTRA, SMA","ERASMUS MC, DEPT GEN PRACTICE, ROTTERDAM, NETHERLANDS. MED CTR RIJNMOND ZUID, DEPT RADIOL, ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT RADIOL, ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT EPIDEMIOL, ROTTERDAM, NETHERLANDS.",ORTHOPEDICS; SPORT SCIENCES,ORTHOPEDICS; SPORT SCIENCES,"BERTHIAUME MJ, 2005, ANN RHEUM DIS, V64, P556, DOI 10.1136/ARD.2004.023796##BHATTACHARYYA T, 2003, J BONE JOINT SURG AM, V85, P156##BODEN SD, 1992, CLIN ORTHOP RELAT R, P177##BRYAN S, 2004, INT J TECHNOL ASSESS, V20, P222, DOI 10.1017/S026646230400100X##CASSCELLS SW, 1978, CLIN ORTHOP RELAT R, P225##DUNCAN J B, 1996, J SOUTH ORTHOP ASSOC, V5, P13##FAHMY NRM, 1983, J BONE JOINT SURG BR, V65, P24##HEINTJES EM, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-45##HOLLINGWORTH W, 2000, CLIN RADIOL, V55, P825, DOI 10.1053/CRAD.2000.0546##KAPLAN LD, 2005, ARTHROSCOPY, V21, P557, DOI 10.1016/J.ARTHRO.2005.01.009##KOLMAN BH, 2004, SKELETAL RADIOL, V33, P91, DOI 10.1007/S00256-003-0707-0##KORNICK J, 1990, RADIOLOGY, V177, P463, DOI 10.1148/RADIOLOGY.177.2.2217786##LAPRADE RF, 1994, AM J SPORT MED, V22, P739, DOI 10.1177/036354659402200603##LEWANDROWSKI KU, 1997, AM J SPORT MED, V25, P486, DOI 10.1177/036354659702500411##MACLURE M, 1987, AM J EPIDEMIOL, V126, P161, DOI 10.1093/AJE/126.2.161##PETERSSON IF, 1997, ANN RHEUM DIS, V56, P493, DOI 10.1136/ARD.56.8.493##TRIESHMANN HW, 1996, ARTHROSCOPY, V12, P550, DOI 10.1016/S0749-8063(96)90193-0##ZANETTI M, 2003, AM J ROENTGENOL, V181, P635, DOI 10.2214/AJR.181.3.1810635",47,2020-11-20,NA
J,WOS:000242718200016,2006,CORTICOSTEROIDS REDUCE THE TENSILE STRENGTH OF ISOLATED COLLAGEN FASCICLES,"BACKGROUND: OVERUSE TENDON INJURIES ARE FREQUENT. CORTICOSTEROID INJECTIONS ARE COMMONLY USED AS TREATMENT, ALTHOUGH THEIR DIRECT EFFECTS ON THE MATERIAL PROPERTIES OF THE TENDON ARE POORLY UNDERSTOOD. PURPOSE: TO EXAMINE THE INFLUENCE OF CORTICOSTEROIDS ON THE TENSILE STRENGTH OF ISOLATED COLLAGEN FASCICLES. STUDY DESIGN: CONTROLLED LABORATORY STUDY. METHODS: SINGLE STRANDS (300-500 MU M) OF RAT-TAIL COLLAGEN FASCICLES WERE INCUBATED IN EITHER HIGH (1 ML OF 40 MGML(-1) MIXED WITH 0.5 ML SALINE 9%) OR LOW (1 ML OF 40 MGML(-1) MIXED WITH 2 ML SALINE 9%) CONCENTRATION OF METHYLPREDNISOLONE ACETATE (DEPOMEDROL) FOR 3 OR 7 DAYS, WHILE THE CONTROL SEGMENT FROM THE SAME FASCICLE WAS KEPT IN SALINE (N = 64). AFTER THE INCUBATION PERIOD, THE FASCICLES UNDERWENT DISPLACEMENT TO FAILURE IN A MECHANICAL TEST RIG AT 0.13 MM/S, AND THEREAFTER HYDROXYLYSYL PYRIDINOLINE AND LYSYL PYRIDINOLINE CROSS-LINK CONTENT WAS EVALUATED IN A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY SYSTEM. DATA FOR EACH GROUP WERE ANALYZED WITH A 2-WAY ANALYSIS OF VARIANCE (TIME X INCUBATION) FOR ULTIMATE STRESS (MEAN STANDARD DEVIATION). RESULTS: IN THE HIGH-CONCENTRATION GROUPS, STRENGTH WAS REDUCED AFTER 3 (16.6 +/- 4.6 MPA) AND 7 (8.6 +/- 1.7 MPA) DAYS COMPARED TO THE CONTROLS (30.2 +/- 5.0 MPA AND 25.6 +/- 4.6 MPA, RESPECTIVELY; P <.05). IN THE LOW-CONCENTRATION GROUPS, STRENGTH WAS REDUCED AFTER 3 (12.0 +/- 3.1 MPA) AND 7 DAYS (10.9 +/- 2.5 MPA) COMPARED TO THE CONTROLS (31.5 +/- 5.0 WA AND 32.4 +/- 5.6 WA, RESPECTIVELY; P <.05). THE AMOUNT OF CROSS-LINKING WAS UNAFFECTED BY THE INTERVENTION. CONCLUSION: DATA SHOW THAT THE TENSILE STRENGTH OF ISOLATED FASCICLES IS MARKEDLY REDUCED AFTER 3- AND 7-DAY INCUBATION IN BOTH HIGH AND LOW CONCENTRATION OF CORTICOSTEROIDS, ALTHOUGH THE OBSERVED EFFECT ON WHOLE TENDON REMAINS UNKNOWN. CLINICAL RELEVANCE: CORTICOSTEROIDS MAY WEAKEN SPECIFIC REGIONS OF THE INJECTED TENDON AND LEAVE IT MORE PRONE TO RUPTURE. THIS WEAKENING EFFECT IS MANIFESTED IN THE INDIVIDUAL COLLAGEN FASCICLES THAT CONSTITUTE THE TENDON.",MECHANICAL-PROPERTIES; STEROID INJECTION; PATELLAR TENDON; CROSS-LINKING; ACHILLES-TENDON; JUMPERS KNEE; STRAIN; RUPTURE,CORTICOSTEROIDS; COLLAGEN FASCICLE; TENSILE STRENGTH; COLLAGEN CROSS-LINKS,AMERICAN JOURNAL OF SPORTS MEDICINE,"HARALDSSON, BT##LANGBERG, H##AAGAARD, P##ZUURMOND, AM##VAN EL, B##DEGROOT, J##KJAER, M##MAGNUSSON, SP","BISPEBJERG HOSP, INST SPORTS MED COPENHAGEN, DK-2400 COPENHAGEN, DENMARK. UNIV SO DENMARK, INST SPORTS EXERCISE & CLIN BIOMECH, ODENSE, DENMARK. TNO QUAL LIFE, TNO PHARMA, BUSINESS UNIT BIOMED RES, LEIDEN, NETHERLANDS. BISPEBJERG HOSP, DEPT PHYSIOTHERAPY, DK-2400 COPENHAGEN, DENMARK.",ORTHOPEDICS; SPORT SCIENCES,ORTHOPEDICS; SPORT SCIENCES,"ALMEKINDERS LC, 2002, KNEE SURG SPORT TR A, V10, P2, DOI 10.1007/S001670100224##BAILEY AJ, 1980, NATURE, V288, P408, DOI 10.1038/288408A0##BAILEY AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047-6374(98)00119-5##BAILEY AJ, 2001, MECH AGEING DEV, V122, P735, DOI 10.1016/S0047-6374(01)00225-1##BALASUBRAMANIAM P, 1972, J BONE JOINT SURG BR, V54, P729##BANK RA, 1996, ANAL BIOCHEM, V240, P167, DOI 10.1006/ABIO.1996.0346##BENNETT MB, 1986, J ZOOL, V209, P537, DOI 10.1111/J.1469-7998.1986.TB03609.X##BUTLER D L, 1978, EXERC SPORT SCI REV, V6, P125##BUTLER DL, 1984, J BIOMECH, V17, P579, DOI 10.1016/0021-9290(84)90090-3##BUTLER DL, 1986, J BIOMECH, V19, P425, DOI 10.1016/0021-9290(86)90019-9##DANIELSEN CC, 1988, J BIOMECH, V21, P207, DOI 10.1016/0021-9290(88)90171-6##DEVKOTA AC, 2003, CLIN BIOMECH, V18, P969, DOI 10.1016/S0268-0033(03)00168-2##EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/ANNUREV.BI.53.070184.003441##FORD LT, 1979, SOUTH MED J, V72, P827, DOI 10.1097/00007611-197907000-00019##FRATZL P, 1998, J STRUCT BIOL, V122, P119, DOI 10.1006/JSBI.1998.3966##FREDBERG U, 1997, SCAND J MED SCI SPOR, V7, P131##FREDBERG U, 1999, SCAND J MED SCI SPOR, V9, P66##FREDBERG U, 2004, SCAND J RHEUMATOL, V33, P94, DOI 10.1080/03009740310004126##HALL GW, 1999, J BIOMECH, V32, P203, DOI 10.1016/S0021-9290(98)00167-5##HALPERN AA, 1977, WESTERN J MED, V127, P378##HARALDSSON BT, 2005, J APPL PHYSIOL, V98, P1006, DOI 10.1152/JAPPLPHYSIOL.00482.2004##HERRICK WC, 1978, J BIOMED MATER RES, V12, P877, DOI 10.1002/JBM.820120610##HUGATE R, 2004, J BONE JOINT SURG AM, V86A, P794, DOI 10.2106/00004623-200404000-00019##ISMAIL A M, 1969, J BONE JOINT SURG BR, V51, P503##KADLER KE, 1996, BIOCHEM J, V316, P1##KAPETANOS G, 1982, CLIN ORTHOP RELAT R, V163, P170##KENNEDY J C, 1976, AM J SPORTS MED, V4, P11, DOI 10.1177/036354657600400103##KER RF, 1988, J ZOOL, V216, P309, DOI 10.1111/J.1469-7998.1988.TB02432.X##KLEINMAN M, 1983, J BONE JOINT SURG AM, V65, P1345, DOI 10.2106/00004623-198365090-00019##MATTHEWS L S, 1974, J SPORTS MED, V2, P349##MILES CA, 2005, J MOL BIOL, V346, P551, DOI 10.1016/J.JMB.2004.12.001##NEHRER S, 1997, ARCH ORTHOP TRAUM SU, V116, P14, DOI 10.1007/BF00434093##NOYES FR, 1977, CLIN ORTHOP RELAT R, P197##PAAVOLA M, 2002, J BONE JOINT SURG AM, V84A, P2062, DOI 10.2106/00004623-200211000-00024##PAAVOLA MIKA, 2002, FOOT ANKLE CLIN, V7, P501, DOI 10.1016/S1083-7515(02)00056-6##PARRY DAD, 1978, PROC R SOC SER B-BIO, V203, P305, DOI 10.1098/RSPB.1978.0107##PHELPS D, 1974, CLIN ORTHOP RELAT R, P345##PUXKANDL R, 2002, PHILOS T R SOC B, V357, P191, DOI 10.1098/RSTB.2001.1033##TATARI H, 2001, ARCH ORTHOP TRAUM SU, V121, P333, DOI 10.1007/S004020000236##UNVERFERTH L J, 1973, J SPORTS MED, V1, P31##WALSH WR, 1995, BIOMATERIALS, V16, P905, DOI 10.1016/0142-9612(95)93114-S##WIGGINS ME, 1995, J BONE JOINT SURG AM, V77A, P1682, DOI 10.2106/00004623-199511000-00006##WREN TAL, 2001, CLIN BIOMECH, V16, P245, DOI 10.1016/S0268-0033(00)00089-9##YAMAMOTO E, 2000, CLIN BIOMECH, V15, P284, DOI 10.1016/S0268-0033(99)00072-8##YAMAMOTO N, 1998, BIO-MED MATER ENG, V8, P83",40,2020-11-20,NA
J,WOS:000242106500011,2006,TIME-DEPENDENT CHANGES IN DONOR BRAIN DEATH RELATED PROCESSES,"DONOR BRAIN DEATH (BD) AFFECTS KIDNEY FUNCTION AND SURVIVAL AFTER TRANSPLANTATION. STUDIES ON BRAIN DEAD KIDNEY DONORS INDICATE THAT, BESIDES INFLAMMATION AND COAGULATION, CYTOPROTECTIVE GENE EXPRESSION IS ACTIVATED AS WELL. HERE, WE EVALUATED IN A TIME-COURSE EXPERIMENT PROGRESSION OF THESE RENAL BD-RELATED PROCESSES. ANIMALS WERE SACRIFICED 0.5, 1, 2 OR 4 H AFTER BD AND COMPARED TO SHAM-OPERATED CONTROLS. PROINFLAMMATORY GENES (E-SELECTIN, MCP-1, IL-6) WERE MASSIVELY UP-REGULATED (P < 0.05) ALREADY 0.5 H AFTER BD. INDUCERS OF PROINFLAMMATORY GENE EXPRESSION WERE EITHER ACTIVATED (NF-KAPPA B) OR INDUCED IN EXPRESSION (EGR-1) AFTER 0.5 H OF BD. INCREASED NUMBERS OF INFILTRATING GRANULOCYTES WERE SEEN IN THE INTERSTITIUM FROM 0.5 H ON. ALSO, EXPRESSION OF PROTECTIVE GENES HO-1 AND HSP70 WERE INCREASED WITHIN 0.5 H. REMARKABLY, REACTIVE OXYGEN SPECIES FORMATION WAS DETECTABLE ONLY IN THE LATER PHASE OF BD. AMONG 14 MEASURED SERUM CYTOKINES, MCP-1 AND KC-PROTEIN WERE SIGNIFICANTLY ELEVATED FROM 0.5 H ON. IN CONCLUSION, A FAST INDUCTION OF PROINFLAMMATORY AND STRESS-INDUCED PROTECTIVE PROCESSES IN BRAIN DEAD DONOR KIDNEYS WAS DEMONSTRATED, PROBABLY TRIGGERED BY CHANGES OCCURRING DURING BD INDUCTION. IMPORTANTLY, HYPOXIA APPEARED NOT TO BE ONE OF THE INITIAL TRIGGERS, AND EARLY INCREASED SYSTEMIC LEVELS OF CHEMOKINES MCP-1 AND KC MAY BE REGARDED AS THE STARTING POINT FOR THE INFLAMMATORY CASCADE IN BRAIN DEAD DONOR KIDNEYS.",NF-KAPPA-B; ORGAN DONORS; IMMUNOLOGICAL ACTIVATION; GENE-EXPRESSION; UP-REGULATION; IN-VITRO; INJURY; RAT; TRANSPLANTATION; KIDNEYS,BRAIN DEATH; CYTOKINES; DONER KIDNEY; OXIDATIVE STRESS,AMERICAN JOURNAL OF TRANSPLANTATION,"SCHUURS, TA##MORARIU, AM##OTTENS, PJ##'T HART, NA##POPMA, SH##LEUVENINK, HGD##PLOEG, RJ","UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT SURG, GRONINGEN, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT BIOMED ENGN, GRONINGEN, NETHERLANDS. CENTOCOR R&D INC, MALVERN, PA USA.",SURGERY; TRANSPLANTATION,SURGERY; TRANSPLANTATION,"AMADO JA, 1995, METABOLISM, V44, P812, DOI 10.1016/0026-0495(95)90198-1##AVLONITIS VS, 2005, AM J TRANSPLANT, V5, P684, DOI 10.1111/J.1600-6143.2005.00755.X##BAEUERLE PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5##BAUER M, 2002, ANTIOXID REDOX SIGN, V4, P749, DOI 10.1089/152308602760598891##CICATIELLO L, 1993, RECEPTOR, V3, P17##DEWAN MZ, 2003, J VIROL, V77, P5286, DOI 10.1128/JVI.77.9.5286-5294.2003##FISHER AJ, 2001, AM J RESP CRIT CARE, V163, P259, DOI 10.1164/AJRCCM.163.1.2005093##FISHER AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8##GJERTSON DW, 2000, KIDNEY INT, V58, P491, DOI 10.1046/J.1523-1755.2000.00195.X##HARBOE M, 1959, SCAND J CLIN LAB INV, V11, P66, DOI 10.3109/00365515909060410##HERIJGERS P, 1996, TRANSPLANTATION, V62, P330, DOI 10.1097/00007890-199608150-00005##IIDA N, 1990, MOL CELL BIOL, V10, P5596, DOI 10.1128/MCB.10.10.5596##KOSIERADZKI M, 2003, TRANSPLANTATION, V75, P1221, DOI 10.1097/01.TP.0000065282.46425.87##KOSSMANN T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005##KUECUEK O, 2005, TRANSPL P, V37, P387, DOI 10.1016/J.TRANSPROCEED.2004.12.165##LEDWITH BJ, 1993, MOL CARCINOGEN, V8, P20, DOI 10.1002/MC.2940080107##LI BB, 1997, ANAL CHEM, V69, P4295, DOI 10.1021/AC970622B##LOPAU K, 2000, TRANSPL INT, V13 SUPPL 1, PS282, DOI 10.1111/J.1432-2277.2000.TB02038.X##MABUCHI S, 2004, CLIN CANCER RES, V10, P7645, DOI 10.1158/1078-0432.CCR-04-0958##MORIMOTO RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/NBT0998-833##MUSSACK T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010##NIJBOER WN, 2004, TRANSPLANTATION, V78, P978, DOI 10.1097/01.TP.0000135565.49535.60##NIJBOER WN, 2004, CURR OPIN ORGAN TRAN, V9, P110##OTTERBEIN LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9##PAHL HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/SJ.ONC.1203239##POU S, 1993, ANAL BIOCHEM, V212, P85, DOI 10.1006/ABIO.1993.1295##PRATSCHKE J, 1999, TRANSPLANTATION, V67, P343, DOI 10.1097/00007890-199902150-00001##PRATSCHKE J, 2000, ANN SURG, V232, P263, DOI 10.1097/00000658-200008000-00017##SAKURAI H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/JBC.274.43.30353##SCHUURS TA, 2004, AM J TRANSPLANT, V4, P1972, DOI 10.1111/J.1600-6143.2004.00607.X##SEGEL LD, 2002, J HEART LUNG TRANSPL, V21, P804, DOI 10.1016/S1053-2498(02)00382-0##SHEN XY, 1990, BIOCHIM BIOPHYS ACTA, V1049, P145, DOI 10.1016/0167-4781(90)90034-Y##SHIVALKAR B, 1992, J MOL CELL CARDIOL, V24, P230##STANGL M, 2001, TRANSPL P, V33, P1284, DOI 10.1016/S0041-1345(00)02479-9##TAKADA M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001##TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601##VAN DEN EIJNDEN MARK M E D, 2003, EXP CLIN TRANSPLANT, V1, P85##VAN DER HOEVEN JAB, 2003, KIDNEY INT, V64, P1874, DOI 10.1046/J.1523-1755.2003.00272.X##VAN DER HOEVEN JAB, 2001, TRANSPLANTATION, V72, P1632, DOI 10.1097/00007890-200111270-00009##VAN DER HOEVEN JAB, 2000, ANN SURG, V232, P804, DOI 10.1097/00000658-200012000-00009##VAN DER HOEVEN JAB, 1999, TRANSPLANTATION, V68, P1884, DOI 10.1097/00007890-199912270-00012##YAN SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168",55,2020-11-20,NA
J,WOS:000242106500017,2006,CD4(+) CD25(BRIGHT+) REGULATORY T CELLS CAN MEDIATE DONOR NONREACTIVITY IN LONG-TERM IMMUNOSUPPRESSED KIDNEY ALLOGRAFT PATIENTS,"CD4(+) CD25(BRIGHT+) FOXP3(+) T CELLS ARE POTENT REGULATORS OF T-CELL REACTIVITY, BUT THEIR POSSIBLE INVOLVEMENT IN DONOR-SPECIFIC NONRESPONSIVENESS AFTER CLINICAL KIDNEY TRANSPLANTATION REMAINS TO BE ELUCIDATED. WE ASSESSED THE PROLIFERATIVE DONOR-REACTIVITY IN 33 KIDNEY ALLOGRAFT RECIPIENTS WHO WERE MAINTAINED ON A COMBINATION OF PROLIFERATION INHIBITORS (MYCOPHENOLATE MOFETIL (MMF) OR AZATHIOPRINE (AZA)) AND PREDNISONE, LONG (> 5 YEARS) AFTER TRANSPLANTATION. OF THE 33 PATIENTS, 8 STILL EXHIBITED DONOR-REACTIVITY, WHEREAS 25 WERE CLASSIFIED AS DONOR NONREACTIVE PATIENTS. WITHIN THESE 25 DONOR NONREACTIVE PATIENTS, WE ASSESSED THE INVOLVEMENT OF CD4(+) CD25(BRIGHT+) REGULATORY T CELLS BOTH BY DEPLETING THEM FROM THE RESPONDER POPULATION AS WELL AS BY RECONSTITUTING THEM TO THE CD25(-/DIM) EFFECTOR POPULATION. THE ABSENCE OF PROLIFERATION IN THESE 25 PATIENTS, WAS ABOLISHED IN 7 (28%) RECIPIENTS UPON DEPLETION OF THE CD4(+) CD25(BRIGHT+) T CELLS. RECONSTITUTION OF THESE CELLS SUPPRESSED THE DONOR-REACTIVITY IN A DOSE-DEPENDENT MANNER. ADDING-BACK CD4(+) CD25(BRIGHT+) T CELLS INHIBITED THE ANTI-THIRD PARTY RESPONSE IN ALL RECIPIENTS, INDICATING THAT FUNCTIONAL CD4(+) CD25(BRIGHT+) T CELLS CIRCULATE DESPITE MORE THEN 5 YEARS OF IMMUNOSUPPRESSIVE TREATMENT. ALTOGETHER, WE CONCLUDE THAT IN LONG-TERM IMMUNOSUPPRESSED KIDNEY ALLOGRAFT PATIENTS FUNCTIONAL REGULATORY CD4(+) CD25(BRIGHT+) T CELLS CIRCULATE BUT THAT THESE CELLS MEDIATE DONOR NON REACTIVITY ONLY IN A SUBSET OF PATIENTS.",DEFECTIVE SUPPRESSOR FUNCTION; IMMUNOLOGICAL SELF-TOLERANCE; TRANSPLANT PATIENTS; MYCOPHENOLATE-MOFETIL; LIVER-TRANSPLANTATION; OPERATIONAL TOLERANCE; IMMUNE REGULATION; IN-VIVO; REJECTION; HYPORESPONSIVENESS,IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; REGULATORY T CELLS; TOLERANCE,AMERICAN JOURNAL OF TRANSPLANTATION,"VELTHUIS, JHL##MOL, WM##WEIMAR, W##BAAN, CC","UNIV MED CTR ROTTERDAM, ERASMUS MC, DEPT INTERNAL MED, NL-3015 GD ROTTERDAM, NETHERLANDS.",SURGERY; TRANSPLANTATION,SURGERY; TRANSPLANTATION,"AKL A, 2005, TRANSPL IMMUNOL, V14, P225, DOI 10.1016/J.TRIM.2005.03.011##ALLISON AC, 2000, IMMUNOPHARMACOLOGY, V47, P63, DOI 10.1016/S0162-3109(00)00186-7##ALLISON AC, 2000, IMMUNOPHARMACOLOGY, V47, P85, DOI 10.1016/S0162-3109(00)00188-0##BAAN CC, 2005, TRANSPLANTATION, V80, P110, DOI 10.1097/01.TP.0000164142.98167.4B##BAECHER-ALLAN C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/JIMMUNOL.167.3.1245##BAKER RJ, 2001, J IMMUNOL, V167, P7199, DOI 10.4049/JIMMUNOL.167.12.7199##BATTAGLIA M, 2006, SEMIN IMMUNOL, V18, P120, DOI 10.1016/J.SMIM.2006.01.007##COENEN JJA, 2006, BLOOD, V107, P1018, DOI 10.1182/BLOOD-2005-07-3032##D'CRUZ LM, 2005, NAT IMMUNOL, V6, P1152, DOI 10.1038/NI1264##DE KLEER IM, 2004, J IMMUNOL, V172, P6435, DOI 10.4049/JIMMUNOL.172.10.6435##EHRENSTEIN MR, 2004, J EXP MED, V200, P277, DOI 10.1084/JEM.20040165##FONTENOT JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/NI1263##GAME DS, 2005, AM J TRANSPLANT, V5, P454, DOI 10.1111/J.1600-6143.2005.00758.X##GAME DS, 2003, J AM SOC NEPHROL, V14, P1652, DOI 10.1097/01.ASN.0000067411.03024.A9##GONDEK DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/JIMMUNOL.174.4.1783##GRACA L, 2002, J EXP MED, V195, P1641, DOI 10.1084/JEM.20012097##GREGOOR PJHS, 2000, TRANSPLANTATION, V70, P143##GROSSMAN WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/J.IMMUNI.2004.09.002##HARA M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/JIMMUNOL.166.6.3789##HORNICK PI, 1998, CIRCULATION, V97, P1257, DOI 10.1161/01.CIR.97.13.1257##KINGSLEY CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/JIMMUNOL.168.3.1080##KRIEGEL MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/JEM.20032158##LAKKIS FG, 2003, J AM SOC NEPHROL, V14, P2402, DOI 10.1097/01.ASN.0000085020.78117.70##LI Y, 2004, AM J TRANSPLANT, V4, P2118, DOI 10.1111/J.1600-6143.2004.00611.X##LINDLEY S, 2005, DIABETES, V54, P92, DOI 10.2337/DIABETES.54.1.92##LIU JW, 2004, TRANSPL IMMUNOL, V13, P239, DOI 10.1016/J.TRIM.2004.10.006##MADAKAMUTIL LT, 2003, J IMMUNOL, V170, P2985, DOI 10.4049/JIMMUNOL.170.6.2985##MASON PD, 1996, KIDNEY INT, V50, P1019, DOI 10.1038/KI.1996.404##RODRIGUEZ DS, 2004, AM J TRANSPLANT, V4, P537, DOI 10.1111/J.1600-6143.2004.00385.X##RONCAROLO MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/J.1600-065X.2001.1820105.X##SAKAGUCHI S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/ANNUREV.IMMUNOL.21.120601.141122##SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151##SUCIU-FOCA N, 2003, TRANSPL IMMUNOL, V11, P235, DOI 10.1016/S0966-3274(03)00052-2##VAN BESOUW NM, 2000, TRANSPLANTATION, V70, P136##VAN DER MAST BJ, 2005, TRANSPLANTATION, V80, P1220, DOI 10.1097/01.TP.0000179642.03665.DD##VANBUSKIRK AM, 2000, J CLIN INVEST, V106, P145, DOI 10.1172/JCI9171##WALDMANN H, 2004, SEMIN IMMUNOL, V16, P119, DOI 10.1016/J.SMIM.2003.12.007##WOOD KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/NRI1027##YOSHIZAWA A, 2005, TRANSPLANT P, V37, P37, DOI 10.1016/J.TRANSPROCEED.2004.12.259",50,2020-11-20,NA
J,WOS:000242881600024,2006,SHORT REPORT: ROLE OF VIRUSES IN KENYAN CHILDREN PRESENTING WITH ACUTE ENCEPHALOPATHY IN A MALARIA-ENDEMIC AREA,"IN MALARIA-ENDEMIC AREAS, IT IS DIFFICULT TO DIFFERENTIATE BETWEEN CEREBRAL MALARIA (CM), BACTERIAL MENINGITIS, AND VIRAL ENCEPHALITIS. WE EXAMINED THE CEREBROSPINAL FLUID OF 49 CHILDREN WHO FULFILLED THE WORLD HEALTH ORGANIZATION'S (WHO) DEFINITION OF CM AND IN 47 ENCEPHALOPATHIC CHILDREN, WITHOUT MALARIA, LOOKING FOR VIRUSES WITH POLYMERASE CHAIN REACTION. IN THE CHILDREN WITH CM, FOUR (9%) HAD EVIDENCE OF HERPES SIMPLEX VIRUS 1 IN THE CEREBROSPINAL FLUID, WHEREAS IN THE ENCEPHALOPATHY GROUP WITHOUT MALARIA, SIX (12%) WERE POSITIVE. A SIGNIFICANT PROPORTION OF CHILDREN WHO FULFIL THE WHO CLINICAL DEFINITION OF CM MAY HAVE VIRAL ENCEPHALITIS.",HIGHLY SENSITIVE ASSAY; PCR; QUANTITATION; PLASMA; SERUM; DNA,NA,AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE,"SCHUBART, CD##MTURI, N##BELD, MGHM##WERTHEIM, PM##NEWTON, CRJC","UNIV AMSTERDAM, ACAD MED CTR, DEPT MED MICROBIOL, LAB CLIN VIROL, NL-1105 AZ AMSTERDAM, NETHERLANDS. KENYA GOVT MED RES CTR, CTR GEOG MED RES COAST, KILIFI, KENYA. INST CHILD HLTH, WOLFSON CTR, NEUROSCI UNIT, LONDON, ENGLAND.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; TROPICAL MEDICINE","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; TROPICAL MEDICINE","BEALES PF, 2000, T ROY SOC TROP MED H, V94, PS1##BELD M, 2004, J CLIN MICROBIOL, V42, P3059, DOI 10.1128/JCM.42.7.3059-3064.2004##BERKLEY JA, 2001, LANCET, V357, P1753, DOI 10.1016/S0140-6736(00)04897-2##BOOM R, 1999, J CLIN MICROBIOL, V37, P1489, DOI 10.1128/JCM.37.5.1489-1497.1999##DE JONG MD, 2000, J CLIN MICROBIOL, V38, P2568, DOI 10.1128/JCM.38.7.2568-2573.2000##SNOW RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2##TAYLOR TE, 2004, NAT MED, V10, P143, DOI 10.1038/NM986",13,2020-11-20,WELLCOME TRUSTWELLCOME TRUST [070114] FUNDING SOURCE: MEDLINE
J,WOS:000242542100013,2006,PERFECT SQUARES FROM PUNCTURED SQUARES,NA,NA,NA,AMERICAN MATHEMATICAL MONTHLY,"LOSSERS, OP","EINDHOVEN UNIV TECHNOL, NL-5600 MB EINDHOVEN, NETHERLANDS.",MATHEMATICS,MATHEMATICS,NA,0,2020-11-20,NA
J,WOS:000242126900003,2006,SEXUAL CONFLICT AND THE EVOLUTION OF FEMALE PREFERENCES FOR INDICATORS OF MALE QUALITY,"MALES AND FEMALES HAVE OPPOSING INTERESTS WHEN IT COMES TO THE HONESTY OF SIGNALS USED IN MATE CHOICE. THE EXISTENCE OF THIS SEXUAL CONFLICT HAS LONG BEEN ACKNOWLEDGED, BUT ITS CONSEQUENCES HAVE NOT BEEN FULLY INVESTIGATED. BY APPLYING ADAPTIVE DYNAMICS METHODS AND INDIVIDUAL-BASED COMPUTER SIMULATIONS TO A STANDARD MODEL FOR GOOD-GENES SEXUAL SELECTION, WE SHOW THAT SEXUAL CONFLICT OVER CONDITION-DEPENDENT SIGNALING CAN PREVENT THE HANDICAP PROCESS FROM EVER ATTAINING AN EVOLUTIONARY EQUILIBRIUM. WE OUTLINE THE PARAMETER CONDITIONS AND PROPERTIES OF THE UNDERLYING GENETICS CONDUCIVE TO NONEQUILIBRIUM BEHAVIOR AND DISCUSS THE POTENTIAL OF SUCH BEHAVIOR TO EXPLAIN THE ELABORATION AND FREQUENT PHYLOGENETIC LOSS OF SEXUALLY SELECTED TRAITS. WE ALSO EVALUATE ITS CONSEQUENCES FOR WELL-ESTABLISHED INSIGHTS OF SEXUAL SELECTION THEORY PREVIOUSLY SHOWN TO APPLY WHEN FEMALE MATING PREFERENCE AND MALE ORNAMENT EXPRESSION DO CONVERGE ON STABLE EQUILIBRIUM LEVELS. CONTRARY TO EQUILIBRIUM EXPECTATION, A CONTINUAL CHANGE OF CONDITION-DEPENDENT SIGNALING ENABLES THE EVOLUTION OF A COSTLY PREFERENCE FOR A PURE EPISTATIC INDICATOR AND THE EVOLUTION OF PREFERENCES FOR REDUNDANT SIGNALS OR A LARGE NUMBER OF INDEPENDENT ORNAMENTS. WE THUS CONCLUDE THAT SEEMINGLY GENERAL RESULTS OF SEXUAL SELECTION THEORY, INSOFAR AS THESE ARE BASED ON EQUILIBRIUM CONSIDERATIONS, DO NOT EXTEND TO CASES WHERE NONEQUILIBRIUM BEHAVIOR OCCURS.",MATE PREFERENCES; GENETIC MODELS; SELECTION; FITNESS; SIGNALS; COEVOLUTION; ORNAMENTS; CHOICE,NONEQUILIBRIUM DYNAMICS; MULTIPLE ORNAMENTS; ADAPTIVE DYNAMICS; REVEALING HANDICAP; CONDITION-DEPENDENT HANDICAP,AMERICAN NATURALIST,"VAN DOORN, GS##WEISSING, FJ","UNIV GRONINGEN, CTR ECOL & EVOLUT STUDIES, NL-9751 NN HAREN, NETHERLANDS.",ECOLOGY; EVOLUTIONARY BIOLOGY,ENVIRONMENTAL SCIENCES & ECOLOGY; EVOLUTIONARY BIOLOGY,"ABRAMS PA, 1993, EVOL ECOL, V7, P465, DOI 10.1007/BF01237642##ANDERSSON MALTE, 1994##BARTON NH, 1991, GENETICS, V127, P229##CANDOLIN U, 2003, BIOL REV, V78, P575, DOI 10.1017/S1464793103006158##CASWELL H, 1989, MATRIX POPULATION MO##CLUTTONBROCK TH, 1982, BEHAVIOUR, V79, P108, DOI 10.1163/156853982X00201##CROW J F, 1970, P591##DIECKMANN U, 1996, J MATH BIOL, V34, P579, DOI 10.1007/BF02409751##DOUCET SM, 2003, BEHAV ECOL, V14, P503, DOI 10.1093/BEHECO/ARG035##FISHER R.A., 1930, GENETICAL THEORY NAT##GAVRILETS S, 2000, NATURE, V403, P886, DOI 10.1038/35002564##GERITZ SAH, 1998, EVOL ECOL, V12, P35, DOI 10.1023/A:1006554906681##GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8##HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/SCIENCE.7123238##HILL GE, 1994, ETHOL ECOL EVOL, V6, P351, DOI 10.1080/08927014.1994.9522986##HOFBAUER J, 1998, EVOLUTIONARY GAMES P, PCH9##HOULE D, 2002, P ROY SOC B-BIOL SCI, V269, P97, DOI 10.1098/RSPB.2001.1823##HUISMAN J, 1999, NATURE, V402, P407, DOI 10.1038/46540##IWASA Y, 1994, EVOLUTION, V48, P853, DOI [10.1111/J.1558-5646.1994.TB01367.X, 10.2307/2410492]##IWASA Y, 1991, EVOLUTION, V45, P1431, DOI [10.2307/2409890, 10.1111/J.1558-5646.1991.TB02646.X]##IWASA Y, 1999, J THEOR BIOL, V200, P97, DOI 10.1006/JTBI.1999.0979##IWASA Y, 1995, NATURE, V377, P420, DOI 10.1038/377420A0##JOHNSTONE RA, 1996, PHILOS T R SOC B, V351, P329, DOI 10.1098/RSTB.1996.0026##LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/PNAS.78.6.3721##LEIMAR O, 2001, SELECTION, V2, P65, DOI DOI 10.1556/SELECT.2.2001.1-2.5##LORCH PD, 2003, EVOL ECOL RES, V5, P867##MATESSI C, 1996, J MATH BIOL, V34, P613, DOI 10.1007/BF02409752##MAYNARD SMITH J., 1985, JOURNAL OF THEORETICAL BIOLOGY, V115, P1##MAYNARD SMITH J., 1973, NATURE LONDON, V246, P15##MEAD LS, 2004, TRENDS ECOL EVOL, V19, P264, DOI 10.1016/J.TREE.2004.03.003##METZ JAJ, 1992, TRENDS ECOL EVOL, V7, P198, DOI 10.1016/0169-5347(92)90073-K##MOLLER AP, 1990, ANIM BEHAV, V40, P1185, DOI 10.1016/S0003-3472(05)80187-3##PEN I, 2000, SELECTION, V1, P59, DOI DOI 10.1556/SELECT.1.2000.1-3.11##POMIANKOWSKI A, 1987, PROC R SOC SER B-BIO, V231, P123, DOI 10.1098/RSPB.1987.0038##POMIANKOWSKI A, 1993, P ROY SOC B-BIOL SCI, V253, P173, DOI 10.1098/RSPB.1993.0099##RICE WR, 1996, NATURE, V381, P232, DOI 10.1038/381232A0##SCHLUTER D, 1993, P ROY SOC B-BIOL SCI, V253, P117, DOI 10.1098/RSPB.1993.0089##SMITH JM, 1991, TRENDS ECOL EVOL, V6, P146, DOI 10.1016/0169-5347(91)90055-3##TAYLOR PD, 1996, J MATH BIOL, V34, P654##VAN DOORN GS, 2004, AM NAT, V164, P173, DOI 10.1086/422203##WEISSING FJ, 1996, J MATH BIOL, V34, P533##WIENS JJ, 2001, TRENDS ECOL EVOL, V16, P517, DOI 10.1016/S0169-5347(01)02217-0##ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3",32,2020-11-20,NA
J,WOS:000242603400002,2006,EXPLORING EVOLUTIONARY CONSTRAINTS IS A TASK FOR AN INTEGRATIVE EVOLUTIONARY BIOLOGY,"JUDGING BY THE VOLUME OF WRITINGS ABOUT EVOLUTIONARY CONSTRAINTS, THEY ARE AN IMPORTANT TOPIC IN EVOLUTIONARY BIOLOGY. HOWEVER, THEIR INVOLVEMENT IN SHAPING PATTERNS OF EVOLUTIONARY CHANGE FROM MORPHOLOGICAL STASIS TO ADAPTIVE RADIATION REMAINS CONTENTIOUS. THIS IS AT LEAST IN PART BECAUSE OF THE PAUCITY OF ROBUST ANALYSES OF POTENTIAL EXAMPLES OF CONSTRAINTS, WHETHER OF A MORE ABSOLUTE OR A RELATIVE NATURE. HERE, WE ARGUE THAT WHAT IS NEEDED TO EXPLORE THE TYPE OF CONSTRAINTS AND BIAS ON EVOLUTIONARY CHANGE THAT MAY EMERGE FROM THE WAY IN WHICH PHENOTYPIC VARIATION IS GENERATED IS AN INTEGRATIVE APPROACH APPLIED TO SYSTEMS THAT CAN BE TACKLED AT DIFFERENT LEVELS OF BIOLOGICAL ORGANIZATION. THIS IS ILLUSTRATED USING RESEARCH ON THE EVOLUTION OF PATTERNS IN BUTTERFLY WING EYESPOTS THAT HAS APPLIED A COMBINATION OF EVOLUTIONARY GENETICS AND EVO-DEVO TO AN EMERGING MODEL SPECIES WITH THE BEGINNINGS OF A COMPARATIVE APPROACH TO DESCRIBE PATTERNS OF VARIABILITY AMONG THE EXTANT TAXA OF TWO SPECIES-RICH GENERA.",BUTTERFLY BICYCLUS-ANYNANA; EVO-DEVO; WING PATTERNS; EYESPOT PATTERNS; DEVELOPMENTAL CONSTRAINTS; NATURAL-SELECTION; GENETICS; CONVERGENCE; LEPIDOPTERA; ADAPTATION,BUTTERFLY EYESPOTS; DEVELOPMENTAL BIAS; NATURAL SELECTION; MORPHOSPACE,AMERICAN NATURALIST,"BRAKEFIELD, PM##ROSKAM, JC","LEIDEN UNIV, INST BIOL, NL-2300 RA LEIDEN, NETHERLANDS.",ECOLOGY; EVOLUTIONARY BIOLOGY,ENVIRONMENTAL SCIENCES & ECOLOGY; EVOLUTIONARY BIOLOGY,"ALBERTSON RC, 2006, HEREDITY, V97, P211, DOI 10.1038/SJ.HDY.6800864##ANTONOVICS J, 1991, TRENDS ECOL EVOL, V6, P166, DOI 10.1016/0169-5347(91)90059-7##ARBESMAN S, 2003, BIOSYSTEMS, V71, P289, DOI 10.1016/S0303-2647(03)00086-8##BELDADE P, 2005, EVOL DEV, V7, P101, DOI 10.1111/J.1525-142X.2005.05011.X##BELDADE P, 2002, NATURE, V415, P315, DOI 10.1038/415315A##BELDADE P, 2003, EVOL DEV, V5, P169, DOI 10.1046/J.1525-142X.2003.03025.X##BELDADE P, 2003, EVOL DEV, V5, P119, DOI 10.1046/J.1525-142X.2003.03018.X##BELDADE P, 2002, NATURE, V416, P844, DOI 10.1038/416844A##BELDADE P, 2002, NAT REV GENET, V3, P442, DOI 10.1038/NRG818##BELDADE P, 2002, P NATL ACAD SCI USA, V99, P14262, DOI 10.1073/PNAS.222236199##BLOWS MW, 2005, ECOLOGY, V86, P1371, DOI 10.1890/04-1209##BRAKEFIELD PM, 2006, TRENDS ECOL EVOL, V21, P362, DOI 10.1016/J.TREE.2006.05.001##BRAKEFIELD PM, 1998, HEREDITY, V80, P265, DOI 10.1046/J.1365-2540.1998.00366.X##BRAKEFIELD PM, 1996, NATURE, V384, P236, DOI 10.1038/384236A0##BRAKEFIELD PM, 2003, ANNU REV ECOL EVOL S, V34, P633, DOI 10.1146/ANNUREV.ECOLSYS.34.011802.132425##BRAKEFIELD PM, 2003, ZOOLOGY, V106, P283, DOI 10.1078/0944-2006-00124##BRAKEFIELD PM, 2006, PHENOTYPIC PLASTICIT, P121##BREUKER CJ, 2002, P ROY SOC B-BIOL SCI, V269, P1233, DOI 10.1098/RSPB.2002.2005##BRUNETTI CR, 2001, CURR BIOL, V11, P1578, DOI 10.1016/S0960-9822(01)00502-4##CONDAMIN M., 1973, MONOGRAPHIE GENRE BI##COOPER TF, 2003, P NATL ACAD SCI USA, V100, P1072, DOI 10.1073/PNAS.0334340100##ELDREDGE N, 2005, PALEOBIOLOGY, V31, P133, DOI 10.1666/0094-8373(2005)031[0133:TDOES]2.0.CO;2##ELENA SF, 2003, NAT REV GENET, V4, P457, DOI 10.1038/NRG1088##FISCHER K, 2006, J EVOLUTION BIOL, V19, P380, DOI 10.1111/J.1420-9101.2005.01046.X##FRANKINO WA, 2005, SCIENCE, V307, P718, DOI 10.1126/SCIENCE.1105409##FRANKINO WA, 2006, IN PRESS EVOLUTION##FRENCH V, 1995, DEV BIOL, V168, P112, DOI 10.1006/DBIO.1995.1065##FRYER G., 1972, CICHLID FISHES GREAT##FULLER RC, 2005, INTEGR COMP BIOL, V45, P391, DOI 10.1093/ICB/45.3.391##GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/RSPB.1979.0086##GOULD STEPHEN J, 2002, STRUCTURE EVOLUTIONA##GRANT PR, 2002, SCIENCE, V296, P707, DOI 10.1126/SCIENCE.1070315##HARMON LJ, 2005, EVOLUTION, V59, P409##JORON M, 2003, NATURE, V424, P191, DOI 10.1038/NATURE01713##KANGAS AT, 2004, NATURE, V432, P211, DOI 10.1038/NATURE02927##KOCHER TD, 1993, MOL PHYLOGENET EVOL, V2, P158, DOI 10.1006/MPEV.1993.1016##LOSOS JB, 2004, NATURE, V432, P505, DOI 10.1038/NATURE03039##LYYTINEN A, 2004, P ROY SOC B-BIOL SCI, V271, P279, DOI 10.1098/RSPB.2003.2571##LYYTINEN A, 2003, OIKOS, V100, P373, DOI 10.1034/J.1600-0706.2003.11935.X##MONTEIRO A, 2001, MOL PHYLOGENET EVOL, V18, P264, DOI 10.1006/MPEV.2000.0872##MONTEIRO A, 1997, EVOLUTION, V51, P1207, DOI 10.1111/J.1558-5646.1997.TB03968.X##MONTEIRO A, 2003, EVOL DEV, V5, P180, DOI 10.1046/J.1525-142X.2003.03029.X##MONTEIRO A, 1997, GENETICS, V146, P287##MONTEIRO AF, 1994, EVOLUTION, V48, P1147, DOI [10.2307/2410374, 10.1111/J.1558-5646.1994.TB05301.X]##REED RD, 2004, CURR BIOL, V14, P1159, DOI 10.1016/J.CUB.2004.06.046##ROBERTSON KA, 2005, P ROY SOC B-BIOL SCI, V272, P1541, DOI 10.1098/RSPB.2005.3142##ROSKAM JC, 1999, BIOL J LINN SOC, V66, P345, DOI 10.1111/J.1095-8312.1999.TB01895.X##SALAZAR-CIUDAD I, 2002, P NATL ACAD SCI USA, V99, P8116, DOI 10.1073/PNAS.132069499##SALZBURGER W, 2004, NATURWISSENSCHAFTEN, V91, P277, DOI 10.1007/S00114-004-0528-6##SCHLICHTING C.D., 1998, PHENOTYPIC EVOLUTION##SCHLUTER D, 1996, EVOLUTION, V50, P1766, DOI 10.1111/J.1558-5646.1996.TB03563.X##SCHLUTER D., 2000, ECOLOGY ADAPTIVE RAD, P296##SCHWENK KURT, 1995, ZOOLOGY (JENA), V98, P251##SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425##STEARNS S.C., 2002, EVOLUTION, V56, P2339##TEMELES EJ, 2003, SCIENCE, V300, P630, DOI 10.1126/SCIENCE.1080003##WIJNGAARDEN PJ, 2002, J EVOLUTION BIOL, V15, P290, DOI 10.1046/J.1420-9101.2002.00380.X##ZIJLSTRA WG, 2004, AM NAT, V163, PE76, DOI 10.1086/383595##ZIJLSTRA WG, 2002, EVOL ECOL RES, V4, P1229",34,2020-11-20,NA
J,WOS:000242914200001,2006,"EFFECT OF NON-INVASIVE VENTILATION ON SURVIVAL, QUALITY OF LIFE, RESPIRATORY FUNCTION AND COGNITION: A REVIEW OF THE LITERATURE","SYMPTOMS OF NOCTURNAL HYPOVENTILATION MAY NEGATIVELY INFLUENCE THE QUALITY OF LIFE (QOL) OF ALS PATIENTS LONG BEFORE RESPIRATORY FAILURE ENSUES. NON-INVASIVE MECHANICAL VENTILATION (NIV) IS CONSIDERED A TREATMENT OPTION FOR NOCTURNAL HYPOVENTILATION. THE PRIMARY OBJECTIVE OF NIV IS IMPROVING QUALITY OF LIFE (QOL). IT MAY ALSO PROLONG LIFE BY SEVERAL MONTHS. A SYSTEMATIC REVIEW OF THE LITERATURE WAS PERFORMED TO ANALYSE WHAT IS KNOWN OF THE EFFECT OF NIV ON SURVIVAL, QOL AND OTHER OUTCOME MEASURES. A COMPUTERIZED LITERATURE SEARCH WAS PERFORMED TO IDENTIFY CONTROLLED CLINICAL TRIALS AND OBSERVATIONAL STUDIES OF TREATMENT OF ALS-ASSOCIATED NOCTURNAL HYPOVENTILATION. FROM 1985 UNTIL MAY 2005. TWELVE STUDIES FULFILLED THE INCLUSION CRITERIA. FOUR STUDIES WERE RETROSPECTIVE, SEVEN PROSPECTIVE AND IN ONE STUDY RANDOMIZATION WAS USED. ALL STUDIES REPORTED BENEFICIAL EFFECTS OF NIV ON ALL OUTCOME MEASURES. IN SEVEN STUDIES NIV WAS ASSOCIATED WITH PROLONGED SURVIVAL IN PATIENTS TOLERANT FOR NIV, AND FIVE STUDIES REPORTED AN IMPROVED QOL. IN CONCLUSION, STUDIES ON THE USE OF NIV IN ALS DIFFER IN STUDY DESIGN AND ENDPOINT DEFINITIONS. ALL STUDIES SUGGEST A BENEFICIAL EFFECT ON QOL AND OTHER OUTCOME MEASURES (EVIDENCE LEVEL CLASS II-III). WELL-DESIGNED RANDOMIZED CONTROLLED TRIALS COMPARING THE EFFECT ON QOL AND SURVIVAL HAVE NOT BEEN PERFORMED.",AMYOTROPHIC-LATERAL-SCLEROSIS; POSITIVE-PRESSURE VENTILATION; MECHANICAL VENTILATION; PRACTICE PARAMETER; PULMONARY-FUNCTION; HOME VENTILATION; ALS PATIENTS; PATIENT; POPULATION; MANAGEMENT,AMYOTROPHIC LATERAL SCLEROSIS; NON-INVASIVE VENTILATION; QUALITY OF LIFE,AMYOTROPHIC LATERAL SCLEROSIS,"PIEPERS, S##VAN DEN BERG, JP##KALMIJN, S##VAN DER POL, WL##WOKKE, JHJ##LINDEMAN, E##VAN DEN BERG, LH","UNIV UTRECHT, MED CTR, DEPT NEUROL, RUDOLF MAGNUS INST NEUROSCI, UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT REHABIL, RUDOLF MAGNUS INST NEUROSCI, UTRECHT, NETHERLANDS. ST ELIZABETH HOSP, MEANDER MED CTR, DEPT REHABIL, AMERSFOORT, NETHERLANDS. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS.",CLINICAL NEUROLOGY,NEUROSCIENCES & NEUROLOGY,"ABOUSSOUAN LS, 2001, MUSCLE NERVE, V24, P403, DOI 10.1002/1097-4598(200103)24:3<403::AID-MUS1013>3.3.CO;2-V##ABOUSSOUAN LS, 1997, ANN INTERN MED, V127, P450, DOI 10.7326/0003-4819-127-6-199709150-00006##ALBERT SM, 1999, NEUROLOGY, V53, P278, DOI 10.1212/WNL.53.2.278##BACH JR, 2002, CHEST, V122, P92, DOI 10.1378/CHEST.122.1.92##BORASIO GD, 1998, J NEUROL, V245, P717, DOI 10.1007/S004150050273##BOURKE SC, 2003, NEUROLOGY, V61, P171, DOI 10.1212/01.WNL.0000076182.13137.38##BRADLEY WG, 2004, AMYOTROPH LATERAL SC, V5, P240, DOI 10.1080/14660820410021249##BUHR-SCHINNER H, 1999, MED KLIN, V94, P102##CAZZOLLI PA, 1996, J NEUROL SCI, V139, P123, DOI 10.1016/0022-510X(96)00099-8##CHANCELLOR AM, 1992, J NEUROL NEUROSUR PS, V55, P1106, DOI 10.1136/JNNP.55.12.1106##DAVID WS, 1997, J NEUROL SCI, V152, PS29, DOI 10.1016/S0022-510X(97)00241-4##DEL AGUILA MA, 2003, NEUROLOGY, V60, P813, DOI 10.1212/01.WNL.0000049472.47709.3B##HARDIMAN O, 2000, J NEUROL, V247, P245, DOI 10.1007/S004150050578##HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/BRAIN/118.3.707##JACKSON CE, 2001, J NEUROL SCI, V191, P75, DOI 10.1016/S0022-510X(01)00617-7##KLEOPA KA, 1999, J NEUROL SCI, V164, P82, DOI 10.1016/S0022-510X(99)00045-3##LECHTZIN N, 2001, NEW ENGL J MED, V344, P533, DOI 10.1056/NEJM200102153440718##LYALL RA, 2001, NEUROLOGY, V57, P153, DOI 10.1212/WNL.57.1.153##MILLER RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311##MILLER RG, 2001, AMYOTROPH LATERAL SC, V2, P3, DOI 10.1080/146608201300079355##MITSUMOTO H, 1999, NEUROLOGY, V53, P248, DOI 10.1212/WNL.53.2.248##MOSS AH, 1993, NEUROLOGY, V43, P438, DOI 10.1212/WNL.43.2.438##NEWSOM-DAVIS IC, 2001, J NEUROL NEUROSUR PS, V71, P482, DOI 10.1136/JNNP.71.4.482##OPPENHEIMER EDWARD ANTHONY, 1993, PALLIATIVE MEDICINE, V7, P49##PINTO AC, 1995, J NEUROL SCI, V129, P19, DOI 10.1016/0022-510X(95)00052-4##SIVAK ED, 2001, AMYOTROPH LATERAL SC, V2, P139, DOI 10.1080/146608201753275724##TANDAN R, 1985, ANN NEUROL, V18, P271, DOI 10.1002/ANA.410180302##WINTERHOLLER MGM, 2001, NERVENARZT, V72, P293, DOI 10.1007/S001150050753",25,2020-11-20,NA
J,WOS:000243261100014,2006,ULTRASOUND-GUIDED BILATERAL CONTINUOUS SCIATIC NERVE BLOCKS WITH STIMULATING CATHETERS FOR POSTOPERATIVE PAIN RELIEF AFTER BILATERAL LOWER LIMB AMPUTATIONS,THE PERFORMANCE OF CONTINUOUS BILATERAL SCIATIC NERVE BLOCKS UNDER ULTRASONOGRAPHIC CONTROL USING STIMULATING CATHETERS IS DESCRIBED IN A 4-YEAR-OLD CHILD WITH VACTERL SYNDROME. ULTRASOUND SHOWED AN ABNORMAL VASCULAR AND NERVE SUPPLY TO THE LOWER LIMBS. THE USE OF ULTRASOUND GUIDANCE MADE SUCCESSFUL CONTINUOUS SCIATIC NERVE BLOCKS POSSIBLE IN A CHILD IN WHOM THE TRADITIONAL METHOD OF NERVE LOCALISATION WAS UNLIKELY TO SUCCEED FOR ANATOMICAL REASONS.,REGIONAL ANESTHESIA; CHILDREN; GUIDANCE; DEFECTS,NA,ANAESTHESIA,"VAN GEFFEN, GJ##SCHEUER, M##MULLER, A##GARDERNIERS, J##GIELEN, M","RADBOUD UNIV MED CTR, DEPT ANAESTHESIOL, NIJMEGEN, NETHERLANDS. RADBOUD UNIV MED CTR, DEPT ORTHOPAED SURG, NIJMEGEN, NETHERLANDS.",ANESTHESIOLOGY,ANESTHESIOLOGY,"CASATI A, 2005, ANESTH ANALG, V101, P1192, DOI 10.1213/01.ANE.0000167232.10305.CD##DADURE C, 2005, BEST PRACT RES-CLIN, V19, P309, DOI 10.1016/J.BPA.2004.11.001##EVANS JA, 1994, AM J MED GENET, V49, P52, DOI 10.1002/AJMG.1320490111##GIAUFRE E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003##GRAY AT, 2003, ANESTH ANALG, V97, P1300, DOI 10.1213/01.ANE.0000086726.00205.30##MARHOFER P, 2005, BRIT J ANAESTH, V94, P7, DOI 10.1093/BJA/AEI002##MARHOFER P, 2004, ANAESTHESIA, V59, P642, DOI 10.1111/J.1365-2044.2004.03669.X##MARTINEZ-FRIAS ML, 1999, AM J MED GENET, V83, P13, DOI 10.1002/(SICI)1096-8628(19990305)83:1<13::AID-AJMG4>3.0.CO;2-X##RAPP HJ, 2004, TECHNIQUES REGIONAL, V8, P179##SCHAFHALTER-ZOPPOTH I, 2004, REGION ANESTH PAIN M, V29, P297, DOI 10.1016/J.RAPM.2003.12.002##SCHWEMMER U, 2004, PEDIATR ANESTH, V14, P1005, DOI 10.1111/J.1460-9592.2004.01372.X##VAN GEFFEN GJ, 2006, ANESTH ANALG, V103, P328, DOI 10.1213/01.ANE.0000221452.72892.2C##VAN GEFFEN GJ, 2006, PEDIATR ANESTH, V16, P330, DOI 10.1111/J.1460-9592.2005.01691.X##VAS L, 2005, PEDIATR ANESTH, V15, P971, DOI 10.1111/J.1460-9592.2005.01620.X##WILLSCHKE H, 2005, BRIT J ANAESTH, V95, P226, DOI 10.1093/BJA/AEI157##WOLFGANG GL, 1984, J BONE JOINT SURG AM, V66A, P453, DOI 10.2106/00004623-198466030-00021",13,2020-11-20,NA
J,WOS:000242144200041,2006,"DEVELOPMENT AND CHARACTERIZATION OF AN INTEGRATED SILICON MICRO FLOW CYTOMETER (VOL 386, PG 2257, 2006)",NA,NA,NA,ANALYTICAL AND BIOANALYTICAL CHEMISTRY,"BERNINI, R##DE NUCCIO, E##BRESCIA, F##MINARDO, A##ZENI, L##SARRO, PM##PALUMBO, R##SCARFI, MR","IREA CNR, I-80124 NAPLES, ITALY. SECONDA UNIV NAPOLI, I-81031 AVERSA, ITALY. DELFT UNIV TECHNOL, ECTM DIMES, NL-2600 GB DELFT, NETHERLANDS. IBB CNR, NAPLES, ITALY.","BIOCHEMICAL RESEARCH METHODS; CHEMISTRY, ANALYTICAL",BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY,"BERNINI R, 2006, ANAL BIOANAL CHEM, V386, P2257, DOI 10.1007/S00216-006-0933-0",2,2020-11-20,NA
J,WOS:000242405300040,2006,DETERMINATION OF PEROXIDE-BASED EXPLOSIVES USING LIQUID CHROMATOGRAPHY WITH ON-LINE INFRARED DETECTION,"A NONDESTRUCTIVE ANALYTICAL METHOD FOR PEROXIDE-BASED EXPLOSIVES DETERMINATION IN SOLID SAMPLES IS DESCRIBED. REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY IN COMBINATION WITH ON-LINE FOURIER TRANSFORM INFRARED (FT-IR) DETECTION IS USED FOR THE ANALYSIS OF TRIACETONETRIPEROXIDE (TATP) AND HEXAMETHYLENETRIPEROXIDE DIAMINE ( HMTD). IN CONTRAST TO OTHER LIQUID CHROMATOGRAPHIC METHODS WITH OPTICAL DETECTION, NO DERIVATIZATION OR DECOMPOSITION OF THE PEROXIDES IS REQUIRED. THE PEROXIDES ARE IDENTIFIED AND QUANTIFIED VIA THEIR CHARACTERISTIC ABSORPTION SPECTRA IN THE MID-INFRARED RANGE OF THE ELECTROMAGNETIC SPECTRUM. THE DETECTION LIMIT OF 0.5 MMOL L-1 FOR HMTD AND 1 MMOL L-1 FOR TATP ALLOWS THE IDENTIFICATION OF THE EXPLOSIVES IN COMPLEX MATRIXES.",TRIACETONE TRIPEROXIDE TATP; TRACE ANALYSIS; LC/MS METHOD; IDENTIFICATION; SPECTROMETRY; LINE; HPLC,NA,ANALYTICAL CHEMISTRY,"SCHULTE-LADBECK, R##EDELMANN, A##QUINTAS, G##LENDL, B##KARST, U","VIENNA UNIV TECHNOL, INST CHEM TECHNOL & ANALYT, A-1060 VIENNA, AUSTRIA. UNIV TWENTE, CHEM ANAL GRP, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV TWENTE, MESA INST NANOTECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV MUNSTER, INST INORGAN & ANALYT CHEM, D-48149 MUNSTER, GERMANY.","CHEMISTRY, ANALYTICAL",CHEMISTRY,"BAYER A, 1900, CHEM BER, V33, P2479##BELLAMY AJ, 1999, J FORENSIC SCI, V44, P603##BISHOP RT, 1996, ANAL CHEM, V68, P4006, DOI 10.1021/AC960295S##BUTTIGIEG GA, 2003, FORENSIC SCI INT, V135, P53, DOI 10.1016/S0379-0738(03)00175-0##COOPER RT, 2001, LOS ANGELES TIM 1229, PA12##COTTE-RODRIGUEZ I, 2006, CHEM COMMUN, P953, DOI 10.1039/B515122H##CROWSON A, 2001, ANALYST, V126, P1689, DOI 10.1039/B107354K##DUBNIKOVA F, 2002, J PHYS CHEM A, V106, P4951, DOI 10.1021/JP014189S##EDELMANN A, 2001, J CHROMATOGR A, V934, P123, DOI 10.1016/S0021-9673(01)01288-2##ENDELMANN A, 2003, ANAL BIOANAL CHEM, V376, P92, DOI 10.1007/S00216-003-1879-0##EVANS HK, 1986, J FORENSIC SCI, V31, P1119##GIELSDORF W, 1981, FRESEN Z ANAL CHEM, V308, P123, DOI 10.1007/BF00469440##GMACHL C, 1999, SCIENCE, V286, P749, DOI 10.1126/SCIENCE.286.5440.749##GROTH P, 1969, ACTA CHEM SCAND, V23, P1311, DOI 10.3891/ACTA.CHEM.SCAND.23-1311##KOK SJ, 2003, J CHROMATOGR A, V1017, P83, DOI 10.1016/J.CHROMA.2003.08.026##LEGLER L, 1881, CHEM BER, V14, P602##MARR A.J., 2003, INT J ION MOBIL SPEC, V6, P59##MULLER D, 2004, J FORENSIC SCI, V49, P935##SCHAEFER WP, 1985, J AM CHEM SOC, V107, P2461, DOI 10.1021/JA00294A043##SCHULTE-LADBECK R, 2003, ANAL CHEM, V75, P731, DOI 10.1021/AC020392N##SCHULTE-LADBECK R, 2002, ANALYST, V127, P1152, DOI 10.1039/B206673B##SOMSEN GW, 1999, J CHROMATOGR A, V856, P213, DOI 10.1016/S0021-9673(99)00280-0##SOMSEN GW, 1996, ANALYST, V121, P1069, DOI 10.1039/AN9962101069##SOMSEN GW, 1994, ANAL CHIM ACTA, V290, P269, DOI 10.1016/0003-2670(94)80113-4##SOMSEN GW, 1996, S HYPH TECHN CHROM B##STAMBOULI A, 2004, FORENSIC SCI INT, V146, PS191, DOI 10.1016/J.FORSCIINT.2004.09.060##SULZLE D, 1988, ACTA CHEM SCAND A, V42, P165, DOI 10.3891/ACTA.CHEM.SCAND.42A-0165##SUROWIEC I, 2005, J CHROMATOGR A, V1080, P132, DOI 10.1016/J.CHROMA.2005.04.082##TODD MW, 2002, APPL PHYS B-LASERS O, V75, P367, DOI 10.1007/S00340-002-0991-8##TURULA VE, 1994, APPL SPECTROSC, V48, P1255, DOI 10.1366/0003702944027390##VONACH R, 1998, J CHROMATOGR A, V824, P159, DOI 10.1016/S0021-9673(98)00570-6##VONACH R, 1997, ANAL CHEM, V69, P4286, DOI 10.1021/AC970307P##VONGRISEWALD C, 1921, CHEM BER, V54, P490##WHITE GM, 1992, J FORENSIC SCI, V37, P652##WIDMER L, 2002, ANALYST, V127, P1627, DOI 10.1039/B208350G##WOLFFENSTEIN R, 1895, CHEM BER, V28, P2265##XU XM, 2004, J FORENSIC SCI, V49, P1230##ZITRIN S, 1984, P INT S AN DET EXPL, P137##1996, INDEPENDENT   1008, P7",56,2020-11-20,NA
J,WOS:000242476600006,2006,EPICARDIUM-DERIVED CELLS ARE IMPORTANT FOR CORRECT DEVELOPMENT OF THE PURKINJE FIBERS IN THE AVIAN HEART,"DURING EMBRYONIC DEVELOPMENT, THE PROEPICARDIAL ORGAN (PEO) GROWS OUT OVER THE HEART SURFACE TO FORM THE EPICARDIUM. FOLLOWING EPITHELIAL-MESENCHYMAL TRANSFORMATION, EPICARDIUM-DERIVED CELLS (EPDCS) MIGRATE INTO THE HEART AND CONTRIBUTE TO THE DEVELOPING CORONARY ARTERIES, TO THE VALVES, AND TO THE MYOCARDIUM. THE PERIPHERAL PURKINJE FIBER NETWORK DEVELOPS FROM DIFFERENTIATING CARDIOMYOCYTES IN THE VENTRICULAR MYOCARDIUM. INTRIGUED BY THE CLOSE SPATIAL RELATIONSHIP BETWEEN THE FINAL DESTINATIONS OF MIGRATING EPDCS AND PURKINJE FIBER DIFFERENTIATION IN THE AVIAN HEART, THAT IS, SURROUNDING THE CORONARY ARTERIES AND AT SUBENDOCARDIAL SITES, WE INVESTIGATED WHETHER INHIBITION OF EPICARDIAL OUTGROWTH WOULD DISTURB CARDIOMYOCYTE DIFFERENTIATION INTO PURKINJE FIBERS. TO THIS END, EPICARDIAL DEVELOPMENT WAS INHIBITED MECHANICALLY WITH A MEMBRANE, OR GENETICALLY, BY SUPPRESSING EPICARDIAL EPITHELIAL-TO-MESENCHYMAL TRANSFORMATION WITH ANTISENSE RETROVIRAL VECTORS AFFECTING ETS TRANSCRIPTION FACTOR LEVELS (N = 4, HH39-41). IN BOTH EPICARDIAL INHIBITION MODELS, WE EVALUATED PURKINJE FIBER DEVELOPMENT BY EAP-300 IMMUNOHISTOCHEMISTRY AND FOUND THAT RESTRAINTS ON EPDC DEVELOPMENT RESULTED IN MORPHOLOGICALLY ABERRANT DIFFERENTIATION OF PURKINJE FIBERS. PURKINJE FIBER HYPOPLASIA WAS OBSERVED BOTH PERIARTERIALLY AND AT SUBENDOCARDIAL POSITIONS. FURTHERMORE, THE CELLS WERE MORPHOLOGICALLY ABNORMAL AND NOT ALIGNED IN ORDERLY PURKINJE FIBERS. WE CONCLUDE THAT EPDCS ARE INSTRUMENTAL IN PURKINJE FIBER DIFFERENTIATION, AND WE HYPOTHESIZE THAT THEY COOPERATE DIRECTLY WITH ENDOTHELIAL AND ENDOCARDIAL CELLS IN THE DEVELOPMENT OF THE PERIPHERAL CONDUCTION SYSTEM.",ENDOTHELIN-CONVERTING ENZYME-1; CARDIAC CONDUCTION SYSTEM; OUTFLOW TRACT; TRANSCRIPTION FACTORS; EMBRYONIC HEART; CHICK-EMBRYOS; NEURAL CREST; MUSCLE-CELLS; CORONARY; DIFFERENTIATION,HEART; EMBRYO; EPICARDIUM; CONDUCTION SYSTEM,ANATOMICAL RECORD PART A-DISCOVERIES IN MOLECULAR CELLULAR AND EVOLUTIONARY BIOLOGY,"ERALP, I##LIE-VENEMA, H##BAX, NAM##WIJFFELS, MCEF##VAN DER LAARSE, A##DERUITER, MC##BOGERS, AJJC##VAN DEN AKKER, NMS##GOURDIE, RG##SCHALIJ, MJ##POELMANN, RE##GITTENBERGER-DE GROOT, AC","LEIDEN UNIV, MED CTR, DEPT ANAT & EMBRYOL, NL-2300 RC LEIDEN, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT CARDIOTHORAC SURG, NL-3000 DR ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT CARDIOL, NL-2300 RC LEIDEN, NETHERLANDS. MED UNIV S CAROLINA, DEPT CELL BIOL & ANAT, CHARLESTON, SC 29425 USA.",ANATOMY & MORPHOLOGY,ANATOMY & MORPHOLOGY,"CHENG G, 2002, DEV DYNAM, V223, P119, DOI 10.1002/DVDY.1244##DEGROOT ACG, 2003, NOVART FDN SYMP, V250, P125##EID H, 1994, J CARDIOVASC PHARM, V24, P715, DOI 10.1097/00005344-199424050-00005##ERALP I, 2005, CIRC RES, V96, P526, DOI 10.1161/01.RES.0000158965.34647.4E##GITTENBERGER-DE GROOT AC, 2000, CIRC RES, V87, P969, DOI 10.1161/01.RES.87.11.969##GITTENBERGER-DE GROOT AC, 1998, CIRC RES, V82, P1043, DOI 10.1161/01.RES.82.10.1043##GITTENBERGER-DE GROT AC, 2003, ANAT REC PART A, V275A, P1109, DOI 10.1002/AR.A.10126##GOURDIE RG, 1998, P NATL ACAD SCI USA, V95, P6815, DOI 10.1073/PNAS.95.12.6815##GOURDIE RG, 1995, DEVELOPMENT, V121, P1423##GOURDIE ROBERT G, 2003, NOVARTIS FOUND SYMP, V250, P110##HALL CE, 2004, DEVELOPMENT, V131, P581, DOI 10.1242/DEV.00947##HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/JMOR.1050880104##HYER J, 1999, P NATL ACAD SCI USA, V96, P13214, DOI 10.1073/PNAS.96.23.13214##KWEE L, 1995, DEVELOPMENT, V121, P489##LIE-VENEMA H, 2005, ANAT REC PART A, V282A, P120, DOI 10.1002/AR.A.20154##LIE-VENEMA H, 2003, CIRC RES, V92, P749, DOI 10.1161/01.RES.0000066662.70010.DB##MANNER J, 1993, ANAT EMBRYOL, V187, P281##MCCABE CF, 1995, DEV DYNAM, V203, P51, DOI 10.1002/AJA.1002030106##NAHIRNEY PC, 2003, DEV DYNAM, V227, P511, DOI 10.1002/DVDY.10335##PEETERS MPFMV, 1999, ANAT EMBRYOL, V199, P367, DOI 10.1007/S004290050235##PEETERS MPFMV, 1997, DEV DYNAM, V208, P338, DOI 10.1002/(SICI)1097-0177(199703)208:3<338::AID-AJA5>3.0.CO;2-J##POELMANN RE, 1993, CIRC RES, V73, P559, DOI 10.1161/01.RES.73.3.559##POELMANN RE, 1998, DEV DYNAM, V212, P373, DOI 10.1002/(SICI)1097-0177(199807)212:3<373::AID-AJA5>3.3.CO;2-T##RECKOVA M, 2003, CIRC RES, V93, P77, DOI 10.1161/01.RES.0000079488.91342.B7##ROTHENBERG F, 2002, DEV DYNAM, V223, P469, DOI 10.1002/DVDY.10077##TAKEBAYASHI-SUZUKI K, 2000, DEVELOPMENT, V127, P3523##TEVOSIAN SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5##VIRAGH S, 1993, ANAT EMBRYOL, V188, P381##WATANABE M, 1998, DEVELOPMENT, V125, P3809##YANG JT, 1995, DEVELOPMENT, V121, P549",36,2020-11-20,"NHLBI NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL HEART LUNG & BLOOD INSTITUTE (NHLBI) [R01 HL056728, HL56728-09] FUNDING SOURCE: MEDLINE; NICHD NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [HD39946-05, P01 HD039946, P01 HD039946-05] FUNDING SOURCE: MEDLINE; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946, P01HD039946] FUNDING SOURCE: NIH REPORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL HEART LUNG & BLOOD INSTITUTE (NHLBI) [R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728, R01HL056728] FUNDING SOURCE: NIH REPORTER"
J,WOS:000242289100047,2006,"PREDICTIVE PERFORMANCE OF THREE MULTIVARIATE DIFFICULT TRACHEAL INTUBATION MODELS: A DOUBLE-BLIND, CASE-CONTROL STUDY",NA,NA,NA,ANESTHESIA AND ANALGESIA,"VAN KLEI, WA##KALKMAN, CJ##MOONS, KGM","OTTAWA GEN HOSP, DEPT ANESTHESIA, OTTAWA, ON K1H 8L6, CANADA. UNIV UTRECHT, MED CTR, DEPT PERIOPERAT CARE & EMERGENCY MED, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 TA UTRECHT, NETHERLANDS.",ANESTHESIOLOGY,ANESTHESIOLOGY,"DEL SOL AI, 2001, STROKE, V32, P1532, DOI 10.1161/01.STR.32.7.1532##MOONS KGM, 2003, ANESTH ANALG, V96, P1843, DOI 10.1213/01.ANE.0000063178.15467.D8##NAGUIB M, 2006, ANESTH ANALG, V102, P818, DOI 10.1213/01.ANE.0000196507.19771.B2##ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY##SHIGA T, 2005, ANESTHESIOLOGY, V103, P429, DOI 10.1097/00000542-200508000-00027##VAN KLEI WA, 2003, EUR J ANAESTH, V20, P612, DOI 10.1097/00003643-200308000-00004",1,2020-11-20,NA
J,WOS:000242470800012,2006,PHARMACOKINETICS AND PHARMACODYNAMICS OF MIDAZOLAM AND METABOLITES IN NONVENTILATED INFANTS AFTER CRANIOFACIAL SURGERY,"BACKGROUND: BECAUSE INFORMATION ON THE OPTIMAL DOSE OF MIDAZOLAM FOR SEDATION OF NONVENTILATED INFANTS AFTER MAJOR SURGERY IS SCANT, A POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODEL IS DEVELOPED FOR THIS SPECIFIC GROUP. METHODS: TWENTY-FOUR OF THE 53 EVALUATED INFANTS (AGED 3-24 MONTHS) ADMITTED TO THE PEDIATRIC SURGERY INTENSIVE CARE UNIT, WHO REQUIRED SEDATION JUDGED NECESSARY ON THE BASIS OF THE COMFORT-BEHAVIOR SCORE AND WERE RANDOMLY ASSIGNED TO RECEIVE MIDAZOLAM, WERE INCLUDED IN THE ANALYSIS. BISPECTRAL INDEX VALUES WERE RECORDED CONCORDANTLY. POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING WAS PERFORMED USING NONMEM V (GLOBOMAX LLC, HANOVER, MD). RESULTS: FOR MIDAZOLAM, TOTAL CLEARANCE WAS 0.157 L/MIN, CENTRAL VOLUME WAS 3.8 L, PERIPHERAL VOLUME WAS 30.2 L, AND INTERCOMPARTMENTAL CLEARANCE WAS 0.30 L/MIN. ASSUMING 60% CONVERSION OF MIDAZOLAM TO 1-OH-MIDAZOLAM, THE VOLUME OF DISTRIBUTION FOR 1-OH-MIDAZOLAM AND 1-OH-MIDAZOLAMGLUCURONIDE WAS 6.7 AND 1.7 L, AND CLEARANCE WAS 0.21 AND 0.047 L/ININ, RESPECTIVELY. DEPTH OF SEDATION USING COMFORT-BEHAVIOR COULD ADEQUATELY BE DESCRIBED BY A BASELINE, POSTANESTHESIA EFFECT (E-MAX MODEL) AND MIDAZOLAM EFFECT (E-MAX MODEL). THE MIDAZOLAM CONCENTRATION AT HALF MAXIMUM EFFECT WAS 0.58 MU M WITH A HIGH INTERINDIVIDUAL VARIABILITY OF 89%. USING THE BISPECTRAL INDEX, IN 57% OF THE INFANTS THE EFFECT OF MIDAZOLAM COULD NOT BE CHARACTERIZED. CONCLUSION: IN NONVENTILATED INFANTS AFTER MAJOR SURGERY, MIDAZOLAM CLEARANCE IS TWO TO FIVE TIMES HIGHER THAN IN VENTILATED CHILDREN. FROM THE MODEL PRESENTED, THE RECOMMENDED INITIAL DOSAGE IS A LOADING DOSE OF 1 MG FOLLOWED BY A CONTINUOUS INFUSION OF 0.5 MG/H DURING THE NIGHT FOR A COMFORT-BEHAVIOR OF 12-14 IN INFANTS AGED 1 YR. LARGE INTERINDIVIDUAL VARIABILITY WARRANTS INDIVIDUAL TITRATION OF MIDAZOLAM IN THESE CHILDREN.",PEDIATRIC INTENSIVE-CARE; TARGET CONTROLLED INFUSION; BISPECTRAL INDEX; POPULATION PHARMACOKINETICS; HEALTHY-VOLUNTEERS; DUTCH CAUCASIANS; COMFORT SCALE; HUMAN LIVER; CHILDREN; SEDATION,NA,ANESTHESIOLOGY,"PEETERS, MYM##PRINS, SA##KNIBBE, CAJ##DEJONGH, J##MATHOT, RAA##WARRIS, C##VAN SCHAIK, RHN##TIBBOEL, D##DANHOF, M","ST ANTONIUS HOSP, DEPT CLIN PHARM, NL-3430 EM NIEUWEGEIN, NETHERLANDS. SOPHIA CHILDRENS UNIV HOSP, ERASMUS MED CTR, DEPT PEDIAT SURG, LEIDEN, NETHERLANDS. LEIDEN UNIV, AMSTERDAM CTR DRUG RES, DIV PHARMACOL, NL-2300 RA LEIDEN, NETHERLANDS.",ANESTHESIOLOGY,ANESTHESIOLOGY,"AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/JPEPSY/17.1.95##BAUER TM, 1995, LANCET, V346, P145, DOI 10.1016/S0140-6736(95)91209-6##BEAL SL, 1999, NONMEM USERS GUIDE##BENNETT NR, 1999, BRIT J ANAESTH, V83, P139##BLUMER JL, 1998, CLIN PHARMACOKINET, V35, P37, DOI 10.2165/00003088-199835010-00003##BURK O, 2002, J BIOL CHEM, V277, P24280, DOI 10.1074/JBC.M202345200##CARNEVALE FRANCO A., 2002, PEDIATR CRIT CARE MED, V3, P177, DOI 10.1097/00130478-200204000-00016##COURTMAN SP, 2003, INTENS CARE MED, V29, P2239, DOI 10.1007/S00134-003-1997-3##DAVIDSON AJ, 2001, ANESTH ANALG, V93, P326, DOI 10.1097/00000539-200108000-00017##DE WILDT SN, 2005, THER DRUG MONIT, V27, P98, DOI 10.1097/00007691-200502000-00018##DE WILDT SN, 2003, CRIT CARE MED, V31, P1952, DOI 10.1097/01.CCM.0000084806.15352.DA##DUNDEE JW, 1984, DRUGS, V28, P519, DOI 10.2165/00003495-198428060-00002##HEIZMANN P, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2220##HUGHES J, 1996, ANN PHARMACOTHER, V30, P27, DOI 10.1177/106002809603000104##ISTA ERWIN, 2005, PEDIATR CRIT CARE MED, V6, P58, DOI 10.1097/01.PCC.0000149318.40279.1A##JOHNSON TN, 2002, BRIT J ANAESTH, V89, P428, DOI 10.1093/BJA/AEF213##KIM DW, 2001, ANESTH ANALG, V93, P1170##KNOESTER PD, 2002, BRIT J CLIN PHARMACO, V53, P501, DOI 10.1046/J.1365-2125.2002.01588.X##LACROIX D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/J.1432-1033.1997.00625.X##LEE TC, 1999, ANESTHESIOLOGY, V90, P451, DOI 10.1097/00000542-199902000-00020##MANDEMA JW, 1992, CLIN PHARMACOL THER, V51, P715, DOI 10.1038/CLPT.1992.84##MATHEWS HML, 1988, BRIT J ANAESTH, V61, P302, DOI 10.1093/BJA/61.3.302##PEETERS MYM, 2006, ANESTHESIOLOGY, V104, P466, DOI 10.1097/00000542-200603000-00013##PRINS SA, 2005, BRIT J ANAESTH, V94, P630, DOI 10.1093/BJA/AEI104##REED MD, 2001, J CLIN PHARMACOL, V41, P1359, DOI 10.1177/00912700122012832##SMIT P, 2005, J CLIN ENDOCR METAB, V90, P5313, DOI 10.1210/JC.2005-0307##SOMMA J, 1998, ANESTHESIOLOGY, V89, P1430, DOI 10.1097/00000542-199812000-00021##STEVENS JC, 2003, J PHARMACOL EXP THER, V307, P573, DOI 10.1124/JPET.103.054841##SWART EL, 2004, BRIT J CLIN PHARMACO, V57, P135, DOI 10.1046/J.1365-2125.2003.01957.X##TRILTSCH AE, 2005, CRIT CARE, V9, PR9, DOI 10.1186/CC2977##TUK B, 1998, J PHARMACOL EXP THER, V284, P202##VAN DER MAREL CD, 2001, CLIN PHARMACOL THER, V70, P82, DOI 10.1067/MCP.2001.116794##VAN DIJK M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0##VAN SCHAIK RHN, 2000, CLIN CHEM, V46, P1834##VAN SCHAIK RHN, 2002, CLIN CHEM, V48, P1668##ZIEGLER WH, 1983, BRIT J CLIN PHARMACO, V16, P63##ZOMORODI K, 1998, ANESTHESIOLOGY, V89, P1418, DOI 10.1097/00000542-199812000-00020",36,2020-11-20,NA
J,WOS:000242713600002,2006,"THE RELATION BETWEEN SOCIAL RANK, NEOPHOBIA AND INDIVIDUAL LEARNING IN STARLINGS","RESEARCHERS WITH DIVERSE INTERESTS IN TOPICS RANGING FROM THE FORMATION OF DOMINANCE HIERARCHIES AND SOCIAL INTELLIGENCE TO ANIMAL PERSONALITIES HAVE PREDICTED SPECIFIC, AND OFTEN CONFLICTING, RELATIONS BETWEEN SOCIAL RANK, NEOPHOBIA AND LEARNING ABILITY. WE INVESTIGATED THE RELATIONS BETWEEN THESE VARIABLES IN CAPTIVE GROUPS OF WILD-CAUGHT STARLINGS, STURNUS VULGARIS, ADOPTING A MULTIDIMENSIONAL APPROACH TO SOCIAL RANK AND NEOPHOBIA. BOTH AGONISTIC AND COMPETITIVE RANK ORDERS WERE DETERMINED FOR EACH GROUP AND WE TESTED INDIVIDUALS IN THE ABSENCE OF THEIR GROUPMATES FOR OBJECT NEOPHOBIA, LATENCY TO FEED IN A NOVEL ENVIRONMENT AND PERFORMANCE ON AN EXTRACTIVE FORAGING TASK. IN EACH STARLING GROUP, THE FASTEST LEARNERS OCCUPIED THE HIGHEST COMPETITIVE RANKS, SUPPORTING THE HYPOTHESIS THAT COGNITIVE ABILITY IS POSITIVELY CORRELATED WITH SOCIAL DOMINANCE. COMPETITIVE RANK ORDERS, HOWEVER, DID NOT CORRELATE SIGNIFICANTLY WITH AGONISTIC RANK ORDERS. SITUATION-SPECIFIC FORAGING NEOPHOBIA WAS SUGGESTED: INDIVIDUALS SHOWED CONSISTENCY IN THEIR LATENCIES TO FEED NEAR A VARIETY OF NOVEL OBJECTS, BUT NO SIGNIFICANT CORRELATION WAS FOUND BETWEEN THIS MEASURE OF OBJECT NEOPHOBIA AND LATENCY TO FEED IN A NOVEL ENVIRONMENT. STARLINGS FASTEST TO FEED IN THE NOVEL ENVIRONMENT WERE FASTEST IN SOLVING THE FORAGING TASK. WE DISCUSS THE IMPLICATIONS OF THESE FINDINGS FOR RESEARCHERS STUDYING HIERARCHY FORMATION IN ANIMAL GROUPS, SOCIAL INTELLIGENCE AND ANIMAL PERSONALITIES. (C) 2006 THE ASSOCIATION FOR THE STUDY OF ANIMAL BEHAVIOUR. PUBLISHED BY ELSEVIER LTD. ALL RIGHTS RESERVED.",HIERARCHY FORMATION; STURNUS-VULGARIS; FLUCTUATING ASYMMETRIES; DOMINANCE HIERARCHIES; FEMALE STARLINGS; ZENAIDA DOVES; COMPETITION; INNOVATION; BEHAVIOR; FOOD,NA,ANIMAL BEHAVIOUR,"BOOGERT, NJ##READER, SM##LALAND, KN","UNIV UTRECHT, HELMHOLTZ INST, NL-3508 TB UTRECHT, NETHERLANDS. UNIV ST ANDREWS, SCH BIOL, CTR SOCIAL LEARNING & COGNIT EVOLUT, ST ANDREWS KY16 9TS, FIFE, SCOTLAND.",BEHAVIORAL SCIENCES; ZOOLOGY,BEHAVIORAL SCIENCES; ZOOLOGY,"BARNARD CJ, 2002, BEHAV PROCESS, V60, P53, DOI 10.1016/S0376-6357(02)00121-3##BATESON M, 1995, ANIM BEHAV, V50, P431, DOI 10.1006/ANBE.1995.0257##BUGNYAR T, 2004, ANIM COGN, V7, P69, DOI 10.1007/S10071-003-0189-4##BUNNELL B N, 1980, PRIMATES, V21, P515, DOI 10.1007/BF02373840##BUNNELL B N, 1980, PRIMATES, V21, P376, DOI 10.1007/BF02390467##BYRNE R. W., 1988, MACHIAVELLIAN INTELL##CAMBEFORT JP, 1981, FOLIA PRIMATOL, V36, P243, DOI 10.1159/000156000##CAMPBELL FM, 1999, ANIM BEHAV, V58, P151, DOI 10.1006/ANBE.1999.1121##CARLIER P, 1996, BEHAVIOUR, V133, P1197, DOI 10.1163/156853996X00369##CHASE ID, 1974, BEHAV SCI, V19, P374, DOI 10.1002/BS.3830190604##CHASE ID, 2002, P NATL ACAD SCI USA, V99, P5744, DOI 10.1073/PNAS.082104199##CHASE ID, 1982, SCIENCE, V216, P439, DOI 10.1126/SCIENCE.216.4544.439##CHASE ID, 1980, AM SOCIOL REV, V45, P905, DOI 10.2307/2094909##CLOUTIER S, 2004, BEHAV PROCESS, V65, P79, DOI 10.1016/J.BEPROC.2003.07.001##COHEN J., 1988, STAT POWER ANAL BEHA##COLEMAN K, 1998, ANIM BEHAV, V56, P927, DOI 10.1006/ANBE.1998.0852##DE VRIES H, 2006, ANIM BEHAV, V71, P585, DOI 10.1016/J.ANBEHAV.2005.05.015##DE VRIES H, 1998, ANIM BEHAV, V55, P827, DOI 10.1006/ANBE.1997.0708##DI BITETTI MS, 2001, ANIM BEHAV, V62, P47, DOI 10.1006/ANBE.2000.1730##DREA CM, 1999, P NATL ACAD SCI USA, V96, P12965, DOI 10.1073/PNAS.96.22.12965##DRENT PJ, 2003, P ROY SOC B-BIOL SCI, V270, P45, DOI 10.1098/RSPB.2002.2168##DUNBAR RIM, 2003, ANNU REV ANTHROPOL, V32, P163, DOI 10.1146/ANNUREV.ANTHRO.32.061002.093158##FAWCETT TW, 2002, ANIM BEHAV, V64, P547, DOI 10.1006/ANBE.2002.3092##FEARE C. J., 1984, STARLING##FERNANDEZ-JURICIC E, 2005, ANIM BEHAV, V69, P73, DOI 10.1016/J.ANBEHAV.2004.01.019##GAMMELL MP, 2003, ANIM BEHAV, V66, P601, DOI 10.1006/ANBE.2003.2226##GIRALDEAU LA, 2000, SOCIAL FORAGING THEO##GREENBERG R, 1984, J COMP PSYCHOL, V98, P131, DOI 10.1037/0735-7036.98.2.131##GREENBERG R, 1983, AM NAT, V122, P444, DOI 10.1086/284148##GREENBERG RUSSELL, 2003, P175##HUMPHREY N. K, 1976, GROWING POINTS ETHOL, P303##KACELNIK A, 2002, ANIM BEHAV, V63, P245, DOI 10.1006/ANBE.2001.1900##KATZIR G, 1982, BEHAVIOUR, V81, P231, DOI 10.1163/156853982X00157##KING MG, 1965, ANIM BEHAV, V13, P504, DOI 10.1016/0003-3472(65)90113-2##KUMMER H, 1985, PHILOS T ROY SOC B, V308, P203, DOI 10.1098/RSTB.1985.0020##LALAND KN, 1999, ANIM BEHAV, V57, P331, DOI 10.1006/ANBE.1998.0967##LANGBEIN J, 2004, APPL ANIM BEHAV SCI, V87, P293, DOI 10.1016/J.APPLANIM.2004.01.007##LEFEBVRE LOUIS, 1996, P107, DOI 10.1016/B978-012273965-1/50007-8##LEHNER PN, 1996, HDB ETHOLOGICAL METH##MARTIN P., 1993, MEASURING BEHAV INTR##NICOL CJ, 1999, ANIM BEHAV, V57, P163, DOI 10.1006/ANBE.1998.0920##POWELL GVN, 1974, ANIM BEHAV, V22, P501, DOI 10.1016/S0003-3472(74)80049-7##READER SM, 2002, P NATL ACAD SCI USA, V99, P4436, DOI 10.1073/PNAS.062041299##READER SM, 2001, INT J PRIMATOL, V22, P787, DOI 10.1023/A:1012069500899##READER SM, 2003, ANIMAL INNOVATION, P3##RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/J.1558-5646.1989.TB04220.X##RICHARDS SM, 1974, ANIM BEHAV, V22, P914, DOI 10.1016/0003-3472(74)90015-3##SEFERTA A, 2001, ETHOLOGY, V107, P281, DOI 10.1046/J.1439-0310.2001.00658.X##SEYFARTH RM, 2002, P NATL ACAD SCI USA, V99, P4141, DOI 10.1073/PNAS.082105099##SIH A, 2004, TRENDS ECOL EVOL, V19, P372, DOI 10.1016/J.TREE.2004.04.009##SOKAL R, 1998, BIOMETRY PRINCIPLES##STAHL J, 2001, ANIM BEHAV, V61, P257, DOI 10.1006/ANBE.2000.1564##SUMMERS RW, 1987, IBIS, V129, P96, DOI 10.1111/J.1474-919X.1987.TB03164.X##SWADDLE JP, 1995, P ROY SOC B-BIOL SCI, V260, P219, DOI 10.1098/RSPB.1995.0083##SWADDLE JP, 1994, P ROY SOC B-BIOL SCI, V255, P147, DOI 10.1098/RSPB.1994.0021##SYME GJ, 1974, ANIM BEHAV, V22, P931, DOI 10.1016/0003-3472(74)90016-5##SYME GJ, 1974, ANIM BEHAV, V22, P486, DOI 10.1016/S0003-3472(74)80048-5##TEBBICH S, 1996, ANIM BEHAV, V52, P1, DOI 10.1006/ANBE.1996.0147##TEMPLETON JJ, 1998, ANIM BEHAV, V55, P79, DOI 10.1006/ANBE.1997.0587##TEMPLETON JJ, 1999, J COMP PSYCHOL, V113, P450, DOI 10.1037/0735-7036.113.4.450##TEMPLETON JJ, 1995, ANIM BEHAV, V49, P1617, DOI 10.1016/0003-3472(95)90084-5##VERVAECKE H, 2000, INT J PRIMATOL, V21, P47, DOI 10.1023/A:1005471512788##VERVAECKE H, 1999, BEHAVIOUR, V136, P423, DOI 10.1163/156853999501405##WEBSTER SJ, 2001, ANIM BEHAV, V62, P23, DOI 10.1006/ANBE.2000.1725##WILSON DS, 1994, TRENDS ECOL EVOL, V9, P442, DOI 10.1016/0169-5347(94)90134-1##WITTER MS, 1994, P ROY SOC B-BIOL SCI, V256, P299, DOI 10.1098/RSPB.1994.0084##WITTER MS, 1997, ANIM BEHAV, V54, P279, DOI 10.1006/ANBE.1996.0443##WITTIG RM, 2003, INT J PRIMATOL, V24, P847, DOI 10.1023/A:1024632923180",132,2020-11-20,NA
J,WOS:000242713600004,2006,CONSISTENT FEEDING POSITIONS OF GREAT TIT PARENTS,"WHEN PARENT BIRDS ARRIVE AT THE NEST TO PROVISION THEIR YOUNG, THEIR POSITION ON THE NEST RIM MAY INFLUENCE WHICH CHICK OR CHICKS ARE FED. AS A RESULT, THE CONSISTENCY OF FEEDING POSITIONS OF THE INDIVIDUAL PARENTS, AND THE DIFFERENCE IN POSITION BETWEEN THE PARENTS, MAY AFFECT HOW EQUITABLY FOOD IS DIVIDED AMONG THE CHICKS. WE STUDIED THE POSITIONS OF PARENT GREAT TITS, PARUS MAJOR, LANDING ON THE NEST TO FEED THEIR CHICKS. INDIVIDUAL PARENTS WERE CONSISTENT IN THEIR POSITION WITHIN OBSERVATION PERIODS, ON DIFFERENT DAYS WITHIN THE SAME BREEDING ATTEMPT, AND AT BREEDING ATTEMPTS IN DIFFERENT YEARS. WITHIN EACH SEX, THERE WERE INDIVIDUAL DIFFERENCES IN POSITION WITHIN SINGLE OBSERVATION BOUTS, IN AVERAGE POSITION ACROSS DAYS WITHIN A BREEDING ATTEMPT, AND IN AVERAGE POSITION ACROSS YEARS. AT THE MAJORITY OF NESTS, THE TWO PARENTS DIFFERED IN POSITIONS. THE DISTRIBUTION OF ANGULAR DISTANCES BETWEEN THE PARENTS DIFFERED FROM THAT EXPECTED IF THE PARENTS' POSITIONS WERE INDEPENDENT, WITH THE OBSERVED MEDIAN BEING LESS THAN THAT EXPECTED. THE ANGULAR DISTANCE BETWEEN THE PARENTS WAS NOT RELATED TO 22 DIFFERENT CHARACTERISTICS OF THE BROOD AND PARENTS. WE CONCLUDE THAT CONSISTENCY (I.E. A DEPARTURE FROM A RANDOM UNIFORM DISTRIBUTION) IN POSITION IS EXPLAINED BY HABIT FORMATION, AND TO A LESSER EXTENT BY AN OVERALL PREFERENCE FOR PARTICULAR LOCATIONS, AND BY NEST CONFIGURATION. WE ALSO CONCLUDE THAT THERE IS LITTLE SCOPE AND NO EVIDENCE FOR THE PARENTS STRATEGICALLY ADJUSTING THEIR ANGULAR SEPARATION. (C) 2006 THE ASSOCIATION FOR THE STUDY OF ANIMAL BEHAVIOUR. PUBLISHED BY ELSEVIER LTD. ALL RIGHTS RESERVED.",BROOD DIVISION; PARUS-MAJOR; CUP; SEX,NA,ANIMAL BEHAVIOUR,"LESSELLS, CM##POELMAN, EH##MATEMAN, AC##CASSEY, P","NETHERLANDS INST ECOL, CTR TERRESTRIAL ECOL, NL-6666 ZG HETEREN, NETHERLANDS. UNIV BIRMINGHAM, SCH BIOSCI, CTR ORNITHOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND.",BEHAVIORAL SCIENCES; ZOOLOGY,BEHAVIORAL SCIENCES; ZOOLOGY,"BATSCHELET E., 1981, CIRCULAR STAT BIOL##FISHER N.I, 1993, STAT ANAL CIRCULAR D##GRIFFITHS R, 1998, MOL ECOL, V7, P1071, DOI 10.1046/J.1365-294X.1998.00389.X##KACELNIK A, 1995, P ROY SOC LOND B BIO, V259, P1723##KILNER RM, 2002, BEHAV ECOL SOCIOBIOL, V52, P400, DOI 10.1007/S00265-002-0533-8##KOLLIKER M, 2000, P ROY SOC B-BIOL SCI, V267, P2127, DOI 10.1098/RSPB.2000.1259##KOLLIKER M, 1998, ANIM BEHAV, V55, P215, DOI 10.1006/ANBE.1997.0571##KOLLIKER M, 2004, ANIM BEHAV, V68, P941, DOI 10.1016/J.ANBEHAV.2003.11.019##LACK D., 1954, P343##LESSELLS CM, 1989, J ANIM ECOL, V58, P815, DOI 10.2307/5126##LESSELLS CM, 2002, PHILOS T R SOC B, V357, P381, DOI 10.1098/RSTB.2001.0928##MALACARNE G, 1994, ETHOL ECOL EVOL, V6, P293, DOI 10.1080/08927014.1994.9522982##MANLEY B. F. J., 1997, RANDOMIZATION BOOTST##MCLAUGHLIN RL, 1985, AUK, V102, P687##MCRAE SB, 1993, BEHAV ECOL SOCIOBIOL, V33, P101##OSTREIHER R, 2001, BEHAV ECOL SOCIOBIOL, V49, P340, DOI 10.1007/S002650000308##PARKER GA, 2002, PHILOS T R SOC B, V357, P295, DOI 10.1098/RSTB.2001.0950##RADFORD AN, 2001, BIRD STUDY, V48, P214, DOI 10.1080/00063650109461220##RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/J.1558-5646.1989.TB04220.X##SLAGSVOLD T, 1997, ANIM BEHAV, V54, P1357, DOI 10.1006/ANBE.1997.0530##SOKAL RR, 1969, BIOMETRY",19,2020-11-20,NA
J,WOS:000243376200002,2006,WNT GRADIENT FORMATION: FROM SOURCE TO SINK,"THE SECRETED GLYCOPROTEINS OF THE WNT FAMILY ACTIVATE A HIGHLY CONSERVED SIGNALLING PATHWAY THAT CONTROLS SEVERAL DEVELOPMENTAL PROCESSES. WRIT LIGANDS FUNCTION AS MORPHOGENS THAT ACT AT A DISTANCE FROM THEIR SOURCE BY ESTABLISHING A CONCENTRATION GRADIENT. THE VARIOUS FATES OF THE WRIT RESPONDING CELLS ALONG THE MORPHOGENETIC FIELD CONTRIBUTE TO THE PRECISE PATTERNING OF THE EMBRYO AND DEPEND ON THE CONCENTRATION OF MORPHOGEN TO WHICH THEY ARE EXPOSED. HOWEVER, THE DIFFERENT MECHANISMS THAT ALLOW THE CONTROLLED FORMATION OF THE WNT GRADIENT ARE UNCLEAR. HERE WE GIVE AN OVERVIEW OF CURRENT UNDERSTANDING OF THE MECHANISMS THAT POTENTIALLY CONTROL THE SPREADING OF THE DROSOPHILA. WRIT ORTHOLOG WINGLESS.",NA,WINGLESS; WNT; MORPHOGEN GRADIENT,ANIMAL BIOLOGY,"COUDREUSE, D##KORSWAGEN, HC","HUBRECHT LAB, NL-3584 CT UTRECHT, NETHERLANDS. CTR BIOMED GENET, NL-3584 CT UTRECHT, NETHERLANDS.",ZOOLOGY,ZOOLOGY,"AMIT S, 2002, GENE DEV, V16, P1066, DOI 10.1101/GAD.230302##BAEG GH, 2001, DEVELOPMENT, V128, P87##BEJSOVEC A, 1995, GENETICS, V139, P309##BINARI RC, 1997, DEVELOPMENT, V124, P2623##CADIGAN KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/GAD.11.24.3286##CADIGAN KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5##CAVALLO RA, 1998, NATURE, V395, P604, DOI 10.1038/26982##CHAMOUN Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/SCIENCE.1064437##CHEN MH, 2004, GENE DEV, V18, P641, DOI 10.1101/GAD.1185804##CHEN Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4##COOKE J, 1995, BIOESSAYS, V17, P93, DOI 10.1002/BIES.950170202##DANIELS DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/NSMB912##DENNIS S, 1999, J CELL SCI, V112, P3815##DORFMAN R, 2001, DEVELOPMENT, V128, P965##DU SJ, 1995, MOL CELL BIOL, V15, P2625##DUBOIS L, 2001, CELL, V105, P613, DOI 10.1016/S0092-8674(01)00375-0##DYSON S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X##FAURE S, 2000, DEVELOPMENT, V127, P2917##GALLET A, 2005, DEV BIOL, V277, P51, DOI 10.1016/J.YDBIO.2004.09.005##GALLET A, 2003, DEV CELL, V4, P191, DOI 10.1016/S1534-5807(03)00031-5##GERLITZ O, 2002, GENE DEV, V16, P1055, DOI 10.1101/GAD.991802##GIRALDEZ AJ, 2002, DEV CELL, V2, P667, DOI 10.1016/S1534-5807(02)00180-6##GLISE B, 2005, DEV CELL, V8, P255, DOI 10.1016/J.DEVCEL.2005.01.003##GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D##GORFINKIEL N, 2005, DEV CELL, V8, P241, DOI 10.1016/J.DEVCEL.2004.12.018##GRAFF JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0##GRECO V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6##GURDON JB, 1999, DEVELOPMENT, V126, P5309##HACKER U, 1997, DEVELOPMENT, V124, P3565##HAERRY TE, 1997, DEVELOPMENT, V124, P3055##HAN C, 2005, DEVELOPMENT, V132, P667, DOI 10.1242/DEV.01636##HART M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8##HOFMANN K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X##HOPPLER S, 1996, GENE DEV, V10, P2805, DOI 10.1101/GAD.10.21.2805##HSIEH JC, 1999, NATURE, V398, P431, DOI 10.1038/18899##KADOWAKI T, 1996, GENE DEV, V10, P3116, DOI 10.1101/GAD.10.24.3116##KIRKPATRICK CA, 2004, DEV CELL, V7, P513, DOI 10.1016/J.DEVCEL.2004.08.004##KREUGER J, 2004, DEV CELL, V7, P503, DOI 10.1016/J.DEVCEL.2004.08.005##LAWRENCE PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0##LECUIT T, 1998, DEVELOPMENT, V125, P4901##LIN XH, 1999, NATURE, V400, P281##LIU GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003##MALOOF JN, 1999, DEVELOPMENT, V126, P37##MAO JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6##MAROIS E, 2006, DEVELOPMENT, V133, P307, DOI 10.1242/DEV.02197##MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/MBC.3.5.521##MCDOWELL N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6##MILLER JR, 2002, GENOME BIOL, V3, P3001, DOI DOI 10.1186/GB-2001-3-1-REVIEWS3001##NEUFELD TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2##NEUMANN CJ, 1997, DEVELOPMENT, V124, P871##NGUYEN M, 1998, CELL, V95, P495, DOI 10.1016/S0092-8674(00)81617-7##NUSSE R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/DEV.00821##PANAKOVA D, 2005, NATURE, V435, P58, DOI 10.1038/NATURE03504##PETERS JM, 1999, NATURE, V401, P345, DOI 10.1038/43830##PFEIFFER R, 2002, DIAM RELAT MATER, V11, P957, DOI 10.1016/S0925-9635(01)00560-X##PFEIFFER S, 2000, CURR BIOL, V10, P321, DOI 10.1016/S0960-9822(00)00381-X##PLOTNIKOV AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3##REICHSMAN F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/JCB.135.3.819##RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J##ROOSE J, 1998, NATURE, V395, P608, DOI 10.1038/26989##SANSON B, 2001, EMBO REP, V2, P1083, DOI 10.1093/EMBO-REPORTS/KVE255##SELLECK SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1##SIMMONDS AJ, 2001, CELL, V105, P197, DOI 10.1016/S0092-8674(01)00311-7##STRIGINI M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X##TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9##TAMAI K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2##TANAKA K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/JBC.M200187200##TANIMOTO H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7##TELEMAN AA, 2000, CELL, V103, P971, DOI 10.1016/S0092-8674(00)00199-9##TOLWINSKI NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7##TSUDA M, 1999, NATURE, V400, P276##UREN A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/JBC.275.6.4374##VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/J.1460-2075.1993.TB06225.X##VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2##WILLERT K, 2003, NATURE, V423, P448, DOI 10.1038/NATURE01611##WILLERT K, 1999, GENE DEV, V13, P1768, DOI 10.1101/GAD.13.14.1768##WOLPERT L, 1989, DEVELOPMENT, V107, P3##WU CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/JBC.M207850200##YAMAMOTO H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/JBC.274.16.10681##ZECCA M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1##ZHAI L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/JBC.M403407200",1,2020-11-20,NA
J,WOS:000243376200003,2006,PEPTIDES AND PROTEINS REGULATING FOOD INTAKE: A COMPARATIVE VIEW,"ENERGY HOMEOSTASIS IS UNDER MULTIPLE ENDOCRINE AND NEURAL CONTROLS THAT INVOLVE BOTH CENTRAL AND PERIPHERAL HORMONES AND NEUROPEPTIDES. DISORDERS OF ENERGY BALANCE (E.G., OBESITAS AND ANOREXIA NERVOSA) ARE CAUSED BY SUBTLE DYSREGULATION OF THESE REGULATORY MECHANISMS. THE HYPOTHALAMIC ARCUATE NUCLEUS IS A MAIN SITE OF CENTRAL REGULATION WHERE TWO DISTINCT SUBPOPULATIONS OF NEURONS CO-EXPRESS EITHER NEUROPEPTIDE Y (NPY) AND AGOUTI-RELATED PROTEIN (AGRP), OR PROOPIOMELANOCORTIN (POMC) AND COCAINE AND AMPHETAMINE-REGULATED TRANSCRIPT (CART): THE FORMER SET OF PEPTIDES INCREASES FOOD INTAKE; THE LATTER DECREASES FOOD INTAKE AND AFFECT ENERGY METABOLISM. KEY PERIPHERAL HORMONES AFFECTING ENERGY METABOLISM INCLUDE CHOLECYSTOKININ (CCK), LEPTIN AND INSULIN, WHICH DECREASE FOOD INTAKE, AND GHRELIN, WHICH INCREASES FOOD INTAKE. CCK AND GHRELIN REGULATE FOOD INTAKE IN THE SHORT TERM (BY AFFECTING MEAL SIZE), WHEREAS LEPTIN AND INSULIN REGULATE FOOD INTAKE OVER LONGER PERIODS SPANNING SEVERAL MEALS. THESE SIGNALS AND THEIR PHYSIOLOGY ARE REASONABLY WELL UNDERSTOOD IN MAMMALS. ON THE OTHER HAND, KNOWLEDGE ON ENERGY METABOLISM IN EARLIER VERTEBRATES IS SCANT. RECENTLY CHARACTERISED CENTRAL FOOD INTAKE REGULATORY MECHANISMS IN FISH SUGGEST THAT THEY OPERATE IN A MANNER SIMILAR TO THEIR MAMMALIAN COUNTERPARTS. PERIPHERAL MECHANISMS HAVE BEEN POORLY STUDIED OUTSIDE MAMMALS. THE RECENT IDENTIFICATION OF LEPTIN IN SEVERAL FISH SPECIES PROVIDES NEW INSIGHTS AND OPPORTUNITIES TO ENHANCE OUR UNDERSTANDING OF THE REGULATION OF FOOD INTAKE. COMPARATIVE ANALYSIS OF THESE PERIPHERAL MECHANISMS MAY SHED NEW LIGHT ON THE FUNCTION AND EVOLUTION OF THE MECHANISMS CONTROLLING ENERGY HOMEOSTASIS. IN THIS REVIEW, WE SUMMARISE RECENT DEVELOPMENTS IN UNDERSTANDING OF MECHANISMS AND SIGNALS THAT REGULATE ENERGY BALANCE IN MAMMALS, AND COMPARE THESE TO WHAT WE NOW KNOW ABOUT THEIR ORTHOLOGUES IN EARLIER VERTEBRATES, WITH A PARTICULAR FOCUS ON BONY FISHES.",CORTICOTROPIN-RELEASING-FACTOR; AGOUTI-RELATED PROTEIN; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA LEVELS; GOLDFISH CARASSIUS-AURATUS; BODY-WEIGHT REGULATION; CYPRINUS-CARPIO L.; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; NEUROPEPTIDE-Y EXPRESSION,ENERGY BALANCE; FOOD INTAKE; HORMONE; LEPTIN; PEPTIDES,ANIMAL BIOLOGY,"GORISSEN, MHAG##FLIK, G##HUISING, MO","RADBOUD UNIV NIJMEGEN, DEPT ANIM PHYSIOL, NL-6525 ED NIJMEGEN, NETHERLANDS.",ZOOLOGY,ZOOLOGY,"AJA S, 2002, BEHAV NEUROSCI, V116, P918, DOI 10.1037/0735-7044.116.5.918##AJA S, 2001, AM J PHYSIOL-REG I, V280, PR1613##ALDMAN G, 1995, GEN COMP ENDOCR, V100, P27, DOI 10.1006/GCEN.1995.1128##AMMAR AA, 2000, AM J PHYSIOL-REG I, V278, PR1627##ARAI M, 2001, ENDOCRINOLOGY, V142, P446, DOI 10.1210/EN.142.1.446##ARVANITI K, 2001, NEUROENDOCRINOLOGY, V73, P227, DOI 10.1159/000054639##BALE TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/ANNUREV.PHARMTOX.44.101802.121410##BARSYTE D, 1999, GEN COMP ENDOCR, V115, P169, DOI 10.1006/GCEN.1999.7290##BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773##BERNIER NJ, 2006, GEN COMP ENDOCR, V146, P45, DOI 10.1016/J.YGCEN.2005.11.016##BERNIER NJ, 1999, GEN COMP ENDOCR, V116, P461, DOI 10.1006/GCEN.1999.7386##BERNIER NJ, 2001, NEUROENDOCRINOLOGY, V73, P248, DOI 10.1159/000054642##BILLINGTON CJ, 1991, AM J PHYSIOL, V260, P321##BONGA SEW, 1997, PHYSIOL REV, V77, P591, DOI 10.1152/PHYSREV.1997.77.3.591##BOORSE GC, 2005, ENDOCRINOLOGY, V146, P4851, DOI 10.1210/EN.2005-0497##BOSTON BA, 1999, ANN NY ACAD SCI, V885, P75##BRENNAN MB, 2003, ANN NY ACAD SCI, V994, P282, DOI 10.1111/J.1749-6632.2003.TB03191.X##BROBERGER C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/PNAS.95.25.15043##BRUNING JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/SCIENCE.289.5487.2122##CARODSO JC, 2003, DNA SEQUENCE, V14, P215##CASTRO MG, 1997, CRIT REV NEUROBIOL, V11, P35##CERDA-REVERTER JM, 2000, J CHEM NEUROANAT, V19, P197, DOI 10.1016/S0891-0618(00)00063-6##CERDA-REVERTER JM, 2003, REGUL PEPTIDES, V115, P101, DOI 10.1016/S0167-0115(03)00144-7##CERDA-REVERTER JM, 2003, ENDOCRINOLOGY, V144, P2336, DOI 10.1210/EN.2002-0213##CERDA-REVERTER JM, 2005, ENDOCRINOLOGY, V146, P1597, DOI 10.1210/EN.2004-1346##CERDA-REVERTER JM, 2003, ENDOCRINOLOGY, V144, P4552, DOI 10.1210/EN.2003-0453##CHAVEZ M, 1995, BEHAV NEUROSCI, V109, P528, DOI 10.1037/0735-7044.109.3.528##CHEN HY, 2004, ENDOCRINOLOGY, V145, P2607, DOI 10.1210/EN.2003-1596##CHEUNG CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/EN.138.10.4489##CHHAJLANI V, 1996, BIOCHEM MOL BIOL INT, V38, P73##CLARK JT, 1987, REGUL PEPTIDES, V17, P31, DOI 10.1016/0167-0115(87)90030-9##CLARK JT, 1985, ENDOCRINOLOGY, V117, P2435, DOI 10.1210/ENDO-117-6-2435##COLEMAN DL, 1969, AM J PHYSIOL, V217, P1298##COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857##COWLEY MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1##COWLEY MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6##CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X##CUMMINGS DE, 2003, GASTROENTEROLOGY, V124, P1532, DOI 10.1016/S0016-5085(03)00350-0##DE LECEA L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/PNAS.95.1.322##DEPEDRO N, 1993, PHYSIOL BEHAV, V53, P517, DOI 10.1016/0031-9384(93)90146-7##DEPEDRO N, 1997, BEHAV NEUROSCI, V111, P398, DOI 10.1037/0735-7044.111.2.398##DORES R. M., 2005, GEN COMP ENDOCR, V142, P193##DOUGLASS J, 1995, J NEUROSCI, V15, P2471##DOYON C, 2005, J ENDOCRINOL, V186, P123, DOI 10.1677/JOE.1.06142##DOYON C, 2003, GEN COMP ENDOCR, V133, P260, DOI 10.1016/S0016-6480(03)00195-3##DUBE MG, 1994, BRAIN RES, V646, P341, DOI 10.1016/0006-8993(94)90103-1##EBERLEIN GA, 1992, J BIOL CHEM, V267, P1517##EDHOLM OG, 1977, J HUM NUTR, V31, P413##ELIAS CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X##ELMQUIST JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3##ELMQUIST JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164##ERICKSON JC, 1996, NATURE, V381, P415, DOI 10.1038/381415A0##FEKETE C, 2000, J NEUROSCI, V20, P9224##FLIK G, 2006, IN PRESS GEN COMP EN##GELINEAU A, 2001, J FISH BIOL, V58, P716, DOI 10.1006/JFBI.2000.1492##GIBBS J, 1973, J COMP PHYSIOL PSYCH, V84, P488, DOI 10.1037/H0034870##HAHN TM, 1998, NAT NEUROSCI, V1, P271##HAITINA T, 2004, BIOCHEM J, V380, P475, DOI 10.1042/BJ20031934##HALFORD JCG, 2004, CURR DRUG TARGETS, V5, P221, DOI 10.2174/1389450043490541##HAYASHIDA T, 2001, DOMEST ANIM ENDOCRIN, V21, P17, DOI 10.1016/S0739-7240(01)00104-7##HEINRICHS SC, 1996, P NATL ACAD SCI USA, V93, P15475, DOI 10.1073/PNAS.93.26.15475##HEINRICHS SC, 2001, BRAIN RES, V900, P177, DOI 10.1016/S0006-8993(01)02286-7##HILL DR, 1987, J NEUROSCI, V7, P2967##HILTON JW, 1987, FISH PHYSIOL BIOCHEM, V4, P113, DOI 10.1007/BF02110878##HIMICK BA, 1994, AM J PHYSIOL, V267, PR841##HIMICK BA, 1996, AM J PHYSIOL-REG I, V271, PR137##HORVATH TL, 1997, BRAIN RES, V756, P283, DOI 10.1016/S0006-8993(97)00184-4##HUISING M, 2004, J MOL ENDOCRINOL, V32, P627, DOI 10.1677/JME.0.0320627##HUISING MO, 2006, J ENDOCRINOL, V189, P1, DOI 10.1677/JOE.1.06591##HUISING MO, 2006, IN PRESS ENDOCRINOLO##HUSZAR D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6##IQBAL J, 2006, ENDOCRINOLOGY, V147, P510, DOI 10.1210/EN.2005-1048##JENSEN J, 2001, COMP BIOCHEM PHYS A, V128, P471, DOI 10.1016/S1095-6433(00)00329-9##JOHNSEN AH, 1998, FRONT NEUROENDOCRIN, V19, P73, DOI 10.1006/FRNE.1997.0163##JOHNSON RM, 2000, J EXP ZOOL, V286, P718, DOI 10.1002/(SICI)1097-010X(20000601)286:7&LT;718::AID-JEZ6&GT;3.0.CO;2-I##JONSSON AC, 1987, GEN COMP ENDOCR, V66, P190, DOI 10.1016/0016-6480(87)90267-X##KAIYA H, 2003, ENDOCRINOLOGY, V144, P5215, DOI 10.1210/EN.2003-1085##KAIYA H, 2003, COMP BIOCHEM PHYS B, V135, P421, DOI 10.1016/S1096-4959(03)00109-X##KAIYA H, 2003, J ENDOCRINOL, V176, P415, DOI 10.1677/JOE.0.1760415##KALRA SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/ER.20.1.68##KALRA SP, 1988, PEPTIDES, V9, P723, DOI 10.1016/0196-9781(88)90112-X##KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/PNAS.88.23.10931##KASTIN AJ, 1999, PEPTIDES, V20, P1449, DOI 10.1016/S0196-9781(99)00156-4##KLOVINS J, 2004, MOL BIOL EVOL, V21, P563, DOI 10.1093/MOLBEV/MSH050##KOJIMA M, 1999, NATURE, V402, P656, DOI 10.1038/45230##KOJIMA M, 2005, PHYSIOL REV, V85, P495, DOI 10.1152/PHYSREV.00012.2004##KOW LM, 1991, PHARMACOL BIOCHEM BE, V38, P359, DOI 10.1016/0091-3057(91)90291-9##KRISTENSEN P, 1998, NATURE, V393, P72, DOI 10.1038/29993##KUROKAWA T, 2005, PEPTIDES, V26, P745, DOI 10.1016/J.PEPTIDES.2004.12.017##KUROKAWA T, 2003, PEPTIDES, V24, P227, DOI 10.1016/S0196-9781(03)00034-2##LAMBERT PD, 1998, SYNAPSE, V29, P293, DOI 10.1002/(SICI)1098-2396(199808)29:4<293::AID-SYN1>3.0.CO;2-0##LARSEN PJ, 2000, OBES RES, V8, P590, DOI 10.1038/OBY.2000.76##LARSSON LI, 1978, HISTOCHEMISTRY, V58, P23, DOI 10.1007/BF00489946##LAWRENCE CB, 2002, ENDOCRINOLOGY, V143, P155, DOI 10.1210/EN.143.1.155##LEDERIS K, 1982, SCIENCE, V213, P1394##LEIBOWITZ SF, 2004, PEPTIDES, V25, P473, DOI 10.1016/J.PEPTIDES.2004.02.006##LEWIS K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/PNAS.121165198##LITTLE TJ, 2005, OBES REV, V6, P297, DOI 10.1111/J.1467-789X.2005.00212.X##LOPEZ M, 2002, NEUROREPORT, V13, P1775, DOI 10.1097/00001756-200210070-00016##LOPEZ-PATINO MA, 1999, EUR J PHARMACOL, V377, P147, DOI 10.1016/S0014-2999(99)00408-2##LOVETT D, 1970, Q J EXP PSYCHOL, V22, P406, DOI 10.1080/14640747008401914##MACNEIL DJ, 2002, EUR J PHARMACOL, V440, P141, DOI 10.1016/S0014-2999(02)01425-5##MARIE LS, 2005, P NATL ACAD SCI USA, V102, P18632, DOI 10.1073/PNAS.0509240102##MARSH DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070##MAZON AF, 2006, J EXP BIOL, V209, P510, DOI 10.1242/JEB.01973##METZ JR, 2004, J ENDOCRINOL, V182, P23##METZ JR, 2006, GEN COMP ENDOCR, V148, P150, DOI 10.1016/J.YGCEN.2006.03.001##MICHAUD EJ, 1993, GENE DEV, V7, P1203, DOI 10.1101/GAD.7.7A.1203##MILLARD AV, 1993, MED ANTHROPOL Q, V7, P3, DOI 10.1525/MAQ.1993.7.1.02A00010##MOMMSEN TP, 1991, REV AQUAT SCI, V4, P225##MOON TW, 1989, CAN J ZOOL, V67, P2189, DOI 10.1139/Z89-309##MOONS L, 1992, PEPTIDES, V13, P37, DOI 10.1016/0196-9781(92)90137-R##MORAN TH, 1986, BRAIN RES, V362, P175, DOI 10.1016/0006-8993(86)91413-7##MORAN TH, 2004, AM J PHYSIOL-GASTR L, V286, PG183, DOI 10.1152/AJPGI.00434.2003##MUSTONEN AM, 2002, J EXP ZOOL, V293, P119, DOI 10.1002/JEZ.10142##NAKAZATO M, 2001, NATURE, V409, P194, DOI 10.1038/35051587##NARNAWARE YK, 2001, COMP BIOCHEM PHYS B, V129, P633, DOI 10.1016/S1096-4959(01)00359-1##NARNAWARE YK, 2000, AM J PHYSIOL-REG I, V279, PR1025##NEARY NM, 2004, CLIN ENDOCRINOL, V60, P153, DOI 10.1046/J.1365-2265.2003.01839.X##NISWENDER KD, 2004, TRENDS ENDOCRIN MET, V15, P362, DOI 10.1016/J.TEM.2004.07.009##OLIVER AS, 1996, GEN COMP ENDOCR, V102, P61, DOI 10.1006/GCEN.1996.0047##PANDYA PK, 1994, BBA-MOL CELL RES, V1224, P117, DOI 10.1016/0167-4889(94)90119-8##PANKSEPP J, 1976, PHARMACOL BIOCHEM BE, V5, P59, DOI 10.1016/0091-3057(76)90329-4##PEYON P, 1999, MOL BRAIN RES, V74, P190, DOI 10.1016/S0169-328X(99)00282-X##QIAN S, 2002, MOL CELL BIOL, V22, P5027, DOI 10.1128/MCB.22.14.5027-5035.2002##QU DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243A0##RAHMOUNI K, 2001, BIOESSAYS, V23, P1095, DOI 10.1002/BIES.10018##REHFELD JF, 1998, CLIN CHEM, V44, P991##REHFELD JF, 1981, AM J PHYSIOL-GASTR L, V240, P255##RICHARD D, 2000, INT J OBESITY, V24, PS36, DOI 10.1038/SJ.IJO.0801275##RILEY LG, 2005, GEN COMP ENDOCR, V142, P234, DOI 10.1016/J.YGCEN.2005.01.009##ROHNERJEANRENAUD F, 1989, ENDOCRINOLOGY, V124, P733, DOI 10.1210/ENDO-124-2-733##SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7##SAITO ES, 2002, EUR J PHARMACOL, V453, P75, DOI 10.1016/S0014-2999(02)02393-2##SAKURAI T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6##SCHWARTZ MW, 2003, DIABETES, V52, P232, DOI 10.2337/DIABETES.52.2.232##SCHWARTZ MW, 2000, NATURE, V404, P661##SCHWARTZ MW, 1996, DIABETES, V45, P531, DOI 10.2337/DIABETES.45.4.531##SCHWARTZ MW, 1992, ENDOCRINOLOGY, V130, P3608, DOI 10.1210/EN.130.6.3608##SEELEY RJ, 2003, NAT REV NEUROSCI, V4, P901, DOI 10.1038/NRN1245##SILVERSTEIN JT, 2000, AM ZOOL, V40, P296, DOI 10.1668/0003-1569(2000)040[0296:TEONAI]2.0.CO;2##SILVERSTEIN JT, 1999, J FISH BIOL, V54, P607, DOI 10.1111/J.1095-8649.1999.TB00639.X##SMITH SM, 2004, ENDOCRINOLOGY, V145, P5202, DOI 10.1210/EN.2004-0708##SOENGAS JL, 2004, J COMP PHYSIOL A, V190, P641, DOI 10.1007/S00359-004-0524-5##SOMERO GN, 2005, ANNU REV PHYSIOL, V67, P25, DOI 10.1146/ANNUREV.PHYSIOL.67.041904.120836##SONG Y, 2003, ENDOCRINE, V22, P257, DOI 10.1385/ENDO:22:3:257##SPIEGELMAN BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9##SPIESS J, 1981, BIOCHEMISTRY-US, V20, P1982, DOI 10.1021/BI00510A038##STANLEY SA, 2001, BRAIN RES, V893, P186, DOI 10.1016/S0006-8993(00)03312-6##STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530A0##SUGINO T, 2004, ANIM REPROD SCI, V82-3, P183, DOI 10.1016/J.ANIREPROSCI.2004.05.001##SUGINO T, 2002, BIOCHEM BIOPH RES CO, V295, P255, DOI 10.1016/S0006-291X(02)00654-X##THORNTON JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/EN.138.11.5063##TSCHOP M, 2000, NATURE, V407, P908, DOI 10.1038/35038090##UNNIAPPAN S, 2004, NEUROENDOCRINOLOGY, V79, P100, DOI 10.1159/000076634##UNNIAPPAN S, 2002, ENDOCRINOLOGY, V143, P4143, DOI 10.1210/EN.2002-220644##VAN DIJK G, 2003, PHYSIOL BEHAV, V79, P575, DOI 10.1016/S0031-9384(03)00125-2##VAN ENCKEVORT FHJ, 2000, J NEUROENDOCRINOL, V12, P177, DOI 10.1046/J.1365-2826.2000.00434.X##VERBALIS JG, 1995, ADV EXP MED BIOL, V395, P209##VERGUSDAL A, 2003, LIPIDS, V38, P289##VOLKOFF H, 2003, BRAIN RES, V972, P90, DOI 10.1016/S0006-8993(03)02507-1##VOLKOFF H, 2001, ENDOCRINOLOGY, V142, P5076, DOI 10.1210/EN.142.12.5076##VOLKOFF H, 2005, GEN COMP ENDOCR, V142, P3, DOI 10.1016/J.YGCEN.2004.11.001##VOLKOFF H, 2000, BRAIN RES, V887, P125, DOI 10.1016/S0006-8993(00)03001-8##WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/PNAS.89.7.3125##WEATHERFORD SC, 1993, AM J PHYSIOL-REG I, V264, P244##WEST DB, 1984, AM J PHYSIOL, V246, P776##WILCOX BJ, 1989, BRAIN RES, V500, P149, DOI 10.1016/0006-8993(89)90308-9##WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/EN.132.5.1939##WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503A0##XU B, 1998, REGUL PEPTIDES, V75-6, P391, DOI 10.1016/S0167-0115(98)00093-7##YAGHOUBIAN S, 2001, COMP BIOCHEM PHYS B, V129, P777, DOI 10.1016/S1096-4959(01)00388-8##ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425A0##ZHENG HY, 2001, BRAIN RES, V896, P153, DOI 10.1016/S0006-8993(00)03256-X",45,2020-11-20,NA
J,WOS:000243376200007,2006,CONSERVING DECLINING SPECIES USING INCOMPLETE DEMOGRAPHIC INFORMATION: WHAT HELP CAN WE EXPECT FROM THE USE OF MATRIX POPULATION MODELS?,"DUE TO HUMAN ACTIVITY, MANY SPECIES HAVE STRONGLY DECLINED IN NUMBER AND ARE CURRENTLY THREATENED WITH EXTINCTION. MANAGEMENT DIRECTED AT CONSERVATION OF THESE SPECIES CAN BENEFIT FROM THE USE OF SIMPLE POPULATION MODELS SUCH AS MATRIX MODELS. HOWEVER, FOR MANY SPECIES, DATA ON SURVIVAL AND REPRODUCTION ARE SCARCE. THEREFORE, WE SET UP A GENERAL FRAMEWORK BASED ON A MATRIX MODEL WITH THREE PARAMETERS: REPRODUCTION, JUVENILE (=FIRST YEAR SURVIVAL) AND ADULT SURVIVAL IN WHICH INCOMPLETE DATA CAN BE ANALYSED. THIS FRAMEWORK IS APPLICABLE TO SPECIES THAT CAN MATURE AFTER THEIR FIRST YEAR OF LIFE. THE POINT IN A CALENDAR YEAR AT WHICH THE POPULATION SIZE IS DETERMINED, I.E. THE CENSUS TIME, IS VARIED. WE DISCUSS THE DIFFERENCES AND THE SIMILARITIES BETWEEN MATRICES MODELLING THE SAME POPULATION AT DIFFERENT CENSUS TIMES. THE POPULATION GROWTH RATE AND THE ELASTICITY OF THE SURVIVAL AND REPRODUCTION PARAMETERS HAVE BEEN DETERMINED ANALYTICALLY. FROM THESE WE MADE, AS A VISUAL DIAGNOSTIC TOOL (GENERAL FRAMEWORK), PLOTS OF THE GROWTH RATE AND THE ELASTICITY PATTERN AND THEIR DEPENDENCE ON ACTUAL VALUES OF THE REPRODUCTION PARAMETER AND THE JUVENILE AND ADULT SURVIVAL. TO ILLUSTRATE THE USE OF THIS FRAMEWORK WE PLOT AND DISCUSS LITERATURE DATA ON SURVIVAL AND/OR REPRODUCTION OF A FEW BIRD SPECIES WITH A JUVENILE STAGE OF ONE YEAR IN THE LIGHT OF OUR MODELLING RESULTS.",GROWTH RATE; GREAT TIT; SURVIVAL; CONSERVATION; ELASTICITY; MANAGEMENT; VIABILITY; BRITAIN,CONSERVATION; ELASTICITY; ENDANGERED; INCOMPLETE DATA; MATRIX POPULATION MODEL; THREATENED,ANIMAL BIOLOGY,"HEMERIK, L##KLOK, C","UNIV WAGENINGEN & RES CTR, DEPT MATH & STAT METHODS, NL-6700 AC WAGENINGEN, NETHERLANDS. ALTERRA, DEPT ECOL & ENVIRONM, NL-6700 AC WAGENINGEN, NETHERLANDS.",ZOOLOGY,ZOOLOGY,"BAUCHAU V, 1995, J APPL STAT, V22, P1031, DOI 10.1080/02664769524775##BEISSINGER SR, 1998, J WILDLIFE MANAGE, V62, P821, DOI 10.2307/3802534##BOTH CHRISTIAAN, 2002, LIMOSA, V75, P41##BOYD H, 2001, ARDEA, V89, P301##BOYD H., 1962, IBIS, V104, P368, DOI 10.1111/J.1474-919X.1962.TB08664.X##CASWELL H, 1984, AQUACULTURE, V43, P123, DOI 10.1016/0044-8486(84)90016-4##CASWELL H., 2001, MATRIX POPULATION MO##CAUGHLEY G, 1994, J ANIM ECOL, V63, P215, DOI 10.2307/5542##CLOBERT J, 1988, J ANIM ECOL, V57, P287, DOI 10.2307/4779##COVAS R, 2004, AUK, V121, P1199, DOI 10.1642/0004-8038(2004)121[1199:JAASIT]2.0.CO;2##CROUSE DT, 1987, ECOLOGY, V68, P1412, DOI 10.2307/1939225##DEKROON H, 1986, ECOLOGY, V67, P1427, DOI 10.2307/1938700##DOAK D, 1994, ECOL APPL, V4, P446, DOI 10.2307/1941949##DONOVAN TM, 1995, CONSERV BIOL, V9, P1380, DOI 10.1046/J.1523-1739.1995.09061380.X##GREEN RE, 1991, BIRD POPULATION STUD, P594##GROOM MARTHA J., 1998, P4##HEPPELL SS, 2000, ECOLOGY, V81, P654, DOI 10.2307/177367##KLOK C, 1998, J ANIM ECOL, V67, P195, DOI 10.1046/J.1365-2656.1998.00186.X##KLOK C, 2006, ACTA BIOTHEOR, V54, P161, DOI 10.1007/S10441-006-7871-2##NORRIS K, 2003, J APPL ECOL, V40, P890, DOI 10.1046/J.1365-2664.2003.00840.X##PASCUAL MA, 1994, ECOL APPL, V4, P393, DOI 10.2307/1941942##PEACH WJ, 1999, J APPL ECOL, V36, P798, DOI 10.1046/J.1365-2664.1999.00445.X##PIERSMA THEUNIS, 1997, WADER STUDY GROUP BULLETIN, V82, P23##SAETHER BE, 2000, ECOLOGY, V81, P642, DOI 10.2307/177366##VAN ROOMEN MARC, 2005, LIMOSA, V78, P21",6,2020-11-20,NA
J,WOS:000243376200008,2006,VORTEX WAKES OF BIRDS: RECENT DEVELOPMENTS USING DIGITAL PARTICLE IMAGE VELOCIMETRY IN A WIND TUNNEL,"A FLYING ANIMAL GENERATES A TRAIL OF WAKE VORTICES THAT CONTAIN INFORMATION ABOUT THE TIME HISTORY AND MAGNITUDE OF AERODYNAMIC FORCES DEVELOPED ON THE WINGS AND BODY. METHODS FOR VISUALISING AND RECORDING WAKE VORTICES HAVE BEEN DEVELOPED, ALLOWING QUANTITATIVE MEASUREMENTS BY DIGITAL PARTICLE IMAGE VELOCIMETRY (DPIV). RESULTS FROM DPIV EXPERIMENTS IN A WIND TUNNEL ARE PRESENTED FOR FOUR PASSERINE SPECIES OF DIFFERING SIZE AND MORPHOLOGY. THE NORMALISED VORTICITY AND ITS INTEGRATED QUANTITY, CIRCULATION (GAMMA) BOTH DECLINE GRADUALLY WITH INCREASING FLIGHT SPEED. THE MEASURED CIRCULATIONS ARE SUCCESSFULLY EXPLAINED BY A SIMPLE AERODYNAMIC MODEL WHERE A NORMALISED CIRCULATION, GAMMA/UC, REPRESENTS HALF THE TIME-AVERAGED LIFT COEFFICIENT, WHICH IS > 2 AT 4 M S(-1) FOR A THRUSH NIGHTINGALE.",KESTREL FALCO-TINNUNCULUS; ANIMAL FLIGHT; THRUSH NIGHTINGALE; SLOW FLIGHT; AERODYNAMICS; KINEMATICS,ADDED MASS; AERODYNAMICS; BIRD FLIGHT; DIGITAL PARTICLE IMAGE VELOCIMETRY; DPIV; VORTEX WAKES,ANIMAL BIOLOGY,"HEDENSTROM, A##VAN GRIETHUIJSEN, L##ROSEN, M##SPEDDING, GR","LUND UNIV, DEPT THEORET ECOL, SE-22362 LUND, SWEDEN. UNIV WAGENINGEN & RES CTR, EXPT ZOOL GRP, NL-6709 PG WAGENINGEN, NETHERLANDS. LUND UNIV, DEPT ANIM ECOL, SE-22362 LUND, SWEDEN. UNIV SO CALIF, DEPT AERONAUT & MECH ENGN, LOS ANGELES, CA 90089 USA.",ZOOLOGY,ZOOLOGY,"DABIRI JO, 2005, J EXP BIOL, V208, P3519, DOI 10.1242/JEB.01813##DABIRI JO, 2006, J EXP BIOL, V209, P2025, DOI 10.1242/JEB.02242##FINCHAM AM, 1997, EXP FLUIDS, V23, P449, DOI 10.1007/S003480050135##HEDENSTROM A, 2006, J R SOC INTERFACE, V3, P263, DOI 10.1098/RSIF.2005.0091##HEDENSTROM A, 2002, TRENDS ECOL EVOL, V17, P415, DOI 10.1016/S0169-5347(02)02568-5##KOKSHAYSKY NV, 1979, NATURE, V279, P146, DOI 10.1038/279146A0##PENNYCUICK CJ, 1997, J EXP BIOL, V200, P1441##PENNYUICK CJ, 1989, BIRD FLIGHT PERFORMA##RAFFEL M., 1997, PARTICLE IMAGE VELOC##RAYNER JMV, 1979, J EXP BIOL, V80, P17##RAYNER JMV, 1979, J FLUID MECH, V91, P697, DOI 10.1017/S0022112079000410##RAYNER JMV, 1979, J FLUID MECH, V91, P731, DOI 10.1017/S0022112079000422##ROSEN M, 2004, J EXP BIOL, V207, P4255, DOI 10.1242/JEB.01283##SPEDDING GR, 1987, J EXP BIOL, V127, P59##SPEDDING GR, 1984, J EXP BIOL, V111, P81##SPEDDING GR, 1986, J EXP BIOL, V125, P287##SPEDDING GR, 2003, J EXP BIOL, V206, P2313, DOI 10.1242/JEB.00423##SPEDDING GR, 2003, EXP FLUIDS, V34, P291, DOI [10.1007/S00348-002-0559-8, 10.1007/S00348-002-0559-8]##SPEDDING GR, 1987, J EXP BIOL, V127, P45##SPEDDING GR, 2006, IN PRESS AIAA J##TYTELL ED, 2003, PHILOS T R SOC B, V358, P1559, DOI 10.1098/RSTB.2003.1355##WARRICK DR, 2005, NATURE, V435, P1094, DOI 10.1038/NATURE03647",24,2020-11-20,NA
J,WOS:000242198300022,2006,"CORRECTIONS FOR: DETECTION OF QTL FOR IMMUNE RESPONSE TO SHEEP RED BLOOD CELLS IN LAYING HENS (VOL 34, PG 422, 2003)",NA,NA,NA,ANIMAL GENETICS,"SIWEK, M##CORNELISSEN, SJB##NIEUWLAND, MGB##BUITENHUIS, AJ##BOVENHUIS, H##CROOIJMANS, RPMA##GROENEN, MAM##VRIES-REILINGH, G##PARMENTIER, HK##VAN DER POEL, JJ","UNIV WAGENINGEN & RES CTR, INST ANIM SCI, ANIM BREEDING & GENET GRP, NL-6700 AH WAGENINGEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, INST ANIM SCI, ADAPT PHYSIOL GRP, NL-6700 AH WAGENINGEN, NETHERLANDS.","AGRICULTURE, DAIRY & ANIMAL SCIENCE; GENETICS & HEREDITY",AGRICULTURE; GENETICS & HEREDITY,"SEATON G, 2002, BIOINFORMATICS, V18, P339, DOI 10.1093/BIOINFORMATICS/18.2.339##SIWEK M, 2003, ANIM GENET, V34, P422, DOI 10.1046/J.0268-9146.2003.01047.X",3,2020-11-20,NA
J,WOS:000242290500003,2006,THE EFFECT OF THE SUPPLY OF RUMEN DEGRADABLE PROTEIN AND METABOLISABLE PROTEIN ON NEGATIVE ENERGY BALANCE AND FERTILITY IN DAIRY COWS,"REPRODUCTION IN DAIRY CATTLE IS NEGATIVELY AFFECTED BY A NEGATIVE ENERGY BALANCE (NEB), A COMBINATION OF THE DEPOSITION OR MOBILISATION OF FAT AND PROTEIN. THE MODE OF ACTION OF NEB ON FERTILITY IS NOT ALWAYS CLEAR, BUT THE SEVERITY, LENGTH, AND PROBABLY ALSO THE NATURE OF THE NEB MAY BE INVOLVED. EXTENSIVE MOBILISATION OF FAT IS EXPECTED TO HAVE DETRIMENTAL EFFECTS ON LIVER FUNCTION DUE TO THE ACCUMULATION OF NON-ESTERIFIED LONG CHAIN FATTY ACIDS, IMPAIRING THE DETOXIFICATION OF AMMONIA INTO UREA. PROTEIN EVALUATION SYSTEMS NOWADAYS USE THE CONCEPT OF METABOLISABLE PROTEIN (MP) AND DISTINGUISH BETWEEN RUMEN DEGRADABLE PROTEIN (RDP) AND RUMEN UNDEGRADABLE PROTEIN (RUP). MOBILISATION OF PROTEIN ITSELF DOES NOT SEEM TO HAVE NEGATIVE EFFECTS ON REPRODUCTION. HOWEVER, WHEN PROTEIN IS EXTENSIVELY DEGRADED IN THE RUMEN OR USED AS AN ENERGY SOURCE, METABOLIC RESIDUES LIKE AMMONIA AND UREA WILL RESULT. SUCH RESIDUES MAY EXERT METABOLIC EFFECTS THAT ARE OFTEN DETRIMENTAL TO REPRODUCTION AND FERTILITY. AMMONIA IS BELIEVED TO PLAY A ROLE STARTING BEFORE OVULATION, WHEREAS UREA MAINLY INTERFERES NEGATIVELY AFTER FERTILISATION. BUT, UREA IS ALSO BELIEVED TO AGGRAVATE THE SEVERITY OF NEB AND ITS EFFECT ON FERTILITY BY PREVENTING OR DELAYING THE START OF CYCLICITY. BESIDES, UREA HAS BEEN SHOWN TO LOWER THE PH IN THE UTERINE FLUID, GIVING RISE TO DISTURBANCES IN FOLLICULAR DEVELOPMENT AND EMBRYONIC GROWTH. IT IS RECOMMENDED TO LIMIT THE LEVEL OF RUMEN DEGRADABLE PROTEIN IN THE DIET TO 10% IN THE DM. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",MILK UREA NITROGEN; REPRODUCTIVE-PERFORMANCE; DIETARY-PROTEIN; FOLLICULAR DEVELOPMENT; CALVING INTERVALS; EARLY LACTATION; CRUDE PROTEIN; FATTY-ACIDS; NUTRITION; PLASMA,ENERGY BALANCE; PROTEIN MOBILISATION; FAT MOBILISATION; NUTRIENTS; FERTILITY; UREA; AMMONIA,ANIMAL REPRODUCTION SCIENCE,"TAMMINGA, S","UNIV WAGENINGEN & RES CTR, DEPT ANIM SCI, ANIM NUTR GRP, NL-6700 AH WAGENINGEN, NETHERLANDS.","AGRICULTURE, DAIRY & ANIMAL SCIENCE; REPRODUCTIVE BIOLOGY",AGRICULTURE; REPRODUCTIVE BIOLOGY,"ARBEL R, 2001, J DAIRY SCI, V84, P600, DOI 10.3168/JDS.S0022-0302(01)74513-4##BANNINK A, 2006, J THEOR BIOL, V238, P36, DOI 10.1016/J.JTBI.2005.05.026##BARTON BA, 1996, J DAIRY SCI, V79, P2225, DOI 10.3168/JDS.S0022-0302(96)76599-2##BOISCLAIR Y. R., 2006, P327##BUTLER WR, 2005, ADV DAIRY TECHNOL, V17, P159##BUTLER WR, 2003, LIVEST PROD SCI, V83, P211, DOI 10.1016/S0301-6226(03)00112-X##BUTLER WR, 1996, J ANIM SCI, V74, P858##BUTLER WR, 1998, J DAIRY SCI, V81, P2533, DOI 10.3168/JDS.S0022-0302(98)70146-8##BUTLER WR, 2000, ANIM REPROD SCI, V60, P449, DOI 10.1016/S0378-4320(00)00076-2##CANFIELD RW, 1990, J DAIRY SCI, V73, P2342, DOI 10.3168/JDS.S0022-0302(90)78916-3##CARROLL DJ, 1994, J DAIRY SCI, V77, P3058, DOI 10.3168/JDS.S0022-0302(94)77248-9##CHAPA AM, 2001, J DAIRY SCI, V84, P908, DOI 10.3168/JDS.S0022-0302(01)74548-1##COTTRILL B, 2002, VET REC, V151, P413, DOI 10.1136/VR.151.14.413##*CVB, 2004, TAB VEEV 2004##DEBOEVER JL, 2005, P 30 M DUTCH SPEAK N##DOEPEL L, 2002, J DAIRY SCI, V85, P2315, DOI 10.3168/JDS.S0022-0302(02)74312-9##FOX DG, 2004, ANIM FEED SCI TECH, V112, P29, DOI 10.1016/J.ANIFEEDSCI.2003.10.006##FRIGGENS NC, 2003, LIVEST PROD SCI, V83, P219, DOI 10.1016/S0301-6226(03)00111-8##GARCIA-BOJALIL CM, 1998, J DAIRY SCI, V81, P1385, DOI 10.3168/JDS.S0022-0302(98)75702-9##GODDEN SM, 2001, J DAIRY SCI, V84, P1397, DOI 10.3168/JDS.S0022-0302(01)70171-3##GUO K, 2004, J DAIRY SCI, V87, P1878, DOI 10.3168/JDS.S0022-0302(04)73346-9##GUSTAFSSON AH, 1993, LIVEST PROD SCI, V37, P91, DOI 10.1016/0301-6226(93)90066-Q##GUSTAFSSON AH, 1993, J DAIRY SCI, V76, P475, DOI 10.3168/JDS.S0022-0302(93)77368-3##HAMMON DS, 2005, ANIM REPROD SCI, V86, P195, DOI 10.1016/J.ANIREPROSCI.2004.08.003##HAMMON DS, 2000, ANIM REPROD SCI, V59, P23, DOI 10.1016/S0378-4320(00)00071-3##HARE E, 2006, J DAIRY SCI, V89, P365, DOI 10.3168/JDS.S0022-0302(06)72102-6##HOF G, 1994, LIVEST PROD SCI, V38, P169, DOI 10.1016/0301-6226(94)90168-6##HOF G, 1997, J DAIRY SCI, V80, P3333, DOI 10.3168/JDS.S0022-0302(97)76309-4##HOJMAN D, 2004, J DAIRY SCI, V87, P1001, DOI 10.3168/JDS.S0022-0302(04)73245-2##JORRITSMA R, 2003, VET RES, V34, P11, DOI 10.1051/VETRES:2002054##LARSON SF, 1997, J DAIRY SCI, V80, P1288, DOI 10.3168/JDS.S0022-0302(97)76058-2##LAVEN RA, 2004, ANIM REPROD SCI, V84, P41, DOI 10.1016/J.ANIREPROSCI.2003.12.008##LAVEN RA, 1999, VET REC, V145, P687##LEROY JLMR, 2004, THERIOGENOLOGY, V62, P1131, DOI 10.1016/J.THERIOGENOLOGY.2003.12.017##MCCORMICK ME, 1999, J DAIRY SCI, V82, P2697, DOI 10.3168/JDS.S0022-0302(99)75526-8##MCNAMARA S, 2003, ANIM REPROD SCI, V79, P45, DOI 10.1016/S0378-4320(03)00111-8##MELENDEZ P, 2000, J DAIRY SCI, V83, P459, DOI 10.3168/JDS.S0022-0302(00)74903-4##NOUSIAINEN J, 2004, J DAIRY SCI, V87, P386, DOI 10.3168/JDS.S0022-0302(04)73178-1##OCON OM, 2003, J DAIRY SCI, V86, P1194, DOI 10.3168/JDS.S0022-0302(03)73703-5##PETIT HV, 2001, CAN J ANIM SCI, V81, P263, DOI 10.4141/A00-096##PUSHPAKUMARA PGA, 2003, THERIOGENOLOGY, V60, P1165, DOI 10.1016/S0093-691X(03)00119-5##RAJALA-SCHUTZ PJ, 2001, J DAIRY SCI, V84, P482, DOI 10.3168/JDS.S0022-0302(01)74498-0##RHOADS ML, 2006, ANIM REPROD SCI, V91, P1, DOI 10.1016/J.ANIREPROSCI.2005.02.009##RHOADS ML, 2004, J DAIRY SCI, V87, P2896, DOI 10.3168/JDS.S0022-0302(04)73420-7##ROBINSON RS, 2002, REPRODUCTION, V124, P119, DOI 10.1530/REP.0.1240119##RULQUIN H, 1993, REC ADV AN, P55##SCHEPERS AJ, 1998, J DAIRY SCI, V81, P579, DOI 10.3168/JDS.S0022-0302(98)75611-5##SINCLAIR KD, 2000, J ANIM SCI, V78, P2670##SKLAN D, 1993, J DAIRY SCI, V76, P216, DOI 10.3168/JDS.S0022-0302(93)77340-3##SON J, 1996, J DAIRY SCI, V79, P822, DOI 10.3168/JDS.S0022-0302(96)76430-5##STAPLES CR, 1998, J DAIRY SCI, V81, P856, DOI 10.3168/JDS.S0022-0302(98)75644-9##STAPLES CR, 2001, P MIDS RUM NUTR C, P21##TAMMINGA S, 1997, LIVEST PROD SCI, V52, P31, DOI 10.1016/S0301-6226(97)00115-2##TAMMINGA S, 1994, LIVEST PROD SCI, V40, P139, DOI 10.1016/0301-6226(94)90043-4##THOMAS C., 2004, FEED MILK NEW APPL F##VAN KNEGSEL ATM, 2005, REPROD NUTR DEV, V45, P665, DOI 10.1051/RND:2005059##VANDEHAAR MJ, 1999, J DAIRY SCI, V82, P1282, DOI 10.3168/JDS.S0022-0302(99)75351-8##VERBIC J, 1990, J AGR SCI, V114, P243, DOI 10.1017/S0021859600072610##VERITE R, 1989, RUMINANT NUTR RECOMM##WESTWOOD CT, 2002, J DAIRY SCI, V85, P3225, DOI 10.3168/JDS.S0022-0302(02)74411-1##WESTWOOD CT, 2000, J DAIRY SCI, V83, P2926, DOI 10.3168/JDS.S0022-0302(00)75193-9##WITTWER FG, 1999, PREV VET MED, V38, P159, DOI 10.1016/S0167-5877(98)00121-4##WOOD GM, 2003, J DAIRY SCI, V86, P2462, DOI 10.3168/JDS.S0022-0302(03)73840-5##ZHU LH, 2000, J DAIRY SCI, V83, P734, DOI 10.3168/JDS.S0022-0302(00)74935-6",39,2020-11-20,NA
J,WOS:000244179600012,2006,DIETARY CARBOHYDRATES WITH DIFFERENT RATES OF FERMENTATION AFFECT FERMENTATION END-PRODUCT PROFILES IN DIFFERENT SITES OF GASTRO-INTESTINAL TRACT OF WEANING PIGLET,"AN IN VIVO EXPERIMENT WAS CONDUCTED TO EXAMINE CHANGES IN FERMENTATION END-PRODUCTS IN THE GASTRO-INTESTINAL TRACT (GIT) OF WEANING PIGLETS BY THE INCLUSION OF FERMENTABLE CARBOHYDRATES IN THE DIET. THE EXPERIMENT WAS REPEATED IN THREE REPLICATES OF 36 PIGLETS. PIGLETS WERE RAISED FREE OF ANTIBIOTICS AND CREEP FEEDING PRIOR TO WEANING AT 4 WEEKS OF AGE. EACH REPLICATE WAS CONDUCTED OVER A PERIOD OF 10 DAYS. THE PIGLETS WERE OFFERED ONE OF TWO DIETARY TREATMENTS: CONTROL DIET (CON), AND FERMENTABLE CARBOHYDRATE ENRICHED DIET (CHO); AND WERE SUBJECTED TO ONE OF THE TWO FASTING TREATMENTS (I) FASTING FOR 2 DAYS IN THE BEGINNING OF THE EXPERIMENTAL PERIOD AND (II) NON-FASTING. PIGLETS WERE SLAUGHTERED ON THE 1ST, 4TH AND 10TH DAY OF EACH PERIOD. DIGESTA SAMPLES WERE COLLECTED FROM: FIRST HALF OF SMALL INTESTINE, SECOND HALF OF SMALL INTESTINE, CAECUM, AND COLON. THE DRY MATTER, VOLATILE FATTY ACID (VFA) PROFILE, AND AMMONIA CONCENTRATIONS WERE ANALYSED. FOOD INTAKE, GROWTH AND FOOD CONVERSION RATIO WERE ALSO RECORDED. THERE WERE NO DIFFERENCES IN PRODUCTION PERFORMANCES SUCH AS GROWTH AND FOOD CONVERSION RATIO (FCR) BETWEEN THE TREATMENT GROUPS. CONCENTRATIONS OF VFA WERE SIGNIFICANTLY HIGHER, WHILE AMMONIA CONCENTRATION WAS SIGNIFICANTLY LOWER IN THE CHO GROUP COMPARED TO THE CON GROUP IN DIFFERENT FERMENTATION SITES WITHIN THE GIT (P < 0.001), AND ON DIFFERENT SLAUGHTERING DAYS (P < 0.05). FASTING HAD NO EFFECT ON FERMENTATION END-PRODUCTS. THIS STUDY CONCLUDES THAT THE ADDITION OF FERMENTABLE CARBOHYDRATES OF VARYING FERMENTABILITIES STIMULATED CARBOHYDRATE FERMENTATION, WITH REDUCTION IN PROTEIN FERMENTATION ALONG THE DIFFERENT PARTS OF GIT STUDIED, IN WEANING PIGLETS.",LARGE-INTESTINE; GROWING PIGS; POLYSACCHARIDES; PREBIOTICS,CARBOHYDRATES; FERMENTATION; PIGLETS; WEANING,ANIMAL SCIENCE,"AWATI, A##WILLIAMS, BA##BOSCH, MW##VERSTEGEN, MWA","UNIV WAGENINGEN & RES CTR, ANIM NUTR GRP, NL-6700 AH WAGENINGEN, NETHERLANDS.","AGRICULTURE, DAIRY & ANIMAL SCIENCE",AGRICULTURE,"BAUER E, 2001, ANIM SCI, V73, P313, DOI 10.1017/S135772980005829X##BAUER E, 2002, THESIS HOHENHIEM U##BEDFORD M. R., 2001, ENZYMES IN FARM ANIMAL NUTRITION, P299, DOI 10.1079/9780851993935.0299##BERNALIER A, 1999, COLONIC MICROBIOTA N, P37, DOI DOI 10.1007/978-94-017-1079-4_3##CUMMINGS JH, 1987, AM J CLIN NUTR, V45, P1243, DOI 10.1093/AJCN/45.5.1243##DROCHNER W., 1991, EAAP PUBLICATION, P367##EWING W., 1994, LIVING GUT INTRO MIC##GASKINS HR, 2001, SWINE NUTR, P585##GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/JN/125.6.1401##HOPWOOD DE, 2003, WEANING THE PIG: CONCEPTS AND CONSEQUENCES, P199##*INT STAND ORG, 1978, 5984 ISO##*INT STAND ORG, 1999, 6496 ISO##JENSEN BB, 1994, APPL ENVIRON MICROB, V60, P1897, DOI 10.1128/AEM.60.6.1897-1904.1994##KNUDSEN KEB, 1991, BRIT J NUTR, V65, P217, DOI 10.1079/BJN19910082##KONSTANTINOV SR, 2004, APPL ENVIRON MICROB, V70, P3821, DOI 10.1128/AEM.70.7.3821-3830.2004##KONSTANTINOV SR, 2003, FEMS MICROBIOL ECOL, V43, P225, DOI 10.1111/J.1574-6941.2003.TB01062.X##LOW AG, 1978, BRIT J NUTR, V39, P515, DOI 10.1079/BJN19780067##MACFARLANE S, 2003, P NUTR SOC, V62, P67, DOI 10.1079/PNS2002207##MARTINEZ-PUIG D, 2003, J NUTR, V133, P134##SEARLE PL, 1984, ANALYST, V109, P549, DOI 10.1039/AN9840900549##STATISTICAL ANALYSIS SYSTEMS INSTITUTE, 1990, SAS US GUID STAT VER##VANDERWAAIJ D, 1989, ANNU REV MICROBIOL, V43, P69, DOI 10.1146/ANNUREV.MICRO.43.1.69##VORAGEN AGJ, 1986, J CHROMATOGR, V370, P113, DOI 10.1016/S0021-9673(00)94679-X##WILLIAMS BA, 2005, ANIM FEED SCI TECH, V123, P445, DOI 10.1016/J.ANIFEEDSCI.2005.04.031##WILLIAMS BA, 2001, NUTR RES REV, V14, P207, DOI 10.1079/NRR200127",6,2020-11-20,NA
J,WOS:000244179600021,2006,PREDICTION OF THE PERCENTAGE LEAN OF PIG CARCASSES WITH A SMALL OR A LARGE NUMBER OF INSTRUMENTAL CARCASS MEASUREMENTS - AN ILLUSTRATION WITH HGP AND VISION,"IN THIS PAPER WE REPORT ON THE RESULTS OF A RECENT DISSECTION EXPERIMENT IN THE NETHERLANDS WHERE PREDICTION FORMULAE FOR THE PERCENTAGE LEAN MEAT IN PIG CARCASSES WITH THE HENNESSY GRADING PROBE (HGP) AND A VISION SYSTEM (FROM NOW ON REFERRED TO AS VISION) WERE DETERMINED. PREDICTIONS WITH THE HGP WERE BASED ON ONE FAT AND ONE MUSCLE DEPTH MEASUREMENT ONLY, WHILE PREDICTIONS WITH VISION WERE BASED ON AS MANY AS 115 DIRECT AND DERIVED MEASUREMENTS. THE DATA FROM THIS DISSECTION EXPERIMENT WERE USED TO ILLUSTRATE THE STATISTICAL CALCULATIONS INVOLVED IN RELATION TO THE NUMBER OF CARCASS MEASUREMENTS. PREDICTION WITH INSTRUMENTS THAT GATHER A LARGE NUMBER OF MEASUREMENTS PER CARCASS IS NOT COVERED BY THE PRESENT EUROPEAN COMMUNITY (EC) REGULATIONS. THEREFORE THE CALCULATIONS WERE CONDUCTED ACCORDING TO NEW REGULATIONS FOR STATISTICAL METHODOLOGY IN PIG CARCASS GRADING THAT ARE EXPECTED TO BE ADOPTED BY THE EC IN THE NEAR FUTURE. THE CALCULATIONS INCLUDED CONSIDERATION OF 3 SUBPOPULATIONS (FEMALES, ENTIRE MALES AND CASTRATED MALES). THE VISION DATA WERE ALSO USED TO SHOW THAT ORDINARY REGRESSION AFTER SELECTION OF A SUBSET OF CARCASS MEASUREMENTS SEVERELY UNDER ESTIMATES THE ACCURACY OF PREDICTION: INSTRUMENTS AND ASSOCIATED PREDICTION FORMULAE ARE SEEMINGLY MUCH MORE ACCURATE THAN THEY TRULY ARE. WHEN STANDARD REGRESSION METHODS ARE USED FOR INSTRUMENTS THAT GATHER A LARGE NUMBER OF MEASUREMENTS, THERE IS A CONSIDERABLE RISK THAT MEASUREMENT INSTRUMENTS WILL BE SELECTED FOR THE WRONG REASONS. ACCURACY OF APPROVED INSTRUMENTS MAY NOT EVEN COMPLY WITH THE EC-REGULATIONS, WITH POOR CONSEQUENCES FOR HARMONIZATION WITHIN THE EC.",SQUARES REGRESSION; PRECISION; EXPENSE; MEAT,CARCASS COMPOSITION; LEAN; LEAST SQUARES; PIGS; PREDICTION; REGRESSION ANALYSIS,ANIMAL SCIENCE,"ENGEL, B##LAMBOOIJ, E##BUIST, WG##REIMERT, H##MATEMAN, G","WAGENINGEN UR, ANIM SCI GRP, NL-8200 AB LELYSTAD, NETHERLANDS.","AGRICULTURE, DAIRY & ANIMAL SCIENCE",AGRICULTURE,"BROWN P., 1993, MEASUREMENT REGRESSI##BUTLER NA, 2000, J ROY STAT SOC B, V62, P585, DOI 10.1111/1467-9868.00252##CAUSEUR D, 2005, J STAT PLAN INFER, V128, P289, DOI 10.1016/J.JSPI.2003.11.003##CAUSEUR D, 2006, IN PRESS STAT HDB AS##CAUSEUR DJ, 1998, BIOMETRICS, V54, P1591, DOI 10.2307/2533683##CONIFFE D, 1985, J ECONOMETRICS, V27, P179##ENGEL B, 1991, ANIM PROD, V53, P353, DOI 10.1017/S0003356100020365##ENGEL B, 2003, ANIM SCI, V76, P199, DOI 10.1017/S1357729800053455##ENGEL B, 1991, BIOMETRICS, V47, P13, DOI 10.2307/2532491##ENGEL B, 1991, STAT ANAL DUTCH DISS##EUPIGCLASS, 2000, STAND PIG CARC CLASS##FEARN T, 1983, APPL STAT, V32, P73##FURNOLS M. FONT I, 2004, SPANISH JOURNAL OF AGRICULTURAL RESEARCH, V2, P545##GUSNANTO A, 2003, J CHEMOMETR, V17, P174, DOI 10.1002/CEM.787##HELLAND IS, 1988, COMMUN STAT SIMULAT, V17, P581, DOI 10.1080/03610918808812681##MARTENS H., 1989, MULTIVARIATE CALIBRA##MONTGOMERY D., 1992, INTRO LINEAR REGRESS##OSTEN DW, 1988, J CHEMOMETR, V2, P79##PAYNE RW, 2000, GUIDE GENSTAT##*STAT AN SYST I IN, 1994, US GUID VERS 6##STONE M, 1990, J ROY STAT SOC B MET, V52, P237##WALSTRA P, PROCEDURE ASSESSMENT##WALSTRA P, 1986, VI484986 EC",10,2020-11-20,NA
J,WOS:000242908400003,2006,ADJUVANT THERAPIES IN MANAGEMENT OF MALIGNANT MELANOMA,NA,NA,NA,ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE,"EGGERMONT, AMM","ERASMUS UNIV, MED CTR, DR DANIEL DEN HOED CANC CTR, DEPT SURG ONCOL, NL-3075 EA ROTTERDAM, NETHERLANDS.",DERMATOLOGY,DERMATOLOGY,"EGGERMONT AMM, 2006, SURG ONCOL CLIN N AM, V15, P439, DOI 10.1016/J.SOC.2005.12.001##EGGERMONT AMM, 2005, LANCET, V366, P1189, DOI 10.1016/S0140-6736(05)67482-X##MORTON DL, 2006, NEW ENGL J MED, V355, P1307, DOI 10.1056/NEJMOA060992##VAN AKKOOI ACJ, 2006, ANN ONCOL, V17, P1578, DOI 10.1093/ANNONC/MDL176",0,2020-11-20,NA
J,WOS:000242609700003,2006,DEPENDENCE OF INTRAMYOCARDIAL PRESSURE AND CORONARY FLOW ON VENTRICULAR LOADING AND CONTRACTILITY: A MODEL STUDY,"THE PHASIC CORONARY ARTERIAL INFLOW DURING THE NORMAL CARDIAC CYCLE HAS BEEN EXPLAINED WITH SIMPLE (WATERFALL, INTRAMYOCARDIAL PUMP) MODELS, EMPHASIZING THE ROLE OF VENTRICULAR PRESSURE. TO EXPLAIN CHANGES IN ISOVOLUMIC AND LOW AFTERLOAD BEATS, THESE MODELS WERE EXTENDED WITH THE EFFECT OF THREE-DIMENSIONAL WALL STRESS, NONLINEAR CHARACTERISTICS OF THE CORONARY BED, AND EXTRAVASCULAR FLUID EXCHANGE. WITH THE ASSOCIATED INCREASE IN THE NUMBER OF MODEL PARAMETERS, A DETAILED PARAMETER SENSITIVITY ANALYSIS HAS BECOME DIFFICULT. THEREFORE WE INVESTIGATED THE PRIMARY RELATIONS BETWEEN VENTRICULAR PRESSURE AND VOLUME, WALL STRESS, INTRAMYOCARDIAL PRESSURE AND CORONARY BLOOD FLOW, WITH A MATHEMATICAL MODEL WITH A LIMITED NUMBER OF PARAMETERS. THE MODEL REPLICATES SEVERAL EXPERIMENTAL OBSERVATIONS: THE PHASIC CHARACTER OF CORONARY INFLOW IS VIRTUALLY INDEPENDENT OF MAXIMUM VENTRICULAR PRESSURE, THE AMPLITUDE OF THE CORONARY FLOW SIGNAL VARIES ABOUT PROPORTIONALLY WITH CARDIAC CONTRACTILITY, AND INTRAMYOCARDIAL PRESSURE IN THE VENTRICULAR WALL MAY EXCEED VENTRICULAR PRESSURE. A PARAMETER SENSITIVITY ANALYSIS SHOWS THAT THE NORMALIZED AMPLITUDE OF CORONARY INFLOW IS MAINLY DETERMINED BY CONTRACTILITY, REFLECTED IN VENTRICULAR PRESSURE AND, AT LOW VENTRICULAR VOLUMES, RADIAL WALL STRESS. NORMALIZED FLOW AMPLITUDE IS LESS SENSITIVE TO MYOCARDIAL CORONARY COMPLIANCE AND RESISTANCE, AND TO THE RELATION BETWEEN ACTIVE FIBER STRESS, TIME, AND SARCOMERE SHORTENING VELOCITY.",VARYING ELASTANCE; BLOOD-FLOW; IMPEDIMENT; STRAIN; CIRCULATION; DETERMINANT; RESISTANCE; STRESS; WALL; DOG,VENTRICULAR MECHANICS; RADIAL WALL STRESS; EMPTY BEATING HEART; LUMPED PARAMETER MODEL; INTRAMYOCARDIAL PUMP,ANNALS OF BIOMEDICAL ENGINEERING,"BOVENDEERD, PHM##BORSJE, P##ARTS, T##VAN DE VOSSE, FN","EINDHOVEN UNIV TECHNOL, DEPT BIOMED ENGN, NL-5600 MB EINDHOVEN, NETHERLANDS. MAASTRICHT UNIV, DEPT BIOPHYS, NL-6200 MD MAASTRICHT, NETHERLANDS.","ENGINEERING, BIOMEDICAL",ENGINEERING,"ARTS T, 1985, J BIOMECH ENG-T ASME, V107, P51, DOI 10.1115/1.3138520##ARTS T, 1991, BIOPHYS J, V59, P93, DOI 10.1016/S0006-3495(91)82201-9##ARTS T, 1978, THESIS U LIMBURG MAA##BASSINGTHWAIGHTE JB, 2001, BASIC RES CARDIOL, V96, P582, DOI 10.1007/S003950170010##BEYAR R, 1993, CARDIOVASC RES, V27, P2254, DOI 10.1093/CVR/27.12.2254##BRUINSMA P, 1988, BASIC RES CARDIOL, V83, P510, DOI 10.1007/BF01906680##CHILIAN WM, 1989, AM J PHYSIOL, V256, PH383##DETOMBE PP, 1991, CIRC RES, V68, P588, DOI 10.1161/01.RES.68.2.588##DOWNEY JM, 1974, CIRC RES, V34, P251, DOI 10.1161/01.RES.34.2.251##FOKKEMA DS, 2005, AM J PHYSIOL-HEART C, V288, PH2450, DOI 10.1152/AJPHEART.00790.2004##GIEZEMAN MJMM, 1994, AM J PHYSIOL, V267, PH1190##HUYGHE JM, 1992, AM J PHYSIOL, V262, PH1256##JANSSEN PM, 1909, AM J PHYSIOL, V269, PH676##KOUWENHOVEN E, 1992, AM J PHYSIOL, V263, PH484##KRAMS R, 1989, BASIC RES CARDIOL, V84, P149, DOI 10.1007/BF01907924##KRAMS R, 1989, AM J PHYSIOL, V257, PH1471##KRAMS R, 1989, AM J PHYSIOL, V257, PH1936##MIHAILESCU LS, 1994, AM J PHYSIOL, V266, PH1233##NIKOLIC S, 1988, CIRC RES, V62, P1210, DOI 10.1161/01.RES.62.6.1210##PAGLIARO P, 1998, EXP PHYSIOL, V83, P821, DOI 10.1113/EXPPHYSIOL.1998.SP004162##RIJCKEN J, 1999, ANN BIOMED ENG, V27, P289, DOI 10.1114/1.147##SPAAN JAE, 1981, CIRC RES, V49, P584, DOI 10.1161/01.RES.49.3.584##SPAAN JAE, 1985, CIRC RES, V56, P293, DOI 10.1161/01.RES.56.3.293##VENDELIN M, 2002, AM J PHYSIOL-HEART C, V283, PH1072, DOI 10.1152/AJPHEART.00874.2001##VIS MA, 1997, AM J PHYSIOL-HEART C, V273, PH1003##VIS MA, 1997, AM J PHYSIOL-HEART C, V272, PH1516##VIS MA, 1997, AM J PHYSIOL-HEART C, V272, PH2963##YIN FCP, 1987, J BIOMECH, V20, P577, DOI 10.1016/0021-9290(87)90279-X##ZINEMANAS D, 1995, AM J PHYSIOL-HEART C, V268, PH633##ZINEMANAS D, 1994, ANN BIOMED ENG, V22, P638, DOI 10.1007/BF02368289",61,2020-11-20,NA
J,WOS:000242609700005,2006,REMOTE NON-INVASIVE STEREOSCOPIC IMAGING OF BLOOD VESSELS: FIRST IN-VIVO RESULTS OF A NEW MULTISPECTRAL CONTRAST ENHANCEMENT TECHNOLOGY,"WE DESCRIBE A CONTACTLESS OPTICAL TECHNIQUE SELECTIVELY ENHANCING SUPERFICIAL BLOOD VESSELS BELOW VARIOUSLY PIGMENTED INTACT HUMAN SKIN BY COMBINING IMAGES IN DIFFERENT SPECTRAL BANDS. TWO CMOS-CAMERAS, WITH APOCHROMATIC LENSES AND DUAL-BAND LED-ARRAYS, SIMULTANEOUSLY STREAMED LEFT (L) AND RIGHT (R) IMAGE DATA TO A DUALPROCESSOR PC. BOTH CAMERAS CAPTURED COLOR IMAGES WITHIN THE VISIBLE RANGE (VIS, 400-780 NM) AND GREY-SCALE IMAGES WITHIN THE NEAR INFRARED RANGE (NIR, 910-920 NM) BY SEQUENTIALLY SWITCHING BETWEEN LED-ARRAY EMISSION BANDS. IMAGE-SIZE-SETTINGS OF 1280 X 1024 FOR VIS & 640 X 512 FOR NIR PRODUCED 12 CYCLES/S (1 CYCLE = 1 VIS L&R-PAIR + I NIR L&R-PAIR). DECREASING IMAGE-SIZE-SETTINGS (640 X 512 FOR VIS AND 320 X 256 FOR NIR) INCREASED CAMERA-SPEED TO 25 CYCLES/S. CONTRASTS FROM BELOW THE TISSUE SURFACE WERE ALGORITHMICALLY DISTINGUISHED FROM SURFACE SHADOWS, REFLECTIONS, ETC. THUS BLOOD VESSELS WERE SELECTIVELY ENHANCED AND BACK-PROJECTED INTO THE STEREOSCOPIC VIS-COLOR-IMAGE USING EITHER A 3D-DISPLAY OR CONVENTIONAL SHUTTER GLASSES. AS A FIRST USABILITY RECONNAISSANCE WE APPLIED THIS CUSTOM-BUILT MOBILE STEREOSCOPIC CAMERA FOR SEVERAL CLINICAL SETTINGS: BLOOD WITHDRAWAL; VEIN INSPECTION IN DARK SKIN; VEIN DETECTION THROUGH IODIDE: VARICOSE VEIN AND NEVI PIGMENTOSUM INSPECTION. OUR TECHNIQUE IMPROVES BLOOD VESSEL VISUALIZATION COMPARED TO THE NAKED EYE, AND SUPPORTS DEPTH PERCEPTION.",VISUALIZATION; VIDEO,MULTISPECTRAL STEREOSCOPY; CONTACTLESS ENHANCED VIEWING OF SUPERFICIAL VASCULATURE; INTUITIVE TECHNOLOGY; RECONNAISSANCE OF FEASIBILITY FOR VARIOUS CLINICAL APPLICATIONS; 3D-DISPLAY,ANNALS OF BIOMEDICAL ENGINEERING,"WIERINGA, FP##MASTIK, F##TEN CATE, FJ##NEUMANN, HAM##VAN DER STEEN, AFW","CTR THORAX, ERASMUS MC, DEPT BIOMED ENGN, NL-3000 DR ROTTERDAM, NETHERLANDS. TNO, QUAL LIFE, LEIDEN, NETHERLANDS. TNO, O2 VIEW BV, LEIDEN, NETHERLANDS. ERASMUS MC, CTR THORAX, DEPT CARDIOL, ROTTERDAM, NETHERLANDS. ERASMUS MC, CTR THORAX, DEPT DERMATOL & VENEROL, ROTTERDAM, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS.","ENGINEERING, BIOMEDICAL",ENGINEERING,"ANDERSON BL, 2006, VISION RES, V46, P1982, DOI 10.1016/J.VISRES.2005.11.024##DALLOW RL, 1974, ARCH OPHTHALMOL-CHIC, V92, P531, DOI 10.1001/ARCHOPHT.1974.01010010545019##DEGRAVE DD, 2005, USE ILLUSORY VISUAL, P112##ELSNER AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E##GOSTOUT CJ, 1995, GASTROINTEST ENDOSC, V41, P218, DOI 10.1016/S0016-5107(95)70341-1##GRONER W, 1999, NAT MED, V5, P1209##HARDY JE, 1996, INVEST RADIOL, V31, P433, DOI 10.1097/00004424-199607000-00006##HAUSTEIN U F, 1967, ASTHET MED (BERL), V16, P155##HAYASHI N, 1994, ENDOSCOPY, V26, P686, DOI 10.1055/S-2007-1009066##JOHNSON LG, 2003, ST HEAL T, V94, P131##JONES CH, 1977, BRIT J RADIOL, V50, P209, DOI 10.1259/0007-1285-50-591-209##KONO M, 2002, APPL OPTICS, V41, P7429, DOI 10.1364/AO.41.007429##ONTIKOVA N M, 1976, MED TEKH, P20##SACHSENWEGER M, 1991, DOC OPHTHALMOL, V78, P1##SHIPLEY T, 1987, DOC OPHTHALMOL, V66, P95, DOI 10.1007/BF00140453##SZOLD A, 2005, SURG ENDOSC, V19, P730, DOI 10.1007/S00464-004-8272-8##TAFFINDER N, 1999, SURG ENDOSC-ULTRAS, V13, P1087, DOI 10.1007/S004649901179##TSE PU, 1999, COGNITIVE PSYCHOL, V39, P37, DOI 10.1006/COGP.1999.0715##WEBB S, PHYS MED IMAGING##WIERINGA FP, 2005, ANN BIOMED ENG, V33, P1034, DOI 10.1007/S10439-005-5763-2##WIERINGA FP, 2005, PATENT NO. 1566142A1##WISSMANNS HF, 1968, MED WELT, V20, P191##WOODS DD, 2002, COGN TECHNOL WORK, P22##YIN C, 2000, VISION RES, V40, P1969, DOI 10.1016/S0042-6989(00)00047-X##ZEMAN HD, 2004, PROTOTYPE VEIN CONTR##1900, ACHTUNDZWANSIGTE VER",21,2020-11-20,NA
J,WOS:000242609700008,2006,DEVELOPMENT OF A DOUBLE-MEMBRANE SOUND GENERATOR FOR APPLICATION IN A VOICE-PRODUCING ELEMENT FOR LARYNGECTOMIZED PATIENTS,"FOR VOICE REHABILITATION AFTER TOTAL LARYNGECTOMY A SHUNT VALVE IS USUALLY PLACED IN THE TRACHEO-ESOPHAGEAL (TE) WALL, THEREBY ENABLING THE PRODUCTION OF A TE VOICE. SOME PATIENTS, HOWEVER, ARE UNABLE TO PRODUCE A VOICE OF SUFFICIENT QUALITY. FURTHERMORE, THE TE VOICE IS LOW PITCHED, WHICH PRESENTS A PROBLEM ESPECIALLY FOR FEMALE LARYNGECTOMIZED PATIENTS. THE VOICE QUALITY AFTER LARYNGECTOMY MIGHT BE IMPROVED BY INTRODUCING A VOICE-PRODUCING ELEMENT (VPE) INTO THE TE SHUNT VALVE. IN THIS STUDY A SOUND GENERATOR WAS DEVELOPED THAT IS SUITABLE FOR APPLICATION IN SUCH A VPE. THIS SOUND GENERATOR CONSISTS OF TWO ELASTIC MEMBRANES PLACED PARALLEL INSIDE A CIRCULAR HOUSING. A SUBSTITUTE VOICE SOURCE IS CREATED WHEN THE MEMBRANES START TO VIBRATE VIA A CONSTANT FLOW OF AIR PASSING BETWEEN THEM. TO DETERMINE THE OPTIMAL MEMBRANE CONFIGURATION FOR PROPER FUNCTIONING UNDER PHYSIOLOGICAL CONDITIONS, UP-SCALED PHYSICAL VPE MODELS WITH DIFFERENT MEMBRANE GEOMETRIES WERE EVALUATED USING IN VITRO EXPERIMENTAL TESTS. FOR CERTAIN MEMBRANE GEOMETRIES THE TESTS SHOWED THAT A BASIC SOUND, CONTAINING MULTIPLE HARMONICS, COULD BE SUCCESSFULLY PRODUCED UNDER PHYSIOLOGICAL AIR PRESSURE AND AIRFLOW CONDITIONS. THE FUNDAMENTAL FREQUENCY (60-95 HZ) AND SOUND PRESSURE LEVEL (57-78 DB, AT 15 CM MICROPHONE DISTANCE) WERE REGULATED VIA CHANGES IN THE DRIVING PRESSURE, THEREBY ENABLING THE POSSIBILITY OF INTONATION IN LARYNGECTOMIZED PATIENTS' SPEECH. THE OBTAINED FREQUENCY RANGE IS CONSIDERED APPROPRIATE FOR PRODUCING A SUBSTITUTE VOICE SOURCE FOR FEMALE PATIENTS. THE GEOMETRY CONSIDERATIONS IN THIS STUDY CAN BE USED FOR THE DEVELOPMENT OF A TRUE SCALE VPE THAT CAN BE EVALUATED CLINICALLY, TO EVENTUALLY REPLACE THE VOICE AFTER LARYNGECTOMY.",VOCAL REHABILITATION; PROSTHESIS; ESOPHAGEAL; SPEAKERS; SPEECH; MODEL,LARYNGECTOMY; VOICE REHABILITATION; SHUNT VALVE; VOICE PROSTHESIS; IN VITRO TEST; SELF-SUSTAINED OSCILLATIONS; AERO-ACOUSTICS; VOICE SOUND,ANNALS OF BIOMEDICAL ENGINEERING,"TACK, JW##VERKERKE, GJ##VAN DER HOUWEN, EB##MAHIEU, HF##SCHUTTE, HK","UNIV GRONINGEN, MED CTR, DEPT BIOMED ENGN, NL-9713 AV GRONINGEN, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, DEPT OTORHINOLARYNGOL, NL-1007 MB AMSTERDAM, NETHERLANDS.","ENGINEERING, BIOMEDICAL",ENGINEERING,"ALGABA J., 1996, 2 INT S LAR TRACH RE, P263##BLOOD GW, 1984, J COMMUN DISORD, V17, P319, DOI 10.1016/0021-9924(84)90034-0##CHEESMAN AD, 1986, J LARYNGOL OTOL, V100, P191, DOI 10.1017/S0022215100098960##COLLIER R, 1975, J ACOUST SOC AM, V58, P249, DOI 10.1121/1.380654##DE VRIES MP, 2003, J ACOUST SOC AM, V113, P2077, DOI 10.1121/1.1560163##DE VRIES MP, 2000, INT J ARTIF ORGANS, V23, P462##FEE MS, 1998, NATURE, V395, P67, DOI 10.1038/25725##FLETCHER N H, 1998, PHYS MUSICAL INSTRUM##FLETCHER NH, 1988, J THEOR BIOL, V135, P455, DOI 10.1016/S0022-5193(88)80270-4##FLETCHER NH, 1993, J ACOUST SOC AM, V93, P2172, DOI 10.1121/1.406857##FLETCHER NH, 1979, ACUSTICA, V43, P65##GREENEWALT CH, 1968, BIRD SONG ACOUSTICS##HAGEN R, 1998, LARYNGO RHINO OTOL, V77, P312, DOI 10.1055/S-2007-996980##HILGERS JM, 1990, LARYNGOSCOPE, V100, P1202##HIRSCHBERG A, 1990, ACUSTICA, V70, P146##MAHIEU HF, 1987, LARYNGOSCOPE, V97, P451##MAHIEU HF, 1988, THESIS##NIJDAM HF, 1982, ARCH OTO-RHINO-LARYN, V237, P27, DOI 10.1007/BF00453713##PANJE WR, 1981, ANN OTO RHINOL LARYN, V90, P116, DOI 10.1177/000348948109000204##QI YY, 1995, J SPEECH HEAR RES, V38, P536, DOI 10.1044/JSHR.3803.536##RATNER B. D., 2004, BIOMATERIALS SCI INT##ROBBINS J, 1984, J SPEECH HEAR DISORD, V49, P202, DOI 10.1044/JSHD.4902.202##SCHUTTE H., 1980, EFFICIENCY VOICE PRO##SINGER MI, 1980, ANN OTO RHINOL LARYN, V89, P829##SRAM F, 1989, INSTRUMENTALSPIEL, P231##'T HART JOHAN, 1990, PERCEPTUAL STUDY INT##TACK JW, 2003, THESIS U TWENTE##VAN DER TORN M, 2001, LARYNGOSCOPE, V111, P336, DOI 10.1097/00005537-200102000-00027##VANDENBERG J, 1956, ACTA PHYSIOL PHARM N, V5, P40",12,2020-11-20,NA
J,WOS:000242609700010,2006,COMPARISON OF DYNAMIC SHEAR PROPERTIES OF THE PORCINE MOLAR AND INCISOR PERIODONTAL LIGAMENT,"THE ROLE OF THE PERIODONTAL LIGAMENT (PDL) IS TO SUPPORT THE TOOTH DURING FUNCTION AND RESIST EXTERNAL FORCES APPLIED TO IT. THE DOMINANT VERTICAL COMPONENT OF THESE FORCES IS ASSOCIATED WITH SHEAR IN THE PDL. THE MECHANICAL RESPONSE TO VERTICAL FORCE MAY, HOWEVER, BE DIFFERENT BETWEEN THE MOLAR AND INCISOR AS THEIR LOADING REGIMEN IS DIFFERENT. THE PRESENT STUDY WAS DESIGNED TO DETERMINE THE VISCOELASTIC BEHAVIOR IN SHEAR OF THE PDL OF THE PORCINE MOLAR AND INCISOR (N=10 FOR EACH). FROM DISSECTED MANDIBLES TRANSVERSE SECTIONS INCLUDING THE MESIAL ROOT OF FIRST MOLAR AND THE INCISAL ROOT WERE OBTAINED AND USED FOR DYNAMIC SHEAR TESTS. SHEAR STRAIN OF 1.0% WAS APPLIED IN SUPEROINFERIOR DIRECTION PARALLEL TO THE ROOT AXIS WITH A WIDE RANGE OF FREQUENCIES (0.01-100 HZ). THE VISCOELASTIC BEHAVIOR WAS CHARACTERIZED BY THE STORAGE AND LOSS MODULUS AND LOSS TANGENT AS A FUNCTION OF THE FREQUENCY. FOR THE INCISOR AND MOLAR, THE COMPLEX AND STORAGE MODULI INCREASED SIGNIFICANTLY WITH THE FREQUENCY. FOR THE INCISOR, THE LOSS MODULUS ALSO INCREASED WITH THE FREQUENCY. THE LOSS MODULUS AND LOSS TANGENT WERE SIGNIFICANTLY (P < 0.05) LARGER IN THE INCISOR THAN IN THE MOLAR. THE PRESENT RESULTS SUGGEST THAT THE INCISAL PDL REVEALED MORE VISCOUS BEHAVIOR DURING DYNAMIC SHEAR THAN THE MOLAR ONE, WHICH MIGHT HAVE IMPORTANT IMPLICATIONS FOR THE PRINCIPAL ROLE OF THE ANTERIOR TEETH SUCH AS PDL SENSATION.",RAT MOLAR; BIOMECHANICAL BEHAVIOR; STRESS-STRAIN; RESPONSES; FORCE; AGE,PERIODONTAL LIGAMENT; DYNAMIC SHEAR PROPERTIES; VISCOELASTICITY,ANNALS OF BIOMEDICAL ENGINEERING,"TANAKA, E##INUBUSHI, T##KOOLSTRA, JH##VAN EIJDEN, TMGJ##SANO, R##TAKAHASHI, K##KAWAI, N##REGO, EB##TANNE, K","HIROSHIMA UNIV, GRAD SCH BIOMED SCI, DEPT ORTHODONT & CRANIOFACIAL DEV BIOL, MINAMI KU, HIROSHIMA 7348553, JAPAN. ACTA, DEPT FUNCT ANAT, AMSTERDAM, NETHERLANDS.","ENGINEERING, BIOMEDICAL",ENGINEERING,"BERKOVITZ BKB, PERIODONTAL LIGAMENT##CHIBA M, 1993, J BIOMECH, V26, P561, DOI 10.1016/0021-9290(93)90017-9##CHRISTENSEN C. M., 1984, ADVANCES IN FOOD RESEARCH, V29, P159, DOI 10.1016/S0065-2628(08)60057-9##COFFEY JP, 1989, J ORAL REHABIL, V16, P529, DOI 10.1111/J.1365-2842.1989.TB01374.X##DRUZINSKY RE, 1993, J THEOR BIOL, V160, P427, DOI 10.1006/JTBI.1993.1028##HELKIMO E, 1977, ACTA ODONTOL SCAND, V35, P297, DOI 10.3109/00016357709064128##KAWAMURA Y, 1964, ADV ORAL BIOL, P77##KOHYAMA K, 2000, J TEXTURE STUD, V31, P577, DOI 10.1111/J.1745-4603.2000.TB01020.X##KOHYAMA K, 2004, ARCH ORAL BIOL, V49, P805, DOI 10.1016/J.ARCHORALBIO.2004.04.006##KOMATSU K, 2004, ARCH ORAL BIOL, V49, P817, DOI 10.1016/J.ARCHORALBIO.2004.04.002##KOMATSU K, 2004, J BIOMECH, V37, P1097, DOI 10.1016/J.JBIOMECH.2003.11.013##KOMATSU K, 1993, ARCH ORAL BIOL, V38, P369, DOI 10.1016/0003-9969(93)90207-3##KOMATSU K, 1998, ANAT REC, V250, P408, DOI 10.1002/(SICI)1097-0185(199804)250:4<408::AID-AR3>3.0.CO;2-T##KOOLSTRA JH, 2002, CRIT REV ORAL BIOL M, V13, P366, DOI 10.1177/154411130201300406##LANGENBACH GEJ, 2001, AM ZOOL, V41, P1338, DOI 10.1668/0003-1569(2001)041[1338:MFMP]2.0.CO;2##LAVELLE CLB, 1998, APPL ORAL PHYSL, P12##LAVIGNE G, 1987, J NEUROPHYSIOL, V58, P342##MOXHAM BJ, 1995, ARCHS ORAL BIOL, V94, P763##PINI M, 2004, J BIOMECH, V37, P111, DOI 10.1016/S0021-9290(03)00234-3##SANCTUARY CS, 2005, J APPL PHYSIOL, V99, P2369, DOI 10.1152/JAPPLPHYSIOL.00486.2005##SHIBATA T, 2006, EUR J ORAL SCI, V114, P74, DOI 10.1111/J.1600-0722.2006.00269.X##SHUTTLEWORTH CA, 1983, INT REV CONNECT TISS, V10, P211##TANAKA E, 2003, CRIT REV ORAL BIOL M, V14, P138, DOI 10.1177/154411130301400207##TANAKA E, 2003, J DENT RES, V82, P228, DOI 10.1177/154405910308200315##TANAKA E, 2006, IN PRESS J BIOMECH, DOI DOI 10.1016/J.BIOMECH.2006.06.022##TANNE K, 1998, BR J ORTHOD, V25, P109##TANNE K, 1995, ANGLE ORTHOD, V65, P123##THROCKMORTON GS, 1980, AM J ORTHOD DENTOFAC, V77, P410, DOI 10.1016/0002-9416(80)90106-2##WATANABE Y, 1997, CONNECT TISSUE RES, V36, P35, DOI 10.3109/03008209709160212##YOSHIDA N, 2001, MED ENG PHYS, V23, P567, DOI 10.1016/S1350-4533(01)00073-X",10,2020-11-20,NA
J,WOS:000241714500041,2006,TIMING OF SURGICAL INTERVENTION IN NECROTIZING PANCREATITIS,NA,NA,NA,PANCREAS,"BESSELINK, MGH##SCHOENMAECKERS, EJP##BUSKENS, E##RIDWAN, BU##VISSER, MR##NIEUWENHUIJS, VB##GOOSZEN, HG","UNIV MED CTR UTRECHT, DEPT SURG, UTRECHT, NETHERLANDS. UNIV MED CTR UTRECHT, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS. UNIV MED CTR UTRECHT, DEPT MICROBIOL, UTRECHT, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,NA,0,2020-11-20,NA
J,WOS:000241714500040,2006,DESCRIBING CT FINDINGS IN ACUTE NECROTIZING PANCREATITIS WITH THE ATLANTA CLASSIFICATION: AN INTEROBSERVER AGREEMENT STUDY,NA,NA,NA,PANCREAS,"BESSELINK, MGH##VAN SANTVOORT, HC##BOLLEN, TL##VAN LEEUWEN, MS##GOOSZEN, HG","UNIV MED CTR, DEPT RADIOL, UTRECHT, NETHERLANDS. UNIV MED CTR, DEPT SURG, UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, DEPT RADIOL, NIEUWEGEIN, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,NA,0,2020-11-20,NA
J,WOS:000241714500046,2006,TOWARDS AN UPDATE OF THE ATLANTA CLASSIFICATION ON ACUTE PANCREATITIS: REVIEW OF NEW AND ABANDONED TERMS,NA,NA,NA,PANCREAS,"BOLLEN, TL##BESSELINK, MGH##VAN SANTVOORT, HC##GOOSZEN, HG##VAN LEEUWEN, MS","ST ANTONIUS HOSP, DEPT RADIOL, NIEUWEGEIN, NETHERLANDS. UNIV MED CTR, DEPT SURG, UTRECHT, NETHERLANDS. UNIV MED CTR, DEPT RADIOL, UTRECHT, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,NA,0,2020-11-20,NA
J,WOS:000241714500047,2006,THE ATLANTA CLASSIFICATION ON ACUTE PANCREATITIS REVISITED: REVIEW OF THE LITERATURE,NA,NA,NA,PANCREAS,"BOLLEN, TL##VAN SANTVOORT, HC##BESSELINK, MGH##VAN LEEUWEN, MS##HORVATH, KD##FREENY, PC##GOOSZEN, HG","ST ANTONIUS HOSP, DEPT RADIOL, NIEUWEGEIN, NETHERLANDS. UNIV MED CTR UTRECHT, DEPT SURG, UTRECHT, NETHERLANDS. UNIV MED CTR UTRECHT, DEPT RADIOL, UTRECHT, NETHERLANDS. UNIV WASHINGTON, MED CTR, DEPT SURG, SEATTLE, WA 98195 USA. UNIV WASHINGTON, MED CTR, DEPT RADIOL, SEATTLE, WA 98195 USA.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,NA,0,2020-11-20,NA
J,WOS:000241714500229,2006,MULTISPECIES PROBIOTICS ABOLISH ACUTE PANCREATITIS-ASSOCIATED MUCOSAL BARRIER FAILURE IN MURINE ILEUM,NA,NA,NA,PANCREAS,"VAN MINNEN, LP##VERHEEM, A##LUTGENDORFF, F##TIMMERMAN, HM##RIJKERS, GT##RYCHTER, J##GOOSZEN, HG##AKKERMANS, LMA##KROESE, ABA","UNIV MED CTR, DEPT SURG, UTRECHT, NETHERLANDS. UNIV MED CTR, DEPT PEDIAT IMMUNOL, UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, DEPT MED MICROBIOL & IMMUNOL, NIEUWEGEIN, NETHERLANDS. UNIV UTRECHT, INST RISK ASSESSMENT SCI, UTRECHT, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,NA,0,2020-11-20,NA
J,WOS:000241714500228,2006,PROPHYLACTIC PROBIOTICS REDUCE BACTERIAL TRANSLOCATION AND IMPROVE OUTCOME IN EXPERIMENTAL PANCREATITIS,NA,NA,NA,PANCREAS,"VAN MINNEN, LP##TIMMERMAN, HM##LUTGENDORFF, F##VERHEEM, A##HARMSEN, W##KONSTANTINOV, SR##SMIDT, H##VISSER, MR##RIJKERS, GT##GOOSZEN, HG##AKKERMANS, LMA","UNIV MED CTR, DEPT SURG, UTRECHT, NETHERLANDS. UNIV MED CTR, DEPT MED MICROBIOL, UTRECHT, NETHERLANDS. UNIV MED CTR, DEPT PEDIAT IMMUNOL, UTRECHT, NETHERLANDS. UNIV WAGENINGEN & RES CTR, MICROBIOL LAB, AGROTECHNOL & FOOD SCI GRP, WAGENINGEN, NETHERLANDS. ST ANTONIUS HOSP, DEPT MED MICROBIOL & IMMUNOL, NIEUWEGEIN, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,NA,0,2020-11-20,NA
J,WOS:000241714500230,2006,VIDEOSCOPIC ASSISTED RETROPERITONEAL DEBRIDEMENT IN INFECTED NECROTIZING PANCREATITIS: INITIAL RESULTS AND THE START OF A NATIONWIDE RANDOMIZED CONTROLLED TRIAL,NA,NA,NA,PANCREAS,"VAN SANTVOORT, HC##BESSELINK, MGH##BOLLEN, TL##VAN LEEUWEN, MS##VAN RAMSHORST, B##GOOSZEN, HG","ST ANTONIUS HOSP, DEPT RADIOL, NIEUWEGEIN, NETHERLANDS. UNIV MED CTR UTRECHT, DEPT SURG, UTRECHT, NETHERLANDS. UNIV MED CTR UTRECHT, DEPT RADIOL, UTRECHT, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,NA,0,2020-11-20,NA
J,WOS:000243484300001,2006,ERSA CONFERENCE PARTICIPATION: DOES LOCATION MATTER?,"THIS ARTICLE ANALYSES PARTICIPATION IN THE ANNUAL EUROPEAN CONGRESSES OF THE REGIONAL SCIENCE ASSOCIATION (ERSA) FROM 1998 THROUGH 2003. WE FORMULATE GOALS THAT THE ERSA CONFERENCES SHOULD AIM AT AND BASED ON THESE AIMS WE FORMULATE HYPOTHESES ABOUT CONFERENCE PARTICIPATION. IN THE EMPIRICAL PART WE TEST HYPOTHESES WITH REGARD TO THE SPATIAL DISTRIBUTION OF THE PARTICIPANTS OVER COUNTRIES, THE DISTRIBUTION OF THE FREQUENCY OF ATTENDANCE AMONG THE PARTICIPANTS, AND THE PRESENCE OF DISTANCE DECAY IN PARTICIPATION. ALL HYPOTHESES ARE CONFIRMED. WE ALSO PAY ATTENTION TO THE RELATION BETWEEN THE FREQUENCY OF ATTENDANCE AND DISTANCE. IN THE CONCLUSIONS WE DERIVE IMPLICATIONS FOR FUTURE CONFERENCES.",REGIONAL SCIENCE; ECONOMICS,CONFERENCE PARTICIPATION; DISTANCE DECAY; CONFERENCE LOCATION,PAPERS IN REGIONAL SCIENCE,"VAN DIJK, J##MAIER, G","UNIV GRONINGEN, FAC SPATIAL SCI, GRONINGEN, NETHERLANDS. UNIV GRONINGEN, URBAN & REG STUDIES INST, GRONINGEN, NETHERLANDS. VIENNA UNIV ECON & BUSINESS ADM, ABT STADT & REG ENTWICKLUNG, VIENNA, AUSTRIA.",ECONOMICS; ENVIRONMENTAL STUDIES; GEOGRAPHY; REGIONAL & URBAN PLANNING,BUSINESS & ECONOMICS; ENVIRONMENTAL SCIENCES & ECOLOGY; GEOGRAPHY; PUBLIC ADMINISTRATION,"ANSELIN L, 1995, PAP REG SCI, V74, P295##BALTAGI BH, 1999, J APPL ECONOM, V14, P423, DOI 10.1002/(SICI)1099-1255(199907/08)14:4<423::AID-JAE536>3.0.CO;2-K##CONROY ME, 1995, J ECON LIT, V33, P1966##DIAMOND JR A.M., 1993, J ECON STUD, V20, P107##DOSWELL C, 2004, SCI WORKS THEORY VS##FLORAX RJGM, 2004, PAP REG SCI, V83, P5, DOI 10.1007/S10110-003-0175-X##GARFIELD E, 1991, J INVENTIVENESS OTHE, V14, P294##ISSERMAN AM, 2004, PAP REG SCI, V83, P91, DOI 10.1007/S10110-003-0178-7##REY SJ, 2000, INT REGIONAL SCI REV, V23, P323, DOI 10.1177/016001700761012837##STEPHAN PE, 1996, J ECON LIT, V34, P1199##STIGLER G, 1982, HIST POLIT ECON, V11, P1##STIGLER GJ, 1982, J POLTICAL EC, V83, P477##STRATHMAN JG, 1992, J REGIONAL SCI, V32, P501, DOI 10.1111/J.1467-9787.1992.TB00202.X##WALDORF BS, 2004, PAP REG SCI, V83, P59, DOI 10.1007/S10110-003-0177-8",9,2020-11-20,NA
J,WOS:000212788700004,2006,THE SUBJECT OF PASTORAL CARE: A DISCUSSION BASED ON THE THEOLOGY OF HENNING LUTHER,"IN THIS ARTICLE THE AUTHOR DISCUSSES THE DIFFERENCES BETWEEN PASTORAL CARE AND PSYCHO-SOCIAL THERAPY. SHE CLARIFIES THE SPECIFIC IDENTITY OF PASTORAL CARE ON THE BASIS OF HENNING LUTHER'S THEOLOGY. HE DISTINGUISHES DIFFERENT ANTHROPOLOGICAL PRESUPPOSITIONS IN PASTORAL CARE AND PSYCHO-SOCIAL THERAPY. CONSEQUENTLY, SHE DEMONSTRATES THE RELEVANCY OF LUTHER'S THEOLOGY FOR TODAY'S PRACTICAL THEOLOGY.",NA,IDENTITY OF PASTORAL CARE; DIFFERENCE BETWEEN PASTORAL CARE AND PSYCHO-SOCIAL HELP ANTHROPOLOGICAL PRESUPPOSITIONS OF PASTORAL CARE,PASTORAL PSYCHOLOGY,"BRUINSMA-DE BEER, J","[BRUINSMA-DE BEER, JOKE] UNIV APPL SCI, TEACHES PASTORAL THEOL WINDESHEIM, ZWOLLE GRUTTO 7, NL-8262 AV KAMPEN, NETHERLANDS.","PSYCHOLOGY, CLINICAL; PSYCHOLOGY, MULTIDISCIPLINARY",PSYCHOLOGY,"ASTLEY J., 2002, ORDINARY THEOLOGY LO##BROWNING D. S., 1984, CARE SOULS CLASSIC T##BROWNING DON S., 1976, MORAL CONTEXT PASTOR##BRUINSMA-DE BEER J., 2006, PASTOR PERSPECTIEF P##CAMPBELL A. V., 1985, PROFESSIONALISM PAST##CAPPS D., 1990, REFRAMING NEW METHOD##GERKIN V. E., 1986, WIDENING HORIZONS PA##GERKIN V. E., 1984, LIVING HUMAN DOCUMEN##GLOCK CY, 1967, COMFORT CHALLENGE DI##HEITINK G., 1977, PASTORAAT ALS HULPVE##HEITINK G., 1998, PASTORALE ZORG THEOL##JACOBS G., 2001, PARADOX KRACHT KWETS##LARTEY E.Y.A., 1997, LIVING COLOUR INTERC##LUTHER H., 1988, DIAKONISCHE SEELSORG, V8, P475##LUTHER HENNING, 1992, RELIG ALLTAG BAUSTEI##MACQUARRIE J., 1986, THEOLOGY CHURCH MINI##NAUTA R., 2003, PRAKTISCHE THEOLOGIE, V30, P318##PARGAMENT KI, 1992, INT J PSYCHOL RELIG, V2, P201, DOI DOI 10.1207/S15327582IJPR0204_##SCHILDERMAN J. B. A. M., 1998, PASTORALE PROFESSION##SCHILDERMAN J. B. A. M., 1999, J EMPIRICAL THEOLOGY, V12, P59##ST JAMES O'CONNOR TH, 2003, J PASTORAL CARE COUN, V57, P3",2,2020-11-20,NA
J,WOS:000242057500007,2006,TREATMENT DECISION MAKING IN PROSTATE CANCER: PATIENTS' PARTICIPATION IN COMPLEX DECISIONS,"OBJECTIVE: (1) TO EXPLORE TO WHAT DEGREE PROSTATE CANCER (PC) PATIENTS FELT THEY HAD PARTICIPATED IN TREATMENT DECISION MAKING (TDM). (2) TO DETERMINE WHETHER PERCEIVED ROLES DURING TDM WERE ASSOCIATED WITH MEDICAL AND SOCIODEMOGRAPHIC VARIABLES. (3) TO EXAMINE TO WHAT EXTENT SATISFACTION WITH TDM WAS RELATED TO PERCEIVED ROLE OR MEDICAL AND SOCIODEMOGRAPHIC VARIABLES. METHODS: PATIENTS (N = 126) WERE RECRUITED IN HOSPITALS AND FROM THE DUTCH PC PATIENT ORGANIZATION. THE RELATIONSHIP BETWEEN PATIENTS' ROLE AND STAGE OF DISEASE, TREATMENT MODALITY, AGE, SOCIAL STATUS AND EDUCATION WAS DETERMINED, AS WELL AS PATIENTS' SATISFACTION WITH TDM. RESULTS: MOST PATIENTS FELT THEY HAD PARTICIPATED IN TDM (AUTONOMOUS 18%, COLLABORATIVE 60%). OLDER PATIENTS AND THOSE WITH ADVANCED DISEASE MORE FREQUENTLY REPORTED NOT HAVING BEEN INVOLVED IN DECISION MAKING. SATISFACTION WITH TDM WAS RELATED TO AGE AND ROLE IN TDM BUT NOT TO STAGE OF DISEASE OR TREATMENT MODALITY. YOUNGER MEN WERE LEAST CONTENT WHEN THEY HAD NOT BEEN INVOLVED IN DECISION MAKING. CONCLUSION: PATIENTS' LEVEL OF PARTICIPATION AND SATISFACTION WITH TDM APPEARS TO BE RELATED TO MEDICAL AND SOCIODEMOGRAPHIC VARIABLES. PRACTICE IMPLICATIONS: SATISFACTION WITH TDM MAY BE RELATED TO PATIENTS' AGE AND ASSUMED ROLE. IT IS RECOMMENDED TO TAKE THIS INTO ACCOUNT WHEN PLANNING TREATMENT FOR PROSTATE CANCER PATIENTS. (C) 2006 ELSEVIER IRELAND LTD. ALL RIGHTS RESERVED.",QUALITY-OF-LIFE; PATIENTS PREFERENCES; NEEDS; MEN,PROSTATE CANCER; PATIENT PARTICIPATION; PATIENT SATISFACTION; PHYSICIAN-PATIENT RELATIONS,PATIENT EDUCATION AND COUNSELING,"FISCHER, M##VISSER, A##VOERMAN, B##GARSSEN, B##VAN ANDEL, G##BENSING, J","HDI, CTR PSYCHOONCOL, NL-3582 JJ UTRECHT, NETHERLANDS. OLVG, DEPT UROL, AMSTERDAM, NETHERLANDS. NETHERLANDS INST HLTH SERV RES, NIVEL, UTRECHT, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; SOCIAL SCIENCES, INTERDISCIPLINARY","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; SOCIAL SCIENCES - OTHER TOPICS","AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/JNCI/85.5.365##BENBASSAT J, 1998, BEHAV MED, V24, P81, DOI 10.1080/08964289809596384##CATALONA WJ, 1994, NEW ENGL J MED, V331, P996##COHEN H, 2003, FAM PRACT, V20, P724, DOI 10.1093/FAMPRA/CMG617##DAVISON BJ, 1997, CANCER NURS, V20, P187, DOI 10.1097/00002820-199706000-00004##DAVISON BJ, 2004, BJU INT, V93, P47, DOI 10.1111/J.1464-410X.2004.04553.X##DAVISON BJ, 2003, BJU INT, V91, P14, DOI 10.1046/J.1464-410X.2003.04005.X##DEGNER LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/JAMA.277.18.1485##FORD S, 2003, HLTH EXPECT, V6, P71##GATTELLARI M, 2001, SOC SCI MED, V52, P1865, DOI 10.1016/S0277-9536(00)00303-8##GWEDE CK, 2005, CANCER-AM CANCER SOC, V104, P1381, DOI 10.1002/CNCR.21330##KEATING NL, 2002, J CLIN ONCOL, V20, P1473, DOI 10.1200/JCO.20.6.1473##KORNBLITH AB, 1994, CANCER-AM CANCER SOC, V73, P2791, DOI 10.1002/1097-0142(19940601)73:11<2791::AID-CNCR2820731123>3.0.CO;2-9##LERNER BH, 2004, J HIST MED ALL SCI, V59, P507, DOI 10.1093/JHMAS/JRH108##MCMURTRY CT, 2003, J AM GERIATR SOC, V51, P1136, DOI 10.1046/J.1532-5415.2003.51367.X##RAMFELT E, 2000, EUR J CANCER CARE, V9, P158, DOI 10.1046/J.1365-2354.2000.00217.X##SAY R, 2006, PATIENT EDUC COUNS, V60, P102, DOI 10.1016/J.PEC.2005.02.003##SCHREURS PJG, 1993, UTRECHTSE COPING LIJ##SHIPLEY WU, 1994, J UROLOGY, V152, P1799, DOI 10.1016/S0022-5347(17)32388-1##STEGINGA SK, 2004, MED DECIS MAKING, V24, P573, DOI 10.1177/0272989X04271044##STEGINGA SK, 2002, BJU INT, V89, P255, DOI 10.1046/J.1464-4096.2001.01741.X##VANANDEL G, 2003, ASPECTS QUALITY HLTH##VANANDEL G, 1998, NED TIJDSCHR CHRON Z, V1, P23##VISSER O, 2002, INCIDENCE CANC NETHE##WALD F., 1990, NED T PSYCHOL, V45, P86##WONG F, 2000, J PSYCHOSOM RES, V49, P13, DOI 10.1016/S0022-3999(99)00109-9##WOOLF SH, 2005, PATIENT EDUC COUNS, V56, P116, DOI 10.1016/J.PEC.2003.12.002",28,2020-11-20,NA
J,WOS:000241004200005,2006,DIFFERENTIATION OF RHABDOMYOSARCOMA CELL LINES USING RETINOIC ACID,"BACKGROUND RHABDOMYOSARCOMA (RMS) IS THE MOST FREQUENT SPORADIC SOFT TISSUE SARCOMA OF CHILDHOOD AND ADOLESCENCE. THE OVERALL 5-YEAR SURVIVAL RATE FOR PATIENTS WITH RMS IS 70% WITH THE USE OF SURGERY, RADIATION, AND CHEMOTHERAPY. NOVEL THERAPEUTIC APPROACHES ARE NECESSARY TO IMPROVE ON THESE OUTCOMES PARTICULARLY AMONG THE MORE AGGRESSIVE ALVEOLAR RMS (ARMS) AND LATE STAGES OF DISEASE, WHERE 5-YEAR SURVIVAL IS LESS THAN 20%. RETINOIDS HAVE BEEN SUCCESSFULLY USED IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APML) AND NEUROBLASTOMA. PURPOSE. HOWEVER, ANALYSIS OF RETINOIDS AS A DIFFERENTIATING AGENT FOR RMS HAS BEEN INCOMPLETE. THIS WORK EXAMINED THE ABILITY OF RETINOIC ACID (RA) TO PROMOTE DIFFERENTIATION OF RMS CELL LINES BY EXAMINING THE EXPRESSION OF MYOGENIC PROTEINS IN FIVE RMS CELL LINES IN RESPONSE TO ALL-TRANS RETINOIC ACID (ATRA) OR 9-CIS RETINOIC ACID (CRA). RESULTS. ANALYSIS OF GROWTH CURVES INDICATES THAT BOTH RETINOIDS SUPPRESS CELL GROWTH OF RH4 AND RH28. RD CELLS ONLY RESPONDED TO-CRA WHEREAS RH30 AND RH18 DID NOT RESPOND. FOLLOWING TREATMENT WITH ATRA FACS ANALYSIS SHOWED AN ALTERED CELL CYCLE WITH THE SAME PATTERN AS THE GROWTH CURVES. ATRA ALTERED CELLULAR MORPHOLOGY OF TWO CELL LINES, RH4 AND RH28, AND INDUCED TROPONIN T EXPRESSION IN THESE CELLS SUGGESTING A DIFFERENTIATING EFFECT. CONCLUSIONS. THESE STUDIES SUGGEST THAT RETINOIDS ARE EFFECTIVE INDUCERS OF GROWTH ARREST AND DIFFERENTIATION IN SOME RMS CELL LINES, AND OFFER A BASIS FOR FURTHER IN VIVO TESTING IN MICE OF ATRA AS A POTENTIAL APPROACH TO ARMS TREATMENT.",ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; ALVEOLAR RHABDOMYOSARCOMA; TRANSCRIPTIONAL REPRESSION; CHROMOSOMAL TRANSLOCATION; MUSCLE DIFFERENTIATION; MYOGENIC CELLS; P53 MUTATIONS; RAR-ALPHA; IN-VITRO,DIFFERENTIATION; MYOD; P53; RETINOIC ACID; RHABDOMYOSARCOMA,PEDIATRIC BLOOD & CANCER,"BARLOW, JW##WILEY, JC##MOUS, M##NARENDRAN, A##GEE, MFW##GOLDBERG, M##SEXSMITH, E##MALKIN, D","UNIV TORONTO, HOSP SICK CHILDREN, DEPT MED BIOPHYS, DIV HEMATOL ONCOL, TORONTO, ON M5G 1X8, CANADA. UNIV TORONTO, TORONTO, ON, CANADA. UNIV AMSTERDAM, DEPT MED, AMSTERDAM, NETHERLANDS. HOSP SICK CHILDREN, DIV ONCOL, TORONTO, ON M5G 1X8, CANADA.",ONCOLOGY; HEMATOLOGY; PEDIATRICS,ONCOLOGY; HEMATOLOGY; PEDIATRICS,"ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/J.1432-0436.1993.TB00632.X##ALLAND L, 1997, NATURE, V387, P49, DOI 10.1038/387049A0##ALRIC S, 1998, ONCOGENE, V16, P273, DOI 10.1038/SJ.ONC.1201484##BENNICELLI JL, 1999, ONCOGENE, V18, P4348, DOI 10.1038/SJ.ONC.1202812##BERNASCONI M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/PNAS.93.23.13164##BIEGEL JA, 1991, GENE CHROMOSOME CANC, V3, P483, DOI 10.1002/GCC.2870030612##COFFEY DC, 2000, MED PEDIATR ONCOL, V35, P577, DOI 10.1002/1096-911X(20001201)35:6<577::AID-MPO18>3.0.CO;2-3##CROUCH GD, 1991, CANCER RES, V51, P4882##DAGHER R, 1999, ONCOLOGIST, V4, P34##DAVIS RJ, 1994, CANCER RES, V54, P2869##DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834##DOUGLASS EC, 1991, GENE CHROMOSOME CANC, V3, P480, DOI 10.1002/GCC.2870030611##ELLIOTT S, 1992, BLOOD, V79, P1916##EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/JBC.270.20.11719##FELIX CA, 1992, CANCER RES, V52, P2243##FIDDLER TA, 1996, MOL CELL BIOL, V16, P5048##FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522##GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/NG1193-230##GARVIN AJ, 1986, AM J PATHOL, V125, P208##GLASS CK, 2000, GENE DEV, V14, P121##HE LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/SJ.ONC.1203088##HE LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/NG0298-126##HEINZEL T, 1997, NATURE, V387, P43, DOI 10.1038/387043A0##KASTNER P, 1997, DEVELOPMENT, V124, P313##KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330A0##LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5##MARKS PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/JNCI/92.15.1210##MAROTO M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7##MASHIYAMA S, 1991, ONCOGENE, V6, P1313##MELNICK A, 1999, BLOOD, V93, P3167, DOI 10.1182/BLOOD.V93.10.3167.410K44_3167_3215##NAGY L, 1999, GENE DEV, V13, P3209, DOI 10.1101/GAD.13.24.3209##OGOSE A, 1995, VIRCHOWS ARCH, V426, P385##PENG HQ, 1993, CANCER RES, V53, P3574##RAMP U, 1995, ANTICANCER RES, V15, P181##RANEY RB, 2001, J PEDIAT HEMATOL ONC, V23, P215, DOI 10.1097/00043426-200105000-00008##SODDU S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/JCB.134.1.193##SORENSEN PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137##TAMIR Y, 1998, ONCOGENE, V17, P347, DOI 10.1038/SJ.ONC.1201929##TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/SCIENCE.8383879##TAYLOR AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z##TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5##YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725A0##YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/PNAS.61.2.477",22,2020-11-20,NA
J,WOS:000241783000001,2006,INITIATING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED CHILDREN IN EUROPE AND THE UNITED STATES: COMPARING CLINICAL PRACTICE TO GUIDELINES AND LITERATURE EVIDENCE,"SEVERAL GUIDELINES ARE AVAILABLE TO GUIDE THE INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV)-INFECTED CHILDREN. THE RECOMMENDATIONS IN THESE GUIDELINES SHOW SIGNIFICANT VARIABILITY. BECAUSE THERE IS NO WELL-ESTABLISHED EVIDENCE ON WHEN TO START HAART, IT IS LEFT TO THE DISCRETION OF THE PEDIATRICIAN WHICH GUIDELINES TO FOLLOW. WE CONDUCTED A SURVEY CONCERNING THE INDICATIONS FOR STARTING ANTIRETROVIRAL THERAPY AMONG PEDIATRICIANS INVOLVED IN THE TREATMENT OF HIV-INFECTED PATIENTS IN EUROPE AND THE UNITED STATES. WE COMPARED THE RESULTS OF THIS SURVEY WITH THE GUIDELINES AVAILABLE AT THE TIME, THE RECENTLY ADAPTED GUIDELINES AND LITERATURE EVIDENCE. OUR RESULTS INDICATE THAT IN CLINICAL PRACTICE HAART WAS INITIATED AT HIGHER VIRAL LOADS AND LOWER CD4 COUNTS THAN RECOMMENDED BY THE GUIDELINES. AMERICAN GUIDELINES RECOMMENDED AND STILL RECOMMEND MORE AGGRESSIVE TREATMENT THAN THE EUROPEAN GUIDELINES, AND THIS IS REFLECTED IN CLINICAL PRACTICE. UNTIL RECENTLY ALL GUIDELINES WERE BASED ON LONG TERM RISK ANALYSES OF PROGRESSION TO ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND DEATH PERFORMED IN COHORT DATA. A RECENT SHORT TERM RISK ANALYSIS MAKES IT POSSIBLE TO CALCULATE THE 6 OR 12-MONTH RISK FOR PROGRESSION TO AIDS OR DEATH FOR AN INDIVIDUAL CHILD. BECAUSE VIRAL LOAD AND CD4 COUNT ARE TYPICALLY MEASURED EVERY 3 MONTHS, ONE CAN ARGUE THAT IT IS CLINICALLY MORE RELEVANT TO BASE THE DECISION OF WHEN TO START HAART ON THE SHORT TERM PROBABILITY OF DISEASE PROGRESSION. GUIDELINES IN EUROPE ARE NOW BASED ON THIS TYPE OF ANALYSIS. THE AMERICAN GUIDELINES ONLY ADOPTED THE THRESHOLDS FOR CD4 AND VIRAL LOAD. THE SHORT TERM RISK ANALYSIS ALSO SHOWS THAT THE RISK FOR DEVELOPING AIDS VARIES MARKEDLY WITH AGE. THIS SHOULD BE REFLECTED IN ALL GUIDELINES. DETERMINING THE ACCEPTABLE RISK OF DISEASE PROGRESSION IS DIFFICULT AND INFLUENCED BY PATIENT-, DOCTOR- AND CULTURE-RELATED FACTORS. THE CONTROVERSY OVER WHETHER OR NOT TO TREAT ASYMPTOMATIC INFANTS IS UNRESOLVED AS WELL. ALL INFANTS HAVE A VERY HIGH RISK OF DISEASE PROGRESSION REGARDLESS OF THEIR VIRAL LOAD OR CD4 COUNT, BUT LIFELONG TREATMENT WITH A POTENTIAL FOR SIGNIFICANT TOXICITIES AND RISK OF DEVELOPING RESISTANCE IS ALSO NOT AN APPEALING OPTION. WE RECOMMEND AN ATTEMPT TO ACHIEVE A CONSENSUS AMONG THE DIFFERENT WORKING GROUPS TO REDUCE THE NUMBER OF DIFFERENT GUIDELINES, WHICH SHOULD BE BASED ON THE LITERATURE EVIDENCE. BECAUSE ALL RISK ANALYSES ARE BASED ON INFORMATION FROM THE PRE-HAART ERA, A HEAD-TO-BEAD TRIAL COMPARING EARLY VERSUS DEFERRED HAART WOULD BE USEFUL. THIS MAY BE DIFFICULT TO ACCOMPLISH. THE FIRST STEP COULD BE AN ANALYSIS OF RETROSPECTIVE DATA FROM COLLABORATIVE COHORT DATA.",DISEASE PROGRESSION; HIV-1-INFECTED CHILDREN; PREDICTIVE-VALUE; VIRAL LOAD; FOLLOW-UP; INFANTS; HIV-1; MORTALITY; SURVIVAL; MARKERS,THERAPY GUIDELINES; HUMAN IMMUNODEFICIENCY VIRUS; CHILDREN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; EUROPE VERSUS UNITED STATES,PEDIATRIC INFECTIOUS DISEASE JOURNAL,"VERWEEL, G##SAAVEDRA-LOZANO, J##VAN ROSSUM, AMC##RAMILO, O##DE GROOT, R","RADBOUD UNIV NIJMEGEN MED CTR, DEPT PEDIAT, NL-6500 HB NIJMEGEN, NETHERLANDS. ERASMUSMC SOPHIA CHILDRENS HOSP, DEPT PEDIAT, DIV PEDIAT INFECT DIS, ROTTERDAM, NETHERLANDS. HOSP FUENLABRADA, MADRID, SPAIN. UNIV TEXAS, SW MED CTR, DALLAS, TX USA.",IMMUNOLOGY; INFECTIOUS DISEASES; PEDIATRICS,IMMUNOLOGY; INFECTIOUS DISEASES; PEDIATRICS,"ABOULKER JP, 2004, AIDS, V18, P237, DOI 10.1097/01.AIDS.0000111388.02002.6B##ABOULKER JP, 2001, ARCH DIS CHILD, V84, P230, DOI 10.1136/ADC.84.3.230##ABRAMS EJ, 2003, AIDS, V17, P867, DOI 10.1097/00002030-200304110-00012##AMAYA RA, 2002, PEDIATR INFECT DIS J, V21, P405, DOI 10.1097/00006454-200205000-00011##BORLEFFS JCC, 2000, ANTIRETROVIRAL TREAT##BURNS DN, 1999, LANCET, V354, PS1##*CDCP, 2005, GUID US ANT AG PED H##*CDCP, 2003, GUID US ANT AG PED H##CENTERS FOR DISEASE CONTROL AND PREVENTION, 1994, MMWR-MORBID MORTAL W, V43, P1##CHADWICK EG, 2005, PEDIATR INFECT DIS J, V24, P793, DOI [10.1097/01.INF.0000111281.93658.DF, 10.1097/01.INF.0000177281.93658.DF]##DE MARTINO M, 2000, JAMA-J AM MED ASSOC, V284, P190, DOI 10.1001/JAMA.284.2.190##DE MARTINO M, 2001, AIDS, V15, P1527, DOI 10.1097/00002030-200108170-00010##DUNN DT, 2003, LANCET, V362, P1605##EGGER M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4##FAYE A, 2004, CLIN INFECT DIS, V39, P1692, DOI 10.1086/425739##FLORENCE E, 2003, HIV MED, V4, P255, DOI 10.1046/J.1468-1293.2003.00156.X##GALLI L, 2000, INT J EPIDEMIOL, V29, P573, DOI 10.1093/INTJEPID/29.3.573##GIBB DM, 2003, BMJ-BRIT MED J, V327, P1019, DOI 10.1136/BMJ.327.7422.1019##*IT GUID ANT THER, 1999, ACTA PAEDIATR, V88, P228##KALISH LA, 1999, J INFECT DIS, V180, P1514, DOI 10.1086/315064##LEONARD EG, 2003, PEDIATR INFECT DIS J, V22, P77, DOI 10.1097/00006454-200301000-00018##MACMILLAN C, 2001, NEUROLOGY, V57, P1402, DOI 10.1212/WNL.57.8.1402##MOFENSON LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441##NIEHUES T, 2001, MONATSSCHR KINDERH, V149, P1372, DOI 10.1007/S001120170027##PALELLA FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007##PALUMBO PE, 1998, JAMA-J AM MED ASSOC, V279, P756, DOI 10.1001/JAMA.279.10.756##SHARLAND M, 2004, HIV MED, V5, P61, DOI 10.1111/J.1468-1293.2004.00227.X##SHARLAND M, 2002, HIV MED, V3, P215, DOI 10.1046/J.1468-1293.2002.00120.X##SHEARER WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901##THORNE C, 2003, ACTA PAEDIATR, V92, P246##TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V##VALENTINE ME, 1998, PEDIATR INFECT DIS J, V17, P18, DOI 10.1097/00006454-199801000-00005##2001, GUIDELINES USE ANTIR",14,2020-11-20,NA
J,WOS:000241778700009,2006,PASSIVE RESPIRATORY MECHANICS MEASURED DURING NATURAL SLEEP IN HEALTHY TERM NEONATES AND INFANTS UP TO 8 WEEKS OF LIFE,"THE SINGLE OCCLUSION TECHNIQUE (SOT) IS A SIMPLE AND NONINVASIVE TECHNIQUE FOR MEASUREMENT OF PASSIVE RESPIRATORY MECHANICS IN INFANTS. REFERENCE VALUES BASED ON MEASUREMENTS OF A LARGE POPULATION OF HEALTHY INFANTS PERFORMED OUTSIDE SPECIALIZED RESEARCH LABORATORIES ARE LACKING. THE AIM OF THIS STUDY WAS TO PRESENT REFERENCE VALUES FOR PASSIVE RESPIRATORY MECHANICS BASED ON A LARGE POPULATION OF HEALTHY TERM NEONATES AND INFANTS MEASURED DURING NATURAL SLEEP IN ROUTINE CARE. AS PART OF THE ONGOING WHEEZING ILLNESSES STUDY LEIDSCHE RIJN (WHISTLER), THE COMPLIANCE (C-RS) AND RESISTANCE (R-RS) OF THE RESPIRATORY SYSTEM WERE MEASURED IN 450 HEALTHY UNSEDATED NEONATES AND INFANTS WITH A MEAN AGE OF 4.6 +/- 1.3 WEEKS. MULTIVARIABLE REGRESSION ANALYSIS, WITH GESTATIONAL AGE, AGE AT MEASUREMENT, BODY SIZE, SEX, AND ETHNICITY AS POSSIBLE PREDICTORS, WAS CARRIED OUT TO ESTIMATE PREDICTION EQUATIONS FOR MEAN C-RS AND R-RS VALUES. TECHNICALLY ACCEPTABLE LUNG FUNCTION MEASUREMENTS COULD BE PERFORMED IN 328 (73%) NEONATES AND INFANTS. MEDIAN C-RS WAS 39.5 (RANGE 14.8-79.1) ML/KPA AND MEDIAN R-RS WAS 7.4 (RANGE 3.8-19.5) KPA/L/SEC. THE FOLLOWING REGRESSION EQUATIONS FOR C-RS AND R-RS WERE OBTAINED: IN C-RS = 1. 677 + 1.3 X 10(-4) XBIRTH WEIGHT (G)+0.030 X BIRTH LENGTH (CM) AND IN R-RS=2.496-3.1X10(-6) X BIRTH LENGTH(3) (CM(3))-0.114 X SEX. WE PROVIDED REFERENCE VALUES FOR PASSIVE RESPIRATORY MECHANICS USING THE SOT IN A LARGE POPULATION OF HEALTHY TERM NEONATES AND INFANTS MEASURED DURING NATURAL SLEEP. THESE DATA PROVIDE A FRAME OF REFERENCE FOR ASSESSING THE NORMALITY OF SOT MEASUREMENTS PERFORMED IN ROUTINE CARE.",SINGLE-OCCLUSION TECHNIQUE; LUNG-FUNCTION; PRETERM INFANTS; CYSTIC-FIBROSIS; SPECIFICATIONS; NEWBORN; GENDER,INFANT; LUNG FUNCTION; REFERENCE VALUES; PREDICTION EQUATIONS; BIRTH COHORT; OCCLUSION; TECHNIQUE,PEDIATRIC PULMONOLOGY,"KATIER, N##UITERWAAL, CSPM##DE JONG, BM##VERHEIJ, TJM##VAN DER ENT, CK","UNIV MED CTR UTRECHT, DEPT PEDIAT PULMONOL, NL-3508 AB UTRECHT, NETHERLANDS. UNIV MED CTR UTRECHT, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 AB UTRECHT, NETHERLANDS.",PEDIATRICS; RESPIRATORY SYSTEM,PEDIATRICS; RESPIRATORY SYSTEM,"CARLSEN KCL, 1994, EUR RESPIR J, V7, P1660##DEWINTER JP, 1995, PEDIATR PULM, V20, P152, DOI 10.1002/PPUL.1950200305##FLETCHER ME, 1992, PEDIATR PULM, V14, P118, DOI 10.1002/PPUL.1950140210##FLETCHER ME, 1996, INFANT RESP FUNCTION, P283##FREY U, 2000, EUR RESPIR J, V16, P731, DOI 10.1034/J.1399-3003.2000.16D28.X##FREY U, 2000, EUR RESPIR J, V16, P1016, DOI 10.1183/09031936.00.16510160##GAPPA M, 2001, EUR RESPIR J, V17, P141, DOI 10.1183/09031936.01.17101410##GROBBEE DE, 2005, EUR J EPIDEMIOL, V20, P285, DOI 10.1007/S10654-004-5689-2##HANRAHAN JP, 1996, AM J RESP CRIT CARE, V154, P670, DOI 10.1164/AJRCCM.154.3.8810604##HAOUZI P, 1991, BIOL NEONATE, V60, P350##HARDY KA, 1989, PEDIATR PULM, V6, P103, DOI 10.1002/PPUL.1950060209##KATIER N, 2005, CHEST, V128, P1822, DOI 10.1378/CHEST.128.3.1822##KATIER N, 2004, EUR J EPIDEMIOL, V19, P895, DOI 10.1023/B:EJEP.0000040530.98310.0C##LODRUP KC, 1992, PEDIATR PULM, V12, P99, DOI 10.1002/PPUL.1950120208##LODRUPCARLSEN KC, 1993, EUR RESPIR J, V6, P1496##MASTERS IB, 1987, PEDIATR PULM, V3, P3, DOI 10.1002/PPUL.1950030104##MORTOLA JP, 1987, PEDIATR PULM, V3, P123, DOI 10.1002/PPUL.1950030215##MORTOLA JP, 1982, J APPL PHYSIOL, V52, P1209##REITERER F, 2003, BIOL NEONATE, V83, P117, DOI 10.1159/000067957##SNEPVANGERS Y, 2004, EARLY HUM DEV, V78, P105, DOI 10.1016/J.EARLHUMDEV.2004.04.004##STOCKS J, 1987, PEDIATR PULM, V3, P71, DOI 10.1002/PPUL.1950030206##STOCKS J, 1994, EUR RESPIR J, V7, P11, DOI 10.1183/09031936.94.07010011##STOCKS J, 1976, PEDIATRICS, V57, P352##STOCKS J, 1997, AM J RESP CRIT CARE, V156, P1855, DOI 10.1164/AJRCCM.156.6.9607056##TAUSSIG LM, 1980, J PEDIATR-US, V97, P668, DOI 10.1016/S0022-3476(80)80039-4##YUKSEL B, 1992, RESP MED, V86, P97, DOI 10.1016/S0954-6111(06)80222-2",15,2020-11-20,NA
J,WOS:000241220200002,2006,ILEOILEAL INTUSSUSCEPTION IN CHILDREN: ULTRASONOGRAPHIC DIFFERENTIATION FROM ILEOCOLIC INTUSSUSCEPTION,"BACKGROUND: THE TREATMENT OF ILEOILEAL INTUSSUSCEPTION IN CHILDREN DIFFERS FROM THAT OF ILEOCOLIC INTUSSUSCEPTION. OBJECTIVE: TO DIFFERENTIATE ILEOILEAL INTUSSUSCEPTION FROM ILEOCOLIC INTUSSUSCEPTION USING ULTRASONOGRAPHY. MATERIALS AND METHODS: WE REVIEWED THE CLINICAL AND ULTRASONOGRAPHIC FINDINGS IN 27 PATIENTS WITH INTUSSUSCEPTION BETWEEN SEPTEMBER 2003 AND JULY 2005. FOR STATISTICAL ANALYSIS THE MANN-WHITNEY TEST WAS APPLIED. RESULTS: REGARDING ILEOILEAL INTUSSUSCEPTIONS, 11 WERE DOCUMENTED IN TEN PATIENTS (SEVEN BOYS, THREE GIRLS; MEAN AGE 3.1 YEARS). SYMPTOMS SUGGESTIVE OF INTUSSUSCEPTION WERE PRESENT IN NINE PATIENTS. THE MEAN DIAMETER WAS 1.5 CM (RANGE 1.1-2.5 CM) AND LENGTH 2.5 CM (RANGE 1.5-6.0 CM). THE INTUSSUSCEPTIONS WERE LOCATED IN THE PARAUMBILICAL REGION (N=6), THE RIGHT UPPER QUADRANT (N=2), THE RIGHT LOWER QUADRANT (N=2), AND THE LEFT LOWER QUADRANT (N=1). REGARDING ILEOCOLIC INTUSSUSCEPTIONS, 16 WERE DOCUMENTED IN 14 PATIENTS (13 BOYS, 1 GIRL; MEAN AGE 1.9 YEARS). ALL PATIENTS HAD SYMPTOMS SUGGESTIVE OF INTUSSUSCEPTION. THE MEAN DIAMETER WAS 3.7 CM (RANGE 3.0-5.5 CM) AND MEAN LENGTH WAS 8.2 CM (RANGE 5.0-12.5 CM). ALL INTUSSUSCEPTIONS WERE LOCATED IN THE RIGHT SIDE OF THE ABDOMEN. THE DIFFERENCE IN DIAMETER AND LENGTH BETWEEN ILEOILEAL AND ILEOCOLIC INTUSSUSCEPTIONS WAS STATISTICALLY SIGNIFICANT (P < 0.05). CONCLUSION: UNLIKE CLINICAL SYMPTOMS, ULTRASONOGRAPHY CAN DIFFERENTIATE BETWEEN ILEOILEAL AND ILEOCOLIC INTUSSUSCEPTION. THE DIAMETER AND LENGTH OF THE INTUSSUSCEPTION ARE THE MAIN CRITERIA.",SMALL-BOWEL INTUSSUSCEPTION; PEDIATRIC-PATIENTS; MANAGEMENT; REDUCTION,INTUSSUSCEPTION; ULTRASOUND; CHILDREN,PEDIATRIC RADIOLOGY,"WIERSMA, F##ALLEMA, JH##HOLSCHER, HC","HAGA TEACHING HOSP, DEPT RADIOL, NL-2545 CH THE HAGUE, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT RADIOL, LEIDEN, NETHERLANDS. HAGA TEACHING HOSP, JULIANA CHILDRENS HOSP, DEPT SURG, THE HAGUE, NETHERLANDS. HAGA TEACHING HOSP, JULIANA CHILDRENS HOSP, DEPT SURG, THE HAGUE, NETHERLANDS.","PEDIATRICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","PEDIATRICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","DEL-POZO G, 1999, RADIOGRAPHICS, V19, P299, DOI 10.1148/RADIOGRAPHICS.19.2.G99MR14299##DELPOZO G, 1996, RADIOLOGY, V199, P688, DOI 10.1148/RADIOLOGY.199.3.8637988##KIM JH, 2004, KOREAN J RADIOL, V5, P178, DOI 10.3348/KJR.2004.5.3.178##KO SF, 2002, WORLD J SURG, V26, P438, DOI 10.1007/S00268-001-0245-7##KORNECKI A, 2000, PEDIATR RADIOL, V30, P58, DOI 10.1007/S002470050015##NAVARRO O, 2000, PEDIATR RADIOL, V30, P594, DOI 10.1007/S002470000261##OZGUNER IF, 2004, J PEDIATR SURG, V39, P1595, DOI 10.1016/J.JPEDSURG.2004.06.036##PUYLAERT JBCM, 1986, RADIOLOGY, V158, P355, DOI 10.1148/RADIOLOGY.158.2.2934762##STROUSE PJ, 2003, PEDIATR RADIOL, V33, P316, DOI 10.1007/S00247-003-0870-4##VERSCHELDEN P, 1992, RADIOLOGY, V184, P771",25,2020-11-20,NA
J,WOS:000241570300001,2006,ALTERED PLACENTAL AND FETAL EXPRESSION OF IGFS AND IGF-BINDING PROTEINS ASSOCIATED WITH INTRAUTERINE GROWTH RESTRICTION IN FETAL SHEEP DURING EARLY AND MID-PREGNANCY,"THE INSULIN-LIKE GROWTH FACTORS (IGFS) ARE POSTULATED TO BE ALTERED IN ASSOCIATION WITH THE DEVELOPMENT OF INTRAUTERINE GROWTH RESTRICTION (IUGR). THE PRESENT STUDIES EXAMINED PLACENTAL AND FETAL HEPATIC MRNA CONCENTRATION OF COMPONENTS OF THE IGF SYSTEM AT TWO TIME POINTS (55 AND 90 D GESTATIONAL AGE, DGA; TERM 147 DGA) IN A HYPERTHERMIA (HT)-INDUCED SHEEP MODEL OF PLACENTAL INSUFFICIENCY-IUGR. MATERNAL PLASMA INSULIN AND IGF-I WERE CONSTANT AT 55 AND 90 DGA AND WERE UNAFFECTED BY TREATMENT. UMBILICAL VEIN INSULIN CONCENTRATIONS TENDED TO BE REDUCED AT 90 DGA FOLLOWING HT EXPOSURE. CARUNCLE IGF-I MRNA WAS INCREASED AT 90 DGA IN HT PLACENTAE (P < 0.05), WHILE COTYLEDON CONCENTRATIONS WERE CONSTANT OVER GESTATION AND UNALTERED BY TREATMENT. IN CONTROL COTYLEDONS, IGF-II MRNA CONCENTRATION INCREASED (P < 0.01) AND IGFBP-3 DECREASED BETWEEN 55 AND 90 DGA (P < 0.01). COTYLEDON IGF-II AND CARUNCLE IGFBP-4 MRNA WERE ELEVATED AT 55 DGA IN HT PLACENTAE COMPARED WITH CONTROL (P < 0.01 AND P < 0.05 RESPECTIVELY). FETAL HEPATIC IGF-I. IGFBP-2, -3 AND -4 CONCENTRATIONS ROSE OVER GESTATION (P < 0.05). BUT THERE WERE NO TREATMENT EFFECTS. THESE DATA SUGGEST THAT CHANGES IN PLACENTAL IGF EXPRESSION IN EARLY AND MID GESTATION MAY PREDISPOSE THE PREGNANCY TO PLACENTAL INSUFFICIENCY, RESULTING IN INADEQUATE SUBSTRATE SUPPLY TO THE DEVELOPING FETUS LATER IN GESTATION.",FACTOR-I; MESSENGER-RNA; CIRCULATING LEVELS; FACTOR SYSTEM; CELL-LINE; INSULIN; MODEL; TERM; RETARDATION; HORMONE,NA,PEDIATRIC RESEARCH,"DE VRIJER, B##DAVIDSEN, ML##WILKENING, RB##ANTHONY, RV##REGNAULT, TRH","ERASMUS UNIV, MED CTR, DIV OBSTET & PRENATAL MED, DEPT OBSTET & GYNECOL, NL-3000 CB ROTTERDAM, NETHERLANDS. UNIV COLORADO, CTR HLTH SCI, DEPT PEDIAT, DIV PERINATAL MED,PERINATAL RES CTR, AURORA, CO 80045 USA. COLORADO STATE UNIV, DEPT BIOMED SCI, ANIM REPROD & BIOTECHNOL LAB, FT COLLINS, CO 80523 USA.",PEDIATRICS,PEDIATRICS,"ABU-AMERO SN, 1998, MOL REPROD DEV, V49, P229, DOI 10.1002/(SICI)1098-2795(199803)49:3<229::AID-MRD2>3.0.CO;2-Q##CARR JM, 1995, J ENDOCRINOL, V145, P545, DOI 10.1677/JOE.0.1450545##CHEUNG PT, 1991, ENDOCRINOLOGY, V129, P1006, DOI 10.1210/ENDO-129-2-1006##DELHANTY PJD, 1993, ENDOCRINOLOGY, V132, P41, DOI 10.1210/EN.132.1.41##EHRHARDT RA, 1995, PLACENTA, V16, P727, DOI 10.1016/0143-4004(95)90016-0##FANT M, 1993, REGUL PEPTIDES, V48, P29, DOI 10.1016/0167-0115(93)90333-4##GALLAHER BW, 1998, J ENDOCRINOL, V159, P501, DOI 10.1677/JOE.0.1590501##GIUDICE LC, 1995, J CLIN ENDOCR METAB, V80, P1548, DOI 10.1210/JC.80.5.1548##HAGEN ASE, 2005, PEDIATR RES, V58, P1228, DOI 10.1203/01.PDR.0000185266.23265.87##HAN VKM, 2000, PLACENTA, V21, P289, DOI 10.1053/PLAC.1999.0498##HAN VKM, 1996, J CLIN ENDOCR METAB, V81, P2680, DOI 10.1210/JC.81.7.2680##JENSEN EC, 1999, J ENDOCRINOL, V161, P485, DOI 10.1677/JOE.0.1610485##KIND KL, 1995, J ENDOCRINOL, V146, P23, DOI 10.1677/JOE.0.1460023##KWON YW, 2004, J INVEST DERMATOL, V123, P152, DOI 10.1111/J.0022-202X.2004.22735.X##LANGFORD K, 1998, HUM REPROD, V13, P1389, DOI 10.1093/HUMREP/13.5.1389##LARSEN T, 1996, CLIN ENDOCRINOL, V45, P315, DOI 10.1046/J.1365-2265.1996.553812.X##LIMESAND SW, 2003, J PHYSIOL-LONDON, V547, P95, DOI 10.1113/JPHYSIOL.2002.026831##LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4##MARTINEZ-CHEQUER JC, 2003, BIOL REPROD, V68, P1112, DOI 10.1095/BIOLREPROD.102.011155##MCLELLAN KC, 1992, ENDOCRINOLOGY, V131, P1619, DOI 10.1210/EN.131.4.1619##MCMULLEN S, 2005, PLACENTA, V26, P25, DOI 10.1016/J.PLACENTA.2004.04.010##MOHAN S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/JOE.0.1750019##NAGATANI S, 2000, ENDOCRINOLOGY, V141, P3965, DOI 10.1210/EN.141.11.3965##NIETODIAZ A, 1996, ACTA OBSTET GYN SCAN, V75, P127, DOI 10.3109/00016349609033303##ONG K, 2000, J CLIN ENDOCR METAB, V85, P4266, DOI 10.1210/JC.85.11.4266##OWENS JA, 1994, J ENDOCRINOL, V140, P5, DOI 10.1677/JOE.0.1400005##REGNAULT TRH, 2003, J PHYSIOL-LONDON, V550, P641, DOI 10.1113/JPHYSIOL.2003.039511##REGNAULT TRH, 2002, PLACENTA, V23, PS119, DOI 10.1053/PLAC.2002.0792##REGNAULT TRH, 1999, J ENDOCRINOL, V162, P433, DOI 10.1677/JOE.0.1620433##REGNAULT TRH, 2002, PLACENTA, V23, P132, DOI 10.1053/PLAC.2001.0757##REYNOLDS TS, 1997, ENDOCRINOLOGY, V138, P886, DOI 10.1210/EN.138.3.886##SHEIKH S, 2001, MOL HUM REPROD, V7, P287, DOI 10.1093/MOLEHR/7.3.287##SOREM K A, 1998, J MATERN FETAL MED, V7, P1##STEGEMAN J H J, 1974, BIJDRAGEN TOT DE DIERKUNDE, V44, P4##TAPANAINEN PJ, 1994, PEDIATR RES, V36, P152, DOI 10.1203/00006450-199408000-00004##THUREEN PJ, 1992, AM J PHYSIOL, V263, PR578##UNTERMAN T, 1990, ENDOCRINOLOGY, V127, P2035, DOI 10.1210/ENDO-127-4-2035##VATNICK I, 1992, AM J PHYSIOL, V263, PR619##VOLPERT O, 1996, ENDOCRINOLOGY, V137, P3871, DOI 10.1210/EN.137.9.3871##WANG CY, 1988, MOL ENDOCRINOL, V2, P217, DOI 10.1210/MEND-2-3-217##WATHES DC, 1998, J DAIRY SCI, V81, P1778, DOI 10.3168/JDS.S0022-0302(98)75747-9",38,2020-11-20,"EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [R01HD041505, R01HD041505, R01HD041505, R01HD041505, R01HD041505] FUNDING SOURCE: NIH REPORTER; NICHD NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (NICHD) [HD41505, R01 HD20761] FUNDING SOURCE: MEDLINE"
J,WOS:000241570300015,2006,FINGERTIP FORCE PLANNING DURING GRASP IS DISRUPTED BY IMPAIRED SENSORIMOTOR INTEGRATION IN CHILDREN WITH HEMIPLEGIC CEREBRAL PALSY,"IN THE PRESENT STUDY WE EXAMINE THE ABILITY OF CHILDREN WITH HEMIPLEGIC CEREBRAL PALSY (CP) TO USE ANTICIPATORY CONTROL OF FINGERTIP FORCES DURING GRASPING, AND WHETHER ANTICIPATORY CONTROL IS FACILITATED BY LIFTS WITH THE CONTRALATERAL HAND. EIGHT CHILDREN WITH CP (AGE 4-13) WERE ASKED TO PERFORM SEVERAL LIFTS OF EITHER A 250-G OR 500-G OBJECT INSTRUMENTED WITH FORCE TRANSDUCERS WITH ONE HAND, FOLLOWED IMMEDIATELY BY SEVERAL LIFTS WITH THE CONTRALATERAL HAND. THIS WAS REPEATED FOR EACH COMBINATION OF WEIGHT AND STARTING (INVOLVED OR NON-INVOLVED) HAND. SIMILAR TO PREVIOUS STUDIES, THE RATE OF LOAD FORCE DEVELOPMENT SHOWED IMPAIRED ANTICIPATORY CONTROL DURING LIFTS WITH THE INVOLVED HAND, INTACT ANTICIPATORY CONTROL IN THE NON-INVOLVED HAND. AND TRANSFER OF ANTICIPATORY CONTROL FROM THE NON-INVOLVED TO THE INVOLVED HAND. SURPRISINGLY, HOWEVER, WE ALSO FOUND A TRANSFER FROM THE INVOLVED HAND TO THE NON-INVOLVED HAND. THE RESULTS SUGGEST THAT THE IMPAIRED ANTICIPATORY CONTROL IN THE INVOLVED HAND IS NOT PURELY A SENSORY OR MOTOR PROBLEM, AND INSTEAD IS DUE TO AN INABILITY TO APPROPRIATELY INTEGRATE SENSORY INFORMATION WITH SUBSEQUENT MOTOR OUTPUT OF THE SAME HAND. THESE RESULTS PROVIDE IMPORTANT INFORMATION ABOUT THE MECHANISMS UNDERLYING IMPAIRED ANTICIPATORY CONTROL, AND MAY HAVE IMPORTANT CLINICAL IMPLICATIONS.",UNDERLYING MOTOR COMMANDS; PRECISION GRIP; ANTICIPATORY CONTROL; SPASTIC HEMIPARESIS; OBJECT MANIPULATION; PREFRONTAL CORTEX; PREMOTOR CORTEX; COORDINATION; BRAIN; INFARCTION,NA,PEDIATRIC RESEARCH,"GORDON, AM##CHARLES, J##STEENBERGEN, B","COLUMBIA UNIV, DEPT BIOBEHAV SCI, COLL TEACHERS, NEW YORK, NY 10027 USA. RADBOUD UNIV, NICI, NL-6500 HE NIJMEGEN, NETHERLANDS.",PEDIATRICS,PEDIATRICS,"ASANUMA H, 1984, J NEUROPHYSIOL, V52, P212##CHOUINARD PA, 2005, J NEUROSCI, V25, P2277, DOI 10.1523/JNEUROSCI.4649-04.2005##DUFF SV, 2003, DEV MED CHILD NEUROL, V45, P746, DOI 10.1017/S00121622030012397##EHRSSON HH, 2003, J NEUROPHYSIOL, V90, P2978, DOI 10.1152/JN.00958.2002##ELIASSON AC, 1992, DEV MED CHILD NEUROL, V34, P216##GORDON AM, 1994, NEUROPSYCHOLOGIA, V32, P555, DOI 10.1016/0028-3932(94)90144-9##GORDON AM, 1993, J NEUROPHYSIOL, V69, P1789##GORDON AM, 1999, DEV MED CHILD NEUROL, V41, P586, DOI 10.1017/S0012162299001231##GORDON AM, 1999, DEV MED CHILD NEUROL, V41, P176, DOI 10.1017/S0012162299000365##GORDON AM, 1999, DEV MED CHILD NEUROL, V41, P166, DOI 10.1017/S0012162299000353##GORDON AM, CHILD CEREBRAL PALSY##HUNG YC, 2004, DEV MED CHILD NEUROL, V46, P746, DOI 10.1017/S0012162204001288##JOHANSEN-BERG H, 2002, P NATL ACAD SCI USA, V99, P14518, DOI 10.1073/PNAS.222536799##JOHANSSON RS, 1984, EXP BRAIN RES, V56, P550##JOHANSSON RS, 1988, EXP BRAIN RES, V71, P59##KAUFMAN A. S., 1990, KAUFMAN BRIEF INTELL##KINOSHITA H, 2000, BRAIN RES, V857, P119, DOI 10.1016/S0006-8993(99)02416-6##KOECHLIN E, 2003, SCIENCE, V302, P1181, DOI 10.1126/SCIENCE.1088545##MACKINNON SE, 1985, J HAND SURG-AM, V10A, P906, DOI 10.1016/S0363-5023(85)80173-8##MURRAY EA, 2000, EXP BRAIN RES, V133, P114, DOI 10.1007/S002210000406##RAGHAVAN P, 2006, BRAIN, V129, P1415, DOI 10.1093/BRAIN/AWL070##SALIMI I, 2000, J NEUROPHYSIOL, V84, P2390##SCHMITZ C, 2005, J NEUROPHYSIOL, V93, P1498, DOI 10.1152/JN.00230.2004##SEITZ RJ, 1998, ARCH NEUROL-CHICAGO, V55, P1081, DOI 10.1001/ARCHNEUR.55.8.1081##STEENBERGEN B, 2000, HUM MOVEMENT SCI, V19, P75, DOI 10.1016/S0167-9457(00)00006-3##STEENBERGEN B, 1996, EXP BRAIN RES, V110, P91, DOI 10.1007/BF00241378##STEENBERGEN B, IN PRESS DISABIL REH##WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ANA.410310502",43,2020-11-20,NA
J,WOS:000241731700082,2006,SCHOOL PERFORMANCE AND SOCIAL-EMOTIONAL BEHAVIOR OF PRIMARY SCHOOL CHILDREN BEFORE AND AFTER A DISASTER,"OBJECTIVES. THE PURPOSE OF THIS WORK WAS TO EVALUATE THE COGNITIVE AND SOCIALEMOTIONAL CONSEQUENCES IN A GENERAL POPULATION OF PRIMARY SCHOOL CHILDREN AFFECTED BY THE FIREWORK DISASTER IN ENSCHEDE, THE NETHERLANDS, ON MAY 13, 2000. THE EXPLOSIONS CAUSED TREMENDOUS DAMAGE IN THE SURROUNDING NEIGHBORHOOD. TWENTY-TWO PEOPLE IMMEDIATELY DIED AND > 1000 WERE INJURED. METHODS. THIS RETROSPECTIVE STUDY ASSESSED SCHOOL PERFORMANCE AND SOCIAL-EMOTIONAL BEHAVIOR BEFORE AND UP TO 3 YEARS AFTER THE DISASTER. OBJECTIVELY MEASURED SCHOOL TEST RESULTS IN SPELLING AND ARITHMETIC/MATHEMATICS AND MULTI-INFORMANT SOCIAL-EMOTIONAL BEHAVIORAL ASSESSMENTS WERE COMPARED BETWEEN EXPOSED AND NONEXPOSED PRIMARY SCHOOL CHILDREN. MULTIVARIATE LOGISTIC-REGRESSION WAS USED TO ASSESS THE RELATIONSHIP BETWEEN EXPOSURE AND COGNITIVE AND SOCIAL-EMOTIONAL FUNCTIONING. RESULTS. ON SCHOOL PERFORMANCES, THE CHILDREN EXPOSED TO THE DISASTER PERFORMED OVER A PERIOD OF 3 YEARS AFTER THE DISASTER AS GOOD AS OR BETTER THAN CLASSMATES, CONTROLS, AND A NATIONAL REFERENCE POPULATION. SHORTLY AFTER THE DISASTER, EXPOSED CHILDREN EVEN SEEMED TO HAVE BETTER SCHOOL TEST RESULTS THAN NONEXPOSED CHILDREN. TWO TO 3 YEARS AFTER THE DISASTER, A SIGNIFICANT EFFECT OF DISASTER EXPOSURE WAS FOUND ON SOCIAL-EMOTIONAL BEHAVIOR. PROBLEMATIC BEHAVIOR WAS REPORTED BY TEACHERS, PARENTS, AND THE SCHOOL DOCTOR. CONCLUSIONS. THIS STUDY DEMONSTRATES A LIMITED INFLUENCE OF DISASTER EXPOSURE ON SCHOOL PERFORMANCE IN PRIMARY SCHOOL CHILDREN. THIS STUDY ALSO SHOWS THAT TEACHERS AND YOUTH HEALTH CARE PRACTITIONERS ESPECIALLY SHOULD BE AWARE OF CHILDREN STARTING SCHOOL SEVERAL YEARS AFTER A DISASTER. ALTHOUGH VERY YOUNG AT THE TIME OF A DISASTER (1-4 YEARS OF AGE), THEY MAY EXPERIENCE DISASTER-RELATED PROBLEMS.",NATURAL DISASTER; SHORT QUESTIONNAIRE; HEALTH-CARE; ADOLESCENTS; SYMPTOMS,DISASTER; CHILDREN; SCHOOL PERFORMANCE; BEHAVIOR; EPIDEMIOLOGY,PEDIATRICS,"SMILDE-VAN DEN DOEL, DA##SMIT, C##WOLLESWINKEL-VAN DEN BOSCH, JH","PALLAS HLTH RES & CONSULTANCY, NL-3065 EK ROTTERDAM, NETHERLANDS. REG HLTH AUTHOR, GGD REGIO TWENTE, YOUTH HEALTHCARE SERV, ENSCHEDE, NETHERLANDS.",PEDIATRICS,PEDIATRICS,"BOUCHIER CAM, 1999, EUR J PUBLIC HEALTH, V9, P200, DOI 10.1093/EURPUB/9.3.200##BURKE JD, 1986, J AM ACAD CHILD PSY, V25, P536, DOI 10.1016/S0002-7138(10)60014-3##*GGD NED, 2000, LAND WERKGR SIGN PSY##GLESER CG, 1981, PROLONGED PSYCHOSOCI##GOEDHART A. W., 2003, MAANDBLAD GEESTELIJK, V58, P1018, DOI [DOI 10.1007/S00787-003-0341-3, 10.1007/S00787-003-0341-3]##GREEN BL, 1991, J AM ACAD CHILD PSY, V30, P945, DOI 10.1097/00004583-199111000-00012##JANSSEN J., 2002, VERANTWOORDING TOETS##MARCH JS, 1997, J AM ACAD CHILD PSY, V36, P1080, DOI 10.1097/00004583-199708000-00015##MCFARLANE AC, 1987, PSYCHOL MED, V17, P727, DOI 10.1017/S0033291700025964##NADER K, 1990, AM J PSYCHIAT, V147, P1526##PFEFFERBAUM B, 2000, PSYCHIATRY, V63, P358, DOI 10.1080/00332747.2000.11024929##PYNOOS RS, 1993, REV PSYCHIAT, V12, P205##ROORDA J, 2004, J EPIDEMIOL COMMUN H, V58, P982, DOI 10.1136/JECH.2003.014613##ROZA SJ, 2003, AM J PSYCHIAT, V160, P2116, DOI 10.1176/APPI.AJP.160.12.2116##SHANNON MP, 1994, J AM ACAD CHILD PSY, V33, P80, DOI 10.1097/00004583-199401000-00012##SHAW JA, 2000, PSYCHIAT QUART, V71, P227, DOI 10.1023/A:1004630127000##SWENSON CC, 1996, AM J ORTHOPSYCHIAT, V66, P122, DOI 10.1037/H0080162##TSUI E, 1993, WISE EVENT COPING CR##VAN WIDENFELT BM, 2003, EUR CHILD ADOLES PSY, V12, P281, DOI 10.1007/S00787-003-0341-3##VOGEL JM, 1993, J CLIN CHILD PSYCHOL, V22, P464, DOI 10.1207/S15374424JCCP2204_7##VOGELS T, 2003, EUR J PUBLIC HEALTH, V13, P353, DOI 10.1093/EURPUB/13.4.353##YULE W, 1992, PSYCHOTHER PSYCHOSOM, V57, P200, DOI 10.1159/000288599",15,2020-11-20,NA
J,WOS:000242318900006,2006,SYNTHETIC PEPTIDES DERIVED FROM HUMAN ANTIMICROBIAL PEPTIDE UBIQUICIDIN ACCUMULATE AT SITES OF INFECTIONS AND ERADICATE (MULTI-DRUG RESISTANT) STAPHYLOCOCCUS AUREUS IN MICE,"THE PRESENCE AND ANTIMICROBIAL ACTIVITY OF ANTIMICROBIAL PEPTIDES (AMPS) HAS BEEN WIDELY RECOGNIZED AS AN EVOLUTIONARY PRESERVED PART OF THE INNATE IMMUNE SYSTEM. BASED ON EVIDENCE IN ANIMAL MODELS AND HUMANS, AMPS ARE NOW POSITIONED AS NOVEL ANTI-INFECTIVE AGENTS. THE CURRENT STUDY AIMED TO EVALUATE THE POTENTIAL ANTIMICROBIAL ACTIVITY OF UBIQUICIDIN AND SMALL SYNTHETIC FRAGMENTS THEREOF TOWARDS METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), AS A HIGH PRIORITY TARGET FOR NOVEL ANTIBIOTICS. IN VITRO KILLING OF MRSA BY SYNTHETIC PEPTIDES DERIVED FROM THE ALPHA-HELIX OR BETA-SHEET DOMAINS OF THE HUMAN CATIONIC PEPTIDE UBIQUICIDIN (UBI 1-59), ALLOWED SELECTION OF AMPS FOR POSSIBLE TREATMENT OF MRSA INFECTIONS. THE STRONGEST ANTIBACTERIAL ACTIVITY WAS OBSERVED FOR THE ENTIRE PEPTIDE UBI 1-59 AND FOR SYNTHETIC FRAGMENTS COMPRISING AMINO ACIDS 31-38. THE AVAILABILITY, CHEMICAL SYNTHESIS OPPORTUNITIES, AND SIZE OF THESE SMALL PEPTIDES, COMBINED WITH THEIR STRONG ANTIMICROBIAL ACTIVITY TOWARDS MRSA MAKE THESE COMPOUNDS PROMISING CANDIDATES FOR ANTIMICROBIAL THERAPY AND DETECTION OF INFECTIONS IN MAN. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",BACTERIAL-INFECTIONS,ANTIMICROBIAL PEPTIDE; SYNTHETIC FRAGMENTS; MRSA; IN VITRO KILLING; EXPERIMENTAL INFECTIONS; MICROBICIDAL ACTIVITY; DETECTION OF INFECTIONS,PEPTIDES,"BROUWER, CPJM##BOGAARDS, SJP##WULFERINK, M##VELDERS, MP##WELLING, MM","LEIDEN UNIV, MED CTR, DEPT RADIOL, NUCL MED SECT, NL-2300 RC LEIDEN, NETHERLANDS. AM PHARMA, BUNNIK, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; ENDOCRINOLOGY & METABOLISM; PHARMACOLOGY & PHARMACY,BIOCHEMISTRY & MOLECULAR BIOLOGY; ENDOCRINOLOGY & METABOLISM; PHARMACOLOGY & PHARMACY,"AKHTAR MS, 2005, J NUCL MED, V46, P567##ALVAREZBRAVO J, 1994, BIOCHEM J, V302, P535, DOI 10.1042/BJ3020535##ALVAREZBRAVO J, 1995, J BIOCHEM-TOKYO, V117, P1312, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A124860##BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F##BRAUNSTEIN A, 2004, ANTIMICROB AGENTS CH, V48, P3127, DOI 10.1128/AAC.48.8.3127-3129.2004##CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/BI00699A002##DEKOSTER HS, 1995, J IMMUNOL METHODS, V187, P179, DOI 10.1016/0022-1759(95)00182-A##GANZ T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2##GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8##HANCOCK R. E. W., 2002, CURRENT DRUG TARGETS - INFECTIOUS DISORDERS, V2, P79, DOI 10.2174/1568005024605855##HIEMSTRA PS, 1999, J LEUKOCYTE BIOL, V66, P423##LUPETTI A, 2003, TRENDS BIOTECHNOL, V21, P70, DOI 10.1016/S0167-7799(02)00032-X##MELENDEZ-ALAFORT L, 2004, NUCL MED BIOL, V31, P373, DOI 10.1016/J.NUCMEDBIO.2003.10.005##NIBBERING PH, 2004, J NUCL MED, V45, P321##TOLLIN M, 2003, PEPTIDES, V24, P523, DOI 10.1016/S0196-9781(03)00114-1##WELLING MM, 2002, NUCL MED BIOL, V29, P413, DOI 10.1016/S0969-8051(02)00292-5##WELLING MM, 2000, EUR J NUCL MED, V27, P292, DOI 10.1007/S002590050036##WELLING MM, 1998, J CLIN INVEST, V102, P1583, DOI 10.1172/JCI3664##ZIJLSTRA S, 2006, APPL RADIAT ISOTOPES, V64, P802, DOI 10.1016/J.APRADISO.2006.02.095",46,2020-11-20,NA
J,WOS:000244262400010,2006,"THE TIME COURSE OF PREVIEW SEARCH WITH COLOR-DEFMED, NOT LUMINANCE-DEFINED, STIMULI","WE EXAMINED THE TIME COURSE OF PREVIEW SEARCH, USING STIMULI THAT WERE DEFINED BY COLOR, BUT NOT BY LUMINANCE CHANGES. WE DEMONSTRATE THAT, UNDER THESE CONDITIONS, SEARCH PERFORMANCE IN A PREVIEW CONDITION IMPROVED SELECTIVELY OVER TIME, RELATIVE TO A BASELINE CONDITION IN WHICH ALL THE ITEMS APPEARED TOGETHER. THE DATA CONFIRM EARLIER REPORTS FROM HUMPHREYS, KYLLINSB AE K, ET AL. (2004) AND WATSON AND HUMPHREYS (1997), WHO USED LUMINANCE-DEFINED STIMULI AND SHOWED A LONG TIME COURSE TO PREVIEW SEARCH. THE DATA CONTRADICT DONK AND VERBURG (2004), WHO ARGUED THAT THE PREVIEW BENEFIT WAS INSTANTANEOUS BUT DID NOT INCLUDE BASELINE CONDITIONS WITH WHICH TO TEST FOR ANY INFLUENCE OF DISTRACTORS EQUIVALENT TO THE OLD ITEMS IN PREVIEW SEARCH, EVEN UNDER NONPREVIEW CONDITIONS. THE DATA SUPPORT THE PROPOSAL THAT THE PRIORITIZATION OF NEW ITEMS IN PREVIEW SEARCH IS A TIME-CONSUMING BUSINESS.",VISUAL MARKING; PARVOCELLULAR GUIDANCE; PRIORITIZING SELECTION; OBJECT CONTINUITY; INHIBITION; ATTENTION; CAPTURE; ONSET; TASK; OLD,NA,PERCEPTION & PSYCHOPHYSICS,"HUMPHREYS, GW##OLIVERS, CNL##BRAITHWAITE, JJ","UNIV BIRMINGHAM, SCH PSYCHOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. VRIJE UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS.","PSYCHOLOGY; PSYCHOLOGY, EXPERIMENTAL",PSYCHOLOGY,"AGTER F, 2005, J EXP PSYCHOL HUMAN, V31, P722, DOI 10.1037/0096-1523.31.4.722##BELOPOLSKY AV, 2005, PSYCHON B REV, V12, P93, DOI 10.3758/BF03196352##BRAITHWAITE JJ, 2006, PERCEPT PSYCHOPHYS, V68, P290, DOI 10.3758/BF03193676##BRAITHWAITE JJ, 2005, PERCEPT PSYCHOPHYS, V67, P1214, DOI 10.3758/BF03193554##BRAITHWAITE JJ, 2003, PERCEPT PSYCHOPHYS, V65, P213, DOI 10.3758/BF03194796##CEPEDA NJ, 1998, PERCEPT PSYCHOPHYS, V60, P727, DOI 10.3758/BF03206059##COLE GG, 2005, PSYCHOL SCI, V16, P270, DOI 10.1111/J.0956-7976.2005.01527.X##DONK M, 2004, PSYCHON B REV, V11, P282, DOI 10.3758/BF03196571##DONK M, 2001, PERCEPT PSYCHOPHYS, V63, P891, DOI 10.3758/BF03194445##HUMPHREYS GW, 1989, J EXP PSYCHOL GEN, V118, P258, DOI 10.1037/0096-3445.118.3.258##HUMPHREYS GW, 2004, PERCEPT PSYCHOPHYS, V66, P713, DOI 10.3758/BF03194967##HUMPHREYS GW, 2004, Q J EXP PSYCHOL-A, V57, P610, DOI 10.1080/02724980343000620##HUMPHREYS GW, 2002, J EXP PSYCHOL HUMAN, V28, P640, DOI 10.1037//0096-1523.28.3.640##JIANG YH, 2002, J EXP PSYCHOL HUMAN, V28, P717, DOI 10.1037/0096-1523.28.3.717##LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416##OLIVERS CNL, 2003, COGNITIVE PSYCHOL, V47, P1, DOI 10.1016/S0010-0285(03)00003-3##RAUSCHENBERGER R, 2003, J EXP PSYCHOL HUMAN, V29, P600, DOI 10.1037/0096-1523.29.3.600##SNOWDEN RJ, 2002, PSYCHOL SCI, V13, P180, DOI 10.1111/1467-9280.00433##TREISMAN A, 1990, J EXP PSYCHOL HUMAN, V16, P459, DOI 10.1037/0096-1523.16.3.459##WATSON DG, 1997, PSYCHOL REV, V104, P90, DOI 10.1037/0033-295X.104.1.90##WATSON DG, 2003, TRENDS COGN SCI, V7, P180, DOI 10.1016/S1364-6613(03)00033-0##YANTIS S, 1994, CAN J EXP PSYCHOL, V48, P182, DOI 10.1037/1196-1961.48.2.182",13,2020-11-20,MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [G9623474] FUNDING SOURCE: MEDLINE
J,WOS:000243213700009,2006,INTERNATIONAL SURVEY OF PERITONEAL DIALYSIS TRAINING PROGRAMS,"OBJECTIVE: TO SURVEY NURSES AROUND THE WORLD ABOUT CURRENT PRACTICES FOR PERITONEAL DIALYSIS (PD) HOME TRAINING PROGRAMS. DESIGN: RANDOM SAMPLING OF NURSES TO COMPLETE A WRITTEN SURVEY FROM THE INTERNATIONAL SOCIETY FOR PERITONEAL DIALYSIS NURSING LIAISON COMMITTEE. SETTINGS: UNITED STATES, CANADA, SOUTH AMERICA (BRAZIL, COLUMBIA), THE NETHERLANDS, HONG KONG. METHODS: SURVEYS AND RESPONSES WERE SENT BY FAX WHENEVER POSSIBLE, OR BY REGULAR MAIL, OR HAND CARRIED, OR CONDUCTED BY TELEPHONE. RESULTS WERE STRATIFIED BY GEOGRAPHIC AREAS AS WELL AS BY CUMULATIVE RESPONSES AND WERE EXPRESSED AS MEDIANS WITH RANGES. KRUSKAL-WALLIS WAS USED TO EVALUATE DIFFERENCES IN RESPONSES. ASSOCIATIONS BETWEEN VARIABLES WERE TESTED WITH PEARSON CORRELATION. UNIVARIATE REGRESSION ANALYSIS WAS USED TO EVALUATE THE IMPACT OF VARIABLES ON PERITONITIS RATES. VARIABLES WITH P < 0.10 WERE INCLUDED IN A MULTIVARIATE ANALYSIS. RESULTS: A TOTAL OF 317 NURSES RESPONDED: 88 IN THE UNITED STATES, 46 IN CANADA, 58 IN SOUTH AMERICA, 58 IN HONG KONG, AND 67 IN THE NETHERLANDS. THIS REPRESENTED 37% OF ALL SURVEYS DISTRIBUTED. RESPONDENTS HAD A MEDIAN OF 12 YEARS' EXPERIENCE IN NEPHROLOGY (RANGE 1-35 YEARS), BUT ONLY 31% HAD A FORMAL BACKGROUND IN ADULT EDUCATION. NEARLY HALF RECEIVED THEIR GUIDANCE TO PATIENT TRAINING FROM A NURSE COLLEAGUE, 11% WERE GUIDED BY A CORPORATE COLLEAGUE, AND 8% WERE SIMPLY SELF-TAUGHT. CLINICS RESPONDING HAD A MEDIAN OF 30 PD PATIENTS (RANGE 1-400) AND REPORTED THEY TRAINED A MEDIAN OF 8 PATIENTS PER YEAR (RANGE 0-86). REPORTED PERITONITIS RATES WERE A MEDIAN 0.46 PER YEAR OR 1 EPISODE EVERY 26 MONTHS. PERITONITIS RATES, HOWEVER, WERE NOT KNOWN BY 53% OF RESPONDENTS. TOTAL TRAINING TIME PER PATIENT HAD A VERY WIDE RANGE OF HOURS, FROM 6 TO 96. THERE WAS NO CORRELATION BETWEEN TRAINING TIME AND PERITONITIS RATES AMONG THE STUDY RESPONDENTS (P = 0.38), NOR WITH ANY OTHER VARIABLES. CONCLUSIONS: THERE IS WIDE VARIATION IN PRACTICES FOR PD PATIENT TRAINING PROGRAMS WITHIN COUNTRIES AND AROUND THE WORLD. TRAINING TIME DID NOT APPEAR TO BE RELATED TO PERITONITIS RATES. RANDOMIZED TRIALS OF TRAINING PRACTICES ARE NEEDED TO DETERMINE WHICH APPROACHES PRODUCE THE BEST OUTCOMES FOR PATIENTS.",NA,PATIENT TRAINING; NURSES; OUTCOMES; CURRENT PRACTICES,PERITONEAL DIALYSIS INTERNATIONAL,"BERNARDINI, J##PRICE, V##FIGUEIREDO, A##RIEMANN, A##LEUNG, D","UNIV PITTSBURGH, PITTSBURGH, PA 15213 USA. ST JOHNS HOSP, ST JOHN, NB, CANADA. PONTIFICIA UNIV CATOLICA RIO GRANDE DO SUL, PORTO ALEGRE, RS, BRAZIL. UNIV AMSTERDAM, ACAD MED CTR, STICHTING DIANET, NL-1105 AZ AMSTERDAM, NETHERLANDS. TUEN MUN HOSP, HONG KONG, HONG KONG, PEOPLES R CHINA.",UROLOGY & NEPHROLOGY,UROLOGY & NEPHROLOGY,"DAVIES S., 2000, PERITONEAL DIALYSIS, V20, PS84##GREEN M, 1983, AANNT J, V10, P42##GUZMAN VM, 1983, AANNT J, V19, P33##HALL GAYLE, 2004, NEPHROL NURS J, V31, P149##HANSON P C, 1979, NEPHROL NURSE, V1, P19##HEKELMAN F P, 1985, J NEPHROL NURS, V2, P56##HOLLOWAY M, 2001, PERITON DIALYSIS INT, V21, P401##KENNEDY J M, 1982, AANNT J, V9, P51##LAUDER S M, 1988, ANNA J, V15, P243##MILLER L, 1985, HOME HEALTHC NURSE, V3, P26, DOI 10.1097/00004045-198505000-00005##NEVILLE A, 2005, PERITON DIALYSIS INT, V25, PS149##PERRAS S T, 1986, ANNA J, V13, P219##PROWANT B, 1981, J AM ASSOC NEPHROL NURSES TECH, V8, P18##RIBBY K J, 1997, PEDIATR NURS, V23, P393##RICHMOND S, 1989, ANNA J, V16, P444##TORNAY ME, 2003, REV SOCIEDAD ESPANOL, V6, P17",42,2020-11-20,NA
J,WOS:000243213700017,2006,INTESTINAL PERFORATIONS IN CHILDREN ON PERITONEAL DIALYSIS,NA,NA,NA,PERITONEAL DIALYSIS INTERNATIONAL,"RAAIJMAKERS, R##MONNENS, LAH##WARRIS, A##SCHRODER, CH","RADBOUD UNIV NIJMEGEN, MED CTR, DEPT PEDIAT NEPHROL, NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, DEPT PEDIAT INFECT DIS, NIJMEGEN, NETHERLANDS. UNIV MED CTR, DEPT PEDIAT NEPHROL, UTRECHT, NETHERLANDS.",UROLOGY & NEPHROLOGY,UROLOGY & NEPHROLOGY,"DAY RE, 1977, ARCH DIS CHILD, V52, P56, DOI 10.1136/ADC.52.1.56##HARWELL CM, 1997, PERITON DIALYSIS INT, V17, P586##HOLLEY JL, 1992, AM J KIDNEY DIS, V19, P162, DOI 10.1016/S0272-6386(12)70126-9##KIEFER T, 1993, AM J KIDNEY DIS, V22, P30, DOI 10.1016/S0272-6386(12)70163-4##LATTA K, 1992, ADV PERIT D, V8, P406##LEVTCHENKO E, 1999, PERITON DIALYSIS INT, V19, P492##MATTHEWS DE, 1990, J PEDIATR SURG, V25, P110, DOI 10.1016/S0022-3468(05)80174-5##SALTZMAN DA, 1998, PEDIATR SURG INT, V13, P268, DOI 10.1007/S003830050313##WAKEEN MJ, 1994, PERITON DIALYSIS INT, V14, P371",0,2020-11-20,NA
J,WOS:000241203800006,2006,DISGUST PROPENSITY AND DISGUST SENSITIVITY: SEPARATE CONSTRUCTS THAT ARE DIFFERENTIALLY RELATED TO SPECIFIC FEARS,"STUDIES CONCENTRATING ON INTERINDIVIDUAL DIFFERENCES IN EXPERIENCING DISGUST HAVE INDICATED THAT DISGUST PROPENSITY IS ASSOCIATED WITH CERTAIN DISORDERS, SUCH AS FEAR OF BLOOD AND FEAR OF SPIDERS (DE JONG & MERCKELBACH, 1998). HOWEVER, CURRENT INDICES OF DISGUST PROPENSITY SUFFER FROM CONCEPTUAL OVERLAP WITH OTHER MEASURES OF PSYCHOPATHOLOGY. MOREOVER, IN ADDITION TO HIGH LEVELS OF DISGUST PROPENSITY, A RELATIVELY NEGATIVE APPRECIATION OF EXPERIENCING THE EMOTION OF DISGUST (DISGUST SENSITIVITY) MAY ALSO BE CRITICALLY INVOLVED IN PSYCHOPATHOLOGY. TO ADDRESS THESE ISSUES, THE DISGUST PROPENSITY AND SENSITIVITY SCALE (DPSS) WAS DEVISED (CAVANAGH & DAVEY, 2000). THIS STUDY EXAMINED ITS PSYCHOMETRIC QUALITIES. STUDENTS (N = 967) COMPLETED THE DPSS, THE DISGUST QUESTIONNAIRE (DQ), THE DISGUST SCALE (DS), THE BLOOD-INJURY PHOBIA QUESTIONNAIRE (BIQ), AND THE FEAR OF SPIDERS QUESTIONNAIRE (FSQ). THE DPSS MEANINGFULLY DIFFERENTIATED BETWEEN DISGUST PROPENSITY AND SENSITIVITY. THESE FACTORS WERE DIFFERENTIALLY RELATED TO BLOOD AND SPIDER FEAR. THE PRESENT FINDINGS SUSTAIN THE IMPORTANCE OF DIFFERENTIATING BETWEEN INDIVIDUAL DIFFERENCES IN DISGUST PROPENSITY AND SENSITIVITY AS FACTORS THAT MAY BE INDEPENDENTLY INVOLVED IN PSYCHOPATHOLOGY. THE DPSS APPEARS A VALUABLE ADDITION TO THE ARSENAL OF INDICES PRESENTLY AVAILABLE IN DISGUST RESEARCH. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",BLOOD-INJECTION-INJURY; SPIDER PHOBIA; INDIVIDUAL-DIFFERENCES; NONCLINICAL SAMPLE; SYMPTOMS; STIMULI; ANXIETY,DISGUST; SCALE DEVELOPMENT; FEAR OF BLOOD; FEAR OF SPIDERS,PERSONALITY AND INDIVIDUAL DIFFERENCES,"VAN OVERVELD, WJM##DE JONG, PJ##PETERS, ML##CAVANAGH, K##DAVEY, GCL","MASTRICHT UNIV, DEPT MED CLIN & EXPT PSYCHOL, NL-6200 MD MAASTRICHT, NETHERLANDS. UNIV GRONINGEN, DEPT CLIN & HLTH PSYCHOL, NL-9700 AB GRONINGEN, NETHERLANDS. UNIV NEWCASTLE UPON TYNE, DEPT CLIN PSYCHOL, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND. UNIV SUSSEX, DEPT PSYCHOL, BRIGHTON BN1 9RH, E SUSSEX, ENGLAND.","PSYCHOLOGY, SOCIAL",PSYCHOLOGY,"CAVANAGH K, 2000, DEV MEASURE INDIVIDU##CLARK LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309##DAVEY GCL, 1994, BRIT J PSYCHOL, V85, P541, DOI 10.1111/J.2044-8295.1994.TB02540.X##DE JONG PJ, 2002, J ANXIETY DISORD, V16, P477, DOI 10.1016/S0887-6185(02)00167-6##DE JONG PJ, 1998, PERS INDIV DIFFER, V24, P153, DOI 10.1016/S0191-8869(97)00178-5##DEJONG PJ, 1997, BEHAV RES THER, V35, P559, DOI 10.1016/S0005-7967(97)00002-8##HAIDT J, 1994, PERS INDIV DIFFER, V16, P701, DOI 10.1016/0191-8869(94)90212-7##HU LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118##JORESKOG K. G., 2002, LISREL 8 54##KLIEGER DM, 1997, J PSYCHOL, V131, P371, DOI 10.1080/00223989709603523##KLINE RB, 1998, PRINCIPLES PRACTICE##MATCHETT G, 1991, BEHAV RES THER, V29, P91, DOI 10.1016/S0005-7967(09)80011-9##MERCKELBACH H, 1999, CLIN PSYCHOL PSYCHOT, V6, P279, DOI 10.1002/(SICI)1099-0879(199910)6:4<279::AID-CPP210>3.0.CO;2-R##MULKENS SAN, 1996, J ABNORM PSYCHOL, V105, P464, DOI 10.1037/0021-843X.105.3.464##MURIS P, 2000, PERS INDIV DIFFER, V29, P1163, DOI 10.1016/S0191-8869(99)00263-9##PAGE AC, 2003, J ANXIETY DISORD, V17, P45, DOI 10.1016/S0887-6185(02)00169-X##PAGE AC, 1994, CLIN PSYCHOL REV, V14, P443, DOI 10.1016/0272-7358(94)90036-1##REISS S, 1986, BEHAV RES THER, V24, P1, DOI 10.1016/0005-7967(86)90143-9##ROZIN P, 1999, J RES PERS, V33, P330, DOI 10.1006/JRPE.1999.2251##ROZIN P, 1984, DEV PSYCHOL, V20, P309, DOI 10.1037/0012-1649.20.2.309##SAWCHUK CN, 2000, BEHAV RES THER, V38, P753, DOI 10.1016/S0005-7967(99)00093-5##SAWCHUK CN, 2002, BEHAV RES THER, V40, P1031, DOI 10.1016/S0005-7967(01)00093-6##SCHAFER JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147##SCHIENLE A, 2003, ANXIETY STRESS COPIN, V16, P185, DOI 10.1080/1061580021000030544##SZYMANSKI J, 1995, J BEHAV THER EXP PSY, V26, P31, DOI 10.1016/0005-7916(94)00072-T##TAYLOR S, 1993, J BEHAV THER EXP PSY, V24, P289, DOI 10.1016/0005-7916(93)90053-Y##THORPE SJ, 1998, BEHAV RES THER, V36, P877, DOI 10.1016/S0005-7967(98)00066-7##TOLIN DF, 1997, BEHAV RES THER, V35, P949, DOI 10.1016/S0005-7967(97)00048-X",199,2020-11-20,ECONOMIC AND SOCIAL RESEARCH COUNCILECONOMIC & SOCIAL RESEARCH COUNCIL (ESRC) [RES-000-23-0839] FUNDING SOURCE: RESEARCHFISH
J,WOS:000241331200002,2006,A NOVEL APPROACH TO ASSESSING ACHIEVEMENT GOALS IN THE CONTEXT OF THE 2 X 2 FRAMEWORK: IDENTIFYING DISTINCT PROFILES OF INDIVIDUALS WITH DIFFERENT DOMINANT ACHIEVEMENT GOALS,"IN TWO STUDIES, INDIVIDUALS' DOMINANT ACHIEVEMENT GOALS WERE ASSESSED USING A NEW, SIMPLE, AND CONCEPTUALLY PRECISE MEASURE BASED ON ELLIOT AND MCGREGOR'S (2001) 2 X 2 FRAMEWORK. NEXT, THE FOUR GROUPS WERE COMPARED IN TERMS OF ACHIEVEMENT-RELEVANT VARIABLES, INCLUDING NEED FOR ACHIEVEMENT, PERFECTIONISM, PERCEIVED COMPETENCE, INTEREST, AND GRADED PERFORMANCE. AS EXPECTED, A VERY HIGH PERCENTAGE (APPROXIMATELY 85%) OF PEOPLE INDICATED THEY HAD A DOMINANT ACHIEVEMENT GOAL. FURTHERMORE, THE RESULTS SUGGEST THAT INDIVIDUALS WITH DIFFERENT DOMINANT ACHIEVEMENT GOALS HAVE CLEAR, DISTINCT PROFILES THAT CAN BE CHARACTERIZED AS POSITIVELY VALENCED (MASTERY-APPROACH), BOTH POSITIVELY AND NEGATIVELY VALENCED (PERFORMANCE-APPROACH), NEGATIVELY VALENCED (PERFORMANCE-AVOIDANCE), OR NEITHER POSITIVELY NOR NEGATIVELY VALENCED (MASTERY-AVOIDANCE).",INTRINSIC MOTIVATION; AVOIDANCE MOTIVATION; HIERARCHICAL MODEL; PERFORMANCE; ORIENTATIONS; VALIDATION; CLASSROOM; TASK; SELF; PERFECTIONISM,MOTIVATION; AVOIDANCE; SELF-EFFICACY; AFFECTIVITY; PERFECTIONISM; REGULATORY FOCUS,PERSONALITY AND SOCIAL PSYCHOLOGY BULLETIN,"VAN YPEREN, NW","UNIV GRONINGEN, DEPT SOCIAL & ORG PSYCHOL, NL-9712 TS GRONINGEN, NETHERLANDS.","PSYCHOLOGY, SOCIAL",PSYCHOLOGY,"AMES C, 1988, J EDUC PSYCHOL, V80, P260, DOI 10.1037/0022-0663.80.3.260##AMES C, 1992, J EDUC PSYCHOL, V84, P261, DOI 10.1037/0022-0663.84.3.261##BARRON KE, 2001, J PERS SOC PSYCHOL, V80, P706, DOI 10.1037//0022-3514.80.5.706##BROPHY J, 2005, EDUC PSYCHOL-US, V40, P167, DOI 10.1207/S15326985EP4003_3##CAMPBELL JD, 2002, PERFECTIONISM THEORY, P181, DOI DOI 10.1037/10458-007##CONROY DE, 2003, J SPORT EXERCISE PSY, V25, P456, DOI 10.1123/JSEP.25.4.456##DECI E.L., 1985, INTRINSIC MOTIVATION##DWECK CS, 1988, PSYCHOL REV, V95, P256, DOI 10.1037/0033-295X.95.2.256##DWECK CS, 1986, AM PSYCHOL, V41, P1040, DOI 10.1037/0003-066X.41.10.1040##ELLIOT A. J., 2005, HDB COMPETENCE MOTIV, P52##ELLIOT AJ, 1999, EDUC PSYCHOL-US, V34, P169, DOI 10.1207/S15326985EP3403_3##ELLIOT AJ, 2001, J PERS SOC PSYCHOL, V80, P501, DOI 10.1037//0022-3514.80.3.501##ELLIOT AJ, 1997, J PERS SOC PSYCHOL, V72, P218, DOI 10.1037/0022-3514.72.1.218##ELLIOT AJ, 1996, J PERS SOC PSYCHOL, V70, P461, DOI 10.1037/0022-3514.70.3.461##ELLIOT AJ, 2001, EDUC PSYCHOL REV, V13, P73, DOI 10.1023/A:1009009018235##ELLIOT AJ, 2004, INT J ED RES##ELLIOT AJ, 2006, HDB MOTIVATIONAL SCI##FINNEY SJ, 2004, EDUC PSYCHOL MEAS, V64, P365, DOI 10.1177/0013164403258465##FLETT G. L., 2002, PERFECTIONISM THEORY##GRANT H, 2003, J PERS SOC PSYCHOL, V85, P541, DOI 10.1037/0022-3514.85.3.541##HARACKIEWICZ JM, 1995, PSYCHOL INQ, V6, P298, DOI 10.1207/S15327965PLI0604_5##HARACKIEWICZ JM, 1993, J PERS SOC PSYCHOL, V65, P904, DOI 10.1037/0022-3514.65.5.904##HARACKIEWICZ JM, 2002, J EDUC PSYCHOL, V94, P638, DOI 10.1037//0022-0663.94.3.638##HARACKIEWICZ JM, 1997, J PERS SOC PSYCHOL, V73, P1284, DOI 10.1037/0022-3514.73.6.1284##HEWITT PL, 1991, J PERS SOC PSYCHOL, V60, P456, DOI 10.1037/0022-3514.60.3.456##HIGGINS ET, 1997, AM PSYCHOL, V52, P1280, DOI 10.1037/0003-066X.52.12.1280##JACKSON DN, 1974, MANUAL PERSONALITY R##JANSSEN O, 2004, ACAD MANAGE J, V47, P368, DOI 10.2307/20159587##JOINER TE, 1995, J SOC CLIN PSYCHOL, V14, P165, DOI 10.1521/JSCP.1995.14.2.165##LEE FK, 2003, J APPL PSYCHOL, V88, P256, DOI 10.1037/0021-9010.88.2.256##LINNENBRINK E., 2000, INTRINSIC EXTRINSIC, P195, DOI DOI 10.1016/B978-012619070-0/50030-1##MEECE JL, 1988, J EDUC PSYCHOL, V80, P514, DOI 10.1037/0022-0663.80.4.514##MIDGLEY C, 1998, CONTEMP EDUC PSYCHOL, V23, P113, DOI 10.1006/CEPS.1998.0965##MIDGLEY C, 2001, J EDUC PSYCHOL, V93, P77, DOI 10.1037//0022-0663.93.1.77##MOLDEN D. C., 2000, INTRINSIC EXTRINSIC, P131, DOI [10.1016/B978-0-12-619070-0.X5020-X, DOI 10.1016/B978-012619070-0/50028-3]##NICHOLLS JG, 1984, PSYCHOL REV, V91, P328, DOI 10.1037/0033-295X.91.3.328##NUNNALLY JC., 1994, PSYCHOMETRIC THEORY##PINTRICH P., 2000, HDB SELF REGULATION, P452, DOI [10.1016/B978-012109890-2/50043-3, DOI 10.1016/B978-012109890-2/50043-3]##RAWSTHORNE L J, 1999, PERS SOC PSYCHOL REV, V3, P326, DOI 10.1207/S15327957PSPR0304_3##RYAN RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68##RYAN RM, 1999, PERS SOC PSYCHOL B, V25, P1509, DOI 10.1177/01461672992510007##SCHWARZER R, 1995, MEASURES HLTH PSYCHO, P35, DOI DOI 10.1037/T00393-000##SHELDON KM, 2001, J PERS SOC PSYCHOL, V80, P325, DOI 10.1037/0022-3514.80.2.325##SKAALVIK EM, 1997, J EDUC PSYCHOL, V89, P71, DOI 10.1037/0022-0663.89.1.71##VALLERAND RJ, 1992, EDUC PSYCHOL MEAS, V52, P1003, DOI 10.1177/0013164492052004025##VALLERAND RJ, 1997, ADV EXP SOC PSYCHOL, V29, P271, DOI 10.1016/S0065-2601(08)60019-2##VAN YPEREN NW, 2003, J PERS SOC PSYCHOL, V85, P1006, DOI 10.1037/0022-3514.85.6.1006##VAN YPEREN NW, 2002, ACAD MANAGE J, V45, P1161, DOI 10.2307/3069431##VANDEWALLE D, 1997, EDUC PSYCHOL MEAS, V57, P995, DOI 10.1177/0013164497057006009##WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063",157,2020-11-20,NA
J,WOS:000242238100004,2006,ANTIDEPRESSANT PREVALENCE FOR YOUTHS: A MULTI-NATIONAL COMPARISON,"OBJECTIVE TO COMPARE ANTIDEPRESSANT PREVALENCE DATA IN YOUTHS ACROSS THREE WESTERN EUROPEAN COUNTRIES (DENMARK, GERMANY, AND THE NETHERLANDS) WITH US REGIONAL DATA IN TERMS OF AGE AND GENDER AND TO SHOW PROPORTIONAL SUBCLASS ANTIDEPRESSANT (ATD) USE. METHOD A POPULATION-BASED ANALYSIS OF ADMINISTRATIVE CLAIMS DATA FOR THE YEAR 2000 WAS UNDERTAKEN IN 0 TO 19-YEAR-OLD ENROLLEES WHO WERE PART OF THE INSURED POPULATIONS FROM FOUR COUNTRIES HAVING A TOTAL OF FROM 72,570 TO 480,680 MEMBERS. RESULTS AID MEDICATION UTILIZATION IN THE US DATASET (1.63%) EXCEEDED THAT OF THREE WESTERN EUROPEAN COUNTRIES (PREVALENCE RANGED FROM 0.11 TO 0.54%) BY AT LEAST 3-FOLD. THERE WERE MAJOR VARIATIONS IN THE USE OF SUBCLASSES: TRICYCLIC ANTIDEPRESSANTS (TCAS) PREDOMINATED IN GERMANY WHILE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRLS) PREDOMINATED IN THE US, DENMARK AND THE NETHERLANDS. CONCLUSIONS CROSS-NATIONAL VARIATIONS SHOULD BE FURTHER EXPLORED TO UNDERSTAND THE FACTORS RELATED TO THESE DIFFERENCES AND HOW PREVALENCE DIFFERENCES RELATE TO EFFECTIVENESS AND SAFETY. COMMUNITY-BASED COHORTS SHOULD BE FOLLOWED TO ESTABLISH OUTCOMES IN THE USUAL PRACTICE SETTING. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",PSYCHOTROPIC MEDICATION; INSURED CHILDREN; UNITED-STATES; ADOLESCENTS; DEPRESSION; TRENDS; NETHERLANDS,PHARMACOEPIDEMIOLOGY; CHILDREN AND ADOLESCENTS; ANTIDEPRESSANTS,PHARMACOEPIDEMIOLOGY AND DRUG SAFETY,"ZITO, JM##TOBI, H##DE JONG-VAN DEN BERG, LTWJV##FEGERT, JM##SAFER, DJ##JANHSEN, K##HANSEN, DG##GARDNER, JF##GLAESKE, G","UNIV MARYLAND, DEPT PHARMACEUT HLTH SERV RES, BALTIMORE, MD 21201 USA. UNIV GRONINGEN, GRONINGEN, NETHERLANDS. UNIV ULM, ULM, GERMANY. JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA. UNIV BREMEN, BREMEN, GERMANY. UNIV SO DENMARK, ODENSE, DENMARK.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY, 2004, PREL REP TASK FORC S##BYCK GR, 2000, PEDIATRICS, V106, P14, DOI 10.1542/PEDS.106.1.14##CLAVENNA A, 2004, BRIT MED J, V328, P711, DOI 10.1136/BMJ.328.7441.711-C##DELATE T, 2004, PSYCHIAT SERV, V55, P387, DOI 10.1176/APPI.PS.55.4.387##GARLAND EJ, 2004, CAN MED ASSOC J, V170, P489##GRAHAM P, 1999, CHILD PSYCHIAT DEV A##HEYMAN I., 2002, CHILD ADOLESCENT PSY, P998##HUGTENBURG JG, 2004, EUR J CLIN PHARMACOL, V60, P377, DOI 10.1007/S00228-004-0765-9##JUREIDINI JN, 2004, BMJ-BRIT MED J, V328, P879, DOI 10.1136/BMJ.328.7444.879##MARTIN A, 2003, ARCH PEDIAT ADOL MED, V157, P997, DOI 10.1001/ARCHPEDI.157.10.997##MCMANUS P, 2000, MED J AUSTRALIA, V173, P458, DOI 10.5694/J.1326-5377.2000.TB139294.X##MURRAY ML, 2004, ARCH DIS CHILD, V89, P1098, DOI 10.1136/ADC.2004.064956##NEWMAN TB, 2004, NEW ENGL J MED, V351, P1595##OLFSON M, 2003, ARCH GEN PSYCHIAT, V60, P978, DOI 10.1001/ARCHPSYC.60.9.978##OLFSON M, 2003, ARCH GEN PSYCHIAT, V60, P1236, DOI 10.1001/ARCHPSYC.60.12.1236##PERCUDANI M, 2005, PSYCHOTHER PSYCHOSOM, V74, P189, DOI 10.1159/000084005##SCHIRM E, 2001, PEDIATRICS, V108, DOI 10.1542/PEDS.108.2.E25##SHATIN D, 2002, AMBUL PEDIATR, V2, P111, DOI 10.1367/1539-4409(2002)002<0111:AUOPBE>2.0.CO;2##THOMSEN PH, 2003, PEDIAT PSYCHOPHARMAC, P746##TOBI H, 2005, PHARMACOEPIDEM DR S, V14, P239, DOI 10.1002/PDS.1081##VITIELLO B, 2004, NEW ENGL J MED, V350, P1489, DOI 10.1056/NEJMP038248##WHITTINGTON CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1##ZITO JM, 2002, PEDIATRICS, V109, P721, DOI 10.1542/PEDS.109.5.721",57,2020-11-20,NA
J,WOS:000242238100008,2006,DISCREPANCIES BETWEEN MEDICATION RECORDS OF ANTICOAGULATION CLINICS AND PHARMACY RECORDS,"PURPOSE TO DETERMINE WHETHER THERE WERE DISCREPANCIES BETWEEN WITH COUMARIN ANTICOAGULANTS INTERACTING MEDICATIONS RECORDED IN MEDICAL FILES OF ANTICOAGULATION CLINICS (AC-RECORDS) AND COMPUTERIZED RECORDS OF COMMUNITY PHARMACIES (PHARMACY RECORDS). METHODS A DESCRIPTIVE STUDY WAS CONDUCTED AT TWO DUTCH ANTICOAGULATION CLINICS (AC'S). RECORDS OF WITH COUMARIN ANTICOAGULANTS INTERACTING DRUGS AT THE AC'S WERE COMPARED WITH THE PHARMACY RECORDS. A DRUG REGISTERED IN THE PHARMACY RECORDS BUT NOT IN THE AC-RECORDS, WAS RECORDED AS A DISCREPANCY, WHILE A DRUG REGISTERED IN AC-RECORDS AS WELL AS IN PHARMACY RECORDS, WAS RECORDED AS A MATCH. RESULTS OF THE 117 IDENTIFIED INTERACTING DRUGS REGISTERED IN PHARMACY RECORDS 32 (27%) WERE NOT REGISTERED IN THE AC-RECORDS. IN FOUR OUT OF SEVEN PATIENTS OF WHOM THE USE OF A PHARMACOKINETICALLY INTERACTING DRUG WAS NOT REGISTERED IN THE AC-RECORDS, SEVERAL INR-VALUES EXCEEDED THE UPPER THERAPEUTIC RANGE. CONCLUSION THIS STUDY DEMONSTRATES THAT A SUBSTANTIAL PERCENTAGE OF DRUGS OF WHICH AN INTERACTION WITH COUMARIN ANTICOAGULANTS CAN BE EXPECTED, IS NOT REGISTERED IN THE MEDICAL FILES OF ANTICOAGULATION CLINICS. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",ACENOCOUMAROL; WARFARIN; DRUGS,ACENOCOUMAROL; DRUG-INTERACTION; PHARMACY RECORDS,PHARMACOEPIDEMIOLOGY AND DRUG SAFETY,"SCHALEKAMP, T##SMIT, C##VAN GEEST-DAALDEROP, JHH##DE VRIES-GOLDSCHMEDING, H##DE BOER, A","UNIV UTRECHT, FAC PHARMACEUT SCI, DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY, UIPS, NL-3508 TB UTRECHT, NETHERLANDS. JEROEN BOSCH HOSP, THROMBOSIS SERV, DEPT LAB CLIN CHEM & HEAMATOL, SHERTOGENBOSCH, NETHERLANDS. SALTRO, GP LAB & THROMBOSIS SERV, UTRECHT, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","CHAN TYK, 1995, ANN PHARMACOTHER, V29, P1274, DOI 10.1177/106002809502901214##CHRISTENSEN DB, 1994, ANN PHARMACOTHER, V28, P99, DOI 10.1177/106002809402800119##HARDER S, 1996, CLIN PHARMACOKINET, V30, P416, DOI 10.2165/00003088-199630060-00002##HIRSH J, 2001, CHEST, V119, P8S, DOI 10.1378/CHEST.119.1_SUPPL.8S##LAU HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1##LEISTER KA, 1981, MED CARE, V19, P658, DOI 10.1097/00005650-198106000-00008##MAAT DM, 2002, ANN PHARMACOTHER, V36, P410##PENNING-VAN BEEST FJA, 2001, THROMB HAEMOSTASIS, V86, P569##SCHALEKAMP T, 2004, CLIN PHARMACOL THER, V75, P394, DOI 10.1016/J.CLPT.2003.12.017##TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802##VISSER LE, 2002, THROMB HAEMOSTASIS, V88, P705##WEN X, 2002, DRUG METAB DISPOS, V30, P631, DOI 10.1124/DMD.30.6.631##2003, STANDARD AFHANDELING",1,2020-11-20,NA
J,WOS:000241971500004,2006,"INFLUENCE OF CYP2D6 POLYMORPHISM ON 3,4-METHYLENEDIOXYMETHAMPHETAMINE ('ECSTASY') CYTOTOXICITY","OBJECTIVES REMARKABLE INTERINDIVIDUAL DIFFERENCES IN 3,4-METHYLENEDIOXYMETHAMPHETAMINE ('ECSTASY')-MEDIATED TOXICITY HAVE BEEN REPORTED IN HUMANS. THEREFORE, WE TESTED WHETHER CYP2D6 OR ITS VARIANT ALLELES AS WELL AS CYP3A4 INFLUENCE THE SUSCEPTIBILITY TO 3,4-METHYLENEDIOXYMETHAMPHETAMINE. METHODS 3,4-METHYLENEDIOXYMETHAMPHETAMINE CYTOTOXICITY WAS DETERMINED IN V79 CELLS EXPRESSING HUMAN WILD-TYPE CYP2D6 (CYP2D6*1), THE LOW-ACTIVITY ALLELES CYP2D6*2, *9, *10, AND *17, AS WELL AS HUMAN CYP3A4. METABOLITES OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE FORMED BY THE DIFFERENT CELL LINES WERE QUANTIFIED BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY/ELECTROCHEMICAL DETECTOR. RESULTS TOXICITY OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE WAS CLEARLY INCREASED IN CELLS EXPRESSING CYP2D6*1 COMPARED WITH THE PARENTAL CELLS DEVOID OF CYP-DEPENDENT ENZYMATIC ACTIVITY. TOXICITY IN V79 CYP2D6*1 CELLS WAS ALSO HIGHER THAN IN V79 CELL LINES EXPRESSING THE LOW-ACTIVITY ALLELES CYP2D6*2, *9, *10, OR *17 IN CONTRAST TO CYP2D6, THE CYP3A4 ISOENZYME DID NOT ENHANCE 3,4-METHYLENEDIOXYMETHAMPHETAMINE TOXICITY. FORMATION OF THE OXIDATIVE 3,4-METHYLENEDIOXYMETHAMPHETAMINE METABOLITE N-METHYL-ALPHA-METHYLDOPAMINE WAS GREATLY ENHANCED IN V79 CELL LINE TRANSFECTED WITH CYP2D6*1 COMPARED TO ALL OTHER CELL LINES. THE INCREASE IN THE CYTOTOXIC EFFECTS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE OBSERVED IN THIS CELL LINE WAS THEREFORE SUSPECTED TO BE A CONSEQUENCE OF THE PRODUCTION OF THIS METABOLITE. THIS WAS FURTHER INVESTIGATED BY TESTING THE CYTOTOXICITY OF N-METHYL-ALPHA S-METHYLDOPAMINE TO THE CONTROL CELL LINE. THE RESULTS CONFIRMED OUR HYPOTHESIS AS THE METABOLITE PROVED TO BE MORE THAN 100-FOLD MORE TOXIC THAN THE PARENT COMPOUND 3,4-METHYLENEDIOXYMETHAMPHETAMINE. CONCLUSIONS CYP2D6*1 MEDIATES 3,4-METHYLENEDIOXY-METHAMPHETAMINE TOXICITY VIA FORMATION OF N-METHYL-ALPHA-METHYLDOPAMINE. THEREFORE, IT WILL BE IMPORTANT TO INVESTIGATE WHETHER CYP2D6 ULTRARAPID METABOLIZERS ARE OVERREPRESENTED IN THE CASES OF 3,4-METHYLENEDIOXY-METHAMPHETAMINE INTOXICATIONS.","ISOLATED RAT HEPATOCYTES; MDMA ECSTASY; CYTOCHROME-P450 2D6; IN-VITRO; ALPHA-METHYLDOPAMINE; DESIGNER DRUGS; 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE 2C-B; 3,4-DIHYDROXYMETHAMPHETAMINE HHMA; ISOPROTERENOL OXIDATION; POOR METABOLIZER","CYP2D6; ECSTASY TOXICITY; METABOLISM; POLYMORPHISM; 3,4-METHYLENEDIOXYMETHAMPHETAMINE",PHARMACOGENETICS AND GENOMICS,"CARMO, H##BRULPORT, M##HERMES, M##OESCH, F##SILVA, R##FERREIRA, LM##BRANCO, PS##DE BOER, D##REMIAO, F##CARVALHO, F##SCHON, MR##KREBSFAENGER, N##DOEHMER, J##BASTOS, MD##HENGSTLER, JG","UNIV PORTO, FAC PHARM, DEPT TOXICOL, REQUIMTE, P-4050047 OPORTO, PORTUGAL. UNIV NOVA LISBOA, REQUIMTE, CQFB, CHEM DEPT,FAC SCI & TECHNOL, MONTE DE CAPARICA, PORTUGAL. UNIV LEIPZIG, DEPT SURG, D-7010 LEIPZIG, GERMANY. UNIV LEIPZIG, CTR TOXICOL, D-7010 LEIPZIG, GERMANY. SCHWARZ BIOSCI GMBH, DEPT PHARMACOL & TOXICOL, MONHEIM, GERMANY. GENPHARM TOX BIOTECH AG, D PLANEGG, MARTINSRIED, GERMANY. UNIV MAINZ, INST TOXICOL, D-6500 MAINZ, GERMANY. UNIV HOSP MAASTRICHT, DEPT CLIN CHEM, MAASTRICHT, NETHERLANDS.",BIOTECHNOLOGY & APPLIED MICROBIOLOGY; GENETICS & HEREDITY; PHARMACOLOGY & PHARMACY,BIOTECHNOLOGY & APPLIED MICROBIOLOGY; GENETICS & HEREDITY; PHARMACOLOGY & PHARMACY,"BERTILSSON L, 2002, BRIT J CLIN PHARMACO, V53, P111, DOI 10.1046/J.0306-5251.2001.01548.X##BINDOLI A, 1992, FREE RADICAL BIO MED, V13, P391, DOI 10.1016/0891-5849(92)90182-G##BINDOLI A, 1989, TOXICOL LETT, V48, P3, DOI 10.1016/0378-4274(89)90180-X##BOGNI A, 2005, TOXICOL IN VITRO, V19, P621, DOI 10.1016/J.TIV.2005.04.001##BOLTON JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/TX9902082##BRAUER RB, 1997, TRANSPLANT INT, V10, P229##CAPELA JP, 2006, J PHARMACOL EXP THER, V316, P53, DOI 10.1124/JPET.105.092577##CARMO H, 2004, N-S ARCH PHARMACOL, V369, P198, DOI 10.1007/S00210-003-0850-0##CARMO H, 2005, TOXICOLOGY, V206, P75, DOI 10.1016/J.TOX.2004.07.004##CARMO H, 2004, J CHROMATOGR B, V811, P143, DOI 10.1016/J.CHROMB.2004.08.026##CARMO H, 2002, J ANAL TOXICOL, V26, P228, DOI 10.1093/JAT/26.4.228##CARVALHO M, 2004, CHEM RES TOXICOL, V17, P623, DOI 10.1021/TX049960F##CARVALHO M, 2004, TOXICOLOGY, V200, P193, DOI 10.1016/J.TOX.2004.03.016##CARVALHO M, 2004, ARCH TOXICOL, V78, P16, DOI 10.1007/S00204-003-0510-7##CARVALHO M, 2002, ARCH TOXICOL, V76, P581, DOI 10.1007/S00204-002-0381-3##COECKE S, 2001, TOXICOL IN VITRO, V15, P553, DOI 10.1016/S0887-2333(01)00061-3##COLADO MI, 1997, BRIT J PHARMACOL, V121, P889, DOI 10.1038/SJ.BJP.0701213##COLADO MI, 1995, BRIT J PHARMACOL, V115, P1281, DOI 10.1111/J.1476-5381.1995.TB15037.X##DE LA TORRE R, 2005, EUR J CLIN PHARMACOL, V61, P551, DOI 10.1007/S00228-005-0965-Y##DE LA TORRE R, 2004, THER DRUG MONIT, V26, P137, DOI 10.1097/00007691-200404000-00009##DE LA TORRE R, 2004, CLIN PHARMACOKINET, V43, P157, DOI 10.2165/00003088-200443030-00002##DE LA TORRE R, 2000, BRIT J CLIN PHARMACO, V49, P104, DOI 10.1046/J.1365-2125.2000.00121.X##DE LETTER EA, 2002, J ANAL TOXICOL, V26, P113, DOI 10.1093/JAT/26.2.113##DE LETTER EA, 2004, FORENSIC SCI INT, V141, P85, DOI 10.1016/J.FORSCIINT.2003.12.015##DE LETTER EA, 2006, MED SCI LAW, V46, P37, DOI 10.1258/RSMMSL.46.1.37##DOEHMER J, 1999, DRUG METAB REV, V31, P423, DOI 10.1081/DMR-100101928##EASTON N, 2003, BRAIN RES, V987, P144, DOI 10.1016/S0006-8993(03)03319-5##ESCOBEDO I, 2005, BRIT J PHARMACOL, V144, P231, DOI 10.1038/SJ.BJP.0706071##FARRE M, 2004, PSYCHOPHARMACOLOGY, V173, P364, DOI 10.1007/S00213-004-1789-7##FORSLING ML, 2002, BRIT J PHARMACOL, V135, P649, DOI 10.1038/SJ.BJP.0704502##FREIMUTH RR, 2001, PHARMACOGENETICS, V11, P747, DOI 10.1097/00008571-200112000-00002##GARCIA-REPETTO R, 2003, FORENSIC SCI INT, V135, P110, DOI 10.1016/S0379-0738(03)00179-8##GILHOOLY TC, 2002, BRIT J CLIN PHARMACO, V54, P69, DOI 10.1046/J.1365-2125.2002.01574.X##GOLLAMUDI R, 1989, NEUROTOXICOLOGY, V10, P455##GREEN AR, 2004, PSYCHOPHARMACOLOGY, V173, P231, DOI 10.1007/S00213-004-1820-Z##GREEN AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/PR.55.3.3##GREENE SL, 2003, AM J EMERG MED, V21, P121, DOI 10.1053/AJEM.2003.50028##HARTUNG TK, 2002, QJM-INT J MED, V95, P431, DOI 10.1093/QJMED/95.7.431##HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O##HIRAMATSU M, 1990, J PHARMACOL EXP THER, V254, P521##INGELMAN-SUNDBERG M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/SJ.TPJ.6500285##JOHNSON M, 1988, J PHARMACOL EXP THER, V244, P977##JONES AL, 1999, ALIMENT PHARM THER, V13, P129##JONES DC, 2005, J PHARMACOL EXP THER, V313, P422, DOI 10.1124/JPET.104.077628##KREBSFAENGER N, 2003, ALTEX-ALTERN TIEREXP, V20, P143##KRETH KP, 2000, BIOCHEM PHARMACOL, V59, P1563, DOI 10.1016/S0006-2952(00)00284-7##KUMAGAI Y, 1991, CHEM RES TOXICOL, V4, P330, DOI 10.1021/TX00021A012##LIM HK, 1991, BIOL MASS SPECTROM, V20, P677, DOI 10.1002/BMS.1200201105##LIM HK, 1989, CHEM RES TOXICOL, V2, P142, DOI 10.1021/TX00009A002##LIN LY, 1992, CHEM RES TOXICOL, V5, P401, DOI 10.1021/TX00027A013##MAS M, 1999, J PHARMACOL EXP THER, V290, P136##MAURER HH, 2000, TOXICOL LETT, V112, P133, DOI 10.1016/S0378-4274(99)00207-6##MAURER HH, 1996, THER DRUG MONIT, V18, P465, DOI 10.1097/00007691-199608000-00027##MCCANN UD, 2000, NEUROPSYCHOBIOLOGY, V42, P11, DOI 10.1159/000026665##MCCANN UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3##MONKS TJ, 2004, THER DRUG MONIT, V26, P132, DOI 10.1097/00007691-200404000-00008##MORGAN MJ, 2000, PSYCHOPHARMACOLOGY, V152, P230, DOI 10.1007/S002130000545##NAGATA K, 2000, ANNU REV PHARMACOL, V40, P159, DOI 10.1146/ANNUREV.PHARMTOX.40.1.159##O'DONOVAN O, 2002, SCRIPTURE HERMENEUT, V3, P309##PARROTT AC, 2001, HUM PSYCHOPHARM CLIN, V16, P557, DOI 10.1002/HUP.351##PHILIP PA, 1999, CANCER CHEMOTH PHARM, V43, P59, DOI 10.1007/S002800050863##RAMAMOORTHY Y, 2001, PHARMACOGENETICS, V11, P477, DOI 10.1097/00008571-200108000-00003##RAMAMOORTHY Y, 2002, BIOCHEM PHARMACOL, V63, P2111, DOI 10.1016/S0006-2952(02)01028-6##REMIAO F, 2002, CHEM RES TOXICOL, V15, P861, DOI 10.1021/TX025518Q##REMIAO F, 1999, J ENZYM INHIB, V15, P47, DOI 10.1080/14756369909030340##SCHIFANO F, 2004, PSYCHOPHARMACOLOGY, V173, P242, DOI 10.1007/S00213-003-1730-5##SCHWAB M, 1999, LANCET, V353, P593, DOI 10.1016/S0140-6736(05)75654-3##SEGURA M, 2001, CHEM RES TOXICOL, V14, P1203, DOI 10.1021/TX010051P##SIMANTOV R, 1997, FASEB J, V11, P141##SOARES ME, 2004, BIOMED CHROMATOGR, V18, P125, DOI 10.1002/BMC.315##STICHT GUIDO, 2003, ARCHIV FUER KRIMINOLOGIE, V211, P73##STUMM G, 1999, FASEB J, V13, P1065##TUCKER GT, 1994, BIOCHEM PHARMACOL, V47, P1151, DOI 10.1016/0006-2952(94)90386-7##ZANGER UM, 2004, N-S ARCH PHARMACOL, V369, P23, DOI 10.1007/S00210-003-0832-2##ZHANG F, 1994, J MED CHEM, V37, P1084, DOI 10.1021/JM00034A006##ZHAO ZY, 1992, CHEM RES TOXICOL, V5, P89, DOI 10.1021/TX00025A015##ZHU BT, 2002, CURR DRUG METAB, V3, P321, DOI 10.2174/1389200023337586",44,2020-11-20,NA
J,WOS:000244233800003,2006,INVOLVEMENT OF CANNABINOID CB1 RECEPTORS IN DRUG ADDICTION: EFFECTS OF RIMONABANT ON BEHAVIORAL RESPONSES INDUCED BY COCAINE,"A LOT OF EVIDENCE INDICATE THAT ENDOCANNABINOIDS AND CANNABINOID CB1 RECEPTORS ARE IMPLICATED IN DRUG ADDICTION. IN THE PRESENT STUDY, WE INVESTIGATED THE EFFECT OF THE CANNABINOID CB1 RECEPTOR ANTAGONIST/PARTIAL AGONIST RIMONABANT ON THE COCAINE-MAINTAINED REINFORCEMENT AND RELAPSE TO COCAINE SEEKING AS WELL AS ON THE COCAINE CHALLENGE-INDUCED HYPERACTIVITY IN SENSITIZED RATS AND ON DISCRIMINATIVE STIMULUS EFFECTS OF COCAINE IN RATS. WE FOUND THAT ENDOCANNABINOIDS WERE NOT INVOLVED IN MAINTENANCE OF COCAINE REINFORCEMENT AND ITS SUBJECTIVE EFFECTS SINCE PHARMACOLOGICAL BLOCKADE OF CANNABINOID CB1 RECEPTORS ALTERED NEITHER SELF-ADMINISTRATION NOR DISCRIMINATIVE STIMULUS EFFECTS OF COCAINE. ON THE OTHER HAND, WITHDRAWAL FROM REPEATED ACCESS OR EXPOSURE TO COCAINE AND THEN A REINSTATEMENT OF COCAINE-SEEKING BEHAVIOR OR A SENSITIZED LOCOMOTOR RESPONSE TO A SINGLE COCAINE CHALLENGE, RESPECTIVELY, WAS POTENTLY REDUCED BY PRETREATMENT WITH RIMONABANT. THE LATTER OBSERVATIONS MAY SHOW THAT REPEATED COCAINE TREATMENT AND THE DRUG WITHDRAWAL PRODUCE-APART FROM BEHAVIORAL EFFECTS-ALSO DIFFERENT NEURAL CONSEQUENCES IN THE ENDOCANNABINOID SYSTEMS IN RATS.",CONDITIONED PLACE PREFERENCE; NUCLEUS-ACCUMBENS; KNOCKOUT MICE; DISCRIMINATIVE STIMULUS; ANTAGONIST SR141716A; SEEKING BEHAVIOR; ENDOCANNABINOID CONTENTS; INTRAVENOUS COCAINE; ETHANOL INTAKE; BRAIN-REGIONS,CANNABINOID CB1 RECEPTORS; COCAINE; DRUG ADDICTION; RIMONABANT,PHARMACOLOGICAL REPORTS,"FILIP, M##GOLDA, A##ZANIEWSKA, M##MCCREARY, AC##NOWAK, E##KOLASIEWICZ, W##PRZEGALINSKI, E","POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND. SOLVAY PHARMACEUT RES, WEESP, NETHERLANDS.",PHARMACOLOGY & PHARMACY,PHARMACOLOGY & PHARMACY,"ANGGADIREDJA K, 2004, NEUROPSYCHOPHARMACOL, V29, P1470, DOI 10.1038/SJ.NPP.1300454##ARNONE M, 1997, PSYCHOPHARMACOLOGY, V132, P104, DOI 10.1007/S002130050326##BASAVARAJAPPA BS, 2003, EUR J PHARMACOL, V466, P73, DOI 10.1016/S0014-2999(03)01557-7##BRAIDA D, 2004, EUR J PHARMACOL, V506, P63, DOI 10.1016/J.EJPHAR.2004.10.043##BRAIDA D, 2001, NEUROSCIENCE, V104, P923, DOI 10.1016/S0306-4522(01)00210-X##BRODKIN J, 1997, J PHARMACOL EXP THER, V282, P1526##CAILLE S, 2003, EUR J NEUROSCI, V18, P3145, DOI 10.1111/J.1460-9568.2003.02961.X##CALLAHAN PM, 1994, PSYCHOPHARMACOLOGY, V115, P110, DOI 10.1007/BF02244759##CASTANE A, 2002, NEUROPHARMACOLOGY, V43, P857, DOI 10.1016/S0028-3908(02)00118-1##CHAPERON F, 1998, PSYCHOPHARMACOLOGY, V135, P324, DOI 10.1007/S002130050518##CHEN JP, 1990, PSYCHOPHARMACOLOGY, V102, P156, DOI 10.1007/BF02245916##COHEN C, 2002, BEHAV PHARMACOL, V13, P451, DOI 10.1097/00008877-200209000-00018##COHEN C, 2005, NEUROPSYCHOPHARMACOL, V30, P145, DOI 10.1038/SJ.NPP.1300541##COLOMBO G, 1998, ALCOHOL ALCOHOLISM, V33, P126##COSSU G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9##DE FONSECA FR, 1999, ACTA PHARMACOL SIN, V20, P1109##DE VRIES TJ, 2003, PSYCHOPHARMACOLOGY, V168, P164, DOI 10.1007/S00213-003-1422-1##DE VRIES TJ, 2001, NAT MED, V7, P1151, DOI 10.1038/NM1001-1151##DELFS JM, 1990, J NEUROSCI, V10, P303##DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175##DI MARZO V, 2000, J NEUROCHEM, V74, P1627, DOI 10.1046/J.1471-4159.2000.0741627.X##ECONOMIDOU D, 2006, PSYCHOPHARMACOLOGY, V183, P394, DOI 10.1007/S00213-005-0199-9##ETTENBERG A, 1999, PHARMACOL BIOCHEM BE, V64, P507, DOI 10.1016/S0091-3057(99)00109-4##FATTORE L, 1999, BEHAV BRAIN RES, V104, P141, DOI 10.1016/S0166-4328(99)00059-5##FATTORE L, 2005, NEUROPHARMACOLOGY, V48, P1097, DOI 10.1016/J.NEUROPHARM.2005.01.022##FATTORE L, 2007, BRAIN RES REV, V53, P1, DOI 10.1016/J.BRAINRESREV.2006.05.003##FILIP M, 2006, PSYCHOPHARMACOLOGY, V183, P482, DOI 10.1007/S00213-005-0197-Y##FILIP M, 2005, PHARMACOL REP, V57, P35##FILIP M, 2001, POL J PHARMACOL, V53, P459##FORGET B, 2005, PSYCHOPHARMACOLOGY, V181, P722, DOI 10.1007/S00213-005-0015-6##FREEDLAND CS, 2001, ALCOHOL CLIN EXP RES, V25, P277, DOI 10.1097/00000374-200102000-00017##GALLATE JE, 1999, EUR J PHARMACOL, V370, P233, DOI 10.1016/S0014-2999(99)00170-3##GONZALEZ B, 2003, PHARMACOL BIOCHEM BE, V75, P577, DOI 10.1016/S0091-3057(03)00115-1##GONZALEZ S, 2004, BRIT J PHARMACOL, V143, P455, DOI 10.1038/SJ.BJP.0705963##GONZALEZ S, 2002, BRAIN RES, V954, P73, DOI 10.1016/S0006-8993(02)03344-9##GRIEBEL G, 2005, BIOL PSYCHIAT, V57, P261, DOI 10.1016/J.BIOPSYCH.2004.10.032##HAMPSON RE, 2000, J NEUROSCI, V20, P8932##HERKENHAM M, 1991, BRAIN RES, V547, P267, DOI 10.1016/0006-8993(91)90970-7##HOUCHI H, 2005, NEUROPSYCHOPHARMACOL, V30, P339, DOI 10.1038/SJ.NPP.1300568##HUESTIS MA, 2001, ARCH GEN PSYCHIAT, V58, P322, DOI 10.1001/ARCHPSYC.58.4.322##HUNGUND BL, 2003, J NEUROCHEM, V84, P698, DOI 10.1046/J.1471-4159.2003.01576.X##JARBE TUC, 2001, PSYCHOPHARMACOLOGY, V156, P369##KALIVAS PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107##KLEIN M, 1998, ANN NY ACAD SCI, V844, P75, DOI 10.1111/J.1749-6632.1998.TB08223.X##KOE BK, 1976, J PHARMACOL EXP THER, V199, P649##LE FOLL B, 2005, J PHARMACOL EXP THER, V312, P875, DOI 10.1124/JPET.104.077974##LE FOLL B, 2004, NEUROREPORT, V15, P2139, DOI 10.1097/00001756-200409150-00028##LEDENT C, 1999, SCIENCE, V283, P401, DOI 10.1126/SCIENCE.283.5400.401##LESSCHER HMB, 2005, EUR NEUROPSYCHOPHARM, V15, P31, DOI 10.1016/J.EURONEURO.2004.04.003##MACKIE K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/ANNUREV.PHARMTOX.46.120604.141254##MALLET PE, 1998, PSYCHOPHARMACOLOGY, V140, P11, DOI 10.1007/S002130050733##MANTSCH JR, 1998, PSYCHOPHARMACOLOGY, V135, P423, DOI 10.1007/S002130050531##MARTIN M, 2000, EUR J NEUROSCI, V12, P4038, DOI 10.1046/J.1460-9568.2000.00287.X##MAS-NIETO M, 2001, BRIT J PHARMACOL, V132, P1809, DOI 10.1038/SJ.BJP.0703990##MCKINZIE DL, 1999, ANN NY ACAD SCI, V877, P788, DOI 10.1111/J.1749-6632.1999.TB09323.X##NAVARRO M, 1997, NEUROREPORT, V8, P491, DOI 10.1097/00001756-199701200-00023##NAVARRO M, 2001, J NEUROSCI, V21, P5344, DOI 10.1523/JNEUROSCI.21-14-05344.2001##PONCELET M, 2003, NEUROSCI LETT, V343, P216, DOI 10.1016/S0304-3940(03)00397-5##PRZEGALINSKI E, 2001, BEHAV PHARMACOL, V12, P109, DOI 10.1097/00008877-200104000-00004##RICE OV, 2002, BRAIN RES, V945, P135, DOI 10.1016/S0006-8993(02)02890-1##RINALDICARMONA M, 1995, LIFE SCI, V56, P1941, DOI 10.1016/0024-3205(95)00174-5##ROBINSON TE, 2000, ADDICTION, V95, PS91##ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P##RODGERS RJ, 2005, BEHAV PHARMACOL, V16, P405, DOI 10.1097/00008877-200509000-00013##RODGERS RJ, 2003, EUR J NEUROSCI, V17, P1279, DOI 10.1046/J.1460-9568.2003.02548.X##ROMERO J, 1997, MOL BRAIN RES, V46, P100, DOI 10.1016/S0169-328X(96)00277-X##SCHENK S, 1999, PSYCHOPHARMACOLOGY, V147, P285, DOI 10.1007/S002130051169##SCHUSTER C R, 1988, PSYCHOPHARMACOL SER, V4, P161##SERRA S, 2002, EUR J PHARMACOL, V443, P95, DOI 10.1016/S0014-2999(02)01594-7##SERRA S, 2001, EUR J PHARMACOL, V430, P369, DOI 10.1016/S0014-2999(01)01379-6##SOLINAS M, 2003, J PHARMACOL EXP THER, V306, P93, DOI 10.1124/JPET.102.047928##SORIA G, 2005, NEUROPSYCHOPHARMACOL, V30, P1670, DOI 10.1038/SJ.NPP.1300707##SPANO MS, 2004, BRIT J PHARMACOL, V143, P343, DOI 10.1038/SJ.BJP.0705932##SUZUKI A, 2004, J NEUROSCI, V24, P4787, DOI 10.1523/JNEUROSCI.5491-03.2004##TANDA G, 2000, NAT NEUROSCI, V3, P1073##TERRANOVA JP, 1996, PSYCHOPHARMACOLOGY, V126, P165, DOI 10.1007/BF02246352##THANOS PK, 2005, BEHAV BRAIN RES, V164, P206, DOI 10.1016/J.BBR.2005.06.021##TONSTAD S, 2006, NUTR METAB CARDIOVAS, V16, P156, DOI 10.1016/J.NUMECD.2005.10.011##TSOU K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3##VINOD KY, 2006, NEUROCHEM INT, V49, P619, DOI 10.1016/J.NEUINT.2006.05.002##VLACHOU S, 2003, BEHAV BRAIN RES, V141, P215, DOI 10.1016/S0166-4328(02)00370-4##WANG L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/PNAS.0336351100##WILEY JL, 1995, J PHARMACOL EXP THER, V275, P1##XI ZX, 2006, J NEUROSCI, V26, P8531, DOI 10.1523/JNEUROSCI.0726-06.2006##ZANIEWSKA M, 2006, EUR J PHARMACOL, V540, P96, DOI 10.1016/J.EJPHAR.2006.04.034",66,2020-11-20,NA
J,WOS:000241567500002,2006,ADENOSINE 5 '-TRIPHOSPHATE AND ADENOSINE AS ENDOGENOUS SIGNALING MOLECULES IN IMMUNITY AND INFLAMMATION,"HUMAN HEALTH IS UNDER CONSTANT THREAT OF A WIDE VARIETY OF DANGERS, BOTH SELF AND NONSELF. THE IMMUNE SYSTEM IS OCCUPIED WITH PROTECTING THE HOST AGAINST SUCH DANGERS IN ORDER TO PRESERVE HUMAN HEALTH. FOR THAT PURPOSE, THE IMMUNE SYSTEM IS EQUIPPED WITH A DIVERSE ARRAY OF BOTH CELLULAR AND NON-CELLULAR EFFECTORS THAT ARE IN CONTINUOUS COMMUNICATION WITH EACH OTHER. THE NATURALLY OCCURRING NUCLEOTIDE ADENOSINE 5'-TRIPHOSPHATE (ATP) AND ITS METABOLITE ADENOSINE (ADO) PROBABLY CONSTITUTE AN INTRINSIC PART OF THIS EXTENSIVE IMMUNOLOGICAL NETWORK THROUGH PURINERGIC SIGNALING BY THEIR COGNATE RECEPTORS, WHICH ARE WIDELY EXPRESSED THROUGHOUT THE BODY. THIS REVIEW PROVIDES A THOROUGH OVERVIEW OF THE EFFECTS OF ATP AND ADO ON MAJOR IMMUNE CELL TYPES. THE OVERWHELMING EVIDENCE INDICATES THAT ATP AND ADO ARE IMPORTANT ENDOGENOUS SIGNALING MOLECULES IN IMMUNITY AND INFLAMMATION. ALTHOUGH THE ROLE OF ATP AND ADO DURING THE COURSE OF INFLAMMATORY AND IMMUNE RESPONSES IN VIVO APPEARS TO BE EXTREMELY COMPLEX, WE PROPOSE THAT THEIR IMMUNOLOGICAL ROLE IS BOTH INTERDEPENDENT AND MULTIFACETED, MEANING THAT THE NATURE OF THEIR EFFECTS MAY SHIFT FROM IMMUNOSTIMULATORY TO IMMUNOREGULATORY OR VICE VERSA DEPENDING ON EXTRACELLULAR CONCENTRATIONS AS WELL AS ON EXPRESSION PATTERNS OF PURINERGIC RECEPTORS AND ECTO-ENZYMES. PURINERGIC SIGNALING THUS CONTRIBUTES TO THE FINE-TUNING OF INFLAMMATORY AND IMMUNE RESPONSES IN SUCH A WAY THAT THE DANGER TO THE HOST IS ELIMINATED EFFICIENTLY WITH MINIMAL DAMAGE TO HEALTHY TISSUES. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; HUMAN DENDRITIC CELLS; TNF-ALPHA PRODUCTION; P2X(7) NUCLEOTIDE RECEPTOR; ARACHIDONIC-ACID RELEASE; HUMAN ENDOTHELIAL-CELLS; EXTRACELLULAR ADENINE-NUCLEOTIDES; CARBOCYCLIC NUCLEOSIDE ANALOG,ATP; ADENOSINE; PURINERGIC RECEPTORS; IMMUNITY; INFLAMMATION,PHARMACOLOGY & THERAPEUTICS,"BOURS, MJL##SWENNEN, ELR##DI VIRGILIO, F##CRONSTEIN, BN##DAGNELIE, PC","MAASTRICHT UNIV, DEPT EPIDEMIOL, NUTR & TOXICOL RES INST MAASTRICHT, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, DEPT PHARMACOL & TOXICOL, NUTR & TOXICOL RES INST MAASTRICHT, NL-6200 MD MAASTRICHT, NETHERLANDS. UNIV FERRARA, DEPT EXPT & DIAGNOST MED, SEC GEN PATHOL, I-44100 FERRARA, ITALY. NYU, SCH MED, DEPT MED, DIV CLIN PHARMACOL, NEW YORK, NY 10016 USA.",PHARMACOLOGY & PHARMACY,PHARMACOLOGY & PHARMACY,"AALTO TK, 1993, AM J PHYSIOL, V264, PC282##ABBRACCHIO MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X##ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4##ADEREM A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/ANNUREV.IMMUNOL.17.1.593##ADINOLFI E, 2002, BLOOD, V99, P706, DOI 10.1182/BLOOD.V99.2.706##ADRIAN K, 2000, BBA-GENE STRUCT EXPR, V1492, P127, DOI 10.1016/S0167-4781(00)00094-4##AGA M, 2004, AM J PHYSIOL-CELL PH, V286, PC923, DOI 10.1152/AJPCELL.00417.2003##AGA M, 2002, J LEUKOCYTE BIOL, V72, P222##AGTERESCH HJ, 1999, DRUGS, V58, P211, DOI 10.2165/00003495-199958020-00002##AIRAS L, 2000, J IMMUNOL, V165, P5411, DOI 10.4049/JIMMUNOL.165.10.5411##AIRAS L, 1995, J EXP MED, V182, P1603, DOI 10.1084/JEM.182.5.1603##AKBAR GKM, 1997, BIOCHEM BIOPH RES CO, V233, P71, DOI 10.1006/BBRC.1997.6396##AL-AYADHI LY, 2004, PHARMACOL RES, V50, P157, DOI 10.1016/J.PHRS.2003.12.018##AL-HUMIDAN A, 1998, CELL IMMUNOL, V188, P12, DOI 10.1006/CIMM.1998.1324##ALAM RAFEUL, 2003, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, V111, PS476##ALDRICH MB, 2000, BIOCHEM BIOPH RES CO, V272, P311, DOI 10.1006/BBRC.2000.2773##ALOISI F, 2001, GLIA, V36, P165, DOI 10.1002/GLIA.1106##ALTIERI DC, 1988, J BIOL CHEM, V263, P7007##ALTIERI DC, 1990, J IMMUNOL, V145, P662##ANDERSON R, 2000, BRIT J PHARMACOL, V130, P717, DOI 10.1038/SJ.BJP.0703344##ANDREI C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/PNAS.0308558101##ANDREI EY, 1999, J PHYS IV, V9, P5, DOI 10.1051/JP4:19991002##ANTONYSAMY MA, 1995, J IMMUNOL, V155, P2813##APASOV S, 2000, BLOOD, V95, P3859##APASOV S, 1993, CURR OPIN IMMUNOL, V5, P404, DOI 10.1016/0952-7915(93)90060-6##APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/J.1600-065X.1995.TB00680.X##APASOV SG, 1999, INT IMMUNOL, V11, P179, DOI 10.1093/INTIMM/11.2.179##APASOV SG, 1997, J IMMUNOL, V158, P5095##APASOV SG, 2001, J CLIN INVEST, V108, P131, DOI 10.1172/JCI200110360##APASOV SG, 1996, J BIOL CHEM, V271, P25677, DOI 10.1074/JBC.271.41.25677##ARMSTRONG JM, 2001, BIOCHEM J, V354, P123, DOI 10.1042/0264-6021:3540123##ARVILOMMI AM, 1997, EUR J IMMUNOL, V27, P248, DOI 10.1002/EJI.1830270137##AVERY RK, 1992, J IMMUNOL, V149, P1265##AXTELL RA, 1990, BLOOD, V75, P1324##AZIZ KA, 2001, SAUDI MED J, V22, P526##BAHARAV E, 2002, DRUG DEVELOP RES, V57, P182, DOI 10.1002/DDR.10148##BAHARAV E, 2005, J RHEUMATOL, V32, P469##BAJPAI A, 1993, CELL IMMUNOL, V148, P130, DOI 10.1006/CIMM.1993.1096##BALAZOVICH KJ, 1990, J IMMUNOL, V144, P631##BALBOA MA, 1999, J BIOL CHEM, V274, P36764, DOI 10.1074/JBC.274.51.36764##BANCHEREAU J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/ANNUREV.IMMUNOL.18.1.767##BARALDI PG, 2003, J MED CHEM, V46, P1318, DOI 10.1021/JM021049D##BARANKIEWICZ J, 1988, J BIOL CHEM, V263, P7094##BARANKIEWICZ J, 1994, ADV EXP MED BIOL, V370, P417##BARDEN JA, 2003, FEBS LETT, V538, P159, DOI 10.1016/S0014-5793(03)00172-8##BARICKMAN BJ, 1999, POPULACAO FAMILIA, V2, P7##BARICORDI OR, 1996, BLOOD, V87, P682, DOI 10.1182/BLOOD.V87.2.682.BLOODJOURNAL872682##BARNES CR, 1995, BIOCHEM PHARMACOL, V50, P1851, DOI 10.1016/0006-2952(95)02078-0##BAZZONI G, 1991, BLOOD, V77, P2042##BEEKHUIZEN H, 1993, J LEUKOCYTE BIOL, V54, P363##BEIGI RD, 2003, BRIT J PHARMACOL, V140, P507, DOI 10.1038/SJ.BJP.0705470##BEIGI RD, 2000, J IMMUNOL, V165, P7189, DOI 10.4049/JIMMUNOL.165.12.7189##BENGTSSON T, 1996, BBA-MOL CELL RES, V1313, P119, DOI 10.1016/0167-4889(96)00059-6##BENGTSSON T, 1996, BLOOD, V87, P4411, DOI 10.1182/BLOOD.V87.10.4411.BLOODJOURNAL87104411##BERCHTOLD S, 1999, FEBS LETT, V458, P424, DOI 10.1016/S0014-5793(99)01197-7##BIANCO F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/JIMMUNOL.174.11.7268##BIGONNESSE F, 2004, BIOCHEMISTRY-US, V43, P5511, DOI 10.1021/BI0362222##BLANCHARD DK, 1991, J IMMUNOL, V147, P2579##BLANCHARD DK, 1995, BLOOD, V85, P3173, DOI 10.1182/BLOOD.V85.11.3173.BLOODJOURNAL85113173##BLAY J, 1997, CANCER RES, V57, P2602##BODIN P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/S000110050341##BODIN P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693##BOEYNAEMS JM, 2003, DRUG DEVELOP RES, V59, P30, DOI 10.1002/DDR.10199##BORCHERDING DR, 1996, J MED CHEM, V39, P2615, DOI 10.1021/JM950906T##BOUAM MG, 1996, AM J PHYSL 1, V270, PC522##BOUCSEIN C, 2003, EUR J NEUROSCI, V17, P2267, DOI 10.1046/J.1460-9568.2003.02663.X##BOUMA MG, 1994, J IMMUNOL, V153, P4159##BOUMA MG, 1997, J IMMUNOL, V158, P5400##BOWLER JW, 2003, BRIT J PHARMACOL, V140, P567, DOI 10.1038/SJ.BJP.0705459##BOWLIN RL, 1995, ARTHRITIS RHEUM, V38, P1485##BOWLIN TL, 1996, DRUG DEVELOP RES, V39, P388, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<388::AID-DDR20>3.0.CO;2-X##BOWLIN TL, 1997, CELL MOL BIOL, V43, P345##BOYLE DL, 2001, J PHARMACOL EXP THER, V296, P495##BRADSHAW M, 1995, J PHARMACOL EXP THER, V273, P1506##BROUGH D, 2003, J IMMUNOL, V170, P3029, DOI 10.4049/JIMMUNOL.170.6.3029##BROUGH D, 2002, MOL CELL NEUROSCI, V19, P272, DOI 10.1006/MCNE.2001.1054##BROUSSAS M, 1999, J LEUKOCYTE BIOL, V66, P495##BSHESH K, 2002, J LEUKOCYTE BIOL, V72, P1027##BUCKLEY KA, 2003, FASEB J, V17, P1401, DOI 10.1096/FJ.02-0940COM##BUDAGIAN V, 2003, J BIOL CHEM, V278, P1549, DOI 10.1074/JBC.M206383200##BUELL G, 1998, BLOOD, V92, P3521, DOI 10.1182/BLOOD.V92.10.3521.422K50_3521_3528##BULLOUGH DA, 1996, CARDIOVASC RES, V32, P328, DOI 10.1016/0008-6363(96)00052-1##BURG ND, 2001, CLIN IMMUNOL, V99, P7, DOI 10.1006/CLIM.2001.5007##BURKEY TH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P312, DOI 10.1016/0167-4889(93)90223-C##BURNSTOCK G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3##BUTLER JJ, 2003, J CELL BIOCHEM, V89, P975, DOI 10.1002/JCB.10562##CADIEUX JS, 2005, J CELL SCI, V118, P1437, DOI 10.1242/JCS.01737##CAIN BS, 1998, J SURG RES, V76, P117, DOI 10.1006/JSRE.1998.5304##CANADAY DH, 2002, INFECT IMMUN, V70, P6456, DOI 10.1128/IAI.70.11.6456-6459.2002##CAPECCHI PL, 2005, J CARD FAIL, V11, P67, DOI 10.1016/J.CARDFAIL.2004.04.005##CASSADA DC, 2002, J VASC SURG, V35, P994, DOI 10.1067/MVA.2002.123091##CASSATELLA MA, 1999, ADV IMMUNOL, V73, P369, DOI 10.1016/S0065-2776(08)60791-9##CHAKER MB, 1984, J INVEST DERMATOL, V82, P496, DOI 10.1111/1523-1747.EP12261031##CHAKFE Y, 2002, J NEUROSCI, V22, P3061, DOI 10.1523/JNEUROSCI.22-08-03061.2002##CHAPLIN DAVID D., 2003, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, V111, PS442##CHEN BC, 2000, BRIT J PHARMACOL, V130, P777, DOI 10.1038/SJ.BJP.0703375##CHEN BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/SJ.BJP.0704334##CHEN BC, 1999, J BIOMED SCI, V6, P425, DOI 10.1159/000025418##CHEN BC, 1998, J BIOL CHEM, V273, P29754, DOI 10.1074/JBC.273.45.29754##CHEN EP, 1999, INT J NUMER ANAL MET, V23, P1, DOI 10.1002/(SICI)1096-9853(199901)23:1<1::AID-NAG892>3.0.CO;2-R##[ç¨‹è£•æ·‡ CHENG YUAI], 2002, [åœ°è´¨å­¦æŠ¥, ACTA GEOLOGICA SINICA], V76, P1##CHESSELL IP, 2001, DRUG DEVELOP RES, V53, P60, DOI 10.1002/DDR.1171##CHIOZZI P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/JCB.138.3.697##CHIOZZI P, 1996, BIOCHEM BIOPH RES CO, V218, P176, DOI 10.1006/BBRC.1996.0031##CHTANOVA T, 2001, ADV IMMUNOL, V78, P233, DOI 10.1016/S0065-2776(01)78005-4##CHUSED TM, 1996, J IMMUNOL, V157, P1371##CIRUELA F, 1996, FEBS LETT, V380, P219, DOI 10.1016/0014-5793(96)00023-3##CLIFFORD EE, 1997, AM J PHYSIOL-CELL PH, V273, PC973##COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531##COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/BJ2630715##COCKCROFT S, 1989, FEBS LETT, V245, P25, DOI 10.1016/0014-5793(89)80184-X##COHEN SB, 2004, J ORTHOP RES, V22, P427, DOI 10.1016/J.ORTHRES.2003.08.011##COLLO G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8##COLONNA M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/NI1141##COMBES P, 2001, J PHARM PHARMACOL, V53, P1153, DOI 10.1211/0022357011776414##COMERFORD KM, 2002, FASEB J, V16, P583, DOI 10.1096/FJ.01-0739FJE##COMMUNI D, 2000, FEBS LETT, V475, P39, DOI 10.1016/S0014-5793(00)01618-5##COMMUNI D, 2001, DRUG DEVELOP RES, V52, P156, DOI 10.1002/DDR.1110##CONIGRAVE AD, 2001, EUR J PHARMACOL, V426, P157, DOI 10.1016/S0014-2999(01)01222-5##CORDERO OJ, 2001, J LEUKOCYTE BIOL, V70, P920##CORREALE P, 1997, IMMUNOL LETT, V55, P69, DOI 10.1016/S0165-2478(96)02687-9##COTTAM HB, 1993, J MED CHEM, V36, P3424, DOI 10.1021/JM00074A024##COUTINHO-SILVA R, 2005, BIOCHEM PHARMACOL, V69, P641, DOI 10.1016/J.BCP.2004.11.012##COUTINHO-SILVA R, 1997, AM J PHYSIOL-CELL PH, V273, PC1793##COUTINHO-SILVA R, 1999, AM J PHYSIOL-CELL PH, V276, PC1139##COX MA, 2005, BIOCHEM BIOPH RES CO, V330, P467, DOI 10.1016/J.BBRC.2005.03.004##CRISTALLI G, 2001, MED RES REV, V21, P105, DOI 10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U##CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/JEM.158.4.1160##CRONSTEIN BN, 2005, PHARMACOL REV, V57, P163, DOI 10.1124/PR.57.2.3##CRONSTEIN BN, 1983, T ASSOC AM PHYSICIAN, V96, P384##CRONSTEIN BN, 1985, J IMMUNOL, V135, P1366##CRONSTEIN BN, 1995, ARTHRITIS RHEUM, V38, P1040, DOI 10.1002/ART.1780380804##CRONSTEIN BN, 1987, CLIN IMMUNOL IMMUNOP, V42, P76, DOI 10.1016/0090-1229(87)90174-7##CRONSTEIN BN, 1986, J CLIN INVEST, V78, P760, DOI 10.1172/JCI112638##CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5##CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201##CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547##DAWICKI DD, 1995, AM J PHYSIOL-LUNG C, V268, PL666##DAY YJ, 2004, AM J PHYSIOL-GASTR L, V286, PG285, DOI 10.1152/AJPGI.00348.2003##DAY YJ, 2005, J IMMUNOL, V174, P5040, DOI 10.4049/JIMMUNOL.174.8.5040##DAY YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483##DELAHARPE J, 1989, J IMMUNOL, V143, P596##DELIKOURAS A, 2003, EUR J IMMUNOL, V33, P3127, DOI 10.1002/EJI.200323566##DELVES PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107##DEMARCO R, 2004, J IMMUNOTHER, V27, PS14, DOI 10.1097/00002371-200411000-00054##DENLINGER LC, 2005, J IMMUNOL, V174, P4424, DOI 10.4049/JIMMUNOL.174.7.4424##DENLINGER LC, 2004, J ENDOTOXIN RES, V10, P137, DOI 10.1179/096805104225004040##DENLINGER LC, 1996, J BIOL CHEM, V271, P337, DOI 10.1074/JBC.271.1.337##DERIAN CK, 1995, J IMMUNOL, V154, P308##DERKS R, 2004, HUM IMMUNOL, V65, P676, DOI 10.1016/J.HUMIMM.2004.04.006##DI VIRGILIO F, 2003, DRUG DEVELOP RES, V59, P171, DOI 10.1002/DDR.10191##DI VIRGILIO F, 2003, BRIT J PHARMACOL, V140, P441, DOI 10.1038/SJ.BJP.0705469##DI VIRGILIO F, 2001, BLOOD, V97, P587, DOI 10.1182/BLOOD.V97.3.587##DI VIRGILIO F, 1998, BIOFACTORS, V8, P301##DI VIRGILIO F, 1998, CELL DEATH DIFFER, V5, P191##DI VIRGILIO FRANCESCO, 2005, PURINERGIC SIGNAL, V1, P205, DOI 10.1007/S11302-005-6312-Z##DI VIRGILIO FRANCESCO, 2005, CURRENT DRUG TARGETS - CARDIOVASCULAR & HAEMATOLOGICAL DISORDERS, V5, P85##DIANZANI C, 1994, EUR J PHARMACOL, V263, P223, DOI 10.1016/0014-2999(94)90547-9##DICKENSON JM, 2003, EUR J PHARMACOL, V474, P43, DOI 10.1016/S0014-2999(03)02041-7##DIVIRGILIO F, 1990, IMMUNOL TODAY, V11, P274, DOI 10.1016/0167-5699(90)90111-L##DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955##DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X##DOMBROWSKI KE, 1995, J IMMUNOL, V154, P6227##DOMBROWSKI KE, 1997, ARCH BIOCHEM BIOPHYS, V340, P10, DOI 10.1006/ABBI.1997.9904##DOMBROWSKI KE, 1998, IMMUNOL REV, V161, P111, DOI 10.1111/J.1600-065X.1998.TB01575.X##DOMBROWSKI KE, 1995, CELL IMMUNOL, V160, P199, DOI 10.1016/0008-8749(95)80028-H##DOMBROWSKI KE, 1993, BIOCHEMISTRY-US, V32, P6515, DOI 10.1021/BI00077A004##DOMBROWSKI KE, 2000, ECTOATPASES RELATED, P145##DONG RP, 1997, J IMMUNOL, V159, P6070##DONG RP, 1996, J IMMUNOL, V156, P1349##DONNELLY-ROBERTS DL, 2004, J PHARMACOL EXP THER, V308, P1053, DOI 10.1124/JPET.103.059600##DOSREIS GA, 1986, CELL IMMUNOL, V101, P213, DOI 10.1016/0008-8749(86)90199-1##DOWDALL JF, 2002, J SURG RES, V108, P61, DOI 10.1006/JSRE.2002.6519##DUBYAK GR, 2000, J AUTONOM NERV SYST, V81, P64, DOI 10.1016/S0165-1838(00)00155-7##DUFFIELD JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240##DUHANT X, 2002, J IMMUNOL, V169, P15, DOI 10.4049/JIMMUNOL.169.1.15##DUHANT XAVIER, 2005, PURINERGIC SIGNAL, V1, P377, DOI 10.1007/S11302-005-8077-9##EDWARDS CK, 1994, J LEUKOCYTE BIOL, V56, P133##EIGLER A, 1997, SCAND J IMMUNOL, V45, P132, DOI 10.1046/J.1365-3083.1997.D01-377.X##EIGLER A, 2000, J LEUKOCYTE BIOL, V68, P97##ELFERINK JGR, 1992, ARCH INT PHARMACOD T, V317, P93##ELLIOTT JI, 2004, DIABETES, V53, P2012, DOI 10.2337/DIABETES.53.8.2012##ELSSNER A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/JIMMUNOL.172.8.4987##ELTZSCHIG HK, 2004, BLOOD, V104, P3986, DOI 10.1182/BLOOD-2004-06-2066##ELTZSCHIG HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/JEM.20050177##ELTZSCHIG HK, 2003, J EXP MED, V198, P783, DOI 10.1084/JEM.20030891##EPPELL BA, 1989, J IMMUNOL, V143, P4141##ERDMANN AA, 2005, BLOOD, V105, P4707, DOI 10.1182/BLOOD-2004-04-1407##ESCHKE D, 2002, N-S ARCH PHARMACOL, V365, P168, DOI 10.1007/S00210-001-0501-2##FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/SCIENCE.6322306##FALLENI A, 1999, J CELL BIOCHEM, V75, P235, DOI 10.1002/(SICI)1097-4644(19991101)75:2<235::AID-JCB6>3.0.CO;2-K##FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770##FALZONI S, 2000, MOL BIOL CELL, V11, P3169, DOI 10.1091/MBC.11.9.3169##FAURSCHOU M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/J.MICINF.2003.09.008##FELSCH A, 1995, J IMMUNOL, V155, P333##FEOKTISTOV I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14##FEOKTISTOV I, 2004, HYPERTENSION, V44, P649, DOI 10.1161/01.HYP.0000144800.21037.A5##FERNANDO KC, 1999, ARCH BIOCHEM BIOPHYS, V362, P197, DOI 10.1006/ABBI.1998.1045##FERRARI D, 2004, J IMMUNOL, V173, P4652, DOI 10.4049/JIMMUNOL.173.7.4652##FERRARI D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8##FERRARI D, 1996, J IMMUNOL, V156, P1531##FERRARI D, 1997, J EXP MED, V185, P579, DOI 10.1084/JEM.185.3.579##FERRARI D, 1997, J IMMUNOL, V159, P1451##FERRARI D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7##FERRARI D, 2000, FASEB J, V14, P2466, DOI 10.1096/FJ.00-0031COM##FILIPPINI A, 1990, J BIOL CHEM, V265, P334##FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/PNAS.87.21.8267##FILIPPINI A, 1990, FASEB J, V4, PA1870##FIRESTEIN GS, 1994, J IMMUNOL, V152, P5853##FIRESTEIN GS, 1996, DRUG DEVELOP RES, V39, P371, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<371::AID-DDR18>3.0.CO;2-4##FIRESTEIN GS, 1995, J IMMUNOL, V154, P326##FISETTE PL, 1996, DRUG DEVELOP RES, V39, P377, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<377::AID-DDR19>3.0.CO;2-Z##FLAMAND N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/MOL.62.2.250##FLAMAND N, 2000, AM J RESP CRIT CARE, V161, PS88, DOI 10.1164/AJRCCM.161.SUPPLEMENT_1.LTTA-18##FLEZAR M, 1992, CAN J PHYSIOL PHARM, V70, P1065, DOI 10.1139/Y92-147##FORDHUTCHINSON AW, 1982, BRIT J PHARMACOL, V76, P367, DOI 10.1111/J.1476-5381.1982.TB09229.X##FORREST CM, 2004, NUCLEOS NUCLEOT NUCL, V23, P1107, DOI 10.1081/NCN-200027369##FORTIN A, 2006, J LEUKOCYTE BIOL, V79, P574, DOI 10.1189/JLB.0505249##FOSSETTA J, 2003, MOL PHARMACOL, V63, P342, DOI 10.1124/MOL.63.2.342##FOTHERINGHAM J, 2004, VIROLOGY, V327, P186, DOI 10.1016/J.VIROL.2004.07.007##FOTHERINGHAM JA, 2004, EUR J PHARMACOL, V497, P87, DOI 10.1016/J.EJPHAR.2004.06.029##FRANCO R, 1997, PROG NEUROBIOL, V52, P283, DOI 10.1016/S0301-0082(97)00013-0##FRANTZ S, 2005, CIRC RES, V96, P15, DOI 10.1161/01.RES.0000153188.68898.AC##FREDHOLM BB, 2001, BIOCHEM PHARMACOL, V61, P443, DOI 10.1016/S0006-2952(00)00570-0##FREDHOLM BB, 1997, GEN PHARMACOL-VASC S, V28, P345, DOI 10.1016/S0306-3623(96)00169-3##FREDHOLM BB, 1996, N-S ARCH PHARMACOL, V354, P262, DOI 10.1007/BF00171056##FREDHOLM BB, 2001, PHARMACOL REV, V53, P527##FREYER DR, 1988, J IMMUNOL, V141, P580##GALLUCCI S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6##GARGETT CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/SJ.BJP.0701081##GARGETT CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/BJ3130529##GARTLAND A, 2003, CRIT REV EUKAR GENE, V13, P243, DOI 10.1615/CRITREVEUKARYOTGENEEXPR.V13.I24.150##GASMI L, 1996, BLOOD, V87, P3442, DOI 10.1182/BLOOD.V87.8.3442.BLOODJOURNAL8783442##GENDRON FP, 2002, CURR DRUG TARGETS, V3, P229, DOI 10.2174/1389450023347713##GEORGIOU JG, 2005, J INVEST DERMATOL, V125, P482, DOI 10.1111/J.0022-202X.2005.23835.X##GESSI S, 2004, CLIN CANCER RES, V10, P5895, DOI 10.1158/1078-0432.CCR-1134-03##GESSI S, 2004, MOL PHARMACOL, V65, P711, DOI 10.1124/MOL.65.3.711##GESSI S, 2001, BRIT J PHARMACOL, V134, P116, DOI 10.1038/SJ.BJP.0704254##GESSI S, 2002, MOL PHARMACOL, V61, P415, DOI 10.1124/MOL.61.2.415##GESSI S, 2005, MOL PHARMACOL, V67, P2137, DOI 10.1124/MOL.104.009225##GILROY DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/NRD1383##GINES S, 2002, BIOCHEM J, V361, P203, DOI 10.1042/0264-6021:3610203##GIROLOMONI G, 1993, J INVEST DERMATOL, V100, P282, DOI 10.1111/1523-1747.EP12469769##GIROLOMONI G, 1992, J INVEST DERMATOL, V99, PS18, DOI 10.1111/1523-1747.EP12668253##GLOVER DK, 2005, AM J PHYSIOL-HEART C, V288, PH1851, DOI 10.1152/AJPHEART.00362.2004##GODING JW, 2000, J LEUKOCYTE BIOL, V67, P285##GOEPFERT C, 2001, CIRCULATION, V104, P3109, DOI 10.1161/HC5001.100663##GOEPFERT C, 2000, MOL MED, V6, P591, DOI 10.1007/BF03401797##GOMEZ G, 2003, INT J BIOCHEM CELL B, V35, P410, DOI 10.1016/S1357-2725(02)00177-2##GOMEZ G, 2001, DRUG DEVELOP RES, V53, P218, DOI 10.1002/DDR.1190##GOMEZ G, 2003, BLOOD, V102, P4472, DOI 10.1182/BLOOD-2002-11-3624##GORDON S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/NRI978##GORDON S, 1999, INFLAMMATION BASIC P, P35##GRAHAMES CBA, 1999, BRIT J PHARMACOL, V127, P1915, DOI 10.1038/SJ.BJP.0702732##GRANSTEIN RD, 2005, J IMMUNOL, V174, P7725, DOI 10.4049/JIMMUNOL.174.12.7725##GRANSTEIN RD, 2002, NAT MED, V8, P336, DOI 10.1038/NM0402-336##GREENBERG SS, 1997, AM J PHYSIOL-LUNG C, V273, PL967##GREENBERG SS, 1996, BIOCHEM BIOPH RES CO, V227, P160, DOI 10.1006/BBRC.1996.1483##GRIFFITHS RJ, 1995, J IMMUNOL, V154, P2821##GRISHAM MB, 1989, AM J PHYSIOL, V257, PH1334##GU B, 1998, BLOOD, V92, P946##GU BJ, 2000, AM J PHYSIOL-CELL PH, V279, PC1189##GUDIPATY L, 2003, AM J PHYSIOL-CELL PH, V285, PC286, DOI 10.1152/AJPCELL.00070.2003##GUERRA AN, 2003, J ENDOTOXIN RES, V9, P256, DOI 10.1179/096805103225001468##GUNTHER G R, 1991, ANN VASC SURG, V5, P325, DOI 10.1007/BF02015292##HAMON Y, 1997, BLOOD, V90, P2911, DOI 10.1182/BLOOD.V90.8.2911##HAND WL, 1990, ANTIMICROB AGENTS CH, V34, P863, DOI 10.1128/AAC.34.5.863##HANLEY PJ, 2004, P NATL ACAD SCI USA, V101, P9479, DOI 10.1073/PNAS.0400733101##HANNON JP, 1998, DRUG DEVELOP RES, V43, P214, DOI 10.1002/(SICI)1098-2299(199804)43:4<214::AID-DDR5>3.0.CO;2-L##HARADA N, 2000, J PHARMACOL EXP THER, V294, P1034##HARDART GE, 1991, INFECT IMMUN, V59, P885, DOI 10.1128/IAI.59.3.885-889.1991##HARDEN TK, 1997, TRENDS PHARMACOL SCI, V18, P43, DOI 10.1016/S0165-6147(97)89795-7##HARISH A, 2003, INT J ONCOL, V23, P1245##HARKNESS RA, 1983, CLIN SCI, V64, P333, DOI 10.1042/CS0640333##HARRIS SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8##HASHIKAWA T, 2004, FASEB J, V18, P131, DOI 10.1096/FJ.03-0011FJE##HASKO G, 2004, TRENDS PHARMACOL SCI, V25, P152, DOI 10.1016/J.TIPS.2004.01.006##HASKO G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/J.IT.2003.11.003##HASKO G, 2000, BRIT J PHARMACOL, V129, P909, DOI 10.1038/SJ.BJP.0703134##HASKO G, 1998, EUR J PHARMACOL, V358, P261, DOI 10.1016/S0014-2999(98)00619-0##HASKO G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/JIMMUNOL.164.2.1013##HASKO G, 1996, J IMMUNOL, V157, P4634##HASKO G, 2000, FASEB J, V14, P2065, DOI 10.1096/FJ.99-0508COM##HEATH WR, 2003, NATURE, V425, P460, DOI 10.1038/425460A##HENTTINEN T, 2003, J BIOL CHEM, V278, P24888, DOI 10.1074/JBC.M300779200##HERRERA C, 2001, MOL PHARMACOL, V59, P127##HERSHFIELD MS, 2005, EUR J IMMUNOL, V35, P25, DOI 10.1002/EJI.200425738##HICKMAN SE, 1994, BLOOD, V84, P2452##HIDE I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/J.1471-4159.2000.0750965.X##HOEBERTZ A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165-6147(03)00123-8##HOFER S, 2003, J INVEST DERMATOL, V121, P300, DOI 10.1046/J.1523-1747.2003.12369.X##HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/PNAS.88.19.8485##HON WM, 1995, BIOCHEM PHARMACOL, V50, P45, DOI 10.1016/0006-2952(95)00111-C##HON WM, 1997, LIFE SCI, V60, P1327, DOI 10.1016/S0024-3205(97)00078-7##HONDA S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001##HOSKIN DW, 2002, INT J CANCER, V99, P386, DOI 10.1002/IJC.10325##HOSKIN DW, 1994, CELL IMMUNOL, V159, P85, DOI 10.1006/CIMM.1994.1297##HOSKIN DW, 1994, INT J CANCER, V59, P854, DOI 10.1002/IJC.2910590625##HU Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/JBC.273.42.27170##HUANG S, 1997, BLOOD, V90, P1600, DOI 10.1182/BLOOD.V90.4.1600.1600_1600_1610##HUFFNAGLE GB, 1997, LUNG BIOL HEALTH DIS, V102, P373##HUMPHREYS BD, 1998, J LEUKOCYTE BIOL, V64, P265##HUMPHREYS BD, 1996, J IMMUNOL, V157, P5627##HUMPHREYS BD, 2000, J BIOL CHEM, V275, P26792##ICHINOSE M, 1995, JPN J PHYSIOL, V45, P707, DOI 10.2170/JJPHYSIOL.45.707##IDZKO M, 2004, J CELL PHYSIOL, V201, P286, DOI 10.1002/JCP.20070##IDZKO M, 2004, J CELL PHYSIOL, V199, P149, DOI 10.1002/JCP.10431##IDZKO M, 2003, BRIT J PHARMACOL, V138, P1244, DOI 10.1038/SJ.BJP.0705145##IDZKO M, 2002, BLOOD, V100, P925, DOI 10.1182/BLOOD.V100.3.925##IKEHARA S, 1981, J IMMUNOL, V127, P1834##IMHOF BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/NRI1375##INOUE K, 2001, DRUG DEVELOP RES, V53, P166, DOI 10.1002/DDR.1184##INTO T, 2002, INFECT IMMUN, V70, P3586, DOI 10.1128/IAI.70.7.3586-3591.2002##INTO T, 2002, MICROBIOL IMMUNOL, V46, P667, DOI 10.1111/J.1348-0421.2002.TB02750.X##JACOBSON KA, 1997, NEUROPHARMACOLOGY, V36, P1157, DOI 10.1016/S0028-3908(97)00104-4##JACOBSON KA, 2002, J MED CHEM, V45, P4057, DOI 10.1021/JM020046Y##JACOBSON MA, 1994, DRUG DEVELOP RES, V31, P282##JAMIESON GP, 1996, J CELL PHYSIOL, V166, P637, DOI 10.1002/(SICI)1097-4652(199603)166:3<637::AID-JCP19>3.0.CO;2-3##JEROME KR, 2004, NEW ENGL J MED, V350, P411, DOI 10.1056/NEJMCIBR032455##JHUN BS, 2004, BIOCHEM BIOPH RES CO, V318, P372, DOI 10.1016/J.BBRC.2004.04.035##JHUN BS, 2005, BIOCHEM BIOPH RES CO, V332, P339, DOI 10.1016/J.BBRC.2005.04.126##JIANG LL, 1997, BIOCHEM BIOPH RES CO, V232, P626, DOI 10.1006/BBRC.1997.6345##JIN JG, 1998, BRIT J PHARMACOL, V123, P789, DOI 10.1038/SJ.BJP.0701665##JIN XW, 1997, J CLIN INVEST, V100, P2849, DOI 10.1172/JCI119833##JOHN GR, 2001, J NEUROSCI, V21, P4134, DOI 10.1523/JNEUROSCI.21-12-04134.2001##JOHNSTON A, 2005, CLIN IMMUNOL, V114, P154, DOI 10.1016/J.CLIM.2004.09.001##JORDAN JE, 1997, J PHARMACOL EXP THER, V280, P301##JORDAN JE, 1999, AM J PHYSIOL-HEART C, V277, PH1895##JURGENSEN CH, 1990, J IMMUNOL, V144, P653##KACZMAREK E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/JBC.271.51.33116##KAHLENBERG JM, 2004, AM J PHYSIOL-CELL PH, V286, PC1100, DOI 10.1152/AJPCELL.00494.2003##KALSI K, 2002, MOL CELL BIOCHEM, V232, P113, DOI 10.1023/A:1014806916844##KANEIDER NC, 2004, THROMB RES, V114, P185, DOI 10.1016/J.THROMRES.2004.06.020##KANNAN S, 2003, CELL BIOL INT, V27, P593, DOI 10.1016/S1065-6995(03)00082-9##KANNAN S, 2002, MED HYPOTHESES, V59, P261, DOI 10.1016/S0306-9877(02)00213-X##KANNAN S, 2001, MED HYPOTHESES, V57, P306, DOI 10.1054/MEHY.2001.1313##KANSAS GS, 1991, J IMMUNOL, V146, P2235##KAS-DEELEN AM, 2001, FEBS LETT, V491, P21, DOI 10.1016/S0014-5793(01)02085-3##KAUFMANN A, 2005, J BIOL CHEM, V280, P32459, DOI 10.1074/JBC.M505301200##KAUL N, 1996, FREE RADICAL BIO MED, V21, P401, DOI 10.1016/0891-5849(96)00178-5##KAWAMURA H, 2005, J IMMUNOL, V174, P1971, DOI 10.4049/JIMMUNOL.174.4.1971##KHAKH BS, 2001, PHARMACOL REV, V53, P107##KHOA ND, 2003, J IMMUNOL, V171, P3991, DOI 10.4049/JIMMUNOL.171.8.3991##KHOA ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/JIMMUNOL.167.7.4026##KILIAN JG, 2005, INT J CARDIOL, V105, P322, DOI 10.1016/J.IJCARD.2005.03.010##KITAKAZE M, 1993, CIRC RES, V73, P524, DOI 10.1161/01.RES.73.3.524##KOHNO Y, 1996, BIOCHEM BIOPH RES CO, V219, P904, DOI 10.1006/BBRC.1996.0331##KOSAKA H, 2003, DRUG DEVELOP RES, V58, P479, DOI 10.1002/DDR.10175##KOSHIBA M, 1999, MOL PHARMACOL, V55, P614##KOSHIBA M, 1997, J BIOL CHEM, V272, P25881, DOI 10.1074/JBC.272.41.25881##KOSHIBA M, 2004, NUCLEOS NUCLEOT NUCL, V23, P1101, DOI 10.1081/NCN-200027368##KOSZALKA P, 2004, CIRC RES, V95, P814, DOI 10.1161/01.RES.0000144796.82787.6F##KOWALUK EA, 2000, EXPERT OPIN INV DRUG, V9, P551, DOI 10.1517/13543784.9.3.551##KOWALUK EA, 2000, J PHARMACOL EXP THER, V295, P1165##KOWALUK EA, 1998, CURR PHARM DESIGN, V4, P403##KOZIAK K, 1999, THROMB HAEMOSTASIS, V82, P1538##KRISHNARAJ R, 1992, CELL IMMUNOL, V141, P306, DOI 10.1016/0008-8749(92)90150-N##KRUMP E, 1996, BRIT J PHARMACOL, V117, P1639, DOI 10.1111/J.1476-5381.1996.TB15334.X##KRUMP E, 1997, J EXP MED, V186, P1401, DOI 10.1084/JEM.186.8.1401##KUBERSKY SM, 1989, INFLAMMATION, V13, P591, DOI 10.1007/BF00916765##KUHNS DB, 1988, LAB INVEST, V58, P448##KUROKI M, 1989, BIOCHEM BIOPH RES CO, V162, P377, DOI 10.1016/0006-291X(89)92007-X##LA SALA A, 2002, BLOOD, V99, P1715, DOI 10.1182/BLOOD.V99.5.1715##LA SALA A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/JIMMUNOL.166.3.1611##LA SALA A, 2003, J LEUKOCYTE BIOL, V73, P339, DOI 10.1189/JLB.0802418##LABASI JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/JIMMUNOL.168.12.6436##LALIBERTE R, 1994, J IMMUNOL, V153, P2168##LALIBERTE RE, 1997, J LEUKOCYTE BIOL, V62, P227##LALIBERTE RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/JBC.274.52.36944##LAMMAS DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7##LANGSTON HP, 2003, J IMMUNOL, V170, P2962, DOI 10.4049/JIMMUNOL.170.6.2962##LAPPAS CM, 2005, EXPERT OPIN INV DRUG, V14, P797, DOI 10.1517/13543784.14.7.797##LAPPAS CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/JIMMUNOL.174.2.1073##LATINI S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/J.1471-4159.2001.00607.X##LAZAROWSKI ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/JBC.272.33.20402##LAZAROWSKI ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/JBC.M003255200##LAZAROWSKI ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/MOL.64.4.785##LE FEUVRE RA, 2002, J BIOL CHEM, V277, P3210, DOI 10.1074/JBC.M104388200##LE MOINE O, 1999, J HEPATOL, V31, P457##LEAL DBR, 2005, BBA-GEN SUBJECTS, V1721, P9, DOI 10.1016/J.BBAGEN.2004.09.006##LEDOUX S, 2003, CIRC RES, V92, P848, DOI 10.1161/01.RES.0000069022.95401.FE##LEE HT, 2004, AM J PHYSIOL-RENAL, V286, PF298, DOI 10.1152/AJPRENAL.00185.2003##LEE HT, 2004, J AM SOC NEPHROL, V15, P102, DOI 10.1097/01.ASN.0000102474.68613.AE##LEE WL, 2003, MICROBES INFECT, V5, P1299, DOI 10.1016/J.MICINF.2003.09.014##LEIBOVICH SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002-9440(10)61170-4##LEMAIRE I, 2003, DRUG DEVELOP RES, V59, P118, DOI 10.1002/DDR.10209##LEMOINE O, 1996, J IMMUNOL, V156, P4408##LENARDO M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/ANNUREV.IMMUNOL.17.1.221##LENNON PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/JEM.188.8.1433##LEONARD EJ, 1987, INFLAMMATION, V11, P229, DOI 10.1007/BF00916023##LESCH ME, 1991, AGENTS ACTIONS, V34, P25, DOI 10.1007/BF01993227##LEVRAUX V, 1993, LIFE SCI, V52, P1917, DOI 10.1016/0024-3205(93)90632-D##LI CKF, 2001, GASTROENTEROLOGY, V120, PA522, DOI 10.1016/S0016-5085(08)82591-7##LI NL, 2000, THROMB HAEMOSTASIS, V84, P381##LIAUDET L, 2002, ANN SURG, V235, P568, DOI 10.1097/00000658-200204000-00016##LIAUDET L, 2001, AM J RESP CRIT CARE, V164, P1213, DOI 10.1164/AJRCCM.164.7.2101013##LIEBERMAN J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/NRI1083##LIMING P, 1999, CHIN MED SCI J, V14, P23##LIN WW, 1997, EUR J PHARMACOL, V321, P121, DOI 10.1016/S0014-2999(96)00930-2##LIN WW, 1996, BRIT J PHARMACOL, V119, P261, DOI 10.1111/J.1476-5381.1996.TB15980.X##LIN WW, 1998, MOL PHARMACOL, V53, P313##LIN WW, 1998, BRIT J PHARMACOL, V123, P1173, DOI 10.1038/SJ.BJP.0701705##LINK AA, 2000, J IMMUNOL, V164, P436, DOI 10.4049/JIMMUNOL.164.1.436##LIPSCOMB MF, 2002, PHYSIOL REV, V82, P97, DOI 10.1152/PHYSREV.00023.2001##LIU HT, 2004, RHEUM DIS CLIN N AM, V30, P19, DOI 10.1016/S0889-857X(03)00107-8##LIU QH, 1999, FEBS LETT, V445, P402, DOI 10.1016/S0014-5793(99)00161-1##LOOMIS WH, 2003, J BIOL CHEM, V278, P4590, DOI 10.1074/JBC.M207868200##LUKASHEV D, 2004, J IMMUNOL, V173, P21, DOI 10.4049/JIMMUNOL.173.1.21##LUKASHEV DE, 2005, DRUG DEVELOP RES, V64, P172, DOI 10.1002/DDR.10428##LUKASHEV DE, 2003, BIOCHEM PHARMACOL, V65, P2081, DOI 10.1016/S0006-2952(03)00158-8##LUTTIKHUIZEN DT, 2004, CELL TISSUE RES, V317, P289, DOI 10.1007/S00441-004-0939-X##MABLEY JG, 2003, AM J PHYSIOL-GASTR L, V284, PG138, DOI 10.1152/AJPGI.00060.2002##MACINO B, 1996, BIOCHEM BIOPH RES CO, V226, P769, DOI 10.1006/BBRC.1996.1427##MACKENZIE A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1##MACKENZIE WM, 1994, CANCER RES, V54, P3521##MACKENZIE WM, 2002, EXP CELL RES, V276, P90, DOI 10.1006/EXCR.2002.5514##MACMICKING J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/ANNUREV.IMMUNOL.15.1.323##MADARA JL, 1993, J CLIN INVEST, V91, P2320, DOI 10.1172/JCI116462##MAJUMDAR S, 2003, ONCOGENE, V22, P1206, DOI 10.1038/SJ.ONC.1206184##MAJUMDAR S, 2001, J IMMUNOL, V167, P2911, DOI 10.4049/JIMMUNOL.167.5.2911##MARKWARDT F, 1997, J PHYSIOL-LONDON, V498, P143, DOI 10.1113/JPHYSIOL.1997.SP021847##MARRIOTT I, 1999, CELL IMMUNOL, V195, P147, DOI 10.1006/CIMM.1999.1531##MARTEAU F, 2004, J LEUKOCYTE BIOL, V76, P796, DOI 10.1189/JLB.0104032##MARTIN KA, 1997, MOL PHARMACOL, V51, P97##MARTIN L, 2006, J PHARMACOL EXP THER, V316, P71, DOI 10.1124/JPET.105.091868##MARTINI C, 1991, ADV EXP MED BIOL, V309, P459##MARTON A, 2001, INT J MOL MED, V8, P617##MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/ANNUREV.IY.12.040194.005015##MATZINGER P, 2001, SCAND J IMMUNOL, V54, P4, DOI 10.1046/J.1365-3083.2001.00974.X##MATZINGER P, 2002, SCIENCE, V296, P301, DOI 10.1126/SCIENCE.1071059##MAYNE M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ANA.1010##MAYNE M, 1999, ANN NEUROL, V45, P633, DOI 10.1002/1531-8249(199905)45:5<633::AID-ANA12>3.0.CO;2-X##MAZZONI A, 2004, J LEUKOCYTE BIOL, V75, P721, DOI 10.1189/JLB.1003482##MCCLOSKEY MA, 1999, J IMMUNOL, V163, P970##MCCOLL SR, 2005, FASEB J, V19, P187, DOI 10.1096/FJ.05-4804FJE##MCGARAUGHTY S, 2001, CNS DRUG REV, V7, P415##MCGARRITY ST, 1989, J IMMUNOL, V142, P1986##MCPHERSON JA, 2001, ARTERIOSCL THROM VAS, V21, P791, DOI 10.1161/01.ATV.21.5.791##MCWHINNEY CD, 1996, EUR J PHARMACOL, V310, P209, DOI 10.1016/0014-2999(96)00272-5##MEHTA SK, 2001, ECOL ENG, V18, P1, DOI 10.1016/S0925-8574(00)00174-9##MELLONI E, 1986, J BIOL CHEM, V261, P1437##MERRILL JT, 1997, ARTHRITIS RHEUM, V40, P1308, DOI 10.1002/ART.16##MESHKI J, 2004, AM J PHYSIOL-CELL PH, V286, PC264, DOI 10.1152/AJPCELL.00287.2003##MILLER JS, 1999, J IMMUNOL, V162, P7376##MINAMINO T, 1996, AM J PHYSIOL-HEART C, V271, PH2622##MINGUET S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/EJI.200425524##MIRABET M, 1997, BRIT J PHARMACOL, V122, P1075, DOI 10.1038/SJ.BJP.0701495##MIRABET M, 1999, J CELL SCI, V112, P491##MIYABE K, 2004, THROMB RES, V114, P29, DOI 10.1016/J.THROMRES.2004.04.003##MIZUMOTO N, 2002, NAT MED, V8, P358, DOI 10.1038/NM0402-358##MOHANTY JG, 2001, J ALLERGY CLIN IMMUN, V107, P849, DOI 10.1067/MAI.2001.114658##MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/JEM.180.4.1499##MONTESINOS MC, 2000, ARTHRITIS RHEUM, V43, P656, DOI 10.1002/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H##MONTESINOS MC, 2003, ARTHRITIS RHEUM-US, V48, P240, DOI 10.1002/ART.10712##MONTESINOS MC, 2001, HANDB EXP PHARM, V151, P303##MONTESINOS MC, 2002, AM J PATHOL, V160, P2009, DOI 10.1016/S0002-9440(10)61151-0##MONTESINOS MC, 1997, J EXP MED, V186, P1615, DOI 10.1084/JEM.186.9.1615##MOOCHHALA SM, 1996, EUR J PHARMACOL, V316, P287, DOI 10.1016/S0014-2999(96)00677-2##MOORE DJ, 2003, MOL BRAIN RES, V118, P10, DOI 10.1016/S0169-328X(03)00330-9##MOORE DJ, 2001, BBA-GENE STRUCT EXPR, V1521, P107, DOI 10.1016/S0167-4781(01)00291-3##MORIGIWA K, 2000, NEUROSCI LETT, V282, P153, DOI 10.1016/S0304-3940(00)00887-9##MORIGIWA K, 2000, NIHON YAKURIGAKU ZASSHI, V115, P185##MORIWAKI Y, 1999, HISTOL HISTOPATHOL, V14, P1321, DOI 10.14670/HH-14.1321##MOSSER DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/JLB.0602325##MUHL H, 2003, EUR J PHARMACOL, V482, P325, DOI 10.1016/J.EJPHAR.2003.09.062##MULLER G, 1993, ARTERIOSCLER THROMB, V13, P1317, DOI 10.1161/01.ATV.13.9.1317##MUNRO R, 1998, DRUG DEVELOP RES, V44, P41, DOI 10.1002/(SICI)1098-2299(199805)44:1<41::AID-DDR6>3.0.CO;2-P##MURGIA M, 1992, BIOCHEM J, V288, P897, DOI 10.1042/BJ2880897##MURPHREE LJ, 2005, BIOCHEM J, V391, P575, DOI 10.1042/BJ20050888##MURPHREE LJ, 2003, J LEUKOC BIOL S, V26##MURPHY JK, 1993, AM J RESP CELL MOL, V9, P505, DOI 10.1165/AJRCMB/9.5.505##MUTINI C, 1999, J IMMUNOL, V163, P1958##NAKAMACHI Y, 2003, ARTHRITIS RHEUM-US, V48, P668, DOI 10.1002/ART.10956##NAKANISHI M, 1991, FEBS LETT, V282, P91, DOI 10.1016/0014-5793(91)80451-8##NAPIERALSKI R, 2003, BIOL CHEM, V384, P483, DOI 10.1515/BC.2003.054##NARRAVULA S, 2000, J IMMUNOL, V165, P5262, DOI 10.4049/JIMMUNOL.165.9.5262##NATHAN C, 2002, NATURE, V420, P846, DOI 10.1038/NATURE01320##NAUM CC, 1991, J LEUKOCYTE BIOL, V49, P83##NELSON JD, 1998, ADV EXP MED BIOL, V438, P1##NEMETH ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/JIMMUNOL.175.12.8260##NEMETH ZH, 2003, J PHARMACOL EXP THER, V306, P1042, DOI 10.1124/JPET.103.052944##NEUFELD M, 2000, BLOOD COAGUL FIBRIN, V11, P505, DOI 10.1097/00001721-200009000-00001##NIELSON CP, 1989, BRIT J PHARMACOL, V97, P882, DOI 10.1111/J.1476-5381.1989.TB12028.X##NIEMELA J, 2004, J IMMUNOL, V172, P1646, DOI 10.4049/JIMMUNOL.172.3.1646##NIHEI OK, 2000, BLOOD, V96, P996, DOI 10.1182/BLOOD.V96.3.996.015K02_996_1005##NIJWEIDE PJ, 1995, CLIN ORTHOP RELAT R, P92##NISHIDA Y, 1984, INT J IMMUNOPHARMACO, V6, P335, DOI 10.1016/0192-0561(84)90051-1##NORTH RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/PHYSREV.00015.2002##ODASHIMA M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/J.GASTRO.2005.05.032##OFLAHERTY JT, 1994, LAB INVEST, V70, P816##OGATA T, 2003, BRAIN RES, V981, P174, DOI 10.1016/S0006-8993(03)03028-2##OHANA G, 2003, BRIT J CANCER, V89, P1552, DOI 10.1038/SJ.BJC.6601315##OHTA A, 2001, NATURE, V414, P916, DOI 10.1038/414916A##OKUSA MD, 2000, AM J PHYSIOL-RENAL, V279, PF809##OLAH MARK E, 2003, MOL INTERV, V3, P370, DOI 10.1124/MI.3.7.370##ONTYD J, 1984, J CHROMATOGR, V307, P404, DOI 10.1016/S0378-4347(00)84113-4##OPPENHEIM JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/J.COI.2005.06.002##ORYU M, 1996, J LEUKOCYTE BIOL, V60, P77##OSHIMI Y, 1999, IMMUNOLOGY, V98, P220##OTTONELLO L, 1999, INFLAMM RES, V48, P637, DOI 10.1007/S000110050515##OTTONELLO L, 2002, ANN NY ACAD SCI, V966, P226, DOI 10.1111/J.1749-6632.2002.TB04219.X##OTTONELLO L, 2002, RHEUMATOLOGY, V41, P1249, DOI 10.1093/RHEUMATOLOGY/41.11.1249##PACHECO R, 2005, P NATL ACAD SCI USA, V102, P9583, DOI 10.1073/PNAS.0501050102##PADEH S, 1991, J IMMUNOL, V146, P1626##PANTHER E, 2003, BLOOD, V101, P3985, DOI 10.1182/BLOOD-2002-07-2113##PANTHER E, 2001, FASEB J, V15, P1963, DOI 10.1096/FJ.01-0169COM##PARKER AL, 1996, AM J PHYSIOL-LUNG C, V270, PL695##PARKIN J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7##PARMELY MJ, 1993, J IMMUNOL, V151, P389##PARVATHENANI LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/JBC.M209478200##PASINI FL, 1985, J IMMUNOPHARMACOL, V7, P203, DOI 10.3109/08923978509047634##PERREGAUX D, 1994, J BIOL CHEM, V269, P15195##PERREGAUX DG, 2000, J IMMUNOL, V165, P4615, DOI 10.4049/JIMMUNOL.165.8.4615##PERRUT M, 1998, P 5 M SUP FLUIDS NIC, V1, P1##PETERSGOLDEN M, 1997, LUNG BIOL HEALTH DIS, V102, P151##PFEILSCHIFTER J, 1989, EUR J BIOCHEM, V186, P509, DOI 10.1111/J.1432-1033.1989.TB15236.X##PIKE MC, 1981, J IMMUNOL, V127, P1444##PIKE MC, 1982, CELL, V28, P107, DOI 10.1016/0092-8674(82)90380-4##PINHAL-ENFIELD G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002-9440(10)63698-X##POELSTRA K, 1992, LAB INVEST, V66, P555##POULIOT M, 2002, J IMMUNOL, V169, P5279, DOI 10.4049/JIMMUNOL.169.9.5279##PRABHAKAR U, 1995, INT J IMMUNOPHARMACO, V17, P221, DOI 10.1016/0192-0561(94)00096-7##PRIEBE T, 1990, CANCER RES, V50, P4328##PRIEBE T, 1988, CANCER RES, V48, P4799##PRIEBE T, 1990, CELL IMMUNOL, V129, P321, DOI 10.1016/0008-8749(90)90208-9##PULENDRAN B, 2004, CURR BIOL, V14, PR30, DOI 10.1016/J.CUB.2003.12.020##RALEVIC V, 1998, PHARMACOL REV, V50, P413##RAMPE D, 2004, J NEUROIMMUNOL, V147, P56, DOI 10.1016/J.JNEUROIM.2003.10.014##REDEGELD F, 1991, J IMMUNOL, V147, P3638##REDEGELD FA, 1999, TRENDS PHARMACOL SCI, V20, P453, DOI 10.1016/S0165-6147(99)01399-1##REDEGELD FA, 1997, BBA-BIOMEMBRANES, V1328, P151, DOI 10.1016/S0005-2736(97)00082-5##REINSTEIN LJ, 1994, HEPATOLOGY, V19, P1445, DOI 10.1016/0270-9139(94)90241-0##RESTA R, 1997, IMMUNOL TODAY, V18, P371, DOI 10.1016/S0167-5699(97)01047-5##REVAN S, 1996, J BIOL CHEM, V271, P17114, DOI 10.1074/JBC.271.29.17114##RICHARD LF, 1998, AM J PHYSIOL-HEART C, V274, PH35##RICHES DWH, 1985, J LEUKOCYTE BIOL, V37, P545##RICHTER J, 1992, J LEUKOCYTE BIOL, V51, P270##RITCHIE PK, 1997, CYTOKINE, V9, P187, DOI 10.1006/CYTO.1996.0153##ROBERTS PA, 1985, BIOCHEM J, V227, P669, DOI 10.1042/BJ2270669##ROBSON SC, 1997, J EXP MED, V185, P153, DOI 10.1084/JEM.185.1.153##ROBSON SC, 2001, DRUG DEVELOP RES, V53, P193, DOI 10.1002/DDR.1188##ROCK KL, 2005, SPRINGER SEMIN IMMUN, V26, P231, DOI 10.1007/S00281-004-0173-3##ROOS D, 2003, MICROBES INFECT, V5, P1307, DOI 10.1016/J.MICINF.2003.09.009##ROSE FR, 1988, J EXP MED, V167, P1186, DOI 10.1084/JEM.167.3.1186##ROSENGREN S, 1995, J IMMUNOL, V154, P5444##ROSENGREN S, 1991, INT J MICROCIRC, V10, P345##ROUNDS S, 1999, AM J PHYSIOL-LUNG C, V277, PL874##RYAN LM, 1991, J RHEUMATOL, V18, P716##RYAN LM, 1996, J RHEUMATOL, V23, P214##SAJJADI FG, 1996, J IMMUNOL, V156, P3435##SALMON JE, 1993, J IMMUNOL, V151, P2775##SALMON JE, 1990, J IMMUNOL, V145, P2235##SALVATORE CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/JBC.275.6.4429##SANDS WA, 2004, MOL PHARMACOL, V66, P1147, DOI 10.1124/MOL.104.001107##SANZ JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/JIMMUNOL.164.9.4893##SCHMEICHEL CJ, 1987, J IMMUNOL, V138, P1896##SCHMID G, 1984, SYST APPL MICROBIOL, V5, P1##SCHMID-ANTOMARCHI H, 1997, J IMMUNOL, V159, P6209##SCHNURR M, 2004, BLOOD, V103, P1391, DOI 10.1182/BLOOD-2003-06-1959##SCHNURR M, 2005, BLOOD, V105, P1582, DOI 10.1182/BLOOD-2004-05-1718##SCHNURR M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/JIMMUNOL.165.8.4704##SCHNURR M, 2003, BLOOD##SCHRIER DJ, 1986, J IMMUNOL, V137, P3284##SEAMAN WE, 2000, ARTHRITIS RHEUM-US, V43, P1204, DOI 10.1002/1529-0131(200006)43:6<1204::AID-ANR3>3.0.CO;2-I##SEIFERT R, 1989, BIOCHEM J, V259, P813, DOI 10.1042/BJ2590813##SEIFERT R, 1989, EUR J BIOCHEM, V181, P277, DOI 10.1111/J.1432-1033.1989.TB14722.X##SEMAN M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8##SEO DR, 2004, NEUROREPORT, V15, P1157, DOI 10.1097/00001756-200405190-00015##SEONG SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/NRI1372##SERHAN CN, 2004, RHEUM DIS CLIN N AM, V30, P69, DOI 10.1016/S0889-857X(03)00117-0##SEYE CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/JBC.M401799200##SEYE CI, 2003, J BIOL CHEM, V278, P24960, DOI 10.1074/JBC.M301439200##SHANLEY TP, 1998, FASEB J, V12, PA766##SHERWOOD EDWARD R, 2004, BEST PRACT RES CLIN ANAESTHESIOL, V18, P385, DOI 10.1016/S1521-6896(03)00116-2##SHIGEMOTO-MOGAMI Y, 2001, J NEUROCHEM, V78, P1339, DOI 10.1046/J.1471-4159.2001.00514.X##SI QS, 1997, IMMUNOPHARMACOLOGY, V36, P1, DOI 10.1016/S0162-3109(96)00158-0##SIEGMUND B, 2001, J PHARMACOL EXP THER, V296, P99##SIKORA A, 1999, J IMMUNOL, V163, P558##SIMON HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/J.1600-065X.2003.00038.X##SIPKA S, 1991, ANN HEMATOL, V63, P45, DOI 10.1007/BF01714961##SIPKA S, 2005, CYTOKINE, V31, P258, DOI 10.1016/J.CYTO.2005.05.002##SITKOVSKY MV, 2005, TRENDS IMMUNOL, V26, P299, DOI 10.1016/J.IT.2005.04.004##SITKOVSKY MV, 2003, BIOCHEM PHARMACOL, V65, P493, DOI 10.1016/S0006-2952(02)01548-4##SITKOVSKY MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/ANNUREV.IMMUNOL.22.012703.104731##SKELTON L, 2003, J IMMUNOL, V171, P1941, DOI 10.4049/JIMMUNOL.171.4.1941##SKOBERNE M, 2004, TRENDS MOL MED, V10, P251, DOI 10.1016/J.MOLMED.2004.04.001##SLUYTER R, 2004, GENES IMMUN, V5, P588, DOI 10.1038/SJ.GENE.6364127##SLUYTER R, 2004, J IMMUNOL, V172, P3399, DOI 10.4049/JIMMUNOL.172.6.3399##SLUYTER R, 2002, INT IMMUNOL, V14, P1415, DOI 10.1093/INTIMM/DXF111##SMAIL EH, 1992, J IMMUNOL, V148, P3588##SMITH D E, 2001, HIV MED, V2, P78, DOI 10.1046/J.1468-1293.2001.00060.X##SMITH PT, 1998, DRUG DEVELOP RES, V45, P229, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<229::AID-DDR21>3.0.CO;2-Z##SMITH SR, 2002, EUR J PHARMACOL, V457, P57, DOI 10.1016/S0014-2999(02)02645-6##SOLLE M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/JBC.M006781200##SOMERS GR, 1998, LAB INVEST, V78, P1375##SOMMER JA, 1999, J ENDOTOXIN RES, V5, P70, DOI 10.1177/09680519990050010501##SONG ZY, 2005, BBA-MOL CELL RES, V1743, P205, DOI 10.1016/J.BBAMCR.2004.12.001##SONOKI K, 2003, EUR J PHARMACOL, V475, P139, DOI 10.1016/S0014-2999(03)02109-5##SOOP A, 2003, SHOCK, V19, P503, DOI 10.1097/01.SHK.0000051756.08171.11##SPERLAGH B, 1998, NEUROCHEM INT, V33, P209, DOI 10.1016/S0197-0186(98)00025-4##SPYCHALA J, 2000, PHARMACOL THERAPEUT, V87, P161, DOI 10.1016/S0163-7258(00)00053-X##STEINBERG TH, 1987, J BIOL CHEM, V262, P3118##STEINBERG TH, 1991, CURR OPIN IMMUNOL, V3, P71, DOI 10.1016/0952-7915(91)90080-K##STEINBERG TH, 1987, J BIOL CHEM, V262, P8884##STEVENSON FK, 2004, BLOOD, V103, P4389, DOI 10.1182/BLOOD-2003-12-4312##STEWART AG, 1993, IMMUNOLOGY, V78, P152##STINCHCOMBE JC, 2003, SEMIN IMMUNOL, V15, P301, DOI 10.1016/J.SMIM.2003.09.003##STOBER CB, 2001, J IMMUNOL, V166, P6276, DOI 10.4049/JIMMUNOL.166.10.6276##STOUT RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/JLB.0504272##STRAUB RH, 2000, J LEUKOCYTE BIOL, V67, P553##STRAUB RH, 2002, J NEUROIMMUNOL, V125, P73, DOI 10.1016/S0165-5728(02)00035-8##STROHMEIER GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447##STUTCHFIELD J, 1990, FEBS LETT, V262, P256, DOI 10.1016/0014-5793(90)80204-V##SUD'INA F, 1998, FEBS LETT, V423, P243, DOI 10.1016/S0014-5793(98)00102-1##SUH BC, 2001, J IMMUNOL, V166, P6754, DOI 10.4049/JIMMUNOL.166.11.6754##SULLIVAN GAIL W, 2003, CURR OPIN INVESTIG DRUGS, V4, P1313##SULLIVAN GW, 2001, BRIT J PHARMACOL, V132, P1017, DOI 10.1038/SJ.BJP.0703893##SULLIVAN GW, 1999, J INFECT DIS, V180, P1550, DOI 10.1086/315084##SULLIVAN GW, 2004, J LEUKOCYTE BIOL, V75, P127, DOI 10.1189/JLB.0603300##SULLIVAN GW, 1995, IMMUNOPHARMACOLOGY, V31, P19, DOI 10.1016/0162-3109(95)00030-0##SULLIVAN GW, 1995, INT J IMMUNOPHARMACO, V17, P793, DOI 10.1016/0192-0561(95)00073-B##SULLIVAN GW, 1990, J IMMUNOL, V145, P1537##SUN CX, 2005, J CLIN INVEST, V115, P35, DOI 10.1172/JCI200522656##SUNG SSJ, 1985, J BIOL CHEM, V260, P546##SURETTE ME, 1999, MOL PHARMACOL, V56, P1055##SURPRENANT A, 1996, SCIENCE, V272, P735, DOI 10.1126/SCIENCE.272.5262.735##SUZUKI T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004##SUZUKI T, 2000, BLOOD, V96, P2584##SWAIN SD, 2003, INFLAMMATION, V27, P45, DOI 10.1023/A:1022639228723##SWENNEN ELR, 2006, FREE RADICAL RES, V40, P53, DOI 10.1080/10715760500364298##SWENNEN ELR, 2005, EUR J IMMUNOL, V35, P852, DOI 10.1002/EJI.200425423##SYNNESTVEDT K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337##SZABO C, 1998, FASEB J, V12, PA243##SZABO C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/SJ.BJP.0702040##TANAKA N, 2004, J PHARMACOL SCI, V95, P174, DOI 10.1254/JPHS.FPJ03036X##TAPPER H, 1996, J LEUKOCYTE BIOL, V59, P613##THERON AJ, 2002, INFLAMM RES, V51, P594, DOI 10.1007/PL00012434##THIEL M, 1992, PFLUG ARCH EUR J PHY, V420, P522, DOI 10.1007/BF00374628##THIEL M, 1997, INFECT IMMUN, V65, P2136, DOI 10.1128/IAI.65.6.2136-2144.1997##THIEL M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/JOURNAL.PBIO.0030174##THIEL M, 1995, J LAB CLIN MED, V126, P275##THIEL M, 1996, J LEUKOCYTE BIOL, V59, P671##THIELE A, 2004, INFECT IMMUN, V72, P1349, DOI 10.1128/IAI.72.3.1349-1357.2004##THOMPSON LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/JEM.20040915##TILLEY SL, 2005, J CLIN INVEST, V115, P13, DOI 10.1172/JCI200524009##TONETTI M, 1994, BIOCHEM BIOPH RES CO, V203, P430, DOI 10.1006/BBRC.1994.2200##TONETTI M, 1995, BIOCHEM BIOPH RES CO, V214, P125, DOI 10.1006/BBRC.1995.2265##TRINCAVELLI ML, 2004, J NEUROCHEM, V91, P1180, DOI 10.1111/J.1471-4159.2004.02793.X##TRINCAVELLI ML, 2002, BIOCHEM PHARMACOL, V64, P625, DOI 10.1016/S0006-2952(02)01222-4##TSUTSUI S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004##TULUC FLORIN, 2005, PURINERGIC SIGNAL, V1, P359, DOI 10.1007/S11302-005-0039-8##VALLEJO AN, 2004, RHEUM DIS CLIN N AM, V30, P135, DOI 10.1016/S0889-857X(03)00114-5##VANWAEG G, 1991, J CLIN INVEST, V87, P305, DOI 10.1172/JCI114987##VARANI K, 1998, BRIT J PHARMACOL, V123, P1723, DOI 10.1038/SJ.BJP.0701758##VARANI K, 2002, FASEB J, V16, P280, DOI 10.1096/FJ.02-0543FJE##VARANI K, 1997, BRIT J PHARMACOL, V122, P386, DOI 10.1038/SJ.BJP.0701378##VARANI K, 1998, DRUG DEVELOP RES, V45, P253, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<253::AID-DDR23>3.0.CO;2-Q##VENTURA MA, 1991, NUCLEOS NUCLEOT, V10, P1195, DOI 10.1080/07328319108047273##VENTURA MA, 1995, MOL PHARMACOL, V47, P104##VERGHESE MW, 1996, J BIOL CHEM, V271, P15597, DOI 10.1074/JBC.271.26.15597##VERHOEF PA, 2003, J IMMUNOL, V170, P5728, DOI 10.4049/JIMMUNOL.170.11.5728##VISSER SS, 2000, BIOCHEM PHARMACOL, V60, P993, DOI 10.1016/S0006-2952(00)00414-7##VON ALBERTINI M, 1998, BIOCHEM BIOPH RES CO, V248, P822, DOI 10.1006/BBRC.1998.9055##VON ANDRIAN UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407##VON KUGELGEN I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/S002100000310##WAKAI A, 2001, SHOCK, V15, P297, DOI 10.1097/00024382-200115040-00008##WALKER BAM, 1989, LAB INVEST, V61, P515##WALKER BAM, 1997, J IMMUNOL, V158, P2926##WALKER BAM, 1991, LAB INVEST, V64, P105##WALKER BAM, 1990, J LEUKOCYTE BIOL, V48, P281##WANG E, 2004, J TRANSL MED, V2, P34, DOI DOI 10.1186/1479-5876-2-34##WARD PA, 1988, LAB INVEST, V58, P37##WARD PA, 1988, LAB INVEST, V58, P438##WARD PA, 1989, CLIN IMMUNOL IMMUNOP, V50, P30, DOI 10.1016/0090-1229(89)90219-5##WARD PA, 1988, BIOCHEM BIOPH RES CO, V154, P746, DOI 10.1016/0006-291X(88)90203-3##WARD PA, 1990, ANN NY ACAD SCI, V603, P108##WARNY M, 2001, J BIOL CHEM, V276, P26051, DOI 10.1074/JBC.M102568200##WATANABE T, 2002, JPN J PHARMACOL, V88, P407, DOI 10.1254/JJP.88.407##WATTERS JJ, 2001, DRUG DEVELOP RES, V53, P91, DOI 10.1002/DDR.1176##WEINSTEIN E, 2004, RHEUM DIS CLIN N AM, V30, P159, DOI 10.1016/S0889-857X(03)00109-1##WEISSMULLER THOMAS, 2005, PURINERGIC SIGNAL, V1, P229, DOI 10.1007/S11302-005-6323-9##WENZELSEIFERT K, 1990, IMMUNOBIOLOGY, V181, P298, DOI 10.1016/S0171-2985(11)80499-7##WERZ OLIVER, 2002, CURRENT DRUG TARGETS - INFLAMMATION AND ALLERGY, V1, P23, DOI 10.2174/1568010023344959##WEWERS MD, 2004, P NATL ACAD SCI USA, V101, P10241, DOI 10.1073/PNAS.0403971101##WIEDLE G, 2001, CRIT REV CL LAB SCI, V38, P1, DOI 10.1080/20014091084164##WILEY JS, 2002, LANCET, V359, P1114, DOI 10.1016/S0140-6736(02)08156-4##WILKIN F, 2002, EUR J IMMUNOL, V32, P2409, DOI 10.1002/1521-4141(200209)32:9<2409::AID-IMMU2409>3.0.CO;2-H##WILKIN F, 2001, J IMMUNOL, V166, P7172, DOI 10.4049/JIMMUNOL.166.12.7172##WILLIAMS BA, 1997, BIOCHEM BIOPH RES CO, V231, P264, DOI 10.1006/BBRC.1997.6077##WILLIAMS BA, 1997, EXP CELL RES, V233, P187, DOI 10.1006/EXCR.1997.3530##WILSON HL, 2004, J IMMUNOL, V173, P1202, DOI 10.4049/JIMMUNOL.173.2.1202##WITKO-SARSAT V, 2000, LAB INVEST, V80, P617, DOI 10.1038/LABINVEST.3780067##WOLLNER A, 1993, AM J RESP CELL MOL, V9, P179, DOI 10.1165/AJRCMB/9.2.179##XAUS J, 1999, J IMMUNOL, V162, P3607##XIA DX, 2000, BIOCHEM PHARMACOL, V60, P717, DOI 10.1016/S0006-2952(00)00367-1##XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303##XING MZ, 1992, J BIOL CHEM, V267, P6602##YAMAKUNI H, 2002, J NEUROIMMUNOL, V129, P43, DOI 10.1016/S0165-5728(02)00179-0##YANG ZQ, 2005, CIRCULATION, V111, P2190, DOI 10.1161/01.CIR.0000163586.62253.A5##YASUI K, 2000, J LEUKOCYTE BIOL, V67, P529##YEGUTKIN G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/SJ.BJP.0703136##YEGUTKIN GG, 2001, FASEB J, V15, P251, DOI 10.1096/FJ.00-0268COM##YEGUTKIN GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439##YEGUTKIN GG, 2003, FASEB J, V17, P1328, DOI 10.1096/FJ.02-1136FJE##YIN YZ, 2001, LEUKEMIA RES, V25, P423, DOI 10.1016/S0145-2126(00)00147-8##YONEYAMA Y, 2005, CLIN CHIM ACTA, V352, P75, DOI 10.1016/J.CCCN.2003.12.026##YONEYAMA Y, 2004, CLIN CHIM ACTA, V342, P99, DOI 10.1016/J.CCCN.2003.12.004##YONEYAMA Y., 2003, ARCHIVES OF GYNECOLOGY AND OBSTETRICS, V267, P205##YONEYAMA Y, 2002, GYNECOL OBSTET INVES, V54, P168, DOI 10.1159/000067886##YONEYAMA Y, 2002, GYNECOL OBSTET INVES, V54, P164, DOI 10.1159/000067885##YONEYAMA Y, 2002, OBSTET GYNECOL, V100, P1266, DOI 10.1016/S0029-7844(02)02247-0##YONEYAMA Y, 2002, OBSTET GYNECOL, V100, P754, DOI 10.1016/S0029-7844(02)02202-0##YONEYAMA Y, 2002, OBSTET GYNECOL, V99, P641, DOI 10.1016/S0029-7844(02)01657-5##ZAHLER S, 1998, DRUG DEVELOP RES, V45, P350, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<350::AID-DDR35>3.0.CO;2-L##ZAHLER S, 1994, CARDIOVASC RES, V28, P1366, DOI 10.1093/CVR/28.9.1366##ZALAVARY S, 1996, J LEUKOCYTE BIOL, V60, P58##ZALAVARY S, 1998, EUR J PHARMACOL, V354, P215, DOI 10.1016/S0014-2999(98)00461-0##ZALAVARY S, 1998, EUR J CELL BIOL, V75, P128, DOI 10.1016/S0171-9335(98)80055-1##ZALAVARY S, 1994, BBA-MOL CELL RES, V1222, P249, DOI 10.1016/0167-4889(94)90176-7##ZAMBON A, 1994, CELL IMMUNOL, V156, P458, DOI 10.1006/CIMM.1994.1190##ZANOVELLO P, 1990, J IMMUNOL, V145, P1545##ZHANG FL, 2002, J PHARMACOL EXP THER, V301, P705, DOI 10.1124/JPET.301.2.705##ZHANG H, 2004, J IMMUNOL, V173, P932, DOI 10.4049/JIMMUNOL.173.2.932##ZHANG JG, 2005, BIOCHEM PHARMACOL, V69, P883, DOI 10.1016/J.BCP.2004.12.008##ZHANG Y, 1994, BIOCHEM PHARMACOL, V48, P2025, DOI 10.1016/0006-2952(94)90501-0##ZHANG Y, 1996, BIOCHEM PHARMACOL, V51, P957, DOI 10.1016/0006-2952(95)02403-4##ZHAO ZQ, 2000, DRUG DEVELOP RES, V49, P266, DOI 10.1002/1098-2299(200004)49:4<266::AID-DDR6>3.0.CO;2-M##ZHAO ZQ, 1996, AM J PHYSIOL-HEART C, V271, PH1456##ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/JCB.112.2.279##ZHOU XQ, 2002, BIOCHEM BIOPH RES CO, V291, P598, DOI 10.1006/BBRC.2002.6473##ZIDEK Z, 2004, EUR J PHARMACOL, V501, P79, DOI 10.1016/J.EJPHAR.2004.08.031##ZIMMER AM, 1992, ANTIBODY IMMUNOCONJ, V5, P285##ZIMMERMANN H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/S002100000309##ZIMMERMANN H, 1996, DRUG DEVELOP RES, V39, P337, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<337::AID-DDR15>3.0.CO;2-Z##ZIMMERMANN H, 1999, TRENDS PHARMACOL SCI, V20, P231, DOI 10.1016/S0165-6147(99)01293-6##ZIMMERMANN H, 1998, DEV CARDIOVASC MED, V209, P342##ZIMMERMANN H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/DDR.1097",679,2020-11-20,NA
J,WOS:000241567500008,2006,STRATEGIES FOR TARGETING T-CELLS IN ALLERGIC DISEASES AND ASTHMA,"T HELPER (TH) 2 LYMPHOCYTES PLAY A CRUCIAL ROLE IN THE INITIATION, PROGRESSION AND PERSISTENCE OF ALLERGIC DISEASES, INCLUDING ASTHMA. DRUGS THAT INTERFERE WITH THE ACTIVATION OF T-CELLS OR MORE SELECTIVELY TH2-SPECIFIC SIGNALING MOLECULES AND DRUGS THAT PREVENT THE SELECTIVE MIGRATION INTO LUNG TISSUE ARE PROMISING NOVEL STRATEGIES FOR THE TREATMENT OF ALLERGIC ASTHMA. ALTHOUGH THE MAINSTAY ASTHMA THERAPY OF INHALED GLUCOCORTICOIDS IS RATHER EFFECTIVE, TARGETING TH2 CELLS MAY BE AN IMPORTANT ALTERNATIVE IN CHILDHOOD. REGULATORY T-CELLS (TREG CELLS) HAVE A PHYSIOLOGICAL ROLE IN PROTECTION OF UNWANTED IMMUNE RESPONSES TO AUTO-ANTIGENS AND ALLERGENS. LITERATURE DATA INDICATE THAT AN IMBALANCE BETWEEN TH2 AND TREG CELLS MAY UNDERLIE DEVELOPMENT AND DISEASE EXPRESSION OF ALLERGIC ASTHMA. DRUGS OR IMMUNOTHERAPIES THAT STIMULATE THESE COUNTER-TREG CELLS MAY LIMIT ABERRANT TH2 RESPONSES LEADING TO SUPPRESSION OF SYMPTOMS. FURTHERMORE, THESE TYPES OF TREATMENTS MAY OFFER THE PERSPECTIVE OF DISEASE MODIFICATION AND LONG-TERM RELIEF OF SYMPTOMS. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",ACTIVATED PROTEIN-KINASE; SELECTIN GLYCOPROTEIN LIGAND-1; INDUCED AIRWAY INFLAMMATION; CC-CHEMOKINE THYMUS; DENDRITIC CELLS; TH2 CELLS; REGULATED CHEMOKINE; IL-5 PRODUCTION; RECEPTOR-GAMMA; MURINE MODEL,ALLERGY; ASTHMA; T LYMPHOCYTE; IMMUNOMODULATION; COSTIMULATION; INFLAMMATION,PHARMACOLOGY & THERAPEUTICS,"HEIJINK, IH##VAN OOSTERHOUT, AJM","UNIV GRONINGEN, MED CTR, LAB ALLERGOL & PULM DIS, NL-9700 RB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT HEMATOL, NL-9700 RB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT PATHOL & LAB MED, NL-9700 RB GRONINGEN, NETHERLANDS.",PHARMACOLOGY & PHARMACY,PHARMACOLOGY & PHARMACY,"ADACHI T, 1999, J IMMUNOL, V163, P939##ANNUNZIATO F, 1999, J LEUKOCYTE BIOL, V65, P691##APPLEMAN LJ, 2002, J IMMUNOL, V168, P2729, DOI 10.4049/JIMMUNOL.168.6.2729##BARNES PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/NRD1524##BARRAT FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/JEM.20011629##BATTAGLIA M, 2005, BLOOD##BERIN MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/AJRCMB.24.4.4360##BLUESTONE JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/NRI1032##BLUESTONE JA, 2005, CURR OPIN IMMUNOL##BOCHNER BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/J.JACI.2003.08.012##BORGES E, 1997, J EXP MED, V185, P573, DOI 10.1084/JEM.185.3.573##BOUSSIOTIS VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144##BYSTRY RS, 2001, NAT IMMUNOL, V2, P1126, DOI 10.1038/NI735##CARAMORI G, 2003, PULM PHARMACOL THER, V16, P247, DOI 10.1016/S1094-5539(03)00070-1##CARAMORI GAETANO, 2004, CURRENT DRUG TARGETS - INFLAMMATION AND ALLERGY, V3, P243, DOI 10.2174/1568010043343750##CHAKRAVARTI S, 2005, J EXP MED##CHIALDA L, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-36##CHOI JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/J.1365-2222.2004.02006.X##CHUNG CD, 2003, J IMMUNOL, V170, P581, DOI 10.4049/JIMMUNOL.170.1.581##COENEN JJ, 2005, BLOOD##COLEMAN P, 2004, NEUROBIOL AGING, V25, P3, DOI 10.1016/J.NEUROBIOLAGING.2003.10.001##CONROY DM, 2003, J LEUKOCYTE BIOL, V74, P558, DOI 10.1189/JLB.0103030##DE JONG EC, 2005, SPRINGER SEMIN IMMUN, V26, P289, DOI 10.1007/S00281-004-0167-1##DEURLOO DT, 2004, CLIN EXP ALLERGY, V34, P17, DOI 10.1111/J.1365-2222.2004.01847.X##DEURLOO DT, 2001, AM J RESP CELL MOL, V25, P751, DOI 10.1165/AJRCMB.25.6.4607##DIAMANT Z, 2005, CLIN EXP ALLERGY, V35, P1080, DOI 10.1111/J.1365-2222.2005.02296.X##DJUKANOVIC R, 1995, EUR RESPIR J, V8, P831##DUAN W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/RCCM.200408-1006OC##DUAN W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/JIMMUNOL.172.11.7053##ENCINAS JA, 2005, J ALLERGY CLIN IMMUN, V116, P1343, DOI 10.1016/J.JACI.2005.08.031##ERIN E. M., 2002, CURRENT DRUG TARGETS - INFLAMMATION AND ALLERGY, V1, P201, DOI 10.2174/1568010023344715##ERPENBECK VJ, 2003, CHEST, V123, P370S##EYNOTT PR, 2004, IMMUNOLOGY, V112, P446, DOI 10.1111/J.1365-2567.2004.01887.X##FINNERTY JP, 1996, EUR RESPIR J, V9, P1672, DOI 10.1183/09031936.96.09081672##FINOTTO S, 2001, J EXP MED, V193, P1247, DOI 10.1084/JEM.193.11.1247##FONTENOT JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/NI904##FU S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/J.1600-6143.2004.00566.X##FUKUDA T, 1991, INT ARCH ALLER A IMM, V94, P259, DOI 10.1159/000235377##GARCIA G, 2005, CURR ALLERGY ASTHM R, V5, P155, DOI 10.1007/S11882-005-0090-0##GOR DO, 2003, NAT IMMUNOL, V4, P503, DOI 10.1038/NI0603-503##GREGORI S, 2002, DIABETES, V51, P1367, DOI 10.2337/DIABETES.51.5.1367##HAMMAD H, 2004, AM J PATHOL, V164, P263, DOI 10.1016/S0002-9440(10)63116-1##HAWRYLOWICZ CM, 2005, J EXP MED, V202, P1459, DOI 10.1084/JEM.20052211##HEIJINK IH, 2004, CLIN EXP ALLERGY, V34, P1356, DOI 10.1111/J.1365-2222.2004.02037.X##HEIJINK IH, 2003, EUR J IMMUNOL, V33, P2206, DOI 10.1002/EJI.200323804##HEIJINK IH, 2002, IMMUNOLOGY, V107, P316, DOI 10.1046/J.1365-2567.2002.01501.X##HERRICK CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/NRI1084##HESSEL EM, 2005, J EXP MED, V202, P1563, DOI 10.1084/JEM.20050631##HIRAI H, 2001, J EXP MED, V193, P255, DOI 10.1084/JEM.193.2.255##HORI S, 2003, SCIENCE, V9, P9##HUMBLES AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/PNAS.261462598##IKEDA RK, 2003, AM J RESP CELL MOL, V28, P655, DOI 10.1165/RCMB.4853##ITO K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/PNAS.132556899##JAFFAR ZH, 1999, J IMMUNOL, V163, P6283##JAIN VV, 2002, J ALLERGY CLIN IMMUN, V110, P867, DOI 10.1067/MAI.2002.129371##JEE YK, 2005, J BIOL CHEM, V280, P23243, DOI 10.1074/JBC.M503659200##KAPSENBERG ML, 1992, CURR OPIN IMMUNOL, V4, P788, DOI 10.1016/0952-7915(92)90063-K##KAPSENBERG ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/NRI1246##KARAGIANNIDIS C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/J.JACI.2004.07.014##KAWASAKI S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/JIMMUNOL.166.3.2055##KEANE-MYERS AM, 1998, J IMMUNOL, V160, P1036##KHADEMI M, 2004, J IMMUNOL, V172, P7169, DOI 10.4049/JIMMUNOL.172.11.7169##KIM CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543##KLINE JN, 2002, AM J PHYSIOL-LUNG C, V283, PL170, DOI 10.1152/AJPLUNG.00402.2001##KREMER JM, 2005, ARTHRITIS RHEUM, V52, P2263, DOI 10.1002/ART.21201##KUBO M, 1997, EMBO J, V16, P4007, DOI 10.1093/EMBOJ/16.13.4007##KUBSCH S, 2003, EUR J IMMUNOL, V33, P1988, DOI 10.1002/EJI.200323600##KUCHROO VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/NRI1111##KWAK YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440##LARCHE M, 1998, J IMMUNOL, V161, P6375##LARSEN CP, 2005, AM J TRANSPLANT, V5, P443, DOI 10.1111/J.1600-6143.2005.00749.X##LIM YC, 2000, MICROCIRCULATION, V7, P201, DOI 10.1038/SJ.MN.7300103##LIN KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/JM980673G##LIPWORTH BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3##LORDAN JL, 2001, J ALLERGY CLIN IMMUN, V108, P976, DOI 10.1067/MAI.2001.119740##LOZA MJ, 2005, BLOOD##LUSTER AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/NI1275##LUTZ MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0##MA W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097##MANGAN PR, 2005, AM J PATHOL, V167, P1661, DOI 10.1016/S0002-9440(10)61249-7##MATHEW A, 2002, J IMMUNOL, V169, P651, DOI 10.4049/JIMMUNOL.169.2.651##MATRICARDI PM, 2003, ALLERGY, V58, P461, DOI 10.1034/J.1398-9995.2003.00175.X##MCINTIRE JJ, 2004, SPRINGER SEMIN IMMUN, V25, P335, DOI 10.1007/S00281-003-0141-3##MCINTIRE JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/NI739##MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X##MEYERS JH, 2005, NAT IMMUNOL##MILLS KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/NRI1485##MORGAN AJ, 2005, J ALLERGY CLIN IMMUN, V116, P594, DOI 10.1016/J.JACI.2005.03.052##MORI A, 1995, INT IMMUNOL, V7, P449, DOI 10.1093/INTIMM/7.3.449##MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/ANNUREV.IY.07.040189.001045##MUELLER C, 2003, ARCH BIOCHEM BIOPHYS, V418, P186, DOI 10.1016/J.ABB.2003.08.006##NAKAYAMA T, 1999, RRD PHOTOCHEM PHOTOB, V3, P103##NEL AE, 2002, J ALLERGY CLIN IMMUN, V109, P758, DOI 10.1067/MAI.2002.124259##NGUYEN XD, 2004, J ALLERGY CLIN IMMUN, V114, P296, DOI 10.1016/J.JACI.2004.04.048##NIE M, 2005, J BIOL CHEM, V280, P2550, DOI 10.1074/JBC.M410616200##NORRIS V, 2005, J ALLERGY CLIN IMMUN, V116, P761, DOI 10.1016/J.JACI.2005.04.045##PANINA-BORDIGNON P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655##PEDERSEN AE, 2004, IMMUNOL LETT, V91, P63, DOI 10.1016/J.IMLET.2003.11.004##PEEK EJ, 2005, AM J RESP CELL MOL B##PITCHER LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/J.IT.2003.08.003##POLANCZYK MJ, 2004, J IMMUNOL, V173, P2227, DOI 10.4049/JIMMUNOL.173.4.2227##POPESCU FD, 2003, J CELL MOL MED, V7, P475, DOI 10.1111/J.1582-4934.2003.TB00251.X##POWELL N, 2001, J ALLERGY CLIN IMMUN, V108, P915, DOI 10.1067/MAI.2001.119742##RENZ H, 2004, CLIN EXP ALLERGY, V34, P167, DOI 10.1111/J.1365-2222.2004.01875.X##RILEY JL, 2005, BLOOD, V105, P13, DOI 10.1182/BLOOD-2004-04-1596##ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504##ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199##ROOK GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8##SAKAGUCHI S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/NI1178##SCHAFER PH, 1999, J IMMUNOL, V162, P7110##SCHUH JM, 2002, FASEB J, V16, P1313, DOI 10.1096/FJ.02-0193FJE##SEDY JR, 2005, NAT IMMUNOL, V6, P90, DOI 10.1038/NI1144##SEKIYA T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/JIMMUNOL.165.4.2205##SEKIYA T, 2002, ALLERGY, V57, P173, DOI 10.1034/J.1398-9995.2002.1S3256.X##SHIRAKAWA T, 1997, SCIENCE, V275, P77, DOI 10.1126/SCIENCE.275.5296.77##SINGH J, 2004, CURR TOP MED CHEM, V4, P1497, DOI 10.2174/1568026043387520##STAPLES KJ, 2001, J IMMUNOL, V167, P2074, DOI 10.4049/JIMMUNOL.167.4.2074##STENTON GR, 2002, J IMMUNOL, V169, P1028, DOI 10.4049/JIMMUNOL.169.2.1028##SUGIMOTO H, 2003, J PHARMACOL EXP THER, V305, P347, DOI 10.1124/JPET.102.046748##SZABO SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3##TANG MLK, 2001, PULM PHARMACOL THER, V14, P203, DOI 10.1006/PUPT.2001.0293##TSUYUKI S, 1997, J EXP MED, V185, P1671, DOI 10.1084/JEM.185.9.1671##TULIC MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/J.JACI.2003.11.001##ULANOVA M, 2005, EXPERT OPIN THER TAR, V9, P901, DOI 10.1517/14728222.9.5.901##UMETSU SE, 2005, NAT IMMUNOL##UNDERWOOD SL, 2002, BRIT J PHARMACOL, V137, P263, DOI 10.1038/SJ.BJP.0704865##VAN NEERVEN RJJ, 1998, CLIN EXP ALLERGY, V28, P808##VAN OOSTERHOUT AJM, 2005, EUR RESPIR J, V26, P918, DOI 10.1183/09031936.05.00011205##VAN OOSTERHOUT AJM, 2005, EUR RESPIR J, V25, P591, DOI 10.1183/09031936.05.00014105##VAN SCHAYCK CP, 2005, EUR RESPIR J, V26, P647, DOI 10.1183/09031936.05.00019805##VANOOSTERHOUT AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/AJRCMB.17.3.2679##WALKER MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441##WILLS-KARP M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579##WOERLY G, 2003, J EXP MED, V198, P411, DOI 10.1084/JEM.20021384##XYSTRAKIS E, 2005, J CLIN INVEST##YAGI H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/INTIMM/DXH165##YAMAMOTO N, 2003, J PHARMACOL EXP THER, V306, P1174, DOI 10.1124/JPET.103.052316##ZHANG DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/JBC.272.34.21597##ZHANG J, 2001, INT IMMUNOL, V13, P377, DOI 10.1093/INTIMM/13.3.377##ZHU C, 2005, NAT IMMUNOL##ZUANY-AMORIM C, 2002, NAT MED, V8, P625, DOI 10.1038/NM0602-625",18,2020-11-20,NA
J,WOS:000243214100036,2006,PROTOPORPHYRIN IX FLUORESCENCE PHOTOBLEACHING AND THE RESPONSE OF RAT BARRETT'S ESOPHAGUS FOLLOWING 5-AMINOLEVULINIC ACID PHOTODYNAMIC THERAPY,"BARRETT'S ESOPHAGUS (BE) CAN EXPERIMENTALLY BE TREATED WITH 5-AMINOLEVULINIC ACID-BASED PHOTODYNAMIC THERAPY (ALA-PDT), IN WHICH ALA, THE PRECURSOR OF THE ENDOGENOUS PHOTOSENSITIZER PROTOPORPHYRIN IX (PPIX) AND SUBSEQUENT IRRADIATION WITH LASER LIGHT ARE APPLIED TO DESTROY THE (PRE)-MALIGNANT TISSUE. ACCURATE DOSIMETRY IS CRITICAL FOR SUCCESSFUL ALA-PDT. HERE, IN VIVO DOSIMETRY AND KINETICS OF PPIX FLUORESCENCE PHOTOBLEACHING WERE STUDIED IN A RAT MODEL OF BE. THE FLUENCE AND FLUENCE RATE WERE STANDARDIZED IN VIVO AND PPIX FLUORESCENCE WAS MEASURED SIMULTANEOUSLY AT THE ESOPHAGEAL WALL DURING ALA-PDT AND PLOTTED AGAINST THE DELIVERED FLUENCE RATHER THAN TIME. RATS WITH BE WERE ADMINISTERED 200 MG KG(-1) ALA (N = 17) OR SERVED AS CONTROL (N = 4). ANIMALS WERE IRRADIATED WITH 633 NM LASER LIGHT AT A MEASURED FLUENCE RATE OF 75 MW CM(-2) AND A FLUENCE OF 54 J CM(-2). LARGE DIFFERENCES WERE OBSERVED IN THE KINETICS OF PPIX FLUORESCENCE PHOTOBLEACHING IN DIFFERENT ANIMALS. HIGH PPIX FLUORESCENCE PHOTOBLEACHING RATES CORRESPONDED WITH TISSUE ABLATION, WHEREAS LOW RATES CORRESPONDED WITH NO DAMAGE TO THE EPITHELIUM. ATTEMPTS TO INFLUENCE TISSUE OXYGENATION BY VARYING BALLOON PRESSURE AND VENTILATION WERE SHOWN NOT TO BE DIRECTLY RESPONSIBLE FOR THE DIFFERENCES IN EFFECT. IN CONCLUSION, IN VIVO DOSIMETRY IS FEASIBLE IN HETEROGENEOUS CONDITIONS SUCH AS BE, AND PPIX FLUORESCENCE PHOTOBLEACHING IS USEFUL TO PREDICT THE TISSUE RESPONSE TO ALA-PDT.",HAIRLESS MOUSE SKIN; SINGLET OXYGEN LUMINESCENCE; HIGH-GRADE DYSPLASIA; IN-VIVO; FLUENCE RATE; INTEGRATING SPHERE; TUMOR OXYGENATION; LIGHT DOSIMETRY; NUDE-MICE; IRRADIANCE,NA,PHOTOCHEMISTRY AND PHOTOBIOLOGY,"BOERE, IA##ROBINSON, DJ##DE BRUIJN, HS##KLUIN, J##TILANUS, HW##STERENBORG, HJCM##DE BRUIN, RWF","ERASMUS MC, EXPT SURG LAB, ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT RADIAT ONCOL, CTR OPT DIAGNOST & THERAPY, ROTTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS,BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS,"BARR H, 1996, LANCET, V348, P584, DOI 10.1016/S0140-6736(96)03054-1##BOERE IA, 2003, PHOTOCHEM PHOTOBIOL, V78, P271, DOI 10.1562/0031-8655(2003)078<0271:MISDAP>2.0.CO;2##COUTIER S, 2002, RADIAT RES, V158, P339, DOI 10.1667/0033-7587(2002)158[0339:EOIFRO]2.0.CO;2##FINLAY JC, 2002, PHOTOCHEM PHOTOBIOL, V75, P282, DOI 10.1562/0031-8655(2002)075<0282:IVMPIN>2.0.CO;2##FINLAY JC, 2001, PHOTOCHEM PHOTOBIOL, V73, P54, DOI 10.1562/0031-8655(2001)073<0054:PBAPIS>2.0.CO;2##FOSTER TH, 1991, RADIAT RES, V126, P296, DOI 10.2307/3577919##GEORGAKOUDI I, 1998, PHOTOCHEM PHOTOBIOL, V67, P612, DOI 10.1562/0031-8655(1998)067<0612:SOOMMO>2.3.CO;2##GEORGAKOUDI I, 2001, GASTROENTEROLOGY, V120, P1620, DOI 10.1053/GAST.2001.24842##HAGE M, 2005, J PATHOL, V205, P57, DOI 10.1002/PATH.1685##KONIG K, 1993, J PHOTOCH PHOTOBIO B, V18, P287, DOI 10.1016/1011-1344(93)80077-M##LEVRAT M, 1962, AM J DIG DIS, V7, P564, DOI 10.1007/BF02236137##MARIJNISSEN JPA, 1996, PHYS MED BIOL, V41, P1191, DOI 10.1088/0031-9155/41/7/008##NIEDRE MJ, 2005, PHOTOCHEM PHOTOBIOL, V81, P941, DOI 10.1562/2005-03-15-TSN-462R.1##NIEDRE MJ, 2005, BRIT J CANCER, V92, P298, DOI 10.1038/SJ.BJC.6602331##PECH O, 2002, EUR J GASTROEN HEPAT, V14, P657, DOI 10.1097/00042737-200206000-00011##RHODES LE, 1997, J INVEST DERMATOL, V108, P87, DOI 10.1111/1523-1747.EP12285644##ROBINSON DJ, 2000, PHOTOCHEM PHOTOBIOL, V72, P794, DOI 10.1562/0031-8655(2000)072<0794:TAAPTO>2.0.CO;2##ROBINSON DJ, 1999, PHOTOCHEM PHOTOBIOL, V69, P61, DOI 10.1111/J.1751-1097.1999.TB05307.X##ROBINSON DJ, 1998, PHOTOCHEM PHOTOBIOL, V67, P140, DOI 10.1562/0031-8655(1998)067<0140:FPOAIP>2.3.CO;2##SANTINI AME, 1984, HDB MICROSURGERY, V2, P437##SCHNELL TG, 2001, GASTROENTEROLOGY, V120, P1607, DOI 10.1053/GAST.2001.25065##SIERSEMA PD, 2005, GASTROINTEST ENDOSC, V62, P503, DOI 10.1016/J.GIE.2005.07.018##SITNIK TM, 1998, BRIT J CANCER, V77, P1386, DOI 10.1038/BJC.1998.231##STAR WM, 1995, PHYS MED BIOL, V40, P1, DOI 10.1088/0031-9155/40/1/001##VAN DEN BOOGERT J, 1998, J PHOTOCH PHOTOBIO B, V44, P29, DOI 10.1016/S1011-1344(98)00102-X##VAN DEN BOOGERT J, 1999, ANN THORAC SURG, V68, P1763, DOI 10.1016/S0003-4975(99)01003-6##VAN VEEN RLP, 2002, LASER SURG MED, V31, P299, DOI 10.1002/LSM.10129##VAN VEEN RLP, 2001, PHYS MED BIOL, V46, P1873, DOI 10.1088/0031-9155/46/7/310##VANSTAVEREN HJ, 1996, PHYS MED BIOL, V41, P579, DOI 10.1088/0031-9155/41/4/001",31,2020-11-20,NA
J,WOS:000243214100043,2006,OPTIMIZING MESO-TETRA-HYDROXYPHENYL-CHLORIN-MEDIATED PHOTODYNAMIC THERAPY FOR BASAL CELL CARCINOMA,"MESO-TETRA-HYDROXYPHENYL-CHLORIN (MTHPC)-MEDIATED PHOTODYNAMIC THERAPY (PDT) HAS SHOWN TO BE EFFECTIVE IN THE TREATMENT OF PATIENTS WITH MULTIPLE BASAL CELL CARCINOMA (BCC). IN THE PRESENT STUDY WE FURTHER OPTIMIZED THE DRUG-LIGHT INTERVAL AND EXAMINED THE CORRELATION BETWEEN PLASMA DRUG LEVELS AND TREATMENT EFFICACY. THIRTEEN PATIENTS WITH MULTIPLE BCC (A TOTAL OF 366 LESIONS) WERE INCLUDED IN THE STUDY. FOLLOWING INTRAVENOUS ADMINISTRATION OF 0.1 MG KG(-1) MTHPC, LESIONS WERE ILLUMINATED WITH 10 J CM(-2) LIGHT (652 NM, 100 MW CM(-2)) AT 12, 24, 48, 72 OR 96 H. PLASMA SAMPLES WERE TAKEN PRIOR TO EACH ILLUMINATION FOR DETERMINATION OF MTHPC LEVELS, AND TUMOR RESPONSE WAS EVALUATED AT 6 MONTHS AND I YEAR. BOTH UNIVARIABLE AND MULTIVARIABLE ANALYSES SHOWED THAT OPTIMAL TREATMENT OUTCOME WAS OBTAINED FOR A DRUG-LIGHT INTERVAL OF 24 H WHEN PLASMA DRUG LEVELS WERE HIGH. OVERALL, GOOD COSMETIC RESULTS WITH LITTLE OR NO SCARRING WERE OBTAINED IN 87% OF THE TREATED LESIONS AND NO SERIOUS SIDE EFFECTS WERE OBSERVED. WE OPTIMIZED MTHPC-MEDIATED PDT FOR PATIENTS SUFFERING FROM MULTIPLE BCC BY DETERMINING THE MOST EFFECTIVE DRUG-LIGHT INTERVAL AND SHOWED THAT THIS TREATMENT OFFERS SIGNIFICANT ADVANTAGES OVER SURGICAL RESECTION.",5-AMINOLEVULINIC ACID; TISSUE DISTRIBUTION; BOWENS-DISEASE; EFFICACY; TETRAHYDROXYPHENYLCHLORIN; MODEL,NA,PHOTOCHEMISTRY AND PHOTOBIOLOGY,"TRIESSCHEIJN, M##RUEVEKAMP, M##ANTONINI, N##NEERING, H##STEWART, FA##BAAS, P","ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DIV EXPT THERAPY H6, NL-1066 CX AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, BIOMETR DEPT, NL-1066 CX AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT DERMATOL, NL-1066 CX AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT THORAC ONCOL, NL-1066 CX AMSTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS,BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS,"BAAS P, 2001, BRIT J DERMATOL, V145, P75, DOI 10.1046/J.1365-2133.2001.04284.X##CALZAVARAPINTON PG, 1996, J PHOTOCH PHOTOBIO B, V36, P225##CHEN B, 2000, CANCER LETT, V150, P111, DOI 10.1016/S0304-3835(99)00381-X##CLARK C, 2003, PHOTODERMATOL PHOTO, V19, P134, DOI 10.1034/J.1600-0781.2003.00024.X##CRAMERS P, 2003, BRIT J CANCER, V88, P283, DOI 10.1038/SJ.BJC.6600682##DOUGHERTY TJ, 1978, CANCER RES, V38, P2628##GUPTA G, 1999, BRIT J DERMATOL, V141, P385##HANLEY JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/AJE/KWF215##MORLET L, 1995, J PHOTOCH PHOTOBIO B, V28, P25, DOI 10.1016/1011-1344(94)07090-B##MORTON CA, 1996, BRIT J DERMATOL, V135, P766, DOI 10.1111/J.1365-2133.1996.TB03887.X##OSEROFF AR, 2006, LASER SURG MED, V38, P417, DOI 10.1002/LSM.20363##RIS HB, 1993, INT J CANCER, V55, P245, DOI 10.1002/IJC.2910550213##RUBIN AI, 2005, NEW ENGL J MED, V353, P2262, DOI 10.1056/NEJMRA044151##SEXTON M, 1990, J AM ACAD DERMATOL, V23, P1118, DOI 10.1016/0190-9622(90)70344-H##TAUB AMY FORMAN, 2004, J DRUGS DERMATOL, V3, PS8##TRIESSCHEIJN M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1161, DOI 10.1562/2005-04-04-RA-474##VEENHUIZEN R, 1997, INT J CANCER, V73, P236, DOI 10.1002/(SICI)1097-0215(19971009)73:2<236::AID-IJC13>3.0.CO;2-D##VEENHUIZEN RB, 1997, INT J CANCER, V73, P230, DOI 10.1002/(SICI)1097-0215(19971009)73:2<230::AID-IJC12>3.0.CO;2-J##WIEGELL SR, 2003, ARCH DERMATOL, V139, P1173, DOI 10.1001/ARCHDERM.139.9.1173##WIERRANI F, 1997, J GYNECOL SURG, V13, P23, DOI 10.1089/GYN.1997.13.23##ZIMMERMANN A, 2003, CANCER CHEMOTH PHARM, V51, P147, DOI 10.1007/S00280-002-0549-9",24,2020-11-20,NA
J,WOS:000242151500001,2006,ROTATING HOPF-KINKS: A REALISTIC PARTICLE MODEL,"A SPECIFIC FORM OF THE HOPF MAP S-3 -> S-2 IS INTRODUCED. THE MAP IS REPRESENTED BY THE FIELDS THETA AND PHI DESCRIBING AN (INFINITELY) EXTENDED TOPOLOGICALLY STABLE FIELD STRUCTURE IN THREE DIMENSIONAL SPACE PERFORMING AN INTERNAL ROTATION. THAT 'BUNCHED' FIELD SHOWS PROPERTIES THAT CAN BE IDENTIFIED WITH PROPERTIES OF A PARTICLE: DISCRETE MASS AND CHARGE, SPIN, LEFT OR RIGHT-HANDED CHIRALITY, AND A FAR-REACHING FIELD OSCILLATING IN PHASE WITH THE INTERNAL ROTATION OF THE STRUCTURE. IN THIS MODEL THE PARTICLE IS NOT INTRODUCED AS A BASIC OBJECT BUT APPEARS AS A SPECIFIC FIELD CONCENTRATION OF THE EXTENDED FIELD, WHICH IS CONSIDERED TO BE THE FUNDAMENTAL ENTITY. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",SINE-GORDON BREATHER,PARTICLE MODEL; CLASSICAL FIELD THEORY; DOMAIN WALLS,PHYSICA D-NONLINEAR PHENOMENA,"ENZ, U",NA,"MATHEMATICS, APPLIED; PHYSICS, FLUIDS & PLASMAS; PHYSICS, MULTIDISCIPLINARY; PHYSICS, MATHEMATICAL",MATHEMATICS; PHYSICS,"DE BROGLIE L, 1926, CR HEBD ACAD SCI, V183, P447##DELEEUW FH, 1980, REP PROG PHYS, V43, P689, DOI 10.1088/0034-4885/43/6/001##DERRICK GH, 1964, J MATH PHYS, V5, P1252, DOI 10.1063/1.1704233##DIRAC PAM, 1951, PROC R SOC LON SER-A, V209, P291, DOI 10.1098/RSPA.1951.0204##EINSTEIN A, 1950, EVOLUTION PHYS, V287##ENZ U, 1986, PHYSICA D, V21, P1, DOI 10.1016/0167-2789(86)90075-8##ENZ U, 1985, PHYSICA D, V17, P116##ENZ U., 1980, PHYSICA D, V1D, P329, DOI 10.1016/0167-2789(80)90030-5##ENZ U, 1978, J MATH PHYS, V19, P1304, DOI 10.1063/1.523828##ENZ U, 1963, PHYS REV, V131, P1392, DOI 10.1103/PHYSREV.131.1392##ENZ U, 1993, COURANTS AMERS ECUEI##ENZ U, 1977, MATH PHYS, V18, P347##FEYNMANN RP, 1965, LECT PHYS 3##GOTTFRIED K., 1984, CONCEPTS PARTICLE PH##KRAG H, 2001, HISTORIES ELECT##MALOZEMOFF A P, 1979, MAGNETIC DOMAIN WALL##MIE G, 1912, ANN PHYS-BERLIN, V37, P511##SCHWEBER SS, 1961, RELATIVISTIC QUANTU##SCOTT AC, 1979, PHYS SCRIPTA, V20, P509, DOI 10.1088/0031-8949/20/3-4/030##SKYRME THR, 1971, J MATH PHYS, V12, P1735, DOI 10.1063/1.1665798##1990, ANN FOND LOUIS BROGL, P15",2,2020-11-20,NA
J,WOS:000242187000094,2006,ELECTROMIGRATED MOLECULAR JUNCTIONS,"WE REPORT ON THE FABRICATION AND CHARACTERIZATION OF MOLECULAR JUNCTIONS WHICH ARE FABRICATED WITH ELECTROMIGRATION AND SUBSEQUENT TRAPPING OF THE MOLECULE FROM SOLUTION. TRANSPORT MEASUREMENTS SHOW MOLECULE-SPECIFIC FEATURES (VIBRATIONAL MODES; GATE COUPLING) AND INDICATE THE PRESENCE OF A SINGLE MOLECULE IN THE GAP. ELECTROMIGRATED JUNCTIONS CAN BE VERY STABLE AND ALLOW FOR TEMPERATURE DEPENDENT MEASUREMENTS, WHICH PROVIDE, NEXT TO GATE DEPENDENT MEASUREMENTS, AN ADDITIONAL TOOL TO PERFORM DETAILED STUDIES OF TRANSMOLECULAR CONDUCTION MECHANISMS. (C) 2006 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM.",TRANSISTORS; FABRICATION,NA,PHYSICA STATUS SOLIDI B-BASIC SOLID STATE PHYSICS,"VAN DER ZANT, HSJ##OSORIO, EA##POOT, M##O'NEILL, K","DELFT UNIV TECHNOL, KAVLI INST NANOSCI, NL-2600 GA DELFT, NETHERLANDS.","PHYSICS, CONDENSED MATTER",PHYSICS,"BOLOTIN KI, 2004, APPL PHYS LETT, V84, P3154, DOI 10.1063/1.1695203##CHAMPAGNE AR, 2005, NANO LETT, V5, P305, DOI 10.1021/NL0480619##DATTA S, 2004, NANOTECHNOLOGY, V15, PS433, DOI 10.1088/0957-4484/15/7/051##HEERSCHE HB, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.017205##HOUCK AA, 2005, NANO LETT, V5, P1685, DOI 10.1021/NL050799I##KERVENNIC YV, 2006, ANGEW CHEM INT EDIT, V45, P2540, DOI 10.1002/ANIE.200503591##KUBATKIN S, 2003, NATURE, V425, P698, DOI 10.1038/NATURE02010##LIANG WJ, 2002, NATURE, V417, P725, DOI 10.1038/NATURE00790##OSORIO EA, UNPUB##PARK H, 2000, NATURE, V407, P57, DOI 10.1038/35024031##PARK J, 2002, NATURE, V417, P722, DOI 10.1038/NATURE00791##POOT M, 2006, NANO LETT, V6, P1031, DOI 10.1021/NL0604513##STRACHAN DR, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1857095##VAN DER ZANT HSJ, 2006, FARADAY DISCUSS, V131, P347, DOI 10.1039/B506240N##XU BQ, 2005, J AM CHEM SOC, V127, P2386, DOI 10.1021/JA042385H##YU LH, 2004, NANO LETT, V4, P79, DOI 10.1021/NL034893F",27,2020-11-20,NA
J,WOS:000242536200015,2006,CONTROL AND MEASUREMENT OF ELECTRON SPINS IN SEMICONDUCTOR QUANTUM DOTS,"WE PRESENT AN OVERVIEW OF EXPERIMENTAL STEPS TAKEN TOWARDS USING THE SPIN OF A SINGLE ELECTRON TRAPPED IN A SEMICONDUCTOR QUANTUM DOT AS A SPIN QUBIT [LOSS AND DIVINCENZO, PHYS. REV. A 57, 120 (1998)]. FABRICATION AND CHARACTERIZATION OF A DOUBLE QUANTUM DOT CONTAINING TWO COUPLED SPINS HAS BEEN ACHIEVED, AS WELL AS INITIALIZATION AND SINGLE-SHOT READ-OUT OF THE SPIN STATE. THE RELAXATION TIME T-1 OF SINGLE-SPIN AND TWO-SPIN STATES WAS FOUND TO BE ON THE ORDER OF A MILLISECOND, DOMINATED BY SPIN-ORBIT INTERACTIONS. THE TIME-AVERAGED DEPHASING TIME T*, DUE TO FLUCTUATIONS IN THE ENSEMBLE OF NUCLEAR SPINS IN THE HOST SEMI-CONDUCTOR, WAS DETERMINED TO BE ON THE ORDER OF SEVERAL TENS OF NANOSCECONDS. COHERENT MANIPULATION OF SINGLE-SPIN STATES CAN BE PERFORMED USING A MICROFABRICATED WIRE LOCATED CLOSE TO THE QUANTUM DOT, WHILE TWO-SPIN INTERACTIONS RELY ON CONTROLLING THE TUNNEL BARRIER CONNECTING THE RESPECTIVE QUANTUM DOTS [PETTA ET AL., SCIENCE 309, 2180 (2005)]. (C) 2006 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM.",COMPUTATION; BLOCKADE; SPECTROSCOPY; COULOMB,NA,PHYSICA STATUS SOLIDI B-BASIC SOLID STATE PHYSICS,"KOUWENHOVEN, LP##ELZERMAN, JM##HANSON, R##VAN BEVEREN, LHW##VANDERSYPEN, LMK","DELFT UNIV TECHNOL, KAVLI INST NANOSCI DELFT, NL-2600 GA DELFT, NETHERLANDS. DELFT UNIV TECHNOL, ERATO MESOSCOP CORRELAT PROJECT, NL-2600 GA DELFT, NETHERLANDS.","PHYSICS, CONDENSED MATTER",PHYSICS,"ASTAFIEV O, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.180507##BURKARD G, 1999, PHYS REV B, V59, P2070, DOI 10.1103/PHYSREVB.59.2070##CIORGA M, 2002, APPL PHYS LETT, V80, P2177, DOI 10.1063/1.1459489##CIORGA M, 2000, PHYS REV B, V61, P16315, DOI 10.1103/PHYSREVB.61.R16315##DIVINCENZO DP, 2000, FORTSCHR PHYS, V48, P771, DOI 10.1002/1521-3978(200009)48:9/11<771::AID-PROP771>3.0.CO;2-E##DIVINCENZO DP, 2000, NATURE, V408, P339, DOI 10.1038/35042541##ELZERMAN JM, 2004, APPL PHYS LETT, V84, P4617, DOI 10.1063/1.1757023##ELZERMAN JM, 2004, NATURE, V430, P431, DOI 10.1039/NATURE02693##ELZERMAN JM, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.161308##ENGEL HA, 2001, PHYS REV LETT, V86, P4648, DOI 10.1103/PHYSREVLETT.86.4648##FIELD M, 1993, PHYS REV LETT, V70, P1311, DOI 10.1103/PHYSREVLETT.70.1311##FUJISAWA T, 2002, NATURE, V419, P278, DOI 10.1038/NATURE00976##GOLOVACH VN, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.016601##HANSON R, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.196802##HANSON R, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.196802##HANSON R, P 39 RENC DE MOR, P56801##JOHNSON AC, 2005, NATURE, V435, P925, DOI 10.1038/NATURE03815##JUNG SW, 2004, APPL PHYS LETT, V85, P768, DOI 10.1063/1.1777802##KOPPENS FHL, 2005, SCIENCE, V309, P1346, DOI 10.1126/SCIENCE.1113719##KOPPENS FHL, IN PRESS NATURE##KOUWENHOVEN LP, 2001, REP PROG PHYS, V64, P701, DOI 10.1088/0034-4885/64/6/201##LOSS D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PHYSREVA.57.120##MARTIN I, 2003, PHYS REV LETT, V90, DOI 10.1103/PHYSREVLETT.90.018301##ONO K, 2002, SCIENCE, V297, P1313, DOI 10.1126/SCIENCE.1070958##PETTA JR, 2005, SCIENCE, V309, P2180, DOI 10.1126/SCIENCE.1116955##PETTA JR, 2001, PHYS REV LETT, V93, P6801##POTOK RM, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.016802##SCHLESER R, 2004, APPL PHYS LETT, V85, P2005, DOI 10.1063/1.1784875##VANDERSYPEN LMK, 2004, APPL PHYS LETT, V85, P4394, DOI 10.1063/1.1815041##VANDERSYPEN LMK, QUANTPH0207059",7,2020-11-20,NA
J,WOS:000242408900015,2006,DEMONSTRATION OF AN ERBIUM-DOPED MICRODISK LASER ON A SILICON CHIP,"AN ERBIUM-DOPED MICROLASER IS DEMONSTRATED UTILIZING SIO2 MICRODISK RESONATORS ON A SILICON CHIP. PASSIVE MICRODISK RESONATORS EXHIBIT WHISPERING-GALLERY-TYPE MODES (WGM'S) WITH INTRINSIC OPTICAL QUALITY FACTORS OF UP TO 6X10(7) AND WERE DOPED WITH TRIVALENT ERBIUM IONS (PEAK CONCENTRATION SIMILAR TO 3.8X10(20) CM(-3)) USING MEV ION IMPLANTATION. COUPLING TO THE FUNDAMENTAL WGM OF THE MICRODISK RESONATOR WAS ACHIEVED BY USING A TAPERED OPTICAL FIBER. UPON PUMPING OF THE I-4(15/2)-> I-4(13/2) ERBIUM TRANSITION AT 1450 NM, A GRADUAL TRANSITION FROM SPONTANEOUS TO STIMULATED EMISSION WAS OBSERVED IN THE 1550-NM BAND. ANALYSIS OF THE PUMP-OUTPUT POWER RELATION YIELDED A PUMP THRESHOLD OF 43 MU W AND ALLOWED MEASURING THE SPONTANEOUS EMISSION COUPLING FACTOR: BETA APPROXIMATE TO 1X10(-3).",RAMAN LASER; MICROCAVITY; NANOCRYSTALS; MODES; SIO2,NA,PHYSICAL REVIEW A,"KIPPENBERG, TJ##KALKMAN, J##POLMAN, A##VAHALA, KJ","CALTECH, DEPT APPL PHYS, PASADENA, CA 91125 USA. FOM, CTR NANOPHOTON, INST AMOLF, NL-1098 SJ AMSTERDAM, NETHERLANDS.","OPTICS; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",OPTICS; PHYSICS,"ARMANI DK, 2003, NATURE, V421, P925, DOI 10.1038/NATURE01371##BRAGINSKII VB, 1990, USP FIZ NAUK+, V160, P157, DOI 10.3367/UFNR.0160.199001F.0157##KIK PG, 2000, APPL PHYS LETT, V76, P2325, DOI 10.1063/1.126334##KIPPENBERG TJ, 2004, OPT LETT, V29, P1224, DOI 10.1364/OL.29.001224##KIPPENBERG TJ, 2003, APPL PHYS LETT, V83, P797, DOI 10.1063/1.1593833##KIPPENBERG TJ, 2002, OPT LETT, V27, P1669, DOI 10.1364/OL.27.001669##MCCALL SL, 1992, APPL PHYS LETT, V60, P289, DOI 10.1063/1.106688##MIN B, 2004, PHYS REV A, V70, DOI 10.1103/PHYSREVA.70.033803##MIN B, 2003, OPT LETT, V28, P1507, DOI 10.1364/OL.28.001507##MIN KS, 1996, APPL PHYS LETT, V69, P2033, DOI 10.1063/1.116870##POLMAN A, 2004, APPL PHYS LETT, V84, P1037, DOI 10.1063/1.1646748##POLMAN A, 1997, J APPL PHYS, V82, P1, DOI 10.1063/1.366265##RONG HS, 2005, NATURE, V433, P292, DOI 10.1038/NATURE03273##SANDOGHDAR V, 1996, PHYS REV A, V54, PR1777, DOI 10.1103/PHYSREVA.54.R1777##SPILLANE SM, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.043902##WEISS DS, 1995, OPT LETT, V20, P1835, DOI 10.1364/OL.20.001835##YANG L, 2003, APPL PHYS LETT, V83, P825, DOI 10.1063/1.1598623##YOKOYAMA H, 1989, J APPL PHYS, V66, P4801, DOI 10.1063/1.343793##ZACHARIAS M, 2002, APPL PHYS LETT, V80, P661, DOI 10.1063/1.1433906",142,2020-11-20,NA
J,WOS:000242408900133,2006,BOGOLIUBOV THEORY OF FESHBACH MOLECULES IN THE BEC-BCS CROSSOVER,"WE PRESENT THE BOGOLIUBOV THEORY FOR THE BOSE-EINSTEIN CONDENSATION OF FESHBACH MOLECULES IN A BALANCED FERMI MIXTURE. BECAUSE THE BOGOLIUBOV THEORY INCLUDES (GAUSSIAN) FLUCTUATIONS, WE CAN IN THIS MANNER ACCURATELY INCORPORATE BOTH THE TWO-BODY AND MANY-BODY ASPECTS OF THE BEC-BCS CROSSOVER THAT OCCURS NEAR A FESHBACH RESONANCE. WE APPLY THE THEORY IN PARTICULAR TO THE VERY BROAD FESHBACH RESONANCE IN ATOMIC LI-6 AT A MAGNETIC FIELD OF B-0=834 G AND FIND GOOD AGREEMENT WITH EXPERIMENTS IN THAT CASE. THE BEC-BCS CROSSOVER FOR MORE NARROW FESHBACH RESONANCES IS ALSO DISCUSSED.",BOSE-EINSTEIN CONDENSATION; GINZBURG-LANDAU THEORY; NUCLEAR REACTIONS; UNIFIED THEORY; ATOMIC GAS; SUPERCONDUCTIVITY; RESONANCES; WEAK,NA,PHYSICAL REVIEW A,"ROMANS, MWJ##STOOF, HTC","UNIV UTRECHT, INST THEORET PHYS, NL-3584 CE UTRECHT, NETHERLANDS.","OPTICS; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",OPTICS; PHYSICS,"ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/SCIENCE.269.5221.198##ANDERSON PW, 1958, PHYS REV, V112, P1900, DOI 10.1103/PHYSREV.112.1900##ASTRAKHARCHIK GE, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.030404##ASTRAKHARCHIK GE, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.200404##BARTENSTEIN M, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.120401##BOGOLIUBOV N. N., 1959, NEW METHOD THEORY SU##BOGOLUROV N.F., 1947, JOURNAL OF PHYSICS, V11, P23##BOURDEL T, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.050401##BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PHYSREVLETT.75.1687##CARLSON J, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.060401##DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PHYSREVLETT.75.3969##DEMARCO B, 1999, SCIENCE, V285, P1703, DOI 10.1126/SCIENCE.285.5434.1703##DEMELO CARS, 1993, PHYS REV LETT, V71, P3202, DOI 10.1103/PHYSREVLETT.71.3202##DIEHL S, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.033615##DIENER RB, CONDMAT0404517, P53401##DRUMMOND PD, 1998, PHYS REV LETT, V81, P3055, DOI 10.1103/PHYSREVLETT.81.3055##DUINE RA, 2004, PHYS REP, V396, P115, DOI 10.1016/J.PHYSREP.2004.03.003##EAGLES DM, 1969, PHYS REV, V186, P456, DOI 10.1103/PHYSREV.186.456##FALCO GM, 2005, PHYS REV A, V71, DOI 10.1103/PHYSREVA.71.063614##FALCO GM, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.130401##FESHBACH H, 1962, ANN PHYS-NEW YORK, V19, P287, DOI 10.1016/0003-4916(62)90221-X##FESHBACH H, 1958, ANN PHYS-NEW YORK, V5, P357, DOI 10.1016/0003-4916(58)90007-1##GALITSKII VM, 1958, SOV PHYS JETP-USSR, V7, P698##GHOSH TK, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.013613##HUGENHOLTZ NM, 1959, PHYS REV, V116, P489, DOI 10.1103/PHYSREV.116.489##JAVANAINEN J, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.110408##JOCHIM S, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.240402##KINAST J, 2005, SCIENCE, V307, P1296, DOI 10.1126/SCIENCE.1109220##KINAST J, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.150402##LEGGETT A. J., 1980, MODERN TRENDS IN THE THEORY OF CONDENSED MATTER. PROCEEDINGS OF THE XVITH KARPACZ WINTER SCHOOL OF THEORETICAL PHYSICS, P13##MACKIE M, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.060403##MORITZ H, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.210401##NOZIERES P, 1985, J LOW TEMP PHYS, V59, P195, DOI 10.1007/BF00683774##NYGAARD N, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.042705##OHASHI Y, 2005, PHYS REV A, V72, DOI 10.1103/PHYSREVA.72.013601##PARTRIDGE GB, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.020404##PERALI A, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.220404##REGAL CA, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.040403##ROMANS MWJ, 2005, PHYS REV LETT, V95, DOI [10.1103/PHYSREVLETT.95.260407, 10.1103/PHYSREVLETT.260407]##STAJIC J, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.060401##STOOF HTC, 1993, PHYS REV B, V47, P7979, DOI 10.1103/PHYSREVB.47.7979##STWALLEY WC, 1976, PHYS REV LETT, V37, P1628, DOI 10.1103/PHYSREVLETT.37.1628##SZYMANSKA MH, 2005, PHYS REV A, V72, DOI 10.1103/PHYSREVA.72.013610##TIESINGA E, 1993, PHYS REV A, V47, P4114, DOI 10.1103/PHYSREVA.47.4114##TIMMERMANS E, 1999, PHYS REP, V315, P199, DOI 10.1016/S0370-1573(99)00025-3##ZHONG F, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.175701##ZWIERLEIN MW, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.120403",10,2020-11-20,NA
J,WOS:000242408900117,2006,FULDE-FERRELL-LARKIN-OVCHINNIKOV VORTEX LATTICE STATES IN FERMIONIC COLD-ATOM SYSTEMS,"CONDENSATION OF ATOM PAIRS WITH FINITE TOTAL MOMENTUM IS EXPECTED IN A PORTION OF THE PHASE DIAGRAM OF A TWO-COMPONENT FERMIONIC COLD-ATOM SYSTEM. THIS UNUSUAL CONDENSATE CAN BE IDENTIFIED BY DETECTING THE EXOTIC HIGHER-LANDAU-LEVEL (HLL) VORTEX LATTICE STATES IT CAN FORM WHEN ROTATED. WITH THIS MOTIVATION, WE HAVE SOLVED THE LINEARIZED GAP EQUATIONS OF A POLARIZED COLD-ATOM SYSTEM IN A LANDAU-LEVEL BASIS TO PREDICT EXPERIMENTAL CIRCUMSTANCES UNDER WHICH HLL VORTEX LATTICE STATES OCCUR.",MAGNETIC-FIELDS; EXCHANGE FIELD; SUPERCONDUCTIVITY; GAS; SUPERFLUIDITY; TEMPERATURES,NA,PHYSICAL REVIEW A,"SHIM, YP##DUINE, RA##MACDONALD, AH","UNIV TEXAS, DEPT PHYS, AUSTIN, TX 78712 USA. UNIV UTRECHT, INST THEORET PHYS, NL-3584 CE UTRECHT, NETHERLANDS.","OPTICS; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",OPTICS; PHYSICS,"AKERA H, 1991, PHYS REV LETT, V67, P2375, DOI 10.1103/PHYSREVLETT.67.2375##BARANOV M, 2002, PHYS SCRIPTA, VT102, P74, DOI 10.1238/PHYSICA.TOPICAL.102A00074##BULGAC A, CONDMAT0606043##BUROVSKI E, 2006, NEW J PHYS, V8, DOI 10.1088/1367-2630/8/8/153##CHEVY F, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.130401##CHEVY F, CONDMAT0605751, P63405##CHIEN CC, 2006, PHYS REV A, V74, DOI 10.1103/PHYSREVA.74.021602##CHIEN CC, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.090402##CLOGSTON AM, 1962, PHYS REV LETT, V9, P266, DOI 10.1103/PHYSREVLETT.9.266##CUI QH, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.214514##DE SILVA TN, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.051602##DE SILVA TN, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.070402##EAGLES DM, 1969, PHYS REV, V186, P456, DOI 10.1103/PHYSREV.186.456##FEDER DL, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.200406##FULDE P, 1964, PHYS REV, V135, PA550, DOI 10.1103/PHYSREV.135.A550##GORKOV LP, 1961, SOV PHYS JETP-USSR, V13, P1018##GUBBELS KB, CONDMAT0606330##HAQUE M, 2006, PHYS REV A, V74, DOI 10.1103/PHYSREVA.74.011602##HO TL, CONDMAT0602568, P53401##IMAMBEKOV A, CONDMAT0604423##KAKUYANAGI K, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.047602##KINNUNEN J, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.110403##KLEIN U, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.134518##LARKIN AI, 1965, ZH EKSP TEOR FIZ, V20, P762##LEGGETT AJ, 1980, J PHYS C SOLID STATE, V41, P7##MACDONALD AH, 1992, PHYS REV B, V45, P10147, DOI 10.1103/PHYSREVB.45.10147##MACHIDA K, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.120407##MARINESCU M, 1998, PHYS REV LETT, V81, P4596, DOI 10.1103/PHYSREVLETT.81.4596##MARTIKAINEN JP, 2006, PHYS REV A, V74, DOI 10.1103/PHYSREVA.74.013602##NORMAN MR, 1995, PHYS REV B, V51, P5927, DOI 10.1103/PHYSREVB.51.5927##NOZIERES P, 1985, J LOW TEMP PHYS, V59, P195, DOI 10.1007/BF00683774##PARISH MM, CONDMAT0605744##PARTRIDGE GB, 2006, SCIENCE, V311, P503, DOI 10.1126/SCIENCE.1122876##PIERI P, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.150404##RADOVAN HA, 2003, NATURE, V425, P51, DOI 10.1038/NATURE01842##REGNAULT N, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.241307##SARMA G, 1963, J PHYS CHEM SOLIDS, V24, P1029, DOI 10.1016/0022-3697(63)90007-6##SCHRIEFFER J R, 1999, THEORY SUPERCONDUCTI##SCHWEIKHARD V, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.040404##SHEEHY DE, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.060401##SHIMAHARA H, 1997, J PHYS SOC JPN, V66, P3591, DOI 10.1143/JPSJ.66.3591##STOOF HTC, 1996, J RES NATL INST STAN, V101, P443, DOI 10.6028/JRES.101.047##STWALLEY WC, 1976, PHYS REV LETT, V37, P1628, DOI 10.1103/PHYSREVLETT.37.1628##TIESINGA E, 1993, PHYS REV A, V47, P4114, DOI 10.1103/PHYSREVA.47.4114##YANG K, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.094512##YI W, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.031604##ZWIERLEIN MW, 2006, NATURE, V442, P54, DOI 10.1038/NATURE04936##ZWIERLEIN MW, 2006, SCIENCE, V311, P492, DOI 10.1126/SCIENCE.1122318##ZWIERLEIN MW, 2005, NATURE, V435, P1047, DOI 10.1038/NATURE03858",14,2020-11-20,NA
J,WOS:000242408900149,2006,INTRINSIC INTENSITY FLUCTUATIONS IN RANDOM LASERS,WE PRESENT A QUANTITATIVE EXPERIMENTAL AND THEORETICAL STUDY OF INTENSITY FLUCTUATIONS IN THE EMITTED LIGHT OF A RANDOM LASER THAT HAS DIFFERENT REALIZATIONS OF DISORDER FOR EVERY PUMP PULSE. A MODEL THAT CLARIFIES THESE INTRINSIC FLUCTUATIONS IS DEVELOPED. WE DESCRIBE THE OUTPUT VERSUS INPUT POWER GRAPHS OF THE RANDOM LASER WITH AN EFFECTIVE SPONTANEOUS EMISSION FACTOR (BETA FACTOR).,STRONGLY SCATTERING MEDIA; STATISTICS; ABSORPTION; EMISSION; LIGHT,NA,PHYSICAL REVIEW A,"VAN DER MOLEN, KL##MOSK, AP##LAGENDIJK, A","UNIV TWENTE, COMPLEX PHOTON SYST, MESA, RES INST, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV TWENTE, DEPT SCI & TECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. FOM, INST ATOM & MOL PHYS, AMOLF, NL-1098 SJ AMSTERDAM, NETHERLANDS.","OPTICS; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",OPTICS; PHYSICS,"ANGELANI L, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.065702##ANGLOS D, 2004, J OPT SOC AM B, V21, P208, DOI 10.1364/JOSAB.21.000208##CAO H, 1998, APPL PHYS LETT, V73, P3656, DOI 10.1063/1.122853##DEYCH LI, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.043902##FROLOV SV, 1999, OPT COMMUN, V162, P241, DOI 10.1016/S0030-4018(99)00089-9##GENACK AZ, 1999, PHYS REV LETT, V82, P715, DOI 10.1103/PHYSREVLETT.82.715##LAWANDY NM, 1994, NATURE, V368, P436, DOI 10.1038/368436A0##LETOKHOV VS, 1968, SOV PHYS JETP-USSR, V26, P835##LING Y, 2001, PHYS REV A, V64, DOI 10.1103/PHYSREVA.64.063808##MILNER V, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.073901##MUJUMDAR S, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.053903##POLSON RC, 2003, IEEE J SEL TOP QUANT, V9, P120, DOI 10.1109/JSTQE.2002.807970##RAMACHANDRAN H, 2002, PRAMANA-J PHYS, V58, P313, DOI 10.1007/S12043-002-0016-Y##RIVAS JG, 2003, OPT COMMUN, V220, P17, DOI 10.1016/S0030-4018(03)01348-8##ROSE A, 2005, NATURE, V434, P876, DOI 10.1038/NATURE03438##SHARMA D, 2006, OPT LETT, V31, P1806, DOI 10.1364/OL.31.001806##SHENG P., 1995, INTRO WAVE SCATTERIN##SIEGMAN A.E., 1986, LASERS##VAN TIGGELEN BA, 1999, PHYS REV E, V59, P7166, DOI 10.1103/PHYSREVE.59.7166##VANALBADA MP, 1985, PHYS REV LETT, V55, P2692##WOERDMAN JP, 2001, ADV ATOM MOL OPT PHY, V47, P205##YAMILOV A, 2005, OPT LETT, V30, P2430, DOI 10.1364/OL.30.002430",48,2020-11-20,NA
J,WOS:000242409100077,2006,FERROELECTRICITY IN THE CYCLOIDAL SPIRAL MAGNETIC PHASE OF MNWO4,"WE INVESTIGATE THE RELATIONSHIPS AMONG MAGNETIC, DIELECTRIC, AND FERROELECTRIC PROPERTIES OF A FRUSTRATED SPIN SYSTEM MNWO4, WHICH UNDERGOES SEVERAL MAGNETIC PHASE TRANSITIONS INCLUDING A COMMENSURATE-INCOMMENSURATE AND A COLLINEAR-NONCOLLINEAR TRANSITION. DIELECTRIC AND PYROELECTRIC MEASUREMENTS SHOW THAT THE TRANSITION INTO A SPIRAL MAGNETIC ORDERED PHASE PRODUCES A FERROELECTRIC STATE. THE DIRECTION OF THE ELECTRIC POLARIZATION IS PERPENDICULAR TO THE SPIN ROTATION AXIS AND THE PROPAGATION VECTOR OF THE SPIRAL. THESE OBSERVATIONS AGREE WELL WITH RECENT THEORETICAL PREDICTIONS THAT A CYCLOIDAL SPIRAL MAGNETIC ORDERING CAN RESULT IN ELECTRIC POLARIZATION. IN A MATERIAL WHERE FERROELECTRICITY IS INDUCED BY MAGNETIC ORDER, WE CAN MAGNETICALLY TUNE THE FERROELECTRIC TRANSITIONS BY EXPLOITING THE DIFFERENCE OF THE NET MAGNETIZATION BETWEEN THE FERROELECTRIC AND NEIGHBORING PARAELECTRIC PHASES",MULTIFERROIC MATERIAL; POLARIZATION; TRANSITIONS; REVERSAL,NA,PHYSICAL REVIEW B,"ARKENBOUT, AH##PALSTRA, TTM##SIEGRIST, T##KIMURA, T","UNIV GRONINGEN, SOLID STATE CHEM LAB, CTR MAT SCI, NL-9747 AG GRONINGEN, NETHERLANDS. BELL LABS, LUCENT TECHNOL, MURRAY HILL, NJ 07974 USA.","MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",MATERIALS SCIENCE; PHYSICS,"AHARONOV Y, 1984, PHYS REV LETT, V53, P319, DOI 10.1103/PHYSREVLETT.53.319##BAK P, 1980, PHYS REV B, V21, P5297, DOI 10.1103/PHYSREVB.21.5297##BAK P, 1982, REP PROG PHYS, V45, P587, DOI 10.1088/0034-4885/45/6/001##COX DE, 1963, J PHYS CHEM SOLIDS, V24, P405, DOI 10.1016/0022-3697(63)90199-9##DACHS H, 1966, SOLID STATE COMMUN, V4, P473, DOI 10.1016/0038-1098(66)90333-4##DACHS H, 1969, SOLID STATE COMMUN, V7, P1015, DOI 10.1016/0038-1098(69)90075-1##DZYALOSHINSKY I, 1958, J PHYS CHEM SOLIDS, V4, P241, DOI 10.1016/0022-3697(58)90076-3##EHRENBERG H, 1997, J PHYS-CONDENS MAT, V9, P3189, DOI 10.1088/0953-8984/9/15/011##FIEBIG M, 2005, J PHYS D APPL PHYS, V38, PR123, DOI 10.1088/0022-3727/38/8/R01##HEYER O, 2006, J PHYS-CONDENS MAT, V18, PL471, DOI 10.1088/0953-8984/18/39/L01##HILL NA, 2000, J PHYS CHEM B, V104, P6694, DOI [10.1021/JP000114X, 10.1021/JPC00114X]##HUR N, 2004, NATURE, V429, P392, DOI 10.1038/NATURE02572##KATSURA H, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.057205##KENZELMANN M, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.087206##KIMURA T, 2003, NATURE, V426, P55, DOI 10.1038/NATURE02018##LARSON A. C., 2004, 86748 LAUR LOS AL NA##LAUTENSCHLAGER G, 1993, PHYS REV B, V48, P6087, DOI 10.1103/PHYSREVB.48.6087##LAWES G, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.087205##MORIYA T, 1960, PHYS REV, V120, P91, DOI 10.1103/PHYSREV.120.91##MOSTOVOY M, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.067601##SAITO K, 1995, J PHYS-CONDENS MAT, V7, P2855, DOI 10.1088/0953-8984/7/14/022##SCHMID H, 1999, FERROELECTRICS, V221, P9, DOI 10.1080/00150199908016431##SCHMID H., 1994, FERROELECTRICS, V162, P317, DOI 10.1080/00150199408245120##SCHMID H, 2003, INTRO COMPLEX MEDIUM, P167##SERGIENKO IA, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.094434##SLEIGHT AW, 1972, ACTA CRYSTALL B-STRU, VB 28, P2899, DOI 10.1107/S0567740872007186##TANIGUCHI K, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.097203##WANKLYN BM, 1972, J MATER SCI, V7, P813, DOI 10.1007/BF00549910##WEITZEL H, 1969, SOLID STATE COMMUN, V7, P1249, DOI 10.1016/0038-1098(69)90187-2##YAMASAKI Y, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.207204",177,2020-11-20,NA
J,WOS:000242409100075,2006,FERROMAGNETISM BELOW 10 K IN MN-DOPED BITE,"FERROMAGNETISM IS OBSERVED BELOW 10 K IN [BI0.75TE0.125MN0.125]TE. THIS MATERIAL HAS THE BITE STRUCTURE, WHICH IS MADE FROM THE STACKING OF TWO TE-BI-TE-BI-TE BLOCKS AND ONE BI-BI BLOCK PER UNIT CELL. CRYSTAL STRUCTURE ANALYSIS SHOWS THAT MN IS LOCALIZED IN THE BI-2 BLOCKS, AND IS ACCOMPANIED BY AN EQUAL AMOUNT OF TE-BI ANTISITE OCCUPANCY IN THE BI2TE3 BLOCKS. THESE TE-BI ANTISITE DEFECTS GREATLY ENHANCE THE MN SOLUBILITY. THIS IS DEMONSTRATED BY COMPARISON OF THE [BI1-XMNX]TE AND [BI1-2XTEXMNX]TE SERIES; IN THE FORMER, THE SOLUBILITY IS LIMITED TO X=0.067, WHILE THE LATTER HAS X(MAX)=0.125. THE MAGNETISM IN [BI1-XMNX]TE CHANGES LITTLE WITH X, WHILE THAT FOR [BI1-2XTEXMNX]TE SHOWS A CLEAR VARIATION, LEADING TO FERROMAGNETISM FOR X>0.067. MAGNETIC HYSTERESIS AND THE ANOMALOUS HALL EFFECT ARE OBSERVED FOR THE FERROMAGNETIC SAMPLES.",SEMICONDUCTORS,NA,PHYSICAL REVIEW B,"BOS, JWG##LEE, M##MOROSAN, E##ZANDBERGEN, HW##LEE, WL##ONG, NP##CAVA, RJ","PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA. PRINCETON UNIV, DEPT PHYS, PRINCETON, NJ 08544 USA. DELFT INST TECHNOL, NATL CTR HIGH RESOLUT ELECTRON MICROSCOPY, DELFT, NETHERLANDS.","MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",MATERIALS SCIENCE; PHYSICS,"BARBARA B, 1988, LECT MODERN MAGNETIS##BAYLISS P, 1991, AM MINERAL, V76, P257##CHOI J, 2005, J APPL PHYS, V97, DOI 10.1063/1.1854451##CHOI J, 2004, PHYS STATUS SOLIDI B, V241, P1541, DOI 10.1002/PSSB.200304527##DAS VD, 1988, PHYS REV B, V37, P4552, DOI 10.1103/PHYSREVB.37.4552##DYCK JS, 2005, PHYS REV B, V71, DOI 10.1103/PHYSREVB.71.115214##DYCK JS, 2003, J APPL PHYS, V94, P7631, DOI 10.1063/1.1626803##DYCK JS, 2002, PHYS REV B, V65, DOI 10.1103/PHYSREVB.65.115212##FERRAND D, 2001, PHYS REV B, V63, DOI 10.1103/PHYSREVB.63.085201##FURDYNA JK, 1988, J APPL PHYS, V64, PR29, DOI 10.1063/1.341700##GAUDIN E, 1995, MATER RES BULL, V30, P549, DOI 10.1016/0025-5408(95)00030-5##GIBBS P, 1985, J PHYS F MET PHYS, V15, P213, DOI 10.1088/0305-4608/15/1/022##HAURY A, 1997, PHYS REV LETT, V79, P511, DOI 10.1103/PHYSREVLETT.79.511##HULLIGER F., 1976, STRUCTURAL CHEM LAYE##JUNGWIRTH T, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.165204##KULBACHINSKII VA, 2002, PHYSICA B, V311, P292, DOI 10.1016/S0921-4526(01)00975-9##LARSON A, 2000, 86748 LAUR LOS AL NA##LEE M. P., IN PRESS##LIND H, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.184101##MACDONALD AH, 2005, NAT MATER, V4, P195, DOI 10.1038/NMAT1325##OHNO H, 1998, SCIENCE, V281, P951, DOI 10.1126/SCIENCE.281.5379.951##STORY T, 1986, PHYS REV LETT, V56, P777, DOI 10.1103/PHYSREVLETT.56.777##WOLF SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/SCIENCE.1065389##YAMANA K, 1979, ACTA CRYSTALLOGR B, V35, P147, DOI 10.1107/S0567740879002788",27,2020-11-20,NA
J,WOS:000242409100041,2006,OPTICAL CONDUCTIVITY OF CHARGE CARRIERS INTERACTING WITH A TWO-LEVEL SYSTEMS RESERVOIR,"USING THE FUNCTIONAL-INTEGRAL METHOD WE INVESTIGATE THE EFFECTIVE DYNAMICS OF A CHARGED PARTICLE COUPLED TO A SET OF TWO-LEVEL SYSTEMS AS A FUNCTION OF TEMPERATURE AND EXTERNAL ELECTRIC FIELD. THE OPTICAL CONDUCTIVITY AND THE DIRECT CURRENT (DC) RESISTIVITY INDUCED BY THE RESERVOIR ARE COMPUTED. THREE DIFFERENT REGIMES ARE FOUND DEPENDING ON THE TWO-LEVEL SYSTEM SPECTRAL FUNCTION, WHICH MAY LEAD TO A NON-DRUDE OPTICAL CONDUCTIVITY IN A CERTAIN RANGE OF PARAMETERS. OUR RESULTS CONTRAST TO THE BEHAVIOR FOUND WHEN CONSIDERING THE USUAL BATH OF HARMONIC OSCILLATORS WHICH WE ARE ABLE TO RECOVER IN THE LIMIT OF VERY LOW TEMPERATURES.",QUANTUM; DYNAMICS,NA,PHYSICAL REVIEW B,"FERRER, AV##CALDEIRA, AO##SMITH, CM","UNIV FED FLUMINENSE, INST FIS, BR-24210346 RIO DE JANEIRO, BRAZIL. UNIV ESTADUAL CAMPINAS, INST FIS GLEB WATAGHIN, DEPT FIS MAT CONDENSADA, BR-13083970 CAMPINAS, SP, BRAZIL. UNIV UTRECHT, INST THEORET PHYS, NL-3584 CE UTRECHT, NETHERLANDS.","MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",MATERIALS SCIENCE; PHYSICS,"BARONE PMVB, 1991, PHYS REV A, V43, P57, DOI 10.1103/PHYSREVA.43.57##CALDEIRA AO, 1983, PHYSICA A, V121, P587, DOI 10.1016/0378-4371(83)90013-4##CALDEIRA AO, 1993, PHYS REV B, V48, P13974, DOI 10.1103/PHYSREVB.48.13974##CALDEIRA AO, 1983, ANN PHYS-NEW YORK, V149, P374, DOI 10.1016/0003-4916(83)90202-6##CASTRO NETO AH, 1993, PHYS REV E, V48, P4037, DOI 10.1103/PHYSREVE.48.4037##DORSEY AT, 1986, PHYS REV A, V33, P1117, DOI 10.1103/PHYSREVA.33.1117##FERRER AV, 2000, PHYS REV B, V61, P2755, DOI 10.1103/PHYSREVB.61.2755##FERRER AV, 2001, PHYS REV B, V64, DOI 10.1103/PHYSREVB.64.104425##FEYNMAN RP, 1963, ANN PHYS-NEW YORK, V24, P118, DOI 10.1016/0003-4916(63)90068-X##GRADSHTEYN I S, 2000, TABLE INTEGRALS PROD##HEDEGARD P, 1987, PHYS SCRIPTA, V35, P609, DOI 10.1088/0031-8949/35/5/001##KATO T, 1998, J PHYS SOC JPN, V67, P2828, DOI 10.1143/JPSJ.67.2828##LEGGETT AJ, 1987, REV MOD PHYS, V59, P1, DOI 10.1103/REVMODPHYS.59.1##MAKRI N, 1999, J PHYS CHEM B, V103, P2823, DOI 10.1021/JP9847540##PROKOF'EV NV, 2000, REP PROG PHYS, V63, P669, DOI 10.1088/0034-4885/63/4/204##WEISS U, 1999, SERIES MODERN CONDEN, V10##ZOTOS X., 2004, STRONG INTERACTIONS",12,2020-11-20,NA
J,WOS:000242409400008,2006,NONLINEAR SCREENING OF CHARGE IMPURITIES IN GRAPHENE,"IT IS SHOWN THAT A ""VACUUM POLARIZATION"" INDUCED BY COULOMB POTENTIAL IN GRAPHENE LEADS TO A STRONG SUPPRESSION OF ELECTRIC CHARGES EVEN FOR UNDOPED CASE (NO CHARGE CARRIERS). A STANDARD LINEAR RESPONSE THEORY IS THEREFORE NOT APPLICABLE TO DESCRIBE THE SCREENING OF CHARGE IMPURITIES IN GRAPHENE. IN PARTICULAR, IT OVERESTIMATES ESSENTIALLY THE CONTRIBUTIONS OF CHARGE IMPURITIES INTO THE RESISTIVITY OF GRAPHENE.",NA,NA,PHYSICAL REVIEW B,"KATSNELSON, MI","RADBOUD UNIV NIJMEGEN, INST MOL & MAT, NL-6525 ED NIJMEGEN, NETHERLANDS.","MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",MATERIALS SCIENCE; PHYSICS,"ABANIN DA, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.176803##ANDO T, 1982, REV MOD PHYS, V54, P437, DOI 10.1103/REVMODPHYS.54.437##ANDO T, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.074716##CASTRO NETO AH, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.205408##GEIM ANDRE, COMMUNICATION##GUSYNIN VP, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.146801##HOHENBERG P, 1964, PHYS REV B, V136, PB864, DOI 10.1103/PHYSREV.136.B864##KATSNELSON MI, 2006, EUR PHYS J B, V51, P157, DOI [10.1140/EPJB/E2006-00203-1, 10.1140/EPJB/E200S-00203-1]##LIEB EH, 1981, REV MOD PHYS, V53, P603, DOI 10.1103/REVMODPHYS.53.603##LIFSHITZ EM, 1977, RELATIVISTIC QUANT 2##MIGDAL AB, 1977, QUALITATIVE METHODS##NOMURA K, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.256602##NOVOSELOV KS, 2005, P NATL ACAD SCI USA, V102, P10451, DOI 10.1073/PNAS.0502848102##NOVOSELOV KS, 2005, NATURE, V438, P197, DOI 10.1038/NATURE04233##NOVOSELOV KS, 2004, SCIENCE, V306, P666, DOI 10.1126/SCIENCE.1102896##PERES NMR, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.125411##PINES D, 1966, THEORY QUANTUM LIQUI, V1##TWORZYDLO J, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.246802##VONSOVSKY SV, 1989, QUANTUM SOLID STATE, PCH5##ZHANG YB, 2005, NATURE, V438, P201, DOI 10.1038/NATURE04235##ZIEGLER K, CONDMAT0604537, P13361",107,2020-11-20,NA
J,WOS:000242409100008,2006,MACROSCOPIC QUANTUM DYNAMICS OF PI JUNCTIONS WITH FERROMAGNETIC INSULATORS,"WE THEORETICALLY INVESTIGATE THE MACROSCOPIC QUANTUM DYNAMICS OF A PI JUNCTION WITH A SUPERCONDUCTOR (S) AND A MULTIFERROIC MATERIAL OR A FERROMAGNETIC INSULATOR (FI). BY DERIVING THE EFFECTIVE ACTION FROM A MICROSCOPIC HAMILTONIAN, A PI-JUNCTION QUBIT (A S-FI-S SUPERCONDUCTING QUANTUM INTERFERENCE DEVICE RING) IS PROPOSED. IN THIS QUBIT, A QUANTUM TWO-LEVEL SYSTEM IS SPONTANEOUSLY GENERATED AND THE EFFECT OF THE QUASIPARTICLE DISSIPATION IS FOUND TO BE VERY WEAK. THESE FEATURES MAKE IT POSSIBLE TO REALIZE A QUIET QUBIT WITH HIGH COHERENCY. WE ALSO INVESTIGATE MACROSCOPIC QUANTUM TUNNELING (MQT) IN CURRENT-BIASED S-FI-S PI JUNCTIONS AND SHOW THAT THE INFLUENCE OF THE QUASIPARTICLE DISSIPATION ON MQT IS NEGLIGIBLY SMALL.",JOSEPHSON-JUNCTIONS; ORBITAL PHYSICS; SUPERCONDUCTORS; OXIDES; QUBIT,NA,PHYSICAL REVIEW B,"KAWABATA, S##KASHIWAYA, S##ASANO, Y##TANAKA, Y##GOLUBOV, AA","UNIV TWENTE, FAC SCI & TECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. AIST, NRI, TSUKUBA, IBARAKI 3058568, JAPAN. AIST, NERI, TSUKUBA, IBARAKI 3058568, JAPAN. HOKKAIDO UNIV, DEPT APPL PHYS, SAPPORO, HOKKAIDO 0608628, JAPAN. NAGOYA UNIV, DEPT APPL PHYS, NAGOYA, AICHI 4648603, JAPAN.","MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",MATERIALS SCIENCE; PHYSICS,"[ANONYMOUS], 2006, MODERN FERRITE TECHN##BALTZER PK, 1965, PHYS REV LETT, V15, P493, DOI 10.1103/PHYSREVLETT.15.493##BARASH YS, 2002, PHYS REV B, V65, DOI 10.1103/PHYSREVB.65.144502##BLATTER G, 2001, PHYS REV B, V63, DOI 10.1103/PHYSREVB.63.174511##BORN F, 2006, PHYS REV B, V74, DOI 10.1103/PHYSREVB.74.140501##BULAEVSKII LN, 1977, JETP LETT+, V25, P290##BUZDIN AI, 2005, REV MOD PHYS, V77, P935, DOI 10.1103/REVMODPHYS.77.935##BUZDIN AI, 1982, JETP LETT+, V35, P178##CALDEIRA AO, 1983, ANN PHYS-NEW YORK, V149, P374, DOI 10.1016/0003-4916(83)90202-6##DIETL T, 2000, SCIENCE, V287, P1019, DOI 10.1126/SCIENCE.287.5455.1019##ECKERN U, 1984, PHYS REV B, V30, P6419, DOI 10.1103/PHYSREVB.30.6419##EERENSTEIN W, 2006, NATURE, V442, P759, DOI 10.1038/NATURE05023##FROLOV SM, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.144505##GAJEK M, CONDMAT0606444##GOLUBOV AA, 2004, REV MOD PHYS, V76, P411, DOI 10.1103/REVMODPHYS.76.411##GRANVILLE S, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.235335##HEERSCHE HB, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.206801##IKEDA K, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2191829##IOFFE LB, 1999, NATURE, V398, P679##KASHIWAYA S, 1999, PHYS REV B, V60, P3572, DOI 10.1103/PHYSREVB.60.3572##KATO T, 1996, J PHYS SOC JPN, V65, P2963, DOI 10.1143/JPSJ.65.2963##KAWABATA S, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.052506##KAWABATA S, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.132505##KAWABATA S, 2005, PHYSICA E, V29, P669, DOI 10.1016/J.PHYSE.2005.06.051##KHOMSKII DI, 2006, J MAGN MAGN MATER, V306, P1, DOI 10.1016/J.JMMM.2006.01.238##KONTOS T, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.137007##KRASNOV VM, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.157002##KULIK IO, 1966, SOV PHYS JETP-USSR, V22, P841##LI YF, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2337872##MARTINIS JM, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.117901##MESERVEY R, 1994, PHYS REP, V238, P173, DOI 10.1016/0370-1573(94)90105-8##MOCHIZUKI M, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/154##MOOIJ JE, 1999, SCIENCE, V285, P1036, DOI 10.1126/SCIENCE.285.5430.1036##NAGAOSA N., 1999, QUANTUM FIELD THEORY##ROBINSON JWA, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.177003##RYAZANOV VV, 2001, PHYS REV LETT, V86, P2427, DOI 10.1103/PHYSREVLETT.86.2427##SELLIER H, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.257005##SHIBA H, 1969, PROG THEOR PHYS, V41, P25, DOI 10.1143/PTP.41.25##TANAKA Y, 1997, PHYSICA C, V274, P357, DOI 10.1016/S0921-4534(97)80002-0##TOKURA Y, 2000, SCIENCE, V288, P462, DOI 10.1126/SCIENCE.288.5465.462##VAVRA O, 2006, PHYS REV B, V74, DOI 10.1103/PHYSREVB.74.020502##WALLRAFF A, 2003, REV SCI INSTRUM, V74, P3740, DOI 10.1063/1.1588752##WEIDES M, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2356104##WEIDES M, 2006, PHYSICA C, V437-38, P349, DOI 10.1016/J.PHYSC.2005.12.046##WEIDES M, CONDMAT0605656##WEISS U, 1999, QUANTUM DISSIPATIVE##XIAO JQ, 1996, PHYS REV LETT, V76, P1727, DOI 10.1103/PHYSREVLETT.76.1727##YAMASAKI Y, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.207204##YAMASHITA T, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.097001##YU Y, 2002, SCIENCE, V296, P889, DOI 10.1126/SCIENCE.1069452##ZAIKIN A. D., 1985, SOVIET PHYSICS - JETP, V62, P137",38,2020-11-20,"GRANTS-IN-AID FOR SCIENTIFIC RESEARCHMINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE AND TECHNOLOGY, JAPAN (MEXT)JAPAN SOCIETY FOR THE PROMOTION OF SCIENCEGRANTS-IN-AID FOR SCIENTIFIC RESEARCH (KAKENHI) [17710081] FUNDING SOURCE: KAKEN"
J,WOS:000242409200079,2006,NONDESTRUCTIVE MEASUREMENT OF ELECTRON SPINS IN A QUANTUM DOT,"WE PROPOSE AND IMPLEMENT A NONDESTRUCTIVE MEASUREMENT THAT DISTINGUISHES BETWEEN TWO-ELECTRON SPIN STATES IN A QUANTUM DOT. IN CONTRAST TO EARLIER EXPERIMENTS WITH QUANTUM DOTS, THE SPINS ARE LEFT BEHIND IN THE STATE CORRESPONDING TO THE MEASUREMENT OUTCOME. BY MEASURING THE SPIN STATES TWICE WITHIN A TIME SHORTER THAN THE RELAXATION TIME T-1, CORRELATIONS BETWEEN THE OUTCOMES OF CONSECUTIVE MEASUREMENTS ARE OBSERVED. THEY DISAPPEAR AS THE WAIT TIME BETWEEN MEASUREMENTS BECOMES COMPARABLE TO T-1. THE CORRELATION BETWEEN THE POSTMEASUREMENT STATE AND THE MEASUREMENT OUTCOME IS MEASURED TO BE SIMILAR TO 90% ON AVERAGE.",SPECTROSCOPY; BLOCKADE; COULOMB,NA,PHYSICAL REVIEW B,"MEUNIER, T##VINK, IT##VAN BEVEREN, LHW##KOPPENS, FHL##TRANITZ, HP##WEGSCHEIDER, W##KOUWENHOVEN, LP##VANDERSYPEN, LMK","DELFT UNIV TECHNOL, KAVLI INST NANOSCI, NL-2600 GA DELFT, NETHERLANDS. UNIV REGENSBURG, INST ANGEW & EXPT PHYS, D-8400 REGENSBURG, GERMANY.","MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",MATERIALS SCIENCE; PHYSICS,"BRAGINSKY VB, 1995, QUANTUM MEASUREMENT##CIORGA M, 2000, PHYS REV B, V61, P16315, DOI 10.1103/PHYSREVB.61.R16315##DIVINCENZO DP, 2000, FORTSCHR PHYS, V48, P771, DOI 10.1002/1521-3978(200009)48:9/11<771::AID-PROP771>3.0.CO;2-E##ELZERMAN JM, 2004, APPL PHYS LETT, V84, P4617, DOI 10.1063/1.1757023##ELZERMAN JM, 2004, NATURE, V430, P431, DOI 10.1039/NATURE02693##ELZERMAN JM, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.161308##ENGEL HA, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.106804##FIELD M, 1993, PHYS REV LETT, V70, P1311, DOI 10.1103/PHYSREVLETT.70.1311##HANSON R, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.196802##JOHNSON AC, 2005, NATURE, V435, P925, DOI 10.1038/NATURE03815##KOPPENS FHL, 2005, SCIENCE, V309, P1346, DOI 10.1126/SCIENCE.1113719##KROUTVAR M, 2004, NATURE, V432, P81, DOI 10.1038/NATURE03008##LEIBFRIED D, 2003, REV MOD PHYS, V75, P281, DOI 10.1103/REVMODPHYS.75.281##PETTA JR, 2005, SCIENCE, V309, P2180, DOI 10.1126/SCIENCE.1116955##PETTA JR, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.186802##SCHLESER R, 2004, APPL PHYS LETT, V85, P2005, DOI 10.1063/1.1784875##VANDERSYPEN LMK, 2004, APPL PHYS LETT, V85, P4394, DOI 10.1063/1.1815041",35,2020-11-20,NA
J,WOS:000242409200066,2006,UNDERSTANDING MOTT'S LAW FROM SCALING OF VARIABLE-RANGE-HOPPING CURRENTS AND INTRINSIC CURRENT FLUCTUATIONS,"WE HAVE USED THE MASTER EQUATION TO SIMULATE VARIABLE-RANGE HOPPING (VRH) OF CHARGES IN A STRONGLY DISORDERED D-DIMENSIONAL ENERGY LANDSCAPE (D=1,2,3). THE CURRENT DISTRIBUTION OVER HOPPING DISTANCES AND HOPPING ENERGIES GIVES A CLEAR INSIGHT INTO THE DIFFERENCE BETWEEN HOPS THAT OCCUR MOST FREQUENTLY, DOMINATE QUANTITATIVELY IN THE INTEGRAL OVER THE MOBILITY DISTRIBUTION, OR ARE CRITICAL ONES THAT STILL NEED TO BE CONSIDERED IN THAT INTEGRAL TO RECOVER THE FULL LOW-TEMPERATURE MOBILITY. THE RECENTLY REPORTED SCALING WITH TEMPERATURE OF THE VRH-CURRENT DISTRIBUTION OVER HOPPING DISTANCES AND HOPPING ENERGIES IS QUANTITATIVELY ANALYZED IN 1D AND 2D, AND ACCURATELY CONFIRMED. BASED ON THIS, WE PRESENT AN ANALYTICAL SCALING THEORY OF VRH, WHICH DISTINGUISHES BETWEEN A SCALING PART OF THE DISTRIBUTION AND AN EXPONENTIAL TAIL, SEPARATED BY CRITICAL CURRENTS THAT SET THE SCALE AND THAT FOLLOW SELF-CONSISTENTLY AT EACH TEMPERATURE. THIS NATURALLY RENDERS MOTT'S LAW FOR THE LOW-TEMPERATURE MOBILITY, IN A WAY AND WITH A PHYSICAL PICTURE DIFFERENT FROM THAT OF THE ESTABLISHED CRITICAL-PERCOLATION-NETWORK APPROACH TO VRH. WE ARGUE THAT CURRENT FLUCTUATIONS AS OBSERVED IN SIMULATIONS ARE INTRINSIC TO VRH AND PLAY AN ESSENTIAL ROLE IN THIS DISTINCTION.",ONE-DIMENSIONAL WIRES; DISORDERED-SYSTEMS; CONDUCTIVITY; MOBILITY; GAP,NA,PHYSICAL REVIEW B,"PASVEER, WF##MICHELS, MAJ","TECH UNIV EINDHOVEN, GRP POLYMER PHYS, EINDHOVEN POLYMER LABS, NL-5600 MB EINDHOVEN, NETHERLANDS. TECH UNIV EINDHOVEN, DUTCH POLYMER INST, NL-5600 MB EINDHOVEN, NETHERLANDS.","MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",MATERIALS SCIENCE; PHYSICS,"AMBEGAOKAR V, 1971, PHYS REV B-SOLID ST, V4, P2612, DOI 10.1103/PHYSREVB.4.2612##ARKHIPOV VI, 2002, PHYS REV B, V65, DOI 10.1103/PHYSREVB.65.165110##BUTCHER PN, 1976, LINEAR NONLINEAR ELE, P348##CASTNER T. G, 1991, HOPPING TRANSPORT SO, V28, P1##CASTNER TG, 2000, PHYS REV B, V61, P16596, DOI 10.1103/PHYSREVB.61.16596##EFROS AL, 1975, J PHYS C SOLID STATE, V8, PL49, DOI 10.1088/0022-3719/8/4/003##FAGGIONATO A, 2006, COMMUN MATH PHYS, V263, P21, DOI 10.1007/S00220-005-1492-5##FISHCHUK II, 2006, PHYS STATUS SOLIDI C, V3, P271, DOI 10.1002/PSSC.200562722##FOWLER AB, 1982, PHYS REV LETT, V48, P196, DOI 10.1103/PHYSREVLETT.48.196##HUIRINIK HP, 2006, PHYS REV B, V73, P4204##LEE PA, 1984, PHYS REV LETT, V53, P2042, DOI 10.1103/PHYSREVLETT.53.2042##LIEN NV, 1997, PHYS REV B, V56, P14960, DOI 10.1103/PHYSREVB.56.14960##MARTENS HCF, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.121203##MCINNES JA, 1979, PHILOS MAG B, V39, P1, DOI 10.1080/13642817908245345##MILLER A, 1960, PHYS REV, V120, P745, DOI 10.1103/PHYSREV.120.745##MOTT NF, 1969, PHILOS MAG, V19, P835, DOI 10.1080/14786436908216338##MOVAGHAR B, 1981, J PHYS C SOLID STATE, V14, P859, DOI 10.1088/0022-3719/14/6/012##PASVEER WF, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.174204##POLLAK M., 1972, JOURNAL OF NON-CRYSTALLINE SOLIDS, V11, P1, DOI 10.1016/0022-3093(72)90304-3##REEDIJK JA, 1999, PHYS REV LETT, V83, P3904, DOI 10.1103/PHYSREVLETT.83.3904##SEROTA RA, 1986, PHYS REV B, V33, P8441, DOI 10.1103/PHYSREVB.33.8441##SEROTA RA, 1988, SOLID STATE COMMUN, V67, P1031, DOI 10.1016/0038-1098(88)91180-5##SHKLOVSKII BI, 1985, ELECT PROPERTIES DOP##SOMOZA AM, 2005, EUROPHYS LETT, V70, P649, DOI 10.1209/EPL/I2005-10030-6##TSIGANKOV DN, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.176602##VISSENBERG MCJM, 1998, PHYS REV B, V57, P12964, DOI 10.1103/PHYSREVB.57.12964##VULETIC T, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.184521##YU ZG, 2001, PHYS REV LETT, V86, P6018, DOI 10.1103/PHYSREVLETT.86.6018##YU ZG, 2001, PHYS REV B, V63, DOI 10.1103/PHYSREVB.63.085202",2,2020-11-20,NA
J,WOS:000242409200042,2006,TOTAL ENERGIES FROM VARIATIONAL FUNCTIONALS OF THE GREEN FUNCTION AND THE RENORMALIZED FOUR-POINT VERTEX,"WE DERIVE VARIATIONAL EXPRESSIONS FOR THE GRAND POTENTIAL OR ACTION IN TERMS OF THE MANY-BODY GREEN FUNCTION G WHICH DESCRIBES THE PROPAGATION OF PARTICLES AND THE RENORMALIZED FOUR-POINT VERTEX GAMMA WHICH DESCRIBES THE SCATTERING OF TWO PARTICLES IN MANY-BODY SYSTEMS. THE MAIN INGREDIENT OF THE VARIATIONAL FUNCTIONALS IS A TERM WE DENOTE AS THE XI-FUNCTIONAL WHICH PLAYS A ROLE ANALOGOUSLY TO THE USUAL PHI-FUNCTIONAL STUDIED BY BAYM [G. BAYM, PHYS. REV. 127, 1391 (1962)] IN CONNECTION WITH THE CONSERVATION LAWS IN MANY-BODY SYSTEMS. WE SHOW THAT ANY XI-DERIVABLE THEORY IS ALSO PHI-DERIVABLE AND THEREFORE RESPECTS THE CONSERVATION LAWS. WE FURTHER SET UP A COMPUTATIONAL SCHEME TO OBTAIN ACCURATE TOTAL ENERGIES FROM OUR VARIATIONAL FUNCTIONALS WITHOUT HAVING TO SOLVE COMPUTATIONALLY EXPENSIVE SETS OF SELF-CONSISTENT EQUATIONS. THE INPUT OF THE FUNCTIONAL IS AN APPROXIMATE GREEN FUNCTION G AND AN APPROXIMATE FOUR-POINT VERTEX GAMMA OBTAINED AT A RELATIVELY LOW COMPUTATIONAL COST. THE VARIATIONAL PROPERTY OF THE FUNCTIONAL GUARANTEES THAT THE ERROR IN THE TOTAL ENERGY IS ONLY OF SECOND ORDER IN DEVIATIONS OF THE INPUT GREEN FUNCTION AND VERTEX FROM THE SELF-CONSISTENT ONES THAT MAKE THE FUNCTIONAL STATIONARY. THE FUNCTIONALS THAT WE WILL CONSIDER FOR PRACTICAL APPLICATIONS CORRESPOND TO INFINITE ORDER SUMMATIONS OF LADDER AND EXCHANGE DIAGRAMS AND ARE THEREFORE PARTICULARLY SUITED FOR APPLICATIONS TO HIGHLY CORRELATED SYSTEMS. THEIR PRACTICAL EVALUATION IS DISCUSSED IN DETAIL.",MEAN-FIELD THEORY; SUPERFLUID SYSTEMS; CONSERVING APPROXIMATIONS; NONEQUILIBRIUM PROCESSES; STATISTICAL MECHANICS; ELECTRONIC-STRUCTURE; PERTURBATION-THEORY; ENTROPY PRINCIPLE; FORMULATION; GAS,NA,PHYSICAL REVIEW B,"VAN LEEUWEN, R##DAHLEN, NE##STAN, A","UNIV GRONINGEN, CTR MAT SCI, NL-9747 AG GRONINGEN, NETHERLANDS.","MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",MATERIALS SCIENCE; PHYSICS,"ALMBLADH CO, 1999, INT J MOD PHYS B, V13, P535, DOI 10.1142/S0217979299000436##ARYASETIAWAN F, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.166401##BAYM G, 1962, PHYS REV, V127, P1391, DOI 10.1103/PHYSREV.127.1391##BICKERS NE, 1991, PHYS REV B, V43, P8044, DOI 10.1103/PHYSREVB.43.8044##BLAIZOT J.-P., 1985, QUANTUM THEORY FINIT##BLOCH C., 1965, STUDIES STAT MECH, VIII##BONITZ M, 1998, QUANTUM KINETIC THEO##CHITRA R, 2001, PHYS REV B, V63, DOI 10.1103/PHYSREVB.63.115110##DAHLEN NE, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1884965##DAHLEN NE, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.012511##DAHLEN NE, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.195102##DAHLEN NE, 2005, INT J QUANTUM CHEM, V101, P512, DOI 10.1002/QUA.20306##DAHLEN NE, 2004, J CHEM PHYS, V120, P6826, DOI 10.1063/1.1650307##DANIELEWICZ P, 1984, ANN PHYS-NEW YORK, V152, P239, DOI 10.1016/0003-4916(84)90092-7##DEDOMINICIS C, 1963, J MATH PHYS, V4, P255, DOI 10.1063/1.1703949##DEDOMINICIS C, 1964, J MATH PHYS, V5, P14, DOI 10.1063/1.1704062##DEDOMINICIS C, 1964, J MATH PHYS, V5, P31, DOI 10.1063/1.1704064##DEDOMINICIS C, 1962, J MATH PHYS, V3, P983, DOI 10.1063/1.1724313##DREIZLER RM, 1990, DENSITY FUNCTIONAL T##GEORGES A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/REVMODPHYS.68.13##HEDIN L, 1965, PHYS REV, V139, PA796, DOI 10.1103/PHYSREV.139.A796##HELGAKER T., 2000, MOL ELECT STRUCTURE##HINDGREN M, 1997, THESIS U LUND##HUGENHOLTZ NM, 1957, PHYSICA, V23, P481, DOI 10.1016/S0031-8914(57)92950-6##JANIS V, 2003, J PHYS-CONDENS MAT, V15, PL311, DOI 10.1088/0953-8984/15/21/102##JANIS V, 1999, PHYS REV B, V60, P11345, DOI 10.1103/PHYSREVB.60.11345##JANIS V, CONDMAT9806118##KADANOFF L., 1989, QUANTUM STAT MECH##KATSNELSON MI, 2002, EUR PHYS J B, V30, P9, DOI 10.1140/EPJB/E2002-00352-1##KELDYSH LV, 1965, SOV PHYS JETP-USSR, V20, P1018##KOTLIAR G, 2006, REV MOD PHYS, V78, P865, DOI 10.1103/REVMODPHYS.78.865##KUBO R, 1957, J PHYS SOC JPN, V12, P570, DOI 10.1143/JPSJ.12.570##KWONG NH, 2000, PHYS REV LETT, V84, P1768, DOI 10.1103/PHYSREVLETT.84.1768##LUTTINGER JM, 1960, PHYS REV, V118, P1417, DOI 10.1103/PHYSREV.118.1417##MARTIN PC, 1959, PHYS REV, V115, P1342, DOI 10.1103/PHYSREV.115.1342##NEGELE J. W., 1988, QUANTUM MANY PARTICL##NOZIERES P., 1964, THEORY INTERACTING F##ORLEWICZ K, 1987, ACTA PHYS POL A, V72, P357##PERDEW J. P., 2003, LECT NOTES PHYS, V620##POTTHOFF M, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.206402##POTTHOFF M, 2003, EUR PHYS J B, V32, P429, DOI 10.1140/EPJB/E2003-00121-8##RUNGE E., 1991, MANY PARTICLE THEORY##SAVRASOV SY, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.245101##SEMKAT D, 1999, PHYS REV E, V59, P1557, DOI 10.1103/PHYSREVE.59.1557##TONG NH, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.115104##VAN LEEUWEN R, 1998, PHYS REV LETT, V80, P1280, DOI 10.1103/PHYSREVLETT.80.1280##VAN LEEUWEN R, 2006, LECT NOTES PHYS, V706, P33##VANLEEUWEN R, 2004, ELECT LIQUID PARADIG##VON BARTH U, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.235109",13,2020-11-20,NA
J,WOS:000242409500042,2006,NEUTRAL KAON INTERFEROMETRY IN AU PLUS AU COLLISIONS AT ROOT(S)(NN) =200GEV,"WE PRESENT THE FIRST STATISTICALLY MEANINGFUL RESULTS FROM TWO-K-S(0) INTERFEROMETRY IN HEAVY-ION COLLISIONS AT ROOT S(NN)=200 GEV. A MODEL THAT TAKES THE EFFECT OF THE STRONG INTERACTION INTO ACCOUNT HAS BEEN USED TO FIT THE MEASURED CORRELATION FUNCTION. THE EFFECTS OF SINGLE AND COUPLED CHANNELS WERE EXPLORED. AT THE MEAN TRANSVERSE MASS < M(T)>=1.07 GEV, WE OBTAIN THE VALUES R=4.09 +/- 0.46(STAT)+/- 0.31(SYS) FM AND LAMBDA=0.92 +/- 0.23(STAT)+/- 0.13(SYS), WHERE R AND LAMBDA ARE THE INVARIANT RADIUS AND CHAOTICITY PARAMETERS, RESPECTIVELY. THE RESULTS ARE QUALITATIVELY CONSISTENT WITH M(T) SYSTEMATICS ESTABLISHED WITH PIONS IN A SCENARIO CHARACTERIZED BY A STRONG COLLECTIVE FLOW.",BOSE-EINSTEIN CORRELATIONS; STRANGE QUARK MATTER; PION INTERFEROMETRY; LATTICE QCD; STAR TPC; PAIRS; MULTIPLICITY; TEMPERATURE; FEMTOSCOPY; PARTICLES,NA,PHYSICAL REVIEW C,"ABELEV, BI##AGGARWAL, MM##AHAMMED, Z##AMONETT, J##ANDERSON, BD##ANDERSON, M##ARKHIPKIN, D##AVERICHEV, GS##BAI, Y##BALEWSKI, J##BARANNIKOVA, O##BARNBY, LS##BAUDOT, J##BEKELE, S##BELAGA, VV##BELLINGERI-LAURIKAINEN, A##BELLWIED, R##BENEDOSSO, F##BHARDWAJ, S##BHASIN, A##BHATI, AK##BICHSEL, H##BIELCIK, J##BIELCIKOVA, J##BLAND, LC##BLYTH, SL##BONNER, BE##BOTJE, M##BOUCHET, J##BRANDIN, AV##BRAVAR, A##BURTON, TP##BYSTERSKY, M##CADMAN, RV##CAI, XZ##CAINES, H##SANCHEZ, MCD##CASTILLO, J##CATU, O##CEBRA, D##CHAJECKI, Z##CHALOUPKA, P##CHATTOPADHYAY, S##CHEN, HF##CHEN, JH##CHENG, J##CHERNEY, M##CHIKANIAN, A##CHRISTIE, W##COFFIN, JP##CORMIER, TM##COSENTINO, MR##CRAMER, JG##CRAWFORD, HJ##DAS, D##DAS, S##DASH, S##DAUGHERITY, M##DE MOURA, MM##DEDOVICH, TG##DEPHILLIPS, M##DEREVSCHIKOV, AA##DIDENKO, L##DIETEL, T##DJAWOTHO, P##DOGRA, SM##DONG, WJ##DONG, X##DRAPER, JE##DU, F##DUNIN, VB##DUNLOP, JC##MAZUMDAR, MRD##ECKARDT, V##EDWARDS, WR##EFIMOV, LG##EMELIANOV, V##ENGELAGE, J##EPPLEY, G##ERAZMUS, B##ESTIENNE, M##FACHINI, P##FATEMI, R##FEDORISIN, J##FILIMONOV, K##FILIP, P##FINCH, E##FINE, V##FISYAK, Y##FU, J##GAGLIARDI, CA##GAILLARD, L##GANTI, MS##GHAZIKHANIAN, V##GHOSH, P##GONZALEZ, JE##GORBUNOV, YG##GOS, H##GREBENYUK, O##GROSNICK, D##GUERTIN, SM##GUIMARAES, KSFF##GUPTA, N##GUTIERREZ, TD##HAAG, B##HALLMAN, TJ##HAMED, A##HARRIS, JW##HE, W##HEINZ, M##HENRY, TW##HEPPLEMANN, S##HIPPOLYTE, B##HIRSCH, A##HJORT, E##HOFFMAN, AM##HOFFMANN, GW##HORNER, MJ##HUANG, HZ##HUANG, SL##HUGHES, EW##HUMANIC, TJ##IGO, G##JACOBS, P##JACOBS, WW##JAKL, P##JIA, F##JIANG, H##JONES, PG##JUDD, EG##KABANA, S##KANG, K##KAPITAN, J##KAPLAN, M##KEANE, D##KECHECHYAN, A##KHODYREV, VY##KIM, BC##KIRYLUK, J##KISIEL, A##KISLOV, EM##KLEIN, SR##KOCOLOSKI, A##KOETKE, DD##KOLLEGGER, T##KOPYTINE, M##KOTCHENDA, L##KOUCHPIL, V##KOWALIK, KL##KRAMER, M##KRAVTSOV, P##KRAVTSOV, VI##KRUEGER, K##KUHN, C##KULIKOV, AI##KUMAR, A##KUZNETSOV, AA##LAMONT, MAC##LANDGRAF, JM##LANGE, S##LAPOINTE, S##LAUE, F##LAURET, J##LEBEDEV, A##LEDNICKY, R##LEE, CH##LEHOCKA, S##LEVINE, MJ##LI, C##LI, Q##LI, Y##LIN, G##LIN, X##LINDENBAUM, SJ##LISA, MA##LIU, F##LIU, H##LIU, J##LIU, L##LIU, Z##LJUBICIC, T##LLOPE, WJ##LONG, H##LONGACRE, RS##LOVE, WA##LU, Y##LUDLAM, T##LYNN, D##MA, GL##MA, JG##MA, YG##MAGESTRO, D##MAHAPATRA, DP##MAJKA, R##MANGOTRA, LK##MANWEILER, R##MARGETIS, S##MARKERT, C##MARTIN, L##MATIS, HS##MATULENKO, YA##MCCLAIN, CJ##MCSHANE, TS##MELNICK, Y##MESCHANIN, A##MILLANE, J##MILLER, ML##MINAEV, NG##MIODUSZEWSKI, S##MIRONOV, C##MISCHKE, A##MISHRA, DK##MITCHELL, J##MOHANTY, B##MOLNAR, L##MOORE, CF##MOROZOV, DA##MUNHOZ, MG##NANDI, BK##NATTRASS, C##NAYAK, TK##NELSON, JM##NETRAKANTI, PK##NOGACH, LV##NURUSHEV, SB##ODYNIEC, G##OGAWA, A##OKOROKOV, V##OLDENBURG, M##OLSON, D##PACHR, M##PAL, SK##PANEBRATSEV, Y##PANITKIN, SY##PAVLINOV, AI##PAWLAK, T##PEITZMANN, T##PEREVOZTCHIKOV, V##PERKINS, C##PERYT, W##PHATAK, SC##PICHA, R##PLANINIC, M##PLUTA, J##POLJAK, N##PORILE, N##PORTER, J##POSKANZER, AM##POTEKHIN, M##POTREBENIKOVA, E##POTUKUCHI, BVKS##PRINDLE, D##PRUNEAU, C##PUTSCHKE, J##RAKNESS, G##RANIWALA, R##RANIWALA, S##RAY, RL##RAZIN, SV##REINNARTH, J##RELYEA, D##RETIERE, F##RIDIGER, A##RITTER, HG##ROBERTS, JB##ROGACHEVSKIY, OV##ROMERO, JL##ROSE, A##ROY, C##RUAN, L##RUSSCHER, MJ##SAHOO, R##SAKUMA, T##SALUR, S##SANDWEISS, J##SARSOUR, M##SAZHIN, PS##SCHAMBACH, J##SCHARENBERG, RP##SCHMITZ, N##SCHWEDA, K##SEGER, J##SELYUZHENKOV, I##SEYBOTH, P##SHABETAI, A##SHAHALIEV, E##SHAO, M##SHARMA, M##SHEN, WQ##SHIMANSKIY, SS##SICHTERMANN, EP##SIMON, F##SINGARAJU, RN##SMIRNOV, N##SNELLINGS, R##SOOD, G##SORENSEN, P##SOWINSKI, J##SPELTZ, J##SPINKA, HM##SRIVASTAVA, B##STADNIK, A##STANISLAUS, TDS##STOCK, R##STOLPOVSKY, A##STRIKHANOV, M##STRINGFELLOW, B##SUAIDE, AAP##SUGARBAKER, E##SUMBERA, M##SUN, Z##SURROW, B##SWANGER, M##SYMONS, TJM##DE TOLEDO, AS##TAI, A##TAKAHASHI, J##TANG, AH##TARNOWSKY, T##THEIN, D##THOMAS, JH##TIMMINS, AR##TIMOSHENKO, S##TOKAREV, M##TRAINOR, TA##TRENTALANGE, S##TRIBBLE, RE##TSAI, OD##ULERY, J##ULLRICH, T##UNDERWOOD, DG##VAN BUREN, G##VAN DER KOLK, N##VAN LEEUWEN, M##MOLEN, AMV##VARMA, R##VASILEVSKI, IM##VASILIEV, AN##VERNET, R##VIGDOR, SE##VIYOGI, YP##VOKAL, S##VOLOSHIN, SA##WAGGONER, WT##WANG, F##WANG, G##WANG, JS##WANG, XL##WANG, Y##WATSON, JW##WEBB, JC##WESTFALL, GD##WETZLER, A##WHITTEN, C##WIEMAN, H##WISSINK, SW##WITT, R##WOOD, J##WU, J##XU, N##XU, QH##XU, Z##YEPES, P##YOO, IK##YUREVICH, VI##ZHAN, W##ZHANG, H##ZHANG, WM##ZHANG, Y##ZHANG, ZP##ZHAO, Y##ZOULKARNEEV, R##ZOULKARNEEVA, Y##ZUBAREV, AN##ZUO, JX","ARGONNE NATL LAB, 9700 S CASS AVE, ARGONNE, IL 60439 USA. UNIV BIRMINGHAM, BIRMINGHAM, W MIDLANDS, ENGLAND. BROOKHAVEN NATL LAB, UPTON, NY 11973 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. UNIV CALIF DAVIS, DAVIS, CA 95616 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90095 USA. CARNEGIE MELLON UNIV, PITTSBURGH, PA 15213 USA. UNIV ILLINOIS, CHICAGO, IL USA. CREIGHTON UNIV, OMAHA, NE 68178 USA. NUCL PHYS INST AS CR, PRAGUE 25068, CZECH REPUBLIC. LAB HIGH ENERGY JINR, DUBNA, RUSSIA. PARTICLE PHYS LAB JINR, DUBNA, RUSSIA. GOETHE UNIV FRANKFURT, FRANKFURT, GERMANY. INST PHYS, BHUBANESWAR 751005, ORISSA, INDIA. INDIAN INST TECHNOL, BOMBAY, MAHARASHTRA, INDIA. INDIANA UNIV, BLOOMINGTON, IN 47408 USA. INST RECH SUBATOM, STRASBOURG, FRANCE. UNIV JAMMU, JAMMU 180001, INDIA. KENT STATE UNIV, KENT, OH 44242 USA. INST MODERN PHYS, LANZHOU, PEOPLES R CHINA. LAWRENCE BERKELEY NATL LAB, BERKELEY, CA 94720 USA. MIT, CAMBRIDGE, MA 02139 USA. MAX PLANCK INST PHYS & ASTROPHYS, MUNICH, GERMANY. MICHIGAN STATE UNIV, E LANSING, MI 48824 USA. MOSCOW ENGN PHYS INST, MOSCOW, RUSSIA. CUNY CITY COLL, NEW YORK, NY 10031 USA. NIKHEF, AMSTERDAM, NETHERLANDS. UNIV UTRECHT, AMSTERDAM, NETHERLANDS. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. PANJAB UNIV, CHANDIGARH 160014, INDIA. PENN STATE UNIV, UNIVERSITY PK, PA 16802 USA. INST HIGH ENERGY PHYS, PROTVINO, RUSSIA. PURDUE UNIV, W LAFAYETTE, IN 47907 USA. PUSAN NATL UNIV, PUSAN, SOUTH KOREA. UNIV RAJASTHAN, JAIPUR 302004, RAJASTHAN, INDIA. RICE UNIV, HOUSTON, TX 77251 USA. UNIV SAO PAULO, SAO PAULO, BRAZIL. UNIV SCI & TECHNOL CHINA, HEFEI 230026, PEOPLES R CHINA. SHANGHAI INST APPL PHYS, SHANGHAI 201800, PEOPLES R CHINA. SUBATECH, NANTES, FRANCE. TEXAS A&M UNIV, COLLEGE STN, TX 77843 USA. UNIV TEXAS AUSTIN, AUSTIN, TX 78712 USA. TSINGHUA UNIV, BEIJING 100084, PEOPLES R CHINA. VALPARAISO UNIV, VALPARAISO, IN 46383 USA. VARIABLE ENERGY CYCLOTRON CTR, KOLKATA 700064, INDIA. WARSAW UNIV TECHNOL, WARSAW, POLAND. UNIV WASHINGTON, SEATTLE, WA 98195 USA. WAYNE STATE UNIV, DETROIT, MI 48201 USA. CCNU HZNU, INST PARTICLE PHYS, WUHAN 430079, PEOPLES R CHINA. YALE UNIV, NEW HAVEN, CT 06520 USA. UNIV ZAGREB, HR-10002 ZAGREB, CROATIA.","PHYSICS, NUCLEAR",PHYSICS,"ABBIENDI G, 2001, EUR PHYS J C, V21, P23, DOI 10.1007/S100520100715##ACHASOV NN, 2003, PHYS REV D, V68, DOI 10.1103/PHYSREVD.68.014006##ACHASOV NN, 2001, PHYS REV D, V63, DOI 10.1103/PHYSREVD.63.094007##ACKERMAN KH, 1999, NUCL PHYS A, V661, P681C, DOI 10.1016/S0375-9474(99)00549-7##ADAMS J, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.112301##ADAMS J, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.262301##ADAMS J, 2005, PHYS REV C, V71, DOI 10.1103/PHYSREVC.71.044906##ADAMS J, NUCLEX0511003##ADAMS JA, IN PRESS##ADLER C, 2004, PHYS LETT B, V595, P143, DOI 10.1016/J.PHYSLETB.2004.06.044##ADLER C, 2001, PHYS REV LETT, V87, DOI [10.1103/PHYSREVLETT.87.182301, 10.1103/PHYSREVLETT.87.262301, 10.1103/PHYSREVLETT.262301]##ADLER C, 2001, NUCL INSTRUM METH A, V461, P337, DOI 10.1016/S0168-9002(00)01238-9##ALEXANDER G, 2003, REP PROG PHYS, V66, P481, DOI 10.1088/0034-4885/66/4/202##ALEXANDER G, 1999, PHYS LETT B, V456, P270, DOI 10.1016/S0370-2693(99)00496-7##ANANTHANARAYAN B, 2001, PHYS REP, V353, P207, DOI 10.1016/S0370-1573(01)00009-6##ANDERSON M, 2003, NUCL INSTRUM METH A, V499, P659, DOI 10.1016/S0168-9002(02)01964-2##ANTINORI F, 1999, NUCL PHYS A, V661, P130C, DOI 10.1016/S0375-9474(99)85015-5##ANTONELLI A, 2002, ECONF C##ARDOUIN D, 1999, PHYS LETT B, V446, P191, DOI 10.1016/S0370-2693(98)01566-4##BACK BB, 2000, PHYS REV LETT, V85, P3100, DOI 10.1103/PHYSREVLETT.85.3100##BACK BB, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.022302##BARU V, 2005, EUR PHYS J A, V23, P523, DOI 10.1140/EPJA/I2004-10105-X##BEKELE S, 2004, THESIS OHIO STATE U##BETTS W, 1997, IEEE T NUCL SCI, V44, P592, DOI 10.1109/23.603717##BUSKULIC D, 1994, Z PHYS C PART FIELDS, V64, P361, DOI 10.1007/BF01560099##EIDELMAN S, 2004, PHYS LETT B, V592, P1, DOI 10.1016/J.PHYSLETB.2004.06.001##GELLMANN M, 1955, PHYS REV, V97, P1387, DOI 10.1103/PHYSREV.97.1387##GREINER C, 1987, PHYS REV LETT, V58, P1825, DOI 10.1103/PHYSREVLETT.58.1825##GYULASSY M, 1992, PHYS LETT B, V286, P211, DOI 10.1016/0370-2693(92)91763-Y##GYULASSY M, 1990, PHYS REV C, V41, PR21, DOI 10.1103/PHYSREVC.41.R21##GYULASSY M, 1989, PHYS LETT B, V217, P181, DOI 10.1016/0370-2693(89)91539-6##HEINZ U, 1996, NUCL PHYS A, V610, PC264, DOI 10.1016/S0375-9474(96)00361-2##JOHNSON SC, 2002, NUCL PHYS A, V698, P603C##KARSCH F, 2002, LECT NOTES PHYS, V583, P209, DOI 10.1007/3-540-45792-5_6##KARSCH F, 1988, Z PHYS C PART FIELDS, V38, P147, DOI 10.1007/BF01574529##KLEIN SR, 1996, IEEE T NUCL SCI, V43, P1768, DOI 10.1109/23.507219##LEDNICKY R, 2004, PHYS ATOM NUCL+, V67, P72, DOI 10.1134/1.1644010##LEDNICKY R, 1982, SOV J NUCL PHYS+, V35, P770##LEDNICKY R, 1998, PHYS ATOM NUCL+, V61, P2050##LEDNICKY R, NUCLTH0501065##LISA MA, 2005, ANNU REV NUCL PART S, V55, P357, DOI 10.1146/ANNUREV.NUCL.55.090704.151533##LYUBOSHITS VL, 1979, SOV J NUCL PHYS+, V30, P407##MARTIN AD, 1977, NUCL PHYS B, V121, P514, DOI 10.1016/0550-3213(77)90169-9##PODGORETSKII M. I., 1989, SOVIET JOURNAL OF PARTICLES AND NUCLEI, V20, P266##PRATT S, 1990, PHYS REV C, V42, P2646, DOI 10.1103/PHYSREVC.42.2646##SOFF S, 1997, J PHYS G NUCL PARTIC, V23, P2095, DOI 10.1088/0954-3899/23/12/035##SPIELES C, 1996, PHYS REV LETT, V76, P1776, DOI 10.1103/PHYSREVLETT.76.1776##SULLIVAN JP, 1993, PHYS REV LETT, V70, P3000, DOI 10.1103/PHYSREVLETT.70.3000##WIEDEMANN UA, 1999, PHYS REP, V319, P145, DOI 10.1016/S0370-1573(99)00032-0##WIEMAN H, 1997, IEEE T NUCL SCI, V44, P671, DOI 10.1109/23.603731##ZAJC WA, 2002, NUCL PHYS A, V698, P39C",38,2020-11-20,NA
J,WOS:000242409700010,2006,MEASUREMENT OF THE TOP QUARK MASS IN THE LEPTON PLUS JETS FINAL STATE WITH THE MATRIX ELEMENT METHOD,"WE PRESENT A MEASUREMENT OF THE TOP QUARK MASS WITH THE MATRIX ELEMENT METHOD IN THE LEPTON+JETS FINAL STATE. AS THE ENERGY SCALE FOR CALORIMETER JETS REPRESENTS THE DOMINANT SOURCE OF SYSTEMATIC UNCERTAINTY, THE MATRIX ELEMENT LIKELIHOOD IS EXTENDED BY AN ADDITIONAL PARAMETER, WHICH IS DEFINED AS A GLOBAL MULTIPLICATIVE FACTOR APPLIED TO THE STANDARD ENERGY SCALE. THE TOP QUARK MASS IS OBTAINED FROM A FIT THAT YIELDS THE COMBINED STATISTICAL AND SYSTEMATIC JET ENERGY SCALE UNCERTAINTY. USING A DATA SET OF 0.4 FB(-1) TAKEN WITH THE D0 EXPERIMENT AT RUN II OF THE FERMILAB TEVATRON COLLIDER, THE MASS OF THE TOP QUARK IS MEASURED USING TOPOLOGICAL INFORMATION TO BE: M(TOP)(CENTER DOT+JETS)(TOPO)=169.2(-7.4)(+5.0)(STAT+JES)(-1.4)(+1.5)(SYST) GEV, AND WHEN INFORMATION ABOUT IDENTIFIED B JETS IS INCLUDED: M(TOP)(CENTER DOT+JETS)(B-TAG)=170.3(-4.5)(+4.1)(STAT+ JES)(-1.8)(+1.2)(SYST) GEV. THE MEASUREMENTS YIELD A JET ENERGY SCALE CONSISTENT WITH THE REFERENCE SCALE.",PRODUCTION CROSS-SECTION; COLLIDER DETECTOR; P(P)OVER-BAR COLLISIONS; FRAGMENTATION FUNCTION; EVENTS,NA,PHYSICAL REVIEW D,"ABAZOV, VM##ABBOTT, B##ABOLINS, M##ACHARYA, BS##ADAMS, M##ADAMS, T##AGELOU, M##AGUILO, E##AHN, SH##AHSAN, M##ALEXEEV, GD##ALKHAZOV, G##ALTON, A##ALVERSON, G##ALVES, GA##ANASTASOAIE, M##ANDEEN, T##ANDERSON, S##ANDRIEU, B##ANZELC, MS##ARNOUD, Y##AROV, M##ASKEW, A##ASMAN, B##JESUS, ACSA##ATRAMENTOV, O##AUTERMANN, C##AVILA, C##AY, C##BADAUD, F##BADEN, A##BAGBY, L##BALDIN, B##BANDURIN, DV##BANERJEE, P##BANERJEE, S##BARBERIS, E##BARGASSA, P##BARINGER, P##BARNES, C##BARRETO, J##BARTLETT, JF##BASSLER, U##BAUER, D##BEALE, S##BEAN, A##BEGALLI, M##BEGEL, M##BELANGER-CHAMPAGNE, C##BELLANTONI, L##BELLAVANCE, A##BENITEZ, JA##BERI, SB##BERNARDI, G##BERNHARD, R##BERNTZON, L##BERTRAM, I##BESANCON, M##BEUSELINCK, R##BEZZUBOV, VA##BHAT, PC##BHATNAGAR, V##BINDER, M##BISCARAT, C##BLACK, KM##BLACKLER, I##BLAZEY, G##BLEKMAN, F##BLESSING, S##BLOCH, D##BLOOM, K##BLUMENSCHEIN, U##BOEHNLEIN, A##BOERIU, O##BOLTON, TA##BORISSOV, G##BOS, K##BOSE, T##BRANDT, A##BROCK, R##BROOIJMANS, G##BROSS, A##BROWN, D##BUCHANAN, NJ##BUCHHOLZ, D##BUEHLER, M##BUESCHER, V##BURDIN, S##BURKE, S##BURNETT, TH##BUSATO, E##BUSZELLO, CP##BUTLER, JM##CALFAYAN, P##CALVET, S##CAMMIN, J##CARON, S##CARVALHO, W##CASEY, BCK##CASON, NM##CASTILLA-VALDEZ, H##CHAKRABARTI, S##CHAKRABORTY, D##CHAN, KM##CHANDRA, A##CHARLES, F##CHEU, E##CHEVALLIER, F##CHO, DK##CHOI, S##CHOUDHARY, B##CHRISTOFEK, L##CLAES, D##CLEMENT, B##CLEMENT, C##COADOU, Y##COOKE, M##COOPER, WE##COPPAGE, D##CORCORAN, M##COUSINOU, MC##COX, B##CREPE-RENAUDIN, S##CUTTS, D##COOKE, M##DA MOTTA, H##DAS, A##DAS, M##DAVIES, B##DAVIES, G##DAVIS, GA##DE, K##DE JONG, P##DE JONG, SJ##DE LA CRUZ-BURELO, E##MARTINS, CDO##DEGENHARDT, JD##DELIOT, F##DEMARTEAU, M##DEMINA, R##DEMINE, P##DENISOV, D##DESAI, S##DIEHL, HT##DIESBURG, M##DOIDGE, M##DOMINGUEZ, A##DONG, H##DUDKO, LV##DUFLOT, L##DUGAD, SR##DUGGAN, D##DUPERRIN, A##DYER, J##DYSHKANT, A##EADS, M##EDMUNDS, D##EDWARDS, T##ELLISON, J##ELMSHEUSER, J##ELVIRA, VD##ENO, S##ERMOLOV, P##EVANS, H##EVDOKIMOV, A##EVDOKIMOV, VN##FATAKIA, SN##FELIGIONI, L##FERAPONTOV, AV##FERBEL, T##FIEDLER, F##FILTHAUT, F##FISHER, W##FISK, HE##FLECK, I##FORD, M##FORTNER, M##FOX, H##FU, S##FUESS, S##GALEA, CF##GALLAS, E##GALYAEV, E##GARCIA, C##GARCIA-BELLIDO, A##GARDNER, J##GAVRILOV, V##GAY, A##GAY, P##GELE, D##GELHAUS, R##GERBER, CE##GERSHTEIN, Y##GILLBERG, D##GINTHER, G##GOLLUB, N##GOMEZ, B##GOUSSIOU, A##GRANNIS, PD##GREENLEE, H##GREENWOOD, ZD##GREGORES, EM##GRENIER, G##GRIS, P##GRIVAZ, JF##GRUNENDAHL, S##GRUNEWALD, MW##GUO, F##GUO, J##GUTIERREZ, G##GUTIERREZ, P##HAAS, A##HADLEY, NJ##HAEFNER, P##HAGOPIAN, S##HALEY, J##HALL, I##HALL, RE##HAN, L##HANAGAKI, K##HANSSON, P##HARDER, K##HAREL, A##HARRINGTON, R##HAUPTMAN, JM##HAUSER, R##HAYS, J##HEBBEKER, T##HEDIN, D##HEGEMAN, JG##HEINMILLER, JM##HEINSON, AP##HEINTZ, U##HENSEL, C##HERNER, K##HESKETH, G##HILDRETH, MD##HIROSKY, R##HOBBS, JD##HOENEISEN, B##HOETH, H##HOHLFELD, M##HONG, SJ##HOOPER, R##HOUBEN, P##HU, Y##HUBACEK, Z##HYNEK, V##IASHVILI, I##ILLINGWORTH, R##ITO, AS##JABEEN, S##JAFFRE, M##JAIN, S##JAKOBS, K##JARVIS, C##JENKINS, A##JESIK, R##JOHNS, K##JOHNSON, C##JOHNSON, M##JONCKHEERE, A##JONSSON, P##JUSTE, A##KAFER, D##KAHN, S##KAJFASZ, E##KALININ, AM##KALK, JM##KALK, JR##KAPPLER, S##KARMANOV, D##KASPER, J##KASPER, P##KATSANOS, I##KAU, D##KAUR, R##KEHOE, R##KERMICHE, S##KHALATYAN, N##KHANOV, A##KHARCHILAVA, A##KHARZHEEV, YM##KHATIDZE, D##KIM, H##KIM, TJ##KIRBY, MH##KLIMA, B##KOHLI, JM##KONRATH, JP##KOPAL, M##KORABLEV, VM##KOTCHER, J##KOTHARI, B##KOUBAROVSKY, A##KOZELOV, AV##KRONINGER, K##KROP, D##KRYEMADHI, A##KUHL, T##KUMAR, A##KUNORI, S##KUPCO, A##KURCA, T##KVITA, J##LAMMERS, S##LANDSBERG, G##LAZOFLORES, J##LE BIHAN, AC##LEBRUN, P##LEE, WM##LEFLAT, A##LEHNER, F##LESNE, V##LEVEQUE, J##LEWIS, P##LI, J##LI, QZ##LIMA, JGR##LINCOLN, D##LINNEMANN, J##LIPAEV, VV##LIPTON, R##LIU, Z##LOBO, L##LOBODENKO, A##LOKAJICEK, M##LOUNIS, A##LOVE, P##LUBATTI, HJ##LYNKER, M##LYON, AL##MACIEL, AKA##MADARAS, RJ##MATTIG, P##MAGASS, C##MAGERKURTH, A##MAGNAN, AM##MAKOVEC, N##MAL, PK##MALBOUISSON, HB##MALIK, S##MALYSHEV, VL##MAO, HS##MARAVIN, Y##MARTENS, M##MCCARTHY, R##MEDER, D##MELNITCHOUK, A##MENDES, A##MENDOZA, L##MERKIN, M##MERRITT, KW##MEYER, A##MEYER, J##MICHAUT, M##MIETTINEN, H##MILLET, T##MITREVSKI, J##MOLINA, J##MONDAL, NK##MONK, J##MOORE, RW##MOULIK, T##MUANZA, GS##MULDERS, M##MULHEARN, M##MUNDAL, O##MUNDIM, L##MUTAF, YD##NAGY, E##NAIMUDDIN, M##NARAIN, M##NAUMANN, NA##NEAL, HA##NEGRET, JP##NEUSTROEV, P##NOEDING, C##NOMEROTSKI, A##NOVAES, SF##NUNNEMANN, T##O'DELL, V##O'NEIL, DC##OBRANT, G##OGURI, V##OLIVEIRA, N##ONOPRIENKO, D##OSHIMA, N##OTEC, R##GARZON, GJOY##OWEN, M##PADLEY, P##PARASHAR, N##PARK, SJ##PARK, SK##PARSONS, J##PARTRIDGE, R##PARUA, N##PATWA, A##PAWLOSKI, G##PEREA, PM##PEREZ, E##PETERS, K##PETROFF, P##PETTENI, M##PIEGAIA, R##PIPER, J##PLEIER, MA##PODESTA-LERMA, PLM##PODSTAVKOV, VM##POGORELOV, Y##POL, ME##POMPOS, A##POPE, BG##POPOV, AV##POTTER, C##DA SILVA, WLP##PROSPER, HB##PROTOPOPESCU, S##QIAN, J##QUADT, A##QUINN, B##RANGEL, MS##RANI, KJ##RANJAN, K##RATOFF, PN##RENKEL, P##REUCROFT, S##RIJSSENBEEK, M##RIPP-BAUDOT, I##RIZATDINOVA, F##ROBINSON, S##RODRIGUES, RF##ROYON, C##RUBINOV, P##RUCHTI, R##RUD, VI##SAJOT, G##SANCHEZ-HERNANDEZ, A##SANDERS, MP##SANTORO, A##SAVAGE, G##SAWYER, L##SCANLON, T##SCHAILE, D##SCHAMBERGER, RD##SCHEGLOV, Y##SCHELLMAN, H##SCHIEFERDECKER, P##SCHMITT, C##SCHWANENBERGER, C##SCHWARTZMAN, A##SCHWIENHORST, R##SEKARIC, J##SENGUPTA, S##SEVERINI, H##SHABALINA, E##SHAMIM, M##SHARY, V##SHCHUKIN, AA##SHEPHARD, WD##SHIVPURI, RK##SHPAKOV, D##SICCARDI, V##SIDWELL, RA##SIMAK, V##SIROTENKO, V##SKUBIC, P##SLATTERY, P##SMITH, RP##SNOW, GR##SNOW, J##SNYDER, S##SOLDNER-REMBOLD, S##SONG, X##SONNENSCHEIN, L##SOPCZAK, A##SOSEBEE, M##SOUSTRUZNIK, K##SOUZA, M##SPURLOCK, B##STARK, J##STEELE, J##STOLIN, V##STONE, A##STOYANOVA, DA##STRANDBERG, J##STRANDBERG, S##STRANG, MA##STRAUSS, M##STROEHMER, R##STROM, D##STROVINK, M##STUTTE, L##SUMOWIDAGDO, S##SVOISKY, P##SZNAJDER, A##TALBY, M##TAMBURELLO, P##TAYLOR, W##TELFORD, P##TEMPLE, J##TILLER, B##TITOV, M##TOKMENIN, VV##TOMOTO, M##TOOLE, T##TORCHIANI, I##TOWERS, S##TREFZGER, T##TRINCAZ-DUVOID, S##TSYBYCHEV, D##TUCHMING, B##TULLY, C##TURCOT, AS##TUTS, PM##UNALAN, R##UVAROV, L##UVAROV, S##UZUNYAN, S##VACHON, B##VAN DEN BERG, PJ##VAN KOOTEN, R##VAN LEEUWEN, WM##VARELAS, N##VARNES, EW##VARTAPETIAN, A##VASILYEV, IA##VAUPEL, M##VERDIER, P##VERTOGRADOV, LS##VERZOCCHI, M##VILLENEUVE-SEGUIER, F##VINT, P##VLIMANT, JR##VON TOERNE, E##VOUTILAINEN, M##VREESWIJK, M##WAHL, HD##WANG, L##WANG, MHLS##WARCHOL, J##WATTS, G##WAYNE, M##WEBER, G##WEBER, M##WEERTS, H##WERMES, N##WETSTEIN, M##WHITE, A##WICKE, D##WILSON, GW##WIMPENNY, SJ##WOBISCH, M##WOMERSLEY, J##WOOD, DR##WYATT, TR##XIE, Y##XUAN, N##YACOOB, S##YAMADA, R##YAN, M##YASUDA, T##YATSUNENKO, YA##YIP, K##YOO, HD##YOUN, SW##YU, C##YU, J##YURKEWICZ, A##ZATSERKLYANIY, A##ZEITNITZ, C##ZHANG, D##ZHAO, T##ZHOU, B##ZHU, J##ZIELINSKI, M##ZIEMINSKA, D##ZIEMINSKI, A##ZUTSHI, V##ZVEREV, EG","UNIV BUENOS AIRES, BUENOS AIRES, DF, ARGENTINA. CTR BRASILEIRO PESQUISAS FIS, LAFEX, RIO DE JANEIRO, BRAZIL. UNIV ESTADO RIO DE JANEIRO, RIO DE JANEIRO, BRAZIL. UNIV ESTADUAL PAULISTA, INST FIS TEOR, BR-01405 SAO PAULO, BRAZIL. SIMON FRASER UNIV, BURNABY, BC V5A 1S6, CANADA. UNIV ALBERTA, EDMONTON, AB, CANADA. MCGILL UNIV, MONTREAL, PQ, CANADA. YORK UNIV, TORONTO, ON M3J 2R7, CANADA. UNIV SCI & TECHNOL CHINA, HEFEI 230026, PEOPLES R CHINA. UNIV LOS ANDES, BOGOTA, COLOMBIA. CHARLES UNIV PRAGUE, CTR PARTICLE PHYS, PRAGUE, CZECH REPUBLIC. CZECH TECH UNIV, CR-16635 PRAGUE, CZECH REPUBLIC. ACAD SCI CZECH REPUBL, INST PHYS, CTR PARTICLE PHYS, PRAGUE, CZECH REPUBLIC. UNIV SAN FREANCISCO QUITO, QUITO, ECUADOR. UNIV CLERMONT FERRAND, CNRS, IN2P3, PHYS CORPUSCULAIRE LAB, CLERMONT FERRAND, FRANCE. UNIV GRENOBLE 1, CNRS, IN2P3, LAB PHYS SUBATOM & COSMOL, GRENOBLE, FRANCE. UNIV MEDITERRANEE, CNRS, CPPM, IN2P3, MARSEILLE, FRANCE. CNRS, LAB ACCELERATEUR LINEAIRE, IN2P3, F-91405 ORSAY, FRANCE. UNIV PARIS 06, LPNHE, IN2P3, CNRS, PARIS, FRANCE. UNIV PARIS 07, LPNHE, IN2P3, CNRS, PARIS, FRANCE. CEA, DAPNIA, SERV PHYS PARTICULES, SACLAY, FRANCE. UNIV STRASBOURG, CNRS, IPHC, IN2P3, STRASBOURG, FRANCE. UNIV HAUTE ALSACE, MULHOUSE, FRANCE. UNIV LYON 1, CNRS, IN2P3, INST PHYS NUCL LYON, F-69622 VILLEURBANNE, FRANCE. RHEIN WESTFAL TH AACHEN, INST PHYS A 3, D-5100 AACHEN, GERMANY. UNIV BONN, INST PHYS, D-5300 BONN, GERMANY. UNIV FREIBURG, INST PHYS, FREIBURG, GERMANY. JOHANNES GUTENBERG UNIV MAINZ, INST PHYS, D-6500 MAINZ, GERMANY. UNIV MUNICH, MUNICH, GERMANY. UNIV WUPPERTAL, FACHBEREICH PHYS, WUPPERTAL, GERMANY. PANJAB UNIV, CHANDIGARH 160014, INDIA. UNIV DELHI, DELHI 110007, INDIA. TATA INST FUNDAMENTAL RES, BOMBAY 400005, MAHARASHTRA, INDIA. UNIV COLL DUBLIN, DUBLIN 2, IRELAND. KOREA UNIV, KOREA DETECTOR LAB, SEOUL 136701, SOUTH KOREA. SUNGKYUNKWAN UNIV, SUWON, SOUTH KOREA. CINVESTAV, MEXICO CITY 14000, DF, MEXICO. NIKHEF, FOM INST, AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, NIKHEF, AMSTERDAM, NETHERLANDS. RADBOUD UNIV NIJMEGEN, NIKHEF, NIJMEGEN, NETHERLANDS. JOINT INST NUCL RES, DUBNA, RUSSIA. INST THEORET & EXPT PHYS, MOSCOW 117259, RUSSIA. MOSCOW MV LOMONOSOV STATE UNIV, MOSCOW, RUSSIA. INST HIGH ENERGY PHYS, PROTVINO, RUSSIA. PETERSBURG NUCL PHYS INST, ST PETERSBURG, RUSSIA. LUND UNIV, LUND, SWEDEN. ROYAL INST TECHNOL, STOCKHOLM, SWEDEN. STOCKHOLM UNIV, S-10691 STOCKHOLM, SWEDEN. UPPSALA UNIV, UPPSALA, SWEDEN. UNIV ZURICH, INST PHYS, ZURICH, SWITZERLAND. UNIV LANCASTER, LANCASTER, ENGLAND. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON, ENGLAND. UNIV MANCHESTER, MANCHESTER, LANCS, ENGLAND. UNIV ARIZONA, TUCSON, AZ 85721 USA. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA. CALIF STATE UNIV FRESNO, FRESNO, CA 93740 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. FLORIDA STATE UNIV, TALLAHASSEE, FL 32306 USA. FERMILAB NATL ACCELERATOR LAB, BATAVIA, IL 60510 USA. UNIV ILLINOIS, CHICAGO, IL 60607 USA. NO ILLINOIS UNIV, DE KALB, IL 60115 USA. NORTHWESTERN UNIV, EVANSTON, IL 60208 USA. INDIANA UNIV, BLOOMINGTON, IN 47405 USA. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. PURDUE UNIV CALUMET, HAMMOND, IN 46323 USA. IOWA STATE UNIV, AMES, IA 50011 USA. UNIV KANSAS, LAWRENCE, KS 66045 USA. KANSAS STATE UNIV, MANHATTAN, KS 66506 USA. LOUISIANA TECH UNIV, RUSTON, LA 71272 USA. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. BOSTON UNIV, BOSTON, MA 02215 USA. NORTHEASTERN UNIV, BOSTON, MA 02115 USA. UNIV MICHIGAN, ANN ARBOR, MI 48109 USA. MICHIGAN STATE UNIV, E LANSING, MI 48824 USA. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV NEBRASKA, LINCOLN, NE 68588 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. SUNY BUFFALO, BUFFALO, NY 14260 USA. COLUMBIA UNIV, NEW YORK, NY 10027 USA. UNIV ROCHESTER, ROCHESTER, NY 14627 USA. SUNY STONY BROOK, STONY BROOK, NY 11794 USA. BROOKHAVEN NATL LAB, UPTON, NY 11973 USA. LANGSTON UNIV, LANGSTON, OK 73050 USA. UNIV OKLAHOMA, NORMAN, OK 73019 USA. OKLAHOMA STATE UNIV, STILLWATER, OK 74078 USA. BROWN UNIV, PROVIDENCE, RI 02912 USA. UNIV TEXAS, ARLINGTON, TX 76019 USA. SO METHODIST UNIV, DALLAS, TX 75275 USA. RICE UNIV, HOUSTON, TX 77005 USA. UNIV VIRGINIA, CHARLOTTESVILLE, VA 22901 USA. UNIV WASHINGTON, SEATTLE, WA 98195 USA.","ASTRONOMY & ASTROPHYSICS; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"ABACHI S, 1995, PHYS REV LETT, V74, P2632, DOI 10.1103/PHYSREVLETT.74.2632##ABACHI S, 1997, PHYS REV LETT, V79, P1197, DOI 10.1103/PHYSREVLETT.79.1197##ABACHI S, 1994, NUCL INSTRUM METH A, V338, P185, DOI 10.1016/0168-9002(94)91312-9##ABAZOV VM, 2006, NUCL INSTRUM METH A, V565, P463, DOI 10.1016/J.NIMA.2006.05.248##ABAZOV VM, 2004, NATURE, V429, P638, DOI 10.1038/NATURE02589##ABAZOV VM, 2005, PHYS LETT B, V606, P25, DOI 10.1016/J.PHYSLETB.2004.11.071##ABAZOV VM, 2005, PHYS LETT B, V626, P35, DOI 10.1016/J.PHYSLETB.2005.08.103##ABAZOV VM, 2005, PHYS LETT B, V626, P45, DOI 10.1016/J.PHYSLETB.2005.08.104##ABAZOVA VM, 2005, NUCL INSTRUM METH A, V552, P372, DOI 10.1016/J.NIMA.2005.07.008##ABBIENDI G, 2003, EUR PHYS J C, V29, P463, DOI 10.1140/EPJC/S2003-01229-X##ABBOTT B, 1998, PHYS REV LETT, V80, P2063, DOI 10.1103/PHYSREVLETT.80.2063##ABBOTT B, 1998, PHYS REV D, V58, DOI 10.1103/PHYSREVD.58.052001##ABBOTT B, 1999, PHYS REV D, V60, DOI 10.1103/PHYSREVD.60.012001##ABE F, 1998, PHYS REV LETT, V80, P2779, DOI 10.1103/PHYSREVLETT.80.2779##ABE F, 1999, PHYS REV LETT, V82, P271, DOI 10.1103/PHYSREVLETT.82.271##ABE F, 1998, PHYS REV LETT, V80, P2767, DOI 10.1103/PHYSREVLETT.80.2767##ABE F, 1995, PHYS REV LETT, V74, P2626, DOI 10.1103/PHYSREVLETT.74.2626##ABE K, 2000, PHYS REV LETT, V84, P4300, DOI 10.1103/PHYSREVLETT.84.4300##ABULENCIA A, 2006, PHYS REV D, V74, DOI 10.1103/PHYSREVD.74.032009##ABULENCIA A, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.152002##ABULENCIA A, 2006, PHYS REV D, V73, DOI 10.1103/PHYSREVD.73.112006##ABULENCIA A, 2006, PHYS REV D, V73, DOI 10.1103/PHYSREVD.73.092002##ABULENCIA A, 2006, PHYS REV D, V73, DOI 10.1103/PHYSREVD.73.032003##ABULENCIA A, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.022004##AFFOLDER F, 2001, PHYS REV D, V63##BERENDS FA, 1991, NUCL PHYS B, V357, P32, DOI 10.1016/0550-3213(91)90458-A##BOWLER MG, 1981, Z PHYS C PART FIELDS, V11, P169, DOI 10.1007/BF01574001##HEISTER A, 2001, PHYS LETT B, V512, P30, DOI 10.1016/S0370-2693(01)00690-6##LAI HL, 2000, EUR PHYS J C, V12, P375, DOI 10.1007/S100529900196##LEPAGE GP, 1978, J COMPUT PHYS, V27, P192##LEPAGE GP, 1980, CORNELL PREPRINT CLN, P80##MAHLON G, 1997, PHYS LETT B, V411, P173, DOI 10.1016/S0370-2693(97)00987-8##MALTONI F, 2003, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2003/02/027##MANGANO ML, 2003, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2003/07/001##PETERSON C, 1983, PHYS REV D, V27, P105, DOI 10.1103/PHYSREVD.27.105##PUMPLIN J, 2002, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2002/07/012##SCHAEL S, 2006, PHYS REP, V427, P257, DOI 10.1016/J.PHYSREP.2005.12.006##SCHIEFERDECKER P, THESIS FERMILAB##SJOSTRAND T, 2001, COMPUT PHYS COMMUN, V135, P238, DOI 10.1016/S0010-4655(00)00236-8##YAO WM, 2006, J PHYS G NUCL PARTIC, V33, P1, DOI 10.1088/0954-3899/33/1/001",45,2020-11-20,"SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/D004284/1, PP/E000487/1] FUNDING SOURCE: RESEARCHFISH"
J,WOS:000242409700006,2006,MEASUREMENT OF THE CP-VIOLATION PARAMETER OF B-0 MIXING AND DECAY WITH P(P)OVER-BAR ->MU MU X DATA,"WE MEASURE THE DIMUON CHARGE ASYMMETRY A IN P (P) OVER BAR COLLISIONS AT A CENTER OF MASS ENERGY ROOT S=1960 GEV. THE DATA WAS RECORDED WITH THE D0 DETECTOR AND CORRESPONDS TO AN INTEGRATED LUMINOSITY OF APPROXIMATELY 1.0 FB(-1). ASSUMING THAT THE ASYMMETRY A IS DUE TO ASYMMETRIC B-0 <->(B) OVER BAR (0) MIXING AND DECAY, WE EXTRACT THE CP-VIOLATION PARAMETER OF B-0 MIXING AND DECAY: ((EPSILON B0))/(1+VERTICAL BAR EPSILON B0 VERTICAL BAR 2)=(AB0)/(4)= -0.0023 +/- 0.0011(STAT)+/- 0.0008(SYST).A(B)(0) IS THE DIMUON CHARGE ASYMMETRY FROM DECAYS OF B-0(B) OVER BAR (0) PAIRS. THE GENERAL CASE, WITH CP VIOLATION IN BOTH B-0 AND B-S(0) SYSTEMS, IS ALSO CONSIDERED. FINALLY WE OBTAIN THE FORWARD-BACKWARD ASYMMETRY THAT QUANTIFIES THE TENDENCY OF MU(+) TO GO IN THE PROTON DIRECTION AND MU(-) TO GO IN THE ANTIPROTON DIRECTION. THE RESULTS ARE CONSISTENT WITH THE STANDARD MODEL AND CONSTRAIN NEW PHYSICS.",PARTICLE PHYSICS; DETECTOR,NA,PHYSICAL REVIEW D,"ABAZOV, VM##ABBOTT, B##ABOLINS, M##ACHARYA, BS##ADAMS, M##ADAMS, T##AGELOU, M##AGUILO, E##AHN, SH##AHSAN, M##ALEXEEV, GD##ALKHAZOV, G##ALTON, A##ALVERSON, G##ALVES, GA##ANASTASOAIE, M##ANDEEN, T##ANDERSON, S##ANDRIEU, B##ANZELC, MS##ARNOUD, Y##AROV, M##ASKEW, A##ASMAN, B##JESUS, ACSA##ATRAMENTOV, O##AUTERMANN, C##AVILA, C##AY, C##BADAUD, F##BADEN, A##BAGBY, L##BALDIN, B##BANDURIN, DV##BANERJEE, P##BANERJEE, S##BARBERIS, E##BARGASSA, P##BARINGER, P##BARNES, C##BARRETO, J##BARTLETT, JF##BASSLER, U##BAUER, D##BEALE, S##BEAN, A##BEGALLI, M##BEGEL, M##BELANGER-CHAMPAGNE, C##BELLANTONI, L##BELLAVANCE, A##BENITEZ, JA##BERI, SB##BERNARDI, G##BERNHARD, R##BERNTZON, L##BERTRAM, I##BESANCON, M##BEUSELINCK, R##BEZZUBOV, VA##BHAT, PC##BHATNAGAR, V##BINDER, M##BISCARAT, C##BLACK, KM##BLACKLER, I##BLAZEY, G##BLEKMAN, F##BLESSING, S##BLOCH, D##BLOOM, K##BLUMENSCHEIN, U##BOEHNLEIN, A##BOERIU, O##BOLTON, TA##BORISSOV, G##BOS, K##BOSE, T##BRANDT, A##BROCK, R##BROOIJMANS, G##BROSS, A##BROWN, D##BUCHANAN, NJ##BUCHHOLZ, D##BUEHLER, M##BUESCHER, V##BURDIN, S##BURKE, S##BURNETT, TH##BUSATO, E##BUSZELLO, CP##BUTLER, JM##CALFAYAN, P##CALVET, S##CAMMIN, J##CARON, S##CARVALHO, W##CASEY, BCK##CASON, NM##CASTILLA-VALDEZ, H##CHAKRABARTI, S##CHAKRABORTY, D##CHAN, KM##CHANDRA, A##CHARLES, F##CHEU, E##CHEVALLIER, F##CHO, DK##CHOI, S##CHOUDHARY, B##CHRISTOFEK, L##CLAES, D##CLEMENT, B##COADOU, Y##COOKE, M##COOPER, WE##COPPAGE, D##CORCORAN, M##COUSINOU, MC##COX, B##CREPE-RENAUDIN, S##CUTTS, D##CWIOK, M##DA MOTTA, H##DAS, A##DAS, M##DAVIES, B##DAVIES, G##DAVIS, GA##DE, K##DE JONG, P##DE JONG, SJ##DE LA CRUZ-BURELO, E##MARTINS, CD##DEGENHARDT, JD##DELIOT, F##DEMARTEAU, M##DEMINA, R##DEMINE, P##DENISOV, D##DENISOV, SP##DESAI, S##DIEHL, HT##DIESBURG, M##DOIDGE, M##DOMINGUEZ, A##DONG, H##DUDKO, LV##DUFLOT, L##DUGAD, SR##DUGGAN, D##DUPERRIN, A##DYER, J##DYSHKANT, A##EADS, M##EDMUNDS, D##EDWARDS, T##ELLISON, J##ELMSHEUSER, J##ELVIRA, VD##ENO, S##ERMOLOV, P##EVANS, H##EVDOKIMOV, A##EVDOKIMOV, VN##FATAKIA, SN##FELIGIONI, L##FERAPONTOV, AV##FERBEL, T##FIEDLER, F##FILTHAUT, F##FISHER, W##FISK, HE##FLECK, I##FORD, M##FORTNER, M##FOX, H##FU, S##FUESS, S##GADFORT, T##GALEA, CF##GALLAS, E##GALYAEV, E##GARCIA, C##GARCIA-BELLIDO, A##GARDNER, J##GAVRILOV, V##GAY, A##GAY, P##GELE, D##GELHAUS, R##GERBER, CE##GERSHTEIN, Y##GILLBERG, D##GINTHER, G##GOLLUB, N##GOMEZ, B##GOUSSIOU, A##GRANNIS, PD##GREENLEE, H##GREENWOOD, ZD##GREGORES, EM##GRENIER, G##GRIS, P##GRIVAZ, JF##GRUNENDAHL, S##GRUNEWALD, MW##GUO, F##GUO, J##GUTIERREZ, G##GUTIERREZ, P##HAAS, A##HADLEY, NJ##HAEFNER, P##HAGOPIAN, S##HALEY, J##HALL, I##HALL, RE##HAN, L##HANAGAKI, K##HANSSON, P##HARDER, K##HAREL, A##HARRINGTON, R##HAUPTMAN, JM##HAUSER, R##HAYS, J##HEBBEKER, T##HEDIN, D##HEGEMAN, JG##HEINMILLER, JM##HEINSON, AP##HEINTZ, U##HENSEL, C##HERNER, K##HESKETH, G##HILDRETH, MD##HIROSKY, R##HOBBS, JD##HOENEISEN, B##HOETH, H##HOHLFELD, M##HONG, SJ##HOOPER, R##HOUBEN, P##HU, Y##HUBACEK, Z##HYNEK, V##IASHVILI, I##ILLINGWORTH, R##ITO, AS##JABEEN, S##JAFFRE, M##JAIN, S##JAKOBS, K##JARVIS, C##JENKINS, A##JESIK, R##JOHNS, K##JOHNSON, C##JOHNSON, M##JONCKHEERE, A##JONSSON, P##JUSTE, A##KAFER, D##KAHN, S##KAJFASZ, E##KALININ, AM##KALK, JM##KALK, JR##KAPPLER, S##KARMANOV, D##KASPER, J##KASPER, P##KATSANOS, I##KAU, D##KAUR, R##KEHOE, R##KERMICHE, S##KHALATYAN, N##KHANOV, A##KHARCHILAVA, A##KHARZHEEV, YM##KHATIDZE, D##KIM, H##KIM, TJ##KIRBY, MH##KLIMA, B##KOHLI, JM##KONRATH, JP##KOPAL, M##KORABLEV, VM##KOTCHER, J##KOTHARI, B##KOUBAROVSKY, A##KOZELOV, AV##KROP, D##KRYEMADHI, A##KUHL, T##KUMAR, A##KUNORI, S##KUPCO, A##KURCA, T##KVITA, J##LAMMERS, S##LANDSBERG, G##LAZOFLORES, J##LE BIHAN, AC##LEBRUN, P##LEE, WM##LEFLAT, A##LEHNER, F##LESNE, V##LEVEQUE, J##LEWIS, P##LI, J##LI, QZ##LIMA, JGR##LINCOLN, D##LINNEMANN, J##LIPAEV, VV##LIPTON, R##LIU, Z##LOBO, L##LOBODENKO, A##LOKAJICEK, M##LOUNIS, A##LOVE, P##LUBATTI, HJ##LYNKER, M##LYON, AL##MACIEL, AKA##MADARAS, RJ##MATTIG, P##MAGASS, C##MAGERKURTH, A##MAGNAN, AM##MAKOVEC, N##MAL, PK##MALBOUISSON, HB##MALIK, S##MALYSHEV, VL##MAO, HS##MARAVIN, Y##MARTENS, M##MCCARTHY, R##MEDER, D##MELNITCHOUK, A##MENDES, A##MENDOZA, L##MERKIN, M##MERRITT, KW##MEYER, A##MEYER, J##MICHAUT, M##MIETTINEN, H##MILLET, T##MITREVSKI, J##MOLINA, J##MONDAL, NK##MONK, J##MOORE, RW##MOULIK, T##MUANZA, GS##MULDERS, M##MULHEARN, M##MUNDAL, O##MUNDIM, L##MUTAF, YD##NAGY, E##NAIMUDDIN, M##NARAIN, M##NAUMANN, NA##NEAL, HA##NEGRET, JP##NEUSTROEV, P##NOEDING, C##NOMEROTSKI, A##NOVAES, SF##NUNNEMANN, T##O'DELL, V##O'NEIL, DC##OBRANT, G##OGURI, V##OLIVEIRA, N##ONOPRIENKO, D##OSHIMA, N##OTEC, R##GARZON, GJOY##OWEN, M##PADLEY, P##PARASHAR, N##PARK, SJ##PARK, SK##PARSONS, J##PARTRIDGE, R##PARUA, N##PATWA, A##PAWLOSKI, G##PEREA, PM##PEREZ, E##PETERS, K##PETROFF, P##PETTENI, M##PIEGAIA, R##PIPER, J##PLEIER, MA##PODESTA-LERMA, PLM##PODSTAVKOV, VM##POGORELOV, Y##POL, ME##POMPOS, A##POPE, BG##POPOV, AV##POTTER, C##DA SILVA, WLP##PROSPER, HB##PROTOPOPESCU, S##QIAN, J##QUADT, A##QUINN, B##RANGEL, MS##RANI, KJ##RANJAN, K##RATOFF, PN##RENKEL, P##REUCROFT, S##RIJSSENBEEK, M##RIPP-BAUDOT, I##RIZATDINOVA, F##ROBINSON, S##RODRIGUES, RF##ROYON, C##RUBINOV, P##RUCHTI, R##RUD, VI##SAJOT, G##SANCHEZ-HERNANDEZ, A##SANDERS, MP##SANTORO, A##SAVAGE, G##SAWYER, L##SCANLON, T##SCHAILE, D##SCHAMBERGER, RD##SCHEGLOV, Y##SCHELLMAN, H##SCHIEFERDECKER, P##SCHMITT, C##SCHWANENBERGER, C##SCHWARTZMAN, A##SCHWIENHORST, R##SEKARIC, J##SENGUPTA, S##SEVERINI, H##SHABALINA, E##SHAMIM, M##SHARY, V##SHCHUKIN, AA##SHEPHARD, WD##SHIVPURI, RK##SHPAKOV, D##SICCARDI, V##SIDWELL, RA##SIMAK, V##SIROTENKO, V##SKUBIC, P##SLATTERY, P##SMITH, RP##SNOW, GR##SNOW, J##SNYDER, S##SOLDNER-REMBOLD, S##SONG, X##SONNENSCHEIN, L##SOPCZAK, A##SOSEBEE, M##SOUSTRUZNIK, K##SOUZA, M##SPURLOCK, B##STARK, J##STEELE, J##STOLIN, V##STONE, A##STOYANOVA, DA##STRANDBERG, J##STRANDBERG, S##STRANG, MA##STRAUSS, M##STROHMER, R##STROM, D##STROVINK, M##STUTTE, L##SUMOWIDAGDO, S##SVOISKY, P##SZNAJDER, A##TALBY, M##TAMBURELLO, P##TAYLOR, W##TELFORD, P##TEMPLE, J##TILLER, B##TITOV, M##TOKMENIN, VV##TOMOTO, M##TOOLE, T##TORCHIANI, I##TOWERS, S##TREFZGER, T##TRINCAZ-DUVOID, S##TSYBYCHEV, D##TUCHMING, B##TULLY, C##TURCOT, AS##TUTS, PM##UNALAN, R##UVAROV, L##UVAROV, S##UZUNYAN, S##VACHON, B##VAN DEN BERG, PJ##VAN KOOTEN, R##VAN LEEUWEN, WM##VARELAS, N##VARNES, EW##VARTAPETIAN, A##VASILYEV, IA##VAUPEL, M##VERDIER, P##VERTOGRADOV, LS##VERZOCCHI, M##VILLENEUVE-SEGUIER, F##VINT, P##VLIMANT, JR##VON TOERNE, E##VOUTILAINEN, M##VREESWIJK, M##WAHL, HD##WANG, L##WANG, MHLS##WARCHOL, J##WATTS, G##WAYNE, M##WEBER, G##WEBER, M##WEERTS, H##WERMES, N##WETSTEIN, M##WHITE, A##WICKE, D##WILSON, GW##WIMPENNY, SJ##WOBISCH, M##WOMERSLEY, J##WOOD, DR##WYATT, TR##XIE, Y##XUAN, N##YACOOB, S##YAMADA, R##YAN, M##YASUDA, T##YATSUNENKO, YA##YIP, K##YOO, HD##YOUN, SW##YU, C##YU, J##YURKEWICZ, A##ZATSERKLYANIY, A##ZEITNITZ, C##ZHANG, D##ZHAO, T##ZHOU, B##ZHU, J##ZIELINSKI, M##ZIEMINSKA, D##ZIEMINSKI, A##ZUTSHI, V##ZVEREV, EG","UNIV BUENOS AIRES, BUENOS AIRES, DF, ARGENTINA. CTR BRASILEIRO PESQUISAS FIS, LAFEX, RIO DE JANEIRO, BRAZIL. UNIV ESTADO RIO DE JANEIRO, RIO DE JANEIRO, BRAZIL. UNIV ESTADUAL PAULISTA, INST FIS TEOR, BR-01405 SAO PAULO, BRAZIL. SIMON FRASER UNIV, BURNABY, BC V5A 1S6, CANADA. UNIV ALBERTA, EDMONTON, AB, CANADA. UNIV SCI & TECHNOL CHINA, HEFEI 230026, PEOPLES R CHINA. UNIV LOS ANDES, BOGOTA, COLOMBIA. CHARLES UNIV PRAGUE, CTR PARTICLE PHYS, PRAGUE, CZECH REPUBLIC. CZECH TECH UNIV, CR-16635 PRAGUE, CZECH REPUBLIC. ACAD SCI CZECH REPUBL, INST PHYS, CTR PARTICLE PHYS, PRAGUE, CZECH REPUBLIC. UNIV SAN FRANCISCO QUITO, QUITO, ECUADOR. UNIV CLERMONT FERRAND, CNRS, IN2P3, PHYS CORPUSCULAIRE LAB, CLERMONT FERRAND, FRANCE. UNIV GRENOBLE 1, CNRS, IN2P3, LAB PHYS SUBATOM & COSMOL, GRENOBLE, FRANCE. UNIV MEDITERRANEE, CNRS, CPPM, IN2P3, MARSEILLE, FRANCE. CNRS, ACCELERATEUR LINEAIRE LAB, IN2P3, F-91405 ORSAY, FRANCE. UNIV PARIS 06, CNRS, IN2P3, LPHNE, PARIS, FRANCE. UNIV PARIS 07, PARIS, FRANCE. CEA, SERV PHYS PARTICULES, DAPNIA, SACLAY, FRANCE. UNIV HAUTE ALSACE, MULHOUSE, FRANCE. UNIV STRASBOURG, CNRS, IPHC, IN2P3, STRASBOURG, FRANCE. UNIV LYON 1, CNRS, IN2P3, INST PHYS NUCL LYON, F-69622 VILLEURBANNE, FRANCE. RHEIN WESTFAL TH AACHEN, INST PHYS A 3, D-5100 AACHEN, GERMANY. UNIV BONN, INST PHYS, BONN, GERMANY. UNIV FREIBURG, INST PHYS, FREIBURG, GERMANY. JOHANNES GUTENBERG UNIV MAINZ, INST PHYS, D-6500 MAINZ, GERMANY. UNIV MUNICH, MUNICH, GERMANY. UNIV WUPPERTAL, FACHBEREICH PHYS, WUPPERTAL, GERMANY. PANJAB UNIV, CHANDIGARH 160014, INDIA. UNIV DELHI, DELHI 110007, INDIA. TATA INST FUNDAMENTAL RES, BOMBAY 400005, MAHARASHTRA, INDIA. UNIV COLL DUBLIN, DUBLIN 2, IRELAND. KOREA UNIV, KOREA DETECTOR LAB, SEOUL 136701, SOUTH KOREA. SUNGKYUNKWAN UNIV, SUWON, SOUTH KOREA. CINVESTAV, MEXICO CITY 14000, DF, MEXICO. UNIV AMSTERDAM, NIKHEF, AMSTERDAM, NETHERLANDS. NIKHEF, FOM INST, AMSTERDAM, NETHERLANDS. RADBOUD UNIV NIJMEGEN, NIKHEF, NIJMEGEN, NETHERLANDS. JOINT INST NUCL RES, DUBNA, RUSSIA. INST THEORET & EXPT PHYS, MOSCOW, RUSSIA. MOSCOW MV LOMONOSOV STATE UNIV, MOSCOW, RUSSIA. INST HIGH ENERGY PHYS, PROTVINO, RUSSIA. PETERSBURG NUCL PHYS INST, ST PETERSBURG, RUSSIA. LUND UNIV, LUND, SWEDEN. ROYAL INST TECHNOL, STOCKHOLM, SWEDEN. UNIV STOCKHOLM, STOCKHOLM, SWEDEN. UPPSALA UNIV, UPPSALA, SWEDEN. UNIV ZURICH, INST PHYS, ZURICH, SWITZERLAND. UNIV LANCASTER, LANCASTER, ENGLAND. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON, ENGLAND. UNIV MANCHESTER, MANCHESTER, LANCS, ENGLAND. UNIV ARIZONA, TUCSON, AZ 85721 USA. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA. CALIF STATE UNIV FRESNO, FRESNO, CA 93740 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. FLORIDA STATE UNIV, TALLAHASSEE, FL 32306 USA. FERMILAB NATL ACCELERATOR LAB, BATAVIA, IL 60510 USA. UNIV ILLINOIS, CHICAGO, IL 60607 USA. NO ILLINOIS UNIV, DE KALB, IL 60115 USA. NORTHWESTERN UNIV, EVANSTON, IL 60208 USA. INDIANA UNIV, BLOOMINGTON, IN 47405 USA. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. PURDUE UNIV CALUMET, HAMMOND, IN 46323 USA. IOWA STATE UNIV, AMES, IA 50011 USA. UNIV KANSAS, LAWRENCE, KS 66045 USA. KANSAS STATE UNIV, MANHATTAN, KS 66506 USA. LOUISIANA TECH UNIV, RUSTON, LA 71272 USA. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. BOSTON UNIV, BOSTON, MA 02215 USA. NORTHEASTERN UNIV, BOSTON, MA 02115 USA. UNIV MICHIGAN, ANN ARBOR, MI 48109 USA. MICHIGAN STATE UNIV, E LANSING, MI 48824 USA. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV NEBRASKA, LINCOLN, NE 68588 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. SUNY BUFFALO, BUFFALO, NY 14260 USA. COLUMBIA UNIV, NEW YORK, NY 10027 USA. UNIV ROCHESTER, ROCHESTER, NY 14627 USA. SUNY STONY BROOK, STONY BROOK, NY 11794 USA. BROOKHAVEN NATL LAB, UPTON, NY 11973 USA. LANGSTON UNIV, LANGSTON, OK 73050 USA. UNIV OKLAHOMA, NORMAN, OK 73019 USA. OKLAHOMA STATE UNIV, STILLWATER, OK 74078 USA. BROWN UNIV, PROVIDENCE, RI 02912 USA. UNIV TEXAS, ARLINGTON, TX 76019 USA. SO METHODIST UNIV, DALLAS, TX 75275 USA. RICE UNIV, HOUSTON, TX 77005 USA. UNIV VIRGINIA, CHARLOTTESVILLE, VA 22901 USA. UNIV WASHINGTON, SEATTLE, WA 98195 USA.","ASTRONOMY & ASTROPHYSICS; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"ABACHI S, 1994, NUCL INSTRUM METH A, V338, P185, DOI 10.1016/0168-9002(94)91312-9##ABAZOV V, HEPPHYSICS0503151##ABAZOV VM, 2006, NUCL INSTRUM METH A, V565, P463, DOI 10.1016/J.NIMA.2006.05.248##ABBOTT B, 2000, PHYS REV LETT, V84, P5478, DOI 10.1103/PHYSREVLETT.84.5478##AUBERT B, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.251802##BRUN R, 1994, W5013 CERN PROGR LIB, P75006##BURAS AJ, 1984, NUCL PHYS B, V245, P369, DOI 10.1016/0550-3213(84)90437-1##EIDELMAN S, 2004, PHYS LETT B, V592, P1, DOI 10.1016/J.PHYSLETB.2004.06.001##HEWETT JL, HEPPH9803370##NAKANO E, 2006, PHYS REV D, V73, DOI 10.1103/PHYSREVD.73.112002##RANDALL L, 1999, NUCL PHYS B, V540, P37, DOI 10.1016/S0550-3213(98)00766-4##SJOSTRAND T, 2001, LUTP0121##YAO WM, 2006, J PHYS G NUCL PARTIC, V33, P1, DOI 10.1088/0954-3899/33/1/001",51,2020-11-20,"SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/D004284/1, PP/E000487/1] FUNDING SOURCE: RESEARCHFISH"
J,WOS:000242409700002,2006,PRECISE BRANCHING RATIO MEASUREMENTS OF THE DECAYS D-0 ->PI(-)PI(+)PI(0) AND D-0 -> K-K+PI(0) RELATIVE TO THE D-0 -> K-PI(+)PI(0) DECAY,"USING 232 FB(-1) OF E(+)E(-) COLLISION DATA RECORDED BY THE BABAR EXPERIMENT, WE MEASURE THE RATES OF THREE-BODY CABIBBO-SUPPRESSED DECAYS OF THE D-0 MESON RELATIVE TO THE CABIBBO-FAVORED DECAY, D-0 -> K-PI(+)PI(0). WE FIND: (B(D0 ->PI-PI+PI 0))/(B(D0 -> K-PI+PI 0))=(10.59 +/- 0.06 +/- 0.13)X10(-2) AND (B(D0 -> K-K+PI 0))/(B(D0 -> K-PI+PI 0))=(2.37 +/- 0.03 +/- 0.04)X10(-2), WHERE THE ERRORS ARE STATISTICAL AND SYSTEMATIC, RESPECTIVELY. THESE MEASUREMENTS ARE SIGNIFICANTLY MORE PRECISE THAN THE CURRENT WORLD AVERAGE MEASUREMENTS.",NA,NA,PHYSICAL REVIEW D,"AUBERT, B##BARATE, R##BONA, M##BOUTIGNY, D##COUDERC, F##KARYOTAKIS, Y##LEES, JP##POIREAU, V##TISSERAND, V##ZGHICHE, A##GRAUGES, E##PALANO, A##CHEN, JC##QI, ND##RONG, G##WANG, P##ZHU, YS##EIGEN, G##OFTE, I##STUGU, B##ABRAMS, GS##BATTAGLIA, M##BROWN, DN##BUTTON-SHAFER, J##CAHN, RN##CHARLES, E##GILL, MS##GROYSMAN, Y##JACOBSEN, RG##KADYK, JA##KERTH, LT##KOLOMENSKY, YG##KUKARTSEV, G##LYNCH, G##MIR, LM##ORIMOTO, TJ##PRIPSTEIN, M##ROE, NA##RONAN, MT##WENZEL, WA##SANCHEZ, PD##BARRETT, M##FORD, KE##HARRISON, TJ##HART, AJ##HAWKES, CM##MORGAN, SE##WATSON, AT##HELD, T##KOCH, H##LEWANDOWSKI, B##PELIZAEUS, M##PETERS, K##SCHROEDER, T##STEINKE, M##BOYD, JT##BURKE, JP##COTTINGHAM, WN##WALKER, D##CUHADAR-DONSZELMANN, T##FULSOM, BG##HEARTY, C##KNECHT, NS##MATTISON, TS##MCKENNA, JA##KHAN, A##KYBERD, P##SALEEM, M##SHERWOOD, DJ##TEODORESCU, L##BLINOV, VE##BUKIN, AD##DRUZHININ, VP##GOLUBEV, VB##ONUCHIN, AP##SEREDNYAKOV, SI##SKOVPEN, YI##SOLODOV, EP##TODYSHEV, KY##BEST, DS##BONDIOLI, M##BRUINSMA, M##CHAO, M##CURRY, S##ESCHRICH, I##KIRKBY, D##LANKFORD, AJ##LUND, P##MANDELKERN, M##MOMMSEN, RK##ROETHEL, W##STOKER, DP##ABACHI, S##BUCHANAN, C##FOULKES, SD##GARY, JW##LONG, O##SHEN, BC##WANG, K##ZHANG, L##HADAVAND, HK##HILL, EJ##PAAR, HP##RAHATLOU, S##SHARMA, V##BERRYHILL, JW##CAMPAGNARI, C##CUNHA, A##DAHMES, B##HONG, TM##KOVALSKYI, D##RICHMAN, JD##BECK, TW##EISNER, AM##FLACCO, CJ##HEUSCH, CA##KROSEBERG, J##LOCKMAN, WS##NESOM, G##SCHALK, T##SCHUMM, BA##SEIDEN, A##SPRADLIN, P##WILLIAMS, DC##WILSON, MG##ALBERT, J##CHEN, E##DVORETSKII, A##FANG, F##HITLIN, DG##NARSKY, I##PIATENKO, T##PORTER, FC##RYD, A##SAMUEL, A##MANCINELLI, G##MEADOWS, BT##MISHRA, K##SOKOLOFF, MD##BLANC, F##BLOOM, PC##CHEN, S##FORD, WT##HIRSCHAUER, JF##KREISEL, A##NAGEL, M##NAUENBERG, U##OLIVAS, A##RUDDICK, WO##SMITH, JG##ULMER, KA##WAGNER, SR##ZHANG, J##CHEN, A##ECKHART, EA##SOFFER, A##TOKI, WH##WILSON, RJ##WINKLMEIER, F##ZENG, Q##ALTENBURG, DD##FELTRESI, E##HAUKE, A##JASPER, H##PETZOLD, A##SPAAN, B##BRANDT, T##KLOSE, V##LACKER, HM##MADER, WF##NOGOWSKI, R##SCHUBERT, J##SCHUBERT, KR##SCHWIERZ, R##SUNDERMANN, JE##VOLK, A##BERNARD, D##BONNEAUD, GR##GRENIER, P##LATOUR, E##THIEBAUX, C##VERDERI, M##CLARK, PJ##GRADL, W##MUHEIM, F##PLAYFER, S##ROBERTSON, AI##XIE, Y##ANDREOTTI, M##BETTONI, D##BOZZI, C##CALABRESE, R##CIBINETTO, G##LUPPI, E##NEGRINI, M##PETRELLA, A##PIEMONTESE, L##PRENCIPE, E##ANULLI, F##BALDINI-FERROLI, R##CALCATERRA, A##DE SANGRO, R##FINOCCHIARO, G##PACETTI, S##PATTERI, P##PERUZZI, IM##PICCOLO, M##RAMA, M##ZALLO, A##BUZZO, A##CAPRA, R##CONTRI, R##LO VETERE, M##MACRI, MM##MONGE, MR##PASSAGGIO, S##PATRIGNANI, C##ROBUTTI, E##SANTRONI, A##TOSI, S##BRANDENBURG, G##CHAISANGUANTHUM, KS##MORII, M##WU, J##DUBITZKY, RS##MARKS, J##SCHENK, S##UWER, U##BARD, DJ##BHIMJI, W##BOWERMAN, DA##DAUNCEY, PD##EGEDE, U##FLACK, RL##NASH, JA##NIKOLICH, MB##VAZQUEZ, WP##BEHERA, PK##CHAI, X##CHARLES, MJ##MALLIK, U##MEYER, NT##ZIEGLER, V##COCHRAN, J##CRAWLEY, HB##DONG, L##EYGES, V##MEYER, WT##PRELL, S##ROSENBERG, EI##RUBIN, AE##GRITSAN, AV##DENIG, AG##FRITSCH, M##SCHOTT, G##ARNAUD, N##DAVIER, M##GROSDIDIER, G##HOCKER, A##LE DIBERDER, F##LEPELTIER, V##LUTZ, AM##OYANGUREN, A##PRUVOT, S##RODIER, S##ROUDEAU, P##SCHUNE, MH##STOCCHI, A##WANG, WF##WORMSER, G##CHENG, CH##LANGE, DJ##WRIGHT, DM##CHAVEZ, CA##FORSTER, IJ##FRY, JR##GABATHULER, E##GAMET, R##GEORGE, KA##HUTCHCROFT, DE##PAYNE, DJ##SCHOFIELD, KC##TOURAMANIS, C##BEVAN, AJ##DI LODOVICO, F##MENGES, W##SACCO, R##COWAN, G##FLAECHER, HU##HOPKINS, DA##JACKSON, PS##MCMAHON, TR##RICCIARDI, S##SALVATORE, F##WREN, AC##BROWN, DN##DAVIS, CL##ALLISON, J##BARLOW, NR##BARLOW, RJ##CHIA, YM##EDGAR, CL##LAFFERTY, GD##NAISBIT, MT##WILLIAMS, JC##YI, JI##CHEN, C##HULSBERGEN, WD##JAWAHERY, A##LAE, CK##ROBERTS, DA##SIMI, G##BLAYLOCK, G##DALLAPICCOLA, C##HERTZBACH, SS##LI, X##MOORE, TB##SAREMI, S##STAENGLE, H##COWAN, R##SCIOLLA, G##SEKULA, SJ##SPITZNAGEL, M##TAYLOR, F##YAMAMOTO, RK##KIM, H##MCLACHLIN, SE##PATEL, PM##ROBERTSON, SH##LAZZARO, A##LOMBARDO, V##PALOMBO, F##BAUER, JM##CREMALDI, L##ESCHENBURG, V##GODANG, R##KROEGER, R##SANDERS, DA##SUMMERS, DJ##ZHAO, HW##BRUNET, S##COTE, D##SIMARD, M##TARAS, P##VIAUD, FB##NICHOLSON, H##CAVALLO, N##DE NARDO, G##FABOZZI, F##GATTO, C##LISTA, L##MONORCHIO, D##PAOLUCCI, P##PICCOLO, D##SCIACCA, C##BAAK, M##RAVEN, G##SNOEK, HL##JESSOP, CP##LOSECCO, JM##ALLMENDINGER, T##BENELLI, G##GAN, KK##HONSCHEID, K##HUFNAGEL, D##JACKSON, PD##KAGAN, H##KASS, R##RAHIMI, AM##TER-ANTONYAN, R##WONG, QK##BLOUNT, NL##BRAU, J##FREY, R##IGONKINA, O##LU, M##RAHMAT, R##SINEV, NB##STROM, D##STRUBE, J##TORRENCE, E##GAZ, A##MARGONI, M##MORANDIN, M##POMPILI, A##POSOCCO, M##ROTONDO, M##SIMONETTO, F##STROILI, R##VOCI, C##BENAYOUN, M##CHAUVEAU, J##BRIAND, H##DAVID, P##DEL BUONO, L##LA VAISSIERE, C##HAMON, O##HARTFIEL, BL##JOHN, MJJ##LERUSTE, P##MALCLES, J##OCARIZ, J##ROOS, L##THERIN, G##GLADNEY, L##PANETTA, J##BIASINI, M##COVARELLI, R##ANGELINI, C##BATIGNANI, G##BETTARINI, S##BUCCI, F##CALDERINI, G##CARPINELLI, M##CENCI, R##FORTI, F##GIORGI, MA##LUSIANI, A##MARCHIORI, G##MAZUR, MA##MORGANTI, M##NERI, N##PAOLONI, E##RIZZO, G##WALSH, JJ##HAIRE, M##JUDD, D##WAGONER, DE##BIESIADA, J##DANIELSON, N##ELMER, P##LAU, YP##LU, C##OLSEN, J##SMITH, AJS##TELNOV, AV##BELLINI, F##CAVOTO, G##D'ORAZIO, A##DEL RE, D##DI MARCO, E##FACCINI, R##FERRAROTTO, F##FERRONI, F##GASPERO, M##GIOI, LL##MAZZONI, MA##MORGANTI, S##PIREDDA, G##POLCI, F##TEHRANI, FS##VOENA, C##EBERT, M##SCHRODER, H##WALDI, R##ADYE, T##DE GROOT, N##FRANEK, B##OLAIYA, EO##WILSON, FF##ALEKSAN, R##EMERY, S##GAIDOT, A##GANZHUR, SF##DE MONCHENAULT, GH##KOZANECKI, W##LEGENDRE, M##VASSEUR, G##YECHE, C##ZITO, M##CHEN, XR##LIU, H##PARK, W##PUROHIT, MV##WILSON, JR##ALLEN, MT##ASTON, D##BARTOLDUS, R##BECHTLE, P##BERGER, N##CLAUS, R##COLEMAN, JP##CONVERY, MR##CRISTINZIANI, M##DINGFELDER, JC##DORFAN, J##DUBOIS-FELSMANN, GP##DUJMIC, D##DUNWOODIE, W##FIELD, RC##GLANZMAN, T##GOWDY, SJ##GRAHAM, MT##HALYO, V##HAST, C##HRYN'OVA, T##INNES, WR##KELSEY, MH##KIM, P##LEITH, DWGS##LI, S##LUITZ, S##LUTH, V##LYNCH, HL##MACFARLANE, DB##MARSISKE, H##MESSNER, R##MULLER, DR##O'GRADY, CP##OZCAN, VE##PERAZZO, A##PERL, M##PULLIAM, T##RATCLIFF, BN##ROODMAN, A##SALNIKOV, AA##SCHINDLER, RH##SCHWIENING, J##SNYDER, A##STELZER, J##SU, D##SULLIVAN, MK##SUZUKI, K##SWAIN, SK##THOMPSON, JM##VA'VRA, J##VAN BAKEL, N##WEAVER, M##WEINSTEIN, AJR##WISNIEWSKI, WJ##WITTGEN, M##WRIGHT, DH##YARRITU, AK##YI, K##YOUNG, CC##BURCHAT, PR##EDWARDS, AJ##MAJEWSKI, SA##PETERSEN, BA##ROAT, C##WILDEN, L##AHMED, S##ALAM, MS##BULA, R##ERNST, JA##JAIN, V##PAN, B##SAEED, MA##WAPPLER, FR##ZAIN, SB##BUGG, W##KRISHNAMURTHY, M##SPANIER, SM##ECKMANN, R##RITCHIE, JL##SATPATHY, A##SCHILLING, CJ##SCHWITTERS, RF##IZEN, JM##LOU, XC##YE, S##BIANCHI, F##GALLO, F##GAMBA, D##BOMBEN, M##BOSISIO, L##CARTARO, C##COSSUTTI, F##DELLA RICCA, G##DITTONGO, S##LANCERI, L##VITALE, L##AZZOLINI, V##MARTINEZ-VIDAL, F##BANERJEE, S##BHUYAN, B##BROWN, CM##FORTIN, D##HAMANO, K##KOWALEWSKI, R##NUGENT, IM##RONEY, JM##SOBIE, RJ##BACK, JJ##HARRISON, PF##LATHAM, TE##MOHANTY, GB##PAPPAGALLO, M##BAND, HR##CHEN, X##CHENG, B##DASU, S##DATTA, M##FLOOD, KT##HOLLAR, JJ##KUTTER, PE##MELLADO, B##MIHALYI, A##PAN, Y##PIERINI, M##PREPOST, R##WU, SL##YU, Z##NEAL, H","LAB ANNECY LE VIEUX PHYS PARTICULES, F-74941 ANNECY LE VIEUX, FRANCE. UNIV BARCELONA, FAC FIS, DEPT ECM, E-08028 BARCELONA, SPAIN. UNIV BARI, DIPARTIMENTO FIS, I-70126 BARI, ITALY. IST NAZL FIS NUCL, I-70126 BARI, ITALY. INST HIGH ENERGY PHYS, BEIJING 100039, PEOPLES R CHINA. UNIV BERGEN, INST PHYS, N-5007 BERGEN, NORWAY. LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. RUHR UNIV BOCHUM, INST EXPT PHYS 1, D-44780 BOCHUM, GERMANY. UNIV BRISTOL, BRISTOL BS8 1TL, AVON, ENGLAND. UNIV BRITISH COLUMBIA, VANCOUVER, BC V6T 1Z1, CANADA. BRUNEL UNIV, UXBRIDGE UB8 3PH, MIDDX, ENGLAND. BUDKER INST NUCL PHYS, NOVOSIBIRSK 630090, RUSSIA. UNIV CALIF IRVINE, IRVINE, CA 92697 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA. UNIV CALIF SANTA BARBARA, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA CRUZ, INST PARTICLE PHYS, SANTA CRUZ, CA 95064 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CINCINNATI, CINCINNATI, OH 45221 USA. UNIV COLORADO, BOULDER, CO 80309 USA. COLORADO STATE UNIV, FT COLLINS, CO 80523 USA. UNIV DORTMUND, INST PHYS, D-44221 DORTMUND, GERMANY. TECH UNIV DRESDEN, INST KERN & TEILCHENPHYS, D-01062 DRESDEN, GERMANY. ECOLE POLYTECH, LAB LEPRINCE RINGUET, F-91128 PALAISEAU, FRANCE. UNIV EDINBURGH, EDINBURGH EH9 3JZ, MIDLOTHIAN, SCOTLAND. UNIV FERRARA, DIPARTIMENTO FIS, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, LAB NAZL FRASCATI, I-00044 FRASCATI, ITALY. UNIV GENOA, DIPARTIMENTO FIS, I-16146 GENOA, ITALY. IST NAZL FIS NUCL, I-16146 GENOA, ITALY. HARVARD UNIV, CAMBRIDGE, MA 02138 USA. HEIDELBERG UNIV, INST PHYS, D-69120 HEIDELBERG, GERMANY. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AZ, ENGLAND. UNIV IOWA, IOWA CITY, IA 52242 USA. IOWA STATE UNIV, AMES, IA 50011 USA. JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA. UNIV KARLSRUHE, INST EXPT KERNPHYS, D-76021 KARLSRUHE, GERMANY. IN2P3, LAB ACCELERATEUR LINEAIRE, CNRS, F-91898 ORSAY, FRANCE. UNIV PARIS 11, CTR SCI ORSAY, F-91898 ORSAY, FRANCE. LAWRENCE LIVERMORE NATL LAB, LIVERMORE, CA 94550 USA. UNIV LIVERPOOL, LIVERPOOL L69 7ZE, MERSEYSIDE, ENGLAND. QUEEN MARY UNIV LONDON, LONDON E1 4NS, ENGLAND. UNIV LONDON ROYAL HOLLOWAY & BEDFORD NEW COLL, EGHAM TW20 0EX, SURREY, ENGLAND. UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA. UNIV MANCHESTER, MANCHESTER M13 9PL, LANCS, ENGLAND. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. UNIV MASSACHUSETTS, AMHERST, MA 01003 USA. MIT, NUCL SCI LAB, CAMBRIDGE, MA 02139 USA. MCGILL UNIV, MONTREAL, PQ H3A 2T8, CANADA. UNIV MILAN, DIPARTIMENTO FIS, I-20133 MILAN, ITALY. IST NAZL FIS NUCL, DIPARTIMENTO FIS, I-20133 MILAN, ITALY. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV MONTREAL, MONTREAL, PQ H3C 3J7, CANADA. MT HOLYOKE COLL, S HADLEY, MA 01075 USA. UNIV NAPLES FEDERICO II, DIPARTIMENTO SCI FIS, I-80126 NAPLES, ITALY. IST NAZL FIS NUCL, DIPARTIMENTO SCI FIS, I-80126 NAPLES, ITALY. NIKHEF H, NATL INST NUCL PHYS, AMSTERDAM, NETHERLANDS. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. UNIV OREGON, EUGENE, OR 97403 USA. UNIV PADUA, DIPARTIMENTO FIS, PADUA, ITALY. IST NAZL FIS NUCL, I-35131 PADUA, ITALY. UNIV PARIS 06, LAB PHYS NUCL & HAUTES ENERGIES, F-75252 PARIS, FRANCE. UNIV PARIS 07, LAB PHYS NUCL & HAUTES ENERGIES, F-75252 PARIS, FRANCE. UNIV PENN, PHILADELPHIA, PA 19104 USA. UNIV PERUGIA, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. IST NAZL FIS NUCL, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. UNIV PISA, DIPARTIMENTO FIS, SCUOLA NORMALE SUPER PISA, I-56127 PISA, ITALY. IST NAZL FIS NUCL, I-56127 PISA, ITALY. PRAIRIE VIEW A&M UNIV, PRAIRIE VIEW, TX 77446 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. UNIV ROMA LA SAPIENZA, DIPARTIMENTO FIS, I-00185 ROME, ITALY. IST NAZL FIS NUCL, I-00185 ROME, ITALY. UNIV ROSTOCK, D-18051 ROSTOCK, GERMANY. RUTHERFORD APPLETON LAB, DIDCOT OX11 0QX, OXON, ENGLAND. CEA SACLAY, DSM DAPNIA, F-91191 GIF SUR YVETTE, FRANCE. UNIV S CAROLINA, COLUMBIA, SC 29208 USA. STANFORD LINEAR ACCELERATOR CTR, STANFORD, CA 94309 USA. STANFORD UNIV, STANFORD, CA 94305 USA. SUNY ALBANY, ALBANY, NY 12222 USA. UNIV TENNESSEE, KNOXVILLE, TN 37996 USA. UNIV TEXAS, AUSTIN, TX 78712 USA. UNIV TEXAS, RICHARDSON, TX 75083 USA. UNIV TURIN, DIPARTIMENTO FIS SPERIMENTALE, TURIN, ITALY. IST NAZL FIS NUCL, TURIN, ITALY. UNIV TRIESTE, DIPARTIMENTO FIS, I-34127 TRIESTE, ITALY. IST NAZL FIS NUCL, I-34127 TRIESTE, ITALY. UNIV VALENCIA, CSIC, IFIC, E-46071 VALENCIA, SPAIN. UNIV VICTORIA, VICTORIA, BC V8W 3P6, CANADA. UNIV WARWICK, DEPT PHYS, WARWICK CV4 7AL, COVENTRY, ENGLAND. UNIV WISCONSIN, MADISON, WI 53706 USA. YALE UNIV, NEW HAVEN, CT 06511 USA.","ASTRONOMY & ASTROPHYSICS; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"AGOSTINELLI S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8##ASNER DM, 1996, PHYS REV D, V54, P4211, DOI 10.1103/PHYSREVD.54.4211##AUBERT B, 2002, NUCL INSTRUM METH A, V479, P1, DOI 10.1016/S0168-9002(01)02012-5##BALTRUSAITIS RM, 1985, PHYS REV LETT, V55, P150, DOI 10.1103/PHYSREVLETT.55.150##BARACCHINI E, 2006, PHYS LETT B, V633, P309, DOI 10.1016/J.PHYSLETB.2005.11.072##BARBERIO E, 1994, COMPUT PHYS COMMUN, V79, P291, DOI 10.1016/0010-4655(94)90074-4##CAWLFIELD C, 2006, PHYS REV D, V74, DOI 10.1103/PHYSREVD.74.031108##DALITZ RH, 1953, PHILOS MAG, V44, P1068##RUBIN P, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.081802##SJOSTRAND T, 2001, COMPUT PHYS COMMUN, V135, P238, DOI 10.1016/S0010-4655(00)00236-8##YAO WM, 2006, J PHYS G NUCL PARTIC, V33, P1, DOI 10.1088/0954-3899/33/1/001",9,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/E000444/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242409700001,2006,MEASUREMENT OF THE BRANCHING FRACTION AND TIME-DEPENDENT CP ASYMMETRY IN THE DECAY B-0 ->(D*+D*-KS0),"WE STUDY THE DECAY B-0 ->(D*+D*-KS0) USING (230 +/- 2)X10(6)B (B) OVER BAR PAIRS COLLECTED BY THE BABAR DETECTOR AT THE PEP-II B FACTORY. WE MEASURE A BRANCHING FRACTION B(B-0 ->(D*+D*-KS0))=(4.4 +/- 0.4 +/- 0.7)X10(-3) AND FIND EVIDENCE FOR THE DECAY B-0 -> D*-DS1+(2536) WITH A SIGNIFICANCE OF 4.6 SIGMA. A TIME-DEPENDENT CP ASYMMETRY ANALYSIS IS ALSO PERFORMED TO STUDY THE POSSIBLE RESONANT CONTRIBUTIONS TO B-0 ->(D*+D*-KS0) AND THE SIGN OF COS2 BETA. OUR MEASUREMENT INDICATES THAT THERE IS A SIZABLE RESONANT CONTRIBUTION TO THE DECAY B-0 ->(D*+D*-KS0) FROM AN UNKNOWN D-S1(+) STATE WITH LARGE WIDTH, AND THAT COS2 BETA IS POSITIVE AT THE 94% CONFIDENCE LEVEL UNDER CERTAIN THEORETICAL ASSUMPTIONS.",MESONS; QUARK,NA,PHYSICAL REVIEW D,"AUBERT, B##BONA, M##BOUTIGNY, D##COUDERC, F##KARYOTAKIS, Y##LEES, JP##POIREAU, V##TISSERAND, V##ZGHICHE, A##GRAUGES, E##PALANO, A##CHEN, JC##QI, ND##RONG, G##WANG, P##ZHU, YS##EIGEN, G##OFTE, I##STUGU, B##ABRAMS, GS##BATTAGLIA, M##BROWN, DN##BUTTON-SHAFER, J##CAHN, RN##CHARLES, E##GILL, MS##GROYSMAN, Y##JACOBSEN, RG##KADYK, JA##KERTH, LT##KOLOMENSKY, YG##KUKARTSEV, G##LYNCH, G##MIR, LM##ORIMOTO, TJ##PRIPSTEIN, M##ROE, NA##RONAN, MT##WENZEL, WA##SANCHEZ, PD##BARRETT, M##FORD, KE##HARRISON, TJ##HART, AJ##HAWKES, CM##WATSON, AT##HELD, T##KOCH, H##LEWANDOWSKI, B##PELIZAEUS, M##PETERS, K##SCHROEDER, T##STEINKE, M##BOYD, JT##BURKE, JP##COTTINGHAM, WN##WALKER, D##ASGEIRSSON, DJ##CUHADAR-DONSZELMANN, T##FULSOM, BG##HEARTY, C##KNECHT, NS##MATTISON, TS##MCKENNA, JA##KHAN, A##KYBERD, P##SALEEM, M##SHERWOOD, DJ##TEODORESCU, L##BLINOV, VE##BUKIN, AD##DRUZHININ, VP##GOLUBEV, VB##ONUCHIN, AP##SEREDNYAKOV, SI##SKOVPEN, YI##SOLODOV, EP##TODYSHEV, KY##BONDIOLI, M##BRUINSMA, M##CHAO, M##CURRY, S##ESCHRICH, I##KIRKBY, D##LANKFORD, AJ##LUND, P##MANDELKERN, M##MOMMSEN, RK##ROETHEL, W##STOKER, DP##ABACHI, S##BUCHANAN, C##FOULKES, SD##GARY, JW##LONG, O##SHEN, BC##WANG, K##ZHANG, L##HADAVAND, HK##HILL, EJ##PAAR, HP##RAHATLOU, S##SHARMA, V##BERRYHILL, JW##CAMPAGNARI, C##CUNHA, A##DAHMES, B##HONG, TM##KOVALSKYI, D##RICHMAN, JD##BECK, TW##EISNER, AM##FLACCO, CJ##HEUSCH, CA##KROSEBERG, J##LOCKMAN, WS##NESOM, G##SCHALK, T##SCHUMM, BA##SEIDEN, A##SPRADLIN, P##WILLIAMS, DC##WILSON, MG##ALBERT, J##CHEN, E##DVORETSKII, A##FANG, F##HITLIN, DG##NARSKY, I##PIATENKO, T##PORTER, FC##RYD, A##MANCINELLI, G##MEADOWS, BT##MISHRA, K##SOKOLOFF, MD##BLANC, F##BLOOM, PC##CHEN, S##FORD, WT##HIRSCHAUER, JF##KREISEL, A##NAGEL, M##NAUENBERG, U##OLIVAS, A##RUDDICK, WO##SMITH, JG##ULMER, KA##WAGNER, SR##ZHANG, J##CHEN, A##ECKHART, EA##SOFFER, A##TOKI, WH##WILSON, RJ##WINKLMEIER, F##ZENG, Q##ALTENBURG, DD##FELTRESI, E##HAUKE, A##JASPER, H##MERKEL, J##PETZOLD, A##SPAAN, B##BRANDT, T##KLOSE, V##LACKER, HM##MADER, WF##NOGOWSKI, R##SCHUBERT, J##SCHUBERT, KR##SCHWIERZ, R##SUNDERMANN, JE##VOLK, A##BERNARD, D##BONNEAUD, GR##LATOUR, E##THIEBAUX, C##VERDERI, M##CLARK, PJ##GRADL, W##MUHEIM, F##PLAYFER, S##ROBERTSON, AI##XIE, Y##ANDREOTTI, M##BETTONI, D##BOZZI, C##CALABRESE, R##CIBINETTO, G##LUPPI, E##NEGRINI, M##PETRELLA, A##PIEMONTESE, L##PRENCIPE, E##ANULLI, F##BALDINI-FERROLI, R##CALCATERRA, A##DE SANGRO, R##FINOCCHIARO, G##PACETTI, S##PATTERI, P##PERUZZI, IM##PICCOLO, M##RAMA, M##ZALLO, A##BUZZO, A##CONTRI, R##LO VETERE, M##MACRI, MM##MONGE, MR##PASSAGGIO, S##PATRIGNANI, C##ROBUTTI, E##SANTRONI, A##TOSI, S##BRANDENBURG, G##CHAISANGUANTHUM, KS##MORII, M##WU, J##DUBITZKY, RS##MARKS, J##SCHENK, S##UWER, U##BARD, DJ##BHIMJI, W##BOWERMAN, DA##DAUNCEY, PD##EGEDE, U##FLACK, RL##NASH, JA##NIKOLICH, MB##VAZQUEZ, WP##BEHERA, PK##CHAI, X##CHARLES, MJ##MALLIK, U##MEYER, NT##ZIEGLER, V##COCHRAN, J##CRAWLEY, HB##DONG, L##EYGES, V##MEYER, WT##PRELL, S##ROSENBERG, EI##RUBIN, AE##GRITSAN, AV##DENIG, AG##FRITSCH, M##SCHOTT, G##ARNAUD, N##DAVIER, M##GROSDIDIER, G##HOCKER, A##LE DIBERDER, F##LEPELTIER, V##LUTZ, AM##OYANGUREN, A##PRUVOT, S##RODIER, S##ROUDEAU, P##SCHUNE, MH##STOCCHI, A##WANG, WF##WORMSER, G##CHENG, CH##LANGE, DJ##WRIGHT, DM##CHAVEZ, CA##FORSTER, IJ##FRY, JR##GABATHULER, E##GAMET, R##GEORGE, KA##HUTCHCROFT, DE##PAYNE, DJ##SCHOFIELD, KC##TOURAMANIS, C##BEVAN, AJ##DI LODOVICO, F##MENGES, W##SACCO, R##COWAN, G##FLAECHER, HU##HOPKINS, DA##JACKSON, PS##MCMAHON, TR##RICCIARDI, S##SALVATORE, F##WREN, AC##BROWN, DN##DAVIS, CL##ALLISON, J##BARLOW, NR##BARLOW, RJ##CHIA, YM##EDGAR, CL##LAFFERTY, GD##NAISBIT, MT##WILLIAMS, JC##YI, JI##CHEN, C##HULSBERGEN, WD##JAWAHERY, A##LAE, CK##ROBERTS, DA##SIMI, G##BLAYLOCK, G##DALLAPICCOLA, C##HERTZBACH, SS##LI, X##MOORE, TB##SAREMI, S##STAENGLE, H##COWAN, R##SCIOLLA, G##SEKULA, SJ##SPITZNAGEL, M##TAYLOR, F##YAMAMOTO, RK##KIM, H##MCLACHLIN, SE##PATEL, PM##ROBERTSON, SH##LAZZARO, A##LOMBARDO, V##PALOMBO, F##BAUER, JM##CREMALDI, L##ESCHENBURG, V##GODANG, R##KROEGER, R##SANDERS, DA##SUMMERS, DJ##ZHAO, HW##BRUNET, S##COTE, D##SIMARD, M##TARAS, P##VIAUD, FB##NICHOLSON, H##CAVALLO, N##DE NARDO, G##FABOZZI, F##GATTO, C##LISTA, L##MONORCHIO, D##PAOLUCCI, P##PICCOLO, D##SCIACCA, C##BAAK, MA##RAVEN, G##SNOEK, HL##JESSOP, CP##LOSECCO, JM##ALLMENDINGER, T##BENELLI, G##CORWIN, LA##GAN, KK##HONSCHEID, K##HUFNAGEL, D##JACKSON, PD##KAGAN, H##KASS, R##RAHIMI, AM##REGENSBURGER, JJ##TER-ANTONYAN, R##WONG, QK##BLOUNT, NL##BRAU, J##FREY, R##IGONKINA, O##KOLB, JA##LU, M##RAHMAT, R##SINEV, NB##STROM, D##STRUBE, J##TORRENCE, E##GAZ, A##MARGONI, M##MORANDIN, M##POMPILI, A##POSOCCO, M##ROTONDO, M##SIMONETTO, F##STROILI, R##VOCI, C##BENAYOUN, M##BRIAND, H##CHAUVEAU, J##DAVID, P##DEL BUONO, L##DE LA VAISSIERE, C##HAMON, O##HARTFIEL, BL##LERUSTE, P##MALCLES, J##OCARIZ, J##ROOS, L##THERIN, G##GLADNEY, L##BIASINI, M##COVARELLI, R##ANGELINI, C##BATIGNANI, G##BETTARINI, S##BUCCI, F##CALDERINI, G##CARPINELLI, M##CENCI, R##FORTI, F##GIORGI, MA##LUSIANI, A##MARCHIORI, G##MAZUR, MA##MORGANTI, M##NERI, N##PAOLONI, E##RIZZO, G##WALSH, JJ##HAIRE, M##JUDD, D##WAGONER, DE##BIESIADA, J##DANIELSON, N##ELMER, P##LAU, YP##LU, C##OLSEN, J##SMITH, AJS##TELNOV, AV##BELLINI, F##CAVOTO, G##D'ORAZIO, A##DEL RE, D##DI MARCO, E##FACCINI, R##FERRAROTTO, F##FERRONI, F##GASPERO, M##LI GIOI, L##MAZZONI, MA##MORGANTI, S##PIREDDA, G##POLCI, F##TEHRANI, FS##VOENA, C##EBERT, M##SCHRODER, H##WALDI, R##ADYE, T##DE GROOT, N##FRANEK, B##OLAIYA, EO##WILSON, FF##ALEKSAN, R##EMERY, S##GAIDOT, A##GANZHUR, SF##DE MONCHENAULT, GH##KOZANECKI, W##LEGENDRE, M##VASSEUR, G##YECHE, C##ZITO, M##CHEN, XR##LIU, H##PARK, W##PUROHIT, MV##WILSON, JR##ALLEN, MT##ASTON, D##BARTOLDUS, R##BECHTLE, P##BERGER, N##CLAUS, R##COLEMAN, JP##CONVERY, MR##CRISTINZIANI, M##DINGFELDER, JC##DORFAN, J##DUBOIS-FELSMANN, GP##DUJMIC, D##DUNWOODIE, W##FIELD, RC##GLANZMAN, T##GOWDY, SJ##GRAHAM, MT##GRENIER, P##HALYO, V##HAST, C##HRYN'OVA, T##INNES, WR##KELSEY, MH##KIM, P##LEITH, DWGS##LI, S##LUITZ, S##LUTH, V##LYNCH, HL##MACFARLANE, DB##MARSISKE, H##MESSNER, R##MULLER, DR##O'GRADY, CP##OZCAN, VE##PERAZZO, A##PERL, M##PULLIAM, T##RATCLIFF, BN##ROODMAN, A##SALNIKOV, AA##SCHINDLER, RH##SCHWIENING, J##SNYDER, A##STELZER, J##SU, D##SULLIVAN, MK##SUZUKI, K##SWAIN, SK##THOMPSON, JM##VA'VRA, J##VAN BAKEL, N##WEAVER, M##WEINSTEIN, AJR##WISNIEWSKI, WJ##WITTGEN, M##WRIGHT, DH##YARRITU, AK##YI, K##YOUNG, CC##BURCHAT, PR##EDWARDS, AJ##MAJEWSKI, SA##PETERSEN, BA##ROAT, C##WILDEN, L##AHMED, S##ALAM, MS##BULA, R##ERNST, JA##JAIN, V##PAN, B##SAEED, MA##WAPPLER, FR##ZAIN, SB##BUGG, W##KRISHNAMURTHY, M##SPANIER, SM##ECKMANN, R##RITCHIE, JL##SATPATHY, A##SCHILLING, CJ##SCHWITTERS, RF##IZEN, JM##LOU, XC##YE, S##BIANCHI, F##GALLO, F##GAMBA, D##BOMBEN, M##BOSISIO, L##CARTARO, C##COSSUTTI, F##DELLA RICCA, G##DITTONGO, S##LANCERI, L##VITALE, L##AZZOLINI, V##LOPEZ-MARCH, N##MARTINEZ-VIDAL, F##BANERJEE, S##BHUYAN, B##BROWN, CM##FORTIN, D##HAMANO, K##KOWALEWSKI, R##NUGENT, IM##RONEY, JM##SOBIE, RJ##BACK, JJ##HARRISON, PF##LATHAM, TE##MOHANTY, GB##PAPPAGALLO, M##BAND, HR##CHEN, X##CHENG, B##DASU, S##DATTA, M##FLOOD, KT##HOLLAR, JJ##KUTTER, PE##MELLADO, B##MIHALYI, A##PAN, Y##PIERINI, M##PREPOST, R##WU, SL##YU, Z##NEAL, H","IN2P3, LAB PHYS PARTICULES, CNRS, ANNCEY LE VIEUX, FRANCE. UNIV SAVOIE, ANNCEY LE VIEUX, FRANCE. UNIV BARCELONA, FAC FIS, DEPT ECM, E-08028 BARCELONA, SPAIN. UNIV BARI, DIPARTIMENTO FIS, I-70126 BARI, ITALY. IST NAZL FIS NUCL, I-70126 BARI, ITALY. ACAD SINICA, INST HIGH ENERGY PHYS, BEIJING 100039, PEOPLES R CHINA. UNIV BERGEN, INST PHYS, N-5007 BERGEN, NORWAY. UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. RUHR UNIV BOCHUM, INST PHYS EXPT, D-44780 BOCHUM, GERMANY. UNIV BRISTOL, BRISTOL BS8 1TL, AVON, ENGLAND. UNIV BRITISH COLUMBIA, VANCOUVER, BC V6T 1Z1, CANADA. BRUNEL UNIV, UXBRIDGE UB8 3PH, MIDDX, ENGLAND. BUDKER INST NUCL PHYS, NOVOSIBIRSK 630090, RUSSIA. UNIV CALIF IRVINE, IRVINE, CA 92697 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA. UNIV CALIF SANTA BARBARA, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA CRUZ, INST PARTICLE PHYS, SANTA CRUZ, CA 95064 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CINCINNATI, CINCINNATI, OH 45221 USA. UNIV COLORADO, BOULDER, CO 80309 USA. COLORADO STATE UNIV, FT COLLINS, CO 80523 USA. UNIV DORTMUND, INST PHYS, D-44221 DORTMUND, GERMANY. TECH UNIV DRESDEN, INST KERN & TEILCHENPHYS, D-01062 DRESDEN, GERMANY. ECOLE POLYTECH, LAB LEPRINCE RINGUET, CNRS, IN2P3, F-91128 PALAISEAU, FRANCE. UNIV EDINBURGH, EDINBURGH EH9 3JZ, MIDLOTHIAN, SCOTLAND. UNIV FERRARA, DIPARTIMENTO FIS, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, DIPARTIMENTO FIS, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, LAB NAZL FRASCATI, I-00044 FRASCATI, ITALY. UNIV GENOA, DIPARTIMENTO FIS, I-16146 GENOA, ITALY. IST NAZL FIS NUCL, I-16146 GENOA, ITALY. HARVARD UNIV, CAMBRIDGE, MA 02138 USA. HEIDELBERG UNIV, INST PHYS, D-69120 HEIDELBERG, GERMANY. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AZ, ENGLAND. UNIV IOWA, IOWA CITY, IA 52242 USA. IOWA STATE UNIV, AMES, IA 50011 USA. JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA. UNIV KARLSRUHE, INST EXPT KERNPHYS, D-76021 KARLSRUHE, GERMANY. IN2P3, CNRS, LAB ACCELERATEUR LINEAIRE, F-91898 ORSAY, FRANCE. UNIV PARIS 11, CTR SCI ORSAY, F-91898 ORSAY, FRANCE. LAWRENCE LIVERMORE NATL LAB, LIVERMORE, CA 94550 USA. UNIV LIVERPOOL, LIVERPOOL L69 7ZE, MERSEYSIDE, ENGLAND. QUEEN MARY UNIV LONDON, LONDON E1 4NS, ENGLAND. UNIV LONDON ROYAL HOLLOWAY & BEDFORD NEW COLL, EGHAM TW20 0EX, SURREY, ENGLAND. UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA. UNIV MANCHESTER, MANCHESTER M13 9PL, LANCS, ENGLAND. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. UNIV MASSACHUSETTS, AMHERST, MA 01003 USA. MIT, NUCL SCI LAB, CAMBRIDGE, MA 02139 USA. MCGILL UNIV, MONTREAL, PQ H3A 2T8, CANADA. UNIV MILAN, DIPARTIMENTO FIS, I-20133 MILAN, ITALY. IST NAZL FIS NUCL, I-20133 MILAN, ITALY. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV MONTREAL, MONTREAL, PQ H3C 3J7, CANADA. MT HOLYOKE COLL, S HADLEY, MA 01075 USA. UNIV NAPLES FEDERICO II, DIPARTIMENTO SCI FIS, I-80126 NAPLES, ITALY. IST NAZL FIS NUCL, I-80126 NAPLES, ITALY. NIKHEF H, NATL INST NUCL PHYS & HIGH ENERGY PHYS, NL-1009 DB AMSTERDAM, NETHERLANDS. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. UNIV OREGON, EUGENE, OR 97403 USA. UNIV PADUA, DIPARTIMENTO FIS, I-35131 PADUA, ITALY. IST NAZL FIS NUCL, I-35131 PADUA, ITALY. UNIV PARIS 07, IN2P3, CNRS, LAB PHYS NUCL & HAUTES ENERGIES, F-75252 PARIS, FRANCE. UNIV PENN, PHILADELPHIA, PA 19104 USA. UNIV PERUGIA, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. IST NAZL FIS NUCL, I-06100 PERUGIA, ITALY. UNIV PISA, DIPARTIMENTO FIS, SCUOLA NORMALE SUPER, I-56127 PISA, ITALY. IST NAZL FIS NUCL, I-56127 PISA, ITALY. PRAIRIE VIEW A&M UNIV, PRAIRIE VIEW, TX 77446 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. UNIV ROMA LA SAPIENZA, DIPARTIMENTO FIS, I-00185 ROME, ITALY. IST NAZL FIS NUCL, I-00185 ROME, ITALY. UNIV ROSTOCK, D-18051 ROSTOCK, GERMANY. RUTHERFORD APPLETON LAB, DIDCOT OX11 0QX, OXON, ENGLAND. CEA, DSM DAPNIA, F-91191 GIF SUR YVETTE, FRANCE. UNIV S CAROLINA, COLUMBIA, SC 29208 USA. STANFORD LINEAR ACCELERATOR CTR, STANFORD, CA 94309 USA. STANFORD UNIV, STANFORD, CA 94305 USA. SUNY ALBANY, ALBANY, NY USA. UNIV TENNESSEE, KNOXVILLE, TN 37996 USA. UNIV TEXAS, AUSTIN, TX 78712 USA. UNIV TEXAS, RICHARDSON, TX 75083 USA. UNIV TURIN, DIPARTIMENTO FIS SPERIMENTALE, I-10125 TURIN, ITALY. IST NAZL FIS NUCL, I-10125 TURIN, ITALY. UNIV TRIESTE, DIPARTIMENTO FIS, I-34127 TRIESTE, ITALY. IST NAZL FIS NUCL, I-34127 TRIESTE, ITALY. UNIV VALENCIA, IFIC, CSIC, E-46071 VALENCIA, SPAIN. UNIV VICTORIA, VICTORIA, BC V8W 3P6, CANADA. UNIV WARWICK, DEPT PHYS, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND. UNIV WISCONSIN, MADISON, WI 53706 USA. YALE UNIV, NEW HAVEN, CT 06511 USA.","ASTRONOMY & ASTROPHYSICS; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"ABE K, 2002, PHYS REV D, V66, DOI 10.1103/PHYSREVD.66.071102##AGOSTINELLI S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8##ALBRECHT H, 1990, Z PHYS C PART FIELDS, V48, P543##AUBERT B, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.161803##AUBERT B, 2003, PHYS REV D, V68, DOI 10.1103/PHYSREVD.68.092001##AUBERT B, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.201802##AUBERT B, 2002, PHYS REV D, V66, DOI 10.1103/PHYSREVD.66.032003##AUBERT B, 2002, NUCL INSTRUM METH A, V479, P1, DOI 10.1016/S0168-9002(01)02012-5##BROWDER TE, 2000, PHYS REV D, V61, DOI 10.1103/PHYSREVD.61.054009##CABIBBO N, 1963, PHYS REV LETT, V10, P531, DOI 10.1103/PHYSREVLETT.10.531##CHARLES J, 1998, PHYS LETT B, V433, P441, DOI 10.1016/S0370-2693(98)00671-6##CHARLES J, 1998, PHYS LETT B, V425, P375, DOI 10.1016/S0370-2693(98)00250-0##COLANGELO P, 1999, PHYS REV D, V60, DOI 10.1103/PHYSREVD.60.033002##EIDELMAN S, 2004, PHYS LETT B, V592, P1, DOI 10.1016/J.PHYSLETB.2004.06.001##FOX GC, 1978, PHYS REV LETT, V41, P1581, DOI 10.1103/PHYSREVLETT.41.1581##GODFREY S, 1991, PHYS REV D, V43, P1679, DOI 10.1103/PHYSREVD.43.1679##GODFREY S, 1985, PHYS REV D, V32, P189, DOI 10.1103/PHYSREVD.32.189##KOBAYASHI M, 1973, PROG THEOR PHYS, V49, P652, DOI 10.1143/PTP.49.652##LONG O, 2003, PHYS REV D, V68, DOI 10.1103/PHYSREVD.68.034010##PIVK M, 2005, NUCL INSTRUM METH A, V555, P356, DOI 10.1016/J.NIMA.2005.08.106",62,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/E000444/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242409700009,2006,MEASUREMENTS OF THE B -> D-* FORM FACTORS USING THE DECAY (B)OVER-BAR(0)-> D(*+)E(-)(V)OVER-BAR(E),"WE MEASURE THE DEPENDENCE OF (B) OVER BAR (0)-> D(*+)E(-)(B) OVER BAR (E) ON THE DECAY ANGLES AND MOMENTUM TRANSFER. THE DATA SAMPLE CONSISTS OF SIMILAR TO 86X10(6) B (B) OVER BAR -PAIRS ACCUMULATED ON THE UPSILON(4S) RESONANCE BY THE BABAR DETECTOR AT THE ASYMMETRIC E(+)E(-) COLLIDER PEP-II. WE SPECIFY THE THREE FORM FACTORS BY TWO RATIOS R-1 AND R-2, AND BY A SINGLE PARAMETER RHO(2) CHARACTERIZING THE POLYNOMIAL REPRESENTING H(A1), THE FUNCTION WHICH DESCRIBES THE MOMENTUM-TRANSFER DEPENDENCE OF THE FORM FACTOR A(1). WE DETERMINE R-1, R-2, AND RHO(2) USING AN UNBINNED MAXIMUM LIKELIHOOD FIT TO THE FULL DECAY DISTRIBUTION. THE RESULTS ARE R-1=1.396 +/- 0.060 +/- 0.035 +/- 0.027, R-2=0.885 +/- 0.040 +/- 0.022 +/- 0.013, AND RHO(2)=1.145 +/- 0.059 +/- 0.030 +/- 0.035. THE STATED UNCERTAINTIES ARE THE STATISTICAL FROM THE DATA, STATISTICAL FROM THE SIZE OF THE MONTE CARLO SAMPLE AND THE SYSTEMATIC UNCERTAINTY, RESPECTIVELY. IN ADDITION, BASED ON THIS MEASUREMENT, WE GIVE AN UPDATED VALUE FOR THE CKM MATRIX ELEMENT VERTICAL BAR V-CB VERTICAL BAR.",CB-VERTICAL-BAR; HEAVY-QUARK SYMMETRY; V-CB; BOUNDS,NA,PHYSICAL REVIEW D,"AUBERT, B##ZGHICHE, A##BOUTIGNY, D##COUDERC, F##KARYOTAKIS, Y##LEES, JP##POIREAU, V##TISSERAND, V##GRITSAN, AV##GRAUGES, E##PALANO, A##PAPPAGALLO, M##CHEN, JC##QI, ND##RONG, G##WANG, P##ZHU, YS##EIGEN, G##OFTE, I##STUGU, B##ABRAMS, GS##BATTAGLIA, M##BEST, DS##BROWN, DN##BUTTON-SHAFER, J##CAHN, RN##CHARLES, E##DAY, CT##GILL, MS##GROYSMAN, Y##JACOBSEN, RG##KADEL, RW##KADYK, J##KERTH, LT##KOLOMENSKY, YG##KUKARTSEV, G##LYNCH, G##MIR, LM##ODDONE, PJ##ORIMOTO, TJ##PRIPSTEIN, M##ROE, NA##RONAN, MT##WENZEL, WA##BARRETT, M##FORD, KE##HARRISON, TJ##HART, AJ##HAWKES, CM##MORGAN, SE##WATSON, AT##FRITSCH, M##GOETZEN, K##KOCH, H##LEWANDOWSKI, B##PELIZAEUS, M##SCHROEDER, T##STEINKE, M##CUHADAR-DONSZELMANN, T##FULSOM, BG##HEARTY, C##KNECHT, NS##MATTISON, TS##MCKENNA, JA##KHAN, A##KYBERD, P##SALEEM, M##TEODORESCU, L##BLINOV, VE##BUKIN, AD##DRUZHININ, VP##GOLUBEV, VB##KRAVCHENKO, EA##ONUCHIN, AP##SEREDNYAKOV, SI##SKOVPEN, YI##SOLODOV, EP##TODYSHEV, KY##BONDIOLI, M##BRUINSMA, M##CHAO, M##CURRY, S##ESCHRICH, I##KIRKBY, D##LANKFORD, AJ##LUND, P##MANDELKERN, M##MOMMSEN, RK##ROETHEL, W##STOKER, DP##ABACHI, S##BUCHANAN, C##FOULKES, SD##GARY, JW##LONG, O##SHEN, BC##WANG, K##ZHANG, L##DEL RE, D##HADAVAND, HK##PAAR, HP##RAHATLOU, S##SHARMA, V##BERRYHILL, JW##CAMPAGNARI, C##CUNHA, A##DAHMES, B##HONG, TM##RICHMAN, JD##BECK, TW##EISNER, AM##FLACCO, CJ##HEUSCH, CA##KROSEBERG, J##LOCKMAN, WS##NESOM, G##SCHALK, T##SCHUMM, BA##SEIDEN, A##SPRADLIN, P##WILLIAMS, DC##WILSON, MG##ALBERT, J##CHEN, E##DUBOIS-FELSMANN, GP##DVORETSKII, A##HITLIN, DG##MINAMORA, JS##NARSKY, I##PIATENKO, T##PORTER, FC##RYD, A##SAMUEL, A##ANDREASSEN, R##MANCINELLI, G##MEADOWS, BT##SOKOLOFF, MD##BLANC, F##BLOOM, PC##CHEN, S##FORD, WT##HIRSCHAUER, JF##KREISEL, A##NAUENBERG, U##OLIVAS, A##RUDDICK, WO##SMITH, JG##ULMER, KA##WAGNER, SR##ZHANG, J##CHEN, A##ECKHART, EA##SOFFER, A##TOKI, WH##WILSON, RJ##WINKLMEIER, F##ZENG, Q##ALTENBURG, DD##FELTRESI, E##HAUKE, A##JASPER, H##SPAAN, B##BRANDT, T##DICKOPP, M##KLOSE, V##LACKER, HM##NOGOWSKI, R##OTTO, S##PETZOLD, A##SCHUBERT, J##SCHUBERT, KR##SCHWIERZ, R##SUNDERMANN, JE##VOLK, A##BERNARD, D##BONNEAUD, GR##GRENIER, P##LATOUR, E##SCHRENK, S##THIEBAUX, C##VASILEIADIS, G##VERDERI, M##BARD, DJ##CLARK, PJ##GRADL, W##MUHEIM, F##PLAYFER, S##XIE, Y##ANDREOTTI, M##BETTONI, D##BOZZI, C##CALABRESE, R##CIBINETTO, G##LUPPI, E##NEGRINI, M##PIEMONTESE, L##ANULLI, F##BALDINI-FERROLI, R##CALCATERRA, A##DE SANGRO, R##FINOCCHIARO, G##PACETTI, S##PATTERI, P##PERUZZI, IM##PICCOLO, M##ZALLO, A##BUZZO, A##CAPRA, R##CONTRI, R##LO VETERE, M##MACRI, MM##MONGE, MR##PASSAGGIO, S##PASSAGGIO, C##ROBUTTI, E##SANTRONI, A##TOSI, S##BRANDENBURG, G##CHAISANGUANTHUM, KS##MORII, M##WU, J##DUBITZKY, RS##MARKS, J##SCHENK, S##UWER, U##BHIMJI, W##BOWERMAN, DA##DAUNCEY, PD##EGEDE, U##FLACK, RL##GAILLARD, JR##NASH, JA##NIKOLICH, MB##VAZQUEZ, WP##CHAI, X##CHARLES, MJ##MADER, WF##MALLIK, U##ZIEGLER, V##COCHRAN, J##CRAWLEY, HB##DONG, L##EYGES, V##MEYER, WT##PRELL, S##ROSENBERG, EI##RUBIN, AE##SCHOTT, G##ARNAUD, N##DAVIER, M##GROSDIDIER, G##HOCKER, A##LE DIBERDER, F##LEPELTIER, V##LUTZ, AM##OYANGUREN, A##PETERSEN, TC##PRUVOT, S##RODIER, S##ROUDEAU, P##SCHUNE, MH##STOCCHI, A##WANG, WF##WORMSER, G##CHENG, CH##LANGE, DJ##WRIGHT, DM##BEVAN, AJ##CHAVEZ, CA##FORSTER, IJ##FRY, JR##GABATHULER, E##GAMET, R##GEORGE, KA##HUTCHCROFT, DE##PAYNE, DJ##SCHOFIELD, KC##TOURAMANIS, C##DI LODOVICO, F##MENGES, W##SACCO, R##BROWN, CL##COWAN, G##FLAECHER, HU##GREEN, MG##HOPKINS, DA##JACKSON, PS##MCMAHON, TR##RICCIARDI, S##SALVATORE, F##BROWN, DN##DAVIS, CL##ALLISON, J##BARLOW, NR##BARLOW, RJ##CHIA, YM##EDGAR, CL##KELLY, MP##LAFFERTY, GD##NAISBIT, MT##WILLIAMS, JC##YI, JI##CHEN, C##HULSBERGEN, WD##JAWAHERY, A##KOVALSKYI, D##LAE, CK##ROBERTS, DA##SIMI, G##BLAYLOCK, G##DALLAPICCOLA, C##HERTZBACH, SS##KOFLER, R##LI, X##MOORE, TB##SAREMI, S##STAENGLE, H##WILLOCQ, SY##COWAN, R##KOENEKE, K##SCIOLLA, G##SEKULA, SJ##SPITZNAGEL, M##TAYLOR, F##YAMAMOTO, RK##KIM, H##PATEL, PM##POTTER, CT##ROBERTSON, SH##LAZZARO, A##LOMBARDO, V##PALOMBO, F##BAUER, JM##CREMALDI, L##ESCHENBURG, V##GODANG, R##KROEGER, R##REIDY, J##SANDERS, DA##SUMMERS, DJ##ZHAO, HW##BRUNET, S##COTE, D##TARAS, P##VIAUD, FB##NICHOLSON, H##CAVALLO, N##DE NARDO, G##FABOZZI, F##GATTO, C##LISTA, L##MONORCHIO, D##PAOLUCCI, P##PICCOLO, D##SCIACCA, C##BAAK, M##BULTEN, H##RAVEN, G##SNOEK, HL##JESSOP, CP##LOSECCO, JM##ALLMENDINGER, T##BENELLI, G##GAN, KK##HONSCHEID, K##HUFNAGEL, D##JACKSON, PD##KAGAN, H##KASS, R##PULLIAM, T##RAHIMI, AM##TER-ANTONYAN, R##WONG, QK##BLOUNT, NL##BRAU, J##FREY, R##IGONKINA, O##LU, M##RAHMAT, R##SINEV, NB##STROM, D##STRUBE, J##TORRENCE, E##GALEAZZI, F##MARGONI, M##MORANDIN, M##POMPILI, A##POSOCCO, M##ROTONDO, M##SIMONETTO, F##STROILI, R##VOCI, C##BENAYOUN, M##CHAUVEAU, J##DAVID, P##DEL BUONO, L##DE LA VAISSIERE, C##HAMON, O##HARTFIEL, BL##JOHN, MJJ##LERUSTE, P##MALCLES, J##OCARIZ, J##ROOS, L##THERIN, G##BEHERA, PK##GLADNEY, L##PANETTA, J##BIASINI, M##COVARELLI, R##PIOPPI, M##ANGELINI, C##BATIGNANI, G##BETTARINI, S##BUCCI, F##CALDERINI, G##CARPINELLI, M##CENCI, R##FORTI, F##GIORGI, MA##LUSIANI, A##MARCHIORI, G##MAZUR, MA##MORGANTI, M##NERI, N##PAOLONI, E##RAMA, M##RIZZO, G##WALSH, J##HAIRE, M##JUDD, D##WAGONER, DE##BIESIADA, J##DANIELSON, N##ELMER, P##LAU, YP##LU, C##OLSEN, J##SMITH, AJS##TELNOV, AV##BELLINI, F##CAVOTO, G##D'ORAZIO, A##DI MARCO, E##FACCINI, R##FERRAROTTO, F##FERRONI, F##GASPERO, M##LI GIOI, L##MAZZONI, MA##MORGANTI, S##PIREDDA, G##POLCI, F##TEHRANI, FS##VOENA, C##SCHRODER, H##WALDI, R##ADYE, T##DE GROOT, N##FRANEK, B##OLAIYA, EO##WILSON, FF##EMERY, S##GAIDOT, A##GANZHUR, SF##DE MONCHENAULT, GH##KOZANECKI, W##LEGENDRE, M##MAYER, B##VASSEUR, G##YECHE, C##ZITO, M##PARK, W##PUROHIT, MV##WEIDEMANN, AW##WILSON, JR##ABE, T##ALLEN, MT##ASTON, D##BARTOLDUS, R##BERGER, N##BOYARSKI, AM##CLAUS, R##COLEMAN, JP##CONVERY, MR##CRISTINZIANI, M##DINGFELDER, JC##DONG, D##DORFAN, J##DUJMIC, D##DUNWOODIE, W##FAN, S##FIELD, RC##GLANZMAN, T##GOWDY, SJ##HADIG, T##HALYO, V##HAST, C##HRYN'OVA, T##INNES, WR##KELSEY, MH##KIM, P##KOCIAN, ML##LEITH, DWGS##LIBBY, J##LUITZ, S##LUTH, V##LYNCH, HL##MACFARLANE, DB##MARSISKE, H##MESSNER, R##MULLER, DR##O'GRADY, CP##OZCAN, VE##PERAZZO, A##PERL, M##RATCLIFF, BN##ROODMAN, A##SALNIKOV, AA##SCHINDLER, RH##SCHWIENING, J##SNYDER, A##STELZER, J##SU, D##SULLIVAN, MK##SUZUKI, K##SWAIN, S##THOMPSON, JM##VA'VRA, J##VAN BAKEL, N##WEAVER, M##WEINSTEIN, AJR##WISNIEWSKI, WJ##WITTGEN, M##WRIGHT, DH##YARRITU, AK##YI, K##YOUNG, CC##BURCHAT, PR##EDWARDS, AJ##MAJEWSKI, SA##PETERSEN, BA##ROAT, C##WILDEN, L##AHMED, S##ALAM, MS##BULA, R##ERNST, JA##JAIN, V##PAN, B##SAEED, MA##WAPPLER, FR##ZAIN, SB##BUGG, W##KRISHNAMURTHY, M##SPANIER, SM##ECKMANN, R##RITCHIE, JL##SATPATHY, A##SCHWITTERS, RF##IZEN, JM##KITAYAMA, I##LOU, XC##YE, S##BIANCHI, F##BONA, M##GALLO, F##GAMBA, D##BOMBEN, M##BOSISIO, L##CARTARO, C##COSSUTTI, F##DELLA RICCA, G##DITTONGO, S##GRANCAGNOLO, S##LANCERI, L##VITALE, L##AZZOLINI, V##MARTINEZ-VIDAL, F##PANVINI, RS##BANERJEE, S##BHUYAN, B##BROWN, CM##FORTIN, D##HAMANO, K##KOWALEWSKI, R##NUGENT, IM##RONEY, JM##SOBIE, RJ##BACK, JJ##HARRISON, PF##LATHAM, TE##MOHANTY, GB##BAND, HR##CHEN, X##CHENG, B##DASU, S##DATTA, M##EICHENBAUM, AM##FLOOD, KT##GRAHAM, MT##HOLLAR, JJ##JOHNSON, JR##KUTTER, PE##LI, H##LIU, R##MELLADO, B##MIHALYI, A##MOHAPATRA, AK##PAN, Y##PIERINI, M##PREPOST, R##TAN, P##WU, SL##YU, Z##NEAL, H","PHYS PARTICULES LAB, F-74941 ANNECY LE VIEUX, FRANCE. UNIV AUTONOMA BARCELONA, IFAE, E-08193 BARCELONA, SPAIN. UNIV BARI, DIPARTIMENTO FIS, I-70126 BARI, ITALY. IST NAZL FIS NUCL, I-70126 BARI, ITALY. INST HIGH ENERGY PHYS, BEIJING 100039, PEOPLES R CHINA. UNIV BERGEN, INST PHYS, N-5007 BERGEN, NORWAY. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA. UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. RUHR UNIV BOCHUM, INST EXPT PHYS, D-44780 BOCHUM, GERMANY. UNIV BRISTOL, BRISTOL BS8 1TL, AVON, ENGLAND. UNIV BRITISH COLUMBIA, VANCOUVER, BC V6T 1Z1, CANADA. BRUNEL UNIV, UXBRIDGE UB8 3PH, MIDDX, ENGLAND. BUDKER INST NUCL PHYS, NOVOSIBIRSK 630090, RUSSIA. UNIV CALIF IRVINE, IRVINE, CA 92697 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA. UNIV CALIF SANTA BARBARA, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA CRUZ, INST PARTICLE PHYS, SANTA CRUZ, CA 95064 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CINCINNATI, CINCINNATI, OH 45221 USA. UNIV COLORADO, BOULDER, CO 80309 USA. COLORADO STATE UNIV, FT COLLINS, CO 80523 USA. UNIV DORTMUND, INST PHYS, D-44221 DORTMUND, GERMANY. TECH UNIV DRESDEN, INST KERN & TEILCHENPHYS, D-01062 DRESDEN, GERMANY. ECOLE POLYTECH, LLR, F-91128 PALAISEAU, FRANCE. UNIV EDINBURGH, EDINBURGH EH9 3JZ, MIDLOTHIAN, SCOTLAND. UNIV FERRARA, DIPARTIMENTO FIS, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, I-44100 FERRARA, ITALY. NAZL FRASCATI LAB, I-00044 FRASCATI, ITALY. IST NAZL FIS NUCL, I-00044 FRASCATI, ITALY. UNIV GENOA, DIPARTIMENTO FIS, I-16146 GENOA, ITALY. IST NAZL FIS NUCL, I-16146 GENOA, ITALY. HARVARD UNIV, CAMBRIDGE, MA 02138 USA. HEIDELBERG UNIV, INST PHYS, D-69120 HEIDELBERG, GERMANY. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AZ, ENGLAND. UNIV IOWA, IOWA CITY, IA 52242 USA. IOWA STATE UNIV, AMES, IA 50011 USA. UNIV KARLSRUHE, INST EXPT KERNPHYS, D-76021 KARLSRUHE, GERMANY. LAB ACCELERATEUR LINEAIRE, F-91898 ORSAY, FRANCE. LAWRENCE LIVERMORE NATL LAB, LIVERMORE, CA 94550 USA. UNIV LIVERPOOL, LIVERPOOL L69 7ZE, MERSEYSIDE, ENGLAND. QUEEN MARY UNIV LONDON, LONDON E1 4NS, ENGLAND. UNIV LONDON ROYAL HOLLOWAY & BEDFORD NEW COLL, EGHAM TW20 0EX, SURREY, ENGLAND. UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA. UNIV MANCHESTER, MANCHESTER M13 9PL, LANCS, ENGLAND. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. UNIV MASSACHUSETTS, AMHERST, MA 01003 USA. MIT, NUCL SCI LAB, CAMBRIDGE, MA 02139 USA. MCGILL UNIV, MONTREAL, PQ H3A 2T8, CANADA. UNIV MILAN, DIPARTIMENTO FIS, I-20133 MILAN, ITALY. IST NAZL FIS NUCL, I-20133 MILAN, ITALY. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV MONTREAL, MONTREAL, PQ H3C 3J7, CANADA. MT HOLYOKE COLL, S HADLEY, MA 01075 USA. UNIV NAPLES FEDERICO II, DIPARTIMENTO SCI FISICHE, I-80126 NAPLES, ITALY. IST NAZL FIS NUCL, I-80126 NAPLES, ITALY. NATL INST NUCL & HIGH ENERGY PHYS, NIKHEF, NL-1009 DB AMSTERDAM, NETHERLANDS. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. UNIV OREGON, EUGENE, OR 97403 USA. UNIV PADUA, DIPARTIMENTO FIS, I-35131 PADUA, ITALY. IST NAZL FIS NUCL, I-35131 PADUA, ITALY. UNIV PARIS 06, LAB PHYS NUCL & HAUTES ENERGIES, F-75252 PARIS, FRANCE. UNIV PARIS 07, LAB PHYS NUCL & HAUTES ENERGIES, F-75252 PARIS, FRANCE. UNIV PENN, PHILADELPHIA, PA 19104 USA. UNIV PERUGIA, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. IST NAZL FIS NUCL, I-06100 PERUGIA, ITALY. UNIV PISA, DIPARTIMENTO FIS, SCUOLA NORMALE SUPER PISA, I-56127 PISA, ITALY. IST NAZL FIS NUCL, I-56127 PISA, ITALY. PRAIRIE VIEW A&M UNIV, PRAIRIE VIEW, TX 77446 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. UNIV ROMA LA SAPIENZA, DIPARTIMENTO FIS, I-00185 ROME, ITALY. IST NAZL FIS NUCL, I-00185 ROME, ITALY. UNIV ROSTOCK, D-18051 ROSTOCK, GERMANY. RUTHERFORD APPLETON LAB, DIDCOT OX11 0QX, OXON, ENGLAND. CEA SACLAY, DSM DAPNIA, F-91191 GIF SUR YVETTE, FRANCE. UNIV S CAROLINA, COLUMBIA, SC 29208 USA. STANFORD LINEAR ACCELERATOR CTR, STANFORD, CA 94309 USA. STANFORD UNIV, STANFORD, CA 94305 USA. SUNY ALBANY, ALBANY, NY 12222 USA. UNIV TENNESSEE, KNOXVILLE, TN 37996 USA. UNIV TEXAS, AUSTIN, TX 78712 USA. UNIV TEXAS, RICHARDSON, TX 75083 USA. UNIV TURIN, DIPARTIMENTO FIS SPERIMENTALE, I-10125 TURIN, ITALY. IST NAZL FIS NUCL, I-10125 TURIN, ITALY. UNIV TRIESTE, DIPARTIMENTO FIS, I-34127 TRIESTE, ITALY. IST NAZL FIS NUCL, I-34127 TRIESTE, ITALY. UNIV VALENCIA, CSIC, IFIC, E-46071 VALENCIA, SPAIN. VANDERBILT UNIV, NASHVILLE, TN 37235 USA. UNIV VICTORIA, VICTORIA, BC V8W 3P6, CANADA. UNIV WARWICK, DEPT PHYS, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND. UNIV WISCONSIN, MADISON, WI 53706 USA. YALE UNIV, NEW HAVEN, CT 06511 USA. JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA. PHYS CORPUSCULAIRE LAB, CLERMONT FERRAND, FRANCE. UNIV PERUGIA, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. UNIV BASILICATA, I-85100 POTENZA, ITALY.","ASTRONOMY & ASTROPHYSICS; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"ABREU P, 2001, PHYS LETT B, V510, P55, DOI 10.1016/S0370-2693(01)00569-X##ACKERSTAFF K, 1997, PHYS LETT B, V395, P128, DOI 10.1016/S0370-2693(97)00056-7##AGOSTINELLI S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8##ALBRECHT H, 1993, Z PHYS C PART FIELDS, V57, P533##AUBERT B, 2005, PHYS REV D, V71, DOI 10.1103/PHYSREVD.71.051502##AUBERT B, 2005, PHYS REV D, V71, DOI 10.1103/PHYSREVD.71.032005##AUBERT B, 2005, PHYS REV LETT, V95, DOI [10.1103/PHYSREVLETT.95.041805, 10.1103/PHYSREVD.73.012006]##AUBERT B, 2002, NUCL INSTRUM METH A, V479, P1, DOI 10.1016/S0168-9002(01)02012-5##*BABAR COLL, 2001, PHYS REV LETT, V87, P1801##BARLOW R, 1993, COMPUT PHYS COMMUN, V77, P219, DOI 10.1016/0010-4655(93)90005-W##BOYD CG, 1996, NUCL PHYS B, V461, P493, DOI 10.1016/0550-3213(95)00653-2##BUSKULIC D, 1997, PHYS LETT B, V395, P373, DOI 10.1016/S0370-2693(97)00071-3##BUSKULIC D, 1995, PHYS LETT B, V359, P236, DOI 10.1016/0370-2693(95)01021-H##CAPRINI I, 1998, NUCL PHYS B, V530, P153, DOI 10.1016/S0550-3213(98)00350-2##CHERNOFF H, 1954, ANN MATH STAT, V25, P579, DOI 10.1214/AOMS/1177728726##CLOSE FE, 1994, NUCL PHYS B, V412, P169, DOI 10.1016/0550-3213(94)90498-7##DUBOSCQ JE, 1996, PHYS REV LETT, V76, P3898, DOI 10.1103/PHYSREVLETT.76.3898##EIDELMAN S, 2004, PHYS LETT B, V592, P1, DOI 10.1016/J.PHYSLETB.2004.06.001##GILL MS, 2004, 794 SLAC UCB##GRINSTEIN B, 2004, PHYS LETT B, V601, P236, DOI 10.1016/J.PHYSLETB.2004.09.060##GRINSTEIN B, 2002, PHYS LETT B, V526, P345, DOI 10.1016/S0370-2693(01)01517-9##ISGUR N, 1990, PHYS LETT B, V237, P527, DOI 10.1016/0370-2693(90)91219-2##JADACH S, 2000, COMPUT PHYS COMMUN, V130, P260, DOI 10.1016/S0010-4655(00)00048-5##LANGE DJ, 2001, NUCL INSTRUM METH A, V462, P152, DOI 10.1016/S0168-9002(01)00089-4##LE YAOUANC A, 2004, PHYS REV D, V69, DOI 10.1103/PHYSREVD.69.094022##LE YAOUANC A, 2003, PHYS REV D, V67, DOI 10.1103/PHYSREVD.67.114009##LE YAOUANC A, 2003, PHYS LETT B, V557, P207, DOI 10.1016/S0370-2693(03)00180-1##LIGETI Z, COMMUNICATION##MANZARI V, 1999, J PHYS G NUCL PARTIC, V25, P473, DOI 10.1088/0954-3899/25/2/037##NEUBERT M, 1994, PHYS REP, V245, P259, DOI 10.1016/0370-1573(94)90091-4##RICHMAN JD, 1995, REV MOD PHYS, V67, P893, DOI 10.1103/REVMODPHYS.67.893##RICHTERWAS E, 1993, PHYS LETT B, V303, P163, DOI 10.1016/0370-2693(93)90062-M##RYD A, 1996, UMI9704221MC UCSB",23,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/E000444/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242409700003,2006,STRUCTURE AT 2175 MEV IN E(+)E(-)->PHI F(0)(980) OBSERVED VIA INITIAL-STATE RADIATION,"WE STUDY THE INITIAL-STATE-RADIATION PROCESSES E(+)E(-)-> K+K-PI(+)PI(-)GAMMA AND E(+)E(-)-> K+K-PI(0)PI(0)GAMMA USING AN INTEGRATED LUMINOSITY OF 232 FB(-1) COLLECTED AT THE UPSILON(4S) MASS WITH THE BABAR DETECTOR AT SLAC. EVEN THOUGH THESE REACTIONS ARE DOMINATED BY INTERMEDIATE STATES WITH EXCITED KAONS, WE ARE ABLE TO STUDY FOR THE FIRST TIME THE CROSS SECTION FOR E(+)E(-)->PHI(1020)F(0)(980) AS A FUNCTION OF CENTER-OF-MASS ENERGY. WE OBSERVE A STRUCTURE NEAR THRESHOLD CONSISTENT WITH A 1(--) RESONANCE WITH MASS M=2.175 +/- 0.010 +/- 0.015 GEV/C(2) AND WIDTH GAMMA=58 +/- 16 +/- 20 MEV. WE OBSERVE NO Y(4260) SIGNAL AND SET A LIMIT OF B-Y ->PHI PI(+)PI(-)CENTER DOT GAMMA(Y)(EE)< 0.4 EV (90% CONFIDENCE LEVEL), WHICH EXCLUDES SOME MODELS.",BHABHA SCATTERING; MONTE-CARLO,NA,PHYSICAL REVIEW D,"AUBERT, B##BONA, M##BOUTIGNY, D##COUDERC, F##KARYOTAKIS, Y##LEES, JP##POIREAU, V##TISSERAND, V##ZGHICHE, A##GRAUGES, E##PALANO, A##CHEN, JC##QI, ND##RONG, G##WANG, P##ZHU, YS##EIGEN, G##OFTE, I##STUGU, B##ABRAMS, GS##BATTAGLIA, M##BROWN, DN##BUTTON-SHAFER, J##CAHN, RN##CHARLES, E##GILL, MS##GROYSMAN, Y##JACOBSEN, RG##KADYK, JA##KERTH, LT##KOLOMENSKY, YG##KUKARTSEV, G##LYNCH, G##MIR, LM##ORIMOTO, TJ##PRIPSTEIN, M##ROE, NA##RONAN, MT##WENZEL, WA##SANCHEZ, PD##BARRETT, M##FORD, KE##HARRISON, TJ##HART, AJ##HAWKES, CM##WATSON, AT##HELD, T##KOCH, H##LEWANDOWSKI, B##PELIZAEUS, M##PETERS, K##SCHROEDER, T##STEINKE, M##BOYD, JT##BURKE, JP##COTTINGHAM, WN##WALKER, D##ASGEIRSSON, DJ##CUHADAR-DONSZELMANN, T##FULSOM, BG##HEARTY, C##KNECHT, NS##MATTISON, TS##MCKENNA, JA##KHAN, A##KYBERD, P##SALEEM, M##SHERWOOD, DJ##TEODORESCU, L##BLINOV, VE##BUKIN, AD##DRUZHININ, VP##GOLUBEV, VB##ONUCHIN, AP##SEREDNYAKOV, SI##SKOVPEN, YI##SOLODOV, EP##TODYSHEV, KY##BONDIOLI, M##BRUINSMA, M##CHAO, M##CURRY, S##ESCHRICH, I##KIRKBY, D##LANKFORD, AJ##LUND, P##MANDELKERN, M##MOMMSEN, RK##ROETHEL, W##STOKER, DP##ABACHI, S##BUCHANAN, C##FOULKES, SD##GARY, JW##LONG, O##SHEN, BC##WANG, K##ZHANG, L##HADAVAND, HK##HILL, EJ##PAAR, HP##RAHATLOU, S##SHARMA, V##BERRYHILL, JW##CAMPAGNARI, C##CUNHA, A##DAHMES, B##HONG, TM##KOVALSKYI, D##RICHMAN, JD##BECK, TW##EISNER, AM##FLACCO, CJ##HEUSCH, CA##KROSEBERG, J##LOCKMAN, WS##NESOM, G##SCHALK, T##SCHUMM, BA##SEIDEN, A##SPRADLIN, P##WILLIAMS, DC##WILSON, MG##ALBERT, J##CHEN, E##DVORETSKII, A##FANG, F##HITLIN, DG##NARSKY, I##PIATENKO, T##PORTER, FC##RYD, A##MANCINELLI, G##MEADOWS, BT##MISHRA, K##SOKOLOFF, MD##BLANC, F##BLOOM, PC##CHEN, S##FORD, WT##HIRSCHAUER, JF##KREISEL, A##NAGEL, M##NAUENBERG, U##OLIVAS, A##RUDDICK, WO##SMITH, JG##ULMER, KA##WAGNER, SR##ZHANG, J##CHEN, A##ECKHART, EA##SOFFER, A##TOKI, WH##WILSON, RJ##WINKLMEIER, F##ZENG, Q##ALTENBURG, DD##FELTRESI, E##HAUKE, A##JASPER, H##MERKEL, J##PETZOLD, A##SPAAN, B##BRANDT, T##KLOSE, V##LACKER, HM##MADER, WF##NOGOWSKI, R##SCHUBERT, J##SCHUBERT, KR##SCHWIERZ, R##SUNDERMANN, JE##VOLK, A##BERNARD, D##BONNEAUD, GR##LATOUR, E##THIEBAUX, C##VERDERI, M##CLARK, PJ##GRADL, W##MUHEIM, F##PLAYFER, S##ROBERTSON, AI##XIE, Y##ANDREOTTI, M##BETTONI, D##BOZZI, C##CALABRESE, R##CIBINETTO, G##LUPPI, E##NEGRINI, M##PETRELLA, A##PIEMONTESE, L##PRENCIPE, E##ANULLI, F##BALDINI-FERROLI, R##CALCATERRA, A##DE SANGRO, R##FINOCCHIARO, G##PACETTI, S##PATTERI, P##PERUZZI, IM##PICCOLO, M##RAMA, M##ZALLO, A##BUZZO, A##CONTRI, R##LO VETERE, M##MACRI, MM##MONGE, MR##PASSAGGIO, S##PATRIGNANI, C##ROBUTTI, E##SANTRONI, A##TOSI, S##BRANDENBURG, G##CHAISANGUANTHUM, KS##MORII, M##WU, J##DUBITZKY, RS##MARKS, J##SCHENK, S##UWER, U##BARD, DJ##BHIMJI, W##BOWERMAN, DA##DAUNCEY, PD##EGEDE, U##FLACK, RL##NASH, JA##NIKOLICH, MB##VAZQUEZ, WP##BEHERA, PK##CHAI, X##CHARLES, MJ##MALLIK, U##MEYER, NT##ZIEGLER, V##COCHRAN, J##CRAWLEY, HB##DONG, L##EYGES, V##MEYER, WT##PRELL, S##ROSENBERG, EI##RUBIN, AE##GRITSAN, AV##DENIG, AG##FRITSCH, M##SCHOTT, G##ARNAUD, N##DAVIER, M##GROSDIDIER, G##HOCKER, A##LE DIBERDER, F##LEPELTIER, V##LUTZ, AM##OYANGUREN, A##PRUVOT, S##RODIER, S##ROUDEAU, P##SCHUNE, MH##STOCCHI, A##WANG, WF##WORMSER, G##CHENG, CH##LANGE, DJ##WRIGHT, DM##CHAVEZ, CA##FORSTER, IJ##FRY, JR##GABATHULER, E##GAMET, R##GEORGE, KA##HUTCHCROFT, DE##PAYNE, DJ##SCHOFIELD, KC##TOURAMANIS, C##BEVAN, AJ##DI LODOVICO, F##MENGES, W##SACCO, R##COWAN, G##FLAECHER, HU##HOPKINS, DA##JACKSON, PS##MCMAHON, TR##RICCIARDI, S##SALVATORE, F##WREN, AC##BROWN, DN##DAVIS, CL##ALLISON, J##BARLOW, NR##BARLOW, RJ##CHIA, YM##EDGAR, CL##LAFFERTY, GD##NAISBIT, MT##WILLIAMS, JC##YI, JI##CHEN, C##HULSBERGEN, WD##JAWAHERY, A##LAE, CK##ROBERTS, DA##SIMI, G##BLAYLOCK, G##DALLAPICCOLA, C##HERTZBACH, SS##LI, X##MOORE, TB##SAREMI, S##STAENGLE, H##COWAN, R##SCIOLLA, G##SEKULA, SJ##SPITZNAGEL, M##TAYLOR, F##YAMAMOTO, RK##KIM, H##MCLACHLIN, SE##PATEL, PM##ROBERTSON, SH##LAZZARO, A##LOMBARDO, V##PALOMBO, F##BAUER, JM##CREMALDI, L##ESCHENBURG, V##GODANG, R##KROEGER, R##SANDERS, DA##SUMMERS, DJ##ZHAO, HW##BRUNET, S##COTE, D##SIMARD, M##TARAS, P##VIAUD, FB##NICHOLSON, H##CAVALLO, N##DE NARDO, G##FABOZZI, F##GATTO, C##LISTA, L##MONORCHIO, D##PAOLUCCI, P##PICCOLO, D##SCIACCA, C##BAAK, MA##RAVEN, G##SNOEK, HL##JESSOP, CP##LOSECCO, JM##ALLMENDINGER, T##BENELLI, G##CORWIN, LA##GAN, KK##HONSCHEID, K##HUFNAGEL, D##JACKSON, PD##KAGAN, H##KASS, R##RAHIMI, AM##REGENSBURGER, JJ##TER-ANTONYAN, R##WONG, QK##BLOUNT, NL##BRAU, J##FREY, R##IGONKINA, O##KOLB, JA##LU, M##RAHMAT, R##SINEV, NB##STROM, D##STRUBE, J##TORRENCE, E##GAZ, A##MARGONI, M##MORANDIN, M##POMPILI, A##POSOCCO, M##ROTONDO, M##SIMONETTO, F##STROILI, R##VOCI, C##BENAYOUN, M##BRIAND, H##CHAUVEAU, J##DAVID, P##DEL BUONO, L##DE LA VAISSIERE, C##HAMON, O##HARTFIEL, BL##LERUSTE, P##MALCLES, J##OCARIZ, J##ROOS, L##THERIN, G##GLADNEY, L##BIASINI, M##COVARELLI, R##ANGELINI, C##BATIGNANI, G##BETTARINI, S##BUCCI, F##CALDERINI, G##CARPINELLI, M##CENCI, R##FORTI, F##GIORGI, MA##LUSIANI, A##MARCHIORI, G##MAZUR, MA##MORGANTI, M##NERI, N##PAOLONI, E##RIZZO, G##WALSH, JJ##HAIRE, M##JUDD, D##WAGONER, DE##BIESIADA, J##DANIELSON, N##ELMER, P##LAU, YP##LU, C##OLSEN, J##SMITH, AJS##TELNOV, AV##BELLINI, F##CAVOTO, G##D'ORAZIO, A##DEL RE, D##MARCO, E##FACCINI, R##FERRAROTTO, F##FERRONI, F##GASPERO, M##GIOI, LL##MAZZONI, MA##MORGANTI, S##PIREDDA, G##POLCI, F##TEHRANI, FS##VOENA, C##EBERT, M##SCHRODER, H##WALDI, R##ADYE, T##DE GROOT, N##FRANEK, B##OLAIYA, EO##WILSON, FF##ALEKSAN, R##EMERY, S##GAIDOT, A##GANZHUR, SF##DE MONCHENAULT, GH##KOZANECKI, W##LEGENDRE, M##VASSEUR, G##YECHE, C##ZITO, M##CHEN, XR##LIU, H##PARK, W##PUROHIT, MV##WILSON, JR##ALLEN, MT##ASTON, D##BARTOLDUS, R##BECHTLE, P##BERGER, N##CLAUS, R##COLEMAN, JP##CONVERY, MR##CRISTINZIANI, M##DINGFELDER, JC##DORFAN, J##DUBOIS-FELSMANN, GP##DUJMIC, D##DUNWOODIE, W##FIELD, RC##GLANZMAN, T##GOWDY, SJ##GRAHAM, MT##GRENIER, P##HALYO, V##HAST, C##HRYN'OVA, T##INNES, WR##KELSEY, MH##KIM, P##LEITH, DWGS##LI, S##LUITZ, S##LUTH, V##LYNCH, HL##MACFARLANE, DB##MARSISKE, H##MESSNER, R##MULLER, DR##O'GRADY, CP##OZCAN, VE##PERAZZO, A##PERL, M##PULLIAM, T##RATCLIFF, BN##ROODMAN, A##SALNIKOV, AA##SCHINDLER, RH##SCHWIENING, J##SNYDER, A##STELZER, J##SU, D##SULLIVAN, MK##SUZUKI, K##SWAIN, SK##THOMPSON, JM##VA'VRA, J##VAN BAKEL, N##WEAVER, M##WEINSTEIN, AJR##WISNIEWSKI, WJ##WITTGEN, M##WRIGHT, DH##YARRITU, AK##YI, K##YOUNG, CC##BURCHAT, PR##EDWARDS, AJ##MAJEWSKI, SA##PETERSEN, BA##ROAT, C##WILDEN, L##AHMED, S##ALAM, MS##BULA, R##ERNST, JA##JAIN, V##PAN, B##SAEED, MA##WAPPLER, FR##ZAIN, SB##BUGG, W##KRISHNAMURTHY, M##SPANIER, SM##ECKMANN, R##RITCHIE, JL##SATPATHY, A##SCHILLING, CJ##SCHWITTERS, RF##IZEN, JM##LOU, XC##YE, S##BIANCHI, F##GALLO, F##GAMBA, D##BOMBEN, M##BOSISIO, L##CARTARO, C##COSSUTTI, F##DELLA RICCA, G##DITTONGO, S##LANCERI, L##VITALE, L##AZZOLINI, V##LOPEZ-MARCH, N##MARTINEZ-VIDAL, F##BANERJEE, S##BHUYAN, B##BROWN, CM##FORTIN, D##HAMANO, K##KOWALEWSKI, R##NUGENT, IM##RONEY, JM##SOBIE, RJ##BACK, JJ##HARRISON, PF##LATHAM, TE##MOHANTY, GB##PAPPAGALLO, M##BAND, HR##CHEN, X##CHENG, B##DASU, S##DATTA, M##FLOOD, KT##HOLLAR, JJ##KUTTER, PE##MELLADO, B##MIHALYI, A##PAN, Y##PIERINI, M##PREPOST, R##WU, SL##YU, Z##NEAL, H","CNRS, LAB PHYS PARTICULES, IN2P3, F-74941 ANNECY LE VIEUX, FRANCE. UNIV SAVOIE, F-74941 ANNECY LE VIEUX, FRANCE. UNIV BARCELONA, FAC FIS, DEPT ECM, E-08028 BARCELONA, SPAIN. UNIV BARI, DIPARTIMENTO FIS, I-70126 BARI, ITALY. IST NAZL FIS NUCL, I-70126 BARI, ITALY. INST HIGH ENERGY PHYS, BEIJING 100039, PEOPLES R CHINA. UNIV BERGEN, INST PHYS, N-5007 BERGEN, NORWAY. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. LAWRENCE BERKELEY NATL LAB, BERKELEY, CA 94720 USA. UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. RUHR UNIV BOCHUM, INST PHYS EXPT 1, D-44780 BOCHUM, GERMANY. UNIV BRISTOL, BRISTOL BS8 1TL, AVON, ENGLAND. UNIV BRITISH COLUMBIA, VANCOUVER, BC V6T 1Z1, CANADA. BRUNEL UNIV, UXBRIDGE UB8 3PH, MIDDX, ENGLAND. BUDKER INST NUCL PHYS, NOVOSIBIRSK 630090, RUSSIA. UNIV CALIF IRVINE, IRVINE, CA 92697 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA. UNIV CALIF SANTA BARBARA, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA CRUZ, INST PARTICLE PHYS, SANTA CRUZ, CA 95064 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CINCINNATI, CINCINNATI, OH 45221 USA. UNIV COLORADO, BOULDER, CO 80309 USA. COLORADO STATE UNIV, FT COLLINS, CO 80523 USA. UNIV DORTMUND, INST PHYS, D-44221 DORTMUND, GERMANY. TECH UNIV DRESDEN, INST KERN & TEILCHENPHYS, D-01062 DRESDEN, GERMANY. ECOLE POLYTECH, CNRS, LAB LEPRINCE RINGUET, IN2P3, F-91128 PALAISEAU, FRANCE. UNIV EDINBURGH, EDINBURGH EH9 3JZ, MIDLOTHIAN, SCOTLAND. UNIV FERRARA, DIPARTIMENTO FIS, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, LAB NAZL FRASCATI, I-00044 FRASCATI, ITALY. UNIV GENOA, DIPARTIMENTO FIS, I-16146 GENOA, ITALY. IST NAZL FIS NUCL, I-16146 GENOA, ITALY. HARVARD UNIV, CAMBRIDGE, MA 02138 USA. HEIDELBERG UNIV, INST PHYS, D-69120 HEIDELBERG, GERMANY. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AZ, ENGLAND. UNIV IOWA, IOWA CITY, IA 52242 USA. IOWA STATE UNIV, AMES, IA 50011 USA. JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA. UNIV KARLSRUHE, INST EXPT KERNPHYS, D-76021 KARLSRUHE, GERMANY. CNRS, IN2P3, LAB ACCELERATEUR LINEAIRE, F-91898 ORSAY, FRANCE. UNIV PARIS 11, CTR SCI ORSAY, F-91898 ORSAY, FRANCE. LAWRENCE LIVERMORE NATL LAB, LIVERMORE, CA 94550 USA. UNIV LIVERPOOL, LIVERPOOL L69 7ZE, MERSEYSIDE, ENGLAND. QUEEN MARY UNIV LONDON, LONDON E1 4NS, ENGLAND. UNIV LONDON ROYAL HOLLOWAY & BEDFORD NEW COLL, EGHAM TW20 0EX, SURREY, ENGLAND. UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA. UNIV MANCHESTER, MANCHESTER M13 9PL, LANCS, ENGLAND. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. UNIV MASSACHUSETTS, AMHERST, MA 01003 USA. MIT, NUCL SCI LAB, CAMBRIDGE, MA 02139 USA. MCGILL UNIV, MONTREAL, PQ H3A 2T8, CANADA. UNIV MILAN, DIPARTIMENTO FIS, I-20133 MILAN, ITALY. IST NAZL FIS NUCL, I-20133 MILAN, ITALY. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV MONTREAL, MONTREAL, PQ H3C 3J7, CANADA. MT HOLYOKE COLL, S HADLEY, MA 01075 USA. UNIV NAPLES FEDERICO II, DIPARTIMENTO SCI FIS, I-80126 NAPLES, ITALY. IST NAZL FIS NUCL, I-80126 NAPLES, ITALY. NATL INST NUCL & HIGH ENERGY PHYS, NIKHEF, NL-1009 DB AMSTERDAM, NETHERLANDS. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. UNIV OREGON, EUGENE, OR 97403 USA. UNIV PADUA, DIPARTIMENTO FIS, I-35131 PADUA, ITALY. IST NAZL FIS NUCL, I-35131 PADUA, ITALY. UNIV PARIS 06, CNRS, IN2P3, LAB PHYS NUCL & HAUTES ENERGIES, F-75252 PARIS, FRANCE. UNIV PARIS 07, F-75252 PARIS, FRANCE. UNIV PENN, PHILADELPHIA, PA 19104 USA. UNIV PERUGIA, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. IST NAZL FIS NUCL, I-06100 PERUGIA, ITALY. UNIV PISA, DIPARTIMENTO FIS, SCUOLA NORMALE SUPER, I-56127 PISA, ITALY. IST NAZL FIS NUCL, I-56127 PISA, ITALY. PRAIRIE VIEW A&M UNIV, PRAIRIE VIEW, TX 77446 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. UNIV ROMA LA SAPIENZA, DIPARTIMENTO FIS, I-00185 ROME, ITALY. IST NAZL FIS NUCL, I-00185 ROME, ITALY. UNIV ROSTOCK, D-18051 ROSTOCK, GERMANY. RUTHERFORD APPLETON LAB, DIDCOT OX11 0QX, OXON, ENGLAND. CEA SACLAY, DSM DAPNIA, F-91191 GIF SUR YVETTE, FRANCE. UNIV S CAROLINA, COLUMBIA, SC 29208 USA. STANFORD LINEAR ACCELERATOR CTR, STANFORD, CA 94309 USA. STANFORD UNIV, STANFORD, CA 94305 USA. SUNY ALBANY, ALBANY, NY 12222 USA. UNIV TENNESSEE, KNOXVILLE, TN 37996 USA. UNIV TEXAS, AUSTIN, TX 78712 USA. UNIV TEXAS, RICHARDSON, TX 75083 USA. UNIV TURIN, DIPARTIMENTO FIS SPERIMENTALE, I-10125 TURIN, ITALY. IST NAZL FIS NUCL, I-10125 TURIN, ITALY. UNIV TRIESTE, DIPARTIMENTO FIS, I-34127 TRIESTE, ITALY. IST NAZL FIS NUCL, I-34127 TRIESTE, ITALY. UNIV VALENCIA, IFIC, CSIC, E-46071 VALENCIA, SPAIN. UNIV VICTORIA, VICTORIA, BC V8W 3P6, CANADA. UNIV WARWICK, DEPT PHYS, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND. UNIV WISCONSIN, MADISON, WI 53706 USA. UNIV BASILICATA, I-85100 POTENZA, ITALY. YALE UNIV, NEW HAVEN, CT 06511 USA.","ASTRONOMY & ASTROPHYSICS; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"AGOSTINELLI S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8##ARBUZOV A. B., 1997, JHEP-JOURNAL OF HIGH ENERGY PHYSICS##AUBERT B, 2006, PHYS REV D, V73, DOI 10.1103/PHYSREVD.73.052003##AUBERT B, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.142001##AUBERT B, 2005, PHYS REV D, V71, DOI 10.1103/PHYSREVD.71.052001##AUBERT B, 2002, NUCL INSTRUM METH A, V479, P1, DOI 10.1016/S0168-9002(01)02012-5##BARBERIO E, 1991, COMPUT PHYS COMMUN, V66, P115, DOI 10.1016/0010-4655(91)90012-A##CAFFO M, 1997, NUOVO CIMENTO A, V110, P515, DOI 10.1007/BF03035898##CAFFO M, 1994, PHYS LETT B, V327, P369, DOI 10.1016/0370-2693(94)90743-9##COAN TE, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.162003##CORDIER A, 1982, PHYS LETT B, V110, P335, DOI 10.1016/0370-2693(82)91267-9##CZYZ H, 2001, EUR PHYS J C, V18, P497, DOI 10.1007/S100520000553##JADACH S, 1995, COMPUT PHYS COMMUN, V85, P453, DOI 10.1016/0010-4655(94)00091-F##LANGE DJ, 2001, NUCL INSTRUM METH A, V462, P152, DOI 10.1016/S0168-9002(01)00089-4##SJOSTRAND T, 1994, COMPUT PHYS COMMUN, V82, P74, DOI 10.1016/0010-4655(94)90132-5##YAO WM, 2006, J PHYS G NUCL PARTIC, V33, P1, DOI 10.1088/0954-3899/33/1/001##ZHU SL, 2005, PHYS LETT B, V625, P212, DOI 10.1016/J.PHYSLETB.2005.08.068",233,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/E000444/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242409700005,2006,MEASUREMENT OF THE RATIO B(B+-> XEV)/B(B-0 -> XEV),"WE REPORT MEASUREMENTS OF THE INCLUSIVE ELECTRON MOMENTUM SPECTRA IN DECAYS OF CHARGED AND NEUTRAL B MESONS, AND OF THE RATIO OF SEMILEPTONIC BRANCHING FRACTIONS B(B+-> XE NU) AND B(B-0 -> XE NU). THESE WERE PERFORMED ON A SAMPLE OF 231X10(6) B (B) OVER BAR EVENTS RECORDED WITH THE BABAR DETECTOR AT THE UPSILON(4S) RESONANCE. EVENTS ARE SELECTED BY FULLY RECONSTRUCTING A HADRONIC DECAY OF ONE B MESON AND IDENTIFYING AN ELECTRON AMONG THE DECAY PRODUCTS OF THE RECOILING (B) OVER BAR MESON. WE OBTAIN B(B+-> XE NU)/B(B-0 -> XE NU)=1.074 +/- 0.041((STAT))+/- 0.026((SYST)).",DECAYS; MESONS,NA,PHYSICAL REVIEW D,"AUBERT, B##BONA, M##BOUTIGNY, D##COUDERC, F##KARYOTAKIS, Y##LEES, JP##POIREAU, V##TISSERAND, V##ZGHICHE, A##GRAUGES, E##PALANO, A##CHEN, JC##QI, ND##RONG, G##WANG, P##ZHU, YS##EIGEN, G##OFTE, I##STUGU, B##ABRAMS, GS##BATTAGLIA, M##BROWN, DN##BUTTON-SHAFER, J##CAHN, RN##CHARLES, E##GILL, MS##GROYSMAN, Y##JACOBSEN, RG##KADYK, JA##KERTH, LT##KOLOMENSKY, YG##KUKARTSEV, G##LYNCH, G##MIR, LM##ORIMOTO, TJ##PRIPSTEIN, M##ROE, NA##RONAN, MT##WENZEL, WA##SANCHEZ, PD##BARRETT, M##FORD, KE##HART, AJ##HARRISON, TJ##HAWKES, CM##WATSON, AT##HELD, T##KOCH, H##LEWANDOWSKI, B##PELIZAEUS, M##PETERS, K##SCHROEDER, T##STEINKE, M##BOYD, JT##BURKE, JP##COTTINGHAM, WN##WALKER, D##ASGEIRSSON, DJ##CUHADAR-DONSZELMANN, T##FULSOM, BG##HEARTY, C##KNECHT, NS##MATTISON, TS##MCKENNA, JA##KHAN, A##KYBERD, P##SALEEM, M##SHERWOOD, DJ##TEODORESCU, L##BLINOV, VE##BUKIN, AD##DRUZHININ, VP##GOLUBEV, VB##ONUCHIN, AP##SEREDNYAKOV, SI##SKOVPEN, YI##SOLODOV, EP##TODYSHEV, KY##BONDIOLI, M##BRUINSMA, M##CHAO, M##CURRY, S##ESCHRICH, I##KIRKBY, D##LANKFORD, AJ##LUND, P##MANDELKERN, M##MOMMSEN, RK##ROETHEL, W##STOKER, DP##ABACHI, S##BUCHANAN, C##FOULKES, SD##GARY, JW##LONG, O##SHEN, BC##WANG, K##ZHANG, L##HADAVAND, HK##HILL, EJ##PAAR, HP##RAHATLOU, S##SHARMA, V##BERRYHILL, JW##CAMPAGNARI, C##CUNHA, A##DAHMES, B##HONG, TM##KOVALSKYI, D##RICHMAN, JD##BECK, TW##EISNER, AM##FLACCO, CJ##HEUSCH, CA##KROSEBERG, J##LOCKMAN, WS##NESOM, G##SCHALK, T##SCHUMM, BA##SEIDEN, A##SPRADLIN, P##WILLIAMS, DC##WILSON, MG##ALBERT, J##CHEN, E##DVORETSKII, A##FANG, F##HITLIN, DG##NARSKY, I##PIATENKO, T##PORTER, FC##RYD, A##MANCINELLI, G##MEADOWS, BT##MISHRA, K##SOKOLOFF, MD##BLANC, F##BLOOM, PC##CHEN, S##FORD, WT##HIRSCHAUER, JF##KREISEL, A##NAGEL, M##NAUENBERG, U##OLIVAS, A##RUDDICK, WO##SMITH, JG##ULMER, KA##WAGNER, SR##ZHANG, J##CHEN, A##ECKHART, EA##SOFFER, A##TOKI, WH##WILSON, RJ##WINKLMEIER, F##ZENG, Q##ALTENBURG, DD##FELTRESI, E##HAUKE, A##JASPER, H##MERKEL, J##PETZOLD, A##SPAAN, B##BRANDT, T##KLOSE, V##LACKER, HM##MADER, WF##NOGOWSKI, R##SCHUBERT, J##SCHUBERT, KR##SCHWIERZ, R##SUNDERMANN, JE##VOLK, A##BERNARD, D##BONNEAUD, GR##LATOUR, E##THIEBAUX, C##VERDERI, M##CLARK, PJ##GRADL, W##MUHEIM, F##PLAYFER, S##ROBERTSON, AI##XIE, Y##ANDREOTTI, M##BETTONI, D##BOZZI, C##CALABRESE, R##CIBINETTO, G##LUPPI, E##NEGRINI, M##PETRELLA, A##PIEMONTESE, L##PRENCIPE, E##ANULLI, F##BALDINI-FERROLI, R##CALCATERRA, A##DE SANGRO, R##FINOCCHIARO, G##PACETTI, S##PATTERI, P##PERUZZI, IM##PICCOLO, M##RAMA, M##ZALLO, A##BUZZO, A##CONTRI, R##LO VETERE, M##MACRI, MM##MONGE, MR##PASSAGGIO, S##PATRIGNANI, C##ROBUTTI, E##SANTRONI, A##TOSI, S##BRANDENBURG, G##CHAISANGUANTHUM, KS##MORII, M##WU, J##DUBITZKY, RS##MARKS, J##SCHENK, S##UWER, U##BHIMJI, W##BOWERMAN, DA##DAUNCEY, PD##EGEDE, U##FLACK, RL##NASH, JA##NIKOLICH, MB##VAZQUEZ, WP##BARD, DJ##BEHERA, PK##CHAI, X##CHARLES, MJ##MALLIK, U##MEYER, NT##ZIEGLER, V##COCHRAN, J##CRAWLEY, HB##DONG, L##EYGES, V##MEYER, WT##PRELL, S##ROSENBERG, EI##RUBIN, AE##GRITSAN, AV##DENIG, AG##FRITSCH, M##SCHOTT, G##ARNAUD, N##DAVIER, M##GROSDIDIER, G##HOCKER, A##LE DIBERDER, F##LEPELTIER, V##LUTZ, AM##OYANGUREN, A##PRUVOT, S##RODIER, S##ROUDEAU, P##SCHUNE, MH##STOCCHI, A##WANG, WF##WORMSER, G##CHENG, CH##LANGE, DJ##WRIGHT, DM##CHAVEZ, CA##FORSTER, IJ##FRY, JR##GABATHULER, E##GAMET, R##GEORGE, KA##HUTCHCROFT, DE##PAYNE, DJ##SCHOFIELD, KC##TOURAMANIS, C##BEVAN, AJ##DI LODOVICO, F##MENGES, W##SACCO, R##COWAN, G##FLAECHER, HU##HOPKINS, DA##JACKSON, PS##MCMAHON, TR##RICCIARDI, S##SALVATORE, F##WREN, AC##BROWN, DN##DAVIS, CL##ALLISON, J##BARLOW, NR##BARLOW, RJ##CHIA, YM##EDGAR, CL##LAFFERTY, GD##NAISBIT, MT##WILLIAMS, JC##YI, JI##CHEN, C##HULSBERGEN, WD##JAWAHERY, A##LAE, CK##ROBERTS, DA##SIMI, G##BLAYLOCK, G##DALLAPICCOLA, C##HERTZBACH, SS##LI, X##MOORE, TB##SAREMI, S##STAENGLE, H##COWAN, R##SCIOLLA, G##SEKULA, SJ##SPITZNAGEL, M##TAYLOR, F##YAMAMOTO, RK##KIM, H##MCLACHLIN, SE##PATEL, PM##ROBERTSON, SH##LAZZARO, A##LOMBARDO, V##PALOMBO, F##BAUER, JM##CREMALDI, L##ESCHENBURG, V##GODANG, R##KROEGER, R##SANDERS, DA##SUMMERS, DJ##ZHAO, HW##BRUNET, S##COTE, D##SIMARD, M##TARAS, P##VIAUD, FB##NICHOLSON, H##CAVALLO, N##DE NARDO, G##FABOZZI, F##GATTO, C##LISTA, L##MONORCHIO, D##PAOLUCCI, P##PICCOLO, D##SCIACCA, C##BAAK, MA##RAVEN, G##SNOEK, HL##JESSOP, CP##LOSECCO, JM##ALLMENDINGER, T##BENELLI, G##CORWIN, LA##GAN, KK##HONSCHEID, K##HUFNAGEL, D##JACKSON, PD##KAGAN, H##KASS, R##RAHIMI, AM##REGENSBURGER, JJ##TER-ANTONYAN, R##WONG, QK##BLOUNT, NL##BRAU, J##FREY, R##IGONKINA, O##KOLB, JA##LU, M##RAHMAT, R##SINEV, NB##STROM, D##STRUBE, J##TORRENCE, E##GAZ, A##MARGONI, M##MORANDIN, M##POMPILI, A##POSOCCO, M##ROTONDO, M##SIMONETTO, F##STROILI, R##VOCI, C##BENAYOUN, M##BRIAND, H##CHAUVEAU, J##DAVID, P##DEL BUONO, L##DE LA VAISSIERE, C##HAMON, O##HARTFIEL, BL##LERUSTE, P##MALCLES, J##OCARIZ, J##ROOS, L##THERIN, G##GLADNEY, L##BIASINI, M##COVARELLI, R##ANGELINI, C##BATIGNANI, G##BETTARINI, S##BUCCI, F##CALDERINI, G##CARPINELLI, M##CENCI, R##FORTI, F##GIORGI, MA##LUSIANI, A##MARCHIORI, G##MAZUR, MA##MORGANTI, M##NERI, N##PAOLONI, E##RIZZO, G##WALSH, JJ##HAIRE, M##JUDD, D##WAGONER, DE##BIESIADA, J##DANIELSON, N##ELMER, P##LAU, YP##LU, C##OLSEN, J##SMITH, AJS##TELNOV, AV##BELLINI, F##CAVOTO, G##D'ORAZIO, A##DEL RE, D##DI MARCO, E##FACCINI, R##FERRAROTTO, F##FERRONI, F##GASPERO, M##GIOI, LL##MAZZONI, MA##MORGANTI, S##PIREDDA, G##POLCI, F##TEHRANI, FS##VOENA, C##EBERT, M##SCHRODER, H##WALDI, R##ADYE, T##DE GROOT, N##FRANEK, B##OLAIYA, EO##WILSON, FF##ALEKSAN, R##EMERY, S##GAIDOT, A##GANZHUR, SF##DE MONCHENAULT, GH##KOZANECKI, W##LEGENDRE, M##VASSEUR, G##YECHE, C##ZITO, M##CHEN, XR##LIU, H##PARK, W##PUROHIT, MV##WILSON, JR##ALLEN, MT##ASTON, D##BARTOLDUS, R##BECHTLE, P##BERGER, N##CLAUS, R##COLEMAN, JP##CONVERY, MR##CRISTINZIANI, M##DINGFELDER, JC##DORFAN, J##DUBOIS-FELSMANN, GP##DUJMIC, D##DUNWOODIE, W##FIELD, RC##GLANZMAN, T##GOWDY, SJ##GRAHAM, MT##GRENIER, P##HALYO, V##HAST, C##HRYN'OVA, T##INNES, WR##KELSEY, MH##KIM, P##LEITH, DWGS##LI, S##LUITZ, S##LUTH, V##LYNCH, HL##MACFARLANE, DB##MARSISKE, H##MESSNER, R##MULLER, DR##O'GRADY, CP##OZCAN, VE##PERAZZO, A##PERL, M##PULLIAM, T##RATCLIFF, BN##ROODMAN, A##SALNIKOV, AA##SCHINDLER, RH##SCHWIENING, J##SNYDER, A##STELZER, J##SU, D##SULLIVAN, MK##SUZUKI, K##SWAIN, SK##THOMPSON, JM##VA'VRA, J##VAN BAKEL, N##WEAVER, M##WEINSTEIN, AJR##WISNIEWSKI, WJ##WITTGEN, M##WRIGHT, DH##YARRITU, AK##YI, K##YOUNG, CC##BURCHAT, PR##EDWARDS, AJ##MAJEWSKI, SA##PETERSEN, BA##ROAT, C##WILDEN, L##AHMED, S##ALAM, MS##BULA, R##ERNST, JA##JAIN, V##PAN, B##SAEED, MA##WAPPLER, FR##ZAIN, SB##BUGG, W##KRISHNAMURTHY, M##SPANIER, SM##ECKMANN, R##RITCHIE, JL##SATPATHY, A##SCHILLING, CJ##SCHWITTERS, RF##IZEN, JM##LOU, XC##YE, S##BIANCHI, F##GALLO, F##GAMBA, D##BOMBEN, M##BOSISIO, L##CARTARO, C##COSSUTTI, F##DELLA RICCA, G##DITTONGO, S##LANCERI, L##VITALE, L##AZZOLINI, V##LOPEZ-MARCH, N##MARTINEZ-VIDAL, F##BANERJEE, S##BHUYAN, B##BROWN, CM##FORTIN, D##HAMANO, K##KOWALEWSKI, R##NUGENT, IM##RONEY, JM##SOBIE, RJ##BACK, JJ##HARRISON, PF##LATHAM, TE##MOHANTY, GB##PAPPAGALLO, M##BAND, HR##CHEN, X##CHENG, B##DASU, S##DATTA, M##FLOOD, KT##HOLLAR, JJ##KUTTER, PE##MELLADO, B##MIHALYI, A##PAN, Y##PIERINI, M##PREPOST, R##WU, SL##YU, Z##NEAL, H","CNRS, IN2P3, LAB PHYS PARTICULES, F-74941 ANNECY LE VIEUX, FRANCE. UNIV SAVOIE, F-74941 ANNECY LE VIEUX, FRANCE. UNIV BARCELONA, FAC FIS, DEPT ECM, E-08028 BARCELONA, SPAIN. UNIV BARI, DIPARTIMENTO FIS, I-70126 BARI, ITALY. IST NAZL FIS NUCL, I-70126 BARI, ITALY. INST HIGH ENERGY PHYS, BEIJING 100039, PEOPLES R CHINA. UNIV BERGEN, INST PHYS, N-5007 BERGEN, NORWAY. LAWRENCE LIVERMORE NATL LAB, BERKELEY, CA 94720 USA. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND. RUHR UNIV BOCHUM, INST EXPT PHYS, D-44780 BOCHUM, GERMANY. UNIV BRISTOL, BRISTOL BS8 1TL, AVON, ENGLAND. UNIV BRITISH COLUMBIA, VANCOUVER, BC V6T 1Z1, CANADA. BRUNEL UNIV, UXBRIDGE UB8 3PH, MIDDX, ENGLAND. BUDKER INST NUCL PHYS, NOVOSIBIRSK 630090, RUSSIA. UNIV CALIF IRVINE, IRVINE, CA 92697 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA. UNIV CALIF RIVERSIDE, RIVERSIDE, CA 92521 USA. UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA. UNIV CALIF SANTA BARBARA, SANTA BARBARA, CA 93106 USA. UNIV CALIF SANTA CRUZ, INST PARTICLE PHYS, SANTA CRUZ, CA 95064 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CINCINNATI, CINCINNATI, OH 45221 USA. UNIV COLORADO, BOULDER, CO 80309 USA. COLORADO STATE UNIV, FT COLLINS, CO 80523 USA. UNIV DORTMUND, INST PHYS, D-44221 DORTMUND, GERMANY. TECH UNIV DRESDEN, INST KERN & TEILCHENPHYS, D-01062 DRESDEN, GERMANY. ECOLE POLYTECH, CNRS, IN2P3, LAB LEPRINCE RINGUET, F-91128 PALAISEAU, FRANCE. UNIV EDINBURGH, EDINBURGH EH9 3JZ, MIDLOTHIAN, SCOTLAND. UNIV FERRARA, DIPARTIMENTO FIS, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, I-44100 FERRARA, ITALY. IST NAZL FIS NUCL, LAB NAZL FRASCATI, I-00044 FRASCATI, ITALY. UNIV GENOA, DIPARTIMENTO FIS, I-16146 GENOA, ITALY. IST NAZL FIS NUCL, I-16146 GENOA, ITALY. HARVARD UNIV, CAMBRIDGE, MA 02138 USA. HEIDELBERG UNIV, INST PHYS, D-69120 HEIDELBERG, GERMANY. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AZ, ENGLAND. UNIV IOWA, IOWA CITY, IA 52242 USA. IOWA STATE UNIV, AMES, IA 50011 USA. JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA. UNIV KARLSRUHE, INST EXPT KERNPHYS, D-76021 KARLSRUHE, GERMANY. CNRS, IN2P3, LAB ACCELERATEUR LINEAIRE, F-91898 ORSAY, FRANCE. UNIV PARIS 11, CTR SCI ORSAY, F-91898 ORSAY, FRANCE. LAWRENCE LIVERMORE NATL LAB, LIVERMORE, CA 94550 USA. UNIV LIVERPOOL, LIVERPOOL L69 7ZE, MERSEYSIDE, ENGLAND. QUEEN MARY UNIV LONDON, LONDON E1 4NS, ENGLAND. UNIV LONDON ROYAL HOLLOWAY & BEDFORD NEW COLL, EGHAM TW20 0EX, SURREY, ENGLAND. UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA. UNIV MANCHESTER, MANCHESTER M13 9PL, LANCS, ENGLAND. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. UNIV MASSACHUSETTS, AMHERST, MA 01003 USA. MIT, NUCL SCI LAB, CAMBRIDGE, MA 02139 USA. MCGILL UNIV, MONTREAL, PQ H3A 2T8, CANADA. UNIV MILAN, DIPARTIMENTO FIS, I-20133 MILAN, ITALY. IST NAZL FIS NUCL, I-20133 MILAN, ITALY. UNIV MISSISSIPPI, UNIVERSITY, MS 38677 USA. UNIV MONTREAL, MONTREAL, PQ H3C 3J7, CANADA. MT HOLYOKE COLL, S HADLEY, MA 01075 USA. UNIV NAPLES FEDERICO II, DIPARTIMENTO SCI FISICHE, I-80126 NAPLES, ITALY. IST NAZL FIS NUCL, I-80126 NAPLES, ITALY. NIKHEF H, NL-1009 DB AMSTERDAM, NETHERLANDS. UNIV NOTRE DAME, NOTRE DAME, IN 46556 USA. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. UNIV OREGON, EUGENE, OR 97403 USA. UNIV PADUA, DIPARTIMENTO FIS, I-35131 PADUA, ITALY. IST NAZL FIS NUCL, I-35131 PADUA, ITALY. UNIV PARIS 06, CNRS, IN2P3, LAB PHYS NUCL & HAUTES ENERGIES, F-75252 PARIS, FRANCE. UNIV PARIS 07, F-75252 PARIS, FRANCE. UNIV PENN, PHILADELPHIA, PA 19104 USA. UNIV PERUGIA, DIPARTIMENTO FIS, I-06100 PERUGIA, ITALY. IST NAZL FIS NUCL, I-06100 PERUGIA, ITALY. UNIV PISA, DIPARTIMENTO FIS, SCUOLA NORMALE SUPER PISA, I-56127 PISA, ITALY. UNIV PISA, IST NAZL FIS NUCL, I-56127 PISA, ITALY. PRAIRIE VIEW A&M UNIV, PRAIRIE VIEW, TX 77446 USA. PRINCETON UNIV, PRINCETON, NJ 08544 USA. UNIV ROMA LA SAPIENZA, DIPARTIMENTO FIS, I-00185 ROME, ITALY. IST NAZL FIS NUCL, I-00185 ROME, ITALY. UNIV ROSTOCK, D-18051 ROSTOCK, GERMANY. RUTHERFORD APPLETON LAB, DIDCOT OX11 0QX, OXON, ENGLAND. CEA SACLAY, DSM DAPNIA, F-91191 GIF SUR YVETTE, FRANCE. UNIV S CAROLINA, COLUMBIA, SC 29208 USA. STANFORD LINEAR ACCELERATOR CTR, STANFORD, CA 94309 USA. STANFORD UNIV, STANFORD, CA 94305 USA. SUNY ALBANY, ALBANY, NY 12222 USA. UNIV TENNESSEE, KNOXVILLE, TN 37996 USA. UNIV TEXAS, AUSTIN, TX 78712 USA. UNIV TEXAS, RICHARDSON, TX 75083 USA. UNIV TURIN, DIPARTIMENTO FIS SPERIMENTALE, I-10125 TURIN, ITALY. IST NAZL FIS NUCL, I-10125 TURIN, ITALY. UNIV TRIESTE, DIPARTIMENTO FIS, I-34127 TRIESTE, ITALY. IST NAZL FIS NUCL, I-34127 TRIESTE, ITALY. UNIV VALENCIA, IFIC, CSIC, E-46071 VALENCIA, SPAIN. UNIV VICTORIA, VICTORIA, BC V8W 3P6, CANADA. UNIV WARWICK, DEPT PHYS, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND. UNIV WISCONSIN, MADISON, WI 53706 USA. YALE UNIV, NEW HAVEN, CT 06511 USA.","ASTRONOMY & ASTROPHYSICS; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"AGOSTINELLI S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8##ALBRECHT H, 1990, Z PHYS C PART FIELDS, V48, P543##ANTREASYAN D, 1983, CRYSTAL BALL NOTE, V321##ARTUSO M, 1997, PHYS LETT B, V399, P321, DOI 10.1016/S0370-2693(97)00336-5##AUBERT B, 2004, PHYS REV D, V70, DOI [10.1103/PHYSREVD.70.091104, 10.1103/PHYSREVD.70.091106]##AUBERT B, 2004, PHYS REV D, V69, DOI [10.1103/PHYSREVD.69.111104, 10.1103/PHYSREVD.69.011102, 10.1103/PHYSREVD.69.032004]##AUBERT B, 2003, PHYS REV D, V67, DOI [10.1103/PHYSREVD.67.091101, 10.1103/PHYSREVD.67.031101]##AUBERT B, 2002, NUCL INSTRUM METH A, V479, P1, DOI 10.1016/S0168-9002(01)02012-5##FOX GC, 1978, PHYS REV LETT, V41, P1581, DOI 10.1103/PHYSREVLETT.41.1581##OKABE T, 2005, PHYS LETT B, V614, P27, DOI 10.1016/J.PHYSLETB.2005.03.060##SCORA D, 1995, PHYS REV D, V52, P2783, DOI 10.1103/PHYSREVD.52.2783##YAO WM, 2006, J PHYS G NUCL PARTIC, V33, P1, DOI 10.1088/0954-3899/33/1/001",8,2020-11-20,SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/E000444/1] FUNDING SOURCE: RESEARCHFISH
J,WOS:000242409800068,2006,NUMERICAL INVESTIGATIONS OF OSCILLONS IN 2 DIMENSIONS,"OSCILLONS, EXTREMELY LONG-LIVING LOCALIZED OSCILLATIONS OF A SCALAR FIELD, ARE STUDIED IN THEORIES WITH QUARTIC AND SINE-GORDON POTENTIALS IN TWO SPATIAL DIMENSIONS. WE PRESENT QUALITATIVE RESULTS CONCENTRATING LARGELY ON A STUDY IN FREQUENCY SPACE VIA FOURIER ANALYSIS OF OSCILLATIONS. OSCILLATIONS TAKE PLACE AT A FUNDAMENTAL FREQUENCY JUST BELOW THE THRESHOLD FOR THE PRODUCTION OF RADIATION, WITH EXPONENTIALLY SUPPRESSED HARMONICS. THE TIME EVOLUTION OF THE OSCILLATION FREQUENCY POINTS INDIRECTLY TO A LIFE TIME OF AT LEAST 10(7) OSCILLATIONS. WE STUDY ALSO ELLIPTICAL PERTURBATIONS OF THE OSCILLON, WHICH ARE SHOWN TO DECAY. WE FINISH BY PRESENTING RESULTS FOR BOOSTED AND COLLIDING OSCILLONS, WHICH POINT TO A SURPRISING PERSISTENCE AND SOLITONLIKE BEHAVIOR.",CONFIGURATIONS,NA,PHYSICAL REVIEW D,"HINDMARSH, M##SALMI, P","UNIV SUSSEX, DEPT PHYS & ASTRON, BRIGHTON BN1 9QH, E SUSSEX, ENGLAND. LEIDEN UNIV, LORENTZ INST THEORET PHYS, NL-2300 RA LEIDEN, NETHERLANDS.","ASTRONOMY & ASTROPHYSICS; PHYSICS, PARTICLES & FIELDS",ASTRONOMY & ASTROPHYSICS; PHYSICS,"ADIB AB, 2002, PHYS REV D, V66, DOI 10.1103/PHYSREVD.66.085011##BOGOLYUBSKII I. L., 1977, ZHURNAL EKSPERIMENTAL'NOI I TEORETICHESKOI FIZIKI, PIS'MA V REDAKTSIYU, V25, P120##BOGOLYUBSKII IL, 1976, JETP LETT+, V24, P12##BROADHEAD M, 2005, PHYS REV D, V72, DOI 10.1103/PHYSREVD.72.043519##COLEMAN S, 1985, NUCL PHYS B, V262, P263, DOI 10.1016/0550-3213(85)90286-X##COPELAND EJ, 2002, PHYS REV D, V65, DOI 10.1103/PHYSREVD.65.103517##COPELAND EJ, 1995, PHYS REV D, V52, P1920, DOI 10.1103/PHYSREVD.52.1920##DYMNIKOVA I., 2000, GRAVITATION & COSMOLOGY, V6, P311##FARHI E, 2005, PHYS REV D, V72, DOI 10.1103/PHYSREVD.72.101701##FODOR G, HEPTH0609023##GLEISER M, 1994, PHYS REV D, V49, P2978, DOI 10.1103/PHYSREVD.49.2978##GLEISER M, 2000, PHYS REV E, V62, P1368, DOI 10.1103/PHYSREVE.62.1368##GLEISER M, 2004, PHYS LETT B, V600, P126, DOI 10.1016/J.PHYSLETB.2004.08.064##GLEISER M, 1996, PHYS REV D, V54, P1626, DOI 10.1103/PHYSREVD.54.1626##GLEISER M, CONDMAT0310157##GLEISER M, HEPTH0602187##GRAHAM N, 2006, PHYS LETT B, V639, P541, DOI 10.1016/J.PHYSLETB.2006.06.070##HONDA EP, 2002, PHYS REV D, V65, DOI 10.1103/PHYSREVD.65.084037##KASUYA S, 2003, PHYS LETT B, V559, P99, DOI 10.1016/S0370-2693(03)00344-7##KOLB EW, 1994, PHYS REV D, V49, P5040, DOI 10.1103/PHYSREVD.49.5040##ONORATO M, 2001, PHYS REV LETT, V86, P5831, DOI 10.1103/PHYSREVLETT.86.5831##PIETTE B, 1998, NONLINEARITY, V11, P1103, DOI 10.1088/0951-7715/11/4/020##POLYAKOV AM, 1974, JETP LETT+, V20, P194##PRASAD MK, 1975, PHYS REV LETT, V35, P760, DOI 10.1103/PHYSREVLETT.35.760##RAJARAMAN R., 1982, SOLITONS INSTANTONS##RIOTTO A, 1996, PHYS LETT B, V365, P64, DOI 10.1016/0370-2693(95)01239-7##THEODORAKIS S, 2000, PHYS REV D, V61, DOI 10.1103/PHYSREVD.61.047701##THOOFT G, 1974, NUCL PHYS B, VB 79, P276##WATKINS R, 1996, DARTHEP9603",45,2020-11-20,NA
J,WOS:000242408700075,2006,STOCHASTIC ORDER PARAMETER EQUATION OF ISOMETRIC FORCE PRODUCTION REVEALED BY DRIFT-DIFFUSION ESTIMATES,"WE ADDRESS TWO QUESTIONS THAT ARE CENTRAL TO UNDERSTANDING HUMAN MOTOR CONTROL VARIABILITY: WHAT KIND OF DYNAMICAL COMPONENTS CONTRIBUTE TO MOTOR CONTROL VARIABILITY (I.E., DETERMINISTIC AND/OR RANDOM ONES), AND HOW ARE THOSE COMPONENTS STRUCTURED? TO THIS END, WE DERIVE A STOCHASTIC ORDER PARAMETER EQUATION FOR ISOMETRIC FORCE PRODUCTION FROM EXPERIMENTAL DATA USING DRIFT-DIFFUSION ESTIMATES. WE SHOW THAT THE FORCE VARIABILITY INCREASES WITH THE REQUIRED FORCE OUTPUT BECAUSE OF A DECREASE OF DETERMINISTIC STABILITY AND AN ACCOMPANYING INCREASE OF NOISE INTENSITY. A STRUCTURAL ANALYSIS REVEALS THAT THE DETERMINISTIC COMPONENT CONSISTS OF A LINEAR CONTROL LOOP, WHILE THE RANDOM COMPONENT INVOLVES A NOISE SOURCE THAT SCALES WITH FORCE OUTPUT. IN ADDITION, WE PRESENT EVIDENCE FOR THE EXISTENCE OF A SUBJECT-INDEPENDENT OVERALL NOISE LEVEL OF HUMAN ISOMETRIC FORCE PRODUCTION.",INTERLIMB COORDINATION; PHASE-TRANSITIONS; NOISE; MODEL; VARIABILITY; LOCOMOTION; BEHAVIOR; SYSTEMS; SIZE,NA,PHYSICAL REVIEW E,"FRANK, TD##FRIEDRICH, R##BEEK, PJ","UNIV MUNSTER, INST THEORET PHYS, D-48149 MUNSTER, GERMANY. FREE UNIV AMSTERDAM, FAC HUMAN MOVEMENT SCI, NL-1081 BT AMSTERDAM, NETHERLANDS. FREE UNIV AMSTERDAM, INST FUNDAMENTAL & CLIN HUMAN MOVEMENT SCI, NL-1081 BT AMSTERDAM, NETHERLANDS.","PHYSICS, FLUIDS & PLASMAS; PHYSICS, MATHEMATICAL",PHYSICS,"ALEXANDER RM, 1989, PHYSIOL REV, V69, P1199##AMAZEEN EL, 1997, J EXP PSYCHOL HUMAN, V23, P1552##BEEK PJ, 1995, HUM MOVEMENT SCI, V14, P573, DOI 10.1016/0167-9457(95)00028-5##BIRO TS, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.132302##BODEKER HU, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/062##BODEKER HU, 2003, PHYS REV E, V67, DOI 10.1103/PHYSREVE.67.056220##CABRERA JL, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.158702##CHEN YQ, 1997, PHYS REV LETT, V79, P4501, DOI 10.1103/PHYSREVLETT.79.4501##COLLINS JJ, 1993, EXP BRAIN RES, V95, P308, DOI 10.1007/BF00229788##COLLINS JJ, 1994, PHYS REV LETT, V73, P764, DOI 10.1103/PHYSREVLETT.73.764##CONWIT RA, 1999, CLIN NEUROPHYSIOL, V110, P1270, DOI 10.1016/S1388-2457(99)00054-1##CORBETTA D, 1999, INT J SPORT PSYCHOL, V30, P507##DAFFERTSHOFER A, 1999, PHYSICA D, V132, P243, DOI 10.1016/S0167-2789(99)00044-5##DAVIDS K, 2006, MOVEMENT SYSTEM VARI##DUARTE M, 2001, PHYS LETT A, V283, P124, DOI 10.1016/S0375-9601(01)00188-8##FITTS PM, 1954, J EXP PSYCHOL, V47, P381, DOI 10.1037/H0055392##FRANK TD, 2005, PHYS REV E, V72, DOI 10.1103/PHYSREVE.72.011112##FRANK TD, 2004, PHYS REV E, V69, DOI 10.1103/PHYSREVE.69.061104##FRANK TD, 2003, PHYS REV E, V68, DOI 10.1103/PHYSREVE.68.021912##FRANK TD, 2005, PHYSICA A, V347, P65, DOI 10.1016/J.PHYSA.2004.08.031##FRANK TD, 2004, PHYS LETT A, V328, P219, DOI 10.1016/J.PHYSLETA.2004.06.012##FRANK TD, 2001, PHYS REV E, V63, DOI 10.1103/PHYSREVE.63.011905##FRANK TD, 2005, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2005/10/P10010##FRANK TD, 2005, SPRINGER SERIES SYNE##FRIEDRICH R, 2000, PHYS LETT A, V271, P217, DOI 10.1016/S0375-9601(00)00334-0##FRIEDRICH R, 2000, PHYS REV LETT, V84, P5224, DOI 10.1103/PHYSREVLETT.84.5224##FRIEDRICH R, 1997, PHYS REV LETT, V78, P863, DOI 10.1103/PHYSREVLETT.78.863##FRIEDRICH R, 1997, PHYSICA D, V102, P147, DOI 10.1016/S0167-2789(96)00235-7##GITTERMAN M, 1999, J PHYS A-MATH GEN, V32, PL293, DOI 10.1088/0305-4470/32/27/101##GUILLOUZIC S, 1999, PHYS REV E, V59, P3970, DOI 10.1103/PHYSREVE.59.3970##HAKEN H., 1996, PRINCIPLES BRAIN FUN##HAKEN H., 2004, SYNERGETICS INTRO AD##HANGGI P, 1985, PHYS REV A, V32, P695, DOI 10.1103/PHYSREVA.32.695##HARRIS CM, 1998, NATURE, V394, P780, DOI 10.1038/29528##HENNEMAN E, 1965, J NEUROPHYSIOL, V28, P560##HENNEMAN E, 1979, INTEGRATION NERVOUS, P13##HORSTHEMKE W., 1984, NOISE INDUCED TRANSI##HOYT DF, 1981, NATURE, V292, P239, DOI 10.1038/292239A0##JAFARI GR, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.226101##KAC M, 1947, SELECTED PAPERS NOIS, P295##KELSO J. A. S., 1995, DYNAMIC PATTERNS SEL##KRISO S, 2002, PHYS LETT A, V299, P287, DOI 10.1016/S0375-9601(02)00288-8##KUUSELA T, 2004, PHYS REV E, V69, DOI 10.1103/PHYSREVE.69.031916##LANGENBERG U, 1998, EXP BRAIN RES, V118, P161, DOI 10.1007/S002210050268##LARRALDE H, 2004, PHYS REV E, V69, DOI 10.1103/PHYSREVE.69.027102##LONGTIN A, 1990, PHYS REV A, V41, P6992, DOI 10.1103/PHYSREVA.41.6992##MADISON G, 2001, J EXP PSYCHOL HUMAN, V27, P411, DOI 10.1037/0096-1523.27.2.411##MATTHEWS PBC, 1996, J PHYSIOL-LONDON, V492, P597, DOI 10.1113/JPHYSIOL.1996.SP021332##MORRISON S, 1996, EXP BRAIN RES, V110, P455##MORRISON S, 1998, J MOTOR BEHAV, V30, P323, DOI 10.1080/00222899809601347##NEWELL KM, 1997, EXP BRAIN RES, V113, P158, DOI 10.1007/BF02454152##PATANARAPEELERT K, UNPUB##PEPER CE, 1995, J EXP PSYCHOL HUMAN, V21, P1117, DOI 10.1037/0096-1523.21.5.1117##PETERKA RJ, 2000, BIOL CYBERN, V82, P335, DOI 10.1007/S004220050587##POST AA, 2000, BIOL CYBERN, V83, P443, DOI 10.1007/S004220000177##PRIPLATA A, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.238101##RENNER C, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.124502##RENNER C, 2001, PHYSICA A, V298, P499, DOI 10.1016/S0378-4371(01)00269-2##RILEY MA, 1997, EXP BRAIN RES, V117, P165, DOI 10.1007/S002210050211##RISKEN H., 1989, FOKKER PLANCK EQUATI##SANCHO JM, 1982, PHYS REV A, V26, P1589, DOI 10.1103/PHYSREVA.26.1589##SANGPOUR P, 2005, PHYS REV B, V71, DOI 10.1103/PHYSREVB.71.155423##SCHOLZ JP, 1987, PHYS LETT A, V123, P390, DOI 10.1016/0375-9601(87)90038-7##SCHONER G, 1986, BIOL CYBERN, V53, P247, DOI 10.1007/BF00336995##SLIFKIN A, 1999, J EXP PSYCHOL HUMAN, V25, P837, DOI 10.1037/0096-1523.25.3.837##STARK L, 1958, NATURE, V182, P857, DOI 10.1038/182857A0##STERNAD D, 2000, J MOTOR BEHAV, V32, P249, DOI 10.1080/00222890009601376##STRATONOVICH R. L., 1963, TOPICS THEORY RANDOM, VI##TASS P, 1996, PHYS REV E, V54, PR2224, DOI 10.1103/PHYSREVE.54.R2224##TASS P, 1998, PHYS REV LETT, V81, P3291, DOI 10.1103/PHYSREVLETT.81.3291##TURVEY MT, 1990, AM PSYCHOL, V45, P938, DOI 10.1037/0003-066X.45.8.938##USUI S, 1982, BIOL CYBERN, V45, P13, DOI 10.1007/BF00387209##VASILAKOS K, 1993, J THEOR BIOL, V165, P389, DOI 10.1006/JTBI.1993.1196##WAECHTER M, 2004, EUR PHYS J B, V41, P259, DOI 10.1140/EPJB/E2004-00317-4",28,2020-11-20,NA
J,WOS:000242408800034,2006,HEAT FLUX INTENSIFICATION BY VORTICAL FLOW LOCALIZATION IN ROTATING CONVECTION,"THE EFFECT OF ROTATION ON TURBULENT CONVECTIVE FLOW BETWEEN PARALLEL PLATES HAS BEEN ASSESSED WITH DIRECT NUMERICAL SIMULATIONS. WITH INCREASING ROTATION-RATE AN INTERESTING TRANSITION IS OBSERVED IN THE VERTICAL-VELOCITY SKEWNESS. THIS TRANSITION INDICATES A LOCALIZATION OF MOTION DIRECTED AWAY FROM THE WALL AND CORRELATES WELL WITH CHANGES OBSERVED IN THE HEAT FLUX, AS WELL AS IN THE THERMAL AND VISCOUS BOUNDARY LAYER THICKNESSES. THE FORMATION OF LOCALIZED INTENSE VORTICAL STRUCTURES PROVIDES FOR INTENSIFIED VERTICAL HEAT TRANSPORT THROUGH EKMAN PUMPING. AT HIGHER ROTATION-RATES THIS IS COUNTERACTED BY THE INHIBITION OF VERTICAL MOTION BY ROTATION AS EXPRESSED IN THE GEOSTROPHIC THERMAL-WIND BALANCE.",RAYLEIGH-BENARD CONVECTION; NONLINEAR CONVECTION; THERMAL TURBULENCE; BOUNDARY-LAYER; PRANDTL NUMBER; TRANSPORT; DEPENDENCE,NA,PHYSICAL REVIEW E,"KUNNEN, RPJ##CLERCX, HJH##GEURTS, BJ","EINDHOVEN UNIV TECHNOL, DEPT PHYS, NL-5600 MB EINDHOVEN, NETHERLANDS. UNIV TWENTE, DEPT APPL MATH, NL-7500 AE ENSCHEDE, NETHERLANDS.","PHYSICS, FLUIDS & PLASMAS; PHYSICS, MATHEMATICAL",PHYSICS,"BASSOM AP, 1994, GEOPHYS ASTRO FLUID, V76, P223, DOI 10.1080/03091929408203666##BOUBNOV BM, 1986, J FLUID MECH, V167, P503, DOI 10.1017/S002211208600294X##BROWN E, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1964987##CASTAING B, 1989, J FLUID MECH, V204, P1, DOI 10.1017/S0022112089001643##CHANDRASEKHAR S., 1961, HYDRODYNAMIC HYDROMA##CONSTANTIN P, 1999, PHYSICA D, V125, P275, DOI 10.1016/S0167-2789(98)00252-8##DEARDORFF JW, 1985, BOUND-LAY METEOROL, V32, P205, DOI 10.1007/BF00121880##GILL A.E., 1982, ATMOSPHERE OCEAN DYN##GROSSMANN S, 2000, J FLUID MECH, V407, P27, DOI 10.1017/S0022112099007545##HUNTER C, 1975, J FLUID MECH, V72, P433, DOI 10.1017/S0022112075003072##JULIEN K, 1996, J FLUID MECH, V322, P243, DOI 10.1017/S0022112096002789##KERR RM, 1996, J FLUID MECH, V310, P139, DOI 10.1017/S0022112096001760##KERR RM, 2000, J FLUID MECH, V419, P325, DOI 10.1017/S0022112000001464##LIU YM, 1997, PHYS REV LETT, V79, P2257, DOI 10.1103/PHYSREVLETT.79.2257##MOENG CH, 1990, J ATMOS SCI, V47, P1149, DOI 10.1175/1520-0469(1990)047<1149:VVSITB>2.0.CO;2##NIEMELA JJ, 2000, NATURE, V404, P837, DOI 10.1038/35009036##PFOTENHAUER JM, 1984, J FLUID MECH, V145, P239, DOI 10.1017/S0022112084002901##ROSSBY HT, 1969, J FLUID MECH, V36, P309, DOI 10.1017/S0022112069001674##SAKAI S, 1997, J FLUID MECH, V333, P85, DOI 10.1017/S0022112096004168##SHRAIMAN BI, 1990, PHYS REV A, V42, P3650, DOI 10.1103/PHYSREVA.42.3650##SPRAGUE M, 2006, J FLUID MECH, V551, P141, DOI 10.1017/S0022112005008499##VERSTAPPEN RWCP, 2003, J COMPUT PHYS, V187, P343, DOI 10.1016/S0021-9991(03)00126-8##WU XZ, 1992, PHYS REV A, V45, P842, DOI 10.1103/PHYSREVA.45.842##ZHONG F, 1993, J FLUID MECH, V249, P135, DOI 10.1017/S0022112093001119",55,2020-11-20,NA
J,WOS:000242408700071,2006,THERMODYNAMICS OF ORGANISMS IN THE CONTEXT OF DYNAMIC ENERGY BUDGET THEORY,"WE CARRY OUT A THERMODYNAMIC ANALYSIS TO AN ORGANISM. IT IS APPLICABLE TO ANY TYPE OF ORGANISM BECAUSE (1) IT IS BASED ON A THERMODYNAMIC FORMALISM APPLICABLE TO ALL OPEN THERMODYNAMIC SYSTEMS AND (2) USES A GENERAL MODEL TO DESCRIBE THE INTERNAL STRUCTURE OF THE ORGANISM-THE DYNAMIC ENERGY BUDGET (DEB) MODEL. OUR RESULTS ON THE THERMODYNAMICS OF DEB ORGANISMS ARE THE FOLLOWING. (1) THERMODYNAMIC CONSTRAINTS FOR THE FOLLOWING TYPES OF ORGANISMS: (A) AEROBIC AND EXOTHERMIC, (B) ANAEROBIC AND EXOTHERMIC, AND (C) ANAEROBIC AND ENDOTHERMIC; SHOWING THAT ANAEROBIC ORGANISMS HAVE A HIGHER THERMODYNAMIC FLEXIBILITY. (2) A WAY TO COMPUTE THE CHANGES IN THE ENTHALPY AND IN THE ENTROPY OF LIVING BIOMASS THAT ACCOMPANY CHANGES IN GROWTH RATE SOLVING THE PROBLEM OF EVALUATING THE THERMODYNAMIC PROPERTIES OF BIOMASS AS A FUNCTION OF THE AMOUNT OF RESERVES. (3) TWO EXPRESSIONS FOR THORNTON'S COEFFICIENT THAT EXPLAIN ITS EXPERIMENTAL VARIABILITY AND THEORETICALLY UNDERPIN ITS USE IN METABOLIC STUDIES. (4) A MECHANISM THAT ORGANISMS IN NON-STEADY-STATE USE TO RID THEMSELVES OF INTERNAL ENTROPY PRODUCTION: ""DILUTION OF ENTROPY PRODUCTION BY GROWTH."" TO DEMONSTRATE THE PRACTICAL APPLICABILITY OF DEB THEORY TO QUANTIFY THERMODYNAMIC CHANGES IN ORGANISMS WE USE PUBLISHED DATA ON KLEBSIELLA AEROGENES GROWING AEROBICALLY IN A CONTINUOUS CULTURE. WE OBTAIN DIFFERENT VALUES FOR MOLAR ENTROPIES OF THE RESERVE AND THE STRUCTURE OF KLEBSIELLA AEROGENES PROVING THAT THE RESERVE DENSITY CONCEPT OF DEB THEORY IS ESSENTIAL IN DISCUSSIONS CONCERNING (A) THE RELATIONSHIP BETWEEN ORGANIZATION AND ENTROPY AND (B) THE MECHANISM OF STORING ENTROPY IN NEW BIOMASS. ADDITIONALLY, OUR RESULTS SUGGEST THAT THE ENTROPY OF DEAD BIOMASS IS SIGNIFICANTLY DIFFERENT FROM THE ENTROPY OF LIVING BIOMASS.",ESCHERICHIA-COLI K-12; MICROBIAL-GROWTH; SACCHAROMYCES-CEREVISIAE; ABSOLUTE ENTROPY; LIVING SYSTEMS; CELLS; HEAT; CALORIMETRY; PNEUMONIAE; ENERGETICS,NA,PHYSICAL REVIEW E,"SOUSA, T##MOTA, R##DOMINGOS, T##KOOIJMAN, SALM","INST SUPER TECN, DEM, ENVIRONM & ENERGY SECT, P-1049001 LISBON, PORTUGAL. VRIJE UNIV AMSTERDAM, DEPT THEORET BIOL, AMSTERDAM, NETHERLANDS.","PHYSICS, FLUIDS & PLASMAS; PHYSICS, MATHEMATICAL",PHYSICS,"BATTLEY EH, 1995, THERMOCHIM ACTA, V250, P337, DOI 10.1016/0040-6031(94)01963-H##BATTLEY EH, 1993, BIOTECHNOL BIOENG, V41, P422, DOI 10.1002/BIT.260410405##BATTLEY EH, 1997, THERMOCHIM ACTA, V298, P37, DOI 10.1016/S0040-6031(97)00108-1##BATTLEY EH, 1999, THERMOCHIM ACTA, V326, P7, DOI 10.1016/S0040-6031(98)00584-X##BATTLEY EH, 1998, THERMOCHIM ACTA, V309, P17, DOI 10.1016/S0040-6031(97)00357-2##BATTLEY EH, 1992, BIOTECHNOL BIOENG, V39, P5, DOI 10.1002/BIT.260390103##BEJAN A., 1988, ADV ENG THERMODYNAMI##BLAXTER K, 1989, ENERYG METABOLISM AN##DE GROOT SR, 1962, NONEQUILIBRIUM THERM##DEAN J. A., 1979, LANGES HDB CHEM##DEMIREL Y, 2002, BIOPHYS CHEM, V97, P87, DOI 10.1016/S0301-4622(02)00069-8##DUBOC P, 1995, THERMOCHIM ACTA, V251, P131, DOI 10.1016/0040-6031(94)02113-3##ESENER AA, 1983, BIOTECHNOL BIOENG, V25, P2803, DOI 10.1002/BIT.260251202##ESENER AA, 1981, BIOTECHNOL BIOENG, V23, P1401, DOI 10.1002/BIT.260230620##ESENER AA, 1981, BIOTECHNOL BIOENG, V23, P1851, DOI 10.1002/BIT.260230812##ESENER AA, 1982, BIOTECHNOL BIOENG, V24, P1445, DOI 10.1002/BIT.260240615##EVANS CGT, 1970, CONTINUOUS CULTURE M##GARBY LARS, 1995, BIOENERGETICS ITS TH##GNAIGER E, 1990, BIOCHIM BIOPHYS ACTA, V1016, P328, DOI 10.1016/0005-2728(90)90164-Y##GUAN YH, 1999, J BIOTECHNOL, V69, P95, DOI 10.1016/S0168-1656(99)00007-3##HANSEN LD, 2004, THERMOCHIM ACTA, V422, P55, DOI 10.1016/J.TCA.2004.05.033##KOOIJMAN AL, 2000, DYNAMIC ENERGY MASS##KOOIJMAN SALM, 2001, PHILOS T R SOC B, V356, P331, DOI 10.1098/RSTB.2000.0771##LAMPRECHT I, 2003, THERMOCHIM ACTA, V405, P1, DOI 10.1016/S0040-6031(03)00123-0##LIU JS, 2001, BIOTECHNOL BIOENG, V75, P170, DOI 10.1002/BIT.1176##MORAN M.J., 2000, FUNDAMENTALS ENG THE##MOROWITZ HJ, 1968, ENERGY FLOW BIOL##NISBET RM, 2000, J ANIM ECOL, V69, P913, DOI 10.1046/J.1365-2656.2000.00448.X##QIAN H, 2005, BIOPHYS CHEM, V114, P213, DOI 10.1016/J.BPC.2004.12.001##ROELS J. A., 1983, ENERGETICS KINETICS##STOCKAR U, 1999, PURE APPL CHEM, V1412, P191##THORNTON WM, 1917, PHILOS MAG, V33, P196, DOI 10.1080/14786440208635627##WALSBERG GE, 2005, J EXP BIOL, V208, P1035, DOI 10.1242/JEB.01477",24,2020-11-20,NA
J,WOS:000242061200015,2006,DETECTION OF MAGNETIC MONOPOLES WITH THE ANTARES DETECTOR,"THE ANTARES COLLABORATION IS CONSTRUCTING A NEUTRINO TELESCOPE ON THE BOTTOM OF THE MEDITERRANEAN SEA. THE MAIN GOAL OF ANTARES IS TO DETECT HIGH-ENERGY COSMIC NEUTRINOS. THE DETECTION PRINCIPLE RELIES ON THE OBSERVATION OF CERENKOV LIGHT EMITTED BY NEUTRINO-INDUCED MUONS. IT IS SHOWN THAT THIS TYPE OF DETECTOR IS ALSO ABLE TO DETECT EXOTIC PARTICLES SUCH AS MAGNETIC MONOPOLES. ABOVE THE CERENKOV LIMIT, MONOPOLES CAN BE DETECTED BECAUSE OF THE EMISSION OF LARGE AMOUNTS OF DIRECT CERENKOV LIGHT. MONOPOLES ARE ALSO DETECTABLE BELOW THE CERENKOV LIMIT THROUGH THE PRODUCTION OF DELTA RAYS, WHICH IN TURN EMIT CERENKOV LIGHT. THE DEVELOPMENT OF A SOFTWARE TRIGGER FOR ANTARES DESIGNED FOR MONOPOLE DETECTION IS PRESENTED. A SIMULATION OF THE DELTA-RAY-INDUCED AND DIRECT CERENKOV LIGHT EMISSION BY MONOPOLES HAS BEEN MADE AND USED TO STUDY THE TRIGGER EFFICIENCY FOR THE DETECTION OF MONOPOLES. TECHNIQUES TO SUPPRESS BACKGROUND AT THE TRIGGER LEVEL ARE PRESENTED, AND PLANS FOR THE FUTURE ARE DISCUSSED.",NA,NA,PHYSICS OF ATOMIC NUCLEI,"VAN RENS, BAP","NIKHEF, AMSTERDAM, NETHERLANDS.","PHYSICS, NUCLEAR; PHYSICS, PARTICLES & FIELDS",PHYSICS,"AHLEN SP, 1976, PHYS REV D, V14, P2935, DOI 10.1103/PHYSREVD.14.2935##BAILEY DJL, 2002, THESIS U OXFORD OXFO##BRUNNER J, GEASIM##DEJONG M, COMMUNICATION##DERKAOUI J, 1998, ASTROPART PHYS, V9, P173, DOI 10.1016/S0927-6505(98)00016-4##DIRAC PAM, 1931, P R SOC LOND A-CONTA, V133, P60, DOI 10.1098/RSPA.1931.0130##FALCHINI E, 2005, P 29 ICRC PUN##GEORGI H, 1974, PHYS REV LETT, V33, P451, DOI 10.1103/PHYSREVLETT.33.451##KEPHART TW, 1996, ASTROPART PHYS, V4, P271, DOI 10.1016/0927-6505(95)00043-7##KING SF, 1998, PHYS LETT B, V422, P135, DOI 10.1016/S0370-2693(98)00058-6##KUZMICHEV LA, 2002, NUCL INSTRUM METH A, V482, P304, DOI 10.1016/S0168-9002(01)01679-5##LAZARIDES G, 1984, PHYS LETT B, V148, P35, DOI 10.1016/0370-2693(84)91605-8##NIESSEN P, 2001, THESIS HUMBOLDT U BE##PARTICLE DATA GROUP, 1998, EUR PHYS J C, VC3, P144##SELTZER SM, 1984, INT J APPL RADIAT IS, V35, P665, DOI 10.1016/0020-708X(84)90113-3##THOOFT G, 1974, NUCL PHYS B, VB 79, P276##TOMPKINS DR, 1965, PHYS REV, V138, PB248, DOI 10.1103/PHYSREV.138.B248##WICK S, ASTROPH0001233",0,2020-11-20,NA
J,WOS:000242408400027,2006,SUCCESSIVE INVERSE POLYNOMIAL INTERPOLATION TO OPTIMIZE SMAGORINSKY'S MODEL FOR LARGE-EDDY SIMULATION OF HOMOGENEOUS TURBULENCE,"WE PROPOSE THE SUCCESSIVE INVERSE POLYNOMIAL INTERPOLATION METHOD TO OPTIMIZE MODEL PARAMETERS IN SUBGRID PARAMETERIZATION FOR LARGE-EDDY SIMULATION. THIS APPROACH IS ILLUSTRATED FOR THE SMAGORINSKY EDDY-VISCOSITY MODEL USED IN HOMOGENEOUS DECAYING TURBULENCE. THE OPTIMAL SMAGORINSKY PARAMETER IS RESOLUTION DEPENDENT AND PROVIDES MINIMAL TOTAL ERROR IN THE RESOLVED KINETIC ENERGY. IT IS APPROXIMATED BY STARTING WITH A ""BRACKETING INTERVAL"" THAT IS OBTAINED FROM SEPARATE ""NO-MODEL"" AND ""DYNAMIC EDDY-VISCOSITY"" LARGE-EDDY SIMULATIONS. THE TOTAL ERROR LEVEL IS REDUCED 3-6 TIMES COMPARED TO THE MAXIMAL INITIAL ERRORS. THE COMPUTATIONAL OVERHEAD OF THE FULL OPTIMIZATION AT RESOLUTION N-3 IS COMPARABLE TO A SINGLE SIMULATION AT (3N/2)(3) GRID CELLS. THE INCREASED ACCURACY IS HIGHER THAN OBTAINED WITH DYNAMIC MODELING AT A RESOLUTION OF (4N)(3). (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",NUMERICAL ERRORS,NA,PHYSICS OF FLUIDS,"GEURTS, BJ##MEYERS, J","UNIV TWENTE, NACM, FAC EEMCS, NL-7500 AE ENSCHEDE, NETHERLANDS. EINDHOVEN UNIV TECHNOL, FAC APPL PHYS, FLUID DYNAM LAB, NL-5600 MB EINDHOVEN, NETHERLANDS. UNIV PARIS 06, MODELISAT MECAN LAB, F-75252 PARIS 05, FRANCE.","MECHANICS; PHYSICS, FLUIDS & PLASMAS",MECHANICS; PHYSICS,"ADAMS NA, 2004, J COMPUT PHYS, V200, P412, DOI 10.1016/J.JCP.2004.04.010##BORIS JP, 1992, FLUID DYN RES, V10, P199, DOI 10.1016/0169-5983(92)90023-P##BRENT RP, 1973, ALGORITHMS MINIMIZAT##DOMARADZKI JA, 2003, PHYS FLUIDS, V15, P3890, DOI 10.1063/1.1624610##FORSYTHE G., 1977, COMPUTER METHODS MAT##FUREBY C, 1999, AIAA J, V37, P544, DOI 10.2514/2.772##FUREBY C, 2002, J COMPUT PHYS, V181, P68, DOI 10.1006/JCPH.2002.7119##GERMANO M, 1991, PHYS FLUIDS A-FLUID, V3, P1760, DOI 10.1063/1.857955##GEURTS BJ, 2003, PHYS FLUIDS, V15, PL13, DOI 10.1063/1.1529180##GEURTS BJ, 2002, PHYS FLUIDS, V14, PL41, DOI 10.1063/1.1480830##GEURTS BJ, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2140022##GEURTS BJ, 2003, ELEMENTS DIRECT LARG##GHOSAL S, 1996, J COMPUT PHYS, V125, P187, DOI 10.1006/JCPH.1996.0088##GUERTS BJ, 1993, J ENG MATH, V27, P293##KRAVCHENKO AG, 1997, J COMPUT PHYS, V131, P310, DOI 10.1006/JCPH.1996.5597##LESIEUR M, 1996, ANNU REV FLUID MECH, V28, P45##LILLY DK, 1992, PHYS FLUIDS A-FLUID, V4, P633, DOI 10.1063/1.858280##MARGOLIN LG, 2006, J TURBUL, V7, P1, DOI 10.1080/14685240500331595##MENEVEAU C, 2000, ANNU REV FLUID MECH, V32, P1, DOI 10.1146/ANNUREV.FLUID.32.1.1##MEYERS J, 2003, PHYS FLUIDS, V15, P2740, DOI 10.1063/1.1597683##MEYERS J, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1879054##POPE SB, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/035##PRESS WH, 1992, NUMERICAL RECIPES C##ROGALLO RS, 1984, ANNU REV FLUID MECH, V16, P99, DOI 10.1146/ANNUREV.FL.16.010184.000531##SAGAUT P, 2005, SCI COMPUTATION##SMAGORINSKY J., 1963, MON WEATHER REV, V91, P99, DOI [DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091]##VREMAN B, 1996, INT J NUMER METH FL, V22, P297",11,2020-11-20,NA
J,WOS:000241517800011,2006,"REAL-TIME TRACE GAS SENSING OF ETHYLENE, PROPANAL AND ACETALDEHYDE FROM HUMAN SKIN IN VIVO","TRACE GASES EMITTED BY HUMAN SKIN IN VIVO ARE MONITORED NON-INVASIVELY AND IN REAL TIME USING LASER-BASED PHOTOACOUSTIC DETECTION AND PROTON-TRANSFER REACTION MASS SPECTROMETRY. A SMALL QUARTZ CUVETTE IS PLACED ON THE SKIN TO CREATE A HEADSPACE FROM WHICH A CARRIER GAS TRANSPORTS THE SKIN EMISSIONS TO THE DETECTION SYSTEMS. THE TRANSPARENCY OF QUARTZ TO ULTRAVIOLET RADIATION (UVR) ALLOWS INVESTIGATION OF UVR-RELATED TRACE GAS EMISSIONS. AS A DEMONSTRATION OF THIS MEASUREMENT SYSTEM, THE EFFECT OF SUPPLEMENTAL INTAKE OF SYSTEMIC ANTIOXIDANTS ON UVR-INDUCED LIPID PEROXIDATION IS INVESTIGATED. THE PRODUCTION BY THE SKIN OF THREE BIOMARKERS OF UVR-INDUCED LIPID PEROXIDATION (ETHYLENE, ACETALDEHYDE AND PROPANAL) ISMONITORED. ALTHOUGH NO SIGNIFICANT EFFECT OF ANTIOXIDANT INTAKE WAS OBSERVED, THE METHOD PRESENTED HERE IS A NOVEL AND PROMISING TECHNIQUE FOR INVESTIGATION OF HUMAN SKIN IN VIVO.",REACTION MASS-SPECTROMETRY; VOLATILE ORGANIC-COMPOUNDS; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; ASCORBIC-ACID; DAMAGE,TRACE GAS DETECTION; DERMATOLOGY; LASER; MASS SPECTROMETRY,PHYSIOLOGICAL MEASUREMENT,"MOESKOPS, BWM##STEEGHS, MML##VAN SWAM, K##CRISTESCU, SM##SCHEEPERS, PTJ##HARREN, FJM","RADBOUD UNIV NIJMEGEN, INST MOL & MAT, DEPT MOL & LASER PHYS, NL-6500 GL NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, NIJMEGEN MED CTR, DEPT EPIDEMIOL & BIOSTAT, NIJMEGEN, NETHERLANDS.","BIOPHYSICS; ENGINEERING, BIOMEDICAL; PHYSIOLOGY",BIOPHYSICS; ENGINEERING; PHYSIOLOGY,"BOAMFA EI, 2004, INT J MASS SPECTROM, V239, P193, DOI 10.1016/J.IJMS.2004.07.017##DE GOUW J, 2003, INT J MASS SPECTROM, V223, P365, DOI 10.1016/S1387-3806(02)00926-0##DEGRUIJL FR, 1997, RADIAT PROT DOSIM, V72, P177, DOI 10.1093/OXFORDJOURNALS.RPD.A032090##DIMITROV NV, 1991, AM J CLIN NUTR, V53, P723##EBERLEIN-KONIG B, 1998, J AM ACAD DERMATOL, V38, P45, DOI 10.1016/S0190-9622(98)70537-7##FANG YZ, 2002, NUTRITION, V18, P872, DOI 10.1016/S0899-9007(02)00916-4##FOOD AND NUTRITION BOARD INSTITUTE OF MEDICINE, 2000, DIET REF INT VIT C V##FUCHS J, 1998, FREE RADICAL BIO MED, V25, P1006, DOI 10.1016/S0891-5849(98)00132-4##HARREN F., 1997, ENCY APPL PHYSICS, V19, P413##HARREN F.J.M., 2000, ENCY ANAL CHEM, P2203##HARREN FJM, 1990, APPL PHYS B-PHOTO, V50, P137, DOI 10.1007/BF00331909##HARREN FJM, 1999, APPL PHYS LETT, V74, P1761, DOI 10.1063/1.123680##HEKKERT ST, 1998, INSTRUM SCI TECHNOL, V26, P157, DOI 10.1080/10739149808002690##KNEEPKENS CMF, 1994, FREE RADICAL BIO MED, V17, P127##LINDINGER W, 1998, CHEM SOC REV, V27, P347, DOI 10.1039/A827347Z##MOLDEUS P, 1986, RESPIRATION, V50, P31##PHILLIPS M, 1992, SCI AM, V267, P74, DOI 10.1038/SCIENTIFICAMERICAN0792-74##SAGAI M, 1980, LIFE SCI, V27, P731, DOI 10.1016/0024-3205(80)90326-4##STEEGHS M, 2004, PLANT PHYSIOL, V135, P47, DOI 10.1104/PP.104.038703##STEEGHS MML, 2006, INT J MASS SPECTROM, V253, P58, DOI 10.1016/J.IJMS.2006.02.015##TOPINKA J, 1989, MUTAT RES, V225, P131, DOI 10.1016/0165-7992(89)90130-9",29,2020-11-20,NA
J,WOS:000242261700011,2006,METABOLOMIC ANALYSIS OF METHYL JASMONATE TREATED BRASSICA RAPA LEAVES BY 2-DIMENSIONAL NMR SPECTROSCOPY,"THE METABOLOMIC ANALYSIS OF BRASSICA RAPA LEAVES TREATED WITH METHYL JASMONATE WAS PERFORMED USING 2-DIMENSIONAL J-RESOLVED NMR SPECTROSCOPY COMBINED WITH MULTIVARIATE DATA ANALYSIS. THE PRINCIPAL COMPONENT ANALYSIS OF THE J-RESOLVED NMR SPECTRA SHOWED DISCRIMINATION BETWEEN CONTROL AND METHYL JASMONATE TREATED PLANTS BY PRINCIPAL COMPONENTS 1 AND 2. WHILE THE LEVEL OF GLUCOSE, SUCROSE AND AMINO ACIDS SHOWED A DECREASE AFTER METHYL JASMONATE TREATMENT, HYDROXYCINNAMATES AND GLUCOSINOLATE WERE HIGHLY INCREASED. METHYL JASMONATE TREATMENT RESULTED IN A LONG-TERM ACCUMULATION OF INDOLE GLUCOSINOLATE AND INDOLE-3-ACETIC ACID, LASTING UP TO 14 DAYS AFTER TREATMENT. MALATE CONJUGATED HYDROXYCINNAMATES ALSO EXHIBITED AN INCREASE UNTIL 14 DAYS AFTER METHYL JASMONATE TREATMENT, THESE COMPOUNDS MIGHT PLAY AN IMPORTANT ROLE IN PLANT DEFENCE RESPONSES MEDIATED BY METHYL JASMONATE. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",H-1-NMR SPECTROSCOPY; OILSEED RAPE; MULTIVARIATE-ANALYSIS; ARABIDOPSIS; ACID; IDENTIFICATION; BIOSYNTHESIS; INVOLVEMENT; INDUCTION; RESPONSES,BRASSICA RAPA; BRASSICACEAE; METABOLOMIC ANALYSIS; J-RESOLVED NMR; MULTIVARIATE ANALYSIS; INDOLE GLUCOSINOLATE; HYDROXYCINNAMATES,PHYTOCHEMISTRY,"LIANG, YS##CHOI, YH##KIM, HK##LINTHORST, HJM##VERPOORTE, R","LEIDEN UNIV, DIV PHARMACOGNOSY, SECT METABOLOM, INST BIOL, NL-2300 RA LEIDEN, NETHERLANDS. LEIDEN UNIV, DIV PLANT CELL PHYSIOL, INST BIOL, NL-2300 RA LEIDEN, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; PLANT SCIENCES,BIOCHEMISTRY & MOLECULAR BIOLOGY; PLANT SCIENCES,"BARTEL B, 1994, P NATL ACAD SCI USA, V91, P6649, DOI 10.1073/PNAS.91.14.6649##BENNETT RN, 1994, NEW PHYTOL, V127, P617, DOI 10.1111/J.1469-8137.1994.TB02968.X##BODNARYK RP, 1994, PHYTOCHEMISTRY, V35, P301, DOI 10.1016/S0031-9422(00)94752-6##BODNARYK RP, 1992, PHYTOCHEMISTRY, V31, P2671, DOI 10.1016/0031-9422(92)83609-3##BRADER G, 2001, PLANT PHYSIOL, V126, P849, DOI 10.1104/PP.126.2.849##BRINDLE JT, 2002, NAT MED, V8, P1439, DOI 10.1038/NM802##CHEN S, 2001, PLANT PHYSIOL BIOCH, V39, P743, DOI 10.1016/S0981-9428(01)01301-8##CHOI HK, 2004, PHYTOCHEMISTRY, V65, P857, DOI 10.1016/J.PHYTOCHEM.2004.01.019##CHOI YH, 2004, PLANT PHYSIOL, V135, P2398, DOI 10.1104/PP.104.041012##CREELMAN RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/ANNUREV.ARPLANT.48.1.355##DOUGHTY KJ, 1995, PHYTOCHEMISTRY, V38, P347, DOI 10.1016/0031-9422(94)00653-B##DU LC, 1995, P NATL ACAD SCI USA, V92, P12505, DOI 10.1073/PNAS.92.26.12505##FARMER EE, 2003, CURR OPIN PLANT BIOL, V6, P372, DOI 10.1016/S1369-5266(03)00045-1##GUNDLACH H, 1992, P NATL ACAD SCI USA, V89, P2389, DOI 10.1073/PNAS.89.6.2389##KEUN HC, 2006, PHARMACOL THERAPEUT, V109, P92, DOI 10.1016/J.PHARMTHERA.2005.06.008##KIM HK, 2005, CHEM PHARM BULL, V53, P105, DOI 10.1248/CPB.53.105##KRAEMER KH, 1999, PLANT CELL REP, V18, P509, DOI 10.1007/S002990050613##LIANG YS, 2006, J CHROMATOGR A, V1112, P148, DOI 10.1016/J.CHROMA.2005.11.114##LU H, 2000, PLANT SCI, V151, P67, DOI 10.1016/S0168-9452(99)00199-5##MOLGAARD P, 1988, PHYTOCHEMISTRY, V27, P2411, DOI 10.1016/0031-9422(88)87005-5##NICHOLSON JK, 2002, NAT REV DRUG DISCOV, V1, P153, DOI 10.1038/NRD728##PRESTERA T, 1996, ANAL BIOCHEM, V239, P168, DOI 10.1006/ABIO.1996.0312##ROHDE A, 2004, PLANT CELL, V16, P2749, DOI 10.1105/TPC.104.023705##ROSTAS M, 2002, J CHEM ECOL, V28, P2449, DOI 10.1023/A:1021427917603##SOLEDADE M., 1998, RECENT RESEARCH DEVELOPMENTS IN AGRICULTURAL & FOOD CHEMISTRY, V2, P513##STELMACH BA, 1999, PHYTOCHEMISTRY, V51, P187, DOI 10.1016/S0031-9422(99)00017-5##VIANT MR, 2003, BIOCHEM BIOPH RES CO, V310, P943, DOI 10.1016/J.BBRC.2003.09.092##WARD JL, 2003, PHYTOCHEMISTRY, V62, P949, DOI 10.1016/S0031-9422(02)00705-7##WEBER H, 2002, TRENDS PLANT SCI, V7, P217, DOI 10.1016/S1360-1385(02)02250-1##WEILER EW, 1993, PHYTOCHEMISTRY, V32, P591, DOI 10.1016/S0031-9422(00)95142-2##ZHAO J, 2005, BIOTECHNOL ADV, V23, P283, DOI 10.1016/J.BIOTECHADV.2005.01.003",85,2020-11-20,NA
J,WOS:000241569600012,2006,A MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION (TAQMAN) ASSAY FOR THE SIMULTANEOUS DETECTION OF MELOIDOGYNE CHITWOODI AND M-FALLAX,"THIS STUDY DESCRIBES A MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION (PCR) APPROACH FOR THE SIMULTANEOUS DETECTION OF MELOIDOGYNE CHITWOODI AND M. FALLAX IN A SINGLE ASSAY. THE APPROACH USES THREE FLUOROGENIC MINOR GROOVE BINDING (MGB) TAQMAN PROBES: ONE FAM-LABELED TO DETECT M. CHITWOODI. ONE VIC-LABELED TO DETECT M. FALLAX, AND ONE NED-LABELED TO DETECT THE INTERNAL AMPLIFICATION CONTROL (IAC) TO MONITOR FALSE NEGATIVE RESULTS. ONE COMMON PRIMER SET IS USED FOR THE AMPLIFICATION OF PART OF THE INTERNAL TRANSCRIBED SPACER (ITS) REGION OF M. CHITWOODI AND M. FALLAX AND ONE PRIMER SET FOR THE AMPLIFICATION OF THE IAC. THE TEST ENABLED DETECTION OF M. CHITWOODI AND/OR M. FALLAX IN DNA SAMPLES EXTRACTED FROM BATCHES OF JUVENILES. FROM SINGLE JUVENILES, AND FROM INFECTED PLANT MATERIAL. COMPARED WITH CURRENT ASSAYS TO DETECT M. CHITWOODI AND M. FALLAX, THE MULTIPLEX REAL-TIME PCR OFFERS THE FOLLOWING ADVANTAGES: IT IS FASTER BECAUSE THE TEST CAN SIMULTANEOUSLY DETECT BOTH QUARANTINE SPECIES WITHOUT THE NEED FOR POST-PCR PROCESSING; AND IT IS AT LEAST 10 TIMES MORE SENSITIVE THAN A COMPARABLE REGULAR PCR ALSO TARGETING THE ITS SEQUENCE. INCLUSION OF THE IAC FACILITATES THE INTERPRETATION OF THE FAM AND VIC CYCLE THRESHOLD (CT) VALUES AND CAN PREVENT THE SCORING OF FALSE NEGATIVE RESULTS WHEN FAM, VIC, AND NED CT VALUES ARE HIGH. THE TEST ALLOWS PRECISE QUANTIFICATION WHEN ONLY ONE OF THE TWO SPECIES IS PRESENT IN THE SAMPLE. HOWEVER, EXPERIMENTS WITH MIXTURES OF GENOMIC DNA OF M. CHITWOODI AND M. FALLAX REVEALED THAT THE ABILITY OF THE MULTIPLEX REALTIME PCR ASSAY TO DETECT SMALL QUANTITIES OF DNA OF ONE SPECIES IS REDUCED WHEN LARGE QUANTITIES OF DNA OF THE OTHER SPECIES ARE PRESENT.",ROOT-KNOT NEMATODES; RIBOSOMAL INTERGENIC SPACER; DNA PROBES; M-HAPLA; PCR; IDENTIFICATION; DIFFERENTIATE; AMPLIFICATION; INCOGNITA; MIXTURES,BULBS; CROCUS; DIAGNOSTICS; FLUORESCENCE; IRIS; MULTIPROBE; POTATO; ROOT-KNOT NEMATODES,PHYTOPATHOLOGY,"ZIJLSTRA, C##VAN HOOF, RA","PLANT RES INT BV, NL-6700 AA WAGENINGEN, NETHERLANDS.",PLANT SCIENCES,PLANT SCIENCES,"CASTAGNONE-SERENO P, 1999, PHYTOPATHOLOGY, V89, P380, DOI 10.1094/PHYTO.1999.89.5.380##HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/PNAS.88.16.7276##KAINZ P, 2000, BBA-GENE STRUCT EXPR, V1494, P23, DOI 10.1016/S0167-4781(00)00200-1##KARSSEN G, 2004, NEMATOLOGY, V6, P59, DOI 10.1163/156854104323072937##KARSSEN G, 2000, PLANT PARASITIC NEMA##KLERKS MM, 2004, J MICROBIOL METH, V59, P337, DOI 10.1016/J.MIMET.2004.07.011##KUTYAVIN IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/NAR/28.2.655##LANDEGREN U, 1997, ANN MED, V29, P585, DOI 10.3109/07853899709007487##PABLEO EC, 1989, J NEMATOL, V21, P260##PETERSEN DJ, 1996, FUND APPL NEMATOL, V19, P601##PETERSEN DJ, 1997, FUND APPL NEMATOL, V20, P619##PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H##TASTET C, 2001, EUR J PLANT PATHOL, V107, P821, DOI 10.1023/A:1012430621164##WILSON IG, 1997, APPL ENVIRON MICROB, V63, P3741, DOI 10.1128/AEM.63.10.3741-3751.1997##WISHART J, 2002, PHYTOPATHOLOGY, V92, P884, DOI 10.1094/PHYTO.2002.92.8.884##ZIJLSTRA C, 2004, EUR J PLANT PATHOL, V110, P855, DOI 10.1007/S10658-004-2492-6##ZIJLSTRA C, 1995, PHYTOPATHOLOGY, V85, P1231, DOI 10.1094/PHYTO-85-1231##ZIJLSTRA C, 2000, NEMATOLOGY, V2, P847, DOI 10.1163/156854100750112798##ZIJLSTRA C, 1997, FUND APPL NEMATOL, V20, P59##ZIJLSTRA C, 1997, FUND APPL NEMATOL, V20, P505##ZIJLSTRA C, 2000, EUR J PLANT PATHOL, V106, P283, DOI 10.1023/A:1008765303364##ZIJLSTRA C, 2000, OEPP EPPO, V30, P575",45,2020-11-20,NA
J,WOS:000241330800002,2006,"TED (G.J.)KLOOSTERMAN: ON INTRAUTERINE GROWTH. THE SIGNIFICANCE OF PRENATAL CARE. STUDIES ON BIRTH WEIGHT, PLACENTAL WEIGHT AND PLACENTAL INDEX","IN THE LAST CENTURY, THERE WAS A HEATED DEBATE ON WHETHER FETAL GROWTH RETARDATION IS CAUSED BY A SMALL PLACENTA OR WHETHER A PLACENTA IS SMALL BECAUSE THE BABY IS SMALL. ONE OF THE ACTIVE PARTICIPANTS IN THIS DEBATE WAS KLOOSTERMAN WHO STUDIED 80,000 BIRTH WEIGHTS, AND 30,000 PLACENTAL WEIGHTS, IN RELATION TO GESTATIONAL AGE AT BIRTH, FETAL SEX, MATERNAL PARITY, AND PERINATAL MORTALITY. HE FOUND THAT PREGNANCIES RELATED TO HEAVIER PLACENTAS LAST LONGER. HE ALSO FOUND THAT, FROM ABOUT 32 WEEKS OF GESTATION ONWARDS, CHILDREN FROM PRIMIPAROUS WOMEN AS COMPARED TO THOSE FROM MULTIPAROUS WOMEN, LIKE TWIN CHILDREN AS COMPARED TO SINGLETON CHILDREN, ARE RELATIVELY GROWTH RETARDED, MOST LIKELY RELATED TO PRIOR RELATIVELY POOR PLACENTAL GROWTH. HE CONCLUDED THAT POOR FETAL GROWTH IS NOT THE CAUSE, BUT THE RESULT OF POOR PLACENTAL GROWTH. THE CLINICAL IMPLICATION OF ALL THESE IS THAT FUTURE EARLY DETECTION OF POOR PLACENTAL GROWTH MAY PROSPECT POOR FETAL GROWTH, AND MAY EVEN ALLOW FOR EARLY INTERVENTIONS TO IMPROVE FETAL OUTCOME. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",PREGNANCY; TWINS,NA,PLACENTA,"BLEKER, OP##BUIMER, M##VAN DER POST, JAM##VAN DER VEEN, F","UNIV AMSTERDAM, ACAD MED CTR, DEPT OBSTET & GYNAECOL, NL-1100 DE AMSTERDAM, NETHERLANDS.",DEVELOPMENTAL BIOLOGY; OBSTETRICS & GYNECOLOGY; REPRODUCTIVE BIOLOGY,DEVELOPMENTAL BIOLOGY; OBSTETRICS & GYNECOLOGY; REPRODUCTIVE BIOLOGY,"BLEKER OP, 1979, BRIT J OBSTET GYNAEC, V86, P111, DOI 10.1111/J.1471-0528.1979.TB10577.X##CLAPP JF, 1995, J SOC GYNECOL INVEST, V2, P19, DOI 10.1016/1071-5576(94)00042-Y##FOX H, 1978, PATHOLOGY PLACENTA, P477##GRUENWALD P, 1970, BIOL NEONATE, V15, P79##GRUENWALD P, 1983, PLACENTA, P4##HAFNER E, 2003, PLACENTA, V24, P336, DOI 10.1053/PLAC.2002.0918##HUIDEKOPER BL, 1983, PROGR VISION, P109##KLOOSTERMAN G J, 1966, NED TIJDSCHR VERLOSKD GYNAECOL, V66, P361##KLOOSTERMAN G J, 1954, GYNAECOLOGIA, V138, P529##KLOOSTERMAN GJ, 1956, GYNAECOLOGIA, V142, P373, DOI 10.1159/000307710##KLOOSTERMAN GJ, 1970, INT J GYNECOL OBSTET, V8, P895, DOI DOI 10.1002/J.1879-3479.1970.TB00313.X##MCKEOWN T, 1953, J ENDOCRINOL, V9, P418, DOI 10.1677/JOE.0.0090418##METZENBAUER M, 2002, Z GEBURTSH NEONATOL, V206, P138, DOI 10.1055/S-2002-33671##VANBILDERBEEK J, 1960, THESIS U AMSTERDAM##WOLF H, 1989, AM J OBSTET GYNECOL, V161, P1140, DOI 10.1016/0002-9378(89)90651-0",30,2020-11-20,NA
J,WOS:000241330800003,2006,COLOUR OSCILLATIONS IN ARTERIOARTERIAL ANASTOMOSES REFLECT NATURAL DIFFERENCES IN DONOR AND RECIPIENT OXYGENATION AND HEMATOCRIT,"OUR AIM WAS TO SHOW THAT THE COLOUR DIFFERENCE BETWEEN BRIGHTER AND DARKER RED, OCCASIONALLY OBSERVED AS AN OSCILLATING BOUNDARY IN THE RECIPIENT AND DONOR PARTS OF AN ARTERIOARTERIAL ANASTOMOSIS IN SEVERE TWIN-TWIN TRANSFUSION SYNDROME (TTTS), IS A CONSEQUENCE OF NATURAL DIFFERENCES IN BLOOD OXYGENATION AND HEMATOCRIT DEVELOPING BETWEEN DONOR AND RECIPIENT TWINS. AS METHOD WE DEFINED A THEORETICAL MODEL OF THE PLACENTA WITH DIMENSIONS FROM PATHOLOGY EXAMINATION. FROM LITERATURE WE DETERMINED THE OPTICAL ABSORPTION AND SCATTERING PROPERTIES OF ALL TISSUE COMPONENTS, AND HEMATOCRIT AND OXYGEN SATURATION VALUES FOR DONOR AND RECIPIENT TWINS. FROM OUR PLACENTAL MODEL WE SIMULATED THE SPECTRUM OF BACK-SCATTERED LIGHT BY STANDARD MONTE CARLO PHOTON PROPAGATION COMPUTATIONS AND CALCULATED THE COLOUR OF CHORIONIC ARTERIAL AND VENOUS BLOOD VESSELS BY APPLYING THE PHYSICS THEORY OF COLOUR PERCEPTION. OUR COMPUTATIONS DEMONSTRATE THAT RECIPIENT ARTERIAL BLOOD IS SOMEWHAT BRIGHTER RED THAN DONOR ARTERIAL BLOOD. THE STRONG COLOUR DIFFERENCES SEEN AFTER LASER COAGULATION OF ALL ANASTOMOSES BUT THE ARTERIOARTERIAL WERE EXPLAINED FROM AN ANGIOTENSIN II CUT-OFF IN THE RECIPIENT DUE TO OBLITERATION OF ARTERIOVENOUS ANASTOMOSES, CAUSING A TEMPORARY INCREASE IN RECIPIENT PLACENTAL PERFUSION AND HENCE IN BLOOD OXYGENATION. IN CONCLUSION, NATURAL DIFFERENCES IN RECIPIENT VERSUS DONOR BLOOD OXYGEN SATURATION AND HEMATOCRIT IN SEVERE TTTS EXPLAIN THE OBSERVED COLOUR DIFFERENCES BETWEEN BRIGHTER AND DARKER RED OBSERVED IN THE RECIPIENT AND DONOR PARTS OF ARTERIOARTERIAL ANASTOMOSES. (C) 2005 ELSEVIER LTD. ALL RIGHTS RESERVED.",ARTERIO-ARTERIAL ANASTOMOSES; FETAL BLOOD; TWIN; ABSORPTION,TWIN-TWIN TRANSFUSION SYNDROME; ARTERIOARTERIAL ANASTOMOSES; RED COLOUR OSCILLATIONS; COLOUR PERCEPTION THEORY; MONTE CARLO SIMULATIONS; MODEL OF THE PLACENTA,PLACENTA,"DE VRIES, HR##AALDERS, MCG##FABER, DJ##VAN DEN WIJNGAARD, JPHM##NIKKELS, PGJ##VAN GEMERT, MJC","UNIV AMSTERDAM, ACAD MED CTR, CTR LASER, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT OBSTET & GYNECOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV MED CTR, DEPT PATHOL, UTRECHT, NETHERLANDS. WILHELMINA CHILDRENS HOSP, UTRECHT, NETHERLANDS.",DEVELOPMENTAL BIOLOGY; OBSTETRICS & GYNECOLOGY; REPRODUCTIVE BIOLOGY,DEVELOPMENTAL BIOLOGY; OBSTETRICS & GYNECOLOGY; REPRODUCTIVE BIOLOGY,"ADAMSON SL, 1990, ULTRASOUND MED BIOL, V16, P19, DOI 10.1016/0301-5629(90)90082-N##BERMUDEZ C, 2002, AM J OBSTET GYNECOL, V187, P489, DOI 10.1067/MOB.2002.124280##BERRY SM, 1995, AM J OBSTET GYNECOL, V172, P1403, DOI 10.1016/0002-9378(95)90469-7##BRAINARD DH, 1995, OSA HDB OPTICS, V1, PCH26##DENBOW M, 1998, PRENATAL DIAG, V18, P941, DOI 10.1002/(SICI)1097-0223(199809)18:9<941::AID-PD427>3.0.CO;2-G##FABER DJ, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.028102##GALEA P, 2005, PRENATAL DIAG, V25, P777, DOI 10.1002/PD.1264##JACQUES S. L., 1995, OPTICAL THERMAL RESP, P73, DOI DOI 10.1007/978-1-4757-6092-7_4##KASINGER W, 1981, SCAND J CLIN LAB INV, V41, P701, DOI 10.3109/00365518109090518##KEIJZER M, 1989, LASER SURG MED, V9, P148, DOI 10.1002/LSM.1900090210##MURAKOSHI T, 2003, J MATERN FETAL NEONATAL MED, V14, P247, DOI 10.1080/JMF.14.4.247.255##QUINTERO R A, 1999, J PERINATOL, V19, P550, DOI 10.1038/SJ.JP.7200292##SENAT MV, 2004, NEW ENGL J MED, V351, P136, DOI 10.1056/NEJMOA032597##SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P129, DOI 10.1111/J.1399-6576.1995.TB04347.X##TAYLOR MJO, 2004, PLACENTA, V25, P742, DOI 10.1016/J.PLACENTA.2004.02.010##TWERSKY V, 1970, J OPT SOC AM, V60, P1084, DOI 10.1364/JOSA.60.001084##VAN DEN WIJNGAARD JPHM, 2005, AM J PHYSIOL-REG I, V288, PR799, DOI 10.1152/AJPREGU.00635.2004##VAN DER HORST CMAM, 1998, NEW ENGL J MED, V338, P1028, DOI 10.1056/NEJM199804093381504##VAN GEMERT MJC, 2004, PLACENTA, V25, P748, DOI 10.1016/J.PLACENTA.2004.04.003##VAN GEMERT MJC, 2001, CURR OPIN OBSTET GYN, V13, P193, DOI 10.1097/00001703-200104000-00015##VERKRUYSSE W, 1999, LASER SURG MED, V25, P131, DOI 10.1002/(SICI)1096-9101(1999)25:2<131::AID-LSM6>3.0.CO;2-8##WYSZECKI G, 1982, COLOR SCI CONCEPTS M, P950##ZIJLSTRA WG, 1991, CLIN CHEM, V37, P1633",2,2020-11-20,NA
J,WOS:000242682100004,2006,VENUS EXPRESS SCIENCE PLANNING,"VENUS EXPRESS IS THE FIRST EUROPEAN MISSION TO THE PLANET VENUS. ITS PAYLOAD CONSISTS OF SEVEN INSTRUMENTS AND WILL INVESTIGATE THE ATMOSPHERE, THE PLASMA ENVIRONMENT, AND THE SURFACE OF VENUS FROM ORBIT. SCIENCE PLANNING IS A COMPLEX PROCESS THAT TAKES INTO ACCOUNT REQUESTS FROM ALL EXPERIMENTS AND THE OPERATIONAL CONSTRAINTS. THE PLANNING OF THE SCIENCE OPERATIONS IS BASED ON SYNERGETIC APPROACH TO PROVIDE GOOD COVERAGE OF SCIENCE THEMES DERIVED FROM THE MAIN MISSION GOALS. TYPICAL OBSERVATIONS IN A SINGLE ORBIT-SO-CALLED ""SCIENCE CASES"" ARE USED TO BUILD THE MISSION SCIENCE ACTIVITY PLAN. THE NOMINAL SCIENCE MISSION (FROM JUNE 4, 2006 TILL OCTOBER 2, 2007) IS DIVIDED IN NINE PHASES DEPENDING ON OBSERVATIONAL CONDITIONS, OCCURRENCES OF THE SOLAR AND EARTH OCCULTATION, AND PARTICULAR SCIENCE GOALS. THE OBSERVATION TIMELINES FOR EACH PHASE WERE DEVELOPED IN A COORDINATED WAY TO OPTIMIZE THE PAYLOAD ACTIVITY, MAXIMIZE THE OVERALL MISSION SCIENCE RETURN, AND TO FIT INTO THE AVAILABLE MISSION BUDGETS. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",NA,VENUS; VENUS EXPRESS; SCIENCE PLANNING,PLANETARY AND SPACE SCIENCE,"TITOV, DV##SVEDHEM, H##KOSCHNY, D##HOOFS, R##BARABASH, S##BERTAUX, JL##DROSSART, P##FORMISANO, V##HAUSLER, B##KORABLEV, O##MARKIEWICZ, WJ##NEVEJANS, D##PATZOLD, M##PICCIONI, G##ZHANG, TL##MERRITT, D##WITASSE, O##ZENDER, J##ACCOMAZZO, A##SWEENEY, M##TRILLARD, D##JANVIER, M##CLOCHET, A","MAX PLANCK INST SONNENSYST FORSCH, D-37191 KATLENBURG LINDAU, GERMANY. ESA, ESTEC, NOORDWIJK, NETHERLANDS. IRF, KIRUNA, SWEDEN. AUSTRIAN ACAD SCI, SPACE RES INST, A-8010 GRAZ, AUSTRIA. INAF, IFSI, ROME, ITALY. CNRS, SERV AERON, F-75700 PARIS, FRANCE. RUSSIAN ACAD SCI, INST SPACE RES, IKI, MOSCOW V71, RUSSIA. UNIV BUNDESWEHR, MUNICH, GERMANY. UNIV COLOGNE, IGM, D-5000 COLOGNE 41, GERMANY. OBSERV PARIS, LESIA, MEUDON, FRANCE. CNR, IASF, I-00185 ROME, ITALY. ESA, ESOC, DARMSTADT, GERMANY. EADS ASTRIUM, TOULOUSE, FRANCE.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"BARABASH S, 2006, IN PRESS PLANET SPAC##BARABASH S, 2006, IN PRESS ESA##BERTAUX JL, 2006, UNPUB PLANET SPACE S##BERTAUX JL, IN PRESS ESA##DROSSART P, 2006, UNPUB SPACE SCI##FORMISANO V, 2006, IN PRESS ESA##FORMISANO V, 2006, UNPUB PLANET SPACE S##HAUSLER B, 2006, IN PRESS ESA##*JPL, 2002, D7669 JPL##KOSCHNY D, 2006, IN PRESS ESA##MARKIEWICZ WJ, 2006, IN PRESS ESA##MARKIEWICZ WJ, 2006, UNPUB PLANET SPACE S##MOROZ VI, 2002, ADV SPACE RES, V29, P215, DOI 10.1016/S0273-1177(01)00571-3##PICCIONI G, 2006, IN PRESS ESA##SVEDHEM H, 2006, UNPUB PLANET SPACE S##SVEDHEM H, 2006, IN PRESS ESA##TITOV DV, 2006, VEXRSSDPL00022##TITOV DV, 2002, ESA##TITOV DV, 2005, VEXRSSDTN0011B##ZHANG TL, 2006, IN PRESS ESA",109,2020-11-20,NA
J,WOS:000242682100005,2006,THE PLANETARY FOURIER SPECTROMETER (PFS) ONBOARD THE EUROPEAN VENUS EXPRESS MISSION,"THE PLANETARY FOURIER SPECTROMETER (PFS) FOR THE VENUS EXPRESS MISSION IS AN INFRARED SPECTROMETER OPTIMIZED FOR ATMOSPHERIC STUDIES. THIS INSTRUMENT HAS A SHORT WAVELENGTH (SW) CHANNEL THAT COVERS THE SPECTRAL RANGE FROM 1700 TO 11400 CM(-1) (0.9-5.5 MU M) AND A LONG WAVELENGTH (LW) CHANNEL THAT COVERS 250-1700 CM(-1) (5.5-15 MU M). BOTH CHANNELS HAVE A UNIFORM SPECTRAL RESOLUTION OF 1.3 CM(-1). THE INSTRUMENT FIELD OF VIEW FOV IS ABOUT 1.6 DEGREES (FWHM) FOR THE SHORT WAVELENGTH CHANNEL AND 2.8 FOR THE LW CHANNEL WHICH CORRESPONDS TO A SPATIAL RESOLUTION OF 7 AND 12 KM WHEN VENUS IS OBSERVED FROM AN ALTITUDE OF 250 KM. PFS CAN PROVIDE UNIQUE DATA NECESSARY TO IMPROVE OUR KNOWLEDGE NOT ONLY OF THE ATMOSPHERIC PROPERTIES BUT ALSO SURFACE PROPERTIES (TEMPERATURE) AND THE SURFACE-ATMOSPHERE INTERACTION (VOLCANIC ACTIVITY). PFS WORKS PRIMARILY AROUND THE PERICENTRE OF THE ORBIT, ONLY OCCASIONALLY OBSERVING VENUS FROM LARGER DISTANCES. EACH MEASUREMENTS TAKES 4.5 S, WITH A REPETITION TIME OF 11.5 S. BY WORKING ROUGHLY 1.5 H AROUND PERICENTRE, A TOTAL OF 460 MEASUREMENTS PER ORBIT WILL BE ACQUIRED PLUS 60 FOR CALIBRATIONS. PFS IS ABLE TO TAKE MEASUREMENTS AT ALL LOCAL TIMES, ENABLING THE RETRIEVAL OF ATMOSPHERIC VERTICAL TEMPERATURE PROFILES ON BOTH THE DAY AND THE NIGHT SIDE. THE PFS MEASURES A HOST OF ATMOSPHERIC AND SURFACE PHENOMENA ON VENUS. THESE INCLUDE THE:(]) THERMAL SURFACE FLUX AT SEVERAL WAVELENGTHS NEAR 1 MU M, WITH CONCURRENT CONSTRAINTS ON SURFACE TEMPERATURE AND EMISSIVITY (INDICATIVE OF COMPOSITION); (2) THE ABUNDANCES OF SEVERAL HIGHLY-DIAGNOSTIC TRACE MOLECULAR SPECIES; (3) ATMOSPHERIC TEMPERATURES FROM 55 TO 100 KM ALTITUDE; (4) CLOUD OPACITIES AND CLOUD-TRACKED WINDS IN THE LOWER-LEVEL CLOUD LAYERS NEAR 50-KM ALTITUDES; (5) CLOUD TOP PRESSURES OF THE UPPERMOST HAZE/CLOUD REGION NEAR 70-80KM ALTITUDE; AND (6) OXYGEN AIRGLOW NEAR THE 100KM LEVEL. ALL OF THESE WILL BE OBSERVED REPEATEDLY DURING THE 500-DAY NOMINAL MISSION OF VENUS EXPRESS TO YIELD AN INCREASED UNDERSTANDING OF METEOROLOGICAL, DYNAMICAL, PHOTOCHEMICAL, AND THERMO-CHEMICAL PROCESSES IN THE VENUS ATMOSPHERE. ADDITIONALLY, PFS WILL SEARCH FOR AND CHARACTERIZE CURRENT VOLCANIC ACTIVITY THROUGH SPATIAL AND TEMPORAL ANOMALIES IN BOTH THE SURFACE THERMAL FLUX AND THE ABUNDANCES OF VOLCANIC TRACE SPECIES IN THE LOWER ATMOSPHERE. MEASUREMENT OF THE 15 MU M CO2 BAND IS VERY IMPORTANT. ITS PROFILE GIVES, BY MEANS OF A COMPLEX TEMPERATURE PROFILE RETRIEVAL TECHNIQUE, THE VERTICAL PRESSURE-TEMPERATURE RELATION, BASIS OF THE GLOBAL ATMOSPHERIC STUDY. PFS IS MADE OF FOUR MODULES CALLED O, E, P AND S BEING, RESPECTIVELY, THE INTERFEROMETER AND PROXIMITY ELECTRONICS, THE DIGITAL CONTROL UNIT, THE POWER SUPPLY AND THE POINTING DEVICE. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",MIDDLE ATMOSPHERE; CLOUD STRUCTURE; DARK SIDE; SURFACE; NIGHTSIDE; RADIATION; EMISSION,VENUS; PLANETARY ATMOSPHERE; SPECTROSCOPY,PLANETARY AND SPACE SCIENCE,"FORMISANO, V##ANGRILLI, F##ARNOLD, G##ATREYA, S##BAINES, KH##BELLUCCI, G##BEZARD, B##BILLEBAUD, F##BIONDI, D##BLECKA, MI##COLANGELI, L##COMOLLI, L##CRISP, D##D'AMORE, M##ENCRENAZ, T##EKONOMOV, A##ESPOSITO, F##FIORENZA, C##FONTI, S##GIURANNA, M##GRASSI, D##GRIEGER, B##GRIGORIEV, A##HELBERT, J##HIRSCH, H##IGNATIEV, N##JUREWICZ, A##KHATUNTSEV, I##LEBONNOIS, S##LELLOUCH, E##MATTANA, A##MATURILLI, A##MENCARELLI, E##MICHALSKA, M##MORENO, JL##MOSHKIN, B##NESPOLI, F##NIKOLSKY, Y##NUCCILLI, F##ORLEANSKI, P##PALOMBA, E##PICCIONI, G##RATAJ, M##RINALDI, G##ROSSI, M##SAGGIN, B##STAM, D##TITOV, D##VISCONTI, G##ZASOVA, L","INAF, IFSI, I-00133 ROME, ITALY. UNIV PADUA, CISAS, I-35131 PADUA, ITALY. DLR, DEUTSCH ZENTRUM LUFT & RAUMFAHRT EV, OPT INFORMAT SYST, D-2439 BERLIN, GERMANY. UNIV MICHIGAN, COLL ENGN, ANN ARBOR, MI 48109 USA. JET PROP LAB, PASADENA, CA 91011 USA. RUSSIAN ACAD SCI, IKI, SPACE RES INST, MOSCOW 117997, RUSSIA. PAS, SRC, PL-00716 WARSAW, POLAND. IST ASTROFIS SPAZIALE IASF INAF, I-00133 ROME, ITALY. OBSERV PARIS, DESPA, DEPT RECH SPATIALE, F-92195 MEUDON, FRANCE. CSIC, IST ASTROFIS ANDALUSIA, GRANADA 13030, SPAIN. UNIV LECCE, DIPARTIMENTO FIS, I-73100 LECCE, ITALY. MAX PLANCK INST AERON, D-37191 KATLENBURG LINDAU, GERMANY. OBSERV PARIS, LESIA, MEUDON SECT, F-92195 MEUDON, FRANCE. UNIV AMSTERDAM, ASTRON INST ANTON PANNEKOEK, NL-1093 SJ AMSTERDAM, NETHERLANDS. CALTECH, JET PROP LAB, DIV EARTH & SPACE SCI, PASADENA, CA 91109 USA. OAC, I-30131 NAPLES, ITALY. UNIV AQUILA, DEPT PHYS, I-67010 COPPITO, ITALY. POLITECN MILAN, I-23900 LECCE, ITALY.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ALLEN DA, 1984, NATURE, V307, P222, DOI 10.1038/307222A0##ATREYA SK, 1986, ATMOSPHERES IONOSPHE, P93##AVDUEVSKIY VS, 1983, VENUS, P681##BAINES KH, 2000, ICARUS, V148, P307, DOI 10.1006/ICAR.2000.6519##BEZARD B, 1990, NATURE, V345, P508, DOI 10.1038/345508A0##CARLSON RW, 1991, SCIENCE, V253, P1541, DOI 10.1126/SCIENCE.253.5027.1541##CARLSON RW, 1993, P LUN PLAN SCI C 24, P253##CONNES P, 1979, ASTROPHYS J, V233, PL29, DOI 10.1086/183070##CRISP D, 1991, SCIENCE, V253, P1263, DOI 10.1126/SCIENCE.11538493##CRISP D, 1997, SPACE SCI S, P353##DEBERGH C, 1991, SCIENCE, V251, P547, DOI 10.1126/SCIENCE.251.4993.547##DOBROVOLSKIS AR, 1993, ICARUS, V103, P276, DOI 10.1006/ICAR.1993.1070##DONAHUE TM, 1993, GEOPHYS RES LETT, V20, P591, DOI 10.1029/93GL00513##FEGLEY B, 1997, ICARUS, V125, P416, DOI 10.1006/ICAR.1996.5628##FORMISANO V, 2005, PLANET SPACE SCI, V53, P963, DOI 10.1016/J.PSS.2004.12.006##GRINSPOON DH, 1993, PLANET SPACE SCI, V41, P515, DOI 10.1016/0032-0633(93)90034-Y##HASHIMOTO GL, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002082##HASHIMOTO GL, 2001, ICARUS, V154, P239, DOI 10.1006/ICAR.2001.6713##KLOSE KB, 1992, J GEOPHYS RES-PLANET, V97, P16353, DOI 10.1029/92JE01865##LECACHEUX J, 1993, PLANET SPACE SCI, V41, P543, DOI 10.1016/0032-0633(93)90035-Z##LIMAYE SS, 1981, J ATMOS SCI, V38, P1220, DOI 10.1175/1520-0469(1981)038<1220:CMOVGS>2.0.CO;2##LINKIN V. M., 1987, COSMIC RESEARCH, V25, P501##MEADOWS VS, 1996, J GEOPHYS RES-PLANET, V101, P4595, DOI 10.1029/95JE03567##MEADOWS VS, 1992, VENUS LPI CONTRIBUTI, V789, P70##MOROZ VI, 2002, PLANET SPACE SCI, V50, P287, DOI 10.1016/S0032-0633(01)00128-3##MOROZ VI, 1981, SPACE SCI REV, V29, P3##PETTENGILL GH, 1992, J GEOPHYS RES-PLANET, V97, P13091, DOI 10.1029/92JE01356##PETTENGILL GH, 1988, J GEOPHYS RES-SOLID, V93, P14881, DOI 10.1029/JB093IB12P14881##PETTENGILL GH, 1996, SCIENCE, V272, P1628, DOI 10.1126/SCIENCE.272.5268.1628##POLLACK JB, 1993, ICARUS, V103, P1, DOI 10.1006/ICAR.1993.1055##SCHOFIELD JT, 1982, ICARUS, V52, P263, DOI 10.1016/0019-1035(82)90112-9##SEIFF A., 1985, ADV SPACE RES, V5, P3, DOI DOI 10.1016/0273-1177(85)90197-8##SPANKUCH D, 1985, KOSM ISSLED, V23, P206##TAYLOR F. W., 1983, VENUS, P650##TAYLOR FW, 1997, SPACE SCI S, P325##TWOMEY S, 1977, J ATMOS SCI, V34, P1085, DOI 10.1175/1520-0469(1977)034<1085:AETTCM>2.0.CO;2##VON ZAHN U., 1983, VENUS, P299##VON ZAHN U., 1985, ADV SPACE RES, V5, P173, DOI DOI 10.1016/0273-1177(85)90201-7##WILSON EH, 2003, PLANET SPACE SCI, V51, P1017, DOI 10.1016/J.PSS.2003.06.003##YUNG YL, 1982, ICARUS, V51, P199, DOI 10.1016/0019-1035(82)90080-X##ZASOVA LV, 2004, ADV SPACE RES, V34, P1655, DOI 10.1016/J.ASR.2003.09.067##ZASOVA LV, 1999, ADV SPACE RES, V23, P1559, DOI 10.1016/S0273-1177(99)00169-6",17,2020-11-20,NA
J,WOS:000242682100012,2006,OUTSTANDING AERONOMY PROBLEMS AT VENUS,"OF ALL THE NON-TERRESTRIAL IONOSPHERES AND THERMOSPHERES IN OUR SOLAR SYSTEM THOSE OF VENUS HAVE BEEN EXPLORED AND STUDIED THE MOST. THIS IS MAINLY BECAUSE OF THE 14 YEAR EXPLORATION OF THE WELL-INSTRUMENTED PIONEER VENUS SPACECRAFT AND THE THEORETICAL STUDIES PROMPTED BY THE RESULTING OBSERVATIONAL INFORMATION. HOWEVER, THERE ARE STILL A NUMBER OF AREAS WHERE THERE ARE IMPORTANT SCIENTIFIC QUESTIONS THAT REMAIN UNANSWERED. THESE AREAS INCLUDE: (I) DYNAMICS OF THE THERMOSPHERE, (II) THE ENERGY MECHANISMS/SOURCES RESPONSIBLE FOR MAINTAINING THE ELEVATED PLASMA TEMPERATURES IN THE IONOSPHERE, (III) AIRGLOW/AURORA INTENSITIES AND THEIR SOURCES, AND (IV) HOT ATOM POPULATIONS. VENUS EXPRESS IS LIKELY TO HELP ADDRESS SOME OF THE QUESTIONS RELATED TO THE AREAS LISTED UNDER (I), (III) AND (IV) ABOVE. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",NEAR-INFRARED OBSERVATIONS; CHARGE-TRANSFER REACTIONS; NIGHTSIDE IONOSPHERE; SOLAR-WIND; METEOR-SHOWERS; MHD SIMULATION; ATMOSPHERE; DYNAMICS; ELECTRONS; TRANSPORT,VENUS; AERONOMY; AIRGLOW; IONOSPHERE; UPPER ATMOSPHERE,PLANETARY AND SPACE SCIENCE,"WITASSE, O##NAGY, AF","EUROPEAN SPACE AGCY, ESTEC, RES & SCI SUPPORT DEPT, SOLAR SYST MISS DIV, NL-2200 AG NOORDWIJK, NETHERLANDS. UNIV MICHIGAN, SPRL, ANN ARBOR, MI 48109 USA.",ASTRONOMY & ASTROPHYSICS,ASTRONOMY & ASTROPHYSICS,"ALCARAZ C, 2004, J PHYS CHEM A, V108, P9998, DOI 10.1021/JP0477755##BOUGHER SW, 1997, VENUS, V11##BRANNON JF, 1993, GEOPHYS RES LETT, V20, P2739, DOI 10.1029/93GL02422##BUTLER DM, 1978, J GEOPHYS RES-SPACE, V83, P2057, DOI 10.1029/JA083IA05P02057##CHEN RH, 1978, J GEOPHYS RES-SPACE, V83, P1133, DOI 10.1029/JA083IA03P01133##CONNES P, 1979, ASTROPHYS J, V233, PL29, DOI 10.1086/183070##CRISP D, 1991, SCIENCE, V253, P1538, DOI 10.1126/SCIENCE.253.5027.1538##CRISP D, 1996, J GEOPHYS RES-PLANET, V101, P4577, DOI 10.1029/95JE03136##DOBE Z, 1995, J GEOPHYS RES, V100, P14507, DOI 10.1029/95JA00331##ELPHIC RC, 1984, GEOPHYS RES LETT, V11, P1007, DOI 10.1029/GL011I010P01007##FOX JI, 1991, SPACE SCI REV, V55, P357##FOX JL, 1991, J GEOPHYS RES, V96, P9821, DOI 10.1029/91JA00252##FOX JL, 2004, ADV SPACE RES-SERIES, V33, P132, DOI 10.1016/J.ASR.2003.08.014##FOX JL, 2001, J GEOPHYS RES-SPACE, V106, P21305, DOI 10.1029/2001JA000069##GREBOWSKY JM, 1998, J ATMOS SOL-TERR PHY, V60, P607, DOI 10.1016/S1364-6826(98)00004-2##GREBOWSKY JM, 2002, GEOPHYS MONOGRAPH, V130##GRINGAUZ KI, 1979, J GEOPHYS RES-SPACE, V84, P2123, DOI 10.1029/JA084IA05P02123##HUESTIS DL, 1993, J GEOPHYS RES-PLANET, V98, P10839, DOI 10.1029/93JE00997##HUNTEN DM, 1983, VENUS##JOINER J, 1996, J GEOPHYS RES, V101, P5239, DOI 10.1029/95JA03517##KLIORE A, 1967, SCIENCE, V158, P1683, DOI 10.1126/SCIENCE.158.3809.1683##KLIORE AJ, 1992, GEOPHYS MONOGRAPH, V66##KNUDSEN WC, 1980, J GEOPHYS RES-SPACE, V85, P7754, DOI 10.1029/JA085IA13P07754##KNUDSEN WC, 1985, J GEOPHYS RES-SPACE, V90, P2695, DOI 10.1029/JA090IA03P02695##KNUDSEN WC, 1980, J GEOPHYS RES-SPACE, V85, P7803, DOI 10.1029/JA085IA13P07803##KRASNOPOLSKY VA, 1981, PLANET SPACE SCI, V29, P925, DOI 10.1016/0032-0633(81)90053-2##MATHUR D, 1995, J PHYS B-AT MOL OPT, V28, P3415, DOI 10.1088/0953-4075/28/15/027##MEADOWS VS, 1996, J GEOPHYS RES-PLANET, V101, P4595, DOI 10.1029/95JE03567##MILLER KL, 1991, SPACE SCI REV, V55, P165##MRAZEK L, 2000, J PHYS CHEM A, V104, P7294, DOI 10.1021/JP0011645##NAGY AF, 1980, J GEOPHYS RES-SPACE, V85, P7795, DOI 10.1029/JA085IA13P07795##NAGY AF, 1981, GEOPHYS RES LETT, V8, P629, DOI 10.1029/GL008I006P00629##NAGY AF, 1997, VENUS, V2##NAGY AF, 2002, GEOPHYS MONOGRAPH, V130##NICOLAS C, 2002, PLANET SPACE SCI, V50, P877, DOI 10.1016/S0032-0633(02)00063-6##OHTSUKI S, 2005, ADV SPACE RES-SERIES, V36, P2038, DOI 10.1016/J.ASR.2005.05.078##PATZOLD M, 2005, SCIENCE, V310, P837, DOI 10.1126/SCIENCE.1117755##PAXTON LJ, 1985, J GEOPHYS RES-SPACE, V90, P5089, DOI 10.1029/JA090IA06P05089##RUSSELL CT, 1991, SPACE SCI REV, V55##RUSSELL CT, 1991, VENUS AERONOMY##SAFVAN CP, 1999, PHYS REV A, V60, PR3361, DOI 10.1103/PHYSREVA.60.R3361##SEIERSEN K, 2003, PHYS REV A, V68, DOI 10.1103/PHYSREVA.68.022708##SELSIS F, 2004, ASTRON ASTROPHYS, V416, P783, DOI 10.1051/0004-6361:20031724##SLANGER T, 2002, GEOPHYS MONOGRAPH, V130##SLANGER TG, 2001, SCIENCE, V291, P463, DOI 10.1126/SCIENCE.291.5503.463##SPENNER K, 1980, J GEOPHYS RES-SPACE, V85, P7655, DOI 10.1029/JA085IA13P07655##SPENNER K, 1996, J GEOPHYS RES-PLANET, V101, P4557, DOI 10.1029/95JE03495##SPENNER K, 1981, J GEOPHYS RES-SPACE, V86, P9170, DOI 10.1029/JA086IA11P09170##SPENNER K, 1997, J GEOPHYS RES-SPACE, V102, P2577, DOI 10.1029/96JA03341##TANAKA T, 1997, J GEOPHYS RES-SPACE, V102, P19805, DOI 10.1029/97JA01474##TANAKA T, 1993, J GEOPHYS RES, V98, P17251, DOI 10.1029/93JA01516##THISSEN R., 2003, GEOPHYS RES LETT, V30, P12, DOI DOI 10.1029/2003GL017007##WHITEHEAD JD, 1989, J ATMOS TERR PHYS, V51, P401, DOI 10.1016/0021-9169(89)90122-0##WITASSE O, 2002, GEOPHYS RES LETT, V29, DOI [10.1029/2002GL014781, 10.1029/2001GL014781]##WITASSE O, 1999, J GEOPHYS RES-SPACE, V104, P24639, DOI 10.1029/1999JA900260",13,2020-11-20,NA
J,WOS:000242150000009,2006,STRUCTURAL CHARACTERISTICS AND PLANT-BENEFICIAL EFFECTS OF BACTERIA COLONIZING THE SHOOTS OF FIELD GROWN CONVENTIONAL AND GENETICALLY MODIFIED T4-LYSOZYME PRODUCING POTATOES,"GENETICALLY MODIFIED POTATOES EXPRESSING ANTIBACTERIAL PROTEIN T4 LYSOZYME MAY OFFER EFFECTIVE CONTROL STRATEGIES FOR BACTERIAL PATHOGENS CAUSING SEVERE POTATO DISEASES. APART FROM THIS BENEFICIAL EFFECT, IT IS VERY IMPORTANT TO INVESTIGATE SUCH ENGINEERED POTATOES CAREFULLY FOR POTENTIAL ADVERSE EFFECTS ON POTATO-ASSOCIATED BACTERIA WHICH FREQUENTLY EXHIBIT PLANT BENEFICIAL FUNCTIONS SUCH AS PLANT GROWTH PROMOTION AND ANTAGONISM TOWARDS PATHOGENS INVADING THE PLANT. TWO FIELD EXPERIMENTS WERE CARRIED OUT IN SPAIN TO ANALYZE THE POTENTIAL EFFECTS OF CONVENTIONAL AND GENETICALLY MODIFIED T4-LYSOZYME PRODUCING POTATOES ON SHOOT-ASSOCIATED BACTERIA. THE FIRST BASELINE FIELD TRIAL 2002 WAS PERFORMED IN MELIANA IN WHICH THREE CONVENTIONAL POTATO LINES, ACHIRANA INTA, DESIREE, AND MERKUR, WERE CULTIVATED AND SAMPLED AT FLOWERING. THE SECOND FIELD TRIAL WAS CONDUCTED IN CELLA IN 2003 IN ORDER TO COMPARE THE EFFECTS OF A SENESCENT TRANSGENIC, T4 LYSOZYME EXPRESSING POTATO TRAIT, DESIREE DL 12, WITH ITS ISOGENIC, NON-TRANSFORMED PARENTAL LINE DESIREE. STRUCTURAL CHARACTERISTICS OF POTATO SHOOT-ASSOCIATED BACTERIA WAS ASSAYED BY 16S RRNA-BASED TERMINAL RESTRICTION FRAGMENT LENGTH POLYMORPHISM (T-RFLP) ANALYSIS AND DOMINANT COMMUNITY MEMBERS WITHIN T-RFLP PROFILES WERE IDENTIFIED BY SEQUENCE ANALYSIS OF GENERATED 16S RRNA GENE LIBRARIES. CULTIVABLE BACTERIA ISOLATED FROM SHOOTS OF POTATOES GROWN IN THE MELIANA FIELD TRIAL WERE MONITORED FOR ANTIBIOSIS AGAINST RALSTONIA SOLANACEARUM, WHEREAS ISOLATES DERIVED FROM SHOOTS OF POTATOES CULTIVATED IN THE CELLA TRIAL WERE SCREENED FOR ANTAGONISM AGAINST RALSTONIA SOLANACEARUM AND RHIZOCTONIA SOLANI, AND FOR 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (ACC) DEAMINASE PRODUCTION. DETERMINED ANTAGONISTS WERE IDENTIFIED BY 16S RRNA GENE ANALYSIS. ALL POTATO TRAITS HOSTED A CULTIVAR-SPECIFIC COMMUNITY OF BACTERIA WITH ANTAGONISM AGAINST THE PATHOGENS AND/OR POTENTIAL TO PRODUCE ACC DEAMINASE. SEVERAL ANTAGONISTS OBTAINED FROM THE CELLA FIELD POTATOES WERE ALSO OBSERVED AS ACC DEAMINASE PRODUCERS. COMMUNITY PROFILING REVEALED A GREATER DIVERSITY DIFFERENTIATION BETWEEN THE SENESCENT T4 LYSOZYME EXPRESSING AND PARENTAL DESIREE LINES GROWN IN THE CELLA FIELD AS COMPARED TO THE VARIATIONS BETWEEN THE THREE FLOWERING CONVENTIONAL LINES CULTIVATED IN THE MELIANA FIELD TRIAL. EFFECTS OF THE TWO VARYING FIELD SITES AND DIFFERENT VEGETATION STAGES WERE GREATER THAN THOSE OF T4 LYSOZYME WHEN INVESTIGATING THE COMMUNITY COMPOSITION OF BACTERIA COLONIZING THE SHOOTS OF THE DESIREE LINE CULTIVATED IN BOTH FIELD TRIALS.",ENDOPHYTIC BACTERIA; TRANSGENIC POTATOES; T4 LYSOZYME; SOIL TYPE; COMMUNITIES; DIVERSITY; ROOTS; RHIZOSPHERE; COTTON; STRESS,T4 LYSOZYME EXPRESSING POTATOES; SHOOT-ASSOCIATED BACTERIA; COMMUNITY COMPOSITION; FUNCTIONAL ABILITIES,PLANT AND SOIL,"RASCHE, F##MARCO-NOALES, E##VELVIS, H##VAN OVERBEEK, LS##LOPEZ, MM##VAN ELSAS, JD##SESSITSCH, A","ARC SEIBERSDORF RES GMBH, DEPT BIORESOURCES, A-2444 SEIBERSDORF, AUSTRIA. INST VALENCIANO INVEST AGR, DEPT PROT VEGETAL & BIOTECNOL, E-46113 MONCADA, SPAIN. PRI, CROP & PROD ECOL, NL-6700 AA WAGENINGEN, NETHERLANDS. UNIV GRONINGEN, CTR BIOL, NL-9751 NN HAREN, NETHERLANDS.",AGRONOMY; PLANT SCIENCES; SOIL SCIENCE,AGRICULTURE; PLANT SCIENCES,"ADAMS PD, 2002, PLANT SOIL, V240, P181, DOI 10.1023/A:1015840224564##AHRENHOLTZ I, 2000, APPL ENVIRON MICROB, V66, P1862, DOI 10.1128/AEM.66.5.1862-1865.2000##ARAUJO WL, 2002, APPL ENVIRON MICROB, V68, P4906, DOI 10.1128/AEM.68.10.4906-4914.2002##BELL CR, 1995, CAN J MICROBIOL, V41, P46, DOI 10.1139/M95-006##BERG G, 2005, FEMS MICROBIOL ECOL, V51, P215, DOI 10.1016/J.FEMSEC.2004.08.006##BROWN CM, 1975, J GEN MICROBIOL, V86, P39, DOI 10.1099/00221287-86-1-39##CHELIUS MK, 2001, MICROB ECOL, V41, P252, DOI 10.1007/S002480000087##CHEN C, 1995, BIOL CONTROL, V5, P83, DOI 10.1006/BCON.1995.1009##CHERNIN L, 2002, BOOK SOIL P, P171##CHERNIN L, 1995, APPL ENVIRON MICROB, V61, P1720, DOI 10.1128/AEM.61.5.1720-1726.1995##DALMASTRI C, 1999, MICROBIAL ECOL, V38, P273, DOI 10.1007/S002489900177##DE VRIES J, 1999, SYST APPL MICROBIOL, V22, P280, DOI 10.1016/S0723-2020(99)80075-7##DUNBAR J, 2000, APPL ENVIRON MICROB, V66, P2943, DOI 10.1128/AEM.66.7.2943-2950.2000##DURING K, 1999, FEBS LETT, V449, P93, DOI 10.1016/S0014-5793(99)00405-6##DURING K, 1994, J PHYTOPATHOL, V141, P159, DOI 10.1111/J.1439-0434.1994.TB01457.X##DURING K, 1996, MOL BREEDING, V2, P297, DOI 10.1007/BF00437908##DURING K, 1993, PLANT J, V3, P587, DOI 10.1046/J.1365-313X.1993.03040587.X##EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/NAR/17.19.7843##ELVIRA-RECUENCO M, 2000, CAN J MICROBIOL, V46, P1036, DOI 10.1139/CJM-46-11-1036##GARBEVA P, 2001, MICROBIAL ECOL, V41, P369, DOI 10.1007/S002480000096##GIRVAN MS, 2003, APPL ENVIRON MICROB, V69, P1800, DOI 10.1128/AEM.69.3.1800-1809.2003##GRICHKO VP, 2001, PLANT PHYSIOL BIOCH, V39, P11, DOI 10.1016/S0981-9428(00)01212-2##HACK H., 1993, NACHRICHTENBLATT DES DEUTSCHEN PFLANZENSCHUTZDIENSTES, V45, P11##HALLMANN J, 1999, SOIL BIOL BIOCHEM, V31, P551, DOI 10.1016/S0038-0717(98)00146-1##HALLMANN J, 1997, CAN J MICROBIOL, V43, P895, DOI 10.1139/M97-131##HEUER H, 1999, FEMS MICROBIOL ECOL, V28, P357, DOI 10.1111/J.1574-6941.1999.TB00590.X##HEUER H, 2002, APPL ENVIRON MICROB, V68, P1325, DOI 10.1128/AEM.68.3.1325-1335.2002##HIPPE S, 1989, EUR J CELL BIOL, V50, P230##KING EO, 1954, J LAB CLIN MED, V44, P301##KLOEPPER JW, 1980, NATURE, V286, P885, DOI 10.1038/286885A0##KUKLINSKY-SOBRAL J, 2004, ENVIRON MICROBIOL, V6, P1244, DOI 10.1111/J.1462-2920.2004.00658.X##LANE DJ, 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.1007/S00227-012-2133-0##LIU WT, 1997, APPL ENVIRON MICROB, V63, P4516, DOI 10.1128/AEM.63.11.4516-4522.1997##LODEWYCKX C, 2002, CRIT REV PLANT SCI, V21, P583, DOI 10.1080/0735-260291044377##LOTTMANN J, 1999, FEMS MICROBIOL ECOL, V29, P365##LUGTENBERG BJJ, 1991, CURR OPIN BIOTECH, V2, P457, DOI 10.1016/S0958-1669(05)80156-9##MALINOWSKI DP, 2000, CROP SCI, V40, P923, DOI 10.2135/CROPSCI2000.404923X##MAYAK S, 2004, PLANT SCI, V166, P525, DOI 10.1016/J.PLANTSCI.2003.10.025##MCINROY JA, 1995, CAN J MICROBIOL, V41, P895, DOI 10.1139/M95-123##OERKE E. C., 1994, CROP PRODUCTION CROP##PATRIQUIN DG, 1978, CAN J MICROBIOL, V24, P734, DOI 10.1139/M78-122##PENROSE DM, 2003, PHYSIOL PLANTARUM, V118, P10, DOI 10.1034/J.1399-3054.2003.00086.X##RASCHE F, 2006, FEMS MICROBIOL ECOL, V56, P219, DOI 10.1111/J.1574-6941.2005.00027.X##RASCHE F, 2006, J APPL ECOL, V43, P555, DOI 10.1111/J.1365-2664.2006.01169.X##SESSITSCH A, 2001, APPL ENVIRON MICROB, V67, P4215, DOI 10.1128/AEM.67.9.4215-4224.2001##SESSITSCH A, 2004, CAN J MICROBIOL, V50, P239, DOI 10.1139/W03-118##SESSITSCH A, 2002, FEMS MICROBIOL ECOL, V39, P23, DOI 10.1111/J.1574-6941.2002.TB00903.X##STURZ AV, 2000, CRIT REV PLANT SCI, V19, P1, DOI 10.1016/S0735-2689(01)80001-0##SURETTE MA, 2003, PLANT SOIL, V253, P381, DOI 10.1023/A:1024835208421##TSUGITA A, 1968, J BIOL CHEM, V243, P391##WANG CX, 2000, CAN J MICROBIOL, V46, P898, DOI 10.1139/CJM-46-10-898##WEISBURG WG, 1991, J BACTERIOL, V43, P1691##YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/ANNUREV.PP.35.060184.001103",28,2020-11-20,NA
J,WOS:000243093700020,2006,LACK OF THE LIGHT-HARVESTING COMPLEX CP24 AFFECTS THE STRUCTURE AND FUNCTION OF THE GRANA MEMBRANES OF HIGHER PLANT CHLOROPLASTS,"THE PHOTOSYSTEM II (PSII) LIGHT-HARVESTING ANTENNA IN HIGHER PLANTS CONTAINS A NUMBER OF HIGHLY CONSERVED GENE PRODUCTS WHOSE FUNCTION IS UNKNOWN. ARABIDOPSIS THALIANA PLANTS DEPLETED OF ONE OF THESE, THE CP24 LIGHT-HARVESTING COMPLEX, HAVE BEEN ANALYZED. CP24-DEFICIENT PLANTS SHOWED A DECREASE IN LIGHT-LIMITED PHOTOSYNTHETIC RATE AND GROWTH, BUT THE PIGMENT AND PROTEIN CONTENT OF THE THYLAKOID MEMBRANES WERE OTHERWISE ALMOST UNCHANGED. HOWEVER, THERE WAS A MAJOR CHANGE IN THE MACROORGANIZATION OF PSII WITHIN THESE MEMBRANES; ELECTRON MICROSCOPY AND IMAGE ANALYSIS REVEALED THE COMPLETE ABSENCE OF THE C2S2M2 LIGHT-HARVESTING COMPLEX II (LHCII)/PSII SUPERCOMPLEX PREDOMINANT IN WILD-TYPE PLANTS. INSTEAD, ONLY C2S2 SUPERCOMPLEXES, WHICH ARE DEFICIENT IN THE LHCIIB M-TRIMERS, WERE FOUND. SPECTROSCOPIC ANALYSIS CONFIRMED THE DISRUPTION OF THE WILD-TYPE MACROORGANIZATION OF PSII. IT WAS FOUND THAT THE FUNCTIONS OF THE PSII ANTENNA WERE DISTURBED: CONNECTIVITY BETWEEN PSII CENTERS WAS REDUCED, AND MAXIMUM PHOTOCHEMICAL YIELD WAS LOWERED; RAPIDLY REVERSIBLE NON-PHOTOCHEMICAL QUENCHING WAS INHIBITED; AND THE STATE TRANSITIONS WERE ALTERED KINETICALLY. CP24 IS THEREFORE AN IMPORTANT FACTOR IN DETERMINING THE STRUCTURE AND FUNCTION OF THE PSII LIGHT-HARVESTING ANTENNA, PROVIDING THE LINKER FOR ASSOCIATION OF THE M-TRIMER INTO THE PSII COMPLEX, ALLOWING A SPECIFIC MACROORGANIZATION THAT IS NECESSARY BOTH FOR MAXIMUM QUANTUM EFFICIENCY AND FOR PHOTOPROTECTIVE DISSIPATION OF EXCESS EXCITATION ENERGY.",PHOTOSYSTEM-II; THYLAKOID MEMBRANES; CHLOROPHYLL FLUORESCENCE; PHOTOSYNTHETIC MEMBRANES; CIRCULAR-DICHROISM; STATE TRANSITIONS; ANTENNA; PROTEINS; ORGANIZATION; IDENTIFICATION,NA,PLANT CELL,"KOVACS, L##DAMKJAER, J##KEREICHE, S##ILIOAIA, C##RUBAN, AV##BOEKEMA, EJ##JANSSON, S##HORTON, P","UNIV SHEFFIELD, DEPT MOL BIOL & BIOTECHNOL, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND. UMEA UNIV, DEPT PLANT PHYSIOL, UMEA PLANT SCI CTR, S-90187 UMEA, SWEDEN. UNIV GRONINGEN, DEPT BIOPHYS CHEM, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, NL-9747 AG GRONINGEN, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; PLANT SCIENCES; CELL BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; PLANT SCIENCES; CELL BIOLOGY,"ALLEN JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6##ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3##ANDERSON JM, 1995, PHOTOSYNTH RES, V46, P129, DOI 10.1007/BF00020423##ANDERSSON J, 2003, PLANT J, V35, P350, DOI 10.1046/J.1365-313X.2003.01811.X##ANDERSSON J, 2001, PLANT CELL, V13, P1193, DOI 10.1105/TPC.13.5.1193##BARZDA V, 1994, BIOCHEMISTRY-US, V33, P10837, DOI 10.1021/BI00201A034##BASSI R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272##BOEKEMA EJ, 2000, J MOL BIOL, V301, P1123, DOI 10.1006/JMBI.2000.4037##BOEKEMA EJ, 1999, BIOCHEMISTRY-US, V38, P2233, DOI 10.1021/BI9827161##BOEKEMA EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/J.1432-1327.1999.00876.X##BRIANTAIS JM, 1979, BIOCHIM BIOPHYS ACTA, V548, P128, DOI 10.1016/0005-2728(79)90193-2##CAMM EL, 1989, BIOCHIM BIOPHYS ACTA, V974, P180, DOI 10.1016/S0005-2728(89)80370-6##CROUCHMAN S, 2006, FEBS LETT, V580, P2053, DOI 10.1016/J.FEBSLET.2006.03.005##DEKKER JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/J.BBABIO.2004.09.009##DELOSME R, 1996, BBA-BIOENERGETICS, V1273, P150, DOI 10.1016/0005-2728(95)00143-3##DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L##DOBRIKOVA AG, 2003, BIOCHEMISTRY-US, V42, P11272, DOI 10.1021/BI034899J##ELRAD D, 2002, PLANT CELL, V14, P1801, DOI 10.1105/TPC.002154##FARBER A, 1997, PLANT PHYSIOL, V115, P1609, DOI 10.1104/PP.115.4.1609##FINZI L, 1989, P NATL ACAD SCI USA, V86, P8748, DOI 10.1073/PNAS.86.22.8748##GANETEG U, 2004, PLANT PHYSIOL, V134, P502, DOI 10.1104/PP.103.033324##GANETEG U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/PP.127.1.150##GARAB G, 2002, BIOCHEMISTRY-US, V41, P15121, DOI 10.1021/BI026157G##GARAB G, 1988, BIOCHEMISTRY-US, V27, P5839, DOI 10.1021/BI00416A003##GREEN BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/ANNUREV.ARPLANT.47.1.685##HALDRUP A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7##HOLT NE, 2004, BIOCHEMISTRY-US, V43, P8281, DOI 10.1021/BI0494020##HORTON P, 2005, FEBS LETT, V579, P4201, DOI 10.1016/J.FEBSLET.2005.07.003##HORTON P, 2005, J EXP BOT, V56, P365, DOI 10.1093/JXB/ERI023##HORTON P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/ANNUREV.ARPLANT.47.1.655##JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1##KELLER D, 1986, J CHEM PHYS, V84, P2972, DOI 10.1063/1.450278##KLIMMEK F, 2006, PLANT PHYSIOL, V140, P793, DOI 10.1104/PP.105.073304##KOBLIZEK M, 2001, PHOTOSYNTH RES, V68, P141, DOI 10.1023/A:1011830015167##KOURIL R, 2005, BIOCHEMISTRY-US, V44, P10935, DOI 10.1021/BI051097A##LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680A0##LAVERGNE J, 1995, BIOPHYS J, V68, P2474, DOI 10.1016/S0006-3495(95)80429-7##LAZAR D, 1999, BBA-BIOENERGETICS, V1412, P1, DOI 10.1016/S0005-2728(99)00047-X##LI XP, 2004, J BIOL CHEM, V279, P22866, DOI 10.1074/JBC.M402461200##LI XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131##LIU ZF, 2004, NATURE, V428, P287, DOI 10.1038/NATURE02373##MONTANE MH, 1998, PLANT PHYSIOL, V118, P227, DOI 10.1104/PP.118.1.227##NEDBAL L, 1999, J PHOTOCH PHOTOBIO B, V48, P154, DOI 10.1016/S1011-1344(99)00032-9##NIYOGI KK, 1997, PLANT CELL, V9, P1369, DOI 10.2307/3870388##OOSTERGETEL GT, 1998, ULTRAMICROSCOPY, V74, P47, DOI 10.1016/S0304-3991(98)00022-9##PASCAL AA, 2005, NATURE, V436, P134, DOI 10.1038/NATURE03795##PETER GF, 1991, J BIOL CHEM, V266, P16745##PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0##RUBAN AV, 2006, J BIOL CHEM, V281, P14981, DOI 10.1074/JBC.M511415200##RUBAN AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3##RUBAN AV, 2003, NATURE, V421, P648, DOI 10.1038/NATURE01344##SIMIDJIEV I, 1997, ANAL BIOCHEM, V250, P169, DOI 10.1006/ABIO.1997.2204##STAUBER EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003##TAKAHASHI H, 2006, P NATL ACAD SCI USA, V103, P477, DOI 10.1073/PNAS.0509952103##TURKINA MV, 2006, MOL CELL PROTEOMICS, V5, P1412, DOI 10.1074/MCP.M600066-MCP200##VAN ROON H, 2000, PHOTOSYNTH RES, V64, P155, DOI 10.1023/A:1006476213540##WALTERS RG, 1996, P NATL ACAD SCI USA, V93, P14204, DOI 10.1073/PNAS.93.24.14204##WENTWORTH M, 2004, BIOCHEMISTRY-US, V43, P501, DOI 10.1021/BI034975I##YAKUSHEVSKA AE, 2003, BIOCHEMISTRY-US, V42, P608, DOI 10.1021/BI027109Z##YAKUSHEVSKA AE, 2001, EUR J BIOCHEM, V268, P6020, DOI 10.1046/J.0014-2956.2001.02505.X",175,2020-11-20,NA
J,WOS:000241240300013,2006,EMPLOYING LIBRARIES OF ZINC FINGER ARTIFICIAL TRANSCRIPTION FACTORS TO SCREEN FOR HOMOLOGOUS RECOMBINATION MUTANTS IN ARABIDOPSIS,"A LIBRARY OF GENES FOR ZINC FINGER ARTIFICIAL TRANSCRIPTION FACTORS (ZF-ATF) WAS GENERATED BY FUSION OF DNA SEQUENCES ENCODING THREE-FINGER CYS(2)HIS(2) ZF DOMAINS TO THE VP16 ACTIVATION DOMAIN UNDER THE CONTROL OF THE PROMOTER OF THE RIBOSOMAL PROTEIN GENE RPS5A FROM ARABIDOPSIS THALIANA. AFTER INTRODUCTION OF THIS LIBRARY INTO AN ARABIDOPSIS HOMOLOGOUS RECOMBINATION (HR) INDICATOR LINE, WE SELECTED PRIMARY TRANSFORMANTS EXHIBITING MULTIPLE SOMATIC RECOMBINATION EVENTS. AFTER PCR-MEDIATED RESCUE OF ZF SEQUENCES, RECONSTITUTED ZF-ATFS WERE RE-INTRODUCED IN THE TARGET LINE. IN THIS MANNER, A ZF-ATF WAS IDENTIFIED THAT LED TO A 200-1000-FOLD INCREASE IN SOMATIC HR (REPLICATED IN AN INDEPENDENT SECOND TARGET LINE). A MUTANT PLANT LINE EXPRESSING THE HR-INDUCING ZF-ATF EXHIBITED INCREASED RESISTANCE TO THE DNA-DAMAGING AGENT BLEOMYCIN AND WAS MORE SENSITIVE TO METHYL METHANESULFONATE (MMS), A COMBINATION OF TRAITS NOT DESCRIBED PREVIOUSLY. OUR RESULTS DEMONSTRATE THAT THE USE OF ZF-ATF POOLS IS HIGHLY REWARDING WHEN SCREENING FOR NOVEL DOMINANT PHENOTYPES IN ARABIDOPSIS.",AGROBACTERIUM-MEDIATED TRANSFORMATION; DNA-DAMAGE; PHENOTYPIC ALTERATION; INCREASE PRODUCTION; GENE-REGULATION; CELLS; THALIANA; PLANTS; PROTEIN; CONSTRUCTION,ZINC FINGER TRANSCRIPTION FACTOR LIBRARIES; CYS(2)HIS(2) ZINC FINGER; HOMOLOGOUS RECOMBINATION; MUTAGENESIS; ARABIDOPSIS; VP16,PLANT JOURNAL,"LINDHOUT, BI##PINAS, JE##HOOYKAAS, PJJ##VAN DER ZAAL, BJ","LEIDEN UNIV, INST BIOL, DEPT MOL & DEV GENET, CLUSIUS LAB, NL-2333 AL LEIDEN, NETHERLANDS.",PLANT SCIENCES,PLANT SCIENCES,"BAGHERIEH-NAJJAR MB, 2005, PLANT J, V43, P789, DOI 10.1111/J.1365-313X.2005.02501.X##BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908##BLANCAFORT P, 2005, P NATL ACAD SCI USA, V102, P11716, DOI 10.1073/PNAS.0501162102##BLANCAFORT P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/MOL.104.002758##BLANCAFORT P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/NBT794##CHARLES K, 1998, CHEM RES TOXICOL, V11, P1580, DOI 10.1021/TX980154G##CHEN IP, 2003, PLANT J, V35, P771, DOI 10.1046/J.1365-313X.2003.01847.X##CLOUGH SJ, 1998, PLANT J, V16, P735, DOI 10.1046/J.1365-313X.1998.00343.X##DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/PNAS.77.12.7347##DREIER B, 2005, J BIOL CHEM, V280, P35588, DOI 10.1074/JBC.M506654200##DREIER B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/JBC.M102604200##DUBEST S, 2004, PLANT J, V39, P334, DOI 10.1111/J.1365-313X.2004.02136.X##DUBEST S, 2002, EMBO REP, V3, P1049, DOI 10.1093/EMBO-REPORTS/KVF211##EBERHARDY SR, 2006, J VIROL, V80, P2873, DOI 10.1128/JVI.80.6.2873-2883.2006##FAVAUDON V, 1982, BIOCHIMIE, V64, P457, DOI 10.1016/S0300-9084(82)80162-4##FRITSCH O, 2004, MOL CELL, V16, P479, DOI 10.1016/J.MOLCEL.2004.09.034##GHERBI H, 2001, EMBO REP, V2, P287, DOI 10.1093/EMBO-REPORTS/KVE069##GUAN X, 2002, P NATL ACAD SCI USA, V99, P13296, DOI 10.1073/PNAS.192412899##HEITZEBERG F, 2004, PLANT J, V38, P954, DOI 10.1111/J.1365-313X.2004.02097.X##HOLMES-DAVIS R, 2005, PLANT MOL BIOL, V57, P411, DOI 10.1007/S11103-004-7820-X##KWON RJ, 2006, BIOTECHNOL LETT, V28, P9, DOI 10.1007/S10529-005-4680-7##LAZO GR, 1991, BIO-TECHNOL, V9, P963, DOI 10.1038/NBT1091-963##LEBEL EG, 1993, P NATL ACAD SCI USA, V90, P422, DOI 10.1073/PNAS.90.2.422##LEE DK, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/NAR/GNH114##LUNDIN C, 2005, NUCLEIC ACIDS RES, V33, P3799, DOI 10.1093/NAR/GKI681##MASSON J, 1992, PLANT J, V2, P829, DOI 10.1111/J.1365-313X.1992.TB00153.X##MASSON JE, 1997, P NATL ACAD SCI USA, V94, P11731, DOI 10.1073/PNAS.94.21.11731##MASSON JE, 1997, GENETICS, V146, P401##MENGISTE T, 1999, EMBO J, V18, P4505, DOI 10.1093/EMBOJ/18.16.4505##MENKE M, 2001, MUTAT RES-GEN TOX EN, V493, P87, DOI 10.1016/S1383-5718(01)00165-6##MOLINIER J, 2005, MUTAT RES-FUND MOL M, V571, P235, DOI 10.1016/J.MRFMMM.2004.09.016##MOLINIER J, 2004, PLANT CELL, V16, P1633, DOI 10.1105/TPC.021378##MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/NAR/8.19.4321##NEUTEBOOM LW, 2006, BIOCHEM BIOPH RES CO, V339, P263, DOI 10.1016/J.BBRC.2005.11.011##NORSKOVLAURITSEN N, 1990, CANCER BIOCHEM BIOPH, V11, P265##OFFRINGA R, 1990, EMBO J, V9, P3077, DOI 10.1002/J.1460-2075.1990.TB07504.X##PARK KS, 2005, J BACTERIOL, V187, P5496, DOI 10.1128/JB.187.15.5496-5499.2005##PARK KS, 2005, BIOTECHNOL PROGR, V21, P664, DOI 10.1021/BP049658X##PARK KS, 2003, NAT BIOTECHNOL, V21, P1208, DOI 10.1038/NBT868##PASZKOWSKI J, 1988, EMBO J, V7, P4021, DOI 10.1002/J.1460-2075.1988.TB03295.X##SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563A0##SCHUERMANN D, 2005, TRENDS GENET, V21, P172, DOI 10.1016/J.TIG.2005.01.002##SEGAL DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/PNAS.96.6.2758##SWOBODA P, 1994, EMBO J, V13, P484, DOI 10.1002/J.1460-2075.1994.TB06283.X##TAKEDA S, 2004, GENE DEV, V18, P782, DOI 10.1101/GAD.295404##VAN EENENNAAM AL, 2004, METAB ENG, V6, P101, DOI 10.1016/J.YMBEN.2003.11.001##WEIGEL D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/PP.122.4.1003##WEIJERS D, 2001, DEVELOPMENT, V128, P4289",19,2020-11-20,NA
J,WOS:000241678400012,2006,TIME-LAPSE ANALYSIS OF STEM-CELL DIVISIONS IN THE ARABIDOPSIS THALIANA ROOT MERISTEM,"IN THE ARABIDOPSIS ROOT, ASYMMETRIC STEM-CELL DIVISIONS PRODUCE DAUGHTERS THAT FORM THE DIFFERENT ROOT CELL TYPES. HERE WE REPORT THE ESTABLISHMENT OF A CONFOCAL TRACKING SYSTEM THAT ALLOWS THE ANALYSIS OF NUMBERS AND ORIENTATIONS OF CELL DIVISIONS IN ROOT STEM CELLS. THE SYSTEM PROVIDES DIRECT EVIDENCE THAT STEM CELLS HAVE LOWER DIVISION RATES THAN CELLS IN THE PROXIMAL MERISTEM. IT ALSO ALLOWS TRACKING OF CELL DIVISION TIMING, WHICH WE HAVE USED TO ANALYSE THE SYNCHRONIZATION OF ROOT CAP DIVISIONS. FINALLY, IT GIVES NEW INSIGHTS INTO LATERAL ROOT CAP FORMATION: EPIDERMAL STEM-CELL DAUGHTERS CAN ROTATE THE ORIENTATION OF THE DIVISION PLANE LIKE THE STEM CELL.",SHOOT APICAL MERISTEM; CAENORHABDITIS-ELEGANS; VISUALIZATION; LINEAGE; NICHE; FATE,CELL CYCLE; GROWTH; PLANT; DEVELOPMENT; IMAGE ANALYSIS; REAL-TIME,PLANT JOURNAL,"CAMPILHO, A##GARCIA, B##VAN DER TOORN, H##VAN WIJK, H##CAMPILHO, A##SCHERES, B","UNIV UTRECHT, DEPT MOL GENET, NL-3508 TA UTRECHT, NETHERLANDS. UNIV PORTO, LAB SINAL IMAGEM BIOMED, INEB, P-4100 OPORTO, PORTUGAL. UNIV UTRECHT, CTR BIOSTAT, NL-3508 TC UTRECHT, NETHERLANDS. UNIV PORTO, FAC ENGN, DEPT ENGN ELECTROTEC COMP, P-4100 OPORTO, PORTUGAL.",PLANT SCIENCES,PLANT SCIENCES,"AIDA M, 2004, CELL, V119, P109, DOI 10.1016/J.CELL.2004.09.018##BASKIN TI, 2000, PLANT MOL BIOL, V43, P545, DOI 10.1023/A:1006383921517##BOISNARD-LORIG C, 2001, PLANT CELL, V13, P495, DOI 10.1105/TPC.13.3.495##BUVAT R., 1952, ANN SCI NAT BOT 11E SER, V13, P199##CLOUGH SJ, 1998, PLANT J, V16, P735, DOI 10.1046/J.1365-313X.1998.00343.X##CLOWES F. A. L., 1956, NEW PHYTOL, V55, P29, DOI 10.1111/J.1469-8137.1956.TB05264.X##CUTLER SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/PNAS.97.7.3718##DOLAN L, 1994, DEVELOPMENT, V120, P2465##DOLAN L, 1993, DEVELOPMENT, V119, P71##DOLZNIG H, 2004, NAT CELL BIOL, V6, P899, DOI 10.1038/NCB1166##FURNER IJ, 1992, DEVELOPMENT, V115, P755##GARCIA B, 2004, LECT NOTES COMPUT SC, V3212, P166##IRISH VF, 1992, DEVELOPMENT, V115, P745##JORGENSEN P, 2002, SCIENCE, V297, P395, DOI 10.1126/SCIENCE.1070850##NANCE J, 2002, DEVELOPMENT, V129, P387##O'CONNELL KF, 1998, GENETICS, V149, P1303##OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076##PERONA P, 1990, IEEE T PATTERN ANAL, V12, P629, DOI 10.1109/34.56205##REDDY GV, 2004, DEVELOPMENT, V131, P4225, DOI 10.1242/DEV.01261##SABATINI S, 2003, GENE DEV, V17, P354, DOI 10.1101/GAD.252503##SCHERES B, 1994, DEVELOPMENT, V120, P2475##SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4##THOMAS C, 1996, SCIENCE, V273, P603, DOI 10.1126/SCIENCE.273.5275.603##VAN DEN BERG C, 1998, NATO ADV SCI I H-CEL, V104, P237##VANDENBERG C, 1997, NATURE, V390, P287, DOI 10.1038/36856##WATT FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/SCIENCE.287.5457.1427##WILDWATER M, 2005, CELL, V123, P1337, DOI 10.1016/J.CELL.2005.09.042",74,2020-11-20,NA
J,WOS:000241892900029,2006,"LARGE EXPRESSION DIFFERENCES IN GENES FOR IRON AND ZINC HOMEOSTASIS, STRESS RESPONSE, AND LIGNIN BIOSYNTHESIS DISTINGUISH ROOTS OF ARABIDOPSIS THALIANA AND THE RELATED METAL HYPERACCUMULATOR THLASPI CAERULESCENS","THE MICRONUTRIENT ZINC HAS AN ESSENTIAL ROLE IN PHYSIOLOGICAL AND METABOLIC PROCESSES IN PLANTS AS A COFACTOR OR STRUCTURAL ELEMENT IN 300 CATALYTIC AND NONCATALYTIC PROTEINS, BUT IT IS VERY TOXIC WHEN AVAILABLE IN ELEVATED AMOUNTS. PLANTS TIGHTLY REGULATE THEIR INTERNAL ZINC CONCENTRATIONS IN A PROCESS CALLED ZINC HOMEOSTASIS. THE EXCEPTIONAL ZINC HYPERACCUMULATOR SPECIES THLASPI CAERULESCENS CAN ACCUMULATE UP TO 3% OF ZINC, BUT ALSO HIGH AMOUNTS OF NICKEL AND CADMIUM, WITHOUT ANY SIGN OF TOXICITY. THIS SHOULD HAVE DRASTIC EFFECTS ON THE ZINC HOMEOSTASIS MECHANISM. WE EXAMINED IN DETAIL THE TRANSCRIPTION PROFILES OF ROOTS OF ARABIDOPSIS THALIANA AND T. CAERULESCENS PLANTS GROWN UNDER DEFICIENT, SUFFICIENT, AND EXCESS SUPPLY OF ZINC. A TOTAL OF 608 ZINC-RESPONSIVE GENES WITH AT LEAST A 3-FOLD DIFFERENCE IN EXPRESSION LEVEL WERE DETECTED IN A. THALIANA AND 352 IN T. CAERULESCENS IN RESPONSE TO CHANGES IN ZINC SUPPLY. ONLY 14% OF THESE GENES WERE ALSO ZINC RESPONSIVE IN A. THALIANA. WHEN COMPARING A. THALIANA WITH T. CAERULESCENS AT EACH ZINC EXPOSURE, MORE THAN 2,200 GENES WERE SIGNIFICANTLY DIFFERENTIALLY EXPRESSED (>= 5-FOLD AND FALSE DISCOVERY RATE, 0.05). WHILE A LARGE FRACTION OF THESE GENES ARE OF YET UNKNOWN FUNCTION, MANY GENES WITH A DIFFERENT EXPRESSION BETWEEN A. THALIANA AND T. CAERULESCENS APPEAR TO FUNCTION IN METAL HOMEOSTASIS, IN ABIOTIC STRESS RESPONSE, AND IN LIGNIN BIOSYNTHESIS. THE HIGH EXPRESSION OF LIGNIN BIOSYNTHESIS GENES CORRESPONDS TO THE DEPOSITION OF LIGNIN IN THE ENDODERMIS, OF WHICH THERE ARE TWO LAYERS IN T. CAERULESCENS ROOTS AND ONLY ONE IN A. THALIANA.",NICOTIANAMINE SYNTHASE GENES; TRANSPORTER GENES; PLASMA-MEMBRANE; METALLICOLOUS POPULATIONS; MICROARRAY ANALYSIS; CHELATE REDUCTASE; PLANT DEFENSINS; CANDIDATE GENES; JASMONIC ACID; TOLERANCE,NA,PLANT PHYSIOLOGY,"VAN DE MORTEL, JE##VILLANUEVA, LA##SCHAT, H##KWEKKEBOOM, J##COUGHLAN, S##MOERLAND, PD##VAN THEMAAT, EVL##KOORNNEEF, M##AARTS, MGM","WAGENINGEN UNIV, GENET LAB, NL-6703 BD WAGENINGEN, NETHERLANDS. VRIJE UNIV AMSTERDAM, FAC EARTH & LIFE SCI, INST ECOL SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. SERVXS BV, NL-2333 AL LEIDEN, NETHERLANDS. AGILENT TECHNOL, WILMINGTON, DE 19808 USA. UNIV AMSTERDAM, BIOINFORMAT LAB, DEPT CLIN EPIDEMIOL BIOSTAT & BIOINFORMAT, ACAD MED CTR, NL-1100 DD AMSTERDAM, NETHERLANDS.",PLANT SCIENCES,PLANT SCIENCES,"ARMENGAUD P, 2004, PLANT PHYSIOL, V136, P2556, DOI 10.1104/PP.104.046482##ASSUNCAO AGL, 2003, NEW PHYTOL, V159, P411, DOI 10.1046/J.1469-8137.2003.00819.X##ASSUNCAO AGL, 2001, PLANT CELL ENVIRON, V24, P217, DOI 10.1111/J.1365-3040.2001.00666.X##ASSUNCAO AGL, 2003, NEW PHYTOL, V159, P351, DOI 10.1046/J.1469-8137.2003.00820.X##BAKER A J M, 1989, BIORECOVERY, V1, P81##BAKER A. J. M., 1992, P291##BECHER M, 2004, PLANT J, V37, P251, DOI 10.1046/J.1365-313X.2003.01959.X##BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/J.2517-6161.1995.TB02031.X##BERT V, 2002, NEW PHYTOL, V155, P47, DOI 10.1046/J.1469-8137.2002.00432.X##BROOKS ROBERT R., 1994, P87, DOI 10.1002/9783527615919.CH4##CLEMENS S, 2002, TRENDS PLANT SCI, V7, P309, DOI 10.1016/S1360-1385(02)02295-1##CLEMENS S, 2001, PLANTA, V212, P475, DOI 10.1007/S004250000458##COLANGELO EP, 2004, PLANT CELL, V16, P3400, DOI 10.1105/TPC.104.024315##COSTAGLIOLI P, 2005, BBA-MOL CELL BIOL L, V1734, P247, DOI 10.1016/J.BBALIP.2005.04.002##CURIE C, 2001, NATURE, V409, P346, DOI 10.1038/35053080##DIDONATO RJ, 2004, PLANT J, V39, P403, DOI 10.1111/J.1365-313X.2004.02128.X##DOUCHKOV D, 2005, PLANT CELL ENVIRON, V28, P365, DOI 10.1111/J.1365-3040.2005.01273.X##DRAGER DB, 2004, PLANT J, V39, P425, DOI 10.1111/J.1365-313X.2004.02143.X##EHLTING J, 2005, PLANT J, V42, P618, DOI 10.1111/J.1365-313X.2005.02403.X##EISEN MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/PNAS.95.25.14863##EREN E, 2004, PLANT PHYSIOL, V136, P3712, DOI 10.1104/PP.104.046292##GENTLEMAN RC, 2004, GENOME BIOL, V5, DOI 10.1186/GB-2004-5-10-R80##GRAVOT A, 2004, FEBS LETT, V561, P22, DOI 10.1016/S0014-5793(04)00072-9##GREEN LS, 2004, PLANT PHYSIOL, V136, P2523, DOI 10.1104/PP.104.045633##GROTZ N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/PNAS.95.12.7220##GUERINOT ML, 1999, CURR OPIN PLANT BIOL, V2, P244, DOI 10.1016/S1369-5266(99)80042-9##HAMMOND JP, 2006, NEW PHYTOL, V170, P239, DOI 10.1111/J.1469-8137.2006.01662.X##HANNOUFA A, 1996, PLANT J, V10, P459, DOI 10.1046/J.1365-313X.1996.10030459.X##HOOKER TS, 2002, PLANT PHYSIOL, V129, P1568, DOI 10.1104/PP.003707##HUSSAIN D, 2004, PLANT CELL, V16, P1327, DOI 10.1105/TPC.020487##INAN G, 2004, PLANT PHYSIOL, V135, P1718, DOI 10.1104/PP.104.041723##KIM D, 2004, PLANT J, V39, P237, DOI 10.1111/J.1365-313X.2004.02126.X##KIM S, 2005, PLANT CELL PHYSIOL, V46, P1809, DOI 10.1093/PCP/PCI196##KOBAE Y, 2004, PLANT CELL PHYSIOL, V45, P1749, DOI 10.1093/PCP/PCI015##LAHNER B, 2003, NAT BIOTECHNOL, V21, P1215, DOI 10.1038/NBT865##LANQUAR V, 2005, EMBO J, V24, P4041, DOI 10.1038/SJ.EMBOJ.7600864##LASAT MM, 1996, PLANT PHYSIOL, V112, P1715, DOI 10.1104/PP.112.4.1715##LEE J, 2004, PLANT MOL BIOL, V54, P805, DOI 10.1007/S11103-004-0190-6##LING HQ, 1999, P NATL ACAD SCI USA, V96, P7098, DOI 10.1073/PNAS.96.12.7098##LOMBI E, 2002, PLANT PHYSIOL, V128, P1359, DOI 10.1104/PP.010731##LUO M, 2000, P NATL ACAD SCI USA, V97, P10637, DOI 10.1073/PNAS.170292997##MAKSYMIEC W, 2005, J PLANT PHYSIOL, V162, P1338, DOI 10.1016/J.JPLPH.2005.01.013##MARSCHNER H., 1995, MINERAL NUTR HIGHER##MCGRATH SP, 1997, PLANT SOIL, V188, P153, DOI 10.1023/A:1004248123948##MEERTS P, 1997, PLANT ECOL, V133, P221, DOI 10.1023/A:1009717619579##MEYERS BC, 2004, GENOME RES, V14, P1641, DOI 10.1101/GR.2275604##MIROUZE M, 2006, PLANT J, V47, P329, DOI 10.1111/J.1365-313X.2006.02788.X##MUKHERJEE I, 2005, PLANTA, V14, P1##PAPOYAN A, 2004, PLANT PHYSIOL, V136, P3814, DOI 10.1104/PP.104.044503##PEER WA, 2003, NEW PHYTOL, V159, P421, DOI 10.1046/J.1469-8137.2003.00822.X##PENCE NS, 2000, P NATL ACAD SCI USA, V97, P4956, DOI 10.1073/PNAS.97.9.4956##PENNINCKX IAMA, 1998, PLANT CELL, V10, P2103, DOI 10.1105/TPC.10.12.2103##PERSANS MW, 2001, P NATL ACAD SCI USA, V98, P9995, DOI 10.1073/PNAS.171039798##PIANELLI K, 2005, TRANSGENIC RES, V14, P739, DOI 10.1007/S11248-005-7159-3##RAMESH SA, 2004, PLANT MOL BIOL, V54, P373, DOI 10.1023/B:PLAN.0000036370.70912.34##RIGOLA D, 2006, NEW PHYTOL, V170, P753, DOI 10.1111/J.1469-8137.2006.01714.X##ROBINSON NJ, 1999, NATURE, V397, P694, DOI 10.1038/17800##ROOSENS NH, 2004, FEBS LETT, V577, P9, DOI 10.1016/J.FEBSLET.2004.08.084##SCHAAF G, 2005, PLANT CELL PHYSIOL, V46, P762, DOI 10.1093/PCP/PCI081##SCHAT H, 1996, EVOLUTION, V50, P1888, DOI [10.1111/J.1558-5646.1996.TB03576.X, 10.2307/2410747]##SCHAT H, 2000, METAL SPECIFIC PATTE##SMYTH GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23##SMYTH GK, 2005, SESS IPM 11 COMP TOO##SMYTH GK, 2004, STAT APPL GENET MOL, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]##SUZUKI K, 1999, SOIL SCI PLANT NUTR, V45, P993, DOI 10.1080/00380768.1999.10414350##TAKAHASHI M, 2003, PLANT CELL, V15, P1263, DOI 10.1105/TPC.010256##TALKE IN, 2006, PLANT PHYSIOL, V142, P148, DOI 10.1104/PP.105.076232##THOMINE S, 2003, PLANT J, V34, P685, DOI 10.1046/J.1365-313X.2003.01760.X##THOMINE S, 2000, P NATL ACAD SCI USA, V97, P4991, DOI 10.1073/PNAS.97.9.4991##THOMMA BPHJ, 2002, PLANTA, V216, P193, DOI 10.1007/S00425-002-0902-6##VAN DER ZAAL BJ, 1999, PLANT PHYSIOL, V119, P1047, DOI 10.1104/PP.119.3.1047##VAN HOOF NALM, 2001, PHYSIOL PLANTARUM, V113, P225, DOI 10.1034/J.1399-3054.2001.1130210.X##VILLANNEVA JM, 1999, GENE DEV, V13, P3160, DOI 10.1101/GAD.13.23.3160##WATERS BM, 2006, PLANT PHYSIOL, V141, P1446, DOI 10.1104/PP.106.082586##WEBER M, 2004, PLANT J, V37, P269, DOI 10.1046/J.1365-313X.2003.01960.X##WINTZ H, 2003, J BIOL CHEM, V278, P47644, DOI 10.1074/JBC.M309338200##WU HL, 2005, PLANT CELL PHYSIOL, V46, P1505, DOI 10.1093/PCP/PCI163##YANG WC, 1999, GENE DEV, V13, P2108, DOI 10.1101/GAD.13.16.2108##YANG YH, 2003, INST MATH S, V40, P403##YANG YH, 2002, NAT REV GENET, V3, P579##ZEIER J, 1998, PLANTA, V206, P349, DOI 10.1007/S004250050410##ZELKO I, 2005, 1 SCI WORKSH MAN COM##ZHOU JM, 1995, MOL GEN GENET, V248, P318, DOI 10.1007/BF02191599",274,2020-11-20,NA
J,WOS:000243445700018,2006,ISOLATION AND CHARACTERIZATION OF A NOVEL POTATO AUXIN/INDOLE-3-ACETIC ACID FAMILY MEMBER (STIAA2) THAT IS INVOLVED IN PETIOLE HYPONASTY AND SHOOT MORPHOGENESIS,"AUXIN/INDOLE-3-ACETID ACID (AUX/IAA) PROTEINS ARE SHORT-LIVED TRANSCRIPTIONAL REGULATORS THAT MEDIATE THEIR RESPONSE THROUGH INTERACTION WITH AUXIN RESPONSE FACTORS (ARE). ALTHOUGH 29 AUX/IAA PROTEINS HAVE BEEN IDENTIFIED IN ARABIDOPSIS THALIANA, THEIR INDIVIDUAL FUNCTIONS ARE STILL POORLY UNDERSTOOD AND ARE LARGELY DEFINED BY OBSERVED GROWTH DEFECTS IN GAIN-OF-FUNCTION MUTANT ALLELES. HERE WE PRESENT THE ISOLATION AND CHARACTERIZATION OF A NOVEL AUX/IAA PROTEIN IN POTATO (SOLANUM TUBEROSUM) THAT IS NAMED STIAA2. DOWN REGULATION OF STIAA2 RESULTS IN DISTINCTIVE PHENOTYPES THAT INCLUDE, INCREASED PLANT HEIGHT, PETIOLE HYPONASTY AND EXTREME CURVATURE OF GROWING LEAF PRIMORDIA IN THE SHOOT APEX. GENE EXPRESSION ANALYSIS OF TRANSGENIC PLANTS WITH REDUCED STIAA2 TRANSCRIPT LEVELS RESULTED IN THE IDENTIFICATION OF A NUMBER OF GENES WITH ALTERED EXPRESSION PROFILES INCLUDING ANOTHER MEMBER OF THE AUX/IAA GENE FAMILY (STIAA). THE PHENOTYPES THAT WERE OBSERVED IN THE STIAA2 SUPPRESSION CLONES CAN BE ASSOCIATED WITH BOTH COMMON AS WELL AS UNIQUE FUNCTIONAL ROLES AMONG AUX/IAA FAMILY MEMBERS INDICATING THE IMPORTANCE OF ANALYZING AUX/IAA EXPRESSION IN DIFFERENT PLANT SPECIES. (C) 2006 ELSEVIER MASSON SAS. ALL RIGHTS RESERVED.",BRASSINOSTEROID-REGULATED GENES; OF-FUNCTION MUTATION; AUX/IAA PROTEINS; AUXIN-RESPONSE; PLANT HORMONES; ABSCISIC-ACID; EXPRESSION; GIBBERELLIN; GROWTH; TRANSCRIPTION,AUX/IAA PROTEIN; SOLANUM TUBEROSUM; HYPONASTY; SHOOT MORPHOGENESIS,PLANT PHYSIOLOGY AND BIOCHEMISTRY,"KLOOSTERMAN, B##VISSER, RGF##BACHEM, CWB","UNIV WAGENINGEN & RES CTR, LAB PLANT BREEDING, DEPT PLANT SCI, GRAD SCH EXPT PLANT SCI, NL-6700 AJ WAGENINGEN, NETHERLANDS.",PLANT SCIENCES,PLANT SCIENCES,"ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/PNAS.91.1.326##ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/JMBI.1990.9999##BACHEM CWB, 1996, PLANT J, V9, P745, DOI 10.1046/J.1365-313X.1996.9050745.X##CARRERA E, 1999, PLANT PHYSIOL, V119, P765, DOI 10.1104/PP.119.2.765##COX MCH, 2004, PLANT PHYSIOL, V136, P2948, DOI 10.1104/PP.104.049197##FAIVRE-RAMPANT O, 2004, J EXP BOT, V55, P613, DOI 10.1093/JXB/ERH075##FU XD, 2003, NATURE, V421, P740, DOI 10.1038/NATURE01387##FUKAKI H, 2002, PLANT J, V29, P153, DOI 10.1046/J.0960-7412.2001.01201.X##GODA H, 2002, PLANT PHYSIOL, V130, P1319, DOI 10.1104/PP.011254##GODA H, 2004, PLANT PHYSIOL, V134, P1555, DOI 10.1104/PP.103.034736##GRAY WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500##GUILFOYLE T, 1998, PLANT PHYSIOL, V118, P341, DOI 10.1104/PP.118.2.341##GUILFOYLE TJ, 1998, CELL MOL LIFE SCI, V54, P619, DOI 10.1007/S000180050190##HAGEN G, 2002, PLANT MOL BIOL, V49, P373, DOI 10.1023/A:1015207114117##HALLIDAY KJ, 2004, CURR BIOL, V14, PR1008, DOI 10.1016/J.CUB.2004.11.025##HEDDEN P, 1997, ANNU REV PLANT PHYS, V48, P431, DOI 10.1146/ANNUREV.ARPLANT.48.1.431##KARIMI M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3##KAZEMI S, 1974, PLANT PHYSIOL, V54, P512, DOI 10.1104/PP.54.4.512##KIM H, 2006, BIOSCI BIOTECH BIOCH, V70, P768, DOI 10.1271/BBB.70.768##KLAHRE U, 1998, PLANT CELL, V10, P1677, DOI 10.1105/TPC.10.10.1677##KLOOSTERMAN B, 2005, PLANT BIOTECHNOL J, V3, P505, DOI 10.1111/J.1467-7652.2005.00141.X##KODA Y, 1983, JPN J CROP SCI, V52, P592, DOI 10.1626/JCS.52.592##KUMAR D, 1974, NEW PHYTOL, V73, P833, DOI 10.1111/J.1469-8137.1974.TB01311.X##LISCUM E, 2002, PLANT MOL BIOL, V49, P387, DOI 10.1023/A:1015255030047##MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/J.1399-3054.1962.TB08052.X##NAGPAL P, 2000, PLANT PHYSIOL, V123, P563, DOI 10.1104/PP.123.2.563##NAKAMURA A, 2006, PLANT J, V45, P193, DOI 10.1111/J.1365-313X.2005.02582.X##NEMHAUSER JL, 2004, PLOS BIOL, V2, P1460, DOI 10.1371/JOURNAL.PBIO.0020258##OVERVOORDE PJ, 2005, PLANT CELL, V17, P3282, DOI 10.1105/TPC.105.036723##ROGG LE, 2001, PLANT CELL, V13, P465, DOI 10.1105/TPC.13.3.465##ROSS JJ, 2000, PLANT J, V21, P547, DOI 10.1046/J.1365-313X.2000.00702.X##ROUSE D, 1998, SCIENCE, V279, P1371, DOI 10.1126/SCIENCE.279.5355.1371##THEOLOGIS A, 1989, BIOTECHNOLOGY, V12, P229##THOMPSON JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/NAR/25.24.4876##TIAN Q, 2002, PLANT CELL, V14, P301, DOI 10.1105/TPC.010283##TIWARI SB, 2004, PLANT CELL, V16, P533, DOI 10.1105/TPC.017384##TIWARI SB, 2001, PLANT CELL, V13, P2809, DOI 10.1105/TPC.13.12.2809##TUSHER VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/PNAS.091062498##ULMASOV T, 1999, P NATL ACAD SCI USA, V96, P5844, DOI 10.1073/PNAS.96.10.5844##ULMASOV T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/TPC.9.11.1963##VAN DOORN WG, 2003, PLANT MOL BIOL, V53, P845, DOI 10.1023/B:PLAN.0000023670.61059.1D##VISSER RGF, 1991, PLANT MOL BIOL, V17, P691, DOI 10.1007/BF00037054##WANG H, 2005, PLANT CELL, V17, P2676, DOI 10.1105/TPC.105.033415##WOODWARD AW, 2005, ANN BOT-LONDON, V95, P707, DOI 10.1093/AOB/MCI083##WORLEY CK, 2000, PLANT J, V21, P553, DOI 10.1046/J.1365-313X.2000.00703.X##XU X, 1998, PLANT PHYSIOL, V117, P575, DOI 10.1104/PP.117.2.575##ZANETTI ME, 2003, PLANT PHYSIOL BIOCH, V41, P755, DOI 10.1016/S0981-9428(03)00099-8",31,2020-11-20,NA
J,WOS:000241837100012,2006,"ANTISENSE DOWN-REGULATION OF STRAWBERRY ENDO-BETA-(1,4)-GLUCANASE GENES DOES NOT PREVENT FRUIT SOFTENING DURING RIPENING","STRAWBERRY (FRAGARIA X ANANASSA DUCH.) FRUIT SOFTENING DURING RIPENING IS ASSOCIATED WITH THE OVERLAPPING PRESENCE OF TWO DIVERGENT ENDO-P(1,4)-GLUCANASES (EC 3.2.1.4; EGASES), CEL1 AND CEL2. ANTISENSE DOWN-REGULATION OF BOTH GENES WAS PERFORMED TO ASSESS THE PRECISE ROLE OF THESE ENDO-BETA-(1,4)-GLUCANASES ON STRAWBERRY FRUIT SOFTENING. CONSTANT DOWN-REGULATION OF CELL EXPRESSION THROUGHOUT RIPENING WAS OBTAINED, WHICH WAS ACCOMPANIED BY REDUCED CELL PROTEIN ACCUMULATION. HOWEVER, DIMINUTION OF THE CELL PROTEIN LEVEL TOGETHER WITH A REDUCTION OF THE TOTAL EGASE ACTIVITY TO 40% OF THE CONTROL LEVEL DID NOT AFFECT FRUIT FIRMNESS, THUS SUGGESTING THAT CELL PROTEIN IS NOT THE MAJOR DETERMINANT OF FRUIT SOFTENING DURING RIPENING. ON THE OTHER HAND, NO SIGNIFICANT REDUCTION OF CEL2 PROTEIN ACCUMULATION WAS FOUND IN ANY OF THE CEL2 TRANSGENIC OR CEL1/CEL2 DOUBLE-TRANSGENIC LINES OBTAINED. THE DIFFICULTIES ENCOUNTERED TO YIELD A STRAWBERRY LINE WITH SIGNIFICANT REDUCTION OF CEL2 EXPRESSION SUGGEST THAT THIS GENE MIGHT BE PLAYING A PIVOTAL ROLE ON FRUIT DEVELOPMENT PRIOR TO RIPENING, THUS ACCOUNTING FOR THE LACK OF CEL2 PROTEIN DOWN-REGULATION OBSERVED. (C) 2006 ELSEVIER IRELAND LTD. ALL RIGHTS RESERVED.","CELL-WALL POLYSACCHARIDES; TRANSGENIC TOMATO FRUIT; FRAGARIA X ANANASSA; MOLECULAR CHARACTERIZATION; PECTATE LYASE; HIGHER-PLANTS; EXPRESSION; ENDO-1,4-BETA-GLUCANASE; ENDO-BETA-1,4-GLUCANASE; SUPPRESSION","ENDO-BETA-(1,4)-GLUCANASE; FRAGARIA X ANANASSA; FRUIT SOFTENING; STRAWBERRY; TRANSGENIC ANTISENSE PLANTS",PLANT SCIENCE,"PALOMER, X##LLOP-TOUS, I##VENDRELL, M##KRENS, FA##SCHAART, JG##BOONE, MJ##VAN DER VALK, H##SALENTIJN, EMJ","PLANT RES INT BV, DEPT BIODIVERS & BREEDING, NL-6708 PB WAGENINGEN, NETHERLANDS. CSIC, INST BIOL MOL BARCELONA, DEPT MOL GENET, BARCELONA 08034, SPAIN. WAGENINGEN UR, DEPT AGROTECHNOL & FOOD INNOVAT, NL-6708 PD WAGENINGEN, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; PLANT SCIENCES,BIOCHEMISTRY & MOLECULAR BIOLOGY; PLANT SCIENCES,"ALMIN KE, 1967, BIOCHIM BIOPHYS ACTA, V139, P248, DOI 10.1016/0005-2744(67)90029-0##BRUMMELL DA, 1999, PLANT MOL BIOL, V40, P615, DOI 10.1023/A:1006269031452##BRUMMELL DA, 1999, PLANT CELL, V11, P2203, DOI 10.1105/TPC.11.11.2203##CIVELLO PM, 1999, PLANT PHYSIOL, V121, P1273, DOI 10.1104/PP.121.4.1273##DURBIN ML, 1988, METHOD ENZYMOL, V160, P342##HARPSTER MH, 2002, PLANT MOL BIOL, V50, P357, DOI 10.1023/A:1019888129013##HARPSTER MH, 2002, PLANT MOL BIOL, V50, P345, DOI 10.1023/A:1019856929126##HARPSTER MH, 1998, PLANT PHYSIOL, V118, P1307, DOI 10.1104/PP.118.4.1307##HUBER DJ, 1984, J FOOD SCI, V49, P1310, DOI 10.1111/J.1365-2621.1984.TB14976.X##JIMENEZ-BERMUDEZ S, 2002, PLANT PHYSIOL, V128, P751, DOI 10.1104/PP.010671##KNEE M, 1977, J EXP BOT, V28, P377, DOI 10.1093/JXB/28.2.377##KOH TH, 2002, POSTHARVEST BIOL TEC, V26, P23, DOI 10.1016/S0925-5214(02)00003-0##LASHBROOK CC, 1998, PLANT J, V13, P303, DOI 10.1046/J.1365-313X.1998.00025.X##LLOP-TOUS I, 1999, PLANT PHYSIOL, V119, P1415, DOI 10.1104/PP.119.4.1415##LUNKENBEIN S, 2006, J AGR FOOD CHEM, V54, P2145, DOI 10.1021/JF052574Z##MEDINAESCOBAR N, 1997, PLANT MOL BIOL, V34, P867, DOI 10.1023/A:1005847326319##MOCTEZUMA E, 2003, J EXP BOT, V54, P2025, DOI 10.1093/JXB/ERG214##MURASHIGE T., 1962, PHYSIOLOGIA PLANTARUM, V15, P473, DOI 10.1111/J.1399-3054.1962.TB08052.X##NEAL GE, 1965, J SCI FOOD AGR, V16, P604, DOI 10.1002/JSFA.2740161006##NOGATA Y, 1993, PHYTOCHEMISTRY, V34, P617, DOI 10.1016/0031-9422(93)85327-N##PALOMER X, 2004, PLANT SCI, V167, P509, DOI 10.1016/J.PLANTSCI.2004.04.017##PAULY M, 1999, PLANT J, V20, P629, DOI 10.1046/J.1365-313X.1999.00630.X##PERKINS-VEAZIE P., 1995, HORTICULTURAL REVIEWS, V17, P267, DOI 10.1002/9780470650585.CH8##PUITE KJ, 1996, PLANT SCI, V119, P125, DOI 10.1016/0168-9452(96)04448-2##SAMBROOK J., 1989, MOL CLONING LAB MANU##SCHAART JG, 2002, PLANT CELL REP, V21, P313, DOI 10.1007/S00299-002-0514-4##SCHUCH W, 1991, HORTSCIENCE, V26, P1517##SELVENDRAN RR, 1985, SEB SEMINAR SERIES, V28, P39##SMITH DL, 2002, PLANT PHYSIOL, V129, P1755, DOI 10.1104/PP.011025##TRAINOTTI L, 2001, J EXP BOT, V52, P1635, DOI 10.1093/JEXBOT/52.361.1635##TRAINOTTI L, 1999, J PLANT PHYSIOL, V154, P355, DOI 10.1016/S0176-1617(99)80180-1##TRAINOTTI L, 1999, PLANT MOL BIOL, V40, P323, DOI 10.1023/A:1006299821980##VANENGELEN FA, 1995, TRANSGENIC RES, V4, P288, DOI 10.1007/BF01969123##WOOLLEY LC, 2001, PLANTA, V214, P11, DOI 10.1007/S004250100577",39,2020-11-20,NA
J,WOS:000242150700004,2006,NUCLEAR FRAGMENTATION AND DNA DEGRADATION DURING PROGRAMMED CELL DEATH IN PETALS OF MORNING GLORY (IPOMOEA NIL),"WE STUDIED DNA DEGRADATION AND NUCLEAR FRAGMENTATION DURING PROGRAMMED CELL DEATH (PCD) IN PETALS OF IPOMOEA NIL (L.) ROTH FLOWERS. THE DNA DEGRADATION, AS OBSERVED ON AGAROSE GELS, SHOWED A LARGE INCREASE. USING DAPI, WHICH STAINS DNA, AND FLOW CYTOMETRY FOR DAPI FLUORESCENCE, WE FOUND THAT THE NUMBER OF DNA MASSES PER PETAL AT LEAST DOUBLED. THIS INDICATED CHROMATIN FRAGMENTATION, EITHER INSIDE OR OUTSIDE THE NUCLEUS. STAINING WITH THE CATIONIC LIPOPHILIC FLUOROPROBE DIOC(6) INDICATED THAT EACH DNA MASS HAD AN EXTERNAL MEMBRANE. FLUORESCENCE MICROSCOPY OF THE NUCLEI AND DNA MASSES REVEALED AN INITIAL DECREASE IN DIAMETER TOGETHER WITH CHROMATIN CONDENSATION. THE DIAMETERS OF THESE CONDENSED NUCLEI WERE ABOUT 70% OF ORIGINAL. TWO POPULATIONS OF NUCLEAR DIAMETER, ONE WITH AN AVERAGE DIAMETER ABOUT HALF OF THE OTHER, WERE OBSERVED AT INITIAL STAGES OF NUCLEAR FRAGMENTATION. THE DIAMETER OF THE DNA MASSES THEN GRADUALLY DECREASED FURTHER. THE SMALLEST OBSERVED DNA MASSES HAD A DIAMETER LESS THAN 10% OF THAT OF THE ORIGINAL NUCLEUS. CYCLOHEXIMIDE TREATMENT ARRESTED THE CYTOMETRICALLY DETERMINED CHANGES IN DNA FLUORESCENCE, INDICATING PROTEIN SYNTHESIS REQUIREMENT. ETHYLENE INHIBITORS (AVG AND 1-MCP) HAD NO EFFECT ON THE CYTOMETRICALLY DETERMINED DNA CHANGES, SUGGESTING THAT THESE PROCESSES ARE NOT CONTROLLED BY ENDOGENOUS ETHYLENE.",ARABIDOPSIS-THALIANA; FLOWER TISSUE; ETHYLENE; APOPTOSIS; SENESCENCE; EXPRESSION; LETHALITY; TRICOLOR; COLOR; IRIS,DNA DEGRADATION; DNA MASS; NUCLEAR FRAGMENTATION; PETAL SENESCENCE; PROGRAMMED CELL DEATH; WILTING,PLANTA,"YAMADA, T##TAKATSU, Y##KASUMI, M##ICHIMURA, K##VAN DOORN, WG","TOKYO UNIV AGR & TECHNOL, GRAD SCH AGR, TOKYO 1838509, JAPAN. IBARAKI AGR CTR, INST PLANT BIOTECHNOL, IBARAKI 3190292, JAPAN. NATL INST FLORICULTURAL SCI, IBARAKI 3058519, JAPAN. UNIV WAGENINGEN & RES CTR, NL-6700 AA WAGENINGEN, NETHERLANDS.",PLANT SCIENCES,PLANT SCIENCES,"ASEN S, 1971, J AM SOC HORTIC SCI, V96, P770##BAUMGARTNER B, 1975, BIOCHEM PHYSIOL PFL, V168, P299##BEUTELMANN P, 1977, PLANT PHYSIOL, V59, P888, DOI 10.1104/PP.59.5.888##BOE R, 1991, EXP CELL RES, V195, P237, DOI 10.1016/0014-4827(91)90523-W##DANON A, 1998, FEBS LETT, V437, P131, DOI 10.1016/S0014-5793(98)01208-3##DINI L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/EXCR.1996.0089##GRBIC V, 1995, PLANT J, V8, P595, DOI 10.1046/J.1365-313X.1995.8040595.X##HANSON AD, 1975, PLANT PHYSIOL, V55, P663, DOI 10.1104/PP.55.4.663##HOCKENBERY D, 1995, AM J PATHOL, V146, P15##KENDE H, 1974, PLANTA, V116, P279, DOI 10.1007/BF00390853##MARUBASHI W, 1999, PLANTA, V210, P168, DOI 10.1007/S004250050667##MATILE P, 1971, J EXP BOT, V22, P759, DOI 10.1093/JXB/22.4.759##MATZKE MA, 1988, PLANT CELL ENVIRON, V11, P157, DOI 10.1111/J.1365-3040.1988.TB01132.X##MCGUIRE RG, 1992, HORTSCIENCE, V27, P1254, DOI 10.21273/HORTSCI.27.12.1254##OBARA K, 2001, PLANT PHYSIOL, V125, P615, DOI 10.1104/PP.125.2.615##SCHUSSLER EE, 2000, AM J BOT, V87, P12, DOI 10.2307/2656680##SUN YD, 2000, AM J VET RES, V61, P51, DOI 10.2460/AJVR.2000.61.51##TARIN JJ, 1998, J REPROD FERTIL, V114, P211, DOI 10.1530/JRF.0.1140211##VAN DER KOP DAM, 2003, PHYSIOL PLANTARUM, V117, P256, DOI 10.1034/J.1399-3054.2003.1170213.X##VAN DOORN WG, 2003, PLANT MOL BIOL, V53, P845, DOI 10.1023/B:PLAN.0000023670.61059.1D##VAN DOORN WG, 2005, TRENDS PLANT SCI, V10, P117, DOI 10.1016/J.TPLANTS.2005.01.006##WANG H, 1996, PLANT CELL, V8, P375, DOI 10.1105/TPC.8.3.375##WINKENBACH F., 1970, BER SCHWEIZ BOT GES, V80, P374##YAMADA T, 2003, PLANTA, V217, P690, DOI 10.1007/S00425-003-1035-2##YAMADA T, 2003, PLANT SCI, V164, P213, DOI 10.1016/S0168-9452(02)00403-X##YAMADA T, 2001, PLANT BIOTECHNOL-NAR, V18, P215##YAO N, 2004, PLANT J, V40, P596, DOI 10.1111/J.1365-313X.2004.02239.X",57,2020-11-20,NA
J,WOS:000242577300037,2006,TIME RESOLVED MEASUREMENTS OF THE CF2 ROTATIONAL TEMPERATURE IN PULSED FLUOROCARBON RF PLASMAS,"KNOWLEDGE OF THE ABSOLUTE DENSITIES OF SMALL RADICALS LIKE CF, CF2 AND CF3 IN FLUOROCARBON PLASMAS IS ESSENTIAL FOR A FUNDAMENTAL UNDERSTANDING OF PLASMA CHEMICAL PROCESSES AND PLASMA SURFACE INTERACTION. INFRARED ABSORPTION SPECTROSCOPY BY MEANS OF TUNABLE DIODE LASERS (IR-TDLAS) WAS ESTABLISHED AND WIDELY USED FOR DENSITY MEASUREMENTS IN THE LAST DECADE. THE OFTEN UNKNOWN PARAMETER IN THE CALCULATION OF ABSOLUTE RADICAL DENSITIES FROM A MEASURED ABSORPTION OF A SINGLE LINE IS THE ROTATIONAL TEMPERATURE. IN PARTICULAR, A STRONG DEPENDENCE OF THE LINE STRENGTH ON ROTATIONAL TEMPERATURE HAS A SIGNIFICANT INFLUENCE ON DENSITY CALCULATION. IN THIS PAPER WE REPORT ON MEASUREMENTS OF THE CF2 ROTATIONAL TEMPERATURE IN CAPACITIVELY COUPLED CF4/H-2 PLASMAS (CCP) WITH RF (13.56 MHZ) POWERS UP TO 200 W. ROTATIONAL TEMPERATURES IN CONTINUOUS AND PULSED MODES OF THE DISCHARGE WERE FOUND TO BE BETWEEN 300 AND 450 K. FURTHERMORE, FIRST MEASUREMENTS OF THE TIME DEPENDENCE OF THE ROTATIONAL TEMPERATURE IN PULSED RF PLASMA ARE PRESENTED. THE ROTATIONAL TEMPERATURE RISES IN THE PLASMA PHASE WITHIN 0.1 S AND GOES DOWN AGAIN TO THE TEMPERATURE OF THE BACKGROUND GAS IN THE PLASMA PAUSE WITHIN 0.5 S. IT IS ALSO SHOWN THAT ACCURATE DENSITY MEASUREMENTS OF THE RADICALS BY MEANS OF SINGLE LINE ABSORPTION NEED CORRECT INFORMATION ABOUT THE ROTATIONAL TEMPERATURE AND CAREFUL SELECTION OF A SUITABLE ABSORPTION LINE.",ABSORPTION-SPECTROSCOPY; LASER ABSORPTION; RADICALS; FILMS; DEPOSITION; DENSITIES; ELECTRON; BEHAVIOR; BANDS,NA,PLASMA SOURCES SCIENCE & TECHNOLOGY,"GABRIEL, O##STEPANOV, S##PFAFFEROTT, M##MEICHSNER, J","ERNST MORITZ ARNDT UNIV GREIFSWALD, INST PHYS, D-17498 GREIFSWALD, GERMANY.","PHYSICS, FLUIDS & PLASMAS",PHYSICS,"BOOTH JP, 2005, PLASMA SOURCES SCI T, V14, P273, DOI 10.1088/0963-0252/14/2/008##BOOTH JP, 1989, J APPL PHYS, V66, P5251, DOI 10.1063/1.343712##BULCOURT N, 2004, J CHEM PHYS, V120, P9499, DOI 10.1063/1.1695313##BURKHOLDER JB, 1988, J MOL SPECTROSC, V127, P362, DOI 10.1016/0022-2852(88)90126-9##CAPPS NE, 1998, J APPL PHYS, V84, P4736, DOI 10.1063/1.368716##CHASE JE, 2003, J VAC SCI TECHNOL A, V21, P607, DOI 10.1116/1.1564028##CRUDEN BA, 2001, J APPL PHYS, V89, P915, DOI 10.1063/1.1334936##DAGOSTINO R, 1983, J APPL PHYS, V54, P1284, DOI 10.1063/1.332193##DAVIES PB, 1983, J MOL SPECTROSC, V102, P193, DOI 10.1016/0022-2852(83)90237-0##FENDEL P, 2005, PLASMA SOURCES SCI T, V14, P1, DOI 10.1088/0963-0252/14/1/001##GEIGL M, 2005, CONTRIB PLASM PHYS, V45, P369, DOI 10.1002/CTPP.200510042##GOTO T, 1996, JPN J APPL PHYS 1, V35, P6521, DOI 10.1143/JJAP.35.6521##HARGIS PJ, 1982, APPL PHYS LETT, V40, P779, DOI 10.1063/1.93257##HAVERLAG M, 1991, J VAC SCI TECHNOL A, V9, P327, DOI 10.1116/1.577509##HAVERLAG M, 1995, PLASMA SOURCES SCI T, V4, P260, DOI 10.1088/0963-0252/4/2/010##HIKOSAKA Y, 1993, JPN J APPL PHYS 2, V32, PL353, DOI 10.1143/JJAP.32.L353##HORI M, 2006, PLASMA SOURCES SCI T, V15, PS74, DOI 10.1088/0963-0252/15/2/S10##INAYOSHI M, 1998, J VAC SCI TECHNOL A, V16, P233, DOI 10.1116/1.580977##KONO A, 1991, J APPL PHYS, V70, P2939, DOI 10.1063/1.349318##LIMB SJ, 1997, J VAC SCI TECHNOL A, V15, P1814, DOI 10.1116/1.580796##LITTAU ME, 2002, J VAC SCI TECHNOL A, V20, P1603, DOI 10.1116/1.1495510##NAKAMURA M, 2001, J APPL PHYS, V90, P580, DOI 10.1063/1.1337090##PENNER S., 1959, QUANTITATIVE MOL SPE##SCHAEPKENS M, 2001, J VAC SCI TECHNOL A, V19, P2946, DOI 10.1116/1.1415361##STOFFELS E, 1998, REV SCI INSTRUM, V69, P116, DOI 10.1063/1.1148486##SUTO O, 1990, CHEM PHYS LETT, V168, P181, DOI 10.1016/0009-2614(90)85126-W##TACHI S, 2003, J VAC SCI TECHNOL A, V21, PS131, DOI 10.1116/1.1601611##THEIL JA, 1999, J VAC SCI TECHNOL B, V17, P2397, DOI 10.1116/1.591102##WORMHOUDT J, 1989, CHEM PHYS LETT, V158, P480, DOI 10.1016/0009-2614(89)87374-9",12,2020-11-20,NA
J,WOS:000242577300038,2006,MODELLING OF A PINCHED CASCADED ARC LIGHT SOURCE USING ARGON,"IN THIS WORK, WE STUDY A CASCADED ARC IN ARGON THAT IS USED AS A BROADBAND LIGHT SOURCE FOR SPECTROSCOPIC APPLICATIONS. IN THIS ARC, THE ARC CHANNEL IS GEOMETRICALLY CONSTRICTED. A NUMERICAL MODEL IS USED TO INVESTIGATE THE PLASMA PARAMETERS AND LIGHT OUTPUT OF THE ARC. IT IS FOUND THAT CONSTRICTING LEADS TO A HIGHER ELECTRON DENSITY IN THE CONSTRICTED AREA, WHICH STRONGLY ENHANCES THE LOCAL BROADBAND EMISSION OF THE PLASMA. A PARAMETER STUDY, IN WHICH THE CURRENT IS VARIED, IS PERFORMED. THE SIMULATED ARC VOLTAGES ARE COMPARED WITH MEASURED ARC VOLTAGES, AND EXCELLENT AGREEMENT IS FOUND. FURTHERMORE, IT IS FOUND THAT THE EMISSIVITY INCREASES STRONGLY FOR INCREASING CURRENT, MAKING THE CURRENT A SUITABLE CONTROL PARAMETER TO CONTROL THE LIGHT OUTPUT OF THE ARC.",CROSS-SECTIONS; SCATTERING; IONIZATION; PLASMAS; CONDUCTIVITY; ELECTRONS; EMISSION; ATOMS,NA,PLASMA SOURCES SCIENCE & TECHNOLOGY,"BROKS, BHP##KEIZER, JG##ZIJLMANS, RAB##VAN DER MULLEN, JJAM","EINDHOVEN UNIV TECHNOL, DEPT APPL PHYS, NL-5600 MD EINDHOVEN, NETHERLANDS.","PHYSICS, FLUIDS & PLASMAS",PHYSICS,"BELL KL, 1984, J PHYS B-AT MOL OPT, V17, P4757, DOI 10.1088/0022-3700/17/23/016##BENOY D, 1993, THESIS EINDHOVEN U T##BEULENS JJ, 1991, PHYS FLUIDS B-PLASMA, V3, P2548, DOI 10.1063/1.859967##BEULENS JJ, 1992, J VAC SCI TECHNOL B, V10, P2387, DOI 10.1116/1.586072##BIRD GA, 1994, MOL GAS DYNAMICS DIR##BROKS BHP, 2006, J PHYS D APPL PHYS, V39, P2384, DOI 10.1088/0022-3727/39/11/012##BROKS BHP, 2005, PHYS REV E, V71, DOI 10.1103/PHYSREVE.71.016401##BURM K, 2001, THESIS EINDHOVEN U T##BURM KTAL, 1998, PLASMA SOURCES SCI T, V7, P395, DOI 10.1088/0963-0252/7/3/018##BURM KTAL, 2001, J PHYS D APPL PHYS, V34, P2000, DOI 10.1088/0022-3727/34/13/311##BURM KTAL, 1999, PHYS PLASMAS, V6, P2628, DOI 10.1063/1.873536##CABANNES F, 1971, REACTIONS PLASMA CON##DASGUPTA A, 1985, PHYS REV A, V32, P3335, DOI 10.1103/PHYSREVA.32.3335##DEGRAAF MJ, 1993, PHYS REV E, V48, P2098, DOI 10.1103/PHYSREVE.48.2098##FROST LS, 1961, J APPL PHYS, V32, P2029, DOI 10.1063/1.1728283##FROST RM, 2001, APPL OPTICS, V36, P1994##HARTGERS A, 2003, THESIS EINDHOVEN U T##HECHT E, 1987, OPTICS##HEER FJD, 1979, J PHYS B-AT MOL OPT, V12, P979, DOI 10.1088/0022-3700/12/6/016##HOFSAESS D, 1978, J QUANT SPECTROSC RA, V19, P339, DOI 10.1016/0022-4073(78)90068-7##JANSSEN GM, 1999, PLASMA SOURCES SCI T, V8, P1, DOI 10.1088/0963-0252/8/1/001##KAASE H, 1979, APPL OPTICS, V18, P2275, DOI 10.1364/AO.18.002275##KOCK M, 1977, J PHYS B-AT MOL OPT, V10, P3421, DOI 10.1088/0022-3700/10/17/016##LELEVKIN WM, 1992, PHYS NONEQUILIBRIUM##MAECKER H, 1956, Z NATURFORSCH PT A, V11, P457##MEULENBROEKS RFG, 1992, PHYS REV LETT, V69, P1379, DOI 10.1103/PHYSREVLETT.69.1379##MINTSEV VB, 2003, CONTRIB PLASM PHYS, V43, P326, DOI 10.1002/CTPP.200310038##MITCHNER M, 1983, PARTIALLY IONIZED GA##MOBLEY CD, 1980, J COMPUT PHYS, V34, P124, DOI 10.1016/0021-9991(80)90117-5##OPPENHEIMER JR, 1928, PHYS REV, V32, P0361, DOI 10.1103/PHYSREV.32.361##ORDONEZ CA, 1994, PHYS PLASMAS, V1, P2515, DOI 10.1063/1.870578##PHELPS AV, 1994, J APPL PHYS, V76, P747, DOI 10.1063/1.357820##POPE SB, 1978, J COMPUT PHYS, V26, P197, DOI 10.1016/0021-9991(78)90091-8##RAGHAVAN R, 2001, J QUANT SPECTROSC RA, V69, P605, DOI 10.1016/S0022-4073(00)00104-7##TAWARA H, 1987, ATOM DATA NUCL DATA, V36, P167, DOI 10.1016/0092-640X(87)90014-3##VAN DER HEIJDEN H, 2002, J PHYS B-AT MOL OPT, V35, P3633, DOI 10.1088/0953-4075/35/17/302##VAN DER MULLEN J, 1999, SPECTROCHIM ACTA B, V54, P1017, DOI 10.1016/S0584-8547(99)00042-7##VAN DIJK J, 2002, J PHYS D APPL PHYS, V35, P2748, DOI 10.1088/0022-3727/35/21/310##VANDIJK J, 2001, THESIS EINDHOVEN U T##WETZEL RC, 1987, PHYS REV A, V35, P559, DOI 10.1103/PHYSREVA.35.559##WILBERS ATM, 1991, J QUANT SPECTROSC RA, V46, P299, DOI 10.1016/0022-4073(91)90094-7##WILBERS ATM, 1991, J QUANT SPECTROSC RA, V45, P1, DOI 10.1016/0022-4073(91)90076-3##WILBERS ATM, 1990, MEAS SCI TECHNOL, V1, P1326, DOI 10.1088/0957-0233/1/12/012##WILBERS ATM, 1991, THESIS EINDHOVEN U T##ZIJLMANS RAB, 2004, INST PHYS CONF SER, P355##ZIJLMANS RAB, 2003, THESIS EINDHOVEN U T",7,2020-11-20,NA
J,WOS:000242577300004,2006,PLASMA NEEDLE FOR IN VIVO MEDICAL TREATMENT: RECENT DEVELOPMENTS AND PERSPECTIVES,"IN THIS PAPER WE DESCRIBE THE HITHERTO UNRAVELLED FACTS ON THE INTERACTIONS OF A COLD ATMOSPHERIC PLASMA WITH LIVING CELLS AND TISSUES. A SPECIALLY DESIGNED SOURCE, PLASMA NEEDLE, IS A LOW-POWER DISCHARGE, WHICH OPERATES UNDER THE THRESHOLD OF TISSUE DAMAGE. WHEN APPLIED PROPERLY, THE NEEDLE DOES NOT CAUSE FATAL CELL INJURY WHICH WOULD RESULT IN CELL DEATH ( NECROSIS). INSTEAD, IT ALLOWS PRECISE AND LOCALIZED CELL REMOVAL BY MEANS OF THE SO-CALLED CELL DETACHMENT. IN ADDITION, PLASMA CAN BE USED FOR BACTERIAL DISINFECTION. BECAUSE OF MILD TREATMENT CONDITIONS, PLASMA DISINFECTION CAN BE PERFORMED IN VIVO, E. G. ON WOUNDS AND DENTAL CAVITIES. PRESENTLY, ONE STRIVES TO OBTAIN A BETTER CONTROL OF THE OPERATING DEVICE. THEREFORE, PLASMA HAS BEEN CHARACTERIZED USING A VARIETY OF DIAGNOSTICS, AND A SMART SYSTEM HAS BEEN DESIGNED FOR THE POSITIONING OF THE DEVICE WITH RESPECT TO THE TREATED SURFACE.",CELLS,NA,PLASMA SOURCES SCIENCE & TECHNOLOGY,"STOFFELS, E##KIEFT, IE##SLADEK, REJ##VAN DEN BEDEM, LJM##VAN DER LAAN, EP##STEINBUCH, M","EINDHOVEN UNIV TECHNOL, DEPT BIOMED ENGN, NL-5600 MB EINDHOVEN, NETHERLANDS. EINDHOVEN UNIV TECHNOL, DEPT MECH ENGN, NL-5600 MB EINDHOVEN, NETHERLANDS.","PHYSICS, FLUIDS & PLASMAS",PHYSICS,"BROK WJM, 2005, J APPL PHYS, V98, DOI 10.1063/1.1944218##CANADY J, 1993, PATENT NO. 5207675##CARMELIET P, 1998, CARDIOVASC RES, V39, P8, DOI 10.1016/S0008-6363(98)00108-4##FRANKLIN G.F., 2002, FEEDBACK CONTROL DYN##GONZALVO YA, 2006, UNPUB SURF COAT TECH##GORISCH G, 1982, LASERS SURGERY MED, V2, P1##KIEFT IE, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/149##KIEFT IE, 2005, IEEE T PLASMA SCI, V33, P771, DOI 10.1109/TPS.2005.844528##KIEFT IE, 2004, PROC SPIE, V5483, P247, DOI 10.1117/12.562983##KIEFT IE, 2004, BIOELECTROMAGNETICS, V25, P362, DOI 10.1002/BEM.20005##KIEFT IE, 2005, THESIS EINDHOVEN U T##KIEFT IE, 2005, PLASMA PROCESSES POL, V295##LAROUSSI M, 2002, IEEE T PLASMA SCI, V30, P1409, DOI 10.1109/TPS.2002.804220##MOISAN M, 2001, INT J PHARMACEUT, V226, P1, DOI 10.1016/S0378-5173(01)00752-9##MORRISON J, 1977, US PATENT, PATENT NO. [4040426, 4, 040, 426]##SLADEK REJ, 2005, J PHYS D APPL PHYS, V38, P1716, DOI 10.1088/0022-3727/38/11/012##SLADEK REJ, 2004, IEEE T PLASMA SCI, V32, P1540, DOI 10.1109/TPS.2004.832636##STOFFELS E, 2004, PLASMA PHYS CONTR F, V46, PB167, DOI 10.1088/0741-3335/46/12B/015##STOFFELS E, 2002, PLASMA SOURCES SCI T, V11, P383, DOI 10.1088/0963-0252/11/4/304##STOFFELS E, 2005, P ICPIG 2005 EINDH N##VANDENBEDEM LJM, 2005, P ICPIG 2005 EINDH N##WAYE JD, 2002, PROBLEMS GEN SURG, V19, P37##WOLOSZKO J, 2002, IEEE T PLASMA SCI, V30, P1376, DOI 10.1109/TPS.2002.801612",258,2020-11-20,NA
J,WOS:000241835100002,2006,ROUTINE HISTOLOGIC EXAMINATION OF 728 MASTECTOMY SCARS: DID IT BENEFIT OUR PATIENTS?,"BACKGROUND: ROUTINE HISTOLOGIC EXAMINATION OF SECONDARILY EXCISED MASTECTOMY SCARS IS CONSIDERED GOOD PRACTICE, EVEN THOUGH THE MICROSCOPIC DETECTION OF A METASTASIS IN CLINICALLY UNSUSPECTED MASTECTOMY SCARS IS RARE. BECAUSE COST-EFFECTIVE USE OF HISTOLOGIC SERVICES IS REQUIRED, THE OCCURRENCE RATE OF METASTASES IN SUCH SCARS NEEDS TO BE ESTABLISHED TO ASSESS THE POSSIBLE BENEFIT OF SUCH ROUTINE EXAMINATION. METHODS: THE HISTOLOGIC OBSERVATIONS ON 728 CLINICALLY UNSUSPECTED SCARS FROM PROPHYLACTIC (N = 151) OR CURATIVE (N = 395) MASTECTOMY OR BREAST-CONSERVATION TREATMENT IN 424 PATIENTS WERE TRACED AND CORRELATED TO THE INDICATION OF INITIAL BREAST SURGERY, POSSIBLE ADJUVANT THERAPY, AND TIME LAPSE BETWEEN INITIAL SURGERY AND SCAR EXAMINATION. RESULTS: IN NONE OF THE 728 SCARS WAS A SCAR METASTASIS OR DE NOVO TUMOR FOUND. CONCLUSIONS: ROUTINE HISTOLOGIC EXAMINATION OF CLINICALLY UNSUSPECTED SCARS EXCISED AT THE TIME OF BREAST RECONSTRUCTION OR SCAR CORRECTION AFTER PROPHYLACTIC OR CURATIVE BREAST SURGERY DID NOT BENEFIT THE AUTHORS' PATIENTS.",BILATERAL PROPHYLACTIC MASTECTOMY; COMPARING RADICAL-MASTECTOMY; SKIN-SPARING MASTECTOMY; BREAST-CANCER; LOCAL RECURRENCE; RANDOMIZED TRIAL; LOCOREGIONAL RECURRENCE; FOLLOW-UP; RECONSTRUCTION; CARCINOMA,NA,PLASTIC AND RECONSTRUCTIVE SURGERY,"WOERDEMAN, LAE##KORTMANN, JBJ##HAGE, JJ","ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT PLAST & RECONSTRUCT SURG, NL-1066 CX AMSTERDAM, NETHERLANDS.",SURGERY,SURGERY,"CARLSON GW, 2003, ANN SURG ONCOL, V10, P108, DOI 10.1245/ASO.2003.03.053##CHAGPAR AB, 2004, AM SURGEON, V70, P425##CIATTO S, 1995, ANN ONCOL, V6, P23##CLEMONS M, 2001, CANCER TREAT REV, V27, P67, DOI 10.1053/CTRV.2000.0204##ENGEL J, 2003, EUR J CANCER, V39, P1794, DOI 10.1016/S0959-8049(03)00422-2##FISHER B, 2002, NEW ENGL J MED, V347, P567, DOI 10.1056/NEJMOA020128##FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102##FISHER B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMOA022152##FISHER ER, 1986, CANCER, V1717, P1724##GRANICK MS, 1987, ANN PLAS SURG, V18, P69, DOI 10.1097/00000637-198701000-00014##HARTMANN LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201##KRONTIRAS H, 2004, BREAST COMPREHENSIVE, P885##LEGGETT CAC, 1980, AUST NZ J SURG, V50, P298, DOI 10.1111/J.1445-2197.1980.TB04122.X##NEWMAN LA, 1998, ANN SURG ONCOL, V5, P620, DOI 10.1007/BF02303832##PRICE P, 1988, RADIOTHER ONCOL, V13, P53, DOI 10.1016/0167-8140(88)90298-8##REBBECK TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188##REID SE, 1996, BRIT J SURG, V83, P313, DOI 10.1002/BJS.1800830308##SIMMONS RM, 2001, AM J SURG, V182, P325, DOI 10.1016/S0002-9610(01)00721-8##SOLDIN MG, 2004, BRIT J PLAST SURG, V57, P143, DOI 10.1016/J.BJPS.2003.11.005##SOLIN LJ, 2004, DIS BREAST, P1067##TENNVALLNITTBY L, 1993, ACTA ONCOL, V32, P641, DOI 10.3109/02841869309092445##VOOGD AC, 1999, CANCER-AM CANCER SOC, V85, P437, DOI 10.1002/(SICI)1097-0142(19990115)85:2<437::AID-CNCR23>3.0.CO;2-1##WILLNER J, 1997, INT J RADIAT ONCOL, V37, P853, DOI 10.1016/S0360-3016(96)00556-1##WILLNER J, 1999, BREAST, V8, P200, DOI 10.1054/BRST.1999.0033##ZAMBACOS GJ, 2005, BRIT J PLAST SURG, V58, P122, DOI 10.1016/J.BJPS.2004.06.030",7,2020-11-20,NA
J,WOS:000242649200011,2006,ASSEMBLY FACTOR OMP85 RECOGNIZES ITS OUTER MEMBRANE PROTEIN SUBSTRATES BY A SPECIES-SPECIFIC C-TERMINAL MOTIF,"INTEGRAL BETA-BARREL PROTEINS ARE FOUND IN THE OUTER MEMBRANES OF GRAM-NEGATIVE BACTERIA, MITOCHONDRIA, AND CHLOROPLASTS. THE ASSEMBLY OF THESE PROTEINS REQUIRES A PROTEINACEOUS APPARATUS OF WHICH OMP85 IS AN EVOLUTIONARY CONSERVED CENTRAL COMPONENT. TO STUDY ITS MOLECULAR MECHANISM, WE HAVE PRODUCED OMP85 FROM ESCHERICHIA COLI IN INCLUSION BODIES AND REFOLDED IT IN VITRO. THE INTERACTION OF OMP85 WITH ITS SUBSTRATE PROTEINS WAS STUDIED IN LIPID-BILAYER EXPERIMENTS, WHERE IT FORMED CHANNELS. THE PROPERTIES OF THESE CHANNELS WERE AFFECTED UPON ADDITION OF UNFOLDED OUTER-MEMBRANE PROTEINS ( OMPS) OR SYNTHETIC PEPTIDES CORRESPONDING TO THEIR C-TERMINAL SIGNATURE SEQUENCES. THE INTERACTION EXHIBITED SPECIES SPECIFICITY, EXPLAINING THE INEFFICIENT ASSEMBLY OF OMPS FROM NEISSERIA IN E. COLI. ACCORDINGLY, THE IN VIVO ASSEMBLY OF THE NEISSERIAL PORIN PORA INTO THE E. COLI OUTER MEMBRANE WAS ACCOMPLISHED AFTER ADAPTING ITS SIGNATURE SEQUENCE. THESE RESULTS DEMONSTRATE THAT THE OMP85 ASSEMBLY MACHINERY RECOGNIZES OMPS BY VIRTUE OF THEIR C-TERMINAL SIGNATURE SEQUENCE.",ESCHERICHIA-COLI K-12; CONSERVED BACTERIAL PROTEIN; PERIPLASMIC CHAPERONE SKP; NEISSERIA-MENINGITIDIS; LEVEL EXPRESSION; BIOGENESIS; PORINS; IDENTIFICATION; TRANSLOCATION; ENVELOPE,NA,PLOS BIOLOGY,"ROBERT, V##VOLOKHINA, EB##SENF, F##BOS, MP##VAN GELDER, P##TOMMASSEN, J","UNIV UTRECHT, DEPT MOL MICROBIOL, UTRECHT, NETHERLANDS. UNIV UTRECHT, INST BIOMEMBRANES, UTRECHT, NETHERLANDS. VRIJE UNIV BRUSSEL VIB, DEPT MOL & CELLULAR INTERACT, B-1050 BRUSSELS, BELGIUM.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS,"BAYAN N, 2006, MOL MICROBIOL, V60, P1, DOI 10.1111/J.1365-2958.2006.05084.X##BEUCHER M, 1995, J BACTERIOL, V177, P2041, DOI 10.1128/JB.177.8.2041-2049.1995##BOLTER B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/PNAS.95.26.15831##BOS MP, 2005, INFECT IMMUN, V73, P6194, DOI 10.1128/IAI.73.9.6194-6197.2005##BOS MP, 2004, CURR OPIN MICROBIOL, V7, P610, DOI 10.1016/J.MIB.2004.10.011##BOS MP, 2004, P NATL ACAD SCI USA, V101, P9417, DOI 10.1073/PNAS.0402340101##COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727A0##DE COCK H, 1999, EUR J BIOCHEM, V259, P96, DOI 10.1046/J.1432-1327.1999.00010.X##DECOCK H, 1997, J MOL BIOL, V269, P473, DOI 10.1006/JMBI.1997.1069##DOERRLER WT, 2005, J BIOL CHEM, V280, P27679, DOI 10.1074/JBC.M504796200##EPPENS EF, 1997, EMBO J, V16, P4295, DOI 10.1093/EMBOJ/16.14.4295##GENTLE I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/JCB.200310092##GOTSCHLICH EC, 1987, P NATL ACAD SCI USA, V84, P8135, DOI 10.1073/PNAS.84.22.8135##HARMS N, 2001, J BIOL CHEM, V276, P18804, DOI 10.1074/JBC.M011194200##HOEKSTRA WPM, 1976, MOL GEN GENET, V145, P109, DOI 10.1007/BF00331565##INOUE K, 2004, PLANT J, V39, P354, DOI 10.1111/J.1365-313X.2004.02135.X##JANSEN C, 2000, EUR J BIOCHEM, V267, P3792, DOI 10.1046/J.1432-1327.2000.01417.X##JANSEN C, 2000, BBA-BIOMEMBRANES, V1464, P284, DOI 10.1016/S0005-2736(00)00155-3##KLOSE M, 1988, J BIOL CHEM, V263, P13291##KOEBNIK R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/J.1365-2958.2000.01983.X##KOZJAK V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/JBC.C300442200##LAZAR SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/JB.178.6.1770-1773.1996##LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/NAR/18.15.4631##LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9##NAKAMURA K, 1976, J BIOCHEM, V80, P1411, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A131414##NIKAIDO H, 1991, J BIOL CHEM, V266, P770##NOUWEN N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/PNAS.96.14.8173##OOMEN CJ, 2004, EMBO J, V23, P1257, DOI 10.1038/SJ.EMBOJ.7600148##OSBORNE AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/ANNUREV.CELLBIO.21.012704.133214##PASCHEN SA, 2003, NATURE, V426, P862, DOI 10.1038/NATURE02208##PETTERSSON A, 1995, INFECT IMMUN, V63, P4181, DOI 10.1128/IAI.63.10.4181-4184.1995##PRILIPOV A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1016/S0378-1097(98)00151-7##REUMANN S, 1999, TRENDS PLANT SCI, V4, P302, DOI 10.1016/S1360-1385(99)01449-1##RUIZ N, 2005, CELL, V121, P307, DOI 10.1016/J.CELL.2005.02.014##SANCHEZ-PULIDO L, 2003, TRENDS BIOCHEM SCI, V28, P523, DOI 10.1016/J.TIBS.2003.08.003##SCHAGGER H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3##SEN K, 1988, J BIOL CHEM, V263, P1182##STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F##SUGAWARA E, 1992, J BIOL CHEM, V267, P2507##SURANA NK, 2004, P NATL ACAD SCI USA, V101, P14497, DOI 10.1073/PNAS.0404679101##TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/J.1460-2075.1983.TB01581.X##TU SL, 2004, PLANT CELL, V16, P2078, DOI 10.1105/TPC.104.023952##VAN GELDER P, 2000, EUR J BIOCHEM, V267, P79, DOI 10.1046/J.1432-1327.2000.00960.X##VOULHOUX R, 2004, RES MICROBIOL, V155, P129, DOI 10.1016/J.RESMIC.2003.11.007##VOULHOUX R, 2003, SCIENCE, V299, P262, DOI 10.1126/SCIENCE.1078973##WALSH NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4##WALTON TA, 2004, MOL CELL, V15, P367, DOI 10.1016/J.MOLCEL.2004.07.023##WERNER J, 2005, MOL MICROBIOL, V57, P1450, DOI 10.1111/J.1365-2958.2005.04775.X##WHITE DA, 1990, MOL MICROBIOL, V4, P769, DOI 10.1111/J.1365-2958.1990.TB00647.X##WU T, 2005, CELL, V121, P235, DOI 10.1016/J.CELL.2005.02.015##YEN MR, 2002, BBA-BIOMEMBRANES, V1562, P6, DOI 10.1016/S0005-2736(02)00359-0",230,2020-11-20,NA
J,WOS:000242649200018,2006,A SIGNALING NETWORK FOR PATTERNING OF NEURONAL CONNECTIVITY IN THE DROSOPHILA BRAIN,"THE PRECISE NUMBER AND PATTERN OF AXONAL CONNECTIONS GENERATED DURING BRAIN DEVELOPMENT REGULATES ANIMAL BEHAVIOR. THEREFORE, UNDERSTANDING HOW DEVELOPMENTAL SIGNALS INTERACT TO REGULATE AXONAL EXTENSION AND RETRACTION TO ACHIEVE PRECISE NEURONAL CONNECTIVITY IS A FUNDAMENTAL GOAL OF NEUROBIOLOGY. WE INVESTIGATED THIS QUESTION IN THE DEVELOPING ADULT BRAIN OF DROSOPHILA AND FIND THAT IT IS REGULATED BY CROSSTALK BETWEEN WNT, FIBROBLAST GROWTH FACTOR ( FGF) RECEPTOR, AND JUN N-TERMINAL KINASE ( JNK) SIGNALING, BUT INDEPENDENT OF NEURONAL ACTIVITY. THE RAC1 GTPASE INTEGRATES A WNT-FRIZZLED-DISHEVELED AXON-STABILIZING SIGNAL AND A BRANCHLESS ( FGF)-BREATHLESS ( FGF RECEPTOR) AXON-RETRACTING SIGNAL TO MODULATE JNK ACTIVITY. JNK ACTIVITY IS NECESSARY AND SUFFICIENT FOR AXON EXTENSION, WHEREAS THE ANTAGONISTIC WNT AND FGF SIGNALS ACT TO BALANCE THE EXTENSION AND RETRACTION REQUIRED FOR THE GENERATION OF THE PRECISE WIRING PATTERN.",FGF RECEPTOR HOMOLOG; GROWTH CONE; PLANAR POLARITY; AXON OUTGROWTH; RHO GTPASES; C-JUN; COMMISSURAL AXONS; CELL-MIGRATION; BETA-CATENIN; WNT PATHWAY,NA,PLOS BIOLOGY,"SRAHNA, M##LEYSSEN, M##CHOI, CM##FRADKIN, LG##NOORDERMEER, JN##HASSAN, BA","KATHOLIEKE UNIV LEUVEN, SCH MED, NEUROGENET LAB,DEPT MOL & DEV GENET, LOUVAIN, BELGIUM. LEIDEN UNIV, MED CTR, DEPT MOL CELL BIOL, DEV NEUROBIOL LAB, LEIDEN, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY; LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS,"ADACHI-YAMADA T, 1999, NATURE, V400, P166, DOI 10.1038/22112##BARR RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0##BEJSOVEC A, 2005, CELL, V120, P11, DOI 10.1016/J.CELL.2004.12.021##BOUTROS M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X##BROUNS MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042##BULOW HE, 2004, NEURON, V42, P367, DOI 10.1016/S0896-6273(04)00246-6##CAPDEVILA J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/ANNUREV.CELLBIO.17.1.87##CLANDININ TR, 2002, NEURON, V35, P827, DOI 10.1016/S0896-6273(02)00876-0##DICKSON BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/SCIENCE.1072165##ESTRACH S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9##FANTO M, 2000, CURR BIOL, V10, P979, DOI 10.1016/S0960-9822(00)00645-X##FRADKIN LG, 2004, DEV BIOL, V272, P362, DOI 10.1016/J.YDBIO.2004.04.034##FREEMAN M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9##GARCIA-ALONSO L, 2000, NEURON, V28, P741, DOI 10.1016/S0896-6273(00)00150-1##GARRITY PA, 1995, CELL, V83, P177, DOI 10.1016/0092-8674(95)90159-0##GOLDSTEIN LSB, 2001, SCIENCE, V291, P2102, DOI 10.1126/SCIENCE.1059766##GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0##HACOHEN N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8##HASSAN BA, 2000, NEURON, V25, P549, DOI 10.1016/S0896-6273(00)81059-4##HILLIARD MA, 2006, DEV CELL, V10, P379, DOI 10.1016/J.DEVCEL.2006.01.013##HUBER AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/ANNUREV.NEURO.26.010302.081139##HUELSKEN J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/JCS.00089##IP YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9##KASTHURI N, 2004, CURR OPIN NEUROBIOL, V14, P105, DOI 10.1016/J.CONB.2004.01.013##KIMURA K, 2003, J HISTOCHEM CYTOCHEM, V51, P429, DOI 10.1177/002215540305100404##KISHIDA S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004##KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/GAD.6.9.1668##KUFFLER DP, 1994, MOL NEUROBIOL, V9, P233, DOI 10.1007/BF02816122##LEE S, 2000, J NEUROSCI, V20, P1096, DOI 10.1523/JNEUROSCI.20-03-01096.2000##LEE T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1##LEPPA S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/SJ.ONC.1203173##LOGAN CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/ANNUREV.CELLBIO.20.010403.113126##LU WG, 2004, CELL, V119, P97, DOI 10.1016/J.CELL.2004.09.019##LUNDQUIST EA, 2003, CURR OPIN NEUROBIOL, V13, P384, DOI 10.1016/S0959-4388(03)00071-0##LUO LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/ANNUREV.NEURO.28.061604.135632##LUO LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547##LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/GAD.8.15.1787##LUO YULING, 1994, CURRENT OPINION IN NEUROBIOLOGY, V4, P648, DOI 10.1016/0959-4388(94)90005-1##LYUKSYUTOVA AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/SCIENCE.1089610##MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8##MEYER G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/J.1471-4159.2002.01185.X##MIKELS AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/JOURNAL.PBIO.0040115##MITCHELL KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1##MOLINE MM, 1999, DEVELOPMENT, V126, P4375##MONTELL DJ, 1999, DEVELOPMENT, V126, P3035##MORALES J, 2002, NEURON, V34, P961, DOI 10.1016/S0896-6273(02)00731-6##NELSON WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/SCIENCE.1094291##NITABACH MN, 2002, J NEUROSCI, V22, P7913##NOSELLI S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9##ORNITZ DM, 2001, GENOME BIOL, V2##PATAPOUTIAN A, 2000, CURR OPIN NEUROBIOL, V10, P392, DOI 10.1016/S0959-4388(00)00100-8##PFEIFFER S, 1999, SEMIN CELL DEV BIOL, V10, P303, DOI 10.1006/SCDB.1999.0306##PRASAD BC, 2006, DEVELOPMENT, V133, P1757, DOI 10.1242/DEV.02357##REED BH, 2001, CURR BIOL, V11, P1098, DOI 10.1016/S0960-9822(01)00318-9##REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/GAD.8.4.428##RING JM, 1993, DEVELOPMENT, P251##ROSSO SB, 2005, NAT NEUROSCI, V8, P34, DOI 10.1038/NN1374##RULIFSON EJ, 2000, MOL CELL, V6, P117, DOI 10.1016/S1097-2765(00)00013-7##SAPIEHA PS, 2003, MOL CELL NEUROSCI, V24, P656, DOI 10.1016/S1044-7431(03)00228-8##SCHMITZ AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/EXCR.2000.5049##SHULMAN JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4##STRUTT H, 2002, DEV CELL, V3, P851, DOI 10.1016/S1534-5807(02)00363-5##SUTHERLAND D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6##TESSIERLAVIGNE M, 1996, SCIENCE, V274, P1123, DOI 10.1126/SCIENCE.274.5290.1123##VERHAGE M, 2000, SCIENCE, V287, P864, DOI 10.1126/SCIENCE.287.5454.864##VOSSHALL LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0##WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/PNAS.83.9.3012##WATTS RJ, 2003, NEURON, V38, P871, DOI 10.1016/S0896-6273(03)00295-2##WILLERT K, 1999, DEVELOPMENT, V126, P4165##WINBERG ML, 2001, NEURON, V32, P53, DOI 10.1016/S0896-6273(01)00446-9##YAMANAKA H, 2002, EMBO REP, V3, P69, DOI 10.1093/EMBO-REPORTS/KVF008##YOSHIKAWA S, 2003, NATURE, V422, P583, DOI 10.1038/NATURE01522##ZHENG XY, 2006, EMBO J, V25, P615, DOI 10.1038/SJ.EMBOJ.7600962",47,2020-11-20,NA
J,WOS:000242374800007,2006,CRITERIA FOR DRUGS USED IN PRE-EXPOSURE PROPHYLAXIS TRIALS AGAINST HIV INFECTION,NA,IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; RESISTANT HIV-1; TRANSMISSION; MACAQUES; MUTATIONS; PERSISTENCE; DIDANOSINE; PREVENTION; PROTECTION,NA,PLOS MEDICINE,"DERDELINCKX, I##WAINBERG, MA##LANGE, JMA##HILL, A##HALIMA, Y##BOUCHER, CAB","UNIV UTRECHT, MED CTR, EIJKMAN WINKLER INST, DEPT VIROL, UTRECHT, NETHERLANDS. MCGILL UNIV, JEWISH GEN HOSP, LADY DAVIS INST MED RES, AIDS CTR, MONTREAL, PQ H3T 1E2, CANADA. UNIV AMSTERDAM, ACAD MED CTR, IATEC, NL-1012 WX AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, CTR POVERTY RELATED COMMUNICABLE DIS, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV LIVERPOOL, PHARMACOL RES LABS, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND. INT AIDS SOC, GENEVA, SWITZERLAND.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,NA,36,2020-11-20,NA
J,WOS:000242374800016,2006,POPULATION PHARMACOKINETICS OF ARTESUNATE AND DIHYDROARTEMISININ FOLLOWING INTRA-RECTAL DOSING OF ARTESUNATE IN MALARIA PATIENTS,"BACKGROUND INTRA-RECTAL ARTESUNATE HAS BEEN DEVELOPED AS A POTENTIALLY LIFE-SAVING TREATMENT OF SEVERE MALARIA IN RURAL VILLAGE SETTINGS WHERE ADMINISTRATION OF PARENTERAL ANTIMALARIAL DRUGS IS NOT POSSIBLE. WE STUDIED THE POPULATION PHARMACOKINETICS OF INTRA-RECTAL ARTESUNATE AND THE RELATIONSHIP WITH PARASITOLOGICAL RESPONSES IN PATIENTS WITH MODERATELY SEVERE FALCIPARUM MALARIA. METHODS AND FINDINGS ADULTS AND CHILDREN IN AFRICA AND SOUTHEAST ASIA WITH MODERATELY SEVERE MALARIA WERE RECRUITED IN TWO PHASE II STUDIES (12 ADULTS FROM SOUTHEAST ASIA AND 11 CHILDREN FROM AFRICA) WITH INTENSIVE SAMPLING PROTOCOLS, AND THREE PHASE III STUDIES (44 CHILDREN FROM SOUTHEAST ASIA, AND 86 CHILDREN AND 26 ADULTS FROM AFRICA) WITH SPARSE SAMPLING. ALL PATIENTS RECEIVED 10 MG/KG ARTESUNATE AS A SINGLE INTRA-RECTAL DOSE OF SUPPOSITORIES. VENOUS BLOOD SAMPLES WERE TAKEN DURING A PERIOD OF 24 H FOLLOWING DOSING. PLASMA ARTESUNATE AND DIHYDROARTEMISININ (DHA, THE MAIN BIOLOGICALLY ACTIVE METABOLITE) CONCENTRATIONS WERE MEASURED BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION. THE PHARMACOKINETIC PROPERTIES OF DHA WERE DETERMINED USING NONLINEAR MIXED-EFFECTS MODELLING. ARTESUNATE IS RAPIDLY HYDROLYSED IN VIVO TO DHA, AND THIS CONTRIBUTES THE MAJORITY OF ANTIMALARIAL ACTIVITY. FOR DHA, A ONE-COMPARTMENT MODEL ASSUMING COMPLETE CONVERSION FROM ARTESUNATE AND FIRST-ORDER APPEARANCE AND ELIMINATION KINETICS GAVE THE BEST FIT TO THE DATA. THE MEAN POPULATION ESTIMATE OF APPARENT CLEARANCE (CL/F) WAS 2.64 (L/KG/ H) WITH 66% INTER-INDIVIDUAL VARIABILITY. THE APPARENT VOLUME OF DISTRIBUTION (V/F) WAS 2.75 (L/KG) WITH 96% INTER-INDIVIDUAL VARIABILITY. THE ESTIMATED DHA POPULATION MEAN ELIMINATION HALF-LIFE WAS 43 MIN. GENDER WAS ASSOCIATED WITH INCREASED MEAN CL/F BY 1.14 (95% CI: 0.36-1.92) (L/KG/H) FOR A MALE COMPARED WITH A FEMALE, AND WEIGHT WAS POSITIVELY ASSOCIATED WITH V/F. LARGER V/FS WERE OBSERVED FOR THE PATIENTS REQUIRING EARLY RESCUE TREATMENT COMPARED WITH THE REMAINDER, INDEPENDENT OF ANY CONFOUNDERS. NO ASSOCIATIONS BETWEEN THE PARASITOLOGICAL RESPONSES AND THE POSTERIOR INDIVIDUAL ESTIMATES OF V/F, CL/F, AND AUC(0-6H) WERE OBSERVED. CONCLUSIONS THE PHARMACOKINETIC PROPERTIES OF DHA WERE AFFECTED ONLY BY GENDER AND BODY WEIGHT. PATIENTS WITH THE LOWEST AREA UNDER THE DHA CONCENTRATION CURVE DID NOT HAVE SLOWER PARASITE CLEARANCE, SUGGESTING THAT RECTAL ARTESUNATE IS WELL ABSORBED IN MOST PATIENTS WITH MODERATELY SEVERE MALARIA. HOWEVER, A NUMBER OF MODELLING ASSUMPTIONS WERE REQUIRED DUE TO THE LARGE INTRA- AND INTER-INDIVIDUAL VARIABILITY OF THE DHA CONCENTRATIONS.",ORAL ARTESUNATE; ARTEMISININ SUPPOSITORIES; FALCIPARUM-MALARIA; CLINICAL EFFICACY; CHILDREN; BIOAVAILABILITY; QUININE; ARTEMETHER; ACID,NA,PLOS MEDICINE,"SIMPSON, JA##AGBENYEGA, T##BARNES, KI##DI PERRI, G##FOLB, P##GOMES, M##KRISHNA, S##KRUDSOOD, S##LOOAREESUWAN, S##MANSOR, S##MCILLERON, H##MILLER, R##MOLYNEUX, M##MWENECHANYA, J##NAVARATNAM, V##NOSTEN, F##OLLIARO, P##PANG, L##RIBEIRO, I##TEMBO, M##VAN VUGT, M##WARD, S##WEERASURIYA, K##WIN, K##WHITE, NJ","UNIV MELBOURNE, CTR MOL ENVIRONM GENET & ANALYT EPIDEMIOL, MELBOURNE, VIC, AUSTRALIA. KWAME NKRUMAH UNIV SCI & TECHNOL, SCH MED SCI, KUMASI, GHANA. UNIV CAPE TOWN, DIV CLIN PHARMACOL, ZA-7700 RONDEBOSCH, SOUTH AFRICA. OSPED AMEDEO SAVOIA, CLIN MALATTIE INFECTT, TURIN, ITALY. S AFRICAN MRC, TYGERBERG, SOUTH AFRICA. WHO, UNICEF, UNDP, WORLD BANK,SPECIAL PROGRAMME RES & TRAINING TROP, CH-1211 GENEVA, SWITZERLAND. UNIV LONDON, CTR INFECT, DIV CELLULAR & MOL MED, LONDON WC1E 7HU, ENGLAND. MAHIDOL UNIV, FAC TROP MED, BANGKOK 10700, THAILAND. UNIV SAINS MALAYSIA, CTR DRUG RES, GEORGE TOWN, MALAYSIA. PFIZER GLOBAL RES & DEV, ANN ARBOR, MI USA. COLL MED, MALAWI LIVERPOOL WELLCOME TRUST CLIN RES PROGRAMM, BLANTYRE, MALAWI. SJOKLO MALARIA RES UNIT, MAE SOT, TAK, THAILAND. MAHIDOL UNIV, WELLCOME TRUST, OXFORD TROP MED RES PROGRAMME, BANGKOK 10700, THAILAND. UNIV OXFORD, CHURCHILL HOSP, CTR TROP MED & VACCINOL, OXFORD OX1 2JD, ENGLAND. DEPT HLTH, MAUI CTY, HI USA. AMSTERDAM MED CTRE, DEPT AIDS & TROP MED, AMSTERDAM, NETHERLANDS. UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, MERSEYSIDE, ENGLAND. WHO, REG OFF SE ASIA, NEW DELHI, INDIA.","MEDICINE, GENERAL & INTERNAL",GENERAL & INTERNAL MEDICINE,"ARNOLD K, 1990, T ROY SOC TROP MED H, V84, P499, DOI 10.1016/0035-9203(90)90012-4##ASHTON M, 1998, CLIN PHARMACOL THER, V63, P482, DOI 10.1016/S0009-9236(98)90044-3##BATTY KT, 1998, BRIT J CLIN PHARMACO, V45, P123, DOI 10.1046/J.1365-2125.1998.00655.X##BETHELL DB, 1997, T ROY SOC TROP MED H, V91, P195, DOI 10.1016/S0035-9203(97)90222-4##FAIZ MA, 2005, LANCET, V366, P717##HALPAAP B, 1998, AM J TROP MED HYG, V58, P365, DOI 10.4269/AJTMH.1998.58.365##HIEN TT, 1992, T ROY SOC TROP MED H, V86, P582, DOI 10.1016/0035-9203(92)90137-2##HIEN TT, 1991, T ROY SOC TROP MED H, V85, P210, DOI 10.1016/0035-9203(91)90024-S##KARUNAJEEWA HA, 2004, ANTIMICROB AGENTS CH, V48, P2966, DOI 10.1128/AAC.48.8.2966-2972.2004##KRISHNA S, 2001, ANTIMICROB AGENTS CH, V45, P509, DOI 10.1128/AAC.45.2.509-516.2001##LI GQ, 1990, CLIN TRIALS QINGHAOS, V1##LI QG, 1998, J PHARM PHARMACOL, V50, P173, DOI 10.1111/J.2042-7158.1998.TB06173.X##LINDSTROM MJ, 1990, BIOMETRICS, V46, P673, DOI 10.2307/2532087##LUXEMBURGER C, 1995, AM J TROP MED HYG, V53, P522, DOI 10.4269/AJTMH.1995.53.522##MITHWANI S, 2004, BRIT J CLIN PHARMACO, V57, P146, DOI 10.1046/J.1365-2125.2003.01986.X##MYINT HY, 2004, T ROY SOC TROP MED H, V98, P73, DOI 10.1016/S0035-9203(03)00014-2##NAVARATNAM V, 2000, CLIN PHARMACOKINET, V39, P255, DOI 10.2165/00003088-200039040-00002##NAVARATNAM V, 1997, J CHROMATOGR B, V692, P157, DOI 10.1016/S0378-4347(96)00505-1##NEALON C, 2002, ANTIMICROB AGENTS CH, V46, P3933, DOI 10.1128/AAC.46.12.3933-3939.2002##NEWTON CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4##PHUONG CXT, 1997, T ROY SOC TROP MED H, V91, P335, DOI 10.1016/S0035-9203(97)90099-7##PRICE R, 1999, AM J TROP MED HYG, V60, P547, DOI 10.4269/AJTMH.1999.60.547##TITULAER HAC, 1990, J PHARM PHARMACOL, V42, P810, DOI 10.1111/J.2042-7158.1990.TB07030.X",42,2020-11-20,WELLCOME TRUSTWELLCOME TRUST FUNDING SOURCE: MEDLINE
J,WOS:000241219600006,2006,ENERGY CONTENT OF ANTARCTIC MESOPELAGIC FISHES: IMPLICATIONS FOR THE MARINE FOOD WEB,"FOR A BETTER UNDERSTANDING OF THE ROLE OF MESOPELAGIC FISH IN THE SOUTHERN OCEAN FOOD WEB, THE ENERGY AND WATER CONTENT OF BATHYLAGUS ANTARCTICUS, ELECTRONA ANTARCTICA AND GYMNOSCOPELUS BRAUERI FROM THE LAZAREV SEA WERE INVESTIGATED. MEAN DRY WEIGHT ENERGY CONTENT OF B. ANTARCTICUS (20.4 KJ G(-1)) WAS SIGNIFICANTLY LOWER THAN IN E. ANTARCTICA AND G. BRAUERI (BOTH 29.4 KJ G(-1)). IN E. ANTARCTICA, AN INCREASE OF DRY WEIGHT ENERGY DENSITY WITH AGE WAS EVIDENT FROM 26.9 KJ G(-1) IN JUVENILES OF LESS THAN 1 YEAR OF AGE TO 32.0 KJ G(-1) IN 3-YEAR-OLD FISH. WATER CONTENT DECREASED WITH SIZE IN ALL THREE SPECIES. ABUNDANT HIGH-ENERGY SPECIES SUCH AS E. ANTARCTICA ARE AT A KEY POSITION IN THE FOOD WEB. DUE TO A MARKED INFLUENCE OF AGE ON ENERGY CONTENT, POPULATION STRUCTURE CAN BE AN IMPORTANT VARIABLE IN ESTIMATES OF ENERGY FLUXES IN THE SOUTHERN OCEAN ECOSYSTEM.",SOUTH SHETLAND ISLANDS; KING-GEORGE-ISLAND; PROXIMATE COMPOSITION; FATTY-ACID; FUR SEALS; ARCTOCEPHALUS-GAZELLA; ELECTRONA-ANTARCTICA; COMMUNITY STRUCTURE; FEEDING ECOLOGY; OPEN WATERS,NA,POLAR BIOLOGY,"VAN DE PUTTE, A##FLORES, H##VOLCKAERT, F##VAN FRANEKER, JA","CATHOLIC UNIV LOUVAIN, AQUAT ECOL LAB, B-3000 LOUVAIN, BELGIUM. IMARES TEXEL, NL-1790 AD DEN BURG, NETHERLANDS. UNIV GRONINGEN, DEPT MARINE BIOL, NL-9750 AA HAREN, NETHERLANDS.",BIODIVERSITY CONSERVATION; ECOLOGY,BIODIVERSITY & CONSERVATION; ENVIRONMENTAL SCIENCES & ECOLOGY,"AINLEY D.G., 1991, JOURNAL OF MARINE SYSTEMS, V2, P111, DOI 10.1016/0924-7963(91)90017-O##AINLEY DG, 1992, MAR ECOL PROG SER, V90, P207, DOI 10.3354/MEPS090207##AINLEY DG, 1994, J ANIM ECOL, V63, P247##ANTHONY JA, 2000, J EXP MAR BIOL ECOL, V248, P53, DOI 10.1016/S0022-0981(00)00159-3##ARNOULD JPY, 1991, ANTARCT SCI, V3, P19, DOI 10.1017/S0954102091000056##BARRERA-ORO E, 2002, ANTARCT SCI, V14, P293, DOI 10.1017/S0954102002000111##BOST CA, 2002, MAR ECOL PROG SER, V227, P51, DOI 10.3354/MEPS227051##CASAUX R, 2004, POLAR BIOL, V27, P59, DOI 10.1007/S00300-003-0559-Z##CASAUX R, 2003, POLAR BIOL, V26, P49, DOI 10.1007/S00300-002-0442-3##CHEREL Y, 1992, IBIS, V134, P118, DOI 10.1111/J.1474-919X.1992.TB08388.X##CLARKE A, 1980, IBIS, V122, P488, DOI 10.1111/J.1474-919X.1980.TB00903.X##CREET S., 1994, MARINE ORNITHOLOGY, V22, P221##DONNELLY J, 1990, MAR BIOL, V106, P13, DOI 10.1007/BF02114670##EDER EB, 2005, MAR ECOL PROG SER, V291, P43, DOI 10.3354/MEPS291043##GEIGER SP, 2000, MAR BIOL, V137, P1091, DOI 10.1007/S002270000428##GON O., 1990, P107##GREELY TM, 1999, MAR BIOL, V133, P145, DOI 10.1007/S002270050453##HARTMAN KJ, 1995, T AM FISH SOC, V124, P347, DOI 10.1577/1548-8659(1995)124<0347:EEDOF>2.3.CO;2##HOPKINS TL, 1993, POLAR BIOL, V13, P389, DOI 10.1007/BF01681980##HUBOLD G., 1985, P445##HULLEY P.A., 1990, P146##KOCK K-H, 1992, ANTARCTIC FISH FISHE, P359##LANCRAFT TM, 1991, POLAR BIOL, V11, P157##LANCRAFT TM, 1989, POLAR BIOL, V9, P225, DOI 10.1007/BF00263770##LAWSON JW, 1998, MAR ECOL PROG SER, V164, P13, DOI 10.3354/MEPS164013##LEA MA, 2002, MAR ECOL PROG SER, V245, P281, DOI 10.3354/MEPS245281##LEA MA, 2002, POLAR BIOL, V25, P843, DOI 10.1007/S00300-002-0428-1##OSMAN LP, 2004, POLAR BIOL, V27, P92, DOI 10.1007/S00300-003-0555-3##PAKHOMOV EA, 1996, MAR ECOL PROG SER, V134, P1, DOI 10.3354/MEPS134001##PAUL AJ, 1998, ESTUAR COAST SHELF S, V47, P251, DOI 10.1006/ECSS.1998.0369##PEDERSEN J, 2001, J FISH BIOL, V59, P380, DOI 10.1111/J.1095-8649.2001.TB00137.X##PHLEGER CF, 1997, ANTARCT SCI, V9, P258, DOI 10.1017/S0954102097000345##PUSCH C, 2004, DEEP-SEA RES PT I, V51, P1685, DOI 10.1016/J.DSR.2004.06.008##QUILLFELDT P, 2002, POLAR BIOL, V25, P216, DOI 10.1007/S00300-001-0332-0##REINHARDT SB, 1986, MAR BIOL, V91, P149, DOI 10.1007/BF00569431##SAADETTIN G, 1998, JI SCI FOOD AGR, V78, P337##SABOURENKOV E, 1990, WGFSA9023 CCAMLR, P433##SIEGEL V, 2004, WGEMM0423 CCAMLR, P1##TIERNEY M, 2002, ANTARCT SCI, V14, P225, DOI 10.1017/S0954102002000020##TORRES JJ, 1988, COMP BIOCHEM PHYS B, V90, P521, DOI 10.1016/0305-0491(88)90291-X##TORRES JJ, 1994, MAR ECOL PROG SER, V113, P221, DOI 10.3354/MEPS113221##VANFRANEKER JA, 1997, DEEP-SEA RES PT II, V44, P435, DOI 10.1016/S0967-0645(96)00078-1##VANFRANEKER JA, 2001, THESIS U GRONINGEN, P274",22,2020-11-20,NA
J,WOS:000242423200005,2006,FROM LOW TO HIGH FERTILITY IN SULAWESI (INDONESIA) DURING THE COLONIAL PERIOD: EXPLAINING THE 'FIRST FERTILITY TRANSITION',"THIS PAPER EXAMINES THE PAST TRANSITION FROM LOW TO HIGH FERTILITY WHICH, IN INDONESIA AS ELSEWHERE, PRECEDED THE RETURN TO LOWER BIRTH RATES. DATA FROM TWO PARTS OF THE ISLAND OF SULAWESI WHERE FERTILITY ROSE DURING THE COLONIAL PERIOD ARE USED TO EXPLAIN BOTH WHY IT ROSE, AND WHY IT WAS ORIGINALLY LOW. ECONOMIC CONDITIONS, IT IS ARGUED, WERE THE MOST IMPORTANT FACTORS, AFFECTING FERTILITY VIA THE SUPPLY OF INCOME AND THE DEMAND FOR LABOUR. TWO SCHEMATIC MODELS OF THE 'FIRST FERTILITY TRANSITION' ARE PROPOSED. IN AREAS WITH LOW POPULATION DENSITIES AND AREA-EXTENSIVE FORMS OF AGRICULTURE RESPONSIVE TO COMMERCIAL STIMULI, BIRTH RATES ROSE AS THE GROWTH OF COMMERCE RAISED LEVELS OF PROSPERITY, FACILITATED MARRIAGE, AND UNDERMINED INSTITUTIONS SUCH AS DEBT-SLAVERY WHICH HAD PREVIOUSLY ACTED TO RESTRICT MARITAL FERTILITY. IN DENSELY POPULATED AREAS WITH LABOUR-INTENSIVE AGRICULTURE AND HEAVY STATE TAXATION IN LABOUR, FERTILITY ROSE IN RESPONSE TO DEMANDS FOR WOMEN'S (AND POSSIBLY CHILD) LABOUR THAT DID NOT NECESSARILY LEAD TO GAINS IN INCOME.",SOUTHEAST-ASIA; POPULATION-DYNAMICS; DEMOGRAPHY; ECONOMY; GROWTH; JAVA,HISTORICAL DEMOGRAPHY; INDONESIA; SULAWESI; FERTILITY TRANSITION; LACTATIONAL AMENORRHOEA; INSTITUTIONAL ECONOMICS; WOMEN'S AUTONOMY; SLAVERY,POPULATION STUDIES-A JOURNAL OF DEMOGRAPHY,"HENLEY, D","ROYAL NETHERLANDS INST SE ASIAN & CARRIBBEAN STUD, KITLV, NL-2300 RA LEIDEN, NETHERLANDS.",DEMOGRAPHY,DEMOGRAPHY,"ABERNETHY VD, 2002, POPUL ENVIRON, V24, P69, DOI 10.1023/A:1020181810894##ADAS M, 1981, COMP STUD SOC HIST, V23, P217, DOI 10.1017/S0010417500013281##ADRIANI N., 1915, TIJDSCHRIFT KONINKLI, V32, P457##ADRIANI N, 1912, BARE ESPREKENDE TORA##AGUIRRE GP, 1998, POP STUD-J DEMOG, V52, P231, DOI 10.1080/0032472031000150396##ALEXANDER J, 1986, CULTURE REPROD ANTHR, P249##ALEXANDER J, 1984, MANKIND, V14, P361##ALEXANDER JENNIFER, 1993, SOJOURN, V8, P250##BENGTSSON T., 2000, POPULATION EC HUNGER##BENPORATH Y, 1980, POPUL DEV REV, V6, P1, DOI 10.2307/1972655##BIRO PS, 1971, SENSUS PENDUDUK 1971##BOEKE J.H., 1953, EC EC POLICY DUAL SO##BOOMGAARD P, 2003, POPUL DEV REV, V29, P197, DOI 10.1111/J.1728-4457.2003.00197.X##BOOMGAARD P, 1989, CHILDREN COLONIAL ST, P1795##BOOMGAARD P, 1996, HIST PAPIEREN LANDSC##BOOMGAARD PETER, 1997, PAPER LANDSCAPES EXP, P61##BOOTH ANNE, 1998, INDONESIAN EC 19 20##BOSERUP E., 1965, CONDITIONS AGR GROWT##BROOKFIELD HAROLD, 2001, EXPLORING AGRODIVERS##BROUWER M, 1936, THESIS RIJKSUNIVERSI##BURCH TK, 1983, DETERMINANTS FERTILI, V2, P532##CALDWELL JC, 2003, POP STUD-J DEMOG, V57, P199, DOI 10.1080/0032472032000097100##CALDWELL JC, 2001, ASIAN POPULATION HIS, P3##CHABOT HT, 1969, BIJDRAGEN TOT TAAL L, V125, P94##COLEMAN D, 1986, STATE POPULATION THE, P14##DE CLERCQ F. S. A., 1891, INDISCH GENOOTSCHAP, P203##DECLERCQ FSA, 1870, TIJDSCHRIFT NEDERLAN, V1870, P94##DELANGE SH, 1897, TIJDSCHRIFT NEDERLAN, P667##DEZWAAN K, 1925, MENSCH MAATSCHAPPIJ, V1, P22##DYSON T, 1985, POPUL DEV REV, V11, P399, DOI 10.2307/1973246##DYSON T, 1983, POPUL DEV REV, V9, P35, DOI 10.2307/1972894##EDELING ACJ, 1875, UNPUB MEMORIE OMTREN##ELSON RE, 1994, VILLAGE JAVA CULTIVA##GEERTZ CLIFFORD, 1963, AGR INVOLUTION PROCE##GOOSZEN A. J., 1999, DEMOGRAPHIC HIST IND##GRAAFLAND, 1898, MINAHASSA HAAR VERLE##GRAAFLAND N., 1867, MINAHASSA HAAR VERLE##GRUDELBACH J, 1847, UNPUB GEVOELEN TOPOG##HENLEY D, 2002, SINGAPORE J TROP GEO, V23, P167, DOI 10.1111/1467-9493.00124##HENLEY D, 2005, FERTILITY FOOD FEVER##HICKSON SJ, 1987, J ANTHR I GREAT BRIT, V16, P136##HICKSON SJ, 1889, NATURALIST N CELEBES##HOLLEMAN FD, 1930, VERSLAG ONDERZOEK IN##HULL TH, 1977, POP STUD-J DEMOG, V31, P43, DOI 10.1080/00324728.1977.10412746##JANSEN A.J.F., 1861, TIJDSCHRIFT TAAL LAN, V10, P221##JEJEEBHOY S., 1995, WOMENS ED AUTONOMY R##JENNIFER ALEXANDER, 1979, SOCIAL ANAL, V3, P22##KNAAP GJ, 1987, KRUIDNAGELEN CHRISTE, P1656##KNAPEN H, 2001, FORESTS FORTUNE ENV##KRUYT A.C., 1938, W TORADJAS MIDDEN CE##KRUYT AC, 1911, ONZE EEUW MAANDSCHRI, V11, P61##KRUYT AC, 1899, TIJDSCHRIFT INDISCHE, V41, P80##KRUYT AC, 1924, KOLONIALE STUDIEN, V8, P33##KRUYT ALB. C., 1903, TIJDSCHRIFT KONINKLI, V20, P190##KRUYT ALB. C., 1899, TIJDSCHRIFT KONINKLI, V16, P593##KUNDIG A., 1934, MEDEDEEL DIENST VOLKSGEZONDHEID NED INDIE, V23, P167##LEE RD, 1997, HDB POPULATION FAM B, V1, P1063, DOI DOI 10.1016/S1574-003X(97)80011-6##LEVINE RA, 1983, DETERMINANTS FERTILI, V2, P666##LICHBACH MI, 1996, COOPERATORS DILEMMA##LORIMER F, 1954, CULTURE HUMAN FERTIL##LUCIEER A., 1924, TIJDSCHRIFT KONINKLI, V41##MARSHALL MAC, 1976, T KINSHIP ADOPTION F, P28##MASON KO, 1997, DEMOGRAPHY, V34, P443, DOI 10.2307/3038299##MCNICOLL G, 1980, POPUL DEV REV, V6, P441, DOI 10.2307/1972410##MEILLASSOUX CLAUDE, 1986, ANTHR ESCLAVAGE VENT##NAG M, 1980, CURR ANTHROPOL, V21, P571, DOI 10.1086/202538##NAG M, 1975, POPULATION SOCIAL OR, P11##NETTING ROBERT M., 1993, SMALLHOLDERS HOUSEHO##NIEBOER HJ, 1903, Z SOCIALWISSENSCHAFT, V6, P715##NORTH DC, 1990, I I CHANGE EC PERFOR##OLSON M, 1965, LOGIC COLLECTIVE ACT##OWEN NG, 1987, J SOUTHEAST ASIAN ST, V18, P45, DOI 10.1017/S0022463400001247##PADOCH C, 1982, MIGRATION ITS ALTERN##PADTBRUGGE ROBERT, 1866, BIJDR TAAL-LAND-V, V13, P304##RABEN R, 1996, THESIS RIJKSUNIVERSI##RAFFLES THOMAS STAMFORD, 1978, HIST JAVA##REID A, 1983, SLAVERY BONDAGE DEPE, P1##REID ANTHONY, 1993, BREAKING CHAINS SLAV, P64##REID ANTHONY, 1998, ASIAN STUDIES REV, V22, P23##REID ANTHONY, 2001, ASIAN POPULATION HIS, P45##REID ANTHONY, 1987, DEATH DIS SE ASIA, P33##ROBERTSON C., 1983, WOMEN SLAVERY AFRICA##SAITO O, 1996, POP STUD-J DEMOG, V50, P537, DOI 10.1080/0032472031000149606##SANTOW G, 1987, POP STUD-J DEMOG, V41, P147, DOI 10.1080/0032472031000142576##SCHRAUWERS ALBERT, 2000, COLONIAL REFORMATION##SCOTT JC, 1972, AM POLIT SCI REV, V66, P91, DOI 10.2307/1959280##SHEPHERD JR, 1995, MARRIAGE MANDATORY A##SMITH A., 1976, INQUIRY NATURE CAUSE##TENGNAGEL JG, 1848, UNPUB BEKNOPE BETREK, V16, P3##TILLEMA H.F., 1926, ZONDER TROPEN GEEN E##TILLEMA HF, 1922, KROMOBLANDA OVER VRA##TOUWEN J., 2001, EXTREMES ARCHIPELAGO##VAN SPREEUWENBERG A.F., 1845, TIJDSCHRIFT NEDERLAN, V7-4, P161##VANBEMMELEN S, 1987, INDONESIAN WOMEN PER, P181##VANDINTER BCA, 1899, TIJDSCHRIFT INDISCHE, V41, P324##VANDOREN JBJ, 1854, FRAGMENTEN REIZEN IN##VANHARENCARSPEL JP, 1873, UNPUB CULTUUR VERSLA##VANRAVESTYN TLW, 1959, TROPICAL GEOGRAPHICA, V11, P61##VERDOORN JA, 1941, THESIS RIJKSUNIVERSI##WALLACE AR, 1987, MALAY ARCHIPELAGO##WHITE B, 1973, HUM ECOL, V1, P217, DOI 10.1007/BF01531182##WHITE B, 1976, THESIS COLUMBIA U##WILSON C, 1999, POP STUD-J DEMOG, V53, P117##WOOD JW, 1998, CURR ANTHROPOL, V39, P99, DOI 10.1086/204700##1933, VOLKSTELLING 1930 PO##1910, ADATRECHTBUNDEL, V3, P1",8,2020-11-20,NA
J,WOS:000241111700005,2006,THE PLURI-FINE TOPOLOGY IS LOCALLY CONNECTED,WE PROVE THAT THE PLURI-FINE TOPOLOGY ON ANY OPEN SET OMEGA IN C-N IS LOCALLY CONNECTED. THIS ANSWERS A QUESTION BY FUGLEDE.,NA,PLURI-FINE TOPOLOGY; PLURISUBHARMONIC FUNCTIONS,POTENTIAL ANALYSIS,"EL MARZGUIOUI, S##WIEGERINCK, J","UNIV AMSTERDAM, KDV INST MATH, NL-1018 TV AMSTERDAM, NETHERLANDS.",MATHEMATICS,MATHEMATICS,"BEDFORD B, 1993, MATH NOTES, V38##BEDFORD E, 1987, J FUNCT ANAL, V72, P225, DOI 10.1016/0022-1236(87)90087-5##BRELOT M, 1971, LECT NOTES MATH, V175##DOOB JL, 1984, CLASSICAL POTENTIAL##EDLUND T, CV0405025 MATHARXIVM##FUGLEDE B, 1986, LECT NOTES MATH, V1198, P133##FUGLEDE B, 1971, ANN I FOURIER, V21, P227, DOI 10.5802/AIF.388##FUGLEDE B, 1974, ANN I FOURIER, P77##FUGLEDE B., 1972, SPRINGER LECT NOTES, V289##HELMS LL, PURE APPL MATH, V22##KLIMEK M., 1991, LONDON MATH SOC MONO, V6##LELONG P., 1945, ANN SCI ECOLE NORM S, V62, P301##THORBIORNSON J, 1988, MONATSH MATH, V105, P245, DOI 10.1007/BF01636932",11,2020-11-20,NA
J,WOS:000242309100003,2006,GENDER-SPECIFIC RISK FACTORS FOR MORTALITY ASSOCIATED WITH INCIDENT CORONARY HEART DISEASE - A PROSPECTIVE COMMUNITY-BASED STUDY,"BACKGROUND. RISK FACTORS FOR MORTALITY IN COMMUNITY-RESIDING PERSONS DEVELOPING CONGESTIVE HEART FAILURE (CHF) AND ACUTE MYOCARDIAL INFARCTION (AMI) MAY DIFFER FOR MALES AND FEMALES. METHOD. PERSONS FROM THE GRONINGEN LONGITUDINAL AGING STUDY WITH INCIDENT CHF (N=274) OR AMI (N=198) WERE IDENTIFIED BETWEEN 1993 AND 1998 AND THEIR SURVIVAL STATUS WAS COLLECTED IN 2001. RISK FACTORS ARE ASSESSED PRIOR TO THE CARDIAC DIAGNOSIS. RESULTS. THE 1-, 5-, 7-YEAR SURVIVAL RATES WERE 65, 53, 50% FOR AMI AND 74, 45, 32% FOR CHF. MULTIVARIATE ANALYSES SHOWED THAT MALE GENDER, HIGH AGE, SMOKING, DIABETES AND LOW PHYSICAL FUNCTION WERE RISK FACTORS FOR MORTALITY AMONG PERSONS WITH CHE FOR AMI, 1 MONTH MORTALITY WAS RELATED TO HIGH AGE AND BASELINE LOW BODY MASS INDEX, WHILE LONGER TERM MORTALITY WAS RELATED TO MALE GENDER AND HIGH AGE. IN ADDITION, DIABETES INCREASED LONGER TERM MORTALITY AMONG FEMALES BUT NOT AMONG MALES WITH AMI. DEPRESSION WAS NOT A RISK FACTOR FOR MORTALITY FOR EITHER CONDITION IN EITHER GENDER. CONCLUSION. MALES WITH CHF OR AMI HAVE WORSE SURVIVAL RATES COMPARED TO FEMALES. RISK FACTORS FOR MORTALITY ARE PREDOMINANTLY SIMILAR FOR MALES AND FEMALES, EXCEPT FOR DIABETES WHICH IS A RISK FACTOR AMONG FEMALES, BUT NOT MALES WITH AMI. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",ACUTE MYOCARDIAL-INFARCTION; SELF-RATED HEALTH; QUALITY-OF-LIFE; CHRONIC MEDICAL CONDITIONS; LONG-TERM MORTALITY; CASE-FATALITY RATES; BODY-MASS INDEX; SEX-DIFFERENCES; CARDIOVASCULAR-DISEASE; DEPRESSION SCALE,MYOCARDIAL INFARCTION; CONGESTIVE HEART FAILURE; DEPRESSION; AGED; DIABETES MELLITUS; SURVIVAL RATE; SEX,PREVENTIVE MEDICINE,"VAN JAARSVELD, CHM##RANCHOR, AV##KEMPEN, GIJM##COYNE, JC##VAN VELDHUISEN, DJ##ORMEL, J##SANDERMAN, R","UNIV GRONINGEN, MED CTR, DEPT PUBL HLTH & HLTH PSYCHOL, NO CTR HEALTHCARE RES, NL-9700 AD GRONINGEN, NETHERLANDS. MAASTRICHT UNIV, SECT MED SOCIOL, NL-6200 MD MAASTRICHT, NETHERLANDS. UNIV PENN, PHILADELPHIA, PA 19104 USA. UNIV GRONINGEN, MED CTR, DEPT CARDIOL, NL-9700 RB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT SOCIAL PSYCHIAT, NL-9700 RB GRONINGEN, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICINE, GENERAL & INTERNAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; GENERAL & INTERNAL MEDICINE","ABILDSTROM SZ, 2003, HEART, V89, P507, DOI 10.1136/HEART.89.5.507##[ANONYMOUS], 1998, REP WHO CONS OB OB P##BAREFOOT JC, 1996, AM J CARDIOL, V78, P613, DOI 10.1016/S0002-9149(96)00380-3##BARRETTCONNOR E, 1997, CIRCULATION, V95, P252, DOI 10.1161/01.CIR.95.1.252##BJELLAND I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3##BOUMA J, 1999, J EPIDEMIOL COMMUN H, V53, P459, DOI 10.1136/JECH.53.8.459##CHEN YT, 1999, AM J MED, V106, P605, DOI 10.1016/S0002-9343(99)00126-6##COYNE JC, 2001, AM J CARDIOL, V88, P526, DOI 10.1016/S0002-9149(01)01731-3##CROWLEY A, 2003, AM HEART J, V146, P824, DOI 10.1016/S0002-8703(03)00406-X##CURTIS JP, 2005, ARCH INTERN MED, V165, P55, DOI 10.1001/ARCHINTE.165.1.55##EISENSTEIN EL, 2005, AM J MED, V118, P981, DOI 10.1016/J.AMJMED.2005.02.017##FONTAINE KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/JAMA.289.2.187##FRASURE-SMITH N, 2003, ARCH GEN PSYCHIAT, V60, P627, DOI 10.1001/ARCHPSYC.60.6.627##FRIED LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/JAMA.279.8.585##GALATIUSJENSEN S, 1996, BMJ-BRIT MED J, V313, P137, DOI 10.1136/BMJ.313.7050.137##GOLDBERG RJ, 1999, J AM COLL CARDIOL, V33, P1533, DOI 10.1016/S0735-1097(99)00040-6##GOTTLIEB SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6##IDLER EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359##ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X##JANGHORBANI M, 1993, INT J EPIDEMIOL, V22, P1056, DOI 10.1093/IJE/22.6.1056##JOINER BL, 1981, AM STAT, V35, P227, DOI 10.2307/2683295##KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/JAMA.241.19.2035##KATTAINEN A, 2004, J CLIN EPIDEMIOL, V57, P513, DOI 10.1016/J.JCLINEPI.2003.10.004##KEMPEN GIJM, 1997, HEALTH PSYCHOL, V16, P539, DOI 10.1037/0278-6133.16.6.539##KEMPEN GIJM, 1996, SOC SCI MED, V43, P1601, DOI 10.1016/S0277-9536(96)00057-3##KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/GERONT/30.4.497##KEMPEN GIJM, 1997, AM J PUBLIC HEALTH, V87, P38, DOI 10.2105/AJPH.87.1.38##KEMPEN GIJM, 1998, J CLIN EPIDEMIOL, V51, P11, DOI 10.1016/S0895-4356(97)00234-5##KOBER L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4##KRIEGSMAN DMW, 1996, J CLIN EPIDEMIOL, V49, P1407, DOI 10.1016/S0895-4356(96)00274-0##LAMBERTS H, 1987, INT CLASSIFICATION P##LEE WL, 2000, DIABETES CARE, V23, P962, DOI 10.2337/DIACARE.23.7.962##LEVY D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMOA020265##MACINTYRE K, 2001, J AM COLL CARDIOL, V38, P729, DOI 10.1016/S0735-1097(01)01465-6##MARANG-VAN DE MHEEN PJ, 2001, INT J EPIDEMIOL, V30, P787, DOI 10.1093/IJE/30.4.787##MAYNARD C, 1997, ARCH INTERN MED, V157, P1379, DOI 10.1001/ARCHINTE.157.12.1379##MIILUNPALO S, 1997, J CLIN EPIDEMIOL, V50, P517, DOI 10.1016/S0895-4356(97)00045-0##ORMEL J, 1997, PSYCHOL MED, V27, P1065, DOI 10.1017/S0033291797005321##ROSENGREN A, 2001, EUR HEART J, V22, P314, DOI 10.1053/EUHJ.2000.2368##SACHDEV M, 2004, J AM COLL CARDIOL, V43, P576, DOI 10.1016/J.JACC.2003.10.031##SPIERS N, 2003, GERONTOLOGIST, V43, P406, DOI 10.1093/GERONT/43.3.406##SPINHOVEN P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382##VACCARINO V, 2001, ANN INTERN MED, V134, P173, DOI 10.7326/0003-4819-134-3-200102060-00007##VAN JAARSVELD CHM, 2002, J CLIN EPIDEMIOL, V55, P1105, DOI 10.1016/S0895-4356(02)00506-1##VAN MELLE JP, 2004, PSYCHOSOM MED, V66, P814, DOI 10.1097/01.PSY.0000146294.82810.9C##WULSIN LR, 2003, PSYCHOSOM MED, V65, P201, DOI 10.1097/01.PSY.0000058371.50240.E3##YUSUF S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9##ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/J.1600-0447.1983.TB09716.X",10,2020-11-20,NA
J,WOS:000242309100005,2006,CARDIOVASCULAR PREVENTION IN THE HARTSLAG LIMBURG PROJECT: EFFECTS OF A HIGH-RISK APPROACH ON BEHAVIORAL RISK FACTORS IN A GENERAL PRACTICE POPULATION,"BACKGROUND. THIS STUDY DESCRIBES A GENERAL-PRACTICE-BASED HIGH-RISK CARDIOVASCULAR PREVENTION APPROACH IN MAASTRICHT, THE NETHERLANDS (1999-2003). THE INTERVENTION CONSISTED OF A COMPLETE REGISTRATION OF RISK FACTORS, OPTIMIZATION OF MEDICAL TREATMENT AND HEALTH COUNSELING ON HIGH FAT CONSUMPTION, SMOKING AND PHYSICAL INACTIVITY. METHODS. BEHAVIORAL EFFECTS WERE ASSESSED IN A TRIAL, RANDOMIZATION BY PRACTICE AND USUAL CARE AS CONTROL. VALIDATED QUESTIONNAIRES WERE COMPLETED BY 1300 PATIENTS AT BASELINE, 1174 AFTER 4 MONTHS (90.3%) AND 1046 (80.5%) AFTER 18 MONTHS. RESULTS. AFTER 4 MONTHS, INTENTION-TO-TREAT ANALYSES REVEALED A DECREASE IN SATURATED FAT INTAKE OF 1.3 POINTS (SCALE RANGING FROM 7 TO 30 POINTS, P=0.000). THIS WAS PARTLY SUSTAINED AFTER 18 MONTHS (-0.5 POINTS, P=0.014). AFTER 18 MONTHS, OBESE INTERVENTION PATIENTS WERE MORE LIKELY TO BE SUFFICIENTLY PHYSICALLY ACTIVE THAN THEIR CONTROL COUNTERPARTS (OR=1.90, P=0.023). NO INTERVENTION EFFECTS WERE FOUND FOR SMOKING. CONCLUSION. GIVEN THE MULTIPLE FACTOR AND MULTIPLE COMPONENT HIGH-RISK APPROACH, THE INTERVENTION HAD MODEST EFFECTS ON ONLY SOME OF THE BEHAVIORAL RISK FACTORS ADDRESSED. PROCESS DATA SHOWED THAT THE REGISTRATION OF RISK FACTORS AND THE OPTIMIZATION OF MEDICAL TREATMENT WERE ONLY PARTLY IMPLEMENTED, THAT THE HEALTH COUNSELING COMPONENT COULD BE FURTHER IMPROVED AND THAT THE INTERVENTION COULD BENEFIT FROM ADDITIONAL HEALTH PROMOTING STRATEGIES. (C) 2006 ELSEVIER INC. ALL TIGHTS RESERVED.",RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; JOINT TASK-FORCE; CLINICAL-PRACTICE; DIETARY INTERVENTION; PHYSICAL-ACTIVITY; HEALTH-EDUCATION; FOLLOW-UP; SMOKING; RECOMMENDATIONS,PREVENTIVE HEALTH SERVICES; CARDIOVASCULAR DISEASES; COUNSELING; RISK REDUCTION BEHAVIOR; FAMILY PRACTICE,PREVENTIVE MEDICINE,"HARTING, J##VAN ASSEMA, P##VAN LIMPT, P##GORGELS, T##VAN REE, J##RULAND, E##VERMEER, F##DE VRIES, NK","MAASTRICHT UNIV, DEPT HLTH EDUC & PROMOT, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, CARE & PUBL HLTH RES INST, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, NUTR & TOXICOL RES INST, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, DEPT GEN PRACTICE, NL-6200 MD MAASTRICHT, NETHERLANDS. UNIV HOSP MAASTRICHT, DEPT CARDIOL, NL-6200 MD MAASTRICHT, NETHERLANDS. REG PUBL HLTH INST, MAASTRICHT, NETHERLANDS. BERNHOVEN HOSP, OSS, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICINE, GENERAL & INTERNAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; GENERAL & INTERNAL MEDICINE","ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B##ANDERSSEN SA, 1996, J INTERN MED, V240, P203, DOI 10.1046/J.1365-2796.1996.22848000.X##ASHENDEN R, 1997, FAM PRACT, V14, P160, DOI 10.1093/FAMPRA/14.2.160##BURKE LE, 1997, ANN BEHAV MED, V19, P239, DOI 10.1007/BF02892289##BURTON LC, 1995, PREV MED, V24, P492, DOI 10.1006/PMED.1995.1078##*CDC, 1998, JAMA-J AM MED ASSOC, V279, P741##COULTER A, 1995, BRIT MED J, V310, P1099##CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/BMJ.309.6960.993##CUPPLES ME, 1999, BMJ-BRIT MED J, V319, P687, DOI 10.1136/BMJ.319.7211.687##CUTLER JA, 1991, PREV MED, V20, P183, DOI 10.1016/0091-7435(91)90019-Z##DE BACKER G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6##DRENTHEN T, 1997, AM J CLIN NUTR, V65, P1943##EBRAHIM S, 1997, BMJ-BRIT MED J, V314, P1666, DOI 10.1136/BMJ.314.7095.1666##*GEZ, 2001, 200119 GEZ HLTH COUN##*GGD, 1998, LIMB GEZ##GREEN L. W., 1986, MEASUREMENT EVALUATI##HARTING J, 2006, PATIENT EDUC COUNS, V61, P142, DOI 10.1016/J.PEC.2005.03.006##HARTING J, 2005, AM J PREV MED, V29, P113, DOI 10.1016/J.AMEPRE.2005.04.012##HARTING J, 2004, PATIENT EDUC COUNS, V54, P107, DOI 10.1016/S0738-3991(03)00194-0##HOOPER L, 2001, BMJ-BRIT MED J, V322, P757, DOI 10.1136/BMJ.322.7289.757##HUGHES J, 2004, ANTIDEPRESSANTS SMOK##HULSCHER MEJ, 1998, HART B, V29, P6##KEMPER HGC, 2000, TIJDSCHR SOC GEZONDH, V78, P180##KETOLA E, 2001, BRIT J GEN PRACT, V51, P291##KETOLA E, 2000, ANN MED, V32, P239, DOI 10.3109/07853890009011767##KOREMANS GM, 2000, HUMANITIES WORKING P, V5, P3##KROMHOUT D, 1999, PREV MED, V29, PS106, DOI 10.1006/PMED.1998.0457##LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/ARCHINTE.155.18.1933##LINDHOLM LH, 1996, J INTERN MED, V240, P13, DOI 10.1046/J.1365-2796.1996.492831000.X##LINDHOLM LH, 1995, BRIT MED J, V310, P1105, DOI 10.1136/BMJ.310.6987.1105##MULLEN PD, 1997, PATIENT EDUC COUNS, V32, P157##PIETERSE ME, 2001, PREV MED, V32, P182, DOI 10.1006/PMED.2000.0791##PYORALA K, 1994, EUR HEART J, V15, P1300##RIGOTTI NA, 2004, COCHRANE LIB##RIMER BK, 2001, HEALTH EDUC BEHAV, V28, P231, DOI 10.1177/109019810102800208##ROE L, 1997, HLTH PROMOTION INTER##RONDA G, 2001, HEALTH PROMOT INT, V16, P305, DOI 10.1093/HEAPRO/16.4.305##ROSE G, 1992, CORONARY HEART DIS E, P311##RULAND E, 1999, HARTSLAG LIMBURG UNI##SILAGY C, 2004, NICOTINE REPLACEMENT##SIMONS-MORTON DG, 1998, AM J PREV MED, V15, P413, DOI 10.1016/S0749-3797(98)00078-6##STEPTOE A, 1999, BRIT MED J, V319, P943, DOI 10.1136/BMJ.319.7215.943##TANG JL, 1998, BMJ-BRIT MED J, V316, P1213, DOI 10.1136/BMJ.316.7139.1213##VAN ASSEMA P, 2001, J HUM NUTR DIET, V14, P377, DOI 10.1046/J.1365-277X.2001.00310.X##VAN DRENTH BB, 1998, BRIT J GEN PRACT, V48, P1054##VANELDERENVANKEMENADE T, 1994, BRIT J CLIN PSYCHOL, V33, P367, DOI 10.1111/J.2044-8260.1994.TB01133.X##VANOERS JAM, 2003, HLTH COURSE 2002 DUT##VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI 10.1037/0033-2909.111.1.23##*VOED, 1991, NAD ADV INZ RICHTL V##WOOD D, 1998, J HYPERTENS, V16, P1407, DOI 10.1097/00004872-199816100-00003##WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/BMJ.308.6924.313##WOOLLARD J, 2003, J CARDIOVASC RISK, V10, P31, DOI 10.1097/00043798-200302000-00007##WORLD HEALTH ORGANIZATION, 2003, DIET NUTR PREV CHRON##WORLD HEALTH ORGANIZATION, 2002, WORLD HLTH REP 2002",12,2020-11-20,NA
J,WOS:000242309100009,2006,THE MOTIVATIONAL DETERMINANTS OF BREAST-FEEDING: PREDICTORS FOR THE CONTINUATION OF BREAST-FEEDING,"OBJECTIVE. THE AIM OF THIS STUDY WAS TO EVALUATE THE MOTIVATIONAL DETERMINANTS OF THE CONTINUATION OF BREAST-FEEDING UNTIL 3 MONTHS POSTPARTUM. METHODS. A PROSPECTIVE COHORT STUDY USING THE INTEGRATED CHANGE MODEL IN 341 WOMEN IN 5 CHILD HEALTH CARE CENTERS. RESULTS. AT BIRTH, 73% OF THE MOTHERS STARTED WITH BREAST-FEEDING AND 39% OF THEM CONTINUED AT LEAST 3 MONTHS POSTPARTUM. MOTHERS WHO CONTINUED FOR 3 MONTHS DIFFERED IN ALMOST ALL THE MOTIVATIONAL DETERMINANTS FROM MOTHERS WHO DISCONTINUED. IN THE MULTIPLE LOGISTIC REGRESSION ANALYSIS, SOCIAL SUPPORT FOR FORMULA FEEDING FROM SIGNIFICANT OTHERS AND SITUATIONAL SELF-EFFICACY FOR BREAST-FEEDING MADE A SIGNIFICANT INDEPENDENT CONTRIBUTION TO THE CONTINUATION OF BREAST-FEEDING. AMONG THE PREDISPOSING DETERMINANTS, THE STRONGEST POSITIVE PREDICTOR OF CONTINUATION WAS THE INTENTION TO RETURN TO WORK AT 1 MONTH POSTPARTUM. CONCLUSION. THE INTEGRATED CHANGE MODEL IS VALID TO EXPLAIN AND PREDICT THE CONTINUATION OF BREAST-FEEDING. HENCE, THE RESULTS MAY BE USED TO TAILOR FUTURE INTERVENTIONS AIMED AT PROMOTING BREAST-FEEDING. IN THE DISCUSSION, WE USE THE RESULTS TO TARGET INTERVENTIONS. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",SMOKING-CESSATION; BEHAVIOR; MODEL; NETHERLANDS; PREVENTION; LACTATION; DURATION; PROGRAM; CANCER; TRIAL,BREAST-FEEDING; ATTITUDES; SOCIAL INFLUENCES; SELF-EFFICACY; INTEGRATED CHANGE MODEL; PLANNED BEHAVIOR; MOTIVATIONAL DETERMINANTS,PREVENTIVE MEDICINE,"KOOLS, EJ##THIJS, C##KESTER, ADM##DE VRIES, H","MAASTRICHT UNIV, DEPT EPIDEMIOL, CAPHRI, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, NUTRIM, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, DEPT METHODOL & STAT, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, DEPT HLTH EDUC & PROMOT, NL-6200 MD MAASTRICHT, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICINE, GENERAL & INTERNAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; GENERAL & INTERNAL MEDICINE","AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T##BAKKER MJ, 2003, PATIENT EDUC COUNS, V49, P35, DOI 10.1016/S0738-3991(02)00038-1##BANDURA A., 1986, SOCIAL FDN THOUGHT A##BLYTH R, 2002, BIRTH-ISS PERINAT C, V29, P278, DOI 10.1046/J.1523-536X.2002.00202.X##BOLMAN C, 2002, PREV MED, V35, P181, DOI 10.1006/PMED.2002.1036##BULK-BUNSCHOTEN AMW, 2001, ACTA PAEDIATR, V90, P1047, DOI 10.1080/080352501316978147##BURGMEIJER RJF, 2001, PGJGD2001 APPL SCI R, P51##CORTINA JM, 1993, J APPL PSYCHOL, V78, P98, DOI 10.1037/0021-9010.78.1.98##DE VRIES H, 1998, PSYCHOL HEALTH, V13, P369, DOI 10.1080/08870449808406757##DE VRIES H, 2005, EUR J CANCER PREV, V14, P39, DOI 10.1097/00008469-200502000-00006##DE VRIES H, 2005, PATIENT EDUC COUNS, V56, P154, DOI 10.1016/J.PEC.2004.01.002##DE VRIES H., 1988, HLTH ED RES, V3, P273, DOI [10.1093/HER/3.3.273, DOI 10.1093/HER/3.3.273]##DENNIS CL, 1999, RES NURS HEALTH, V22, P399, DOI 10.1002/(SICI)1098-240X(199910)22:5<399::AID-NUR6>3.0.CO;2-4##DEVRIES H, 2003, HEALTH EDUC RES, V18, P611, DOI 10.1093/HER/CYG031##JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101##KOOLS EJ, 2005, HEALTH EDUC BEHAV, V32, P809, DOI 10.1177/1090198105277327##KOOLS EJ, 2005, PREV MED, V40, P60, DOI 10.1016/J.YPMED.2004.05.013##LANTING CI, 2005, ACTA PAEDIATR, V94, P935, DOI 10.1080/08035250510036723##LANTING CI, 2005, JPB2005212 TNO KVL##LECHNER L, 2002, EUR J CANCER PREV, V11, P333, DOI 10.1097/00008469-200208000-00004##PIETERSE ME, 2001, PREV MED, V32, P182, DOI 10.1006/PMED.2000.0791##PIPER S, 1996, BIRTH-ISS PERINAT C, V23, P7, DOI 10.1111/J.1523-536X.1996.TB00454.X##PROCHASKA JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38##QUARLES A, 1994, MATERN CHILD NURS J, V22, P102##RADEMAKERS GM, 1998, DETERMINANTEN KEUZE##ROGERS IS, 1997, EARLY HUM DEV, V49, P45##SCOTT JA, 1999, ACTA PAEDIATR, V88, P416, DOI 10.1080/08035259950169800##SHAABAN M, 1994, CONTRACEPTION, V50, P35##*STAT CORP, 2001, STAT STAT SOFTW REL##TERMOTE MCL, 1999, BORSTVOEDING ONZE ZO, P1##VISNESS CM, 1997, AM J PUBLIC HEALTH, V87, P945, DOI 10.2105/AJPH.87.6.945##WORLD HEALTH ORGANIZATION, 2001, OPT DUR EXCL BREASTF##WORLD HEALTH ORGANIZATION, 1998, EV 10 STEPS SUCC BRE",31,2020-11-20,NA
J,WOS:000240104400005,2006,RETRIEVING RANDOM MEDIA,"BENJAMINI ASKED WHETHER THE SCENERY RECONSTRUCTION METHODS OF MATZINGER (SEE E.G. [21], [22], [20]) CAN BE DONE IN POLYNOMIAL TIME. IN THIS ARTICLE, WE GIVE THE FOLLOWING ANSWER FOR A 2-COLOR SCENERY AND SIMPLE RANDOM WALK WITH HOLDING: WE PROVE THAT A PIECE OF THE SCENERY OF LENGTH OF THE ORDER 3(N) SUPERCRIPT STOP AROUND THE ORIGIN CAN BE RECONSTRUCTED - UP TO A REFLECTION AND A SMALL TRANSLATION - WITH HIGH PROBABILITY FROM THE FIRST 2(.)3(10 ALPHA N) SUPERCRIPT STOP OBSERVATIONS WITH A CONSTANT ALPHA > 0 INDEPENDENT OF N. THUS, THE NUMBER OF OBSERVATIONS NEEDED IS POLYNOMIAL IN THE LENGTH OF THE PIECE OF SCENERY WHICH WE RECONSTRUCT. THE PROBABILITY THAT THE RECONSTRUCTION FAILS TENDS TO 0 AS N -> 0. IN CONTRAST TO [21], [22], AND [20], THE PROOFS IN THIS ARTICLE ARE ALL CONSTRUCTIVE. OUR RECONSTRUCTION ALGORITHM IS AN ALGORITHM IN THE SENSE OF COMPUTER SCIENCE. THIS IS THE FIRST ARTICLE WHICH SHOWS THAT THE SCENERY RECONSTRUCTION IS ALSO POSSIBLE IN THE 2-COLOR CASE WITH HOLDING. THE CASE WITH HOLDING IS MUCH MORE DIFFICULT THAN [22] AND REQUIRES COMPLETELY DIFFERENT METHODS.","RANDOM-WALK PATH; RANDOM SCENERY; T,T-1 TRANSFORMATION; LOOSELY BERNOULLI; MIXING PROPERTIES; RECONSTRUCTION; COLORS",NA,PROBABILITY THEORY AND RELATED FIELDS,"MATZINGER, H##ROLLES, SWW","GEORGIA INST TECHNOL, SCH MATH, ATLANTA, GA 30332 USA. UNIV BIELEFELD, DEPT MATH, D-33501 BIELEFELD, GERMANY. EINDHOVEN UNIV TECHNOL, DEPT MATH & COMP SCI, NL-5600 MB EINDHOVEN, NETHERLANDS.",STATISTICS & PROBABILITY,MATHEMATICS,"BENJAMINI I, 1996, J ANAL MATH, V69, P97, DOI 10.1007/BF02787104##BURDZY K, 1993, PROG PROBAB, V33, P67##DEN HOLLANDER F, 1997, J ANAL MATH, V72, P165##DENHOLLANDER WTF, 1988, ANN PROBAB, V16, P1788##DURRETT R., 1996, PROBABILITY THEORY E##HEICKLEN D, 2000, ADV MATH, V156, P157, DOI 10.1006/AIMA.2000.1940##HOFFMAN C, 2003, P AM MATH SOC, V131, P3731, DOI 10.1090/S0002-9939-03-07206-X##HOWARD C. D., 1996, COMB PROBAB COMPUT, V5, P247##HOWARD CD, 1996, RANDOM STRUCT ALGOR, V8, P59, DOI 10.1002/(SICI)1098-2418(199601)8:1<59::AID-RSA3>3.0.CO;2-Q##HOWARD CD, 1997, STAT PROBABIL LETT, V34, P123, DOI 10.1016/S0167-7152(96)00173-3##KALIKOW SA, 1982, ANN MATH, V115, P393, DOI 10.2307/1971397##KEANE M, 1986, PHYSICA A, V138, P183, DOI 10.1016/0378-4371(86)90179-2##KESTEN H, 1998, DIMACS SER DISCRET M, V41, P75##KESTEN H, 1996, MICROSURVEYS DISCRET, P171##LEVIN DA, 2004, RANDOM STRUCT ALGOR, V25, P91, DOI 10.1002/RSA.20018##LEVIN DA, 2001, ANN PROBAB, V29, P1637##LINDENSTRAUSS E, 1999, RANDOM STRUCT ALGOR, V14, P71, DOI 10.1002/(SICI)1098-2418(1999010)14:1<71::AID-RSA4>3.0.CO;2-9##LOWE M, 2004, ELECTRON J PROBAB, V9, P436##LOWE M, 2002, ANN APPL PROBAB, V12, P1322##LOWE M, 2003, STOCH PROC APPL, V105, P175, DOI 10.1016/S0304-4149(03)00003-6##MATZINGER H, 2005, ANN APPL PROBAB, V15, P778, DOI 10.1214/105051604000000972##MATZINGER H, 1999, RANDOM STRUCT ALGOR, V15, P196, DOI 10.1002/(SICI)1098-2418(199909)15:2<196::AID-RSA5>3.3.CO;2-R##MATZINGER H, 2003, PROBAB THEORY REL, V125, P539##MATZINGER H, 2005, RANDOM STRUCTURES AL##ROLLES S, 2002, THESIS U AMSTERDAM",5,2020-11-20,NA
J,WOS:000243452100005,2006,DESIGN STUDY OF A CAPACITIVE PRESSURE SENSOR IN NON-SILICON MATERIALS,"THIS ARTICLE REPORTS ON THE DESIGN OF A CAPACITIVE PRESSURE SENSOR FABRICATED IN NON-SILICON MATERIALS. THE SENSOR CONSISTS OF A THIN MEMBRANE PLACED PARALLEL TO A RIGID REFERENCE PLANE. THE MEMBRANE AND THE REFERENCE PLANE ACT AS TWO ELECTRODES OF A CAPACITOR. DEFLECTION OF THE MEMBRANE DUE TO PRESSURE DIFFERENCES RESULTS IN CHANGES IN CAPACITY. THESE CAPACITY CHANGES ARE PROCESSED TO CALCULATE THE PRESSURE ON THE MEMBRANE. SEVERAL THERMO-MECHANICAL PERFORMANCE ASPECTS OF THE SENSOR WERE ADDRESSED DURING THE DESIGN STAGE. PROMISING VARIANTS OF THE SENSOR WERE BUILT AND SUBJECTED TO MECHANICAL TESTS. IN ADDITION, NUMERICAL TECHNIQUES WERE UTILIZED TO ASSESS THE PERFORMANCE OF CERTAIN VARIANTS BEFORE BUILDING AND TESTING PHYSICAL PROTOTYPES. THE APPLICATION OF THIS COMBINATION OF PHYSICAL EXPERIMENTS AND NUMERICAL SIMULATIONS IS DEMONSTRATED FOR THE SELECTION OF A SUITABLE MEMBRANE MATERIAL AND MEMBRANE DIMENSIONS (DIAMETER AND THICKNESS), THE SPECIFICATION OF THE SUBSTRATE THICKNESS IN CASE THE SENSOR IS MOUNTED ON THE BACKSIDE OF AN ELECTRONICS HOUSING, AND THE SELECTION OF A SUITABLE SOLDER INTERCONNECT MATERIAL AND INTERCONNECT DIMENSIONS. A CRITICAL ASPECT IN THE LATTER CASE WAS THE CREEP BEHAVIOUR OF THE SOLDER MATERIAL, WHICH HAD TO BE MINIMIZED IN ORDER TO OBTAIN AN ACCEPTABLE LONG-TERM ACCURACY OF THE SENSOR. A SENSOR MEMBRANE AND AN INTERCONNECT DESIGN WERE FINALLY SPECIFIED ON THE BASIS OF THE OUTCOME OF THE DESIGN STUDIES. IT PROVED TO MEET THE FUNCTIONAL DEMANDS IMPOSED BY THE TARGETED APPLICATION ON A LABORATORY SCALE. IT WILL BE SUBJECTED TO RELIABILITY AND LIFETIME ASSESSMENT TESTS IN A NEXT PHASE.",NA,PRESSURE SENSOR; ASSEMBLY AND PACKAGING; SOLDERING; AUSN20; VIRTUAL PROTOTYPING,PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART C-JOURNAL OF MECHANICAL ENGINEERING SCIENCE,"MEUWISSEN, MHH##VENINGA, EP##TIJDINK, MWWJ##MEIJERINK, MGH","TNO SCI & IND, NL-5600 HE EINDHOVEN, NETHERLANDS.","ENGINEERING, MECHANICAL",ENGINEERING,"BHOTE KEKI R., 2000, WORLD CLASS QUALITY##CAMPBELL SA, 1998, SEMICONDUCTOR MACHIN##CLECH JP, 2004, REV ANAL LEAD FREE S##DARVEAUX R, 1992, IEEE T COMPON HYBR, V15, P1013, DOI 10.1109/33.206925##KHANNA P.K., 2004, MST NEWS, V4, P40##LAU JH, 1995, BALL GRID ARRAY TECH, PCH13##RICHERSON D.W., 1992, MODERN CERAMIC ENG P##ROY RA, 1990, PRIMER TAGUCHI METHO##SZE S. M., 1994, SEMICONDUCTOR SENSOR##TIMOSHENKO S., 1959, THEORY PLATES SHELLS##WEIBULL W, 1951, J APPL MECH-T ASME, V18, P293##WIESE S, 2002, EUROSIME 2002, P79",3,2020-11-20,NA
J,WOS:000243452100008,2006,COMPARISON BETWEEN MICROFABRICATION TECHNOLOGIES FOR METAL TOOLING,"THIS PAPER IS BASED ON THE INFORMATION GATHERED WITHIN THE MULTI-MATERIAL MICRO-MANUFACTURE (4M) NETWORK ACTIVITIES IN THE PROCESSING OF METALS DIVISION (TASK 7.2 'TOOLING') (WWW.4M-NET.ORG). THE AIM OF THE TASK INVOLVES A SYSTEMATIC ANALYSIS OF THE PARTNERS' EXPERTISE IN DIFFERENT MICROTECHNOLOGIES FOR PROCESSING TOOLING INSERTS MADE OF METAL. THE FOLLOWING TECHNOLOGIES HAVE BEEN ANALYSED: MICROMILLING, MICRO-ELECTRODISCHARGE MACHINING (EDM, INCLUDING WIRE-EDM, SINKING-EDM, AND EDM-MILLING), LASER MICROMACHINING, ELECTROFORMING, AND ELECTROCHEMICAL MILLING (ECF) (AN ELECTROCHEMICAL MACHINING INNOVATIVE PROCESS PROPOSED BY HSG-IMAT). CONSIDERED TOOL-INSERT MATERIALS ARE NICKEL FOR ELECTROFORMING, STAINLESS STEEL FOR ECF, AND TOOL STEEL (AISI H13) FOR ALL OTHER PROCESSES. TYPICAL FEATURES (RIBS, CHANNELS, PINS, AND HOLES) REQUIRED BY MICRO-OPTICS, MICROFLUIDICS, AND SENSOR AND ACTUATOR APPLICATIONS HAVE BEEN SELECTED TO FORM THE BENCHMARK PART AND TO CARRY OUT THIS ANALYSIS. THE RESULTS PROVIDE A GLOBAL COMPARISON BETWEEN THE MICROMANUFACTURING PROCESSES MENTIONED EARLIER IN TERMS OF TECHNICAL CAPABILITIES AND COST EFFECTIVENESS OF DIFFERENT FEATURE MACHININGS. AS A SECOND RESULT, THE CURRENT LIMITATIONS OF THESE TECHNOLOGIES CONCERNING FEATURE SIZES, SURFACE FINISH, ASPECT RATIOS, ETC. HAVE BEEN IDENTIFIED. THE MAIN CONCLUSION DRAWN IS THE ABSENCE OF A CONSOLIDATED TECHNOLOGY TO PRODUCE THREE-DIMENSIONAL FREE-FORM SHAPES SMALLER THAN 100-200 MU M TO DATE.",NA,MICROMILLING; MICRO-ELECTRODISCHARGE MACHINING; LASER MICROMACHINING; ELECTROCHEMICAL MILLING; ELECTROFORMING; TOOLING,PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART C-JOURNAL OF MECHANICAL ENGINEERING SCIENCE,"URIARTE, L##HERRERO, A##IVANOV, A##OOSTERLING, H##STAEMMLER, L##TANG, PT##ALLEN, D","FDN TEKNIKER, GIPUZKOA 20600, SPAIN. CARDIFF UNIV, MFG ENGN CTR, CARDIFF, WALES. TNO IND TECHNOL, EINDHOVEN, NETHERLANDS. IMAT, HSG, STUTTGART, GERMANY. DEPT MFG ENGN & MANAGEMENT, LYNGBY, DENMARK. CRANFIELD UNIV, SCH IND & MFG SCI, CRANFIELD MK43 0AL, BEDS, ENGLAND.","ENGINEERING, MECHANICAL",ENGINEERING,"ALLEN D, 2000, P SOC PHOTO-OPT INS, V4019, P531, DOI 10.1117/12.382322##ALMOND H, 2000, PROC SPIE, V4019, P446, DOI 10.1117/12.382302##ALTING L, 2003, CIRP ANN-MANUF TECHN, V52, P635, DOI 10.1016/S0007-8506(07)60208-X##BLEYS P, 2004, P ISEM, V14, P139##EHRFELD W, 1996, P SOC PHOTO-OPT INS, V2879, P332##HERRERO A, 2001, P 10 ICPE YOK JAP 18, P967##HO KH, 2003, INT J MACH TOOL MANU, V43, P1287, DOI 10.1016/S0890-6955(03)00162-7##KLOCKE F, 2004, P ISEM, V14, P579##LUBATSCHOWSKI H, 1995, P SOC PHOTO-OPT INS, V2632, P2##MASUZAWA T, 2000, CIRP ANNALS 2000: MANUFACTURING TECHNOLOGY, VOL 49/2/2000, P473##MASUZAWA T, 2003, P ISEM 13, V1, P3##PHAM DT, 2004, P I MECH ENG B-J ENG, V218, P1, DOI 10.1243/095440504772830156##TAKACS J, 1998, J LASER APPL, V10, P18##TAKAHASHI T, 1998, RRD PURE APPL CHEM, V2, P515##TAKEUCHI Y., 1996, ANN CIRP, V45, P401, DOI DOI 10.1016/S0007-8506(07)63090-X##WECK M, 2000, INT SEM PREC ENG MIC, P113##ZHAO W, 2004, P ISEM, V14, P573",41,2020-11-20,NA
J,WOS:000242874600004,2006,"'SCREWSTONES' FROM THE LOWER CARBONIFEROUS (MISSISSIPPIAN; VISEAN, BRIGANTIAN) AT BRADFORD DALE, YOULGRAVE, DERBYSHIRE, AND A NEW SPECIES OF GILBERTSOCRINUS PHILLIPS (ECHINODERMATA, CRINOIDEA)","SCREWSTONES ARE CHERT CLASTS FROM THE LOWER CARBONIFEROUS (MISSISSIPPIAN) OF DERBYSHIRE IN WHICH THE INTERNAL MOULDS OF THE AXIAL CANAL OF CRINOID PLURICOLUMNALS HAVE A SCREW-LIKE APPEARANCE. THEY ARE COMMONLY REGARDED AS CURIOSITIES, BUT CHERT CAN PRESERVE THE MORPHOLOGICAL DETAILS OF CRINOID OSSICLES EXQUISITELY. THE THECAE OF GILBERTSOCRINUS OCCUR ONLY IN THE TOURNAISIAN (IVORIAN TO CHADIAN) OF THE BRITISH ISLES, YET THEIR DISTINCTIVE COLUMNALS RANGE FROM UPPER DEVONIAN (FAMENNIAN) TO VISEAN (BRIGANTIAN) IN THE SAME REGION. THE YOUNGEST SUCH COLUMNALS, ROUNDED IN OUTLINE WITH A NARROW TO MODERATELY BROAD MARGINAL CRENULARIUM, A BROAD PENTALOBATE LUMEN, AND HETEROMORPHIC WITH TWO ORDERS OF INTERNODAL, ARE DESCRIBED AS GILBERTSOCRINUS FIONAE SP. NOV. FROM CHERTS OF THE MONSAL DATE LIMESTONE FORMATION OF YOULGRAVE, DERBYSHIRE.",ENGLAND,NA,PROCEEDINGS OF THE YORKSHIRE GEOLOGICAL SOCIETY,"DONOVAN, SK","MUSEUM NATL HIST NAT, DEPT GEOL, NL-2300 RA LEIDEN, NETHERLANDS.",GEOLOGY,GEOLOGY,"AITKENHEAD N., 1985, MEMOIR BRIT GEOLOGIC, V111##AUSICH WI, 2006, P YORKS GEOL SOC, V56, P91, DOI 10.1144/PYGS.56.2.91##BASSLER RS, FOSSILIUM CATALOG 83, V1##BROWN H. G., 1854, LETHAEA GEOGNOSTICA, P2##CARSON GA, 1991, TAPHONOMY RELEASING, P455##DONOVAN S. K., 1997, B MIZUNAMI FOSSIL MU, V23, P1##DONOVAN SK, 1990, J PALEONTOL, V64, P988, DOI 10.1017/S0022336000020059##DONOVAN SK, 2003, P YORKS GEOL SOC, V54, P253, DOI 10.1144/PYGS.54.4.253##DONOVAN SK, 1992, N W GEOLOGIST, V2, P33##FORD TD, 2002, ROCKS SCENERY PEAK D##GEORGE TN, 1976, 7 GEOL SOC LOND##GLUCHOWSKI E, 2005, P YORKS GEOL SOC, V55, P161, DOI 10.1144/PYGS.55.3.161##*I GEOL SCI, 1982, CLASS AR BRIT GEOL##LE MENN J, 1985, MEMOIRES SOC GEOLOGI, V30##LYON S.S., 1859, AM J SCI 2, V28, P233##MILLER J.S., 1821, NATURAL HIST CRINOID##MOORE R. C., 1943, 46 GEOL SOC AM##MOORE RC, 1968, U KANSAS PALEONTOLOG, V8, P1##MOORE RC, 1968, U KANSAS PALEONTOLOG, V9, P1##PHILLIPS J, 1836, ILLUSTRATION GEOL S2##RIDDLE S.W., 1988, P641##RIEUWERTS JH, 1998, GLOSSARY DERBYSHIRE##STUKALINA GA, 1997, PALEONTOL J, V31, P409##UBAGHS G., 1978, TREATISE INVERTEBR T, PT58##UBAGHS G, 1978, TREATISE INVERTEBR T, V2, PT408##WACHSMUTH C., 1885, P ACAD NAT SCI PHILA, V37, P223##WEBSTER G. D., 2003, 363 GEOL SOC AM##WEBSTER GD, 1974, J PALEONTOL, V48, P1283##WOODS M, 1999, DISCOVERING GEOLOGY##WRIGHT J, 1955, MONOGRAPH PALAEONT 1, V1, P191##WRIGHT J., 1956, MONOGRAPH PALAEONT 3, V1, P273##WRIGHT J., 1958, MONOGRAPH PALAEONT 4, V1, P307##WRIGHT J, 1951, MONOGRAPH PALAEONT 3, V1, P47##WRIGHT J, 1950, MONOGRAPH PALAEONT 2, V1, P25##WRIGHT J, 1954, MONOGRAPH PALAEONT 5, V1, P149##WRIGHT J, 1950, MONOGRAPH PALAEONTOG, V1, P1##WRIGHT J., 1955, MONOGRAPH PALAEONT 2, V1, P255##WRIGHT J., 1960, MONOGRAPH PALAEONT 5, V1, P329##WRIGHT J, 1952, MONOGRAPH PALAEONT 4, V1, P103",8,2020-11-20,NA
J,WOS:000241062700001,2006,"VENTRICULAR REPOLARIZATION: AN OVERVIEW OF (PATHO)PHYSIOLOGY, SYMPATHETIC EFFECTS AND GENETIC ASPECTS","MOST TEXTBOOK KNOWLEDGE ON VENTRICULAR REPOLARIZATION IS BASED ON ANIMAL DATA RATHER THAN ON DATA FROM THE IN VIVO HUMAN HEART. YET, THESE DATA HAVE BEEN EXTRAPOLATED TO THE HUMAN HEART, OFTEN WITHOUT AN APPROPRIATE CAVEAT. HERE, WE REVIEW MULTIPLE ASPECTS OF REPOLARIZATION, FROM BASIC MEMBRANE CURRENTS TO CELLULAR ASPECTS INCLUDING EXTRINSIC FACTORS SUCH AS THE EFFECTS OF THE SYMPATHETIC NERVOUS SYSTEM. WE CRITICALLY DISCUSS SOME MECHANISTIC ASPECTS OF THE GENESIS OF THE T-WAVE OF THE ECG IN THE HUMAN HEART. OBVIOUSLY, THE T-WAVE RESULTS FROM THE SUMMATION OF REPOLARIZATION ALL OVER THE HEART. THE T-WAVE IN A LOCAL ELECTROGRAM IDEALLY REFLECTS LOCAL REPOLARIZATION. THE REPOLARIZATION MOMENT IS COMPOSED OF THE MOMENT OF LOCAL ACTIVATION PLUS LOCAL ACTION POTENTIAL DURATION (APD) AT 90% REPOLARIZATION (APD(90)). THE DURATION OF THE LATTER LARGELY DEPENDS ON THE BALANCE BETWEEN L-TYPE CA2+ CURRENT AND THE DELAYED RECTIFIER CURRENTS. GENERALLY SPEAKING, THERE IS AN INVERSE RELATIONSHIP BETWEEN LOCAL ACTIVATION TIME AND LOCAL APD90, LEADING TO LESS DISPERSION IN REPOLARIZATION MOMENTS THAN IN ACTIVATION MOMENTS OR IN APD90. IN TRANSMURAL DIRECTION, THE TIME NEEDED FOR ACTIVATION FROM ENDOCARDIUM TOWARD EPICARDIUM HAS BEEN CONSIDERED TO BE OVERCOMPENSATED BY SHORTER APD90 AT THE EPICARDIUM, LEADING TO THE EARLIEST REPOLARIZATION AT THE SUBEPICARDIUM. IN ADDITION, MID-MYOCARDIAL CELLS WOULD DISPLAY THE LATEST REPOLARIZATION MOMENTS. THE SPARSE HUMAN DATA AVAILABLE, HOWEVER, DO NOT SHOW ANY TRANSMURAL DISPERSION IN REPOLARIZATION MOMENT. ALSO, THE EFFECT OF ADRENERGIC STIMULATION ON APD90 HAS BEEN STUDIED MAINLY IN ANIMALS. AGAIN, SPARSE HUMAN DATA SUGGEST THAT THE EFFECT OF ADRENERGIC STIMULATION IS DIFFERENT IN THE HUMAN HEART COMPARED TO MANY OTHER MAMMALIAN HEARTS. FINALLY, ASPECTS OF THE LONG QT SYNDROME ARE DISCUSSED, BECAUSE THIS INTRINSIC GENETIC DISEASE RESULTS FROM REPOLARIZATION DISORDERS WITH EXTRINSIC ASPECTS. (C) 2005 PUBLISHED BY ELSEVIER LTD.",LONG-QT-SYNDROME; ACTION-POTENTIAL PROLONGATION; CALCIUM-CHANNEL MODULATION; AUTONOMIC NERVOUS-SYSTEM; T-WAVE; EARLY AFTERDEPOLARIZATIONS; CARDIAC-ARRHYTHMIA; REFRACTORY PERIODS; GUINEA-PIG; HEART-RATE,T-WAVE; ACTION POTENTIAL; DISPERSION; BETA-ADRENOCEPTOR BLOCKADE; LONG QT SYNDROME,PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY,"CONRATH, CE##OPTHOF, T","UNIV UTRECHT, MED CTR, DEPT CARDIOL, UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT MED PHYSIOL, UTRECHT, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, EXPT & MOL CARDIOL GRP, NL-1105 AZ AMSTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS,BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS,"ABBOTT GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X##ABILDSKOV J. A., 1991, J CARDIOVASC ELECTR, V2, P355, DOI 10.1111/J.1540-8167.1991.TB01332.X##ABILDSKOV JA, 1976, AM HEART J, V92, P210, DOI 10.1016/S0002-8703(76)80256-6##ABILDSKOV JA, 1962, CIRC RES, V11, P247, DOI 10.1161/01.RES.11.2.247##ALLESSIE MA, 1976, CIRC RES, V39, P168, DOI 10.1161/01.RES.39.2.168##[ANONYMOUS], 1989, NEW ENGL J MED, V321, P406##ANTZELEVITCH C, 1999, J CARDIOVASC ELECTR, V10, P1124, DOI 10.1111/J.1540-8167.1999.TB00287.X##ANYUKHOVSKY EP, 1999, J CARDIOVASC ELECTR, V10, P244, DOI 10.1111/J.1540-8167.1999.TB00667.X##ANYUKHOVSKY EP, 1996, CIRCULATION, V94, P1981, DOI 10.1161/01.CIR.94.8.1981##ATTWELL D, 1988, LANCET, V1, P1136##BATCHVAROV VN, 2002, AM J PHYSIOL-HEART C, V282, PH2356, DOI 10.1152/AJPHEART.00860.2001##BAZETT HC, 1920, HEART-J STUD CIRC, V7, P353##BENSON DW, 2003, J CLIN INVEST, V112, P1019, DOI 10.1172/JCI200318062##BOYLE NG, 2001, J CARDIOVASC ELECTR, V12, P421, DOI 10.1046/J.1540-8167.2001.00421.X##BROOKS CM, 1955, EXCITABILITY HEART, P188##BURGESS M J, 1969, J ELECTROCARDIOL, V2, P101##BURGESS MJ, 1982, J ELECTROCARDIOL, V15, P1##BURTON FL, 2001, CARDIOVASC RES, V50, P10, DOI 10.1016/S0008-6363(01)00197-3##CARMELIET E, 1999, PHYSIOL REV, V79, P917##CHATTERJEE K, 1969, BRIT HEART J, V31, P770##CHEN QY, 1998, NATURE, V392, P293##CHENG JH, 1999, CARDIOVASC RES, V43, P135, DOI 10.1016/S0008-6363(99)00061-9##CLAYTON RH, 2004, PROG BIOPHYS MOL BIO, V85, P473, DOI 10.1016/J.PBIOMOLBIO.2003.12.002##CONRATH CE, 2004, CIRCULATION, V110, P365##CONRATH CE, 2004, CARDIOVASC RES, V62, P407, DOI 10.1016/J.CARDIORES.2004.02.016##CONRATH CE, 2002, CARDIOVASC RES, V53, P770, DOI 10.1016/S0008-6363(01)00477-1##CONRATH CE, 2005, THESIS U UTRECHT THE, PCH3##CORONEL R, 2005, HEART RHYTHM, V2, P170, DOI 10.1016/J.HRTHM.2004.11.024##CORONEL R, 2002, CARDIOVASC RES, V54, P11, DOI 10.1016/S0008-6363(02)00249-3##CORR PB, 1986, HEART CARDIOVASCULAR, P1343##COSTARDJACKLE A, 1989, CIRCULATION, V80, P1412, DOI 10.1161/01.CIR.80.5.1412##COWAN JC, 1988, BRIT HEART J, V60, P424##CRANEFIELD PF, 1975, CONDUCTION CARDIAC I##CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5##DANIK S, 2002, AM J PHYSIOL-HEART C, V283, PH372, DOI 10.1152/AJPHEART.01091.2001##DE BAKKER JMT, 2002, J CARDIOVASC PHARM, V39, P328, DOI 10.1097/00005344-200203000-00002##DEAN JW, 1990, J PHYSIOL-LONDON, V429, P387, DOI 10.1113/JPHYSIOL.1990.SP018263##DROUIN E, 1995, J AM COLL CARDIOL, V26, P185, DOI 10.1016/0735-1097(95)00167-X##DUKES ID, 1984, J PHYSIOL-LONDON, V355, P523, DOI 10.1113/JPHYSIOL.1984.SP015436##DURRER D, 1970, CIRCULATION, V41, P899, DOI 10.1161/01.CIR.41.6.899##ELSON JJ, 1981, AM J PHYSIOL, V240, PH738##FRANZ MR, 1988, J CLIN INVEST, V82, P972, DOI 10.1172/JCI113706##FRANZ MR, 2003, J CARDIOVASC ELECTR, V14, PS140, DOI 10.1046/J.1540.8167.90303.X##FRANZ MR, 1991, PROG CARDIOVASC DIS, V33, P369, DOI 10.1016/0033-0620(91)90003-5##FRANZ MR, 1994, J AM COLL CARDIOL, V23, P1554, DOI 10.1016/0735-1097(94)90655-6##FRANZ MR, 1987, CIRCULATION, V75, P379, DOI 10.1161/01.CIR.75.2.379##FUNCKBRENTANO C, 1993, AM J CARDIOL, V72, PB17, DOI 10.1016/0002-9149(93)90035-B##GAIDE MS, 1984, EXPERIENTIA, V40, P694, DOI 10.1007/BF01949727##GARCIACALVO R, 1992, PACE, V15, P1492, DOI 10.1111/J.1540-8159.1992.TB02923.X##HAN J, 1964, CIRC RES, V14, P516, DOI 10.1161/01.RES.14.6.516##HAN J, 1964, CIRC RES, V14, P44, DOI 10.1161/01.RES.14.1.44##HANDA Y, 1982, N-S ARCH PHARMACOL, V318, P330, DOI 10.1007/BF00501173##HARTZELL HC, 1992, J CARDIOVASC ELECTR, V3, P567, DOI 10.1111/J.1540-8167.1992.TB01937.X##HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4##HOFFMAN B.F., 1960, ELECTROPHYSIOLOGY HE##HORAN LG, 1978, CIRC RES, V42, P750, DOI 10.1161/01.RES.42.6.750##INOUE H, 1987, CIRC RES, V60, P942, DOI 10.1161/01.RES.60.6.942##ITOH T, 2001, J HUM GENET, V46, P38, DOI 10.1007/S100380170123##JAKOB H, 1988, BRIT J PHARMACOL, V94, P584, DOI 10.1111/J.1476-5381.1988.TB11564.X##JANSE MJ, 1985, CIRCULATION, V72, P585, DOI 10.1161/01.CIR.72.3.585##JANSE MJ, 1969, CIRC RES, V24, P251, DOI 10.1161/01.RES.24.2.251##JANSE MJ, 1989, PHYSIOL REV, V69, P1049##JANSE MJ, 1998, CARDIOVASC RES, V39, P165, DOI 10.1016/S0008-6363(97)00313-1##JANSE MJ, 2005, IN PRESS CIRCULATION##KASS RS, 1982, J PHYSIOL-LONDON, V322, P541, DOI 10.1113/JPHYSIOL.1982.SP014054##KIMURA S, 1984, ARCH INT PHARMACOD T, V268, P46##KLEBER AG, 1986, CIRCULATION, V73, P189, DOI 10.1161/01.CIR.73.1.189##KODAMA I, 1984, J MOL CELL CARDIOL, V16, P247, DOI 10.1016/S0022-2828(84)80591-X##KORS JA, 1999, CIRCULATION, V99, P1458, DOI 10.1161/01.CIR.99.11.1458##KRALIOS FA, 1975, AM J PHYSIOL, V228, P1621##KUO CS, 1983, CIRCULATION, V67, P1356, DOI 10.1161/01.CIR.67.6.1356##LEE JH, 1991, J PHARMACOL EXP THER, V258, P681##LEPESCHKIN E, 1952, CIRCULATION, V6, P378, DOI 10.1161/01.CIR.6.3.378##LERICHE R, 1931, CR SOC BIOL, V108, P547##LI Q, 1990, PROG CLIN BIOL RES, V327, P743##LIU DW, 1995, CIRC RES, V76, P351, DOI 10.1161/01.RES.76.3.351##LOCATI EH, 1998, CIRCULATION, V97, P2237, DOI 10.1161/01.CIR.97.22.2237##LU ZB, 2001, CIRCULATION, V104, P951, DOI 10.1161/HC3401.093151##MALIK M, 2000, J CARDIOVASC ELECTR, V11, P835, DOI 10.1111/J.1540-8167.2000.TB00061.X##MALIK M, 2001, J CARDIOVASC ELECTR, V12, P411, DOI 10.1046/J.1540-8167.2001.00411.X##MALIK M, 2000, EUR HEART J, V21, P955, DOI 10.1053/EUHJ.2000.2070##MCDONALD TF, 1994, PHYSIOL REV, V74, P365##MILLAR CK, 1985, CIRCULATION, V72, P1372, DOI 10.1161/01.CIR.72.6.1372##MIRVIS DM, 2005, BRAUNWALDS HEART DIS, P107##MISIER ARR, 1995, CIRCULATION, V91, P2566, DOI 10.1161/01.CIR.91.10.2566##MISIER ARR, 1992, J AM COLL CARDIOL, V19, P1531##MOHLER PJ, 2003, NATURE, V421, P634, DOI 10.1038/NATURE01335##MOSS AJ, 1999, AM J CARDIOL, V84, P876, DOI 10.1016/S0002-9149(99)00458-0##MOSS AJ, 2000, CIRCULATION, V101, P616, DOI 10.1161/01.CIR.101.6.616##MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929##MOSS AJ, 1971, NEW ENGL J MED, V285, P903, DOI 10.1056/NEJM197110142851607##MUBAGWA K, 1994, J CARDIOVASC ELECTR, V5, P659, DOI 10.1111/J.1540-8167.1994.TB01189.X##OPTHOF T, 1991, CIRC RES, V68, P1204, DOI 10.1161/01.RES.68.5.1204##OPTHOF T, 1993, CARDIOVASC RES, V27, P1954, DOI 10.1093/CVR/27.11.1954##PRIORI SG, 1994, CIRCULATION, V89, P1681, DOI 10.1161/01.CIR.89.4.1681##PUDDU PE, 1988, CIRCULATION, V77, P935, DOI 10.1161/01.CIR.77.4.935##RANDALL WC, 1963, AM J PHYSIOL, V205, P1227##RAUTAHARJU PM, 2002, J CARDIOVASC ELECTR, V13, P1211, DOI 10.1046/J.1540-8167.2002.01211.X##RENSMA PL, 1988, CIRC RES, V62, P395, DOI 10.1161/01.RES.62.2.395##REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569A0##RODEN DM, 1985, CIRC RES, V56, P857, DOI 10.1161/01.RES.56.6.857##ROGERS MC, 1973, ANESTHESIOLOGY, V39, P525, DOI 10.1097/00000542-197311000-00013##ROSEN MR, 1998, CARDIOVASC RES, V40, P469, DOI 10.1016/S0008-6363(98)00208-9##ROSEN MR, 2002, CIRCULATION, V106, P2173, DOI 10.1161/01.CIR.0000036741.27574.CE##ROSENBAUM MB, 1982, AM J CARDIOL, V50, P213, DOI 10.1016/0002-9149(82)90169-2##SAFFITZ JE, 1999, CARDIOVASC RES, V42, P309, DOI 10.1016/S0008-6363(99)00023-1##SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77##SAVARD P, 1991, J AUTONOM NERV SYST, V34, P47, DOI 10.1016/0165-1838(91)90007-P##SCHOTT JJ, 1999, NAT GENET, V23, P20, DOI 10.1038/12618##SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381##SCHWARTZ PJ, 2001, CIRCULATION, V103, P89##SCHWARTZ PJ, 1982, ANN NY ACAD SCI, V382, P162, DOI 10.1111/J.1749-6632.1982.TB55214.X##SCHWARTZ PJ, 1991, CIRCULATION, V84, P503, DOI 10.1161/01.CIR.84.2.503##SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, P589##SCHWARTZ PJ, 1988, NERVOUS CONTROL CARD, P225##SHIMIZU W, 1994, J CARDIOVASC ELECTR, V5, P438, DOI 10.1111/J.1540-8167.1994.TB01183.X##SHIMIZU W, 1991, CIRCULATION, V84, P1915, DOI 10.1161/01.CIR.84.5.1915##SHVILKIN A, 1998, CIRCULATION, V97, P1810, DOI 10.1161/01.CIR.97.18.1810##SICOURI S, 1991, CIRC RES, V68, P1729, DOI 10.1161/01.RES.68.6.1729##SPLAWSKI I, 1997, NAT GENET, V17, P338, DOI 10.1038/NG1197-338##SZENTADRASSY N, 2005, CARDIOVASC RES, V65, P851, DOI 10.1016/J.CARDIORES.2004.11.022##TAGGART P, 2000, J MOL CELL CARDIOL, V32, P621, DOI 10.1006/JMCC.2000.1105##TAGGART P, 2003, CIRCULATION, V107, P285, DOI 10.1161/01.CIR.0000044941.13346.74##TAGGART P, 2001, CARDIOVASC RES, V50, P454, DOI 10.1016/S0008-6363(01)00223-1##TILL JA, 1988, AM J CARDIOL, V62, P1319, DOI 10.1016/0002-9149(88)90289-5##TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5##TSUJI Y, 2002, CIRCULATION, V106, P2012, DOI 10.1161/01.CIR.0000031160.86313.24##VELDKAMP MW, 2001, EUR HEART J, V22, P955, DOI 10.1053/EUHJ.2000.2499##VERKERK AO, 2000, CARDIOVASC RES, V47, P124, DOI 10.1016/S0008-6363(00)00064-X##VOLDERS PGA, 1999, CIRCULATION, V99, P206, DOI 10.1161/01.CIR.99.2.206##VOS MA, 1998, CIRCULATION, V98, P1125, DOI 10.1161/01.CIR.98.11.1125##WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3##WANG Q, 1996, NAT GENET, V12, P17, DOI 10.1038/NG0196-17##WEISS JN, 1999, CIRCULATION, V99, P2819, DOI 10.1161/01.CIR.99.21.2819##WIENER N, 1946, ARCH INST CARDIOL MEX, V16, P205##WILDE AAM, 1999, J AM COLL CARDIOL, V33, P327, DOI 10.1016/S0735-1097(98)00578-6##WILLIAMS EMV, 1984, J CLIN PHARMACOL, V24, P129, DOI 10.1002/J.1552-4604.1984.TB01822.X##WILLIAMS EMV, 1975, PHARMACOL THER   B, V1, P115##WILSON FN, 1935, AM HEART J, V10, P46##WILSON FN, 1931, T ASSOC AM PHYSICIAN, V46, P29##XIA YL, 2005, HEART RHYTHM, V2, P162, DOI 10.1016/J.HRTHM.2004.11.011##YAN GX, 1998, CIRCULATION, V98, P1928, DOI 10.1161/01.CIR.98.18.1928##YAN GX, 1998, CIRCULATION, V98, P1921, DOI 10.1161/01.CIR.98.18.1921##YANOWITZ F, 1966, CIRC RES, V18, P416, DOI 10.1161/01.RES.18.4.416##ZABEL M, 2000, J AM COLL CARDIOL, V36, P1654, DOI 10.1016/S0735-1097(00)00921-9##ZABEL M, 1998, J CARDIOVASC ELECTR, V9, P1279, DOI 10.1111/J.1540-8167.1998.TB00103.X##ZABEL M, 1995, J AM COLL CARDIOL, V25, P746, DOI 10.1016/0735-1097(94)00446-W##ZAREBA W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404##ZAZA A, 1991, CIRC RES, V68, P1191, DOI 10.1161/01.RES.68.5.1191",74,2020-11-20,NA
J,WOS:000242507600012,2006,"REACTION TIME INHIBITION, WORKING MEMORY AND 'DELAY AVERSION' PERFORMANCE: GENETIC INFLUENCES AND THEIR INTERPRETATION","BACKGROUND. FOR CANDIDATE ENDOPHENOTYPES TO BE USEFUL FOR PSYCHIATRIC GENETIC RESEARCH, THEY FIRST OF ALL NEED TO SHOW SIGNIFICANT GENETIC INFLUENCES. TO ADDRESS THE RELATIVE LACK OF PREVIOUS DATA, WE SET TO INVESTIGATE THE EXTENT OF GENETIC AND ENVIRONMENTAL INFLUENCES ON PERFORMANCE IN A SET OF THEORETICALLY DRIVEN COGNITIVE-EXPERIMENTAL TASKS IN A LARGE TWIN SAMPLE. WE FURTHER AIMED TO ILLUSTRATE HOW TEST-RETEST RELIABILITY OF THE MEASURES AFFECTS THE ESTIMATES. METHOD. FOUR-HUNDRED 7- TO 9-YEAR-OLD TWIN PAIRS WERE ASSESSED INDIVIDUALLY ON TASKS MEASURING REACTION TIME, INHIBITION, WORKING MEMORY AND 'DELAY AVERSION' PERFORMANCE. TEST-RETEST RELIABILITY DATA ON SOME OF THE KEY MEASURES WERE AVAILABLE FROM A PREVIOUS STUDY. RESULTS. SEVERAL KEY MEASURES OF REACTION TIME, INHIBITION AND WORKING-MEMORY PERFORMANCE INDICATED A MODERATE DEGREE OF GENETIC INFLUENCE. COMBINING DATA ACROSS THEORETICALLY RELATED TASKS INCREASED THE HERITABILITY ESTIMATES, AS ILLUSTRATED BY THE HERITABILITY ESTIMATES OF 60% FOR MEAN REACTION TIME AND 50% FOR REACTION-TIME VARIABILITY. PSYCHOMETRIC PROPERTIES (RELIABILITY OR CEILING EFFECTS) HAD A SUBSTANTIAL INFLUENCE ON THE ESTIMATES FOR SOME MEASURES. CONCLUSIONS. THE DATA SUPPORT THE USEFULNESS OF SEVERAL OF THE VARIABLES FOR ENDOPHENOTYPE STUDIES THAT AIM TO LINK GENES TO COGNITIVE AND MOTIVATIONAL PROCESSES. IMPORTANTLY, THE DATA ALSO ILLUSTRATE SPECIFIC CONDITIONS UNDER WHICH THE TRUE EXTENT OF GENETIC INFLUENCES MAY BE UNDERESTIMATED AND HENCE THE USEFULNESS FOR GENETIC MAPPING STUDIES COMPROMISED, AND SUGGEST WAYS TO ADDRESS THIS.",TEST-RETEST RELIABILITY; ADHD CHILDREN; ATTENTION; PRESCHOOLERS; HERITABILITY; CHILDHOOD; SPEED; TWINS; IQ,NA,PSYCHOLOGICAL MEDICINE,"KUNTSI, J##ROGERS, H##SWINARD, G##BORGER, N##VAN DER MEERE, J##RIJSDIJK, F##ASHERSON, P","KINGS COLL LONDON, INST PSYCHIAT, MRC, SOCIAL GENET & DEV PSYCHIAT CTR, LONDON SE5 8AF, ENGLAND. UNIV GRONINGEN, DEPT DEV & EXPT CLIN PSYCHOL, GRONINGEN, NETHERLANDS.","PSYCHOLOGY, CLINICAL; PSYCHIATRY; PSYCHOLOGY",PSYCHOLOGY; PSYCHIATRY,"ANDO J, 2001, BEHAV GENET, V31, P615, DOI 10.1023/A:1013353613591##ANOKHIN AP, 2003, NEUROREPORT, V14, P1975, DOI 10.1097/00001756-200310270-00019##BORGER N, 2000, BIOL PSYCHOL, V51, P247, DOI 10.1016/S0301-0511(99)00040-X##BURNHAM KP, 2002, MODEL SELECTION MULT##DOYLE AE, 2005, BIOL PSYCHIAT, V57, P1324, DOI 10.1016/J.BIOPSYCH.2005.03.015##GOTTESMAN II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/APPI.AJP.160.4.636##GOTTESMAN II, 1973, BRIT J PSYCHIAT, V122, P15, DOI 10.1192/BJP.122.1.15##GROOT AS, 2004, J CHILD PSYCHOL PSYC, V45, P306, DOI 10.1111/J.1469-7610.2004.00222.X##KUNTSI J, 2005, BIOL PSYCHIAT, V57, P647, DOI 10.1016/J.BIOPSYCH.2004.12.032##KUNTSI J, 2001, BRIT J DEV PSYCHOL, V19, P339, DOI 10.1348/026151001166137##KUNTSI J, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-40##LETH-STEENSEN C, 2000, ACTA PSYCHOL, V104, P167, DOI 10.1016/S0001-6918(00)00019-6##LUCIANO M, 2001, BEHAV GENET, V31, P581, DOI 10.1023/A:1013397428612##NEALE MC, 1997, BEHAV GENET, V27, P113, DOI 10.1023/A:1025681223921##NEALE MC, 1992, METHODOLOGY GENETIC##NEALE MC, 1997, MX STAT MODELLING##PRICE T S, 2000, TWIN RES, V3, P129, DOI 10.1375/136905200320565391##RIJSDIJK FV, 1998, BEHAV BRAIN RES, V95, P77, DOI 10.1016/S0166-4328(97)00212-X##ROUSSON V, 2002, STAT MED, V21, P3431, DOI 10.1002/SIM.1253##SATTLER J., 1992, ASSESSMENT CHILDREN##SLUSAREK M, 2001, J AM ACAD CHILD PSY, V40, P355, DOI 10.1097/00004583-200103000-00016##SONUGABARKE EJS, 1992, J CHILD PSYCHOL PSYC, V33, P387, DOI 10.1111/J.1469-7610.1992.TB00874.X##SPINATH FM, 2003, INTELLIGENCE, V31, P195, DOI 10.1016/S0160-2896(02)00110-1##STINS JF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-49##STINS JF, 2005, BEHAV GENET, V35, P407, DOI 10.1007/S10519-004-3875-3##TROUTON A, 2002, TWIN RES, V5, P444, DOI 10.1375/136905202320906255##VANDERMEERE J, 1995, PERCEPT MOTOR SKILL, V81, P259, DOI 10.2466/PMS.1995.81.1.259##WECHSLER D, 1991, WECHSLER INTELLIGENC##WILLIAMS LJ, 1994, STRUCT EQU MODELING, V1, P161, DOI 10.1080/10705519409539970",92,2020-11-20,"WELLCOME TRUSTWELLCOME TRUST [070345, GR070345MF] FUNDING SOURCE: MEDLINE"
J,WOS:000242507600014,2006,FEAR OF FALLING MORE IMPORTANT THAN PAIN AND DEPRESSION FOR FUNCTIONAL RECOVERY AFTER SURGERY FOR HIP FRACTURE IN OLDER PEOPLE,"BACKGROUND. DEPRESSION AND COGNITIVE FUNCTIONING HAVE A NEGATIVE IMPACT ON FUNCTIONAL RECOVERY AFTER HIP FRACTURE SURGERY IN OLDER PEOPLE, AND THE SAME HAS BEEN SUGGESTED FOR PAIN AND FEAR OF FALLING. THESE VARIABLES, HOWEVER, HAVE NEVER BEEN STUDIED TOGETHER, NOR HAS THE TIMING OF PSYCHIATRIC ASSESSMENT BEEN TAKEN INTO ACCOUNT. METHOD. TWO PARALLEL, RANDOMIZED CONTROLLED TRIALS WERE UNDERTAKEN AIMING TO PREVENT AND TREAT DEPRESSION AFTER HIP FRACTURE SURGERY IN OLDER PEOPLE. MULTIPLE LOGISTIC REGRESSION ANALYSES CORRECTED FOR AGE AND PRE-MORBID LEVEL OF FUNCTIONING WERE PERFORMED TO EVALUATE THE EFFECT OF DEPRESSIVE SYMPTOMS (15-ITEM GERIATRIC DEPRESSION SCALE, GDS), PAIN (WONG-BAKER PAIN SCALE), COGNITIVE FUNCTIONING (MINI-MENTAL STATE EXAMINATION, MMSE) AND FEAR OF FALLING (MODIFIED FALLS EFFICACY SCALE, MFES) WITHIN 2 WEEKS AFTER SURGERY AND 6 WEEKS LATER ON FUNCTIONAL RECOVERY AT 6 MONTHS. MAIN OUTCOME MEASURES WERE PERFORMANCE-BASED MEASURES (UP-AND-GO TEST, GAIT TEST, FUNCTIONAL REACH) AND THE SELF-REPORT SICKNESS IMPACT PROFILE (SIP) QUESTIONNAIRE TO ASSESS THE IMPACT OF THE HIP FRACTURE ON ACTIVITIES OF DAILY LIVING (ADL). RESULTS. TWO HUNDRED AND NINETY-ONE PATIENTS PARTICIPATED AND OUTCOME MEASURES FOR 187 (64%) PATIENTS WERE AVAILABLE AT 6 MONTHS. ALL MENTAL HEALTH VARIABLES INTERFERED WITH FUNCTIONAL RECOVERY. HOWEVER, IN THE FINAL MULTIVARIATE MODEL, COGNITIVE FUNCTIONING AND FEAR OF FALLING ASSESSED 6 WEEKS AFTER SURGERY CONSISTENTLY PREDICTED FUNCTIONAL RECOVERY, WHEREAS PAIN AND DEPRESSIVE SYMPTOMS WERE NO LONGER SIGNIFICANT. CONCLUSION. FEAR OF FALLING AND COGNITIVE FUNCTIONING MAY BE MORE IMPORTANT THAN PAIN AND DEPRESSION TO PREDICT FUNCTIONAL RECOVERY AFTER HIP FRACTURE SURGERY. REHABILITATION STRATEGIES SHOULD TAKE THIS INTO ACCOUNT.",PSYCHIATRIC-ILLNESS; COGNITIVE IMPAIRMENT; POSTOPERATIVE PAIN; PROSPECTIVE COHORT; ELDERLY-PATIENTS; FOLLOW-UP; MORTALITY; OUTCOMES; PREDICTORS; REHABILITATION,NA,PSYCHOLOGICAL MEDICINE,"VOSHAAR, RCO##BANERJEE, S##HORAN, M##BALDWIN, R##PENDLETON, N##PROCTOR, R##TARRIER, N##WOODWARD, Y##BURNS, A","UNIV MANCHESTER, UNIV S MANCHESTER HOSP, DIV PSYCHIAT, EDUC & RES UNIT, MANCHESTER M23 9LT, LANCS, ENGLAND. INST PSYCHIAT, LONDON, ENGLAND. MANCHESTER MENTAL HLTH & SOCIAL CARE TRUST, MANCHESTER, LANCS, ENGLAND. RADBOUD UNIV NIJMEGEN MED CTR, NIJMEGEN, NETHERLANDS.","PSYCHOLOGY, CLINICAL; PSYCHIATRY; PSYCHOLOGY",PSYCHOLOGY; PSYCHIATRY,"ANDERSEN EM, 1995, J AM GERIATR SOC, V43, P1030, DOI 10.1111/J.1532-5415.1995.TB05569.X##BELOOSESKY Y, 2002, CLIN REHABIL, V16, P321, DOI 10.1191/0269215502CR497OA##BERGER R, 1998, J CLIN BAS CARDIOL, V1, P19##BOOCKVAR KS, 2003, J AM GERIATR SOC, V51, P399, DOI 10.1046/J.1532-5415.2003.51115.X##BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/J.1532-5415.1993.TB06708.X##BURNS RB, 1999, MED CARE, V37, P285, DOI 10.1097/00005650-199903000-00008##CORNWALL R, 2004, CLIN ORTHOP RELAT R, P64, DOI 10.1097/01.BLO.0000132406.37763.B3##DELEON CFM, 1996, J GERONTOL B-PSYCHOL, V51, PS183, DOI 10.1093/GERONB/51B.4.S183##DIAMOND TH, 1997, MED J AUSTRALIA, V167, P412, DOI 10.5694/J.1326-5377.1997.TB126646.X##DUNCAN PW, 1992, J GERONTOL, V47, PM93, DOI 10.1093/GERONJ/47.3.M93##DUNCAN PW, 1990, J GERONTOL, V45, PM192, DOI 10.1093/GERONJ/45.6.M192##FEINSTEIN A., 1999, COGNITIVE NEUROREHAB, P230##FITZGERALD JF, 1990, J GEN INTERN MED, V5, P298, DOI 10.1007/BF02600395##FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6##FOX KM, 1996, J AM GERIATR SOC, V44, P371, DOI 10.1111/J.1532-5415.1996.TB06404.X##FRANSEN M, 2002, J AM GERIATR SOC, V50, P685, DOI 10.1046/J.1532-5415.2002.50163.X##GRUBER-BALDINI AL, 2003, J AM GERIATR SOC, V51, P1227, DOI 10.1046/J.1532-5415.2003.51406.X##HAENTJENS P, 2005, INJURY, V36, P842, DOI 10.1016/J.INJURY.2005.02.002##HANNAN EL, 2001, JAMA-J AM MED ASSOC, V285, P2736, DOI 10.1001/JAMA.285.21.2736##HEALY WL, 2004, CLIN ORTHOP RELAT R, V429, P43##HEIKKINEN T, 2005, SCAND J SURG, V94, P59, DOI 10.1177/145749690509400115##HERRICK C, 2004, J AM GERIATR SOC, V52, P2062, DOI 10.1111/J.1532-5415.2004.52566.X##HILL KD, 1996, ARCH PHYS MED REHAB, V77, P1025, DOI 10.1016/S0003-9993(96)90063-5##HOLMES J, 2000, PSYCHOL MED, V30, P921, DOI 10.1017/S0033291799002548##HOLMES JD, 2000, AGE AGEING, V29, P537, DOI 10.1093/AGEING/29.6.537##JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735##KEMPEN GIJM, 2003, INT J GERIATR PSYCH, V18, P14, DOI 10.1002/GPS.768##KITAMURA S, 1998, CLIN ORTHOP RELAT R, V348, P29##KOVAL KJ, 1998, CLIN ORTHOP RELAT R, P22##KOVAL KJ, 1995, CLIN ORTHOP RELAT R, P150##KYO T, 1993, CLIN ORTHOP RELAT R, P215##LENZE EJ, 2004, INT J GERIATR PSYCH, V19, P472, DOI 10.1002/GPS.1116##LYNCH EP, 1998, ANESTH ANALG, V86, P781##MAGAZINER J, 1990, J GERONTOL, V45, PM101, DOI 10.1093/GERONJ/45.3.M101##MAGAZINER J, 2003, AM J EPIDEMIOL, V157, P1023, DOI 10.1093/AJE/KWG081##MAGAZINER J, 1998, AM J PUBLIC HEALTH, V79, P274##MAROTTOLI RA, 1994, AM J PUBLIC HEALTH, V84, P1807, DOI 10.2105/AJPH.84.11.1807##MAROTTOLI RA, 1992, J AM GERIATR SOC, V40, P861, DOI 10.1111/J.1532-5415.1992.TB01980.X##MCKEE KJ, 2002, DISABIL REHABIL, V24, P327, DOI 10.1080/09638280110093686##MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8##MORRISON RS, 2003, J GERONTOL A-BIOL, V58, P76##MORRISON RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X##MOSSEY JM, 1989, AM J PUBLIC HEALTH, V79, P279, DOI 10.2105/AJPH.79.3.279##MURPHY E, 1988, BRIT J PSYCHIAT, V152, P347, DOI 10.1192/BJP.152.3.347##MYERS AM, 1996, J GERONTOL A-BIOL, V51, PM37, DOI 10.1093/GERONA/51A.1.M37##NIGHTINGALE S, 2001, LANCET, V357, P1264, DOI 10.1016/S0140-6736(00)04421-4##OHAYON MM, 2003, ARCH GEN PSYCHIAT, V60, P39, DOI 10.1001/ARCHPSYC.60.1.39##PARKER MJ, 1993, J BONE JOINT SURG BR, V75, P797##PETRELLA RJ, 2000, ARCH FAM MED, V9, P339, DOI 10.1001/ARCHFAMI.9.4.339##PITSAER E, 1993, INJURY, V24, P35, DOI 10.1016/0020-1383(93)90080-P##PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/J.1532-5415.1991.TB01616.X##POWELL LE, 1995, J GERONTOL A-BIOL, V50, PM28, DOI 10.1093/GERONA/50A.1.M28##ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/JAMA.265.8.993##SALKELD G, 2000, BMJ-BRIT MED J, V320, P341, DOI 10.1136/BMJ.320.7231.341##SALTZ CC, 1998, J GERONTOL SOC WORK, V30, P167##SHEIKH J. I., 1986, CLIN GERONTOLOGY GUI, P165, DOI DOI 10.1300/J018V05N01-09##SVENSSON O, 1996, J BONE JOINT SURG BR, V78B, P115##THORNGREN KG, 1993, CLIN ORTHOP RELAT R, P76##TINETTI ME, 1993, J GERONTOL, V48, P35, DOI 10.1093/GERONJ/48.SPECIAL_ISSUE.35##VANDERSLUIJS JA, 1991, ACTA ORTHOP SCAND, V62, P567, DOI 10.3109/17453679108994498##VELLAS BJ, 1997, AGE AGEING, V26, P189, DOI 10.1093/AGEING/26.3.189##WHITNEY C, 1995, J PUBLIC HEALTH MED, V17, P429##WONG D., 1998, PEDIAT NURS, V14, P9##YARDLEY L, 2002, GERONTOLOGIST, V42, P17, DOI 10.1093/GERONT/42.1.17##YOUNG Y, 1997, J AM GERIATR SOC, V45, P288, DOI 10.1111/J.1532-5415.1997.TB00942.X##YOUNG Y, 1996, J GERONTOL A-BIOL, V51, PM158, DOI 10.1093/GERONA/51A.4.M158##ZUCKERMAN JD, 2000, J ORTHOP TRAUMA, V14, P26, DOI 10.1097/00005131-200001000-00006",61,2020-11-20,NA
J,WOS:000242289300004,2006,HOW THE BRAIN BLINKS: TOWARDS A NEUROCOGNITIVE MODEL OF THE ATTENTIONAL BLINK,"WHEN PEOPLE MONITOR A VISUAL STREAM OF RAPIDLY PRESENTED STIMULI FOR TWO TARGETS (T1 AND T2), THEY OFTEN MISS T2 IF IT FALLS INTO A TIME WINDOW OF ABOUT HALF A SECOND AFTER T1 ONSET-THE ATTENTIONAL BLINK (AB). WE PROVIDE AN OVERVIEW OF RECENT NEUROSCIENTIFIC STUDIES DEVOTED TO ANALYZE THE NEURAL PROCESSES UNDERLYING THE AB AND THEIR TEMPORAL DYNAMICS. THE AVAILABLE EVIDENCE POINTS TO AN ATTENTIONAL NETWORK INVOLVING TEMPORAL, RIGHT-PARIETAL AND FRONTAL CORTEX, AND SUGGESTS THAT THE COMPONENTS OF THIS NEURAL NETWORK INTERACT BY MEANS OF SYNCHRONIZATION AND STIMULUS-INDUCED DESYNCHRONIZATION IN THE BETA FREQUENCY RANGE. WE SET UP A NEUROCOGNITIVE SCENARIO DESCRIBING HOW THE AB MIGHT EMERGE AND WHY IT DEPENDS ON THE PRESENCE OF MASKS AND THE OTHER EVENT(S) THE TARGETS ARE EMBEDDED IN. THE SCENARIO SUPPORTS THE IDEA THAT THE AB ARISES FROM ""BIASED COMPETITION"", WITH THE TOP-DOWN BIAS BEING GENERATED BY PARIETAL-FRONTAL INTERACTIONS AND THE COMPETITION TAKING PLACE BETWEEN STIMULUS CODES IN TEMPORAL CORTEX.",DUAL-TASK INTERFERENCE; PARIETAL CORTEX; TIME-COURSE; SYNCHRONIZATION; STIMULUS; MASKING; INVOLVEMENT; SUPPRESSION; INHIBITION; MODULATION,NA,PSYCHOLOGICAL RESEARCH-PSYCHOLOGISCHE FORSCHUNG,"HOMMEL, B##KESSLER, K##SCHMITZ, F##GROSS, J##AKYUREK, E##SHAPIRO, K##SCHNITZLER, A","LEIDEN UNIV, COGNIT PSYCHOL UNIT, DEPT PSYCHOL, NL-2300 LEIDEN, NETHERLANDS. UNIV DUSSELDORF, D-4000 DUSSELDORF, GERMANY. UNIV WALES, BANGOR, GWYNEDD, WALES.","PSYCHOLOGY, EXPERIMENTAL",PSYCHOLOGY,"ADCOCK RA, 2000, P NATL ACAD SCI USA, V97, P3567, DOI 10.1073/PNAS.060588897##ARNELL KM, 2004, PSYCHON B REV, V11, P77, DOI 10.3758/BF03206464##BEHRMANN M, 2004, CURR OPIN NEUROBIOL, V14, P212, DOI 10.1016/J.CONB.2004.03.012##BIBBIG A, 2002, J NEUROPHYSIOL, V88, P1634, DOI 10.1152/JN.2002.88.4.1634##BREHAUT JC, 1999, PERCEPT PSYCHOPHYS, V61, P1436, DOI 10.3758/BF03206192##BROADBENT DE, 1987, PERCEPT PSYCHOPHYS, V42, P105, DOI 10.3758/BF03210498##BUNDESEN C, 1990, PSYCHOL REV, V97, P523, DOI 10.1037/0033-295X.97.4.523##CHUN MM, 1995, J EXP PSYCHOL HUMAN, V21, P109##CORBETTA M, 2000, NAT NEUROSCI, V3, P292, DOI 10.1038/73009##DEHAENE S, 2001, NAT NEUROSCI, V4, P752, DOI 10.1038/89551##DEHAENE S, 2003, P NATL ACAD SCI USA, V100, P8520, DOI 10.1073/PNAS.1332574100##DELL'ACQUA R, 2003, PSYCHOPHYSIOLOGY, V40, P629, DOI 10.1111/1469-8986.00064##DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/ANNUREV.NEURO.18.1.193##DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279A0##DILOLLO V, 2005, IN PRESS PSYCHOL RES##DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/J.1469-8986.1981.TB01815.X##DOWNAR J, 2001, NEUROIMAGE, V14, P1256, DOI 10.1006/NIMG.2001.0946##DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433##DUNCAN J, 1994, NATURE, V369, P313, DOI 10.1038/369313A0##DUNCAN J., 1996, ATTENTION PERFORM, P549##FEINSTEIN JS, 2005, IN PRESS CONSCIOUS C##FELL J, 2002, CONSCIOUS COGN, V11, P114, DOI 10.1006/CCOG.2001.0536##FRIEDMAN-HILL SR, 2003, P NATL ACAD SCI USA, V100, P4263, DOI 10.1073/PNAS.0730772100##GIESBRECHT B, 2004, BRAIN COGNITION, V55, P303, DOI 10.1016/J.BANDC.2004.02.026##GOLDBERG ME, 2002, ANN NY ACAD SCI, V956, P205, DOI 10.1111/J.1749-6632.2002.TB02820.X##GROSS J, 2004, P NATL ACAD SCI USA, V101, P13050, DOI 10.1073/PNAS.0404944101##HOMMEL B, 2004, TRENDS COGN SCI, V8, P494, DOI 10.1016/J.TICS.2004.08.007##HOMMEL B, 2005, IN PRESS Q J EXP P A##JOLICOEUR P, 2002, ATTENTION PERFORM, V19, P558##JOLICOEUR P, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P309##JOLICOEUR P, 1998, COGNITIVE PSYCHOL, V36, P138, DOI 10.1006/COGP.1998.0684##KESSLER K, 2005, IN PRESS EUR J NEURO##KESSLER K, 2005, IN PRESS NEUROIMAGE##KOPELL N, 2000, P NATL ACAD SCI USA, V97, P1867, DOI 10.1073/PNAS.97.4.1867##KRANCZIOCH C, 2003, COGNITIVE BRAIN RES, V17, P177, DOI 10.1016/S0926-6410(03)00092-2##KRISTOFF.AB, 1967, SCIENCE, V158, P1337, DOI 10.1126/SCIENCE.158.3806.1337##LIANG HL, 2002, NEUROREPORT, V13, P2011, DOI 10.1097/00001756-200211150-00004##LUCK SJ, 1996, NATURE, V383, P616, DOI 10.1038/383616A0##LUPIANEZ J, 2001, Q J EXP PSYCHOL-A, V54, P753, DOI 10.1080/02724980042000453##LUPIANEZ J, 1999, J GEN PSYCHOL, V126, P392, DOI 10.1080/00221309909595373##MARCANTONI WS, 2003, BRAIN COGNITION, V53, P318, DOI 10.1016/S0278-2626(03)00134-9##MAROIS R, 2000, NEURON, V28, P299, DOI 10.1016/S0896-6273(00)00104-5##MAROIS R, 2004, NEURON, V41, P465, DOI 10.1016/S0896-6273(04)00012-1##MCARTHUR G, 1999, NEUROREPORT, V10, P3691, DOI 10.1097/00001756-199911260-00042##MENON V, 1997, NEUROREPORT, V8, P3029, DOI 10.1097/00001756-199709290-00007##MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P191, DOI 10.1016/0028-3932(68)90019-5##POPPEL E, 1997, TRENDS COGN SCI, V1, P56, DOI 10.1016/S1364-6613(97)01008-5##POTTER MC, 2002, J EXP PSYCHOL HUMAN, V28, P1149, DOI 10.1037//0096-1523.28.5.1149##POTTER MC, 1998, J EXP PSYCHOL LEARN, V24, P979, DOI 10.1037/0278-7393.24.4.979##RAYMOND JE, 2003, PSYCHOL SCI, V14, P54, DOI 10.1111/1467-9280.01418##RAYMOND JE, 1992, J EXP PSYCHOL HUMAN, V18, P849, DOI 10.1037/0096-1523.18.3.849##RICHER F, 1996, NEUROPSYCHOLOGIA, V34, P509, DOI 10.1016/0028-3932(95)00132-8##RICHER F, 1998, BRAIN COGNITION, V37, P173##ROLKE B, 2001, PSYCHOPHYSIOLOGY, V38, P165, DOI 10.1017/S0048577201991504##SHAPIRO K, 2002, CURR BIOL, V12, P1320, DOI 10.1016/S0960-9822(02)01040-0##SHAPIRO KL, 1994, J EXP PSYCHOL HUMAN, V20, P357, DOI 10.1037/0096-1523.20.2.357##SHAPIRO KL, 2001, LIMITS ATTENTION TEM, P1##SHEPPARD DM, 2002, PSYCHOL SCI, V13, P410, DOI 10.1111/1467-9280.00473##SZAMEITAT AJ, 2002, J COGNITIVE NEUROSCI, V14, P1184, DOI 10.1162/089892902760807195##TREISMAN A, 1996, CURR OPIN NEUROBIOL, V6, P171, DOI 10.1016/S0959-4388(96)80070-5##TURVEY MT, 1973, PSYCHOL REV, V80, P1, DOI 10.1037/H0033872##VISSER TAW, 1999, PSYCHOL BULL, V125, P458, DOI 10.1037/0033-2909.125.4.458##VOGEL EK, 2002, PSYCHON B REV, V9, P739, DOI 10.3758/BF03196329##VON STEIN A, 1999, CEREB CORTEX, V9, P137, DOI 10.1093/CERCOR/9.2.137##WASZAK F, 2003, COGNITIVE PSYCHOL, V46, P361, DOI 10.1016/S0010-0285(02)00520-0##WASZAK F, 2005, IN PRESS MEM COGNIT##WOJCIULIK E, 1999, NEURON, V23, P747, DOI 10.1016/S0896-6273(01)80033-7##WROBEL A, 2000, ACTA NEUROBIOL EXP, V60, P247",58,2020-11-20,NA
J,WOS:000242939600009,2006,FROM AFFECTIVE VALENCE TO MOTIVATIONAL DIRECTION - THE FRONTAL ASYMMETRY OF EMOTION REVISED,NA,PREFRONTAL CORTEX; BRAIN,NA,PSYCHOLOGICAL SCIENCE,"VAN HONK, J##SCHUTTER, DJLG","UNIV UTRECHT, DEPT PSYCHOL, HELMHOLTZ RES INST, NL-3584 CS UTRECHT, NETHERLANDS.","PSYCHOLOGY, MULTIDISCIPLINARY",PSYCHOLOGY,"ALEMAN A, 2002, COGNITIVE BRAIN RES, V14, P300, DOI 10.1016/S0926-6410(02)00109-X##D'ALFONSO AAL, 2000, NEUROSCI LETT, V280, P195, DOI 10.1016/S0304-3940(00)00781-3##DAVIDSON R. J, 1984, EMOTIONS COGNITION B, P320##DAVIDSON RJ, 2004, BIOL PSYCHOL, V67, P219, DOI 10.1016/J.BIOPSYCHO.2004.03.008##FOX NA, 1991, AM PSYCHOL, V46, P863, DOI 10.1037/0003-066X.46.8.863##HARMON-JONES E, 2006, PSYCHOL SCI, V17, P434, DOI 10.1111/J.1467-9280.2006.01724.X##HARMON-JONES E, 2004, BIOL PSYCHOL, V67, P51, DOI 10.1016/J.BIOPSYCHO.2004.03.003##JAY SCHULKIN, 2003, RETHINKING HOMEOSTAS##VAN HONK J, 2003, PSYCHONEUROENDOCRINO, V28, P941, DOI 10.1016/S0306-4530(02)00116-6##VAN HONK JACK, 2006, COGN NEUROPSYCHIATRY, V11, P285, DOI 10.1080/13546800500233728##WEGNER D. M., 1993, HDB MENTAL CONTROL",83,2020-11-20,NA
J,WOS:000242939600014,2006,ATTENUATING THE LINK BETWEEN THREATENED EGOTISM AND AGGRESSION,"RESEARCH HAS FOUND THAT NARCISSISTS BEHAVE AGGRESSIVELY WHEN THEY RECEIVE A BLOW TO THEIR EGO. THE CURRENT STUDIES EXAMINED WHETHER NARCISSISTIC AGGRESSION, COULD BE REDUCED BY INDUCING A UNIT RELATION, BETWEEN, THE TARGET OF AGGRESSION AND THE AGGRESSOR. EXPERIMENTAL PARTICIPANTS WERE TOLD THAT THEY SHARED EITHER A BIRTHDAY (STUDY 1) OR A FINGERPRINT TYPE (STUDY 2) WITH A PARTNER. CONTROL PARTICIPANTS WERE NOT GIVEN ANY INFORMATION INDICATING SIMILARITY TO THEIR PARTNER. BEFORE AGGRESSION WAS MEASURED, THE PARTNERS CRITICIZED ESSAYS WRITTEN BY THE PARTICIPANTS. AGGRESSION WAS MEASURED BY ALLOWING PARTICIPANTS TO GIVE THEIR PARTNER LOAD BLASTS OF NOISE THROUGH A PAIR OF HEADPHONES. FIT THE CONTROL GROUPS, NARCISSISTS WERE ESPECIALLY AGGRESSIVE TOWARD THEIR PARTNER. HOWEVER, NARCISSISTIC AGGRESSION, WAS COMPLETELY ATTENUATED, EVEN. UNDER EGO THREAT, WHEN PARTICIPANTS BELIEVED THEY SHARED A KEY SIMILARITY WITH THEIR PARTNER.",SELF-HATE LEAD; CONSTRUCT-VALIDITY; NARCISSISM; ESTEEM; IMAGE; LOVE,NA,PSYCHOLOGICAL SCIENCE,"KONRATH, S##BUSHMAN, BJ##CAMPBELL, WK","UNIV MICHIGAN, INST SOCIAL RES, ANN ARBOR, MI 48106 USA. VRIJE UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS. UNIV GEORGIA, ATHENS, GA 30602 USA.","PSYCHOLOGY, MULTIDISCIPLINARY",PSYCHOLOGY,"AIKEN LS, 1991, MULTIPLE REGRESSION##ANDERSON C. A., 1997, REV GEN PSYCHOL, V1, P19, DOI [10.1037/1089-2680.1.1.19, DOI 10.1037/1089-2680.1.1.19]##BAUMEISTER RF, 1996, PSYCHOL REV, V103, P5, DOI 10.1037/0033-295X.103.1.5##BURGER JM, 2004, PERS SOC PSYCHOL B, V30, P35, DOI 10.1177/0146167203258838##BUSHMAN BJ, 2003, J PERS SOC PSYCHOL, V84, P1027, DOI 10.1037/0022-3514.84.5.1027##BUSHMAN BJ, 2002, J RES PERS, V36, P543, DOI 10.1016/S0092-6566(02)00502-0##BUSHMAN BJ, 1998, J PERS SOC PSYCHOL, V75, P219, DOI 10.1037//0022-3514.75.1.219##CAMPBELL WK, 2002, PERS SOC PSYCHOL B, V28, P358, DOI 10.1177/0146167202286007##CAMPBELL WK, 2004, J PERS ASSESS, V83, P29, DOI 10.1207/S15327752JPA8301_04##CAMPBELL WK, 2000, J RES PERS, V34, P329, DOI 10.1006/JRPE.2000.2282##CARROLL L, 1987, PSYCHOL REP, V61, P355, DOI 10.2466/PR0.1987.61.2.355##EMMONS RA, 1984, J PERS ASSESS, V48, P291, DOI 10.1207/S15327752JPA4803_11##FINCH JF, 1989, PERS SOC PSYCHOL B, V15, P222, DOI 10.1177/0146167289152009##GAERTNER L, IN PRESS SOCIAL OUTC##GIANCOLA PR, 1995, AGGRESSIVE BEHAV, V21, P199, DOI 10.1002/1098-2337(1995)21:3<199::AID-AB2480210303>3.0.CO;2-Q##HEIDER F., 1958, PSYCHOL INTERPERSONA##JACCARD J, 1990, INTERACTION EFFECTS##MILLAR JG, 1998, METHODS CHEM ECOLOGY, V1, P1##MONCUR M, 1994, COMMUNICATION##OTOOLE M. E., 1999, SCH SHOOTER THREAT A##PAULHUS DL, 2004, MULTIVAR BEHAV RES, V39, P303, DOI 10.1207/S15327906MBR3902_7##RASKIN R, 1988, J PERS SOC PSYCHOL, V54, P890, DOI 10.1037/0022-3514.54.5.890##ROSENBERG M., 1965, SOC ADOLESCENT SELF##SEDIKIDES C, 2001, PSYCHOL INQ, V12, P237##SEDIKIDES C, 1998, J PERS SOC PSYCHOL, V74, P378, DOI 10.1037/0022-3514.74.2.378##STUCKE TS, 2002, J PERS, V70, P509##STUCKE TS, 2003, EUR J PERSONALITY, V17, P465, DOI 10.1002/PER.497##TAYLOR SP, 1967, J PERS, V35, P297, DOI 10.1111/J.1467-6494.1967.TB01430.X##TWENGE JM, 2003, PERS SOC PSYCHOL B, V29, P261, DOI 10.1177/0146167202239051##WATSON PJ, 1984, J PERS ASSESS, V48, P301, DOI 10.1207/S15327752JPA4803_12",86,2020-11-20,NA
J,WOS:000242939600015,2006,FORGETTING OF PRIOR REMEMBERING IN PERSONS REPORTING RECOVERED MEMORIES OF CHILDHOOD SEXUAL ABUSE,"CASE STUDIES OF INDIVIDUALS REPORTING RECOVERED MEMORIES OF CHILDHOOD SEXUAL ABUSE SUGGEST THAT SOME OVERESTIMATE THEIR PRIOR FORGETTING OF THE ABUSE. PEOPLE REPORTING RECOVERED OR CONTINUOUS MEMORIES OF CHILDHOOD SEXUAL ABUSE AND CONTROL SUBJECTS REPORTING NO HISTORY OF ABUSE PARTICIPATED IN TWO EXPERIMENTS EXAMINING THIS 'FORGOT IT ALL ALONG"" PHENOMENON. PARTICIPANTS IN EXPERIMENT 1 WERE MORE LIKELY TO FORGET THAT THEY HAD PREVIOUSLY RECALLED A STUDIED ITEM IF THEY WERE CITED TO THINK OF IT DIFFERENTLY ON TWO RECALL TESTS THAN IF THEY WERE CUED TO THINK OF IT IN THE SAME WAY ON. THE TWO TESTS. THIS EFFECT WAS STRONGER FOR RECOVERED-MEMORY PARTICIPANTS THAN FOR CONTINUOUS-MEMORY AND CONTROL PARTICIPANTS. IN EXPERIMENT 2, PARTICIPANTS RECALLED AUTOBIOGRAPHICAL EVENTS THREE TIMES OVER A PERIOD OF 4 MONTHS. MUCH AS IN EXPERIMENT 1, THEY UNDERESTIMATED PRIOR REMEMBERING WHEN. THE EVENTS HAD BEEN RECALLED IN A DIFFERENT EMOTIONAL FRAME (POSITIVE VS. NEGATIVE) ON THE PREVIOUS OCCASION. THIS UNDERESTIMATION WAS MORE PRONOUNCED FOR RECOVERED-MEMORY PARTICIPANTS THAN, FOR CONTINUOUS-MEMORY AND CONTROL PARTICIPANTS.",FALSE MEMORIES; DISTORTION; TRAUMA,NA,PSYCHOLOGICAL SCIENCE,"GERAERTS, E##ARNOLD, MM##LINDSAY, DS##MERCKELBACH, H##JELICIC, M##HAUER, B","MAASTRICHT UNIV, DEPT EXPT PSYCHOL, NL-6200 MD MAASTRICHT, NETHERLANDS. UNIV SOUTHAMPTON, SCH PSYCHOL, SOUTHAMPTON, HANTS, ENGLAND. UNIV VICTORIA, DEPT PSYCHOL, VICTORIA, BC, CANADA. MAASTRICHT UNIV, FAC LAW, MAASTRICHT, NETHERLANDS.","PSYCHOLOGY, MULTIDISCIPLINARY",PSYCHOLOGY,"ARNOLD MM, 2002, J EXP PSYCHOL LEARN, V28, P521, DOI 10.1037//0278-7393.28.3.521##ARNOLD MM, 2005, MEMORY, V13, P533, DOI 10.1080/09658210444000214##BROWN D., 1999, J PSYCHIAT LAW, V27, P5##CLANCY SA, 2000, PSYCHOL SCI, V11, P26, DOI 10.1111/1467-9280.00210##CLANCY SA, 1999, J TRAUMA STRESS, V12, P559, DOI 10.1023/A:1024704815234##GERAERTS E, 2005, CONSCIOUS COGN, V14, P602, DOI 10.1016/J.CONCOG.2005.01.006##GERAERTS E, 2006, BEHAV RES THER, V44, P1129, DOI 10.1016/J.BRAT.2005.09.001##GOLDEN H, 2001, J APPL SOC PSYCHOL, V31, P73, DOI 10.1111/J.1559-1816.2001.TB02483.X##JOHNSON MK, 1993, PSYCHOL BULL, V114, P3, DOI 10.1037/0033-2909.114.1.3##JOSLYN S, 2001, MEM COGNITION, V29, P789, DOI 10.3758/BF03196408##KIHLSTROM JF, 2004, CLIN PSYCHOL-SCI PR, V11, P34, DOI 10.1093/CLIPSY/BPH057##KILLEEN PR, 2005, PSYCHOL SCI, V16, P345, DOI 10.1111/J.0956-7976.2005.01538.X##LINDSAY S., 2001, RECOVERED MEMORIES S, P71##LOFTUS EF, 2003, AM PSYCHOL, V58, P867, DOI 10.1037/0003-066X.58.11.867##LOFTUS EF, 1997, NATO ADV SCI I A-LIF, V291, P171##MCNALLY R. J., 2003, REMEMBERING TRAUMA##MCNALLY RJ, 2005, J ABNORM PSYCHOL, V114, P147, DOI 10.1037/0021-843X.114.1.147##MCNALLY RJ, 2004, CLIN PSYCHOL-SCI PR, V11, P29, DOI 10.1093/CLIPSY/BPH056##MELCHERT TP, 1999, J INTERPERS VIOLENCE, V14, P1172, DOI 10.1177/088626099014011004##MERCKELBACH H, 2006, APPL COGNITIVE PSYCH, V20, P33, DOI 10.1002/ACP.1153##NEISSER U, 1992, EMORY S COG, V4, P9, DOI 10.1017/CBO9780511664069.003##PADILLA-WALKER LM, 2002, APPL COGNITIVE PSYCH, V16, P515, DOI 10.1002/ACP.809##PARKS TE, 1999, AM J PSYCHOL, V112, P365, DOI 10.2307/1423636##PORTER S, 2000, PSYCHOL SCI, V11, P507, DOI 10.1111/1467-9280.00297##RUBIN DC, 2004, MEMORY, V12, P715, DOI 10.1080/09658210344000512##SCHACTER DL, 1995, SCI AM, V272, P135##SCHOOLER J. W., 2001, J AGGRESS MALTREAT T, V4, P105, DOI [DOI 10.1300/J146V04N02_06, 10.1300/J146V04N02_06]##SCHOOLER J. W., 1999, TRAUMA MEMORY, P203##SCHOOLER JW, 1997, NATO ADV SCI I A-LIF, V291, P379##SHOBE KK, 2001, RECOVERED MEMORIES S, P95##TALARICO JM, 2003, PSYCHOL SCI, V14, P455, DOI 10.1111/1467-9280.02453",30,2020-11-20,NA
J,WOS:000243095800003,2006,PREDICTION OF TREATMENT RESPONSE BY HPA-AXIS AND GLUCOCORTICOID RECEPTOR POLYMORPHISMS IN MAJOR DEPRESSION,"OBJECTIVE: WE INVESTIGATED WHETHER TREATMENT RESPONSE IS PREDICTED BY HYPOTHALAMUS-PITUITARY-ADRENAL (HPA) AXIS PARAMETERS, OR BY GENETIC POLYMORPHISMS IN THE GLUCOCORTICOID RECEPTOR (GR), THAT REGULATES ITS FEEDBACK. METHODS: NINETY-EIGHT OUTPATIENTS COMPLETED 8 WEEKS OF PAROXETINE TREATMENT. TREATMENT RESPONSE WAS DEFINED AS A 50% DECREASE IN HAMILTON RATING SCALE FOR DEPRESSION (HRSD) RATINGS. AT BASELINE, 24H URINARY CORTISOL EXCRETION, AND CORTISOL AND ACTH CONCENTRATIONS IN A DEX/CRH TEST WERE MEASURED. THE PRESENCE OF POLYMORPHISMS IN THE GR DNA SEQUENCE (BCLL, ER22/23EK, N363S) WAS DETERMINED. PREDICTION OF TREATMENT RESPONSE WAS ANALYSED BY CALCULATING RESPONSE RATES PER TERTILE OF AN HPA-AXIS PARAMETER AND PER GR GENOTYPE. RESULTS: THE RESPONSE RATE IN THE HIGH ACTH TERTILE WAS SIGNIFICANTLY TOWER AS COMPARED TO THE INTERMEDIATE TERTILE, BUT NOT COMPARED TO THE TOW TERTILE (RESPONSE RATES FROM HIGH TO LOW TERTILE: 33%, 67% AND 42%). CARRIERS OF THE BCLI POLYMORPHISM HAD HIGHER ACTH VALUES THAN NON-CARRIERS (BASELINE ACTH: 3 VERSUS 5 NG/L, P = 0.02) AND SHOWED A TREND TOWARDS TOWER DECREASE OF HRSD RATES THAN NON-CARRIERS (HRSD DECREASE: 8 VERSUS 11, RESPECTIVELY, P = 0.07). IN A SUBGROUP OF BCLI CARRIERS, PATIENTS IN THE HIGH ACTH TERTILE HAD A LOWER DECREASE IN HRSD AND TOWER RESPONSE RATES THAN PATIENTS IN THE TOW ACTH TERTILES (HRSD DECREASE FROM HIGH TO LOW TERTILE: 5, 9 AND 11, P < 0.01). CONCLUSION: THE RESULTS SUGGEST THAT HYPERACTIVITY OF THE HPA-AXIS PREDICT WORSE TREATMENT OUTCOME. THE BCLI POLYMORPHISM EXPLAINS, IN PART, DEX/CRH TEST RESULTS AND TENDS TO BE ASSOCIATED WITH WORSE TREATMENT OUTCOME. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",CORTISOL RESPONSE; CRH TEST; IN-VIVO; GENE; SENSITIVITY; ANTIDEPRESSANTS; INCREASES; HORMONE; DST,MAJOR DEPRESSION; PREDICTION; DEX/CRH TEST; GLUCOCORTICOID RECEPTOR; POLYMORPHISM; PAROXETINE,PSYCHONEUROENDOCRINOLOGY,"BROUWER, JP##APPELHOF, BC##VAN ROSSUM, EFC##KOPER, JW##FLIERS, E##HUYSER, J##SCHENE, AH##TIJSSEN, JGP##VAN DYCK, R##LAMBERTS, SWJ##WIERSINGA, WM##HOOGENDIJK, WJG","ACAD MED CTR, DEPT ENDOCRINOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. ACAD MED CTR, DEPT PSYCHIAT, NL-1105 AZ AMSTERDAM, NETHERLANDS. ACAD MED CTR, DEPT CARDIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT INTERNAL MED, NL-3015 GD ROTTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, DEPT PSYCHIAT, NL-1081 HJ AMSTERDAM, NETHERLANDS.",ENDOCRINOLOGY & METABOLISM; NEUROSCIENCES; PSYCHIATRY,ENDOCRINOLOGY & METABOLISM; NEUROSCIENCES & NEUROLOGY; PSYCHIATRY,"AMERICAN PSYCHIATRIC ASSOCIATION, 1994, DIAGN STAT MAN MENT##APPELHOF BC, 2004, J CLIN ENDOCR METAB, V89, P6271, DOI 10.1210/JC.2004-1147##BOSKUIL MJ, 1998, NETH J MED, V53, P153##BSCHOR T, 2002, NEUROPSYCHOPHARMACOL, V27, P470, DOI 10.1016/S0893-133X(02)00323-8##DE KLOET ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/ER.19.3.269##HATZINGER M, 2002, J PSYCHIAT RES, V36, P287, DOI 10.1016/S0022-3956(02)00021-3##HEUSER I, 1994, J PSYCHIAT RES, V28, P341, DOI 10.1016/0022-3956(94)90017-5##HOLSBOER F, 1996, ENDOCR REV, V17, P187, DOI 10.1210/ER.17.2.187##HUIZENGA NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/JC.83.1.144##KORNSTEIN SG, 2001, J CLIN PSYCHIAT, V62, P11##MEIJ BP, 1996, DOMEST ANIM ENDOCRIN, V13, P465, DOI 10.1016/0739-7240(96)00075-6##MULLER MB, 2004, NEUROENDOCRINOLOGY, V79, P1, DOI 10.1159/000076041##NELSON JC, 1997, AM J PSYCHIAT, V154, P1497, DOI 10.1176/AJP.154.11.1497##OKUGAWA G, 1999, J NEUROENDOCRINOL, V11, P887##PANARELLI M, 1998, J CLIN ENDOCR METAB, V83, P1846, DOI 10.1210/JC.83.6.1846##RAADSHEER FC, 1994, NEUROENDOCRINOLOGY, V60, P436, DOI 10.1159/000126778##RIBEIRO SCM, 1993, AM J PSYCHIAT, V150, P1618##ROSMOND R, 2000, OBES RES, V8, P211, DOI 10.1038/OBY.2000.24##THASE ME, 1997, J CLIN PSYCHIAT, V58, P23##VAN ROSSUM EFC, 2002, DIABETES, V51, P3128, DOI 10.2337/DIABETES.51.10.3128##VAN ROSSUM EFC, 2003, CLIN ENDOCRINOL, V59, P585, DOI 10.1046/J.1365-2265.2003.01888.X##WUST S, 2004, J CLIN ENDOCR METAB, V89, P565, DOI 10.1210/JC.2003-031148##ZOBEL AW, 2001, J PSYCHIAT RES, V35, P83, DOI 10.1016/S0022-3956(01)00013-9",101,2020-11-20,NA
J,WOS:000243095800006,2006,ORAL PROGESTERONE DECREASES SACCADIC EYE VELOCITY AND INCREASES SEDATION IN WOMEN,"THE AIM OF THIS STUDY WAS TO INVESTIGATE THE NEUROPHYSIOLOGICAL AND BEHAVIOURAL EFFECTS OF A SINGLE DOSE OF PROGESTERONE IN WOMEN. ALLOPREGNANOLONE IS A METABOLITE OF PROGESTERONE AND A POTENT POSITIVE MODULATOR OF THE GABA(A) RECEPTOR AND PRODUCES SEDATIVE AND ANXIOLYTIC EFFECTS. THIS STUDY WAS DESIGNED TO EXAMINE THE EFFECT OF ORAL PROGESTERONE AND THE METABOLITE ALLOPREGNANOLONE IN WOMEN. WOMEN (N = 15) IN THEIR FOLLICULAR PHASE RECEIVED ORAL PROGESTERONE (400 MG) OR PLACEBO. DEPENDENT MEASURES INCLUDED PLASMA LEVELS OF PROGESTERONE AND ALLOPREGNANOLONE, SACCADIC EYE VELOCITY (SEV), SUBJECTIVE RATINGS (VISUAL ANALOGUE SCALES), AND REACTION TIME. ADMINISTRATION OF PROGESTERONE DECREASED SEV AND INCREASED SEDATION. THIS EFFECT IS PROBABLY DUE TO ENHANCED GABA ACTIVITY. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",PREMENSTRUAL-SYNDROME; ALLOPREGNANOLONE; METABOLITES; RECEPTOR; BRAIN; PERFORMANCE; VOLUNTEERS; ANESTHESIA; MODULATORS; STEROIDS,ORAL PROGESTERONE; ALLOPREGNANOLONE; SACCADIC EYE MOVEMENT; SEDATION; BEHAVIOURAL MEASURES; WOMEN,PSYCHONEUROENDOCRINOLOGY,"VAN BROEKHOVEN, F##BACKSTROM, T##VERKES, RJ","RADBOUD UNIV NIJMEGEN MED CTR, DEPT PSYCHIAT, UNIT CLIN PSYCHOPHARMACOL & NEUROPSYCHIAT, NL-6500 HB NIJMEGEN, NETHERLANDS. NORRLANDS UNIV HOSP, UMEA NEUROSTEROID RES CTR, SE-90185 UMEA, SWEDEN.",ENDOCRINOLOGY & METABOLISM; NEUROSCIENCES; PSYCHIATRY,ENDOCRINOLOGY & METABOLISM; NEUROSCIENCES & NEUROLOGY; PSYCHIATRY,"ANDREEN L, 2006, MATURITAS, V54, P238, DOI 10.1016/J.MATURITAS.2005.11.005##ARAFAT ES, 1988, AM J OBSTET GYNECOL, V159, P1203, DOI 10.1016/0002-9378(88)90448-6##BOND A, 1974, BRIT J MED PSYCHOL, V47, P211, DOI 10.1111/J.2044-8341.1974.TB02285.X##DELIGNIERES B, 1995, MATURITAS, V21, P251, DOI 10.1016/0378-5122(94)00882-8##FORTUYN HAD, 2004, PSYCHONEUROENDOCRINO, V29, P1341, DOI 10.1016/J.PSYNEUEN.2004.02.003##FREEMAN EW, 1993, NEUROENDOCRINOLOGY, V58, P478, DOI 10.1159/000126579##FRIESS E, 1997, AM J PHYSIOL, V272, P885##GRON G, 1997, NEUROPSYCHOBIOLOGY, V35, P147, DOI 10.1159/000119336##LANCEL M, 1996, AM J PHYSIOL-ENDOC M, V271, PE763##MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/SCIENCE.2422758##PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/PNAS.88.10.4553##PURDY RH, 1990, STEROIDS, V55, P290, DOI 10.1016/0039-128X(90)90031-6##SCHILLER PH, 2003, EUR J NEUROSCI, V18, P3127, DOI 10.1111/J.1460-9568.2003.03036.X##SCHILLER PH, 2005, PROG BRAIN RES, V149, P157, DOI 10.1016/S0079-6123(05)49012-3##SODERPALM AHV, 2004, PSYCHONEUROENDOCRINO, V29, P339, DOI 10.1016/S0306-4530(03)00033-7##STROMSTEDT M, 1993, MOL PHARMACOL, V44, P1077##TIMBY E, 2006, PSYCHOPHARMACOLOGY, V186, P414, DOI 10.1007/S00213-005-0148-7##TURKMEN S, 2004, EUR J NEUROSCI, V20, P1604, DOI 10.1111/J.1460-9568.2004.03610.X##VAN BROEKHOVEN F, 2003, PSYCHOPHARMACOLOGY, V165, P97, DOI 10.1007/S00213-002-1257-1##VAN STEVENINCK AL, 1999, J PSYCHOPHARMACOL, V13, P10, DOI 10.1177/026988119901300102##VANSELOW W, 1996, J PSYCHOSOM OBST GYN, V17, P29, DOI 10.3109/01674829609025661##WANG MD, 1996, J CLIN ENDOCR METAB, V81, P1076, DOI 10.1210/JC.81.3.1076##WANG MD, 1995, BRIT J ANAESTH, V74, P553, DOI 10.1093/BJA/74.5.553##WIELAND S, 1991, BRAIN RES, V565, P263, DOI 10.1016/0006-8993(91)91658-N##WIRTH MM, 2006, BIOL PSYCHOL  0810##ZHU D, 2004, BRIT J ANAESTH, V93, P560, DOI 10.1093/BJA/AEH233",17,2020-11-20,NA
J,WOS:000243095800009,2006,HPA- AND HPT-AXIS ALTERATIONS IN CHRONIC POSTTRAUMATIC STRESS DISORDER,"POSTTRAUMATIC STRESS DISORDER (PTSD) HAS BEEN ASSOCIATED WITH DYSREGUTATION OF THE HYPOTHALAMUS-PITUITARY-ADRENAL (HPA) AXIS AS WELL AS OF THE HYPOTHALAMUS-PITUITARY-THYROID (HPT) AXIS. FINDINGS HAVE NOT BEEN CONSISTENT AND MAY DEPEND ON METHODOLOGICAL ISSUES LIKE CONTROLLING FOR RELEVANT VARIABLES. THIS STUDY EXAMINES THE LEVELS OF SIX HPA AND HPT-AXIS RELATED HORMONES IN CIVILIAN PTSD PATIENTS WITHOUT PSYCHOTROPIC MEDICATION. IN A CROSS SECTIONAL STUDY, 39 CHRONIC PTSD PATIENTS AND 44 HEALTHY VOLUNTEERS WERE INCLUDED. PSYCHOMETRIC INSTRUMENTS INCLUDED SCID, SI-PTSD, IES-R AND BDI. THE PLASMA HORMONES LEVELS ASSESSED WERE CORTISOL, DEHYDROEPIANDROSTERONE (DHEA), AND DEHYDROEPIANDROSTERONE SULFATE (DHEA-S), PROTACTIN, THYROTROPIN (TSH), AND FREE THYROXIN (FT4). RESULTS SHOWED THAT PATIENTS HAD SIGNIFICANTLY LOWER PLASMA CORTISOL, PROLACTIN AND TSH LEVELS COMPARED TO THE COMPARISON GROUP. THE DIFFERENCE BETWEEN TSH LEVELS IN PATIENTS AND COMPARISON SUBJECTS ONLY EMERGED AFTER CONTROLLING FOR RELEVANT BACKGROUND VARIABLES. FURTHERMORE, THE SEVERITY OF PTSD SYMPTOMS WAS NEGATIVELY RELATED TO CORTISOL LEVELS. SECONDARY ANALYSES REVEALED NO STATISTICALLY SIGNIFICANT EFFECT OF COMORBID DEPRESSION (26% OF PATIENTS) ON ANY OF THE HORMONE LEVELS. COMPLEX FEEDBACK MECHANISMS ARE LIKELY TO RESULT IN ALTERED LEVELS OF STRESS RELATED HORMONES IN PTSD, AND RESULTS DEPEND ON CONTROLLING FOR RELEVANT VARIABLES. FURTHER RESEARCH WITH LONGITUDINAL DESIGNS IS NEEDED TO FIND OUT WHETHER THESE LOWER HORMONE LEVELS ARE PREEXISTING RISK FACTORS OR CONSEQUENCE OF TRAUMA AND WHETHER THESE ALTERATIONS ARE DELETERIOUS OR ADAPTIVE. (C) 2006 PUBLISHED BY ELSEVIER LTD.",URINARY CORTISOL EXCRETION; PITUITARY-ADRENAL ACTIVITY; DEHYDROEPIANDROSTERONE-SULFATE; DEPRESSED-PATIENTS; SYMPTOMS; PTSD; DEXAMETHASONE; WOMEN; VETERANS; NEUROENDOCRINOLOGY,POSTTRAUMATIC STRESS DISORDER; HYPOTHALAMUS-PITUITARY-ADRENAL (HPA) AXIS; HYPOTHALAMUS-PITUITARY-THYROID (HPT) AXIS; CORTISOL; TSH; DEPRESSION,PSYCHONEUROENDOCRINOLOGY,"OLFF, M##GUZELCAN, Y##DE VRIES, GJ##ASSIES, J##GERSONS, BPR","UNIV AMSTERDAM, ACAD MED CTR, DEPT PSYCHIAT, CTR PSYCHOL TRAUMA, NL-1105 AZ AMSTERDAM, NETHERLANDS. MENTAL HLTH CARESHERTOGENBOSCH, SHERTOGENBOSCH, NETHERLANDS.",ENDOCRINOLOGY & METABOLISM; NEUROSCIENCES; PSYCHIATRY,ENDOCRINOLOGY & METABOLISM; NEUROSCIENCES & NEUROLOGY; PSYCHIATRY,"ACKERMAN PT, 1998, CHILD ABUSE NEGLECT, V22, P759, DOI 10.1016/S0145-2134(98)00062-3##AERNI A, 2004, AM J PSYCHIAT, V161, P1488, DOI 10.1176/APPI.AJP.161.8.1488##ALTEMUS M, 2003, AM J PSYCHIAT, V160, P1705, DOI 10.1176/APPI.AJP.160.9.1705##AMERICAN PSYCHIATRIC ASSOCIATION, 1994, DIAGN STAT MAN MENT##ANISMAN H, 2001, AM J PSYCHIAT, V158, P1509, DOI 10.1176/APPI.AJP.158.9.1509##ASSIES J, 2004, PSYCHIAT RES, V128, P117, DOI 10.1016/J.PSYCHRES.2004.05.016##BAKER DG, 1999, AM J PSYCHIAT, V156, P585##BECK A T, 1974, MOD PROBL PHARMACOPSYCHIATRY, V7, P151##BREMNER JD, 1997, AM J PSYCHIAT, V154, P624##CARLIER IVE, 1998, PSYCHOSOM MED, V60, P42, DOI 10.1097/00006842-199801000-00010##CREAMER M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/J.BRAT.2003.07.010##DAVIDSON J, 1989, J NERV MENT DIS, V177, P336, DOI 10.1097/00005053-198906000-00003##DAVIDSSON P, 1999, MICROELECTRON ENG, V45, P1, DOI 10.1016/S0167-9317(98)00255-X##DELAHANTY DL, 2000, BIOL PSYCHIAT, V48, P940, DOI 10.1016/S0006-3223(00)00896-9##EHLERT U, 2001, BIOL PSYCHOL, V57, P141, DOI 10.1016/S0301-0511(01)00092-8##GOENJIAN AK, 2003, J TRAUMA STRESS, V16, P319, DOI 10.1023/A:1024453632458##GROSSMAN R, 1996, BIOL PSYCHIAT, V40, P1100, DOI 10.1016/S0006-3223(95)00600-1##HALBREICH U, 1989, PSYCHONEUROENDOCRINO, V14, P365, DOI 10.1016/0306-4530(89)90006-1##HEINRICHS M, 2005, AM J PSYCHIAT, V162, P2276, DOI 10.1176/APPI.AJP.162.12.2276##KALIMI M, 1994, MOL CELL BIOCHEM, V131, P99, DOI 10.1007/BF00925945##KROBOTH PD, 1999, J CLIN PHARMACOL, V39, P327, DOI 10.1177/00912709922007903##LEMIEUX AM, 1995, PSYCHOSOM MED, V57, P105, DOI 10.1097/00006842-199503000-00002##LINDLEY SE, 2004, BIOL PSYCHIAT, V55, P940, DOI 10.1016/J.BIOPSYCH.2003.12.021##MASON J, 1994, ARCH GEN PSYCHIAT, V51, P629##MASON JW, 1968, PSYCHOSOM MED, V30, P666, DOI 10.1097/00006842-196809000-00024##MCEWEN BS, 1999, ANN NY ACAD SCI, V896, P30, DOI 10.1111/J.1749-6632.1999.TB08103.X##OLFF M, 2005, PSYCHONEUROENDOCRINO, V30, P974, DOI 10.1016/J.PSYNEUEN.2005.04.009##OLFF M, 1999, PSYCHIAT RES, V85, P7, DOI 10.1016/S0165-1781(98)00139-5##OLFF M, 2005, NEUROSCI BIOBEHAV R, V29, P457, DOI 10.1016/J.NEUBIOREV.2004.12.006##OLFF M, IN PRES PSYCHOL B##OQUENDO MA, 2003, NEUROPSYCHOPHARMACOL, V28, P591, DOI 10.1038/SJ.NPP.1300050##PICO-ALFONSO MA, 2004, BIOL PSYCHIAT, V56, P233, DOI 10.1016/J.BIOPSYCH.2004.06.001##PITMAN RK, 1990, BIOL PSYCHIAT, V27, P245, DOI 10.1016/0006-3223(90)90654-K##PRANGE AJ, 1999, PSYCHOSOM MED, V61, P139, DOI 10.1097/00006842-199903000-00002##RAISON CL, 2003, AM J PSYCHIAT, V160, P1554, DOI 10.1176/APPI.AJP.160.9.1554##RASMUSSON AM, 2004, NEUROPSYCHOPHARMACOL, V29, P1546, DOI 10.1038/SJ.NPP.1300432##RASMUSSON AM, 2003, CNS SPECTRUMS, V8, P651, DOI 10.1017/S1092852900008841##RASMUSSON AM, 2001, BIOL PSYCHIAT, V50, P965, DOI 10.1016/S0006-3223(01)01264-1##RIBEIRO SCM, 1993, AM J PSYCHIAT, V150, P1618##ROHLEDER N, 2004, BIOL PSYCHIAT, V55, P745, DOI 10.1016/J.BIOPSYCH.2003.11.018##SAPOLSKY RM, 1986, ENDOCR REV, V7, P284, DOI 10.1210/EDRV-7-3-284##SONDERGAARD HP, 2002, PSYCHOTHER PSYCHOSOM, V71, P298, DOI 10.1159/000064806##SOUTHWICK SM, 1993, ARCH GEN PSYCHIAT, V50, P266##SPITZER B, 1995, STRUCTURED CLIN INTE##SPIVAK B, 2000, PSYCHOL MED, V30, P1227, DOI 10.1017/S0033291799002731##WANG S, 1999, PSYCHOSOM MED, V61, P131, DOI 10.1097/00006842-199903000-00001##YEHUDA R, 1990, J NERV MENT DIS, V178, P366, DOI 10.1097/00005053-199006000-00004##YEHUDA R, 1991, AM J PSYCHIAT, V148, P499##YEHUDA R, 2004, AM J PSYCHIAT, V161, P1397, DOI 10.1176/APPI.AJP.161.8.1397##YEHUDA R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3##YEHUDA R, 2004, PSYCHONEUROENDOCRINO, V29, P389, DOI 10.1016/S0306-4530(03)00052-0##YEHUDA R, 1995, AM J PSYCHIAT, V152, P982##YEHUDA R, 1998, BIOL PSYCHIAT, V44, P56, DOI 10.1016/S0006-3223(98)80007-3##YEHUDA R, 1992, BIOL PSYCHIAT S, V31, P171, DOI DOI 10.1016/0006-3223(92)90609-4##YOUNG EA, 2004, ARCH GEN PSYCHIAT, V61, P394, DOI 10.1001/ARCHPSYC.61.4.394",100,2020-11-20,NA
J,WOS:000243095800012,2006,CORTISOL RESPONSES TO PSYCHOLOGICAL STRESS IN ADULTS AFTER PRENATAL EXPOSURE TO THE DUTCH FAMINE,"EXPERIMENTAL STUDIES IN ANIMALS SHOW THAT PRENATAL UNDERNUTRITION LEADS TO LIFELONG ALTERATIONS IN THE ACTIVITY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS. SOME STUDIES HAVE SHOWN ASSOCIATIONS BETWEEN LOW BIRTH WEIGHT AND AN INCREASED HPA RESPONSE TO PSYCHOLOGICAL STRESS. WE TESTED THE HYPOTHESIS THAT PRENATAL EXPOSURE TO THE DUTCH 1944-1945 FAMINE LEADS TO AN ELEVATED HPA RESPONSE TO PSYCHOLOGICAL STRESS IN ADULT LIFE. WE MEASURED SALIVARY CORTISOL RESPONSES TO A PSYCHOLOGICAL STRESS PROTOCOL AMONG 694 ADULTS WHO WERE BORN AS TERM SINGLETONS IN AMSTERDAM, THE NETHERLANDS, AROUND THE TIME OF THE 1944-1945 DUTCH FAMINE. WE COMPARED CORTISOL PROFILES OF PARTICIPANTS EXPOSED TO FAMINE DURING LATE (N = 120), MID (N = 100), OR EARLY GESTATION (N = 62) TO PROFILES OF PARTICIPANTS UNEXPOSED TO FAMINE DURING GESTATION (N = 412). THE MEAN INCREASE IN CORTISOL CONCENTRATIONS FROM BASELINE WAS 30% (95% CL 23-37). THERE WERE NO STATISTICALLY SIGNIFICANT DIFFERENCES IN THE MEAN PROFILE OF CORTISOL RESPONSE TO THE PSYCHOLOGICAL STRESS PROTOCOL BETWEEN PARTICIPANTS EXPOSED AND UNEXPOSED TO FAMINE IN UTERO. THE MEAN SEX AND BMI ADJUSTED DIFFERENCE IN CORTISOL RESPONSE FOR THOSE EXPOSED COMPARED TO THOSE UNEXPOSED WAS -6% (95% CL: -15 TO 2). THE CORTISOL PROFILES OF THOSE EXPOSED IN LATE (-4% [95% CL: -16 TO 7]), MID (-9% [95% CL: -22 TO 3]) OR EARLY GESTATION (-4% [95% CL: -20 TO 10]) DID NOT DIFFER FROM THE PROFILE OF THOSE UNEXPOSED TO FAMINE. WE CONCLUDE THAT PRENATAL EXPOSURE TO FAMINE DOES NOT SEEM TO BE ASSOCIATED WITH THE RESPONSE OF THE HPA AXIS TO PSYCHOLOGICAL STRESS. HOWEVER, THE STRESS PROTOCOL WE HAVE USED MAY HAVE BEEN UNSUCCESSFUL IN INDUCING A STRONG ENOUGH HPA AXIS ACTIVATION TO BE ABLE TO DETECT FAMINE RELATED DIFFERENCES. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",PITUITARY-ADRENAL AXIS; LOW-BIRTH-WEIGHT; MATERNAL NUTRIENT RESTRICTION; GLUCOSE-TOLERANCE; BLOOD-PRESSURE; GLUCOCORTICOIDS; UNDERNUTRITION; MALNUTRITION; CHILDREN; PROGRAMS,PRENATAL FAMINE; HPA AXIS; PSYCHOLOGICAL STRESS; SALIVARY CORTISOL,PSYCHONEUROENDOCRINOLOGY,"DE ROOIJ, SR##PAINTER, RC##PHILLIPS, DIW##OSMOND, C##TANCK, MWT##BOSSUYT, PMM##ROSEBOOM, TJ","UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, NL-1100 DD AMSTERDAM, NETHERLANDS. UNIV SOUTHAMPTON, MRC, EPIDEMIOL RESOURCE CTR, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND.",ENDOCRINOLOGY & METABOLISM; NEUROSCIENCES; PSYCHIATRY,ENDOCRINOLOGY & METABOLISM; NEUROSCIENCES & NEUROLOGY; PSYCHIATRY,"BARKER JDP, 1998, MOTHERS BABIES HLTH##BLOOMFIELD FH, 2003, ENDOCRINOLOGY, V144, P2933, DOI 10.1210/EN.2003-0189##CLEEMAN JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/JAMA.285.19.2486##DAHLGREN J, 1998, CLIN ENDOCRINOL, V49, P353, DOI 10.1046/J.1365-2265.1998.00514.X##DE ROOIJ SR, 2006, DIABETOLOGIA, V49, P637, DOI 10.1007/S00125-005-0136-9##DE ROOIJ SR, 2006, EUR J ENDOCRINOL, V155, P153, DOI 10.1530/EJE.1.02193##DICKERSON SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355##FALL CHD, 2002, J CLIN ENDOCR METAB, V87, P2001, DOI 10.1210/JC.87.5.2001##HAWKINS P, 2000, REPROD FERT DEVELOP, V12, P443, DOI 10.1071/RD99071##HENRIKSEN T, 2002, ACTA OBSTET GYN SCAN, V81, P112, DOI 10.1034/J.1600-0412.2002.810204.X##JONES A, 2006, J CLIN ENDOCR METAB, V91, P1868, DOI 10.1210/JC.2005-2077##KAJANTIE E, 2004, CLIN ENDOCRINOL, V60, P201, DOI 10.1046/J.1365-2265.2003.01965.X##KUDIELKA BM, 2004, PSYCHONEUROENDOCRINO, V29, P83, DOI 10.1016/S0306-4530(02)00146-4##LESAGE J, 2002, J NEUROENDOCRINOL, V14, P135, DOI 10.1046/J.0007-1331.2001.00753.X##LESAGE J, 2001, ENDOCRINOLOGY, V142, P1692, DOI 10.1210/EN.142.5.1692##LEVITT NS, 2000, J CLIN ENDOCR METAB, V85, P4611, DOI 10.1210/JCEM.85.12.7039##LINGAS RI, 2001, NEUROENDOCRINOLOGY, V73, P302, DOI 10.1159/000054647##PAINTER RC, 2006, J HYPERTENS, V24, P1771, DOI 10.1097/01.HJH.0000242401.45591.E7##PAINTER RC, 2006, AM J CLIN NUTR, V84, P322##PHILLIPS DIW, 2000, HYPERTENSION, V35, P1301, DOI 10.1161/01.HYP.35.6.1301##PHILLIPS DIW, 2006, J PHYSIOL-LONDON, V572, P45, DOI 10.1113/JPHYSIOL.2005.104695##RAVELLI ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9##REYNOLDS RM, 2001, J CLIN ENDOCR METAB, V86, P245, DOI 10.1210/JC.86.1.245##REYNOLDS RM, 2005, EUR J ENDOCRINOL, V152, P249, DOI 10.1530/EJE.1.01846##ROSEBOOM TJ, 2000, HEART, V84, P595, DOI 10.1136/HEART.84.6.595##TRIENEKENS G, 1985, TUSSEN VOLK HONGER##WELBERG LAM, 2001, J NEUROENDOCRINOL, V13, P113, DOI 10.1046/J.1365-2826.2001.00601.X##WOOD PJ, 1997, J ENDOCRINOL, V155, PP71##WUST S, 2005, PSYCHONEUROENDOCRINO, V30, P591, DOI 10.1016/J.PSYNEUEN.2005.01.008",37,2020-11-20,"MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [U1475000001] FUNDING SOURCE: RESEARCHFISH; MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [MC_U147585827, MC_UP_A620_1014] FUNDING SOURCE: MEDLINE"
J,WOS:000241400900007,2006,CHRONIC INTRAGASTRIC ADMINISTRATION OF GAMMA-BUTYROLACTONE PRODUCES PHYSICAL DEPENDENCE IN BABOONS,"RATIONALE ABUSE OF GAMMA-HYDROXYBUTYRATE (GHB) AND ITS PRECURSORS IS A PUBLIC HEALTH CONCERN. GAMMA-BUTYROLACTONE (GBL) IS FOUND IN COMMERCIALLY AVAILABLE PRODUCTS AND, WHEN INGESTED, IS METABOLIZED TO GHB. OBJECTIVE THE GOAL WAS TO EVALUATE THE PHYSICAL DEPENDENCE POTENTIAL AND BEHAVIORAL EFFECTS OF GBL. METHODS VEHICLE AND THEN GBL WERE ADMINISTERED CONTINUOUSLY ( 24 H PER DAY) IN BABOONS ( PAPIO ANUBIS, N=5) VIA INTRAGASTRIC CATHETERS. GBL DOSING WAS INITIATED AT 100 MG/KG/DAY AND THEN PROGRESSIVELY INCREASED STEPWISE BY INCREMENTS OF 100 MG/KG TO A FINAL DOSE OF 600 MG/KG. THE NUMBER OF FOOD PELLETS EARNED, FINE- MOTOR TASK PERFORMANCE, AND OBSERVED BEHAVIORS WERE USED AS DEPENDENT MEASURES. PRECIPITATED WITHDRAWAL WAS EVALUATED AFTER ADMINISTRATION OF GABA-B AND BENZODIAZEPINE RECEPTOR ANTAGONISTS DURING CHRONIC GBL DOSING (400-600 MG/KG). SPONTANEOUS WITHDRAWAL WAS EVALUATED AFTER DISCONTINUATION OF CHRONIC GBL 600 MG/KG. BLOOD GHB LEVELS WERE DETERMINED DURING CHRONIC DOSING OF EACH GBL DOSE BY ISOTOPE DILUTION ASSAY. RESULTS CHRONIC GBL DOSE-DEPENDENTLY DECREASED FOOD-MAINTAINED BEHAVIOR, DISRUPTED PERFORMANCE ON THE FINE-MOTOR TASK, AND PRODUCED SIGNS OF SEDATION AND MUSCLE RELAXATION. THE GABA-B ANTAGONIST SGS742 [ 56 MG/KG, INTRAMUSCULAR (IM)] PRECIPITATED A WITHDRAWAL SYNDROME, WHEREAS THE BENZODIAZEPINE ANTAGONIST FLUMAZENIL (5 MG/KG, IM) PRODUCED LITTLE OR NO EFFECT. SIGNS OF PHYSICAL DEPENDENCE WERE ALSO DEMONSTRATED WHEN CHRONIC GBL DOSING WAS DISCONTINUED. ANALYSIS OF PLASMA INDICATED GBL WAS METABOLIZED TO GHB; LEVELS WERE 825 TO 1,690 MU MOL L(-1) GHB AND 2,430 TO 3,785 MU MOL L(-1) GHB AFTER WEEK 1 OF 400 AND 600 MG/KG/DAY, RESPECTIVELY. CONCLUSIONS THESE DATA INDICATE THAT, LIKE GHB, CHRONIC GBL DOSING PRODUCED PHYSICAL DEPENDENCE THAT LIKELY INVOLVED THE GABA-B RECEPTOR.",DAILY DOSING REGIMEN; GABA-B RECEPTORS; HYDROXYBUTYRIC-ACID; LOCOMOTOR-ACTIVITY; GHB; WITHDRAWAL; PHARMACOKINETICS; ANTAGONIST; TOLERANCE; BACLOFEN,WITHDRAWAL; GHB; GABA-B RECEPTOR ANTAGONISTS; OPERANT BEHAVIOR,PSYCHOPHARMACOLOGY,"GOODWIN, AK##GRIFFITHS, RR##BROWN, PR##FROESTL, W##JAKOBS, C##GIBSON, KM##WEERTS, EM","JOHNS HOPKINS BAYVIEW BEHAV BIOL RES CTR, BALTIMORE, MD 21224 USA. JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA. JOHNS HOPKINS UNIV, SCH MED, DEPT COMPARAT MED, BALTIMORE, MD 21205 USA. JOHNS HOPKINS UNIV, SCH MED, DEPT SURG, BALTIMORE, MD 21205 USA. AC IMMUNE SA, LAUSANNE, SWITZERLAND. VRIJE UNIV AMSTERDAM, MED CTR, DEPT CLIN CHEM & PEDIAT, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV PITTSBURGH, SCH MED, DIV MED GENET, DEPT PEDIAT,CHILDRENS HOSP, PITTSBURGH, PA USA. UNIV PITTSBURGH, SCH MED, CHILDRENS HOSP, DEPT PATHOL, PITTSBURGH, PA USA. UNIV PITTSBURGH, SCH MED, CHILDRENS HOSP, DEPT HUMAN GENET, PITTSBURGH, PA USA.",NEUROSCIENCES; PHARMACOLOGY & PHARMACY; PSYCHIATRY,NEUROSCIENCES & NEUROLOGY; PHARMACOLOGY & PHARMACY; PSYCHIATRY,"ATOR NA, 2000, DRUG ALCOHOL DEPEN, V61, P69, DOI 10.1016/S0376-8716(00)00122-8##BAKER LE, 2005, PSYCHOPHARMACOLOGY, V181, P458, DOI 10.1007/S00213-005-0003-X##BAKER LE, 2004, PSYCHOPHARMACOLOGY, V174, P220, DOI 10.1007/S00213-003-1744-Z##BANIA TC, 2003, ACAD EMERG MED, V10, P697, DOI 10.1111/J.1553-2712.2003.TB00062.X##BLACK J, 2003, J TOXICOL-CLIN TOXIC, V41, P131, DOI 10.1081/CLT-120019128##BORGEN LA, 2004, J CLIN PHARMACOL, V44, P253, DOI 10.1177/0091270003262795##CARAI MAM, 2005, ANN EMERG MED, V45, P614, DOI 10.1016/J.ANNEMERGMED.2004.12.013##CARAI MAM, 2001, EUR J PHARMACOL, V428, P315, DOI 10.1016/S0014-2999(01)01334-6##CARTER LP, 2004, J PHARMACOL EXP THER, V308, P182, DOI 10.1124/JPET.103.058909##CARTER LP, 2003, J PHARMACOL EXP THER, V305, P668, DOI 10.1124/JPET.102.047860##COLOMBO G, 1995, EUR J PHARMACOL, V285, P103, DOI 10.1016/0014-2999(95)00493-5##COLOMBO G, 1998, PHYSIOL BEHAV, V64, P293, DOI 10.1016/S0031-9384(98)00062-6##CRAIG K, 2000, J EMERG MED, V18, P65, DOI 10.1016/S0736-4679(99)00163-8##DYER JE, 2001, ANN EMERG MED, V37, P147, DOI 10.1067/MEM.2001.112985##GIANUTSOS G, 1984, N-S ARCH PHARMACOL, V328, P62, DOI 10.1007/BF00496108##GIANUTSOS G, 1978, J PHARMACOL EXP THER, V207, P859##GIBSON KM, 1990, BIOMED ENVIRON MASS, V19, P89, DOI 10.1002/BMS.1200190207##GOODWIN AK, 2005, PSYCHOPHARMACOLOGY, V180, P342, DOI 10.1007/S00213-005-2165-Y##ITZHAK Y, 2002, ANN NY ACAD SCI, V965, P451##KAMINSKI BJ, 2003, BEHAV PHARMACOL, V14, P331, DOI 10.1097/01.FBP.0000082131.08343.0E##KAUPMANN K, 2003, EUR J NEUROSCI, V18, P2722, DOI 10.1111/J.1460-9568.2003.03013.X##KOEK W, 2005, J PHARMACOL EXP THER, V314, P170, DOI 10.1124/JPET.105.083394##KOEK W, 2004, J PHARMACOL EXP THER, V308, P904, DOI 10.1124/JPET.103.056093##LADINSKY H, 1983, N-S ARCH PHARMACOL, V322, P42, DOI 10.1007/BF00649351##LETTIERI J, 1978, RES COMMUN CHEM PATH, V22, P107##LETTIERI JT, 1979, J PHARMACOL EXP THER, V208, P7##LOBINA C, 1999, PHARMACOL BIOCHEM BE, V64, P363, DOI 10.1016/S0091-3057(99)00046-5##LUKAS SE, 1982, PHARMACOL BIOCHEM BE, V17, P823, DOI 10.1016/0091-3057(82)90366-5##MCDONOUGH M, 2004, DRUG ALCOHOL DEPEN, V75, P3, DOI 10.1016/J.DRUGALCDEP.2004.01.012##MIOTTO K, 2001, AM J ADDICTION, V10, P232##NICHOLSON KL, 2001, DRUG ALCOHOL DEPEN, V63, P1, DOI 10.1016/S0376-8716(00)00191-5##NISSBRANDT H, 1996, J NEURAL TRANSM, V103, P1255, DOI 10.1007/BF01271186##PALATINI P, 1993, EUR J CLIN PHARMACOL, V45, P353##PALMER ROBERT B, 2004, TOXICOL REV, V23, P21, DOI 10.2165/00139709-200423010-00003##ROSENBERG MH, 2003, AM J DRUG ALCOHOL AB, V29, P487, DOI 10.1081/ADA-120020529##ROTH R. H., 1966, INT J NEUROPHARMACOL, V5, P421##SCHARF MB, 1998, SLEEP, V21, P507, DOI 10.1093/SLEEP/21.5.507##SCHMIDT-MUTTER C, 1998, EUR J PHARMACOL, V342, P21, DOI 10.1016/S0014-2999(97)01503-3##SCHNEIR AB, 2001, J EMERG MED, V21, P31, DOI 10.1016/S0736-4679(01)00324-9##SERRA M, 1991, PSYCHOPHARMACOLOGY, V104, P351, DOI 10.1007/BF02246035##SHUMATE JS, 1979, RES COMMUN CHEM PATH, V25, P241##SIVILOTTI MLA, 2001, ANN EMERG MED, V38, P660, DOI 10.1067/MEM.2001.119454##SNEAD OC, 1996, BIOCHEM PHARMACOL, V52, P1235, DOI 10.1016/0006-2952(96)00477-7##SNEAD OC, 1991, NEUROPHARMACOLOGY, V30, P161, DOI 10.1016/0028-3908(91)90199-L##WEERTS EM, 2005, PSYCHOPHARMACOLOGY, V179, P678, DOI 10.1007/S00213-004-2079-0##WEERTS EM, 1998, J PHARMACOL EXP THER, V285, P41##WEERTS EM, 1998, BEHAV PHARMACOL, V9, P285##WINTER JC, 1981, PSYCHOPHARMACOLOGY, V73, P372, DOI 10.1007/BF00426468##YANAGITA T, 1970, J PHARMACOL EXP THER, V172, P163",21,2020-11-20,"NIDA NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) [R01 DA014919, R01 DA14919, F31 DA019294-01] FUNDING SOURCE: MEDLINE; NINDS NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE (NINDS) [R01 NS 40270] FUNDING SOURCE: MEDLINE; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE (NINDS) [R01NS040270, R01NS040270, R01NS040270, R01NS040270, R01NS040270, R01NS040270, R01NS040270, R01NS040270, R01NS040270, R01NS040270] FUNDING SOURCE: NIH REPORTER; NATIONAL INSTITUTE ON DRUG ABUSEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) [R01DA014919, F32DA019294, R01DA014919, R01DA014919, R01DA014919, R01DA014919, R01DA014919, R01DA014919, R01DA014919, R01DA014919] FUNDING SOURCE: NIH REPORTER"
J,WOS:000241626200003,2006,ATTENTIONAL CAPACITY FOR PROCESSING CONCURRENT STIMULI IS LARGER ACROSS SENSORY MODALITIES THAN WITHIN A MODALITY,"ONE FINDING IN ATTENTION RESEARCH IS THAT VISUAL AND AUDITORY ATTENTION MECHANISMS ARE LINKED TOGETHER. SUCH A LINK WOULD PREDICT A CENTRAL, AMODAL CAPACITY LIMIT IN PROCESSING VISUAL AND AUDITORY STIMULI. HERE WE SHOW THAT THIS IS NOT THE CASE. LETTER STREAMS WERE ACCOMPANIED BY ASYNCHRONOUSLY PRESENTED STREAMS OF AUDITORY, VISUAL, AND AUDIOVISUAL OBJECTS. EITHER THE LETTER STREAMS OR THE VISUAL, AUDITORY, OR AUDIOVISUAL PARTS OF THE OBJECT STREAMS WERE ATTENDED. ATTENDING TO VARIOUS ASPECTS OF THE OBJECTS RESULTED IN MODULATIONS OF THE LETTER-STREAM-ELICITED STEADY-STATE EVOKED POTENTIALS (SSVEPS). SSVEPS WERE LARGER WHEN AUDITORY OBJECTS WERE ATTENDED THAN WHEN EITHER VISUAL OBJECTS ALONE OR WHEN AUDITORY AND VISUAL OBJECT STIMULI WERE ATTENDED TOGETHER. SSVEP AMPLITUDES WERE THE SAME IN THE LATTER CONDITIONS, INDICATING THAT ATTENTIONAL CAPACITY BETWEEN MODALITIES IS LARGER THAN ATTENTIONAL CAPACITY WITHIN ONE AND THE SAME MODALITY.",SELECTIVE ATTENTION; SPATIAL ATTENTION; NEURAL MECHANISMS; STEADY-STATE; BLINK; AREAS; LINKS,EEG; ELECTROPHYSIOLOGY; INTERMODAL ATTENTION; OSCILLATIONS; MULTISENSORY PROCESSING,PSYCHOPHYSIOLOGY,"TALSMA, D##DOTY, TJ##STROWD, R##WOLDORFF, MG","VRIJE UNIV AMSTERDAM, COGNIT PSYCHOL DEPT, NL-1081 BT AMSTERDAM, NETHERLANDS. DUKE UNIV, CTR COGNIT NEUROSCI, DURHAM, NC USA.","PSYCHOLOGY, BIOLOGICAL; NEUROSCIENCES; PHYSIOLOGY; PSYCHOLOGY; PSYCHOLOGY, EXPERIMENTAL",PSYCHOLOGY; NEUROSCIENCES & NEUROLOGY; PHYSIOLOGY,"ARNELL KM, 1996, INT J PSYCHOL, V31, P2094##ARNELL KM, 1999, J EXP PSYCHOL HUMAN, V25, P630, DOI 10.1037/0096-1523.25.3.630##BANICH MT, 2000, J COGNITIVE NEUROSCI, V12, P988, DOI 10.1162/08989290051137521##BERTELSON P, 2000, PERCEPT PSYCHOPHYS, V62, P321, DOI 10.3758/BF03205552##CORBETTA M, 2000, NAT NEUROSCI, V3, P292, DOI 10.1038/73009##CORBETTA M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/NRN755##DE RUITER MB, 1998, BIOL PSYCHOL, V49, P269, DOI 10.1016/S0301-0511(98)00046-5##DUNCAN J, 1997, NATURE, V387, P808, DOI 10.1038/42947##EIMER M, 1998, PSYCHOPHYSIOLOGY, V35, P313, DOI 10.1017/S004857729897086X##EIMER M, 2002, PSYCHOPHYSIOLOGY, V39, P437, DOI 10.1017/S0048577201393162##ESCERA C, 2000, AUDIOL NEURO-OTOL, V5, P151, DOI 10.1159/000013877##GIESBRECHT B, 2003, NEUROIMAGE, V19, P496, DOI 10.1016/S1053-8119(03)00162-9##HESLENFELD DJ, 1997, BIOL PSYCHOL, V45, P183, DOI 10.1016/S0301-0511(96)05228-3##HILLYARD S.A, 1984, CORTICAL INTEGRATION, P395##HOPFINGER JB, 2000, NAT NEUROSCI, V3, P284##JOLICOEUR P, 1999, PSYCHON B REV, V6, P87, DOI 10.3758/BF03210813##KASTNER S, 2000, ANNU REV NEUROSCI, V23, P315, DOI 10.1146/ANNUREV.NEURO.23.1.315##LABERGE D., 1995, ATTENTIONAL PROCESSI##MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909##MULLER MM, 1998, COGNITIVE BRAIN RES, V6, P249, DOI 10.1016/S0926-6410(97)00036-0##MULLER MM, 2000, CLIN NEUROPHYSIOL, V111, P1544, DOI 10.1016/S1388-2457(00)00371-0##MULLER MM, 2003, NATURE, V424, P309, DOI 10.1038/NATURE01812##MULLER MM, 1998, NAT NEUROSCI, V1, P631, DOI 10.1038/2865##SCHROGER E, 2000, CLIN NEUROPHYSIOL, V111, P1450, DOI 10.1016/S1388-2457(00)00337-0##SENKOWSKI D, 2005, EXP BRAIN RES, V166, P411, DOI 10.1007/S00221-005-2381-Z##SHOMSTEIN S, 2006, J NEUROSCI, V26, P435, DOI 10.1523/JNEUROSCI.4408-05.2006##TALSMA D, 2005, J COGNITIVE NEUROSCI, V17, P1098, DOI 10.1162/0898929054475172##TALSMA D, 2002, PSYCHOPHYSIOLOGY, V39, P689, DOI 10.1017/S004857720200152X##TALSMA D, 2001, PSYCHOPHYSIOLOGY, V38, P736, DOI 10.1111/1469-8986.3850736##TALSMA D., 2005, EVENT RELATED POTENT, P115##TALSMA D, IN PRESS CEREBRAL CO##VROOMEN J, 2001, ACTA PSYCHOL, V108, P21, DOI 10.1016/S0001-6918(00)00068-8##WOLDORFF MG, 1991, PSYCHOPHYSIOLOGY, V28, P30, DOI 10.1111/J.1469-8986.1991.TB03384.X##WOLDORFF MG, 2004, J COGNITIVE NEUROSCI, V16, P149, DOI 10.1162/089892904322755638",55,2020-11-20,"NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE (NINDS) [R01NS051048, R01NS051048, R01NS051048, R01NS051048, R01NS051048, R01NS051048, R01NS051048, R01NS051048, R01NS051048, R01NS051048, R01NS051048] FUNDING SOURCE: NIH REPORTER; NIMH NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) [R01-MH64015] FUNDING SOURCE: MEDLINE; NINDS NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE (NINDS) [R01-NS051048] FUNDING SOURCE: MEDLINE"
J,WOS:000241626200016,2006,ACUTE CORTISOL ADMINISTRATION REDUCES SUBJECTIVE FATIGUE IN HEALTHY WOMEN,"TREATMENT WITH CORTISOL HAS BEEN FOUND TO DECREASE FATIGUE AND INCREASE FEELINGS OF VIGOR IN BOTH PATIENTS AND HEALTHY MALE SUBJECTS. WE OBTAINED SELF-REPORTS OF MOOD BEFORE 35 MG CORTISOL OR PLACEBO INGESTION, 70 MIN LATER, AND AFTER THE HEALTHY FEMALE SUBJECTS PERFORMED COGNITIVE TASKS FOR 1 H IN A DOUBLE-BLIND WITHIN-SUBJECT STUDY. CORTISOL DECREASED FATIGUE, INCREASED VIGOR, AND TENDED TO DECREASE TENSION. EFFECTS ON FATIGUE WERE LARGEST AFTER TASK PERFORMANCE, WHEN FATIGUE HAD INCREASED, SUGGESTING THAT IMPROVEMENT OF FATIGUE BY CORTISOL IS OBSERVED WHEN SUBJECTS ARE FATIGUED. THIS IS THE FIRST STUDY TO DEMONSTRATE IMPROVEMENTS IN FATIGUE IN HEALTHY FEMALE SUBJECTS; THIS IS PARTICULARLY RELEVANT BECAUSE OF THE HIGH PREVALENCE OF HYPOCORTISOLIMIC FATIGUE SYNDROMES IN WOMEN AND RECENT EVIDENCE THAT MANY PSYCHIATRIC DISORDERS MAY INVOLVE STRESS-INDUCED HYPOCORTISOLEMIA THAT IS RESPONSIVE TO CORTISOL REPLACEMENT.",PITUITARY-ADRENAL AXIS; STRESS; HUMANS; DEPRESSION; SYMPTOMS,CORTISOL; FATIGUE; VIGOR; HEALTHY WOMEN; HYPOCORTISOLEMIA,PSYCHOPHYSIOLOGY,"TOPS, M##VAN PEER, JM##WIJERS, AA##KORF, J","UNIV OREGON, NEUROINFORMAT CTR, EUGENE, OR 97403 USA. UNIV GRONINGEN, DEPT EXPT & WORK PSYCHOL, NL-9712 TS GRONINGEN, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT PSYCHIAT, NL-9700 RB GRONINGEN, NETHERLANDS. LEIDEN UNIV, SECT CLIN & HLTH PSYCHOL, NL-2300 RB LEIDEN, NETHERLANDS.","PSYCHOLOGY, BIOLOGICAL; NEUROSCIENCES; PHYSIOLOGY; PSYCHOLOGY; PSYCHOLOGY, EXPERIMENTAL",PSYCHOLOGY; NEUROSCIENCES & NEUROLOGY; PHYSIOLOGY,"AVNDERPLOEG HM, 1980, MANUAL ZELFBEOORDELI##BOUMAN TK, 1985, GEDRAG, V13, P1324##CHAPOTOT F, 1998, J CLIN ENDOCR METAB, V83, P4263, DOI 10.1210/JC.83.12.4263##FADEEV V V, 2001, NEUROSCI BEHAV PHYSIOL, V31, P237, DOI 10.1023/A:1010318130933##FRIES E, 2005, PSYCHONEUROENDOCRINO, V30, P1010, DOI 10.1016/J.PSYNEUEN.2005.04.006##GOLD PW, 1999, P ASSOC AM PHYSICIAN, V111, P22, DOI 10.1046/J.1525-1381.1999.09423.X##JULIANO LM, 2004, PSYCHOPHARMACOLOGY, V176, P1, DOI 10.1007/S00213-004-2000-X##LOZADA F, 1984, J AM DENT ASSOC, V109, P269, DOI 10.14219/JADA.ARCHIVE.1984.0349##PICARDI A, 2005, PSYCHOTHER PSYCHOSOM, V74, P371, DOI 10.1159/000087785##PLIHAL W, 1996, PSYCHONEUROENDOCRINO, V21, P515, DOI 10.1016/S0306-4530(96)00011-X##PRATT JJ, 1978, CLIN CHEM, V24, P1869##PRUESSNER JC, 2004, J NEUROSCI, V24, P2825, DOI 10.1523/JNEUROSCI.3422-03.2004##REUTER M, 2002, NEUROPSYCHOBIOLOGY, V46, P41, DOI 10.1159/000063575##RUBIN GJ, 2002, BRIT J SURG, V89, P971, DOI 10.1046/J.1365-2168.2002.02138.X##SAPOLSKY RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/ER.21.1.55##SCHELLING G, 2004, BIOL PSYCHIAT, V55, P627, DOI 10.1016/J.BIOPSYCH.2003.09.014##SCHUDER SE, 2005, ANN NY ACAD SCI, V1057, P466, DOI 10.1196/ANNALS.1356.036##SORAVIA LM, 2006, P NATL ACAD SCI USA, V103, P5585, DOI 10.1073/PNAS.0509184103##TOPS M., 2004, GEDRAG ORGAN, V17, P32##TOPS M, 2006, UNPUB REJECTION SENS##TOPS M, 2006, NEUROSCI LETT, V404, P39, DOI 10.1016/J.NEULET.2006.05.038##VGONTZAS AN, 2001, J CLIN ENDOCR METAB, V86, P3787, DOI 10.1210/JC.86.8.3787##VGONTZAS AN, 2001, J CLIN ENDOCR METAB, V86, P1489, DOI 10.1210/JC.86.4.1489##VONZERSSEN D, 1976, PSYCHOTROPIC ACTION, P195##WALD F., 1990, NED T PSYCHOL, V45, P86##WHEATLAND R, 2005, MED HYPOTHESES, V65, P287, DOI 10.1016/J.MEHY.2005.02.031",22,2020-11-20,NA
J,WOS:000242259300010,2006,IMMUNE AND ENDOCRINE FUNCTION IN BURNOUT SYNDROME,"OBJECTIVE: BURNOUT IS A STRESS-INDUCED WORK-RELATED SYNDROME. IT IS ASSOCIATED WITH A HIGHER INCIDENCE OF INFECTIONS POSSIBLY POINTING TO A COMPROMISED IMMUNE SYSTEM. IN THE PRESENT STUDY, ENDOCRINE AND EX VIVO IMMUNE FUNCTION OF SEVERE CASES OF BURNOUT WERE INVESTIGATED. METHODS: ENDOCRINE AND IMMUNE VARIABLES WERE COMPARED IN 56 PERSONS WITH BURNOUT AND 38 HEALTHY CONTROL SUBJECTS. CORTISOL AFTER AWAKENING, AFTER A LOW-DOSE DEXAMETHASONE, AND DEHYDROEPIANDROSTERONE-SULPHATE (DHEAS) WERE ANALYZED FROM SALIVA. PERIPHERAL BLOOD WAS ANALYZED FOR T, B, AND NK CELL NUMBER AND IN VITRO MITOGEN-INDUCED PRO- AND ANTIINFLAMMATORY CYTOKINE RELEASE. THE CAPACITY OF DEXAMETHASONE TO REGULATE CYTOKINE RELEASE WAS COMPARED BETWEEN THE GROUPS. RESULTS: THE BURNOUT GROUP SHOWED AN INCREASED PRODUCTION OF THE ANTIINFLAMMATORY CYTOKINE INTERLEUKIN-10 (IL-10) BY MONOCYTES AFTER LIPOPOLYSACCHARIDE STIMULATION. NO DIFFERENCES WERE OBSERVED IN IL-10 RELEASE INDUCED BY THE T-CELL MITOGEN PHA NOR IN THE PROINFLAMMATORY CYTOKINES GAMMA INTERFERON AND TUMOR NECROSIS FACTOR ALPHA. THE CAPACITY OF DEXAMETHASONE TO REGULATE CYTOKINE RELEASE DID NOT DIFFER BETWEEN THE GROUPS. THE NUMBER OF PERIPHERAL BLOOD T CELLS, B CELLS, OR NK CELLS WAS NOT DIFFERENT EITHER. THE BURNOUT GROUP SHOWED HIGHER DHEAS LEVELS BUT NO DIFFERENCE IN CORTISOL LEVELS AFTER AWAKENING OR AFTER DEXAMETHASONE INTAKE IN COMPARISON TO CONTROLS. CONCLUSION: PRODUCTION OF THE ANTIINFLAMMATORY CYTOKINE IL-10 BY MONOCYTES WAS INCREASED IN INDIVIDUALS WITH BURNOUT SYNDROME. IT SEEMS UNLIKELY THAT GLUCOCORTICOIDS OR CHANGES IN GLUCOCORTICOID RECEPTOR FUNCTION PLAY A ROLE IN THIS HIGHER IL-10 PRODUCTION.",CHRONIC-FATIGUE-SYNDROME; DEXAMETHASONE-SUPPRESSION; CYTOKINE PRODUCTION; CORTISOL-LEVELS; DEHYDROEPIANDROSTERONE; SENSITIVITY; HORMONES; SULFATE; SAMPLE; CURVE,BURNOUT; CYTOKINES; IL-10; MONOCYTE; GLUCOCORTICOIDS; DHEAS,PSYCHOSOMATIC MEDICINE,"MOMMERSTEEG, PMC##HEIJNEN, CJ##KAVELAARS, A##VAN DOORNEN, LJP","UNIV UTRECHT, DEPT HLTH PSYCHOL, NL-3508 TC UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, LAB PSYCHONEUROIMMUNOL, NL-3508 TC UTRECHT, NETHERLANDS.","PSYCHIATRY; PSYCHOLOGY; PSYCHOLOGY, MULTIDISCIPLINARY",PSYCHIATRY; PSYCHOLOGY,"AMERICAN PSYCHIATRIC ASSOCIATION, 1994, DIAGN STAT MAN MENT##APPELS A, 1989, J PSYCHOSOM RES, V33, P727, DOI 10.1016/0022-3999(89)90088-3##ARRINDELL WA, 1981, NEDERLANDS TIJDSCHRI, V36, P77##ASSIES J, 2004, PSYCHIAT RES, V128, P117, DOI 10.1016/J.PSYCHRES.2004.05.016##BARGELLINI A, 2000, OCCUP ENVIRON MED, V57, P453, DOI 10.1136/OEM.57.7.453##BOUMA J, 1995, METEN SYMPTOMEN DEPR, P1##BULTMANN U, 2000, J OCCUP HEALTH PSYCHOL, V5, P411, DOI 10.1037/1076-8998.5.4.411##CANALS J, 1997, PERS INDIV DIFFER, V23, P593, DOI 10.1016/S0191-8869(97)00093-7##CHEN CCG, 2004, SEMIN REPROD MED, V22, P369, DOI 10.1055/S-2004-861553##CHENG CF, 2000, J INTERF CYTOK RES, V20, P471, DOI 10.1089/10799900050023889##COHEN J., 1988, STAT POWER ANAL BEHA##COHEN S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037/0278-6133.17.3.214##COLE MA, 2000, PSYCHONEUROENDOCRINO, V25, P151, DOI 10.1016/S0306-4530(99)00045-1##ELENKOV IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/J.1749-6632.2002.TB04229.X##GAAB J, 2005, PSYCHONEUROENDOCRINO, V30, P188, DOI 10.1016/J.PSYNEUEN.2004.06.008##GLASER R, 2005, BRAIN BEHAV IMMUN, V19, P91, DOI 10.1016/J.BBI.2004.09.001##GROSSI G, 2003, J PSYCHOSOM RES, V55, P309, DOI 10.1016/S0022-3999(02)00633-5##GUPTA S, 1997, J PSYCHIAT RES, V31, P149, DOI 10.1016/S0022-3956(96)00063-5##GWALTNEY JM, 2002, AM J MED, V112, P13S##KAVELAARS A, 2000, J CLIN ENDOCR METAB, V85, P692, DOI 10.1210/JC.85.2.692##KIECOLT-GLASER JK, 2002, PSYCHOSOM MED, V64, P15, DOI 10.1097/00006842-200201000-00004##KIRSCHBAUM C, 1999, PSYCHOSOM MED, V61, P154, DOI 10.1097/00006842-199903000-00006##KROBOTH PD, 1999, J CLIN PHARMACOL, V39, P327, DOI 10.1177/00912709922007903##KUDIELKA BM, 2003, PSYCHOSOM MED, V65, P313, DOI 10.1097/01.PSY.0000058374.50240.BF##LYALL M, 2003, J PSYCHOSOM RES, V55, P79, DOI 10.1016/S0022-3999(02)00515-9##MAIER SF, 1998, PSYCHOL REV, V105, P83, DOI 10.1037/0033-295X.105.1.83##MASLACH C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/ANNUREV.PSYCH.52.1.397##MEIJMAN TF, 1990, WORK STRESS, V4, P65, DOI 10.1080/02678379008256965##MOCH SL, 2003, ENDOCRINE, V21, P267, DOI 10.1385/ENDO:21:3:267##MOHREN DCL, 2003, J PSYCHOSOM RES, V55, P201, DOI 10.1016/S0022-3999(02)00517-2##MOMMERSTEEG PMC, 2006, HEALTH PSYCHOL, V25, P243, DOI 10.1037/0278-6133.25.2.243##MOMMERSTEEG PMC, 2006, PSYCHONEUROENDOCRINO, V31, P216, DOI 10.1016/J.PSYNEUEN.2005.07.003##NAKAMURA H, 1999, J PSYCHOSOM RES, V46, P569, DOI 10.1016/S0022-3999(99)00009-4##PATARCA R, 2001, ANN NY ACAD SCI, V933, P185##PRUESSNER JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7##PRUESSNER JC, 1997, LIFE SCI, V61, P2539, DOI 10.1016/S0024-3205(97)01008-4##REEVES WC, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-25##SCHAUFELI W, 1998, BURNOUT COMPANION ST##SCHAUFELI WB, 2001, PSYCHOL HEALTH, V16, P565, DOI 10.1080/08870440108405527##SHIROM A, 2005, WORK STRESS, V19, P263, DOI 10.1080/02678370500376649##SHIRTCLIFF EA, 2001, PSYCHONEUROENDOCRINO, V26, P165, DOI 10.1016/S0306-4530(00)00042-1##STOCKL J, 1999, J CLIN INVEST, V104, P957, DOI 10.1172/JCI7255##VAN DER VEN A, 2003, PSYCHOSOM MED, V65, P194, DOI 10.1097/01.PSY.0000058378.50240.80##VAN DIERENDONCK D., 2000, UBOS UTRECHTSE BURNO##VERCOULEN JHMM AM, 1999, GEDRAGSTHERAPIE, P131##VISSER J, 1998, J INFECT DIS, V177, P451, DOI 10.1086/517373##VISSER J, 2001, J NEUROIMMUNOL, V119, P343, DOI 10.1016/S0165-5728(01)00400-3##*WHO, 1994, ICD10 INT STAT CLASS##WIRTZ PH, 2003, PSYCHOSOM MED, V65, P672, DOI 10.1097/01.PSY.0000062529.39901.C7##WOLF OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1##YOUNG AH, 2002, AM J PSYCHIAT, V159, P1237, DOI 10.1176/APPI.AJP.159.7.1237",58,2020-11-20,NA
J,WOS:000241198300009,2006,TERRORISM AND CRITICAL INFRASTRUCTURES: IMPLICATIONS FOR PUBLIC-PRIVATE CRISIS MANAGEMENT,"THE SPATE OF TERRORIST ATTACKS IN NEW YORK, LONDON AND MADRID HAS RAISED SOME SIGNIFICANT ISSUES FOR THE PUBLIC MANAGEMENT OF CRITICAL INFRASTRUCTURES. IN MANY COUNTRIES, PRIVATIZATIONS IN THE 1980S AND 1990S HAVE TRANSFERRED KEY ELEMENTS OF THE CRITICAL INFRASTRUCTURE TO PRIVATE COMPANIES. BECAUSE THESE INFRASTRUCTURES ARE OF MAJOR SIGNIFICANCE TO OUR SOCIETIES AND ECONOMIES, THEY MUST BE PROTECTED AGAINST PROLONGED PERIODS OF BREAKDOWN. THE 'NEW' TERRORISM HAS THE POTENTIAL TO DO JUST THAT. THE MANAGEMENT OF THIS NEW THREAT IS A COMPLEX TASK, WHICH INVARIABLY WILL BE UNDERTAKEN BY BOTH PUBLIC AND PRIVATE ACTORS. THEY MUST DEAL WITH THE CORE CHALLENGES OF THE PREVENTION OF ATTACKS, EFFECTIVE COMMUNICATION OF INFORMATION ACROSS ORGANIZATIONAL BOUNDARIES AND THE 'OWNERSHIP' OF CRISIS DECISION-MAKING. THIS ARTICLE CONSIDERS THESE ISSUES WITHIN THE CONTEXT OF THE BROADER RESEARCH AREAS OF PUBLIC MANAGEMENT AND CRISIS MANAGEMENT.",NA,NA,PUBLIC MONEY & MANAGEMENT,"BOIN, A##SMITH, D","LEIDEN UNIV, DEPT PUBL ADM, NL-2300 RA LEIDEN, NETHERLANDS. UNIV GLASGOW, DEPT BUSINESS & MANAGEMENT, GLASGOW G12 8QQ, LANARK, SCOTLAND.",PUBLIC ADMINISTRATION,PUBLIC ADMINISTRATION,"AHMED NM, 2006, LONDON BOMBINGS INDE##BAER MARTHA, 2005, SAFE RACE PROTECT OU##BAWER B, 2006, WHILE EUROPE SLEPT R##BOIN R.A., 2005, POLITICS CRISIS MANA##BOIN RA, 2006, IN PRESS J EUROPEAN##BOSSIE DAVID N., 2004, INTELLIGENCE FAILURE##CESARI JOCELYNE, 2004, ISLAM DEMOCRACY MEET##COMFORD LK, 1988, MANAGING DISASTERS S##CORLETT JA, 2003, TERRORISM PHILOS APP##CRENSHAW MARTHA, 2004, ATTACKING TERRORISM, P74##CRONIN AK, 2004, ATTACKING TERRORISM, P19##ECONOMIST, 2006, ECONOMIST, V380, P9##ELLIOTT M, 2006, TIME, V168, P18##FLYNN S, 2004, AM VULNERABLE OUR GO##GERGES FAWAZ, 2005, FAR ENEMY WHY JIHAD##GRIFFIN DAVID RAY, 2004, NEW PEARL HARBOUR DI##GUILLEMIN J, 2005, BIOL WEAPONS INVENTI##KEAN TH, 2004, 9 11 COMMISSION REPR##LAQUEUR W, 2004, NO END WAR##MCGRORY DANIEL, 2006, SUICIDE FACTORY ABU##PERROW CHARLES, 1984, NORMAL ACCIDENTS LIV##POSNER RA, 2005, PREVENTING SURPRISE##READER I, 2002, TERROR POLIT VIOLENC, V14, P147##ROCHLIN G., 1996, J CONTING CRISIS MAN, V4, P55, DOI DOI 10.1111/J.1468-5973.1996.TB00077.X##SCHULMAN P., 2004, J CONTING CRISIS MAN, V12, P14, DOI DOI 10.1111/J.0966-0879.2004.01201003.X##SCHWARTZ S, 2006, SPECTATOR, V301, P14##SMITH D., 2006, KEY READINGS CRISIS##SMITH D., 1990, IND CRISIS Q, V4, P263, DOI DOI 10.1177/108602669000400402##SMITH D., 2006, KEY READINGS CRISIS, P301##SOROS G, 2006, AGE FALLIBILITY CONS##T HART P., 2001, MANAGING CRISES THRE, P28##THOMAS E, 2006, NEWSWEEK, V148, P20##TULLOCH J, 2006, ONE DAY JULY EXPERIE##WEICK KE, 1999, RES ORGAN BEHAV, V21, P81##WEINBERG L, 2005, TERRORISM BEGINNERS##WILDAVSKY A, 1998, SEARCHING SAFETY##WILLIAMS C., 2004, TERRORISM EXPLAINED##2006, ECONOMIST, V380, P20",31,2020-11-20,NA
J,WOS:000242745200003,2006,NEWS AND CORPORATE REPUTATION: EMPIRICAL FINDINGS FROM THE NETHERLANDS,"THIS ARTICLE EXAMINES THE INFLUENCE OF BUSINESS NEWS ON CORPORATE REPUTATION. A PANEL SURVEY WAS USED TO MEASURE THE REPUTATIONS OF SIX COMPANIES AND TWO PROFESSIONAL SECTORS. MEDIA COVERAGE WAS ANALYZED BY FOCUSING ON THE TONE OF TWO DIFFERENT TYPES OF NEWS. NEWS ABOUT THE SUCCESSES OF THE COMPANIES - SUCH AS HIGHER PROFITS - IMPROVED THEIR REPUTATIONS. IN ADDITION, SOME COMPANIES' REPUTATION IMPROVED THE MORE THEY WERE CRITICIZED BY THEIR COMPETITORS IN THE NEWS. IT IS ARGUED ON BASIS OF THESE EMPIRICAL FINDINGS THAT THE REPUTATION OF THE PARTY ATTACKING A COMPANY IN THE NEWS IS CRUCIAL IN DETERMINING ITS INFLUENCE ON THE REPUTATION OF THE BESIEGED COMPANY. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",NA,BUSINESS NEWS; CORPORATE REPUTATION; CORPORATE IMAGE; PUBLIC OPINION; SURVEY; CONTENT ANALYSIS; BANDWAGON; HORSE RACE,PUBLIC RELATIONS REVIEW,"MEIJER, MM##KLEINNIJENHUIS, J","VRIJE UNIV AMSTERDAM, FAC SOCIAL SCI, CTR STUDY PHILANTHROPY, NL-1081 HV AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, FAC SOCIAL SCI, DEPT COMMUN SCI, NL-1081 HV AMSTERDAM, NETHERLANDS.",BUSINESS; COMMUNICATION,BUSINESS & ECONOMICS; COMMUNICATION,"CAMERON G. T., 1994, J PUBLIC RELAT RES, V6, P185, DOI DOI 10.1207/S1532754XJPRR0603_03##CARROLL C. E., 2003, CORPORATE REPUTATION, V6, P36, DOI DOI 10.1057/PALGRAVE.CRR.1540188##DEEPHOUSE DL, 2000, J MANAGE, V26, P1091, DOI 10.1177/014920630002600602##DERIDDER J, 1994, THESIS U AMSTERDAM##FOMBRUN C, 1990, ACAD MANAGE J, V33, P233, DOI 10.2307/256324##FOMBRUN C. J., 1996, REPUTATION REALIZING##IRWIN GA, 2002, PUBLIC OPIN QUART, V66, P92, DOI 10.1086/338632##KLEINNIJENHUIS J, 1997, ANN M AM POL SCI ASS##KLEINNIJENHUIS J, 2003, PUINHOPEN HET NIEUWS##LAZARSFELD P. F., 1944, PEOPLES CHOICE VOTER##MEIJER M.M., 2004, DOES SUCCESS BREED S##MEIJER MM, 2006, J COMMUN, V56, P543, DOI 10.1111/J.1460-2466.2006.00300.X##OSGOOD CE, 1955, PSYCHOL REV, V62, P42, DOI 10.1037/H0048153##SHAH DV, 2002, PUBLIC OPIN QUART, V66, P339, DOI 10.1086/341396##WARTICK S., 1992, BUSINESS SOC, V31, P33, DOI DOI 10.1177/000765039203100104",36,2020-11-20,NA
J,WOS:000242011100008,2006,QUALITY AND RELIABILITY PROBLEMS FROM A CONSUMER'S PERSPECTIVE: AN INCREASING PROBLEM OVERLOOKED BY BUSINESSES?,"CURRENTLY, MANY BUSINESSES IN THE CONSUMER ELECTRONICS INDUSTRY ARE FACING AN INCREASING NUMBER OF CONSUMER COMPLAINTS, DESPITE THE APPLICATION OF QUALITY TOOLS THAT PROVED TO BE VERY POWERFUL IN THE PAST. WE ASSESSED OVER 20 NEW PRODUCT DEVELOPMENT PROJECTS, TO UNDERSTAND THE REASONS BEHIND THE RISING NUMBER OF CONSUMER COMPLAINTS. WE FOUND THAT BUSINESSES ARE DEVELOPING MORE INNOVATIVE PRODUCTS THAT ARE BROUGHT TO THE MARKET FASTER, WITH INHERENTLY HIGHER UNCERTAINTIES ON THE CONSUMER EXPECTATIONS OF THESE PRODUCTS. CURRENT ANALYSES OF CONSUMER COMPLAINTS SOLELY FOCUS ON CHECKING IF THE PRODUCT IS FUNCTIONING ACCORDING TO THE TECHNICAL SPECIFICATION, AND THESE ANALYSES SHOW A RISING NUMBER OF CONSUMER COMPLAINTS WHERE NO FAILURE COULD BE ESTABLISHED. WHEN LOOKING AT PRODUCT QUALITY AND RELIABILITY FROM A CONSUMER'S PERSPECTIVE, WE FOUND THAT CONSUMERS COMPLAIN NOT ONLY ABOUT TECHNICAL PRODUCT FAILURES BUT ALSO WHEN THE PRODUCT DOES NOT SATISFY THEIR EXPECTATIONS. IN THIS PAPER WE WILL TAKE THE PERSPECTIVE OF THE CONSUMER TO ANALYSE DISSATISFACTION WITH NEW PRODUCTS FROM VARIOUS AVAILABLE SOURCES, WHICH WERE NOT SET-UP FOR QUALITY AND RELIABILITY PURPOSES. WE WILL SHOW THAT ANALYSING INFORMATION FROM THESE SOURCES GIVES BETTER INFORMATION, ESPECIALLY ON THE NON-TECHNICAL FAILURES COMPARED WITH THE TRADITIONAL QUALITY AND RELIABILITY SOURCES. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",CUSTOMER SATISFACTION; PRODUCT DEVELOPMENT; SALESPERSON; TYPOLOGY,PRODUCT QUALITY AND RELIABILITY; PRODUCT INNOVATION; NEW PRODUCT DEVELOPMENT; CONSUMER REQUIREMENTS; CONSUMER DISSATISFACTION; QUALITY INFORMATION FLOWS; QUALITY MANAGEMENT,QUALITY AND RELIABILITY ENGINEERING INTERNATIONAL,"DEN OUDEN, E##YUAN, L##SONNEMANS, PJM##BROMBACHER, AC","PHILIPS APPL TECHNOL IND CONSULTING, NL-5600 MD EINDHOVEN, NETHERLANDS. EINDHOVEN UNIV TECHNOL, DEPT TECHNOL MANAGEMENT, NL-5600 MB EINDHOVEN, NETHERLANDS.","ENGINEERING, MULTIDISCIPLINARY; ENGINEERING, INDUSTRIAL; OPERATIONS RESEARCH & MANAGEMENT SCIENCE",ENGINEERING; OPERATIONS RESEARCH & MANAGEMENT SCIENCE,"ANTONIDES G., 1999, PRODUCT CONSUMENT##ANTONIDES G, 1998, CONSUMER BEHAV EUROP##BROMBACHER AC, 2005, RELIAB ENG SYST SAFE, V88, P137, DOI 10.1016/J.RESS.2004.07.003##BROMBACHER AC, 2005, RELIAB ENG SYST SAFE, V88, P125, DOI 10.1016/J.RESS.2004.07.001##CHO Y, 2002, ADV CONSUM RES, V29, P318##COLE M., 2000, INFORMATION SYSTEMS FRONTIERS, V1, P349, DOI 10.1023/A:1010009923913##CREVELING C.M., 2003, DESIGN 6 SIGMA TECHN##CROSBY P.B., 1979, QUALITY IS FREE##DEMING W. E., 1986, OUT CRISIS##DENOUDEN E, 2005, IN PRESS J PRODUCT I##DUHAIME CP, 1988, J CONSUMER SATISFACT, V1, P53##EVANS J. R., 1999, MANAGEMENT CONTROL Q##GARCIA R, 2002, J PROD INNOVAT MANAG, V19, P110, DOI 10.1016/S0737-6782(01)00132-1##GEUDENS WHJ, 2005, P IEEE ANN REL MAINT##GIANFORTE G, 2003, CALL CTR CONTACT CTR##GOFF BG, 1997, J RETAILING, V73, P171, DOI 10.1016/S0022-4359(97)90002-6##HAN SH, 2001, INT J IND ERGONOM, V28, P143, DOI 10.1016/S0169-8141(01)00025-7##JOHNSTON R, 1998, J CONSUMER SATISFACT, V11, P69##JURAN JM, 1980, QUALITY PLANNING ANA##KANO N, 1984, J JAPANESE SOC QUALI, V14, P3948##KENNEDY MS, 2001, J BUS RES, V51, P73, DOI 10.1016/S0148-2963(99)00039-9##KOPP EF, 2001, P 48 ANN C SOC TECHN##LJUNGBERG LY, 2003, MATER DESIGN, V24, P519, DOI 10.1016/S0261-3069(03)00094-3##MATZLER K, 1998, TECHNOVATION, V18, P25, DOI 10.1016/S0166-4972(97)00072-2##MINDERHOUD S, 2005, RELIAB ENG SYST SAFE, V88, P127, DOI 10.1016/J.RESS.2004.07.002##MOHR J, 2001, MARKETING HIGH TECHN##MOORE GA, 1999, CROSSING CHASM##MURTREY MC, 2001, P 48 ANN C SOC TECHN##PETKOVA V, 2000, THESIS EINDHOVEN U T##ROGERS E.M., 2003, DIFFUSION INNOVATION##SHACKEL B, 1991, HUMAN FACTORS INFORM##SINGH J, 1990, J RETAILING, V66, P57##STATT D., 1997, UNDERSTANDING CONSUM##VAN NES N, 2003, THESIS ERASMUS U ROT##WALTERS D., 1988, STRATEGIC RETAILING##WELLS W. D., 1996, CONSUMER BEHAV##ZIKMUND W. G., 2003, CUSTOMER RELATIONSHI",41,2020-11-20,NA
J,WOS:000242011100009,2006,HYPOTHESIS GENERATION IN QUALITY IMPROVEMENT PROJECTS: APPROACHES FOR EXPLORATORY STUDIES,"IN QUALITY IMPROVEMENT PROJECTS-SUCH AS SIX SIGMA PROJECTS-AN EXPLORATORY PHASE CAN BE DISCERNED, DURING WHICH POSSIBLE CAUSES, INFLUENCE FACTORS OR VARIATION SOURCES ARE IDENTIFIED. IN A SUBSEQUENT CONFIRMATORY PHASE THE EFFECTS OF THESE POSSIBLE CAUSES ARE EXPERIMENTALLY VERIFIED. WHEREAS THE CONFIRMATORY PHASE IS WELL UNDERSTOOD, IN BOTH THE STATISTICAL SCIENCES AND PHILOSOPHY OF SCIENCE, THE EXPLORATORY PHASE IS POORLY UNDERSTOOD. THIS PAPER AIMS TO PROVIDE A FRAMEWORK FOR THE TYPE OF REASONING IN THE EXPLORATORY PHASE BY REVIEWING RELEVANT THEORIES IN PHILOSOPHY OF SCIENCE, ARTIFICIAL INTELLIGENCE AND MEDICAL DIAGNOSIS. FURTHERMORE, THE PAPER PROVIDES A CLASSIFICATION AND DESCRIPTION OF APPROACHES THAT COULD BE FOLLOWED FOR THE IDENTIFICATION OF POSSIBLE CAUSES. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",NA,DISCOVERY; PROBLEM-SOLVING; ABDUCTION; CLUE GENERATION; EXPLORATORY DATA ANALYSIS; DIAGNOSIS,QUALITY AND RELIABILITY ENGINEERING INTERNATIONAL,"DE MAST, J##BERGMAN, M","UNIV AMSTERDAM, INST BUSINESS & IND STAT, NL-1018 TV AMSTERDAM, NETHERLANDS.","ENGINEERING, MULTIDISCIPLINARY; ENGINEERING, INDUSTRIAL; OPERATIONS RESEARCH & MANAGEMENT SCIENCE",ENGINEERING; OPERATIONS RESEARCH & MANAGEMENT SCIENCE,"ALTSHULLER G., 1999, INNOVATION ALGORITHM##ALTSHULLER GENRICH, 1996, SUDDENLY INVENTOR AP##BEVERIDGE WIB, 1953, ART SCI INVESTIGATIO, P65##BHOTE KR, 1991, WORLD CLASS QUALITY##BISGAARD S, 1996, QUAL ENG, V9, P157, DOI DOI 10.1080/08982119608919028##BOX G.E.P., 1992, QUALITY RELIABILITY, V8, P17##BOX GEP, 1999, J QUAL TECHNOL, V31, P1##BOYLES RA, 1996, J QUAL TECHNOL, V28, P91##BREYFOGLE F.W., 1999, IMPLEMENTING 6 SIGMA##DE BONO E., 1970, LATERAL THINKING TXB##DE MAST J., 2004, QUALITY ENGINEERING, V16, P407, DOI 10.1081/QEN-120027943##DE MAST J., 2004, INTERNATIONAL JOURNAL OF QUALITY RELIABILITY MANAGEMENT, V21, P198, DOI 10.1108/02656710410516989##DE MAST J, 2003, QUAL RELIAB ENG INT, V19, P255, DOI 10.1002/QRE.580##DEMAST J, 2002, THESIS U AMSTERDAM##DEWEY J., 1997, WE THINK##ELSTEIN A. S. L., 1978, MED PROBLEM SOLVING##FRIEDMAN JH, 1974, IEEE T COMPUT, VC 23, P881, DOI 10.1109/T-C.1974.224051##GANO DL, 2001, ASQ'S 55TH ANNUAL QUALITY CONGRESS PROCEEDINGS, P110##GRYNA FM, 1988, JURANS QUALITY HDB##ISHIKAWA K, 1982, GUIDE QUALITY CONTRO##ISHIKAWA K, 1989, INTRO QUALITY CONTRO, P231##JURAN J. M., 1989, JURAN LEADERSHIP QUA##KEPNER C. H., 1997, NEW RATIONAL MANAGER##KITCHER P, 1998, ROUTLEDGE ENCY PHILO, V3##LANGLEY P, 1987, SCI DISCOVERY COMPUT, P24##LOSEE J., 2001, HIST INTRO PHILOS SC##MAGNANI L, 1999, MODEL-BASED REASONING IN SCIENTIFIC DISCOVERY, P219##MAGNANI L, 2002, P 2002 INT WORKSH CO, V3, P1226##MAHER P, 1998, ROUTLEDGE ENCY PHILO, V4##MAYO D.G., 1996, ERROR GROWTH EXPT KN##NICKLES T, 1998, ROUTLEDGE ENCY PHILO, V3##NIINILUOTO I, 1999, PHILOS SCI, V66, PS436, DOI 10.1086/392744##PEIRCE C. S., 1931, COLLECTED PAPERS, VI-VIII##POLANYI M., 1958, PERSONAL KNOWLEDGE##POPPER K, 2002, LOGIC SCI DISCOVERY##POPPER KARL., 1963, CONJECTURES REFUTATI##ROSS P.J., 1988, TAGUCHI TECHNIQUES Q##SALMON W, 1984, SCI EXPLANATION CAUS##SHAININ P, 1993, ASQC ANN QUAL C P, V47, P554##SHAININ RD, 1993, QUAL ENG, V5, P433, DOI DOI 10.1080/08982119308918984##SHEWHART WA, 1986, STAT METHOD VIEWPO##SMITH M, 2005, CHEM WORLD-UK, V2, P24, DOI 10.1039/B509023G##THAGARD P, 2004, HDB RATIONALITY##THAGARD P, 1992, CONCEPTUAL REVOLUTIO##TUKEY J.W., 1977, EXPLORATORY DATA ANA##TUKEY JW, 1980, AM STAT, V34, P23, DOI 10.2307/2682991",10,2020-11-20,NA
J,WOS:000241949500010,2006,THE CLINICAL SIGNIFICANCE OF ADAPTATION TO CHANGING HEALTH: A META-ANALYSIS OF RESPONSE SHIFT,"WHEN INDIVIDUALS EXPERIENCE CHANGES IN THEIR HEALTH STATES, THEY MAY ALTER THEIR INTERNAL STANDARDS, VALUES, OR CONCEPTUALIZATION OF QUALITY OF LIFE (QOL). SUCH 'RESPONSE SHIFTS' CAN AFFECT OR DISTORT QOL OUTCOME MEASUREMENT, WHICH IS OF PARTICULAR CONCERN WHEN EVALUATING MEDICAL OR PSYCHOSOCIAL INTERVENTIONS. ALTHOUGH CLINICIANS AND RESEARCHERS ACKNOWLEDGE THE OCCURRENCE OF RESPONSE SHIFTS, LITTLE IS KNOWN ABOUT THE MAGNITUDE AND CLINICAL SIGNIFICANCE OF THOSE EFFECTS. TO FILL THIS GAP IN KNOWLEDGE ABOUT RESPONSE SHIFT PHENOMENA, WE PERFORMED A META-ANALYSIS ON PUBLISHED QOL ARTICLES ON RESPONSE SHIFT. EXTENSIVE LITERATURE SEARCHES AND MULTIPLE CONTACTS WITH RESEARCHERS YIELDED A COLLECTION OF 494 ARTICLES FOR POTENTIAL REVIEWING. WE RETAINED ONLY PUBLISHED LONGITUDINAL STUDIES THAT MEASURED RESPONSE SHIFT, RESULTING IN 26, OF WHICH 19 REPORTED THE REQUISITE DATA FOR COMPUTING AN EFFECT SIZE (ES). WE CALCULATED AND COMPARED THE ESS FOR EACH STUDY WITH REGARD TO POTENTIAL MODERATOR VARIABLES: THE QOL DOMAINS MEASURED, DISEASE GROUP INVESTIGATED, SAMPLE SIZE, AND RESPONSE SHIFT METHOD USED. WE RATED STUDIES FOR QUALITY TO ALLOW ES WEIGHTING. WHEN WE EXAMINED ES ABSOLUTE VALUES, WE FOUND THAT ES MAGNITUDE WAS SMALL, WITH THE LARGEST ESS DETECTED FOR FATIGUE, FOLLOWED BY GLOBAL QOL, PHYSICAL ROLE LIMITATION, PSYCHOLOGICAL WELL-BEING, AND PAIN (MEAN VERTICAL BAR ESWEIGHTED VERTICAL BAR = 0.32, 0.30, 0.24, 0.12, AND 0.08, RESPECTIVELY). ESS VARIED CONSIDERABLY IN DIRECTION. AGGREGATING RAW ES SCORES OVER ALL STUDIES LED TO POSITIVE AND NEGATIVE VALUES CANCELING EACH OTHER OUT (MEAN DIRECTIONAL ESWEIGHTED = 0.17, 0.02, -0.01, 0.06, AND 0.02, RESPECTIVELY). WE FOUND LITTLE EVIDENCE OF AN EFFECT FOR THE MODERATOR VARIABLES EXAMINED. A DEFINITIVE CONCLUSION ON THE CLINICAL SIGNIFICANCE OF RESPONSE SHIFT CANNOT CURRENTLY BE DRAWN FROM EXISTING STUDIES. FOR A NUMBER OF REASONS, ES ESTIMATES WERE PRIMARILY BASED ON THEN-TEST RESULTS, A METHOD THAT IS NOT WITHOUT CRITICISM, SUCH AS ITS SUSCEPTIBILITY TO RECALL BIAS. WE RECOMMEND A STANDARDIZED APPROACH FOR REPORTING RESULTS OF FUTURE RESPONSE SHIFT RESEARCH TO ADVANCE THE FIELD AND TO FACILITATE INTERPRETATION AND COMPARISONS ACROSS STUDIES.",QUALITY-OF-LIFE; TRUE CHANGE; CANCER-PATIENTS; INTERVENTION; POSTSTROKE; PERCEPTION; FATIGUE; TIME,ADAPTATION; CLINICAL SIGNIFICANCE; META-ANALYSIS; QUALITY OF LIFE; RESPONSE SHIFT,QUALITY OF LIFE RESEARCH,"SCHWARTZ, CE##BODE, R##REPUCCI, N##BECKER, J##SPRANGERS, MAG##FAYERS, PM","DELTAQUEST FDN INC, CONCORD, MA 01742 USA. SOCIAL SECTORS DEV STRATEGIES INC, BOSTON, MA USA. UNIV MASSACHUSETTS, SCH MED, DEPT MED, DIV PALLIAT MED, WORCESTER, MA 01605 USA. NORTHWESTERN UNIV, FEINBERG SCH MED, DEPT PHYS MED & REHABIL, CHICAGO, IL 60611 USA. HLTH ASSESSMENT LAB, WALTHAM, MA USA. QUALITYMETRIC INC, WALTHAM, MA USA. UNIV AMSTERDAM, ACAD MED CTR, DEPT PSYCHOL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV ABERDEEN, SCH MED, ABERDEEN AB9 2ZD, SCOTLAND. NORWEGIAN UNIV SCI & TECHNOL, N-7034 TRONDHEIM, NORWAY.","HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","HEALTH CARE SCIENCES & SERVICES; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","ADANG EMM, 1998, TRANSPL INT, V11, P11, DOI 10.1007/S001470050095##AHMED S, 2005, QUAL LIFE RES, V14, P2247, DOI 10.1007/S11136-005-8118-4##AHMED S, 2005, QUAL LIFE RES, V14, P611, DOI 10.1007/S11136-004-3708-0##AHMED S, 2004, J CLIN EPIDEMIOL, V57, P561, DOI 10.1016/J.JCLINEPI.2003.11.003##BAR-ON D, 2000, SOC INDIC RES, V49, P37, DOI 10.1023/A:1006933612340##BERNHARD J, 2004, QUAL LIFE RES, V13, P1187, DOI 10.1023/B:QURE.0000037485.59681.7D##BERNHARD J, 2001, EUR J CANCER, V37, P1729, DOI 10.1016/S0959-8049(01)00196-4##BERNHARD J, 1999, ANN ONCOL, V10, P775, DOI 10.1023/A:1008311918967##CARVER CS, 2000, SOC SCI MED, V50, P1715, DOI 10.1016/S0277-9536(99)00412-8##CELLA D, 2002, QUAL LIFE RES, V11, P207, DOI 10.1023/A:1015276414526##COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155##COHEN J., 1988, STAT POWER ANAL BEHA##HAGEDOORN M, 2002, J CLIN EPIDEMIOL, V55, P176, DOI 10.1016/S0895-4356(01)00438-3##JANSEN SJT, 2000, QUAL LIFE RES, V9, P603, DOI 10.1023/A:1008928617014##JANSEN SJT, 2000, MED DECIS MAKING, V20, P62, DOI 10.1177/0272989X0002000108##JOORE MA, 2002, QUAL LIFE RES, V11, P299, DOI 10.1023/A:1015598807510##KAHNEMAN D, 1990, PROSPECT THEORY ANAL, P140##LEPORE SJ, 2000, RESPONSE SHIFTS PROS, V8395, P37##MOSTELLER F, 1996, ANNU REV PUBL HEALTH, V17, P1, DOI 10.1146/ANNUREV.PU.17.050196.000245##NORMAN GR, 2003, QUAL LIFE RES, V12, P239, DOI 10.1023/A:1023211129926##OBISESAN OLANREWAJU, 2005, AM J THER, V12, P142, DOI 10.1097/01.MJT.0000140214.02583.85##OORT FJ, 2005, QUAL LIFE RES, V14, P599, DOI 10.1007/S11136-004-0831-X##OORT FJ, 2005, QUAL LIFE RES, V14, P587, DOI 10.1007/S11136-004-0830-Y##POSTULART D, 2000, MED DECIS MAKING, V20, P186, DOI 10.1177/0272989X0002000204##RAPKIN BD, 2000, ADAPTATION CHANGING, P53, DOI DOI 10.1037/10382-004##RAPKIN BRUCE D, 2004, HEALTH QUAL LIFE OUTCOMES, V2, P14, DOI 10.1186/1477-7525-2-14##REES J, 2003, BJU INT, V92, P703, DOI 10.1046/J.1464-410X.2003.04462.X##REES JONATHAN, 2005, HEALTH QUAL LIFE OUTCOMES, V3, P21, DOI 10.1186/1477-7525-3-21##SCHWARTZ CAROLYN E, 2004, HEALTH QUAL LIFE OUTCOMES, V2, P16, DOI 10.1186/1477-7525-2-16##SCHWARTZ CAROLYN E, 2004, J PALLIAT MED, V7, P233, DOI 10.1089/109662104773709350##SCHWARTZ CE, 2004, PSYCHOL HEALTH, V19, P51, DOI 10.1080/0887044031000118456##SCHWARTZ CE, 2002, ARCH INTERN MED, V162, P1611, DOI 10.1001/ARCHINTE.162.14.1611##SCHWARTZ CE, 1999, PSYCHO-ONCOL, V8, P344, DOI 10.1002/(SICI)1099-1611(199907/08)8:4<344::AID-PON399>3.0.CO;2-T##SLOAN JA, 2005, J CLIN EPIDEMIOL, V58, P1217, DOI 10.1016/J.JCLINEPI.2005.07.009##SPRANGERS MAG, 1999, ACTA ONCOL, V38, P709##TIMMERMAN AA, 2003, ARCH OTOLARYNGOL, V129, P987, DOI 10.1001/ARCHOTOL.129.9.987##VISSER MRM, 2005, QUAL LIFE RES, V14, P629, DOI 10.1007/S11136-004-2577-X##VISSER MRM, 2000, J PAIN SYMPTOM MANAG, V20, P12, DOI 10.1016/S0885-3924(00)00148-2##WYRWICH KW, 2006, IN PRESS QUAL LIFE R",43,2020-11-20,NA
J,WOS:000243286300017,2006,"SEVERNAYA ZEMLYA, ARCTIC RUSSIA: A NUCLEATION AREA FOR KARA SEA ICE SHEETS DURING THE MIDDLE TO LATE QUATERNARY","QUATERNARY GLACIAL STRATIGRAPHY AND RELATIVE SEA-LEVEL CHANGES REVEAL AT LEAST FOUR EXPANSIONS OF THE KARA SEA ICE SHEET OVER THE SEVERNAYA ZEMLYA ARCHIPELAGO AT 79 DEGREES N IN THE RUSSIAN ARCTIC, AS INDICATED FROM TILLS INTERBEDDED WITH MARINE SEDIMENTS, EXPOSED IN STRATIGRAPHIC SUPERPOSITION, AND FROM RAISED-BEACH SEQUENCES THAT OCCUR AT ALTITUDES UP TO 140 M A.S.L. CHRONOLOGIC CONTROL IS PROVIDED BY AMS C-14, ELECTRON-SPIN RESONANCE, GREEN-STIMULATED LUMINESCENCE, AND ASPARTIC-ACID GEOCHRONOLOGY. MAJOR GLACIATIONS FOLLOWED BY DEGLACIATION AND MARINE INUNDATION OCCURRED DURING MIS 10-9, MIS 8-7, MIS 6-5E AND MIS 5D-3. THE MIS 6-5E EVENT, ASSOCIATED WITH THE HIGH MARINE LIMIT, IMPLIES ICE-SHEET THICKNESS OF > 2000M ONLY 200KM FROM THE DEEP ARCTIC OCEAN, CONSISTENT WITH PUBLISHED EVIDENCE OF ICE GROUNDING AT SIMILAR TO 1000M WATER DEPTH IN THE CENTRAL ARCTIC OCEAN. TILL FABRICS AND GLACIAL TECTONICS RECORD REPEATED EXPANSIONS OF LOCAL ICE CAPS EXCLUSIVELY, SUGGESTING WET-BASED ICE CAP ADVANCE FOLLOWED BY COLD-BASED REGIONAL ICE-SHEET EXPANSION. LOCAL ICE CAPS OVER HIGHLAND SITES ALONG THE PERIMETER OF THE SHALLOW KARA SEA, INCLUDING THE BYRRANGA MOUNTAINS, APPEAR TO HAVE REPEATEDLY FOSTERED INITIATION OF A LARGE KARA SEA ICE SHEET, WITH EXCEPTION OF THE LAST GLACIAL MAXIMUM (MIS 2), WHEN KARA SEA ICE DID NOT IMPACT SEVERNAYA ZEMLYA AND BARELY GRACED NORTHERNMOST TAYMYR PENINSULA. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",WESTERN YAMAL PENINSULA; LAST GLACIAL MAXIMUM; TAYMYR PENINSULA; NORTHERN EURASIA; MARGINAL ZONE; LUMINESCENCE; PLEISTOCENE; SIBERIA; SEDIMENTS; HISTORY,NA,QUATERNARY SCIENCE REVIEWS,"MOLLER, P##LUBINSKI, DJ##INGOLFSSON, O##FORMAN, SL##SEIDENKRANTZ, MS##BOLSHIYANOV, DY##LOKRANTZ, H##ANTONOV, O##PAVLOV, M##LJUNG, K##ZEEBERG, J##ANDREEV, A","LUND UNIV, DEPT GEOL, GEOBIOSPHERE SCI CTR, SE-22362 LUND, SWEDEN. UNIV COLORADO, INST ARTIC & ALPINE RES, BOULDER, CO 80309 USA. UNIV ICELAND, DEPT GEOG & GEOL, IS-101 REYKJAVIK, ICELAND. UNIV ILLINOIS, DEPT EARTH & ENVIRONM SCI, CHICAGO, IL 60607 USA. AARHUS UNIV, DEPT EARTH SCI, DK-8000 AARHUS, DENMARK. ARCTIC & ANTARCTIC RES INST, ST PETERSBURG 199397, RUSSIA. GEOL SURVEY SWEDEN, SE-75128 UPPSALA, SWEDEN. VSEGEI AP KARPINSKY ALL RUSSIA RES GEOL INST, ST PETERSBURG 199106, RUSSIA. NETHERLANDS INST FISHERY RES, RIVO, NL-1970 AB IJMUIDEN, NETHERLANDS. FORSCH STELLE POTSDAM, ALFRED WEGENER INST POLAR & MEERESFORSCH, D-14473 POTSDAM, GERMANY.","GEOGRAPHY, PHYSICAL; GEOSCIENCES, MULTIDISCIPLINARY",PHYSICAL GEOGRAPHY; GEOLOGY,"ALEXANDERSON H, 2002, J QUATERNARY SCI, V17, P361, DOI 10.1002/JQS.677##ALEXANDERSON H, 2001, GLOBAL PLANET CHANGE, V31, P427, DOI 10.1016/S0921-8181(01)00133-3##ANDREEV AA, 1997, GEOGR PHYS QUATERN, V51, P379, DOI 10.7202/033137AR##ARKHIPOV S. A., 1989, PLEISTOTSEN SIBIRI S, P19##ARKHIPOV SA, 1986, QUATERNARY SCI REV, V5, P463##ASTAKHOV V, 2004, DEV QUA SCI, V2, P309##ASTAKHOV V, 2004, QUATERNARY SCI REV, V23, P1285, DOI 10.1016/J.QUASCIREV.2003.12.011##ASTAKHOV V, 2001, GLOBAL PLANET CHANGE, V31, P283, DOI 10.1016/S0921-8181(01)00125-4##ASTAKHOV V, 1998, QUATERN INT, V45-6, P19, DOI 10.1016/S1040-6182(97)00003-7##BENN DI, 1995, SEDIMENTOLOGY, V42, P735, DOI 10.1111/J.1365-3091.1995.TB00406.X##BENN DI, 1996, QUATERNARY SCI REV, V15, P23, DOI 10.1016/0277-3791(95)00082-8##BERGER GW, 2004, J QUATERNARY SCI, V19, P513, DOI 10.1002/JQS.847##BLIECK ALAIN R. M., 2002, GEODIVERSITAS, V24, P805##BOLSHIYANOV DY, 1995, GIDROMETEOIZDAT##BOULTON GS, 1987, J GEOPHYS RES-SOLID, V92, P9059, DOI 10.1029/JB092IB09P09059##BOUMA A. H., 1962, SEDIMENTOLOGY SOME F##BRUMBY S, 1994, QUATERNARY SCI REV, V13, P157, DOI 10.1016/0277-3791(94)90042-6##BUDE SO, 1997, THESIS CHRISTIAN ALB##EICKEN H., 1998, LAND OCEAN SYSTEMS S, P469##ELLIOTT T., 1986, SEDIMENTARY ENV FACI, P155##ENGLAND J, 1999, QUATERNARY SCI REV, V18, P421, DOI 10.1016/S0277-3791(98)00070-5##EYLES N, 1983, SEDIMENTOLOGY, V30, P393, DOI 10.1111/J.1365-3091.1983.TB00679.X##FAIN J, 1999, QUATERNARY SCI REV, V18, P231, DOI 10.1016/S0277-3791(98)00056-0##FEYLING-HANSSEN R., 1983, NPD B, V2, P109##FISHER EL, 1990, SERIYA GEOGRAFICHESK, V6, P109##FORMAN SL, 1999, GEOLOGY, V27, P807, DOI 10.1130/0091-7613(1999)027<0807:LQSOWY>2.3.CO;2##FORMAN SL, 2002, QUATERNARY RES, V57, P355, DOI 10.1006/QRES.2002.2322##FORMAN SL, 1997, GEOPHYS RES LETT, V24, P885, DOI 10.1029/97GL00761##FORMAN SL, 1999, ARCT ANTARCT ALP RES, V31, P4##FORMAN SL, 2000, EOS T AM GEOPHYS UN, V81, P169##FUNDER S, 2002, PALAEOGEOGR PALAEOCL, V184, P275, DOI 10.1016/S0031-0182(02)00256-0##GROSSWALD MG, 1998, QUATERN INT, V45-6, P3, DOI 10.1016/S1040-6182(97)00002-5##GUDINA V. I., 1973, GEOL GEOFIZ, V175, P1##GUDINA VI, 1989, J FORAMIN RES, V19, P20, DOI 10.2113/GSJFR.19.1.20##HALD M, 1992, J FORAMIN RES, V22, P347, DOI 10.2113/GSJFR.22.4.347##HART J, 2001, QUATERN INT, V86, P45, DOI 10.1016/S0277-3791(01)00066-X##HART JK, 1994, EARTH SURF PROC LAND, V19, P15, DOI 10.1002/ESP.3290190103##HJORT C, 2004, DEV QUA SCI, V2, P359##HJORT C, 2003, POLARFORSKNINGSSEKRE, P80##JAIN M, 2003, RADIAT MEAS, V37, P67, DOI 10.1016/S1350-4487(02)00165-8##JAKOBSSON M, 2001, GLOBAL PLANET CHANGE, V31, P1, DOI 10.1016/S0921-8181(01)00110-2##JAKOBSSON M, 2000, AM GEOPHYS UNION, V81, P89##KAUFMAN DS, 1998, QUATERNARY SCI REV, V17, P987, DOI 10.1016/S0277-3791(97)00086-3##KIND NV, 1982, ANTROPOGEN TAYMYRA##KNIES J, 2001, GLOBAL PLANET CHANGE, V31, P45, DOI 10.1016/S0921-8181(01)00112-6##KOTLYAKOV VM, 2004, QUATERNARY SCI REV, V23, P1371, DOI 10.1016/J.QUASCIREV.2003.12.013##LAMBECK K, 2001, SCIENCE, V292, P679, DOI 10.1126/SCIENCE.1059549##LAMBECK K, IN PRESS BOREAS##LOKRANTZ H, 2003, J QUATERNARY SCI, V18, P527, DOI 10.1002/JQS.771##LORANGE K, 1977, THESIS U OSLO NORWAY##LOWE DR, 1982, J SEDIMENT PETROL, V52, P279, DOI 10.1306/212F7F31-2B24-11D7-8648000102C1865D##LYKKEANDERSEN AL, 1987, BOREAS, V16, P345##MACKENSEN A, 1995, MICROPALEONTOLOGY, V41, P342, DOI 10.2307/1485808##MACKENSEN A, 1997, BERICHTE POLARFORSCH, V243, P1##MAKEEV VM, 1979, DOKL AKAD NAUK SSSR+, V245, P421##MAKEYEV VM, 1986, POLAR GEOGRAPHY GEOL, V10, P331##MAKEYEV VM, 1992, GEOKHRONOLOGIYA CHET, P132##MANGERUD J, 1992, QUATERNARY RES, V38, P1, DOI 10.1016/0033-5894(92)90027-G##MANGERUD J, 1975, QUATERNARY RES, V5, P263, DOI 10.1016/0033-5894(75)90028-9##MARK DM, 1973, GEOL SOC AM BULL, V84, P1369, DOI 10.1130/0016-7606(1973)84<1369:AOAODI>2.0.CO;2##MEJDAHL V, 1994, QUATERNARY SCI REV, V13, P403, DOI 10.1016/0277-3791(94)90049-3##MOLLER P, 1999, BOREAS, V28, P92##MOLLER P, UNPUB GLACIAL PALAEO##MOLLER P, 1999, QUATERNARY ENV EURAS, P41##MOLODKOV A, 1998, QUATERNARY SCI REV, V17, P1077, DOI 10.1016/S0277-3791(98)00030-4##MOLODKOV A, 1988, QUATERNARY SCI REV, V7, P477, DOI 10.1016/0277-3791(88)90049-2##MOLODKOV AN, 2002, SEDIMENT GEOL, V150, P185, DOI 10.1016/S0037-0738(01)00275-5##NEMEC W, 1990, COARSE GRAINED DELTA, V10, P29, DOI DOI 10.1002/9781444303858.CH3##NIESSEN F, 1997, TERRA NOVA, V9, P208##OLSSON IU, 1980, RADIOCARBON, V22, P662, DOI 10.1017/S0033822200010031##POLYAK L, 2002, J FORAMIN RES, V32, P252, DOI 10.2113/32.3.252##POLYAK L, 2001, NATURE, V410, P453, DOI 10.1038/35068536##PORSILD MP, 1918, GEOGR REV, V6, P215, DOI 10.2307/207815##PRESCOTT JR, 1994, RADIAT MEAS, V23, P497, DOI 10.1016/1350-4487(94)90086-8##RAAB A, 2003, QUATERNARY SCI REV, V22, P2267, DOI 10.1016/S0277-3791(03)00139-2##RICHARDSON CA, 1994, RADIAT MEAS, V23, P587, DOI 10.1016/1350-4487(94)90104-X##ROSING J, 1986, HAVETS ENHJORNING WO##SAKS V. N., 1953, QUATERNARY PERIOD SO##SCHELLMANN G, 1997, QUATERNARY SCI REV, V16, P465, DOI 10.1016/S0277-3791(96)00104-7##SEIDENKRANTZ MS, 1993, PALAEOGEOGR PALAEOCL, V102, P103, DOI 10.1016/0031-0182(93)90008-7##SIEGERT MJ, 2004, QUATERNARY SCI REV, V23, P1273, DOI 10.1016/J.QUASCIREV.2003.12.010##SIEGERT MJ, 2002, AM SCI, V90, P32##SINGHVI AK, 1982, NATURE, V295, P313, DOI 10.1038/295313A0##SPIELHAGEN RF, 2004, QUATERNARY SCI REV, V23, P1455, DOI 10.1016/J.QUASCIREV.2003.12.015##STAFFORD TW, 1991, J ARCHAEOL SCI, V18, P35, DOI 10.1016/0305-4403(91)90078-4##STEINSUND PI, 1994, BENTHIC FORMAINIFERA##SVENDSEN JI, 2004, QUATERNARY SCI REV, V23, P1229, DOI 10.1016/J.QUASCIREV.2003.12.008##TAYLOR RE, 1987, RADIOCARBON DATING A##URVANTSEV NN, 1931, CHETVERTICHNOGO PERI, V3, P23##VAIKMAE R, 1988, DATA GLACIOLOGICAL S, V40, P127##VAN DER PLICHT J, 2004, RADIOCARBON, V46, P1225, DOI 10.1017/S0033822200033117##VELICHKO AA, 1984, LATE QUATERNARY ENV, P35##VOLKOVA V.S., 2000, UNIFITSIROVANNAYA RE##WEAVER AJ, 1995, NATURE, V378, P135, DOI 10.1038/378135A0",29,2020-11-20,NA
J,WOS:000241401000001,2006,ANALYSIS OF A SIMPLE MARKOVIAN RE-ENTRANT LINE WITH INFINITE SUPPLY OF WORK UNDER THE LBFS POLICY,"WE CONSIDER A TWO MACHINE 3 STEP RE-ENTRANT LINE, WITH AN INFINITE SUPPLY OF WORK. THE SERVICE DISCIPLINE IS LAST BUFFER FIRST SERVED. PROCESSING TIMES ARE INDEPENDENT EXPONENTIALLY DISTRIBUTED. WE ANALYZE THIS SYSTEM, OBTAINING STEADY STATE BEHAVIOR AND SAMPLE PATH PROPERTIES.",QUEUING-NETWORKS; OPTIMIZATION; STABILITY,QUEUEING; MANUFACTURING; PRIORITY SCHEDULING; MARKOVIAN MULTICLASS QUEUEING NETWORKS; LAST BUFFER FIRST SERVED DISCIPLINE; INFINITE VIRTUAL BUFFERS; STEADY STATE DISTRIBUTIONS; SAMPLE PATH PROPERTIES; GI/M/1 QUEUE,QUEUEING SYSTEMS,"ADAN, I##WEISS, G","TECH UNIV EINDHOVEN, DEPT MATH & COMP SCI, NL-5600 MB EINDHOVEN, NETHERLANDS. UNIV HAIFA, DEPT STAT, IL-31905 HAIFA, ISRAEL.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; OPERATIONS RESEARCH & MANAGEMENT SCIENCE",COMPUTER SCIENCE; OPERATIONS RESEARCH & MANAGEMENT SCIENCE,"CHEN M, 2003, QUEUEING SYST, V44, P313, DOI 10.1023/A:1025130105303##CHEN RR, 1999, QUEUEING SYST, V32, P65, DOI 10.1023/A:1019182903300##COHEN J., 1982, SINGLE SERVER QUEUE##DAI JG, 1996, MATH OPER RES, V21, P115, DOI 10.1287/MOOR.21.1.115##FOSTER FG, 1953, ANN MATH STAT, V24, P355, DOI 10.1214/AOMS/1177728976##HARRISON J. M., 1988, P IMA WORKSH STOCH D##KLEINROCK L., 1975, QUEUEING SYSTEMS, V1##KUMAR P. R., 1993, QUEUEING SYSTEMS THEORY AND APPLICATIONS, V13, P87, DOI 10.1007/BF01158930##KUMAR S, 1994, IEEE T AUTOMAT CONTR, V39, P1600, DOI 10.1109/9.310033##NAZARATHY Y, 2001, THESIS U HAIFA##ROSS S.M., 1983, STOCHASTIC PROCESSES##WEISS G, 2004, J OPER RES SOC JPN, V47, P304, DOI 10.15807/JORSJ.47.304##WEISS G, 1999, P 37 ALL C, P577##WEISS G, 1995, P IMA WORKSH STOCH N",16,2020-11-20,NA
J,WOS:000241401000003,2006,INSENSITIVE VERSUS EFFICIENT DYNAMIC LOAD BALANCING IN NETWORKS WITHOUT BLOCKING,"SO-CALLED WHITTLE NETWORKS HAVE RECENTLY BEEN SHOWN TO GIVE TIGHT APPROXIMATIONS FOR THE PERFORMANCE OF NON-LOCALLY BALANCED NETWORKS WITH BLOCKING, INCLUDING PRACTICAL ROUTING POLICIES SUCH AS JOINING THE SHORTEST QUEUE. IN THE PRESENT PAPER, WE TURN THE ATTENTION TO NETWORKS WITHOUT BLOCKING. TO THIS END, WE CONSIDER A SET OF ""INSENSITIVE"" DYNAMIC LOAD BALANCING SCHEMES PRESERVING THE STRUCTURE OF WHITTLE NETWORKS IN THE CASE OF INFINITE BUFFERS AND EXAMINE THEIR EFFICIENCY. USING HAUSDORFF'S THEOREM, WE PROVE THAT THE OPTIMAL INSENSITIVE SCHEMES ARE STATIC IN THIS CASE, I.E., ROUTING DECISIONS DO NOT DEPEND ON THE CURRENT STATE OF THE QUEUES. ON THE OTHER HAND, SIMULATIONS SHOW THAT THE PERFORMANCE OF STATIC POLICIES IS GENERALLY MUCH WORSE THAN THAT OF ""NON BALANCED"" SENSITIVE DYNAMIC POLICIES. THIS DEMONSTRATES THAT STRICT INSENSITIVITY AND EFFICIENCY MAY BE INCOMPATIBLE OBJECTIVES FOR NETWORKS WITH DYNAMIC LOAD BALANCING IN CASE OF INFINITE BUFFERS.",NA,LOAD BALANCING; INSENSITIVITY; WHITTLE NETWORKS; HAUSDORFF'S THEOREM; INFINITE BUFFERING,QUEUEING SYSTEMS,"JONCKHEERE, M","CWI, NL-1098 SJ AMSTERDAM, NETHERLANDS.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; OPERATIONS RESEARCH & MANAGEMENT SCIENCE",COMPUTER SCIENCE; OPERATIONS RESEARCH & MANAGEMENT SCIENCE,"BONALD T, 2003, QUEUEING SYST, V44, P69, DOI 10.1023/A:1024094807532##BONALD T, 2002, PERFORM EVALUATION, V49, P193, DOI 10.1016/S0166-5316(02)00110-4##BONALD T, 2005, IN PRESS QUEUEING SY##BONALD T, 2004, P JOINT INT C MEAS M, P367##CHAO X, 1998, QUEUEING SYST, V28, P377, DOI 10.1023/A:1019115626557##CHOQUET G, 1960, ANN I FOURIER GRENOB, V10, P333##EPHREMIDES A, 1980, IEEE T AUTOMAT CONTR, V25, P690, DOI 10.1109/TAC.1980.1102445##FELLER W., 1971, INTRO PROBABILITY TH, V2##GUPTA J. C., 1999, SANKHYA A, V61A, P286##HARDY G.H., 1949, DIVERGENT SERIES##HAUSDORFF F, 1921, MATH Z##HILDEBRANDT TH, 1933, ANN MATH##HORDIJK A, 1992, PROBAB ENG INFORM SC, V6, P495, DOI DOI 10.1017/S0269964800002692##JONCKHEERE M, 2005, P ACM SIGM##KELLY F., 1979, REVERSIBILITY STOCHA##PHELPS RR, 1966, VANNOSTRAND MATH STU, V7##SERFOZO R, 1999, INTRO STOCHASTIC NET##TOWSLEY D, 1992, IEEE T AUTOMAT CONTR, V37, P1446, DOI 10.1109/9.159590##WHITT W, 1986, OPER RES, V34, P226##WINSTON W, 1977, J APPL PROBAB, V14, P181, DOI 10.2307/3213271",5,2020-11-20,NA
J,WOS:000241739900006,2006,THE THREE FACES OF LEADERSHIP.,NA,NA,NA,R & D MANAGEMENT,"FISSCHER, O","UNIV TWENTE, TWENTE, NETHERLANDS.",BUSINESS; MANAGEMENT,BUSINESS & ECONOMICS,"HATCH MJ, 2004, 3 FACES LEADERSHIP",0,2020-11-20,NA
J,WOS:000242185600080,2006,X-RAY ABSORPTION NEAR-EDGE SPECTROSCOPIC STUDY OF NICKEL CATALYSTS,"NI-ISOCYANIDE AND NI-ACAC COMPLEXES HAVE BEEN STUDIED BY X-RAY ABSORPTION SPECTROSCOPY. THEORETICAL ANALYSIS HAS BEEN DONE USING SELF-CONSISTENT FULL MULTIPLE SCATTERING (MS) APPROACH WITHIN BOTH MUFFIN-TIN (MT) MODEL OF THE POTENTIAL AND NON-MT FINITE DEFERENCE METHOD. FOR THE ISOCYANIDE COMPLEX, IT WAS SHOWN THAT MS THEORETICAL SPECTRA REPRODUCE ALL STRUCTURAL DETAILS OF THE X-RAY ABSORPTION NEAR-EDGE STRUCTURE (XANES), BUT ALSO THAT IT IS IMPORTANT TO CONSIDER THE NON-MT EFFECTS IN THE POTENTIAL FOR A CORRECT SIMULATION OF THE SHAPE OF THE PRE-EDGE STRUCTURES. THE CONTRIBUTION OF A NON-CONSTANT POTENTIAL IN THE INTERSTITIAL REGIONS IS EXTREMELY IMPORTANT FOR THE INTERPRETATION OF THE XANES OF NI(ACAC)(2). (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",EPOXIDATION; COMPLEXES,XANES; NON-MUFFIN-TIN EFFECTS; CATALYSIS; NI-ISOCYANIDE COMPLEX; NI-ACAC COMPLEX,RADIATION PHYSICS AND CHEMISTRY,"SOLDATOV, AV##SMOLENTSEV, G##KRAVTSOVA, A##YALOVEGA, G##FEITERS, MC##METSELAAR, GA##JOLY, Y","ROSTOV STATE UNIV, FAC PHYS, ROSTOV NA DONU 344090, RUSSIA. RADBOUD UNIV NIJMEGEN, DEPT ORGAN CHEM, INST MOL & MAT, NL-6525 ED NIJMEGEN, NETHERLANDS. UNIV GRENOBLE 1, CNRS, CRISTALLOG LAB, F-38042 GRENOBLE, FRANCE.","CHEMISTRY, PHYSICAL; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL",CHEMISTRY; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS,"BIANCONI A, 1989, XRAY ABSORPTION PRIN, P573##BLAHA P., 2001, WIEN2K AUGMENTED PLA##FEITERS MC, 2005, IND ENG CHEM RES, V44, P8631, DOI 10.1021/IE050208Z##HURSTHOUSE MB, 1982, J CHEM SOC DALTON, P307, DOI 10.1039/DT9820000307##JOLY Y, 2001, PHYS REV B, V63, DOI 10.1103/PHYSREVB.63.125120##KANTERS JA, 1989, ACTA CRYSTALLOGR C, V45, P16, DOI 10.1107/S0108270188009497##NATOLI CR, 2003, J SYNCHROTRON RADIAT, V10, P26, DOI 10.1107/S0909049502017247##NOLTE RJM, 1994, CHEM SOC REV, V23, P11, DOI 10.1039/CS9942300011##REHR JJ, 2005, COORDIN CHEM REV, V249, P131, DOI 10.1016/J.CCR.2004.02.014##WENTZEL BB, 1998, J CHEM SOC DALTON, P2241, DOI 10.1039/A801175C",12,2020-11-20,NA
J,WOS:000241828200022,2006,CT: A NEW NONDESTRUCTIVE METHOD FOR VISUALIZING AND CHARACTERIZING ANCIENT ROMAN GLASS FRAGMENTS IN SITU IN BLOCKS OF SOIL,"A RARE, COMPLETE ANCIENT ROMAN BURIAL SITE WAS DISCOVERED NEAR THE DUTCH VILLAGE OF BOCHOLTZ. IN ADDITION TO MANY PRESERVED GRAVE OFFERINGS, THERE WERE COUNTLESS FRAGMENTS OF DETERIORATED GLASS OBJECTS STILL BURIED IN THE GROUND. THIS GLASS WAS IN VERY POOR CONDITION, HOWEVER, AND THERE WAS NO POSSIBILITY OF EXCAVATING IT DIRECTLY. INSTEAD, ARCHEOLOGISTS WORKING AT THE SITE DECIDED TO DIG UP BLOCKS OF SOIL CONTAINING THE GLASS FRAGMENTS. HIGH-RESOLUTION SPIRAL COMPUTED TOMOGRAPHY (CT) WITH MULTIPLANAR REFORMATION, SHADED-SURFACE-DISPLAY RENDERING, AND VOLUME RENDERING WAS USED TO OBTAIN DETAILED INFORMATION ABOUT THE POSITION, NUMBER, AND FORM OF THE DETERIORATED GLASS FRAGMENTS. CT-GUIDED REMOVAL OF THE SOIL MADE IT POSSIBLE TO RESTORE SOME OF THE OBJECTS EXCAVATED FROM THE BLOCKS. IN FIVE OF THE 14 EXCAVATED OBJECTS, A CORRECT ISINGS CLASSIFICATION COULD BE MADE BASED ON THE CT FINDINGS. IN ADDITION, CT WAS VERY IMPORTANT FOR THE RECONSTRUCTION OF THE LAYOUT OF THE BURIAL CHAMBER, THE COMPILATION OF A LIST OF GRAVE CONTENTS, AND THE POSITIONING OF THESE CONTENTS WITHIN THE CHAMBER.",NA,NA,RADIOGRAPHICS,"JANSEN, RJ##POULUS, M##KOTTMAN, J##DE GROOT, T##HUISMAN, DJ##STOKER, J","UNIV AMSTERDAM, ACAD MED CTR, DEPT RADIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. NATL SERV ARCHAEOL HERITAGE, AMERSFOORT, NETHERLANDS.","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","DE GROOT T., 2006, RAPPORTAGE ARCHEOLOG, V127##ISINGS C, 1962, ANN 2 C JOURN INT VE, P69##ISINGS C, 1971, ARCHAEOLOGICA TRAIEC, V9##ISINGS C., 1957, ROMAN GLASS DATED FI##VANDENHURK LJ, 1986, TUMULI ROMAN PERIOD",14,2020-11-20,NA
J,WOS:000241519400009,2006,DETECTION OF SIMULATED NODULES ON CLINICAL RADIOGRAPHS: DOSE REDUCTION AT DIGITAL POSTEROANTERIOR CHEST RADIOGRAPHY,"PURPOSE: TO DETERMINE TO WHAT EXTENT DOSE REDUCTION RESULTS IN DECREASED DETECTION OF SIMULATED NODULES ON PATIENT DIGITAL POSTEROANTERIOR (PA) CHEST RADIOGRAPHS. MATERIALS AND METHODS: RAW DATA FROM 20 CLINICAL DIGITAL PA CHEST IMAGES THAT WERE REPORTED AS HAVING NORMAL FINDINGS AND THAT WERE OBTAINED WITH A SLOT-SCAN CHARGE-COUPLED DEVICE SYSTEM WERE USED. FOR RESEARCH PROTOCOL THAT CONCERNS DATA WITH PATIENT IDENTITIES CONCEALED, INSTITUTIONAL REVIEW BOARD APPROVAL IS NOT REQUIRED. ONE HUNDRED TWENTY NODULES VARYING IN SIZE AND SIGNAL INTENSITY WERE DIGITALLY SIMULATED AND ADDED TO THE CHEST IMAGES. HARD COPIES WERE PRINTED TO REPRESENT A 100% DOSE AND, BY ADDING NOISE, TO REPRESENT SIMULATED PATIENT DOSES OF 50%, 25%, AND 12%. FOUR RADIOLOGISTS REVIEWED IMAGES. EACH LESION WAS REGISTERED AS ""DETECTED"" OR ""NOT DETECTED."" A SEMIPARAMETRIC LOGISTIC REGRESSION MODEL WAS USED FOR STATISTICAL ANALYSIS. RESULTS: THE DECREASE IN RADIATION DOSE FROM 100% TO 50%, 25%, OR 12% HAD NO EFFECT ON LESION DETECTION IN THE LUNGS. THE DECREASE IN RADIATION DOSE HAD AN EFFECT ON LESION DETECTION IN THE MEDIASTINUM, AS PROBABILITIES DETERIORATED FROM THE 100% DOSE TO THE 50%, 25%, AND 12% DOSE WITH EACH STEP. PROBABILITIES OF SMALLER DETECTION RATES WHEN COMPARED WITH THAT OF THE REFERENCE CATEGORY (100% DOSE) WERE 0.97 (95% CONFIDENCE INTERVAL [CI]: -0.86, 0.012) FOR THE 50% DOSE, 1 (CI: -0.59, -0.61) FOR THE 25% DOSE, AND 1 (CI: -2.41, -1.22) FOR THE 12% DOSE. CIS FOR THE EFFECTS WERE ON THE LOG(ODDS). DETECTION PROBABILITY DECREASED WITH SMALLER AND LOWER SIGNAL INTENSITY LESIONS. CONCLUSION: AT CLINICAL DIGITAL RADIOGRAPHY, DOSE REDUCTION RESULTED IN DECREASED OBSERVER DETECTION OF SIMULATED NODULES IN THE MEDIASTINUM BUT NOT IN THE LUNGS.",FLAT-PANEL DETECTOR; SCREEN-FILM RADIOGRAPHY; COUPLED-DEVICE RADIOGRAPHY; SUBTLE LUNG NODULES; AMORPHOUS-SILICON; IMAGE QUALITY; STORAGE PHOSPHOR; CONVENTIONAL RADIOGRAPHY; DIAGNOSTIC PERFORMANCE; SELENIUM,NA,RADIOLOGY,"KROFT, LJM##VELDKAMP, WJH##MERTENS, BJA##VAN DELFT, JPA##GELEIJNS, J","LEIDEN UNIV, MED CTR, DEPT RADIOL, NL-2333 ZA LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT MED STAT, NL-2333 ZA LEIDEN, NETHERLANDS.","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","BACHER K, 2003, AM J ROENTGENOL, V181, P923, DOI 10.2214/AJR.181.4.1810923##BATH M, 2005, RADIAT PROT DOSIM, V114, P85, DOI 10.1093/RPD/NCH575##BERNHARDT TM, 1999, RADIOLOGY, V213, P445, DOI 10.1148/RADIOLOGY.213.2.R99NV20445##BRAKE GMT, 1999, IEEE T MED IMAGING, V18, P628, DOI 10.1109/42.790462##FINK C, 2002, AM J ROENTGENOL, V178, P481, DOI 10.2214/AJR.178.2.1780481##GANTEN M, 2003, AM J ROENTGENOL, V181, P171, DOI 10.2214/AJR.181.1.1810171##GARMER M, 2000, AM J ROENTGENOL, V174, P75, DOI 10.2214/AJR.174.1.1740075##HAKANSSON M, 2005, RADIAT PROT DOSIM, V114, P114, DOI 10.1093/RPD/NCH574##KROFT LJM, 2005, AM J ROENTGENOL, V185, P339, DOI 10.2214/AJR.185.2.01850339##KROFT LJM, 2004, RADIOLOGY, V231, P156, DOI 10.1148/RADIOL.2311030206##METZ S, 2005, RADIOLOGY, V234, P776, DOI 10.1148/RADIOL.2343031805##PEP MS, 2003, OXFORD STAT SCI SERI, V3, P66##RAPP-BERNHARDT U, 2003, RADIOLOGY, V227, P484, DOI 10.1148/RADIOL.2272010839##SAMEI E, 2004, MED PHYS, V31, P2687, DOI 10.1118/1.1783531##SAMEI E, 2003, RADIOLOGY, V228, P76, DOI 10.1148/RADIOL.2273020509##SAMEI E, 1999, RADIOLOGY, V213, P727, DOI 10.1148/RADIOLOGY.213.3.R99DC19727##SCHAEFERPROKOP CM, 1996, RADIOLOGY, V201, P45, DOI 10.1148/RADIOLOGY.201.1.8816519##STROTZER M, 1998, INVEST RADIOL, V33, P98, DOI 10.1097/00004424-199802000-00007##STROTZER M, 2002, AM J ROENTGENOL, V178, P169, DOI 10.2214/AJR.178.1.1780169##VAN HEESEWIJK HPM, 2001, INVEST RADIOL, V36, P455, DOI 10.1097/00004424-200108000-00004##VANHEESEWIJK HPM, 1996, AM J ROENTGENOL, V167, P403, DOI 10.2214/AJR.167.2.8686616##VELDKAMP WJ, 2005, BIOMED TECH BERL S, V50, P425##VELDKAMP WJH, 2005, RADIOLOGY, V235, P857, DOI 10.1148/RADIOL.2353031919",13,2020-11-20,NA
J,WOS:000241519400016,2006,PROSTATE CANCER LOCALIZATION WITH DYNAMIC CONTRAST-ENHANCED MR IMAGING AND PROTON MR SPECTROSCOPIC IMAGING,"PURPOSE: TO PROSPECTIVELY DETERMINE THE ACCURACIES OF T2-WEIGHTED MAGNETIC RESONANCE (MR) IMAGING, DYNAMIC CONTRAST MATERIAL-ENHANCED MR IMAGING, AND QUANTITATIVE THREE-DIMENSIONAL (3D) PROTON MR SPECTROSCOPIC IMAGING OF THE ENTIRE PROSTATE FOR PROSTATE CANCER LOCALIZATION, WITH WHOLE-MOUNT HISTOPATHOLOGIC SECTION FINDINGS AS THE REFERENCE STANDARD. MATERIALS AND METHODS: THIS STUDY WAS APPROVED BY THE INSTITUTIONAL REVIEW BOARD, AND INFORMED CONSENT WAS OBTAINED FROM ALL PATIENTS. THIRTY-FOUR CONSECUTIVE MEN WITH A MEAN AGE OF 60 YEARS AND A MEAN PROSTATE-SPECIFIC ANTIGEN LEVEL OF 8 NG/ML WERE EXAMINED. THE MEDIAN BIOPSY GLEASON SCORE WAS 6. T2-WEIGHTED MR IMAGING, DYNAMIC CONTRAST-ENHANCED MR IMAGING, AND 3D MR SPECTROSCOPIC IMAGING WERE PERFORMED, AND ON THE BASIS OF THE IMAGE DATA, TWO READERS WITH DIFFERENT LEVELS OF EXPERIENCE RECORDED THE LOCATION OF THE SUSPICIOUS PERIPHERAL ZONE AND CENTRAL GLAND TUMOR NODULES ON EACH OF 14 STANDARDIZED REGIONS OF INTEREST (ROIS) IN THE PROSTATE. THE DEGREE OF DIAGNOSTIC CONFIDENCE FOR EACH ROI WAS RECORDED ON A FIVE-POINT SCALE. LOCALIZATION ACCURACY AND ROI-BASED RECEIVER OPERATING CHARACTERISTIC (ROC) CURVES WERE CALCULATED. RESULTS: FOR BOTH READERS, AREAS UNDER THE ROC CURVE FOR T2-WEIGHTED MR, DYNAMIC CONTRAST-ENHANCED MR, AND 3D MR SPECTROSCOPIC IMAGING WERE 0.68, 0.91, AND 0.80, RESPECTIVELY. READER ACCURACY IN TUMOR LOCALIZATION WITH DYNAMIC CONTRAST-ENHANCED IMAGING WAS SIGNIFICANTLY BETTER THAN THAT WITH QUANTITATIVE SPECTROSCOPIC IMAGING (P < .01). READER ACCURACY IN TUMOR LOCALIZATION WITH BOTH DYNAMIC CONTRAST-ENHANCED IMAGING AND SPECTROSCOPIC IMAGING WAS SIGNIFICANTLY BETTER THAN THAT WITH T2-WEIGHTED IMAGING (P < .01). CONCLUSION: COMPARED WITH USE OF T2-WEIGHTED MR IMAGING, USE OF DYNAMIC CONTRAST-ENHANCED MR IMAGING AND 3D MR SPECTROSCOPIC IMAGING FACILITATED SIGNIFICANTLY IMPROVED ACCURACY IN PROSTATE CANCER LOCALIZATION.",ENDORECTAL MR; RADICAL PROSTATECTOMY; OBSERVER-PERFORMANCE; DIAGNOSTIC-ACCURACY; INITIAL-EXPERIENCE; RADIATION-THERAPY; TUMOR VOLUME; BIOPSY; TISSUE; PARAMETERS,NA,RADIOLOGY,"FUTTERER, JJ##HEIJMINK, SWTPJ##SCHEENEN, TWJ##VELTMAN, J##HUISMAN, HJ##VOS, P##HULSBERGEN-VAN DE KAA, CA##WITJES, JA##KRABBE, PFM##HEERSCHAP, A##BARENTSZ, JO","RADBOUD UNIV NIJMEGEN MED CTR, DEPT RADIOL, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, DEPT PATHOL, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, DEPT UROL, NL-6500 HB NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, DEPT MED TECHNOL ASSESSMENT, NL-6500 HB NIJMEGEN, NETHERLANDS.","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","AUGUSTIN H, 2003, EUR UROL, V43, P455, DOI 10.1016/S0302-2838(03)00139-8##BOSSUYT PM, 2003, RADIOLOGY, V226, P24, DOI 10.1148/RADIOL.2261021292##BOTTOMLEY PA, 1987, ANN NY ACAD SCI, V508, P333, DOI 10.1111/J.1749-6632.1987.TB32915.X##BUCKLEY DL, 2004, RADIOLOGY, V233, P709, DOI 10.1148/RADIOL.2333032098##CHAKRABORTY DP, 2004, MED PHYS, V31, P2313, DOI 10.1118/1.1769352##CHAKRABORTY DP, 1990, RADIOLOGY, V174, P873, DOI 10.1148/RADIOLOGY.174.3.2305073##CHEN ME, 2000, CANCER, V89, P1800, DOI 10.1002/1097-0142(20001015)89:8<1800::AID-CNCR21>3.0.CO;2-D##COAKLEY FV, 2002, RADIOLOGY, V223, P91, DOI 10.1148/RADIOL.2231010575##DHINGSA R, 2004, RADIOLOGY, V230, P215, DOI 10.1148/RADIOL.2301021562##DODD LE, 2004, ACAD RADIOL, V11, P462, DOI 10.1016/S1076-6332(03)00814-6##DONAHUE KM, 1995, MAGN RESON MED, V34, P423, DOI 10.1002/MRM.1910340320##ELLIS WJ, 1994, J UROLOGY, V152, P2304, DOI 10.1016/S0022-5347(17)31663-4##ENGELBRECHT MR, 2003, RADIOLOGY, V229, P248, DOI 10.1148/RADIOL.2291020200##HEERSCHAP A, 1997, ANTICANCER RES, V17, P1455##HITTMAIR K, 1994, MAGNET RESON MED, V31, P567, DOI 10.1002/MRM.1910310516##HUISMAN HJ, 2001, J MAGN RESON IMAGING, V13, P607, DOI 10.1002/JMRI.1085##IHAKA R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.1080/10618600.1996.10474713##JAGER GJ, 1996, AM J ROENTGENOL, V166, P845, DOI 10.2214/AJR.166.4.8610561##JAGER GJ, 1997, RADIOLOGY, V203, P645, DOI 10.1148/RADIOLOGY.203.3.9169683##JUNG JA, 2004, RADIOLOGY, V233, P701, DOI 10.1148/RADIOL.2333030672##KIESSLING F, 2003, RADIOLOGE, V43, P474, DOI 10.1007/S00117-003-0911-X##KOVAR DA, 1998, J MAGN RESON IMAGING, V8, P1126, DOI 10.1002/JMRI.1880080519##KURHANEWICZ J, 1996, RADIOLOGY, V198, P795, DOI 10.1148/RADIOLOGY.198.3.8628874##MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001##OBUCHOWSKI NA, 2000, ACAD RADIOL, V7, P516, DOI 10.1016/S1076-6332(00)80324-4##OGURA K, 2001, UROLOGY, V57, P721, DOI 10.1016/S0090-4295(00)01072-4##PADHANI AR, 2000, CLIN RADIOL, V55, P99, DOI 10.1053/CRAD.1999.0327##PONCHIETTI R, 1999, EUR UROL, V35, P32, DOI 10.1159/000019816##PUCAR D, 2005, RADIOLOGY, V236, P545, DOI 10.1148/RADIOL.2362040739##QAYYUM A, 2004, AM J ROENTGENOL, V183, P1079, DOI 10.2214/AJR.183.4.1831079##RUTTER CM, 2000, ACAD RADIOL, V7, P413, DOI 10.1016/S1076-6332(00)80381-5##SALO JO, 1987, PROSTATE, V10, P1, DOI 10.1002/PROS.2990100103##SALOMON L, 1999, EUR UROL, V35, P289, DOI 10.1159/000019863##SCHEENEN TW, 2005, P 13 M INT SO MAGN R##SCHEENEN TWJ, 2004, MAGN RESON MED, V52, P80, DOI 10.1002/MRM.20103##SCHEIDLER J, 1999, RADIOLOGY, V213, P473, DOI 10.1148/RADIOLOGY.213.2.R99NV23473##SOBIN L, 1997, TNM CLASSIFICATION M##STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L##TOFTS PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S##VAN DORSTEN FA, 2004, J MAGN RESON IMAGING, V20, P279, DOI 10.1002/JMRI.20113##WEFER AE, 2000, J UROLOGY, V164, P400, DOI 10.1016/S0022-5347(05)67370-3##WHITE S, 1995, RADIOLOGY, V195, P385, DOI 10.1148/RADIOLOGY.195.2.7724756##ZAKIAN KL, 2005, RADIOLOGY, V234, P804, DOI 10.1148/RADIOL.2343040363##ZAKIAN KL, 2003, RADIOLOGY, V229, P241, DOI 10.1148/RADIOL.2291021383##ZELEFSKY MJ, 2002, SEMIN RADIAT ONCOL, V12, P229, DOI 10.1053/SRAO.2002.00000##ZHENG B, 2005, MED PHYS, V32, P1031, DOI 10.1118/1.1884766",392,2020-11-20,NA
J,WOS:000241519400023,2006,CHILDHOOD WHITE MATTER DISORDERS: QUANTITATIVE MR IMAGING AND SPECTROSCOPY,"PURPOSE: TO PROSPECTIVELY INVESTIGATE WHETHER QUANTITATIVE MAGNETIC RESONANCE (MR) PARAMETERS, INCLUDING MAGNETIZATION TRANSFER RATIO (MTR), APPARENT DIFFUSION COEFFICIENT (ADC), FRACTIONAL ANISOTROPY (FA), AND MR SPECTROSCOPIC METABOLITE CONCENTRATIONS, ALLOW FOR DISCRIMINATION BETWEEN DIFFERENT TYPES OF PATHOLOGIC CONDITIONS THAT UNDERLIE SIGNAL INTENSITY ABNORMALITIES IN WHITE MATTER. MATERIALS AND METHODS: INSTITUTIONAL REVIEW BOARD APPROVAL AND INFORMED CONSENT WERE OBTAINED. FORTY-ONE PATIENTS (19 MALE, 22 FEMALE; MEAN AGE, 15.4 YEARS) AND 41 CONTROL SUBJECTS (25 MALE, 16 FEMALE; MEAN AGE, 11.3 YEARS) WERE INCLUDED. TWELVE PATIENTS HAD A HYPOMYELINATING DISORDER; 14, A DEMYELINATING DISORDER; FIVE, A DISORDER CHARACTERIZED BY MYELIN VACUOLATION; AND 10, A DISORDER CHARACTERIZED BY CYSTIC DEGENERATION. REGIONS OF INTEREST WERE SELECTED WITHIN THE PARIETAL WHITE MATTER AND WERE TRANSFERRED TO THE CORRESPONDING SECTIONS OF THE GENERATED ADC, FA, AND MTR MAPS TO EXTRACT QUANTITATIVE MEASUREMENTS. LINEAR DISCRIMINANT ANALYSIS AND UNIVARIATE ANALYSIS OF COVARIANCE WERE USED FOR STATISTICAL EVALUATION. RESULTS: LINEAR DISCRIMINANT ANALYSIS SHOWED THAT 95% OF PATIENTS WERE CORRECTLY CLASSIFIED BY USING TOTAL CREATINE, CHOLINECONTAINING COMPOUNDS, MYO-INOSITOL, MTR, AND ADC. IN THE HYPOMYELINATION GROUP, ALL MR PARAMETERS WERE CLOSE TO NORMAL, WITH THE EXCEPTION OF ELEVATED TOTAL CREATINE (P <.03) AND MYO-INOSITOL (P <.001) LEVELS AND DECREASED MTR VALUES (P <.001). IN THE DEMYELINATION GROUP, THE LEVELS OF CHOLINE-CONTAINING COMPOUNDS (P <.02) AND MYOINOSITOL (P <.001) WERE HIGHLY ELEVATED. IN THE MYELIN VACUOLATION AND CYSTIC DEGENERATION GROUPS, HIGH ADC VALUES (P <.001) AND VARIABLE DECREASES IN ALL MR SPECTROSCOPIC METABOLITES WERE SEEN. MTR WAS SIGNIFICANTLY REDUCED (P <.001) IN THE CYSTIC DEGENERATION GROUP. CONCLUSION: QUANTITATIVE MR TECHNIQUES CAN BE USED TO DISCRIMINATE BETWEEN DIFFERENT TYPES OF WHITE MATTER DISORDERS AND TO CLASSIFY WHITE MATTER LESIONS OF UNKNOWN ORIGIN WITH RESPECT TO UNDERLYING PATHOLOGIC CONDITIONS. (C) RSNA, 2006",MAGNETIC-RESONANCE-SPECTROSCOPY; PELIZAEUS-MERZBACHER-DISEASE; DIFFUSION TENSOR MRI; MEGALENCEPHALIC LEUKOENCEPHALOPATHY; METACHROMATIC LEUKODYSTROPHY; METABOLIC ABNORMALITIES; SUBCORTICAL CYSTS; BRAIN-METABOLITES; KRABBE-DISEASE; PROTON MRS,NA,RADIOLOGY,"VAN DER VOORN, JP##POUWELS, PJW##HART, AAM##SERRARENS, J##WILLEMSEN, MAAP##KREMER, HPH##BARKHOF, F##VAN DER KNAAP, MS","VRIJE UNIV AMSTERDAM, MED CTR, DEPT CHILD NEUROL, NL-1007 MB AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, DEPT PHYS & MED TECHNOL, NL-1007 MB AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, DEPT RADIOL, NL-1007 MB AMSTERDAM, NETHERLANDS. UNIV NIJMEGEN, MED CTR, DEPT CHILD NEUROL, NIJMEGEN, NETHERLANDS. UNIV NIJMEGEN, MED CTR, DEPT NEUROL, NIJMEGEN, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, NL-1105 AZ AMSTERDAM, NETHERLANDS.","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","BARKER PB, 2004, J CHILD NEUROL, V19, P559, DOI 10.1177/088307380401900801##BROCKMANN K, 2003, NEUROLOGY, V60, P819, DOI 10.1212/01.WNL.0000049469.29011.E9##BROCKMANN K, 2003, NEURORADIOLOGY, V45, P137, DOI 10.1007/S00234-002-0931-7##DE STEFANO N, 2001, J NEUROL, V248, P403, DOI 10.1007/S004150170182##ENGELBRECHT V, 2002, RADIOLOGY, V222, P410, DOI 10.1148/RADIOL.2222010492##ERNST T, 1993, J MAGN RESON SER B, V102, P1, DOI 10.1006/JMRB.1993.1055##GUO AC, 2001, RADIOLOGY, V218, P809, DOI 10.1148/RADIOLOGY.218.3.R01MR14809##HORSFIELD MA, 2002, NMR BIOMED, V15, P570, DOI 10.1002/NBM.787##JENNRICH R.I., 1977, STAT METHODS DIGITAL##JONES DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H##KRUSE B, 1993, J NEUROL, V241, P68, DOI 10.1007/BF00869766##MCLACHLAN G., 1992, DISCRIMINANT ANAL ST##MILLER DH, 1990, DEV MED CHILD NEUROL, V32, P97##OGUZ KK, 2004, NEUROPEDIATRICS, V35, P279, DOI 10.1055/S-2004-821301##ONO J, 1994, BRAIN DEV-JPN, V16, P219, DOI 10.1016/0387-7604(94)90073-6##PIZZINI F, 2003, AM J NEURORADIOL, V24, P1683##PLECKO B, 2003, NEUROPEDIATRICS, V34, P127##POUWELS PJW, 1999, PEDIATR RES, V46, P474, DOI 10.1203/00006450-199910000-00019##PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/MRM.1910300604##SIJENS PE, 2005, EUR RADIOL, V15, P2377, DOI 10.1007/S00330-005-2783-0##SPALICE A, 2000, PEDIATR RADIOL, V30, P171, DOI 10.1007/S002470050039##SYMMS M, 2004, J NEUROL NEUROSUR PS, V75, P1235, DOI 10.1136/JNNP.2003.032714##VAN DER KNAAP MS, 2002, AM J NEURORADIOL, V23, P1466##VAN DER KNAAP MS, 2001, DEV MED CHILD NEUROL, V43, P705, DOI 10.1017/S001216220100127X##VAN WAESBERGHE JHTM, 1999, ANN NEUROL, V46, P747##VANDERKNAAP MS, 1997, NEUROLOGY, V48, P845, DOI 10.1212/WNL.48.4.845##VENABLES WN, 2002, MODERN APPL STAT##ZARIFI MK, 2001, J CHILD NEUROL, V16, P522, DOI 10.1177/088307380101600713",61,2020-11-20,NA
J,WOS:000241519400026,2006,FEMALE PELVIS: MR IMAGING AT 3.0 T WITH SENSITIVITY ENCODING AND FLIP-ANGLE SWEEP TECHNIQUE,"THIS STUDY HAD INSTITUTIONAL REVIEW BOARD APPROVAL; ALL 33 PATIENTS (MEAN AGE, 47 YEARS +/- 16 [ STANDARD DEVIATION]) GAVE INFORMED CONSENT. THE AIM WAS TO PROSPECTIVELY EVALUATE THE DIAGNOSTIC IMAGE QUALITY YIELDED BY A 3.0-T T2-WEIGHTED TURBO SPIN-ECHO MAGNETIC RESONANCE IMAGING SEQUENCE WITH A VERY SHORT IMAGING TIME VERSUS THAT YIELDED BY A STANDARD 3.0- T SEQUENCE AT IMAGING OF THE FEMALE PELVIS. SIGNAL-TO-NOISE RATIO AND DELINEATION OF GYNECOLOGIC DISORDERS WERE APPROXIMATELY EQUAL BETWEEN THE TWO SEQUENCES. THE MAJORITY OF TISSUE CONTRASTS WERE COMPARABLE, BUT CONTRAST BETWEEN FLUID AND MUSCLE WAS SIGNIFICANTLY HIGHER AND MOTION ARTIFACTS WERE REDUCED (P=.001 FOR BOTH) WITH THE SHORT IMAGING TIME SEQUENCE. THE FAST SEQUENCE MAINTAINED OR IMPROVED IMAGE QUALITY AND THUS SEEMS TO BE ADVANTAGEOUS FOR UNCOOPERATIVE PATIENTS. (C) RSNA, 2006",MAGNETIC-RESONANCE ANGIOGRAPHY; CONTRAST; ARTERIES; BRAIN; TESLA,NA,RADIOLOGY,"MORAKKABATI-SPITZ, N##SCHILD, HH##KUHL, CK##LUTTERBEY, G##VON FALKENHAUSEN, M##TRABER, F##GIESEKE, J","UNIV BONN, DEPT RADIOL, D-53105 BONN, GERMANY. PHILIPS MED SYST, BEST, NETHERLANDS.","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","AL-KWIFI O, 2002, MAGN RESON IMAGING, V20, P181, DOI 10.1016/S0730-725X(02)00486-1##BRIELLMANN RS, 2003, EPILEPTIC DISORD, V5, P3##FELMLEE JP, 2002, P 8 M INT SOC MAGN R##GIESEKE J, 2004, P 12 M INT SOC MAGN, P74##GIESEKE J, 2005, P 13 M INT SOC MAGN, P459##GIESEKE J, 2004, NEURORADIOLOGY, V46, P122##GILLARD JH, 2001, BRIT J RADIOL, V74, P642, DOI 10.1259/BJR.74.883.740642##HENNIG J, 2003, MAGN RESON MED, V49, P527, DOI 10.1002/MRM.10391##HENNIG J, 2001, MAGNET RESON MED, V46, P6, DOI 10.1002/MRM.1153##KUHL CK, 2005, RADIOLOGY, V234, P517, DOI 10.1148/RADIOL.2342031626##LIN C, 2001, P 9 ANN M ISMRM GLAS, V11, P[21, 1391]##MORAKKABATI-SPITZ N, 2005, EUR RADIOL, V15, P639, DOI 10.1007/S00330-004-2589-5##NAKAI T, 2001, J COMPUT ASSIST TOMO, V25, P436, DOI 10.1097/00004728-200105000-00018##NOBAUER-HUHMANN IM, 2002, INVEST RADIOL, V37, P114, DOI 10.1097/00004424-200203000-00003##THOMAS SD, 2002, J MAGN RESON IMAGING, V15, P479, DOI 10.1002/JMRI.10085##VONFALKENHAUSEN M, 2004, P 1I M INT SOC MAGN, P904##WANSAPURA JP, 1999, JMRI-J MAGN RESON IM, V9, P531, DOI 10.1002/(SICI)1522-2586(199904)9:4<531::AID-JMRI4>3.0.CO;2-L##WILLINEK WA, 2003, RADIOLOGY, V229, P913, DOI 10.1148/RADIOL.2293020782##YONEOKA Y, 2002, J NEUROIMAGING, V12, P231, DOI 10.1177/10528402012003004",25,2020-11-20,NA
J,WOS:000241519400034,2006,VESSEL WALL CALCIFICATIONS AT MULTI-DETECTOR ROW CT ANGIOGRAPHY IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: EFFECT ON CLINICAL UTILITY AND CLINICAL PREDICTORS,"PURPOSE: TO EVALUATE RETROSPECTIVELY THE EFFECT OF VESSEL WALL CALCIFICATIONS ON THE CLINICAL UTILITY OF MULTI-DETECTOR ROW COMPUTED TOMOGRAPHIC (CT) ANGIOGRAPHY PERFORMED IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE AND TO IDENTIFY CLINICAL PREDICTORS FOR THE PRESENCE OF VESSEL WALL CALCIFICATIONS. MATERIALS AND METHODS: THE STUDY WAS APPROVED BY THE HOSPITAL INSTITUTIONAL REVIEW BOARD, AND INFORMED CONSENT WAS OBTAINED FROM ALL PATIENTS. FOR THIS STUDY THE AUTHORS INCLUDED PATIENTS FROM TWO RANDOMIZED CONTROLLED TRIALS THAT MEASURED THE COSTS AND EFFECTS OF DIAGNOSTIC IMAGING IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE. ALL PATIENTS UNDERWENT CT ANGIOGRAPHY AND WERE FOLLOWED UP FOR 6 MONTHS. CLINICAL UTILITY WAS MEASURED ON THE BASIS OF THERAPEUTIC CONFIDENCE (RATED ON A 10-POINT SCALE) IN THE RESULTS OF INITIAL CT ANGIOGRAPHY AND THE NEED FOR ADDITIONAL VASCULAR IMAGING. UNIVARIABLE AND MULTIVARIABLE LOGISTIC AND LINEAR REGRESSION ANALYSIS AND THE AREA UNDER THE RECEIVER OPERATING CHARACTERISTIC CURVE WERE USED TO EVALUATE THE EFFECT OF VESSEL WALL CALCIFICATIONS ON THE CLINICAL UTILITY OF CT ANGIOGRAPHY AND THE USE OF PATIENT CHARACTERISTICS TO PREDICT THE NUMBER OF CALCIFIED SEGMENTS AT CT ANGIOGRAPHY. RESULTS: A TOTAL OF 145 PATIENTS WERE INCLUDED (MEAN AGE, 64 YEARS; 70% MEN). THE AUTHORS FOUND THAT THE NUMBER OF CALCIFIED SEGMENTS WAS A SIGNIFICANT PREDICTOR OF THE NEED FOR ADDITIONAL IMAGING (P = .001) AND OF THE CONFIDENCE SCORES (P = .001). THE NUMBER OF CALCIFIED SEGMENTS DISCRIMINATED BETWEEN PATIENTS WHO REQUIRED ADDITIONAL IMAGING AFTER CT ANGIOGRAPHY AND THOSE WHO DID NOT (AREA UNDER THE RECEIVER OPERATING CHARACTERISTIC CURVE, 0.66; 95% CONFIDENCE INTERVAL: 0.54, 0.77). AGE, DIABETES MELLITUS, AND CARDIAC DISEASE WERE SIGNIFICANT PREDICTORS OF THE NUMBER OF CALCIFIED SEGMENTS IN BOTH THE UNIVARIABLE AND MULTIVARIABLE ANALYSES (P < .05). CONCLUSION: VESSEL WALL CALCIFICATIONS DECREASE THE CLINICAL UTILITY OF CT ANGIOGRAPHY IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE. DIABETES MELLITUS, CARDIAC DISEASE, AND ELDERLY AGE ( OLDER THAN 84 YEARS) ARE INDEPENDENTLY PREDICTIVE FOR THE PRESENCE OF VESSEL WALL CALCIFICATIONS. (C) RSNA, 2006.",DIGITAL-SUBTRACTION-ANGIOGRAPHY; RANDOMIZED CONTROLLED-TRIAL; OCCLUSIVE DISEASE; MR-ANGIOGRAPHY; INTEROBSERVER AGREEMENT; LOWER-EXTREMITIES; SPIRAL CT; AORTA,NA,RADIOLOGY,"OUWENDIJK, R##KOCK, MCJM##VAN DIJK, LC##VAN SAMBEEK, MRHM##STIJNEN, T##HUNINK, MGM","ERASMUS MC ROTTERDAM, PROGRAM ASSESSMENT RADIOL TECHNOL, NL-3015 GE ROTTERDAM, NETHERLANDS. ERASMUS MC ROTTERDAM, DEPT RADIOL, NL-3015 GE ROTTERDAM, NETHERLANDS. ERASMUS MC ROTTERDAM, DEPT EPIDEMIOL & BIOSTAT, NL-3015 GE ROTTERDAM, NETHERLANDS. ERASMUS MC ROTTERDAM, DEPT VASC SURG, NL-3015 GE ROTTERDAM, NETHERLANDS. HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA.","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ADRAGAO T, 2004, NEPHROL DIAL TRANSPL, V19, P1480, DOI 10.1093/NDT/GFH217##ADRIAENSEN MEAPM, 2004, RADIOLOGY, V233, P385, DOI 10.1148/RADIOL.2331031595##CATALANO C, 2004, RADIOLOGY, V231, P555, DOI 10.1148/RADIOL.2312020920##KOCK MCJM, 2005, RADIOLOGY, V237, P727, DOI 10.1148/RADIOL.2372040616##MARTIN ML, 2003, AM J ROENTGENOL, V180, P1085, DOI 10.2214/AJR.180.4.1801085##OFER A, 2003, AM J ROENTGENOL, V180, P719, DOI 10.2214/AJR.180.3.1800719##OTA H, 2004, AM J ROENTGENOL, V182, P201, DOI 10.2214/AJR.182.1.1820201##OUWENDIJK R, 2005, AM J ROENTGENOL, V185, P1261, DOI 10.2214/AJR.04.1296##OUWENDIJK R, 2005, RADIOLOGY, V236, P1094, DOI 10.1148/RADIOL.2363041140##PORTUGALLER HR, 2004, EUR RADIOL, V14, P1681, DOI 10.1007/S00330-004-2289-1##ROMANO M, 2004, EUR J RADIOL, V50, P303, DOI 10.1016/S0720-048X(03)00118-9##RUBIN GD, 2000, RADIOLOGY, V215, P670, DOI 10.1148/RADIOLOGY.215.3.R00JN18670##RUBIN GD, 1994, RADIOLOGY, V190, P181, DOI 10.1148/RADIOLOGY.190.1.8259402##TINS B, 2001, BRIT J RADIOL, V74, P219, DOI 10.1259/BJR.74.879.740219##WILLMANN JK, 2003, RADIOLOGY, V226, P798, DOI 10.1148/RADIOL.2271020014##YAMAMOTO H, 2002, INT J CARDIOVAS IMAG, V18, P391, DOI 10.1023/A:1016051606758",59,2020-11-20,NA
J,WOS:000242694800005,2006,RELATIONSHIP BETWEEN CLINICAL FACTORS AND THE INCIDENCE OF TOXICITY AFTER INTRA-ARTERIAL CHEMORADIATION FOR HEAD AND NECK CANCER,"BACKGROUND AND PURPOSE: CONCOMITANT CHEMORADIATION IS MORE AND MORE USED FOR ADVANCED HEAD AND NECK CANCER. IT IMPROVES LOCAL CONTROL AND SURVIVAL COMPARED TO RADIOTHERAPY ALONE, BUT GOES ALONG WITH SERIOUS TOXICITY. THIS STUDY WAS SET UP TO DETERMINE THE RELATIONSHIP BETWEEN PATIENT-, TUMOUR- AND TREATMENT-RELATED FACTORS AND ACUTE/LATE TOXICITY AFTER CONCOMITANT CHEMORADIATION. PATIENTS AND METHODS: ONE HUNDRED AND TWENTY-FIVE CONSECUTIVE PATIENTS WITH NEWLY DIAGNOSED INOPERABLE STAGE III AND IV HEAD AND NECK CANCER WERE ENROLLED FOR INTRA-ARTERIAI CHEMORADIATION. THERE WERE 28 WOMEN (22%) AND 97 MEN (78%) AND THE MEAN AGE WAS 55 YEARS (RANGE 30-80). ONE HUNDRED AND NINE PATIENTS HAD STAGE IV DISEASE (87%), 16 PATIENTS (13%) HAD STAGE III DISEASE. STATISTICAL ANALYSES WERE PERFORMED TO IDENTIFY AN ASSOCIATION BETWEEN FACTORS AND ACUTE/LATE TOXICITY. RESULTS: THERE WERE EIGHT TREATMENT-RELATED DEATHS (6%). SEVERE ACUTE TOXICITY (GRADE 3-4), MAINLY MUCOSITIS AND DYSPHAGIA AS CATEGORIZED BY THE RTOG TOXICITY CRITERIA, WAS RECORDED IN 51% OF THE PATIENTS. LEUCOPENIA (GRADE 3-4) OCCURRED IN 39% AND ASPIRATION PNEUMONIA IN 20% OF PATIENTS. TRACHEOTOMY WAS NECESSARY IN 15 (12%) PATIENTS. NEUROLOGICAL COMPLICATIONS DURING TREATMENT OCCURRED IN 3 (2%) PATIENTS. SEVERE LATE TOXICITY OCCURRED IN 34% OF THE PATIENTS. THE MOST IMPORTANT OF THESE WERE PNEUMONIA (14%), OSTEORADIONECROSIS (9%) AND SWALLOWING PROBLEMS WITH PERMANENT PERCUTANEOUS GASTROSTOMY (20%). STATISTICAL ANALYSIS DID SHOW A SIGNIFICANT ASSOCIATION BETWEEN SITE AND SEVERE ACUTE MUCOSITIS (P = 6.007), SITE AND OSTEORADIONECROSIS (P = 0.014) AND AGE AND XEROSTOMIA (P = 0.004). CONCLUSIONS: CHEMORADIATION IS FREQUENTLY ASSOCIATED WITH SERIOUS TOXICITY. ORAL CAVITY TUMOURS AND OLDER AGE ARE RELATED TO ACUTE MUCOSITIS/OSTEORADIONECROSIS AND XEROSTOMIA, RESPECTIVELY. (C) 2006 PUBLISHED BY ELSEVIER IRELAND LTD.",SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; STAGE OROPHARYNX CARCINOMA; RADIATION-THERAPY; RANDOMIZED-TRIAL; SIMULTANEOUS RADIOCHEMOTHERAPY; CONCOMITANT CHEMOTHERAPY; DOSE CISPLATIN; RADIOTHERAPY; CHEMORADIOTHERAPY,HEAD AND NECK NEOPLASMS; CHEMORADIATION; INTRA-ARTERIAL INFUSIONS; RADPLAT; UNIVARIABLE ANALYSIS; TOXICITY,RADIOTHERAPY AND ONCOLOGY,"VAN DEN BROEK, GB##BALM, AJM##VAN DEN BREKEL, MWM##HAUPTMANN, M##SCHORNAGEL, JH##RASCH, CRN","ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT HEAD & NECK ONCOL & SURG, NL-1066 CX AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT MOL BIOL, NL-1066 CX AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT MED ONCOL, NL-1066 CX AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT RADIAT ONCOL, NL-1066 CX AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT OTORHINOLARYNGOL, NL-1105 AZ AMSTERDAM, NETHERLANDS.","ONCOLOGY; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ONCOLOGY; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ADELSTEIN DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008##ALLAL AS, 1997, ANN ONCOL, V8, P681, DOI 10.1023/A:1008260720076##BALM A J, 1995, FACIAL PLAST SURG, V11, P91, DOI 10.1055/S-2008-1064524##BALM AJM, 2004, HEAD NECK-J SCI SPEC, V26, P485, DOI 10.1002/HED.20006##BARTELINK H, 2002, EUR J CANCER, V38, P667, DOI 10.1016/S0959-8049(01)00425-7##BERNIER J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMOA032641##BRIZEL DM, 1998, NEW ENGL J MED, V338, P1798, DOI 10.1056/NEJM199806183382503##CALAIS G, 1999, J NATL CANCER I, V91, P2081, DOI 10.1093/JNCI/91.24.2081##COOPER JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMOA032646##DENIS F, 2004, J CLIN ONCOL, V22, P69, DOI 10.1200/JCO.2004.08.021##FRANCHIN G, 1995, CANCER-AM CANCER SOC, V75, P1025, DOI 10.1002/1097-0142(19950215)75:4<1025::AID-CNCR2820750419>3.0.CO;2-2##GLASER M G, 1993, CLIN ONCOL (R COLL RADIOL), V5, P286, DOI 10.1016/S0936-6555(05)80902-1##HOMMA A, 2004, CANCER J, V10, P326, DOI 10.1097/00130404-200409000-00010##HOMMA A, 2005, HEAD NECK-J SCI SPEC, V27, P65, DOI 10.1002/HED.20116##JEREMIC B, 1997, RADIOTHER ONCOL, V43, P29, DOI 10.1016/S0167-8140(97)00048-0##MARCIAL VA, 1990, CANCER-AM CANCER SOC, V66, P1861, DOI 10.1002/1097-0142(19901101)66:9<1861::AID-CNCR2820660902>3.0.CO;2-I##ROBBINS KT, 2000, HEAD NECK-J SCI SPEC, V22, P687, DOI 10.1002/1097-0347(200010)22:7<687::AID-HED8>3.0.CO;2-W##ROBBINS KT, 1997, INT J RADIAT ONCOL, V38, P263, DOI 10.1016/S0360-3016(97)00092-8##SOBIN L, 1997, TNM CLASSIFICATION M##TROTTI A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8##VAN DEN BROEK GB, 2004, CANCER-AM CANCER SOC, V101, P1809, DOI 10.1002/CNCR.20556##WENDT TG, 1998, J CLIN ONCOL, V16, P1318, DOI 10.1200/JCO.1998.16.4.1318",22,2020-11-20,NA
J,WOS:000242694800009,2006,DOSIMETRIC PRE-TREATMENT VERIFICATION OF IMRT USING AN EPID; CLINICAL EXPERIENCE,"BACKGROUND AND PURPOSE: IN OUR CLINIC A QA PROGRAM FOR IMRT VERIFICATION, FULLY BASED ON DOSIMETRIC MEASUREMENTS WITH ELECTRONIC PORTAL IMAGING DEVICES (EPID), HAS BEEN RUNNING FOR OVER 3 YEARS. THE PROGRAM INCLUDES A PRE-TREATMENT DOSIMETRIC CHECK OF ALL IMRT FIELDS. DURING A COMPLETE TREATMENT SIMULATION AT THE LINAC, A PORTAL DOSE IMAGE (PDI) IS ACQUIRED WITH THE EPID FOR EACH PATIENT FIELD AND COMPARED WITH A PREDICTED PDI. IN THIS PAPER, THE RESULTS OF THIS PRETREATMENT PROCEDURE ARE ANALYSED, AND INTERCEPTED ERRORS ARE REPORTED. AN AUTOMATED IMAGE ANALYSIS PROCEDURE IS PROPOSED TO LIMIT THE NUMBER OF FIELDS THAT NEED HUMAN INTERVENTION IN PDI COMPARISON. MATERIALS AND METHODS: MOST OF OUR ANALYSES ARE PERFORMED USING THE GAMMA INDEX WITH 3% LOCAL DOSE DIFFERENCE AND 3 MM DISTANCE TO AGREEMENT AS REFERENCE VALUES. SCALAR PARAMETERS ARE DERIVED FROM THE GAMMA VALUES TO SUMMARIZE THE AGREEMENT BETWEEN MEASURED AND PREDICTED 2D PDIS. AREAS WITH ALL PIXELS HAVING GAMMA VALUES LARGER THAN ONE ARE EVALUATED, MAKING DECISIONS BASED ON CLINICALLY RELEVANT CRITERIA MORE STRAIGHTFORWARD. RESULTS: IN 270 PATIENTS, THE PRE-TREATMENT CHECKS REVEALED FOUR CLINICALLY RELEVANT ERRORS. CALCULATION OF STATISTICS FOR A GROUP OF 75 PATIENTS SHOWED THAT THE PATIENT-AVERAGED MEAN GAMMA VALUE INSIDE THE FIELD WAS 0.43 +/- 0.13 (1 SD) AND ONLY 6.1 +/- 6.8% OF PIXELS HAD A GAMMA VALUE LARGER THAN ONE. WITH THE PROPOSED AUTOMATED IMAGE ANALYSIS SCHEME, VISUAL INSPECTION OF IMAGES CAN BE AVOIDED IN 2/3 OF THE CASES. CONCLUSION: EPIDS MAY BE USED FOR HIGH ACCURACY AND HIGH RESOLUTION ROUTINE VERIFICATION OF IMRT FIELDS TO INTERCEPT CLINICALLY RELEVANT DOSIMETRIC ERRORS PRIOR TO THE START OF TREATMENT. FOR THE MAJORITY OF FIELDS, PDI COMPARISON CAN FULLY RELY ON AN AUTOMATED PROCEDURE, AVOIDING EXCESSIVE WORKLOAD. (C) 2006 ELSEVIER IRELAND LTD. ALL RIGHTS RESERVED.",3-DIMENSIONAL DOSE RECONSTRUCTION; QUANTITATIVE-EVALUATION; PORTAL DOSIMETRY; DELIVERY; SYSTEM; BEAMS,QUALITY ASSURANCE; INTENSITY MODULATED RADIOTHERAPY; EPID; PORTAL DOSIMETRY,RADIOTHERAPY AND ONCOLOGY,"VAN ZIJTVELD, M##DIRKX, MLP##DE BOER, HCJ##HEIJMEN, BJM","ERASMUS MC DANIEL DEN HOED CANC CTR, DEPT RADIAT ONCOL, DIV MED PHYS, NL-3705 EA ROTTERDAM, NETHERLANDS.","ONCOLOGY; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ONCOLOGY; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","BUCCIOLINI M, 2004, MED PHYS, V31, P161, DOI 10.1118/1.1631093##BUDGELL GJ, 2005, PHYS MED BIOL, V50, P103, DOI 10.1088/0031-9155/50/1/009##CHILDRESS NL, 2003, INT J RADIAT ONCOL, V56, P1464, DOI 10.1016/S0360-3016(03)00430-9##CHILDRESS NL, 2005, MED PHYS, V32, P153, DOI 10.1118/1.1829171##CHILDRESS NL, 2005, MED PHYS, V32, P838, DOI 10.1118/1.1879272##DEPUYDT T, 2002, RADIOTHER ONCOL, V62, P309, DOI 10.1016/S0167-8140(01)00497-2##ESSERS M, 2001, RADIOTHER ONCOL, V60, P215, DOI 10.1016/S0167-8140(01)00317-6##FRANKEN EM, 2006, MED PHYS, V33, P888, DOI 10.1118/1.2172746##FRANKEN EM, 2004, MED PHYS, V31, P2549, DOI 10.1118/1.1785893##HEIJMEN BJM, 1995, PHYS MED BIOL, V40, P1943, DOI 10.1088/0031-9155/40/11/012##KROONWIJK M, 1998, RADIOTHER ONCOL, V49, P125, DOI 10.1016/S0167-8140(98)00122-4##LOSASSO T, 1998, MED PHYS, V25, P1919, DOI 10.1118/1.598381##LOUWE RJW, 2003, MED PHYS, V30, P2376, DOI 10.1118/1.1589496##LOW DA, 2003, MED PHYS, V30, P2455, DOI 10.1118/1.1598711##LOW DA, 1998, MED PHYS, V25, P656, DOI 10.1118/1.598248##PARTRIDGE M, 2002, MED PHYS, V29, P1847, DOI 10.1118/1.1494988##PASMA KL, 1999, MED PHYS, V26, P2373, DOI 10.1118/1.598752##PASMA KL, 1998, PHYS MED BIOL, V43, P2047, DOI 10.1088/0031-9155/43/8/004##PASMA KL, 1999, INT J RADIAT ONCOL, V45, P1297, DOI 10.1016/S0360-3016(99)00328-4##RENNER WD, 2003, MED PHYS, V30, P2996, DOI 10.1118/1.1610771##STECIW S, 2005, MED PHYS, V32, P600, DOI 10.1118/1.1843471##STOCK M, 2005, PHYS MED BIOL, V50, P399, DOI 10.1088/0031-9155/50/3/001##VAN ESCH A, 2004, RADIOTHER ONCOL, V71, P223, DOI 10.1016/J.RADONC.2004.02.018##VIEIRA SC, 2004, INT J RADIAT ONCOL, V60, P981, DOI 10.1016/J.IJROBP.2004.06.025##VIEIRA SC, 2002, MED PHYS, V29, P2034, DOI 10.1118/1.1501141##VIEIRA SC, 2003, PHYS MED BIOL, V48, P157, DOI 10.1088/0031-9155/48/2/302##WARTEKIN B, 2003, MED PHYS, V30, P3143##WINKLER P, 2005, PHYS MED BIOL, V50, P643, DOI 10.1088/0031-9155/50/4/006",55,2020-11-20,NA
J,WOS:000242698700009,2006,INFLUENCE OF NEEDLE POSITION ON LUMBAR SEGMENTAL NERVE ROOT BLOCK SELECTIVITY,"BACKGROUND AND OBJECTIVES: IN PATIENTS WITH CHRONIC LOW BACK PAIN RADIATING TO THE LEG, SEGMENTAL NERVE ROOT BLOCKS (SNRBS) ARE PERFORMED TO PREDICT SURGICAL OUTCOME AND IDENTIFY THE PUTATIVE SYMPTOMATIC SPINAL NERVE. EPIDURAL SPREAD MAY LEAD TO FALSE INTERPRETATION, AFFECTING CLINICAL DECISION MAKING. SYSTEMATIC FLUOROSCOPIC ANALYSIS OF EPIDURAL LOCAL ANESTHETIC SPREAD AND ITS RELATIONSHIP TO NEEDLE TIP LOCATION HAS NOT BEEN PUBLISHED TO DATE. STUDY AIMS INCLUDE ASSESSMENT OF EPIDURAL LOCAL ANESTHETIC SPREAD AND ITS RELATIONSHIP TO NEEDLE POSITION DURING FLUOROSCOPY-ASSISTED BLOCKS. METHODS: PATIENTS SCHEDULED FOR L4, L5, AND S1 BLOCKS WERE INCLUDED IN THIS PROSPECTIVE OBSERVATIONAL STUDY. UNDER FLUOROSCOPY AND ELECTROSTIMULATION, THEY RECEIVED 0.5 ML OF A MIXTURE CONTAINING LIDOCAINE 5 MG AND IOHEXOL 75 MG. X-RAYS WITH NEEDLE TIP AND CONTRAST WERE SCORED FOR NO EPIDURAL SPREAD (GRADE 0), LOCAL SPREAD EPIDURALLY (GRADE 1), OR TO ADJACENT NERVE ROOTS (GRADE 2). RESULTS: SIXTY-FIVE PATIENTS WERE ANALYZED FOR EPIDURAL SPREAD, 62 FOR NEEDLE POSITION. GRADE I EPIDURAL SPREAD OCCURRED IN 47% OF L4 AND 28% OF L5 BLOCKS AND GRADE 2 SPREAD IN 3 BLOCKS (5%; L5 N = 1, S1 N = 2). FOR LUMBAR BLOCKS, THE NEEDLE WAS MOST FREQUENTLY FOUND IN THE LATERAL UPPER HALF OF THE INTERVERTEBRAL FORAMEN. EPIDURAL SPREAD OCCURRED MORE FREQUENTLY WITH MEDIAL NEEDLE POSITIONS (P=.06). CONCLUSION: THE FINDINGS SUGGEST (P=.06) THAT THE RISK OF GRADE 1 AND 2 LUMBAR EPIDURAL SPREAD, WHICH RESULTS IN DECREASED SNRB SELECTIVITY, IS GREATER WITH MEDIAL NEEDLE POSITIONS IN THE INTERVERTEBRAL FORAMEN. THE VARIABILITY IN ANATOMIC POSITION OF THE DORSAL ROOT GANGLION NECESSITATES ELECTROSTIMULATION TO GUIDE SNRB IN ADDITION TO FLUOROSCOPY.",LOW-BACK-PAIN; RADICULAR PAIN; DOUBLE-BLIND; LOCAL-ANESTHETICS; SCIATICA; INFILTRATION; DIAGNOSIS; RADICULOGRAPHY; INJECTION; GANGLIA,SEGMENTAL NERVE ROOT BLOCK; CHRONIC LOW BACK PAIN; SELECTIVITY,REGIONAL ANESTHESIA AND PAIN MEDICINE,"WOLFF, AP##GROEN, GJ##WILDER-SMITH, OH","RADBOUD UNIV NIJMEGEN, NIJMEGEN MED CTR, DEPT ANESTHESIOL, PAIN CTR, NL-6500 HB NIJMEGEN, NETHERLANDS. UNIV UTRECHT, MED CTR, DIV PERIOPERAT MED & EMERGENCY CARE, DEPT ANESTHESIOL, UTRECHT, NETHERLANDS. BERNHOVEN HOSP, DEPT ANESTHESIOL, PAIN CTR, OSS, NETHERLANDS.",ANESTHESIOLOGY,ANESTHESIOLOGY,"AKKERVEEKEN PF, 1993, NEURO-ORTHOPEDICS, V14, P81##CASTRO W H, 1994, EUR SPINE J, V3, P255, DOI 10.1007/BF02226574##DERBY R, 1992, SPINE, V17, PS176, DOI 10.1097/00007632-199206001-00020##DOOLEY JF, 1988, SPINE, V13, P79, DOI 10.1097/00007632-198801000-00019##EVERETT CLIFFORD R, 2005, PAIN PHYSICIAN, V8, P225##FURMAN MB, 2000, PAIN, V85, P526, DOI 10.1016/S0304-3959(99)00293-6##GAJRAJ NM, 2004, REGION ANESTH PAIN M, V29, P243, DOI 10.1016/J.RAPM.2003.12.025##GAUCI A, 2004, MANUAL RF TECHNIQUES, P7##GEURTS JWM, 2003, LANCET, V361, P21, DOI 10.1016/S0140-6736(03)12115-0##GROEN GJ, 1990, AM J ANAT, V188, P282, DOI 10.1002/AJA.1001880307##HASUE M, 1989, SPINE, V14, P1261##HAUEISEN DC, 1985, CLIN ORTHOP RELAT R, P179##HAYNSWORTH ROBERT F JR, 2003, PAIN PHYSICIAN, V6, P517##HERRON L D, 1989, J SPINAL DISORD, V2, P75##HOGAN QH, 1997, ANESTHESIOLOGY, V86, P216, DOI 10.1097/00000542-199701000-00026##HUSTON CW, 2005, ARCH PHYS MED REHAB, V86, P277, DOI 10.1016/J.APMR.2004.02.018##KREMPEN JF, 1974, J BONE JOINT SURG AM, VA 56, P1435, DOI 10.2106/00004623-197456070-00011##KREMPEN JF, 1975, ORTHOP CLIN N AM, V6, P311##KUSLICH SD, 1991, ORTHOP CLIN N AM, V22, P181##MACADAEG K, 2001, PAIN MED, V2, P245##MANCHIKANTI L, 2001, PAIN PHYSICIAN, V4, P308##NITTA H, 1993, SPINE, V18, P1782, DOI 10.1097/00007632-199310000-00011##NORTH RB, 1996, PAIN, V65, P77, DOI 10.1016/0304-3959(95)00170-0##PORTER DG, 1999, BRIT J NEUROSURG, V13, P290##QUINN SF, 1988, AM J ROENTGENOL, V151, P1213, DOI 10.2214/AJR.151.6.1213##SCHUTZ H, 1973, CAN J SURG, V16, P217##STANLEY D, 1990, SPINE, V15, P540, DOI 10.1097/00007632-199006000-00020##STOLKER RJ, 1994, PAIN, V58, P1, DOI 10.1016/0304-3959(94)90180-5##TAJIMA T, 1980, SPINE, V5, P68, DOI 10.1097/00007632-198001000-00013##WOLFF AP, 2001, REGION ANESTH PAIN M, V26, P147, DOI 10.1053/RAPM.2001.21436##WOLFF AP, 2004, ANESTH ANALG, V99, P496",18,2020-11-20,NA
J,WOS:000243026200005,2006,DEVOLUTION AND THE INTERREGIONAL INEQUALITIES IN HEALTH AND HEALTHCARE IN SPAIN,"THE DESIRABILITY OF DEVOLUTION OF GOVERNMENT RESPONSIBILITIES IS OFTEN QUESTIONED ON THE GROUNDS OF REGIONAL COHESION CONCERNS. THIS FEATURE IS ESPECIALLY RELEVANT IN WELFARE POLICY AREAS SUCH AS HEALTHCARE SERVICES GIVEN THEIR IMPACT ON AN INDIVIDUAL'S WELL-BEING. THIS PAPER EXAMINES THE EFFECTS OF HEALTH SYSTEM DEVOLUTION ON THE EMERGENCE OF INTER-TERRITORIAL INEQUALITIES IN HEALTHCARE OUTCOMES ( MORTALITY) AND OUTPUTS ( HEALTHCARE EXPENDITURE) IN THE SPANISH NATIONAL HEALTH SYSTEM ( NHS). BASED ON AN EMPIRICAL MODEL FOR REGIONAL HEALTH EXPENDITURE, AND DRAWING FROM A BATTERY OF INEQUALITY INDICATORS ( SOME TAKEN FROM PREVIOUS STUDIES, OTHER ESTIMATED ANEW), THE FOLLOWING RESULTS ARE OBTAINED. FIRST, HEALTHCARE DEVOLUTION HAS NOT LED TO AN EXPANSION OF REGIONAL INEQUALITIES IN HEALTHCARE OUTCOMES AND OUTPUTS. SECOND, THERE IS NO CLEAR-CUT EVIDENCE THAT DEVOLUTION INCREASES PUBLIC HEALTH EXPENDITURE ( IN REAL TERMS) IN DEVOLVED REGION-STATES, WITH THE EXCEPTION OF FISCALLY ACCOUNTABLE AUTONOMOUS COMMUNITIES (ACS). FINALLY, REGIONAL HEALTH EXPENDITURE IS EXPLAINED BY DIFFERENCES IN NEED AND HIGHER RELIANCE HEALTHCARE INPUTS USE, SIZE EFFECTS AS WELL AS THE REGION-SPECIFIC ECONOMIC AND DEMOGRAPHIC DIMENSION IN ADDITION TO REGIONAL INCOME.",FEDERALISM; SERVICES; JUSTICE; SYSTEM,REGIONAL INEQUALITIES; POLITICAL INTERACTIONS; POLITICAL ACCOUNTABILITY; SPANISH NATIONAL HEALTH SYSTEM (NHS),REGIONAL STUDIES,"COSTA-FONT, J##RICO, A","LONDON SCH ECON, LSE HLTH & SOCIAL CARE, LONDON WC2A 2AE, ENGLAND. UNIV BARCELONA, DEPT TEORIA ECON, BARCELONA, SPAIN. ERASMUS UNIV, ROTTERDAM, NETHERLANDS. UNIV OSLO, FAC MED, INST HLTH MANAGEMENT & HLTH EOCN, N-0317 OSLO, NORWAY.",ECONOMICS; ENVIRONMENTAL STUDIES; GEOGRAPHY; REGIONAL & URBAN PLANNING,BUSINESS & ECONOMICS; ENVIRONMENTAL SCIENCES & ECOLOGY; GEOGRAPHY; PUBLIC ADMINISTRATION,"ANTON TJ, 1997, J HEALTH POLIT POLIC, V22, P691, DOI 10.1215/03616878-22-3-691##ARSNEAULT S, 2000, STATE LOCAL GOVT REV, V32, P49##BANTING KEITH G., 1987, WELFARE STATE CANADI##BARDHAN P, 2002, J ECON PERSPECT, V16, P185, DOI 10.1257/089533002320951037##BESLEY T, 2003, OXFORD REV ECON POL, V19, P235, DOI 10.1093/OXREP/19.2.235##BESLEY T, 1995, AM ECON REV, V85, P25##BESLEY T, 1999, CENTRALISED VS DECEN##BOSSERT T, 2003, B WORLD HEALTH ORGAN, V18, P95##BOYNE GA, 1993, ENVIRON PLANN C, V11, P35, DOI 10.1068/C110035##BRENNAN G, 1983, TAX ASSIGNMENT FEDER, P52##COSTA J, 2003, HEALTH ECON, V12, P587, DOI 10.1002/HEC.756##COSTA-FONT J, 2006, PUBLIC CHOICE, V128, P477, DOI 10.1007/S11127-005-9011-Y##COSTA-I-FONT J, 2005, INT J HEALTH PLAN M, V20, P41, DOI 10.1002/HPM.795##DEMANUEL E, 2001, EVALUACION POLITICAS##DILEO D, 1996, SPECTRUM, V69, P6##GEORGE A, 2003, WORKING PAPER SERIES, V13##GOW JAMES IAIN, 1994, LEARNING OTHERS ADM##HEALD D., 1998, REGIONAL FEDERAL STU, V8, P23##KNEEBONE RD, 1992, APPL ECON, V24, P1293, DOI 10.1080/00036849200000088##LEWIS SJ, 2001, CAN MED ASSOC J, V164, P343##LITVAK J, 1998, RETHINKING DECENTRAL##LOPEZ-CASASNOVAS G, 2005, HEALTH ECON, V14, PS221, DOI 10.1002/HEC.1038##LOVERING J, 1999, INT J URBAN REGIONAL, V23, P379, DOI 10.1111/1468-2427.00202##MARKUSEN A, 1994, INT REGIONAL SCI REV, V16, P3##MORGAN K, 2001, REG STUD, V35, P343, DOI 10.1080/00343400123419##OATES W, 1972, POLITICAL EC FEDERAL##ODONNELL G, 1999, SELF RESTRAINING STA, P29##PASSELL P, 1978, STATE POLICIES FEDER##POWELL M, 2001, SOC POLICY ADMIN, V35, P181, DOI 10.1111/1467-9515.00226##REDWOOD J, 1999, DEATH BRIT##REVELLI F, 2002, APPL ECON, V34, P1723, DOI 10.1080/00036840210122353##REVELLI F, 2001, APPL ECON, V33, P1101, DOI 10.1080/00036840010007164##RICO A, 2005, J HEALTH POLIT POLIC, V30, P231, DOI 10.1215/03616878-30-1-2-231##RICO A, 1998, W EUROPEAN POLITICS, V21, P180##RICO A, 2000, SPAIN HLTH CARE SYST##RICO A, 2001, SUCCESS FAILURE GOVE##RODRIGUEZ-POSE A, 2003, ENVIRON PLANN C, V21, P333, DOI 10.1068/C0235##RUBINFELD DL, 1987, HDB PUBLIC EC, P571##SALMON PIERRE, 1987, OXFORD REV ECON POL, V3, P24, DOI [DOI 10.1093/OXREP/3.2.24, DOI 10.1093/OXREP/3.2.24]##SCHEDLER ANDREAS, 1999, SELF RESTRAINING STA, P13##TIEBOUT CM, 1956, J POLIT ECON, V64, P416, DOI 10.1086/257839##URBANOS R., 2000, HACIENDA PUBLICA ESP, V153, P139##URBANOS R, 2001, 200115 FEDEA##WENNBERG JE, 2002, HEALTH AFFAIR, V13, P96##WOODS KJ, 2004, INT J HEALTH SERV, V34, P323, DOI 10.2190/TTJP-FLC3-2DGM-JNE9",20,2020-11-20,NA
J,WOS:000242168700011,2006,EFFECT OF CUMULUS MORPHOLOGY AND MATURATION STAGE ON THE CRYOPRESERVABILITY OF EQUINE OOCYTES,"OOCYTE CRYOPRESERVATION IS A POTENTIALLY VALUABLE WAY OF PRESERVING THE FEMALE GERM LINE. HOWEVER, THE DEVELOPMENTAL COMPETENCE OF CRYOPRESERVED OOCYTES IS PRESENTLY POOR. THIS STUDY INVESTIGATED WHETHER THE MORPHOLOGY OF THE CUMULUS COMPLEX SURROUNDING AN IMMATURE EQUINE OOCYTE AND/OR THE OOCYTE'S STAGE OF MATURATION AFFECT ITS CRYOPRESERVABILITY. COMPACT (CP) AND EXPANDED (EX) CUMULUS OOCYTE COMPLEXES (COCS) WERE VITRIFIED EITHER SHORTLY AFTER RECOVERY (GERMINAL VESICLE STAGE, GV) OR AFTER MATURATION IN VITRO (IVM); CRYOPROTECTANT-TREATED AND -UNTREATED NON-FROZEN OOCYTES SERVED AS CONTROLS. IN EXPERIMENT 1, OOCYTES MATURED IN VITRO AND THEN VITRIFIED, OR VICE VERSA, WERE EXAMINED FOR MATURATION STAGE AND MEIOTIC SPINDLE QUALITY. CP AND EX COCS VITRIFIED AT THE GV STAGE MATURED AT SIMILAR RATES DURING SUBSEQUENT IVM (41 VS 46% MIL), BUT MEIOTIC SPINDLE QUALITY WAS BETTER FOR CP THAN EX (63 VS 33% NORMAL SPINDLES). VITRIFYING OOCYTES AFTER IVM RESULTED IN DISAPPOINTING POST-WARMING SPINDLE QUALITY (32 VS 28% NORMAL FOR CP VS EX). IN EXPERIMENT 11, OOCYTES FROM CP AND EX COCS VITRIFIED AT THE GV OR MIL STAGES WERE FERTILIZED BY INTRACYTOPLASMIC SPERM INJECTION (ICSI) AND MONITORED FOR CLEAVAGE AND BLASTOCYST FORMATION. OOCYTES VITRIFIED PRIOR TO IVM YIELDED HIGHER CLEAVAGE RATES (34 AND 27% FOR CP AND EX CCICS) THAN THOSE VITRIFIED AFTER IVM (16 AND 4%). HOWEVER, ONLY ONE BLASTOCYST WAS PRODUCED FROM A SPERM-INJECTED VITRIFIED-WARMED OOCYTE (0.4 VS 9.3% AND 13% BLASTOCYSTS FOR CRYOPROTECTANT-EXPOSED AND -UNTREATED CONTROLS). IT IS CONCLUDED THAT, WHEN VITRIFICATION IS THE CHOSEN METHOD OF CRYOPRESERVATION, CP EQUINE CCICS AT THE GV STAGE OFFER THE BEST CHANCE OF AN MII OOCYTE WITH A NORMAL SPINDLE AND THE POTENTIAL FOR FERTILIZATION; HOWEVER, DEVELOPMENTAL COMPETENCE IS STILL REDUCED DRAMATICALLY.",INTRACYTOPLASMIC SPERM INJECTION; IN-VITRO MATURATION; INITIAL CHROMATIN CONFIGURATION; II HUMAN OOCYTES; BOVINE OOCYTES; DEVELOPMENTAL COMPETENCE; HORSE OOCYTES; MEIOTIC COMPETENCE; INVITRO MATURATION; GERMINAL VESICLE,NA,REPRODUCTION,"THARASANIT, T##COLLEONI, S##LAZZARI, G##COLENBRANDER, B##GALLI, C##STOUT, TAE","UNIV UTRECHT, FAC MED VET, DEPT EQUINE SCI, NL-3584 CM UTRECHT, NETHERLANDS. IST SPERIMENTALE ITALIANO LAZZARO SPALLANZANI, LAB TECNOL RIPROD, CIZ, I-26100 CREMONA, ITALY. UNIV BOLOGNA, DIPARTIMENTO CLIN VET, BOLOGNA, ITALY.",DEVELOPMENTAL BIOLOGY; REPRODUCTIVE BIOLOGY,DEVELOPMENTAL BIOLOGY; REPRODUCTIVE BIOLOGY,"AGCA Y, 1998, MOL REPROD DEV, V49, P408, DOI 10.1002/(SICI)1098-2795(199804)49:4&LT;408::AID-MRD8&GT;3.0.CO;2-R##ALM H, 1996, J REPROD FERTIL, V107, P215, DOI 10.1530/JRF.0.1070215##ARAV A, 1996, CRYOBIOLOGY, V33, P589, DOI 10.1006/CRYO.1996.0062##ATABAY EC, 2004, THERIOGENOLOGY, V61, P15, DOI 10.1016/S0093-691X(03)00179-1##BLONDIN P, 1995, MOL REPROD DEV, V41, P54, DOI 10.1002/MRD.1080410109##BOISO I, 2002, HUM REPROD, V17, P1885, DOI 10.1093/HUMREP/17.7.1885##CARROLL J, 1990, J REPROD FERTIL, V90, P547, DOI 10.1530/JRF.0.0900547##CHEN C, 1986, LANCET, V1, P884, DOI 10.1016/S0140-6736(86)90989-X##CHEN SU, 2003, MOL CELL ENDOCRINOL, V202, P101, DOI 10.1016/S0303-7207(03)00070-4##CHOI YH, 2004, REPRODUCTION, V127, P187, DOI 10.1530/REP.1.00087##COMIZZOLI P, 2004, BIOL REPROD, V71, P598, DOI 10.1095/BIOLREPROD.104.027920##DELCAMPO MR, 1995, THERIOGENOLOGY, V43, P1141, DOI 10.1016/0093-691X(95)00086-N##DELL'AQUILA ME, 1997, HUM REPROD, V12, P2766, DOI 10.1093/HUMREP/12.12.2766##DELL'AQUILA ME, 2001, MOL REPROD DEV, V60, P79, DOI 10.1002/MRD.1064##DIEZ C, 2005, THERIOGENOLOGY, V64, P317, DOI 10.1016/J.THERIOGENOLOGY.2004.11.023##FAN HY, 2004, BIOL REPROD, V70, P535, DOI 10.1095/BIOLREPROD.103.022830##GALLI C, 2001, THERIOGENOLOGY, V55, P1341, DOI 10.1016/S0093-691X(01)00486-1##HINRICHS K, 1993, BIOL REPROD, V48, P363, DOI 10.1095/BIOLREPROD48.2.363##HINRICHS K, 1997, BIOL REPROD, V57, P377, DOI 10.1095/BIOLREPROD57.2.377##HINRICHS K, 2000, BIOL REPROD, V62, P1402, DOI 10.1095/BIOLREPROD62.5.1402##HINRICHS K, 1997, EQUINE VET J SUPPL, P43##HOCHI S, 1996, CRYOBIOLOGY, V33, P300, DOI 10.1006/CRYO.1996.0030##HOCHI S, 1994, THERIOGENOLOGY, V42, P1085, DOI 10.1016/0093-691X(94)90856-7##HOCHI S, 1998, THERIOGENOLOGY, V49, P787, DOI 10.1016/S0093-691X(98)00028-4##HURTT AE, 2000, THERIOGENOLOGY, V54, P119, DOI 10.1016/S0093-691X(00)00330-7##IMOEDEMHE DG, 1992, J ASSIST REPROD GEN, V9, P323, DOI 10.1007/BF01203954##ISACHENKO EF, 1999, HUM REPROD, V14, P400, DOI 10.1093/HUMREP/14.2.400##JONES A, 2004, HUM REPROD, V19, P1861, DOI 10.1093/HUMREP/DEH313##KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/BIOLREPROD52.4.709##LAZZARI G, 2002, BIOL REPROD, V67, P767, DOI 10.1095/BIOLREPROD.102.004481##LEIBO SP, 1980, J MEMBRANE BIOL, V53, P179, DOI 10.1007/BF01868823##LIM JM, 1992, THERIOGENOLOGY, V37, P351, DOI 10.1016/0093-691X(92)90193-U##LIM JM, 1991, THERIOGENOLOGY, V35, P1225, DOI 10.1016/0093-691X(91)90368-N##LONERGAN P, 1994, MOL REPROD DEV, V37, P48, DOI 10.1002/MRD.1080370107##MACLELLAN LJ, 2002, THERIOGENOLOGY, V58, P911, DOI 10.1016/S0093-691X(02)00920-2##MACULLAGH P, 1989, BINARY DATA, P98##MARTINO A, 1996, BIOL REPROD, V54, P1059, DOI 10.1095/BIOLREPROD54.5.1059##MEN HS, 2002, THERIOGENOLOGY, V57, P1095, DOI 10.1016/S0093-691X(01)00679-3##OTOI T, 1995, CRYOBIOLOGY, V32, P455, DOI 10.1006/CRYO.1995.1045##PARK SE, 1997, FERTIL STERIL, V68, P920, DOI 10.1016/S0015-0282(97)00365-8##PARKS JE, 1992, THERIOGENOLOGY, V37, P59, DOI 10.1016/0093-691X(92)90247-O##PARRISH JJ, 1988, BIOL REPROD, V38, P1171, DOI 10.1095/BIOLREPROD38.5.1171##PELLICER A, 1988, FERTIL STERIL, V50, P805##POMAR FJR, 2005, THERIOGENOLOGY, V63, P2254, DOI 10.1016/J.THERIOGENOLOGY.2004.10.015##PORCU E, 2001, SEMIN REPROD MED, V19, P221, DOI 10.1055/S-2001-18041##RHO GJ, 2002, MOL REPROD DEV, V63, P464, DOI 10.1002/MRD.10196##RIENZI L, 2004, HUM REPROD, V19, P655, DOI 10.1093/HUMREP/DEH101##RUFFING NA, 1993, CRYOBIOLOGY, V30, P562, DOI 10.1006/CRYO.1993.1059##SATHANANTHAN AH, 1988, GAMETE RES, V21, P385, DOI 10.1002/MRD.1120210407##SAUNDERS KM, 1999, BIOL REPROD, V61, P178, DOI 10.1095/BIOLREPROD61.1.178##SCOTT TJ, 2001, THERIOGENOLOGY, V55, P705, DOI 10.1016/S0093-691X(01)00438-1##SIMERLY C, 1993, METHOD ENZYMOL, V225, P516##SUN QY, 2003, J REPROD DEVELOP, V49, P347, DOI 10.1262/JRD.49.347##THARASANIT T, 2006, MOL REPROD DEV, V73, P627, DOI 10.1002/MRD.20432##TREMOLEDA JL, 2001, MOL REPROD DEV, V60, P260, DOI 10.1002/MRD.1086##TREMOLEDA JL, 2003, BIOL REPROD, V69, P1895, DOI 10.1095/BIOLREPROD.103.018515##TREMOLEDA JL, 2003, BIOL REPROD, V69, P186, DOI 10.1095/BIOLREPROD.102.012823##VAJTA G, 1998, MOL REPROD DEV, V51, P53, DOI 10.1002/(SICI)1098-2795(199809)51:1&LT;53::AID-MRD6&GT;3.0.CO;2-V##VANBLERKOM J, 1994, MICROSC RES TECHNIQ, V27, P165, DOI 10.1002/JEMT.1070270209##VERLHAC MH, 1994, DEVELOPMENT, V120, P1017",35,2020-11-20,NA
J,WOS:000242935000007,2006,PERFORMANCE AND BEHAVIOUR OF RABBIT DOES IN A GROUP-HOUSING SYSTEM WITH NATURAL MATING OR ARTIFICIAL INSEMINATION,"THIS STUDY COMPARED REPRODUCTIVE PERFORMANCE AND BEHAVIOUR OF DOES RAISED IN A GROUP-HOUSING SYSTEM AND IN A REGULAR CAGE SYSTEM. THE GROUP-HOUSING PEN WAS DIVIDED INTO DIFFERENT FUNCTIONAL AREAS FOR SUCKLING, RESTING, AND EATING AND SPECIAL HIDING AREAS FOR KITS WHEN THEY HAD LEFT THE NEST-BOXES AND DOES TO FAVOUR THE SPECIES SPECIFIC BEHAVIOURAL TRAITS. DOES HAD ACCESS TO THEIR NEST-BOX BY MEANS OF AN INDIVIDUAL ELECTRONIC NEST-BOX RECOGNITION SYSTEM (ENRS) ACTIVATED BY A CODED TRANSPONDER PLACED IN THEIR EARTAGS. EIGHT DOES WERE HOUSED IN EACH PEN. NATURAL MATING (NM, WITH A BUCK IN THE GROUP) OR ARTIFICIAL INSEMINATIONS (AI) WERE APPLIED. LITTER SIZE, KIT MORTALITY AND KIT WEIGHT AT 14 D OF AGE WERE SIMILAR FOR GROUP-HOUSING AND CAGES WHEN NM WERE APPLIED. WITH A NATURAL REPRODUCTION RHYTHM GROUP-HOUSING LED TO AN INCREASE OF +38% OF LITTERS. HOWEVER, FROM A MANAGEMENT POINT OF VIEW, A CYCLED PRODUCTION SYSTEM WITH AI IS PREFERRED. WITH AI AND GROUP-HOUSING, A LOWER KINDLING RATE AND A LOWER KIT WEIGHT AT WEANING WERE FOUND. THE LOWER KINDLING RATE WAS PARTLY CAUSED BY PSEUDO-PREGNANCIES THAT WERE FOUND IN 23% (P < 0.01) OF THE DOES IN THE GROUP-HOUSING SYSTEM AGAINST 0% IN THE CONTROL GROUP. SIXTEEN TO 20% OF THE DOES IN THE GROUP-HOUSING SYSTEM HAD SKIN INJURIES, WHICH IS AN INDICATOR FOR AGGRESSION AMONG DOES. MOST OF THE INJURIES WERE SEEN ON THE BODY AND MOST OF THEM WERE SUPERFICIAL BITES. BASED ON THE RESULTS OF THIS STUDY, IT CAN BE CONCLUDED THAT GROUP-HOUSING OF RABBIT DOES SEEMS POSSIBLE, BUT MORE RESEARCH IS NEEDED TO SOLVE THE PROBLEMS OF THE DECREASED KINDLING RATE AND OCCURRENCE OF PSEUDO-PREGNANCIES, THE LOWER WEIGHT AT WEANING AND AGGRESSIVENESS AMONG DOES.",ZEALAND WHITE-RABBITS; ORYCTOLAGUS-CUNICULUS; LABORATORY CAGES,RABBITS; REPRODUCTION; GROUP-HOUSING; BEHAVIOUR; WELFARE; PSEUDO-PREGNANCY,REPRODUCTION NUTRITION DEVELOPMENT,"ROMMERS, JM##BOITI, C##DE JONG, I##BRECCHIA, G","UNIV WAGENINGEN & RES CTR, ANIM SCI GRP, NL-8200 AB LELYSTAD, NETHERLANDS. UNIV PERUGIA, DIPARTIMENTO SCI BIOPATOL & IGIENE PROD ANIM & AL, SEZ FISIOL VET, LAB BIOTECNOL, I-06100 PERUGIA, ITALY.",DEVELOPMENTAL BIOLOGY; NUTRITION & DIETETICS; REPRODUCTIVE BIOLOGY; ZOOLOGY,DEVELOPMENTAL BIOLOGY; NUTRITION & DIETETICS; REPRODUCTIVE BIOLOGY; ZOOLOGY,"BOITI C, 1996, P 6 WORLD RABB C 9 1, V2, P45##CHEEKE PR, 1987, RABBIT PRODUCTION##CHU LR, 2004, APPL ANIM BEHAV SCI, V85, P121, DOI 10.1016/J.APPLANIM.2003.09.011##COENEN E, 2004, NOK KONTAKTBLAD, V2, P10##COENEN E, 2004, NOK KONTAKTBLAD, V2, P9##COENEN E, 2003, NOK KONTAKTBLAD, V6, P6##COENEN E, 2002, NOK KONTAKTBLAD, V4, P10##COENEN E, 2004, NOK KONTAKTBLAD, V2, P24##GUNN D, 1995, APPL ANIM BEHAV SCI, V45, P277, DOI 10.1016/0168-1591(95)00627-5##HAFEZ ESE, 1970, REPROD BREEDING TECH##HANSEN LT, 2000, APPL ANIM BEHAV SCI, V68, P163, DOI 10.1016/S0168-1591(00)00093-9##KALLE G., 1994, DGS, V25, P16##MIRABITO L., 1999, P 8 JOURN RECH CUN P, P67##MYKOTOWYCZ R, 1975, INT J BEHAV BIOL, V52, P104##RUIS MAW, 2003, NOK KONTAKTBLAD, V6, P6##RUIS MAW, IN PRESS COST 848 EU##STAUFFACHER M, 1992, ANIM WELFARE, V1, P105##THEAUCLEMENT M, 2000, P 7 WORLD RABB C VAL, VA, P259##VASTRADE FM, 1986, APPL ANIM BEHAV SCI, V16, P165, DOI 10.1016/0168-1591(86)90109-7",34,2020-11-20,NA
J,WOS:000241921100014,2006,FSH RECEPTOR GENOTYPE IS ASSOCIATED WITH PREGNANCY BUT NOT WITH OVARIAN RESPONSE IN IVF,"TWO VERY COMMON SINGLE NUCLEOTIDE POLYMORPHISMS AT POSITIONS 307 AND 680 IN EXON 10 OF THE FSH RECEPTOR GENE HAVE BEEN ASSOCIATED WITH OVARIAN RESPONSE IN IVE THIS OBSERVATIONAL STUDY EVALUATED THE ROLE OF THE FSH RECEPTOR GENOTYPE IN THE PREDICTION OF POOR RESPONSE AND CLINICAL PREGNANCY IN IVF IN COMPARISON WITH OTHER MARKERS, SUCH AS AGE, BASAL FSH, ANTI-MULLERIAN HORMONE AND ANTRAL FOLLICLE COUNT. IN ADDITION, THE IN-VITRO CAMP RESPONSE TOWARDS RECOMBINANT FSH IN CULTURED GRANULOSA CELLS OF PATIENTS WITH DIFFERENT FSH RECEPTOR GENOTYPES WAS DETERMINED. A TOTAL OF 105 IVF PATIENTS UNDERGOING OVARIAN STIMULATION IN A LONG SUPPRESSION PROTOCOL WERE INCLUDED IN THE STUDY. THE OVARIAN RESPONSE WAS COMPARABLE BETWEEN PATIENTS WITH DIFFERENT FSH RECEPTOR GENOTYPES. PATIENTS WITH POLYMORPHISM SER/SER HAD IMPLANTATION AND PREGNANCY RATES THAT WERE THREE TIMES HIGHER COMPARED WITH PATIENTS WITH POLYMORPHISM ASN/ASN. FSH RECEPTOR GENOTYPE WAS NOT ASSOCIATED WITH A POOR RESPONSE IN IVF, BUT SHOWED A POSITIVE ASSOCIATION WITH PREGNANCY, INDEPENDENT OF AGE. THERE WAS NO DIFFERENCE IN CAMP PRODUCTION IN CULTURED GRANULOSA CELLS OF PATIENTS WITH DIFFERENT FSH RECEPTOR GENOTYPES (N=62). IT IS CONCLUDED THAT FSH RECEPTOR GENOTYPE IS ASSOCIATED WITH PREGNANCY IN IVF, BUT NOT WITH OVARIAN RESPONSE.",FOLLICLE-STIMULATING-HORMONE; IN-VITRO FERTILIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; PROTEIN-KINASE-B; LUTEINIZING-HORMONE; GENE-EXPRESSION; WOMEN; ISOFORMS; EXON-10; GONADOTROPINS,FSH RECEPTOR; IMPLANTATION RATE; IVF; POLYMORPHISM; POOR RESPONSE; PREGNANCY RATE,REPRODUCTIVE BIOMEDICINE ONLINE,"KLINKERT, ER##TE VELDE, ER##WEIMA, S##VAN ZANDVOORT, PM##HANSSEN, RGJM##NILSSON, PR##DE JONG, FH##LOOMAN, CWN##BROEKMANS, FJM","UNIV MED CTR UTRECHT, DEPT REPROD MED, DIV PERINATOL & GYNECOL, NL-3584 CX UTRECHT, NETHERLANDS. NV ORGANON, DEPT PHARMACOL, SECT FERTIL & CONTRACEPT, NL-5340 BH OSS, NETHERLANDS. UNIV MED CTR UTRECHT, DEPT MED GENET, NL-3584 CX UTRECHT, NETHERLANDS. ERASMUS MC, DEPT INTERNAL MED, ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT PUBL HLTH, ROTTERDAM, NETHERLANDS.",OBSTETRICS & GYNECOLOGY; REPRODUCTIVE BIOLOGY,OBSTETRICS & GYNECOLOGY; REPRODUCTIVE BIOLOGY,"AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9##ALBERTINI DF, 2001, REPRODUCTION, V121, P647, DOI 10.1530/REP.0.1210647##ANDERIESZ C, 2000, HUM REPROD, V15, P1140, DOI 10.1093/HUMREP/15.5.1140##BANCSI LFJMM, 2002, FERTIL STERIL, V77, P328, DOI 10.1016/S0015-0282(01)02983-1##BEHRE HM, 2005, PHARMACOGENET GENOM, V15, P451, DOI 10.1097/01.FPC.0000167330.92786.5E##CALDER M.D., 2003, REPROD BIOL ENDOCRIN, V1, P1##CALDER MD, 2005, FERTIL STERIL, V83, P1077, DOI 10.1016/J.FERTNSTERT.2004.12.012##CHEN L, 1994, BIOL REPROD, V51, P290, DOI 10.1095/BIOLREPROD51.2.290##CONWAY GS, 1999, CLIN ENDOCRINOL, V51, P97, DOI 10.1046/J.1365-2265.1999.00745.X##DAELEMANS C, 2004, J CLIN ENDOCR METAB, V89, P6310, DOI 10.1210/JC.2004-1044##DE CASTRO F, 2003, FERTIL STERIL, V80, P571, DOI 10.1016/S0015-0282(03)00795-7##DE KONING CH, 2006, HUM REPROD, V21, P443, DOI 10.1093/HUMREP/DEI317##FALCONER H, 2005, ACTA OBSTET GYN SCAN, V84, P806, DOI 10.1111/J.0001-6349.2005.00736.X##GONZALEZ-ROBAYNA IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/ME.14.8.1283##GREB RR, 2005, J CLIN ENDOCR METAB, V90, P4866, DOI 10.1210/JC.2004-2268##GROMOLL J, 1994, J MOL ENDOCRINOL, V12, P265, DOI 10.1677/JME.0.0120265##KECK C, 2005, REPROD BIOMED ONLINE, V11, P562, DOI 10.1016/S1472-6483(10)61164-9##KLINKERT ER, 2004, FERTIL STERIL, V81, P1247, DOI 10.1016/J.FERTNSTERT.2003.10.030##LAVEN JSE, 2003, FERTIL STERIL, V80, P986, DOI 10.1016/S0015-0282(03)01115-4##LOUTRADIS D, 2006, J ASSIST REPROD GEN, V23, P177, DOI 10.1007/S10815-005-9015-Z##MAYORGA MP, 2000, J CLIN ENDOCR METAB, V85, P3365, DOI 10.1210/JC.85.9.3365##NG EHY, 2000, HUM REPROD, V15, P1937, DOI 10.1093/HUMREP/15.9.1937##OKTAY K, 1997, J CLIN ENDOCR METAB, V82, P3748, DOI 10.1210/JC.82.11.3748##PALMER SS, 2005, REPROD BIOMED ONLINE, V10, P45##POPOVIC-TODOROVIC B, 2003, HUM REPROD, V18, P2275, DOI 10.1093/HUMREP/DEG472##RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/ER.15.6.725##ROUSSEAUMERCK MF, 1993, GENOMICS, V15, P222, DOI 10.1006/GENO.1993.1041##SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/MEND-4-12-1856##SHEMESH M, 2001, REPRODUCTION, V121, P835, DOI 10.1530/REP.0.1210835##SIMONI M, 2002, HUM REPROD UPDATE, V8, P413, DOI 10.1093/HUMUPD/8.5.413##SIMONI M, 1999, J CLIN ENDOCR METAB, V84, P751, DOI 10.1210/JC.84.2.751##SIMONI M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/ER.18.6.739##SUDO S, 2002, MOL HUM REPROD, V8, P893, DOI 10.1093/MOLEHR/8.10.893##VANKOOIJ RJ, 1996, FERTIL STERIL, V66, P769, DOI 10.1016/S0015-0282(16)58634-8##ZELEZNIK AJ, 2003, ENDOCRINOLOGY, V144, P3985, DOI 10.1210/EN.2003-0293",63,2020-11-20,NA
J,WOS:000241715600001,2006,ACCURACY OF SPECIES IDENTITY OF COMMERCIAL BACTERIAL CULTURES INTENDED FOR PROBIOTIC OR NUTRITIONAL USE,"INDEPENDENT STUDIES HAVE INDICATED THAT THE MICROBIOLOGICAL COMPOSITION OF SEVERAL COMMERCIAL PROBIOTIC PRODUCTS DOES NOT CORRESPOND TO THE PRODUCT LABEL INFORMATION. THE PRESENT STUDY SET OUT TO INVESTIGATE TO WHAT EXTENT THESE PROBLEMS MAY BE DUE TO THE USE OF MISIDENTIFIED CULTURES AT THE ONSET OF PRODUCTION. FOR THIS PURPOSE, 213 CULTURES OF LACTIC ACID BACTERIA (LAB) AND PROPIONIBACTERIA INTENDED FOR PROBIOTIC OR NUTRITIONAL USE WERE COLLECTED FROM 26 MANUFACTURERS OF PROBIOTIC PRODUCTS, THREE INTERNATIONAL CULTURE COLLECTIONS AND ONE RESEARCH INSTITUTE. THE ACCURACY OF THE TAXONOMIC IDENTITY PROVIDED BY THE STRAIN DEPOSITOR WAS ASSESSED THROUGH A POLYPHASIC APPROACH BASED ON VALIDATED AND STANDARDIZED IDENTIFICATION METHODS INCLUDING FLUORESCENT AMPLIFIED FRAGMENT LENGTH POLYMORPHISM (FAFLP) AND REPETITIVE DNA ELEMENT (REP)-PCR FINGERPRINTING, PROTEIN PROFILING AND PARTIAL 16S RDNA SEQUENCING. THE MAJORITY OF THE CULTURES WERE RECEIVED AS MEMBERS OF THE GENERA LACTOBACILLUS (57%) AND BIFIDOBACTERIUM (22%); HOWEVER, PROPIONIBACTERIA, ENTEROCOCCI, LACTOCOCCUS LACTIS (SUBSP. LACTIS), STREPTOCOCCUS THERMOPHILUS AND PEDIOCOCCI WERE ALSO OBTAINED. UPON REIDENTIFICATION, 46 CASES OF MISIDENTIFICATION AT THE GENUS LEVEL (N = 19) OR SPECIES LEVEL (N = 27) WERE RECORDED, INCLUDING 34 COMMERCIAL PROBIOTIC CULTURES DEPOSITED BY 10 DIFFERENT COMPANIES. THE FINDING THAT MORE THAN 28% OF THE COMMERCIAL CULTURES INTENDED FOR HUMAN AND/OR ANIMAL PROBIOTIC USE WERE MISIDENTIFIED AT THE GENUS OR SPECIES LEVEL SUGGESTS THAT MANY CASES OF PROBIOTIC PRODUCT MISLABELING ORIGINATE FROM THE INCORPORATION OF INCORRECTLY IDENTIFIED STRAINS. A LARGE NUMBER OF THESE DISCREPANCIES COULD BE RELATED TO THE USE OF METHODS WITH LIMITED TAXONOMIC RESOLUTION (E.G., API STRIPS) OR THAT ARE UNSUITABLE FOR RELIABLE IDENTIFICATION UP TO SPECIES LEVEL (E.G., PULSED-FIELD GEL ELECTROPHORESIS AND RANDOMLY AMPLIFIED POLYMORPHIC DNA ANALYSIS). THE CURRENT STUDY HAS AGAIN HIGHLIGHTED THAT RELIABLE IDENTIFICATION OF LAB AND PROPIONIBACTERIA REQUIRES MOLECULAR METHODS WITH A HIGH TAXONOMIC RESOLUTION THAT ARE LINKED TO UP-TO-DATE IDENTIFICATION LIBRARIES. (C) 2006 ELSEVIER MASSON SAS. ALL RIGHTS RESERVED.",FRAGMENT-LENGTH-POLYMORPHISM; POLYMERASE-CHAIN-REACTION; LACTIC-ACID BACTERIA; BIFIDOBACTERIUM-ANIMALIS; LACTOBACILLUS-PARACASEI; SEQUENCE-ANALYSIS; COMB-NOV; IDENTIFICATION; DNA; PCR,PRODUCT LABELING; FAFLP; REP-PCR; LACTOBACILLUS; BIFIDOBACTERIUM,RESEARCH IN MICROBIOLOGY,"HUYS, G##VANCANNEYT, M##D'HAENE, K##VANKERCKHOVEN, V##GOOSSENS, H##SWINGS, J","UNIV GHENT, MICROBIOL LAB, B-9000 GHENT, BELGIUM. UNIV GHENT, BCCM TM, LMG BACTERIA COLLECT, B-9000 GHENT, BELGIUM. UNIV ANTWERP, LAB MED MICROBIOL, B-2610 ANTWERP, BELGIUM. LEIDEN UNIV, MED CTR, NL-2300 LEIDEN, NETHERLANDS.",MICROBIOLOGY,MICROBIOLOGY,"BAELE M, 2002, J MICROBIOL METH, V50, P263, DOI 10.1016/S0167-7012(02)00035-0##BOYD MA, 2005, J CLIN MICROBIOL, V43, P5309, DOI 10.1128/JCM.43.10.5309-5311.2005##CAI YM, 2000, MICROBIOL IMMUNOL, V44, P815, DOI 10.1111/J.1348-0421.2000.TB02568.X##COLLADO MC, 2006, EUR FOOD RES TECHNOL, V222, P112, DOI 10.1007/S00217-005-0093-Z##COLLINS MD, 1989, INT J SYST BACTERIOL, V39, P105, DOI 10.1099/00207713-39-2-105##DELLAGLIO F, 2002, INT J SYST EVOL MICR, V52, P285, DOI 10.1099/00207713-52-1-285##DICKS LMT, 1996, INT J SYST BACTERIOL, V46, P337, DOI 10.1099/00207713-46-1-337##DRISKO J, 2005, DIGEST DIS SCI, V50, P1113, DOI [10.1007/S10620-005-2931-Z, 10.1007/S10620-005-2714-6]##FASOLI S, 2003, INT J FOOD MICROBIOL, V82, P59, DOI 10.1016/S0168-1605(02)00259-3##GANCHEVA A, 1999, SYST APPL MICROBIOL, V22, P573, DOI 10.1016/S0723-2020(99)80011-3##GEVERS D, 2001, FEMS MICROBIOL LETT, V205, P31, DOI 10.1016/S0378-1097(01)00439-6##HAMILTON-MILLER JMT, 1999, PUBLIC HEALTH NUTR, V2, P223, DOI 10.1017/S1368980099000282##HAMILTON-MILLER JMT, 2002, INT J FOOD MICROBIOL, V72, P175, DOI 10.1016/S0168-1605(01)00703-6##HOA NT, 2000, APPL ENVIRON MICROB, V66, P5241, DOI 10.1128/AEM.66.12.5241-5247.2000##HOLZAPFEL WH, 1998, INT J FOOD MICROBIOL, V41, P85, DOI 10.1016/S0168-1605(98)00044-0##KAUFMANN P, 1997, APPL ENVIRON MICROB, V63, P1268, DOI 10.1128/AEM.63.4.1268-1273.1997##KLEIN G, 1998, INT J FOOD MICROBIOL, V41, P103, DOI 10.1016/S0168-1605(98)00049-X##MASCO L, 2005, INT J FOOD MICROBIOL, V102, P221, DOI 10.1016/J.IJFOODMICRO.2004.11.018##MASCO L, 2004, INT J SYST EVOL MICR, V54, P1137, DOI 10.1099/IJS.0.03011-0##MASCO L, 2003, SYST APPL MICROBIOL, V26, P557, DOI 10.1078/072320203770865864##MERCENIER A, 2003, CURR PHARM DESIGN, V9, P175, DOI 10.2174/1381612033392224##MEUNIER JR, 1993, RES MICROBIOL, V144, P373, DOI 10.1016/0923-2508(93)90194-7##MIYAKE T, 1998, MICROBIOL IMMUNOL, V42, P661, DOI 10.1111/J.1348-0421.1998.TB02337.X##NASER SM, 2006, INT J SYST EVOL MICR, V56, P355, DOI 10.1099/IJS.0.64001-0##NIEMANN S, 1997, J APPL MICROBIOL, V82, P477, DOI 10.1046/J.1365-2672.1997.00141.X##OLIVE DM, 1999, J CLIN MICROBIOL, V37, P1661, DOI 10.1128/JCM.37.6.1661-1669.1999##PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/J.1472-765X.1989.TB00262.X##POT B., 1994, CHEM METHODS PROKARY, P493##REUTER G, 2002, FOOD RES INT, V35, P117, DOI 10.1016/S0963-9969(01)00172-7##SAARELA M, 2000, J BIOTECHNOL, V84, P197, DOI 10.1016/S0168-1656(00)00375-8##SAKATA S, 2002, INT J SYST EVOL MICR, V52, P1945, DOI [10.1099/IJS.0.02221-0, 10.1099/00207713-52-6-1945]##SANDERS ME, 1999, ANTON LEEUW INT J G, V76, P293, DOI 10.1023/A:1002029204834##TEMMERMAN R, 2004, TRENDS FOOD SCI TECH, V15, P348, DOI 10.1016/J.TIFS.2003.12.007##TEMMERMAN R, 2003, INT J FOOD MICROBIOL, V81, P1, DOI 10.1016/S0168-1605(02)00162-9##TEMMERMAN R, 2003, APPL ENVIRON MICROB, V69, P220, DOI 10.1128/AEM.69.1.220-226.2003##THOMPSON FL, 2001, SYST APPL MICROBIOL, V24, P520, DOI 10.1078/0723-2020-00067##TORRIANI S, 2001, APPL ENVIRON MICROB, V67, P3450, DOI 10.1128/AEM.67.8.3450-3454.2001##VANKERCKHOVEN VANESSA V., 2004, MICROBIAL ECOLOGY IN HEALTH AND DISEASE, V16, P131, DOI 10.1080/08910600410032349##VENTURA M, 2004, ANTON LEEUW INT J G, V86, P205, DOI 10.1023/B:ANTO.0000047930.11029.EC##VENTURA M, 2003, APPL ENVIRON MICROB, V69, P7517, DOI 10.1128/AEM.69.12.7517-7522.2003##VENTURA M, 2003, APPL ENVIRON MICROB, V69, P6908, DOI 10.1128/AEM.69.11.6908-6922.2003##VENTURA M, 2000, SYST APPL MICROBIOL, V23, P504, DOI 10.1016/S0723-2020(00)80024-7##VERSALOVIC JAMES, 1994, METHODS IN MOLECULAR AND CELLULAR BIOLOGY, V5, P25##WEISS N, 1983, SYST APPL MICROBIOL, V4, P552, DOI 10.1016/S0723-2020(83)80012-5##YEUNG PSM, 2004, J APPL MICROBIOL, V97, P1095, DOI 10.1111/J.1365-2672.2004.02400.X##YEUNG PSM, 2002, J DAIRY SCI, V85, P1039, DOI 10.3168/JDS.S0022-0302(02)74164-7",111,2020-11-20,NA
J,WOS:000242599900011,2006,ANNOTATED BIBLIOGRAPHY OF RESEARCH IN THE TEACHING OF ENGLISH,NA,NA,NA,RESEARCH IN THE TEACHING OF ENGLISH,"BEACH, R##BIGELOW, M##DILLON, D##GALDA, L##HELMAN, L##KALNIN, JS##LEWIS, C##O'BRIEN, D##JORGENSEN, K##LIANG, L##RIJLAARSDAM, G##JANSSEN, T","UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA. UNIV KANSAS, LAWRENCE, KS 66045 USA. UNIV UTAH, SALT LAKE CITY, UT 84112 USA. UNIV AMSTERDAM, NL-1012 WX AMSTERDAM, NETHERLANDS.",EDUCATION & EDUCATIONAL RESEARCH,EDUCATION & EDUCATIONAL RESEARCH,NA,0,2020-11-20,NA
J,WOS:000241384800001,2006,PERSPECTIVES ON THE INTEGRATION OF OLDER MEN AND WOMEN,"THIS INTRODUCTION TO THE SPECIAL ISSUE ""SOCIAL INTEGRATION IN LATER LIFE"" ADDRESSES THE BACKGROUND IDEAS AND CONCEPTS OF THE ARTICLES ENCOMPASSING RESEARCH INTO THE EXTENT AND QUALITY OF OLDER ADULTS' INTEGRATION IN ORGANIZATIONS, FAMILY, AND PERSONAL NETWORKS. A ROUGH CONCEPTUAL FRAMEWORK IS PROVIDED, DISTINGUISHING BETWEEN TYPES OF INTEGRATION AND DIFFERENT UNITS OF ANALYSIS. THE MACRO LEVEL OF SOCIETY AND ITS SOCIAL INSTITUTIONS AS WELL AS SMALLER GROUPS AND THE SOCIAL LOCATIONS OF INDIVIDUALS ARE ADDRESSED. ON A MACRO LEVEL, INTEGRATION AND SEGREGATION ARE JUXTAPOSED, BUILDING ON CLASSIC DISCUSSIONS OF INTEGRATION, AS WELL AS RECENT IDEAS ABOUT SOCIAL RESOURCES, WELFARE STATES, AND REKINDLED CONSIDERATIONS OF AGE SEGREGATION. AT THE INDIVIDUAL LEVEL, THE CONCEPTS OF INTEGRATION AND ISOLATION AND THE SUBJECTIVE ASSESSMENTS OF EMBEDDEDNESS AND LONELINESS ARE CONTRASTED.",LONELINESS,SOCIAL INTEGRATION; OLDER ADULTS; SOCIAL ISOLATION; SEGREGATION; EMBEDDEDNESS; LONELINESS,RESEARCH ON AGING,"GIERVELD, JD##HAGESTAD, GO","VRIJE UNIV AMSTERDAM, FAC SOCIAL SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. NORWEGIAN SOCIAL RES OSLO, OSLO, NORWAY.",GERONTOLOGY,GERIATRICS & GERONTOLOGY,"ATTIASDONFUT C, 2000, MYTH GENERATIONAL CO, P1##AVRAMOV D, 2002, PEOPLE DEMOGRAPHY SO##BELLAH R. N., 1991, GOOD SOC##BELLAH RN, 1985, HABITS HEART INDIVID##BREHM SS, 2002, INTIMATE RELATIONSHI##COLEMAN J, 1990, FDN SOCIAL THEORY##CUMMING E., 1961, GROWING OLD PROCESS##DEJONGGIERVELD J, 1987, J PERS SOC PSYCHOL, V53, P119, DOI 10.1037/0022-3514.53.1.119##ESPING-ANDERSEN G., 1999, SOCIAL FDN POSTINDUS##GIERVELD JD, 2004, J MARRIAGE FAM, V66, P236##GIERVELD JD, 2006, CAMBRIDGE HANDBOOK OF PERSONAL RELATIONSHIPS, P485, DOI 10.1017/CBO9780511606632.027##GUILLEMARD AM, 1993, ANNU REV SOCIOL, V19, P469##HAGESTAD G.O., 2001, HDB BIOL AGING, P3##JOHNSON D P, 1987, JOURNAL OF CROSS-CULTURAL GERONTOLOGY, V2, P257, DOI 10.1007/BF00160684##KAWACHI I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491##KOHLI M, 2000, 2 LEBENSHALFTE GESEL, V1, P176##KOHLI M, 2005, ANN REV GERONTOLOGY, V24, P266##KUNEMUND H, 2000, 2 LEBENSHALFTE GESEL, V1, P277##LANDECKER WS, 1952, SOC FORCES, V30, P394, DOI 10.2307/2572339##LANDECKER WS, 1951, AM J SOCIOL, V56, P332, DOI 10.1086/220757##LAWTON PM, 1980, ENV AGING##MCCANN RM, 2002, AGEISM STEREOTYPING##O'RAND A. M., 2001, HDB AGING SOCIAL SCI, P197##PIPHER M, 1999, ANOTHER COUNTRY NEGO##PUTNAM R. D., 2000, BOWLING ALONE COLLAP##REMERY C, 2003, POPUL RES POLICY REV, V22, P21, DOI 10.1023/A:1023543307473##RIESMAN DN, 1950, LONELY CROWD STUDY N##RIFKIN J., 2004, EUROPEAN DREAM EUROP##ROKACH A, 2001, SOC INDIC RES, V53, P17, DOI 10.1023/A:1007183101458##ROSOW I., 1967, SOCIAL INTEGRATION A##SLATER P, 1970, PURSUIT LONELINESS A##STEVENS N, 2001, AGEING SOC, V21, P183, DOI 10.1017/S0144686X01008108##UHLENBERG P, 2004, AGEING SOC, V24, P5, DOI 10.1017/S0144686X0300151X##UHLENBERG P, 2000, GERONTOLOGIST, V40, P261, DOI 10.1093/GERONT/40.3.261##VAN TILBURG T, 1998, J SOC PERS RELAT, V15, P740, DOI 10.1177/0265407598156002",19,2020-11-20,NA
J,WOS:000241384800006,2006,"MARRIAGE, SOCIAL INTEGRATION, AND LONELINESS IN THE SECOND HALF OF LIFE - A COMPARISON OF DUTCH AND GERMAN MEN AND WOMEN","ALTHOUGH MARRIAGE IS USUALLY CONSIDERED TO BE SOCIALLY INTEGRATIVE, SOME STUDIES INDICATE THAT IT CAN BE PRIVATIZING, ENCLOSING COUPLES IN ISOLATED DYADS. THIS STUDY COMPARED THE AVAILABILITY OF SUPPORT, COMPANIONSHIP, AND NEGATIVE RELATIONAL EXPERIENCES IN VARIOUS TYPES OF RELATIONSHIPS FOR MARRIED MEN AND WOMEN AGED 40 TO 85 YEARS IN THE NETHERLANDS AND GERMANY. THE DUTCH DEMONSTRATED A MORE VARIED PATTERN OF RELATIONSHIPS BEYOND THE NUCLEAR FAMILY THAN THE GERMANS BUT ALSO REPORTED WORRYING ABOUT A GREATER VARIETY OF PEOPLE. IN BOTH COUNTRIES, MEN RELIED MORE STRONGLY ON THEIR PARTNERS, WHEREAS WOMEN HAD MORE VARIED NETWORKS AND EXPERIENCED MORE WORRIES. A CONTINUUM OF SOCIAL INVOLVEMENT CAN BE DRAWN WITH GERMAN MEN, FOR WHOM MARRIAGE IS PRIVATIZING, AT ONE END AND DUTCH WOMEN, FOR WHOM MARRIAGE IS HIGHLY SOCIALLY INTEGRATING, AT THE OTHER. LONELINESS WAS RELATED TO THE PROVISIONS OF SOCIAL RELATIONS, BUT NO NATIONAL AND GENDER DIFFERENCES IN PREDICTORS OF LONELINESS WERE FOUND.",OLDER-ADULTS; SUPPORT; PATTERNS; FAMILIES; COUPLES; GENDER,SOCIAL INTEGRATION; LONELINESS; GENDER; MARRIAGE; SOCIAL RELATIONS,RESEARCH ON AGING,"STEVENS, N##WESTERHOF, GJ","RADBOUD UNIV NIJMEGEN, CTR PSYCHOGERONTOL, NL-6500 HE NIJMEGEN, NETHERLANDS.",GERONTOLOGY,GERIATRICS & GERONTOLOGY,"ACITELLI LK, 1994, J PERS SOC PSYCHOL, V67, P688, DOI 10.1037/0022-3514.67.4.688##ALTERGOTT K, 1985, SOCIAL BONDS LATER L, P51##ANTONUCCI T, 2001, HDB PSYCHOL AGING, P427##BODE C, 2003, THESIS U NIJMEGEN##CUTRONA C. E., 1996, SOCIAL SUPPORT COUPL##DAATLAND SO, 2001, Z GERONTOL GERIATR, V34, P16, DOI 10.1007/S003910170086##DE JONG GIERVELD J., 1995, LIVING ARRANGEMENTS, P155##DE JONG GIERVELD J, 1985, APPLIED PSYCHOL MEAS, V9, P289, DOI DOI 10.1177/014662168500900307##DITTMANNKOHLI F, 2001, 2 LEBENSHALFTE PSYCH##DYKSTRA PA, 1993, J SOC PERS RELAT, V10, P355, DOI 10.1177/0265407593103004##DYKSTRA PA, 1990, NEXT NONKIN IMPORTAN##HOFSTEDE G, 2001, CULTURES CONSEQUENCE##KENDIG H, 1999, AGEING SOC, V19, P185, DOI 10.1017/S0144686X99007278##KUNEMUND H, 1999, AGEING SOC, V19, P93, DOI 10.1017/S0144686X99007205##LYONS KS, 2000, AGING MENT HEALTH, V4, P234, DOI 10.1080/713649930##PERLMAN D, 1981, PERS RELATIONSHIP, P31##PINQUART M, 2003, J SOC PERS RELAT, V20, P31, DOI 10.1177/0265407503020001186##PINQUART M, 2001, BASIC APPL SOC PSYCH, V23, P245, DOI 10.1207/S15324834BASP2304_2##QUIROUETTE C, 1992, INT J AGING HUM DEV, V34, P257, DOI 10.2190/35PY-3AXX-XT1V-71LR##ROOK K.S., 1990, SOCIAL SUPPORT INTER, P219##*SCP, 2000, SOC CULT RAPP 2000 N##SMITH J, 1998, PSYCHOL AGING, V13, P676, DOI 10.1037/0882-7974.13.4.676##SONNENBERG CM, 2000, ACTA PSYCHIAT SCAND, V101, P286, DOI 10.1034/J.1600-0447.2000.101004286.X##STEVENS NL, IN PRESS J SOCIAL PE##STEVERINK N, 2001, DUTCH AGING SURVEY O##STROEBE W, 1987, BEREAVEMENT HLTH PSY##TORNSTAM L, 1992, J SOC PERS RELAT, V9, P197, DOI 10.1177/0265407592092003##VAN TILBURG T, 1998, J SOC PERS RELAT, V15, P740, DOI 10.1177/0265407598156002##VAN TILBURG T. G., 1995, LIVING ARRANGEMENTS, P83##WALEN HR, 2000, J SOC PERS RELAT, V17, P5, DOI 10.1177/0265407500171001##WALKER A, 1993, AGEING EUROPE",39,2020-11-20,NA
J,WOS:000241384800007,2006,LONG-STANDING NONKIN RELATIONSHIPS OF OLDER ADULTS IN THE NETHERLANDS AND THE UNITED STATES,"THE MAIN RESEARCH QUESTIONS OF THIS STUDY WERE (1) HOW LONG HAVE ADULTS IN THE NETHERLANDS AND THE UNITED STATES KNOWN MEMBERS OF THEIR NONKIN NETWORKS? (2) WHAT ARE THE PREDICTORS OF LONG-STANDING NONKIN RELATIONSHIPS? AND (3) WHICH PREDICTORS ARE RECOGNIZABLE IN BOTH SOCIETIES? THE DATA CAME FROM THE NESTOR-LSN SURVEY (3,229 ADULTS AGED 55 TO 89 YEARS IN THE NETHERLANDS) AND FROM THE NORTHERN CALIFORNIA COMMUNITY STUDY (N=1,050, WITH 225 RESPONDENTS AGED 55 TO 91 YEARS IN THE UNITED STATES). IN BOTH COUNTRIES, THE DURATION OF NONKIN RELATIONSHIPS WAS RELATED TO THE ABSENCE OF NETWORK-DISTURBING VARIABLES (E.G., THE NUMBER OF YEARS SINCE THE LAST MOVE), NETWORK-SUSTAINING VARIABLES (E.G., DISTANCE TO NONKIN), AND OTHER NETWORK PROPERTIES (E.G., HOMOGENEITY). NATIONALLY BASED DIFFERENCES WERE ALSO OBSERVED (E.G., HAVING A CAR WAS RELATED TO STABLE RELATIONSHIPS ONLY IN THE UNITED STATES, AND THE SPECIAL INTEGRATIVE FUNCTIONS OF EXCLUSIVE FRIENDSHIPS WERE ELICITED ONLY IN EUROPE).",PERSONAL NETWORKS; LATER LIFE; AGE; FRIENDSHIP; LONELINESS; STABILITY; NEIGHBORS; SUPPORT; DECADE,SOCIAL INTEGRATION; CROSS-CULTURAL; DURATION; NONKIN RELATIONSHIPS,RESEARCH ON AGING,"GIERVELD, JD##PERLMAN, D","NETHERLANDS INTERDISCIPLINARY DEMOG INST, NL-2502 AR THE HAGUE, NETHERLANDS. VRIJE UNIV AMSTERDAM, FAC SOCIAL SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV BRITISH COLUMBIA, VANCOUVER, BC V5Z 1M9, CANADA.",GERONTOLOGY,GERIATRICS & GERONTOLOGY,"ADAMS RG, 2000, J AGING STUD, V14, P117, DOI 10.1016/S0890-4065(00)80019-5##AJROUCH KJ, 2005, J GERONTOL B-PSYCHOL, V60, PS311, DOI 10.1093/GERONB/60.6.S311##ANTONUCCI TC, 1994, WOMEN GROWING OLDER, P239##BREHM SS, 2002, INTIMATE RELATIONSHI##CANTOR MH, 1979, RES AGING, V1, P434, DOI DOI 10.1177/016402757914002##DETOCQUEVILLE A, 2004, DEMOCRACY AM, V1, P8405##DYKSTRA PA, 1990, NEXT NONKIN IMPORTAN##FELD SL, 1997, SOC NETWORKS, V19, P91, DOI 10.1016/S0378-8733(96)00293-6##FERRAND A, 1996, SEXUALITY SOCIAL SCI, P265##FISCHER CLAUDE S., 1982, DWELL FRIENDS PERSON##GEERS AL, 1998, CURR PSYCHOL, V17, P3, DOI 10.1007/S12144-998-1017-4##GIERVELD JD, 1993, ADV PERSONAL RELATIO, V4, P195##HOLLINGER F, 1990, EUROPEAN SOCIOLOGICA, V0006##IKKINK KK, 1999, SOC NETWORKS, V21, P131##JOHNSON D P, 1987, JOURNAL OF CROSS-CULTURAL GERONTOLOGY, V2, P257, DOI 10.1007/BF00160684##KAHN R. L., 1980, LIFE-SPAN DEV BEHAV, DOI DOI 10.1177/016502548000300303##KNIPSCHEER KCP, 1995, LIVING ARRANGEMENTS##LAUMANN E, 1973, BONDS PLURALISM FORM##LITWAK E, 1969, AM SOCIOL REV, V34, P465, DOI 10.2307/2091957##MENDELSON MJ, 1999, CAN J BEHAV SCI, V31, P130, DOI 10.1037/H0087080##MONSOUR M, 2002, WOMEN MEN FRIENDS RE##MORGAN DL, 1996, SOC NETWORKS, V19, P9##PUTNAM R. D., 2000, BOWLING ALONE COLLAP##RIESMAN DN, 1950, LONELY CROWD STUDY N##RIFKIN J., 2004, EUROPEAN DREAM EUROP##ROKACH A, 2001, SOC INDIC RES, V53, P17, DOI 10.1023/A:1007183101458##SCHUTZ ALFRED, 1967, PHENOMENOLOGY SOCIAL##SHEA L, 1988, J SOC PERS RELAT, V5, P83, DOI 10.1177/0265407588051005##SLATER P, 1970, PURSUIT LONELINESS##SUITOR J, 1997, SOC NETWORKS, V19, P51, DOI 10.1016/S0378-8733(96)00290-0##SUITOR JJ, 1997, SOC NETWORKS, V19, P1, DOI 10.1016/S0378-8733(96)00287-0##THOMESE F, 2003, PERS RELATIONSHIP, V10, P535, DOI 10.1046/J.1475-6811.2003.00064.X##TREIMAN DJ, 1985, GENDER LIFE COURSE, P213##UHLENBERG P, 2004, AGEING SOC, V24, P5, DOI 10.1017/S0144686X0300151X##VAN DUIJN MAJ, 1999, SOC NETWORKS, V21, P187, DOI 10.1016/S0378-8733(99)00009-X##VAN TILBURG T, 1998, J GERONTOL B-PSYCHOL, V53, PS313, DOI 10.1093/GERONB/53B.6.S313##VAN TILBURG T, 1998, J SOC PERS RELAT, V15, P740, DOI 10.1177/0265407598156002##WAGNER M., 1999, BERLIN AGING STUDY A, P282, DOI DOI 10.1017/CBO9780511586545.011##WEISS R., 1974, DOING OTHERS, P17##WELLMAN B, 1997, SOC NETWORKS, V19, P27, DOI 10.1016/S0378-8733(96)00289-4",11,2020-11-20,NA
J,WOS:000241384800008,2006,OFF THE BEATEN TRACK - CHILDLESSNESS AND SOCIAL INTEGRATION IN LATE LIFE,"AIMING TO UNCOVER THE SOCIALLY INTEGRATING FUNCTIONS OF PARENTHOOD, THIS STUDY FOCUSED ON DIFFERENCES IN NETWORK SIZE BETWEEN OLDER ADULTS WITH AND WITHOUT CHILDREN, USING SURVEY DATA FROM AMSTERDAM (N=661) AND BERLIN (N=516). EXPLICIT ATTENTION WAS PAID TO DIVERSITY AMONG THE CHILDLESS AND TO THEIR BIOGRAPHICAL PASTS. THE PATTERN OF RESULTS WAS SIMILAR FOR BOTH COUNTRIES. THOSE WHO NEVER HAD CHILDREN HAD SMALLER NETWORKS IN OLD AGE THAN PARENTS, A FINDING PARTIALLY ATTRIBUTABLE TO A MORE LIMITED SUPPLY OF KIN. THERE WAS NO EVIDENCE FOR A COMPETING HYPOTHESIS, NAMELY, THAT CHILDLESSNESS IS A MEANS FOR GREATER SOCIABILITY. CONTRARY TO EXPECTATIONS, THOSE WHO HAD OUTLIVED THEIR CHILDREN WERE NOT MORE SOCIALLY ISOLATED THAN THOSE WHO HAD NEVER HAD CHILDREN. NEITHER WAS THERE SUPPORT FOR THE EXPECTATION THAT PARENTHOOD-HISTORY DIFFERENCES WOULD BE GREATER AMONG WOMEN THAN MEN. LAST, THE FINDINGS SHOWED THAT PARENTHOOD CONTRIBUTES TO SOCIAL INTEGRATION INDEPENDENTLY OF MARRIAGE AND EMPLOYMENT.",AGE; SUPPORT,SOCIAL INTEGRATION; CHILDLESSNESS; NETWORK SIZE; MARITAL HISTORY; OLDER MEN AND WOMEN,RESEARCH ON AGING,"DYKSTRA, PA","NETHERLANDS INTERDISCIPLINARY DEMOG INST, NL-2502 AR THE HAGUE, NETHERLANDS.",GERONTOLOGY,GERIATRICS & GERONTOLOGY,"ARBER S, 1991, GENDER LATER LIFE SO##BALTES P. B., 1999, BERLIN AGING STUDY A##BATESON MC, 1989, COMPOSING LIFE##BERKMAN LF, 2000, SOC SCI MED, V51, P843, DOI 10.1016/S0277-9536(00)00065-4##CAMPBELL LD, 1999, J FAM ISSUES, V20, P114, DOI 10.1177/019251399020001006##CHOI NG, 1994, GERONTOLOGIST, V34, P353, DOI 10.1093/GERONT/34.3.353##CONNIDIS IA, 1994, CAN J AGING, V13, P510, DOI 10.1017/S071498080000636X##CONNIDIS IA, 1990, J GERONTOL, V45, PS141, DOI 10.1093/GERONJ/45.4.S141##CROW G, 2004, SOCIAL NETWORKS SOCI, P7##DORBRITZ J, 1996, Z BEVOLKERUNGSWISSEN, V21, P231##DYKSTRA PA, IN PRESS BLACKWELL E##DYKSTRA PA, 2004, SOCIAL NETWORKS SOCI, P117##DYKSTRA PA, IN PRESS J FAMILY IS##DYKSTRA PA, 1995, LIVING ARRANGEMENTS, P97##EGGEBEEN D, 1985, FAM RELAT, V34, P251, DOI 10.2307/583899##FURSTENBERG FF, 2005, J MARRIAGE FAM, V67, P809, DOI 10.1111/J.1741-3737.2005.00177.X##GERSON KATHLEEN, 1985, HARD CHOICES WOMEN D##HAGESTAD G. O, 2000, GENERATIONS GENDER P, P125##HAGESTAD GO, IN PRESS J FAMILY IS##HAGESTAD GO, 1985, HDB AGING SOCIAL SCI, P35##HAKIM C., 2000, WORK LIFESTYLE CHOIC##HEINZ W. R., 1991, THEORETICAL ADV LIFE, P9##HENKENS K, 1994, J APPL SOC PSYCHOL, V24, P1927, DOI 10.1111/J.1559-1816.1994.TB00568.X##HIRD MJ, 2000, J COMP FAM STUD, V31, P347, DOI 10.3138/JCFS.31.3.347##HOUSE JS, 1988, ANNU REV SOCIOL, V14, P293, DOI 10.1146/ANNUREV.SO.14.080188.001453##HOUSER BB, 1984, PSYCHOL WOMEN QUART, V8, P395, DOI 10.1111/J.1471-6402.1984.TB00647.X##KAHN R. L., 1980, LIFE-SPAN DEV BEHAV, DOI DOI 10.1177/016502548000300303##KENDIG HL, 1988, J GERONTOL, V43, PS31, DOI 10.1093/GERONJ/43.2.S31##KOHLI M., 1991, TIME RETIREMENT COMP##KOLLER BARBARA, 2001, 7 IAB##KOROPECKYJ-COX T, 1998, J GERONTOL B-PSYCHOL, V53, PS303, DOI 10.1093/GERONB/53B.6.S303##LANG FR, 2004, FAMILIES AGEING SOC, P64, DOI DOI 10.1093/0199251169.003.0005##LANG FR, 1994, GESTALTUNG INFORMELL##LETHERBY G, 2002, SOCIOL INQ, V72, P7, DOI 10.1111/1475-682X.00003##LIEFBROER AC, 2000, LEVENSLOPEN VERANDER##LIN N., 2001, SOCIAL CAPITAL THEOR##LUBBEN J., 2004, SOCIAL NETWORKS SOCI, P20##MAAS I, 1999, BERLIN AGING STUDY A, P83##MARGOLIS OS, 1988, GRIEF LOSS ADULT CHI##MUGFORD S, 1986, AGEING FAMILIES SOCI, P38##MULLER W, 1983, STRUKTURWANDEL FRAUE, P55##NEUGARTEN BL, 1986, DAEDALUS-US, V115, P31##NEUGARTEN BL, 1973, LIFE SPAN DEV PSYCH, P53##PORTES A, 2000, SOCIOL FORUM, V15, P1, DOI 10.1023/A:1007537902813##POTT-BUTER H., 1993, FACTS FAIRY TALES FE##PUTNAM R. D., 2000, BOWLING ALONE COLLAP##ROSSI A. S., 1990, HUMAN BONDING PARENT##RUBIN SIMON SHIMSHON, 1993, P285, DOI 10.1017/CBO9780511664076.020##SIXMA H, 1983, MENS MAATSCHAPPIJ, V58, P360##UCHINO BN, 2004, SOCIAL SUPPORT PHYS##VAN TILBURG T. G., 1995, LIVING ARRANGEMENTS, P83##VANGROENOU B, 1995, LIVING ARRANGEMENTS, P185##VEEVERS JE, 1980, CHILDLESS CHOICE##WAGNER M, 2001, Z ERZIEHWISS, V4, P529##WAGNER M., 1999, BERLIN AGING STUDY A, P282, DOI DOI 10.1017/CBO9780511586545.011##WEGENER B., 1988, KRITIK PRESTIGES##WOOLLETT A, 1991, MOTHERHOOD MEANINGS, P47##WU Z, 1998, J GERONTOL B-PSYCHOL, V53, PS324, DOI 10.1093/GERONB/53B.6.S324",36,2020-11-20,NA
J,WOS:000241384800009,2006,POSTSCRIPT,NA,NA,NA,RESEARCH ON AGING,"KNIPSCHEER, K","FREE UNIV AMSTERDAM, FAC SOCIAL SCI, DEPT SOCIAL CULTURAL SCI, NL-1081 HV AMSTERDAM, NETHERLANDS.",GERONTOLOGY,GERIATRICS & GERONTOLOGY,NA,0,2020-11-20,NA
J,WOS:000243286200007,2006,RESEARCH QUALITY AND EFFICIENCY - AN ANALYSIS OF ASSESSMENTS AND MANAGEMENT ISSUES IN DUTCH ECONOMICS AND BUSINESS RESEARCH PROGRAMS,"ASSESSMENTS OF QUALITY AND PRODUCTIVITY OF ACADEMIC RESEARCH PROGRAMS BECOME MORE AND MORE IMPORTANT IN GAINING FINANCIAL SUPPORT, IN HIRING AND PROMOTING RESEARCH STAFF, AND IN BUILDING ACADEMIC REPUTATION. MOST ASSESSMENTS ARE BASED ON PEER REVIEW OR ON BIBLIOMETRIC INFORMATION. IN THIS PAPER WE ANALYZE BOTH BIBLIOMETRIC DATA AND PEER REVIEW ASSESSMENTS OF 169 RESEARCH GROUPS IN ECONOMICS, ECONOMETRICS AND BUSINESS ADMINISTRATION. THE EVALUATIONS ARE ACHIEVED IN TWO INDEPENDENT ROUNDS IN 1995 AND IN 2001, PERMITTING REPLICATION OF OUR STUDY. THE PURPOSE OF THIS STUDY IS TWOFOLD. IN THE FIRST PART WE WANT TO SEE TO WHAT DEGREE BIBLIOMETRIC INFORMATION RELATES TO PEER REVIEW JUDGMENTS. THE RESULTS CONVEY HOW EVALUATORS WEIGHT DIFFERENT OUTPUT CATEGORIES IN THEIR FINAL OVERALL JUDGMENT OF ACADEMIC QUALITY. THE RESULTS ALSO HAVE PRACTICAL MEANING, SINCE THEY INDICATE WHAT THE PREDICTIVE ABILITY OF BIBLIOMETRIC DATA IS FOR FUTURE PEER REVIEW OUTCOMES. IN THE SECOND PART OF THIS STUDY WE AIM AT EXPLAINING DIFFERENCES IN RESEARCH OUTPUT QUALITY AND PRODUCTIVITY BY ORGANIZATIONAL FACTORS, LIKE SIZE OF THE RESEARCH GROUP, COMPOSITION OF STAFF, SOURCES OF RESEARCH FUNDING AND ACADEMIC DISCIPLINE. IN THIS PART, A COMPOSITE INDICATOR IS USED TO REPRESENT THE REVIEW COMMITTEES' OVERALL ASSESSMENT. THE BIBLIOMETRIC DATA MOST STRONGLY RELATED TO THE PEER REVIEWS' OVERALL ASSESSMENT ARE USED TO CONSTRUCT DATA ENVELOPMENT ANALYSES' EFFICIENCY SCORES AS MEASURE OF RESEARCH PRODUCTIVITY. THE MAIN CONCLUSIONS FROM OUR STUDY ARE THAT THE NUMBER OF PUBLICATIONS IN INTERNATIONAL TOP JOURNALS IS THE BEST PREDICTOR OF PEER REVIEW ASSESSMENT RESULTS. CHANGES IN THE CLASSIFICATION OF BIBLIOMETRIC INFORMATION, AS INTRODUCED IN THE SECOND EVALUATION ROUND, DO NOT ALTER THIS CONCLUSION. SIZE OF THE RESEARCH GROUP APPEARS TO BE THE ONLY PERMANENT CHARACTERISTIC ASSOCIATED WITH RESEARCH QUALITY AND PRODUCTIVITY. SIZE IS POSITIVELY RELATED TO RESEARCH QUALITY BUT NEGATIVELY RELATED TO RESEARCH PRODUCTIVITY. LARGER GROUPS APPEAR TO HAVE THE POTENTIAL TO IMPROVE QUALITY, BUT AS GROUPS BECOME LARGER, THEY ALSO EXPERIENCE PROBLEMS IN MAINTAINING THE RESEARCH PRODUCTIVITY OF THE RESEARCH TEAM'S MEMBERS. THE REMAINING ORGANIZATIONAL CHARACTERISTICS APPEAR TO BE TEMPORARILY RELATED TO RESEARCH QUALITY AND PRODUCTIVITY. IN THE FIRST EVALUATION ROUND, RESEARCH PRODUCTIVITY AND QUALITY ARE ASSOCIATED WITH THE DISCIPLINE VARIABLE: RESEARCH PROGRAMS IN MORE QUANTITATIVE AREAS AND CHARACTERIZED BY A HIGHER LEVEL OF PARADIGM DEVELOPMENT LIKE ECONOMETRICS AND OPERATIONS RESEARCH ACHIEVED HIGHER LEVELS OF RESEARCH QUALITY AND PRODUCTIVITY THAN PROGRAMS IN MORE DIVERSE AND LESS QUANTITATIVE AREAS LIKE BUSINESS ADMINISTRATION. THIS RELATION HOWEVER IS NOT PERMANENT, SINCE IT BECOMES INSIGNIFICANT IN THE SECOND EVALUATION ROUND. INSTEAD, FUNDING RELATIONS BECOME MORE APPARENT IN THE SECOND REVIEW ROUND. THE RELATIVE AMOUNT OF NATIONAL FUNDING IN THE RESEARCH GROUP'S FUNDING BECOMES POSITIVELY RELATED TO ACADEMIC QUALITY, WHEREAS THE PORTION OF INCOME FROM COMMITTED RESEARCH IS NEGATIVELY RELATED TO ACADEMIC QUALITY OF THE PROGRAMS' RESEARCH OUTPUT. THIS MAY HAVE BEEN CAUSED BY THE INCREASED IMPORTANCE OF ALTERNATIVE SOURCES OF RESEARCH FUNDING IN THE PERIOD OF THE SECOND REVIEW. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",DATA ENVELOPMENT ANALYSIS; ACCOUNTING-RESEARCH; UNIVERSITY-RESEARCH; DETERMINANTS; INFERENCE; JOURNALS; MODELS; OUTPUT,DETERMINANTS OF RESEARCH EFFICIENCY; RESEARCH QUALITY; NON-PARAMETRIC ANALYSIS; RESEARCH IN ECONOMICS AND BUSINESS ADMINISTRATION; LONGITUDINAL ANALYSIS OF MICRO-UNITS OF PRODUCTION,RESEARCH POLICY,"GROOT, T##GARCIA-VALDERRAMA, T","FREE UNIV AMSTERDAM, FAC ECON & BUSINESS ADM, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV CADIZ, CADIZ, SPAIN.",MANAGEMENT,BUSINESS & ECONOMICS,"ANDERSON R. I., 2000, J REAL ESTATE LIT, V8, P3##ANDERSON RI, 1998, J REAL ESTATE RES, V16, P139, DOI DOI 10.5555/REES.16.2.T51014250M1G6Q40##BALLAS A, 2003, CONTEMP ACCOUNT RES, V20, P619, DOI 10.1506/MLWH-KBTM-ET47-LYKH##BANKER RD, 1984, MANAGE SCI, V30, P1078, DOI 10.1287/MNSC.30.9.1078##BANKER RD, 1997, MANAGE SCI, V43, P1709, DOI 10.1287/MNSC.43.12.1709##BANKER RD, 2001, EVALUATING CONTEXTUA##BARDHAN IR, 1998, J PROD ANAL, V9, P249, DOI 10.1023/A:1018339122236##BARON JN, 1993, J EC LIT##BEATTIE V, 2004, PUBLISHING PATTERNS##BEYER JM, 1978, SOCIOL QUART, V19, P68, DOI 10.1111/J.1533-8525.1978.TB02172.X##BRINN A., 1996, ACCOUNTING BUSINESS, P265##BROWN L. D., 1994, CONTEMP ACCOUNT RES, V11, P223, DOI DOI 10.1111/J.1911-384.1994.TB00442.X##BROWN LD, 1985, J ACCOUNTING RES, V23, P84, DOI 10.2307/2490908##BROWN PD, 1996, BIOL FERT SOILS, V21, P7, DOI 10.1007/BF00335986##CHARNES A, 1978, EUR J OPER RES, V2, P429, DOI 10.1016/0377-2217(78)90138-8##CHERCHYE L, 2005, RES POLICY, V34, P495, DOI 10.1016/J.RESPOL.2005.03.005##COELLI T. J., 2005, INTRO EFFICIENCY PRO##COOPER W. W., 2000, DATA ENVELOPMENT ANA##CROOM DL, 1970, NATURE      SEP, P1173##DWYER P., 1994, ISSUES ACCOUNTING ED, V9, P231##DYCKMAN TR, 1984, J ACCOUNTING RES, V22, P225, DOI 10.2307/2490710##GARCIAVALDERRAM.T, 2002, TECHNOLOGY COMMERCIA##GROOT T., 1999, FINANCIAL ACCOUNTABI, V15, P355##GROOT TLC, 1988, MANAGEMENT UNIVERSIT##GROOT TLC, 1999, FINANCIEEL MANAGEMEN##GROSSKOPF S, 1996, J PROD ANAL, V7, P161, DOI 10.1007/BF00157039##HAIR JR J.F., 1998, MULTIVARIATE DATA AN##HALL T. W., 1991, ADV ACCOUNTING, V8, P161##HARZING A.W., 2000, J QUALITY LIST##HASSELBACK JR, 2000, BENCHMARKS EVALUATIN##HAZEU CA, 1983, EC STAT BERICHTEN, V68, P163##HOLLINGSWORTH BRUCE, 2003, HEALTH CARE MANAG SCI, V6, P203, DOI 10.1023/A:1026255523228##HULL R. P., 1990, ACCOUNT HORIZ, V4, P77##JOHNES G, 1988, RES POLICY, V17, P171, DOI 10.1016/0048-7333(88)90041-8##KONRAD AM, 1990, ADMIN SCI QUART, V35, P258, DOI 10.2307/2393391##KOOREMAN P, 1995, EC STAT BERICHTEN, V80, P493##KUHN TS, 1970, STRUCTURE SCI REVOLU##LODAHL J. B., 1973, RES HIGH EDUC, V1, P191, DOI DOI 10.1007/BF00991529##LOFT A, 2002, EUROPEAN ACCOUNTING, V11, P43, DOI DOI 10.1080/09638180220124734##MOED HF, 1985, RES POLICY, V14, P131, DOI 10.1016/0048-7333(85)90012-5##MORRIS JL, 1990, ACCOUNTING ED J, V3, P46##NEDERHOF AJ, 1993, RES POLICY, V22, P353, DOI 10.1016/0048-7333(93)90005-3##NEDERHOF AJ, 1987, SCIENTOMETRICS, V11, P330##NEWMAN JM, 1993, J APPL PSYCHOL, V78, P518##NUNNALLY JC, 1978, PSYCHOMETRIC THEORY##PARKER L., 1998, ACCOUNTING AUDITING, V11, P371, DOI DOI 10.1108/09513579810231420##PFEFFER J, 1993, ACAD MANAGE REV, V18, P599, DOI 10.2307/258592##RAY SC, 1991, MANAGE SCI, V37, P1620, DOI 10.1287/MNSC.37.12.1620##RINIA EJ, 1998, RES POLICY, V27, P95, DOI 10.1016/S0048-7333(98)00026-2##SCHROEDER R. G., 1988, ACCOUNTING ED J, P1##SIMAR L, 2007, J ECONOMETRICS, V136, P31, DOI 10.1016/J.JECONOM.2005.07.009##STERKEN E, 2000, MAANDBLAD ACCOUNTANC, V74, P73##THANASSOULIS E, 1995, EUR J OPER RES, V80, P588, DOI 10.1016/0377-2217(94)00139-4##TIMMERMANS WA, 1984, U HOGESCHOOL, V30, P109##VAN FLEET DD, 2000, J MANAGE, V26, P839, DOI 10.1016/S0149-2063(00)00060-X##*VSNU, 1990, NOT OND##*VSNU, 2002, ASS RES QUAL BUS ADM##*VSNU, 1994, GIDS ASS RES PROT 19##*VSNU, 2002, ASS RES QUAL EC##*VSNU, 1995, QUAL ASS RES EC##*VSNU VVCW, 1991, PERF MET OND EC FAC##WANG HJ, 2002, J PROD ANAL, V18, P129, DOI 10.1023/A:1016565719882##WEI QL, 1995, EUR J OPER RES, V80, P691, DOI 10.1016/0377-2217(94)00145-3##WESTERHEIJDEN DF, 1996, SOL BAS BESL EFF OND##WHITTINGTON G, 1997, BRIT ACCOUNT REV, V29, P181##WHITTINGTON G, 1993, BRIT ACCOUNT REV, V25, P383##ZIVNEY T., 1995, ISSUES ACCOUNTING ED, V10, P1##ZUMPANO LV, 1994, J AM REAL ESTATE URB, V22, P497",45,2020-11-20,NA
J,WOS:000242184800005,2006,OPTIMISING WASTE TREATMENT SYSTEMS - PART A: METHODOLOGY AND TECHNOLOGICAL DATA FOR OPTIMISING ENERGY PRODUCTION AND ECONOMIC PERFORMANCE,"THE TREATMENT AND UTILISATION OF BIOMASS RESIDUES AND WASTE FOR ENERGY AND RECYCLING CAN CONTRIBUTE SIGNIFICANTLY TO GREENHOUSE GAS EMISSION REDUCTION. THEREFORE, A WASTE TREATMENT STRUCTURE SHOULD BE DESIGNED FOR AN EFFICIENT SAVING OF FOSSIL PRIMARY ENERGY IN TERMS OF MAXIMAL PRIMARY ENERGY SAVINGS OR MINIMAL COSTS PER UNIT OF PRIMARY ENERGY SAVINGS. HOWEVER, THIS IS A COMPLEX TASK, GIVEN THE LARGE NUMBER OF TECHNOLOGIES, RECYCLING OPTIONS AND THEIR LOGISTIC CONSEQUENCES, THAT NECESSITATE AN INTEGRATED ANALYSIS. ALSO, ON LONGER TERM VARIOUS NEW AND IMPROVED TECHNOLOGIES BECOME AVAILABLE WHICH CAN AFFECT PERFORMANCES FOR OPTIONS FROM AN ECONOMIC AND/OR ENERGY POINT OF VIEW. FOR THAT REASON, AN OPTIMISATION TOOL, THAT OPTIMISES A BIOMASS AND WASTE TREATMENT SYSTEM FOR A GIVEN AMOUNT OF BIOMASS AND WASTE, IS DEVELOPED IN THIS STUDY. THIS OPTIMAL BIOMASS AND WASTE TREATMENT SYSTEM IS COMPOSED OF SEVERAL TREATMENT INSTALLATIONS, THAT ARE CHARACTERISED BY SCALE, LOCATION AND KIND OF TECHNOLOGY. IMPORTANT ASPECTS THAT ARE TAKEN INTO ACCOUNT IN THE ANALYSIS ARE HEAT DISTRIBUTION, BIOMASS AND WASTE TRANSPORT AND ECONOMIES OF SCALE. A BROAD VARIETY OF TECHNOLOGIES FOR MATERIAL RECYCLING, CONVERSION OF BIOMASS AND/OR WASTE TO HEAT, ELECTRICITY OR TRANSPORTATION FUEL ARE INCLUDED IN THE OPTIMISATION TOOL. PERFORMANCE DATA OF THESE TECHNOLOGIES ARE BASED ON AN EXTENSIVE REVIEW. EXAMPLES OF INCLUDED TECHNOLOGIES COMPRISE: INTEGRATED GASIFICATION WITH COMBINED CYCLE, WASTE INCINERATION, PYROLYSIS, DIGESTION, CO-FIRING IN FOSSIL POWER PLANTS, BIOMASS INCINERATION, HYDRO-THERMAL UPGRADING, PAPER RECYCLING AND CHIPBOARD PRODUCTION. A COMPARISON OF THE DIFFERENT TECHNOLOGIES IN RELATION TO SCALE SHOWS THAT PRIMARY ENERGY SAVINGS AND COSTS PER UNIT OF PRIMARY ENERGY SAVINGS DIVERGE SIGNIFICANTLY. IN GENERAL, THE OPTIMISATION TOOL DEVELOPED HERE IS SUITABLE FOR ANALYSES OF OPTIMAL BIOMASS AND WASTE TREATMENT STRUCTURES IN DIFFERENT REGIONS WITH REGARD TO PRIMARY ENERGY SAVINGS AND THEIR COSTS. BY MEANS OF SCENARIO ANALYSIS, ROBUST OPTIMAL SOLUTIONS IN TERMS OF PRIMARY ENERGY SAVINGS AND THEIR COSTS CAN BE IDENTIFIED AND THE INFLUENCE OF IMPORTANT PARAMETERS CAN BE ANALYSED. A CASE STUDY OF THE DUTCH BIOMASS AND WASTE TREATMENT SYSTEMS HAS BEEN CARRIED OUT WITH THE OPTIMISATION TOOL AND IS PRESENTED IN PART TWO OF THIS ARTICLE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",POWER; HEAT,SOLID WASTE; RECYCLING; PRIMARY ENERGY SAVINGS; OPTIMISATION; WASTE TREATMENT; BIOMASS,RESOURCES CONSERVATION AND RECYCLING,"DORNBURG, V##FAAIJ, APC##MEULEMAN, B","UNIV UTRECHT, COPERNICUS INST, DEPT SCI TECHNOL & SOC, NL-3584 CS UTRECHT, NETHERLANDS.","ENGINEERING, ENVIRONMENTAL; ENVIRONMENTAL SCIENCES",ENGINEERING; ENVIRONMENTAL SCIENCES & ECOLOGY,"*AOO, 1998, IN THERM VERW GEL HO##BERGER C, 1998, SYST ENG MOD WAST MA##BERGSMA GC, 1997, AFWEGING ENERGETISCH##BESTEBROER SJ, 1996, VGB KRAFTWERKSTECHN, V76, P570##BILITEWSKI B, 1994, ABFALLWIRTSCHAFT EIN##DEKANT HF, 2000, STUDIE VOORSCHAKELIN##DORNBURG V, 2001, BIOMASS BIOENERG, V21, P91, DOI 10.1016/S0961-9534(01)00030-7##DORNBURG V, 2001, SCENARIO ONTWIKKELIN##FAAIJ A, 1998, RESOUR CONSERV RECY, V22, P47, DOI 10.1016/S0921-3449(97)00043-8##FAAIJ A, 2000, 1 WORLD C BIOM EN IN##FAAIJ A, 1998, LONG TERM PERSPECTIV##*FBT, 1994, FLUID BED COMB GAS G##FEENSTRA F, 1995, LOGISTIEK BIJ INZAME##FOCKENS S, 1994, ONTWIKKELINGEN TOTAL##HARDTLEIN M, 1996, WANN RECHNEN GROSS 1##HENKES W, 1998, RECYCLINGMAGAZIN, V24, P8##HEUVEL EJM, 1994, 9414 BTG NOVEM EWAB##HOLMGREN K, 2004, RESOUR CONSERV RECY, V43, P51, DOI 10.1016/J.RESCONREC.2004.05.001##*IEA, 1998, ADV THERM CONV TECHN##ISING M, 1998, 1385 VDI##JAHRAUS B, 1993, BRENNST-WARME-KRAFT, V45, P438##KALTSCHMITT M, 1998, BIOMASS GASTIFICATIO##KALTSCHMITT M., 1997, NACHWACHSENDE ENERGI##KLOOTWIJK M, 1998, ENERGIE EFFICIENT DR##MEULEMAN B, 1998, OPTIMALISATIEMODEL O##*OK I, 1999, ER BAS EN UMW EN PRO##OSSEBAARD ME, 1994, WARMTEDISTRIBUTE TEC##PFEIFFER AE, 1992, OPTIMALISATIE OPBREN##*RECYCLENET, 2000, REC WORLD REC REC IN##ROSCH C, 1997, MONITORING NACHWACHS##ROSCH C, 1998, BIOMASS GASIFICATION, PCH6##SAS HJW, 1994, VERWIJDERING HUISHOU##SOLANTAUSTA Y, 1997, ELECT PRODUCTION ADV##SUNDBERG J, 1997, SYST ENG MOD WAST MA##TANSKANEN JH, 2000, RESOUR CONSERV RECY, V30, P111, DOI 10.1016/S0921-3449(00)00056-2##TIJMENSEN MJA, 2002, BIOMASS BIOENERG, V23, P129, DOI 10.1016/S0961-9534(02)00037-5##VANDENBROEK R, 1995, JOU2CT930397 EUR COM##VANHALEN CJG, 2000, BEDRIJFSECONOMISCHE##VANHEIJNINGEN RJJ, 1992, MEER ENERGIEKENTALLE##VEENENDAAL R, 1994, GASIFICATION WASTE E##VROONHOF JTT, 1994, BIJLAGEN BIJ RAPPORT##WANG FS, 1998, SYST ENG MOD WAST MA##WIEGEL U, 1997, MULLMAGAZIN, P64##RESOUR CONSERV RECY, DOI DOI 10.1016/J.RESCONREC.2006.02.002",34,2020-11-20,NA
J,WOS:000242521200012,2006,ASSESSMENT OF NEONATAL RESUSCITATION SKILLS: A RELIABLE AND VALID SCORING SYSTEM,"OBJECTIVE: TO STUDY THE RELIABILITY AND VALIDITY OF A SCORING INSTRUMENT FOR THE ASSESSMENT OF NEONATAL RESUSCITATION SKILLS IN A TRAINING SETTING. METHODS: FOURTEEN PAEDIATRIC RESIDENTS PERFORMED A NEONATAL RESUSCITATION ON A MANIKIN, WHILE BEING RECORDED WITH A VIDEO CAMERA. THE VIDEOTAPES WERE ANALYSED USING AN EXISTING SCORING INSTRUMENT WITH AN ESTABLISHED FACE AND CONTENT VALIDITY, ADJUSTED FOR USE IN A TRAINING SETTING. INTRA- AND INTER-RATER RELIABILITY WERE ASSESSED BY COMPARING THE RATINGS OF THE VIDEOTAPES OF THREE RATERS, ONE OF WHO RATED THE VIDEOTAPES TWICE. INTRA-CLASS COEFFICIENTS (]CC) WERE CALCULATED FOR THE SUM SCORE, PERCENTAGES OF AGREEMENT AND KAPPA COEFFICIENTS FOR THE INDIVIDUAL ITEMS. TO STUDY CONSTRUCT VALIDITY, THE PERFORMANCE OF A SECOND RESUSCITATION OF BY RESIDENTS WAS ASSESSED AFTER THEY HAD RECEIVED FEEDBACK ON THEIR FIRST PERFORMANCE. RESULTS: THE ICC WERE 0.95 AND 0.77 FOR INTRA- AND INTER-RATER RELIABILITY, RESPECTIVELY. THE MEDIAN PERCENTAGE OF INTRA-RATER AGREEMENT WAS 100%; INTER-RATER AGREEMENT 78.6-84.0%. THE MEDIAN KAPPA WAS 0.85 FOR INTRA-RATER RELIABILITY, AND 0.42-0.59 FOR INTER-RATER RELIABILITY. RESIDENTS SHOWED A 10% IMPROVEMENT (95% CONFIDENCE INTERVAL -4; 23%) ON PERFORMANCE OF A SECOND RESUSCITATION, WHICH SUPPORTS THE INSTRUMENT'S CONSTRUCT VALIDITY. CONCLUSION: A USEFUL AND VALID INSTRUMENT WITH GOOD INTRA-RATER AND REASONABLE INTER-RATER RELIABILITY IS NOW AVAILABLE FOR THE ASSESSMENT OF NEONATAL RESUSCITATION SKILLS IN A TRAINING SETTING. ITS RELIABILITY CAN BE IMPROVED BY USING A MORE ADVANCED MANIKIN AND BY TRAINING OF THE RATERS. (C) 2006 ELSEVIER IRELAND LTD. ALL RIGHTS RESERVED.",BASIC LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; PERFORMANCE; CARE,NEONATAL RESUSCITATION; MANIKIN; EDUCATION; TRAINING,RESUSCITATION,"VAN DER HEIDE, PA##VAN TOLEDO-EPPINGA, L##VAN DER HEIDE, M##VAN DER LEE, JH","UNIV AMSTERDAM, EMMA CHILDRENS HOSP, CTR PAEDIAT CLIN EPIDEMIOL, ACAD MED CTR, NL-1100 DD AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, EMMA CHILDRENS HOSP, DEPT NEONATOL, ACAD MED CTR, AMSTERDAM, NETHERLANDS. ISALA CLIN, DIV NEONATOL, PRINCESS AMALIA DEPT PAEDIAT, ZWOLLE, NETHERLANDS.",CRITICAL CARE MEDICINE; EMERGENCY MEDICINE,GENERAL & INTERNAL MEDICINE; EMERGENCY MEDICINE,"ALTMAN P, 1991, PRACTICAL STAT MED R##BERDEN HJJM, 1992, RESUSCITATION, V23, P21, DOI 10.1016/0300-9572(92)90159-A##BRENNAN RT, 1996, RESUSCITATION, V32, P85, DOI 10.1016/0300-9572(96)00967-7##CARBINE DN, 2000, PEDIATRICS, V106, P654, DOI 10.1542/PEDS.106.4.654##CRONIN C, 2001, MED EDUC, V35, P1013, DOI 10.1046/J.1365-2923.2001.01055.X##DONNELLY PD, 1998, RESUSCITATION, V36, P51, DOI 10.1016/S0300-9572(97)00092-0##DUNN S, 1992, J CONTIN EDUC NURS, V23, P118##JANSEN JJM, 1997, RESUSCITATION, V34, P35, DOI 10.1016/S0300-9572(96)01028-3##KACZOROWSKI J, 1998, FAM MED, V30, P705##LAWN JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5##LESTER CA, 1997, RESUSCITATION, V34, P43, DOI 10.1016/S0300-9572(96)01046-5##MITCHELL ANN, 2002, ADV NEONATAL CARE, V2, P316, DOI 10.1053/ADNC.2002.36831##NIERMEYER S, 2000, PEDIATRICS, V106##PALMEKILANDER C, 1992, ACTA PAEDIATR, V81, P739, DOI 10.1111/J.1651-2227.1992.TB12094.X##PERLMAN JM, 1995, ARCH PEDIAT ADOL MED, V149, P20, DOI 10.1001/ARCHPEDI.1995.02170130022005##RYAN C A, 1999, NEONATAL NETW, V18, P25##SINGHAL N, 2001, J PERINATOL, V21, P388, DOI 10.1038/SJ.JP.7210551##STREINER D. L., 1995, HLTH MEASUREMENT SCA",43,2020-11-20,NA
J,WOS:000242645300001,2006,DENDRITIC CELL-MEDIATED HIV-1 TRANSMISSION TO T CELLS OF LAD-1 PATIENTS IS IMPAIRED DUE TO THE DEFECT IN LFA-1,"BACKGROUND: DENDRITIC CELLS (DC) HAVE BEEN PROPOSED TO MEDIATE SEXUAL HIV-1 TRANSMISSION BY CAPTURING THE VIRUS IN THE MUCOSA AND SUBSEQUENTLY PRESENTING IT TO CD4(+) T CELLS. WE HAVE DEMONSTRATED BEFORE THAT DC SUBSETS EXPRESSING HIGHER LEVELS OF INTERCELLULAR ADHESION MOLECULE-1 (ICAM-1) ARE BETTER HIV-1 TRANSMITTERS. ICAM-1 BINDS LEUKOCYTE FUNCTION-ASSOCIATED MOLECULE-1 (LFA-1) ON T CELLS, AN INTEGRIN RESPONSIBLE FOR ADHESION AND SIGNALING AT THE IMMUNOLOGICAL SYNAPSE. TO CORROBORATE THE IMPORTANCE OF THE ICAM-1 - LFA-1 INTERACTION, WE PERFORMED TRANSMISSION EXPERIMENTS TO LFA-1 NEGATIVE LEUKOCYTES FROM LEUKOCYTE ADHESION DEFICIENCY TYPE 1 (LAD-1) PATIENTS. RESULTS: WE CLEARLY SHOW THAT DC-MEDIATED HIV-1 TRANSMISSION TO LAD-1 T CELLS IS IMPAIRED IN COMPARISON TO HEALTHY CONTROLS. FURTHERMORE, HIV-1 TRANSMISSION TO T CELLS FROM A UNIQUE LAD-1 PATIENT WITH A WELL CHARACTERIZED LFA-1 ACTIVATION DEFECT WAS IMPAIRED AS WELL, DEMONSTRATING THAT ACTIVATION OF LFA-1 IS CRUCIAL FOR EFFICIENT TRANSMISSION. DECREASED CELL ADHESION BETWEEN DC AND LAD-1 T CELLS COULD ALSO BE ILLUSTRATED BY SIGNIFICANTLY SMALLER DC-T CELL CLUSTERS AFTER HIV-1 TRANSMISSION. CONCLUSION: BY MAKING USE OF LFA-1 DEFECT CELLS FROM UNIQUE PATIENTS, THIS STUDY PROVIDES MORE INSIGHT INTO THE MECHANISM OF HIV-1 TRANSMISSION BY DC. THIS MAY OFFER NEW TREATMENT OPTIONS TO REDUCE SEXUAL TRANSMISSION OF HIV-1.",SIMIAN IMMUNODEFICIENCY VIRUS; LEUKOCYTE ADHESION DEFICIENCY; INTRAVAGINAL INOCULATION; PRODUCTIVE INFECTION; AVIDITY REGULATION; LYMPHOCYTE ARREST; HOST ICAM-1; INTEGRINS; AFFINITY; BINDING,NA,RETROVIROLOGY,"GROOT, F##KUIJPERS, TW##BERKHOUT, B##DE JONG, EC","UNIV AMSTERDAM, DEPT CELL BIOL & HISTOL, ACAD MED CTR, NL-1012 WX AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN RETROVIROL, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, DIV PEDIAT HEMATOL IMMUNOL & INFECT DIS, EMMA CHILDRENS HOSP, NL-1105 AZ AMSTERDAM, NETHERLANDS.",VIROLOGY,VIROLOGY,"ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/ANNUREV.ME.38.020187.001135##ANDERSON ME, 2003, PEPTIDES, V24, P487, DOI 10.1016/S0196-9781(03)00083-4##ARRIGHI JF, 2004, J EXP MED, V200, P1279, DOI 10.1084/JEM.20041356##ATARASHI K, 2005, J IMMUNOL, V174, P1424, DOI 10.4049/JIMMUNOL.174.3.1424##BANCHEREAU J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/ANNUREV.IMMUNOL.18.1.767##BANCHEREAU J, 1998, NATURE, V392, P245, DOI 10.1038/32588##BOUNOU S, 2004, FASEB J, V18, P1294, DOI 10.1096/FJ.04-1755FJE##BROMLEY SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/ANNUREV.IMMUNOL.19.1.375##CAIRO CW, 2006, IMMUNITY, V25, P297, DOI 10.1016/J.IMMUNI.2006.06.012##CARMAN CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/J.CEB.2003.08.003##CHOI YK, 2003, J PATHOL, V201, P616, DOI 10.1002/PATH.1482##CONSTANTIN G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1##DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1##DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619A0##FORTIN JF, 1998, J VIROL, V72, P2105, DOI 10.1128/JVI.72.3.2105-2112.1998##GANESH L, 2004, J VIROL, V78, P11980, DOI 10.1128/JVI.78.21.11980-11987.2004##GIGUERE JF, 2004, J VIROL, V78, P12062, DOI 10.1128/JVI.78.21.12062-12065.2004##GROOT F, 2006, BLOOD, V108, P1957, DOI 10.1182/BLOOD-2006-03-010918##HIOE CE, 2001, J VIROL, V75, P1077, DOI 10.1128/JVI.75.2.1077-1082.2001##HOGG N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/J.1600-065X.2002.18614.X##HOGG N, 2000, MATRIX BIOL, V19, P211, DOI 10.1016/S0945-053X(00)00066-4##HU JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000##INGULLI E, 1997, J EXP MED, V185, P2133, DOI 10.1084/JEM.185.12.2133##KUIJPERS TW, 1997, J CLIN INVEST, V100, P1725, DOI 10.1172/JCI119697##LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D##LIU G, 2001, J MED CHEM, V44, P1202, DOI 10.1021/JM000503F##MCDONALD D, 2003, SCIENCE, V300, P1295, DOI 10.1126/SCIENCE.1084238##POPE M, 2003, NAT MED, V9, P847, DOI 10.1038/NM0703-847##PORTER JC, 2002, J IMMUNOL, V168, P6330, DOI 10.4049/JIMMUNOL.168.12.6330##ROWLAND-JONES SL, 1999, CURR BIOL, V9, PR248, DOI 10.1016/S0960-9822(99)80155-9##SANDERS RW, 2002, J VIROL, V76, P7812, DOI 10.1128/JVI.76.15.7812-7821.2002##SHAMRI R, 2005, NAT IMMUNOL, V6, P497, DOI 10.1038/NI1194##SHIMAOKA M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3##SPIRA AI, 1996, J EXP MED, V183, P215, DOI 10.1084/JEM.183.1.215##SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425A0##SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9##STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/ANNUREV.IY.09.040191.001415##TARDIF MR, 2005, J IMMUNOL, V175, P926, DOI 10.4049/JIMMUNOL.175.2.926##TARDIF MR, 2003, J VIROL, V77, P12299, DOI 10.1128/JVI.77.22.12299-12309.2003##TSUNETSUGU-YOKOTA Y, 1997, VIROLOGY, V239, P259, DOI 10.1006/VIRO.1997.8895##VAN KOOYK Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0##VAN KOOYK Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/JBC.274.38.26869##VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811A0##VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/PNAS.88.17.7538##WEITZ-SCHMIDT G, 2001, NAT MED, V7, P687, DOI 10.1038/89058##WLODAWER A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/ANNUREV.BIOPHYS.27.1.249",22,2020-11-20,NA
J,WOS:000242408600037,2006,DIELECTRIC WATER SORPTION ANALYSIS,"THE SORPTION OF WATER VAPOR IN KAPTON (R) (POLYIMIDE) FILMS HAS BEEN INVESTIGATED WITH A NEW METHOD, DIELECTRIC SORPTION ANALYSIS (DSA). THE TECHNIQUE IS BASED ON HIGH-RESOLUTION TIME-RESOLVED CAPACITANCE MEASUREMENTS PERFORMED DURING EXPOSURE OF AN ORGANIC COATING TO HUMIDIFIED NITROGEN. THE BASIS OF THE METHOD IS DESCRIBED TOGETHER WITH EXPERIMENTAL DETAILS RELATED TO THE CAPACITANCE MEASUREMENT, LONG-TERM STABILITY, REPRODUCIBILITY, AND OTHER CHARACTERISTICS OF THE SETUP. THE TECHNIQUE ALLOWS THE DETERMINATION OF THE SORPTION/DESORPTION AND DIFFUSION CHARACTERISTICS OF A COATING ON A TIME SCALE VARYING FROM SECONDS TO DAYS. MASS TRANSPORT PROPERTIES DERIVED FROM COMPLEMENTARY WEIGHT MEASUREMENTS ARE IN GOOD AGREEMENT WITH THE DSA RESULTS. REAL-TIME MONITORING OF THE MOISTURE SORPTION IN ORGANIC COATINGS DEMONSTRATES THE POTENTIAL OF THE TECHNIQUE IN THE FIELD OF NONDESTRUCTIVE COATING INSPECTION AND TESTING. (C) 2006 AMERICAN INSTITUTE OF PHYSICS.",DIFFUSION; VAPOR,NA,REVIEW OF SCIENTIFIC INSTRUMENTS,"PENON, MG##PICKEN, SJ##WUBBENHORST, M##DE VOS, G##VAN TURNHOUT, J","DELFT UNIV TECHNOL, FAC SCI APPL, DEPT NANOSTRUCTURED MAT, NL-2628 BL DELFT, NETHERLANDS. KATHOLIEKE UNIV LEUVEN, ACOUST & THERMAL PHYS SECT, BE-3001 HEVERLEE, BELGIUM.","INSTRUMENTS & INSTRUMENTATION; PHYSICS, APPLIED",INSTRUMENTS & INSTRUMENTATION; PHYSICS,"BUCHNER R, 1999, CHEM PHYS LETT, V306, P57, DOI 10.1016/S0009-2614(99)00455-8##CHIN JW, 1999, J APPL POLYM SCI, V71, P483, DOI 10.1002/(SICI)1097-4628(19990118)71:3<483::AID-APP15>3.0.CO;2-S##COMIJN J, 1985, POLYM PERMEABILITY, P11##CRANK J, 1968, DIFFUSION POLYM, P260##CRANK J, 1975, MATH DIFFUSION, P44##GARCIA-SANCHEZ MF, 2003, J CHEM EDUC, V80, P1062##HAYWARD D, 1997, POLYMER, V38, P1151, DOI 10.1016/S0032-3861(96)00614-3##HEIM M, 1996, J VAC SCI TECHNOL B, V14, P1498, DOI 10.1116/1.589126##LANDAU LD, 1960, ELECTRODYNAMICS CONT, P46##LINDQVIST SA, 1985, CORROSION, V41, P69, DOI 10.5006/1.3581974##LOOYENGA H, 1965, PHYSICA, V31, P401, DOI 10.1016/0031-8914(65)90045-5##MARCUS P, 1995, CORROSION MECH THEOR, P581##OKAMOTO KI, 1992, J POLYM SCI POL PHYS, V30, P1223, DOI 10.1002/POLB.1992.090301107##PIRINGER O.-G., 2000, PLASTIC PACKAGING MA##RABEK JF, 1980, EXPT METHODS POLYM C, P601##STEEMAN P.A.M., 2003, BROADBAND DIELECTRIC, P495##SUN YM, 1996, POLYMER, V37, P3921, DOI 10.1016/0032-3861(96)00221-2##TALBOT A, 1956, BRIT J APPL PHYS, V7, P96, DOI 10.1088/0508-3443/7/3/304##WYPYCH G, 2001, HDB SOLVENTS, P305",16,2020-11-20,NA
J,WOS:000244134100005,2006,THE PREVALENCE OF COMMON MENTAL DISORDERS IN URBAN SLUMS WITH DISPLACED PERSONS IN COLOMBIA,"OBJECTIVES. TO INVESTIGATE THE PREVALENCE OF COMMON MENTAL DISORDERS IN GROUPS WITH A HIGH PERCENTAGE OF FAMILIES WHO HAVE BEEN DISPLACED BY ARMED CONFLICT AND POLITICAL INSTABILITY AND ARE LIVING IN URBAN SLUM AREAS ON THE OUTSKIRTS OF SINCELEJO, A CITY IN THE DEPARTMENT OF SUCRE, COLOMBIA. METHODS. A CROSS-SECTIONAL STUDY WAS CONDUCTED, WITH TWO-STAGE RANDOM CLUSTER SAMPLING, IN SLUM NEIGHBORHOODS OF SINCELEJO THAT CONTAIN A HIGH PERCENTAGE OF DISPLACED PERSONS. A HOUSEHOLD SURVEY OF PERSONS 18 YEARS OLD OR OLDER WAS USED TO DETERMINE THE PRESENCE OF COMMON MENTAL DISORDERS-PSYCHOSOMATIC DISORDERS, ANXIETY, AND DEPRESSION-IN THE POPULATION STUDIED. A SCORE OF 7 OR MORE ON THE FIRST 20 QUESTIONS OF THE SELF-REPORTING QUESTIONNAIRE (SRQ) OF THE WORLD HEALTH ORGANIZATION WAS USED TO DETERMINE THE PRESENCE OF A COMMON MENTAL DISORDER. WE SEARCHED FOR ASSOCIATIONS AMONG THE STUDIED VARIABLES (AGE GROUP, GENDER, TYPE OF HEALTH CARE CARD, AND LENGTH OF RESIDENCE IN THE NEIGHBORHOOD) AND AMONG THOSE VARIABLES AND THE SCORE ON THE SRQ. THE CHI-SQUARE TEST WAS USED, WITH STATISTICAL SIGNIFICANCE SET AT 0.05. LOGISTIC REGRESSION WAS CARRIED OUT WITH ALL THE RELATED VARIABLES. RESULTS. THE PREVALENCE OF COMMON MENTAL DISORDERS IN THE ADULT POPULATION OF THE NEIGHBORHOODS STUDIED WAS 27.2% (95% CONFIDENCE INTERVAL (95% CI) = 24.0% TO 30.0%); 13.6% (95% CI = 11.4% TO 16.1%) OF THE POPULATION SURVEYED HAD PROBLEMS WITH EXCESSIVE ALCOHOL CONSUMPTION. THERE WAS AN ASSOCIATION BETWEEN THE PREVALENCE OF COMMON MENTAL DISORDERS AND THE TYPE OF HEALTH CARE CARD USED (ODDS RATIO = 1.66 FOR PERSONS USING THE HEALTH CARE CARD FOR DISPLACED PERSONS VERSUS PERSONS USING OTHER TYPES OF HEALTH CARE CARDS). IN ADDITION, THERE WAS AN ASSOCIATION BETWEEN THE PREVALENCE OF COMMON MENTAL DISORDERS AND GENDER (OR = 1.78 FOR WOMEN); THIS ASSOCIATION REMAINED AFTER ADJUSTING FOR OTHER EXPLANATORY VARIABLES. CONCLUSIONS. USING THE STUDY CRITERIA (TYPE OF HEALTH CARE CARD AND LENGTH OF TIME LIVING IN THE SLUM AREA), IT WAS DIFFICULT TO SEPARATE THE DISPLACED PERSONS FROM OTHER PERSONS LIVING IN THE SAME SLUM AREAS, AND THUS TO MEASURE THE PREVALENCE OF COMMON MENTAL DISORDERS AMONG JUST THE DISPLACED PERSONS. THE PREVALENCE OF COMMON MENTAL DISORDERS IN THE URBAN POPULATION STUDIED SHOWED A STATISTICAL ASSOCIATION WITH THE TYPE OF HEALTH CARE CARD, WHICH IN TURN DETERMINED THE LEVEL OF ACCESS TO PUBLIC HEALTH SERVICES. THIS ASSOCIATION BETWEEN THE TYPE OF HEALTH CARE CARD HELD AND THE PREVALENCE OF COMMON MENTAL DISORDERS IS STRONG ENOUGH TO JUSTIFY PROVIDING MENTAL HEALTH CARE SERVICES TO PERSONS WHO HAVE THE HEALTH CARE CARD FOR DISPLACED PERSONS.",PRIMARY HEALTH-CARE; PSYCHIATRIC-DISORDER; COMMUNITY; POVERTY,MENTAL HEALTH; REFUGEES; VIOLENCE; COLOMBIA,REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH,"PUERTAS, G##RIOS, C##DEL VALLE, H","FRONTERAS HOLANDA, HARARE, ZIMBABWE. FRONTERAS HOLANDA, DEPT ASUNTOS HUMANITARIOS MED, AMSTERDAM, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","AL-LAWATI J., 2000, MED SCI, V2, P105##ANDRADE L, 2000, B WORLD HEALTH ORGAN, V78, P413##[ANONYMOUS], 1994, WHOMNHPSF948##ARAYA R, 2001, BRIT J PSYCHIAT, V178, P228, DOI 10.1192/BJP.178.3.228##BOELAERT M, 1998, NUTR GUIDELINES##CACERES D, 2001, PERFIL EPIDEMIOLOGIC##*CODHES, 2004, CODHES INFORM, P1##*COL MPS, 2003, PAN NAC SAL ENF MENT##FULLILOVE MT, 1996, AM J PSYCHIAT, V153, P1516##HARDING TW, 1980, PSYCHOL MED, V10, P231, DOI 10.1017/S0033291700043993##LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415##LORANT V, 2003, AM J EPIDEMIOL, V157, P98, DOI 10.1093/AJE/KWF182##MUMFORD DB, 2000, BRIT J PSYCHIAT, V177, P557, DOI 10.1192/BJP.177.6.557##*OPS, 2003, PERF EP POBL DESPL P##PATEL V, 1999, SOC SCI MED, V49, P1461, DOI 10.1016/S0277-9536(99)00208-7##PATEL V, 2003, LANCET, V361, P33, DOI 10.1016/S0140-6736(03)12119-8##PENAYO U, 1990, ACTA PSYCHIAT SCAND, V82, P82, DOI 10.1111/J.1600-0447.1990.TB01361.X##PICCINELLI M, 1997, GENDER DIFFERENCES E##*RSS, SIST UN REG POBL DES##USTUN T.B., 1995, MENTAL ILLNESS GEN H##WEICH S, 1998, BMJ-BRIT MED J, V317, P115, DOI 10.1136/BMJ.317.7151.115",31,2020-11-20,NA
J,WOS:000247254400002,2006,OPTIMISATION OF HOT METAL DESULPHURISATION AT BOS2 CORUS STRIP PRODUCTS IJMUIDEN,"AS PART OF THE PROJECT TO INCREASE THE ANNUAL PRODUCTION OF BOS2 AT CORUS STRIP PRODUCTS IJMUIDEN TO 6.5 MILLION TONNES STEEL, HOT METAL DESULPHURISATION BY LADLE TREATMENT REPLACED THE TORPEDO INJECTION SYSTEM IN 2001. INITIALLY, CALCIUM CARBIDE AND MAGNESIUM WERE USED AS REAGENTS. IN 2002 A PROJECT WAS STARTED TO IMPROVE THE EFFICIENCY OF THE DESULPHURISATION OPERATION. A PROCESS MODEL BASED ON FUNDAMENTALS WAS DERIVED TO IMPROVE THE UNDERSTANDING OF THE UNDERLYING MECHANISMS. THIS HELPED ACHIEVE A 10% REDUCTION OF REAGENT CONSUMPTION BY OPTIMISING THE CARRIER GAS FLOW RATE. TO REDUCE THE TREATMENT COSTS, CALCIUM CARBIDE WAS REPLACED BY LIME. THE CHANGE IN SLAG PROPERTIES LED TO AN INCREASE IN HOT METAL LOSS. TO HELP THE OPERATOR DIFFERENTIATE BETWEEN HOT METAL AND SLAG, AN AMEPA INFRARED CAMERA SYSTEM HAS BEEN INSTALLED. HOT METAL SAMPLES AND SAMPLES FROM THE TOP LAYER TAKEN AT VARIOUS STAGES DURING DESULPHURISATION WERE ANALYSED. THE RESULTS SHOWED THAT EXCESS MGS REMAINS IN THE HOT METAL AFTER TREATMENT INDICATING THE NEED TO IMPROVE THE ABSORPTION OF REACTION PRODUCTS INTO THE SLAG. TRIALS WITH LIME POST INJECTION RESULTED IN LOWER FINAL SULPHUR CONTENT AND IMPROVED SLAG REMOVAL, WHICH SHOWS POTENTIAL FOR REDUCED REAGENT CONSUMPTION AND OVER-ALL TREATMENT TIME. PLANT TRIALS WITH THE HERAEUS ELECTRO-NITE HOT METAL SULPHUR SENSOR DURING INJECTION OF REAGENTS WERE CONDUCTED WITH GOOD RESULTS. THE SENSORS WILL BE APPLIED TO REDUCE OVER-TREATMENT.",NA,NA,REVUE DE METALLURGIE-CAHIERS D INFORMATIONS TECHNIQUES,"VISSER, HJ##BOOM, R##GRAVELAND, E##OVERBOSCH, A##KNORREN, L","DELFT UNIV TECHNOL, NETHERLANDS INST MET RES, DELFT, NETHERLANDS. CORUS RES DEV & TECHNOL, IJMUIDEN, NETHERLANDS. CORUS STRIP PROD, IJMUIDEN, NETHERLANDS.",METALLURGY & METALLURGICAL ENGINEERING,METALLURGY & METALLURGICAL ENGINEERING,"BROCKHOFF, 2006, 5 EOSC AACH GERM JUN##COOK, 2004, ONLINE SULPHUR IMMER, P659##IRONS G. A., 1981, IRONMAK STEELMAK, V8, P114##SAHAI Y, 1982, METALL TRANS B, V13, P193, DOI 10.1007/BF02664576##VISSER H. J., 2005, 3 ICS CHARL US MAY 9, P369##ZHAO YF, 1994, IRONMAK STEELMAK, V21, P303",1,2020-11-20,NA
J,WOS:000242325200007,2006,REGIONAL DIFFERENCES IN NUTRIENT LIMITATION IN FLOODPLAINS OF SELECTED EUROPEAN RIVERS: IMPLICATIONS FOR REHABILITATION OF CHARACTERISTIC FLOODPLAIN VEGETATION,"EXTREMELY HIGH RIVER DISCHARGES IN 1993 AND 1995 ALONG THE DUTCH RIVERS RHINE AND MEUSE HAVE INCREASED THE PUBLIC AWARENESS OF POSSIBLE SAFETY THREATS. AS A RESULT THE 'SPACE FOR RIVERS' PROGRAM WAS IMPLEMENTED, AIMING AT RESTORING PHYSICAL SPACE FOR THE RIVERS IN COMBINATION WITH ECOLOGICAL REHABILITATION. HOWEVER, THE DEVELOPMENT OF SPECIES-RICH VEGETATION TYPES IN THESE FLOODPLAIN AREAS IS LAGGING BEHIND RESTORATION TARGETS AND BIOGEOCHEMICAL CONSTRAINTS MAY PLAY A VITAL ROLE IN THIS. BIOGEOCHEMICAL, HYDROLOGICAL AND VEGETATION DATA WERE COLLECTED IN I I I PLOTS IN BOTH REHABILITATED AND ORIGINAL FLOODPLAINS IN REGULATED AND MORE PRISTINE RIVER SYSTEMS IN THE NETHERLANDS AND POLAND. SOIL NUTRIENT AND SOIL PORE WATER DATA WERE SUMMARIZED BY FACTOR ANALYSIS AND THE SUBSEQUENT PRINCIPAL COMPONENTS WERE COMPARED TO VEGETATION AND HYDROLOGICAL DATA BY CORRELATION ANALYSIS. THE CORRELATION ANALYSES BETWEEN VEGETATION PARAMETERS INCLUDING NUTRIENT STOICHIOMETRY AND THE BIOGEOCHEMICAL SOIL VARIABLES RESULTED IN A REMARKABLE DIFFERENCE BETWEEN PRISTINE AND IMPACTED RIVER SYSTEMS. THE RESULTS SUGGEST A CLEAR N-LIMITATION OF PLANT GROWTH IN PRISTINE FLOODPLAINS, AND APPARENT ABSENCE OF LIMITATION IN REGULATED, IMPACTED FLOODPLAINS. IN ADDITION, RESULTS INDICATE THAT FLOODING EVENTS DO NOT LEAD TO ONE-WAY TRANSPORT OF SEDIMENT AND NUTRIENTS FROM THE RIVER INTO THE FLOODPLAINS; RATHER THEY INDICATE THAT HIGHLY DYNAMIC HYDROLOGICAL CONDITIONS PREVENT SOILS FROM ACCUMULATING ORGANIC MATTER AND NUTRIENTS. THIS STUDY SHOWS THAT NUTRIENT LIMITATION IN REGULATED FLOODPLAINS SHIFTED FROM DISTINCTLY N-LIMITED PLANT GROWTH TO NO NUTRIENT LIMITATION AT ALL, PROBABLY DUE TO DECADES OF HIGH FERTILIZER AND MANURE APPLICATION AND NUTRIENT INPUT BY THE RIVERS DURING FLOODING. THE CONSEQUENCE OF OUR FINDINGS FOR REHABILITATION ACTIVITIES IS THAT IT MIGHT BE NECESSARY TO RESTORE NITROGEN LIMITATION IN FLOODPLAIN SYSTEMS IN ORDER TO CREATE OPPORTUNITIES FOR A SPECIES-RICH FLOODPLAIN VEGETATION, THROUGH NUTRIENT REMOVAL BY HAYMAKING. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",N-P RATIOS; ECOLOGICAL REHABILITATION; LOWLAND RIVERS; PRESENT STATE; LAND-USE; RHINE; PLANT; RESTORATION; DYNAMICS; MEUSE,ECOLOGICAL REHABILITATION; FLOODPLAIN; HERBACEOUS VEGETATION; NUTRIENT LIMITATION; POLAND; REGULATED RIVER; THE NETHERLANDS,RIVER RESEARCH AND APPLICATIONS,"ANTHEUNISSE, AM##LOEB, R##LAMERS, LPM##VERHOEVEN, JTA","UNIV UTRECHT, INST ENVIRONM BIOL, NL-3508 TD UTRECHT, NETHERLANDS. RADBOUD UNIV NIJMEGEN, DEPT AQUAT ECOL & ENVIRONM BIOL, INST WATER & WETLAND RES, NL-6525 ED NIJMEGEN, NETHERLANDS.",ENVIRONMENTAL SCIENCES; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; WATER RESOURCES,"ADMIRAAL W, 1993, HYDROBIOLOGIA, V265, P97, DOI 10.1007/BF00007264##BAL D, 1995, HDB NATUURDOELTYPEN##BALDWIN DS, 2000, REGUL RIVER, V16, P457, DOI 10.1002/1099-1646(200009/10)16:5&LT;457::AID-RRR597&GT;3.0.CO;2-B##BARKMAN J. J., 1964, ACTA BOT NEER, V13, P394##BISCHOFF A, 2002, BIOL CONSERV, V104, P25, DOI 10.1016/S0006-3207(01)00151-3##BISCHOFF A, 2001, REGUL RIVER, V17, P171, DOI 10.1002/RRR.612##BISSELS S, 2004, BIOL CONSERV, V118, P641, DOI 10.1016/J.BIOCON.2003.10.013##BOEYE D, 1997, J VEG SCI, V8, P415, DOI 10.2307/3237333##BREMNER JM, 1982, AGRON MONOGR, V9, P621##BUIJSE AD, 2002, FRESHWATER BIOL, V47, P889, DOI 10.1046/J.1365-2427.2002.00915.X##CALS MJR, 1998, AQUAT CONSERV, V8, P61, DOI 10.1002/(SICI)1099-0755(199801/02)8:1<61::AID-AQC267>3.0.CO;2-8##CASANOVA MT, 2000, PLANT ECOL, V147, P237, DOI 10.1023/A:1009875226637##CHBAB EH, 1995, PHYS CHEM EARTH, V20, P455, DOI DOI 10.1016/S0079-1946(96)00005-5##DOMBROWSKI A, 2002, BUG RIVER VALLEY ECO##DYNESIUS M, 1994, SCIENCE, V266, P753, DOI 10.1126/SCIENCE.266.5186.753##ENGELHARDT C, 1999, ACTA HYDROCH HYDROB, V27, P325, DOI 10.1002/(SICI)1521-401X(199911)27:5&LT;325::AID-AHEH325&GT;3.0.CO;2-A##*EUR UN, 2000, WAT FRAM WORK DIR ES##GIELCZEWSKI M, 2003, NAREW RIVER BASIN MO##GLASBY GP, 2004, SCI TOTAL ENVIRON, V330, P249, DOI 10.1016/J.SCITOTENV.2004.04.004##GUSEWELL S, 2004, NEW PHYTOL, V164, P243, DOI 10.1111/J.1469-8137.2004.01192.X##GUSEWELL S, 2003, ECOL APPL, V13, P372, DOI 10.1890/1051-0761(2003)013[0372:BNRAIO]2.0.CO;2##HEILER G, 1995, REGUL RIVER, V11, P351, DOI 10.1002/RRR.3450110309##HOHENSINNER S, 2004, RIVER RES APPL, V20, P25, DOI 10.1002/RRA.719##HOOIJER A, 2004, RIVER RES APPL, V20, P343, DOI 10.1002/RRA.781##HOUBA VJG, 1989, SOIL PLANT ANAL SERI##JONGMAN RHG, 1992, REGUL RIVER, V7, P279, DOI 10.1002/RRR.3450070306##JUNK W J, 1989, CANADIAN SPECIAL PUBLICATION OF FISHERIES AND AQUATIC SCIENCES, V106, P110##KOERSELMAN W, 1996, J APPL ECOL, V33, P1441, DOI 10.2307/2404783##LAMERS LPM, 2006, HYDROBIOLOGIA, V565, P165, DOI 10.1007/S10750-005-1912-8##LAMERS LPM, 1998, ENVIRON SCI TECHNOL, V32, P199, DOI 10.1021/ES970362F##LORENZ CM, 1997, REGUL RIVER, V13, P501##MALISAUSKAS AP, 2001, LANDBAUFORSCH VOLK, V51, P87##*MIN VOLKSH RUIMT, 1996, BEL RUIMT RIV##NIENHUIS PH, 2001, HYDROBIOLOGIA, V444, P85, DOI 10.1023/A:1017509410951##OETKEN M, 2005, ENVIRON POLLUT, V134, P87, DOI 10.1016/J.ENVPOL.2004.08.001##OGDEN RW, 2002, HYDROBIOLOGIA, V489, P277, DOI 10.1023/A:1023293925854##PEDROLI B, 2001, LANDSCAPE ECOL, V17, P5, DOI 10.1023/A:1015221425315##PFISTER L, 2004, RIVER RES APPL, V20, P229, DOI 10.1002/RRA.775##PRACH K, 1996, ACTA BOT GALLICA, V143, P441, DOI 10.1080/12538078.1996.10515740##SCHILDERMAN PAEL, 1999, ECOTOX ENVIRON SAFE, V44, P241, DOI 10.1006/EESA.1999.1827##SCHROPP MHI, 1998, AQUAT CONSERV, V8, P53, DOI 10.1002/(SICI)1099-0755(199801/02)8:1<53::AID-AQC260>3.0.CO;2-O##SPINK A, 1998, REGUL RIVER, V14, P203, DOI 10.1002/(SICI)1099-1646(199803/04)14:2&LT;203::AID-RRR498&GT;3.0.CO;2-7##THOMS MC, 2003, GEOMORPHOLOGY, V56, P335, DOI 10.1016/S0169-555X(03)00160-0##TOCKNER K, 2002, ENVIRON CONSERV, V29, P308, DOI 10.1017/S037689290200022X##TOCKNER K, 2000, HYDROL PROCESS, V14, P2861, DOI 10.1002/1099-1085(200011/12)14:16/17&LT;2861::AID-HYP124&GT;3.0.CO;2-F##VAN DER MEIJDEN R., 1996, HEUKELS FLORA NEDERL##VAN GEEST GJ, 2005, HYDROBIOLOGIA, V539, P239, DOI 10.1007/S10750-004-4879-Y##VAN OORSCHOT M, 1998, REGUL RIVER, V14, P313, DOI 10.1002/(SICI)1099-1646(199807/08)14:4&LT;313::AID-RRR506&GT;3.0.CO;2-U##VAN OORSCHOT M, 2000, ACTA OECOL, V21, P49, DOI 10.1016/S1146-609X(00)00116-8##VAN OORSCHOT MMP, 1994, GLOBAL WETLANDS OLD, P133##VANDERPOORTEN A, 1999, ENVIRON POLLUT, V104, P401, DOI 10.1016/S0269-7491(98)00170-5##VANDIJK GM, 1995, REGUL RIVER, V11, P377, DOI 10.1002/RRR.3450110311##VANECK W, 2004, FLOODING TOLERANCE D##VANOORSCHOT M, 1997, J ECOL, V85, P167, DOI 10.2307/2960649##VENTERINK HO, 2002, PLANT SOIL, V243, P119, DOI 10.1023/A:1019993510737##VERHOEVEN JTA, 1996, TRENDS ECOL EVOL, V11, P494, DOI 10.1016/S0169-5347(96)10055-0##VERHOEVEN JTA, 1998, NEW CONCEPTS FOR SUSTAINABLE MANAGEMENT OF RIVER BASINS, P229##VERVUREN PJA, 2003, J ECOL, V91, P135, DOI 10.1046/J.1365-2745.2003.00749.X##WASSEN MJ, 1998, ACTA BOT NEERL, V47, P241##WILLBY NJ, 2001, NEW PHYTOL, V152, P463, DOI 10.1046/J.0028-646X.2001.00274.X##WINTER HV, 2003, J FISH BIOL, V63, P871, DOI 10.1046/J.1095-8649.2003.00193.X##WOLFERT HP, 2001, GEOMORPHOLOGICAL CHA, P153##WOLFF W. J., 1978, THE BREAKDOWN AND RESTORATION OF ECOSYSTEMS., P169",23,2020-11-20,NA
J,WOS:000241702800009,2006,SLX9P FACILITATES EFFICIENT ITS1 PROCESSING OF PRE-RRNA IN SACCHAROMYCES CEREVISIAE,"SLX9P (YGR081CP) IS A NONESSENTIAL YEAST PROTEIN PREVIOUSLY LINKED GENETICALLY WITH THE DNA HELICASE SGS1P. HERE WE REPORT THAT SLX9P IS INVOLVED IN RIBOSOME BIOGENESIS IN THE YEAST SACCHAROMYCES CEREVISIAE. DELETION OF SLX9 RESULTS IN A MILD GROWTH DEFECT AND A REDUCTION IN THE LEVEL OF 18S RRNA. CO-IMMUNOPRECIPITATION EXPERIMENTS SHOWED THAT SLX9P IS ASSOCIATED WITH 35S, 23S, AND 20S PRE-RRNA, AS WELL AS U3 SNORNA AND, THUS, IS A BONA FIDE COMPONENT OF PRE-RIBOSOMES. THE MOST STRIKING EFFECTS ON PRE-RRNA PROCESSING RESULTING FROM DELETION OF SLX9 IS THE ACCUMULATION OF THE MUTUALLY EXCLUSIVE 21S AND 27SA2 PRE-RRNA. FURTHERMORE, DELETION OF SLX9 IS SYNTHETICALLY LETHAL WITH MUTATIONS IN RRP5P THAT BLOCK CLEAVAGE AT EITHER SITE A2 OR A3. WE CONCLUDE THAT SLX9P HAS A UNIQUE ROLE IN THE PROCESSING EVENTS RESPONSIBLE FOR SEPARATING THE 66S AND 43S PRE-RIBOSOMAL PARTICLES. INTERESTINGLY, HOMOLOGS OF SLX9P WERE FOUND ONLY IN OTHER YEAST SPECIES, INDICATING THAT THE PROTEIN HAS BEEN CONSIDERABLY LESS WELL CONSERVED DURING EVOLUTION THAN THE MAJORITY OF TRANS-ACTING PROCESSING FACTORS.",DNA-REPLICATION; U3 SNORNP; PROTEIN; BIOGENESIS; RRP5P; SITE; MATURATION; COMPONENT; DOMAIN; STEPS,YEAST; RIBOSOME BIOGENESIS; PRE-RRNA PROCESSING,RNA,"BAX, R##RAUE, HA##VOS, JC","VRIJE UNIV AMSTERDAM, SECT BIOCHEM & MOL BIOL, FEW, DEPT CHEM & PHARMCEUT SCI,FAC SCI,BIOCENTRUM AMST, NL-1081 HV AMSTERDAM, NETHERLANDS.",BIOCHEMISTRY & MOLECULAR BIOLOGY,BIOCHEMISTRY & MOLECULAR BIOLOGY,"ALLMANG C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/NAR/28.8.1684##BENNETT RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/JBC.273.16.9644##BOROVJAGIN AV, 2005, NUCLEIC ACIDS RES, V33, P4995, DOI 10.1093/NAR/GKI815##CHEN WD, 2003, NUCLEIC ACIDS RES, V31, P690, DOI 10.1093/NAR/GKG145##DEUTSCHBAUER AM, 2005, GENETICS, V169, P1915, DOI 10.1534/GENETICS.104.036871##DEZ C, 2004, CURR OPIN MICROBIOL, V7, P631, DOI 10.1016/J.MIB.2004.10.007##DU YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0##EPPENS NA, 1999, RNA, V5, P779, DOI 10.1017/S1355838299990313##EPPENS NA, 2002, NUCLEIC ACIDS RES, V30, P4222, DOI 10.1093/NAR/GKF538##FABER AW, 2006, BIOCHEM BIOPH RES CO, V345, P796, DOI 10.1016/J.BBRC.2006.04.166##FABER AW, 2004, RNA, V10, P1946, DOI 10.1261/RNA.7155904##FATICA A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6##FROMONT-RACINE M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2##GALLAGHER JEG, 2004, GENE DEV, V18, P2506, DOI 10.1101/GAD.1226604##GAVIN AC, 2006, NATURE, V440, P631, DOI 10.1038/NATURE04532##GAVIN AC, 2002, NATURE, V415, P141, DOI 10.1038/415141A##GELPERIN D, 2001, RNA, V7, P1268, DOI 10.1017/S1355838201013073##GHAEMMAGHAMI S, 2003, NATURE, V425, P737, DOI 10.1038/NATURE02046##GIAEVER G, 2002, NATURE, V418, P387, DOI 10.1038/NATURE00935##GRANDI P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8##GRANNEMAN S, 2004, EXP CELL RES, V296, P43, DOI 10.1016/J.YEXCR.2004.03.016##HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/J.1460-2075.1994.TB06530.X##JANSEN R, 1993, EMBO J, V12, P2549, DOI 10.1002/J.1460-2075.1993.TB05910.X##KASER A, 2001, BIOL CHEM, V382, P1637, DOI 10.1515/BC.2001.199##KILLIAN A, 2004, ONCOGENE, V23, P8597, DOI 10.1038/SJ.ONC.1207845##LAFONTAINE DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X##LEE SJ, 1997, P NATL ACAD SCI USA, V94, P13536, DOI 10.1073/PNAS.94.25.13536##LEGER-SILVESTRE I, 2005, J BIOL CHEM, V280, P38177, DOI 10.1074/JBC.M506916200##MILKEREIT P, 2003, J BIOL CHEM, V278, P4072, DOI 10.1074/JBC.M208898200##OOI SL, 2003, NAT GENET, V35, P277, DOI 10.1038/NG1258##PESTOV DG, 2001, NUCLEIC ACIDS RES, V29, P3621, DOI 10.1093/NAR/29.17.3621##RAUE HA, 2004, MOL BIOL INTELL UNIT, P199##SCHAFER T, 2003, EMBO J, V22, P1370, DOI 10.1093/EMBOJ/CDG121##SIKORSKI RS, 1989, GENETICS, V122, P19##STEINMETZ LM, 2002, NAT GENET, V31, P400, DOI 10.1038/NG929##VANROBAYS E, 2003, MOL CELL BIOL, V23, P2083, DOI 10.1128/MCB.23.6.2083-2095.2003##VENEMA J, 1998, METH MOL B, V77, P257##VENEMA J, 1996, EMBO J, V15, P5701, DOI 10.1002/J.1460-2075.1996.TB00954.X##VENEMA J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/ANNUREV.GENET.33.1.261##VENEMA J, 1995, YEAST, V11, P1629, DOI 10.1002/YEA.320111607##VOS HR, 2004, EUKARYOT CELL, V3, P1504, DOI 10.1128/EC.3.6.1504-1512.2004##VOS HR, 2004, NUCLEIC ACIDS RES, V32, P5827, DOI 10.1093/NAR/GKH904##WEHNER KA, 2002, MOL CELL, V9, P329, DOI 10.1016/S1097-2765(02)00438-0##ZHANG YX, 2002, CELL, V109, P849, DOI 10.1016/S0092-8674(02)00805-X",16,2020-11-20,NA
J,WOS:000242884000008,2006,STRUCTURAL CHARACTERIZATION OF TISSUE-SPECIFIC GALACTAN FROM FLAX FIBERS BY H-1 NMR AND MALDI TOF MASS SPECTROMETRY,"A HIGH-MOLECULAR-MASS POLYSACCHARIDE GALACTAN (M 2000 KDA) WAS ISOLATED FROM FLAX AT THE STAGE OF CELL WALL THICKENING OF THE BAST FIBER DEVELOPMENT. THE POLYMER STRUCTURE WAS STUDIED BY H-1 NMR SPECTROSCOPY AND MALDI TOF MASS SPECTROMETRY. IT IS BUILT UP OF GAL (59%), RHA (15%), GAIA (23%), AND ARA (3%) RESIDUES. THE GALACTAN BACKBONE CONSISTS OF SUCCESSIVELY ALTERNATING MONOMER DISACCHARIDE UNITS (-> 4GALAL -> 2RHA1 -> ->)(N) AND IS SIMILAR IN ITS STRUCTURE TO THE BACKBONE OF RHAMNOGALACTURONAN-1 (RG-I). RHAMNOSE RESIDUES BEAR IN POSITION 4 BETA-(1 -> 4)-GALACTOSE SIDE CHAINS OF VARIOUS LENGTHS WITH A POLYMERIZATION DEGREE OF UP TO 28 OR HIGHER. A PART OF THE SIDE CHAINS HAVE BRANCHINGS.",PLANT-CELL WALLS; LINUM-USITATISSIMUM L; RHAMNOGALACTURONAN-I; POLYSACCHARIDES; OLIGOSACCHARIDES; IDENTIFICATION; SPECTROSCOPY; TRANSITION; PECTINS; COMPLEX,GALACTAN; LINUM USITATISSIMUM L.; MALDI TOF MS; PLANT FIBERS; RHAMNOGALACTURONAN-1,RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY,"GUR'YANOV, O##GORSHKOVA, T##KABEL, M##SCHOLS, H##VAN DAM, JEG","RUSSIAN ACAD SCI, KAZAN SCI CTR, KAZAN INST BIOCHEM & BIOPHYS, KAZAN 420111, RUSSIA. WAGENINGEN UNIV, DEPT AGROTECHNOL & FOOD SCI, FOOD CHEM LAB, WAGENINGEN, NETHERLANDS. WAGENINGEN UNIV, RES CTR AGROTECHNOL & FOOD INNOVAT, WAGENINGEN, NETHERLANDS.","BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY, ORGANIC",BIOCHEMISTRY & MOLECULAR BIOLOGY; CHEMISTRY,"CARPITA N., 2000, CELL WALL BIOCH MOL, P52##COLQUHOUN IJ, 1990, CARBOHYD RES, V206, P131, DOI 10.1016/0008-6215(90)84012-J##CUMMING CM, 2005, PLANTA, V222, P546, DOI 10.1007/S00425-005-1560-2##DARBRE A., 1989, PRACTICAL PROTEIN CH##DAVIS EA, 1990, CARBOHYD RES, V197, P205, DOI 10.1016/0008-6215(90)84143-I##DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/AC60111A017##FRY S. C., 1988, GROWING PLANT CELL W##GIRAULT R, 1997, INT J BIOL MACROMOL, V21, P179, DOI 10.1016/S0141-8130(97)00059-7##GORDON AJ, 1972, CLEMISTS COMPANION H##GORSHKOVA T, 2006, PLANTA, V223, P149, DOI 10.1007/S00425-005-0118-7##GORSHKOVA TA, 1996, PLANT PHYSIOL, V110, P721, DOI 10.1104/PP.110.3.721##GORSHKOVA TA, 2003, IND CROP PROD, V18, P213, DOI 10.1016/S0926-6690(03)00043-8##GORSHKOVA TA, 2004, IND CROP PROD, V19, P217, DOI 10.1016/J.INDCROP.2003.10.002##GORSHKOVA TA, 2005, PLANT BIOSYST, V139, P88, DOI 10.1080/11263500500056070##GOUBET F, 1995, CARBOHYD POLYM, V27, P221, DOI 10.1016/0144-8617(95)00063-D##HANNUKSELA T, 2004, CARBOHYD RES, V339, P301, DOI 10.1016/J.CARRES.2003.10.025##HARVEY DJ, 2003, INT J MASS SPECTROM, V226, P1, DOI 10.1016/S1387-3806(02)00968-5##MCDOUGALL GJ, 1993, CARBOHYD RES, V241, P227, DOI 10.1016/0008-6215(93)80109-R##MCNEIL M, 1980, PLANT PHYSIOL, V66, P1128, DOI 10.1104/PP.66.6.1128##MCNEIL M, 1982, PLANT PHYSIOL, V70, P1586, DOI 10.1104/PP.70.6.1586##MOONEY C, 2001, J BIOTECHNOL, V89, P205, DOI 10.1016/S0168-1656(01)00299-1##MORVAN C, 2003, PLANT PHYSIOL BIOCH, V41, P935, DOI 10.1016/J.PLAPHY.2003.07.001##SELVENDRAN RR, 1987, METHOD BIOCHEM ANAL, V32, P26##VANHAZENDONK JM, 1996, CARBOHYD RES, V291, P141, DOI 10.1016/S0008-6215(96)00160-7##VINCKEN JP, 2003, PLANT PHYSIOL, V132, P1781, DOI 10.1104/PP.103.022350##YORK WS, 1990, CARBOHYD RES, V200, P9, DOI 10.1016/0008-6215(90)84179-X##ZAIKIN VG, 2001, BASICS MASS SPECTROM",5,2020-11-20,NA
J,WOS:000242102600003,2006,PLASMA SEMICARBAZIDE-SENSITIVE AMINE OXIDASE IS MODERATELY DECREASED BY PRONOUNCED EXOGENOUS HYPERINSULINEMIA BUT IS NOT ASSOCIATED WITH INSULIN SENSITIVITY AND BODY FAT,"OBJECTIVE. SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) IS WIDELY EXPRESSED IN ADIPOSE TISSUE, WHERE IT MAY CONTRIBUTE TO STIMULATION OF GLUCOSE TRANSPORT VIA GLUT4 RECRUITMENT. WE TESTED THE RELATIONSHIPS OF SOLUBLE SSAO, AS REFLECTED BY ITS PLASMA ACTIVITY, WITH INSULIN SENSITIVITY AND INDICES OF BODY FAT, AND DETERMINED WHETHER INSULIN IS INVOLVED IN REGULATING PLASMA SSAO ACTIVITY. MATERIAL AND METHODS. IN 24 NON-DIABETIC SUBJECTS, THE RELATIONSHIPS OF PLASMA SSAO ACTIVITY WITH INSULIN SENSITIVITY (M-VALUE AND FREE FATTY ACID (FFA) SUPPRESSION DURING A 3-H HYPERINSULINEMIC (8.3 MU U KG(-1) S(-1)), EUGLYCEMIC CLAMP), BODY MASS INDEX (BMI 25.5 +/- 3.1 KG M(-2)), WAIST- HIP RATIO AND FAT MASS WERE ASSESSED. IN 16 SUBJECTS, THE EFFECT OF INSULIN INFUSION, ADMINISTERED AT A RATE OF 8.3 MU U KG(-1) S(-1) DURING 3 H, FOLLOWED BY 3-H INSULIN INFUSION AT A HIGH RATE OF 41.7 MU U KG(-1) S(-1) ON PLASMA SSAO ACTIVITY WAS DETERMINED. IN THE OTHER 8 SUBJECTS, THE RESPONSE OF PLASMA SSAO ACTIVITY TO 24- H INSULIN INFUSED AT 8.3 MU U KG(-1) S(-1) WAS ASSESSED. RESULTS. THERE WERE NO RELATIONSHIPS ( ALL P > 0.10) OF PLASMA SSAO ACTIVITY (215 +/- 60 MU U L-1) WITH THE M-VALUE OR WITH ANY INDICES OF BODY FAT AND FFA BEFORE AND AFTER INSULIN SUPPRESSION. PLASMA SSAO ACTIVITY CHANGED BY 27.2 (95% CI, -14.5 TO + 0.2)% AFTER 3 H (NS) AND DECREASED BY 10.1 (95% CI, 19.2 TO 1)% AFTER 6 H OF INSULIN INFUSION ( P < 0.05). PLASMA SSAO ACTIVITY DID NOT SIGNIFICANTLY CHANGE AFTER 8 H ( CHANGE 0.4 ( 95% CI, -15.3 TO + 16.2) %, NS) AND AFTER 24 H ( CHANGE 28.8 ( 95% CI, 227.4 TO +9.7) %, NS) OF INSULIN INFUSION. CONCLUSIONS. IT IS UNLIKELY THAT CIRCULATING SSAO IS A CLINICALLY IMPORTANT MARKER OF INSULIN SENSITIVITY ON GLUCOSE AND FATTY ACID METABOLISM. THE REDUCTION IN PLASMA SSAO ACTIVITY IN RESPONSE TO PRONOUNCED HYPERINSULINEMIA SUGGESTS THAT INSULIN IS INVOLVED IN THE REGULATION OF THE SOLUBLE FORM OF THIS ENZYME.",VASCULAR ADHESION PROTEIN-1; DEPENDENT DIABETES-MELLITUS; GLUCOSE-TRANSPORT; CELL-SURFACE; ADIPOCYTES,BODY FAT; INSULIN; INSULIN SENSITIVITY; M-VALUE; SEMICARBAZIDE-SENSITIVE AMINE OXIDASE,SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION,"DULLAART, RPF##RIEMENS, SC##BOOMSMA, F","UNIV GRONINGEN, CTR MED, DEPT ENDOCRINOL, NL-9700 RB GRONINGEN, NETHERLANDS. ERASMUS MC, DEPT INTERNAL MED, ROTTERDAM, NETHERLANDS.","MEDICINE, RESEARCH & EXPERIMENTAL",RESEARCH & EXPERIMENTAL MEDICINE,"ABELLA A, 2004, DIABETOLOGIA, V47, P429, DOI 10.1007/S00125-004-1346-2##ABELLA A, 2003, J PHYSIOL BIOCHEM, V59, P153, DOI 10.1007/BF03179910##BOOMSMA F, 2005, DIABETOLOGIA, V48, P1002, DOI 10.1007/S00125-005-1716-4##BOOMSMA F, 2005, MED SCI MONITOR, V11, PRA122##BOOMSMA F, 2003, BBA-PROTEINS PROTEOM, V1647, P48, DOI 10.1016/S1570-9639(03)00047-5##BOOMSMA F, 1999, DIABETOLOGIA, V42, P233, DOI 10.1007/S001250051143##BOOMSMA F, 2001, DIABETOLOGIA, V44, P388##ENRIQUE-TARANCON G, 1998, J BIOL CHEM, V273, P8025, DOI 10.1074/JBC.273.14.8025##JALKANEN S, 2001, EMBO J, V20, P3893, DOI 10.1093/EMBOJ/20.15.3893##JENSEN MD, 1991, METABOLISM, V40, P406, DOI 10.1016/0026-0495(91)90152-M##LUKASKI HC, 1985, AM J CLIN NUTR, V41, P810##MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883##MESZAROS Z, 1999, METABOLISM, V48, P113, DOI 10.1016/S0026-0495(99)90019-7##SALMI M, 2002, AM J PATHOL, V161, P2255, DOI 10.1016/S0002-9440(10)64501-4##SMITH DJ, 1998, J EXP MED, V188, P17, DOI 10.1084/JEM.188.1.17##STOLEN CM, 2004, CIRC RES, V95, P50, DOI 10.1161/01.RES.0000134630.68877.2F##VANDIJK J, 1995, J CHROMATOGR B, V663, P43, DOI 10.1016/0378-4347(94)00408-W##VISENTIN V, 2004, OBES RES, V12, P547, DOI 10.1038/OBY.2004.62##WEISS HG, 2003, METABOLISM, V52, P688, DOI 10.1016/S0026-0495(03)00028-3##1999, WHONCDNCS99",6,2020-11-20,NA
J,WOS:000241491800006,2006,EFFECT OF VARIOUS TEST MEALS ON GASTRIC AND JEJUNAL CARBON DIOXIDE: A STUDY IN HEALTHY SUBJECTS,"OBJECTIVE. THE NORMAL PATTERN OF CARBON DIOXIDE (CO2) LEVELS IN THE HUMAN STOMACH AND SMALL BOWEL AFTER MEALS IS UNKNOWN. THE INTRALUMINAL CARBON DIOXIDE LEVEL IS A SENSITIVE AND EARLY MARKER FOR ORGAN MUCOSAL ISCHEMIA. CO2 LEVELS IN BOTH THE STOMACH AND SMALL BOWEL ARE INFLUENCED BY MULTIPLE FACTORS OTHER THAN ADEQUACY OF PERFUSION. GASTRIC ACID PRODUCTION, SALIVARY BICARBONATE AND CO2 PRODUCED OR ABSORBED BY MEALS ARE THE DISTURBING VARIABLES. PROLONGED GASTRIC (AND JEJUNAL) TONOMETRY AFTER MEALS CAN BE OF ADDITIONAL VALUE IN THE WORK-UP OF PATIENTS SUSPECTED OF (CHRONIC) GASTROINTESTINAL ISCHEMIA. THE PURPOSE OF THIS STUDY WAS TO CHALLENGE THESE PROBLEMS USING IN VITRO TESTED MEALS AND A RIGID ACID-SUPPRESSION REGIMEN IN A GROUP OF HEALTHY SUBJECTS. MATERIAL AND METHODS. STANDARD MEALS WERE TESTED IN VITRO ON THE ABILITY TO PRODUCE AND BUFFER CO2. MEALS WITH THE LEAST CO2 VARIATIONS WERE SUBSEQUENTLY USED IN HEALTHY SUBJECTS. TONOMETRY OF THE STOMACH AND JEJUNUM WAS PERFORMED FOR 24 H, WITH OPTIMAL AND CONTROLLED ACID SUPPRESSION. RESULTS. TEN SUBJECTS WERE ENROLLED IN THE STUDY. ACID PRODUCTION WAS SUFFICIENTLY SUPPRESSED. THE GASTRIC PCO2 BASELINE (FASTING) WAS 6.5 (1.0), AND SIGNIFICANTLY LOWER THAN THE JEJUNUM PCO2 BASELINE OF 7.6 (0.9) KPA. THE GASTRIC BASELINE DURING THE DAY WAS 6.9 (1.6), AND SIGNIFICANTLY LOWER THAN THE GASTRIC BASELINE DURING THE NIGHT OF 8.0 (1.8), SUGGESTING A DIURNAL VARIATION OF PCO2. INCREASES IN PCO2 LEVELS WERE SEEN IN ALL SUBJECTS, AFTER MEALS AND BETWEEN MEALS. CONCLUSIONS. PROLONGED GASTRIC AND JEJUNAL TONOMETRY IS FEASIBLE IN HUMANS. PCO2 LEVELS WERE SEEN TO PEAK AFTER, BUT ALSO IN-BETWEEN, MOST MEALS. THE DIURNAL VARIATION IN PCO2 MIGHT REFLECT REVERSIBLE GASTRIC MUCOSAL ISCHEMIA.",DUODENOGASTRIC REFLUX; BICARBONATE SECRETION; HUMAN ESOPHAGUS; BLOOD-FLOW; TONOMETRY; PCO2; PH; VOLUNTEERS; DUODENUM; STOMACH,BICARBONATE; CARBON DIOXIDE; CHRONIC MESENTERIC ISCHEMIA; GASTRIC CARBON DIOXIDE; MUCOSAL ISCHEMIA; SMALL-BOWEL CARBON DIOXIDE; TONOMETRY,SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY,"MENSINK, PBF##GEELKERKEN, RH##HUISMAN, AB##KUIPERS, EJ##KOLKMAN, JJ","ERASMUS UNIV, MED CTR, DEPT GASTROENTEROL & HEPATOL, NL-3015 GD ROTTERDAM, NETHERLANDS. MED SPECTRUM TWENTE, DEPT GASTROENTEROL, ENSCHEDE, NETHERLANDS. MED SPECTRUM TWENTE, DEPT VASC SURG, ENSCHEDE, NETHERLANDS. MED SPECTRUM TWENTE, DEPT INTERVENT RADIOL, ENSCHEDE, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,"BROWN CM, 1993, GUT, V34, P872, DOI 10.1136/GUT.34.7.872##BYRNE JP, 1999, PHYSIOL MEAS, V20, P149, DOI 10.1088/0967-3334/20/2/304##CAMPBELL JA, 1933, Q J EXP PHYSIOL, V22, P159##CHAPMAN MV, 2002, J CARDIOTHOR VASC AN, V16, P304, DOI 10.1053/JCAN.2002.124138##DOHGOMORI HIROSHI, 2003, J ANESTH, V17, P284, DOI 10.1007/S00540-003-0190-8##FIDDIANGREEN RG, 1989, J CARDIOVASC SURG, V30, P852##GIRELLI CM, 1996, AM J GASTROENTEROL, V91, P648##HANNIBAL S, 1983, EUR J CLIN INVEST, V13, P455, DOI 10.1111/J.1365-2362.1983.TB00128.X##HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025##HUMPHREY SP, 2001, J PROSTHET DENT, V85, P162, DOI 10.1067/MPR.2001.113778##ISENBERG JI, 1986, SCAND J GASTROENTERO, V21, P106, DOI 10.3109/00365528609093825##KNICHWITZ G, 1998, CRIT CARE MED, V26, P1550, DOI 10.1097/00003246-199809000-00023##KOLKMAN JJ, 1998, SCAND J GASTROENTERO, V33, P3, DOI 10.1080/003655298750027146##KOLKMAN JJ, 1999, J CRIT CARE, V14, P34, DOI 10.1016/S0883-9441(99)90006-0##KOLKMAN JJ, 2000, BRIT J ANAESTH, V84, P74##LEODOLTER A, 2003, DIGESTION, V67, P179, DOI 10.1159/000072056##MCIVER MA, 1926, AM J PHYSIOL, V76, P92##MERTZNIELSEN A, 1997, GUT, V40, P582, DOI 10.1136/GUT.40.5.582##OVESEN L, 1986, GASTROENTEROLOGY, V90, P958, DOI 10.1016/0016-5085(86)90873-5##PARKER DR, 1995, EUR J GASTROEN HEPAT, V7, P435##REES WDW, 1979, GUT, V20, P963, DOI 10.1136/GUT.20.11.963##RUNE SJ, 1972, ACTA HEPATO-GASTRO, V19, P386##SCHOEN R, 1925, DTSCH ARCH KLIN MED##SEVERINGHAUS JW, 1958, J APPL PHYSIOL, V13, P515##SIEBER C, 1992, GUT, V33, P497, DOI 10.1136/GUT.33.4.497##SINGER MV, 1987, SCAND J GASTROENTERO, V22, P1, DOI 10.3109/00365528709089768##VEALE D, 1994, CHRONOBIOL INT, V11, P200, DOI 10.3109/07420529409057241##VEERMAN DP, 1995, HYPERTENSION, V26, P55, DOI 10.1161/01.HYP.26.1.55##WINSHIP DH, 1974, GASTROENTEROLOGY, V66, P181",14,2020-11-20,NA
J,WOS:000241491800014,2006,SYSTEMIC AND REGIONAL HAEMODYNAMICS IN PIGS WITH ACUTE LIVER FAILURE AND THE EFFECT OF ALBUMIN DIALYSIS,"OBJECTIVE. ACUTE LIVER FAILURE (ALF) IS HAEMODYNAMICALLY CHARACTERIZED BY A HYPERDYNAMIC CIRCULATION. THE AIMS OF THIS STUDY WERE TO INVESTIGATE THE SYSTEMIC AND REGIONAL HAEMODYNAMICS IN ALF, TO MEASURE CHANGES IN NITRIC OXIDE METABOLITES (NOX) AND TO EVALUATE WHETHER THESE HAEMODYNAMIC DISTURBANCES COULD BE ATTENUATED WITH ALBUMIN DIALYSIS. MATERIAL AND METHODS. NORWEGIAN LANDRACE PIGS (23 - 30 KG) WERE RANDOMLY ALLOCATED TO GROUPS AS CONTROLS (SHAM-OPERATION, N = 8), ALF (HEPATIC DEVASCULARIZATION, N = 8) AND ALF + ALBUMIN DIALYSIS (N = 8). ALBUMIN DIALYSIS WAS STARTED 2 H AFTER ALF INDUCTION AND CONTINUED FOR 4 H. SYSTEMIC AND REGIONAL HAEMODYNAMICS WERE MONITORED. CREATININE CLEARANCE, NITRITE/ NITRATE AND CATECHOLAMINES WERE MEASURED. A REPEATED MEASURES ANOVA WAS USED TO ANALYSE THE DATA. RESULTS. IN THE ALF GROUP, THE CARDIAC INDEX INCREASED (P-GT < 0.0001), WHILE MEAN ARTERIAL PRESSURE (P-G = 0.02) AND SYSTEMIC VASCULAR RESISTANCE DECREASED (PGT < 0.0001). RENAL RESISTANCE (P-G = 0.04) AND HIND-LEG RESISTANCE (P-GT = 0.003) DECREASED IN ALF. THERE WAS NO DIFFERENCE IN JEJUNAL BLOOD FLOW BETWEEN THE GROUPS. ALF PIGS DEVELOPED RENAL DYSFUNCTION WITH INCREASED SERUM CREATININE (P-GT = 0.002) AND DECREASED CREATININE CLEARANCE (P = 0.02). CATECHOLAMINES WERE SIGNIFICANTLY HIGHER IN ALF, BUT NOX LEVELS WERE NOT DIFFERENT. ALBUMIN DIALYSIS DID NOT ATTENUATE THESE HAEMODYNAMIC OR RENAL DISTURBANCES. CONCLUSIONS. THE HAEMODYNAMIC DISTURBANCES DURING THE EARLY PHASE OF ALF ARE CHARACTERIZED BY PROGRESSIVE SYSTEMIC VASODILATATION WITH NO ASSOCIATED CHANGES IN METABOLITES OF NO. RENAL VASCULAR RESISTANCE DECREASED AND RENAL DYSFUNCTION DEVELOPED INDEPENDENTLY OF CHANGES IN RENAL BLOOD FLOW. AFTER 4 H OF ALBUMIN DIALYSIS THERE WAS NO ATTENUATION OF THE HAEMODYNAMIC OR RENAL DISTURBANCES.",ADSORBENTS RECIRCULATING SYSTEM; FULMINANT HEPATIC-FAILURE; INTRACRANIAL-PRESSURE; HEPATORENAL-SYNDROME; BIOARTIFICIAL LIVER; PROTEIN S-100-BETA; DRAINED VISCERA; METABOLIC FLUX; MANAGEMENT; BLOOD,ALBUMIN DIALYSIS; ARTIFICIAL ORGANS; HEPATORENAL SYNDROME; HYPERDYNAMIC CIRCULATION,SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY,"YTREBO, LM##SEN, S##ROSE, C##DAVIES, NA##NEDREDAL, GI##FUSKEVAAG, OM##TEN HAVE, GAM##PRINZEN, FW##WILLIAMS, R##DEUTZ, NEP##JALAN, R##REVHAUG, A","UCL, INST HEPATOL, LIVER FAILURE GRP, LONDON WC1E 6HX, ENGLAND. UNIV HOSP NO NORWAY, DEPT DIGEST SURG, TROMSO, NORWAY. UNIV HOSP NO NORWAY, DEPT CLIN PHARMACOL, TROMSO, NORWAY. MAX DELBRUCK CTR MOL MED, DEPT CELLULAR NEUROSCI, BERLIN, GERMANY. MAASTRICHT UNIV, DEPT SURG, MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, CARDIOVASC RES INST, MAASTRICHT, NETHERLANDS.",GASTROENTEROLOGY & HEPATOLOGY,GASTROENTEROLOGY & HEPATOLOGY,"ANAND R, 2002, GUT, V50, P111, DOI 10.1136/GUT.50.1.111##DEUTZ NEP, 1991, GASTROENTEROLOGY, V101, P1613, DOI 10.1016/0016-5085(91)90399-6##ELLIS A, 1996, SEMIN LIVER DIS, V16, P379, DOI 10.1055/S-2007-1007251##GINES P, 2003, LANCET, V362, P1819, DOI 10.1016/S0140-6736(03)14903-3##GIOVANNONI G, 1997, ANN CLIN BIOCHEM, V34, P193, DOI 10.1177/000456329703400212##HALLEMEESCH MM, 2001, LAB ANIM-UK, V35, P101, DOI 10.1258/0023677011911426##JALAN R, 2005, J HEPATOL, V42, PS115, DOI 10.1016/J.JHEP.2004.11.010##JALAN R, 2003, J HEPATOL, V38, P24, DOI 10.1016/S0168-8278(02)00334-3##JAVLE P, 1998, GUT, V43, P272, DOI 10.1136/GUT.43.2.272##KASRAVI FB, 1996, HEPATOLOGY, V23, P97, DOI 10.1053/JHEP.1996.V23.PM0008550055##KUSHNIR MM, 2002, CLIN CHEM, V48, P323##MARLEY R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011##MIRANDA KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/NIOX.2000.0319##MITZNER SR, 2000, LIVER TRANSPLANT, V6, P277, DOI 10.1053/LV.2000.6355##POLSON J, 2005, HEPATOLOGY, V41, P1179, DOI 10.1002/HEP.20703##RAHMAN TM, 2000, INT J EXP PATHOL, V81, P145##RAMLOW W, 1993, ASAIO J, V39, P621##ROSE B, 2001, CLIN PHYSL ACID BASE##SCHMIDT LE, 2003, LIVER TRANSPLANT, V9, P290, DOI 10.1053/JLTS.2003.50051##SCHNEIDER F, 1994, HEPATOLOGY, V19, P38, DOI 10.1002/HEP.1840190108##SEN S, 2004, LIVER TRANSPLANT, V10, P1109, DOI 10.1002/LT.20236##SEN S, 2004, INTENS CARE MED, V30, P496, DOI 10.1007/S00134-003-2141-0##SEN S, 2003, HEPATOLOGY, V38, P540A##SEN S, 2003, INT J BIOCHEM CELL B, V35, P1306, DOI 10.1016/S1357-2725(03)00045-1##SORKINE P, 2001, CRIT CARE MED, V29, P1332, DOI 10.1097/00003246-200107000-00006##STANGE J, 1996, INT J ARTIF ORGANS, V19, P677##STANGE J, 1993, ARTIF ORGANS, V17, P809##TENHAVE GAM, 1996, LAB ANIM-UK, V30, P347, DOI 10.1258/002367796780739862##TREWBY PN, 1977, GUT, V18, P1021, DOI 10.1136/GUT.18.12.1021##VANOOSTERHOUT NFM, 1995, AM J PHYSIOL-HEART C, V269, PH725, DOI 10.1152/AJPHEART.1995.269.2.H725##YTREBO LM, 2002, SCAND J GASTROENTERO, V37, P1077, DOI 10.1080/003655202320378293##YTREBO LM, 2001, SCAND J CLIN LAB INV, V61, P217##YTREBO LM, 2001, CRIT CARE MED, V29, P1989, DOI 10.1097/00003246-200110000-00023##YTREBO LM, 2000, SCAND J GASTROENTERO, V35, P546",22,2020-11-20,NA
J,WOS:000242474600016,2006,EVALUATION OF THE DRIED BLOOD SPOT FILTER PAPER TECHNOLOGY AND FIVE TESTING STRATEGIES OF HIV-1 AND HIV-2 INFECTIONS IN WEST AFRICA,"SIMPLE ROBUST APPROACHES ARE NEEDED TO MONITOR THE PREVALENCE AND INCIDENCE OF HIV IN AFRICA. THE AIM OF THIS STUDY WAS TO EVALUATE THE USE OF DRIED BLOOD SPOT (DBS) AS AN ALTERNATIVE TO SERUM OR PLASMA FOR SENTINEL SURVEILLANCE. PAIRED DBS AND BLOOD SAMPLES WERE OBTAINED FROM 200 PATIENTS ATTENDING A GENITO-URINARY MEDICINE CLINIC IN WEST AFRICA. THE GOLD STANDARD OF DIAGNOSIS WAS BASED ON THE COMBINATION OF 3 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) USING SERUM. THE PRESENCE OF HIV ANTIBODIES IN ELUATES OF DRIED BLOOD SPOTS WAS DETECTED BY ELISA, GELATIN PARTICLE ASSAY (GPA) AND PEPTI-LAV 1-2 IN 5 DIFFERENT TESTING STRATEGIES. ALL 200 ELUATES WERE TESTED INDIVIDUALLY, AND IN ADDITION POOLS OF 5 ELUATES EACH WERE TESTED. THE SENSITIVITY OF THE TESTING STRATEGIES RANGED FROM 95.0% (83.1-99.4%) TO 100% AND THE SPECIFICITY FROM 97.5% (93.7-99.3%) TO 100%. TESTING IN POOLS OF 5 DID NOT AFFECT SENSITIVITY. DRIED BLOOD SPOTS WERE EASY TO WORK WITH. TEST KIT AND LABORATORY CONSUMABLE COSTS VARIED BETWEEN 492 POUND AND 1037 POUND (UNPOOLED STRATEGIES) AND 163 POUND AND 421 POUND (POOLED). THE MONOSPECIFIC ELISAS USED IN THIS STUDY ARE NO LONGER IN PRODUCTION; CURRENTLY AVAILABLE DIFFERENTIATING ASSAYS NEED TO BE TESTED. DBS ARE RECOMMENDED FOR SENTINEL SURVEILLANCE IN AFRICA.",HUMAN-IMMUNODEFICIENCY-VIRUS; WHOLE-BLOOD; ANTIBODIES; PREVALENCE; SURVEILLANCE; ABIDJAN; SAMPLES; WOMEN; DISKS,NA,SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES,"SARGE-NJIE, R##VAN DER LOEFF, MS##CEESAY, S##CUBITT, D##SABALLY, S##CORRAH, T##WHITTLE, H","MRC LABS, FAJARA, GAMBIA. NATL AIDS SECRETARIAT, BANJUL, GAMBIA. INST CHILD HLTH, LONDON, ENGLAND.",INFECTIOUS DISEASES,INFECTIOUS DISEASES,"BEEBE JL, 1990, J CLIN MICROBIOL, V28, P808, DOI 10.1128/JCM.28.4.808-810.1990##BEHETS F, 1992, J CLIN MICROBIOL, V30, P1179, DOI 10.1128/JCM.30.5.1179-1182.1992##BERRY N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904##BOILLOT F, 1997, INT J TUBERC LUNG D, V1, P493##CAHOONYOUNG B, 1989, J CLIN MICROBIOL, V27, P1893, DOI 10.1128/JCM.27.8.1893-1895.1989##EVENGARD B, 1988, BRIT MED J, V297, P1178, DOI 10.1136/BMJ.297.6657.1178##FARZADEGAN H, 1987, J INFECT DIS, V155, P1073, DOI 10.1093/INFDIS/155.5.1073##FARZADEGAN H, 1978, LANCET, V1, P362##HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901##ILONA LF, 2003, J CLIN VIROL, V26, P39, DOI 10.1016/S1386-6532(02)00019-7##LINDHARDT BO, 1987, J VIROL METHODS, V18, P73, DOI 10.1016/0166-0934(87)90112-1##MARLINK R, 1996, AIDS, V10, P689, DOI 10.1097/00002030-199606001-00002##MARTIN LS, 1985, J INFECT DIS, V152, P400, DOI 10.1093/INFDIS/152.2.400##NKENGASONG JN, 1999, AIDS, V13, P109, DOI 10.1097/00002030-199901140-00015##NKENGASONG JN, 1998, J CLIN MICROBIOL, V36, P123, DOI 10.1128/JCM.36.1.123-127.1998##PAPPAIOANOU M, 1993, AIDS, V7, P483, DOI 10.1097/00002030-199304000-00005##PARKER SP, 1999, J CLIN PATHOL S, V2, P1##PECKHAM CS, 1990, LANCET, V335, P516, DOI 10.1016/0140-6736(90)90746-R##SHIBATA M, 1994, J VIROL METHODS, V46, P279, DOI 10.1016/0166-0934(94)90111-2##SOLOMON SS, 2002, INT J STD AIDS, V13, P25, DOI 10.1258/0956462021924578##TAMARA T, 1996, LANCET, V348, P893, DOI 10.1016/S0140-6736(05)64765-4##VAN DER LOEFF MFS, 2000, AIDS, V14, P1276, DOI 10.1097/00002030-200006160-00027##VAN DER LOEFF MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.AIDS.0000076303.76477.49##VANDENAKKER R, 1990, AIDS, V4, P90, DOI 10.1097/00002030-199001000-00016##VEJTORP M, 1981, ACTA PATH MICRO IM B, V89, P369##VERSTRAETEN T, 1998, TROP MED INT HEALTH, V3, P747##WASSILAK SGF, 1984, PEDIATR INFECT DIS J, V3, P117, DOI 10.1097/00006454-198403000-00007##*WHO, 2004, 14 WHO",17,2020-11-20,NA
J,WOS:000242474600028,2006,NECROTIZING FASCIITIS CAUSED BY SALMONELLA ENTERITIDIS,A 57-YEAR-OLD IMMUNOCOMPROMIZED FEMALE DEVELOPED A NECROTIZING FASCIITIS WITH SEPSIS A FEW DAYS AFTER ABDOMINAL COMPLAINTS AND DIARRHOEA. SURGERY WAS PERFORMED BECAUSE OF PROGRESSIVE WORSENING OF THE PATIENT'S SITUATION AND DURING SURGERY THE DECISION WAS MADE TO PERFORM AN AMPUTATION. AFTER SURGERY THE PATIENT WAS BROUGHT TO THE INTENSIVE CARE DEPARTMENT FOR A FEW DAYS. SHE RECOVERED FROM HER SEPSIS WITHIN A FEW DAYS. CULTURES SHOWED SALMONELLA ENTERITIDIS.,NA,NA,SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES,"ANDRIESSEN, MJG##KOTSOPOULOS, AMM##BLOEMERS, FW##VAN SCHIJNDEL, RJMS##GIRBES, ARJ","VRIJE UNIV AMSTERDAM, MED CTR, DEPT INTENS CARE, AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, DEPT SURG, AMSTERDAM, NETHERLANDS.",INFECTIOUS DISEASES,INFECTIOUS DISEASES,"COHEN JI, 1987, MEDICINE, V66, P349, DOI 10.1097/00005792-198709000-00003##HASHAM S, 2005, BMJ-BRIT MED J, V330, P830, DOI 10.1136/BMJ.330.7495.830##JORRING S, 1994, SCAND J INFECT DIS, V26, P619, DOI 10.3109/00365549409011822##SANCHEZ C, 1984, SCAND J INFECT DIS, V16, P321, DOI 10.3109/00365548409070408##SANTOS-JUANES J, 2005, SCAND J INFECT DIS, V37, P309, DOI 10.1080/00365540410021225##SUWANNAROJ S, 2001, JCR-J CLIN RHEUMATOL, V7, P83, DOI 10.1097/00124743-200104000-00006",2,2020-11-20,NA
J,WOS:000243205200013,2006,TERMITE ACTIVITY IN RELATION TO NATURAL GRASSLAND SOIL ATTRIBUTES,"SOIL-FEEDING TERMITES TRANSPORT SOIL FOR MOUND BUILDING, AND THIS PROCESS CAN AFFECT SOIL CHARACTERISTICS. TO VERIFY THE INFLUENCE OF SOIL TERMITE ACTIVITY ON SOIL CHARACTERISTICS, SAMPLES WERE COLLECTED FROM TOP, BOTTOM AND CENTER OF TERMITE MOUNDS, AND OF THE ADJACENT AREA, TO ASSESS CHEMICAL AND PHYSICAL PROPERTIES AND MINERALOGICAL COMPOSITION. FOUR REPLICATES OF TERMITE MOUNDS AND RESPECTIVE ADJACENT AREAS WERE RANDOMLY SAMPLED IN LAGES, CAPAO ALTO, PAINEL, SAO JOSE DO CERRITO AND COXILHA RICA (STATE OF SANTA CATARINA, SOUTHERN BRAZIL). RESULTS OF CHEMICAL ANALYSES SHOWED A GREATER CONTENT OF K, P, CA, MG AND ORGANIC C IN THE INNER PART OF TERMITE MOUNDS, ACCOMPANIED BY LOWER PH IN RELATION TO SOIL OF THE ADJACENT AREA. THERE WERE NO DIFFERENCES REGARDING CLAY MINERAL COMPOSITION BETWEEN TERMITE MOUNDS AND ADJACENT SOIL, HOWEVER THE PROPORTION OF SAND AND CLAY DIFFERED BETWEEN THEM. IT IS CONCLUDED THAT TERMITES MODIFY SOIL CHARACTERISTICS DUE TO GREAT VOLUME OF SOIL TRANSPORTED PER ASCENSUM FOR MOUND CONSTRUCTION (VARYING FROM 20.9 M(3) HA(-1) TO 136.6 M(3) HA(-1), IN THIS STUDY) WHICH PROMOTES A STRONG PEDO-BIOPERTURBATION AND AFFECTS NUTRIENT CYCLING AND SOIL PHYSICAL PROPERTIES.",FEEDING TERMITE; MOUNDS; INTENSIFICATION; MACROTERMES; ISOPTERA,CHEMICAL AND PHYSICAL SOIL PROPERTIES; CLAY MINERALS; SOIL BIOLOGY; TERMITE MOUNDS,SCIENTIA AGRICOLA,"KASCHUK, G##SANTOS, JCP##ALMEIDA, JA##SINHORATI, DC##BERTON-JUNIOR, JF","UDESC, CAV, DEPT SOLOS, BR-88520000 LAGES, SC, BRAZIL. EMBRAPA SOJA, LAB BIOTECNOL SOLOS, BR-86001970 LONDRINA, PR, BRAZIL. WUR PLANT PROD SYST GRP, NL-6700 AK WAGENINGEN, NETHERLANDS.","AGRICULTURE, MULTIDISCIPLINARY",AGRICULTURE,"BLACK HIJ, 1997, APPL SOIL ECOL, V6, P37, DOI 10.1016/S0929-1393(96)00153-9##BRAUMAN A, 2000, EUR J SOIL BIOL, V36, P117, DOI 10.1016/S1164-5563(00)01058-X##BRUNE A, 1996, J INSECT PHYSIOL, V42, P1121, DOI 10.1016/S0022-1910(96)00036-4##BRUNE A, 1995, APPL ENVIRON MICROB, V61, P2681, DOI 10.1128/AEM.61.7.2681-2687.1995##DANGERFIELD JM, 1998, J TROP ECOL, V14, P507, DOI 10.1017/S0266467498000364##DONOVAN SE, 2001, PEDOBIOLOGIA, V45, P1, DOI 10.1078/0031-4056-00063##EGGLETON P, 2001, ECOL RES, V16, P941, DOI 10.1046/J.1440-1703.2001.00444.X##*EMPR BRAS PESQ AG, 1979, MAN MET AN SOL##*FAO, 1988, 60 FAO UNESCO##HOLT JA, 1998, APPL SOIL ECOL, V9, P183, DOI 10.1016/S0929-1393(98)00073-0##JI R, 2000, SOIL BIOL BIOCHEM, V32, P1281, DOI 10.1016/S0038-0717(00)00046-8##JONES DT, 2003, J APPL ECOL, V40, P380, DOI 10.1046/J.1365-2664.2003.00794.X##JOUQUET P, 2002, INSECT SOC, V49, P1, DOI 10.1007/S00040-002-8269-Z##JOUQUET P, 2002, EUR J SOIL SCI, V53, P521, DOI 10.1046/J.1365-2389.2002.00492.X##JUNGERIUS PD, 1999, CATENA, V34, P349, DOI 10.1016/S0341-8162(98)00106-4##LAL R, 1988, AGR ECOSYST ENVIRON, V24, P101, DOI 10.1016/0167-8809(88)90059-X##LEE KE, 1971, TERMITES SOILS##LEONARD J, 2001, GEODERMA, V104, P17, DOI 10.1016/S0016-7061(01)00054-4##LOPEZ-HERNANDEZ D, 2001, SOIL BIOL BIOCHEM, V33, P747, DOI 10.1016/S0038-0717(00)00220-0##MANDO A, 1999, SOIL USE MANAGE, V15, P123, DOI 10.1111/J.1475-2743.1999.TB00075.X##MIKLOS AW, 1993, B I BIODINAMICO DESE, V11, P9##MIKLOS AW, 1995, CURSO AGR ECOLOGICA, V1##OHKUMA M, 2003, APPL MICROBIOL BIOT, V61, P1, DOI 10.1007/S00253-002-1189-Z##SAS, 1999, SAS US GUID STAT VER##SCHAEFER CER, 2001, AUST J SOIL RES, V39, P909, DOI 10.1071/SR00093##SCHULZE DARRELL G., 2002, P1##SHEIKH KH, 1982, SOIL BIOL BIOCHEM, V14, P359, DOI 10.1016/0038-0717(82)90006-2##TEDESCO MJ, 1985, B TECNICO UFRGS, V5##WATSON JP, 1975, GEODERMA, V14, P147, DOI 10.1016/0016-7061(75)90073-7##WHITTIG L. D., 1986, METHODS OF SOIL ANALYSIS. PART 1. PHYSICAL AND MINERALOGICAL METHODS, P331##1986, GABINETE PLANEJAMENT",26,2020-11-20,NA
J,WOS:000242622300011,2006,NANOSPINTRONICS WITH CARBON NANOTUBES,"ONE OF THE ACTUAL CHALLENGES OF SPINTRONICS IS THE REALIZATION OF A SPIN TRANSISTOR ALLOWING CONTROL OF SPIN TRANSPORT THROUGH AN ELECTROSTATIC GATE. IN THIS PAPER, WE REPORT ON DIFFERENT EXPERIMENTS WHICH DEMONSTRATE GATE CONTROL OF SPIN TRANSPORT IN A CARBON NANOTUBE CONNECTED TO FERROMAGNETIC LEADS. WE ALSO DISCUSS SOME THEORETICAL APPROACHES WHICH CAN BE USED TO ANALYSE SPIN TRANSPORT IN THESE SYSTEMS. WE EMPHASIZE THE ROLES OF THE GATE-TUNABLE QUASI-BOUND STATES INSIDE THE NANOTUBE AND THE COHERENT SPIN-DEPENDENT SCATTERING AT THE INTERFACES BETWEEN THE NANOTUBE AND ITS FERROMAGNETIC CONTACTS.",ELECTRICAL SPIN INJECTION; ELECTRONIC-PROPERTIES; POLARIZED TRANSPORT; FIELD; MAGNETORESISTANCE; OSCILLATIONS; PRECESSION; SPINTRONICS; SENSITIVITY; PHYSICS,NA,SEMICONDUCTOR SCIENCE AND TECHNOLOGY,"COTTET, A##KONTOS, T##SAHOO, S##MAN, HT##CHOI, MS##BELZIG, W##BRUDER, C##MORPURGO, AF##SCHONENBERGER, C","UNIV PARIS 11, PHYS SOLIDES LAB, F-91405 ORSAY, FRANCE. ECOLE NORMALE SUPER, LAB PIERRE AIGRAIN, F-75231 PARIS 05, FRANCE. UNIV BASEL, INST PHYS, CH-4056 BASEL, SWITZERLAND. DELFT UNIV TECHNOL, FAC APPL PHYS, KAVLI INST NANOSCI, NL-2628 CJ DELFT, NETHERLANDS. KOREA UNIV, DEPT PHYS, SEOUL 136701, SOUTH KOREA. UNIV KONSTANZ, DEPT PHYS, D-78457 CONSTANCE, GERMANY.","ENGINEERING, ELECTRICAL & ELECTRONIC; MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, CONDENSED MATTER",ENGINEERING; MATERIALS SCIENCE; PHYSICS,"ALEINER IL, 2002, PHYS REP, V358, P309, DOI 10.1016/S0370-1573(01)00063-1##ANDO T, 2000, J PHYS SOC JPN, V69, P1757, DOI 10.1143/JPSJ.69.1757##AUSLAENDER OM, 2005, SCIENCE, V308, P88, DOI 10.1126/SCIENCE.1107821##BABIC B, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.195408##BABIC B, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.235419##BACHTOLD A, 2001, PHYS REV LETT, V87, DOI 10.1103/PHYSREVLETT.87.166801##BACHTOLD A, 1999, NATURE, V397, P673, DOI 10.1038/17755##BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PHYSREVLETT.61.2472##BALENTS L, 2000, PHYS REV LETT, V85, P3464, DOI 10.1103/PHYSREVLETT.85.3464##BALENTS L, 2001, PHYS REV B, V64, DOI 10.1103/PHYSREVB.64.035310##BANDOW S, 1998, APPL PHYS A-MATER, V67, P23, DOI 10.1007/S003390050733##BARNAS J, 1998, PHYS REV LETT, V80, P1058, DOI 10.1103/PHYSREVLETT.80.1058##BEUNEU F, 1978, PHYS REV B, V18, P2422, DOI 10.1103/PHYSREVB.18.2422##BEZRYADIN A, 1998, PHYS REV LETT, V80, P4036, DOI 10.1103/PHYSREVLETT.80.4036##BINASCH G, 1989, PHYS REV B, V39, P4828, DOI 10.1103/PHYSREVB.39.4828##BLANTER YM, 2000, PHYS REP, V336, P1, DOI 10.1016/S0370-1573(99)00123-4##BOCKRATH M, 1999, NATURE, V397, P598##BOURLON B, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.176806##BRATAAS A, 2001, EUR PHYS J B, V22, P99, DOI 10.1007/PL00011139##BRATAAS A, 1999, PHYS REV B, V59, P93, DOI 10.1103/PHYSREVB.59.93##BRATAAS A, 2000, PHYS REV LETT, V84, P2481, DOI 10.1103/PHYSREVLETT.84.2481##BRAUN M, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.195345##BUITELAAR MR, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.256801##BUITELAAR MR, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.156801##BULKA BR, 2000, PHYS REV B, V62, P1186, DOI 10.1103/PHYSREVB.62.1186##CHOI MS, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.056601##CHTCHELKATCHEV NM, 2001, JETP LETT+, V74, P323, DOI 10.1134/1.1421408##CLAYE AS, 2000, PHYS REV B, V62, PR4845, DOI 10.1103/PHYSREVB.62.R4845##COLLINS PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/SCIENCE.287.5459.1801##COTTET A, 2006, EUROPHYS LETT, V74, P320, DOI 10.1209/EPL/I2006-10006-0##COTTET A, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.180503##COTTET A, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.206801##COTTET A, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.115315##COTTET A, 2006, CONDMAT0605264##CUEVAS JC, 2001, PHYS REV B, V64, DOI 10.1103/PHYSREVB.64.104502##DATTA S, 1990, APPL PHYS LETT, V56, P665, DOI 10.1063/1.102730##DE MARTINO A, 2005, J PHYS-CONDENS MAT, V17, P5523, DOI 10.1088/0953-8984/17/36/008##FERT A, 2001, PHYS REV B, V64, DOI 10.1103/PHYSREVB.64.184420##GAJEK M, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.020406##GAO B, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.196802##GAZZA CJ, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.193108##HAO X, 1990, PHYS REV B, V42, P8235, DOI 10.1103/PHYSREVB.42.8235##HU CM, 1998, PHYS REV LETT, V87##HUERTAS-HERNANDO D, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.047003##HUERTAS-HERNANDO D, 2000, PHYS REV B, V62, P5700, DOI 10.1103/PHYSREVB.62.5700##HUESO LE, 2005, CONDMAT0511697##IMAMURA H, 1999, PHYS REV B, V59, P6017, DOI 10.1103/PHYSREVB.59.6017##JARILLO-HERRERO P, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.156802##JAVEY A, 2003, NATURE, V424, P654, DOI 10.1038/NATURE01797##JEDEMA FJ, 2002, NATURE, V416, P713, DOI 10.1038/416713A##JEDEMA FJ, 2001, NATURE, V410, P345, DOI 10.1038/35066533##JENSEN A, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.035419##JENSEN A, 2003, THESIS TU DENMARK CO##JHI SH, 2000, PHYS REV LETT, V85, P1710, DOI 10.1103/PHYSREVLETT.85.1710##JULLIERE M, 1975, PHYS LETT A, V54, P225, DOI 10.1016/0375-9601(75)90174-7##KHAETSKII AV, 2000, PHYS REV B, V61, P12639, DOI 10.1103/PHYSREVB.61.12639##KIM JR, 2002, PHYS REV B, V66, DOI 10.1103/PHYSREVB.66.233401##KIM W, 2003, NANO LETT, V3, P193, DOI 10.1021/NL0259232##KONG J, 2000, SCIENCE, V287, P622, DOI 10.1126/SCIENCE.287.5453.622##KONIG J, 2005, LECT NOTES PHYS, V658, P145##KONIG J, 2003, PHYS REV LETT, V90, DOI 10.1103/PHYSREVLETT.90.166602##KOPU J, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.094501##KRUGER M, 2003, NEW J PHYS, V5, DOI 10.1088/1367-2630/5/1/138##KRUGER M, 2001, APPL PHYS LETT, V78, P1291, DOI 10.1063/1.1350427##LIANG WJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.126801##LIANG WJ, 2001, NATURE, V411, P665, DOI 10.1038/35079517##LOPEZ R, 2003, PHYS REV LETT, V90, DOI 10.1103/PHYSREVLETT.90.116602##MAN HT, 2003, PHYS REV B, V73##MARTINEK J, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.121302##MARTINEK J, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.247202##MARTINEK J, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.127203##MEIER L, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2198102##MEIR Y, 1991, PHYS REV LETT, V66, P3048, DOI 10.1103/PHYSREVLETT.66.3048##MEIR Y, 1992, PHYS REV LETT, V68, P2512, DOI 10.1103/PHYSREVLETT.68.2512##MILLIS A, 1988, PHYS REV B, V38, P4504, DOI 10.1103/PHYSREVB.38.4504##MORIYAMA S, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.186806##NAGABHIRAVA B, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2164367##NYGARD J, 2000, NATURE, V408, P342, DOI 10.1038/35042545##ONO K, 1998, J PHYS SOC JPN, V67, P2852, DOI 10.1143/JPSJ.67.2852##PASUPATHY AN, 2004, SCIENCE, V306, P86, DOI 10.1126/SCIENCE.1102068##PECA CS, 2003, PHYS REV B, V68, DOI 10.1103/PHYSREVB.68.205423##PETIT P, 1997, PHYS REV B, V56, P9275, DOI 10.1103/PHYSREVB.56.9275##PRINZ GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/SCIENCE.282.5394.1660##RASHBA EI, 2000, PHYS REV B, V62, PR16267, DOI 10.1103/PHYSREVB.62.R16267##SAHOO S, 2005, NAT PHYS, V1, P99, DOI 10.1038/NPHYS149##SAHOO S, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1882761##SAHOO S, 2005, THESIS U BASEL BASEL##SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080##SALVETAT JP, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.075440##SAPMAZ S, 2005, PHYS REV B, V71, DOI 10.1103/PHYSREVB.71.153402##SCHAPERS T, 2001, PHYS REV B, V64, DOI 10.1103/PHYSREVB.64.125314##SEMENOV YG, 2006, CONDMAT0602425##SERGUEEV N, 2002, PHYS REV B, V65, DOI 10.1103/PHYSREVB.65.165303##SHCMIDT G, 2000, PHYS REV B, V62, P4790##SHEN K, 2003, PHYS REV B, V68, DOI 10.1103/PHYSREVB.68.165418##SHIMADA H, 1998, J PHYS SOC JPN, V67, P1359, DOI 10.1143/JPSJ.67.1359##SWIRKOWICZ R, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.193312##SWIRKOWICZ R, 2006, J PHYS-CONDENS MAT, V18, P2291, DOI 10.1088/0953-8984/18/7/016##TANS SJ, 1998, NATURE, V394, P761, DOI 10.1038/29494##TOKUYASU T, 1988, PHYS REV B, V38, P8823, DOI 10.1103/PHYSREVB.38.8823##TOMBROS N, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.233403##TSUKAGOSHI K, 1999, NATURE, V401, P572##TSUKAGOSHI K, 2000, SUPERLATTICE MICROST, V27, P565, DOI 10.1006/SPMI.2000.0885##TSYMBAL EY, 2003, PHYS REV LETT, V90, DOI 10.1103/PHYSREVLETT.90.186602##UTSUMI Y, 2005, PHYS REV B, V71, DOI 10.1103/PHYSREVB.245116##VAN DER MOLEN SJ, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.220406##WETZELS W, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.020407##WEYMANN I, 2005, PHYS REV B, V72, DOI 10.1103/PHYSREVB.72.115334##WUNDERLICH J, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.077201##YAO Z, 1999, NATURE, V402, P273, DOI 10.1038/46241##ZHANG P, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.286803##ZHAO B, 2002, J APPL PHYS, V91, P7026, DOI 10.1063/1.1452227##ZHAO EH, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.134510##ZUTIC I, 2004, REV MOD PHYS, V76, P323, DOI 10.1103/REVMODPHYS.76.323##ZUTIC I, 2005, NAT PHYS, V1, P85, DOI 10.1038/NPHYS164",92,2020-11-20,NA
J,WOS:000242622300008,2006,QUANTUM DOTS IN CARBON NANOTUBES,"IN THIS OVERVIEW PAPER, WE PRESENT LOW-TEMPERATURE ELECTRONIC TRANSPORT MEASUREMENTS OF CARBON NANOTUBE QUANTUM DOTS WITH A BACK GATE. IN A SEMICONDUCTING TUBE, CHARGE CARRIERS COULD BE COMPLETELY DEPLETED. THE ADDITION ENERGY AND THE EXCITATION SPECTRUM HAVE BEEN STUDIED AS A FUNCTION OF THE NUMBER OF CHARGES (ELECTRONS OR HOLES), ONE BY ONE. WE OBSERVE ELECTRON-HOLE SYMMETRY, WHICH IS A DIRECT CONSEQUENCE OF THE SYMMETRIC BAND STRUCTURE OF THE NANOTUBE. THE EXCITATION SPECTRUM FOR METALLIC NANOTUBES EXHIBITS FOUR-FOLD SHELL FILLING AND IS COMPLETELY DESCRIBED BY AN EXTENDED CONSTANT-INTERACTION MODEL. FURTHERMORE, NANOTUBES WITH A FOUR-FOLD SHELL STRUCTURE ARE INVESTIGATED IN A PARALLEL MAGNETIC FIELD. THE MAGNETIC FIELD INDUCES A LARGE SPLITTING BETWEEN THE TWO ORBITAL STATES OF EACH SHELL, DEMONSTRATING THEIR OPPOSITE MAGNETIC MOMENT AND DETERMINING TRANSITIONS IN THE SPIN AND ORBITAL CONFIGURATION OF THE QUANTUM DOT GROUND STATE. ALSO, A SMALL COUPLING IS FOUND BETWEEN ORBITALS WITH OPPOSITE MAGNETIC MOMENTS LEADING TO ANTI-CROSSING BEHAVIOUR AT ZERO FIELD. CURRENT-VOLTAGE CHARACTERISTICS OF SUSPENDED CARBON NANOTUBE QUANTUM DOTS SHOW AN ADDITIONAL SERIES OF STEPS EQUALLY SPACED IN VOLTAGE. THE ENERGY SCALE OF THIS HARMONIC, LOW-ENERGY EXCITATION SPECTRUM IS CONSISTENT WITH THAT OF THE LONGITUDINAL LOW-K PHONON MODE (STRETCHING MODE) IN THE NANOTUBE. FINALLY, WE REPORT ON A FULLY TUNABLE CARBON NANOTUBE DOUBLE QUANTUM DOT. WE PERFORIN INELASTIC TRANSPORT SPECTROSCOPY VIA THE EXCITED STATES IN THE DOUBLE QUANTUM DOT, A NECESSARY STEP TOWARDS THE IMPLEMENTATION OF NEW MICROWAVE-BASED EXPERIMENTS FOR QUANTUM INFORMATION TECHNOLOGY.",ELECTRON-TRANSPORT; TRANSISTORS; PHONONS,NA,SEMICONDUCTOR SCIENCE AND TECHNOLOGY,"SAPMAZ, S##JARILLO-HERRERO, P##KOUWENHOVEN, LP##VAN DER ZANT, HSJ","DELFT UNIV TECHNOL, KAVLI INST NANOSCI, NL-2600 GA DELFT, NETHERLANDS.","ENGINEERING, ELECTRICAL & ELECTRONIC; MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, CONDENSED MATTER",ENGINEERING; MATERIALS SCIENCE; PHYSICS,"AJIKI H, 1993, J PHYS SOC JPN, V62, P2470, DOI 10.1143/JPSJ.62.2470##BABIC B, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.195408##BACHTOLD A, 2001, SCIENCE, V294, P1317, DOI 10.1126/SCIENCE.1065824##BIERCUK MJ, 2005, NANO LETT, V5, P1267, DOI 10.1021/NL050364V##BOCKRATH M, 1999, NATURE, V397, P598##BOCKRATH M, 1997, SCIENCE, V275, P1922, DOI 10.1126/SCIENCE.275.5308.1922##BRAIG S, 2003, PHYS REV B, V68, DOI 10.1103/PHYSREVB.68.205324##BRONIKOWSKI MJ, 2001, J VAC SCI TECHNOL A, V19, P1800, DOI 10.1116/1.1380721##COBDEN DH, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.046803##DE FRANCESCHI S, 2001, PHYS REV LETT, V86, P878, DOI 10.1103/PHYSREVLETT.86.878##DE MARTINO A, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.235418##DEKKER C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658##DRESSELHAUS MS, 2000, ADV PHYS, V49, P705, DOI 10.1080/000187300413184##DRESSELHAUS MS, 1996, SCI FULLERENES CARBO##FUHRER MS, 2000, SCIENCE, V288, P494, DOI 10.1126/SCIENCE.288.5465.494##FUJISAWA T, 1998, SCIENCE, V282, P932, DOI 10.1126/SCIENCE.282.5390.932##GRABERT H., 1992, SINGLE CHARGE TUNNEL##GRABER MR, 2006, PHYS REV B, V74, DOI 10.1103/PHYSREVB.74.075427##HAUSLER W, 1993, PHYS REV B, V47, P16353, DOI 10.1103/PHYSREVB.47.16353##HEINZE S, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.106801##IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056A0##JARILLO-HERRERO P, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.156802##JARILLO-HERRERO P, 2006, NATURE, V439, P953, DOI 10.1038/NATURE04550##JARILLO-HERRERO P, 2005, NATURE, V434, P484, DOI 10.1038/NATURE03422##JARILLO-HERRERO P, 2004, NATURE, V429, P389, DOI 10.1038/NATURE02568##JAVEY A, 2003, NATURE, V424, P654, DOI 10.1038/NATURE01797##JORGENSNE HI, 2006, CONDMAT0606374##KASUMOV AY, 1999, SCIENCE, V284, P1508, DOI 10.1126/SCIENCE.284.5419.1508##KOCH J, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.206804##KOGAN A, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.166602##KOUWENHOVEN LP, 2001, REP PROG PHYS, V64, P701, DOI 10.1088/0034-4885/64/6/201##LANDAU L. D., 1986, THEORY ELASTICITY##LEMAY SG, 2001, NATURE, V412, P617, DOI 10.1038/35088013##LEROY BJ, 2004, NATURE, V432, P371, DOI 10.1038/NATURE03046##LIANG WJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.126801##LIANG WJ, 2001, NATURE, V411, P665, DOI 10.1038/35079517##LOSS D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PHYSREVA.57.120##MAKAROVSKI A, 2005, CONDMAT0508401##MASON N, 2004, SCIENCE, V303, P655, DOI 10.1126/SCIENCE.1093605##MCEUEN PL, 2000, PHYS WORLD, V13, P31##MINOT ED, 2004, NATURE, V428, P536, DOI 10.1038/NATURE02425##MITRA A, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.245302##MORIYAMA S, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.186806##MORPURGO AF, 1999, SCIENCE, V286, P263, DOI 10.1126/SCIENCE.286.5438.263##NYGARD J, 2000, NATURE, V408, P342, DOI 10.1038/35042545##NYGARD J, 2001, APPL PHYS LETT, V79, P4216, DOI 10.1063/1.1428117##OREG Y, 2000, PHYS REV LETT, V85, P365, DOI 10.1103/PHYSREVLETT.85.365##PARK H, 2000, NATURE, V407, P57, DOI 10.1038/35024031##PARK JW, 2001, APPL PHYS LETT, V79, P1363, DOI 10.1063/1.1396318##POSTMA HWC, 2000, ADV MATER, V12, P1299, DOI 10.1002/1521-4095(200009)12:17<1299::AID-ADMA1299>3.0.CO;2-O##SAPMAZ S, 2005, NEW J PHYS, V7, DOI 10.1088/1367-2630/7/1/243##SAPMAZ S, 2005, PHYS REV B, V71, DOI 10.1103/PHYSREVB.71.153402##SAPMAZ S, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.026801##SAPMAZ S, 2003, PHYS REV B, V67, DOI 10.1103/PHYSREVB.67.235414##SAPMAZ S, 2006, NANO LETT, V6, P1350, DOI 10.1021/NL052498E##SASAKI S, 2000, NATURE, V405, P764, DOI 10.1038/35015509##SAZONOVA V, 2004, NATURE, V431, P284, DOI 10.1038/NATURE02905##SCHATZ G. C., 1993, QUANTUM MECH CHEM##SUZUURA H, 2002, PHYS REV B, V65, DOI 10.1103/PHYSREVB.65.235412##TANS SJ, 1997, ANTURE, V386, P474##TARUCHA S, 1996, PHYS REV LETT, V77, P3613, DOI 10.1103/PHYSREVLETT.77.3613##VAN DER WIEL WG, 2003, REV MOD PHYS, V75, P1, DOI 10.1103/REVMODPHYS.75.1##WIGNER E, 1934, PHYS REV, V46, P1002, DOI 10.1103/PHYSREV.46.1002",34,2020-11-20,NA
J,WOS:000242895400005,2006,NEW STRATEGIES FOR THE TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM,"IN RECENT YEARS, NEW OPPORTUNITIES HAVE EMERGED THAT HAVE THE POTENTIAL TO CHANGE RAPIDLY THE THERAPEUTIC SCENARIO OF PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM (VTE). SELECTED PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) CAN BE TREATED EFFECTIVELY AND SAFELY AT HOME WITH FIXED DOSES OF LOW MOLECULAR WEIGHT HEPARINS. THE PROMPT ADMINISTRATION OF COMPRESSION ELASTIC STOCKINGS IN ADDITION TO ANTICOAGULANT DRUGS IN PATIENTS WITH ACUTE DVT HAS THE POTENTIAL TO HALVE THE RATE OF LATE POSTTHROMBOTIC SEQUELAE. THE LONG-TERM USE OF LOW MOLECULAR WEIGHT HEPARINS IS LIKELY TO BE MORE EFFECTIVE THAN ORAL ANTICOAGULANTS FOR THE SECONDARY PREVENTION OF VTE IN PATIENTS WITH ADVANCED MALIGNANCY. PATIENTS WITH PULMONARY EMBOLISM AND RIGHT VENTRICULAR DYSFUNCTION MIGHT BENEFIT FROM THE EARLY ADMINISTRATION OF THROMBOLYTIC DRUGS IN COMBINATION WITH HEPARIN TO A GREATER EXTENT THAN FROM HEPARIN ALONE. DESPITE AN IMPRESSIVE AMOUNT OF CLINICAL INFORMATION ON THE PROPER DURATION OF ORAL ANTICOAGULANTS IN PATIENTS WITH UNPROVOKED VTE, THE OPTIMAL LONG-TERM TREATMENT OF THESE PATIENTS REMAINS UNDEFINED. FINALLY, NEW CATEGORIES OF DRUGS ARE EMERGING THAT HAVE THE POTENTIAL TO REPLACE CONVENTIONAL ANTICOAGULANTS IN THE NEAR FUTURE. THEY INCLUDE COMPOUNDS THAT INHIBIT FACTOR XA OR THROMBIN.",MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; ORAL ANTICOAGULANT-THERAPY; INTRAVENOUS UNFRACTIONATED HEPARIN; INTENSITY WARFARIN THERAPY; ACUTE PULMONARY-EMBOLISM; LONG-TERM; BLEEDING COMPLICATIONS; COMPRESSION STOCKINGS; SECONDARY PREVENTION,VENOUS THROMBOEMBOLISM; DEEP VEIN THROMBOSIS; PULMONARY EMBOLISM; ANTICOAGULATION; THROMBOPHILIA; HEPARIN; WARFARIN; ELASTIC STOCKINGS,SEMINARS IN THROMBOSIS AND HEMOSTASIS,"PRANDONI, P##LENSING, AWA##PESAVENTO, R","UNIV PADUA, DEPT MED & SURG SCI, CHAIR INTERNAL MED 2, I-35128 PADUA, ITALY. UNIV AMSTERDAM, ACAD MED CTR, CTR VASC MED, NL-1105 AZ AMSTERDAM, NETHERLANDS.",HEMATOLOGY; PERIPHERAL VASCULAR DISEASE,HEMATOLOGY; CARDIOVASCULAR SYSTEM & CARDIOLOGY,"AGNELLI G, 2003, ANN INTERN MED, V139, P19, DOI 10.7326/0003-4819-139-1-200307010-00008##AGNELLI G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302##BRANDJES DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7##BULLER HR, 2004, CHEST, V126, P401S, DOI 10.1378/CHEST.126.3_SUPPL.401S##BULLER HR, 2004, ANN INTERN MED, V140, P867, DOI 10.7326/0003-4819-140-11-200406010-00007##BULLER HR, 2004, J THROMB HAEMOST, V2, P47##BULLER HR, 2003, NEW ENGL J MED, V349, P1695##FIESSINGER JN, 2005, JAMA-J AM MED ASSOC, V293, P681, DOI 10.1001/JAMA.293.6.681##GOLDHABER SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5##GRIFONI S, 2000, CIRCULATION, V101, P2817, DOI 10.1161/01.CIR.101.24.2817##HANSSON PO, 2000, ARCH INTERN MED, V160, P769, DOI 10.1001/ARCHINTE.160.6.769##HEIT JA, 2000, ARCH INTERN MED, V160, P761, DOI 10.1001/ARCHINTE.160.6.761##HIRSH J, 2004, CHEST, V126, P188S, DOI 10.1378/CHEST.126.3_SUPPL.188S##HUTTEN BA, 2000, J CLIN ONCOL, V18, P3078, DOI 10.1200/JCO.2000.18.17.3078##KEARON C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMOA035422##KEARON C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201##KONSTANTINIDES S, 2002, NEW ENGL J MED, V347, P1143, DOI 10.1056/NEJMOA021274##KOOPMAN MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102##LEE AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMOA025313##LEVINE M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101##MEYER G, 2002, ARCH INTERN MED, V162, P1729, DOI 10.1001/ARCHINTE.162.15.1729##PALARETI G, 2000, THROMB HAEMOSTASIS, V84, P805##PALARETI G, 2006, NEW ENGL J MED, V355, P1780, DOI 10.1056/NEJMOA054444##PRANDONI P, 2002, BLOOD, V100, P3484, DOI 10.1182/BLOOD-2002-01-0108##PRANDONI P, 2004, ANN INTERN MED, V141, P249, DOI 10.7326/0003-4819-141-4-200408170-00004##PRANDONI P, 2004, ANN INTERN MED, V140, P925, DOI 10.7326/0003-4819-140-11-200406010-00015##PRANDONI P, 1997, HAEMATOLOGICA, V82, P423##PRANDONI P, 2002, ANN INTERN MED, V137, P955, DOI 10.7326/0003-4819-137-12-200212170-00008##PRANDONI P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001##QUINLAN DJ, 2004, ANN INTERN MED, V140, P175, DOI 10.7326/0003-4819-140-3-200402030-00008##RIDKER PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMOA035029##SCHULMAN S, 2003, NEW ENGL J MED, V349, P1713, DOI 10.1056/NEJMOA030104##SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501##SIMONNEAU G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002##TENCATE JW, 1997, NEW ENGL J MED, V337, P657##WELLS PS, 2005, ARCH INTERN MED, V165, P733, DOI 10.1001/ARCHINTE.165.7.733",4,2020-11-20,NA
J,WOS:000242895400009,2006,MANAGEMENT OF THE POSTTHROMBOTIC SYNDROME: THE ROTTERDAM APPROACH,"THE POSTTHROMBOTIC SYNDROME (PTS) AFFECTS THE DEEP VENOUS SYSTEM, AND MAY ALSO EXTEND TO THE SUPERFICIAL VENOUS SYSTEM OF THE LEGS IN PATIENTS WITH A DOCUMENTED HISTORY OF DEEP VEIN THROMBOSIS. CLINICAL SYMPTOMS OF PTS MAY VARY CONSIDERABLY AND RANGE FROM SCARCELY VISIBLE SKIN CHANGES TO CHANGES IN PIGMENTATION, PAIN, DISCOMFORT, VENOUS ECTASIA, EDEMA, AND ULCERATION. OUR VIEW BASED ON STANDARD INVESTIGATIONS AND THE PROPER PLACE OF ADVANCED INVESTIGATIONS REGARDING THE ETIOLOGY AND PATHOPHYSIOLOGY OF PTS HAS LEAD TO THE ROTTERDAM APPROACH, INCORPORATING THE EVIDENCE-BASED DIAGNOSTICS AND TREATMENTS AVAILABLE FOR PTS. HIGH-QUALITY DUPLEX SONOGRAPHY IS MANDATORY IN ALL PATIENTS, PROVIDING ANATOMICAL AND FUNCTIONAL (REFLUX) INFORMATION ON BOTH THE DEEP AND SUPERFICIAL VENOUS SYSTEMS, AND NON- OR PARTIALLY RECANALIZED VEINS (OCCLUSION) CAN ALSO BE DETECTED USING THIS TECHNIQUE. IF THE RESULTS OF DUPLEX SONOGRAPHY ARE NOT CLEAR OR A VENOUS DESOBSTRUCTION PROCEDURE IS TO TAKE PLACE, PHLEBOGRAPHY WILL BE THE INVESTIGATION OF CHOICE. THERE IS A LOT OF EVIDENCE THAT MEDICAL ELASTIC STOCKINGS (MECS) ARE EFFECTIVE IN THE PREVENTION OF PTS WITH DOCUMENTED REFLUX, OBSTRUCTION, OR BOTH. WHEN PRESCRIBING MECS, IT IS IMPORTANT TO EXAMINE BOTH ELASTICITY AND HYSTERESIS OF THE FABRIC OF THE STOCKINGS TO APPLY THE CORRECT DYNAMIC PRESSURE FOR EACH INDIVIDUAL PATIENT. PATIENTS WITH DOCUMENTED PTS SHOULD RECEIVE LIFE-LONG FOLLOW-UP.",CHRONIC VENOUS INSUFFICIENCY; COMPRESSION STOCKINGS; PERICAPILLARY FIBRIN; CLINICAL-COURSE; FOLLOW-UP; THERAPY; THROMBOSIS; LEG,POSTTHROMBOTIC SYNDROME; DEEP VEIN THROMBOSIS; DUPLEX SONOGRAPHY; PHLEBOGRAPHY; ELASTIC STOCKINGS; ROTTERDAM MODEL,SEMINARS IN THROMBOSIS AND HEMOSTASIS,"WENTEL, TD##NEUMANN, HAM","UNIV MED CTR, DEPT DERMATOL & VENEREOL, ERASMUS MED CTR, NL-3000 CA ROTTERDAM, NETHERLANDS.",HEMATOLOGY; PERIPHERAL VASCULAR DISEASE,HEMATOLOGY; CARDIOVASCULAR SYSTEM & CARDIOLOGY,"BLAAUW GHM, 1993, PHLEBOLOGIE, V6, P2531##BOLLINGER A, 1982, INT J MICROCIRC, V1, P5##BRANDJES DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7##BURNAND KG, 1982, BMJ-BRIT MED J, V285, P1071, DOI 10.1136/BMJ.285.6348.1071##CHARPY J, 1956, TROUBLES TROPHIQUES##DEVLEESCHAUWER P, 1984, ACTA CHIR BELG, V84, P31##*DUTCH SOC DERM VE, 2005, RICHTL DIAGN BEH ULC##EDWARDS AT, 1992, BRIT J SURG, V79, P1144, DOI 10.1002/BJS.1800791109##EKLOF B, 2004, J VASC SURG, V40, P1248, DOI 10.1016/J.JVS.2004.09.027##*EUR COMM STAND, 2001, 12718 ENV EUR COMM S##FALANGA V, 1993, LANCET, V341, P1006, DOI 10.1016/0140-6736(93)91085-Z##FISCHER H, 1979, PHLEBOLOGIE, V32, P171##HAENEN JH, 2001, J VASC SURG, V34, P649, DOI 10.1067/MVA.2001.118810##JUNGER M, 1998, VASA-J VASCULAR DIS, V27, P73##KOLBACH DN, 2005, EUR J VASC ENDOVASC, V30, P404, DOI 10.1016/J.EJVS.2005.06.006##NEUMANN H A, 1999, CURR PROBL DERMATOL, V27, P114##NEUMANN HAM, 1996, VASA-J VASCULAR DIS, V25, P127##NEUMANN HAM, 1998, DERMATOL SURG, V24, P765##NEUMANN HAM, 1995, WOUND HEALING SKIN P, P115##NICOLAIDES AN, 2000, CIRCULATION, V102, PE126, DOI 10.1161/01.CIR.102.20.E126##NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/J.1365-2796.1992.TB00565.X##PALMA E C, 1960, J CARDIOVASC SURG (TORINO), V1, P94##PARTSCH H, 1981, HAUTARZT, V32, P53##PORTER JM, 1995, J VASC SURG, V21, P635, DOI 10.1016/S0741-5214(95)70195-8##PRANDONI P, 2004, ANN INTERN MED, V141, P249, DOI 10.7326/0003-4819-141-4-200408170-00004##PRANDONI P, 1997, HAEMATOLOGICA, V82, P423##PRANDONI P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001##RUTHERFORD RB, 2000, J VASC SURG, V31, P1307, DOI 10.1067/MVA.2000.107094##SCHMELLER W, 1996, HAUTARZT, V47, P676, DOI 10.1007/S001050050488##SMITH PDC, 1988, BRIT MED J, V296, P1726, DOI 10.1136/BMJ.296.6638.1726##STOLK R, 2004, DERMATOL SURG, V30, P729, DOI 10.1111/J.1524-4725.2004.30203.X##TAWES RL, 2003, J VASC SURG, V37, P545, DOI 10.1067/MVA.2003.131##VAN DEN OEVER R, 1998, INT ANGIOL, V17, P161##VERAART JCM, 1995, SCRIPTA PHLEBOLOGICA, V3, P25##WIDMER LK, 1967, SCHWEIZ MED WSCHR, V97, P107",7,2020-11-20,NA
J,WOS:000244741400006,2006,SIMULATION IN UNIVERSITY EDUCATION: THE ARTIFICIAL AGENT PSI AS A TEACHING TOOL,"ONE WEAKNESS OF UNDERGRADUATE PSYCHOLOGY EDUCATION IN GERMANY IS THAT STUDENTS DO NOT HAVE MANY OPPORTUNITIES TO PRACTICE THEIR THEORETICAL KNOWLEDGE. TO FILL THIS GAP, A NEW TEACHING APPROACH HAS BEEN INTRODUCED TO THE CURRICULUM AT THE UNIVERSITY OF BAMBERG, GERMANY. THE STUDENTS CONDUCT EXPERIMENTS WITH AN ARTIFICIAL AGENT, A COMPUTER SIMULATION ORIGINATING FROM A COGNITIVE MODELING APPROACH. THE AGENT, CALLED ""PSI"" (SEE HTTP://WEB.UNI-BAMBERG.DE/PPP/INSTTHEOPSY/SOFTWARE FOR VARIOUS VERSIONS), IS THE IMPLEMENTATION OF THE PSI THEORY (SEE DORNER, D., 1999, BAUPLAN FUR EINE SEELE, ROWOHLT, REINBEK). THE PSI THEORY INTEGRATES APPROACHES TO COGNITION, EMOTIONS, MOTIVATION, HUMAN ACTION REGULATION, AND PERCEPTION. ONE MAJOR BENEFIT OF THE WORK WITH THE SIMULATION (BESIDES THE STUDENTS GAINING PRACTICAL EXPERIENCE) IS THAT IT IS POSSIBLE TO CONVEY KNOWLEDGE ABOUT PSYCHOLOGICAL PROCESSES AND THAT INTERACTION OF DIFFERENT PROCESSES DIFFICULT TO ISOLATE IN NATURAL AGENTS BECOME CLEARLY VISIBLE TO STUDENTS. IN THE EVALUATION OF THE COURSE, STUDENTS RATED THE COURSE AS A VALUABLE ADDENDUM TO THE TRADITIONAL EDUCATION IN PSYCHOLOGY.",NA,AGENTS; EDUCATION; COGNITIVE MODELING; TRAINING,SIMULATION-TRANSACTIONS OF THE SOCIETY FOR MODELING AND SIMULATION INTERNATIONAL,"KUNZEL, J##HAMMER, V","UNILEVER FOOD & HLTH RES INST, NL-3133 AT VLAARDINGEN, NETHERLANDS. UNIV WURZBURG, D-97074 WURZBURG, GERMANY.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; COMPUTER SCIENCE, SOFTWARE ENGINEERING",COMPUTER SCIENCE,"ANDERSON JR, 2004, PSYCHOL REV, V111, P1036, DOI 10.1037/0033-295X.111.4.1036##ANDERSON JR, 2001, CARN S COGN, P227##BACH J., 2003, P ICCM 5 INT C COGN, P15##BRUNER J., 1990, ACTS MEANING##CORBETT AT, 1993, ARTIFICIAL INTELLIGE##DORNER D, 1997, P INT S SYSTEM LIFE, P17##DORNER D, 1990, EMOTIONSPSYCHOLOGIE, P293##DORNER D, 1999, BAUPLAN SEELE##DORNER D, 2003, P 5 INT C COGN MOD B, P75##DORNER D, 2002, MECH SEELENWAGENS NE##HAMMER V, 2004, CAMPUS 2004 KOMMEN D, P202##KUNZEL J, 2004, LOGIC OF ARTIFICIAL LIFE: ABSTRACTING AND SYNTHESIZING THE PRINCIPLES OF LIVING SYSTEMS, P83##NEWELL A., 1990, UNIFIED THEORIES COG##OMODEI MM, 1995, BEHAV RES METH INSTR, V27, P303, DOI 10.3758/BF03200423##RITTER FE, 2000, HUMAN COMPUTER INTER, P125##STROHSCHNEIDER S., 2004, SIMULATION & GAMING, V35, P394, DOI 10.1177/1046878104266225",1,2020-11-20,NA
J,WOS:000244741400007,2006,MODELING AND SIMULATION IN INQUIRY LEARNING: CHECKING SOLUTIONS AND GIVING INTELLIGENT ADVICE,"INQUIRY LEARNING IS A DIDACTIC APPROACH IN WHICH STUDENTS ACQUIRE KNOWLEDGE AND SKILLS THROUGH PROCESSES OF THEORY BUILDING AND EXPERIMENTATION. COMPUTER MODELING AND SIMULATION CAN PLAY A PROMINENT ROLE WITHIN THIS APPROACH. STUDENTS CONSTRUCT REPRESENTATIONS OF PHYSICAL SYSTEMS USING MODELING. USING SIMULATION, THEY EXECUTE THESE REPRESENTATIONS TO STUDY THE PHENOMENA OR SYSTEMS MODELED. HOWEVER, THE MODELING TASK IS COMPLEX, AND STUDENTS CAN FAIL TO CREATE ADEQUATE MODELS, WHICH PREVENTS EFFECTIVE LEARNING. THIS NECESSITATES SUPPORTIVE MEASURES TO SCAFFOLD THE MODELING PROCESSES. IN THIS PAPER, WE ADDRESS THE ISSUE OF DESIGNING SUCH SUPPORT THROUGH THE DEVELOPMENT OF INTELLIGENT ADVICE TO BE INCORPORATED IN MODELING ENVIRONMENTS. THE ADVICE IS BASED ON THE DEFINITION OF A FAMILY OF REFERENCE SOLUTIONS FOR EACH MODELING PROBLEM, ON THE COMPARISON OF THE REFERENCE SOLUTIONS WITH THE STUDENTS' SOLUTIONS, AND ON THE USE OF AN ADVICE KNOWLEDGE BASE. THIS ADVICE GUIDES THE STUDENTS TO THE CONSTRUCTION OF A BETTER SOLUTION, HELPING THEM ACQUIRE THE KNOWLEDGE REQUIRED FOR SUCCESSFUL MODELING AND FOR THE CORRECTION OF MODELING MISTAKES. IN A COLLABORATIVE SESSION, HAVING THE ADVICE ENCOURAGES DISCUSSION BETWEEN STUDENTS ABOUT THE ADVICE AND THE BEST WAY OF PROCEEDING. EMPIRICAL VALIDATIONS OF THE ADVICE APPROACH ARE PRESENTED.",COMPUTER-SIMULATIONS; ENVIRONMENTS; DESIGN,INQUIRY LEARNING; INTELLIGENT SOLUTION ANALYSIS; SYSTEM DYNAMICS MODELING,SIMULATION-TRANSACTIONS OF THE SOCIETY FOR MODELING AND SIMULATION INTERNATIONAL,"BRAVO, C##VAN JOOLINGEN, WR##DE JONG, T","UNIV CASTILLA LA MANCHA, DEPT INFORMAT SYST & TECHNOL, COMP ENGN SCH, CIUDAD REAL 13071, SPAIN. UNIV TWENTE, DEPT INSTRUCT TECHNOL, FAC BEHAV SCI, NL-7500 AE ENSCHEDE, NETHERLANDS.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; COMPUTER SCIENCE, SOFTWARE ENGINEERING",COMPUTER SCIENCE,"ANDERSON JR, 1995, J LEARN SCI, V4, P167, DOI 10.1207/S15327809JLS0402_2##BLOSTEIN D., 1996, GRAPH GRAMMARS AND THEIR APPLICATION TO COMPUTER SCIENCE. 5TH INTERNATIONAL WORKSHOP. SELECTED PAPERS, P38##BRAVO C, 2006, COMPUT EDUC, V46, P152, DOI 10.1016/J.COMPEDU.2004.07.009##BRAVO C, 2006, UNPUB INT J SCI ED##BRAVO C, 2006, J NETW COMPUT APPL, V29, P321, DOI 10.1016/J.JNCA.2005.01.003##CONSTANTINOGONZ.MA, 2001, ARTIF INTELL, P176##DE JONG T, 2006, SCIENCE, V312, P532, DOI 10.1126/SCIENCE.1127750##DE JONG T, 1998, REV EDUC RES, V68, P179, DOI 10.3102/00346543068002179##DE JONG T., 2006, HANDLING COMPLEXITY, P107##DE LARA J, 2002, LECT NOTES COMPUT SC, V2306, P174##FORRESTER JW, 1961, IND DYNAMICS##FORRESTER JW, 1975, COLLECTED PAPERS JW##HANSEN E., 1990, EDUCATIONAL TECHNOLOGY, V30, P13##KOEDINGER KR, 2004, LECT NOTES COMPUT SC, V3220, P162##LIEBERMAN H, 2001, YOUR WISH IS MY COMM##LOHNER S, 2003, INSTR SCI, V31, P395, DOI 10.1023/A:1025746813683##MARK M. A., 1993, JOURNAL OF ARTIFICIAL INTELLIGENCE IN EDUCATION, V4, P129##MATSUDA N., 2003, P ICCE2003, P1163##MITROVIC A, 2003, LECT NOTES ARTIF INT, V2702, P313##MITROVIC A, 2001, LNCS LNAI, V2070, P931##OHLSSON S, 1994, NATO ASI SER, V125, P167##PAOLUCCI M, 1996, LECT NOTES COMPUTER, V1086, P372##ROTHENHOFER D, 1993, P ICCE93 TAIW, P300##SURAWEERA P., 2004, INT J ARTIFICIAL INT, V14, P375##SURAWEERA P, 2002, LECT NOTES COMPUTER, V2363, P671##SUTHERS D, 1993, P 13 INT JOINT C ART, P1208##TOTH JA, 1997, P ART INT ED, P302##VAN JOOLINGEN WR, 2005, COMPUT HUM BEHAV, V21, P671, DOI 10.1016/J.CHB.2004.10.039",16,2020-11-20,NA
J,WOS:000242181700017,2006,ALTERED SKIN-TEMPERATURE REGULATION IN NARCOLEPSY RELATES TO SLEEP PROPENSITY,"STUDY OBJECTIVES: IN HEALTHY SUBJECTS, SLEEP PROPENSITY INCREASES WHEN THE DISTAL SKIN TEMPERATURE INCREASES RELATIVE TO THE PROXIMAL SKIN TEMPERATURE. THIS INCREASE RESULTS FROM INCREASED BLOOD FLOW IN THE SKIN OF THE EXTREMITIES AND IS, AMONG OTHER FACTORS, CONTROLLED BY THE HYPOTHALAMIC CIRCADIAN CLOCK, AS IS SLEEP. BECAUSE NARCOLEPSY IS CHARACTERIZED BY HYPOTHALAMIC ALTERATIONS, WE STUDIED SKIN TEMPERATURE IN NARCOLEPTIC PATIENTS IN RELATION TO THEIR CHARACTERISTICALLY INCREASED SLEEP PROPENSITY DURING THE DAY. DESIGN: DISTAL AND PROXIMAL SKIN TEMPERATURE AND THEIR GRADIENT (DPG) WERE MEASURED DURING A MULTIPLE SLEEP LATENCY TEST. THIS ALLOWED TEMPERATURE TO BE STUDIED DURING WAKEFULNESS, AT SLEEP ONSET AND DURING SLEEP. SETTING: TERTIARY NARCOLEPSY REFERRAL CENTER IN A UNIVERSITY HOSPITAL. PATIENTS: FIFTEEN UNMEDICATED NARCOLEPSY PATIENTS WITH CATAPLEXY AND 15 CONTROLS. INTERVENTIONS: NONE. MEASUREMENTS AND RESULTS: IN SUBJECTS IN THE WAKING STATE, DPG WAS HIGHER IN NARCOLEPTICS THAN IN CONTROLS THROUGHOUT THE DAY (TIME BY GROUP INTERACTION, P < .0001), DUE TO INCREASED DISTAL SKIN TEMPERATURE AND DECREASED PROXIMAL SKIN TEMPERATURE. THE INCREASE IN DPG WAS RELATED TO A SHORTER SUBSEQUENT SLEEP-ONSET LATENCY (P = .02). ONCE ASLEEP, NARCOLEPTICS MAINTAINED THEIR ELEVATED DISTAL SKIN TEMPERATURE AND DPG (P < .0001), WHEREAS PROXIMAL SKIN TEMPERATURE INCREASED TO REACH NORMAL LEVELS. CONCLUSIONS: THIS IS THE FIRST DEMONSTRATION OF A DRAMATIC ALTERATION OF DAYTIME SKIN TEMPERATURE CONTROL IN NARCOLEPSY. EVEN AWAKE NARCOLEPTIC PATIENTS SHOWED A DPG HIGHER THAN THAT WHICH HEALTHY CONTROLS ACHIEVE WHEN ASLEEP. THIS OBSERVATION SUGGESTS THAT HYPOCRETIN DEFICIENCY IN NARCOLEPSY AFFECTS SKIN-TEMPERATURE REGULATION AND INVITES FURTHER EXAMINATION. SKIN-TEMPERATURE CONTROL MIGHT ULTIMATELY EVEN HAVE THERAPEUTIC IMPLICATIONS FOR THE ALLEVIATION OF NARCOLEPTIC SYMPTOMS.",HYPOTHALAMIC NEURONS; DAYTIME SLEEPINESS; CIRCADIAN-RHYTHMS; ANESTHETIZED RATS; BODY-TEMPERATURE; LATENCY TEST; BLOOD-FLOW; ONSET; OREXIN; DEPRIVATION,MULTIPLE SLEEP LATENCY TEST; NARCOLEPSY; THERMOREGULATION; SKIN TEMPERATURE; SLEEP,SLEEP,"FRONCZEK, R##OVEREEM, S##LAMMERS, GJ##VAN DIJK, JG##VAN SOMEREN, EJW","NETHERLANDS INST NEUROSCI, NL-1105 BA AMSTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT NEUROL & CLIN NEUROPHYSIOL, LEIDEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, DEPT NEUROL, NIJMEGEN, NETHERLANDS. VU UNIV, MED CTR, DEPT NEUROL, AMSTERDAM, NETHERLANDS. VU UNIV, MED CTR, DEPT CLIN NEUROPHYSIOL, AMSTERDAM, NETHERLANDS. VU UNIV, MED CTR, DEPT MED PSYCHOL, AMSTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY; NEUROSCIENCES,NEUROSCIENCES & NEUROLOGY,"BALASKO MARTA, 1999, ACTA PHYSIOLOGICA HUNGARICA, V86, P219##BROUGHTON R, 1986, SLEEP, V9, P205, DOI 10.1093/SLEEP/9.1.205##CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/SLEEP/9.4.519##CERRI M, 2005, NEUROSCIENCE, V135, P627, DOI 10.1016/J.NEUROSCIENCE.2005.06.039##CHEN CT, 2000, AM J PHYSIOL-REG I, V278, PR692##DANTZ B, 1994, ELECTROEN CLIN NEURO, V90, P24, DOI 10.1016/0013-4694(94)90110-4##ESPA F, 2001, REV NEUROL-FRANCE, V157, PS87##JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/SLEEP/14.6.540##JOHNSON JM, 1986, J APPL PHYSIOL, V61, P1613##KAYABA Y, 2003, AM J PHYSIOL-REG I, V285, PR581, DOI 10.1152/AJPREGU.00671.2002##KRAUCHI K, 2000, AM J PHYSIOL-REG I, V278, PR741, DOI 10.1152/AJPREGU.2000.278.3.R741##KRAUCHI K, 2006, AM J PHYSIOL-REG I, V290, PR1052, DOI 10.1152/AJPREGU.00381.2005##KRAUCHI K, 1999, NATURE, V401, P36, DOI 10.1038/43366##LANDIS CA, 1998, SLEEP, V21, P101, DOI 10.1093/SLEEP/21.1.101##LITTNER MR, 2005, SLEEP, V28, P113, DOI 10.1093/SLEEP/28.1.113##MAGNUSSEN G, 1939, ACTA PSYCHIAT NEUROL, P39##MAYER G, 1997, PHARMACOL BIOCHEM BE, V58, P395, DOI 10.1016/S0091-3057(97)00241-4##MOSKO SS, 1983, SLEEP, V6, P137, DOI 10.1093/SLEEP/6.2.137##OVEREEM S, 2001, J CLIN NEUROPHYSIOL, V18, P78, DOI 10.1097/00004691-200103000-00002##PEYRON C, 1998, J NEUROSCI, V18, P9996##PEYRON C, 2000, NAT MED, V6, P991, DOI 10.1038/79690##POLLAK CP, 1994, PHARMACOL BIOCHEM BE, V47, P65, DOI 10.1016/0091-3057(94)90112-0##RAYMANN RJEM, 2005, AM J PHYSIOL-REG I, V288, PR1589, DOI 10.1152/AJPREGU.00492.2004##RECHTSCHAFFEN A, 1968, MANUAL STANDARDIZED##ROGERS AE, 1994, SLEEP, V17, P590, DOI 10.1093/SLEEP/17.7.590##RUBINSTEIN EH, 1990, ANESTHESIOLOGY, V73, P541, DOI 10.1097/00000542-199009000-00027##SAPER CB, 2005, NATURE, V437, P1257, DOI 10.1038/NATURE04284##SAPER CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6##SMITH JE, 1998, BRAIN RES, V786, P153, DOI 10.1016/S0006-8993(97)01437-6##TWISK JWR., 2003, APPL LONGITUDINAL DA##LICHTENBELT WDV, 2006, PHYSIOL BEHAV, V88, P489, DOI 10.1016/J.PHYSBEH.2006.04.026##VAN SOMEREN EJW, 2002, AGEING RES REV, V1, P721, DOI 10.1016/S1568-1637(02)00030-2##VAN SOMEREN EJW, 2000, CHRONOBIOL INT, V17, P313, DOI 10.1081/CBI-100101050##VANSOMEREN EJW, 2006, IN PRESS PROG BRAIN##WANG J, 2001, NEUROSCI LETT, V315, P49, DOI 10.1016/S0304-3940(01)02322-9##YOSHIDA K, 2005, NEUROSCIENCE, V133, P1039, DOI 10.1016/J.NEUROSCIENCE.2005.03.044##YOSS RE, 1957, STAFF M MAYO CLIN, P320##ZHANG YH, 1997, J PHYSIOL-LONDON, V503, P177, DOI 10.1111/J.1469-7793.1997.177BI.X##2005, INT CLASSIFICATION S",52,2020-11-20,NA
J,WOS:000241307600008,2006,DIP-PEN NANOLITHOGRAPHY ON (BIO)REACTIVE MONOLAYER AND BLOCK-COPOLYMER PLATFORMS: DEPOSITION OF LINES OF SINGLE MACROMOLECULES,"THE APPLICATION OF ATOMIC FORCE MICROSCOPY (AFM) TIP-MEDIATED MOLECULAR TRANSFER (DIP-PEN NANOLITHOGRAPHY OR DPN) TO FABRICATE NANO-PATTERNED (BIO)REACTIVE PLATFORMS BASED ON DENDRIMERS ON REACTIVE SELF-ASSEMBLED MONOLAYER (SAM) AND POLYMER THIN FILMS IS DISCUSSED. THE TRANSFER OF HIGH-MOLAR-MASS POLYAMIDOAMINE (PAMAM) DENDRIMERS (GENERATION 5) AND THE RAPID IN SITU COVALENT ATTACHMENT OF THE DEPOSITED ADSORBATES ONTO REACTIVE N-HYDROXYSUCCINIMIDE (NHS) TERMINATED SAMS ON GOLD AND NHS-ACTIVATED POLYSTYRENE-BLOCK-POLY (TERT-BUTYL ACRYLATE) (PS690-B-PTBA(1210)) BLOCK COPOLYMER THIN FILMS WERE INVESTIGATED AS STRATEGIES TO SUPPRESS LINE BROADENING BY SURFACE DIFFUSION IN DPN. BY EXPLOITING CAREFULLY CONTROLLED ENVIRONMENTAL CONDITIONS (SUCH AS TEMPERATURE AND RELATIVE HUMIDITY), SCAN RATES, AND IN PARTICULAR THE COVALENT ATTACHMENT OF THE DENDRIMERS TO THE REACTIVE FILMS, THE OBSERVED LINE BROADENING AND HENCE THE LATERAL DIFFUSION OF DENDRIMERS WAS SUBSTANTIALLY LESS PRONOUNCED COMPARED TO THAT OBSERVED WITH DPN OF THIOLS ON GOLD. BY THIS METHOD, HIGH-DEFINITION PATTERNS OF DENDRIMERS WERE CONVENIENTLY FABRICATED DOWN TO 30-NM LENGTH SCALES. THE PRESENCE OF PRIMARY AMINO GROUPS IN THE DEPOSITED DENDRIMERS ULTIMATELY OFFERS THE POSSIBILITY TO ANCHOR BIOCHEMICALLY RELEVANT MOLECULES, SUCH AS PROTEINS AND POLYPEPTIDES, TO THESE NANOSTRUCTURED PLATFORMS FOR A WIDE RANGE OF POSSIBLE APPLICATIONS IN THE LIFE SCIENCES AND IN PARTICULAR FOR THE INVESTIGATION OF CONTROLLED CELL-SURFACE INTERACTIONS.",SELF-ASSEMBLED MONOLAYERS; TEMPERATURE-DEPENDENCE; INTERFACIAL REACTIONS; MENISCUS FORMATION; POLYMER SURFACES; FORCE MICROSCOPY; NANOMETER-SCALE; PROTEIN; CONFINEMENT; DENDRIMERS,BIOINTERFACES; NANOLITHOGRAPHY; PATTERNING; REACTIVE FILMS; SCANNING PROBE MICROSCOPY,SMALL,"SALAZAR, RB##SHOVSKY, A##SCHONHERR, H##VANCSO, GJ","UNIV TWENTE, MESA INST NANOTECHNOL, NL-7500 AE ENSCHEDE, NETHERLANDS. UNIV TWENTE, FAC SCI & TECHNOL, DEPT MAT SCI & TECHNOL POLYMERS, NL-7500 AE ENSCHEDE, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CHEMISTRY, PHYSICAL; NANOSCIENCE & NANOTECHNOLOGY; MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",CHEMISTRY; SCIENCE & TECHNOLOGY - OTHER TOPICS; MATERIALS SCIENCE; PHYSICS,"ANTONCIK E, 2005, SURF SCI, V599, PL369, DOI 10.1016/J.SUSC.2005.09.037##ARNOLD M, 2004, CHEMPHYSCHEM, V5, P383, DOI 10.1002/CPHC.200301014##AULETTA T, 2004, ANGEW CHEM INT EDIT, V43, P369, DOI 10.1002/ANIE.200352767##AULETTA T, 2004, ANGEW CHEM, V116, P373, DOI DOI 10.1002/ANGE.200352767##BRAY D, 1998, NATURE, V393, P85, DOI 10.1038/30018##CAMARERO JA, 2004, J AM CHEM SOC, V126, P14730, DOI 10.1021/JA0456611##CHEN CS, 2005, MRS BULL, V30, P194, DOI 10.1557/MRS2005.52##CHEN CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/SCIENCE.276.5317.1425##CURTIS A, 1997, BIOMATERIALS, V18, P1573, DOI 10.1016/S0142-9612(97)00144-0##DEGENHART GH, 2004, LANGMUIR, V20, P6216, DOI 10.1021/LA049580U##DORDI B, 2003, LANGMUIR, V19, P5780, DOI 10.1021/LA0343066##EWING GE, 2006, CHEM REV, V106, P1511, DOI 10.1021/CR040369X##FALCONNET D, 2004, ADV FUNCT MATER, V14, P749, DOI 10.1002/ADFM.200305182##FENG CJ, IN PRESS##FENG CL, 2005, LANGMUIR, V21, P2356, DOI 10.1021/LA047490J##FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/SCIENCE.1990438##GARCIA R, 2006, CHEM SOC REV, V35, P29, DOI 10.1039/B501599P##GERMAIN RN, 1997, CURR BIOL, V7, PR640, DOI 10.1016/S0960-9822(06)00323-X##GINGER DS, 2004, ANGEW CHEM INT EDIT, V43, P30, DOI 10.1002/ANIE.200300608##GINGER DS, 2003, ANGEW CHEM, V116, P30##GUO LJ, 2004, J PHYS D APPL PHYS, V37, PR123, DOI 10.1088/0022-3727/37/11/R01##HAMPTON JR, 2005, J PHYS CHEM B, V109, P23118, DOI 10.1021/JP055264S##HONG SH, 1999, SCIENCE, V286, P523, DOI 10.1126/SCIENCE.286.5439.523##HUISMAN BH, 1999, ANGEW CHEM INT EDIT, V38, P2248, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2248::AID-ANIE2248>3.3.CO;2-T##HUISMAN BH, 1999, ANGEW CHEM, V111, P2385##JANG JY, 2001, J CHEM PHYS, V115, P2721, DOI 10.1063/1.1384550##JASCHKE M, 1995, LANGMUIR, V11, P1061, DOI 10.1021/LA00004A004##KHADEMHOSSEINI A, 2006, P NATL ACAD SCI USA, V103, P2480, DOI 10.1073/PNAS.0507681102##KRAMER S, 2003, CHEM REV, V103, P4367, DOI 10.1021/CR020704M##LEE KB, 2002, SCIENCE, V295, P1702, DOI 10.1126/SCIENCE.1067172##LEE KB, 2004, NANO LETT, V4, P1869, DOI 10.1021/NL049002Y##LEE KB, 2003, J AM CHEM SOC, V125, P5588, DOI 10.1021/JA034236P##LI HW, 2002, NANO LETT, V2, P347, DOI [10.1021/NL025503C, 10.1021/N1025503C]##LI J, 2000, LANGMUIR, V16, P5613, DOI 10.1021/LA000035C##LIEBAU M, 2001, ADV FUNCT MATER, V11, P147, DOI 10.1002/1616-3028(200104)11:2<147::AID-ADFM147>3.0.CO;2-W##LIM JH, 2003, ANGEW CHEM INT EDIT, V42, P2309, DOI 10.1002/ANIE.200351256##LIM JH, 2003, ANGEW CHEM, V115, P2411##LOCKHART DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701##LUSSI JW, 2004, PROG SURF SCI, V76, P55, DOI 10.1016/J.PROGSURF.2004.05.013##MCKENDRY R, 2002, NANO LETT, V2, P713, DOI 10.1021/NL020247P##MEYLAN WM, 1996, ENVIRON TOXICOL CHEM, V15, P100, DOI 10.1002/ETC.5620150205##MRKSICH M, 2002, CURR OPIN CHEM BIOL, V6, P794, DOI 10.1016/S1367-5931(02)00362-9##NATH N, 2004, SURF SCI, V570, P98, DOI 10.1016/J.SUSC.2004.06.182##PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/PNAS.91.11.5022##PICKERING JP, 1999, APPL SURF SCI, V148, P147, DOI 10.1016/S0169-4332(99)00220-2##PINER RD, 1999, SCIENCE, V283, P661, DOI 10.1126/SCIENCE.283.5402.661##PIRRUNG M. C., 2002, ANGEW CHEM, V114, P1326##PIRRUNG MC, 2002, ANGEW CHEM INT EDIT, V41, P1277, DOI 10.1002/1521-3773(20020415)41:8<1276::AID-ANIE1276>3.0.CO;2-2##ROZHOK S, 2003, J PHYS CHEM B, V107, P751, DOI 10.1021/JP021550H##ROZHOK S, 2004, J PHYS CHEM B, V108, P7814, DOI 10.1021/JP0401269##SCHONHERR H, 2003, LANGMUIR, V19, P10843, DOI 10.1021/LA034887Z##SCHONHERR H, 2005, MACROMOL SYMP, V230, P149, DOI 10.1002/MASY.200551154##SCHWARTZ PV, 2002, LANGMUIR, V18, P4041, DOI 10.1021/LA011652J##SPATZ JP, 2004, NANOBIOTECHNOLOGY##WEEKS BL, 2005, LANGMUIR, V21, P8096, DOI 10.1021/LA0512087##WEEKS BL, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.255505##WILLMANN R, 2002, CELL MOL LIFE SCI, V59, P1296, DOI 10.1007/S00018-002-8509-4##WONG JY, 2004, SURF SCI, V570, P119, DOI 10.1016/J.SUSC.2004.06.186##YU F, 2004, J AM CHEM SOC, V126, P8902, DOI 10.1021/JA048583Q",31,2020-11-20,NA
J,WOS:000241949800008,2006,A 15-YEAR OPEN STUDY ON A COHORT OF WEST-AFRICAN OUT-PATIENTS WITH A CHRONIC PSYCHOSIS,"BACKGROUND WE WANTED TO FIND OUT IF THE ADDITIONAL COSTS OF DEPOT NEUROLEPTIC IN COMPARISON TO ORAL MEDICATION WAS JUSTIFIED BY A DECREASE IN ADMISSION DAYS. METHODS AN OPEN STUDY ON A COHORT OF CHRONIC PSYCHOTIC OUT-PATIENTS (N = 45) CONSISTING OF A RETROSPECTIVE 10-YEAR PERIOD ON ORAL MEDICATION FOLLOWED BY A PROSPECTIVE 5-YEAR PERIOD OF TREATMENT WITH HALOPERIDOL DECANOATE. AFTER RECORDING SOCIO-DEMOGRAPHIC CHARACTERISTICS AND A DSM-III-R DIAGNOSIS, PATIENTS WERE ASSESSED BEFORE AND AFTER THE ADMINISTRATION OF DEPOT NEUROLEPTIC WITH THE BPRS, THE NOSIE, THE SDRS AND A LIST OF SIDE EFFECTS. A SEMI-STRUCTURED INTERVIEW WAS CONDUCTED WITH THE PATIENTS AND THEIR FAMILIES TO ASK ABOUT THE CHANGE IN SOCIAL RELATIONSHIPS WITH FAMILY MEMBERS AND OTHER PEOPLE AFTER STARTING THE DEPOT TREATMENT. SOCIAL INTERVENTION WAS LIMITED TO INVOLVEMENT OF THE FAMILY IN THE MONTHLY DEPOT MEDICATION OUTPATIENT CLINIC AND TO AN EXPLANATION OF THE RATIONALE OF FOLLOW-UP TREATMENT AND DEINSTITUTIONALISATION OF PSYCHIATRIC CARE IN THE VILLAGE OF ORIGIN. RESULTS THE NUMBER OF ADMISSION DAYS DECREASED FROM AN AVERAGE OF 100 DAYS A YEAR ON ORAL MEDICATION TO 5 DAYS A YEAR ON DEPOT NEUROLEPTIC. PATIENTS REPORT A SHARP DECREASE IN SYMPTOMS PARALLELED BY AN INCREASE IN SOCIAL FUNCTIONING OVER THE FIRST 3 MONTHS. AFTER 6-9 MONTHS THIS PATTERN STABILISED AND WAS MAINTAINED OVER THE PERIOD FROM 1 TO 5 YEARS WHEREAS THE DOSAGE WAS FURTHER DECREASED TO AN AVERAGE OF 1 CC DECANOATE OR 20 HALDOL EQUIVALENTS MONTHLY. CONCLUSIONS THIS STUDY SUGGESTS THAT DEPOT NEUROLEPTIC IN THE CONTEXT OF A PUBLIC MENTAL HEALTH APPROACH IS A HIGHLY EFFECTIVE AND FEASIBLE TREATMENT FOR WEST AFRICAN PATIENTS SUFFERING FROM A CHRONIC FUNCTIONAL PSYCHOSIS.",EXPRESSED EMOTION; SCHIZOPHRENIC-PATIENTS; MAINTENANCE; DYSFUNCTION; WITHDRAWAL; RELAPSE,CHRONIC PSYCHOSIS; SCHIZOPHRENIA; AFRICA; ANTI-PSYCHOTIC MEDICATION; DEPOT MEDICATION; CAM,SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY,"DE JONG, JTVM##KOMPROE, IH","HEALTHNET TPO, PUBL HLTH & RES, NL-1074 VJ AMSTERDAM, NETHERLANDS. MINIST HLTH & PSYCHIAT HOSP, GUINEA BISSAU, SOUTH AFRICA. VRIJE UNIV AMSTERDAM, DEPT MENTAL HLTH & CULTURE, MED CTR, AMSTERDAM, NETHERLANDS. BOSTON UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02118 USA.",PSYCHIATRY,PSYCHIATRY,"ANDERS SL, 2003, PSYCHIATR REHABIL J, V27, P51, DOI 10.2975/27.2003.51.58##[ANONYMOUS], 1997, JAMA-J AM MED ASSOC, V277, P925##BINDER RL, 1987, AM J PSYCHIAT, V144, P1494##CLARE AW, 1978, PSYCHOL MED, V8, P589, DOI 10.1017/S0033291700018808##DAVIDHIZAR R, 1985, PATIENT EDUC COUNS, V7, P137, DOI 10.1016/0738-3991(85)90004-7##DE JONG J. T. V. M., 1987, DESCENT AFRICAN PSYC##DEJONG J, 2002, TRANSCULT PSYCHIATRY, V39, P422, DOI DOI 10.1177/136346150203900402##DEJONG J., 2004, BROKEN SPIRITS TREAT, P159##DEJONG JTV, 2001, COLONIALISM PSYCHIAT##DEJONG JTVM, 1996, PSYCHOL MED, V26, P97, DOI 10.1017/S0033291700033742##EDGERTON RB, 1994, BRIT J PSYCHIAT, V164, P222, DOI 10.1192/BJP.164.2.222##FAN ZH, 1994, BRIT J PSYCHIAT, V165, P45, DOI 10.1192/S0007125000292970##FERNANDO J, 1984, ACTA PSYCHIAT SCAND, V69, P175, DOI 10.1111/J.1600-0447.1984.TB02483.X##FRANK JD, 1993, PERSUASION HEALLING##GILBERT PL, 1995, ARCH GEN PSYCHIAT, V52, P173##GREENBERG RN, 1984, CLIN THER, V6, P592##HONIGFEL.G, 1966, PSYCHOL REP, V19, P180, DOI 10.2466/PR0.1966.19.1.180##HONIGFELD G, 1965, J CLIN PSYCHOL, V21, P65, DOI 10.1002/1097-4679(196501)21:1<65::AID-JCLP2270210122>3.0.CO;2-I##JENKINS JH, 1992, AM J PSYCHIAT, V149, P9##KAVANAGH DJ, 1992, BRIT J PSYCHIAT, V160, P601, DOI 10.1192/BJP.160.5.601##LEFF J, 1987, BRITISH JOURNAL OF PSYCHIATRY, V151, P166, DOI 10.1192/BJP.151.2.166##LIN K, 1993, PSYCHOPHARMACOLOGY P##LIN KM, 1995, TRANSCULT PSYCHIATRY, V32, P3##LINN MW, 1969, J PSYCHIATR RES, V6, P299, DOI 10.1016/0022-3956(69)90023-5##MARTYNSYELLOWE IS, 1992, BRIT J PSYCHIAT, V161, P779, DOI 10.1192/BJP.161.6.779##MURTHY RS, 1998, PSYCHIATR SERV, V49, P967, DOI 10.1176/PS.49.7.967##NUECHTERLEIN KH, 1986, PSYCHOPHARMACOL BULL, V22, P633##OEHL M, 2000, ACTA PSYCHIAT SCAND, V102, P83, DOI 10.1034/J.1600-0447.2000.00016.X##OVERALL JE, 1962, PSYCHOL REP, V10, P799##SRAMEK J, 1991, HOSP COMMUNITY PSYCH, V42, P590##TUNINGER E, 1997, ACTA PSYCHIAT SCAND, V96, P347, DOI 10.1111/J.1600-0447.1997.TB09928.X##VENTURA J, 1992, BRIT J PSYCHIAT, V161, P615, DOI 10.1192/BJP.161.5.615##VOLAVKA J, 1995, ARCH GEN PSYCHIAT, V52, P837##WANG JH, 2001, CLIN PHARMACOL THER, V70, P42, DOI 10.1067/MCP.2001.116513##WIG NN, 1987, BRIT J PSYCHIAT, V151, P156, DOI 10.1192/BJP.151.2.156",3,2020-11-20,NA
J,WOS:000241780900005,2006,ACCESS POINT ANALYSIS ON THE STATE OF HEALTH CARE SERVICES IN SOUTH AFRICAN PRISONS: A QUALITATIVE EXPLORATION OF CORRECTIONAL HEALTH CARE WORKERS' AND INMATES' PERSPECTIVES IN KWAZULU-NATAL AND MPUMALANGA,"THIS PAPER EXPLORES INMATES AND PRISON HEALTH CARE WORKERS PERCEPTIONS OF THE STATE OF HEALTH CARE SERVICES IN FOUR CORRECTIONAL FACILITIES IN SOUTH AFRICA. STRUCTURAL AND ORGANISATIONAL ISSUES ARE EXPLORED IN TERMS OF HOW THEY IMPACT THE DELIVERY AND PROVISION OF HEALTH CARE TO INMATES WITHIN CORRECTIONAL FACILITIES. ADDITIONALLY, THE STUDY FORMS AN ACCESS POINT ANALYSIS OF PRISONS AS A HEALTH CARE SETTING AS PART OF THE DEVELOPMENT AND TESTING OF A STI/HIV HEALTH EDUCATION INTERVENTION FOR SOON TO BE RELEASED INMATES. FOCUS GROUP DISCUSSIONS (6-8 PARTICIPANTS PER GROUP) WERE CONDUCTED WITH MALE INMATES IN FOUR FACILITIES IN KWAZULU-NATAL AND MPUMALANGA PROVINCES. INDIVIDUAL FACE-TO-FACE INTERVIEWS WERE CONDUCTED WITH EIGHT HEALTH PERSONNEL TO GET A VIEW FROM BOTH PROVIDERS AND END USERS OF HEALTH CARE IN CORRECTIONAL SETTINGS. DATA WERE ANALYSED THEMATICALLY. WE FOUND STRONG EVIDENCE OF PRISON BEING A STRATEGIC POINT TO INCREASE ACCESS TO HEALTH SERVICES FOR OFFENDERS. CURATIVE SERVICES WITHIN PRISONS WERE WELL ESTABLISHED AND RUNNING DESPITE THE PRESENCE OF CERTAIN CHALLENGES VARYING ACROSS INSTITUTIONS. PREVENTION PROGRAMMES EMERGED AS AN AREA THAT REQUIRES STRONGER EMPHASIS TO FACILITATE IMPARTING SKILLS AND PROMOTING SAFER PRACTICES FOR INMATES UPON RELEASE. PEER-LED EDUCATION PROGRAMMES EMERGED AS A KEY ASPECT OF PREPARATION FOR RELEASE AND COMMUNITY REINTEGRATION AMONGST INMATES. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",NA,SOUTH AFRICA; PRISONS; HEALTH CARE WORKERS; HIV/AIDS PREVENTION; HEALTH EDUCATION,SOCIAL SCIENCE & MEDICINE,"SIFUNDA, S##REDDY, PS##BRAITHWAITE, R##STEPHENS, T##RUITER, RAC##VAN DEN BORNE, B","MRC, ZA-7505 CAPE TOWN, SOUTH AFRICA. UNIV MAASTRICHT, DEPT EXPT PSYCHOL, MAASTRICHT, NETHERLANDS. UNIV MAASTRICHT, DEPT HLTH EDUC & PROMOT, MAASTRICHT, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; SOCIAL SCIENCES, BIOMEDICAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; BIOMEDICAL SOCIAL SCIENCES","BRAITHWAITE RL, 1996, PRISONS AIDS##CUMMINGS TG, 1997, ORG DEV CHANGE##*DEP CORR SERV, 2002, PRIS CUST##*DEP CORR SERV, 2003, GEAR REH POL DOC##FOREMAN M, 1999, AIDS MEN TAKING RISK##HAMMETT TM, 1998, HEALTH EDUC BEHAV, V25, P99, DOI 10.1177/109019819802500108##JACOB, 2000, INT J DRUG POLICY, V11, P325, DOI 10.1016/S0955-3959(00)00050-5##LONG J., 2004, INTERNATIONAL JOURNAL OF DRUG POLICY, V15, P139, DOI 10.1016/S0955-3959(03)00090-2##MAHON N, 1996, AM J PUBLIC HEALTH, V86, P1211, DOI 10.2105/AJPH.86.9.1211##MINTZBERG H, 1993, STRUCTURE 5S##PATTON MQ, 2002, QUALITATIVE RES EVAL, P339##POLAND B, 2001, SETTINGS HLTH PROMOT##REDDY P, 1998, SOC SCI MED, V47, P1445, DOI 10.1016/S0277-9536(98)00230-5##SIFUNDA S, 2005, IN PRESS HLTH ED RES##SIFUNDA S, 2005, UNPUB PSYCHOSOCIAL D##STOLLER N, 2003, SOC SCI MED, V56, P2263, DOI 10.1016/S0277-9536(02)00226-5##VANHEERDEN J, 1995, S AFR MED J, V85, P345##WATSON R, 2004, INT J NURS STUD, V41, P119, DOI 10.1016/S0020-7489(03)00128-7",15,2020-11-20,"NIDA NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) [1-R01-DA-12331-01A1] FUNDING SOURCE: MEDLINE; NATIONAL INSTITUTE ON DRUG ABUSEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) [R01DA012331, R01DA012331, R01DA012331, R01DA012331, R01DA012331, R01DA012331, R01DA012331, R01DA012331, R01DA012331] FUNDING SOURCE: NIH REPORTER"
J,WOS:000241780900014,2006,DO DUTCH DOCTORS COMMUNICATE DIFFERENTLY WITH IMMIGRANT PATIENTS THAN WITH DUTCH PATIENTS?,"THE AIM OF THIS STUDY WAS TO GAIN DEEPER INSIGHT INTO RELATIONAL ASPECTS OF THE MEDICAL COMMUNICATION PATTERN IN INTERCULTURAL CONSULTATIONS AT GP PRACTICES IN THE NETHERLANDS. WE ASK WHETHER THERE ARE DIFFERENCES IN THE VERBAL INTERACTION OF DUTCH GPS WITH IMMIGRANT AND DUTCH PATIENTS. DATA WERE DRAWN FROM 144 ADULT PATIENT INTERVIEWS AND VIDEO OBSERVATIONS OF CONSULTATIONS BETWEEN THE PATIENTS AND 31 DUTCH GPS. THE PATIENT GROUP CONSISTED OF 61 NON-WESTERN IMMIGRANTS (TURKISH, MOROCCAN, SURINAMESE, ANTILLEAN, CAPE VERDIAN) AND 83 DUTCH PARTICIPANTS. AFFECTIVE AND INSTRUMENTAL ASPECTS OF VERBAL COMMUNICATION WERE ASSESSED USING ROTER'S INTERACTION ANALYSIS SYSTEM (RIAS). PATIENTS' CULTURAL BACKGROUND WAS ASSESSED BY ETHNICITY, LANGUAGE PROFICIENCY, LEVEL OF EDUCATION, RELIGIOSITY AND CULTURAL VIEWS (IN TERMS OF BEING MORE TRADITIONAL OR MORE MODERN). CONSULTATIONS WITH THE NON-WESTERN IMMIGRANT PATIENTS (ESPECIALLY THOSE FROM TURKEY AND MOROCCO) WERE WELL OVER 2 MIN SHORTER, AND THE POWER DISTANCE BETWEEN GPS AND THESE PATIENTS WAS GREATER WHEN COMPARED TO THE DUTCH PATIENTS. MAJOR DIFFERENCES IN VERBAL INTERACTION WERE OBSERVED ON THE AFFECTIVE BEHAVIOR DIMENSIONS, BUT NOT ON THE INSTRUMENTAL DIMENSIONS. DOCTORS INVESTED MORE IN TRYING TO UNDERSTAND THE IMMIGRANT PATIENTS, WHILE IN THE CASE OF DUTCH PATIENTS THEY SHOWED MORE INVOLVEMENT AND EMPATHY. DUTCH PATIENTS SEEMED TO BE MORE ASSERTIVE IN THE MEDICAL CONVERSATION. THE DIFFERENCES ARE DISCUSSED IN TERMS OF PATIENTS' ETHNIC BACKGROUND, CULTURAL VIEWS (E.G. PRACTICING A RELIGION) AND LINGUISTIC BARRIERS. IT IS CONCLUDED THAT ATTENTION TO CULTURAL DIVERSITY DOES MATTER, AS THIS LEADS TO DIFFERENT MEDICAL COMMUNICATION PATTERNS. A TWO-WAY STRATEGY IS RECOMMENDED FOR IMPROVING MEDICAL COMMUNICATION, WITH IMPLICATIONS FOR BOTH DOCTOR AND PATIENT BEHAVIOR. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",HEALTH-CARE; INTERCULTURAL COMMUNICATION; GENERAL-PRACTICE; PHYSICIAN; QUALITY; INTERPRETER; DISPARITIES; RACE; RACE/ETHNICITY; PERCEPTIONS,MEDICAL COMMUNICATION; INTERCULTURAL COMMUNICATION; GENERAL PRACTICE; INTERETHNIC DIFFERENCES; IMMIGRANTS; HEALTH CARE; THE NETHERLANDS,SOCIAL SCIENCE & MEDICINE,"MEEUWESEN, L##HARMSEN, JAM##BERNSEN, RMD##BRUIJNZEELS, MA","UNIV UTRECHT, RES SCH PSYCHOL & HLTH, INTERDISCIPLINARY SOCIAL SCI DEPT, NL-3508 TC UTRECHT, NETHERLANDS. ERASMUS MC ROTTERDAM, DEPT GEN PRACTICE, ROTTERDAM, NETHERLANDS. UNITED ARAB EMIRATES UNIV, DEPT COMMUNITY MED, AL AIN, U ARAB EMIRATES. ERASMUS MC ROTTERDAM, DEPT HLTH POLICY & MANAGEMENT, ROTTERDAM, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; SOCIAL SCIENCES, BIOMEDICAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; BIOMEDICAL SOCIAL SCIENCES","BOT H, 2005, DIALOGUE INTERPRETIN##BRAMAN AC, 2004, PERS INDIV DIFFER, V37, P815, DOI 10.1016/J.PAID.2003.10.009##CASS A, 2002, MED J AUSTRALIA, V176, P466, DOI 10.5694/J.1326-5377.2002.TB04517.X##COOPER LA, 2003, ANN INTERN MED, V139, P907, DOI 10.7326/0003-4819-139-11-200312020-00009##COOPER-PATRICK L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/JAMA.282.6.583##DOESCHER MP, 2000, ARCH FAM MED, V9, P1156, DOI 10.1001/ARCHFAMI.9.10.1156##EDWARDS A, 2003, PATIENT EDUC COUNS, V50, P33, DOI 10.1016/S0738-3991(03)00077-6##FERGUSON WJ, 2002, FAM MED, V34, P353##FLORES G, 2005, MED CARE RES REV, V62, P255, DOI 10.1177/1077558705275416##GASS SM, 1991, MISCOMMUNICATION PRO, P121##GERITS YC, 2001, TIJDSCHRIFT GEZONDHE, V79, P15##GUDYKUNST WB, 1994, BRIDGING DIFFERENCES##HARMSEN H, 2005, BRIT J GEN PRACT, V55, P343##HARMSEN J A M, 2006, J IMMIGR MINOR HEALTH, V8, P115, DOI 10.1007/S10903-006-8520-6##HARMSEN JAM, 2005, PATIENT EDUC COUNS, V59, P171, DOI 10.1016/J.PEC.2004.11.003##HARMSEN JAM, 2003, WHEN CULTURES M MED##HOFSTEDE G., 1991, CULTURE ORG SOFTWARE##HOFSTEDE G, 2001, CULTURES CONSEQUENCE##*ISEO, 1987, BET MET, V1##JACOBS EA, 2003, LANGUAGE BARRIERS HL##JOHNSON RL, 2004, AM J PUBLIC HEALTH, V94, P2084, DOI 10.2105/AJPH.94.12.2084##KIESLER DJ, 2003, SOC SCI MED, V57, P1707, DOI 10.1016/S0277-9536(02)00558-0##KIRMAYER LJ, 2003, CAN J PSYCHIAT, V48, P145##KLEINMAN MA, 1980, PATIENTS HEALERS CON##LEMAN P, 1997, J ACCID EMERG MED, V14, P98##LILLIEBLANTON M, 1996, SOC SCI MED, V43, P83, DOI 10.1016/0277-9536(95)00337-1##LINELL PER, 1991, ASYMMETRIES DIALOGUE, P1##LUIJTEN MCG, 1995, HUISARTSEN ACHTERSTA##MEEUWESEN L, 1991, SOC SCI MED, V32, P1143, DOI 10.1016/0277-9536(91)90091-P##NIERKENS V, 2002, PATIENT EDUC COUNS, V46, P253, DOI 10.1016/S0738-3991(01)00161-6##PHINNEY JS, 1996, AM PSYCHOL, V51, P918, DOI 10.1037/0003-066X.51.9.918##RAMIREZ AG, 2003, PATIENT EDUC COUNS, V50, P51, DOI 10.1016/S0738-3991(03)00080-6##RIVADENEYRA R, 2000, AM J MED, V108, P470, DOI 10.1016/S0002-9343(99)00445-3##ROTER DL, 1993, ROTER METHOD INTERAC##SAHA S, 1999, ARCH INTERN MED, V159, P997, DOI 10.1001/ARCHINTE.159.9.997##SAHA S, 2003, AM J PUBLIC HEALTH, V93, P1713, DOI 10.2105/AJPH.93.10.1713##SCHELLEVIS FG, 2004, TWEEDE NATL STUDIE Z##SCHOUTEN BC, 2006, IN PRESS PATIENT ED##SEELEMAN C, 2005, EEN ARTS VANDEWERELD##SLEATH B, 2003, CLIN THER, V25, P1739, DOI 10.1016/S0149-2918(03)80166-2##TRIANDIS HC, 1995, INDIVIDUALISM COLLEC##VAN RYN M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X##VAN RYN M, 2003, AM J PUBLIC HEALTH, V93, P248, DOI 10.2105/AJPH.93.2.248##VAN WIERINGEN JCM, 2002, EUR J PUBLIC HEALTH, V12, P63, DOI 10.1093/EURPUB/12.1.63##VANDENBRINKMUIN.A, 2004, OOG COMMUNICATIE HUI##VANDERVLUGT MJ, 1992, BEHAV RES METH INSTR, V24, P147, DOI 10.3758/BF03203488##YOUNG M, 1996, HEALTH COMMUN, V8, P29, DOI 10.1207/S15327027HC0801_2",68,2020-11-20,NA
J,WOS:000241780900017,2006,THE PREDICTION OF BEREAVEMENT OUTCOME: DEVELOPMENT OF AN INTEGRATIVE RISK FACTOR FRAMEWORK,"WE PROPOSE AN INTEGRATIVE RISK FACTOR FRAMEWORK TO ENHANCE UNDERSTANDING OF INDIVIDUAL DIFFERENCES IN ADJUSTMENT TO BEREAVEMENT AND TO ENCOURAGE MORE SYSTEMATIC ANALYSIS OF FACTORS CONTRIBUTING TO BEREAVEMENT OUTCOME (E.G., EXAMINATION OF INTERACTIONS BETWEEN VARIABLES AND ESTABLISHING PATHWAYS IN THE ADAPTATION PROCESS). THE EXAMINATION OF INDIVIDUAL DIFFERENCES IN ADAPTATION TO BEREAVEMENT IS ESSENTIAL FOR PRACTICAL (E.G. TARGETING HIGH RISK INDIVIDUALS FOR INTERVENTION) AND THEORETICAL (E.G. TESTING THE VALIDITY OF THEORETICAL CLAIMS ABOUT SOURCES OF DIFFERENCES) PURPOSES. AND YET, EXISTING THEORETICAL APPROACHES HAVE NOT LED TO SYSTEMATIC EMPIRICAL EXAMINATION AND EMPIRICAL STUDIES IN THE CURRENT LITERATURE ARE FRAUGHT WITH SHORTCOMINGS. DERIVED FROM COGNITIVE STRESS THEORY [LAZARUS, R. S. & FOLKMAN, S. (1984). STRESS, APPRAISAL, AND COPING. NEW YORK: SPRINGER] AND THE STRESSOR-SPECIFIC DUAL PROCESS MODEL OF COPING WITH BEREAVEMENT [STROEBE, M. S., & SCHUT, H. A. W. (1999). THE DUAL PROCESS MODEL OF COPING WITH BEREAVEMENT: RATIONALE AND DESCRIPTION. DEATH STUDIES, 23, 197-224], THE FRAMEWORK INCORPORATES AN ANALYSIS OF STRESSORS, INTRAFINTERPERSONAL RISK/PROTECTIVE FACTORS, AND APPRAISAL AND COPING PROCESSES THAT ARE POSTULATED TO IMPACT ON OUTCOME. ADVANTAGES OF USING THE APPROACH ARE OUTLINED. CHALLENGES IN UNDERTAKING SUCH RESEARCH ARE ADDRESSED. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",DEATH; ADJUSTMENT; ADAPTATION; WIDOWHOOD; SUICIDE; SPOUSE; GRIEF; RECOVERY; ANXIETY; PARENTS,GRIEF; COPING; HEALTH; BEREAVEMENT; FACTOR FRAMEWORK,SOCIAL SCIENCE & MEDICINE,"STROEBE, MS##FOLKMAN, S##HANSSON, RO##SCHUT, H","UNIV UTRECHT, DEPT CLIN PSYCHOL, NL-3508 TC UTRECHT, NETHERLANDS. UNIV CALIF SAN FRANCISCO, OSHER CTR INTEGRAT MED, SAN FRANCISCO, CA 94143 USA. UNIV TULSA, DEPT PSYCHOL, TULSA, OK 74104 USA.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; SOCIAL SCIENCES, BIOMEDICAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; BIOMEDICAL SOCIAL SCIENCES","AARTSEN MJ, 2004, PSYCHOL MED, V34, P1##AGERBO E, 2005, J EPIDEMIOL COMMUN H, V59, P407, DOI 10.1136/JECH.2004.024950##ARCHER J., 1999, NATURE GRIEF EVOLUTI##BOELEN PA, 2005, COMPLICATED GRIEF AS##BOERNER K, 2004, PSYCHOL AGING, V19, P668, DOI 10.1037/0882-7974.19.4.668##BONANNO G.A., 2001, HDB BEREAVEMENT RES, P493, DOI [10.1037/10436-021, DOI 10.1037/10436-021]##BONANNO GA, 1999, PSYCHOL BULL, V125, P760, DOI 10.1037/0033-2909.125.6.760##BONANNO GA, 2004, PSYCHOL AGING, V19, P260, DOI 10.1037/0882-7974.19.2.260##BOWLBY J, 1980, ATTACHMENT LOSS, V3##CARR D, 2000, J GERONTOL B-PSYCHOL, V55, PS197, DOI 10.1093/GERONB/55.4.S197##CARR D, 2005, LATE LIFE WIDOWHOOD##CEREL J, 1999, J AM ACAD CHILD PSY, V38, P672, DOI 10.1097/00004583-199906000-00013##CLEIREN MPH, 1993, BEREAVEMENT ADAPTATI##DAVIS CG, 1998, J PERS SOC PSYCHOL, V75, P561, DOI 10.1037/0022-3514.75.2.561##DYREGROV K, 2003, DEATH STUD, V27, P143, DOI 10.1080/07481180302892##EYETSEMITAN F, 1998, DEATH STUD, V22, P469, DOI 10.1080/074811898201461##FARBEROW NL, 1992, J GERONTOL, V47, PP357, DOI 10.1093/GERONJ/47.6.P357##FIELD NP, 2003, J CONSULT CLIN PSYCH, V71, P110, DOI 10.1037/0022-006X.71.1.110##FOLKMAN S., 2001, HDB BEREAVEMENT RES, P563, DOI DOI 10.1037/10436-024##FRISTAD MA, 2001, OMEGA-J DEATH DYING, V42, P321, DOI 10.2190/MC87-GQMC-VCDV-UL3U##HAINE RA, 2003, DEATH STUD, V27, P619, DOI 10.1080/07481180302894##HANSSON RO, 1994, RELATIONSHIPS OLD AG##HANSSON RO, IN PRESS BEREAVEMENT##JORDAN JR, 2003, DEATH STUD, V27, P765, DOI 10.1080/713842360##KLASS D., 1996, CONTINUING BONDS NEW##KREICBERGS U, 2004, PSYCHOL MED, V34, P1431, DOI 10.1017/S0033291704002740##LAST JM, 1995, DICT EPIDEMIOLOGY##LAZARUS R.S., 1984, STRESS APPRAISAL COP##LEE GR, 2001, J GERONTOL B-PSYCHOL, V56, PS56, DOI 10.1093/GERONB/56.1.S56##LI J, 2004, NEUROLOGY, V62, P726, DOI 10.1212/01.WNL.0000113766.21896.B1##LOPATA H. Z., 1996, CURRENT WIDOWHOOD MY##LUCAS RE, 2003, J PERS SOC PSYCHOL, V84, P527, DOI 10.1037/0022-3514.84.3.527##LUECKEN LJ, 2006, DEV PSYCHOPATHOL, V18, P295, DOI 10.1017/S0954579406060160##MARTIKAINEN P, 1998, EPIDEMIOLOGY, V9, P530, DOI 10.1097/00001648-199809000-00010##MEIJ LWD, 2005, J CONSULT CLIN PSYCH, V73, P617, DOI 10.1037/0022-006X.73.4.617##MOSKOWITZ JT, 2003, DEATH STUD, V27, P471, DOI 10.1080/07481180390197624##NADEAU J. W., 2001, HDB BEREAVEMENT RES, DOI DOI 10.1037/10436-014##NEIMEYER RA, 1995, CONSTRUCTIVISM PSYCH##NOLENHOEKSEMA SK, 1999, COPING LOSS##O'CONNOR MF, 2002, J PSYCHOSOM RES, V52, P183, DOI 10.1016/S0022-3999(02)00292-1##ONG AD, 2005, PERS INDIV DIFFER, V38, P1057, DOI 10.1016/J.PAID.2004.07.004##PARGAMENT KENNETH I., 1997, PSYCHOL RELIG COPING##PARKES C. M., 1983, RECOVERY BEREAVEMENT##PARKES C. M., 1972, BEREAVEMENT STUDIES##PARKES C.M., 1996, BEREAVEMENT STUDIES##PARKES CM, 1986, BEREAVEMENT STUDIES##PARKES CM, 2001, HDB BEREAVEMENT RES, P25, DOI DOI 10.1037/10436-001##PENNEBAKER J. W., 2001, HDB BEREAVEMENT RES, P517, DOI DOI 10.1037/10436-022##PRIGERSON HG, 2000, GERONTOLOGIST, V40, P349, DOI 10.1093/GERONT/40.3.349##RAPHAEL B, 2001, HDB BEREAVEMENT RES, P587##RAPHAEL BEVERLEY, 1997, P373##ROSENBLATT P, 2004, ETHNIC VARIATIONS DY, P13##SANDERS CM, 1999, GRIEF MOURNING DEALI##SCHAEFER J. A., 2001, HDB BEREAVEMENT RES, P145##SCHULZ R, 2001, JAMA-J AM MED ASSOC, V285, P3123, DOI 10.1001/JAMA.285.24.3123##SCHUT H., 2001, HDB BEREAVEMENT RES, P705, DOI DOI 10.1037/10436-029##SCHWARZER R., 1989, PSYCHOL HEALTH, V3, P1, DOI DOI 10.1080/08870448908400361##SHAVER PR, 2001, HDB BEREAVEMENT RES, P63, DOI DOI 10.1037/10436-003##STROEBE M, 1999, DEATH STUD, V23, P197, DOI 10.1080/074811899201046##STROEBE M, 2005, REV GEN PSYCHOL, V9, P48, DOI 10.1037/1089-2680.9.1.48##STROEBE M., 2001, REV GEN PSYCHOL, V5, P62, DOI [10.1037//1089-2680.5.1.62, DOI 10.1037/1089-2680.5.1.62]##STROEBE M. S., 2004, INT J PSYCHOL RELIG, V14, P23, DOI [10.1207/S15327582IJPR1401_2, DOI 10.1207/S15327582IJPR1401_2]##STROEBE MARGARET S., 1993, P175, DOI 10.1017/CBO9780511664076.013##STROEBE W, 2005, CLIN PSYCHOL REV, V25, P395, DOI 10.1016/J.CPR.2005.01.004##STROEBE W, 1988, J SOC ISSUES, V44, P143, DOI 10.1111/J.1540-4560.1988.TB02082.X##STROEBE W., 2001, HDB BEREAVEMENT RES, P349, DOI DOI 10.1037/10436-015##STROEBE W, 1987, BEREAVEMENT HLTH PSY##VACHON MLS, 1982, AM J PSYCHIAT, V139, P998##WALTER T., 1999, BEREAVEMENT CULTURE##WIJNGAARDS L, UNPUB PATTERNS ATTAC##WORTMAN CB, 2001, HDB BEREAVEMENT RES, P405, DOI DOI 10.1037/10436-017##ZISOOK S, 1994, PSYCHIAT RES, V52, P1, DOI 10.1016/0165-1781(94)90114-7",139,2020-11-20,NA
J,WOS:000241653600008,2006,"""EVERYONE DIES, SO YOU MIGHT AS WELL HAVE FUN""! ATTITUDES OF DUTCH YOUTHS ABOUT THEIR HEALTH LIFESTYLE","MOST WESTERN SOCIETIES SEEM TO HAVE EMBARKED ON A RUNAWAY WEIGHT-GAIN TRAIN, EQUIPPED WITH TOO MANY ACCELERATORS AND NOT ENOUGH BRAKES. ADOLESCENTS HAVE BEEN IDENTIFIED AS A PUBLIC HEALTH RISK GROUP IN THIS AREA. TO UNCOVER YOUTHS' ATTITUDES ABOUT THEIR HEALTH LIFESTYLE, WITH A FOCUS ON OVERWEIGHTNESS, WE CONDUCTED A DISCOURSE ANALYSIS USING Q-METHODOLOGY. FEMALE, DUTCH YOUTHS BETWEEN 12 AND 15 YEARS RANK-ORDERED STATEMENTS ON ISSUES LIKE EATING BEHAVIOUR, OVERWEIGHTNESS, HEALTH RISKS, HEALTH PERCEPTIONS AND MOTIVATIONS/OBSTACLES FOR ADOPTING A HEALTHIER LIFESTYLE. Q-FACTOR ANALYSIS REVEALED FIVE ATTITUDES: ""CAREFREE SPORTY"", ""WORRYING DEPENDENT"", ""CONTENDED INDEPENDENT"", ""LOOKS OVER CONTENT"" AND ""INDIFFERENT SOLITARY"". THE YOUTHS WERE ALL MORE OR LESS UNINTERESTED IN THEIR OWN HEALTH BUT FOR DIFFERENT REASONS. FOR MOST OF THESE YOUTHS, NEITHER CURRENT NOR FUTURE HEALTH IS OF MAJOR CONCERN, BECAUSE THEY FEEL PHYSICALLY FIT, ARE GENERALLY SATISFIED AND HAPPY, OR SIMPLY DO NOT CARE. SOME ARE CONCERNED ABOUT THEIR EATING BEHAVIOUR DUE TO THE CONSEQUENCES IT HAS ON APPEARANCE, BEING PHYSICALLY UNFIT OR OVERWEIGHT. EVEN SO, THIS PREOCCUPATION WITH EATING APPEARS FAR FROM HEALTHY. ONLY ONE OF THE FIVE HEALTH LIFESTYLE ATTITUDES IDENTIFIED COMBINES HEALTHY EATING AND EXERCISING BEHAVIOUR. MOST YOUTHS APPEAR TO HAVE LITTLE KNOWLEDGE AND MANY QUESTIONS REGARDING HEALTH AND OVERWEIGHTNESS. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",QUALITY-OF-LIFE; CHILDHOOD OBESITY; PHYSICAL-ACTIVITY; SOCIOECONOMIC-STATUS; UNITED-STATES; OVERWEIGHT; CONSUMPTION; CHILDREN; ADOLESCENTS; WEIGHT,ADOLESCENTS; ATTITUDE; HEALTH LIFESTYLE; OBESITY; THE NETHERLANDS,SOCIAL SCIENCE & MEDICINE,"VAN EXEL, NJA##DE GRAAF, G##BROUWER, WBF","ERASMUS MC, IMTA, ROTTERDAM, NETHERLANDS. ERASMUS MC, IBMG, ROTTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, FAC SOCIAL SCI, DEPT PUBL ADM & ORG SCI, AMSTERDAM, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; SOCIAL SCIENCES, BIOMEDICAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; BIOMEDICAL SOCIAL SCIENCES","BERKEY CS, 2003, PEDIATRICS, V111, P836, DOI 10.1542/PEDS.111.4.836##BOYNTON-JARRETT R, 2003, PEDIATRICS, V112, P1321, DOI 10.1542/PEDS.112.6.1321##BROWN S.R., 1980, POLITICAL SUBJECTIVI##BROWN SR, 1996, QUAL HEALTH RES, V6, P561, DOI 10.1177/104973239600600408##BROWNE RB, 1993, J AM CULTURE, V16, P91##COLE TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/BMJ.320.7244.1240##CROSS RM, 2005, HEALTH EDUC RES, V20, P206, DOI 10.1093/HER/CYG121##DANIELS SR, 2005, CIRCULATION, V111, P1999, DOI 10.1161/01.CIR.0000161369.71722.10##DIETZ WH, 2001, BRIT MED J, V322, P313, DOI 10.1136/BMJ.322.7282.313##EISENMANN JC, 2002, OBES RES, V10, P379, DOI 10.1038/OBY.2002.52##FLEGAL KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/JAMA.293.15.1861##FONSECA H, 2005, EUR J PUBLIC HEALTH, V15, P323, DOI 10.1093/EURPUB/CKI071##FRIEDLANDER SL, 2003, ARCH PEDIAT ADOL MED, V157, P1206, DOI 10.1001/ARCHPEDI.157.12.1206##GIAMMATTEI J, 2003, ARCH PEDIAT ADOL MED, V157, P882, DOI 10.1001/ARCHPEDI.157.9.882##GILLILAND FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/AJE/KWG175##GORTMAKER SL, 1996, ARCH PEDIAT ADOL MED, V150, P356, DOI 10.1001/ARCHPEDI.1996.02170290022003##GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406##GRAHAM MA, 2000, PERCEPT MOTOR SKILL, V90, P1187, DOI 10.2466/PMS.90.3.1187-1193##GUNNELL DJ, 1998, AM J CLIN NUTR, V67, P1111##HAJER M. A., 1997, POLITICS ENV DISCOUR##*ILSI, 2000, OV OB EUR CHILDR AD##JAMES J, 2004, BMJ-BRIT MED J, V328, P1237, DOI 10.1136/BMJ.38077.458438.EE##JANSSEN I, 2004, PEDIATRICS, V113, P1187, DOI 10.1542/PEDS.113.5.1187##LUDWIG DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1##MANSON JE, 2003, JAMA-J AM MED ASSOC, V289, P229, DOI 10.1001/JAMA.289.2.229##MARSHALL SJ, 2004, INT J OBESITY, V28, P1238, DOI 10.1038/SJ.IJO.0802706##MATHESON DM, 2004, AM J CLIN NUTR, V79, P1088##MCCARTHY HD, 2003, BRIT MED J, V326, P624, DOI 10.1136/BMJ.326.7390.624##MCMURRAY RG, 2000, OBES RES, V8, P130, DOI 10.1038/OBY.2000.14##MENDELSON BK, 1996, J APPL DEV PSYCHOL, V17, P321, DOI 10.1016/S0193-3973(96)90030-1##*NHS HDA, 2003, MAN OB OV AN DIET PH##RISDON A, 2003, SOC SCI MED, V56, P375, DOI 10.1016/S0277-9536(02)00043-6##ROBINSON TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/JAMA.282.16.1561##ROSSNER S, 1998, ACTA PAEDIATR, V87, P1, DOI 10.1080/08035259850157778##RYAN CJ, 2004, NURS RES, V53, P363, DOI 10.1097/00006199-200411000-00004##SEIDELL JC, 1999, ACTA PAEDIATR, V88, P46, DOI 10.1111/J.1651-2227.1999.TB14350.X##SMITH N., 2001, CURRENT SYSTEMS PSYC##SNETHEN J A, 2001, PEDIATR NURS, V27, P159##SNETHEN JA, 2001, PEDIAT NURSING, V27, P164##SPURGEON DAVID, 2002, BMJ, V324, P1416##STENNER PHD, 2003, SOC SCI MED, V57, P2161, DOI 10.1016/S0277-9536(03)00070-4##STENNER PHD, 2000, SOC SCI MED, V51, P439, DOI 10.1016/S0277-9536(99)00475-X##STEPHENSON W, 1935, CHARACT PERSON, V4, P17##STOREY ML, 2003, INT J FOOD SCI NUTR, V54, P491, DOI 10.1080/09637480310001622350##STRADMEIJER M, 2000, INT J EAT DISORDER, V27, P110, DOI 10.1002/(SICI)1098-108X(200001)27:1<110::AID-EAT14>3.0.CO;2-5##STRAUSS RS, 2003, ARCH PEDIAT ADOL MED, V157, P746, DOI 10.1001/ARCHPEDI.157.8.746##STRAUSS RS, 2001, ARCH PEDIAT ADOL MED, V155, P897, DOI 10.1001/ARCHPEDI.155.8.897##STRAUSS RS, 2000, PEDIATRICS, V105, PART. NO., DOI 10.1542/PEDS.105.1.E15##STURM R, 2001, PUBLIC HEALTH, V115, P229, DOI 10.1016/S0033-3506(01)00449-8##SWINBURN B, 2004, BMJ-BRIT MED J, V329, P736, DOI 10.1136/BMJ.329.7468.736##TROIANO RP, 1998, PEDIATRICS, V101, P497##VAN EXEL NJA, 2005, Q METHODOLOGY SNEAK##VAN TUBERGEN G. N., 1979, OPERANT SUBJECTIVITY, V2##VEREECKEN CA, 2005, EUR J PUBLIC HEALTH, V15, P224, DOI 10.1093/EURPUB/CKI005##WANG YF, 2001, INT J EPIDEMIOL, V30, P1129, DOI 10.1093/IJE/30.5.1129##WHITAKER RC, 2003, ARCH PEDIAT ADOL MED, V157, P725, DOI 10.1001/ARCHPEDI.157.8.725##WHO, 1998, OB PREV MAN GLOB EP##WRIGHT CM, 2001, BRIT MED J, V323, P1280, DOI 10.1136/BMJ.323.7324.1280##YARNELL JWG, 2001, ACTA PAEDIATR, V90, P1435, DOI 10.1080/08035250152708860",52,2020-11-20,NA
J,WOS:000241653600009,2006,"SOMATIC COMPLAINTS AND HEALTH CARE USE IN CHILDREN: MOOD, EMOTION AWARENESS AND SENSE OF COHERENCE","IN THIS STUDY, WE COMPARED SEVERAL ASPECTS OF THE EMOTIONAL FUNCTIONING OF SCHOOLCHILDREN REPORTING VERY FEW SOMATIC COMPLAINTS (N = 59), SCHOOLCHILDREN REPORTING MANY SOMATIC COMPLAINTS (N = 61), AND A CLINICAL GROUP OF CHILDREN WITH FUNCTIONAL ABDOMINAL COMPLAINTS WHO VISITED THE OUTPATIENT CLINICAL OF THE VU UNIVERSITY MEDICAL CENTRE IN AMSTERDAM (N = 33). THE CHILDREN HAD AN AVERAGE AGE OF 10.6 YEARS. WE STUDIED WHETHER GENERAL MOODS (HAPPINESS, ANGER, FEAR, AND SADNESS), SYMPTOMS OF DEPRESSIVENESS, EMOTION AWARENESS, AND SENSE OF COHERENCE CONTRIBUTED TO GROUP CLASSIFICATION. EIGHTY-THREE PERCENT OF THE SCHOOLCHILDREN REPORTING VERY FEW SOMATIC COMPLAINTS WERE IDENTIFIED CORRECTLY ON THE BASIS OF BETTER EMOTIONAL FUNCTIONING. HOWEVER, THERE WAS LITTLE DIFFERENCE IN THE EMOTIONAL FUNCTIONING OF SCHOOLCHILDREN WITH MANY SOMATIC COMPLAINTS AND THAT OF THE CLINICAL GROUP. WE CONCLUDED THAT THE VARIABLES STUDIED ARE VALUABLE FOR DIFFERENTIATING CHILDREN WHO ARE TROUBLED BY SOMATIC COMPLAINTS FROM CHILDREN EXPERIENCING FEW SOMATIC COMPLAINTS. THE RESULTS STRESS THE EXISTENCE OF EMOTIONAL PROBLEMS IN CHILDREN REPORTING MANY SOMATIC COMPLAINTS. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",RECURRENT ABDOMINAL-PAIN; STRESS; ADOLESCENTS; ALEXITHYMIA; PSYCHOPATHOLOGY; PERSONALITY; ADJUSTMENT; DEPRESSION; PREVALENCE; ANXIETY,SOMATIC COMPLAINTS; MOOD; EMOTION AWARENESS; SENSE OF COHERENCE; CHILDREN; THE NETHERLANDS,SOCIAL SCIENCE & MEDICINE,"JELLESMA, FC##RIEFFE, C##MEERUM TERWOGT, M##KNEEPKENS, CMF","LEIDEN UNIV, LEIDEN, NETHERLANDS. VRIJE UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, AMSTERDAM, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; SOCIAL SCIENCES, BIOMEDICAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; BIOMEDICAL SOCIAL SCIENCES","ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z##BHATIA V, 2005, J GASTROEN HEPATOL, V20, P332, DOI 10.1111/J.1440-1746.2004.03508.X##CAMPO JV, 2004, PEDIATRICS, V113, P817, DOI 10.1542/PEDS.113.4.817##CARRASCO GA, 2003, EUR J PHARMACOL, V463, P235, DOI 10.1016/S0014-2999(03)01285-8##CATTO-SMITH AG, 2005, MED J AUSTRALIA, V182, P242, DOI 10.5694/J.1326-5377.2005.TB06677.X##COHEN O, 2003, EUR J PERSONALITY, V17, P309, DOI 10.1002/PER.493##CROFFIE JM, 2000, CLIN PEDIATR, V39, P267, DOI 10.1177/000992280003900502##DAMASIO AR, 1998, BRAIN RES REV, V26, P83, DOI 10.1016/S0165-0173(97)00064-7##DE GUCHT V, 2004, PERS INDIV DIFFER, V36, P1655, DOI 10.1016/J.PAID.2003.06.012##DORN LD, 2003, J AM ACAD CHILD PSY, V42, P66, DOI 10.1097/00004583-200301000-00012##EGGER HL, 1999, J AM ACAD CHILD PSY, V38, P852, DOI 10.1097/00004583-199907000-00015##FIELDS L, 1997, CLIN PSYCHOL REV, V17, P937, DOI 10.1016/S0272-7358(97)00033-0##GEYER S, 1997, SOC SCI MED, V44, P1771, DOI 10.1016/S0277-9536(96)00286-9##GRABE HJ, 2004, AM J PSYCHIAT, V161, P1299, DOI 10.1176/APPI.AJP.161.7.1299##KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995##MEERUM TERWOGT M., 2006, GEDRAG GEZONDHEID, V34, P18##PALLANT JF, 2002, PERS INDIV DIFFER, V33, P39, DOI 10.1016/S0191-8869(01)00134-9##PENNEBAKER JW, 2000, SCI SELF REPORT IMPL, P301##PERQUIN CW, 2000, PAIN, V87, P51, DOI 10.1016/S0304-3959(00)00269-4##PETERSEN S, 2003, SCAND J PUBLIC HEALT, V31, P367, DOI 10.1080/14034940210165064##RAFTER JA, 2002, SIAM REV, V44, P259, DOI 10.1137/S0036144501357233##RAMCHANDANI PG, 2005, PEDIATRICS, V116, P46, DOI 10.1542/PEDS.2004-1854##RIEFFE C, 2006, PERS INDIV DIFFER, V40, P123, DOI 10.1016/J.PAID.2005.05.013##RIEFFE C, UNPUB PSYCHOMETRIC P##RIEFFE C, IN PRESS EMOTION REG##RIEFFE C, 2004, EUR J DEV PSYCHOL, V1, P31, DOI 10.1080/17405620344000013##ROTH-ISIGKEIT A, 2004, ACTA PAEDIATR, V93, P258, DOI 10.1080/08035250310022577##SEGERSTROM SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601##SIFNEOS PE, 1973, PSYCHOTHER PSYCHOSOM, V22, P255, DOI 10.1159/000286529##TIMBREMONT B, 2001, GEDRAGSTHERAPIE, V34, P229##TORSHEIM T, 2001, SOC SCI MED, V53, P603, DOI 10.1016/S0277-9536(00)00370-1##TSIGOS C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4",51,2020-11-20,NA
J,WOS:000240693900002,2006,SOIL AGGREGATION AND BACTERIAL COMMUNITY STRUCTURE AS AFFECTED BY TILLAGE AND COVER CROPPING IN THE BRAZILIAN CERRADOS,"MICROBIAL-BASED INDICATORS OF SOIL QUALITY ARE BELIEVED TO BE MORE DYNAMIC THAN THOSE BASED ON PHYSICAL AND CHEMICAL PROPERTIES. RECENT DEVELOPMENTS IN MOLECULAR BIOLOGY BASED TECHNIQUES HAVE LED TO RAPID AND RELIABLE TOOLS TO CHARACTERIZE MICROBIAL COMMUNITY STRUCTURES. WE DETERMINED THE EFFECTS OF CONVENTIONAL AND NO-TILLAGE IN CROPPING SYSTEMS WITH AND WITHOUT COVER CROPS ON BACTERIAL COMMUNITY STRUCTURE, TOTAL ORGANIC CARBON (TOC) AND SOIL AGGREGATION. TILLAGE AND ROTATION DID NOT AFFECT TOC FROM BULK SOIL. HOWEVER, TOC WAS GREATER IN THE LARGEST AGGREGATE SIZE CLASS (7.98-19 MM), AND HAD GREATER MEAN-WEIGHT DIAMETER UNDER NO-TILLAGE THAN UNDER CONVENTIONAL TILLAGE IN THE 0-5 CM SOIL LAYER. SOIL BACTERIAL COMMUNITY STRUCTURE, BASED ON DENATURING GRADIENT GEL ELECTROPHORESIS OF POLYMERASE CHAIN REACTION AMPLIFIED DNA (PCR/DGGE) USING TWO DIFFERENT GENES AS BIOMARKERS, 16S RRNA AND RPOB GENES, INDICATED DIFFERENT POPULATIONS IN RESPONSE TO CULTIVATION, TILLAGE AND DEPTH, BUT NOT DUE TO COVER CROPPING. SOIL BACTERIAL COMMUNITY STRUCTURE AND MEANWEIGHT DIAMETER OF SOIL AGGREGATES INDICATED ALTERATIONS IN SOIL CONDITIONS DUE TO TILLAGE SYSTEM. (C) 2005 ELSEVIER B.V. ALL RIGHTS RESERVED.",GRADIENT GEL-ELECTROPHORESIS; MICROBIAL DIVERSITY; NO-TILLAGE; MANAGEMENT; GENES; PCR; SUSTAINABILITY; ROTATION; BIOMASS; SYSTEMS,CERRADOS; RPOB; 16S RDNA; DGGE PROFILING; NO-TILLAGE; SOIL STRUCTURE,SOIL & TILLAGE RESEARCH,"PEIXOTO, RS##COUTINHO, HLC##MADARI, B##MACHADO, PLOA##RUMJANEK, NG##VAN ELSAS, JD##SELDIN, L##ROSADO, AS","UNIV FED RIO DE JANEIRO, CCS, INST MICROBIOL PROF PAULO DE GOES, BR-21941590 RIO DE JANEIRO, BRAZIL. EMBRAPA SOLOS, BR-22460000 RIO DE JANEIRO, BRAZIL. EMBRAPA AGROBIOL, SAO PAULO, RJ, BRAZIL. UNIV GRONINGEN, DEPT MICROBIAL ECOL, NL-9750 RA HAREN, NETHERLANDS.",SOIL SCIENCE,AGRICULTURE,"ADAMOLI J, 1987, SOLOS CERRADOS TECNO, P33##ANDRADE DS, 2003, ADV AGROECOL, P51##ANGERS DA, 1993, CAN J SOIL SCI, V73, P39, DOI 10.4141/CJSS93-004##BOON N, 2002, FEMS MICROBIOL ECOL, V39, P101, DOI 10.1111/J.1574-6941.2002.TB00911.X##BURNS MA, 1999, APPL ENVIRON MICROB, V65, P2994##CASTRO FILHO C., 2002, SOIL AND TILLAGE RESEARCH, V65, P45, DOI 10.1016/S0167-1987(01)00275-6##CLEGG CD, 2003, FEMS MICROBIOL ECOL, V43, P263, DOI 10.1111/J.1574-6941.2003.TB01066.X##DAHLLOF I, 2000, APPL ENVIRON MICROB, V66, P3376, DOI 10.1128/AEM.66.8.3376-3380.2000##DORAN JW, 2002, AGR ECOSYST ENVIRON, V88, P119, DOI 10.1016/S0167-8809(01)00246-8##FRANZLUEBBERS AJ, 2002, SOIL TILL RES, V66, P95, DOI 10.1016/S0167-1987(02)00018-1##GUPTA VVSR, 1988, SOIL BIOL BIOCHEM, V20, P777, DOI 10.1016/0038-0717(88)90082-X##HAYNES RJ, 2000, BIOL FERT SOILS, V30, P270, DOI 10.1007/S003740050002##HEUER H., 1997, MODERN SOIL MICROBIOLOGY., P353##IWAMOTO T, 2000, FEMS MICROBIOL ECOL, V32, P129, DOI 10.1111/J.1574-6941.2000.TB00707.X##KARLEN DL, 1994, SOIL TILL RES, V32, P313, DOI 10.1016/0167-1987(94)00427-G##KEMPER W. D., 1986, METHODS OF SOIL ANALYSIS. PART 1. PHYSICAL AND MINERALOGICAL METHODS, P425##KENNEDY AC, 1995, PLANT SOIL, V170, P75, DOI 10.1007/BF02183056##MACHADO PLOD, 2001, NUTR CYCL AGROECOSYS, V61, P119##MADARI B, 2005, SOIL TILL RES, V80, P185, DOI 10.1016/J.STILL.2004.03.006##MOLLET C, 1997, MOL MICROBIOL, V26, P1005, DOI 10.1046/J.1365-2958.1997.6382009.X##MUYZER G, 1998, ANTON LEEUW INT J G, V73, P127, DOI 10.1023/A:1000669317571##MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695, DOI 10.1128/AEM.59.3.695-700.1993##NUBEL U, 1996, J BACTERIOL, V178, P5636##OADES JM, 1991, AUST J SOIL RES, V29, P815, DOI 10.1071/SR9910815##OLDEMAN LR, 1994, SOIL RESILIENCE AND SUSTAINABLE LAND USE, P99##OYEDELE DJ, 1999, SOIL TILL RES, V50, P105, DOI 10.1016/S0167-1987(98)00200-1##PEIXOTO RS, 2002, LETT APPL MICROBIOL, V35, P316, DOI 10.1046/J.1472-765X.2002.01183.X##POWLSON DS, 2001, NUTR CYCL AGROECOSYS, V61, P41, DOI 10.1023/A:1013338028454##ROBERTSON G. PHILIP, 1997, P347##SA JCD, 2001, SOIL SCI SOC AM J, V65, P1486##SALAKO FK, 1999, GEODERMA, V91, P103, DOI 10.1016/S0016-7061(99)00006-3##SALINAS-GARCIA JR, 2002, SOIL TILL RES, V66, P143, DOI 10.1016/S0167-1987(02)00022-3##SAMBROOK J., 1989, MOL CLONING LAB MANU##VAN ELSAS JD, 2002, BIODEGRADATION, V13, P29, DOI 10.1023/A:1016393915414##VAN ELSAS JD, 1998, J MICROBIOL METH, V32, P133, DOI 10.1016/S0167-7012(98)00025-6##VANELSAS JD, 1997, BIOL FERT SOILS, V24, P188, DOI 10.1007/S003740050230##YOUNG IM, 2001, SOIL TILL RES, V61, P33, DOI 10.1016/S0167-1987(01)00188-X",78,2020-11-20,NA
J,WOS:000246825400020,2006,SOME VIEWS ON DETERMINANTS OF INNOVATIVE OUTCOMES OF SOUTH AFRICAN FIRMS: AN EXPLORATORY ANALYSIS USING FIRM-LEVEL DATA,"WE REPORT ON AN ATTEMPT TO IDENTIFY THE MAJOR DETERMINANTS OF INNOVATION IN MANUFACTURING AND NON-MANUFACTURING FIRMS IN SOUTH AFRICA. RESULTS ARE REPORTED USING DATA COLLECTED WITHIN THE FRAMEWORK OF THE SOUTH AFRICAN INNOVATION SURVEY OF 2001. THIS THEORY-BASED EXPLORATORY, EMPIRICAL RESEARCH SHOWS THAT INNOVATIVE OUTCOMES ARE INFLUENCED BY THE EXTENT TO WHICH FIRMS HAVE INTERNAL KNOWLEDGE RESOURCES AND USE INTERNAL AND EXTERNAL KNOWLEDGE AND INFORMATION SOURCES. HOWEVER, RESULTS DIFFER FOR SUB-SAMPLES. INCREMENTAL AND NON-MANUFACTURING INNOVATORS ARE IMITATORS, WHEREAS RADICAL AND MANUFACTURING INNOVATORS PROFIT FROM THEIR INTERNAL SOURCES ONLY. WE ADVOCATE A MORE DECENTRALIZED TECHNOLOGY AND INNOVATION POLICY FOR THE COUNTRY.",PRODUCT INNOVATION; NETWORKS; ENTERPRISES; MATTER,NA,SOUTH AFRICAN JOURNAL OF SCIENCE,"OERLEMANS, LAG##PRETORIUS, MW","TILBURG UNIV, DEPT ORG STUDIES, NL-5000 LE TILBURG, NETHERLANDS. UNIV PRETORIA, DEPT ENGN & TECHNOL MANAGEMENT, ZA-0002 PRETORIA, SOUTH AFRICA.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"ABRATT R, 1993, IND MARKET MANAG, V22, P169, DOI 10.1016/0019-8501(93)90002-O##[ANONYMOUS], 2002, S AFR NAT RES DEV ST##ARUNDEL A, 1998, TECHNOL ANAL STRATEG, V10, P157, DOI 10.1080/09537329808524309##BISHOP P, 1999, APPL ECON, V31, P443, DOI 10.1080/000368499324156##BLANKLEY W, 2005, S AFR J SCI, V101, P151##COHEN WM, 1990, ADMIN SCI QUART, V35, P128, DOI 10.2307/2393553##COMBS JG, 1999, STRATEGIC MANAGE J, V20, P867, DOI 10.1002/(SICI)1097-0266(199909)20:9<867::AID-SMJ55>3.0.CO;2-6##DOSI G, 1988, J ECON LIT, V26, P1120##FREEL MS, 1999, TECHNOVATION, V19, P707, DOI 10.1016/S0166-4972(99)00082-6##GRANT RM, 1996, STRATEGIC MANAGE J, V17, P109, DOI 10.1002/SMJ.4250171110##GUMEDE V, 2004, SMALL BUS ECON, V22, P379##HAGE J., 1997, CONT CAPITALISM EMBE, P94##HARABI N, 1997, TECHNOVATION, V17, P627, DOI 10.1016/S0166-4972(97)00064-3##KALLEBERG AL, 1996, ORG AM ANAL STRUCTUR, P3##KATZ D, 1966, SOCIAL PSYCHOL ORG##LOVE JH, 1999, REV IND ORGAN, V15, P43, DOI 10.1023/A:1007757110963##LUNDVALL BA, 2002, RES POLICY, V31, P213, DOI 10.1016/S0048-7333(01)00137-8##NELSON R.R., 2000, REGIONAL INNOVATION, P11##OERLEMANS LAG, 1998, TIJDSCHR ECON SOC GE, V89, P298, DOI 10.1111/1467-9663.00029##OZCELIK E, 2004, RES POLICY, V33, P409, DOI 10.1016/J.RESPOL.2003.09.011##PARKER H, 2000, IND MANAGE DATA SYST, V100, P255, DOI 10.1108/02635570010301179##POLANYI M., 1958, PERSONAL KNOWLEDGE P##PYKA A., 2002, EUROPEAN J INNOVATIO, V5, P152, DOI DOI 10.1108/14601060210436727##ROGERS M, 2004, SMALL BUS ECON, V22, P141, DOI 10.1023/B:SBEJ.0000014451.99047.69##ROOKS G, 2005, S AFR J SCI, V101, P149##SOONTIENS W., 2002, MANAGE DECIS, V40, P710##STERNBERG R, 2000, EUR PLAN STUD, V8, P389, DOI 10.1080/713666420##WHITLEY R, 2002, IND CORP CHANGE, V11, P497, DOI 10.1093/ICC/11.3.497",12,2020-11-20,NA
J,WOS:000242515100006,2006,"USE OF NITRATE TO MITIGATE RESERVOIR SOURING IN BONGA DEEPWATER DEVELOPMENT, OFFSHORE NIGERIA","THE BONGA FIELD, LOCATED IN DEEP WATER OFF THE NIGERIAN COAST, NEEDS PRESSURE SUPPORT TO EFFECTIVELY RECOVER HYDROCARBONS. THE STRATEGY IS TO INJECT 300,000 BWPD OF SEAWATER FROM THE START OF OIL PRODUCTION. DURING THE FIELD DEVELOPMENT IN 1999, IT WAS CONCLUDED THAT BONGA WAS EXPECTED TO SUFFER FROM RESERVOIR SOURING AND THAT MITIGATION WOULD BE NECESSARY. INITIAL DATA GATHERING INDICATED THAT THE H2S CONTENT RESULTING FROM RESERVOIR SOURING WAS NOT EXPECTED TO EXCEED 50 PARTS PER MILLION(VOLUME-BASED) [PPM(V)] IN THE GAS PHASE. INITIALLY NANO-FILTRATION TO REDUCE THE SULFATE LEVEL IN THE SEAWATER WAS IDENTIFIED TO MITIGATE RESERVOIR SOURING, BUT BECAUSE OF THE HIGH CAPITAL-EXPENDITURE (CAPEX) COSTS, IT WAS DROPPED AND, BECAUSE THERE WERE NO OTHER PROVEN MITIGATION TECHNIQUES AVAILABLE, IT WAS DECIDED TO OPERATE WITHOUT MITIGATION. THE STRATEGY FOR THIS PROJECT WAS TO LET THE RESERVOIR SOUR AND HANDLE THE H2S WITH SOUR-SERVICE MATERIALS AND SCAVENGING FACILITIES TOPSIDE. THE FACILITIES WERE DESIGNED TO HANDLE A MAXIMUM LEVEL OF 50-PPM(V) H2S. AS DETAILED DESIGN PROGRESSED AND MORE FIELD DATA BECAME AVAILABLE. DOUBTS WERE RAISED ON THE SUITABILITY OF THIS APPROACH. THE STRATEGY TO LET THE RESERVOIR SOUR AND HANDLE THE H2S AT SURFACE WAS RE-EVALUATED IN 2003. IT WAS FOUND THAT H2S LEVELS ARE LIKELY TO EXCEED 50 PPM(V). SINCE THEN, A NEW STRATEGY WITH MITIGATION WAS ADOPTED. SEVERAL OPERATORS HAD VERIFIED THAT NITRATE INJECTION IS AN EFFECTIVE MITIGATION TECHNIQUE TO CONTROL H2S DEVELOPMENT. HOWEVER. TO DATE, THE MAIN APPLICATION FOR NITRATE HAD BEEN THE REDUCTION OF H2S IN ALREADY-SOUR FIELDS, AND THE EXPERIENCE FOR THE USE OF NITRATE FROM THE START OF THE WATER-INJECTION SCHEME WAS LIMITED. THIS PAPER PRESENTS A DETAILED EVALUATION OF THE POTENTIAL FOR RESERVOIR SOURING RESULTING FROM BIOGENIC RESERVOIR SOURING IN THE BONGA FIELD AND THE WORK DONE TO PREDICT H2S LEVELS. THE PAPER FOCUSES ON THE SELECTION OF NITRATE AS A MITIGATION METHOD.",NA,NA,SPE PRODUCTION & OPERATIONS,"KUIJVENHOVEN, C##BOSTOCK, A##CHAPPELL, D##NOIROT, JC##KHAN, A","SHELLS RES CTR, RIJSWIJK, NETHERLANDS.","ENGINEERING, PETROLEUM",ENGINEERING,"BARTH T, 1991, APPL GEOCHEM, V6, P1, DOI 10.1016/0883-2927(91)90059-X##*EN I, 2003, SIM NITR RED BACT NR##FLATVAL K.B., 2004, SPE AS PAC OIL GAS C##LANTZ RB, 1971, QUANTITATIVE EVALUAT##LARSEN J, 2004, NACE CORR C NEW ORL##REINSEL A, 1995, THESIS MONTANA STATE##SUNDE E, 2004, NACE CORR C NEW ORL",2,2020-11-20,NA
J,WOS:000241884700001,2006,PHYSICAL CAPACITY IN WHEELCHAIR-DEPENDENT PERSONS WITH A SPINAL CORD INJURY: A CRITICAL REVIEW OF THE LITERATURE,"STUDY DESIGN: REVIEW OF PUBLICATIONS. OBJECTIVE: TO ASSESS THE LEVEL OF PHYSICAL CAPACITY ( PEAK OXYGEN UPTAKE, PEAK POWER OUTPUT, MUSCLE STRENGTH OF THE UPPER EXTREMITY AND RESPIRATORY FUNCTION) IN WHEELCHAIR-DEPENDENT PERSONS WITH A SPINAL CORD INJURY (SCI). SETTING: ERASMUS MC, UNIVERSITY MEDICALCENTRE ROTTERDAM, THE NETHERLANDS. METHODS: PUBMED (MEDLINE) SEARCH OF PUBLICATIONS FROM 1980 ONWARDS. STUDIES WERE SYSTEMATICALLY ASSESSED. WEIGHTED MEANS WERE CALCULATED FOR BASELINE VALUES. RESULTS: IN TETRAPLEGIA, THE WEIGHTED MEAN FOR PEAK OXYGEN UPTAKE WAS 0.89 L/MIN FOR THE WHEELCHAIR EXERCISE TEST ( WCE) AND 0.87 L/MIN FOR ARM-CRANKING OR HAND-CYCLING ( ACE). THE PEAK POWER OUTPUT WAS 26W (WCE) AND 40W (ACE). IN PARAPLEGIA, THE PEAK OXYGEN UPTAKE WAS 2.10 L/MIN ( WCE) AND 1.51 L/MIN ( ACE), WHEREAS THE PEAK POWER OUTPUT WAS 74W ( ACE) AND 85W ( WCE). IN PARAPLEGIA, MUSCLE STRENGTH OF THE UPPER EXTREMITY AND RESPIRATORY FUNCTION WERE COMPARABLE TO THAT IN THE ABLE-BODIED POPULATION. IN TETRAPLEGIA MUSCLE STRENGTH VARIED GREATLY, AND RESPIRATORY FUNCTION WAS REDUCED TO 55 - 59% OF THE PREDICTED VALUES FOR AN AGE-, GENDER- AND HEIGHT-MATCHED ABLE-BODIED POPULATION. CONCLUSIONS: PHYSICAL CAPACITY IS REDUCED AND VARIES IN SCI. THE VARIATION BETWEEN RESULTS IS CAUSED BY POPULATION AND METHODOLOGICAL DIFFERENCES. STANDARDIZED MEASUREMENT OF PHYSICAL CAPACITY IS NEEDED TO FURTHER DEVELOP COMPARATIVE VALUES FOR CLINICAL PRACTICE AND REHABILITATION RESEARCH.",MAXIMUM PHYSIOLOGICAL-RESPONSES; INDEPENDENCE MEASURE FIM; MANUAL MUSCLE TEST; PEAK OXYGEN-UPTAKE; QUALITY-OF-LIFE; ARM CRANKING; PULMONARY-FUNCTION; WORK CAPACITY; ENDURANCE CAPACITY; FUNCTIONAL STATUS,REVIEW; SPINAL CORD INJURY; PHYSICAL ENDURANCE; EXERCISE TOLERANCE; MUSCLE WEAKNESS; RESPIRATORY FUNCTION,SPINAL CORD,"HAISMA, JA##VAN DER WOUDE, LHV##STAM, HJ##BERGEN, MP##SLUIS, TAR##BUSSMANN, JBJ","ERASMUS UNIV, CTR MED, DEPT REHABIL MED, NL-3000 CA ROTTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, FAC HUMAN MOVEMENT SCI, INST FUNDAMENTAL & CLIN HUMAN MOVEMENT SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. RIJNDAM REHABIL CTR, ROTTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY; REHABILITATION,NEUROSCIENCES & NEUROLOGY; REHABILITATION,"ALMENOFF PL, 1995, LUNG, V173, P297##ALMENOFF PL, 1995, PARAPLEGIA, V33, P274, DOI 10.1038/SC.1995.62##BENINATO M, 2004, SPINAL CORD, V42, P533, DOI 10.1038/SJ.SC.3101635##BERGH U, 1976, J APPL PHYSIOL, V41, P191##BERNARD PL, 2000, SPINAL CORD, V38, P16, DOI 10.1038/SJ.SC.3100956##BOUGENOT MP, 2003, SPINAL CORD, V41, P451, DOI 10.1038/SJ.SC.3101475##BRYDEN AM, 2004, ARCH PHYS MED REHAB, V85, P1880, DOI 10.1016/J.APMR.2004.01.042##BURNS AS, 2001, SPINE, V26, PS137, DOI 10.1097/00007632-200112151-00023##BURNS SP, 2005, AM J PHYS MED REHAB, V84, P22, DOI 10.1097/01.PHM.0000150790.99514.C6##COOPER RA, 1992, PARAPLEGIA, V30, P573, DOI 10.1038/SC.1992.117##COUTTS KD, 1995, PARAPLEGIA, V33, P419, DOI 10.1038/SC.1995.93##DALLMEIJER AJ, 2005, J REHABIL RES DEV, V42, P55, DOI 10.1682/JRRD.2004.08.0081##DALLMEIJER AJ, 2004, SPINAL CORD, V42, P91, DOI 10.1038/SJ.SC.3101566##DALLMEIJER AJ, 2001, SPINAL CORD, V39, P577, DOI 10.1038/SJ.SC.3101215##DALLMEIJER AJ, 1997, SCAND J REHABIL MED, V29, P181##DALLMEIJER AJ, 1999, MED SCI SPORT EXER, V31, P1330, DOI 10.1097/00005768-199909000-00015##DALLMEIJER AJ, 1999, MED SCI SPORT EXER, V31, P1111, DOI 10.1097/00005768-199908000-00006##DEVIVO MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6##DITUNNO JF, 1992, ARCH PHYS MED REHAB, V73, P431##ELLENBERG M, 1989, PARAPLEGIA, V27, P261, DOI 10.1038/SC.1989.39##FIGONI S F, 1990, J AM PARAPLEGIA SOC, V13, P63##FUJIWARA T, 1999, SPINAL CORD, V37, P58, DOI 10.1038/SJ.SC.3100715##GARDNER MJ, 1986, BRIT MED J, V292, P810, DOI 10.1136/BMJ.292.6523.810##GASS EM, 1995, PARAPLEGIA, V33, P267, DOI 10.1038/SC.1995.60##GASS GC, 1984, MED SCI SPORT EXER, V16, P355##GASS GC, 1980, SCAND J REHABIL MED, V12, P61##GRINN DR, 2000, CHEST, V118, P1397, DOI 10.1378/CHEST.118.5.1397##HARTUNG GH, 1993, EUR J APPL PHYSIOL O, V66, P362, DOI 10.1007/BF00237783##HERBISON GJ, 1996, SPINAL CORD, V34, P543, DOI 10.1038/SC.1996.98##HJELTNES N, 1990, PARAPLEGIA, V28, P428, DOI 10.1038/SC.1990.57##HJELTNES N, 1998, SPINAL CORD, V36, P691, DOI 10.1038/SJ.SC.3100687##HJELTNES N, 1986, SCAND J REHABIL MED, V18, P65##HOOKER SP, 1993, EUR J APPL PHYSIOL O, V67, P563, DOI 10.1007/BF00241655##HOOKER SP, 1993, MED SCI SPORT EXER, V25, P1115##HOPMAN MT, 2004, ARCH PHYS MED REHAB, V85, P319, DOI 10.1016/J.APMR.2003.02.001##HOPMAN MTE, 1996, EUR J APPL PHYSIOL O, V74, P172, DOI 10.1007/BF00376510##HOPMAN MTE, 1998, INT J SPORTS MED, V19, P98, DOI 10.1055/S-2007-971889##JACOBS PL, 2001, MED SCI SPORT EXER, V33, P711##JANSSEN TWJ, 2002, J REHABIL RES DEV, V39, P29##KELLEY A, 2003, CHEST, V123, P725, DOI 10.1378/CHEST.123.3.725##KERK JK, 1995, MED SCI SPORT EXER, V27, P913##KNECHTLE B, 2003, EUR J APPL PHYSIOL, V90, P614, DOI 10.1007/S00421-003-0920-5##KNECHTLE B, 2001, SPINAL CORD, V39, P633, DOI 10.1038/SJ.SC.3101229##LASKOMCCARTHEY P, 1991, MED SCI SPORT EXER, V23, P1097##LIAW MY, 2000, ARCH PHYS MED REHAB, V81, P752, DOI 10.1053/APMR.2000.5619##LINN WS, 2000, ARCH PHYS MED REHAB, V81, P757, DOI 10.1053/APMR.2000.3868##LINN WS, 2001, SPINAL CORD, V39, P263, DOI 10.1038/SJ.SC.3101155##LOUGHEED MD, 2002, AM J RESP CRIT CARE, V166, P370, DOI 10.1164/RCCM.2109003##MANNS PJ, 1999, ARCH PHYS MED REHAB, V80, P1566, DOI 10.1016/S0003-9993(99)90331-3##MARINO RJ, 1993, PARAPLEGIA, V31, P225, DOI 10.1038/SC.1993.41##MARINO RJ, 1995, PARAPLEGIA, V33, P510, DOI 10.1038/SC.1995.111##MARTEL G, 1991, PARAPLEGIA, V29, P447, DOI 10.1038/SC.1991.61##MAY LA, 1997, ARCH PHYS MED REHAB, V78, P251, DOI 10.1016/S0003-9993(97)90029-0##MOSSBERG K, 1999, SPINAL CORD, V37, P569, DOI 10.1038/SJ.SC.3100875##MURAKI S, 2000, EUR J APPL PHYSIOL O, V81, P28, DOI 10.1007/PL00013793##NOREAU L, 1993, INT J REHABIL RES, V16, P265##NOREAU L, 1992, PARAPLEGIA, V30, P563, DOI 10.1038/SC.1992.116##NOREAU L, 1995, SPORTS MED, V20, P226, DOI 10.2165/00007256-199520040-00003##NOREAU L, 1998, SPINAL CORD, V36, P716, DOI 10.1038/SJ.SC.3100646##OTOOLE ML, 1987, MED SCI SPORT EXER, V19, P45##PHILLIPS BA, 2000, ARCH PHYS MED REHAB, V81, P653, DOI 10.1053/MR.2000.4413##RASCHE W, 1993, EUR J APPL PHYSIOL O, V66, P328, DOI 10.1007/BF00237777##RUTCHIK A, 1998, ARCH PHYS MED REHAB, V79, P293, DOI 10.1016/S0003-9993(98)90009-0##SCHILERO GJ, 2005, CHEST, V127, P149, DOI 10.1378/CHEST.127.1.149##SCHILERO GJ, 2004, J REHABIL RES DEV, V41, P59, DOI 10.1682/JRRD.2004.01.0059##SCHMID A, 1998, J APPL PHYSIOL, V85, P635##SCHMID A, 1998, AM J PHYS MED REHAB, V77, P527, DOI 10.1097/00002060-199811000-00015##SCHWARTZ S, 1992, ARCH PHYS MED REHAB, V73, P1063##SILVA AC, 1998, SPINAL CORD, V36, P240, DOI 10.1038/SJ.SC.3100575##SIMARD C, 1993, CAN J APPL PHYSIOL, V18, P163, DOI 10.1139/H93-013##SPUNGEN AM, 1993, PARAPLEGIA, V31, P404, DOI 10.1038/SC.1993.67##SPUNGEN AM, 1997, SPINAL CORD, V35, P652, DOI 10.1038/SJ.SC.3100489##SPUNGEN AM, 1999, MT SINAI J MED, V66, P201##STEINBERG LL, 2000, BRAZ J MED BIOL RES, V33, P913, DOI 10.1590/S0100-879X2000000800007##STEWART MW, 2000, ARCH PHYS MED REHAB, V81, P394, DOI 10.1053/MR.2000.4417##VAN DER WOUDE LHV, 2002, AM J PHYS MED REHAB, V81, P261, DOI 10.1097/00002060-200204000-00004##VAN TUIJL JH, 2002, SPINAL CORD, V40, P51, DOI 10.1038/SJ.SC.3101261##VEEGER H E J, 1991, MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, V23, P1201##VERHAGEN AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0##VINET A, 1996, SPINAL CORD, V34, P288, DOI 10.1038/SC.1996.52##WALKER J, 1989, PARAPLEGIA, V27, P278, DOI 10.1038/SC.1989.41##WANG TG, 2002, ARCH PHYS MED REHAB, V83, P491, DOI 10.1053/APMR.2002.30937##WICKS JR, 1983, MED SCI SPORT EXER, V15, P224##WINSLOW C, 2003, AM J PHYS MED REHAB, V82, P803, DOI 10.1097/01.PHM.0000078184.08835.01##YAMASAKI M, 1998, SPINAL CORD, V36, P579, DOI 10.1038/SJ.SC.3100610##YEKUTIEL M, 1989, PARAPLEGIA, V27, P58, DOI 10.1038/SC.1989.9",122,2020-11-20,NA
J,WOS:000241884700004,2006,DEMOGRAPHICS OF THE DUTCH MULTICENTER PROSPECTIVE COHORT STUDY 'RESTORATION OF MOBILITY IN SPINAL CORD INJURY REHABILITATION',"STUDY DESIGN: A MULTICENTER PROSPECTIVE COHORT STUDY. OBJECTIVE: TO COMPARE THE DEMOGRAPHIC DATA OF THE INCLUDED POPULATION WITH OTHER STUDIED SPINAL CORD INJURY (SCI) POPULATIONS IN THE INTERNATIONAL LITERATURE. SETTING: EIGHT DUTCH REHABILITATION CENTERS WITH A SPECIALIZED SCI UNIT. METHODS: A TOTAL OF 205 INDIVIDUALS WITH SCI PARTICIPATED IN THIS STUDY. INFORMATION ABOUT PERSONAL, LESION AND REHABILITATION CHARACTERISTICS WERE COLLECTED AT THE BEGINNING OF ACTIVE REHABILITATION BY MEANS OF A QUESTIONNAIRE. RESULTS: THE RESEARCH GROUP MAINLY CONSISTED OF MEN (74%), OF INDIVIDUALS WITH A PARAPLEGIA (59%), AND HAD A COMPLETE LESION (68%). THE SCI WAS MAINLY CAUSED BY A TRAUMA (75%), PRINCIPALLY DUE TO A TRAFFIC ACCIDENT (42%). THE LENGTH OF CLINICAL REHABILITATION VARIED BETWEEN 2 MONTHS AND MORE THAN A YEAR, WHICH SEEMED TO BE DEPENDENT ON THE LESION CHARACTERISTICS AND RELATED COMORBIDITY. CONCLUSIONS: THE PERSONAL AND LESION CHARACTERISTICS OF THE SUBJECTS OF THE MULTI-CENTER STUDY WERE COMPARABLE TO DATA OF OTHER STUDIES, ALTHOUGH FEWER OLDER SUBJECTS AND SUBJECTS WITH AN INCOMPLETE LESION WERE INCLUDED DUE TO THE INCLUSION CRITERIA 'AGE' AND 'WHEELCHAIR-DEPENDENT'. THE LENGTH OF STAY IN REHABILITATION CENTERS IN THE NETHERLANDS WAS LONGER COMPARED TO DENMARK BUT MUCH LONGER THAN IN EG AUSTRALIA AND THE USA.",WHEELCHAIR SKILL PERFORMANCE; LENGTH-OF-STAY; INPATIENT REHABILITATION; EPIDEMIOLOGY; LESIONS; PEOPLE; LIFE; NETHERLANDS; PROPULSION; DISCHARGE,SPINAL CORD INJURY; REHABILITATION; DEMOGRAPHY,SPINAL CORD,"DE GROOT, S##DALLMEIJER, AJ##POST, MWM##VAN ASBECK, FWA##NENE, AV##ANGENOT, ELD##VAN DER WOUDE, LHV","VRIJE UNIV AMSTERDAM, FAC HUMAN MOVEMENT SCI, INST FUNDAMENTAL & CLIN HUMAN MOVEMENT SCI, NL-1081 BT AMSTERDAM, NETHERLANDS. REHABIL CTR AMSTERDAM, AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, CTR MED, DEPT REHABIL MED, AMSTERDAM, NETHERLANDS. IRV, HOENSBROEK, NETHERLANDS. REHABIL CTR DE HOOGSTRAAT, UTRECHT, NETHERLANDS. REHABIL CTR HET ROESSINGH, ENSCHEDE, NETHERLANDS.",CLINICAL NEUROLOGY; REHABILITATION,NEUROSCIENCES & NEUROLOGY; REHABILITATION,"BECK D, 1997, REVALIDATIE DWARSLAE##BECKER BE, 1999, ARCH PHYS MED REHAB, V80, P1514, DOI 10.1016/S0003-9993(99)90266-6##BIERINGSORENSEN F, 1990, PARAPLEGIA, V28, P105, DOI 10.1038/SC.1990.13##CELANI MG, 2001, ARCH PHYS MED REHAB, V82, P589, DOI 10.1053/APMR.2001.21948##DALLMEIJER AJ, 2005, J REHABIL RES DEV, V42, P55, DOI 10.1682/JRRD.2004.08.0081##DALLMEIJER AJ, 1999, MED SCI SPORT EXER, V31, P1330, DOI 10.1097/00005768-199909000-00015##DE GROOT S, 2005, ARCH PHYS MED REHAB, V86, P1452, DOI 10.1016/J.APMR.2004.11.025##DEARWATER SR, 1986, MED SCI SPORT EXER, V18, P541##DEPAZ AC, 1992, PARAPLEGIA, V30, P636##EASTWOOD EA, 1999, ARCH PHYS MED REHAB, V80, P1457, DOI 10.1016/S0003-9993(99)90258-7##HART C, 1994, PARAPLEGIA, V32, P709, DOI 10.1038/SC.1994.115##KILKENS OJ, 2005, ARCH PHYS MED REHAB, V86, P2119, DOI 10.1016/J.APMR.2004.12.040##KILKENS OJ, 2005, ARCH PHYS MED REHAB, V86, P1575, DOI 10.1016/J.APMR.2005.03.020##KILKENS OJ, 2004, ARCH PHYS MED REHAB, V85, P424, DOI 10.1016/J.APMR.2003.05.006##KILKENS OJ, 2002, ARCH PHYS MED REHAB, V83, P1783, DOI 10.1053/APMR.2002.36066##KILKENS OJE, 2005, J REHABIL RES DEV, V42, P65, DOI 10.1682/JRRD.2004.08.0093##KILKENS OJE, 2003, CLIN REHABIL, V17, P418, DOI 10.1191/0269215503CR633OA##LUCKE KT, 2004, QUAL LIFE RES, V13, P97, DOI 10.1023/B:QURE.0000015284.95515.17##MACPHEE AH, 2004, ARCH PHYS MED REHAB, V85, P41, DOI 10.1016/S0003-9993(03)00364-2##MAHARAJ JC, 1996, SPINAL CORD, V34, P549, DOI 10.1038/SC.1996.99##MARINO RJ, 2000, INT STANDARDS NEUROL##MARTINEZ-MORENO M, 1991, PARAPLEGIA, V28, P180##MARTINS F, 1998, SPINAL CORD, V36, P574, DOI 10.1038/SJ.SC.3100657##NOBUNAGA AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2##NOREAU L, 1995, SPORTS MED, V20, P226, DOI 10.2165/00007256-199520040-00003##POST M, 1997, LIVING SPINAL CORD I##POST MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3##RAADSEN HP, 1990, LEVEN MET DWARSLAESI##RONEN J, 2004, SPINAL CORD, V42, P353, DOI 10.1038/SJ.SC.3101590##SCHONHERR MC, 1996, SPINAL CORD, V34, P679, DOI 10.1038/SC.1996.123##SEELEN HAM, 1998, J ELECTROMYOGR KINES, V8, P23, DOI 10.1016/S1050-6411(97)00002-3##SILBERSTEIN B, 1995, PARAPLEGIA, V33, P322, DOI 10.1038/SC.1995.72##SOOPRAMANIEN A, 1994, PARAPLEGIA, V32, P715, DOI 10.1038/SC.1994.116##TOOTH L, 2003, SPINAL CORD, V41, P220, DOI 10.1038/SJ.SC.3101433##VAN ASBECK FWA, 2000, SPINAL CORD, V38, P420, DOI 10.1038/SJ.SC.3101003##VANASBECK FWA, 1987, FUNCTIONEREN MET DW##VANDRONGELEN S, 2006, EPUB SPINAL CORD, V44, P152, DOI DOI 10.1038/SJ.SC3101826##WHITENECK GG, 1993, AGING SPINAL CORD IN",64,2020-11-20,NA
J,WOS:000241857900001,2006,"THE EFFECT OF INFLIXIMAB, A MONOCLONAL ANTIBODY AGAINST TNF-ALPHA, ON DISC HERNIATION RESORPTION - A RANDOMIZED CONTROLLED STUDY","STUDY DESIGN. RANDOMIZED, CONTROLLED STUDY. OBJECTIVE. TO EVALUATE THE EFFECT OF INFLIXIMAB ON HERNIATED NUCLEUS PULPOSUS (HNP) RESORPTION. SUMMARY OF BACKGROUND DATA. ALTHOUGH THE EFFECTS OF TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) ON HNP RESORPTION ARE NOT FULLY UNDERSTOOD, TNF-ALPHA APPEARS TO BE AN ESSENTIAL MEDIATOR IN HNP RESORPTION. METHODS. AS PART OF A SUBSTUDY OF THE FIRST II STUDY, MAGNETIC RESONANCE IMAGES ( MRIS) WERE OBTAINED FROM 21 PATIENTS WHO WERE CANDIDATES FOR DISCECTOMY AT WEEKS 0, 2, 12, AND 26 AFTER RECEIVING A SINGLE INFUSION OF EITHER 5 MG/KG INFLIXIMAB (11 PATIENTS) OR PLACEBO (10 PATIENTS). THE VOLUME (MM(3)) OF HNP, THICKNESS (MM) AND EXTENT (%) OF RIM ENHANCEMENT, AND PRESENCE OF NERVE ROOT EDEMA WERE ASSESSED. RESULTS. HNP VOLUME DECREASED SIGNIFICANTLY FROM BASELINE TO 6 MONTHS IN BOTH TREATMENT GROUPS (P < 0.01), WITH NO DIFFERENCE NOTED BETWEEN THE INFLIXIMAB AND PLACEBO GROUPS. BY WEEK 2, RIM ENHANCEMENT THICKNESS INCREASED SIGNIFICANTLY IN THE INFLIXIMAB GROUP COMPARED WITH THE PLACEBO GROUP (P = 0.003). TWO PATIENTS IN EACH GROUP REQUIRED BACK SURGERY BEFORE THE 6-MONTH ASSESSMENT. CONCLUSIONS. INFLIXIMAB DID NOT APPEAR TO INTERFERE WITH DISC HERNIATION RESORPTION OVER A 6-MONTH PERIOD.",NATURAL-HISTORY; LUMBAR DISC; FOLLOW-UP; SCIATICA; ANGIOGENESIS,INFLIXIMAB; DISC HERNIATION RESORPTION; SCIATICA; MAGNETIC RESONANCE IMAGING; TUMOR NECROSIS FACTOR,SPINE,"AUTIO, RA##KARPPINEN, J##NIINIMAKI, J##OJALA, R##VEEGER, N##KORHONEN, T##HURRI, H##TERVONEN, O","PIETARSAARI HOSP, DEPT RADIOL, PIETARSAARI 68601, FINLAND. OULU UNIV HOSP, DEPT DIAGNOST RADIOL, OULU, FINLAND. FINNISH INST OCCUPAT HLTH, DEPT OCCUPAT MED, HELSINKI, FINLAND. OULU UNIV HOSP, DEPT PHYS MED & REHABIL, OULU, FINLAND. ORTON ORTHOPAED HOSP, HELSINKI, FINLAND. UNIV GRONINGEN, MED CTR, TRIAL COORDINAT CTR, GRONINGEN, NETHERLANDS. OULU DEACONESS INST, OULU, FINLAND.",CLINICAL NEUROLOGY; ORTHOPEDICS,NEUROSCIENCES & NEUROLOGY; ORTHOPEDICS,"AUTIO RA, 2004, SPINE, V29, P1601, DOI 10.1097/01.BRS.0000132511.46818.67##AUTIO RA, 2006, SPINE, V31, P1247, DOI 10.1097/01.BRS.0000217681.83524.4A##AUTIO RA, 2002, SPINE, V27, P1433, DOI 10.1097/00007632-200207010-00012##BUSH K, 1992, SPINE, V17, P1205, DOI 10.1097/00007632-199210000-00013##DOITA M, 2001, SPINE, V26, P1522, DOI 10.1097/00007632-200107150-00004##HARO H, 2002, J ORTHOP RES, V20, P409, DOI 10.1016/S0736-0266(01)00150-4##IGARASHI T, 2000, SPINE, V25, P2975, DOI 10.1097/00007632-200012010-00003##IKEDA T, 1996, J SPINAL DISORD, V9, P136##ITO T, 1996, SPINE, V21, P230, DOI 10.1097/00007632-199601150-00014##KARPPINEN J, 2003, SPINE, V28, P750, DOI 10.1097/00007632-200304150-00004##KATO T, 2004, J ORTHOP RES, V22, P895, DOI 10.1016/J.ORTHRES.2003.11.008##KOMORI H, 1998, SPINE, V23, P67, DOI 10.1097/00007632-199801010-00015##KORHONEN T, 2004, SPINE, V29, P2115, DOI 10.1097/01.BRS.0000141179.58778.6C##KOTHONEN T, 2005, SPINE, V30, P2724##OLMARKER K, 2001, SPINE, V26, P863, DOI 10.1097/00007632-200104150-00007##SAAL JA, 1990, SPINE, V15, P683, DOI 10.1097/00007632-199007000-00013##CURRENT SUMMARY PROD",18,2020-11-20,NA
J,WOS:000241857900005,2006,AN IN VITRO ORGAN CULTURING SYSTEM FOR INTERVERTEBRAL DISC EXPLANTS WITH VERTEBRAL ENDPLATES - A FEASIBILITY STUDY WITH OVINE CAUDAL DISCS,"STUDY DESIGN. WHOLE OVINE CAUDAL INTERVERTEBRAL DISCS WITH VERTEBRAL ENDPLATES WERE CULTURED UNDER UNIAXIAL DIURNAL LOADING FOR 7 DAYS. OBJECTIVES. TO ESTABLISH AND CHARACTERIZE AN ORGAN CULTURE SYSTEM FOR INTERVERTEBRAL DISCS, IN WHICH DISC CELLS MAY BE ""MAINTAINED"" IN THEIR NATIVE THREE-DIMENSIONAL ENVIRONMENT UNDER LOAD. SUMMARY OF BACKGROUND DATA. IN VITRO CULTURING OF ENTIRE DISCS WITH PRESERVED BIOLOGIC AND STRUCTURAL INTEGRITY WOULD BE A USEFUL MODEL TO STUDY THE EFFECTS OF NUTRITION AND MECHANICAL LOADING. METHODS. TO MAINTAIN ENDPLATE PERMEABILITY, SHEEP WERE SYSTEMICALLY ANTICOAGULATED BEFORE DEATH AND THEIR CAUDAL VASCULATURE WAS EVACUATED WITH SALINE POSTMORTEM. THE FIRST 4 CAUDAL DISCS WERE EXPLANTED WITH THEIR ADJACENT ENDPLATES AND CULTURED IN BIOREACTORS UNDER UNIAXIAL DIURNAL LOADING (0.2 MPA FOR 8 HOURS AND 0.8 MPA FOR 16 HOURS) FOR 4 OR 7 DAYS. SOLUTE TRANSPORT INTO THE CENTER OF THE DISC WAS MEASURED AFTER 4 DAYS OF CULTURE USING A LOW MOLECULAR WEIGHT FLUORESCENT MARKER. CELL VIABILITY, GLYCOSAMINOGLYCAN SYNTHESIS RATE, AND GENE EXPRESSION PROFILE WERE MEASURED AFTER 7 DAYS OF CULTURE AND COMPARED WITH FRESH TISSUE. RESULTS. FLUORESCENT IMAGES SHOWED THAT SOLUTES COULD DIFFUSE INTO THE DISC UNDER BOTH STATIC AND DIURNAL LOADING, BUT PENETRATION THROUGH THE ENDPLATE INCREASED WITH DIURNAL LOADING. CELL VIABILITY AND GLYCOSAMINOGLYCAN SYNTHESIS RATES REMAINED UNCHANGED AFTER 7 DAYS OF CULTURE. EXPRESSION OF CATABOLIC GENES WAS SIGNIFICANTLY UP-REGULATED, WHEREAS ANABOLIC GENES TENDED TO BE DOWN-REGULATED AFTER 7 DAYS. CONCLUSIONS. WITH THIS NOVEL PREPARATION AND CULTURING TECHNIQUE, ENDPLATE PERMEABILITY COULD BE MAINTAINED, WHICH ALLOWED CULTURING OF INTACT DISC EXPLANTS WITH ENDPLATES FOR UP TO 7 DAYS.",MESSENGER-RNA LEVELS; HYDROSTATIC-PRESSURE; NUCLEUS PULPOSUS; GENE-EXPRESSION; ARTICULAR-CARTILAGE; DIFFERENT REGIONS; METABOLISM; MATRIX; CELLS; VIABILITY,INTERVERTEBRAL DISC; VERTEBRAL ENDPLATES; IN VITRO; DIFFUSION; CELL VIABILITY; GLYCOSAMINOGLYCAN; GENE EXPRESSION; SHEEP,SPINE,"GANTENBEIN, B##GRUNHAGEN, T##LEE, CR##VAN DONKELAAR, CC##ALINI, M##ITO, K","AO RES INST, CH-7270 DAVOS, SWITZERLAND. EINDHOVEN UNIV TECHNOL, DEPT BIOMED ENGN, EINDHOVEN, NETHERLANDS. UNIV OXFORD, PHYSIOL LAB, OXFORD OX1 3PT, ENGLAND.",CLINICAL NEUROLOGY; ORTHOPEDICS,NEUROSCIENCES & NEUROLOGY; ORTHOPEDICS,"ACAROGLU ER, 1995, SPINE, V20, P2690, DOI 10.1097/00007632-199512150-00010##ADAMS MA, 2000, SPINE, V25, P1625, DOI 10.1097/00007632-200007010-00005##ALA-KOKKO L, 2002, ANN MED, V34, P42, DOI 10.1080/078538902317338634##BAER AE, 2001, J ORTHOPAED RES, V19, P2, DOI 10.1016/S0736-0266(00)00003-6##BAYLISS MT, 1986, J ORTHOPAED RES, V4, P10, DOI 10.1002/JOR.1100040102##BERT JL, 1980, BIOCHEM J, V191, P761, DOI 10.1042/BJ1910761##BIBBY S, 2004, DEGENERATIVE DISC DI, P23##BIBBY SRS, 2005, SPINE, V30, P487, DOI 10.1097/01.BRS.0000154619.38122.47##BIBBY SRS, 2004, EUR SPINE J, V13, P695, DOI 10.1007/S00586-003-0616-X##BIBBY SRS, 2002, SPINE, V27, P2220, DOI 10.1097/00007632-200210150-00007##BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013##BOUBRIAK OA, 2003, EXP EYE RES, V76, P701, DOI 10.1016/S0014-4835(03)00053-8##CHIBA K, 1998, SPINE, V23, P1821, DOI 10.1097/00007632-199809010-00002##CHIBA K, 1997, SPINE, V22, P2885, DOI 10.1097/00007632-199712150-00011##FERGUSON SJ, 2004, J BIOMECH, V37, P213, DOI 10.1016/S0021-9290(03)00250-1##GRAD S, 2003, J BIOMED MATER RES A, V66A, P571, DOI 10.1002/JBM.A.10007##HIRANO N, 1988, SPINE, V13, P1291, DOI 10.1097/00007632-198811000-00015##HOLM S, 2004, J SPINAL DISORD TECH, V17, P64, DOI 10.1097/00024720-200402000-00012##HORNER HA, 2001, SPINE, V26, P2543, DOI 10.1097/00007632-200112010-00006##HORNER HA, 2002, SPINE, V27, P1018, DOI 10.1097/00007632-200205150-00004##HUTTON WC, 2000, SPINE, V25, P2993, DOI 10.1097/00007632-200012010-00006##HUTTON WC, 1999, SPINE, V24, P1507, DOI 10.1097/00007632-199908010-00002##HUWKINS DWL, 1988, BIOL INTERVERTEBRAL##IATRIDIS JC, 1999, SPINE, V24, P996, DOI 10.1097/00007632-199905150-00013##ISHIHARA H, 1996, J APPL PHYSIOL, V80, P839##KASRA M, 2003, J ORTHOPAED RES, V21, P597, DOI 10.1016/S0736-0266(03)00027-5##KAWAGUCHI Y, 1999, SPINE, V24, P2456, DOI 10.1097/00007632-199912010-00006##KIM JG, 2002, SPINE, V27, P813##LEE CR, 2006, SPINE, V31, P515, DOI 10.1097/01.BRS.0000201302.59050.72##LEE CR, 2005, ANAL BIOCHEM, V341, P372, DOI 10.1016/J.AB.2004.10.005##LIVAK KJ, 2001, METHODS, V25, P402, DOI 10.1006/METH.2001.1262##LOTZ JC, 2000, SPINE, V25, P1477, DOI 10.1097/00007632-200006150-00005##MACLEAN JL, 2004, J ORTHOP RES, V22, P1193, DOI 10.1016/J.ORTHRES.2004.04.004##MASUDA K, 2005, SPINE, V30, P5, DOI 10.1097/01.BRS.0000148152.04401.20##NEIDLINGER-WILKE C, 2005, J NEUROSURG-SPINE, V2, P457, DOI 10.3171/SPI.2005.2.4.0457##NIMER E, 2003, BIOPHYS CHEM, V106, P125, DOI 10.1016/S0301-4622(03)00157-1##OGATA K, 1981, SPINE, V6, P211, DOI 10.1097/00007632-198105000-00003##OSHIMA H, 1993, J ORTHOP RES, V11, P332, DOI 10.1002/JOR.1100110304##QUINN TM, 2001, J BIOMECH, V34, P1463, DOI 10.1016/S0021-9290(01)00112-9##RENO C, 1997, BIOTECHNIQUES, V22, P1082, DOI 10.2144/97226BM16##RISBUD MV, 2003, SPINE, V28, P2652, DOI 10.1097/01.BRS.0000099384.58981.C6##ROBERTS S, 2000, SPINE, V25, P3005, DOI 10.1097/00007632-200012010-00007##SCHNEIDERMAN R, 1995, ARCH BIOCHEM BIOPHYS, V324, P159, DOI 10.1006/ABBI.1995.9914##SEKI S, 2005, NAT GENET, V37, P607, DOI 10.1038/NG1557##SOKAL R.R., 1995, BIOMETRY##URBAN JPG, 2004, SPINE, V29, P2700, DOI 10.1097/01.BRS.0000146499.97948.52##URBAN JPG, 1981, CONNECT TISSUE RES, V9, P1, DOI 10.3109/03008208109160234##WALSH AJL, 2004, J BIOMECH, V37, P329, DOI 10.1016/S0021-9290(03)00290-2##WANG JY, 2001, SPINE, V26, P1747, DOI 10.1097/00007632-200108150-00003##WILKE HJ, 1999, SPINE, V24, P755, DOI 10.1097/00007632-199904150-00005##WILKE HJ, 1997, ANAT RECORD, V247, P542, DOI 10.1002/(SICI)1097-0185(199704)247:4<542::AID-AR13>3.0.CO;2-P##WILKE HJ, 1997, SPINE, V22, P2365, DOI 10.1097/00007632-199710150-00009##WISEMAN MA, 2005, SPINE, V30, P505, DOI 10.1097/01.BRS.0000154615.22311.66",86,2020-11-20,NA
J,WOS:000241197000003,2006,ON MODELING PANELS OF TIME SERIES,"THIS PAPER REVIEWS RESEARCH ISSUES IN MODELING PANELS OF TIME SERIES. EXAMPLES OF THIS TYPE OF DATA ARE ANNUALLY OBSERVED MACROECONOMIC INDICATORS FOR ALL COUNTRIES IN THE WORLD, DAILY RETURNS ON THE INDIVIDUAL STOCKS LISTED IN THE S&P500, AND THE SALES RECORDS OF ALL ITEMS IN A RETAIL STORE. A PANEL OF TIME SERIES CONCERNS THE CASE WHERE THE CROSS-SECTIONAL DIMENSION AND THE TIME DIMENSION ARE LARGE. OFTEN, THERE IS NO A PRIORI REASON TO SELECT A FEW SERIES OR TO AGGREGATE THE SERIES OVER THE CROSS-SECTIONAL DIMENSION. THE USE OF, FOR EXAMPLE, A VECTOR AUTOREGRESSION OR OTHER TYPES OF MULTIVARIATE MODELS THEN BECOMES CUMBERSOME. PANEL MODELS AND ASSOCIATED ESTIMATION TECHNIQUES ARE MORE USEFUL. DUE TO THE LARGE TIME DIMENSION, ONE SHOULD HOWEVER INCORPORATE THE TIME-SERIES FEATURES. AND, THE MODELS SHOULD NOT HAVE TOO MANY PARAMETERS TO FACILITATE INTERPRETATION. THIS PAPER DISCUSSES REPRESENTATION, ESTIMATION AND INFERENCE OF RELEVANT MODELS AND DISCUSSES RECENTLY PROPOSED MODELING APPROACHES THAT EXPLICITLY AIM TO MEET THESE REQUIREMENTS. THE PAPER CONCLUDES WITH SOME REFLECTIONS ON THE USEFULNESS OF LARGE DATA SETS. THESE CONCERN SAMPLE SELECTION ISSUES AND THE NOTION THAT MORE DETAIL ALSO REQUIRES MORE COMPLEX MODELS.",INFERENCE; ROOTS,PANEL DATA; TIME SERIES; LATENT CLASS,STATISTICA NEERLANDICA,"FRANSES, PH","ERASMUS UNIV, INST ECONOMETR, NL-3000 DR ROTTERDAM, NETHERLANDS.",STATISTICS & PROBABILITY,MATHEMATICS,"BALTAGI B. H., 1995, ECONOMETRIC ANAL PAN##BLATTBERG RC, 1991, J AM STAT ASSOC, V86, P304, DOI 10.2307/2290562##BLUNDELL R, 1993, AM ECON REV, V83, P570##DONKERS B, 2003, J MARKETING RES, V40, P492, DOI 10.1509/JMKR.40.4.492.19395##ENGLE RF, 1996, OXFORD B ECON STAT, V58, P615##FOK D, 2005, J APPL ECONOMET, V20, P811, DOI 10.1002/JAE.822##FRANSES P. H, 1998, TIME SERIES MODELS B##FRANSES PH, 2004, CONCISE INTRO ECONOM##FRANSES PH, 1999, 9905 ER U EC I##GONZALO J., 1999, COINTEGRATION CAUSAL, P212##GRANGER C. W. J., 1990, DISAGGREGATION ECONO, P17##GRANGER CWJ, 1998, STAT NEERL, V52, P258, DOI 10.1111/1467-9574.00084##GROEN JJJ, 2003, J BUS ECON STAT, V21, P295, DOI 10.1198/073500103288618972##HAHN JY, 2002, ECONOMETRICA, V70, P1639, DOI 10.1111/1468-0262.00344##HARRIS RDF, 1999, J ECONOMETRICS, V91, P201, DOI 10.1016/S0304-4076(98)00076-1##HJELLVIK V, 1999, BIOMETRIKA, V86, P573, DOI 10.1093/BIOMET/86.3.573##HOLTZEAKIN D, 1988, ECONOMETRICA, V56, P1371, DOI 10.2307/1913103##HOOGSTRATE AJ, 2000, J BUS ECON STAT, V18, P274, DOI 10.2307/1392261##HSIAO C., 1986, ANAL PANEL DATA##KIPPERS J, 2003, STAT NEERL, V57, P484, DOI 10.1111/1467-9574.00241##KIPPERS J, 2003, 200325 ER U EC I##LEVIN A, 2002, J ECONOMETRICS, V108, P1, DOI 10.1016/S0304-4076(01)00098-7##MOON HR, 2000, ECONOMET THEOR, V16, P927, DOI 10.1017/S026646660016606X##NICKELL S, 1981, ECONOMETRICA, V49, P1417, DOI 10.2307/1911408##O'CONNELL PGJ, 1998, J INT ECON, V44, P1, DOI 10.1016/S0022-1996(97)00017-2##PAAP R, 2005, J DEV ECON, V77, P553, DOI 10.1016/J.JDEVECO.2004.05.001##PAAP R, 2002, STAT NEERL, V56, P2, DOI 10.1111/1467-9574.00060##PAPELL DH, 1997, J INT ECON, V43, P313, DOI 10.1016/S0022-1996(96)01467-5##PESARAN MH, 1999, J AM STAT ASSOC, V94, P621, DOI 10.2307/2670182##PHILLIPS PCB, 1999, ECONOMETRICA, V67, P1057, DOI 10.1111/1468-0262.00070##STOCK JH, 2001, J ECON PERSPECT, V15, P101, DOI 10.1257/JEP.15.4.101##STOCK JH, 2002, J BUS ECON STAT, V20, P147, DOI 10.1198/073500102317351921##SWAMY PAVB, 1970, ECONOMETRICA, V38, P311, DOI 10.2307/1913012##VANNIEROP E, 2002, ERS200265MKT ER RES##VOGELSANG TJ, 2005, J ECONOMETRICS, V126, P1, DOI 10.1016/J.JECONOM.2004.02.004##WEDEL M., 1999, MARKET SEGMENTATION##ZELLNER A, 2001, MACROECON DYN, V5, P673",1,2020-11-20,NA
J,WOS:000241893600017,2006,"REFLECTIONS ON THE EUROPEAN UNION EURYTHRON NETWORK MEETING ""MOLECULAR CONTROL OF ERYTHROPOIESIS,"" SEPTEMBER 22-23, 2005, ISTITUTO SUPERIORE DI SANITA, ROME, ITALY","RED BLOOD CELLS (RBCS) MEDIATE OXYGEN TRANSPORT THROUGHOUT THE BODY, A FUNCTION THAT IS ESSENTIAL FOR LIFE. RBCS ARE CONTINUOUSLY PRODUCED VIA A PROCESS CALLED ERYTHROPOIESIS. ANEMIAS ( INSUFFICIENT NUMBERS OF FUNCTIONAL RBCS), CAUSED BY FAILURE OF ERYTHROPOIESIS, ARE A MAJOR CAUSE OF DISEASE WORLDWIDE. HEREDITARY ANEMIAS CONSTITUTE THE MOST COMMON HUMAN GENETIC DISORDERS; THEY HAVE NO EFFECTIVE CURE YET. THE EUROPEAN RESEARCH TRAINING NETWORK EURYTHRON FOLLOWS A MULTIDISCIPLINARY APPROACH TO CLARIFY THE IMPORTANT MOLECULAR MECHANISMS IN NORMAL AND PATHOLOGICAL ERYTHROPOIESIS, WITH A VIEW TO DEVELOP NOVEL THERAPIES TO CURE THE ANEMIAS. THE AIM IS TO GENERATE A COMPREHENSIVE MOLECULAR DESCRIPTION OF MECHANISMS GOVERNING SPECIFICATION OF HEMATOPOIETIC STEM CELLS IN EMBRYOGENESIS, LINEAGE COMMITMENT, DIFFERENTIATION, AND POSTMITOTIC MATURATION OF RBCS. WE REPORT ON THE EURYTHRON MEETING IN ROME, IN WHICH NOVEL APPROACHES IN STEM CELL AND ERYTHROID CELL BIOLOGY, INCLUDING IN VITRO EXPANSION OF PRIMARY CELLS, BIOCHEMISTRY OF RECEPTOR/SIGNAL TRANSDUCTION COMPLEXES AND TRANSCRIPTION FACTORS, AND (EPI) GENETICS, WERE DISCUSSED.",TRANSCRIPTION FACTORS; MAMMALIAN-CELLS; ERYTHROID-CELLS; PLACENTA; GATA-1; MEGAKARYOCYTES; EXPRESSION; MUTATIONS; PREVENTS; REPAIR,HEMATOPOIETIC STEM CELLS; COMMITMENT; HEMATOPOIESIS; ERYTHROPOIESIS; NETWORKS,STEM CELLS,"MIGLIACCIO, AR##PHILIPSEN, S","ERASMUS UNIV, MED CTR, DEPT CELL BIOL, NL-3000 CA ROTTERDAM, NETHERLANDS. IST SUPER SANITA, I-00161 ROME, ITALY.",CELL & TISSUE ENGINEERING; BIOTECHNOLOGY & APPLIED MICROBIOLOGY; ONCOLOGY; CELL BIOLOGY; HEMATOLOGY,CELL BIOLOGY; BIOTECHNOLOGY & APPLIED MICROBIOLOGY; ONCOLOGY; HEMATOLOGY,"ALVAREZ-SILVA M, 2003, DEVELOPMENT, V130, P5437, DOI 10.1242/DEV.00755##ANGUITA E, 2002, BLOOD, V100, P3450, DOI 10.1182/BLOOD-2002-05-1409##BROMAN KW, 2005, NAT GENET, V37, P209, DOI 10.1038/NG0305-209##BROWN CT, 2002, DEV BIOL, V246, P86, DOI 10.1006/DBIO.2002.0619##BYSTRYKH L, 2005, NAT GENET, V37, P225, DOI 10.1038/NG1497##CAROTTA S, 2004, BLOOD, V104, P1873, DOI 10.1182/BLOOD-2004-02-0570##CENTURIONE L, 2004, BLOOD, V104, P3573, DOI 10.1182/BLOOD-2004-01-0193##CHURCHILL G, 2004, NAT GENET, V36, P1133, DOI 10.1038/NG1104-1133##CIAU-UITZ A, 2000, CELL, V102, P787, DOI 10.1016/S0092-8674(00)00067-2##CRISPINO JD, 2005, PEDIATR BLOOD CANCER, V44, P40, DOI 10.1002/PBC.20066##CUSTODIO N, 1999, EMBO J, V18, P2855, DOI 10.1093/EMBOJ/18.10.2855##CUSTODIO N, 2004, RNA, V10, P622, DOI 10.1261/RNA.5258504##DE BOER E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/PNAS.1332608100##DOLZNIG H, 2004, METH MOLEC MED, V105, P323##FERREIRA R, 2005, MOL CELL BIOL, V25, P1215, DOI 10.1128/MCB.25.4.1215-1227.2005##FLINT J, 2001, HUM MOL GENET, V10, P371, DOI 10.1093/HMG/10.4.371##FRANCASTEL C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8##FRANCASTEL C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/PNAS.211444898##GEKAS C, 2005, DEV CELL, V8, P365, DOI 10.1016/J.DEVCEL.2004.12.016##GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2##HACEIN-BEY-ABINA S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314##JOOSTEN M, 2004, J BIOL CHEM, V279, P38169, DOI 10.1074/JBC.M401283200##KAMMINGA LM, 2006, BLOOD, V107, P2170, DOI 10.1182/BLOOD-2005-09-3585##LOOSE M, 2004, DEV BIOL, V271, P467, DOI 10.1016/J.YDBIO.2004.04.014##NUTT SL, 1999, NATURE, V401, P556##OTTERSBACH K, 2005, DEV CELL, V8, P377, DOI 10.1016/J.DEVCEL.2005.02.001##PILAT S, 2005, P NATL ACAD SCI USA, V102, P12101, DOI 10.1073/PNAS.0505624102##REKHTMAN N, 1999, GENE DEV, V13, P1398, DOI 10.1101/GAD.13.11.1398##RODRIGUEZ P, 2005, EMBO J, V24, P2354, DOI 10.1038/SJ.EMBOJ.7600702##SCHUH AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005##SIERAKOWSKA H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/PNAS.93.23.12840##SUWANMANEE T, 2002, MOL THER, V6, P718, DOI 10.1006/MTHE.2002.0805##TANGE TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/J.CEB.2004.03.012##VANNUCCHI A, 2004, PATHOL BIOL, V52, P275, DOI 10.1016/J.PATBIO.2004.02.008##VONLINDERN M, 2005, HAEMATOLOGICA, V90, PA1441",0,2020-11-20,NA
J,WOS:000242060200005,2006,"5,8-EPIDIOXYSTEROLS AND RELATED DERIVATIVES FROM A CHINESE SOFT CORAL SINULARIA FLEXIBILIS","CHROMATOGRAPHIC SEPARATION OF THE METHANOLIC EXTRACT OF THE MARINE SOFT CORAL, SINULARIA FLEXIBILIS, RESULTED IN THE ISOLATION AND CHARACTERIZATION OF FOUR NEW STEROLS, 5 ALPHA,8 ALPHA-EPIDIOXYGORGOSTA-6-EN-3 BETA-OMICRON L (1), 5 ALPHA,8 ALPHA-EPIDIOXYGORGOSTA-6,9(11)-DIEN-3 BETA-OMICRON L (2), 22 ALPHA,28-EPIDIOXYCHOLESTA-5,23(EPSILON)-DIEN-3 BETA-OMICRON L (3) AND ITS C-22 EPIMER (4), ALONG WITH NINE KNOWN STEROLS. THE STRUCTURES OF THE NEW COMPOUNDS WERE DETERMINED ON THE BASIS OF EXTENSIVE SPECTROSCOPIC DATA (IR, MS, H-1 AND C-13 NMR, HMQC, HMBC, AND NOESY) ANALYSES. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.","5-ALPHA,8-ALPHA-EPIDIOXY STEROLS; CHEMICAL-CONSTITUENTS; GENUS",SOFT CORAL; SINULARIA FLEXIBILIS; STEROLS; STRUCTURE IDENTIFICATION,STEROIDS,"YU, SJ##DENG, ZW##VAN OFWEGEN, LP##PROKSCH, P##LIN, WH","PEKING UNIV, STATE KEY LAB NAT & BIOMIMET DRUGS, BEIJING 100083, PEOPLES R CHINA. BEIJING NORMAL UNIV, CHEM & TEST CTR, BEIJING 100073, PEOPLES R CHINA. NATL MUSEUM NAT HIST NAT, NL-2300 RA LEIDEN, NETHERLANDS. UNIV DUSSELDORF, INST PHARMACEUT BIOL, D-40225 DUSSELDORF, GERMANY.",BIOCHEMISTRY & MOLECULAR BIOLOGY; ENDOCRINOLOGY & METABOLISM,BIOCHEMISTRY & MOLECULAR BIOLOGY; ENDOCRINOLOGY & METABOLISM,"AHMED AF, 2003, STEROIDS, V68, P377, DOI 10.1016/S0039-128X(03)00036-9##ANJANEYULU ASR, 1995, J CHEM RES, P142##ANJANEYULU ASR, 1995, J SCI IND RES INDIA, V54, P637##BOCKING T, 2000, EUR J BIOCHEM, V267, P1607, DOI 10.1046/J.1432-1327.2000.01179.X##DUH CY, 1998, TETRAHEDRON LETT, V39, P7121, DOI 10.1016/S0040-4039(98)01512-3##DUH CY, 1998, J NAT PROD, V61, P844, DOI 10.1021/NP980021V##ELENKOV I, 1994, COMP BIOCHEM PHYS B, V107, P547, DOI 10.1016/0305-0491(94)90183-X##FAULKNER DJ, 1997, NAT PROD REP, V14, P259, DOI 10.1039/NP9971400259##FLEURY BG, 2004, J EXP MAR BIOL ECOL, V303, P115, DOI 10.1016/J.JEMBE.2003.11.006##GUNATILAKA AAL, 1981, J ORG CHEM, V46, P3860, DOI 10.1021/JO00332A020##HSIEH PW, 2003, NAT PROD RES, V17, P409, DOI 10.1080/14786910310001617677##JIMENEZ C, 1989, J NAT PROD, V52, P619, DOI 10.1021/NP50063A023##JIN PF, 2005, STEROIDS, V70, P487, DOI 10.1016/J.STEROIDS.2005.01.001##LABARRE SC, 1986, MAR ECOL PROG SER, V28, P147, DOI 10.3354/MEPS028147##LAGES BG, 2006, J EXP MAR BIOL ECOL, V328, P127, DOI 10.1016/J.JEMBE.2005.07.011##LUO XD, 2001, ACTA BOT SIN, V43, P426##PAUL VJ, 2006, NAT PROD REP, V23, P153, DOI 10.1039/B404735B##RAMESH P, 1999, STEROIDS, V64, P785, DOI 10.1016/S0039-128X(99)00069-0##SHEU JH, 2000, J NAT PROD, V63, P149, DOI 10.1021/NP9903954##SUBRAHMANYAM C, 1995, INDIAN J CHEM B, V34, P1114##TANAKA J, 2002, TETRAHEDRON, V58, P6259, DOI 10.1016/S0040-4020(02)00625-7##VAN AK, 1994, J EXP MAR BIOL ECOL, V178, P17##VENKATESWARLU Y, 1999, J NAT PROD, V62, P756, DOI 10.1021/NP9804076##VOLKMAN JK, 1999, PHYTOCHEMISTRY, V52, P659, DOI 10.1016/S0031-9422(99)00251-4##WANG JF, 2004, ACTA CRYSTALLOGR E, V60, PO764, DOI 10.1107/S160053680400813X##WILSON S, 2001, ORG GEOCHEM, V32, P1257, DOI 10.1016/S0146-6380(01)00084-5##YASUNORI Y, 1998, CHEM PHARM BULL, V46, P944##ZHANG GW, 2003, YINGYONG HUAXUE, V20, P1021",25,2020-11-20,NA
J,WOS:000242006800001,2006,ANNEALED ASYMPTOTICS FOR THE PARABOLIC ANDERSON MODEL WITH A MOVING CATALYST,"THIS PAPER DEALS WITH THE SOLUTION U TO THE PARABOLIC ANDERSON EQUATION PARTIAL DERIVATIVE U/PARTIAL DERIVATIVE T = KAPPA DELTA U+XI U ON THE LATTICE Z(D). WE CONSIDER THE CASE WHERE THE POTENTIAL IS TIME-DEPENDENT AND HAS THE FORM XI(T, X) = DELTA(0)(X - Y-T) WITH Y-T BEING A SIMPLE RANDOM WALK WITH JUMP RATE 2D RHO. THE SOLUTION U MAY BE INTERPRETED AS THE CONCENTRATION OF A REACTANT UNDER THE INFLUENCE OF A SINGLE CATALYST PARTICLE Y-T. IN THE FIRST PART OF THE PAPER WE SHOW THAT THE MOMENT LYAPUNOV EXPONENTS COINCIDE WITH THE UPPER BOUNDARY OF THE SPECTRUM OF CERTAIN HAMILTONIANS. IN THE SECOND PART WE STUDY INTERMITTENCY IN TERMS OF THE MOMENT LYAPUNOV EXPONENTS AS A FUNCTION OF THE MODEL PARAMETERS KAPPA AND RHO. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",INTERMITTENCY,PARABOLIC ANDERSON PROBLEM; CATALYTIC RANDOM MEDIUM; INTERMITTENCY; MOMENT LYAPUNOV EXPONENTS,STOCHASTIC PROCESSES AND THEIR APPLICATIONS,"GARTNER, J##HEYDENREICH, M","TECH UNIV EINDHOVEN, DEPT MATH & COMP SCI, NL-5600 MB EINDHOVEN, NETHERLANDS. TECH UNIV BERLIN, INST MATH, D-10623 BERLIN, GERMANY.",STATISTICS & PROBABILITY,MATHEMATICS,"CARMONA R., 1996, RANDOM OPER STOCH EQ, V4, P43##CARMONA R. A., 1994, MEMOIRS AM MATH SOC, V518##CARMONA RA, 1995, PROBAB THEORY REL, V102, P433, DOI 10.1007/BF01198845##CRANSTON M, 2002, ACTA MATH U COMENIAN, V71, P163##EBELING W, 1984, J STAT PHYS, V37, P369, DOI 10.1007/BF01011839##GARTNER J, 2005, INTERACTING STOCHASTIC SYSTEMS, P153, DOI 10.1007/3-540-27110-4_8##GARTNER J, 1990, COMMUN MATH PHYS, V132, P613, DOI 10.1007/BF02156540##GARTNER J, 2004, IN PRESS ANN PROBAB##KESTEN H., 2003, ELECTRON J PROBAB, V8, P1##ZELDOVICH Y. B., 1988, SOV SCI REV C, V7, P1",7,2020-11-20,NA
J,WOS:000242006800005,2006,POLYMER PINNING AT AN INTERFACE,"WE CONSIDER A (1 + 1)-DIMENSIONAL HYDROPHOBIC HOMOPOLYMER, IN INTERACTION WITH AN OIL-WATER INTERFACE. IN Z(2), THE INTERFACE IS MODELLED BY THE X AXIS, THE OIL IS ABOVE, THE WATER IS BELOW, AND THE POLYMER CONFIGURATIONS ARE GIVEN BY A SIMPLE RANDOM WALK (S-I)(I >= 0). THE HYDROPHOBICITY OF EACH MONOMER TENDS TO DELOCALIZE THE POLYMER IN THE UPPER HALF-PLANE, THROUGH A REWARD H > 0 FOR EACH MONOMER IN THE OIL AND A PENALTY -H < 0 FOR EACH MONOMER IN THE WATER. ON THE OTHER HAND, THE CHAIN RECEIVES A RANDOM REWARD (OR PENALTY) WHEN CROSSING THE INTERFACE, DEPENDING ON A LOCAL RANDOM CHARGE ATTACHED TO THE INTERFACE. AT SITE I THIS REWARD IS P(1 + S ZETA(I)), WHERE (ZETA(I))(I >= 1) IS A SEQUENCE OF I.I.D. CENTERED RANDOM VARIABLES, AND S >= 0, BETA >= 0. SINCE THE REWARD IS POSITIVE ON AVERAGE, THE INTERFACE ATTRACTS THE POLYMER AND A LOCALIZATION EFFECT MAY ARISE. WE TRANSFORM THE MEASURE OF EACH TRAJECTORY WITH THE HAMILTONIAN BETA SIGMA(N)(I=1) (1 + S ZETA(I))1({SI=0}) + H SIGMA(N)(I=1) SIGN(S-I), AND STUDY THE CRITICAL CURVE H(C)(S)(BETA) THAT SEPARATES THE (BETA, H)- PLANE INTO A LOCALIZED AND A DELOCALIZED PHASE FOR S FIXED. IT IS NOT DIFFICULT TO SHOW THAT H(C)(S)(BETA) >= H(C)(0)(BETA) FOR ALL S >= 0 WITH THE FORMER EXPLICITLY COMPUTABLE. IN THIS ARTICLE WE GIVE A METHOD FOR IMPROVING IN A QUANTITATIVE WAY THIS LOWER BOUND. TO THAT END, WE TRANSFORM THE STRATEGY DEVELOPED BY BOLTHAUSEN AND DEN HOLLANDER IN [E. BOLTHAUSEN, F. DEN HOLLANDER, LOCALIZATION FOR A POLYMER NEAR AN INTERFACE, ANN. PROBAB. 25 (3) (1997) 1334-1366], BY TAKING INTO ACCOUNT THE FACT THAT THE CHAIN CAN TARGET THE SITES WHERE IT COMES BACK TO THE ORIGIN. THE IMPROVED LOWER BOUND IS INTERESTING EVEN FOR THE CASE WHERE ONLY THE INTERACTION AT THE INTERFACE IS ACTIVE, I.E., FOR THE PURE PINNING MODEL. OUR BOUND IMPROVES AN EARLIER BOUND OF ALEXANDER AND SIDORAVICIUS IN [K. ALEXANDER, V. SIDORAVICIUS PINNING OF POLYMERS AND INTERFACES BY RANDOM POTENTIAL, 2005 (PREPRINT). AVAILABLE ON: ARXIV.ORG E-PRINT ARCHIVE: MATH.PR/0501028]. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",LOCALIZATION TRANSITION; RANDOM-WALK; DISORDER,POLYMERS; LOCALIZATION-DELOCALIZATION TRANSITION; PINNING; RANDOM WALK; WETTING,STOCHASTIC PROCESSES AND THEIR APPLICATIONS,"PETRELIS, N","EURANDOM, NL-5600 MB EINDHOVEN, NETHERLANDS. LAB MATH RAPHAEL SALEM, CNRS, UMR 6085, F-76821 MONT ST AIGNAN, FRANCE.",STATISTICS & PROBABILITY,MATHEMATICS,"ALEXANDER K, PINNING POLYM INTERF##BISKUP M, 1999, ANN APPL PROBAB, V9, P668##BODINEAU T, 2004, J STAT PHYS, V117, P801, DOI 10.1007/S10955-004-5705-7##BOLTHAUSEN E, 1997, ANN PROBAB, V25, P1334##DERRIDA B, 1992, J STAT PHYS, V66, P1189, DOI 10.1007/BF01054419##FORGACS G, 1988, J STAT PHYS, V51, P29, DOI 10.1007/BF01015319##GAREL T, 2005, EUR PHYS J B, V46, P117, DOI 10.1140/EPJB/E2005-00241-L##GIACOMIN G, 2005, PROBAB THEORY RELATE##GIACOMIN G, 2003, LECT NOTES##ISOZAKI Y, 2001, STOCH PROC APPL, V96, P261, DOI 10.1016/S0304-4149(01)00118-1##JAMES EW, 2003, J PHYS A-MATH GEN, V36, P11575, DOI 10.1088/0305-4470/36/46/003##JANVRESSE E, 2004, STOCHASTIC PROCESS A, V115, P1323##KALLABIS H, 1995, PHYS REV LETT, V75, P1578, DOI 10.1103/PHYSREVLETT.75.1578##LIGGETT T, 1985, INTERACTING PARTICLE##LINDVALL T., 1992, LECT COUPLING METHOD##POLAND D, 1966, J CHEM PHYS, V45, P1464, DOI 10.1063/1.1727786##SINAI YG, 1993, THEOR PROBAB APPL+, V38, P382, DOI 10.1137/1138036",3,2020-11-20,NA
J,WOS:000242163300008,2006,BIOLOGICALLY EFFECTIVE DOSE IN TOTAL-BODY IRRADIATION AND HEMATOPOIETIC STEM CELL TRANSPLANTATION,"BACKGROUND AND PURPOSE: TOTAL-BODY IRRADIATION (TBI) IS AN IMPORTANT PART OF THE CONDITIONING REGIMEN FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES. THE RESULTS AFTER TREATMENT WITH VARIOUS TBI REGIMENS WERE COMPARED, AND DOSE-EFFECT RELATIONSHIPS FOR THE ENDPOINTS RELAPSE INCIDENCE, DISEASE-FREE SURVIVAL, TREATMENT-RELATED MORTALITY, AND OVERALL SURVIVAL WERE DERIVED. THE AIM WAS TO DEFINE REQUIREMENTS FOR AN OPTIMAL TREATMENT SCHEDULE WITH RESPECT TO LEUKEMIC CELL KILL AND LATE NORMAL-TISSUE MORBIDITY. MATERIAL AND METHODS: A LITERATURE SEARCH WAS PERFORMED. THREE RANDOMIZED STUDIES, FOUR STUDIES COMPARING RESULTS OF TWO OR THREE TBI REGIMENS, AND NINE REPORTS WITH RESULTS OF ONE SPECIFIC TBI REGIMEN WERE IDENTIFIED. BIOLOGICALLY EFFECTIVE DOSES (BEDS) WERE CALCULATED. THE RESULTS OF THE RANDOMIZED STUDIES AND THE STUDIES COMPARING RESULTS OF TWO OR THREE TBI REGIMENS WERE POOLED, AND THE POOLED RELATIVE RISK (RR) WAS CALCULATED FOR THE TREATMENTS WITH HIGH BED VALUES VERSUS TREATMENTS WITH A LOW BED. BED-EFFECT RELATIONSHIPS WERE OBTAINED. RESULTS: RRS FOR THE HIGH BED TREATMENTS WERE SIGNIFICANTLY LOWER FOR RELAPSE INCIDENCE, NOT SIGNIFICANTLY DIFFERENT FOR DISEASE-FREE SURVIVAL AND TREATMENT-RELATED MORTALITY, AND SIGNIFICANTLY HIGHER FOR OVERALL SURVIVAL. BED-EFFECT RELATIONSHIPS INDICATE A DECREASE IN RELAPSE INCIDENCE AND TREATMENT-RELATED MORTALITY AND AN INCREASE IN DISEASE-FREE AND OVERALL SURVIVAL WITH HIGHER BED VALUES. CONCLUSION: ""MORE DOSE IS BETTER"", PROVIDED THAT A TBI SETTING IS USED LIMITING THE BEDS OF LUNGS, KIDNEYS, AND EYE LENSES.",BONE-MARROW-TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE NONLYMPHOBLASTIC LEUKEMIA; 1ST COMPLETE REMISSION; VERSUS-HOST-DISEASE; TERM-FOLLOW-UP; RENAL DYSFUNCTION; AFFECTS PROGNOSIS; IN-VIVO; TOXICITY,ALLOGENEIC HSCT; BED; EUKEMIA; ORGAN SHIELDING; TBI,STRAHLENTHERAPIE UND ONKOLOGIE,"KAL, HB##VAN KEMPEN-HARTEVELD, ML##HEIJENBROK-KAL, MH##STRUIKMANS, H","UNIV UTRECHT, MED CTR, DEPT RADIOTHERAPY, NL-3584 CX UTRECHT, NETHERLANDS. UNIV MED CTR ROTTERDAM, ERASMUS MC, DEPT EPIDEMIOL & BIOSTAT, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT RADIOTHERAPY, LEIDEN, NETHERLANDS.","ONCOLOGY; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ONCOLOGY; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ALTSCHULER C, 1990, INT J RADIAT ONCOL, V19, P1151, DOI 10.1016/0360-3016(90)90220-E##BARENDSEN GW, 1982, INT J RADIAT ONCOL, V8, P1981, DOI 10.1016/0360-3016(82)90459-X##BELKACEMI Y, 1998, STRAHLENTHER ONKOL, V174, P92, DOI 10.1007/BF03038482##BIERI S, 2001, INT J RADIAT ONCOL, V49, P1071, DOI 10.1016/S0360-3016(00)01491-7##BORG M, 2002, INT J RADIAT ONCOL, V54, P1165, DOI 10.1016/S0360-3016(02)03039-0##CHAO NJ, 1991, BLOOD, V78, P1923##CLIFT RA, 1990, BLOOD, V76, P1867##CLIFT RA, 1998, BLOOD, V92, P1455, DOI 10.1182/BLOOD.V92.4.1455##COOPERMAN J, 2004, STEM CELLS, V22, P1111, DOI 10.1634/STEMCELLS.22-6-1111##CORVO R, 2002, BONE MARROW TRANSPL, V30, P717, DOI 10.1038/SJ.BMT.1703701##CORVO R, 1999, INT J RADIAT ONCOL, V43, P497, DOI 10.1016/S0360-3016(98)00441-6##DALE RG, 1989, BRIT J RADIOL, V62, P241, DOI 10.1259/0007-1285-62-735-241##DAVIS HP, 1988, BONE MARROW TRANSPL, V3, P349##DEEG HJ, 1986, BONE MARROW TRANSPL, V1, P151##DIMOPOULOS MA, 1994, AM J HEMATOL, V46, P82, DOI 10.1002/AJH.2830460205##DU W, 1998, BONE MARROW TRANSPL, V21, P1043, DOI 10.1038/SJ.BMT.1701210##FRASSONI F, 1989, BRIT J HAEMATOL, V73, P211, DOI 10.1111/J.1365-2141.1989.TB00254.X##FYLES GM, 1991, BONE MARROW TRANSPL, V8, P453##GALE RP, 1991, INT J RADIAT ONCOL, V20, P631, DOI 10.1016/0360-3016(91)90081-E##GIRINSKY T, 2000, J CLIN ONCOL, V18, P981, DOI 10.1200/JCO.2000.18.5.981##GONZALEZ-VILA V, 1990, RADIOTHER ONCOL, V18 SUPPL 1, P110, DOI 10.1016/0167-8140(90)90187-2##HEINZELMANN F, 2006, STRAHLENTHER ONKOL, V182, P222, DOI 10.1007/S00066-006-1468-1##IGAKI H, 2005, STRAHLENTHER ONKOL, V181, P704, DOI 10.1007/S00066-005-1405-8##JUCKETT MB, 2001, BONE MARROW TRANSPL, V27, P451, DOI 10.1038/SJ.BMT.1702797##KAL HB, 2005, STRAHLENTHER ONKOL, V181, P717, DOI 10.1007/S00066-005-1407-6##KAL HB, 2004, STRAHLENTHER ONKOL, V180, P798, DOI 10.1007/S00066-004-1276-4##KAL HB, 2006, INT J RADIAT ONCOL, V65, P1228, DOI 10.1016/J.IJROBP.2006.02.021##KIM TH, 1990, INT J RADIAT ONCOL, V19, P889, DOI 10.1016/0360-3016(90)90009-9##LAWTON CA, 1997, BONE MARROW TRANSPL, V20, P1069, DOI 10.1038/SJ.BMT.1701022##LONG G D, 1997, BIOL BLOOD MARROW TRANSPLANT, V3, P324##MIRALBELL R, 1996, J CLIN ONCOL, V14, P579, DOI 10.1200/JCO.1996.14.2.579##NIETO Y, 2006, BIOL BLOOD MARROW TR, V12, P217, DOI 10.1016/J.BBMT.2005.10.012##OZSAHIN M, 1992, CANCER, V69, P2853, DOI 10.1002/1097-0142(19920601)69:11<2853::AID-CNCR2820691135>3.0.CO;2-2##PREISLER HD, 1992, BLOOD, V80, P2600##REGNIER R, 1990, RADIOTHER ONCOL, V18 SUPPL 1, P128, DOI 10.1016/0167-8140(90)90192-Y##RESBEUT M, 1995, INT J RADIAT ONCOL, V31, P509, DOI 10.1016/0360-3016(94)00446-R##SCARPATI D, 1990, RADIOTHER ONCOL, V18 SUPPL 1, P135, DOI 10.1016/0167-8140(90)90194-2##SHANK B, 1993, RADIOTHER ONCOL, V27, P30, DOI 10.1016/0167-8140(93)90041-6##SHAPIRA MY, 2004, BONE MARROW TRANSPL, V34, P155, DOI 10.1038/SJ.BMT.1704540##STEEL GG, 2002, BASIC CLIN RADIOBIOL##SUTTON L, 1993, BONE MARROW TRANSPL, V12, P583##THAMES HD, 1987, FRACTIONATION RADIOT##VALLS A, 1990, RADIOTHER ONCOL, V18 SUPPL 1, P151, DOI 10.1016/0167-8140(90)90198-6##VAN KEMPEN-HARTEVELD ML, 2002, INT J RADIAT ONCOL, V52, P1367, DOI 10.1016/S0360-3016(01)02758-4##VRIESENDORP HM, 1991, INT J RADIAT ONCOL, V20, P635, DOI 10.1016/0360-3016(91)90082-F",31,2020-11-20,NA
J,WOS:000218083900004,2006,UNLOCKING SYNERGIES BETWEEN BUSINESS UNITS: INTERNAL VALUE CREATION AT ROYAL VOPAK,"THIS PAPER EXAMINES THE PROCESS OF CREATING AND EXPLOITING SYNERGIES BETWEEN BUSINESS UNITS OF A MULTI-UNIT CORPORATION AND THE CREATION OF INTERNAL VALUE BY COMBINING AND EXPLOITING KNOWLEDGE. IT OFFERS A FRAMEWORK TO CREATE AND MANAGE SUCH SYNERGIES AND UNDERTAKES AN EMPIRICAL TEST THROUGH IN-DEPTH STUDY ACROSS THREE BUSINESS UNITS OF ROYAL VOPAK, A DUTCH-BASED GLOBAL MULTI-UNIT CORPORATION. FINALLY, IT OFFERS LESSONS FOR CORPORATE MANAGERS TRYING TO CREATE AND MANAGE CROSS-UNIT SYNERGIES. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",NA,NA,STRATEGIC CHANGE-BRIEFINGS IN ENTREPRENEURIAL FINANCE,"ANSARI, S##SCHOUTEN, M##VERWAAL, E","[ANSARI, SHAHZAD; VERWAAL, ERNST] RSM ERASMUS UNIV, STRATEG MANAGEMENT & INT BUSINESS, ROTTERDAM, NETHERLANDS. [SCHOUTEN, MARTIJN] RSM ERASMUS UNIV, ROYAL VOPAK & RES ASSOCIATE, IND SERV, ROTTERDAM, NETHERLANDS.","BUSINESS, FINANCE",BUSINESS & ECONOMICS,"ALCHIAN AA, 1972, AM ECON REV, V62, P777##ANSOFF I. H., 1965, CORPORATE STRATEGY##BARNETT WP, 2002, IND CORP CHANGE, V11, P289, DOI 10.1093/ICC/11.2.289##BARNEY JB, 2001, ACAD MANAGE REV, V26, P41, DOI 10.2307/259393##BRANDENBURGER A.M., 1996, COOPETITION##COASE RH, 1937, ECONOMICA-NEW SER, V4, P386, DOI 10.1111/J.1468-0335.1937.TB00002.X##DAVIS PS, 1992, STRATEGIC MANAGE J, V13, P349, DOI 10.1002/SMJ.4250130504##DAVIS R, 1993, MANAGE SCI, V39, P1334, DOI 10.1287/MNSC.39.11.1334##DESS G, 1993, STRATEGIC MANAGEMENT, P248##DOUMA M. U., 1997, THESIS##DOZ YL, 1996, STRATEGIC MANAGE J, V17, P55, DOI 10.1002/SMJ.4250171006##DYER JH, 2003, ORGAN SCI, V14, P57, DOI 10.1287/ORSC.14.1.57.12806##DYER JH, 1998, ACAD MANAGE REV, V23, P660, DOI 10.2307/259056##EDWARDS C, 2005, BUS WEEK, P35##GROSSMAN LEV, 2005, TIME MAGAZINE##GRUCA TS, 1997, LONG RANGE PLANN, V30, P605, DOI 10.1016/S0024-6301(97)00039-3##GULATI R, 1995, ACAD MANAGE J, V38, P85, DOI 10.2307/256729##KROPOTKIN P, 1902, MUTUAL AID FACTOR EV##KVALE S, 1996, INTERVIEWS INTRO QUA##MARKIDES CC, 1994, STRATEGIC MANAGE J, V15, P149##MINTZBERG H., 1998, STRATEGY SAFARI##PORTER M. E., 1985, COMPETITIVE ADVANTAG##PORTER ME, 1996, HARVARD BUS REV, V74, P61##SCHOLZ C, 1987, LONG RANGE PLANN, V20, P78, DOI 10.1016/0024-6301(87)90158-0##TSAI WP, 2001, ACAD MANAGE J, V44, P996, DOI 10.2307/3069443##TSAI WP, 1998, ACAD MANAGE J, V41, P464, DOI 10.2307/257085##WILLIAMSON O. E., 1985, EC I CAPITALISM",1,2020-11-20,NA
J,WOS:000218083900006,2006,PERFORMANCE DIFFERENCES ACROSS STRATEGIC GROUPS: AN EXAMINATION OF FINANCIAL MARKET-BASED PERFORMANCE MEASURES,"ONE OF THE MORE INTERESTING ISSUES IN THE STRATEGIC MANAGEMENT FIELD IS THE QUESTION OF WHETHER INTRA-INDUSTRY PERFORMANCE DIFFERENCES EXIST, PARTICULARLY ACROSS STRATEGIC GROUPS. MOST OF THE EXISTING STUDIES HAVE USED ACCOUNTING MEASURES OF PERFORMANCE DESPITE THE DOCUMENTED WEAKNESSES OF SUCH MEASURES. THIS PAPER EXAMINES WHETHER FINANCIAL MARKET-BASED MEASURES OF PERFORMANCE ARE SUPERIOR TO ACCOUNTING-BASED MEASURES IN IDENTIFYING PERFORMANCE DIFFERENCES ACROSS STRATEGIC GROUPS. HYPOTHESES ARE TESTED ON DATA FROM AN EXISTING SAMPLE OF FIRMS IN THE US PHARMACEUTICAL INDUSTRY. THE EMPIRICAL RESULTS INDICATE THAT PERFORMANCE DIFFERENCES ARE MORE LIKELY TO EXIST ACROSS STRATEGIC GROUPS WHEN FINANCIAL MARKET PERFORMANCE MEASURES ARE USED. SUGGESTIONS FOR FURTHER REFINEMENTS ARE MADE AND LIMITATIONS OF THE STUDY ARE DISCUSSED. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",NA,NA,STRATEGIC CHANGE-BRIEFINGS IN ENTREPRENEURIAL FINANCE,"PANDIAN, JR##THOMAS, H##FURRER, O##BOGNER, WC","[PANDIAN, J. RAJENDRAN] UNIV WOLLONGONG, DEPT MANAGEMENT, WOLLONGONG, NSW, AUSTRALIA. [THOMAS, HOWARD] WARWICK BUSINESS SCH, COVENTRY, W MIDLANDS, ENGLAND. [FURRER, OLIVIER] NIJMEGEN SCH MANAGEMENT, NIJMEGEN, NETHERLANDS. [BOGNER, WILLIAM C.] GEORGIA STATE UNIV, DEPT MANAGEMENT, ATLANTA, GA 30303 USA.","BUSINESS, FINANCE",BUSINESS & ECONOMICS,"ATHANASSOPOULOS AD, 2003, J MANAGE STUD, V40, P921, DOI 10.1111/1467-6486.00365##BARNEY J.B., 2002, GAINING SUSTAINING C##BARNEY JB, 1990, MANAGE DECIS ECON, V11, P187, DOI 10.1002/MDE.4090110306##BOGNER W.C., 1994, STRATEGIC GROUPS STR, P299##BOGNER WC, 1996, STRATEGIC MANAGE J, V17, P85, DOI 10.1002/(SICI)1097-0266(199602)17:2<85::AID-SMJ785>3.0.CO;2-D##BOGNER WC, 1991, THESIS##BOGNER WC, 1992, DRUGS TO MARKET##CAVES RE, 1977, Q J ECON, V91, P421##CHAKRAVARTHY BS, 1986, STRATEGIC MANAGE J, V7, P437, DOI 10.1002/SMJ.4250070505##COOL K, 1993, STRATEGIC MANAGE J, V14, P47, DOI 10.1002/SMJ.4250140106##COOL K, 1988, STRATEGIC MANAGE J, V9, P207, DOI 10.1002/SMJ.4250090302##COOL KO, 1987, MANAGE SCI, V33, P1102, DOI 10.1287/MNSC.33.9.1102##DESS GG, 1984, ACAD MANAGE J, V27, P467, DOI 10.2307/256040##DOYLE P., 2000, VALUE BASED MARKETIN##DRANOVE D, 1998, STRATEGIC MANAGE J, V19, P1029, DOI 10.1002/(SICI)1097-0266(1998110)19:11<1029::AID-SMJ992>3.0.CO;2-L##FERGUSON TD, 2000, STRATEGIC MANAGE J, V21, P1195, DOI 10.1002/1097-0266(200012)21:12<1195::AID-SMJ138>3.0.CO;2-R##FIEGENBAUM A, 1995, STRATEGIC MANAGE J, V16, P461, DOI 10.1002/SMJ.4250160605##FIEGENBAUM A, 1990, STRATEGIC MANAGE J, V11, P197, DOI 10.1002/SMJ.4250110303##FIEGENBAUM A, 1987, MANAGE DECIS ECON, V8, P139, DOI 10.1002/MDE.4090080208##FIEGENBAUM A, 1990, J MANAGE STUD, V27, P133, DOI 10.1111/J.1467-6486.1990.TB00757.X##FIEGENBAUM A., 1987, THESIS##FRAZIER GL, 1983, J MARKETING, V47, P59, DOI 10.2307/1251493##GIBBS PA, 1993, STRATEGIC MANAGE J, V14, P51, DOI 10.1002/SMJ.4250140906##HATTEN KJ, 1987, STRATEGIC MANAGE J, V8, P329, DOI 10.1002/SMJ.4250080404##HAWAWINI G, 2003, STRATEGIC MANAGE J, V24, P1, DOI 10.1002/SMJ.278##HOSKISSON RE, 1993, STRATEGIC MANAGE J, V14, P215, DOI 10.1002/SMJ.4250140305##HUNT M.S., 1972, THESIS##JENSEN MC, 1976, J FINANC ECON, V3, P305, DOI 10.1016/0304-405X(76)90026-X##KEATS BW, 1988, J MANAGE, V16, P61##KETCHEN DJ, 1997, ACAD MANAGE J, V40, P223, DOI 10.2307/257028##LAWLESS MW, 1989, J MANAGE, V15, P649, DOI 10.1177/014920638901500412##LEE J, 2002, STRATEGIC MANAGE J, V23, P727, DOI 10.1002/SMJ.250##LUBATKIN M, 1986, ACAD MANAGE REV, V11, P497, DOI 10.2307/258307##MASCARENHAS B, 1989, STRATEGIC MANAGE J, V10, P475, DOI 10.1002/SMJ.4250100506##MCGEE J, 1986, STRATEGIC MANAGE J, V7, P141, DOI 10.1002/SMJ.4250070204##MCGEE J., 2003, OXFORD HDB STRATEGY, V1##NAIR A, 2001, STRATEGIC MANAGE J, V22, P221, DOI 10.1002/SMJ.154##NAYYAR PR, 1993, STRATEGIC MANAGE J, V14, P569, DOI 10.1002/SMJ.4250140802##OSBORNE JD, 2001, STRATEGIC MANAGE J, V22, P435, DOI 10.1002/SMJ.166##OSTER S, 1982, REV ECON STAT, V64, P376, DOI 10.2307/1925935##PALICH LE, 2000, STRATEGIC MANAGE J, V21, P155, DOI 10.1002/(SICI)1097-0266(200002)21:2<155::AID-SMJ82>3.0.CO;2-2##PORTER ME, 1979, REV ECON STAT, V61, P214, DOI 10.2307/1924589##RAPPAPORT A, 1986, CREATING SHAREHOLDER##TANG M., 1992, MANAGERIAL DECISION, V13, P323##TEECE DJ, 1997, STRATEGIC MANAGE J, V18, P509, DOI 10.1002/(SICI)1097-0266(199708)18:7<509::AID-SMJ882>3.0.CO;2-Z##THOMAS H, 1988, J MANAGE STUD, V25, P537, DOI 10.1111/J.1467-6486.1988.TB00046.X##WERNERFELT B, 1984, STRATEGIC MANAGE J, V5, P171, DOI 10.1002/SMJ.4250050207##ZUNIGA-VICENTE JA, 2004, J BUS RES, V57, P1378, DOI 10.1016/S0148-2963(03)00071-7",6,2020-11-20,NA
J,WOS:000241798800014,2006,TGF-BETA 1 POLYMORPHISMS AND RISK OF MYOCARDIAL INFARCTION AND STROKE - THE ROTTERDAM STUDY,"BACKGROUND AND PURPOSE-INFLAMMATION PLAYS A PIVOTAL ROLE IN THE PATHOGENESIS OF ATHEROSCLEROSIS AND OF CARDIOVASCULAR AND CEREBROVASCULAR COMPLICATIONS. TRANSFORMING GROWTH FACTOR-BETA 1 (TGF-BETA 1) IS A PLEIOTROPIC CYTOKINE WITH A CENTRAL ROLE IN INFLAMMATION. LITTLE IS KNOWN OF THE RELATION OF VARIATIONS WITHIN THE GENE AND RISK OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASE. WE THEREFORE INVESTIGATED 5 POLYMORPHISMS IN THE TGF-BETA 1 GENE (-800 G/A, -509 C/T, CODON 10 LEU/PRO, CODON 25 ARG/PRO, AND CODON 263 THR/ILE) IN RELATION TO THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN A POPULATION-BASED STUDY. METHODS-PARTICIPANTS (N=6456) OF THE ROTTERDAM STUDY WERE INCLUDED IN THE CURRENT STUDY. ANALYSES OF THE RELATIONS OF GENOTYPES WITH THE RISK OF MYOCARDIAL INFARCTION AND STROKE WERE PERFORMED ACCORDING TO COX PROPORTIONAL-HAZARDS METHODS. ALL ANALYSES WERE ADJUSTED FOR AGE, SEX, CONVENTIONAL CARDIOVASCULAR RISK FACTORS, AND MEDICAL HISTORY. RESULTS-WE FOUND NO ASSOCIATION WITH THE RISK OF MYOCARDIAL INFARCTION. A SIGNIFICANTLY INCREASED RISK OF STROKE WAS FOUND, ASSOCIATED WITH THE T ALLELE OF THE -509 C/T POLYMORPHISM, (RELATIVE RISK, 1.26; (95% CI, 1.06 TO 1.49) AND THE PRO VARIANT OF THE CODON 10 POLYMORPHISM (RELATIVE RISK, 1.24; 95% CI, 1.04 TO 1.48). CONCLUSIONS-NO ASSOCIATION BETWEEN THE TGF-BETA 1 POLYMORPHISMS AND MYOCARDIAL INFARCTION WAS OBSERVED; HOWEVER, THE -509 C/T AND CODON 10 LEU/PRO POLYMORPHISMS WERE ASSOCIATED WITH THE RISK OF STROKE.",GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 GENE; TGF-BETA; DISEASE; HYPERPLASIA; EXPRESSION,MYOCARDIAL INFARCTION; POLYMORPHISMS; STROKE; TRANSFORMING GROWTH FACTOR-BETA,STROKE,"SIE, MPS##UITTERLINDEN, AG##BOS, MJ##ARP, PP##BRETELER, MMB##KOUDSTAAL, PJ##POLS, HAP##HOFMAN, A##VAN DUIJN, CM##WITTEMAN, JCM","ERASMUS MC, DEPT EPIDEMIOL & BIOSTAT, NL-3000 CA ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT INTERNAL MED, NL-3000 CA ROTTERDAM, NETHERLANDS. ERASMUS MC, DEPT NEUROL, NL-3000 CA ROTTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY; PERIPHERAL VASCULAR DISEASE,NEUROSCIENCES & NEUROLOGY; CARDIOVASCULAR SYSTEM & CARDIOLOGY,"BOTS ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432##CAMBIEN F, 1996, HYPERTENSION, V28, P881, DOI 10.1161/01.HYP.28.5.881##CIPOLLONE F, 2004, STROKE, V35, P2253, DOI 10.1161/01.STR.0000140739.45472.9C##GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/NM0195-74##GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460A0##GRAINGER DJ, 1995, BIOL REV, V70, P571, DOI 10.1111/J.1469-185X.1995.TB01652.X##GRAINGER DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/HMG/8.1.93##HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007##HOLWEG CTJ, 2001, TRANSPLANTATION, V71, P1463, DOI 10.1097/00007890-200105270-00018##KANZAKI T, 1995, ARTERIOSCL THROM VAS, V15, P1951, DOI 10.1161/01.ATV.15.11.1951##MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/ANNUREV.CB.06.110190.003121##METCALFE JC, 1995, BIOCHEM SOC T, V23, P403, DOI 10.1042/BST0230403##NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027##OHJI T, 1995, THROMB HAEMOSTASIS, V73, P812##RAO M, 2004, KIDNEY INT, V66, P419, DOI 10.1111/J.1523-1755.2004.00748.X##ROBERTSON AKL, 2003, J CLIN INVEST, V112, P1342, DOI 10.1172/JCI200318607##ROSS R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207##SALTIS J, 1996, CLIN EXP PHARMACOL P, V23, P193, DOI 10.1111/J.1440-1681.1996.TB02595.X##SCHULICK AH, 1998, P NATL ACAD SCI USA, V95, P6983, DOI 10.1073/PNAS.95.12.6983##SIE MPS, 2006, ARTERIOSCL THROM VAS, V26, P212, DOI 10.1161/01.ATV.0000194099.65024.17##SYRRIS P, 1998, CLIN SCI, V95, P659, DOI 10.1042/CS0950659##TASHIRO H, 2002, CORONARY ARTERY DIS, V13, P139, DOI 10.1097/00019501-200205000-00001##VANBEMMEL JH, 1990, METHOD INFORM MED, V29, P346##WANG XL, 1998, CLIN SCI, V95, P745, DOI 10.1042/CS19980292##WANG XL, 1997, CARDIOVASC RES, V34, P404, DOI 10.1016/S0008-6363(97)00033-3##WHO WORLD HEALTH ORGANIZATION, 1992, INT STAT CLASS DIS R##WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070##YOKOTA M, 2000, CIRCULATION, V101, P2783, DOI 10.1161/01.CIR.101.24.2783",54,2020-11-20,NA
J,WOS:000241798800015,2006,"HIGH VON WILLEBRAND FACTOR LEVELS INCREASE THE RISK OF FIRST ISCHEMIC STROKE - INFLUENCE OF ADAMTS13, INFLAMMATION, AND GENETIC VARIABILITY","BACKGROUND AND PURPOSE-ELEVATED VON WILLEBRAND FACTOR (VWF) CONCENTRATIONS ARE ASSOCIATED WITH AN INCREASED RISK OF ISCHEMIC HEART DISEASE. SEVERAL FACTORS INFLUENCE VWF ANTIGEN LEVELS AND ACTIVITY, INCLUDING BLOOD GROUP, GENETIC VARIABILITY, ACUTE-PHASE RESPONSE, AND PROTEOLYSIS BY A DISINTEGRIN AND METALLOPROTEASE WITH THROMBOSPONDIN MOTIF (ADAMTS 13), A DETERMINANT OF PROTEOLYTIC CLEAVAGE OF VWF. WE ASSESSED HOW THESE FACTORS AFFECT THE RELATION BETWEEN VWF AND THE OCCURRENCE OF STROKE TO UNDERSTAND THE UNDERLYING MECHANISM. METHODS-IN A CASE-CONTROL STUDY OF 124 FIRST-EVER ISCHEMIC STROKE PATIENTS AND 125 AGE- AND SEX-MATCHED CONTROLS, WE STUDIED VWF ANTIGEN (VWF:AG), VWF RISTOCETIN COFACTOR ACTIVITY (VWF:RCO), ADAMTS13 ACTIVITY, THE -1793C/G POLYMORPHISM IN THE VWF GENE, AND C-REACTIVE PROTEIN. RESULTS-VWF ANTIGEN AND ACTIVITY LEVELS WERE SIGNIFICANTLY HIGHER IN CASES THAN IN CONTROLS. THE RELATIVE RISK OF ISCHEMIC STROKE WAS HIGHEST IN INDIVIDUALS IN THE UPPER QUARTILE OF VWF:AG (ODDS RATIO, 3.2; 95% CI, 1.4 TO 7.5) AND VWF:RCO (ODDS RATIO, 2.1; 95% CI, 0.9 TO 4.8) COMPARED WITH INDIVIDUALS IN THE LOWEST QUARTILES. IN INDIVIDUALS WITH ADAMTS 13 IN THE LOWEST QUARTILE, THE RELATIVE RISK OF STROKE WAS 1.7 (95% CI, 0.7 TO 3.9) COMPARED WITH THE HIGHEST QUARTILE. C-REACTIVE PROTEIN, ADAMTS 13, AND GENETIC VARIATION DID NOT AFFECT THE ASSOCIATION BETWEEN VWF AND THE RELATIVE RISK OF STROKE, WHEREAS BLOOD GROUP DID AFFECT THE ASSOCIATION. CONCLUSIONS-VWF ANTIGEN AND ACTIVITY ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE ISCHEMIC STROKE. THIS RELATION IS UNAFFECTED BY THE SEVERITY OF THE ACUTE-PHASE RESPONSE OR BY GENETIC VARIATION OR DEGRADATION.",THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; HEMOSTATIC FACTORS; FACTOR-VIII; POLYMORPHISM; MARKERS,ADAMTS13; HEMOSTASIS; ISCHEMIC STROKE; VON WILLEBRAND FACTOR,STROKE,"BONGERS, TN##DE MAAT, MPM##VAN GOOR, MLPJ##BHAGWANBALI, V##VAN VILET, HHDM##GARCIA, EBG##DIPPEL, DWJ##LEEBEEK, FWG","ERASMUS UNIV, MED CTR, DEPT HAEMATOL, NL-3015 GE ROTTERDAM, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT NEUROL, NL-3015 GE ROTTERDAM, NETHERLANDS.",CLINICAL NEUROLOGY; PERIPHERAL VASCULAR DISEASE,NEUROSCIENCES & NEUROLOGY; CARDIOVASCULAR SYSTEM & CARDIOLOGY,"CATTO AJ, 1997, THROMB HAEMOSTASIS, V77, P1104##DANESH J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMOA032804##FENG DL, 2001, CIRCULATION, V104, P140, DOI 10.1161/01.CIR.104.2.140##FOLSOM AR, 1999, CIRCULATION, V100, P736, DOI 10.1161/01.CIR.100.7.736##GILL JC, 1987, BLOOD, V69, P1691##HARVEY PJ, 2000, BRIT J HAEMATOL, V109, P349, DOI 10.1046/J.1365-2141.2000.02000.X##LEEBEEK FWG, 2005, J THROMB HAEMOST, V3, P2211, DOI 10.1111/J.1538-7836.2005.01484.X##LEVY GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008##LOOF AH, 2001, BRIT J HAEMATOL, V112, P1087, DOI 10.1046/J.1365-2141.2001.02622-5.X##MANNUCCI PM, 2004, BRIT J HAEMATOL, V126, P213, DOI 10.1111/J.1365-2141.2004.05009.X##MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306##MOHLKE KL, 1999, CELL, V96, P111, DOI 10.1016/S0092-8674(00)80964-2##NISHIO K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/PNAS.0402041101##SANCHEZ-LUCEROS A, 2004, THROMB HAEMOSTASIS, V92, P1320, DOI 10.1160/TH03-11-0683##SMITH FB, 1997, ARTERIOSCL THROM VAS, V17, P3321, DOI 10.1161/01.ATV.17.11.3321##SUADICANI P, 2002, J CARDIOVASC RISK, V9, P191, DOI 10.1097/00043798-200208000-00003##THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003##TSAI HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203##VAN DER MEER IM, 2004, BRIT J HAEMATOL, V124, P343, DOI 10.1046/J.1365-2141.2003.04776.X##VON BECKERATH N, 2004, BLOOD COAGUL FIBRIN, V15, P61, DOI 10.1097/00001721-200401000-00010##WOODWARD M, 2005, STROKE, V36, P2143, DOI 10.1161/01.STR.0000181754.38408.4C##ZHENG XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/JBC.C100515200",166,2020-11-20,NA
J,WOS:000241798800031,2006,MEDIUM-TERM VARIABILITY OF BLOOD PRESSURE AND POTENTIAL UNDERDIAGNOSIS OF HYPERTENSION IN PATIENTS WITH PREVIOUS TRANSIENT ISCHEMIC ATTACK OR MINOR STROKE,"BACKGROUND AND PURPOSE-BLOOD PRESSURE (BP) IS A MAJOR RISK FACTOR FOR STROKE. HOWEVER, THE VARIABILITY OF SYSTOLIC AND DIASTOLIC BP (SBP AND DBP) MEANS THAT SINGLE MEASUREMENTS DO NOT PROVIDE A RELIABLE MEASURE OF USUAL BP. ALTHOUGH 24-HOUR AMBULATORY BP MONITORING CAN CORRECT FOR THE EFFECTS OF SHORT-TERM VARIATION, THERE IS ALSO IMPORTANT MEDIUM-TERM VARIABILITY. THE EXTENT OF MEDIUM-TERM VARIABILITY IN BP IS MOST MARKED IN PATIENTS WITH A PREVIOUS TRANSIENT ISCHEMIC ATTACK (TIA) OR STROKE. WE STUDIED THE POTENTIAL IMPACT OF THIS VARIABILITY ON THE LIKELY RECOGNITION OF HYPERTENSION. METHODS-WE ANALYZED MULTIPLE REPEATED MEASUREMENTS OF BP IN 3 LARGE COHORTS WITH A TIA OR MINOR STROKE: THE UK-TIA TRIAL (N=2098), THE DUTCH TIA TRIAL (N=2953), AND THE EUROPEAN CAROTID SURGERY TRIAL (ECST; N=2646). REGRESSION DILUTION RATIOS AND COEFFICIENTS OF VARIATION WERE CALCULATED FOR SBP AND DBP FROM BASELINE AND REPEATED MEASUREMENTS DURING THE SUBSEQUENT 12 MONTHS. CATEGORIZATION BASED ON SINGLE BASELINE MEASUREMENTS WAS ALSO COMPARED WITH CATEGORIZATION BASED ON THE SUBSEQUENT ""USUAL"" BP. RESULTS-THE CORRELATION BETWEEN MEASUREMENTS OF BP AT BASELINE AND 3 TO 5 MONTHS LATER WAS POOR (R-2 FROM 0.17 TO 0.31 FOR SBP AND FROM 0.10 TO 0.20 FOR DBP). CATEGORIZATION OF PATIENTS BY BASELINE VALUES RESULTED IN SUBSTANTIAL MISCLASSIFICATION IN RELATION TO USUAL BP. FOR EXAMPLE, OF PATIENTS WITH AN SBP < 140 MM HG AT BASELINE, THE PERCENTAGE WITH A USUAL SBP >= 140 MM HG WAS 31.6% IN THE UK-TIA TRIAL, 48.2% IN THE DUTCH TIA TRIAL, AND 57.7% IN THE ECST. AT LEAST 3 CONSECUTIVE MEASUREMENTS OF SBP < 120 MM HG WERE REQUIRED TO BE > 90% CERTAIN THAT SUBSEQUENT USUAL SBP WOULD NOT BE >= 140 MM HG. CONCLUSIONS-GIVEN THE GREATER MEDIUM-TERM VARIABILITY OF BP IN PATIENTS WITH A PREVIOUS TIA OR STROKE THAN IN THE GENERAL POPULATION, SINGLE MEASUREMENTS OF ""NORMAL"" OR ""LOW"" BP WILL SUBSTANTIALLY UNDERESTIMATE THE TRUE PREVALENCE OF HYPERTENSION.",WITHIN-PERSON VARIABILITY; REGRESSION DILUTION; WHITE-COAT; FOLLOW-UP; RISK,HYPERTENSION; PREVENTION; RISK FACTORS; STROKE,STROKE,"CUFFE, RL##HOWARD, SC##ALGRA, A##WARLOW, CP##ROTHWELL, PM","UNIV OXFORD, DEPT CLIN NEUROL, STROKE PREVENT RES UNIT, OXFORD, ENGLAND. UNIV UTRECHT, MED CTR, RUDOLF MAGNUS INST NEUROSCI, DEPT NEUROL, UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS. UNIV EDINBURGH, DEPT CLIN NUTR, EDINBURGH, MIDLOTHIAN, SCOTLAND.",CLINICAL NEUROLOGY; PERIPHERAL VASCULAR DISEASE,NEUROSCIENCES & NEUROLOGY; CARDIOVASCULAR SYSTEM & CARDIOLOGY,"CELIS H, 2002, BLOOD PRESSURE, V11, P352, DOI 10.1080/080370502321095311##CICCONETTI P, 2000, ARCH GERONTOL GERIAT, V30, P225, DOI 10.1016/S0167-4943(00)00052-2##CLARKE R, 1999, AM J EPIDEMIOL, V150, P341##DONNAN GA, 2003, J HYPERTENS, V21, PS25, DOI 10.1097/00004872-200306005-00006##ESPOSTI LD, 2004, PHARMACOECONOMICS, V22, P907##FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/JNNP.54.12.1044##FARRELL B, 1998, LANCET, V351, P1379, DOI 10.1016/S0140-6736(97)09292-1##*GUID SUBC, 1999, BLOOD PRESSURE, V8, P1##HATA Y, 2000, HYPERTENS RES, V23, P553, DOI 10.1291/HYPRES.23.553##HEBEL JR, 1980, J CHRON DIS, V33, P745, DOI 10.1016/0021-9681(80)90062-4##HOWARD SC, 2003, J CLIN EPIDEMIOL, V56, P1084, DOI 10.1016/S0895-4356(03)00267-1##IMAI Y, 1997, AM J HYPERTENS, V10, P1281, DOI 10.1016/S0895-7061(97)00277-X##KLUNGEL OH, 2000, J CLIN EPIDEMIOL, V53, P1158, DOI 10.1016/S0895-4356(00)00228-6##KLUNGEL OH, 1999, STROKE, V30, P1312, DOI 10.1161/01.STR.30.7.1312##LEWINGTON S, 2002, LANCET, V360, P1903##MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9##MACMAHON S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5##OHKUBO T, 2005, J AM COLL CARDIOL, V46, P508, DOI 10.1016/J.JACC.2005.03.070##PICKERING TG, 2005, CIRCULATION, V111, P697, DOI [10.1161/01.CIR.0000154900.76284.F6, 10.1161/01.HYP.0000150859.47929.8E]##RAMSAY LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/SJ.JHH.1000917##ROBINSON T, 1997, CEREBROVASC DIS, V7, P214, DOI 10.1159/000108194##RODGERS A, 1998, LANCET, V352, P1801##RODGERS A, 1996, BRIT MED J, V313, P147, DOI 10.1136/BMJ.313.7050.147##ROMAN MJ, 2001, ARTERIOSCL THROM VAS, V21, P1507, DOI 10.1161/HQ0901.095149##ROSNER B, 1979, J CHRON DIS, V32, P451, DOI 10.1016/0021-9681(79)90105-X##ROSNER B, 1983, AM J EPIDEMIOL, V117, P429, DOI 10.1093/OXFORDJOURNALS.AJE.A113561##ROTHWELL PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2##SHEPARD DS, 1981, J CHRON DIS, V34, P191, DOI 10.1016/0021-9681(81)90064-3##STRAESSEN J, 1990, J HYPERTENS, V8, P393##TURNBULL F, 2003, LANCET, V362, P1527##VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801##VERDECCHIA P, 2005, HYPERTENSION, V45, P203, DOI 10.1161/01.HYP.0000151623.49780.89##1997, ARCH INTERN MED, V157, P2413",24,2020-11-20,NA
J,WOS:000241551700003,2006,AN AUGMENTED LAGRANGIAN OPTIMIZATION METHOD FOR INFLATABLE STRUCTURES ANALYSIS PROBLEMS,"THIS PAPER DESCRIBES THE DEVELOPMENT OF AN AUGMENTED LAGRANGIAN OPTIMIZATION METHOD FOR THE NUMERICAL SIMULATION OF THE INFLATION PROCESS IN THE DESIGN OF INFLATABLE SPACE STRUCTURES. ALTHOUGH THE NEWTON-RAPHSON SCHEME WAS PROVEN TO BE EFFICIENT FOR SOLVING MANY NONLINEAR PROBLEMS, IT CAN LEAD TO LACK OF CONVERGENCE WHEN IT IS APPLIED TO THE SIMULATION OF THE INFLATION PROCESS. AS A RESULT, IT IS RECOMMENDED TO USE AN OPTIMIZATION ALGORITHM TO FIND THE MINIMUM ENERGY CONFIGURATION THAT SATISFIES THE EQUILIBRIUM EQUATIONS CHARACTERIZING THE FINAL SHAPE OF THE INFLATED STRUCTURE SUBJECT TO AN INTERNAL PRESSURE. ON TOP OF THAT, GIVEN THAT SOME DEGREES OF FREEDOM MAY BE LINKED, THE OPTIMUM MAY BE CONSTRAINED, AND SPECIFIC OPTIMIZATION METHODS FOR CONSTRAINED PROBLEMS MUST BE CONSIDERED. THE PAPER PRESENTS THE FORMULATION AND THE AUGMENTED LAGRANGIAN METHOD (ALM) DEVELOPED IN SAMCEF MECANO FOR INFLATABLE STRUCTURES ANALYSIS PROBLEMS. THE RELATED QUASI-UNCONSTRAINED OPTIMIZATION PROBLEM IS SOLVED WITH A NONLINEAR CONJUGATE GRADIENT METHOD. THE WOLFE CONDITIONS ARE USED IN CONJUNCTION WITH A CUBIC INTERPOLATION FOR THE LINE SEARCH. EQUALITY CONSTRAINTS ARE CONSIDERED AND CAN BE EASILY TREATED BY THE ALM FORMULATION. NUMERICAL APPLICATIONS PRESENT SIMULATIONS OF UNCONSTRAINED AND CONSTRAINED INFLATION PROCESSES (I.E., WHERE THE MOTION OF SOME NODES IS RULED BY A RIGID BODY ELEMENT RESTRICTION AND/OR PROBLEMS INCLUDING CONTACT CONDITIONS).",ENERGY MINIMIZATION; FORMULATION,AUGMENTED LAGRANGIAN METHOD; CONJUGATE GRADIENTS METHOD; INFLATABLE STRUCTURES; CONTACT,STRUCTURAL AND MULTIDISCIPLINARY OPTIMIZATION,"BRUYNEEL, M##JETTEUR, P##GRANVILLE, D##LANGLOIS, S##FLEURY, C","SAMTECH SA, LIEGE, BELGIUM. ESTEC, TEC MCS, NOORDWIJK, NETHERLANDS. UNIV LIEGE, ASMA DEPT, LIEGE, BELGIUM.","COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; ENGINEERING, MULTIDISCIPLINARY; MECHANICS",COMPUTER SCIENCE; ENGINEERING; MECHANICS,"BAGINSKI F, 1995, AIAA J, V33, P764, DOI 10.2514/3.12407##BAGINSKI FE, 2003, AIAA J, V41, P304, DOI 10.2514/2.1945##BOUZIDI R, 2004, COMPUT STRUCT, V82, P1961, DOI 10.1016/J.COMPSTRUC.2004.03.057##BRUYNEEL M, 2002, STRUCT MULTIDISCIP O, V24, P263, DOI 10.1007/S00158-002-0238-7##BRUYNEEL M, 2005, EUR C SPAC STRUCT MA##BRUYNEEL M, 2005, INT C TEXT COMP INFL##FREDERIC BONNANS J, 2003, NUMERICAL OPTIMIZATI##GILL P.E., 1981, PRACTICAL OPTIMIZATI##JETTEUR P, 2003, THIN MEMBRANE ELEMEN##LITTLE GH, 1987, COMPUT STRUCT, V26, P871, DOI 10.1016/0045-7949(87)90037-X##MIJAR AR, 2004, STRUCT MULTIDISCIP O, V28, P99, DOI 10.1007/S00158-004-0423-Y##MORRIS AJ, 1982, FDN STRUCTURAL OPTIM##NOCEDAL J, 1999, SPRINGER SERIES OPER##ONATE E, 2005, INT C TEXT COMP INFL##SCHMIT LA, 1980, AIAA J, V18, P1252, DOI 10.2514/3.50877##TIELKING JT, 1974, J APPL MECH-T ASME, V41, P491, DOI 10.1115/1.3423315##TROUFFLARD J, 2005, INT C TEXT COMP INFL",3,2020-11-20,NA
J,WOS:000242598700003,2006,SPATIAL PERIODIC CONTACT STRESS AND CRITICAL CURRENT OF A NB3SN STRAND MEASURED IN TARSIS,"WE HAVE DEVELOPED A NEW PROBE FOR TESTING THE INFLUENCE OF LOCAL CONTACT LOAD FROM CROSSING SUPERCONDUCTING NB3SN STRANDS. THE PROBE IS PART OF THE TARSIS SETUP FOR STRAND STRESS-STRAIN CHARACTERIZATION. THE RESULTS FROM THE TARSIS SETUP WITH DIFFERENT PROBES DEVELOPED FOR THE CHARACTERIZATION OF AXIAL TENSILE STRESS-STRAIN, SPATIAL PERIODIC BENDING, CONTACT FROM CROSSING STRANDS AND HOMOGENEOUS TRANSVERSE LOAD ENABLE DISCRIMINATION IN PERFORMANCE REDUCTION PER SPECIFIC LOAD TYPE AND PER STRAND TYPE. IN PARTICULAR, THE ELECTROMAGNETIC CHARGING OF NB3SN CABLE IN CONDUIT CONDUCTORS (CICC) CAUSES TRANSVERSE CONTACT AND BENDING STRAINS IN THE WIRES AND HENCE IN THE NB3SN FILAMENTS. MORE THAN EVER, FOR HIGH ELECTROMAGNETIC LOADS, SUCH AS IN THE CONDUCTORS DESIGNED FOR THE INTERNATIONAL THERMONUCLEAR EXPERIMENTAL REACTOR (ITER), THE TRANSVERSE LOAD CAUSES SIGNIFICANT LOCAL STRAIN CONCENTRATIONS IN COMBINATION WITH STRAIN DIFFERENCES DUE TO THE THERMAL CONTRACTION OF THE COMPOSITE MATERIALS. THESE HIGH LOCAL STRAINS IN THE STRANDS DEGRADE THE SUPERCONDUCTING PROPERTIES SIGNIFICANTLY. WE REPORT ON THE DESIGN OF THE PROBE AND THE FIRST RESULTS DEMONSTRATING THE INFLUENCE OF PERIODIC TRANSVERSE CONTACT LOAD FROM CROSSING STRANDS, USING A WAVELENGTH OF 5 MM ON AN NB3SN POWDER-IN-TUBE PROCESSED STRAND. THE CYCLIC BEHAVIOUR IN TERMS OF CRITICAL CURRENT AND N-VALUE INVOLVES A COMPONENT REPRESENTING A PERMANENT REDUCTION AS WELL AS A FACTOR EXPRESSING REVERSIBLE (ELASTIC) BEHAVIOUR AS A FUNCTION OF THE APPLIED LOAD. THE RESULTS OF THE PROBE ARE USED AS INPUT FOR THE MECHANICAL AND ELECTROMAGNETIC MODELLING OF A FULL-SIZE ITER NB3SN CONDUCTOR IN ORDER TO OPTIMIZE THE FINAL CABLE DESIGN.",TRANSVERSE STRESS; VOID FRACTION; CONDUCTORS; IMPACT,NA,SUPERCONDUCTOR SCIENCE & TECHNOLOGY,"NIJHUIS, A##ILYIN, Y##WESSEL, WAJ","UNIV TWENTE, FAC SCI & TECHNOL, LOW TEMP DIV, NL-7500 AE ENSCHEDE, NETHERLANDS.","PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",PHYSICS,"BOSCHMAN H, 1990, ADV CRYOGEN ENG, V36, P93##BRAY SL, 1992, ADV CRYOG ENG, V38, P643##EKIN JW, 1991, J APPL PHYS, V69, P4436, DOI 10.1063/1.348372##EKIN JW, 1980, P TOP C A15 SUP, P187##EKIN JW, 1988, ADV CRYOG ENG MAT, V34, P547##ILYIN Y, 2006, IEEE T APPL SUPERCON, V16, P1249, DOI 10.1109/TASC.2006.870801##MITCHELL N, 2005, SUPERCOND SCI TECH, V18, PS396, DOI 10.1088/0953-2048/18/12/029##MITCHELL N, 2006, ASSESSMENT CONDUCTOR##NIJHUIS A, 2005, SUPERCOND SCI TECH, V18, PS273, DOI 10.1088/0953-2048/18/12/009##NIJHUIS A, 2006, SUPERCOND SCI TECH, V19, P945, DOI 10.1088/0953-2048/19/9/011##NIJHUIS A, 2005, IEEE T APPL SUPERCON, V15, P1633, DOI 10.1109/TASC.2005.849214##NIJHUIS A, 2006, IN PRESS SUPERCOND S, V19##PASZTOR G, 1994, IEEE T MAGN, V30, P1938, DOI 10.1109/20.305643##SPECKING W, 1988, ADV CRYOGEN ENG, V34, P569##VAN DEN EIJNDEN NC, 2005, SUPERCOND SCI TECH, V18, P1523, DOI 10.1088/0953-2048/18/11/020##VANOORT JM, 2000, THESIS U TWENTE##WESSEL WAJ, 2004, AIP CONF PROC, V711, P466##ZANINO R, 2005, SUPERCOND SCI TECH, V18, PS376, DOI 10.1088/0953-2048/18/12/026",32,2020-11-20,NA
J,WOS:000242598700010,2006,CRITICAL CURRENT AND STRAND STIFFNESS OF THREE TYPES OF NB3SN STRAND SUBJECTED TO SPATIAL PERIODIC BENDING,"KNOWLEDGE OF THE INFLUENCE OF BENDING ON THE CRITICAL CURRENT (I-C) OF NB3SN STRANDS IS ESSENTIAL FOR THE UNDERSTANDING OF THE REDUCTION IN PERFORMANCE DUE TO TRANSVERSE ELECTROMAGNETIC LOAD. IN PARTICULAR, FOR THE LARGE CABLE-IN-CONDUIT CONDUCTORS (CICCS) MEANT FOR THE INTERNATIONAL THERMONUCLEAR EXPERIMENTAL REACTOR (ITER), WE EXPECT THAT BENDING IS THE DOMINANT MECHANISM FOR THIS DEGRADATION. WE HAVE MEASURED THE IC OF A BRONZE, A POWDER-IN-TUBE AND AN INTERNAL TIN PROCESSED NB3SN STRAND WHEN SUBJECTED TO SPATIAL PERIODIC BENDING USING BENDING WAVELENGTHS FROM 5 TO 10 MM. TWO OF THESE STRANDS WERE APPLIED IN MODEL COILS FOR THE ITER. WE FOUND THAT THE TESTED STRANDS BEHAVE ACCORDING TO THE SO-CALLED LOW INTERFILAMENT RESISTIVITY LIMIT, CONFIRMING FULL CURRENT TRANSFER BETWEEN THE FILAMENTS. THIS IS SUPPORTED BY AC COUPLING LOSS MEASUREMENTS GIVING AN INDICATION OF THE INTERFILAMENT CURRENT TRANSFER LENGTH. THE REDUCTION OF IC DUE TO BENDING STRAIN CAN THEN BE SIMPLY DERIVED FROM THE BENDING AMPLITUDE AND THE IC VERSUS AXIAL APPLIED STRAIN (EPSILON) RELATION. THIS I-C(EPSILON) SENSITIVITY CAN VARY FOR DIFFERENT STRAND TYPES BUT SINCE THE ELECTROMAGNETIC FORCE IS THE DRIVING PARAMETER FOR STRAND BENDING IN A CICC, THE STIFFNESS OF THE STRANDS DEFINITIVELY PLAYS A KEY ROLE, WHICH IS CONFIRMED BY THE RESULTS PRESENTED.",CRITICAL-CURRENT DENSITY; MULTIFILAMENTARY SUPERCONDUCTORS; VOID FRACTION; TEMPERATURE; CONDUCTORS; DEPENDENCE; BEHAVIOR; LOSSES; STRESS; IMPACT,NA,SUPERCONDUCTOR SCIENCE & TECHNOLOGY,"NIJHUIS, A##ILYIN, Y##WESSEL, WAJ##ABBAS, W","UNIV TWENTE, FAC SCI & TECHNOL, LOW TEMP DIV, NL-7500 AE ENSCHEDE, NETHERLANDS.","PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",PHYSICS,"BRUZZONE P., 1996, ADV CRYOG ENG MAT, V42B, P1351##CAMPBELL AM, 1982, CRYOGENICS, V22, P3, DOI 10.1016/0011-2275(82)90015-7##EKIN JW, 1978, J APPL PHYS, V49, P3406, DOI 10.1063/1.325245##EKIN JW, 1980, P TOP C A15 SUP, P187##EKIN JW, 1988, ADV CRYOG ENG MAT, V34, P547##GODEKE A, 2004, REV SCI INSTRUM, V75, P5112, DOI 10.1063/1.1819384##HOJO M, 2004, PHYSICA C, V412, P1261, DOI 10.1016/J.PHYSC.2004.02.218##ILYIN Y, 2006, IEEE T APPL SUPERCON, V16, P1249, DOI 10.1109/TASC.2006.870801##KATAGIRI K, 2001, PHYSICA C, V357, P1302, DOI 10.1016/S0921-4534(01)00482-8##KNOOPERS HGM, 1997, P EUCAS 97 VELDHOVEN, V158, P1271##LEE PJ, 1997, UW TESTING METHODS C##MITCHELL N, 2005, SUPERCOND SCI TECH, V18, PS396, DOI 10.1088/0953-2048/18/12/029##MITCHELL N, 2005, CRYOGENICS, V45, P501, DOI 10.1016/J.CRYOGENICS.2005.06.003##MITCHELL N, 2004, PHYSICA C, V401, P28, DOI 10.1016/J.PHYSC.2003.09.008##MITCHELL N, 2003, FUSION ENG DES, V66-68, P971, DOI 10.1016/S0920-3796(03)00237-0##MITCHELL N, 2006, IN PRESS SUPERCOND S, V19##NIJHUIS A, 2006, SUPERCOND SCI TECH, V19, P1089, DOI 10.1088/0953-2048/19/11/001##NIJHUIS A, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2195118##NIJHUIS A, 2005, SUPERCOND SCI TECH, V18, PS273, DOI 10.1088/0953-2048/18/12/009##NIJHUIS A, 2006, SUPERCOND SCI TECH, V19, P945, DOI 10.1088/0953-2048/19/9/011##NIJHUIS A, 2005, IEEE T APPL SUPERCON, V15, P1633, DOI 10.1109/TASC.2005.849214##NIJHUIS A, 2005, IEEE T APPL SUPERCON, V15, P3466, DOI 10.1109/TASC.2005.849060##NIJHUIS A, 2004, IEEE T APPL SUPERCON, V14, P1464, DOI 10.1109/TASC.2004.830654##NYILAS A, 2006, AIP CONF PROC, V824, P582##RIES G, 1977, IEEE T MAGN, V13, P524, DOI 10.1109/TMAG.1977.1059310##TAYLOR DMJ, 2005, SUPERCOND SCI TECH, V18, PS241, DOI 10.1088/0953-2048/18/12/005##ULBRICHT A, 2003, FUSION ENG DES, V66-68, P103, DOI 10.1016/S0920-3796(03)00140-6##VAN DEN EIJNDEN NC, 2005, SUPERCOND SCI TECH, V18, P1523, DOI 10.1088/0953-2048/18/11/020##VERWEIJ AP, 1993, SUPERCOLLIDER, V5, P587##WESSEL WAJ, 2004, AIP CONF PROC, V711, P466##ZANINO R, 2005, SUPERCOND SCI TECH, V18, PS376, DOI 10.1088/0953-2048/18/12/026##ZANINO R, 2004, IEEE T APPL SUPERCON, V14, P1519, DOI 10.1109/TASC.2004.830682",42,2020-11-20,NA
J,WOS:000242126200002,2006,INTERNATIONAL INTEGRATED DATABASE FOR THE EVALUATION OF SEVERE SEPSIS AND DROTRECOGIN ALFA (ACTIVATED) THERAPY: ANALYSIS OF EFFICACY AND SAFETY DATA IN A LARGE SURGICAL COHORT,"BACKGROUND. THE INTERNATIONAL INTEGRATED DATABASE FOR THE EVALUATION OF SEVERE SEPSIS AND DROTRECOGIN A FA (ACTIVATED) THERAPY INCLUDES AN EXTENSIVE COHORT OF SURGICAL PATIENTS (165914459; 37%). THIS DATABASE BROADENS THE EXPERIENCE REPORTED ON A COMPARATIVELY SMALL SET OF SURGICAL PATIENTS FROM THE PIVOTAL PROTEIN C WORLDWIDE EVALUATION IN SEVERE SEPSIS TRIAL TO EXAMINE ISSUES OF SAFETY AND EFFICACY IN A MUCH LARGER COHORT. METHODS. WE CONDUCTED A RETROSPECTIVE ANALYSIS OF PROSPECTIVELY DEFINED OUTCOMES FROM 5 INTEGRATED CLINICAL STUDIES OF SEVERE SEPSIS. MULTIVARIABLE ANALYSES INCORPORATED PROPENSITY SCORES, TREATMENT, AND SIGNIFICANT BASELINE RISK FACTORS AS INDEPENDENT VARIABLES IN LOGISTIC REGRESSION MODELS FOR 2 OUTCOMES: SERIOUS ADVERSE EVENTS THAT WERE OBSERVED DURING INFUSION AND 28-DAY, ALL-CAUSE MORTALITY RATES. ADJUSTED ODDS RATIOS WERE CALCULATED FOR CLINICALLY IMPORTANT STRATA. MULTIPLE SUBCATEGORIES OF SERIOUS BLEEDING-EVENT RATES ARE PRESENTED. RESULTS. ALTHOUGH SURGICAL PATIENTS WHO WERE TREATED WITH DROTRECOGIN A (A [ACTIVATED] (DROTAA) EXPERIENCED A GREATER PROPORTION OF SERIOUS BLEEDING EVENTS DURING THE INFUSION PERIOD, MOST OF THE PATIENTS WERE TREATED WITHOUT FATAL CONSEQUENCE. A 10.7% ABSOLUTE ALL CAUSE MORTALITY RISK REDUCTION (ADJUSTED ODDS RATIO, 0.66; 95% CI, 0.45-0.97) WAS OBSERVED FOR DROTAA-TREATED, HIGH-RISK (ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION II, >= 25) SURGICAL PATIENTS. WE COULD NOT DEMONSTRATE A SURVIVAL BENEFIT IN DROLAA-TREATED, LOW-RISK (ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION II, < 25) SURGICAL PATIENTS. WHEN SURGICAL PATIENTS WERE STRATIFIED BY NUMBER OF ORGAN DYSFUNCTIONS, ABSOLUTE RISK REDUCTIONS WERE OBSERVED IN BOTH CATEGORIES: MULTIORGAN (4.3%) AND SINGLE (4.5%). CONCLUSION. INTERNATIONAL INTEGRATED DATABASE FOR THE EVALUATION OF SEVERE SEPSIS AND DROTRECOGIN A FA (ACTIVATED) THERAPY ANALYSES AFFIRMED THE FAVORABLE BENEFITLRISK PROFILE OF DROTAA FOR SURGICAL PATIENTS. THE SERIOUS ADVERSE EVENT RATE THAT WAS EXPERIENCED BY SURGICAL PATIENTS DURING THE STUDY DRUG INFUSION PERIOD WAS 7.5 % IN THE DROTAA-TREATED GROUP VERSUS 6 3 % IN THE PLACEBO-TREATED GROUP (ODDS RATIO, 1. 41; 95 % CI, 0. 89-2.25). THE CLINICAL BENEFIT OF DROTAA THERAPY PARALLELED BASELINE RISK OF DEATH AND SUBSTANTIATED FINDINGS FROM THE PROTEIN C WORLDWIDE EVALUATION IN SEVERE SEPSIS STUDY. FUTURE ANALYSES ARE NEEDED TO EVALUATE THE SPECIAL RELATIONSHIPS AMONG SEPSIS SEVERITY, BLEEDING MANAGEMENT, AND THE POSTOPERATIVE TIMING OF DROTAA ADMINISTRATION.",SECRETORY PHOSPHOLIPASE A(2); PROTEIN-C; SELECTIVE INHIBITOR; MEDICAL DICTIONARY; TRIAL ENHANCE; LY315920NA/S-5920; COAGULOPATHY; INFLAMMATION; MORTALITY; SCORE,NA,SURGERY,"PAYEN, D##SABLOTZKI, A##BARIE, PS##RAMSAY, G##LOWRY, S##WILLIAMS, M##SARWAT, S##NORTHRUP, J##TOLAND, P##BOOTH, FVM","LAROBOISIERE UNIV HOSP, DEPT ANESTHESIOL & CRIT CARE, F-75010 PARIS, FRANCE. UNIV HALLE WITTENBERG, CLIN ANESTHESIOL & INTENS CARE MED, D-4010 HALLE, GERMANY. CORNELL UNIV, WILL MED COLL, DEPT SURG, DIC CRIT CARE & TRAUMA, ITHACA, NY 14853 USA. CORNELL UNIV, WILL MED COLL, DEPT PUBL HLTH, DIC CRIT CARE & TRAUMA, ITHACA, NY 14853 USA. ATRIUM MED CTR, HEERLEN, NETHERLANDS. ROBERT WOOD JOHNSON MED CTR, DEPT SURG, NEW BRUNSWICK, NJ USA. ELI LILLY & CO, CRIT CARE DIV, INDIANAPOLIS, IN 46285 USA.",SURGERY,SURGERY,"ABRAHAM E, 2003, CRIT CARE MED, V31, P718, DOI 10.1097/01.CCM.0000053648.42884.89##ABRAHAM E, 2005, NEW ENGL J MED, V353, P1332, DOI 10.1056/NEJMOA050935##ANGUS DC, 2003, CRIT CARE MED, V31, P1, DOI 10.1097/00003246-200301000-00001##ASSMANN SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0##BARIE PS, 2004, AM J SURG, V188, P212, DOI 10.1016/J.AMJSURG.2004.06.008##BEILMAN GREG J, 2004, SURG INFECT (LARCHMT), V5, P289, DOI 10.1089/SUR.2004.5.289##BERNARD GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003##BERNARD GR, 2004, CHEST, V125, P2206, DOI 10.1378/CHEST.125.6.2206##BERNARD GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001##BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/CHEST.101.6.1644##BROWN EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018-199920020-00002##BROWN EG, 2003, DRUG SAFETY, V26, P145, DOI 10.2165/00002018-200326030-00002##D'AGOSTINO RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B##DELLINGER RP, 2004, CRIT CARE MED, V32, P1448##DELLINGER RP, 2004, CRIT CARE MED, V32, P2169##DERHASCHNIG U, 2003, BLOOD, V102, P2093, DOI 10.1182/BLOOD-2003-02-0416##DHAINAUT JF, 2004, J THROMB HAEMOST, V2, P1924, DOI 10.1111/J.1538-7836.2004.00955.X##DHAINAUT JFO, 2003, THROMB HAEMOSTASIS, V90, P642, DOI 10.1160/TH02-11-0270##FRY DE, 2003, SOURCE CONTROL GUIDE, P53##FRY DONALD E, 2004, SURG INFECT (LARCHMT), V5, P253, DOI 10.1089/SUR.2004.5.253##GARRISON RN, 1998, ANN SURG, V227, P851, DOI 10.1097/00000658-199806000-00008##GULLER U, 2004, J AM COLL SURGEONS, V198, P441, DOI 10.1016/J.JAMCOLLSURG.2003.09.017##JOFFE MM, 1999, AM J EPIDEMIOL, V150, P327##JOYCE DE, 2002, CRIT CARE MED, V30, PS288, DOI 10.1097/00003246-200205001-00019##KALIL AC, 2004, SHOCK, V21, P222, DOI 10.1097/01.SHK.0000116778.27924.79##KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009##LEVI M, 2003, J THROMB THROMBOLYS, V16, P43, DOI 10.1023/B:THRO.0000014592.27892.11##LEVI M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807##MACIAS WL, 2004, CRIT CARE MED, V32, PS223, DOI 10.1097/01.CCM.0000126120.49367.AC##MANNS BJ, 2002, NEW ENGL J MED, V347, P993, DOI 10.1056/NEJMSA020969##MERLINO JAMES I, 2004, SURG INFECT (LARCHMT), V5, P21, DOI 10.1089/109629604773860273##NICK JA, 2004, BLOOD, V104, P3878, DOI 10.1182/BLOOD-2004-06-2140##PITTAS AG, 2004, ARCH INTERN MED, V164, P2005, DOI 10.1001/ARCHINTE.164.18.2005##RIVERS E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMOA010307##RUBIN DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_PART_2-199710151-00064##SASHEGYI A, 2006, CURR MED RES OPIN, V22, P1001, DOI 10.1185/030079906X104713##SIMON R, 1982, BRIT J CLIN PHARMACO, V14, P473, DOI 10.1111/J.1365-2125.1982.TB02015.X##TALMOR M, 1999, ARCH SURG-CHICAGO, V134, P81, DOI 10.1001/ARCHSURG.134.1.81##VINCENT JL, 2005, CRIT CARE MED, V33, P2266, DOI 10.1097/01.CCM.0000181729.46010.83##VINCENT JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/S001340050156##VINCENT JL, 2002, CRIT CARE, V6, PS1, DOI 10.1186/CC1860##ZEIHER BG, 2005, CRIT CARE MED, V33, P1741, DOI 10.1097/01.CCM.0000171540.54520.69",19,2020-11-20,NA
J,WOS:000242379400030,2006,TECHNIQUE FOR INSTANT STAPLING OF THE SIGMOID MESENTERY AND MESORECTUM IN LAPAROSCOPIC COLORECTAL SURGERY,"BACKGROUND: DISSECTION OF THE MESENTERY OF THE DISTAL SIGMOID OR RECTUM BEFORE TRANSECTION WITH A LINEAR STAPLER IN LAPAROSCOPIC COLORECTAL SURGERY IS TIME CONSUMING, CAN CAUSE IRRITATING BLEEDING, AND CAN HARM THE VASCULARIZATION OF THE DISTAL PART OF THE BOWEL ANASTOMOSIS. METHODS: A NEW LINEAR STAPLING TECHNIQUE IN LAPAROSCOPIC COLORECTAL SURGERY IS PRESENTED. THIS TECHNIQUE IS USED TO PERFORM TRANSECTION OF THE DISTAL SIGMOID OR PROXIMAL RECTUM WITH A LINEAR STAPLER BY INSTANT STAPLING OF BOTH THE MESENTERY/MESORECTAL FAT AND THE INTESTINE INSTEAD OF STANDARD PRELIMINARY DISSECTION. THIS TECHNIQUE WAS PERFORMED IN A PILOT STUDY OF 27 LAPAROSCOPIC COLORECTAL OPERATIONS FOR BENIGN OR MALIGNANT DISEASE. RESULTS: IN NONE OF THE 27 PATIENTS WAS LEAKAGE OF THE ANASTOMOSIS OBSERVED. CONCLUSIONS: THIS NEW TECHNIQUE IS SAFE AND EFFECTIVE. IT SAVES TIME, AVOIDS TROUBLESOME DISSECTION OF THE MESENTERY/MESORECTUM, WHICH CAN CAUSE BLEEDING OR DAMAGE TO THE BOWEL, AND PRESERVES VASCULARIZATION OF THE DISTAL PART OF THE ANASTOMOSIS.",NA,ANASTOMOSIS; COLORECTAL SURGERY; INSTANT STAPLING TECHNIQUE; LAPAROSCOPIC SURGERY; STAPLING TECHNIQUE,SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES,"VAN DEURZEN, DFP##MANNAERTS, GHH##LANGE, JF","ST FRANCISCUS GASTHUIS, DEPT SURG, ROTTERDAM, NETHERLANDS. MED CTR RIJNMOND ZUID, DEPT SURG, ROTTERDAM, NETHERLANDS.",SURGERY,SURGERY,"JACOBS M, 1991, SURG LAPAROSC ENDOSC, V1, P144##VELDKAMP R, 2004, SURG ENDOSC, V18, P1163, DOI 10.1007/S00464-003-8253-3",3,2020-11-20,NA
J,WOS:000241842600002,2006,PROBABILITY ALL THE WAY UP,"RICHARD JEFFREY'S RADICAL PROBABILISM ('PROBABILITY ALL THE WAY DOWN') IS AUGMENTED BY THE CLAIM THAT PROBABILITY CANNOT BE TURNED INTO CERTAINTY, EXCEPT BY DATA THAT LOGICALLY EXCLUDE ALL ALTERNATIVES. ONCE WE START BEING UNCERTAIN, NO AMOUNT OF UPDATING WILL FREE US FROM THE TREADMILL OF UNCERTAINTY. THIS CLAIM IS CAST FIRST IN OBJECTIVIST AND THEN IN SUBJECTIVIST TERMS.",NA,NA,SYNTHESE,"ATKINSON, D##PEIJNENBURG, J","UNIV GRONINGEN, NL-9712 GL GRONINGEN, NETHERLANDS.",HISTORY & PHILOSOPHY OF SCIENCE; PHILOSOPHY,HISTORY & PHILOSOPHY OF SCIENCE; PHILOSOPHY,"ATKINSON D, 1999, SYNTHESE, V118, P307, DOI 10.1023/A:1005242414754##JEFFREY R, 1992, PROBABILITY ART JUDG##JEFFREY R, 1965, LOGIC DECISION##JEFFREY RC, 2001, THEORETICAL ASPECTS##LEWIS CI, 1946, ANAL KNOWLEDGE VALUA##REICHENBACH H, 1938, EXPERIENCE PREDICTIO",0,2020-11-20,NA
J,WOS:000241842600007,2006,"THE SECRET OF MY SUCCESS (VOL 151, PG 201, 2006)","IN AN INFORMATION STATE WHERE VARIOUS AGENTS HAVE BOTH FACTUAL KNOWLEDGE AND KNOWLEDGE ABOUT EACH OTHER, ANNOUNCEMENTS CAN BE MADE THAT CHANGE THE STATE OF INFORMATION. SUCH INFORMATIVE ANNOUNCEMENTS CAN HAVE THE CURIOUS PROPERTY THAT THEY BECOME FALSE BECAUSE THEY ARE ANNOUNCED. THE MOST TYPICAL EXAMPLE OF THAT IS 'FACT P IS TRUE AND YOU DON'T KNOW THAT', AFTER WHICH YOU KNOW THAT P, WHICH ENTAILS THE NEGATION OF THE ANNOUNCEMENT FORMULA. THE ANNOUNCEMENT OF SUCH A FORMULA IN A GIVEN INFORMATION STATE IS CALLED AN UNSUCCESSFUL UPDATE. A SUCCESSFUL FORMULA IS A FORMULA THAT ALWAYS BECOMES COMMON KNOWLEDGE AFTER BEING ANNOUNCED. ANALYSIS OF INFORMATION SYSTEMS AND 'PHILOSOPHICAL PUZZLES' REVEALS A GROWING NUMBER OF DYNAMIC PHENOMENA THAT CAN BE DESCRIBED OR EXPLAINED BY UNSUCCESSFUL UPDATES. THIS INCREASES OUR UNDERSTANDING OF SUCH PHILOSOPHICAL PROBLEMS. WE ALSO INVESTIGATE THE SYNTACTIC CHARACTERIZATION OF THE SUCCESSFUL FORMULAS.",NA,NA,SYNTHESE,"VAN DITMARSCH, H##KOOI, B","UNIV OTAGO, DUNEDIN 9015, NEW ZEALAND. UNIV GRONINGEN, NL-9718 CW GRONINGEN, NETHERLANDS.",HISTORY & PHILOSOPHY OF SCIENCE; PHILOSOPHY,HISTORY & PHILOSOPHY OF SCIENCE; PHILOSOPHY,"ALCHOURRON CE, 1985, J SYMBOLIC LOGIC, V50, P510, DOI 10.2307/2274239##BALTAG A, 2003, TARK 98##BARWISE J, 1981, J PHILOS, V78, P369, DOI 10.2307/2026481##FAGIN R, 1995, REASONING KNOWLEDGE##FREUDENTHAL H, 1969, NIEUW ARCH WISK, V7, P152##GAMOW G, 1958, PUZZLE MATH##GARDENFORS P, 1988, KNOWLEDGE FLUX MODEL##GERBRANDY J, 1999, ILLC DISSERTATION SE##HINTIKKA J., 1962, KNOWLEDGE BELIEF INT##KAHN C. H., 1979, ART THOUGHT HERACLIT##KIRKMAN T. P., 1847, CAMBRIDGE DUBLIN MAT, V2, P191##KVANVIG J. L., 1998, ROUTLEDGE ENCY PHILO, V7, P211##MAKARYCHEV KS, 2001, MATH INTELL, V23, P41, DOI 10.1007/BF03024516##MCCARTHY J, 1990, FORMALIZING COMMON S##MOSES Y, 1986, DISTRIB COMPUT, V1, P167, DOI 10.1007/BF01661170##O'CONNER D., 1948, MIND, V57, P358##PLAZA J., 1989, P 4 INT S METH INT S, P201##QUINE W. V. O., 1953, MIND, V62, P65##SCRIVEN M, 1951, MIND, V60, P403##SORENSEN R.A., 1988, BLINDSPOTS##VAN DITMARSCH H, 2000, ILLC DISSERTATION SE##VAN DITMARSCH H, 2002, GAME THEORY APPL, V8, P1##VAN DITMARSCH H. P., 2003, STUDIA LOGICA, V75, P31, DOI 10.1023/A:1026168632319##VAN DITMARSCH H, 2006, SYNTHESE, V151, P201, DOI 10.1007/S11229-005-3384-9##VANBENTHEM JFA, 2002, IN PRESS P LOG C 200##VANDITMARSCH HP, 2005, UNPUB DYNAMIC EPISTE##WEISS P., 1952, MIND, V61, P265",2,2020-11-20,NA
J,WOS:000243494400009,2006,TREATING SOCIO-TECHNICAL SYSTEMS AS ENGINEERING SYSTEMS: SOME CONCEPTUAL PROBLEMS,"SYSTEMS ENGINEERING HAS BEEN PLAGUED BY THE PROBLEM OF HOW TO SEPARATE A SYSTEM FROM ITS ENVIRONMENT OR CONTEXT, IN PARTICULAR FROM ITS SOCIAL CONTEXT. WE PROPOSE TO INCLUDE ANYTHING IN THE SYSTEM THAT IS NECESSARY FOR PERFORMING ITS INTENDED FUNCTION AND THAT MAY BE THE OBJECT OF DESIGN. FOR CERTAIN ENGINEERING SYSTEMS, SUCH AS CIVIL AVIATION SYSTEMS, THIS IMPLIES THAT HUMAN AGENTS AND SOCIAL INSTITUTIONS HAVE TO BE TAKEN AS INTEGRAL PARTS OF THESE SYSTEMS. THESE 'SOCIO-TECHNICAL' SYSTEMS ARE OF A HYBRID NATURE BECAUSE THEY ARE CONSTITUTED BY DIFFERENT KINDS OF ELEMENTS, INTENTIONAL AND NON-INTENTIONAL: SOCIAL INSTITUTIONS, HUMAN AGENTS AND TECHNICAL ARTEFACTS. THIS PAPER ANALYSES TWO DIFFERENT ROLES THAT HUMAN AGENTS, AS ELEMENTS OF SOCIO-TECHNICAL SYSTEMS, MAY PLAY WITH REGARD TO TECHNICAL ARTEFACTS. FURTHERMORE, IT DISCUSSES SOME CONCEPTUAL PROBLEMS CONCERNING THE MODELLING OF SOCIO-TECHNICAL SYSTEMS THAT ARE DUE TO THE HYBRID NATURE OF THESE SYSTEMS. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",NA,SOCIO-TECHNICAL SYSTEMS; ARTEFACTS; HUMAN AGENTS; SOCIAL INSTITUTIONS; MODEL,SYSTEMS RESEARCH AND BEHAVIORAL SCIENCE,"KROES, P##FRANSSEN, M##VAN DE POEL, I##OTTENS, M","DELFT UNIV TECHNOL, DEPT PHILOSOPHY, NL-2628 BX DELFT, NETHERLANDS.","MANAGEMENT; SOCIAL SCIENCES, INTERDISCIPLINARY",BUSINESS & ECONOMICS; SOCIAL SCIENCES - OTHER TOPICS,"AUYANG SY, 2004, ENG ENDLESS FRONTIER##BIJKER W.E., 1992, SHAPING TECHNOLOGY B##HOUKES W., 2002, DESIGN STUDIES, V23, P303, DOI DOI 10.1016/S0142-694X(01)00040-0##HOUKES W, 2005, STUDIES HIST PHILO A##HUGHES T.P., 1987, SOCIAL CONSTRUCTION, P51, DOI DOI 10.1177/030631289019001010##JACKSON MC, 1991, SYSTEMS METHODOLOGY##KROES PETER, 2002, DESIGN STUDIES, V23, P287, DOI DOI 10.1016/S0142-694X(01)00039-4##LATOUR BRUNO, 1993, WE HAVE NEVER BEEN M##*MIT ESD, 2002, MIT ESD WORK PAP SER, P19##SIMON H. A., 1996, SCI ARTIFICIAL",41,2020-11-20,NA
J,WOS:000243127900006,2006,DNA SEQUENCE EVOLUTION IN FAST EVOLVING MITOCHONDRIAL DNA NAD1 EXONS IN GERANIACEAE AND PLANTAGINACEAE,"PREVIOUSLY, NUCLEOTIDE SUBSTITUTION RATES IN MITOCHONDRIAL DNA OF GERANIACEAE AND PLANTAGINACEAE HAVE BEEN SHOWN TO BE EXCEPTIONALLY HIGH COMPARED WITH OTHER ANGIOSPERM MTDNA LINEAGES. IT HAS ALSO BEEN SHOWN THAT MTDNA INTRONS WERE LOST IN GERANIACEAE AND PLANTAGINACEAE. IN THIS STUDY WE COMPILE 127 DNA SEQUENCES FROM TWO PARTIAL EXONS OF THE MTDNA NAD1 GENE IN GERANIACEAE, PLANTAGINACEAE, AND OTHER ANGIOSPERM GROUPS FOR WHICH RATE ACCELERATIONS HAVE NOT BEEN REPORTED, TO ASSESS THE EXTENT AND NATURE OF THE NUCLEOTIDE SUBSTITUTION RATE ACCELERATION. WHEREAS LITORELLA APPEARS TO HAVE UNDERGONE A RATE ACCELERATION COMPARABLE TO THAT OBSERVED IN PLANTAGO, THE GERANIACEAN SISTER GROUP REPRESENTATIVE HYPSEOCHARIS BILOBA HAS NOT, INDICATING THAT THE RATE CHANGE HAS OCCURRED BETWEEN THE SPLIT OF HYPSEOCHARIS AND THE REST OF THE GERANIACEAE. SILENT/NONSILENT RATE RATIOS OMEGA HAVE DECREASED THREEFOLD IN THE ""FAST MTDNA"" CLADES COMPARED WITH OTHER ANGIOSPERMS, WHEREAS THEIR CODON USAGE BIAS IS AROUND 20% LOWER. ABSENCE OF RNA EDITING IN GERANIACEAN AND PLANTAGO MTDNA GENES IS CONFIRMED. POSSIBLE CAUSES FOR THE EXCEPTIONAL SUBSTITUTION RATE ACCELERATIONS OBSERVED IN THESE LINEAGES ARE DISCUSSED IN TERMS OF THE RETROPROCESSING PROCESS OR THE POSSIBILITY OF AFFECTED MITOCHONDRIAL DNA POLYMERASE GAMMA PROOFREADING ACCURACY CONTROL.",CHLOROPLAST DNA; LAND PLANTS; SUBSTITUTION RATES; GENE CONTENT; CODON USAGE; RNA; PHYLOGENY; GENOME; NUCLEUS; INTRONS,GERANIACEAE; MTDNA; NAD1; PLANTAGINACEAE; RETROPROCESSING; SILENT RATE; SUBSTITUTION RATE,TAXON,"BAKKER, FT##BREMAN, F##MERCKX, V","NATL HERBARIUM NEDERLAND, WAGENINGEN UNIV BRANCH, NL-6703 BL WAGENINGEN, NETHERLANDS. KATHOLIEKE UNIV LEUVEN, LAB PLANT SYST, B-3001 HEVERLEE, BELGIUM.",PLANT SCIENCES; EVOLUTIONARY BIOLOGY,PLANT SCIENCES; EVOLUTIONARY BIOLOGY,"ADAMS J L, 1999, CURR OPIN DRUG DISCOV DEVEL, V2, P96##ADAMS KL, 2000, NATURE, V408, P354, DOI 10.1038/35042567##ADAMS KL, 2002, P NATL ACAD SCI USA, V99, P9905, DOI 10.1073/PNAS.042694899##ARAYA A, 1994, PHYSIOL PLANTARUM, V91, P543, DOI 10.1111/J.1399-3054.1994.TB02986.X##AVISE JC, 2000, PHYLOGEOGRAPHY PHYLO##BAKKER FT, 2000, AM J BOT, V87, P727, DOI 10.2307/2656859##BAKKER FT, 2004, TAXON, V53, P17, DOI 10.2307/4135485##BERGTHORSSON U, 2004, P NATL ACAD SCI USA, V101, P17747, DOI 10.1073/PNAS.0408336102##BLANCHARD JL, 1995, J MOL EVOL, V41, P397, DOI 10.1007/BF00160310##BOCK R, 1994, EMBO J, V13, P4623, DOI 10.1002/J.1460-2075.1994.TB06784.X##BOWE LM, 1996, MOL BIOL EVOL, V13, P1159, DOI 10.1093/OXFORDJOURNALS.MOLBEV.A025680##BULLERWELL CE, 2004, CURR OPIN MICROBIOL, V7, P528, DOI 10.1016/J.MIB.2004.08.008##CHAW SM, 2000, P NATL ACAD SCI USA, V97, P4086, DOI 10.1073/PNAS.97.8.4086##CHO Y, 2004, P NATL ACAD SCI USA, V101, P17741, DOI 10.1073/PNAS.0408302101##CONKLIN PL, 1991, GENE DEV, V5, P1407, DOI 10.1101/GAD.5.8.1407##DALEY DO, 2002, PLANT J, V30, P11, DOI 10.1046/J.1365-313X.2002.01263.X##DELSUC F, 2005, NAT REV GENET, V6, P361, DOI 10.1038/NRG1603##DELWICHE CF, 1997, PLANT SYST EVOL, P53##DEMESURE B, 1995, MOL ECOL, V4, P129, DOI 10.1111/J.1365-294X.1995.TB00201.X##DOMBROVSKA O, 2004, MOL PHYLOGENET EVOL, V32, P246, DOI 10.1016/J.YMPEV.2003.12.013##DUMOLIN-LAPEGUE S, 1998, MOL BIOL EVOL, V15, P1321, DOI 10.1093/OXFORDJOURNALS.MOLBEV.A025860##FARRIS JS, 1996, CLADISTICS, V12, P99, DOI 10.1111/J.1096-0031.1996.TB00196.X##FREUDENSTEIN JV, 2004, AM J BOT, V91, P149, DOI 10.3732/AJB.91.1.149##FREUDENSTEIN JV, 2001, SYST BOT, V26, P643##GRAY MW, 1999, CURR OPIN GENET DEV, V9, P678, DOI 10.1016/S0959-437X(99)00030-1##GRAY MW, 1998, NUCLEIC ACIDS RES, V26, P865, DOI 10.1093/NAR/26.4.865##HAJIBABAEI M, 2006, P NATL ACAD SCI USA, V103, P968, DOI 10.1073/PNAS.0510466103##HEBERT PDN, 2004, PLOS BIOL, V2, P1657, DOI 10.1371/JOURNAL.PBIO.0020312##IKEMURA T, 1985, MOL BIOL EVOL, V2, P13##KAGUNI LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/ANNUREV.BIOCHEM.72.121801.161455##KNOOP V, 2004, CURR GENET, V46, P123, DOI 10.1007/S00294-004-0522-8##KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/BI00429A011##LEE MSY, 2000, SYST BIOL, V49, P829, DOI 10.1080/106351500750049879##MADDISON WP, 1992, MACCLADE ANAL PHYLOG##MALEK O, 1996, EMBO J, V15, P1403, DOI 10.1002/J.1460-2075.1996.TB00482.X##MERCKX V, IN PRESS AM J BOT, V93##MORTON BR, 1993, J MOL EVOL, V37, P273, DOI 10.1007/BF00175504##MOWER JP, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-96##NICKRENT DL, 2000, MOL BIOL EVOL, V17, P1885, DOI 10.1093/OXFORDJOURNALS.MOLBEV.A026290##NIXON KC, 1999, CLADISTICS, V15, P407, DOI 10.1111/J.1096-0031.1999.TB00277.X##PALMER JD, 2000, P NATL ACAD SCI USA, V97, P6960, DOI 10.1073/PNAS.97.13.6960##PALMER JD, 2004, AM J BOT, V91, P1437, DOI 10.3732/AJB.91.10.1437##PALMER JD, 1988, J MOL EVOL, V28, P87, DOI 10.1007/BF02143500##PALMER JD, 1997, NATURE, V387, P454, DOI 10.1038/387454A0##PARKINSON CL, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-73##PETERSEN G, 2006, MONOCOTS COMP BIOL E, P52##POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369##POSADA D, 2001, P NATL ACAD SCI USA, V98, P13757, DOI 10.1073/PNAS.241370698##PRUCHNER D, 2001, MOL GENET GENOMICS, V266, P608, DOI 10.1007/S004380100577##REN FR, 2005, SYST BIOL, V54, P808, DOI 10.1080/10635150500354688##ROZAS J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/BIOINFORMATICS/BTG359##SASAKI Y, 2001, J BIOL CHEM, V276, P3937, DOI 10.1074/JBC.M008166200##SHARP PM, 1986, J MOL EVOL, V24, P28, DOI 10.1007/BF02099948##SIKES DS, 2001, PAUPRAT PAUP IMPLEME##SOLTIS PS, 2004, AM J BOT, V91, P1614, DOI 10.3732/AJB.91.10.1614##STADEN R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361##SWOFFORD D. L., 2002, PAUP PHYLOGENETIC AN##THORSNESS PE, 1996, INT REV CYTOL, V165, P207, DOI 10.1016/S0074-7696(08)62223-8##TILLICH M, 2005, PLANT J, V43, P708, DOI 10.1111/J.1365-313X.2005.02484.X##TURMEL M, 2003, PLANT CELL, V15, P1888, DOI 10.1105/TPC.013169##VANDERSTRAETEN S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/JBC.273.37.23690##WRIGHT F, 1990, GENE, V87, P23, DOI 10.1016/0378-1119(90)90491-9##YANG ZH, 1997, COMPUT APPL BIOSCI, V13, P555##YOKOBORI S, 1995, NATURE, V377, P490, DOI 10.1038/377490A0##ZITO F, 1997, PLANT MOL BIOL, V33, P79, DOI 10.1023/A:1005734809834",23,2020-11-20,NA
J,WOS:000242522300006,2006,DEVELOPING FUNDAMENTAL PRINCIPLES FOR TEACHER EDUCATION PROGRAMS AND PRACTICES,"TRADITIONAL APPROACHES TO TEACHER EDUCATION ARE INCREASINGLY CRITIQUED FOR THEIR LIMITED RELATIONSHIP TO STUDENT TEACHERS' NEEDS AND FOR THEIR MEAGER IMPACT ON PRACTICE; MANY PLEAS ARE HEARD FOR A RADICAL NEW AND EFFECTIVE PEDAGOGY OF TEACHER EDUCATION IN WHICH THEORY AND PRACTICE ARE LINKED EFFECTIVELY. ALTHOUGH VARIOUS ATTEMPTS TO RESTRUCTURE TEACHER EDUCATION HAVE BEEN PUBLISHED, NO COHERENT BODY OF KNOWLEDGE EXISTS ABOUT CENTRAL PRINCIPLES UNDERLYING TEACHER EDUCATION PROGRAMS THAT ARE RESPONSIVE TO THE EXPECTATIONS, NEEDS AND PRACTICES OF STUDENT TEACHERS. BY ANALYZING EFFECTIVE FEATURES OF PROGRAMS IN AUSTRALIA, CANADA, AND THE NETHERLANDS, THIS STUDY CONTRIBUTES AN INITIAL FRAMEWORK OF SEVEN FUNDAMENTAL PRINCIPLES TO GUIDE THE DEVELOPMENT OF RESPONSIVE TEACHER EDUCATION PROGRAMS THAT MAKE A DIFFERENCE. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",EXPERIENCE,PEDAGOGY OF TEACHER EDUCATION; THEORY-PRACTICE-RELATIONSHIP; TEACHER EDUCATORS,TEACHING AND TEACHER EDUCATION,"KOTTHAGEN, F##LOUGHRAN, J##RUSSELL, T","VRIJE UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS. UNIV UTRECHT, NL-3508 TC UTRECHT, NETHERLANDS. MONASH UNIV, CLAYTON, VIC 3168, AUSTRALIA. QUEENS UNIV, KINGSTON, ON, CANADA.",EDUCATION & EDUCATIONAL RESEARCH,EDUCATION & EDUCATIONAL RESEARCH,"ADMIRAAL W. F., 1998, LEARNING ENV RES, V1, P59, DOI DOI 10.1023/A:1009936715640##ANDERSON G, 1994, STUDYING YOUR OWN SC##ASHTON PT, 1996, ED RES, V25, P21##BAIRD JR, 1992, LEARNING PEEL EXPERI##BARNES D, 1975, COMMUNICATION CURRIC##BARONE T., 1996, HDB RES TEACHER ED, P1108##BEN-PERETZ M., 1995, INT ENCY TEACHING TE, P543##BERRY A, 2004, INT HDB SELF STUDY T, P1295, DOI DOI 10.1007/978-1-4020-6545-3##BERRY A, 2002, IMPROVING TEACHER ED, P13##BODE BOYD H., 1940, WE LEARN##BOUD D., 1985, REFLECTION TURNING E##BROOKFIELD S., 1995, BECOMING CRITICALLY##BROUWER N, 2005, AM EDUC RES J, V42, P153, DOI 10.3102/00028312042001153##BROWN J. S., 1989, ED RES, V18, P32, DOI DOI 10.3102/0013189X018001032##BULLOUGH R., 2001, BECOMING STUDENT TEA##BULLOUGH RV, 1997, J EDUC TEACHING, V23, P215, DOI DOI 10.1080/02607479719972##CALDERHEAD J, 1993, CONCEPTUALIZING REFL##CARLSON HL, 1999, TEACH TEACH, V5, P203, DOI DOI 10.1080/1354060990050205##CLANDININ D. J., 1995, TEACHERS WHO TEACH T, P25##CLIFT RT, 1990, ENCOURAGING REFLECTI##COBB P, 1999, ED RES, V28, P4, DOI DOI 10.3102/0013189X028002004##COCHRAN-SMITH M., 1993, INSIDE OUTSIDE TEACH##COCHRAN-SMITH M., 2005, STUDYING TEACHER ED##COLE AL, 1993, AM EDUC RES J, V30, P473, DOI 10.2307/1163298##COLE AL, 1997, TEACH TEACH, V3, P7, DOI DOI 10.1080/1354060970030102##COOK-SATHER A., 2002, ED RES, V31, P3, DOI DOI 10.3102/0013189X031004003##DAMASIO AR, 1994, DESCARTES ERROR EMOT##DARLING-HAMMOND L., 1994, PROFESSIONAL DEV SCH##DEWEY J., 1933, WE THINK##DUCHARME ER, 1993, LIVES TEACHERS ED##ELLIOT J, 1991, ACTION RES ED CHANGE##FEIMAN-NEMSER S., 1986, HDB RES TEACHING, P505##FENSTERMACHER GD, 1997, TEACHING TEACHING PU, PR8##FOSNOT CATHERINE T., 1996, CONSTRUCTIVISM THEOR##FREUDENTHAL H, 1978, WEEDING SOWING PREFA##GALESLOOT L. J., 1997, PEDAGOGISCHE STUDIEN, V74, P249##GOODLAD J, 1990, TEACHERS OUR NATIONS##GRIMMETT PP, 1988, REFLECTION TEACHER E##HAMILTON ML, 1998, RECONCEPTUALISING TE##HERMANS J. J., 1993, TEACHER ED, V9, P111##KESSELS J. P. A. M., 1996, ED RES, V25, P17, DOI DOI 10.3102/0013189X025003017##KOETSIER C., 1997, TEACHER ED SCH PARTN, P113##KOETSIER CP, 1995, J EDUC TEACHING, V21, P333, DOI 10.1080/02607479550038545##KORTHAGEN F, 2001, LINKING PRACTICE THE##KORTHAGEN F. A. J., 1999, ED RES, V28, P4, DOI DOI 10.3102/0013189X028004004##KORTHAGEN FAJ, 1985, J TEACH EDUC, V36, P11, DOI 10.1177/002248718503600502##LABOSKEY V. K., 1994, DEV REFLECTIVE PRACT##LABOSKEY V. L., 2004, INT HDB SELF STUDY T, P817, DOI DOI 10.1007/978-1-4020-6545-3_21##LANIER J., 1986, HDB RES TEACHING, P527##LATHER P. A., 1991, GETTING SMART FEMINI##LORTIE D. C., 1975, SCHOOLTEACHER##LOUGHRAN J., 2006, DEV PEDAGOGY TEACHER##LOUGHRAN J., 1997, TEACHING TEACHING PU, P57##LOUGHRAN J. J., 1996, DEVELOPING REFLECTIV##LOUGHRAN JJ, 2002, J TEACH EDUC, V53, P33, DOI 10.1177/0022487102053001004##MARTIN AK, 2001, M CAN SOC STUD ED QU##MCINTYRE D, 1992, BRIT J EDUC STUD, V40, P264, DOI 10.2307/3120894##MERRIAM S. B., 1998, QUALITATIVE RES CASE##MULLER-FOHRBRODT G., 1978, PRAXISSCHOCK BEI JUN##MYERS C. B., 2002, IMPROVING TEACHER ED, P130##NORTHFIELD J., 1983, RES SCI EDUC, V13, P185##NORTHFIELD J. R., 1997, TEACHING TEACHING PU, P48##OSTERMAN K., 1993, REFLECTIVE PRACTICE##PUTNAM RT, 1997, INT HDB TEACHERS TEA, V2, P1223##RICHARDSON V., 1997, CONSTRUCTIVIST TEACH##RUSSELL T., 1997, PURPOSE PASSION PEDA##RUSSELL T., 1999, REFLECTING TEACHING, P219##RUSSELL T, 2002, IMPROVING TEACHER ED, P73##RUSSELL T, 1995, TEACHERS WHO TEACH T, P95##RUSSELL T., 1995, TEACHERS WHO TEACH T, P187##SANDLIN RA, 1992, ACTION TEACHER ED, V14, P16, DOI DOI 10.1080/01626620.1993.10463137##SCHON DA, 1987, ED REFLECTIVE PRACTI##SCHON DA, 1983, REFLECTIVE PRACTITIO##SEGALL A., 2002, DISTURBING PRACTICE##SIGEL I, 1977, COGNITIVE DEV BIRTH##STAKE R.E., 1982, REV J PHILOS SOCIAL, V7, P1##STEVENSON R, 1996, ETHN ED RES FOR PHIL##STOFFLETT RT, 1994, J RES SCI TEACH, V31, P31, DOI 10.1002/TEA.3660310105##TIGCHELAAR A., 2000, TRENDS DUTCH TEACHER, P185##TOM AR, 1997, REDESIGNING TEACHER##UPITIS R. B, 2000, WHO WILL TEACH CASE##VAN MANEN M., 1999, RES TEACHING METHODO, P13##VEDDER J, 1984, ORIENTATIE BEROEP LE##VEDDER J, 1987, M ASS TEACH ED EUR B##VEENMAN S, 1984, REV EDUC RES, V54, P143, DOI 10.3102/00346543054002143##WIDEEN M, 1998, REV EDUC RES, V68, P130, DOI 10.2307/1170752##ZEICHNER K.M., 2001, HDB RES TEACHING, P298##ZEICHNER K. M., 1995, ED ACTION RES BECOMI, P13##ZEICHNER KM, 1981, J TEACH EDUC, V32, P7, DOI 10.1177/002248718103200302",378,2020-11-20,NA
J,WOS:000242522300010,2006,TEACHING PORTFOLIOS IN HIGHER EDUCATION AND THEIR EFFECTS: AN EXPLORATIVE STUDY,"ALTHOUGH MANY AUTHORS CLAIM BENEFITS OF TEACHING PORTFOLIOS FOR USE IN HIGHER EDUCATION SETTINGS, THERE ARE FEW EMPIRICAL STUDIES THAT INVESTIGATE THESE BENEFITS. THIS ARTICLE DEALS WITH THE QUESTION OF WHETHER TEACHING PORTFOLIOS ARE USED IN HIGHER EDUCATION, AND IF SO, WHICH EFFECTS THEY BRING ABOUT. FURTHERMORE, THE ATTITUDE OF TEACHERS TOWARDS THE USE OF TEACHING PORTFOLIOS IS EXAMINED. THE STUDY SHOWS THAT CURRENTLY NOT VERY MANY TEACHERS ARE USING TEACHING PORTFOLIOS. WHEN USED, A TEACHING PORTFOLIO IS AN INSTRUMENT THAT CAN BRING ABOUT SOME IMPORTANT POSITIVE EFFECTS. RESPONDENTS REPORT THAT, DUE TO THE USE OF PORTFOLIOS, THEY WERE STIMULATED TO REFLECT ON THEIR OWN TEACHING, TO ACTUALISE THE LEARNING CONTENT, TO IMPROVE THEIR COURSE MATERIALS, TO SEARCH FOR ALTERNATIVE EDUCATIONAL METHODS, ETC. WHEN TEACHERS ARE USING TEACHING PORTFOLIOS IT IS IMPORTANT THAT, BESIDES ANY NEGATIVE EFFECTS, THEY ALSO EXPERIENCE POSITIVE EFFECTS. IF THIS IS NOT THE CASE, TEACHERS WILL SEE THE TEACHING PORTFOLIO ONLY AS AN EXTRA ADMINISTRATIVE INCONVENIENCE. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",TEACHERS; TOOL,NA,TEACHING AND TEACHER EDUCATION,"RIJDT, C##TIQUET, E##DOCHY, F##DEVOLDER, M","UNIV MAASTRICHT, DEPT EDUC INNOVAT & IT, MAASTRICHT, NETHERLANDS. KATHOLIEKE UNIV LEUVEN, CTR RES TEACHING & TRAINING METHODOL, LOUVAIN, BELGIUM. PROV INST HIGHER VOCAT EDUC, HASSELT, BELGIUM.",EDUCATION & EDUCATIONAL RESEARCH,EDUCATION & EDUCATIONAL RESEARCH,"ATHANASES SZ, 1994, ELEM SCHOOL J, V94, P421, DOI 10.1086/461776##BARATZSNOWDEN J, 1991, J PERS EVAL EDUC, V5, P133##BARRETT H., 2000, ELECT TEACHING PORTF##BARTON J, 1993, J TEACH EDUC, V44, P200, DOI 10.1177/002248719304400307##BERK R., 1999, ED SCI TECHNOLOGY PE##BIRD T, 1990, NEW HDB TEACHER EVAL, P241##BORKO H, 1997, J TEACH EDUC, V48, P345, DOI 10.1177/0022487197048005004##BURNS CW, 1999, STUDIES ED EVALUATIO, V25, P131##CENTRA JA, 1994, J HIGH EDUC, V65, P555, DOI 10.2307/2943778##CENTRA JA, 1993, REFLECTIVE FACULTY E##COLLINS A, 1993, J RES SCI TEACH, V30, P1103, DOI 10.1002/TEA.3660300908##DARLING LF, 2001, TEACH TEACH EDUC, V17, P107, DOI 10.1016/S0742-051X(00)00041-X##DAVIES A, 2003, OPTIMIZING NEW MODES##DOCHY F, 2003, LEARN INSTR, V13, P533, DOI 10.1016/S0959-4752(02)00025-7##DOOLITTLE P, 1994, 385608 ERIC ED##FREDERICK L, 2000, EDUCATION, V120, P634##GILLIES RM, 2004, LEARN INSTR, V14, P197, DOI 10.1016/S0959-4752(03)00068-9##GREEN JAMES E., 1996, TEACHER PORTFOLIO ST##GROVER BW, 1991, J PERS EVAL EDUC, V5, P103, DOI 10.1007/BF00117332##HAERTEL EH, 1992, REV RES EDUC, V17, P3##HURST B, 1998, PHI DELTA KAPPAN, V79, P578##JARVINEN A., 1995, ASSESS EVAL HIGH EDU, V20, P25, DOI [DOI 10.1080/0260293950200104, 10.1080/0260293950200104]##KELCHTERMANS G, 1993, TEACH TEACH EDUC, V9, P443, DOI 10.1016/0742-051X(93)90029-G##KNIGHT M., 1994, PORTFOLIO ASSESSMENT##LABOSKEY VK, 2000, PHI DELTA KAPPAN, V81, P590##LALLY A, 2000, ART DOCUMENTATION, V19, P48##MATHERS NJ, 1999, MED EDUC, V33, P521, DOI 10.1046/J.1365-2923.1999.00407.X##MEYER DK, 1999, J TEACH EDUC, V50, P131, DOI 10.1177/002248719905000206##MILES M., 2000, HDB QUALITATIVE RES, P769, DOI DOI 10.1177/0002764204273170##MURRAY JP, 1995, 8 ASHE ERIC##POWELL LAURAINE A., 2000, EUROPEAN J TEACHER E, V23, P37##SCHON DA, 1987, ED REFLECTIVE PRACTI##SELDIN P., 1997, TEACHING PORTFOLIO P##SILVERMAN D, 2000, DOING QUALITATIVE RE##SMITH HL, 2001, DISCRETE CONT DYN-B, V1, P183, DOI 10.3934/DCDSB.2001.1.183##SNADDEN D, 1999, MED EDUC, V33, P478, DOI 10.1046/J.1365-2923.1999.00446.X##TAYLOR C. T., 1997, ED ASSESSMENT, V4, P123##TAYLOR L, 1994, ASSESS EVAL HIGH EDU, V19, P109##TILLEMA H., 1998, SCAND J EDUC RES, V42, P193, DOI DOI 10.1080/0031383980420206##TILLEMA H. H, 1998, STUDIES ED EVALUATIO, V24, P263, DOI [10.1016/S0191-491X(98)00017-0.10.1016/S0191-491X(98)00017-0, DOI 10.1016/S0191-491X(98)00017-0]##TILLEMA HH, 2000, STUDIES ED EVALUATIO, V26, P193, DOI DOI 10.1016/S0191-491X(00)00015-8##WADE RC, 1996, TEACH TEACH EDUC, V12, P63, DOI 10.1016/0742-051X(95)00022-C##WEEKS P, 1996, INT J ACAD DEV, P70##WOLF K, 1991, PHI DELTA KAPPAN, V73, P129##WOLF K., 1998, TEACHER ED Q, V25, P9##WOLF K, 1996, ED LEADERSHIP  MAR, P34##WRIGHT W. A., 1999, INNOVATIVE HIGHER ED, V24, P89##ZEICHNER K, 2001, TEACH TEACH EDUC, V17, P613, DOI 10.1016/S0742-051X(01)00017-8",24,2020-11-20,NA
J,WOS:000215244900003,2006,MAJOR SYSTEM CHANGE THROUGH STEPWISE RECONFIGURATION: A MULTI-LEVEL ANALYSIS OF THE TRANSFORMATION OF AMERICAN FACTORY PRODUCTION (1850-1930),"THE COMMON VIEW IS THAT MAJOR TRANSITIONS COME ABOUT THROUGH BREAKTHROUGHS OF TECHNOLOGICAL DISCONTINUITIES. THIS ARTICLE PROPOSES GRADUAL AND STEPWISE RECONFIGURATION AS AN ALTERNATIVE TRANSITION PATHWAY. IN IT, NEW ELEMENTS ARE ADOPTED IN THE EXISTING SOCIO-TECHNICAL REGIME TO HELP SOLVE PARTICULAR PROBLEMS. BUT AS MORE IS LEARNED AND CIRCUMSTANCES CHANGE, THESE ELEMENTS MAY TRIGGER FURTHER CHANGES IN TECHNOLOGY, USER PRACTICE, INFRASTRUCTURE, AND POLICIES, EVENTUALLY ALTERING THE BASIC ARCHITECTURE OF THE REGIME. THESE NOTIONS ARE INTEGRATED IN A MULTI-LEVEL PERSPECTIVE ON TRANSITIONS AND SYSTEM CHANGES. THE RESULTING RECONFIGURATION PERSPECTIVE IS ILLUSTRATED WITH A HISTORICAL CASE STUDY OF THE TRANSITION FROM TRADITIONAL FACTORIES TO MASS PRODUCTION IN AMERICA (1850-1930). THE ANALYSIS SHOWS THAT MASS PRODUCTION WAS THE LAST STEP IN A MUCH LONGER RECONFIGURATION PROCESS INVOLVING CUMULATIVE CHANGES IN MACHINE TOOLS, BUILDING MATERIALS, MATERIALS HANDLING TECHNOLOGIES, POWER GENERATION, AND POWER-DISTRIBUTION TECHNOLOGIES. THE RECONFIGURATION PERSPECTIVE HAS WIDER RELEVANCE FOR OTHER SYSTEMS THAT FUNCTION THROUGH THE INTERPLAY OF MULTIPLE TECHNOLOGIES, E. G., AGRICULTURE, RETAILING, AND HOSPITALS. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",TECHNOLOGICAL DISCONTINUITIES; HISTORICAL-PERSPECTIVE; DOMINANT DESIGNS; INNOVATION; SOCIOLOGY,TRANSITION; RECONFIGURATION; MULTI-LEVEL PERSPECTIVE; FACTORY PRODUCTION,TECHNOLOGY IN SOCIETY,"GEELS, FW","[GEELS, FRANK W.] EINDHOVEN UNIV, DEPT TECHNOL MANAGEMENT, IPO 2-10,POB 513, NL-5600 MB EINDHOVEN, NETHERLANDS.","SOCIAL ISSUES; SOCIAL SCIENCES, INTERDISCIPLINARY",SOCIAL ISSUES; SOCIAL SCIENCES - OTHER TOPICS,"ABERNATHY WJ, 1978, TECHNOL REV, V80, P40##ANDERSON P, 1990, ADMIN SCI QUART, V35, P604, DOI 10.2307/2393511##BALDWIN CY, 1997, HARVARD BUS REV, V75, P84##BANHAM R, 1986, CONCRETE ATLANTIS US##BELZ F.M., 2004, SYSTEM INNOVATION TR, P97##BIGGS LINDY, 1996, RATIONAL FACTORY ARC##BOWERS B., 1995, ENCY HIST TECHNOLOGY, P350##CHANDLER JR ALFRED D., 1977, VISIBLE HAND MANAGER##CHRISTENSEN C.M., 1997, INNOVATORS DILEMMA##CHRISTOPHER FREEMAN, 2001, TIME GOES IND REVOLU##COOPER AC, 1976, BUS HORIZONS, V19, P61, DOI 10.1016/0007-6813(76)90024-0##DAVID PA, 1990, AM ECON REV, V80, P355##DAVID PA, 1991, COMPUTER DYNAMO MODE, P315##DAVID PA, 1992, IND CORP CHANGE, V1, P129, DOI DOI 10.1093/ICC/1.1.129##DEVINE WD, 1983, J ECON HIST, V43, P347, DOI 10.1017/S0022050700029673##DUBOFF R., 1979, ELECT POWER AM MANUF##ELZEN B, 2004, SYSTEM INNOVATION TR##FARAGHER JM, 1997, OUT MANY HIST AM PEO##GEELS F, 2005, TECHNOL SOC, V27, P363, DOI 10.1016/J.TECHSOC.2005.04.008##GEELS FW, 2004, RES POLICY, V33, P897, DOI 10.1016/J.RESPOL.2004.01.015##GEELS FW, 2005, TECHNOLOGICAL TRANSITIONS AND SYSTEM INNOVATIONS: A CO-EVOLUTIONARY AND SOCIO-TECHNICAL ANALYSIS, P1, DOI 10.4337/9781845424596##GEELS FW, 2002, RES POLICY, V31, P1257, DOI 10.1016/S0048-7333(02)00062-8##GERSICK CJG, 1991, ACAD MANAGE REV, V16, P10, DOI 10.2307/258605##GOLDFARB B., 2001, SOCIAL SCI RES NETWO##GRUBLER A, 1991, 918 INT I APPL SYST##GRUNDMANN R, 1994, CHANGING LARGE TECHNICAL SYSTEMS, P265##HABAKKUK H.J., 1962, AM BRIT TECHNOLOGY 1##HENDERSON RM, 1990, ADMIN SCI QUART, V35, P9, DOI 10.2307/2393549##HOOGMA R., 2002, EXPT SUSTAINABLE TRA##HOUNSHELL D. A., 1984, AM SYSTEM MASS PRODU##HUGHES T.P., 1987, SOCIAL CONSTRUCTION, P51, DOI DOI 10.1177/030631289019001010##HUNTER LC, 1991, HIST IND POWER US 17##KEMP R, 1998, TECHNOL ANAL STRATEG, V10, P175, DOI 10.1080/09537329808524310##KLEPPER S, 1996, AM ECON REV, V86, P562##LATOUR B., 1991, SOCIOLOGY MONSTERS E, P103##LATOUR BRUNO, 1993, CLEF BERLIN AUTRES L##LEWIS R, 2001, TECHNOL CULT, V42, P665, DOI 10.1353/TECH.2001.0172##NYE DAVID E., 1990, ELECT AM SOCIAL MEAN##RIP A., 1998, HUMAN CHOICE CLIMATE, V2, P327, DOI DOI 10.1007/BF02887432##ROSENBERG N, 1982, INSIDE BLACK BOX TEC##ROSENBERG N, 1976, PERSPECTIVES TECHNOL, P9##SABEL C, 1985, PAST PRESENT, P133##SABEL C., 1997, WORLD POSSIBILITIES##SANCHEZ R, 1996, STRATEGIC MANAGE J, V17, P63, DOI 10.1002/SMJ.4250171107##SCHOT J, 1994, FUTURES, V26, P1060, DOI 10.1016/0016-3287(94)90073-6##SCRANTON P., 1997, ENDLESS NOVELTY SPEC##SONENBLUM S., 1990, ELECT AM EC, P325##STAUDENMAIER J., 1995, RESISTANCE NEW TECHN, P147##SUAREZ FF, 1995, STRATEGIC MANAGE J, V16, P415, DOI 10.1002/SMJ.4250160602##TUSHMAN ML, 1992, RES ORGAN BEHAV, V14, P311##TUSHMAN ML, 1986, ADMIN SCI QUART, V31, P439, DOI 10.2307/2392832##TUSHMAN ML, 1998, RES ORGAN BEHAV, V20, P231##VAN CAPPELLE P., 1908, ELEKT HARE VOORTBREN##VAN DRIEL H, 2005, TECHNOL CULT, V46, P51##VANLENTE D, 1988, TECHNIEK IDEOLOGIE O##VONMEIER A, 1994, CHANGING LARGE TECHNICAL SYSTEMS, P211",46,2020-11-20,DUTCH KNOWLEDGE NETWORK ON SYSTEM INNOVATION (KSI)
J,WOS:000215244900005,2006,TAMING MONSTERS: THE CULTURAL DOMESTICATION OF NEW TECHNOLOGY,"CENTRAL TO PUBLIC DISCOMFORT ABOUT NEW TECHNOLOGIES IS THE NOTION THAT THEY ARE UNNATURAL. EXPERTS OFTEN SUPPOSE THAT BETTER KNOWLEDGE OF TECHNOLOGY AND RISKS WOULD HELP OVERCOME PUBLIC AVERSION. THIS ASSUMPTION TURNS OUT TO BE FAIRLY FRUITLESS, OFTEN EVEN INCREASING SOCIAL POLARIZATION. THE PATTERN OF DIVERGING RISK ASSESSMENTS ABOUT TECHNOLOGY MIGHT BE IMPROVED BY A BETTER UNDERSTANDING OF THE MORAL GUT FEELINGS AT STAKE. HOWEVER, CURRENT TECHNOLOGY ETHICS DOES NOT SEEM TO BE EQUIPPED FOR ELABORATING THEORIES TO EXPLAIN PUBLIC DISCOMFORT. EITHER PUBLIC FEAR IS NOT TAKEN SERIOUSLY, OR ETHICAL-THEORETICAL RATIONALIZATIONS OF MORAL INTUITIONS LEAD TO UNSATISFACTORY, NATURALIST CONSTRUCTIONS, SUCH AS THE INTRINSIC VALUE OF NATURE. FOR A BETTER UNDERSTANDING OF CURRENT RISK CONTROVERSIES, A DETOUR IS MADE TO THE CULTURAL ANTHROPOLOGY OF MARY DOUGLAS ON PRE-MODERN IDEAS REGARDING DANGER. THIS OFFERS SOME CLARIFYING INSIGHTS INTO MODERN PERCEPTIONS OF TECHNOLOGICAL RISKS. DEPARTING FROM ANTHROPOLOGICAL OBSERVATIONS, A SO-CALLED MONSTER THEORY IS SKETCHED, WHICH GIVES AN EXPLANATION FOR THE FASCINATION WITH AND AVERSION TOWARDS NEW TECHNOLOGY, LEAVING ASIDE ` NATURALIST' AND ` NATURE-SKEPTIC' EXPLANATIONS OF TECHNOLOGY ETHICS. MONSTER THEORY OFFERS A POINT OF DEPARTURE FOR A NEW, PRAGMATIC APPROACH TO CONTROVERSIES ABOUT NEW TECHNOLOGY, THE APPROACH BEING NAMED A PRAGMATIST MONSTER-ETHICS. IT TELLS US WE HAVE TO REFLECT ON AND SHIFT CULTURAL CATEGORIES AS WELL AS TO ADAPT TECHNOLOGIES IN ORDER TO DOMESTICATE OUR TECHNOLOGICAL 'MONSTERS'. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",NA,NA,TECHNOLOGY IN SOCIETY,"SMITS, M","[SMITS, MARTIJNTJE] EINDHOVEN TECH UNIV, DEPT TECHNOL MANAGEMENT HIST PHILOSOPHY & TECHNOL, EINDHOVEN, NETHERLANDS.","SOCIAL ISSUES; SOCIAL SCIENCES, INTERDISCIPLINARY",SOCIAL ISSUES; SOCIAL SCIENCES - OTHER TOPICS,"BARTHES ROLAND., 1957, MYTHOLOGIES##BORGMANN ACHTERHUIS H., 2000, J SOC PHILOS TECHNOL, V6##CALLON M, 1986, MAPPING DYNAMICS SCI##CARSON R., 1947, COLLIERS, V120, P49##COHEN JEFFREY JEROME, 1996, MONSTER THEORY READI##COMMONER B, 1971, CLOSING CIRCLE NATUR##DASHTON L, 1998, WONDERS ORDER NATURE, P1150##DOUGLAS M., 1978, CULTURAL BIAS##DOUGLAS M., 1966, PURITY DANGER ANAL C##DOUGLAS M., 1975, IMPLICIT MEANINGS ES##DOUGLAS M, 1982, RISK CULTURE ESSAY S##DU GAY P., 1997, DOING CULTURAL STUDI##DWORKIN R., 1998, NY TIMES##HARAWAY D.J., 1991, SIMIANS CYBORGS WOME##HARD M, 1998, INTELLECTUAL APPROPR##KEULARTZ J, 2004, SCI TECHNOL HUM VAL, V29, P3, DOI 10.1177/0162243903259188##KOUSBROEK R., 2001, INGENIEUR, P49##LATOUR BRUNO, 1993, WE HAVE NEVER BEEN M##LIE M, 1996, MAKING TECHNOLOGY OU##MACKENZIE WAJCMAN, 1985, SOCIAL SHAPING SCI T##MAILER N., 1963, ESQUIRE     MAY##MEIKLE J. L., 1997, AM PLASTIC CULTURAL##MIDGLEY M, 2000, HASTINGS CENT REP, V30, P7, DOI 10.2307/3527881##RIP A., 1995, MANAGING TECHNOLOGY##SHELLEY WOLLSTONECRAFT M., 1992, FRANKENSTEIN MODERN, V1818##SMITS M., 2002, CULTURELE DOMESTICAT##SOPER K., 1995, WHAT IS NATURE CULTU##SWIERSTRA T., 2002, PRAGMATIST ETHICS TE, P223##THE GUARDIAN, 2003, GUARDIAN##VAN WILLIGENBURG, 1999, FILOS PRAKTIJK, V20, P203##WINNER L, 1997, AUTONOMOUS TECHNOLOG##YARSLEY VE, 1941, SCI DIG, V10, P57",36,2020-11-20,NA
J,WOS:000241798000005,2006,"HIGH-RESOLUTION FINE MAPPING OF PS-2, A MUTATED GENE CONFERRING FUNCTIONAL MALE STERILITY IN TOMATO DUE TO NON-DEHISCENT ANTHERS","FUNCTIONAL MALE STERILITY IS AN IMPORTANT TRAIT FOR THE PRODUCTION OF HYBRID SEEDS. AMONG THE GENES CODING FOR FUNCTIONAL MALE STERILITY IN TOMATO IS THE POSITIONAL STERILITY GENE PS-2. PS-2 IS MONOGENIC RECESSIVE, CONFERS NON-DEHISCENT ANTHERS AND IS THE MOST SUITABLE FOR PRACTICAL USES. IN ORDER TO HAVE TOOLS FOR MOLECULAR-ASSISTED SELECTION (MAS) WE FINE MAPPED THE PS-2 LOCUS. THIS WAS DONE IN AN F-2 SEGREGATING POPULATION DERIVED FROM THE INTERSPECIFIC CROSS BETWEEN A FUNCTIONALLY MALE STERILE LINE (PS-2/PS-2; SOLANUM LYCOPERSICUM) AND A FUNCTIONALLY MALE FERTILE LINE (S. PIMPINELLIFOLIUM). HERE WE REPORT THE PROCEDURE THAT HAS LED TO THE HIGH-RESOLUTION FINE MAPPING OF THE PS-2 LOCUS IN A 1.65 CM INTERVAL DELIMITED BY MARKERS T0958 AND T0635 ON THE SHORT ARM OF CHROMOSOME 4. THE PRESENCE OF MANY COS MARKERS IN THE LOCAL HIGH-RESOLUTION MAP ALLOWED US TO STUDY THE SYNTENY BETWEEN TOMATO AND ARABIDOPSIS AT THE PS-2 LOCUS REGION. NO OBVIOUS CANDIDATE GENE FOR PS-2 WAS IDENTIFIED AMONG THE KNOWN FUNCTIONAL MALE STERILITY GENES IN ARABIDOPSIS.",JASMONIC ACID BIOSYNTHESIS; LYCOPERSICON-ESCULENTUM; ARABIDOPSIS; IDENTIFICATION; REGIONS; MARKERS; MUTANT; AFLP; MAP; POLYMORPHISM,NA,THEORETICAL AND APPLIED GENETICS,"GORGUET, B##SCHIPPER, D##VAN HEUSDEN, AW##LINDHOUT, P","UNIV WAGENINGEN & RES CTR, GRAD SCH EXPT PLANT SCI, LAB PLANT BREEDING, NL-6700 AJ WAGENINGEN, NETHERLANDS.",AGRONOMY; PLANT SCIENCES; GENETICS & HEREDITY; HORTICULTURE,AGRICULTURE; PLANT SCIENCES; GENETICS & HEREDITY,"ARESHCHENKOVA T, 1999, GENOME, V42, P536, DOI 10.1139/GEN-42-3-536##ARESHCHENKOVA T, 2002, THEOR APPL GENET, V104, P229, DOI 10.1007/S00122-001-0775-2##ATANASSOVA B, 1999, EUPHYTICA, V107, P13, DOI 10.1023/A:1003527714805##ATANASSOVA B, 1991, REP TOMATO GENET COO, V41, P12##CHENG JJ, 1999, CHINESE J PHYSIOL, V42, P103##FEYS BJF, 1994, PLANT CELL, V6, P751, DOI 10.1105/TPC.6.5.751##FINKERS R, 2002, P PAG 10, P201##FULTON TM, 2002, PLANT CELL, V14, P1457, DOI 10.1105/TPC.010479##GEORGIEV H., 1991, GENETIC IMPROVEMENT, V14, P83##GOLDBERG RB, 1993, PLANT CELL, V5, P1247##HAANSTRA JPW, 1999, THEOR APPL GENET, V99, P254, DOI 10.1007/S001220051231##HUALA E, 2001, NUCLEIC ACIDS RES, V29, P102, DOI 10.1093/NAR/29.1.102##ISHIGURO S, 2001, PLANT CELL, V13, P2191, DOI 10.1105/TPC.13.10.2191##KU HM, 2001, GENOME, V44, P470, DOI 10.1139/GEN-44-3-470##MCCONN M, 1996, PLANT CELL, V8, P403, DOI 10.1105/TPC.8.3.403##MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828, DOI 10.1073/PNAS.88.21.9828##MUELLER LA, 2005, PLANT PHYSIOL, V138, P1310, DOI 10.1104/PP.105.060707##MYBURG AA, 2000, PROTOCOL HIGH THROUG##NEFF MM, 2002, TRENDS GENET, V18, P613, DOI 10.1016/S0168-9525(02)02820-2##PARK JH, 2002, PLANT J, V31, P1, DOI 10.1046/J.1365-313X.2002.01328.X##PETERS JL, 2003, TRENDS PLANT SCI, V8, P484, DOI 10.1016/J.TPLANTS.2003.09.002##REMINGTON DL, 2001, P NATL ACAD SCI USA, V98, P11479, DOI 10.1073/PNAS.201394398##SANDERS PM, 2000, PLANT CELL, V12, P1041, DOI 10.1105/TPC.12.7.1041##STEINER-LANGE S, 2003, PLANT J, V34, P519, DOI 10.1046/J.1365-313X.2003.01745.X##STEWART CN, 1993, BIOTECHNIQUES, V14, P748##STINTZI A, 2000, P NATL ACAD SCI USA, V97, P10625, DOI 10.1073/PNAS.190264497##SULIMAN-POLLATSCHEK S, 2002, CELL MOL BIOL LETT, V7, P583##TANKSLEY SD, 1992, GENETICS, V132, P1141##VANOOIJEN JW, 2001, JOINMAP 3 0 SOFTW CA##VON MALEK B, 2002, PLANTA, V216, P187, DOI 10.1007/S00425-002-0906-2##VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/NAR/23.21.4407##VOSMAN B, 1992, THEOR APPL GENET, V85, P239, DOI 10.1007/BF00222865##WANG H, 1993, NUCLEIC ACIDS RES, V21, P4153, DOI 10.1093/NAR/21.17.4153##XIE DX, 1998, SCIENCE, V280, P1091, DOI 10.1126/SCIENCE.280.5366.1091",6,2020-11-20,NA
J,WOS:000241891200002,2006,DOES AN APPEAL TO THE COMMON GOOD JUSTIFY INDIVIDUAL SACRIFICES FOR GENOMIC RESEARCH?,"IN GENOMIC RESEARCH THE IDEAL STANDARD OF FREE, INFORMED, PRIOR, AND EXPLICIT CONSENT IS BELIEVED TO RESTRICT IMPORTANT RESEARCH STUDIES. FOR CERTAIN TYPES OF GENOMIC RESEARCH OTHER FORMS OF CONSENT ARE THEREFORE PROPOSED WHICH ARE ETHICALLY JUSTIFIED BY AN APPEAL TO THE COMMON GOOD. THIS NOTION IS OFTEN USED IN A GENERAL SENSE AND THIS FORMS A WEAK BASIS FOR THE USE OF WEAKER FORMS OF CONSENT. HERE WE EXAMINE HOW THE NOTION OF THE COMMON GOOD CAN BE RELATED TO INDIVIDUAL HEALTH, HEALTH CARE, AND GENOMIC RESEARCH AND WE USE THIS ANALYSIS TO PROPOSE MORE PRECISE CRITERIA TO JUSTIFY FORMS OF CONSENT WHICH DIVERGE FROM THE IDEAL STANDARD.",HEALTH,GENOMICS; GENOMIC RESEARCH; INFORMED CONSENT; PUBLIC INTERSEST; COMMON GOOD,THEORETICAL MEDICINE AND BIOETHICS,"HOEDEMAEKERS, R##GORDIJN, B##PIJNENBURG, M","RADBOUD UNIV NIJMEGEN, MED CTR, DEPT ETH PHILOSOPHY & HIST MED 137, NL-6500 HB NIJMEGEN, NETHERLANDS.","ETHICS; SOCIAL ISSUES; SOCIAL SCIENCES, BIOMEDICAL",SOCIAL SCIENCES - OTHER TOPICS; SOCIAL ISSUES; BIOMEDICAL SOCIAL SCIENCES,"ANDERSEN B, 1999, BRIT MED J, V318, P1565, DOI 10.1136/BMJ.318.7197.1565##BESKOW LM, 2001, JAMA-J AM MED ASSOC, V286, P2315, DOI 10.1001/JAMA.286.18.2315##BUROWS B, 1997, B MED ETHICS   JAN, P11##*CIOMS, 1991, INT GUID ETH REV EP##COLLINS F, 2001, TEST APPR SUBC LAB H##COLLINS FS, 2003, NATURE, V422, P835, DOI 10.1038/NATURE01626##COUNCIL FOR INTERNATIONAL ORGANISATIONS OF MEDICAL SCIENCES (CIOMS), 2002, INT ETH GUID BIOM RE##COUNCIL OF EUROPE, 1997, CONV HUM RIGHTS BIOM, V4.4##DWORKIN R, 1992, COMMUNITARIANISM IND, P205##FURNESS P, 2004, BMJ-BRIT MED J, V328, P533, DOI 10.1136/BMJ.328.7439.533##HOEDEMAEKERS R, 2003, HEALTH CARE ANAL, V11, P287, DOI 10.1023/B:HCAN.0000010057.43321.B2##HOWARD K, 2004, NAT REV DRUG DISCOV, V3, P725, DOI 10.1038/NRD1515##JENNINGS B, 1987, HASTINGS CENT REP, V17, PS6##LONDON AJ, 2003, HASTINGS CENT REP, V33, P17, DOI 10.2307/3528632##*MANN ASS IC ETH S, 2004, IC HLTH SECT DAT ACT##PASINI N, 2001, SOLIDARITY HLTH SOCI, P309##PORN I, 1993, THEOR MED, V14, P295, DOI 10.1007/BF00996337##STOUTHARD MEA, 2000, EUR J PUBLIC HEALTH, V10, P24, DOI 10.1093/EURPUB/10.1.24##STREINER D, 1995, HLTH MEASUREMENT SCA, P35##TAYLOR C, 1995, PHILOS ARGUMENTS, P181##TROUET C, 2004, J MED ETHICS, V30, P99, DOI 10.1136/JME.2003.003467##WHITBECK C, 1981, CONCEPTS HLTH DIS IN, P611##WORLD HEALTH ORGANIZATION, 1948, WHO DEF HLTH##*WORLD MED ASS, 2004, DEC HELS GEN ASS",11,2020-11-20,NA
J,WOS:000437759500005,2006,TAKING THE RIGHT TO EXIT SERIOUSLY,"BOTH DIVERSITY AND AUTONOMY LIBERALS AGREE THAT ADULTS HAVE THE RIGHT TO EXIT FROM VOLUNTARY ASSOCIATIONS. AS CHILDREN DO NOT HAVE THIS RIGHT, THE PARADOXICAL CHARACTER OF THE UPBRINGING OF CHILDREN IN FUNDAMENTALIST AND ULTRA-ORTHODOX COMMUNITIES IS EVIDENT. DIVERSITY LIBERALS LIKE GALSTON AND SPINNER-HALEV SEEM TO TAKE AN AMBIVALENT POSITION WITH REGARD TO THE RIGHT TO EXIT, BECAUSE THEY WANT TO DEFEND BOTH THE CHILD'S FUTURE RIGHT TO EXIT, WHICH REQUIRES PARTICULAR CAPACITIES, AS WELL AS THE PARENTAL RIGHT TO UPBRINGING ACCORDING TO THEIR CONCEPTION OF THE GOOD EVEN IF THIS UNDERMINES THE REQUIRED CAPACITIES. WE DEFEND THAT PEOPLE NEED TO BE AT LEAST AUTARCHIC, THAT IS SELF-DETERMINING AND MORALLY ACCOUNTABLE, IN ORDER TO BE ABLE TO EXERCISE THEIR RIGHT TO EXIT. SINCE THIS RIGHT IS A CIVIC FREEDOM RIGHT, THE STATE HAS THE RIGHT AND DUTY TO ENSURE THAT CHILDREN WILL BE ABLE TO DEVELOP INTO AUTARCHIC PERSONS. THEREFORE, OUR CLAIM IS THAT SCHOOL EDUCATION SHOULD AIM FOR MINIMAL AUTONOMY AND THAT SUCH EDUCATION SHOULD BE COMPULSORY. WE ARGUE THAT THIS WILL NOT UNDERMINE LEGITIMATE DIVERSITY AND THEREFORE THAT GALSTON AND SPINNER-HALEV SHOULD BE ABLE TO TAKE AN UNEQUIVOCAL POSITION.",NA,AUTARCHY; AUTONOMY; CHILDREN'S RIGHTS; DIVERSITY LIBERALISM; PARENTAL RIGHTS; RIGHT TO EXIT,THEORY AND RESEARCH IN EDUCATION,"SPIECKER, B##DE RUYTER, D##STEUTEL, J","[SPIECKER, BEN; DE RUYTER, DORET; STEUTEL, JAN] VRIJE UNIV AMSTERDAM, DEPT PHILOSOPHY & HIST EDUC, AMSTERDAM, NETHERLANDS.",EDUCATION & EDUCATIONAL RESEARCH,EDUCATION & EDUCATIONAL RESEARCH,"AMMERMAN N. T., 1988, BIBLE BELIEVERS FUND##BENN STANLEY, 1988, THEORY FREEDOM##CALLAN E., 1997, CREATING CITIZENS PO##DE RUYTER D, 2001, RELIG EDUC, V96, P193, DOI 10.1080/00344080152472352##DE RUYTER DJ, 2003, J PHILOS EDUC, V37, P467, DOI 10.1111/1467-9752.00339##GALSTON WA, 1995, ETHICS, V105, P516, DOI 10.1086/293725##GALSTON WA, 2002, LIBERAL PLURALISM IM##GUTMANN A, 1995, ETHICS, V105, P557, DOI 10.1086/293727##KOHLBERG L., 1984, ESSAYS MORAL DEV, V2##KOHLBERG L., 1981, ESSAYS MORAL DEV, V1##KYMLICKA W., 2002, CONT POLITICAL PHILO##LEVINSON MEIRA, 1999, DEMANDS LIBERAL ED##NUCCI L., 2001, ED MORAL DOMAIN##RAWLS J., 1993, POLITICAL LIBERALISM##RAWLS J., 1972, THEORY JUSTICE##ROSENBLUM N, 1998, MEMBERSHIP MORALPE##SNIK G., 1999, PEDAGOGISCH TIJDSCHR, V24, P125##SPIECKER BEN, 1991, FREEDOM INDOCTRINATI, P16##SPINNER-HALEV JEFF, 2000, SURVIVING DIVERSITY##STEUTEL J. W., 1991, FREEDOM INDOCTRINATI, P58##THIESSEN E. J., 1993, TEACHING COMMITMENT##VOJAK C., 2004, THEORY RES ED, V2, P189",4,2020-11-20,NA
J,WOS:000241546900003,2006,ACID-BASE BALANCE OF UMBILICAL ARTERY BLOOD OF LIVEBORN PIGLETS AT BIRTH AND ITS RELATION WITH FACTORS AFFECTING DELIVERY OF INDIVIDUAL PIGLETS,"IN THE LIMITED NUMBER OF STUDIES THAT REPORTED ON THE RELATION BETWEEN FACTORS AFFECTING BIRTH OF INDIVIDUAL PIGLETS AND ACID-BASE BALANCE VALUES AT BIRTH, PREDOMINANTLY SIMPLE CORRELATION COEFFICIENTS HAVE BEEN USED. THE AIM OF THE PRESENT STUDY WAS TO ANALYSE THE RELATION BETWEEN FACTORS AFFECTING DELIVERY OF INDIVIDUAL LIVEBORN PIGLETS AND ACID-BASE BALANCE VALUES (PH, P-CO2, HCO3- AND BEECF) AT BIRTH. IN TOTAL 201 PIGLETS ORIGINATING FROM 44 LITTERS WERE USED FOR THE COLLECTION OF BLOOD SAMPLES FROM THE UMBILICAL ARTERY IMMEDIATELY AFTER BIRTH, PREFERABLY IN THE PERIOD OF APNEA. BLOOD SAMPLES WERE ANALYSED WITH THE ISTAT (R) PORTABLE CLINICAL ANALYSER. SIGNIFICANTLY LOWER PH, HCO3-, BEECF AND SIGNIFICANTLY HIGHER P-CO2 LEVELS WERE FOUND IN POSTERIORLY PRESENTED PIGLETS, INDEPENDENTLY OF THE CONDITION OF THE UMBILICAL CORD, BIRTH WEIGHT AND CUMULATIVE BIRTH INTERVAL/RANK. INDEPENDENTLY OF PRESENTATION, BIRTH WEIGHT AND RANK, PIGLETS BORN WITH RUPTURED UMBILICAL CORDS SHOWED SIGNIFICANTLY LOWER PH VALUES. NEXT TO THAT, INCREASING BIRTH WEIGHTS RESULTED IN INCREASING HCO3- AND BEECF VALUES AT BIRTH, INDEPENDENTLY OF PRESENTATION, CONDITION OF THE UMBILICAL CORD AND CUMULATIVE BIRTH INTERVAL/RANK. BOTH AN INCREASE IN CUMULATIVE BIRTH INTERVAL AND IN RANK WAS ASSOCIATED WITH A SIGNIFICANT DECREASE OF PH, HCO3-, BEECF AND INCREASE OF P-CO2 LEVELS IN UMBILICAL CORD BLOOD AT BIRTH. TOGETHER THESE RESULTS DEMONSTRATE FOR THE FIRST TIME THAT A CLEAR RELATION EXISTS BETWEEN (FACTORS AFFECTING) THE PROGRESS OF DELIVERY AND ACID-BASE BALANCE VALUES IN A POLYTOCOUS SPECIES LIKE THE PIG. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",NEWBORN PIGLETS; PERINATAL MORTALITY; PARTURITION; VIABILITY; GAS; PIG; ASPHYXIA; ANALYZER; PH; STILLBIRTH,PIGLET; PRESENTATION; BIRTH WEIGHT; BIRTH INTERVAL; ACID-BASE BALANCE,THERIOGENOLOGY,"VAN DIJK, AJ##VAN DER LENDE, T##TAVERNE, MAM","UNIV UTRECHT, FAC VET MED, DEPT VET PHARMACOL PHARM & TOXICOL, NL-3508 TD UTRECHT, NETHERLANDS. UNIV WAGENINGEN & RES CTR, ANIM SCI GRP, DIV ANIM RESOURCES, NL-8200 AB LELYSTAD, NETHERLANDS. UNIV UTRECHT, FAC VET MED, DEPT FARM ANIM HLTH, NL-3584 CL UTRECHT, NETHERLANDS.",REPRODUCTIVE BIOLOGY; VETERINARY SCIENCES,REPRODUCTIVE BIOLOGY; VETERINARY SCIENCES,"ANDREN B, 1982, ACTA VET SCAND, V23, P581##BRENNER KV, 1977, MONATSH VETERINARMED, V32, P850##CHAN WW, 1993, ANIM REPROD SCI, V34, P43, DOI 10.1016/0378-4320(93)90048-V##CHIANG FE, 1997, RES VET SCI, V63, P107, DOI 10.1016/S0034-5288(97)90001-1##CHRISTIANSON WT, 1992, VET CLIN N AM-FOOD A, V8, P623, DOI 10.1016/S0749-0720(15)30708-8##DZIUK P, 1979, ANIM REPROD SCI, V2, P335, DOI 10.1016/0378-4320(79)90057-5##GLAWISCHNIG E, 1980, COMMUNICATION, V87, P441##GROSENBAUGH DA, 1998, J AM VET MED ASSOC, V213, P691##HERPIN P, 1996, J ANIM SCI, V74, P2067##HERPIN P, 2001, J ANIM SCI, V79, P5##LAUTERBACH K, 1987, ARCH EXP VET MED, V41, P522##LEENHOUWERS JI, 1999, LIVEST PROD SCI, V57, P243, DOI 10.1016/S0301-6226(98)00171-7##LINDERKAMP O, 1981, PEDIATR RES, V15, P53, DOI 10.1203/00006450-198101000-00013##LOW JA, 1994, AM J OBSTET GYNECOL, V170, P1081, DOI 10.1016/S0002-9378(94)70101-6##RANDALL GCB, 1971, CAN J COMPARAT MED, V35, P141##RANDALL GCB, 1992, ANIM REPROD SCI, V28, P309, DOI 10.1016/0378-4320(92)90117-V##RANDALL GCB, 1972, BIOL NEONATE, V20, P68, DOI 10.1159/000240447##RANDALL GCB, 1972, VET REC, V90, P183, DOI 10.1136/VR.90.7.183##RANDALL GCB, 1982, RES VET SCI, V32, P278, DOI 10.1016/S0034-5288(18)32380-4##ROSS MG, 2002, AM J OBSTET GYNECOL, V187, P1, DOI 10.1067/MOB.2002.123204##*SAS I, 1990, SAS STAT US GUID##SCHUIJT G, 1992, THESIS UTRECHT U, P57##SEDIAME S, 1999, EUR RESPIR J, V14, P214, DOI 10.1034/J.1399-3003.1999.14A36.X##SILVERMAN S C, 2002, EQUINE VET J SUPPL, P551##STANTON HC, 1974, J ANIM SCI, V38, P1037##SVENDSEN LS, 1991, ACTA VET SCAND, V32, P287##SZENCI O, 1985, ACTA VET HUNG, V33, P199##SZENCI O, 1988, J VET MED A, V35, P572##TAVERNE MAM, 1979, BIOL REPROD, V21, P1125, DOI 10.1095/BIOLREPROD21.5.1125##VAN DIJK AJ, 2005, THERIOGENOLOGY, V64, P1573, DOI 10.1016/J.THERIOGENOLOGY.2005.03.017##VAN RENS BTTM, 2004, THERIOGENOLOGY, V62, P331, DOI 10.1016/J.THERIOGENOLOGY.2003.10.008##VERWAERDE P, 2002, RES VET SCI, V73, P71, DOI 10.1016/S0034-5288(02)00065-6##WILHELM VU, 1997, BERL MUNCH TIERARZTL, V90, P92##ZALESKI HM, 1993, CAN J ANIM SCI, V73, P649, DOI 10.4141/CJAS93-069##ZALESKI HM, 1993, J ANIM SCI, V71, P298, DOI 10.2527/1993.712298X",21,2020-11-20,NA
J,WOS:000241628400010,2006,STATIN TREATMENT AND REDUCED RISK OF PNEUMONIA IN PATIENTS WITH DIABETES,"BACKGROUND: RECENT PROGNOSTIC STUDIES HAVE SHOWN THAT PREVIOUS TREATMENT WITH STATINS IS ASSOCIATED WITH A BETTER OUTCOME IN PATIENTS ADMITTED TO HOSPITAL WITH PNEUMONIA. BECAUSE OF AN INCREASED RISK OF PNEUMONIA IN PATIENTS WITH DIABETES, WE ASSESSED THE EFFECTS OF STATIN USE ON THE OCCURRENCE OF PNEUMONIA IN ADULT DIABETIC PATIENTS. METHODS: ALL PATIENTS WITH A DIAGNOSIS OF DIABETES ( TYPES 1 AND 2) ENLISTED IN THE UK GENERAL PRACTICE RESEARCH DATABASE BETWEEN 1 JUNE 1987 AND 21 JANUARY 2001 WERE INCLUDED. A CASE-CONTROL STUDY WAS PERFORMED WITH CASES DEFINED AS PATIENTS WITH A FIRST RECORDED DIAGNOSIS OF PNEUMONIA. FOR EACH CASE UP TO FOUR CONTROLS WERE MATCHED BY AGE, SEX, PRACTICE, AND INDEX DATE. PATIENTS WERE CLASSIFIED AS CURRENT USERS WHEN THE INDEX DATE WAS BETWEEN THE START AND END DATE OF STATIN TREATMENT. CONDITIONAL MULTIPLE LOGISTIC REGRESSION ANALYSIS WAS USED TO ESTIMATE THE STRENGTH OF THE ASSOCIATION BETWEEN STATIN TREATMENT AND THE OCCURRENCE OF PNEUMONIA. RESULTS: STATINS WERE USED IN 1.1% OF 4719 CASES AND IN 2.1% OF 15 322 MATCHED CONTROLS ( CRUDE ODDS RATIO ( OR) 0.51, 95% CI 0.37 TO 0.68). AFTER ADJUSTING FOR POTENTIAL CONFOUNDERS, TREATMENT WITH STATINS WAS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN THE RISK OF PNEUMONIA ( ADJUSTED OR 0.49, 95% CI 0.35 TO 0.69). THE ASSOCIATION WAS CONSISTENT AMONG RELEVANT SUBGROUPS ( CARDIOVASCULAR DISEASES, PULMONARY DISEASES) AND INDEPENDENT OF THE USE OF OTHER PRESCRIPTION DRUGS. CONCLUSIONS: THE USE OF STATINS IS ASSOCIATED WITH A CONSIDERABLE REDUCTION IN THE RISK OF PNEUMONIA IN DIABETIC PATIENTS. IN ADDITION TO LOWERING THE RISK OF CARDIOVASCULAR DISEASE, STATINS MAY BE USEFUL IN PREVENTING RESPIRATORY INFECTIONS.",COMMUNITY-ACQUIRED PNEUMONIA; POPULATION-BASED COHORT; INFLUENZA VACCINES; SOCIAL-CLASS; MORTALITY; SEPSIS; DRUGS; INFLAMMATION; POSTCODES; ACCURACY,NA,THORAX,"VAN DE GARDE, EMW##HAK, E##SOUVEREIN, PC##HOES, AW##VAN DEN BOSCH, JMM##LEUFKENS, HGM","UIPS, DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY, NL-3583 CA UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, DEPT CLIN PHARM, NIEUWEGEIN, NETHERLANDS. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, DEPT PULM DIS, NIEUWEGEIN, NETHERLANDS.",RESPIRATORY SYSTEM,RESPIRATORY SYSTEM,"ALMIRALL J, 1999, EUR RESPIR J, V13, P349, DOI 10.1183/09031936.99.13234999##ALMOG Y, 2003, CHEST, V124, P740, DOI 10.1378/CHEST.124.2.740##ALMOG Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1##ARONSKY D, 2005, AM J MED QUAL, V20, P319, DOI 10.1177/1062860605280358##DANESH J, 1999, BRIT MED J, V318, P843, DOI 10.1136/BMJ.318.7187.843##DE BRUIN ML, 2005, DIABETES CARE, V28, P440, DOI 10.2337/DIACARE.28.2.440##FESSLER MB, 2005, AM J RESP CRIT CARE, V171, P606, DOI 10.1164/RCCM.200406-729OC##FINE MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/JAMA.275.2.134##FRY AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/JAMA.294.21.2712##GUEVARA RE, 1999, AM J EPIDEMIOL, V149, P282, DOI 10.1093/OXFORDJOURNALS.AJE.A009804##HACKAM DG, 2006, LANCET, V367, P413, DOI 10.1016/S0140-6736(06)68041-0##JEFFERSON T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4##JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/BMJ.302.6779.766##JICK SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/PHCO.23.5.686.32205##KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4##KWAK B, 2000, NAT MED, V6, P1399##LAHEIJ RJF, 2004, JAMA-J AM MED ASSOC, V292, P1955, DOI 10.1001/JAMA.292.16.1955##MCLOONE P, 1999, BRIT MED J, V319, P1003, DOI 10.1136/BMJ.319.7215.1003##MORTENSEN EM, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-82##MORTENSEN EM, 2002, ARCH INTERN MED, V162, P1059, DOI 10.1001/ARCHINTE.162.9.1059##MOUTSCHEN M, 2005, REV MED LIEGE, V60, P541##MULLER LMAJ, 2005, CLIN INFECT DIS, V41, P281, DOI 10.1086/431587##NAKAGAWA T, 1997, ARCH INTERN MED, V157, P321, DOI 10.1001/ARCHINTE.157.3.321##RUIZ M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/AJRCCM.160.2.9808045##SHORR AF, 2005, CLIN CHEST MED, V26, P123, DOI 10.1016/J.CCM.2004.10.003##THOMSEN RW, 2006, CRIT CARE MED, V34, P1080, DOI 10.1097/01.CCM.0000207345.92928.E4##VALDEZ R, 1999, AM J PUBLIC HEALTH, V89, P1715, DOI 10.2105/AJPH.89.11.1715##VERDEL BM, 2006, ANN PHARMACOTHER, V40, P1040, DOI 10.1345/APH.1G642##WHITE DA, 2004, CLIN CHEST MED, V25, P179, DOI 10.1016/S0272-5231(03)00134-5",100,2020-11-20,NA
J,WOS:000241628400019,2006,INHALED CORTICOSTEROIDS AND LONG TERM OUTCOME IN ADULTS WITH ASTHMA,NA,LUNG-FUNCTION DECLINE; CHILDREN,NA,THORAX,"MERKUS, PJFM##DE JONGSTE, JC","ERASMUS UNIV, SOPHIA CHILDRENS HOSP, MED CTR, NL-3015 GJ ROTTERDAM, NETHERLANDS.",RESPIRATORY SYSTEM,RESPIRATORY SYSTEM,"DIJKSTRA A, 2006, THORAX, V61, P105, DOI 10.1136/THX.2004.039271##ERNST P, 2006, THORAX, V61, P93, DOI 10.1136/THX.2005.042010##LANGE P, 2006, THORAX, V61, P100, DOI 10.1136/THX.2004.037978##MERKUS PJFM, 2004, EUR RESPIR J, V23, P861, DOI 10.1183/09031936.04.00031504##SONT JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/AJRCCM.159.4.9806052##SZEFLER S, 2000, NEW ENGL J MED, V343, P1054",1,2020-11-20,NA
J,WOS:000242168400003,2006,"THROMBIN GENERATION, A FUNCTION TEST OF THE HAEMOSTATIC-THROMBOTIC SYSTEM","BY THE USE OF A FLUOROGENIC THROMBIN SUBSTRATE AND CONTINUOUS CALIBRATION OF EACH INDIVIDUAL SAMPLE, IT IS NOW POSSIBLE TO OBTAIN A THROMBIN GENERATION (TG) CURVE (OR THROMBOGRAM) IN PLASMA, WITH OR WITHOUT PLATELETS, IN AN EASY ROUTINE PROCEDURE AT HIGH THROUGHPUT AND WITH AN ACCEPTABLE EXPERIMENTAL ERROR (< 5%). EVIDENCE IS GROWING THAT THE PARAMETERS OF THE THROMBOGRAM, AND NOTABLY THE AREA UNDER THE CURVE (ENDOGENOUS THROMBIN POTENTIAL, ETP), ARE USEFUL IN ASSESSING BLEEDING- OR THROMBOTIC RISK AND ITS MODIFICATION BY ANTITHROMBOTIC- OR HAEMOSTATIC TREATMENT. AVAILABLE DATA STRONGLY SUGGEST THAT CONDITIONS (CONGENITAL, ACQUIRED, DRUG-INDUCED) THAT INCREASE TG ALL CAUSE A THROMBOTIC TENDENCY AND THAT CONDITIONS THAT DECREASE TG PREVENT THROMBOSIS BUT, BEYOND A LIMIT, CAUSE BLEEDING. DIMINUTION OF TG IS A COMMON DENOMINATOR OF ALL ANTI-THROMBOTIC TREATMENT,INCLUDING ANTI-PLATELET DRUGS. THE THROMBOGRAM CAN ALSO BE USED AS A TOOL IN THE SEARCH FOR NEW ANTITHROMBOTICS AND REFLECTS THE HAEMORRHAGIC OR THROMBOTIC SIDE EFFECTS OF OTHER DRUGS (E.G. ORAL CONTRACEPTIVES). THE THROMBOGRAM THUS IS A PROMISING NEW APPROACH TO CLINICAL MANAGEMENT OF BLEEDING AND THROMBOTIC DISEASE AS WELL AS A TOOL IN DRUG RESEARCH AND EPIDEMIOLOGY. OUR EXPERIENCE AT THIS MOMENT IS INSUFFICIENT, HOWEVER, TO ALREADY CLEARLY DEFINE ITS LIMITS.",PLATELET-RICH PLASMA; ACUTE MYOCARDIAL-INFARCTION; ACTIVATED PROTEIN-C; SEVERE HEMOPHILIA-A; PROTHROMBIN-CONVERTING ACTIVITY; ORAL ANTICOAGULANT-THERAPY; TISSUE FACTOR ACTIVATION; WHOLE-BLOOD COAGULATION; RECOMBINANT FACTOR VIIA; MEDIATED TRANSPORT,THROMBIN GENERATION; HYPERCOAGULABILITY; ANTITHROMBOTICS; HAEMOPHILIA,THROMBOSIS AND HAEMOSTASIS,"HEMKER, HC##AL DIERI, R##DE SMEDT, E##BEGUIN, S","UNIV MAASTRICHT, CARDIOVASC RES INST, SYNAPSE BV, NL-6200 MD MAASTRICHT, NETHERLANDS.",HEMATOLOGY; PERIPHERAL VASCULAR DISEASE,HEMATOLOGY; CARDIOVASCULAR SYSTEM & CARDIOLOGY,"AL DIERI R, 2002, THROMB HAEMOSTASIS, V88, P576##ALEDORT LM, 2003, PATHOPHYSIOL HAEMO T, V33, P2, DOI 10.1159/000071635##ANAND M, 2005, PATHOPHYSIOL HAEMO T, V34, P109, DOI 10.1159/000089931##BADIMON JJ, 1999, CIRCULATION, V99, P1780, DOI 10.1161/01.CIR.99.14.1780##BADIMON L, 1991, BLOOD, V78, P423##BARROWCLIFFE TW, 2006, HAEMOPHILIA, V12, P76, DOI 10.1111/J.1365-2516.2006.01262.X##BARROWCLIFFE TW, 1975, THROMB DIATH HAEMOST, V33, P271, DOI 10.1055/S-0038-1647880##BARROWCLIFFE TW, 1984, THROMB HAEMOSTASIS, V52, P7##BEGUIN S, 1997, THROMB HAEMOSTASIS, V78, P590##BEGUIN S, 1992, THROMB HAEMOSTASIS, V68, P136##BEGUIN S, 1989, THROMB HAEMOSTASIS, V61, P25##BEGUIN S, 2004, J THROMB HAEMOST, V2, P170, DOI 10.1111/J.1538-7836.2004.00558.X##BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/J.1432-1033.1982.TB05898.X##BIGGS R, 1953, HUMAN BLOOD COAGULAT##BOMBELI T, 1997, BLOOD, V89, P2429, DOI 10.1182/BLOOD.V89.7.2429##BUTENAS S, 1997, THROMB HAEMOSTASIS, V78, P1193##CELI A, 2003, J THROMB HAEMOST, V1, P60, DOI 10.1046/J.1538-7836.2003.T01-1-00033.X##DARGAUD Y, 2005, HAEMOPHILIA, V11, P552, DOI 10.1111/J.1365-2516.2005.01141.X##DARGAUD Y, 2005, THROMB HAEMOSTASIS, V93, P475, DOI 10.1160/TH04-10-0706##DOWNEY C, 1997, BRIT J HAEMATOL, V98, P68, DOI 10.1046/J.1365-2141.1997.1062972.X##ERMAKOVA EA, 2005, PATHOPHYSIOL HAEMO T, V34, P135, DOI 10.1159/000089933##FABER CG, 2003, PATHOPHYSIOL HAEMO T, V33, P52, DOI 10.1159/000071642##FALATI S, 2003, J EXP MED, V197, P1585, DOI 10.1084/JEM.20021868##FLYNN PD, 1997, BLOOD, V89, P4378, DOI 10.1182/BLOOD.V89.12.4378##FOGELSON AL, 2005, PATHOPHYSIOL HAEMO T, V34, P91, DOI 10.1159/000089930##FRESSINAUD E, 1992, BLOOD, V80, P988##FURIE BC, 2006, BLOOD CELLS MOL DIS##GAST A, 1994, ARTERIOSCLER THROMB, V14, P1466, DOI 10.1161/01.ATV.14.9.1466##GIESEN PLA, 1991, J BIOL CHEM, V266, P1379##GIESEN PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/PNAS.96.5.2311##GIROUD M, 1998, NEUROL RES, V20, P15##GROSS PL, 2005, J LEUKOCYTE BIOL, V78, P1318, DOI 10.1189/JLB.0405193##GURFINKEL E, 1994, BRIT HEART J, V71, P151##HAIDER AW, 1996, CIRCULATION, V94, P2072, DOI 10.1161/01.CIR.94.9.2072##HAIDL H, 2006, THROMB HAEMOSTASIS, V95, P772, DOI 10.1160/TH05-10-0685##HARTERT H, 1951, Z GES EXP MED, V117, P189, DOI 10.1007/BF02044776##HEDNER U, 2006, SEMIN HEMATOL, V43, PS105, DOI 10.1053/J.SEMINHEMATOL.2005.11.025##HEDNER U, 2004, SEMIN HEMATOL, V41, P35, DOI 10.1053/J.SEMINHEMATOL.2003.11.008##HEMKER HC, 2000, THROMB HAEMOSTASIS, V83, P589##HEMKER HC, 2006, THROMB HAEMOSTASIS, V95, P756, DOI 10.1160/TH06-03-0162##HEMKER HC, 1967, NATURE, V215, P1201, DOI 10.1038/2151201A0##HEMKER HC, 2006, J THROMB HAEMOST, V4, P710, DOI 10.1111/J.1538-7836.2005.01783.X##HEMKER HC, 2005, J THROMB HAEMOST, V3, P2399, DOI 10.1111/J.1538-7836.2005.01565.X##HEMKER HC, 2002, PATHOPHYSIOL HAEMO T, V32, P249, DOI 10.1159/000073575##HEMKER HC, 1992, ADV EXP MED BIOL, V313, P221##HEMKER HC, 1995, THROMB HAEMOSTASIS, V74, P134##HEMKER HC, 1986, THROMB HAEMOSTASIS, V56, P9##HEMKER HC, 1993, THROMB HAEMOSTASIS, V70, P617##HEMKER HC, 1967, NATURE, V215, P248, DOI 10.1038/215248A0##HERAS M, 1990, CIRCULATION, V82, P1476, DOI 10.1161/01.CIR.82.4.1476##INAUEN W, 1990, ARTERIOSCLEROSIS, V10, P607, DOI 10.1161/01.ATV.10.4.607##INGERSLEV J, 2003, HAEMOPHILIA, V9, P348, DOI 10.1046/J.1365-2516.2003.00767.X##JACKSON CM, 2003, PATHOPHYSIOL HAEMO T, V33, P43, DOI 10.1159/000071641##JENSEN AH, 1976, PATHOL BIOL, V24, P6##JOSSO F, 1982, HAEMOSTASIS, V12, P309##JOSSO F, 1971, BLOOD-J HEMATOL, V38, P9, DOI 10.1182/BLOOD.V38.1.9.9##KESSELS H, 1994, THROMB HAEMOSTASIS, V72, P78##KEULARTS IMLW, 2001, THROMB HAEMOSTASIS, V85, P1060##KEULARTS IMLW, 2000, THROMB HAEMOSTASIS, V84, P638##KUMAR R, 1995, THROMB HAEMOSTASIS, V74, P962##KYRLE PA, 1998, ARTERIOSCL THROM VAS, V18, P1287, DOI 10.1161/01.ATV.18.8.1287##LAVELLE SM, 1998, IRISH J MED SCI, V167, P216, DOI 10.1007/BF02937415##LEE AP, 2005, BR DENT J, V198, P26##LEE APH, 2005, BRIT DENT J, V198, P33, DOI 10.1038/SJ.BDJ.4811955##LISMAN T, 2002, BLOOD, V99, P175, DOI 10.1182/BLOOD.V99.1.175##LOBANOV AI, 2005, PATHOPHYSIOL HAEMO T, V34, P121, DOI 10.1159/000089932##LUDDINGTON RJ, 2005, CLIN LAB HAEMATOL, V27, P81, DOI 10.1111/J.1365-2257.2005.00681.X##MANN KG, 2003, J THROMB HAEMOST, V1, P1504, DOI 10.1046/J.1538-7836.2003.00298.X##MANN KG, 2006, BLOOD CELLS MOL DIS##MARONGIU F, 1990, THROMB RES, V59, P905, DOI 10.1016/0049-3848(90)90114-R##MARTINEZ-SALES V, 1998, HAEMOSTASIS, V28, P301##MUSIAL J, 1997, THROMB HAEMOSTASIS, V78, P1173##MUSIAL J, 1997, THROMB RES, V85, P367##NESHEIM ME, 1979, J BIOL CHEM, V254, P952##NICOLAES GAF, 1997, BLOOD COAGUL FIBRIN, V8, P28, DOI 10.1097/00001721-199701000-00006##NOSSEL HL, 1974, J CLIN INVEST, V54, P43, DOI 10.1172/JCI107749##O'BRIEN J, 2000, LANCET, V355, P1295##POULSEN LH, 2006, SCAND J CLIN LAB INV, V66, P329, DOI 10.1080/00365510600672783##REGNAULT V, 2003, THROMB HAEMOSTASIS, V89, P208##REVERTER JC, 1996, J CLIN INVEST, V98, P863, DOI 10.1172/JCI118859##RIVARD GE, 2005, J THROMB HAEMOST, V3, P2039, DOI 10.1111/J.1538-7836.2005.01513.X##ROOS J, 1980, LANCET, V2, P989##ROSING J, 1997, BRIT J HAEMATOL, V97, P233, DOI 10.1046/J.1365-2141.1997.192707.X##ROSING J, 1980, J BIOL CHEM, V255, P274##ROTTEVEEL RC, 1993, THROMB HAEMOSTASIS, V70, P959##SAMBRANO GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573##SCHUBERT L, 1968, ANN OSTET GINECOL, V90, P48##SERNERI GGN, 1987, LANCET, V1, P937##SERNERI GGN, 1995, LANCET, V345, P1201##SIEGEMUND T, 2003, THROMB HAEMOSTASIS, V90, P781, DOI 10.1160/TH03-01-0027##SILJANDER P, 1996, BLOOD, V87, P4651, DOI 10.1182/BLOOD.V87.11.4651.BLOODJOURNAL87114651##SIM DS, 2005, MICROCIRCULATION, V12, P301, DOI 10.1080/10739680590925682##SORENSEN B, 2003, J THROMB HAEMOST, V1, P551, DOI 10.1046/J.1538-7836.2003.00075.X##SOSKIN P, 1994, BLOOD COAGUL FIBRIN, V5, P965, DOI 10.1097/00001721-199412000-00014##SOSKIN P, 1994, EUR HEART J, V15, P479, DOI 10.1093/OXFORDJOURNALS.EURHEARTJ.A060530##SZCZEKLIK A, 1994, THROMB HAEMOSTASIS, V72, P988##TANAKA M, 1994, THROMB RES, V76, P289, DOI 10.1016/0049-3848(94)90200-3##TURECEK PETER L, 2004, CURR HEMATOL REP, V3, P331##TURECEK PL, 2003, PATHOPHYSIOL HAEMO T, V33, P16, DOI 10.1159/000071637##VANDEIJK WA, 1983, HAEMOSTASIS, V13, P192##VARADI K, 2004, HAEMOPHILIA, V10, P17, DOI 10.1111/J.1365-2516.2004.00936.X##VARADI K, 2003, J THROMB HAEMOST, V1, P2374, DOI 10.1046/J.1538-7836.2003.00450.X##VELIK-SALCHNER C, 2006, THROMB RES, V117, P597, DOI 10.1016/J.THROMRES.2005.05.015##WEISS EJ, 2002, BLOOD, V100, P3240, DOI 10.1182/BLOOD-2002-05-1470##WIELDERS S, 1997, THROMB HAEMOSTASIS, V77, P629",333,2020-11-20,NA
J,WOS:000242168400007,2006,"PERFORMANCE GOALS FOR THE LABORATORY TESTING OF ANTITHROMBIN, PROTEIN C AND PROTEIN S","TO ACHIEVE A RELIABLE ANALYTICAL QUALITY FOR BOTH MONITORING AND DIAGNOSTIC TESTING, LABORATORIES NEED TO FULFIL THE WIDELY ACCEPTED ANALYTICAL PERFORMANCE GOALS BASED ON THE BIOLOGICAL VARIATION OF THE ANALYTES OF TESTING. NOT ONLY IS THE SHORT-TERM ANALYTICAL PERFORMANCE,WHICH REGULARLY IS ASSESSED BY INTERNAL QUALITY CONTROL PROCEDURES,OF IMPORTANCE, BUT ALSO THE LONG-TERM ANALYTICAL PERFORMANCE. TO ASSESS THE LONG-TERM ANALYTICAL PERFORMANCE, DATA OBTAINED FROM AN EXTERNAL QUALITY ASSESSMENT PROGRAMME CAN BE USED. IN THIS STUDY WE HAVE USED THE EVALUATION MODEL DESIGNED BY THE ECAT FOUNDATION FOR THE ASSESSMENT OF THE LONGTERM ANALYTICAL PERFORMANCE, INCLUDING IMPRECISION, BIAS AND TOTAL ANALYTICAL ERROR. THE MODEL WAS APPLIED TO THE DATA FROM 136 DIFFERENT LABORATORIES FOR THE ASSAY OF ANTITHROMBIN (ACTIVITY), PROTEIN C (ACTIVITY AND ANTIGEN) AND PROTEIN S (ACTIVITY, TOTAL AND FREE ANTIGEN). THE IMPRECISION (MEDIAN; RANGE), REFLECTED BY THE LONG-TERM ANALYTICAL COEFFICIENT OF VARIATION (LCV(A)), WAS THE LOWEST FOR ANTITHROMBIN (7.6%; 2.6 - 43.8%) AND THE HIGHEST FOR PROTEIN S ACTIVITY (17.2%; 4.3 - 88.6%). FOR BIAS AND TOTAL ERROR THE SAME PATTERN WAS OBSERVED (ANTITHROMBIN:3.8%; 0.3 - 17.1% AND 9.1%; 3.4 - 34.3%, RESPECTIVELY; PROTEIN S ACTIVITY: 12.8%; 3.1 - 34.8% AND 24.5%; 9.9 - 87.0%, RESPECTIVELY). FOR THE MAJORITY OF THE LABORATORIES (70 - 85%) THE IMPRECISION CONTRIBUTES CONSIDERABLY MORE TO THE TOTAL ERROR THAN THE BIAS. HOWEVER THE EFFECT OF THE BIAS ON THE ANALYTICAL QUALITY IS NOT NEGLIGIBLE. ASSAYS FOR ANTITHROMBIN, PROTEIN C AND PROTEIN S ARE MAINLY USED FOR DIAGNOSTIC TESTING. ABOUT 70 - 100% OF THE LABORATORIES CAN FULFIL THE DESIRABLE PERFORMANCE GOAL FOR IMPRECISION. THE DESIRABLE PERFORMANCE GOAL FOR BIAS WAS REACHED BY 50 - 95% OF THE LABORATORIES. IN ALL CASES THE HIGHEST NUMBERS OF LABORATORIES FULFILLING PERFORMANCE GOALS WAS OBTAINED FOR THE PROTEIN C VARIABLES. TO IMPROVE THE ANALYTICAL QUALITY IN ASSAYS OF ANTITHROMBIN, PROTEIN C AND PROTEIN S IT IS HIGHLY RECOMMENDED THAT PRIMARILY IMPRECISION (NON-SYSTEMATIC FAILURES) BE SUPPRESSED. HOWEVER THE EFFECT OF THE BIAS (SYSTEMATIC FAILURES) ON THE ANALYTICAL QUALITY SHOULD NOT BE NEGLECTED. A USEFUL TOOL FOR DETERMINING THE IMPRECISION (LCV(A)) AND BIAS IS THE LONG-TERM ANALYTICAL PERFORMANCE EVALUATION MODEL AS USED BY THE ECAT FOUNDATION.",EXTERNAL QUALITY ASSESSMENT; LONG-TERM; BIOLOGICAL VARIATION; HEMOSTATIC FACTORS; INTRAINDIVIDUAL VARIABILITY; INHERITED THROMBOPHILIA; INTERNATIONAL STANDARD; ASSESSMENT PROGRAM; ANGINA-PECTORIS; COAGULATION,THROMBOPHILIA; ANALYTICAL PERFORMANCE; LONG-TERM; EQA,THROMBOSIS AND HAEMOSTASIS,"MEIJER, P##HAVERKATE, F##KLUFT, C","ECAT FDN, LEIDEN, NETHERLANDS.",HEMATOLOGY; PERIPHERAL VASCULAR DISEASE,HEMATOLOGY; CARDIOVASCULAR SYSTEM & CARDIOLOGY,"BERTINA RM, 1999, LAB TECHNIQUES THROM, P141##BLOMBACK M, 1992, THROMB HAEMOSTASIS, V67, P70##BUTTNER J, 1994, EUR J CLIN CHEM CLIN, V32, P571##CHAMBLESS L E, 1992, ANN EPIDEMIOL, V2, P723##COSTONGS GMPJ, 1985, J CLIN CHEM CLIN BIO, V23, P405##COTLOVE E, 1970, CLIN CHEM, V16, P1028##DE MOERLOOSE P, 1998, SEMIN THROMB HEMOST, V24, P321, DOI 10.1055/S-2007-996020##DEMAAT MPM, 1996, ARTERIOSCL THROM VAS, V16, P1156, DOI 10.1161/01.ATV.16.9.1156##DOT D, 1992, ANN CLIN BIOCHEM, V29, P422, DOI 10.1177/000456329202900409##DOUMAS BT, 1997, CLIN CHIM ACTA, V260, P145, DOI 10.1016/S0009-8981(96)06493-5##EHRMEYER SS, 1985, CLIN CHEM, V31, P106##FRASER CG, 1990, CLIN CHEM, V36, P1625##FRASER CG, 1992, EUR J CLIN CHEM CLIN, V30, P311##FRASER CG, 1997, ANN CLIN BIOCHEM, V34, P8, DOI 10.1177/000456329703400103##FRASER CG, 1993, CLIN CHEM, V39, P1447##FRASER CG, 1999, SCAND J CLIN LAB INV, V59, P487, DOI 10.1080/00365519950185210##FUENTESARDERIU X, 1991, ANN CLIN BIOCHEM, V28, P393, DOI 10.1177/000456329102800414##GOWANS EMS, 1988, SCAND J CLIN LAB INV, V48, P757, DOI 10.3109/00365518809088757##GROTH T, 1993, UPSALA J MED SCI, V98, P259, DOI 10.3109/03009739309179320##HARRIS EK, 1979, AM J CLIN PATHOL, V72, P364##HAVERKATE F, 1996, FIBRINOLYSIS, V10, P169, DOI 10.1016/S0268-9499(96)80079-8##HUBBARD AR, 1988, THROMB HAEMOSTASIS, V59, P464##HUBBARD AR, 1997, THROMB HAEMOSTASIS, V78, P1237##KIRKWOOD TBL, 1980, THROMB HAEMOSTASIS, V43, P10##KLEE GG, 1993, CLIN CHEM, V39, P1514##LANE DA, 1996, THROMB HAEMOSTASIS, V76, P651##LANE DA, 1996, THROMB HAEMOSTASIS, V76, P824##LIBEER JC, 1996, EUR J CLIN CHEM CLIN, V34, P665##MARCKMANN P, 1992, ATHEROSCLEROSIS, V96, P235, DOI 10.1016/0021-9150(92)90070-W##MEIJER P, 2005, SEMIN THROMB HEMOST, V31, P59, DOI 10.1055/S-2005-863806##MEIJER P, 2003, J THROMB HAEMOST, V1, P748, DOI 10.1046/J.1538-7836.2003.00141.X##MEIJER P, 2002, CLIN CHEM, V48, P1011##MICHIELS JJ, 1998, SEMIN THROMB HEMOST, V24, P309, DOI 10.1055/S-2007-996019##MINA A, 2006, CLIN CHEM LAB MED, V44, P86, DOI 10.1515/CCLM.2006.017##NGUYEN ND, 1995, THROMB HAEMOSTASIS, V73, P256##PETERSEN PH, 1996, EUR J CLIN CHEM CLIN, V34, P983##RICOS C, 1999, SCAND J CLIN LAB INV, V59, P491##RIESE H, 2001, FIBRINOLYSIS PROTEOL, V15, P9, DOI 10.1054/FIPR.2001.0099##SALOMAA V, 1998, THROMB HAEMOSTASIS, V79, P969##STOCKL D, 1995, EUR J CLIN CHEM CLIN, V33, P157##THOMPSON SG, 1989, THROMB HAEMOSTASIS, V61, P301##THOMPSON SG, 1987, THROMB HAEMOSTASIS, V58, P1073##WALKER ID, 2001, BRIT J HAEMATOL, V114, P512, DOI 10.1046/J.1365-2141.2001.02981.X",14,2020-11-20,NA
J,WOS:000242557600013,2006,BIOCHEMICAL MARKERS IN THE FOLLOW-UP OF MEDULLARY THYROID CANCER,"MEDULLARY THYROID CANCER (MTC) SHARES BIOCHEMICAL FEATURES WITH OTHER NEUROENDOCRINE TUMORS BUT THE PARTICULAR CHARACTERISTICS ARE LARGELY UNEXPLORED. WE INVESTIGATED THE BIOCHEMICAL NEUROENDOCRINE PROFILE OF MTC AND WHETHER SPECIFIC MARKERS COULD BE USEFUL IN FOLLOW-UP. IN ADDITION TO THE STANDARD TUMOR MARKER CALCITONIN, PLASMA CARCINO-EMBRYONIC ANTIGEN (CEA), PLASMA CATECHOLAMINES, (PLATELET) SEROTONIN, CHROMOGRANIN A, TRYPTASE, AND URINARY MARKERS OF CATECHOLAMINE, HISTAMINE, AND SEROTONIN METABOLISM WERE PROSPECTIVELY DETERMINED IN 46 PATIENTS WITH HISTOLOGICALLY PROVEN MTC. PATIENTS WERE DIVIDED ACCORDING TO THE STAGE OF DISEASE: GROUP 1, NO EVIDENCE; GROUP 2, STABLE DISEASE (SD); AND GROUP 3, PROGRESSIVE DISEASE (PD). PLASMA DOPAMINE WAS INCREASED IN THE MAJORITY OF THE PATIENTS WITH SD AND PD; HOWEVER IT DID NOT CORRELATE WITH EXTENT OF DISEASE. ELEVATED PLASMA PLATELET LEVELS OF SEROTONIN WERE ONLY PRESENT IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA 2 WITH SD OR PD BUT DID NOT DIFFER BETWEEN THOSE GROUPS. HISTAMINE METABOLITES WERE ELEVATED IN 20% OF PATIENTS WITH SD AND PD. IN ADDITION TO PLASMA CALCITONIN, ONLY CEA AND CHROMOGRANIN A COULD DIFFERENTIATE BETWEEN STABLE AND PROGRESSIVE MTC. MTCS ARE CAPABLE OF SYNTHESIZING CATECHOLAMINES, SEROTONIN, AND HISTAMINE METABOLITES UNDERSCORING THAT MTCS HAVE METABOLIC CHARACTERISTICS IN COMMON WITH OTHER NEUROENDOCRINE TUMORS. THUS FAR, CLINICAL USEFULNESS AND RELEVANCE SEEMS LIMITED. THE MOST USEFUL MARKERS IN THE FOLLOW-UP OF MTC ARE PLASMA CALCITONIN AND CEA.",POSITRON-EMISSION-TOMOGRAPHY; CHROMOGRANIN-A; CARCINOID-TUMORS; CATECHOLAMINE METABOLITES; CARCINOEMBRYONIC ANTIGEN; CELL-LINE; CALCITONIN; SEROTONIN; 5-HYDROXYTRYPTAMINE; PHEOCHROMOCYTOMA,NA,THYROID,"DE GROOT, JWB##KEMA, IP##BREUKELMAN, H##VAN DER VEER, E##WIGGERS, T##PLUKKER, JTM##WOLFFENBUTTEL, BHR##LINKS, TP","UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT ENDOCRINOL, NL-9700 RB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT SURG ONCOL, NL-9700 AB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, DEPT PATHOL & LAB MED, GRONINGEN, NETHERLANDS.",ENDOCRINOLOGY & METABOLISM,ENDOCRINOLOGY & METABOLISM,"BARAKAT MT, 2004, ENDOCR-RELAT CANCER, V11, P1, DOI 10.1677/ERC.0.0110001##BLIND E, 1992, THYROID, V2, P5, DOI 10.1089/THY.1992.2.5##BUSNARDO B, 1984, CANCER, V53, P278, DOI 10.1002/1097-0142(19840115)53:2<278::AID-CNCR2820530216>3.0.CO;2-Z##DAY R, 2002, NEUROENDOCRINOL LETT, V23, P447##DE GROOT JWB, 2004, ANN SURG ONCOL, V11, P786, DOI 10.1245/ASO.2004.10.015##ENGBAEK F, 1985, EUR J CANCER CLIN ON, V21, P469, DOI 10.1016/0277-5379(85)90039-2##ENGELBACH M, 2000, J CLIN ENDOCR METAB, V85, P1890, DOI 10.1210/JC.85.5.1890##FELDMAN JM, 1979, AM J MED SCI, V278, P39, DOI 10.1097/00000441-197907000-00005##FRANKE WG, 2000, ANTICANCER RES, V20, P5257##GOLDSTEIN DS, 2003, J PHARMACOL EXP THER, V305, P800, DOI 10.1124/JPET.103.049270##HANNA FWF, 1997, J ENDOCRINOL, V152, P275, DOI 10.1677/JOE.0.1520275##HARACH HR, 1993, J CLIN PATHOL, V46, P113, DOI 10.1136/JCP.46.2.113##HOCEVAR M, 2001, EUR J SURG ONCOL, V27, P219, DOI 10.1053/EJSO.2000.1032##HOEGERLE S, 2001, EUR J NUCL MED, V28, P64, DOI 10.1007/S002590000404##KEELING CA, 1988, CLIN NUCL MED, V13, P260, DOI 10.1097/00003072-198804000-00007##KEMA IP, 1993, J CHROMATOGR-BIOMED, V617, P181, DOI 10.1016/0378-4347(93)80486-N##KEMA IP, 1992, CLIN CHEM, V38, P1730##KEMA IP, 1993, CLIN CHIM ACTA, V221, P143, DOI 10.1016/0009-8981(93)90029-4##KEMA IP, 1994, CLIN CHEM, V40, P86##LEBOULLEUX S, 2004, CLIN ENDOCRINOL, V61, P299, DOI 10.1111/J.1365-2265.2004.02037.X##LIPPMAN SM, 1982, J CLIN ENDOCR METAB, V54, P233, DOI 10.1210/JCEM-54-2-233##MATSUKI Y, 2003, MODERN PATHOL, V16, P72, DOI 10.1097/01.MP.0000044485.14910.3A##MEIJER WG, 2000, CLIN CHEM, V46, P1588##MEIJER WG, 2003, CLIN CHEM, V49, P586, DOI 10.1373/49.4.586##MUSKIET FAJ, 1979, CLIN CHEM, V25, P1708##NOBELS FRE, 1997, J CLIN ENDOCR METAB, V82, P2622, DOI 10.1210/JC.82.8.2622##OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803##OISHI S, 1986, ENDOCRINOL JAPON, V33, P309##ORLANDI F, 2001, ENDOCR-RELAT CANCER, V8, P135, DOI 10.1677/ERC.0.0080135##PACAK K, 2004, ENDOCR REV, V25, P568, DOI 10.1210/ER.2003-0032##PACINI F, 2004, THYROID NEOPLASIA##PEARSE AGE, 1968, PROC R SOC SER B-BIO, V170, P71, DOI 10.1098/RSPB.1968.0025##PEARSE AGE, 1980, CLIN ENDOCRINOL META, V9, P211, DOI 10.1016/S0300-595X(80)80030-2##RUSSO AF, 1996, MOL NEUROBIOL, V13, P257, DOI 10.1007/BF02740626##SAAD MF, 1984, J CLIN ENDOCR METAB, V58, P889, DOI 10.1210/JCEM-58-5-889##TAMIR H, 1990, J NEUROSCI, V10, P3743##TUCKER L E, 1984, MO MED, V81, P607##TUCKER LE, 1984, MO MED, V81, P620##URIBE M, 1985, AM J SURG PATHOL, V9, P577, DOI 10.1097/00000478-198508000-00003##VAN DER HORST-SCHRIVERS ANOUK N A, 2004, NEUROENDOCRINOLOGY, V80 SUPPL 1, P28##WYMENGA ANM, 1995, ANN INTERN MED, V123, P636, DOI 10.7326/0003-4819-123-8-199510150-00023##ZABEL M, 1997, HISTOL HISTOPATHOL, V12, P283",31,2020-11-20,NA
J,WOS:000241999300002,2006,UNSUCCESSFUL LAPAROSCOPIC CASTRATION IN A CRYPTORCHID FRISIAN STALLION,"A 2-YEAR-OLD UNILATERAL INGUINAL CRYPTORCHID FRISIAN STALLION WAS CASTRATED BY BILATERAL LAPAROSCOPIC INTRA-ABDOMINAL SPERMATIC CORD TRANSECTION. BECAUSE BLOOD TESTOSTERONE LEVELS WERE STILL HIGH ON POSTOPERATIVE DAY 7, BOTH TESTICLES WERE REMOVED USING AN OPEN APPROACH. PATHOLOGY REVEALED THE PRESENCE OF VITAL LEYDIG-CELLS IN BOTH TESTES. FAILURE OF THE LAPAROSCOPIC CASTRATION IN THIS HORSE WAS ATTRIBUTED TO AN ALTERNATE BLOOD SUPPLY TO THE TESTES BY VESSELS DERIVED FROM THE CREMASTER AND/OR EXTERNAL PUDENDAL ARTERY.",TESTIS; TRANSECTION; DIVISION; VESSELS,NA,TIJDSCHRIFT VOOR DIERGENEESKUNDE,"VOERMANS, M##VAN DER VELDEN, MA","UNIV UTRECHT, FAC DIERGENEESKUNDE, DEPT GEZONDHEIDSZORG PAARD, NL-3508 TC UTRECHT, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,"COLLIN B, 1973, ANAT HISTOL EMBRYOL, V2, P46##DAVIS EW, 1997, VET SURG, V26, P326, DOI 10.1111/J.1532-950X.1997.TB01505.X##DELAHUNTA A, 1986, APPL VET ANATOMY, P287##FISCHER AT, 1998, EQUINE VET J, V30, P105, DOI 10.1111/J.2042-3306.1998.TB04468.X##FISCHER AT, 1992, J AM VET MED ASSOC, V201, P1705##HENDRICKSON DA, 1997, VET SURG, V26, P335, DOI 10.1111/J.1532-950X.1997.TB01507.X##JANTOSOVICOVA J, 1983, GEGENBAURS MORPHOL JAHRB, V129, P467##KING LR, 1998, J UROLOGY, V160, P2457, DOI 10.1016/S0022-5347(01)62210-9##NOORDHUIZENSTASSEN EN, 1986, INT J ANDROL, V9, P141, DOI 10.1111/J.1365-2605.1986.TB00877.X##NOORDHUIZENSTASSEN EN, 1983, INT J ANDROL, V6, P509, DOI 10.1111/J.1365-2605.1983.TB00342.X##RAVASSE P, 1992, ANN CHIR, V46, P497##RIJKENHUIZEN ABM, 2002, PFERDEHEILKUNDE, V18, P12##RIJKENHUIZEN ABM, 1999, PFERDEHEILKUNDE, V15, P425, DOI 10.21836/PEM19990504##RUTGERS LJE, 1989, TIJDSCHR DIERGENEESK, V114, P493##SENGER PL, 1999, PATHWAYS PREGNANCY P, P101##VAN DER VELDEN MA, 2005, TIJDSCHR DIERGENEESK, V130, P312##VOERMANS M, 2006, EQUINE VET J, V38, P35, DOI 10.2746/042516406775374234##WILSON DG, 1996, J AM VET MED ASSOC, V209, P112",2,2020-11-20,NA
J,WOS:000241999300005,2006,"ANALYSIS OF THE REPORT ""HOMEOPATHY, A SOLUTION FOR CALF DIARRHOEA!""",NA,NA,NA,TIJDSCHRIFT VOOR DIERGENEESKUNDE,"LUMEIJ, JT##TESKE, E##PELLICAAN, CHP","UNIV UTRECHT, FAC DIERGENEESKUNDE, DEPT GEZELSCHAPSDIEREN, NL-3508 TC UTRECHT, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,NA,0,2020-11-20,NA
J,WOS:000242400200006,2006,PLATELET-RICH PLASMA: QUANTIFICATION OF GROWTH FACTOR LEVELS AND THE EFFECT ON GROWTH AND DIFFERENTIATION OF RAT BONE MARROW CELLS,"PLATELET-RICH PLASMA (PRP) IS A NEW APPLICATION OF TISSUE ENGINEERING AND A DEVELOPING AREA FOR CLINICIANS AND RESEARCHERS. IT IS A STORAGE VEHICLE OF GROWTH FACTORS (GFS) SUCH AS PLATELET-DERIVED GROWTH FACTOR ( PDGF)AA, -BB, -AB; TRANSFORMING GROWTH FACTOR (TGF)-BETA 1 AND -2; PLATELET-DERIVED EPIDERMAL GROWTH FACTOR (PDEGF); PLATELET-DERIVED ANGIOGENESIS FACTOR (PDAF); INSULIN GROWTH FACTOR-1 (IGF-1); AND PLATELET FACTOR-4 (PF-4), WHICH ARE KNOWN TO INFLUENCE BONE REGENERATION. HOWEVER, ANIMAL AND CLINICAL STUDIES REVEAL DIFFERENT RESULTS WITH THE USE OF PRP AND ITS EFFECT ON BONE HEALING. THIS COULD BE DUE TO THE DIFFERENCES BETWEEN SPECIES, THAT IS, DIFFERENCES BETWEEN SPECIES IN GF CONCENTRATIONS OR VARIATION IN PRESENCE OF GFS BETWEEN THE VARIOUS PRPS. IN THIS STUDY, RAT BONE MARROW CELLS WERE CULTURED IN PRP-COATED WELLS OR IN UNCOATED WELLS FOR 16 DAYS IN OSTEOGENIC MEDIUM, AND ANALYZED ON CELL GROWTH ( DNA CONTENT) AND CELL DIFFERENTIATION ( ALKALINE PHOSPHATASE [ ALP] ACTIVITY, CALCIUM CONTENT, SCANNING ELECTRON MICROSCOPY, AND QPCR). THE CONCENTRATIONS OF TGF-BETA 1, PDGF-AA, PDGF-AB, AND PDGF-BB IN RAT, GOAT, AND HUMAN PRP WERE SUBSEQUENTLY DETERMINED. THE RESULTS SHOWED THAT PRP STIMULATED INITIAL CELL GROWTH AND HAD NO EFFECT ON ALP ACTIVITY. THE CALCIUM MEASUREMENTS SHOWED A SIGNIFICANT INCREASE IN CALCIUM AT DAYS 8, 12, AND 16. THE REAL-TIME PCR RESULTS SHOWED THAT PRP UPREGULATED OSTEOCALCIN AT DAY 1 AND COLLAGEN TYPE I AT DAY 8. OVERALL, THE IMMUNOASSAYS REVEALED THAT HUMAN PRP CONTAINED HIGHER CONCENTRATIONS OF GROWTH FACTORS PER PLATELET COMPARED TO RAT AND GOAT PRP. GOAT PRP SHOWED HIGHER CONCENTRATIONS OF GROWTH FACTORS PER PLATELET AS COMPARED TO RAT PRP EXCEPT FOR PDGF-BB, WHICH HAD A HIGHER CONCENTRATION IN RAT PRP. TGF-BETA 1 WAS THE MOST ABUNDANT GROWTH FACTOR IN ALL 3 PRPS. ON THE BASIS OF OUR RESULTS, WE CONCLUDE THAT PLATELET-RICH PLASMA CONTAINS OSTEO-INDUCTIVE GROWTH FACTORS, WHICH ARE PROBABLY SPECIES RELATED. HOWEVER, WE CANNOT GENERALIZE THE RESULTS BECAUSE OF LARGE INTRASPECIES VARIATIONS. FURTHER, WE CONCLUDE THAT RAT PRP GEL STIMULATES INITIAL GROWTH AND DIFFERENTIATION OF RAT BONE MARROW CELLS IN VITRO.",IN-VITRO; AUTOGENOUS BONE; STROMAL CELLS; PROLIFERATION; RECONSTRUCTION; REGENERATION; OSTEOBLASTS; MITOGENESIS; IMPLANTS; GRAFTS,NA,TISSUE ENGINEERING,"VAN DEN DOLDER, J##MOOREN, R##VLOON, APG##STOELINGA, PJW##JANSEN, JA","RADBOUD UNIV NIJMEGEN, MED CTR, DEPT PERIODONTOL, NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, DEPT BIOMAT, NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, MED CTR, DEPT ORAL & MAXILLOFACIAL SURG, NIJMEGEN, NETHERLANDS.",CELL & TISSUE ENGINEERING,CELL BIOLOGY,"AGHALOO TL, 2002, J ORAL MAXIL SURG, V60, P1176, DOI 10.1053/JOMS.2002.34994##ANNUNZIATA M, 2005, J PERIODONT RES, V1##ARPORNMAEKLONG P, 2004, INT J ORAL MAX SURG, V33, P60, DOI 10.1054/IJOM.2003.0492##CHOI BH, 2005, INT J ORAL MAX SURG, V34, P420, DOI 10.1016/J.IJOM.2004.10.018##CHOI BH, 2004, INT J ORAL MAX SURG, V33, P56, DOI 10.1054/IJOM.2003.0466##DAVIDAI G, 1992, AM J PHYSIOL, V263, PE205##FENNIS JPM, 2005, INT J ORAL MAX SURG, V34, P158, DOI 10.1016/J.IJOM.2004.06.004##GRUBER R, 2002, CLIN ORAL IMPLAN RES, V13, P529, DOI 10.1034/J.1600-0501.2002.130513.X##HAYNESWORTH SE, 2002, 48 M ORTH RES SOC BO##HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/EN.134.3.1423##LANDESBERG R, 2000, J ORAL MAXIL SURG, V58, P297, DOI 10.1016/S0278-2391(00)90058-2##LIVAK KJ, 2001, METHODS, V25, P402, DOI 10.1006/METH.2001.1262##LU L, 2005, J BONE JOINT SURG, V83, PS82##LUCARELLI E, 2003, BIOMATERIALS, V24, P3095, DOI 10.1016/S0142-9612(03)00114-5##MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317##MARX R E, 2001, IMPLANT DENT, V10, P225##MARX RE, 2004, J ORAL MAXIL SURG, V62, P489, DOI 10.1016/J.JOMS.2003.12.003##MARX RE, 1998, ORAL SURG ORAL MED O, V85, P638, DOI 10.1016/S1079-2104(98)90029-4##MENDONCA-CARIDAD JJ, 2006, INT J ORAL MAX SURG, V35, P88, DOI 10.1016/J.IJOM.2005.06.017##OHVA M, 2005, CLIN ORAL IMPLAN RES, V16, P622##OPREA WE, 2003, J CRANIOFAC SURG, V14, P292, DOI 10.1097/00001665-200305000-00006##PAQUES M, 1999, OPHTHALMOLOGY, V106, P932, DOI 10.1016/S0161-6420(99)00512-6##SANCHEZ AR, 2005, INT J ORAL MAX IMPL, V20, P526##SANDY J, 1998, BONE, V23, P17, DOI 10.1016/S8756-3282(98)00067-2##SOFFER E, 2004, CLIN ORAL IMPLAN RES, V15, P581, DOI 10.1111/J.1600-0501.2004.01063.X##THOR A, 2005, CLIN IMPLANT DENT R, V7, P209, DOI 10.1111/J.1708-8208.2005.TB00066.X##TOZUM TOLGA FIKRET, 2003, J CAN DENT ASSOC, V69, P664##TSAY RC, 2005, J ORAL MAXIL SURG, V63, P521, DOI 10.1016/J.JOMS.2004.09.012##WEIBRICH G, 2004, BONE, V34, P665, DOI 10.1016/J.BONE.2003.12.010##WEIBRICH G, 2002, MUND KIEFER GESICHTSCHIR, V6, P168##WEIBRICH G, 2001, INT J ORAL MAX IMPL, V16, P693##YANG DH, 2000, CYTOKINE, V12, P1271, DOI 10.1006/CYTO.2000.0707",192,2020-11-20,NA
J,WOS:000242400200020,2006,ENGINEERING OF BIOLOGICALLY ACTIVE LIVING HEART VALVE LEAFLETS USING HUMAN UMBILICAL CORD-DERIVED PROGENITOR CELLS,"THIS STUDY DEMONSTRATES THE ENGINEERING OF BIOLOGICALLY ACTIVE HEART VALVE LEAFLETS USING PRENATALLY AVAILABLE HUMAN UMBILICAL CORD-DERIVED PROGENITOR CELLS AS THE ONLY CELL SOURCE. WHARTON'S JELLY-DERIVED CELLS AND UMBILICAL CORD BLOOD-DERIVED ENDOTHELIAL PROGENITOR CELLS WERE SUBSEQUENTLY SEEDED ON BIODEGRADABLE SCAFFOLDS AND CULTURED IN A BIOMIMETIC SYSTEM UNDER BIOCHEMICAL OR MECHANICAL STIMULATION OR BOTH. DEPENDING ON THE STIMULATION, LEAFLETS SHOWED MATURE LAYERED TISSUE FORMATION WITH FUNCTIONAL ENDOTHELIA AND EXTRACELLULAR MATRIX PRODUCTION COMPARABLE WITH THAT OF NATIVE TISSUES. THIS DEMONSTRATES THE FEASIBILITY OF HEART VALVE LEAFLET FABRICATION FROM PRENATAL UMBILICAL CORD-DERIVED PROGENITOR CELLS AS A FURTHER STEP IN OVERCOMING THE LACK OF LIVING AUTOLOGOUS REPLACEMENTS WITH GROWTH AND REGENERATION POTENTIAL FOR THE REPAIR OF CONGENITAL MALFORMATION.",ACUTE MYOCARDIAL-INFARCTION; IN-VITRO; AORTIC-VALVE; REGENERATION ENHANCEMENT; ENDOTHELIAL-CELLS; STEM-CELLS; GLYCOSAMINOGLYCANS; TRANSPLANTATION; COLLAGEN; FIBROBLASTS,NA,TISSUE ENGINEERING,"SCHMIDT, D##MOL, A##ODERMATT, B##NEUENSCHWANDER, S##BREYMANN, C##GOSSI, M##GENONI, M##ZUND, G##HOERSTRUP, SP","UNIV HOSP ZURICH, CLIN CARDIOVASC SURG, CH-8091 ZURICH, SWITZERLAND. UNIV ZURICH, DEPT SURG RES, CH-8091 ZURICH, SWITZERLAND. EINDHOVEN UNIV TECHNOL, DEPT BIOMED ENGN, EINDHOVEN, NETHERLANDS. UNIV HOSP ZURICH, INST CLIN PATHOL, ZURICH, SWITZERLAND. UNIV HOSP ZURICH, DEPT GYNECOL & OBSTET, ZURICH, SWITZERLAND. ETH, INST POLYMERS, ZURICH, SWITZERLAND.",CELL & TISSUE ENGINEERING,CELL BIOLOGY,"ASAHARA T, 1997, SCIENCE, V275, P964, DOI 10.1126/SCIENCE.275.5302.964##ASSMUS B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD##BANKOWSKI E, 1996, EUR J OBSTET GYN R B, V66, P109, DOI 10.1016/0301-2115(96)02390-1##DAILEY L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/J.CYTOGFR.2005.01.007##DELLA ROCCA F, 2000, ANN THORAC SURG, V70, P1594, DOI 10.1016/S0003-4975(00)01979-2##DESMOULIERE A, 1992, LAB INVEST, V67, P716##FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5##FELD SM, 1995, KIDNEY INT, V48, P45, DOI 10.1038/KI.1995.265##GRIESE DP, 2003, CIRCULATION, V108, P2710, DOI 10.1161/01.CIR.0000096490.16596.A6##HAMMERMEISTER KE, 1993, NEW ENGL J MED, V328, P1289, DOI 10.1056/NEJM199305063281801##HARKEN DE, 1962, AM J CARDIOL, V9, P292, DOI 10.1016/0002-9149(62)90047-4##HIROSE S, 2003, WORLD J SURG, V27, P87, DOI 10.1007/S00268-002-6742-5##HOERSTRUP SP, 2000, CIRCULATION, V102, P44##HOERSTRUP SP, 2002, ANN THORAC SURG, V74, P46, DOI 10.1016/S0003-4975(02)03649-4##HOERSTRUP SP, 2002, CIRCULATION, V106, PI143, DOI 10.1161/01.CIR.0000032872.55215.05##HOERSTRUP SP, 2000, TISSUE ENG, V6, P75, DOI 10.1089/107632700320919##HUR J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06##HUSZAR G, 1980, ANAL BIOCHEM, V105, P424, DOI 10.1016/0003-2697(80)90481-9##KAUSHAL S, 2001, NAT MED, V7, P1035, DOI 10.1038/NM0901-1035##KAWAMOTO A, 2001, CIRCULATION, V103, P634##KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5##KOHL T, 2000, CIRCULATION, V102, P1602, DOI 10.1161/01.CIR.102.14.1602##KOHL T, 1997, CIRCULATION, V95, P1048##MAYER J E JR, 1995, SEMIN THORAC CARDIOVASC SURG, V7, P130##MESSIER RH, 1994, J SURG RES, V57, P1, DOI 10.1006/JSRE.1994.1102##MOL A, 2005, ANN BIOMED ENG, V33, P1778, DOI 10.1007/S10439-005-8025-4##MOL A, 2005, BIOMATERIALS, V26, P3113, DOI 10.1016/J.BIOMATERIALS.2004.08.007##MOL A, 2003, THORAC CARDIOV SURG, V51, P78, DOI 10.1055/S-2003-38993##NIKLASON LE, 1999, SCIENCE, V284, P489, DOI 10.1126/SCIENCE.284.5413.489##PESCE M, 2003, CIRC RES, V93, PE51, DOI 10.1161/01.RES.0000090624.04507.45##QUINTERO RA, 2001, LANCET, V357, P1947, DOI 10.1016/S0140-6736(00)05084-4##RABKIN E, 2002, J HEART VALVE DIS, V11, P308##SARUGASER R, 2005, STEM CELLS, V23, P220, DOI 10.1634/STEMCELLS.2004-0166##SCHACHINGER V, 2004, J AM COLL CARDIOL, V44, P1690, DOI 10.1016/J.JACC.2004.08.014##SCHMIDT CE, 2000, BIOMATERIALS, V21, P2215, DOI 10.1016/S0142-9612(00)00148-4##SCHMIDT D, 2005, EUR J CARDIO-THORAC, V27, P795, DOI 10.1016/J.EJCTS.2005.01.064##SCHMIDT D, 2004, ANN THORAC SURG, V78, P2094, DOI 10.1016/J.ATHORACSUR.2004.06.052##SCHOEN FJ, 1999, J BIOMED MATER RES, V47, P439, DOI 10.1002/(SICI)1097-4636(19991215)47:4<439::AID-JBM1>3.0.CO;2-O##SCHOEN FJ, 2001, CARDIOVASC PATHOL, P629##SHINOKA T, 1995, ANN THORAC SURG, V60, PS513, DOI 10.1016/0003-4975(95)00733-4##SHIROTA T, 2003, BIOMATERIALS, V24, P2295, DOI 10.1016/S0142-9612(03)00042-5##SHIROTA T, 2003, TISSUE ENG, V9, P127, DOI 10.1089/107632703762687609##SOBOLEWSKI K, 1997, BIOL NEONATE, V71, P11##SUTHERLAND FWH, 2005, CIRCULATION, V111, P2783, DOI 10.1161/CIRCULATIONAHA.104.498378##THOMAS KA, 1987, FASEB J, V1, P434##URBICH C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78##WANG HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/STEMCELLS.2004-0013##ZHANG K, 1996, BIOL SIGNAL, V5, P232",72,2020-11-20,NA
J,WOS:000242689200004,2006,TOWARDS CATALYTIC CASCADE REACTIONS: ASYMMETRIC SYNTHESIS USING COMBINED CHEMO-ENZYMATIC CATALYSTS,"THE COMBINATION OF IMMOBILISED RH-MONOPHOS (5-ALTUD-1) AND ACYLASE I AFFORDED A CHEMO-ENZYMATIC ONE-POT PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF AMINO ACIDS IN WATER, WITHOUT THE NEED FOR ISOLATION OF INTERMEDIATES. IN ADDITION, THE ENZYMATIC HYDROLYSIS INCREASES THE ENANTIOPURITY OF THE PRODUCT FROM 95% EE TO > 98% EE. COMPATIBILITY STUDIES REVEALED THAT COMPARTMENTALISATION OF THE CATALYSTS IS ESSENTIAL TO ACHIEVE HIGH YIELDS AND OPTICAL PURITIES.",ORGANIC-SYNTHESIS; METAL-COMPLEXES; AMINO-ACIDS; HYDROGENATION; IMMOBILIZATION; ALUMINOSILICATE; LIGANDS; SILICA,AMINOACYLASE; ASYMMETRIC CATALYSIS; CASCADE REACTION; HYDROGENATION; IMMOBILISATION,TOPICS IN CATALYSIS,"SIMONS, C##HANEFELD, U##ARENDS, IWCE##MASCHMEYER, T##SHELDON, RA","DELFT UNIV TECHNOL, LAB APPL ORGAN CHEM & CATALYSIS, NL-2628 BL DELFT, NETHERLANDS. DELFT UNIV TECHNOL, LAB BIOCATALYSIS & ORGAN CHEM, NL-2628 BL DELFT, NETHERLANDS. UNIV SYDNEY, SCH CHEM, LAB ADV CATALYSIS SUSTAINABIL, SYDNEY, NSW 2006, AUSTRALIA.","CHEMISTRY, APPLIED; CHEMISTRY, PHYSICAL",CHEMISTRY,"AUGUSTINE R, 1999, CHEM COMMUN, P1257, DOI 10.1039/A903205C##BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/JA00053A020##BODE ML, 2003, BIOTECHNOL BIOENG, V84, P710, DOI 10.1002/BIT.10828##BRUGGINK A, 2003, ORG PROCESS RES DEV, V7, P622, DOI 10.1021/OP0340311##BURK MJ, 1993, J AM CHEM SOC, V115, P10125, DOI 10.1021/JA00075A031##CHENAULT HK, 1989, J AM CHEM SOC, V111, P6354, DOI 10.1021/JA00198A055##CLAVER C, 2000, CHEM COMMUN, P961##DE REGE FM, 2000, CHEM COMMUN, P1797, DOI 10.1039/B003354P##DUMONT W, 1973, J AM CHEM SOC, V95, P8295, DOI 10.1021/JA00806A015##FABER K, 1997, BIOTRANSFORMATION OR##FAN QH, 2002, CHEM REV, V102, P3385, DOI 10.1021/CR010341A##HEMS WP, PATENT NO. 2002036261##HULST R, 1994, TETRAHEDRON-ASYMMETR, V5, P699, DOI 10.1016/0957-4166(94)80032-4##JANSEN JC, 2001, CHEM COMMUN, P713, DOI 10.1039/B101000J##KNOWLES WS, 2002, ANGEW CHEM INT EDIT, V41, P1999##LEADBEATER NE, 2002, CHEM REV, V102, P3217, DOI 10.1021/CR010361C##LEE SG, 2003, CHEM COMMUN, P2624, DOI 10.1039/B309304B##MALMSTROM T, 1999, DALTON T, P2871##OHKUMA T, 2001, ADV SYNTH CATAL, V343, P369##PAMIES O, 2003, CHEM REV, V103, P3247, DOI 10.1021/CR020029G##POLIAKOFF M, 2002, SCIENCE, V297, P807, DOI 10.1126/SCIENCE.297.5582.807##REETZ MT, 2000, ANGEW CHEM INT EDIT, V39, P3889, DOI 10.1002/1521-3773(20001103)39:21<3889::AID-ANIE3889>3.0.CO;2-T##REICHARDT C, 1994, CHEM REV, V94, P2319, DOI 10.1021/CR00032A005##SCHENCK TG, 1985, INORG CHEM, V24, P2334, DOI 10.1021/IC00209A003##SCHOEVAART R, 2004, TOP CATAL, V27, P3, DOI 10.1023/B:TOCA.0000013536.27551.13##SHAN Z, 2001, MICROPOR MESOPOR MAT, V48, P181, DOI 10.1016/S1387-1811(01)00342-0##SHAN Z, 2001, CHEM-EUR J, V7, P1437, DOI 10.1002/1521-3765(20010401)7:7<1437::AID-CHEM1437>3.3.CO;2-D##SHELDON RA, 2005, GREEN CHEM, V7, P267, DOI 10.1039/B418069K##SHELDON RA, 1994, CHEMTECH, V24, P38##SHELDON RA, 1998, CATAL TODAY, V41, P387, DOI 10.1016/S0920-5861(98)00027-3##SIMONS C, 2006, ADV SYNTH CATAL, V348, P471, DOI 10.1002/ADSC.200505395##SIMONS C, 2004, CHEM COMMUN, P2830, DOI 10.1039/B411506F##SIMONS C, 2004, CHEM-EUR J, V10, P5829, DOI 10.1002/CHEM.200400528##VAN DEN BERG M, 2003, ADV SYNTH CATAL, V345, P308, DOI 10.1002/ADSC.200390026##VAN DEN BERG M, 2000, J AM CHEM SOC, V122, P11539, DOI 10.1021/JA002507F##VINEYARD BD, 1977, J AM CHEM SOC, V99, P5946, DOI 10.1021/JA00460A018##WAGNER HH, 2001, J CATAL, V203, P150, DOI 10.1006/JCAT.2001.3296",52,2020-11-20,NA
J,WOS:000242689200015,2006,THE HETEROGENEOUS ADVANTAGE: BIODIESEL BY CATALYTIC REACTIVE DISTILLATION,"THE INCENTIVES FOR USING BIODIESEL AS RENEWABLE FUEL AND THE DIFFICULTIES ASSOCIATED WITH ITS PRODUCTION ARE OUTLINED. THE PROS AND CONS OF MANUFACTURING BIODIESEL VIA FATTY ACID ESTERIFICATION USING SOLID ACID CATALYSTS ARE INVESTIGATED. FINDING A SUITABLE CATALYST THAT IS ACTIVE, SELECTIVE, AND STABLE UNDER THE PROCESS CONDITIONS IS THE MAJOR CHALLENGE. THE MOST PROMISING CANDIDATES WERE FOUND TO BE THE SULFATED METAL OXIDES THAT CAN BE USED TO DEVELOP A SUSTAINABLE ESTERIFICATION PROCESS BASED ON CATALYTIC REACTIVE DISTILLATION.",FATTY-ACID ESTERIFICATION; HIGH-SURFACE-AREA; SULFATED-ZIRCONIA; DESIGN,BIODIESEL; REACTIVE DISTILLATION; ESTERIFICATION; SOLID ACID CATALYSTS; MIXED METAL OXIDES,TOPICS IN CATALYSIS,"KISS, AA##OMOTA, F##DIMIAN, AC##ROTHENBERG, G","UNIV AMSTERDAM, VANT HOFF INST MOL SCI, NL-1018 WV AMSTERDAM, NETHERLANDS.","CHEMISTRY, APPLIED; CHEMISTRY, PHYSICAL",CHEMISTRY,"ARDIZZONE S, 1999, CATAL LETT, V62, P59, DOI 10.1023/A:1019026417623##BLUMBERG KO, 2003, LOW SULFUR GASOLINE##BUCZEK B., 2004, INFORM - INTERNATIONAL NEWS ON FATS, OILS AND RELATED MATERIALS, V15, P186##CLARK JH, 2002, ACCOUNTS CHEM RES, V35, P791, DOI 10.1021/AR010072A##CLARK JH, 2000, J CATAL, V193, P348, DOI 10.1006/JCAT.2000.2912##DEMIRBAS A, 2003, ENERG EXPLOR EXPLOIT, V21, P475, DOI 10.1260/014459803322986295##ECORMIER MA, 2003, J CATAL, V215, P57, DOI 10.1016/S0021-9517(02)00150-1##GRAEDEL T. E., 2002, HDB GREEN CHEM TECHN, P56##HARMER MA, 1996, J AM CHEM SOC, V118, P7708, DOI 10.1021/JA9541950##HARMER MA, 2001, APPL CATAL A-GEN, V221, P45, DOI 10.1016/S0926-860X(01)00794-3##HARMER MA, 1998, ADV MATER, V10, P1255, DOI 10.1002/(SICI)1521-4095(199810)10:15<1255::AID-ADMA1255>3.0.CO;2-T##HARMER MA, 2000, GREEN CHEM, V2, P7, DOI 10.1039/A907892D##HARMER MA, 2002, HDB GREEN CHEM TECHN, P86##KAMIYA Y, 2004, CATAL LETT, V94, P45, DOI 10.1023/B:CATL.0000019329.82828.E4##KISS AA, 2006, ADV SYNTH CATAL, V348, P75, DOI 10.1002/ADSC.200505160##KORBITZ W, 1999, RENEW ENERG, V16, P1078, DOI 10.1016/S0960-1481(98)00406-6##KOSTER R, 2001, J CATAL, V204, P333, DOI 10.1006/JCAT.2001.3356##LOTERO E, 2005, IND ENG CHEM RES, V44, P5353, DOI 10.1021/IE049157G##MA FR, 1999, BIORESOURCE TECHNOL, V70, P1, DOI 10.1016/S0960-8524(99)00025-5##MATSUDA H, 1998, CATAL LETT, V56, P241, DOI 10.1023/A:1019085818706##OKUHARA T, 2002, CHEM REV, V102, P3641, DOI 10.1021/CR0103569##OMOTA F, 2003, CHEM ENG SCI, V58, P3175, DOI 10.1016/S0009-2509(03)00154-4##OMOTA F, 2003, CHEM ENG SCI, V58, P3159, DOI 10.1016/S0009-2509(03)00165-9##SCHOENMAKERS HG, 2003, CHEM ENG PROCESS, V42, P145, DOI 10.1016/S0255-2701(02)00085-5##SHEEHAN J, 1988, LIFE CYCLE INVENTORY##SHEEHAN J., 1998, OVERVIEW BIODIESEL P##STEINIGEWEG S, 2003, IND ENG CHEM RES, V42, P3612, DOI 10.1021/IE020925I##SUBAWALLA H, 1999, IND ENG CHEM RES, V38, P3696, DOI 10.1021/IE990008L##TAYLOR R, 2000, CHEM ENG SCI, V55, P5183, DOI 10.1016/S0009-2509(00)00120-2##VAN DER WAAL JC, 2001, ROY SOC CH, P27##VONTHUIJL E, 2003, OVERVIEW BIOFUEL TEC##WILSON K, 2000, J MOL CATAL A-CHEM, V159, P309, DOI 10.1016/S1381-1169(00)00185-0##YADAV GD, 2004, J CATAL, V224, P218, DOI 10.1016/J.JCAT.2004.02.021##YADAV GD, 1999, MICROPOR MESOPOR MAT, V33, P1, DOI 10.1016/S1387-1811(99)00147-X",165,2020-11-20,NA
J,WOS:000242689200019,2006,HIGH THROUGHPUT SCREENING OF MONOPHOS INSTANT LIGAND LIBRARY LEADS TO A TON-SCALE ASYMMETRIC HYDROGENATION PROCESS,"THE DEVELOPMENT OF CATALYTIC PROCESSES FOR PHARMACEUTICALS INTERMEDIATES IS OFTEN UNDER SEVERE TIME-PRESSURE. TO COPE WITH THIS CONSTRAINT, HIGH THROUGHPUT EXPERIMENTATION (HTE) METHODS HAVE BEEN IMPLEMENTED FOR CATALYST FINDING. IN THIS ARTICLE, WE PRESENT THE HTE PROTOCOLS PUT IN PLACE AT DSM IN THE AREA OF ENANTIOSELECTIVE HYDROGENATION. THEY MOSTLY RELY ON LIBRARIES OF MONODENTATE CHIRAL PHOSPHORAMIDITES LIGANDS. WE APPLIED OUR INSTANT LIGAND LIBRARY TECHNOLOGY TO SOLVE A REAL-LIFE CASE, I.E. THE ASYMMETRIC HYDROGENATION OF AN ALPHA-SUBSTITUTED CINNAMIC ACID DERIVATIVE. THIS HAS LED TO A MULTI-TON SCALE PROCESS.",RH-CATALYZED HYDROGENATION; MONODENTATE P-LIGANDS; ENANTIOSELECTIVE CONJUGATE ADDITION; TROPOS PHOSPHORUS-LIGANDS; COMBINATORIAL APPROACH; BIDENTATE LIGANDS; PHOSPHORAMIDITE LIGANDS; OLEFIN HYDROGENATION; PARALLEL SYNTHESIS; FINE CHEMICALS,ASYMMETRIC HYDROGENATION; PHOSPHORAMIDITE; LIGANDS LIBRARY; MIXTURE OF LIGANDS; HIGH THROUGHPUT EXPERIMENTATION; ALPHA-SUBSTITUTED CINNAMIC ACID,TOPICS IN CATALYSIS,"LEFORT, L##BOOGERS, JAF##DE VRIES, AHM##DE VRIES, JG","DSM RES & PATENTS, ADV SYNTH CATALYSIS & DEV, NL-6160 MD GELEEN, NETHERLANDS.","CHEMISTRY, APPLIED; CHEMISTRY, PHYSICAL",CHEMISTRY,"AGER DJ, 2005, HDB CHIRAL FINE CHEM##BERNSMANN H, 2005, J ORG CHEM, V70, P943, DOI 10.1021/JO048374O##BLASER H.-U, 2004, ASYMMETRIC CATALYSIS##BLASER HU, 2003, CHEM COMMUN, P293, DOI 10.1039/B209968N##BLASER HU, 2003, ADV SYNTH CATAL, V345, P103, DOI 10.1002/ADSC.200390000##BREIT B, 2005, ANGEW CHEM INT EDIT, V44, P1640, DOI 10.1002/ANIE.200462499##BREIT B, 2005, ANGEW CHEM, V117, P4401##BROWN JM, 2004, COMPREHENSIVE ASYMME, P121##CLAVER C, 2000, CHEM COMMUN, P961##DAHMEN S, 2001, SYNTHESIS-STUTTGART, P1431##DE VRIES JG, 2003, EUR J ORG CHEM, V2003, P799##DEVRIES AHM, 1996, ANGEW CHEM INT EDIT, V35, P2374, DOI 10.1002/ANIE.199623741##DEVRIES AHM, 2005, CHIM OGGI, V23, P18##DING KL, 2004, CHEM-EUR J, V10, P2872, DOI 10.1002/CHEM.200305707##FERINGA BL, 2000, ACCOUNTS CHEM RES, V33, P346, DOI 10.1021/AR990084K##GENNARI C, 2003, CHEM REV, V103, P3071, DOI 10.1021/CR020058R##GILBERTSON SR, 1999, TETRAHEDRON, V55, P11609, DOI 10.1016/S0040-4020(99)00682-1##HAGEMEYER A, 2001, APPL CATAL A-GEN, V221, P23, DOI 10.1016/S0926-860X(01)00886-9##HARTWIG J, 2005, NATURE, V437, P487, DOI 10.1038/437487A##HAWKINS JM, 2004, ANGEW CHEM INT EDIT, V43, P3224, DOI 10.1002/ANIE.200330072##HEROLD P, PATENT NO. 0202500##HOEN R, 2006, ORG BIOMOL CHEM, V4, P613, DOI 10.1039/B517096F##HOEN R, 2005, ANGEW CHEM INT EDIT, V44, P4209, DOI 10.1002/ANIE.200500784##HOEN R, 2004, ORG LETT, V6, P1433, DOI 10.1021/OL049726G##HOVEYDA A, 2002, HDB COMBINATORIAL CH, V2, P991##HUTTENLOCH O, 2002, CHEM-EUR J, V8, P4767, DOI 10.1002/1521-3765(20021018)8:20<4767::AID-CHEM4767>3.0.CO;2-O##JERPHAGNON T, 2004, TETRAHEDRON-ASYMMETR, V15, P2101, DOI 10.1016/J.TETASY.2004.04.037##LAPOINTE AM, 1999, J COMB CHEM, V1, P101, DOI 10.1021/CC980013X##LEFORT L, 2004, ORG LETT, V6, P1733, DOI 10.1021/OL049510E##MONTI C, 2005, CHEM-EUR J, V11, P6701, DOI 10.1002/CHEM.200500464##MONTI C, 2004, TETRAHEDRON LETT, V45, P6859, DOI 10.1016/J.TETLET.2004.07.100##OHKUMA T., 2000, CATALYTIC ASYMMETRIC, P1##PANELLA L, 2006, J ORG CHEM, V71, P2026, DOI 10.1021/JO052451D##PANELLA L, 2005, ORG LETT, V7, P4177, DOI 10.1021/OL051559C##PENA D, 2003, ORG BIOMOL CHEM, V1, P1087, DOI 10.1039/B302097E##PENA D, 2002, J AM CHEM SOC, V124, P14552, DOI 10.1021/JA028235T##PENA D, 2003, ORG LETT, V5, P475, DOI 10.1021/OL027457T##REETZ MT, 2001, ANGEW CHEM INT EDIT, V40, P284, DOI 10.1002/1521-3773(20010119)40:2<284::AID-ANIE284>3.0.CO;2-N##REETZ MT, 2005, J AM CHEM SOC, V127, P10305, DOI 10.1021/JA052025+##REETZ MT, 2005, ANGEW CHEM INT EDIT, V44, P2959, DOI 10.1002/ANIE.200462612##REETZ MT, 2004, TETRAHEDRON, V60, P9709, DOI 10.1016/J.TET.2004.07.042##REETZ MT, 2004, TETRAHEDRON-ASYMMETR, V15, P2165, DOI 10.1016/J.TETASY.2004.04.038##REETZ MT, 2003, TETRAHEDRON LETT, V44, P4593, DOI 10.1016/S0040-4039(03)00976-6##REETZ MT, 2003, ANGEW CHEM INT EDIT, V42, P790, DOI 10.1002/ANIE.200390209##REETZ MT, 2000, ANGEW CHEM INT EDIT, V39, P3889, DOI 10.1002/1521-3773(20001103)39:21<3889::AID-ANIE3889>3.0.CO;2-T##SLAGT VF, 2004, J AM CHEM SOC, V126, P4056, DOI 10.1021/JA038955F##SLAGT VF, 2003, ANGEW CHEM INT EDIT, V42, P5619, DOI 10.1002/ANIE.200352525##SLAGT VF, 2003, CHEM COMMUN, P2474, DOI 10.1039/B306683E##SLAGT VF, 2003, ANGEW CHEM, V115, P5771##STURM T, 2003, ADV SYNTH CATAL, V345, P160, DOI 10.1002/ADSC.200390003##TAKACS JM, 2004, J AM CHEM SOC, V126, P4494, DOI 10.1021/JA049873+##VAN DEN BERG M, 2003, ADV SYNTH CATAL, V345, P308, DOI 10.1002/ADSC.200390026##VAN DEN BERG M, 2002, ADV SYNTH CATAL, V344, P1003, DOI 10.1002/1615-4169(200210)344:9<1003::AID-ADSC1003>3.0.CO;2-M##VAN DEN BERG M, 2000, J AM CHEM SOC, V122, P11539, DOI 10.1021/JA002507F##VANROOY A, 1995, THESIS U AMSTERDAM",18,2020-11-20,NA
J,WOS:000241316100006,2006,INTERMEDIATE DIMENSIONS OF PRODUCTS,WE CONSTRUCT UNDER THE CONTINUUM HYPOTHESIS AN EXAMPLE OF A COMPACT SPACE NO FINITE POWER OF WHICH CONTAINS AN INFINITE CLOSED SUBSET THAT IS OF FINITE DIMENSION GREATER THAN 0. THIS IS A PARTIAL ANSWER TO A QUESTION OF THE THIRD AUTHOR. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.,TRANSFORMATIONS; SUBSETS,CONTINUUM HYPOTHESIS; INFINITE-DIMENSIONAL PRODUCT; RESOLUTION; INTERMEDIATE DIMENSION,TOPOLOGY AND ITS APPLICATIONS,"FEDORCHUK, VV##IVANOV, AV##VAN MILL, J","VRIJE UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS. MOSCOW MV LOMONOSOV STATE UNIV, MOSCOW, RUSSIA. PETROZAVODSK STATE UNIV, PETROZAVODSK, RUSSIA.","MATHEMATICS, APPLIED; MATHEMATICS",MATHEMATICS,"BEGLE E. G., 1955, MICH MATH J, V3, P179##BEGLE EG, 1950, ANN MATH, V51, P534, DOI 10.2307/1969366##BING RH, 1967, GENERAL TOPOLOGY ITS, V2, P56##BREDON GE, 1997, SHEAF THEORY, V170##DYER E, 1956, ANN MATH, V63, P15, DOI 10.2307/1969988##ENGELKING R, 1995, THEORY DIMENSIONS FI##FEDORCHUK VV, 1975, MATH USSR SB, V25, P37##FEDORCHUK VV, 1969, SOV MATH DOKL, V10, P314##FEDORCHUK VV, 1973, SOV MATH DOKL, V14, P1808##FEDORCHUK VV, 2004, ENCY GEN TOPOLOGY, P223##FEDORCUK VV, 1968, SOV MATH DOKL, V9, P1148##HENDERSON DW, 1967, AM J MATH, V89, P105, DOI 10.2307/2373100##HENDERSON DW, 1960, TOP SEM WISC, P141##IVANOV AV, 1978, DOKL AKAD NAUK SSSR+, V239, P1037##POL R, 1990, OPEN PROBLEMS TOPOLO, P279##RUBIN LR, 1980, MICH MATH J, V27, P65##SKLJARENKO EG, 1963, DOKL AKAD NAUK SSSR, V149, P264##SKLJARENKO EG, 1964, USP MAT NAUK, V19, P47##SKLJARENKO EG, 1962, DOKL AKAD NAUK SSSR, V143, P1053##VAN MILL J., 2001, INFINITE DIMENSIONAL##VANMILL J, 1983, FUND MATH, V118, P93, DOI 10.4064/FM-118-2-93-102##VIETORIS L, 1927, MATH ANN, V97, P454, DOI 10.1007/BF01447877##WALSH JJ, 1979, TOPOLOGY, V18, P91, DOI 10.1016/0040-9383(79)90017-X##WATSON S, 1992, RECENT PROGR GEN TOP, P673##ZARELUA AV, 1972, THEORY SETS TOPOLOGY, P509",3,2020-11-20,NA
J,WOS:000242557100020,2006,CONFIRMATION OF ORGANIC MICROPOLLUTANTS DETECTED IN ENVIRONMENTAL SAMPLES BY LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY: ACHIEVEMENTS AND PITFALLS,"DIFFERENT APPROACHES TO THE CONFIRMATION OF PESTICIDES AND ANTIBIOTICS DETECTED IN ENVIRONMENTAL WATERS HAVE BEEN EVALUATED USING LIQUID CHROMATOGRAPHY (LC) HYPHENATED TO MASS SPECTROMETRY (MS) - BOTH TRIPLE QUADRUPOLE (QQQ) AND HYBRID QUADRUPOLE-TIME-OF-FLIGHT (Q-TOF) ANALYZERS. AFTER ANALYZING MORE THAN 100 GROUNDWATER AND SURFACE-WATER SAMPLES, WE DISCUSS IN THIS ARTICLE THE MAIN ACHIEVEMENTS AND PITFALLS OF LGMS IN CONFIRMATION OF POSITIVE FINDINGS. THE ACQUISITION OF, AT LEAST, TWO SPECIFIC SELECTED REACTION MONITORING (SRM) TRANSITIONS FOR EACH ANALYTE WHEN USING LC-TANDEM MS (LC-MS2) QQQ WAS FOUND TO BE AN EFFICIENT AND SIMPLE WAY OF ACHIEVING SAFE CONFIRMATION, WHILE THE USE OF ONLY ONE TRANSITION WOULD HAVE RESULTED IN SOME FALSE POSITIVES IN THE SAMPLES ANALYZED. THE USE OF NON-SPECIFIC TRANSITIONS, SUCH AS THOSE INVOLVING THE LOSS OF WATER, MIGHT SPORADICALLY RESULT IN FALSE POSITIVE FINDINGS EVEN AFTER ACQUIRING TWO TRANSITIONS, AS THE PROBABILITY OF FINDING INTERFERENCES SHARING THE SAME TRANSITION INCREASES. MOREOVER, SOME FALSE NEGATIVES MIGHT BE REPORTED WHEN ACQUIRING TWO TRANSITIONS WHEN ONE OF THEM IS SHARED BY AN INTERFERENT, AS IT WOULD AFFECT THE EXPERIMENTAL ION-ABUNDANCE RATIO. THIS POSSIBILITY IS MORE LIKELY TO OCCUR AT SUB-PPB ANALYTE CONCENTRATIONS THAN AT HIGHER CONCENTRATIONS. FOR THIS REASON, WE FOUND THAT THE ACQUISITION OF THE HIGHEST NUMBER OF AVAILABLE TRANSITIONS WAS AN EFFICIENT WAY TO IMPROVE RELIABILITY IN THE CONFIRMATION PROCESS. THE USE OF Q-TOF-MS CAN PROVIDE AN ULTIMATE, UNEQUIVOCAL CONFIRMATION OF POSITIVE FINDINGS, DUE TO ITS INHERENT ADVANTAGES OF ACCURATE MASS AND ACQUISITION OF COMPLETE PRODUCT-ION SPECTRA. HOWEVER, FALSE NEGATIVES COULD BE REPORTED IF A CO-ELUTING ISOBARIC INTERFERENCE WAS PRESENT. IN THAT CASE, WE FOUND THAT A MORE EFFICIENT CHROMATOGRAPHIC SEPARATION WAS THE BEST WAY TO IMPROVE THE CONFIRMATION PROCESS. THE LOWER SENSITIVITY OF Q-TOF IN COMPARISON TO QQQ CAN BE ONE DRAWBACK OF THIS APPROACH, WHICH CAN HAMPER THE CONFIRMATION AT VERY LOW ANALYTE CONCENTRATION LEVELS. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",SOLID-PHASE EXTRACTION; QUADRUPOLE-TIME; TRANSFORMATION PRODUCTS; SOIL SAMPLES; WATER; PESTICIDES; ELUCIDATION; RESIDUES; LEVEL; ANTIBIOTICS,ANTIBIOTIC; CONFIRMATION; ENVIRONMENTAL SAMPLE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ORGANIC MICROPOLLUTANT; PESTICIDE,TRAC-TRENDS IN ANALYTICAL CHEMISTRY,"POZO, OJ##SANCHO, JV##IBANEZ, M##HERNANDEZ, F##NIESSEN, WMA","UNIV JAUME 1, RES INST PESTICIDES & WATER, E-12071 CASTELLON DE LA PLANA, SPAIN. HYPHEN MASSSPEC CONSULTANCY, NL-2332 XT LEIDEN, NETHERLANDS.","CHEMISTRY, ANALYTICAL",CHEMISTRY,"CARDENAS S, 2005, TRAC-TREND ANAL CHEM, V24, P477, DOI 10.1016/J.TRAC.2005.03.006##*EUR COMM, 2004, SANCO104762003 EUR C##FERRER I, 2005, ANAL CHEM, V77, P2818, DOI 10.1021/AC048458X##*FOOD DRUG ADM, 2001, 118 FOOD DRUG ADM##GEERDINK RB, 2002, J CHROMATOGR A, V970, P65, DOI 10.1016/S0021-9673(02)00234-0##HERNANDEZ F, 2004, ANAL CHEM, V76, P4349, DOI 10.1021/AC049768I##HERNANDEZ F, 2001, J CHROMATOGR A, V939, P1, DOI 10.1016/S0021-9673(01)01334-6##HERNANDEZ F, 2005, TRENDS ANAL CHEM, V24, P569##HERNANDO MD, 2006, ANAL BIOANAL CHEM, V385, P985, DOI 10.1007/S00216-006-0394-5##HIRSCH R, 1998, J CHROMATOGR A, V815, P213, DOI 10.1016/S0021-9673(98)00335-5##IBANEZ M, 2006, ANAL BIOANAL CHEM, V384, P448, DOI 10.1007/S00216-005-0167-6##IBANEZ M, 2005, J CHROMATOGR A, V1081, P145, DOI 10.1016/J.CHROMA.2005.05.041##IBANEZ M, 2005, RAPID COMMUN MASS SP, V19, P169, DOI 10.1002/RCM.1764##IBANEZ M, 2004, ANAL CHEM, V76, P1328, DOI 10.1021/AC035200I##MA WT, 2004, ANAL BIOANAL CHEM, V378, P1828, DOI 10.1007/S00216-004-2523-3##POZO OJ, 2006, J CHROMATOGR A, V1103, P83, DOI 10.1016/J.CHROMA.2005.10.073##QUINTANA JB, 2006, ANAL CHEM, V78, P1644, DOI 10.1021/AC0517186##REEMTSMA T, 2003, J CHROMATOGR A, V1000, P477, DOI 10.1016/S0021-9673(03)00507-7##RIVIER L, 2003, ANAL CHIM ACTA, V492, P69, DOI 10.1016/S0003-2670(03)00889-4##SANCHO JV, 2006, ANAL BIOANAL CHEM, V386, P987, DOI 10.1007/S00216-006-0532-0##SANCHO JV, 2004, ANALYST, V129, P38, DOI 10.1039/B312236K##SECCIA S, 2005, ANAL CHIM ACTA, V553, P21, DOI 10.1016/J.ACA.2005.08.006##STOLKER AAM, 2004, ANAL BIOANAL CHEM, V378, P955, DOI 10.1007/S00216-003-2253-Y##TILL AE, 2005, SCI TOTAL ENVIRON, V350, P273, DOI 10.1016/J.SCITOTENV.2005.04.005##VAN EENOO P, 2004, CHROMATOGRAPHIA, V59, PS39, DOI 10.1365/S10337-004-0198-8##VEGA AB, 2005, ANAL CHIM ACTA, V538, P117, DOI 10.1016/J.ACA.2005.02.003##*WADA, 2004, TD2003IDCR WADA",96,2020-11-20,NA
J,WOS:000241524700018,2006,"BIOCHEMICAL, MOLECULAR CHARACTERIZATION, AND GLYCOPROTEOMIC ANALYSES OF ALPHA(1)-PROTEINASE INHIBITOR PRODUCTS USED FOR REPLACEMENT THERAPY","BACKGROUND: ISOELECTRIC FOCUSING (IEF) OF ALPHA(1)-PROTEINASE INHIBITOR (A1PI) SHOWS THAT COMMERCIAL PRODUCTS AND PLASMA HAVE DIFFERENT GLYCOISOFORM BAND PATTERNS. THOSE IN ARALAST (GRIFOLS BIOLOGICALS) REFLECT AN ANODAL SHIFT OF GLYCOISOFORMS, WHICH HAS CAUSED CONCERN. THE PROTEIN, INCLUDING GLYCOPROTEOMIC ANALYSES, AND STRUCTURAL FEATURES OF A1PI PRODUCTS WERE INVESTIGATED BY STATE-OF-THE-ART TECHNIQUES. STUDY DESIGN AND METHODS: BATCHES FROM ARALAST, PROLASTIN (BAYER), AND ZEMAIRA (AVENTIS BEHRING LLC) WERE ANALYZED BY HIGH-RESOLUTION IEF AND HIGH-PERFORMANCE SIZE-EXCLUSION CHROMATOGRAPHY (HP-SEC). PREPARATIVE SEPARATED ISOFORMS FROM IEF WERE FURTHER PURIFIED BY CHROMATOGRAPHY AND SUBJECTED TO MASS SPECTROMETRY FOR SEQUENCE ANALYSES, PEPTIDE MAPPING, AND GLYCOSYLATION ANALYSIS. DEAMIDATION WAS QUANTIFIED BY ENZYMATIC ISOASPARTATE DETECTION. MULTIPLE SEQUENCE ALIGNMENTS AND STRUCTURAL BIOINFORMATICS ANALYSES WERE PERFORMED. RESULTS: IN HP-SEC, PROLASTIN HAD THE HIGHEST AGGREGATE CONTENT AT APPROXIMATELY 30 PERCENT. ISOFORMS FROM ALL PRODUCTS PURIFIED BY HIGH-RESOLUTION IEF WERE SEQUENCED WITH AN AMINO ACID COVERAGE OF MORE THAN 98 PERCENT. DEAMIDATION OF ASN116 AND ASN314 IN A1PI WAS TO FOUND TO SOME EXTENT IN ALL PRODUCTS AND CONFIRMED QUANTITATIVELY BY ENZYMATIC ANALYSIS. THERE WERE NO SIGNS OF METHIONINE OXIDATION. CYS232 WAS FOUND TO BE CYSTEINYLATED IN A1PI IN PROLASTIN AND ARALAST AS IN PLASMA, BUT NOT IN ZEMAIRA. ALL PRODUCTS SHOWED TRUNCATION OF THE C-TERMINAL LYSINE. INTACT A1PI CONCENTRATES CONTAINED MAINLY DIANTENNARY, DISIALYLATED AND SMALLER AMOUNTS OF TRIANTENNARY, TRISIALYLATED N-GLYCANS. THE PERCENTAGE OF FUCOSYLATION WAS SIMILAR IN ALL PRODUCTS. SITE-SPECIFIC GLYCAN ANALYSIS REVEALED BANDS M6 CONTAINED ONLY DIANTENNARY GLYCANS, WHEREAS THE MORE ACIDIC BANDS M4 AND M2 ALSO CARRIED TRIANTENNARY STRUCTURES. THE MOST ACIDIC ISOFORMS, M2 IN PROLASTIN AND ZEMAIRA AND M0 IN ARALAST, ADDITIONALLY EXHIBITED TETRAANTENNARY N-GLYCANS. CONCLUSION: PROTEIN CHEMICAL CHARACTERIZATION OF A1PI SHOWED THAT ALL A1PI PRODUCTS TO SOME EXTENT DIFFER FROM A1PI CIRCULATING IN HUMAN PLASMA. BIOINFORMATIC ANALYSIS INDICATED THAT REMOVAL OF C-TERMINAL LYS394 AND CYSTEINYLATION OF CYS232 ARE UNLIKELY TO AFFECT STRUCTURE AND/OR FUNCTION OF A1PI BUT CYSTEINYLATION MAY INFLUENCE INTERACTION BETWEEN A1PI AND ITS PHYSIOLOGIC LIGANDS. ARALAST, PROLASTIN, AND ZEMAIRA CONTAIN THE SAME SET OF N-GLYCANS IN THE SAME RATIOS AS THOSE IN NORMAL HUMAN PLASMA A1PI. TRI- AND TETRAANTENNARY STRUCTURES ARE RESPONSIBLE FOR THE PARTITIONING INTO IEF ISOFORMS, WITH THE MIGRATION SHIFT OF ARALAST NOT BEING DUE TO ANY DIFFERENCE IN THE N-GLYCOSYLATION, BUT TO THE PARTIAL LOSS OF THE C-TERMINAL LYSINE.",HUMAN ALPHA-1-PROTEINASE INHIBITOR; MASS-SPECTROMETRY; HUMAN ALPHA-1-ANTITRYPSIN; GEL-ELECTROPHORESIS; PROTEIN; ALPHA(1)-ANTITRYPSIN; DEAMIDATION; METHIONINE; RESIDUES; ISOFORMS,NA,TRANSFUSION,"KOLARICH, D##TURECEK, PL##WEBER, A##MITTERER, A##GRANINGER, M##MATTHIESSEN, P##NICOLAES, GAF##ALTMANN, F##SCHWARZ, HP","BAXTER BIOSCI, A-1220 VIENNA, AUSTRIA. UNIV NAT RESOURCES & APPL LIFE SCI, VIENNA, AUSTRIA. UNIV LIMBURG, CARDIOVASC RES INST, DEPT BIOCHEM, NL-6200 MD MAASTRICHT, NETHERLANDS.",HEMATOLOGY,HEMATOLOGY,"BERMAN HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/NAR/28.1.235##BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/ABIO.1995.1468##BRANTLY M, 1996, ALPHA 1 ANTITRYPSIN, P45##CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329A0##CARRELL RW, 1981, FEBS LETT, V135, P301, DOI 10.1016/0014-5793(81)80805-8##CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/NAR/16.22.10881##COWDEN DI, 2005, CURR MED RES OPIN, V21, P877, DOI 10.1185/030079905X46395##DEGROOT BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O##GASTEIGER E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/NAR/GKG563##GEIGER T, 1987, J BIOL CHEM, V262, P785##GLASER CB, 1982, INT J PEPT PROT RES, V20, P56##GUEROIS R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4##GUILE GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/ABIO.1996.0351##HARRIS RJ, 1995, J CHROMATOGR A, V705, P129, DOI 10.1016/0021-9673(94)01255-D##JEPPSSON JO, 1985, J CHROMATOGR, V327, P173, DOI 10.1016/S0021-9673(01)81646-0##JEPPSSON JO, 1982, CLIN CHEM, V28, P219##JOHNSON D, 1978, J BIOL CHEM, V253, P7142##JOHNSON D, 1979, J BIOL CHEM, V254, P4022##KARLSSON H, 2005, PROTEOMICS, V5, P1431, DOI 10.1002/PMIC.200401010##KOLARICH D, 2006, PROTEOMICS, V6, P3369, DOI 10.1002/PMIC.200500751##KUEPPERS F, 2005, CHEST, V128, P262S, DOI 10.1378/CHEST.128.4_MEETINGABSTRACTS.262S##LAURELL CB, 1978, CHEM PHYSL HUMAN PLA, P329##LEHMANN WD, 2000, PROTEIN SCI, V9, P2260, DOI 10.1110/PS.9.11.2260##MA BY, 2004, BIOCHEM BIOPH RES CO, V317, P60, DOI 10.1016/J.BBRC.2004.03.012##MANZELLA SM, 1995, J BIOL CHEM, V270, P21665, DOI 10.1074/JBC.270.37.21665##MEGA T, 1980, J BIOL CHEM, V255, P4057##MILLS K, 2003, GLYCOBIOLOGY, V13, P73, DOI 10.1093/GLYCOB/CWG026##MILLS PB, 2001, PROTEOMICS, V1, P778, DOI 10.1002/1615-9861(200106)1:6<778::AID-PROT778>3.0.CO;2-H##MOLL M, 2004, J VIROL, V78, P7274, DOI 10.1128/JVI.78.13.7274-7278.2004##MORAIS VA, 2003, BBA-GEN SUBJECTS, V1619, P133, DOI 10.1016/S0304-4165(02)00448-8##NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/ELPS.1150090603##ROBINSON NE, 2001, P NATL ACAD SCI USA, V98, P4367, DOI 10.1073/PNAS.071066498##RUDD PM, 2001, PROTEOMICS, V1, P285, DOI 10.1002/1615-9861(200102)1:2<285::AID-PROT285>3.3.CO;2-7##RUDD PM, 1997, NATURE, V388, P205, DOI 10.1038/40677##TAGGART C, 2000, J BIOL CHEM, V275, P27258##TAKAHASHI M, 2003, GLYCOCONJUGATE J, V20, P207, DOI 10.1023/B:GLYC.0000024252.63695.5C##TYAGI SC, 1992, BIOCHEMISTRY-US, V31, P10584, DOI 10.1021/BI00158A022##VAUGHAN L, 1982, BIOCHIM BIOPHYS ACTA, V701, P339, DOI 10.1016/0167-4838(82)90237-0##WILSON NL, 2002, J PROTEOME RES, V1, P521, DOI 10.1021/PR025538D##WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532",51,2020-11-20,NA
J,WOS:000240963800002,2006,COMPOSITE TISSUE ALLOTRANSPLANTATION OF THE HAND AND FACE: A NEW FRONTIER IN TRANSPLANT AND RECONSTRUCTIVE SURGERY,"EACH YEAR AN ESTIMATED 7-MILLION PEOPLE IN THE USA NEED COMPOSITE TISSUE RECONSTRUCTION BECAUSE OF SURGICAL EXCISION OF TUMORS, ACCIDENTS AND CONGENITAL MALFORMATIONS. LIMB AMPUTEES ALONE COMPRISE OVER 1.2 MILLION OF THESE. THIS FIGURE IS MORE THAN DOUBLE THE NUMBER OF SOLID ORGANS NEEDED FOR TRANSPLANTATION. COMPOSITE TISSUE ALLOTRANSPLANTATION IN THE FORM OF HAND AND FACIAL TISSUE TRANSPLANTATION ARE NOW A CLINICAL REALITY. THE DISCOVERY, IN THE LATE 1990S, THAT THE SAME IMMUNOTHERAPY USED ROUTINELY IN KIDNEY TRANSPLANTATION WAS ALSO EFFECTIVE IN PREVENTING SKIN REJECTION MADE THIS POSSIBLE. WHILE THESE NEW TREATMENTS SEEM LIKE MAJOR ADVANCEMENTS MOST OF THE SURGICAL, IMMUNOLOGICAL AND ETHICAL METHODS USED ARE NOT NEW AT ALL AND HAVE BEEN AROUND AND ROUTINELY USED IN CLINICAL PRACTICE FOR SOME TIME. IN THIS REVIEW OF COMPOSITE TISSUE ALLOTRANSPLANTATION, WE: (I) OUTLINE THE LIMITATIONS OF CONVENTIONAL RECONSTRUCTIVE METHODS FOR TREATING SEVERE FACIAL DISFIGUREMENT, (II) REVIEW THE HISTORY OF COMPOSITE TISSUE ALLOTRANSPLANTATION, (III) DISCUSS THE CHRONOLOGICAL SCIENTIFIC ADVANCES THAT HAVE MADE IT POSSIBLE, (IV) FOCUS ON THE TWO UNIQUE CLINICAL SCENARIOS OF HAND AND FACE TRANSPLANTATION, AND (V) REFLECT ON THE CRITICAL ISSUES THAT MUST BE ADDRESSED AS WE MOVE THIS NEW FRONTIER TOWARD BECOMING A TREATMENT IN MAINSTREAM MEDICINE.",ISOLATED RABBIT FORELIMB; CYCLOSPORINE-A DELIVERY; LONG-TERM SURVIVAL; FACIAL TRANSPLANTATION; LIMB ALLOGRAFTS; PHARMACOKINETIC ADVANTAGE; SUBCLINICAL REJECTION; MANDIBULAR ALLOGRAFTS; INDEFINITE SURVIVAL; PERIPHERAL-NERVE,COMPOSITE TISSUE ALLOTRANSPLANTATION; ETHICS; FACE TRANSPLANT; HAND TRANSPLANT; IMMUNOSUPPRESSION,TRANSPLANT INTERNATIONAL,"GANDER, B##BROWN, CS##VASILIC, D##FURR, A##BANIS, JC##CUNNINGHAM, M##WIGGINS, O##MALDONADO, C##WHITAKER, I##PEREZ-ABADIA, G##FRANK, JM##BARKER, JH","UNIV LOUISVILLE, DEPT SURG, LOUISVILLE, KY 40202 USA. UNIV UTRECHT, DEPT PLAST RECONSTRUCT & HAND SURG, UTRECHT, NETHERLANDS. UNIV LOUISVILLE, DEPT SOCIOL, LOUISVILLE, KY 40292 USA. UNIV LOUISVILLE, DEPT COMMUN, LOUISVILLE, KY 40292 USA. UNIV LOUISVILLE, DEPT PHILOSOPHY, LOUISVILLE, KY 40292 USA. UNIV LOUISVILLE, SCH MED, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, LOUISVILLE, KY 40292 USA. MORRISTON HOSP, WELSH NATL PLAST SURG UNIT, DEPT PLAST RECONSTRUCT & BURNS SURG, SWANSEA, W GLAM, WALES. GOETHE UNIV FRANKFURT, DEPT TRAUMA SURG, D-6000 FRANKFURT, GERMANY.",SURGERY; TRANSPLANTATION,SURGERY; TRANSPLANTATION,"AGICH GJ, 2004, AM J BIOETHICS, V4, P25, DOI 10.1080/15265160490496921##*AM SOC REC MICR F, 2006, POS AM SOC REC MICR##ANKENY RA, 2004, AM J BIOETHICS, V4, P35, DOI 10.1080/15265160490496750##*ASRM, 2006, FAC TRANSPL ASRM ASP##BAIN JR, 2000, MICROSURG, V20, P384, DOI 10.1002/1098-2752(2000)20:8<384::AID-MICR7>3.0.CO;2-W##BANIS JC, 2004, AM J BIOETHICS, V4, PW23, DOI 10.1080/15265160490508945##BARKER J, 2004, INT J SURG, V2, P8##BARKER J, 2003, NAKED SCI FACE FUTUR##BARKER JH, 2002, TRANSPLANTATION, V73, P832, DOI 10.1097/00007890-200203150-00033##BARKER JH, 2000, MICROSURG, V20, P359, DOI 10.1002/1098-2752(2000)20:8<359::AID-MICR3>3.0.CO;2-B##BARKER JH, 1998, TRANSPLANT P, V30, P2691##BARKER JH, 2006, IN PRESS PLAST RECON##BAYLIS F, 2004, AM J BIOETHICS, V4, P30, DOI 10.1080/15265160490496804##BLACK K, 1991, COMPOSITE TISSUE TRA##BLACK KS, 1982, NEW ENGL J MED, V306, P368##BLACK KS, 1985, TRANSPLANTATION, V39, P365, DOI 10.1097/00007890-198504000-00005##BOREL JF, 1994, AGENTS ACTIONS, V43, P179, DOI 10.1007/BF01986686##BROUHA P, 2006, MICROSURG, V26, P144, DOI 10.1002/MICR.20227##BROUHA PCR, 2004, TRANSPL INT, V17, P341, DOI 10.1111/J.1432-2277.2004.TB00453.X##BUNGER C, 1823, J CHIR AUGENHEILK, V4, P569##BUTLER PEM, 2006, J PLAST RECONSTR AES, V59, P211, DOI 10.1016/J.BJPS.2006.01.001##BUTLER PEM, 2004, AM J BIOETHICS, V4, P16, DOI 10.1080/15265160490496589##CALNE RY, 1979, LANCET, V2, P1033##CAPLAN A, 2004, AM J BIOETHICS, V4, P18, DOI 10.1080/15265160490496930##CARREL A, 1983, JAMA-J AM MED ASSOC, V250, P944, DOI 10.1001/JAMA.250.7.944##CHAMBERS T, 2004, AM J BIOETHICS, V4, P20, DOI 10.1080/15265160490496769##CUNNINGHAM M, 2004, EUR J TRAUMA, V30, P12##DANIEL RK, 1986, J HAND SURG-AM, V11A, P1##DAVARAGINE J, 1952, LEGGENDA AUREA, P648##DOI K, 1979, PLAST RECONSTR SURG, V64, P613, DOI 10.1097/00006534-197964050-00003##DOUGHERTY H, 2003, BURNS GIRL TO HAVE 1##DUBERNARD JM, 1999, LANCET, V353, P1315, DOI 10.1016/S0140-6736(99)02062-0##FAGEEH W, 2002, INT J GYNECOL OBSTET, V76, P245, DOI 10.1016/S0020-7292(01)00597-5##FRANCOIS CG, 2000, MICROSURG, V20, P360, DOI 10.1002/1098-2752(2000)20:8<360::AID-MICR4>3.3.CO;2-5##FRANCOIS CG, 2006, IN PRESS TRANSPLANTA##FRITZ WD, 1984, ANN SURG, V199, P211, DOI 10.1097/00000658-198402000-00014##FURNAS DW, 1983, TRANSPL P, V15, P3063##GILBERT R, 1964, MED TRIB MED NEWS, V5, P20##GNUDI MT, 1976, LIFE TIMES GASPARE T, P285##GOERING S, 2004, AM J BIOETHICS, V4, P37, DOI 10.1080/15265160490906583##GOLD ME, 1991, ANN PLAS SURG, V26, P125, DOI 10.1097/00000637-199102000-00004##GOLDBERG VM, 1980, J BONE JOINT SURG AM, V62, P414, DOI 10.2106/00004623-198062030-00011##GOLDWYN RM, 1966, PLAST RECONSTR SURG, V37, P184, DOI 10.1097/00006534-196603000-00002##GORANTLA V, 2001, EUR J TRAUMA, V7, P267##GORANTLA V, 2000, SURG FORUM, V51, P578##GORANTLA VS, 2003, TRANSPLANTATION, V75, P922, DOI 10.1097/01.TP.0000058302.45424.03##GRATWOHL A, 1986, LAB ANIM, V20, P213, DOI 10.1258/002367786780865692##GRUBER SA, 2000, MICROSURG, V20, P407, DOI 10.1002/1098-2752(2000)20:8<407::AID-MICR11>3.0.CO;2-B##GUIMBERTEAU JC, 1992, PLAST RECONSTR SURG, V89, P1135, DOI 10.1097/00006534-199206000-00023##GUTHRIE C., 1912, BLOOD VESSEL SURG, P37##HEWITT CW, 1985, TRANSPLANTATION, V39, P360, DOI 10.1097/00007890-198504000-00004##HOFMANN GO, 2000, MICROSURG, V20, P375##HOVIUS SER, 1992, PLAST RECONSTR SURG, V89, P700, DOI 10.1097/00006534-199204000-00020##JIANG HQ, 2005, PLAST RECONSTR SURG, V115, P31E, DOI 10.1097/01.PRS.0000153038.31865.02##JONES JW, 1999, SURGERY, V126, P384, DOI 10.1067/MSY.1999.99166##JONES JW, 2000, NEW ENGL J MED, V343, P468, DOI 10.1056/NEJM200008173430704##JONES TR, 1998, TRANSPLANT P, V30, P2746, DOI 10.1016/S0041-1345(98)00802-1##KANITAKIS J, 2005, EUR J DERMATOL, V15, P235##KANITAKIS J, 2003, TRANSPLANTATION, V76, P688, DOI 10.1097/01.TP.0000079458.81970.9A##KANITAKIS J, 2001, TRANSPLANT P, V33, P1722, DOI 10.1016/S0041-1345(00)02657-9##KNIHA H, 1989, ANN PLAS SURG, V22, P135, DOI 10.1097/00000637-198902000-00008##LANCE EM, 1971, J BONE JOINT SURG AM, VA 53, P1137, DOI 10.2106/00004623-197153060-00010##LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/SCIENCE.8493529##LANZETTA M, 2005, TRANSPLANTATION, V79, P1210, DOI 10.1097/01.TP.0000157118.28394.FA##LANZETTA M, 2004, TRANSPLANT P, V36, P675, DOI 10.1016/J.TRANSPROCEED.2004.03.008##LEE WPA, 1991, PLAST RECONSTR SURG, V87, P401, DOI 10.1097/00006534-199103000-00001##LEVI DM, 2003, LANCET, V361, P2173, DOI 10.1016/S0140-6736(03)13769-5##LEVINE E, 2005, ANN PLAS SURG, V54, P502, DOI 10.1097/01.SAP.0000155282.48465.94##LUBBE AS, 1996, CANCER RES, V56, P4694##LUBBE AS, 1996, CANCER RES, V56, P4686##MACKINNON SE, 1992, PLAST RECONSTR SURG, V90, P695, DOI 10.1097/00006534-199210000-00024##MACKINNON SE, 1996, J NEUROSURG, V84, P671, DOI 10.3171/JNS.1996.84.4.0671##MACKINNON SE, 2001, PLAST RECONSTR SURG, V107, P1419, DOI 10.1097/00006534-200105000-00016##MAJZOUB RK, 2006, J HAND SURG-AM, V31A, P295, DOI 10.1016/J.JHSA.2005.09.013##MASCHKE KJ, 2004, AM J BIOETHICS, V4, P33, DOI 10.1080/15265160490496796##MCCABE S, 1998, TRANSPLANT P, V30, P2783, DOI 10.1016/S0041-1345(98)00808-2##MILES SH, 2004, AM J BIOETHICS, V4, P39, DOI 10.1080/15265160490496741##MIYAGI M, 2005, CLIN TRANSPLANT, V19, P456, DOI 10.1111/J.1399-0012.2005.00303.X##MORREIM EH, 2004, AM J BIOETHICS, V4, P27, DOI 10.1080/15265160490496697##MORRIS P, 2003, FACIAL TRANSPLANTATI##MORRIS PJ, 1981, TRANSPLANTATION, V32, P349##MURRAY JE, 1955, SURG FORUM, V6, P432##NANKIVELL BRIAN J., 2003, NEW ENGLAND JOURNAL OF MEDICINE, V349, P2326, DOI 10.1056/NEJMOA020009##OKIE S, 2006, NEW ENGL J MED, V354, P889, DOI 10.1056/NEJMP068005##OLESEN A, 2006, CHINESE FACE TRANSPL##PASCUAL M, 2002, NEW ENGL J MED, V346, P580, DOI 10.1056/NEJMRA011295##PEREZ-ABADIA G, 2003, TRANSPL INT, V16, P835, DOI 10.1111/J.1432-2277.2003.TB00251.X##PETIT F, 2004, AM J BIOETHICS, V4, P14, DOI 10.1080/15265160490496868##PRABHUNE KA, 2003, TRANSPLANTATION, V76, P1548, DOI 10.1097/01.TP.0000085288.12571.65##PRABHUNE KA, 2000, MICROSURG, V20, P441, DOI 10.1002/1098-2752(2000)20:8<441::AID-MICR16>3.0.CO;2-A##PRESS BHJ, 1986, ANN PLAS SURG, V16, P313, DOI 10.1097/00000637-198604000-00007##PRUZINSKY T, 2006, FACIAL TRAUMA FACIAL##RANDZIO J, 1991, ANN PLAS SURG, V26, P140, DOI 10.1097/00000637-199102000-00006##REN XP, 2000, MICROSURG, V20, P143, DOI 10.1002/(SICI)1098-2752(2000)20:3<143::AID-MICR9>3.0.CO;2-9##REYNOLDS C, 2006, IN PRESS LARYNGOSCOP##ROBERTSON JA, 2004, AM J BIOETHICS, V4, P32, DOI 10.1080/15265160490496840##ROBINSON E, 1996, BRIT J PLAST SURG, V49, P281, DOI 10.1016/S0007-1226(96)90156-3##RUMSEY N, 2004, AM J BIOETHICS, V4, P22, DOI 10.1080/15265160490496903##RUSH D, 1998, J AM SOC NEPHROL, V9, P2129##SHIRBACHEH MV, 1999, J PHARMACOL EXP THER, V289, P1196##SHIRBACHEH MV, 1999, J PHARMACOL EXP THER, V289, P1191##SHIRBACHEH MV, 1998, TRANSPLANT P, V30, P2739, DOI 10.1016/S0041-1345(98)00800-8##SHIRBACHEH MV, 1999, J PHARMACOL EXP THER, V289, P1185##SHISHIDO S, 2003, J AM SOC NEPHROL, V14, P1046, DOI 10.1097/01.ASN.0000056189.02819.32##SHRIBACHEH M, 1998, 7 IFSSH C 24 27 MAY##SILISKI JM, 1984, ARCH ORTHOP TRAUM SU, V103, P26, DOI 10.1007/BF00451315##STARK GB, 1987, TRANSPLANT P, V19, P3968##STEVENAGE SV, 1999, BRIT J PSYCHOL, V90, P221, DOI 10.1348/000712699161369##STROME M, 2001, NEW ENGL J MED, V344, P1676, DOI 10.1056/NEJM200105313442204##STRONG C, 2004, AM J BIOETHICS, V4, P13, DOI 10.1080/15265160490496985##TOLEDO-PEREYRA LH, 2003, J INVEST SURG, V16, P243, DOI 10.1080/08941930390230883##TRACHTMAN H, 2004, AM J BIOETHICS, V4, PW33, DOI 10.1080/15265160490508963##USTUNER ET, 2000, MICROSURG, V20, P400, DOI 10.1002/1098-2752(2000)20:8<400::AID-MICR10>3.0.CO;2-Z##WAMKE P, 2005, LANCET, V366, P1984##WIGGINS OP, 2004, AM J BIOETHICS, V4, P1, DOI 10.1080/15265160490496507##*WORK GROUP CCNE, 2006, COMP TISS ALL FAC FU##YE EM, 1998, BURNS, V24, P646, DOI 10.1016/S0305-4179(98)00081-3##ZIMMERMANN KW, 1998, 1 LEG GRAVE MIRACLE##2006, DOCTORS CHINESE FACE##1964, MED TRIB MED NEWS, V5, P23##2003, L M MURPHY APOLOGY##1997, 1 INT S COMP TISS AL##2006, CHINAS 1 FACE TRANSP##2006, CHINESE FACE OP MAN##2000, 2 INT S COMP TISS AL",72,2020-11-20,NA
J,WOS:000240963800006,2006,THE INFLUENCE OF OBESITY ON SHORT- AND LONG-TERM GRAFT AND PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION,"TO DETERMINE SHORT- AND LONG-TERM PATIENT AND GRAFT SURVIVAL IN OBESE [BODY MASS INDEX (BMI) >= 30 KG/M(2)] AND NONOBESE (BMI < 30 KG/M(2)) RENAL TRANSPLANT PATIENTS WE RETROSPECTIVELY ANALYZED OUR NATIONAL-DATABASE. PATIENTS 18 YEARS OR OLDER RECEIVING A PRIMARY TRANSPLANT AFTER 1993 WERE INCLUDED. A TOTAL OF 1871 PATIENTS WERE INCLUDED IN THE NONOBESE GROUP AND 196 IN THE OBESE GROUP. IN THE OBESE GROUP THERE WERE SIGNIFICANTLY MORE FEMALES (52% VS. 38.6%, P < 0.01) AND PATIENTS WERE SIGNIFICANTLY OLDER [52 YEARS (43-59) VS. 48 YEARS (37-58); P < 0.05]. PATIENT SURVIVAL AND GRAFT SURVIVAL WERE SIGNIFICANTLY DECREASED IN OBESE RENAL TRANSPLANT RECIPIENTS (1 AND 5 YEAR PATIENT SURVIVAL WERE RESPECTIVELY 94% VS. 97% AND 81% VS. 89%, P < 0.01; 1 AND 5 YEAR GRAFT SURVIVAL WERE RESPECTIVELY 86% VS. 92% AND 71% VS. 80%, P < 0.01). INITIAL BMI WAS AN INDEPENDENT PREDICTOR FOR PATIENT DEATH AND GRAFT FAILURE. THIS LARGE RETROSPECTIVE STUDY SHOWS THAT BOTH GRAFT AND PATIENT SURVIVAL ARE SIGNIFICANTLY LOWER IN OBESE RENAL TRANSPLANT RECIPIENTS.",BODY-MASS-INDEX; RISK-FACTOR; KIDNEY-TRANSPLANTATION; ALLOGRAFT SURVIVAL; MORBID-OBESITY; IMPACT; OUTCOMES; DISEASE; WEIGHT,GRAFT SURVIVAL; OBESITY; PATIENT SURVIVAL; RENAL TRANSPLANTATION,TRANSPLANT INTERNATIONAL,"AALTEN, J##CHRISTIAANS, MH##DE FIJTER, H##HENE, R##VAN DER HEIJDE, JH##ROODNAT, J##SURACHNO, J##HOITSMA, A","UNIV MED CTR ST RADBOUD, DEPT NEPHROL, NL-6500 HB NIJMEGEN, NETHERLANDS. UNIV HOSP MAASTRICHT, DEPT NEPHROL, MAASTRICHT, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT NEPHROL, LEIDEN, NETHERLANDS. UNIV MED CTR, DEPT NEPHROL, UTRECHT, NETHERLANDS. UNIV GRONINGEN, MED CTR, DEPT NEPHROL, GRONINGEN, NETHERLANDS. ERASMUS UNIV, MED CTR, DEPT NEPHROL, ROTTERDAM, NETHERLANDS. ACAD MED CTR, DEPT NEPHROL, AMSTERDAM, NETHERLANDS.",SURGERY; TRANSPLANTATION,SURGERY; TRANSPLANTATION,"BENNETT WM, 2004, CLIN TRANSPLANT, V18, P89, DOI 10.1046/J.1399-0012.2003.00131.X##DRAFTS HH, 1997, CLIN TRANSPLANT, V11, P493##ECKEL RH, 1998, CIRCULATION, V97, P2099, DOI 10.1161/01.CIR.97.21.2099##EL-AGROUDY AE, 2004, TRANSPLANTATION, V77, P1381, DOI 10.1097/01.TP.0000120949.86038.62##FRIEDMAN AN, 2003, AM J KIDNEY DIS, V41, P480, DOI 10.1053/AJKD.2003.50059##GILL IS, 1993, TRANSPLANT P, V25, P1047##GLANTON CW, 2003, KIDNEY INT, V63, P647, DOI 10.1046/J.1523-1755.2003.00761.X##HALME L, 1997, TRANSPLANT INT, V10, P284##HOWARD RJ, 2002, TRANSPLANTATION, V73, P53, DOI 10.1097/00007890-200201150-00009##JOHNSON DW, 2002, TRANSPLANTATION, V74, P675, DOI 10.1097/00007890-200209150-00015##KRAMER H, 2006, IN PRESS J AM SOC NE##MARKS WH, 2004, AM J SURG, V187, P635, DOI 10.1016/J.AMJSURG.2004.01.015##MASSARWEH NN, 2005, TRANSPLANTATION, V80, P1430, DOI 10.1097/01.TP.0000181094.68259.88##MEIER-KRIESCHE HU, 2002, TRANSPLANTATION, V73, P70, DOI 10.1097/00007890-200201150-00013##MEIER-KRIESCHE HU, 1999, TRANSPLANTATION, V68, P1294, DOI 10.1097/00007890-199911150-00013##MODLIN CS, 1997, TRANSPLANTATION, V64, P599, DOI 10.1097/00007890-199708270-00009##PIRSCH J, 1995, TRANSPLANTATION, V59, P633##PISCHON T, 2001, NEPHROL DIAL TRANSPL, V16, P14, DOI 10.1093/NDT/16.1.14##UDGIRI NR, 2003, TRANSPLANTATION, V76, P1652, DOI 10.1097/01.TP.0000084529.56527.4C##YAMAMOTO S, 2002, CLIN TRANSPLANT, V16, P252, DOI 10.1034/J.1399-0012.2002.01080.X",71,2020-11-20,NA
J,WOS:000242294500012,2006,LIVING DONOR KIDNEY EXCHANGE FOR BOTH ABO-INCOMPATIBLE AND CROSSMATCH POSITIVE DONOR-RECIPIENT COMBINATIONS,"BACKGROUND. STRATEGIES TO DECREASE THE WAIT TIME FOR KIDNEY TRANSPLANTATION INCLUDE THE USE OF LIVING DONOR KIDNEYS. HOWEVER, IT IS NOT ALWAYS POSSIBLE TO DONATE DIRECTLY, DUE TO ABO BLOOD TYPE INCOMPATIBILITY OR A POSITIVE CROSSMATCH. THEREFORE, OTHER OPTIONS WERE EXPLORED, INCLUDING A PROGRAM FOR LIVING DONOR KIDNEY EXCHANGE. METHODS. ALL DUTCH KIDNEY TRANSPLANTATION CENTERS AGREED ON A COMMON DONOR KIDNEY EXCHANGE PROTOCOL. THE DUTCH TRANSPLANTATION FOUNDATION IS RESPONSIBLE FOR THE ALLOCATION, CROSSMATCHES ARE CENTRALLY PERFORMED, AND EXCHANGES TAKE PLACE ON AN ANONYMOUS BASIS. DONORS TRAVEL TO THE RECIPIENT CENTERS. SURGICAL PROCEDURES ARE SIMULTANEOUSLY SCHEDULED. RESULTS. FROM JANUARY 2004, WE REGISTERED IN TOTAL 116 COMBINATIONS CONSISTING OF BLOOD TYPE-INCOMPATIBLE PAIRS (N = 62) AND POSITIVE CROSSMATCH PAIRS (N = 54). IN EIGHT MATCH PROCEDURES WE CREATED 58 NEW DONOR-RECIPIENT COMBINATIONS WITH NEGATIVE CROSSMATCHES, INCLUDING SIX TRIPLETS AND 20 DOUBLETS. IT PROVED TO BE SIGNIFICANTLY (P =.0014) LESS DIFFICULT TO FIND A SOLUTION FOR THE CROSSMATCH-POSITIVE COMBINATIONS THAN FOR THE BLOOD TYPEINCOMPATIBLE COMBINATIONS (67% VS 35%). CONCLUSION. THE DUTCH NATIONAL LIVING DONOR KIDNEY EXCHANGE PROGRAM RESULTED IN A 50% SUCCESS RATE. COMBINING BLOOD TYPE-INCOMPATIBLE AND CROSSMATCH-POSITIVE DONORRECIPIENT PAIRS IN ONE PROGRAM IS A REALISTIC OPTION FOR ALL BLOOD TYPE COMBINATIONS.",NA,NA,TRANSPLANTATION PROCEEDINGS,"DE KLERK, M##HAASE-KROMWIJK, BJJM##CLAAS, FHJ##WITVLIET, M##WEIMAR, W","ERASMUS MC, DEPT INTERNAL MED TRANSPLANTAT, OFF D408, NL-3000 CA ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",IMMUNOLOGY; SURGERY; TRANSPLANTATION,IMMUNOLOGY; SURGERY; TRANSPLANTATION,"DE KLERK M, 2004, ETHICAL, LEGAL, AND SOCIAL ISSUES IN ORGAN TRANSPLANTATION, P255##KEIZER KM, 2005, TRANSPLANT P, V37, P589, DOI 10.1016/J.TRANSPROCEED.2004.12.096##TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601",6,2020-11-20,NA
J,WOS:000242294500021,2006,DONOR-REACTIVE CYTOKINE PRODUCTION AFTER HLA-IDENTICAL LIVING RELATED KIDNEY TRANSPLANTATION: A PROTEIN-ARRAY ANALYSIS,"IN THE PRESENT PILOT STUDY, WE INVESTIGATED WHICH PROTEINS ARE PRODUCED AFTER DONOR STIMULATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM RECIPIENTS OF HLA-IDENTICAL LIVING RELATED KIDNEY TRANSPLANT. WE USED A PROTEIN-ARRAY ANALYSIS TO DETERMINE CYTOKINES, CHEMOKINES, AND GROWTH FACTORS IN SUPERNATANT FROM DONOR-STIMULATED MIXED LYMPHOCYTE REACTION CULTURES. AUTOLOGOUS CULTURES WERE CONSIDERED TO BE NEGATIVE CONTROLS. IN 38 OUT OF 42 PROTEINS (90%), THE DONOR RESPONSE WAS HIGHER COMPARED WITH THE AUTOLOGOUS RESPONSE. THEREFORE, WE CONCLUDED THAT EVEN AFTER HLA-IDENTICAL LIVING RELATED KIDNEY TRANSPLANTATION WE COULD MEASURE A DONOR-REACTIVE RESPONSE, WHICH WE ASSUMED WAS DIRECTED TOWARD MINOR HISTOCOMPATIBILITY OR NON-HLA ANTIGENS.",MINOR HISTOCOMPATIBILITY ANTIGENS; FREQUENCY,NA,TRANSPLANTATION PROCEEDINGS,"GERRITS, JH##VAN DE WETERING, J##WEIMAR, W##VAN BESOUW, NM","UNIV MED CTR ROTTERDAM, EREASMUS MC, DEPT INTERNAL MED TRANSPLANTAT, NL-3000 CA ROTTERDAM, NETHERLANDS.",IMMUNOLOGY; SURGERY; TRANSPLANTATION,IMMUNOLOGY; SURGERY; TRANSPLANTATION,"GERRITS JH, 2005, TRANSPL P, V37, P752, DOI 10.1016/J.TRANSPROCEED.2004.11.105##JOOSTEN SA, 2005, LANCET, V365, P1522, DOI 10.1016/S0140-6736(05)66434-3##MALARKANNAN S, 2005, TRANSPLANT REV, V19, P1##SPIERINGS E, 2004, TRENDS IMMUNOL, V25, P56, DOI 10.1016/J.IT.2003.12.002##VAN BESOUW NM, 2003, TRANSPLANTATION, V75, P1400, DOI 10.1097/01.TP.0000064376.78084.50",2,2020-11-20,NA
J,WOS:000242060100007,2006,BOUNDS AND APPROXIMATIONS FOR THE FIXED-CYCLE TRAFFIC-LIGHT QUEUE,"THIS PAPER DEALS WITH THE FIXED-CYCLE TRAFFIC-LIGHT (FCTL) QUEUE, WHERE VEHICLES ARRIVE AT AN INTERSECTION CONTROLLED BY A TRAFFIC LIGHT AND FORM A QUEUE. THE TRAFFIC LIGHT ALTERNATES BETWEEN GREEN AND RED PERIODS, AND DELAYED VEHICLES ARE ASSUMED TO DEPART DURING THE GREEN PERIOD AT EQUAL TIME INTERVALS. THE KEY PERFORMANCE CHARACTERISTIC IN THE FCTL QUEUE IS THE SO-CALLED MEAN OVERFLOW, DEFINED AS THE MEAN QUEUE LENGTH AT THE END OF A GREEN PERIOD. AN EXACT SOLUTION FOR THE MEAN OVERFLOW IS AVAILABLE, BUT IT HAS BEEN CONSIDERED TO BE OF LITTLE PRACTICAL VALUE BECAUSE IT REQUIRES SOME NUMERICAL PROCEDURES. THEREFORE, MOST OF THE LITERATURE ON THE FCTL QUEUE IS ABOUT DERIVING APPROXIMATIONS FOR THE MEAN OVERFLOW. IN DERIVING THESE APPROXIMATIONS, MOST AUTHORS FIRST APPROXIMATE THE FCTL QUEUE BY A BULK-SERVICE QUEUE, APPROXIMATE THE MEAN OVERFLOW IN THE BULK-SERVICE QUEUE, AND USE THIS AS AN APPROXIMATION FOR THE MEAN OVERFLOW IN THE FCTL QUEUE. SO FAR NO QUANTITATIVE COMPARISON OF BOTH MODELS HAS BEEN GIVEN. WE COMPARE BOTH MODELS AND ASSESS THE QUALITY OF THE APPROXIMATION FOR VARIOUS SETTINGS OF THE PARAMETER VALUES. IN THIS COMPARISON AND THROUGHOUT THE PAPER WE DO NOT RESTRICT OURSELVES TO POISSON ARRIVALS, BUT CONSIDER A MORE GENERAL ARRIVAL PROCESS INSTEAD. WE DISCUSS THE NUMERICAL ISSUES THAT NEED TO BE RESOLVED TO CALCULATE THE EXACT EXPRESSION FOR THE MEAN OVERFLOW IN BOTH QUEUES AND SHOW THAT CLEAR COMPUTATIONAL SCHEMES ARE AVAILABLE. NEXT, WE PRESENT SEVERAL BOUNDS AND APPROXIMATIONS OF THE MEAN OVERFLOW THAT DO NOT REQUIRE NUMERICAL PROCEDURES. IN PARTICULAR, WE DERIVE A NEW APPROXIMATION BASED ON THE HEAVY TRAFFIC LIMIT AND A SCALING ARGUMENT. WE COMPARE THE NEW BOUNDS AND APPROXIMATION WITH THE EXISTING ONES. WE ELABORATE ON THE IMPACT OF SEVERAL PARAMETERS, LIKE THE LENGTH OF THE GREEN AND RED PERIOD AND THE VARIANCE OF THE ARRIVAL DISTRIBUTION. EACH OF THESE PARAMETERS TURNS OUT TO BE CRUCIAL.",NA,TRAFFIC LIGHT; FIXED-TIME CONTROL; OVERFLOW; BULK-SERVICE QUEUE; APPROXIMATIONS; BOUNDS; MEAN DELAY,TRANSPORTATION SCIENCE,"VAN DEN BROEK, MS##VAN LEEUWAARDEN, JSH##ADAN, IJBE##BOXMA, OJ","EINDHOVEN UNIV TECHNOL, NL-5600 MB EINDHOVEN, NETHERLANDS. EURANDOM, NL-5600 MB EINDHOVEN, NETHERLANDS.",OPERATIONS RESEARCH & MANAGEMENT SCIENCE; TRANSPORTATION; TRANSPORTATION SCIENCE & TECHNOLOGY,OPERATIONS RESEARCH & MANAGEMENT SCIENCE; TRANSPORTATION,"BAILEY NTJ, 1954, J ROY STAT SOC B, V16, P80, DOI 10.1111/J.2517-6161.1954.TB00149.X##BECKMANN M.J., 1956, STUDIES EC TRANSPORT##DARROCH JN, 1964, ANN MATH STAT, V35, P380, DOI 10.1214/AOMS/1177703761##DENTENEER D, 2005, MATH METHOD OPER RES, V61, P85, DOI 10.1007/S001860400388##MCNEIL DR, 1968, J APPL PROBAB, V5, P624, DOI 10.2307/3211926##MEISSL P, 1963, MATH TECHNIK WIRTSCH, V10, P63##MILLER AJ, 1963, OPER RES QUART, V14, P373, DOI 10.2307/3006800##NEWELL GF, 1965, SIAM REV, V7, P223, DOI 10.1137/1007038##NEWELL GF, 1960, ANN MATH STAT, V31, P589, DOI 10.1214/AOMS/1177705787##OHNO K., 1978, TRANSPORTATION SCIENCE, V12, P29, DOI 10.1287/TRSC.12.1.29##VAN LEEUWAARDEN JSH, 2006, TRANSPORT SCI, V40, P189, DOI 10.1287/TRSC.1050.0125##WEBSTER FV, 1966, ROAD RES LAB TECH RE, V56##WEBSTER FV, 1958, ROAD RES LAB TECH RE, V39",18,2020-11-20,NA
J,WOS:000242296600005,2006,THE ARCHITECTURE OF PICEA SITCHENSIS STRUCTURAL ROOT SYSTEMS ON HORIZONTAL AND SLOPING TERRAIN,"THE COARSE ROOT SYSTEMS OF 24 SITKA SPRUCE (PICEA SITCHENSIS (BONG.) CARR.) TREES, FROM A 40-YEAR-OLD PLANTATION IN WEST SCOTLAND, WERE EXTRACTED, DIGITISED IN THREE DIMENSIONS, AND ROOT TOPOLOGY WAS RECORDED. ROOTS WERE FROM TREES GROWN ON A STEEP (CA. 30 DEGREES) NORTH-FACING SLOPE, AND FROM AN ADJACENT HORIZONTAL AREA WITH SIMILAR GLEYED MINERAL SOIL. THE PREVAILING WIND WAS ACROSS-SLOPE FROM THE WEST. ANALYSIS OF BELOW-GROUND PARTS OF THE TREES IN COMPARISON WITH THOSE ABOVE-GROUND REVEALED A POSITIVE LINEAR RELATIONSHIP BETWEEN COARSE ROOT VOLUME AND STEM VOLUME. MOST NON-DIRECTIONAL CHARACTERISTICS OF THE ROOT SYSTEMS WERE SIMILAR BETWEEN TREES ON THE SLOPE AND ON FLAT TERRAIN. ALLOCATION OF ROOT MASS AROUND TREES WAS EXAMINED IN RELATION TO THE SLOPE AND THE PREVAILING WIND DIRECTION. TREES ON THE HORIZONTAL AREA HAD MORE ROOT MASS IN LEEWARD SECTORS THAN OTHER SECTORS, BUT TREES ON THE SLOPES HAD MORE ROOT MASS IN THE WINDWARD SECTORS THAN OTHER SECTORS. CENTRES OF MASS OF THE ROOT SYSTEMS FROM THE HORIZONTAL PART OF THE SITE WERE NOT SIGNIFICANTLY CLUSTERED IN ANY DIRECTION, BUT ROOT SYSTEMS OF TREES ON THE SLOPE HAD CENTRES OF MASS SIGNIFICANTLY CLUSTERED ACROSS THE SLOPE IN THE WINDWARD DIRECTION. FOR TREES ON THE SLOPE, THE MEAN DIRECTION OF THE LARGEST SECTOR WITHOUT STRUCTURAL ROOTS WAS 4 DEGREES FROM NORTH, I.E. DOWNSLOPE. THE RESULTS ARE DISCUSSED IN RELATION TO SOIL CHARACTERISTICS AND THE BIOMECHANICAL BEHAVIOUR OF TREES ON SLOPES.",SITKA SPRUCE; LATERAL ROOTS; TREE STABILITY; DOUGLAS-FIR; BIOMASS; WIND; RESPONSES; GROWTH; ORIENTATION; WINDTHROW,ROOT ARCHITECTURE; STRUCTURE; ANCHORAGE; SLOPE; WIND ACTION,TREES-STRUCTURE AND FUNCTION,"NICOLL, BC##BERTHIER, S##ACHIM, A##GOUSKOU, K##DANJON, F##VAN BEEK, LPH","FORESTRY COMMISS ROSLIN, NO RES STN, ROSLIN EH25 9SY, MIDLOTHIAN, SCOTLAND. INRA, EPHYSE, F-33611 GAZINET, FRANCE. UNIV UTRECHT, DEPT PHYS GEOG, UTRECHT CTR GEOSCI, UTRECHT, NETHERLANDS.",FORESTRY,FORESTRY,"ACHIM A., 2003, P INT C WIND EFF TRE, P231##ARMSTRONG W, 1976, J APPL ECOL, V13, P585, DOI 10.2307/2401805##COUTTS MP, 1989, ANN SCI FOREST, V46, PS277, DOI 10.1051/FOREST:19890565##COUTTS MP, 1986, FORESTRY, V59, P173, DOI 10.1093/FORESTRY/59.2.173##COUTTS MP, 1991, NEW PHYTOL, V119, P227, DOI 10.1111/J.1469-8137.1991.TB01025.X##COUTTS MP, 1983, FORESTRY, V56, P1, DOI 10.1093/FORESTRY/56.1.1##COUTTS MP, 1993, NEW PHYTOL, V124, P277, DOI 10.1111/J.1469-8137.1993.TB03817.X##COUTTS MP, 1990, FORESTRY, V63, P143, DOI 10.1093/FORESTRY/63.2.143##COUTTS MP, 1999, PLANT SOIL, V217, P1, DOI 10.1023/A:1004578032481##DANJON F, 2005, NEW PHYTOL, V168, P387, DOI 10.1111/J.1469-8137.2005.01497.X##DANJON F, 1999, PLANT SOIL, V211, P241, DOI 10.1023/A:1004680824612##DEANS JD, 1983, PLANT SOIL, V71, P189, DOI 10.1007/BF02182654##DI IORIO A, 2005, ANN BOT-LONDON, V95, P351, DOI 10.1093/AOB/MCI033##DREXHAGE M, 2001, FORESTRY, V74, P491, DOI 10.1093/FORESTRY/74.5.491##DREXHAGE M, 1998, CAN J FOREST RES, V28, P13, DOI 10.1139/CJFR-28-1-13##EKANAYAKE JAGATH C., 1997, NEW ZEALAND JOURNAL OF FORESTRY SCIENCE, V27, P216##FAYLE D.C.F., 1968, RADIAL GROWTH TREE R##FAYLE DCF, 1980, ENV ROOT BEHAV GEOBI, P93##FRASER AI, 1967, FORESTRY COMMISSION, V40##GARDINER B. A., 1995, P41, DOI 10.1017/CBO9780511600425.003##GODIN C, 2000, ANN FOREST SCI, V57, P413##GRUBER F, 1999, ALLG FORST JAGDZTG, V170, P213##HENDERSON R, 1983, FORESTRY, V56, P121, DOI 10.1093/FORESTRY/56.2.121##HINTIKKA V, 1972, METSANTUTKIMUSLAITOK, V76, P1##HOFFMANN CW, 2001, FOREST ECOL MANAG, V149, P103, DOI 10.1016/S0378-1127(00)00548-X##KENNEDY F, 2002, IDENTIFICATION SOILS##KRAMER MG, 2004, ECOLOGY, V85, P2230, DOI 10.1890/02-4098##LAING EV, 1932, FORESTRY COMMISSION, V13##LEVY PE, 2004, FORESTRY, V77, P421, DOI 10.1093/FORESTRY/77.5.421##MARDIA KV, 2000, STAT DIRECTIONAL DAT##MARLER TE, 1997, PLANT SOIL, V195, P37, DOI 10.1023/A:1004231009366##MAYER H, 1987, TREES-STRUCT FUNCT, V1, P195, DOI 10.1007/BF01816816##MCMICHAEL BL, 1993, ENVIRON EXP BOT, V33, P53, DOI 10.1016/0098-8472(93)90055-K##MCMINN R. G., 1963, CANADIAN JOUR BOT, V41, P105, DOI 10.1139/B63-010##MOFFAT AJ, 1998, 14198ERB ARB ADV INF##MOU P, 1997, J APPL ECOL, V34, P645, DOI 10.2307/2404913##NICOLL B. C., 1995, P276, DOI 10.1017/CBO9780511600425.017##NICOLL BC, 2005, CAN J FOREST RES, V35, P2360, DOI 10.1139/X05-157##NICOLL BC, 1996, TREE PHYSIOL, V16, P891##PARR A, 2004, FOREST ECOL MANAG, V195, P97, DOI 10.1016/J.FORECO.2004.02.033##QUINE C P, 1991, SCOTTISH FORESTRY, V45, P175##QUINE CP, 1991, FORESTRY, V64, P385, DOI 10.1093/FORESTRY/64.4.385##RUFELT H, 1965, ENCY PLANT PHYSL, P322##SAINJU UM, 1993, PLANT SOIL, V150, P87, DOI 10.1007/BF00779179##SAKALS ME, 2004, CAN J FOREST RES, V34, P950, DOI [10.1139/X03-268, 10.1139/X03-268]##SAVILL PS, 1976, FORESTRY, V49, P133, DOI 10.1093/FORESTRY/49.2.133##SINOQUET H, 1997, TREES-STRUCT FUNCT, V11, P265, DOI 10.1007/S004680050084##SINOQUET HERVE, 1997, SILVA FENNICA, V31, P265##STOKES A, 1995, J EXP BOT, V46, P1139, DOI 10.1093/JXB/46.9.1139##STOKES A, 1997, CAN J FOREST RES, V27, P1049, DOI 10.1139/CJFR-27-7-1049##STOKES A, 1996, J EXP BOT, V47, P693, DOI 10.1093/JXB/47.5.693##STOKES A., 1995, P264, DOI 10.1017/CBO9780511600425.016##SUNDSTROM E, 1999, PLANT SOIL, V217, P65, DOI 10.1023/A:1004693031375##TAMASI E, 2005, TREES-STRUCT FUNCT, V19, P374, DOI 10.1007/S00468-004-0396-X##THIES WG, 1996, CAN J FOREST RES, V26, P237, DOI 10.1139/X26-027##WAGG JWB, 1967, DEP PUBLICATION NUMB, V1192##WATSON A, 1995, VEGETATION AND SLOPES, P161##WATSON ALEX, 1997, NEW ZEALAND JOURNAL OF FORESTRY SCIENCE, V27, P205##WU TH, 1988, FOREST SCI, V34, P980##YEATMAN CW, 1955, FORESTRY COMMISSION, V21##ZHOU Y, 1997, PLANT SOIL, V190, P77, DOI 10.1023/A:1004263205165##2000, 3SPACE FASTRAK USERS",36,2020-11-20,NA
J,WOS:000241719800006,2006,CARDIOVASCULAR POLYCYSTINS: INSIGHTS FROM AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND TRANSGENIC ANIMAL MODELS,"MUTATIONS IN THE PKD1 AND PKD2 POLYCYSTIN GENES ARE RESPONSIBLE FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD), ONE OF THE MOST PREVALENT GENETIC KIDNEY DISORDERS. ADPKD IS A MULTISYSTEM DISEASE CHARACTERIZED BY THE FORMATION OF NUMEROUS FLUID-FILLED CYSTS IN THE KIDNEYS, THE PANCREAS, AND THE LIVER. MOREOVER, MAJOR CARDIOVASCULAR MANIFESTATIONS ARE COMMON COMPLICATIONS IN ADPKD. INTRACRANIAL ANEURYSMS AND ARTERIAL HYPERTENSION ARE AMONG THE LEADING CAUSES OF MORTALITY IN THIS DISEASE. IN THE PRESENT REVIEW, WE SUMMARIZE OUR CURRENT UNDERSTANDING OF THE ROLE OF POLYCYSTINS IN THE DEVELOPMENT, MAINTENANCE, AND FUNCTION OF THE CARDIOVASCULAR SYSTEM.",SMOOTH-MUSCLE-CELLS; PKD1 GENE; ENDOTHELIAL DYSFUNCTION; INTRACRANIAL ANEURYSMS; CATION CHANNEL; CHROMOSOMAL LOCALIZATION; CELLULAR-LOCALIZATION; VASCULAR EXPRESSION; MOLECULAR-BASIS; PRIMARY CILIUM,NA,TRENDS IN CARDIOVASCULAR MEDICINE,"BICHET, D##PETERS, D##PATEL, AJ##DELMAS, P##HONORE, E","CNRS, UMR 6097, INST PHARMACOL MOL & CELLULAIRE, F-06560 VALBONNE, FRANCE. LEIDEN UNIV, MED CTR, CTR HUMAN & CLIN GENET, NL-2300 RC LEIDEN, NETHERLANDS. IFR JEAN ROCHE, FAC MED, LAB NEUROPHYSIOL CELLULAIRE, F-13916 MARSEILLE, FRANCE.",CARDIAC & CARDIOVASCULAR SYSTEMS,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"BASORA N, 2002, J AM SOC NEPHROL, V13, P293##BOUCHER C, 2004, EUR J HUM GENET, V12, P347, DOI 10.1038/SJ.EJHG.5201162##BOULTER C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/PNAS.211191098##CHAPMAN AB, 1993, AM J KIDNEY DIS, V22, P526, DOI 10.1016/S0272-6386(12)80924-3##CHAPMAN AB, 1992, NEW ENGL J MED, V327, P916, DOI 10.1056/NEJM199209243271303##CONWAY SJ, 2003, GENESIS, V35, P1, DOI 10.1002/GENE.10152##DELMAS P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/JBC.M110483200##DELMAS P, 2004, FASEB J, V18, P740, DOI 10.1096/FJ.03-0319FJE##DELMAS P, 2005, PFLUG ARCH EUR J PHY, V451, P264, DOI 10.1007/S00424-005-1431-5##DEVUYST O, 2003, NEPHROL DIAL TRANSPL, V18, P2211, DOI 10.1093/NDT/GFG351##FORMAN JR, 2005, J MOL BIOL, V349, P861, DOI 10.1016/J.JMB.2005.04.008##GABOW PA, 1993, AM J KIDNEY DIS, V22, P511, DOI 10.1016/S0272-6386(12)80921-8##GALLAGHER AR, 2002, CELL MOL LIFE SCI, V59, P682, DOI 10.1007/S00018-002-8457-Z##GAO ZQ, 2004, J BIOL CHEM, V279, P14225, DOI 10.1074/JBC.M312223200##GONZALEZ-PERRETT S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/PNAS.021456598##GRIFFIN MD, 1997, J AM SOC NEPHROL, V8, P616##GUO L, 2000, GENOMICS, V64, P241, DOI 10.1006/GENO.2000.6131##HANAOKA K, 2000, NATURE, V408, P990##HATEBOER N, 1999, KIDNEY INT, V56, P34, DOI 10.1046/J.1523-1755.1999.00541.X##HATEBOER N, 1999, LANCET, V353, P103, DOI 10.1016/S0140-6736(98)03495-3##HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/NG0695-151##IBRAGHIMOV-BESKROVNAYA O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/HMG/9.11.1641##IBRAGHIMOVBESKROVNAYA O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/PNAS.94.12.6397##KIM K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/PNAS.040550097##KIP SN, 2005, CIRC RES, V96, P873, DOI 10.1161/01.RES.0000163278.68142.8A##KLEIN IHHT, 2001, J AM SOC NEPHROL, V12, P2427##KOCAMAN O, 2004, AM J KIDNEY DIS, V43, P854, DOI 10.1053/J.AJKD.2004.01.011##KOULEN P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/NCB754##LAKKIS M, 2003, NEPHRON EXP NEPHROL, V93, PE3, DOI 10.1159/000066648##LANTINGA-VAN LEEUWEN IS, 2004, HUM MOL GENET, V13, P3069, DOI 10.1093/HMG/DDH336##LI Q, 2003, J MOL BIOL, V325, P949, DOI 10.1016/S0022-2836(02)01333-5##LOGHMANADHAM M, 2001, J AM SOC NEPHROL, V12, PA2797##MAGISTRONI R, 2003, J AM SOC NEPHROL, V14, P1164, DOI 10.1097/01.ASN.0000061774.90975.25##MALHAS AN, 2002, J AM SOC NEPHROL, V13, P19##MAROTO R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/NCB1218##MOCHIZUKI T, 1996, SCIENCE, V272, P1339, DOI 10.1126/SCIENCE.272.5266.1339##MONTELL C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3##MOY GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/JCB.133.4.809##NAULI SM, 2004, BIOESSAYS, V26, P844, DOI 10.1002/BIES.20069##NAULI SM, 2003, NAT GENET, V33, P129, DOI 10.1038/NG1076##PARNELL SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/BBRC.1998.9514##PERSU A, 2002, HUM MOL GENET, V11, P229, DOI 10.1093/HMG/11.3.229##PETERS DJM, 1999, J PATHOL, V188, P439, DOI 10.1002/(SICI)1096-9896(199908)188:4<439::AID-PATH367>3.0.CO;2-P##PIRSON Y, 2002, J AM SOC NEPHROL, V13, P269##PRAETORIUS HA, 2003, CURR OPIN NEPHROL HY, V12, P517, DOI 10.1097/00041552-200309000-00006##PRITCHARD L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/HMG/9.18.2617##PURI S, 2004, J BIOL CHEM, V279, P55455, DOI 10.1074/JBC.M402905200##QIAN F, 2005, J BIOL CHEM, V280, P40723, DOI 10.1074/JBC.M509650200##QIAN F, 1997, AM J HUM GENET, V61, P1000, DOI 10.1086/301618##QIAN F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6##QIAN F, 1997, NAT GENET, V16, P179, DOI 10.1038/NG0697-179##QIAN Q, 2003, J AM SOC NEPHROL, V14, P2280, DOI 10.1097/01.ASN.0000080185.38113.A3##QIAN Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/HMG/DDG190##ROSSETTI S, 2003, LANCET, V361, P2196, DOI 10.1016/S0140-6736(03)13773-7##ROSSETTI S, 2002, J AM SOC NEPHROL, V13, P1230, DOI 10.1097/01.ASN.0000013300.11876.37##SCHIEVINK WI, 1992, J AM SOC NEPHROL, V3, P88##SUTTERS M, 2003, J LAB CLIN MED, V141, P91, DOI 10.1067/MLC.2003.13##TORRES VE, 2001, J AM SOC NEPHROL, V12, P1##TSIOKAS L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/PNAS.96.7.3934##TSIOKAS L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/PNAS.94.13.6965##VOLK T, 2003, CARDIOVASC RES, V58, P76, DOI 10.1016/S0008-6363(02)00858-1##WANG D, 2000, J AM SOC NEPHROL, V11, P1371##WANG D, 2003, KIDNEY INT, V64, P1381, DOI 10.1046/J.1523-1755.2003.00236.X##WANG D, 1997, J HYPERTENS, V15, P925, DOI 10.1097/00004872-199715090-00002##WATNICK T, 1999, AM J HUM GENET, V65, P1561, DOI 10.1086/302657##WESTON BS, 2003, FEBS LETT, V538, P8, DOI 10.1016/S0014-5793(03)00130-3##WU GQ, 2000, NAT GENET, V24, P75##WU GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6##XU GM, 2001, J BIOL CHEM, V276, P46544, DOI 10.1074/JBC.M107828200##YUASA T, 2004, GENOMICS, V84, P126, DOI 10.1016/J.YGENO.2004.02.008##YUASA T, 2002, GENOMICS, V79, P376, DOI 10.1006/GENO.2002.6719",28,2020-11-20,NA
J,WOS:000242291300005,2006,TOWARDS A TRUE NEURAL STANCE ON CONSCIOUSNESS,"CONSCIOUSNESS IS TRADITIONALLY DEFINED IN MENTAL OR PSYCHOLOGICAL TERMS. IN TRYING TO FIND ITS NEURAL BASIS, INTROSPECTIVE OR BEHAVIORAL OBSERVATIONS ARE CONSIDERED THE GOLD STANDARD, TO WHICH NEURAL MEASURES SHOULD BE FITTED. I ARGUE THATTHIS POSES SERIOUS PROBLEMS FOR UNDERSTANDING THE MIND-BRAIN RELATIONSHIP. TO SOLVE THESE PROBLEMS, NEURAL AND BEHAVIORAL MEASURES SHOULD BE PUT ON AN EQUAL FOOTING. I ILLUSTRATE THIS BY AN EXAMPLE FROM VISUAL NEUROSCIENCE, IN WHICH BOTH NEURAL AND BEHAVIORAL ARGUMENTS CONVERGE TOWARDS A COHERENT SCIENTIFIC DEFINITION OF VISUAL CONSCIOUSNESS. HOWEVER, TO ACCEPT THIS DEFINITION, WE NEED TO LET GO OF OUR INTUITIVE OR PSYCHOLOGICAL NOTIONS OF CONSCIOUS EXPERIENCE AND LET THE NEUROSCIENCE ARGUMENTS HAVE THEIR WAY. ONLY BY MOVING OUR NOTION OF MIND TOWARDS THAT OF BRAIN CAN PROGRESS BE MADE.",CORTICAL ACTIVATION; VISUAL-ATTENTION; DISTINCT MODES; AWARENESS; PERCEPTION; V1; RECOGNITION; INFORMATION; BLINDSIGHT; VISIBILITY,NA,TRENDS IN COGNITIVE SCIENCES,"LAMME, VAF","UNIV AMSTERDAM, DEPT PSYCHOL, NL-1018 WB AMSTERDAM, NETHERLANDS.","BEHAVIORAL SCIENCES; NEUROSCIENCES; PSYCHOLOGY, EXPERIMENTAL",BEHAVIORAL SCIENCES; NEUROSCIENCES & NEUROLOGY; PSYCHOLOGY,"AZZOPARDI P, 2003, NEUROPSYCHOLOGIA, V41, P1738, DOI 10.1016/S0028-3932(03)00176-3##BECHARA A, 1997, SCIENCE, V275, P1293, DOI 10.1126/SCIENCE.275.5304.1293##BECK DM, 2001, NAT NEUROSCI, V4, P645, DOI 10.1038/88477##BLAKE R, 2002, NAT REV NEUROSCI, V3, P13, DOI 10.1038/NRN701##BLOCK N, 2005, TRENDS COGN SCI, V9, P46, DOI 10.1016/J.TICS.2004.12.006##BLOCK N, 1996, TRENDS NEUROSCI, V19, P456, DOI 10.1016/S0166-2236(96)20049-9##BOYER JL, 2005, P NATL ACAD SCI USA, V102, P16875, DOI 10.1073/PNAS.0505332102##CHALMERS D. J., 1995, J CONSCIOUSNESS STUD, V2, P200, DOI DOI 10.1093/ACPR0F##CRICK F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/NN0203-119##CRICK F, 1998, CEREB CORTEX, V8, P97, DOI 10.1093/CERCOR/8.2.97##CRICK F, 1996, NATURE, V379, P485, DOI 10.1038/379485A0##DEHAENE S, 1998, NATURE, V395, P597, DOI 10.1038/26967##DEHAENE S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/J.TICS.2006.03.007##DRIVER J, 1998, NAT NEUROSCI, V1, P17, DOI 10.1038/217##ELLIOTT R, 1998, J NEUROSCI, V18, P4697##ENGEL AK, 2001, TRENDS COGN SCI, V5, P16, DOI 10.1016/S1364-6613(00)01568-0##FLOHR H, 1998, TOXICOL LETT, V101, P23, DOI 10.1016/S0378-4274(98)00161-1##GAZZANIGA MS, 2005, NAT REV NEUROSCI, V6, P653, DOI 10.1038/NRN1723##GOEBEL R, 2001, VISION RES, V41, P1459, DOI 10.1016/S0042-6989(01)00069-4##HAYNES JD, 2005, NEURON, V46, P811, DOI 10.1016/J.NEURON.2005.05.012##JAMES TW, 2003, BRAIN, V126, P2463, DOI 10.1093/BRAIN/AWG248##JOLIJ J, 2005, P NATL ACAD SCI USA, V102, P10747, DOI 10.1073/PNAS.0500834102##KENTRIDGE RW, 1999, P ROY SOC B-BIOL SCI, V266, P1805, DOI 10.1098/RSPB.1999.0850##KIM CY, 2005, TRENDS COGN SCI, V9, P381, DOI 10.1016/J.TICS.2005.06.012##LAMME VAF, 2003, TRENDS COGN SCI, V7, P12, DOI 10.1016/S1364-6613(02)00013-X##LAMME VAF, 2000, TRENDS NEUROSCI, V23, P571, DOI 10.1016/S0166-2236(00)01657-X##LAMME VAF, 2004, NEURAL NETWORKS, V17, P861, DOI 10.1016/J.NEUNET.2004.02.005##LAMME VAF, 2002, J COGNITIVE NEUROSCI, V14, P1044, DOI 10.1162/089892902320474490##LAMME VAF, 2000, VISION RES, V40, P1507, DOI 10.1016/S0042-6989(99)00243-6##LANDMAN R, 2004, NEUROREPORT, V15, P2211, DOI 10.1097/00001756-200410050-00013##LANDMAN R, 2003, VISION RES, V43, P149, DOI 10.1016/S0042-6989(02)00402-9##MACK A., 1998, INATTENTIONAL BLINDN##MACKNIK SL, 1998, NAT NEUROSCI, V1, P144, DOI 10.1038/393##MAROIS R, 2004, NEURON, V41, P465, DOI 10.1016/S0896-6273(04)00012-1##MOUTOUSSIS K, 2002, P NATL ACAD SCI USA, V99, P9527, DOI 10.1073/PNAS.142305699##PASCUAL-LEONE A, 2001, SCIENCE, V292, P510, DOI 10.1126/SCIENCE.1057099##POLONSKY A, 2000, NAT NEUROSCI, V3, P1153##REES G, 1999, SCIENCE, V286, P2504, DOI 10.1126/SCIENCE.286.5449.2504##REES G, 2002, NEUROCASE, V8, P387, DOI 10.1093/NEUCAS/8.5.387##REES G, 2002, NAT REV NEUROSCI, V3, P261, DOI 10.1038/NRN783##ROLLS ET, 1999, J COGNITIVE NEUROSCI, V11, P300, DOI 10.1162/089892999563409##SCHOLTE HS, 2006, BRAIN RES, V1076, P106, DOI 10.1016/J.BRAINRES.2005.10.051##SILVANTO J, 2005, CEREB CORTEX, V15, P1736, DOI 10.1093/CERCOR/BHI050##SIMONS DJ, 2005, TRENDS COGN SCI, V9, P16, DOI 10.1016/J.TICS.2004.11.006##SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/SCIENCE.270.5237.758##SPERRY R, 1984, NEUROPSYCHOLOGIA, V22, P661, DOI 10.1016/0028-3932(84)90093-9##STOERIG P, 1997, BRAIN, V120, P535, DOI 10.1093/BRAIN/120.3.535##SUPER H, 2001, NAT NEUROSCI, V4, P304, DOI 10.1038/85170##THOMPSON KG, 1999, NAT NEUROSCI, V2, P283, DOI 10.1038/6398##TONG F., 2001, BRAIN MIND, V2, P55, DOI DOI 10.1023/A:1017942718744##TONONI G, 1998, SCIENCE, V282, P1846, DOI 10.1126/SCIENCE.282.5395.1846##TONONI GIULIO, 2004, BMC NEUROSCI, V5, P42, DOI 10.1186/1471-2202-5-42##TREISMAN AM, 1998, CURR OPIN NEUROBIOL, V8, P218, DOI 10.1016/S0959-4388(98)80143-8##WATANABE T, 2001, NATURE, V413, P844, DOI 10.1038/35101601##WOLFE JM, 1999, MIT BRAD COGN PSYCH, P71",435,2020-11-20,NA
J,WOS:000242196300010,2006,"CURRENT CONCEPTS IN RET-RELATED GENETICS, SIGNALING AND THERAPEUTICS","THE RECEPTOR TYROSINE KINASE RET IS EXPRESSED IN CELL LINEAGES DERIVED FROM THE NEURAL CREST AND HAS A KEY ROLE IN REGULATING CELL PROLIFERATION, MIGRATION, DIFFERENTIATION AND SURVIVAL DURING EMBRYOGENESIS. GERMLINE AND SOMATIC MUTATIONS IN RET THAT PRODUCE CONSTITUTIVELY ACTIVATED RECEPTORS CAUSE THE CANCER SYNDROME MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 AND SEVERAL ENDOCRINE AND NEURAL-CREST-DERIVED TUMORS, WHEREAS MUTATIONS RESULTING IN NONFUNCTIONAL RET OR LOWER EXPRESSION OF RET ARE FOUND IN INDIVIDUALS AFFECTED WITH HIRSCHSPRUNG DISEASE. THIS REVIEW FOCUSES ON THE GENETICS AND MOLECULAR MECHANISMS UNDERLYING THE DIFFERENT INHERITED HUMAN NEURAL-CREST-RELATED DISORDERS IN WHICH RET DYSFUNCTION HAS A CRUCIAL ROLE AND DISCUSSES RET AS A POTENTIAL THERAPEUTIC TARGET.",MULTIPLE ENDOCRINE NEOPLASIA; MEDULLARY-THYROID CARCINOMA; SPORADIC HIRSCHSPRUNG-DISEASE; RECEPTOR TYROSINE KINASE; ENTERIC NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; AUTOPHOSPHORYLATION SITES; CELL-PROLIFERATION; SEQUENCE VARIANT; POINT MUTATION,NA,TRENDS IN GENETICS,"PLAZA-MENACHO, I##BURZYNSKI, GM##DE GROOT, JW##EGGEN, BJL##HOFSTRA, RMW","UNIV GRONINGEN, MED CTR, DEPT GENET, NL-9700 RB GRONINGEN, NETHERLANDS. UNIV GRONINGEN, DEPT DEV GENET, NL-9700 RB GRONINGEN, NETHERLANDS.",GENETICS & HEREDITY,GENETICS & HEREDITY,"ACTON DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/SJ.ONC.1203648##AIRAKSINEN MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/MCNE.1999.0754##ARIGHI E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/J.CYTOGFR.2005.05.010##ARIGHI E, 2004, MOL ENDOCRINOL, V18, P1004, DOI 10.1210/ME.2003-0173##BALOH RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3##BARLOW A, 2003, NEURON, V40, P905, DOI 10.1016/S0896-6273(03)00730-X##BAUMGARTNER-PARZER SM, 2005, J CLIN ENDOCR METAB, V90, P6232, DOI 10.1210/JC.2005-1278##BERARD I, 2004, CLIN GENET, V65, P150, DOI 10.1111/J.0009-9163.2004.00172.X##BOCCIARDI R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/SJ.ONC.1201413##BONGARZONE I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/SJ.ONC.1201759##BORREGO S, 2003, AM J HUM GENET, V72, P88, DOI 10.1086/345466##BROMBERG JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553##BROOKS AS, 2005, CLIN GENET, V67, P6, DOI 10.1111/J.1399-0004.2004.00319.X##BURZYNSKI GM, 2005, AM J HUM GENET, V76, P850, DOI 10.1086/429589##BURZYNSKI GM, 2004, EUR J HUM GENET, V12, P604, DOI 10.1038/SJ.EJHG.5201199##CARLOMAGNO F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/EN.139.8.3613##CARLOMAGNO F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/JNCI/DJJ069##CARLOMAGNO F, 2002, CANCER RES, V62, P1077##CARNEY JA, 1976, NEW ENGL J MED, V295, P1287, DOI 10.1056/NEJM197612022952304##CARRASQUILLO MM, 2002, NAT GENET, V32, P237, DOI 10.1038/NG998##CEBRIAN A, 2005, J CLIN ENDOCR METAB, V90, P6268, DOI 10.1210/JC.2004-2449##CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/BBRC.1993.2392##CERCHIA L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/JOURNAL.PBIO.0030123##COHEN MS, 2002, SURGERY, V132, P960, DOI 10.1067/MSY.2002.128562##DE GRAAFF E, 2001, GENE DEV, V15, P2433, DOI 10.1101/GAD.205001##DE GROOT JWB, 2006, SURGERY, V139, P806, DOI 10.1016/J.SURG.2005.10.019##ELISEI R, 2004, J CLIN ENDOCR METAB, V89, P5823, DOI 10.1210/JC.2004-0312##EMISON ES, 2005, NATURE, V434, P857, DOI 10.1038/NATURE03467##FITZE G, 2003, HUM MOL GENET, V12, P3207, DOI 10.1093/HMG/DDG354##FITZE GUIDO, 2003, HUM MUTAT, V22, P177, DOI 10.1002/HUMU.9161##FRECHE B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/JBC.M505707200##FUKUDA T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/JBC.M200643200##GARCIA-BARCELO M, 2005, HUM MOL GENET, V14, P191, DOI 10.1093/HMG/DDI015##GATH R, 2001, GUT, V48, P671, DOI 10.1136/GUT.48.5.671##GESTBLOM C, 1999, AM J PATHOL, V155, P2167, DOI 10.1016/S0002-9440(10)65534-4##GIMM O, 1999, ONCOGENE, V18, P1369, DOI 10.1038/SJ.ONC.1202418##GRICE EA, 2005, HUM MOL GENET, V14, P3837, DOI 10.1093/HMG/DDI408##GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3##GRISERI P, 2005, HUM MUTAT, V25, P189, DOI 10.1002/HUMU.20135##GSCHWIND A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/NRC1360##HANSFORD JR, 2000, J MED GENET, V37, P817, DOI 10.1136/JMG.37.11.817##HENNIGE AM, 2001, ENDOCRINOLOGY, V142, P4441, DOI 10.1210/EN.142.10.4441##HOFSTRA RMW, 2000, HUM MUTAT, V15, P418, DOI 10.1002/(SICI)1098-1004(200005)15:5<418::AID-HUMU3>3.0.CO;2-2##HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5##ICHIHARA M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7##ITO S, 1997, CANCER RES, V57, P2870##IWASHITA T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/SJ.ONC.1202742##IWASHITA T, 2001, GASTROENTEROLOGY, V121, P24, DOI 10.1053/GAST.2001.25515##JING SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2##KAWAI K, 2000, CANCER RES, V60, P5254##KAWAMOTO Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/JBC.M312600200##KLUGBAUER S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/SJ.ONC.1202824##LIU X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/JBC.271.10.5309##MARCOS C, 1996, INT J DEV BIOL, VSUPPL 1, P137S##MCCALLION AS, 2003, P NATL ACAD SCI USA, V100, P1826, DOI 10.1073/PNAS.0337540100##MCWHINNEY SR, 2003, J CLIN ENDOCR METAB, V88, P4911, DOI 10.1210/JC.2003-030245##MENACHO IP, 2005, CANCER RES, V65, P1729, DOI 10.1158/0008-5472.CAN-04-2363##MICHIELS FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/PNAS.94.7.3330##MOGRABI B, 2001, MOL CELL BIOL, V21, P6719, DOI 10.1128/MCB.21.20.6719-6730.2001##MURAKAMI H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/BBRC.1999.1186##MURAKAMI H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/JBC.M202336200##MYERS SM, 1995, ONCOGENE, V11, P2039##PARISI MA, 2000, CURR OPIN PEDIATR, V12, P610, DOI 10.1097/00008480-200012000-00017##PARTHASARATHY R, 1999, CANCER RES, V59, P3911##PELET A, 2005, J MED GENET, V42, DOI 10.1136/JMG.2004.028746##PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7##PUTZER BM, 2004, TRENDS MOL MED, V10, P351, DOI 10.1016/J.MOLMED.2004.06.002##ROBLEDO M, 2003, CANCER RES, V63, P1814##RUIZ A, 2001, CLIN ENDOCRINOL, V55, P399, DOI 10.1046/J.1365-2265.2001.01328.X##SAARMA M, 2001, TRENDS NEUROSCI, V24, P427, DOI 10.1016/S0166-2236(00)01864-6##SALVATORE D, 2001, CANCER RES, V61, P1426##SANCANDI M, 2003, J MED GENET, V40, P714, DOI 10.1136/JMG.40.9.714##SANTORO M, 1990, ONCOGENE, V5, P1595##SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/ANNUREV.BI.64.070195.003201##SCHUBERT WH, 2001, J HYDROMETEOROL, V2, P3, DOI 10.1175/1525-7541(2001)002<0005:>2.0.CO;2##SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380A0##SIPPLE JH, 1961, AM J MED, V31, P163, DOI 10.1016/0002-9343(61)90234-0##SMITH-HICKS CL, 2000, EMBO J, V19, P612, DOI 10.1093/EMBOJ/19.4.612##TAKAHASHI M, 1999, HUM MUTAT, V13, P331, DOI 10.1002/(SICI)1098-1004(1999)13:4<331::AID-HUMU11>3.3.CO;2-R##TSUI-PIERCHALA B, 2002, NEURON, V33, P261, DOI 10.1016/S0896-6273(01)00585-2##WIENCH M, 2004, CANCER DETECT PREV, V28, P231, DOI 10.1016/J.CDP.2004.04.002##YANO L, 2000, HUM GENE THER, V11, P995, DOI 10.1089/10430340050015301##YIP L, 2003, ARCH SURG-CHICAGO, V138, P409, DOI 10.1001/ARCHSURG.138.4.409##YUAN ZL, 2004, MOL CELL BIOL, V24, P9390, DOI 10.1128/MCB.24.21.9390-9400.2004##ZATELLI MC, 2005, ENDOCRINOLOGY, V146, P2692, DOI 10.1210/EN.2005-0001",78,2020-11-20,NA
J,WOS:000242294400001,2006,MOLECULAR PROGRAMMING OF STEM CELLS INTO MESODIENCEPHALIC DOPAMINERGIC NEURONS,"IN A SCREEN FOR HOMEOBOX TRANSCRIPTION FACTORS EXPRESSED IN THE EMBRYONIC VENTRAL MIDBRAIN, ANDERSSON ET AL. RECENTLY IDENTIFIED LMX1A AND MSX1. USING IN OVO ELECTROPORATION IN CHICK EMBRYOS, THEY SHOWED THAT THESE FACTORS ARE CRUCIAL FOR INITIATING THE DIFFERENTIATION OF NEUROEPITHELIAL PROGENITOR NEURONS INTO MESODIENCEPHALIC DOPAMINERGIC (MDDA) NEURONS. LMX1A ALSO INITIATED A DEVELOPMENTAL PROGRAM THAT DROVE AN MDDA PHENOTYPE IN MOUSE EMBRYONIC STEM CELLS. THIS INDICATES THAT THESE FACTORS CAN BE EXPLOITED IN CELL-REPLACEMENT STRATEGIES FOR TREATMENT OF PARKINSON'S DISEASE.",VERTEBRATE CNS; NEURAL-TUBE; ROOF PLATE; MIDBRAIN; FATE; IDENTIFICATION; NEUROGENIN-2; IDENTITY; DREHER; SYSTEM,NA,TRENDS IN NEUROSCIENCES,"BURBACH, JPH##SMIDT, MP","UNIV MED CTR UTRECHT, DEPT PHARMACOL & ANAT, RUDOLF MAGNUS INST NEUROSCI, NL-3508 AB UTRECHT, NETHERLANDS.",NEUROSCIENCES,NEUROSCIENCES & NEUROLOGY,"ANDERSSON E, 2006, CELL, V124, P393, DOI [10.1016/J.CELL.2005.10.037, 10.1016/J.CELL.2005.10.037]##ANDERSSON E, 2006, DEVELOPMENT, V133, P507, DOI 10.1242/DEV.02224##CHIZHIKOV VV, 2004, J NEUROSCI, V24, P5694, DOI 10.1523/JNEUROSCI.0758-04.2004##FAILLI V, 2002, MECH DEVELOP, V118, P225, DOI 10.1016/S0925-4773(02)00254-X##GUILLEMOT F, 2005, CURR OPIN CELL BIOL, V17, P639, DOI 10.1016/J.CEB.2005.09.006##HYNES M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X##KELE J, 2006, DEVELOPMENT, V133, P495, DOI 10.1242/DEV.02223##KIM JH, 2002, NATURE, V418, P50, DOI 10.1038/NATURE00900##KUWAMURA M, 2005, DEV BRAIN RES, V155, P99, DOI 10.1016/J.DEVBRAINRES.2004.12.009##LEE SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536##LIU Y, 2004, DEVELOPMENT, V131, P1017, DOI 10.1242/DEV.00994##MILLONIG JH, 2000, NATURE, V403, P764##PRAKASH N, 2006, DEVELOPMENT, V133, P89, DOI 10.1242/DEV.02181##RHINN M, 2001, CURR OPIN NEUROBIOL, V11, P34, DOI 10.1016/S0959-4388(00)00171-9##SMIDT MP, 2000, NAT NEUROSCI, V3, P337##SMIDT MP, 2004, DEVELOPMENT, V131, P1145, DOI 10.1242/DEV.01022##SMITS SM, 2006, PROG NEUROBIOL, V78, P1, DOI 10.1016/J.PNEUROBIO.2005.12.003##SMITS SM, 2003, EUR J NEUROSCI, V18, P1731, DOI 10.1046/J.1460-9568.2003.02885.X##WIJCHERS PJEC, 2006, BRAIN RES, V1068, P23, DOI 10.1016/J.BRAINRES.2005.11.022##YE WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3",37,2020-11-20,NA
J,WOS:000241407400012,2006,"COSTS OF PATIENT MANAGEMENT OF VISCERAL LEISHMANIASIS IN MUZAFFARPUR, BIHAR, INDIA","OBJECTIVES TO IDENTIFY AND QUANTIFY THE DIRECT AND INDIRECT ECONOMIC COST OF TREATMENT FOR VISCERAL LEISHMANIASIS (VL) WITH CONVENTIONAL AMPHOTERICIN B DEOXYCHOLATE, CURRENTLY THE FIRST-LINE TREATMENT IN MUZAFFARPUR. METHODS COSTS OF PATIENT MANAGEMENT FOR VL WERE ESTIMATED FROM A SOCIETAL AND HOUSEHOLD PERSPECTIVE BY MEANS OF A QUESTIONNAIRE DESIGNED FOR THIS STUDY, INTERVIEWS AND FINANCIAL REPORTS. RESULTS THE TOTAL COST OF CARE PER EPISODE OF VL FROM THE SOCIETAL PERSPECTIVE WAS ESTIMATED AT US$355, EQUIVALENT TO 58% OF ANNUAL HOUSEHOLD INCOME. THE LARGEST COST CATEGORY WAS MEDICAL COSTS (55%), FOLLOWED BY INDIRECT COSTS (36%) AND NON-MEDICAL COSTS (9%). THE COST FROM THE HOUSEHOLD PERSPECTIVE WAS EQUIVALENT TO US$217. THE LARGEST COST CATEGORY WAS INDIRECT COSTS (59%), FOLLOWED BY MEDICAL COSTS (27%) AND NON-MEDICAL COSTS (15%). LOSS OF INCOME BECAUSE OF ILLNESS AND HOSPITALIZATION AND EXPENSES FOR DRUGS WERE THE LARGEST COST COMPONENTS. CONCLUSIONS THE ECONOMIC COSTS RELATED TO VL ARE SUBSTANTIAL, BOTH TO SOCIETY AND THE PATIENT. PUBLIC HEALTH AUTHORITIES IN BIHAR SHOULD FOCUS ON POLICIES THAT DETECT VL IN THE EARLY STAGE AND IMPLEMENT INTERVENTIONS THAT MINIMIZE THE BURDEN TO HOUSEHOLDS AFFECTED BY VL.",AMPHOTERICIN-B; ECONOMIC COSTS; HOUSEHOLDS; MALARIA; CARE; EXPENDITURE; BURDEN; POLICY,VISCERAL LEISHMANIASIS; KALA-AZAR; BIHAR; COST ANALYSIS; DIRECT COSTS; INDIRECT COSTS,TROPICAL MEDICINE & INTERNATIONAL HEALTH,"MEHEUS, F##BOELAERT, M##BALTUSSEN, R##SUNDAR, S","ROYAL TROP INST, NL-1090 HA AMSTERDAM, NETHERLANDS. BANARAS HINDU UNIV, INST MED SCI, VARANASI 221005, UTTAR PRADESH, INDIA. ERASMUS MC, INST MED TECHNOL ASSESSMENT, ROTTERDAM, NETHERLANDS. INST TROP MED, B-2000 ANTWERP, BELGIUM. UNIV ANTWERP, INST DEV POLICY & MANAGEMENT, B-2020 ANTWERP, BELGIUM.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; TROPICAL MEDICINE","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; TROPICAL MEDICINE","AHLUWALIA IB, 2003, AM J TROP MED HYG, V69, P624, DOI 10.4269/AJTMH.2003.69.624##ASENSOOKYERE WK, 1997, SOC SCI MED, V45, P659, DOI 10.1016/S0277-9536(96)00383-8##BALTUSSEN R, 2005, HLTH POLICY   1118##BARNUM H, 1993, PUBLIC HOSP DEV COUN##BROUWER W, 2001, EC EVALUATION HLTH C, P68##BRYCESON A, 2001, TROP MED INT HEALTH, V6, P928, DOI 10.1046/J.1365-3156.2001.00795.X##CHO-MIN-NAING, 2004, ACTA TROP, V92, P173, DOI 10.1016/J.ACTATROPICA.2003.12.005##CREESE A, 1994, COST ANAL PRIMARY HL##DESJEUX P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0##DRUMMOND MF, 1997, METHODS EC EVALUATIO##DURAISAMY P, 2006, AIDS CARE, V18, P121, DOI 10.1080/09540120500159359##ETTLING M, 1994, TROP MED PARASITOL, V45, P74##GUERIN PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X##HUTTON G, 2005, HEALTH POLICY PLANN, V20, P252, DOI 10.1093/HEAPOL/CZI025##KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5##MEESSEN B, 2003, TROP MED INT HEALTH, V8, P581, DOI 10.1046/J.1365-3156.2003.01081.X##MUGISHA F, 2002, TROP MED INT HEALTH, V7, P187, DOI 10.1046/J.1365-3156.2002.00835.X##MURRAY H W, 2000, INT J INFECT DIS, V4, P158, DOI 10.1016/S1201-9712(00)90078-X##MURRAY HW, 2004, AM J TROP MED HYG, V71, P787, DOI 10.4269/AJTMH.2004.71.787##OLLIARO PL, 2005, LANCET INFECT DIS, V5, P763, DOI 10.1016/S1473-3099(05)70296-6##RIJAL S, 2006, T ROY SOC TROP MED H, V100, P838, DOI 10.1016/J.TRSTMH.2005.09.017##RIJAL S, 2003, T ROY SOC TROP MED H, V97, P350, DOI 10.1016/S0035-9203(03)90167-2##SAUERBORN R, 1996, SOC SCI MED, V43, P291, DOI 10.1016/0277-9536(95)00375-4##SAUERBORN R, 1991, TROP MED PARASITOL, V42, P219##SCULPHER M, 2001, EC EVALUATION HLTH C, P94##SHARMA DA, 2006, TROP MED INT HEALTH, V11, P757, DOI 10.1111/J.1365-3156.2006.01604.X##SUNDAR S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971##SUNDAR S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/J.1365-3156.2001.00778.X##SUNDAR S, 2001, BRIT MED J, V323, P419, DOI 10.1136/BMJ.323.7310.419##TAN-TORRES EDEJER T, 2003, MAKING CHOICES HLTH##THAKUR CP, 2000, T ROY SOC TROP MED H, V94, P156, DOI 10.1016/S0035-9203(00)90255-4##VAN DAMME W, 2004, TROP MED INT HEALTH, V9, P273, DOI 10.1046/J.1365-3156.2003.01194.X##*WHO, 2005, WHOIVB0510##*WHO, 2000, 116 WHO##WORLD BANK, 2005, BIH DEV STRAT",36,2020-11-20,NA
J,WOS:000241407400017,2006,ANNUAL MASS TREATMENT WITH ALBENDAZOLE MIGHT ELIMINATE HUMAN OESOPHAGOSTOMIASIS FROM THE ENDEMIC FOCUS IN NORTHERN GHANA,"AS A FOLLOW-UP TO THE STUDY BY ZIEM ET AL., IN THIS ISSUE, EFFORTS TO CONTROL HUMAN OESOPHAGOSTOMIASIS AND HOOKWORM INFECTIONS IN NORTHERN GHANA WERE PURSUED, AND THE RESULTS EVALUATED IN COLLABORATION WITH THE LYMPHATIC FILARIASIS ELIMINATION PROGRAMME. THIS PHASE OF EVALUATION OF THE IMPACT OF MASS TREATMENT WAS NO LONGER LIMITED TO A SMALL-SCALE RESEARCH SETTING: IT WAS DONE BOTH IN THE CONTEXT OF AN OPERATIONALLY VIABLE NATIONAL CONTROL PROGRAMME AND AS A CONTINUATION OF THE OESOPHAGOSTOMUM INTERVENTION RESEARCH PROJECT (OIRP). THE METHODS OF EVALUATION INCLUDED CLASSICAL STOOL EXAMINATION WITH KATO THICK SMEARS, STOOL CULTURE AND ULTRASOUND EXAMINATION OF THE COLON WALL. THE RESULTS SHOWED THAT YEARLY POPULATION-BASED ALBENDAZOLE-IVERMECTIN TREATMENT IN 11 VILLAGES SCATTERED OVER NORTH-EASTERN GHANA, WITH A TREATMENT COVERAGE OF 70-75%, RESULTED IN A REDUCTION OF OESOPHAGOSTOMUM PREVALENCE FROM ABOUT 20% PRE-INTERVENTION TO LESS THAN 1% AFTER 2 YEARS OF MASS TREATMENT. SIMULTANEOUSLY, HOOKWORM PREVALENCE WENT DOWN FROM 70% TO APPROXIMATELY 15%. THE DATA, HOWEVER, CANNOT BE READILY COMPARED WITH THOSE OF ZIEM ET AL. BECAUSE OF THE RELATIVELY CRUDE DIAGNOSTIC (SINGLE STOOL CULTURES) SCREENING SYSTEM THAT HAD TO BE USED FOR THE EVALUATION OF THE LARGE-SCALE CONTROL PROGRAMME. IN THE RESEARCH AREA OF THE OIRP, INTERRUPTION OF MASS TREATMENT RESULTED IN A RISING HOOKWORM PREVALENCE. THE OESOPHAGOSTOMUM PREVALENCE, ON THE OTHER HAND, CONTINUED TO GO DOWN. TRANSMISSION OF HUMAN OESOPHAGOSTOMIASIS APPEARS INTERRUPTIBLE AND SMALL NUMBERS OF PERSISTENT CASES OF OESOPHAGOSTOMUM INFECTION WERE SHOWN INSUFFICIENT TO SERVE AS A NUCLEUS OF RENEWED SPREAD OF THE INFECTION. THE DATA SUGGEST THAT BOTH THE INFECTION WITH AND THE PATHOLOGY DUE TO HUMAN OESOPHAGOSTOMIASIS CAN BE ELIMINATED AND THAT ELIMINATION IS LIKELY TO BE ACHIEVED THROUGH OPERATIONALLY FEASIBLE ALBENDAZOLE-IVERMECTIN TREATMENT AS USED BY THE GLOBAL ALLIANCE FOR THE ELIMINATION OF LYMPHATIC FILARIASIS.",BIFURCUM; PATHOLOGY,HUMAN OESOPHAGOSTOMIASIS; ALBENDAZOLE; ELIMINATION,TROPICAL MEDICINE & INTERNATIONAL HEALTH,"ZIEM, JB##OLSEN, A##MAGNUSSEN, P##HORTON, J##SPANNBRUCKER, N##YELIFARI, L##BIRITWUM, KN##POLDERMAN, AM","LEIDEN UNIV, MED CTR, DEPT PARASITOL, NL-2300 RC LEIDEN, NETHERLANDS. UNIV DEV STUDIES, SCH MED & HLTH SCI, TAMALE, GHANA. INST HLTH RES & DEV, CHARLOTTENLUND, DENMARK. UNIV LIVERPOOL, DEPT PHARMACOL & THERAPEUT, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND. BOARD PUBL HLTH NEURUPPIN, BONN, GERMANY. GHANA HLTH SERV, REG HLTH DIRECTORATE, DIS CONTROL UNIT, BOLGATANGA, GHANA. GHANA HLTH SERV, HLTH RES UNIT, LYMPHAT FILARIASIS ELIMINAT PROGRAMME, ACCRA, GHANA.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; TROPICAL MEDICINE","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; TROPICAL MEDICINE","DE GRUIJTER JM, 2005, PARASITOLOGY, V129, P1##GIGASE P., 1987, HELMINTH ZOONOSIS, P223##HAAF E., 1964, TROP GEOGR MED, V16, P49##POLDERMAN AM, 1999, PARASITOL TODAY, V15, P129, DOI 10.1016/S0169-4758(99)01428-3##STOREY PA, 2001, CLIN INFECT DIS, V33, P166, DOI 10.1086/321809##YELIFARI L, 2005, T ROY SOC TROP MED H, V99, P32, DOI 10.1016/J.TRSTMH.2004.02.007##ZIEM JB, 2005, T ROY SOC TROP MED H, V99, P417, DOI 10.1016/J.TRSTMH.2004.07.008##ZIEM JB, IN PRESS T ROYAL SOC, V100, P760##ZIEM JB, 2006, TROP MED INT HEALTH, V11, P1764, DOI 10.1111/J.1365-3156.2006.01729.X",4,2020-11-20,NA
J,WOS:000241407400018,2006,IMPACT OF REPEATED MASS TREATMENT ON HUMAN OESOPHAGOSTOMUM AND HOOKWORM INFECTIONS IN NORTHERN GHANA,"OESOPHAGOSTOMUM BIFURCUM IS A COMMON PARASITE OF HUMANS CAUSING DISEASE IN PARTS OF NORTHERN GHANA AND NORTHERN TOGO. THE IMPACT OF REPEATED MASS TREATMENT WITH ALBENDAZOLE ON INFECTION WITH O. BIFURCUM AND HOOKWORM IS ANALYSED AND THE RESULTS COMPARED WITH THOSE IN A CONTROL AREA WHERE NO TREATMENT WAS GIVEN. AT BASELINE, O. BIFURCUM AND HOOKWORM PREVALENCES WERE 53.0% AND 86.9%, RESPECTIVELY (N = 1011). AFTER 12 MONTHS, FOLLOWING TWO ROUNDS OF ALBENDAZOLE TREATMENT, PREVALENCES DECREASED SIGNIFICANTLY TO 5.4% FOR O. BIFURCUM AND 36.8% FOR HOOKWORM (N = 535). TWENTY-FOUR MONTHS AFTER THE BASELINE SURVEY AND FOLLOWING A TOTAL OF FOUR ROUNDS OF TREATMENT, PREVALENCES WERE FURTHER REDUCED TO 0.8% AND 23.4% FOR O. BIFURCUM AND HOOKWORM, RESPECTIVELY (N = 478). OVERALL, THERE WAS A SIGNIFICANT DECREASE IN THE LARVAL COUNTS, MEASURED AS GEOMETRIC MEAN LARVAL COUNT PER 4 G OF STOOL OF O. BIFURCUM FROM 3.0 TO 0.1 AND OF HOOKWORM FROM 47.2 TO 1.8. THE FOURTH MASS TREATMENT WAS CARRIED OUT IN APRIL 2003 BY THE LYMPHATIC FILARIASIS ELIMINATION PROGRAMME. OVERALL, COMPLIANCE TO TREATMENT VARIED FROM 70% TO 80%. IN THE CONTROL AREA, OESOPHAGOSTOMUM PREVALENCE INCREASED FROM 18.5% TO 37.0% AND THE INTENSITY FROM 0.4 TO 1.4. FOR HOOKWORM, BOTH PREVALENCE (86.1-91.3%) AND INTENSITY (54.8-74.3) INCREASED BUT NOT TO A SIGNIFICANT LEVEL. THE PROSPECTS OF ELIMINATING HUMAN OESOPHAGOSTOMIASIS FROM THE INTERVENTION AREA, WHILE SIMULTANEOUSLY ACHIEVING AN IMPORTANT REDUCTION OF HOOKWORM PREVALENCES BY ALBENDAZOLE MASS TREATMENT, ARE DISCUSSED.",BIFURCUM; ALBENDAZOLE; TOGO,MASS TREATMENT; CONTROL; OESOPHAGOSTOMUM BIFURCUM; HOOKWORM; GHANA,TROPICAL MEDICINE & INTERNATIONAL HEALTH,"ZIEM, JB##MAGNUSSEN, P##OLSEN, A##HORTON, J##ASIGRI, VLL##POLDERMAN, AM","LEIDEN UNIV, MED CTR, DEPT PARASITOL, NL-2300 RC LEIDEN, NETHERLANDS. UNIV DEV STUDIES, SCH MED & HLTH SCI, TAMALE, GHANA. DBL INST HLTH RES & DEV, CHARLOTTENLUND, DENMARK. UNIV LIVERPOOL, DEPT PHARMACOL & THERAPEUT, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND. GHANA HLTH SERV, PARASIT DIS RES CTR, TAMALE, GHANA.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; TROPICAL MEDICINE","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; TROPICAL MEDICINE","BARROWCLOUGH H, 1979, TROP GEOGR MED, V31, P133##BLOTKAMP J, 1993, J HELMINTHOL, V67, P49, DOI 10.1017/S0022149X00012840##DASH K M, 1973, INTERNATIONAL JOURNAL FOR PARASITOLOGY, V3, P843, DOI 10.1016/0020-7519(73)90075-1##DE ROCHARS MB, 2004, AM J TROP MED HYG, V71, P466, DOI 10.4269/AJTMH.2004.71.466##GIGASE P., 1987, HELMINTH ZOONOSIS, P223##HAAF E., 1964, TROP GEOGR MED, V16, P49##KREPEL HP, 1993, T ROY SOC TROP MED H, V87, P87, DOI 10.1016/0035-9203(93)90437-U##OTTESEN EA, 1999, PARASITOL TODAY, V15, P382, DOI 10.1016/S0169-4758(99)01486-6##PIT DSS, 1999, AM J TROP MED HYG, V61, P951, DOI 10.4269/AJTMH.1999.61.951##POLDERMAN AM, 1999, PARASITOL TODAY, V15, P129, DOI 10.1016/S0169-4758(99)01428-3##POLDERMAN AM, 1991, AM J TROP MED HYG, V44, P336, DOI 10.4269/AJTMH.1991.44.336##STOREY PA, 2000, BRIT J RADIOL, V73, P328, DOI 10.1259/BJR.73.867.10817053##YELIFARI L, 2005, T ROY SOC TROP MED H, V99, P32, DOI 10.1016/J.TRSTMH.2004.02.007##ZIEM JB, 2005, T ROY SOC TROP MED H, V99, P417, DOI 10.1016/J.TRSTMH.2004.07.008##ZIEM JB, 2004, ANN TROP MED PARASIT, V98, P385, DOI 10.1179/000349804225003370##ZIEM JB, TROPICAL MED INT HLT, V11, P1759",14,2020-11-20,NA
J,WOS:000243517400001,2006,"HABITAT ASSOCIATION OF AMPHIBIANS IN EAST AFRICAN BUSH- AND GRASSLAND: AN EXAMPLE FROM MERU NATIONAL PARK, KENYA","THE AMPHIBIAN DIVERSITY IN DIFFERENT VEGETATION COMMUNITIES WAS INVESTIGATED IN MERU NATIONAL PARK (KENYA), USING TRANSECT SAMPLING, DRIFT-FENCES, PITFALLS AND OPPORTUNISTIC COLLECTION. ACACIA WOODED GRASSLAND HAD HIGHEST AMPHIBIAN DIVERSITY (H' = 2.071, D = 6.74), ACACIA-COMMIPHORA BUSHLAND RANKED SECOND (H' = 1.858, D = 5.88) AND COMBRETUM WOODED GRASSLAND RANKED THIRD (H' = 1.581, D = 5.08). ACACIA WOODED GRASSLAND HAD THE HIGHEST AMPHIBIAN ABUNDANCE (N = 173 INDIVIDUALS) AND SPECIES RICHNESS (10 SPECIES). COMBRETUM WOODED GRASSLAND HAD EIGHT SPECIES WITH LESS ABUNDANCE (N = 113 INDIVIDUALS), WHILE THE ACACIA - COMMIPHORA BUSHLAND HAD SEVEN SPECIES ONLY, WITH HIGHER ABUNDANCE (N = 144 INDIVIDUALS). DETRENDED CORRESPONDENCE ANALYSIS SHOWED THE PLOTS, WHICH OCCUR CLOSE TOGETHER WITH SIMILAR SPECIES COMPOSITION. CORRESPONDENCE ANALYSIS WAS PERFORMED TO INVESTIGATE THE ASSOCIATION OF AMPHIBIAN SPECIES WITH PLANT ASSEMBLAGES. THERE WAS A POSITIVE LINEAR CORRELATION BETWEEN AMPHIBIAN SPECIES RICHNESS AND PLANT SPECIES DIVERSITY IN ALL VEGETATION COMMUNITIES. HOWEVER, AS THE SPEARMAN RANK TEST COULD NOT ESTABLISH ANY SIGNIFICANT CORRELATION BETWEEN PLANT AND AMPHIBIAN DIVERSITIES IN THE RESPECTIVE HABITATS, THE AMPHIBIANS RECORDED IN THE PRESENT STUDY AREA CANNOT BE USED AS SURROGATE ORGANISMS TO EVALUATE ENVIRONMENTAL CHANGES.",NA,ANURANS; SPECIES RICHNESS; ABUNDANCE; AFROTROPICS,TROPICAL ZOOLOGY,"WASONGA, DV##BEKELE, A##LOTTERS, S##BALAKRISHNAN, M","UNIV ADDIS ABABA, DEPT BIOL, ADDIS ABABA, ETHIOPIA. NATL MUSEUMS KENYA, DEPT HERPETOL, NAIROBI, KENYA. UNIV AMSTERDAM, INST BIODIVERS & ECOSYST DYNAM, NL-1098 SM AMSTERDAM, NETHERLANDS.",ZOOLOGY,ZOOLOGY,"AMENT J G, 1975, JOURNAL OF THE EAST AFRICA NATURAL HISTORY SOCIETY AND NATIONAL MUSEUM, V154, P1##BENNUN L.A., 1999, IMPORTANT BIRD AREAS##BRAAK CJF, 1988, 8802 LWA AGR MATH GR##DUELLMAN WE, 1999, PATTERNS OF DISTRIBUTION OF AMPHIBIANS: A GLOBAL PERSPECTIVE, P1##DUELLMAN WE, 1978, PUBLICATIONS MUSEUM, V65, P1##GREENACRE M. J., 1984, THEORY APPL CORRESPO##HEYER W R, 1994, MEASURING MONITORING##KARNS DR, 1986, FIELD HERPETOLOGY ME##KATI V, 2004, CONSERV BIOL, V18, P667, DOI 10.1111/J.1523-1739.2004.00465.X##KREBS C. J., 1999, ECOLOGICAL METHODOLO##LOTTERS S, 2001, BIOL GEMAN PROGRAMME, P162##LOTTERS S, IN PRESS SALAMANDRA##MAGURRAN A. E, 1988, ECOLOGICAL DIVERSITY##MUELLER-DOMBOIS D, 1974, AIMS METHODS VEGETAT##PEET R.K., 1974, ANNUAL REV ECOL SYST, V5, P285, DOI 10.1146/ANNUREV.ES.05.110174.001441##RODEL M.-O, 2000, HERPETOFAUNA W AFRIC, VI##RODEL MO, 2004, ECOTROPICA, V10, P1##SCHICK S, 2004, REPTILIA, V46, P39##STUART SN, 2004, SCIENCE, V306, P1783, DOI 10.1126/SCIENCE.1103538##TER BRAAK CJF, 1987, VEGETATIO, V69, P69, DOI 10.1007/BF00038688##WHITE F, 1983, VEGETATION AFRICA DE",0,2020-11-20,NA
J,WOS:000242445600004,2006,HARMONIC INTRAVASCULAR ULTRASOUND IMAGING WITH A DUAL-FREQUENCY CATHETER,"RECENT STUDIES HAVE SHOWN THE FEASIBILITY OF TISSUE AND CONTRAST HARMONIC IMAGING WITH A PROTOTYPE NONLINEAR INTRAVASCULAR ULTRASOUND (IVUS) SYSTEM USING A CONVENTIONAL SINGLE-ELEMENT ROTATING IVUS CATHETER. IN THIS STUDY, A DUAL-FREQUENCY TRANSDUCER ELEMENT WAS MOUNTED IN AN IVUS CATHETER AND ITS SECOND HARMONIC IMAGING PERFORMANCE WAS INVESTIGATED AND COMPARED WITH THAT OF A CONVENTIONAL IVUS CATHETER. HYDROPHONE MEASUREMENTS SHOWED A TRANSMIT EFFICIENCY IMPROVEMENT OF > 6 DB FOR THE DUAL-FREQUENCY CATHETER AT 20 MHZ. IN VITRO PHANTOM EXPERIMENTS SHOWED A SIGNAL-TO NOISE RATIO IMPROVEMENT OF > 5 DB IN SECOND HARMONIC MODE AT 40 MHZ (H40) WITH THE DUAL-FREQUENCY CATHETER, WHEN USING EQUAL TRANSMIT VOLTAGE FOR BOTH CATHETERS. FINALLY, IN VIVO EXPERIMENTS WERE CONDUCTED AND SHOWED IMAGE IMPROVEMENT IN H40 ACQUISITIONS WITH RESPECT TO THE CONVENTIONAL IVUS CATHETER.",DISTORTION,TISSUE HARMONIC IMAGING; CATHETER; DUAL-FREQUENCY; INTRAVASCULAR ULTRASOUND; IVUS; TRANSDUCER; HIGH-FREQUENCY,ULTRASOUND IN MEDICINE AND BIOLOGY,"FRIJLINK, ME##GOERTZ, DE##VOS, HJ##TESSELAAR, E##BLACQUIERE, G##GISOLF, A##KRAMS, R##VAN DER STEEN, AFW","UNIV ROTTERDAM, MED CTR, ERASMUS MC, THORAX CTR EE23 02, NL-3000 DR ROTTERDAM, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS. DELFT UNIV TECHNOL, DELFT, NETHERLANDS. TNO SCI & IND, DELFT, NETHERLANDS.","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ACOUSTICS; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","AVERKIOU MA, 1997, J ACOUST SOC AM, V102, P2539, DOI 10.1121/1.420308##BOUAKAZ A, 2002, ULTRASOUND MED BIOL, V28, P59, DOI 10.1016/S0301-5629(01)00460-4##CHERIN EW, 2002, ULTRASOUND MED BIOL, V28, P635, DOI 10.1016/S0301-5629(02)00498-2##CHRISTOPHER T, 1997, IEEE T ULTRASON FERR, V44, P125, DOI 10.1109/58.585208##DEKORTE CL, 1997, ULTRASONIC IMAGING, V19, P112, DOI 10.1177/016173469701900202##DUCK F.A., 1990, PHYS PROPERTIES TISS##DUCK FA, 2002, ULTRASOUND MED BIOL, V28, P1, DOI 10.1016/S0301-5629(01)00463-X##FOSTER FS, 2000, IEEE T ULTRASON FERR, V47, P1363, DOI 10.1109/58.883525##FRIJLINK ME, 2005, ULTRASOUND MED BIOL, V31, P1335, DOI 10.1016/J.ULTRASMEDBIO.2005.06.006##FRIJLINK ME, IN PRESS IEEE T ULTR##GOERTZ DE, 2006, ULTRASOUND MED BIOL, V32, P569, DOI 10.1016/J.ULTRASMEDBIO.2006.01.002##GOERTZ DE, 2005, IEEE ULTR S SEPT ROT, V1, P2003##HAMILTON M.F., 1998, NONLINEAR ACOUSTICS##HOSSACK JA, 2000, ULTRASON, P1021, DOI 10.1109/ULTSYM.2000.921498##HUMPHREY VF, 2000, ULTRASONICS, V38, P267, DOI 10.1016/S0041-624X(99)00122-5##MEYER R, 1999, IEEE ULTR S OCT CEAS, V2, P1299##MUIR TG., 1980, ACOUST IMAG, V9, P93##NATIONAL RESEARCH COUNCIL, 1996, GUID CAR US LAB AN##SAIJO Y., 2003, VASCULAR ULTRASOUND##SCHAAR JA, 2005, HERZ, V30, P125, DOI 10.1007/S00059-005-2642-4##SIMPSON DH, 1999, IEEE T ULTRASON FERR, V46, P372, DOI 10.1109/58.753026##SNOOK KA, 2002, IEEE T ULTRASON FERR, V49, P169, DOI 10.1109/58.985701##TAKEUCHI S, 2002, JPN J APPL PHYS 1, V41, P3619, DOI 10.1143/JJAP.41.3619##VANDERSTEEN AFW, 1999, IEEE ULTR S, V2, P1537##VOS HJ, 2005, IEEE T ULTRASON FERR, V52, P2418, DOI 10.1109/TUFFC.2005.1563286",25,2020-11-20,NA
J,WOS:000243172300003,2006,HEALTH AND EFFICIENCY IN TRIMIX VERSUS AIR BREATHING IN COMPRESSED AIR WORKERS.,"VAN REES VELLINGA TP, VERHOEVEN AC, VAN DIJK FJH, STERK W. HEALTH AND EFFICIENCY IN TRIMIX VERSUS AIR BREATHING IN COMPRESSED AIR WORKERS. UNDERSEA HYPERB MED 2006; 33(6):419-427. THE WESTERN SCHELDT TUNNELING PROJECT IN THE NETHERLANDS PROVIDED A UNIQUE OPPORTUNITY TO EVALUATE THE EFFECTS OF TRIMIX USAGE ON THE HEALTH OF COMPRESSED AIR WORKERS AND THE EFFICIENCY OF THE PROJECT. DATA ANALYSIS ADDRESSED 318 EXPOSURES TO COMPRESSED AIR AT 3.9-4.4 BAR GAUGE AND 52 EXPOSURES TO TRIMIX (25% OXYGEN, 25% HELIUM, AND 50% NITROGEN) AT 4.6-4.8 BAR GAUGE. RESULTS REVEALED THREE INCIDENTS OF DECOMPRESSION SICKNESS ALL OF WHICH INVOLVED THE USE OF COMPRESSED AIR. DURING EXPOSURE TO COMPRESSED AIR, THE EFFECTS OF NITROGEN NARCOSIS WERE MANIFESTED IN OPERATIONAL ERRORS AND INCREASED FATIGUE AMONG THE WORKERS. WHEN USING TRIMIX, LESS EFFORT WAS REQUIRED FOR BREATHING, AND MANDATORY DECOMPRESSION TIMES FOR STAYS OF A SPECIFIC DURATION AND MAXIMUM DEPTH WERE CONSIDERABLY SHORTER. WE CONCLUDE THAT IT MIGHT BE RATIONAL - FOR BOTH MEDICAL AND OPERATIONAL REASONS TO USE BREATHING GASES WITH LOWER NITROGEN FRACTIONS (E.G., TRIMIX) FOR DEEP-CAISSON WORK AT PRESSURES EXCEEDING 3 BAR GAUGE, ALTHOUGH DEFINITIVE STUDIES ARE NEEDED.",NA,NA,UNDERSEA AND HYPERBARIC MEDICINE,"VELLINGA, TPV##VERHOEVEN, AC##VAN DIJK, FJH##STERK, W","UNIV AMSTERDAM, ACAD MED CTR, CORONEL INST OCCUPAT & ENVIRONM HLTH, NL-1012 WX AMSTERDAM, NETHERLANDS. ARBOUNIE, OCCUPAT HLTH SERV, UTRECHT, NETHERLANDS. DADCODAT, ZUIDWOLDE, NETHERLANDS.","MARINE & FRESHWATER BIOLOGY; MEDICINE, RESEARCH & EXPERIMENTAL",MARINE & FRESHWATER BIOLOGY; RESEARCH & EXPERIMENTAL MEDICINE,"BENNET P, 2003, BENNETT ELLIOTTS PHY, P300##BENNETT M, 2002, S PACIFIC UNDERWATER, V32, P90##CHOUTEAU J, 1969, PHYSIOLOGY MEDICINE, P491##CLARK JM, 2003, BENNETT ELLIOTTS PHY, P402##EDMONDS C, 1992, DIVING SUBAQUATIC ME, P215##FOWLER B, 1985, UNDERSEA BIOMED RES, V12, P369##HAMILTON RW, 2001, 49 WORKSH UND HYP ME, P65##HAMILTON RW, 1994, ENG HLTH COMPRESSED, P509##HAMILTON RW, 2001, 49 WORKSH UND HYP ME, P55##HIRATA T, 1994, ENG HLTH COMPRESSED, P519##HOBSON BA, 1987, VALIDATION DECOMPRES, P25##HOMER LD, 1985, UNDERSEA BIOMED RES, V12, P239##KINDWALL EP, 1997, UNDERSEA HYPERBAR M, V24, P337##KINDWALL EP, 2003, BENNETT ELLIOTTS PHY, P17##KOBAYASHI K, 1994, EUBS 1994 P IST TURK, P336##LAMBERTSEN CJ, 1988, EXP LUNG RES, V14, P1035, DOI 10.3109/01902148809064191##LEPECHON JC, 2001, 49 WORKSH UND HYP ME, P15##LUTHER G, 1994, ENG HLTH COMPRESSED, P539##MOCHIZUKI T, 2002, UNDERSEA HYPERBAR M, V29, P158##SPARROW L, 2000, UNDERSEA HYPERBAR M, V27, P125##STERK W, 1991, OPERATIONAL DIVE DEC, P3##STERK W, 1986, P 12 ANN M EUR UND B, P55##STERK W, 2000, P 26 ANN SCI M EUR U, P98##STERK W, 1997, DECOMPRESSION SURFAC, P3##STERK W, 2003, P 2 INT C ENG HLTH C, P115##STERK W., 2000, UNDERSEA HYPERB ME S, V27, P20##TAKASHIMA R, 1996, UNDERSEA HYPERBARI S, V23, P34##TAKASHIMA R, 1996, P INT JOINT M MIL GR, P437##VELLINGA TPV, 2000, P 26 ANN SCI M EUR U, P85",7,2020-11-20,NA
J,WOS:000242592500024,2006,"CLINICAL UTILITY OF ""BLIND PLACEMENT"" PROSTATIC STENT IN PATIENTS WITH BENIGN PROSTATIC OBSTRUCTION: A PROSPECTIVE STUDY","OBJECTIVES. TO ASSESS THE EFFICACY AND SAFETY OF TWO VERSIONS OF A BLIND PLACEMENT TEMPORARY PROSTATIC STENT IN THE TREATMENT OF PATIENTS WITH BENIGN PROSTATIC OBSTRUCTION. METHODS. TWO VERSIONS OF A PROSTATIC STENT (BLIND PLACEMENT STENT 1 [BPS-1) AND BPS-2) WERE BLINDLY INSERTED IN AN OUTPATIENT SETTING UNDER LOCAL ANESTHESIA. AN ASSESSMENT OF VOIDING FUNCTION, SYMPTOM SCORES, AND COMPLICATIONS WAS PERFORMED AT BASELINE, DIRECTLY AFTER STENT INSERTION, AND AT 14 AND 28 DAYS AFTER STENT PLACEMENT. RESULTS. A TOTAL OF 55 MEN WERE ENROLLED IN THE TRIAL. MOST STENTS OF BOTH TYPES WERE SUCCESSFULLY PLACED. SPONTANEOUS VOIDING WAS ACHIEVED IN ALL PATIENTS IMMEDIATELY AFTER STENT INSERTION, WITH IMPROVEMENTS IN VOIDING PARAMETERS AND SYMPTOM SCORES. IN PATIENTS WITH THE BPS-1, MIGRATION OCCURRED IN 85%. IN PATIENTS WITH THE BPS-2, MIGRATION OCCURRED IN 5%. THE MEDIAN INDWELLING TIME OF THE STENT WAS 16 AND 38 DAYS FOR THE BPS-1 AND BPS-2, RESPECTIVELY. REMOVAL WAS SUCCESSFUL IN ALL BUT 1 CASE (BPS-2). CONCLUSIONS. THE BPS-1 IS NOT SUITABLE FOR CLINICAL PRACTICE BECAUSE OF THE SIGNIFICANTLY HIGH MIGRATION RATE. THE BULBAR SEGMENT OF THE BPS-2 CAN PREVENT STENT MIGRATION. HOWEVER, PATIENTS EXPERIENCED SIGNIFICANT DISCOMFORT AFTER INSERTION OF THE BPS-2. THE VOIDING PARAMETERS AND SYMPTOM SCORES OF THE BPS-2 WERE NOT SIGNIFICANTLY IMPROVED. THEREFORE, THE BPS-2 IS ALSO NOT USEFUL FOR CLINICAL PRACTICE. ADDITIONAL ADJUSTMENT IN THE DESIGN OF THE BPS IS NEEDED TO OVERCOME THESE PROBLEMS.",BLADDER OUTLET OBSTRUCTION; HIGH-RISK PATIENTS; URINARY RETENTION; INTRAURETHRAL CATHETER; HYPERPLASIA; EXPERIENCE,NA,UROLOGY,"KIJVIKAI, K##VAN DIJK, M##PES, PL##LERTSITHICHAI, P##WIJKSTRA, H##DE LA ROSETTE, J","UNIV AMSTERDAM, ACAD MED CTR, DEPT UROL, NL-1105 AZ AMSTERDAM, NETHERLANDS. MAHIDOL UNIV, RAMATHIBODI HOSP, DEPT UROL, BANGKOK 10700, THAILAND. MAHIDOL UNIV, RAMATHIBODI HOSP, DEPT SURG, BANGKOK 10700, THAILAND.",UROLOGY & NEPHROLOGY,UROLOGY & NEPHROLOGY,"CHIU AW, 1991, EUR UROL, V19, P304##CORICA AP, 2004, BJU INT, V93, P346, DOI 10.1111/J.1464-410X.2003.04613.X##DJAVAN B, 1999, J UROLOGY, V161, P144, DOI 10.1016/S0022-5347(01)62085-8##FITZPATRICK JM, 2002, CAMPBELLS UROLOGY, P1379##ISOTALO T, 2001, BJU INT, V88, P30, DOI 10.1046/J.1464-410X.2001.02250.X##MASOOD S, 2004, BJU INT, V94, P1271, DOI 10.1111/J.1464-410X.2004.05155.X##NIELSEN KK, 1990, BRIT J UROL, V65, P500, DOI 10.1111/J.1464-410X.1990.TB14795.X##NISSENKORN I, 1990, EUR UROL, V18, P286##NORDLING J, 1992, J UROLOGY, V147, P645, DOI 10.1016/S0022-5347(17)37333-0##OESTERLING JE, 1994, UROLOGY, V44, P353, DOI 10.1016/S0090-4295(94)80093-6##PERRY MJA, 2002, BJU INT, V90, P216, DOI 10.1046/J.1464-410X.2002.02888.X##POULSEN AL, 1993, BRIT J UROL, V72, P331, DOI 10.1111/J.1464-410X.1993.TB00728.X##SASSINE AM, 1994, EUR UROL, V25, P131##SCHAEFFER AJ, 1986, UROL CLIN N AM, V13, P735##TRAXER O, 2000, EUR UROL, V38, P272, DOI 10.1159/000020293##VAN DIJK MM, 2005, UROLOGY, V66, P845, DOI 10.1016/J.UROLOGY.2005.04.030##YACHIA D, 1994, BRIT J UROL, V74, P47, DOI 10.1111/J.1464-410X.1994.TB16545.X",5,2020-11-20,NA
J,WOS:000242592500025,2006,IS IT POSSIBLE TO IMPROVE ELDERLY MALE BLADDER FUNCTION BY HAVING THEM DRINK MORE WATER? A RANDOMIZED TRIAL OF EFFECTS OF INCREASED FLUID INTAKE/URINE OUTPUT ON MALE LOWER URINARY TRACT FUNCTION,"OBJECTIVES. SEVERAL ANIMAL STUDIES HAVE SHOWN THAT BLADDER PERFORMANCE IMPROVES AS A RESULT OF DIURESIS. WHETHER INCREASED URINE OUTPUT ALSO HAS BENEFICIAL EFFECTS ON ELDERLY MALE BLADDER FUNCTION AND LOWER URINARY TRACT SYMPTOMS IS UNKNOWN. METHODS. WE PERFORMED A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF 141 MEN, 55 TO 75 YEARS OF AGE, WITH MODERATE LOWER URINARY TRACT SYMPTOMS. THE EXPERIMENTAL GROUP DRANK 1.5 L OF EXTRA WATER DAILY. THE CONTROL GROUP CONSUMED ONE TABLESPOON OF PLACEBO SYRUP DAILY. AFTER 6 MONTHS, WE EVALUATED BLADDER CONTRACTILITY, VOIDED VOLUMES, AND THE SEVERITY OF LOWER URINARY TRACT SYMPTOMS. THE ACTUAL INCREASE IN WATER CONSUMPTION WAS MEASURED USING THE DEUTERIUM URINE DILUTION METHOD. RESULTS. WATER CONSUMPTION IN THE INTERVENTION GROUP INCREASED BY 359 ML (95% CONFIDENCE INTERVAL [CI) 171 TO 548) PER 24 HOURS COMPARED WITH THE CONTROL GROUP. AT 6 MONTHS, NO STATISTICALLY SIGNIFICANT EFFECT WAS FOUND IN THE MAXIMAL FLOW RATE (0.9 ML/S, 95% CI -0.4 TO 2.2) COMPARED WITH PLACEBO. A STATISTICALLY SIGNIFICANT EFFECT WAS FOUND FOR BLADDER PRESSURE (20 CM H2O, 95% CI 6 TO 34) AND BLADDER WALL STRESS (1.9 N/CM(2), 95% CI 0.3 TO 3.5). IN ADDITION, IT SHOWED THAT THE EXPERIMENTAL GROUP HAD GREATER MAXIMAL (44 ML, 95% CI -1 TO 90) AND AVERAGE (26 ML, 95% CI 1 TO 51) VOIDED VOLUMES PER URINATION. THE SUBJECTIVE EFFECT PARAMETERS IMPROVED IN BOTH GROUPS, BUT NO STATISTICALLY SIGNIFICANT DIFFERENCES WERE FOUND BETWEEN THE TWO GROUPS. CONCLUSIONS. IT SEEMS POSSIBLE TO IMPROVE SOME ASPECTS OF MALE BLADDER FUNCTION BY DRINKING MORE WATER. HOWEVER, THE EFFECTS ARE TOO SMALL TO BE CLINICALLY RELEVANT.",BENIGN PROSTATIC HYPERPLASIA; OUTLET OBSTRUCTION; INFRAVESICAL OBSTRUCTION; BODY-COMPOSITION; WALL THICKNESS; LABELED WATER; SYMPTOM SCORE; BASE-LINE; FOLLOW-UP; MEN,NA,UROLOGY,"SPIGT, M##VAN SCHAYCK, O##KNIPSCHILD, P##WESTERTERP, K##DE BEEK, GV##VAN KERREBROECK, P##PEL, J##VAN MASTRIGT, R##KNOTTNERUS, A","MAASTRICHT UNIV, DEPT GEN PRACTICE, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, DEPT HUMAN BIOL, NL-6200 MD MAASTRICHT, NETHERLANDS. MAASTRICHT UNIV, DEPT UROL, NL-6200 MD MAASTRICHT, NETHERLANDS. ERASMUS MC, DEPT UROL, ROTTERDAM, NETHERLANDS.",UROLOGY & NEPHROLOGY,UROLOGY & NEPHROLOGY,"BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5##BOSCH JLHR, 1995, BRIT J UROL, V75, P622, DOI 10.1111/J.1464-410X.1995.TB07421.X##BROSS S, 2001, J UROLOGY, V166, P1130, DOI 10.1016/S0022-5347(05)65934-4##BROWN CT, 2003, BJU INT, V92, P53, DOI 10.1046/J.1464-410X.2003.04268.X##BROWN CT, 2004, EUR UROL, V46, P254, DOI 10.1016/J.EURURO.2004.02.008##CHUNG JWNCHF, 2004, UROLOGY, V63, P56, DOI 10.1016/J.UROLOGY.2003.08.030##DAS AK, 2002, NEUROUROL URODYNAM, V21, P160, DOI 10.1002/NAU.10045##ELDIN KE, 1996, UROLOGY, V48, P393##GISOLF KWH, 2000, EUR UROL, V38, P45, DOI 10.1159/000020251##HAKENBERG OW, 2000, NEUROUROL URODYNAM, V19, P585, DOI 10.1002/1520-6777(2000)19:5<585::AID-NAU5>3.0.CO;2-U##JENSEN KME, 1995, WORLD J UROL, V13, P21##KOJIMA M, 1997, J UROLOGY, V157, P476, DOI 10.1016/S0022-5347(01)65178-4##LEVIN RM, 1997, EUR UROL, V32, P15##OHNISHI N, 1999, UROLOGY, V54, P183, DOI 10.1016/S0090-4295(99)00134-X##PEL JJM, 2002, NEUROUROL URODYNAM, V21, P117, DOI 10.1002/NAU.10046##PEL JJM, 1999, NEUROUROL URODYNAM, V18, P455, DOI 10.1002/(SICI)1520-6777(1999)18:5<455::AID-NAU7>3.0.CO;2-S##ROEHRBORN CG, 2000, UROLOGY, V56, P12, DOI 10.1016/S0090-4295(00)00743-3##SAITO M, 1999, UROL INT, V62, P93, DOI 10.1159/000030365##SCHRODER A, 2001, UROLOGY, V58, P608, DOI 10.1016/S0090-4295(01)01291-2##SPIGT MG, 2005, J CLIN EPIDEMIOL, V58, P350, DOI 10.1016/J.JCLINEPI.2004.08.009##SPIGT MG, 2004, UROLOGY, V64, P499, DOI 10.1016/J.UROLOGY.2004.04.010##SPIGT MG, 2004, MED HYPOTHESES, V62, P448, DOI 10.1016/J.MEHY.2003.10.004##TAMMELA TLJ, 1993, J UROLOGY, V150, P204, DOI 10.1016/S0022-5347(17)35447-2##TARCAN T, 1998, BRIT J UROL, V82, P26##TWISK J, 2004, J CLIN EPIDEMIOL, V57, P223, DOI 10.1016/J.JCLINEPI.2003.07.009##VAN MASTRIGT R, 1999, BJU INT, V84, P195##VICKERS AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/BMJ.323.7321.1123##WESTERTERP KR, 1999, P NUTR SOC, V58, P945, DOI 10.1017/S0029665199001251##WESTERTERP KR, 1995, OBES RES, V3, P49, DOI 10.1002/J.1550-8528.1995.TB00007.X",11,2020-11-20,NA
J,WOS:000242592500052,2006,USE OF POSITRON EMISSION TOMOGRAPHY IN SPINDLE CELL CARCINOMA OF THE PENIS,"A 60-YEAR-OLD MAN PRESENTED WITH SPINDLE CELL CARCINOMA OF THE PENIS. HE UNDERWENT SURGERY AND ADDITIONAL POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY SCANS TO EVALUATE FOR POSSIBLE METASTASES. POSITRON EMISSION TOMOGRAPHY SHOWED A LEFT INGUINAL AND PARAVESICAL HOT SPOT ON THE RIGHT. ONLY THE LEFT INGUINAL LESION COULD BE CONFIRMED ON COMPUTED TOMOGRAPHY. THE PATIENT UNDERWENT ADDITIONAL SURGERY WITH CURATIVE INTENT. THREE MONTHS LATER, THE PATIENT UNDERWENT REPEAT COMPUTED TOMOGRAPHY, WHICH REVEALED AN OSTEOLYTIC PROCESS IN THE RIGHT ACETABULUM. THIS LESION CORRESPONDED WITH THE RIGHT PARAVESICAL HOT SPOT ON THE POSITRON EMISSION TOMOGRAPHY SCAN 3 MONTHS EARLIER.",NA,NA,UROLOGY,"LEIJTE, JAP##OLMOS, RAV##MENS, JWM##HORENBLAS, S","ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT UROL, NL-1066 CX AMSTERDAM, NETHERLANDS. ANTONI VAN LEEUWENHOEK HOSP, NETHERLANDS CANC INST, DEPT NUCL MED, NL-1066 CX AMSTERDAM, NETHERLANDS. DR DANIEL DEN HOED CANC CTR, ERASMUS MED CTR, DEPT RADIOTHERAPY, NL-3008 AE ROTTERDAM, NETHERLANDS.",UROLOGY & NEPHROLOGY,UROLOGY & NEPHROLOGY,"ANTONINI C, 1997, ADV CLIN PATH, V1, P281##GAMBHIR SS, 2001, J NUCL MED, V42, P1S##INAI K, 1984, GAN NO RINSHO, V30, P99##LONT AP, 2004, J UROLOGY, V172, P932, DOI 10.1097/01.JU.0000136363.90911.E5##MANGLANI KS, 1980, CANCER, V46, P2266, DOI 10.1002/1097-0142(19801115)46:10<2266::AID-CNCR2820461026>3.0.CO;2-Y##PATEL B, 1982, UROLOGY, V19, P93, DOI 10.1016/0090-4295(82)90060-7##PRASAD KAUSHAL K, 2003, INDIAN J PATHOL MICROBIOL, V46, P236##RAVIZZINI GC, 2001, J UROLOGY, V165, P1633, DOI 10.1016/S0022-5347(05)66372-0##SABIN LH, 2002, TNM CLASSIFICATION M##SCHEURING S, 2005, BIOPHARM INT, V18, P46##SHIMAMOTO TSUTOMU, 2005, HINYOKIKA KIYO, V51, P775##SOLSONA E, 2004, EUR UROL, V46, P1, DOI 10.1016/J.EURURO.2004.03.007##TABATABAEI S, 2005, J UROLOGY, V174, P923, DOI 10.1097/01.JU.0000170234.14519.19##VELAZQUEZ EF, 2005, AM J SURG PATHOL, V29, P1152, DOI 10.1097/01.PAS.0000160440.46394.A8##WOOD EW, 1972, J UROLOGY, V107, P990, DOI 10.1016/S0022-5347(17)61190-X",1,2020-11-20,NA
J,WOS:000243724900006,2006,QUANTIFYING MINIMUM MONOLITH SIZE AND SOLUTE DILUTION FROM MULTI-COMPARTMENT PERCOLATION SAMPLER DATA,"PREFERENTIAL FLOW AFFECTS SOLUTE TRANSPORT IN NATURAL SOILS, LEADING TO HIGH SPATIOTEMPORAL VARIATION OF CONCENTRATION. A MULTICOMPARTMENT SOLUTE SAMPLER (MCS), YIELDING MULTIPLE BREAKTHROUGH CURVES AT A GIVEN DEPTH, CAN MONITOR TRACER MOVEMENT IN A HETEROGENEOUS SOIL. WE PRESENT A TECHNIQUE TO ESTIMATE FROM MCS DATA WHETHER A SOIL MONOLITH IS SUFFICIENTLY LARGE TO CAPTURE PREFERENTIAL FLOW, WHICH IS A NECESSITY FOR TRACER BREAKTHROUGH CURVES TO BE REPRESENTATIVE. FOR SEVERAL SOILS, WE ESTIMATE THAT AN MCS SHOULD BE LARGER THAN 0.1 TO 0.2 M(2). WE ALSO EXPAND DILUTION THEORY TO ANALYZE THE CONCENTRATION VARIATIONS OF A TRACER PASSING THE CONTROL PLANE MONITORED BY THE MCS, IN ADDITION TO THE CONVENTIONAL PLUME SPREADING ANALYSIS. WE CHARACTERIZE THE SET OF LOCALLY OBSERVED BREAKTHROUGH CURVES BY THE ENTROPY-BASED DILUTION INDEX. FOR GIVEN FIRST AND SECOND-CENTRAL MOMENT, THE SPATIALLY UNIFORM LOG-NORMAL BREAKTHROUGH CURVE MAXIMIZES THE DILUTION INDEX. THE RATIO BETWEEN OBSERVED AND MAXIMUM DILUTION INDEX IS DENOTED REACTOR RATIO. FOR A 300-COMPARTMENT SOLUTE SAMPLER, COVERING AN AREA OF 0.75 M(2), WE COMPUTE A REACTOR RATIO OF 0.665, COMPARED WITH 0.04 FOR STOCHASTIC-CONVECTIVE AND 1 FOR CONVECTIVE-DISPERSIVE TRANSPORT. WITH A SINGLE, LARGE COLLECTOR THE REACTOR RATIO WOULD BE 0.958, SEVERELY UNDERESTIMATING CONCENTRATION VARIATIONS. LARGE COLLECTOR AREAS ARE CLEARLY INADEQUATE TO ESTIMATE DILUTION. VALUES OF THE DILUTION INDEX AND THE REACTOR RATIO FOR INDIVIDUAL SAMPLING COMPARTMENTS INDICATE EFFICIENT LONGITUDINAL MIXING IN MOST BUT NOT ALL CASES, AND CONSIDERABLE SPATIAL VARIATION OF THE LEACHING PROCESS.",SANDY VADOSE ZONE; SPATIAL VARIABILITY; HETEROGENEOUS SOIL; PREFERENTIAL FLOW; TRANSPORT; DISPERSION; WATER; MEDIA,NA,VADOSE ZONE JOURNAL,"DE ROOIJ, GH##CIRPKA, OA##STAGNITTI, F##VUURENS, SH##BOLL, J","UNIV WAGENINGEN & RES CTR, DEPT ENVIRONM SCI SUB DEP WATER RESOURCES, SOIL PHYS ECOHYDROL & GROUNDWATER MANAGEMENT GRP, NL-6709 PA WAGENINGEN, NETHERLANDS. SWISS FED INST AQUAT SCI & TECHNOL, DEPT WATER RESOURCES & DRINKING WATER, CH-8600 DUBENDORF, SWITZERLAND. SCH ECOL & ENVIRONM, WARRNAMBOOL, VIC, AUSTRALIA. UNIV IDAHO, DEPT BIOL & AGR ENGN, MOSCOW, ID 83844 USA.",ENVIRONMENTAL SCIENCES; SOIL SCIENCE; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; AGRICULTURE; WATER RESOURCES,"ABRAMOWITZ M., 1964, HDB MATH FUNCTIONS F, V55##BOLL J, 1997, WATER RESOUR RES, V33, P2655, DOI 10.1029/97WR02588##CIRPKA OA, 2002, WATER RESOUR RES, V38, DOI 10.1029/2001WR001262##DAGAN G, 1979, SOIL SCI SOC AM J, V43, P461, DOI 10.2136/SSSAJ1979.03615995004300030008X##DE ROOIJ G.H., 2004, HDB BETA DISTRIBUTIO, P535##DE ROOIJ GH, 2002, J CONTAM HYDROL, V54, P329, DOI 10.1016/S0169-7722(01)00185-1##DE ROOIJ GH, 2000, SOIL SCI SOC AM J, V64, P499, DOI 10.2136/SSSAJ2000.642499X##DEROOIJ GH, 1996, THESIS WAGENINGEN AG##GUPTA A.K., 2004, HDB BETA DISTRIBUTIO, P33##JANSSEN GMCM, 2006, WATER RESOUR RES, V42, DOI 10.1029/2005WR004042##JURY WA, 1990, TRANSFER FUNCTIONS S##KAPOOR V, 1998, WATER RESOUR RES, V34, P1181, DOI 10.1029/97WR03608##KAPUR J.N., 1989, MAXIMUM ENTROPY MODE##KITANIDIS PK, 1994, WATER RESOUR RES, V30, P2011, DOI 10.1029/94WR00762##KREFT A, 1978, CHEM ENG SCI, V33, P1471, DOI 10.1016/0009-2509(78)85196-3##KUNG KJS, 1990, GEODERMA, V46, P59, DOI 10.1016/0016-7061(90)90007-V##KUNG KJS, 1990, GEODERMA, V46, P51, DOI 10.1016/0016-7061(90)90006-U##LENNARTZ B, 1998, HYDROL PROCESS, V12, P1939, DOI 10.1002/(SICI)1099-1085(19981015)12:12&LT;1939::AID-HYP655&GT;3.0.CO;2-O##MALLANTS D, 1996, HYDROL PROCESS, V10, P55, DOI 10.1002/(SICI)1099-1085(199601)10:1&LT;55::AID-HYP299&GT;3.0.CO;2-N##MALLANTS D, 1994, J CONTAM HYDROL, V17, P91, DOI 10.1016/0169-7722(94)90016-7##POLETIKA NN, 1994, SOIL SCI SOC AM J, V58, P999, DOI 10.2136/SSSAJ1994.03615995005800040001X##QUISENBERRY VL, 1994, SOIL SCI SOC AM J, V58, P1294, DOI 10.2136/SSSAJ1994.03615995005800050003X##SASSNER M, 1994, WATER RESOUR RES, V30, P735, DOI 10.1029/93WR02985##SIMMONS CS, 1982, WATER RESOUR RES, V18, P1193, DOI 10.1029/WR018I004P01193##STAGNITTI F, 1998, NEW ZEAL J AGR RES, V41, P603, DOI 10.1080/00288233.1998.9513344##STAGNITTI F, 1999, J HYDROL, V215, P59, DOI 10.1016/S0022-1694(98)00261-3##STROCK JS, 2001, SOIL SCI SOC AM J, V65, P1607, DOI 10.2136/SSSAJ2001.1607##URSINO N, 2001, ADV WATER RESOUR, V24, P877, DOI 10.1016/S0309-1708(01)00014-8##VAN ES H.M., 2002, SSSA BOOK SER, P1",6,2020-11-20,NA
J,WOS:000243724900021,2006,ROOT WATER EXTRACTION AND LIMITING SOIL HYDRAULIC CONDITIONS ESTIMATED BY NUMERICAL SIMULATION,"ROOT DENSITY, SOIL HYDRAULIC FUNCTIONS, AND HYDRAULIC HEAD GRADIENTS PLAY AN IMPORTANT ROLE IN THE DETERMINATION OF TRANSPIRATION-RATE-LIMITING SOIL WATER CONTENTS. WE DEVELOPED AN IMPLICIT NUMERICAL ROOT WATER EXTRACTION MODEL TO SOLVE THE RICHARDS EQUATION FOR THE MODELING OF RADIAL ROOT WATER EXTRACTION. THE AVERAGE SOIL WATER CONTENT AT THE MOMENT ROOT WATER POTENTIAL DROPPED BELOW A DEFINED CRITICAL VALUE WAS THEN ESTIMATED. THE DEPENDENCE OF AVERAGE WATER CONTENT AT THE ONSET OF PLANT WATER STRESS ON POTENTIAL TRANSPIRATION AND ROOT DENSITY WAS COMPARED WITH AN ANALYTICAL SOLUTION FOR HYDRAULIC CONDITIONS IN THE ROOT SPHERE. THE CRITICAL VALUE WAS A FUNCTION OF POTENTIAL TRANSPIRATION RATE, SOIL HYDRAULIC PROPERTIES, AND ROOT DENSITY. MATRIC FLUX POTENTIAL APPEARS TO BE A CONVENIENT HYDRAULIC PROPERTY TO DETERMINE THE ONSET OF LIMITING HYDRAULIC CONDITIONS, AS NUMERICAL SIMULATIONS SHOWED THAT, AT ONSET, MATRIC FLUX POTENTIAL VS. DISTANCE FROM THE ROOT SURFACE IS INDEPENDENT OF SOIL TYPE. THIS WAS ALSO DETERMINED ANALYTICALLY UNDER THE CONSTANT-RATE ASSUMPTION. MEAN WATER CONTENT OCCURS AT ABOUT 0.53 TIMES THE HALF-DISTANCE BETWEEN ROOTS. THIS ALLOWS CALCULATION OF THE MEAN LIMITING SOIL WATER CONTENT AND PRESSURE HEAD FROM THE MATRIC FLUX POTENTIAL AT THIS DISTANCE, WHICH IS A FUNCTION OF TRANSPIRATION RATE AND ROOT DENSITY ONLY. A NOMOGRAM WAS DEVELOPED THAT-GIVEN THE TRANSPIRATION RATE, THE ROOT DENSITY, AND THE SOIL HYDRAULIC FUNCTIONS-ALLOWS DETERMINATION OF THE VALUES OF MEAN WATER CONTENT AND MEAN PRESSURE HEAD THAT OCCUR AT THE ONSET OF TRANSPIRATION REDUCTION.",UPTAKE PARAMETERS; STOMATAL CONTROL; USE EFFICIENCY; SCALE MODEL; RESISTANCE; L.; DYNAMICS; GROWTH; DEPTH; ZONE,NA,VADOSE ZONE JOURNAL,"VAN LIER, QD##METSELAAR, K##VAN DAM, JC","UNIV SAO PAULO, EXACT SCI DEPT, ESALQ, BR-13418900 PIRACICABA, SP, BRAZIL. UNIV WAGENINGEN & RES CTR, DEPT ENVIRONM SCI, NL-6709 PA WAGENINGEN, NETHERLANDS.",ENVIRONMENTAL SCIENCES; SOIL SCIENCE; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; AGRICULTURE; WATER RESOURCES,"ADEOYE KB, 1981, PLANT PHYSIOL, V68, P44, DOI 10.1104/PP.68.1.44##AMATO M, 2002, CROP SCI, V42, P773, DOI 10.2135/CROPSCI2002.0773##ALLEN R. G., 1998, FAO IRRIGATION AND DRAINAGE PAPER, DOI 10.5194/BG-9-3943-2012##CARBON BA, 1973, AUST J SOIL RES, V11, P33, DOI 10.1071/SR9730033C##CARSLAW H.S., 1946, CONDUCTION HEAT SOLI##COWAN I. R., 1965, J APPL ECOL, V2, P221, DOI 10.2307/2401706##DARDANELLI JL, 2004, FIELD CROP RES, V87, P59, DOI 10.1016/J.FCR.2003.09.008##DARRAH PR, 2006, EUR J SOIL SCI, V57, P13, DOI 10.1111/J.1365-2389.2006.00786.X##DOORENBOS J, 1986, 33 FAO UN##FEDDES RA, 1988, J HYDROL, V100, P69, DOI 10.1016/0022-1694(88)90182-5##GARDNER W. R., 1960, SOIL SCI, V89, P63, DOI 10.1097/00010694-196002000-00001##GARDNER W. R., 1964, AGRON J, V56, P41##GRAVEEL JG, 2002, SOIL TILL RES, V68, P153, DOI 10.1016/S0167-1987(02)00118-6##HAINSWORTH JM, 1986, SOIL SCI SOC AM J, V50, P841, DOI 10.2136/SSSAJ1986.03615995005000040003X##HEINEN M, 2001, AGRONOMIE, V21, P285, DOI 10.1051/AGRO:2001124##HILLEL D, 1976, SOIL SCI, V121, P242, DOI 10.1097/00010694-197604000-00009##HOMAEE M, 2002, SOIL SCI SOC AM J, V66, P1764, DOI 10.2136/SSSAJ2002.1764##HUPET F, 2002, WATER RESOUR RES, V38, DOI 10.1029/2002WR001556##HUPET F, 2003, WATER RESOUR RES, V39, DOI 10.1029/2003WR002046##LIU FL, 2005, PLANT SCI, V168, P831, DOI 10.1016/J.PLANTSCI.2004.10.016##LIU FL, 2005, ENVIRON EXP BOT, V54, P33, DOI 10.1016/J.ENVEXPBOT.2004.05.002##MOLDRUP P, 1992, SOIL SCI, V153, P87, DOI 10.1097/00010694-199202000-00001##PERSONNE E, 2003, AGRONOMIE, V23, P153, DOI 10.1051/AGRO:2002081##PHILIP J.R., 1957, P INT C IRRIG DRAIN, P125##PIETOLA L, 2005, AGR ECOSYST ENVIRON, V108, P135, DOI 10.1016/J.AGEE.2005.01.009##PULLAN AJ, 1990, WATER RESOUR RES, V26, P1219, DOI 10.1029/WR026I006P01219##RAATS PAC, 1977, SOIL SCI SOC AM J, V41, P294, DOI 10.2136/SSSAJ1977.03615995004100020025X##RAATS PAC, 2006, IN PRESS UPTAKE WATE##ROOSE T, 2004, J THEOR BIOL, V228, P155, DOI 10.1016/J.JTBI.2003.12.012##STALHAM MA, 2001, J AGR SCI, V137, P251, DOI 10.1017/S0021859601001332##TARDIEU F, 1992, PLANT SOIL, V140, P291, DOI 10.1007/BF00010606##VAN DAM JC, 2000, J HYDROL, V233, P72, DOI 10.1016/S0022-1694(00)00227-4##VANGENUCHTEN MT, 1980, SOIL SCI SOC AM J, V44, P892, DOI 10.2136/SSSAJ1980.03615995004400050002X##VANNOORDWIJK M, 1993, GEODERMA, V56, P277, DOI 10.1016/0016-7061(93)90117-4##VANNOORDWIJK M, 1987, NETH J AGR SCI, V35, P487##WARRICK AW, 1977, WATER RESOUR RES, V13, P203, DOI 10.1029/WR013I001P00203##WILLIGEN DE P, 1987, THESIS AGR U WAGENIN##WOSTEN J, 2001, 153 RES I GROEN RUIM##ZUO Q, 2002, SOIL SCI, V167, P561, DOI 10.1097/00010694-200209000-00001##ZUR B, 1982, AGRON J, V74, P99, DOI 10.2134/AGRONJ1982.00021962007400010026X",60,2020-11-20,NA
J,WOS:000240922000374,2006,COST-EFFECTIVENESS OF MASS VACCINATION WITH A ROTAVIRUS VACCINE IN THE NETHERLANDS,NA,NA,NA,VALUE IN HEALTH,"AL, MJ##GOOSSENS, L##HOVELS, AM##MICHIELSEN, CP##STANDAERT, BA","ERASMUS MC, ROTTERDAM, NETHERLANDS. GLAXOSMITHKLINE INC, ZEIST, NETHERLANDS. GLAXOSMITHKLINE BIOL, RIXENSART, BELGIUM.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000091,2006,SWITCH PATTERNS AROUND PATENT EXPIRY WITH ECONOMIC IMPLICATIONS FOR THE NETHERLANDS,NA,NA,NA,VALUE IN HEALTH,"BOERSMA, C##KLOK, RM##POSTMA, MJ","UNIV GRONINGEN, GUIDE, GRONINGEN, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000479,2006,NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO INCREASED RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION OR STROKE,NA,NA,NA,VALUE IN HEALTH,"BREEKVELDT-POSTMA, NS##SIISKONEN, SJ##PENNING-VAN BEEST, FJ##FALVEY, H##VINCZE, G##ERKENS, JA##HERINGS, RM","PHARMO INST DRUG OUTCOMES RES, UTRECHT, NETHERLANDS. NOVARTIS PHARMA AG, BASEL, SWITZERLAND.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,2,2020-11-20,NA
J,WOS:000240922000053,2006,TREATMENT WITH INHALED CORTICOSTEROIDS IN ASTHMA TOO OFTEN DISCONTINUED,NA,NA,NA,VALUE IN HEALTH,"BREEKVELDT-POSTMA, NS##KOERSELMAN, J##ERKENS, JA##VAN DER MOLEN, T##LAMMERS, JWJ##HERINGS, RM","PHARMO INST, UTRECHT, NETHERLANDS. UNIV GRONINGEN, GRONINGEN, NETHERLANDS. UNIV MED CTR UTRECHT, UTRECHT, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000184,2006,COST-EFFECTIVENESS OF A POTENTIAL FUTURE HELICOBACTER PYLORI VACCINE IN THE NETHERLANDS,NA,NA,NA,VALUE IN HEALTH,"DE VRIES, R##KLOK, RM##BROUWERS, J##POSTMA, MJ","UNIV GRONINGEN, GUIDE, GRONINGEN, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000402,2006,COST-EFFECTIVENESS OF LONG ACTING METHYLPHENIDATE-OROS IN ADHD YOUTHS WITH SUBOPTIMAL SYMPTOM CONTROL ON IMMEDIATE-RELEASE METHYLPHENIDATE IN THE NETHERLANDS,NA,NA,NA,VALUE IN HEALTH,"FABER, A##VAN AGTHOVEN, M##KALVERDIJK, L##TOBI, H##DE JONG-VAN DEN BERG, L##ANNEMANS, L##POSTMA, MJ","UNIV GRONINGEN, GRONINGEN, NETHERLANDS. JANSSEN CILAG BV, TILBURG, NETHERLANDS. UNIV MED CTR GRONINGEN, GRONINGEN, NETHERLANDS. HLTH ECON & OUTCOMES RES, BRUSSELS, BELGIUM.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000071,2006,THE COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS: ACCOUNTING FOR MEDICAL COSTS IN LONGER LIFE EXPECTANCIES,NA,NA,NA,VALUE IN HEALTH,"FEENSTRA, TL##VAN BAAL, P##HOOGENVEEN, R##VIJGEN, SM##BEMELMANS, WJ","NATL INST PUBL HLTH & ENVIRONM, NL-3720 BA BILTHOVEN, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,1,2020-11-20,NA
J,WOS:000240922000233,2006,LINGUISTIC VALIDATION OF THE MENSTRUAL DISTRESS QUESTIONNAIRE (MDQ) IN AN INTERNATIONAL STUDY FOR A NEW COMBINED ORAL CONTRACEPTIVE PILL,NA,NA,NA,VALUE IN HEALTH,"FERNANDEZ, N##MEAR, I##MOOS, R##JOHANNES, EJ","MAPI RES INST, LYON, FRANCE. STANFORD SCH MED, STANFORD, CA USA. ORGANON, BH, OSS, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000470,2006,THE CONSTRUCT VALIDITY AND TEST-RETEST RELIABILITY OF THE INHALED CORTICOSTEROID QUESTIONNAIRE (ICQ): A PATIENT SELF-REPORTED SIDE EFFECT SCALE,NA,NA,NA,VALUE IN HEALTH,"FOSTER, JM##VAN SONDEREN, E##LEE, AJ##SANDERMAN, R##VAN DER MOLEN, T","UNIV GRONINGEN, GRONINGEN, NETHERLANDS. UNIV ABERDEEN, ABERDEEN, SCOTLAND.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000279,2006,MEASURING PATIENT-REPORTED SIDE EFFECTS OF DRUGS: ITS IMPORTANCE AND METHODOLOGICAL CHALLENGES,NA,NA,NA,VALUE IN HEALTH,"FOSTER, JM##VAN DER MOLEN, T##CAESER, M##HANNAFORD, P","UNIV GRONINGEN, GRONINGEN, NETHERLANDS. ALTANA PHARMA AG, CONSTANCE, GERMANY. UNIV ABERDEEN, ABERDEEN, SCOTLAND.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000526,2006,COSTS ASSOCIATED WITH DRUG USE IN THE NONADHERENCE TO CHOLESTEROL MANAGEMENT GUIDELINES FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN AN ELDERLY POPULATION: THE ROTTERDAM STUDY,NA,NA,NA,VALUE IN HEALTH,"GUMBS, PD##VERSCHUREN, WMM##MANTEL-TEEUWISSE, AK##DE WIT, GA##HOFMAN, A##TRIENEKENS, PH##STRICKER, BHC##DE, BA##KLUNGEL, OH","UNIV UTRECHT, UTRECHT, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, NL-3720 BA BILTHOVEN, NETHERLANDS. ERASMUS UNIV, ROTTERDAM, NETHERLANDS. STICHTING TROMBOSEDIENST ARTSENLAB RIJNMOND, ROTTERDAM, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000060,2006,CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS OF CHOLESTEROL LOWERING DRUGS: A SYSTEMATIC REVIEW,NA,NA,NA,VALUE IN HEALTH,"GUMBS, PD##VERSCHUREN, WMM##MANTEL-TEEUWISSE, AK##DE WIT, GA##DE BOER, A##KLUNGEL, OH","UNIV UTRECHT, UTRECHT, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, NL-3720 BA BILTHOVEN, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000041,2006,DIFFERENCES IN PERCENTAGE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) REDUCTION AND GOAL ATTAINMENT AMONG NEWLY INITIATED USERS OF STATINS IN A REAL LIFE SETTING,NA,NA,NA,VALUE IN HEALTH,"HEINTJES, E##HIRSCH, MW##O'DONNELL, JC##HERINGS, RM","PHARMO INST, UTRECHT, NETHERLANDS. ASTRA ZENECA UK LTD, MACCLESFIELD, CHESHIRE, ENGLAND.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000478,2006,THE EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH OTHER STATINS - RESULTS FROM A ROUTINE CLINICAL PRACTICE SETTING IN THE UK,NA,NA,NA,VALUE IN HEALTH,"HIRSCH, MW##O'DONNELL, JC##JANSEN, JP","ASTRAZENECA LTD, MACCLESFIELD, CHESHIRE, ENGLAND. MAPI VALUES, HOUTEN, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000273,2006,ECONOMIC DECISION MODELLING: CALCULATION OF TOTAL NET MONETARY BENEFITS OF GUIDELINE IMPLEMENTATION INTO CLINICAL PRACTICE,NA,NA,NA,VALUE IN HEALTH,"HOOMANS, T##AMENT, A##EVERS, S##SEVERENS, JL","MAASTRICHT UNIV, MAASTRICHT, NETHERLANDS. UNIV LIMBURG, ACAD HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000250,2006,PERSISTENCE WITH TIOTROPIUM: A COMPARISON WITH ESTABLISHED MEDICATIONS FOR COPD,NA,NA,NA,VALUE IN HEALTH,"KOERSELMAN, J##BREEKVELDT-POSTMA, NS##ERKENS, JA##PETTITT, D##ANTON, SF##HERINGS, RM","PHARMO INST, UTRECHT, NETHERLANDS. PFIZER INC, NEW YORK, NY USA. BOEHRINGER INGELHEIM PHARMACEUT INC, RIDGEFIELD, CT 06877 USA.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000205,2006,INDIRECT COSTS OF BETA THALASSEMIA MAJOR: RESULTS FROM THE ITACA STUDY,NA,NA,NA,VALUE IN HEALTH,"KROL, M##RAVERA, S##UYL-DE GROOT, C##CAPPELLINI, M##SCALONE, L##MANTOVANI, LG","INST MED TECHNOL ASSESSMENT, ROTTERDAM, NETHERLANDS. UNIV MILAN, CTR PHARMACOECON, MILAN, ITALY. REGINA ELENA HOSP, IRCSS FDN POLICLIN, CONGENITAL ANEMIA CTR, MILAN, ITALY. UNIV NAPLES FEDERICO II, NAPLES, ITALY.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000031,2006,BREAKING THE SILENCE: THE EFFECTS OF EXPLICIT INSTRUCTIONS ON INCORPORATING INCOME IN TTO EXCERCISES,NA,NA,NA,VALUE IN HEALTH,"KROL, M##BROUWER, W##SENDI, P","INST MED TECHNOL ASSESSMENT, ROTTERDAM, NETHERLANDS. INST CLIN EPIDEMIOL, BASEL, SWITZERLAND.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,1,2020-11-20,NA
J,WOS:000240922000114,2006,ZOLEDRONIC ACID IN THE LONG-TERM MANAGEMENT OF PAGET'S DISEASE OF THE BONE IN GERMANY - A COST-AVING APPROACH?,NA,NA,NA,VALUE IN HEALTH,"KURTH, AA##KOTOWA, W##FRICKE, FU##QUEDNAU, K##MAIWENN, JA","ORTHOPAD UNIV KLIN STIFTUNG FRIEDRICHSHEIM, FRANKFURT, GERMANY. FRICKE & PIRK GMBH, NURNBERG, GERMANY. NOVARTIS PHARMA GMBH, NURNBERG, GERMANY. INST MED TECHNOL ASSESSMENT, ROTTERDAM, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,1,2020-11-20,NA
J,WOS:000240922000426,2006,QUALITY OF LIFE IN PATIENTS WITH BIPOLAR DISORDER IN 5 EUROPEAN COUNTRIES,NA,NA,NA,VALUE IN HEALTH,"LEEUWENKAMP, O##PERRY, R##MORLOCK, R##JONES, E##TAYLOR, T","ORGANON INT INC, OSS, NETHERLANDS. ADELPHI GRP PROD, BOLLINGTON, CHESHIRE, ENGLAND. PFIZER INC, NEW YORK, NY USA. PFIZER, ANN ARBOR, MI USA.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000427,2006,IMPACT OF NEGATIVE SYMPTOMS ON FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA IN FIVE EUROPEAN COUNTRIES,NA,NA,NA,VALUE IN HEALTH,"LEEUWENKAMP, O##PERRY, R##MORLOCK, R##JONES, E##TAYLOR, T","ORGANON INT BV, NL-5340 BH OSS, NETHERLANDS. ADELPHI GRP PROD, BOLLINGTON, CHESHIRE, ENGLAND. PFIZER INC, NEW YORK, NY USA. PFIZER, ANN ARBOR, MI USA.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000416,2006,"ANALYSIS OF A MULTINATIONAL, CROSS-SECTIONAL SURVEY OF PHYSICIAN DESCRIPTIONS AND PERCEPTIONS OF PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA",NA,NA,NA,VALUE IN HEALTH,"LEEUWENKAMP, O##PERRY, R##MILLIGAN, G##MORLOCK, R##LECRUBIER, Y","ORGANON INT BV, NL-5340 BH OSS, NETHERLANDS. ADELPHI GRP PROD, BOLLINGTON, CHESHIRE, ENGLAND. PFIZER INC, NEW YORK, NY USA. HOP LA PITIE SALPETRIERE, PARIS, FRANCE.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000410,2006,RESOURCE USE AMONG PATIENTS WITH SCHIZOPHRENIA IN 5 EUROPEAN COUNTRIES,NA,NA,NA,VALUE IN HEALTH,"LEEUWENKAMP, O##PERRY, R##MORLOCK, R##JONES, E##TAYLOR, T","ORGANON INT BV, NL-5340 BH OSS, NETHERLANDS. ADELPHI GRP PROD, BOLLINGTON, CHESHIRE, ENGLAND. PFIZER INC, NEW YORK, NY USA. PFIZER, ANN ARBOR, MI USA.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000389,2006,ASSOCIATION BETWEEN CHANGES ON THE NEGATIVE SYMPTOM ASSESSMENT SCALE AND MEASUREES OF FUNCTIONAL OUTCOME IN SCHIZOPHRENIA,NA,NA,NA,VALUE IN HEALTH,"LEEUWENKAMP, O##VELLIGAN, D##WANG, M##HAIG, G##LANCASTER, S##TAYLOR, T##ALPHS, L","ORGANON INT BV, NL-5340 BH OSS, NETHERLANDS. UNIV TEXAS SAN ANTONIO, SAN ANTONIO, TX 78285 USA. PFIZER INC, ANN ARBOR, MI USA.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000390,2006,A 3-MONTH ASSESSMENT OF TREATMENT PRESCRIBED TO PATIENTS WITH ADHD AND ITS IMPACT ON CLINICAL SEVERITY AND QOL OUTCOMES ACROSS 10 EUROPEAN COUNTRIES. RESULTS FROM ATTENTION DEFICIT/HYPERACTIVITY DISODER OBSERVATIONAL RESEARCH IN EUROPE (ADORE),NA,NA,NA,VALUE IN HEALTH,"LORENZO, MJM##POOLE, L##SPIEL, G##DALSGAARD, S##FALISSARD, B##LE HEUZEY, MF##ROTHENBERGER, A##DOPFNER, M##BALDURSSON, G##CURATOLO, P##PEREIRA, RR##VLASVELD, L##NOVIK, T##HERVAS, A##PREUSS, U##STEINHAUSEN, HC##RASMUSSEN, P##COGHILL, D##RILEY, AW##FORREST, CB","ELI LILLY & CO, WINDLESHAM, SURREY, ENGLAND. LANDESKRANKENHAUS KLAGENFURT, KLAGENFURT, AUSTRIA. PSYKIATR HOSP CHILDREN & ADOLOSCENTS, RISSKOV, DENMARK. HOP PAUL BROUSSE, PARIS, FRANCE. HOP ROBERT DEBRE, F-75019 PARIS, FRANCE. UNIV GOTTINGEN, D-3400 GOTTINGEN, GERMANY. KLIN & POLIKLIN PSYCHIAT & PSYCHOTHERAPIE, COLOGNE, GERMANY. LANDSPITALI UNIV HOSP, REYKJAVIK, ICELAND. CLIN ST ALESSANDRO, ROME, ITALY. REINIER DE GRAAF GASTHUIS, DELFT, NETHERLANDS. BUPA POLIKLIN ENHET, DRAMMEN, NORWAY. CAP RAMBLA, BARCELONA, SPAIN. KINDER & JUGENDPSYCH POLIKLIN, BERN, SWITZERLAND. FMH KINDER & JUGENDPSYCHIAT, ZURICH, SWITZERLAND. BNK, GOTHENBURG, SWEDEN. CTR CHILD HLTH, DUNDEE, SCOTLAND. JOHNS HOPKINS BLOOMBERG SCH PUBL HLTH, BALTIMORE, MD USA. MED CENTRUM RIJNMOND ZUID, ROTTERDAM, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000248,2006,EXPECTED VALUE OF PERFECT INFORMATION: A PRACTICAL EXAMPLE OF REDUCING DECISION UNCERTAINTY BY CONDUCTING ADDITIONAL RESEARCH,NA,NA,NA,VALUE IN HEALTH,"OOSTENBRINK, JB##RUTTEN-VAN MOLKEN, M##OPPE, M##AL, MJ","ERASMUS MC, ROTTERDAM, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000603,2006,LOSS OF TREATMENT BENEFIT DUE TO LOW COMPLIANCE WITH BISPHOSPHONATE THERAPY,NA,NA,NA,VALUE IN HEALTH,"PENNING-VAN BEEST, FJA##VAN DEN BOOGAARD, CHA##ERKENS, JA##OLSON, M##HERINGS, RMC","PHARMO INST, UTRECHT, NETHERLANDS. NOVARTIS PHARMA AG, BASEL, SWITZERLAND.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000058,2006,PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION,NA,NA,NA,VALUE IN HEALTH,"POMPEN, M##NOVAK, A##POSTMUS, P##GOK, M##GYLDMARK, M","ROCHE NEDERLAND BV, WOERDEN, NETHERLANDS. VU UNIV MED CTR, AMSTERDAM, NETHERLANDS. F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,3,2020-11-20,NA
J,WOS:000240922000254,2006,MEASURING DISEASE-SPECIFIC UTILITIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTH- AND EXACERBATION PROFILES,NA,NA,NA,VALUE IN HEALTH,"RUTTEN-VAN MOLKEN, M##HOOGENDOORN-LIPS, M##LAMERS, L","ERASMUS MC, ROTTERDAM, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000386,2006,COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): IMPACT OF COEXISTING CONDITIONS,NA,NA,NA,VALUE IN HEALTH,"SCHLANDER, M##SCHWARZ, O##FOSTER, EM##HAKKAART-VAN ROIJEN, L##JENSEN, PS##PERSSON, U##SANTOSH, PJ##TROTT, GE","INST INNOVAT & VALUAT HLTH CARE, ESCHBORN, GERMANY. UNIV N CAROLINA, CHAPEL HILL, NC USA. INST MED TECHNOL ASSESSMENT, ROTTERDAM, NETHERLANDS. COLUMBIA UNIV, NEW YORK, NY USA. SWEDISH INST HLTH ECON, IHE, LUND, SWEDEN. GREAT ORMOND ST HOSP CHILDREN, INST CHILD HLTH, LONDON WC1N 3JH, ENGLAND. UNIV WURZBURG, ASCHAFFENBURG, GERMANY. NIMH, BETHESDA, MD 20892 USA.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,3,2020-11-20,NA
J,WOS:000240922000395,2006,FUNCTIONAL IMPAIRMENT OF PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): AN ALTERNATIVE COST-EFFECTIVENESS ANALYSIS OF CLINICALLY PROVEN TREATMENT STRATEGIES BASED UPON THE NIMH MTA STUDY,NA,NA,NA,VALUE IN HEALTH,"SCHLANDER, M##SCHWARZ, O##HAKKAART-VAN ROIJEN, L##JENSEN, PS##PERSSON, U##SANTOSH, PJ##TROTT, GE","INST INNOVAT & VALUAT HLTH CARE, ESCHBORN, GERMANY. INST MED TECHNOL ASSESSMENT, ROTTERDAM, NETHERLANDS. COLUMBIA UNIV, NEW YORK, NY USA. SWEDISH INST HLTH ECON, IHE, LUND, SWEDEN. GREAT ORMOND ST HOSP SICK CHILDREN, INST CHILD HLTH, LONDON WC1N 3JH, ENGLAND. UNIV WURZBURG, ASCHAFFENBURG, GERMANY. NIMH, BETHESDA, MD 20892 USA.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,4,2020-11-20,NA
J,WOS:000240922000394,2006,COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN FIVE JURISDICTIONS,NA,NA,NA,VALUE IN HEALTH,"SCHLANDER, M##SCHWARZ, O##HAKKAART-VAN ROIJEN, L##JENSEN, PS##PERSSON, U##SANTOSH, PJ##TROTT, GE","INST INNOVAT & VALUAT HLTH CARE, ESCHBORN, GERMANY. INST MED TECHNOL ASSESSMENT, ROTTERDAM, NETHERLANDS. COLUMBIA UNIV, NEW YORK, NY USA. SWEDISH INST HLTH ECON, IHE, LUND, SWEDEN. GREAT ORMOND ST HOSP SICK CHILDREN, INST CHILD HLTH, LONDON WC1N 3JH, ENGLAND. UNIV WURZBURG, ASCHAFFENBURG, GERMANY. NIMH, BETHESDA, MD 20892 USA.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,4,2020-11-20,NA
J,WOS:000240922000092,2006,ANALYSIS OF COST OF ILLNESS IN THE NETHERLANDS IN 2003: INTEGRATING NATIONAL AND INTERNATIONAL PERSPECTIVES ON HEALTH CARE COSTS,NA,NA,NA,VALUE IN HEALTH,"SLOBBE, LCJ##KOMMER, GJ##POLDER, JJ","NATL INST PUBL HLTH & ENVIRONM, NL-3720 BA BILTHOVEN, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000554,2006,CHARACTERIZATION OF HYPERTENSIVE PATIENTS WHO MIGHT BENEFIT FROM A COMBINATION OF TWO DRUGS IN ONE PILL FOR REDUCTION OF CARDIOVASCULAR RISK,NA,NA,NA,VALUE IN HEALTH,"STURKENBOOM, MC##BORGMAN, MV##VAN KINTS, A##MOLLER, RA##FITZGERALD, K##ROSA, K##CRAMER, JA","ERASMUS UNIV, MED CTR, SOEST, NETHERLANDS. ERASMUS UNIV, MED CTR, ROTTERDAM, NETHERLANDS. PFIZER, NEW YORK, NY USA. MAPI VALUES, BOSTON, MA USA. MAPI VALUES USA LLC, BOSTON, MA USA. YALE UNIV, SCH MED, WEST HAVEN, CT 06516 USA.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000008,2006,RATES AND RISKS OF STARTING INSULIN IN DIABETES MELLITUS TYPE-2 PATIENTS,NA,NA,NA,VALUE IN HEALTH,"STURKENBOOM, MC##DIELEMAN, JP##VAN DER LEI, J","ERASMUS UNIV, MED CTR, SOEST, NETHERLANDS. ERASMUS UNIV, MED CTR, ROTTERDAM, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000469,2006,PATIENT-PERCEIVED SIDE EFFECTS OF CICLESONIDE AS COMPARED TO FLUTICASONE PROPIONATE IN THE TREATMENT OF MODERATE ASTHMA USING THE INHALED CORTICOSTEROID QUESTIONNAIRE,NA,NA,NA,VALUE IN HEALTH,"VAN DER MOLEN, T##LEICHTL, S##CAESER, M","UNIV GRONINGEN, GRONINGEN, NETHERLANDS. ALTANA PHARMA AG, CONSTANCE, GERMANY.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,2,2020-11-20,NA
J,WOS:000240922000584,2006,HEALTH-RELATED QUALITY-OF-LIFE AND UTILITY IN DUTCH GLAUCOMA PATIENTS,NA,NA,NA,VALUE IN HEALTH,"VAN GESTEL, A##SCHOUTEN, JS##WEBERS, CA##BECKERS, HJ##SCHROOTEN, MA##SEVERENS, JL##HENDRIKSE, F","UNIV LIMBURG, ACAD HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000380,2006,LONG TERM EFFECT OF WARD PHARMACY CONTROLLED ADMINISTRATION OF ANTIBIOTICS ON ANTIMICROBIAL TREATMENT COSTS,NA,NA,NA,VALUE IN HEALTH,"VAN HULST, M##DEKENS, KG##VOGELS, WHM##POSTMA, MJ##VISSER, T","MARTINI HOSP, GUIDE, GRONINGEN, NETHERLANDS. MARTINI HOSP, INFECT DIS LAB, GRONINGEN, NETHERLANDS. UNIV GRONINGEN, GUIDE, GRONINGEN, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000363,2006,COST-EFFECTIVENESS OF INTERVENTIONS ENSURING BLOOD TRANSFUSION SAFETY IN AFRICA,NA,NA,NA,VALUE IN HEALTH,"VAN, HM##DHINGRA-KUMAR, N##VAN DER SCHAAF, IP##SIBINGA, CTS##POSTMA, MJ","UNIV GRONINGEN, INST DRUG EXPLORAT, MARTINI HOSP, GRONINGEN, NETHERLANDS. WHO, CH-1211 GENEVA, SWITZERLAND. VU, AMSTERDAM, NETHERLANDS. SANQUIN CONSULTING SERV, GRONINGEN, NETHERLANDS. UNIV GRONINGEN, GUIDE, GRONINGEN, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000203,2006,SOCIETAL COSTS OF ALLOGENEIC BLOOD TRANSFUSION IN THE NETHERLANDS,NA,NA,NA,VALUE IN HEALTH,"VAN HULST, M##KLOK, RM##ESCHBACH, ME##POSTMA, MJ","UNIV GRONINGEN, INST DRUG EXPLORAT, MARTINI HOSP, GRONINGEN, NETHERLANDS. UNIV GRONINGEN, INST DRUG EXPLORAT, GRONINGEN, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000239,2006,COST-EFFECTIVENESS OF ROFLUMILAST IN THE UK: A 1-YEAR STUDY IN PATIENTS WITH SEVERE TO VERY SEVERE COPD,NA,NA,NA,VALUE IN HEALTH,"VAN NOOTEN, F##RUTTEN-VAN MOLKEN, M##LINDEMANN, M##SANDTMANN, R","ERASMUS MC, ROTTERDAM, NETHERLANDS. ALTANA PHARMA AG, CONSTANCE, GERMANY.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000240922000614,2006,THE ESTIMATION OF COST-EFFECTIVENESS THRESHOLDS PRIOR TO THE START OF LARGE CLINICAL STUDIES,NA,NA,NA,VALUE IN HEALTH,"VAN STAA, TP##COOPER, C##LEUFKENS, HG","GEN PRACTICE RES DATABASE, LONDON, ENGLAND. UNIV SOUTHAMPTON, SOUTHAMPTON, HANTS, ENGLAND. UNIV UTRECHT, UTRECHT, NETHERLANDS.",ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES,BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES,NA,0,2020-11-20,NA
J,WOS:000242844400006,2006,MURINE MODELS OF MYOCARDIAL AND LIMB ISCHEMIA: DIAGNOSTIC END-POINTS AND RELEVANCE TO CLINICAL PROBLEMS,"ISCHEMIC DISEASE REPRESENTS THE NEW EPIDEMIC WORLDWIDE. ANIMAL MODELS OF ISCHEMIC DISEASE ARE USEFUL BECAUSE THEY CAN HELP US TO UNDERSTAND THE UNDERLYING PATHOGENETIC MECHANISMS AND DEVELOP NEW THERAPIES. THE PRESENT REVIEW ARTICLE SUMMARIZES THE RESULTS OF A CONSENSUS CONFERENCE ON THE STATUS AND FUTURE DEVELOPMENT OF EXPERIMENTATION IN THE FIELD OF CARDIOVASCULAR MEDICINE USING MURINE MODELS OF PERIPHERAL AND MYOCARDIAL ISCHEMIA. THE STARTING POINT WAS TO RECOGNIZE THE LIMITS OF THE APPROACH, WHICH MAINLY DERIVE FROM SPECIES- AND DISEASE-RELATED DIFFERENCES IN CARDIOVASCULAR PHYSIOLOGY. FOR INSTANCE, THE MOUSE HEART BEATS AT A RATE 10 TIMES FASTER THAN THE HUMAN HEART. FURTHERMORE, HEALING PROCESSES ARE MORE RAPID IN ANIMALS, AS THEY RELY ON MECHANISMS THAT MAY HAVE LOST RELEVANCE IN MAN. THE MAIN OBJECTIVE OF THE AUTHORS WAS TO PROPOSE GENERAL GUIDELINES, DIAGNOSTIC END POINTS AND RELEVANCE TO CLINICAL PROBLEMS. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.",ENDOTHELIAL GROWTH-FACTOR; COLLATERAL VESSEL DEVELOPMENT; APOLIPOPROTEIN-E-DEFICIENT; VEIN BYPASS GRAFTS; GENE-TRANSFER; MOUSE MODEL; INFARCT SIZE; HISTOLOGICAL CLASSIFICATION; ATHEROSCLEROTIC LESIONS; NEOINTIMA HYPERPLASIA,ISCHEMIA; MOUSE MODELS; MYOCARDIAL INFARCTION; WOUND HEALING; BLOOD FLOW,VASCULAR PHARMACOLOGY,"MADEDDU, P##EMANUELI, C##SPILLMANN, F##MELONI, M##BOUBY, N##RICHER, C##ALHENC-GELAS, F##VAN WEEL, V##EEFTING, D##QUAX, PHA##HU, Y##XU, Q##HEMDAHL, AL##VAN GOLDE, J##HUIJBERTS, M##DE LUSSANET, Q##BOUDIER, HS##COUFFINHAL, T##DUPLAA, C##CHIMENTI, S##STASZEWSKY, L##LATINI, R##BAUMANS, V##LEVY, BI","UNIV BRISTOL, BRISTOL ROYAL INFIRM, BRISTOL HEART INST, BRISTOL BS2 8HW, AVON, ENGLAND. INSERM, U652367, PARIS, FRANCE. LEIDEN UNIV, MED CTR, DEPT SURG, LEIDEN, NETHERLANDS. TNO, PG, LEIDEN, NETHERLANDS. UNIV LONDON ST GEORGES HOSP, DEPT CARDIAC & VASC SCI, LONDON, ENGLAND. KAROLINSKA INST, S-10401 STOCKHOLM, SWEDEN. MASTRICHT UNIV HOSP, DEPT INTERNAL MED, MAASTRICHT, NETHERLANDS. MASTRICHT UNIV HOSP, DEPT RADIOL, MAASTRICHT, NETHERLANDS. CARDIOVASC RES INST MAASTRICHT, MAASTRICHT, NETHERLANDS. UNIV BORDEAUX, BORDEAUX, FRANCE. INSERM, U441, PESSAC, FRANCE. MARIO NEGRI INST PHARMACOL RES, DEPT CARDIOVASC RES, I-20157 MILAN, ITALY. UNIV UTRECHT, DEPT LAB ANIM SCI, NL-3508 TC UTRECHT, NETHERLANDS. INSERM, U689, PARIS, FRANCE.",PHARMACOLOGY & PHARMACY,PHARMACOLOGY & PHARMACY,"ANVERSA P, 1986, CIRC RES, V58, P26, DOI 10.1161/01.RES.58.1.26##ANVERSA P, 1985, AM J PATHOL, V118, P484##ARRAS M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877##AZIZI M, 2005, J CLIN INVEST, V115, P780, DOI 10.1172/JCI200523669##BAUMANS V, 2004, GENE THER, V11, PS64, DOI 10.1038/SJ.GT.3302371##BERGAYA S, 2001, CIRC RES, V88, P593, DOI 10.1161/01.RES.88.6.593##BREITENEDER-GELEFF S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6##BRULL D, 2001, LANCET, V358, P1155, DOI 10.1016/S0140-6736(01)06273-0##CALARA F, 2001, J PATHOL, V195, P257, DOI 10.1002/PATH.915##CALIGIURI G, 1999, P NATL ACAD SCI USA, V96, P6920, DOI 10.1073/PNAS.96.12.6920##CALIGIURI G, 2003, MOL MED, V9, P10, DOI 10.1007/BF03402102##CARMELIET P, 2000, NAT MED, V6, P389, DOI 10.1038/74651##CHERWEK DH, 2003, AM J PHYSIOL-HEART C, V279, PH932##CHEVAL L, 2000, PRACT APPROACH SER, P139##COHEN M, 1986, CIRCULATION, V74, P469, DOI 10.1161/01.CIR.74.3.469##COUFFINHAL T, 1998, AM J PATHOL, V152, P1667##COUFFINHAL T, 1999, CIRCULATION, V99, P3188, DOI 10.1161/01.CIR.99.24.3188##*COUNC EUR, 1985, 123 ETS COUNC EUR##CRAWLEY JN, 1998, WHATS WRONG MY MOUSE##DEINDL E, 2001, CIRC RES, V89, P779, DOI 10.1161/HH2101.098613##DUVALL CL, 2004, AM J PHYSIOL-HEART C, V287, PH302, DOI 10.1152/AJPHEART.00928.2003##EMANUELI C, 2004, DIABETES, V53, P1096, DOI 10.2337/DIABETES.53.4.1096##EMANUELI C, 2004, CIRCULATION, V110, P1638, DOI 10.1161/01.CIR.0000142051.36244.83##EMANUELI C, 2002, CIRCULATION, V106, P993, DOI 10.1161/01.CIR.0000027104.33206.C8##EMANUELI C, 2001, CIRCULATION, V103, P125##EMANUELI C, 1999, CIRCULATION, V100, P2359, DOI 10.1161/01.CIR.100.23.2359##ENTMAN ML, 2000, AM J PHYSIOL-HEART C, V278, PH1017##ENTMAN ML, 1991, FASEB J, V5, P2529##*EUR COUNC DIR, 1986, 86609EEC EUR COUNC D##EZAN J, 2004, CARDIOVASC RES, V63, P731, DOI 10.1016/J.CARDIORES.2004.05.006##FARREHI PM, 1998, CIRCULATION, V97, P1002##FIORDALISO F, 2000, LAB INVEST, V80, P513, DOI 10.1038/LABINVEST.3780057##FRANGOGIANNIS NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5##GOROG DA, 2003, J MOL CELL CARDIOL, V35, P705, DOI 10.1016/S0022-2828(03)00082-8##GRAIANI G, 2005, HYPERTENSION, V46, P433, DOI 10.1161/01.HYP.0000174986.73346.BA##GRAIANI G, 2004, DIABETOLOGIA, V47, P1047, DOI 10.1007/S00125-004-1414-7##HANSEN PR, 1995, CIRCULATION, V91, P1872, DOI 10.1161/01.CIR.91.6.1872##HEIL M, 2004, CIRC RES, V95, P449, DOI 10.1161/01.RES.0000141145.78900.44##HEIL M, 2004, CIRC RES, V94, P671, DOI 10.1161/01.RES.0000122041.73808.B5##HEMDAHL AL, 2004, AM J PHYSIOL-HEART C, V287, PH872, DOI 10.1152/AJPHEART.01083.2003##HERSHEY JC, 2001, CARDIOVASC RES, V49, P618, DOI 10.1016/S0008-6363(00)00232-7##HIMORI N, 1989, AM J PHYSIOL, V256, PH1719##HO HKV, 2004, CIRCULATION, V109, P1314, DOI 10.1161/01.CIR.0000118465.36018.2D##HOEFER IE, 2004, CIRC RES, V94, P1179, DOI 10.1161/01.RES.0000126922.18222.F0##HU YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628##HU YH, 2002, CIRC RES, V91, PE13, DOI 10.1161/01.RES.0000037090.34760.EE##HU YH, 1999, CIRCULATION, V100, P861, DOI 10.1161/01.CIR.100.8.861##HUANG W, 2001, P NATL ACAD SCI USA, V98, P13330, DOI 10.1073/PNAS.231476798##ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/PNAS.91.10.4431##IWAGURO H, 2002, CIRCULATION, V105, P732, DOI 10.1161/HC0602.103673##JACOBI J, 2004, CIRCULATION, V110, P2424, DOI 10.1161/01.CIR.0000145142.85645.EA##JORDAN BF, 2004, MAGNET RESON MED, V52, P391, DOI 10.1002/MRM.20155##KAJSTURA J, 2001, DIABETES, V50, P1414, DOI 10.2337/DIABETES.50.6.1414##KAJSTURA J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60##KURZ KD, 1990, THROMB RES, V60, P269, DOI 10.1016/0049-3848(90)90106-M##LAMFERS MLM, 2001, GENE THER, V8, P534, DOI 10.1038/SJ.GT.3301437##LARDENOYE JHP, 2002, CIRC RES, V91, P577, DOI 10.1161/01.RES.0000036901.58329.D7##LEITGES M, 2001, J CLIN INVEST, V108, P1505##LIBBY P, 2002, NATURE, V420, P868, DOI 10.1038/NATURE01323##LINDBERG T, 2000, ACTA PAEDIATR, V89, P1, DOI 10.1080/080352500750028933##MADEDDU P, 2004, FASEB J, V18, P1737, DOI 10.1096/FJ.04-2192FJE##MAESTRI R, 2003, HYPERTENSION, V41, P1151, DOI 10.1161/01.HYP.0000064180.55222.DF##MASAKI I, 2002, CIRC RES, V90, P966, DOI 10.1161/01.RES.0000019540.41697.60##MAYR U, 2002, CIRC RES, V90, P197, DOI 10.1161/HH0202.103715##MEDVEDEV OS, 1993, AM HEART J, V126, P764, DOI 10.1016/0002-8703(93)90927-2##MENETON P, 2001, P NATL ACAD SCI USA, V98, P2634, DOI 10.1073/PNAS.051619598##MERTENS C, 2000, ALTEX-ALTERN TIEREXP, V17, P15##MOTWANI JG, 1998, CIRCULATION, V97, P916, DOI 10.1161/01.CIR.97.9.916##NOSSULI TO, 2000, AM J PHYSIOL-HEART C, V278, PH1049##PFEFFER JM, 1991, AM J PHYSIOL, V260, PH1406, DOI 10.1152/AJPHEART.1991.260.5.H1406##PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503##QUAX PHA, 2001, CIRCULATION, V103, P562, DOI 10.1161/01.CIR.103.4.562##REDDICK RL, 1998, ATHEROSCLEROSIS, V140, P297, DOI 10.1016/S0021-9150(98)00133-6##RIVARD A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0##RONA G, 1959, ARCH PATHOL, V67, P443##ROSENFELD MICHAEL E, 2002, CURR ATHEROSCLER REP, V4, P238, DOI 10.1007/S11883-002-0025-3##ROTH DM, 2002, AM J PHYSIOL-HEART C, V282, PH2134, DOI 10.1152/AJPHEART.00845.2001##RUSSINOFF D. M., 1992, JOURNAL OF AUTOMATED REASONING, V8, P3##SCHATTEMAN GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087##SCHOLZ D, 2002, J MOL CELL CARDIOL, V34, P775, DOI 10.1006/JMCC.2002.2013##SELYE H., 1960, ANGIOLOGY, V11, P398, DOI 10.1177/000331976001100505##SILVESTRE JS, 2002, CIRC RES, V90, P1072, DOI 10.1161/01.RES.0000019892.41157.24##SILVESTRE JS, 2000, CIRC RES, V87, P448##SMANUELI C, 2003, DIABETOLOGIA, V46, P67##SMANUELI C, 2002, CIRCULATION, V106, P2257##SMITHIES O, 2000, KIDNEY INT, V58, P2265, DOI 10.1046/J.1523-1755.2000.00411.X##SPILLMAN F, 2006, LOCAL GENE TRANSFER##STARY HC, 2000, ARTERIOSCL THROM VAS, V20, P1177, DOI 10.1161/01.ATV.20.5.1177##STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512##STEPANOVIC V, 2003, CIRC RES, V92, P1247, DOI 10.1161/01.RES.0000074906.98021.55##TORSNEY E, 2004, CIRC RES, V94, P1466, DOI 10.1161/01.RES.0000129570.06647.00##TRABOLD F, 2002, HYPERTENSION, V40, P90, DOI 10.1161/01.HYP.0000021747.43346.95##VAN DER MEER M, 2001, LAB ANIM-UK, V35, P379, DOI 10.1258/0023677011911859##VAN WEEL V, 2004, CIRC RES, V95, P58, DOI 10.1161/01.RES.0000133247.69803.C3##VANHERCK H, 1994, AUTOIMMUNE DIS MODEL, P303##VIRMANI R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262##VON DER THUSEN JH, 2002, CIRCULATION, V105, P2064, DOI 10.1161/01.CIR.0000015502.97828.93##WILLIAMS H, 2002, ARTERIOSCL THROM VAS, V22, P788, DOI 10.1161/01.ATV.0000014587.66321.B4##WRIGHT MJ, 2001, GENE THER, V8, P1833, DOI 10.1038/SJ.GT.3301614##XU QB, 2004, AM J PATHOL, V165, P1, DOI 10.1016/S0002-9440(10)63270-1##XU QB, 2003, CIRC RES, V93, PE76, DOI 10.1161/01.RES.0000097864.24725.60##YANG XP, 1999, AM J PHYSIOL-HEART C, V277, PH1967##YIN H, 2005, J BIOL CHEM, V280, P8022, DOI 10.1074/JBC.M407179200##YLA-HERTTUALA S, 2004, TRENDS CARDIOVAS MED, V14, P295, DOI 10.1016/J.TCM.2004.09.001##YOUNG JL, 2002, MICROCIRCULATION, V9, P35, DOI 10.1038/SJ.MN.7800120##ZHONG JP, 2003, J CLIN INVEST, V112, P30, DOI 10.1172/JCI200317034##ZOU YP, 2000, CIRC RES, V86, P434, DOI 10.1161/01.RES.86.4.434##ZOU YP, 1998, AM J PATHOL, V153, P1301, DOI 10.1016/S0002-9440(10)65675-1##ZURAW B, 2001, LANCET, V358, P1116, DOI 10.1016/S0140-6736(01)06300-0",42,2020-11-20,NA
J,WOS:000241776700008,2006,INVESTIGATION OF THE INTERACTION BETWEEN BUPRENORPHINE AND SUFENTANIL DURING ANAESTHESIA FOR OVARIECTOMY IN DOGS,"OBJECTIVE: TO INVESTIGATE THE EFFECT OF BUPRENORPHINE PRE-TREATMENT ON SUFENTANIL REQUIREMENTS IN FEMALE DOGS UNDERGOING OVARIECTOMY. STUDY DESIGN: RANDOMIZED, 'BLINDED', PROSPECTIVE CLINICAL STUDY. ANIMALS: THIRTY HEALTHY FEMALE DOGS REFERRED FOR OVARIECTOMY. MATERIALS AND METHODS: DOGS WERE RANDOMLY ASSIGNED TO ONE OF TWO PRE-ANAESTHETIC TREATMENT GROUPS. THOSE IN THE BUPRENORPHINE GROUP (B) RECEIVED BUPRENORPHINE 20 MU G KG(-1) AND ACEPROMAZINE 0.03 MG KG(-1) IM. CONTROL GROUP (C) ANIMALS RECEIVED AN EQUAL VOLUME OF NACL 0.9% AND ACEPROMAZINE 0.03 MG KG(-1) IM. THE ANAESTHETIC TECHNIQUE WAS IDENTICAL IN BOTH GROUPS. PRE-ANAESTHETIC MEDICATION CONSISTED OF INTRAVENOUS (IV) SUFENTANIL (1.0 MU G KG(-1)) AND MIDAZOLAM (0.05 MG KG(-1)) AND INTRAMUSCULAR ATROPINE (0.03 MG KG(-1)). ANAESTHESIA WAS INDUCED WITH PROPOFOL AND MAINTAINED WITH A CONSTANT RATE INFUSION OF SUFENTANIL (1.0 MU G KG(-1) HOUR(-1)) AND WITH OXYGEN-ISOFLURANE. VENTILATION WAS CONTROLLED MECHANICALLY. OVARIECTOMY WAS PERFORMED USING A STANDARD TECHNIQUE. BASELINE HEART RATE (HR) AND DIRECT MEAN ARTERIAL BLOOD PRESSURE (MAP) WERE RECORDED BEFORE THE FIRST INCISION. INCREASES IN HR AND MAP OF >= 20% OVER BASELINE AND, OR SPONTANEOUS VENTILATION WERE CONTROLLED USING IV SUFENTANIL (1.0 MU G KG(-1)) REPEATED AFTER 5 MINUTES IF HAEMODYNAMIC VARIABLES REMAINED ELEVATED OR ATTEMPTS AT SPONTANEOUS VENTILATION PERSISTED. ANALYSIS OF VARIANCE WAS USED TO DETERMINE GROUP DIFFERENCES IN MEAN AND MEDIAN HR AND MAP AND TO COMPARE THE MAXIMUM HR AND MAP ATTAINED DURING SURGERY. POISSON REGRESSION WAS USED TO COMPARE THE NUMBER OF SUFENTANIL INJECTIONS REQUIRED IN BOTH GROUPS. RESULTS: GROUP B REQUIRED 2.46 TIMES MORE SUFENTANIL INJECTIONS (P = 0.00487) THAN DOGS IN GROUP C TO MAINTAIN HAEMODYNAMIC STABILITY AND PREVENT SPONTANEOUS VENTILATION DURING SURGERY. GROUP B DOGS ALSO HAD A SIGNIFICANTLY HIGHER (P = 0.034) MARGINAL MEAN OF THE LOG MAXIMUM MAP (4.756 +/- 0.036) COMPARED WITH GROUP C (4.642 +/- 0.036). CONCLUSIONS: PRE-TREATMENT WITH BUPRENORPHINE APPEARS TO NEGATIVELY INFLUENCE THE ANTINOCICEPTIVE EFFICACY OF INTRA-OPERATIVE SUFENTANIL. CLINICAL RELEVANCE: WITHHOLDING BUPRENORPHINE THERAPY 6-8 HOURS BEFORE ANAESTHESIA INCORPORATING PURE MU RECEPTOR AGONISTS IS PROBABLY ADVISABLE. ALTERNATIVE METHODS OF ANALGESIA SHOULD BE PROVIDED IN THIS PERIOD.",OPIOID RECEPTOR ANTAGONIST; MIXED AGONIST-ANTAGONIST; POSTOPERATIVE ANALGESIA; RESPIRATORY DEPRESSION; MU-OPIOIDS; MORPHINE; FENTANYL; ANTINOCICEPTION; BRADYCARDIA; RESPONSES,ANAESTHESIA; ANTINOCICEPTION; BUPRENORPHINE; DOGS; OPIOID; SUFENTANIL,VETERINARY ANAESTHESIA AND ANALGESIA,"JARAMILLO, LAG##MURRELL, JC##HELLEBREKERS, LJ","UNIV UTRECHT, FAC VET MED, DEPT EQUINE SCI, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, FAC VET MED, DEPT CLIN SCI & COMPAN ANIM, NL-3508 GA UTRECHT, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,"BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/BJA/57.2.192##BRODBELT DC, 1997, J VET PHARMACOL THER, V20, P284, DOI 10.1046/J.1365-2885.1997.00060.X##CARDINAL V, 2004, CAN J ANAESTH, V51, P806, DOI 10.1007/BF03018453##COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/J.1476-5381.1977.TB07533.X##COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/J.1476-5381.1977.TB07532.X##COWAN A, 2003, INT J CLIN PRACT, P3##DOBBINS S, 2002, J AM ANIM HOSP ASSOC, V38, P507, DOI 10.5326/0380507##DOMINO KB, 1999, ANESTHESIOLOGY, V90, P1053, DOI 10.1097/00000542-199904000-00019##DUM JE, 1981, BRIT J PHARMACOL, V74, P627, DOI 10.1111/J.1476-5381.1981.TB10473.X##EVANS J. M., 1984, CLIN ANAESTHESIOL, V2, P243##FLECKNELL PA, 1989, LAB ANIM, V23, P147, DOI 10.1258/002367789780863655##FREYE E, 2000, ANESTH ANALG, V90, P1359, DOI 10.1097/00000539-200006000-00018##GARRETT ER, 1990, BIOPHARM DRUG DISPOS, V11, P311, DOI 10.1002/BDD.2510110403##GREEN DW, 1985, ANAESTHESIA, V40, P371##HUG CC, 1990, ANESTHESIOLOGY, V73, P1, DOI 10.1097/00000542-199007000-00001##JOUBERT KE, 2001, J S AFR VET ASSOC, V72, P57##KAZAMA T, 1998, ANESTHESIOLOGY, V89, P894, DOI 10.1097/00000542-199810000-00014##LASCELLES BDX, 2003, VET ANAESTH ANALG, V30, P108, DOI 10.1046/J.1467-2995.2003.00133_19.X##LASCELLES BDX, 2000, ANIMAL PAIN PRACTICE, P85##LATASCH L, 2002, ARZNEIMITTEL-FORSCH, V52, P870##LEANDER JD, 1987, NEUROPHARMACOLOGY, V26, P1445, DOI 10.1016/0028-3908(87)90112-2##LEANDER JD, 1988, EUR J PHARMACOL, V151, P457, DOI 10.1016/0014-2999(88)90543-2##LIZASOAIN I, 1991, GEN PHARMACOL, V22, P297, DOI 10.1016/0306-3623(91)90452-C##MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517##MOENIRALAM HS, 1998, AM J PHYSIOL, V275, P440##MORGAN D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035##NOLAN A, 1987, BRIT J PHARMACOL, V92, P527, DOI 10.1111/J.1476-5381.1987.TB11353.X##OTTO KA, 2003, RES VET SCI, V75, P103, DOI 10.1016/S0034-5288(03)00077-8##OTTO KA, 2001, VET REC, V149, P80, DOI 10.1136/VR.149.3.80##PASCOE P, 2000, VET CLIN N AM-SMALL, P85##PICK CG, 1997, BRAIN RES, V744, P41, DOI 10.1016/S0006-8993(96)01069-4##PRAKANRATTANA U, 2002, J MED ASS THAI, V85, P807##ROUGHAN JV, 2004, BEHAV PHARMACOL, V15, P461, DOI 10.1097/00008877-200411000-00002##ROUGHAN JV, 2002, LAB ANIM-UK, V36, P322, DOI 10.1258/002367702320162423##ROVATI LC, 1987, MED SCI RES-BIOCHEM, V15, P659##SADEE W, 1982, J PHARMACOL EXP THER, V223, P157##STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/J.1476-5381.1956.TB00006.X##STEWART LSA, 2003, CONTEMP TOP LAB ANIM, V42, P28##TAYLOR PM, 2001, J VET PHARMACOL THER, V24, P391, DOI 10.1046/J.1365-2885.2001.368GOBLIN.X##TAYLOR PM, 2003, VET ANAESTH ANALG, V30, P51##TYERS MB, 1980, BRIT J PHARMACOL, V69, P503, DOI 10.1111/J.1476-5381.1980.TB07041.X##WALKER EA, 1995, J PHARMACOL EXP THER, V273, P1345##WHITE PF, 1989, ANESTH ANALG, V68, P177, DOI 10.1213/00000539-198902000-00020##YEOMANS DC, 1996, PAIN, V68, P141, DOI 10.1016/S0304-3959(96)03177-6##YEOMANS DC, 1994, PAIN, V59, P85, DOI 10.1016/0304-3959(94)90051-5##ZBINDEN AM, 1994, ANESTHESIOLOGY, V80, P261, DOI 10.1097/00000542-199402000-00005",10,2020-11-20,NA
J,WOS:000241942200019,2006,EFFECTS OF GROWTH HORMONE SECRETAGOGUES ON THE RELEASE OF ADENOHYPOPHYSEAL HORMONES IN YOUNG AND OLD HEALTHY DOGS,"THE EFFECTS OF THREE GROWTH HORMONE SECRETAGOGUES (GHSS), GHRELIN, GROWTH HORMONE-RELEASING PEPTIDE-6 (GHRP-6), AND GROWTH HORMONE-RELEASING HORMONE (GHRH), ON THE RELEASE OF ADENOHYPOPHYSEAL HORMONES, GROWTH HORMONE (GH), ADRENOCORTICOTROPIC HORMONE (ACTH), THYROID-STIMULATING HORMONE (TSH), LUTEINISING HORMONE (LH), PROLACTIN (PRL) AND ON CORTISOL WERE INVESTIGATED IN YOUNG AND OLD HEALTHY BEAGLE DOGS. GHRELIN PROVED TO BE THE MOST POTENT GHS IN YOUNG DOGS, WHEREAS IN OLD DOGS GHRH ADMINISTRATION WAS ASSOCIATED WITH THE HIGHEST PLASMA GH CONCENTRATIONS. THE MEAN PLASMA GH RESPONSE AFTER ADMINISTRATION OF GHRELIN WAS SIGNIFICANTLY LOWER IN THE OLD DOGS COMPARED WITH THE YOUNG DOGS. THE MEAN PLASMA GH CONCENTRATION AFTER GHRH AND GHRP-6 ADMINISTRATION WAS LOWER IN THE OLD DOGS COMPARED WITH THE YOUNG DOGS, BUT THIS DIFFERENCE DID NOT REACH STATISTICAL SIGNIFICANCE. IN BOTH AGE GROUPS, THE GHSS WERE SPECIFIC FOR GH RELEASE AS THEY DID NOT CAUSE SIGNIFICANT ELEVATIONS IN THE PLASMA CONCENTRATIONS OF ACTH, CORTISOL, TSH, LH, AND PRL. IT IS CONCLUDED THAT IN YOUNG DOGS, GHRELIN IS A MORE POWERFUL STIMULATOR OF GH RELEASE THAN EITHER GHRH OR GHRP-6. AGEING IS ASSOCIATED WITH A DECREASE IN GH-RELEASING CAPACITY OF GHRELIN, WHEREAS THIS DECLINE IS CONSIDERABLY LOWER FOR GHRH OR GHRP-6. (C) 2005 ELSEVIER LTD. ALL RIGHTS RESERVED.",MESSENGER-RIBONUCLEIC-ACID; PITUITARY-ADRENAL AXIS; FACTOR-I; GH SECRETAGOGUE; SYNTHETIC HEXAPEPTIDE; ACYLATED PEPTIDE; GHRELIN; SECRETION; HEXARELIN; AGE,AGEING; CANINE; GHRELIN; GROWTH HORMONE-RELEASING HORMONE; GROWTH HORMONE-RELEASING PEPTIDE-6,VETERINARY JOURNAL,"BHATTI, SFM##DUCHATEAU, L##VAN HAM, LML##DE VLIEGHER, SP##MOL, JA##RIJNBERK, A##KOOISTRA, HS","UNIV GHENT, FAC MED VET, DEPT SMALL ANIM MED & CLIN BIOL, B-9820 MERELBEKE, BELGIUM. UNIV GHENT, FAC MED VET, DEPT PHYSIOL BIOCHEM & BIOMETR, B-9820 MERELBEKE, BELGIUM. UNIV GHENT, FAC MED VET, DEPT OBSTET REPROD & HERD HLTH, B-9820 MERELBEKE, BELGIUM. UNIV UTRECHT, FAC VET MED, DEPT CLIN SCI COMPAN ANIM, NL-3508 TD UTRECHT, NETHERLANDS.",VETERINARY SCIENCES,VETERINARY SCIENCES,"ALOI JA, 1994, J CLIN ENDOCRINOLOGY, V81, P4249##ARVAT E, 1997, PEPTIDES, V18, P885, DOI 10.1016/S0196-9781(97)00016-8##ARVAT E, 2001, J CLIN ENDOCR METAB, V86, P1169, DOI 10.1210/JC.86.3.1169##ARVAT E, 1998, PITUITARY, V1, P51, DOI 10.1023/A:1009970909015##BHATTI SFM, 2002, MOL CELL ENDOCRINOL, V197, P97, DOI 10.1016/S0303-7207(02)00293-9##BORST SE, 1994, J AM GERIATR SOC, V42, P528, DOI 10.1111/J.1532-5415.1994.TB04976.X##BOWERS C.Y., 1977, MOL ENDOCRINOL, P287##BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/ENDO-114-5-1537##BOWERS CY, 2001, J CLIN ENDOCR METAB, V86, P1464, DOI 10.1210/JC.86.4.1464##BOWERS CY, 1993, J CLIN ENDOCR METAB, V76, P817, DOI 10.1210/JC.76.4.817##BOWERS CY, 1992, P 74 ANN M END SOC, P172##BROGLIO F, 2003, J CLIN ENDOCR METAB, V88, P1537, DOI 10.1210/JC.2002-021504##CARPINO PA, 2003, BIOORGAN MED CHEM, V11, P581, DOI 10.1016/S0968-0896(02)00433-9##CASANUEVA FF, 1999, TRENDS ENDOCRIN MET, V10, P30, DOI 10.1016/S1043-2760(98)00116-7##CEDA GP, 1986, ENDOCRINOLOGY, V118, P2109, DOI 10.1210/ENDO-118-5-2109##CELLA SG, 1993, NEUROENDOCRINOLOGY, V57, P432, DOI 10.1159/000126389##CELLA SG, 1995, PEPTIDES, V16, P81, DOI 10.1016/0196-9781(94)00149-Z##CELLA SG, 1989, ACTA ENDOCRINOL-COP, V121, P177, DOI 10.1530/ACTA.0.1210177##CHAPMAN IM, 1996, J CLIN ENDOCR METAB, V81, P4249, DOI 10.1210/JC.81.12.4249##COLONNA VD, 1994, NEUROCHEM INT, V25, P5##CORPAS E, 1992, J CLIN ENDOCR METAB, V75, P530, DOI 10.1210/JC.75.2.530##DATE Y, 2000, ENDOCRINOLOGY, V141, P4255, DOI 10.1210/EN.141.11.4255##DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/EDRV-10-1-68##DICKSON SL, 1997, ENDOCRINOLOGY, V138, P771, DOI 10.1210/EN.138.2.771##EIGENMANN JE, 1981, ACTA ENDOCRINOL-COP, V98, P514, DOI 10.1530/ACTA.0.0980514##EVERITT A, 1989, J GERONTOL, V44, PB139, DOI 10.1093/GERONJ/44.6.B139##FINKELSTEIN JW, 1972, J CLIN ENDOCR METAB, V35, P665, DOI 10.1210/JCEM-35-5-665##FRANCHIMONT P, 1989, ACTA ENDOCRINOL-COP, V120, P121, DOI 10.1530/ACTA.0.1200121##FRAWLEY LS, 1991, ENDOCR REV, V12, P337, DOI 10.1210/EDRV-12-4-337##GHIGO E, 1994, J CLIN ENDOCR METAB, V78, P693, DOI 10.1210/JC.78.3.693##GHIGO E, 1999, ENDOCRINE RESPONSE A, P152##GIUSTINA A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/ER.19.6.717##HAYASHIDA T, 2001, DOMEST ANIM ENDOCRIN, V21, P17, DOI 10.1016/S0739-7240(01)00104-7##HICKEY G, 1994, ENDOCRINOLOGY, V134, P695, DOI 10.1210/EN.134.2.695##JACKS T, 1996, ENDOCRINOLOGY, V137, P5284, DOI 10.1210/EN.137.12.5284##KELIJMAN M, 1991, J AM GERIATR SOC, V39, P295, DOI 10.1111/J.1532-5415.1991.TB01654.X##KOJIMA M, 1999, NATURE, V402, P656, DOI 10.1038/45230##KORBONITS M, 1999, J CLIN ENDOCR METAB, V84, P2489, DOI 10.1210/JC.84.7.2489##LAMBERTS SWJ, 1999, GROWTH HORMONE SECRE, P1##LOCHE S, 1995, J CLIN ENDOCR METAB, V80, P674, DOI 10.1210/JC.80.2.674##MASSOUD AF, 1996, J CLIN ENDOCR METAB, V81, P4338, DOI 10.1210/JC.81.12.4338##MOMANY FA, 1981, ENDOCRINOLOGY, V108, P31, DOI 10.1210/ENDO-108-1-31##MUCCIOLI G, 2002, EUR J PHARMACOL, V440, P235, DOI 10.1016/S0014-2999(02)01432-2##MULLER EE, 1999, PHYSIOL REV, V79, P511##MULLER EE, 2002, NEUROBIOL AGING, V23, P907, DOI 10.1016/S0197-4580(02)00026-X##NETT TM, 1975, P SOC EXP BIOL MED, V148, P134, DOI 10.3181/00379727-148-38491##NICOLAS V, 1994, J CLIN ENDOCR METAB, V78, P1011, DOI 10.1210/JC.78.5.1011##OKKENS AC, 1985, VET QUART, V7, P169, DOI 10.1080/01652176.1985.9693978##PATCHETT AA, 1995, P NATL ACAD SCI USA, V92, P7001, DOI 10.1073/PNAS.92.15.7001##PONG SS, 1996, MOL ENDOCRINOL, V10, P57, DOI 10.1210/ME.10.1.57##RAUN K, 1998, EUR J ENDOCRINOL, V139, P552, DOI 10.1530/EJE.0.1390552##RENNER U, 1994, J CLIN ENDOCR METAB, V78, P1090, DOI 10.1210/JC.78.5.1090##RIGAMONTI AE, 1999, EUR J ENDOCRINOL, V141, P313, DOI 10.1530/EJE.0.1410313##RINDI G, 2002, HISTOCHEM CELL BIOL, V117, P511, DOI 10.1007/S00418-002-0415-1##RUDMAN D, 1985, J AM GERIATR SOC, V33, P800, DOI 10.1111/J.1532-5415.1985.TB04195.X##SEOANE LM, 2000, EUR J ENDOCRINOL, V143, PR7, DOI 10.1530/EJE.0.143R007##SMITH RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/ER.18.5.621##SONNTAG WE, 1980, ENDOCRINOLOGY, V107, P1875, DOI 10.1210/ENDO-107-6-1875##SVENSSON J, 1998, J CLIN ENDOCR METAB, V83, P362, DOI 10.1210/JC.83.2.362##TAKAYA K, 2000, J CLIN ENDOCR METAB, V85, P4908, DOI 10.1210/JC.85.12.4908##THOMAS GB, 1997, ENDOCRINOLOGY, V138, P1585, DOI 10.1210/EN.138.4.1585##TOMASETTO C, 2001, PEPTIDES, V22, P2055, DOI 10.1016/S0196-9781(01)00557-5##VANEEKELEN JA, 1995, BIOL SCI MED SCI, V50, P83##WALKER RF, 1990, LIFE SCI, V47, P29, DOI 10.1016/0024-3205(90)90563-7##WALKER RF, 1991, LIFE SCI, V49, P1499, DOI 10.1016/0024-3205(91)90050-L##WILSHIRE GB, 1995, J CLIN ENDOCR METAB, V80, P608, DOI 10.1210/JC.80.2.608##ZADIK Z, 1985, J CLIN ENDOCR METAB, V60, P513, DOI 10.1210/JCEM-60-3-513",11,2020-11-20,NA
J,WOS:000242225800029,2006,UNTITLED - REPLY,NA,NA,NA,VETERINARY PATHOLOGY,"KUIKEN, T##FOSTER, G","ERASMUS UNIV, MED CTR, DEPT VIROL, ROTTERDAM, NETHERLANDS. SAC VET SERV, INVERNESS, SCOTLAND.",PATHOLOGY; VETERINARY SCIENCES,PATHOLOGY; VETERINARY SCIENCES,"KUIKEN T, 2006, VET PATHOL, V43, P321, DOI 10.1354/VP.43-3-321",0,2020-11-20,NA
J,WOS:000240539000002,2006,TRANSMISSION OF ENCEPHALOMYOCARDITIS VIRUS IN PIGS ESTIMATED FROM FIELD DATA IN BELGIUM BY MEANS OF R-0,"TRANSMISSION OF ENCEPHALOMYOCARDITIS-VIRUS ( EMCV) HAS BEEN ESTIMATED IN EXPERIMENTS, BUT NEVER USING FIELD DATA. IN THIS FIELD STUDY, A FARM IN BELGIUM WAS SELECTED WHERE THE PRESENCE OF EMCV WAS CONFIRMED BY NECROPSY AND VIRUS ISOLATION. SEROLOGY WAS USED TO ESTIMATE THE TRANSMISSION PARAMETER R-0. IN ONE COMPARTMENT WITH 630 PIGS, 6 PENS WERE FULLY SAMPLED, IN THE REMAINING 38 PENS, 2 RANDOMLY SELECTED PIGS WERE BLED. THE 151 PIGS WERE BLED TWICE AND THEIR SERUM WAS TESTED IN A VIRUS NEUTRALISATION TEST. SEROPREVALENCE AT THE FIRST AND SECOND SAMPLING WAS 41 AND 43% RESPECTIVELY, WITH A CUT OFF VALUE OF 1: 40. R-0 WAS ESTIMATED FOR 2 SCENARIOS, IN- AND EXCLUDING MORTALITY BASED ON THE FINAL SIZES FROM THE SEROLOGICAL RESULTS OF THE SECOND SAMPLING. THE R-0 FOR THE FULLY SAMPLED PENS WAS ESTIMATED BETWEEN 0.6 AND 1.7, THE COMBINED ESTIMATED R-0 OF THESE 6 PENS WAS 1.36 (95%-CI 0.93-2.23). THE MEDIAN OF THE ESTIMATED R-0 OF THE PARTIALLY SAMPLED PENS WAS 1.3 AND 1.4. SAMPLING TWO PIGS PER PEN PROVIDED INSIGHT INTO THE SPREAD OF THE VIRUS IN THE COMPARTMENT, WHILE THE FULLY SAMPLED PENS PROVIDED AN ACCURATE ESTIMATION OF R-0. THE LOW R-0 STRONGLY SUGGESTS THAT EMCV IS NOT VERY EFFECTIVELY TRANSMITTED BETWEEN PIGS. THE NUMBER OF SEROPOSITIVE PIGS IN A PEN AND THE SPREAD IN THE COMPARTMENT SUGGESTS THAT OTHER ROUTES OF INFECTION ARE MORE IMPORTANT, IN THIS CASE MOST LIKELY RODENTS. PREVENTING VIRAL SPREAD SHOULD THEREFORE BE FOCUSSED ON RODENT CONTROL INSTEAD OF REDUCTION OF CONTACT BETWEEN PIGS.",INFECTION; EMCV; QUANTIFICATION; SWINE,ENCEPHALOMYOCARDITIS VIRUS; PIGS; TRANSMISSION; R-0; FIELD DATA,VETERINARY RESEARCH,"KLUIVERS, M##MAURICE, H##VYT, P##KOENEN, F##NIELEN, M","UNIV UTRECHT, FAC VET MED, DEPT FARM ANIM HLTH, NL-3584 CL UTRECHT, NETHERLANDS. UNIV WAGENINGEN & RES CTR, DEPT SOCIAL SCI, BUSINESS ECON GRP, NL-6706 KN WAGENINGEN, NETHERLANDS. ANIM HLTH CARE FLANDERS, TORHOUT, BELGIUM. CODA, CERVA, VAR, SECT EPIZOOT DIS,DEPT VIROL, B-1180 BRUSSELS, BELGIUM.",VETERINARY SCIENCES,VETERINARY SCIENCES,"ACLAND H. M., 1989, VIRUS INFECTIONS OF PORCINES., P259##AUGUSTIJN M, 2006, TIJDSCHR DIERGENEESK, V131, P40##BILLINIS C, 2004, VET MICROBIOL, V99, P187, DOI 10.1016/J.VETMIC.2004.01.002##DEJONG MCM, 1994, VACCINE, V12, P761, DOI 10.1016/0264-410X(94)90229-1##DEJONG MCM, 1995, PREV VET MED, V25, P183, DOI 10.1016/0167-5877(95)00538-2##DIEKMANN O, 1990, J MATH BIOL, V28, P365##FONI E, 1993, J VET MED B, V40, P347, DOI 10.1111/J.1439-0450.1993.TB00149.X##GUALANDI GL, 1989, MICROBIOLOGICA, V12, P129##JOO H.S, 1999, DIS SWINE, P139##JUNGEBLUT CW, 1943, AM J PUBLIC HEALTH N, V33, P169, DOI 10.2105/AJPH.33.2.169##JUNGEBLUT CW, 1940, J EXP MED, V72, P407, DOI 10.1084/JEM.72.4.407##KLINKENBERG D, 2002, EPIDEMIOL INFECT, V128, P293, DOI 10.1017/S0950268801006537##KOENEN F, 1999, J VET MED B, V46, P217##KOENEN F, 2002, CT984146 CODASERVAVA##KROESE AH, 2001, SOCIETY FOR VETERINARY EPIDEMIOLOGY AND PREVENTIVE MEDICINE, PROCEEDINGS, PXXI##LITTLEJOHNS IR, 1975, AUST VET J, V51, P416, DOI 10.1111/J.1751-0813.1975.TB15790.X##MAURICE H, 2005, EPIDEMIOL INFECT, V133, P547, DOI 10.1017/S0950268804003668##MAURICE H, 2002, VET MICROBIOL, V88, P301, DOI 10.1016/S0378-1135(02)00127-X##PAPADOPOULOU EP, 1992, INT PIG VET SOC HAG, P106##PASCHALERIPAPADOPOULOU E, 1990, VET REC, V126, P364##SANGAR DV, 1977, VET REC, V100, P240, DOI 10.1136/VR.100.12.240##SEAMAN JT, 1986, AUST VET J, V63, P292, DOI 10.1111/J.1751-0813.1986.TB08069.X##SHIBATA I, 1993, J VET MED SCI, V55, P117, DOI 10.1292/JVMS.55.117##SPYROU V, 2004, VET RES, V35, P113, DOI 10.1051/VETRES:2003044##VANDERHALLEN H, 1997, J VIROL METHODS, V66, P83, DOI 10.1016/S0166-0934(97)02214-3##VANREGENMORTEL M, 2000, VIRUS TAXONOMY, P667##VELTHUIS AGJ, 2002, EPIDEMIOL INFECT, V128, P193, DOI 10.1017/S0950268801006707##ZIMMERMAN J, 1993, J VET DIAGN INVEST, V5, P317, DOI 10.1177/104063879300500302##ZIMMERMAN J J, 1990, J VET DIAGN INVEST, V2, P347##ZIMMERMAN JJ, 1994, HDB ZOONOSES B, P423",13,2020-11-20,NA
J,WOS:000244275600007,2006,DIFFERENCES IN THE PHARMACOLOGICAL ACTIVATION OF VISUAL OPSINS,"OPSINS, LIKE MANY OTHER G-PROTEIN-COUPLED RECEPTORS, SUSTAIN CONSTITUTIVE ACTIVITY IN THE ABSENCE OF LIGAND. IN PARTIALLY BLEACHED RODS AND CONES, OPSIN'S ACTIVITY CLOSES CGMP-GATED CHANNELS AND PRODUCES A STATE OF ""PIGMENT ADAPTATION"" WITH REDUCED SENSITIVITY TO LIGHT AND ACCELERATED FLASH RESPONSE KINETICS. THE TRUNCATED RETINAL ANALOGUE, BETA-IONONE, FURTHER DESENSITIZES PARTIALLY BLEACHED GREEN-SENSITIVE SALAMANDER RODS, BUT ENABLES PARTIALLY BLEACHED RED-SENSITIVE CONES TO RECOVER DARK-ADAPTED PHYSIOLOGY. STRUCTURAL DIFFERENCES BETWEEN ROD AND CONE OPSINS WERE PROPOSED TO EXPLAIN THE EFFECT. RODS AND CONES, HOWEVER, ALSO CONTAIN DIFFERENT TRANSDUCINS, RAISING THE POSSIBILITY THAT G-PROTEIN TYPE DETERMINES THE PHOTORECEPTOR-SPECIFIC EFFECTS OF BETA-IONONE. TO TEST THE TWO HYPOTHESES, WE APPLIED BETA-IONONE TO PARTIALLY BLEACHED BLUE-SENSITIVE RODS AND CONES OF SALAMANDER, TWO CELLS THAT COUPLE THE SAME CONE-LIKE OPSIN TO EITHER ROD OR CONE TRANSDUCIN, RESPECTIVELY. IMMUNOCYTOCHEMISTRY CONFIRMED THAT ALL SALAMANDER RODS CONTAIN ONE FORM OF TRANSDUCIN, WHEREAS ALL CONES CONTAIN ANOTHER. BETA-IONONE ENHANCED PIGMENT ADAPTATION IN BLUE-SENSITIVE RODS, BUT IT ALSO DID SO IN BLUE- AND UV-SENSITIVE CONES. FURTHERMORE, ALL RECOMBINANT SALAMANDER ROD AND CONE OPSINS, WITH THE EXCEPTION OF THE RED-SENSITIVE CONE OPSIN, ACTIVATED ROD TRANSDUCIN UPON THE ADDITION OF BETA-IONONE. THUS OPSIN STRUCTURE DETERMINES THE IDENTITY OF BETA-IONONE AS AN AGONIST OR AN INVERSE AGONIST AND IN THAT RESPECT DISTINGUISHES THE RED-SENSITIVE CONE OPSIN FROM ALL OTHERS.",COUPLED RECEPTOR KINASE; PROTEIN BETA-SUBUNIT; CONE PHOTORECEPTORS; SALAMANDER RODS; VERTEBRATE PHOTORECEPTORS; PALMITOYLATION SITES; MOLECULAR-CLONING; RETINAL CONES; GAMMA-SUBUNIT; BINDING-SITE,ROD; CONE; RHODOPSIN; TRANSDUCIN; PHOTOTRANSDUCTION,VISUAL NEUROSCIENCE,"ISAYAMA, T##CHEN, Y##KONO, M##DEGRIP, WJ##MA, JX##CROUCH, RK","HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02114 USA. UNIV OKLAHOMA, HLTH SCI CTR, DEPT CELL BIOL, OKLAHOMA CITY, OK USA. MED UNIV S CAROLINA, DEPT OPHTHALMOL, STORM EYE RES INST, CHARLESTON, SC 29425 USA. UNIV NIJMEGEN, DEPT BIOCHEM, NCMLS, NIJMEGEN, NETHERLANDS.",NEUROSCIENCES; OPHTHALMOLOGY,NEUROSCIENCES & NEUROLOGY; OPHTHALMOLOGY,"ATTWELL DI, 1983, J PHYSIOL-LONDON, V341, PP74##BAEHR W, 1982, J BIOL CHEM, V257, P6452##CHEN N, 1996, INVEST OPHTH VIS SCI, V37, P1907##CLAPHAM DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/ANNUREV.PHARMTOX.37.1.167##CORSON DW, 2000, J GEN PHYSIOL, V116, P283, DOI 10.1085/JGP.116.2.283##CRAFT CM, 1994, J BIOL CHEM, V269, P4613##DAS J, 2004, BIOCHEMISTRY-US, V43, P5532, DOI 10.1021/BI036097U##DEAN DM, 2002, P NATL ACAD SCI USA, V99, P8372, DOI 10.1073/PNAS.122681899##DOWNES GB, 1999, GENOMICS, V62, P544, DOI 10.1006/GENO.1999.5992##EBREY T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8##FAIN GL, 2001, PHYSIOL REV, V81, P117##FUNG K.Y., 1992, COMPUT GRAPH FORUM, V3, P267##HISATOMI O, 1998, FEBS LETT, V424, P159, DOI 10.1016/S0014-5793(98)00162-8##HORRIGAN DM, 2005, J GEN PHYSIOL, V126, P453, DOI 10.1085/JGP.200509387##JIN J, 1993, NEURON, V11, P513, DOI 10.1016/0896-6273(93)90155-K##JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/PNAS.86.23.9606##KEFALOV VJ, 1999, J GEN PHYSIOL, V113, P491, DOI 10.1085/JGP.113.3.491##KEFALOV VJ, 2005, NEURON, V46, P879, DOI 10.1016/J.NEURON.2005.05.009##KEFALOV VJ, 2001, NEURON, V29, P749, DOI 10.1016/S0896-6273(01)00249-5##KONO M, 2006, FEBS LETT, V580, P229, DOI 10.1016/J.FEBSLET.2005.12.002##LEE RH, 1992, J BIOL CHEM, V267, P24776##MA JX, 2001, VISUAL NEUROSCI, V18, P393, DOI 10.1017/S0952523801183057##MA JX, 2001, NEURON, V32, P451, DOI 10.1016/S0896-6273(01)00482-2##MAKINO CL, 1991, J PHYSIOL-LONDON, V442, P761, DOI 10.1113/JPHYSIOL.1991.SP018818##MAKINO CL, 1999, BIOPHYS J, V77, P1024, DOI 10.1016/S0006-3495(99)76953-5##MAKINO CL, 1996, J GEN PHYSIOL, V108, P27, DOI 10.1085/JGP.108.1.27##MATSUMOTO H, 1975, BIOCHIM BIOPHYS ACTA, V404, P300, DOI 10.1016/0304-4165(75)90337-2##MCBEE JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7##MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/BI00185A017##MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5783, DOI 10.1021/BI00185A016##NIR I, 1992, J HISTOCHEM CYTOCHEM, V40, P343, DOI 10.1177/40.3.1372630##ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/JBC.270.15.8495##OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8##PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/PNAS.89.22.10882##PITTLER SJ, 1992, FEBS LETT, V313, P103, DOI 10.1016/0014-5793(92)81422-I##RIEKE F, 2000, NEURON, V26, P181, DOI 10.1016/S0896-6273(00)81148-4##ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B##ROBINSON PR, 2000, METHOD ENZYMOL, V315, P207##RYAN JC, 2001, MOL VIS, V7, P222##RYAN JC, 2000, VISUAL NEUROSCI, V17, P847, DOI 10.1017/S0952523800176047##SACHS K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/JBC.275.9.6189##SAKUMA H, 1996, FEBS LETT, V382, P105, DOI 10.1016/0014-5793(96)00163-9##SHERRY DM, 1998, VISUAL NEUROSCI, V15, P1175, DOI 10.1017/S0952523898156201##SMITH WC, 2000, INVEST OPHTH VIS SCI, V41, P2445##VISSERS PMAM, 1996, FEBS LETT, V396, P26, DOI 10.1016/0014-5793(96)01064-2##WEISS ER, 2001, J NEUROSCI, V21, P9175, DOI 10.1523/JNEUROSCI.21-23-09175.2001##WEISS LG, 1998, BEHAV HEALTHC TOM, V7, P27##WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697##XU L, 1998, MOL VIS, V4, P10##YOKOYAMA S, 2000, PROG RETIN EYE RES, V19, P385, DOI 10.1016/S1350-9462(00)00002-1",17,2020-11-20,"NATIONAL EYE INSTITUTEUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL EYE INSTITUTE (NEI) [P30EY014104, R01EY012231, P30EY014104, R29EY011358, R01EY012231, R01EY004939, R21EY015650, R01EY012231, R01EY004939, P30EY014104, R01EY012231, R01EY012231, R01EY004939, P30EY014104, R01EY004939, R01EY011358, R01EY004939, P30EY014104, R01EY013748, R01EY004939, R01EY004939, P30EY014104, P30EY014104, R01EY013748, R01EY011358, P30EY014104, R01EY004939, R01EY012231, P30EY014104, P30EY014104, P30EY014104, P30EY014104, R01EY012231, P30EY014104, R24EY014793, P30EY014104, P30EY014104, R24EY014793, R01EY012231, P30EY014104, R01EY012231, R01EY012231, R01EY011358, R01EY004939, R01EY012231, R01EY013748, P30EY014104, P30EY014104, R24EY014793, P30EY014104, R24EY014793, P30EY014104, R01EY004939, R01EY011358, R01EY004939, P30EY014104, R33EY015650, P30EY014104, R01EY004939, R01EY012231, R01EY011358, R01EY004939, P30EY014104, R01EY011358, R01EY004939, R01EY011358, R29EY011358, R01EY004939, P30EY014104, R01EY004939, R01EY004939, R21EY015650, R01EY004939, R01EY012231, P30EY014104, R01EY004939, P30EY014104, P30EY014104, R01EY004939, R01EY004939, P30EY014104, P30EY014104, R01EY011358, R01EY004939, P30EY014104, P30EY014104, R01EY004939, R01EY004939, P30EY014104, P30EY014104, R29EY011358, R01EY004939, R01EY004939, R24EY014793, R01EY004939, R01EY004939, P30EY014104, R33EY015650, P30EY014104, R01EY011358, P30EY014104, P30EY014104, P30EY014104, R01EY012231, R29EY011358, P30EY014104, R33EY015650, R01EY011358, R01EY004939, R29EY011358, P30EY014104, P30EY014104, R01EY012231, R01EY012231, R01EY012231, R01EY004939, P30EY014104] FUNDING SOURCE: NIH REPORTER; NEI NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL EYE INSTITUTE (NEI) [EY014104, R24 EY014793, EY12231, EY15650, EY014793, R01 EY013748, EY11358, R01 EY004939, R01 EY012231, R21 EY015650, P30 EY014104, EY04939, R01 EY011358, EY013748] FUNDING SOURCE: MEDLINE"
J,WOS:000242628300010,2006,ELECTROKINETIC COPPER AND IRON MIGRATION IN ANAEROBIC GRANULAR SLUDGE,"THE APPLICATION OF LOW-LEVEL DIRECT ELECTRIC CURRENT (0.15 MA CM(-2)) AS AN ELECTROKINETIC TECHNIQUE TO TREAT COPPER-CONTAMINATED MESOPHILIC ANAEROBIC GRANULAR SLUDGE WAS INVESTIGATED. THE SLUDGE WAS OBTAINED FROM A FULL SCALE UASB REACTOR TREATING PAPER-MILL WASTEWATER AND WAS ARTIFICIALLY CONTAMINATED BY CU(NO3)(2) OR CUEDTA(2-) WITH INITIAL COPPER CONCENTRATIONS OF 1000 MG . KG(-1) WET SLUDGE. THE EFFECT OF DIFFERENT ELECTROKINETIC CELL LAYOUTS, PH AND EDTA CONCENTRATIONS ON THE MIGRATION OF COPPER AND IRON DURING ELECTROKINETIC TREATMENT WERE EVALUATED. BOTH, THE PH OF THE SLUDGE CAKE OR THE COPPER COMPLEXATION WITH EDTA SIGNIFICANTLY AFFECTED THE MIGRATION DIRECTION OF COPPER. IN AN 'OPEN' CELL (SLUDGE CAKE IN DIRECT CONTACT WITH AIR), THE HIGHEST COPPER MOBILITY WAS OBSERVED AT PH 2.5 IN BOTH CU(NO3)(2) OR CUEDTA(2-) AMENDED SLUDGE. THE HIGHEST COPPER ACCUMULATION WAS AT THE CATHODE (22 +/- 2)% WITH CUEDTA(2-) AS CONTAMINANT. IN A 'CLOSED' CELL (SLUDGE CAKE NOT IN CONTACT WITH AIR), THE HIGHEST ACCUMULATION WAS OBTAINED FOR CUEDTA(2-) AT THE ANODE AND AMOUNTED TO 4(+/- 0.5)% AND 2(+/- 0.05)%, RESPECTIVELY, AT A FINAL PH OF 4.2 AND 7.7 IN THE SLUDGE CAKE.",TREATED WOOD WASTE; HEAVY-METALS; PILOT-SCALE; REMOVAL; REMEDIATION; SOIL; WATER; EXTRACTION; CHROMIUM; FRACTIONATION,ELECTROMIGRATION; COPPER; IRON; GRANULAR SLUDGE; PH,WATER AIR AND SOIL POLLUTION,"VIRKUTYTE, J##SILLANPAA, M##LENS, P","UNIV WAGENINGEN & RES CTR, SUBDEPT ENVIRONM TECHNOL, WAGENINGEN, NETHERLANDS. UNIV KUOPIO, LAB APPL ENVIRONM CHEM, DEPT ENVIRONM SCI, FIN-50101 MIKKELI, FINLAND.",ENVIRONMENTAL SCIENCES; METEOROLOGY & ATMOSPHERIC SCIENCES; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; METEOROLOGY & ATMOSPHERIC SCIENCES; WATER RESOURCES,"ABRAMOVITCH RA, 2003, CHEMOSPHERE, V53, P1077, DOI 10.1016/S0045-6535(03)00572-1##ACAR YB, 1996, J GEOTECH ENG-ASCE, V122, P173, DOI 10.1061/(ASCE)0733-9410(1996)122:3(173)##ACAR YB, 1993, ENVIRON SCI TECHNOL, V27, P2638, DOI 10.1021/ES00049A002##ALLOWAY B. J., 1995, HEAVY METALS SOILS##ALSHAWABKEH AN, 1999, J ENVIRON ENG, V125, P27, DOI 10.1061/(ASCE)0733-9372(1999)125:1(27)##BOLAN NS, 2003, SCI TOTAL ENVIRON, V309, P225, DOI 10.1016/S0048-9697(03)00052-4##DIJKSTRA E, 1998, GEODERMA, V61, P4495##DOBERMANN A., 2000, RICE NUTR DISORDERS##EMERY T, 1991, IRON YOUR HLTH FACTS##FJALLBORG B, 2003, ENVIRON INT, V28, P761, DOI 10.1016/S0160-4120(02)00121-6##HARAN BS, 1996, ENVIRON PROG, V15, P166, DOI 10.1002/EP.670150315##HASHIMOTO S, 2004, CHEMOSPHERE, V54, P89, DOI 10.1016/S0045-6535(03)00673-8##HERNANDEZ L, 2003, SCI TOTAL ENVIRON, V312, P195, DOI 10.1016/S0048-9697(03)00223-7##ITO A, 2000, WATER RES, V34, P751, DOI 10.1016/S0043-1354(99)00215-8##KARI FG, 1996, WATER RES, V30, P122, DOI 10.1016/0043-1354(95)00125-5##KIM SO, 2002, WATER RES, V36, P4765, DOI 10.1016/S0043-1354(02)00141-0##KIM WS, 2005, J HAZARD MATER, V118, P93, DOI 10.1016/J.JHAZMAT.2004.10.001##LEE HH, 2000, J HAZARD MATER, V77, P227, DOI 10.1016/S0304-3894(00)00251-X##LENS P, 1999, WATER SCI TECHNOL, V39, P187, DOI 10.1016/S0273-1223(99)00167-5##LI ZM, 1997, J HAZARD MATER, V55, P295, DOI 10.1016/S0304-3894(97)00021-6##LIN CY, 1999, WATER RES, V33, P409, DOI 10.1016/S0043-1354(98)00211-5##MAINI G, 2000, ENVIRON SCI TECHNOL, V34, P1081, DOI 10.1021/ES990551T##MATTSON ED, 1995, AM CHEM SOC, P11##MERCER JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7##MOHAMMADI T, 2005, SEP PURIF TECHNOL, V41, P73, DOI 10.1016/J.SEPPUR.2004.04.007##MULLIGAN CN, 2004, ENVIRON INT, V30, P587, DOI 10.1016/J.ENVINT.2003.11.001##NOWACK B, 2002, ENVIRON SCI TECHNOL, V36, P4009, DOI 10.1021/ES025683S##OSUNA MB, 2004, J ENVIRON QUAL, V33, P1256, DOI 10.2134/JEQ2004.1256##OTTOSEN LM, 2002, J HAZARD MATER, V91, P205, DOI 10.1016/S0304-3894(01)00388-0##OTTOSEN LM, 1992, ELECTROKINETIC CLEAN##POL LWH, 2004, WATER RES, V38, P1376, DOI 10.1016/J.WATRES.2003.12.002##POPOV K, 1999, COLLOID SURFACE A, V160, P135, DOI 10.1016/S0927-7757(99)00359-3##REDDY KR, 1997, J HAZARD MATER, V55, P135, DOI 10.1016/S0304-3894(97)00020-4##REDDY KR, 2003, ADV ENVIRON RES, V7, P353, DOI 10.1016/S1093-0191(02)00005-9##SAH JG, 1998, J HAZARD MATER, V58, P301, DOI 10.1016/S0304-3894(97)00140-4##SEGURA M, 2004, TRAC-TREND ANAL CHEM, V23, P194, DOI 10.1016/S0165-9936(04)00502-3##SHEPPARD DS, 2000, APPL GEOCHEM, V15, P513, DOI 10.1016/S0883-2927(99)00055-4##SILLANPAA M, 2001, SCI TOTAL ENVIRON, V267, P23, DOI 10.1016/S0048-9697(00)00723-3##STRAUB KL, 2001, FEMS MICROBIOL ECOL, V34, P181, DOI 10.1016/S0168-6496(00)00088-X##TURER D, 2005, J HAZARD MATER, V119, P167, DOI 10.1016/J.JHAZMAT.2004.12.003##VAN HULLEBUSCH ED, 2005, TALANTA, V65, P549, DOI 10.1016/J.TALANTA.2004.07.024##VANCAUWENBERGHE L, 1997, ELECTROKINETICS TECH, P1##VELIZAROVA E, 2004, J HAZARD MATER, V107, P103, DOI 10.1016/J.JHAZMAT.2003.09.011##VELIZAROVA E, 2002, J HAZARD MATER, V94, P147, DOI 10.1016/S0304-3894(02)00063-8##VIRKUTYTE J, 2005, ENVIRON POLLUT, V138, P517, DOI 10.1016/J.ENVPOL.2005.04.009##VIRKUTYTE J, 2004, INT J SURF MIN RECLA, V18, P220##WIECZOREK S, 2005, ENG GEOL, V77, P203, DOI 10.1016/J.ENGGEO.2004.07.011##YEUNG AT, 1997, J HAZARD MATER, V55, P221, DOI 10.1016/S0304-3894(97)00017-4##YUAN C, 2003, ADV ENVIRON RES, V7, P727, DOI 10.1016/S1093-0191(02)00030-8",6,2020-11-20,NA
J,WOS:000242628300012,2006,THE IMPACT OF BIOTURBATION BY SMALL MAMMALS ON HEAVY METAL REDISTRIBUTION IN AN EMBANKED FLOODPLAIN OF THE RIVER RHINE,"FLOODPLAINS ALONG LARGE EUROPEAN RIVERS ARE DIFFUSELY POLLUTED WITH HEAVY METALS DUE TO EMISSIONS IN THE PAST. BECAUSE OF LOW MOBILITY OF HEAVY METALS IN FLOODPLAIN SOILS AND IMPROVEMENTS OF WATER QUALITY, THESE POLLUTANTS WILL REMAIN IN PLACE, AND CAN GRADUALLY BECOME COVERED WITH LESS CONTAMINATED SEDIMENTS. BIOTURBATORS, ESPECIALLY EARTHWORMS, CAN PLAY AN IMPORTANT ROLE IN THE MIXING AND SURFACING OF CONTAMINATED SUBSTRATE. SURFACED SUBSTRATE CAN BE REDISTRIBUTED BY RECURRENT FLOODING EVENTS, EVEN TO AREAS OUTSIDE THE FLOODPLAIN. THE QUESTION REMAINED TO WHAT EXTENT BIOTURBATION BY SMALL MAMMALS CONTRIBUTES TO THE REDISTRIBUTION OF HEAVY METALS FROM RIVER SEDIMENTS IN FLOODPLAINS. EXTENSIVE FIELDWORK ON BIOTURBATORS SUCH AS VOLES, MOLES AND EARTHWORMS AND THEIR DISTRIBUTION PATTERNS, AS WELL AS ON SEDIMENT DEPOSITION AND BIOTURBATION, WAS CONDUCTED AT THE 'AFFERDENSCHE EN DEESTSCHE WAARDEN' FLOODPLAIN OVER THE YEARS 2001-2003. FIELD DATA WERE COMBINED WITH DATA OF EXPERIMENTS IN FIELD ENCLOSURES AND SUBSTRATE COLUMNS TO CALCULATE THE AMOUNTS OF SEDIMENT AND HEAVY METALS (ZN, CU, PB AND CD) REDISTRIBUTED DURING THE FLOODS AS WELL AS ON AN ANNUAL BASIS. MOLES AND VOLES SURFACED CONSIDERABLE AMOUNTS OF SUBSTRATE AND HEAVY METALS, BUT NOT AS MUCH AS EARTHWORMS WHICH CONTRIBUTE A SUBSTANTIAL PROPORTION OF THE TOTAL DEPOSITION AND REDISTRIBUTION DURING FLOODS. ALTHOUGH THE IMPACT OF MOLES AND VOLES ON THE REDISTRIBUTION DURING FLOODS WAS ONLY LOCALLY IMPORTANT, ON AN ANNUAL BASIS THE BIOTURBATION ACTIVITY OF ESPECIALLY MOLES IN FLOODPLAINS CANNOT BE NEGLECTED. THE ANNUAL AMOUNTS OF SUBSTRATE AND HEAVY METALS SURFACED BY ALL INVESTIGATED BIOTURBATORS WERE EVEN LARGER THAN THE TOTAL AMOUNTS OF SUBSTRATE AND HEAVY METALS DEPOSITED DURING FLOODS.",ECOLOGICAL RISK-ASSESSMENT; SPATIAL VARIABILITY; SEDIMENTATION; SOIL; EARTHWORMS,BIOTURBATION; EARTHWORMS; FLOODPLAINS; HEAVY METALS; MOLES; REDISTRIBUTION; SEDIMENT; SMALL MAMMALS; VOLES,WATER AIR AND SOIL POLLUTION,"WIJNHOVEN, S##THONON, I##VAN DER VELDE, G##LEUVEN, R##ZORN, M##EIJSACKERS, H##SMITS, T","RADBOUD UNIV NIJMEGEN, FAC SCI, CTR WATER & SOC, NL-6500 GL NIJMEGEN, NETHERLANDS. UNIV UTRECHT, FAC GEOSCI, DEPT PHYS GEOG, NL-3508 TC UTRECHT, NETHERLANDS. RADBOUD UNIV NIJMEGEN, INST WETLAND & WATER RES, DEPT ANIM ECOL & ECOPHYSIOL, NL-6500 GL NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, INST WETLAND & WATER RES, DEPT ENVIRONM SCI, NL-6500 GL NIJMEGEN, NETHERLANDS. FREE UNIV AMSTERDAM, INST ECOL SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV WAGENINGEN & RES CTR, NL-6700 HB WAGENINGEN, NETHERLANDS. ERASMUS UNIV, FAC SOCIAL SCI, NL-3000 DR ROTTERDAM, NETHERLANDS.",ENVIRONMENTAL SCIENCES; METEOROLOGY & ATMOSPHERIC SCIENCES; WATER RESOURCES,ENVIRONMENTAL SCIENCES & ECOLOGY; METEOROLOGY & ATMOSPHERIC SCIENCES; WATER RESOURCES,"ANDERSEN DC, 2000, J MAMMAL, V81, P1087, DOI 10.1644/1545-1542(2000)081<1087:MPORSM>2.0.CO;2##BRAUN-BLANQUET J., 1932, PLANT SOCIOLOGY STUD##CISZEWSKI D, 2003, WATER AIR SOIL POLL, V143, P81, DOI 10.1023/A:1022825103974##EDWARDS GR, 1999, J APPL ECOL, V36, P434, DOI 10.1046/J.1365-2664.1999.00411.X##EIJSACKERS HJP, 2000, NEW APPROACHES TO RIVER MANAGEMENT, P307##GABLER HE, 1997, J GEOCHEM EXPLOR, V58, P185, DOI 10.1016/S0375-6742(96)00061-1##GODFREY G, 1969, LIFE MOLE, P152##HAECK J, 1969, NETHERLANDS JOURNAL OF ZOOLOGY, V19, P145##KOOISTRA L, 2005, ENVIRON SCI TECHNOL, V39, P2177, DOI 10.1021/ES049814W##KOOISTRA L, 2001, ENVIRON MANAGE, V28, P359, DOI 10.1007/S0026702433##KWADIJK J, 1994, CLIMATIC CHANGE, V27, P199, DOI 10.1007/BF01093591##LAMBERT CP, 1987, GEOGR ANN A, V69, P393, DOI 10.2307/521353##LANGE R, 1994, ZOOGDIEREN W EUROPA, P400##LEUVEN R. S. E. W., 2005, ARCHIV FUER HYDROBIOLOGIE SUPPLEMENT, V155, P657##MIDDELKOOP H, 2002, HYDROL PROCESS, V16, P47, DOI 10.1002/HYP.283##MIDDELKOOP H, 1998, EARTH SURF PROC LAND, V23, P561, DOI 10.1002/(SICI)1096-9837(199806)23:6&LT;561::AID-ESP870&GT;3.0.CO;2-5##MIDDELKOOP H, 2000, NETH J GEOSCI, V79, P411##MITCHELL P., 1988, P43##MULLERLEMANS H, 1996, J ENVIRON RADIOACTIV, V31, P7, DOI 10.1016/0265-931X(95)00029-A##NIENHUIS PH, 2002, HYDROBIOLOGIA, V478, P53, DOI 10.1023/A:1021070428566##PEBESMA EJ, 1998, COMPUT GEOSCI-UK, V24, P17, DOI 10.1016/S0098-3004(97)00082-4##ROBINSON CT, 2002, FRESHWATER BIOL, V47, P661, DOI 10.1046/J.1365-2427.2002.00921.X##SCHEU S, 1987, OECOLOGIA, V72, P192, DOI 10.1007/BF00379266##SCHRODER TJ, 2005, THESIS WAGENINGEN U, P172##SILVA W, 2001, 2001031 ARNH DELFT##THONON I, 2005, EARTH SURF PROC LAND, V30, P1327, DOI 10.1002/ESP.1239##THONON I, 2003, IAHS-AISH P, P37##THONON I, 2006, THESIS UTRECHT U UTR##TYLER AN, 2001, CATENA, V43, P81, DOI 10.1016/S0341-8162(00)00127-2##VAN VLIET PCJ, 2005, ENVIRON POLLUT, V138, P505, DOI 10.1016/J.ENVPOL.2005.04.010##VERBEKE A, 1997, THESIS ECOLE NATL VE##VINK R, 1999, WATER SCI TECHNOL, V39, P215, DOI 10.1016/S0273-1223(99)00338-8##WIJNHOVEN S, 2006, HYDROBIOLOGIA, V565, P135, DOI 10.1007/S10750-005-1910-X##WIJNHOVEN S, 2006, ENVIRON POLLUT, V140, P444, DOI 10.1016/J.ENVPOL.2005.08.011##WIJNHOVEN S, 2005, ACTA THERIOL, V50, P453, DOI 10.1007/BF03192639##WITTE GR, 1997, MAULWURF TALPA EUROP, P213##ZANDBERG B, 1999, 99001 DIR GEN PUBL W##ZORN MI, 2005, PEDOBIOLOGIA, V49, P189, DOI 10.1016/J.PEDOBI.2004.08.004##ZORN ML, 2004, THESIS VU AMSTERDAM, P121",21,2020-11-20,NA
J,WOS:000241654600001,2006,GROUNDBREAKING PAPERS IN WATER RESEARCH 1967-2006,NA,NA,NA,WATER RESEARCH,"VAN LOOSDRECHT, M","DELFT UNIV TECHNOL, NL-2628 BC DELFT, NETHERLANDS.","ENGINEERING, ENVIRONMENTAL; ENVIRONMENTAL SCIENCES; WATER RESOURCES",ENGINEERING; ENVIRONMENTAL SCIENCES & ECOLOGY; WATER RESOURCES,NA,0,2020-11-20,NA
J,WOS:000241654600004,2006,POTENTIAL PHOSPHORUS RECOVERY IN A WWTP WITH THE BCFS (R) PROCESS: INTERACTIONS WITH THE BIOLOGICAL PROCESS,"THE BCFS (R) PROCESS WAS DEVELOPED TO OPTIMIZE THE ACTIVITY OF DENITRIFYING AND P-REMOVING BACTERIA. IN THIS TECHNOLOGY IN COMBINATION WITH OPTIMAL OPERATING CONDITIONS FOR BIOLOGICAL NITROGEN REMOVAL, CHEMICAL PRECIPITATION OF PHOSPHORUS IS USED TO ENSURE COMPLIANCE WITH EFFLUENT STANDARDS REGARDING PHOSPHORUS. THIS WORK ADDRESSES THE POTENTIAL OF THE BCFS (R) TECHNOLOGY FOR PHOSPHORUS RECOVERY AND THE INTERACTIONS WITH THE BIOLOGICAL PROCESS. THE TUD MODEL CALIBRATED FOR THE HARDENBERG WWTP WAS USED. NITRIFICATION WAS THE BIOLOGICAL PROCESS MOST INFLUENCED BY THE P STRIPPER OPERATION; HOWEVER, FURTHER RESEARCH IS NEEDED INTO THE EFFECT OF LIMITING PHOSPHATE CONCENTRATIONS. PHOSPHATE REMOVAL IN THE ANAEROBIC REACTOR CAUSES A DECREASE IN THE SLUDGE POLY-P CONTENT. THE EVALUATION OF THE PROCESS OPERATION UNDER DYNAMIC CONDITIONS SHOWED THAT THE P STRIPPER USE FOR PHOSPHATE RECOVERY DOES NOT IMPLY COMPLICATED CONTROL STRATEGIES. THE USE OF THE BCFS (R) FOR PHOSPHATE RECOVERY IMPLIES A CHANGE IN THE DESIGN PHILOSOPHY NOT ONLY TO ACHIEVE THE EFFLUENT REQUIREMENTS BUT ALSO TO MAXIMIZE THE ANAEROBIC PHOSPHATE RELEASE AND THEREBY RECOVERY. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",NITROSOMONAS-EUROPAEA; NUTRIENT REMOVAL; POLYPHOSPHATE; SLUDGE,BCFS (R) TECHNOLOGY; BIOLOGICAL WASTEWATER TREATMENT; MODELLING; NITRIFICATION; PHOSPHATE RECOVERY,WATER RESEARCH,"BARAT, R##VAN LOOSDRECHT, MCM","UNIV POLITECN VALENCIA, DEPT HYDRAUL ENGN & ENVIRONM, VALENCIA 46022, SPAIN. DELFT UNIV TECHNOL, DEPT BIOTECHNOL, NL-2628 BC DELFT, NETHERLANDS.","ENGINEERING, ENVIRONMENTAL; ENVIRONMENTAL SCIENCES; WATER RESOURCES",ENGINEERING; ENVIRONMENTAL SCIENCES & ECOLOGY; WATER RESOURCES,"BOUZAS A, 2002, ENVIRON TECHNOL, V23, P863, DOI 10.1080/09593332308618359##CHAIN P, 2003, J BACTERIOL, V185, P2759, DOI 10.1128/JB.185.9.2759-2773.2003##DOYLE JD, 2002, WATER RES, V36, P3925, DOI 10.1016/S0043-1354(02)00126-4##EIGENER U, 1972, ARCH MIKROBIOL, V81, P367, DOI 10.1007/BF00412643##JONSSON K, 2005, C P IWA SPEC C NUTR##KIURU HJ, 1998, WATER SCI TECHNOL, V38, P63, DOI 10.1016/S0273-1223(98)00391-6##MEIJER SCF, 2001, WATER RES, V35, P2711, DOI 10.1016/S0043-1354(00)00567-4##MEIJER SCF, 2004, THESIS TU DELFT NEDE##MINO T, 1998, WATER RES, V32, P3193, DOI 10.1016/S0043-1354(98)00129-8##REICHERT P, 1994, WATER SCI TECHNOL, V30, P21##REOLEVELD PJ, 2001, WATER SCI TECHNOL, V45, P145##TAKACS I, IWA SPEC C NUTR MAN##TERRY KR, 1970, J BACTERIOL, V103, P199, DOI 10.1128/JB.103.1.199-206.1970##VAN LOOSDRECHT MCM, 1998, WATER SCI TECHNOL, V37, P209, DOI 10.1016/S0273-1223(98)00290-X##VANHOOREN H, 1996, 624 COST##VERBANCK M, 1995, JOURNEE ETUDE CBIAWQ##VOLLERTSEN J, 2005, IWA SPEC C NUTR MAN",37,2020-11-20,NA
J,WOS:000241654600019,2006,DEAMOX - NEW BIOLOGICAL NITROGEN REMOVAL PROCESS BASED ON ANAEROBIC AMMONIA OXIDATION COUPLED TO SULPHIDE-DRIVEN CONVERSION OF NITRATE INTO NITRITE,"THIS PAPER REPORTS ABOUT THE SUCCESSFUL LABORATORY TESTING OF A NEW NITROGEN REMOVAL PROCESS CALLED DEAMOX (DENITRIFYING AMMONIUM OXIDATION) FOR TREATMENT OF TYPICAL STRONG NITROGENOUS WASTEWATER SUCH AS BAKER'S YEAST EFFLUENT. THE CONCEPT OF THIS PROCESS COMBINES THE RECENTLY DISCOVERED ANAMMOX (ANAEROBIC AMMONIUM OXIDATION) REACTION WITH AUTOTROPHIC DENITRIFYING CONDITIONS USING SULPHIDE AS AN ELECTRON DONOR FOR THE PRODUCTION OF NITRITE FROM NITRATE WITHIN AN ANAEROBIC BIOFILM. TO GENERATE SULPHIDE AND AMMONIA, A UPFLOW ANAEROBIC SLUDGE BED (UASB) REACTOR WAS USED AS A PRE-TREATMENT STEP. THE UASB EFFLUENT WAS SPLIT AND PARTIALLY FED TO A NITRIFYING REACTOR (TO GENERATE NITRATE) AND THE REMAINING PART WAS DIRECTLY FED TO THE DEAMOX REACTOR WHERE THIS STREAM WAS MIXED WITH THE NITRIFIED EFFLUENT. STABLE PROCESS PERFORMANCE AND VOLUMETRIC NITROGEN LOADING RATES OF THE DEAMOX REACTOR WELL ABOVE 1000 MG N/L/D WITH TOTAL NITROGEN REMOVAL EFFICIENCIES OF AROUND 90% WERE OBTAINED AFTER LONG-TERM (410 DAYS) OPTIMISATION OF THE PROCESS. IMPORTANT PREREQUISITES FOR THIS PERFORMANCE ARE APPROPRIATE INFLUENT RATIOS OF THE KEY SPECIES FED TO THE DEAMOX REACTOR, NAMELY INFLUENT N-NOX/N-NH4 RATIOS > 1.2 (STOICHIOMETRY OF THE ANAMMOX REACTION) AND INFLUENT S-H2S/N-NO3 RATIOS > 0.57 MG S/MG N (STOICHIOMETRY OF THE SULPHIDE-DRIVEN DENITRIFICATION OF NITRATE TO NITRITE). THE PAPER FURTHER DESCRIBES SOME CHARACTERISTICS OF THE DEAMOX SLUDGE AS WELL AS THE PRELIMINARY RESULTS OF ITS MICROBIOLOGICAL CHARACTERISATION. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.",RICH WASTE-WATER; OXYGEN CONCENTRATION; BIOFILM REACTOR; SHARON PROCESS; ANAMMOX; NITRIFICATION; MICROORGANISMS; SLUDGE,ANAMMOX; AUTOTROPHIC DENITRIFICATION; DEAMOX; NITROGEN REMOVAL; SULPHIDE,WATER RESEARCH,"KALYUZHNYI, S##GLADCHENKO, M##MULDER, A##VERSPRILLE, B","MOSCOW MV LOMONOSOV STATE UNIV, FAC CHEM, DEPT CHEM ENZYMOL, MOSCOW 119992, RUSSIA. AMECON, NL-2623 EW DELFT, NETHERLANDS. BIOTHANE SYST INT, NL-2623 EW DELFT, NETHERLANDS.","ENGINEERING, ENVIRONMENTAL; ENVIRONMENTAL SCIENCES; WATER RESOURCES",ENGINEERING; ENVIRONMENTAL SCIENCES & ECOLOGY; WATER RESOURCES,"AMERICAN PUBLIC HEALTH ASSOCIATION, 1995, STAND METH EX WAT WA##BERNET N, 2001, J ENVIRON ENG, V127, P266, DOI 10.1061/(ASCE)0733-9372(2001)127:3(266)##EGLI K, 2001, ARCH MICROBIOL, V175, P198, DOI 10.1007/S002030100255##FUX C, 2002, J BIOTECHNOL, V99, P295, DOI 10.1016/S0168-1656(02)00220-1##GARRIDO JM, 1997, BIOTECHNOL BIOENG, V53, P168##HELLINGA C, 1998, WATER SCI TECHNOL, V37, P135, DOI 10.1016/S0273-1223(98)00281-9##HENZE M., 1997, WASTEWATER TREATMENT##HIPPEN A., 1996, MEDEDELINGEN FACULTEIT LANDBOUWKUNDIGE EN TOEGEPASTE BIOLOGISCHE WETENSCHAPPEN UNIVERSITEIT GENT, V61, P1967##HIPPEN A, 2001, WATER SCI TECHNOL, V44, P39##IMAJO U, 2004, WATER SCI TECHNOL, V49, P155##JETTEN MIKE S. M., 2002, RE/VIEWS IN ENVIRONMENTAL SCIENCE AND BIO/TECHNOLOGY, V1, P51, DOI 10.1023/A:1015191724542##KALYUZHNYI SV, 1996, BIORESOURCE TECHNOL, V55, P47, DOI 10.1016/0960-8524(95)00100-X##KALYUZHNYI SV, 2003, MANUFACTURE ALCOHOL, V3, P20##KARTAL BORAN, 2004, REVIEWS IN ENVIRONMENTAL SCIENCE AND BIO/TECHNOLOGY, V3, P255, DOI 10.1007/S11157-004-7247-5##KOSTER IW, 1989, THESIS WAGENINGEN U##KUAI LP, 1998, APPL ENVIRON MICROB, V64, P4500##LIU Y, 2001, J ENVIRON SCI HEAL A, V36, P1027, DOI 10.1081/ESE-100104129##MULDER A, 1995, FEMS MICROBIOL ECOL, V16, P177, DOI 10.1111/J.1574-6941.1995.TB00281.X##MULDER A, 2006, PATENT NO. 2006022539##MULDER JW, 2001, WATER SCI TECHNOL, V43, P127##NIZINA TN, 2005, COMMUNICATION##PROKOPENKO MG, 2006, EARTH PLANET SC LETT, V242, P186, DOI 10.1016/J.EPSL.2005.11.044##SCHMIDT JE, 2004, WATER SCI TECHNOL, V49, P69##SLIEKERS AO, 2002, WATER RES, V36, P2475, DOI 10.1016/S0043-1354(01)00476-6##STROUS M, 1999, NATURE, V400, P446##STROUS M, 1998, APPL MICROBIOL BIOT, V50, P589, DOI 10.1007/S002530051340##TOKUTOMI T, 2004, WATER SCI TECHNOL, V49, P81##VAN DONGEN U, 2001, WATER SCI TECHNOL, V44, P153##VERSTRAETE W, 1998, ENVIRON POLLUT, V102, P717, DOI 10.1016/S0269-7491(98)80104-8",126,2020-11-20,NA
J,WOS:000242599800002,2006,CAN PHOTOSYNTHESIS-RELATED PARAMETERS BE USED TO ESTABLISH THE ACTIVITY OF ACETOLACTATE SYNTHASE-INHIBITING HERBICIDES ON WEEDS?,"THE APPLICATION OF THE ACETOLACTATE SYNTHASE (ALS)-INHIBITING HERBICIDE METSULFURON ON GREENHOUSE- AND FIELD-GROWN BLACK NIGHTSHADE AND GREENHOUSE-GROWN LADYSTHUMB RESULTED IN PROGRESSIVE INHIBITION OF THE LEVEL OF CARBON DIOXIDE CO2) FIXATION, THE RELATIVE QUANTUM EFFICIENCY OF ELECTRON TRANSPORT THROUGH PHOTOSYSTEM I ((PHI(PSI)) AND II (PHI(PSI)), AND THE LEAF CHLOROPHYLL CONTENT. PHOTOSYNTHETIC-RELATED MEASUREMENTS, MEASURED 2 TO 4 D AFTER TREATMENT (DAT) AT PHOTON FLUX DENSITIES OF 400 TO 500 MU MOL M(-2) S(-1) PROVIDED VALUABLE INFORMATION BEFORE THE VISUAL SYMPTOMS THAT FIRST APPEARED AT 7 TO 10 DAT WITH THE HERBICIDE. MEASUREMENTS OF THE QUANTUM EFFICIENCY FOR ELECTRON TRANSPORT BY PHOTOSYSTEM II AND THE LOSS IN LEAF CHLOROPHYLL CONTENT APPEARED TO BE TWO OF THE MOST PRACTICAL PARAMETERS TO USE WHEN DESIGNING AN EARLY DETECTION METHOD TO ASSESS THE TOXICITY OF METSULFURON. THE USE OF CHLOROPHYLL FLUORESCENCE WOULD REQUIRE A COMPARISON OF STEADY-STATE PHI(PSII) MEASUREMENTS FOR CONTROL AND TREATED PLANTS, WHICH COULD BE REALIZED BY EITHER MEASURING IN TIME (BEFORE/AFTER APPLICATION) OR SPACE (TREATED/ UNTREATED PATCH).",CHLOROPHYLL FLUORESCENCE; ELECTRON-TRANSPORT; MAIZE; LIGHT; ASSIMILATION; TEMPERATURE; METABOLISM; OXIDATION; RESPONSES; GROWTH,ALS; CHLOROPHYLL; FLUORESCENCE; PHOTOSYNTHESIS,WEED SCIENCE,"RIETHMULLER-HAAGE, I##BASTIAANS, L##KROPFF, MJ##HARBINSON, J##KEMPENAAR, C","UNIV WAGENINGEN & RES CTR, CROP & WEED ECOL GRP, DEPT PLANT SCI, NL-6700 AK WAGENINGEN, NETHERLANDS.",AGRONOMY; PLANT SCIENCES,AGRICULTURE; PLANT SCIENCES,"BAKER NR, 2004, J EXP BOT, V55, P1607, DOI 10.1093/JXB/ERH196##BARBAGALLO RP, 2003, PLANT PHYSIOL, V132, P485, DOI 10.1104/PP.102.018093##BARTAK M, 2005, LICHENOLOGIST, V37, P433, DOI 10.1017/S0024282905014945##BERNACCHI CJ, 2002, PLANT PHYSIOL, V130, P1992, DOI 10.1104/PP.008250##BLAIR AM, 1988, PESTIC SCI, V22, P195, DOI 10.1002/PS.2780220303##DE GROOT CC, 2003, J EXP BOT, V54, P1957, DOI 10.1093/JXB/ERG193##DEELL JR, 1999, J FOOD SCI, V64, P501, DOI 10.1111/J.1365-2621.1999.TB15071.X##DEVINE M D, 1989, REVIEWS OF WEED SCIENCE, V4, P191##*EPA US, 2004, PEST MARK EST US 200##GASTON S, 2003, PLANT PHYSIOL, V133, P1351, DOI 10.1104/PP.103.027805##HARBINSON J, 1991, PLANT PHYSIOL, V97, P41, DOI 10.1104/PP.97.1.41##HARBINSON J, 1990, PHOTOSYNTH RES, V25, P213, DOI 10.1007/BF00033162##HARBINSON J, 1993, PLANT PHYSIOL, V103, P649, DOI 10.1104/PP.103.2.649##HARBINSON J, 1990, PLANT PHYSIOL, V94, P545, DOI 10.1104/PP.94.2.545##HARBINSON J, 1987, PLANT CELL ENVIRON, V10, P131, DOI 10.1111/J.1365-3040.1987.TB02089.X##INSKEEP WP, 1985, PLANT PHYSIOL, V77, P483, DOI 10.1104/PP.77.2.483##JUDY B. M., 1990, PROCEEDINGS OF THE 43RD ANNUAL MEETING OF THE SOUTHERN WEED SCIENCE SOCIETY., P358##JUDY BM, 1991, PLANT PHYTOTOXICITY, P308##KEMPENAAR C, 2004, DECISION SUPPORT SYSTEMS IN POTATO PRODUCTION: BRINGING MODELS TO PRACTICE, P186##KEMPENAAR C, 2002, 12TH EWRS (EUROPEAN WEED RESEARCH SOCIETY) SYMPOSIUM 2002, WAGENINGEN, PROCEEDINGS, P98##KETEL DH, 1996, WEED SCI, V44, P1##KINGSTON-SMITH AH, 1999, PLANT CELL ENVIRON, V22, P1071, DOI 10.1046/J.1365-3040.1999.00469.X##KINGSTONSMITH AH, 1997, PLANT PHYSIOL, V114, P1039, DOI 10.1104/PP.114.3.1039##LICHTENTHALER HK, 1988, CRC CR REV ANAL CHEM, V19, PS29, DOI 10.1080/15476510.1988.10401466##MYERS DA, 1999, TREE PHYSIOL, V19, P235##NEDBAL L, 2000, PHOTOSYNTH RES, V66, P3, DOI 10.1023/A:1010729821876##ODASZ-ALBRIGTSEN AM, 2000, CAN J BOT, V78, P1021, DOI 10.1139/CJB-78-8-1021##PERCIVAL M. P., 1991, HERBICIDES., P1##PETERSON DE, 2001, HERBICIDE MODE ACTIO##POPOVIC R., 2003, PRACTICAL APPLICATIONS OF CHLOROPHYLL FLUORESCENCE IN PLANT BIOLOGY, P151##RASCHER U, 2000, PLANT CELL ENVIRON, V23, P1397, DOI 10.1046/J.1365-3040.2000.00650.X##RHODES D, 1987, PLANT PHYSIOL, V84, P775, DOI 10.1104/PP.84.3.775##RIETHMULLER-HAAGE I, 2006, PHOTOSYNTH RES, V88, P331, DOI 10.1007/S11120-006-9062-Z##SCHREIBER U, 2003, PAM NEWS, V1, P1##SHANER DL, 1991, PLANT PHYSIOL, V97, P1339, DOI 10.1104/PP.97.4.1339##SHANER DL, 1992, BIOSYNTHESIS MOL REG##SUTTLE JC, 1982, CAN J BOT, V60, P741, DOI 10.1139/B82-097##TISSUE DT, 1997, OECOLOGIA, V109, P28, DOI 10.1007/S004420050054",17,2020-11-20,NA
J,WOS:000242298700003,2006,ESTIMATING THE ANGLE OF ATTACK FROM BLADE PRESSURE MEASUREMENTS ON THE NREL PHASE VI ROTOR USING A FREE WAKE VORTEX MODEL: AXIAL CONDITIONS,"BLADE ELEMENT MOMENTUM (BEM) METHODS ARE STILL THE MOST COMMON METHODS USED FOR PREDICTING THE AERODYNAMIC LOADS DURING THE AEROELASTIC DESIGN OF WIND TURBINE BLADES. HOWEVER, THEIR ACCURACY IS LIMITED BY THE AVAILABILITY OF RELIABLE AEROFOIL DATA. OWING TO THE 3D NATURE OF THE FLOW OVER WIND TURBINE BLADES, THE AEROFOIL CHARACTERISTICS WILL VARY CONSIDERABLY FROM THE 2D AEROFOIL CHARACTERISTICS, ESPECIALLY AT THE INBOARD SECTIONS OF THE BLADES. DETAILED SURFACE PRESSURE MEASUREMENTS ON THE BLADE SURFACES MAY BE USED TO DERIVE MORE REALISTIC AEROFOIL DATA. HOWEVER, IN DOING SO, KNOWLEDGE OF THE ANGLE OF ATTACK DISTRIBUTIONS IS REQUIRED THIS STUDY PRESENTS A METHOD IN WHICH A FREE WAKE VORTEX MODEL IS USED TO DERIVE SUCH DISTRIBUTIONS FOR THE NREL PHASE VI WIND TURBINE UNDER DIFFERENT OPERATING CONDITIONS. THE DERIVED FREE WOKE GEOMETRY SOLUTIONS ARE PLOTTED TOGETHER WITH THE CORRESPONDING WAKE CIRCULATION DISTRIBUTION. THESE PLOTS PROVIDE BETTER INSIGHT INTO HOW CIRCULATION FORMED AT THE BLADES IS EVENTUALLY DIFFUSED INTO THE WOKE. THE FREE WAKE MODEL IS DESCRIBED AND ITS NUMERICAL BEHAVIOUR IS EXAMINED. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",NA,WIND TURBINE; AEROFOIL DATA; NREL PHASE VI EXPERIMENTS; FREE WAKE VORTEX MODEL; WAKE CIRCULATION,WIND ENERGY,"SANT, T##VAN KUIK, G##VAN BUSSEL, GJW","UNIV MALTA, FAC ENGN, DEPT MECH ENGN, MSIDA 07, MALTA. DELFT UNIV TECHNOL, FAC AEROSP ENGN, SECT WIND ENERGY, NL-2629 HS DELFT, NETHERLANDS.","ENERGY & FUELS; ENGINEERING, MECHANICAL",ENERGY & FUELS; ENGINEERING,"ANANTHAN S, 2002, 58 ANN FOR TECHN DIS##BAGAI A, 1995, J AM HELICOPTER SOC, V40, P29, DOI 10.4050/JAHS.40.29##BRUINING A, 1993, DUTIVW93065R##CHAVIAROPOULOS PK, 2000, J FLUID ENG-T ASME, V122, P330, DOI 10.1115/1.483261##DU ZH, 1998, 980021 AIAA##GERBER B, 2004, P SPEC TOP C SCI MAK, P98##GIGUERE P., 1999, NRELSR50026173##GUPTA S, 2004, 20040828 AIAA##HAND M M, 2001, NRELTP50029955##HIMMELSKAMP H., 1947, THESIS GOTTINGEN##JOHANSEN J, 2004, P SPEC TOP C SCI MAK, P9##LAINO DJ, 2002, WIND ENERGY, V5, P227, DOI DOI 10.1002/WE.69##LEISHMAN J.G., 2000, PRINCIPLES HELICOPTE##LEISHMAN JG, 2002, J AIRCRAFT, V39, P759, DOI 10.2514/2.3022##LINDENBURG C, 2003, ECNC03025##RONSTEN G, 1991, P EWEC 91, P214##SANT T, 2004, P EWEA C LOND, P117##SCHMITZ S, 2005, 20050593 AIAA##SCHRECK S, 2002, WIND ENERGY, V5, P77, DOI DOI 10.1002/WE.72##SCHRECK S, 2004, P SPEC TOP C SCI MAK, P166##SCHRECK S, 2003, 20030520 AIAA##SNEL H., 1993, ECNC93052##SORENSEN N. N., 2002, WIND ENERGY, V5, P151, DOI DOI 10.1002/WE.64##TANGLER J. L., 2002, WIND ENERGY, V5, P245##TANGLER JL, 2004, WIND ENERGY, V7, P247, DOI 10.1002/WE.122##TONGCHITPAKDEE C, 2005, 20050773 AIAA##VAN GARREL A, 2003, ECNC03079##VAN ROOIJ R.P.O.M., 2002, P WORLD WIND EN C EX##VANROOIJ RPJ, 1996, DUTIW96087R##VANROOIJ RPJ, 2003, P EWEA C MADR##VERMEER LJ, 2001, 20010030 AIAA",58,2020-11-20,NA
J,WOS:000242298700004,2006,INTEGRATION OF WIND POWER IN THE LIBERALIZED DUTCH ELECTRICITY MARKET,"WIND POWER IS BECOMING A LARGE-SCALE ELECTRICITY GENERATION TECHNOLOGY IN A NUMBER OF EUROPEAN COUNTRIES, INCLUDING THE NETHERLANDS. OWING TO THE VARIABILITY AND UNPREDICTABILITY OF WIND POWER PRODUCTION, LARGE-SCALE WIND POWER CAN BE FORESEEN TO HAVE LARGE CONSEQUENCES FOR BALANCING GENERATION AND DEMAND IN POWER SYSTEMS. AS AN ESSENTIAL ASPECT OF THE DUTCH MARKET DESIGN, PARTICIPANTS ARE ENCOURAGED TO ACT ACCORDING TO THEIR ENERGY PROGRAMS, AS SUBMITTED DAY-AHEAD TO THE SYSTEM OPERATOR. THIS PROGRAM RESPONSIBILITY SHIFTS THE BURDEN OF BALANCING WIND POWER AWAY FROM THE SYSTEM OPERATOR TO THE MARKET. HOWEVER, THE SYSTEM OPERATOR REMAINS THE RESPONSIBLE PARTY FOR BALANCING ANY GENERATION/LOAD IMBALANCES THAT MAY STILL BE ARISING IN REAL TIME. IN THIS ARTICLE, FEATURES THAT ARE UNIQUE FOR THE DUTCH MARKET DESIGN ARE PRESENTED AND THEIR IMPLICATIONS ON THE SYSTEM INTEGRATION OF WIND POWER ARE INVESTIGATED. IT IS SHOWN THAT THE DUTCH MARKET DESIGN PENALIZES THE INTERMITTENT NATURE OF WIND POWER. A DISCUSSION OF OPPORTUNITIES AND THREATS OF BALANCING WIND POWER BY USE OF MARKET FORCES IS PROVIDED. LAST, AN OUTLINE IS GIVEN OF FUTURE WORK. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.",NA,WIND POWER; MARKET; POWER SYSTEM BALANCING; PROGRAM RESPONSIBLE PARTIES,WIND ENERGY,"UMMELS, BC##GIBESCU, M##KLING, WL##PAAP, GC","DELFT UNIV TECHNOL, ELECT POWER SYST GRP, NL-2628 CD DELFT, NETHERLANDS. EINDHOVEN UNIV TECHNOL, POWER SYST LAB, NL-5600 MB EINDHOVEN, NETHERLANDS. TENNET BV, ARNHEM, NETHERLANDS.","ENERGY & FUELS; ENGINEERING, MECHANICAL",ENERGY & FUELS; ENGINEERING,"[ANONYMOUS], 2004, INT WIND POW EUR POW##AUER H, 2004, COST TECHNICAL CONST##BEUNE R, 2006, P METH SEC PEAK LOAD##*BUND WIND, 2004, REG LEIST WIND##DANY G, 2000, THESIS RTWH AACHEN G##DOHERTY R, 2003, IEEE BOL POW TECHN C, P7##*DTE DUTCH OFF EN, 2006, SYST##*EN DK, 2004, SYST PLAN 2004##*EON NETZ, 2004, WIND REP 2004##*EWEA, 2006, WIND POW INST EUR EN##GOUVEIA EM, 2004, 8 INT C PROB METH AP##HOLTTINEN H, 2004, THESIS HELSINKI U TE##HUTTING HK, 1999, P EUR WIND EN C NIC, P399##*ILEX EN CONS, 2004, OP RES REQ WIND POW##JENSEN JK, 2002, ENERGINET DK WIND EN##JENSEN JK, 2002, NEW CHALLENGES TRANS##MILBORROW D, 2004, WINDPOWER MONTHLY, V20, P2##SLOOTWEG JG, 2002, INPASSING WINDVERMOG, P30##STRBAC G, 2002, 080SCAR ILEX EN CONS##TENNE T, 2002, IMPLEMENTATION RULES##TENNE T, 2002, BSNES06064##*UCTE, 2006, POL 1 LOAD FREQ CONT##*UCTE, 2004, IN PRESS WIND POW UC##UMMELS BC, 2005, P COP OFFSH WIND##UMMELS BC, 2006, P IEEE PES GEN M MON",17,2020-11-20,NA
J,WOS:000241331900009,2006,CROSSOVER OF BURNOUT AND ENGAGEMENT IN WORK TEAMS,"THIS STUDY INVESTIGATES THE CROSSOVER OF BURNOUT AND WORK ENGAGEMENT AMONG 2,229 ROYAL DUTCH CONSTABULARY OFFICERS, WORKING IN ONE OF 85 TEAMS. THE AUTHORS HYPOTHESIZED THAT BOTH STATES MAY TRANSFER FROM TEAMS TO INDIVIDUAL TEAM MEMBERS. THE RESULTS OF MULTILEVEL ANALYSES CONFIRM THIS CROSSOVER PHENOMENON BY SHOWING THAT TEAM-LEVEL BURNOUT AND WORK ENGAGEMENT ARE RELATED TO INDIVIDUAL TEAM MEMBERS' BURNOUT (I.E., EXHAUSTION, CYNICISM, AND REDUCED PROFESSIONAL EFFICACY) AND WORK ENGAGEMENT (VIGOR, DEDICATION, AND ABSORPTION), AFTER CONTROLLING FOR INDIVIDUAL MEMBERS' JOB DEMANDS AND RESOURCES. THE IMPLICATIONS OF THESE FINDINGS FOR INTERVENTIONS AIMED AT THE PROMOTION OF EMPLOYEE WELL-BEING ARE DISCUSSED.",DEMANDS-RESOURCES MODEL; JOB DEMANDS; PERFORMANCE; SATISFACTION; CONTAGION; ABSENCE; LEVEL,BURNOUT; CROSSOVER; EMOTIONAL CONTAGION; WORK ENGAGEMENT,WORK AND OCCUPATIONS,"BAKKER, AB##VAN EMMERIK, H##EUWEMA, MC","ERASMUS UNIV, ROTTERDAM, NETHERLANDS. UNIV UTRECHT, DEPT SOCIOL, NL-3508 TC UTRECHT, NETHERLANDS. UNIV UTRECHT, DEPT SOCIAL & ORG PSYCHOL, NL-3508 TC UTRECHT, NETHERLANDS.",INDUSTRIAL RELATIONS & LABOR; SOCIOLOGY,BUSINESS & ECONOMICS; SOCIOLOGY,"BAKKER A. B., 2003, INT J STRESS MANAGE, V10, P16, DOI DOI 10.1037/1072-5245.10.1.16##BAKKER AB, 2005, J ADV NURS, V51, P276, DOI 10.1111/J.1365-2648.2005.03494.X##BAKKER AB, 2003, ADV PSY RES, V25, P13##BAKKER AB, 2004, HUM RESOUR MANAGE-US, V43, P83, DOI 10.1002/HRM.20004##BAKKER AB, 2003, J VOCAT BEHAV, V62, P341, DOI 10.1016/S0001-8791(02)00030-1##BAKKER AB, 2002, ANXIETY STRESS COPIN, V15, P245, DOI 10.1080/1061580021000020716##BAKKER AB, 2001, J SOC CLIN PSYCHOL, V20, P82, DOI 10.1521/JSCP.20.1.82.22251##BAKKER AB, 2000, J APPL SOC PSYCHOL, V30, P2289, DOI 10.1111/J.1559-1816.2000.TB02437.X##BAVELAS JB, 1987, EMPATHY ITS DEV, P317##BERNIERI FJ, 1988, J PERS SOC PSYCHOL, V54, P243, DOI 10.1037/0022-3514.54.2.243##BURKE RJ, 1995, HUM RELAT, V48, P187, DOI 10.1177/001872679504800205##BUUNK BP, 1993, S AP PSYC S, P53##CHANG A, 2001, SMALL GR RES, V32, P379, DOI 10.1177/104649640103200401##CHERNISS C., 1980, PROFESSIONAL BURNOUT##DEMEROUTI E, 2000, J ADV NURS, V32, P454, DOI 10.1046/J.1365-2648.2000.01496.X##DEMEROUTI E, 2001, J APPL PSYCHOL, V86, P499, DOI 10.1037//0021-9010.86.3.499##DEVINE DJ, 1999, SMALL GR RES, V30, P678, DOI 10.1177/104649649903000602##EDELWICH J., 1980, BURNOUT STAGES DISIL##FIRTH H, 1989, J OCCUP PSYCHOL, V62, P55, DOI 10.1111/J.2044-8325.1989.TB00477.X##FURDA J, 1995, THESIS UTRECHT U NET##GOLEMBIEWSKI RT, 1996, PUBLIC PRODUCTIVITY, V20, P56##GRAEN G. B., 1991, J MANAGEMENT SYSTEMS, V3, P25##GULLY SM, 2002, J APPL PSYCHOL, V87, P819, DOI 10.1037/0021-9010.87.5.819##HACKMAN J. R., 1980, WORK REDESIGN##HARTER JK, 2002, J APPL PSYCHOL, V87, P268, DOI 10.1037/0021-9010.87.2.268##HATFIELD E., 1994, EMOTIONAL CONTAGION##HOX J., 2002, MULTILEVEL ANAL TECH##HSEE CK, 1990, COGNITION EMOTION, V4, P327, DOI 10.1080/02699939008408081##JACKSON SE, 1986, J APPL PSYCHOL, V71, P630, DOI 10.1037/0021-9010.71.4.630##KAHILL S, 1988, CAN PSYCHOL, V29, P284, DOI 10.1037/H0079772##KARASEK R. A., 1985, JOB CONTENT QUESTION##LAIRD JD, 1984, J PERS SOC PSYCHOL, V47, P909, DOI 10.1037/0022-3514.47.4.909##LEBLANC P, 1994, THESIS AMSTERDAM##LEITER MP, 1996, ANXIETY STRESS COPIN, V9, P229, DOI 10.1080/10615809608249404##MASLACH C, 1996, MASLACH BURNOUT INVE##MASLACH C, 1997, TRUTH BURNOUT ORG CA##ORGAN DW, 1994, J MANAGE, V20, P465, DOI 10.1177/014920639402000208##PETTY R. E., 1986, ADV EXPT SOCIAL PSYC, P123, DOI DOI 10.1016/S0065-2601(08)60214-2##SALANOVA M, 2005, J APPL PSYCHOL, V90, P1217, DOI 10.1037/0021-9010.90.6.1217##SALANOVA M, 2002, J HAPPINESS STUD, V3, P71, DOI [DOI 10.1023/A:1015630930326, 10.1023/A]##SCHAUFELI W, 1998, BURNOUT COMPANION ST##SCHAUFELI W. B., 2001, GEDRAG ORGAN, V14, P229##SCHAUFELI W.B., 1996, MASLACH BURNOUT INVE##SCHAUFELI W.B., 2003, UTRECHT WORK ENGAGEM##SCHAUFELI WB, 2002, J CROSS CULT PSYCHOL, V33, P464, DOI 10.1177/0022022102033005003##SCHAUFELI WB, 2004, J ORGAN BEHAV, V25, P293, DOI 10.1002/JOB.248##SCHAUFELI WB, 2001, PSYCHOLOOG, V36, P422##SHIROTA A., 1989, INTERNATIONAL JOURNAL OF AQUACULTURE AND FISHERIES TECHNOLOGY, V1, P25##SIEGMAN AW, 1982, INTERACTION RHYTHMS, P249##SNIJDERS T.A.B., 1999, MULTILEVEL ANAL INTR##SONNENTAG S, 1994, J OCCUP ORGAN PSYCH, V67, P327, DOI 10.1111/J.2044-8325.1994.TB00571.X##TOTTERDELL P, 2000, J APPL PSYCHOL, V85, P848, DOI 10.1037/0021-9010.85.6.848##VAN DIERENDONCK D., 2000, UBOS UTRECHTSE BURNO##VAN VELDHOVEN M, 1994, METEN PSYCHOSOCIALE##WESTMAN M, 1999, J OCCUP HEALTH PSYCHOL, V4, P269, DOI 10.1037/1076-8998.4.3.269##WESTMAN M, 2001, HUM RELAT, V54, P717, DOI 10.1177/0018726701546002##WESTMAN M., 2002, RES OCCUPATIONAL STR, V2, P143, DOI DOI 10.1016/S1479-3555(02)02004-8##WOLPIN J, 1991, HUM RELAT, V44, P193, DOI 10.1177/001872679104400205",253,2020-11-20,NA
J,WOS:000242154500015,2006,FALSE-POSITIVE LESIONS DETECTED BY FLUORESCENCE CYSTOSCOPY: ANY ASSOCIATION WITH P53 AND P16 EXPRESSION?,"TO DETERMINE P53 AND P16 STATUS AS MOLECULAR MARKERS OF BLADDER CANCER, IN HISTOLOGICALLY PROVEN BENIGN BLADDER BIOPSIES, OBTAINED FROM LESIONS SUSPECT FOR MALIGNANCY AS JUDGED BY FLUORESCENCE CYSTOSCOPY. IMMUNOHISTOCHEMICAL (IHC) STAINING WAS PERFORMED FOR P53 AND P16, USING THE ANTIBODIES DO-7 AND AB-4, RESPECTIVELY. THE TISSUE SECTIONS WERE SCORED IN PERCENTAGES OF NUCLEAR STAINING FOR P53 AND P16. OF 247 BIOPSIES, 41/49 LESIONS APPEARED SUSPICIOUS ON FLUORESCENCE CYSTOSCOPY, BUT WERE HISTOPATHOLOGICALLY BENIGN. 2/40 (5%) WERE >= 20% P53 POSITIVE AS COMPARED TO 7/128 (5.5%) OF ALL HISTOPATHOLOGICALLY BENIGN BIOPSIES. 24/37 (64.9%) WERE P16 NEGATIVE (< 5% POSITIVE CELLS) AS COMPARED TO 84/125 (67.2%) OF ALL BENIGN BIOPSIES. MOST BIOPSIES HAD A MODERATE TO HIGH DEGREE OF CHRONIC CYSTITIS. FALSE POSITIVE LESIONS OF FLUORESCENCE CYSTOSCOPY DID NOT DIFFER FROM BENIGN LESIONS DETECTED BY STANDARD WHITE LIGHT CYSTOSCOPY WITH REGARD TO P53 AND P16 IMMUNOREACTIVITY. LITTLE EVIDENCE REMAINS FOR THESE LESIONS TO BE PRE-MALIGNANT.",TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; NUCLEAR ACCUMULATION; UROTHELIAL CARCINOMA; GENETIC ALTERATIONS; CHROMOSOME-9; PREVALENCE; MUTATIONS; STAGE,BLADDER CANCER; HEXAMINOLEVULINATE; FLUORESCENCE CYSTOSCOPY; P53; P16,WORLD JOURNAL OF UROLOGY,"HENDRICKSEN, K##MOONEN, PMJ##DER HEIJDEN, AG##WITJES, JA","RADBOUD UNIV NIJMEGEN, MED CTR, DEPT UROL, NL-6500 HB NIJMEGEN, NETHERLANDS.",UROLOGY & NEPHROLOGY,UROLOGY & NEPHROLOGY,"BAUD E, 1998, INT J CANCER, V77, P821, DOI 10.1002/(SICI)1097-0215(19980911)77:6<821::AID-IJC3>3.3.CO;2-M##CORDONCARDO C, 1994, INT J CANCER, V56, P347, DOI 10.1002/IJC.2910560309##CORDONCARDO C, 1994, ADV ONCOLOGY, P71##EPSTEIN JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001##ESRIG D, 1993, AM J PATHOL, V143, P1389##FILBECK T, 1999, UROLOGY, V53, P77, DOI 10.1016/S0090-4295(98)00430-0##FRIEDRICH MG, 2001, EUR UROL, V40, P518, DOI 10.1159/000049829##GRIMBERGEN MCM, 2003, EUR UROL, V44, P51, DOI 10.1016/S0302-2838(03)00210-0##HERMANN GG, 1998, J UROLOGY, V159, P91, DOI 10.1016/S0022-5347(01)64021-7##JICHLINSKI P, 2003, J UROLOGY, V170, P226, DOI 10.1097/01.JU.0000060782.52358.04##JOCHAM D, 2005, J UROLOGY, V174, P862, DOI 10.1097/01.JU.0000169257.19841.2A##JUNKER K, 2003, UROLOGY, V62, P1134, DOI 10.1016/S0090-4295(03)00692-7##MALATS W, 2005, LANCET ONCOL, V6, P678##MCSHANE LM, 2000, CLIN CANCER RES, V6, P1854##OBERMANN EC, 2003, J PATHOL, V199, P50, DOI 10.1002/PATH.1259##SCHMIDBAUER J, 2004, J UROLOGY, V171, P135, DOI 10.1097/01.JU.0000100480.70769.0E##SHARIAT SF, 2000, UROLOGY, V56, P735, DOI 10.1016/S0090-4295(00)00756-1##SIMONEAU AR, 1996, CANCER RES, V56, P5039##STOEHR R, 2005, EUR UROL, V47, P58, DOI 10.1016/J.EURURO.2004.07.012##TZAI TS, 2004, UROL ONCOL-SEMIN ORI, V22, P112, DOI 10.1016/S1078-1439(03)00176-5",10,2020-11-20,NA
J,WOS:000242916600005,2006,THE KIT LIGAND/C-KIT RECEPTOR SYSTEM IN GOAT OVARIES: GENE EXPRESSION AND PROTEIN LOCALIZATION,"RELATIVELY LITTLE INFORMATION IS AVAILABLE ON THE LOCAL FACTORS THAT REGULATE FOLLICULOGENESIS IN GOATS. TO EXAMINE THE POSSIBILITY THAT THE KIT LIGAND (KL) SYSTEM IS EXPRESSED THROUGHOUT THE FOLLICULOGENESIS, WE STUDIED THE PRESENCE AND DISTRIBUTION OF KL AND ITS RECEPTOR, C-KIT, IN GOAT OVARIES. OVARIES OF GOATS WERE COLLECTED AND EITHER FIXED IN PARAFORMALDEHYDE FOR IMMUNOHISTOCHERNICAL LOCALIZATION OF KL AND C-KIT PROTEINS, OR USED FOR THE ISOLATION OF FOLLICLES, LUTEAL CELLS, SURFACE EPITHELIUM AND MEDULLARY SAMPLES TO STUDY MRNA EXPRESSION FOR KL AND C-KIT, USING THE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (RTPCR). KL PROTEIN AND MRNA WERE FOUND IN FOLLICLES AT ALL STAGES OF DEVELOPMENT, I.E. PRIMORDIAL, PRIMARY, SECONDARY, SMALL AND LARGE ANTRAL FOLLICLES, AS WELL AS IN CORPORA LUTEA, SURFACE EPITHELIUM AND MEDULLARY TISSUE. ANTRAL FOLLICLES EXPRESSED BOTH KL-1 AND KL-2 MRNAS, WHILE EARLIER STAGED FOLLICLES EXPRESSED KL-I TRANSCRIPT ONLY. KL PROTEIN WAS DEMONSTRATED IN GRANULOSA CELLS FROM THE PRIMORDIAL FOLLICLE ONWARD. ITS MRNA COULD BE DETECTED IN GRANULOSA CELLS ISOLATED FROM ANTRAL FOLLICLES AND OCCASIONALLY IN THEIR THECA CELLS. C-KIT MRNA WAS EXPRESSED IN ALL ANTRAL FOLLICULAR COMPARTMENTS AND AT ALL STAGES OF FOLLICULAR DEVELOPMENT. C-KIT PROTEIN WAS PREDOMINANTLY FOUND IN OOCYTES FROM THE PRIMORDIAL FOLLICLE STAGE ONWARDS, IN THECA CELLS OF ANTRAL FOLLICLES, AS WELL AS IN CORPORA LUTEA, SURFACE EPITHELIUM AND MEDULLARY TISSUE, PARTICULARLY IN THE WALL OF BLOOD VESSELS, WHICH MAY INDICATE THESE CELLS AS THE MAIN SITES OF ACTION OF KL. IT IS CONCLUDED THAT THE KL/C-KIT SYSTEM, IN GOAT OVARIES, IS WIDESPREAD AND THAT IT MAY BE INVOLVED IN THE REGULATION OF VARIOUS LOCAL PROCESSES, INCLUDING FOLLICULOGENESIS AND LUTEAL ACTIVITY.",STEM-CELL FACTOR; MESSENGER-RIBONUCLEIC-ACID; SURFACE EPITHELIAL-CELLS; C-KIT; FOLLICLE DEVELOPMENT; GROWTH-FACTOR; PREANTRAL FOLLICLES; TYROSINE KINASE; FETAL OVARIES; CORPUS-LUTEUM,C-KIT; FOLLICLES; GOAT; KIT LIGAND; OVARY,ZYGOTE,"SILVA, JRV##VAN DEN HURK, R##VAN TOL, HTA##ROELEN, BAJ##FIGUEIREDO, JR","UNIV ESTADUAL CEARA, FAC VET MED, BR-60740000 FORTALEZA, CEARA, BRAZIL. UNIV UTRECHT, FAC VET MED, DEPT FARM ANIM HLTH, UTRECHT, NETHERLANDS.",CELL BIOLOGY; DEVELOPMENTAL BIOLOGY; REPRODUCTIVE BIOLOGY,CELL BIOLOGY; DEVELOPMENTAL BIOLOGY; REPRODUCTIVE BIOLOGY,"ALLARD EK, 1996, BIOL REPROD, V55, P185, DOI 10.1095/BIOLREPROD55.1.185##BEDELL MA, 1995, GENE DEV, V9, P455, DOI 10.1101/GAD.9.4.455##BRANKIN VICTORIA, 2003, REPROD BIOL ENDOCRINOL, V1, P55, DOI 10.1186/1477-7827-1-55##BROUDY VC, 1997, BLOOD, V90, P1345, DOI 10.1182/BLOOD.V90.4.1345.1345_1345_1364##CLARK DE, 1996, J REPROD FERTIL, V106, P329, DOI 10.1530/JRF.0.1060329##DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809A0##DRIANCOURT MA, 2000, REV REPROD, V5, P143, DOI 10.1530/REVREPROD/5.3.143##ECKERY DC, 2002, BIOL REPROD, V66, P346, DOI 10.1095/BIOLREPROD66.2.346##EPPIG JJ, 2001, REPRODUCTION, V122, P829, DOI 10.1530/REP.0.1220829##GENTRY PC, 1996, BIOL REPROD, V54, P970, DOI 10.1095/BIOLREPROD54.5.970##GENTRY PC, 1998, BIOL REPROD, V59, P983, DOI 10.1095/BIOLREPROD59.4.983##GOUGEON A, 2000, MOL CELL ENDOCRINOL, V163, P33, DOI 10.1016/S0303-7207(00)00220-3##HORIE K, 1991, BIOL REPROD, V45, P547, DOI 10.1095/BIOLREPROD45.4.547##HOYER PE, 2005, MOL CELL ENDOCRINOL, V234, P1, DOI 10.1016/J.MCE.2004.09.012##HUANG CTF, 2001, BIOL REPROD, V64, P451, DOI 10.1095/BIOLREPROD64.2.451##HUANG EJ, 1993, DEV BIOL, V157, P100, DOI 10.1006/DBIO.1993.1115##HUANG EJ, 1992, MOL BIOL CELL, V3, P349##ISMAIL RS, 1996, MOL REPROD DEV, V43, P458, DOI 10.1002/(SICI)1098-2795(199604)43:4&LT;458::AID-MRD8&GT;3.0.CO;2-O##ISMAIL RS, 1999, ONCOGENE, V18, P4734, DOI 10.1038/SJ.ONC.1202865##JUENGEL JL, 2000, BIOL REPROD, V62, P1467, DOI 10.1095/BIOLREPROD62.6.1467##KANG JS, 2003, J HISTOCHEM CYTOCHEM, V51, P1447, DOI 10.1177/002215540305101105##KURODA H, 1988, DEV BIOL, V126, P71, DOI 10.1016/0012-1606(88)90240-0##LAITINEN M, 1995, ENDOCRINOLOGY, V136, P4407, DOI 10.1210/EN.136.10.4407##LUCCI CM, 1999, ANIM REPROD SCI, V56, P39, DOI 10.1016/S0378-4320(99)00031-7##MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/DBIO.1993.1114##MANOVA K, 1990, DEVELOPMENT, V110, P1057##MCNATTY KP, 1999, J REPROD FERTIL, P3##MIYAMOTO T, 1997, ATHEROSCLEROSIS, V129, P207, DOI 10.1016/S0021-9150(96)06043-1##MOTRO B, 1993, DEV DYNAM, V197, P69, DOI 10.1002/AJA.1001970107##NILSSON E, 2001, J SOC GYNECOL INVEST, V8, PS17, DOI 10.1016/S1071-5576(00)00099-X##OTSUKA F, 2002, P NATL ACAD SCI USA, V99, P8060, DOI 10.1073/PNAS.122066899##PARROTT JA, 1999, ENDOCRINOLOGY, V140, P4262, DOI 10.1210/EN.140.9.4262##PARROTT JA, 2000, MOL REPROD DEV, V55, P55, DOI 10.1002/(SICI)1098-2795(200001)55:1&LT;55::AID-MRD8&GT;3.0.CO;2-L##PARROTT JA, 1997, ENDOCRINOLOGY, V138, P3819, DOI 10.1210/EN.138.9.3819##PARROTT JA, 2000, ENDOCRINOLOGY, V141, P2532, DOI 10.1210/EN.141.7.2532##REYNAUD K, 2000, MOL REPROD DEV, V56, P483, DOI 10.1002/1098-2795(200008)56:4&LT;483::AID-MRD6&GT;3.0.CO;2-O##SILVA JRV, 2005, MOL REPROD DEV, V70, P11, DOI 10.1002/MRD.20127##TISDALL DJ, 1997, J MOL ENDOCRINOL, V18, P127, DOI 10.1677/JME.0.0180127##TISDALL DJ, 1999, J REPROD FERTIL, V116, P277, DOI 10.1530/JRF.0.1160277##VAN DEN HURK R, 2005, THERIOGENOLOGY, V63, P1717, DOI 10.1016/J.THERIOGENOLOGY.2004.08.005##VAN TOL HTA, 1998, MOL REPROD DEV, V51, P315, DOI 10.1002/(SICI)1098-2795(199811)51:3&LT;315::AID-MRD11&GT;3.0.CO;2-1##VANDENHURK R, 1994, J REPROD FERTIL, V100, P137, DOI 10.1530/JRF.0.1000137##YOSHIDA H, 1997, DEV BIOL, V184, P122, DOI 10.1006/DBIO.1997.8503",36,2020-11-20,NA
J,WOS:000242317500072,2006,EFFECTS OF UV PHOTON IRRADIATION ON SIOX (0 < X < 2) STRUCTURAL PROPERTIES,"THIN FILMS OF A-SIOX (0 < X < 2) WERE PREPARED BY REACTIVE R.F. MAGNETRON SPUTTERING FROM A POLYCRYSTALLINE-SILICON TARGET IN AN AR/O-2 GAS MIXTURE. THE OXYGEN PARTIAL PRESSURE IN THE DEPOSITION CHAMBER WAS VARIED SO AS TO OBTAIN FILMS WITH DIFFERENT VALUES OF X. THE PLASMA WAS MONITORED, DURING DEPOSITIONS, BY OPTICAL EMISSION SPECTROSCOPY (OES) SYSTEM. ENERGY DISPERSIVE X-RAY (EDX) MEASUREMENTS AND INFRA-RED (IR) SPECTROSCOPY WERE USED TO STUDY THE COMPOSITIONAL AND STRUCTURAL PROPERTIES OF THE DEPOSITED LAYERS. STRUCTURAL MODIFICATIONS OF SIOX THIN FILMS HAVE BEEN INDUCED BY UV PHOTONS' BOMBARDMENT (WAVELENGTH OF 248 NM) USING A PULSED LASER. IR SPECTROSCOPY AND X-RAY PHOTOEMISSION SPECTROSCOPY (XPS) WERE USED TO INVESTIGATE THE STRUCTURAL CHANGES AS A FUNCTION OF X VALUE AND INCIDENT ENERGY. SIOX PHASE SEPARATION BY SPINODAL DECOMPOSITION WAS REVEALED. THE IR PEAK POSITION SHIFTED TOWARDS HIGH WAVENUMBER VALUES WHEN THE LASER ENERGY IS INCREASED. VALUES CORRESPONDING TO THE SIO2 MATERIAL (ONLY SI4+) HAVE BEEN FOUND FOR LASER IRRADIATED SAMPLES, INDEPENDENTLY ON THE ORIGINAL X VALUE. THE PHASE SEPARATION PROCESS HAS A THRESHOLD ENERGY THAT IS IN AGREEMENT WITH THEORETICAL VALUES CALCULATED FOR THE DISSOCIATION ENERGY OF THE INVESTIGATED MATERIAL. FOR HIGH VALUES OF THE LASER ENERGY, CRYSTALLINE SILICON EMBEDDED IN OXYGEN-RICH SILICON OXIDE WAS REVEALED BY RAMAN SPECTROSCOPY. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",CRYSTALLIZATION; INTERFACE; FILMS,OPTICAL EMISSION SPECTROSCOPY (OES); X-RAY PHOTOEMISSION SPECTROSCOPY (XPS); R.F. MAGNETRON SPUTTERING,APPLIED SURFACE SCIENCE,"TOMOZEIU, N","R&D OCE TECHNOL BV, NL-5900 MA VENLO, NETHERLANDS. UNIV BUCHAREST, FAC PHYS, BUCHAREST, ROMANIA.","CHEMISTRY, PHYSICAL; MATERIALS SCIENCE, COATINGS & FILMS; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER",CHEMISTRY; MATERIALS SCIENCE; PHYSICS,"AICHMAYR G, 1998, PHYS STATUS SOLIDI A, V166, P659, DOI 10.1002/(SICI)1521-396X(199804)166:2<659::AID-PSSA659>3.0.CO;2-U##ARNOLDBIK WM, 2005, PHYS REV B, V71, DOI 10.1103/PHYSREVB.71.125329##BELL FG, 1988, PHYS REV B, V37, P8383, DOI 10.1103/PHYSREVB.37.8383##HAMANN DR, 2000, PHYS REV B, V61, P9899, DOI 10.1103/PHYSREVB.61.9899##HAYASHI S, 1996, J LUMIN, V70, P352, DOI 10.1016/0022-2313(96)00070-1##HINDS BJ, 1998, J VAC SCI TECHNOL B, V16, P2171, DOI 10.1116/1.590302##HOHL A, 2003, J NON-CRYST SOLIDS, V320, P255, DOI 10.1016/S0022-3093(03)00031-0##JANOTTA A, 2004, J APPL PHYS, V95, P4060, DOI 10.1063/1.1667008##LUCOVSKY G, 1983, PHYS REV B, V28, P3225, DOI 10.1103/PHYSREVB.28.3225##PAVESI L, 2000, NATURE, V408, P440, DOI 10.1038/35044012##SZE SM, 1981, PHYS SEMICONDUCTOR D, P850##TOMOZEIU N, 2002, J OPTOELECTRON ADV M, V4, P513##VAN HAPERT JJ, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.245202##VANHAPERT JJ, 2002, THESIS UTRECHT U##WAGNER C, 1978, HDB XRAY PHOTOELECTR, P57##WATANABE H, 1993, J NONCRYST SOLIDS, V164, P1085##ZHANG M, 1997, J APPL PHYS, V82, P4912, DOI 10.1063/1.366356##1967, HDB CHEM PHYS, PF149",18,2020-11-20,NA
J,WOS:000241792800061,2006,HSP27 IS SUFFICIENT AND REQUIRED FOR PREVENTION OF TACHYCARDIA INDUCED REMODELING IN A CELL MODEL FOR TACHYPACING,NA,NA,NA,CIRCULATION,"BRUNDEL, BJ##OI, XY##YEH, YH##SHIROSHITA-TAKESHITA, A##CHARTIER, D##HENNING, RH##KAMPINGA, HH##NATTEL, S","UNIV GRONINGEN, MED CTR, GRONINGEN, NETHERLANDS. MONTREAL HEART INST, MONTREAL, PQ H1T 1C8, CANADA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792800073,2006,THROMBOSPONDIN-2 PROTECTS AGAINST UNCONTROLLED CARDIAC INFLAMMATION AND OXIDATIVE STRESS DURING DOXORUBICIN-INDUCED MYOCARDITIS,NA,NA,NA,CIRCULATION,"SWINNEN, M##VANHOUTTE, D##DENADEL, B##CARMELIET, P##PINTO, YM##HEYMANS, S","DEPT CARDIOL, MAASTRICHT, NETHERLANDS. KATHOLIEKE UNIV LEUVEN, CTR TRANSGENE TECHNOL & GENE THERAPY, LOUVAIN, BELGIUM.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800079,2006,"DOWN REGULATION OF THE NOVEL TRANSCRIPTIONAL REGULATOR OF CARDIAC HYPERTROPHY, KRUPPEL-LIKE FACTOR 15, IS MEDIATED BY TGF-BETA INDUCED P38 ACTIVATION IN VIVO AND IN VITRO.",NA,NA,NA,CIRCULATION,"LEENDERS, JJ##POKHAREL, S##CREEMERS, EE##HERIAS, V##DE WINDT, LJ##TEN DIJKE, P##MOLKENTIN, JD##VAN BILSEN, M##VAN LEEUWEN, RE##JAIN, MK##HEYMANS, S##PINTO, YM","MAASTRICHT UNIV, MAASTRICHT, NETHERLANDS. UNIV TEXAS, SW MED CTR, DALLAS, TX USA. HUBRECHT LAB, UTRECHT, NETHERLANDS. LEIDEN UNIV, LEIDEN, NETHERLANDS. UNIV CINCINNATI, CHILDRENS HOSP, MED CTR, CINCINNATI, OH USA. NORWEGIAN UNIV SCI & TECHNOL, N-7034 TRONDHEIM, NORWAY. HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800120,2006,POTENTIAL PLAQUE STABILIZING EFFECTS OF IGF-1 IN ATHEROSCLEROSIS,NA,NA,NA,CIRCULATION,"VON DER THUSEN, JH##VAN HEININGEN, S##VAN BERKEL, TJ##BIESSEN, EA","LEIDEN AMSTERDAM CTR DRUG RES, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800165,2006,AUTOANTIBODY PROFILING AS RAPID AND NON-INVASIVE DIAGNOSTIC TOOL FOR THE PRESENCE OF RUPTURED ATHEROSCLEROTIC LESIONS,NA,NA,NA,CIRCULATION,"CLEUTJENS, KB##FABER, BC##ROUSCH, M##HACKENG, TM##VINK, C##GEUSENS, PP##SIJBERS, AM##BLACK, D##KITSLAAR, PJ##DAEMEN, MJ","UNIV MAASTRICHT, DEPT PATHOL, MAASTRICHT, NETHERLANDS. UNIV MAASTRICHT, DEPT BIOCHEM, MAASTRICHT, NETHERLANDS. UNIV MAASTRICHT, DEPT MED MICROBIOL, MAASTRICHT, NETHERLANDS. UNIV MAASTRICHT, DEPT RHEUMATOL, MAASTRICHT, NETHERLANDS. NV ORGANON, DEPT MOL DESIGN & INFORMAT, NL-5340 BH OSS, NETHERLANDS. UNIV MAASTRICHT, DEPT GEN SURG, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800168,2006,LOW LEVELS OF EXTRA DOMAIN A CONTAINING FIBRONECTIN IN HUMAN ATHEROSCLEROTIC PLAQUES ARE ASSOCIATED WITH A VULNERABLE PLAQUE PHENOTYPE,NA,NA,NA,CIRCULATION,"VAN KEULEN, JK##DE KLEIJN, DP##NIJHUIS, MMO##BUSSER, E##VELEMA, E##FIJNHEER, R##VAN DER GRAAF, Y","EXPT CARDIOL, UTRECHT, NETHERLANDS. LAB THROMBOSIS & HAEMOSTASIS, DEPT HAEMOSTASIS, UTRECHT, NETHERLANDS. JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800202,2006,DEFICIENCY OF CD40L REDUCES THE INCIDENCE OF AORTIC ANEURYSM FORMATION AND PREVENTS AORTIC RUPTURE,NA,NA,NA,CIRCULATION,"BECKERS, L##DAEMEN, MJ##DAUGHERTY, A##LUTGENS, E","UNIV KENTUCKY, LEXINGTON, KY 40506 USA. UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800206,2006,PREDICTORS OF NECROTIC CORE VOLUME: AN IN VIVO VIRTUAL HISTOLOGY INTRAVASCULAR ULTRASOUND (VH-IVUS) ANALYSIS OF 880 PATIENTS FROM THE GLOBAL VH REGISTRY,NA,NA,NA,CIRCULATION,"GARCIA-GARCIA, H##SERRUYS, PW##MINTZ, GS##SAITO, S##KLAUSS, V##MARGOLIS, MP##CARLIER, S##SCHWARTZ, R","ERASMUS UNIV, THORAX CTR, ROTTERDAM 102, NETHERLANDS. CARDIOVASC RES FDN, NEW YORK, NY USA. NIHON UNIV, ITABASHI HOSP, TOKYO, JAPAN. KLINIKUM INNENSTADT, MUNICH, GERMANY. VOLCANO CORP, RANCHO CORDOVA, CA USA. MINNEAPOLIS HEART INST FDN, MINNEAPOLIS, MN USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800253,2006,ADULT MESENCHYMAL STEM CELLS FROM PATIENTS WITH ISCHEMIC HEART DISEASE DIFFERENTIATE INTO A VASCULAR PHENOTYPE AND IMPROVE LEFT VENTRICULAR FUNCTION AFTER ACUTE MYOCARDIAL INFARCTION IN NOD/SCID MICE: A 9.4T MRI STUDY,NA,NA,NA,CIRCULATION,"GRAUSS, RW##WINTER, EM##STEENDIJK, P##VAN TUYN, J##STEIJN, RV##HOGERS, B##VAN DER GEEST, R##VAN DER WALL, EE##GITTENBERGER-DE GROOT, AC##VAN DER LAARSE, A##DE VRIES, AA##SCHALIJ, MJ##ATSMA, DE","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800299,2006,"LXR ACTIVATION REDUCES EXPRESSION OF RENIN, ACE, AND ANGIOTENSIN RECEPTOR TYPE 1 IN KIDNEY AND HEART",NA,NA,NA,CIRCULATION,"KUIPERS, I##VAN GENNE, L##VAN VELDHUISEN, DJ##VAN GILST, WH##DE BOER, RA","UMCG, GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800338,2006,MURINE TISSUE FACTOR PATHWAY INHIBITOR-2 AGGRAVATES INJURY-INDUCED HYPERPLASIA BUT REDUCES PLAQUE STABILITY,NA,NA,NA,CIRCULATION,"DE NOOIJER, R##LUCERNA, M##DE JAGER, S##BOT, I##KRAAIJEVELD, A##LUTTERS, B##VAN SANTBRINK, P##JUKEMA, WJ##VAN BERKEL, TJ##BIESSEN, EA","LEIDEN UNIV, LEIDEN, NETHERLANDS. LEIDEN UNIV HOSP, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800337,2006,ACTIVATION OF NUCLEAR ORPHAN RECEPTOR NUR77 BY 6-MERCAPTOPURINE PROTECTS AGAINST NEOINTIMA FORMATION,NA,NA,NA,CIRCULATION,"PIRES, NM##POLS, TW##DE VRIES, MR##VAN TIEL, CM##BONTA, PI##VOS, M##ARKENBOUT, EK##PANNEKOEK, H##JUKEMA, JW##QUAX, PH##DE VRIES, CJ","TNO QUAL LIFE, LEIDEN, NETHERLANDS. ACAD MED CTR, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800364,2006,NUR77 NUCLEAR RECEPTOR IS A NOVEL TARGET FOR INTERVENTION IN VASCULAR PATHOLOGIES.,NA,NA,NA,CIRCULATION,"DE WAARD, V##POLS, TW##BONTA, P##VAN TIEL, CM##ARKENBOUT, EK##PANNEKOEK, H##DE VRIES, CJ","ACAD MED CTR, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800366,2006,THE TRANSCRIPTION FACTOR TWIST-1 IS SPECIFICALLY EXPRESSED IN MACROPHAGE DERIVED FOAM CELLS,NA,NA,NA,CIRCULATION,"JAMNONGLUK, WV##KISTERS, N##CLEUTJENS, KB##FLEDDERUS, JO##VOLGER, OL##DAEMEN, MJ##BIJNENS, AP","UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS. UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800421,2006,HUMAN EMBRYONIC STEM CELL-DERIVED CARDIOMYOCYTES SURVIVE AND MATURE AFTER INTRAMYOCARDIAL TRANSPLANTATION IN THE MOUSE HEART,NA,NA,NA,CIRCULATION,"VAN LAAKE, LW##PASSIER, R##KLOOTS, J##LIPS, DJ##WARD-VAN OOSTWAARD, D##VAN DEN BRINK, SE##TERTOOLEN, LI##DOEVENDANS, PA##MUMMERY, CI","UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS. HUBRECHT LAB, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800454,2006,IMPAIRED RENAL FUNCTION IS NOT ONLY RELATED TO DECREASED CARDIAC OUTPUT BUT ALSO TO INCREASED VENOUS PRESSURE IN PATIENTS WITH CARDIAC DYSFUNCTION,NA,NA,NA,CIRCULATION,"DAMMAN, K##SMILDE, TD##VOORS, AA##VAN DER BIJ, W##NAVIS, G##VAN VELDHUISEN, DJ##HILLEGE, HI","UNIV GRONINGEN, MED CTR, GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800481,2006,NEOVASCULARISATION AFTER ERYTHROPOIETIN TREATMENT IN HEART FAILURE IS ASSOCIATED WITH INCREASED MYOCARDIAL HOMING AND VASCULAR INCORPORATION OF ENDOTHELIAL PROGENITOR CELLS,NA,NA,NA,CIRCULATION,"WESTENBRINK, BD##OESEBURG, H##LIPSIC, E##VOORS, AA##HARMSEN, MC##VAN VELDHUISEN, DJ##VAN GILST, WH##SCHOEMAKER, RG","UNIV GRONINGEN, MED CTR, GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800491,2006,THE GROWTH FACTOR PRESENTING ISOFORM CD44V3 IS HIGHLY EXPRESSED DURING COLLATERAL ARTERY GROWTH AND MEDIATES PERFUSION RESTORATION AFTER FEMORAL ARTERY LIGATION,NA,NA,NA,CIRCULATION,"BOT, PT##GRUNDMANN, SB##VAN ROYEN, N##VAN DER NEUT, R##PALS, ST##PASTERKAMP, G##PIEK, JJ##HOEFER, I","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800493,2006,MYOCYTE ENHANCER FACTOR 2A IS A POTENT REGULATOR OF ANGIOGENESIS AND OF ERYTHROCYTE EXTRAVASATION IN ATHEROSCLEROTIC PLAQUES.,NA,NA,NA,CIRCULATION,"KRAAIJEILD, A##LUCERNA, M##YU, HX##JUKEMA, WJ##VAN BERKEL, TJ##DE WINDT, LJ##BIESSEN, EA","LEIDEN UNIV, LACDR, LEIDEN, NETHERLANDS. NETHERLANDS INST DEV BIOL, HUBRECHT LAB, NL-3584 CT UTRECHT, NETHERLANDS. LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800524,2006,LENTIVIRAL BLOCKADE OF THE SDF-1 ALPHA/CXCR4 PATHWAY IN LEUKOCYTES AGGRAVATES ATHEROSCLEROTIC LESION DEVELOPMENT,NA,NA,NA,CIRCULATION,"BOT, I##ZERNECKE, A##VAN, TJ##WEBER, C##BIESSEN, EA","LEIDEN UNIV, LACDR, LEIDEN, NETHERLANDS. UNIV HOSP AACHEN, DEPT MOL CARDIOVASC RSCH, AACHEN, GERMANY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800532,2006,THE OBESITY-LINKED GENE ADIPONUTRIN IS HIGHLY REGULATED BY A WESTERN-TYPE DIET IN LIVER PARENCHYMAL CELLS OF LDL RECEPTOR DEFICIENT MICE,NA,NA,NA,CIRCULATION,"HOEKSTRA, M##STITZINGER, M##OUT, R##VAN ECK, M##VAN BERKEL, TJ##KUIPER, J","LACDR, DIV BIOPHARMACEUT, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800535,2006,AGGRESSIVE CHOLESTEROL REDUCTION WITH HIGH-DOSE STATINS IMPROVES PROGNOSIS IN PERIPHERAL ARTERIAL DISEASE,NA,NA,NA,CIRCULATION,"FERINGA, HH##DUNKELGRUN, M##HOEKS, S##VAN DOMBURG, R##VIDAKOVIC, R##KARAGIANNIS, S##AZIZI, F##WELTEN, G##LAMERIS, T##SCHOUTEN, O##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792800584,2006,LOCAL LENTIVIRAL SHRNA MEDIATED SILENCING OF CCR2 INHIBITS INTIMAL HYPERPLASIA IN APOE3LEIDEN MICE,NA,NA,NA,CIRCULATION,"BOT, I##EEFTING, D##DE VRIES, MR##VAN BOCKEL, H##VAN BERKEL, TJ##BIESSEN, EA##QUAX, PH","LEIDEN UNIV, LEIDEN, NETHERLANDS. TNO, GAUBIUS LAB, LEIDEN, NETHERLANDS. LUMC, DEPT VASC, LEIDEN, NETHERLANDS. LEIDEN UNIV, LACDR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800594,2006,CARDIOMYOCYTE-RESTRICTED OVEREXPRESSION OF C-TYPE NATRIURETIC PEPTIDE PREVENTS CARDIAC HYPERTROPHY INDUCED BY MYOCARDIAL INFARCTION IN MICE,NA,NA,NA,CIRCULATION,"WANG, Y##DE WAARD, M##STEMER-KOCK, A##DUNCKER, D##WALTHER, T","CHARITE UNIV MED BERLIN, BERLIN, GERMANY. EMC, ROTTERDAM, NETHERLANDS. FREE UNIV BERLIN, D-1000 BERLIN, GERMANY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792800633,2006,PRESSURE OVERLOAD-INDUCED RIGHT VENTRICULAR DILATATION IS ASSOCIATED WITH RE-EXPRESSION OF MYOCARDIAL TENASCIN-C AND INCREASED PLASMA LEVELS OF TENASCIN-C,NA,NA,NA,CIRCULATION,"HESSEL, MHM##STEENDIJK, P##DEN ADEL, B##SCHUTTE, CI##VAN DER LAARSE, A","LEIDEN UNIV, CTR MED, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792800680,2006,CRP AND RISK OF VASCULAR EVENTS IN PROSPER,NA,NA,NA,CIRCULATION,"SATTAR, N##MURRAY, H##BLAUW, G##BOLLEN, E##BUCKLEY, B##COBBE, S##FORD, I##GAW, A##HYLAND, M##JUKEMA, W##KAMPER, A##MACFARLANE, P##MURPHY, M##PACKARD, C##PERRY, I##STOTT, D##SWEENEY, B##TWOMEY, C##WESTENDORP, R##SHEPHERD, J","GLASGOW ROYAL INFIRM, GLASGOW G4 0SF, LANARK, SCOTLAND. UNIV GLASGOW, GLASGOW, LANARK, SCOTLAND. LEIDEN UNIV, LEIDEN, NETHERLANDS. NATL UNIV IRELAND UNIV COLL CORK, CORK, IRELAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792801076,2006,THE KRUPPEL-LIKE FACTOR KLF15 IS A NOVEL REGULATOR OF CARDIOMYOCYTE HYPERTROPHY,NA,NA,NA,CIRCULATION,"FISCH, S##GRAY, SJ##HEYMANS, S##WANG, B##HALDAR, S##PFISTER, O##CUI, L##KUMAR, A##LIN, Z##SEN-BANERJEE, S##DAS, H##PETERSEN, C##MENDE, U##BURLEIGH, B##ZHU, Y##PINTO, Y##LIAO, R##JAIN, MK","BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA. UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS. HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA. TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801080,2006,LYSOSOMAL INTEGRAL MEMBRANE PROTEIN-2 IS A NOVEL COMPONENT OF THE INTERCALATED DISC AND ESSENTIAL FOR A COMPENSATORY HYPERTROPHIC RESPONSE TO PRESSURE-OVERLOAD,NA,NA,NA,CIRCULATION,"SCHROEN, B##LEENDERS, JJ##VAN ERK, A##VAN LOON, M##VAN LEEUWEN, R##BERTRAND, A##CLAUSSEN, C##SAFTIG, P##HEYMANS, S##PINTO, YM","UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS. HUBRECHT LAB, UTRECHT, NETHERLANDS. UNIV KIEL, KIEL, GERMANY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801105,2006,HEART FAILURE IS ASSOCIATED WITH ABNORMAL C-TERMINAL SPLICING VARIANTS OF THE CARDIAC SODIUM CHANNEL,NA,NA,NA,CIRCULATION,"SHANG, LJL##PFAHNL, AE##JIAO, Z##BANACH, K##FAHRENBACH, J##ROSSENBACKER, T##DOEVENDANS, PA##WEISS, D##TAYLOR, WR##DUDLEY, SC","EMORY UNIV, VAMC, DECATUR, GA 60153 USA. LOYOLA UNIV, B-3000 MAYWOOD, IL USA. CATHOLIC UNIV LOUVAIN, LOUVAIN, BELGIUM. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, 30322, NETHERLANDS. EMORY UNIV, ATLANTA, GA USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801202,2006,IMPORTANCE OF MACROPHAGE CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) FOR DETERMINING SERUM CHOLESTERYL ESTER TRANSFER ACTIVITY AND ATHEROSCLEROSIS,NA,NA,NA,CIRCULATION,"VAN ECK, M##YE, D##HILDEBRAND, RB##KRUIJT, JK##HOEKSTRA, M##VAN BERKEL, TJ","LEIDEN AMSTERDAM CTR DRUG RES, LEIDEN, NETHERLANDS. NATL PUBL HLTH INST, SF-00140 HELSINKI, FINLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801215,2006,COLONY FORMING UNIT-ENDOTHELIAL CELLS ARE DERIVED FROM CD14(+) MONOCYTES AND NEED SUPPORT BY T-CELLS,NA,NA,NA,CIRCULATION,"VAN BEEM, RT##NOORT, WA##KLEIJER, M##VAN DER SCHOOT, CE##ZWAGINGA, JJ","SANQUIN RES, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,2,2020-11-20,NA
J,WOS:000241792801230,2006,CONTRIBUTION OF INHERITED DISEASES TO (ABORTED) SUDDEN CARDIAC DEATH IN CHILDHOOD,NA,NA,NA,CIRCULATION,"HOFMAN, N##TAN, HL##CLUR, SA##ALDERS, M##VAN LANGEN, IM##WILDE, AA","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801253,2006,FORCED EXPRESSION OF MYOCARDIN IN MESENCHYMAL STEM CELLS FROM ISCHEMIC HEART DISEASE PATIENTS INDUCES DIFFERENTIATION INTO A CARDIOMYOCYTE PHENOTYPE AND IMPROVES LEFT VENTRICULAR FUNCTION AFTER MYOCARDIAL INFARCTION IN NOD/SCID MICE,NA,NA,NA,CIRCULATION,"GRAUSS, RW##VAN TUYN, J##STEENDIJK, P##WINTER, EM##STEIJN, RV##HOGERS, B##VAN DER GEEST, R##VAN DER WALL, EE##GITTENBERGER-DE GROOT, AC##VAN DER LAARSE, A##DE VRIES, AA##SCHALIJ, MJ##ATSMA, DE","LEIDEN UNIV, MED CTR, NL-2300 RA LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801364,2006,EFFECTS OF EZETIMIBE AND/OR SIMVASTATIN ON LDL RECEPTOR PROTEIN AND ON LDL RECEPTOR AND HMG-COA REDUCTASE GENE EXPRESSION IN MONONUCLEAR BLOOD CELLS: A RANDOMIZED TRIAL IN HEALTHY MEN,NA,NA,NA,CIRCULATION,"GOUNI-BERTHOLD, I##BERTHOLD, HK##KO, Y##GYLLING, H##PLAT, J##KRONE, W","UNIV COLOGNE, DEPT INTERNAL MED 2, COLOGNE, GERMANY. DRUG COMMISS GERMAN MED ASSOC, BERLIN, GERMANY. UNIV BONN, MED POLIKLIN, D-5300 BONN, GERMANY. UNIV KUOPIO, DEPT CLIN NUTR, FIN-70211 KUOPIO, FINLAND. MAASTRICHT UNIV, DEPT HUMAN BIOL, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801379,2006,HYPERTHYROIDISM DECREASES PLASMA HDL CHOLESTEROL BY INHIBITION OF HEPATIC ABCA1 EXPRESSION,NA,NA,NA,CIRCULATION,"TANCEVSKI, I##WEHINGER, A##DEMETZ, E##HUBER, J##HOCHEGGER, K##ELLER, P##SCHGOER, W##FIEVET, C##STELLAARD, F##KUIPERS, F##FOEGER, B##PATSCH, JR##RITSCH, A","MED UNIV INNSBRUCK, INNSBRUCK, AUSTRIA. INST PASTEUR, LILLE, FRANCE. UNIV GRONINGEN HOSP, GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801376,2006,ELEVATED MACROPHAGE EXPRESSION OF PHOSPHOLIPID TRANSFER PROTEIN CAUSES ATHEROSCLEROSIS,NA,NA,NA,CIRCULATION,"VAN HAPEREN, R##SAMYN, H##MOERLAND, M##VAN GENT, T##PEETERS, M##GROSVELD, F##VAN TOL, A##DE CROM, R","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792801385,2006,PLAQUE COMPONENTS IN CORONARY ARTERY DISEASE INCREASE AT DIFFERENT RATES: A VIRTUAL HISTOLOGY INTRAVASCULAR ULTRASOUND REPORT FROM THE GLOBAL VH-IVUS REGISTRY,NA,NA,NA,CIRCULATION,"ERBEL, R##GARCIA-GARCIA, H##MOSES, J##PIEPER, M##WHITE, R##SANO, K##MINTZ, GS##SERRUYS, PW","WESTDEUTSCH HERZZENTRUM ESSEN, THORAX CTR, ESSEN, GERMANY. ERASMUS UNIV, ROTTERDAM, NETHERLANDS. COLUMBIA UNIV, NEW YORK, NY USA. HERZZENTRUM BODENSEE, KREUZLINGEN, SWITZERLAND. ABBOT VASC, SANTA CLARA, CA USA. CARDIOVASC RES FDN, NEW YORK, NY USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801383,2006,INCREASED OXIDATIVE STRESS DUE TO DYSFUNCTIONAL HDL IN SCAVENGER RECEPTOR BI KNOCKOUT MICE,NA,NA,NA,CIRCULATION,"VAN ECK, M##HOEKSTRA, M##HILDEBRAND, RB##YAO, YM##STENGEL, D##TIETGE, UJ##NINIO, E##VAN BERKEL, TJ##PRATICO, D","LEIDEN AMSTERDAM CTR DRUG RES, LEIDEN, NETHERLANDS. UNIV PENN, PHILADELPHIA, PA 19104 USA. INSERM, U525, PARIS, FRANCE. UNIV GRONINGEN, UNIV MED CTR GRONINGEN, GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801446,2006,PRESERVATION OF LEFT VENTRICULAR FUNCTION AND ATTENUATION OF REMODELLING AFTER TRANSPLANTATION OF HUMAN EPICARDIUM-DERIVED CELLS INTO THE INFARCTED MOUSE HEART,NA,NA,NA,CIRCULATION,"WINTER, EM##GRAUSS, RW##HOGERS, B##VAN TUYN, J##VAN DER GEEST, R##STEIJN, RV##LIE-VENEMA, H##STEENDIJK, P","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801501,2006,HIF PATHWAY IS ASSOCIATED WITH PROGRESSION AND NEOVASCULARIZATION OF HUMAN ATHEROSCLEROSIS,NA,NA,NA,CIRCULATION,"SLUIMER, J##GASC, JM##KISTERS, N##GELPKE, MDS##CLEUTJENS, JP##WOUTERS, BG##VAN DEN AKKER, LH##CORVOL, P##DAEMEN, MJ##BIJNENS, AP","UNIV MAASTRICHT, INST CARDIOVASC RES, DEPT PATHOL, MAASTRICHT, NETHERLANDS. COLL FRANCE, INSERM, U36, F-75231 PARIS, FRANCE. NV ORGANON, DEPT MOL DESIGN & INFORMAT, NL-5340 BH OSS, NETHERLANDS. MAASTRICHT UNIV, RES INST GROWTH & DEV, RADIAT ONCOL LAB, MAASTRICHT, NETHERLANDS. MAASLAND HOSP, DEPT SURG, SITTARD, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801505,2006,MATERNAL HYPERCHOLESTEROLEMIA ACCELERATES ATHEROSCLEROSIS DEVELOPMENT IN ADULT HETEROZYGOUS APOLIPOPROTEIN E OFFSPRING,NA,NA,NA,CIRCULATION,"ALKEMADE, FE##GITTENBERGER-DE GROOT, AC##SCHIEL, AE##VANMUNSTEREN, CJ##HAVEKES, LM##VAN DIJK, KW##DERUITER, MC","LEIDEN UNIV, MED CTR, DEPT ANAT & EMBRYOL, LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT HUMAN GENET, LEIDEN, NETHERLANDS. TNO, IVVO, GAUBIUS LAB, NL-2300 AK LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801502,2006,ENDOVASCULAR STENTS ARE A POTENTIAL NEW INTRA-ARTERIAL DELIVERY PLATFORM FOR PRO-ARTERIOGENIC GROWTH FACTORS,NA,NA,NA,CIRCULATION,"GRUNDMANN, S##HOEFER, IE##VAN ROYEN, N##GONZALEZ, N##TIJSMA, EJ##PASTERKAMP, G##PIEK, JJ","UNIV AMSTERDAM, ACAD MED CTR, DEPT CARDIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV UTRECHT, DEPT EXPT CARDIOL, UTRECHT, NETHERLANDS. MEDTRON NEDERLANDS, BAKKEN RES CTR, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801515,2006,HETEROZYGOSITY FOR A MUTATION IN THE EXTRACELLULAR DOMAIN OF SR-BI IS ASSOCIATED WITH HIGH HDL CHOLESTEROL LEVELS IN A FAMILY OF CAUCASIAN DESCENT,NA,NA,NA,CIRCULATION,"VERGEER, M##HOVINGH, K##VISSERS, MN##KASTELEIN, JJ##KUIVENHOVEN, JA","ACAD MED CTR, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,3,2020-11-20,NA
J,WOS:000241792801519,2006,RESTORATION OF ENDOTHELIAL FUNCTION AFTER INFUSION OF RECONSTITUTED HIGH-DENSITY LIPOPROTEIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS,NA,NA,NA,CIRCULATION,"NIEUWDORP, M##BISOENDIAL, RJ##OP 'T ROODT, J##VERGEER, M##LEVELS, JM##BIRJMOHUN, RS##BASSER, R##RABELINK, AJ##KASTELEIN, JJ##STROES, ES","AMC, AMSTERDAM, NETHERLANDS. LUMC, LEIDEN, NETHERLANDS. CSL BIOPLASMA INC, PARKVILLE, VIC, AUSTRALIA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801520,2006,SHORT TERM ADMINISTRATION OF RECONSTITUTED APOAI DISCS INCREASES CIRCULATING PROGENITOR CELLS IN TYPE 2 DIABETES,NA,NA,NA,CIRCULATION,"VAN OOSTROM, O##NIEUWDORP, M##WESTERWEEL, PE##HOEFER, IE##STROES, ES##VERHAAR, MC","UNIV UTRECHT, MED CTR, DEPT VASC MED, UTRECHT, NETHERLANDS. ACAD MED CTR, DEPT VASC MED, AMSTERDAM, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT EXPT CARDIOL, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801525,2006,OXLDL-PULSED DENDRITIC CELLS: AN IMMUNOTHERAPY IN ATHEROSCLEROSIS,NA,NA,NA,CIRCULATION,"HABETS, KL##VAN PUIJVELDE, GH##VAN DUIVENVOORDE, LM##VAN WANROOIJ, EJ##DE VOS, P##TERVAERT, JWC##VAN BERKEL, TJ##TOES, RE##KUIPER, J","LUMC, DEPT RHEUMATOL, LEIDEN, NETHERLANDS. LACDR, DIV BIOPHARMACEUT, LEIDEN, NETHERLANDS. CARIM, DEPT CLIN & EXPT IMMUNOL, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801528,2006,DNA VACCINATION AGAINST IL-17 ATTENUATES ATHEROSCLEROSIS IN LDL RECEPTOR DEFICIENT MICE,NA,NA,NA,CIRCULATION,"VAN ES, T##HAUER, AD##VAN PUIJVELDE, GH##VAN WANROOIJ, EJ##DE VOS, P##PETERSE, N##VAN BERKEL, TJ##KUIPER, J","LEIDEN UNIV, DIV BIOPHARMACEUT, LACDR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801527,2006,IMMUNOMODULATION WITH OCH-PRIMED DENDRITIC CELLS AMELIORATES ATHEROSCLEROSIS,NA,NA,NA,CIRCULATION,"VAN PUIJVELDE, GH##HABETS, KL##LITJENS, RE##VAN DULVENVOORDE, LM##VAN WANROOIJ, EJ##DE VOS, P##VAN DER MAREL, GA##OVERKLEEFT, HS##TERVAERT, JWC##VAN BERKEL, TJ##TOES, RE##KUIPER, J","LEIDEN UNIV, DIV BIOPHARMACEUT, LACDR, LEIDEN, NETHERLANDS. LEIDEN INST CHEM, LEIDEN, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT RHEUMATOL, LEIDEN, NETHERLANDS. CARIM, DEPT CLIN & EXPT IMMUNOL, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801535,2006,"CD40 INTERACTS WITH FILAMIN, BUT SIGNALING IN MACROPHAGES DOES NOT REQUIRE LIPID RAFT TRANSLOCATION",NA,NA,NA,CIRCULATION,"DONNERS, M##BECKERS, L##STAN, R##DAEMEN, M##LUTGENS, E","CARDIOVASC RES INST MAASTRICHT, DEPT PATHOL, MAASTRICHT, NETHERLANDS. DARTMOUTH COLL SCH MED, DEPT PATHOL, ANGIOGENESIS RSCH CTR, HANOVER, NH USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801585,2006,THE ROLE OF STATINS IN REDUCING CENTRAL SYMPATHETIC OUTFLOW IN CHF,NA,NA,NA,CIRCULATION,"GOMES, ME##AENGEVAEREN, WR##LENDERS, JW##BELLERSEN, L##SMITS, P##VERHEUGT, FW##TACK, CJ","RADBOUD UNIV NIJMEGEN, MED CTR, NIJMEGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801604,2006,PROTECTIVE EFFECT OF SMAD3 DEFICIENCY ON CARDIAC FUNCTION AFTER MYOCARDIAL INFARCTION,NA,NA,NA,CIRCULATION,"GOURNANS, MJ##SLUIJTER, J##VAN MIDDELAAR, B##TIMMERS, L","UMCU, HLCU, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801606,2006,LOSS OF SPARC RESULTS IN INCREASED CARDIAC RUPTURE AND HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION,NA,NA,NA,CIRCULATION,"SCHELLINGS, MW##VAN LOON, M##SAGE, H##PINTO, YM##HEYMANS, S","BENAROYA RSCH INST, SEATTLE, WA USA. DEPT CARDIOL, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792801619,2006,EXCHANGE OF C-TERMINAL TRUNCATED TROPONIN I INTO HUMAN CARDIOMYOCYTES PRESERVES FORCE RESPONSES TO BETA-ADRENERGIC STIMULATION AND INCREASED PRELOAD,NA,NA,NA,CIRCULATION,"NAROLSKA, NA##BOONTJE, NM##MUSTERS, RJ##DEPPERMANN, S##JACUET, K##MURPHY, AM##D FOSTER, B##VAN EYK, JE##VAN DER VELDEN, J##STIENEN, GJ","VRIJE UNIV AMSTERDAM, MED CTR, AMSTERDAM, NETHERLANDS. FORSCHUNGSLABOR MOL KARDIOL, BOCHUM, GERMANY. JOHNS HOPKINS UNIV, BALTIMORE, MD USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801660,2006,CD127 IS REQUIRED FOR MACROPHAGE AND REGULATORY T CELL FUNCTION AND HAS A PROTECTIVE ROLE IN ATHEROSCLEROSIS,NA,NA,NA,CIRCULATION,"VAN WANROOIJ, EJ##VAN PUIJVELDE, G##HAPP, H##DE VOS, P##VAN BERKEL, T##KULPER, J","BIOPHARMACEUT, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801666,2006,HIGH IP-10 LEVELS IDENTIFY PLAQUES WITH A VULNERABLE PHENOTYPE,NA,NA,NA,CIRCULATION,"LIPTON, J##SEGERS, D##CHENG, C##DUCKERS, H##KRAMS, R##TEMPEL, D##BUSSER, E##DE KLEIJN, D##MOLL, FL##PASTERKAMP, G","ERASMUS MC, ROTTERDAM, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792801663,2006,MHCII-DEFICIENCY ATTENUATES THE DEVELOPMENT OF ATHEROSCLEROSIS IN LDLR-/- MICE,NA,NA,NA,CIRCULATION,"SMOCK, ML##HEERINGA, P##VAN DE GAAR, J##DAEMEN, MJ##WILLEM, J##TERVAERT, C##LINGENS, E","UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS. UNIV GRONINGEN, NL-9700 AB GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802001,2006,ENHANCED ATHEROGENESIS AND ALTERED HIGH DENSITY LIPOPROTEIN IN PATIENTS WITH CROHN'S DISEASE,NA,NA,NA,CIRCULATION,"VAN LEUVEN, SI##HEZEMANS, R##LEVELS, H##VAN DEVENTER, SJ##KASTELEIN, JJ##STROES, ES##DE GROOT, E##HOMMES, DW","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,2,2020-11-20,NA
J,WOS:000241792802017,2006,LACTADHERIN-DEPENDENT PHAGOCYTOSIS OF APOPTOTIC CELLS IS REQUIRED FOR A PROTECTIVE IMMUNE RESPONSE IN ATHEROSCLEROSIS,NA,NA,NA,CIRCULATION,"AIT-OUFELLA, H##KINUGAWA, K##ZOLL, J##SIMON, T##BODDAERT, J##HEENEMAN, S##BLANC-BRUDE, O##BARATEAU, V##POTTEAUX, S##MERVAL, R##ESPOSITO, B##DAEMEN, M##LESECHE, G##BOULANGER, C##TEDGUI, A##MALLAT, Z","INSERM, U689, PARIS, FRANCE. CARIM, DEPT PATHOL, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802019,2006,"FTY720, A SYNTHETIC SPHINGOSINE 1-PHOSPHATE (S1P) ANALOGUE, INHIBITS DEVELOPMENT OF ATHEROSCLEROSIS IN LDL RECEPTOR-DEFICIENT MICE",NA,NA,NA,CIRCULATION,"NOFER, JR##MARTINE, B##MARTIN, B##VAN BERKEL, TJ##ASSMANN, G##BIESSEN, EA","UNIV MUNSTER, MUNSTER, GERMANY. LEIDEN UNIV, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802027,2006,PIM-1 REGULATES CARDIOMYOCYTE SURVIVAL DOWNSTREAM OF AKT,NA,NA,NA,CIRCULATION,"MURASKI, JA##FRANSIOLI, J##GUDE, N##MARTINDALE, J##GLEMBOTSKI, C##MAGNUSON, N##BERNS, A##SUSSMAN, MA","SAN DIEGO STATE UNIV, SAN DIEGO, CA 92182 USA. WASHINGTON STATE UNIV, PULLMAN, WA 99164 USA. NETHERLANDS CANC INST, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792802058,2006,THE ALTERED RESPONSE OF BONE MARROW DERIVED ENDOTHELIAL PROGENITOR CELLS FROM NORMAL AND HEART FAILURE RATS TO ANGIOTENSIN-(1-7),NA,NA,NA,CIRCULATION,"QIAN, C##ROKS, AJ##VAN GILST, WH##SCHOEMAKER, RG","UNIV GRONINGEN, UNIV MED CTR GRONINGEN, GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802137,2006,APOLIPOPROTEINA-II IS INVERSELY ASSOCIATED WITH RISK OF FUTURE CORONARY ARTERY DISEASE,NA,NA,NA,CIRCULATION,"BIRJMOHUN, RS##DALLINGA-THIE, G##STROES, ES##KULVENHOVEN, JA##WAREHAM, N##LUBEN, R##DAY, NE##KASTELEIN, JJ##BOEKHOLDT, M##KHAW, KT","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. ERASMUS MC, ROTTERDAM, NETHERLANDS. MRC, EPIDEMIOL UNIT, CAMBRIDGE, ENGLAND. UNIV CAMBRIDGE, INST PUBL HLTH, DEPT PUBL HLTH & PRIMARY CARE, CAMBRIDGE, ENGLAND. UNIV CAMBRIDGE, INST PUBL HLTH & PRIMARY CARE, DEPT PUBL HLTH & PRIMARY CARE, CAMBRIDGE, ENGLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802197,2006,HUMAN VENTRICULAR SCAR FIBROBLASTS DO NOT CONDUCT ELECTRICAL CURRENT OVER CONSIDERABLE DISTANCES IN AN EXPERIMENTAL CONDUCTION BLOCK IN CARDIOMYOCYTE CULTURES IN CONTRAST TO MESENCHYMAL STEM CELLS FROM ISCHEMIC HEART DISEASE PATIENTS.,NA,NA,NA,CIRCULATION,"PIJNAPPELS, DA##SCHALIJ, MJ##VAN DER LAARSE, A##VAN TUYN, J##YPEY, DL##VAN DER WALL, EE##DE VRIES, AA##ATSMA, DE","LEIDEN UNIV MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802196,2006,PREDOMINANT VULNERABILITY OF THE RIGHT VENTRICLE TO ARRHYTHMIAS IN AGED MOUSE HEARTS.,NA,NA,NA,CIRCULATION,"STEIN, M##VAN RIJEN, HV##NOORMAN, M##ENGELEN, MA##VAN VEEN, TA##BOULAKSIL, M##JANSEN, AT##VAN OOSTERHOUT, MF##HAUER, RN##DE BAKKER, JM","UNIV MED CTR UTRECHT, HEART LUNG CTR, UTRECHT, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS. UNIV MED CTR UTRECHT, DEPT PATHOL, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802217,2006,LOSS OF UROKINASE PLASMINOGEN ACTIVATOR EXPRESSION IN MACROPHAGES RETARDS AORTIC ATHEROSCLEROSIS IN APOLIPOPROTEIN E-NULL MICE,NA,NA,NA,CIRCULATION,"KRISHNAN, RM##WU, A##SLEZICKI, KI##BUBEN, A##KREMEN, M##DICHEK, HL##DICHEK, DA","MAASTRICHT UNIV, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802214,2006,INCREASED INCIDENCE OF INFARCT RUPTURE IN MICE WITH A MUTANT FORM OF ALPHAE CATENIN,NA,NA,NA,CIRCULATION,"VAN DEN BORNE, SW##DAEMEN, MJ##SMITS, JF##BLANKESTEIJN, WM","MAASTRICHT UNIV, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802224,2006,NGAL AND NGAL/MMP-9 COMPLEX IN CAROTID PLAQUES AND ABDOMINAL AORTIC ANEURYSMS,NA,NA,NA,CIRCULATION,"HELLINGS, W##PASTERKAMP, G##MOLL, FL##VAN OOSTERHOUT, MF##DE VRIES, JPP##VELEMA, E##BUSSER, E##DE KLEIJN, DP##SLUIJTER, JP","UMC UTRECHT, UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, NIEUWEGEIN, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802223,2006,TRANSCRIPT LEVELS OF GENES INVOLVED IN RECEPTOR AND INFLAMMASOME-MEDIATED INITIATION PATHWAYS OF APOPTOSIS ARE ELEVATED DURING LESION PROGRESSION OF HUMAN ATHEROSCLEROSIS,NA,NA,NA,CIRCULATION,"KISTERS, N##HERIAS, MV##WIJNANDS, EP##GELPKE, MDS##BAURSCHMIDT, S##CLEUTJENS, KB##DAEMEN, MJ##BIJNENS, AP","UNIV MAASTRICHT, CARDIOVASC RES INST MAASTRICHT, MAASTRICHT, NETHERLANDS. NV ORGANON, DEPT MOL DESIGN & INFORMAT, NL-5340 BH OSS, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802241,2006,INHIBITION OF THE INTERACTION BETWEEN PLATELET FACTOR 4 AND RANTES REDUCES ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE,NA,NA,NA,CIRCULATION,"KOENEN, RR##VON HUNDELSHAUSEN, P##ZERNECKE, A##LIEHN, EA##HACKENG, TM##KUNGL, AJ##WEBER, C","UNIV HOSP AACHEN, AACHEN, GERMANY. UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS. GRAZ UNIV, GRAZ, AUSTRIA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802244,2006,TRIGLYCERIDE-MEDIATED LEUKOCYTE ACTIVATION: A POTENTIAL MECHANISM FOR ATHEROGENESIS,NA,NA,NA,CIRCULATION,"ALIPOUR, A##OOSTROM, AJ##IZRAELJAN, A##COLLINS, J##FRAYN, KN##ELTE, JWF##CABEZAS, MC","ST FRANCISCUS GASTHUIS, DEPT INTERNAL MED, ROTTERDAM, NETHERLANDS. ST ANTONIUS HOSP, DEPT CARDIOL, NIEUWEGEIN, NETHERLANDS. UNIV OXFORD, NUFFIELD DEPT CLIN MED, OXFORD, ENGLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792802243,2006,LYSOPHOSPHATIDIC ACID: A TWO-FACED KEY ACTOR IN ATHEROGENESIS,NA,NA,NA,CIRCULATION,"BOT, M##BOT, I##DE JAGER, SC##VAN BERKEL, TJ##BIESSEN, EA","LACDR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802245,2006,CELL-TYPE SPECIFIC CD40(L) SIGNALING IN ATHEROSCLEROSIS: ROLE OF PLATELET AND LEUKOCYTE CD40(L) ON PLAQUE DEVELOPMENT,NA,NA,NA,CIRCULATION,"LIEVENS, D##MUNNIX, IC##BECKERS, L##DONNERS, MM##NOELLE, RJ##DE WINTHER, MP##HEEMSKERK, JW##DAEMEN, MJ##LUTGENS, E","UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS. DARTMOUTH COLL SCH MED, HANOVER, NH USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802254,2006,CORONARY PLAQUE CHARACTERISTICS ON MULTI-SLICE COMPUTED TOMOGRAPHY IN STABLE VERSUS UNSTABLE ANGINA PECTORIS,NA,NA,NA,CIRCULATION,"PUNDZIUTE, G##SCHUIJF, JD##JUKEMA, WJ##BOERSMA, E##DE ROOS, A##VAN DER WALL, EE##BAX, JJ","LEIDEN UNIV, MED CTR, DEPT CARDIOL, LEIDEN, NETHERLANDS. ERASMUS UNIV, DEPT EPIDEMIOL & STAT, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT RADIOL, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802296,2006,"STATINS REDUCE PERIOPERATIVE MYOCARDIAL ISCHEMIA, TROPONIN T RELEASE AND MORTALITY IN MAJOR VASCULAR SURGERY",NA,NA,NA,CIRCULATION,"FERINGA, HH##BAX, JJ##NOORDZIJ, PG##VIDAKOVIC, R##KARAGIANNIS, SE##HOEKS, S##DUNKELGRUN, M##SCHOUTEN, O##VAN DOMBURG, R##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802323,2006,FIRST CLINICAL EXPERIENCE WITH THE CHRONICLE (R) IMPLANTABLE HEMODYNAMIC MONITOR IN PATIENTS ON THE HEART TRANSPLANT WAITING LIST,NA,NA,NA,CIRCULATION,"SCHNNOECKEL, M##LAMM, P##WOLF, M##KACZMAREK, I##REITERS, P##HILL, MR##REICHART, B","UNIV MUNICH, MUNICH, GERMANY. MEDTRONIC INC, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802378,2006,BETA-BLOCKER THERAPY ALTERS MYOFILAMENT FUNCTION IN PATIENTS WITH CONGESTIVE HEART FAILURE,NA,NA,NA,CIRCULATION,"HAMDANI, N##VAN HEEREBEEK, L##BORBELY, A##BOONTJE, NM##NIESSEN, HW##STIENEN, GJ##PAULUS, WJ##VAN DER VELDEN, J","PHYSIOL ICAR VUMC, AMSTERDAM, NETHERLANDS. PATHOL ICAR VUMC, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802400,2006,A PROGNOSTIC RISK INDEX PREDICTS LONG-TERM MORTALITY IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE,NA,NA,NA,CIRCULATION,"FERINGA, HH##VAN WANING, VH##DE LIELDE, I##BAX, JJ##BOERSMA, E##SCHOUTEN, O##NOORDZIJ, PG##DUNKELGRUN, M##KARAGIANNIS, S##VIDAKOVIC, R##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792802445,2006,THE EFFECTS OF PULMONARY VALVE REPLACEMENT IN ADULT PATIENTS WITH TETRALOGY OF FALLOT,NA,NA,NA,CIRCULATION,"VAN HUYSDUYNEN, BH##HENKENS, IR##SWENNE, CA##DRAISMA, HH##MAAN, AC##HAZEKAMP, MG##DE ROOS, A##SCHALIJ, MJ##VAN DER WALL, EE##VLIEGEN, HW","LEIDEN UNIV, MED CENTRUM, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802515,2006,NEW ONSET ATRIAL FIBRILLATION IS AN INDEPENDENT PREDICTOR OF IN-HOSPITAL AND SHORT TERM MORTALITY IN PATIENTS ADMITTED WITH HEART FAILURE. RESULTS OF THE EURO HEART FAILURE SURVEY,NA,NA,NA,CIRCULATION,"RIVERO-AYERZA, M##REIMER, WSO##THEUNS, DA##LENZEN, M##JORDAENS, LJ##KOMAJDA, M##CLELAND, JJ","ERASMUS MC, ROTTERDAM, NETHERLANDS. CASTLE HILL HOSP, KINGSTON UPON HULL, YORKS, ENGLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802518,2006,MYOCARDIAL INTERNAL STRAIN FRACTION PREDICTS VOLUME RESPONSE IN PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY,NA,NA,NA,CIRCULATION,"JANSEN, A##KIM, B##BRACKE, F##VAN GELDER, B##STARC, V##PRINZEN, FW","CATHARINA HOSP, EINDHOVEN, NETHERLANDS. UNIV LJUBLJANA, INST PHYSIOL, LJUBLJANA, SLOVENIA. UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,2,2020-11-20,NA
J,WOS:000241792802524,2006,NON INVASIVE MOLECULAR IMAGING OF INFLAMMATION/APOPTOSIS WITH TC-99M-ANNEXIN A5 REVEALS PLAQUE INSTABILITY IN PATIENTS WITH SIGNIFICANT CAROTID ARTERY STENOSIS.,NA,NA,NA,CIRCULATION,"WOLTERS, S##APPLEBY, S##TORDOIR, J##TEULE, J##DAEMEN, M##NARULA, J##REUTELINGSPERGER, C##HOFSTRA, L","MAASTRICHT UNIV & HOSP, MAASTRICHT, NETHERLANDS. UNIV CALIF IRVINE, IRVINE, CA USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802526,2006,GENDER ASSOCIATED DIFFERENCES IN PLAQUE PHENOTYPE OF PATIENTS WITH HEMODYNAMICALLY SIGNIFICANT CAROTID STENOSIS,NA,NA,NA,CIRCULATION,"HELLINGS, WE##MOLL, FL##VERHOEVEN, B##DE KLEIJN, DP##DE VRIES, JPP##SELDENRIJK, KA##VAN DEN BROEK, T##BUSSER, E##VELEMA, E##PASTERKAMP, G","UMC UTRECHT, UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, NIEUWEGEIN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802637,2006,SPECKLE TRACKING RADIAL STRAIN REVEALS LEFT VENTRICULAR DYSSYNCHRONY IN PATIENTS WITH PERMANENT RIGHT VENTRICULAR PACING,NA,NA,NA,CIRCULATION,"TOPS, LF##SCHALIJ, MJ##HOLMAN, ER##VAN ERVEN, L##VAN DER WALL, EE##BAX, JJ","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792802639,2006,TISSUE SYNCHRONIZATION IMAGING ACCURATELY MEASURES LEFT VENTRICULAR DYSSYNCHRONY AND PREDICTS RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY,NA,NA,NA,CIRCULATION,"VAN DE VEIRE, NR##BLEEKER, GB##DE SUTTER, J##YPENBURG, C##HOLMAN, ER##VAN DER WALL, EE##SCHALIJ, MJ##BAX, JJ","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS. STATE UNIV GHENT HOSP, B-9000 GHENT, BELGIUM.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803005,2006,EXTRAVASCULAR COMPRESSIVE FORCES LIMIT SUBENDOCARDIAL PERFUSION RESERVE IN SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY,NA,NA,NA,CIRCULATION,"KNAAPEN, P##GERMANS, T##TEN CATE, FJ##TEN BERG, JM##DIJKMANS, PA##VAN ROSSUM, AC##LAMMERTSMA, AA##VISSER, FC","VU UNIV MED CTR, AMSTERDAM, NETHERLANDS. ERASMUS MC, ROTTERDAM, NETHERLANDS. MED CTR, NIEUWEGEIN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803018,2006,PRENATAL HYPOXIC STRESS CAUSES CARDIOMYOPATHY INVOLVING CARDIOMYOCYTE SPECIFIC VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING,NA,NA,NA,CIRCULATION,"TINTU, A##ROUWET, E##AHMAD, S##AHMED, A##VAN BILSEN, M##CARMELIET, P##EICHMANN, A##HARKS, E##HOFSTRA, L##LAMERS, W##NARULA, J##LE NOBLE, F","UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS. UNIV HOSP, MAASTRICHT, NETHERLANDS. UNIV BIRMINGHAM, BIRMINGHAM, W MIDLANDS, ENGLAND. UNIV LOUVAIN, CTR TRANSGENE TECHNOL & GENE THERAPY, LOUVAIN, BELGIUM. COLL FRANCE, INSERM, U36, F-75231 PARIS, FRANCE. UNIV CALIF IRVINE, MED CTR, IRVINE, CA USA. MAX DELBRUCK CTR MOL MED, BERLIN, GERMANY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,2,2020-11-20,NA
J,WOS:000241792803037,2006,A NOVEL ANNEXIN A5 PROBE TO DETECT CELL DEATH IN VIVO NON INVASIVELY USING PET/CT,NA,NA,NA,CIRCULATION,"WOLTERS, SL##DIRKSEN, A##BOERSMA, H##HOFSTRA, L##HACKENG, T##REUTELINGSPERGER, C","MAASTRICHT UNIV & HOSP, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803042,2006,DIAGNOSTIC ACCURACY OF DUAL SOURCE COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY IN PATIENTS REFERRED FOR CONVENTIONAL ANGIOGRAPHY,NA,NA,NA,CIRCULATION,"WEUSTINK, AC##MOLLET, NR##MEIJBOOM, WB##KRESTIN, GP##DE FEYTER, PM","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803047,2006,DIAGNOSTIC ACCURACY OF 64-SLICE COMPUTED TOMOGRAPHY VERSUS CONVENTIONAL CORONARY ANGIOGRAPHY: RESULTS OF 180 CONSECUTIVE PATIENTS.,NA,NA,NA,CIRCULATION,"MEIJBOOM, WB##MOLLET, NR##VAN MIEGHEM, CA##WEUSTINK, A##PUGLIESE, F##VOURVOURI, E##BAKS, T##CADEMARTIRI, F##KRESTIN, GP##DE FEYTER, PJ","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792803102,2006,AUTOFLUORESCENCE PREDICTS ONE YEAR INCIDENCE OF MAJOR ADVERSE CARDIAC EVENTS AFTER ACUTE MYOCARDIAL INFARCTION,NA,NA,NA,CIRCULATION,"MULDER, DJ##VAN HAEIST, PI##GRAAFF, R##GANS, RO##ZIJLSTRA, F##SMIT, AJ","UNIV GRONINGEN, MED CTR, GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803160,2006,TOTAL SUM OF ST DEVIATION IS AN INDEPENDENT PREDICTOR FOR THE DEVELOPMENT OF VENTRICULAR FIBRILLATION DURING A FIRST MYOCARDIAL INFARCTION,NA,NA,NA,CIRCULATION,"BOUHIOUF, A##DE JONG, JS##WILDE, AA##DEKKER, LR","AMC, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803181,2006,NOVEL ULTRASOUND-CONTRAST-AGENT DILUTION METHOD FOR ASSESSMENT OF LEFT VENTRICULAR EJECTION FRACTION,NA,NA,NA,CIRCULATION,"JANSEN, AH##MISCHI, M##VAN DANTZIG, JM##BRACKE, F##PEELS, K##VAN HEMEL, NM##KORSTEN, HH","CATHARINA HOSP, EINDHOVEN, NETHERLANDS. UNIV UTRECHT, UTRECHT, NETHERLANDS. TECH UNIV EINDHOVEN, NL-5600 MB EINDHOVEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803182,2006,CONTRAST ECHOCARDIOGRAPHY IMPROVES INTEROBSERVER AGREEMENT FOR WALL MOTION SCORE INDEX AND CORRELATION WITH EJECTION FRACTION,NA,NA,NA,CIRCULATION,"VAN DE VEN, AR##GALEMA, TW##VAN DOMBURG, RT##VLETTER, WB##KRENNING, BJ##CATE, FJT##GELEIJNSE, ML","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803183,2006,SEVERE HYPOTENSION DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY IS ASSOCIATED WITH ADVERSE LONG TERM CARDIAC OUTCOME WHILE BETA-BLOCKERS HAVE A BENEFICIAL EFFECT IN THIS POPULATION,NA,NA,NA,CIRCULATION,"DUNKELGRUN, M##HOEKS, S##FERINGA, H##SCHOUTEN, O##KARAGIANNIS, S##NOORDZIJ, P##VIDAKOVIC, R##DE LIEFDE, I##VAN DOMBURG, R##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,2,2020-11-20,NA
J,WOS:000241792803216,2006,"NT-PROBNP SHOULD BE USED IN THE DEFINITION OF THE ""CARDIO-RENAL SYNDROME""",NA,NA,NA,CIRCULATION,"VAN KIMMENADE, RR##JANUZZI, JL##BAGGISH, A##LAINCHBURY, J##BAYES-GENIS, A##RICHARDS, AM##PINTO, YM","UNIV HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS. MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA. CHRISTCHURCH HOSP, CHRISTCHURCH, NEW ZEALAND. HOSP SANTA CREU & SANT PAU, E-08025 BARCELONA, SPAIN.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803235,2006,WHAT IS THE OPTIMAL PHARMACOLOGICAL PROPHYLAXIS FOR THE PREVENTION OF DEEP-VEIN THROMBOSIS AND PULMONARY EMBOLISM IN PATIENTS WITH ACUTE ISCHEMIC STROKE?,NA,NA,NA,CIRCULATION,"KAMPHUISEN, P##AGNELLI, G","ACAD MED CTR, AMSTERDAM, NETHERLANDS. UNIV PERUGIA, I-06100 PERUGIA, ITALY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803261,2006,ABDOMINAL AORTIC ANEURYSM SCREENING USING A HAND-HELD ULTRASOUND VOLUME SCANNER: A PILOT STUDY,NA,NA,NA,CIRCULATION,"VIDAKOVIC, R##SCHOUTEN, O##FERINGA, HH##DUNKELGRUN, M##KARAGIANNIS, S##MERKS, E##BOSCH, J##BOM, N##NESKOVIC, AN##BAX, JJ##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS. DEDINJE CARDIOVASC INST, BELGRADE, SERBIA. LEIDEN UNIV, CTR MED, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803265,2006,MR IMAGING OF ATHEROSCLEROTIC LESIONS IN RABBIT AORTAS USING GADOFOSVESET,NA,NA,NA,CIRCULATION,"LOBBES, M##HEENEMAN, S##MISERUS, RJ##LEINER, T##KESSELS, F##WIETHOFF, A##DAEMEN, M##VAN ENGELSHOVEN, J##KOOI, ME","UNIV HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS. CLIN EPIDEMIOL & MTA, MAASTRICHT, NETHERLANDS. EPIX MED, CAMBRIDGE, MA USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803270,2006,TARGETED ALPHA-V INTEGRIN IMAGING DEFINES SPATIAL AND TEMPORAL CHANGES IN THE ANGIOGENIC PROCESS POST MYOCARDIAL INFARCTION,NA,NA,NA,CIRCULATION,"SAHUL, Z##DIONE, DP##DOBRUCKI, L##KALINOWSKI, L##BRENNAN, M##MEKKAOUI, C##CAVALIERE, P##HAWLEY, C##HU, X##HARAMIS, H##EVANS, PM##WEYMAN, C##LIU, YH##MADRI, J##SINUSAS, AJ","YALE UNIV, NEW HAVEN, CT USA. GE HEALTHCARE, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792803280,2006,CLINICAL PRESENTATION AND OUTCOMES IN CHILDREN AFFECTED BY A BRUGADA SYNDROME,NA,NA,NA,CIRCULATION,"PROBST, V##DENJOY, I##MEREGALLI, P##VELTMANN, C##AMIRAULT, JC##JESEL, L##MANSOURATI, J##SACHER, F##VILLAIN, E##LE MAREC, H##LUPOGLAZOFF, JM##WILDE, A","CHU NANTES, SERV CARDIOL, INST THORAX, F-44035 NANTES 01, FRANCE. HOSP ROBERT DEBRE, PARIS, FRANCE. ACAD MED CTR, DEPT CLIN & EXPT PHARMACOL, AMSTERDAM, NETHERLANDS. UNIV HEIDELBERG, FAC CLIN MED, UNIV HOSP MANNHEIM, DEPT MED CARDIOL 1, D-6800 MANNHEIM, GERMANY. CHU STRASBOURG, SERV CARDIOL, F-67000 STRASBOURG, FRANCE. CHU BREST, SERV CARDIOL, F-29285 BREST, FRANCE. CHU BORDEAUX, SERV CARDIOL, BORDEAUX, FRANCE. HOP NECKER ENFANTS MALAD, SERV CARDIOL PEDIAT, PARIS, FRANCE. HOP ROBERT DEBRE, UNIT CARDIOL NEONATALE, PARIS, FRANCE.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803298,2006,OPTIMAL SITE PACING IN CHILDREN: CHRONIC LV PACING PREVENTS THE LOSS IN FUNCTION ASSOCIATED WITH CHRONIC RV PACING,NA,NA,NA,CIRCULATION,"VAN GELDORP, IE##VANAGT, WY##BAUERSFELD, U##TOMASKE, M##PRINZEN, FW##DELHAAS, T","UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS. UNIV ZURICH HOSP, CH-8091 ZURICH, SWITZERLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803316,2006,EIGHT-YEAR CLINICAL OUTCOME AFTER RADIOACTIVE STENT IMPLANTATION: A MATCHED-PROPENSITY CONTROLLED COHORT STUDY,NA,NA,NA,CIRCULATION,"SIANOS, G##PAPAFAKLIS, MI##VAN DOMBURG, RT##VAN GESTEL, YR##VAN DER GIESSEN, WJ##SERRUYS, PW","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803337,2006,DO DRUG-ELUTING STENTS REMAIN SUPERIOR TO BARE METAL STENTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AFTER 3 YEARS OF FOLLOW-UP? INSIGHTS INTO THE RESEARCH AND T-SEARCH REGISTRIES,NA,NA,NA,CIRCULATION,"DAEMEN, J##GARCIA-GARCIA, HM##KUKREJA, N##SIANOS, G##DE JAEGERE, PP##VAN DOMBURG, RT##SERRUYS, PW","ERASMUS MC, THORAXCTR, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803340,2006,INCIDENCE AND PREDICTORS OF ANGIOGRAPHIC STENT THROMBOSIS IN PATIENTS TREATED WITH DRUG-ELUTING STENT IMPLANTATION FOR ST SEGMENT ELEVATION MYOCARDIAL INFARCTION,NA,NA,NA,CIRCULATION,"SIANOS, G##PAPAFAKLIS, MI##DAEMEN, J##VAINA, S##VAN MIEGHEM, CA##VAN DOMBURG, RT##MICHALIS, LK##SERRUYS, PW","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803357,2006,PLASMA B-TYPE NATRIURETIC PEPTIDE LEVELS PREDICT ATRIAL FIBRILLATION IN A POPULATION-BASED COHORT,NA,NA,NA,CIRCULATION,"ASSELBERGS, FW##VAN DEN BERG, MP##BAKKER, SJ##SIGNOROVITCH, JE##HILLEGE, HL##DE ZEEUW, D##VAN GILST, WH##VAN VELDHUISEN, DJ","UNIV GRONINGEN, UNIV MED CTR GRONINGEN, GRONINGEN, NETHERLANDS. HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803371,2006,THE EFFECT OF PREVENTIVE CORONARY REVASCULARIZATION ON POSTOPERATIVE OUTCOME IN PATIENTS UNDERGOING MAJOR VASCULAR SURGERY WITH EXTENSIVE STRESS-INDUCED MYOCARDIAL ISCHEMIA DURING PREOPERATIVE TESTING.,NA,NA,NA,CIRCULATION,"POLDERMANS, D##SCHOUTEN, O##VIDAKOVIC, F##BAX, JJ##FERINGA, HH##DUNKELGRUN, M##DE JAEGERE, PJ##VAN SAMBEEK, MR##KARAGIANNIS, SE##BOERSMA, E","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792803415,2006,N-TERMINAL PRO-BNP PREDICTS SEVERE LATE REJECTION IN HEART TRANSPLANT RECIPIENTS,NA,NA,NA,CIRCULATION,"KNOOK, AH##CALISKAN, K##VALK, SD##BOERSMA, E##BALK, AH","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803455,2006,INFLUENCE OF HEART RATE ON THE PRESENCE OF MOTION ARTEFACTS AND IMAGE RECONSTRUCTION WITH DUAL SOURCE COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY,NA,NA,NA,CIRCULATION,"WEUSTINK, A##MOLLET, NR##WILLEM, B##KRESTIN, GP##DE FEYTER, PJ","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803462,2006,PREOPERATIVE COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY TO DETECT SIGNIFICANT CORONARY ARTERY STENOSIS IN PATIENTS REFERRED FOR VALVE SURGERY,NA,NA,NA,CIRCULATION,"MEIJBOOM, WB##MOLLET, NR##VAN MIEGHEM, CA##KLUIN, J##PUGLIESE, F##WEUSTINK, A##BOGERS, AJ##KRESTIN, GP##DE FEYTER, PJ","ERASMUS MC, THORAXCTR, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803479,2006,"IMPACT OF LATE INCOMPLETE STENT APPOSITION AFTER SIROLIMUS-ELUTING STENT IMPLANTATION ON 3-YEAR CLINICAL EVENTS. INTRAVASCULAR ULTRASOUND ANALYSIS FROM THE MULTICENTER, RANDOMIZED, RAVEL, E-SIRIUS AND SIRIUS TRIALS",NA,NA,NA,CIRCULATION,"HOFFMANN, R##MORICE, MC##MOSES, J##FITZGERALD, P##SERRUYS, P##SCHOFER, J##BREITHARDT, G##STOLL, P##LEON, M","INST CARDIOVASC PARIS SUD, PARIS, FRANCE. COLUMBIA UNIV, NEW YORK, NY USA. STANFORD UNIV, STANFORD, CA 94305 USA. ERASMUS MC, ROTTERDAM, NETHERLANDS. CTR CARDIOL & VASC INTERVENT, HAMBURG, GERMANY. UNIV MUNSTER, D-4400 MUNSTER, GERMANY. CORDIS, BRUSSELS, BELGIUM.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803480,2006,THE IMPACT OF GENDER ON THE CLINICAL OUTCOME AFTER PERCUTANEOUS CORONARY REVASCULARIZATION: A REPORT FROM THE ARTS II TRIAL,NA,NA,NA,CIRCULATION,"MORICE, MC##VOUDRIS, V##VAINA, S##SZURAWITZKI, G##KRANKENHAUS, E##FONTANELLI, A##ENDRESEN, K##KRANJEC, I##WITTEBOLS, K##STOLL, HP##SERRUYS, PW","INST CARDIOVASC PARIS SUD, MASSY, FRANCE. ONASSIS CARDIAC SURG CTR, ATHENS, GREECE. ERASMUS MC, THORAXCTR, ROTTERDAM, NETHERLANDS. ELISABETH HOSP, ESSEN, GERMANY. SAN BORTOLO HOSP, VICENZA, ITALY. UNIV OSLO, RIKSHOSP, N-0027 OSLO, NORWAY. CLIN CTR LJUBLJANA, LJUBLJANA, SLOVENIA. CORDIS JOHNSON & JOHNSON, CLIN RSCH EUROPE, WATERLOO, BELGIUM.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792803483,2006,THE MISSION! INTERVENTION STUDY: PROSPECTIVE RANDOMIZED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DRUG-ELUTING STENTS VERSUS BARE-METAL STENTS FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION,NA,NA,NA,CIRCULATION,"VAN DER HOEVEN, BL##LIEM, SS##JUKEMA, JW##OEMRAWSINGH, PV##PUTTER, H##TRINES, SA##BRUSCHKE, AV##ATSMA, DE##BOOTSMA, M##ZEPPENFELD, K##VAN DER WALL, EE##SCHALIJ, MJ","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS. MED CTR HAAGLANDEN, THE HAGUE, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803544,2006,LONG-TERM OUTCOME AFTER RESTRICTIVE ANNULOPLASTY AND CORONARY REVASCULARIZATION IN ISCHEMIC MITRAL REGURGITATION,NA,NA,NA,CIRCULATION,"VAN DE VEIRE, NR##BRAUN, J##WESTENBERG, JJ##KLAUTZ, RJ##VERSTEEGH, MI##HOLMAN, ER##VAN DER WALL, EE##DION, RA##BAX, JJ","STATE UNIV GHENT HOSP, B-9000 GHENT, BELGIUM. LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803585,2006,UTILITY OF I-123-MIBG SCINTIGRAPHY IN SUBJECTS WITH HEART FAILURE FOR ASSESSMENT OF RISK FOR A MAJOR CARDIAC EVENT: A EUROPEAN MULTI-CENTER STUDY,NA,NA,NA,CIRCULATION,"AGOSTIM, D##VERBERNE, HJ##POVINEC, P##BURCHERT, W##SAMBUCETI, G##KNUUTI, J##UNLU, M##TAMAS, C##FREDERIC, H##ESTORCH, M##JACOBSON, AF","CHU COTE NACRE, NL-1105 AZ CAEN, FRANCE. UNIV AMSTERDAM, ACAD MED CTR, AMSTERDAM, NETHERLANDS. UNIV SCH MED, BRATISLAVA, SLOVAKIA. INST MOL BIOPHYS RADIOPHARM & NUKL MED, BAD OEYNHAUSEN, GERMANY. UNIV GENOA, GENOA, ITALY. TURKU UNIV, CENT HOSP, TURKU, FINLAND. GAZI UNIV, ANKARA, TURKEY. HOSPIER FREDERIC JOLIOT, ORSAY, FRANCE. HOSP SANTA CREU & SANT PAU, BARCELONA, SPAIN. GE HEALTHCARE, PRINCETON, NJ USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792803583,2006,INTRATHORACIC IMPEDANCE MONITORING TO PREDICT DECOMPENSATED HEART FAILURE,NA,NA,NA,CIRCULATION,"YPENBURG, C##BAX, JJ##SCHALIJ, MJ##VAN ERVEN, L","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803597,2006,INCREASE OF 1-YEAR MORTALITY AFTER PERIOPERATIVE BETA-BLOCKER WITHDRAWAL IN VASCULAR SURGERY PATIENTS,NA,NA,NA,CIRCULATION,"HOEKS, SE##OP REIMER, WJS##VAN URK, H##JORNING, PJ##KLINIEKEN, I##BOERSMA, E##SIMOONS, ML##BAX, JJ##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS. ISALA KLIN, ZWOLLE, NETHERLANDS. LEIDEN UNIV MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803616,2006,ROLE OF SCAR TISSUE ON RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY,NA,NA,NA,CIRCULATION,"YPENBURG, C##SCHALIJ, MJ##BLEEKER, GB##STEENDIJK, P##DIBBETS, P##STOKKEL, MP##VAN DER WALL, EE##BAX, JJ","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792803620,2006,ANATOMICAL VERSUS FUNCTIONAL ASSESSMENT OF CORONARY ARTERY DISEASE: A COMPARATIVE REGIONAL ANALYSIS OF NON INVASIVE CORONARY ANGIOGRAPHY AND CORONARY CALCIUM SCORING BY MSCT WITH MYOCARDIAL PERFUSION IMAGING BY SPECT,NA,NA,NA,CIRCULATION,"SCHUIJF, JD##WIJNS, W##JUKEMA, JW##DECRAMER, I##ATSMA, DE##DE ROOS, A##STOKKEL, MP##DIBBETS-SCHNEIDER, P##VAN DER WALL, EE##BAX, JJ","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS. CARDIOVASC CTR AALST, AALST, BELGIUM.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792803642,2006,THE LONG-TERM EFFICACY OF SIROLIMUS- AND PACLITAXEL-ELUTING STENTS AS COMPARED TO BARE METAL STENTS IN PATIENTS WITH DIABETES MELLITUS,NA,NA,NA,CIRCULATION,"DAEMEN, J##GARCIA-GARCIA, HM##KUKREJA, N##DE JAEGER, PP##VAN DOMBURG, RT##SERRUYS, PW","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804003,2006,RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM GENE POLYMORPHISMS INFLUENCE ALTERATIONS IN CARDIAC HYPERTROPHY DURING LONG-TERM FOLLOW-UP IN HYPERTROPHIC CARDIOMYOPATHY,NA,NA,NA,CIRCULATION,"MICHELS, M##KOFFLARD, MJ##TEN CATE, FJ##DANSER, AH","ERASMUS MC, ROTTERDAM, NETHERLANDS. ALBERT SCHWEITZER HOSP, DORDRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792804071,2006,ELECTROPHYSIOLOGICAL AND ARRHYTHMOGENIC EFFECTS OF INTRAMYOCARDIAL BONE MARROW CELL INJECTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE,NA,NA,NA,CIRCULATION,"BEERES, SL##ZEPPENFELD, K##BAX, JJ##VAN DER WALL, EE##ATSMA, DE##SCHALIJ, MJ","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792804107,2006,THE LONG TERM PROGNOSTIC VALUE OF NEW WALL MOTION ABNORMALITIES DURING THE RECOVERY PHASE OF DOBUTAMINE STRESS ECHOCARDIOGRAPHY IN PATIENTS RECEIVING ACUTE BETA-BLOCKADE,NA,NA,NA,CIRCULATION,"KARAGIANNIS, SE##VANDOMBURG, R##FERINGA, HH","ERASMUS MC, ROTTERDAM, NETHERLANDS. LEIDEN UNIV MED CTR, LEIDEN, NETHERLANDS. ONASSIS CARDIAC SURG CTR, ATHENS, GREECE.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804116,2006,UNEXPECTEDLY LOW INCIDENCE OF ATRIAL FIBRILLATION IN HEART FAILURE PATIENTS TREATED BY CARDIAC RESYNCHRONIZATION THERAPY,NA,NA,NA,CIRCULATION,"LECLERCQ, C##PEDELETTI, L##RITTER, P##VAN GELDER, I##STELLBRINK, C##PAUL, V##DAUBERT, C","CAREGGI HOSP, FLORENCE, ITALY. CTR CHIRURG VAL OR, ST CLOUD, FRANCE. ACAD ZIEKENHUIS GRONINGEN, GRONINGEN, NETHERLANDS. BIELEFELD HOSP, BIELEFELD, GERMANY. ST PETERS HOSP, CHERTSEY SURREY, ENGLAND. UNIV HOSP, RENNES, FRANCE.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804196,2006,REVERSE RIGHT VENTRICULAR REMODELING AFTER PULMONARY ENDARTERECTOMY ASSESSED BY MRI,NA,NA,NA,CIRCULATION,"TULEVSKI, I##REESINK, HJ##JAMIESON, S##MARCUS, JT##NOORDEGRAAF, AV##KLOEK, JJ##BRESSER, P","AMC, AMSTERDAM, NETHERLANDS. UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA. VU, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804200,2006,CARDIOVASCULAR RISK FACTORS AFFECT AGE DISTRIBUTION OF ATHEROSCLEROTIC DISEASE BURDEN AS ASSESSED BY MAGNETIC RESONANCE IMAGING,NA,NA,NA,CIRCULATION,"AGUIAR, SH##WEINSHELBAUM, KB##MANI, V##POSTLEY, JE##BHANGOO, A##TEN, S##MITCHELL, DG##SALAND, J##STARC, TJ##VAN DER GEEST, RJ##REIBER, JH##BELAMARICH, P##WILLIAMS, CL##HUDGINS, LC##FUSTER, V##GIDDING, SS##FAYAD, ZA","MT SINAI MED CTR, NEW YORK, NY 10029 USA. ALFRED I DUPONT HOSP CHILDREN, WILMINGTON, DE USA. ROCKEFELLER UNIV, NEW YORK, NY 10021 USA. COLUMBIA UNIV, MED CTR, NEW YORK, NY USA. MONTEFIORE, CHILDRENS HOSP, NEW YORK, NY USA. LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS. THOMAS JEFFERSON UNIV, PHILADELPHIA, PA 19107 USA. MAIMONIDES HOSP, NEW YORK, NY USA. COLUMBIA UNIV, COLL PHYS & SURG, NEW YORK, NY USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804229,2006,SAFETY AND FEASIBILITY OF ELECTIVE HIGH-RISK PERCUTANEOUS CORONARY INTERVENTION PROCEDURES WITH LEFT VENTRICULAR SUPPORT OF THE IMPELLA RECOVER LP 2.5 DEVICE,NA,NA,NA,CIRCULATION,"SJAUW, KD##REMMELINK, M##VIS, MM##VAN DER SCHAAF, RJ##KOCH, KT##BAAN, J##TIJSSEN, JG##PIEK, JJ##DE WINTER, RJ##HENRIQUES, JP","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804300,2006,IMPACT OF PREOPERATIVE PATIENT SELECTION BY MYOCARDIAL VIABILITY ASSESSMENT VIA PET IN PATIENTS WITH SEVERE IMPAIRED LV-FUNCTION AFTER CABG,NA,NA,NA,CIRCULATION,"BOEHM, J##WILDHIRT, SM##BAUERNSCHMITT, R##HAAS, F##WAGENPFEIL, S##WOTTKE, M##SCHWAIGER, M##LANGE, R","GERMAN HEART CTR, D-8000 MUNICH, GERMANY. UMC UTRECHT, DEPT CARDIOTHORAC SURG, UTRECHT, NETHERLANDS. INST MED STAT & EPIDEMIOL, MUNICH, GERMANY. DEPT NUCL MED, MUNICH, GERMANY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804330,2006,STIFFNESS OF HYPERTROPHIED CARDIOMYOCYTES DIFFERS IN AORTIC STENOSIS AND ARTERIAL HYPERTENSION,NA,NA,NA,CIRCULATION,"FALCAO-PIRES, I##HAMDANI, N##VAN DER VELDEN, J##STIENEN, GJ##NIESSEN, HW##GAVINA, C##ALMEIDA, J##PINHO, P##LEITE-MOREIRA, AF##PAULUS, WJ","VUMC PHYSIOL, AMSTERDAM, NETHERLANDS. VUMC PATHOL, AMSTERDAM, NETHERLANDS. UNIV PORTO, P-4100 OPORTO, PORTUGAL.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804335,2006,MYOFILAMENT DYSFUNCTION IN HUMAN CARDIOMYOCYTES WITH FABRY DISEASE,NA,NA,NA,CIRCULATION,"CHIMENTI, C##VAN DER VELDEN, J##HAMDANI, N##BOONTJE, NM##VERARDO, R##STIENEN, GJ##GAUDIO, C##RUSSO, MA##PAULUS, WJ##FRUSTACI, A","UNIV ROMA LA SAPIENZA, I-00161 ROME, ITALY. FREE UNIV AMSTERDAM, NL-1007 MC AMSTERDAM, NETHERLANDS. NATL INST INFECT DIS L SPALLANZANI, ROME, ITALY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804358,2006,NON-INVASIVE VISUALIZATION OF THE CARDIAC VENOUS SYSTEM IN CORONARY ARTERY DISEASE PATIENTS USING 64-SLICE COMPUTED TOMOGRAPHY,NA,NA,NA,CIRCULATION,"VAN DE VEIRE, NR##SCHUIJF, JD##DE SUTTER, J##DEVOS, D##BLEEKER, GB##DE ROOS, A##VAN DER WALL, EE##SCHALIJ, MJ##BAX, JJ","GHENT UNIV HOSP, B-9000 GHENT, BELGIUM. LEIDEN UNIV, MED CTR, NL-2300 RA LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804372,2006,A NEW FUNCTIONAL GENOMIC APPROACH TO IDENTIFY SOLUBLE MEDIATORS OF ATHEROSCLEROTIC PLAQUE STABILIZATION,NA,NA,NA,CIRCULATION,"LUTGENS, SP##HEENEMAN, S##VINK, PM##VAN ELSAS, A##SIJBERS, AM##LUTGENS, E##DAEMEN, MJ##CLEUTJENS, KB","UNIV LIMBURG, DEPT PATHOL, NL-6200 MD MAASTRICHT, NETHERLANDS. NV ORGANON, DEPT PHARMACOL, OSS, NETHERLANDS. NV ORGANON, DEPT TARGET DISCOVERY, OSS, NETHERLANDS. NV ORGANON, DEPT MOL DESIGN & INFORMAT, OSS, NETHERLANDS. DEPT PATHOL, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804374,2006,THE APOA5 GENE IS ASSOCIATED WITH FAMILIAL COMBINED HYPERLIPIDEMIA AND DYSLIPIDEMIA,NA,NA,NA,CIRCULATION,"VAN DER VLEUTEN, GM##ISAACS, A##ZENG, WW##TER AVEST, E##TALMUD, PJ##DALLINGA-THIE, GM##VAN DUIJN, CM##STALENHOEF, AF##DE GRAAF, J","RADBOUD UNIV NIJMEGEN, NIJMEGEN, NETHERLANDS. ERASMUS UNIV, MED CTR, NL-3000 DR ROTTERDAM, NETHERLANDS. PEKING UNION MED COLL, BEIJING, PEOPLES R CHINA. CHINESE ACAD MED SCI, BEIJING, PEOPLES R CHINA. UCL ROYAL FREE & UNIV COLL MED SCH, LONDON, ENGLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804402,2006,OUTCOME OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS IN ADULTS WITH CONGENITAL HEART DISEASE: A MULTICENTRE STUDY,NA,NA,NA,CIRCULATION,"YAP, SC##ROOS-HESSELINK, JW##HOENDERMIS, E##BUDTS, W##VLIEGEN, HW##MULDER, BJ##VAN DIJK, AP##SCHALIJ, MJ##DRENTHEN, W","ERASMUS MC, ROTTERDAM, NETHERLANDS. UNIV GRONINGEN, MED CNTR, GRONINGEN, NETHERLANDS. UNIV HOSP LEUVEN, LOUVAIN, BELGIUM. LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS. ACAD MED CTR, AMSTERDAM, NETHERLANDS. UNIV NIJMEGEN, MED CTR, NIJMEGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804437,2006,HYBRID ABLATION AND PREVENTIVE PACING THERAPY TO CONTROL PERSISTENT ATRIAL FIBRILLATION: THE HAPPI-AF TRIAL,NA,NA,NA,CIRCULATION,"REDDY, VY##NEUZIL, P##TABORSKY, M##SKODA, J##ALBERS, B##ROGER, G##MOUTON, S","MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA. NA HOMOLCE HOSP, PRAGUE, CZECH REPUBLIC. VITATRON BV, ARNHEM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804445,2006,PROGNOSTIC VALUE OF MULTI-SLICE COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY IN PATIENTS WITH KNOWN OR SUSPECTED CORONARY ARTERY DISEASE,NA,NA,NA,CIRCULATION,"PUNDZIUTE, G##SCHUIJF, JD##JUKEMA, WJ##BOERSMA, E##DE ROOS, A##VAN DER WALL, EE##BAX, JJ","LEIDEN UNIV, MED CTR, DEPT CARDIOL, LEIDEN, NETHERLANDS. ERASMUS UNIV, DEPT EPIDEMIOL & STAT, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT RADIOL, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804471,2006,FONDAPARINUX VERSUS CONTROL (PLACEBO OR UNFRACTIONATED HEPARIN) AS AN ADJUNCT TO THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION: AN OASIS 6 SUBSTUDY,NA,NA,NA,CIRCULATION,"PETERS, RJ##JOYNER, C##BASSAND, JP##AFZAL, R##CHROLAVICIUS, S##MEHTA, SR##BUDAJ, A##FOX, KA##YUSUF, S","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV TORONTO, TORONTO, ON, CANADA. UNIV BESANCON, F-25030 BESANCON, FRANCE. MCMASTER UNIV, HAMILTON, ON, CANADA. GROCHOWSKI HOSP, WARSAW, POLAND. UNIV EDINBURGH, EDINBURGH, MIDLOTHIAN, SCOTLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,5,2020-11-20,NA
J,WOS:000241792804473,2006,EFFECTS OF FONDAPARINUX IN PATIENTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION NON-ELIGIBLE FOR REPERFUSION TREATMENT,NA,NA,NA,CIRCULATION,"WALLENTIN, LC##MEHTA, SR##AFZAL, R##CHROLAVICIUS, S##GRANGER, CB##BUDAJ, A##PETERS, RJ##BASSAND, JP##FOX, KA##YUSUF, S","UPPSALA CLIN RES CTR, UPPSALA, SWEDEN. MCMASTER UNIV, DEPT MED, HAMILTON, ON, CANADA. DUKE UNIV, DURHAM, NC 27706 USA. GROCHOWSKI HOSP, DIV CARDIOL, WARSAW, POLAND. UNIV AMSTERDAM, DIV CARDIOL, AMSTERDAM, NETHERLANDS. UNIV BESANCON, DIV CARDIOL, F-25030 BESANCON, FRANCE. UNIV EDINBURGH, CARDIOVASC RES DIV, EDINBURGH, MIDLOTHIAN, SCOTLAND. MCMASTER UNIV, HAMILTON, ON, CANADA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,3,2020-11-20,NA
J,WOS:000241792804477,2006,ASPIRIN AND MEDIUM INTENSITY COUMADIN VERSUS ASPIRIN ALONE IN THE PREVENTION OF REOCCLUSION AFTER SUCCESSFUL THROMBOLYSIS FOR SUSPECTED ACUTE MYOCARDIAL INFARCTION: 5-YEAR FOLLOW-UP OF THE APRICOT-2 TRIAL,NA,NA,NA,CIRCULATION,"VAN DEN BERGH, PJ##BROUWER, MA##KIEVIT, PC##AENGEVAEREN, WR##VEEN, G##LUIJTEN, HE##VAN BOVEN, AJ##HERTZBERGER, DP##VERHEUGT, FW","UNIV NIJMEGEN, MED CTR, NIJMEGEN, NETHERLANDS. INTERUNIV CARDIOL INST NETHERLANDS, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804487,2006,SEXUAL PROBLEMS IN HEART FAILURE PATIENTS COMPARED TO A COMMUNITY DWELLING ELDERLY POPULATION WITHOUT CARDIAC DISEASE,NA,NA,NA,CIRCULATION,"JAARSMA, T##LUTTIK, ML##RANCHOR, AV##VAN VELDHUISEN, DJ","UNIV GRONINGEN, MED CTR, GRONINGEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804534,2006,SUPERIORITY OF APOB/APOA1 RATIO FOR PREDICTING CARDIOVASCULAR RISK IN POOLED ANALYSES OF THE INCREMENTAL DECREASE IN ENDPOINTS THROUGH AGGRESSIVE LIPID-LOWERING (IDEAL) AND TREATING TO NEW TARGETS (TNT) TRIALS,NA,NA,NA,CIRCULATION,"KASTELEIN, JJ##HOLME, I##BARTER, P##OLSSON, AG##CATER, NB##DEMICCO, DA##GAFFNEY, M##SZAREK, M##LAROSA, JC##PEDERSEN, TR","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. ULLEVAAL UNIV HOSP, OSLO, NORWAY. HEART RES INST, SYDNEY, NSW, AUSTRALIA. LINKOPING UNIV HOSP, S-58185 LINKOPING, SWEDEN. PFIZER INC, NEW YORK, NY USA. NYU, CTR HLTH SCI, NEW YORK, NY USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792804560,2006,AMINO-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE TESTING IS SUPERIOR TO NEW YORK HEART ASSOCIATION CLASSIFICATION FOR PREDICTION OF ONE-YEAR MORTALITY IN PATIENTS WITH ACUTE HEART FAILURE: RESULTS FROM THE INTERNATIONAL COLLABORATIVE OF NT-PROBNP STUDY,NA,NA,NA,CIRCULATION,"BAGGISH, AL##RICHARDS, AM##VAN KIMMENADE, RR##BAYES-GENIS, A##LAINCHBURY, J##PINTO, Y##JANUZZI, JL","MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA. CHRISTCHURCH HOSP, CHRISTCHURCH, NEW ZEALAND. ACAD HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS. HOSP SANTA CREU & SANT PAU, BARCELONA, SPAIN.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804566,2006,THE VALUE OF SOLUBLE ST2 MEASUREMENT FOR THE DIAGNOSTIC AND PROGNOSTIC EVALUATION OF PATIENTS WITH ACUTE DYSPNEA,NA,NA,NA,CIRCULATION,"JANUZZI, JL##PEACOCK, WF##JESSE, RL##MAISEL, AS##NEWELL, JB##BAGGISH, AL##SAKHUJA, R##O'DONOGHUE, M##CHEN, AA##VAN KIMMENADE, RR##LEWANDROWSKI, KB##WU, AB","MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA. CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA. VIRGINIA COMMONWEALTH UNIV, RICHMOND, VA USA. UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA. ACAD HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS. UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804568,2006,A NOVEL TBX5 MUTATION LEADS TO ENHANCED DNA-BINDING IN A FAMILY WITH HOLT-ORAM SYNDROME AND PAROXYSMAL ATRIAL FIBRILLATION,NA,NA,NA,CIRCULATION,"POSTMA, A##VD MEERAKKER, J##ILGUN, A##CHRISTOFFELS, V##BARNETT, P##MATHIJSSEN, I##LAM, J##DEPREZ, RL##MOORMAN, A","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804569,2006,THE COMMON LQT1 MUTATION KCNQ1/A341V PREDICTS HIGH RISK OF CARDIAC EVENTS IN DIFFERENT ETHNIC BACKGROUNDS,NA,NA,NA,CIRCULATION,"SCHWARTZ, PJ##SPAZZOLINI, C##CROTTI, L##VICENTINI, A##HORIE, M##MOSS, AJ##SHIMIZU, W##SCHULZE-BAHR, E##WILDE, AA","IRCCS, POLICLIN SAN MATTEO, PAVIA, ITALY. UNIV PAVIA, I-27100 PAVIA, ITALY. SHIGA UNIV MED SCI, OTSU, SHIGA, JAPAN. UNIV ROCHESTER, MED CTR, ROCHESTER, NY 14642 USA. NATL CARDIOVASC CTR, OSAKA, JAPAN. UNIV KLINIKUM MUNSTER, MUNSTER, GERMANY. UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804575,2006,PRIMARY INHERITED ELECTRICAL HEART DISEASE: YIELD OF MOLECULAR GENETIC TESTING IN FAMILIAL AND ISOLATED CASES: A TEN YEAR EXPERIENCE IN THE NETHERLANDS,NA,NA,NA,CIRCULATION,"HOFMAN, N##TAN, HL##VAN LANGEN, IM##BIRNIE, E##MANNENS, MM##WILDE, AA","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792804609,2006,NONCARDIAC SURGERY AFTER CORONARY STENTING; EARLY SURGERY AND INTERRUPTION OF ANTIPLATELET THERAPY ARE ASSOCIATED WITH AN INCREASE IN MAJOR ADVERSE CARDIAC EVENTS,NA,NA,NA,CIRCULATION,"SCHOUTEN, O##VAN DOMBURG, RT##BAX, JJ##DE JAEGERE, PJ##DUNKELGRUN, M##FERINGA, HH##HOEKS, S##VIDAKOVIC, R##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, NL-2300 RA LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804621,2006,PRENATALLY FABRICATED AUTOLOGOUS HUMAN LIVING HEART VALVES BASED ON FETAL AMNIOTIC FLUID-DERIVED PROGENITORS AS SINGLE CELL SOURCE,NA,NA,NA,CIRCULATION,"SCHMIDT, D##ACHERMANN, J##BREYMANN, C##ODERMATT, B##MOL, A##GENONI, M##ZUND, G##HOERSTRUP, SP","UNIV ZURICH HOSP, CARDIOVASC SURG CLIN, CH-8091 ZURICH, SWITZERLAND. HUMAN GENET LAB, ZURICH, SWITZERLAND. UNIV ZURICH HOSP, OBSTET RES, FETO MATERNAL HAEMATOL RES GRP, ZURICH, SWITZERLAND. HIRSLANDEN CLIN GRP ZURICH, OBGYN CTR SEEFELD, GGS, ZURICH, SWITZERLAND. UNIV ZURICH HOSP, INST CLIN PATHOL, ZURICH, SWITZERLAND. TECH UNIV EINDHOVEN, DEPT BIOMED ENGN, NL-5600 MB EINDHOVEN, NETHERLANDS. UNIV ZURICH HOSP, CARDIOVASC SURG CLIN, ZURICH, SWITZERLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804644,2006,COMBINED EMBOLIC PROTECTION AND THROMBECTOMY IN PERCUTANEOUS CORONARY INTERVENTION OF ACUTE MYOCARDIAL INFARCTION USING THE PROXIS (R)-DEVICE,NA,NA,NA,CIRCULATION,"ALIDJAN, F","ACAD MED CTR, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804693,2006,ELDERLY PATIENTS UNDERGOING MAJOR NON-CARDIAC SURGERY: PERIOPERATIVE AND LONG-TERM RISK REDUCTION,NA,NA,NA,CIRCULATION,"FERINGA, HH##DE LIEFDE, I##HOEKS, S##DUNKELGRUN, M##NOORDZIJ, PG##KARAGIANNIS, S##VIDAKOVIC, R##SCHOUTEN, O##BAX, JJ##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, CTR MED, NL-2300 RA LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792804692,2006,LONG-TERM PROGNOSIS OF VASCULAR SURGERY PATIENTS USING PERIOPERATIVE TROPONIN T RELEASE: IS THERE A THRESHOLD?,NA,NA,NA,CIRCULATION,"FERINGA, HH##VIDAKOVIC, R##KARAGIANNIS, S##DUNKELGRUM, M##SCHOUTEN, O##VAN DOMBURG, R##HOEKS, S##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805015,2006,STRONG HUMAN TISSUE-ENGINEERED BLOOD VESSELS: CULTURED IN WEEKS INSTEAD OF MONTHS,NA,NA,NA,CIRCULATION,"STEKELENBURG, M##RUTTEN, MC##BAAIJENS, FP##SNOECKX, LH","EINDHOVEN UNIV TECHNOL, NL-5600 MB EINDHOVEN, NETHERLANDS. MAASTRICHT UNIV, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805057,2006,RIGHT VENTRICULAR PUMP FUNCTION IS IMPROVED BY SUBOPTIMAL LEFT VENTRICULAR RESYNCHRONIZATION IN CANINE LBBB HEARTS,NA,NA,NA,CIRCULATION,"VAN KERCKHOVEN, R##STORM, R##VERNOOY, K##VAN HUNNIK, A##KUIPER, M##CORNELUSSEN, R##PRINZEN, FW","UNIV MAASTRICHT, CARIM, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792805062,2006,EXTENT OF VIABILITY TO PREDICT RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY,NA,NA,NA,CIRCULATION,"YPENBURG, C##SCHALIJ, MJ##BLEEKER, GB##STEENDIJK, P##DIBBETS, P##STOKKEL, MP##VAN DER WALL, EE##BAX, JJ","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805063,2006,INCREASE OF LOWER PACING RATE REDUCES CARDIAC CONGESTION IN PATIENTS WITH HEART FAILURE AND CRT,NA,NA,NA,CIRCULATION,"BRAUNSCHWEIG, F##BRUNS, HJ##GADLER, F##ERSGARD, D##STAHLBERG, M##GRANDJEAN, PA##HILL, M","KAROLINSKA UNIV HOSP, STOCKHOLM, SWEDEN. MEDTRONIC NEDERLANDS, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805138,2006,FAVOURABLE ONE YEAR OUTCOME FOLLOWING DRUG ELUTING STENT IMPLANTATION IN NON BIFURCATIONAL LESIONS INVOLVING UNPROTECTED LEFT MAIN CORONARY ARTERY: A MULTICENTER REGISTRY,NA,NA,NA,CIRCULATION,"CHIEFFO, A##PARK, SJ##VALGIMIGLI, M##KIM, YH##SHEIBAN, I##DAEMEN, J##TRUFFA, A##MONTORFANO, M##AIROLDI, F##MELZI, G##LEE, CW##HONG, K##PARK, SW##SERRUYS, PW","SAN RAFFAELE SCI INST, I-20132 MILAN, ITALY. ASAN MED CTR, SEOUL, SOUTH KOREA. ERASMUS MC, ROTTERDAM, NETHERLANDS. SAN GIOVANNI BATTISTA HOSP, TURIN, ITALY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805139,2006,THE IMPACT OF MULTIVESSEL DISEASE ON LONG-TERM MORTALITY IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION IS DUE TO THE PRESENCE OF A CHRONIC TOTAL OCCLUSION,NA,NA,NA,CIRCULATION,"VAN DER SCHAAF, RJ##VIS, MM##SJAUW, KD##KOCH, KT##BAAN, J##TIJSSEN, JG##PIEK, JJ##DE WINTER, RJ##HENRIQUES, JP","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805151,2006,MYOCARDIAL PERFUSION SCINTIGRAPHY VERSUS INTRACORONARY FLOW VELOCITY RESERVE IN MULTIVESSEL CORONARY ARTERY DISEASE: LONG TERM CLINICAL FOLLOW-UP,NA,NA,NA,CIRCULATION,"CHAMULEAU, SA##VAN ECK-SMIT, BL##DIJKGRAAF, MG##TIJSSEN, JG##PIEK, JJ","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805152,2006,PRE-STENT FRACTIONAL FLOW RESERVE AND STENT DIAMETER PREDICT OPTIMAL POST STENT FRACTIONAL FLOW RESERVE: IMPLICATIONS FOR SELECTION OF DRUG ELUTING STENTS,NA,NA,NA,CIRCULATION,"SAMADY, H##MCDANIEL, MC##VELEDAR, E##DE BRUYNE, B##PIJLS, NH##HELMY, TA##MAVROMATIS, K##GHAZZAL, ZM##VACCARINO, V","EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA. CARDIOVASC CTR AALST, AALST, BELGIUM. CATHARINA HOSP, EINDHOVEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805173,2006,SHOULD ALL PATIENTS PRESENTING WITH SHORTLASTING NEW ONSET ATRIAL FIBRILLATION RECEIVE ANTICOAGULATION?,NA,NA,NA,CIRCULATION,"DINH, T##BUKKEMS, SF##CRIJNS, HJ##TIELEMAN, RG","UNIV HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805210,2006,INTENSIVE LIPID LOWERING WITH ATORVASTATIN IS ASSOCIATED WITH SIGNIFICANT CARDIOVASCULAR BENEFITS IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE: THE TREATING TO NEW TARGETS (TNT) STUDY,NA,NA,NA,CIRCULATION,"SHEPHERD, J##WENGER, NK##KASTELEIN, JJ##BITTNER, V##DEEDWANIA, P##LAROSA, JC","UNIV GLASGOW, GLASGOW, LANARK, SCOTLAND. EMORY UNIV, SCH MED, ATLANTA, GA USA. UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS. UNIV ALABAMA, BIRMINGHAM, AL USA. UCSF, SCH MED, FRESNO, CA USA. VA CENT CALIF HEALTHCARE SYST, FRESNO, CA USA. SUNY HLTH SCI CTR, NEW YORK, NY USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805225,2006,CIRCULATING WHITE BLOOD CELLS AMPLIFY OXIDATIVE STRESS IN CONGESTIVE HEART FAILURE,NA,NA,NA,CIRCULATION,"IJSSELMUIDEN, AJ##MUSTERS, RJ##LEYTE, A##TANGELDER, GJ##DE RUITER, G##LAARMAN, GJ##PAULUS, WJ","VUMC PHYSIOL, AMSTERDAM, NETHERLANDS. OLVG HEMATOL & CHEM, AMSTERDAM, NETHERLANDS. OLVG CARDIOL, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805226,2006,SYSTEMIC OXIDATIVE STRESS IS INCREASED IN PATIENTS WITH HEART FAILURE,NA,NA,NA,CIRCULATION,"KISHIMOTO, C##SHIOJI, K##NAKAMURA, H##YODOI, J##NIMATA, M##TAMAKI, S##HASHIMOTO, T##KAWAI, C","VUMC PHYSIOL, AMSTERDAM, NETHERLANDS. OLVG HEMATOL & CHEM, AMSTERDAM, NETHERLANDS. OLVG CARDIOL, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805233,2006,"FIBROSIS, AGES OR STIFF CARDIOMYOCYTES: WHICH ONE TO BLAME FOR THE HIGH DIASTOLIC STIFFNESS OF THE DIABETIC HEART?",NA,NA,NA,CIRCULATION,"VAN HEEREBEEK, L##HANDOKO, ML##HAMDANI, N##NIESSEN, HW##VAN DER VELDEN, J##STIENEN, G##LAARMAN, GJ##PAULUS, WJ","VUMC PHYSIOL, AMSTERDAM, NETHERLANDS. OLVG CARDIOL, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805260,2006,"LONG-TERM EFFECT OF PERINDOPRIL ON CORONARY ATHEROSCLEROSIS PROGRESSION: RESULTS FROM THE MULTICENTER, RANDOMIZED PERINDOPRIL'S PROSPECTIVE EFFECT ON CORONARY ATHEROSCLEROSIS BY ANGIOGRAPHY AND INTRAVASCULAR ULTRASOUND EVALUATION (PERSPECTIVE) STUDY, AN EUROPA SUBSTUDY",NA,NA,NA,CIRCULATION,"GARCIA-GARCIA, HM##RODRIGUEZ-GRANILLO, GA##VOS, J##BRUINING, N##DE WINTER, S##LIGTHART, JM##DECKERS, J##SIMOONS, ML##FOX, KM##DE FEYTER, PJ","ERASMUS UNIV, THORAXCTR, MED CTR, NL-3000 DR ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805270,2006,EXPERIENCE WITH 21 FRENCH PERCUTANEOUS COREVALVE AORTIC VALVE REPLACEMENT IN PATIENTS UNSUITABLE FOR SURGICAL AORTIC VALVE REPLACEMENT,NA,NA,NA,CIRCULATION,"GRUBE, E##LABORDE, JC##CARTIER, R##GERCKENS, U##SERRUYS, PW##DEJAEGERE, P##SCHULER, G##DEN HEIJER, P##BOSMANS, J##RUIZ, CE##BONAN, R","INST CARDIOL MONTREAL, MONTREAL, PQ 10021, CANADA. LENOX HILL HOSP, D-7010 NEW YORK, NY USA. UNIV LEIPZIG, CTR HEART, NL-3000 DR LEIPZIG, GERMANY. ERASMUS UNIV, THORAXCTR, ROTTERDAM, NETHERLANDS. CLIN PASTEUR, TOULOUSE, FRANCE. HELIOS KLIN, SIEGBURG, GERMANY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,1,2020-11-20,NA
J,WOS:000241792805277,2006,AGE-DEPENDENT EFFECT OF ABCIXIMAB IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH PERCUTANEOUS CORONARY INTERVENTIONS,NA,NA,NA,CIRCULATION,"MEHILLI, J##NDREPEPA, G##KASTRATI, A##NEUMANN, FJ##TEN BERG, J##BRUSKINA, O##DOTZER, F##SEYFARTH, M##DIRSCHINGER, J##PACHE, J##BERGER, PB##SCHOMIG, A","DEUTSCH HERZZENTRUM MUNICH, MUNICH, GERMANY. DUKE CLIN RES INST, DURHAM, NC USA. TECH UNIV MUNICH, KLINIKUM RECHTS ISAR, MED KLIN 1, D-8000 MUNICH, GERMANY. ST ANTONIUS HOSP, NIEUWEGEIN, NETHERLANDS. HERZ ZENTRUM BAD KROZINGEN, BAD KROZINGEN, GERMANY.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805294,2006,DOES DIASTOLIC HEART FAILURE EVOLVE TO SYSTOLIC HEART FAILURE?,NA,NA,NA,CIRCULATION,"HANDOKO, ML##VAN HEEREBEEK, L##BRONZWAER, JG##PAULUS, WJ","VUMC PHYSIOL, AMSTERDAM, NETHERLANDS. VUMC CARDIOL, AMSTERDAM, NETHERLANDS. VUMC PHYSIOL, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,4,2020-11-20,NA
J,WOS:000241792805309,2006,"ENDOVASCULAR REPAIR OF ABDOMINAL AORTIC ANEURYSM IS ASSOCIATED WITH REDUCED PERIOPERATIVE MYOCARDIAL ISCHEMIA DURING CONTINUOUS 12-LEAD ECG MONITORING, TROPONIN T RELEASE AND ALL-CAUSE MORTALITY",NA,NA,NA,CIRCULATION,"FERINGA, HH##BAX, JJ##SCHOUTEN, O##VAN DOMBURG, RT##DUNKELGRUN, M##VAN SAMBEEK, MR##NOORDZIJ, PG##VIDAKOVIC, R##HOEKS, S##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, CTR MED, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805306,2006,ASSESSMENT OF CORONARY BIFURCATION LESIONS WITH 64-SLICE COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY,NA,NA,NA,CIRCULATION,"VAN MIEGHEM, CA##MEIJBOOM, WB##CADEMARTIRI, F##MOLLET, NR##WEUSTINK, A##KRESTIN, GP##SERRUYS, PW##DE FEYLER, PJ","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805330,2006,EPICARDIAL ADIPOSE TISSUE IS ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS AND CORONARY ARTERY CALCIFICATION: A POPULATION BASED STUDY,NA,NA,NA,CIRCULATION,"DE VOS, AM##PROKOP, M##ROOS, K##MEIJS, MF##RUTTEN, A##MOSTERD, A##CRAMER, MJM##VELTHUIS, BK##RENSING, BJ##DOEVENDANS, PA##VAN DER SCHOUW, YT##BOTS, ML","UNIV UTRECHT, MED CTR, JULIUS CTR, NL-3508 TC UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, NIEUWEGEIN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805367,2006,SHOULD WE ABANDON THE PARADIGM OF WITHHOLDING ORAL ANTICOAGULATION IN PAROXYSMAL ATRIAL FIBRILLATION?,NA,NA,NA,CIRCULATION,"DINH, T##NIEUWLAAT, R##CAPUCCI, A##OLSSON, SB##LEVY, S##VARDAS, PE##CRIJNS, HJ","UNIV HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS. GUGLIELMO SALICETO HOSP, PIACENZA, ITALY. UNIV LUND HOSP, S-22185 LUND, SWEDEN. CHU NORD, MARSEILLE, FRANCE. UNIV HOSP HERAKLION, IRAKLION, GREECE.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805366,2006,GUIDELINE ADHERENT ANTITHROMBOTIC TREATMENT IS ASSOCIATED WITH IMPROVED CARDIOVASCULAR OUTCOME COMPARED TO UNDERTREATMENT IN REAL-LIFE ATRIAL FIBRILLATION PATIENTS AT HIGH RISK FOR STROKE,NA,NA,NA,CIRCULATION,"NIEUWLAAT, R##OLSSON, SB##CAPUCCI, A##DAVIES, DW##ALLOT, E##CRIJNS, H","UNIV HOSP MAASTRICHT, S-22185 MAASTRICHT, NETHERLANDS. UNIV LUND HOSP, LUND, SWEDEN. GUGLIELMO DA SALICETO HOSP, PIACENZA, ITALY. ST MARYS HOSP, LONDON, ENGLAND. UNIV HOSP NANCY, NANCY, FRANCE.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805384,2006,INTERACTION BETWEEN C-REACTIVE PROTEIN AND COMPLEMENT INHIBITOR FACTOR H AND RISK OF MYOCARDIAL INFARCTION. THE ROTTERDAM STUDY.,NA,NA,NA,CIRCULATION,"KARDYS, I##DE MAAT, MP##KLAVER, CC##DESPRIET, DD##UITTERLINDEN, AG##HOFMAN, A##DE JONG, PT##WITTEMAN, JC","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805429,2006,EXERCISE TRAINING INCREASES OXYGEN UPTAKE EFFICIENCY IN HEART FAILURE,NA,NA,NA,CIRCULATION,"GADEMAN, MG##SWENNE, CA##VERWEY, HF##VAN DE VOOREN, H##VAN EXEL, HJ##LUCAS, CM##CLEUREN, GV##SCHALIJ, MJ##VAN DER WALL, EE","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS. RIJNLANDS REHABIL CTR, LEIDEN, NETHERLANDS. RIJNLAND HOSP, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805480,2006,TNF-ALPHA PRODUCTION FOLLOWING TOLL-LIKE RECEPTOR STIMULATION AND CD11B EXPRESSION AN MONOCYTES IS RELATED TO BODY-MASS INDEX IN ATHEROSCLEROTIC PATIENTS,NA,NA,NA,CIRCULATION,"VERSTEEG, D##HOEFER, IE##SCHONEVELD, A##STRIJDER, C##BUSSER, E##STELLA, P##DOEVENDANS, P##PASTORKAMP, G","UMC UTRECHT, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805506,2006,LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ACTIVITY AND RISK OF HEART FAILURE. THE ROTTERDAM STUDY.,NA,NA,NA,CIRCULATION,"KARDYS, I##VAN VARK, LC##BLEUMINK, GS##KNETSCH, AM##DECKERS, JW##HOFMAN, A##STRICKER, BH##WITTEMAN, JC","ERASMUS MED CNTR, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805545,2006,"GRANULOCYTE COUNTS AND NOT MONOCYTE OR LYMPHOCYTE COUNTS ARE ASSOCIATED WITH INCREASED RISK OF CORONARY HEART DISEASE, CARDIOVASCULAR DISEASE AND TOTAL MORTALITY IN 16,108 APPARENTLY HEALTHY MEN AND WOMEN IN THE EPIC-NORFOLK PROSPECTIVE POPULATION STUDY",NA,NA,NA,CIRCULATION,"RANA, JS##BOEKHOLDT, M##JUKEMA, W##BINGHAM, SA##DAY, NE##WAREHAM, NJ##KASTELEIN, JJ##KHAW, KT","UNIV PITTSBURGH, PITTSBURGH, PA USA. UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS. MRC DUNN NUTR UNIT, CAMBRIDGE, ENGLAND. UNIV CAMBRIDGE, CAMBRIDGE, ENGLAND. MRC, EPIDEMIOL UNIT, CAMBRIDGE, ENGLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805554,2006,THE EFFECTS OF LOW-DOSE SIMVASTATIN AND EZETIMIBE COMPARED TO HIGH-DOSE SIMVASTATIN ON POSTPRANDIAL LIPIDS AND ENDOTHELIAL FUNCTION IN PATIENTS WITH THE METABOLIC SYNDROME,NA,NA,NA,CIRCULATION,"OLIJHOEK, JK##HAJER, GR##VAN DER GRAAT, Y##DALLINGA-THIE, GM##VISSEREN, FL","UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS. ERASMUS UNIV, MED CTR, ROTTERDAM, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805558,2006,ALTERED HOMEOSTATIC RESPONSE TO POSTURAL CHANGE AND LOSS OF CAPILLARY AUTOREGULATION IN DIABETIC (TYPE 1) NEPHROPATHY,NA,NA,NA,CIRCULATION,"KAMPHUISEN, P##TAMSMA, JT","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805633,2006,CHOLESTEROL LEVELS IN DIFFERENT LDL SUBCLASSES AND CHD INCIDENCE APPARENTLY HEALTHY MEN AND WOMEN: THE EPIC-NORFOLK PROSPECTIVE POPULATION STUDY,NA,NA,NA,CIRCULATION,"ARSENAULT, BJ##LEMIEUX, I##DESPRES, JP##BOEKHOLDT, MS##WAREHAM, NJ##BINGHAM, SA##KHAW, KT","HOP LAVAL, RES CTR, STE FOY, PQ, CANADA. UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. MRC, EPIDEMIOL UNIT, CAMBRIDGE, ENGLAND. MRC, DUNN NUTR UNIT, CAMBRIDGE CB4 1XJ, ENGLAND. INST PUBL HLTH & PRIMARY CARE, CAMBRIDGE, ENGLAND.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805667,2006,HIGH-DOSE ATORVASTATIN THERAPY CAN COMPLETELY REVERSE MONOCYTE DYSFUNCTION IN HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY ARTERY DISEASE,NA,NA,NA,CIRCULATION,"CZEPLUCH, FS##WALTENBERGER, J","UNIV MAASTRICHT, MAASTRICHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805669,2006,STATINS AND ACE-INHIBITORS PREVENT RENAL DETERIORATION IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE,NA,NA,NA,CIRCULATION,"FERINGA, HH##WELTEN, G##HOEKS, S##DUNKELGRUN, M##AZIZI, F##VAN GESTEL, Y##VIDAKOVIC, R##SCHOUTEN, O##VAN DOMBURG, R##DE LIEFDE, I##KARAGIANNIS, S##POLDERMANS, D","ERASMUS MC, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805726,2006,LONG TERM SURVIVAL AFTER FIRST MYOCARDIAL INFARCTION IS NOT DETERMINED BY THE OCCURRENCE OF VENTRICULAR FIBRILLATION IN THE ACUTE PHASE BUT FAMILY HISTORY FOR SUDDEN DEATH IS DETRIMENTAL,NA,NA,NA,CIRCULATION,"DE JONG, JS##WILDE, AA##HENRIQUES, JP##DEKKER, LR","AMC, AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805725,2006,RISK FACTORS FOR PRIMARY VENTRICULAR FIBRILLATION DURING ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS.,NA,NA,NA,CIRCULATION,"GHEERAERT, P##DE BUYZERE, M##TAEYMANS, Y##GILLEBERT, T##HENRIQUES, J##DE BACKER, G##DE BACQUER, D","UNIV HOSP, GHENT, BELGIUM. ACAD MED CTR, AMSTERDAM, NETHERLANDS. UNIV GHENT, DEPT PUBL HLTH, GHENT, BELGIUM.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000241792805724,2006,DEFIBRILLATION SUCCESS IS NOT MEANINGFULLY ASSOCIATED WITH DURATION OF THE PRE-SHOCK PAUSE IN CHEST COMPRESSIONS,NA,NA,NA,CIRCULATION,"KOSTER, RW##WALKER, RG##CHAPMAN, FW","ACAD MED CTR, AMSTERDAM, NETHERLANDS. MEDTRONIC EMERGENCY RESPONSE SYST, REDMOND, WA USA.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,2,2020-11-20,NA
J,WOS:000241666800014,2006,INDUCTION OF ORAL TOLERANCE TO OXIDIZED LOW-DENSITY LIPOPROTEIN AMELIORATES ATHEROSCLEROSIS,"BACKGROUND - OXIDATION OF LOW-DENSITY LIPOPROTEIN ( LDL) AND THE SUBSEQUENT PROCESSING OF OXIDIZED LDL ( OXLDL) BY MACROPHAGES RESULTS IN ACTIVATION OF SPECIFIC T CELLS, WHICH CONTRIBUTES TO THE DEVELOPMENT OF ATHEROSCLEROSIS. ORAL TOLERANCE INDUCTION AND THE SUBSEQUENT ACTIVATION OF REGULATORY T CELLS MAY BE AN ADEQUATE THERAPY FOR THE TREATMENT OF ATHEROSCLEROSIS. METHODS AND RESULTS - TOLERANCE TO OXLDL AND MALONDIALDEHYDE-TREATED LDL ( MDA-LDL) WAS INDUCED IN LDL RECEPTOR(-/-) MICE FED A WESTERN-TYPE DIET BY ORAL ADMINISTRATION OF OXLDL OR MDA-LDL BEFORE THE INDUCTION OF ATHEROGENESIS. ORAL TOLERANCE TO OXLDL RESULTED IN A SIGNIFICANT ATTENUATION OF THE INITIATION ( 30% TO 71%; P < 0.05) AND PROGRESSION ( 45%; P < 0.05) OF ATHEROGENESIS. TOLERANCE TO OXLDL INDUCED A SIGNIFICANT INCREASE IN CD4(+)CD25(+)FOXP3(+) CELLS IN SPLEEN AND MESENTERIC LYMPH NODES, AND THESE CELLS SPECIFICALLY RESPONDED TO OXLDL WITH INCREASED TRANSFORMING GROWTH FACTOR-BETA PRODUCTION. TOLERANCE TO OXLDL ALSO INCREASED THE MRNA EXPRESSION OF FOXP3, CTLA-4, AND CD25 IN THE PLAQUE. IN CONTRAST, TOLERANCE TO MDA-LDL DID NOT AFFECT ATHEROGENESIS. CONCLUSIONS - OXLDL-SPECIFIC T CELLS, PRESENT IN LDL RECEPTOR(-/-) MICE AND IMPORTANT CONTRIBUTORS IN THE IMMUNE RESPONSE LEADING TO ATHEROSCLEROTIC PLAQUE, CAN BE COUNTERACTED BY OXLDL-SPECIFIC CD4(+)D25(+)FOXP3(+) REGULATORY T CELLS ACTIVATED VIA ORAL TOLERANCE INDUCTION TO OXLDL. WE CONCLUDE THAT THE INDUCTION OF ORAL TOLERANCE TO OXLDL MAY BE A PROMISING STRATEGY TO MODULATE THE IMMUNE RESPONSE DURING ATHEROGENESIS AND A NEW WAY TO TREAT ATHEROSCLEROSIS.",RECEPTOR-DEFICIENT MICE; REGULATORY T-CELLS; APOLIPOPROTEIN E-DEFICIENT; GROWTH-FACTOR-BETA; IN-VIVO; TRANSGENIC MICE; POTENTIAL ROLE; TGF-BETA; LYMPHOCYTES; ANTIGEN,ATHEROSCLEROSIS; IMMUNE SYSTEM; T CELLS; TOLERANCE INDUCTION,CIRCULATION,"VAN PUIJVELDE, GHM##HAUER, AD##DE VOS, P##VAN DEN HEUVEL, R##VAN HERWIJNEN, MJC##VAN DER ZEE, R##VAN EDEN, W##VAN BERKEL, TJC##KUIPER, J","LEIDEN UNIV, DIV BIOPHARMACEUT, NL-2300 RA LEIDEN, NETHERLANDS. UNIV UTRECHT, DEPT INFECT DIS & IMMUNOL, NL-3508 TC UTRECHT, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"AIT-OUFELLA H, 2006, NAT MED, V12, P178, DOI 10.1038/NM1343##BENAGIANO M, 2003, P NATL ACAD SCI USA, V100, P6658, DOI 10.1073/PNAS.1135726100##CHANG MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/JEM.20031763##CHEN WJ, 2003, CYTOKINE GROWTH F R, V14, P85, DOI 10.1016/S1359-6101(03)00003-0##CHEN YH, 1996, P NATL ACAD SCI USA, V93, P388, DOI 10.1073/PNAS.93.1.388##CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177A0##COBELENS PM, 2002, RHEUMATOLOGY, V41, P775, DOI 10.1093/RHEUMATOLOGY/41.7.775##DAVENPORT P, 2003, AM J PATHOL, V163, P1117, DOI 10.1016/S0002-9440(10)63471-2##ELHAGE R, 2003, CARDIOVASC RES, V59, P234, DOI 10.1016/S0008-6363(03)00343-2##FRIEDMAN A, 1996, ANN NY ACAD SCI, V778, P103, DOI 10.1111/J.1749-6632.1996.TB21119.X##GEORGE J, 2004, CARDIOVASC RES, V62, P603, DOI 10.1016/J.CARDIORES.2004.01.028##HANSSON GK, 2000, ANN NY ACAD SCI, V902, P53##HANSSON GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/HQ1201.100220##HARATS D, 2002, J AM COLL CARDIOL, V40, P1333, DOI 10.1016/S0735-1097(02)02135-6##HAUER AD, 2005, CIRCULATION, V112, P1054, DOI 10.1161/CIRCULATIONAHA.104.533463##HORI S, 2003, SCIENCE, V299, P1057, DOI 10.1126/SCIENCE.1079490##KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/JEM.163.5.1037##LIBBY P, 2002, NATURE, V420, P868, DOI 10.1038/NATURE01323##LIU LM, 1993, J EXP MED, V177, P1299, DOI 10.1084/JEM.177.5.1299##MA SW, 2004, P NATL ACAD SCI USA, V101, P5680, DOI 10.1073/PNAS.0307420101##MACDONALD TT, 1983, EUR J IMMUNOL, V13, P138, DOI 10.1002/EJI.1830130209##MALLAT Z, 2005, CURR OPIN LIPIDOL, V16, P518, DOI 10.1097/01.MOL.0000182532.11512.90##MARON R, 2002, CIRCULATION, V106, P1708, DOI 10.1161/01.CIR.0000029750.99462.30##MARON R, 2002, INT IMMUNOL, V14, P131, DOI 10.1093/INTIMM/14.2.131##MASSAGUE J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/ANNUREV.BIOCHEM.67.1.753##MATTINGLY JA, 1984, CELL IMMUNOL, V86, P46, DOI 10.1016/0008-8749(84)90357-5##MELAMED D, 1993, EUR J IMMUNOL, V23, P935, DOI 10.1002/EJI.1830230426##NAKAMURA K, 2001, J EXP MED, V194, P629, DOI 10.1084/JEM.194.5.629##PINDERSKI LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA##REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1##ROSS R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207##SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T##SCHIOPU A, 2004, CIRCULATION, V110, P2047, DOI 10.1161/01.CIR.0000143162.56057.B5##SCOTT FW, 2002, DIABETES, V51, P73, DOI 10.2337/DIABETES.51.1.73##SHI FD, 1999, J IMMUNOL, V162, P5757##STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/PNAS.92.9.3893##TOUSSIROT ERIC A., 2002, CURRENT DRUG TARGETS - INFLAMMATION AND ALLERGY, V1, P45, DOI 10.2174/1568010023344850##VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282##VAZ N M, 1981, MEMORIAS DO INSTITUTO OSWALDO CRUZ, V76, P83##VON DER THUSEN JH, 2001, FASEB J, V15, P2730, DOI 10.1096/FJ.01-0483FJE##VON DER THUSEN JH, 2001, CIRCULATION, V103, P1164, DOI 10.1161/01.CIR.103.8.1164##WATSON AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/JBC.272.21.13597##WHITMAN SC, 2002, J INTERF CYTOK RES, V22, P661, DOI 10.1089/10799900260100141##ZHANG XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/JIMMUNOL.167.8.4245",132,2020-11-20,NA
J,WOS:000241666800016,2006,HEDGEHOG MORPHOGEN IN CARDIOVASCULAR DISEASE,"IN THIS REVIEW, WE FOCUS ON THE BASIC BIOLOGY OF THE IMPORTANT DEVELOPMENTAL HEDGEHOG ( HH) PROTEIN FAMILY, ITS GENERAL FUNCTION IN DEVELOPMENT, PATHWAY MECHANISMS, AND GENE DISCOVERY AND NOMENCLATURE. HH FUNCTION IN CARDIOVASCULAR DEVELOPMENT AND RECENT FINDINGS CONCERNING HH SIGNALING IN ISCHEMIA MODELS ARE DISCUSSED IN MORE DETAIL, AND FUTURE PERSPECTIVES ARE PROPOSED. IN LIGHT OF THE RECENT DISCOVERY OF HH TRANSPORT BY INSECT LIPOPHORIN, WE ALSO HYPOTHESIZE A ROLE FOR LOW-DENSITY LIPOPROTEIN ( LDL) IN MAMMALIAN HH TRANSPORT, CREATING A SURPRISING ROLE FOR LDL IN CARDIOVASCULAR DISEASE.",LEFT-RIGHT ASYMMETRY; SONIC-HEDGEHOG; POLARIZING ACTIVITY; RETINOIC ACID; PATHWAYS; MOUSE; GENE; IDENTIFICATION; DROSOPHILA; PROTEINS,ANGIOGENESIS; ISCHEMIA; SIGNAL TRANSDUCTION; RECEPTORS; HEDGEHOG; CHOLESTEROL,CIRCULATION,"BIJLSMA, MF##PEPPELENBOSCH, MP##SPEK, CA","UNIV GRONINGEN, MED CTR, DEPT CELL BIOL, NL-9713 AV GRONINGEN, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, CTR EXPT & MOL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,"ALTABA ARI, 1999, DEVELOPMENT, V126, P3205##ALTABA ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5##ASHE HL, 2006, DEVELOPMENT, V133, P385, DOI 10.1242/DEV.02238##BHARDWAJ G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282##BIJLSMA MF, 2004, BIOESSAYS, V26, P387, DOI 10.1002/BIES.20007##BRISCOE J, 2005, DEV CELL, V8, P143, DOI 10.1016/J.DEVCEL.2005.01.008##BRISCOE J, 2004, 45 KAR I NOB C STOCK##BYRD N, 2002, DEVELOPMENT, V129, P361##BYRD N, 2004, TRENDS CARDIOVAS MED, V14, P308, DOI 10.1016/J.TCM.2004.09.003##CHEN JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/GAD.1025302##COOPER AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/DEV.02021##COOPER MK, 2003, NAT GENET, V33, P508, DOI 10.1038/NG1134##DAVIES JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/SCIENCE.290.5500.2295##ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3##EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0##FAROKHZAD OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/PNAS.0601755103##FENG J, 2004, DEVELOPMENT, V131, P4357, DOI 10.1242/DEV.01301##FRANK-KAMENETSKY MARIA, 2002, J BIOL, V1, P10, DOI 10.1186/1475-4924-1-10##GIANAKOPOULOS PJ, 2005, J BIOL CHEM, V280, P21022, DOI 10.1074/JBC.M502977200##GRAFF JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8##HAHN H, 1998, NAT MED, V4, P619, DOI 10.1038/NM0598-619##HAO LM, 2006, DEV DYNAM, V235, P1469, DOI 10.1002/DVDY.20721##HOUGHTON J, 2004, SCIENCE, V306, P1568, DOI 10.1126/SCIENCE.1099513##HURLSTONE AFL, 2003, NATURE, V425, P633, DOI 10.1038/NATURE02028##INGHAM PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/GAD.938601##INGRAM WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/SJ.ONC.1205975##KALDERON D, 2000, CELL, V103, P371, DOI 10.1016/S0092-8674(00)00129-X##KATO M, 2001, BIOCHEM BIOPH RES CO, V289, P472, DOI 10.1006/BBRC.2001.5976##KELLEY RI, 2000, J MED GENET, V37, P321, DOI 10.1136/JMG.37.5.321##KIM PCW, 2001, J PEDIATR SURG, V36, P381, DOI 10.1053/JPSU.2001.20722##KOEBERNICK K, 2002, DIFFERENTIATION, V70, P69, DOI 10.1046/J.1432-0436.2002.700201.X##KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4##KUSANO KF, 2005, NAT MED, V11, P1197, DOI 10.1038/NM1313##KUSANO KF, 2004, ARTERIOSCL THROM VAS, V24, P2102, DOI 10.1161/01.ATV.0000144813.44650.75##LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8##LIU JD, 2006, DEV BIOL, V290, P373, DOI 10.1016/J.YDBIO.2005.11.033##LOWREY JA, 2002, J IMMUNOL, V169, P1869, DOI 10.4049/JIMMUNOL.169.4.1869##MARIGO V, 1996, NATURE, V384, P176, DOI 10.1038/384176A0##MCCARTHY MJ, 1999, J VASC SURG, V30, P261, DOI 10.1016/S0741-5214(99)70136-9##MEYERS EN, 1999, SCIENCE, V285, P403, DOI 10.1126/SCIENCE.285.5426.403##MOTOYAMA J, 1998, NAT GENET, V18, P104, DOI 10.1038/NG0298-104##NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795A0##ORFORD JL, 2000, AM J CARDIOL, V86, P6H, DOI 10.1016/S0002-9149(00)01094-8##PANAKOVA D, 2005, NATURE, V435, P58, DOI 10.1038/NATURE03504##PAYNE RM, 1995, CIRCULATION, V91, P494, DOI 10.1161/01.CIR.91.2.494##PEPINSKY RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/JBC.273.22.14037##POLA R, 2001, NAT MED, V7, P706, DOI 10.1038/89083##POLA R, 2003, CIRCULATION, V108, P479, DOI 10.1161/01.CIR.0000080338.60981.FA##PORTER JA, 1996, SCIENCE, V274, P255, DOI 10.1126/SCIENCE.274.5285.255##RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2##RISAU W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/ANNUREV.CB.11.110195.000445##SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B##STEWART GA, 2002, J IMMUNOL, V169, P5451, DOI 10.4049/JIMMUNOL.169.10.5451##TAIPALE J, 2002, NATURE, V418, P892, DOI 10.1038/NATURE00989##TAIPALE J, 2001, NATURE, V411, P349, DOI 10.1038/35077219##TANAKA Y, 2005, NATURE, V435, P172, DOI 10.1038/NATURE03494##THEROND P, 2004, 45 KAR I NOB C STOCK##TSUKUI T, 1999, P NATL ACAD SCI USA, V96, P11376, DOI 10.1073/PNAS.96.20.11376##VAN DEN BRINK GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/GAST.2001.26261##VAN HOOF D, 2002, J CELL SCI, V115, P4001, DOI 10.1242/JCS.00113##VANDENHEUVEL M, 1996, NATURE, V382, P547, DOI 10.1038/382547A0##VARJOSALO M, 2006, DEV CELL, V10, P177, DOI 10.1016/J.DEVCEL.2005.12.014##YOON JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/JBC.M105708200##ZHANG XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3##ZOU HY, 1996, SCIENCE, V272, P738, DOI 10.1126/SCIENCE.272.5262.738",29,2020-11-20,NA
J,WOS:000241792800014,2006,DRUG-ELUTING STENTS: THE BEGINNING OF THE END OR THE END OF THE BEGINNING?,NA,NA,NA,CIRCULATION,"SERRUYS, P","ERASMUS UNIV, ROTTERDAM, NETHERLANDS.",CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR SYSTEM & CARDIOLOGY,NA,0,2020-11-20,NA
J,WOS:000214214100003,2006,A MODEL-BASED INTEGRATION AND TESTING METHOD TO REDUCE SYSTEM DEVELOPMENT EFFORT,"NEW METHODS AND TECHNIQUES ARE NEEDED TO REDUCE THE VERY COSTLY INTEGRATION AND TEST EFFORT (IN TERMS OF LEAD TIME, COSTS, RESOURCES) IN THE DEVELOPMENT OF HIGH-TECH MULTI-DISCIPLINARY SYSTEMS. TO FACILITATE THIS EFFORT REDUCTION, WE PROPOSE A METHOD CALLED MODEL-BASED INTEGRATION. THIS METHOD ALLOWS TO INTEGRATE FORMAL EXECUTABLE MODELS OF SYSTEM COMPONENTS THAT ARE NOT YET PHYSICALLY REALIZED WITH AVAILABLE REALIZATIONS OF OTHER COMPONENTS. THE COMBINATION OF MODELS AND REALIZATIONS IS THEN USED FOR EARLY ANALYSIS OF THE INTEGRATED SYSTEM BY MEANS OF VALIDATION, VERIFICATION, AND TESTING. THIS ANALYSIS ENABLES EARLY DETECTION AND PREVENTION OF PROBLEMS THAT WOULD OTHERWISE OCCUR DURING REAL INTEGRATION, RESULTING IN A SIGNIFICANT REDUCTION OF EFFORT INVESTED IN THE THE REAL INTEGRATION AND TEST PHASES. THIS PAPER ILLUSTRATES HOW MODELS OF COMPONENTS, DEVELOPED FOR MODEL-BASED INTEGRATION, CAN BE USED FOR AUTOMATED MODEL-BASED TESTING, WHICH ALLOWS TIME-EFFICIENT DETERMINATION OF THE CONFORMANCE OF COMPONENT REALIZATIONS WITH RESPECT TO THEIR REQUIREMENTS. THE COMBINATION OF MODEL-BASED INTEGRATION AND MODEL-BASED TESTING IS PRACTICALLY ILLUSTRATED IN A REALISTIC INDUSTRIAL CASE STUDY. RESULTS OBTAINED FROM THIS STUDY ENCOURAGE FURTHER RESEARCH ON MODEL-BASED INTEGRATION AS A PROMINENT METHOD TO REDUCE THE INTEGRATION AND TEST EFFORT.",NA,MODEL-BASED INTEGRATION; MODEL-BASED TESTING; INDUSTRIAL CASE STUDY,ELECTRONIC NOTES IN THEORETICAL COMPUTER SCIENCE,"BRASPENNING, NCWM##VAN DE MORTEL-FRONCZAK, JM##ROODA, JE","[BRASPENNING, N. C. W. M.; VAN DE MORTEL-FRONCZAK, J. M.; ROODA, J. E.] EINDHOVEN UNIV TECHNOL, DEPT ENGN MECH, POB 513, NL-5600 MB EINDHOVEN, NETHERLANDS.","COMPUTER SCIENCE, THEORY & METHODS",COMPUTER SCIENCE,"[ANONYMOUS], TANGRAM PROJ##BAETEN JCM, 1990, CAMBRIDGE TRACTS THE, V18##BOEHM B, 2001, COMPUTER, V34, P135, DOI 10.1109/2.962984##BOHNENKAMP H, 2005, LECT NOTES COMPUT SC, V3582, P173##BORTNIK E, 2005, J LOGIC ALGEBR PROGR, V65, P51, DOI 10.1016/J.JLAP.2005.05.001##BRATTHALL L, 2000, INFORM SOFTWARE TECH, V42, P947, DOI 10.1016/S0950-5849(00)00129-4##BRINKSMA E, 2001, LNCS, V2067, P187, DOI DOI 10.1007/3-540-45510-8_9##BROY M., 2001, EMBEDDED SOFTWARE, P51##BUDINSKY FJ, 1996, IBM SYST J, V35, P151, DOI 10.1147/SJ.352.0151##DE VRIES R. G., 1998, ENST, V98, P115##DEVRIES RG, 2001, BRICS NOTES SERIES, P61##FRANTZEN L., 2005, LNCS, V3395, P1##GOMAA H., 2000, DESIGNING CONCURRENT##HARTMAN A, 2002, MODEL BASED TEST GEN##HOLZMANN GJ, 1997, IEEE T SOFTWARE ENG, V23, P279, DOI 10.1109/32.588521##KLEPPE A. G., 2003, MDA EXPLAINED MODEL##LIU X., 2003, SOFTWARE ENABLED CON, P105##OGREN I, 2000, SYSTEMS ENG, V3, P38##ROWSON JA, 1994, ACM IEEE D, P439##TRCKA . N, 2005, COMPUTER SCI REPORTS##TRETMANS J, 2003, 1 EUR C MOD DRIV SOF##VAN BEEK D. A., 2005, COMPUTER SCI REPORTS##VAN BEEK DA, 2006, J LOGIC ALGEBR PROGR, V68, P129, DOI 10.1016/J.JLAP.2005.10.005##VAN DER BIJL M, 2004, LECT NOTES COMPUT SC, V2931, P86",10,2020-11-20,"NETHERLANDS MINISTRY OF ECONOMIC AFFAIRSMINISTRY OF ECONOMIC AFFAIRS, NETHERLANDS [TSIT2026]"
J,WOS:000243414100005,2006,"MORPHOLOGICAL AND MOLECULAR CHARACTERISATION OF MYCOSPHAERELLACEAE ASSOCIATED WITH THE INVASIVE WEED, CHROMOLAENA ODORATA","CHROMOLAENA ODORATA, ORIGINATING FROM SOUTH AND CENTRAL AMERICA, IS A BUSHY SHRUB INVASIVE IN MANY TROPICAL AND SUBTROPICAL REGIONS OF THE WORLD. SEVERAL SPECIES OF MYCOSPHAERELLACEAE HAVE BEEN REPORTED ON C. ODORATA IN RECENT YEARS AS POTENTIAL BIOLOGICAL CONTROL AGENTS. AS A RESULT, SEVERAL EXPLORATORY TRIPS WERE UNDERTAKEN TO SOUTH, NORTH AND CENTRAL AMERICA FROM 1988 UNTIL 1997 TO SURVEY FOR PATHOGENS ON C. ODORATA. THREE NEW SPECIES OF PASSALORA, AND ONE SPECIES OF SEPTORIA AND PSEUDOCERCOSPORA, RESPECTIVELY, ARE NEWLY DESCRIBED. FURTHERMORE, SEPTORIA EKMANIANA AND PASSALORA PERFOLIATI WERE ALSO CONFIRMED FROM CHROMOLAENA DURING THE COURSE OF THIS STUDY.",PHYLOGENETIC REASSESSMENT; BIOLOGICAL-CONTROL; LEAF-SPOT; EUCALYPTUS; ANAMORPHS; SPP.; PATHOGENS; STENELLA,BIOLOGICAL CONTROL; MORPHOLOGY; PLANT PATHOGENS; PHYLOGENETICS,FUNGAL DIVERSITY,"DEN BREEYEN, A##GROENEWALD, JZ##VERKLEY, GJM##CROUS, PW","CBS FUNGAL BIODIVERS CTR, NL-3584 CT UTRECHT, NETHERLANDS. ARC PPRI, WEEDS RES DIV, ZA-7599 STELLENBOSCH, SOUTH AFRICA.",MYCOLOGY,MYCOLOGY,"APTROOT A, 2006, CBS BIODIVERSITY SER, V5, P1##AVIS TJ, 2001, CAN J PLANT PATHOL, V23, P8, DOI 10.1080/07060660109506902##BAGYANARAYANA G, 1999, SYDOWIA, V51, P1##BARRETO RW, 1994, MYCOL RES, V98, P1107, DOI 10.1016/S0953-7562(09)80196-2##BRAUN U, 1998, MONOGRAPH CERCOSPORE, V2##CORTINAS MN, 2006, STUD MYCOL, P133, DOI 10.3114/SIM.55.1.133##CROUS PW, 2006, STUD MYCOL, P189, DOI 10.3114/SIM.55.1.189##CROUS PW, 2006, STUD MYCOL, P163, DOI 10.3114/SIM.55.1.163##CROUS PW, 2006, STUD MYCOL, P99, DOI 10.3114/SIM.55.1.99##CROUS PW, 2005, AUSTRALAS PLANT PATH, V34, P463, DOI 10.1071/AP05082##CROUS PW, 2004, STUD MYCOL, P195##CROUS PW, 2004, STUD MYCOL, P457##CROUS PW, 2004, STUD MYCOL, P415##CROUS PW, 2003, CBS BIODIVERSITY SER, V1, P1##CRUTTWELL R.E., 1974, TECHNICAL BULL COMMONW INST BIOL CONTROL, VNO. 17, P87##CRUTTWELLMCFADY.RE, 2003, AUSTR J ENTOMOLOGY, V42, P294##ELANGO DE, 1993, INT J PEST MANAGE, V39, P393, DOI 10.1080/09670879309371829##ELLIS MB, 1971, DEMATIACEOUS HYPHOMY##GAMS W, 1998, CBS COURSE MYCOLOGY##GROENEWALD M, 2006, MYCOLOGIA, V98, P275, DOI 10.3852/MYCOLOGIA.98.2.275##HOLM L. G., 1977, WORLDS WORST WEEDS D##KIRSCHNER R, 2004, FUNGAL DIVERS, V17, P57##LEE S, 2004, STUD MYCOL, V50, P235##LEE SB, 1990, PCR PROTOCOLS GUIDE, P282, DOI DOI 10.1016/B978-0-12-372180-8.50038-X##MCFADYEN RC, 1996, AGR ECOSYST ENVIRON, V59, P89, DOI 10.1016/0167-8809(96)01035-3##MUNIAPPAN R, 1988, P 1 INT WORKSH BIOL##RAMBAUT A., 2002, SEQUENCE ALIGNMENT E##RAYNER AW, 1970, MYCOLOGICAL COLOUR C##SCHUBERT K, 2005, FUNGAL DIVERS, V20, P187##SWOFFORD D.L., 2002, PAUP 4 0B10 PHYLOGEN##TEBEEST DO, 1991, MICROBIAL CONTROL WE##VANDERWOUDE C., 2005, PLAN NATL DELIMITING, P15##WHITE TJ, 1990, GUIDE METHODS APPL, P315",28,2020-11-20,NA
J,WOS:000243414100013,2006,"A FIRST ASSESSMENT OF THE TICOLICHEN BIODIVERSITY INVENTORY IN COSTA RICA: THE GENUS COENOGONIUM (OSTROPALES : COENOGONIA-CEAE), WITH A WORLD-WIDE KEY AND CHECKLIST AND A PHENOTYPE-BASED CLADISTIC ANALYSIS","A TREATMENT OF FILAMENTOUS AND CRUSTOSE SPECIES OF THE LICHEN GENUS COENOGONIUM IN COSTA RICA IS PRESENTED, REPORTING A TOTAL OF 48 TAXA, INCLUDING SEVEN OF UNRESOLVED TAXONOMIC STATUS. EIGHT SPECIES AND ONE FORM ARE DESCRIBED AS NEW TO SCIENCE: C. ACICULATUM LOCKING & APTROOT SP. NOV., C. BARBATUM LUCKING, APTROOT & UMANA SP. NOV., C. HYSSOTHALLINUM APTROOT & LUCKING SP. NOV., C. KALBII APTROOT, LUCKING & UMANA SP. NOV., C. LUTEOCITRINUM RIVAS PLATA, LUCKING & UMANA SP. NOV., C. MAGDALENAE RIVAS PLATA, LUCKING & LIZANO SP. NOV., C. SAEPINCOLA APTROOT, SIPINAN & LUCKING SP. NOV., C. SIQUIRRENSE F. DENTICULATUM RIVAS PLATA & LUCKING F. NOV., C. STRIGOSUM RIVAS PLATA, LUCKING & CHAVES SP. NOV. THE FOLLOWING NEW LUCKING F NOV.. C. COMBINATIONS AND NOMENCLATURAL NOVELTIES ARE INTRODUCED: C. ANIONIANUM LUCKING, APTROOT & SIPMAN NOM. NOV., C. ATROLUTEUM (VAIN.) LUCKING, APTROOT & SIPMAN COMB. NOV., C. BACILLIFERUM (MALME) LUCKING, APTROOT & SIPINAN COMB. NOV., C. DEGENERI (KALB & VEZDA) KALB & LUCKING COMB. NOV., C. EXIMIUM (VEZDA) KALB & LUCKING COMB. NOV., C. FREDERICI (KALB) KALB & LUCKING COMB. NOV., C. ISIDATUM (G. THOR & VEZDA) LUCKING, APTROOT & SIPMAN COMB. NOV., C. ISIDIIGERUM (VEZDA & OSORIO) LOCKING, APTROOT & SIPINAN COMB. NOV., C. ISIDIOSUM (BREUSS) RIVAS PLATA, LUCKING, UMANA & CHAVES COMB. NOV., C. LUTEOLUM (KALB) KALB & LUCKING COMB. NOV., C. NEPALENSE (G. THOR & VEZDA) LUCKING, APTROOT & SIPMAN COMB. NOV., C. PERMINUTUM (MALME) LUCKING, APTROOT & SIPMAN COMB. ET STAT. NOV., C. PERSISTENS (MALME) LOCKING, APTROOT & SIPMAN COMB. ET STAT. NOV., C. PERTENUE (STIRT.) KALB & LOCKING COMB. NOV., C. POESII (VEZDA & FARKAS) LOCKING, APTROOT & SIPMAN COMB. NOV., C. PUSILLUM (MONT.) LOCKING, APTROOT & SIPMAN COMB. NOV., C. PYROPHTHALMUM (MONT.) LOCKING, APTROOT & SIPMAN COMB. NOV., C. STENOSPORUM (MALME) LOCKING, APTROOT & SIPMAN COMB. NOV., C. STRAMINEUM (APTROOT & SEAWARD) LOCKING, APTROOT & SIPMAN COMB. NOV., C. SUBDENTATUM (VEZDA & G. THOR) RIVAS PLATA, LUCKING, UMANA & CHAVES COMB. NOV., C. SUBDILUTUM (MALME) LOCKING, APTROOT & SIPMAN COMB. NOV., C. SUBFALLACIOSUM (VEZDA & FARKAS) LOCKING, APTROOT & SIPMAN COMB. NOV., C. SUBSQUAMOSUM (APTROOT & SEAWARD) LOCKING, APTROOT & SIPMAN COMB. NOV., C. TAVARESIANUM (VEZDA) LOCKING, APTROOT & SIPMAN COMB. NOV., AND C. WEBERI (VEZDA) LOCKING, APTROOT & SIPMAN COMB. NOV. COENOGONIUM COMPLEXUM NYL. IS ESTABLISHED AS A SYNONYM OF C. TUCKERMANII. TEN SPECIES ARE NEW RECORDS FOR COSTA RICA. A PHENOTYPE-BASED CLADISTIC ANALYSIS OF 54 TAXA USING 49 CHARACTERS SUPPORTS MERGING DIMERELLA WITH COENOGONIUM AND SUGGESTS POLYPHYLETIC ORIGIN OF SPECIES WITH FILAMENTOUS THALLUS STRUCTURE. AS ADDITIONAL RESULT OF OUR STUDIES, WE PRESENT A WORLD-WIDE WORKING KEY TO THE 82 ACCEPTED SPECIES OF COENOGOIUM AND AN UPDATED CHECKLIST INCLUDING THE STATUS OF 186 FURTHER NAMES IN COENOGONIUM AND ITS TWELVE GENERIC SYNONYMS BIATORINOPSIS, BYSSIPLACA, COENOGONIOMYCELLA, COENOGONIOMYCES, COENOMYCOGONIUM, DIDYMOPYCNOMYCES, DIMERELLA, FLABELLOMYCES, HOLOCOENIS, LECANIOPSIS, MICROPHIALE, AND MYCOCOENOGONIUM.",FOLIICOLOUS LICHEN FLORA; GREEN ALGAL LICHEN; GOMPHILLACEAE; GYALECTACEAE; ASCOMYCOTA; PHYLOGENY; ADDITIONS; LINKII; BRAZIL; FUNGI,DIMERELLA; LICHENS; NEW COMBINATIONS; NEW SPECIES,FUNGAL DIVERSITY,"PLATA, ER##LUCKING, R##APTROOT, A##SIPMAN, HJM##CHAVES, JL##UMANA, L##LIZANO, D","FIELD MUSEUM NAT HIST, DEPT BOT, CHICAGO, IL 60605 USA. UNIV PERUANA CAYETANO HEREDIA, LAB CULTIVO TEJIDOS VEGETALES, LIMA, PERU. ABL HERBARIUM, NL-3762 XX SOEST, NETHERLANDS. BOT MUSEUM, D-14191 BERLIN, GERMANY. INBIO, LAB HONGOS, SANTO DOMINGO DE HEREDIA, COSTA RICA. UNIV COSTA RICA, ESCUELA BIOL, SAN JOSE, COSTA RICA.",MYCOLOGY,MYCOLOGY,"ANDRES JA, 2001, NOVA HEDWIGIA, V73, P409##ARGOVIENSIS JM, 1881, GREVILLEA, V10, P87##ARGOVIENSIS JM, 1894, B SOC ROY BOT BELG, V32, P122##AWASTHI D.D., 1991, BIBLIO LICHENOLOGICA, V40, P1##BREUSS O., 2002, LINZER BIOLOGISCHE BEITRAEGE, V34, P1053##BRODO I., 2001, LICHENS N AM##CACERES M, 2000, NOVA HEDWIGIA, V70, P217##CHAVES JL, 2004, BRYOLOGIST, V107, P242##DAVIS JS, 1994, BRYOLOGIST, V97, P186, DOI 10.2307/3243760##DODGE C. W., 1953, ANN. MO. BOT. GDN., V40, P271, DOI 10.2307/2394552##DODGE CARROLL WILLIAM, 1933, ANN MISSOURI BOT GARDEN, V20, P373, DOI 10.2307/2394665##DODGE CW, 1966, COMITE NATL FRANCAIS, V15, P1##EHRENBERG CG, 1820, HORAE PHYS BEROLINEN, V1820, P77##ESSLINGER TL, 2005, CUMULATIVE CHECKLIST##GALLOWAY D., 1985, FLORA NZ LICHENS##GLUCK H, 1896, FLORA, V82, P268##GRUMMANN VJ, 1963, CATALOGUS LICHENUM G##HARADA H, 1997, BRYOLOGIST, V100, P454##HARADA H, 2004, LICHENOLOGY, V2, P1##HARIOT P, 1891, J BOT, V5, P288##KALB K, 1992, HERZOGIA, V9, P45##KANTVILAS G, 1999, FLORA AUSTR SUPPLEME, V9, P1##KARLING JS, 1934, ANN BOT-LONDON, V48, P823, DOI 10.1093/OXFORDJOURNALS.AOB.A090480##KAUFF F, 2002, MOL PHYLOGENET EVOL, V25, P138, DOI 10.1016/S1055-7903(02)00214-2##KOPPE F, 1937, DECHENIANA, V94, P215##LAKATOS M, 2004, J PHYCOL, V40, P70, DOI 10.1111/J.0022-3646.2004.02-205.X##LOPEZ-BAUTISTA JM, 2003, INT J SYST EVOL MICR, V53, P2099, DOI 10.1099/IJS.0.02256-0##LOPEZ-BAUTISTA JM, 2002, CONSTANCEA, V83##LUCKING R, 2006, LICHENOLOGIST, V38, P131, DOI 10.1017/S0024282905005657##LUCKING R, 2005, LICHENOLOGIST, V37, P123, DOI 10.1017/S0024282905014660##LUCKING R, 2003, LICHENOLOGIST, V35, P33, DOI 10.1006/LICH.2002.0430##LUCKING R, 1999, LICHENOLOGIST, V31, P359, DOI 10.1006/LICH.1999.0205##LUCKING R, 2002, BOT J LINN SOC, V139, P171, DOI 10.1046/J.1095-8339.2002.00058.X##LUCKING R, 2006, IN PRESS TAXON##LUCKING R., 2001, BIBLIOTHECA LICHENOL, V78, P247##LUCKING R, 2004, 5 IAL S LICH FOC AUG##LUCKING R., 2000, BOT JB SYSTEMATIK, V122, P1##LUCKING R, 2004, IN PRESS FLORA NEOTR##MAGNUSSON A. H. A., 1944, ARKIV BOT, V31A, P1##MALCOLM WM, 2004, AUSTRALASIAN LICHENO, V54, P19##MALCOLM WM, 2005, AUSTRALASIAN LICHENO, V56, P25##MALME G. 0., 1937, ARK BOT, V29A, P1##MALME GUST. O., 1934, ARKIV BOT [STOCKHOLM], V26A, P1##MEIER JL, 1983, AM J BOT, V70, P400, DOI 10.2307/2443248##NELSEN MP, 2006, LICHENOLOGIST, V38, P251, DOI 10.1017/S0024282906005573##NYLANDER W., 1862, ANN SCI NATURELLES, V16, P88##NYLANDER W., 1862, ANN SCI NAT BOT BIOL, V16, P83##NYLANDER W., 1859, ANN SCI NAT BOT BIOL, V11, P205##NYLANDER W, 1862, BOT Z, V20, P177##OSORIO HECTOR S., 2001, COMUNICACIONES BOTANICAS DE LOS MUSEOS NACIONALES DE HISTORIA NATURAL Y ANTROPOLOGIA, V6, P1##POE S, 2000, PHYLOGENETIC ANAL MO##PUYMALY A, 1935, BOTANISTE, V27, P323##REDINGER KM, 2004, REV BRYOLOGIQUE LICH, V6, P201##RYAN BD, 2004, LICHEN FLORA GREATER, V2##SANTESSON R, 1952, SYMB BOT UPSAL, V12, P1##SCHADE F A, 1932, BEIHEFTE BOT ZENTRAL, V49, P421##SEAWARD MRD, 2004, LICHENOLOGIST, V36, P119, DOI 10.1017/S002428290401401X##SHCWENDENER S, 1862, FLORA, V45, P225##SIMMER H, 1899, ALLGEM BOT Z, V5, P189##SKUJA H, 1933, ACTA HORTI BOT U LAT, V8, P21##SMITH AL, 1906, J BOT, V44, P260##STOCKERWORGOTTER E, 1997, SYMBIOSIS, V23, P117##SWOFFORD DL, 2003, PAUP PHYLOGENETC ANA##THOMAS MA, 1996, LICHENOLOGIST, V28, P341##THOMAS MA, 1997, BIBLIOTHECA LICHENOL, V67, P183##UYENCO FLORDELIZ R., 1963, BRYOLOGIST, V66, P217##UYENCO FR, 1963, THESIS MICHIGAN STAT##UYENCO R., 1965, T AM MICROSC SOC, V84, P1##VAINIO EA, 1899, BEIBL, V3, P121##VANHERK K, 2004, VELDGIDS KORSTMOSSEN##VEZDA A, 1994, NOVA HEDWIGIA, V58, P123##VEZDA A, 1969, FOLIA GEOBOTANICA AND PHYTOTAXONOMICA, V4, P443##VEZDA A, 1988, FOLIA GEOBOT PHYTOTX, V23, P187##VEZDA A, 2004, ACTA MUSEI RICHNOVIE, V11, P57##VEZDA A., 1975, KHUMBU HIMAL, V6, P127##WILEY EO, 1991, COMPLEAT CLADIST##XAVIER FILHO L., 1983, B SOC BROTERIANA, V56, P115",66,2020-11-20,NA
J,WOS:000243414100014,2006,"EUCALYPTUS MICROFUNGI KNOWN FROM CULTURE. 2. ALYSIDIELLA, FUSCULINA AND PHLOGICYLINDRIUM GENERA NOVA, WITH NOTES ON SOME OTHER POORLY KNOWN TAXA","ALTHOUGH NUMEROUS MICROFUNGI HAVE BEEN DESCRIBED FROM EUCALYPTUS IN RECENT YEARS, THIS PLANT GENUS REMAINS A RICH SUBSTRATE COLONIZED BY NUMEROUS UNDESCRIBED SPECIES. IN THE PRESENT STUDY SEVERAL SPECIES AND GENERA OF ASCOMYCETES WERE COLLECTED FROM SYMPTOMATIC LEAVES OR FROM LEAF LITTER OF THIS HOST IN AUSTRALIA, SOUTH AFRICA AND EUROPE. NEW GENERA INCLUDE THOSE ENCOMPASSING ALYSIDIELLA PARASITICA AND PHLOGICYLINDRIUM EUCALYPTI GENERA ET SPP. NOV. (HYPHOMYCETES), AND FUSCULINA EUCALYPTI GEN. ET SP. NOV. (A COELOMYCETE). NEW SPECIES INCLUDE COLLETOGLOEOPSIS BLAKELYI, C. CONSIDENIANAE, C. DIMORPHA, ELSINOE EUCALYPTORUM, HARKNESSIA RHABDOSPHAERA, NEOFUSICOCCUM CORTICOSAE AND STANINWARDIA SUTTONII. A NEW COMBINATION IS PROPOSED FOR MICROSPHAEROPSIS EUCALYPTI IN READERIELLA, WHILE NEW CULTURES, HOSTS AND DISTRIBUTION RECORDS ARE REPORTED FOR CYTOSPORA DIATRYPELLOIDEA, MYCOSPHAERELLA SWARTII, PLECTOSPHAERA EUCALYPTI AND VALSA FABIANAE.",PHYLOGENETIC REASSESSMENT; MYCOSPHAERELLA SPP.; CYLINDROCLADIUM ANAMORPHS; FUNGI; GENUS; SPECIATION; AUSTRALIA,ITS RDNA SEQUENCE DATA; MICROFUNGI; MORPHOLOGY; PURE CULTURE; SYSTEMATICS,FUNGAL DIVERSITY,"SUMMERELL, BA##GROENEWALD, JZ##CARNEGIE, AJ##SUMMERBELL, RC##CROUS, PW","CENT BUR SCHIMMELCULTURES, FUNGAL BIODIVERS CTR, NL-3584 CT UTRECHT, NETHERLANDS. ROYAL BOT GARDENS & DOMAIN TRUST, SYDNEY, NSW 2000, AUSTRALIA. NSW DEPT PRIMARY IND, BEECROFT, NSW 2119, AUSTRALIA.",MYCOLOGY,MYCOLOGY,"ADAMS GC, 2005, STUD MYCOL, PIX##BARBER PA, 2005, MYCOL RES, V109, P1347, DOI 10.1017/S0953756205003989##CORTINAS MN, 2006, STUD MYCOL, P133, DOI 10.3114/SIM.55.1.133##CROUS PW, 2006, STUD MYCOL, P13, DOI 10.3114/SIM.55.1.13##CROUS PW, 2006, STUD MYCOL, P53, DOI 10.3114/SIM.55.1.53##CROUS PW, 2006, STUD MYCOL, P235, DOI 10.3114/SIM.55.1.235##CROUS PW, 2006, STUD MYCOL, P99, DOI 10.3114/SIM.55.1.99##CROUS PW, 2006, STUD MYCOL, P213, DOI 10.3114/SIM.55.1.213##CROUS PW, 2004, STUD MYCOL, P195##CROUS PW, 2004, STUD MYCOL, P457##CROUS PW, 2004, STUD MYCOL, P415##CROUS PW, 2001, MYCOLOGIA, V93, P1081, DOI 10.2307/3761670##CROUS PW, 2000, STUD MYCOL, P107##CROUS PW, 1998, MYCOLOGIA MEMOIR, V21, P1##CROUS PW, 2002, TAXONOMY PATHOLOGY C##DE BEER ZW, 2006, STUD MYCOL, P289, DOI 10.3114/SIM.55.1.289##DE HOOG GS, 1998, MYCOSES, V41, P183, DOI 10.1111/J.1439-0507.1998.TB00321.X##FARR DF, 2005, MYCOLOGIA, V97, P730, DOI 10.3852/MYCOLOGIA.97.3.730##GAMS W, 1998, CBS COURSE MYCOLOGY##GRYZENHOUT M, 2004, STUD MYCOL, P119##GRYZENHOUT M, 2006, STUD MYCOL, P35, DOI 10.3114/SIM.55.1.35##HUNTER GC, 2006, STUD MYCOL, P147, DOI 10.3114/SIM.55.1.147##LEE S, 2004, STUD MYCOL, P235##LEE SB, 1990, PCR PROTOCOLS GUIDE, P282, DOI DOI 10.1016/B978-0-12-372180-8.50038-X##NAG RAJ TR, 1993, COELOMYCETOUS ANAMOR##NAKABONGE G, 2006, STUD MYCOL, P255, DOI 10.3114/SIM.55.1.255##NIEKERK JM, 2004, MYCOL RES, V108, P283, DOI 10.1017/S0953756204009268##PARK R. F., 2000, DISEASES AND PATHOGENS OF EUCALYPTS, P153##PARK RF, 1984, T BRIT MYCOL SOC, V83, P93, DOI 10.1016/S0007-1536(84)80249-1##PASCOE IG, 1990, MYCOL RES, V94, P675, DOI 10.1016/S0953-7562(09)80668-0##RAYNER AW, 1970, MYCOLOGICAL COLOUR C##SANKARAN KC, 1995, MYCOL PAP, V170, P1##SLIPPERS B, 2004, STUD MYCOL, P343##SLIPPERS B, 2004, MYCOLOGIA, V96, P1030, DOI 10.2307/3762087##SLIPPERS B, 2004, MYCOLOGIA, V96, P83, DOI 10.2307/3761991##SUTTON BC, 1971, T BRIT MYCOL SOC, V57, P539, DOI 10.1016/S0007-1536(71)80071-2##SUTTON BC, 1980, COELOMYCETES FUNGI I##SWART HJ, 1988, T BRIT MYCOL SOC, V90, P633, DOI 10.1016/S0007-1536(88)80069-X##VAN NIEKERK JM, 2005, AUSTRALAS PLANT PATH, V34, P27, DOI 10.1071/AP04072##VAN RENSBURG JCJ, 2006, STUD MYCOL, P65, DOI 10.3114/SIM.55.1.65##WHITE TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1",65,2020-11-20,NA
J,WOS:000240296300006,2006,"UPPER BOUND ON THE NUMBER OF VERTICES OF POLYHEDRA WITH 0, 1-CONSTRAINT MATRICES","IN THIS NOTE WE GIVE UPPER BOUNDS FOR THE NUMBER OF VERTICES OF THE POLYHEDRON P (A, B) = {X IS AN ELEMENT OF R-D: AX <= B) WHEN THE M X D CONSTRAINT MATRIX A IS SUBJECTED TO CERTAIN RESTRICTION. FOR INSTANCE, IF A IS A 0/1-MATRIX, THEN THERE CAN BE AT MOST D! VERTICES AND THIS BOUND IS TIGHT, OR IF THE ENTRIES OF A ARE NON-NEGATIVE INTEGERS SO THAT EACH ROW SUMS TO AT MOST C, THEN THERE CAN BE AT MOST C-D VERTICES. THESE BOUNDS ARE CONSEQUENCES OF A MORE GENERAL THEOREM THAT THE NUMBER OF VERTICES OF P (A, B) IS AT MOST D! (.) W/D, WHERE W IS THE VOLUME OF THE CONVEX HULL OF THE ZERO VECTOR AND THE ROW VECTORS OF A, AND D IS THE SMALLEST ABSOLUTE VALUE OF ANY NON-ZERO D X D SUBDETERMINANT OF A. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NA,COMPUTATIONAL GEOMETRY; POLYHEDRON; UPPER BOUNDS; LINEAR PROGRAMMING,INFORMATION PROCESSING LETTERS,"ELBASSIONI, K##LOTKER, Z##SEIDEL, R","CTR WISKUNDE & INFORMAT, NL-1098 SJ AMSTERDAM, NETHERLANDS. MAX PLANCK INST INFORMAT, D-66123 SAARBRUCKEN, GERMANY. UNIV SAARLAND, DEPT COMP SCI, D-66123 SAARBRUCKEN, GERMANY.","COMPUTER SCIENCE, INFORMATION SYSTEMS",COMPUTER SCIENCE,"BARROW DL, 1979, AM MATH MON, V86, P50, DOI 10.2307/2320304##FLEINER T, 2000, EUR J COMBIN, V21, P121, DOI 10.1006/EUJC.1999.0326##GRUJBAUM B, 2003, GRADUATE TEXTS MATH, V221##MARICHAL JL, UNPUB VOLUME FORMULA##WALLNER A, 2005, P 4 INT S IMPR PROB, P388##ZIEGLER GM, 1995, LECT POLYTOPES GRADU, V152",1,2020-11-20,NA
J,WOS:000241866200009,2006,VALIDATION OF MODIS AEROSOL OBSERVATIONS OVER THE NETHERLANDS WITH GLOBE STUDENT MEASUREMENTS,"WE HAVE ESTABLISHED A NETWORK OF SECONDARY SCHOOLS IN THE NETHERLANDS WITH STUDENTS ROUTINELY MEASURING AEROSOL OPTICAL THICKNESS (AOT) AT TWO WAVELENGTHS WITH HAND-HELD SUN PHOTOMETERS. STUDENTS HAVE PERFORMED MORE THAN 400 MEASUREMENTS BETWEEN JANUARY 2002 AND OCTOBER 2005 OVER MORE THAN 12 LOCATIONS WITHIN THE NETHERLANDS AS A CONTRIBUTION TO GLOBAL LEARNING AND OBSERVATIONS TO BENEFIT THE ENVIRONMENT (GLOBE). WE HAVE DEVELOPED AN IMPROVED AOT RETRIEVAL ALGORITHM THAT ACCOUNTS FOR THE EFFECTIVE WAVELENGTH OF THE BROAD-BAND GLOBE DETECTORS AND FOR THE SPATIOTEMPORAL VARIATION OF OZONE. RESULTS FROM A THEORETICAL ERROR ANALYSIS INDICATE THAT GLOBE MEASUREMENTS ACHIEVE A PRECISION BETTER THAN 0.02 AOT FOR BOTH CHANNELS. COMPARISONS WITH PROFESSIONAL INSTRUMENTS GENERALLY GIVE HIGH CORRELATIONS AND LOW SCATTER AND BIAS. FROM THESE TESTS, WE CONCLUDE THAT STUDENT DATA ARE SCIENTIFICALLY VALID AND MAY BE USED TO VALIDATE MODIS AOT RETRIEVALS OVER THE NETHERLANDS. WE FIND THAT OVER LAND, MODIS AOT IS BIASED BY +0.03 (470 NM) AND -0.01 AOT (660 NM). OVER COASTAL AREAS, MODIS OVERESTIMATES AOT BY 0.10 (470 NM) AND 0.08 AOT (660 NM). SEASONALLY AVERAGED MODIS OBSERVATIONS OVER NORTHWESTERN EUROPE SHOW RELATIVELY HIGHEST AOT VALUES OVER THE REGION OF FLANDERS AND THE NETHERLANDS, WITH A SEASONAL CYCLE PEAKING IN SPRING/SUMMER. OUR STUDY SHOWS THE POTENTIAL OF SECONDARY SCHOOL-BASED NETWORKS IN ADDITION TO EXISTING, PROFESSIONAL NETWORKS THAT HAVE MUCH LESS SPATIAL COVERAGE.",SATELLITE-OBSERVATIONS; SUN PHOTOMETER; OPTICAL DEPTH; AIR-MASS; AERONET; LAND; NETWORK; MODEL,NA,JOURNAL OF GEOPHYSICAL RESEARCH-ATMOSPHERES,"BOERSMA, KF##DE VROOM, JP","ROYAL NETHERLANDS METEOROL INST, NL-3730 AE DE BILT, NETHERLANDS.",METEOROLOGY & ATMOSPHERIC SCIENCES,METEOROLOGY & ATMOSPHERIC SCIENCES,"BALTENSPERGER U., 2004, WMO GAW EXP WORKSH G##BARNABA F, 2004, ATMOS CHEM PHYS, V4, P2367, DOI 10.5194/ACP-4-2367-2004##BROOKS DR, 2001, J GEOPHYS RES-ATMOS, V106, P4733, DOI 10.1029/2000JD900545##BUTLER D., 2003, J GEOSCI ED, V51, P9, DOI DOI 10.5408/1089-9995-51.1.9##CHAMBERS LH, 2005, EOS T AGU, V86, PF382##CHU DA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013205##CHU DA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003179##DEUZE JL, 2001, J GEOPHYS RES-ATMOS, V106, P4913, DOI 10.1029/2000JD900364##DEVROOM JP, 2004, TR267 R NETH MET I##ESKES H. J, 2005, ATMOS CHEM PHYS DISC, V5, P4429, DOI [10.5194/ACPD-5-4429-2005, DOI 10.5194/ACPD-5-4429-2005]##ESKES HJ, 2003, Q J ROY METEOR SOC, V129, P1663, DOI 10.1256/QJ.02.14##GONZALEZ CR, 2003, ATMOS CHEM PHYS, V3, P521##HOLBEN BN, 1998, REMOTE SENS ENVIRON, V66, P1, DOI 10.1016/S0034-4257(98)00031-5##ICHOKU C, 2002, GEOPHYS RES LETT, V29, P8006, DOI DOI 10.1029/2001GL013206##*INT PAN CLIM CHAN, 2001, CLIM CHANG 2001 SCI##KAHN RA, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD004706##KIEHL JT, 1993, SCIENCE, V260, P311, DOI 10.1126/SCIENCE.260.5106.311##KING MD, 1999, B AM METEOROL SOC, V80, P2229, DOI 10.1175/1520-0477(1999)080<2229:RSOTAF>2.0.CO;2##LEVY RC, 2005, J ATMOS SCI, V62, P974, DOI 10.1175/JAS3391.1##MIMS FM, 1992, APPL OPTICS, V31, P6965, DOI 10.1364/AO.31.006965##MIMS FM, 1999, B AM METEOROL SOC, V80, P1421, DOI 10.1175/1520-0477(1999)080<1421:AIHMNF>2.0.CO;2##REMER LA, 2005, J ATMOS SCI, V62, P947, DOI 10.1175/JAS3385.1##SCHAAP M, 2004, ATMOS CHEM PHYS, V4##SMIRNOV A, 2000, REMOTE SENS ENVIRON, V73, P337, DOI 10.1016/S0034-4257(00)00109-7##STAMMES P, 2000, J AEROSOL SCI, V31, PS283##STOWE LL, 1997, J GEOPHYS RES-ATMOS, V102, P16923, DOI 10.1029/96JD02132##THOMASON LW, 1983, J ATMOS SCI, V40, P1851, DOI 10.1175/1520-0469(1983)040<1851:TEOAAW>2.0.CO;2##TORRES O, 2002, J ATMOS SCI, V59, P398, DOI 10.1175/1520-0469(2002)059<0398:ALTROA>2.0.CO;2##VEEFKIND JP, 1999, J GEOPHYS RES-ATMOS, V104, P2253, DOI 10.1029/98JD02816##YOUNG AT, 1994, APPL OPTICS, V33, P1108, DOI 10.1364/AO.33.001108",13,2020-11-20,NA
J,WOS:000241866200003,2006,CLOUD PROPERTY RETRIEVALS FOR CLIMATE MONITORING: IMPLICATIONS OF DIFFERENCES BETWEEN SPINNING ENHANCED VISIBLE AND INFRARED IMAGER (SEVIRI) ON METEOSAT-8 AND ADVANCED VERY HIGH RESOLUTION RADIOMETER (AVHRR) ON NOAA-17,"IN THE FRAMEWORK OF THE SATELLITE APPLICATION FACILITY ON CLIMATE MONITORING (CM-SAF) AN ALGORITHM WAS DEVELOPED TO RETRIEVE CLOUD PHYSICAL PROPERTIES (CPP) FROM THE SPINNING ENHANCED VISIBLE AND INFRARED IMAGER (SEVIRI) ON BOARD THE METEOSAT SECOND GENERATION (METEOSAT-8) AND THE ADVANCED VERY HIGH RESOLUTION RADIOMETER (AVHRR) ON BOARD THE NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) SATELLITES. THIS PAPER PRESENTS THE CPP ALGORITHM AND DETERMINES IF SEVIRI CAN BE USED TOGETHER WITH AVHRR TO BUILD A CONSISTENT AND ACCURATE DATA SET OF CLOUD OPTICAL THICKNESS (COT) AND CLOUD LIQUID WATER PATH (CLWP) OVER EUROPE FOR CLIMATE RESEARCH PURPOSES. AFTER QUANTIFYING THE DIFFERENCES IN 0.6 AND 1.6 MU M OPERATIONAL CALIBRATED REFLECTANCES OF SEVIRI AND AVHRR, A RECALIBRATION PROCEDURE IS PROPOSED TO NORMALIZE AND ABSOLUTELY CALIBRATE THESE REFLECTANCES. THE EFFECTS OF RECALIBRATION, SPATIAL RESOLUTION, AND VIEWING GEOMETRY DIFFERENCES ON THE SEVIRI AND AVHRR CLOUD PROPERTY RETRIEVALS ARE EVALUATED. THE INTERCOMPARISON OF 0.6 AND 1.6 MU M OPERATIONALLY CALIBRATED REFLECTANCES INDICATES SIMILAR TO 6 AND SIMILAR TO 26% HIGHER REFLECTANCES FOR SEVIRI THAN FOR AVHRR. THESE DISCREPANCIES RESULT IN RETRIEVAL DIFFERENCES BETWEEN AVHRR AND SEVIRI OF SIMILAR TO 8% FOR COT AND SIMILAR TO 60% FOR CLWP. OWING TO RECALIBRATION THESE DIFFERENCES REDUCE TO SIMILAR TO 5%, WHILE THE MAGNITUDE OF THE MEDIAN COT AND CLWP VALUES OF AVHRR DECREASE SIMILAR TO 2 AND SIMILAR TO 60% AND THE SEVIRI VALUES INCREASE SIMILAR TO 10 AND SIMILAR TO 55%, RESPECTIVELY. THE DIFFERENCES IN SPATIAL RESOLUTION AND VIEWING GEOMETRY SLIGHTLY INFLUENCE THE RETRIEVAL PRECISION. THUS THE CPP ALGORITHM CAN BE USED TO BUILD A CONSISTENT AND HIGH-QUALITY DATA SET OF SEVIRI AND AVHRR RETRIEVED CLOUD PROPERTIES FOR CLIMATE RESEARCH PURPOSES, PROVIDED THE INSTRUMENT REFLECTANCES ARE RECALIBRATED, PREFERABLY GUIDED BY THE SATELLITE OPERATORS.",OPTICAL-THICKNESS; LIQUID WATER; ISCCP; MODIS; STRATOCUMULUS; INFERENCE; PRODUCTS; CHANNELS; RADIUS,NA,JOURNAL OF GEOPHYSICAL RESEARCH-ATMOSPHERES,"ROEBELING, RA##FEIJT, AJ##STAMMES, P","ROYAL NETHERLANDS METEOROL INST, NL-3730 AE DE BILT, NETHERLANDS. NASA, GODDARD INST SPACE STUDIES, NEW YORK, NY 10025 USA.",METEOROLOGY & ATMOSPHERIC SCIENCES,METEOROLOGY & ATMOSPHERIC SCIENCES,"ANDERSON G.P., 1986, AFGLTR860110##CAHALAN RF, 1994, J ATMOS SCI, V51, P2434, DOI 10.1175/1520-0469(1994)051<2434:TAOFSC>2.0.CO;2##CESS RD, 1989, SCIENCE, V245, P513, DOI 10.1126/SCIENCE.245.4917.513##DAVIS A, 1997, J ATMOS SCI, V54, P241, DOI 10.1175/1520-0469(1997)054<0241:TLSBIS>2.0.CO;2##DEHAAN JF, 1987, ASTRON ASTROPHYS, V183, P371##DOELLING DR, 2004, EUMET SAT MET SAT DA##FEIJT A, 2004, ATMOS RES, V72, P3, DOI 10.1016/J.ATMOSRES.2004.03.031##GOVAERTS Y, 2004, EUMMSGTEN040024 EUME##GOVAERTS YM, 2004, IEEE T GEOSCI REMOTE, V42, P176, DOI 10.1109/TGRS.2003.815406##GUENTHER B, 1998, IEEE T GEOSCI REMOTE, V36, P1142, DOI 10.1109/36.701021##HAN QY, 1994, J CLIMATE, V7, P465, DOI 10.1175/1520-0442(1994)007<0465:NGSOED>2.0.CO;2##HANSEN JE, 1974, J ATMOS SCI, V31, P1137, DOI 10.1175/1520-0469(1974)031<1137:IOTPOV>2.0.CO;2##HEIDINGER AK, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD002035##HESS M, 1998, J QUANT SPECTROSC RA, V60, P301, DOI 10.1016/S0022-4073(98)00007-7##HOUGHTON J.T., 2001, CLIMATE CHANGE 2001##JOLIVET D, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005205##KING MD, 2004, J ATMOS OCEAN TECH, V21, P857, DOI 10.1175/1520-0426(2004)021<0857:RSOLWA>2.0.CO;2##KNAP WH, 2005, APPL OPTICS, V44, P4060, DOI 10.1364/AO.44.004060##LOEB NG, 1998, J CLIMATE, V11, P215, DOI 10.1175/1520-0442(1998)011<0215:IOMSCO>2.0.CO;2##MINNIS P, 1993, J ATMOS SCI, V50, P1279, DOI 10.1175/1520-0469(1993)050<1279:IOCCPU>2.0.CO;2##NAKAJIMA T, 1990, J ATMOS SCI, V47, P1878, DOI 10.1175/1520-0469(1990)047<1878:DOTOTA>2.0.CO;2##NAKAJIMA TY, 1995, J ATMOS SCI, V52, P4043, DOI 10.1175/1520-0469(1995)052<4043:WADOCM>2.0.CO;2##PLATNICK S, 2001, J QUANT SPECTROSC RA, V68, P57, DOI 10.1016/S0022-4073(00)00015-7##RAO CRN, 1995, INT J REMOTE SENS, V16, P1931, DOI 10.1080/01431169508954530##ROEBELING RA, 2005, 200502 WR KON NED ME##ROSENFELD D, 2004, B AM METEOROL SOC, V85, P873, DOI 10.1175/BAMS-85-6-873##ROSSOW WB, 1999, B AM METEOROL SOC, V80, P2261, DOI 10.1175/1520-0477(1999)080<2261:AIUCFI>2.0.CO;2##ROSSOW WB, 1991, B AM METEOROL SOC, V72, P2, DOI 10.1175/1520-0477(1991)072<0002:ICDP>2.0.CO;2##STAMMES P, 2001, STUD GEO OP, P385##STAMMES P, 2005, IRS 2004 CURRENT PRO##STEPHENS GL, 1978, J ATMOS SCI, V35, P2133, DOI 10.1175/1520-0469(1978)035<2133:RPIEWC>2.0.CO;2##VARNAI T, 2002, J ATMOS SCI, V59, P1607, DOI 10.1175/1520-0469(2002)059<1607:OOTDRE>2.0.CO;2##WATTS PD, 1998, 97181 EUMETSAT ITT E##WIELICKI BA, 1992, J GEOPHYS RES-ATMOS, V97, P12799, DOI 10.1029/92JD01061##WOICK H, 2002, ADV SPACE RES, V30, P2405, DOI 10.1016/S0273-1177(02)80290-3##WU X, 2003, CGMS 31 M ASC SWITZ",135,2020-11-20,NA
J,WOS:000241866700001,2006,A QUICK RESPONSE OF THE EQUATORIAL OCEAN TO ANTARCTIC SEA ICE/SALINITY ANOMALIES,"THE POTENTIAL MECHANISMS FOR A QUICK RESPONSE OF THE EQUATORIAL OCEAN TO PROCESSES OCCURRING IN THE HIGH-LATITUDE SOUTHERN OCEAN HAVE BEEN INVESTIGATED. IN THE SOUTHERN OCEAN AT THE DRAKE PASSAGE LATITUDES, THERE IS AN ZONALLY UNBOUNDED ""CHANNEL'', THE ANTARCTIC CIRCUMPOLAR CURRENT BELT (ACCB). IT IS DEMONSTRATED THAT IN A MULTICONNECTED DOMAIN SUCH AS THE ACCB, SIGNALS GENERATED BY ANOMALIES IN THE SOUTHERN OCEAN SEA ICE COVER/SALINITY DISTRIBUTION CAN PROPAGATE IN A WAVE-LIKE MANNER IN THE FORM OF FAST MOVING BAROTROPIC ROSSBY WAVES. A DISTURBANCE INDUCED NEAR THE DRAKE PASSAGE IS DEMONSTRATED TO GENERATE A ROSSBY WAVE THAT PROPAGATES ACROSS THE PACIFIC IN ONLY A FEW DAYS. THIS SIGNAL IS REFLECTED AT THE WESTERN BOUNDARY OF THE PACIFIC AND GENERATES AN EQUATORWARD PROPAGATING COASTALLY TRAPPED KELVIN WAVE. THE RESULTING TEMPERATURE ANOMALY MOVES NORTHWARD ALONG THE WESTERN COASTLINE UP TO THE VICINITY OF THE EQUATOR AND INCREASES IN AMPLITUDE OVER TIME. THE ANOMALY IN THE WESTERN EDGE OF EQUATORIAL PACIFIC THEN BEGINS TO PROPAGATE EASTWARD ALONG THE EQUATOR AS A TRAPPED EQUATORIAL WAVE. AFTER ABOUT 2-3 MONTHS THIS WAVE REACHES THE EASTERN COAST, REFLECTS, AND GENERATES THE COASTAL TRAPPED WAVE, WHICH PROPAGATES NORTH AND SOUTH ALONG THE COASTLINE IN BOTH HEMISPHERES. THIS PROCESS IS SUGGESTED AS ONE POSSIBLE DIRECT MECHANISM BY WHICH THE EXTRATROPICAL OCEAN CAN INDUCE ANOMALIES IN THE EQUATORIAL OCEAN.",NINO-SOUTHERN OSCILLATION; WEDDELL SEA; CIRCUMPOLAR CURRENT; ICE EXTENT; CIRCULATION; VARIABILITY; CLIMATE; MODEL; TELECONNECTIONS; ATMOSPHERE,NA,JOURNAL OF GEOPHYSICAL RESEARCH-OCEANS,"IVCHENKO, VO##ZALESNY, VB##DRINKWATER, MR##SCHROTER, J","NATL OCEANOG CTR SOUTHAMPTON, SOUTHAMPTON SO14 3ZH, HANTS, ENGLAND. RUSSIAN ACAD SCI, INST NUMER MATH, MOSCOW 119991, RUSSIA. EUROPEAN SPACE AGCY, EUROPEAN SPACE RES & TECHNOL CTR, NL-2201 AZ NOORDWIJK, NETHERLANDS. ALFRED WEGENER INST POLAR & MARINE RES, D-27570 BREMERHAVEN, GERMANY.",OCEANOGRAPHY,OCEANOGRAPHY,"BROMWICH DH, 1998, J GEOPHYS RES-ATMOS, V103, P11173, DOI 10.1029/98JD00624##CARLETON AM, 1988, J CLIMATE, V1, P379, DOI 10.1175/1520-0442(1988)001<0379:SISOTS>2.0.CO;2##CUNNINGHAM SA, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2001JC001147##DELECLUSE P, 1996, OKEANOLOGIYA+, V36, P26##DRINKWATER MR, 2001, ANN GLACIOL, V33, P125, DOI 10.3189/172756401781818446##GREZIO A, 2005, Q J ROY METEOR SOC, V131, P833, DOI 10.1256/QJ.03.213##GRIFFIES SM, 2000, OCEAN MODEL, V2, P123, DOI 10.1016/S1463-5003(00)00014-7##HARMS S, 2001, J GEOPHYS RES-OCEANS, V106, P9057, DOI 10.1029/1999JC000027##HOLLAND WR, 1975, NUMERICAL MODELS OCE, P168##IVCHENKO VO, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020472##IVCHENKO VO, 1997, J PHYS OCEANOGR, V27, P5, DOI 10.1175/1520-0485(1997)027<0005:AKEBAI>2.0.CO;2##IVCHENKO VO, 1996, J PHYS OCEANOGR, V26, P753, DOI 10.1175/1520-0485(1996)026<0753:TDOTAC>2.0.CO;2##JAMES IN, 1988, Q J ROY METEOR SOC, V114, P619, DOI 10.1256/SMSQJ.48104##JOHNSON HL, 2002, J PHYS OCEANOGR, V32, P1121, DOI 10.1175/1520-0485(2002)032<1121:ATFTSA>2.0.CO;2##KAROLY DJ, 1989, J CLIMATE, V2, P1239, DOI 10.1175/1520-0442(1989)002<1239:SHCFAW>2.0.CO;2##KAWASE M, 1987, J PHYS OCEANOGR, V17, P2294, DOI 10.1175/1520-0485(1987)017<2294:EODOCD>2.0.CO;2##KWOK R, 2002, J CLIMATE, V15, P487, DOI 10.1175/1520-0442(2002)015<0487:SOCASI>2.0.CO;2##LEVITUS S., 1982, 13 NOAA##LIGHTHIL.MJ, 1969, PHILOS TR R SOC S-A, V265, P45, DOI 10.1098/RSTA.1969.0040##MARCHUK GL, 2003, RUSS J NUMER ANAL M, V18, P307, DOI 10.1163/156939803769210975##MEREDITH MP, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021169##MO KC, 1985, MON WEATHER REV, V113, P22, DOI 10.1175/1520-0493(1985)113<0022:TITSH>2.0.CO;2##OLBERS D, 2001, OCEAN DYNAM, V52, P79, DOI DOI 10.1007/S10236-001-0010-3##ORSI A. H., 2005, HYDROGRAPHIC ATLAS W, V1##PENG GB, 1989, CHINESE SCI BULL, V34, P1463##PETERSON RG, 1998, J GEOPHYS RES-OCEANS, V103, P24573, DOI 10.1029/98JC01947##PHILANDER SGH, 1980, J GEOPHYS RES-OCEANS, V85, P1123, DOI 10.1029/JC085IC02P01123##RICHARDSON G, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021586##SARKISYAN A. S., 1977, NUMERICAL ANAL PREDI##SCHMIDT GA, 1996, TELLUS A, V48, P158, DOI 10.1034/J.1600-0870.1996.00009.X##SIMMONDS I, 1995, J CLIMATE, V8, P637, DOI 10.1175/1520-0442(1995)008<0637:RBTIVO>2.0.CO;2##STEPHENS C, 2002, WORLD OCEAN ATLAS 20, V1##STRASS VH, 1998, ANTAR RES S, V74, P123##TIMMERMANN R, 2001, ANN GLACIOL-SER, V33, P419, DOI 10.3189/172756401781818121##TREGUIER AM, 1992, J GEOPHYS RES-OCEANS, V97, P687, DOI 10.1029/91JC02350##TRENBERTH KE, 1998, J GEOPHYS RES-OCEANS, V103, P14291, DOI 10.1029/97JC01444##TURNER J, 2004, INT J CLIMATOL, V24, P1, DOI 10.1002/JOC.965##VENEGAS SA, 2001, GEOPHYS RES LETT, V28, P3301, DOI 10.1029/2001GL012991##VENEGAS SA, 2001, J GEOPHYS RES-OCEANS, V106, P16747, DOI 10.1029/2000JC000594##WHITE WB, 1996, NATURE, V380, P699, DOI 10.1038/380699A0##YUAN XJ, 2000, J CLIMATE, V13, P1697, DOI 10.1175/1520-0442(2000)013<1697:ASIEVA>2.0.CO;2##YUAN XJ, 1996, NATURE, V380, P673, DOI 10.1038/380673A0##ZALESNY VB, 1996, RUSS J NUMER ANAL M, V11, P421, DOI 10.1515/RNAM.1996.11.5.421##ZHANG YX, 2001, ANN GLACIOL, V33, P539, DOI 10.3189/172756401781818644",19,2020-11-20,NA
J,WOS:000241492700044,2006,MONTE CARLO SIMULATION OF UNIAXIAL TENSION OF AN AMORPHOUS POLYETHYLENE-LIKE POLYMER GLASS,"ATOMISTIC MONTE CARLO (MC) SIMULATIONS OF UNIAXIAL TENSION OF AN AMORPHOUS LINEAR POLYETHYLENE (PE)-LIKE POLYMER GLASS HAVE BEEN CARRIED OUT. A UNITED-ATOM MODEL HAS BEEN USED WHERE PE CHAINS ARE REPRESENTED BY BEADS CONNECTED BY FLEXIBLE SPRINGS. HIGHLY EFFICIENT END-BRIDGING MC MOVES HAVE BEEN USED TO FIRST EQUILIBRATE THE POLYMER IN THE MELT AND THEN COOL TO A TEMPERATURE BELOW ITS GLASS TRANSITION TEMPERATURE. A MIX OF EFFICIENT MC MOVES HAS ALSO BEEN USED TO SIMULATE THE DEFORMATION DYNAMICS. UPON UNIAXIAL DEFORMATION THE STRESS RESPONSE TO THE STRAIN IS INITIALLY LINEAR ELASTIC, SUBSEQUENTLY AS THE STRAIN INCREASES FURTHER YIELDING IS OBSERVED, AND FINALLY STRAIN HARDENING IS DEVELOPED. THE SIMULATED YOUNG MODULUS AND POISSON RATIO TAKE REALISTIC VALUES. FURTHERMORE, THE TEMPERATURE AND STRAIN RATE DEPENDENCIES OF STRESS-STRAIN CURVES HAVE BEEN INVESTIGATED, AND THE RESULTS ARE IN QUALITATIVE AGREEMENT WITH THE EXPERIMENTAL OBSERVATIONS. CHAIN CONFORMATION AND ENERGY AND STRESS PARTITIONING WITH INCREASING STRAIN ARE FOLLOWED IN DETAIL. DURING THE DEFORMATION THE CHAINS ADOPT MORE EXTENDED CONFORMATIONS, AND THE FRACTION OF DYADS IN THE TRANS STATE INCREASES. IN THE ELASTIC REGION MECHANICAL WORK DONE ON THE SAMPLE IS PRIMARILY STORED AS NONBONDED INTERNAL ENERGY, WHEREAS FROM THE YIELD REGION ONWARD THE INTRACHAIN CONTRIBUTIONS START TO PLAY A ROLE.",MOLECULAR-DYNAMICS SIMULATION; ATOMISTIC SIMULATION; DEFORMATION; MELTS; ALGORITHM; STRESS; STRAIN; CHAIN; MODEL; EVOLUTION,NA,MACROMOLECULES,"LI, J##MULDER, T##VORSELAARS, B##LYULIN, AV##MICHELS, MAJ","TECH UNIV EINDHOVEN, GRP POLYMER PHYS, EINDHOVEN POLYMER LABS, NL-5600 MB EINDHOVEN, NETHERLANDS. TECH UNIV EINDHOVEN, DUTCH POLYMER INST, NL-5600 MB EINDHOVEN, NETHERLANDS. FUDAN UNIV, MINIST EDUC CHINA, KEY LAB MOL ENGN POLYMERS, SHANGHAI 200433, PEOPLES R CHINA. FUDAN UNIV, DEPT MACROMOL SCI, SHANGHAI 200433, PEOPLES R CHINA.",POLYMER SCIENCE,POLYMER SCIENCE,"ALLEN M. P., 1987, COMPUTER SIMULATION##ARRUDA EM, 1993, INT J PLASTICITY, V9, P697, DOI 10.1016/0749-6419(93)90034-N##BANDRUP J., 1966, POLYM HDB##BROSTOW W, 1986, FAILURE PLASTICS##BROWN D, 1991, MACROMOLECULES, V24, P2075, DOI 10.1021/MA00008A056##CAPALDI FM, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.175505##CAPALDI FM, 2004, POLYMER, V45, P1391, DOI 10.1016/J.POLYMER.2003.07.011##CHUI C, 1999, MACROMOLECULES, V32, P3795, DOI 10.1021/MA9815399##DODD LR, 1993, MOL PHYS, V78, P961, DOI 10.1080/00268979300100641##DODD LR, 1994, ADV POLYM SCI, V116, P249, DOI 10.1007/BFB0080201##HASAN OA, 1993, POLYMER, V34, P5085, DOI 10.1016/0032-3861(93)90252-6##HOLZL T, 1999, COMPUT THEOR POLYM S, V9, P99, DOI 10.1016/S1089-3156(99)00019-7##KARAYIANNIS NC, 2002, J CHEM PHYS, V117, P5465, DOI 10.1063/1.1499480##KENNEDY MA, 1994, MACROMOLECULES, V27, P5297, DOI 10.1021/MA00097A009##LYULIN AV, 2005, EUROPHYS LETT, V71, P618, DOI 10.1209/EPL/I2005-10133-0##LYULIN AV, 2004, MACROMOLECULES, V37, P8785, DOI 10.1021/MA049737P##MAVRANTZAS VG, 1999, MACROMOLECULES, V32, P5072, DOI 10.1021/MA981745G##MCKECHNIE JI, 1993, MACROMOLECULES, V26, P198, DOI 10.1021/MA00053A030##MELICK HGH, 2002, THESIS TU EINDHOVEN##OGURA I, 1995, POLYMER, V36, P1375, DOI 10.1016/0032-3861(95)95914-M##OSPINA SA, 2003, MATER RES INNOV, V7, P27, DOI [10.1007/S10019-002-0219-X, 10.1080/14328917.2003.11784755]##OSPINA SA, 2004, E POLYM##PANT PVK, 1995, MACROMOLECULES, V28, P7224, DOI 10.1021/MA00125A027##PAUL W, 1997, MACROMOLECULES, V30, P7772, DOI 10.1021/MA971184D##RYCKAERT JP, 1975, CHEM PHYS LETT, V30, P123, DOI 10.1016/0009-2614(75)85513-8##SIEPMANN JI, 1992, MOL PHYS, V75, P59, DOI 10.1080/00268979200100061##SMITH W, 1993, CCP5 INFO Q, P14##THEODOROU DN, 1993, MAKROMOL CHEM-THEOR, V2, P191##THEODOROU DN, 1985, MACROMOLECULES, V18, P1467, DOI 10.1021/MA00149A018##VACATELLO M, 1980, J CHEM PHYS, V73, P548, DOI 10.1063/1.439853##WARD IM, 2004, INTRO MECH PROPERTIE##WITTKOP M, 1994, PHYS REV E, V49, P5472, DOI 10.1103/PHYSREVE.49.5472",34,2020-11-20,NA
J,WOS:000242200800001,2006,"DRUG RESISTANCE TO SULPHADOXINE-PYRIMETHAMINE IN PLASMODIUM FALCIPARUM MALARIA IN MLIMBA, TANZANIA","BACKGROUND: SULPHADOXINE-PYRIMETHAMINE (SP) HAS BEEN AND IS CURRENTLY USED FOR TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN MANY AFRICAN COUNTRIES. NEVERTHELESS, THE RESPONSE OF PARASITES TO SP TREATMENT HAS SHOWN SIGNIFICANT VARIATION BETWEEN INDIVIDUALS. METHODS: THE GENES FOR DIHYDROFOLATE REDUCTASE (DHFR) AND DIHYDROPTEROATE SYNTHASE (DHPS) WERE USED AS MARKERS, TO INVESTIGATE PARASITE RESISTANCE TO SP IN 141 CHILDREN AGED LESS THAN 5 YEARS. PARASITE DNA WAS EXTRACTED BY CHELEX METHOD FROM BLOOD SAMPLES COLLECTED AND PRESERVED ON FILTER PAPERS. SUBSEQUENTLY, POLYMERASE CHAIN REACTION (PCR) AND RESTRICTION FRAGMENT LENGTH POLYMORPHISM (PCR-RFLP) WERE APPLIED TO DETECT THE SP RESISTANCE-ASSOCIATED POINT MUTATIONS ON DHFR AND DHPS. COMMONLY REPORTED POINT MUTATIONS AT CODONS 51, 59, 108 AND 164 IN THE DHFR AND CODONS 437, 540 AND 581 IN THE DHPS DOMAINS WERE EXAMINED. RESULTS: CHILDREN INFECTED WITH PARASITES HARBOURING A RANGE OF SINGLE TO QUINTUPLE DHFR/DHPS MUTATIONS WERE ERRATICALLY CURED WITH SP. HOWEVER, THE QUINTUPLE DHFR/DHPS MUTANT GENOTYPES WERE MOSTLY ASSOCIATED WITH TREATMENT FAILURES. HIGH PROPORTION OF SP RESISTANCE-ASSOCIATED POINT MUTATIONS WAS DETECTED IN THIS STUDY BUT THE ADEQUATE CLINICAL RESPONSE (89.4%) OBSERVED CLINICALLY AT DAY 14 OF FOLLOW UP REFLECTS THE ROLE OF SEMI-IMMUNITY PROTECTION AND PARASITE CLEARANCE IN THE POPULATION. CONCLUSION: IN MONITORING DRUG RESISTANCE TO SP, CONCURRENT STUDIES ON POSSIBLE CONFOUNDING FACTORS PERTAINING TO DEVELOPMENT OF RESISTANCE IN FALCIPARUM MALARIA SHOULD BE CONSIDERED. THE SP RESISTANCE POTENTIAL DETECTED IN THIS STUDY, CAUTIONS ON ITS USEFUL THERAPEUTIC LIFE AS AN INTERIM FIRSTLINE DRUG AGAINST MALARIA IN TANZANIA AND OTHER MALARIA-ENDEMIC COUNTRIES.",DIHYDROPTEROATE-SYNTHETASE GENES; DIHYDROFOLATE-REDUCTASE; CHLORPROGUANIL-DAPSONE; ANTIFOLATE RESISTANCE; PROGUANIL RESISTANCE; MOLECULAR MARKERS; TREATMENT FAILURE; IN-VIVO; MUTATIONS; SYNTHASE,NA,MALARIA JOURNAL,"MBUGI, EV##MUTAYOBA, BM##MALISA, AL##BALTHAZARY, ST##NYAMBO, TB##MSHINDA, H","SOKOINE UNIV AGR, FAC VET MED, DEPT VET PHYSIOL BIOCHEM PHARMACOL & TOXICOL, MOROGORO, TANZANIA. SOKOINE UNIV AGR, FAC SCI, DEPT BIOL SCI, MOROGORO, TANZANIA. MUHIMBILI UNIV, COLL HLTH SCI, SCH MED, DEPT BIOCHEM, DAR ES SALAAM, TANZANIA. IFAKARA HLTH RES & DEV CTR, MOROGORO, TANZANIA. WAGENINGEN UNIV, DEPT ANIM SCI, CELL BIOL & IMMUNOL GRP, NL-6700 AH WAGENINGEN, NETHERLANDS.",INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,INFECTIOUS DISEASES; PARASITOLOGY; TROPICAL MEDICINE,"AHMED A, 2004, ANTIMICROB AGENTS CH, V48, P879, DOI 10.1128/AAC.48.3.879-889.2004##ALIFRANGIS M, 2003, AM J TROP MED HYG, V69, P601, DOI 10.4269/AJTMH.2003.69.601##AUBOUY A, 2003, J ANTIMICROB CHEMOTH, V52, P43, DOI 10.1093/JAC/DKG294##BABIKER HA, 1999, T ROY SOC TROP MED H, V93, PS11, DOI 10.1016/S0035-9203(99)90321-8##BASCO LK, 2002, AM J TROP MED HYG, V67, P383, DOI 10.4269/AJTMH.2002.67.383##BASCO LK, 2000, J INFECT DIS, V182, P624, DOI 10.1086/315731##BISWAS S, 2004, J POSTGRAD MED, V50, P17##BWIJO B, 2003, ACTA TROP, V85, P363, DOI 10.1016/S0001-706X(02)00264-4##CLYDE D F, 1954, EAST AFR MED J, V31, P41##CLYDE D. F., 1957, TRANS ROY SOC TROP MED AND HYG, V51, P505, DOI 10.1016/0035-9203(57)90039-1##DANIS M, 2003, FUND CLIN PHARMACOL, V17, P155, DOI 10.1046/J.1472-8206.2003.00165.X##DEPECOULAS PE, 1995, EXP PARASITOL, V80, P483, DOI 10.1006/EXPR.1995.1060##DURAISINGH MT, 1998, EXP PARASITOL, V89, P1, DOI 10.1006/EXPR.1998.4274##FELGER I, 1999, T ROY SOC TROP MED H, V93, PS3##FOLEY M, 1992, MOL BIOCHEM PARASIT, V53, P241, DOI 10.1016/0166-6851(92)90026-G##GYANG FN, 1992, EXP PARASITOL, V74, P470, DOI 10.1016/0014-4894(92)90209-S##HASTINGS MD, 2002, T ROY SOC TROP MED H, V96, P674, DOI 10.1016/S0035-9203(02)90349-4##JAFARI S, 2003, ANN TROP MED PARASIT, V97, P119, DOI 10.1179/000349803235001552##JELINEK T, 1999, AM J TROP MED HYG, V61, P463, DOI 10.4269/AJTMH.1999.61.463##KHALIL I, 2003, AM J TROP MED HYG, V68, P586, DOI 10.4269/AJTMH.2003.68.586##KITUA AY, 2000, INT WORKSH PHD COURS, P5##KUBLIN JG, 1998, LANCET, V351, P1629, DOI 10.1016/S0140-6736(98)24022-0##KUBLIN JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566##KYABAYINZE D, 2003, AM J TROP MED HYG, V69, P247, DOI 10.4269/AJTMH.2003.69.247##LE BRAS J, 2003, FUND CLIN PHARMACOL, V17, P147, DOI 10.1046/J.1472-8206.2003.00164.X##MISRA S.P., 1996, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES INDIA SECTION B (BIOLOGICAL SCIENCES), V66, P123##MOCKENHAUPT FP, 2005, TROP MED INT HEALTH, V10, P512, DOI 10.1111/J.1365-3156.2005.01427.X##MSHINDA H, 2000, THESIS U BASEL BASEL, P165##MUGITTU K, 2004, AM J TROP MED HYG, V71, P696, DOI 10.4269/AJTMH.2004.71.696##MUTABINGWA T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9##NZILA AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520##OMAR SA, 2001, T ROY SOC TROP MED H, V95, P315, DOI 10.1016/S0035-9203(01)90250-0##PEARCE RJ, 2003, ANTIMICROB AGENTS CH, V47, P1347, DOI 10.1128/AAC.47.4.1347-1354.2003##PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/PNAS.87.8.3018##PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/AJTMH.1995.52.565##PLOWE CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159##RONN AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7##SAMBROOK J., 1989, MOL CLONING LAB MANU##SIRAWARAPORN W, 1997, P NATL ACAD SCI USA, V94, P1124, DOI 10.1073/PNAS.94.4.1124##*STI, 1999, REP OV STI MAL, P10##TAKAHASHI T, 2000, J CLIN MICROBIOL, V38, P3161, DOI 10.1128/JCM.38.9.3161-3164.2000##TRIGLIA T, 1994, P NATL ACAD SCI USA, V91, P7149, DOI 10.1073/PNAS.91.15.7149##WANG P, 1995, MOL BIOCHEM PARASIT, V71, P115, DOI 10.1016/0166-6851(95)00041-X##WANG P, 1997, MOL BIOCHEM PARASIT, V89, P161, DOI 10.1016/S0166-6851(97)00114-X##*WHO, 2003, MICR IMM BS2024 MAL##WICHMANN O, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-17##WINSTANLEY PA, 2002, MICROBES INFECT, V4, P157, DOI 10.1016/S1286-4579(01)01523-4##YUVANIYAMA J, 2003, NAT STRUCT BIOL, V10, P357, DOI 10.1038/NSB921",17,2020-11-20,NA
J,WOS:000241879500072,2006,ANGIOGENESIS-INDEPENDENT TUMOR GROWTH MEDIATED BY STEM-LIKE CANCER CELLS,"IN THIS WORK, HIGHLY INFILTRATIVE BRAIN TUMORS WITH A STEM-LIKE PHENOTYPE WERE ESTABLISHED BY XENOTRANSPLANTATION OF HUMAN BRAIN TUMORS IN IMMUNODEFICIENT NUDE RATS. THESE TUMORS COOPTED THE HOST VASCULATURE AND PRESENTED AS AN AGGRESSIVE DISEASE WITHOUT SIGNS OF ANGIOGENESIS. THE MALIGNANT CELLS EXPRESSED NEURAL STEM CELL MARKERS, SHOWED A MIGRATORY BEHAVIOR SIMILAR TO NORMAL HUMAN NEURAL STEM CELLS, AND GAVE RISE TO TUMORS IN VIVO AFTER REGRAFTING. SERIAL PASSAGES IN ANIMALS GRADUALLY TRANSFORMED THE TUMORS INTO AN ANGIOGENESIS-DEPENDENT PHENOTYPE. THIS PROCESS WAS CHARACTERIZED BY A REDUCTION IN STEM CELLS MARKERS. GENE EXPRESSION PROFILING COMBINED WITH HIGH THROUGHPUT IMMUNOBLOTTING ANALYSES OF THE ANGIOGENIC AND NONANGIOGENIC TUMORS IDENTIFIED DISTINCT SIGNALING NETWORKS IN THE TWO PHENOTYPES. FURTHERMORE, PROINVASIVE GENES WERE UP-REGULATED AND ANGIOGENESIS SIGNALING GENES WERE DOWN-REGULATED IN THE STEM-LIKE TUMORS. IN CONTRAST, PROINVASIVE GENES WERE DOWN-REGULATED IN THE ANGIOGENESIS-DEPENDENT TUMORS DERIVED FROM THE STEM-LIKE TUMORS. THE DESCRIBED ANGIOGENESIS-INDEPENDENT TUMOR GROWTH AND THE UNCOUPLING OF INVASION AND ANGIOGENESIS, REPRESENTED BY THE STEM-LIKE CANCER CELLS AND THE CELLS DERIVED FROM THEM, RESPECTIVELY, POINT AT TWO COMPLETELY INDEPENDENT MECHANISMS THAT DRIVE TUMOR PROGRESSION. THIS ARTICLE UNDERLINES THE NEED FOR DEVELOPING THERAPIES THAT SPECIFICALLY TARGET THE STEM-LIKE CELL POOLS IN TUMORS.",IN-VIVO; PHASE-I; PROSPECTIVE IDENTIFICATION; PROSTATE-CANCER; BRAIN; EXPRESSION; GLIOMAS; ENDOSTATIN; THERAPY; MARKERS,GLIOMA; INVASIVENESS; VESSEL COOPTION,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,"SAKARIASSEN, PO##PRESTEGARDEN, L##WANG, J##SKAFTNESMO, KO##MAHESPARAN, R##MOLTHOFF, C##SMINIA, P##SUNDLISAETER, E##MISRA, A##TYSNES, BB##CHEKENYA, M##PETERS, H##LENDE, G##KALLAND, KH##OYAN, AM##PETERSEN, K##JONASSEN, I##VAN DER KOGEL, A##FEUERSTEIN, BG##TERZIS, AJA##BJERKVIG, R##ENGER, PO","UNIV BERGEN, DEPT BIOMED, SAC, NORLUX NEUROONCOL, N-5009 BERGEN, NORWAY. HAUKELAND HOSP, DEPT NEUROSURG, N-5021 BERGEN, NORWAY. HAUKELAND HOSP, DEPT MICROBIOL & IMMUNOL, N-5021 BERGEN, NORWAY. VRIJE UNIV AMSTERDAM, MED CTR, SECT RADIOBIOL, DEPT NUCL MED, NL-1081 HV AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, SECT RADIOBIOL, POSITRON EMISS TOMOG CTR, NL-1081 HV AMSTERDAM, NETHERLANDS. VRIJE UNIV AMSTERDAM, MED CTR, SECT RADIOBIOL, DEPT RADIAT ONCOL, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV CALIF SAN FRANCISCO, DEPT NEUROSURG, SAN FRANCISCO, CA 94143 USA. UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA. UNIV NIJMEGEN, MED CTR, DEPT RADIAT ONCOL, NL-6500 HB NIJMEGEN, NETHERLANDS. UNIV BERGEN, GADE INST, N-5021 BERGEN, NORWAY. UNIV BERGEN, DEPT INFORMAT, N-5021 BERGEN, NORWAY. UNIFOB AS, BERGEN CTR COMPUTAT SCI, N-5021 BERGEN, NORWAY. NORLUX NEUROONCOL, CTR RECH PUBL SANTE, L-1150 LUXEMBOURG, LUXEMBOURG.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"ABOODY KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/PNAS.97.23.12846##AKELLA NS, 2004, J MAGN RESON IMAGING, V20, P913, DOI 10.1002/JMRI.20202##AL-HAJJ M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/PNAS.0530291100##BJERKVIG R, 1990, J NEUROSURG, V72, P463, DOI 10.3171/JNS.1990.72.3.0463##BJERKVIG R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/NRC1740##BLOUW B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6##BONNET D, 2005, CELL PROLIFERAT, V38, P357, DOI 10.1111/J.1365-2184.2005.00353.X##BOUSCARY D, 2005, BRIT J HAEMATOL, V131, P609, DOI 10.1111/J.1365-2141.2005.05817.X##BRABLETZ T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/NRC1694##BREM S, 2005, NEURO-ONCOLOGY, V7, P246, DOI 10.1215/S1152851704000869##CARMELIET P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478##COLLINS AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018##COLLINS VP, 2004, J NEUROL NEUROSUR PS, V75, P2, DOI 10.1136/JNNP.2004.040337##DVORAK P, 2006, FEBS LETT, V580, P2869, DOI 10.1016/J.FEBSLET.2006.01.095##DYSVIK B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/BIOINFORMATICS/17.4.369##EISTERER W, 2002, MOL THER, V5, P352, DOI 10.1006/MTHE.2002.0573##ENGEBRAATEN O, 1999, J NEUROSURG, V90, P125, DOI 10.3171/JNS.1999.90.1.0125##ENGEBRAATEN O, 1993, INT J CANCER, V53, P209, DOI 10.1002/IJC.2910530206##ENGLUND U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/EXNR.2001.7750##FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182##GAGNER JP, 2005, BRAIN PATHOL, V15, P342##GARBER K, 2002, NAT BIOTECHNOL, V20, P1067, DOI 10.1038/NBT1102-1067##GJERTSEN BT, 2002, J HEMATOTH STEM CELL, V11, P469, DOI 10.1089/15258160260090933##HALVORSEN OJ, 2005, INT J ONCOL, V26, P329##HANSMA AHG, 2005, ANN ONCOL, V16, P1695, DOI 10.1093/ANNONC/MDI318##HOLASH J, 1999, SCIENCE, V284, P1994, DOI 10.1126/SCIENCE.284.5422.1994##HURELBRINK CB, 2002, EUR J NEUROSCI, V15, P1255, DOI 10.1046/J.1460-9568.2002.01959.X##IGNATOVA TN, 2002, GLIA, V39, P193, DOI 10.1002/GLIA.10094##KARCHER S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/IJC.21648##KLEIHUES P, 1999, NEURO ONCOL, V1, P44, DOI 10.1093/NEUONC/1.1.44##KUNKEL P, 2001, CANCER RES, V61, P6624##LIN HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/SJ.BJC.6602862##LIU L, 2005, J MOL MED, V83, P917, DOI 10.1007/S00109-005-0700-2##MAHESPARAN R, 2003, ACTA NEUROPATHOL, V105, P49, DOI 10.1007/S00401-002-0610-0##MARSHALL E, 2002, SCIENCE, V295, P2198, DOI 10.1126/SCIENCE.295.5563.2198##MARX J, 2003, SCIENCE, V301, P1308, DOI 10.1126/SCIENCE.301.5638.1308##NAKANO I, 2006, PEDIATR RES, V59, P54R, DOI 10.1203/01.PDR.0000203568.63482.F9##NAUMOV GN, 2006, JNCI-J NATL CANCER I, V98, P316, DOI 10.1093/JNCI/DJJ068##O'DONNELL A, 2005, BRIT J CANCER, V93, P876, DOI 10.1038/SJ.BJC.6602797##OKABE M, 2001, NATURE, V411, P94, DOI 10.1038/35075094##REYA T, 2001, NATURE, V414, P105, DOI 10.1038/35102167##RIBATTI D, 2005, CURR CANCER DRUG TAR, V5, P573, DOI 10.2174/156800905774932806##RIBATTI D, 2005, BRIT J HAEMATOL, V128, P303, DOI 10.1111/J.1365-2141.2004.05291.X##RICH JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936##SCHULTZ C, 2002, CANCER RES, V62, P6270##SHI Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/JBC.M409630200##SHIELDS AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337##SINGH SK, 2003, CANCER RES, V63, P5821##SINGH SK, 2004, NATURE, V432, P396, DOI 10.1038/NATURE03128##SNIJDERS AM, 2001, NAT GENET, V29, P263, DOI 10.1038/NG754##VILLA A, 2000, EXP NEUROL, V161, P67, DOI 10.1006/EXNR.1999.7237##VISTED T, 2003, FRONT BIOSCI-LANDMRK, V8, PE289, DOI 10.2741/1026##WANG J, 2005, BIOCHEM BIOPH RES CO, V330, P123, DOI 10.1016/J.BBRC.2005.02.140##WEDAM SB, 2006, J CLIN ONCOL, V24, P769, DOI 10.1200/JCO.2005.03.4645##YUAN XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/SJ.ONC.1208311",174,2020-11-20,NA
J,WOS:000241879500085,2006,TACTILE GUIDANCE OF PREY CAPTURE IN ETRUSCAN SHREWS,"WHEREAS VISUOMOTOR BEHAVIORS AND VISUAL OBJECT RECOGNITION HAVE BEEN STUDIED IN DETAIL, WE KNOW RELATIVELY LITTLE ABOUT TACTILE OBJECT REPRESENTATIONS. WE INVESTIGATE A NEW MODEL SYSTEM FOR THE TACTILE GUIDANCE OF BEHAVIOR, NAMELY PREY (CRICKET) CAPTURE BY ONE OF THE SMALLEST MAMMALS, THE ETRUSCAN SHREW, SUNCUS ETRUSCUS. BECAUSE OF THEIR HIGH METABOLIC RATE AND NOCTURNAL LIFESTYLE, ETRUSCAN SHREWS ARE FORCED TO DETECT, OVERWHELM, AND KILL PREY IN LARGE NUMBERS IN DARKNESS. CRICKETS ARE EXQUISITELY MECHANOSENSITIVE, FAST-MOVING PREY, ALMOST AS BIG AS THE SHREW ITSELF. SHREWS SUCCEED IN HUNTING BY LATERALIZED, PRECISE, AND FAST ATTACKS. REMOVAL EXPERIMENTS DEMONSTRATE THAT BOTH MACROVIBRISSAE AND MICROVIBRISSAE ARE REQUIRED FOR PREY CAPTURE, WITH THE MACROVIBRISSAE BEING INVOLVED IN ATTACK TARGETING. EXPERIMENTS WITH ARTIFICIAL PREY REPLICA SHOW THAT TACTILE SHAPE CUES ARE BOTH NECESSARY AND SUFFICIENT FOR EVOKING ATTACKS. PREY REPRESENTATIONS ARE MOTION- AND SIZE-INVARIANT. SHREWS DISTINGUISH AND MEMORIZE PREY FEATURES. CORRECTIVE MANEUVERS AND CRICKET SHAPE MANIPULATION EXPERIMENTS INDICATE THAT SHREW BEHAVIOR IS GUIDED BY GESTALT-LIKE PREY DESCRIPTIONS. THUS, TACTILE OBJECT RECOGNITION IN ETRUSCAN SHREWS SHARES CHARACTERISTICS OF HUMAN VISUAL OBJECT RECOGNITION, BUT IT PROCEEDS FASTER AND OCCURS IN A 20,000-TIMES-SMALLER BRAIN.",ORIENTATION; INTEGRATION; SORICIDAE; BEHAVIOR; CRICKET; MUSCLE,ACTIVE TOUCH; BARREL CORTEX; OBJECT RECOGNITION; SUNCUS ETRUSCUS; WHISKER,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,"ANJUM, F##TURNI, H##MULDER, PGH##VAN DER BURG, J##BRECHT, M","ERASMUS MC, DEPT NEUROSCI, NL-3000 DR ROTTERDAM, NETHERLANDS. INST BEHAV ECOL, D-72070 TUBINGEN, GERMANY. ERASMUS MC, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS.",MULTIDISCIPLINARY SCIENCES,SCIENCE & TECHNOLOGY - OTHER TOPICS,"BRANIS M, 1994, ADV BIOL SHREWS SPEC, V18, P189##BRECHT M, 1997, BEHAV BRAIN RES, V84, P81, DOI 10.1016/S0166-4328(97)83328-1##BRINCAT SL, 2006, NEURON, V49, P17, DOI 10.1016/J.NEURON.2005.11.026##BROCA P., 1861, B SOC ANAT PARIS, V6, P330, DOI DOI 10.1093/ACPROF:OSO/9780195177640.003.0018##CATANIA KC, 2005, NATURE, V433, P519, DOI 10.1038/NATURE03250##CATANIA KC, 1999, J COMP NEUROL, V410, P55##CHURCHFIELD S, 1994, ADV BIOL SHREWS, V18, P77##DEHNHARDT G, 2001, SCIENCE, V293, P102, DOI 10.1126/SCIENCE.1060514##DEHNHARDT G, 1990, NATO ADV SCI I A-LIF, V196, P435##EWERT J.-P., 1984, P247##EWERT JP, 1979, BRAIN BEHAV EVOLUT, V16, P38, DOI 10.1159/000121822##GIBSON JJ, 1962, PSYCHOL REV, V69, P477, DOI 10.1037/H0046962##GNATZY W, 1996, NATURWISSENSCHAFTEN, V83, P467, DOI 10.1007/BF01144015##GRUNWALD A, 1969, Z VERGL PHYSIOL, V65, P191, DOI 10.1007/BF00297683##GUICROBLES E, 1989, BEHAV BRAIN RES, V31, P285, DOI 10.1016/0166-4328(89)90011-9##HABERL W, 1993, THESIS U VIENNA VIEN##HUSTERT R, 1995, J EXP BIOL, V198, P1275##HUSTON KA, 1986, J NEUROPHYSIOL, V56, P1196##JIN TE, 2004, J NEUROSCI, V24, P3386, DOI 10.1523/JNEUROSCI.5151-03.2004##JURGENS KD, 2002, J EXP BIOL, V205, P2161##PETERS T, 1999, J EXP BIOL, V202, P2461##SACHDEV RNS, 2002, J NEUROPHYSIOL, V87, P1440, DOI 10.1152/JN.00539.2001##SCHMIDT-NIELSEN K, 1984, SCALING WHY IS ANIMA##SCHNITZLER HU, 2003, TRENDS ECOL EVOL, V18, P386, DOI 10.1016/S0169-5347(03)00185-X##SIRETEANU R, 2000, VISION RES, V40, P2925, DOI 10.1016/S0042-6989(00)00145-0##SPITZENBERGER F, 1990, SAUGETIERE EUROPAS, P375##STEINER A.L., 1986, P63##TANAKA K, 1997, CURR OPIN NEUROBIOL, V7, P523, DOI 10.1016/S0959-4388(97)80032-3##TAUBER E, 1995, J EXP BIOL, V198, P1895##TINBERGEN N., 1951, STUDY INSTINCT##TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5##VONUEXKULL J., 1909, UMWELT INNENWELT TIE##WARD JP, 1993, PRIMATE LATERALITY C##WILLIAMS H, 1992, J NEUROBIOL, V23, P1006, DOI 10.1002/NEU.480230807",80,2020-11-20,NA
